Number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
and	O
their	O
sensitivity	O
to	O
hormone	O
action	O
.	O
<EOS>	B-X
Number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
lymphocytes	B-X
and	B-X
their	B-X
sensitivity	B-X
to	B-X
hormone	B-X
action	B-X
.	B-X
<EOS>	B-X
Mechanisms	B-X
of	B-X
glucocorticoid	B-X
reduction	B-X
in	B-X
asthmatic	B-X
subjects	B-X
treated	B-X
with	B-X
intravenous	B-X
immunoglobulin	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
polymorphonuclear	B-X
and	B-X
mononuclear	B-X
leucocytes	B-X
.	B-X
Concentrations	B-X
and	B-X
binding	B-X
characteristics	B-X
.	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GCR	B-X
)	B-X
in	B-X
double	B-X
-	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
,	B-X
double	B-X
-	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
and	B-X
CD4	B-X
or	B-X
CD8	B-X
single	B-X
-	B-X
positive	B-X
(	B-X
SP	B-X
)	B-X
cell	B-X
populations	B-X
was	B-X
assessed	B-X

The	O
study	O
demonstrated	O
a	O
decreased	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
hypercholesterolemic	O
subjects	O
,	O
and	O
an	O
elevated	O
level	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

In	O
the	O
lymphocytes	B-cell_type
with	O
a	O
high	O
GR	B-protein
number	O
,	O
dexamethasone	O
inhibited	O
[	O
3H	O
]	O
-thymidine	O
and	O
[	O
3H	O
]	O
-acetate	O
incorporation	O
into	O
DNA	O
and	O
cholesterol	O
,	O
respectively	O
,	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
control	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
In	B-X
the	B-X
lymphocytes	B-X
with	B-X
a	B-X
high	B-X
GR	B-X
number	B-X
,	B-X
dexamethasone	B-X
inhibited	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
thymidine	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
acetate	B-X
incorporation	B-X
into	B-X
DNA	B-X
and	B-X
cholesterol	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
the	B-X
same	B-X
manner	B-X
as	B-X
in	B-X
the	B-X
control	B-X
cells	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
a	B-X
decreased	B-X
GR	B-X
number	B-X
resulted	B-X
in	B-X
a	B-X
less	B-X
efficient	B-X
dexamethasone	B-X
inhibition	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
labeled	B-X
compounds	B-X
<EOS>	B-X
These	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
sensitivity	B-X
of	B-X
lymphocytes	B-X
to	B-X
glucocorticoids	B-X
changed	B-X
only	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
GR	B-X
level	B-X
<EOS>	B-X
Number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
lymphocytes	B-X
and	B-X
their	B-X
sensitivity	B-X
to	B-X
hormone	B-X
action	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
a	O
decreased	O
GR	B-protein
number	O
resulted	O
in	O
a	O
less	O
efficient	O
dexamethasone	O
inhibition	O
of	O
the	O
incorporation	O
of	O
labeled	O
compounds	O
.	O

These	O
data	O
showed	O
that	O
the	O
sensitivity	O
of	O
lymphocytes	B-cell_type
to	O
glucocorticoids	O
changed	O
only	O
with	O
a	O
decrease	O
of	O
GR	B-protein
level	O
.	O
<EOS>	B-X
These	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
sensitivity	B-X
of	B-X
lymphocytes	B-X
to	B-X
glucocorticoids	B-X
changed	B-X
only	B-X
with	B-X
a	B-X
decrease	B-X
of	B-X
GR	B-X
level	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
glucocorticoid	B-X
resistance	B-X
is	B-X
not	B-X
associated	B-X
with	B-X
increased	B-X
AP	B-X
-	B-X
1	B-X
<EOS>	B-X
In	B-X
vitro	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
was	B-X
measured	B-X
using	B-X
the	B-X
MTT	B-X
assay	B-X
<EOS>	B-X
Whether	B-X
this	B-X
has	B-X
any	B-X
causal	B-X
relationship	B-X
to	B-X
glucocorticoid	B-X
resistance	B-X
is	B-X
unknown	B-X

[	O
1	B-protein
,	I-protein
25-Dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
and	O
T-	B-cell_type
and	I-cell_type
B-lymphocyte	I-cell_type
count	O
in	O
patients	O
with	O
glomerulonephritis	O
]	O

Content	O
of	O
receptors	O
to	O
hormonal	O
form	O
of	O
vitamin	O
D3	O
,	O
1.25	O
(	O
OH	O
)	O
2D3	O
,	O
constituted	O
27.3	O
fmole/mg	O
of	O
protein	O
in	O
lymphocytes	B-cell_type
of	O
peripheric	O
blood	O
of	O
children	O
with	O
glomerulonephritis	O
.	O
<EOS>	B-X
3	B-X
fmole	B-X
/	B-X
mg	B-X
of	B-X
protein	B-X
in	B-X
lymphocytes	B-X
of	B-X
peripheric	B-X
blood	B-X
of	B-X
children	B-X
with	B-X
glomerulonephritis	B-X
<EOS>	B-X
[	B-X
1,25	B-X
-	B-X
Dihydroxyvitamin	B-X
D3	B-X
receptors	B-X
in	B-X
lymphocytes	B-X
and	B-X
T	B-X
-	B-X
	B-X
and	B-X
B	B-X
-	B-X
lymphocyte	B-X
count	B-X
in	B-X
patients	B-X
with	B-X
glomerulonephritis	B-X
]	B-X
.	B-X
<EOS>	B-X
Content	B-X
of	B-X
receptors	B-X
to	B-X
hormonal	B-X
form	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
1	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
1	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
normalized	B-X
also	B-X
the	B-X
T	B-X
lymphocytes	B-X
content	B-X
in	B-X
peripheric	B-X
blood	B-X

In	O
the	O
patients	O
concentration	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
was	O
decreased	O
down	O
to	O
2.04	O
mmole/L	O
and	O
1.09	O
mmole/L	O
,	O
respectively	O
,	O
while	O
an	O
increase	O
in	O
parathormone	O
(	O
PTH	O
)	O
by	O
36	O
%	O
and	O
a	O
distinct	O
decrease	O
in	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
lower	O
than	O
1.25	O
ng/ml	O
)	O
was	O
found	O
in	O
blood	O
;	O
content	O
of	O
cAMP	O
was	O
also	O
decreased	O
in	O
lymphocytes	O
by	O
33	O
%	O
.	O

At	O
the	O
same	O
time	O
,	O
total	O
content	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
was	O
decreased	O
1.5-fold	O
in	O
peripheric	O
blood	O
.	O
<EOS>	B-X
At	B-X
the	B-X
same	B-X
time	B-X
,	B-X
total	B-X
content	B-X
of	B-X
T	B-X
lymphocytes	B-X
was	B-X
decreased	B-X
1	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
1	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
normalized	B-X
also	B-X
the	B-X
T	B-X
lymphocytes	B-X
content	B-X
in	B-X
peripheric	B-X
blood	B-X
<EOS>	B-X
25	B-X
ng	B-X
/	B-X
ml	B-X
)	B-X
was	B-X
found	B-X
in	B-X
blood	B-X
;	B-X
content	B-X
of	B-X
cAMP	B-X
was	B-X
also	B-X
decreased	B-X
in	B-X
lymphocytes	B-X
by	B-X
33	B-X
%	B-X
<EOS>	B-X
09	B-X
mmole	B-X
/	B-X
L	B-X
,	B-X
respectively	B-X
,	B-X
while	B-X
an	B-X
increase	B-X
in	B-X
parathormone	B-X
(	B-X
PTH	B-X
)	B-X
by	B-X
36	B-X
%	B-X
and	B-X
a	B-X
distinct	B-X
decrease	B-X
in	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
concentration	B-X
(	B-X
lower	B-X
than	B-X
1	B-X

Treatment	O
with	O
I-hydroxyvitamin	O
D3	O
(	O
1-1.5	O
mg	O
daily	O
,	O
within	O
4	O
weeks	O
)	O
led	O
to	O
normalization	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
and	O
of	O
25	O
(	O
OH	O
)	O
D	O
,	O
but	O
did	O
not	O
affect	O
the	O
PTH	O
content	O
in	O
blood	O
.	O

Concentration	O
of	O
the	O
receptors	B-protein
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
was	O
elevated	O
up	O
to	O
39.7	O
fmole/mg	O
after	O
I	O
week	O
of	O
the	O
treatment	O
,	O
whereas	O
it	O
was	O
decreased	O
to	O
the	O
initial	O
level	O
24.8	O
fmole/mg	O
within	O
4	O
weeks	O
;	O
simultaneous	O
alteration	O
in	O
the	O
cAMP	O
content	O
was	O
observed	O
in	O
lymphocytes	B-cell_type
.	O

Treatment	O
with	O
1-	O
(	O
OH	O
)	O
D3	O
normalized	O
also	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
content	O
in	O
peripheric	O
blood	O
.	O

The	O
data	O
obtained	O
suggest	O
that	O
under	O
conditions	O
of	O
glomerulonephritis	O
only	O
high	O
content	O
of	O
receptors	B-protein
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
in	O
lymphocytes	B-cell_type
enabled	O
to	O
perform	O
the	O
cell	O
response	O
to	O
the	O
hormone	O
effect	O
.	O

Tumor	O
and	O
serum	O
beta-2-microglobulin	O
expression	O
in	O
women	O
with	O
breast	O
cancer	O
.	O
<EOS>	B-X
Tumor	B-X
and	B-X
serum	B-X
beta	B-X
-	B-X
2	B-X
-	B-X
microglobulin	B-X
expression	B-X
in	B-X
women	B-X
with	B-X
breast	B-X
cancer	B-X
.	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
the	B-X
tumor	B-X
expression	B-X
of	B-X
beta	B-X
-	B-X
2	B-X
-	B-X
microglobulin	B-X
(	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
)	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
tumor	B-X
biologic	B-X
behavior	B-X
,	B-X
the	B-X
authors	B-X
studied	B-X
specimens	B-X
of	B-X
breast	B-X
carcinomas	B-X
from	B-X
60	B-X
consecutive	B-X
female	B-X
patients	B-X
<EOS>	B-X
Presence	B-X
of	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
was	B-X
analyzed	B-X
by	B-X
immunohistochemistry	B-X
<EOS>	B-X
Beta	B-X
2	B-X
-	B-X
M	B-X
serum	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
an	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
in	B-X
samples	B-X
from	B-X
22	B-X
of	B-X
the	B-X
above	B-X
women	B-X

To	O
investigate	O
whether	O
the	O
tumor	B-cell_type
expression	O
of	O
beta-2-microglobulin	B-protein
(	O
beta	B-protein
2-M	I-protein
)	O
could	O
serve	O
as	O
a	O
marker	O
of	O
tumor	O
biologic	O
behavior	O
,	O
the	O
authors	O
studied	O
specimens	O
of	O
breast	B-cell_type
carcinomas	I-cell_type
from	O
60	O
consecutive	O
female	O
patients	O
.	O

Presence	O
of	O
beta	B-protein
2-M	I-protein
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O
<EOS>	B-X
Presence	B-X
of	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
was	B-X
analyzed	B-X
by	B-X
immunohistochemistry	B-X
<EOS>	B-X
Tumor	B-X
and	B-X
serum	B-X
beta	B-X
-	B-X
2	B-X
-	B-X
microglobulin	B-X
expression	B-X
in	B-X
women	B-X
with	B-X
breast	B-X
cancer	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significantly	B-X
positive	B-X
association	B-X
between	B-X
tumor	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
and	B-X
the	B-X
degree	B-X
of	B-X
lymphocytic	B-X
infiltration	B-X
in	B-X
the	B-X
tumor	B-X
tissue	B-X
<EOS>	B-X
Beta	B-X
2	B-X
-	B-X
M	B-X
serum	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
an	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
in	B-X
samples	B-X
from	B-X
22	B-X
of	B-X
the	B-X
above	B-X
women	B-X

No	O
significant	O
correlations	O
were	O
found	O
between	O
tumor	B-protein
beta	I-protein
2-M	I-protein
expression	O
and	O
several	O
histologic	O
attributes	O
such	O
as	O
type	O
,	O
histologic	O
and	O
nuclear	O
grades	O
,	O
mitotic	O
index	O
,	O
necrosis	O
,	O
vascular	O
invasion	O
,	O
and	O
lymphocytic	O
infiltration	O
.	O
<EOS>	B-X
No	B-X
significant	B-X
correlations	B-X
were	B-X
found	B-X
between	B-X
tumor	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
and	B-X
several	B-X
histologic	B-X
attributes	B-X
such	B-X
as	B-X
type	B-X
,	B-X
histologic	B-X
and	B-X
nuclear	B-X
grades	B-X
,	B-X
mitotic	B-X
index	B-X
,	B-X
necrosis	B-X
,	B-X
vascular	B-X
invasion	B-X
,	B-X
and	B-X
lymphocytic	B-X
infiltration	B-X
<EOS>	B-X
However	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significantly	B-X
positive	B-X
association	B-X
between	B-X
tumor	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
and	B-X
the	B-X
degree	B-X
of	B-X
lymphocytic	B-X
infiltration	B-X
in	B-X
the	B-X
tumor	B-X
tissue	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
the	B-X
tumor	B-X
expression	B-X
of	B-X
beta	B-X
-	B-X
2	B-X
-	B-X
microglobulin	B-X
(	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
)	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
tumor	B-X
biologic	B-X
behavior	B-X
,	B-X
the	B-X
authors	B-X
studied	B-X
specimens	B-X
of	B-X
breast	B-X
carcinomas	B-X
from	B-X
60	B-X
consecutive	B-X
female	B-X
patients	B-X
<EOS>	B-X
Although	B-X
some	B-X
of	B-X
the	B-X
highest	B-X
values	B-X
had	B-X
been	B-X
obtained	B-X
in	B-X
women	B-X
with	B-X
larger	B-X
(	B-X
T4	B-X
)	B-X
primary	B-X
tumors	B-X
,	B-X
the	B-X
authors	B-X
failed	B-X
to	B-X
detect	B-X
any	B-X
statistical	B-X
relationship	B-X
between	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
in	B-X
the	B-X
tumor	B-X
with	B-X
serum	B-X
levels	B-X
or	B-X
between	B-X
serum	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
and	B-X
the	B-X
above	B-X
histologic	B-X
,	B-X
laboratory	B-X
,	B-X
and	B-X
clinical	B-X
factors	B-X

Likewise	O
,	O
beta	B-protein
2-M	I-protein
was	O
not	O
associated	O
with	O
markers	O
of	O
disease	O
extension	O
such	O
as	O
TNM	O
,	O
(	O
UICC	O
,	O
classification	O
of	O
malignant	B-cell_type
tumors	I-cell_type
)	O
staging	O
and	O
axillary	O
lymph	O
node	O
involvement	O
or	O
with	O
estrogen	O
,	O
progesterone	O
,	O
and	O
glucocorticoid	O
receptor	O
levels	O
.	O
<EOS>	B-X
Competitive	B-X
binding	B-X
assays	B-X
were	B-X
performed	B-X
to	B-X
examine	B-X
kinetic	B-X
parameters	B-X
for	B-X
estrogen	B-X
,	B-X
progesterone	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Both	B-X
bioassays	B-X
are	B-X
member	B-X
of	B-X
a	B-X
panel	B-X
of	B-X
CALUX	B-X
reporter	B-X
cell	B-X
lines	B-X
derived	B-X
from	B-X
the	B-X
human	B-X
U2	B-X
-	B-X
OS	B-X
osteosarcoma	B-X
cell	B-X
line	B-X
,	B-X
all	B-X
using	B-X
highly	B-X
selective	B-X
reporter	B-X
constructs	B-X
based	B-X
with	B-X
a	B-X
basal	B-X
promoter	B-X
element	B-X
linked	B-X
to	B-X
multimerized	B-X
response	B-X
elements	B-X
,	B-X
allowing	B-X
efficient	B-X
and	B-X
specific	B-X
measurement	B-X
of	B-X
compounds	B-X
interfering	B-X
with	B-X
androgen	B-X
,	B-X
estrogen	B-X
,	B-X
progesterone	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
MFM	B-X
-	B-X
223	B-X
human	B-X
mammary	B-X
cancer	B-X
cells	B-X
contain	B-X
a	B-X
very	B-X
high	B-X
level	B-X
of	B-X
androgen	B-X
receptors	B-X
(	B-X
160	B-X
fmol	B-X
/	B-X
mg	B-X
protein	B-X
)	B-X
and	B-X
low	B-X
levels	B-X
of	B-X
estrogen	B-X
,	B-X
progesterone	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
<	B-X
20	B-X
fmol	B-X
/	B-X
mg	B-X
protein	B-X
)	B-X
<EOS>	B-X
[	B-X
The	B-X
status	B-X
of	B-X
receptors	B-X
in	B-X
laryngeal	B-X
carcinoma	B-X
:	B-X
a	B-X
study	B-X
of	B-X
receptors	B-X
for	B-X
estrogen	B-X
,	B-X
progesterone	B-X
,	B-X
androgens	B-X
and	B-X
glucocorticoids	B-X
]	B-X
.	B-X

However	O
,	O
there	O
was	O
a	O
significantly	O
positive	O
association	O
between	O
tumor	B-protein
beta	I-protein
2-M	I-protein
expression	O
and	O
the	O
degree	O
of	O
lymphocytic	O
infiltration	O
in	O
the	O
tumor	O
tissue	O
.	O
<EOS>	B-X
However	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significantly	B-X
positive	B-X
association	B-X
between	B-X
tumor	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
and	B-X
the	B-X
degree	B-X
of	B-X
lymphocytic	B-X
infiltration	B-X
in	B-X
the	B-X
tumor	B-X
tissue	B-X
<EOS>	B-X
No	B-X
significant	B-X
correlations	B-X
were	B-X
found	B-X
between	B-X
tumor	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
and	B-X
several	B-X
histologic	B-X
attributes	B-X
such	B-X
as	B-X
type	B-X
,	B-X
histologic	B-X
and	B-X
nuclear	B-X
grades	B-X
,	B-X
mitotic	B-X
index	B-X
,	B-X
necrosis	B-X
,	B-X
vascular	B-X
invasion	B-X
,	B-X
and	B-X
lymphocytic	B-X
infiltration	B-X
<EOS>	B-X
Although	B-X
some	B-X
of	B-X
the	B-X
highest	B-X
values	B-X
had	B-X
been	B-X
obtained	B-X
in	B-X
women	B-X
with	B-X
larger	B-X
(	B-X
T4	B-X
)	B-X
primary	B-X
tumors	B-X
,	B-X
the	B-X
authors	B-X
failed	B-X
to	B-X
detect	B-X
any	B-X
statistical	B-X
relationship	B-X
between	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
in	B-X
the	B-X
tumor	B-X
with	B-X
serum	B-X
levels	B-X
or	B-X
between	B-X
serum	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
and	B-X
the	B-X
above	B-X
histologic	B-X
,	B-X
laboratory	B-X
,	B-X
and	B-X
clinical	B-X
factors	B-X
<EOS>	B-X
Likewise	B-X
,	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
markers	B-X
of	B-X
disease	B-X
extension	B-X
such	B-X
as	B-X
TNM	B-X
,	B-X
(	B-X
UICC	B-X
,	B-X
classification	B-X
of	B-X
malignant	B-X
tumors	B-X
)	B-X
staging	B-X
and	B-X
axillary	B-X
lymph	B-X
node	B-X
involvement	B-X
or	B-X
with	B-X
estrogen	B-X
,	B-X
progesterone	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X

Beta	B-protein
2-M	I-protein
serum	O
levels	O
were	O
determined	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
in	O
samples	O
from	O
22	O
of	O
the	O
above	O
women	O
.	O
<EOS>	B-X
Beta	B-X
2	B-X
-	B-X
M	B-X
serum	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
an	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
in	B-X
samples	B-X
from	B-X
22	B-X
of	B-X
the	B-X
above	B-X
women	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
the	B-X
tumor	B-X
expression	B-X
of	B-X
beta	B-X
-	B-X
2	B-X
-	B-X
microglobulin	B-X
(	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
)	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
tumor	B-X
biologic	B-X
behavior	B-X
,	B-X
the	B-X
authors	B-X
studied	B-X
specimens	B-X
of	B-X
breast	B-X
carcinomas	B-X
from	B-X
60	B-X
consecutive	B-X
female	B-X
patients	B-X
<EOS>	B-X
Tumor	B-X
and	B-X
serum	B-X
beta	B-X
-	B-X
2	B-X
-	B-X
microglobulin	B-X
expression	B-X
in	B-X
women	B-X
with	B-X
breast	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Likewise	B-X
,	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
markers	B-X
of	B-X
disease	B-X
extension	B-X
such	B-X
as	B-X
TNM	B-X
,	B-X
(	B-X
UICC	B-X
,	B-X
classification	B-X
of	B-X
malignant	B-X
tumors	B-X
)	B-X
staging	B-X
and	B-X
axillary	B-X
lymph	B-X
node	B-X
involvement	B-X
or	B-X
with	B-X
estrogen	B-X
,	B-X
progesterone	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X

Although	O
some	O
of	O
the	O
highest	O
values	O
had	O
been	O
obtained	O
in	O
women	O
with	O
larger	O
(	O
T4	O
)	O
primary	O
tumors	O
,	O
the	O
authors	O
failed	O
to	O
detect	O
any	O
statistical	O
relationship	O
between	O
beta	B-protein
2-M	I-protein
expression	O
in	O
the	O
tumor	O
with	O
serum	O
levels	O
or	O
between	O
serum	B-protein
beta	I-protein
2-M	I-protein
and	O
the	O
above	O
histologic	O
,	O
laboratory	O
,	O
and	O
clinical	O
factors	O
.	O
<EOS>	B-X
Although	B-X
some	B-X
of	B-X
the	B-X
highest	B-X
values	B-X
had	B-X
been	B-X
obtained	B-X
in	B-X
women	B-X
with	B-X
larger	B-X
(	B-X
T4	B-X
)	B-X
primary	B-X
tumors	B-X
,	B-X
the	B-X
authors	B-X
failed	B-X
to	B-X
detect	B-X
any	B-X
statistical	B-X
relationship	B-X
between	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
in	B-X
the	B-X
tumor	B-X
with	B-X
serum	B-X
levels	B-X
or	B-X
between	B-X
serum	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
and	B-X
the	B-X
above	B-X
histologic	B-X
,	B-X
laboratory	B-X
,	B-X
and	B-X
clinical	B-X
factors	B-X
<EOS>	B-X
However	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significantly	B-X
positive	B-X
association	B-X
between	B-X
tumor	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
expression	B-X
and	B-X
the	B-X
degree	B-X
of	B-X
lymphocytic	B-X
infiltration	B-X
in	B-X
the	B-X
tumor	B-X
tissue	B-X
<EOS>	B-X
Likewise	B-X
,	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
markers	B-X
of	B-X
disease	B-X
extension	B-X
such	B-X
as	B-X
TNM	B-X
,	B-X
(	B-X
UICC	B-X
,	B-X
classification	B-X
of	B-X
malignant	B-X
tumors	B-X
)	B-X
staging	B-X
and	B-X
axillary	B-X
lymph	B-X
node	B-X
involvement	B-X
or	B-X
with	B-X
estrogen	B-X
,	B-X
progesterone	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
the	B-X
tumor	B-X
expression	B-X
of	B-X
beta	B-X
-	B-X
2	B-X
-	B-X
microglobulin	B-X
(	B-X
beta	B-X
2	B-X
-	B-X
M	B-X
)	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
tumor	B-X
biologic	B-X
behavior	B-X
,	B-X
the	B-X
authors	B-X
studied	B-X
specimens	B-X
of	B-X
breast	B-X
carcinomas	B-X
from	B-X
60	B-X
consecutive	B-X
female	B-X
patients	B-X

[	O
Preliminary	O
observation	O
of	O
level	O
free-form	B-protein
E	I-protein
receptor	I-protein
levels	O
in	O
serum	O
of	O
normal	O
childbearing-aged	O
and	O
pregnant	O
women	O
]	O
<EOS>	B-X
[	B-X
Preliminary	B-X
observation	B-X
of	B-X
level	B-X
free	B-X
-	B-X
form	B-X
E	B-X
receptor	B-X
levels	B-X
in	B-X
serum	B-X
of	B-X
normal	B-X
childbearing	B-X
-	B-X
aged	B-X
and	B-X
pregnant	B-X
women	B-X
]	B-X
.	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
there	B-X
is	B-X
a	B-X
relationship	B-X
between	B-X
a	B-X
change	B-X
in	B-X
T	B-X
cell	B-X
function	B-X
and	B-X
pregnancy	B-X
<EOS>	B-X
In	B-X
137	B-X
cases	B-X
of	B-X
childbearing	B-X
-	B-X
aged	B-X
and	B-X
pregnant	B-X
women	B-X
,	B-X
free	B-X
form	B-X
E	B-X
receptor	B-X
levels	B-X
(	B-X
sE	B-X
)	B-X
in	B-X
serum	B-X
were	B-X
measured	B-X
by	B-X
ELISA	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
sE	B-X
was	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
first	B-X
trimester	B-X
,	B-X
slightly	B-X
higher	B-X
in	B-X
the	B-X
second	B-X
trimester	B-X
,	B-X
and	B-X
recovered	B-X
to	B-X
normal	B-X
in	B-X
the	B-X
third	B-X
trimester	B-X

In	O
137	O
cases	O
of	O
childbearing-aged	O
and	O
pregnant	O
women	O
,	O
free	B-protein
form	I-protein
E	I-protein
receptor	I-protein
levels	O
(	O
sE	B-protein
)	O
in	O
serum	O
were	O
measured	O
by	O
ELISA	O
.	O

The	O
level	O
of	O
sE	B-protein
was	O
significantly	O
decreased	O
during	O
the	O
first	O
trimester	O
,	O
slightly	O
higher	O
in	O
the	O
second	O
trimester	O
,	O
and	O
recovered	O
to	O
normal	O
in	O
the	O
third	O
trimester	O
.	O
<EOS>	B-X
The	B-X
level	B-X
of	B-X
sE	B-X
was	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
first	B-X
trimester	B-X
,	B-X
slightly	B-X
higher	B-X
in	B-X
the	B-X
second	B-X
trimester	B-X
,	B-X
and	B-X
recovered	B-X
to	B-X
normal	B-X
in	B-X
the	B-X
third	B-X
trimester	B-X
<EOS>	B-X
The	B-X
level	B-X
remained	B-X
lower	B-X
in	B-X
29	B-X
PIH	B-X
women	B-X
but	B-X
appeared	B-X
higher	B-X
in	B-X
overdue	B-X
pregnancies	B-X
as	B-X
compared	B-X
with	B-X
the	B-X
normal	B-X
3rd	B-X
trimester	B-X
range	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
there	B-X
is	B-X
a	B-X
relationship	B-X
between	B-X
a	B-X
change	B-X
in	B-X
T	B-X
cell	B-X
function	B-X
and	B-X
pregnancy	B-X
<EOS>	B-X
[	B-X
Preliminary	B-X
observation	B-X
of	B-X
level	B-X
free	B-X
-	B-X
form	B-X
E	B-X
receptor	B-X
levels	B-X
in	B-X
serum	B-X
of	B-X
normal	B-X
childbearing	B-X
-	B-X
aged	B-X
and	B-X
pregnant	B-X
women	B-X
]	B-X
.	B-X

The	O
level	O
remained	O
lower	O
in	O
29	O
PIH	O
women	O
but	O
appeared	O
higher	O
in	O
overdue	O
pregnancies	O
as	O
compared	O
with	O
the	O
normal	O
3rd	O
trimester	O
range	O
.	O
<EOS>	B-X
The	B-X
level	B-X
remained	B-X
lower	B-X
in	B-X
29	B-X
PIH	B-X
women	B-X
but	B-X
appeared	B-X
higher	B-X
in	B-X
overdue	B-X
pregnancies	B-X
as	B-X
compared	B-X
with	B-X
the	B-X
normal	B-X
3rd	B-X
trimester	B-X
range	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
sE	B-X
was	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
first	B-X
trimester	B-X
,	B-X
slightly	B-X
higher	B-X
in	B-X
the	B-X
second	B-X
trimester	B-X
,	B-X
and	B-X
recovered	B-X
to	B-X
normal	B-X
in	B-X
the	B-X
third	B-X
trimester	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
there	B-X
is	B-X
a	B-X
relationship	B-X
between	B-X
a	B-X
change	B-X
in	B-X
T	B-X
cell	B-X
function	B-X
and	B-X
pregnancy	B-X
<EOS>	B-X
[	B-X
Preliminary	B-X
observation	B-X
of	B-X
level	B-X
free	B-X
-	B-X
form	B-X
E	B-X
receptor	B-X
levels	B-X
in	B-X
serum	B-X
of	B-X
normal	B-X
childbearing	B-X
-	B-X
aged	B-X
and	B-X
pregnant	B-X
women	B-X
]	B-X
.	B-X

The	O
results	O
indicate	O
that	O
there	O
is	O
a	O
relationship	O
between	O
a	O
change	O
in	O
T	B-cell_type
cell	I-cell_type
function	O
and	O
pregnancy	O
.	O

Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
:	O
role	O
in	O
the	O
regulation	O
of	O
human	B-DNA
interleukin-2	I-DNA
gene	I-DNA
expression	O
.	O
<EOS>	B-X
Kappa	B-X
B	B-X
-	B-X
specific	B-X
DNA	B-X
binding	B-X
proteins	B-X
:	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
these	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
have	B-X
a	B-X
role	B-X
in	B-X
the	B-X
coordinate	B-X
regulation	B-X
of	B-X
this	B-X
growth	B-X
factor	B-X
-	B-X
growth	B-X
factor	B-X
receptor	B-X
gene	B-X
system	B-X
that	B-X
controls	B-X
T	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
These	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
(	B-X
80	B-X
to	B-X
90	B-X
and	B-X
50	B-X
to	B-X
55	B-X
kilodaltons	B-X
)	B-X
similarly	B-X
interact	B-X
with	B-X
the	B-X
functional	B-X
kappa	B-X
B	B-X
enhancer	B-X
present	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
promoter	B-X
<EOS>	B-X
Activation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
-	B-X
lymphocytes	B-X
through	B-X
CD2	B-X
plus	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
long	B-X
-	B-X
term	B-X
nuclear	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
.	B-X

Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
,	O
like	O
induction	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
and	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
,	O
is	O
shown	O
to	O
be	O
modulated	O
by	O
a	O
kappa	B-protein
B-like	I-protein
enhancer	I-protein
element	I-protein
.	O
<EOS>	B-X
Transcriptional	B-X
activation	B-X
of	B-X
the	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
gene	B-X
,	B-X
like	B-X
induction	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
alpha	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
)	B-X
gene	B-X
and	B-X
the	B-X
type	B-X
1	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
be	B-X
modulated	B-X
by	B-X
a	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
enhancer	B-X
element	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
these	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
have	B-X
a	B-X
role	B-X
in	B-X
the	B-X
coordinate	B-X
regulation	B-X
of	B-X
this	B-X
growth	B-X
factor	B-X
-	B-X
growth	B-X
factor	B-X
receptor	B-X
gene	B-X
system	B-X
that	B-X
controls	B-X
T	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
These	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
(	B-X
80	B-X
to	B-X
90	B-X
and	B-X
50	B-X
to	B-X
55	B-X
kilodaltons	B-X
)	B-X
similarly	B-X
interact	B-X
with	B-X
the	B-X
functional	B-X
kappa	B-X
B	B-X
enhancer	B-X
present	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
promoter	B-X
<EOS>	B-X
Kappa	B-X
B	B-X
-	B-X
specific	B-X
DNA	B-X
binding	B-X
proteins	B-X
:	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
.	B-X

Mutation	O
of	O
a	O
kappa	B-DNA
B	I-DNA
core	I-DNA
sequence	I-DNA
identified	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
(	O
-206	O
to	O
-195	O
)	O
partially	O
inhibits	O
both	O
mitogen-	O
and	O
HTLV-I	O
Tax-mediated	O
activation	O
of	O
this	O
transcription	B-protein
unit	I-protein
and	O
blocks	O
the	O
specific	O
binding	O
of	O
two	O
inducible	B-protein
cellular	I-protein
factors	I-protein
.	O
<EOS>	B-X
Mutation	B-X
of	B-X
a	B-X
kappa	B-X
B	B-X
core	B-X
sequence	B-X
identified	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
(	B-X
	B-X
-	B-X
206	B-X
to	B-X
	B-X
-	B-X
195	B-X
)	B-X
partially	B-X
inhibits	B-X
both	B-X
mitogen	B-X
-	B-X
	B-X
and	B-X
HTLV	B-X
-	B-X
I	B-X
Tax	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
this	B-X
transcription	B-X
unit	B-X
and	B-X
blocks	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
two	B-X
inducible	B-X
cellular	B-X
factors	B-X
<EOS>	B-X
These	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
(	B-X
80	B-X
to	B-X
90	B-X
and	B-X
50	B-X
to	B-X
55	B-X
kilodaltons	B-X
)	B-X
similarly	B-X
interact	B-X
with	B-X
the	B-X
functional	B-X
kappa	B-X
B	B-X
enhancer	B-X
present	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
promoter	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
these	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
have	B-X
a	B-X
role	B-X
in	B-X
the	B-X
coordinate	B-X
regulation	B-X
of	B-X
this	B-X
growth	B-X
factor	B-X
-	B-X
growth	B-X
factor	B-X
receptor	B-X
gene	B-X
system	B-X
that	B-X
controls	B-X
T	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
Kappa	B-X
B	B-X
-	B-X
specific	B-X
DNA	B-X
binding	B-X
proteins	B-X
:	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
.	B-X

These	O
kappa	B-protein
B-specific	I-protein
proteins	I-protein
(	O
80	O
to	O
90	O
and	O
50	O
to	O
55	O
kilodaltons	O
)	O
similarly	O
interact	O
with	O
the	O
functional	O
kappa	B-protein
B	I-protein
enhancer	I-protein
present	O
in	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
These	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
(	B-X
80	B-X
to	B-X
90	B-X
and	B-X
50	B-X
to	B-X
55	B-X
kilodaltons	B-X
)	B-X
similarly	B-X
interact	B-X
with	B-X
the	B-X
functional	B-X
kappa	B-X
B	B-X
enhancer	B-X
present	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
promoter	B-X
<EOS>	B-X
Kappa	B-X
B	B-X
-	B-X
specific	B-X
DNA	B-X
binding	B-X
proteins	B-X
:	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
these	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
have	B-X
a	B-X
role	B-X
in	B-X
the	B-X
coordinate	B-X
regulation	B-X
of	B-X
this	B-X
growth	B-X
factor	B-X
-	B-X
growth	B-X
factor	B-X
receptor	B-X
gene	B-X
system	B-X
that	B-X
controls	B-X
T	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
a	B-X
kappa	B-X
B	B-X
core	B-X
sequence	B-X
identified	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
(	B-X
	B-X
-	B-X
206	B-X
to	B-X
	B-X
-	B-X
195	B-X
)	B-X
partially	B-X
inhibits	B-X
both	B-X
mitogen	B-X
-	B-X
	B-X
and	B-X
HTLV	B-X
-	B-X
I	B-X
Tax	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
this	B-X
transcription	B-X
unit	B-X
and	B-X
blocks	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
two	B-X
inducible	B-X
cellular	B-X
factors	B-X

These	O
data	O
suggest	O
that	O
these	O
kappa	B-protein
B-specific	I-protein
proteins	I-protein
have	O
a	O
role	O
in	O
the	O
coordinate	O
regulation	O
of	O
this	O
growth	O
factor-growth	O
factor	O
receptor	O
gene	O
system	O
that	O
controls	O
T	B-cell_type
cell	I-cell_type
proliferation	O
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
these	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
have	B-X
a	B-X
role	B-X
in	B-X
the	B-X
coordinate	B-X
regulation	B-X
of	B-X
this	B-X
growth	B-X
factor	B-X
-	B-X
growth	B-X
factor	B-X
receptor	B-X
gene	B-X
system	B-X
that	B-X
controls	B-X
T	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
Kappa	B-X
B	B-X
-	B-X
specific	B-X
DNA	B-X
binding	B-X
proteins	B-X
:	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
These	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
proteins	B-X
(	B-X
80	B-X
to	B-X
90	B-X
and	B-X
50	B-X
to	B-X
55	B-X
kilodaltons	B-X
)	B-X
similarly	B-X
interact	B-X
with	B-X
the	B-X
functional	B-X
kappa	B-X
B	B-X
enhancer	B-X
present	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
promoter	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
a	B-X
kappa	B-X
B	B-X
core	B-X
sequence	B-X
identified	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
(	B-X
	B-X
-	B-X
206	B-X
to	B-X
	B-X
-	B-X
195	B-X
)	B-X
partially	B-X
inhibits	B-X
both	B-X
mitogen	B-X
-	B-X
	B-X
and	B-X
HTLV	B-X
-	B-X
I	B-X
Tax	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
this	B-X
transcription	B-X
unit	B-X
and	B-X
blocks	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
two	B-X
inducible	B-X
cellular	B-X
factors	B-X

Novel	O
region	O
within	O
the	O
V	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
responsible	O
for	O
tissue	O
and	O
stage-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
in	O
human	B-cell_type
lymphoid	I-cell_type
neoplasms	I-cell_type
.	O

Immunoglobulin	B-protein
gene-specific	I-protein
transacting	I-protein
factors	I-protein
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
lymphoid	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O
<EOS>	B-X
Immunoglobulin	B-X
gene	B-X
-	B-X
specific	B-X
transacting	B-X
factors	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
lymphoid	B-X
tissue	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
<EOS>	B-X
This	B-X
region	B-X
is	B-X
located	B-X
within	B-X
the	B-X
920	B-X
bp	B-X
fragment	B-X
located	B-X
210	B-X
bp	B-X
upstream	B-X
from	B-X
the	B-X
coding	B-X
region	B-X
and	B-X
this	B-X
fragment	B-X
represents	B-X
a	B-X
possible	B-X
novel	B-X
DNA	B-X
region	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
stage	B-X
-	B-X
	B-X
and	B-X
tissue	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
<EOS>	B-X
Novel	B-X
region	B-X
within	B-X
the	B-X
V	B-X
kappa	B-X
gene	B-X
promoter	B-X
is	B-X
responsible	B-X
for	B-X
tissue	B-X
and	B-X
stage	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
in	B-X
human	B-X
lymphoid	B-X
neoplasms	B-X
.	B-X
<EOS>	B-X
Previously	B-X
described	B-X
enhancement	B-X
of	B-X
in	B-X
vitro	B-X
transcription	B-X
that	B-X
was	B-X
only	B-X
seen	B-X
with	B-X
nuclear	B-X
extracts	B-X
derived	B-X
from	B-X
B	B-X
-	B-X
cell	B-X
neoplasms	B-X
corresponding	B-X
to	B-X
the	B-X
late	B-X
stages	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
dependent	B-X
on	B-X
the	B-X
actions	B-X
of	B-X
these	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
on	B-X
the	B-X
DNA	B-X
region	B-X
within	B-X
the	B-X
V	B-X
kappa	B-X
gene	B-X
promoter	B-X

The	O
role	O
of	O
these	O
factors	O
in	O
B-cell	B-cell_type
differentiation	O
and	O
stage-specific	O
expression	O
of	O
these	O
genes	O
is	O
,	O
however	O
,	O
not	O
fully	O
understood	O
.	O

We	O
have	O
used	O
a	O
model	O
of	O
human	O
lymphoid	O
neoplasia	O
to	O
address	O
this	O
question	O
.	O

Different	O
fragments	O
of	O
unrearranged	B-DNA
human	I-DNA
variable	I-DNA
region	I-DNA
of	O
immunoglobulin	B-DNA
kappa	I-DNA
gene	I-DNA
(	O
V	B-DNA
kappa	I-DNA
)	O
were	O
used	O
for	O
cell-free	O
in	O
vitro	O
transcription	O
and	O
DNA	O
mobility	O
shift	O
assays	O
.	O
<EOS>	B-X
Different	B-X
fragments	B-X
of	B-X
unrearranged	B-X
human	B-X
variable	B-X
region	B-X
of	B-X
immunoglobulin	B-X
kappa	B-X
gene	B-X
(	B-X
V	B-X
kappa	B-X
)	B-X
were	B-X
used	B-X
for	B-X
cell	B-X
-	B-X
free	B-X
in	B-X
vitro	B-X
transcription	B-X
and	B-X
DNA	B-X
mobility	B-X
shift	B-X
assays	B-X
<EOS>	B-X
Previously	B-X
described	B-X
enhancement	B-X
of	B-X
in	B-X
vitro	B-X
transcription	B-X
that	B-X
was	B-X
only	B-X
seen	B-X
with	B-X
nuclear	B-X
extracts	B-X
derived	B-X
from	B-X
B	B-X
-	B-X
cell	B-X
neoplasms	B-X
corresponding	B-X
to	B-X
the	B-X
late	B-X
stages	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
dependent	B-X
on	B-X
the	B-X
actions	B-X
of	B-X
these	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
on	B-X
the	B-X
DNA	B-X
region	B-X
within	B-X
the	B-X
V	B-X
kappa	B-X
gene	B-X
promoter	B-X
<EOS>	B-X
This	B-X
region	B-X
is	B-X
located	B-X
within	B-X
the	B-X
920	B-X
bp	B-X
fragment	B-X
located	B-X
210	B-X
bp	B-X
upstream	B-X
from	B-X
the	B-X
coding	B-X
region	B-X
and	B-X
this	B-X
fragment	B-X
represents	B-X
a	B-X
possible	B-X
novel	B-X
DNA	B-X
region	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
stage	B-X
-	B-X
	B-X
and	B-X
tissue	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
these	B-X
factors	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
and	B-X
stage	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
is	B-X
,	B-X
however	B-X
,	B-X
not	B-X
fully	B-X
understood	B-X

Previously	O
described	O
enhancement	O
of	O
in	O
vitro	O
transcription	O
that	O
was	O
only	O
seen	O
with	O
nuclear	O
extracts	O
derived	O
from	O
B-cell	B-cell_type
neoplasms	I-cell_type
corresponding	O
to	O
the	O
late	O
stages	O
of	O
B-cell	B-cell_type
differentiation	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
actions	O
of	O
these	O
factor	O
(	O
s	O
)	O
on	O
the	O
DNA	O
region	O
within	O
the	O
V	B-DNA
kappa	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

This	O
region	O
is	O
located	O
within	O
the	O
920	O
bp	O
fragment	O
located	O
210	O
bp	O
upstream	O
from	O
the	O
coding	O
region	O
and	O
this	O
fragment	O
represents	O
a	O
possible	O
novel	O
DNA	O
region	O
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
stage-	O
and	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

[	O
Determination	O
of	O
the	O
sensitivity	O
to	O
glucocorticoids	B-protein
in	O
vitro	O
]	O
<EOS>	B-X
These	B-X
cell	B-X
lines	B-X
suggest	B-X
that	B-X
multiple	B-X
mechanisms	B-X
contribute	B-X
to	B-X
glucocorticoid	B-X
resistance	B-X
in	B-X
canine	B-X
MCT	B-X
cells	B-X
<EOS>	B-X
The	B-X
main	B-X
reason	B-X
for	B-X
treatment	B-X
failure	B-X
is	B-X
drug	B-X
resistance	B-X
,	B-X
most	B-X
commonly	B-X
to	B-X
glucocorticoids	B-X
(	B-X
GCs	B-X
)	B-X
<EOS>	B-X
Plasma	B-X
Exosomes	B-X
Transfer	B-X
miR	B-X
-	B-X
885	B-X
-	B-X
3p	B-X
Targeting	B-X
the	B-X
AKT	B-X
/	B-X
NFκB	B-X
Signaling	B-X
Pathway	B-X
to	B-X
Improve	B-X
the	B-X
Sensitivity	B-X
of	B-X
Intravenous	B-X
Glucocorticoid	B-X
Therapy	B-X
Against	B-X
Graves	B-X
Ophthalmopathy	B-X
.	B-X
<EOS>	B-X
À	B-X
ce	B-X
jour	B-X
,	B-X
les	B-X
mécanismes	B-X
impliqués	B-X
dans	B-X
la	B-X
résistance	B-X
aux	B-X
glucocorticoïdes	B-X
dans	B-X
les	B-X
MCT	B-X
canins	B-X
restent	B-X
mal	B-X
définis	B-X

A	O
modified	O
method	O
for	O
the	O
determination	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
is	O
suggested	O
.	O
<EOS>	B-X
A	B-X
modified	B-X
method	B-X
for	B-X
the	B-X
determination	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
lymphocytes	B-X
is	B-X
suggested	B-X
<EOS>	B-X
[	B-X
Determination	B-X
of	B-X
the	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
in	B-X
vitro	B-X
]	B-X
.	B-X
<EOS>	B-X
The	B-X
principal	B-X
distinction	B-X
of	B-X
the	B-X
method	B-X
is	B-X
standardization	B-X
by	B-X
the	B-X
lymphocyte	B-X
count	B-X
in	B-X
a	B-X
sample	B-X
(	B-X
1	B-X
mln	B-X
)	B-X
and	B-X
the	B-X
labeled	B-X
hormone	B-X
concentration	B-X
<EOS>	B-X
Examinations	B-X
of	B-X
70	B-X
children	B-X
aged	B-X
4	B-X
to	B-X
15	B-X
suffering	B-X
from	B-X
the	B-X
nephrotic	B-X
form	B-X
of	B-X
glomerulonephritis	B-X
have	B-X
made	B-X
it	B-X
possible	B-X
to	B-X
distinguish	B-X
two	B-X
groups	B-X
of	B-X
patients	B-X
:	B-X
with	B-X
relatively	B-X
high	B-X
values	B-X
of	B-X
specific	B-X
binding	B-X
X	B-X
=	B-X
6820	B-X

The	O
principal	O
distinction	O
of	O
the	O
method	O
is	O
standardization	O
by	O
the	O
lymphocyte	B-cell_type
count	O
in	O
a	O
sample	O
(	O
1	O
mln	O
)	O
and	O
the	O
labeled	O
hormone	B-protein
concentration	O
.	O

The	O
modification	O
saves	O
time	O
and	O
money	O
,	O
limits	O
the	O
range	O
of	O
the	O
data	O
variations	O
,	O
and	O
makes	O
use	O
of	O
a	O
lesser	O
volume	O
of	O
blood	O
.	O
<EOS>	B-X
The	B-X
modification	B-X
saves	B-X
time	B-X
and	B-X
money	B-X
,	B-X
limits	B-X
the	B-X
range	B-X
of	B-X
the	B-X
data	B-X
variations	B-X
,	B-X
and	B-X
makes	B-X
use	B-X
of	B-X
a	B-X
lesser	B-X
volume	B-X
of	B-X
blood	B-X
<EOS>	B-X
These	B-X
results	B-X
permit	B-X
regarding	B-X
the	B-X
specific	B-X
binding	B-X
value	B-X
as	B-X
a	B-X
prognostic	B-X
criterion	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
corticosteroid	B-X
therapy	B-X
;	B-X
this	B-X
allows	B-X
a	B-X
wide	B-X
employment	B-X
of	B-X
the	B-X
described	B-X
method	B-X
in	B-X
practical	B-X
nephrology	B-X
<EOS>	B-X
The	B-X
principal	B-X
distinction	B-X
of	B-X
the	B-X
method	B-X
is	B-X
standardization	B-X
by	B-X
the	B-X
lymphocyte	B-X
count	B-X
in	B-X
a	B-X
sample	B-X
(	B-X
1	B-X
mln	B-X
)	B-X
and	B-X
the	B-X
labeled	B-X
hormone	B-X
concentration	B-X
<EOS>	B-X
Dynamic	B-X
studies	B-X
have	B-X
not	B-X
shown	B-X
any	B-X
statistically	B-X
significant	B-X
changes	B-X
in	B-X
the	B-X
specific	B-X
binding	B-X
values	B-X

Examinations	O
of	O
70	O
children	O
aged	O
4	O
to	O
15	O
suffering	O
from	O
the	O
nephrotic	O
form	O
of	O
glomerulonephritis	O
have	O
made	O
it	O
possible	O
to	O
distinguish	O
two	O
groups	O
of	O
patients	O
:	O
with	O
relatively	O
high	O
values	O
of	O
specific	O
binding	O
X	O
=	O
6820.1	O
+/-	O
530.0	O
(	O
n	O
=	O
30	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
2.04	O
)	O
,	O
this	O
corresponding	O
to	O
a	O
clinical	O
form	O
of	O
hormone	B-protein
-sensitive	O
glomerulonephritis	O
,	O
and	O
with	O
relatively	O
low	O
values	O
of	O
specific	O
binding	O
X	O
=	O
1815.2	O
+/-	O
302.8	O
(	O
n	O
=	O
40	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
1.96	O
)	O
,	O
that	O
corresponds	O
to	O
hormone	B-protein
-resistant	O
glomerulonephritis	O
.	O
<EOS>	B-X
Examinations	B-X
of	B-X
70	B-X
children	B-X
aged	B-X
4	B-X
to	B-X
15	B-X
suffering	B-X
from	B-X
the	B-X
nephrotic	B-X
form	B-X
of	B-X
glomerulonephritis	B-X
have	B-X
made	B-X
it	B-X
possible	B-X
to	B-X
distinguish	B-X
two	B-X
groups	B-X
of	B-X
patients	B-X
:	B-X
with	B-X
relatively	B-X
high	B-X
values	B-X
of	B-X
specific	B-X
binding	B-X
X	B-X
=	B-X
6820	B-X
<EOS>	B-X
04	B-X
)	B-X
,	B-X
this	B-X
corresponding	B-X
to	B-X
a	B-X
clinical	B-X
form	B-X
of	B-X
hormone	B-X
-	B-X
sensitive	B-X
glomerulonephritis	B-X
,	B-X
and	B-X
with	B-X
relatively	B-X
low	B-X
values	B-X
of	B-X
specific	B-X
binding	B-X
X	B-X
=	B-X
1815	B-X
<EOS>	B-X
These	B-X
results	B-X
permit	B-X
regarding	B-X
the	B-X
specific	B-X
binding	B-X
value	B-X
as	B-X
a	B-X
prognostic	B-X
criterion	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
corticosteroid	B-X
therapy	B-X
;	B-X
this	B-X
allows	B-X
a	B-X
wide	B-X
employment	B-X
of	B-X
the	B-X
described	B-X
method	B-X
in	B-X
practical	B-X
nephrology	B-X
<EOS>	B-X
The	B-X
principal	B-X
distinction	B-X
of	B-X
the	B-X
method	B-X
is	B-X
standardization	B-X
by	B-X
the	B-X
lymphocyte	B-X
count	B-X
in	B-X
a	B-X
sample	B-X
(	B-X
1	B-X
mln	B-X
)	B-X
and	B-X
the	B-X
labeled	B-X
hormone	B-X
concentration	B-X

Dynamic	O
studies	O
have	O
not	O
shown	O
any	O
statistically	O
significant	O
changes	O
in	O
the	O
specific	O
binding	O
values	O
.	O
<EOS>	B-X
Significant	B-X
directional	B-X
asymmetry	B-X
is	B-X
caused	B-X
by	B-X
the	B-X
legs	B-X
bending	B-X
backward	B-X
<EOS>	B-X
Chaotic	B-X
attractors	B-X
can	B-X
undergo	B-X
sudden	B-X
and	B-X
qualitative	B-X
changes	B-X
as	B-X
a	B-X
parameter	B-X
is	B-X
varied	B-X
<EOS>	B-X
Flocking	B-X
of	B-X
two	B-X
unfriendly	B-X
species	B-X
:	B-X
The	B-X
two	B-X
-	B-X
species	B-X
Vicsek	B-X
model	B-X
.	B-X
<EOS>	B-X
Chaotic	B-X
saddles	B-X
and	B-X
interior	B-X
crises	B-X
in	B-X
a	B-X
dissipative	B-X
nontwist	B-X
system	B-X
.	B-X

These	O
results	O
permit	O
regarding	O
the	O
specific	O
binding	O
value	O
as	O
a	O
prognostic	O
criterion	O
in	O
the	O
assessment	O
of	O
corticosteroid	B-protein
therapy	O
;	O
this	O
allows	O
a	O
wide	O
employment	O
of	O
the	O
described	O
method	O
in	O
practical	O
nephrology	O
.	O
<EOS>	B-X
These	B-X
results	B-X
permit	B-X
regarding	B-X
the	B-X
specific	B-X
binding	B-X
value	B-X
as	B-X
a	B-X
prognostic	B-X
criterion	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
corticosteroid	B-X
therapy	B-X
;	B-X
this	B-X
allows	B-X
a	B-X
wide	B-X
employment	B-X
of	B-X
the	B-X
described	B-X
method	B-X
in	B-X
practical	B-X
nephrology	B-X
<EOS>	B-X
The	B-X
principal	B-X
distinction	B-X
of	B-X
the	B-X
method	B-X
is	B-X
standardization	B-X
by	B-X
the	B-X
lymphocyte	B-X
count	B-X
in	B-X
a	B-X
sample	B-X
(	B-X
1	B-X
mln	B-X
)	B-X
and	B-X
the	B-X
labeled	B-X
hormone	B-X
concentration	B-X
<EOS>	B-X
The	B-X
modification	B-X
saves	B-X
time	B-X
and	B-X
money	B-X
,	B-X
limits	B-X
the	B-X
range	B-X
of	B-X
the	B-X
data	B-X
variations	B-X
,	B-X
and	B-X
makes	B-X
use	B-X
of	B-X
a	B-X
lesser	B-X
volume	B-X
of	B-X
blood	B-X
<EOS>	B-X
04	B-X
)	B-X
,	B-X
this	B-X
corresponding	B-X
to	B-X
a	B-X
clinical	B-X
form	B-X
of	B-X
hormone	B-X
-	B-X
sensitive	B-X
glomerulonephritis	B-X
,	B-X
and	B-X
with	B-X
relatively	B-X
low	B-X
values	B-X
of	B-X
specific	B-X
binding	B-X
X	B-X
=	B-X
1815	B-X

Octamer-binding	B-protein
proteins	I-protein
from	O
B	B-cell_line
or	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
stimulate	O
transcription	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
in	O
vitro	O
.	O
<EOS>	B-X
Octamer	B-X
-	B-X
binding	B-X
proteins	B-X
from	B-X
B	B-X
or	B-X
HeLa	B-X
cells	B-X
stimulate	B-X
transcription	B-X
of	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
promoter	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Cell	B-X
type	B-X
-	B-X
specificity	B-X
elements	B-X
of	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
gene	B-X
enhancer	B-X
.	B-X
<EOS>	B-X
The	B-X
ubiquitous	B-X
octamer	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
is	B-X
sufficient	B-X
for	B-X
transcription	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
<EOS>	B-X
Identification	B-X
of	B-X
novel	B-X
ubiquitous	B-X
and	B-X
cell	B-X
type	B-X
-	B-X
specific	B-X
factors	B-X
that	B-X
specifically	B-X
recognize	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
and	B-X
kappa	B-X
light	B-X
chain	B-X
promoters	B-X
.	B-X

The	O
B-cell	B-cell_type
-type	O
specificity	O
of	O
the	O
immunoglobulin	B-protein
(	O
Ig	B-protein
)	O
heavy-chain	O
and	O
light-chain	O
promoters	O
is	O
mediated	O
by	O
an	O
octanucleotide	B-DNA
(	I-DNA
OCTA	I-DNA
)	I-DNA
element	I-DNA
,	O
ATGCAAAT	O
,	O
that	O
is	O
also	O
a	O
functional	O
component	O
of	O
other	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
promoters	I-DNA
,	O
such	O
as	O
snRNA	O
and	O
histone	O
H2B	O
promoters	O
.	O
<EOS>	B-X
The	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
type	B-X
specificity	B-X
of	B-X
the	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
heavy	B-X
-	B-X
chain	B-X
and	B-X
light	B-X
-	B-X
chain	B-X
promoters	B-X
is	B-X
mediated	B-X
by	B-X
an	B-X
octanucleotide	B-X
(	B-X
OCTA	B-X
)	B-X
element	B-X
,	B-X
ATGCAAAT	B-X
,	B-X
that	B-X
is	B-X
also	B-X
a	B-X
functional	B-X
component	B-X
of	B-X
other	B-X
RNA	B-X
polymerase	B-X
II	B-X
promoters	B-X
,	B-X
such	B-X
as	B-X
snRNA	B-X
and	B-X
histone	B-X
H2B	B-X
promoters	B-X
<EOS>	B-X
Because	B-X
NF	B-X
-	B-X
A1	B-X
can	B-X
stimulate	B-X
Ig	B-X
transcription	B-X
,	B-X
the	B-X
inability	B-X
of	B-X
this	B-X
factor	B-X
to	B-X
activate	B-X
in	B-X
vivo	B-X
the	B-X
Ig	B-X
promoter	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
as	B-X
the	B-X
snRNA	B-X
promoters	B-X
probably	B-X
reflects	B-X
a	B-X
difference	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
OCTA	B-X
element	B-X
in	B-X
these	B-X
two	B-X
types	B-X
of	B-X
promoters	B-X
<EOS>	B-X
Surprisingly	B-X
,	B-X
addition	B-X
of	B-X
either	B-X
affinity	B-X
-	B-X
enriched	B-X
NF	B-X
-	B-X
A2	B-X
or	B-X
NF	B-X
-	B-X
A1	B-X
to	B-X
either	B-X
a	B-X
HeLa	B-X
extract	B-X
or	B-X
a	B-X
partially	B-X
purified	B-X
reaction	B-X
system	B-X
specifically	B-X
stimulates	B-X
the	B-X
Ig	B-X
promoter	B-X
<EOS>	B-X
Octamer	B-X
-	B-X
binding	B-X
proteins	B-X
from	B-X
B	B-X
or	B-X
HeLa	B-X
cells	B-X
stimulate	B-X
transcription	B-X
of	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
promoter	B-X
in	B-X
vitro	B-X
.	B-X

Two	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
the	O
OCTA	B-DNA
element	I-DNA
have	O
been	O
identified	O
.	O

NF-A1	B-protein
is	O
present	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
whereas	O
the	O
presence	O
of	O
NF-A2	B-protein
is	O
essentially	O
confined	O
to	O
B	B-cell_type
cells	I-cell_type
,	O
leading	O
to	O
the	O
hypothesis	O
that	O
NF-A2	B-protein
activates	O
cell-type-specific	O
transcription	O
of	O
the	O
Ig	B-DNA
promoter	I-DNA
and	O
NF-A1	B-protein
mediates	O
the	O
other	O
responses	O
of	O
the	O
OCTA	B-DNA
element	I-DNA
.	O

Extracts	O
of	O
the	O
B-cell	B-cell_line
line	I-cell_line
,	O
BJA-B	B-cell_line
,	O
contain	O
high	O
levels	O
of	O
NF-A2	B-protein
and	O
specifically	O
transcribe	O
Ig	B-DNA
promoters	I-DNA
.	O
<EOS>	B-X
Extracts	B-X
of	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
line	B-X
,	B-X
BJA	B-X
-	B-X
B	B-X
,	B-X
contain	B-X
high	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
A2	B-X
and	B-X
specifically	B-X
transcribe	B-X
Ig	B-X
promoters	B-X
<EOS>	B-X
Surprisingly	B-X
,	B-X
addition	B-X
of	B-X
either	B-X
affinity	B-X
-	B-X
enriched	B-X
NF	B-X
-	B-X
A2	B-X
or	B-X
NF	B-X
-	B-X
A1	B-X
to	B-X
either	B-X
a	B-X
HeLa	B-X
extract	B-X
or	B-X
a	B-X
partially	B-X
purified	B-X
reaction	B-X
system	B-X
specifically	B-X
stimulates	B-X
the	B-X
Ig	B-X
promoter	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
extracts	B-X
from	B-X
HeLa	B-X
cells	B-X
transcribed	B-X
the	B-X
Ig	B-X
promoter	B-X
poorly	B-X
<EOS>	B-X
NF	B-X
-	B-X
A1	B-X
is	B-X
present	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
,	B-X
whereas	B-X
the	B-X
presence	B-X
of	B-X
NF	B-X
-	B-X
A2	B-X
is	B-X
essentially	B-X
confined	B-X
to	B-X
B	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
hypothesis	B-X
that	B-X
NF	B-X
-	B-X
A2	B-X
activates	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
transcription	B-X
of	B-X
the	B-X
Ig	B-X
promoter	B-X
and	B-X
NF	B-X
-	B-X
A1	B-X
mediates	B-X
the	B-X
other	B-X
responses	B-X
of	B-X
the	B-X
OCTA	B-X
element	B-X

In	O
contrast	O
,	O
extracts	O
from	O
HeLa	B-cell_line
cells	I-cell_line
transcribed	O
the	O
Ig	B-DNA
promoter	I-DNA
poorly	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
extracts	B-X
from	B-X
HeLa	B-X
cells	B-X
transcribed	B-X
the	B-X
Ig	B-X
promoter	B-X
poorly	B-X
<EOS>	B-X
Octamer	B-X
-	B-X
binding	B-X
proteins	B-X
from	B-X
B	B-X
or	B-X
HeLa	B-X
cells	B-X
stimulate	B-X
transcription	B-X
of	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
promoter	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Extracts	B-X
of	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
line	B-X
,	B-X
BJA	B-X
-	B-X
B	B-X
,	B-X
contain	B-X
high	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
A2	B-X
and	B-X
specifically	B-X
transcribe	B-X
Ig	B-X
promoters	B-X
<EOS>	B-X
Two	B-X
nuclear	B-X
proteins	B-X
that	B-X
bind	B-X
specifically	B-X
and	B-X
with	B-X
high	B-X
affinity	B-X
to	B-X
the	B-X
OCTA	B-X
element	B-X
have	B-X
been	B-X
identified	B-X

Surprisingly	O
,	O
addition	O
of	O
either	O
affinity-enriched	O
NF-A2	O
or	O
NF-A1	O
to	O
either	O
a	O
HeLa	O
extract	O
or	O
a	O
partially	O
purified	O
reaction	O
system	O
specifically	O
stimulates	O
the	O
Ig	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Surprisingly	B-X
,	B-X
addition	B-X
of	B-X
either	B-X
affinity	B-X
-	B-X
enriched	B-X
NF	B-X
-	B-X
A2	B-X
or	B-X
NF	B-X
-	B-X
A1	B-X
to	B-X
either	B-X
a	B-X
HeLa	B-X
extract	B-X
or	B-X
a	B-X
partially	B-X
purified	B-X
reaction	B-X
system	B-X
specifically	B-X
stimulates	B-X
the	B-X
Ig	B-X
promoter	B-X
<EOS>	B-X
Extracts	B-X
of	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
line	B-X
,	B-X
BJA	B-X
-	B-X
B	B-X
,	B-X
contain	B-X
high	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
A2	B-X
and	B-X
specifically	B-X
transcribe	B-X
Ig	B-X
promoters	B-X
<EOS>	B-X
NF	B-X
-	B-X
A1	B-X
is	B-X
present	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
,	B-X
whereas	B-X
the	B-X
presence	B-X
of	B-X
NF	B-X
-	B-X
A2	B-X
is	B-X
essentially	B-X
confined	B-X
to	B-X
B	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
hypothesis	B-X
that	B-X
NF	B-X
-	B-X
A2	B-X
activates	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
transcription	B-X
of	B-X
the	B-X
Ig	B-X
promoter	B-X
and	B-X
NF	B-X
-	B-X
A1	B-X
mediates	B-X
the	B-X
other	B-X
responses	B-X
of	B-X
the	B-X
OCTA	B-X
element	B-X
<EOS>	B-X
Because	B-X
NF	B-X
-	B-X
A1	B-X
can	B-X
stimulate	B-X
Ig	B-X
transcription	B-X
,	B-X
the	B-X
inability	B-X
of	B-X
this	B-X
factor	B-X
to	B-X
activate	B-X
in	B-X
vivo	B-X
the	B-X
Ig	B-X
promoter	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
as	B-X
the	B-X
snRNA	B-X
promoters	B-X
probably	B-X
reflects	B-X
a	B-X
difference	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
OCTA	B-X
element	B-X
in	B-X
these	B-X
two	B-X
types	B-X
of	B-X
promoters	B-X

This	O
suggests	O
that	O
the	O
constitutive	O
OCTA-binding	B-protein
factor	I-protein
NF-A1	I-protein
can	O
activate	O
transcription	O
of	O
the	O
Ig	B-DNA
promoter	I-DNA
and	O
that	O
B-cell	B-cell_type
-specific	O
transcription	O
of	O
this	O
promoter	O
,	O
at	O
least	O
in	O
vitro	O
,	O
is	O
partially	O
due	O
to	O
a	O
quantitative	O
difference	O
in	O
the	O
amount	O
of	O
OCTA-binding	B-protein
protein	I-protein
.	O
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
constitutive	B-X
OCTA	B-X
-	B-X
binding	B-X
factor	B-X
NF	B-X
-	B-X
A1	B-X
can	B-X
activate	B-X
transcription	B-X
of	B-X
the	B-X
Ig	B-X
promoter	B-X
and	B-X
that	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
transcription	B-X
of	B-X
this	B-X
promoter	B-X
,	B-X
at	B-X
least	B-X
in	B-X
vitro	B-X
,	B-X
is	B-X
partially	B-X
due	B-X
to	B-X
a	B-X
quantitative	B-X
difference	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
OCTA	B-X
-	B-X
binding	B-X
protein	B-X
<EOS>	B-X
Because	B-X
NF	B-X
-	B-X
A1	B-X
can	B-X
stimulate	B-X
Ig	B-X
transcription	B-X
,	B-X
the	B-X
inability	B-X
of	B-X
this	B-X
factor	B-X
to	B-X
activate	B-X
in	B-X
vivo	B-X
the	B-X
Ig	B-X
promoter	B-X
to	B-X
the	B-X
same	B-X
degree	B-X
as	B-X
the	B-X
snRNA	B-X
promoters	B-X
probably	B-X
reflects	B-X
a	B-X
difference	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
OCTA	B-X
element	B-X
in	B-X
these	B-X
two	B-X
types	B-X
of	B-X
promoters	B-X
<EOS>	B-X
Octamer	B-X
-	B-X
binding	B-X
proteins	B-X
from	B-X
B	B-X
or	B-X
HeLa	B-X
cells	B-X
stimulate	B-X
transcription	B-X
of	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
promoter	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Surprisingly	B-X
,	B-X
addition	B-X
of	B-X
either	B-X
affinity	B-X
-	B-X
enriched	B-X
NF	B-X
-	B-X
A2	B-X
or	B-X
NF	B-X
-	B-X
A1	B-X
to	B-X
either	B-X
a	B-X
HeLa	B-X
extract	B-X
or	B-X
a	B-X
partially	B-X
purified	B-X
reaction	B-X
system	B-X
specifically	B-X
stimulates	B-X
the	B-X
Ig	B-X
promoter	B-X

Because	O
NF-A1	B-protein
can	O
stimulate	O
Ig	B-protein
transcription	O
,	O
the	O
inability	O
of	O
this	O
factor	O
to	O
activate	O
in	O
vivo	O
the	O
Ig	B-DNA
promoter	I-DNA
to	O
the	O
same	O
degree	O
as	O
the	O
snRNA	B-DNA
promoters	I-DNA
probably	O
reflects	O
a	O
difference	O
in	O
the	O
context	O
of	O
the	O
OCTA	B-DNA
element	I-DNA
in	O
these	O
two	O
types	O
of	O
promoters	B-DNA
.	O

Identification	O
of	O
a	O
putative	O
regulator	O
of	O
early	B-DNA
T	I-DNA
cell	I-DNA
activation	I-DNA
genes	I-DNA
.	O

Molecules	O
involved	O
in	O
the	O
antigen	O
receptor-dependent	O
regulation	O
of	O
early	B-DNA
T	I-DNA
cell	I-DNA
activation	I-DNA
genes	I-DNA
were	O
investigated	O
with	O
the	O
use	O
of	O
functional	O
sequences	O
of	O
the	O
T	B-protein
cell	I-protein
activation-specific	I-protein
enhancer	I-protein
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

One	O
of	O
these	O
sequences	O
forms	O
a	O
protein	O
complex	O
,	O
NFAT-1	B-protein
,	O
specifically	O
with	O
nuclear	O
extracts	O
of	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
One	B-X
of	B-X
these	B-X
sequences	B-X
forms	B-X
a	B-X
protein	B-X
complex	B-X
,	B-X
NFAT	B-X
-	B-X
1	B-X
,	B-X
specifically	B-X
with	B-X
nuclear	B-X
extracts	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
putative	B-X
regulator	B-X
of	B-X
early	B-X
T	B-X
cell	B-X
activation	B-X
genes	B-X
.	B-X
<EOS>	B-X
The	B-X
binding	B-X
site	B-X
for	B-X
this	B-X
complex	B-X
activated	B-X
a	B-X
linked	B-X
promoter	B-X
after	B-X
transfection	B-X
into	B-X
antigen	B-X
receptor	B-X
-	B-X
activated	B-X
T	B-X
cells	B-X
but	B-X
not	B-X
other	B-X
cell	B-X
types	B-X
<EOS>	B-X
NFAT	B-X
-	B-X
1	B-X
,	B-X
or	B-X
a	B-X
very	B-X
similar	B-X
protein	B-X
,	B-X
bound	B-X
functional	B-X
sequences	B-X
of	B-X
the	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
;	B-X
the	B-X
LTR	B-X
of	B-X
this	B-X
virus	B-X
is	B-X
known	B-X
to	B-X
be	B-X
stimulated	B-X
during	B-X
early	B-X
T	B-X
cell	B-X
activation	B-X

This	O
complex	O
appeared	O
10	O
to	O
25	O
minutes	O
before	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O
<EOS>	B-X
This	B-X
complex	B-X
appeared	B-X
10	B-X
to	B-X
25	B-X
minutes	B-X
before	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
<EOS>	B-X
The	B-X
binding	B-X
site	B-X
for	B-X
this	B-X
complex	B-X
activated	B-X
a	B-X
linked	B-X
promoter	B-X
after	B-X
transfection	B-X
into	B-X
antigen	B-X
receptor	B-X
-	B-X
activated	B-X
T	B-X
cells	B-X
but	B-X
not	B-X
other	B-X
cell	B-X
types	B-X
<EOS>	B-X
Studies	B-X
with	B-X
inhibitors	B-X
of	B-X
protein	B-X
synthesis	B-X
indicated	B-X
that	B-X
the	B-X
time	B-X
of	B-X
synthesis	B-X
of	B-X
the	B-X
activator	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
corresponds	B-X
to	B-X
the	B-X
time	B-X
of	B-X
appearance	B-X
of	B-X
NFAT	B-X
-	B-X
1	B-X
<EOS>	B-X
These	B-X
characteristics	B-X
suggest	B-X
that	B-X
NFAT	B-X
-	B-X
1	B-X
transmits	B-X
signals	B-X
initiated	B-X
at	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X

Studies	O
with	O
inhibitors	O
of	O
protein	O
synthesis	O
indicated	O
that	O
the	O
time	O
of	O
synthesis	O
of	O
the	O
activator	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
corresponds	O
to	O
the	O
time	O
of	O
appearance	O
of	O
NFAT-1	B-protein
.	O

NFAT-1	B-protein
,	O
or	O
a	O
very	O
similar	O
protein	O
,	O
bound	O
functional	O
sequences	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
;	O
the	O
LTR	B-DNA
of	O
this	O
virus	O
is	O
known	O
to	O
be	O
stimulated	O
during	O
early	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O
<EOS>	B-X
We	B-X
also	B-X
identified	B-X
promoter	B-X
and	B-X
enhancer	B-X
elements	B-X
of	B-X
the	B-X
human	B-X
ITGAE	B-X
gene	B-X
,	B-X
encoding	B-X
CD103	B-X
,	B-X
involved	B-X
in	B-X
its	B-X
induction	B-X
by	B-X
these	B-X
transcriptional	B-X
regulators	B-X
<EOS>	B-X
NFAT	B-X
compose	B-X
a	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
turned	B-X
on	B-X
during	B-X
T	B-X
cell	B-X
activation	B-X
<EOS>	B-X
NFAT	B-X
-	B-X
1	B-X
hyper	B-X
-	B-X
activation	B-X
by	B-X
methionine	B-X
enkephalin	B-X
(	B-X
MENK	B-X
)	B-X
significantly	B-X
induces	B-X
cell	B-X
apoptosis	B-X
of	B-X
rats	B-X
C6	B-X
glioma	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Compared	B-X
with	B-X
control	B-X
mice	B-X
,	B-X
VAD	B-X
mice	B-X
displayed	B-X
excessive	B-X
inflammation	B-X
and	B-X
more	B-X
severe	B-X
liver	B-X
pathology	B-X
,	B-X
with	B-X
increased	B-X
death	B-X
during	B-X
persistent	B-X
infection	B-X

The	O
binding	B-DNA
site	I-DNA
for	O
this	O
complex	O
activated	O
a	O
linked	O
promoter	O
after	O
transfection	O
into	O
antigen	B-cell_type
receptor-activated	I-cell_type
T	I-cell_type
cells	I-cell_type
but	O
not	O
other	O
cell	O
types	O
.	O

These	O
characteristics	O
suggest	O
that	O
NFAT-1	B-protein
transmits	O
signals	O
initiated	O
at	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O

Characterization	O
of	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	O
human	B-cell_line
IM-9	I-cell_line
lymphocytes	I-cell_line
.	O
<EOS>	B-X
Characterization	B-X
of	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Although	B-X
putatively	B-X
identified	B-X
more	B-X
than	B-X
10	B-X
years	B-X
ago	B-X
,	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
in	B-X
human	B-X
tissues	B-X
remain	B-X
poorly	B-X
characterized	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
T3	B-X
binding	B-X
sites	B-X
present	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocyte	B-X
nuclei	B-X
and	B-X
extracts	B-X
thereof	B-X
are	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
<EOS>	B-X
As	B-X
a	B-X
first	B-X
step	B-X
towards	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
thyroid	B-X
hormone	B-X
action	B-X
in	B-X
man	B-X
we	B-X
have	B-X
characterized	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
nuclei	B-X
of	B-X
the	B-X
human	B-X
lymphoblastoid	B-X
line	B-X
,	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X

Although	O
putatively	O
identified	O
more	O
than	O
10	O
years	O
ago	O
,	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
in	O
human	O
tissues	O
remain	O
poorly	O
characterized	O
.	O
<EOS>	B-X
Although	B-X
putatively	B-X
identified	B-X
more	B-X
than	B-X
10	B-X
years	B-X
ago	B-X
,	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
in	B-X
human	B-X
tissues	B-X
remain	B-X
poorly	B-X
characterized	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
As	B-X
a	B-X
first	B-X
step	B-X
towards	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
thyroid	B-X
hormone	B-X
action	B-X
in	B-X
man	B-X
we	B-X
have	B-X
characterized	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
nuclei	B-X
of	B-X
the	B-X
human	B-X
lymphoblastoid	B-X
line	B-X
,	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X
<EOS>	B-X
These	B-X
cells	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
to	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
human	B-X
T3	B-X
receptors	B-X

As	O
a	O
first	O
step	O
towards	O
understanding	O
the	O
mechanism	O
of	O
thyroid	O
hormone	O
action	O
in	O
man	O
we	O
have	O
characterized	O
T3	B-protein
binding	I-protein
sites	I-protein
in	O
nuclei	O
of	O
the	O
human	B-cell_line
lymphoblastoid	I-cell_line
line	I-cell_line
,	O
IM-9	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
As	B-X
a	B-X
first	B-X
step	B-X
towards	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
thyroid	B-X
hormone	B-X
action	B-X
in	B-X
man	B-X
we	B-X
have	B-X
characterized	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
nuclei	B-X
of	B-X
the	B-X
human	B-X
lymphoblastoid	B-X
line	B-X
,	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X
<EOS>	B-X
The	B-X
same	B-X
assay	B-X
system	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
hierarchy	B-X
of	B-X
affinities	B-X
for	B-X
a	B-X
range	B-X
of	B-X
natural	B-X
and	B-X
synthetic	B-X
analogues	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
T3	B-X
binding	B-X
sites	B-X
present	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocyte	B-X
nuclei	B-X
and	B-X
extracts	B-X
thereof	B-X
are	B-X
thyroid	B-X
hormone	B-X
receptors	B-X

In	O
whole	O
cell	O
experiments	O
at	O
37	O
degrees	O
C	O
,	O
nuclear	O
binding	O
of	O
[	B-protein
125I	I-protein
]	I-protein
T3	I-protein
was	O
saturable	O
(	O
Kd	O
34	O
+/-	O
6	O
pmol/l	O
)	O
and	O
of	O
finite	O
capacity	O
(	O
approximately	O
equal	O
to	O
350	O
sites/cell	O
)	O
.	O
<EOS>	B-X
In	B-X
whole	B-X
cell	B-X
experiments	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
,	B-X
nuclear	B-X
binding	B-X
of	B-X
[	B-X
125I	B-X
]	B-X
T3	B-X
was	B-X
saturable	B-X
(	B-X
Kd	B-X
34	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
6	B-X
pmol	B-X
/	B-X
l	B-X
)	B-X
and	B-X
of	B-X
finite	B-X
capacity	B-X
(	B-X
approximately	B-X
equal	B-X
to	B-X
350	B-X
sites	B-X
/	B-X
cell	B-X
)	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
T3	B-X
binding	B-X
sites	B-X
present	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocyte	B-X
nuclei	B-X
and	B-X
extracts	B-X
thereof	B-X
are	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
<EOS>	B-X
Separation	B-X
of	B-X
bound	B-X
from	B-X
free	B-X
[	B-X
125I	B-X
]	B-X
T3	B-X
in	B-X
the	B-X
extracts	B-X
was	B-X
achieved	B-X
using	B-X
the	B-X
calcium	B-X
phosphate	B-X
matrix	B-X
,	B-X
hydroxyapatite	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
0	B-X
<EOS>	B-X
Under	B-X
these	B-X
conditions	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
nuclear	B-X
extracts	B-X
were	B-X
present	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
22	B-X

The	O
binding	B-protein
sites	I-protein
were	O
extracted	O
from	O
a	O
nuclear	O
pellet	O
by	O
treatment	O
with	O
0.4	O
mol/l	O
KCl	O
and	O
sonication	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
sites	B-X
were	B-X
extracted	B-X
from	B-X
a	B-X
nuclear	B-X
pellet	B-X
by	B-X
treatment	B-X
with	B-X
0	B-X
<EOS>	B-X
The	B-X
same	B-X
assay	B-X
system	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
hierarchy	B-X
of	B-X
affinities	B-X
for	B-X
a	B-X
range	B-X
of	B-X
natural	B-X
and	B-X
synthetic	B-X
analogues	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
T3	B-X
binding	B-X
sites	B-X
present	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocyte	B-X
nuclei	B-X
and	B-X
extracts	B-X
thereof	B-X
are	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
<EOS>	B-X
Separation	B-X
of	B-X
bound	B-X
from	B-X
free	B-X
[	B-X
125I	B-X
]	B-X
T3	B-X
in	B-X
the	B-X
extracts	B-X
was	B-X
achieved	B-X
using	B-X
the	B-X
calcium	B-X
phosphate	B-X
matrix	B-X
,	B-X
hydroxyapatite	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
0	B-X

Separation	O
of	O
bound	O
from	O
free	O
[	B-protein
125I	I-protein
]	I-protein
T3	I-protein
in	O
the	O
extracts	O
was	O
achieved	O
using	O
the	O
calcium	O
phosphate	O
matrix	O
,	O
hydroxyapatite	O
at	O
a	O
concentration	O
of	O
0.3	O
ml	O
of	O
a	O
150	O
g/l	O
slurry	O
.	O

Rectilinear	O
Scatchard	O
plots	O
were	O
obtained	O
only	O
when	O
the	O
hydroxyapatite	O
was	O
washed	O
with	O
a	O
buffer	O
containing	O
0.5	O
%	O
Triton	O
X-100	O
.	O
<EOS>	B-X
Rectilinear	B-X
Scatchard	B-X
plots	B-X
were	B-X
obtained	B-X
only	B-X
when	B-X
the	B-X
hydroxyapatite	B-X
was	B-X
washed	B-X
with	B-X
a	B-X
buffer	B-X
containing	B-X
0	B-X
<EOS>	B-X
Under	B-X
these	B-X
conditions	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
nuclear	B-X
extracts	B-X
were	B-X
present	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
22	B-X
<EOS>	B-X
The	B-X
binding	B-X
sites	B-X
were	B-X
extracted	B-X
from	B-X
a	B-X
nuclear	B-X
pellet	B-X
by	B-X
treatment	B-X
with	B-X
0	B-X
<EOS>	B-X
As	B-X
a	B-X
first	B-X
step	B-X
towards	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
thyroid	B-X
hormone	B-X
action	B-X
in	B-X
man	B-X
we	B-X
have	B-X
characterized	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
nuclei	B-X
of	B-X
the	B-X
human	B-X
lymphoblastoid	B-X
line	B-X
,	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X

Under	O
these	O
conditions	O
T3	B-protein
binding	I-protein
sites	I-protein
in	O
the	O
nuclear	O
extracts	O
were	O
present	O
at	O
a	O
concentration	O
of	O
22.4	O
+/-	O
8.6	O
fmol/mg	O
protein	O
and	O
showed	O
an	O
affinity	O
of	O
(	O
Kd	O
,	O
room	O
temperature	O
)	O
140	O
+/-	O
10	O
pmol/l	O
.	O

The	O
same	O
assay	O
system	O
was	O
used	O
to	O
determine	O
the	O
hierarchy	O
of	O
affinities	O
for	O
a	O
range	O
of	O
natural	O
and	O
synthetic	O
analogues	O
.	O
<EOS>	B-X
The	B-X
same	B-X
assay	B-X
system	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
hierarchy	B-X
of	B-X
affinities	B-X
for	B-X
a	B-X
range	B-X
of	B-X
natural	B-X
and	B-X
synthetic	B-X
analogues	B-X
<EOS>	B-X
These	B-X
cells	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
to	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
human	B-X
T3	B-X
receptors	B-X
<EOS>	B-X
The	B-X
binding	B-X
sites	B-X
were	B-X
extracted	B-X
from	B-X
a	B-X
nuclear	B-X
pellet	B-X
by	B-X
treatment	B-X
with	B-X
0	B-X
<EOS>	B-X
As	B-X
a	B-X
first	B-X
step	B-X
towards	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
thyroid	B-X
hormone	B-X
action	B-X
in	B-X
man	B-X
we	B-X
have	B-X
characterized	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
nuclei	B-X
of	B-X
the	B-X
human	B-X
lymphoblastoid	B-X
line	B-X
,	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X

Calling	O
T3	O
100	O
,	O
the	O
order	O
of	O
potencies	O
observed	O
was	O
:	O
Triac	O
,	O
500	O
;	O
3	O
,	O
5-diiodo-3'-isopropylthyronine	O
,	O
89	O
;	O
T4	O
,	O
32	O
;	O
3	O
,	O
5-dimethyl-3'isopropylthyronine	O
2	O
;	O
3	O
,	O
5-T2	O
,	O
0.7	O
,	O
rT3	O
,	O
0.4	O
;	O
3'5'-T2	O
,	O
less	O
than	O
0.01	O
.	O
<EOS>	B-X
Calling	B-X
T3	B-X
100	B-X
,	B-X
the	B-X
order	B-X
of	B-X
potencies	B-X
observed	B-X
was	B-X
:	B-X
Triac	B-X
,	B-X
500	B-X
;	B-X
3,5	B-X
-	B-X
diiodo	B-X
-	B-X
3'	B-X
-	B-X
isopropylthyronine	B-X
,	B-X
89	B-X
;	B-X
T4	B-X
,	B-X
32	B-X
;	B-X
3,5	B-X
-	B-X
dimethyl	B-X
-	B-X
3'isopropylthyronine	B-X
2	B-X
;	B-X
3,5	B-X
-	B-X
T2	B-X
,	B-X
0	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
T3	B-X
binding	B-X
sites	B-X
present	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocyte	B-X
nuclei	B-X
and	B-X
extracts	B-X
thereof	B-X
are	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
<EOS>	B-X
The	B-X
same	B-X
assay	B-X
system	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
hierarchy	B-X
of	B-X
affinities	B-X
for	B-X
a	B-X
range	B-X
of	B-X
natural	B-X
and	B-X
synthetic	B-X
analogues	B-X
<EOS>	B-X
As	B-X
a	B-X
first	B-X
step	B-X
towards	B-X
understanding	B-X
the	B-X
mechanism	B-X
of	B-X
thyroid	B-X
hormone	B-X
action	B-X
in	B-X
man	B-X
we	B-X
have	B-X
characterized	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
nuclei	B-X
of	B-X
the	B-X
human	B-X
lymphoblastoid	B-X
line	B-X
,	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X

These	O
results	O
suggest	O
that	O
the	O
T3	B-protein
binding	I-protein
sites	I-protein
present	O
in	O
human	B-cell_line
IM-9	I-cell_line
lymphocyte	I-cell_line
nuclei	O
and	O
extracts	O
thereof	O
are	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
T3	B-X
binding	B-X
sites	B-X
present	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocyte	B-X
nuclei	B-X
and	B-X
extracts	B-X
thereof	B-X
are	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
<EOS>	B-X
Under	B-X
these	B-X
conditions	B-X
T3	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
nuclear	B-X
extracts	B-X
were	B-X
present	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
22	B-X
<EOS>	B-X
These	B-X
cells	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
to	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
human	B-X
T3	B-X
receptors	B-X
<EOS>	B-X
The	B-X
binding	B-X
sites	B-X
were	B-X
extracted	B-X
from	B-X
a	B-X
nuclear	B-X
pellet	B-X
by	B-X
treatment	B-X
with	B-X
0	B-X

These	O
cells	O
may	O
be	O
a	O
useful	O
tool	O
to	O
increase	O
our	O
understanding	O
of	O
human	B-protein
T3	I-protein
receptors	I-protein
<EOS>	B-X
These	B-X
cells	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
to	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
human	B-X
T3	B-X
receptors	B-X
<EOS>	B-X
The	B-X
same	B-X
assay	B-X
system	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
hierarchy	B-X
of	B-X
affinities	B-X
for	B-X
a	B-X
range	B-X
of	B-X
natural	B-X
and	B-X
synthetic	B-X
analogues	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
T3	B-X
binding	B-X
sites	B-X
present	B-X
in	B-X
human	B-X
IM	B-X
-	B-X
9	B-X
lymphocyte	B-X
nuclei	B-X
and	B-X
extracts	B-X
thereof	B-X
are	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
<EOS>	B-X
The	B-X
combination	B-X
of	B-X
FRET	B-X
and	B-X
ChIP	B-X
assays	B-X
is	B-X
a	B-X
powerful	B-X
tool	B-X
useful	B-X
in	B-X
understanding	B-X
ligand	B-X
-	B-X
selective	B-X
dynamic	B-X
VDR	B-X
conformations	B-X
and	B-X
the	B-X
development	B-X
of	B-X
selective	B-X
VDR	B-X
modulators	B-X

Definition	O
of	O
T-cell	B-protein
specific	I-protein
DNA-binding	I-protein
factors	I-protein
that	O
interact	O
with	O
a	O
3'-silencer	B-DNA
in	O
the	O
CD4+	B-DNA
T-cell	I-DNA
gene	I-DNA
Rpt-1	I-DNA
.	O
<EOS>	B-X
Definition	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
specific	B-X
DNA	B-X
-	B-X
binding	B-X
factors	B-X
that	B-X
interact	B-X
with	B-X
a	B-X
3'	B-X
-	B-X
silencer	B-X
in	B-X
the	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
gene	B-X
Rpt	B-X
-	B-X
1	B-X
.	B-X
<EOS>	B-X
We	B-X
discuss	B-X
the	B-X
possibility	B-X
that	B-X
DNA	B-X
-	B-X
binding	B-X
factors	B-X
may	B-X
coregulate	B-X
HIV	B-X
-	B-X
1	B-X
and	B-X
Rpt	B-X
-	B-X
1	B-X
gene	B-X
expression	B-X
through	B-X
a	B-X
common	B-X
transcriptional	B-X
silencer	B-X
element	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
region	B-X
3	B-X
'	B-X
to	B-X
the	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
gene	B-X
Rpt	B-X
-	B-X
1	B-X
(	B-X
encoding	B-X
regulatory	B-X
protein	B-X
T	B-X
-	B-X
lymphocyte	B-X
1	B-X
)	B-X
led	B-X
to	B-X
the	B-X
definition	B-X
of	B-X
a	B-X
silencer	B-X
element	B-X
that	B-X
inhibits	B-X
heterologous	B-X
gene	B-X
expression	B-X
in	B-X
certain	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
lines	B-X
but	B-X
not	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
non	B-X
-	B-X
lymphoid	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Formation	B-X
of	B-X
this	B-X
complex	B-X
was	B-X
selectively	B-X
inhibited	B-X
by	B-X
the	B-X
region	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
containing	B-X
a	B-X
silencer	B-X
element	B-X

Analysis	O
of	O
the	O
region	O
3	O
'	O
to	O
the	O
CD4+	B-DNA
T-cell	I-DNA
gene	I-DNA
Rpt-1	I-DNA
(	O
encoding	O
regulatory	O
protein	O
T-lymphocyte	B-protein
1	I-protein
)	O
led	O
to	O
the	O
definition	O
of	O
a	O
silencer	B-DNA
element	I-DNA
that	O
inhibits	O
heterologous	B-DNA
gene	I-DNA
expression	O
in	O
certain	O
CD4+	B-cell_type
T-cell	I-cell_type
lines	I-cell_type
but	O
not	O
in	O
B-cell	B-cell_type
or	O
non-lymphoid	B-cell_type
cell	I-cell_type
lines	I-cell_type
.	O
<EOS>	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
levels	B-X
of	B-X
organic	B-X
cation	B-X
/	B-X
carnitine	B-X
transporter	B-X
(	B-X
OCTN	B-X
)	B-X
2	B-X
,	B-X
one	B-X
of	B-X
the	B-X
drug	B-X
uptake	B-X
transporters	B-X
expressed	B-X
in	B-X
both	B-X
cell	B-X
lines	B-X
,	B-X
were	B-X
decreased	B-X
only	B-X
in	B-X
Raji	B-X
cells	B-X
<EOS>	B-X
While	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
human	B-X
Müller	B-X
glia	B-X
cell	B-X
line	B-X
MIO	B-X
-	B-X
M1	B-X
revealed	B-X
507	B-X
cell	B-X
surface	B-X
proteins	B-X
in	B-X
total	B-X
,	B-X
with	B-X
18	B-X
proteins	B-X
significantly	B-X
more	B-X
abundant	B-X
after	B-X
stimulation	B-X
(	B-X
ratio	B-X
≥	B-X
2	B-X
)	B-X
,	B-X
the	B-X
surfaceome	B-X
of	B-X
primary	B-X
RMG	B-X
comprised	B-X
1425	B-X
proteins	B-X
,	B-X
among	B-X
them	B-X
79	B-X
proteins	B-X
with	B-X
significantly	B-X
higher	B-X
abundance	B-X
in	B-X
the	B-X
stimulated	B-X
state	B-X
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
recent	B-X
advances	B-X
of	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
factors	B-X
,	B-X
from	B-X
neuroimmune	B-X
to	B-X
inflammatory	B-X
regulators	B-X
,	B-X
shaping	B-X
the	B-X
size	B-X
and	B-X
functional	B-X
properties	B-X
of	B-X
unconventional	B-X
T	B-X
cell	B-X
subsets	B-X
in	B-X
non	B-X
-	B-X
lymphoid	B-X
organs	B-X
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
FPR3	B-X
can	B-X
be	B-X
regarded	B-X
as	B-X
a	B-X
new	B-X
target	B-X
to	B-X
control	B-X
sepsis	B-X
,	B-X
and	B-X
the	B-X
newly	B-X
generated	B-X
Fpr3	B-X
-	B-X
based	B-X
pepducin	B-X
can	B-X
be	B-X
used	B-X
for	B-X
the	B-X
development	B-X
of	B-X
anti	B-X
-	B-X
septic	B-X
agents	B-X

Functional	O
silencer	B-DNA
activity	O
in	O
vivo	O
was	O
associated	O
with	O
the	O
presence	O
of	O
a	O
specific	O
silencer-DNA-protein	B-protein
complex	I-protein
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
T-cell	B-cell_type
extracts	O
.	O
<EOS>	B-X
Functional	B-X
silencer	B-X
activity	B-X
in	B-X
vivo	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
specific	B-X
silencer	B-X
-	B-X
DNA	B-X
-	B-X
protein	B-X
complex	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
with	B-X
T	B-X
-	B-X
cell	B-X
extracts	B-X
<EOS>	B-X
Definition	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
specific	B-X
DNA	B-X
-	B-X
binding	B-X
factors	B-X
that	B-X
interact	B-X
with	B-X
a	B-X
3'	B-X
-	B-X
silencer	B-X
in	B-X
the	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
gene	B-X
Rpt	B-X
-	B-X
1	B-X
.	B-X
<EOS>	B-X
Formation	B-X
of	B-X
this	B-X
complex	B-X
was	B-X
selectively	B-X
inhibited	B-X
by	B-X
the	B-X
region	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
containing	B-X
a	B-X
silencer	B-X
element	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
region	B-X
3	B-X
'	B-X
to	B-X
the	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
gene	B-X
Rpt	B-X
-	B-X
1	B-X
(	B-X
encoding	B-X
regulatory	B-X
protein	B-X
T	B-X
-	B-X
lymphocyte	B-X
1	B-X
)	B-X
led	B-X
to	B-X
the	B-X
definition	B-X
of	B-X
a	B-X
silencer	B-X
element	B-X
that	B-X
inhibits	B-X
heterologous	B-X
gene	B-X
expression	B-X
in	B-X
certain	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
lines	B-X
but	B-X
not	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
non	B-X
-	B-X
lymphoid	B-X
cell	B-X
lines	B-X

Formation	O
of	O
this	O
complex	O
was	O
selectively	O
inhibited	O
by	O
the	O
region	O
in	O
HIV-1	B-DNA
containing	O
a	O
silencer	B-DNA
element	I-DNA
.	O
<EOS>	B-X
Formation	B-X
of	B-X
this	B-X
complex	B-X
was	B-X
selectively	B-X
inhibited	B-X
by	B-X
the	B-X
region	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
containing	B-X
a	B-X
silencer	B-X
element	B-X
<EOS>	B-X
We	B-X
discuss	B-X
the	B-X
possibility	B-X
that	B-X
DNA	B-X
-	B-X
binding	B-X
factors	B-X
may	B-X
coregulate	B-X
HIV	B-X
-	B-X
1	B-X
and	B-X
Rpt	B-X
-	B-X
1	B-X
gene	B-X
expression	B-X
through	B-X
a	B-X
common	B-X
transcriptional	B-X
silencer	B-X
element	B-X
<EOS>	B-X
Definition	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
specific	B-X
DNA	B-X
-	B-X
binding	B-X
factors	B-X
that	B-X
interact	B-X
with	B-X
a	B-X
3'	B-X
-	B-X
silencer	B-X
in	B-X
the	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
gene	B-X
Rpt	B-X
-	B-X
1	B-X
.	B-X
<EOS>	B-X
Functional	B-X
silencer	B-X
activity	B-X
in	B-X
vivo	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
specific	B-X
silencer	B-X
-	B-X
DNA	B-X
-	B-X
protein	B-X
complex	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
with	B-X
T	B-X
-	B-X
cell	B-X
extracts	B-X

We	O
discuss	O
the	O
possibility	O
that	O
DNA-binding	B-protein
factors	I-protein
may	O
coregulate	O
HIV-1	O
and	O
Rpt-1	O
gene	O
expression	O
through	O
a	O
common	O
transcriptional	B-DNA
silencer	I-DNA
element	I-DNA
.	O
<EOS>	B-X
We	B-X
discuss	B-X
the	B-X
possibility	B-X
that	B-X
DNA	B-X
-	B-X
binding	B-X
factors	B-X
may	B-X
coregulate	B-X
HIV	B-X
-	B-X
1	B-X
and	B-X
Rpt	B-X
-	B-X
1	B-X
gene	B-X
expression	B-X
through	B-X
a	B-X
common	B-X
transcriptional	B-X
silencer	B-X
element	B-X
<EOS>	B-X
Definition	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
specific	B-X
DNA	B-X
-	B-X
binding	B-X
factors	B-X
that	B-X
interact	B-X
with	B-X
a	B-X
3'	B-X
-	B-X
silencer	B-X
in	B-X
the	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
gene	B-X
Rpt	B-X
-	B-X
1	B-X
.	B-X
<EOS>	B-X
Formation	B-X
of	B-X
this	B-X
complex	B-X
was	B-X
selectively	B-X
inhibited	B-X
by	B-X
the	B-X
region	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
containing	B-X
a	B-X
silencer	B-X
element	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
region	B-X
3	B-X
'	B-X
to	B-X
the	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
gene	B-X
Rpt	B-X
-	B-X
1	B-X
(	B-X
encoding	B-X
regulatory	B-X
protein	B-X
T	B-X
-	B-X
lymphocyte	B-X
1	B-X
)	B-X
led	B-X
to	B-X
the	B-X
definition	B-X
of	B-X
a	B-X
silencer	B-X
element	B-X
that	B-X
inhibits	B-X
heterologous	B-X
gene	B-X
expression	B-X
in	B-X
certain	B-X
CD4+	B-X
T	B-X
-	B-X
cell	B-X
lines	B-X
but	B-X
not	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
non	B-X
-	B-X
lymphoid	B-X
cell	B-X
lines	B-X

Congenital	O
immunodeficiencies	O
associated	O
with	O
absence	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
on	O
lymphocytes	B-cell_type
result	O
from	O
distinct	O
mutations	O
in	O
trans-acting	B-protein
factors	I-protein
.	O
<EOS>	B-X
Congenital	B-X
immunodeficiencies	B-X
associated	B-X
with	B-X
absence	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
antigens	B-X
on	B-X
lymphocytes	B-X
result	B-X
from	B-X
distinct	B-X
mutations	B-X
in	B-X
trans	B-X
-	B-X
acting	B-X
factors	B-X
.	B-X
<EOS>	B-X
In	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
derived	B-X
from	B-X
two	B-X
independent	B-X
class	B-X
II	B-X
-	B-X
deficient	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
patients	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
drastic	B-X
decrease	B-X
in	B-X
transcription	B-X
rates	B-X
of	B-X
the	B-X
class	B-X
II	B-X
genes	B-X
<EOS>	B-X
Coordinate	B-X
regulation	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
gene	B-X
expression	B-X
during	B-X
development	B-X
and	B-X
coinduction	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
by	B-X
soluble	B-X
factors	B-X
suggests	B-X
that	B-X
common	B-X
trans	B-X
-	B-X
acting	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
control	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
<EOS>	B-X
Further	B-X
studies	B-X
show	B-X
that	B-X
genes	B-X
governing	B-X
the	B-X
expression	B-X
of	B-X
class	B-X
II	B-X
antigens	B-X
fall	B-X
into	B-X
at	B-X
least	B-X
three	B-X
complementation	B-X
groups	B-X
;	B-X
two	B-X
of	B-X
these	B-X
were	B-X
previously	B-X
unidentified	B-X
in	B-X
mutant	B-X
cell	B-X
lines	B-X
generated	B-X
in	B-X
vitro	B-X

Coordinate	O
regulation	O
of	O
HLA	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
during	O
development	O
and	O
coinduction	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
by	O
soluble	B-protein
factors	I-protein
suggests	O
that	O
common	O
trans-acting	B-protein
factor	I-protein
(	O
s	O
)	O
control	O
expression	O
of	O
these	O
genes	O
.	O
<EOS>	B-X
Coordinate	B-X
regulation	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
gene	B-X
expression	B-X
during	B-X
development	B-X
and	B-X
coinduction	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
by	B-X
soluble	B-X
factors	B-X
suggests	B-X
that	B-X
common	B-X
trans	B-X
-	B-X
acting	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
control	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
<EOS>	B-X
When	B-X
these	B-X
cell	B-X
lines	B-X
are	B-X
fused	B-X
,	B-X
class	B-X
II	B-X
genes	B-X
are	B-X
reexpressed	B-X
,	B-X
indicating	B-X
that	B-X
immunodeficiencies	B-X
in	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
patients	B-X
are	B-X
the	B-X
result	B-X
of	B-X
two	B-X
distinct	B-X
mutations	B-X
<EOS>	B-X
Congenital	B-X
immunodeficiencies	B-X
associated	B-X
with	B-X
absence	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
antigens	B-X
on	B-X
lymphocytes	B-X
result	B-X
from	B-X
distinct	B-X
mutations	B-X
in	B-X
trans	B-X
-	B-X
acting	B-X
factors	B-X
.	B-X
<EOS>	B-X
In	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
derived	B-X
from	B-X
two	B-X
independent	B-X
class	B-X
II	B-X
-	B-X
deficient	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
patients	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
drastic	B-X
decrease	B-X
in	B-X
transcription	B-X
rates	B-X
of	B-X
the	B-X
class	B-X
II	B-X
genes	B-X

In	O
B-lymphoblastoid	B-cell_type
cell	I-cell_type
lines	I-cell_type
derived	O
from	O
two	O
independent	O
class	O
II-deficient	O
bare	O
lymphocyte	O
syndrome	O
patients	O
,	O
we	O
observed	O
a	O
drastic	O
decrease	O
in	O
transcription	O
rates	O
of	O
the	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
In	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
derived	B-X
from	B-X
two	B-X
independent	B-X
class	B-X
II	B-X
-	B-X
deficient	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
patients	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
drastic	B-X
decrease	B-X
in	B-X
transcription	B-X
rates	B-X
of	B-X
the	B-X
class	B-X
II	B-X
genes	B-X
<EOS>	B-X
Congenital	B-X
immunodeficiencies	B-X
associated	B-X
with	B-X
absence	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
antigens	B-X
on	B-X
lymphocytes	B-X
result	B-X
from	B-X
distinct	B-X
mutations	B-X
in	B-X
trans	B-X
-	B-X
acting	B-X
factors	B-X
.	B-X
<EOS>	B-X
When	B-X
these	B-X
cell	B-X
lines	B-X
are	B-X
fused	B-X
,	B-X
class	B-X
II	B-X
genes	B-X
are	B-X
reexpressed	B-X
,	B-X
indicating	B-X
that	B-X
immunodeficiencies	B-X
in	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
patients	B-X
are	B-X
the	B-X
result	B-X
of	B-X
two	B-X
distinct	B-X
mutations	B-X
<EOS>	B-X
Further	B-X
studies	B-X
show	B-X
that	B-X
genes	B-X
governing	B-X
the	B-X
expression	B-X
of	B-X
class	B-X
II	B-X
antigens	B-X
fall	B-X
into	B-X
at	B-X
least	B-X
three	B-X
complementation	B-X
groups	B-X
;	B-X
two	B-X
of	B-X
these	B-X
were	B-X
previously	B-X
unidentified	B-X
in	B-X
mutant	B-X
cell	B-X
lines	B-X
generated	B-X
in	B-X
vitro	B-X

When	O
these	O
cell	O
lines	O
are	O
fused	O
,	O
class	B-DNA
II	I-DNA
genes	I-DNA
are	O
reexpressed	O
,	O
indicating	O
that	O
immunodeficiencies	O
in	O
bare	O
lymphocyte	O
syndrome	O
patients	O
are	O
the	O
result	O
of	O
two	O
distinct	O
mutations	O
.	O
<EOS>	B-X
When	B-X
these	B-X
cell	B-X
lines	B-X
are	B-X
fused	B-X
,	B-X
class	B-X
II	B-X
genes	B-X
are	B-X
reexpressed	B-X
,	B-X
indicating	B-X
that	B-X
immunodeficiencies	B-X
in	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
patients	B-X
are	B-X
the	B-X
result	B-X
of	B-X
two	B-X
distinct	B-X
mutations	B-X
<EOS>	B-X
In	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
derived	B-X
from	B-X
two	B-X
independent	B-X
class	B-X
II	B-X
-	B-X
deficient	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
patients	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
drastic	B-X
decrease	B-X
in	B-X
transcription	B-X
rates	B-X
of	B-X
the	B-X
class	B-X
II	B-X
genes	B-X
<EOS>	B-X
Congenital	B-X
immunodeficiencies	B-X
associated	B-X
with	B-X
absence	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
antigens	B-X
on	B-X
lymphocytes	B-X
result	B-X
from	B-X
distinct	B-X
mutations	B-X
in	B-X
trans	B-X
-	B-X
acting	B-X
factors	B-X
.	B-X
<EOS>	B-X
Coordinate	B-X
regulation	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
gene	B-X
expression	B-X
during	B-X
development	B-X
and	B-X
coinduction	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
by	B-X
soluble	B-X
factors	B-X
suggests	B-X
that	B-X
common	B-X
trans	B-X
-	B-X
acting	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
control	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X

Further	O
studies	O
show	O
that	O
genes	O
governing	O
the	O
expression	O
of	O
class	B-protein
II	I-protein
antigens	I-protein
fall	O
into	O
at	O
least	O
three	O
complementation	O
groups	O
;	O
two	O
of	O
these	O
were	O
previously	O
unidentified	O
in	O
mutant	B-cell_line
cell	I-cell_line
lines	I-cell_line
generated	O
in	O
vitro	O
.	O
<EOS>	B-X
Further	B-X
studies	B-X
show	B-X
that	B-X
genes	B-X
governing	B-X
the	B-X
expression	B-X
of	B-X
class	B-X
II	B-X
antigens	B-X
fall	B-X
into	B-X
at	B-X
least	B-X
three	B-X
complementation	B-X
groups	B-X
;	B-X
two	B-X
of	B-X
these	B-X
were	B-X
previously	B-X
unidentified	B-X
in	B-X
mutant	B-X
cell	B-X
lines	B-X
generated	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Congenital	B-X
immunodeficiencies	B-X
associated	B-X
with	B-X
absence	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
antigens	B-X
on	B-X
lymphocytes	B-X
result	B-X
from	B-X
distinct	B-X
mutations	B-X
in	B-X
trans	B-X
-	B-X
acting	B-X
factors	B-X
.	B-X
<EOS>	B-X
Though	B-X
the	B-X
mutation	B-X
in	B-X
at	B-X
least	B-X
one	B-X
mutant	B-X
line	B-X
generated	B-X
in	B-X
vitro	B-X
(	B-X
RJ2	B-X
<EOS>	B-X
In	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
derived	B-X
from	B-X
two	B-X
independent	B-X
class	B-X
II	B-X
-	B-X
deficient	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
patients	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
drastic	B-X
decrease	B-X
in	B-X
transcription	B-X
rates	B-X
of	B-X
the	B-X
class	B-X
II	B-X
genes	B-X

In	O
addition	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
discrete	O
complexes	O
,	O
NFX1.1	B-protein
and	O
NFX1.2	B-protein
,	O
that	O
bind	O
to	O
the	O
DRA	B-DNA
X	I-DNA
consensus	I-DNA
element	I-DNA
.	O

Though	O
the	O
mutation	O
in	O
at	O
least	O
one	O
mutant	B-cell_line
line	I-cell_line
generated	O
in	O
vitro	O
(	O
RJ2.2.5	B-cell_line
)	O
affects	O
products	O
functioning	O
via	O
interaction	O
with	O
the	O
X	B-DNA
box	I-DNA
,	O
clear	O
alterations	O
in	O
either	O
NFX1.1	B-protein
or	O
NFX1.2	B-protein
are	O
not	O
found	O
in	O
any	O
of	O
the	O
mutant	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
vivo	O
responsiveness	O
to	O
glucocorticoid	O
correlated	O
with	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
normal	O
humans	O
.	O
<EOS>	B-X
In	B-X
vivo	B-X
responsiveness	B-X
to	B-X
glucocorticoid	B-X
correlated	B-X
with	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
in	B-X
normal	B-X
humans	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
individual	B-X
differences	B-X
are	B-X
preserved	B-X
both	B-X
in	B-X
glucocorticoid	B-X
responsiveness	B-X
and	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
in	B-X
normal	B-X
humans	B-X
<EOS>	B-X
Simultaneous	B-X
measurements	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
by	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
revealed	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
linearly	B-X
correlated	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
0007	B-X
)	B-X
,	B-X
and	B-X
between	B-X
the	B-X
maximum	B-X
decrease	B-X
in	B-X
lymphocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X

Dexamethasone	O
loading	O
tests	O
(	O
0.1	O
mg	O
dexamethasone/kg	O
,	O
iv	O
)	O
were	O
performed	O
in	O
18	O
normal	O
males	O
to	O
evaluate	O
the	O
individual	O
responsiveness	O
to	O
glucocorticoid	O
.	O
<EOS>	B-X
1	B-X
mg	B-X
dexamethasone	B-X
/	B-X
kg	B-X
,	B-X
iv	B-X
)	B-X
were	B-X
performed	B-X
in	B-X
18	B-X
normal	B-X
males	B-X
to	B-X
evaluate	B-X
the	B-X
individual	B-X
responsiveness	B-X
to	B-X
glucocorticoid	B-X
<EOS>	B-X
Simultaneous	B-X
measurements	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
by	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
revealed	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
linearly	B-X
correlated	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
There	B-X
were	B-X
inter	B-X
-	B-X
individual	B-X
differences	B-X
in	B-X
increase	B-X
in	B-X
peripheral	B-X
blood	B-X
polymorphonuclear	B-X
leukocyte	B-X
count	B-X
,	B-X
decrease	B-X
in	B-X
peripheral	B-X
blood	B-X
lymphocyte	B-X
count	B-X
,	B-X
and	B-X
increase	B-X
in	B-X
plasma	B-X
free	B-X
fatty	B-X
acids	B-X
levels	B-X
after	B-X
dexamethasone	B-X
injection	B-X
<EOS>	B-X
0007	B-X
)	B-X
,	B-X
and	B-X
between	B-X
the	B-X
maximum	B-X
decrease	B-X
in	B-X
lymphocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X

There	O
were	O
inter-individual	O
differences	O
in	O
increase	O
in	O
peripheral	B-cell_type
blood	I-cell_type
polymorphonuclear	I-cell_type
leukocyte	I-cell_type
count	O
,	O
decrease	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocyte	I-cell_type
count	O
,	O
and	O
increase	O
in	O
plasma	O
free	O
fatty	O
acids	O
levels	O
after	O
dexamethasone	O
injection	O
.	O
<EOS>	B-X
There	B-X
were	B-X
inter	B-X
-	B-X
individual	B-X
differences	B-X
in	B-X
increase	B-X
in	B-X
peripheral	B-X
blood	B-X
polymorphonuclear	B-X
leukocyte	B-X
count	B-X
,	B-X
decrease	B-X
in	B-X
peripheral	B-X
blood	B-X
lymphocyte	B-X
count	B-X
,	B-X
and	B-X
increase	B-X
in	B-X
plasma	B-X
free	B-X
fatty	B-X
acids	B-X
levels	B-X
after	B-X
dexamethasone	B-X
injection	B-X
<EOS>	B-X
There	B-X
were	B-X
also	B-X
significant	B-X
correlations	B-X
between	B-X
the	B-X
maximum	B-X
increase	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
individual	B-X
differences	B-X
are	B-X
preserved	B-X
both	B-X
in	B-X
glucocorticoid	B-X
responsiveness	B-X
and	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
in	B-X
normal	B-X
humans	B-X
<EOS>	B-X
In	B-X
vivo	B-X
responsiveness	B-X
to	B-X
glucocorticoid	B-X
correlated	B-X
with	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
in	B-X
normal	B-X
humans	B-X
.	B-X

In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
and	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	B-cell_type
(	O
r	O
=	O
0.7514	O
,	O
p	O
less	O
than	O
0.0003	O
)	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significant	B-X
correlation	B-X
between	B-X
the	B-X
maximum	B-X
increase	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
and	B-X
the	B-X
maximum	B-X
decrease	B-X
in	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
There	B-X
were	B-X
also	B-X
significant	B-X
correlations	B-X
between	B-X
the	B-X
maximum	B-X
increase	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
0007	B-X
)	B-X
,	B-X
and	B-X
between	B-X
the	B-X
maximum	B-X
decrease	B-X
in	B-X
lymphocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
Simultaneous	B-X
measurements	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
by	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
revealed	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
linearly	B-X
correlated	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X

Simultaneous	O
measurements	O
of	O
glucocorticoid	B-protein
receptor	I-protein
content	O
by	O
whole-cell	O
assay	O
revealed	O
that	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
linearly	O
correlated	O
with	O
that	O
in	O
the	O
corresponding	O
lymphocytes	B-cell_type
(	O
r	O
=	O
0.9482	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
.	O
<EOS>	B-X
Simultaneous	B-X
measurements	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
by	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
revealed	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
linearly	B-X
correlated	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
In	B-X
vivo	B-X
responsiveness	B-X
to	B-X
glucocorticoid	B-X
correlated	B-X
with	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
in	B-X
normal	B-X
humans	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significant	B-X
correlation	B-X
between	B-X
the	B-X
maximum	B-X
increase	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
and	B-X
the	B-X
maximum	B-X
decrease	B-X
in	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
There	B-X
were	B-X
also	B-X
significant	B-X
correlations	B-X
between	B-X
the	B-X
maximum	B-X
increase	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X

There	O
were	O
also	O
significant	O
correlations	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
and	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
r	O
=	O
0.7239	O
,	O
p	O
less	O
than	O
0.0007	O
)	O
,	O
and	O
between	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	B-cell_type
and	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
lymphocytes	B-cell_type
(	O
r	O
=	O
0.7703	O
,	O
p	O
less	O
than	O
0.0002	O
)	O
.	O
<EOS>	B-X
There	B-X
were	B-X
also	B-X
significant	B-X
correlations	B-X
between	B-X
the	B-X
maximum	B-X
increase	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
Simultaneous	B-X
measurements	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
by	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
revealed	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
linearly	B-X
correlated	B-X
with	B-X
that	B-X
in	B-X
the	B-X
corresponding	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significant	B-X
correlation	B-X
between	B-X
the	B-X
maximum	B-X
increase	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
and	B-X
the	B-X
maximum	B-X
decrease	B-X
in	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
There	B-X
were	B-X
inter	B-X
-	B-X
individual	B-X
differences	B-X
in	B-X
increase	B-X
in	B-X
peripheral	B-X
blood	B-X
polymorphonuclear	B-X
leukocyte	B-X
count	B-X
,	B-X
decrease	B-X
in	B-X
peripheral	B-X
blood	B-X
lymphocyte	B-X
count	B-X
,	B-X
and	B-X
increase	B-X
in	B-X
plasma	B-X
free	B-X
fatty	B-X
acids	B-X
levels	B-X
after	B-X
dexamethasone	B-X
injection	B-X

These	O
results	O
suggest	O
that	O
individual	O
differences	O
are	O
preserved	O
both	O
in	O
glucocorticoid	O
responsiveness	O
and	O
in	O
glucocorticoid	B-protein
receptor	I-protein
content	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
normal	O
humans	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
individual	B-X
differences	B-X
are	B-X
preserved	B-X
both	B-X
in	B-X
glucocorticoid	B-X
responsiveness	B-X
and	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
in	B-X
normal	B-X
humans	B-X
<EOS>	B-X
In	B-X
vivo	B-X
responsiveness	B-X
to	B-X
glucocorticoid	B-X
correlated	B-X
with	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
in	B-X
normal	B-X
humans	B-X
.	B-X
<EOS>	B-X
There	B-X
were	B-X
also	B-X
significant	B-X
correlations	B-X
between	B-X
the	B-X
maximum	B-X
increase	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
polymorphonuclear	B-X
leukocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
0007	B-X
)	B-X
,	B-X
and	B-X
between	B-X
the	B-X
maximum	B-X
decrease	B-X
in	B-X
lymphocytes	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
lymphocytes	B-X
(	B-X
r	B-X
=	B-X
0	B-X

Estradiol	O
receptors	O
in	O
the	O
cytosol	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
hepatitis	O
B	O
virus	O
carriers	O
treated	O
with	O
interferon-alpha	B-protein
.	O
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
hepatitis	B-X
B	B-X
virus	B-X
carriers	B-X
treated	B-X
with	B-X
interferon	B-X
-	B-X
alpha	B-X
.	B-X
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
interferon	B-X
-	B-X
alpha	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
on	B-X
estradiol	B-X
receptors	B-X
were	B-X
studied	B-X
in	B-X
asymptomatic	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
carriers	B-X
,	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
and	B-X
normal	B-X
controls	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
mononuclear	B-X
cells	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
asymptomatic	B-X
HBV	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
,	B-X
compared	B-X
to	B-X
normal	B-X
controls	B-X
<EOS>	B-X
This	B-X
low	B-X
level	B-X
of	B-X
cytosol	B-X
estradiol	B-X
receptors	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
was	B-X
increased	B-X
by	B-X
the	B-X
administration	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X

Estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
the	O
effects	O
of	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
on	O
estradiol	B-protein
receptors	I-protein
were	O
studied	O
in	O
asymptomatic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
carriers	O
,	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
and	O
normal	O
controls	O
.	O
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
interferon	B-X
-	B-X
alpha	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
on	B-X
estradiol	B-X
receptors	B-X
were	B-X
studied	B-X
in	B-X
asymptomatic	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
carriers	B-X
,	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
and	B-X
normal	B-X
controls	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
mononuclear	B-X
cells	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
asymptomatic	B-X
HBV	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
,	B-X
compared	B-X
to	B-X
normal	B-X
controls	B-X
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
hepatitis	B-X
B	B-X
virus	B-X
carriers	B-X
treated	B-X
with	B-X
interferon	B-X
-	B-X
alpha	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
when	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
were	B-X
incubated	B-X
with	B-X
IFN	B-X
-	B-X
alpha	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
level	B-X
of	B-X
cytosol	B-X
estradiol	B-X
receptors	B-X
also	B-X
increased	B-X
by	B-X
increasing	B-X
the	B-X
concentration	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X

The	O
level	O
of	O
estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
was	O
significantly	O
lower	O
in	O
asymptomatic	O
HBV	O
carriers	O
and	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
,	O
compared	O
to	O
normal	O
controls	O
.	O
<EOS>	B-X
The	B-X
level	B-X
of	B-X
estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
mononuclear	B-X
cells	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
asymptomatic	B-X
HBV	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
,	B-X
compared	B-X
to	B-X
normal	B-X
controls	B-X
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
interferon	B-X
-	B-X
alpha	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
on	B-X
estradiol	B-X
receptors	B-X
were	B-X
studied	B-X
in	B-X
asymptomatic	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
carriers	B-X
,	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
and	B-X
normal	B-X
controls	B-X
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
hepatitis	B-X
B	B-X
virus	B-X
carriers	B-X
treated	B-X
with	B-X
interferon	B-X
-	B-X
alpha	B-X
.	B-X
<EOS>	B-X
This	B-X
low	B-X
level	B-X
of	B-X
cytosol	B-X
estradiol	B-X
receptors	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
was	B-X
increased	B-X
by	B-X
the	B-X
administration	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X

This	O
low	O
level	O
of	O
cytosol	O
estradiol	B-protein
receptors	I-protein
in	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
was	O
increased	O
by	O
the	O
administration	O
of	O
IFN-alpha	B-protein
.	O
<EOS>	B-X
This	B-X
low	B-X
level	B-X
of	B-X
cytosol	B-X
estradiol	B-X
receptors	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
was	B-X
increased	B-X
by	B-X
the	B-X
administration	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
when	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
were	B-X
incubated	B-X
with	B-X
IFN	B-X
-	B-X
alpha	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
level	B-X
of	B-X
cytosol	B-X
estradiol	B-X
receptors	B-X
also	B-X
increased	B-X
by	B-X
increasing	B-X
the	B-X
concentration	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
mononuclear	B-X
cells	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
asymptomatic	B-X
HBV	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
,	B-X
compared	B-X
to	B-X
normal	B-X
controls	B-X
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
hepatitis	B-X
B	B-X
virus	B-X
carriers	B-X
treated	B-X
with	B-X
interferon	B-X
-	B-X
alpha	B-X
.	B-X

In	O
addition	O
,	O
when	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
were	O
incubated	O
with	O
IFN-alpha	B-protein
in	O
vitro	O
,	O
the	O
level	O
of	O
cytosol	O
estradiol	B-protein
receptors	I-protein
also	O
increased	O
by	O
increasing	O
the	O
concentration	O
of	O
IFN-alpha	B-protein
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
when	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
were	B-X
incubated	B-X
with	B-X
IFN	B-X
-	B-X
alpha	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
level	B-X
of	B-X
cytosol	B-X
estradiol	B-X
receptors	B-X
also	B-X
increased	B-X
by	B-X
increasing	B-X
the	B-X
concentration	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
<EOS>	B-X
This	B-X
low	B-X
level	B-X
of	B-X
cytosol	B-X
estradiol	B-X
receptors	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
was	B-X
increased	B-X
by	B-X
the	B-X
administration	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
hepatitis	B-X
B	B-X
virus	B-X
carriers	B-X
treated	B-X
with	B-X
interferon	B-X
-	B-X
alpha	B-X
.	B-X
<EOS>	B-X
Estradiol	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
interferon	B-X
-	B-X
alpha	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
on	B-X
estradiol	B-X
receptors	B-X
were	B-X
studied	B-X
in	B-X
asymptomatic	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
carriers	B-X
,	B-X
patients	B-X
with	B-X
chronic	B-X
hepatitis	B-X
B	B-X
and	B-X
normal	B-X
controls	B-X

We	O
previously	O
reported	O
that	O
the	O
response	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
to	O
estrogen	O
is	O
impaired	O
in	O
HBV	O
carriers	O
,	O
and	O
our	O
present	O
results	O
suggested	O
that	O
this	O
may	O
be	O
due	O
to	O
the	O
low	O
level	O
of	O
estradiol	B-protein
receptors	I-protein
in	O
the	O
cytosol	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
.	O

Association	O
of	O
increased	O
lytic	O
effector	O
cell	O
function	O
with	O
high	O
estrogen	B-protein
receptor	I-protein
levels	O
in	O
tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
.	O
<EOS>	B-X
Association	B-X
of	B-X
increased	B-X
lytic	B-X
effector	B-X
cell	B-X
function	B-X
with	B-X
high	B-X
estrogen	B-X
receptor	B-X
levels	B-X
in	B-X
tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
ER	B-X
levels	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
increased	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
in	B-X
tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
were	B-X
assayed	B-X
for	B-X
their	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
activity	B-X
and	B-X
for	B-X
the	B-X
function	B-X
of	B-X
activated	B-X
cytotoxic	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
as	B-X
assessed	B-X
by	B-X
lectin	B-X
-	B-X
dependent	B-X
cellular	B-X
cytotoxicity	B-X
(	B-X
LDCC	B-X
)	B-X
<EOS>	B-X
Although	B-X
the	B-X
enhanced	B-X
NK	B-X
cell	B-X
activity	B-X
and	B-X
LDCC	B-X
were	B-X
closely	B-X
associated	B-X
with	B-X
high	B-X
levels	B-X
(	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
)	B-X
of	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
content	B-X
in	B-X
the	B-X
primary	B-X
tumor	B-X
,	B-X
no	B-X
other	B-X
clinical	B-X
or	B-X
histologic	B-X
correlation	B-X
between	B-X
the	B-X
increase	B-X
in	B-X
either	B-X
parameter	B-X
of	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
could	B-X
be	B-X
found	B-X

Tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
were	O
assayed	O
for	O
their	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
and	O
for	O
the	O
function	O
of	O
activated	O
cytotoxic	B-cell_type
T-cells	I-cell_type
,	O
as	O
assessed	O
by	O
lectin-dependent	O
cellular	O
cytotoxicity	O
(	O
LDCC	O
)	O
.	O
<EOS>	B-X
Tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
were	B-X
assayed	B-X
for	B-X
their	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
activity	B-X
and	B-X
for	B-X
the	B-X
function	B-X
of	B-X
activated	B-X
cytotoxic	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
as	B-X
assessed	B-X
by	B-X
lectin	B-X
-	B-X
dependent	B-X
cellular	B-X
cytotoxicity	B-X
(	B-X
LDCC	B-X
)	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
had	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
NK	B-X
activity	B-X
and	B-X
in	B-X
LDCC	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
healthy	B-X
control	B-X
individuals	B-X
<EOS>	B-X
Although	B-X
the	B-X
enhanced	B-X
NK	B-X
cell	B-X
activity	B-X
and	B-X
LDCC	B-X
were	B-X
closely	B-X
associated	B-X
with	B-X
high	B-X
levels	B-X
(	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
)	B-X
of	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
content	B-X
in	B-X
the	B-X
primary	B-X
tumor	B-X
,	B-X
no	B-X
other	B-X
clinical	B-X
or	B-X
histologic	B-X
correlation	B-X
between	B-X
the	B-X
increase	B-X
in	B-X
either	B-X
parameter	B-X
of	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
could	B-X
be	B-X
found	B-X
<EOS>	B-X
Association	B-X
of	B-X
increased	B-X
lytic	B-X
effector	B-X
cell	B-X
function	B-X
with	B-X
high	B-X
estrogen	B-X
receptor	B-X
levels	B-X
in	B-X
tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
.	B-X

Tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
had	O
a	O
significant	O
increase	O
in	O
NK	B-cell_type
activity	O
and	O
in	O
LDCC	O
,	O
as	O
compared	O
with	O
healthy	O
control	O
individuals	O
.	O
<EOS>	B-X
Tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
had	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
NK	B-X
activity	B-X
and	B-X
in	B-X
LDCC	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
healthy	B-X
control	B-X
individuals	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
were	B-X
assayed	B-X
for	B-X
their	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
activity	B-X
and	B-X
for	B-X
the	B-X
function	B-X
of	B-X
activated	B-X
cytotoxic	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
as	B-X
assessed	B-X
by	B-X
lectin	B-X
-	B-X
dependent	B-X
cellular	B-X
cytotoxicity	B-X
(	B-X
LDCC	B-X
)	B-X
<EOS>	B-X
Although	B-X
the	B-X
enhanced	B-X
NK	B-X
cell	B-X
activity	B-X
and	B-X
LDCC	B-X
were	B-X
closely	B-X
associated	B-X
with	B-X
high	B-X
levels	B-X
(	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
)	B-X
of	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
content	B-X
in	B-X
the	B-X
primary	B-X
tumor	B-X
,	B-X
no	B-X
other	B-X
clinical	B-X
or	B-X
histologic	B-X
correlation	B-X
between	B-X
the	B-X
increase	B-X
in	B-X
either	B-X
parameter	B-X
of	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
could	B-X
be	B-X
found	B-X
<EOS>	B-X
Thus	B-X
,	B-X
ER	B-X
levels	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
increased	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
in	B-X
tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X

Although	O
the	O
enhanced	O
NK	B-cell_type
cell	I-cell_type
activity	O
and	O
LDCC	O
were	O
closely	O
associated	O
with	O
high	O
levels	O
(	O
greater	O
than	O
31	O
fmol/mg	O
)	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
content	O
in	O
the	O
primary	O
tumor	O
,	O
no	O
other	O
clinical	O
or	O
histologic	O
correlation	O
between	O
the	O
increase	O
in	O
either	O
parameter	O
of	O
cytotoxic	B-cell_type
effector	I-cell_type
cell	I-cell_type
function	O
could	O
be	O
found	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
enhanced	B-X
NK	B-X
cell	B-X
activity	B-X
and	B-X
LDCC	B-X
were	B-X
closely	B-X
associated	B-X
with	B-X
high	B-X
levels	B-X
(	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
)	B-X
of	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
content	B-X
in	B-X
the	B-X
primary	B-X
tumor	B-X
,	B-X
no	B-X
other	B-X
clinical	B-X
or	B-X
histologic	B-X
correlation	B-X
between	B-X
the	B-X
increase	B-X
in	B-X
either	B-X
parameter	B-X
of	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
could	B-X
be	B-X
found	B-X
<EOS>	B-X
Four	B-X
immunological	B-X
parameters	B-X
were	B-X
investigated	B-X
:	B-X
measurement	B-X
of	B-X
lavage	B-X
derived	B-X
T	B-X
cell	B-X
proliferation	B-X
in	B-X
response	B-X
to	B-X
limited	B-X
culture	B-X
with	B-X
interleukin	B-X
2	B-X
;	B-X
measurement	B-X
of	B-X
changes	B-X
in	B-X
the	B-X
frequency	B-X
of	B-X
donor	B-X
reactive	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X
;	B-X
assay	B-X
of	B-X
the	B-X
level	B-X
of	B-X
donor	B-X
cell	B-X
binding	B-X
IgG	B-X
antibody	B-X
in	B-X
recipient	B-X
plasma	B-X
;	B-X
and	B-X
measurement	B-X
of	B-X
the	B-X
antibody	B-X
dependent	B-X
cell	B-X
mediated	B-X
cytotoxic	B-X
response	B-X
to	B-X
donor	B-X
cells	B-X
after	B-X
labelling	B-X
with	B-X
recipient	B-X
plasma	B-X
<EOS>	B-X
Thus	B-X
,	B-X
ER	B-X
levels	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
increased	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
in	B-X
tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Association	B-X
of	B-X
increased	B-X
lytic	B-X
effector	B-X
cell	B-X
function	B-X
with	B-X
high	B-X
estrogen	B-X
receptor	B-X
levels	B-X
in	B-X
tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
.	B-X

Thus	O
,	O
ER	B-protein
levels	O
greater	O
than	O
31	O
fmol/mg	O
might	O
be	O
associated	O
with	O
increased	O
cytotoxic	B-cell_type
effector	I-cell_type
cell	I-cell_type
function	O
in	O
tumor-bearing	O
patients	O
with	O
breast	O
cancer	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
ER	B-X
levels	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
might	B-X
be	B-X
associated	B-X
with	B-X
increased	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
in	B-X
tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Association	B-X
of	B-X
increased	B-X
lytic	B-X
effector	B-X
cell	B-X
function	B-X
with	B-X
high	B-X
estrogen	B-X
receptor	B-X
levels	B-X
in	B-X
tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
.	B-X
<EOS>	B-X
Although	B-X
the	B-X
enhanced	B-X
NK	B-X
cell	B-X
activity	B-X
and	B-X
LDCC	B-X
were	B-X
closely	B-X
associated	B-X
with	B-X
high	B-X
levels	B-X
(	B-X
greater	B-X
than	B-X
31	B-X
fmol	B-X
/	B-X
mg	B-X
)	B-X
of	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
content	B-X
in	B-X
the	B-X
primary	B-X
tumor	B-X
,	B-X
no	B-X
other	B-X
clinical	B-X
or	B-X
histologic	B-X
correlation	B-X
between	B-X
the	B-X
increase	B-X
in	B-X
either	B-X
parameter	B-X
of	B-X
cytotoxic	B-X
effector	B-X
cell	B-X
function	B-X
could	B-X
be	B-X
found	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
bearing	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
were	B-X
assayed	B-X
for	B-X
their	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
activity	B-X
and	B-X
for	B-X
the	B-X
function	B-X
of	B-X
activated	B-X
cytotoxic	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
as	B-X
assessed	B-X
by	B-X
lectin	B-X
-	B-X
dependent	B-X
cellular	B-X
cytotoxicity	B-X
(	B-X
LDCC	B-X
)	B-X

Properties	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
lymphocytes	I-cell_line
from	O
patients	O
with	O
familial	O
cortisol	O
resistance	O
.	O
<EOS>	B-X
Properties	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
-	B-X
transformed	B-X
lymphocytes	B-X
from	B-X
patients	B-X
with	B-X
familial	B-X
cortisol	B-X
resistance	B-X
.	B-X
<EOS>	B-X
Reduced	B-X
numbers	B-X
and	B-X
normal	B-X
affinity	B-X
of	B-X
GR	B-X
were	B-X
found	B-X
in	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
-	B-X
transformed	B-X
lymphocytes	B-X
from	B-X
both	B-X
patients	B-X
while	B-X
the	B-X
son	B-X
and	B-X
daughter	B-X
had	B-X
normal	B-X
numbers	B-X
and	B-X
affinity	B-X
of	B-X
GR	B-X
<EOS>	B-X
Although	B-X
the	B-X
percentages	B-X
of	B-X
nuclear	B-X
bound	B-X
GR	B-X
were	B-X
similar	B-X
in	B-X
both	B-X
patients	B-X
and	B-X
normal	B-X
controls	B-X
,	B-X
the	B-X
absolute	B-X
amounts	B-X
of	B-X
nuclear	B-X
bound	B-X
GR	B-X
of	B-X
the	B-X
patients	B-X
were	B-X
about	B-X
one	B-X
-	B-X
half	B-X
that	B-X
of	B-X
normal	B-X
controls	B-X
<EOS>	B-X
In	B-X
a	B-X
previous	B-X
report	B-X
of	B-X
two	B-X
patients	B-X
with	B-X
familial	B-X
glucocorticoid	B-X
resistance	B-X
due	B-X
to	B-X
reduced	B-X
numbers	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
GR	B-X
)	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
decreased	B-X
numbers	B-X
of	B-X
GR	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
cells	B-X
and	B-X
cultured	B-X
fibroblasts	B-X
but	B-X
normal	B-X
affinity	B-X
of	B-X
GR	B-X
in	B-X
both	B-X
patients	B-X

In	O
a	O
previous	O
report	O
of	O
two	O
patients	O
with	O
familial	O
glucocorticoid	O
resistance	O
due	O
to	O
reduced	O
numbers	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
,	O
we	O
have	O
shown	O
decreased	O
numbers	O
of	O
GR	B-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
cultured	B-cell_line
fibroblasts	I-cell_line
but	O
normal	O
affinity	O
of	O
GR	B-protein
in	O
both	O
patients	O
.	O

In	O
this	O
study	O
,	O
peripheral	B-cell_type
lymphocytes	I-cell_type
from	O
these	O
patients	O
,	O
one	O
patient	O
's	O
son	O
and	O
daughter	O
,	O
and	O
normal	O
subjects	O
were	O
transformed	O
with	O
Epstein-Barr	O
virus	O
.	O

Reduced	O
numbers	O
and	O
normal	O
affinity	O
of	O
GR	B-protein
were	O
found	O
in	O
the	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
lymphocytes	I-cell_line
from	O
both	O
patients	O
while	O
the	O
son	O
and	O
daughter	O
had	O
normal	O
numbers	O
and	O
affinity	O
of	O
GR	B-protein
.	O

The	O
thermal	O
stability	O
of	O
GR	B-protein
and	O
thermal	O
activation	O
of	O
cytosolic	B-protein
receptors	I-protein
in	O
both	O
patients	O
were	O
found	O
to	O
be	O
normal	O
.	O
<EOS>	B-X
The	B-X
thermal	B-X
stability	B-X
of	B-X
GR	B-X
and	B-X
thermal	B-X
activation	B-X
of	B-X
cytosolic	B-X
receptors	B-X
in	B-X
both	B-X
patients	B-X
were	B-X
found	B-X
to	B-X
be	B-X
normal	B-X
<EOS>	B-X
The	B-X
thermal	B-X
stability	B-X
and	B-X
the	B-X
sedimentation	B-X
coefficient	B-X
in	B-X
a	B-X
sucrose	B-X
density	B-X
gradient	B-X
of	B-X
the	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
and	B-X
normal	B-X
subjects	B-X
were	B-X
similar	B-X
<EOS>	B-X
Although	B-X
the	B-X
percentages	B-X
of	B-X
nuclear	B-X
bound	B-X
GR	B-X
were	B-X
similar	B-X
in	B-X
both	B-X
patients	B-X
and	B-X
normal	B-X
controls	B-X
,	B-X
the	B-X
absolute	B-X
amounts	B-X
of	B-X
nuclear	B-X
bound	B-X
GR	B-X
of	B-X
the	B-X
patients	B-X
were	B-X
about	B-X
one	B-X
-	B-X
half	B-X
that	B-X
of	B-X
normal	B-X
controls	B-X
<EOS>	B-X
Reduced	B-X
numbers	B-X
and	B-X
normal	B-X
affinity	B-X
of	B-X
GR	B-X
were	B-X
found	B-X
in	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
-	B-X
transformed	B-X
lymphocytes	B-X
from	B-X
both	B-X
patients	B-X
while	B-X
the	B-X
son	B-X
and	B-X
daughter	B-X
had	B-X
normal	B-X
numbers	B-X
and	B-X
affinity	B-X
of	B-X
GR	B-X

Although	O
the	O
percentages	O
of	O
nuclear	O
bound	O
GR	B-protein
were	O
similar	O
in	O
both	O
patients	O
and	O
normal	O
controls	O
,	O
the	O
absolute	O
amounts	O
of	O
nuclear	O
bound	O
GR	B-protein
of	O
the	O
patients	O
were	O
about	O
one-half	O
that	O
of	O
normal	O
controls	O
.	O

These	O
abnormal	O
properties	O
of	O
GR	B-protein
(	O
reduced	O
numbers	O
of	O
GR	B-protein
)	O
were	O
preserved	O
in	O
the	O
transformed	B-cell_line
cells	I-cell_line
from	O
the	O
patients	O
.	O

Octamer	O
transcription	O
factors	O
1	O
and	O
2	O
each	O
bind	O
to	O
two	O
different	O
functional	B-DNA
elements	I-DNA
in	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Octamer	B-X
transcription	B-X
factors	B-X
1	B-X
and	B-X
2	B-X
each	B-X
bind	B-X
to	B-X
two	B-X
different	B-X
functional	B-X
elements	B-X
in	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
promoter	B-X
.	B-X
<EOS>	B-X
The	B-X
ubiquitous	B-X
octamer	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
is	B-X
sufficient	B-X
for	B-X
transcription	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
<EOS>	B-X
The	B-X
exact	B-X
role	B-X
of	B-X
these	B-X
different	B-X
proteins	B-X
in	B-X
directing	B-X
the	B-X
tissue	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
is	B-X
unclear	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
demonstrates	B-X
that	B-X
both	B-X
the	B-X
ubiquitous	B-X
and	B-X
lymphoid	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
octamer	B-X
transcription	B-X
factors	B-X
(	B-X
OTF	B-X
-	B-X
1	B-X
and	B-X
OTF	B-X
-	B-X
2	B-X
,	B-X
respectively	B-X
)	B-X
interact	B-X
specifically	B-X
with	B-X
each	B-X
of	B-X
the	B-X
two	B-X
conserved	B-X
sequence	B-X
elements	B-X
,	B-X
forming	B-X
either	B-X
homo	B-X
-	B-X
	B-X
or	B-X
heterodimeric	B-X
complexes	B-X

Immunoglobulin	B-DNA
heavy-chain	I-DNA
genes	I-DNA
contain	O
two	O
conserved	B-DNA
sequence	I-DNA
elements	I-DNA
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
:	O
the	O
octamer	O
ATGCAAAT	O
and	O
the	O
heptamer	O
CTCATGA	O
.	O

Both	O
of	O
these	O
elements	O
are	O
required	O
for	O
normal	B-DNA
cell-specific	I-DNA
promoter	I-DNA
function	O
.	O
<EOS>	B-X
We	B-X
find	B-X
that	B-X
this	B-X
down	B-X
-	B-X
regulation	B-X
may	B-X
be	B-X
required	B-X
for	B-X
normal	B-X
ductal	B-X
expression	B-X
of	B-X
cytokeratin	B-X
K19	B-X
<EOS>	B-X
We	B-X
also	B-X
show	B-X
that	B-X
myogenin	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
expression	B-X
in	B-X
vivo	B-X
and	B-X
physically	B-X
binds	B-X
to	B-X
the	B-X
Tcap	B-X
promoter	B-X
during	B-X
embryogenesis	B-X
<EOS>	B-X
Enhancers	B-X
are	B-X
distal	B-X
cis	B-X
-	B-X
regulatory	B-X
elements	B-X
required	B-X
for	B-X
cell	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
and	B-X
cell	B-X
fate	B-X
determination	B-X
<EOS>	B-X
The	B-X
gonadotropin	B-X
-	B-X
releasing	B-X
hormone	B-X
cell	B-X
-	B-X
specific	B-X
element	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
puberty	B-X
and	B-X
estrous	B-X
cyclicity	B-X
.	B-X

The	O
present	O
study	O
demonstrates	O
that	O
both	O
the	O
ubiquitous	B-protein
and	I-protein
lymphoid-cell-specific	I-protein
octamer	I-protein
transcription	I-protein
factors	I-protein
(	O
OTF-1	B-protein
and	O
OTF-2	B-protein
,	O
respectively	O
)	O
interact	O
specifically	O
with	O
each	O
of	O
the	O
two	O
conserved	B-DNA
sequence	I-DNA
elements	I-DNA
,	O
forming	O
either	O
homo-	B-protein
or	I-protein
heterodimeric	I-protein
complexes	I-protein
.	O
<EOS>	B-X
The	B-X
electron	B-X
transfer	B-X
pathway	B-X
was	B-X
predicted	B-X
in	B-X
Micromonas	B-X
CAO	B-X
and	B-X
the	B-X
overall	B-X
structure	B-X
of	B-X
the	B-X
CAO	B-X
active	B-X
site	B-X
was	B-X
conserved	B-X
even	B-X
though	B-X
it	B-X
forms	B-X
a	B-X
heterodimeric	B-X
complex	B-X
<EOS>	B-X
Through	B-X
a	B-X
multilevel	B-X
approach	B-X
based	B-X
on	B-X
AD	B-X
datasets	B-X
and	B-X
a	B-X
novel	B-X
chemogenetic	B-X
method	B-X
that	B-X
resolves	B-X
the	B-X
genomic	B-X
binding	B-X
profile	B-X
of	B-X
dimeric	B-X
transcription	B-X
factors	B-X
(	B-X
ChIPmera	B-X
)	B-X
,	B-X
we	B-X
find	B-X
that	B-X
CREB3L2	B-X
-	B-X
ATF4	B-X
activates	B-X
a	B-X
transcription	B-X
network	B-X
that	B-X
interacts	B-X
with	B-X
roughly	B-X
half	B-X
of	B-X
the	B-X
genes	B-X
differentially	B-X
expressed	B-X
in	B-X
AD	B-X
,	B-X
including	B-X
subsets	B-X
associated	B-X
with	B-X
β	B-X
-	B-X
amyloid	B-X
and	B-X
tau	B-X
neuropathologies	B-X
<EOS>	B-X
The	B-X
findings	B-X
overall	B-X
reveal	B-X
differential	B-X
transcription	B-X
factor	B-X
dimerization	B-X
as	B-X
a	B-X
mechanism	B-X
linking	B-X
disease	B-X
stimuli	B-X
to	B-X
the	B-X
development	B-X
of	B-X
pathogenic	B-X
cellular	B-X
states	B-X
<EOS>	B-X
Structural	B-X
insights	B-X
into	B-X
the	B-X
chromodomain	B-X
of	B-X
Oxpecker	B-X
in	B-X
complex	B-X
with	B-X
histone	B-X
H3	B-X
lysine	B-X
9	B-X
trimethylation	B-X
reveal	B-X
a	B-X
transposon	B-X
silencing	B-X
mechanism	B-X
by	B-X
heterodimerization	B-X
.	B-X

This	O
was	O
surprising	O
,	O
since	O
the	O
heptamer	O
and	O
octamer	O
sequence	O
motifs	O
bear	O
no	O
obvious	O
similarity	O
to	O
each	O
other	O
.	O
<EOS>	B-X
This	B-X
was	B-X
surprising	B-X
,	B-X
since	B-X
the	B-X
heptamer	B-X
and	B-X
octamer	B-X
sequence	B-X
motifs	B-X
bear	B-X
no	B-X
obvious	B-X
similarity	B-X
to	B-X
each	B-X
other	B-X
<EOS>	B-X
Binding	B-X
of	B-X
either	B-X
factor	B-X
to	B-X
the	B-X
octamer	B-X
element	B-X
occurred	B-X
independently	B-X
<EOS>	B-X
Immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
genes	B-X
contain	B-X
two	B-X
conserved	B-X
sequence	B-X
elements	B-X
5	B-X
'	B-X
to	B-X
the	B-X
site	B-X
of	B-X
transcription	B-X
initiation	B-X
:	B-X
the	B-X
octamer	B-X
ATGCAAAT	B-X
and	B-X
the	B-X
heptamer	B-X
CTCATGA	B-X
<EOS>	B-X
The	B-X
degeneracy	B-X
in	B-X
sequences	B-X
recognized	B-X
by	B-X
the	B-X
OTFs	B-X
may	B-X
be	B-X
important	B-X
in	B-X
widening	B-X
the	B-X
range	B-X
over	B-X
which	B-X
gene	B-X
expression	B-X
can	B-X
be	B-X
modulated	B-X
and	B-X
in	B-X
establishing	B-X
cell	B-X
type	B-X
specificity	B-X

Binding	O
of	O
either	O
factor	O
to	O
the	O
octamer	B-DNA
element	I-DNA
occurred	O
independently	O
.	O

However	O
,	O
OTF	B-protein
interaction	O
with	O
the	O
heptamer	B-DNA
sequence	I-DNA
appeared	O
to	O
require	O
the	O
presence	O
of	O
an	O
intact	O
octamer	O
motif	O
and	O
occurred	O
with	O
a	O
spacing	O
of	O
either	O
2	B-DNA
or	I-DNA
14	I-DNA
base	I-DNA
pairs	I-DNA
between	O
the	O
two	O
elements	O
,	O
suggesting	O
coordinate	O
binding	O
resulting	O
from	O
protein-protein	O
interactions	O
.	O
<EOS>	B-X
However	B-X
,	B-X
OTF	B-X
interaction	B-X
with	B-X
the	B-X
heptamer	B-X
sequence	B-X
appeared	B-X
to	B-X
require	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
intact	B-X
octamer	B-X
motif	B-X
and	B-X
occurred	B-X
with	B-X
a	B-X
spacing	B-X
of	B-X
either	B-X
2	B-X
or	B-X
14	B-X
base	B-X
pairs	B-X
between	B-X
the	B-X
two	B-X
elements	B-X
,	B-X
suggesting	B-X
coordinate	B-X
binding	B-X
resulting	B-X
from	B-X
protein	B-X
-	B-X
protein	B-X
interactions	B-X
<EOS>	B-X
The	B-X
degeneracy	B-X
in	B-X
sequences	B-X
recognized	B-X
by	B-X
the	B-X
OTFs	B-X
may	B-X
be	B-X
important	B-X
in	B-X
widening	B-X
the	B-X
range	B-X
over	B-X
which	B-X
gene	B-X
expression	B-X
can	B-X
be	B-X
modulated	B-X
and	B-X
in	B-X
establishing	B-X
cell	B-X
type	B-X
specificity	B-X
<EOS>	B-X
Octamer	B-X
transcription	B-X
factors	B-X
1	B-X
and	B-X
2	B-X
each	B-X
bind	B-X
to	B-X
two	B-X
different	B-X
functional	B-X
elements	B-X
in	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
genes	B-X
contain	B-X
two	B-X
conserved	B-X
sequence	B-X
elements	B-X
5	B-X
'	B-X
to	B-X
the	B-X
site	B-X
of	B-X
transcription	B-X
initiation	B-X
:	B-X
the	B-X
octamer	B-X
ATGCAAAT	B-X
and	B-X
the	B-X
heptamer	B-X
CTCATGA	B-X

The	O
degeneracy	O
in	O
sequences	O
recognized	O
by	O
the	O
OTFs	B-protein
may	O
be	O
important	O
in	O
widening	O
the	O
range	O
over	O
which	O
gene	O
expression	O
can	O
be	O
modulated	O
and	O
in	O
establishing	O
cell	O
type	O
specificity	O
.	O
<EOS>	B-X
The	B-X
degeneracy	B-X
in	B-X
sequences	B-X
recognized	B-X
by	B-X
the	B-X
OTFs	B-X
may	B-X
be	B-X
important	B-X
in	B-X
widening	B-X
the	B-X
range	B-X
over	B-X
which	B-X
gene	B-X
expression	B-X
can	B-X
be	B-X
modulated	B-X
and	B-X
in	B-X
establishing	B-X
cell	B-X
type	B-X
specificity	B-X
<EOS>	B-X
However	B-X
,	B-X
OTF	B-X
interaction	B-X
with	B-X
the	B-X
heptamer	B-X
sequence	B-X
appeared	B-X
to	B-X
require	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
intact	B-X
octamer	B-X
motif	B-X
and	B-X
occurred	B-X
with	B-X
a	B-X
spacing	B-X
of	B-X
either	B-X
2	B-X
or	B-X
14	B-X
base	B-X
pairs	B-X
between	B-X
the	B-X
two	B-X
elements	B-X
,	B-X
suggesting	B-X
coordinate	B-X
binding	B-X
resulting	B-X
from	B-X
protein	B-X
-	B-X
protein	B-X
interactions	B-X
<EOS>	B-X
This	B-X
was	B-X
surprising	B-X
,	B-X
since	B-X
the	B-X
heptamer	B-X
and	B-X
octamer	B-X
sequence	B-X
motifs	B-X
bear	B-X
no	B-X
obvious	B-X
similarity	B-X
to	B-X
each	B-X
other	B-X
<EOS>	B-X
Octamer	B-X
transcription	B-X
factors	B-X
1	B-X
and	B-X
2	B-X
each	B-X
bind	B-X
to	B-X
two	B-X
different	B-X
functional	B-X
elements	B-X
in	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
promoter	B-X
.	B-X

Identification	O
of	O
a	O
novel	O
lymphoid	B-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
(	O
OTF-2B	B-protein
)	O
by	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
.	O
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
lymphoid	B-X
specific	B-X
octamer	B-X
binding	B-X
protein	B-X
(	B-X
OTF	B-X
-	B-X
2B	B-X
)	B-X
by	B-X
proteolytic	B-X
clipping	B-X
bandshift	B-X
assay	B-X
(	B-X
PCBA	B-X
)	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
present	B-X
evidence	B-X
for	B-X
yet	B-X
another	B-X
B	B-X
cell	B-X
specific	B-X
octamer	B-X
binding	B-X
protein	B-X
of	B-X
75	B-X
kd	B-X
(	B-X
OTF	B-X
-	B-X
2B	B-X
)	B-X
<EOS>	B-X
The	B-X
lymphoid	B-X
cell	B-X
specific	B-X
octamer	B-X
binding	B-X
protein	B-X
of	B-X
60	B-X
kd	B-X
(	B-X
OTF	B-X
-	B-X
2A	B-X
)	B-X
specifically	B-X
stimulates	B-X
Ig	B-X
promoters	B-X
which	B-X
consist	B-X
essentially	B-X
of	B-X
a	B-X
TATA	B-X
-	B-X
box	B-X
and	B-X
an	B-X
octamer	B-X
sequence	B-X
upstream	B-X
of	B-X
it	B-X
<EOS>	B-X
An	B-X
apparent	B-X
paradox	B-X
is	B-X
that	B-X
the	B-X
same	B-X
sequence	B-X
serves	B-X
as	B-X
an	B-X
upstream	B-X
promoter	B-X
or	B-X
enhancer	B-X
element	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
housekeeping	B-X
genes	B-X
such	B-X
as	B-X
the	B-X
histone	B-X
H2B	B-X
and	B-X
U	B-X
snRNA	B-X
genes	B-X

The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
found	O
in	O
the	O
promoters	O
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
heavy	I-DNA
and	I-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
and	O
in	O
the	O
heavy	B-DNA
chain	I-DNA
enhancer	I-DNA
and	O
is	O
a	O
major	O
determinant	O
of	O
the	O
cell	O
type	O
specific	O
expression	O
of	O
Ig	B-DNA
genes	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O

An	O
apparent	O
paradox	O
is	O
that	O
the	O
same	O
sequence	O
serves	O
as	O
an	O
upstream	B-DNA
promoter	I-DNA
or	I-DNA
enhancer	I-DNA
element	I-DNA
in	O
a	O
variety	O
of	O
housekeeping	B-DNA
genes	I-DNA
such	O
as	O
the	O
histone	B-DNA
H2B	I-DNA
and	I-DNA
U	I-DNA
snRNA	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
An	B-X
apparent	B-X
paradox	B-X
is	B-X
that	B-X
the	B-X
same	B-X
sequence	B-X
serves	B-X
as	B-X
an	B-X
upstream	B-X
promoter	B-X
or	B-X
enhancer	B-X
element	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
housekeeping	B-X
genes	B-X
such	B-X
as	B-X
the	B-X
histone	B-X
H2B	B-X
and	B-X
U	B-X
snRNA	B-X
genes	B-X
<EOS>	B-X
The	B-X
differential	B-X
usage	B-X
of	B-X
this	B-X
regulatory	B-X
sequence	B-X
motif	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
different	B-X
species	B-X
of	B-X
octamer	B-X
binding	B-X
proteins	B-X
<EOS>	B-X
The	B-X
octamer	B-X
sequence	B-X
ATGCAAAT	B-X
is	B-X
found	B-X
in	B-X
the	B-X
promoters	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
heavy	B-X
and	B-X
light	B-X
chain	B-X
genes	B-X
and	B-X
in	B-X
the	B-X
heavy	B-X
chain	B-X
enhancer	B-X
and	B-X
is	B-X
a	B-X
major	B-X
determinant	B-X
of	B-X
the	B-X
cell	B-X
type	B-X
specific	B-X
expression	B-X
of	B-X
Ig	B-X
genes	B-X
in	B-X
B	B-X
cells	B-X
<EOS>	B-X
From	B-X
several	B-X
findings	B-X
,	B-X
including	B-X
the	B-X
absence	B-X
of	B-X
OTF	B-X
-	B-X
2B	B-X
(	B-X
but	B-X
not	B-X
OTF	B-X
-	B-X
2A	B-X
)	B-X
from	B-X
a	B-X
lymphocyte	B-X
line	B-X
that	B-X
can	B-X
not	B-X
respond	B-X
to	B-X
the	B-X
IgH	B-X
enhancer	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
role	B-X
of	B-X
the	B-X
novel	B-X
octamer	B-X
factor	B-X
in	B-X
the	B-X
long	B-X
range	B-X
activation	B-X
by	B-X
the	B-X
IgH	B-X
enhancer	B-X

The	O
differential	O
usage	O
of	O
this	O
regulatory	O
sequence	O
motif	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
different	O
species	O
of	O
octamer	B-protein
binding	I-protein
proteins	I-protein
.	O
<EOS>	B-X
The	B-X
differential	B-X
usage	B-X
of	B-X
this	B-X
regulatory	B-X
sequence	B-X
motif	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
different	B-X
species	B-X
of	B-X
octamer	B-X
binding	B-X
proteins	B-X
<EOS>	B-X
Here	B-X
we	B-X
present	B-X
evidence	B-X
for	B-X
yet	B-X
another	B-X
B	B-X
cell	B-X
specific	B-X
octamer	B-X
binding	B-X
protein	B-X
of	B-X
75	B-X
kd	B-X
(	B-X
OTF	B-X
-	B-X
2B	B-X
)	B-X
<EOS>	B-X
An	B-X
apparent	B-X
paradox	B-X
is	B-X
that	B-X
the	B-X
same	B-X
sequence	B-X
serves	B-X
as	B-X
an	B-X
upstream	B-X
promoter	B-X
or	B-X
enhancer	B-X
element	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
housekeeping	B-X
genes	B-X
such	B-X
as	B-X
the	B-X
histone	B-X
H2B	B-X
and	B-X
U	B-X
snRNA	B-X
genes	B-X
<EOS>	B-X
The	B-X
lymphoid	B-X
cell	B-X
specific	B-X
octamer	B-X
binding	B-X
protein	B-X
of	B-X
60	B-X
kd	B-X
(	B-X
OTF	B-X
-	B-X
2A	B-X
)	B-X
specifically	B-X
stimulates	B-X
Ig	B-X
promoters	B-X
which	B-X
consist	B-X
essentially	B-X
of	B-X
a	B-X
TATA	B-X
-	B-X
box	B-X
and	B-X
an	B-X
octamer	B-X
sequence	B-X
upstream	B-X
of	B-X
it	B-X

One	O
species	O
of	O
100	O
kd	O
,	O
designated	O
OTF-1	B-protein
,	O
is	O
present	O
in	O
all	O
cell	O
types	O
and	O
may	O
exert	O
its	O
activating	O
function	O
only	O
when	O
it	O
can	O
interact	O
with	O
additional	O
adjacent	O
transcription	B-protein
factors	I-protein
.	O
<EOS>	B-X
One	B-X
species	B-X
of	B-X
100	B-X
kd	B-X
,	B-X
designated	B-X
OTF	B-X
-	B-X
1	B-X
,	B-X
is	B-X
present	B-X
in	B-X
all	B-X
cell	B-X
types	B-X
and	B-X
may	B-X
exert	B-X
its	B-X
activating	B-X
function	B-X
only	B-X
when	B-X
it	B-X
can	B-X
interact	B-X
with	B-X
additional	B-X
adjacent	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
the	B-X
proteolytic	B-X
clipping	B-X
bandshift	B-X
assay	B-X
(	B-X
PCBA	B-X
)	B-X
technique	B-X
to	B-X
distinguish	B-X
the	B-X
three	B-X
different	B-X
forms	B-X
found	B-X
in	B-X
B	B-X
cells	B-X
<EOS>	B-X
The	B-X
octamer	B-X
sequence	B-X
ATGCAAAT	B-X
is	B-X
found	B-X
in	B-X
the	B-X
promoters	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
heavy	B-X
and	B-X
light	B-X
chain	B-X
genes	B-X
and	B-X
in	B-X
the	B-X
heavy	B-X
chain	B-X
enhancer	B-X
and	B-X
is	B-X
a	B-X
major	B-X
determinant	B-X
of	B-X
the	B-X
cell	B-X
type	B-X
specific	B-X
expression	B-X
of	B-X
Ig	B-X
genes	B-X
in	B-X
B	B-X
cells	B-X
<EOS>	B-X
From	B-X
several	B-X
findings	B-X
,	B-X
including	B-X
the	B-X
absence	B-X
of	B-X
OTF	B-X
-	B-X
2B	B-X
(	B-X
but	B-X
not	B-X
OTF	B-X
-	B-X
2A	B-X
)	B-X
from	B-X
a	B-X
lymphocyte	B-X
line	B-X
that	B-X
can	B-X
not	B-X
respond	B-X
to	B-X
the	B-X
IgH	B-X
enhancer	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
role	B-X
of	B-X
the	B-X
novel	B-X
octamer	B-X
factor	B-X
in	B-X
the	B-X
long	B-X
range	B-X
activation	B-X
by	B-X
the	B-X
IgH	B-X
enhancer	B-X

The	O
lymphoid	B-protein
cell	I-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
of	O
60	O
kd	O
(	O
OTF-2A	B-protein
)	O
specifically	O
stimulates	O
Ig	B-DNA
promoters	I-DNA
which	O
consist	O
essentially	O
of	O
a	O
TATA-box	B-DNA
and	O
an	O
octamer	B-DNA
sequence	I-DNA
upstream	O
of	O
it	O
.	O

Here	O
we	O
present	O
evidence	O
for	O
yet	O
another	O
B	B-protein
cell	I-protein
specific	I-protein
octamer	I-protein
binding	I-protein
protein	I-protein
of	O
75	O
kd	O
(	O
OTF-2B	B-protein
)	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
present	B-X
evidence	B-X
for	B-X
yet	B-X
another	B-X
B	B-X
cell	B-X
specific	B-X
octamer	B-X
binding	B-X
protein	B-X
of	B-X
75	B-X
kd	B-X
(	B-X
OTF	B-X
-	B-X
2B	B-X
)	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
lymphoid	B-X
specific	B-X
octamer	B-X
binding	B-X
protein	B-X
(	B-X
OTF	B-X
-	B-X
2B	B-X
)	B-X
by	B-X
proteolytic	B-X
clipping	B-X
bandshift	B-X
assay	B-X
(	B-X
PCBA	B-X
)	B-X
.	B-X
<EOS>	B-X
The	B-X
differential	B-X
usage	B-X
of	B-X
this	B-X
regulatory	B-X
sequence	B-X
motif	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
different	B-X
species	B-X
of	B-X
octamer	B-X
binding	B-X
proteins	B-X
<EOS>	B-X
An	B-X
apparent	B-X
paradox	B-X
is	B-X
that	B-X
the	B-X
same	B-X
sequence	B-X
serves	B-X
as	B-X
an	B-X
upstream	B-X
promoter	B-X
or	B-X
enhancer	B-X
element	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
housekeeping	B-X
genes	B-X
such	B-X
as	B-X
the	B-X
histone	B-X
H2B	B-X
and	B-X
U	B-X
snRNA	B-X
genes	B-X

From	O
several	O
findings	O
,	O
including	O
the	O
absence	O
of	O
OTF-2B	B-protein
(	O
but	O
not	O
OTF-2A	B-protein
)	O
from	O
a	O
lymphocyte	B-cell_line
line	I-cell_line
that	O
can	O
not	O
respond	O
to	O
the	O
IgH	B-DNA
enhancer	I-DNA
,	O
we	O
propose	O
a	O
role	O
of	O
the	O
novel	B-protein
octamer	I-protein
factor	I-protein
in	O
the	O
long	O
range	O
activation	O
by	O
the	O
IgH	B-DNA
enhancer	I-DNA
.	O
<EOS>	B-X
From	B-X
several	B-X
findings	B-X
,	B-X
including	B-X
the	B-X
absence	B-X
of	B-X
OTF	B-X
-	B-X
2B	B-X
(	B-X
but	B-X
not	B-X
OTF	B-X
-	B-X
2A	B-X
)	B-X
from	B-X
a	B-X
lymphocyte	B-X
line	B-X
that	B-X
can	B-X
not	B-X
respond	B-X
to	B-X
the	B-X
IgH	B-X
enhancer	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
role	B-X
of	B-X
the	B-X
novel	B-X
octamer	B-X
factor	B-X
in	B-X
the	B-X
long	B-X
range	B-X
activation	B-X
by	B-X
the	B-X
IgH	B-X
enhancer	B-X
<EOS>	B-X
An	B-X
apparent	B-X
paradox	B-X
is	B-X
that	B-X
the	B-X
same	B-X
sequence	B-X
serves	B-X
as	B-X
an	B-X
upstream	B-X
promoter	B-X
or	B-X
enhancer	B-X
element	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
housekeeping	B-X
genes	B-X
such	B-X
as	B-X
the	B-X
histone	B-X
H2B	B-X
and	B-X
U	B-X
snRNA	B-X
genes	B-X
<EOS>	B-X
The	B-X
octamer	B-X
sequence	B-X
ATGCAAAT	B-X
is	B-X
found	B-X
in	B-X
the	B-X
promoters	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
heavy	B-X
and	B-X
light	B-X
chain	B-X
genes	B-X
and	B-X
in	B-X
the	B-X
heavy	B-X
chain	B-X
enhancer	B-X
and	B-X
is	B-X
a	B-X
major	B-X
determinant	B-X
of	B-X
the	B-X
cell	B-X
type	B-X
specific	B-X
expression	B-X
of	B-X
Ig	B-X
genes	B-X
in	B-X
B	B-X
cells	B-X
<EOS>	B-X
The	B-X
differential	B-X
usage	B-X
of	B-X
this	B-X
regulatory	B-X
sequence	B-X
motif	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
different	B-X
species	B-X
of	B-X
octamer	B-X
binding	B-X
proteins	B-X

We	O
have	O
used	O
the	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
technique	O
to	O
distinguish	O
the	O
three	O
different	O
forms	O
found	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

This	O
analysis	O
indicates	O
that	O
the	O
75	O
kd-species	O
OTF-2B	B-protein
is	O
closely	O
related	O
to	O
the	O
60	B-protein
kd	I-protein
species	I-protein
OTF-2A	I-protein
.	O

Inhibition	O
of	O
interleukin	B-protein
2	I-protein
-induced	O
proliferation	O
of	O
cloned	B-cell_line
murine	I-cell_line
T	I-cell_line
cells	I-cell_line
by	O
glucocorticoids	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
interleukin	B-X
2	B-X
-	B-X
induced	B-X
proliferation	B-X
of	B-X
cloned	B-X
murine	B-X
T	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
Possible	B-X
involvement	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
.	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
glucocorticoids	B-X
to	B-X
inhibit	B-X
interleukin	B-X
2	B-X
(	B-X
IL	B-X
2	B-X
)	B-X
	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
proliferation	B-X
in	B-X
two	B-X
cytotoxic	B-X
T	B-X
cell	B-X
(	B-X
CTL	B-X
)	B-X
clones	B-X
has	B-X
been	B-X
studied	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
DEX	B-X
on	B-X
the	B-X
proliferation	B-X
of	B-X
the	B-X
cytotoxic	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
CTLL	B-X
-	B-X
2	B-X
cell	B-X
line	B-X
are	B-X
completely	B-X
opposite	B-X
<EOS>	B-X
Differential	B-X
effects	B-X
of	B-X
N	B-X
-	B-X
acetyl	B-X
-	B-X
l	B-X
-	B-X
cysteine	B-X
on	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
	B-X
vs	B-X
IL	B-X
-	B-X
12	B-X
-	B-X
driven	B-X
proliferation	B-X
of	B-X
a	B-X
T	B-X
cell	B-X
clone	B-X
:	B-X
implications	B-X
for	B-X
distinct	B-X
signalling	B-X
pathways	B-X
.	B-X

Possible	O
involvement	O
of	O
an	O
inhibitory	B-protein
protein	I-protein
.	O
<EOS>	B-X
Autoantibodies	B-X
against	B-X
complement	B-X
factor	B-X
B	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
<EOS>	B-X
Possible	B-X
Role	B-X
of	B-X
<EOS>	B-X
Conserved	B-X
allosteric	B-X
inhibition	B-X
mechanism	B-X
in	B-X
SLC1	B-X
transporters	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
allosteric	B-X
modulation	B-X
of	B-X
ASCT2	B-X
via	B-X
non	B-X
-	B-X
competitive	B-X
inhibitors	B-X
is	B-X
unknown	B-X

The	O
ability	O
of	O
glucocorticoids	O
to	O
inhibit	O
interleukin	B-protein
2	I-protein
(	O
IL	B-protein
2	I-protein
)	O
-induced	O
T	B-cell_type
cell	I-cell_type
proliferation	O
in	O
two	O
cytotoxic	B-cell_line
T	I-cell_line
cell	I-cell_line
(	I-cell_line
CTL	I-cell_line
)	I-cell_line
clones	I-cell_line
has	O
been	O
studied	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
glucocorticoids	B-X
to	B-X
inhibit	B-X
interleukin	B-X
2	B-X
(	B-X
IL	B-X
2	B-X
)	B-X
	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
proliferation	B-X
in	B-X
two	B-X
cytotoxic	B-X
T	B-X
cell	B-X
(	B-X
CTL	B-X
)	B-X
clones	B-X
has	B-X
been	B-X
studied	B-X
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
these	B-X
hormones	B-X
may	B-X
also	B-X
affect	B-X
T	B-X
cell	B-X
proliferation	B-X
by	B-X
inhibiting	B-X
IL	B-X
2	B-X
activity	B-X
<EOS>	B-X
The	B-X
action	B-X
of	B-X
these	B-X
hormones	B-X
possibly	B-X
involves	B-X
the	B-X
synthesis	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
,	B-X
since	B-X
the	B-X
presence	B-X
of	B-X
cycloheximide	B-X
during	B-X
the	B-X
incubation	B-X
with	B-X
Dx	B-X
prevented	B-X
the	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
interleukin	B-X
2	B-X
-	B-X
induced	B-X
proliferation	B-X
of	B-X
cloned	B-X
murine	B-X
T	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
Possible	B-X
involvement	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
.	B-X

A	O
complete	O
inhibition	O
of	O
DNA	O
synthesis	O
by	O
dexamethasone	O
(	O
Dx	O
)	O
could	O
be	O
observed	O
when	O
IL	B-cell_line
2-depleted	I-cell_line
cultures	I-cell_line
of	O
CTL	B-cell_line
were	O
either	O
incubated	O
for	O
6	O
h	O
with	O
the	O
hormone	B-protein
prior	O
to	O
the	O
addition	O
of	O
IL	B-protein
2	I-protein
or	O
treated	O
simultaneously	O
with	O
Dx	O
and	O
a	O
low	O
concentration	O
of	O
IL	B-protein
2	I-protein
.	O

No	O
significant	O
reduction	O
in	O
the	O
number	O
and	O
affinity	O
of	O
IL	B-protein
2	I-protein
receptors	I-protein
was	O
seen	O
after	O
6	O
h	O
incubation	O
with	O
Dx	O
.	O
<EOS>	B-X
No	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
number	B-X
and	B-X
affinity	B-X
of	B-X
IL	B-X
2	B-X
receptors	B-X
was	B-X
seen	B-X
after	B-X
6	B-X
h	B-X
incubation	B-X
with	B-X
Dx	B-X
<EOS>	B-X
The	B-X
action	B-X
of	B-X
these	B-X
hormones	B-X
possibly	B-X
involves	B-X
the	B-X
synthesis	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
,	B-X
since	B-X
the	B-X
presence	B-X
of	B-X
cycloheximide	B-X
during	B-X
the	B-X
incubation	B-X
with	B-X
Dx	B-X
prevented	B-X
the	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
interleukin	B-X
2	B-X
-	B-X
induced	B-X
proliferation	B-X
of	B-X
cloned	B-X
murine	B-X
T	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
Possible	B-X
involvement	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
.	B-X
<EOS>	B-X
The	B-X
order	B-X
of	B-X
potency	B-X
observed	B-X
with	B-X
the	B-X
different	B-X
steroids	B-X
indicated	B-X
that	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
mediated	B-X
through	B-X
binding	B-X
to	B-X
a	B-X
specific	B-X
glucocorticoid	B-X
receptor	B-X

The	O
order	O
of	O
potency	O
observed	O
with	O
the	O
different	O
steroids	O
indicated	O
that	O
this	O
inhibitory	O
effect	O
was	O
mediated	O
through	O
binding	O
to	O
a	O
specific	O
glucocorticoid	B-protein
receptor	I-protein
.	O
<EOS>	B-X
The	B-X
order	B-X
of	B-X
potency	B-X
observed	B-X
with	B-X
the	B-X
different	B-X
steroids	B-X
indicated	B-X
that	B-X
this	B-X
inhibitory	B-X
effect	B-X
was	B-X
mediated	B-X
through	B-X
binding	B-X
to	B-X
a	B-X
specific	B-X
glucocorticoid	B-X
receptor	B-X
<EOS>	B-X
The	B-X
action	B-X
of	B-X
these	B-X
hormones	B-X
possibly	B-X
involves	B-X
the	B-X
synthesis	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
,	B-X
since	B-X
the	B-X
presence	B-X
of	B-X
cycloheximide	B-X
during	B-X
the	B-X
incubation	B-X
with	B-X
Dx	B-X
prevented	B-X
the	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
these	B-X
hormones	B-X
may	B-X
also	B-X
affect	B-X
T	B-X
cell	B-X
proliferation	B-X
by	B-X
inhibiting	B-X
IL	B-X
2	B-X
activity	B-X
<EOS>	B-X
No	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
number	B-X
and	B-X
affinity	B-X
of	B-X
IL	B-X
2	B-X
receptors	B-X
was	B-X
seen	B-X
after	B-X
6	B-X
h	B-X
incubation	B-X
with	B-X
Dx	B-X

The	O
action	O
of	O
these	O
hormones	B-protein
possibly	O
involves	O
the	O
synthesis	O
of	O
an	O
inhibitory	B-protein
protein	I-protein
(	O
s	O
)	O
,	O
since	O
the	O
presence	O
of	O
cycloheximide	O
during	O
the	O
incubation	O
with	O
Dx	O
prevented	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O
<EOS>	B-X
The	B-X
action	B-X
of	B-X
these	B-X
hormones	B-X
possibly	B-X
involves	B-X
the	B-X
synthesis	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
,	B-X
since	B-X
the	B-X
presence	B-X
of	B-X
cycloheximide	B-X
during	B-X
the	B-X
incubation	B-X
with	B-X
Dx	B-X
prevented	B-X
the	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
<EOS>	B-X
No	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
number	B-X
and	B-X
affinity	B-X
of	B-X
IL	B-X
2	B-X
receptors	B-X
was	B-X
seen	B-X
after	B-X
6	B-X
h	B-X
incubation	B-X
with	B-X
Dx	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
interleukin	B-X
2	B-X
-	B-X
induced	B-X
proliferation	B-X
of	B-X
cloned	B-X
murine	B-X
T	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
Possible	B-X
involvement	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
.	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
glucocorticoids	B-X
to	B-X
inhibit	B-X
interleukin	B-X
2	B-X
(	B-X
IL	B-X
2	B-X
)	B-X
	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
proliferation	B-X
in	B-X
two	B-X
cytotoxic	B-X
T	B-X
cell	B-X
(	B-X
CTL	B-X
)	B-X
clones	B-X
has	B-X
been	B-X
studied	B-X

Furthermore	O
,	O
supernatant	O
from	O
Dx-treated	O
CTL	B-cell_line
contained	O
a	O
nondialyzable	O
factor	O
which	O
inhibited	O
DNA	O
synthesis	O
and	O
cell	O
growth	O
of	O
CTL	B-cell_line
clones	I-cell_line
induced	O
by	O
IL	B-protein
2	I-protein
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
supernatant	B-X
from	B-X
Dx	B-X
-	B-X
treated	B-X
CTL	B-X
contained	B-X
a	B-X
nondialyzable	B-X
factor	B-X
which	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
and	B-X
cell	B-X
growth	B-X
of	B-X
CTL	B-X
clones	B-X
induced	B-X
by	B-X
IL	B-X
2	B-X
<EOS>	B-X
A	B-X
complete	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
by	B-X
dexamethasone	B-X
(	B-X
Dx	B-X
)	B-X
could	B-X
be	B-X
observed	B-X
when	B-X
IL	B-X
2	B-X
-	B-X
depleted	B-X
cultures	B-X
of	B-X
CTL	B-X
were	B-X
either	B-X
incubated	B-X
for	B-X
6	B-X
h	B-X
with	B-X
the	B-X
hormone	B-X
prior	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
IL	B-X
2	B-X
or	B-X
treated	B-X
simultaneously	B-X
with	B-X
Dx	B-X
and	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
IL	B-X
2	B-X
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
these	B-X
hormones	B-X
may	B-X
also	B-X
affect	B-X
T	B-X
cell	B-X
proliferation	B-X
by	B-X
inhibiting	B-X
IL	B-X
2	B-X
activity	B-X
<EOS>	B-X
No	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
number	B-X
and	B-X
affinity	B-X
of	B-X
IL	B-X
2	B-X
receptors	B-X
was	B-X
seen	B-X
after	B-X
6	B-X
h	B-X
incubation	B-X
with	B-X
Dx	B-X

Blocking	O
of	O
IL	B-protein
2	I-protein
synthesis	O
and	O
IL	B-protein
2	I-protein
receptor	I-protein
formation	O
have	O
been	O
proposed	O
as	O
one	O
of	O
the	O
major	O
mechanisms	O
of	O
glucocorticoid-induced	O
immunosuppression	O
.	O
<EOS>	B-X
Blocking	B-X
of	B-X
IL	B-X
2	B-X
synthesis	B-X
and	B-X
IL	B-X
2	B-X
receptor	B-X
formation	B-X
have	B-X
been	B-X
proposed	B-X
as	B-X
one	B-X
of	B-X
the	B-X
major	B-X
mechanisms	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
immunosuppression	B-X
<EOS>	B-X
A	B-X
complete	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
by	B-X
dexamethasone	B-X
(	B-X
Dx	B-X
)	B-X
could	B-X
be	B-X
observed	B-X
when	B-X
IL	B-X
2	B-X
-	B-X
depleted	B-X
cultures	B-X
of	B-X
CTL	B-X
were	B-X
either	B-X
incubated	B-X
for	B-X
6	B-X
h	B-X
with	B-X
the	B-X
hormone	B-X
prior	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
IL	B-X
2	B-X
or	B-X
treated	B-X
simultaneously	B-X
with	B-X
Dx	B-X
and	B-X
a	B-X
low	B-X
concentration	B-X
of	B-X
IL	B-X
2	B-X
<EOS>	B-X
No	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
number	B-X
and	B-X
affinity	B-X
of	B-X
IL	B-X
2	B-X
receptors	B-X
was	B-X
seen	B-X
after	B-X
6	B-X
h	B-X
incubation	B-X
with	B-X
Dx	B-X
<EOS>	B-X
The	B-X
action	B-X
of	B-X
these	B-X
hormones	B-X
possibly	B-X
involves	B-X
the	B-X
synthesis	B-X
of	B-X
an	B-X
inhibitory	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
,	B-X
since	B-X
the	B-X
presence	B-X
of	B-X
cycloheximide	B-X
during	B-X
the	B-X
incubation	B-X
with	B-X
Dx	B-X
prevented	B-X
the	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X

Our	O
results	O
indicate	O
that	O
these	O
hormones	B-protein
may	O
also	O
affect	O
T	B-cell_type
cell	I-cell_type
proliferation	O
by	O
inhibiting	O
IL	B-protein
2	I-protein
activity	O
.	O
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
these	B-X
hormones	B-X
may	B-X
also	B-X
affect	B-X
T	B-X
cell	B-X
proliferation	B-X
by	B-X
inhibiting	B-X
IL	B-X
2	B-X
activity	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
inhibition	B-X
of	B-X
murine	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
by	B-X
CGRP	B-X
and	B-X
VIP	B-X
is	B-X
mediated	B-X
by	B-X
different	B-X
mechanisms	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
growth	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
glucocorticoids	B-X
and	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
involve	B-X
distinct	B-X
aspects	B-X
of	B-X
cytokine	B-X
activities	B-X
<EOS>	B-X
Collectively	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
physiologic	B-X
concentrations	B-X
of	B-X
PGE2	B-X
and	B-X
DEX	B-X
,	B-X
which	B-X
alone	B-X
have	B-X
no	B-X
effect	B-X
on	B-X
anti	B-X
-	B-X
CD3	B-X
mAb	B-X
-	B-X
induced	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
,	B-X
act	B-X
synergistically	B-X
to	B-X
inhibit	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
as	B-X
well	B-X
as	B-X
IL	B-X
-	B-X
2	B-X
synthesis	B-X

Identification	O
and	O
purification	O
of	O
a	O
human	B-protein
immunoglobulin-enhancer-binding	I-protein
protein	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
that	O
activates	O
transcription	O
from	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
promoter	I-DNA
in	O
vitro	O
.	O
<EOS>	B-X
Identification	B-X
and	B-X
purification	B-X
of	B-X
a	B-X
human	B-X
immunoglobulin	B-X
-	B-X
enhancer	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
that	B-X
activates	B-X
transcription	B-X
from	B-X
a	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
promoter	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
``	B-X
Footprint	B-X
''	B-X
and	B-X
methylation	B-X
-	B-X
interference	B-X
analyses	B-X
have	B-X
shown	B-X
that	B-X
purified	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
has	B-X
a	B-X
binding	B-X
activity	B-X
specific	B-X
for	B-X
the	B-X
kappa	B-X
light	B-X
chain	B-X
enhancer	B-X
sequence	B-X
<EOS>	B-X
The	B-X
enhancer	B-X
-	B-X
binding	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
found	B-X
only	B-X
in	B-X
cells	B-X
that	B-X
transcribe	B-X
immunoglobulin	B-X
light	B-X
chain	B-X
genes	B-X
,	B-X
has	B-X
been	B-X
purified	B-X
from	B-X
nuclear	B-X
extracts	B-X
of	B-X
Namalwa	B-X
cells	B-X
(	B-X
human	B-X
Burkitt	B-X
lymphoma	B-X
cells	B-X
)	B-X
by	B-X
sequence	B-X
-	B-X
specific	B-X
DNA	B-X
affinity	B-X
chromatography	B-X
<EOS>	B-X
The	B-X
purified	B-X
factor	B-X
activated	B-X
in	B-X
vitro	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
I	B-X
promoter	B-X
by	B-X
binding	B-X
to	B-X
an	B-X
upstream	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
binding	B-X
site	B-X

The	O
enhancer-binding	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
is	O
found	O
only	O
in	O
cells	O
that	O
transcribe	O
immunoglobulin	B-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
,	O
has	O
been	O
purified	O
from	O
nuclear	O
extracts	O
of	O
Namalwa	B-cell_line
cells	I-cell_line
(	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
)	O
by	O
sequence-specific	O
DNA	O
affinity	O
chromatography	O
.	O
<EOS>	B-X
The	B-X
enhancer	B-X
-	B-X
binding	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
found	B-X
only	B-X
in	B-X
cells	B-X
that	B-X
transcribe	B-X
immunoglobulin	B-X
light	B-X
chain	B-X
genes	B-X
,	B-X
has	B-X
been	B-X
purified	B-X
from	B-X
nuclear	B-X
extracts	B-X
of	B-X
Namalwa	B-X
cells	B-X
(	B-X
human	B-X
Burkitt	B-X
lymphoma	B-X
cells	B-X
)	B-X
by	B-X
sequence	B-X
-	B-X
specific	B-X
DNA	B-X
affinity	B-X
chromatography	B-X
<EOS>	B-X
Identification	B-X
and	B-X
purification	B-X
of	B-X
a	B-X
human	B-X
immunoglobulin	B-X
-	B-X
enhancer	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
that	B-X
activates	B-X
transcription	B-X
from	B-X
a	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
promoter	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
The	B-X
purified	B-X
factor	B-X
activated	B-X
in	B-X
vitro	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
I	B-X
promoter	B-X
by	B-X
binding	B-X
to	B-X
an	B-X
upstream	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
binding	B-X
site	B-X
<EOS>	B-X
``	B-X
Footprint	B-X
''	B-X
and	B-X
methylation	B-X
-	B-X
interference	B-X
analyses	B-X
have	B-X
shown	B-X
that	B-X
purified	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
has	B-X
a	B-X
binding	B-X
activity	B-X
specific	B-X
for	B-X
the	B-X
kappa	B-X
light	B-X
chain	B-X
enhancer	B-X
sequence	B-X

The	O
purified	O
NF-kappa	B-protein
B	I-protein
has	O
been	O
identified	O
as	O
a	O
51-kDa	B-protein
polypeptide	I-protein
by	O
UV-crosslinking	O
analysis	O
.	O
<EOS>	B-X
The	B-X
purified	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
51	B-X
-	B-X
kDa	B-X
polypeptide	B-X
by	B-X
UV	B-X
-	B-X
crosslinking	B-X
analysis	B-X
<EOS>	B-X
The	B-X
purified	B-X
factor	B-X
activated	B-X
in	B-X
vitro	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
I	B-X
promoter	B-X
by	B-X
binding	B-X
to	B-X
an	B-X
upstream	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
binding	B-X
site	B-X
<EOS>	B-X
``	B-X
Footprint	B-X
''	B-X
and	B-X
methylation	B-X
-	B-X
interference	B-X
analyses	B-X
have	B-X
shown	B-X
that	B-X
purified	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
has	B-X
a	B-X
binding	B-X
activity	B-X
specific	B-X
for	B-X
the	B-X
kappa	B-X
light	B-X
chain	B-X
enhancer	B-X
sequence	B-X
<EOS>	B-X
The	B-X
enhancer	B-X
-	B-X
binding	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
found	B-X
only	B-X
in	B-X
cells	B-X
that	B-X
transcribe	B-X
immunoglobulin	B-X
light	B-X
chain	B-X
genes	B-X
,	B-X
has	B-X
been	B-X
purified	B-X
from	B-X
nuclear	B-X
extracts	B-X
of	B-X
Namalwa	B-X
cells	B-X
(	B-X
human	B-X
Burkitt	B-X
lymphoma	B-X
cells	B-X
)	B-X
by	B-X
sequence	B-X
-	B-X
specific	B-X
DNA	B-X
affinity	B-X
chromatography	B-X

``	O
Footprint	O
''	O
and	O
methylation-interference	O
analyses	O
have	O
shown	O
that	O
purified	O
NF-kappa	B-protein
B	I-protein
has	O
a	O
binding	O
activity	O
specific	O
for	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
enhancer	I-DNA
sequence	I-DNA
.	O

The	O
purified	O
factor	O
activated	O
in	O
vitro	O
transcription	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
promoter	I-DNA
by	O
binding	O
to	O
an	O
upstream	B-DNA
NF-kappa	I-DNA
B-binding	I-DNA
site	I-DNA

Lymphocyte	B-cell_type
glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
depression	O
:	O
normal	O
values	O
following	O
recovery	O
.	O
<EOS>	B-X
Lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
depression	B-X
:	B-X
normal	B-X
values	B-X
following	B-X
recovery	B-X
.	B-X
<EOS>	B-X
The	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
in	B-X
lymphocytes	B-X
from	B-X
the	B-X
recovered	B-X
depressed	B-X
group	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
from	B-X
that	B-X
of	B-X
the	B-X
control	B-X
group	B-X
<EOS>	B-X
This	B-X
study	B-X
shows	B-X
that	B-X
the	B-X
reduction	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
numbers	B-X
which	B-X
occurs	B-X
during	B-X
acute	B-X
depressive	B-X
illness	B-X
does	B-X
not	B-X
persist	B-X
on	B-X
recovery	B-X
and	B-X
is	B-X
,	B-X
therefore	B-X
,	B-X
state	B-X
-	B-X
dependent	B-X
<EOS>	B-X
Although	B-X
the	B-X
mean	B-X
plasma	B-X
cortisol	B-X
concentration	B-X
in	B-X
recovered	B-X
depressives	B-X
was	B-X
higher	B-X
than	B-X
in	B-X
control	B-X
subjects	B-X
,	B-X
the	B-X
difference	B-X
only	B-X
just	B-X
reached	B-X
significance	B-X

The	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	O
in	O
lymphocytes	B-cell_type
and	O
plasma	O
cortisol	O
concentrations	O
were	O
measured	O
in	O
20	O
patients	O
who	O
had	O
recovered	O
from	O
major	O
depressive	O
disorder	O
and	O
20	O
healthy	O
control	O
subjects	O
.	O
<EOS>	B-X
The	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
in	B-X
lymphocytes	B-X
and	B-X
plasma	B-X
cortisol	B-X
concentrations	B-X
were	B-X
measured	B-X
in	B-X
20	B-X
patients	B-X
who	B-X
had	B-X
recovered	B-X
from	B-X
major	B-X
depressive	B-X
disorder	B-X
and	B-X
20	B-X
healthy	B-X
control	B-X
subjects	B-X
<EOS>	B-X
The	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
in	B-X
lymphocytes	B-X
from	B-X
the	B-X
recovered	B-X
depressed	B-X
group	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
from	B-X
that	B-X
of	B-X
the	B-X
control	B-X
group	B-X
<EOS>	B-X
Although	B-X
the	B-X
mean	B-X
plasma	B-X
cortisol	B-X
concentration	B-X
in	B-X
recovered	B-X
depressives	B-X
was	B-X
higher	B-X
than	B-X
in	B-X
control	B-X
subjects	B-X
,	B-X
the	B-X
difference	B-X
only	B-X
just	B-X
reached	B-X
significance	B-X
<EOS>	B-X
Lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
depression	B-X
:	B-X
normal	B-X
values	B-X
following	B-X
recovery	B-X
.	B-X

The	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	O
in	O
lymphocytes	B-cell_type
from	O
the	O
recovered	O
depressed	O
group	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
control	O
group	O
.	O

Although	O
the	O
mean	O
plasma	O
cortisol	O
concentration	O
in	O
recovered	O
depressives	O
was	O
higher	O
than	O
in	O
control	O
subjects	O
,	O
the	O
difference	O
only	O
just	O
reached	O
significance	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
mean	B-X
plasma	B-X
cortisol	B-X
concentration	B-X
in	B-X
recovered	B-X
depressives	B-X
was	B-X
higher	B-X
than	B-X
in	B-X
control	B-X
subjects	B-X
,	B-X
the	B-X
difference	B-X
only	B-X
just	B-X
reached	B-X
significance	B-X
<EOS>	B-X
The	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
in	B-X
lymphocytes	B-X
and	B-X
plasma	B-X
cortisol	B-X
concentrations	B-X
were	B-X
measured	B-X
in	B-X
20	B-X
patients	B-X
who	B-X
had	B-X
recovered	B-X
from	B-X
major	B-X
depressive	B-X
disorder	B-X
and	B-X
20	B-X
healthy	B-X
control	B-X
subjects	B-X
<EOS>	B-X
Lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
depression	B-X
:	B-X
normal	B-X
values	B-X
following	B-X
recovery	B-X
.	B-X
<EOS>	B-X
The	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
in	B-X
lymphocytes	B-X
from	B-X
the	B-X
recovered	B-X
depressed	B-X
group	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
from	B-X
that	B-X
of	B-X
the	B-X
control	B-X
group	B-X

This	O
study	O
shows	O
that	O
the	O
reduction	O
in	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
which	O
occurs	O
during	O
acute	O
depressive	O
illness	O
does	O
not	O
persist	O
on	O
recovery	O
and	O
is	O
,	O
therefore	O
,	O
state-dependent	O
.	O

Identification	O
and	O
purification	O
of	O
a	O
human	B-protein
lymphoid-specific	I-protein
octamer-binding	I-protein
protein	I-protein
(	O
OTF-2	B-protein
)	O
that	O
activates	O
transcription	O
of	O
an	O
immunoglobulin	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O
<EOS>	B-X
Identification	B-X
and	B-X
purification	B-X
of	B-X
a	B-X
human	B-X
lymphoid	B-X
-	B-X
specific	B-X
octamer	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
OTF	B-X
-	B-X
2	B-X
)	B-X
that	B-X
activates	B-X
transcription	B-X
of	B-X
an	B-X
immunoglobulin	B-X
promoter	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
ubiquitous	B-X
and	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
octamer	B-X
-	B-X
binding	B-X
factors	B-X
,	B-X
we	B-X
identified	B-X
several	B-X
additional	B-X
proteins	B-X
,	B-X
one	B-X
of	B-X
which	B-X
is	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
,	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
kappa	B-X
promoter	B-X
<EOS>	B-X
The	B-X
specific	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
pure	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
factor	B-X
was	B-X
indistinguishable	B-X
from	B-X
that	B-X
of	B-X
the	B-X
affinity	B-X
-	B-X
purified	B-X
ubiquitous	B-X
factor	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
chromatographic	B-X
separation	B-X
of	B-X
ubiquitous	B-X
and	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
octamer	B-X
-	B-X
binding	B-X
proteins	B-X

The	O
octamer	O
sequence	O
5'-ATGCAAAT	O
,	O
in	O
either	O
orientation	O
,	O
serves	O
as	O
an	O
upstream	B-DNA
element	I-DNA
in	O
a	O
variety	O
of	O
promoters	B-DNA
and	O
also	O
occurs	O
as	O
a	O
modular	B-DNA
enhancer	I-DNA
element	I-DNA
.	O

It	O
is	O
of	O
particular	O
interest	O
in	O
immunoglobulin	B-DNA
genes	I-DNA
since	O
it	O
is	O
found	O
in	O
the	O
upstream	B-DNA
regions	I-DNA
of	O
all	O
heavy	B-DNA
and	I-DNA
light	I-DNA
chain	I-DNA
promoters	I-DNA
and	O
in	O
the	O
heavy	B-DNA
chain	I-DNA
enhancer	I-DNA
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
necessary	O
for	O
cell-specific	O
expression	O
.	O
<EOS>	B-X
It	B-X
is	B-X
of	B-X
particular	B-X
interest	B-X
in	B-X
immunoglobulin	B-X
genes	B-X
since	B-X
it	B-X
is	B-X
found	B-X
in	B-X
the	B-X
upstream	B-X
regions	B-X
of	B-X
all	B-X
heavy	B-X
and	B-X
light	B-X
chain	B-X
promoters	B-X
and	B-X
in	B-X
the	B-X
heavy	B-X
chain	B-X
enhancer	B-X
,	B-X
both	B-X
of	B-X
which	B-X
are	B-X
known	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
cell	B-X
-	B-X
specific	B-X
expression	B-X
<EOS>	B-X
This	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
octamer	B-X
-	B-X
binding	B-X
factor	B-X
,	B-X
in	B-X
pure	B-X
form	B-X
,	B-X
activated	B-X
transcription	B-X
from	B-X
a	B-X
kappa	B-X
light	B-X
chain	B-X
promoter	B-X
in	B-X
vitro	B-X
,	B-X
thus	B-X
demonstrating	B-X
that	B-X
it	B-X
is	B-X
indeed	B-X
a	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
transcription	B-X
factor	B-X
for	B-X
this	B-X
gene	B-X
<EOS>	B-X
The	B-X
octamer	B-X
sequence	B-X
5'	B-X
-	B-X
ATGCAAAT	B-X
,	B-X
in	B-X
either	B-X
orientation	B-X
,	B-X
serves	B-X
as	B-X
an	B-X
upstream	B-X
element	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
promoters	B-X
and	B-X
also	B-X
occurs	B-X
as	B-X
a	B-X
modular	B-X
enhancer	B-X
element	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
ubiquitous	B-X
and	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
octamer	B-X
-	B-X
binding	B-X
factors	B-X
,	B-X
we	B-X
identified	B-X
several	B-X
additional	B-X
proteins	B-X
,	B-X
one	B-X
of	B-X
which	B-X
is	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
,	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
kappa	B-X
promoter	B-X

We	O
report	O
here	O
the	O
chromatographic	O
separation	O
of	O
ubiquitous	B-protein
and	I-protein
B	I-protein
cell-specific	I-protein
octamer-binding	I-protein
proteins	I-protein
.	O

The	O
B	B-protein
cell	I-protein
factor	I-protein
was	O
purified	O
to	O
homogeneity	O
using	O
affinity	O
chromatography	O
and	O
consists	O
of	O
three	O
peptides	O
of	O
62	O
,	O
61	O
,	O
and	O
58.5	O
+/-	O
1.5	O
kd	O
.	O

Each	O
of	O
the	O
polypeptides	O
was	O
renatured	O
after	O
SDS-PAGE	O
and	O
shown	O
to	O
bind	O
to	O
the	O
octamer	O
sequence	O
.	O

The	O
specific	O
DNA	O
binding	O
activity	O
of	O
the	O
pure	O
B	B-protein
cell-specific	I-protein
factor	I-protein
was	O
indistinguishable	O
from	O
that	O
of	O
the	O
affinity-purified	B-protein
ubiquitous	I-protein
factor	I-protein
.	O
<EOS>	B-X
The	B-X
specific	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
pure	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
factor	B-X
was	B-X
indistinguishable	B-X
from	B-X
that	B-X
of	B-X
the	B-X
affinity	B-X
-	B-X
purified	B-X
ubiquitous	B-X
factor	B-X
<EOS>	B-X
This	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
octamer	B-X
-	B-X
binding	B-X
factor	B-X
,	B-X
in	B-X
pure	B-X
form	B-X
,	B-X
activated	B-X
transcription	B-X
from	B-X
a	B-X
kappa	B-X
light	B-X
chain	B-X
promoter	B-X
in	B-X
vitro	B-X
,	B-X
thus	B-X
demonstrating	B-X
that	B-X
it	B-X
is	B-X
indeed	B-X
a	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
transcription	B-X
factor	B-X
for	B-X
this	B-X
gene	B-X
<EOS>	B-X
Identification	B-X
and	B-X
purification	B-X
of	B-X
a	B-X
human	B-X
lymphoid	B-X
-	B-X
specific	B-X
octamer	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
OTF	B-X
-	B-X
2	B-X
)	B-X
that	B-X
activates	B-X
transcription	B-X
of	B-X
an	B-X
immunoglobulin	B-X
promoter	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
ubiquitous	B-X
and	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
octamer	B-X
-	B-X
binding	B-X
factors	B-X
,	B-X
we	B-X
identified	B-X
several	B-X
additional	B-X
proteins	B-X
,	B-X
one	B-X
of	B-X
which	B-X
is	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
,	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
kappa	B-X
promoter	B-X

This	O
B	B-protein
cell-specific	I-protein
octamer-binding	I-protein
factor	I-protein
,	O
in	O
pure	O
form	O
,	O
activated	O
transcription	O
from	O
a	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
promoter	I-DNA
in	O
vitro	O
,	O
thus	O
demonstrating	O
that	O
it	O
is	O
indeed	O
a	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
for	O
this	O
gene	O
.	O

In	O
addition	O
to	O
the	O
ubiquitous	B-protein
and	I-protein
B	I-protein
cell-specific	I-protein
octamer-binding	I-protein
factors	I-protein
,	O
we	O
identified	O
several	O
additional	O
proteins	O
,	O
one	O
of	O
which	O
is	O
B	B-cell_type
cell	I-cell_type
-specific	O
,	O
that	O
interact	O
with	O
the	O
kappa	B-DNA
promoter	I-DNA
.	O

Decreased	O
deoxyribonucleic	O
acid	O
binding	O
of	O
glucocorticoid-receptor	B-protein
complex	I-protein
in	O
cultured	O
skin	B-cell_line
fibroblasts	I-cell_line
from	O
a	O
patient	O
with	O
the	O
glucocorticoid	O
resistance	O
syndrome	O
.	O
<EOS>	B-X
Decreased	B-X
deoxyribonucleic	B-X
acid	B-X
binding	B-X
of	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complex	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
the	B-X
glucocorticoid	B-X
resistance	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
To	B-X
explain	B-X
the	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
,	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
GR	B-X
)	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
leukocytes	B-X
and	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
forearm	B-X
skin	B-X
biopsy	B-X
were	B-X
characterized	B-X
and	B-X
compared	B-X
with	B-X
the	B-X
results	B-X
of	B-X
similar	B-X
studies	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
The	B-X
thermal	B-X
stability	B-X
and	B-X
the	B-X
sedimentation	B-X
coefficient	B-X
in	B-X
a	B-X
sucrose	B-X
density	B-X
gradient	B-X
of	B-X
the	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
and	B-X
normal	B-X
subjects	B-X
were	B-X
similar	B-X
<EOS>	B-X
In	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
,	B-X
there	B-X
was	B-X
also	B-X
decreased	B-X
binding	B-X
capacity	B-X

A	O
patient	O
with	O
the	O
syndrome	O
of	O
glucocorticoid	O
resistance	O
was	O
studied	O
.	O
<EOS>	B-X
A	B-X
patient	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
glucocorticoid	B-X
resistance	B-X
was	B-X
studied	B-X
<EOS>	B-X
Five	B-X
patients	B-X
with	B-X
biochemical	B-X
and	B-X
/	B-X
or	B-X
clinical	B-X
generalized	B-X
glucocorticoid	B-X
resistance	B-X
without	B-X
alterations	B-X
in	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
gene	B-X
.	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
expression	B-X
level	B-X
and	B-X
binding	B-X
affinity	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
in	B-X
endogenous	B-X
Cushing	B-X
's	B-X
syndrome	B-X
patients	B-X
<EOS>	B-X
We	B-X
propose	B-X
an	B-X
additional	B-X
and	B-X
complementary	B-X
underlying	B-X
mechanism	B-X
of	B-X
glucocorticoid	B-X
resistance	B-X

A	O
27-yr-old	O
woman	O
initially	O
was	O
diagnosed	O
as	O
having	O
Cushing	O
's	O
disease	O
,	O
based	O
on	O
the	O
findings	O
of	O
high	O
plasma	O
ACTH	O
and	O
serum	O
cortisol	O
levels	O
,	O
increased	O
urinary	O
cortisol	O
secretion	O
,	O
resistance	O
to	O
adrenal	O
suppression	O
with	O
dexamethasone	O
,	O
and	O
bilateral	O
adrenal	O
hyperplasia	O
by	O
computed	O
tomography	O
and	O
scintigraphy	O
of	O
the	O
adrenal	O
glands	O
.	O
<EOS>	B-X
A	B-X
27	B-X
-	B-X
yr	B-X
-	B-X
old	B-X
woman	B-X
initially	B-X
was	B-X
diagnosed	B-X
as	B-X
having	B-X
Cushing	B-X
's	B-X
disease	B-X
,	B-X
based	B-X
on	B-X
the	B-X
findings	B-X
of	B-X
high	B-X
plasma	B-X
ACTH	B-X
and	B-X
serum	B-X
cortisol	B-X
levels	B-X
,	B-X
increased	B-X
urinary	B-X
cortisol	B-X
secretion	B-X
,	B-X
resistance	B-X
to	B-X
adrenal	B-X
suppression	B-X
with	B-X
dexamethasone	B-X
,	B-X
and	B-X
bilateral	B-X
adrenal	B-X
hyperplasia	B-X
by	B-X
computed	B-X
tomography	B-X
and	B-X
scintigraphy	B-X
of	B-X
the	B-X
adrenal	B-X
glands	B-X
<EOS>	B-X
The	B-X
thermal	B-X
stability	B-X
and	B-X
the	B-X
sedimentation	B-X
coefficient	B-X
in	B-X
a	B-X
sucrose	B-X
density	B-X
gradient	B-X
of	B-X
the	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
and	B-X
normal	B-X
subjects	B-X
were	B-X
similar	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
patient	B-X
's	B-X
glucocorticoid	B-X
resistance	B-X
was	B-X
due	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
receptor	B-X
for	B-X
glucocorticoids	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
GR	B-X
complex	B-X
to	B-X
DNA	B-X
<EOS>	B-X
Decreased	B-X
deoxyribonucleic	B-X
acid	B-X
binding	B-X
of	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complex	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
the	B-X
glucocorticoid	B-X
resistance	B-X
syndrome	B-X
.	B-X

However	O
,	O
she	O
had	O
no	O
signs	O
or	O
symptoms	O
of	O
Cushing	O
's	O
syndrome	O
.	O
<EOS>	B-X
However	B-X
,	B-X
some	B-X
of	B-X
the	B-X
patients	B-X
with	B-X
seronegative	B-X
rheumatoid	B-X
arthritis	B-X
are	B-X
misdiagnosed	B-X
<EOS>	B-X
The	B-X
postoperative	B-X
course	B-X
is	B-X
good	B-X
and	B-X
there	B-X
are	B-X
no	B-X
signs	B-X
of	B-X
recurrence	B-X
for	B-X
6	B-X
months	B-X
after	B-X
the	B-X
operation	B-X
<EOS>	B-X
The	B-X
oral	B-X
lesions	B-X
had	B-X
significant	B-X
improvement	B-X
after	B-X
4	B-X
weeks	B-X
of	B-X
treatment	B-X
<EOS>	B-X
Type	B-X
2	B-X
hyper	B-X
-	B-X
IgM	B-X
syndrome	B-X
with	B-X
a	B-X
rare	B-X
variant	B-X
of	B-X
AICDA	B-X
gene	B-X
mutation	B-X
in	B-X
a	B-X
young	B-X
woman	B-X
.	B-X

During	O
a	O
5-yr	O
follow-up	O
,	O
no	O
clinical	O
abnormalities	O
developed	O
,	O
although	O
hypercortisolism	O
persisted	O
.	O
<EOS>	B-X
During	B-X
a	B-X
5	B-X
-	B-X
yr	B-X
follow	B-X
-	B-X
up	B-X
,	B-X
no	B-X
clinical	B-X
abnormalities	B-X
developed	B-X
,	B-X
although	B-X
hypercortisolism	B-X
persisted	B-X
<EOS>	B-X
Decreased	B-X
deoxyribonucleic	B-X
acid	B-X
binding	B-X
of	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complex	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
the	B-X
glucocorticoid	B-X
resistance	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
Nuclear	B-X
translocation	B-X
of	B-X
GR	B-X
complexes	B-X
from	B-X
the	B-X
patient	B-X
was	B-X
also	B-X
slightly	B-X
decreased	B-X
<EOS>	B-X
End	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
was	B-X
suspected	B-X

End-organ	O
resistance	O
to	O
cortisol	O
was	O
suspected	O
.	O
<EOS>	B-X
End	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
was	B-X
suspected	B-X
<EOS>	B-X
Primary	B-X
cortisol	B-X
resistance	B-X
in	B-X
man	B-X
.	B-X
A	B-X
glucocorticoid	B-X
receptor	B-X
-	B-X
mediated	B-X
disease	B-X
.	B-X
<EOS>	B-X
To	B-X
study	B-X
this	B-X
apparent	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
cells	B-X
<EOS>	B-X
To	B-X
clarify	B-X
the	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
GR	B-X
)	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X

To	O
explain	O
the	O
end-organ	O
resistance	O
to	O
cortisol	O
,	O
the	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
and	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
a	O
forearm	O
skin	O
biopsy	O
were	O
characterized	O
and	O
compared	O
with	O
the	O
results	O
of	O
similar	O
studies	O
in	O
normal	O
subjects	O
.	O
<EOS>	B-X
To	B-X
explain	B-X
the	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
,	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
GR	B-X
)	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
leukocytes	B-X
and	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
forearm	B-X
skin	B-X
biopsy	B-X
were	B-X
characterized	B-X
and	B-X
compared	B-X
with	B-X
the	B-X
results	B-X
of	B-X
similar	B-X
studies	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
Decreased	B-X
deoxyribonucleic	B-X
acid	B-X
binding	B-X
of	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complex	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
the	B-X
glucocorticoid	B-X
resistance	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
patient	B-X
's	B-X
glucocorticoid	B-X
resistance	B-X
was	B-X
due	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
receptor	B-X
for	B-X
glucocorticoids	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
GR	B-X
complex	B-X
to	B-X
DNA	B-X
<EOS>	B-X
The	B-X
thermal	B-X
stability	B-X
and	B-X
the	B-X
sedimentation	B-X
coefficient	B-X
in	B-X
a	B-X
sucrose	B-X
density	B-X
gradient	B-X
of	B-X
the	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
and	B-X
normal	B-X
subjects	B-X
were	B-X
similar	B-X

The	O
patient	O
's	O
GR	B-protein
in	O
whole	O
cell	O
assays	O
had	O
an	O
increased	O
dissociation	O
constant	O
(	O
Kd	O
)	O
.	O

In	O
the	O
cytosol	O
of	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
the	O
patient	O
,	O
there	O
was	O
also	O
decreased	O
binding	O
capacity	O
.	O
<EOS>	B-X
In	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
,	B-X
there	B-X
was	B-X
also	B-X
decreased	B-X
binding	B-X
capacity	B-X
<EOS>	B-X
Nuclear	B-X
translocation	B-X
of	B-X
GR	B-X
complexes	B-X
from	B-X
the	B-X
patient	B-X
was	B-X
also	B-X
slightly	B-X
decreased	B-X
<EOS>	B-X
Decreased	B-X
deoxyribonucleic	B-X
acid	B-X
binding	B-X
of	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complex	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
the	B-X
glucocorticoid	B-X
resistance	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
GR	B-X
complex	B-X
activation	B-X
,	B-X
analyzed	B-X
by	B-X
DEAE	B-X
-	B-X
cellulose	B-X
chromatography	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
patient	B-X

The	O
thermal	O
stability	O
and	O
the	O
sedimentation	O
coefficient	O
in	O
a	O
sucrose	O
density	O
gradient	O
of	O
the	O
receptors	O
in	O
the	O
cytosol	O
of	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
from	O
the	O
patient	O
and	O
normal	O
subjects	O
were	O
similar	O
.	O

GR	B-cell_line
complex	I-cell_line
activation	I-cell_line
,	O
analyzed	O
by	O
DEAE-cellulose	B-cell_line
chromatography	I-cell_line
,	O
was	O
decreased	O
in	O
the	O
patient	O
.	O
<EOS>	B-X
GR	B-X
complex	B-X
activation	B-X
,	B-X
analyzed	B-X
by	B-X
DEAE	B-X
-	B-X
cellulose	B-X
chromatography	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
patient	B-X
<EOS>	B-X
In	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
,	B-X
there	B-X
was	B-X
also	B-X
decreased	B-X
binding	B-X
capacity	B-X
<EOS>	B-X
Nuclear	B-X
translocation	B-X
of	B-X
GR	B-X
complexes	B-X
from	B-X
the	B-X
patient	B-X
was	B-X
also	B-X
slightly	B-X
decreased	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
patient	B-X
's	B-X
glucocorticoid	B-X
resistance	B-X
was	B-X
due	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
affinity	B-X
of	B-X
the	B-X
receptor	B-X
for	B-X
glucocorticoids	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
GR	B-X
complex	B-X
to	B-X
DNA	B-X

DNA	B-DNA
binding	O
of	O
the	O
GR	B-protein
complex	I-protein
after	O
temperature-induced	O
activation	O
was	O
lower	O
in	O
the	O
patient	O
than	O
in	O
normal	O
subjects	O
.	O
<EOS>	B-X
DNA	B-X
binding	B-X
of	B-X
the	B-X
GR	B-X
complex	B-X
after	B-X
temperature	B-X
-	B-X
induced	B-X
activation	B-X
was	B-X
lower	B-X
in	B-X
the	B-X
patient	B-X
than	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
The	B-X
thermal	B-X
stability	B-X
and	B-X
the	B-X
sedimentation	B-X
coefficient	B-X
in	B-X
a	B-X
sucrose	B-X
density	B-X
gradient	B-X
of	B-X
the	B-X
receptors	B-X
in	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
and	B-X
normal	B-X
subjects	B-X
were	B-X
similar	B-X
<EOS>	B-X
To	B-X
explain	B-X
the	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
,	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
GR	B-X
)	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
leukocytes	B-X
and	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
forearm	B-X
skin	B-X
biopsy	B-X
were	B-X
characterized	B-X
and	B-X
compared	B-X
with	B-X
the	B-X
results	B-X
of	B-X
similar	B-X
studies	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
Decreased	B-X
deoxyribonucleic	B-X
acid	B-X
binding	B-X
of	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complex	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
the	B-X
glucocorticoid	B-X
resistance	B-X
syndrome	B-X
.	B-X

Nuclear	O
translocation	O
of	O
GR	B-protein
complexes	I-protein
from	O
the	O
patient	O
was	O
also	O
slightly	O
decreased	O
.	O
<EOS>	B-X
Nuclear	B-X
translocation	B-X
of	B-X
GR	B-X
complexes	B-X
from	B-X
the	B-X
patient	B-X
was	B-X
also	B-X
slightly	B-X
decreased	B-X
<EOS>	B-X
In	B-X
the	B-X
cytosol	B-X
of	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
the	B-X
patient	B-X
,	B-X
there	B-X
was	B-X
also	B-X
decreased	B-X
binding	B-X
capacity	B-X
<EOS>	B-X
Decreased	B-X
deoxyribonucleic	B-X
acid	B-X
binding	B-X
of	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complex	B-X
in	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
the	B-X
glucocorticoid	B-X
resistance	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
End	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
was	B-X
suspected	B-X

These	O
results	O
suggest	O
that	O
the	O
patient	O
's	O
glucocorticoid	O
resistance	O
was	O
due	O
to	O
a	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
glucocorticoids	O
and	O
a	O
decrease	O
in	O
the	O
binding	O
of	O
the	O
GR	B-protein
complex	I-protein
to	O
DNA	B-DNA
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O
<EOS>	B-X
006	B-X
)	B-X
,	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
To	B-X
produce	B-X
DCs	B-X
,	B-X
monocytes	B-X
were	B-X
cultivated	B-X
with	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
and	B-X
interleukin	B-X
-	B-X
4	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
)	B-X
<EOS>	B-X
The	B-X
linkage	B-X
between	B-X
chronic	B-X
inflammation	B-X
and	B-X
iCCA	B-X
progression	B-X
is	B-X
well	B-X
established	B-X
,	B-X
but	B-X
the	B-X
roles	B-X
of	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
remain	B-X
unrevealed	B-X
<EOS>	B-X
Event	B-X
-	B-X
related	B-X
analysis	B-X
demonstrated	B-X
1	B-X

Sensitive	O
and	O
receptor-mediated	O
regulation	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
.	B-X
Sensitive	B-X
and	B-X
receptor	B-X
-	B-X
mediated	B-X
regulation	B-X
by	B-X
1,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
in	B-X
normal	B-X
human	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
physiology	B-X
of	B-X
hematopoiesis	B-X
<EOS>	B-X
The	B-X
regulation	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
expression	B-X
is	B-X
seen	B-X
in	B-X
both	B-X
normal	B-X
human	B-X
mitogen	B-X
-	B-X
activated	B-X
T	B-X
lymphocytes	B-X
and	B-X
T	B-X
lymphocytes	B-X
from	B-X
a	B-X
line	B-X
(	B-X
S	B-X
-	B-X
LB1	B-X
)	B-X
transformed	B-X
with	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
expression	B-X
by	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
can	B-X
occur	B-X
independently	B-X
of	B-X
interleukin	B-X
2	B-X
regulation	B-X
and	B-X
is	B-X
probably	B-X
mediated	B-X
through	B-X
cellular	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptors	B-X

We	O
show	O
that	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
[	O
OH	O
]	O
2D3	O
)	O
,	O
the	O
most	O
hormonally	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
modulates	O
sensitively	O
and	O
specifically	O
both	O
the	O
protein	O
and	O
messenger	B-RNA
RNA	I-RNA
accumulation	O
of	O
the	O
multilineage	B-protein
growth	I-protein
factor	I-protein
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
1,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
(	B-X
1,25	B-X
[	B-X
OH	B-X
]	B-X
2D3	B-X
)	B-X
,	B-X
the	B-X
most	B-X
hormonally	B-X
active	B-X
metabolite	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
modulates	B-X
sensitively	B-X
and	B-X
specifically	B-X
both	B-X
the	B-X
protein	B-X
and	B-X
messenger	B-X
RNA	B-X
accumulation	B-X
of	B-X
the	B-X
multilineage	B-X
growth	B-X
factor	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
<EOS>	B-X
The	B-X
regulation	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
expression	B-X
is	B-X
seen	B-X
in	B-X
both	B-X
normal	B-X
human	B-X
mitogen	B-X
-	B-X
activated	B-X
T	B-X
lymphocytes	B-X
and	B-X
T	B-X
lymphocytes	B-X
from	B-X
a	B-X
line	B-X
(	B-X
S	B-X
-	B-X
LB1	B-X
)	B-X
transformed	B-X
with	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
expression	B-X
by	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
can	B-X
occur	B-X
independently	B-X
of	B-X
interleukin	B-X
2	B-X
regulation	B-X
and	B-X
is	B-X
probably	B-X
mediated	B-X
through	B-X
cellular	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptors	B-X
<EOS>	B-X
Granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
.	B-X
Sensitive	B-X
and	B-X
receptor	B-X
-	B-X
mediated	B-X
regulation	B-X
by	B-X
1,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
in	B-X
normal	B-X
human	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
.	B-X

The	O
regulation	O
of	O
GM-CSF	B-protein
expression	O
is	O
seen	O
in	O
both	O
normal	B-cell_type
human	I-cell_type
mitogen-activated	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
T	B-cell_line
lymphocytes	I-cell_line
from	I-cell_line
a	I-cell_line
line	I-cell_line
(	I-cell_line
S-LB1	I-cell_line
)	I-cell_line
transformed	I-cell_line
with	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lymphotropic	I-cell_line
virus	I-cell_line
1	I-cell_line
(	O
HTLV-1	O
)	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
a	O
HTLV-1	B-cell_line
transformed	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
(	O
Ab-VDR	B-cell_line
)	O
established	O
from	O
a	O
patient	O
with	O
vitamin	O
D-resistant	O
rickets	O
type	O
II	O
with	O
undetectable	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
cellular	I-protein
receptors	I-protein
are	O
resistant	O
to	O
the	O
action	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Inhibition	O
of	O
GM-CSF	B-protein
expression	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
occur	O
independently	O
of	O
interleukin	B-protein
2	I-protein
regulation	O
and	O
is	O
probably	O
mediated	O
through	O
cellular	B-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
expression	B-X
by	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
can	B-X
occur	B-X
independently	B-X
of	B-X
interleukin	B-X
2	B-X
regulation	B-X
and	B-X
is	B-X
probably	B-X
mediated	B-X
through	B-X
cellular	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptors	B-X
<EOS>	B-X
The	B-X
regulation	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
expression	B-X
is	B-X
seen	B-X
in	B-X
both	B-X
normal	B-X
human	B-X
mitogen	B-X
-	B-X
activated	B-X
T	B-X
lymphocytes	B-X
and	B-X
T	B-X
lymphocytes	B-X
from	B-X
a	B-X
line	B-X
(	B-X
S	B-X
-	B-X
LB1	B-X
)	B-X
transformed	B-X
with	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
physiology	B-X
of	B-X
hematopoiesis	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
cells	B-X
from	B-X
a	B-X
HTLV	B-X
-	B-X
1	B-X
transformed	B-X
T	B-X
lymphocyte	B-X
line	B-X
(	B-X
Ab	B-X
-	B-X
VDR	B-X
)	B-X
established	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
vitamin	B-X
D	B-X
-	B-X
resistant	B-X
rickets	B-X
type	B-X
II	B-X
with	B-X
undetectable	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
cellular	B-X
receptors	B-X
are	B-X
resistant	B-X
to	B-X
the	B-X
action	B-X
of	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X

We	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
may	O
be	O
important	O
in	O
the	O
physiology	O
of	O
hematopoiesis	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
physiology	B-X
of	B-X
hematopoiesis	B-X
<EOS>	B-X
Among	B-X
the	B-X
four	B-X
isoforms	B-X
(	B-X
Mef2A	B-X
,	B-X
2B	B-X
,	B-X
2C	B-X
,	B-X
and	B-X
2D	B-X
)	B-X
,	B-X
Mef2C	B-X
was	B-X
also	B-X
found	B-X
to	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
hematopoiesis	B-X
<EOS>	B-X
Myogenic	B-X
enhancer	B-X
factor2	B-X
(	B-X
Mef2	B-X
)	B-X
consists	B-X
of	B-X
a	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
morphogenesis	B-X
of	B-X
skeletal	B-X
,	B-X
cardiac	B-X
and	B-X
smooth	B-X
muscle	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
1,25D	B-X
-	B-X
induced	B-X
monocytic	B-X
differentiation	B-X
,	B-X
and	B-X
CD14	B-X
expression	B-X
in	B-X
particular	B-X
,	B-X
are	B-X
mediated	B-X
through	B-X
activation	B-X
of	B-X
ERK5	B-X
-	B-X
Mef2C	B-X
-	B-X
C	B-X
/	B-X
EBPβ	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
that	B-X
Mef2C	B-X
does	B-X
not	B-X
seem	B-X
to	B-X
modulate	B-X
cell	B-X
cycle	B-X
progression	B-X

Altered	O
interaction	O
between	O
triiodothyronine	O
and	O
its	O
nuclear	B-protein
receptors	I-protein
in	O
absence	O
of	O
cortisol	O
:	O
a	O
proposed	O
mechanism	O
for	O
increased	O
thyrotropin	O
secretion	O
in	O
corticosteroid	O
deficiency	O
states	O
.	O
<EOS>	B-X
Altered	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
in	B-X
absence	B-X
of	B-X
cortisol	B-X
:	B-X
a	B-X
proposed	B-X
mechanism	B-X
for	B-X
increased	B-X
thyrotropin	B-X
secretion	B-X
in	B-X
corticosteroid	B-X
deficiency	B-X
states	B-X
.	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
a	B-X
possible	B-X
role	B-X
of	B-X
cortisol	B-X
in	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
was	B-X
examined	B-X
at	B-X
the	B-X
level	B-X
of	B-X
circulating	B-X
lymphocytes	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
primary	B-X
or	B-X
secondary	B-X
adrenocortical	B-X
failure	B-X
<EOS>	B-X
The	B-X
influence	B-X
of	B-X
cortisol	B-X
on	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
discussed	B-X
here	B-X
might	B-X
account	B-X
for	B-X
the	B-X
clinical	B-X
observations	B-X
mentioned	B-X
above	B-X
<EOS>	B-X
The	B-X
affinity	B-X
of	B-X
these	B-X
receptors	B-X
was	B-X
found	B-X
to	B-X
be	B-X
decreased	B-X
,	B-X
by	B-X
more	B-X
than	B-X
50	B-X
%	B-X
on	B-X
average	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cortisol	B-X
treatments	B-X

Thyroid	O
hormones	O
occasionally	O
appear	O
less	O
effective	O
when	O
administered	O
alone	O
to	O
patients	O
with	O
panhypopituitarism	O
,	O
and	O
manifestations	O
suggestive	O
of	O
hypothyroidism	O
have	O
been	O
reported	O
in	O
patients	O
suffering	O
from	O
untreated	O
Addison	O
's	O
disease	O
.	O
<EOS>	B-X
Thyroid	B-X
hormones	B-X
occasionally	B-X
appear	B-X
less	B-X
effective	B-X
when	B-X
administered	B-X
alone	B-X
to	B-X
patients	B-X
with	B-X
panhypopituitarism	B-X
,	B-X
and	B-X
manifestations	B-X
suggestive	B-X
of	B-X
hypothyroidism	B-X
have	B-X
been	B-X
reported	B-X
in	B-X
patients	B-X
suffering	B-X
from	B-X
untreated	B-X
Addison	B-X
's	B-X
disease	B-X
<EOS>	B-X
The	B-X
affinity	B-X
of	B-X
these	B-X
receptors	B-X
was	B-X
found	B-X
to	B-X
be	B-X
decreased	B-X
,	B-X
by	B-X
more	B-X
than	B-X
50	B-X
%	B-X
on	B-X
average	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cortisol	B-X
treatments	B-X
<EOS>	B-X
Altered	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
in	B-X
absence	B-X
of	B-X
cortisol	B-X
:	B-X
a	B-X
proposed	B-X
mechanism	B-X
for	B-X
increased	B-X
thyrotropin	B-X
secretion	B-X
in	B-X
corticosteroid	B-X
deficiency	B-X
states	B-X
.	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
a	B-X
possible	B-X
role	B-X
of	B-X
cortisol	B-X
in	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
was	B-X
examined	B-X
at	B-X
the	B-X
level	B-X
of	B-X
circulating	B-X
lymphocytes	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
primary	B-X
or	B-X
secondary	B-X
adrenocortical	B-X
failure	B-X

In	O
the	O
latter	O
condition	O
,	O
thyrotropin	O
secretion	O
is	O
increased	O
:	O
this	O
occurs	O
already	O
after	O
as	O
little	O
as	O
2	O
days	O
of	O
temporary	O
withdrawal	O
of	O
therapy	O
with	O
substitution	O
doses	O
of	O
corticosteroids	O
while	O
circulating	O
levels	O
of	O
thyroid	O
hormones	O
remain	O
within	O
normal	O
limits	O
.	O

Therefore	O
,	O
a	O
possible	O
role	O
of	O
cortisol	O
in	O
interaction	O
between	O
triiodothyronine	O
and	O
its	O
nuclear	B-protein
receptors	I-protein
was	O
examined	O
at	O
the	O
level	O
of	O
circulating	O
lymphocytes	O
obtained	O
from	O
patients	O
with	O
primary	O
or	O
secondary	O
adrenocortical	O
failure	O
.	O
<EOS>	B-X
We	B-X
assessed	B-X
linsitinib	B-X
against	B-X
placebo	B-X
to	B-X
investigate	B-X
efficacy	B-X
in	B-X
patients	B-X
with	B-X
advanced	B-X
adrenocortical	B-X
carcinoma	B-X
<EOS>	B-X
Thorough	B-X
diagnostics	B-X
lead	B-X
to	B-X
a	B-X
conclusion	B-X
,	B-X
that	B-X
the	B-X
symptoms	B-X
was	B-X
the	B-X
first	B-X
manifestation	B-X
of	B-X
primary	B-X
pigmented	B-X
nodular	B-X
adrenocortical	B-X
disease	B-X
(	B-X
PPNAD	B-X
)	B-X
<EOS>	B-X
The	B-X
clinical	B-X
presentation	B-X
of	B-X
adrenocortical	B-X
carcinoma	B-X
is	B-X
vague	B-X
and	B-X
nonspecific	B-X
,	B-X
it	B-X
is	B-X
challenging	B-X
to	B-X
identify	B-X
complications	B-X
of	B-X
pregnancy	B-X
with	B-X
adrenocortical	B-X
carcinoma	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
patients	B-X
with	B-X
more	B-X
severe	B-X
cirrhosis	B-X
have	B-X
decreased	B-X
rate	B-X
of	B-X
free	B-X
cortisol	B-X
elimination	B-X
and	B-X
decreased	B-X
maximal	B-X
cortisol	B-X
secretion	B-X
rate	B-X
,	B-X
which	B-X
is	B-X
a	B-X
measure	B-X
of	B-X
adrenocortical	B-X
function	B-X

The	O
affinity	O
of	O
these	O
receptors	O
was	O
found	O
to	O
be	O
decreased	O
,	O
by	O
more	O
than	O
50	O
%	O
on	O
average	O
,	O
in	O
the	O
absence	O
of	O
cortisol	O
treatments	O
.	O
<EOS>	B-X
The	B-X
affinity	B-X
of	B-X
these	B-X
receptors	B-X
was	B-X
found	B-X
to	B-X
be	B-X
decreased	B-X
,	B-X
by	B-X
more	B-X
than	B-X
50	B-X
%	B-X
on	B-X
average	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cortisol	B-X
treatments	B-X
<EOS>	B-X
Altered	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
in	B-X
absence	B-X
of	B-X
cortisol	B-X
:	B-X
a	B-X
proposed	B-X
mechanism	B-X
for	B-X
increased	B-X
thyrotropin	B-X
secretion	B-X
in	B-X
corticosteroid	B-X
deficiency	B-X
states	B-X
.	B-X
<EOS>	B-X
In	B-X
the	B-X
latter	B-X
condition	B-X
,	B-X
thyrotropin	B-X
secretion	B-X
is	B-X
increased	B-X
:	B-X
this	B-X
occurs	B-X
already	B-X
after	B-X
as	B-X
little	B-X
as	B-X
2	B-X
days	B-X
of	B-X
temporary	B-X
withdrawal	B-X
of	B-X
therapy	B-X
with	B-X
substitution	B-X
doses	B-X
of	B-X
corticosteroids	B-X
while	B-X
circulating	B-X
levels	B-X
of	B-X
thyroid	B-X
hormones	B-X
remain	B-X
within	B-X
normal	B-X
limits	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
a	B-X
possible	B-X
role	B-X
of	B-X
cortisol	B-X
in	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
was	B-X
examined	B-X
at	B-X
the	B-X
level	B-X
of	B-X
circulating	B-X
lymphocytes	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
primary	B-X
or	B-X
secondary	B-X
adrenocortical	B-X
failure	B-X

This	O
change	O
was	O
promptly	O
corrected	O
upon	O
resumption	O
of	O
therapy	O
.	O
<EOS>	B-X
This	B-X
change	B-X
was	B-X
promptly	B-X
corrected	B-X
upon	B-X
resumption	B-X
of	B-X
therapy	B-X
<EOS>	B-X
The	B-X
influence	B-X
of	B-X
cortisol	B-X
on	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
discussed	B-X
here	B-X
might	B-X
account	B-X
for	B-X
the	B-X
clinical	B-X
observations	B-X
mentioned	B-X
above	B-X
<EOS>	B-X
The	B-X
affinity	B-X
of	B-X
these	B-X
receptors	B-X
was	B-X
found	B-X
to	B-X
be	B-X
decreased	B-X
,	B-X
by	B-X
more	B-X
than	B-X
50	B-X
%	B-X
on	B-X
average	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cortisol	B-X
treatments	B-X
<EOS>	B-X
Altered	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
in	B-X
absence	B-X
of	B-X
cortisol	B-X
:	B-X
a	B-X
proposed	B-X
mechanism	B-X
for	B-X
increased	B-X
thyrotropin	B-X
secretion	B-X
in	B-X
corticosteroid	B-X
deficiency	B-X
states	B-X
.	B-X

The	O
number	O
of	O
binding	O
sites	O
was	O
not	O
significantly	O
modified	O
.	O
<EOS>	B-X
The	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
,	B-X
binding	B-X
constant	B-X
,	B-X
entropy	B-X
and	B-X
enthalpy	B-X
changes	B-X
of	B-X
the	B-X
binding	B-X
process	B-X
were	B-X
obtained	B-X
<EOS>	B-X
The	B-X
binding	B-X
strength	B-X
and	B-X
binding	B-X
sites	B-X
of	B-X
DAU	B-X
were	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
AO	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
AO	B-X
in	B-X
the	B-X
ternary	B-X
system	B-X
weakened	B-X
the	B-X
binding	B-X
of	B-X
DAU	B-X
to	B-X
MUC1	B-X
-	B-X
TD	B-X
<EOS>	B-X
A	B-X
model	B-X
of	B-X
zinc	B-X
dynamics	B-X
evoked	B-X
by	B-X
intense	B-X
stimulation	B-X
at	B-X
the	B-X
cleft	B-X
of	B-X
hippocampal	B-X
mossy	B-X
fiber	B-X
synapses	B-X
.	B-X

The	O
influence	O
of	O
cortisol	O
on	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
discussed	O
here	O
might	O
account	O
for	O
the	O
clinical	O
observations	O
mentioned	O
above	O
.	O
<EOS>	B-X
The	B-X
influence	B-X
of	B-X
cortisol	B-X
on	B-X
thyroid	B-X
hormone	B-X
receptors	B-X
discussed	B-X
here	B-X
might	B-X
account	B-X
for	B-X
the	B-X
clinical	B-X
observations	B-X
mentioned	B-X
above	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
a	B-X
possible	B-X
role	B-X
of	B-X
cortisol	B-X
in	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
was	B-X
examined	B-X
at	B-X
the	B-X
level	B-X
of	B-X
circulating	B-X
lymphocytes	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
primary	B-X
or	B-X
secondary	B-X
adrenocortical	B-X
failure	B-X
<EOS>	B-X
Altered	B-X
interaction	B-X
between	B-X
triiodothyronine	B-X
and	B-X
its	B-X
nuclear	B-X
receptors	B-X
in	B-X
absence	B-X
of	B-X
cortisol	B-X
:	B-X
a	B-X
proposed	B-X
mechanism	B-X
for	B-X
increased	B-X
thyrotropin	B-X
secretion	B-X
in	B-X
corticosteroid	B-X
deficiency	B-X
states	B-X
.	B-X
<EOS>	B-X
This	B-X
change	B-X
was	B-X
promptly	B-X
corrected	B-X
upon	B-X
resumption	B-X
of	B-X
therapy	B-X

Inhibition	O
by	O
cortisol	O
of	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
.	O
<EOS>	B-X
Hypothalamic	B-X
-	B-X
pituitary	B-X
-	B-X
adrenal	B-X
axis	B-X
function	B-X
,	B-X
psychopathological	B-X
traits	B-X
,	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
activity	B-X
in	B-X
anorexia	B-X
nervosa	B-X
.	B-X
<EOS>	B-X
Indomethacin	B-X
inhibits	B-X
circulating	B-X
PGE2	B-X
and	B-X
reverses	B-X
postexercise	B-X
suppression	B-X
of	B-X
natural	B-X
killer	B-X
cell	B-X
activity	B-X
.	B-X
<EOS>	B-X
Lymphocyte	B-X
subsets	B-X
,	B-X
mitogen	B-X
-	B-X
mediated	B-X
lymphocyte	B-X
-	B-X
proliferation	B-X
,	B-X
cytokine	B-X
levels	B-X
,	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cytotoxic	B-X
activity	B-X
were	B-X
also	B-X
assayed	B-X
<EOS>	B-X
In	B-X
vitro	B-X
morphine	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
development	B-X
of	B-X
LAK	B-X
cell	B-X
activity	B-X

The	O
effects	O
of	O
cortisol	O
on	O
the	O
natural	B-cell_type
killer	I-cell_type
(	O
NK	O
)	O
activity	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
(	I-cell_type
PBM	I-cell_type
)	I-cell_type
cells	I-cell_type
were	O
studied	O
in	O
vitro	O
using	O
a	O
direct	O
4-h	O
51Cr-release	O
assay	O
and	O
K	B-cell_line
562	I-cell_line
cell	I-cell_line
line	I-cell_line
as	O
a	O
target	O
.	O

Preincubation	O
for	O
20	O
h	O
of	O
PBM	B-cell_type
cells	I-cell_type
drawn	O
from	O
healthy	O
donors	O
with	O
1	O
X	O
10	O
(	O
-8	O
)	O
to	O
1	O
X	O
10	O
(	O
-5	O
)	O
M	O
cortisol	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
NK	B-cell_type
cell	I-cell_type
activity	O
.	O

The	O
magnitude	O
of	O
the	O
suppression	O
was	O
directly	O
related	O
to	O
the	O
steroid	O
concentration	O
and	O
inversely	O
related	O
to	O
the	O
number	O
of	O
effector	B-cell_type
cells	I-cell_type
.	O

Cortisol	O
was	O
able	O
to	O
minimize	O
the	O
enhancement	O
of	O
NK	O
cytotoxicity	O
obtainable	O
in	O
the	O
presence	O
of	O
immune	O
interferon	O
(	O
IFN-gamma	O
)	O
.	O
<EOS>	B-X
Cortisol	B-X
was	B-X
able	B-X
to	B-X
minimize	B-X
the	B-X
enhancement	B-X
of	B-X
NK	B-X
cytotoxicity	B-X
obtainable	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
immune	B-X
interferon	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
<EOS>	B-X
Since	B-X
the	B-X
effect	B-X
of	B-X
cortisol	B-X
was	B-X
additive	B-X
to	B-X
that	B-X
of	B-X
PgE2	B-X
and	B-X
was	B-X
not	B-X
changed	B-X
by	B-X
phosphodiesterase	B-X
inhibitors	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
the	B-X
hormone	B-X
acts	B-X
at	B-X
a	B-X
level	B-X
different	B-X
from	B-X
the	B-X
adenylate	B-X
cyclase	B-X
-	B-X
phosphodiesterase	B-X
system	B-X
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
endogenous	B-X
glucocorticoids	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NK	B-X
cell	B-X
-	B-X
mediated	B-X
cytotoxicity	B-X
<EOS>	B-X
Data	B-X
obtained	B-X
with	B-X
the	B-X
use	B-X
of	B-X
antiglucocorticoids	B-X
and	B-X
the	B-X
anti	B-X
-	B-X
CBG	B-X
antibody	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
role	B-X
both	B-X
of	B-X
high	B-X
-	B-X
affinity	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
of	B-X
CBG	B-X
in	B-X
mediating	B-X
cortisol	B-X
action	B-X
on	B-X
the	B-X
human	B-X
NK	B-X
cell	B-X
activity	B-X

A	O
significantly	O
higher	O
suppression	O
was	O
achieved	O
after	O
sequential	O
exposure	O
of	O
PBM	B-cell_type
cells	I-cell_type
to	O
cortisol	O
and	O
equimolar	O
levels	O
of	O
prostaglandin	O
E2	O
(	O
PgE2	O
)	O
.	O
<EOS>	B-X
A	B-X
significantly	B-X
higher	B-X
suppression	B-X
was	B-X
achieved	B-X
after	B-X
sequential	B-X
exposure	B-X
of	B-X
PBM	B-X
cells	B-X
to	B-X
cortisol	B-X
and	B-X
equimolar	B-X
levels	B-X
of	B-X
prostaglandin	B-X
E2	B-X
(	B-X
PgE2	B-X
)	B-X
<EOS>	B-X
The	B-X
magnitude	B-X
of	B-X
the	B-X
suppression	B-X
was	B-X
directly	B-X
related	B-X
to	B-X
the	B-X
steroid	B-X
concentration	B-X
and	B-X
inversely	B-X
related	B-X
to	B-X
the	B-X
number	B-X
of	B-X
effector	B-X
cells	B-X
<EOS>	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
cortisol	B-X
was	B-X
partially	B-X
or	B-X
totally	B-X
prevented	B-X
by	B-X
the	B-X
concomitant	B-X
incubation	B-X
with	B-X
equimolar	B-X
amounts	B-X
of	B-X
11	B-X
-	B-X
deoxycortisol	B-X
and	B-X
RU	B-X
486	B-X
but	B-X
not	B-X
of	B-X
progesterone	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
cortisol	B-X
on	B-X
the	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
activity	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
(	B-X
PBM	B-X
)	B-X
cells	B-X
were	B-X
studied	B-X
in	B-X
vitro	B-X
using	B-X
a	B-X
direct	B-X
4	B-X
-	B-X
h	B-X
51Cr	B-X
-	B-X
release	B-X
assay	B-X
and	B-X
K	B-X
562	B-X
cell	B-X
line	B-X
as	B-X
a	B-X
target	B-X

The	O
concomitant	O
incubation	O
with	O
theophylline	O
and	O
isobutyl-methylxanthine	O
failed	O
to	O
enhance	O
the	O
cortisol-induced	O
suppression	O
,	O
whereas	O
PgE2-dependent	O
inhibition	O
significantly	O
increased	O
after	O
exposure	O
of	O
PBM	B-cell_type
cells	I-cell_type
to	O
methyl-xanthines	O
.	O
<EOS>	B-X
The	B-X
concomitant	B-X
incubation	B-X
with	B-X
theophylline	B-X
and	B-X
isobutyl	B-X
-	B-X
methylxanthine	B-X
failed	B-X
to	B-X
enhance	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
suppression	B-X
,	B-X
whereas	B-X
PgE2	B-X
-	B-X
dependent	B-X
inhibition	B-X
significantly	B-X
increased	B-X
after	B-X
exposure	B-X
of	B-X
PBM	B-X
cells	B-X
to	B-X
methyl	B-X
-	B-X
xanthines	B-X
<EOS>	B-X
Preincubation	B-X
for	B-X
20	B-X
h	B-X
of	B-X
PBM	B-X
cells	B-X
drawn	B-X
from	B-X
healthy	B-X
donors	B-X
with	B-X
1	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
8	B-X
)	B-X
to	B-X
1	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
5	B-X
)	B-X
M	B-X
cortisol	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
NK	B-X
cell	B-X
activity	B-X
<EOS>	B-X
The	B-X
magnitude	B-X
of	B-X
the	B-X
suppression	B-X
was	B-X
directly	B-X
related	B-X
to	B-X
the	B-X
steroid	B-X
concentration	B-X
and	B-X
inversely	B-X
related	B-X
to	B-X
the	B-X
number	B-X
of	B-X
effector	B-X
cells	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
cortisol	B-X
on	B-X
the	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
activity	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
(	B-X
PBM	B-X
)	B-X
cells	B-X
were	B-X
studied	B-X
in	B-X
vitro	B-X
using	B-X
a	B-X
direct	B-X
4	B-X
-	B-X
h	B-X
51Cr	B-X
-	B-X
release	B-X
assay	B-X
and	B-X
K	B-X
562	B-X
cell	B-X
line	B-X
as	B-X
a	B-X
target	B-X

The	O
inhibitory	O
effect	O
of	O
cortisol	O
was	O
partially	O
or	O
totally	O
prevented	O
by	O
the	O
concomitant	O
incubation	O
with	O
equimolar	O
amounts	O
of	O
11-deoxycortisol	O
and	O
RU	O
486	O
but	O
not	O
of	O
progesterone	O
.	O
<EOS>	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
CST	B-X
-	B-X
14	B-X
and	B-X
SS	B-X
-	B-X
14	B-X
on	B-X
insulin	B-X
was	B-X
unaffected	B-X
by	B-X
ghrelin	B-X
that	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
reduced	B-X
insulin	B-X
secretion	B-X
per	B-X
se	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
adenosine	B-X
was	B-X
partially	B-X
inhibited	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
100	B-X
μM	B-X
8	B-X
-	B-X
SPT	B-X
,	B-X
an	B-X
antagonist	B-X
of	B-X
adenosine	B-X
receptors	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
it	B-X
was	B-X
the	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
to	B-X
investigate	B-X
the	B-X
acute	B-X
effects	B-X
of	B-X
cortisol	B-X
on	B-X
functional	B-X
hemispheric	B-X
asymmetries	B-X
<EOS>	B-X
Inhibitory	B-X
effect	B-X
of	B-X
ATP	B-X
on	B-X
contraction	B-X
force	B-X
of	B-X
studied	B-X
skeletal	B-X
muscles	B-X
becomes	B-X
twice	B-X
less	B-X
pronounced	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
norepinephrine	B-X

Treatment	O
of	O
NK	B-cell_type
effectors	I-cell_type
with	O
a	O
monoclonal	B-protein
anti-human	I-protein
corticosteroid-binding	I-protein
globulin	I-protein
(	I-protein
CBG	I-protein
)	I-protein
antibody	I-protein
produced	O
an	O
enhancement	O
of	O
the	O
spontaneous	O
NK	B-cell_type
activity	O
and	O
a	O
partial	O
suppression	O
of	O
cortisol-mediated	O
effects	O
.	O

Our	O
results	O
suggest	O
that	O
endogenous	O
glucocorticoids	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
NK	O
cell-mediated	O
cytotoxicity	O
.	O
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
endogenous	B-X
glucocorticoids	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NK	B-X
cell	B-X
-	B-X
mediated	B-X
cytotoxicity	B-X
<EOS>	B-X
Inhibition	B-X
by	B-X
cortisol	B-X
of	B-X
human	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
activity	B-X
.	B-X
<EOS>	B-X
Cortisol	B-X
was	B-X
able	B-X
to	B-X
minimize	B-X
the	B-X
enhancement	B-X
of	B-X
NK	B-X
cytotoxicity	B-X
obtainable	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
immune	B-X
interferon	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
<EOS>	B-X
Data	B-X
obtained	B-X
with	B-X
the	B-X
use	B-X
of	B-X
antiglucocorticoids	B-X
and	B-X
the	B-X
anti	B-X
-	B-X
CBG	B-X
antibody	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
role	B-X
both	B-X
of	B-X
high	B-X
-	B-X
affinity	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
of	B-X
CBG	B-X
in	B-X
mediating	B-X
cortisol	B-X
action	B-X
on	B-X
the	B-X
human	B-X
NK	B-X
cell	B-X
activity	B-X

Since	O
the	O
effect	O
of	O
cortisol	O
was	O
additive	O
to	O
that	O
of	O
PgE2	O
and	O
was	O
not	O
changed	O
by	O
phosphodiesterase	B-protein
inhibitors	O
,	O
it	O
is	O
conceivable	O
that	O
the	O
hormone	O
acts	O
at	O
a	O
level	O
different	O
from	O
the	O
adenylate	B-protein
cyclase	I-protein
-	O
phosphodiesterase	B-protein
system	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
cortisol	B-X
on	B-X
expression	B-X
of	B-X
PGDH	B-X
in	B-X
the	B-X
chorion	B-X
reverses	B-X
a	B-X
tonic	B-X
stimulatory	B-X
effect	B-X
of	B-X
progesterone	B-X
,	B-X
potentially	B-X
through	B-X
a	B-X
paracrine	B-X
or	B-X
autocrine	B-X
action	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
EPA	B-X
on	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
the	B-X
HPA	B-X
axis	B-X
,	B-X
and	B-X
multidrug	B-X
resistance	B-X
are	B-X
connected	B-X
through	B-X
the	B-X
action	B-X
of	B-X
a	B-X
transport	B-X
protein	B-X
called	B-X
p	B-X
-	B-X
glycoprotein	B-X
(	B-X
p	B-X
-	B-X
gp	B-X
)	B-X
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
differential	B-X
effects	B-X
of	B-X
cortisol	B-X
and	B-X
estradiol	B-X
on	B-X
intrauterine	B-X
PGH	B-X
synthase	B-X
-	B-X
II	B-X
(	B-X
PGHS	B-X
-	B-X
II	B-X
)	B-X
expression	B-X
and	B-X
PG	B-X
production	B-X
may	B-X
be	B-X
because	B-X
of	B-X
the	B-X
tissue	B-X
specific	B-X
expression	B-X
of	B-X
the	B-X
glucocorticoid	B-X
and	B-X
estradiol	B-X
receptors	B-X
(	B-X
GR	B-X
and	B-X
ER	B-X
,	B-X
respectively	B-X
)	B-X
within	B-X
the	B-X
intrauterine	B-X
tissues	B-X
<EOS>	B-X
Effects	B-X
of	B-X
prostaglandin	B-X
F	B-X
(	B-X
2alpha	B-X
)	B-X
on	B-X
sources	B-X
of	B-X
progesterone	B-X
and	B-X
pregnancy	B-X
in	B-X
intact	B-X
,	B-X
ovariectomized	B-X
,	B-X
and	B-X
hysterectomized	B-X
90	B-X
-	B-X
100	B-X
day	B-X
pregnant	B-X
ewes	B-X

Data	O
obtained	O
with	O
the	O
use	O
of	O
antiglucocorticoids	O
and	O
the	O
anti-CBG	B-protein
antibody	I-protein
are	O
compatible	O
with	O
a	O
role	O
both	O
of	O
high-affinity	O
glucocorticoid	B-protein
receptors	I-protein
and	O
of	O
CBG	B-protein
in	O
mediating	O
cortisol	O
action	O
on	O
the	O
human	B-cell_type
NK	I-cell_type
cell	I-cell_type
activity	O
.	O
<EOS>	B-X
Data	B-X
obtained	B-X
with	B-X
the	B-X
use	B-X
of	B-X
antiglucocorticoids	B-X
and	B-X
the	B-X
anti	B-X
-	B-X
CBG	B-X
antibody	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
role	B-X
both	B-X
of	B-X
high	B-X
-	B-X
affinity	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
of	B-X
CBG	B-X
in	B-X
mediating	B-X
cortisol	B-X
action	B-X
on	B-X
the	B-X
human	B-X
NK	B-X
cell	B-X
activity	B-X
<EOS>	B-X
Preincubation	B-X
for	B-X
20	B-X
h	B-X
of	B-X
PBM	B-X
cells	B-X
drawn	B-X
from	B-X
healthy	B-X
donors	B-X
with	B-X
1	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
8	B-X
)	B-X
to	B-X
1	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
5	B-X
)	B-X
M	B-X
cortisol	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
NK	B-X
cell	B-X
activity	B-X
<EOS>	B-X
The	B-X
magnitude	B-X
of	B-X
the	B-X
suppression	B-X
was	B-X
directly	B-X
related	B-X
to	B-X
the	B-X
steroid	B-X
concentration	B-X
and	B-X
inversely	B-X
related	B-X
to	B-X
the	B-X
number	B-X
of	B-X
effector	B-X
cells	B-X
<EOS>	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
cortisol	B-X
was	B-X
partially	B-X
or	B-X
totally	B-X
prevented	B-X
by	B-X
the	B-X
concomitant	B-X
incubation	B-X
with	B-X
equimolar	B-X
amounts	B-X
of	B-X
11	B-X
-	B-X
deoxycortisol	B-X
and	B-X
RU	B-X
486	B-X
but	B-X
not	B-X
of	B-X
progesterone	B-X

Interaction	O
of	O
cell-type-specific	B-protein
nuclear	I-protein
proteins	I-protein
with	O
immunoglobulin	B-DNA
VH	I-DNA
promoter	I-DNA
region	I-DNA
sequences	I-DNA
.	O
<EOS>	B-X
Interaction	B-X
of	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
nuclear	B-X
proteins	B-X
with	B-X
immunoglobulin	B-X
VH	B-X
promoter	B-X
region	B-X
sequences	B-X
.	B-X
<EOS>	B-X
Identification	B-X
of	B-X
novel	B-X
ubiquitous	B-X
and	B-X
cell	B-X
type	B-X
-	B-X
specific	B-X
factors	B-X
that	B-X
specifically	B-X
recognize	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
and	B-X
kappa	B-X
light	B-X
chain	B-X
promoters	B-X
.	B-X
<EOS>	B-X
This	B-X
octanucleotide	B-X
,	B-X
in	B-X
reverse	B-X
orientation	B-X
,	B-X
is	B-X
also	B-X
found	B-X
in	B-X
all	B-X
light	B-X
chain	B-X
variable	B-X
region	B-X
(	B-X
VL	B-X
)	B-X
genes	B-X
,	B-X
and	B-X
in	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
transcriptional	B-X
enhancer	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
specific	B-X
interaction	B-X
of	B-X
C1	B-X
with	B-X
crucial	B-X
control	B-X
elements	B-X
of	B-X
light	B-X
chain	B-X
and	B-X
heavy	B-X
chain	B-X
promoters	B-X
strongly	B-X
suggests	B-X
a	B-X
functional	B-X
role	B-X
in	B-X
immunoglobulin	B-X
gene	B-X
transcription	B-X
control	B-X

All	O
human	B-DNA
and	I-DNA
murine	I-DNA
immunoglobulin	I-DNA
heavy	I-DNA
chain	I-DNA
variable	I-DNA
region	I-DNA
(	I-DNA
VH	I-DNA
)	I-DNA
genes	I-DNA
contain	O
the	O
sequence	O
ATGCAAAT	O
approximately	O
70	O
nucleotides	O
5	O
'	O
from	O
the	O
site	O
of	O
transcription	O
initiation	O
.	O
<EOS>	B-X
All	B-X
human	B-X
and	B-X
murine	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
variable	B-X
region	B-X
(	B-X
VH	B-X
)	B-X
genes	B-X
contain	B-X
the	B-X
sequence	B-X
ATGCAAAT	B-X
approximately	B-X
70	B-X
nucleotides	B-X
5	B-X
'	B-X
from	B-X
the	B-X
site	B-X
of	B-X
transcription	B-X
initiation	B-X
<EOS>	B-X
This	B-X
octanucleotide	B-X
,	B-X
in	B-X
reverse	B-X
orientation	B-X
,	B-X
is	B-X
also	B-X
found	B-X
in	B-X
all	B-X
light	B-X
chain	B-X
variable	B-X
region	B-X
(	B-X
VL	B-X
)	B-X
genes	B-X
,	B-X
and	B-X
in	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
transcriptional	B-X
enhancer	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
detected	B-X
a	B-X
DNA	B-X
-	B-X
protein	B-X
interaction	B-X
that	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
cell	B-X
-	B-X
type	B-X
specificity	B-X
of	B-X
immunoglobulin	B-X
expression	B-X
,	B-X
and	B-X
we	B-X
have	B-X
determined	B-X
that	B-X
a	B-X
sequence	B-X
upstream	B-X
of	B-X
the	B-X
octamer	B-X
participates	B-X
in	B-X
an	B-X
interaction	B-X
with	B-X
a	B-X
nuclear	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
<EOS>	B-X
Here	B-X
we	B-X
establish	B-X
that	B-X
nuclear	B-X
extracts	B-X
from	B-X
distinct	B-X
cell	B-X
types	B-X
differ	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
octamer	B-X
-	B-X
containing	B-X
fragments	B-X

This	O
octanucleotide	O
,	O
in	O
reverse	O
orientation	O
,	O
is	O
also	O
found	O
in	O
all	O
light	B-DNA
chain	I-DNA
variable	I-DNA
region	I-DNA
(	I-DNA
VL	I-DNA
)	I-DNA
genes	I-DNA
,	O
and	O
in	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
transcriptional	I-DNA
enhancer	I-DNA
.	O
<EOS>	B-X
This	B-X
octanucleotide	B-X
,	B-X
in	B-X
reverse	B-X
orientation	B-X
,	B-X
is	B-X
also	B-X
found	B-X
in	B-X
all	B-X
light	B-X
chain	B-X
variable	B-X
region	B-X
(	B-X
VL	B-X
)	B-X
genes	B-X
,	B-X
and	B-X
in	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
transcriptional	B-X
enhancer	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
nuclear	B-X
proteins	B-X
with	B-X
immunoglobulin	B-X
VH	B-X
promoter	B-X
region	B-X
sequences	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
detected	B-X
a	B-X
DNA	B-X
-	B-X
protein	B-X
interaction	B-X
that	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
cell	B-X
-	B-X
type	B-X
specificity	B-X
of	B-X
immunoglobulin	B-X
expression	B-X
,	B-X
and	B-X
we	B-X
have	B-X
determined	B-X
that	B-X
a	B-X
sequence	B-X
upstream	B-X
of	B-X
the	B-X
octamer	B-X
participates	B-X
in	B-X
an	B-X
interaction	B-X
with	B-X
a	B-X
nuclear	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
<EOS>	B-X
Transfection	B-X
studies	B-X
have	B-X
established	B-X
that	B-X
this	B-X
octamer	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
lymphoid	B-X
-	B-X
specific	B-X
transcription	B-X
of	B-X
immunoglobulin	B-X
genes	B-X

Transfection	O
studies	O
have	O
established	O
that	O
this	O
octamer	O
is	O
involved	O
in	O
the	O
lymphoid-specific	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O
<EOS>	B-X
Transfection	B-X
studies	B-X
have	B-X
established	B-X
that	B-X
this	B-X
octamer	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
lymphoid	B-X
-	B-X
specific	B-X
transcription	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
<EOS>	B-X
Octamer	B-X
-	B-X
containing	B-X
fragments	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
bind	B-X
a	B-X
factor	B-X
present	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
;	B-X
however	B-X
,	B-X
identical	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
in	B-X
both	B-X
B	B-X
lymphoid	B-X
and	B-X
non	B-X
-	B-X
lymphoid	B-X
cells	B-X
<EOS>	B-X
This	B-X
octanucleotide	B-X
,	B-X
in	B-X
reverse	B-X
orientation	B-X
,	B-X
is	B-X
also	B-X
found	B-X
in	B-X
all	B-X
light	B-X
chain	B-X
variable	B-X
region	B-X
(	B-X
VL	B-X
)	B-X
genes	B-X
,	B-X
and	B-X
in	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
transcriptional	B-X
enhancer	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
nuclear	B-X
proteins	B-X
with	B-X
immunoglobulin	B-X
VH	B-X
promoter	B-X
region	B-X
sequences	B-X
.	B-X

Octamer-containing	B-DNA
fragments	I-DNA
have	O
been	O
reported	O
to	O
bind	O
a	O
factor	O
present	O
in	O
nuclear	O
extracts	O
of	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
;	O
however	O
,	O
identical	O
binding	O
activity	O
was	O
detected	O
in	O
both	O
B	B-cell_line
lymphoid	I-cell_line
and	I-cell_line
non-lymphoid	I-cell_line
cells	I-cell_line
.	O

Here	O
we	O
establish	O
that	O
nuclear	O
extracts	O
from	O
distinct	O
cell	O
types	O
differ	O
in	O
their	O
ability	O
to	O
interact	O
with	O
octamer-containing	B-DNA
fragments	I-DNA
.	O
<EOS>	B-X
Here	B-X
we	B-X
establish	B-X
that	B-X
nuclear	B-X
extracts	B-X
from	B-X
distinct	B-X
cell	B-X
types	B-X
differ	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
octamer	B-X
-	B-X
containing	B-X
fragments	B-X
<EOS>	B-X
Octamer	B-X
-	B-X
containing	B-X
fragments	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
bind	B-X
a	B-X
factor	B-X
present	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
;	B-X
however	B-X
,	B-X
identical	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
in	B-X
both	B-X
B	B-X
lymphoid	B-X
and	B-X
non	B-X
-	B-X
lymphoid	B-X
cells	B-X
<EOS>	B-X
We	B-X
have	B-X
also	B-X
detected	B-X
a	B-X
DNA	B-X
-	B-X
protein	B-X
interaction	B-X
that	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
cell	B-X
-	B-X
type	B-X
specificity	B-X
of	B-X
immunoglobulin	B-X
expression	B-X
,	B-X
and	B-X
we	B-X
have	B-X
determined	B-X
that	B-X
a	B-X
sequence	B-X
upstream	B-X
of	B-X
the	B-X
octamer	B-X
participates	B-X
in	B-X
an	B-X
interaction	B-X
with	B-X
a	B-X
nuclear	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
<EOS>	B-X
Transfection	B-X
studies	B-X
have	B-X
established	B-X
that	B-X
this	B-X
octamer	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
lymphoid	B-X
-	B-X
specific	B-X
transcription	B-X
of	B-X
immunoglobulin	B-X
genes	B-X

We	O
have	O
also	O
detected	O
a	O
DNA-protein	O
interaction	O
that	O
may	O
be	O
involved	O
in	O
the	O
cell-type	O
specificity	O
of	O
immunoglobulin	B-protein
expression	O
,	O
and	O
we	O
have	O
determined	O
that	O
a	O
sequence	O
upstream	O
of	O
the	O
octamer	O
participates	O
in	O
an	O
interaction	O
with	O
a	O
nuclear	B-protein
protein	I-protein
(	O
s	O
)	O
.	O

Preferential	O
transcription	O
of	O
HTLV-I	B-DNA
LTR	I-DNA
in	O
cell-free	O
extracts	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
producing	O
HTLV-I	B-protein
viral	I-protein
proteins	I-protein
.	O

The	O
promoters	B-DNA
of	O
the	O
adenovirus	B-DNA
2	I-DNA
major	I-DNA
late	I-DNA
gene	I-DNA
,	O
the	O
mouse	B-DNA
beta-globin	I-DNA
gene	I-DNA
,	O
the	O
mouse	B-DNA
immunoglobulin	I-DNA
VH	I-DNA
gene	I-DNA
and	O
the	O
LTR	B-DNA
of	O
the	O
human	O
T-lymphotropic	O
retrovirus	O
type	O
I	O
were	O
tested	O
for	O
their	O
transcription	O
activities	O
in	O
cell-free	O
extracts	O
of	O
four	O
cell	O
lines	O
;	O
HeLa	B-cell_line
,	O
CESS	B-cell_line
(	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
,	O
MT-1	B-cell_line
(	O
HTLV-I-infected	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
without	O
viral	O
protein	O
synthesis	O
)	O
,	O
and	O
MT-2	B-cell_line
(	O
HTLV-I-infected	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
producing	O
viral	B-protein
proteins	I-protein
)	O
.	O

LTR	B-DNA
was	O
preferentially	O
transcribed	O
in	O
the	O
extracts	O
of	O
MT-2	B-cell_line
although	O
the	O
other	O
three	O
genes	O
were	O
transcribed	O
with	O
relatively	O
constant	O
efficiencies	O
in	O
different	O
extracts	O
.	O
<EOS>	B-X
LTR	B-X
was	B-X
preferentially	B-X
transcribed	B-X
in	B-X
the	B-X
extracts	B-X
of	B-X
MT	B-X
-	B-X
2	B-X
although	B-X
the	B-X
other	B-X
three	B-X
genes	B-X
were	B-X
transcribed	B-X
with	B-X
relatively	B-X
constant	B-X
efficiencies	B-X
in	B-X
different	B-X
extracts	B-X
<EOS>	B-X
Mixing	B-X
of	B-X
HeLa	B-X
and	B-X
MT	B-X
-	B-X
2	B-X
extracts	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
LTR	B-X
-	B-X
specific	B-X
stimulating	B-X
activity	B-X
in	B-X
MT	B-X
-	B-X
2	B-X
extracts	B-X
<EOS>	B-X
Preferential	B-X
transcription	B-X
of	B-X
HTLV	B-X
-	B-X
I	B-X
LTR	B-X
in	B-X
cell	B-X
-	B-X
free	B-X
extracts	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
producing	B-X
HTLV	B-X
-	B-X
I	B-X
viral	B-X
proteins	B-X
.	B-X
<EOS>	B-X
The	B-X
results	B-X
agree	B-X
well	B-X
with	B-X
the	B-X
previous	B-X
in	B-X
vivo	B-X
studies	B-X
on	B-X
the	B-X
promoter	B-X
activity	B-X
of	B-X
HTLV	B-X
-	B-X
I	B-X
LTR	B-X

The	O
results	O
agree	O
well	O
with	O
the	O
previous	O
in	O
vivo	O
studies	O
on	O
the	O
promoter	O
activity	O
of	O
HTLV-I	B-DNA
LTR	I-DNA
.	O
<EOS>	B-X
The	B-X
results	B-X
agree	B-X
well	B-X
with	B-X
the	B-X
previous	B-X
in	B-X
vivo	B-X
studies	B-X
on	B-X
the	B-X
promoter	B-X
activity	B-X
of	B-X
HTLV	B-X
-	B-X
I	B-X
LTR	B-X
<EOS>	B-X
Mixing	B-X
of	B-X
HeLa	B-X
and	B-X
MT	B-X
-	B-X
2	B-X
extracts	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
LTR	B-X
-	B-X
specific	B-X
stimulating	B-X
activity	B-X
in	B-X
MT	B-X
-	B-X
2	B-X
extracts	B-X
<EOS>	B-X
LTR	B-X
was	B-X
preferentially	B-X
transcribed	B-X
in	B-X
the	B-X
extracts	B-X
of	B-X
MT	B-X
-	B-X
2	B-X
although	B-X
the	B-X
other	B-X
three	B-X
genes	B-X
were	B-X
transcribed	B-X
with	B-X
relatively	B-X
constant	B-X
efficiencies	B-X
in	B-X
different	B-X
extracts	B-X
<EOS>	B-X
Preferential	B-X
transcription	B-X
of	B-X
HTLV	B-X
-	B-X
I	B-X
LTR	B-X
in	B-X
cell	B-X
-	B-X
free	B-X
extracts	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
producing	B-X
HTLV	B-X
-	B-X
I	B-X
viral	B-X
proteins	B-X
.	B-X

Mixing	O
of	O
HeLa	O
and	O
MT-2	O
extracts	O
revealed	O
the	O
presence	O
of	O
a	O
LTR-specific	O
stimulating	O
activity	O
in	O
MT-2	O
extracts	O
.	O
<EOS>	B-X
Mixing	B-X
of	B-X
HeLa	B-X
and	B-X
MT	B-X
-	B-X
2	B-X
extracts	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
LTR	B-X
-	B-X
specific	B-X
stimulating	B-X
activity	B-X
in	B-X
MT	B-X
-	B-X
2	B-X
extracts	B-X
<EOS>	B-X
LTR	B-X
was	B-X
preferentially	B-X
transcribed	B-X
in	B-X
the	B-X
extracts	B-X
of	B-X
MT	B-X
-	B-X
2	B-X
although	B-X
the	B-X
other	B-X
three	B-X
genes	B-X
were	B-X
transcribed	B-X
with	B-X
relatively	B-X
constant	B-X
efficiencies	B-X
in	B-X
different	B-X
extracts	B-X
<EOS>	B-X
The	B-X
results	B-X
agree	B-X
well	B-X
with	B-X
the	B-X
previous	B-X
in	B-X
vivo	B-X
studies	B-X
on	B-X
the	B-X
promoter	B-X
activity	B-X
of	B-X
HTLV	B-X
-	B-X
I	B-X
LTR	B-X
<EOS>	B-X
The	B-X
promoters	B-X
of	B-X
the	B-X
adenovirus	B-X
2	B-X
major	B-X
late	B-X
gene	B-X
,	B-X
the	B-X
mouse	B-X
beta	B-X
-	B-X
globin	B-X
gene	B-X
,	B-X
the	B-X
mouse	B-X
immunoglobulin	B-X
VH	B-X
gene	B-X
and	B-X
the	B-X
LTR	B-X
of	B-X
the	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
retrovirus	B-X
type	B-X
I	B-X
were	B-X
tested	B-X
for	B-X
their	B-X
transcription	B-X
activities	B-X
in	B-X
cell	B-X
-	B-X
free	B-X
extracts	B-X
of	B-X
four	B-X
cell	B-X
lines	B-X
;	B-X
HeLa	B-X
,	B-X
CESS	B-X
(	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
-	B-X
transformed	B-X
human	B-X
B	B-X
cell	B-X
line	B-X
)	B-X
,	B-X
MT	B-X
-	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
-	B-X
infected	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
without	B-X
viral	B-X
protein	B-X
synthesis	B-X
)	B-X
,	B-X
and	B-X
MT	B-X
-	B-X
2	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
-	B-X
infected	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
producing	B-X
viral	B-X
proteins	B-X
)	B-X

A	O
nuclear	B-protein
factor	I-protein
that	O
binds	O
to	O
a	O
conserved	O
sequence	O
motif	O
in	O
transcriptional	B-DNA
control	I-DNA
elements	I-DNA
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O
<EOS>	B-X
A	B-X
nuclear	B-X
factor	B-X
that	B-X
binds	B-X
to	B-X
a	B-X
conserved	B-X
sequence	B-X
motif	B-X
in	B-X
transcriptional	B-X
control	B-X
elements	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
<EOS>	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
NFIII	B-X
could	B-X
function	B-X
both	B-X
in	B-X
adenovirus	B-X
DNA	B-X
replication	B-X
and	B-X
in	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
several	B-X
groups	B-X
of	B-X
genes	B-X
sharing	B-X
the	B-X
octanucleotide	B-X
sequence	B-X
<EOS>	B-X
Promoter	B-X
and	B-X
enhancer	B-X
elements	B-X
containing	B-X
a	B-X
conserved	B-X
sequence	B-X
motif	B-X
are	B-X
recognized	B-X
by	B-X
nuclear	B-X
factor	B-X
III	B-X
,	B-X
a	B-X
protein	B-X
stimulating	B-X
adenovirus	B-X
DNA	B-X
replication	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
sought	B-X
nuclear	B-X
factors	B-X
that	B-X
might	B-X
bind	B-X
specifically	B-X
to	B-X
these	B-X
two	B-X
regulatory	B-X
elements	B-X
by	B-X
application	B-X
of	B-X
a	B-X
modified	B-X
gel	B-X
electrophoresis	B-X
DNA	B-X
binding	B-X
assay	B-X

Trans-acting	B-protein
factors	I-protein
that	O
mediate	O
B-cell	O
specific	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
have	O
been	O
postulated	O
based	O
on	O
an	O
analysis	O
of	O
the	O
expression	O
of	O
exogenously	O
introduced	O
immunoglobulin	B-DNA
gene	I-DNA
recombinants	I-DNA
in	O
lymphoid	B-cell_type
and	I-cell_type
non-lymphoid	I-cell_type
cells	I-cell_type
.	O

Two	O
B-cell-specific	O
,	O
cis-acting	B-DNA
transcriptional	I-DNA
regulatory	I-DNA
elements	I-DNA
have	O
been	O
identified	O
.	O
<EOS>	B-X
Two	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
,	B-X
cis	B-X
-	B-X
acting	B-X
transcriptional	B-X
regulatory	B-X
elements	B-X
have	B-X
been	B-X
identified	B-X
<EOS>	B-X
A	B-X
nuclear	B-X
factor	B-X
that	B-X
binds	B-X
to	B-X
a	B-X
conserved	B-X
sequence	B-X
motif	B-X
in	B-X
transcriptional	B-X
control	B-X
elements	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
<EOS>	B-X
This	B-X
element	B-X
directs	B-X
lymphoid	B-X
-	B-X
specific	B-X
transcription	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
viral	B-X
enhancers	B-X
<EOS>	B-X
We	B-X
have	B-X
sought	B-X
nuclear	B-X
factors	B-X
that	B-X
might	B-X
bind	B-X
specifically	B-X
to	B-X
these	B-X
two	B-X
regulatory	B-X
elements	B-X
by	B-X
application	B-X
of	B-X
a	B-X
modified	B-X
gel	B-X
electrophoresis	B-X
DNA	B-X
binding	B-X
assay	B-X

One	O
element	O
is	O
located	O
in	O
the	O
intron	O
between	O
the	O
variable	O
(	O
V	O
)	O
and	O
constant	O
(	O
C	O
)	O
regions	O
of	O
both	O
heavy	B-DNA
and	I-DNA
kappa	I-DNA
light-chain	I-DNA
genes	I-DNA
and	O
acts	O
as	O
a	O
transcriptional	O
enhancer	O
.	O
<EOS>	B-X
One	B-X
element	B-X
is	B-X
located	B-X
in	B-X
the	B-X
intron	B-X
between	B-X
the	B-X
variable	B-X
(	B-X
V	B-X
)	B-X
and	B-X
constant	B-X
(	B-X
C	B-X
)	B-X
regions	B-X
of	B-X
both	B-X
heavy	B-X
and	B-X
kappa	B-X
light	B-X
-	B-X
chain	B-X
genes	B-X
and	B-X
acts	B-X
as	B-X
a	B-X
transcriptional	B-X
enhancer	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
human	B-X
B	B-X
-	B-X
cell	B-X
nuclear	B-X
factor	B-X
(	B-X
IgNF	B-X
-	B-X
A	B-X
)	B-X
that	B-X
binds	B-X
to	B-X
DNA	B-X
sequences	B-X
in	B-X
the	B-X
upstream	B-X
regions	B-X
of	B-X
both	B-X
the	B-X
mouse	B-X
heavy	B-X
and	B-X
kappa	B-X
light	B-X
-	B-X
chain	B-X
gene	B-X
promoters	B-X
and	B-X
also	B-X
to	B-X
the	B-X
mouse	B-X
heavy	B-X
-	B-X
chain	B-X
gene	B-X
enhancer	B-X
<EOS>	B-X
The	B-X
second	B-X
element	B-X
is	B-X
found	B-X
upstream	B-X
of	B-X
both	B-X
heavy	B-X
and	B-X
kappa	B-X
light	B-X
-	B-X
chain	B-X
gene	B-X
promoters	B-X
<EOS>	B-X
This	B-X
sequence	B-X
-	B-X
specific	B-X
binding	B-X
is	B-X
probably	B-X
mediated	B-X
by	B-X
a	B-X
highly	B-X
conserved	B-X
sequence	B-X
motif	B-X
,	B-X
ATTTGCAT	B-X
,	B-X
present	B-X
in	B-X
all	B-X
three	B-X
transcriptional	B-X
elements	B-X

The	O
second	O
element	B-DNA
is	O
found	O
upstream	O
of	O
both	O
heavy	B-DNA
and	I-DNA
kappa	I-DNA
light-chain	I-DNA
gene	I-DNA
promoters	I-DNA
.	O
<EOS>	B-X
The	B-X
second	B-X
element	B-X
is	B-X
found	B-X
upstream	B-X
of	B-X
both	B-X
heavy	B-X
and	B-X
kappa	B-X
light	B-X
-	B-X
chain	B-X
gene	B-X
promoters	B-X
<EOS>	B-X
These	B-X
two	B-X
elements	B-X
both	B-X
are	B-X
required	B-X
for	B-X
efficient	B-X
kappa	B-X
chain	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Two	B-X
regulatory	B-X
elements	B-X
for	B-X
immunoglobulin	B-X
kappa	B-X
light	B-X
chain	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
One	B-X
element	B-X
is	B-X
located	B-X
in	B-X
the	B-X
intron	B-X
between	B-X
the	B-X
variable	B-X
(	B-X
V	B-X
)	B-X
and	B-X
constant	B-X
(	B-X
C	B-X
)	B-X
regions	B-X
of	B-X
both	B-X
heavy	B-X
and	B-X
kappa	B-X
light	B-X
-	B-X
chain	B-X
genes	B-X
and	B-X
acts	B-X
as	B-X
a	B-X
transcriptional	B-X
enhancer	B-X

This	O
element	O
directs	O
lymphoid-specific	O
transcription	O
even	O
in	O
the	O
presence	O
of	O
viral	B-DNA
enhancers	I-DNA
.	O
<EOS>	B-X
This	B-X
element	B-X
directs	B-X
lymphoid	B-X
-	B-X
specific	B-X
transcription	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
viral	B-X
enhancers	B-X
<EOS>	B-X
First	B-X
,	B-X
the	B-X
V	B-X
H	B-X
promoter	B-X
region	B-X
between	B-X
position	B-X
	B-X
-	B-X
154	B-X
and	B-X
+57	B-X
was	B-X
shown	B-X
to	B-X
direct	B-X
lymphocyte	B-X
-	B-X
specific	B-X
transcription	B-X
of	B-X
a	B-X
bacterial	B-X
gpt	B-X
gene	B-X
,	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
viral	B-X
enhancer	B-X
<EOS>	B-X
Replacing	B-X
the	B-X
lymphocyte	B-X
-	B-X
specific	B-X
IgH	B-X
enhancer	B-X
with	B-X
a	B-X
viral	B-X
enhancer	B-X
did	B-X
not	B-X
affect	B-X
tissue	B-X
specificity	B-X
of	B-X
mu	B-X
Ig	B-X
gene	B-X
expression	B-X
<EOS>	B-X
A	B-X
nuclear	B-X
factor	B-X
that	B-X
binds	B-X
to	B-X
a	B-X
conserved	B-X
sequence	B-X
motif	B-X
in	B-X
transcriptional	B-X
control	B-X
elements	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
.	B-X

We	O
have	O
sought	O
nuclear	O
factors	O
that	O
might	O
bind	O
specifically	O
to	O
these	O
two	O
regulatory	B-DNA
elements	I-DNA
by	O
application	O
of	O
a	O
modified	O
gel	O
electrophoresis	O
DNA	O
binding	O
assay	O
.	O
<EOS>	B-X
We	B-X
have	B-X
sought	B-X
nuclear	B-X
factors	B-X
that	B-X
might	B-X
bind	B-X
specifically	B-X
to	B-X
these	B-X
two	B-X
regulatory	B-X
elements	B-X
by	B-X
application	B-X
of	B-X
a	B-X
modified	B-X
gel	B-X
electrophoresis	B-X
DNA	B-X
binding	B-X
assay	B-X
<EOS>	B-X
We	B-X
have	B-X
sought	B-X
nuclear	B-X
factors	B-X
that	B-X
bind	B-X
specifically	B-X
to	B-X
an	B-X
upstream	B-X
fragment	B-X
(	B-X
	B-X
-	B-X
245	B-X
to	B-X
+75	B-X
bp	B-X
)	B-X
of	B-X
the	B-X
murine	B-X
I	B-X
-	B-X
A	B-X
beta	B-X
chain	B-X
gene	B-X
that	B-X
contains	B-X
the	B-X
conserved	B-X
sequences	B-X
by	B-X
application	B-X
of	B-X
a	B-X
modified	B-X
gel	B-X
electrophoresis	B-X
DNA	B-X
binding	B-X
assay	B-X
<EOS>	B-X
A	B-X
nuclear	B-X
factor	B-X
that	B-X
binds	B-X
to	B-X
a	B-X
conserved	B-X
sequence	B-X
motif	B-X
in	B-X
transcriptional	B-X
control	B-X
elements	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
human	B-X
B	B-X
-	B-X
cell	B-X
nuclear	B-X
factor	B-X
(	B-X
IgNF	B-X
-	B-X
A	B-X
)	B-X
that	B-X
binds	B-X
to	B-X
DNA	B-X
sequences	B-X
in	B-X
the	B-X
upstream	B-X
regions	B-X
of	B-X
both	B-X
the	B-X
mouse	B-X
heavy	B-X
and	B-X
kappa	B-X
light	B-X
-	B-X
chain	B-X
gene	B-X
promoters	B-X
and	B-X
also	B-X
to	B-X
the	B-X
mouse	B-X
heavy	B-X
-	B-X
chain	B-X
gene	B-X
enhancer	B-X

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
human	B-protein
B-cell	I-protein
nuclear	I-protein
factor	I-protein
(	O
IgNF-A	B-protein
)	O
that	O
binds	O
to	O
DNA	B-DNA
sequences	I-DNA
in	O
the	O
upstream	B-DNA
regions	I-DNA
of	O
both	O
the	O
mouse	B-DNA
heavy	I-DNA
and	I-DNA
kappa	I-DNA
light-chain	I-DNA
gene	I-DNA
promoters	I-DNA
and	O
also	O
to	O
the	O
mouse	B-DNA
heavy-chain	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O

This	O
sequence-specific	O
binding	O
is	O
probably	O
mediated	O
by	O
a	O
highly	O
conserved	O
sequence	O
motif	O
,	O
ATTTGCAT	O
,	O
present	O
in	O
all	O
three	O
transcriptional	B-DNA
elements	I-DNA
.	O
<EOS>	B-X
This	B-X
sequence	B-X
-	B-X
specific	B-X
binding	B-X
is	B-X
probably	B-X
mediated	B-X
by	B-X
a	B-X
highly	B-X
conserved	B-X
sequence	B-X
motif	B-X
,	B-X
ATTTGCAT	B-X
,	B-X
present	B-X
in	B-X
all	B-X
three	B-X
transcriptional	B-X
elements	B-X
<EOS>	B-X
A	B-X
nuclear	B-X
factor	B-X
that	B-X
binds	B-X
to	B-X
a	B-X
conserved	B-X
sequence	B-X
motif	B-X
in	B-X
transcriptional	B-X
control	B-X
elements	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
<EOS>	B-X
One	B-X
element	B-X
is	B-X
located	B-X
in	B-X
the	B-X
intron	B-X
between	B-X
the	B-X
variable	B-X
(	B-X
V	B-X
)	B-X
and	B-X
constant	B-X
(	B-X
C	B-X
)	B-X
regions	B-X
of	B-X
both	B-X
heavy	B-X
and	B-X
kappa	B-X
light	B-X
-	B-X
chain	B-X
genes	B-X
and	B-X
acts	B-X
as	B-X
a	B-X
transcriptional	B-X
enhancer	B-X
<EOS>	B-X
This	B-X
element	B-X
directs	B-X
lymphoid	B-X
-	B-X
specific	B-X
transcription	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
viral	B-X
enhancers	B-X

Interestingly	O
,	O
a	O
factor	O
showing	O
similar	O
binding	O
specificity	O
to	O
IgNF-A	B-DNA
is	O
also	O
present	O
in	O
human	B-cell_line
HeLa	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
a	B-X
factor	B-X
showing	B-X
similar	B-X
binding	B-X
specificity	B-X
to	B-X
IgNF	B-X
-	B-X
A	B-X
is	B-X
also	B-X
present	B-X
in	B-X
human	B-X
HeLa	B-X
cells	B-X
<EOS>	B-X
We	B-X
have	B-X
sought	B-X
nuclear	B-X
factors	B-X
that	B-X
might	B-X
bind	B-X
specifically	B-X
to	B-X
these	B-X
two	B-X
regulatory	B-X
elements	B-X
by	B-X
application	B-X
of	B-X
a	B-X
modified	B-X
gel	B-X
electrophoresis	B-X
DNA	B-X
binding	B-X
assay	B-X
<EOS>	B-X
This	B-X
element	B-X
directs	B-X
lymphoid	B-X
-	B-X
specific	B-X
transcription	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
viral	B-X
enhancers	B-X
<EOS>	B-X
This	B-X
sequence	B-X
-	B-X
specific	B-X
binding	B-X
is	B-X
probably	B-X
mediated	B-X
by	B-X
a	B-X
highly	B-X
conserved	B-X
sequence	B-X
motif	B-X
,	B-X
ATTTGCAT	B-X
,	B-X
present	B-X
in	B-X
all	B-X
three	B-X
transcriptional	B-X
elements	B-X

The	O
new	O
world	O
primates	O
as	O
animal	O
models	O
of	O
glucocorticoid	O
resistance	O
.	O
<EOS>	B-X
The	B-X
new	B-X
world	B-X
primates	B-X
as	B-X
animal	B-X
models	B-X
of	B-X
glucocorticoid	B-X
resistance	B-X
.	B-X
<EOS>	B-X
Molecular	B-X
basis	B-X
of	B-X
glucocorticoid	B-X
-	B-X
resistant	B-X
syndromes	B-X
.	B-X
<EOS>	B-X
The	B-X
low	B-X
affinity	B-X
leads	B-X
to	B-X
an	B-X
increased	B-X
loss	B-X
of	B-X
specific	B-X
bound	B-X
ligand	B-X
during	B-X
thermal	B-X
activation	B-X
<EOS>	B-X
The	B-X
common	B-X
element	B-X
that	B-X
would	B-X
explain	B-X
the	B-X
apparent	B-X
resistance	B-X
to	B-X
six	B-X
steroid	B-X
hormones	B-X
in	B-X
New	B-X
World	B-X
primates	B-X
remains	B-X
unknown	B-X

Many	O
New	O
World	O
primate	O
species	O
have	O
greatly	O
increased	O
plasma	O
cortisol	O
concentrations	O
,	O
decreased	O
plasma	O
cortisol	O
binding	O
globulin	O
capacity	O
and	O
affinity	O
,	O
marked	O
resistance	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
to	O
suppression	O
by	O
dexamethasone	O
,	O
and	O
no	O
biological	O
evidence	O
of	O
glucocorticoid	O
excess	O
.	O
<EOS>	B-X
Many	B-X
New	B-X
World	B-X
primate	B-X
species	B-X
have	B-X
greatly	B-X
increased	B-X
plasma	B-X
cortisol	B-X
concentrations	B-X
,	B-X
decreased	B-X
plasma	B-X
cortisol	B-X
binding	B-X
globulin	B-X
capacity	B-X
and	B-X
affinity	B-X
,	B-X
marked	B-X
resistance	B-X
of	B-X
the	B-X
hypothalamic	B-X
-	B-X
pituitary	B-X
-	B-X
adrenal	B-X
axis	B-X
to	B-X
suppression	B-X
by	B-X
dexamethasone	B-X
,	B-X
and	B-X
no	B-X
biological	B-X
evidence	B-X
of	B-X
glucocorticoid	B-X
excess	B-X
<EOS>	B-X
The	B-X
New	B-X
World	B-X
primates	B-X
,	B-X
unlike	B-X
men	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
primary	B-X
cortisol	B-X
resistance	B-X
,	B-X
have	B-X
compensated	B-X
for	B-X
their	B-X
condition	B-X
with	B-X
intra	B-X
-	B-X
adrenal	B-X
and	B-X
mineralocorticoid	B-X
receptor	B-X
adaptations	B-X
<EOS>	B-X
Thus	B-X
,	B-X
unlike	B-X
Old	B-X
World	B-X
primates	B-X
,	B-X
cortisol	B-X
in	B-X
New	B-X
World	B-X
primates	B-X
has	B-X
only	B-X
weak	B-X
sodium	B-X
-	B-X
retaining	B-X
potency	B-X
because	B-X
the	B-X
aldosterone	B-X
receptor	B-X
has	B-X
a	B-X
low	B-X
affinity	B-X
for	B-X
cortisol	B-X
<EOS>	B-X
The	B-X
ratios	B-X
of	B-X
nuclear	B-X
to	B-X
cytosolic	B-X
hormone	B-X
-	B-X
receptor	B-X
-	B-X
complexes	B-X
and	B-X
of	B-X
cytosolic	B-X
activated	B-X
to	B-X
unactivated	B-X
receptor	B-X
complexes	B-X
in	B-X
intact	B-X
cells	B-X
are	B-X
similar	B-X
to	B-X
Old	B-X
World	B-X
primates	B-X

These	O
primates	O
also	O
have	O
high	O
levels	O
of	O
circulating	O
progesterone	O
,	O
estrogen	O
,	O
mineralocorticoid	O
,	O
androgen	O
and	O
vitamin	O
D	O
.	O
<EOS>	B-X
These	B-X
primates	B-X
also	B-X
have	B-X
high	B-X
levels	B-X
of	B-X
circulating	B-X
progesterone	B-X
,	B-X
estrogen	B-X
,	B-X
mineralocorticoid	B-X
,	B-X
androgen	B-X
and	B-X
vitamin	B-X
D	B-X
<EOS>	B-X
The	B-X
New	B-X
World	B-X
primates	B-X
,	B-X
unlike	B-X
men	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
primary	B-X
cortisol	B-X
resistance	B-X
,	B-X
have	B-X
compensated	B-X
for	B-X
their	B-X
condition	B-X
with	B-X
intra	B-X
-	B-X
adrenal	B-X
and	B-X
mineralocorticoid	B-X
receptor	B-X
adaptations	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
target	B-X
tissues	B-X
that	B-X
have	B-X
been	B-X
examined	B-X
(	B-X
circulating	B-X
mononuclear	B-X
lymphocytes	B-X
and	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
)	B-X
have	B-X
normal	B-X
concentrations	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
with	B-X
decreased	B-X
affinity	B-X
for	B-X
dexamethasone	B-X
<EOS>	B-X
The	B-X
new	B-X
world	B-X
primates	B-X
as	B-X
animal	B-X
models	B-X
of	B-X
glucocorticoid	B-X
resistance	B-X
.	B-X

The	O
glucocorticoid	O
target	O
tissues	O
that	O
have	O
been	O
examined	O
(	O
circulating	B-cell_type
mononuclear	I-cell_type
lymphocytes	I-cell_type
and	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
)	O
have	O
normal	O
concentrations	O
of	O
glucocorticoid	B-protein
receptors	I-protein
with	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O
<EOS>	B-X
The	B-X
glucocorticoid	B-X
target	B-X
tissues	B-X
that	B-X
have	B-X
been	B-X
examined	B-X
(	B-X
circulating	B-X
mononuclear	B-X
lymphocytes	B-X
and	B-X
cultured	B-X
skin	B-X
fibroblasts	B-X
)	B-X
have	B-X
normal	B-X
concentrations	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
with	B-X
decreased	B-X
affinity	B-X
for	B-X
dexamethasone	B-X
<EOS>	B-X
These	B-X
primates	B-X
also	B-X
have	B-X
high	B-X
levels	B-X
of	B-X
circulating	B-X
progesterone	B-X
,	B-X
estrogen	B-X
,	B-X
mineralocorticoid	B-X
,	B-X
androgen	B-X
and	B-X
vitamin	B-X
D	B-X
<EOS>	B-X
Thus	B-X
,	B-X
unlike	B-X
Old	B-X
World	B-X
primates	B-X
,	B-X
cortisol	B-X
in	B-X
New	B-X
World	B-X
primates	B-X
has	B-X
only	B-X
weak	B-X
sodium	B-X
-	B-X
retaining	B-X
potency	B-X
because	B-X
the	B-X
aldosterone	B-X
receptor	B-X
has	B-X
a	B-X
low	B-X
affinity	B-X
for	B-X
cortisol	B-X
<EOS>	B-X
The	B-X
New	B-X
World	B-X
primates	B-X
,	B-X
unlike	B-X
men	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
primary	B-X
cortisol	B-X
resistance	B-X
,	B-X
have	B-X
compensated	B-X
for	B-X
their	B-X
condition	B-X
with	B-X
intra	B-X
-	B-X
adrenal	B-X
and	B-X
mineralocorticoid	B-X
receptor	B-X
adaptations	B-X

Transformation	O
of	O
B-lymphocytes	B-cell_type
with	O
the	O
Epstein-Barr	O
virus	O
leads	O
to	O
glucocorticoid	B-protein
receptor	I-protein
induction	O
that	O
is	O
less	O
than	O
that	O
observed	O
with	O
cells	O
from	O
Old	O
World	O
primates	O
.	O
<EOS>	B-X
Transformation	B-X
of	B-X
B	B-X
-	B-X
lymphocytes	B-X
with	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
leads	B-X
to	B-X
glucocorticoid	B-X
receptor	B-X
induction	B-X
that	B-X
is	B-X
less	B-X
than	B-X
that	B-X
observed	B-X
with	B-X
cells	B-X
from	B-X
Old	B-X
World	B-X
primates	B-X
<EOS>	B-X
The	B-X
ratios	B-X
of	B-X
nuclear	B-X
to	B-X
cytosolic	B-X
hormone	B-X
-	B-X
receptor	B-X
-	B-X
complexes	B-X
and	B-X
of	B-X
cytosolic	B-X
activated	B-X
to	B-X
unactivated	B-X
receptor	B-X
complexes	B-X
in	B-X
intact	B-X
cells	B-X
are	B-X
similar	B-X
to	B-X
Old	B-X
World	B-X
primates	B-X
<EOS>	B-X
These	B-X
primates	B-X
also	B-X
have	B-X
high	B-X
levels	B-X
of	B-X
circulating	B-X
progesterone	B-X
,	B-X
estrogen	B-X
,	B-X
mineralocorticoid	B-X
,	B-X
androgen	B-X
and	B-X
vitamin	B-X
D	B-X
<EOS>	B-X
The	B-X
low	B-X
affinity	B-X
leads	B-X
to	B-X
an	B-X
increased	B-X
loss	B-X
of	B-X
specific	B-X
bound	B-X
ligand	B-X
during	B-X
thermal	B-X
activation	B-X

The	O
receptor	O
in	O
these	O
cells	O
has	O
a	O
low	O
affinity	O
for	O
dexamethasone	O
.	O

The	O
low	O
affinity	O
leads	O
to	O
an	O
increased	O
loss	O
of	O
specific	O
bound	O
ligand	O
during	O
thermal	O
activation	O
.	O

Meroreceptor	O
generation	O
is	O
normal	O
.	O
<EOS>	B-X
Meroreceptor	B-X
generation	B-X
is	B-X
normal	B-X
<EOS>	B-X
Viral	B-X
receptor	B-X
induction	B-X
is	B-X
decreased	B-X
in	B-X
both	B-X
patient	B-X
and	B-X
marmoset	B-X
cells	B-X
<EOS>	B-X
The	B-X
receptor	B-X
in	B-X
these	B-X
cells	B-X
has	B-X
a	B-X
low	B-X
affinity	B-X
for	B-X
dexamethasone	B-X
<EOS>	B-X
Mero	B-X
-	B-X
receptor	B-X
accumulated	B-X
rapidly	B-X
in	B-X
ANLL	B-X
cytosols	B-X
in	B-X
a	B-X
time	B-X
-	B-X
dependent	B-X
fashion	B-X

The	O
molecular	O
weight	O
of	O
the	O
receptor	O
,	O
determined	O
by	O
SDS-PAGE	O
,	O
is	O
similar	O
to	O
that	O
of	O
Old	O
World	O
primates	O
(	O
approximately	O
92	O
,	O
000	O
)	O
and	O
the	O
activation	O
pattern	O
per	O
se	O
,	O
examined	O
in	O
vitro	O
by	O
heating	O
cytosol	O
and	O
performing	O
phosphocellulose	O
chromatography	O
,	O
appears	O
similar	O
to	O
that	O
of	O
human	O
controls	O
.	O
<EOS>	B-X
The	B-X
molecular	B-X
weight	B-X
of	B-X
the	B-X
receptor	B-X
,	B-X
determined	B-X
by	B-X
SDS	B-X
-	B-X
PAGE	B-X
,	B-X
is	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
Old	B-X
World	B-X
primates	B-X
(	B-X
approximately	B-X
92,000	B-X
)	B-X
and	B-X
the	B-X
activation	B-X
pattern	B-X
per	B-X
se	B-X
,	B-X
examined	B-X
in	B-X
vitro	B-X
by	B-X
heating	B-X
cytosol	B-X
and	B-X
performing	B-X
phosphocellulose	B-X
chromatography	B-X
,	B-X
appears	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
human	B-X
controls	B-X
<EOS>	B-X
Thus	B-X
,	B-X
unlike	B-X
Old	B-X
World	B-X
primates	B-X
,	B-X
cortisol	B-X
in	B-X
New	B-X
World	B-X
primates	B-X
has	B-X
only	B-X
weak	B-X
sodium	B-X
-	B-X
retaining	B-X
potency	B-X
because	B-X
the	B-X
aldosterone	B-X
receptor	B-X
has	B-X
a	B-X
low	B-X
affinity	B-X
for	B-X
cortisol	B-X
<EOS>	B-X
The	B-X
ratios	B-X
of	B-X
nuclear	B-X
to	B-X
cytosolic	B-X
hormone	B-X
-	B-X
receptor	B-X
-	B-X
complexes	B-X
and	B-X
of	B-X
cytosolic	B-X
activated	B-X
to	B-X
unactivated	B-X
receptor	B-X
complexes	B-X
in	B-X
intact	B-X
cells	B-X
are	B-X
similar	B-X
to	B-X
Old	B-X
World	B-X
primates	B-X
<EOS>	B-X
The	B-X
New	B-X
World	B-X
primates	B-X
,	B-X
unlike	B-X
men	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
primary	B-X
cortisol	B-X
resistance	B-X
,	B-X
have	B-X
compensated	B-X
for	B-X
their	B-X
condition	B-X
with	B-X
intra	B-X
-	B-X
adrenal	B-X
and	B-X
mineralocorticoid	B-X
receptor	B-X
adaptations	B-X

The	O
ratios	O
of	O
nuclear	O
to	O
cytosolic	B-protein
hormone-receptor-complexes	I-protein
and	O
of	O
cytosolic	O
activated	O
to	O
unactivated	B-protein
receptor	I-protein
complexes	I-protein
in	O
intact	O
cells	O
are	O
similar	O
to	O
Old	O
World	O
primates	O
.	O
<EOS>	B-X
The	B-X
ratios	B-X
of	B-X
nuclear	B-X
to	B-X
cytosolic	B-X
hormone	B-X
-	B-X
receptor	B-X
-	B-X
complexes	B-X
and	B-X
of	B-X
cytosolic	B-X
activated	B-X
to	B-X
unactivated	B-X
receptor	B-X
complexes	B-X
in	B-X
intact	B-X
cells	B-X
are	B-X
similar	B-X
to	B-X
Old	B-X
World	B-X
primates	B-X
<EOS>	B-X
Transformation	B-X
of	B-X
B	B-X
-	B-X
lymphocytes	B-X
with	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
leads	B-X
to	B-X
glucocorticoid	B-X
receptor	B-X
induction	B-X
that	B-X
is	B-X
less	B-X
than	B-X
that	B-X
observed	B-X
with	B-X
cells	B-X
from	B-X
Old	B-X
World	B-X
primates	B-X
<EOS>	B-X
The	B-X
common	B-X
element	B-X
that	B-X
would	B-X
explain	B-X
the	B-X
apparent	B-X
resistance	B-X
to	B-X
six	B-X
steroid	B-X
hormones	B-X
in	B-X
New	B-X
World	B-X
primates	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
The	B-X
molecular	B-X
weight	B-X
of	B-X
the	B-X
receptor	B-X
,	B-X
determined	B-X
by	B-X
SDS	B-X
-	B-X
PAGE	B-X
,	B-X
is	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
Old	B-X
World	B-X
primates	B-X
(	B-X
approximately	B-X
92,000	B-X
)	B-X
and	B-X
the	B-X
activation	B-X
pattern	B-X
per	B-X
se	B-X
,	B-X
examined	B-X
in	B-X
vitro	B-X
by	B-X
heating	B-X
cytosol	B-X
and	B-X
performing	B-X
phosphocellulose	B-X
chromatography	B-X
,	B-X
appears	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
human	B-X
controls	B-X

Results	O
from	O
mixing	O
studies	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
a	O
binding	O
inhibitor	O
(	O
s	O
)	O
or	O
a	O
deficient	O
cytosolic	O
positive	O
modifier	O
(	O
s	O
)	O
of	O
binding	O
underlies	O
the	O
findings	O
in	O
these	O
primates	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
CSF	B-X
biomarker	B-X
levels	B-X
may	B-X
be	B-X
predictive	B-X
of	B-X
future	B-X
risk	B-X
of	B-X
cognitive	B-X
decline	B-X
in	B-X
non	B-X
-	B-X
demented	B-X
PD	B-X
patients	B-X
<EOS>	B-X
Hearing	B-X
loss	B-X
was	B-X
associated	B-X
with	B-X
amyloid	B-X
binding	B-X
in	B-X
younger	B-X
-	B-X
old	B-X
individuals	B-X
only	B-X
,	B-X
and	B-X
with	B-X
cognitive	B-X
decline	B-X
in	B-X
both	B-X
age	B-X
groups	B-X
<EOS>	B-X
The	B-X
present	B-X
work	B-X
aims	B-X
to	B-X
determine	B-X
whether	B-X
FTO	B-X
genetic	B-X
variants	B-X
are	B-X
associated	B-X
with	B-X
bipolar	B-X
disorder	B-X
and	B-X
obesity	B-X
,	B-X
and	B-X
to	B-X
perform	B-X
an	B-X
in	B-X
silico	B-X
prediction	B-X
of	B-X
variant	B-X
-	B-X
dependent	B-X
functional	B-X
impact	B-X
on	B-X
the	B-X
developing	B-X
brain	B-X
transcriptome	B-X
<EOS>	B-X
McCallion	B-X
P11	B-X
Utilization	B-X
of	B-X
a	B-X
sensitized	B-X
chemical	B-X
mutagenesis	B-X
screen	B-X
to	B-X
identify	B-X
genetic	B-X
modifiers	B-X
of	B-X
retinal	B-X
dysplasia	B-X
in	B-X
homozygous	B-X
Nr2e3	B-X

The	O
New	O
World	O
primates	O
,	O
unlike	O
men	O
with	O
the	O
syndrome	O
of	O
primary	O
cortisol	O
resistance	O
,	O
have	O
compensated	O
for	O
their	O
condition	O
with	O
intra-adrenal	O
and	O
mineralocorticoid	O
receptor	O
adaptations	O
.	O
<EOS>	B-X
The	B-X
New	B-X
World	B-X
primates	B-X
,	B-X
unlike	B-X
men	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
primary	B-X
cortisol	B-X
resistance	B-X
,	B-X
have	B-X
compensated	B-X
for	B-X
their	B-X
condition	B-X
with	B-X
intra	B-X
-	B-X
adrenal	B-X
and	B-X
mineralocorticoid	B-X
receptor	B-X
adaptations	B-X
<EOS>	B-X
These	B-X
primates	B-X
also	B-X
have	B-X
high	B-X
levels	B-X
of	B-X
circulating	B-X
progesterone	B-X
,	B-X
estrogen	B-X
,	B-X
mineralocorticoid	B-X
,	B-X
androgen	B-X
and	B-X
vitamin	B-X
D	B-X
<EOS>	B-X
Many	B-X
New	B-X
World	B-X
primate	B-X
species	B-X
have	B-X
greatly	B-X
increased	B-X
plasma	B-X
cortisol	B-X
concentrations	B-X
,	B-X
decreased	B-X
plasma	B-X
cortisol	B-X
binding	B-X
globulin	B-X
capacity	B-X
and	B-X
affinity	B-X
,	B-X
marked	B-X
resistance	B-X
of	B-X
the	B-X
hypothalamic	B-X
-	B-X
pituitary	B-X
-	B-X
adrenal	B-X
axis	B-X
to	B-X
suppression	B-X
by	B-X
dexamethasone	B-X
,	B-X
and	B-X
no	B-X
biological	B-X
evidence	B-X
of	B-X
glucocorticoid	B-X
excess	B-X
<EOS>	B-X
The	B-X
common	B-X
element	B-X
that	B-X
would	B-X
explain	B-X
the	B-X
apparent	B-X
resistance	B-X
to	B-X
six	B-X
steroid	B-X
hormones	B-X
in	B-X
New	B-X
World	B-X
primates	B-X
remains	B-X
unknown	B-X

Thus	O
,	O
unlike	O
Old	O
World	O
primates	O
,	O
cortisol	O
in	O
New	O
World	O
primates	O
has	O
only	O
weak	O
sodium-retaining	O
potency	O
because	O
the	O
aldosterone	B-protein
receptor	I-protein
has	O
a	O
low	O
affinity	O
for	O
cortisol	O
.	O

The	O
common	O
element	O
that	O
would	O
explain	O
the	O
apparent	O
resistance	O
to	O
six	O
steroid	O
hormones	O
in	O
New	O
World	O
primates	O
<EOS>	B-X
The	B-X
common	B-X
element	B-X
that	B-X
would	B-X
explain	B-X
the	B-X
apparent	B-X
resistance	B-X
to	B-X
six	B-X
steroid	B-X
hormones	B-X
in	B-X
New	B-X
World	B-X
primates	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
Transformation	B-X
of	B-X
B	B-X
-	B-X
lymphocytes	B-X
with	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
leads	B-X
to	B-X
glucocorticoid	B-X
receptor	B-X
induction	B-X
that	B-X
is	B-X
less	B-X
than	B-X
that	B-X
observed	B-X
with	B-X
cells	B-X
from	B-X
Old	B-X
World	B-X
primates	B-X
<EOS>	B-X
The	B-X
ratios	B-X
of	B-X
nuclear	B-X
to	B-X
cytosolic	B-X
hormone	B-X
-	B-X
receptor	B-X
-	B-X
complexes	B-X
and	B-X
of	B-X
cytosolic	B-X
activated	B-X
to	B-X
unactivated	B-X
receptor	B-X
complexes	B-X
in	B-X
intact	B-X
cells	B-X
are	B-X
similar	B-X
to	B-X
Old	B-X
World	B-X
primates	B-X
<EOS>	B-X
The	B-X
New	B-X
World	B-X
primates	B-X
,	B-X
unlike	B-X
men	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
primary	B-X
cortisol	B-X
resistance	B-X
,	B-X
have	B-X
compensated	B-X
for	B-X
their	B-X
condition	B-X
with	B-X
intra	B-X
-	B-X
adrenal	B-X
and	B-X
mineralocorticoid	B-X
receptor	B-X
adaptations	B-X

Acetylation	O
and	O
modulation	O
of	O
erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
activity	O
by	O
interaction	O
with	O
histone	B-protein
acetyltransferases	I-protein
.	O
<EOS>	B-X
Acetylation	B-X
and	B-X
modulation	B-X
of	B-X
erythroid	B-X
Krüppel	B-X
-	B-X
like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
activity	B-X
by	B-X
interaction	B-X
with	B-X
histone	B-X
acetyltransferases	B-X
.	B-X
<EOS>	B-X
We	B-X
find	B-X
that	B-X
EKLF	B-X
is	B-X
an	B-X
acetylated	B-X
transcription	B-X
factor	B-X
,	B-X
and	B-X
that	B-X
it	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
CBP	B-X
,	B-X
p300	B-X
,	B-X
and	B-X
P	B-X
/	B-X
CAF	B-X
<EOS>	B-X
EKLF	B-X
is	B-X
required	B-X
for	B-X
integrity	B-X
of	B-X
the	B-X
chromatin	B-X
structure	B-X
at	B-X
the	B-X
beta	B-X
-	B-X
like	B-X
globin	B-X
locus	B-X
,	B-X
and	B-X
it	B-X
interacts	B-X
with	B-X
a	B-X
positive	B-X
-	B-X
acting	B-X
factor	B-X
in	B-X
vivo	B-X
<EOS>	B-X
However	B-X
,	B-X
its	B-X
interactions	B-X
with	B-X
these	B-X
histone	B-X
acetyltransferases	B-X
are	B-X
not	B-X
equivalent	B-X
,	B-X
as	B-X
CBP	B-X
and	B-X
p300	B-X
,	B-X
but	B-X
not	B-X
P	B-X
/	B-X
CAF	B-X
,	B-X
utilize	B-X
EKLF	B-X
as	B-X
a	B-X
substrate	B-X
for	B-X
in	B-X
vitro	B-X
acetylation	B-X
within	B-X
its	B-X
trans	B-X
-	B-X
activation	B-X
region	B-X

Erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
is	O
a	O
red	B-protein
cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
that	O
is	O
crucial	O
for	O
consolidating	O
the	O
switch	O
to	O
high	O
levels	O
of	O
adult	O
beta-globin	O
expression	O
during	O
erythroid	O
ontogeny	O
.	O
<EOS>	B-X
Erythroid	B-X
Krüppel	B-X
-	B-X
like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
is	B-X
a	B-X
red	B-X
cell	B-X
-	B-X
specific	B-X
transcriptional	B-X
activator	B-X
that	B-X
is	B-X
crucial	B-X
for	B-X
consolidating	B-X
the	B-X
switch	B-X
to	B-X
high	B-X
levels	B-X
of	B-X
adult	B-X
beta	B-X
-	B-X
globin	B-X
expression	B-X
during	B-X
erythroid	B-X
ontogeny	B-X
<EOS>	B-X
These	B-X
results	B-X
establish	B-X
EKLF	B-X
as	B-X
a	B-X
tissue	B-X
-	B-X
specific	B-X
transcription	B-X
factor	B-X
that	B-X
undergoes	B-X
post	B-X
-	B-X
translational	B-X
acetylation	B-X
and	B-X
suggest	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
EKLF	B-X
is	B-X
able	B-X
to	B-X
alter	B-X
chromatin	B-X
structure	B-X
and	B-X
induce	B-X
beta	B-X
-	B-X
globin	B-X
expression	B-X
within	B-X
the	B-X
beta	B-X
-	B-X
like	B-X
globin	B-X
cluster	B-X
<EOS>	B-X
The	B-X
functional	B-X
effects	B-X
of	B-X
these	B-X
interactions	B-X
are	B-X
that	B-X
CBP	B-X
and	B-X
p300	B-X
,	B-X
but	B-X
not	B-X
P	B-X
/	B-X
CAF	B-X
,	B-X
enhance	B-X
EKLF	B-X
's	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
beta	B-X
-	B-X
globin	B-X
promoter	B-X
in	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
We	B-X
find	B-X
that	B-X
EKLF	B-X
is	B-X
an	B-X
acetylated	B-X
transcription	B-X
factor	B-X
,	B-X
and	B-X
that	B-X
it	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
CBP	B-X
,	B-X
p300	B-X
,	B-X
and	B-X
P	B-X
/	B-X
CAF	B-X

EKLF	B-protein
is	O
required	O
for	O
integrity	O
of	O
the	O
chromatin	O
structure	O
at	O
the	O
beta-like	B-DNA
globin	I-DNA
locus	I-DNA
,	O
and	O
it	O
interacts	O
with	O
a	O
positive-acting	B-protein
factor	I-protein
in	O
vivo	O
.	O
<EOS>	B-X
EKLF	B-X
is	B-X
required	B-X
for	B-X
integrity	B-X
of	B-X
the	B-X
chromatin	B-X
structure	B-X
at	B-X
the	B-X
beta	B-X
-	B-X
like	B-X
globin	B-X
locus	B-X
,	B-X
and	B-X
it	B-X
interacts	B-X
with	B-X
a	B-X
positive	B-X
-	B-X
acting	B-X
factor	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Acetylation	B-X
and	B-X
modulation	B-X
of	B-X
erythroid	B-X
Krüppel	B-X
-	B-X
like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
activity	B-X
by	B-X
interaction	B-X
with	B-X
histone	B-X
acetyltransferases	B-X
.	B-X
<EOS>	B-X
We	B-X
find	B-X
that	B-X
EKLF	B-X
is	B-X
an	B-X
acetylated	B-X
transcription	B-X
factor	B-X
,	B-X
and	B-X
that	B-X
it	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
CBP	B-X
,	B-X
p300	B-X
,	B-X
and	B-X
P	B-X
/	B-X
CAF	B-X
<EOS>	B-X
Erythroid	B-X
Krüppel	B-X
-	B-X
like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
is	B-X
a	B-X
red	B-X
cell	B-X
-	B-X
specific	B-X
transcriptional	B-X
activator	B-X
that	B-X
is	B-X
crucial	B-X
for	B-X
consolidating	B-X
the	B-X
switch	B-X
to	B-X
high	B-X
levels	B-X
of	B-X
adult	B-X
beta	B-X
-	B-X
globin	B-X
expression	B-X
during	B-X
erythroid	B-X
ontogeny	B-X

We	O
find	O
that	O
EKLF	B-protein
is	O
an	O
acetylated	B-protein
transcription	I-protein
factor	I-protein
,	O
and	O
that	O
it	O
interacts	O
in	O
vivo	O
with	O
CBP	B-protein
,	O
p300	B-protein
,	O
and	O
P/CAF	B-protein
.	O
<EOS>	B-X
We	B-X
find	B-X
that	B-X
EKLF	B-X
is	B-X
an	B-X
acetylated	B-X
transcription	B-X
factor	B-X
,	B-X
and	B-X
that	B-X
it	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
CBP	B-X
,	B-X
p300	B-X
,	B-X
and	B-X
P	B-X
/	B-X
CAF	B-X
<EOS>	B-X
Acetylation	B-X
and	B-X
modulation	B-X
of	B-X
erythroid	B-X
Krüppel	B-X
-	B-X
like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
activity	B-X
by	B-X
interaction	B-X
with	B-X
histone	B-X
acetyltransferases	B-X
.	B-X
<EOS>	B-X
Erythroid	B-X
Krüppel	B-X
-	B-X
like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
is	B-X
a	B-X
red	B-X
cell	B-X
-	B-X
specific	B-X
transcriptional	B-X
activator	B-X
that	B-X
is	B-X
crucial	B-X
for	B-X
consolidating	B-X
the	B-X
switch	B-X
to	B-X
high	B-X
levels	B-X
of	B-X
adult	B-X
beta	B-X
-	B-X
globin	B-X
expression	B-X
during	B-X
erythroid	B-X
ontogeny	B-X
<EOS>	B-X
However	B-X
,	B-X
its	B-X
interactions	B-X
with	B-X
these	B-X
histone	B-X
acetyltransferases	B-X
are	B-X
not	B-X
equivalent	B-X
,	B-X
as	B-X
CBP	B-X
and	B-X
p300	B-X
,	B-X
but	B-X
not	B-X
P	B-X
/	B-X
CAF	B-X
,	B-X
utilize	B-X
EKLF	B-X
as	B-X
a	B-X
substrate	B-X
for	B-X
in	B-X
vitro	B-X
acetylation	B-X
within	B-X
its	B-X
trans	B-X
-	B-X
activation	B-X
region	B-X

However	O
,	O
its	O
interactions	O
with	O
these	O
histone	B-protein
acetyltransferases	I-protein
are	O
not	O
equivalent	O
,	O
as	O
CBP	B-protein
and	O
p300	B-protein
,	O
but	O
not	O
P/CAF	B-protein
,	O
utilize	O
EKLF	B-protein
as	O
a	O
substrate	O
for	O
in	O
vitro	O
acetylation	O
within	O
its	O
trans-activation	O
region	O
.	O
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
the	B-X
histone	B-X
acetyltransferase	B-X
complex	B-X
Hat1	B-X
-	B-X
Hat2	B-X
and	B-X
transcription	B-X
factor	B-X
AmyR	B-X
provides	B-X
a	B-X
molecular	B-X
brake	B-X
to	B-X
regulate	B-X
amylase	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
10	B-X
histone	B-X
acetyltransferases	B-X
in	B-X
cassava	B-X
and	B-X
found	B-X
that	B-X
the	B-X
transcript	B-X
of	B-X
MeHAM1	B-X
showed	B-X
the	B-X
highest	B-X
induction	B-X
to	B-X
CBB	B-X
<EOS>	B-X
The	B-X
first	B-X
identified	B-X
histone	B-X
acetyltransferase	B-X
was	B-X
Hat1	B-X
/	B-X
KAT1	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
lysine	B-X
(	B-X
K	B-X
)	B-X
acetyltransferases	B-X
<EOS>	B-X
Many	B-X
N	B-X
-	B-X
terminal	B-X
acetyltransferases	B-X
(	B-X
NATs	B-X
)	B-X
enzymes	B-X
play	B-X
important	B-X
role	B-X
in	B-X
the	B-X
post	B-X
-	B-X
translational	B-X
modification	B-X
of	B-X
histone	B-X
tails	B-X

The	O
functional	O
effects	O
of	O
these	O
interactions	O
are	O
that	O
CBP	B-protein
and	O
p300	B-protein
,	O
but	O
not	O
P/CAF	B-protein
,	O
enhance	O
EKLF	B-protein
's	O
transcriptional	O
activation	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Although	B-X
a	B-X
functional	B-X
synergy	B-X
between	B-X
central	B-X
actions	B-X
of	B-X
estrogens	B-X
and	B-X
leptin	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
protect	B-X
against	B-X
metabolic	B-X
disturbances	B-X
,	B-X
the	B-X
underlying	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
this	B-X
crosstalk	B-X
have	B-X
remained	B-X
elusive	B-X
<EOS>	B-X
We	B-X
further	B-X
discovered	B-X
that	B-X
trimethoprim	B-X
strongly	B-X
interrupts	B-X
the	B-X
interaction	B-X
of	B-X
Snail	B-X
with	B-X
CREB	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CBP	B-X
)	B-X
	B-X
/	B-X
p300	B-X
,	B-X
which	B-X
consequently	B-X
suppresses	B-X
Snail	B-X
acetylation	B-X
and	B-X
promotes	B-X
Snail	B-X
degradation	B-X
through	B-X
the	B-X
ubiquitin	B-X
-	B-X
proteasome	B-X
pathway	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
directly	B-X
disrupting	B-X
β	B-X
-	B-X
catenin	B-X
's	B-X
interactions	B-X
with	B-X
these	B-X
nuclear	B-X
partners	B-X
holds	B-X
promise	B-X
for	B-X
the	B-X
effective	B-X
and	B-X
selective	B-X
suppression	B-X
of	B-X
the	B-X
aberrant	B-X
activation	B-X
of	B-X
Wnt	B-X
/	B-X
β	B-X
-	B-X
catenin	B-X
signaling	B-X
<EOS>	B-X
Pneumonia	B-X
,	B-X
a	B-X
severe	B-X
infectious	B-X
respiratory	B-X
disease	B-X
,	B-X
is	B-X
one	B-X
of	B-X
the	B-X
leading	B-X
causes	B-X
of	B-X
mortality	B-X
and	B-X
morbidity	B-X
in	B-X
children	B-X

These	O
results	O
establish	O
EKLF	B-protein
as	O
a	O
tissue-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
undergoes	O
post-translational	O
acetylation	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
EKLF	B-protein
is	O
able	O
to	O
alter	O
chromatin	O
structure	O
and	O
induce	O
beta-globin	O
expression	O
within	O
the	O
beta-like	B-DNA
globin	I-DNA
cluster	I-DNA
.	O
<EOS>	B-X
These	B-X
results	B-X
establish	B-X
EKLF	B-X
as	B-X
a	B-X
tissue	B-X
-	B-X
specific	B-X
transcription	B-X
factor	B-X
that	B-X
undergoes	B-X
post	B-X
-	B-X
translational	B-X
acetylation	B-X
and	B-X
suggest	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
EKLF	B-X
is	B-X
able	B-X
to	B-X
alter	B-X
chromatin	B-X
structure	B-X
and	B-X
induce	B-X
beta	B-X
-	B-X
globin	B-X
expression	B-X
within	B-X
the	B-X
beta	B-X
-	B-X
like	B-X
globin	B-X
cluster	B-X
<EOS>	B-X
Erythroid	B-X
Krüppel	B-X
-	B-X
like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
is	B-X
a	B-X
red	B-X
cell	B-X
-	B-X
specific	B-X
transcriptional	B-X
activator	B-X
that	B-X
is	B-X
crucial	B-X
for	B-X
consolidating	B-X
the	B-X
switch	B-X
to	B-X
high	B-X
levels	B-X
of	B-X
adult	B-X
beta	B-X
-	B-X
globin	B-X
expression	B-X
during	B-X
erythroid	B-X
ontogeny	B-X
<EOS>	B-X
The	B-X
functional	B-X
effects	B-X
of	B-X
these	B-X
interactions	B-X
are	B-X
that	B-X
CBP	B-X
and	B-X
p300	B-X
,	B-X
but	B-X
not	B-X
P	B-X
/	B-X
CAF	B-X
,	B-X
enhance	B-X
EKLF	B-X
's	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
beta	B-X
-	B-X
globin	B-X
promoter	B-X
in	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
However	B-X
,	B-X
its	B-X
interactions	B-X
with	B-X
these	B-X
histone	B-X
acetyltransferases	B-X
are	B-X
not	B-X
equivalent	B-X
,	B-X
as	B-X
CBP	B-X
and	B-X
p300	B-X
,	B-X
but	B-X
not	B-X
P	B-X
/	B-X
CAF	B-X
,	B-X
utilize	B-X
EKLF	B-X
as	B-X
a	B-X
substrate	B-X
for	B-X
in	B-X
vitro	B-X
acetylation	B-X
within	B-X
its	B-X
trans	B-X
-	B-X
activation	B-X
region	B-X

Recognition	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
2	I-protein
tegument	I-protein
proteins	I-protein
by	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
infiltrating	O
human	O
genital	O
herpes	O
lesions	O
.	O
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
The	B-X
antigens	B-X
recognized	B-X
by	B-X
many	B-X
HSV	B-X
-	B-X
specific	B-X
CD4	B-X
T	B-X
cells	B-X
localizing	B-X
to	B-X
genital	B-X
HSV	B-X
-	B-X
2	B-X
lesions	B-X
are	B-X
unknown	B-X
<EOS>	B-X
Reactivity	B-X
with	B-X
the	B-X
tegument	B-X
protein	B-X
encoded	B-X
by	B-X
UL21	B-X
was	B-X
identified	B-X
for	B-X
an	B-X
additional	B-X
patient	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
herpes	B-X
simplex	B-X
tegument	B-X
proteins	B-X
are	B-X
processed	B-X
for	B-X
antigen	B-X
presentation	B-X
in	B-X
vivo	B-X
and	B-X
are	B-X
possible	B-X
candidate	B-X
compounds	B-X
for	B-X
herpes	B-X
simplex	B-X
vaccines	B-X

The	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
HSV	O
infection	O
.	O
<EOS>	B-X
The	B-X
local	B-X
cellular	B-X
immune	B-X
response	B-X
to	B-X
herpes	B-X
simplex	B-X
virus	B-X
(	B-X
HSV	B-X
)	B-X
is	B-X
important	B-X
in	B-X
the	B-X
control	B-X
of	B-X
recurrent	B-X
HSV	B-X
infection	B-X
<EOS>	B-X
Reactivation	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
2	B-X
(	B-X
HSV	B-X
-	B-X
2	B-X
)	B-X
from	B-X
latency	B-X
causes	B-X
viral	B-X
shedding	B-X
that	B-X
develops	B-X
into	B-X
recurrent	B-X
genital	B-X
lesions	B-X
<EOS>	B-X
CXCR3	B-X
ligand	B-X
mRNA	B-X
levels	B-X
were	B-X
selectively	B-X
increased	B-X
in	B-X
skin	B-X
biopsy	B-X
specimens	B-X
from	B-X
persons	B-X
with	B-X
recurrent	B-X
HSV	B-X
-	B-X
2	B-X
,	B-X
while	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
the	B-X
CCR10	B-X
ligand	B-X
CCL27	B-X
were	B-X
equivalent	B-X
in	B-X
lesion	B-X
and	B-X
control	B-X
skin	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
herpes	B-X
simplex	B-X
tegument	B-X
proteins	B-X
are	B-X
processed	B-X
for	B-X
antigen	B-X
presentation	B-X
in	B-X
vivo	B-X
and	B-X
are	B-X
possible	B-X
candidate	B-X
compounds	B-X
for	B-X
herpes	B-X
simplex	B-X
vaccines	B-X

The	O
antiviral	O
functions	O
of	O
infiltrating	B-cell_type
CD4-bearing	I-cell_type
T	I-cell_type
cells	I-cell_type
may	O
include	O
cytotoxicity	O
,	O
inhibition	O
of	O
viral	O
growth	O
,	O
lymphokine	O
secretion	O
,	O
and	O
support	O
of	O
humoral	O
and	O
CD8	O
responses	O
.	O
<EOS>	B-X
The	B-X
antiviral	B-X
functions	B-X
of	B-X
infiltrating	B-X
CD4	B-X
-	B-X
bearing	B-X
T	B-X
cells	B-X
may	B-X
include	B-X
cytotoxicity	B-X
,	B-X
inhibition	B-X
of	B-X
viral	B-X
growth	B-X
,	B-X
lymphokine	B-X
secretion	B-X
,	B-X
and	B-X
support	B-X
of	B-X
humoral	B-X
and	B-X
CD8	B-X
responses	B-X
<EOS>	B-X
The	B-X
antigens	B-X
recognized	B-X
by	B-X
many	B-X
HSV	B-X
-	B-X
specific	B-X
CD4	B-X
T	B-X
cells	B-X
localizing	B-X
to	B-X
genital	B-X
HSV	B-X
-	B-X
2	B-X
lesions	B-X
are	B-X
unknown	B-X
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
Some	B-X
tegument	B-X
-	B-X
specific	B-X
CD4	B-X
T	B-X
-	B-X
cell	B-X
clones	B-X
exhibited	B-X
cytotoxic	B-X
activity	B-X
against	B-X
HSV	B-X
-	B-X
infected	B-X
cells	B-X

The	O
antigens	O
recognized	O
by	O
many	O
HSV-specific	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
localizing	O
to	O
genital	O
HSV-2	O
lesions	O
are	O
unknown	O
.	O
<EOS>	B-X
The	B-X
antigens	B-X
recognized	B-X
by	B-X
many	B-X
HSV	B-X
-	B-X
specific	B-X
CD4	B-X
T	B-X
cells	B-X
localizing	B-X
to	B-X
genital	B-X
HSV	B-X
-	B-X
2	B-X
lesions	B-X
are	B-X
unknown	B-X
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
T	B-X
cells	B-X
recognizing	B-X
antigens	B-X
encoded	B-X
within	B-X
map	B-X
units	B-X
0	B-X
<EOS>	B-X
Separate	B-X
epitopes	B-X
in	B-X
VP22	B-X
were	B-X
defined	B-X
for	B-X
T	B-X
-	B-X
cell	B-X
clones	B-X
from	B-X
each	B-X
of	B-X
three	B-X
patients	B-X

T	B-cell_type
cells	I-cell_type
recognizing	O
antigens	O
encoded	O
within	O
map	O
units	O
0.67	O
to	O
0.73	O
of	O
HSV	B-DNA
DNA	I-DNA
are	O
frequently	O
recovered	O
from	O
herpetic	O
lesions	O
.	O
<EOS>	B-X
73	B-X
of	B-X
HSV	B-X
DNA	B-X
are	B-X
frequently	B-X
recovered	B-X
from	B-X
herpetic	B-X
lesions	B-X
<EOS>	B-X
T	B-X
cells	B-X
recognizing	B-X
antigens	B-X
encoded	B-X
within	B-X
map	B-X
units	B-X
0	B-X
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
herpes	B-X
simplex	B-X
tegument	B-X
proteins	B-X
are	B-X
processed	B-X
for	B-X
antigen	B-X
presentation	B-X
in	B-X
vivo	B-X
and	B-X
are	B-X
possible	B-X
candidate	B-X
compounds	B-X
for	B-X
herpes	B-X
simplex	B-X
vaccines	B-X

Expression	O
cloning	O
with	O
this	O
region	O
of	O
DNA	O
now	O
shows	O
that	O
tegument	B-protein
protein	I-protein
VP22	B-protein
and	O
the	O
viral	B-protein
dUTPase	I-protein
,	O
encoded	O
by	O
genes	B-DNA
UL49	I-DNA
and	I-DNA
UL50	I-DNA
,	O
respectively	O
,	O
are	O
T-cell	B-protein
antigens	I-protein
.	O
<EOS>	B-X
Expression	B-X
cloning	B-X
with	B-X
this	B-X
region	B-X
of	B-X
DNA	B-X
now	B-X
shows	B-X
that	B-X
tegument	B-X
protein	B-X
VP22	B-X
and	B-X
the	B-X
viral	B-X
dUTPase	B-X
,	B-X
encoded	B-X
by	B-X
genes	B-X
UL49	B-X
and	B-X
UL50	B-X
,	B-X
respectively	B-X
,	B-X
are	B-X
T	B-X
-	B-X
cell	B-X
antigens	B-X
<EOS>	B-X
Reactivity	B-X
with	B-X
the	B-X
tegument	B-X
protein	B-X
encoded	B-X
by	B-X
UL21	B-X
was	B-X
identified	B-X
for	B-X
an	B-X
additional	B-X
patient	B-X
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
Three	B-X
new	B-X
epitopes	B-X
were	B-X
identified	B-X
in	B-X
VP16	B-X
,	B-X
a	B-X
tegument	B-X
protein	B-X
associated	B-X
with	B-X
VP22	B-X

Separate	O
epitopes	B-protein
in	O
VP22	B-protein
were	O
defined	O
for	O
T-cell	B-cell_line
clones	I-cell_line
from	O
each	O
of	O
three	O
patients	O
.	O
<EOS>	B-X
Separate	B-X
epitopes	B-X
in	B-X
VP22	B-X
were	B-X
defined	B-X
for	B-X
T	B-X
-	B-X
cell	B-X
clones	B-X
from	B-X
each	B-X
of	B-X
three	B-X
patients	B-X
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
Three	B-X
new	B-X
epitopes	B-X
were	B-X
identified	B-X
in	B-X
VP16	B-X
,	B-X
a	B-X
tegument	B-X
protein	B-X
associated	B-X
with	B-X
VP22	B-X
<EOS>	B-X
73	B-X
of	B-X
HSV	B-X
DNA	B-X
are	B-X
frequently	B-X
recovered	B-X
from	B-X
herpetic	B-X
lesions	B-X

Reactivity	O
with	O
the	O
tegument	B-protein
protein	I-protein
encoded	O
by	O
UL21	B-DNA
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O
<EOS>	B-X
Reactivity	B-X
with	B-X
the	B-X
tegument	B-X
protein	B-X
encoded	B-X
by	B-X
UL21	B-X
was	B-X
identified	B-X
for	B-X
an	B-X
additional	B-X
patient	B-X
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
Expression	B-X
cloning	B-X
with	B-X
this	B-X
region	B-X
of	B-X
DNA	B-X
now	B-X
shows	B-X
that	B-X
tegument	B-X
protein	B-X
VP22	B-X
and	B-X
the	B-X
viral	B-X
dUTPase	B-X
,	B-X
encoded	B-X
by	B-X
genes	B-X
UL49	B-X
and	B-X
UL50	B-X
,	B-X
respectively	B-X
,	B-X
are	B-X
T	B-X
-	B-X
cell	B-X
antigens	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
herpes	B-X
simplex	B-X
tegument	B-X
proteins	B-X
are	B-X
processed	B-X
for	B-X
antigen	B-X
presentation	B-X
in	B-X
vivo	B-X
and	B-X
are	B-X
possible	B-X
candidate	B-X
compounds	B-X
for	B-X
herpes	B-X
simplex	B-X
vaccines	B-X

Three	O
new	O
epitopes	O
were	O
identified	O
in	O
VP16	B-protein
,	O
a	O
tegument	B-protein
protein	I-protein
associated	O
with	O
VP22	B-protein
.	O
<EOS>	B-X
Three	B-X
new	B-X
epitopes	B-X
were	B-X
identified	B-X
in	B-X
VP16	B-X
,	B-X
a	B-X
tegument	B-X
protein	B-X
associated	B-X
with	B-X
VP22	B-X
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
T	B-X
cells	B-X
recognizing	B-X
antigens	B-X
encoded	B-X
within	B-X
map	B-X
units	B-X
0	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
herpes	B-X
simplex	B-X
tegument	B-X
proteins	B-X
are	B-X
processed	B-X
for	B-X
antigen	B-X
presentation	B-X
in	B-X
vivo	B-X
and	B-X
are	B-X
possible	B-X
candidate	B-X
compounds	B-X
for	B-X
herpes	B-X
simplex	B-X
vaccines	B-X

Some	O
tegument-specific	B-cell_line
CD4	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
exhibited	O
cytotoxic	O
activity	O
against	O
HSV-infected	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Some	B-X
tegument	B-X
-	B-X
specific	B-X
CD4	B-X
T	B-X
-	B-X
cell	B-X
clones	B-X
exhibited	B-X
cytotoxic	B-X
activity	B-X
against	B-X
HSV	B-X
-	B-X
infected	B-X
cells	B-X
<EOS>	B-X
The	B-X
antiviral	B-X
functions	B-X
of	B-X
infiltrating	B-X
CD4	B-X
-	B-X
bearing	B-X
T	B-X
cells	B-X
may	B-X
include	B-X
cytotoxicity	B-X
,	B-X
inhibition	B-X
of	B-X
viral	B-X
growth	B-X
,	B-X
lymphokine	B-X
secretion	B-X
,	B-X
and	B-X
support	B-X
of	B-X
humoral	B-X
and	B-X
CD8	B-X
responses	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
herpes	B-X
simplex	B-X
tegument	B-X
proteins	B-X
are	B-X
processed	B-X
for	B-X
antigen	B-X
presentation	B-X
in	B-X
vivo	B-X
and	B-X
are	B-X
possible	B-X
candidate	B-X
compounds	B-X
for	B-X
herpes	B-X
simplex	B-X
vaccines	B-X
<EOS>	B-X
T	B-X
cells	B-X
recognizing	B-X
antigens	B-X
encoded	B-X
within	B-X
map	B-X
units	B-X
0	B-X

These	O
results	O
suggest	O
that	O
herpes	B-protein
simplex	I-protein
tegument	I-protein
proteins	I-protein
are	O
processed	O
for	O
antigen	O
presentation	O
in	O
vivo	O
and	O
are	O
possible	O
candidate	O
compounds	O
for	O
herpes	O
simplex	O
vaccines	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
herpes	B-X
simplex	B-X
tegument	B-X
proteins	B-X
are	B-X
processed	B-X
for	B-X
antigen	B-X
presentation	B-X
in	B-X
vivo	B-X
and	B-X
are	B-X
possible	B-X
candidate	B-X
compounds	B-X
for	B-X
herpes	B-X
simplex	B-X
vaccines	B-X
<EOS>	B-X
Recognition	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
tegument	B-X
proteins	B-X
by	B-X
CD4	B-X
T	B-X
cells	B-X
infiltrating	B-X
human	B-X
genital	B-X
herpes	B-X
lesions	B-X
.	B-X
<EOS>	B-X
Reactivity	B-X
with	B-X
the	B-X
tegument	B-X
protein	B-X
encoded	B-X
by	B-X
UL21	B-X
was	B-X
identified	B-X
for	B-X
an	B-X
additional	B-X
patient	B-X
<EOS>	B-X
The	B-X
local	B-X
cellular	B-X
immune	B-X
response	B-X
to	B-X
herpes	B-X
simplex	B-X
virus	B-X
(	B-X
HSV	B-X
)	B-X
is	B-X
important	B-X
in	B-X
the	B-X
control	B-X
of	B-X
recurrent	B-X
HSV	B-X
infection	B-X

Fibrinogen	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O
<EOS>	B-X
Fibrinogen	B-X
activates	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcription	B-X
factors	B-X
in	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X
<EOS>	B-X
Fibrinogen	B-X
also	B-X
caused	B-X
activation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
but	B-X
not	B-X
SP1	B-X
or	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
factors	B-X
<EOS>	B-X
Adhesion	B-X
to	B-X
extracellular	B-X
matrices	B-X
is	B-X
known	B-X
to	B-X
modulate	B-X
leukocyte	B-X
activation	B-X
,	B-X
although	B-X
the	B-X
mechanisms	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
<EOS>	B-X
UTI	B-X
inhibited	B-X
LPS	B-X
-	B-X
induced	B-X
increases	B-X
in	B-X
both	B-X
TF	B-X
activities	B-X
and	B-X
TF	B-X
mRNA	B-X
expression	B-X
in	B-X
monocytes	B-X
without	B-X
affecting	B-X
the	B-X
viability	B-X

Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O
<EOS>	B-X
Although	B-X
it	B-X
is	B-X
known	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
integrin	B-X
receptors	B-X
to	B-X
extracellular	B-X
matrix	B-X
proteins	B-X
provides	B-X
co	B-X
-	B-X
stimulatory	B-X
signals	B-X
to	B-X
naive	B-X
T	B-X
cells	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
these	B-X
signals	B-X
are	B-X
critical	B-X
for	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
fibrin	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
proinflammatory	B-X
cytokine	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
and	B-X
sought	B-X
to	B-X
explore	B-X
mechanisms	B-X
responsible	B-X
for	B-X
this	B-X
induction	B-X
<EOS>	B-X
Their	B-X
receptor	B-X
repertoire	B-X
is	B-X
well	B-X
known	B-X
,	B-X
but	B-X
less	B-X
is	B-X
known	B-X
how	B-X
these	B-X
receptor	B-X
-	B-X
ligand	B-X
interactions	B-X
impact	B-X
the	B-X
degranulation	B-X
process	B-X
and	B-X
the	B-X
responsiveness	B-X
to	B-X
subsequent	B-X
activation	B-X
<EOS>	B-X
Proteolysis	B-X
and	B-X
remodeling	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
occur	B-X
physiologically	B-X
in	B-X
processes	B-X
such	B-X
as	B-X
tissue	B-X
morphogenesis	B-X
and	B-X
repair	B-X
and	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
complex	B-X
cell	B-X
functions	B-X
,	B-X
including	B-X
proliferation	B-X
and	B-X
differentiation	B-X

Mononuclear	B-cell_type
phagocytes	I-cell_type
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
.	O
<EOS>	B-X
Mononuclear	B-X
phagocytes	B-X
are	B-X
exposed	B-X
to	B-X
fibrinous	B-X
provisional	B-X
matrix	B-X
throughout	B-X
migration	B-X
into	B-X
inflammatory	B-X
foci	B-X
,	B-X
so	B-X
this	B-X
study	B-X
was	B-X
undertaken	B-X
to	B-X
determine	B-X
whether	B-X
fibrinogen	B-X
triggers	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Cells	B-X
stimulated	B-X
with	B-X
fibrinogen	B-X
(	B-X
10	B-X
-	B-X
100	B-X
microg	B-X
/	B-X
ml	B-X
)	B-X
	B-X
/	B-X
Mn2+	B-X
(	B-X
50	B-X
microM	B-X
)	B-X
for	B-X
2	B-X
h	B-X
were	B-X
examined	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
Fibrinogen	B-X
also	B-X
caused	B-X
activation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
but	B-X
not	B-X
SP1	B-X
or	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
factors	B-X
<EOS>	B-X
Blocking	B-X
mAbs	B-X
against	B-X
CD18	B-X
and	B-X
CD11b	B-X
abrogated	B-X
fibrinogen	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X

U937	B-cell_line
cells	I-cell_line
differentiated	O
with	O
PMA	O
in	O
nonadherent	B-cell_line
culture	I-cell_line
were	O
shown	O
to	O
express	O
two	O
fibrinogen-binding	B-protein
integrins	I-protein
,	O
predominately	O
CD11b/CD18	B-protein
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c/CD18	B-protein
.	O
<EOS>	B-X
U937	B-X
cells	B-X
differentiated	B-X
with	B-X
PMA	B-X
in	B-X
nonadherent	B-X
culture	B-X
were	B-X
shown	B-X
to	B-X
express	B-X
two	B-X
fibrinogen	B-X
-	B-X
binding	B-X
integrins	B-X
,	B-X
predominately	B-X
CD11b	B-X
/	B-X
CD18	B-X
,	B-X
and	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
CD11c	B-X
/	B-X
CD18	B-X
<EOS>	B-X
Cells	B-X
stimulated	B-X
with	B-X
fibrinogen	B-X
(	B-X
10	B-X
-	B-X
100	B-X
microg	B-X
/	B-X
ml	B-X
)	B-X
	B-X
/	B-X
Mn2+	B-X
(	B-X
50	B-X
microM	B-X
)	B-X
for	B-X
2	B-X
h	B-X
were	B-X
examined	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
contact	B-X
with	B-X
fibrinogen	B-X
-	B-X
derived	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
mononuclear	B-X
phagocyte	B-X
activation	B-X
by	B-X
signaling	B-X
through	B-X
CD11b	B-X
/	B-X
CD18	B-X
,	B-X
resulting	B-X
in	B-X
selective	B-X
activation	B-X
of	B-X
transcriptional	B-X
regulatory	B-X
factors	B-X
,	B-X
including	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
effects	B-X
on	B-X
transcriptional	B-X
regulation	B-X
,	B-X
U937	B-X
cells	B-X
were	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
containing	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
enhancer	B-X
(	B-X
bearing	B-X
two	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
sites	B-X
)	B-X
coupled	B-X
to	B-X
a	B-X
chloramphenicol	B-X
acetyltransferase	B-X
(	B-X
CAT	B-X
)	B-X
reporter	B-X

Cells	O
stimulated	O
with	O
fibrinogen	B-protein
(	O
10-100	O
microg/ml	O
)	O
/Mn2+	O
(	O
50	O
microM	O
)	O
for	O
2	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
<EOS>	B-X
Cells	B-X
stimulated	B-X
with	B-X
fibrinogen	B-X
(	B-X
10	B-X
-	B-X
100	B-X
microg	B-X
/	B-X
ml	B-X
)	B-X
	B-X
/	B-X
Mn2+	B-X
(	B-X
50	B-X
microM	B-X
)	B-X
for	B-X
2	B-X
h	B-X
were	B-X
examined	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
6	B-X
-	B-X
fold	B-X
,	B-X
2	B-X
)	B-X
fibrinogen	B-X
/	B-X
Mn2+	B-X
for	B-X
2	B-X
h	B-X
,	B-X
inducing	B-X
CAT	B-X
activity	B-X
by	B-X
3	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
contact	B-X
with	B-X
fibrinogen	B-X
-	B-X
derived	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
mononuclear	B-X
phagocyte	B-X
activation	B-X
by	B-X
signaling	B-X
through	B-X
CD11b	B-X
/	B-X
CD18	B-X
,	B-X
resulting	B-X
in	B-X
selective	B-X
activation	B-X
of	B-X
transcriptional	B-X
regulatory	B-X
factors	B-X
,	B-X
including	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
Cells	B-X
were	B-X
subsequently	B-X
stimulated	B-X
with	B-X
1	B-X
)	B-X
PMA	B-X
for	B-X
24	B-X
h	B-X
,	B-X
inducing	B-X
CAT	B-X
activity	B-X
by	B-X
2	B-X

NF-kappa	B-protein
B	I-protein
activation	O
,	O
minimal	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
,	O
was	O
substantially	O
up-regulated	O
by	O
fibrinogen	B-protein
.	O
<EOS>	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
,	B-X
minimal	B-X
in	B-X
unstimulated	B-X
cells	B-X
,	B-X
was	B-X
substantially	B-X
up	B-X
-	B-X
regulated	B-X
by	B-X
fibrinogen	B-X
<EOS>	B-X
Fibrinogen	B-X
activates	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcription	B-X
factors	B-X
in	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X
<EOS>	B-X
2	B-X
-	B-X
fold	B-X
,	B-X
or	B-X
3	B-X
)	B-X
costimulation	B-X
with	B-X
fibrinogen	B-X
and	B-X
PMA	B-X
,	B-X
inducing	B-X
5	B-X
<EOS>	B-X
Adhesion	B-X
to	B-X
extracellular	B-X
matrices	B-X
is	B-X
known	B-X
to	B-X
modulate	B-X
leukocyte	B-X
activation	B-X
,	B-X
although	B-X
the	B-X
mechanisms	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X

Fibrinogen	B-protein
also	O
caused	O
activation	O
of	O
AP-1	B-protein
,	O
but	O
not	O
SP1	B-protein
or	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	I-protein
CREB	I-protein
)	I-protein
factors	I-protein
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
axonal	B-X
BDNF	B-X
increased	B-X
dendritic	B-X
growth	B-X
from	B-X
the	B-X
neuronal	B-X
cell	B-X
body	B-X
in	B-X
a	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
	B-X
-	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
exposure	B-X
to	B-X
a	B-X
magnetic	B-X
environment	B-X
had	B-X
a	B-X
positive	B-X
influence	B-X
on	B-X
neurodifferentiation	B-X
through	B-X
the	B-X
modulation	B-X
of	B-X
calcium	B-X
channels	B-X
'	B-X
activity	B-X
and	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
phosphorylation	B-X
<EOS>	B-X
The	B-X
anti	B-X
-	B-X
depressive	B-X
mechanism	B-X
of	B-X
RH	B-X
determined	B-X
by	B-X
measuring	B-X
the	B-X
5	B-X
-	B-X
HT	B-X
levels	B-X
,	B-X
the	B-X
expressions	B-X
of	B-X
cAMP	B-X
-	B-X
response	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
and	B-X
brain	B-X
-	B-X
derived	B-X
neurotrophic	B-X
factor	B-X
(	B-X
BDNF	B-X
)	B-X
in	B-X
cortex	B-X
and	B-X
hippocampus	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
Transcription	B-X
factor	B-X
CREB	B-X
(	B-X
cAMP	B-X
Response	B-X
Element	B-X
-	B-X
binding	B-X
protein	B-X
)	B-X
also	B-X
determines	B-X
the	B-X
gene	B-X
expression	B-X
of	B-X
BDNF	B-X

Blocking	O
mAbs	B-protein
against	O
CD18	B-protein
and	O
CD11b	B-protein
abrogated	O
fibrinogen	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O
<EOS>	B-X
Blocking	B-X
mAbs	B-X
against	B-X
CD18	B-X
and	B-X
CD11b	B-X
abrogated	B-X
fibrinogen	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
<EOS>	B-X
2	B-X
-	B-X
fold	B-X
,	B-X
or	B-X
3	B-X
)	B-X
costimulation	B-X
with	B-X
fibrinogen	B-X
and	B-X
PMA	B-X
,	B-X
inducing	B-X
5	B-X
<EOS>	B-X
Mononuclear	B-X
phagocytes	B-X
are	B-X
exposed	B-X
to	B-X
fibrinous	B-X
provisional	B-X
matrix	B-X
throughout	B-X
migration	B-X
into	B-X
inflammatory	B-X
foci	B-X
,	B-X
so	B-X
this	B-X
study	B-X
was	B-X
undertaken	B-X
to	B-X
determine	B-X
whether	B-X
fibrinogen	B-X
triggers	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
7	B-X
-	B-X
fold	B-X
the	B-X
CAT	B-X
activity	B-X
induced	B-X
by	B-X
PMA	B-X
alone	B-X

To	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
U937	B-cell_line
cells	I-cell_line
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
(	O
bearing	O
two	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
)	O
coupled	O
to	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
effects	B-X
on	B-X
transcriptional	B-X
regulation	B-X
,	B-X
U937	B-X
cells	B-X
were	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
containing	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
enhancer	B-X
(	B-X
bearing	B-X
two	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
sites	B-X
)	B-X
coupled	B-X
to	B-X
a	B-X
chloramphenicol	B-X
acetyltransferase	B-X
(	B-X
CAT	B-X
)	B-X
reporter	B-X
<EOS>	B-X
Adhesion	B-X
to	B-X
extracellular	B-X
matrices	B-X
is	B-X
known	B-X
to	B-X
modulate	B-X
leukocyte	B-X
activation	B-X
,	B-X
although	B-X
the	B-X
mechanisms	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
<EOS>	B-X
U937	B-X
cells	B-X
differentiated	B-X
with	B-X
PMA	B-X
in	B-X
nonadherent	B-X
culture	B-X
were	B-X
shown	B-X
to	B-X
express	B-X
two	B-X
fibrinogen	B-X
-	B-X
binding	B-X
integrins	B-X
,	B-X
predominately	B-X
CD11b	B-X
/	B-X
CD18	B-X
,	B-X
and	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
CD11c	B-X
/	B-X
CD18	B-X
<EOS>	B-X
Fibrinogen	B-X
also	B-X
caused	B-X
activation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
but	B-X
not	B-X
SP1	B-X
or	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
factors	B-X

Cells	O
were	O
subsequently	O
stimulated	O
with	O
1	O
)	O
PMA	O
for	O
24	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
2.6-fold	O
,	O
2	O
)	O
fibrinogen	B-protein
/Mn2+	O
for	O
2	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
3.2-fold	O
,	O
or	O
3	O
)	O
costimulation	O
with	O
fibrinogen	B-protein
and	O
PMA	O
,	O
inducing	O
5.7-fold	O
the	O
CAT	O
activity	O
induced	O
by	O
PMA	O
alone	O
.	O
<EOS>	B-X
Cells	B-X
were	B-X
subsequently	B-X
stimulated	B-X
with	B-X
1	B-X
)	B-X
PMA	B-X
for	B-X
24	B-X
h	B-X
,	B-X
inducing	B-X
CAT	B-X
activity	B-X
by	B-X
2	B-X
<EOS>	B-X
U937	B-X
cells	B-X
differentiated	B-X
with	B-X
PMA	B-X
in	B-X
nonadherent	B-X
culture	B-X
were	B-X
shown	B-X
to	B-X
express	B-X
two	B-X
fibrinogen	B-X
-	B-X
binding	B-X
integrins	B-X
,	B-X
predominately	B-X
CD11b	B-X
/	B-X
CD18	B-X
,	B-X
and	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
CD11c	B-X
/	B-X
CD18	B-X
<EOS>	B-X
Cells	B-X
stimulated	B-X
with	B-X
fibrinogen	B-X
(	B-X
10	B-X
-	B-X
100	B-X
microg	B-X
/	B-X
ml	B-X
)	B-X
	B-X
/	B-X
Mn2+	B-X
(	B-X
50	B-X
microM	B-X
)	B-X
for	B-X
2	B-X
h	B-X
were	B-X
examined	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
2	B-X
-	B-X
fold	B-X
,	B-X
or	B-X
3	B-X
)	B-X
costimulation	B-X
with	B-X
fibrinogen	B-X
and	B-X
PMA	B-X
,	B-X
inducing	B-X
5	B-X

We	O
conclude	O
that	O
contact	O
with	O
fibrinogen-derived	B-protein
proteins	I-protein
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b/CD18	B-protein
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	B-protein
regulatory	I-protein
factors	I-protein
,	O
including	O
NF-kappa	B-protein
B	I-protein
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
contact	B-X
with	B-X
fibrinogen	B-X
-	B-X
derived	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
mononuclear	B-X
phagocyte	B-X
activation	B-X
by	B-X
signaling	B-X
through	B-X
CD11b	B-X
/	B-X
CD18	B-X
,	B-X
resulting	B-X
in	B-X
selective	B-X
activation	B-X
of	B-X
transcriptional	B-X
regulatory	B-X
factors	B-X
,	B-X
including	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
Adhesion	B-X
to	B-X
extracellular	B-X
matrices	B-X
is	B-X
known	B-X
to	B-X
modulate	B-X
leukocyte	B-X
activation	B-X
,	B-X
although	B-X
the	B-X
mechanisms	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
<EOS>	B-X
Cells	B-X
stimulated	B-X
with	B-X
fibrinogen	B-X
(	B-X
10	B-X
-	B-X
100	B-X
microg	B-X
/	B-X
ml	B-X
)	B-X
	B-X
/	B-X
Mn2+	B-X
(	B-X
50	B-X
microM	B-X
)	B-X
for	B-X
2	B-X
h	B-X
were	B-X
examined	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
Fibrinogen	B-X
also	B-X
caused	B-X
activation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
but	B-X
not	B-X
SP1	B-X
or	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
factors	B-X

Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
and	I-cell_type
monocytes	I-cell_type
and	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
lupus	O
express	O
estrogen	O
receptor	O
transcripts	O
similar	O
to	O
those	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O

OBJECTIVE	O
:	O
To	O
identify	O
and	O
characterize	O
estrogen	B-RNA
receptor	I-RNA
(	I-RNA
ER	I-RNA
)	I-RNA
transcripts	I-RNA
expressed	O
in	O
immune	B-cell_type
cells	I-cell_type
of	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
healthy	O
donors	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
and	B-X
characterize	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
transcripts	B-X
expressed	B-X
in	B-X
immune	B-X
cells	B-X
of	B-X
patients	B-X
with	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
and	B-X
healthy	B-X
donors	B-X
<EOS>	B-X
There	B-X
were	B-X
no	B-X
notable	B-X
differences	B-X
in	B-X
the	B-X
ER	B-X
transcripts	B-X
between	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
and	B-X
T	B-X
cells	B-X
were	B-X
prepared	B-X
from	B-X
patients	B-X
with	B-X
SLE	B-X
(	B-X
n	B-X
=	B-X
6	B-X
)	B-X
and	B-X
healthy	B-X
donors	B-X
(	B-X
n	B-X
=	B-X
8	B-X
)	B-X
<EOS>	B-X
Whether	B-X
the	B-X
detected	B-X
transcripts	B-X
are	B-X
translated	B-X
into	B-X
functional	B-X
receptor	B-X
proteins	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X

METHODS	O
:	O
Peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
prepared	O
from	O
patients	O
with	O
SLE	O
(	O
n	O
=	O
6	O
)	O
and	O
healthy	O
donors	O
(	O
n	O
=	O
8	O
)	O
.	O

T	B-cell_type
cells	I-cell_type
were	O
separated	O
into	O
CD4	B-cell_type
and	O
CD8	B-cell_type
.	O
<EOS>	B-X
The	B-X
RBD	B-X
and	B-X
N	B-X
were	B-X
separately	B-X
expressed	B-X
in	B-X
<EOS>	B-X
Among	B-X
these	B-X
are	B-X
memory	B-X
CD8	B-X
<EOS>	B-X
726	B-X
in	B-X
the	B-X
training	B-X
set	B-X
and	B-X
0	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
TILs	B-X
and	B-X
these	B-X
parameters	B-X
have	B-X
been	B-X
examined	B-X
separately	B-X

Some	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
estradiol	O
,	O
PMA	O
,	O
and	O
ionomycin	O
.	O

Epstein-Barr	O
virus-transformed	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
n	O
=	O
7	O
)	O
and	O
B	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
(	O
n	O
=	O
2	O
)	O
established	O
from	O
patients	O
with	O
SLE	O
and	O
a	O
healthy	O
individual	O
were	O
used	O
as	O
a	O
B	O
cell	O
source	O
.	O

These	O
cells	O
were	O
examined	O
for	O
ER	B-RNA
mRNA	I-RNA
by	O
reverse	O
transcription	O
nested	O
polymerase	O
chain	O
reaction	O
.	O
<EOS>	B-X
X	B-X
-	B-X
box	B-X
binding	B-X
protein1	B-X
(	B-X
XBP	B-X
-	B-X
1	B-X
)	B-X
spliced	B-X
form	B-X
was	B-X
examined	B-X
by	B-X
reverse	B-X
transcriptase	B-X
-	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT	B-X
-	B-X
PCR	B-X
)	B-X
<EOS>	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
CRT	B-X
,	B-X
CNX	B-X
and	B-X
ERp57	B-X
were	B-X
examined	B-X
using	B-X
immunohistochemistry	B-X
or	B-X
immunofluorescence	B-X
,	B-X
western	B-X
blot	B-X
analysis	B-X
and	B-X
reverse	B-X
transcription‑quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT‑qPCR	B-X
)	B-X
<EOS>	B-X
The	B-X
relationship	B-X
between	B-X
resistin	B-X
messenger	B-X
ribonucleic	B-X
acid	B-X
(	B-X
mRNA	B-X
)	B-X
and	B-X
ER	B-X
stress	B-X
markers	B-X
mRNA	B-X
was	B-X
analyzed	B-X
by	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
in	B-X
isolated	B-X
monocytes	B-X
of	B-X
30	B-X
healthy	B-X
volunteers	B-X
<EOS>	B-X
The	B-X
data	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
statistical	B-X
software	B-X
of	B-X
Graph	B-X
Pad	B-X
Prism	B-X
5	B-X

Amplified	O
cDNA	B-DNA
were	O
sequenced	O
by	O
standard	O
methods	O
.	O
<EOS>	B-X
Baiting	B-X
out	B-X
a	B-X
full	B-X
length	B-X
sequence	B-X
from	B-X
unmapped	B-X
RNA	B-X
-	B-X
seq	B-X
data	B-X
.	B-X
<EOS>	B-X
Usually	B-X
,	B-X
unmapped	B-X
RNA	B-X
-	B-X
seq	B-X
reads	B-X
have	B-X
been	B-X
considered	B-X
as	B-X
useless	B-X
and	B-X
been	B-X
trashed	B-X
or	B-X
ignored	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
257	B-X
smears	B-X
were	B-X
positive	B-X
in	B-X
the	B-X
microscopic	B-X
examination	B-X
,	B-X
i	B-X
<EOS>	B-X
Briefly	B-X
,	B-X
total	B-X
DNA	B-X
from	B-X
ToLCNDV	B-X
-	B-X
infected	B-X
tomato	B-X
was	B-X
extracted	B-X
using	B-X
standard	B-X
cetyl	B-X
trimethylammonium	B-X
bromide	B-X
method	B-X

RESULTS	O
:	O
In	O
all	O
cells	O
tested	O
,	O
ER	B-RNA
mRNA	I-RNA
was	O
expressed	O
without	O
prior	O
in	O
vitro	O
stimulation	O
.	O
<EOS>	B-X
In	B-X
all	B-X
cells	B-X
tested	B-X
,	B-X
ER	B-X
mRNA	B-X
was	B-X
expressed	B-X
without	B-X
prior	B-X
in	B-X
vitro	B-X
stimulation	B-X
<EOS>	B-X
Peripheral	B-X
blood	B-X
T	B-X
cells	B-X
and	B-X
monocytes	B-X
and	B-X
B	B-X
cell	B-X
lines	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
lupus	B-X
express	B-X
estrogen	B-X
receptor	B-X
transcripts	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
normal	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
identify	B-X
and	B-X
characterize	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
transcripts	B-X
expressed	B-X
in	B-X
immune	B-X
cells	B-X
of	B-X
patients	B-X
with	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
and	B-X
healthy	B-X
donors	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
variants	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
disease	B-X
activity	B-X
or	B-X
medication	B-X

Partial	O
sequences	O
from	O
exons	B-DNA
1-8	I-DNA
were	O
nearly	O
identical	O
to	O
the	O
published	O
sequence	O
of	O
the	O
human	B-RNA
ER	I-RNA
mRNA	I-RNA
.	O

There	O
were	O
no	O
notable	O
differences	O
in	O
the	O
ER	B-RNA
transcripts	I-RNA
between	O
patients	O
and	O
healthy	O
controls	O
.	O
<EOS>	B-X
There	B-X
were	B-X
no	B-X
notable	B-X
differences	B-X
in	B-X
the	B-X
ER	B-X
transcripts	B-X
between	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
and	B-X
T	B-X
cells	B-X
were	B-X
prepared	B-X
from	B-X
patients	B-X
with	B-X
SLE	B-X
(	B-X
n	B-X
=	B-X
6	B-X
)	B-X
and	B-X
healthy	B-X
donors	B-X
(	B-X
n	B-X
=	B-X
8	B-X
)	B-X
<EOS>	B-X
To	B-X
identify	B-X
and	B-X
characterize	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
transcripts	B-X
expressed	B-X
in	B-X
immune	B-X
cells	B-X
of	B-X
patients	B-X
with	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
and	B-X
healthy	B-X
donors	B-X
<EOS>	B-X
Monocytes	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
B	B-X
cells	B-X
in	B-X
patients	B-X
express	B-X
transcripts	B-X
of	B-X
the	B-X
normal	B-X
wild	B-X
type	B-X
ER	B-X
and	B-X
the	B-X
hormone	B-X
binding	B-X
domain	B-X
variants	B-X
in	B-X
vivo	B-X

Variant	O
receptor	O
transcripts	O
lacking	O
exon	B-DNA
5	I-DNA
or	O
exon	B-DNA
7	I-DNA
,	O
which	O
encodes	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
,	O
were	O
identified	O
in	O
the	O
majority	O
of	O
the	O
cells	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
previously	B-X
described	B-X
transcripts	B-X
lacking	B-X
exon	B-X
3	B-X
or	B-X
exon	B-X
4	B-X
,	B-X
or	B-X
retaining	B-X
part	B-X
of	B-X
intron	B-X
3	B-X
,	B-X
we	B-X
identified	B-X
novel	B-X
isoforms	B-X
lacking	B-X
exon	B-X
2	B-X
,	B-X
along	B-X
with	B-X
isoforms	B-X
lacking	B-X
multiple	B-X
exons	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
isoform	B-X
which	B-X
lacks	B-X
the	B-X
5	B-X
'	B-X
exon	B-X
,	B-X
but	B-X
includes	B-X
the	B-X
transmembrane	B-X
domain	B-X
,	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
TREM2	B-X
-	B-X
	B-X
p	B-X
<EOS>	B-X
Multiple	B-X
cryptic	B-X
exons	B-X
and	B-X
C	B-X
-	B-X
terminally	B-X
-	B-X
truncated	B-X
ERα	B-X
variant	B-X
mRNAs	B-X
were	B-X
identified	B-X
in	B-X
rats	B-X
and	B-X
mice	B-X
<EOS>	B-X
The	B-X
three	B-X
TREM2	B-X
transcripts	B-X
were	B-X
expressed	B-X
in	B-X
brain	B-X
cortex	B-X
in	B-X
the	B-X
three	B-X
datasets	B-X

Precise	O
deletion	O
of	O
the	O
exons	O
suggests	O
that	O
they	O
are	O
alternatively	O
spliced	O
transcripts	O
.	O
<EOS>	B-X
Precise	B-X
deletion	B-X
of	B-X
the	B-X
exons	B-X
suggests	B-X
that	B-X
they	B-X
are	B-X
alternatively	B-X
spliced	B-X
transcripts	B-X
<EOS>	B-X
Three	B-X
deletions	B-X
of	B-X
>	B-X
or=	B-X
2	B-X
exons	B-X
were	B-X
detected	B-X
by	B-X
MLPA	B-X
<EOS>	B-X
Each	B-X
of	B-X
the	B-X
two	B-X
deletions	B-X
found	B-X
in	B-X
the	B-X
variant	B-X
cDNAs	B-X
is	B-X
precisely	B-X
encoded	B-X
by	B-X
an	B-X
exon	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
forms	B-X
of	B-X
GMP	B-X
-	B-X
140	B-X
are	B-X
derived	B-X
from	B-X
alternative	B-X
splicing	B-X
of	B-X
mRNA	B-X
<EOS>	B-X
Regulated	B-X
splicing	B-X
of	B-X
the	B-X
fibronectin	B-X
EDA	B-X
exon	B-X
is	B-X
essential	B-X
for	B-X
proper	B-X
skin	B-X
wound	B-X
healing	B-X
and	B-X
normal	B-X
lifespan	B-X
.	B-X

Whether	O
the	O
detected	O
transcripts	O
are	O
translated	O
into	O
functional	B-protein
receptor	I-protein
proteins	I-protein
remains	O
to	O
be	O
determined	O
.	O
<EOS>	B-X
transmitted	B-X
by	B-X
the	B-X
G	B-X
protein	B-X
-	B-X
coupled	B-X
estrogen	B-X
receptor	B-X
(	B-X
GPER	B-X
)	B-X
remains	B-X
to	B-X
be	B-X
rather	B-X
elusive	B-X
<EOS>	B-X
Unhatched	B-X
bovine	B-X
blastocysts	B-X
express	B-X
all	B-X
transcripts	B-X
of	B-X
the	B-X
estrogen	B-X
biosynthetic	B-X
pathway	B-X
,	B-X
but	B-X
steroid	B-X
hormone	B-X
synthesis	B-X
could	B-X
not	B-X
yet	B-X
be	B-X
demonstrated	B-X
.	B-X
<EOS>	B-X
Whether	B-X
P2X	B-X
receptors	B-X
(	B-X
ionotropic	B-X
ATP	B-X
purinergic	B-X
receptors	B-X
,	B-X
including	B-X
P2X3	B-X
receptor	B-X
and	B-X
P2X7	B-X
receptor	B-X
)	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
alterations	B-X
of	B-X
these	B-X
disorders	B-X
still	B-X
remains	B-X
unclear	B-X
<EOS>	B-X
qPCR	B-X
was	B-X
performed	B-X
to	B-X
detect	B-X
the	B-X
changes	B-X
in	B-X
important	B-X
gene	B-X
transcriptions	B-X
,	B-X
and	B-X
immunohistochemistry	B-X
and	B-X
western	B-X
blot	B-X
analysis	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
determine	B-X
protein	B-X
expression	B-X

In	O
vitro	O
stimulation	O
did	O
not	O
affect	O
ER	B-RNA
mRNA	I-RNA
expression	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
insulin	B-X
secretion	B-X
was	B-X
unaltered	B-X
in	B-X
islets	B-X
of	B-X
mice	B-X
lacking	B-X
the	B-X
known	B-X
molecular	B-X
thiazide	B-X
targets	B-X
NCC	B-X
or	B-X
NDCBE	B-X
<EOS>	B-X
His	B-X
studies	B-X
ranged	B-X
from	B-X
uptake	B-X
of	B-X
K	B-X
<EOS>	B-X
In	B-X
vitro	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
α	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
1β	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
expression	B-X
in	B-X
LPS	B-X
-	B-X
stimulated	B-X
RAW264	B-X
<EOS>	B-X
Intestinal	B-X
epithelial	B-X
dysfunction	B-X
is	B-X
critical	B-X
in	B-X
the	B-X
development	B-X
of	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X

The	O
presence	O
of	O
variants	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
or	O
medication	O
.	O
<EOS>	B-X
There	B-X
were	B-X
no	B-X
intraoperative	B-X
or	B-X
postoperative	B-X
complications	B-X
<EOS>	B-X
13	B-X
)	B-X
of	B-X
patients	B-X
without	B-X
and	B-X
with	B-X
appendicitis	B-X
,	B-X
respectively	B-X
<EOS>	B-X
This	B-X
wide	B-X
range	B-X
of	B-X
variation	B-X
poses	B-X
a	B-X
significant	B-X
number	B-X
of	B-X
patients	B-X
at	B-X
risk	B-X
due	B-X
to	B-X
delay	B-X
in	B-X
management	B-X
<EOS>	B-X
Serology	B-X
was	B-X
positive	B-X
for	B-X
Yersinia	B-X
enterocolitica	B-X
for	B-X
the	B-X
same	B-X
patient	B-X
without	B-X
appendicitis	B-X
and	B-X
two	B-X
patients	B-X
with	B-X
appendicitis	B-X
(	B-X
p=0	B-X

CONCLUSION	O
:	O
Monocytes	B-cell_type
,	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
B	B-cell_type
cells	I-cell_type
in	O
patients	O
express	O
transcripts	O
of	O
the	O
normal	O
wild	B-protein
type	I-protein
ER	I-protein
and	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
variants	I-protein
in	O
vivo	O
.	O

DNA	O
damaging	O
agents	O
induce	O
expression	O
of	O
Fas	B-protein
ligand	I-protein
and	O
subsequent	O
apoptosis	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
via	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
.	O

Apoptosis	O
induced	O
by	O
DNA	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
Fas	O
(	O
CD95	O
)	O
.	O
<EOS>	B-X
Apoptosis	B-X
induced	B-X
by	B-X
DNA	B-X
damage	B-X
and	B-X
other	B-X
stresses	B-X
can	B-X
proceed	B-X
via	B-X
expression	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
and	B-X
ligation	B-X
of	B-X
its	B-X
receptor	B-X
,	B-X
Fas	B-X
(	B-X
CD95	B-X
)	B-X
<EOS>	B-X
A	B-X
nondegradable	B-X
mutant	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
blocked	B-X
both	B-X
FasL	B-X
expression	B-X
and	B-X
apoptosis	B-X
induced	B-X
by	B-X
DNA	B-X
damage	B-X
but	B-X
not	B-X
Fas	B-X
ligation	B-X
<EOS>	B-X
2	B-X
kb	B-X
FasL	B-X
promoter	B-X
responded	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
as	B-X
well	B-X
as	B-X
coexpression	B-X
with	B-X
p65	B-X
Rel	B-X
or	B-X
Fos	B-X
/	B-X
Jun	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
contributes	B-X
to	B-X
stress	B-X
-	B-X
induced	B-X
apoptosis	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
FasL	B-X

We	O
report	O
that	O
activation	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
NF-kappa	I-protein
B	I-protein
and	I-protein
AP-1	I-protein
is	O
crucially	O
involved	O
in	O
FasL	B-protein
expression	O
induced	O
by	O
etoposide	O
,	O
teniposide	O
,	O
and	O
UV	O
irradiation	O
.	O
<EOS>	B-X
We	B-X
report	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
crucially	B-X
involved	B-X
in	B-X
FasL	B-X
expression	B-X
induced	B-X
by	B-X
etoposide	B-X
,	B-X
teniposide	B-X
,	B-X
and	B-X
UV	B-X
irradiation	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
contributes	B-X
to	B-X
stress	B-X
-	B-X
induced	B-X
apoptosis	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
FasL	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
relevant	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
eliminated	B-X
these	B-X
responses	B-X
<EOS>	B-X
A	B-X
nondegradable	B-X
mutant	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
blocked	B-X
both	B-X
FasL	B-X
expression	B-X
and	B-X
apoptosis	B-X
induced	B-X
by	B-X
DNA	B-X
damage	B-X
but	B-X
not	B-X
Fas	B-X
ligation	B-X

A	O
nondegradable	B-protein
mutant	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
blocked	O
both	O
FasL	B-protein
expression	O
and	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
but	O
not	O
Fas	O
ligation	O
.	O

These	O
stimuli	O
also	O
induced	O
the	O
stress-activated	O
kinase	O
pathway	O
(	O
SAPK/JNK	O
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O
<EOS>	B-X
These	B-X
stimuli	B-X
also	B-X
induced	B-X
the	B-X
stress	B-X
-	B-X
activated	B-X
kinase	B-X
pathway	B-X
(	B-X
SAPK	B-X
/	B-X
JNK	B-X
)	B-X
,	B-X
which	B-X
was	B-X
required	B-X
for	B-X
the	B-X
maximal	B-X
induction	B-X
of	B-X
apoptosis	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
relevant	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
eliminated	B-X
these	B-X
responses	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
contributes	B-X
to	B-X
stress	B-X
-	B-X
induced	B-X
apoptosis	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
FasL	B-X
<EOS>	B-X
2	B-X
kb	B-X
FasL	B-X
promoter	B-X
responded	B-X
to	B-X
DNA	B-X
damage	B-X
,	B-X
as	B-X
well	B-X
as	B-X
coexpression	B-X
with	B-X
p65	B-X
Rel	B-X
or	B-X
Fos	B-X
/	B-X
Jun	B-X

A	O
1.2	O
kb	O
FasL	B-DNA
promoter	I-DNA
responded	O
to	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p65	B-protein
Rel	I-protein
or	O
Fos/Jun	B-protein
.	O
<EOS>	B-X
Genomic	B-X
and	B-X
epigenomic	B-X
responses	B-X
to	B-X
aspirin	B-X
in	B-X
human	B-X
colonic	B-X
organoids	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggested	B-X
that	B-X
LCC	B-X
promoted	B-X
terminal	B-X
differentiations	B-X
of	B-X
ovarian	B-X
cancer	B-X
cells	B-X
and	B-X
sensitized	B-X
them	B-X
to	B-X
paclitaxel	B-X
through	B-X
activating	B-X
the	B-X
Fos	B-X
/	B-X
Jun	B-X
pathway	B-X
<EOS>	B-X
There	B-X
are	B-X
hundreds	B-X
of	B-X
different	B-X
types	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
body	B-X
<EOS>	B-X
found	B-X
that	B-X
if	B-X
a	B-X
transcription	B-X
factor	B-X
could	B-X
no	B-X
longer	B-X
find	B-X
its	B-X
place	B-X
on	B-X
an	B-X
enhancer	B-X
,	B-X
it	B-X
stopped	B-X
others	B-X
from	B-X
binding	B-X
even	B-X
if	B-X
their	B-X
own	B-X
places	B-X
had	B-X
not	B-X
changed	B-X

Mutations	O
in	O
the	O
relevant	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
AP-1	I-DNA
binding	I-DNA
sites	I-DNA
eliminated	O
these	O
responses	O
.	O
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
relevant	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
eliminated	B-X
these	B-X
responses	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
contributes	B-X
to	B-X
stress	B-X
-	B-X
induced	B-X
apoptosis	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
FasL	B-X
<EOS>	B-X
We	B-X
report	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
crucially	B-X
involved	B-X
in	B-X
FasL	B-X
expression	B-X
induced	B-X
by	B-X
etoposide	B-X
,	B-X
teniposide	B-X
,	B-X
and	B-X
UV	B-X
irradiation	B-X
<EOS>	B-X
These	B-X
stimuli	B-X
also	B-X
induced	B-X
the	B-X
stress	B-X
-	B-X
activated	B-X
kinase	B-X
pathway	B-X
(	B-X
SAPK	B-X
/	B-X
JNK	B-X
)	B-X
,	B-X
which	B-X
was	B-X
required	B-X
for	B-X
the	B-X
maximal	B-X
induction	B-X
of	B-X
apoptosis	B-X

Thus	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
contributes	O
to	O
stress-induced	O
apoptosis	O
via	O
the	O
expression	O
of	O
FasL	B-protein
.	O
<EOS>	B-X
Thus	B-X
,	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
contributes	B-X
to	B-X
stress	B-X
-	B-X
induced	B-X
apoptosis	B-X
via	B-X
the	B-X
expression	B-X
of	B-X
FasL	B-X
<EOS>	B-X
We	B-X
report	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
crucially	B-X
involved	B-X
in	B-X
FasL	B-X
expression	B-X
induced	B-X
by	B-X
etoposide	B-X
,	B-X
teniposide	B-X
,	B-X
and	B-X
UV	B-X
irradiation	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
the	B-X
relevant	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
eliminated	B-X
these	B-X
responses	B-X
<EOS>	B-X
A	B-X
nondegradable	B-X
mutant	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
blocked	B-X
both	B-X
FasL	B-X
expression	B-X
and	B-X
apoptosis	B-X
induced	B-X
by	B-X
DNA	B-X
damage	B-X
but	B-X
not	B-X
Fas	B-X
ligation	B-X

A	O
small	O
,	O
nonpeptidyl	O
mimic	O
of	O
granulocyte-colony-stimulating	B-protein
factor	I-protein
[	O
see	O
commetns	O
]	O
<EOS>	B-X
A	B-X
small	B-X
,	B-X
nonpeptidyl	B-X
mimic	B-X
of	B-X
granulocyte	B-X
-	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
[	B-X
see	B-X
commetns	B-X
]	B-X
.	B-X
<EOS>	B-X
Recombinant	B-X
forms	B-X
of	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
are	B-X
used	B-X
clinically	B-X
to	B-X
treat	B-X
neutropenias	B-X
<EOS>	B-X
A	B-X
potential	B-X
therapeutic	B-X
role	B-X
for	B-X
small	B-X
nonpeptidyl	B-X
compounds	B-X
that	B-X
mimic	B-X
human	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
.	B-X
<EOS>	B-X
Selective	B-X
binding	B-X
and	B-X
oligomerization	B-X
of	B-X
the	B-X
murine	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
receptor	B-X
by	B-X
a	B-X
low	B-X
molecular	B-X
weight	B-X
,	B-X
nonpeptidyl	B-X
ligand	B-X
.	B-X

A	O
nonpeptidyl	O
small	O
molecule	O
SB	O
247464	O
,	O
capable	O
of	O
activating	O
granulocyte-colony-stimulating	B-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
signal	O
transduction	O
pathways	O
,	O
was	O
identified	O
in	O
a	O
high-throughput	O
assay	O
in	O
cultured	B-cell_type
cells	I-cell_type
.	O

Like	O
G-CSF	B-protein
,	O
SB	O
247464	O
induced	O
tyrosine	O
phosphorylation	O
of	O
multiple	B-protein
signaling	I-protein
proteins	I-protein
and	O
stimulated	O
primary	B-cell_type
murine	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
to	O
form	O
granulocytic	B-cell_type
colonies	I-cell_type
in	O
vitro	O
.	O
<EOS>	B-X
Like	B-X
G	B-X
-	B-X
CSF	B-X
,	B-X
SB	B-X
247464	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
multiple	B-X
signaling	B-X
proteins	B-X
and	B-X
stimulated	B-X
primary	B-X
murine	B-X
bone	B-X
marrow	B-X
cells	B-X
to	B-X
form	B-X
granulocytic	B-X
colonies	B-X
in	B-X
vitro	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
small	B-X
molecule	B-X
can	B-X
activate	B-X
a	B-X
receptor	B-X
that	B-X
normally	B-X
binds	B-X
a	B-X
relatively	B-X
large	B-X
protein	B-X
ligand	B-X
<EOS>	B-X
A	B-X
small	B-X
,	B-X
nonpeptidyl	B-X
mimic	B-X
of	B-X
granulocyte	B-X
-	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
[	B-X
see	B-X
commetns	B-X
]	B-X
.	B-X
<EOS>	B-X
A	B-X
nonpeptidyl	B-X
small	B-X
molecule	B-X
SB	B-X
247464	B-X
,	B-X
capable	B-X
of	B-X
activating	B-X
granulocyte	B-X
-	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
G	B-X
-	B-X
CSF	B-X
)	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
was	B-X
identified	B-X
in	B-X
a	B-X
high	B-X
-	B-X
throughput	B-X
assay	B-X
in	B-X
cultured	B-X
cells	B-X

It	O
also	O
elevated	O
peripheral	B-cell_type
blood	I-cell_type
neutrophil	I-cell_type
counts	O
in	O
mice	O
.	O
<EOS>	B-X
and	B-X
sampled	B-X
the	B-X
peripheral	B-X
blood	B-X
and	B-X
organs	B-X
at	B-X
time	B-X
points	B-X
up	B-X
to	B-X
24	B-X
h	B-X
<EOS>	B-X
In	B-X
asphyxiated	B-X
neonates	B-X
,	B-X
elevated	B-X
peripheral	B-X
neutrophil	B-X
counts	B-X
are	B-X
associated	B-X
with	B-X
poorer	B-X
neurological	B-X
outcomes	B-X
<EOS>	B-X
Given	B-X
this	B-X
,	B-X
anti	B-X
-	B-X
inflammatory	B-X
therapies	B-X
may	B-X
prove	B-X
beneficial	B-X
in	B-X
improving	B-X
neutrophil	B-X
functionality	B-X
in	B-X
the	B-X
elderly	B-X
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
provide	B-X
novel	B-X
evidence	B-X
that	B-X
products	B-X
of	B-X
age	B-X
-	B-X
related	B-X
inflammation	B-X
modulate	B-X
neutrophil	B-X
phenotype	B-X
in	B-X
vivo	B-X

The	O
extracellular	O
domain	O
of	O
the	O
murine	B-protein
G-CSF	I-protein
receptor	I-protein
was	O
required	O
for	O
the	O
activity	O
of	O
SB	O
247464	O
,	O
suggesting	O
that	O
the	O
compound	O
acts	O
by	O
oligomerizing	B-protein
receptor	I-protein
chains	I-protein
.	O
<EOS>	B-X
The	B-X
extracellular	B-X
domain	B-X
of	B-X
the	B-X
murine	B-X
G	B-X
-	B-X
CSF	B-X
receptor	B-X
was	B-X
required	B-X
for	B-X
the	B-X
activity	B-X
of	B-X
SB	B-X
247464	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
compound	B-X
acts	B-X
by	B-X
oligomerizing	B-X
receptor	B-X
chains	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
small	B-X
molecule	B-X
can	B-X
activate	B-X
a	B-X
receptor	B-X
that	B-X
normally	B-X
binds	B-X
a	B-X
relatively	B-X
large	B-X
protein	B-X
ligand	B-X
<EOS>	B-X
A	B-X
small	B-X
,	B-X
nonpeptidyl	B-X
mimic	B-X
of	B-X
granulocyte	B-X
-	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
[	B-X
see	B-X
commetns	B-X
]	B-X
.	B-X
<EOS>	B-X
It	B-X
also	B-X
elevated	B-X
peripheral	B-X
blood	B-X
neutrophil	B-X
counts	B-X
in	B-X
mice	B-X

The	O
results	O
indicate	O
that	O
a	O
small	O
molecule	O
can	O
activate	O
a	O
receptor	O
that	O
normally	O
binds	O
a	O
relatively	O
large	O
protein	O
ligand	O
.	O
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
small	B-X
molecule	B-X
can	B-X
activate	B-X
a	B-X
receptor	B-X
that	B-X
normally	B-X
binds	B-X
a	B-X
relatively	B-X
large	B-X
protein	B-X
ligand	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
small	B-X
beta	B-X
-	B-X
turn	B-X
peptidomimetic	B-X
can	B-X
activate	B-X
a	B-X
tyrosine	B-X
kinase	B-X
neurotrophin	B-X
receptor	B-X
that	B-X
normally	B-X
binds	B-X
a	B-X
relatively	B-X
large	B-X
protein	B-X
ligand	B-X
<EOS>	B-X
They	B-X
believe	B-X
it	B-X
is	B-X
likely	B-X
that	B-X
different	B-X
ligands	B-X
can	B-X
bind	B-X
to	B-X
the	B-X
diverse	B-X
protein	B-X
conformations	B-X
sampled	B-X
in	B-X
the	B-X
course	B-X
of	B-X
normal	B-X
protein	B-X
conformational	B-X
fluctuations	B-X
<EOS>	B-X
Instead	B-X
of	B-X
a	B-X
viral	B-X
protein	B-X
,	B-X
a	B-X
drug	B-X
can	B-X
be	B-X
targeted	B-X
at	B-X
a	B-X
cellular	B-X
protein	B-X

Minimal	O
residual	O
disease	O
in	O
acute	O
myelogenous	O
leukemia	O
with	O
PML/RAR	B-protein
alpha	I-protein
or	O
AML1/ETO	B-RNA
mRNA	I-RNA
and	O
phenotypic	O
analysis	O
of	O
possible	O
T	B-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
in	O
bone	O
marrow	O
.	O
<EOS>	B-X
Assessment	B-X
of	B-X
residual	B-X
disease	B-X
in	B-X
acute	B-X
leukemia	B-X
by	B-X
means	B-X
of	B-X
polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
<EOS>	B-X
The	B-X
t	B-X
(	B-X
15	B-X
;	B-X
17	B-X
)	B-X
translocation	B-X
in	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
APL	B-X
)	B-X
yields	B-X
a	B-X
PML	B-X
/	B-X
RAR	B-X
-	B-X
alpha	B-X
fusion	B-X
messenger	B-X
RNA	B-X
species	B-X
that	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
reverse	B-X
transcription	B-X
-	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT	B-X
-	B-X
PCR	B-X
)	B-X
amplification	B-X
<EOS>	B-X
[	B-X
Monitoring	B-X
of	B-X
minimal	B-X
residual	B-X
disease	B-X
with	B-X
the	B-X
combined	B-X
detection	B-X
of	B-X
PML	B-X
/	B-X
RAR	B-X
alpha	B-X
and	B-X
RAR	B-X
alpha	B-X
/	B-X
PML	B-X
rearrangements	B-X
in	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
]	B-X
.	B-X
<EOS>	B-X
Minimal	B-X
residual	B-X
disease	B-X
was	B-X
prospectively	B-X
monitored	B-X
using	B-X
this	B-X
technique	B-X
in	B-X
six	B-X
patients	B-X

Here	O
we	O
studied	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
who	O
have	O
PML/RAR	B-protein
alpha	I-protein
or	O
AML1/ETO	B-protein
as	O
well	O
as	O
the	O
phenotypic	O
analysis	O
of	O
lymphocyte	B-cell_type
subsets	I-cell_type
involved	O
in	O
antitumor	O
immunity	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
studied	B-X
minimal	B-X
residual	B-X
disease	B-X
(	B-X
MRD	B-X
)	B-X
of	B-X
patients	B-X
with	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
who	B-X
have	B-X
PML	B-X
/	B-X
RAR	B-X
alpha	B-X
or	B-X
AML1	B-X
/	B-X
ETO	B-X
as	B-X
well	B-X
as	B-X
the	B-X
phenotypic	B-X
analysis	B-X
of	B-X
lymphocyte	B-X
subsets	B-X
involved	B-X
in	B-X
antitumor	B-X
immunity	B-X
<EOS>	B-X
Minimal	B-X
residual	B-X
disease	B-X
in	B-X
acute	B-X
myelogenous	B-X
leukemia	B-X
with	B-X
PML	B-X
/	B-X
RAR	B-X
alpha	B-X
or	B-X
AML1	B-X
/	B-X
ETO	B-X
mRNA	B-X
and	B-X
phenotypic	B-X
analysis	B-X
of	B-X
possible	B-X
T	B-X
and	B-X
natural	B-X
killer	B-X
cells	B-X
in	B-X
bone	B-X
marrow	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
still	B-X
remain	B-X
to	B-X
be	B-X
confirmed	B-X
by	B-X
further	B-X
studies	B-X
of	B-X
the	B-X
functional	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
of	B-X
T	B-X
/	B-X
NK	B-X
cells	B-X
of	B-X
AML	B-X
in	B-X
remission	B-X
<EOS>	B-X
The	B-X
T	B-X
/	B-X
NK	B-X
subsets	B-X
in	B-X
the	B-X
BM	B-X
of	B-X
MRD	B-X
-	B-X
negative	B-X
(	B-X
MRD	B-X
-	B-X
	B-X
)	B-X
LT	B-X
(	B-X
MRD	B-X
-	B-X
	B-X
/	B-X
LT	B-X
)	B-X
patients	B-X
showed	B-X
similar	B-X
numbers	B-X
of	B-X
cells	B-X
as	B-X
normal	B-X
volunteers	B-X

Eight	O
patients	O
in	O
long-term	O
(	O
LT	O
;	O
3	O
to	O
15	O
years	O
)	O
and	O
15	O
patients	O
in	O
short-term	O
(	O
ST	O
;	O
up	O
to	O
3	O
years	O
)	O
remission	O
were	O
studied	O
.	O
<EOS>	B-X
Eight	B-X
patients	B-X
in	B-X
long	B-X
-	B-X
term	B-X
(	B-X
LT	B-X
;	B-X
3	B-X
to	B-X
15	B-X
years	B-X
)	B-X
and	B-X
15	B-X
patients	B-X
in	B-X
short	B-X
-	B-X
term	B-X
(	B-X
ST	B-X
;	B-X
up	B-X
to	B-X
3	B-X
years	B-X
)	B-X
remission	B-X
were	B-X
studied	B-X
<EOS>	B-X
Four	B-X
of	B-X
the	B-X
eight	B-X
patients	B-X
in	B-X
LT	B-X
and	B-X
7	B-X
of	B-X
the	B-X
15	B-X
patients	B-X
in	B-X
ST	B-X
remission	B-X
were	B-X
MRD	B-X
-	B-X
positive	B-X
<EOS>	B-X
Although	B-X
all	B-X
MRD	B-X
-	B-X
positive	B-X
patients	B-X
in	B-X
LT	B-X
remission	B-X
are	B-X
still	B-X
until	B-X
now	B-X
event	B-X
-	B-X
free	B-X
,	B-X
3	B-X
of	B-X
the	B-X
7	B-X
MRD	B-X
-	B-X
positive	B-X
(	B-X
MRD+	B-X
)	B-X
patients	B-X
in	B-X
ST	B-X
remission	B-X
soon	B-X
relapsed	B-X
<EOS>	B-X
The	B-X
total	B-X
populations	B-X
of	B-X
CD4+	B-X
,	B-X
CD8+	B-X
and	B-X
CD56+	B-X
[	B-X
possible	B-X
T	B-X
-	B-X
cell	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
T	B-X
/	B-X
NK	B-X
)	B-X
populations	B-X
]	B-X
in	B-X
the	B-X
BM	B-X
of	B-X
ST	B-X
patients	B-X
and	B-X
MRD+	B-X
/	B-X
LT	B-X
patients	B-X
were	B-X
significantly	B-X
(	B-X
p	B-X
<	B-X

Using	O
the	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT	O
)	O
assay	O
,	O
the	O
limit	O
of	O
detection	O
was	O
10	O
(	O
-5	O
)	O
to	O
10	O
(	O
-6	O
)	O
for	O
PML/RAR	B-RNA
alpha	I-RNA
transcript	I-RNA
and	O
10	O
(	O
-4	O
)	O
to	O
10	O
(	O
-5	O
)	O
for	O
the	O
AML1/ETO	B-RNA
transcript	I-RNA
.	O
<EOS>	B-X
Using	B-X
the	B-X
reverse	B-X
transcription	B-X
-	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT	B-X
)	B-X
assay	B-X
,	B-X
the	B-X
limit	B-X
of	B-X
detection	B-X
was	B-X
10	B-X
(	B-X
	B-X
-	B-X
5	B-X
)	B-X
to	B-X
10	B-X
(	B-X
	B-X
-	B-X
6	B-X
)	B-X
for	B-X
PML	B-X
/	B-X
RAR	B-X
alpha	B-X
transcript	B-X
and	B-X
10	B-X
(	B-X
	B-X
-	B-X
4	B-X
)	B-X
to	B-X
10	B-X
(	B-X
	B-X
-	B-X
5	B-X
)	B-X
for	B-X
the	B-X
AML1	B-X
/	B-X
ETO	B-X
transcript	B-X
<EOS>	B-X
These	B-X
results	B-X
still	B-X
remain	B-X
to	B-X
be	B-X
confirmed	B-X
by	B-X
further	B-X
studies	B-X
of	B-X
the	B-X
functional	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
of	B-X
T	B-X
/	B-X
NK	B-X
cells	B-X
of	B-X
AML	B-X
in	B-X
remission	B-X
<EOS>	B-X
Eight	B-X
patients	B-X
in	B-X
long	B-X
-	B-X
term	B-X
(	B-X
LT	B-X
;	B-X
3	B-X
to	B-X
15	B-X
years	B-X
)	B-X
and	B-X
15	B-X
patients	B-X
in	B-X
short	B-X
-	B-X
term	B-X
(	B-X
ST	B-X
;	B-X
up	B-X
to	B-X
3	B-X
years	B-X
)	B-X
remission	B-X
were	B-X
studied	B-X
<EOS>	B-X
Although	B-X
all	B-X
MRD	B-X
-	B-X
positive	B-X
patients	B-X
in	B-X
LT	B-X
remission	B-X
are	B-X
still	B-X
until	B-X
now	B-X
event	B-X
-	B-X
free	B-X
,	B-X
3	B-X
of	B-X
the	B-X
7	B-X
MRD	B-X
-	B-X
positive	B-X
(	B-X
MRD+	B-X
)	B-X
patients	B-X
in	B-X
ST	B-X
remission	B-X
soon	B-X
relapsed	B-X

Simultaneously	O
,	O
T	B-cell_type
lymphocyte	I-cell_type
subsets	I-cell_type
and	O
NK	B-cell_type
cells	I-cell_type
from	O
the	O
peripheral	O
blood	O
(	O
PB	O
)	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
were	O
investigated	O
by	O
flow	O
cytometric	O
analysis	O
.	O
<EOS>	B-X
Simultaneously	B-X
,	B-X
T	B-X
lymphocyte	B-X
subsets	B-X
and	B-X
NK	B-X
cells	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
(	B-X
PB	B-X
)	B-X
and	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
were	B-X
investigated	B-X
by	B-X
flow	B-X
cytometric	B-X
analysis	B-X
<EOS>	B-X
Four	B-X
of	B-X
the	B-X
eight	B-X
patients	B-X
in	B-X
LT	B-X
and	B-X
7	B-X
of	B-X
the	B-X
15	B-X
patients	B-X
in	B-X
ST	B-X
remission	B-X
were	B-X
MRD	B-X
-	B-X
positive	B-X
<EOS>	B-X
The	B-X
percentages	B-X
of	B-X
the	B-X
T	B-X
/	B-X
NK	B-X
-	B-X
cell	B-X
subsets	B-X
in	B-X
the	B-X
PB	B-X
were	B-X
not	B-X
significantly	B-X
different	B-X
among	B-X
these	B-X
groups	B-X
<EOS>	B-X
Basically	B-X
,	B-X
the	B-X
total	B-X
percentage	B-X
of	B-X
the	B-X
CD4+	B-X
,	B-X
CD8+	B-X
and	B-X
CD56+	B-X
cell	B-X
populations	B-X
in	B-X
the	B-X
BM	B-X
was	B-X
increased	B-X
and	B-X
in	B-X
the	B-X
following	B-X
order	B-X
:	B-X
MRD	B-X
-	B-X
	B-X
/	B-X
LT	B-X
patients	B-X
,	B-X
normal	B-X
volunteers	B-X
,	B-X
MRD+	B-X
/	B-X
LT	B-X
patients	B-X
and	B-X
MRD+	B-X
or	B-X
	B-X
-	B-X
	B-X
/	B-X
ST	B-X
patients	B-X

Four	O
of	O
the	O
eight	O
patients	O
in	O
LT	O
and	O
7	O
of	O
the	O
15	O
patients	O
in	O
ST	O
remission	O
were	O
MRD-positive	O
.	O

Although	O
all	O
MRD-positive	O
patients	O
in	O
LT	O
remission	O
are	O
still	O
until	O
now	O
event-free	O
,	O
3	O
of	O
the	O
7	O
MRD-positive	O
(	O
MRD+	O
)	O
patients	O
in	O
ST	O
remission	O
soon	O
relapsed	O
.	O

The	O
total	O
populations	O
of	O
CD4	B-protein
+	O
,	O
CD8	B-protein
+	O
and	O
CD56	B-protein
+	O
[	O
possible	O
T-cell	B-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
T/NK	I-cell_type
)	I-cell_type
populations	I-cell_type
]	O
in	O
the	O
BM	O
of	O
ST	O
patients	O
and	O
MRD+/LT	O
patients	O
were	O
significantly	O
(	O
p	O
<	O
.01	O
)	O
low	O
.	O
<EOS>	B-X
The	B-X
total	B-X
populations	B-X
of	B-X
CD4+	B-X
,	B-X
CD8+	B-X
and	B-X
CD56+	B-X
[	B-X
possible	B-X
T	B-X
-	B-X
cell	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
T	B-X
/	B-X
NK	B-X
)	B-X
populations	B-X
]	B-X
in	B-X
the	B-X
BM	B-X
of	B-X
ST	B-X
patients	B-X
and	B-X
MRD+	B-X
/	B-X
LT	B-X
patients	B-X
were	B-X
significantly	B-X
(	B-X
p	B-X
<	B-X
<EOS>	B-X
Basically	B-X
,	B-X
the	B-X
total	B-X
percentage	B-X
of	B-X
the	B-X
CD4+	B-X
,	B-X
CD8+	B-X
and	B-X
CD56+	B-X
cell	B-X
populations	B-X
in	B-X
the	B-X
BM	B-X
was	B-X
increased	B-X
and	B-X
in	B-X
the	B-X
following	B-X
order	B-X
:	B-X
MRD	B-X
-	B-X
	B-X
/	B-X
LT	B-X
patients	B-X
,	B-X
normal	B-X
volunteers	B-X
,	B-X
MRD+	B-X
/	B-X
LT	B-X
patients	B-X
and	B-X
MRD+	B-X
or	B-X
	B-X
-	B-X
	B-X
/	B-X
ST	B-X
patients	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
difference	B-X
of	B-X
the	B-X
possible	B-X
T	B-X
/	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
in	B-X
the	B-X
BM	B-X
may	B-X
strongly	B-X
influence	B-X
clinical	B-X
and	B-X
molecular	B-X
remission	B-X
<EOS>	B-X
These	B-X
results	B-X
still	B-X
remain	B-X
to	B-X
be	B-X
confirmed	B-X
by	B-X
further	B-X
studies	B-X
of	B-X
the	B-X
functional	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
of	B-X
T	B-X
/	B-X
NK	B-X
cells	B-X
of	B-X
AML	B-X
in	B-X
remission	B-X

The	O
CD8+	B-cell_type
CD28+	I-cell_type
population	I-cell_type
showed	O
the	O
same	O
tendency	O
(	O
p	O
<	O
.01-.02	O
)	O
.	O
<EOS>	B-X
The	B-X
CD8+	B-X
CD28+	B-X
population	B-X
showed	B-X
the	B-X
same	B-X
tendency	B-X
(	B-X
p	B-X
<	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
difference	B-X
of	B-X
the	B-X
possible	B-X
T	B-X
/	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
in	B-X
the	B-X
BM	B-X
may	B-X
strongly	B-X
influence	B-X
clinical	B-X
and	B-X
molecular	B-X
remission	B-X
<EOS>	B-X
Four	B-X
of	B-X
the	B-X
eight	B-X
patients	B-X
in	B-X
LT	B-X
and	B-X
7	B-X
of	B-X
the	B-X
15	B-X
patients	B-X
in	B-X
ST	B-X
remission	B-X
were	B-X
MRD	B-X
-	B-X
positive	B-X
<EOS>	B-X
The	B-X
total	B-X
populations	B-X
of	B-X
CD4+	B-X
,	B-X
CD8+	B-X
and	B-X
CD56+	B-X
[	B-X
possible	B-X
T	B-X
-	B-X
cell	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
T	B-X
/	B-X
NK	B-X
)	B-X
populations	B-X
]	B-X
in	B-X
the	B-X
BM	B-X
of	B-X
ST	B-X
patients	B-X
and	B-X
MRD+	B-X
/	B-X
LT	B-X
patients	B-X
were	B-X
significantly	B-X
(	B-X
p	B-X
<	B-X

The	O
T/NK	B-cell_type
subsets	I-cell_type
in	O
the	O
BM	O
of	O
MRD-negative	O
(	O
MRD-	O
)	O
LT	O
(	O
MRD-/LT	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	O
cells	O
as	O
normal	O
volunteers	O
.	O

Basically	O
,	O
the	O
total	O
percentage	O
of	O
the	O
CD4+	B-cell_type
,	I-cell_type
CD8+	I-cell_type
and	I-cell_type
CD56+	I-cell_type
cell	I-cell_type
populations	I-cell_type
in	O
the	O
BM	O
was	O
increased	O
and	O
in	O
the	O
following	O
order	O
:	O
MRD-/LT	O
patients	O
,	O
normal	O
volunteers	O
,	O
MRD+/LT	O
patients	O
and	O
MRD+	O
or	O
-/ST	O
patients	O
.	O
<EOS>	B-X
Overall	B-X
panelists	B-X
reported	B-X
infrequent	B-X
use	B-X
of	B-X
prognostic	B-X
calculators	B-X
and	B-X
observing	B-X
variability	B-X
in	B-X
patient	B-X
prognostication	B-X
and	B-X
goals	B-X
of	B-X
care	B-X
decisions	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
normal	B-X
values	B-X
of	B-X
these	B-X
parameters	B-X
in	B-X
healthy	B-X
Japanese	B-X
populations	B-X
remain	B-X
unknown	B-X
;	B-X
thus	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
investigate	B-X
these	B-X
values	B-X
in	B-X
such	B-X
a	B-X
population	B-X
<EOS>	B-X
Intensive	B-X
clinical	B-X
support	B-X
is	B-X
required	B-X
initially	B-X
to	B-X
provide	B-X
education	B-X
prior	B-X
to	B-X
MPV	B-X
,	B-X
and	B-X
at	B-X
the	B-X
time	B-X
of	B-X
extubation	B-X
for	B-X
both	B-X
patient	B-X
and	B-X
treating	B-X
clinicians	B-X
<EOS>	B-X
The	B-X
feasibility	B-X
of	B-X
using	B-X
mouthpiece	B-X
ventilation	B-X
in	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
for	B-X
post	B-X
-	B-X
extubation	B-X
breathing	B-X
support	B-X
after	B-X
acute	B-X
tetraplegia	B-X
.	B-X

The	O
percentages	O
of	O
the	O
T/NK-cell	B-cell_type
subsets	I-cell_type
in	O
the	O
PB	O
were	O
not	O
significantly	O
different	O
among	O
these	O
groups	O
.	O

Thus	O
,	O
the	O
difference	O
of	O
the	O
possible	O
T/NK-cell	B-cell_type
phenotype	O
in	O
the	O
BM	O
may	O
strongly	O
influence	O
clinical	O
and	O
molecular	O
remission	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
difference	B-X
of	B-X
the	B-X
possible	B-X
T	B-X
/	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
in	B-X
the	B-X
BM	B-X
may	B-X
strongly	B-X
influence	B-X
clinical	B-X
and	B-X
molecular	B-X
remission	B-X
<EOS>	B-X
The	B-X
percentages	B-X
of	B-X
the	B-X
T	B-X
/	B-X
NK	B-X
-	B-X
cell	B-X
subsets	B-X
in	B-X
the	B-X
PB	B-X
were	B-X
not	B-X
significantly	B-X
different	B-X
among	B-X
these	B-X
groups	B-X
<EOS>	B-X
Basically	B-X
,	B-X
the	B-X
total	B-X
percentage	B-X
of	B-X
the	B-X
CD4+	B-X
,	B-X
CD8+	B-X
and	B-X
CD56+	B-X
cell	B-X
populations	B-X
in	B-X
the	B-X
BM	B-X
was	B-X
increased	B-X
and	B-X
in	B-X
the	B-X
following	B-X
order	B-X
:	B-X
MRD	B-X
-	B-X
	B-X
/	B-X
LT	B-X
patients	B-X
,	B-X
normal	B-X
volunteers	B-X
,	B-X
MRD+	B-X
/	B-X
LT	B-X
patients	B-X
and	B-X
MRD+	B-X
or	B-X
	B-X
-	B-X
	B-X
/	B-X
ST	B-X
patients	B-X
<EOS>	B-X
The	B-X
total	B-X
populations	B-X
of	B-X
CD4+	B-X
,	B-X
CD8+	B-X
and	B-X
CD56+	B-X
[	B-X
possible	B-X
T	B-X
-	B-X
cell	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
T	B-X
/	B-X
NK	B-X
)	B-X
populations	B-X
]	B-X
in	B-X
the	B-X
BM	B-X
of	B-X
ST	B-X
patients	B-X
and	B-X
MRD+	B-X
/	B-X
LT	B-X
patients	B-X
were	B-X
significantly	B-X
(	B-X
p	B-X
<	B-X

These	O
results	O
still	O
remain	O
to	O
be	O
confirmed	O
by	O
further	O
studies	O
of	O
the	O
functional	O
anti-tumor	O
immunity	O
of	O
T/NK	B-cell_type
cells	I-cell_type
of	O
AML	B-cell_type
in	O
remission	O
.	O
<EOS>	B-X
These	B-X
results	B-X
still	B-X
remain	B-X
to	B-X
be	B-X
confirmed	B-X
by	B-X
further	B-X
studies	B-X
of	B-X
the	B-X
functional	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
of	B-X
T	B-X
/	B-X
NK	B-X
cells	B-X
of	B-X
AML	B-X
in	B-X
remission	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
difference	B-X
of	B-X
the	B-X
possible	B-X
T	B-X
/	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
in	B-X
the	B-X
BM	B-X
may	B-X
strongly	B-X
influence	B-X
clinical	B-X
and	B-X
molecular	B-X
remission	B-X
<EOS>	B-X
The	B-X
total	B-X
populations	B-X
of	B-X
CD4+	B-X
,	B-X
CD8+	B-X
and	B-X
CD56+	B-X
[	B-X
possible	B-X
T	B-X
-	B-X
cell	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
T	B-X
/	B-X
NK	B-X
)	B-X
populations	B-X
]	B-X
in	B-X
the	B-X
BM	B-X
of	B-X
ST	B-X
patients	B-X
and	B-X
MRD+	B-X
/	B-X
LT	B-X
patients	B-X
were	B-X
significantly	B-X
(	B-X
p	B-X
<	B-X
<EOS>	B-X
Four	B-X
of	B-X
the	B-X
eight	B-X
patients	B-X
in	B-X
LT	B-X
and	B-X
7	B-X
of	B-X
the	B-X
15	B-X
patients	B-X
in	B-X
ST	B-X
remission	B-X
were	B-X
MRD	B-X
-	B-X
positive	B-X

Mycobacterium	O
tuberculosis	O
mannose-capped	O
lipoarabinomannan	O
can	O
induce	O
NF-kappaB	B-protein
-dependent	O
activation	O
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O
<EOS>	B-X
Tuberculosis	B-X
has	B-X
emerged	B-X
as	B-X
an	B-X
epidemic	B-X
,	B-X
extended	B-X
by	B-X
the	B-X
large	B-X
number	B-X
of	B-X
individuals	B-X
infected	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
Mycobacterium	B-X
tuberculosis	B-X
mannose	B-X
-	B-X
capped	B-X
lipoarabinomannan	B-X
can	B-X
induce	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
long	B-X
terminal	B-X
repeat	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
tuberculosis	B-X
ManLAM	B-X
resulted	B-X
in	B-X
clear	B-X
induction	B-X
of	B-X
the	B-X
luciferase	B-X
gene	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
,	B-X
but	B-X
not	B-X
the	B-X
kappaB	B-X
-	B-X
mutated	B-X
,	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
region	B-X
<EOS>	B-X
tuberculosis	B-X
)	B-X
could	B-X
activate	B-X
transcription	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
in	B-X
T	B-X
cells	B-X
with	B-X
the	B-X
use	B-X
of	B-X
an	B-X
in	B-X
vitro	B-X
cell	B-X
culture	B-X
system	B-X

The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose-capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O

These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4	B-protein
-expressing	O
T	B-cell_type
lymphocytes	I-cell_type
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O
<EOS>	B-X
These	B-X
experiments	B-X
are	B-X
of	B-X
prime	B-X
importance	B-X
considering	B-X
that	B-X
CD4	B-X
-	B-X
expressing	B-X
T	B-X
lymphocytes	B-X
represent	B-X
the	B-X
major	B-X
virus	B-X
reservoir	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
infected	B-X
individuals	B-X
<EOS>	B-X
The	B-X
implication	B-X
of	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
(	B-X
s	B-X
)	B-X
,	B-X
protein	B-X
kinase	B-X
A	B-X
and	B-X
/	B-X
or	B-X
protein	B-X
kinase	B-X
C	B-X
was	B-X
highlighted	B-X
by	B-X
the	B-X
abrogation	B-X
of	B-X
the	B-X
ManLAM	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
-	B-X
driven	B-X
gene	B-X
expression	B-X
using	B-X
herbimycin	B-X
A	B-X
and	B-X
H7	B-X
<EOS>	B-X
tuberculosis	B-X
can	B-X
upregulate	B-X
HIV	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
could	B-X
thus	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
influence	B-X
the	B-X
pathogenesis	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
<EOS>	B-X
tuberculosis	B-X
)	B-X
could	B-X
activate	B-X
transcription	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
in	B-X
T	B-X
cells	B-X
with	B-X
the	B-X
use	B-X
of	B-X
an	B-X
in	B-X
vitro	B-X
cell	B-X
culture	B-X
system	B-X

Using	O
the	O
1G5	B-cell_line
cell	I-cell_line
line	I-cell_line
harbouring	O
the	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV-1	B-DNA
LTR-dependent	I-DNA
gene	I-DNA
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
1G5	B-X
cell	B-X
line	B-X
harbouring	B-X
the	B-X
luciferase	B-X
reporter	B-X
gene	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
,	B-X
it	B-X
was	B-X
first	B-X
found	B-X
that	B-X
culture	B-X
protein	B-X
filtrates	B-X
(	B-X
CFP	B-X
)	B-X
from	B-X
M	B-X
<EOS>	B-X
tuberculosis	B-X
or	B-X
purified	B-X
ManLAM	B-X
could	B-X
activate	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
-	B-X
dependent	B-X
gene	B-X
expression	B-X
unlike	B-X
similarly	B-X
prepared	B-X
CFP	B-X
extracts	B-X
devoid	B-X
of	B-X
ManLAM	B-X
<EOS>	B-X
The	B-X
implication	B-X
of	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
(	B-X
s	B-X
)	B-X
,	B-X
protein	B-X
kinase	B-X
A	B-X
and	B-X
/	B-X
or	B-X
protein	B-X
kinase	B-X
C	B-X
was	B-X
highlighted	B-X
by	B-X
the	B-X
abrogation	B-X
of	B-X
the	B-X
ManLAM	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
-	B-X
driven	B-X
gene	B-X
expression	B-X
using	B-X
herbimycin	B-X
A	B-X
and	B-X
H7	B-X
<EOS>	B-X
Finally	B-X
,	B-X
the	B-X
ManLAM	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
transcription	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
the	B-X
autocrine	B-X
or	B-X
paracrine	B-X
action	B-X
of	B-X
endogenous	B-X
TNF	B-X
-	B-X
alpha	B-X

The	O
implication	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	I-protein
s	I-protein
)	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
and/or	O
protein	B-protein
kinase	I-protein
C	I-protein
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	O
LTR-driven	O
gene	O
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O
<EOS>	B-X
SRC	B-X
tyrosine	B-X
kinase	B-X
is	B-X
a	B-X
particularly	B-X
interesting	B-X
candidate	B-X
as	B-X
the	B-X
mediator	B-X
of	B-X
the	B-X
protein	B-X
kinase	B-X
A	B-X
-	B-X
driven	B-X
sperm	B-X
protein	B-X
tyrosine	B-X
phosphorylation	B-X
<EOS>	B-X
The	B-X
identities	B-X
of	B-X
the	B-X
phosphorylated	B-X
sperm	B-X
-	B-X
protein	B-X
substrates	B-X
and	B-X
the	B-X
kinase	B-X
(	B-X
s	B-X
)	B-X
responsible	B-X
for	B-X
their	B-X
tyrosine	B-X
phosphorylation	B-X
have	B-X
fostered	B-X
major	B-X
questions	B-X
regarding	B-X
this	B-X
pathway	B-X
<EOS>	B-X
The	B-X
capacity	B-X
of	B-X
DA	B-X
neurons	B-X
to	B-X
synthesize	B-X
DA	B-X
was	B-X
not	B-X
altered	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
change	B-X
in	B-X
protein	B-X
kinase	B-X
A	B-X
-	B-X
mediated	B-X
Ser	B-X
(	B-X
40	B-X
)	B-X
phosphorylation	B-X
of	B-X
tyrosine	B-X
hydroxylase	B-X
<EOS>	B-X
Phosphorylation	B-X
of	B-X
tyrosine	B-X
residues	B-X
and	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
substrates	B-X
were	B-X
determined	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
immunoblotting	B-X
with	B-X
specific	B-X
antibodies	B-X

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	I-protein
.	O

M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	B-DNA
gene	I-DNA
placed	O
under	O
the	O
control	O
of	O
the	O
wild-type	B-DNA
,	I-DNA
but	I-DNA
not	I-DNA
the	I-DNA
kappaB-mutated	I-DNA
,	I-DNA
HIV-1	I-DNA
LTR	I-DNA
region	I-DNA
.	O

Finally	O
,	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	O
LTR	O
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	B-protein
TNF-alpha	I-protein
.	O
<EOS>	B-X
Finally	B-X
,	B-X
the	B-X
ManLAM	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
transcription	B-X
was	B-X
found	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
the	B-X
autocrine	B-X
or	B-X
paracrine	B-X
action	B-X
of	B-X
endogenous	B-X
TNF	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Two	B-X
hours	B-X
later	B-X
there	B-X
was	B-X
dose	B-X
-	B-X
related	B-X
production	B-X
of	B-X
IL	B-X
-	B-X
1alpha	B-X
along	B-X
with	B-X
ear	B-X
swelling	B-X
and	B-X
accumulation	B-X
of	B-X
skin	B-X
water	B-X
,	B-X
all	B-X
of	B-X
which	B-X
were	B-X
partially	B-X
prevented	B-X
by	B-X
intraperitoneal	B-X
injection	B-X
of	B-X
antibody	B-X
against	B-X
murine	B-X
IL	B-X
-	B-X
1alpha	B-X
<EOS>	B-X
tuberculosis	B-X
ManLAM	B-X
led	B-X
to	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
<EOS>	B-X
Using	B-X
the	B-X
traditional	B-X
criteria	B-X
employed	B-X
to	B-X
determine	B-X
autocrine	B-X
or	B-X
paracrine	B-X
functions	B-X
our	B-X
review	B-X
shows	B-X
that	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
their	B-X
role	B-X
as	B-X
lymphocyte	B-X
messengers	B-X
,	B-X
certain	B-X
cytokines	B-X
are	B-X
autocrine	B-X
or	B-X
paracrine	B-X
regulators	B-X
of	B-X
anterior	B-X
pituitary	B-X
function	B-X
and	B-X
growth	B-X

The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV-1	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
.	O

Human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
quasispecies	O
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	O
factor	O
recruitment	O
in	O
human	B-cell_type
glial	I-cell_type
cells	I-cell_type
and	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
long	B-X
terminal	B-X
repeat	B-X
quasispecies	B-X
differ	B-X
in	B-X
basal	B-X
transcription	B-X
and	B-X
nuclear	B-X
factor	B-X
recruitment	B-X
in	B-X
human	B-X
glial	B-X
cells	B-X
and	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
LTR	B-X
sequence	B-X
changes	B-X
can	B-X
significantly	B-X
affect	B-X
basal	B-X
LTR	B-X
function	B-X
and	B-X
transcription	B-X
factor	B-X
recruitment	B-X
,	B-X
which	B-X
may	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
alter	B-X
the	B-X
course	B-X
of	B-X
viral	B-X
replication	B-X
in	B-X
cells	B-X
of	B-X
CNS	B-X
and	B-X
immune	B-X
system	B-X
origin	B-X
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
impact	B-X
of	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
sequence	B-X
diversity	B-X
on	B-X
LTR	B-X
-	B-X
directed	B-X
gene	B-X
expression	B-X
in	B-X
cells	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
and	B-X
immune	B-X
system	B-X
,	B-X
we	B-X
amplified	B-X
and	B-X
cloned	B-X
LTRs	B-X
from	B-X
proviral	B-X
DNA	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
peripheral	B-X
blood	B-X
<EOS>	B-X
Transient	B-X
expression	B-X
analyses	B-X
in	B-X
cells	B-X
of	B-X
neuroglial	B-X
and	B-X
lymphocytic	B-X
origin	B-X
demonstrated	B-X
that	B-X
some	B-X
of	B-X
these	B-X
LTRs	B-X
had	B-X
activities	B-X
which	B-X
varied	B-X
significantly	B-X
from	B-X
the	B-X
LAI	B-X
LTR	B-X
in	B-X
U	B-X
-	B-X
373	B-X
MG	B-X
cells	B-X
(	B-X
an	B-X
astrocytoma	B-X
cell	B-X
line	B-X
)	B-X
as	B-X
well	B-X
as	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
a	B-X
CD4	B-X
-	B-X
positive	B-X
lymphocyte	B-X
cell	B-X
line	B-X
)	B-X

The	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
HIV-1	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	O
genome	O
.	O
<EOS>	B-X
The	B-X
generation	B-X
of	B-X
genomic	B-X
diversity	B-X
during	B-X
the	B-X
course	B-X
of	B-X
infection	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
affect	B-X
all	B-X
aspects	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
,	B-X
including	B-X
expression	B-X
of	B-X
the	B-X
proviral	B-X
genome	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
LTR	B-X
sequence	B-X
changes	B-X
can	B-X
significantly	B-X
affect	B-X
basal	B-X
LTR	B-X
function	B-X
and	B-X
transcription	B-X
factor	B-X
recruitment	B-X
,	B-X
which	B-X
may	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
alter	B-X
the	B-X
course	B-X
of	B-X
viral	B-X
replication	B-X
in	B-X
cells	B-X
of	B-X
CNS	B-X
and	B-X
immune	B-X
system	B-X
origin	B-X
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
impact	B-X
of	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
sequence	B-X
diversity	B-X
on	B-X
LTR	B-X
-	B-X
directed	B-X
gene	B-X
expression	B-X
in	B-X
cells	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
and	B-X
immune	B-X
system	B-X
,	B-X
we	B-X
amplified	B-X
and	B-X
cloned	B-X
LTRs	B-X
from	B-X
proviral	B-X
DNA	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
peripheral	B-X
blood	B-X
<EOS>	B-X
Transient	B-X
expression	B-X
analyses	B-X
in	B-X
cells	B-X
of	B-X
neuroglial	B-X
and	B-X
lymphocytic	B-X
origin	B-X
demonstrated	B-X
that	B-X
some	B-X
of	B-X
these	B-X
LTRs	B-X
had	B-X
activities	B-X
which	B-X
varied	B-X
significantly	B-X
from	B-X
the	B-X
LAI	B-X
LTR	B-X
in	B-X
U	B-X
-	B-X
373	B-X
MG	B-X
cells	B-X
(	B-X
an	B-X
astrocytoma	B-X
cell	B-X
line	B-X
)	B-X
as	B-X
well	B-X
as	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
a	B-X
CD4	B-X
-	B-X
positive	B-X
lymphocyte	B-X
cell	B-X
line	B-X
)	B-X

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
sequence	O
diversity	O
on	O
LTR-directed	B-DNA
gene	I-DNA
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	O
LTRs	B-DNA
from	O
proviral	O
DNA	O
in	O
HIV-1-infected	O
peripheral	O
blood	O
.	O

Sequence	O
analysis	O
of	O
nineteen	O
LTRs	B-DNA
cloned	O
from	O
2	O
adult	O
and	O
3	O
pediatric	O
patients	O
revealed	O
an	O
average	O
of	O
33	O
nucleotide	O
changes	O
(	O
with	O
respect	O
to	O
the	O
sequence	O
of	O
the	O
LAI	B-DNA
LTR	I-DNA
)	O
within	O
the	O
455-bp	B-DNA
U3	I-DNA
region	I-DNA
.	O

Transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	O
and	O
lymphocytic	O
origin	O
demonstrated	O
that	O
some	O
of	O
these	O
LTRs	B-DNA
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
LAI	B-DNA
LTR	I-DNA
in	O
U-373	B-cell_line
MG	I-cell_line
cells	I-cell_line
(	O
an	O
astrocytoma	B-cell_line
cell	I-cell_line
line	I-cell_line
)	O
as	O
well	O
as	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
CD4-positive	B-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
)	O
.	O

While	O
LTRs	B-DNA
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
U-373	B-cell_line
MG	I-cell_line
cells	I-cell_line
also	O
yielded	O
high	O
activities	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
the	O
LTRs	B-DNA
were	O
generally	O
more	O
active	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
when	O
compared	O
to	O
the	O
LAI	B-DNA
LTR	I-DNA
.	O

Differences	O
in	O
LTR	B-DNA
sequence	I-DNA
also	O
resulted	O
in	O
differences	O
in	O
transcription	O
factor	O
recruitment	O
to	O
cis-acting	B-DNA
sites	I-DNA
within	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
LTR	B-DNA
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
<EOS>	B-X
Differences	B-X
in	B-X
LTR	B-X
sequence	B-X
also	B-X
resulted	B-X
in	B-X
differences	B-X
in	B-X
transcription	B-X
factor	B-X
recruitment	B-X
to	B-X
cis	B-X
-	B-X
acting	B-X
sites	B-X
within	B-X
the	B-X
U3	B-X
region	B-X
of	B-X
the	B-X
LTR	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
LTR	B-X
sequence	B-X
changes	B-X
can	B-X
significantly	B-X
affect	B-X
basal	B-X
LTR	B-X
function	B-X
and	B-X
transcription	B-X
factor	B-X
recruitment	B-X
,	B-X
which	B-X
may	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
alter	B-X
the	B-X
course	B-X
of	B-X
viral	B-X
replication	B-X
in	B-X
cells	B-X
of	B-X
CNS	B-X
and	B-X
immune	B-X
system	B-X
origin	B-X
<EOS>	B-X
In	B-X
particular	B-X
,	B-X
naturally	B-X
occurring	B-X
sequence	B-X
variation	B-X
impacted	B-X
transcription	B-X
factor	B-X
binding	B-X
to	B-X
an	B-X
activating	B-X
transcription	B-X
factor	B-X
/	B-X
cAMP	B-X
response	B-X
element	B-X
binding	B-X
(	B-X
ATF	B-X
/	B-X
CREB	B-X
)	B-X
binding	B-X
site	B-X
(	B-X
located	B-X
between	B-X
the	B-X
LEF	B-X
-	B-X
1	B-X
and	B-X
distal	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
)	B-X
that	B-X
we	B-X
identified	B-X
in	B-X
previous	B-X
studies	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
<EOS>	B-X
Transient	B-X
expression	B-X
analyses	B-X
in	B-X
cells	B-X
of	B-X
neuroglial	B-X
and	B-X
lymphocytic	B-X
origin	B-X
demonstrated	B-X
that	B-X
some	B-X
of	B-X
these	B-X
LTRs	B-X
had	B-X
activities	B-X
which	B-X
varied	B-X
significantly	B-X
from	B-X
the	B-X
LAI	B-X
LTR	B-X
in	B-X
U	B-X
-	B-X
373	B-X
MG	B-X
cells	B-X
(	B-X
an	B-X
astrocytoma	B-X
cell	B-X
line	B-X
)	B-X
as	B-X
well	B-X
as	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
a	B-X
CD4	B-X
-	B-X
positive	B-X
lymphocyte	B-X
cell	B-X
line	B-X
)	B-X

In	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	B-protein
factor	I-protein
binding	O
to	O
an	O
activating	B-protein
transcription	I-protein
factor	I-protein
/	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
(	O
ATF	B-protein
/	O
CREB	B-protein
)	O
binding	O
site	O
(	O
located	O
between	O
the	O
LEF-1	B-DNA
and	I-DNA
distal	I-DNA
NF-kappaB	I-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

These	O
findings	O
suggest	O
that	O
LTR	B-DNA
sequence	I-DNA
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	O
function	O
and	O
transcription	O
factor	O
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
LTR	B-X
sequence	B-X
changes	B-X
can	B-X
significantly	B-X
affect	B-X
basal	B-X
LTR	B-X
function	B-X
and	B-X
transcription	B-X
factor	B-X
recruitment	B-X
,	B-X
which	B-X
may	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
alter	B-X
the	B-X
course	B-X
of	B-X
viral	B-X
replication	B-X
in	B-X
cells	B-X
of	B-X
CNS	B-X
and	B-X
immune	B-X
system	B-X
origin	B-X
<EOS>	B-X
Differences	B-X
in	B-X
LTR	B-X
sequence	B-X
also	B-X
resulted	B-X
in	B-X
differences	B-X
in	B-X
transcription	B-X
factor	B-X
recruitment	B-X
to	B-X
cis	B-X
-	B-X
acting	B-X
sites	B-X
within	B-X
the	B-X
U3	B-X
region	B-X
of	B-X
the	B-X
LTR	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
<EOS>	B-X
In	B-X
particular	B-X
,	B-X
naturally	B-X
occurring	B-X
sequence	B-X
variation	B-X
impacted	B-X
transcription	B-X
factor	B-X
binding	B-X
to	B-X
an	B-X
activating	B-X
transcription	B-X
factor	B-X
/	B-X
cAMP	B-X
response	B-X
element	B-X
binding	B-X
(	B-X
ATF	B-X
/	B-X
CREB	B-X
)	B-X
binding	B-X
site	B-X
(	B-X
located	B-X
between	B-X
the	B-X
LEF	B-X
-	B-X
1	B-X
and	B-X
distal	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
)	B-X
that	B-X
we	B-X
identified	B-X
in	B-X
previous	B-X
studies	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
long	B-X
terminal	B-X
repeat	B-X
quasispecies	B-X
differ	B-X
in	B-X
basal	B-X
transcription	B-X
and	B-X
nuclear	B-X
factor	B-X
recruitment	B-X
in	B-X
human	B-X
glial	B-X
cells	B-X
and	B-X
lymphocytes	B-X
.	B-X

HMG	B-protein
box	I-protein
containing	I-protein
transcription	I-protein
factors	I-protein
in	O
lymphocyte	B-cell_type
differentiation	O
.	O
<EOS>	B-X
HMG	B-X
box	B-X
containing	B-X
transcription	B-X
factors	B-X
in	B-X
lymphocyte	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
An	B-X
HMG	B-X
-	B-X
box	B-X
-	B-X
containing	B-X
T	B-X
-	B-X
cell	B-X
factor	B-X
required	B-X
for	B-X
thymocyte	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
Tcf	B-X
-	B-X
1	B-X
controls	B-X
an	B-X
essential	B-X
step	B-X
in	B-X
thymocyte	B-X
differentiation	B-X
<EOS>	B-X
A	B-X
common	B-X
ancestor	B-X
of	B-X
the	B-X
mammalian	B-X
transcription	B-X
factors	B-X
TCF	B-X
-	B-X
1	B-X
and	B-X
TCF	B-X
-	B-X
1	B-X
alpha	B-X
/	B-X
LEF	B-X
-	B-X
1	B-X
expressed	B-X
in	B-X
chicken	B-X
T	B-X
cells	B-X
.	B-X

The	O
identification	O
of	O
the	O
mammalian	B-DNA
sex-determining	I-DNA
gene	I-DNA
Sry	I-DNA
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
large	O
family	O
of	O
related	O
(	O
'	O
HMG	B-protein
box	I-protein
'	O
)	O
transcription	B-protein
factors	I-protein
that	O
control	O
developmental	O
events	O
in	O
yeast	O
,	O
C.	O
elegans	O
,	O
Drosophila	O
and	O
vertebrates	O
.	O

In	O
lymphocyte	B-cell_type
differentiation	O
,	O
several	O
HMG	B-protein
box	I-protein
proteins	I-protein
play	O
a	O
decisive	O
role	O
.	O
<EOS>	B-X
In	B-X
lymphocyte	B-X
differentiation	B-X
,	B-X
several	B-X
HMG	B-X
box	B-X
proteins	B-X
play	B-X
a	B-X
decisive	B-X
role	B-X
<EOS>	B-X
Sox	B-X
-	B-X
4	B-X
is	B-X
important	B-X
for	B-X
very	B-X
early	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
TCF	B-X
-	B-X
1	B-X
/	B-X
LEF	B-X
-	B-X
1	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
early	B-X
thymocyte	B-X
development	B-X
<EOS>	B-X
In	B-X
flies	B-X
,	B-X
this	B-X
pathway	B-X
controls	B-X
segment	B-X
polarity	B-X
;	B-X
in	B-X
Xenopus	B-X
it	B-X
controls	B-X
the	B-X
definition	B-X
of	B-X
the	B-X
body	B-X
axis	B-X
<EOS>	B-X
TCF	B-X
/	B-X
LEF	B-X
proteins	B-X
have	B-X
recently	B-X
been	B-X
found	B-X
to	B-X
constitute	B-X
a	B-X
downstream	B-X
component	B-X
of	B-X
the	B-X
Wingless	B-X
/	B-X
Wnt	B-X
signal	B-X
transduction	B-X
pathway	B-X

Sox-4	B-protein
is	O
important	O
for	O
very	O
early	O
B-cell	O
differentiation	O
,	O
while	O
TCF-1	B-protein
/	O
LEF-1	B-protein
play	O
a	O
crucial	O
role	O
in	O
early	O
thymocyte	O
development	O
.	O
<EOS>	B-X
Sox	B-X
-	B-X
4	B-X
is	B-X
important	B-X
for	B-X
very	B-X
early	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
,	B-X
while	B-X
TCF	B-X
-	B-X
1	B-X
/	B-X
LEF	B-X
-	B-X
1	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
early	B-X
thymocyte	B-X
development	B-X
<EOS>	B-X
In	B-X
lymphocyte	B-X
differentiation	B-X
,	B-X
several	B-X
HMG	B-X
box	B-X
proteins	B-X
play	B-X
a	B-X
decisive	B-X
role	B-X
<EOS>	B-X
These	B-X
insights	B-X
in	B-X
the	B-X
molecular	B-X
events	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
TCF	B-X
/	B-X
LEF	B-X
function	B-X
in	B-X
these	B-X
organisms	B-X
may	B-X
eventually	B-X
lead	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
function	B-X
of	B-X
these	B-X
HMG	B-X
box	B-X
proteins	B-X
in	B-X
lymphoid	B-X
development	B-X
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
the	B-X
mammalian	B-X
sex	B-X
-	B-X
determining	B-X
gene	B-X
Sry	B-X
has	B-X
led	B-X
to	B-X
the	B-X
discovery	B-X
of	B-X
a	B-X
large	B-X
family	B-X
of	B-X
related	B-X
(	B-X
'HMG	B-X
box	B-X
'	B-X
)	B-X
transcription	B-X
factors	B-X
that	B-X
control	B-X
developmental	B-X
events	B-X
in	B-X
yeast	B-X
,	B-X
C	B-X

TCF/LEF	B-protein
proteins	I-protein
have	O
recently	O
been	O
found	O
to	O
constitute	O
a	O
downstream	O
component	O
of	O
the	O
Wingless/Wnt	O
signal	O
transduction	O
pathway	O
.	O
<EOS>	B-X
TCF	B-X
/	B-X
LEF	B-X
proteins	B-X
have	B-X
recently	B-X
been	B-X
found	B-X
to	B-X
constitute	B-X
a	B-X
downstream	B-X
component	B-X
of	B-X
the	B-X
Wingless	B-X
/	B-X
Wnt	B-X
signal	B-X
transduction	B-X
pathway	B-X
<EOS>	B-X
In	B-X
flies	B-X
,	B-X
this	B-X
pathway	B-X
controls	B-X
segment	B-X
polarity	B-X
;	B-X
in	B-X
Xenopus	B-X
it	B-X
controls	B-X
the	B-X
definition	B-X
of	B-X
the	B-X
body	B-X
axis	B-X
<EOS>	B-X
HMG	B-X
box	B-X
containing	B-X
transcription	B-X
factors	B-X
in	B-X
lymphocyte	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
These	B-X
insights	B-X
in	B-X
the	B-X
molecular	B-X
events	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
TCF	B-X
/	B-X
LEF	B-X
function	B-X
in	B-X
these	B-X
organisms	B-X
may	B-X
eventually	B-X
lead	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
function	B-X
of	B-X
these	B-X
HMG	B-X
box	B-X
proteins	B-X
in	B-X
lymphoid	B-X
development	B-X

In	O
flies	O
,	O
this	O
pathway	O
controls	O
segment	O
polarity	O
;	O
in	O
Xenopus	O
it	O
controls	O
the	O
definition	O
of	O
the	O
body	O
axis	O
.	O
<EOS>	B-X
In	B-X
flies	B-X
,	B-X
this	B-X
pathway	B-X
controls	B-X
segment	B-X
polarity	B-X
;	B-X
in	B-X
Xenopus	B-X
it	B-X
controls	B-X
the	B-X
definition	B-X
of	B-X
the	B-X
body	B-X
axis	B-X
<EOS>	B-X
These	B-X
insights	B-X
in	B-X
the	B-X
molecular	B-X
events	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
TCF	B-X
/	B-X
LEF	B-X
function	B-X
in	B-X
these	B-X
organisms	B-X
may	B-X
eventually	B-X
lead	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
function	B-X
of	B-X
these	B-X
HMG	B-X
box	B-X
proteins	B-X
in	B-X
lymphoid	B-X
development	B-X
<EOS>	B-X
TCF	B-X
/	B-X
LEF	B-X
proteins	B-X
have	B-X
recently	B-X
been	B-X
found	B-X
to	B-X
constitute	B-X
a	B-X
downstream	B-X
component	B-X
of	B-X
the	B-X
Wingless	B-X
/	B-X
Wnt	B-X
signal	B-X
transduction	B-X
pathway	B-X
<EOS>	B-X
HMG	B-X
box	B-X
containing	B-X
transcription	B-X
factors	B-X
in	B-X
lymphocyte	B-X
differentiation	B-X
.	B-X

Deregulation	O
of	O
the	O
pathway	O
occurs	O
in	O
several	O
human	B-cell_type
tumors	I-cell_type
.	O
<EOS>	B-X
Deregulation	B-X
of	B-X
metabolic	B-X
pathways	B-X
have	B-X
been	B-X
described	B-X
during	B-X
the	B-X
onset	B-X
and	B-X
progression	B-X
of	B-X
CCA	B-X
<EOS>	B-X
Deregulation	B-X
of	B-X
AKT	B-X
-	B-X
mTOR	B-X
Signaling	B-X
Contributes	B-X
to	B-X
Chemoradiation	B-X
Resistance	B-X
in	B-X
Lung	B-X
Squamous	B-X
Cell	B-X
Carcinoma	B-X
.	B-X
<EOS>	B-X
Cancer	B-X
-	B-X
related	B-X
muscle	B-X
wasting	B-X
occurs	B-X
in	B-X
most	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Further	B-X
reduction	B-X
of	B-X
mTOR	B-X
signalling	B-X
,	B-X
as	B-X
seen	B-X
in	B-X
Raptor	B-X
ko	B-X
animals	B-X
,	B-X
leads	B-X
to	B-X
a	B-X
1	B-X

These	O
insights	O
in	O
the	O
molecular	O
events	O
that	O
are	O
involved	O
in	O
TCF/LEF	B-protein
function	O
in	O
these	O
organisms	O
may	O
eventually	O
lead	O
to	O
the	O
understanding	O
of	O
the	O
function	O
of	O
these	O
HMG	B-protein
box	I-protein
proteins	I-protein
in	O
lymphoid	O
development	O

Transcriptional	O
regulation	O
by	O
C/EBP	B-protein
alpha	I-protein
and	I-protein
-beta	I-protein
in	O
the	O
expression	O
of	O
the	O
gene	O
for	O
the	O
MRP14	B-protein
myeloid	I-protein
calcium	I-protein
binding	I-protein
protein	I-protein
.	O

Transcriptional	O
regulation	O
of	O
the	O
gene	O
for	O
the	O
myeloid	B-protein
calcium	I-protein
binding	I-protein
protein	I-protein
,	O
MRP14	B-protein
,	O
was	O
investigated	O
in	O
human	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
Transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
gene	B-X
for	B-X
the	B-X
myeloid	B-X
calcium	B-X
binding	B-X
protein	B-X
,	B-X
MRP14	B-X
,	B-X
was	B-X
investigated	B-X
in	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Transcriptional	B-X
regulation	B-X
by	B-X
C	B-X
/	B-X
EBP	B-X
alpha	B-X
and	B-X
	B-X
-	B-X
beta	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
for	B-X
the	B-X
MRP14	B-X
myeloid	B-X
calcium	B-X
binding	B-X
protein	B-X
.	B-X
<EOS>	B-X
Among	B-X
several	B-X
known	B-X
transcription	B-X
factor	B-X
binding	B-X
motifs	B-X
,	B-X
nuclear	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
VD3	B-X
-	B-X
treated	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
and	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
bound	B-X
to	B-X
the	B-X
CCAAT	B-X
/	B-X
enhancer	B-X
binding	B-X
protein	B-X
(	B-X
C	B-X
/	B-X
EBP	B-X
)	B-X
	B-X
-	B-X
binding	B-X
motif	B-X
that	B-X
was	B-X
located	B-X
in	B-X
the	B-X
upstream	B-X
region	B-X
of	B-X
the	B-X
MRP14	B-X
gene	B-X
(	B-X
	B-X
-	B-X
81	B-X
)	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
competitive	B-X
gel	B-X
mobility	B-X
-	B-X
shift	B-X
assay	B-X
<EOS>	B-X
The	B-X
luciferase	B-X
activity	B-X
of	B-X
the	B-X
C	B-X
/	B-X
EBP	B-X
motif	B-X
in	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
was	B-X
increased	B-X
by	B-X
VD3	B-X
treatment	B-X

The	O
MRP14	B-DNA
gene	I-DNA
was	O
not	O
expressed	O
in	O
monoblastic	B-cell_line
ML-1	I-cell_line
cells	I-cell_line
,	O
promonocytic	B-cell_line
U-937	I-cell_line
cells	I-cell_line
,	O
or	O
promyelocytic	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Novel	B-X
benzo	B-X
chromene	B-X
derivatives	B-X
:	B-X
design	B-X
,	B-X
synthesis	B-X
,	B-X
molecular	B-X
docking	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
and	B-X
apoptosis	B-X
induction	B-X
in	B-X
human	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
whether	B-X
the	B-X
combined	B-X
action	B-X
of	B-X
EMFs	B-X
and	B-X
black	B-X
carbon	B-X
(	B-X
BC	B-X
)	B-X
particles	B-X
induced	B-X
cell	B-X
damage	B-X
and	B-X
a	B-X
pro	B-X
-	B-X
apoptotic	B-X
response	B-X
in	B-X
the	B-X
HL	B-X
-	B-X
60	B-X
promyelocytic	B-X
cell	B-X
line	B-X
when	B-X
exposed	B-X
to	B-X
2	B-X
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
influence	B-X
and	B-X
mechanism	B-X
of	B-X
atorvastatin	B-X
on	B-X
glycolysis	B-X
of	B-X
adriamycin	B-X
resistant	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
APL	B-X
)	B-X
cell	B-X
line	B-X
HL	B-X
-	B-X
60	B-X
/	B-X
ADM	B-X
<EOS>	B-X
Specifically	B-X
,	B-X
perillaldehyde	B-X
induced	B-X
lipid	B-X
peroxidation	B-X
,	B-X
decreased	B-X
glutathione	B-X
peroxidase	B-X
4	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
depleted	B-X
intracellular	B-X
glutathione	B-X
on	B-X
HL	B-X
-	B-X
60	B-X
promyelocytic	B-X
leukemia	B-X
cells	B-X

On	O
the	O
other	O
hand	O
,	O
the	O
gene	O
was	O
expressed	O
in	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
HL-60	B-cell_line
cells	I-cell_line
treated	O
with	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
.	O
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
gene	B-X
was	B-X
expressed	B-X
in	B-X
monocytic	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
and	B-X
in	B-X
the	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
treated	B-X
with	B-X
1,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD3	B-X
)	B-X
<EOS>	B-X
The	B-X
MRP14	B-X
gene	B-X
was	B-X
not	B-X
expressed	B-X
in	B-X
monoblastic	B-X
ML	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
promonocytic	B-X
U	B-X
-	B-X
937	B-X
cells	B-X
,	B-X
or	B-X
promyelocytic	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
<EOS>	B-X
An	B-X
antibody	B-X
for	B-X
C	B-X
/	B-X
EBP	B-X
alpha	B-X
super	B-X
-	B-X
shifted	B-X
the	B-X
nucleoprotein	B-X
complex	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
but	B-X
not	B-X
in	B-X
the	B-X
VD3	B-X
-	B-X
treated	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
,	B-X
whereas	B-X
an	B-X
antibody	B-X
for	B-X
C	B-X
/	B-X
EBP	B-X
beta	B-X
blocked	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
complex	B-X
with	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
the	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
but	B-X
not	B-X
with	B-X
that	B-X
of	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
The	B-X
luciferase	B-X
activity	B-X
of	B-X
the	B-X
C	B-X
/	B-X
EBP	B-X
motif	B-X
in	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
was	B-X
increased	B-X
by	B-X
VD3	B-X
treatment	B-X

The	O
level	O
of	O
MRP14	B-protein
in	O
VD3-treated	O
HL-60	B-cell_line
cells	I-cell_line
was	O
two-fold	O
higher	O
than	O
that	O
in	O
THP-1	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
The	B-X
level	B-X
of	B-X
MRP14	B-X
in	B-X
VD3	B-X
-	B-X
treated	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
was	B-X
two	B-X
-	B-X
fold	B-X
higher	B-X
than	B-X
that	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
The	B-X
C	B-X
/	B-X
EBP	B-X
motif	B-X
in	B-X
the	B-X
MRP14	B-X
gene	B-X
was	B-X
confirmed	B-X
to	B-X
function	B-X
as	B-X
a	B-X
regulatory	B-X
region	B-X
in	B-X
VD3	B-X
-	B-X
treated	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
and	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
by	B-X
the	B-X
assay	B-X
<EOS>	B-X
The	B-X
MRP14	B-X
gene	B-X
was	B-X
not	B-X
expressed	B-X
in	B-X
monoblastic	B-X
ML	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
promonocytic	B-X
U	B-X
-	B-X
937	B-X
cells	B-X
,	B-X
or	B-X
promyelocytic	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
<EOS>	B-X
Since	B-X
C	B-X
/	B-X
EBP	B-X
beta	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
VD3	B-X
-	B-X
untreated	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
by	B-X
immunoblotting	B-X
,	B-X
VD3	B-X
activated	B-X
C	B-X
/	B-X
EBP	B-X
beta	B-X
to	B-X
bind	B-X
to	B-X
the	B-X
motif	B-X
,	B-X
probably	B-X
through	B-X
post	B-X
-	B-X
translational	B-X
modification	B-X

Among	O
several	O
known	O
transcription	B-DNA
factor	I-DNA
binding	I-DNA
motifs	I-DNA
,	O
nuclear	B-protein
protein	I-protein
(	I-protein
s	I-protein
)	I-protein
of	O
VD3-treated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
bound	O
to	O
the	O
CCAAT/enhancer	B-DNA
binding	I-DNA
protein	I-DNA
(	I-DNA
C/EBP	I-DNA
)	I-DNA
-binding	I-DNA
motif	I-DNA
that	O
was	O
located	O
in	O
the	O
upstream	B-DNA
region	I-DNA
of	O
the	O
MRP14	B-DNA
gene	I-DNA
(	O
-81	O
)	O
,	O
as	O
evidenced	O
by	O
the	O
competitive	O
gel	O
mobility-shift	O
assay	O
.	O

An	O
antibody	O
for	O
C/EBP	B-protein
alpha	I-protein
super-shifted	O
the	O
nucleoprotein	B-protein
complex	I-protein
in	O
THP-1	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
the	O
VD3-treated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
,	O
whereas	O
an	O
antibody	O
for	O
C/EBP	B-protein
beta	I-protein
blocked	O
the	O
formation	O
of	O
the	O
complex	O
with	O
the	O
nuclear	B-protein
factor	I-protein
of	O
the	O
HL-60	B-cell_line
cells	I-cell_line
but	O
not	O
with	O
that	O
of	O
THP-1	B-cell_line
cells	I-cell_line
.	O

An	O
anti-C/EBP	B-protein
delta	I-protein
antibody	I-protein
had	O
no	O
effect	O
on	O
the	O
complex	O
in	O
either	O
cell	O
.	O
<EOS>	B-X
An	B-X
anti	B-X
-	B-X
C	B-X
/	B-X
EBP	B-X
delta	B-X
antibody	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
complex	B-X
in	B-X
either	B-X
cell	B-X
<EOS>	B-X
Transcriptional	B-X
regulation	B-X
by	B-X
C	B-X
/	B-X
EBP	B-X
alpha	B-X
and	B-X
	B-X
-	B-X
beta	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
for	B-X
the	B-X
MRP14	B-X
myeloid	B-X
calcium	B-X
binding	B-X
protein	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
to	B-X
examine	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
C	B-X
/	B-X
EBP	B-X
motif	B-X
,	B-X
we	B-X
transfected	B-X
several	B-X
constructed	B-X
luciferase	B-X
reporter	B-X
DNAs	B-X
into	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
and	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
it	B-X
was	B-X
concluded	B-X
that	B-X
C	B-X
/	B-X
EBP	B-X
alpha	B-X
and	B-X
	B-X
-	B-X
beta	B-X
were	B-X
able	B-X
to	B-X
bind	B-X
to	B-X
the	B-X
C	B-X
/	B-X
EBP	B-X
motif	B-X
,	B-X
and	B-X
that	B-X
C	B-X
/	B-X
EBP	B-X
alpha	B-X
bound	B-X
to	B-X
the	B-X
motif	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
and	B-X
C	B-X
/	B-X
EBP	B-X
beta	B-X
bound	B-X
to	B-X
that	B-X
in	B-X
the	B-X
VD3	B-X
-	B-X
treated	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X

Thus	O
,	O
it	O
was	O
concluded	O
that	O
C/EBP	B-protein
alpha	I-protein
and	I-protein
-beta	I-protein
were	O
able	O
to	O
bind	O
to	O
the	O
C/EBP	B-protein
motif	I-protein
,	O
and	O
that	O
C/EBP	B-protein
alpha	I-protein
bound	O
to	O
the	O
motif	O
in	O
THP-1	B-cell_line
cells	I-cell_line
and	O
C/EBP	B-protein
beta	I-protein
bound	O
to	O
that	O
in	O
the	O
VD3-treated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
to	O
examine	O
the	O
transcriptional	O
activity	O
of	O
the	O
C/EBP	B-protein
motif	I-protein
,	O
we	O
transfected	O
several	O
constructed	O
luciferase	B-DNA
reporter	I-DNA
DNAs	I-DNA
into	O
HL-60	B-cell_line
cells	I-cell_line
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

The	O
luciferase	O
activity	O
of	O
the	O
C/EBP	B-protein
motif	I-protein
in	O
HL-60	B-cell_line
cells	I-cell_line
was	O
increased	O
by	O
VD3	O
treatment	O
.	O

The	O
C/EBP	B-protein
motif	I-protein
in	O
the	O
MRP14	B-DNA
gene	I-DNA
was	O
confirmed	O
to	O
function	O
as	O
a	O
regulatory	O
region	O
in	O
VD3-treated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
by	O
the	O
assay	O
.	O

Since	O
C/EBP	B-protein
beta	I-protein
was	O
also	O
detected	O
in	O
VD3-untreated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
by	O
immunoblotting	O
,	O
VD3	O
activated	O
C/EBP	B-protein
beta	I-protein
to	O
bind	O
to	O
the	O
motif	O
,	O
probably	O
through	O
post-translational	O
modification	O
.	O

Patients	O
with	O
high-risk	O
myelodysplastic	O
syndrome	O
can	O
have	O
polyclonal	O
or	O
clonal	O
haemopoiesis	O
in	O
complete	O
haematological	O
remission	O
.	O
<EOS>	B-X
Clonal	B-X
evolution	B-X
to	B-X
myelodysplastic	B-X
syndrome	B-X
	B-X
/	B-X
	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
was	B-X
16	B-X
%	B-X
at	B-X
25	B-X
years	B-X
in	B-X
IST	B-X
patients	B-X
,	B-X
1	B-X
<EOS>	B-X
In	B-X
AML	B-X
patients	B-X
after	B-X
allogeneic	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
transplantation	B-X
the	B-X
presence	B-X
of	B-X
clonal	B-X
hematopoiesis	B-X
-	B-X
associated	B-X
mutations	B-X
in	B-X
complete	B-X
remission	B-X
did	B-X
not	B-X
associate	B-X
with	B-X
inferior	B-X
clinical	B-X
outcome	B-X
<EOS>	B-X
Patients	B-X
with	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
often	B-X
reach	B-X
complete	B-X
remission	B-X
,	B-X
but	B-X
relapse	B-X
rates	B-X
remain	B-X
high	B-X
<EOS>	B-X
A	B-X
customized	B-X
Myelo	B-X
-	B-X
panel	B-X
showed	B-X
clonal	B-X
hematopoiesis	B-X
in	B-X
all	B-X
five	B-X
patients	B-X

The	O
clonality	O
of	O
mature	B-cell_type
peripheral	I-cell_type
blood-derived	I-cell_type
myeloid	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
bone	B-cell_type
marrow	I-cell_type
haemopoietic	I-cell_type
progenitors	I-cell_type
from	O
18	O
females	O
with	O
myelodysplasia	O
(	O
MDS	O
)	O
(	O
five	O
refractory	O
anaemia	O
,	O
RA	O
;	O
one	O
RA	O
with	O
ringed	B-cell_type
sideroblasts	I-cell_type
,	O
RARS	O
;	O
three	O
chronic	O
myelomonocytic	O
leukaemia	O
,	O
CMML	O
;	O
four	O
RA	O
with	O
excess	O
of	O
blasts	O
,	O
RAEB	O
;	O
five	O
RAEB	O
in	O
transformation	O
,	O
RAEB-t	O
)	O
was	O
studied	O
by	O
X-chromosome	B-DNA
inactivation	O
analysis	O
.	O

Using	O
the	O
human	O
androgen-receptor	O
(	O
HUMARA	O
)	O
assay	O
,	O
we	O
analysed	O
the	O
clonal	O
patterns	O
of	O
highly	B-cell_type
purified	I-cell_type
immature	I-cell_type
CD34+	I-cell_type
38-	I-cell_type
and	I-cell_type
committed	I-cell_type
CD34+	I-cell_type
38+	I-cell_type
marrow-derived	I-cell_type
progenitors	I-cell_type
,	O
and	O
CD16+	B-cell_type
14-	I-cell_type
granulocytes	I-cell_type
,	O
CD14+	B-cell_type
monocytes	I-cell_type
,	O
CD3+	B-cell_type
T	I-cell_type
and	I-cell_type
CD19+	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
from	O
peripheral	O
blood	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
human	B-X
androgen	B-X
-	B-X
receptor	B-X
(	B-X
HUMARA	B-X
)	B-X
assay	B-X
,	B-X
we	B-X
analysed	B-X
the	B-X
clonal	B-X
patterns	B-X
of	B-X
highly	B-X
purified	B-X
immature	B-X
CD34+	B-X
38	B-X
-	B-X
	B-X
and	B-X
committed	B-X
CD34+	B-X
38+	B-X
marrow	B-X
-	B-X
derived	B-X
progenitors	B-X
,	B-X
and	B-X
CD16+	B-X
14	B-X
-	B-X
	B-X
granulocytes	B-X
,	B-X
CD14+	B-X
monocytes	B-X
,	B-X
CD3+	B-X
T	B-X
and	B-X
CD19+	B-X
B	B-X
lymphocytes	B-X
from	B-X
peripheral	B-X
blood	B-X
<EOS>	B-X
After	B-X
high	B-X
-	B-X
dose	B-X
non	B-X
-	B-X
myeloablative	B-X
chemotherapy	B-X
,	B-X
polyclonal	B-X
haemopoiesis	B-X
was	B-X
reinstalled	B-X
in	B-X
the	B-X
mature	B-X
myeloid	B-X
cells	B-X
and	B-X
immature	B-X
and	B-X
committed	B-X
marrow	B-X
progenitors	B-X
in	B-X
three	B-X
of	B-X
four	B-X
patients	B-X
achieving	B-X
complete	B-X
haematological	B-X
remission	B-X
<EOS>	B-X
All	B-X
patients	B-X
,	B-X
except	B-X
one	B-X
with	B-X
RA	B-X
,	B-X
had	B-X
predominance	B-X
of	B-X
a	B-X
single	B-X
clone	B-X
in	B-X
their	B-X
granulocytes	B-X
and	B-X
monocytes	B-X
<EOS>	B-X
X	B-X
-	B-X
chromosome	B-X
inactivation	B-X
patterns	B-X
of	B-X
CD19+	B-X
B	B-X
cells	B-X
were	B-X
highly	B-X
concordant	B-X
with	B-X
CD3+	B-X
T	B-X
cells	B-X
except	B-X
for	B-X
two	B-X
patients	B-X
(	B-X
one	B-X
RA	B-X
,	B-X
one	B-X
CMML	B-X
)	B-X
with	B-X
monoclonal	B-X
B	B-X
and	B-X
polyclonal	B-X
T	B-X
lymphocytes	B-X
,	B-X
therefore	B-X
suggesting	B-X
a	B-X
clonal	B-X
mutation	B-X
in	B-X
a	B-X
progenitor	B-X
common	B-X
to	B-X
the	B-X
myeloid	B-X
and	B-X
B	B-X
-	B-X
lymphoid	B-X
lineages	B-X
or	B-X
the	B-X
coexistence	B-X
of	B-X
MDS	B-X
and	B-X
a	B-X
B	B-X
-	B-X
cell	B-X
disorder	B-X
in	B-X
these	B-X
particular	B-X
patients	B-X

In	O
high-risk	O
patients	O
(	O
RAEB	O
,	O
RAEB-t	O
)	O
,	O
clonality	O
analysis	O
was	O
performed	O
before	O
and	O
after	O
intensive	O
remission-induction	O
treatment	O
.	O
<EOS>	B-X
In	B-X
high	B-X
-	B-X
risk	B-X
patients	B-X
(	B-X
RAEB	B-X
,	B-X
RAEB	B-X
-	B-X
t	B-X
)	B-X
,	B-X
clonality	B-X
analysis	B-X
was	B-X
performed	B-X
before	B-X
and	B-X
after	B-X
intensive	B-X
remission	B-X
-	B-X
induction	B-X
treatment	B-X
<EOS>	B-X
After	B-X
high	B-X
-	B-X
dose	B-X
non	B-X
-	B-X
myeloablative	B-X
chemotherapy	B-X
,	B-X
polyclonal	B-X
haemopoiesis	B-X
was	B-X
reinstalled	B-X
in	B-X
the	B-X
mature	B-X
myeloid	B-X
cells	B-X
and	B-X
immature	B-X
and	B-X
committed	B-X
marrow	B-X
progenitors	B-X
in	B-X
three	B-X
of	B-X
four	B-X
patients	B-X
achieving	B-X
complete	B-X
haematological	B-X
remission	B-X
<EOS>	B-X
All	B-X
patients	B-X
,	B-X
except	B-X
one	B-X
with	B-X
RA	B-X
,	B-X
had	B-X
predominance	B-X
of	B-X
a	B-X
single	B-X
clone	B-X
in	B-X
their	B-X
granulocytes	B-X
and	B-X
monocytes	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
CD3+	B-X
T	B-X
lymphocytes	B-X
were	B-X
polyclonal	B-X
or	B-X
oligoclonal	B-X
in	B-X
14	B-X
/	B-X
18	B-X
patients	B-X

All	O
patients	O
,	O
except	O
one	O
with	O
RA	O
,	O
had	O
predominance	O
of	O
a	O
single	O
clone	O
in	O
their	O
granulocytes	B-cell_type
and	O
monocytes	B-cell_type
.	O
<EOS>	B-X
All	B-X
patients	B-X
,	B-X
except	B-X
one	B-X
with	B-X
RA	B-X
,	B-X
had	B-X
predominance	B-X
of	B-X
a	B-X
single	B-X
clone	B-X
in	B-X
their	B-X
granulocytes	B-X
and	B-X
monocytes	B-X
<EOS>	B-X
The	B-X
same	B-X
clonal	B-X
pattern	B-X
was	B-X
found	B-X
in	B-X
CD34+	B-X
progenitor	B-X
cells	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
CD3+	B-X
T	B-X
lymphocytes	B-X
were	B-X
polyclonal	B-X
or	B-X
oligoclonal	B-X
in	B-X
14	B-X
/	B-X
18	B-X
patients	B-X
<EOS>	B-X
Patients	B-X
with	B-X
high	B-X
-	B-X
risk	B-X
myelodysplastic	B-X
syndrome	B-X
can	B-X
have	B-X
polyclonal	B-X
or	B-X
clonal	B-X
haemopoiesis	B-X
in	B-X
complete	B-X
haematological	B-X
remission	B-X
.	B-X

The	O
same	O
clonal	O
pattern	O
was	O
found	O
in	O
CD34+	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
same	B-X
clonal	B-X
pattern	B-X
was	B-X
found	B-X
in	B-X
CD34+	B-X
progenitor	B-X
cells	B-X
<EOS>	B-X
The	B-X
same	B-X
polyclonal	B-X
pattern	B-X
was	B-X
found	B-X
in	B-X
the	B-X
progeny	B-X
of	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
HLA	B-X
-	B-X
DR	B-X
-	B-X
	B-X
derived	B-X
long	B-X
-	B-X
term	B-X
culture	B-X
-	B-X
initiating	B-X
cells	B-X
<EOS>	B-X
In	B-X
a	B-X
third	B-X
ECP	B-X
patient	B-X
,	B-X
polyclonal	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
could	B-X
only	B-X
be	B-X
found	B-X
in	B-X
the	B-X
first	B-X
peripheral	B-X
blood	B-X
collection	B-X
<EOS>	B-X
The	B-X
self	B-X
-	B-X
renewal	B-X
potential	B-X
of	B-X
cell	B-X
subpopulations	B-X
was	B-X
also	B-X
assessed	B-X
using	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
assays	B-X

In	O
contrast	O
,	O
CD3+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
polyclonal	O
or	O
oligoclonal	O
in	O
14/18	O
patients	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
CD3	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
CD28	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
Ts	B-X
phenotypes	B-X
were	B-X
not	B-X
inducible	B-X
during	B-X
24	B-X
-	B-X
hour	B-X
PMA	B-X
/	B-X
ionomycin	B-X
or	B-X
PHA	B-X
stimulation	B-X
(	B-X
all	B-X
P	B-X
=	B-X
NS	B-X
)	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
in	B-X
other	B-X
lymphoid	B-X
organs	B-X
(	B-X
pancreatic	B-X
lymph	B-X
nodes	B-X
and	B-X
spleens	B-X
)	B-X
analyzed	B-X
by	B-X
FACS	B-X
,	B-X
the	B-X
B	B-X
:	B-X
T	B-X
ratio	B-X
was	B-X
1:1	B-X
<EOS>	B-X
The	B-X
most	B-X
common	B-X
clinical	B-X
form	B-X
was	B-X
transverse	B-X
myelitis	B-X
(	B-X
14	B-X
/	B-X
18	B-X
patients	B-X
,	B-X
77	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
VST	B-X
could	B-X
be	B-X
neither	B-X
expanded	B-X
nor	B-X
primed	B-X
in	B-X
a	B-X
donor	B-X
without	B-X
evidence	B-X
of	B-X
prior	B-X
infection	B-X

X-chromosome	B-DNA
inactivation	O
patterns	O
of	O
CD19+	B-cell_type
B	I-cell_type
cells	I-cell_type
were	O
highly	O
concordant	O
with	O
CD3+	B-cell_type
T	I-cell_type
cells	I-cell_type
except	O
for	O
two	O
patients	O
(	O
one	O
RA	O
,	O
one	O
CMML	O
)	O
with	O
monoclonal	B-cell_type
B	I-cell_type
and	I-cell_type
polyclonal	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
therefore	O
suggesting	O
a	O
clonal	O
mutation	O
in	O
a	O
progenitor	B-cell_type
common	O
to	O
the	O
myeloid	B-cell_type
and	I-cell_type
B-lymphoid	I-cell_type
lineages	I-cell_type
or	O
the	O
coexistence	O
of	O
MDS	O
and	O
a	O
B-cell	O
disorder	O
in	O
these	O
particular	O
patients	O
.	O

After	O
high-dose	O
non-myeloablative	O
chemotherapy	O
,	O
polyclonal	O
haemopoiesis	O
was	O
reinstalled	O
in	O
the	O
mature	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
and	O
immature	O
and	O
committed	B-cell_type
marrow	I-cell_type
progenitors	I-cell_type
in	O
three	O
of	O
four	O
patients	O
achieving	O
complete	O
haematological	O
remission	O
.	O
<EOS>	B-X
After	B-X
high	B-X
-	B-X
dose	B-X
non	B-X
-	B-X
myeloablative	B-X
chemotherapy	B-X
,	B-X
polyclonal	B-X
haemopoiesis	B-X
was	B-X
reinstalled	B-X
in	B-X
the	B-X
mature	B-X
myeloid	B-X
cells	B-X
and	B-X
immature	B-X
and	B-X
committed	B-X
marrow	B-X
progenitors	B-X
in	B-X
three	B-X
of	B-X
four	B-X
patients	B-X
achieving	B-X
complete	B-X
haematological	B-X
remission	B-X
<EOS>	B-X
Patients	B-X
with	B-X
high	B-X
-	B-X
risk	B-X
myelodysplastic	B-X
syndrome	B-X
can	B-X
have	B-X
polyclonal	B-X
or	B-X
clonal	B-X
haemopoiesis	B-X
in	B-X
complete	B-X
haematological	B-X
remission	B-X
.	B-X
<EOS>	B-X
Therefore	B-X
we	B-X
conclude	B-X
that	B-X
most	B-X
haematological	B-X
remissions	B-X
in	B-X
MDS	B-X
are	B-X
associated	B-X
with	B-X
restoration	B-X
of	B-X
polyclonal	B-X
haemopoiesis	B-X
<EOS>	B-X
In	B-X
high	B-X
-	B-X
risk	B-X
patients	B-X
(	B-X
RAEB	B-X
,	B-X
RAEB	B-X
-	B-X
t	B-X
)	B-X
,	B-X
clonality	B-X
analysis	B-X
was	B-X
performed	B-X
before	B-X
and	B-X
after	B-X
intensive	B-X
remission	B-X
-	B-X
induction	B-X
treatment	B-X

Therefore	O
we	O
conclude	O
that	O
most	O
haematological	O
remissions	O
in	O
MDS	O
are	O
associated	O
with	O
restoration	O
of	O
polyclonal	O
haemopoiesis	O
.	O
<EOS>	B-X
Therefore	B-X
we	B-X
conclude	B-X
that	B-X
most	B-X
haematological	B-X
remissions	B-X
in	B-X
MDS	B-X
are	B-X
associated	B-X
with	B-X
restoration	B-X
of	B-X
polyclonal	B-X
haemopoiesis	B-X
<EOS>	B-X
After	B-X
high	B-X
-	B-X
dose	B-X
non	B-X
-	B-X
myeloablative	B-X
chemotherapy	B-X
,	B-X
polyclonal	B-X
haemopoiesis	B-X
was	B-X
reinstalled	B-X
in	B-X
the	B-X
mature	B-X
myeloid	B-X
cells	B-X
and	B-X
immature	B-X
and	B-X
committed	B-X
marrow	B-X
progenitors	B-X
in	B-X
three	B-X
of	B-X
four	B-X
patients	B-X
achieving	B-X
complete	B-X
haematological	B-X
remission	B-X
<EOS>	B-X
The	B-X
same	B-X
clonal	B-X
pattern	B-X
was	B-X
found	B-X
in	B-X
CD34+	B-X
progenitor	B-X
cells	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
CD3+	B-X
T	B-X
lymphocytes	B-X
were	B-X
polyclonal	B-X
or	B-X
oligoclonal	B-X
in	B-X
14	B-X
/	B-X
18	B-X
patients	B-X

Prominent	O
sex	O
steroid	O
metabolism	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Prominent	B-X
sex	B-X
steroid	B-X
metabolism	B-X
in	B-X
human	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Looking	B-X
beyond	B-X
the	B-X
dogma	B-X
of	B-X
genomic	B-X
steroid	B-X
action	B-X
:	B-X
insights	B-X
and	B-X
facts	B-X
of	B-X
the	B-X
1990s	B-X
.	B-X
<EOS>	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
sex	B-X
hormone	B-X
metabolism	B-X
,	B-X
including	B-X
androgen	B-X
synthesis	B-X
,	B-X
occurs	B-X
in	B-X
lymphocytes	B-X
,	B-X
and	B-X
may	B-X
modulate	B-X
immune	B-X
response	B-X
<EOS>	B-X
Differential	B-X
effects	B-X
of	B-X
estradiol	B-X
and	B-X
progesterone	B-X
on	B-X
human	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
vitro	B-X
.	B-X

Steroid	O
metabolism	O
was	O
investigated	O
in	O
cultured	B-cell_line
human	I-cell_line
B-lymphoblastoid	I-cell_line
cells	I-cell_line
(	O
B-LCL	B-cell_line
)	O
,	O
and	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Gene	O
expression	O
was	O
examined	O
by	O
reverse-transcription	O
polymerase	O
chain	O
reaction	O
amplification	O
(	O
RT-PCR	O
)	O
.	O
<EOS>	B-X
Fas	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
were	B-X
examined	B-X
by	B-X
reverse	B-X
transcription‑quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
and	B-X
western	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
Gene	B-X
expression	B-X
studies	B-X
were	B-X
carried	B-X
out	B-X
using	B-X
reverse	B-X
transcriptase	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT	B-X
-	B-X
qPCR	B-X
)	B-X
<EOS>	B-X
Leptin	B-X
mRNA	B-X
expression	B-X
in	B-X
SAT	B-X
was	B-X
measured	B-X
using	B-X
quantitative	B-X
real	B-X
-	B-X
time	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
real	B-X
-	B-X
time	B-X
RT	B-X
-	B-X
PCR	B-X
)	B-X
amplification	B-X
<EOS>	B-X
Expression	B-X
of	B-X
H19	B-X
,	B-X
hTERT	B-X
,	B-X
and	B-X
hTR	B-X
were	B-X
examined	B-X
by	B-X
quantitative	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qRT	B-X
-	B-X
PCR	B-X
)	B-X

Appropriate	O
sized	O
transcripts	B-RNA
were	O
detected	O
in	O
both	O
cultured	O
and	O
fresh	O
peripheral	B-cell_type
lymphocytes	I-cell_type
for	O
CYP11A	B-protein
,	O
CYP17	B-protein
,	O
HSD11L	B-protein
(	O
11beta-hydroxysteroid	B-protein
dehydrogenase	I-protein
I	I-protein
)	O
,	O
HSD17B1	B-protein
(	O
17beta-hydroxysteroid	B-protein
dehydrogenase	I-protein
type	I-protein
I	I-protein
)	O
and	O
SRD5A1	B-protein
(	O
5alpha-reductase	B-protein
I	I-protein
)	O
.	O
<EOS>	B-X
Appropriate	B-X
sized	B-X
transcripts	B-X
were	B-X
detected	B-X
in	B-X
both	B-X
cultured	B-X
and	B-X
fresh	B-X
peripheral	B-X
lymphocytes	B-X
for	B-X
CYP11A	B-X
,	B-X
CYP17	B-X
,	B-X
HSD11L	B-X
(	B-X
11beta	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
I	B-X
)	B-X
,	B-X
HSD17B1	B-X
(	B-X
17beta	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
type	B-X
I	B-X
)	B-X
and	B-X
SRD5A1	B-X
(	B-X
5alpha	B-X
-	B-X
reductase	B-X
I	B-X
)	B-X
<EOS>	B-X
Corresponding	B-X
enzymatic	B-X
activity	B-X
was	B-X
detectable	B-X
only	B-X
for	B-X
17	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
and	B-X
5alpha	B-X
-	B-X
reductase	B-X
,	B-X
respectively	B-X
producing	B-X
testosterone	B-X
and	B-X
5alpha	B-X
-	B-X
dihydrotestosterone	B-X
<EOS>	B-X
There	B-X
was	B-X
minimal	B-X
expression	B-X
of	B-X
HSD3B1	B-X
and	B-X
HSD3B2	B-X
(	B-X
3beta	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
I	B-X
and	B-X
II	B-X
)	B-X
in	B-X
B	B-X
-	B-X
LCL	B-X
and	B-X
T	B-X
cells	B-X
<EOS>	B-X
Steroid	B-X
metabolism	B-X
was	B-X
investigated	B-X
in	B-X
cultured	B-X
human	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cells	B-X
(	B-X
B	B-X
-	B-X
LCL	B-X
)	B-X
,	B-X
and	B-X
peripheral	B-X
blood	B-X
T	B-X
and	B-X
B	B-X
cells	B-X

B-LCL	O
,	O
but	O
not	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
expressed	O
CYP11B	B-protein
.	O
<EOS>	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
<EOS>	B-X
4	B-X
%	B-X
and	B-X
human	B-X
B	B-X
-	B-X
LCL	B-X
cells	B-X
by	B-X
up	B-X
to	B-X
20	B-X
%	B-X
<EOS>	B-X
Ex	B-X
vivo	B-X
PBMC	B-X
isolated	B-X
before	B-X
and	B-X
up	B-X
to	B-X
1	B-X
year	B-X
after	B-X
challenge	B-X
were	B-X
exposed	B-X
to	B-X
three	B-X
S	B-X
<EOS>	B-X
XLP	B-X
B	B-X
-	B-X
LCLs	B-X
showed	B-X
the	B-X
upregulated	B-X
level	B-X
of	B-X
CD20	B-X
,	B-X
CD38	B-X
and	B-X
CD86	B-X
cell	B-X
surface	B-X
expression	B-X
and	B-X
downregulation	B-X
of	B-X
CD40	B-X
,	B-X
CD80	B-X
and	B-X
CD150	B-X
expression	B-X

There	O
was	O
minimal	O
expression	O
of	O
HSD3B1	B-protein
and	O
HSD3B2	B-protein
(	O
3beta-hydroxysteroid	B-protein
dehydrogenase	I-protein
I	I-protein
and	I-protein
II	I-protein
)	O
in	O
B-LCL	B-cell_line
and	O
T	B-cell_type
cells	I-cell_type
.	O

Transcripts	O
for	O
CYP19	B-protein
and	O
HSD11K	B-protein
were	O
not	O
detected	O
.	O

Corresponding	O
enzymatic	O
activity	O
was	O
detectable	O
only	O
for	O
17-hydroxysteroid	B-protein
dehydrogenase	I-protein
and	O
5alpha-reductase	B-protein
,	O
respectively	O
producing	O
testosterone	O
and	O
5alpha-dihydrotestosterone	O
.	O
<EOS>	B-X
Corresponding	B-X
enzymatic	B-X
activity	B-X
was	B-X
detectable	B-X
only	B-X
for	B-X
17	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
and	B-X
5alpha	B-X
-	B-X
reductase	B-X
,	B-X
respectively	B-X
producing	B-X
testosterone	B-X
and	B-X
5alpha	B-X
-	B-X
dihydrotestosterone	B-X
<EOS>	B-X
Appropriate	B-X
sized	B-X
transcripts	B-X
were	B-X
detected	B-X
in	B-X
both	B-X
cultured	B-X
and	B-X
fresh	B-X
peripheral	B-X
lymphocytes	B-X
for	B-X
CYP11A	B-X
,	B-X
CYP17	B-X
,	B-X
HSD11L	B-X
(	B-X
11beta	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
I	B-X
)	B-X
,	B-X
HSD17B1	B-X
(	B-X
17beta	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
type	B-X
I	B-X
)	B-X
and	B-X
SRD5A1	B-X
(	B-X
5alpha	B-X
-	B-X
reductase	B-X
I	B-X
)	B-X
<EOS>	B-X
There	B-X
was	B-X
minimal	B-X
expression	B-X
of	B-X
HSD3B1	B-X
and	B-X
HSD3B2	B-X
(	B-X
3beta	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
I	B-X
and	B-X
II	B-X
)	B-X
in	B-X
B	B-X
-	B-X
LCL	B-X
and	B-X
T	B-X
cells	B-X
<EOS>	B-X
One	B-X
metabolite	B-X
thought	B-X
to	B-X
be	B-X
deoxycorticosterone	B-X
was	B-X
identified	B-X
by	B-X
GC	B-X
/	B-X
MS	B-X
as	B-X
6alpha	B-X
-	B-X
hydroxypregnanolone	B-X

Steroid	O
identities	O
were	O
confirmed	O
by	O
gas	O
chromatography/mass	O
spectrometry	O
(	O
GC/MS	O
)	O
.	O
<EOS>	B-X
Their	B-X
identities	B-X
were	B-X
confirmed	B-X
by	B-X
means	B-X
of	B-X
mass	B-X
spectrometry	B-X
<EOS>	B-X
The	B-X
identity	B-X
of	B-X
estrogenic	B-X
molecules	B-X
in	B-X
the	B-X
urine	B-X
of	B-X
group	B-X
B	B-X
(	B-X
17beta	B-X
-	B-X
estradiol	B-X
,	B-X
17alpha	B-X
-	B-X
estradiol	B-X
)	B-X
was	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography	B-X
-	B-X
mass	B-X
spectrometry	B-X
(	B-X
GC	B-X
/	B-X
MS	B-X
)	B-X
<EOS>	B-X
The	B-X
chemical	B-X
identity	B-X
of	B-X
the	B-X
cortisol	B-X
was	B-X
confirmed	B-X
by	B-X
liquid	B-X
chromatography	B-X
-	B-X
mass	B-X
spectrometry	B-X
(	B-X
LC	B-X
/	B-X
MS2	B-X
)	B-X
with	B-X
[	B-X
corrected	B-X
]	B-X
mass	B-X
spectrometry	B-X
-	B-X
mass	B-X
spectrometry	B-X
analyses	B-X
<EOS>	B-X
ATD	B-X
was	B-X
found	B-X
to	B-X
be	B-X
extensively	B-X
metabolized	B-X
,	B-X
and	B-X
its	B-X
metabolites	B-X
could	B-X
not	B-X
be	B-X
easily	B-X
characterized	B-X
by	B-X
gas	B-X
chromatography	B-X
/	B-X
mass	B-X
spectrometry	B-X
(	B-X
GC	B-X
/	B-X
MS	B-X
)	B-X
due	B-X
to	B-X
insufficient	B-X
sensitivity	B-X

One	O
metabolite	O
thought	O
to	O
be	O
deoxycorticosterone	O
was	O
identified	O
by	O
GC/MS	O
as	O
6alpha-hydroxypregnanolone	O
.	O
<EOS>	B-X
One	B-X
metabolite	B-X
thought	B-X
to	B-X
be	B-X
deoxycorticosterone	B-X
was	B-X
identified	B-X
by	B-X
GC	B-X
/	B-X
MS	B-X
as	B-X
6alpha	B-X
-	B-X
hydroxypregnanolone	B-X
<EOS>	B-X
Corresponding	B-X
enzymatic	B-X
activity	B-X
was	B-X
detectable	B-X
only	B-X
for	B-X
17	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
and	B-X
5alpha	B-X
-	B-X
reductase	B-X
,	B-X
respectively	B-X
producing	B-X
testosterone	B-X
and	B-X
5alpha	B-X
-	B-X
dihydrotestosterone	B-X
<EOS>	B-X
Steroid	B-X
metabolism	B-X
was	B-X
investigated	B-X
in	B-X
cultured	B-X
human	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cells	B-X
(	B-X
B	B-X
-	B-X
LCL	B-X
)	B-X
,	B-X
and	B-X
peripheral	B-X
blood	B-X
T	B-X
and	B-X
B	B-X
cells	B-X
<EOS>	B-X
Prominent	B-X
sex	B-X
steroid	B-X
metabolism	B-X
in	B-X
human	B-X
lymphocytes	B-X
.	B-X

It	O
was	O
concluded	O
that	O
sex	O
hormone	O
metabolism	O
,	O
including	O
androgen	O
synthesis	O
,	O
occurs	O
in	O
lymphocytes	O
,	O
and	O
may	O
modulate	O
immune	O
response	O
.	O
<EOS>	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
sex	B-X
hormone	B-X
metabolism	B-X
,	B-X
including	B-X
androgen	B-X
synthesis	B-X
,	B-X
occurs	B-X
in	B-X
lymphocytes	B-X
,	B-X
and	B-X
may	B-X
modulate	B-X
immune	B-X
response	B-X
<EOS>	B-X
Prominent	B-X
sex	B-X
steroid	B-X
metabolism	B-X
in	B-X
human	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Corresponding	B-X
enzymatic	B-X
activity	B-X
was	B-X
detectable	B-X
only	B-X
for	B-X
17	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
and	B-X
5alpha	B-X
-	B-X
reductase	B-X
,	B-X
respectively	B-X
producing	B-X
testosterone	B-X
and	B-X
5alpha	B-X
-	B-X
dihydrotestosterone	B-X
<EOS>	B-X
Steroid	B-X
identities	B-X
were	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography	B-X
/	B-X
mass	B-X
spectrometry	B-X
(	B-X
GC	B-X
/	B-X
MS	B-X
)	B-X

Human	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
hair	O
follicles	O
are	O
good	O
sources	O
of	O
mRNA	B-RNA
for	O
the	O
pterin	B-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	O
HNF1	B-protein
for	O
mutation	O
detection	O
.	O
<EOS>	B-X
Human	B-X
white	B-X
blood	B-X
cells	B-X
and	B-X
hair	B-X
follicles	B-X
are	B-X
good	B-X
sources	B-X
of	B-X
mRNA	B-X
for	B-X
the	B-X
pterin	B-X
carbinolamine	B-X
dehydratase	B-X
/	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
for	B-X
mutation	B-X
detection	B-X
.	B-X
<EOS>	B-X
Pterin	B-X
carbinolamine	B-X
dehydratase	B-X
/	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
(	B-X
PCD	B-X
/	B-X
DCoH	B-X
)	B-X
is	B-X
a	B-X
protein	B-X
that	B-X
has	B-X
a	B-X
dual	B-X
function	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
is	B-X
the	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
that	B-X
is	B-X
able	B-X
to	B-X
activate	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
HNF1	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
the	B-X
PCD	B-X
/	B-X
DCoH	B-X
mRNA	B-X
is	B-X
present	B-X
in	B-X
human	B-X
white	B-X
blood	B-X
cells	B-X
and	B-X
hair	B-X
follicles	B-X

Pterin	B-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	O
HNF1	B-protein
(	O
PCD/DCoH	B-protein
)	O
is	O
a	O
protein	O
that	O
has	O
a	O
dual	O
function	O
.	O

It	O
is	O
a	O
pterin	B-protein
4alpha-carbinolamine	I-protein
dehydratase	I-protein
that	O
is	O
involved	O
in	O
the	O
regeneration	O
of	O
the	O
cofactor	B-protein
tetrahydrobiopterin	I-protein
during	O
the	O
phenylalanine	O
hydroxylase-	O
catalyzed	O
hydroxylation	O
of	O
phenylalanine	O
.	O
<EOS>	B-X
It	B-X
is	B-X
a	B-X
pterin	B-X
4alpha	B-X
-	B-X
carbinolamine	B-X
dehydratase	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
regeneration	B-X
of	B-X
the	B-X
cofactor	B-X
tetrahydrobiopterin	B-X
during	B-X
the	B-X
phenylalanine	B-X
hydroxylase	B-X
-	B-X
	B-X
catalyzed	B-X
hydroxylation	B-X
of	B-X
phenylalanine	B-X
<EOS>	B-X
The	B-X
enzyme	B-X
,	B-X
carbinolamine	B-X
dehydratase	B-X
,	B-X
catalyzes	B-X
the	B-X
dehydration	B-X
of	B-X
the	B-X
carbinolamine	B-X
to	B-X
quinonoid	B-X
dihydropterin	B-X
<EOS>	B-X
This	B-X
finding	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
role	B-X
of	B-X
the	B-X
carbinolamine	B-X
dehydratase	B-X
in	B-X
the	B-X
phenylalanine	B-X
hydroxylation	B-X
reaction	B-X
<EOS>	B-X
Mutation	B-X
in	B-X
the	B-X
4a	B-X
-	B-X
carbinolamine	B-X
dehydratase	B-X
gene	B-X
leads	B-X
to	B-X
mild	B-X
hyperphenylalaninemia	B-X
with	B-X
defective	B-X
cofactor	B-X
metabolism	B-X
.	B-X

In	O
addition	O
,	O
it	O
is	O
the	O
dimerization	O
cofactor	O
of	O
HNF1	B-protein
that	O
is	O
able	O
to	O
activate	O
the	O
transcriptional	O
activity	O
of	O
HNF1	B-protein
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
is	B-X
the	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
that	B-X
is	B-X
able	B-X
to	B-X
activate	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
HNF1	B-X
<EOS>	B-X
Pterin	B-X
carbinolamine	B-X
dehydratase	B-X
/	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
(	B-X
PCD	B-X
/	B-X
DCoH	B-X
)	B-X
is	B-X
a	B-X
protein	B-X
that	B-X
has	B-X
a	B-X
dual	B-X
function	B-X
<EOS>	B-X
Human	B-X
white	B-X
blood	B-X
cells	B-X
and	B-X
hair	B-X
follicles	B-X
are	B-X
good	B-X
sources	B-X
of	B-X
mRNA	B-X
for	B-X
the	B-X
pterin	B-X
carbinolamine	B-X
dehydratase	B-X
/	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
for	B-X
mutation	B-X
detection	B-X
.	B-X
<EOS>	B-X
It	B-X
is	B-X
a	B-X
pterin	B-X
4alpha	B-X
-	B-X
carbinolamine	B-X
dehydratase	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
regeneration	B-X
of	B-X
the	B-X
cofactor	B-X
tetrahydrobiopterin	B-X
during	B-X
the	B-X
phenylalanine	B-X
hydroxylase	B-X
-	B-X
	B-X
catalyzed	B-X
hydroxylation	B-X
of	B-X
phenylalanine	B-X

Deficiencies	O
in	O
the	O
gene	O
for	O
this	O
dual	B-protein
functional	I-protein
protein	I-protein
result	O
in	O
hyperphenylalaninemia	O
.	O
<EOS>	B-X
Deficiencies	B-X
in	B-X
the	B-X
gene	B-X
for	B-X
this	B-X
dual	B-X
functional	B-X
protein	B-X
result	B-X
in	B-X
hyperphenylalaninemia	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
the	B-X
PCD	B-X
/	B-X
DCoH	B-X
mRNA	B-X
is	B-X
present	B-X
in	B-X
human	B-X
white	B-X
blood	B-X
cells	B-X
and	B-X
hair	B-X
follicles	B-X
<EOS>	B-X
Taking	B-X
advantage	B-X
of	B-X
this	B-X
finding	B-X
,	B-X
a	B-X
sensitive	B-X
,	B-X
rapid	B-X
and	B-X
convenient	B-X
method	B-X
for	B-X
screening	B-X
mutations	B-X
occurring	B-X
in	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
this	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
is	B-X
the	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
that	B-X
is	B-X
able	B-X
to	B-X
activate	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
HNF1	B-X

Here	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
the	O
PCD/DCoH	B-RNA
mRNA	I-RNA
is	O
present	O
in	O
human	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
hair	O
follicles	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
the	B-X
PCD	B-X
/	B-X
DCoH	B-X
mRNA	B-X
is	B-X
present	B-X
in	B-X
human	B-X
white	B-X
blood	B-X
cells	B-X
and	B-X
hair	B-X
follicles	B-X
<EOS>	B-X
Deficiencies	B-X
in	B-X
the	B-X
gene	B-X
for	B-X
this	B-X
dual	B-X
functional	B-X
protein	B-X
result	B-X
in	B-X
hyperphenylalaninemia	B-X
<EOS>	B-X
Human	B-X
white	B-X
blood	B-X
cells	B-X
and	B-X
hair	B-X
follicles	B-X
are	B-X
good	B-X
sources	B-X
of	B-X
mRNA	B-X
for	B-X
the	B-X
pterin	B-X
carbinolamine	B-X
dehydratase	B-X
/	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
for	B-X
mutation	B-X
detection	B-X
.	B-X
<EOS>	B-X
Taking	B-X
advantage	B-X
of	B-X
this	B-X
finding	B-X
,	B-X
a	B-X
sensitive	B-X
,	B-X
rapid	B-X
and	B-X
convenient	B-X
method	B-X
for	B-X
screening	B-X
mutations	B-X
occurring	B-X
in	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
this	B-X
gene	B-X
has	B-X
been	B-X
described	B-X

Taking	O
advantage	O
of	O
this	O
finding	O
,	O
a	O
sensitive	O
,	O
rapid	O
and	O
convenient	O
method	O
for	O
screening	O
mutations	O
occurring	O
in	O
the	O
coding	O
region	O
of	O
this	O
gene	O
has	O
been	O
described	O
.	O
<EOS>	B-X
Taking	B-X
advantage	B-X
of	B-X
this	B-X
finding	B-X
,	B-X
a	B-X
sensitive	B-X
,	B-X
rapid	B-X
and	B-X
convenient	B-X
method	B-X
for	B-X
screening	B-X
mutations	B-X
occurring	B-X
in	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
this	B-X
gene	B-X
has	B-X
been	B-X
described	B-X
<EOS>	B-X
Deficiencies	B-X
in	B-X
the	B-X
gene	B-X
for	B-X
this	B-X
dual	B-X
functional	B-X
protein	B-X
result	B-X
in	B-X
hyperphenylalaninemia	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
the	B-X
PCD	B-X
/	B-X
DCoH	B-X
mRNA	B-X
is	B-X
present	B-X
in	B-X
human	B-X
white	B-X
blood	B-X
cells	B-X
and	B-X
hair	B-X
follicles	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
is	B-X
the	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF1	B-X
that	B-X
is	B-X
able	B-X
to	B-X
activate	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
HNF1	B-X

Copyright	O
1998	O
Academic	O
Press	O
.	O
<EOS>	B-X
Copyright	B-X
2001	B-X
Academic	B-X
Press	B-X
<EOS>	B-X
Copyright	B-X
2000	B-X
Academic	B-X
Press	B-X
<EOS>	B-X
)	B-X
Copyright	B-X
2001	B-X
Academic	B-X
Press	B-X
<EOS>	B-X
109	B-X
,	B-X
2279	B-X
(	B-X
1998	B-X
)	B-X
]	B-X
for	B-X
standard	B-X
propanal	B-X

Biochemical	O
characterization	O
of	O
the	O
NF-Y	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
during	O
B	O
lymphocyte	O
development	O
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
NF-Y	B-protein
,	O
plays	O
a	O
critical	O
role	O
in	O
tissue-specific	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
transcription	O
.	O

In	O
this	O
report	O
the	O
biochemical	O
properties	O
of	O
the	O
heterotrimeric	B-protein
NF-Y	I-protein
complex	I-protein
have	O
been	O
characterized	O
during	O
stage-specific	O
B-cell	O
development	O
,	O
and	O
in	O
several	O
class	B-cell_line
II-	I-cell_line
mutant	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
which	O
represent	O
distinct	O
bare	O
lymphocyte	O
syndrome	O
class	O
II	O
genetic	O
complementation	O
groups	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biochemical	B-X
properties	B-X
of	B-X
the	B-X
heterotrimeric	B-X
NF	B-X
-	B-X
Y	B-X
complex	B-X
have	B-X
been	B-X
characterized	B-X
during	B-X
stage	B-X
-	B-X
specific	B-X
B	B-X
-	B-X
cell	B-X
development	B-X
,	B-X
and	B-X
in	B-X
several	B-X
class	B-X
II	B-X
-	B-X
	B-X
mutant	B-X
B	B-X
-	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
represent	B-X
distinct	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
class	B-X
II	B-X
genetic	B-X
complementation	B-X
groups	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
Y	B-X
complex	B-X
derived	B-X
from	B-X
class	B-X
II+	B-X
mature	B-X
B	B-X
-	B-X
cells	B-X
bound	B-X
with	B-X
high	B-X
affinity	B-X
to	B-X
anion	B-X
exchangers	B-X
,	B-X
and	B-X
eluted	B-X
as	B-X
an	B-X
intact	B-X
trimeric	B-X
complex	B-X
,	B-X
whereas	B-X
,	B-X
NF	B-X
-	B-X
Y	B-X
derived	B-X
from	B-X
class	B-X
II	B-X
-	B-X
	B-X
plasma	B-X
B	B-X
-	B-X
cells	B-X
,	B-X
and	B-X
from	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
group	B-X
II	B-X
cell	B-X
lines	B-X
,	B-X
RJ2	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
class	B-X
II+	B-X
mature	B-X
B	B-X
-	B-X
cells	B-X
NF	B-X
-	B-X
Y	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
protein	B-X
cofactor	B-X
,	B-X
PC4	B-X
,	B-X
which	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
NF	B-X
-	B-X
Y	B-X
-	B-X
mediated	B-X
transcriptional	B-X
control	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
,	B-X
NF	B-X
-	B-X
Y	B-X
,	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
tissue	B-X
-	B-X
specific	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
gene	B-X
transcription	B-X

The	O
NF-Y	B-protein
complex	I-protein
derived	O
from	O
class	B-cell_type
II+	I-cell_type
mature	I-cell_type
B-cells	I-cell_type
bound	O
with	O
high	O
affinity	O
to	O
anion	B-protein
exchangers	I-protein
,	O
and	O
eluted	O
as	O
an	O
intact	O
trimeric	B-protein
complex	I-protein
,	O
whereas	O
,	O
NF-Y	B-protein
derived	O
from	O
class	B-cell_type
II-	I-cell_type
plasma	I-cell_type
B-cells	I-cell_type
,	O
and	O
from	O
bare	B-cell_line
lymphocyte	I-cell_line
syndrome	I-cell_line
group	I-cell_line
II	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
RJ2.2.5	B-cell_line
and	O
RM3	B-cell_line
,	O
dissociated	O
into	O
discrete	O
NF-YA	B-protein
and	O
NF-YB	B-protein
:	I-protein
C	I-protein
subunit	B-protein
fractions	I-protein
.	O
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
Y	B-X
complex	B-X
derived	B-X
from	B-X
class	B-X
II+	B-X
mature	B-X
B	B-X
-	B-X
cells	B-X
bound	B-X
with	B-X
high	B-X
affinity	B-X
to	B-X
anion	B-X
exchangers	B-X
,	B-X
and	B-X
eluted	B-X
as	B-X
an	B-X
intact	B-X
trimeric	B-X
complex	B-X
,	B-X
whereas	B-X
,	B-X
NF	B-X
-	B-X
Y	B-X
derived	B-X
from	B-X
class	B-X
II	B-X
-	B-X
	B-X
plasma	B-X
B	B-X
-	B-X
cells	B-X
,	B-X
and	B-X
from	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
group	B-X
II	B-X
cell	B-X
lines	B-X
,	B-X
RJ2	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
class	B-X
II+	B-X
mature	B-X
B	B-X
-	B-X
cells	B-X
NF	B-X
-	B-X
Y	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
protein	B-X
cofactor	B-X
,	B-X
PC4	B-X
,	B-X
which	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
NF	B-X
-	B-X
Y	B-X
-	B-X
mediated	B-X
transcriptional	B-X
control	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
<EOS>	B-X
Recombination	B-X
of	B-X
the	B-X
MPC11	B-X
plasma	B-X
B	B-X
-	B-X
cell	B-X
derived	B-X
NF	B-X
-	B-X
Y	B-X
A	B-X
:	B-X
B	B-X
:	B-X
C	B-X
complex	B-X
with	B-X
the	B-X
low	B-X
molecular	B-X
mass	B-X
protein	B-X
fraction	B-X
,	B-X
NF	B-X
-	B-X
Y	B-X
-	B-X
associated	B-X
factors	B-X
(	B-X
YAFs	B-X
)	B-X
,	B-X
derived	B-X
from	B-X
mature	B-X
A20	B-X
B	B-X
-	B-X
cell	B-X
nuclei	B-X
,	B-X
conferred	B-X
high	B-X
affinity	B-X
anion	B-X
exchange	B-X
binding	B-X
to	B-X
NF	B-X
-	B-X
Y	B-X
as	B-X
an	B-X
intact	B-X
trimeric	B-X
complex	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biochemical	B-X
properties	B-X
of	B-X
the	B-X
heterotrimeric	B-X
NF	B-X
-	B-X
Y	B-X
complex	B-X
have	B-X
been	B-X
characterized	B-X
during	B-X
stage	B-X
-	B-X
specific	B-X
B	B-X
-	B-X
cell	B-X
development	B-X
,	B-X
and	B-X
in	B-X
several	B-X
class	B-X
II	B-X
-	B-X
	B-X
mutant	B-X
B	B-X
-	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
represent	B-X
distinct	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
class	B-X
II	B-X
genetic	B-X
complementation	B-X
groups	B-X

Recombination	O
of	O
the	O
MPC11	B-protein
plasma	I-protein
B-cell	I-protein
derived	I-protein
NF-Y	I-protein
A	I-protein
:	I-protein
B	I-protein
:	I-protein
C	I-protein
complex	I-protein
with	O
the	O
low	O
molecular	O
mass	O
protein	O
fraction	O
,	O
NF-Y-associated	B-protein
factors	I-protein
(	O
YAFs	B-protein
)	O
,	O
derived	O
from	O
mature	O
A20	O
B-cell	O
nuclei	O
,	O
conferred	O
high	O
affinity	O
anion	O
exchange	O
binding	O
to	O
NF-Y	B-protein
as	O
an	O
intact	B-protein
trimeric	I-protein
complex	I-protein
.	O

Recombination	O
of	O
the	O
native	B-protein
NF-YA	I-protein
:	I-protein
B	I-protein
:	I-protein
C	I-protein
complex	I-protein
with	O
the	O
transcriptional	B-protein
cofactor	I-protein
,	O
PC4	B-protein
,	O
likewise	O
conferred	O
high	B-protein
affinity	I-protein
NF-Y	I-protein
binding	O
to	O
anion	B-protein
exchangers	I-protein
,	O
and	O
stabilized	O
NF-Y	B-protein
interaction	O
with	O
CCAAT-box	B-DNA
DNA	I-DNA
motifs	I-DNA
in	O
vitro	O
.	O

Interaction	O
between	O
PC4	B-protein
and	O
NF-Y	B-protein
was	O
mapped	O
to	O
the	O
C-terminal	B-protein
region	I-protein
of	O
PC4	B-protein
,	O
and	O
the	O
subunit	B-protein
interaction	I-protein
subdomain	I-protein
of	O
the	O
highly	B-protein
conserved	I-protein
DNA	I-protein
binding-subunit	I-protein
interaction	I-protein
domain	I-protein
(	O
DBD	B-protein
)	O
of	O
NF-YA	B-protein
.	O

These	O
results	O
suggest	O
that	O
in	O
class	B-cell_type
II+	I-cell_type
mature	I-cell_type
B-cells	I-cell_type
NF-Y	B-protein
is	O
associated	O
with	O
the	O
protein	O
cofactor	O
,	O
PC4	B-protein
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
NF-Y-mediated	O
transcriptional	O
control	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
class	B-X
II+	B-X
mature	B-X
B	B-X
-	B-X
cells	B-X
NF	B-X
-	B-X
Y	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
protein	B-X
cofactor	B-X
,	B-X
PC4	B-X
,	B-X
which	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
NF	B-X
-	B-X
Y	B-X
-	B-X
mediated	B-X
transcriptional	B-X
control	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
Y	B-X
complex	B-X
derived	B-X
from	B-X
class	B-X
II+	B-X
mature	B-X
B	B-X
-	B-X
cells	B-X
bound	B-X
with	B-X
high	B-X
affinity	B-X
to	B-X
anion	B-X
exchangers	B-X
,	B-X
and	B-X
eluted	B-X
as	B-X
an	B-X
intact	B-X
trimeric	B-X
complex	B-X
,	B-X
whereas	B-X
,	B-X
NF	B-X
-	B-X
Y	B-X
derived	B-X
from	B-X
class	B-X
II	B-X
-	B-X
	B-X
plasma	B-X
B	B-X
-	B-X
cells	B-X
,	B-X
and	B-X
from	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
group	B-X
II	B-X
cell	B-X
lines	B-X
,	B-X
RJ2	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biochemical	B-X
properties	B-X
of	B-X
the	B-X
heterotrimeric	B-X
NF	B-X
-	B-X
Y	B-X
complex	B-X
have	B-X
been	B-X
characterized	B-X
during	B-X
stage	B-X
-	B-X
specific	B-X
B	B-X
-	B-X
cell	B-X
development	B-X
,	B-X
and	B-X
in	B-X
several	B-X
class	B-X
II	B-X
-	B-X
	B-X
mutant	B-X
B	B-X
-	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
represent	B-X
distinct	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
class	B-X
II	B-X
genetic	B-X
complementation	B-X
groups	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
,	B-X
NF	B-X
-	B-X
Y	B-X
,	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
tissue	B-X
-	B-X
specific	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
gene	B-X
transcription	B-X

Arrest	O
of	O
B	O
lymphocyte	O
terminal	O
differentiation	O
by	O
CD40	O
signaling	O
:	O
mechanism	O
for	O
lack	O
of	O
antibody-secreting	B-cell_type
cells	I-cell_type
in	O
germinal	O
centers	O
.	O
<EOS>	B-X
Arrest	B-X
of	B-X
B	B-X
lymphocyte	B-X
terminal	B-X
differentiation	B-X
by	B-X
CD40	B-X
signaling	B-X
:	B-X
mechanism	B-X
for	B-X
lack	B-X
of	B-X
antibody	B-X
-	B-X
secreting	B-X
cells	B-X
in	B-X
germinal	B-X
centers	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
B	B-X
cell	B-X
differentiation	B-X
by	B-X
CD40	B-X
engagement	B-X
could	B-X
not	B-X
be	B-X
overcome	B-X
by	B-X
either	B-X
mitogens	B-X
or	B-X
cytokines	B-X
,	B-X
but	B-X
could	B-X
be	B-X
reversed	B-X
by	B-X
antibodies	B-X
that	B-X
interfere	B-X
with	B-X
the	B-X
CD40	B-X
/	B-X
gp39	B-X
interaction	B-X
<EOS>	B-X
Despite	B-X
extensive	B-X
research	B-X
,	B-X
the	B-X
role	B-X
of	B-X
CD40	B-X
signaling	B-X
in	B-X
B	B-X
cell	B-X
terminal	B-X
differentiation	B-X
remains	B-X
controversial	B-X
<EOS>	B-X
This	B-X
arrest	B-X
is	B-X
manifested	B-X
at	B-X
a	B-X
molecular	B-X
level	B-X
as	B-X
a	B-X
reduction	B-X
in	B-X
mRNA	B-X
levels	B-X
of	B-X
secretory	B-X
immunoglobulin	B-X
gene	B-X
products	B-X
such	B-X
as	B-X
mu	B-X
(	B-X
s	B-X
)	B-X
and	B-X
J	B-X
chain	B-X
as	B-X
well	B-X
as	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
transcriptional	B-X
regulator	B-X
BLIMP	B-X
-	B-X
1	B-X

Despite	O
extensive	O
research	O
,	O
the	O
role	O
of	O
CD40	B-protein
signaling	O
in	O
B	O
cell	O
terminal	O
differentiation	O
remains	O
controversial	O
.	O

Here	O
we	O
show	O
that	O
CD40	B-protein
engagement	O
arrests	O
B	O
cell	O
differentiation	O
prior	O
to	O
plasma	O
cell	O
formation	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
CD40	B-X
engagement	B-X
arrests	B-X
B	B-X
cell	B-X
differentiation	B-X
prior	B-X
to	B-X
plasma	B-X
cell	B-X
formation	B-X
<EOS>	B-X
Despite	B-X
extensive	B-X
research	B-X
,	B-X
the	B-X
role	B-X
of	B-X
CD40	B-X
signaling	B-X
in	B-X
B	B-X
cell	B-X
terminal	B-X
differentiation	B-X
remains	B-X
controversial	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
B	B-X
cell	B-X
differentiation	B-X
by	B-X
CD40	B-X
engagement	B-X
could	B-X
not	B-X
be	B-X
overcome	B-X
by	B-X
either	B-X
mitogens	B-X
or	B-X
cytokines	B-X
,	B-X
but	B-X
could	B-X
be	B-X
reversed	B-X
by	B-X
antibodies	B-X
that	B-X
interfere	B-X
with	B-X
the	B-X
CD40	B-X
/	B-X
gp39	B-X
interaction	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
secretory	B-X
immunoglobulin	B-X
is	B-X
not	B-X
produced	B-X
by	B-X
B	B-X
cells	B-X
that	B-X
are	B-X
actively	B-X
engaged	B-X
by	B-X
gp39	B-X
-	B-X
expressing	B-X
T	B-X
cells	B-X

This	O
arrest	O
is	O
manifested	O
at	O
a	O
molecular	O
level	O
as	O
a	O
reduction	O
in	O
mRNA	O
levels	O
of	O
secretory	O
immunoglobulin	O
gene	O
products	O
such	O
as	O
mu	O
(	O
s	O
)	O
and	O
J	O
chain	O
as	O
well	O
as	O
the	O
loss	O
of	O
the	O
transcriptional	B-protein
regulator	I-protein
BLIMP-1	B-protein
.	O

Furthermore	O
,	O
the	O
inhibition	O
of	O
B	O
cell	O
differentiation	O
by	O
CD40	B-protein
engagement	O
could	O
not	O
be	O
overcome	O
by	O
either	O
mitogens	B-protein
or	O
cytokines	B-protein
,	O
but	O
could	O
be	O
reversed	O
by	O
antibodies	O
that	O
interfere	O
with	O
the	O
CD40	B-protein
/	O
gp39	B-protein
interaction	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
B	B-X
cell	B-X
differentiation	B-X
by	B-X
CD40	B-X
engagement	B-X
could	B-X
not	B-X
be	B-X
overcome	B-X
by	B-X
either	B-X
mitogens	B-X
or	B-X
cytokines	B-X
,	B-X
but	B-X
could	B-X
be	B-X
reversed	B-X
by	B-X
antibodies	B-X
that	B-X
interfere	B-X
with	B-X
the	B-X
CD40	B-X
/	B-X
gp39	B-X
interaction	B-X
<EOS>	B-X
IgE	B-X
inhibition	B-X
after	B-X
CD14	B-X
engagement	B-X
was	B-X
exerted	B-X
at	B-X
the	B-X
B	B-X
cell	B-X
level	B-X
,	B-X
inasmuch	B-X
as	B-X
it	B-X
was	B-X
observed	B-X
not	B-X
only	B-X
in	B-X
T	B-X
cell	B-X
-	B-X
dependent	B-X
IgE	B-X
induction	B-X
i	B-X
<EOS>	B-X
Arrest	B-X
of	B-X
B	B-X
lymphocyte	B-X
terminal	B-X
differentiation	B-X
by	B-X
CD40	B-X
signaling	B-X
:	B-X
mechanism	B-X
for	B-X
lack	B-X
of	B-X
antibody	B-X
-	B-X
secreting	B-X
cells	B-X
in	B-X
germinal	B-X
centers	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
these	B-X
findings	B-X
provide	B-X
a	B-X
basis	B-X
for	B-X
further	B-X
understanding	B-X
of	B-X
allergic	B-X
responses	B-X
and	B-X
modulation	B-X
by	B-X
immunotherapy	B-X
,	B-X
where	B-X
repeated	B-X
exposure	B-X
to	B-X
large	B-X
concentrations	B-X
of	B-X
allergen	B-X
,	B-X
administered	B-X
by	B-X
means	B-X
of	B-X
injection	B-X
,	B-X
enhance	B-X
IgG	B-X
responses	B-X
and	B-X
downregulate	B-X
IgE	B-X
synthesis	B-X

These	O
data	O
suggest	O
that	O
secretory	O
immunoglobulin	O
is	O
not	O
produced	O
by	O
B	B-cell_type
cells	I-cell_type
that	O
are	O
actively	O
engaged	O
by	O
gp39-expressing	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
COVID	B-X
-	B-X
19	B-X
vaccines	B-X
that	B-X
elicit	B-X
a	B-X
durable	B-X
IgA	B-X
response	B-X
may	B-X
have	B-X
utility	B-X
in	B-X
preventing	B-X
infection	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
secretory	B-X
HE4	B-X
played	B-X
a	B-X
novel	B-X
pro	B-X
-	B-X
survival	B-X
autocrine	B-X
role	B-X
and	B-X
was	B-X
a	B-X
target	B-X
of	B-X
the	B-X
anti	B-X
-	B-X
HE4	B-X
nanobody	B-X
to	B-X
improve	B-X
the	B-X
therapeutic	B-X
effects	B-X
of	B-X
cisplatin	B-X
-	B-X
based	B-X
chemotherapy	B-X
<EOS>	B-X
The	B-X
partial	B-X
neutralizing	B-X
effect	B-X
of	B-X
anti	B-X
-	B-X
ApoE	B-X
antibody	B-X
and	B-X
the	B-X
immunogold	B-X
labeling	B-X
of	B-X
the	B-X
two	B-X
proteins	B-X
on	B-X
secreted	B-X
virions	B-X
indicates	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
conserved	B-X
during	B-X
ZIKV	B-X
intracellular	B-X
trafficking	B-X
and	B-X
release	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
another	B-X
member	B-X
of	B-X
the	B-X
Flaviviridae	B-X
also	B-X
interacts	B-X
with	B-X
ApoE	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
could	B-X
be	B-X
a	B-X
common	B-X
mechanism	B-X
for	B-X
the	B-X
viruses	B-X
from	B-X
this	B-X
family	B-X

A	O
positively	O
charged	O
alpha-lipoic	O
acid	O
analogue	O
with	O
increased	O
cellular	O
uptake	O
and	O
more	O
potent	O
immunomodulatory	O
activity	O
.	O
<EOS>	B-X
A	B-X
positively	B-X
charged	B-X
alpha	B-X
-	B-X
lipoic	B-X
acid	B-X
analogue	B-X
with	B-X
increased	B-X
cellular	B-X
uptake	B-X
and	B-X
more	B-X
potent	B-X
immunomodulatory	B-X
activity	B-X
.	B-X
<EOS>	B-X
LA	B-X
-	B-X
Plus	B-X
is	B-X
thus	B-X
an	B-X
improved	B-X
form	B-X
of	B-X
LA	B-X
with	B-X
increased	B-X
therapeutic	B-X
potential	B-X
<EOS>	B-X
At	B-X
150	B-X
microM	B-X
LA	B-X
-	B-X
Plus	B-X
,	B-X
but	B-X
not	B-X
LA	B-X
,	B-X
inhibited	B-X
TNFalpha	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
<EOS>	B-X
Both	B-X
LA	B-X
and	B-X
LA	B-X
-	B-X
Plus	B-X
synergised	B-X
with	B-X
selenium	B-X
in	B-X
inhibiting	B-X
H2O2	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X

alpha-Lipoic	O
acid	O
(	O
LA	O
)	O
is	O
taken	O
up	O
by	O
cells	O
and	O
reduced	O
to	O
its	O
potent	O
dithiol	O
form	O
,	O
dihydrolipoate	O
(	O
DHLA	O
)	O
,	O
much	O
of	O
which	O
is	O
rapidly	O
effluxed	O
out	O
from	O
cells	O
.	O
<EOS>	B-X
alpha	B-X
-	B-X
Lipoic	B-X
acid	B-X
(	B-X
LA	B-X
)	B-X
is	B-X
taken	B-X
up	B-X
by	B-X
cells	B-X
and	B-X
reduced	B-X
to	B-X
its	B-X
potent	B-X
dithiol	B-X
form	B-X
,	B-X
dihydrolipoate	B-X
(	B-X
DHLA	B-X
)	B-X
,	B-X
much	B-X
of	B-X
which	B-X
is	B-X
rapidly	B-X
effluxed	B-X
out	B-X
from	B-X
cells	B-X
<EOS>	B-X
LA	B-X
-	B-X
Plus	B-X
is	B-X
thus	B-X
an	B-X
improved	B-X
form	B-X
of	B-X
LA	B-X
with	B-X
increased	B-X
therapeutic	B-X
potential	B-X
<EOS>	B-X
To	B-X
improve	B-X
retention	B-X
in	B-X
cells	B-X
,	B-X
the	B-X
LA	B-X
molecule	B-X
was	B-X
modified	B-X
to	B-X
confer	B-X
a	B-X
positive	B-X
charge	B-X
at	B-X
physiological	B-X
pH	B-X
<EOS>	B-X
Both	B-X
LA	B-X
and	B-X
LA	B-X
-	B-X
Plus	B-X
synergised	B-X
with	B-X
selenium	B-X
in	B-X
inhibiting	B-X
H2O2	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X

To	O
improve	O
retention	O
in	O
cells	O
,	O
the	O
LA	O
molecule	O
was	O
modified	O
to	O
confer	O
a	O
positive	O
charge	O
at	O
physiological	O
pH	O
.	O

N	O
,	O
N-dimethyl	O
,	O
N'-2-amidoethyl-lipoate	O
was	O
synthesized	O
.	O
<EOS>	B-X
N	B-X
,	B-X
N	B-X
-	B-X
dimethyl	B-X
,	B-X
N'	B-X
-	B-X
2	B-X
-	B-X
amidoethyl	B-X
-	B-X
lipoate	B-X
was	B-X
synthesized	B-X
<EOS>	B-X
To	B-X
improve	B-X
retention	B-X
in	B-X
cells	B-X
,	B-X
the	B-X
LA	B-X
molecule	B-X
was	B-X
modified	B-X
to	B-X
confer	B-X
a	B-X
positive	B-X
charge	B-X
at	B-X
physiological	B-X
pH	B-X
<EOS>	B-X
A	B-X
positively	B-X
charged	B-X
alpha	B-X
-	B-X
lipoic	B-X
acid	B-X
analogue	B-X
with	B-X
increased	B-X
cellular	B-X
uptake	B-X
and	B-X
more	B-X
potent	B-X
immunomodulatory	B-X
activity	B-X
.	B-X
<EOS>	B-X
alpha	B-X
-	B-X
Lipoic	B-X
acid	B-X
(	B-X
LA	B-X
)	B-X
is	B-X
taken	B-X
up	B-X
by	B-X
cells	B-X
and	B-X
reduced	B-X
to	B-X
its	B-X
potent	B-X
dithiol	B-X
form	B-X
,	B-X
dihydrolipoate	B-X
(	B-X
DHLA	B-X
)	B-X
,	B-X
much	B-X
of	B-X
which	B-X
is	B-X
rapidly	B-X
effluxed	B-X
out	B-X
from	B-X
cells	B-X

The	O
protonated	O
form	O
of	O
the	O
new	O
molecule	O
is	O
referred	O
to	O
as	O
LA-Plus	O
.	O

The	O
uptake	O
of	O
LA-Plus	O
by	O
human	B-cell_type
Wurzburg	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
higher	O
compared	O
to	O
that	O
of	O
LA	O
.	O
<EOS>	B-X
The	B-X
uptake	B-X
of	B-X
LA	B-X
-	B-X
Plus	B-X
by	B-X
human	B-X
Wurzburg	B-X
T	B-X
cells	B-X
was	B-X
higher	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
LA	B-X
<EOS>	B-X
The	B-X
protonated	B-X
form	B-X
of	B-X
the	B-X
new	B-X
molecule	B-X
is	B-X
referred	B-X
to	B-X
as	B-X
LA	B-X
-	B-X
Plus	B-X
<EOS>	B-X
Several	B-X
-	B-X
fold	B-X
higher	B-X
amounts	B-X
of	B-X
DHLA	B-X
-	B-X
Plus	B-X
,	B-X
the	B-X
corresponding	B-X
reduced	B-X
form	B-X
of	B-X
LA	B-X
-	B-X
Plus	B-X
,	B-X
were	B-X
detected	B-X
in	B-X
LA	B-X
-	B-X
Plus	B-X
treated	B-X
cells	B-X
compared	B-X
to	B-X
the	B-X
amount	B-X
of	B-X
DHLA	B-X
found	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
LA	B-X
<EOS>	B-X
To	B-X
improve	B-X
retention	B-X
in	B-X
cells	B-X
,	B-X
the	B-X
LA	B-X
molecule	B-X
was	B-X
modified	B-X
to	B-X
confer	B-X
a	B-X
positive	B-X
charge	B-X
at	B-X
physiological	B-X
pH	B-X

Several-fold	O
higher	O
amounts	O
of	O
DHLA-Plus	O
,	O
the	O
corresponding	O
reduced	O
form	O
of	O
LA-Plus	O
,	O
were	O
detected	O
in	O
LA-Plus	O
treated	O
cells	O
compared	O
to	O
the	O
amount	O
of	O
DHLA	O
found	O
in	O
cells	O
treated	O
with	O
LA	O
.	O

At	O
100	O
microM	O
,	O
LA	O
did	O
not	O
but	O
LA-Plus	O
inhibited	O
H2O2	O
induced	O
NF-kappaB	B-protein
activation	O
and	O
NF-kappaB	B-protein
directed	O
IL-2	B-protein
receptor	I-protein
expression	O
.	O
<EOS>	B-X
TQ	B-X
at	B-X
100	B-X
microM	B-X
and	B-X
CDDP	B-X
at	B-X
5	B-X
muM	B-X
inhibited	B-X
cell	B-X
proliferation	B-X
by	B-X
nearly	B-X
90	B-X
%	B-X
and	B-X
the	B-X
combination	B-X
showed	B-X
synergism	B-X
<EOS>	B-X
TQ	B-X
was	B-X
able	B-X
to	B-X
inhibit	B-X
cell	B-X
proliferation	B-X
,	B-X
reduce	B-X
cell	B-X
viability	B-X
and	B-X
induce	B-X
apoptosis	B-X
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
Payne	B-X
(	B-X
1990	B-X
)	B-X
,	B-X
the	B-X
diagnosis	B-X
of	B-X
the	B-X
genus	B-X
Nudaciraxine	B-X
Price	B-X
,	B-X
1962	B-X
is	B-X
amended	B-X
as	B-X
follows	B-X
:	B-X
vaginal	B-X
pore	B-X
dorsal	B-X
,	B-X
median	B-X
to	B-X
submedian	B-X
,	B-X
armed	B-X
or	B-X
not	B-X
with	B-X
horn	B-X
-	B-X
like	B-X
spines	B-X
<EOS>	B-X
TQ	B-X
down	B-X
regulated	B-X
NF	B-X
-	B-X
kappaB	B-X
expression	B-X
which	B-X
may	B-X
explain	B-X
its	B-X
various	B-X
cellular	B-X
activities	B-X
and	B-X
this	B-X
activity	B-X
may	B-X
prove	B-X
useful	B-X
in	B-X
overcoming	B-X
CDDP	B-X
resistance	B-X
from	B-X
over	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X

Both	O
LA	O
and	O
LA-Plus	O
synergised	O
with	O
selenium	O
in	O
inhibiting	O
H2O2	O
induced	O
NF-kappaB	B-protein
activation	O
.	O
<EOS>	B-X
Both	B-X
LA	B-X
and	B-X
LA	B-X
-	B-X
Plus	B-X
synergised	B-X
with	B-X
selenium	B-X
in	B-X
inhibiting	B-X
H2O2	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
<EOS>	B-X
At	B-X
150	B-X
microM	B-X
LA	B-X
-	B-X
Plus	B-X
,	B-X
but	B-X
not	B-X
LA	B-X
,	B-X
inhibited	B-X
TNFalpha	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
<EOS>	B-X
At	B-X
100	B-X
microM	B-X
,	B-X
LA	B-X
did	B-X
not	B-X
but	B-X
LA	B-X
-	B-X
Plus	B-X
inhibited	B-X
H2O2	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
directed	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
expression	B-X
<EOS>	B-X
At	B-X
5	B-X
microM	B-X
LA	B-X
-	B-X
Plus	B-X
,	B-X
but	B-X
not	B-X
LA	B-X
,	B-X
protected	B-X
against	B-X
both	B-X
spontaneous	B-X
and	B-X
etoposide	B-X
induced	B-X
apoptosis	B-X
in	B-X
rat	B-X
thymocytes	B-X

At	O
150	O
microM	O
LA-Plus	O
,	O
but	O
not	O
LA	O
,	O
inhibited	O
TNFalpha	B-protein
induced	O
NF-kappaB	B-protein
activation	O
.	O

At	O
5	O
microM	O
LA-Plus	O
,	O
but	O
not	O
LA	O
,	O
protected	O
against	O
both	O
spontaneous	O
and	O
etoposide	O
induced	O
apoptosis	O
in	O
rat	B-cell_type
thymocytes	I-cell_type
.	O
<EOS>	B-X
Glucose	B-X
,	B-X
rotenone	B-X
,	B-X
or	B-X
antimycin	B-X
A	B-X
alone	B-X
resulted	B-X
in	B-X
an	B-X
increase	B-X
of	B-X
NO	B-X
production	B-X
<EOS>	B-X
7	B-X
cells	B-X
stimulated	B-X
with	B-X
10	B-X
microg	B-X
/	B-X
mL	B-X
of	B-X
lipopolysaccharide	B-X
and	B-X
50	B-X
U	B-X
/	B-X
mL	B-X
of	B-X
interferon	B-X
-	B-X
gamma	B-X
was	B-X
measured	B-X
directly	B-X
by	B-X
electron	B-X
spin	B-X
resonance	B-X
using	B-X
spin	B-X
-	B-X
trapping	B-X
techniques	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
mitochondrial	B-X
cofactor	B-X
alpha	B-X
-	B-X
lipoic	B-X
acid	B-X
[	B-X
R	B-X
(	B-X
+	B-X
)	B-X
LA	B-X
]	B-X
or	B-X
its	B-X
lipoamide	B-X
analogue	B-X
,	B-X
2	B-X
-	B-X
	B-X
(	B-X
N	B-X
,	B-X
N	B-X
-	B-X
dimethylamine	B-X
)	B-X
ethylamido	B-X
lipoate	B-X
[	B-X
R	B-X
(	B-X
+	B-X
)	B-X
LA	B-X
-	B-X
plus	B-X
]	B-X
,	B-X
on	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
in	B-X
RAW	B-X
264	B-X
<EOS>	B-X
Inhibitory	B-X
effect	B-X
of	B-X
alpha	B-X
-	B-X
lipoic	B-X
acid	B-X
and	B-X
its	B-X
positively	B-X
charged	B-X
amide	B-X
analogue	B-X
on	B-X
nitric	B-X
oxide	B-X
production	B-X
in	B-X
RAW	B-X
264.7	B-X
macrophages	B-X
.	B-X

LA-Plus	O
is	O
thus	O
an	O
improved	O
form	O
of	O
LA	O
with	O
increased	O
therapeutic	O
potential	O
.	O
<EOS>	B-X
LA	B-X
-	B-X
Plus	B-X
is	B-X
thus	B-X
an	B-X
improved	B-X
form	B-X
of	B-X
LA	B-X
with	B-X
increased	B-X
therapeutic	B-X
potential	B-X
<EOS>	B-X
A	B-X
positively	B-X
charged	B-X
alpha	B-X
-	B-X
lipoic	B-X
acid	B-X
analogue	B-X
with	B-X
increased	B-X
cellular	B-X
uptake	B-X
and	B-X
more	B-X
potent	B-X
immunomodulatory	B-X
activity	B-X
.	B-X
<EOS>	B-X
Several	B-X
-	B-X
fold	B-X
higher	B-X
amounts	B-X
of	B-X
DHLA	B-X
-	B-X
Plus	B-X
,	B-X
the	B-X
corresponding	B-X
reduced	B-X
form	B-X
of	B-X
LA	B-X
-	B-X
Plus	B-X
,	B-X
were	B-X
detected	B-X
in	B-X
LA	B-X
-	B-X
Plus	B-X
treated	B-X
cells	B-X
compared	B-X
to	B-X
the	B-X
amount	B-X
of	B-X
DHLA	B-X
found	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
LA	B-X
<EOS>	B-X
At	B-X
5	B-X
microM	B-X
LA	B-X
-	B-X
Plus	B-X
,	B-X
but	B-X
not	B-X
LA	B-X
,	B-X
protected	B-X
against	B-X
both	B-X
spontaneous	B-X
and	B-X
etoposide	B-X
induced	B-X
apoptosis	B-X
in	B-X
rat	B-X
thymocytes	B-X

Carrier	O
identification	O
in	O
X-linked	O
immunodeficiency	O
diseases	O
.	O
<EOS>	B-X
Carrier	B-X
identification	B-X
in	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
diseases	B-X
.	B-X
<EOS>	B-X
This	B-X
PCR	B-X
assay	B-X
provides	B-X
a	B-X
rapid	B-X
method	B-X
for	B-X
carrier	B-X
detection	B-X
of	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiencies	B-X
,	B-X
and	B-X
has	B-X
allowed	B-X
us	B-X
to	B-X
expand	B-X
the	B-X
phenotype	B-X
of	B-X
XSCID	B-X
<EOS>	B-X
Comparative	B-X
mapping	B-X
of	B-X
canine	B-X
and	B-X
human	B-X
proximal	B-X
Xq	B-X
and	B-X
genetic	B-X
analysis	B-X
of	B-X
canine	B-X
X	B-X
-	B-X
linked	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
.	B-X
<EOS>	B-X
Carrier	B-X
identification	B-X
in	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
disorders	B-X
can	B-X
be	B-X
based	B-X
on	B-X
the	B-X
demonstration	B-X
of	B-X
non	B-X
-	B-X
random	B-X
X	B-X
inactivation	B-X
(	B-X
NRXI	B-X
)	B-X
in	B-X
affected	B-X
blood	B-X
cell	B-X
lineages	B-X
when	B-X
growth	B-X
is	B-X
impaired	B-X
in	B-X
cells	B-X
expressing	B-X
the	B-X
abnormal	B-X
gene	B-X

OBJECTIVE	O
:	O
Carrier	O
identification	O
in	O
X-linked	O
immunodeficiency	O
disorders	O
can	O
be	O
based	O
on	O
the	O
demonstration	O
of	O
non-random	O
X	O
inactivation	O
(	O
NRXI	O
)	O
in	O
affected	B-cell_type
blood	I-cell_type
cell	I-cell_type
lineages	I-cell_type
when	O
growth	O
is	O
impaired	O
in	O
cells	O
expressing	O
the	O
abnormal	B-DNA
gene	I-DNA
.	O
<EOS>	B-X
Carrier	B-X
identification	B-X
in	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
disorders	B-X
can	B-X
be	B-X
based	B-X
on	B-X
the	B-X
demonstration	B-X
of	B-X
non	B-X
-	B-X
random	B-X
X	B-X
inactivation	B-X
(	B-X
NRXI	B-X
)	B-X
in	B-X
affected	B-X
blood	B-X
cell	B-X
lineages	B-X
when	B-X
growth	B-X
is	B-X
impaired	B-X
in	B-X
cells	B-X
expressing	B-X
the	B-X
abnormal	B-X
gene	B-X
<EOS>	B-X
This	B-X
PCR	B-X
assay	B-X
provides	B-X
a	B-X
rapid	B-X
method	B-X
for	B-X
carrier	B-X
detection	B-X
of	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiencies	B-X
,	B-X
and	B-X
has	B-X
allowed	B-X
us	B-X
to	B-X
expand	B-X
the	B-X
phenotype	B-X
of	B-X
XSCID	B-X
<EOS>	B-X
Carrier	B-X
identification	B-X
in	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
diseases	B-X
.	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
utility	B-X
of	B-X
seeking	B-X
evidence	B-X
of	B-X
NRXI	B-X
to	B-X
test	B-X
the	B-X
carrier	B-X
status	B-X
of	B-X
women	B-X
in	B-X
families	B-X
affected	B-X
by	B-X
X	B-X
-	B-X
linked	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
XSCID	B-X
)	B-X
and	B-X
X	B-X
-	B-X
linked	B-X
hypogammaglobulinaemia	B-X
(	B-X
XLH	B-X
)	B-X
,	B-X
to	B-X
identify	B-X
as	B-X
carriers	B-X
the	B-X
mothers	B-X
of	B-X
boys	B-X
with	B-X
SCID	B-X
or	B-X
hypogammaglobulinaemia	B-X
whose	B-X
phenotype	B-X
suggested	B-X
X	B-X
-	B-X
linkage	B-X
and	B-X
to	B-X
infer	B-X
X	B-X
-	B-X
linkage	B-X
in	B-X
boys	B-X
with	B-X
SCID	B-X
or	B-X
hypogammaglobulinaemia	B-X
whose	B-X
disease	B-X
was	B-X
not	B-X
clearly	B-X
X	B-X
-	B-X
linked	B-X
on	B-X
the	B-X
basis	B-X
either	B-X
of	B-X
family	B-X
history	B-X
or	B-X
clinical	B-X
and	B-X
immunological	B-X
characteristics	B-X

We	O
examined	O
the	O
utility	O
of	O
seeking	O
evidence	O
of	O
NRXI	O
to	O
test	O
the	O
carrier	O
status	O
of	O
women	O
in	O
families	O
affected	O
by	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
and	O
X-linked	O
hypogammaglobulinaemia	O
(	O
XLH	O
)	O
,	O
to	O
identify	O
as	O
carriers	O
the	O
mothers	O
of	O
boys	O
with	O
SCID	O
or	O
hypogammaglobulinaemia	O
whose	O
phenotype	O
suggested	O
X-linkage	O
and	O
to	O
infer	O
X-linkage	O
in	O
boys	O
with	O
SCID	O
or	O
hypogammaglobulinaemia	O
whose	O
disease	O
was	O
not	O
clearly	O
X-linked	O
on	O
the	O
basis	O
either	O
of	O
family	O
history	O
or	O
clinical	O
and	O
immunological	O
characteristics	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
serum	B-X
levels	B-X
of	B-X
soluble	B-X
B	B-X
-	B-X
cell	B-X
maturation	B-X
antigen	B-X
(	B-X
sBCMA	B-X
)	B-X
in	B-X
childhood	B-X
-	B-X
onset	B-X
systemic	B-X
lupus	B-X
erythematous	B-X
(	B-X
cSLE	B-X
)	B-X
patients	B-X
with	B-X
renal	B-X
involvement	B-X
,	B-X
and	B-X
to	B-X
elucidate	B-X
their	B-X
association	B-X
with	B-X
clinical	B-X
characteristics	B-X
<EOS>	B-X
Only	B-X
one	B-X
domain	B-X
,	B-X
``	B-X
ability	B-X
to	B-X
participate	B-X
in	B-X
daily	B-X
activities	B-X
''	B-X
,	B-X
met	B-X
criteria	B-X
for	B-X
a	B-X
core	B-X
domain	B-X
;	B-X
25	B-X
domains	B-X
met	B-X
criteria	B-X
for	B-X
an	B-X
optional	B-X
recommendation	B-X
:	B-X
8	B-X
Patient	B-X
Impacts	B-X
,	B-X
5	B-X
Implementation	B-X
Outcomes	B-X
,	B-X
5	B-X
Participant	B-X
Characteristics	B-X
,	B-X
3	B-X
OAMP	B-X
Characteristics	B-X
and	B-X
4	B-X
Clinician	B-X
Characteristics	B-X
<EOS>	B-X
Thus	B-X
,	B-X
in	B-X
order	B-X
to	B-X
make	B-X
clinical	B-X
antiviral	B-X
treatment	B-X
decisions	B-X
in	B-X
children	B-X
with	B-X
an	B-X
immune	B-X
tolerant	B-X
phase	B-X
,	B-X
a	B-X
comprehensive	B-X
understanding	B-X
of	B-X
the	B-X
natural	B-X
history	B-X
of	B-X
HBV	B-X
infection	B-X
,	B-X
as	B-X
well	B-X
as	B-X
its	B-X
relationship	B-X
with	B-X
disease	B-X
progression	B-X
and	B-X
whether	B-X
prompt	B-X
treatment	B-X
can	B-X
alter	B-X
the	B-X
natural	B-X
history	B-X
and	B-X
prognosis	B-X
,	B-X
is	B-X
very	B-X
important	B-X
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
mainly	B-X
focus	B-X
on	B-X
the	B-X
need	B-X
for	B-X
new	B-X
and	B-X
improved	B-X
vaccines	B-X
;	B-X
the	B-X
definition	B-X
of	B-X
and	B-X
the	B-X
need	B-X
for	B-X
adjuvants	B-X
;	B-X
the	B-X
characteristics	B-X
and	B-X
mechanisms	B-X
of	B-X
human	B-X
-	B-X
compatible	B-X
adjuvants	B-X
;	B-X
the	B-X
current	B-X
status	B-X
of	B-X
vaccine	B-X
adjuvants	B-X
,	B-X
mucosal	B-X
vaccine	B-X
adjuvants	B-X
,	B-X
and	B-X
adjuvants	B-X
in	B-X
clinical	B-X
development	B-X
;	B-X
and	B-X
future	B-X
directions	B-X

METHODOLOGY	O
:	O
A	O
polymerase	O
chain	O
reaction-based	O
method	O
was	O
used	O
to	O
amplify	O
a	O
polymorphic	O
CAG	B-DNA
repeat	I-DNA
in	O
the	O
first	B-DNA
exon	I-DNA
of	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
after	O
selective	O
digestion	O
of	O
the	O
active	B-DNA
X	I-DNA
chromosome	I-DNA
with	O
a	O
methylation-sensitive	B-protein
enzyme	I-protein
,	O
HpaII	B-protein
to	O
distinguish	O
between	O
the	O
paternal	B-DNA
and	I-DNA
maternal	I-DNA
alleles	I-DNA
and	O
to	O
identify	O
their	O
methylation	O
status	O
.	O
<EOS>	B-X
A	B-X
polymerase	B-X
chain	B-X
reaction	B-X
-	B-X
based	B-X
method	B-X
was	B-X
used	B-X
to	B-X
amplify	B-X
a	B-X
polymorphic	B-X
CAG	B-X
repeat	B-X
in	B-X
the	B-X
first	B-X
exon	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
gene	B-X
after	B-X
selective	B-X
digestion	B-X
of	B-X
the	B-X
active	B-X
X	B-X
chromosome	B-X
with	B-X
a	B-X
methylation	B-X
-	B-X
sensitive	B-X
enzyme	B-X
,	B-X
HpaII	B-X
to	B-X
distinguish	B-X
between	B-X
the	B-X
paternal	B-X
and	B-X
maternal	B-X
alleles	B-X
and	B-X
to	B-X
identify	B-X
their	B-X
methylation	B-X
status	B-X
<EOS>	B-X
The	B-X
finding	B-X
of	B-X
NRXI	B-X
in	B-X
the	B-X
mother	B-X
of	B-X
a	B-X
boy	B-X
with	B-X
a	B-X
SCID	B-X
variant	B-X
showed	B-X
her	B-X
to	B-X
be	B-X
a	B-X
carrier	B-X
of	B-X
XSCID	B-X
and	B-X
establishes	B-X
that	B-X
her	B-X
son	B-X
has	B-X
XSCID	B-X
,	B-X
not	B-X
otherwise	B-X
evident	B-X
from	B-X
available	B-X
data	B-X
<EOS>	B-X
Carrier	B-X
identification	B-X
in	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
disorders	B-X
can	B-X
be	B-X
based	B-X
on	B-X
the	B-X
demonstration	B-X
of	B-X
non	B-X
-	B-X
random	B-X
X	B-X
inactivation	B-X
(	B-X
NRXI	B-X
)	B-X
in	B-X
affected	B-X
blood	B-X
cell	B-X
lineages	B-X
when	B-X
growth	B-X
is	B-X
impaired	B-X
in	B-X
cells	B-X
expressing	B-X
the	B-X
abnormal	B-X
gene	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
utility	B-X
of	B-X
seeking	B-X
evidence	B-X
of	B-X
NRXI	B-X
to	B-X
test	B-X
the	B-X
carrier	B-X
status	B-X
of	B-X
women	B-X
in	B-X
families	B-X
affected	B-X
by	B-X
X	B-X
-	B-X
linked	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
XSCID	B-X
)	B-X
and	B-X
X	B-X
-	B-X
linked	B-X
hypogammaglobulinaemia	B-X
(	B-X
XLH	B-X
)	B-X
,	B-X
to	B-X
identify	B-X
as	B-X
carriers	B-X
the	B-X
mothers	B-X
of	B-X
boys	B-X
with	B-X
SCID	B-X
or	B-X
hypogammaglobulinaemia	B-X
whose	B-X
phenotype	B-X
suggested	B-X
X	B-X
-	B-X
linkage	B-X
and	B-X
to	B-X
infer	B-X
X	B-X
-	B-X
linkage	B-X
in	B-X
boys	B-X
with	B-X
SCID	B-X
or	B-X
hypogammaglobulinaemia	B-X
whose	B-X
disease	B-X
was	B-X
not	B-X
clearly	B-X
X	B-X
-	B-X
linked	B-X
on	B-X
the	B-X
basis	B-X
either	B-X
of	B-X
family	B-X
history	B-X
or	B-X
clinical	B-X
and	B-X
immunological	B-X
characteristics	B-X

RESULTS	O
:	O
Heterozygosity	O
was	O
found	O
in	O
24	O
of	O
31	O
female	O
subjects	O
(	O
77	O
%	O
)	O
.	O
<EOS>	B-X
Heterozygosity	B-X
was	B-X
found	B-X
in	B-X
24	B-X
of	B-X
31	B-X
female	B-X
subjects	B-X
(	B-X
77	B-X
%	B-X
)	B-X
<EOS>	B-X
886	B-X
(	B-X
	B-X
-	B-X
10_	B-X
-	B-X
31	B-X
)	B-X
del	B-X
that	B-X
is	B-X
specific	B-X
to	B-X
Chinese	B-X
population	B-X
was	B-X
found	B-X
in	B-X
5	B-X
out	B-X
of	B-X
9	B-X
families	B-X
,	B-X
with	B-X
a	B-X
mutation	B-X
rate	B-X
of	B-X
28	B-X
%	B-X
(	B-X
5	B-X
/	B-X
18	B-X
)	B-X
<EOS>	B-X
Compound	B-X
heterozygotes	B-X
had	B-X
much	B-X
lower	B-X
RT	B-X
<EOS>	B-X
3	B-X
years	B-X
,	B-X
15	B-X
were	B-X
sickle	B-X
cell	B-X
trait	B-X
(	B-X
AS	B-X
)	B-X
consisted	B-X
of	B-X
nine	B-X
males	B-X
and	B-X
six	B-X
females	B-X
aged	B-X
30+	B-X
/	B-X
	B-X
-	B-X
15	B-X

As	O
anticipated	O
,	O
NRXI	O
could	O
be	O
demonstrated	O
in	O
all	O
lymphoid	B-cell_type
cells	I-cell_type
studied	O
from	O
obligate	O
carriers	O
of	O
XSCID	O
and	O
an	O
obligate	O
carrier	O
of	O
XLH	O
but	O
not	O
on	O
a	O
carrier	O
of	O
X-linked	O
immunodeficiency	O
with	O
hyper-IgM	B-protein
.	O

The	O
finding	O
of	O
NRXI	O
in	O
the	O
mother	O
of	O
a	O
boy	O
with	O
a	O
SCID	O
variant	O
showed	O
her	O
to	O
be	O
a	O
carrier	O
of	O
XSCID	O
and	O
establishes	O
that	O
her	O
son	O
has	O
XSCID	O
,	O
not	O
otherwise	O
evident	O
from	O
available	O
data	O
.	O
<EOS>	B-X
The	B-X
finding	B-X
of	B-X
NRXI	B-X
in	B-X
the	B-X
mother	B-X
of	B-X
a	B-X
boy	B-X
with	B-X
a	B-X
SCID	B-X
variant	B-X
showed	B-X
her	B-X
to	B-X
be	B-X
a	B-X
carrier	B-X
of	B-X
XSCID	B-X
and	B-X
establishes	B-X
that	B-X
her	B-X
son	B-X
has	B-X
XSCID	B-X
,	B-X
not	B-X
otherwise	B-X
evident	B-X
from	B-X
available	B-X
data	B-X
<EOS>	B-X
As	B-X
anticipated	B-X
,	B-X
NRXI	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
all	B-X
lymphoid	B-X
cells	B-X
studied	B-X
from	B-X
obligate	B-X
carriers	B-X
of	B-X
XSCID	B-X
and	B-X
an	B-X
obligate	B-X
carrier	B-X
of	B-X
XLH	B-X
but	B-X
not	B-X
on	B-X
a	B-X
carrier	B-X
of	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
with	B-X
hyper	B-X
-	B-X
IgM	B-X
<EOS>	B-X
A	B-X
polymerase	B-X
chain	B-X
reaction	B-X
-	B-X
based	B-X
method	B-X
was	B-X
used	B-X
to	B-X
amplify	B-X
a	B-X
polymorphic	B-X
CAG	B-X
repeat	B-X
in	B-X
the	B-X
first	B-X
exon	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
gene	B-X
after	B-X
selective	B-X
digestion	B-X
of	B-X
the	B-X
active	B-X
X	B-X
chromosome	B-X
with	B-X
a	B-X
methylation	B-X
-	B-X
sensitive	B-X
enzyme	B-X
,	B-X
HpaII	B-X
to	B-X
distinguish	B-X
between	B-X
the	B-X
paternal	B-X
and	B-X
maternal	B-X
alleles	B-X
and	B-X
to	B-X
identify	B-X
their	B-X
methylation	B-X
status	B-X
<EOS>	B-X
This	B-X
PCR	B-X
assay	B-X
provides	B-X
a	B-X
rapid	B-X
method	B-X
for	B-X
carrier	B-X
detection	B-X
of	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiencies	B-X
,	B-X
and	B-X
has	B-X
allowed	B-X
us	B-X
to	B-X
expand	B-X
the	B-X
phenotype	B-X
of	B-X
XSCID	B-X

CONCLUSIONS	O
:	O
This	O
PCR	O
assay	O
provides	O
a	O
rapid	O
method	O
for	O
carrier	O
detection	O
of	O
X-linked	O
immunodeficiencies	O
,	O
and	O
has	O
allowed	O
us	O
to	O
expand	O
the	O
phenotype	O
of	O
XSCID	O
<EOS>	B-X
This	B-X
PCR	B-X
assay	B-X
provides	B-X
a	B-X
rapid	B-X
method	B-X
for	B-X
carrier	B-X
detection	B-X
of	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiencies	B-X
,	B-X
and	B-X
has	B-X
allowed	B-X
us	B-X
to	B-X
expand	B-X
the	B-X
phenotype	B-X
of	B-X
XSCID	B-X
<EOS>	B-X
Carrier	B-X
identification	B-X
in	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
diseases	B-X
.	B-X
<EOS>	B-X
Carrier	B-X
identification	B-X
in	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
disorders	B-X
can	B-X
be	B-X
based	B-X
on	B-X
the	B-X
demonstration	B-X
of	B-X
non	B-X
-	B-X
random	B-X
X	B-X
inactivation	B-X
(	B-X
NRXI	B-X
)	B-X
in	B-X
affected	B-X
blood	B-X
cell	B-X
lineages	B-X
when	B-X
growth	B-X
is	B-X
impaired	B-X
in	B-X
cells	B-X
expressing	B-X
the	B-X
abnormal	B-X
gene	B-X
<EOS>	B-X
A	B-X
polymerase	B-X
chain	B-X
reaction	B-X
-	B-X
based	B-X
method	B-X
was	B-X
used	B-X
to	B-X
amplify	B-X
a	B-X
polymorphic	B-X
CAG	B-X
repeat	B-X
in	B-X
the	B-X
first	B-X
exon	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
gene	B-X
after	B-X
selective	B-X
digestion	B-X
of	B-X
the	B-X
active	B-X
X	B-X
chromosome	B-X
with	B-X
a	B-X
methylation	B-X
-	B-X
sensitive	B-X
enzyme	B-X
,	B-X
HpaII	B-X
to	B-X
distinguish	B-X
between	B-X
the	B-X
paternal	B-X
and	B-X
maternal	B-X
alleles	B-X
and	B-X
to	B-X
identify	B-X
their	B-X
methylation	B-X
status	B-X

Leukocyte-endothelial	O
interaction	O
is	O
augmented	O
by	O
high	O
glucose	O
concentrations	O
and	O
hyperglycemia	O
in	O
a	O
NF-kB-dependent	O
fashion	O
.	O

We	O
addressed	O
the	O
role	O
of	O
hyperglycemia	O
in	O
leukocyte-endothelium	O
interaction	O
under	O
flow	O
conditions	O
by	O
exposing	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
for	O
24	O
h	O
to	O
normal	O
(	O
5	O
mM	O
)	O
,	O
high	O
concentration	O
of	O
glucose	O
(	O
30	O
mM	O
)	O
,	O
advanced	O
glycosylation	O
end	O
product-albumin	B-protein
(	O
100	O
microg/ml	O
)	O
,	O
or	O
hyperglycemic	O
(	O
174-316	O
mg/dl	O
)	O
sera	O
from	O
patients	O
with	O
diabetes	O
and	O
abnormal	O
hemoglobin	O
A1c	O
(	O
8.1+/-1.4	O
%	O
)	O
.	O
<EOS>	B-X
We	B-X
addressed	B-X
the	B-X
role	B-X
of	B-X
hyperglycemia	B-X
in	B-X
leukocyte	B-X
-	B-X
endothelium	B-X
interaction	B-X
under	B-X
flow	B-X
conditions	B-X
by	B-X
exposing	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
for	B-X
24	B-X
h	B-X
to	B-X
normal	B-X
(	B-X
5	B-X
mM	B-X
)	B-X
,	B-X
high	B-X
concentration	B-X
of	B-X
glucose	B-X
(	B-X
30	B-X
mM	B-X
)	B-X
,	B-X
advanced	B-X
glycosylation	B-X
end	B-X
product	B-X
-	B-X
albumin	B-X
(	B-X
100	B-X
microg	B-X
/	B-X
ml	B-X
)	B-X
,	B-X
or	B-X
hyperglycemic	B-X
(	B-X
174	B-X
-	B-X
316	B-X
mg	B-X
/	B-X
dl	B-X
)	B-X
sera	B-X
from	B-X
patients	B-X
with	B-X
diabetes	B-X
and	B-X
abnormal	B-X
hemoglobin	B-X
A1c	B-X
(	B-X
8	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
of	B-X
nuclear	B-X
extracts	B-X
of	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
exposed	B-X
for	B-X
1	B-X
h	B-X
to	B-X
30	B-X
mM	B-X
glucose	B-X
revealed	B-X
an	B-X
intense	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
endothelial	B-X
cells	B-X
with	B-X
the	B-X
corresponding	B-X
mouse	B-X
mAb	B-X
significantly	B-X
inhibited	B-X
glucose	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
67+	B-X
/	B-X
	B-X
-	B-X
16	B-X
,	B-X
83+	B-X
/	B-X
	B-X
-	B-X
12	B-X
,	B-X
62+	B-X
/	B-X
	B-X
-	B-X
8	B-X
versus	B-X
144+	B-X
/	B-X
	B-X
-	B-X
21	B-X
cells	B-X
/	B-X
	B-X
mm2	B-X
)	B-X
<EOS>	B-X
Stable	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
glucose	B-X
-	B-X
treated	B-X
as	B-X
well	B-X
as	B-X
to	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
stimulated	B-X
endothelial	B-X
cells	B-X
was	B-X
preceded	B-X
by	B-X
short	B-X
interaction	B-X
of	B-X
leukocytes	B-X
with	B-X
the	B-X
endothelial	B-X
surface	B-X

At	O
the	O
end	O
of	O
incubation	O
endothelial	B-cell_type
cells	I-cell_type
were	O
perfused	O
with	O
total	O
leukocyte	O
suspension	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1.5	O
dyn/cm2	O
)	O
.	O

Rolling	O
and	O
adherent	B-cell_type
cells	I-cell_type
were	O
evaluated	O
by	O
digital	O
image	O
processing	O
.	O
<EOS>	B-X
Rolling	B-X
and	B-X
adherent	B-X
cells	B-X
were	B-X
evaluated	B-X
by	B-X
digital	B-X
image	B-X
processing	B-X
<EOS>	B-X
The	B-X
number	B-X
of	B-X
rolling	B-X
and	B-X
adhering	B-X
platelets	B-X
reached	B-X
a	B-X
peak	B-X
(	B-X
555	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
65	B-X
/	B-X
mm	B-X
per	B-X
min	B-X
and	B-X
25	B-X
<EOS>	B-X
97	B-X
)	B-X
,	B-X
determining	B-X
both	B-X
as	B-X
suitable	B-X
predictors	B-X
for	B-X
the	B-X
evaluation	B-X
of	B-X
material	B-X
induced	B-X
thrombogenicity	B-X
<EOS>	B-X
Platelet	B-X
-	B-X
endothelial	B-X
interactions	B-X
in	B-X
postischemic	B-X
retina	B-X
were	B-X
evaluated	B-X
in	B-X
vivo	B-X
with	B-X
a	B-X
scanning	B-X
laser	B-X
ophthalmoscope	B-X

Results	O
showed	O
that	O
30	O
mM	O
glucose	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
the	O
number	O
of	O
adherent	B-cell_type
leukocytes	I-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
in	O
respect	O
to	O
control	O
(	O
5	O
mM	O
glucose	O
;	O
151+/-19	O
versus	O
33+/-8	O
cells/mm2	O
)	O
.	O
<EOS>	B-X
01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
endothelial	B-X
cells	B-X
in	B-X
respect	B-X
to	B-X
control	B-X
(	B-X
5	B-X
mM	B-X
glucose	B-X
;	B-X
151+	B-X
/	B-X
	B-X
-	B-X
19	B-X
versus	B-X
33+	B-X
/	B-X
	B-X
-	B-X
8	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X
<EOS>	B-X
Advanced	B-X
glycosylation	B-X
end	B-X
product	B-X
-	B-X
albumin	B-X
significantly	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adhering	B-X
leukocytes	B-X
in	B-X
respect	B-X
to	B-X
native	B-X
albumin	B-X
used	B-X
as	B-X
control	B-X
(	B-X
110+	B-X
/	B-X
	B-X
-	B-X
16	B-X
versus	B-X
66+	B-X
/	B-X
	B-X
-	B-X
7	B-X
,	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
of	B-X
nuclear	B-X
extracts	B-X
of	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
exposed	B-X
for	B-X
1	B-X
h	B-X
to	B-X
30	B-X
mM	B-X
glucose	B-X
revealed	B-X
an	B-X
intense	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
endothelial	B-X
cells	B-X
with	B-X
the	B-X
corresponding	B-X
mouse	B-X
mAb	B-X
significantly	B-X
inhibited	B-X
glucose	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
67+	B-X
/	B-X
	B-X
-	B-X
16	B-X
,	B-X
83+	B-X
/	B-X
	B-X
-	B-X
12	B-X
,	B-X
62+	B-X
/	B-X
	B-X
-	B-X
8	B-X
versus	B-X
144+	B-X
/	B-X
	B-X
-	B-X
21	B-X
cells	B-X
/	B-X
	B-X
mm2	B-X
)	B-X

A	O
similar	O
response	O
was	O
induced	O
by	O
endothelial	O
stimulation	O
with	O
IL-1beta	B-protein
,	O
here	O
used	O
as	O
positive	O
control	O
(	O
195+/-20	O
cells/mm2	O
)	O
.	O
<EOS>	B-X
A	B-X
similar	B-X
response	B-X
was	B-X
induced	B-X
by	B-X
endothelial	B-X
stimulation	B-X
with	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
(	B-X
195+	B-X
/	B-X
	B-X
-	B-X
20	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X
<EOS>	B-X
The	B-X
number	B-X
of	B-X
rolling	B-X
cells	B-X
on	B-X
endothelial	B-X
surface	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
high	B-X
glucose	B-X
level	B-X
<EOS>	B-X
01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
endothelial	B-X
cells	B-X
in	B-X
respect	B-X
to	B-X
control	B-X
(	B-X
5	B-X
mM	B-X
glucose	B-X
;	B-X
151+	B-X
/	B-X
	B-X
-	B-X
19	B-X
versus	B-X
33+	B-X
/	B-X
	B-X
-	B-X
8	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X
<EOS>	B-X
Confocal	B-X
fluorescence	B-X
microscopy	B-X
studies	B-X
showed	B-X
that	B-X
30	B-X
mM	B-X
glucose	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
endothelial	B-X
surface	B-X
expression	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X

The	O
number	O
of	O
rolling	B-cell_type
cells	I-cell_type
on	O
endothelial	O
surface	O
was	O
not	O
affected	O
by	O
high	O
glucose	O
level	O
.	O
<EOS>	B-X
We	B-X
measure	B-X
the	B-X
number	B-X
of	B-X
platelets	B-X
adsorbed	B-X
at	B-X
the	B-X
channel	B-X
surface	B-X
as	B-X
a	B-X
function	B-X
of	B-X
both	B-X
time	B-X
and	B-X
space	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
hyaluronan	B-X
binding	B-X
protein	B-X
CD44	B-X
on	B-X
tumour	B-X
cell	B-X
surfaces	B-X
was	B-X
evaluated	B-X
using	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
a	B-X
distinct	B-X
population	B-X
of	B-X
circulating	B-X
human	B-X
non	B-X
-	B-X
adherent	B-X
endothelial	B-X
forming	B-X
cells	B-X
and	B-X
their	B-X
recruitment	B-X
via	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
3	B-X
.	B-X
<EOS>	B-X
The	B-X
first	B-X
step	B-X
of	B-X
this	B-X
process	B-X
is	B-X
the	B-X
capture	B-X
of	B-X
flowing	B-X
platelets	B-X
by	B-X
adhesive	B-X
molecules	B-X
located	B-X
at	B-X
the	B-X
wounded	B-X
vessel	B-X
wall	B-X

Stable	O
adhesion	O
of	O
leukocytes	B-cell_type
to	O
glucose-treated	O
as	O
well	O
as	O
to	O
IL-1beta-stimulated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
was	O
preceded	O
by	O
short	O
interaction	O
of	O
leukocytes	B-cell_type
with	O
the	O
endothelial	O
surface	O
.	O
<EOS>	B-X
Stable	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
glucose	B-X
-	B-X
treated	B-X
as	B-X
well	B-X
as	B-X
to	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
stimulated	B-X
endothelial	B-X
cells	B-X
was	B-X
preceded	B-X
by	B-X
short	B-X
interaction	B-X
of	B-X
leukocytes	B-X
with	B-X
the	B-X
endothelial	B-X
surface	B-X
<EOS>	B-X
The	B-X
distance	B-X
travelled	B-X
by	B-X
leukocytes	B-X
before	B-X
arrest	B-X
on	B-X
30	B-X
mM	B-X
glucose	B-X
,	B-X
or	B-X
on	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
treated	B-X
endothelial	B-X
cells	B-X
,	B-X
was	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
high	B-X
glucose	B-X
concentration	B-X
and	B-X
hyperglycemia	B-X
promote	B-X
leukocyte	B-X
adhesion	B-X
to	B-X
the	B-X
endothelium	B-X
through	B-X
upregulation	B-X
of	B-X
cell	B-X
surface	B-X
expression	B-X
of	B-X
adhesive	B-X
proteins	B-X
,	B-X
possibly	B-X
depending	B-X
on	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
endothelial	B-X
cells	B-X
with	B-X
the	B-X
corresponding	B-X
mouse	B-X
mAb	B-X
significantly	B-X
inhibited	B-X
glucose	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
67+	B-X
/	B-X
	B-X
-	B-X
16	B-X
,	B-X
83+	B-X
/	B-X
	B-X
-	B-X
12	B-X
,	B-X
62+	B-X
/	B-X
	B-X
-	B-X
8	B-X
versus	B-X
144+	B-X
/	B-X
	B-X
-	B-X
21	B-X
cells	B-X
/	B-X
	B-X
mm2	B-X
)	B-X

The	O
distance	O
travelled	O
by	O
leukocytes	B-cell_type
before	O
arrest	O
on	O
30	O
mM	O
glucose	O
,	O
or	O
on	O
IL-1beta-treated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
,	O
was	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
higher	O
than	O
that	O
observed	O
for	O
leukocytes	B-cell_type
adhering	O
on	O
control	O
endothelium	O
(	O
30	O
mM	O
glucose	O
:	O
76.7+/-3.5	O
;	O
IL1beta	O
:	O
69.7+/-4	O
versus	O
5	O
mM	O
glucose	O
:	O
21.5+/-5	O
microm	O
)	O
.	O
<EOS>	B-X
The	B-X
distance	B-X
travelled	B-X
by	B-X
leukocytes	B-X
before	B-X
arrest	B-X
on	B-X
30	B-X
mM	B-X
glucose	B-X
,	B-X
or	B-X
on	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
treated	B-X
endothelial	B-X
cells	B-X
,	B-X
was	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
Stable	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
glucose	B-X
-	B-X
treated	B-X
as	B-X
well	B-X
as	B-X
to	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
stimulated	B-X
endothelial	B-X
cells	B-X
was	B-X
preceded	B-X
by	B-X
short	B-X
interaction	B-X
of	B-X
leukocytes	B-X
with	B-X
the	B-X
endothelial	B-X
surface	B-X
<EOS>	B-X
01	B-X
)	B-X
higher	B-X
than	B-X
that	B-X
observed	B-X
for	B-X
leukocytes	B-X
adhering	B-X
on	B-X
control	B-X
endothelium	B-X
(	B-X
30	B-X
mM	B-X
glucose	B-X
:	B-X
76	B-X
<EOS>	B-X
01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
endothelial	B-X
cells	B-X
in	B-X
respect	B-X
to	B-X
control	B-X
(	B-X
5	B-X
mM	B-X
glucose	B-X
;	B-X
151+	B-X
/	B-X
	B-X
-	B-X
19	B-X
versus	B-X
33+	B-X
/	B-X
	B-X
-	B-X
8	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X

Functional	O
blocking	O
of	O
E-selectin	B-protein
,	O
intercellular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
on	O
endothelial	B-cell_type
cells	I-cell_type
with	O
the	O
corresponding	O
mouse	B-protein
mAb	I-protein
significantly	O
inhibited	O
glucose-induced	O
increase	O
in	O
leukocyte	O
adhesion	O
(	O
67+/-16	O
,	O
83+/-12	O
,	O
62+/-8	O
versus	O
144+/-21	O
cells/	O
mm2	O
)	O
.	O
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
endothelial	B-X
cells	B-X
with	B-X
the	B-X
corresponding	B-X
mouse	B-X
mAb	B-X
significantly	B-X
inhibited	B-X
glucose	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
67+	B-X
/	B-X
	B-X
-	B-X
16	B-X
,	B-X
83+	B-X
/	B-X
	B-X
-	B-X
12	B-X
,	B-X
62+	B-X
/	B-X
	B-X
-	B-X
8	B-X
versus	B-X
144+	B-X
/	B-X
	B-X
-	B-X
21	B-X
cells	B-X
/	B-X
	B-X
mm2	B-X
)	B-X
<EOS>	B-X
01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
endothelial	B-X
cells	B-X
in	B-X
respect	B-X
to	B-X
control	B-X
(	B-X
5	B-X
mM	B-X
glucose	B-X
;	B-X
151+	B-X
/	B-X
	B-X
-	B-X
19	B-X
versus	B-X
33+	B-X
/	B-X
	B-X
-	B-X
8	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X
<EOS>	B-X
Confocal	B-X
fluorescence	B-X
microscopy	B-X
studies	B-X
showed	B-X
that	B-X
30	B-X
mM	B-X
glucose	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
endothelial	B-X
surface	B-X
expression	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
<EOS>	B-X
Advanced	B-X
glycosylation	B-X
end	B-X
product	B-X
-	B-X
albumin	B-X
significantly	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adhering	B-X
leukocytes	B-X
in	B-X
respect	B-X
to	B-X
native	B-X
albumin	B-X
used	B-X
as	B-X
control	B-X
(	B-X
110+	B-X
/	B-X
	B-X
-	B-X
16	B-X
versus	B-X
66+	B-X
/	B-X
	B-X
-	B-X
7	B-X
,	B-X
P	B-X
<	B-X
0	B-X

Confocal	O
fluorescence	O
microscopy	O
studies	O
showed	O
that	O
30	O
mM	O
glucose	O
induced	O
an	O
increase	O
in	O
endothelial	O
surface	O
expression	O
of	O
E-selectin	B-protein
,	O
intercellular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
.	O
<EOS>	B-X
Confocal	B-X
fluorescence	B-X
microscopy	B-X
studies	B-X
showed	B-X
that	B-X
30	B-X
mM	B-X
glucose	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
endothelial	B-X
surface	B-X
expression	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
endothelial	B-X
cells	B-X
with	B-X
the	B-X
corresponding	B-X
mouse	B-X
mAb	B-X
significantly	B-X
inhibited	B-X
glucose	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
67+	B-X
/	B-X
	B-X
-	B-X
16	B-X
,	B-X
83+	B-X
/	B-X
	B-X
-	B-X
12	B-X
,	B-X
62+	B-X
/	B-X
	B-X
-	B-X
8	B-X
versus	B-X
144+	B-X
/	B-X
	B-X
-	B-X
21	B-X
cells	B-X
/	B-X
	B-X
mm2	B-X
)	B-X
<EOS>	B-X
Stable	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
glucose	B-X
-	B-X
treated	B-X
as	B-X
well	B-X
as	B-X
to	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
stimulated	B-X
endothelial	B-X
cells	B-X
was	B-X
preceded	B-X
by	B-X
short	B-X
interaction	B-X
of	B-X
leukocytes	B-X
with	B-X
the	B-X
endothelial	B-X
surface	B-X
<EOS>	B-X
A	B-X
similar	B-X
response	B-X
was	B-X
induced	B-X
by	B-X
endothelial	B-X
stimulation	B-X
with	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
(	B-X
195+	B-X
/	B-X
	B-X
-	B-X
20	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X

Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
nuclear	O
extracts	O
of	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HUVEC	O
)	O
exposed	O
for	O
1	O
h	O
to	O
30	O
mM	O
glucose	O
revealed	O
an	O
intense	O
NF-kB	B-protein
activation	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
of	B-X
nuclear	B-X
extracts	B-X
of	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
exposed	B-X
for	B-X
1	B-X
h	B-X
to	B-X
30	B-X
mM	B-X
glucose	B-X
revealed	B-X
an	B-X
intense	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
<EOS>	B-X
01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
endothelial	B-X
cells	B-X
in	B-X
respect	B-X
to	B-X
control	B-X
(	B-X
5	B-X
mM	B-X
glucose	B-X
;	B-X
151+	B-X
/	B-X
	B-X
-	B-X
19	B-X
versus	B-X
33+	B-X
/	B-X
	B-X
-	B-X
8	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X
<EOS>	B-X
We	B-X
addressed	B-X
the	B-X
role	B-X
of	B-X
hyperglycemia	B-X
in	B-X
leukocyte	B-X
-	B-X
endothelium	B-X
interaction	B-X
under	B-X
flow	B-X
conditions	B-X
by	B-X
exposing	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
for	B-X
24	B-X
h	B-X
to	B-X
normal	B-X
(	B-X
5	B-X
mM	B-X
)	B-X
,	B-X
high	B-X
concentration	B-X
of	B-X
glucose	B-X
(	B-X
30	B-X
mM	B-X
)	B-X
,	B-X
advanced	B-X
glycosylation	B-X
end	B-X
product	B-X
-	B-X
albumin	B-X
(	B-X
100	B-X
microg	B-X
/	B-X
ml	B-X
)	B-X
,	B-X
or	B-X
hyperglycemic	B-X
(	B-X
174	B-X
-	B-X
316	B-X
mg	B-X
/	B-X
dl	B-X
)	B-X
sera	B-X
from	B-X
patients	B-X
with	B-X
diabetes	B-X
and	B-X
abnormal	B-X
hemoglobin	B-X
A1c	B-X
(	B-X
8	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
high	B-X
glucose	B-X
concentration	B-X
and	B-X
hyperglycemia	B-X
promote	B-X
leukocyte	B-X
adhesion	B-X
to	B-X
the	B-X
endothelium	B-X
through	B-X
upregulation	B-X
of	B-X
cell	B-X
surface	B-X
expression	B-X
of	B-X
adhesive	B-X
proteins	B-X
,	B-X
possibly	B-X
depending	B-X
on	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X

Treatment	O
of	O
HUVEC	O
exposed	O
to	O
high	O
glucose	O
with	O
the	O
NF-kB	B-protein
inhibitors	I-protein
pyrrolidinedithiocarbamate	O
(	O
100	O
microM	O
)	O
and	O
tosyl-phe-chloromethylketone	O
(	O
25	O
microM	O
)	O
significantly	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
HUVEC	O
treated	O
with	O
glucose	O
alone	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
HUVEC	B-X
exposed	B-X
to	B-X
high	B-X
glucose	B-X
with	B-X
the	B-X
NF	B-X
-	B-X
kB	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
100	B-X
microM	B-X
)	B-X
and	B-X
tosyl	B-X
-	B-X
phe	B-X
-	B-X
chloromethylketone	B-X
(	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
reduced	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
05	B-X
)	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
HUVEC	B-X
treated	B-X
with	B-X
glucose	B-X
alone	B-X
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
endothelial	B-X
cells	B-X
with	B-X
the	B-X
corresponding	B-X
mouse	B-X
mAb	B-X
significantly	B-X
inhibited	B-X
glucose	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
67+	B-X
/	B-X
	B-X
-	B-X
16	B-X
,	B-X
83+	B-X
/	B-X
	B-X
-	B-X
12	B-X
,	B-X
62+	B-X
/	B-X
	B-X
-	B-X
8	B-X
versus	B-X
144+	B-X
/	B-X
	B-X
-	B-X
21	B-X
cells	B-X
/	B-X
	B-X
mm2	B-X
)	B-X
<EOS>	B-X
Stable	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
glucose	B-X
-	B-X
treated	B-X
as	B-X
well	B-X
as	B-X
to	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
stimulated	B-X
endothelial	B-X
cells	B-X
was	B-X
preceded	B-X
by	B-X
short	B-X
interaction	B-X
of	B-X
leukocytes	B-X
with	B-X
the	B-X
endothelial	B-X
surface	B-X

A	O
significant	O
(	O
P	O
<	O
0.01	O
)	O
inhibitory	O
effect	O
on	O
glucose-induced	O
leukocyte	O
adhesion	O
was	O
observed	O
after	O
blocking	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
with	O
staurosporine	O
(	O
5	O
nM	O
)	O
.	O
<EOS>	B-X
01	B-X
)	B-X
inhibitory	B-X
effect	B-X
on	B-X
glucose	B-X
-	B-X
induced	B-X
leukocyte	B-X
adhesion	B-X
was	B-X
observed	B-X
after	B-X
blocking	B-X
protein	B-X
kinase	B-X
C	B-X
activity	B-X
with	B-X
staurosporine	B-X
(	B-X
5	B-X
nM	B-X
)	B-X
<EOS>	B-X
01	B-X
)	B-X
higher	B-X
than	B-X
that	B-X
observed	B-X
for	B-X
leukocytes	B-X
adhering	B-X
on	B-X
control	B-X
endothelium	B-X
(	B-X
30	B-X
mM	B-X
glucose	B-X
:	B-X
76	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
high	B-X
glucose	B-X
concentration	B-X
and	B-X
hyperglycemia	B-X
promote	B-X
leukocyte	B-X
adhesion	B-X
to	B-X
the	B-X
endothelium	B-X
through	B-X
upregulation	B-X
of	B-X
cell	B-X
surface	B-X
expression	B-X
of	B-X
adhesive	B-X
proteins	B-X
,	B-X
possibly	B-X
depending	B-X
on	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
<EOS>	B-X
05	B-X
)	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
HUVEC	B-X
treated	B-X
with	B-X
glucose	B-X
alone	B-X

When	O
HUVEC	O
were	O
treated	O
with	O
specific	O
antisense	O
oligodesoxynucleotides	O
against	O
PKCalpha	B-protein
and	I-protein
PKCepsilon	I-protein
isoforms	I-protein
before	O
the	O
addition	O
of	O
30	O
mM	O
glucose	O
,	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
reduction	O
in	O
the	O
adhesion	O
was	O
also	O
seen	O
.	O
<EOS>	B-X
When	B-X
HUVEC	B-X
were	B-X
treated	B-X
with	B-X
specific	B-X
antisense	B-X
oligodesoxynucleotides	B-X
against	B-X
PKCalpha	B-X
and	B-X
PKCepsilon	B-X
isoforms	B-X
before	B-X
the	B-X
addition	B-X
of	B-X
30	B-X
mM	B-X
glucose	B-X
,	B-X
a	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
endothelial	B-X
cells	B-X
in	B-X
respect	B-X
to	B-X
control	B-X
(	B-X
5	B-X
mM	B-X
glucose	B-X
;	B-X
151+	B-X
/	B-X
	B-X
-	B-X
19	B-X
versus	B-X
33+	B-X
/	B-X
	B-X
-	B-X
8	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X
<EOS>	B-X
The	B-X
distance	B-X
travelled	B-X
by	B-X
leukocytes	B-X
before	B-X
arrest	B-X
on	B-X
30	B-X
mM	B-X
glucose	B-X
,	B-X
or	B-X
on	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
treated	B-X
endothelial	B-X
cells	B-X
,	B-X
was	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
We	B-X
addressed	B-X
the	B-X
role	B-X
of	B-X
hyperglycemia	B-X
in	B-X
leukocyte	B-X
-	B-X
endothelium	B-X
interaction	B-X
under	B-X
flow	B-X
conditions	B-X
by	B-X
exposing	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
for	B-X
24	B-X
h	B-X
to	B-X
normal	B-X
(	B-X
5	B-X
mM	B-X
)	B-X
,	B-X
high	B-X
concentration	B-X
of	B-X
glucose	B-X
(	B-X
30	B-X
mM	B-X
)	B-X
,	B-X
advanced	B-X
glycosylation	B-X
end	B-X
product	B-X
-	B-X
albumin	B-X
(	B-X
100	B-X
microg	B-X
/	B-X
ml	B-X
)	B-X
,	B-X
or	B-X
hyperglycemic	B-X
(	B-X
174	B-X
-	B-X
316	B-X
mg	B-X
/	B-X
dl	B-X
)	B-X
sera	B-X
from	B-X
patients	B-X
with	B-X
diabetes	B-X
and	B-X
abnormal	B-X
hemoglobin	B-X
A1c	B-X
(	B-X
8	B-X

Advanced	O
glycosylation	O
end	O
product-albumin	B-protein
significantly	O
increased	O
the	O
number	O
of	O
adhering	B-cell_type
leukocytes	I-cell_type
in	O
respect	O
to	O
native	B-protein
albumin	I-protein
used	O
as	O
control	O
(	O
110+/-16	O
versus	O
66+/-7	O
,	O
P	O
<	O
0.01	O
)	O
.	O
<EOS>	B-X
Advanced	B-X
glycosylation	B-X
end	B-X
product	B-X
-	B-X
albumin	B-X
significantly	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adhering	B-X
leukocytes	B-X
in	B-X
respect	B-X
to	B-X
native	B-X
albumin	B-X
used	B-X
as	B-X
control	B-X
(	B-X
110+	B-X
/	B-X
	B-X
-	B-X
16	B-X
versus	B-X
66+	B-X
/	B-X
	B-X
-	B-X
7	B-X
,	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
endothelial	B-X
cells	B-X
in	B-X
respect	B-X
to	B-X
control	B-X
(	B-X
5	B-X
mM	B-X
glucose	B-X
;	B-X
151+	B-X
/	B-X
	B-X
-	B-X
19	B-X
versus	B-X
33+	B-X
/	B-X
	B-X
-	B-X
8	B-X
cells	B-X
/	B-X
mm2	B-X
)	B-X
<EOS>	B-X
At	B-X
the	B-X
end	B-X
of	B-X
incubation	B-X
endothelial	B-X
cells	B-X
were	B-X
perfused	B-X
with	B-X
total	B-X
leukocyte	B-X
suspension	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1	B-X
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
intercellular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
endothelial	B-X
cells	B-X
with	B-X
the	B-X
corresponding	B-X
mouse	B-X
mAb	B-X
significantly	B-X
inhibited	B-X
glucose	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
67+	B-X
/	B-X
	B-X
-	B-X
16	B-X
,	B-X
83+	B-X
/	B-X
	B-X
-	B-X
12	B-X
,	B-X
62+	B-X
/	B-X
	B-X
-	B-X
8	B-X
versus	B-X
144+	B-X
/	B-X
	B-X
-	B-X
21	B-X
cells	B-X
/	B-X
	B-X
mm2	B-X
)	B-X

Sera	O
from	O
diabetic	O
patients	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
enhanced	O
leukocyte	O
adhesion	O
as	O
compared	O
with	O
controls	O
,	O
despite	O
normal	O
levels	O
of	O
IL-1beta	B-protein
and	O
TNFalpha	B-protein
in	O
these	O
sera	O
.	O
<EOS>	B-X
01	B-X
)	B-X
enhanced	B-X
leukocyte	B-X
adhesion	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
,	B-X
despite	B-X
normal	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
1beta	B-X
and	B-X
TNFalpha	B-X
in	B-X
these	B-X
sera	B-X
<EOS>	B-X
01	B-X
)	B-X
inhibitory	B-X
effect	B-X
on	B-X
glucose	B-X
-	B-X
induced	B-X
leukocyte	B-X
adhesion	B-X
was	B-X
observed	B-X
after	B-X
blocking	B-X
protein	B-X
kinase	B-X
C	B-X
activity	B-X
with	B-X
staurosporine	B-X
(	B-X
5	B-X
nM	B-X
)	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
high	B-X
glucose	B-X
concentration	B-X
and	B-X
hyperglycemia	B-X
promote	B-X
leukocyte	B-X
adhesion	B-X
to	B-X
the	B-X
endothelium	B-X
through	B-X
upregulation	B-X
of	B-X
cell	B-X
surface	B-X
expression	B-X
of	B-X
adhesive	B-X
proteins	B-X
,	B-X
possibly	B-X
depending	B-X
on	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
<EOS>	B-X
Sera	B-X
from	B-X
diabetic	B-X
patients	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0	B-X

These	O
data	O
indicate	O
that	O
high	O
glucose	O
concentration	O
and	O
hyperglycemia	O
promote	O
leukocyte	O
adhesion	O
to	O
the	O
endothelium	O
through	O
upregulation	O
of	O
cell	O
surface	O
expression	O
of	O
adhesive	O
proteins	O
,	O
possibly	O
depending	O
on	O
NF-kB	B-protein
activation	O
.	O

Ikaros	B-protein
in	O
hemopoietic	B-cell_line
lineage	I-cell_line
determination	O
and	O
homeostasis	O
.	O
<EOS>	B-X
Ikaros	B-X
in	B-X
hemopoietic	B-X
lineage	B-X
determination	B-X
and	B-X
homeostasis	B-X
.	B-X
<EOS>	B-X
Studies	B-X
on	B-X
an	B-X
Ikaros	B-X
null	B-X
mutation	B-X
have	B-X
revealed	B-X
an	B-X
essential	B-X
role	B-X
for	B-X
this	B-X
factor	B-X
in	B-X
lymphoid	B-X
cell	B-X
fate	B-X
determination	B-X
and	B-X
at	B-X
subsequent	B-X
branch	B-X
points	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
differentiation	B-X
pathway	B-X
<EOS>	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
role	B-X
of	B-X
Ikaros	B-X
,	B-X
the	B-X
founding	B-X
member	B-X
of	B-X
a	B-X
unique	B-X
family	B-X
of	B-X
zinc	B-X
finger	B-X
transcription	B-X
factors	B-X
in	B-X
this	B-X
developmental	B-X
process	B-X
<EOS>	B-X
Studies	B-X
on	B-X
the	B-X
molecular	B-X
mechanisms	B-X
that	B-X
control	B-X
hemopoietic	B-X
differentiation	B-X
have	B-X
focused	B-X
on	B-X
signaling	B-X
cascades	B-X
and	B-X
nuclear	B-X
effectors	B-X
that	B-X
drive	B-X
this	B-X
complex	B-X
developmental	B-X
system	B-X
in	B-X
a	B-X
regulated	B-X
fashion	B-X

Studies	O
on	O
the	O
molecular	O
mechanisms	O
that	O
control	O
hemopoietic	O
differentiation	O
have	O
focused	O
on	O
signaling	O
cascades	O
and	O
nuclear	O
effectors	O
that	O
drive	O
this	O
complex	O
developmental	O
system	O
in	O
a	O
regulated	O
fashion	O
.	O

Here	O
we	O
review	O
the	O
role	O
of	O
Ikaros	B-protein
,	O
the	O
founding	O
member	O
of	O
a	O
unique	O
family	O
of	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
this	O
developmental	O
process	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
role	B-X
of	B-X
Ikaros	B-X
,	B-X
the	B-X
founding	B-X
member	B-X
of	B-X
a	B-X
unique	B-X
family	B-X
of	B-X
zinc	B-X
finger	B-X
transcription	B-X
factors	B-X
in	B-X
this	B-X
developmental	B-X
process	B-X
<EOS>	B-X
Studies	B-X
on	B-X
the	B-X
molecular	B-X
mechanisms	B-X
that	B-X
control	B-X
hemopoietic	B-X
differentiation	B-X
have	B-X
focused	B-X
on	B-X
signaling	B-X
cascades	B-X
and	B-X
nuclear	B-X
effectors	B-X
that	B-X
drive	B-X
this	B-X
complex	B-X
developmental	B-X
system	B-X
in	B-X
a	B-X
regulated	B-X
fashion	B-X
<EOS>	B-X
Differences	B-X
in	B-X
the	B-X
phenotypes	B-X
of	B-X
a	B-X
null	B-X
and	B-X
a	B-X
dominant	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
Ikaros	B-X
mutation	B-X
provide	B-X
insight	B-X
into	B-X
a	B-X
regulatory	B-X
network	B-X
through	B-X
which	B-X
Ikaros	B-X
proteins	B-X
exert	B-X
their	B-X
effects	B-X
in	B-X
development	B-X
<EOS>	B-X
In	B-X
addition	B-X
a	B-X
comparative	B-X
analysis	B-X
of	B-X
the	B-X
hemopoietic	B-X
stem	B-X
cell	B-X
and	B-X
precursor	B-X
compartment	B-X
resulting	B-X
from	B-X
the	B-X
two	B-X
Ikaros	B-X
mutations	B-X
reveals	B-X
a	B-X
profound	B-X
yet	B-X
not	B-X
absolute	B-X
requirement	B-X
for	B-X
Ikaros	B-X
in	B-X
the	B-X
production	B-X
and	B-X
differentiation	B-X
of	B-X
these	B-X
populations	B-X

Studies	O
on	O
an	O
Ikaros	B-protein
null	O
mutation	O
have	O
revealed	O
an	O
essential	O
role	O
for	O
this	O
factor	O
in	O
lymphoid	B-cell_type
cell	I-cell_type
fate	O
determination	O
and	O
at	O
subsequent	O
branch	O
points	O
of	O
the	O
T	B-cell_type
cell	I-cell_type
differentiation	O
pathway	O
.	O

Differences	O
in	O
the	O
phenotypes	O
of	O
a	O
null	O
and	O
a	O
dominant	O
negative	O
(	O
DN	O
)	O
Ikaros	O
mutation	O
provide	O
insight	O
into	O
a	O
regulatory	O
network	O
through	O
which	O
Ikaros	B-protein
proteins	I-protein
exert	O
their	O
effects	O
in	O
development	O
.	O

In	O
addition	O
a	O
comparative	O
analysis	O
of	O
the	O
hemopoietic	B-cell_type
stem	I-cell_type
cell	I-cell_type
and	O
precursor	O
compartment	O
resulting	O
from	O
the	O
two	O
Ikaros	B-DNA
mutations	I-DNA
reveals	O
a	O
profound	O
yet	O
not	O
absolute	O
requirement	O
for	O
Ikaros	B-protein

Induction	O
of	O
early	B-protein
B	I-protein
cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
and	O
multiple	B-DNA
B	I-DNA
lineage	I-DNA
genes	I-DNA
by	O
the	O
basic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factor	I-protein
E12	B-protein
.	O

The	O
transcription	B-protein
factors	I-protein
encoded	O
by	O
the	O
E2A	B-protein
and	O
early	B-protein
B	I-protein
cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
genes	O
are	O
required	O
for	O
the	O
proper	O
development	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

However	O
,	O
the	O
absence	O
of	O
B	B-cell_type
lineage	I-cell_type
cells	I-cell_type
in	O
E2A-	O
and	O
EBF-deficient	O
mice	O
has	O
made	O
it	O
difficult	O
to	O
determine	O
the	O
function	O
or	O
relationship	O
between	O
these	O
proteins	O
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
measurement	B-X
error	B-X
,	B-X
mediation	B-X
analysis	B-X
can	B-X
infer	B-X
partial	B-X
mediation	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
causal	B-X
relationship	B-X
between	B-X
the	B-X
candidate	B-X
mediator	B-X
and	B-X
the	B-X
target	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
is	B-X
not	B-X
very	B-X
well	B-X
known	B-X
about	B-X
the	B-X
role	B-X
of	B-X
LEA	B-X
proteins	B-X
in	B-X
response	B-X
to	B-X
dehydration	B-X
stress	B-X
in	B-X
P	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
biological	B-X
processes	B-X
other	B-X
than	B-X
the	B-X
tapetum	B-X
development	B-X
controlled	B-X
by	B-X
the	B-X
EMS1	B-X
signal	B-X
are	B-X
not	B-X
clear	B-X
<EOS>	B-X
The	B-X
rate	B-X
of	B-X
escape	B-X
from	B-X
one	B-X
cell	B-X
to	B-X
another	B-X
is	B-X
obtained	B-X
from	B-X
the	B-X
multidimensional	B-X
rate	B-X
theory	B-X
of	B-X
Langer	B-X

We	O
report	O
the	O
identification	O
of	O
a	O
novel	O
model	O
system	O
in	O
which	O
the	O
role	O
of	O
E2A	B-protein
and	O
EBF	B-protein
in	O
the	O
regulation	O
of	O
multiple	O
B	O
lineage	O
traits	O
can	O
be	O
studied	O
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
novel	B-X
model	B-X
system	B-X
in	B-X
which	B-X
the	B-X
role	B-X
of	B-X
E2A	B-X
and	B-X
EBF	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
multiple	B-X
B	B-X
lineage	B-X
traits	B-X
can	B-X
be	B-X
studied	B-X
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
this	B-X
macrophage	B-X
line	B-X
,	B-X
E12	B-X
induces	B-X
expression	B-X
of	B-X
EBF	B-X
and	B-X
together	B-X
these	B-X
transcription	B-X
factors	B-X
coordinately	B-X
regulate	B-X
numerous	B-X
B	B-X
lineage	B-X
-	B-X
associated	B-X
genes	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
the	B-X
E2A	B-X
protein	B-X
E12	B-X
in	B-X
this	B-X
macrophage	B-X
line	B-X
results	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
many	B-X
B	B-X
lineage	B-X
genes	B-X
,	B-X
including	B-X
EBF	B-X
,	B-X
IL7Ralpha	B-X
,	B-X
lambda5	B-X
,	B-X
and	B-X
Rag	B-X
-	B-X
1	B-X
,	B-X
and	B-X
the	B-X
ability	B-X
to	B-X
induce	B-X
kappa	B-X
light	B-X
chain	B-X
in	B-X
response	B-X
to	B-X
mitogen	B-X
<EOS>	B-X
Activation	B-X
of	B-X
EBF	B-X
may	B-X
be	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
functions	B-X
of	B-X
E12	B-X
in	B-X
regulating	B-X
the	B-X
B	B-X
lineage	B-X
phenotype	B-X
since	B-X
expression	B-X
of	B-X
EBF	B-X
alone	B-X
leads	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
E12	B-X
-	B-X
inducible	B-X
traits	B-X

We	O
found	O
that	O
the	O
conversion	O
of	O
70Z/3	B-cell_line
pre-B	I-cell_line
lymphocytes	I-cell_line
to	O
cells	O
with	O
a	O
macrophage-like	O
phenotype	O
is	O
associated	O
with	O
the	O
loss	O
of	O
E2A	B-protein
and	O
EBF	B-protein
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
conversion	B-X
of	B-X
70Z	B-X
/	B-X
3	B-X
pre	B-X
-	B-X
B	B-X
lymphocytes	B-X
to	B-X
cells	B-X
with	B-X
a	B-X
macrophage	B-X
-	B-X
like	B-X
phenotype	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
E2A	B-X
and	B-X
EBF	B-X
<EOS>	B-X
Activation	B-X
of	B-X
EBF	B-X
may	B-X
be	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
functions	B-X
of	B-X
E12	B-X
in	B-X
regulating	B-X
the	B-X
B	B-X
lineage	B-X
phenotype	B-X
since	B-X
expression	B-X
of	B-X
EBF	B-X
alone	B-X
leads	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
E12	B-X
-	B-X
inducible	B-X
traits	B-X
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
this	B-X
macrophage	B-X
line	B-X
,	B-X
E12	B-X
induces	B-X
expression	B-X
of	B-X
EBF	B-X
and	B-X
together	B-X
these	B-X
transcription	B-X
factors	B-X
coordinately	B-X
regulate	B-X
numerous	B-X
B	B-X
lineage	B-X
-	B-X
associated	B-X
genes	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
the	B-X
E2A	B-X
protein	B-X
E12	B-X
in	B-X
this	B-X
macrophage	B-X
line	B-X
results	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
many	B-X
B	B-X
lineage	B-X
genes	B-X
,	B-X
including	B-X
EBF	B-X
,	B-X
IL7Ralpha	B-X
,	B-X
lambda5	B-X
,	B-X
and	B-X
Rag	B-X
-	B-X
1	B-X
,	B-X
and	B-X
the	B-X
ability	B-X
to	B-X
induce	B-X
kappa	B-X
light	B-X
chain	B-X
in	B-X
response	B-X
to	B-X
mitogen	B-X

Moreover	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
the	O
E2A	B-protein
protein	O
E12	B-protein
in	O
this	O
macrophage	B-cell_line
line	I-cell_line
results	O
in	O
the	O
induction	O
of	O
many	B-DNA
B	I-DNA
lineage	I-DNA
genes	I-DNA
,	O
including	O
EBF	B-protein
,	O
IL7Ralpha	B-protein
,	O
lambda5	B-protein
,	O
and	O
Rag-1	O
,	O
and	O
the	O
ability	O
to	O
induce	O
kappa	B-protein
light	I-protein
chain	I-protein
in	O
response	O
to	O
mitogen	O
.	O

Activation	O
of	O
EBF	B-protein
may	O
be	O
one	O
of	O
the	O
critical	O
functions	O
of	O
E12	B-protein
in	O
regulating	O
the	O
B	O
lineage	O
phenotype	O
since	O
expression	O
of	O
EBF	B-protein
alone	O
leads	O
to	O
the	O
activation	O
of	O
a	O
subset	O
of	O
E12	B-protein
-inducible	O
traits	O
.	O

Our	O
data	O
demonstrate	O
that	O
,	O
in	O
the	O
context	O
of	O
this	O
macrophage	B-cell_line
line	I-cell_line
,	O
E12	B-protein
induces	O
expression	O
of	O
EBF	B-protein
and	O
together	O
these	O
transcription	B-protein
factors	I-protein
coordinately	O
regulate	O
numerous	O
B	B-DNA
lineage-associated	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
this	B-X
macrophage	B-X
line	B-X
,	B-X
E12	B-X
induces	B-X
expression	B-X
of	B-X
EBF	B-X
and	B-X
together	B-X
these	B-X
transcription	B-X
factors	B-X
coordinately	B-X
regulate	B-X
numerous	B-X
B	B-X
lineage	B-X
-	B-X
associated	B-X
genes	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
novel	B-X
model	B-X
system	B-X
in	B-X
which	B-X
the	B-X
role	B-X
of	B-X
E2A	B-X
and	B-X
EBF	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
multiple	B-X
B	B-X
lineage	B-X
traits	B-X
can	B-X
be	B-X
studied	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
the	B-X
E2A	B-X
protein	B-X
E12	B-X
in	B-X
this	B-X
macrophage	B-X
line	B-X
results	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
many	B-X
B	B-X
lineage	B-X
genes	B-X
,	B-X
including	B-X
EBF	B-X
,	B-X
IL7Ralpha	B-X
,	B-X
lambda5	B-X
,	B-X
and	B-X
Rag	B-X
-	B-X
1	B-X
,	B-X
and	B-X
the	B-X
ability	B-X
to	B-X
induce	B-X
kappa	B-X
light	B-X
chain	B-X
in	B-X
response	B-X
to	B-X
mitogen	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
encoded	B-X
by	B-X
the	B-X
E2A	B-X
and	B-X
early	B-X
B	B-X
cell	B-X
factor	B-X
(	B-X
EBF	B-X
)	B-X
genes	B-X
are	B-X
required	B-X
for	B-X
the	B-X
proper	B-X
development	B-X
of	B-X
B	B-X
lymphocytes	B-X

Activation-induced	O
down-regulation	O
of	O
retinoid	B-protein
receptor	I-protein
RXRalpha	I-protein
expression	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Role	O
of	O
cell	O
cycle	O
regulation	O
.	O
<EOS>	B-X
Under	B-X
hypoxic	B-X
conditions	B-X
<EOS>	B-X
CENPF	B-X
is	B-X
a	B-X
potential	B-X
oncogene	B-X
and	B-X
prognostic	B-X
marker	B-X
in	B-X
RCC	B-X
<EOS>	B-X
Palmitic	B-X
acid	B-X
impairs	B-X
INS	B-X
-	B-X
1	B-X
cells	B-X
and	B-X
alters	B-X
the	B-X
global	B-X
gene	B-X
expression	B-X
profile	B-X
.	B-X
<EOS>	B-X
β	B-X
-	B-X
Hydroxybutyrate	B-X
alleviates	B-X
cartilage	B-X
senescence	B-X
through	B-X
hnRNP	B-X
A1	B-X
-	B-X
mediated	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
PTEN	B-X
.	B-X

A	O
5.4-kilobase	B-RNA
mRNA	I-RNA
,	O
the	O
expression	O
of	O
which	O
is	O
down-regulated	O
after	O
treatment	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
with	O
various	O
T	O
cell-activating	O
agents	O
,	O
was	O
isolated	O
using	O
an	O
mRNA	O
differential	O
display	O
method	O
.	O
<EOS>	B-X
4	B-X
-	B-X
kilobase	B-X
mRNA	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
which	B-X
is	B-X
down	B-X
-	B-X
regulated	B-X
after	B-X
treatment	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
with	B-X
various	B-X
T	B-X
cell	B-X
-	B-X
activating	B-X
agents	B-X
,	B-X
was	B-X
isolated	B-X
using	B-X
an	B-X
mRNA	B-X
differential	B-X
display	B-X
method	B-X
<EOS>	B-X
6	B-X
kilobases	B-X
of	B-X
this	B-X
RNA	B-X
,	B-X
which	B-X
represents	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
RXRalpha	B-X
mRNA	B-X
,	B-X
the	B-X
sequence	B-X
of	B-X
which	B-X
has	B-X
not	B-X
been	B-X
previously	B-X
described	B-X
<EOS>	B-X
Activation	B-X
-	B-X
induced	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
retinoid	B-X
receptor	B-X
RXRalpha	B-X
expression	B-X
in	B-X
human	B-X
T	B-X
lymphocytes	B-X
.	B-X
Role	B-X
of	B-X
cell	B-X
cycle	B-X
regulation	B-X
.	B-X
<EOS>	B-X
The	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
RXRalpha	B-X
mRNA	B-X
was	B-X
found	B-X
to	B-X
be	B-X
regulated	B-X
at	B-X
the	B-X
post	B-X
-	B-X
transcriptional	B-X
level	B-X
and	B-X
involved	B-X
new	B-X
protein	B-X
synthesis	B-X

Nucleotide	O
sequence	O
analysis	O
identified	O
the	O
5	B-RNA
'	I-RNA
end	I-RNA
of	O
this	O
RNA	B-RNA
as	O
human	B-RNA
retinoid	I-RNA
receptor	I-RNA
RXRalpha	I-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
Nucleotide	B-X
sequence	B-X
analysis	B-X
identified	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
this	B-X
RNA	B-X
as	B-X
human	B-X
retinoid	B-X
receptor	B-X
RXRalpha	B-X
mRNA	B-X
<EOS>	B-X
6	B-X
kilobases	B-X
of	B-X
this	B-X
RNA	B-X
,	B-X
which	B-X
represents	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
RXRalpha	B-X
mRNA	B-X
,	B-X
the	B-X
sequence	B-X
of	B-X
which	B-X
has	B-X
not	B-X
been	B-X
previously	B-X
described	B-X
<EOS>	B-X
Activation	B-X
-	B-X
induced	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
retinoid	B-X
receptor	B-X
RXRalpha	B-X
expression	B-X
in	B-X
human	B-X
T	B-X
lymphocytes	B-X
.	B-X
Role	B-X
of	B-X
cell	B-X
cycle	B-X
regulation	B-X
.	B-X
<EOS>	B-X
These	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
RXRalpha	B-X
expression	B-X
in	B-X
T	B-X
lymphocytes	B-X
are	B-X
coupled	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
there	B-X
is	B-X
tight	B-X
regulatory	B-X
control	B-X
of	B-X
RXRalpha	B-X
expression	B-X
during	B-X
the	B-X
transition	B-X
from	B-X
G0	B-X
/	B-X
G1	B-X
to	B-X
S	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X

Here	O
,	O
we	O
report	O
the	O
nucleotide	O
sequence	O
of	O
3.6	B-DNA
kilobases	I-DNA
of	O
this	O
RNA	O
,	O
which	O
represents	O
the	O
3	B-RNA
'	I-RNA
end	I-RNA
of	O
RXRalpha	B-RNA
mRNA	I-RNA
,	O
the	O
sequence	O
of	O
which	O
has	O
not	O
been	O
previously	O
described	O
.	O

Activated	O
PBMCs	B-cell_type
also	O
expressed	O
lower	O
levels	O
of	O
RXRalpha	B-protein
protein	O
,	O
and	O
a	O
DNA	O
binding	O
assay	O
showed	O
that	O
the	O
activation-induced	O
loss	O
of	O
RXRalpha	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
correlated	O
with	O
the	O
loss	O
of	O
DNA	O
binding	O
activity	O
of	O
this	O
protein	O
.	O

We	O
present	O
evidence	O
that	O
the	O
transition	O
from	O
G0/G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
results	O
in	O
the	O
down-regulation	O
of	O
RXRalpha	B-protein
expression	O
and	O
that	O
cell	O
cycle	O
inhibitors	O
,	O
which	O
block	O
the	O
cells	O
in	O
G1	O
phase	O
,	O
prevent	O
this	O
down-regulation	O
.	O

The	O
decrease	O
in	O
the	O
levels	O
of	O
RXRalpha	B-RNA
mRNA	I-RNA
was	O
found	O
to	O
be	O
regulated	O
at	O
the	O
post-transcriptional	O
level	O
and	O
involved	O
new	O
protein	O
synthesis	O
.	O
<EOS>	B-X
The	B-X
decrease	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
RXRalpha	B-X
mRNA	B-X
was	B-X
found	B-X
to	B-X
be	B-X
regulated	B-X
at	B-X
the	B-X
post	B-X
-	B-X
transcriptional	B-X
level	B-X
and	B-X
involved	B-X
new	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
These	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
RXRalpha	B-X
expression	B-X
in	B-X
T	B-X
lymphocytes	B-X
are	B-X
coupled	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
and	B-X
there	B-X
is	B-X
tight	B-X
regulatory	B-X
control	B-X
of	B-X
RXRalpha	B-X
expression	B-X
during	B-X
the	B-X
transition	B-X
from	B-X
G0	B-X
/	B-X
G1	B-X
to	B-X
S	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
Activated	B-X
PBMCs	B-X
also	B-X
expressed	B-X
lower	B-X
levels	B-X
of	B-X
RXRalpha	B-X
protein	B-X
,	B-X
and	B-X
a	B-X
DNA	B-X
binding	B-X
assay	B-X
showed	B-X
that	B-X
the	B-X
activation	B-X
-	B-X
induced	B-X
loss	B-X
of	B-X
RXRalpha	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
correlated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
this	B-X
protein	B-X
<EOS>	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
transition	B-X
from	B-X
G0	B-X
/	B-X
G1	B-X
to	B-X
S	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
results	B-X
in	B-X
the	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
RXRalpha	B-X
expression	B-X
and	B-X
that	B-X
cell	B-X
cycle	B-X
inhibitors	B-X
,	B-X
which	B-X
block	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
,	B-X
prevent	B-X
this	B-X
down	B-X
-	B-X
regulation	B-X

These	O
observations	O
indicate	O
that	O
the	O
levels	O
of	O
RXRalpha	B-protein
expression	O
in	O
T	O
lymphocytes	O
are	O
coupled	O
to	O
cell	O
cycle	O
progression	O
,	O
and	O
there	O
is	O
tight	O
regulatory	O
control	O
of	O
RXRalpha	B-protein
expression	O
during	O
the	O
transition	O
from	O
G0/G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Epidemiology	O
and	O
pathogenesis	O
of	O
AIDS-related	O
lymphomas	O
.	O
<EOS>	B-X
Clinical	B-X
and	B-X
Therapeutic	B-X
Implications	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
Virus	B-X
in	B-X
HIV	B-X
-	B-X
Related	B-X
Lymphomas	B-X
.	B-X
<EOS>	B-X
[	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
and	B-X
lymphoma	B-X
]	B-X
.	B-X
<EOS>	B-X
1	B-X
%	B-X
)	B-X
,	B-X
and	B-X
diffuse	B-X
large	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
(	B-X
0	B-X
<EOS>	B-X
This	B-X
review	B-X
summarizes	B-X
epidemiology	B-X
,	B-X
pathogenesis	B-X
,	B-X
pathology	B-X
,	B-X
and	B-X
current	B-X
treatment	B-X
landscape	B-X
in	B-X
HIV	B-X
associated	B-X
lymphoma	B-X

Among	O
patients	O
with	O
congenital	O
and	O
acquired	O
immunodeficiencies	O
,	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHLs	O
)	O
are	O
the	O
most	O
common	O
tumors	O
of	O
the	O
immune	O
system	O
.	O
<EOS>	B-X
Among	B-X
patients	B-X
with	B-X
congenital	B-X
and	B-X
acquired	B-X
immunodeficiencies	B-X
,	B-X
non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHLs	B-X
)	B-X
are	B-X
the	B-X
most	B-X
common	B-X
tumors	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
<EOS>	B-X
In	B-X
the	B-X
setting	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
infection	B-X
,	B-X
as	B-X
many	B-X
as	B-X
10	B-X
%	B-X
to	B-X
20	B-X
%	B-X
of	B-X
people	B-X
ultimately	B-X
developed	B-X
NHLs	B-X
<EOS>	B-X
Important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HIV	B-X
-	B-X
associated	B-X
NHL	B-X
are	B-X
cytokines	B-X
and	B-X
other	B-X
factors	B-X
that	B-X
induce	B-X
B	B-X
-	B-X
cell	B-X
proliferation	B-X
and	B-X
increase	B-X
the	B-X
likelihood	B-X
of	B-X
mutations	B-X
of	B-X
c	B-X
-	B-X
myc	B-X
,	B-X
bcl	B-X
-	B-X
6	B-X
,	B-X
and	B-X
other	B-X
tumor	B-X
-	B-X
suppressor	B-X
genes	B-X
with	B-X
carcinogenic	B-X
potential	B-X
<EOS>	B-X
Elucidation	B-X
of	B-X
the	B-X
factors	B-X
that	B-X
contribute	B-X
to	B-X
the	B-X
high	B-X
incidence	B-X
of	B-X
NHL	B-X
among	B-X
patients	B-X
infected	B-X
with	B-X
HIV	B-X
provides	B-X
insights	B-X
into	B-X
important	B-X
elements	B-X
of	B-X
lymphomagenesis	B-X

In	O
the	O
setting	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
,	O
as	O
many	O
as	O
10	O
%	O
to	O
20	O
%	O
of	O
people	O
ultimately	O
developed	O
NHLs	O
.	O

These	O
tumors	O
are	O
clinically	O
aggressive	O
,	O
frequently	O
involve	O
extranodal	O
sites	O
,	O
and	O
often	O
exhibit	O
unique	O
features	O
that	O
distinguish	O
them	O
from	O
NHL	O
arising	O
in	O
individuals	O
with	O
other	O
forms	O
of	O
immunosuppression	O
.	O
<EOS>	B-X
These	B-X
tumors	B-X
are	B-X
clinically	B-X
aggressive	B-X
,	B-X
frequently	B-X
involve	B-X
extranodal	B-X
sites	B-X
,	B-X
and	B-X
often	B-X
exhibit	B-X
unique	B-X
features	B-X
that	B-X
distinguish	B-X
them	B-X
from	B-X
NHL	B-X
arising	B-X
in	B-X
individuals	B-X
with	B-X
other	B-X
forms	B-X
of	B-X
immunosuppression	B-X
<EOS>	B-X
Elucidation	B-X
of	B-X
the	B-X
factors	B-X
that	B-X
contribute	B-X
to	B-X
the	B-X
high	B-X
incidence	B-X
of	B-X
NHL	B-X
among	B-X
patients	B-X
infected	B-X
with	B-X
HIV	B-X
provides	B-X
insights	B-X
into	B-X
important	B-X
elements	B-X
of	B-X
lymphomagenesis	B-X
<EOS>	B-X
Among	B-X
patients	B-X
with	B-X
congenital	B-X
and	B-X
acquired	B-X
immunodeficiencies	B-X
,	B-X
non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHLs	B-X
)	B-X
are	B-X
the	B-X
most	B-X
common	B-X
tumors	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
<EOS>	B-X
In	B-X
the	B-X
setting	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
infection	B-X
,	B-X
as	B-X
many	B-X
as	B-X
10	B-X
%	B-X
to	B-X
20	B-X
%	B-X
of	B-X
people	B-X
ultimately	B-X
developed	B-X
NHLs	B-X

Important	O
in	O
the	O
development	O
of	O
HIV-associated	O
NHL	O
are	O
cytokines	B-protein
and	O
other	O
factors	O
that	O
induce	O
B-cell	O
proliferation	O
and	O
increase	O
the	O
likelihood	O
of	O
mutations	O
of	O
c-myc	B-DNA
,	O
bcl-6	B-DNA
,	O
and	O
other	O
tumor-suppressor	B-DNA
genes	I-DNA
with	O
carcinogenic	O
potential	O
.	O
<EOS>	B-X
Important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HIV	B-X
-	B-X
associated	B-X
NHL	B-X
are	B-X
cytokines	B-X
and	B-X
other	B-X
factors	B-X
that	B-X
induce	B-X
B	B-X
-	B-X
cell	B-X
proliferation	B-X
and	B-X
increase	B-X
the	B-X
likelihood	B-X
of	B-X
mutations	B-X
of	B-X
c	B-X
-	B-X
myc	B-X
,	B-X
bcl	B-X
-	B-X
6	B-X
,	B-X
and	B-X
other	B-X
tumor	B-X
-	B-X
suppressor	B-X
genes	B-X
with	B-X
carcinogenic	B-X
potential	B-X
<EOS>	B-X
Specific	B-X
forms	B-X
of	B-X
HIV	B-X
-	B-X
associated	B-X
NHL	B-X
are	B-X
linked	B-X
to	B-X
expression	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
	B-X
-	B-X
latent	B-X
proteins	B-X
;	B-X
the	B-X
newly	B-X
described	B-X
DNA	B-X
virus	B-X
,	B-X
Karposi	B-X
's	B-X
sarcoma	B-X
-	B-X
associated	B-X
herpesvirus	B-X
/	B-X
human	B-X
herpesvirus	B-X
-	B-X
8	B-X
(	B-X
KSHV	B-X
/	B-X
HHV	B-X
-	B-X
8	B-X
)	B-X
;	B-X
and	B-X
perhaps	B-X
HIV	B-X
<EOS>	B-X
Elucidation	B-X
of	B-X
the	B-X
factors	B-X
that	B-X
contribute	B-X
to	B-X
the	B-X
high	B-X
incidence	B-X
of	B-X
NHL	B-X
among	B-X
patients	B-X
infected	B-X
with	B-X
HIV	B-X
provides	B-X
insights	B-X
into	B-X
important	B-X
elements	B-X
of	B-X
lymphomagenesis	B-X
<EOS>	B-X
Among	B-X
patients	B-X
with	B-X
congenital	B-X
and	B-X
acquired	B-X
immunodeficiencies	B-X
,	B-X
non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHLs	B-X
)	B-X
are	B-X
the	B-X
most	B-X
common	B-X
tumors	B-X
of	B-X
the	B-X
immune	B-X
system	B-X

Specific	O
forms	O
of	O
HIV-associated	O
NHL	O
are	O
linked	O
to	O
expression	O
of	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
-latent	I-protein
proteins	I-protein
;	O
the	O
newly	O
described	O
DNA	O
virus	O
,	O
Karposi	O
's	O
sarcoma-associated	O
herpesvirus/human	O
herpesvirus-8	O
(	O
KSHV/HHV-8	O
)	O
;	O
and	O
perhaps	O
HIV	O
.	O
<EOS>	B-X
Specific	B-X
forms	B-X
of	B-X
HIV	B-X
-	B-X
associated	B-X
NHL	B-X
are	B-X
linked	B-X
to	B-X
expression	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
	B-X
-	B-X
latent	B-X
proteins	B-X
;	B-X
the	B-X
newly	B-X
described	B-X
DNA	B-X
virus	B-X
,	B-X
Karposi	B-X
's	B-X
sarcoma	B-X
-	B-X
associated	B-X
herpesvirus	B-X
/	B-X
human	B-X
herpesvirus	B-X
-	B-X
8	B-X
(	B-X
KSHV	B-X
/	B-X
HHV	B-X
-	B-X
8	B-X
)	B-X
;	B-X
and	B-X
perhaps	B-X
HIV	B-X
<EOS>	B-X
Elucidation	B-X
of	B-X
the	B-X
factors	B-X
that	B-X
contribute	B-X
to	B-X
the	B-X
high	B-X
incidence	B-X
of	B-X
NHL	B-X
among	B-X
patients	B-X
infected	B-X
with	B-X
HIV	B-X
provides	B-X
insights	B-X
into	B-X
important	B-X
elements	B-X
of	B-X
lymphomagenesis	B-X
<EOS>	B-X
Important	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HIV	B-X
-	B-X
associated	B-X
NHL	B-X
are	B-X
cytokines	B-X
and	B-X
other	B-X
factors	B-X
that	B-X
induce	B-X
B	B-X
-	B-X
cell	B-X
proliferation	B-X
and	B-X
increase	B-X
the	B-X
likelihood	B-X
of	B-X
mutations	B-X
of	B-X
c	B-X
-	B-X
myc	B-X
,	B-X
bcl	B-X
-	B-X
6	B-X
,	B-X
and	B-X
other	B-X
tumor	B-X
-	B-X
suppressor	B-X
genes	B-X
with	B-X
carcinogenic	B-X
potential	B-X
<EOS>	B-X
These	B-X
tumors	B-X
are	B-X
clinically	B-X
aggressive	B-X
,	B-X
frequently	B-X
involve	B-X
extranodal	B-X
sites	B-X
,	B-X
and	B-X
often	B-X
exhibit	B-X
unique	B-X
features	B-X
that	B-X
distinguish	B-X
them	B-X
from	B-X
NHL	B-X
arising	B-X
in	B-X
individuals	B-X
with	B-X
other	B-X
forms	B-X
of	B-X
immunosuppression	B-X

Elucidation	O
of	O
the	O
factors	O
that	O
contribute	O
to	O
the	O
high	O
incidence	O
of	O
NHL	O
among	O
patients	O
infected	O
with	O
HIV	O
provides	O
insights	O
into	O
important	O
elements	O
of	O
lymphomagenesis	O
.	O

Matrix	B-protein
metalloproteinase	I-protein
expression	O
in	O
human	O
breast	O
cancer	O
:	O
an	O
immunohistochemical	O
study	O
including	O
correlation	O
with	O
cathepsin	B-protein
D	I-protein
,	O
type	B-protein
IV	I-protein
collagen	I-protein
,	O
laminin	B-protein
,	O
fibronectin	B-protein
,	O
EGFR	B-protein
,	O
c-erbB-2	B-protein
oncoprotein	I-protein
,	O
p53	B-protein
,	O
steroid	O
receptors	O
status	O
and	O
proliferative	O
indices	O
.	O
<EOS>	B-X
Matrix	B-X
metalloproteinase	B-X
expression	B-X
in	B-X
human	B-X
breast	B-X
cancer	B-X
:	B-X
an	B-X
immunohistochemical	B-X
study	B-X
including	B-X
correlation	B-X
with	B-X
cathepsin	B-X
D	B-X
,	B-X
type	B-X
IV	B-X
collagen	B-X
,	B-X
laminin	B-X
,	B-X
fibronectin	B-X
,	B-X
EGFR	B-X
,	B-X
c	B-X
-	B-X
erbB	B-X
-	B-X
2	B-X
oncoprotein	B-X
,	B-X
p53	B-X
,	B-X
steroid	B-X
receptors	B-X
status	B-X
and	B-X
proliferative	B-X
indices	B-X
.	B-X
<EOS>	B-X
The	B-X
current	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
matrix	B-X
metalloproteinase	B-X
3	B-X
(	B-X
MMP	B-X
-	B-X
3	B-X
,	B-X
stromelysin	B-X
-	B-X
1	B-X
)	B-X
in	B-X
correlation	B-X
with	B-X
the	B-X
expression	B-X
of	B-X
Basement	B-X
Membrane	B-X
(	B-X
BM	B-X
)	B-X
antigen	B-X
(	B-X
type	B-X
IV	B-X
collagen	B-X
,	B-X
laminin	B-X
)	B-X
,	B-X
fibronectin	B-X
,	B-X
cathepsin	B-X
D	B-X
,	B-X
p53	B-X
,	B-X
c	B-X
-	B-X
erbB	B-X
-	B-X
2	B-X
,	B-X
proliferative	B-X
activity	B-X
(	B-X
Ki	B-X
-	B-X
67	B-X
,	B-X
PCNA	B-X
)	B-X
,	B-X
steroid	B-X
receptor	B-X
content	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
other	B-X
conventional	B-X
clinicopathological	B-X
parameters	B-X
in	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Matrix	B-X
metalloproteinases	B-X
(	B-X
MMPs	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
enzymes	B-X
thought	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
both	B-X
normal	B-X
connective	B-X
tissue	B-X
matrix	B-X
remodelling	B-X
and	B-X
accelerated	B-X
breakdown	B-X
associated	B-X
with	B-X
tumour	B-X
development	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
ST1	B-X
expression	B-X
in	B-X
breast	B-X
cancer	B-X
tissue	B-X
is	B-X
irrespective	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
component	B-X
,	B-X
the	B-X
proteolytic	B-X
enzyme	B-X
cathepsin	B-X
D	B-X
and	B-X
the	B-X
growth	B-X
fraction	B-X
of	B-X
the	B-X
tumour	B-X
,	B-X
and	B-X
that	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
new	B-X
prognostic	B-X
marker	B-X
in	B-X
breast	B-X
cancer	B-X

Matrix	B-protein
metalloproteinase	I-protein
s	O
(	O
MMPs	B-protein
)	O
are	O
a	O
group	O
of	O
enzymes	O
thought	O
to	O
be	O
responsible	O
for	O
both	O
normal	O
connective	O
tissue	O
matrix	O
remodelling	O
and	O
accelerated	O
breakdown	O
associated	O
with	O
tumour	O
development	O
.	O

The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
immunohistochemical	O
expression	O
of	O
matrix	B-protein
metalloproteinase	I-protein
3	I-protein
(	O
MMP-3	B-protein
,	O
stromelysin-1	B-protein
)	O
in	O
correlation	O
with	O
the	O
expression	O
of	O
Basement	B-protein
Membrane	I-protein
(	I-protein
BM	I-protein
)	I-protein
antigen	I-protein
(	O
type	B-protein
IV	I-protein
collagen	I-protein
,	O
laminin	B-protein
)	O
,	O
fibronectin	B-protein
,	O
cathepsin	B-protein
D	I-protein
,	O
p53	B-protein
,	O
c-erbB-2	B-protein
,	O
proliferative	O
activity	O
(	O
Ki-67	B-protein
,	O
PCNA	B-protein
)	O
,	O
steroid	O
receptor	O
content	O
as	O
well	O
as	O
to	O
the	O
other	O
conventional	O
clinicopathological	O
parameters	O
in	O
breast	O
cancer	O
.	O

This	O
study	O
was	O
performed	O
on	O
a	O
series	O
of	O
frozen	O
and	O
paraffin	O
sections	O
from	O
84	O
breast	O
cancer	O
specimens	O
by	O
immunohistochemistry	O
using	O
the	O
monoclonal	B-protein
antibody	I-protein
MMP-3	I-protein
(	O
Ab-1	B-protein
)	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
a	B-X
series	B-X
of	B-X
frozen	B-X
and	B-X
paraffin	B-X
sections	B-X
from	B-X
84	B-X
breast	B-X
cancer	B-X
specimens	B-X
by	B-X
immunohistochemistry	B-X
using	B-X
the	B-X
monoclonal	B-X
antibody	B-X
MMP	B-X
-	B-X
3	B-X
(	B-X
Ab	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
ST1	B-X
in	B-X
carcinoma	B-X
cells	B-X
was	B-X
strongly	B-X
associated	B-X
with	B-X
its	B-X
presence	B-X
in	B-X
the	B-X
stroma	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
ST1	B-X
expression	B-X
in	B-X
breast	B-X
cancer	B-X
tissue	B-X
is	B-X
irrespective	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
component	B-X
,	B-X
the	B-X
proteolytic	B-X
enzyme	B-X
cathepsin	B-X
D	B-X
and	B-X
the	B-X
growth	B-X
fraction	B-X
of	B-X
the	B-X
tumour	B-X
,	B-X
and	B-X
that	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
new	B-X
prognostic	B-X
marker	B-X
in	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Stromelysin	B-X
-	B-X
1	B-X
(	B-X
ST1	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
about	B-X
10	B-X
%	B-X
of	B-X
epithelial	B-X
cells	B-X
in	B-X
the	B-X
control	B-X
groups	B-X
(	B-X
cases	B-X
of	B-X
fibrocystic	B-X
and	B-X
benign	B-X
proliferative	B-X
breast	B-X
disease	B-X
)	B-X
,	B-X
while	B-X
expression	B-X
(	B-X
>	B-X
10	B-X
%	B-X
of	B-X
expression	B-X
)	B-X
was	B-X
detected	B-X
in	B-X
89	B-X

Stromelysin-1	B-protein
(	O
ST1	B-protein
)	O
was	O
observed	O
in	O
about	O
10	O
%	O
of	O
epithelial	B-cell_type
cells	I-cell_type
in	O
the	O
control	O
groups	O
(	O
cases	O
of	O
fibrocystic	O
and	O
benign	O
proliferative	O
breast	O
disease	O
)	O
,	O
while	O
expression	O
(	O
>	O
10	O
%	O
of	O
expression	O
)	O
was	O
detected	O
in	O
89.7	O
%	O
of	O
tumours	O
.	O
<EOS>	B-X
Stromelysin	B-X
-	B-X
1	B-X
(	B-X
ST1	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
about	B-X
10	B-X
%	B-X
of	B-X
epithelial	B-X
cells	B-X
in	B-X
the	B-X
control	B-X
groups	B-X
(	B-X
cases	B-X
of	B-X
fibrocystic	B-X
and	B-X
benign	B-X
proliferative	B-X
breast	B-X
disease	B-X
)	B-X
,	B-X
while	B-X
expression	B-X
(	B-X
>	B-X
10	B-X
%	B-X
of	B-X
expression	B-X
)	B-X
was	B-X
detected	B-X
in	B-X
89	B-X
<EOS>	B-X
This	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
a	B-X
series	B-X
of	B-X
frozen	B-X
and	B-X
paraffin	B-X
sections	B-X
from	B-X
84	B-X
breast	B-X
cancer	B-X
specimens	B-X
by	B-X
immunohistochemistry	B-X
using	B-X
the	B-X
monoclonal	B-X
antibody	B-X
MMP	B-X
-	B-X
3	B-X
(	B-X
Ab	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
The	B-X
current	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
matrix	B-X
metalloproteinase	B-X
3	B-X
(	B-X
MMP	B-X
-	B-X
3	B-X
,	B-X
stromelysin	B-X
-	B-X
1	B-X
)	B-X
in	B-X
correlation	B-X
with	B-X
the	B-X
expression	B-X
of	B-X
Basement	B-X
Membrane	B-X
(	B-X
BM	B-X
)	B-X
antigen	B-X
(	B-X
type	B-X
IV	B-X
collagen	B-X
,	B-X
laminin	B-X
)	B-X
,	B-X
fibronectin	B-X
,	B-X
cathepsin	B-X
D	B-X
,	B-X
p53	B-X
,	B-X
c	B-X
-	B-X
erbB	B-X
-	B-X
2	B-X
,	B-X
proliferative	B-X
activity	B-X
(	B-X
Ki	B-X
-	B-X
67	B-X
,	B-X
PCNA	B-X
)	B-X
,	B-X
steroid	B-X
receptor	B-X
content	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
other	B-X
conventional	B-X
clinicopathological	B-X
parameters	B-X
in	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Matrix	B-X
metalloproteinases	B-X
(	B-X
MMPs	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
enzymes	B-X
thought	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
both	B-X
normal	B-X
connective	B-X
tissue	B-X
matrix	B-X
remodelling	B-X
and	B-X
accelerated	B-X
breakdown	B-X
associated	B-X
with	B-X
tumour	B-X
development	B-X

The	O
expression	O
of	O
ST1	B-protein
in	O
carcinoma	O
cells	O
was	O
strongly	O
associated	O
with	O
its	O
presence	O
in	O
the	O
stroma	O
(	O
p	O
<	O
0.001	O
)	O
.	O
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
ST1	B-X
in	B-X
carcinoma	B-X
cells	B-X
was	B-X
strongly	B-X
associated	B-X
with	B-X
its	B-X
presence	B-X
in	B-X
the	B-X
stroma	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
This	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
a	B-X
series	B-X
of	B-X
frozen	B-X
and	B-X
paraffin	B-X
sections	B-X
from	B-X
84	B-X
breast	B-X
cancer	B-X
specimens	B-X
by	B-X
immunohistochemistry	B-X
using	B-X
the	B-X
monoclonal	B-X
antibody	B-X
MMP	B-X
-	B-X
3	B-X
(	B-X
Ab	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
Stromelysin	B-X
-	B-X
1	B-X
(	B-X
ST1	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
about	B-X
10	B-X
%	B-X
of	B-X
epithelial	B-X
cells	B-X
in	B-X
the	B-X
control	B-X
groups	B-X
(	B-X
cases	B-X
of	B-X
fibrocystic	B-X
and	B-X
benign	B-X
proliferative	B-X
breast	B-X
disease	B-X
)	B-X
,	B-X
while	B-X
expression	B-X
(	B-X
>	B-X
10	B-X
%	B-X
of	B-X
expression	B-X
)	B-X
was	B-X
detected	B-X
in	B-X
89	B-X
<EOS>	B-X
Matrix	B-X
metalloproteinase	B-X
expression	B-X
in	B-X
human	B-X
breast	B-X
cancer	B-X
:	B-X
an	B-X
immunohistochemical	B-X
study	B-X
including	B-X
correlation	B-X
with	B-X
cathepsin	B-X
D	B-X
,	B-X
type	B-X
IV	B-X
collagen	B-X
,	B-X
laminin	B-X
,	B-X
fibronectin	B-X
,	B-X
EGFR	B-X
,	B-X
c	B-X
-	B-X
erbB	B-X
-	B-X
2	B-X
oncoprotein	B-X
,	B-X
p53	B-X
,	B-X
steroid	B-X
receptors	B-X
status	B-X
and	B-X
proliferative	B-X
indices	B-X
.	B-X

A	O
significantly	O
positive	O
correlation	O
was	O
found	O
between	O
ST1	B-protein
expression	O
,	O
and	O
p53	B-protein
tumour	O
suppressor	O
gene	O
product	O
(	O
p	O
=	O
0.004	O
)	O
,	O
and	O
a	O
relationship	O
with	O
c-erbB-2	B-protein
protein	O
and	O
progesterone	O
receptor	O
status	O
was	O
also	O
indicated	O
.	O

These	O
findings	O
suggest	O
that	O
ST1	B-protein
expression	O
in	O
breast	O
cancer	O
tissue	O
is	O
irrespective	O
of	O
the	O
expression	O
of	O
the	O
extracellular	O
matrix	O
component	O
,	O
the	O
proteolytic	B-protein
enzyme	I-protein
cathepsin	B-protein
D	I-protein
and	O
the	O
growth	O
fraction	O
of	O
the	O
tumour	O
,	O
and	O
that	O
it	O
could	O
be	O
a	O
potential	O
new	O
prognostic	O
marker	O
in	O
breast	O
cancer	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
ST1	B-X
expression	B-X
in	B-X
breast	B-X
cancer	B-X
tissue	B-X
is	B-X
irrespective	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
component	B-X
,	B-X
the	B-X
proteolytic	B-X
enzyme	B-X
cathepsin	B-X
D	B-X
and	B-X
the	B-X
growth	B-X
fraction	B-X
of	B-X
the	B-X
tumour	B-X
,	B-X
and	B-X
that	B-X
it	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
new	B-X
prognostic	B-X
marker	B-X
in	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
The	B-X
current	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
matrix	B-X
metalloproteinase	B-X
3	B-X
(	B-X
MMP	B-X
-	B-X
3	B-X
,	B-X
stromelysin	B-X
-	B-X
1	B-X
)	B-X
in	B-X
correlation	B-X
with	B-X
the	B-X
expression	B-X
of	B-X
Basement	B-X
Membrane	B-X
(	B-X
BM	B-X
)	B-X
antigen	B-X
(	B-X
type	B-X
IV	B-X
collagen	B-X
,	B-X
laminin	B-X
)	B-X
,	B-X
fibronectin	B-X
,	B-X
cathepsin	B-X
D	B-X
,	B-X
p53	B-X
,	B-X
c	B-X
-	B-X
erbB	B-X
-	B-X
2	B-X
,	B-X
proliferative	B-X
activity	B-X
(	B-X
Ki	B-X
-	B-X
67	B-X
,	B-X
PCNA	B-X
)	B-X
,	B-X
steroid	B-X
receptor	B-X
content	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
other	B-X
conventional	B-X
clinicopathological	B-X
parameters	B-X
in	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Matrix	B-X
metalloproteinase	B-X
expression	B-X
in	B-X
human	B-X
breast	B-X
cancer	B-X
:	B-X
an	B-X
immunohistochemical	B-X
study	B-X
including	B-X
correlation	B-X
with	B-X
cathepsin	B-X
D	B-X
,	B-X
type	B-X
IV	B-X
collagen	B-X
,	B-X
laminin	B-X
,	B-X
fibronectin	B-X
,	B-X
EGFR	B-X
,	B-X
c	B-X
-	B-X
erbB	B-X
-	B-X
2	B-X
oncoprotein	B-X
,	B-X
p53	B-X
,	B-X
steroid	B-X
receptors	B-X
status	B-X
and	B-X
proliferative	B-X
indices	B-X
.	B-X
<EOS>	B-X
This	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
a	B-X
series	B-X
of	B-X
frozen	B-X
and	B-X
paraffin	B-X
sections	B-X
from	B-X
84	B-X
breast	B-X
cancer	B-X
specimens	B-X
by	B-X
immunohistochemistry	B-X
using	B-X
the	B-X
monoclonal	B-X
antibody	B-X
MMP	B-X
-	B-X
3	B-X
(	B-X
Ab	B-X
-	B-X
1	B-X
)	B-X

Use	O
of	O
transfected	B-cell_line
liver	I-cell_line
cells	I-cell_line
to	O
evaluate	O
potential	O
mechanisms	O
of	O
alcohol-induced	O
liver	O
injury	O
[	O
see	O
comments	O
]	O
<EOS>	B-X
Use	B-X
of	B-X
transfected	B-X
liver	B-X
cells	B-X
to	B-X
evaluate	B-X
potential	B-X
mechanisms	B-X
of	B-X
alcohol	B-X
-	B-X
induced	B-X
liver	B-X
injury	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
transfected	B-X
liver	B-X
cell	B-X
lines	B-X
can	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
mechanisms	B-X
for	B-X
increased	B-X
injurious	B-X
factors	B-X
and	B-X
decreased	B-X
protective	B-X
factors	B-X
in	B-X
alcoholic	B-X
liver	B-X
injury	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
Kupffer	B-X
cell	B-X
-	B-X
targeted	B-X
approaches	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
therapeutic	B-X
strategy	B-X
against	B-X
many	B-X
inflammatory	B-X
diseases	B-X
including	B-X
early	B-X
alcohol	B-X
-	B-X
induced	B-X
liver	B-X
injury	B-X
<EOS>	B-X
This	B-X
system	B-X
may	B-X
be	B-X
useful	B-X
to	B-X
assess	B-X
the	B-X
effects	B-X
of	B-X
ethanol	B-X
on	B-X
TNF	B-X
-	B-X
induced	B-X
hepatocyte	B-X
IL	B-X
-	B-X
8	B-X
production	B-X

There	O
is	O
increased	O
activity	O
of	O
the	O
proinflammatory	B-protein
cytokine	I-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
in	O
alcoholic	O
liver	O
disease	O
(	O
ALD	O
)	O
.	O
<EOS>	B-X
There	B-X
is	B-X
increased	B-X
activity	B-X
of	B-X
the	B-X
proinflammatory	B-X
cytokine	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
in	B-X
alcoholic	B-X
liver	B-X
disease	B-X
(	B-X
ALD	B-X
)	B-X
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
inhibits	B-X
hepatic	B-X
macrophage	B-X
(	B-X
HM	B-X
)	B-X
cytokine	B-X
expression	B-X
,	B-X
and	B-X
retinoids	B-X
are	B-X
depleted	B-X
in	B-X
alcoholic	B-X
liver	B-X
disease	B-X
(	B-X
ALD	B-X
)	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
serum	B-X
levels	B-X
of	B-X
the	B-X
proinflammatory	B-X
cytokines	B-X
TNF	B-X
-	B-X
alpha	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
may	B-X
serve	B-X
as	B-X
predictive	B-X
biomarkers	B-X
for	B-X
progression	B-X
of	B-X
ALD	B-X
<EOS>	B-X
It	B-X
is	B-X
generally	B-X
accepted	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
and	B-X
increased	B-X
release	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
other	B-X
mediators	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
alcoholic	B-X
liver	B-X
disease	B-X
(	B-X
ALD	B-X
)	B-X

Hepatic	O
neutrophil	O
infiltration	O
is	O
a	O
principal	O
injurious	O
manifestation	O
of	O
ALD	O
.	O
<EOS>	B-X
Hepatic	B-X
neutrophil	B-X
infiltration	B-X
is	B-X
a	B-X
principal	B-X
injurious	B-X
manifestation	B-X
of	B-X
ALD	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
transfected	B-X
liver	B-X
cell	B-X
lines	B-X
can	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
mechanisms	B-X
for	B-X
increased	B-X
injurious	B-X
factors	B-X
and	B-X
decreased	B-X
protective	B-X
factors	B-X
in	B-X
alcoholic	B-X
liver	B-X
injury	B-X
<EOS>	B-X
In	B-X
the	B-X
second	B-X
set	B-X
of	B-X
experiments	B-X
,	B-X
HepG2	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
25	B-X
to	B-X
100	B-X
mmol	B-X
concentrations	B-X
of	B-X
ethanol	B-X
<EOS>	B-X
However	B-X
,	B-X
after	B-X
long	B-X
-	B-X
term	B-X
(	B-X
10	B-X
weeks	B-X
)	B-X
culture	B-X
with	B-X
ethanol	B-X
,	B-X
there	B-X
was	B-X
no	B-X
induction	B-X
of	B-X
MnSOD	B-X
by	B-X
ethanol	B-X
and	B-X
there	B-X
was	B-X
a	B-X
diminished	B-X
induction	B-X
of	B-X
MnSOD	B-X
in	B-X
response	B-X
to	B-X
TNF	B-X

TNF	B-protein
can	O
induce	O
cellular	O
oxidative	O
injury	O
directly	O
,	O
and	O
indirectly	O
by	O
inducing	O
neutrophil	O
chemotactic	O
factor	O
(	O
IL-8	B-protein
)	O
production	O
by	O
hepatocytes	O
.	O
<EOS>	B-X
TNF	B-X
can	B-X
induce	B-X
cellular	B-X
oxidative	B-X
injury	B-X
directly	B-X
,	B-X
and	B-X
indirectly	B-X
by	B-X
inducing	B-X
neutrophil	B-X
chemotactic	B-X
factor	B-X
(	B-X
IL	B-X
-	B-X
8	B-X
)	B-X
production	B-X
by	B-X
hepatocytes	B-X
<EOS>	B-X
The	B-X
objectives	B-X
of	B-X
these	B-X
studies	B-X
were	B-X
to	B-X
investigate	B-X
mechanisms	B-X
for	B-X
induction	B-X
of	B-X
an	B-X
injurious	B-X
factor	B-X
(	B-X
IL	B-X
-	B-X
8	B-X
)	B-X
and	B-X
a	B-X
protective	B-X
factor	B-X
(	B-X
MnSOD	B-X
)	B-X
in	B-X
the	B-X
HepG2	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
<EOS>	B-X
This	B-X
system	B-X
may	B-X
be	B-X
useful	B-X
to	B-X
assess	B-X
the	B-X
effects	B-X
of	B-X
ethanol	B-X
on	B-X
TNF	B-X
-	B-X
induced	B-X
hepatocyte	B-X
IL	B-X
-	B-X
8	B-X
production	B-X
<EOS>	B-X
Manganous	B-X
superoxide	B-X
dismutase	B-X
(	B-X
MnSOD	B-X
)	B-X
is	B-X
an	B-X
antioxidant	B-X
protective	B-X
factor	B-X

IL-8	B-protein
activates	O
and	O
chemotactically	O
attracts	O
neutrophils	O
to	O
the	O
liver	O
where	O
they	O
release	O
oxidizing	O
substances	O
.	O

Patients	O
with	O
ALD	O
also	O
have	O
decreased	O
protective	B-protein
factors	I-protein
for	O
cellular	O
oxidative	O
injury	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
ALD	B-X
also	B-X
have	B-X
decreased	B-X
protective	B-X
factors	B-X
for	B-X
cellular	B-X
oxidative	B-X
injury	B-X
<EOS>	B-X
Use	B-X
of	B-X
transfected	B-X
liver	B-X
cells	B-X
to	B-X
evaluate	B-X
potential	B-X
mechanisms	B-X
of	B-X
alcohol	B-X
-	B-X
induced	B-X
liver	B-X
injury	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
transfected	B-X
liver	B-X
cell	B-X
lines	B-X
can	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
mechanisms	B-X
for	B-X
increased	B-X
injurious	B-X
factors	B-X
and	B-X
decreased	B-X
protective	B-X
factors	B-X
in	B-X
alcoholic	B-X
liver	B-X
injury	B-X
<EOS>	B-X
Our	B-X
study	B-X
provides	B-X
a	B-X
strong	B-X
rationale	B-X
to	B-X
evaluate	B-X
AR	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
and	B-X
to	B-X
test	B-X
AR	B-X
inhibitors	B-X
to	B-X
ameliorate	B-X
alcohol	B-X
-	B-X
induced	B-X
liver	B-X
injury	B-X

Manganous	B-protein
superoxide	I-protein
dismutase	I-protein
(	O
MnSOD	B-protein
)	O
is	O
an	O
antioxidant	B-protein
protective	I-protein
factor	I-protein
.	O
<EOS>	B-X
Manganous	B-X
superoxide	B-X
dismutase	B-X
(	B-X
MnSOD	B-X
)	B-X
is	B-X
an	B-X
antioxidant	B-X
protective	B-X
factor	B-X
<EOS>	B-X
Manganous	B-X
superoxide	B-X
dismutase	B-X
(	B-X
MnSOD	B-X
)	B-X
scavenges	B-X
potentially	B-X
toxic	B-X
superoxide	B-X
radicals	B-X
produced	B-X
in	B-X
the	B-X
mitochondria	B-X
<EOS>	B-X
Induction	B-X
of	B-X
manganous	B-X
superoxide	B-X
dismutase	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
:	B-X
possible	B-X
protective	B-X
mechanism	B-X
.	B-X
<EOS>	B-X
Induction	B-X
of	B-X
synthesis	B-X
of	B-X
manganous	B-X
superoxide	B-X
dismutase	B-X
in	B-X
L	B-X
-	B-X
M	B-X
(	B-X
pNTnF	B-X
)	B-X
cells	B-X
carrying	B-X
an	B-X
inducible	B-X
TNF	B-X
gene	B-X
.	B-X

The	O
objectives	O
of	O
these	O
studies	O
were	O
to	O
investigate	O
mechanisms	O
for	O
induction	O
of	O
an	O
injurious	B-protein
factor	I-protein
(	O
IL-8	B-protein
)	O
and	O
a	O
protective	B-protein
factor	I-protein
(	O
MnSOD	B-protein
)	O
in	O
the	O
HepG2	B-cell_line
human	I-cell_line
hepatoma	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

In	O
the	O
first	O
set	O
of	O
experiments	O
,	O
IL-8	B-DNA
gene	I-DNA
reporter	I-DNA
constructs	I-DNA
were	O
used	O
to	O
transiently	O
transfect	O
a	O
derivative	O
(	O
MVh2E1-9	B-cell_line
)	O
of	O
the	O
HepG2	B-cell_line
cell	I-cell_line
line	I-cell_line
which	O
expresses	O
P-4502E1	B-protein
and	O
metabolizes	O
ethanol	O
.	O
<EOS>	B-X
In	B-X
the	B-X
first	B-X
set	B-X
of	B-X
experiments	B-X
,	B-X
IL	B-X
-	B-X
8	B-X
gene	B-X
reporter	B-X
constructs	B-X
were	B-X
used	B-X
to	B-X
transiently	B-X
transfect	B-X
a	B-X
derivative	B-X
(	B-X
MVh2E1	B-X
-	B-X
9	B-X
)	B-X
of	B-X
the	B-X
HepG2	B-X
cell	B-X
line	B-X
which	B-X
expresses	B-X
P	B-X
-	B-X
4502E1	B-X
and	B-X
metabolizes	B-X
ethanol	B-X
<EOS>	B-X
In	B-X
the	B-X
second	B-X
set	B-X
of	B-X
experiments	B-X
,	B-X
HepG2	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
25	B-X
to	B-X
100	B-X
mmol	B-X
concentrations	B-X
of	B-X
ethanol	B-X
<EOS>	B-X
Further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
assess	B-X
the	B-X
effect	B-X
of	B-X
this	B-X
diminished	B-X
induction	B-X
of	B-X
MnSOD	B-X
with	B-X
chronic	B-X
ethanol	B-X
culture	B-X
on	B-X
HepG2	B-X
cell	B-X
susceptibility	B-X
to	B-X
TNF	B-X
cytotoxicity	B-X
<EOS>	B-X
Inactivation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
3'NF	B-X
-	B-X
IL	B-X
-	B-X
6	B-X
DNA	B-X
binding	B-X
sites	B-X
decreased	B-X
IL	B-X
-	B-X
8	B-X
gene	B-X
transcriptional	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
TNF	B-X
while	B-X
inactivation	B-X
of	B-X
the	B-X
5'NF	B-X
-	B-X
IL	B-X
-	B-X
6	B-X
binding	B-X
site	B-X
increased	B-X
IL	B-X
-	B-X
8	B-X
gene	B-X
transcriptional	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
TNF	B-X

Inactivation	O
of	O
the	O
NF-kappaB	B-DNA
and	I-DNA
3'NF-IL-6	I-DNA
DNA	I-DNA
binding	I-DNA
sites	I-DNA
decreased	O
IL-8	B-DNA
gene	I-DNA
transcriptional	O
activation	O
in	O
response	O
to	O
TNF	B-protein
while	O
inactivation	O
of	O
the	O
5'NF-IL-6	B-DNA
binding	I-DNA
site	I-DNA
increased	O
IL-8	B-DNA
gene	I-DNA
transcriptional	O
activity	O
in	O
response	O
to	O
TNF	B-protein
.	O

This	O
system	O
may	O
be	O
useful	O
to	O
assess	O
the	O
effects	O
of	O
ethanol	O
on	O
TNF	B-protein
-induced	O
hepatocyte	O
IL-8	B-protein
production	O
.	O
<EOS>	B-X
This	B-X
system	B-X
may	B-X
be	B-X
useful	B-X
to	B-X
assess	B-X
the	B-X
effects	B-X
of	B-X
ethanol	B-X
on	B-X
TNF	B-X
-	B-X
induced	B-X
hepatocyte	B-X
IL	B-X
-	B-X
8	B-X
production	B-X
<EOS>	B-X
Further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
assess	B-X
the	B-X
effect	B-X
of	B-X
this	B-X
diminished	B-X
induction	B-X
of	B-X
MnSOD	B-X
with	B-X
chronic	B-X
ethanol	B-X
culture	B-X
on	B-X
HepG2	B-X
cell	B-X
susceptibility	B-X
to	B-X
TNF	B-X
cytotoxicity	B-X
<EOS>	B-X
TNF	B-X
can	B-X
induce	B-X
cellular	B-X
oxidative	B-X
injury	B-X
directly	B-X
,	B-X
and	B-X
indirectly	B-X
by	B-X
inducing	B-X
neutrophil	B-X
chemotactic	B-X
factor	B-X
(	B-X
IL	B-X
-	B-X
8	B-X
)	B-X
production	B-X
by	B-X
hepatocytes	B-X
<EOS>	B-X
However	B-X
,	B-X
after	B-X
long	B-X
-	B-X
term	B-X
(	B-X
10	B-X
weeks	B-X
)	B-X
culture	B-X
with	B-X
ethanol	B-X
,	B-X
there	B-X
was	B-X
no	B-X
induction	B-X
of	B-X
MnSOD	B-X
by	B-X
ethanol	B-X
and	B-X
there	B-X
was	B-X
a	B-X
diminished	B-X
induction	B-X
of	B-X
MnSOD	B-X
in	B-X
response	B-X
to	B-X
TNF	B-X

In	O
the	O
second	O
set	O
of	O
experiments	O
,	O
HepG2	B-cell_line
cells	I-cell_line
were	O
cultured	O
in	O
25	O
to	O
100	O
mmol	O
concentrations	O
of	O
ethanol	O
.	O
<EOS>	B-X
In	B-X
the	B-X
second	B-X
set	B-X
of	B-X
experiments	B-X
,	B-X
HepG2	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
25	B-X
to	B-X
100	B-X
mmol	B-X
concentrations	B-X
of	B-X
ethanol	B-X
<EOS>	B-X
Both	B-X
TNF	B-X
and	B-X
ethanol	B-X
increased	B-X
HepG2	B-X
cell	B-X
MnSOD	B-X
activity	B-X
in	B-X
short	B-X
-	B-X
term	B-X
(	B-X
72	B-X
hr	B-X
)	B-X
cultures	B-X
with	B-X
ethanol	B-X
<EOS>	B-X
In	B-X
the	B-X
first	B-X
set	B-X
of	B-X
experiments	B-X
,	B-X
IL	B-X
-	B-X
8	B-X
gene	B-X
reporter	B-X
constructs	B-X
were	B-X
used	B-X
to	B-X
transiently	B-X
transfect	B-X
a	B-X
derivative	B-X
(	B-X
MVh2E1	B-X
-	B-X
9	B-X
)	B-X
of	B-X
the	B-X
HepG2	B-X
cell	B-X
line	B-X
which	B-X
expresses	B-X
P	B-X
-	B-X
4502E1	B-X
and	B-X
metabolizes	B-X
ethanol	B-X
<EOS>	B-X
Further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
assess	B-X
the	B-X
effect	B-X
of	B-X
this	B-X
diminished	B-X
induction	B-X
of	B-X
MnSOD	B-X
with	B-X
chronic	B-X
ethanol	B-X
culture	B-X
on	B-X
HepG2	B-X
cell	B-X
susceptibility	B-X
to	B-X
TNF	B-X
cytotoxicity	B-X

Both	O
TNF	B-protein
and	O
ethanol	O
increased	O
HepG2	B-cell_line
cell	I-cell_line
MnSOD	B-protein
activity	O
in	O
short-term	O
(	O
72	O
hr	O
)	O
cultures	O
with	O
ethanol	O
.	O
<EOS>	B-X
Both	B-X
TNF	B-X
and	B-X
ethanol	B-X
increased	B-X
HepG2	B-X
cell	B-X
MnSOD	B-X
activity	B-X
in	B-X
short	B-X
-	B-X
term	B-X
(	B-X
72	B-X
hr	B-X
)	B-X
cultures	B-X
with	B-X
ethanol	B-X
<EOS>	B-X
In	B-X
the	B-X
second	B-X
set	B-X
of	B-X
experiments	B-X
,	B-X
HepG2	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
25	B-X
to	B-X
100	B-X
mmol	B-X
concentrations	B-X
of	B-X
ethanol	B-X
<EOS>	B-X
Further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
assess	B-X
the	B-X
effect	B-X
of	B-X
this	B-X
diminished	B-X
induction	B-X
of	B-X
MnSOD	B-X
with	B-X
chronic	B-X
ethanol	B-X
culture	B-X
on	B-X
HepG2	B-X
cell	B-X
susceptibility	B-X
to	B-X
TNF	B-X
cytotoxicity	B-X
<EOS>	B-X
However	B-X
,	B-X
after	B-X
long	B-X
-	B-X
term	B-X
(	B-X
10	B-X
weeks	B-X
)	B-X
culture	B-X
with	B-X
ethanol	B-X
,	B-X
there	B-X
was	B-X
no	B-X
induction	B-X
of	B-X
MnSOD	B-X
by	B-X
ethanol	B-X
and	B-X
there	B-X
was	B-X
a	B-X
diminished	B-X
induction	B-X
of	B-X
MnSOD	B-X
in	B-X
response	B-X
to	B-X
TNF	B-X

However	O
,	O
after	O
long-term	O
(	O
10	O
weeks	O
)	O
culture	O
with	O
ethanol	O
,	O
there	O
was	O
no	O
induction	O
of	O
MnSOD	B-protein
by	O
ethanol	O
and	O
there	O
was	O
a	O
diminished	O
induction	O
of	O
MnSOD	B-protein
in	O
response	O
to	O
TNF	B-protein
.	O

Further	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
effect	O
of	O
this	O
diminished	O
induction	O
of	O
MnSOD	B-protein
with	O
chronic	O
ethanol	O
culture	O
on	O
HepG2	B-cell_line
cell	I-cell_line
susceptibility	O
to	O
TNF	B-cell_line
cytotoxicity	I-cell_line
.	O

We	O
conclude	O
that	O
transfected	O
liver	B-cell_line
cell	I-cell_line
lines	I-cell_line
can	O
be	O
used	O
to	O
evaluate	O
mechanisms	O
for	O
increased	O
injurious	B-protein
factors	I-protein
and	O
decreased	O
protective	B-protein
factors	I-protein
in	O
alcoholic	O
liver	O
injury	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
transfected	B-X
liver	B-X
cell	B-X
lines	B-X
can	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
mechanisms	B-X
for	B-X
increased	B-X
injurious	B-X
factors	B-X
and	B-X
decreased	B-X
protective	B-X
factors	B-X
in	B-X
alcoholic	B-X
liver	B-X
injury	B-X
<EOS>	B-X
Use	B-X
of	B-X
transfected	B-X
liver	B-X
cells	B-X
to	B-X
evaluate	B-X
potential	B-X
mechanisms	B-X
of	B-X
alcohol	B-X
-	B-X
induced	B-X
liver	B-X
injury	B-X
.	B-X
<EOS>	B-X
The	B-X
objectives	B-X
of	B-X
these	B-X
studies	B-X
were	B-X
to	B-X
investigate	B-X
mechanisms	B-X
for	B-X
induction	B-X
of	B-X
an	B-X
injurious	B-X
factor	B-X
(	B-X
IL	B-X
-	B-X
8	B-X
)	B-X
and	B-X
a	B-X
protective	B-X
factor	B-X
(	B-X
MnSOD	B-X
)	B-X
in	B-X
the	B-X
HepG2	B-X
human	B-X
hepatoma	B-X
cell	B-X
line	B-X
<EOS>	B-X
Patients	B-X
with	B-X
ALD	B-X
also	B-X
have	B-X
decreased	B-X
protective	B-X
factors	B-X
for	B-X
cellular	B-X
oxidative	B-X
injury	B-X

Tissue	O
factor	O
transcription	O
driven	O
by	O
Egr-1	B-protein
is	O
a	O
critical	O
mechanism	O
of	O
murine	B-protein
pulmonary	I-protein
fibrin	I-protein
deposition	O
in	O
hypoxia	O
.	O
<EOS>	B-X
Tissue	B-X
factor	B-X
transcription	B-X
driven	B-X
by	B-X
Egr	B-X
-	B-X
1	B-X
is	B-X
a	B-X
critical	B-X
mechanism	B-X
of	B-X
murine	B-X
pulmonary	B-X
fibrin	B-X
deposition	B-X
in	B-X
hypoxia	B-X
.	B-X
<EOS>	B-X
We	B-X
now	B-X
show	B-X
that	B-X
transcription	B-X
factor	B-X
early	B-X
-	B-X
growth	B-X
-	B-X
response	B-X
gene	B-X
product	B-X
(	B-X
Egr	B-X
-	B-X
1	B-X
)	B-X
is	B-X
rapidly	B-X
activated	B-X
in	B-X
hypoxia	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
transcription	B-X
and	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
in	B-X
hypoxic	B-X
lung	B-X
<EOS>	B-X
A	B-X
central	B-X
role	B-X
for	B-X
Egr	B-X
-	B-X
1	B-X
in	B-X
hypoxia	B-X
-	B-X
mediated	B-X
tissue	B-X
factor	B-X
expression	B-X
was	B-X
confirmed	B-X
by	B-X
experiments	B-X
with	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
;	B-X
wild	B-X
-	B-X
type	B-X
mice	B-X
subjected	B-X
to	B-X
oxygen	B-X
deprivation	B-X
expressed	B-X
tissue	B-X
factor	B-X
and	B-X
showed	B-X
fibrin	B-X
deposition	B-X
,	B-X
but	B-X
hypoxic	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
displayed	B-X
neither	B-X
tissue	B-X
factor	B-X
nor	B-X
fibrin	B-X
<EOS>	B-X
We	B-X
have	B-X
demonstrated	B-X
previously	B-X
that	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
normobaric	B-X
hypoxia	B-X
pulmonary	B-X
fibrin	B-X
deposition	B-X
is	B-X
a	B-X
result	B-X
of	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
,	B-X
especially	B-X
in	B-X
oxygen	B-X
-	B-X
deprived	B-X
mononuclear	B-X
phagocytes	B-X
(	B-X
MPs	B-X
)	B-X

Local	O
hypoxemia	O
and	O
stasis	O
trigger	O
thrombosis	O
.	O
<EOS>	B-X
Local	B-X
hypoxemia	B-X
and	B-X
stasis	B-X
trigger	B-X
thrombosis	B-X
<EOS>	B-X
Tissue	B-X
factor	B-X
transcription	B-X
driven	B-X
by	B-X
Egr	B-X
-	B-X
1	B-X
is	B-X
a	B-X
critical	B-X
mechanism	B-X
of	B-X
murine	B-X
pulmonary	B-X
fibrin	B-X
deposition	B-X
in	B-X
hypoxia	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
demonstrated	B-X
previously	B-X
that	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
normobaric	B-X
hypoxia	B-X
pulmonary	B-X
fibrin	B-X
deposition	B-X
is	B-X
a	B-X
result	B-X
of	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
,	B-X
especially	B-X
in	B-X
oxygen	B-X
-	B-X
deprived	B-X
mononuclear	B-X
phagocytes	B-X
(	B-X
MPs	B-X
)	B-X
<EOS>	B-X
Gel	B-X
-	B-X
shift	B-X
analysis	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
hypoxic	B-X
MPs	B-X
and	B-X
HeLa	B-X
cells	B-X
demonstrated	B-X
increased	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
serum	B-X
response	B-X
region	B-X
(	B-X
SRR	B-X
;	B-X
	B-X
-	B-X
111	B-X
/	B-X
+14	B-X
bp	B-X
)	B-X
of	B-X
the	B-X
tissue	B-X
factor	B-X
promoter	B-X
at	B-X
Egr	B-X
-	B-X
1	B-X
motifs	B-X

We	O
have	O
demonstrated	O
previously	O
that	O
in	O
a	O
murine	O
model	O
of	O
normobaric	O
hypoxia	O
pulmonary	O
fibrin	B-protein
deposition	O
is	O
a	O
result	O
of	O
expression	O
of	O
tissue	B-protein
factor	I-protein
,	O
especially	O
in	O
oxygen-deprived	B-protein
mononuclear	I-protein
phagocytes	I-protein
(	O
MPs	B-protein
)	O
.	O

We	O
now	O
show	O
that	O
transcription	B-protein
factor	I-protein
early-growth-response	I-protein
gene	I-protein
product	I-protein
(	O
Egr-1	B-protein
)	O
is	O
rapidly	O
activated	O
in	O
hypoxia	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
is	O
responsible	O
for	O
transcription	O
and	O
expression	O
of	O
tissue	B-protein
factor	I-protein
in	O
hypoxic	O
lung	O
.	O
<EOS>	B-X
We	B-X
now	B-X
show	B-X
that	B-X
transcription	B-X
factor	B-X
early	B-X
-	B-X
growth	B-X
-	B-X
response	B-X
gene	B-X
product	B-X
(	B-X
Egr	B-X
-	B-X
1	B-X
)	B-X
is	B-X
rapidly	B-X
activated	B-X
in	B-X
hypoxia	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
transcription	B-X
and	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
in	B-X
hypoxic	B-X
lung	B-X
<EOS>	B-X
Tissue	B-X
factor	B-X
transcription	B-X
driven	B-X
by	B-X
Egr	B-X
-	B-X
1	B-X
is	B-X
a	B-X
critical	B-X
mechanism	B-X
of	B-X
murine	B-X
pulmonary	B-X
fibrin	B-X
deposition	B-X
in	B-X
hypoxia	B-X
.	B-X
<EOS>	B-X
A	B-X
central	B-X
role	B-X
for	B-X
Egr	B-X
-	B-X
1	B-X
in	B-X
hypoxia	B-X
-	B-X
mediated	B-X
tissue	B-X
factor	B-X
expression	B-X
was	B-X
confirmed	B-X
by	B-X
experiments	B-X
with	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
;	B-X
wild	B-X
-	B-X
type	B-X
mice	B-X
subjected	B-X
to	B-X
oxygen	B-X
deprivation	B-X
expressed	B-X
tissue	B-X
factor	B-X
and	B-X
showed	B-X
fibrin	B-X
deposition	B-X
,	B-X
but	B-X
hypoxic	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
displayed	B-X
neither	B-X
tissue	B-X
factor	B-X
nor	B-X
fibrin	B-X
<EOS>	B-X
These	B-X
data	B-X
delineate	B-X
a	B-X
novel	B-X
biology	B-X
for	B-X
hypoxia	B-X
-	B-X
induced	B-X
fibrin	B-X
deposition	B-X
,	B-X
in	B-X
which	B-X
oxygen	B-X
deprivation	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
,	B-X
resulting	B-X
in	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
,	B-X
has	B-X
an	B-X
unexpected	B-X
and	B-X
central	B-X
role	B-X

MPs	B-protein
and	O
HeLa	B-cell_line
cells	I-cell_line
subjected	O
to	O
hypoxia	O
(	O
pO2	O
approximately	O
13	O
torr	O
)	O
had	O
increased	O
levels	O
of	O
tissue	B-RNA
factor	I-RNA
transcripts	I-RNA
(	O
approximately	O
18-fold	O
)	O
and	O
an	O
increased	O
rate	O
of	O
transcription	O
(	O
approximately	O
15-fold	O
)	O
,	O
based	O
on	O
nuclear	O
run-on	O
analysis	O
.	O

Gel-shift	O
analysis	O
of	O
nuclear	O
extracts	O
from	O
hypoxic	B-protein
MPs	I-protein
and	O
HeLa	B-cell_line
cells	I-cell_line
demonstrated	O
increased	O
DNA-binding	O
activity	O
at	O
the	O
serum	B-DNA
response	I-DNA
region	I-DNA
(	O
SRR	O
;	O
-111/+14	O
bp	O
)	O
of	O
the	O
tissue	B-DNA
factor	I-DNA
promoter	I-DNA
at	O
Egr-1	B-DNA
motifs	I-DNA
.	O
<EOS>	B-X
Gel	B-X
-	B-X
shift	B-X
analysis	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
hypoxic	B-X
MPs	B-X
and	B-X
HeLa	B-X
cells	B-X
demonstrated	B-X
increased	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
serum	B-X
response	B-X
region	B-X
(	B-X
SRR	B-X
;	B-X
	B-X
-	B-X
111	B-X
/	B-X
+14	B-X
bp	B-X
)	B-X
of	B-X
the	B-X
tissue	B-X
factor	B-X
promoter	B-X
at	B-X
Egr	B-X
-	B-X
1	B-X
motifs	B-X
<EOS>	B-X
We	B-X
now	B-X
show	B-X
that	B-X
transcription	B-X
factor	B-X
early	B-X
-	B-X
growth	B-X
-	B-X
response	B-X
gene	B-X
product	B-X
(	B-X
Egr	B-X
-	B-X
1	B-X
)	B-X
is	B-X
rapidly	B-X
activated	B-X
in	B-X
hypoxia	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
transcription	B-X
and	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
in	B-X
hypoxic	B-X
lung	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
chimeric	B-X
plasmids	B-X
containing	B-X
wild	B-X
-	B-X
type	B-X
or	B-X
mutant	B-X
SRR	B-X
from	B-X
the	B-X
tissue	B-X
factor	B-X
promoter	B-X
showed	B-X
that	B-X
intact	B-X
Sp1	B-X
sites	B-X
are	B-X
necessary	B-X
for	B-X
basal	B-X
promoter	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
integrity	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
sites	B-X
was	B-X
required	B-X
for	B-X
hypoxia	B-X
-	B-X
enhanced	B-X
expression	B-X
<EOS>	B-X
Using	B-X
32P	B-X
-	B-X
labeled	B-X
Egr	B-X
consensus	B-X
oligonucleotide	B-X
,	B-X
we	B-X
observed	B-X
induction	B-X
of	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
hypoxic	B-X
lung	B-X
and	B-X
HeLa	B-X
cells	B-X
because	B-X
of	B-X
activation	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
,	B-X
by	B-X
means	B-X
of	B-X
supershift	B-X
analysis	B-X

Using	O
32P-labeled	O
Egr	O
consensus	O
oligonucleotide	O
,	O
we	O
observed	O
induction	O
of	O
DNA-binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
lung	O
and	O
HeLa	B-cell_line
cells	I-cell_line
because	O
of	O
activation	O
of	O
Egr-1	B-protein
,	O
by	O
means	O
of	O
supershift	O
analysis	O
.	O
<EOS>	B-X
Using	B-X
32P	B-X
-	B-X
labeled	B-X
Egr	B-X
consensus	B-X
oligonucleotide	B-X
,	B-X
we	B-X
observed	B-X
induction	B-X
of	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
hypoxic	B-X
lung	B-X
and	B-X
HeLa	B-X
cells	B-X
because	B-X
of	B-X
activation	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
,	B-X
by	B-X
means	B-X
of	B-X
supershift	B-X
analysis	B-X
<EOS>	B-X
MPs	B-X
and	B-X
HeLa	B-X
cells	B-X
subjected	B-X
to	B-X
hypoxia	B-X
(	B-X
pO2	B-X
approximately	B-X
13	B-X
torr	B-X
)	B-X
had	B-X
increased	B-X
levels	B-X
of	B-X
tissue	B-X
factor	B-X
transcripts	B-X
(	B-X
approximately	B-X
18	B-X
-	B-X
fold	B-X
)	B-X
and	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
transcription	B-X
(	B-X
approximately	B-X
15	B-X
-	B-X
fold	B-X
)	B-X
,	B-X
based	B-X
on	B-X
nuclear	B-X
run	B-X
-	B-X
on	B-X
analysis	B-X
<EOS>	B-X
A	B-X
central	B-X
role	B-X
for	B-X
Egr	B-X
-	B-X
1	B-X
in	B-X
hypoxia	B-X
-	B-X
mediated	B-X
tissue	B-X
factor	B-X
expression	B-X
was	B-X
confirmed	B-X
by	B-X
experiments	B-X
with	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
;	B-X
wild	B-X
-	B-X
type	B-X
mice	B-X
subjected	B-X
to	B-X
oxygen	B-X
deprivation	B-X
expressed	B-X
tissue	B-X
factor	B-X
and	B-X
showed	B-X
fibrin	B-X
deposition	B-X
,	B-X
but	B-X
hypoxic	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
displayed	B-X
neither	B-X
tissue	B-X
factor	B-X
nor	B-X
fibrin	B-X
<EOS>	B-X
Gel	B-X
-	B-X
shift	B-X
analysis	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
hypoxic	B-X
MPs	B-X
and	B-X
HeLa	B-X
cells	B-X
demonstrated	B-X
increased	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
serum	B-X
response	B-X
region	B-X
(	B-X
SRR	B-X
;	B-X
	B-X
-	B-X
111	B-X
/	B-X
+14	B-X
bp	B-X
)	B-X
of	B-X
the	B-X
tissue	B-X
factor	B-X
promoter	B-X
at	B-X
Egr	B-X
-	B-X
1	B-X
motifs	B-X

Transient	O
transfection	O
of	O
HeLa	B-cell_line
cells	I-cell_line
with	O
chimeric	B-DNA
plasmids	I-DNA
containing	O
wild-type	B-protein
or	I-protein
mutant	I-protein
SRR	I-protein
from	O
the	O
tissue	B-DNA
factor	I-DNA
promoter	I-DNA
showed	O
that	O
intact	B-DNA
Sp1	I-DNA
sites	I-DNA
are	O
necessary	O
for	O
basal	O
promoter	O
activity	O
,	O
whereas	O
the	O
integrity	O
of	O
Egr-1	B-DNA
sites	I-DNA
was	O
required	O
for	O
hypoxia-enhanced	O
expression	O
.	O
<EOS>	B-X
Transient	B-X
transfection	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
chimeric	B-X
plasmids	B-X
containing	B-X
wild	B-X
-	B-X
type	B-X
or	B-X
mutant	B-X
SRR	B-X
from	B-X
the	B-X
tissue	B-X
factor	B-X
promoter	B-X
showed	B-X
that	B-X
intact	B-X
Sp1	B-X
sites	B-X
are	B-X
necessary	B-X
for	B-X
basal	B-X
promoter	B-X
activity	B-X
,	B-X
whereas	B-X
the	B-X
integrity	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
sites	B-X
was	B-X
required	B-X
for	B-X
hypoxia	B-X
-	B-X
enhanced	B-X
expression	B-X
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
the	B-X
efficient	B-X
repression	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
6	B-X
promoter	B-X
by	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
was	B-X
investigated	B-X
in	B-X
HeLa	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
plasmid	B-X
constructs	B-X
containing	B-X
different	B-X
IL	B-X
-	B-X
6	B-X
promoter	B-X
elements	B-X
linked	B-X
to	B-X
the	B-X
herpesvirus	B-X
thymidine	B-X
kinase	B-X
gene	B-X
(	B-X
tk	B-X
)	B-X
promoter	B-X
and	B-X
the	B-X
bacterial	B-X
chloramphenicol	B-X
acetyltransferase	B-X
gene	B-X
(	B-X
cat	B-X
)	B-X
and	B-X
cotransfected	B-X
with	B-X
cDNA	B-X
vectors	B-X
constitutively	B-X
expressing	B-X
either	B-X
the	B-X
active	B-X
wild	B-X
-	B-X
type	B-X
or	B-X
inactive	B-X
mutant	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
<EOS>	B-X
When	B-X
pAV2	B-X
is	B-X
transfected	B-X
into	B-X
human	B-X
cells	B-X
together	B-X
with	B-X
helper	B-X
adenovirus	B-X
particles	B-X
,	B-X
the	B-X
AAV	B-X
genome	B-X
is	B-X
rescued	B-X
from	B-X
the	B-X
recombinant	B-X
plasmid	B-X
and	B-X
replicated	B-X
to	B-X
produce	B-X
infectious	B-X
AAV	B-X
particles	B-X
at	B-X
high	B-X
efficiency	B-X
<EOS>	B-X
Imperfect	B-X
palindromic	B-X
nucleotide	B-X
sequence	B-X
motifs	B-X
moderately	B-X
related	B-X
to	B-X
the	B-X
consensus	B-X
GR	B-X
-	B-X
responsive	B-X
element	B-X
(	B-X
GRE	B-X
)	B-X
motif	B-X
were	B-X
present	B-X
at	B-X
the	B-X
Inr	B-X
,	B-X
the	B-X
TATA	B-X
box	B-X
,	B-X
and	B-X
the	B-X
MRE	B-X
II	B-X
site	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
6	B-X
promoter	B-X
;	B-X
although	B-X
MRE	B-X
I	B-X
and	B-X
a	B-X
GR	B-X
-	B-X
binding	B-X
site	B-X
between	B-X
	B-X
-	B-X
201	B-X
and	B-X
	B-X
-	B-X
210	B-X
in	B-X
IL	B-X
-	B-X
6	B-X
both	B-X
lacked	B-X
a	B-X
discernible	B-X
inverted	B-X
repeat	B-X
motif	B-X
,	B-X
their	B-X
sequences	B-X
showed	B-X
considerable	B-X
similarity	B-X
with	B-X
negative	B-X
GRE	B-X
sequences	B-X
in	B-X
other	B-X
Dex	B-X
-	B-X
repressed	B-X
genes	B-X

A	O
central	O
role	O
for	O
Egr-1	B-protein
in	O
hypoxia-mediated	O
tissue	O
factor	O
expression	O
was	O
confirmed	O
by	O
experiments	O
with	O
homozygous	O
Egr-1	B-protein
null	O
mice	O
;	O
wild-type	O
mice	O
subjected	O
to	O
oxygen	B-protein
deprivation	I-protein
expressed	I-protein
tissue	I-protein
factor	I-protein
and	O
showed	O
fibrin	B-protein
deposition	O
,	O
but	O
hypoxic	O
homozygous	O
Egr-1	B-protein
null	O
mice	O
displayed	O
neither	O
tissue	B-protein
factor	I-protein
nor	O
fibrin	B-protein
.	O
<EOS>	B-X
A	B-X
central	B-X
role	B-X
for	B-X
Egr	B-X
-	B-X
1	B-X
in	B-X
hypoxia	B-X
-	B-X
mediated	B-X
tissue	B-X
factor	B-X
expression	B-X
was	B-X
confirmed	B-X
by	B-X
experiments	B-X
with	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
;	B-X
wild	B-X
-	B-X
type	B-X
mice	B-X
subjected	B-X
to	B-X
oxygen	B-X
deprivation	B-X
expressed	B-X
tissue	B-X
factor	B-X
and	B-X
showed	B-X
fibrin	B-X
deposition	B-X
,	B-X
but	B-X
hypoxic	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
displayed	B-X
neither	B-X
tissue	B-X
factor	B-X
nor	B-X
fibrin	B-X
<EOS>	B-X
We	B-X
now	B-X
show	B-X
that	B-X
transcription	B-X
factor	B-X
early	B-X
-	B-X
growth	B-X
-	B-X
response	B-X
gene	B-X
product	B-X
(	B-X
Egr	B-X
-	B-X
1	B-X
)	B-X
is	B-X
rapidly	B-X
activated	B-X
in	B-X
hypoxia	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
transcription	B-X
and	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
in	B-X
hypoxic	B-X
lung	B-X
<EOS>	B-X
These	B-X
data	B-X
delineate	B-X
a	B-X
novel	B-X
biology	B-X
for	B-X
hypoxia	B-X
-	B-X
induced	B-X
fibrin	B-X
deposition	B-X
,	B-X
in	B-X
which	B-X
oxygen	B-X
deprivation	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
,	B-X
resulting	B-X
in	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
,	B-X
has	B-X
an	B-X
unexpected	B-X
and	B-X
central	B-X
role	B-X
<EOS>	B-X
We	B-X
have	B-X
demonstrated	B-X
previously	B-X
that	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
normobaric	B-X
hypoxia	B-X
pulmonary	B-X
fibrin	B-X
deposition	B-X
is	B-X
a	B-X
result	B-X
of	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
,	B-X
especially	B-X
in	B-X
oxygen	B-X
-	B-X
deprived	B-X
mononuclear	B-X
phagocytes	B-X
(	B-X
MPs	B-X
)	B-X

These	O
data	O
delineate	O
a	O
novel	O
biology	O
for	O
hypoxia-induced	O
fibrin	B-protein
deposition	O
,	O
in	O
which	O
oxygen	O
deprivation-induced	O
activation	O
of	O
Egr-1	B-protein
,	O
resulting	O
in	O
expression	O
of	O
tissue	B-protein
factor	I-protein
,	O
has	O
an	O
unexpected	O
and	O
central	O
role	O
.	O
<EOS>	B-X
These	B-X
data	B-X
delineate	B-X
a	B-X
novel	B-X
biology	B-X
for	B-X
hypoxia	B-X
-	B-X
induced	B-X
fibrin	B-X
deposition	B-X
,	B-X
in	B-X
which	B-X
oxygen	B-X
deprivation	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
,	B-X
resulting	B-X
in	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
,	B-X
has	B-X
an	B-X
unexpected	B-X
and	B-X
central	B-X
role	B-X
<EOS>	B-X
We	B-X
have	B-X
demonstrated	B-X
previously	B-X
that	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
normobaric	B-X
hypoxia	B-X
pulmonary	B-X
fibrin	B-X
deposition	B-X
is	B-X
a	B-X
result	B-X
of	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
,	B-X
especially	B-X
in	B-X
oxygen	B-X
-	B-X
deprived	B-X
mononuclear	B-X
phagocytes	B-X
(	B-X
MPs	B-X
)	B-X
<EOS>	B-X
A	B-X
central	B-X
role	B-X
for	B-X
Egr	B-X
-	B-X
1	B-X
in	B-X
hypoxia	B-X
-	B-X
mediated	B-X
tissue	B-X
factor	B-X
expression	B-X
was	B-X
confirmed	B-X
by	B-X
experiments	B-X
with	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
;	B-X
wild	B-X
-	B-X
type	B-X
mice	B-X
subjected	B-X
to	B-X
oxygen	B-X
deprivation	B-X
expressed	B-X
tissue	B-X
factor	B-X
and	B-X
showed	B-X
fibrin	B-X
deposition	B-X
,	B-X
but	B-X
hypoxic	B-X
homozygous	B-X
Egr	B-X
-	B-X
1	B-X
null	B-X
mice	B-X
displayed	B-X
neither	B-X
tissue	B-X
factor	B-X
nor	B-X
fibrin	B-X
<EOS>	B-X
We	B-X
now	B-X
show	B-X
that	B-X
transcription	B-X
factor	B-X
early	B-X
-	B-X
growth	B-X
-	B-X
response	B-X
gene	B-X
product	B-X
(	B-X
Egr	B-X
-	B-X
1	B-X
)	B-X
is	B-X
rapidly	B-X
activated	B-X
in	B-X
hypoxia	B-X
,	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
transcription	B-X
and	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
in	B-X
hypoxic	B-X
lung	B-X

Kinetics	O
of	O
cytokine	O
and	O
NFAT	O
gene	O
expression	O
in	O
human	B-cell_line
interleukin-2-dependent	I-cell_line
T	I-cell_line
lymphoblasts	I-cell_line
stimulated	O
via	O
T-cell	B-protein
receptor	I-protein
.	O
<EOS>	B-X
Kinetics	B-X
of	B-X
cytokine	B-X
and	B-X
NFAT	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
via	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
analysed	B-X
the	B-X
kinetics	B-X
and	B-X
nature	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
-	B-X
derived	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibodies	B-X
or	B-X
Lens	B-X
culinaris	B-X
lectin	B-X
(	B-X
LCL	B-X
)	B-X
<EOS>	B-X
The	B-X
kinetics	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
expression	B-X
was	B-X
faster	B-X
,	B-X
being	B-X
at	B-X
its	B-X
peak	B-X
level	B-X
1	B-X
hr	B-X
after	B-X
stimulation	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
stimulation	B-X
also	B-X
induced	B-X
a	B-X
very	B-X
rapid	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
jun	B-X
,	B-X
c	B-X
-	B-X
fos	B-X
and	B-X
NFATc1	B-X
(	B-X
NFATc	B-X
)	B-X
genes	B-X
,	B-X
the	B-X
gene	B-X
products	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
cytokine	B-X
gene	B-X
expression	B-X

T	B-cell_type
cells	I-cell_type
respond	O
to	O
mitogenic	O
or	O
antigenic	O
stimulation	O
by	O
proliferation	O
and	O
by	O
turning	O
on	O
cytokine	O
gene	O
expression	O
.	O
<EOS>	B-X
We	B-X
discovered	B-X
that	B-X
T	B-X
cells	B-X
respond	B-X
to	B-X
minute	B-X
-	B-X
scale	B-X
oscillations	B-X
of	B-X
activation	B-X
signal	B-X
by	B-X
stimulating	B-X
optoCAR	B-X
T	B-X
cells	B-X
with	B-X
tunable	B-X
pulse	B-X
trains	B-X
of	B-X
light	B-X
<EOS>	B-X
T	B-X
cells	B-X
selectively	B-X
filter	B-X
oscillatory	B-X
signals	B-X
on	B-X
the	B-X
minutes	B-X
timescale	B-X
.	B-X
<EOS>	B-X
We	B-X
engineered	B-X
T	B-X
cells	B-X
to	B-X
respond	B-X
to	B-X
light	B-X
as	B-X
a	B-X
stimulus	B-X
by	B-X
building	B-X
an	B-X
optogenetically	B-X
controlled	B-X
chimeric	B-X
antigen	B-X
receptor	B-X
(	B-X
optoCAR	B-X
)	B-X
<EOS>	B-X
T	B-X
cells	B-X
experience	B-X
complex	B-X
temporal	B-X
patterns	B-X
of	B-X
stimulus	B-X
via	B-X
receptor	B-X
-	B-X
ligand	B-X
-	B-X
binding	B-X
interactions	B-X
with	B-X
surrounding	B-X
cells	B-X

Here	O
we	O
have	O
analysed	O
the	O
kinetics	O
and	O
nature	O
of	O
cytokine	O
production	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood-derived	I-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
stimulated	O
with	O
anti-CD3	B-protein
antibodies	I-protein
or	O
Lens	B-protein
culinaris	I-protein
lectin	I-protein
(	O
LCL	B-protein
)	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
analysed	B-X
the	B-X
kinetics	B-X
and	B-X
nature	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
-	B-X
derived	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibodies	B-X
or	B-X
Lens	B-X
culinaris	B-X
lectin	B-X
(	B-X
LCL	B-X
)	B-X
<EOS>	B-X
Kinetics	B-X
of	B-X
cytokine	B-X
and	B-X
NFAT	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
via	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Culture	B-X
density	B-X
and	B-X
age	B-X
-	B-X
dependent	B-X
interactions	B-X
of	B-X
3T3	B-X
AND	B-X
SV3T3	B-X
cells	B-X
with	B-X
immobilized	B-X
and	B-X
soluble	B-X
Lens	B-X
culinaris	B-X
lectin	B-X
.	B-X
<EOS>	B-X
Lectins	B-X
as	B-X
inducers	B-X
of	B-X
interferon	B-X
-	B-X
gamma	B-X
production	B-X
in	B-X
human	B-X
lymphocytes	B-X
:	B-X
lentil	B-X
lectin	B-X
is	B-X
highly	B-X
efficient	B-X
.	B-X

T	B-cell_type
cells	I-cell_type
were	O
purified	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
primarily	O
activated	O
with	O
anti-CD3	B-protein
antibodies	I-protein
and	O
cultured	O
in	O
the	O
presence	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O
<EOS>	B-X
T	B-X
cells	B-X
were	B-X
purified	B-X
from	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
and	B-X
primarily	B-X
activated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibodies	B-X
and	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
<EOS>	B-X
T	B-X
cells	B-X
respond	B-X
to	B-X
mitogenic	B-X
or	B-X
antigenic	B-X
stimulation	B-X
by	B-X
proliferation	B-X
and	B-X
by	B-X
turning	B-X
on	B-X
cytokine	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Steady	B-X
-	B-X
state	B-X
mRNA	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
IL	B-X
-	B-X
10	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
peaked	B-X
at	B-X
3	B-X
hr	B-X
after	B-X
anti	B-X
-	B-X
CD3	B-X
stimulation	B-X
and	B-X
declined	B-X
rapidly	B-X
thereafter	B-X
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
analysed	B-X
the	B-X
kinetics	B-X
and	B-X
nature	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
-	B-X
derived	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibodies	B-X
or	B-X
Lens	B-X
culinaris	B-X
lectin	B-X
(	B-X
LCL	B-X
)	B-X

Anti-CD3-restimulated	O
T	B-cell_type
cells	I-cell_type
(	O
mainly	O
CD8+	O
)	O
produced	O
IL-2	B-protein
,	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
low	O
levels	O
of	O
IL-4	B-RNA
and	I-RNA
IL-10	I-RNA
transcripts	I-RNA
and	O
proteins	O
.	O
<EOS>	B-X
Anti	B-X
-	B-X
CD3	B-X
-	B-X
restimulated	B-X
T	B-X
cells	B-X
(	B-X
mainly	B-X
CD8+	B-X
)	B-X
produced	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
and	B-X
tumour	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
low	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
transcripts	B-X
and	B-X
proteins	B-X
<EOS>	B-X
Steady	B-X
-	B-X
state	B-X
mRNA	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
IL	B-X
-	B-X
10	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
peaked	B-X
at	B-X
3	B-X
hr	B-X
after	B-X
anti	B-X
-	B-X
CD3	B-X
stimulation	B-X
and	B-X
declined	B-X
rapidly	B-X
thereafter	B-X
<EOS>	B-X
Anti	B-X
-	B-X
CD3	B-X
-	B-X
stimulated	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
was	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
,	B-X
whereas	B-X
IL	B-X
-	B-X
10	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
genes	B-X
were	B-X
readily	B-X
induced	B-X
independent	B-X
of	B-X
ongoing	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
In	B-X
LCL	B-X
-	B-X
stimulated	B-X
cells	B-X
the	B-X
cytokine	B-X
production	B-X
pattern	B-X
was	B-X
very	B-X
similar	B-X

No	O
IL-6	B-DNA
gene	I-DNA
expression	O
was	O
observed	O
.	O
<EOS>	B-X
Further	B-X
,	B-X
targeted	B-X
gene	B-X
expression	B-X
and	B-X
non	B-X
-	B-X
targeted	B-X
metabolomics	B-X
analysis	B-X
were	B-X
conducted	B-X
<EOS>	B-X
We	B-X
observed	B-X
increased	B-X
TNF	B-X
and	B-X
IL6	B-X
expression	B-X
when	B-X
expression	B-X
levels	B-X
from	B-X
all	B-X
brain	B-X
regions	B-X
were	B-X
combined	B-X
<EOS>	B-X
7	B-X
cells	B-X
were	B-X
exposed	B-X
to	B-X
laser	B-X
irradiation	B-X
under	B-X
different	B-X
laser	B-X
parameters	B-X
(	B-X
0	B-X
<EOS>	B-X
Animal	B-X
models	B-X
of	B-X
HALI	B-X
were	B-X
prepared	B-X
using	B-X
95	B-X
%	B-X
concentrations	B-X
of	B-X
oxygen	B-X

In	O
LCL-stimulated	B-cell_type
cells	I-cell_type
the	O
cytokine	O
production	O
pattern	O
was	O
very	O
similar	O
.	O
<EOS>	B-X
In	B-X
LCL	B-X
-	B-X
stimulated	B-X
cells	B-X
the	B-X
cytokine	B-X
production	B-X
pattern	B-X
was	B-X
very	B-X
similar	B-X
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
analysed	B-X
the	B-X
kinetics	B-X
and	B-X
nature	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
-	B-X
derived	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibodies	B-X
or	B-X
Lens	B-X
culinaris	B-X
lectin	B-X
(	B-X
LCL	B-X
)	B-X
<EOS>	B-X
No	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
was	B-X
observed	B-X
<EOS>	B-X
Anti	B-X
-	B-X
CD3	B-X
-	B-X
restimulated	B-X
T	B-X
cells	B-X
(	B-X
mainly	B-X
CD8+	B-X
)	B-X
produced	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
and	B-X
tumour	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
low	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
transcripts	B-X
and	B-X
proteins	B-X

Steady-state	O
mRNA	O
levels	O
of	O
IL-2	B-protein
,	O
IL-10	B-protein
and	O
IFN-gamma	B-protein
peaked	O
at	O
3	O
hr	O
after	O
anti-CD3	O
stimulation	O
and	O
declined	O
rapidly	O
thereafter	O
.	O
<EOS>	B-X
Steady	B-X
-	B-X
state	B-X
mRNA	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
IL	B-X
-	B-X
10	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
peaked	B-X
at	B-X
3	B-X
hr	B-X
after	B-X
anti	B-X
-	B-X
CD3	B-X
stimulation	B-X
and	B-X
declined	B-X
rapidly	B-X
thereafter	B-X
<EOS>	B-X
Anti	B-X
-	B-X
CD3	B-X
-	B-X
restimulated	B-X
T	B-X
cells	B-X
(	B-X
mainly	B-X
CD8+	B-X
)	B-X
produced	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
and	B-X
tumour	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
low	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
transcripts	B-X
and	B-X
proteins	B-X
<EOS>	B-X
T	B-X
cells	B-X
were	B-X
purified	B-X
from	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
and	B-X
primarily	B-X
activated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibodies	B-X
and	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
<EOS>	B-X
Anti	B-X
-	B-X
CD3	B-X
-	B-X
stimulated	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
was	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
,	B-X
whereas	B-X
IL	B-X
-	B-X
10	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
genes	B-X
were	B-X
readily	B-X
induced	B-X
independent	B-X
of	B-X
ongoing	B-X
protein	B-X
synthesis	B-X

The	O
kinetics	O
of	O
TNF-alpha	B-RNA
mRNA	I-RNA
expression	O
was	O
faster	O
,	O
being	O
at	O
its	O
peak	O
level	O
1	O
hr	O
after	O
stimulation	O
.	O
<EOS>	B-X
The	B-X
kinetics	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
expression	B-X
was	B-X
faster	B-X
,	B-X
being	B-X
at	B-X
its	B-X
peak	B-X
level	B-X
1	B-X
hr	B-X
after	B-X
stimulation	B-X
<EOS>	B-X
Kinetics	B-X
of	B-X
cytokine	B-X
and	B-X
NFAT	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
via	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
analysed	B-X
the	B-X
kinetics	B-X
and	B-X
nature	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
-	B-X
derived	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibodies	B-X
or	B-X
Lens	B-X
culinaris	B-X
lectin	B-X
(	B-X
LCL	B-X
)	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
stimulation	B-X
also	B-X
induced	B-X
a	B-X
very	B-X
rapid	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
jun	B-X
,	B-X
c	B-X
-	B-X
fos	B-X
and	B-X
NFATc1	B-X
(	B-X
NFATc	B-X
)	B-X
genes	B-X
,	B-X
the	B-X
gene	B-X
products	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
cytokine	B-X
gene	B-X
expression	B-X

Anti-CD3-stimulated	O
IL-2	B-DNA
gene	I-DNA
expression	O
was	O
down-regulated	O
by	O
protein	O
synthesis	O
inhibitor	O
,	O
whereas	O
IL-10	B-DNA
,	I-DNA
IFN-gamma	I-DNA
and	I-DNA
TNF-alpha	I-DNA
genes	I-DNA
were	O
readily	O
induced	O
independent	O
of	O
ongoing	O
protein	O
synthesis	O
.	O
<EOS>	B-X
Anti	B-X
-	B-X
CD3	B-X
-	B-X
stimulated	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
was	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
,	B-X
whereas	B-X
IL	B-X
-	B-X
10	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
genes	B-X
were	B-X
readily	B-X
induced	B-X
independent	B-X
of	B-X
ongoing	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
Anti	B-X
-	B-X
CD3	B-X
-	B-X
restimulated	B-X
T	B-X
cells	B-X
(	B-X
mainly	B-X
CD8+	B-X
)	B-X
produced	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
and	B-X
tumour	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
low	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
transcripts	B-X
and	B-X
proteins	B-X
<EOS>	B-X
Steady	B-X
-	B-X
state	B-X
mRNA	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
IL	B-X
-	B-X
10	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
peaked	B-X
at	B-X
3	B-X
hr	B-X
after	B-X
anti	B-X
-	B-X
CD3	B-X
stimulation	B-X
and	B-X
declined	B-X
rapidly	B-X
thereafter	B-X
<EOS>	B-X
Kinetics	B-X
of	B-X
cytokine	B-X
and	B-X
NFAT	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
via	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
.	B-X

T-cell	B-protein
receptor	I-protein
stimulation	O
also	O
induced	O
a	O
very	O
rapid	O
expression	O
of	O
c-jun	B-DNA
,	I-DNA
c-fos	I-DNA
and	I-DNA
NFATc1	I-DNA
(	I-DNA
NFATc	I-DNA
)	I-DNA
genes	I-DNA
,	O
the	O
gene	O
products	O
of	O
which	O
are	O
involved	O
in	O
cytokine	O
gene	O
expression	O
.	O
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
stimulation	B-X
also	B-X
induced	B-X
a	B-X
very	B-X
rapid	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
jun	B-X
,	B-X
c	B-X
-	B-X
fos	B-X
and	B-X
NFATc1	B-X
(	B-X
NFATc	B-X
)	B-X
genes	B-X
,	B-X
the	B-X
gene	B-X
products	B-X
of	B-X
which	B-X
are	B-X
involved	B-X
in	B-X
cytokine	B-X
gene	B-X
expression	B-X
<EOS>	B-X
T	B-X
cells	B-X
respond	B-X
to	B-X
mitogenic	B-X
or	B-X
antigenic	B-X
stimulation	B-X
by	B-X
proliferation	B-X
and	B-X
by	B-X
turning	B-X
on	B-X
cytokine	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Kinetics	B-X
of	B-X
cytokine	B-X
and	B-X
NFAT	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
interleukin	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
via	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
.	B-X
<EOS>	B-X
The	B-X
kinetics	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
expression	B-X
was	B-X
faster	B-X
,	B-X
being	B-X
at	B-X
its	B-X
peak	B-X
level	B-X
1	B-X
hr	B-X
after	B-X
stimulation	B-X

In	O
conclusion	O
,	O
the	O
cytokines	B-protein
synthesized	O
by	O
IL-2-dependent	B-cell_type
T	I-cell_type
cells	I-cell_type
were	O
predominantly	O
IL-2	B-protein
,	O
IFN-gamma	B-protein
and	O
TNF-alpha	B-protein
.	O
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
cytokines	B-X
synthesized	B-X
by	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
T	B-X
cells	B-X
were	B-X
predominantly	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Anti	B-X
-	B-X
CD3	B-X
-	B-X
stimulated	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
was	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
,	B-X
whereas	B-X
IL	B-X
-	B-X
10	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
genes	B-X
were	B-X
readily	B-X
induced	B-X
independent	B-X
of	B-X
ongoing	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
analysed	B-X
the	B-X
kinetics	B-X
and	B-X
nature	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
-	B-X
derived	B-X
T	B-X
lymphoblasts	B-X
stimulated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibodies	B-X
or	B-X
Lens	B-X
culinaris	B-X
lectin	B-X
(	B-X
LCL	B-X
)	B-X
<EOS>	B-X
In	B-X
LCL	B-X
-	B-X
stimulated	B-X
cells	B-X
the	B-X
cytokine	B-X
production	B-X
pattern	B-X
was	B-X
very	B-X
similar	B-X

An	O
animal	O
model	O
to	O
study	O
local	O
oxidation	O
of	O
LDL	O
and	O
its	O
biological	O
effects	O
in	O
the	O
arterial	O
wall	O
.	O
<EOS>	B-X
An	B-X
animal	B-X
model	B-X
to	B-X
study	B-X
local	B-X
oxidation	B-X
of	B-X
LDL	B-X
and	B-X
its	B-X
biological	B-X
effects	B-X
in	B-X
the	B-X
arterial	B-X
wall	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
simple	B-X
model	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
analyze	B-X
the	B-X
mechanisms	B-X
behind	B-X
and	B-X
biological	B-X
effects	B-X
of	B-X
LDL	B-X
oxidation	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Mainly	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
cell	B-X
culture	B-X
studies	B-X
,	B-X
oxLDL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
produce	B-X
many	B-X
biological	B-X
effects	B-X
that	B-X
influence	B-X
the	B-X
atherosclerotic	B-X
process	B-X
<EOS>	B-X
Within	B-X
6	B-X
hours	B-X
,	B-X
an	B-X
accumulation	B-X
of	B-X
apolipoprotein	B-X
B	B-X
and	B-X
epitopes	B-X
present	B-X
on	B-X
oxLDL	B-X
are	B-X
detected	B-X
in	B-X
the	B-X
arterial	B-X
endothelium	B-X
and	B-X
media	B-X

Oxidized	O
LDL	O
(	O
oxLDL	O
)	O
is	O
present	O
in	O
atherosclerotic	O
lesions	O
and	O
is	O
believed	O
to	O
play	O
a	O
key	O
role	O
in	O
atherogenesis	O
.	O
<EOS>	B-X
Oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
is	B-X
present	B-X
in	B-X
atherosclerotic	B-X
lesions	B-X
and	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
atherogenesis	B-X
<EOS>	B-X
The	B-X
uptake	B-X
of	B-X
oxidatively	B-X
modified	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
Ox	B-X
-	B-X
LDL	B-X
)	B-X
by	B-X
intimal	B-X
macrophages	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
atherosclerosis	B-X
<EOS>	B-X
Induction	B-X
of	B-X
heat	B-X
shock	B-X
protein	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
oxidized	B-X
low	B-X
density	B-X
lipoprotein	B-X
.	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
oxLDL	B-X
is	B-X
associated	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
endothelium	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X

Mainly	O
on	O
the	O
basis	O
of	O
cell	O
culture	O
studies	O
,	O
oxLDL	O
has	O
been	O
shown	O
to	O
produce	O
many	O
biological	O
effects	O
that	O
influence	O
the	O
atherosclerotic	O
process	O
.	O
<EOS>	B-X
Mainly	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
cell	B-X
culture	B-X
studies	B-X
,	B-X
oxLDL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
produce	B-X
many	B-X
biological	B-X
effects	B-X
that	B-X
influence	B-X
the	B-X
atherosclerotic	B-X
process	B-X
<EOS>	B-X
An	B-X
animal	B-X
model	B-X
to	B-X
study	B-X
local	B-X
oxidation	B-X
of	B-X
LDL	B-X
and	B-X
its	B-X
biological	B-X
effects	B-X
in	B-X
the	B-X
arterial	B-X
wall	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
simple	B-X
model	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
analyze	B-X
the	B-X
mechanisms	B-X
behind	B-X
and	B-X
biological	B-X
effects	B-X
of	B-X
LDL	B-X
oxidation	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
is	B-X
present	B-X
in	B-X
atherosclerotic	B-X
lesions	B-X
and	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
atherogenesis	B-X

To	O
study	O
LDL	O
oxidation	O
in	O
vivo	O
,	O
we	O
have	O
established	O
a	O
model	O
in	O
which	O
Sprague-Dawley	O
rats	O
are	O
given	O
a	O
single	O
injection	O
of	O
unmodified	O
human	O
LDL	O
(	O
>	O
or	O
=	O
4	O
mg/kg	O
body	O
weight	O
)	O
.	O

Within	O
6	O
hours	O
,	O
an	O
accumulation	O
of	O
apolipoprotein	O
B	O
and	O
epitopes	B-protein
present	O
on	O
oxLDL	O
are	O
detected	O
in	O
the	O
arterial	O
endothelium	O
and	O
media	O
.	O
<EOS>	B-X
Within	B-X
6	B-X
hours	B-X
,	B-X
an	B-X
accumulation	B-X
of	B-X
apolipoprotein	B-X
B	B-X
and	B-X
epitopes	B-X
present	B-X
on	B-X
oxLDL	B-X
are	B-X
detected	B-X
in	B-X
the	B-X
arterial	B-X
endothelium	B-X
and	B-X
media	B-X
<EOS>	B-X
An	B-X
animal	B-X
model	B-X
to	B-X
study	B-X
local	B-X
oxidation	B-X
of	B-X
LDL	B-X
and	B-X
its	B-X
biological	B-X
effects	B-X
in	B-X
the	B-X
arterial	B-X
wall	B-X
.	B-X
<EOS>	B-X
Injection	B-X
of	B-X
LDL	B-X
enriched	B-X
with	B-X
the	B-X
antioxidant	B-X
probucol	B-X
resulted	B-X
in	B-X
arterial	B-X
accumulation	B-X
of	B-X
apolipoprotein	B-X
B	B-X
,	B-X
but	B-X
the	B-X
expression	B-X
of	B-X
oxLDL	B-X
-	B-X
specific	B-X
epitopes	B-X
was	B-X
reduced	B-X
at	B-X
24	B-X
hours	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
oxLDL	B-X
is	B-X
associated	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
endothelium	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X

The	O
presence	O
of	O
oxLDL	O
is	O
associated	O
with	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
in	O
the	O
endothelium	O
as	O
well	O
as	O
endothelial	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
oxLDL	B-X
is	B-X
associated	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
endothelium	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
<EOS>	B-X
Oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
is	B-X
present	B-X
in	B-X
atherosclerotic	B-X
lesions	B-X
and	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
atherogenesis	B-X
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
simple	B-X
model	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
analyze	B-X
the	B-X
mechanisms	B-X
behind	B-X
and	B-X
biological	B-X
effects	B-X
of	B-X
LDL	B-X
oxidation	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Within	B-X
6	B-X
hours	B-X
,	B-X
an	B-X
accumulation	B-X
of	B-X
apolipoprotein	B-X
B	B-X
and	B-X
epitopes	B-X
present	B-X
on	B-X
oxLDL	B-X
are	B-X
detected	B-X
in	B-X
the	B-X
arterial	B-X
endothelium	B-X
and	B-X
media	B-X

Injection	O
of	O
LDL	O
enriched	O
with	O
the	O
antioxidant	O
probucol	O
resulted	O
in	O
arterial	O
accumulation	O
of	O
apolipoprotein	O
B	O
,	O
but	O
the	O
expression	O
of	O
oxLDL-specific	O
epitopes	O
was	O
reduced	O
at	O
24	O
hours	O
.	O
<EOS>	B-X
Injection	B-X
of	B-X
LDL	B-X
enriched	B-X
with	B-X
the	B-X
antioxidant	B-X
probucol	B-X
resulted	B-X
in	B-X
arterial	B-X
accumulation	B-X
of	B-X
apolipoprotein	B-X
B	B-X
,	B-X
but	B-X
the	B-X
expression	B-X
of	B-X
oxLDL	B-X
-	B-X
specific	B-X
epitopes	B-X
was	B-X
reduced	B-X
at	B-X
24	B-X
hours	B-X
<EOS>	B-X
Within	B-X
6	B-X
hours	B-X
,	B-X
an	B-X
accumulation	B-X
of	B-X
apolipoprotein	B-X
B	B-X
and	B-X
epitopes	B-X
present	B-X
on	B-X
oxLDL	B-X
are	B-X
detected	B-X
in	B-X
the	B-X
arterial	B-X
endothelium	B-X
and	B-X
media	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
oxLDL	B-X
is	B-X
associated	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
endothelium	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
<EOS>	B-X
Oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
is	B-X
present	B-X
in	B-X
atherosclerotic	B-X
lesions	B-X
and	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
atherogenesis	B-X

Thus	O
,	O
this	O
simple	O
model	O
has	O
the	O
potential	O
to	O
analyze	O
the	O
mechanisms	O
behind	O
and	O
biological	O
effects	O
of	O
LDL	O
oxidation	O
in	O
vivo	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
simple	B-X
model	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
analyze	B-X
the	B-X
mechanisms	B-X
behind	B-X
and	B-X
biological	B-X
effects	B-X
of	B-X
LDL	B-X
oxidation	B-X
in	B-X
vivo	B-X
<EOS>	B-X
An	B-X
animal	B-X
model	B-X
to	B-X
study	B-X
local	B-X
oxidation	B-X
of	B-X
LDL	B-X
and	B-X
its	B-X
biological	B-X
effects	B-X
in	B-X
the	B-X
arterial	B-X
wall	B-X
.	B-X
<EOS>	B-X
Mainly	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
cell	B-X
culture	B-X
studies	B-X
,	B-X
oxLDL	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
produce	B-X
many	B-X
biological	B-X
effects	B-X
that	B-X
influence	B-X
the	B-X
atherosclerotic	B-X
process	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
oxLDL	B-X
is	B-X
associated	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
endothelium	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X

Molecular	O
mechanisms	O
of	O
promoter	O
regulation	O
of	O
the	O
gp34	B-DNA
gene	I-DNA
that	O
is	O
trans-activated	O
by	O
an	O
oncoprotein	B-protein
Tax	I-protein
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
.	O
<EOS>	B-X
Molecular	B-X
mechanisms	B-X
of	B-X
promoter	B-X
regulation	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
that	B-X
is	B-X
trans	B-X
-	B-X
activated	B-X
by	B-X
an	B-X
oncoprotein	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
by	B-X
the	B-X
Tax	B-X
oncoprotein	B-X
of	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
)	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
was	B-X
activated	B-X
by	B-X
HTLV	B-X
-	B-X
I	B-X
Tax	B-X
in	B-X
the	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
Jurkat	B-X
,	B-X
in	B-X
which	B-X
endogenous	B-X
gp34	B-X
is	B-X
induced	B-X
by	B-X
Tax	B-X
<EOS>	B-X
Our	B-X
results	B-X
imply	B-X
complex	B-X
regulation	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
and	B-X
suggest	B-X
implication	B-X
of	B-X
gp34	B-X
in	B-X
proliferation	B-X
of	B-X
HTLV	B-X
-	B-X
I	B-X
infected	B-X
T	B-X
cells	B-X

We	O
investigated	O
the	O
molecular	O
mechanism	O
of	O
transcriptional	O
activation	O
of	O
the	O
gp34	B-DNA
gene	I-DNA
by	O
the	O
Tax	B-protein
oncoprotein	I-protein
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
by	B-X
the	B-X
Tax	B-X
oncoprotein	B-X
of	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
)	B-X
<EOS>	B-X
Molecular	B-X
mechanisms	B-X
of	B-X
promoter	B-X
regulation	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
that	B-X
is	B-X
trans	B-X
-	B-X
activated	B-X
by	B-X
an	B-X
oncoprotein	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
Our	B-X
results	B-X
imply	B-X
complex	B-X
regulation	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
and	B-X
suggest	B-X
implication	B-X
of	B-X
gp34	B-X
in	B-X
proliferation	B-X
of	B-X
HTLV	B-X
-	B-X
I	B-X
infected	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
was	B-X
activated	B-X
by	B-X
HTLV	B-X
-	B-X
I	B-X
Tax	B-X
in	B-X
the	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
Jurkat	B-X
,	B-X
in	B-X
which	B-X
endogenous	B-X
gp34	B-X
is	B-X
induced	B-X
by	B-X
Tax	B-X

gp34	B-protein
is	O
a	O
type	B-protein
II	I-protein
transmembrane	I-protein
molecule	I-protein
belonging	O
to	O
the	O
tumor	O
necrosis	O
factor	O
family	O
and	O
is	O
constitutively	O
expressed	O
on	O
HTLV-I-producing	B-cell_type
cells	I-cell_type
but	O
not	O
normal	B-cell_type
resting	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
transcriptional	O
regulatory	O
region	O
of	O
the	O
gp34	B-DNA
gene	I-DNA
was	O
activated	O
by	O
HTLV-I	O
Tax	B-protein
in	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
,	O
in	O
which	O
endogenous	O
gp34	B-protein
is	O
induced	O
by	O
Tax	B-protein
.	O

Sequence	O
analysis	O
demonstrated	O
that	O
two	O
NF-kappaB-like	B-DNA
elements	I-DNA
(	O
1	O
and	O
2	O
)	O
were	O
present	O
in	O
the	O
regulatory	B-DNA
region	I-DNA
.	O
<EOS>	B-X
Sequence	B-X
analysis	B-X
demonstrated	B-X
that	B-X
two	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
(	B-X
1	B-X
and	B-X
2	B-X
)	B-X
were	B-X
present	B-X
in	B-X
the	B-X
regulatory	B-X
region	B-X
<EOS>	B-X
Chloramphenicol	B-X
acetyltransferase	B-X
assays	B-X
indicated	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
1	B-X
was	B-X
Tax	B-X
-	B-X
responsive	B-X
,	B-X
although	B-X
the	B-X
activity	B-X
was	B-X
lower	B-X
than	B-X
that	B-X
the	B-X
native	B-X
promoter	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
2	B-X
elevated	B-X
promoter	B-X
activity	B-X
when	B-X
combined	B-X
with	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
1	B-X
,	B-X
indicating	B-X
cooperative	B-X
function	B-X
of	B-X
the	B-X
elements	B-X
for	B-X
maximum	B-X
promoter	B-X
function	B-X
<EOS>	B-X
Chloramphenicol	B-X
acetyltransferase	B-X
reporter	B-X
assays	B-X
using	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
identified	B-X
an	B-X
upstream	B-X
region	B-X
that	B-X
reduced	B-X
transcription	B-X
from	B-X
cognate	B-X
and	B-X
noncognate	B-X
core	B-X
promoters	B-X
in	B-X
a	B-X
Tax	B-X
-	B-X
independent	B-X
manner	B-X

Both	O
NF-kappaB-like	B-DNA
elements	I-DNA
were	O
able	O
to	O
bind	O
to	O
NF-kappaB	B-protein
or	O
its	O
related	O
factor	O
(	O
s	O
)	O
in	O
a	O
Tax	B-protein
-dependent	O
manner	O
.	O
<EOS>	B-X
Both	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
were	B-X
able	B-X
to	B-X
bind	B-X
to	B-X
NF	B-X
-	B-X
kappaB	B-X
or	B-X
its	B-X
related	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
in	B-X
a	B-X
Tax	B-X
-	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
2	B-X
elevated	B-X
promoter	B-X
activity	B-X
when	B-X
combined	B-X
with	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
1	B-X
,	B-X
indicating	B-X
cooperative	B-X
function	B-X
of	B-X
the	B-X
elements	B-X
for	B-X
maximum	B-X
promoter	B-X
function	B-X
<EOS>	B-X
Unlike	B-X
typical	B-X
NF	B-X
-	B-X
kappaB	B-X
elements	B-X
,	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
in	B-X
gp34	B-X
were	B-X
not	B-X
activated	B-X
by	B-X
treatment	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
phorbol	B-X
ester	B-X
despite	B-X
induction	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
binding	B-X
activity	B-X
<EOS>	B-X
Chloramphenicol	B-X
acetyltransferase	B-X
reporter	B-X
assays	B-X
using	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
identified	B-X
an	B-X
upstream	B-X
region	B-X
that	B-X
reduced	B-X
transcription	B-X
from	B-X
cognate	B-X
and	B-X
noncognate	B-X
core	B-X
promoters	B-X
in	B-X
a	B-X
Tax	B-X
-	B-X
independent	B-X
manner	B-X

Chloramphenicol	B-protein
acetyltransferase	I-protein
assays	O
indicated	O
that	O
NF-kappaB-like	B-DNA
element	I-DNA
1	I-DNA
was	O
Tax	B-protein
-responsive	O
,	O
although	O
the	O
activity	O
was	O
lower	O
than	O
that	O
the	O
native	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Chloramphenicol	B-X
acetyltransferase	B-X
assays	B-X
indicated	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
1	B-X
was	B-X
Tax	B-X
-	B-X
responsive	B-X
,	B-X
although	B-X
the	B-X
activity	B-X
was	B-X
lower	B-X
than	B-X
that	B-X
the	B-X
native	B-X
promoter	B-X
<EOS>	B-X
Chloramphenicol	B-X
acetyltransferase	B-X
reporter	B-X
assays	B-X
using	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
identified	B-X
an	B-X
upstream	B-X
region	B-X
that	B-X
reduced	B-X
transcription	B-X
from	B-X
cognate	B-X
and	B-X
noncognate	B-X
core	B-X
promoters	B-X
in	B-X
a	B-X
Tax	B-X
-	B-X
independent	B-X
manner	B-X
<EOS>	B-X
Sequence	B-X
analysis	B-X
demonstrated	B-X
that	B-X
two	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
(	B-X
1	B-X
and	B-X
2	B-X
)	B-X
were	B-X
present	B-X
in	B-X
the	B-X
regulatory	B-X
region	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
2	B-X
elevated	B-X
promoter	B-X
activity	B-X
when	B-X
combined	B-X
with	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
1	B-X
,	B-X
indicating	B-X
cooperative	B-X
function	B-X
of	B-X
the	B-X
elements	B-X
for	B-X
maximum	B-X
promoter	B-X
function	B-X

NF-kappaB	B-protein
-like	O
element	O
2	O
elevated	O
promoter	O
activity	O
when	O
combined	O
with	O
NF-kappaB-like	B-DNA
element	I-DNA
1	I-DNA
,	O
indicating	O
cooperative	O
function	O
of	O
the	O
elements	O
for	O
maximum	O
promoter	O
function	O
.	O
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
2	B-X
elevated	B-X
promoter	B-X
activity	B-X
when	B-X
combined	B-X
with	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
element	B-X
1	B-X
,	B-X
indicating	B-X
cooperative	B-X
function	B-X
of	B-X
the	B-X
elements	B-X
for	B-X
maximum	B-X
promoter	B-X
function	B-X
<EOS>	B-X
Both	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
were	B-X
able	B-X
to	B-X
bind	B-X
to	B-X
NF	B-X
-	B-X
kappaB	B-X
or	B-X
its	B-X
related	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
in	B-X
a	B-X
Tax	B-X
-	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
Chloramphenicol	B-X
acetyltransferase	B-X
reporter	B-X
assays	B-X
using	B-X
the	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
identified	B-X
an	B-X
upstream	B-X
region	B-X
that	B-X
reduced	B-X
transcription	B-X
from	B-X
cognate	B-X
and	B-X
noncognate	B-X
core	B-X
promoters	B-X
in	B-X
a	B-X
Tax	B-X
-	B-X
independent	B-X
manner	B-X
<EOS>	B-X
Sequence	B-X
analysis	B-X
demonstrated	B-X
that	B-X
two	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
like	B-X
elements	B-X
(	B-X
1	B-X
and	B-X
2	B-X
)	B-X
were	B-X
present	B-X
in	B-X
the	B-X
regulatory	B-X
region	B-X

Unlike	O
typical	O
NF-kappaB	B-DNA
elements	I-DNA
,	O
the	O
NF-kappaB-like	B-DNA
elements	I-DNA
in	O
gp34	B-protein
were	O
not	O
activated	O
by	O
treatment	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
phorbol	O
ester	O
despite	O
induction	O
of	O
the	O
NF-kappaB	B-protein
-like	O
binding	O
activity	O
.	O

Chloramphenicol	B-protein
acetyltransferase	I-protein
reporter	O
assays	O
using	O
the	O
region	O
upstream	O
of	O
the	O
NF-kappaB-like	B-DNA
elements	I-DNA
identified	O
an	O
upstream	O
region	O
that	O
reduced	O
transcription	O
from	O
cognate	B-DNA
and	I-DNA
noncognate	I-DNA
core	I-DNA
promoters	I-DNA
in	O
a	O
Tax-independent	O
manner	O
.	O

Our	O
results	O
imply	O
complex	O
regulation	O
of	O
expression	O
of	O
the	O
gp34	B-DNA
gene	I-DNA
and	O
suggest	O
implication	O
of	O
gp34	B-protein
in	O
proliferation	O
of	O
HTLV-I	O
infected	O
T	O
cells	O
.	O
<EOS>	B-X
Our	B-X
results	B-X
imply	B-X
complex	B-X
regulation	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
and	B-X
suggest	B-X
implication	B-X
of	B-X
gp34	B-X
in	B-X
proliferation	B-X
of	B-X
HTLV	B-X
-	B-X
I	B-X
infected	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
regulatory	B-X
region	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
was	B-X
activated	B-X
by	B-X
HTLV	B-X
-	B-X
I	B-X
Tax	B-X
in	B-X
the	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
Jurkat	B-X
,	B-X
in	B-X
which	B-X
endogenous	B-X
gp34	B-X
is	B-X
induced	B-X
by	B-X
Tax	B-X
<EOS>	B-X
Molecular	B-X
mechanisms	B-X
of	B-X
promoter	B-X
regulation	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
that	B-X
is	B-X
trans	B-X
-	B-X
activated	B-X
by	B-X
an	B-X
oncoprotein	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
gp34	B-X
gene	B-X
by	B-X
the	B-X
Tax	B-X
oncoprotein	B-X
of	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
)	B-X

beta-Amyloid	B-protein
fibrils	I-protein
activate	O
parallel	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
in	O
microglia	B-cell_type
and	O
THP1	B-cell_line
monocytes	I-cell_line
.	O
<EOS>	B-X
beta	B-X
-	B-X
Amyloid	B-X
fibrils	B-X
activate	B-X
parallel	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
pathways	B-X
in	B-X
microglia	B-X
and	B-X
THP1	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Abeta	B-X
stimulated	B-X
the	B-X
rapid	B-X
,	B-X
transient	B-X
activation	B-X
of	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
and	B-X
ERK2	B-X
in	B-X
microglia	B-X
and	B-X
ERK2	B-X
in	B-X
THP1	B-X
monocytes	B-X
<EOS>	B-X
Fibrillar	B-X
forms	B-X
of	B-X
beta	B-X
-	B-X
amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
which	B-X
are	B-X
the	B-X
primary	B-X
constituents	B-X
of	B-X
senile	B-X
plaques	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
activate	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
signal	B-X
transduction	B-X
cascades	B-X
,	B-X
resulting	B-X
in	B-X
inflammatory	B-X
responses	B-X
in	B-X
microglia	B-X
<EOS>	B-X
Importantly	B-X
,	B-X
the	B-X
stress	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
(	B-X
SAPKs	B-X
)	B-X
were	B-X
not	B-X
significantly	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
Abeta	B-X

The	O
senile	O
plaques	O
of	O
Alzheimer	O
's	O
disease	O
are	O
foci	O
of	O
local	O
inflammatory	O
responses	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
acute	B-protein
phase	I-protein
proteins	I-protein
and	O
oxidative	O
damage	O
.	O
<EOS>	B-X
The	B-X
senile	B-X
plaques	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
are	B-X
foci	B-X
of	B-X
local	B-X
inflammatory	B-X
responses	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
acute	B-X
phase	B-X
proteins	B-X
and	B-X
oxidative	B-X
damage	B-X
<EOS>	B-X
Senile	B-X
plaques	B-X
are	B-X
foci	B-X
of	B-X
local	B-X
inflammatory	B-X
processes	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
numerous	B-X
activated	B-X
microglia	B-X
and	B-X
acute	B-X
phase	B-X
proteins	B-X
<EOS>	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
a	B-X
devastating	B-X
neurological	B-X
disorder	B-X
characterized	B-X
by	B-X
loss	B-X
of	B-X
cognitive	B-X
skills	B-X
and	B-X
progressive	B-X
dementia	B-X
<EOS>	B-X
The	B-X
tyrosine	B-X
kinases	B-X
Lyn	B-X
,	B-X
Syk	B-X
,	B-X
and	B-X
FAK	B-X
were	B-X
activated	B-X
on	B-X
exposure	B-X
of	B-X
microglia	B-X
and	B-X
THP1	B-X
monocytes	B-X
to	B-X
Abeta	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
generation	B-X
of	B-X
superoxide	B-X
radicals	B-X

Fibrillar	B-protein
forms	I-protein
of	O
beta-amyloid	B-protein
(	O
Abeta	B-protein
)	O
,	O
which	O
are	O
the	O
primary	O
constituents	O
of	O
senile	O
plaques	O
,	O
have	O
been	O
shown	O
to	O
activate	O
tyrosine	O
kinase-dependent	O
signal	O
transduction	O
cascades	O
,	O
resulting	O
in	O
inflammatory	O
responses	O
in	O
microglia	B-cell_type
.	O
<EOS>	B-X
Fibrillar	B-X
forms	B-X
of	B-X
beta	B-X
-	B-X
amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
which	B-X
are	B-X
the	B-X
primary	B-X
constituents	B-X
of	B-X
senile	B-X
plaques	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
activate	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
signal	B-X
transduction	B-X
cascades	B-X
,	B-X
resulting	B-X
in	B-X
inflammatory	B-X
responses	B-X
in	B-X
microglia	B-X
<EOS>	B-X
We	B-X
report	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
rat	B-X
microglia	B-X
and	B-X
human	B-X
THP1	B-X
monocytes	B-X
to	B-X
fibrillar	B-X
Abeta	B-X
results	B-X
in	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
two	B-X
parallel	B-X
signal	B-X
transduction	B-X
cascades	B-X
involving	B-X
members	B-X
of	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
superfamily	B-X
<EOS>	B-X
beta	B-X
-	B-X
Amyloid	B-X
fibrils	B-X
activate	B-X
parallel	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
pathways	B-X
in	B-X
microglia	B-X
and	B-X
THP1	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Importantly	B-X
,	B-X
the	B-X
stress	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
(	B-X
SAPKs	B-X
)	B-X
were	B-X
not	B-X
significantly	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
Abeta	B-X

However	O
,	O
the	O
downstream	O
signaling	O
pathways	O
mediating	O
Abeta	B-protein
-induced	O
inflammatory	O
events	O
are	O
not	O
well	O
characterized	O
.	O
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
gx	B-X
-	B-X
50	B-X
could	B-X
inhibit	B-X
the	B-X
Aβ	B-X
-	B-X
induced	B-X
inflammatory	B-X
response	B-X
in	B-X
microglia	B-X
via	B-X
α7	B-X
nAChR	B-X
activity	B-X
,	B-X
which	B-X
might	B-X
be	B-X
a	B-X
successful	B-X
therapeutic	B-X
target	B-X
against	B-X
AD	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
upregulation	B-X
of	B-X
fl	B-X
-	B-X
APP	B-X
protein	B-X
and	B-X
products	B-X
may	B-X
drive	B-X
downstream	B-X
events	B-X
that	B-X
dysregulate	B-X
tau	B-X
homeostasis	B-X
and	B-X
inflammatory	B-X
responses	B-X
that	B-X
contribute	B-X
to	B-X
propagation	B-X
of	B-X
AD	B-X
pathogenesis	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
gx	B-X
-	B-X
50	B-X
on	B-X
α7	B-X
nAChR	B-X
and	B-X
Aβ	B-X
-	B-X
induced	B-X
inflammation	B-X
in	B-X
microglia	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
the	B-X
α7	B-X
nicotinic	B-X
acetylcholine	B-X
receptor	B-X
(	B-X
α7	B-X
nAChR	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
link	B-X
between	B-X
inflammation	B-X
and	B-X
neurodegeneration	B-X
,	B-X
which	B-X
is	B-X
closely	B-X
associated	B-X
with	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X

We	O
report	O
that	O
exposure	O
of	O
primary	B-cell_type
rat	I-cell_type
microglia	I-cell_type
and	O
human	B-cell_line
THP1	I-cell_line
monocytes	I-cell_line
to	O
fibrillar	B-protein
Abeta	I-protein
results	O
in	O
the	O
tyrosine	B-protein
kinase	I-protein
-dependent	O
activation	O
of	O
two	O
parallel	O
signal	O
transduction	O
cascades	O
involving	O
members	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
MAPK	I-protein
)	I-protein
superfamily	I-protein
.	O
<EOS>	B-X
We	B-X
report	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
rat	B-X
microglia	B-X
and	B-X
human	B-X
THP1	B-X
monocytes	B-X
to	B-X
fibrillar	B-X
Abeta	B-X
results	B-X
in	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
two	B-X
parallel	B-X
signal	B-X
transduction	B-X
cascades	B-X
involving	B-X
members	B-X
of	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
superfamily	B-X
<EOS>	B-X
Exposure	B-X
of	B-X
microglia	B-X
and	B-X
THP1	B-X
monocytes	B-X
to	B-X
Abeta	B-X
resulted	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
RSK1	B-X
and	B-X
RSK2	B-X
and	B-X
phosphorylation	B-X
of	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
at	B-X
Ser133	B-X
,	B-X
providing	B-X
a	B-X
mechanism	B-X
for	B-X
Abeta	B-X
-	B-X
induced	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Fibrillar	B-X
forms	B-X
of	B-X
beta	B-X
-	B-X
amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
which	B-X
are	B-X
the	B-X
primary	B-X
constituents	B-X
of	B-X
senile	B-X
plaques	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
activate	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
signal	B-X
transduction	B-X
cascades	B-X
,	B-X
resulting	B-X
in	B-X
inflammatory	B-X
responses	B-X
in	B-X
microglia	B-X
<EOS>	B-X
The	B-X
senile	B-X
plaques	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
are	B-X
foci	B-X
of	B-X
local	B-X
inflammatory	B-X
responses	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
acute	B-X
phase	B-X
proteins	B-X
and	B-X
oxidative	B-X
damage	B-X

Abeta	B-protein
stimulated	O
the	O
rapid	O
,	O
transient	O
activation	O
of	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
1	I-protein
(	O
ERK1	B-protein
)	O
and	O
ERK2	B-protein
in	O
microglia	B-cell_type
and	O
ERK2	B-protein
in	O
THP1	B-cell_line
monocytes	I-cell_line
.	O
<EOS>	B-X
Abeta	B-X
stimulated	B-X
the	B-X
rapid	B-X
,	B-X
transient	B-X
activation	B-X
of	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
and	B-X
ERK2	B-X
in	B-X
microglia	B-X
and	B-X
ERK2	B-X
in	B-X
THP1	B-X
monocytes	B-X
<EOS>	B-X
beta	B-X
-	B-X
Amyloid	B-X
fibrils	B-X
activate	B-X
parallel	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
pathways	B-X
in	B-X
microglia	B-X
and	B-X
THP1	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Importantly	B-X
,	B-X
the	B-X
stress	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
(	B-X
SAPKs	B-X
)	B-X
were	B-X
not	B-X
significantly	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
Abeta	B-X
<EOS>	B-X
We	B-X
report	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
rat	B-X
microglia	B-X
and	B-X
human	B-X
THP1	B-X
monocytes	B-X
to	B-X
fibrillar	B-X
Abeta	B-X
results	B-X
in	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
two	B-X
parallel	B-X
signal	B-X
transduction	B-X
cascades	B-X
involving	B-X
members	B-X
of	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
superfamily	B-X

A	O
second	O
superfamily	B-protein
member	I-protein
,	O
p38	B-protein
MAPK	I-protein
,	O
was	O
also	O
activated	O
with	O
similar	O
kinetics	O
.	O
<EOS>	B-X
A	B-X
second	B-X
superfamily	B-X
member	B-X
,	B-X
p38	B-X
MAPK	B-X
,	B-X
was	B-X
also	B-X
activated	B-X
with	B-X
similar	B-X
kinetics	B-X
<EOS>	B-X
Importantly	B-X
,	B-X
the	B-X
stress	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
(	B-X
SAPKs	B-X
)	B-X
were	B-X
not	B-X
significantly	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
Abeta	B-X
<EOS>	B-X
Downstream	B-X
effectors	B-X
of	B-X
the	B-X
MAPK	B-X
signal	B-X
transduction	B-X
cascades	B-X
include	B-X
MAPKAP	B-X
kinases	B-X
,	B-X
such	B-X
as	B-X
RSK1	B-X
and	B-X
RSK2	B-X
,	B-X
as	B-X
well	B-X
as	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
The	B-X
senile	B-X
plaques	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
are	B-X
foci	B-X
of	B-X
local	B-X
inflammatory	B-X
responses	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
acute	B-X
phase	B-X
proteins	B-X
and	B-X
oxidative	B-X
damage	B-X

Scavenger	B-protein
receptor	I-protein
and	O
receptor	B-protein
for	I-protein
advanced	I-protein
glycated	I-protein
end	I-protein
products	I-protein
(	O
RAGE	B-protein
)	O
ligands	O
failed	O
to	O
activate	O
ERK	B-protein
and	O
p38	B-protein
MAPK	I-protein
in	O
the	O
absence	O
of	O
significant	O
increases	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
demonstrating	O
that	O
scavenger	B-protein
receptors	I-protein
and	O
RAGE	B-protein
are	O
not	O
linked	O
to	O
these	O
pathways	O
.	O

Importantly	O
,	O
the	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
(	O
SAPKs	B-protein
)	O
were	O
not	O
significantly	O
activated	O
in	O
response	O
to	O
Abeta	B-protein
.	O
<EOS>	B-X
Stress	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
(	B-X
SAPKs	B-X
)	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
controlling	B-X
several	B-X
steps	B-X
of	B-X
mRNA	B-X
biogenesis	B-X
<EOS>	B-X
Importantly	B-X
,	B-X
p38	B-X
interacted	B-X
with	B-X
and	B-X
directly	B-X
phosphorylated	B-X
SKIIP	B-X
,	B-X
thereby	B-X
altering	B-X
its	B-X
activity	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
osmostress	B-X
has	B-X
an	B-X
impact	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
alternative	B-X
splicing	B-X
(	B-X
AS	B-X
)	B-X
,	B-X
which	B-X
is	B-X
partly	B-X
mediated	B-X
through	B-X
the	B-X
action	B-X
of	B-X
p38	B-X
SAPK	B-X
<EOS>	B-X
Splicing	B-X
network	B-X
analysis	B-X
revealed	B-X
a	B-X
functional	B-X
connection	B-X
between	B-X
p38	B-X
and	B-X
the	B-X
spliceosome	B-X
component	B-X
SKIIP	B-X
,	B-X
whose	B-X
depletion	B-X
abolished	B-X
a	B-X
significant	B-X
fraction	B-X
of	B-X
p38	B-X
-	B-X
mediated	B-X
AS	B-X
changes	B-X

Downstream	O
effectors	O
of	O
the	O
MAPK	O
signal	O
transduction	O
cascades	O
include	O
MAPKAP	B-protein
kinases	I-protein
,	O
such	O
as	O
RSK1	B-protein
and	O
RSK2	B-protein
,	O
as	O
well	O
as	O
transcription	B-protein
factors	I-protein
.	O
<EOS>	B-X
Downstream	B-X
effectors	B-X
of	B-X
the	B-X
MAPK	B-X
signal	B-X
transduction	B-X
cascades	B-X
include	B-X
MAPKAP	B-X
kinases	B-X
,	B-X
such	B-X
as	B-X
RSK1	B-X
and	B-X
RSK2	B-X
,	B-X
as	B-X
well	B-X
as	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
downstream	B-X
signaling	B-X
pathways	B-X
mediating	B-X
Abeta	B-X
-	B-X
induced	B-X
inflammatory	B-X
events	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
<EOS>	B-X
Fibrillar	B-X
forms	B-X
of	B-X
beta	B-X
-	B-X
amyloid	B-X
(	B-X
Abeta	B-X
)	B-X
,	B-X
which	B-X
are	B-X
the	B-X
primary	B-X
constituents	B-X
of	B-X
senile	B-X
plaques	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
activate	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
signal	B-X
transduction	B-X
cascades	B-X
,	B-X
resulting	B-X
in	B-X
inflammatory	B-X
responses	B-X
in	B-X
microglia	B-X
<EOS>	B-X
The	B-X
senile	B-X
plaques	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
are	B-X
foci	B-X
of	B-X
local	B-X
inflammatory	B-X
responses	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
acute	B-X
phase	B-X
proteins	B-X
and	B-X
oxidative	B-X
damage	B-X

Exposure	O
of	O
microglia	B-cell_type
and	O
THP1	B-cell_line
monocytes	I-cell_line
to	O
Abeta	B-protein
resulted	O
in	O
the	O
activation	O
of	O
RSK1	B-protein
and	O
RSK2	B-protein
and	O
phosphorylation	O
of	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
at	O
Ser133	O
,	O
providing	O
a	O
mechanism	O
for	O
Abeta	B-protein
-induced	O
changes	O
in	O
gene	O
expression	O
<EOS>	B-X
Exposure	B-X
of	B-X
microglia	B-X
and	B-X
THP1	B-X
monocytes	B-X
to	B-X
Abeta	B-X
resulted	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
RSK1	B-X
and	B-X
RSK2	B-X
and	B-X
phosphorylation	B-X
of	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
at	B-X
Ser133	B-X
,	B-X
providing	B-X
a	B-X
mechanism	B-X
for	B-X
Abeta	B-X
-	B-X
induced	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
<EOS>	B-X
We	B-X
report	B-X
that	B-X
exposure	B-X
of	B-X
primary	B-X
rat	B-X
microglia	B-X
and	B-X
human	B-X
THP1	B-X
monocytes	B-X
to	B-X
fibrillar	B-X
Abeta	B-X
results	B-X
in	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
two	B-X
parallel	B-X
signal	B-X
transduction	B-X
cascades	B-X
involving	B-X
members	B-X
of	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
superfamily	B-X
<EOS>	B-X
Abeta	B-X
stimulated	B-X
the	B-X
rapid	B-X
,	B-X
transient	B-X
activation	B-X
of	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
and	B-X
ERK2	B-X
in	B-X
microglia	B-X
and	B-X
ERK2	B-X
in	B-X
THP1	B-X
monocytes	B-X
<EOS>	B-X
The	B-X
senile	B-X
plaques	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
are	B-X
foci	B-X
of	B-X
local	B-X
inflammatory	B-X
responses	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
acute	B-X
phase	B-X
proteins	B-X
and	B-X
oxidative	B-X
damage	B-X

Regulation	O
of	O
cellular	B-protein
retinoic	I-protein
acid	I-protein
binding	I-protein
protein	I-protein
(	O
CRABP	B-protein
II	I-protein
)	O
during	O
human	B-cell_type
monocyte	I-cell_type
differentiation	O
in	O
vitro	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
cellular	B-X
retinoic	B-X
acid	B-X
binding	B-X
protein	B-X
(	B-X
CRABP	B-X
II	B-X
)	B-X
during	B-X
human	B-X
monocyte	B-X
differentiation	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Cellular	B-X
retinoic	B-X
acid	B-X
binding	B-X
proteins	B-X
(	B-X
CRABP	B-X
)	B-X
are	B-X
low	B-X
molecular	B-X
weight	B-X
proteins	B-X
whose	B-X
precise	B-X
function	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
(	B-X
1	B-X
)	B-X
that	B-X
the	B-X
availability	B-X
and	B-X
the	B-X
metabolism	B-X
of	B-X
retinoids	B-X
may	B-X
be	B-X
different	B-X
in	B-X
MAC	B-X
compared	B-X
to	B-X
MO	B-X
and	B-X
dendritic	B-X
cells	B-X
and	B-X
(	B-X
2	B-X
)	B-X
that	B-X
this	B-X
may	B-X
influence	B-X
differentiation	B-X
and	B-X
activation	B-X
of	B-X
those	B-X
cells	B-X
<EOS>	B-X
By	B-X
representative	B-X
difference	B-X
analysis	B-X
we	B-X
found	B-X
that	B-X
CRABP	B-X
II	B-X
is	B-X
also	B-X
strongly	B-X
expressed	B-X
in	B-X
human	B-X
monocyte	B-X
-	B-X
derived	B-X
macrophages	B-X
(	B-X
MAC	B-X
)	B-X
but	B-X
not	B-X
in	B-X
freshly	B-X
isolated	B-X
monocytes	B-X
(	B-X
MO	B-X
)	B-X

Cellular	B-protein
retinoic	I-protein
acid	I-protein
binding	I-protein
proteins	I-protein
(	O
CRABP	B-protein
)	O
are	O
low	B-protein
molecular	I-protein
weight	I-protein
proteins	I-protein
whose	O
precise	O
function	O
remains	O
unknown	O
.	O
<EOS>	B-X
Cellular	B-X
retinoic	B-X
acid	B-X
binding	B-X
proteins	B-X
(	B-X
CRABP	B-X
)	B-X
are	B-X
low	B-X
molecular	B-X
weight	B-X
proteins	B-X
whose	B-X
precise	B-X
function	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
cellular	B-X
retinoic	B-X
acid	B-X
binding	B-X
protein	B-X
(	B-X
CRABP	B-X
II	B-X
)	B-X
during	B-X
human	B-X
monocyte	B-X
differentiation	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Molecular	B-X
cloning	B-X
of	B-X
two	B-X
human	B-X
cellular	B-X
retinoic	B-X
acid	B-X
-	B-X
binding	B-X
proteins	B-X
(	B-X
CRABP	B-X
)	B-X
.	B-X
Retinoic	B-X
acid	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
CRABP	B-X
-	B-X
II	B-X
but	B-X
not	B-X
CRABP	B-X
-	B-X
I	B-X
in	B-X
adult	B-X
human	B-X
skin	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
skin	B-X
fibroblasts	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
They	B-X
bind	B-X
retinoids	B-X
and	B-X
may	B-X
thereby	B-X
modulate	B-X
the	B-X
intracellular	B-X
steady	B-X
-	B-X
state	B-X
concentration	B-X
of	B-X
retinoids	B-X

They	O
bind	O
retinoids	O
and	O
may	O
thereby	O
modulate	O
the	O
intracellular	O
steady-state	O
concentration	O
of	O
retinoids	O
.	O
<EOS>	B-X
They	B-X
bind	B-X
retinoids	B-X
and	B-X
may	B-X
thereby	B-X
modulate	B-X
the	B-X
intracellular	B-X
steady	B-X
-	B-X
state	B-X
concentration	B-X
of	B-X
retinoids	B-X
<EOS>	B-X
Cellular	B-X
retinoic	B-X
acid	B-X
binding	B-X
proteins	B-X
(	B-X
CRABP	B-X
)	B-X
are	B-X
low	B-X
molecular	B-X
weight	B-X
proteins	B-X
whose	B-X
precise	B-X
function	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
(	B-X
1	B-X
)	B-X
that	B-X
the	B-X
availability	B-X
and	B-X
the	B-X
metabolism	B-X
of	B-X
retinoids	B-X
may	B-X
be	B-X
different	B-X
in	B-X
MAC	B-X
compared	B-X
to	B-X
MO	B-X
and	B-X
dendritic	B-X
cells	B-X
and	B-X
(	B-X
2	B-X
)	B-X
that	B-X
this	B-X
may	B-X
influence	B-X
differentiation	B-X
and	B-X
activation	B-X
of	B-X
those	B-X
cells	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
cellular	B-X
retinoic	B-X
acid	B-X
binding	B-X
protein	B-X
(	B-X
CRABP	B-X
II	B-X
)	B-X
during	B-X
human	B-X
monocyte	B-X
differentiation	B-X
in	B-X
vitro	B-X
.	B-X

Whereas	O
CRABP	B-protein
I	I-protein
is	O
ubiquitously	O
expressed	O
,	O
CRABP	B-protein
II	I-protein
is	O
mainly	O
detected	O
in	O
various	O
cell	O
types	O
of	O
the	O
skin	O
.	O
<EOS>	B-X
Whereas	B-X
CRABP	B-X
I	B-X
is	B-X
ubiquitously	B-X
expressed	B-X
,	B-X
CRABP	B-X
II	B-X
is	B-X
mainly	B-X
detected	B-X
in	B-X
various	B-X
cell	B-X
types	B-X
of	B-X
the	B-X
skin	B-X
<EOS>	B-X
By	B-X
representative	B-X
difference	B-X
analysis	B-X
we	B-X
found	B-X
that	B-X
CRABP	B-X
II	B-X
is	B-X
also	B-X
strongly	B-X
expressed	B-X
in	B-X
human	B-X
monocyte	B-X
-	B-X
derived	B-X
macrophages	B-X
(	B-X
MAC	B-X
)	B-X
but	B-X
not	B-X
in	B-X
freshly	B-X
isolated	B-X
monocytes	B-X
(	B-X
MO	B-X
)	B-X
<EOS>	B-X
Adherence	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
MO	B-X
differentiation	B-X
,	B-X
induced	B-X
CRABP	B-X
II	B-X
expression	B-X
,	B-X
but	B-X
the	B-X
addition	B-X
of	B-X
10	B-X
(	B-X
	B-X
-	B-X
7	B-X
)	B-X
M	B-X
retinoic	B-X
acid	B-X
inhibited	B-X
the	B-X
upregulation	B-X
of	B-X
CRABP	B-X
II	B-X
expression	B-X
during	B-X
MO	B-X
/	B-X
MAC	B-X
differentiation	B-X
<EOS>	B-X
The	B-X
CRABP	B-X
II	B-X
mRNA	B-X
was	B-X
gradually	B-X
upregulated	B-X
during	B-X
differentiation	B-X
from	B-X
MO	B-X
to	B-X
MAC	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
2	B-X
%	B-X
serum	B-X

By	O
representative	O
difference	O
analysis	O
we	O
found	O
that	O
CRABP	B-protein
II	I-protein
is	O
also	O
strongly	O
expressed	O
in	O
human	B-cell_type
monocyte-derived	I-cell_type
macrophages	I-cell_type
(	O
MAC	B-cell_type
)	O
but	O
not	O
in	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
(	O
MO	B-cell_type
)	O
.	O

The	O
CRABP	B-RNA
II	I-RNA
mRNA	I-RNA
was	O
gradually	O
upregulated	O
during	O
differentiation	O
from	O
MO	B-cell_type
to	O
MAC	B-cell_type
in	O
the	O
presence	O
of	O
2	O
%	O
serum	O
.	O

Adherence	O
,	O
which	O
is	O
important	O
for	O
MO	B-cell_type
differentiation	O
,	O
induced	O
CRABP	B-protein
II	I-protein
expression	O
,	O
but	O
the	O
addition	O
of	O
10	O
(	O
-7	O
)	O
M	O
retinoic	O
acid	O
inhibited	O
the	O
upregulation	O
of	O
CRABP	B-protein
II	I-protein
expression	O
during	O
MO/MAC	O
differentiation	O
.	O
<EOS>	B-X
Adherence	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
MO	B-X
differentiation	B-X
,	B-X
induced	B-X
CRABP	B-X
II	B-X
expression	B-X
,	B-X
but	B-X
the	B-X
addition	B-X
of	B-X
10	B-X
(	B-X
	B-X
-	B-X
7	B-X
)	B-X
M	B-X
retinoic	B-X
acid	B-X
inhibited	B-X
the	B-X
upregulation	B-X
of	B-X
CRABP	B-X
II	B-X
expression	B-X
during	B-X
MO	B-X
/	B-X
MAC	B-X
differentiation	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
cellular	B-X
retinoic	B-X
acid	B-X
binding	B-X
protein	B-X
(	B-X
CRABP	B-X
II	B-X
)	B-X
during	B-X
human	B-X
monocyte	B-X
differentiation	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Whereas	B-X
CRABP	B-X
I	B-X
is	B-X
ubiquitously	B-X
expressed	B-X
,	B-X
CRABP	B-X
II	B-X
is	B-X
mainly	B-X
detected	B-X
in	B-X
various	B-X
cell	B-X
types	B-X
of	B-X
the	B-X
skin	B-X
<EOS>	B-X
The	B-X
CRABP	B-X
II	B-X
mRNA	B-X
was	B-X
gradually	B-X
upregulated	B-X
during	B-X
differentiation	B-X
from	B-X
MO	B-X
to	B-X
MAC	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
2	B-X
%	B-X
serum	B-X

As	O
MO	B-cell_type
can	O
differentiate	O
along	O
the	O
classical	O
pathway	O
not	O
only	O
to	O
MAC	B-cell_type
but	O
also	O
to	O
dendritic	O
cells	O
we	O
analyzed	O
the	O
expression	O
of	O
CRABP	B-protein
II	I-protein
in	O
MO-derived	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
cultured	O
with	O
10	O
%	O
FCS	B-protein
,	O
IL-4	B-protein
,	O
and	O
GM-CSF	B-protein
.	O
<EOS>	B-X
Significantly	B-X
higher	B-X
total	B-X
mutation	B-X
numbers	B-X
and	B-X
neoantigens	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
CS2	B-X
group	B-X
,	B-X
along	B-X
with	B-X
specific	B-X
mutations	B-X
in	B-X
TTN	B-X
,	B-X
MUC16	B-X
,	B-X
and	B-X
ARID1A	B-X
<EOS>	B-X
Ten	B-X
classical	B-X
clustering	B-X
algorithms	B-X
were	B-X
executed	B-X
to	B-X
recognize	B-X
patients	B-X
with	B-X
different	B-X
molecular	B-X
features	B-X
using	B-X
the	B-X
``	B-X
MOVICS	B-X
''	B-X
package	B-X
in	B-X
R	B-X
<EOS>	B-X
In	B-X
Met	B-X
(	B-X
high	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
Met	B-X
ligand	B-X
HGF	B-X
further	B-X
sustained	B-X
proliferation	B-X
,	B-X
clonogenicity	B-X
,	B-X
expression	B-X
of	B-X
self	B-X
-	B-X
renewal	B-X
markers	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
invasion	B-X
in	B-X
vitro	B-X
<EOS>	B-X
The	B-X
similar	B-X
diversity	B-X
in	B-X
clinical	B-X
outcomes	B-X
between	B-X
CS1	B-X
and	B-X
CS2	B-X
groups	B-X
was	B-X
successfully	B-X
validated	B-X
in	B-X
the	B-X
external	B-X
cohorts	B-X
,	B-X
GSE62254	B-X
,	B-X
GSE26253	B-X
,	B-X
GSE15459	B-X
,	B-X
and	B-X
GSE84437	B-X

In	O
contrast	O
to	O
MAC	B-cell_type
,	O
MO-derived	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
showed	O
an	O
extremely	O
low	O
expression	O
of	O
CRABP	B-protein
II	I-protein
.	O
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
MAC	B-X
,	B-X
MO	B-X
-	B-X
derived	B-X
dendritic	B-X
cells	B-X
showed	B-X
an	B-X
extremely	B-X
low	B-X
expression	B-X
of	B-X
CRABP	B-X
II	B-X
<EOS>	B-X
As	B-X
MO	B-X
can	B-X
differentiate	B-X
along	B-X
the	B-X
classical	B-X
pathway	B-X
not	B-X
only	B-X
to	B-X
MAC	B-X
but	B-X
also	B-X
to	B-X
dendritic	B-X
cells	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
of	B-X
CRABP	B-X
II	B-X
in	B-X
MO	B-X
-	B-X
derived	B-X
dendritic	B-X
cells	B-X
cultured	B-X
with	B-X
10	B-X
%	B-X
FCS	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
and	B-X
GM	B-X
-	B-X
CSF	B-X
<EOS>	B-X
From	B-X
these	B-X
results	B-X
we	B-X
conclude	B-X
(	B-X
1	B-X
)	B-X
that	B-X
the	B-X
availability	B-X
and	B-X
the	B-X
metabolism	B-X
of	B-X
retinoids	B-X
may	B-X
be	B-X
different	B-X
in	B-X
MAC	B-X
compared	B-X
to	B-X
MO	B-X
and	B-X
dendritic	B-X
cells	B-X
and	B-X
(	B-X
2	B-X
)	B-X
that	B-X
this	B-X
may	B-X
influence	B-X
differentiation	B-X
and	B-X
activation	B-X
of	B-X
those	B-X
cells	B-X
<EOS>	B-X
Adherence	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
MO	B-X
differentiation	B-X
,	B-X
induced	B-X
CRABP	B-X
II	B-X
expression	B-X
,	B-X
but	B-X
the	B-X
addition	B-X
of	B-X
10	B-X
(	B-X
	B-X
-	B-X
7	B-X
)	B-X
M	B-X
retinoic	B-X
acid	B-X
inhibited	B-X
the	B-X
upregulation	B-X
of	B-X
CRABP	B-X
II	B-X
expression	B-X
during	B-X
MO	B-X
/	B-X
MAC	B-X
differentiation	B-X

From	O
these	O
results	O
we	O
conclude	O
(	O
1	O
)	O
that	O
the	O
availability	O
and	O
the	O
metabolism	O
of	O
retinoids	O
may	O
be	O
different	O
in	O
MAC	B-cell_type
compared	O
to	O
MO	B-cell_type
and	O
dendritic	B-cell_type
cells	I-cell_type
and	O
(	O
2	O
)	O
that	O
this	O
may	O
influence	O
differentiation	O
and	O
activation	O
of	O
those	O
cells	O
.	O

Transcription	B-protein
factor	I-protein
B-cell-specific	I-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
is	O
differentially	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
in	O
subsets	O
of	O
B-cell	O
lymphomas	O
.	O

The	O
paired	B-DNA
box	I-DNA
containing	I-DNA
gene	I-DNA
PAX-5	B-DNA
encodes	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
(	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
)	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
B-lymphocyte	O
development	O
.	O

Despite	O
its	O
known	O
involvement	O
in	O
a	O
rare	O
subtype	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
a	O
detailed	O
examination	O
of	O
BSAP	B-protein
expression	O
in	O
NHL	O
has	O
not	O
been	O
previously	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
normal	O
and	O
malignant	O
lymphoid	O
tissues	O
and	O
cell	B-cell_line
lines	I-cell_line
,	O
including	O
102	O
cases	O
of	O
B-cell	O
NHL	O
,	O
23	O
cases	O
of	O
T-	O
and	O
null-cell	O
NHL	O
,	O
and	O
18	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
normal	B-X
and	B-X
malignant	B-X
lymphoid	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
102	B-X
cases	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
NHL	B-X
,	B-X
23	B-X
cases	B-X
of	B-X
T	B-X
-	B-X
	B-X
and	B-X
null	B-X
-	B-X
cell	B-X
NHL	B-X
,	B-X
and	B-X
18	B-X
cases	B-X
of	B-X
Hodgkin	B-X
's	B-X
disease	B-X
<EOS>	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
a	B-X
52	B-X
-	B-X
kD	B-X
BSAP	B-X
band	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
not	B-X
in	B-X
non	B-X
-	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
plasma	B-X
cell	B-X
lines	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
BSAP	B-X
expression	B-X
is	B-X
largely	B-X
restricted	B-X
to	B-X
lymphomas	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
lineage	B-X
and	B-X
that	B-X
BSAP	B-X
expression	B-X
varies	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
subsets	B-X
and	B-X
subtypes	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
NHL	B-X
<EOS>	B-X
The	B-X
high	B-X
levels	B-X
of	B-X
BSAP	B-X
,	B-X
especially	B-X
those	B-X
found	B-X
in	B-X
large	B-X
-	B-X
cell	B-X
lymphomas	B-X
and	B-X
in	B-X
some	B-X
follicular	B-X
lymphomas	B-X
,	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
deregulated	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
PAX	B-X
-	B-X
5	B-X
in	B-X
certain	B-X
B	B-X
-	B-X
cell	B-X
malignancies	B-X

Normal	O
lymphoid	O
tissues	O
showed	O
strong	O
nuclear	O
BSAP	B-protein
expression	O
in	O
mantle	B-cell_type
zone	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
less	O
intense	O
reactivity	O
in	O
follicular	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
and	O
no	O
expression	O
in	O
cells	O
of	O
the	O
T-cell-rich	O
zones	O
.	O

Monocytoid	B-cell_type
B	I-cell_type
cells	I-cell_type
showed	O
weak	O
expression	O
,	O
whereas	O
plasma	B-cell_type
cells	I-cell_type
and	O
extrafollicular	B-cell_type
large	I-cell_type
transformed	I-cell_type
B	I-cell_type
cells	I-cell_type
were	O
negative	O
.	O
<EOS>	B-X
Monocytoid	B-X
B	B-X
cells	B-X
showed	B-X
weak	B-X
expression	B-X
,	B-X
whereas	B-X
plasma	B-X
cells	B-X
and	B-X
extrafollicular	B-X
large	B-X
transformed	B-X
B	B-X
cells	B-X
were	B-X
negative	B-X
<EOS>	B-X
Normal	B-X
lymphoid	B-X
tissues	B-X
showed	B-X
strong	B-X
nuclear	B-X
BSAP	B-X
expression	B-X
in	B-X
mantle	B-X
zone	B-X
B	B-X
cells	B-X
,	B-X
less	B-X
intense	B-X
reactivity	B-X
in	B-X
follicular	B-X
center	B-X
B	B-X
cells	B-X
,	B-X
and	B-X
no	B-X
expression	B-X
in	B-X
cells	B-X
of	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
rich	B-X
zones	B-X
<EOS>	B-X
All	B-X
of	B-X
the	B-X
13	B-X
(	B-X
100	B-X
%	B-X
)	B-X
B	B-X
-	B-X
cell	B-X
chronic	B-X
lymphocytic	B-X
leukemias	B-X
(	B-X
B	B-X
-	B-X
CLLs	B-X
)	B-X
,	B-X
21	B-X
of	B-X
(	B-X
100	B-X
%	B-X
)	B-X
mantle	B-X
cells	B-X
(	B-X
MCLs	B-X
)	B-X
,	B-X
and	B-X
20	B-X
of	B-X
21	B-X
(	B-X
95	B-X
%	B-X
)	B-X
follicular	B-X
lymphomas	B-X
(	B-X
FLs	B-X
)	B-X
were	B-X
positive	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
BSAP	B-X
expression	B-X
is	B-X
largely	B-X
restricted	B-X
to	B-X
lymphomas	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
lineage	B-X
and	B-X
that	B-X
BSAP	B-X
expression	B-X
varies	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
subsets	B-X
and	B-X
subtypes	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
NHL	B-X

Of	O
the	O
102	O
B-cell	O
NHLs	O
,	O
83	O
(	O
81	O
%	O
)	O
demonstrated	O
BSAP	B-protein
expression	O
.	O
<EOS>	B-X
Of	B-X
the	B-X
102	B-X
B	B-X
-	B-X
cell	B-X
NHLs	B-X
,	B-X
83	B-X
(	B-X
81	B-X
%	B-X
)	B-X
demonstrated	B-X
BSAP	B-X
expression	B-X
<EOS>	B-X
All	B-X
of	B-X
the	B-X
13	B-X
(	B-X
100	B-X
%	B-X
)	B-X
B	B-X
-	B-X
cell	B-X
chronic	B-X
lymphocytic	B-X
leukemias	B-X
(	B-X
B	B-X
-	B-X
CLLs	B-X
)	B-X
,	B-X
21	B-X
of	B-X
(	B-X
100	B-X
%	B-X
)	B-X
mantle	B-X
cells	B-X
(	B-X
MCLs	B-X
)	B-X
,	B-X
and	B-X
20	B-X
of	B-X
21	B-X
(	B-X
95	B-X
%	B-X
)	B-X
follicular	B-X
lymphomas	B-X
(	B-X
FLs	B-X
)	B-X
were	B-X
positive	B-X
<EOS>	B-X
Despite	B-X
its	B-X
known	B-X
involvement	B-X
in	B-X
a	B-X
rare	B-X
subtype	B-X
of	B-X
non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
,	B-X
a	B-X
detailed	B-X
examination	B-X
of	B-X
BSAP	B-X
expression	B-X
in	B-X
NHL	B-X
has	B-X
not	B-X
been	B-X
previously	B-X
reported	B-X
<EOS>	B-X
Eight	B-X
of	B-X
12	B-X
(	B-X
67	B-X
%	B-X
)	B-X
marginal	B-X
zone	B-X
lymphoma	B-X
cases	B-X
showed	B-X
negative	B-X
or	B-X
low	B-X
BSAP	B-X
levels	B-X
,	B-X
and	B-X
17	B-X
of	B-X
24	B-X
(	B-X
71	B-X
%	B-X
)	B-X
large	B-X
B	B-X
-	B-X
cell	B-X
lymphomas	B-X
displayed	B-X
moderate	B-X
to	B-X
strong	B-X
expression	B-X

All	O
of	O
the	O
13	O
(	O
100	O
%	O
)	O
B-cell	O
chronic	O
lymphocytic	O
leukemias	O
(	O
B-CLLs	O
)	O
,	O
21	O
of	O
(	O
100	O
%	O
)	O
mantle	B-cell_type
cells	I-cell_type
(	O
MCLs	B-cell_type
)	O
,	O
and	O
20	O
of	O
21	O
(	O
95	O
%	O
)	O
follicular	O
lymphomas	O
(	O
FLs	O
)	O
were	O
positive	O
.	O

Moderate	O
staining	O
intensities	O
were	O
found	O
in	O
most	O
B-CLL	O
and	O
FL	O
cases	O
,	O
whereas	O
most	O
MCLs	B-cell_type
showed	O
strong	O
reactions	O
,	O
paralleling	O
the	O
strong	O
reactivity	O
of	O
nonmalignant	B-cell_type
mantle	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Moderate	B-X
staining	B-X
intensities	B-X
were	B-X
found	B-X
in	B-X
most	B-X
B	B-X
-	B-X
CLL	B-X
and	B-X
FL	B-X
cases	B-X
,	B-X
whereas	B-X
most	B-X
MCLs	B-X
showed	B-X
strong	B-X
reactions	B-X
,	B-X
paralleling	B-X
the	B-X
strong	B-X
reactivity	B-X
of	B-X
nonmalignant	B-X
mantle	B-X
cells	B-X
<EOS>	B-X
None	B-X
of	B-X
the	B-X
23	B-X
T	B-X
-	B-X
	B-X
and	B-X
null	B-X
-	B-X
cell	B-X
lymphomas	B-X
reacted	B-X
with	B-X
the	B-X
BSAP	B-X
antisera	B-X
,	B-X
whereas	B-X
in	B-X
Hodgkin	B-X
's	B-X
disease	B-X
,	B-X
2	B-X
of	B-X
4	B-X
(	B-X
50	B-X
%	B-X
)	B-X
nodular	B-X
lymphocytic	B-X
predominance	B-X
and	B-X
5	B-X
of	B-X
14	B-X
(	B-X
36	B-X
%	B-X
)	B-X
classical	B-X
cases	B-X
showed	B-X
weak	B-X
nuclear	B-X
or	B-X
nucleolar	B-X
BSAP	B-X
reactions	B-X
in	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
tumor	B-X
cells	B-X
<EOS>	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
a	B-X
52	B-X
-	B-X
kD	B-X
BSAP	B-X
band	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
not	B-X
in	B-X
non	B-X
-	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
plasma	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Monocytoid	B-X
B	B-X
cells	B-X
showed	B-X
weak	B-X
expression	B-X
,	B-X
whereas	B-X
plasma	B-X
cells	B-X
and	B-X
extrafollicular	B-X
large	B-X
transformed	B-X
B	B-X
cells	B-X
were	B-X
negative	B-X

Eight	O
of	O
12	O
(	O
67	O
%	O
)	O
marginal	O
zone	O
lymphoma	O
cases	O
showed	O
negative	O
or	O
low	O
BSAP	B-protein
levels	O
,	O
and	O
17	O
of	O
24	O
(	O
71	O
%	O
)	O
large	O
B-cell	O
lymphomas	O
displayed	O
moderate	O
to	O
strong	O
expression	O
.	O

None	O
of	O
the	O
23	O
T-	O
and	O
null-cell	O
lymphomas	O
reacted	O
with	O
the	O
BSAP	B-protein
antisera	O
,	O
whereas	O
in	O
Hodgkin	O
's	O
disease	O
,	O
2	O
of	O
4	O
(	O
50	O
%	O
)	O
nodular	O
lymphocytic	O
predominance	O
and	O
5	O
of	O
14	O
(	O
36	O
%	O
)	O
classical	O
cases	O
showed	O
weak	O
nuclear	O
or	O
nucleolar	O
BSAP	B-protein
reactions	O
in	O
a	O
fraction	O
of	O
the	O
tumor	B-cell_type
cells	I-cell_type
.	O

Western	O
blot	O
analysis	O
showed	O
a	O
52-kD	O
BSAP	B-protein
band	O
in	O
B-cell	B-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
non-B-cell	B-cell_line
or	I-cell_line
plasma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
mutant	B-X
IRF4	B-X
protein	B-X
in	B-X
control	B-X
lymphoblastoid	B-X
B	B-X
cell	B-X
lines	B-X
reduced	B-X
the	B-X
expression	B-X
of	B-X
BLIMP	B-X
-	B-X
1	B-X
and	B-X
XBP1	B-X
(	B-X
key	B-X
transcription	B-X
factors	B-X
in	B-X
plasma	B-X
cell	B-X
differentiation	B-X
)	B-X
<EOS>	B-X
Patients	B-X
'	B-X
low	B-X
blood	B-X
plasmablast	B-X
/	B-X
plasma	B-X
cell	B-X
and	B-X
naïve	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cell	B-X
counts	B-X
contrasted	B-X
with	B-X
high	B-X
terminal	B-X
effector	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cell	B-X
counts	B-X
<EOS>	B-X
BCMA	B-X
is	B-X
considered	B-X
a	B-X
validated	B-X
target	B-X
in	B-X
multiple	B-X
myeloma	B-X
but	B-X
whether	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
lymphomas	B-X
can	B-X
be	B-X
targeted	B-X
by	B-X
the	B-X
BCMAxCD3	B-X
T	B-X
-	B-X
cell	B-X
redirector	B-X
teclistamab	B-X
is	B-X
currently	B-X
unknown	B-X
<EOS>	B-X
The	B-X
hot	B-X
accretion	B-X
flow	B-X
around	B-X
Kerr	B-X
black	B-X
holes	B-X
is	B-X
strongly	B-X
magnetized	B-X

We	O
conclude	O
that	O
BSAP	B-protein
expression	O
is	O
largely	O
restricted	O
to	O
lymphomas	O
of	O
B-cell	B-cell_type
lineage	I-cell_type
and	O
that	O
BSAP	B-protein
expression	O
varies	O
in	O
B-cell	B-cell_type
subsets	I-cell_type
and	O
subtypes	O
of	O
B-cell	O
NHL	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
BSAP	B-X
expression	B-X
is	B-X
largely	B-X
restricted	B-X
to	B-X
lymphomas	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
lineage	B-X
and	B-X
that	B-X
BSAP	B-X
expression	B-X
varies	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
subsets	B-X
and	B-X
subtypes	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
NHL	B-X
<EOS>	B-X
The	B-X
high	B-X
levels	B-X
of	B-X
BSAP	B-X
,	B-X
especially	B-X
those	B-X
found	B-X
in	B-X
large	B-X
-	B-X
cell	B-X
lymphomas	B-X
and	B-X
in	B-X
some	B-X
follicular	B-X
lymphomas	B-X
,	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
deregulated	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
PAX	B-X
-	B-X
5	B-X
in	B-X
certain	B-X
B	B-X
-	B-X
cell	B-X
malignancies	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activator	B-X
protein	B-X
(	B-X
BSAP	B-X
)	B-X
is	B-X
differentially	B-X
expressed	B-X
in	B-X
B	B-X
cells	B-X
and	B-X
in	B-X
subsets	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
lymphomas	B-X
.	B-X
<EOS>	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
a	B-X
52	B-X
-	B-X
kD	B-X
BSAP	B-X
band	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
not	B-X
in	B-X
non	B-X
-	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
plasma	B-X
cell	B-X
lines	B-X

The	O
high	O
levels	O
of	O
BSAP	B-protein
,	O
especially	O
those	O
found	O
in	O
large-cell	B-cell_type
lymphomas	I-cell_type
and	O
in	O
some	O
follicular	B-cell_type
lymphomas	I-cell_type
,	O
may	O
be	O
a	O
consequence	O
of	O
deregulated	O
gene	O
expression	O
and	O
suggest	O
a	O
possible	O
involvement	O
of	O
PAX-5	B-DNA
in	O
certain	O
B-cell	O
malignancies	O
.	O
<EOS>	B-X
The	B-X
high	B-X
levels	B-X
of	B-X
BSAP	B-X
,	B-X
especially	B-X
those	B-X
found	B-X
in	B-X
large	B-X
-	B-X
cell	B-X
lymphomas	B-X
and	B-X
in	B-X
some	B-X
follicular	B-X
lymphomas	B-X
,	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
deregulated	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
PAX	B-X
-	B-X
5	B-X
in	B-X
certain	B-X
B	B-X
-	B-X
cell	B-X
malignancies	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
BSAP	B-X
expression	B-X
is	B-X
largely	B-X
restricted	B-X
to	B-X
lymphomas	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
lineage	B-X
and	B-X
that	B-X
BSAP	B-X
expression	B-X
varies	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
subsets	B-X
and	B-X
subtypes	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
NHL	B-X
<EOS>	B-X
Despite	B-X
its	B-X
known	B-X
involvement	B-X
in	B-X
a	B-X
rare	B-X
subtype	B-X
of	B-X
non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
,	B-X
a	B-X
detailed	B-X
examination	B-X
of	B-X
BSAP	B-X
expression	B-X
in	B-X
NHL	B-X
has	B-X
not	B-X
been	B-X
previously	B-X
reported	B-X
<EOS>	B-X
Normal	B-X
lymphoid	B-X
tissues	B-X
showed	B-X
strong	B-X
nuclear	B-X
BSAP	B-X
expression	B-X
in	B-X
mantle	B-X
zone	B-X
B	B-X
cells	B-X
,	B-X
less	B-X
intense	B-X
reactivity	B-X
in	B-X
follicular	B-X
center	B-X
B	B-X
cells	B-X
,	B-X
and	B-X
no	B-X
expression	B-X
in	B-X
cells	B-X
of	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
rich	B-X
zones	B-X

This	O
is	O
a	O
US	O
government	O
work	O
.	O
<EOS>	B-X
This	B-X
study	B-X
relies	B-X
on	B-X
the	B-X
2021	B-X
U	B-X
<EOS>	B-X
Analyses	B-X
will	B-X
be	B-X
according	B-X
to	B-X
the	B-X
intention	B-X
to	B-X
treat	B-X
principle	B-X
<EOS>	B-X
Overall	B-X
survival	B-X
was	B-X
analysed	B-X
by	B-X
intention	B-X
to	B-X
treat	B-X
<EOS>	B-X
Eight	B-X
-	B-X
year	B-X
overall	B-X
survival	B-X
rates	B-X
were	B-X
90	B-X

There	O
are	O
no	O
restrictions	O
on	O
its	O
use	O
.	O
<EOS>	B-X
The	B-X
study	B-X
has	B-X
opened	B-X
up	B-X
many	B-X
new	B-X
directions	B-X
for	B-X
future	B-X
research	B-X
<EOS>	B-X
The	B-X
average	B-X
length	B-X
of	B-X
stay	B-X
in	B-X
the	B-X
hospital	B-X
was	B-X
6	B-X
<EOS>	B-X
Average	B-X
patient	B-X
satisfaction	B-X
was	B-X
4	B-X
<EOS>	B-X
There	B-X
were	B-X
43	B-X
emergency	B-X
interventions	B-X
in	B-X
39	B-X
patients	B-X
(	B-X
10	B-X
percutaneous	B-X
drain	B-X
;	B-X
33	B-X
surgery	B-X
)	B-X

Mitogen	O
and	O
growth	O
factor-induced	O
activation	O
of	O
a	O
STAT-like	B-protein
molecule	I-protein
in	O
channel	B-cell_type
catfish	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Mitogen	B-X
and	B-X
growth	B-X
factor	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
a	B-X
STAT	B-X
-	B-X
like	B-X
molecule	B-X
in	B-X
channel	B-X
catfish	B-X
lymphoid	B-X
cells	B-X
.	B-X
<EOS>	B-X
This	B-X
article	B-X
describes	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
putative	B-X
STAT	B-X
molecule	B-X
in	B-X
the	B-X
channel	B-X
catfish	B-X
(	B-X
Ictalurus	B-X
punctatus	B-X
)	B-X
,	B-X
the	B-X
first	B-X
report	B-X
of	B-X
such	B-X
a	B-X
molecule	B-X
in	B-X
a	B-X
'lower	B-X
'	B-X
vertebrate	B-X
<EOS>	B-X
Purification	B-X
of	B-X
the	B-X
proteins	B-X
present	B-X
in	B-X
these	B-X
DNA	B-X
complexes	B-X
confirms	B-X
that	B-X
the	B-X
catfish	B-X
reactive	B-X
molecule	B-X
binds	B-X
to	B-X
the	B-X
interferon	B-X
-	B-X
gamma	B-X
activation	B-X
site	B-X
sequence	B-X
<EOS>	B-X
This	B-X
presumed	B-X
catfish	B-X
STAT	B-X
binds	B-X
the	B-X
mammalian	B-X
interferon	B-X
-	B-X
gamma	B-X
activation	B-X
site	B-X
,	B-X
a	B-X
known	B-X
motif	B-X
of	B-X
mammalian	B-X
STAT	B-X
binding	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
electromobility	B-X
shift	B-X
assays	B-X

This	O
article	O
describes	O
the	O
identification	O
of	O
a	O
putative	B-protein
STAT	I-protein
molecule	I-protein
in	O
the	O
channel	O
catfish	O
(	O
Ictalurus	O
punctatus	O
)	O
,	O
the	O
first	O
report	O
of	O
such	O
a	O
molecule	O
in	O
a	O
'lower	O
'	O
vertebrate	O
.	O

A	O
monoclonal	B-protein
antibody	I-protein
against	O
human	B-protein
STAT6	I-protein
recognizes	O
an	O
approximately	O
100	B-protein
kDa	I-protein
molecule	I-protein
that	O
becomes	O
activated	O
and	O
translocates	O
to	O
the	O
nucleus	O
upon	O
both	O
growth	O
factor	O
and	O
mitogen	O
stimulation	O
of	O
catfish	O
leukocytes	O
.	O

This	O
presumed	O
catfish	B-protein
STAT	I-protein
binds	O
the	O
mammalian	B-DNA
interferon-gamma	I-DNA
activation	I-DNA
site	I-DNA
,	O
a	O
known	O
motif	O
of	O
mammalian	O
STAT	O
binding	O
,	O
as	O
shown	O
by	O
electromobility	O
shift	O
assays	O
.	O

Purification	O
of	O
the	O
proteins	O
present	O
in	O
these	O
DNA	B-protein
complexes	I-protein
confirms	O
that	O
the	O
catfish	O
reactive	O
molecule	O
binds	O
to	O
the	O
interferon-gamma	B-DNA
activation	I-DNA
site	I-DNA
sequence	I-DNA
.	O

These	O
results	O
suggest	O
that	O
STAT	B-protein
molecules	I-protein
have	O
been	O
highly	O
conserved	O
in	O
vertebrate	O
evolution	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
STAT	B-X
molecules	B-X
have	B-X
been	B-X
highly	B-X
conserved	B-X
in	B-X
vertebrate	B-X
evolution	B-X
<EOS>	B-X
Collectively	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
,	B-X
the	B-X
NtSOCS	B-X
-	B-X
1	B-X
and	B-X
3	B-X
might	B-X
play	B-X
significant	B-X
role	B-X
(	B-X
s	B-X
)	B-X
in	B-X
innate	B-X
immune	B-X
response	B-X
,	B-X
while	B-X
NtSOCS	B-X
-	B-X
2	B-X
may	B-X
be	B-X
more	B-X
involved	B-X
in	B-X
metabolic	B-X
regulation	B-X
<EOS>	B-X
Tissue	B-X
specific	B-X
expression	B-X
results	B-X
showed	B-X
that	B-X
,	B-X
NtSOCS	B-X
-	B-X
1	B-X
,	B-X
2	B-X
and	B-X
3	B-X
were	B-X
constitutively	B-X
expressed	B-X
in	B-X
all	B-X
nine	B-X
tissues	B-X
examined	B-X
<EOS>	B-X
This	B-X
article	B-X
describes	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
putative	B-X
STAT	B-X
molecule	B-X
in	B-X
the	B-X
channel	B-X
catfish	B-X
(	B-X
Ictalurus	B-X
punctatus	B-X
)	B-X
,	B-X
the	B-X
first	B-X
report	B-X
of	B-X
such	B-X
a	B-X
molecule	B-X
in	B-X
a	B-X
'lower	B-X
'	B-X
vertebrate	B-X

Isolation	O
and	O
analysis	O
of	O
a	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
variant	I-cell_line
exhibiting	O
constitutively	O
phosphorylated	B-protein
Ser133	I-protein
cAMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
.	O

In	O
driving	O
T	O
cell	O
proliferation	O
,	O
IL-2	B-protein
stimulates	O
a	O
new	O
program	O
of	O
gene	O
expression	O
that	O
includes	O
proliferating	B-protein
cell	I-protein
nuclear	I-protein
antigen	I-protein
(	O
PCNA	B-protein
)	O
,	O
a	O
requisite	O
processivity	O
factor	O
for	O
DNA	B-protein
polymerase	I-protein
delta	I-protein
.	O
<EOS>	B-X
In	B-X
driving	B-X
T	B-X
cell	B-X
proliferation	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
stimulates	B-X
a	B-X
new	B-X
program	B-X
of	B-X
gene	B-X
expression	B-X
that	B-X
includes	B-X
proliferating	B-X
cell	B-X
nuclear	B-X
antigen	B-X
(	B-X
PCNA	B-X
)	B-X
,	B-X
a	B-X
requisite	B-X
processivity	B-X
factor	B-X
for	B-X
DNA	B-X
polymerase	B-X
delta	B-X
<EOS>	B-X
In	B-X
L2	B-X
cells	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
inhibited	B-X
the	B-X
following	B-X
:	B-X
cAMP	B-X
-	B-X
independent	B-X
CREB	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
L2	B-X
and	B-X
L2	B-X
variant	B-X
cells	B-X
were	B-X
tested	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
responsiveness	B-X
and	B-X
rapamycin	B-X
sensitivity	B-X
with	B-X
respect	B-X
to	B-X
specific	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
L2	B-X
variant	B-X
cells	B-X
,	B-X
CREB	B-X
kinase	B-X
activity	B-X
was	B-X
constitutively	B-X
high	B-X
;	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
blocked	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X

PCNA	B-protein
transcription	O
is	O
regulated	O
in	O
part	O
through	O
tandem	O
CRE	B-DNA
sequences	I-DNA
in	O
the	O
promoter	B-protein
and	I-protein
CRE	I-protein
binding	I-protein
proteins	I-protein
;	O
IL-2	B-protein
stimulates	O
CREB	O
phosphorylation	O
in	O
the	O
resting	B-cell_line
cloned	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
,	O
L2	B-cell_line
.	O
<EOS>	B-X
PCNA	B-X
transcription	B-X
is	B-X
regulated	B-X
in	B-X
part	B-X
through	B-X
tandem	B-X
CRE	B-X
sequences	B-X
in	B-X
the	B-X
promoter	B-X
and	B-X
CRE	B-X
binding	B-X
proteins	B-X
;	B-X
IL	B-X
-	B-X
2	B-X
stimulates	B-X
CREB	B-X
phosphorylation	B-X
in	B-X
the	B-X
resting	B-X
cloned	B-X
T	B-X
lymphocyte	B-X
,	B-X
L2	B-X
<EOS>	B-X
Isolation	B-X
and	B-X
analysis	B-X
of	B-X
a	B-X
T	B-X
cell	B-X
clone	B-X
variant	B-X
exhibiting	B-X
constitutively	B-X
phosphorylated	B-X
Ser133	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
alone	B-X
is	B-X
not	B-X
sufficient	B-X
to	B-X
drive	B-X
PCNA	B-X
expression	B-X
and	B-X
L2	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
After	B-X
culturing	B-X
L2	B-X
cells	B-X
for	B-X
greater	B-X
than	B-X
91	B-X
days	B-X
,	B-X
we	B-X
consistently	B-X
isolate	B-X
a	B-X
stable	B-X
variant	B-X
that	B-X
exhibits	B-X
constitutive	B-X
CREB	B-X
phosphorylation	B-X

After	O
culturing	O
L2	B-cell_line
cells	I-cell_line
for	O
greater	O
than	O
91	O
days	O
,	O
we	O
consistently	O
isolate	O
a	O
stable	O
variant	O
that	O
exhibits	O
constitutive	O
CREB	O
phosphorylation	O
.	O
<EOS>	B-X
After	B-X
culturing	B-X
L2	B-X
cells	B-X
for	B-X
greater	B-X
than	B-X
91	B-X
days	B-X
,	B-X
we	B-X
consistently	B-X
isolate	B-X
a	B-X
stable	B-X
variant	B-X
that	B-X
exhibits	B-X
constitutive	B-X
CREB	B-X
phosphorylation	B-X
<EOS>	B-X
PCNA	B-X
transcription	B-X
is	B-X
regulated	B-X
in	B-X
part	B-X
through	B-X
tandem	B-X
CRE	B-X
sequences	B-X
in	B-X
the	B-X
promoter	B-X
and	B-X
CRE	B-X
binding	B-X
proteins	B-X
;	B-X
IL	B-X
-	B-X
2	B-X
stimulates	B-X
CREB	B-X
phosphorylation	B-X
in	B-X
the	B-X
resting	B-X
cloned	B-X
T	B-X
lymphocyte	B-X
,	B-X
L2	B-X
<EOS>	B-X
In	B-X
driving	B-X
T	B-X
cell	B-X
proliferation	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
stimulates	B-X
a	B-X
new	B-X
program	B-X
of	B-X
gene	B-X
expression	B-X
that	B-X
includes	B-X
proliferating	B-X
cell	B-X
nuclear	B-X
antigen	B-X
(	B-X
PCNA	B-X
)	B-X
,	B-X
a	B-X
requisite	B-X
processivity	B-X
factor	B-X
for	B-X
DNA	B-X
polymerase	B-X
delta	B-X
<EOS>	B-X
L2	B-X
and	B-X
L2	B-X
variant	B-X
cells	B-X
were	B-X
tested	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
responsiveness	B-X
and	B-X
rapamycin	B-X
sensitivity	B-X
with	B-X
respect	B-X
to	B-X
specific	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X

L2	B-cell_line
and	I-cell_line
L2	I-cell_line
variant	I-cell_line
cells	I-cell_line
were	O
tested	O
for	O
IL-2	B-protein
responsiveness	O
and	O
rapamycin	O
sensitivity	O
with	O
respect	O
to	O
specific	O
kinase	O
activity	O
,	O
PCNA	O
expression	O
and	O
proliferation	O
.	O
<EOS>	B-X
L2	B-X
and	B-X
L2	B-X
variant	B-X
cells	B-X
were	B-X
tested	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
responsiveness	B-X
and	B-X
rapamycin	B-X
sensitivity	B-X
with	B-X
respect	B-X
to	B-X
specific	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
L2	B-X
cells	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
inhibited	B-X
the	B-X
following	B-X
:	B-X
cAMP	B-X
-	B-X
independent	B-X
CREB	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
L2	B-X
variant	B-X
cells	B-X
,	B-X
CREB	B-X
kinase	B-X
activity	B-X
was	B-X
constitutively	B-X
high	B-X
;	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
blocked	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
IL	B-X
-	B-X
2	B-X
induces	B-X
a	B-X
rapamycin	B-X
-	B-X
sensitive	B-X
,	B-X
cAMP	B-X
-	B-X
independent	B-X
CREB	B-X
kinase	B-X
activity	B-X
in	B-X
L2	B-X
cells	B-X

In	O
L2	B-cell_line
cells	I-cell_line
,	O
IL-2	B-protein
stimulated	O
and	O
rapamycin	O
inhibited	O
the	O
following	O
:	O
cAMP-independent	O
CREB	B-protein
kinase	I-protein
activity	O
,	O
PCNA	O
expression	O
and	O
proliferation	O
.	O
<EOS>	B-X
In	B-X
L2	B-X
cells	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
inhibited	B-X
the	B-X
following	B-X
:	B-X
cAMP	B-X
-	B-X
independent	B-X
CREB	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
L2	B-X
and	B-X
L2	B-X
variant	B-X
cells	B-X
were	B-X
tested	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
responsiveness	B-X
and	B-X
rapamycin	B-X
sensitivity	B-X
with	B-X
respect	B-X
to	B-X
specific	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
IL	B-X
-	B-X
2	B-X
induces	B-X
a	B-X
rapamycin	B-X
-	B-X
sensitive	B-X
,	B-X
cAMP	B-X
-	B-X
independent	B-X
CREB	B-X
kinase	B-X
activity	B-X
in	B-X
L2	B-X
cells	B-X
<EOS>	B-X
In	B-X
L2	B-X
variant	B-X
cells	B-X
,	B-X
CREB	B-X
kinase	B-X
activity	B-X
was	B-X
constitutively	B-X
high	B-X
;	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
blocked	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X

In	O
L2	B-cell_line
variant	I-cell_line
cells	I-cell_line
,	O
CREB	B-protein
kinase	I-protein
activity	O
was	O
constitutively	O
high	O
;	O
IL-2	B-protein
stimulated	O
and	O
rapamycin	O
blocked	O
PCNA	O
expression	O
and	O
proliferation	O
.	O
<EOS>	B-X
In	B-X
L2	B-X
variant	B-X
cells	B-X
,	B-X
CREB	B-X
kinase	B-X
activity	B-X
was	B-X
constitutively	B-X
high	B-X
;	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
blocked	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
L2	B-X
and	B-X
L2	B-X
variant	B-X
cells	B-X
were	B-X
tested	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
responsiveness	B-X
and	B-X
rapamycin	B-X
sensitivity	B-X
with	B-X
respect	B-X
to	B-X
specific	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
L2	B-X
cells	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
inhibited	B-X
the	B-X
following	B-X
:	B-X
cAMP	B-X
-	B-X
independent	B-X
CREB	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
Isolation	B-X
and	B-X
analysis	B-X
of	B-X
a	B-X
T	B-X
cell	B-X
clone	B-X
variant	B-X
exhibiting	B-X
constitutively	B-X
phosphorylated	B-X
Ser133	B-X
cAMP	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
.	B-X

These	O
results	O
indicate	O
that	O
IL-2	B-protein
induces	O
a	O
rapamycin-sensitive	O
,	O
cAMP-independent	O
CREB	B-protein
kinase	I-protein
activity	O
in	O
L2	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
IL	B-X
-	B-X
2	B-X
induces	B-X
a	B-X
rapamycin	B-X
-	B-X
sensitive	B-X
,	B-X
cAMP	B-X
-	B-X
independent	B-X
CREB	B-X
kinase	B-X
activity	B-X
in	B-X
L2	B-X
cells	B-X
<EOS>	B-X
In	B-X
L2	B-X
cells	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
stimulated	B-X
and	B-X
rapamycin	B-X
inhibited	B-X
the	B-X
following	B-X
:	B-X
cAMP	B-X
-	B-X
independent	B-X
CREB	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
L2	B-X
and	B-X
L2	B-X
variant	B-X
cells	B-X
were	B-X
tested	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
responsiveness	B-X
and	B-X
rapamycin	B-X
sensitivity	B-X
with	B-X
respect	B-X
to	B-X
specific	B-X
kinase	B-X
activity	B-X
,	B-X
PCNA	B-X
expression	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
driving	B-X
T	B-X
cell	B-X
proliferation	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
stimulates	B-X
a	B-X
new	B-X
program	B-X
of	B-X
gene	B-X
expression	B-X
that	B-X
includes	B-X
proliferating	B-X
cell	B-X
nuclear	B-X
antigen	B-X
(	B-X
PCNA	B-X
)	B-X
,	B-X
a	B-X
requisite	B-X
processivity	B-X
factor	B-X
for	B-X
DNA	B-X
polymerase	B-X
delta	B-X

However	O
,	O
phosphorylation	O
of	O
CREB	B-protein
alone	O
is	O
not	O
sufficient	O
to	O
drive	O
PCNA	B-protein
expression	O
and	O
L2	O
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
IL-2	B-protein
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
evodiamine	B-X
markedly	B-X
reduced	B-X
TLR2,3,4	B-X
protein	B-X
expression	B-X
and	B-X
the	B-X
phosphorylated	B-X
protein	B-X
of	B-X
C	B-X
/	B-X
EBPβ	B-X
and	B-X
CREB	B-X
<EOS>	B-X
Consistently	B-X
,	B-X
inhibition	B-X
of	B-X
Rac1	B-X
prevented	B-X
endothelial	B-X
proliferation	B-X
and	B-X
migration	B-X
after	B-X
OGD	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
effects	B-X
of	B-X
sleep	B-X
deprivation	B-X
(	B-X
SD	B-X
)	B-X
remain	B-X
elusive	B-X
and	B-X
currently	B-X
there	B-X
is	B-X
no	B-X
effective	B-X
therapy	B-X
to	B-X
alleviate	B-X
these	B-X
effects	B-X
<EOS>	B-X
However	B-X
,	B-X
very	B-X
little	B-X
is	B-X
known	B-X
about	B-X
what	B-X
happens	B-X
in	B-X
the	B-X
MgN	B-X
-	B-X
amygdala	B-X
pathway	B-X
during	B-X
fear	B-X
recall	B-X
and	B-X
extinction	B-X
,	B-X
in	B-X
which	B-X
conditional	B-X
fear	B-X
decreases	B-X
with	B-X
repeated	B-X
presentations	B-X
of	B-X
the	B-X
auditory	B-X
stimulus	B-X
alone	B-X

Serotonin	O
derivative	O
,	O
N-	O
(	O
p-coumaroyl	O
)	O
serotonin	O
,	O
inhibits	O
the	O
production	O
of	O
TNF-alpha	B-protein
,	O
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
,	O
and	O
IL-6	B-protein
by	O
endotoxin-stimulated	B-cell_type
human	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
Serotonin	B-X
derivative	B-X
,	B-X
N	B-X
-	B-X
	B-X
(	B-X
p	B-X
-	B-X
coumaroyl	B-X
)	B-X
serotonin	B-X
,	B-X
inhibits	B-X
the	B-X
production	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
by	B-X
endotoxin	B-X
-	B-X
stimulated	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
ELISA	B-X
assay	B-X
revealed	B-X
that	B-X
the	B-X
production	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
was	B-X
inhibited	B-X
by	B-X
CS	B-X
<EOS>	B-X
We	B-X
have	B-X
reported	B-X
that	B-X
N	B-X
-	B-X
	B-X
(	B-X
p	B-X
-	B-X
coumaroyl	B-X
)	B-X
serotonin	B-X
(	B-X
CS	B-X
)	B-X
and	B-X
its	B-X
derivatives	B-X
with	B-X
antioxidative	B-X
activity	B-X
are	B-X
present	B-X
in	B-X
safflower	B-X
seeds	B-X
<EOS>	B-X
CS	B-X
at	B-X
50	B-X
-	B-X
200	B-X
microM	B-X
reduced	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
,	B-X
interleukin	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
)	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
activities	B-X
in	B-X
the	B-X
culture	B-X
supernatants	B-X
from	B-X
LPS	B-X
-	B-X
stimulated	B-X
human	B-X
blood	B-X
monocytes	B-X
without	B-X
cytotoxicity	B-X

We	O
have	O
reported	O
that	O
N-	O
(	O
p-coumaroyl	O
)	O
serotonin	O
(	O
CS	O
)	O
and	O
its	O
derivatives	O
with	O
antioxidative	O
activity	O
are	O
present	O
in	O
safflower	O
seeds	O
.	O

As	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
are	O
implicated	O
in	O
the	O
signaling	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
we	O
examined	O
whether	O
CS	O
has	O
a	O
suppressive	O
effect	O
on	O
inflammatory	B-protein
cytokine	I-protein
generation	O
from	O
human	B-cell_type
monocyte	I-cell_type
s	O
in	O
vitro	O
.	O

CS	O
at	O
50-200	O
microM	O
reduced	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
and	O
IL-6	B-protein
activities	O
in	O
the	O
culture	O
supernatants	O
from	O
LPS-stimulated	B-cell_line
human	I-cell_line
blood	I-cell_line
monocytes	I-cell_line
without	O
cytotoxicity	O
.	O
<EOS>	B-X
CS	B-X
at	B-X
50	B-X
-	B-X
200	B-X
microM	B-X
reduced	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
,	B-X
interleukin	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
)	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
activities	B-X
in	B-X
the	B-X
culture	B-X
supernatants	B-X
from	B-X
LPS	B-X
-	B-X
stimulated	B-X
human	B-X
blood	B-X
monocytes	B-X
without	B-X
cytotoxicity	B-X
<EOS>	B-X
Serotonin	B-X
derivative	B-X
,	B-X
N	B-X
-	B-X
	B-X
(	B-X
p	B-X
-	B-X
coumaroyl	B-X
)	B-X
serotonin	B-X
,	B-X
inhibits	B-X
the	B-X
production	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
by	B-X
endotoxin	B-X
-	B-X
stimulated	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
reported	B-X
that	B-X
N	B-X
-	B-X
	B-X
(	B-X
p	B-X
-	B-X
coumaroyl	B-X
)	B-X
serotonin	B-X
(	B-X
CS	B-X
)	B-X
and	B-X
its	B-X
derivatives	B-X
with	B-X
antioxidative	B-X
activity	B-X
are	B-X
present	B-X
in	B-X
safflower	B-X
seeds	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
CS	B-X
has	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
proinflammatory	B-X
cytokine	B-X
production	B-X
from	B-X
monocytes	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
is	B-X
based	B-X
in	B-X
part	B-X
on	B-X
the	B-X
suppression	B-X
of	B-X
cytokine	B-X
mRNA	B-X
expression	B-X
through	B-X
inhibition	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X

ELISA	O
assay	O
revealed	O
that	O
the	O
production	O
of	O
TNF-alpha	B-protein
,	O
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
,	O
and	O
IL-6	B-protein
was	O
inhibited	O
by	O
CS	O
.	O
<EOS>	B-X
ELISA	B-X
assay	B-X
revealed	B-X
that	B-X
the	B-X
production	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
was	B-X
inhibited	B-X
by	B-X
CS	B-X
<EOS>	B-X
Serotonin	B-X
derivative	B-X
,	B-X
N	B-X
-	B-X
	B-X
(	B-X
p	B-X
-	B-X
coumaroyl	B-X
)	B-X
serotonin	B-X
,	B-X
inhibits	B-X
the	B-X
production	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
by	B-X
endotoxin	B-X
-	B-X
stimulated	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
CS	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
CS	B-X
has	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
proinflammatory	B-X
cytokine	B-X
production	B-X
from	B-X
monocytes	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
is	B-X
based	B-X
in	B-X
part	B-X
on	B-X
the	B-X
suppression	B-X
of	B-X
cytokine	B-X
mRNA	B-X
expression	B-X
through	B-X
inhibition	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X

Northern	O
blot	O
analysis	O
showed	O
that	O
LPS-induced	O
expression	O
of	O
these	O
cytokine	B-RNA
mRNA	I-RNA
in	O
monocytes	B-cell_type
was	O
suppressed	O
by	O
CS	O
.	O
<EOS>	B-X
Northern	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
LPS	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
these	B-X
cytokine	B-X
mRNA	B-X
in	B-X
monocytes	B-X
was	B-X
suppressed	B-X
by	B-X
CS	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
CS	B-X
has	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
proinflammatory	B-X
cytokine	B-X
production	B-X
from	B-X
monocytes	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
is	B-X
based	B-X
in	B-X
part	B-X
on	B-X
the	B-X
suppression	B-X
of	B-X
cytokine	B-X
mRNA	B-X
expression	B-X
through	B-X
inhibition	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
<EOS>	B-X
ELISA	B-X
assay	B-X
revealed	B-X
that	B-X
the	B-X
production	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
was	B-X
inhibited	B-X
by	B-X
CS	B-X
<EOS>	B-X
As	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
are	B-X
implicated	B-X
in	B-X
the	B-X
signaling	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
CS	B-X
has	B-X
a	B-X
suppressive	B-X
effect	B-X
on	B-X
inflammatory	B-X
cytokine	B-X
generation	B-X
from	B-X
human	B-X
monocytes	B-X
in	B-X
vitro	B-X

NF-kappaB	O
activation	O
was	O
also	O
inhibited	O
by	O
CS	O
.	O
<EOS>	B-X
Also	B-X
,	B-X
ROCK	B-X
activity	B-X
was	B-X
determined	B-X
in	B-X
T	B-X
<EOS>	B-X
Macrophage	B-X
activation	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
abdominal	B-X
aortic	B-X
aneurysm	B-X
(	B-X
AAA	B-X
)	B-X
development	B-X
<EOS>	B-X
COPD	B-X
-	B-X
like	B-X
disease	B-X
and	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
lungs	B-X
<EOS>	B-X
ADAR1	B-X
Non	B-X
-	B-X
Editing	B-X
Function	B-X
in	B-X
Macrophage	B-X
Activation	B-X
and	B-X
Abdominal	B-X
Aortic	B-X
Aneurysm	B-X
.	B-X

These	O
findings	O
indicate	O
that	O
CS	O
has	O
a	O
suppressive	O
effect	O
on	O
proinflammatory	O
cytokine	O
production	O
from	O
monocytes	B-cell_type
,	O
and	O
this	O
effect	O
is	O
based	O
in	O
part	O
on	O
the	O
suppression	O
of	O
cytokine	B-RNA
mRNA	I-RNA
expression	O
through	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
.	O

Elevated	O
expression	O
of	O
differentiation	B-RNA
inhibitory	I-RNA
factor	I-RNA
nm23	I-RNA
mRNA	I-RNA
in	O
monoblastic	O
crisis	O
of	O
a	O
patient	O
with	O
chronic	O
myelogenous	O
leukemia	O
.	O
<EOS>	B-X
Elevated	B-X
expression	B-X
of	B-X
differentiation	B-X
inhibitory	B-X
factor	B-X
nm23	B-X
mRNA	B-X
in	B-X
monoblastic	B-X
crisis	B-X
of	B-X
a	B-X
patient	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
our	B-X
previous	B-X
report	B-X
that	B-X
nm23	B-X
gene	B-X
is	B-X
overexpressed	B-X
in	B-X
monocytic	B-X
leukemia	B-X
<EOS>	B-X
We	B-X
report	B-X
an	B-X
example	B-X
of	B-X
elevated	B-X
expression	B-X
of	B-X
nm23	B-X
mRNA	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
who	B-X
developed	B-X
monoblastic	B-X
crisis	B-X
<EOS>	B-X
Relative	B-X
levels	B-X
of	B-X
nm23	B-X
-	B-X
H1	B-X
and	B-X
	B-X
-	B-X
H2	B-X
mRNA	B-X
extracted	B-X
from	B-X
the	B-X
patient	B-X
's	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
bone	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
were	B-X
measured	B-X
by	B-X
quantitative	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X

Differentiation	B-protein
inhibitory	I-protein
factor	I-protein
nm23	B-DNA
gene	I-DNA
has	O
been	O
found	O
to	O
be	O
expressed	O
in	O
high	O
quantities	O
in	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
especially	O
in	O
acute	O
monocytic	O
leukemia	O
(	O
AML-M5	O
)	O
and	O
is	O
suggested	O
as	O
a	O
new	O
prognostic	O
factor	O
in	O
AML-M5	O
.	O
<EOS>	B-X
Differentiation	B-X
inhibitory	B-X
factor	B-X
nm23	B-X
gene	B-X
has	B-X
been	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
high	B-X
quantities	B-X
in	B-X
acute	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
,	B-X
especially	B-X
in	B-X
acute	B-X
monocytic	B-X
leukemia	B-X
(	B-X
AML	B-X
-	B-X
M5	B-X
)	B-X
and	B-X
is	B-X
suggested	B-X
as	B-X
a	B-X
new	B-X
prognostic	B-X
factor	B-X
in	B-X
AML	B-X
-	B-X
M5	B-X
<EOS>	B-X
We	B-X
report	B-X
an	B-X
example	B-X
of	B-X
elevated	B-X
expression	B-X
of	B-X
nm23	B-X
mRNA	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
who	B-X
developed	B-X
monoblastic	B-X
crisis	B-X
<EOS>	B-X
Proliferated	B-X
blastic	B-X
cells	B-X
were	B-X
positive	B-X
for	B-X
non	B-X
-	B-X
specific	B-X
esterase	B-X
,	B-X
and	B-X
the	B-X
serum	B-X
lysozyme	B-X
level	B-X
was	B-X
elevated	B-X
and	B-X
diagnosed	B-X
as	B-X
monoblastic	B-X
crisis	B-X
<EOS>	B-X
These	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
our	B-X
previous	B-X
report	B-X
that	B-X
nm23	B-X
gene	B-X
is	B-X
overexpressed	B-X
in	B-X
monocytic	B-X
leukemia	B-X

We	O
report	O
an	O
example	O
of	O
elevated	O
expression	O
of	O
nm23	B-RNA
mRNA	I-RNA
in	O
a	O
patient	O
with	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
who	O
developed	O
monoblastic	O
crisis	O
.	O

Relative	O
levels	O
of	O
nm23-H1	B-RNA
and	I-RNA
-H2	I-RNA
mRNA	I-RNA
extracted	O
from	O
the	O
patient	O
's	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
bone	B-cell_type
marrow	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
were	O
measured	O
by	O
quantitative	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
.	O
<EOS>	B-X
Relative	B-X
levels	B-X
of	B-X
nm23	B-X
-	B-X
H1	B-X
and	B-X
	B-X
-	B-X
H2	B-X
mRNA	B-X
extracted	B-X
from	B-X
the	B-X
patient	B-X
's	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
bone	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
were	B-X
measured	B-X
by	B-X
quantitative	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
nm23	B-X
-	B-X
H1	B-X
mRNA	B-X
in	B-X
CML	B-X
cells	B-X
at	B-X
the	B-X
chronic	B-X
phase	B-X
was	B-X
as	B-X
high	B-X
as	B-X
that	B-X
in	B-X
bone	B-X
marrow	B-X
cells	B-X
from	B-X
healthy	B-X
volunteers	B-X
<EOS>	B-X
Proliferated	B-X
blastic	B-X
cells	B-X
were	B-X
positive	B-X
for	B-X
non	B-X
-	B-X
specific	B-X
esterase	B-X
,	B-X
and	B-X
the	B-X
serum	B-X
lysozyme	B-X
level	B-X
was	B-X
elevated	B-X
and	B-X
diagnosed	B-X
as	B-X
monoblastic	B-X
crisis	B-X
<EOS>	B-X
We	B-X
report	B-X
an	B-X
example	B-X
of	B-X
elevated	B-X
expression	B-X
of	B-X
nm23	B-X
mRNA	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
who	B-X
developed	B-X
monoblastic	B-X
crisis	B-X

The	O
level	O
of	O
nm23-H1	B-RNA
mRNA	I-RNA
in	O
CML	B-cell_line
cells	I-cell_line
at	O
the	O
chronic	O
phase	O
was	O
as	O
high	O
as	O
that	O
in	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
healthy	O
volunteers	O
.	O

The	O
mRNA	O
level	O
of	O
nm23-H2	B-protein
was	O
slightly	O
below	O
the	O
normal	O
level	O
.	O
<EOS>	B-X
The	B-X
mRNA	B-X
level	B-X
of	B-X
nm23	B-X
-	B-X
H2	B-X
was	B-X
slightly	B-X
below	B-X
the	B-X
normal	B-X
level	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
nm23	B-X
-	B-X
H1	B-X
mRNA	B-X
in	B-X
CML	B-X
cells	B-X
at	B-X
the	B-X
chronic	B-X
phase	B-X
was	B-X
as	B-X
high	B-X
as	B-X
that	B-X
in	B-X
bone	B-X
marrow	B-X
cells	B-X
from	B-X
healthy	B-X
volunteers	B-X
<EOS>	B-X
At	B-X
blastic	B-X
crisis	B-X
,	B-X
however	B-X
,	B-X
expression	B-X
of	B-X
both	B-X
nm23	B-X
-	B-X
H1	B-X
and	B-X
	B-X
-	B-X
H2	B-X
mRNA	B-X
was	B-X
elevated	B-X
to	B-X
about	B-X
three	B-X
to	B-X
nine	B-X
times	B-X
of	B-X
that	B-X
at	B-X
the	B-X
chronic	B-X
phase	B-X
<EOS>	B-X
We	B-X
report	B-X
an	B-X
example	B-X
of	B-X
elevated	B-X
expression	B-X
of	B-X
nm23	B-X
mRNA	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
who	B-X
developed	B-X
monoblastic	B-X
crisis	B-X

At	O
blastic	O
crisis	O
,	O
however	O
,	O
expression	O
of	O
both	O
nm23-H1	B-RNA
and	I-RNA
-H2	I-RNA
mRNA	I-RNA
was	O
elevated	O
to	O
about	O
three	O
to	O
nine	O
times	O
of	O
that	O
at	O
the	O
chronic	O
phase	O
.	O
<EOS>	B-X
At	B-X
blastic	B-X
crisis	B-X
,	B-X
however	B-X
,	B-X
expression	B-X
of	B-X
both	B-X
nm23	B-X
-	B-X
H1	B-X
and	B-X
	B-X
-	B-X
H2	B-X
mRNA	B-X
was	B-X
elevated	B-X
to	B-X
about	B-X
three	B-X
to	B-X
nine	B-X
times	B-X
of	B-X
that	B-X
at	B-X
the	B-X
chronic	B-X
phase	B-X
<EOS>	B-X
The	B-X
mRNA	B-X
level	B-X
of	B-X
nm23	B-X
-	B-X
H2	B-X
was	B-X
slightly	B-X
below	B-X
the	B-X
normal	B-X
level	B-X
<EOS>	B-X
Differentiation	B-X
inhibitory	B-X
factor	B-X
nm23	B-X
gene	B-X
has	B-X
been	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
high	B-X
quantities	B-X
in	B-X
acute	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
,	B-X
especially	B-X
in	B-X
acute	B-X
monocytic	B-X
leukemia	B-X
(	B-X
AML	B-X
-	B-X
M5	B-X
)	B-X
and	B-X
is	B-X
suggested	B-X
as	B-X
a	B-X
new	B-X
prognostic	B-X
factor	B-X
in	B-X
AML	B-X
-	B-X
M5	B-X
<EOS>	B-X
Relative	B-X
levels	B-X
of	B-X
nm23	B-X
-	B-X
H1	B-X
and	B-X
	B-X
-	B-X
H2	B-X
mRNA	B-X
extracted	B-X
from	B-X
the	B-X
patient	B-X
's	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
bone	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
were	B-X
measured	B-X
by	B-X
quantitative	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X

Proliferated	B-cell_type
blastic	I-cell_type
cells	I-cell_type
were	O
positive	O
for	O
non-specific	B-protein
esterase	I-protein
,	O
and	O
the	O
serum	O
lysozyme	O
level	O
was	O
elevated	O
and	O
diagnosed	O
as	O
monoblastic	O
crisis	O
.	O
<EOS>	B-X
Proliferated	B-X
blastic	B-X
cells	B-X
were	B-X
positive	B-X
for	B-X
non	B-X
-	B-X
specific	B-X
esterase	B-X
,	B-X
and	B-X
the	B-X
serum	B-X
lysozyme	B-X
level	B-X
was	B-X
elevated	B-X
and	B-X
diagnosed	B-X
as	B-X
monoblastic	B-X
crisis	B-X
<EOS>	B-X
We	B-X
report	B-X
an	B-X
example	B-X
of	B-X
elevated	B-X
expression	B-X
of	B-X
nm23	B-X
mRNA	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
who	B-X
developed	B-X
monoblastic	B-X
crisis	B-X
<EOS>	B-X
These	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
our	B-X
previous	B-X
report	B-X
that	B-X
nm23	B-X
gene	B-X
is	B-X
overexpressed	B-X
in	B-X
monocytic	B-X
leukemia	B-X
<EOS>	B-X
Differentiation	B-X
inhibitory	B-X
factor	B-X
nm23	B-X
gene	B-X
has	B-X
been	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
high	B-X
quantities	B-X
in	B-X
acute	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
,	B-X
especially	B-X
in	B-X
acute	B-X
monocytic	B-X
leukemia	B-X
(	B-X
AML	B-X
-	B-X
M5	B-X
)	B-X
and	B-X
is	B-X
suggested	B-X
as	B-X
a	B-X
new	B-X
prognostic	B-X
factor	B-X
in	B-X
AML	B-X
-	B-X
M5	B-X

The	O
patient	O
received	O
combined	O
chemotherapy	O
but	O
response	O
was	O
partial	O
.	O
<EOS>	B-X
The	B-X
brain	B-X
metastasis	B-X
responded	B-X
to	B-X
local	B-X
radiotherapy	B-X
but	B-X
progressed	B-X
again	B-X
in	B-X
a	B-X
short	B-X
time	B-X
<EOS>	B-X
The	B-X
patient	B-X
received	B-X
carboplatin	B-X
and	B-X
etoposide	B-X
with	B-X
concurrent	B-X
initiation	B-X
of	B-X
envafolimab	B-X
<EOS>	B-X
The	B-X
patient	B-X
was	B-X
scheduled	B-X
to	B-X
receive	B-X
8	B-X
cycles	B-X
of	B-X
single	B-X
-	B-X
drug	B-X
maintenance	B-X
therapy	B-X
with	B-X
pembrolizumab	B-X
after	B-X
surgery	B-X
<EOS>	B-X
The	B-X
patient	B-X
achieved	B-X
enhanced	B-X
recovery	B-X
with	B-X
normal	B-X
urination	B-X
and	B-X
no	B-X
syncope	B-X
after	B-X
surgery	B-X

These	O
findings	O
are	O
compatible	O
with	O
our	O
previous	O
report	O
that	O
nm23	B-DNA
gene	I-DNA
is	O
overexpressed	O
in	O
monocytic	O
leukemia	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
our	B-X
previous	B-X
report	B-X
that	B-X
nm23	B-X
gene	B-X
is	B-X
overexpressed	B-X
in	B-X
monocytic	B-X
leukemia	B-X
<EOS>	B-X
Proliferated	B-X
blastic	B-X
cells	B-X
were	B-X
positive	B-X
for	B-X
non	B-X
-	B-X
specific	B-X
esterase	B-X
,	B-X
and	B-X
the	B-X
serum	B-X
lysozyme	B-X
level	B-X
was	B-X
elevated	B-X
and	B-X
diagnosed	B-X
as	B-X
monoblastic	B-X
crisis	B-X
<EOS>	B-X
Elevated	B-X
expression	B-X
of	B-X
differentiation	B-X
inhibitory	B-X
factor	B-X
nm23	B-X
mRNA	B-X
in	B-X
monoblastic	B-X
crisis	B-X
of	B-X
a	B-X
patient	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
The	B-X
patient	B-X
received	B-X
combined	B-X
chemotherapy	B-X
but	B-X
response	B-X
was	B-X
partial	B-X

Increased	O
transcription	O
decreases	O
the	O
spontaneous	O
mutation	O
rate	O
at	O
the	O
thymidine	B-DNA
kinase	I-DNA
locus	I-DNA
in	O
human	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Increased	B-X
transcription	B-X
decreases	B-X
the	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
at	B-X
the	B-X
thymidine	B-X
kinase	B-X
locus	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
explored	B-X
whether	B-X
transcription	B-X
level	B-X
affects	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
human	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
increased	B-X
transcription	B-X
level	B-X
stimulates	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
yeast	B-X
<EOS>	B-X
Transcription	B-X
increases	B-X
DNA	B-X
repair	B-X
efficiency	B-X
and	B-X
modulates	B-X
the	B-X
distribution	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
DNA	B-X
damage	B-X

Transcription	O
increases	O
DNA	O
repair	O
efficiency	O
and	O
modulates	O
the	O
distribution	O
of	O
certain	O
types	O
of	O
DNA	O
damage	O
.	O
<EOS>	B-X
Transcription	B-X
increases	B-X
DNA	B-X
repair	B-X
efficiency	B-X
and	B-X
modulates	B-X
the	B-X
distribution	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
DNA	B-X
damage	B-X
<EOS>	B-X
The	B-X
resulting	B-X
decrease	B-X
in	B-X
muscle	B-X
strength	B-X
and	B-X
motility	B-X
irreversibly	B-X
impacts	B-X
quality	B-X
of	B-X
life	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
increased	B-X
transcription	B-X
level	B-X
stimulates	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
yeast	B-X
<EOS>	B-X
Increased	B-X
transcription	B-X
decreases	B-X
the	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
at	B-X
the	B-X
thymidine	B-X
kinase	B-X
locus	B-X
in	B-X
human	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
increased	O
transcription	O
level	O
stimulates	O
spontaneous	O
mutation	O
rate	O
in	O
yeast	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
increased	B-X
transcription	B-X
level	B-X
stimulates	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
yeast	B-X
<EOS>	B-X
We	B-X
explored	B-X
whether	B-X
transcription	B-X
level	B-X
affects	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
human	B-X
cells	B-X
<EOS>	B-X
Increased	B-X
transcription	B-X
decreases	B-X
the	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
at	B-X
the	B-X
thymidine	B-X
kinase	B-X
locus	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
<EOS>	B-X
Transcription	B-X
increases	B-X
DNA	B-X
repair	B-X
efficiency	B-X
and	B-X
modulates	B-X
the	B-X
distribution	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
DNA	B-X
damage	B-X

We	O
explored	O
whether	O
transcription	O
level	O
affects	O
spontaneous	O
mutation	O
rate	O
in	O
human	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
We	B-X
explored	B-X
whether	B-X
transcription	B-X
level	B-X
affects	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
human	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
increased	B-X
transcription	B-X
level	B-X
stimulates	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
yeast	B-X
<EOS>	B-X
Increased	B-X
transcription	B-X
decreases	B-X
the	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
at	B-X
the	B-X
thymidine	B-X
kinase	B-X
locus	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
humans	B-X
may	B-X
have	B-X
evolved	B-X
different	B-X
or	B-X
additional	B-X
mechanisms	B-X
to	B-X
deal	B-X
with	B-X
transcription	B-X
related	B-X
spontaneous	B-X
mutagenesis	B-X

We	O
first	O
developed	O
two	O
thymidine	B-cell_line
kinase	I-cell_line
(	I-cell_line
tk	I-cell_line
)	I-cell_line
inducible	I-cell_line
human	I-cell_line
cell	I-cell_line
lines	I-cell_line
using	O
the	O
Gal4-Estrogen	O
receptor	O
system	O
.	O
<EOS>	B-X
We	B-X
first	B-X
developed	B-X
two	B-X
thymidine	B-X
kinase	B-X
(	B-X
tk	B-X
)	B-X
inducible	B-X
human	B-X
cell	B-X
lines	B-X
using	B-X
the	B-X
Gal4	B-X
-	B-X
Estrogen	B-X
receptor	B-X
system	B-X
<EOS>	B-X
Spontaneous	B-X
mutation	B-X
rate	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
human	B-X
cell	B-X
lines	B-X
after	B-X
induction	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
report	B-X
in	B-X
yeast	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
increased	B-X
transcription	B-X
level	B-X
stimulates	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
yeast	B-X
<EOS>	B-X
We	B-X
explored	B-X
whether	B-X
transcription	B-X
level	B-X
affects	B-X
spontaneous	B-X
mutation	B-X
rate	B-X
in	B-X
human	B-X
cells	B-X

In	O
our	O
TK6i-G3	B-cell_line
and	I-cell_line
G9	I-cell_line
tk	I-cell_line
heterozygous	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
active	O
tk	B-DNA
allele	I-DNA
is	O
linked	O
to	O
an	O
inducible	O
promoter	B-DNA
element	I-DNA
.	O

Tk	B-RNA
mRNA	I-RNA
is	O
induced	O
following	O
treatment	O
with	O
estrogen	O
.	O
<EOS>	B-X
Tk	B-X
mRNA	B-X
is	B-X
induced	B-X
following	B-X
treatment	B-X
with	B-X
estrogen	B-X
<EOS>	B-X
Their	B-X
effect	B-X
is	B-X
tissue	B-X
-	B-X
	B-X
and	B-X
compound	B-X
-	B-X
specific	B-X
and	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
energetic	B-X
balance	B-X
<EOS>	B-X
In	B-X
this	B-X
tissue	B-X
,	B-X
betaBHC	B-X
action	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
the	B-X
anti	B-X
-	B-X
estrogen	B-X
ICI	B-X
-	B-X
182780	B-X
<EOS>	B-X
This	B-X
experimental	B-X
setting	B-X
produced	B-X
results	B-X
that	B-X
were	B-X
different	B-X
than	B-X
those	B-X
obtained	B-X
following	B-X
acute	B-X
treatments	B-X

Spontaneous	O
mutation	O
rate	O
was	O
significantly	O
decreased	O
in	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
after	O
induction	O
in	O
contrast	O
to	O
the	O
report	O
in	O
yeast	O
.	O

Thus	O
,	O
humans	O
may	O
have	O
evolved	O
different	O
or	O
additional	O
mechanisms	O
to	O
deal	O
with	O
transcription	O
related	O
spontaneous	O
mutagenesis	O
.	O
<EOS>	B-X
Viruses	B-X
have	B-X
evolved	B-X
complex	B-X
and	B-X
dynamic	B-X
interactions	B-X
with	B-X
their	B-X
host	B-X
cells	B-X
to	B-X
enable	B-X
viral	B-X
replication	B-X
<EOS>	B-X
These	B-X
cleaned	B-X
outputs	B-X
were	B-X
collated	B-X
at	B-X
different	B-X
geographic	B-X
levels	B-X
to	B-X
provide	B-X
standardised	B-X
datasets	B-X
<EOS>	B-X
Through	B-X
extensive	B-X
engagement	B-X
with	B-X
relevant	B-X
literature	B-X
,	B-X
we	B-X
created	B-X
two	B-X
complementary	B-X
meta	B-X
-	B-X
conceptual	B-X
frameworks	B-X
to	B-X
represent	B-X
and	B-X
evaluate	B-X
states	B-X
of	B-X
mental	B-X
illness	B-X
and	B-X
health	B-X
<EOS>	B-X
The	B-X
tests	B-X
available	B-X
,	B-X
and	B-X
their	B-X
indications	B-X
,	B-X
have	B-X
evolved	B-X
,	B-X
with	B-X
many	B-X
advances	B-X
,	B-X
both	B-X
in	B-X
technology	B-X
and	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
neural	B-X
basis	B-X
of	B-X
the	B-X
waveforms	B-X
,	B-X
now	B-X
facilitating	B-X
more	B-X
precise	B-X
evaluation	B-X
of	B-X
physiology	B-X
and	B-X
pathophysiology	B-X

Copyright	O
1998	O
Elsevier	O
Science	O
B.V	O
.	O
<EOS>	B-X
Copyright	B-X
1998	B-X
Elsevier	B-X
Science	B-X
B	B-X
<EOS>	B-X
All	B-X
rights	B-X
reserved	B-X
<EOS>	B-X
Proprioceptive	B-X
control	B-X
of	B-X
posture	B-X
:	B-X
a	B-X
review	B-X
of	B-X
new	B-X
concepts	B-X
.	B-X
<EOS>	B-X
Knee	B-X
kinetics	B-X
in	B-X
trans	B-X
-	B-X
tibial	B-X
amputee	B-X
gait	B-X
.	B-X

All	O
rights	O
reserved	O
.	O
<EOS>	B-X
All	B-X
rights	B-X
reserved	B-X
<EOS>	B-X
06	B-X
)	B-X
for	B-X
respiratory	B-X
disease	B-X
,	B-X
1	B-X
<EOS>	B-X
Asymmetrically	B-X
coordinated	B-X
CoB	B-X
<EOS>	B-X
Mean	B-X
HbA1c	B-X
levels	B-X
decreased	B-X
from	B-X
8	B-X

Mutation	O
of	O
BCL-6	B-DNA
gene	I-DNA
in	O
normal	O
B	B-cell_type
cells	I-cell_type
by	O
the	O
process	O
of	O
somatic	O
hypermutation	O
of	O
Ig	B-DNA
genes	I-DNA
.	O
<EOS>	B-X
Mutation	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
gene	B-X
in	B-X
normal	B-X
B	B-X
cells	B-X
by	B-X
the	B-X
process	B-X
of	B-X
somatic	B-X
hypermutation	B-X
of	B-X
Ig	B-X
genes	B-X
.	B-X
<EOS>	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
in	B-X
normal	B-X
germinal	B-X
center	B-X
B	B-X
cells	B-X
:	B-X
evidence	B-X
of	B-X
somatic	B-X
hypermutation	B-X
acting	B-X
outside	B-X
Ig	B-X
loci	B-X
.	B-X
<EOS>	B-X
No	B-X
mutations	B-X
were	B-X
found	B-X
in	B-X
several	B-X
housekeeping	B-X
genes	B-X
isolated	B-X
from	B-X
cells	B-X
that	B-X
had	B-X
very	B-X
high	B-X
levels	B-X
of	B-X
somatic	B-X
hypermutation	B-X
of	B-X
their	B-X
Ig	B-X
genes	B-X
<EOS>	B-X
Immunoglobulin	B-X
transgenes	B-X
as	B-X
targets	B-X
for	B-X
somatic	B-X
hypermutation	B-X
.	B-X

Immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
genes	I-DNA
are	O
hypermutated	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
that	O
are	O
the	O
precursors	O
to	O
memory	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
mutations	O
are	O
linked	O
to	O
transcription	O
initiation	O
,	O
but	O
non-Ig	B-DNA
promoters	I-DNA
are	O
permissible	O
for	O
the	O
mutation	O
process	O
;	O
thus	O
,	O
other	O
genes	O
expressed	O
in	O
mutating	O
B	B-cell_type
cells	I-cell_type
may	O
also	O
be	O
subject	O
to	O
somatic	O
hypermutation	O
.	O
<EOS>	B-X
The	B-X
mutations	B-X
are	B-X
linked	B-X
to	B-X
transcription	B-X
initiation	B-X
,	B-X
but	B-X
non	B-X
-	B-X
Ig	B-X
promoters	B-X
are	B-X
permissible	B-X
for	B-X
the	B-X
mutation	B-X
process	B-X
;	B-X
thus	B-X
,	B-X
other	B-X
genes	B-X
expressed	B-X
in	B-X
mutating	B-X
B	B-X
cells	B-X
may	B-X
also	B-X
be	B-X
subject	B-X
to	B-X
somatic	B-X
hypermutation	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
gene	B-X
in	B-X
normal	B-X
B	B-X
cells	B-X
by	B-X
the	B-X
process	B-X
of	B-X
somatic	B-X
hypermutation	B-X
of	B-X
Ig	B-X
genes	B-X
.	B-X
<EOS>	B-X
Significant	B-X
mutations	B-X
were	B-X
not	B-X
observed	B-X
in	B-X
c	B-X
-	B-X
MYC	B-X
,	B-X
S14	B-X
,	B-X
or	B-X
alpha	B-X
-	B-X
fetoprotein	B-X
(	B-X
AFP	B-X
)	B-X
genes	B-X
,	B-X
but	B-X
BCL	B-X
-	B-X
6	B-X
was	B-X
highly	B-X
mutated	B-X
in	B-X
a	B-X
large	B-X
proportion	B-X
of	B-X
memory	B-X
B	B-X
cells	B-X
of	B-X
normal	B-X
individuals	B-X
<EOS>	B-X
Immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
genes	B-X
are	B-X
hypermutated	B-X
in	B-X
B	B-X
lymphocytes	B-X
that	B-X
are	B-X
the	B-X
precursors	B-X
to	B-X
memory	B-X
B	B-X
cells	B-X

Significant	O
mutations	O
were	O
not	O
observed	O
in	O
c-MYC	B-DNA
,	I-DNA
S14	I-DNA
,	I-DNA
or	I-DNA
alpha-fetoprotein	I-DNA
(	I-DNA
AFP	I-DNA
)	I-DNA
genes	I-DNA
,	O
but	O
BCL-6	B-protein
was	O
highly	O
mutated	O
in	O
a	O
large	O
proportion	O
of	O
memory	B-cell_type
B	I-cell_type
cells	I-cell_type
of	O
normal	O
individuals	O
.	O
<EOS>	B-X
Some	B-X
of	B-X
these	B-X
mutations	B-X
provide	B-X
increased	B-X
fitness	B-X
,	B-X
giving	B-X
rise	B-X
to	B-X
clones	B-X
which	B-X
,	B-X
at	B-X
times	B-X
,	B-X
can	B-X
replace	B-X
the	B-X
entire	B-X
surface	B-X
area	B-X
of	B-X
tissues	B-X
<EOS>	B-X
VLGR1	B-X
is	B-X
expressed	B-X
almost	B-X
ubiquitously	B-X
,	B-X
but	B-X
is	B-X
mainly	B-X
found	B-X
in	B-X
the	B-X
CNS	B-X
and	B-X
in	B-X
the	B-X
sensory	B-X
cells	B-X
of	B-X
the	B-X
eye	B-X
and	B-X
inner	B-X
ear	B-X
<EOS>	B-X
Targeted	B-X
genetic	B-X
screening	B-X
might	B-X
be	B-X
too	B-X
restricted	B-X
to	B-X
identify	B-X
a	B-X
genetic	B-X
cause	B-X
underlying	B-X
the	B-X
phenotype	B-X
of	B-X
poor	B-X
embryo	B-X
development	B-X
for	B-X
all	B-X
patients	B-X
<EOS>	B-X
Multi	B-X
-	B-X
omic	B-X
analyses	B-X
were	B-X
performed	B-X
on	B-X
these	B-X
and	B-X
in	B-X
-	B-X
house	B-X
data	B-X
to	B-X
investigate	B-X
molecular	B-X
determinants	B-X
of	B-X
tumor	B-X
aggressiveness	B-X

The	O
mutation	O
pattern	O
was	O
similar	O
to	O
that	O
of	O
Ig	B-DNA
genes	I-DNA
.	O
<EOS>	B-X
The	B-X
mutational	B-X
landscape	B-X
of	B-X
MALT	B-X
lymphomas	B-X
is	B-X
wide	B-X
,	B-X
and	B-X
the	B-X
most	B-X
frequent	B-X
mutations	B-X
are	B-X
:	B-X
<EOS>	B-X
Dysregulation	B-X
of	B-X
these	B-X
processes	B-X
has	B-X
been	B-X
linked	B-X
to	B-X
B	B-X
cell	B-X
lymphomagenesis	B-X
<EOS>	B-X
AID	B-X
-	B-X
induced	B-X
mutations	B-X
are	B-X
linked	B-X
with	B-X
transcription	B-X
initiation	B-X
and	B-X
elongation	B-X
<EOS>	B-X
Mutational	B-X
patterns	B-X
along	B-X
different	B-X
evolution	B-X
paths	B-X
of	B-X
follicular	B-X
lymphoma	B-X
.	B-X

CD28-mediated	O
activation	O
in	O
CD45RA+	B-cell_type
and	I-cell_type
CD45RO+	I-cell_type
T	I-cell_type
cells	I-cell_type
:	O
enhanced	O
levels	O
of	O
reactive	O
oxygen	O
intermediates	O
and	O
c-Rel	O
nuclear	O
translocation	O
in	O
CD45RA+	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
CD28	B-X
-	B-X
mediated	B-X
activation	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
T	B-X
cells	B-X
:	B-X
enhanced	B-X
levels	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
nuclear	B-X
translocation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
.	B-X
<EOS>	B-X
Because	B-X
the	B-X
CD28	B-X
costimulus	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
(	B-X
ROIs	B-X
)	B-X
,	B-X
the	B-X
intracellular	B-X
ROI	B-X
levels	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
cells	B-X
were	B-X
compared	B-X
by	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
Long	B-X
exposure	B-X
(	B-X
24	B-X
h	B-X
)	B-X
induced	B-X
stronger	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
in	B-X
CD45RA+	B-X
cells	B-X
than	B-X
in	B-X
CD45RO+	B-X
cells	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
nuclear	B-X
c	B-X
-	B-X
Rel	B-X
protein	B-X
indicated	B-X
that	B-X
after	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
the	B-X
level	B-X
of	B-X
c	B-X
-	B-X
Rel	B-X
was	B-X
higher	B-X
in	B-X
CD45RA+	B-X
cells	B-X

We	O
have	O
analyzed	O
the	O
effect	O
of	O
complete	O
T	O
cell	O
activation	O
(	O
anti-CD3	B-protein
plus	O
anti-CD28	B-protein
)	O
on	O
the	O
activation	O
of	O
NF-kappaB	B-protein
in	O
CD45RA+	B-cell_type
(	I-cell_type
naive	I-cell_type
)	I-cell_type
and	I-cell_type
CD45RO+	I-cell_type
(	I-cell_type
memory/effector	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effect	B-X
of	B-X
complete	B-X
T	B-X
cell	B-X
activation	B-X
(	B-X
anti	B-X
-	B-X
CD3	B-X
plus	B-X
anti	B-X
-	B-X
CD28	B-X
)	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
CD45RA+	B-X
(	B-X
naive	B-X
)	B-X
and	B-X
CD45RO+	B-X
(	B-X
memory	B-X
/	B-X
effector	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
nuclear	B-X
c	B-X
-	B-X
Rel	B-X
protein	B-X
indicated	B-X
that	B-X
after	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
the	B-X
level	B-X
of	B-X
c	B-X
-	B-X
Rel	B-X
was	B-X
higher	B-X
in	B-X
CD45RA+	B-X
cells	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
IkappaBalpha	B-X
indicated	B-X
that	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
induced	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
degradation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
but	B-X
in	B-X
CD45RO+	B-X
cells	B-X
the	B-X
degradation	B-X
process	B-X
was	B-X
more	B-X
rapid	B-X
<EOS>	B-X
Because	B-X
the	B-X
CD28	B-X
costimulus	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
(	B-X
ROIs	B-X
)	B-X
,	B-X
the	B-X
intracellular	B-X
ROI	B-X
levels	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
cells	B-X
were	B-X
compared	B-X
by	B-X
flow	B-X
cytometry	B-X

Long	O
exposure	O
(	O
24	O
h	O
)	O
induced	O
stronger	O
NF-kappaB	B-protein
DNA	O
binding	O
in	O
CD45RA+	B-cell_type
cells	I-cell_type
than	O
in	O
CD45RO+	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Long	B-X
exposure	B-X
(	B-X
24	B-X
h	B-X
)	B-X
induced	B-X
stronger	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
in	B-X
CD45RA+	B-X
cells	B-X
than	B-X
in	B-X
CD45RO+	B-X
cells	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
nuclear	B-X
c	B-X
-	B-X
Rel	B-X
protein	B-X
indicated	B-X
that	B-X
after	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
the	B-X
level	B-X
of	B-X
c	B-X
-	B-X
Rel	B-X
was	B-X
higher	B-X
in	B-X
CD45RA+	B-X
cells	B-X
<EOS>	B-X
ROIs	B-X
were	B-X
produced	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
but	B-X
more	B-X
strongly	B-X
in	B-X
CD45RA+	B-X
cells	B-X
<EOS>	B-X
CD28	B-X
-	B-X
mediated	B-X
activation	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
T	B-X
cells	B-X
:	B-X
enhanced	B-X
levels	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
nuclear	B-X
translocation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
.	B-X

Analysis	O
of	O
the	O
nuclear	B-protein
c-Rel	I-protein
protein	I-protein
indicated	O
that	O
after	O
anti-CD3+anti-CD28	O
stimulation	O
the	O
level	O
of	O
c-Rel	B-protein
was	O
higher	O
in	O
CD45RA+	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
nuclear	B-X
c	B-X
-	B-X
Rel	B-X
protein	B-X
indicated	B-X
that	B-X
after	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
the	B-X
level	B-X
of	B-X
c	B-X
-	B-X
Rel	B-X
was	B-X
higher	B-X
in	B-X
CD45RA+	B-X
cells	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
IkappaBalpha	B-X
indicated	B-X
that	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
induced	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
degradation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
but	B-X
in	B-X
CD45RO+	B-X
cells	B-X
the	B-X
degradation	B-X
process	B-X
was	B-X
more	B-X
rapid	B-X
<EOS>	B-X
Long	B-X
exposure	B-X
(	B-X
24	B-X
h	B-X
)	B-X
induced	B-X
stronger	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
in	B-X
CD45RA+	B-X
cells	B-X
than	B-X
in	B-X
CD45RO+	B-X
cells	B-X
<EOS>	B-X
ROIs	B-X
were	B-X
produced	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
but	B-X
more	B-X
strongly	B-X
in	B-X
CD45RA+	B-X
cells	B-X

Analysis	O
of	O
the	O
cytoplasmic	O
inhibitor	O
IkappaBalpha	B-protein
indicated	O
that	O
anti-CD3+anti-CD28	O
stimulation	O
induced	O
a	O
long-lasting	O
degradation	O
in	O
CD45RA+	B-cell_type
cells	I-cell_type
but	O
in	O
CD45RO+	B-cell_type
cells	I-cell_type
the	O
degradation	O
process	O
was	O
more	O
rapid	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
IkappaBalpha	B-X
indicated	B-X
that	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
induced	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
degradation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
but	B-X
in	B-X
CD45RO+	B-X
cells	B-X
the	B-X
degradation	B-X
process	B-X
was	B-X
more	B-X
rapid	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
nuclear	B-X
c	B-X
-	B-X
Rel	B-X
protein	B-X
indicated	B-X
that	B-X
after	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
the	B-X
level	B-X
of	B-X
c	B-X
-	B-X
Rel	B-X
was	B-X
higher	B-X
in	B-X
CD45RA+	B-X
cells	B-X
<EOS>	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effect	B-X
of	B-X
complete	B-X
T	B-X
cell	B-X
activation	B-X
(	B-X
anti	B-X
-	B-X
CD3	B-X
plus	B-X
anti	B-X
-	B-X
CD28	B-X
)	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
CD45RA+	B-X
(	B-X
naive	B-X
)	B-X
and	B-X
CD45RO+	B-X
(	B-X
memory	B-X
/	B-X
effector	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
Long	B-X
exposure	B-X
(	B-X
24	B-X
h	B-X
)	B-X
induced	B-X
stronger	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
in	B-X
CD45RA+	B-X
cells	B-X
than	B-X
in	B-X
CD45RO+	B-X
cells	B-X

Because	O
the	O
CD28	O
costimulus	O
is	O
known	O
to	O
induce	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
,	O
the	O
intracellular	O
ROI	O
levels	O
in	O
CD45RA+	B-cell_type
and	I-cell_type
CD45RO+	I-cell_type
cells	I-cell_type
were	O
compared	O
by	O
flow	O
cytometry	O
.	O
<EOS>	B-X
Because	B-X
the	B-X
CD28	B-X
costimulus	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
(	B-X
ROIs	B-X
)	B-X
,	B-X
the	B-X
intracellular	B-X
ROI	B-X
levels	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
cells	B-X
were	B-X
compared	B-X
by	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
CD28	B-X
-	B-X
mediated	B-X
activation	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
T	B-X
cells	B-X
:	B-X
enhanced	B-X
levels	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
nuclear	B-X
translocation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effect	B-X
of	B-X
complete	B-X
T	B-X
cell	B-X
activation	B-X
(	B-X
anti	B-X
-	B-X
CD3	B-X
plus	B-X
anti	B-X
-	B-X
CD28	B-X
)	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
CD45RA+	B-X
(	B-X
naive	B-X
)	B-X
and	B-X
CD45RO+	B-X
(	B-X
memory	B-X
/	B-X
effector	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
IkappaBalpha	B-X
indicated	B-X
that	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
induced	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
degradation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
but	B-X
in	B-X
CD45RO+	B-X
cells	B-X
the	B-X
degradation	B-X
process	B-X
was	B-X
more	B-X
rapid	B-X

ROIs	O
were	O
produced	O
in	O
both	O
cell	O
types	O
,	O
but	O
more	O
strongly	O
in	O
CD45RA+	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
ROIs	B-X
were	B-X
produced	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
but	B-X
more	B-X
strongly	B-X
in	B-X
CD45RA+	B-X
cells	B-X
<EOS>	B-X
Long	B-X
exposure	B-X
(	B-X
24	B-X
h	B-X
)	B-X
induced	B-X
stronger	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
in	B-X
CD45RA+	B-X
cells	B-X
than	B-X
in	B-X
CD45RO+	B-X
cells	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
nuclear	B-X
c	B-X
-	B-X
Rel	B-X
protein	B-X
indicated	B-X
that	B-X
after	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
the	B-X
level	B-X
of	B-X
c	B-X
-	B-X
Rel	B-X
was	B-X
higher	B-X
in	B-X
CD45RA+	B-X
cells	B-X
<EOS>	B-X
CD28	B-X
-	B-X
mediated	B-X
activation	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
T	B-X
cells	B-X
:	B-X
enhanced	B-X
levels	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
nuclear	B-X
translocation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
.	B-X

The	O
data	O
presented	O
in	O
this	O
study	O
further	O
emphasize	O
the	O
differences	O
between	O
CD45RA+	B-cell_type
and	I-cell_type
CD45RO+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
ROI-dependent	O
signaling	O
pathways	O
.	O
<EOS>	B-X
The	B-X
data	B-X
presented	B-X
in	B-X
this	B-X
study	B-X
further	B-X
emphasize	B-X
the	B-X
differences	B-X
between	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
T	B-X
lymphocytes	B-X
in	B-X
ROI	B-X
-	B-X
dependent	B-X
signaling	B-X
pathways	B-X
<EOS>	B-X
Because	B-X
the	B-X
CD28	B-X
costimulus	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
(	B-X
ROIs	B-X
)	B-X
,	B-X
the	B-X
intracellular	B-X
ROI	B-X
levels	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
cells	B-X
were	B-X
compared	B-X
by	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
ROIs	B-X
were	B-X
produced	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
but	B-X
more	B-X
strongly	B-X
in	B-X
CD45RA+	B-X
cells	B-X
<EOS>	B-X
Long	B-X
exposure	B-X
(	B-X
24	B-X
h	B-X
)	B-X
induced	B-X
stronger	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
in	B-X
CD45RA+	B-X
cells	B-X
than	B-X
in	B-X
CD45RO+	B-X
cells	B-X

Non-Hodgkin	O
's	O
lymphoma	O
involving	O
bilateral	O
breasts	O
[	O
see	O
comments	O
]	O
<EOS>	B-X
Diffuse	B-X
Large	B-X
B	B-X
-	B-X
Cell	B-X
Non	B-X
-	B-X
Hodgkin	B-X
Lymphoma	B-X
Involving	B-X
Multiple	B-X
Different	B-X
Organs	B-X
in	B-X
a	B-X
Young	B-X
Adult	B-X
with	B-X
<EOS>	B-X
All	B-X
cases	B-X
exhibited	B-X
unilateral	B-X
breast	B-X
involvement	B-X
<EOS>	B-X
6	B-X
%	B-X
)	B-X
patients	B-X
had	B-X
right	B-X
-	B-X
sided	B-X
breast	B-X
involvement	B-X
but	B-X
no	B-X
bilateral	B-X
breast	B-X
involvement	B-X
at	B-X
diagnosis	B-X
<EOS>	B-X
Primary	B-X
breast	B-X
lymphoma	B-X
is	B-X
an	B-X
extremely	B-X
rare	B-X
disease	B-X

We	O
describe	O
here	O
two	O
cases	O
of	O
diffuse	O
large	O
cell	O
type	O
non-Hodgkin	O
's	O
lymphoma	O
affecting	O
the	O
bilateral	O
breasts	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
here	B-X
two	B-X
cases	B-X
of	B-X
diffuse	B-X
large	B-X
cell	B-X
type	B-X
non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
affecting	B-X
the	B-X
bilateral	B-X
breasts	B-X
<EOS>	B-X
Non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
involving	B-X
bilateral	B-X
breasts	B-X
.	B-X
<EOS>	B-X
The	B-X
contralateral	B-X
tumor	B-X
in	B-X
one	B-X
case	B-X
appeared	B-X
17	B-X
months	B-X
after	B-X
the	B-X
first	B-X
mastectomy	B-X
,	B-X
whereas	B-X
the	B-X
bilateral	B-X
tumors	B-X
occurred	B-X
concurrently	B-X
in	B-X
the	B-X
other	B-X
patient	B-X
who	B-X
was	B-X
pregnant	B-X
and	B-X
showed	B-X
widespread	B-X
dissemination	B-X
at	B-X
initial	B-X
presentation	B-X
<EOS>	B-X
There	B-X
were	B-X
no	B-X
apparent	B-X
pathological	B-X
features	B-X
of	B-X
lymphomas	B-X
of	B-X
mucosa	B-X
-	B-X
associated	B-X
lymphoid	B-X
tissue	B-X
origin	B-X

The	O
contralateral	O
tumor	O
in	O
one	O
case	O
appeared	O
17	O
months	O
after	O
the	O
first	O
mastectomy	O
,	O
whereas	O
the	O
bilateral	O
tumors	O
occurred	O
concurrently	O
in	O
the	O
other	O
patient	O
who	O
was	O
pregnant	O
and	O
showed	O
widespread	O
dissemination	O
at	O
initial	O
presentation	O
.	O
<EOS>	B-X
The	B-X
contralateral	B-X
tumor	B-X
in	B-X
one	B-X
case	B-X
appeared	B-X
17	B-X
months	B-X
after	B-X
the	B-X
first	B-X
mastectomy	B-X
,	B-X
whereas	B-X
the	B-X
bilateral	B-X
tumors	B-X
occurred	B-X
concurrently	B-X
in	B-X
the	B-X
other	B-X
patient	B-X
who	B-X
was	B-X
pregnant	B-X
and	B-X
showed	B-X
widespread	B-X
dissemination	B-X
at	B-X
initial	B-X
presentation	B-X
<EOS>	B-X
Both	B-X
patients	B-X
developed	B-X
progressive	B-X
disease	B-X
despite	B-X
chemo	B-X
-	B-X
radiotherapy	B-X
and	B-X
died	B-X
of	B-X
leukemic	B-X
manifestations	B-X
<EOS>	B-X
Lymphoma	B-X
cells	B-X
from	B-X
both	B-X
cases	B-X
showed	B-X
the	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
immunophenotype	B-X
and	B-X
had	B-X
rearrangements	B-X
of	B-X
the	B-X
BCL6	B-X
gene	B-X
<EOS>	B-X
There	B-X
were	B-X
no	B-X
apparent	B-X
pathological	B-X
features	B-X
of	B-X
lymphomas	B-X
of	B-X
mucosa	B-X
-	B-X
associated	B-X
lymphoid	B-X
tissue	B-X
origin	B-X

Lymphoma	B-cell_type
cells	I-cell_type
from	O
both	O
cases	O
showed	O
the	O
mature	O
B-cell	O
immunophenotype	O
and	O
had	O
rearrangements	O
of	O
the	O
BCL6	B-DNA
gene	I-DNA
.	O
<EOS>	B-X
Lymphoma	B-X
cells	B-X
from	B-X
both	B-X
cases	B-X
showed	B-X
the	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
immunophenotype	B-X
and	B-X
had	B-X
rearrangements	B-X
of	B-X
the	B-X
BCL6	B-X
gene	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
CD45	B-X
-	B-X
	B-X
population	B-X
(	B-X
35	B-X
%	B-X
)	B-X
showed	B-X
CD19+	B-X
,	B-X
CD20+	B-X
,	B-X
and	B-X
CD10+	B-X
immunophenotype	B-X
with	B-X
monotypic	B-X
surface	B-X
Lambda	B-X
immunoglobulin	B-X
light	B-X
chain	B-X
expression	B-X
<EOS>	B-X
Immunophenotype	B-X
of	B-X
primary	B-X
cutaneous	B-X
diffuse	B-X
large	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
,	B-X
leg	B-X
-	B-X
type	B-X
(	B-X
PCLBCL	B-X
-	B-X
LT	B-X
)	B-X
suggests	B-X
a	B-X
germinal	B-X
center	B-X
-	B-X
experienced	B-X
B	B-X
lymphocyte	B-X
(	B-X
BCL2+	B-X
MUM1+	B-X
BCL6+	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
<EOS>	B-X
FISH	B-X
analysis	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
IGH	B-X
/	B-X
BCL2	B-X
rearrangement	B-X

Both	O
patients	O
developed	O
progressive	O
disease	O
despite	O
chemo-radiotherapy	O
and	O
died	O
of	O
leukemic	O
manifestations	O
.	O
<EOS>	B-X
Both	B-X
patients	B-X
developed	B-X
progressive	B-X
disease	B-X
despite	B-X
chemo	B-X
-	B-X
radiotherapy	B-X
and	B-X
died	B-X
of	B-X
leukemic	B-X
manifestations	B-X
<EOS>	B-X
The	B-X
contralateral	B-X
tumor	B-X
in	B-X
one	B-X
case	B-X
appeared	B-X
17	B-X
months	B-X
after	B-X
the	B-X
first	B-X
mastectomy	B-X
,	B-X
whereas	B-X
the	B-X
bilateral	B-X
tumors	B-X
occurred	B-X
concurrently	B-X
in	B-X
the	B-X
other	B-X
patient	B-X
who	B-X
was	B-X
pregnant	B-X
and	B-X
showed	B-X
widespread	B-X
dissemination	B-X
at	B-X
initial	B-X
presentation	B-X
<EOS>	B-X
Lymphoma	B-X
cells	B-X
from	B-X
both	B-X
cases	B-X
showed	B-X
the	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
immunophenotype	B-X
and	B-X
had	B-X
rearrangements	B-X
of	B-X
the	B-X
BCL6	B-X
gene	B-X
<EOS>	B-X
Non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
involving	B-X
bilateral	B-X
breasts	B-X
.	B-X

There	O
were	O
no	O
apparent	O
pathological	O
features	O
of	O
lymphomas	O
of	O
mucosa-associated	O
lymphoid	O
tissue	O
origin	O
<EOS>	B-X
There	B-X
were	B-X
no	B-X
apparent	B-X
pathological	B-X
features	B-X
of	B-X
lymphomas	B-X
of	B-X
mucosa	B-X
-	B-X
associated	B-X
lymphoid	B-X
tissue	B-X
origin	B-X
<EOS>	B-X
The	B-X
contralateral	B-X
tumor	B-X
in	B-X
one	B-X
case	B-X
appeared	B-X
17	B-X
months	B-X
after	B-X
the	B-X
first	B-X
mastectomy	B-X
,	B-X
whereas	B-X
the	B-X
bilateral	B-X
tumors	B-X
occurred	B-X
concurrently	B-X
in	B-X
the	B-X
other	B-X
patient	B-X
who	B-X
was	B-X
pregnant	B-X
and	B-X
showed	B-X
widespread	B-X
dissemination	B-X
at	B-X
initial	B-X
presentation	B-X
<EOS>	B-X
We	B-X
describe	B-X
here	B-X
two	B-X
cases	B-X
of	B-X
diffuse	B-X
large	B-X
cell	B-X
type	B-X
non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
affecting	B-X
the	B-X
bilateral	B-X
breasts	B-X
<EOS>	B-X
Non	B-X
-	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
involving	B-X
bilateral	B-X
breasts	B-X
.	B-X

Biochemical	O
characterization	O
of	O
MIP-1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
.	O
<EOS>	B-X
Biochemical	B-X
characterization	B-X
of	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
.	B-X
<EOS>	B-X
A	B-X
family	B-X
of	B-X
hematopoietic	B-X
specific	B-X
transcription	B-X
factors	B-X
,	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
family	B-X
,	B-X
has	B-X
recently	B-X
been	B-X
identified	B-X
<EOS>	B-X
They	B-X
are	B-X
intimately	B-X
involved	B-X
in	B-X
regulating	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
huMIP	B-X
-	B-X
1	B-X
alpha	B-X
gene	B-X
in	B-X
monocytes	B-X
,	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
and	B-X
transformed	B-X
B	B-X
-	B-X
cells	B-X
<EOS>	B-X
The	B-X
biochemical	B-X
and	B-X
immunological	B-X
properties	B-X
of	B-X
rCsMF6	B-X
/	B-X
HDM	B-X
were	B-X
analyzed	B-X

A	O
family	O
of	O
hematopoietic	B-protein
specific	I-protein
transcription	I-protein
factors	I-protein
,	O
MIP-1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
(	I-protein
MNP	I-protein
)	I-protein
family	I-protein
,	O
has	O
recently	O
been	O
identified	O
.	O
<EOS>	B-X
A	B-X
family	B-X
of	B-X
hematopoietic	B-X
specific	B-X
transcription	B-X
factors	B-X
,	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
family	B-X
,	B-X
has	B-X
recently	B-X
been	B-X
identified	B-X
<EOS>	B-X
Biochemical	B-X
characterization	B-X
of	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
.	B-X
<EOS>	B-X
They	B-X
are	B-X
intimately	B-X
involved	B-X
in	B-X
regulating	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
huMIP	B-X
-	B-X
1	B-X
alpha	B-X
gene	B-X
in	B-X
monocytes	B-X
,	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
and	B-X
transformed	B-X
B	B-X
-	B-X
cells	B-X
<EOS>	B-X
One	B-X
member	B-X
of	B-X
the	B-X
family	B-X
(	B-X
MNP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
promoter	B-X
activity	B-X
in	B-X
monocytes	B-X
and	B-X
B	B-X
-	B-X
cells	B-X
,	B-X
while	B-X
another	B-X
(	B-X
MNP	B-X
-	B-X
2	B-X
)	B-X
is	B-X
required	B-X
for	B-X
full	B-X
promotor	B-X
activity	B-X
in	B-X
T	B-X
-	B-X
cells	B-X

They	O
are	O
intimately	O
involved	O
in	O
regulating	O
the	O
transcription	O
of	O
the	O
huMIP-1	B-DNA
alpha	I-DNA
gene	I-DNA
in	O
monocytes	B-cell_type
,	O
T-cells	B-cell_type
,	O
and	O
transformed	B-cell_type
B-cells	I-cell_type
.	O
<EOS>	B-X
They	B-X
are	B-X
intimately	B-X
involved	B-X
in	B-X
regulating	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
huMIP	B-X
-	B-X
1	B-X
alpha	B-X
gene	B-X
in	B-X
monocytes	B-X
,	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
and	B-X
transformed	B-X
B	B-X
-	B-X
cells	B-X
<EOS>	B-X
A	B-X
family	B-X
of	B-X
hematopoietic	B-X
specific	B-X
transcription	B-X
factors	B-X
,	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
family	B-X
,	B-X
has	B-X
recently	B-X
been	B-X
identified	B-X
<EOS>	B-X
Biochemical	B-X
characterization	B-X
of	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
.	B-X
<EOS>	B-X
One	B-X
member	B-X
of	B-X
the	B-X
family	B-X
(	B-X
MNP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
promoter	B-X
activity	B-X
in	B-X
monocytes	B-X
and	B-X
B	B-X
-	B-X
cells	B-X
,	B-X
while	B-X
another	B-X
(	B-X
MNP	B-X
-	B-X
2	B-X
)	B-X
is	B-X
required	B-X
for	B-X
full	B-X
promotor	B-X
activity	B-X
in	B-X
T	B-X
-	B-X
cells	B-X

One	O
member	O
of	O
the	O
family	O
(	O
MNP-1	B-protein
)	O
is	O
essential	O
for	O
promoter	O
activity	O
in	O
monocytes	B-cell_type
and	O
B-cells	B-cell_type
,	O
while	O
another	O
(	O
MNP-2	B-protein
)	O
is	O
required	O
for	O
full	O
promotor	O
activity	O
in	O
T-cells	B-cell_type
.	O
<EOS>	B-X
One	B-X
member	B-X
of	B-X
the	B-X
family	B-X
(	B-X
MNP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
promoter	B-X
activity	B-X
in	B-X
monocytes	B-X
and	B-X
B	B-X
-	B-X
cells	B-X
,	B-X
while	B-X
another	B-X
(	B-X
MNP	B-X
-	B-X
2	B-X
)	B-X
is	B-X
required	B-X
for	B-X
full	B-X
promotor	B-X
activity	B-X
in	B-X
T	B-X
-	B-X
cells	B-X
<EOS>	B-X
A	B-X
third	B-X
member	B-X
of	B-X
the	B-X
family	B-X
(	B-X
MNP	B-X
-	B-X
3	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
PMA	B-X
induced	B-X
HL60	B-X
cells	B-X
and	B-X
probably	B-X
has	B-X
a	B-X
role	B-X
in	B-X
monocyte	B-X
differentiation	B-X
<EOS>	B-X
They	B-X
are	B-X
intimately	B-X
involved	B-X
in	B-X
regulating	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
huMIP	B-X
-	B-X
1	B-X
alpha	B-X
gene	B-X
in	B-X
monocytes	B-X
,	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
and	B-X
transformed	B-X
B	B-X
-	B-X
cells	B-X
<EOS>	B-X
A	B-X
family	B-X
of	B-X
hematopoietic	B-X
specific	B-X
transcription	B-X
factors	B-X
,	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
family	B-X
,	B-X
has	B-X
recently	B-X
been	B-X
identified	B-X

A	O
third	O
member	O
of	O
the	O
family	O
(	O
MNP-3	B-protein
)	O
is	O
expressed	O
in	O
PMA	B-cell_line
induced	I-cell_line
HL60	I-cell_line
cells	I-cell_line
and	O
probably	O
has	O
a	O
role	O
in	O
monocyte	O
differentiation	O
.	O

In	O
this	O
communication	O
we	O
demonstrate	O
by	O
two	O
techniques	O
that	O
MNP-1	B-protein
and	O
MNP-2	B-protein
are	O
distinct	O
but	O
related	O
factors	O
,	O
and	O
we	O
present	O
further	O
evidence	O
to	O
show	O
that	O
MNP-1	B-protein
acts	O
as	O
a	O
heterodimer	B-protein
.	O
<EOS>	B-X
In	B-X
this	B-X
communication	B-X
we	B-X
demonstrate	B-X
by	B-X
two	B-X
techniques	B-X
that	B-X
MNP	B-X
-	B-X
1	B-X
and	B-X
MNP	B-X
-	B-X
2	B-X
are	B-X
distinct	B-X
but	B-X
related	B-X
factors	B-X
,	B-X
and	B-X
we	B-X
present	B-X
further	B-X
evidence	B-X
to	B-X
show	B-X
that	B-X
MNP	B-X
-	B-X
1	B-X
acts	B-X
as	B-X
a	B-X
heterodimer	B-X
<EOS>	B-X
A	B-X
third	B-X
member	B-X
of	B-X
the	B-X
family	B-X
(	B-X
MNP	B-X
-	B-X
3	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
PMA	B-X
induced	B-X
HL60	B-X
cells	B-X
and	B-X
probably	B-X
has	B-X
a	B-X
role	B-X
in	B-X
monocyte	B-X
differentiation	B-X
<EOS>	B-X
They	B-X
are	B-X
intimately	B-X
involved	B-X
in	B-X
regulating	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
huMIP	B-X
-	B-X
1	B-X
alpha	B-X
gene	B-X
in	B-X
monocytes	B-X
,	B-X
T	B-X
-	B-X
cells	B-X
,	B-X
and	B-X
transformed	B-X
B	B-X
-	B-X
cells	B-X
<EOS>	B-X
A	B-X
family	B-X
of	B-X
hematopoietic	B-X
specific	B-X
transcription	B-X
factors	B-X
,	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
family	B-X
,	B-X
has	B-X
recently	B-X
been	B-X
identified	B-X

Bcl-3	B-protein
expression	O
and	O
nuclear	O
translocation	O
are	O
induced	O
by	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
erythropoietin	B-protein
in	O
proliferating	B-cell_type
human	I-cell_type
erythroid	I-cell_type
precursors	I-cell_type
.	O
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
nuclear	B-X
translocation	B-X
are	B-X
induced	B-X
by	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
and	B-X
erythropoietin	B-X
in	B-X
proliferating	B-X
human	B-X
erythroid	B-X
precursors	B-X
.	B-X
<EOS>	B-X
In	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
an	B-X
erythroleukemia	B-X
cell	B-X
line	B-X
,	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
and	B-X
erythropoietin	B-X
(	B-X
Epo	B-X
)	B-X
greatly	B-X
enhanced	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
protein	B-X
and	B-X
mRNA	B-X
levels	B-X
in	B-X
association	B-X
with	B-X
stimulation	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
involvement	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
hematopoietic	B-X
growth	B-X
factor	B-X
-	B-X
stimulated	B-X
erythroid	B-X
proliferation	B-X
and	B-X
differentiation	B-X
was	B-X
examined	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
protein	B-X
was	B-X
also	B-X
highly	B-X
expressed	B-X
in	B-X
early	B-X
burst	B-X
-	B-X
forming	B-X
unit	B-X
-	B-X
erythroid	B-X
(	B-X
BFU	B-X
-	B-X
E	B-X
)	B-X
	B-X
-	B-X
derived	B-X
erythroid	B-X
precursors	B-X
(	B-X
day	B-X
7	B-X
)	B-X
and	B-X
decreased	B-X
during	B-X
maturation	B-X
(	B-X
days	B-X
10	B-X
and	B-X
14	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
is	B-X
involved	B-X
in	B-X
normal	B-X
erythroid	B-X
proliferation	B-X

Bcl-3	B-protein
is	O
a	O
proto-oncogene	B-DNA
involved	O
in	O
the	O
chromosomal	O
translocation	O
t	B-DNA
(	I-DNA
14	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
found	O
in	O
some	O
patients	O
with	O
chronic	O
lymphocytic	O
leukemia	O
.	O

It	O
shares	O
structural	O
similarities	O
with	O
and	O
is	O
a	O
member	O
of	O
the	O
IkappaB	B-protein
family	I-protein
of	O
proteins	O
.	O
<EOS>	B-X
It	B-X
shares	B-X
structural	B-X
similarities	B-X
with	B-X
and	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
IkappaB	B-X
family	B-X
of	B-X
proteins	B-X
<EOS>	B-X
All	B-X
these	B-X
typical	B-X
characteristics	B-X
indicated	B-X
that	B-X
the	B-X
AiIkappaB	B-X
should	B-X
be	B-X
classified	B-X
into	B-X
IkappaB	B-X
family	B-X
proteins	B-X
<EOS>	B-X
Structure	B-X
and	B-X
evolution	B-X
of	B-X
the	B-X
human	B-X
IKBA	B-X
gene	B-X
.	B-X
<EOS>	B-X
To	B-X
examine	B-X
further	B-X
the	B-X
evolutionary	B-X
relationship	B-X
between	B-X
human	B-X
IkappaBalpha	B-X
and	B-X
other	B-X
members	B-X
of	B-X
its	B-X
gene	B-X
family	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
phylogenetic	B-X
analysis	B-X

In	O
this	O
report	O
,	O
involvement	O
of	O
Bcl-3	B-protein
in	O
hematopoietic	O
growth	O
factor-stimulated	O
erythroid	O
proliferation	O
and	O
differentiation	O
was	O
examined	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
involvement	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
hematopoietic	B-X
growth	B-X
factor	B-X
-	B-X
stimulated	B-X
erythroid	B-X
proliferation	B-X
and	B-X
differentiation	B-X
was	B-X
examined	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
nuclear	B-X
translocation	B-X
are	B-X
induced	B-X
by	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
and	B-X
erythropoietin	B-X
in	B-X
proliferating	B-X
human	B-X
erythroid	B-X
precursors	B-X
.	B-X
<EOS>	B-X
In	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
an	B-X
erythroleukemia	B-X
cell	B-X
line	B-X
,	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
and	B-X
erythropoietin	B-X
(	B-X
Epo	B-X
)	B-X
greatly	B-X
enhanced	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
protein	B-X
and	B-X
mRNA	B-X
levels	B-X
in	B-X
association	B-X
with	B-X
stimulation	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
these	B-X
hematopoietic	B-X
cells	B-X
,	B-X
Bcl	B-X
-	B-X
3	B-X
was	B-X
hyperphosphorylated	B-X

In	O
TF-1	B-cell_line
cells	I-cell_line
,	O
an	O
erythroleukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
greatly	O
enhanced	O
Bcl-3	B-protein
expression	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
in	O
association	O
with	O
stimulation	O
of	O
proliferation	O
.	O
<EOS>	B-X
In	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
an	B-X
erythroleukemia	B-X
cell	B-X
line	B-X
,	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
and	B-X
erythropoietin	B-X
(	B-X
Epo	B-X
)	B-X
greatly	B-X
enhanced	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
protein	B-X
and	B-X
mRNA	B-X
levels	B-X
in	B-X
association	B-X
with	B-X
stimulation	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
nuclear	B-X
translocation	B-X
are	B-X
induced	B-X
by	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
and	B-X
erythropoietin	B-X
in	B-X
proliferating	B-X
human	B-X
erythroid	B-X
precursors	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
involvement	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
hematopoietic	B-X
growth	B-X
factor	B-X
-	B-X
stimulated	B-X
erythroid	B-X
proliferation	B-X
and	B-X
differentiation	B-X
was	B-X
examined	B-X
<EOS>	B-X
Overexpression	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
by	B-X
transient	B-X
transfection	B-X
along	B-X
with	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
factors	B-X
p50	B-X
or	B-X
p52	B-X
resulted	B-X
in	B-X
significant	B-X
induction	B-X
of	B-X
an	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
-	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
kappaB	B-X
-	B-X
TATA	B-X
-	B-X
luceriferase	B-X
reporter	B-X
plasmid	B-X
,	B-X
demonstrating	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
has	B-X
a	B-X
positive	B-X
role	B-X
in	B-X
transactivation	B-X
of	B-X
kappaB	B-X
-	B-X
containing	B-X
genes	B-X
in	B-X
erythroid	B-X
cells	B-X

Bcl-3	B-protein
protein	O
was	O
also	O
highly	O
expressed	O
in	O
early	B-cell_type
burst-forming	I-cell_type
unit-erythroid	I-cell_type
(	I-cell_type
BFU-E	I-cell_type
)	I-cell_type
-derived	I-cell_type
erythroid	I-cell_type
precursors	I-cell_type
(	O
day	O
7	O
)	O
and	O
decreased	O
during	O
maturation	O
(	O
days	O
10	O
and	O
14	O
)	O
,	O
suggesting	O
that	O
Bcl-3	B-protein
is	O
involved	O
in	O
normal	O
erythroid	O
proliferation	O
.	O
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
protein	B-X
was	B-X
also	B-X
highly	B-X
expressed	B-X
in	B-X
early	B-X
burst	B-X
-	B-X
forming	B-X
unit	B-X
-	B-X
erythroid	B-X
(	B-X
BFU	B-X
-	B-X
E	B-X
)	B-X
	B-X
-	B-X
derived	B-X
erythroid	B-X
precursors	B-X
(	B-X
day	B-X
7	B-X
)	B-X
and	B-X
decreased	B-X
during	B-X
maturation	B-X
(	B-X
days	B-X
10	B-X
and	B-X
14	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
is	B-X
involved	B-X
in	B-X
normal	B-X
erythroid	B-X
proliferation	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
nuclear	B-X
translocation	B-X
are	B-X
induced	B-X
by	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
and	B-X
erythropoietin	B-X
in	B-X
proliferating	B-X
human	B-X
erythroid	B-X
precursors	B-X
.	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
bound	B-X
to	B-X
a	B-X
kappaB	B-X
enhancer	B-X
in	B-X
the	B-X
c	B-X
-	B-X
myb	B-X
promoter	B-X
together	B-X
with	B-X
NF	B-X
-	B-X
kappaB2	B-X
/	B-X
p52	B-X
and	B-X
this	B-X
binding	B-X
activity	B-X
was	B-X
enhanced	B-X
by	B-X
GM	B-X
-	B-X
CSF	B-X
stimulation	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
certain	B-X
kappaB	B-X
-	B-X
containing	B-X
genes	B-X
involved	B-X
in	B-X
hematopoiesis	B-X
,	B-X
including	B-X
c	B-X
-	B-X
myb	B-X

In	O
these	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
Bcl-3	B-protein
was	O
hyperphosphorylated	O
.	O
<EOS>	B-X
In	B-X
these	B-X
hematopoietic	B-X
cells	B-X
,	B-X
Bcl	B-X
-	B-X
3	B-X
was	B-X
hyperphosphorylated	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
involvement	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
hematopoietic	B-X
growth	B-X
factor	B-X
-	B-X
stimulated	B-X
erythroid	B-X
proliferation	B-X
and	B-X
differentiation	B-X
was	B-X
examined	B-X
<EOS>	B-X
Upon	B-X
stimulation	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
with	B-X
GM	B-X
-	B-X
CSF	B-X
or	B-X
Epo	B-X
,	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
was	B-X
dramatically	B-X
enhanced	B-X
<EOS>	B-X
It	B-X
shares	B-X
structural	B-X
similarities	B-X
with	B-X
and	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
IkappaB	B-X
family	B-X
of	B-X
proteins	B-X

GM-CSF	B-protein
and	O
Epo	B-protein
modulated	O
the	O
subcellular	O
localization	O
of	O
Bcl-3	B-protein
.	O
<EOS>	B-X
GM	B-X
-	B-X
CSF	B-X
and	B-X
Epo	B-X
modulated	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
<EOS>	B-X
Upon	B-X
stimulation	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
with	B-X
GM	B-X
-	B-X
CSF	B-X
or	B-X
Epo	B-X
,	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
was	B-X
dramatically	B-X
enhanced	B-X
<EOS>	B-X
It	B-X
shares	B-X
structural	B-X
similarities	B-X
with	B-X
and	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
IkappaB	B-X
family	B-X
of	B-X
proteins	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
is	B-X
a	B-X
proto	B-X
-	B-X
oncogene	B-X
involved	B-X
in	B-X
the	B-X
chromosomal	B-X
translocation	B-X
t	B-X
(	B-X
14	B-X
;	B-X
19	B-X
)	B-X
found	B-X
in	B-X
some	B-X
patients	B-X
with	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X

Upon	O
stimulation	O
of	O
TF-1	B-cell_line
cells	I-cell_line
with	O
GM-CSF	B-protein
or	O
Epo	B-protein
,	O
the	O
nuclear	O
translocation	O
of	O
Bcl-3	B-protein
was	O
dramatically	O
enhanced	O
.	O
<EOS>	B-X
The	B-X
proportion	B-X
of	B-X
apoptotic	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
after	B-X
incubation	B-X
with	B-X
crhGM	B-X
-	B-X
CSF	B-X
for	B-X
72h	B-X
was	B-X
lower	B-X
than	B-X
that	B-X
of	B-X
cells	B-X
incubated	B-X
with	B-X
other	B-X
rhGM	B-X
-	B-X
CSFs	B-X
<EOS>	B-X
Identification	B-X
of	B-X
novel	B-X
ALK2	B-X
inhibitors	B-X
and	B-X
their	B-X
effect	B-X
on	B-X
cancer	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
proliferation	B-X
/	B-X
survival	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
or	B-X
PBMCs	B-X
after	B-X
long	B-X
-	B-X
term	B-X
stimulation	B-X
(	B-X
72	B-X
-	B-X
168h	B-X
)	B-X
was	B-X
higher	B-X
at	B-X
low	B-X
concentrations	B-X
of	B-X
crhGM	B-X
-	B-X
CSF	B-X
(	B-X
15	B-X
-	B-X
30pM	B-X
)	B-X
than	B-X
that	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
other	B-X
GM	B-X
-	B-X
CSFs	B-X
<EOS>	B-X
The	B-X
present	B-X
formulation	B-X
process	B-X
ensured	B-X
good	B-X
reproducibility	B-X
and	B-X
over	B-X
89	B-X
%	B-X
protein	B-X
encapsulation	B-X
efficiency	B-X
,	B-X
and	B-X
practically	B-X
feasible	B-X
to	B-X
adapt	B-X
to	B-X
scaled	B-X
productions	B-X

Overexpression	O
of	O
Bcl-3	B-protein
in	O
TF-1	B-cell_line
cells	I-cell_line
by	O
transient	O
transfection	O
along	O
with	O
the	O
NF-kappaB	B-protein
factors	I-protein
p50	I-protein
or	I-protein
p52	I-protein
resulted	O
in	O
significant	O
induction	O
of	O
an	O
human	B-DNA
immunodeficiency	I-DNA
virus-type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
kappaB-TATA-luceriferase	I-DNA
reporter	I-DNA
plasmid	I-DNA
,	O
demonstrating	O
that	O
Bcl-3	B-protein
has	O
a	O
positive	O
role	O
in	O
transactivation	O
of	O
kappaB-containing	B-DNA
genes	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Overexpression	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
by	B-X
transient	B-X
transfection	B-X
along	B-X
with	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
factors	B-X
p50	B-X
or	B-X
p52	B-X
resulted	B-X
in	B-X
significant	B-X
induction	B-X
of	B-X
an	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
-	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
kappaB	B-X
-	B-X
TATA	B-X
-	B-X
luceriferase	B-X
reporter	B-X
plasmid	B-X
,	B-X
demonstrating	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
has	B-X
a	B-X
positive	B-X
role	B-X
in	B-X
transactivation	B-X
of	B-X
kappaB	B-X
-	B-X
containing	B-X
genes	B-X
in	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
cotransfection	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
with	B-X
p52	B-X
or	B-X
p50	B-X
in	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
resulted	B-X
in	B-X
significant	B-X
activation	B-X
of	B-X
a	B-X
c	B-X
-	B-X
myb	B-X
kappaB	B-X
-	B-X
TATA	B-X
-	B-X
luceriferase	B-X
reporter	B-X
plasmid	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
nuclear	B-X
translocation	B-X
are	B-X
induced	B-X
by	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
and	B-X
erythropoietin	B-X
in	B-X
proliferating	B-X
human	B-X
erythroid	B-X
precursors	B-X
.	B-X
<EOS>	B-X
In	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
an	B-X
erythroleukemia	B-X
cell	B-X
line	B-X
,	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
and	B-X
erythropoietin	B-X
(	B-X
Epo	B-X
)	B-X
greatly	B-X
enhanced	B-X
Bcl	B-X
-	B-X
3	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
protein	B-X
and	B-X
mRNA	B-X
levels	B-X
in	B-X
association	B-X
with	B-X
stimulation	B-X
of	B-X
proliferation	B-X

Stimulation	O
with	O
GM-CSF	B-protein
enhanced	O
c-myb	B-RNA
mRNA	I-RNA
expression	O
in	O
these	O
cells	O
.	O
<EOS>	B-X
Stimulation	B-X
with	B-X
GM	B-X
-	B-X
CSF	B-X
enhanced	B-X
c	B-X
-	B-X
myb	B-X
mRNA	B-X
expression	B-X
in	B-X
these	B-X
cells	B-X
<EOS>	B-X
Upon	B-X
stimulation	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
with	B-X
GM	B-X
-	B-X
CSF	B-X
or	B-X
Epo	B-X
,	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
was	B-X
dramatically	B-X
enhanced	B-X
<EOS>	B-X
Pretreatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
TNF	B-X
enhanced	B-X
their	B-X
responsiveness	B-X
to	B-X
subsequent	B-X
treatment	B-X
with	B-X
interleukin	B-X
1	B-X
<EOS>	B-X
The	B-X
drug	B-X
also	B-X
caused	B-X
an	B-X
initial	B-X
increase	B-X
in	B-X
c	B-X
-	B-X
myb	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
subsequent	B-X
decrease	B-X
below	B-X
baseline	B-X
levels	B-X

Bcl-3	B-protein
in	O
nuclear	O
extracts	O
of	O
TF-1	B-cell_line
cells	I-cell_line
bound	O
to	O
a	O
kappaB	B-DNA
enhancer	I-DNA
in	O
the	O
c-myb	B-DNA
promoter	I-DNA
together	O
with	O
NF-kappaB2/p52	B-protein
and	O
this	O
binding	O
activity	O
was	O
enhanced	O
by	O
GM-CSF	B-protein
stimulation	O
.	O
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
bound	B-X
to	B-X
a	B-X
kappaB	B-X
enhancer	B-X
in	B-X
the	B-X
c	B-X
-	B-X
myb	B-X
promoter	B-X
together	B-X
with	B-X
NF	B-X
-	B-X
kappaB2	B-X
/	B-X
p52	B-X
and	B-X
this	B-X
binding	B-X
activity	B-X
was	B-X
enhanced	B-X
by	B-X
GM	B-X
-	B-X
CSF	B-X
stimulation	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
is	B-X
a	B-X
proto	B-X
-	B-X
oncogene	B-X
involved	B-X
in	B-X
the	B-X
chromosomal	B-X
translocation	B-X
t	B-X
(	B-X
14	B-X
;	B-X
19	B-X
)	B-X
found	B-X
in	B-X
some	B-X
patients	B-X
with	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
<EOS>	B-X
Upon	B-X
stimulation	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
with	B-X
GM	B-X
-	B-X
CSF	B-X
or	B-X
Epo	B-X
,	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
was	B-X
dramatically	B-X
enhanced	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
protein	B-X
was	B-X
also	B-X
highly	B-X
expressed	B-X
in	B-X
early	B-X
burst	B-X
-	B-X
forming	B-X
unit	B-X
-	B-X
erythroid	B-X
(	B-X
BFU	B-X
-	B-X
E	B-X
)	B-X
	B-X
-	B-X
derived	B-X
erythroid	B-X
precursors	B-X
(	B-X
day	B-X
7	B-X
)	B-X
and	B-X
decreased	B-X
during	B-X
maturation	B-X
(	B-X
days	B-X
10	B-X
and	B-X
14	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
is	B-X
involved	B-X
in	B-X
normal	B-X
erythroid	B-X
proliferation	B-X

Furthermore	O
,	O
cotransfection	O
of	O
Bcl-3	B-protein
with	O
p52	B-protein
or	O
p50	B-protein
in	O
TF-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
significant	O
activation	O
of	O
a	O
c-myb	B-DNA
kappaB-TATA-luceriferase	I-DNA
reporter	I-DNA
plasmid	I-DNA
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
cotransfection	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
with	B-X
p52	B-X
or	B-X
p50	B-X
in	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
resulted	B-X
in	B-X
significant	B-X
activation	B-X
of	B-X
a	B-X
c	B-X
-	B-X
myb	B-X
kappaB	B-X
-	B-X
TATA	B-X
-	B-X
luceriferase	B-X
reporter	B-X
plasmid	B-X
<EOS>	B-X
Overexpression	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
by	B-X
transient	B-X
transfection	B-X
along	B-X
with	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
factors	B-X
p50	B-X
or	B-X
p52	B-X
resulted	B-X
in	B-X
significant	B-X
induction	B-X
of	B-X
an	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
-	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
kappaB	B-X
-	B-X
TATA	B-X
-	B-X
luceriferase	B-X
reporter	B-X
plasmid	B-X
,	B-X
demonstrating	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
has	B-X
a	B-X
positive	B-X
role	B-X
in	B-X
transactivation	B-X
of	B-X
kappaB	B-X
-	B-X
containing	B-X
genes	B-X
in	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
Upon	B-X
stimulation	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
with	B-X
GM	B-X
-	B-X
CSF	B-X
or	B-X
Epo	B-X
,	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
was	B-X
dramatically	B-X
enhanced	B-X
<EOS>	B-X
The	B-X
NFKB	B-X
-	B-X
2	B-X
gene	B-X
codes	B-X
for	B-X
an	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
related	B-X
transcription	B-X
factor	B-X
containing	B-X
rel	B-X
-	B-X
polyG	B-X
-	B-X
ankyrin	B-X
domains	B-X

These	O
findings	O
suggest	O
that	O
Bcl-3	B-protein
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
certain	O
kappaB-containing	B-DNA
genes	I-DNA
involved	O
in	O
hematopoiesis	O
,	O
including	O
c-myb	B-DNA
.	O
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
certain	B-X
kappaB	B-X
-	B-X
containing	B-X
genes	B-X
involved	B-X
in	B-X
hematopoiesis	B-X
,	B-X
including	B-X
c	B-X
-	B-X
myb	B-X
<EOS>	B-X
It	B-X
shares	B-X
structural	B-X
similarities	B-X
with	B-X
and	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
IkappaB	B-X
family	B-X
of	B-X
proteins	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
involvement	B-X
of	B-X
Bcl	B-X
-	B-X
3	B-X
in	B-X
hematopoietic	B-X
growth	B-X
factor	B-X
-	B-X
stimulated	B-X
erythroid	B-X
proliferation	B-X
and	B-X
differentiation	B-X
was	B-X
examined	B-X
<EOS>	B-X
Bcl	B-X
-	B-X
3	B-X
protein	B-X
was	B-X
also	B-X
highly	B-X
expressed	B-X
in	B-X
early	B-X
burst	B-X
-	B-X
forming	B-X
unit	B-X
-	B-X
erythroid	B-X
(	B-X
BFU	B-X
-	B-X
E	B-X
)	B-X
	B-X
-	B-X
derived	B-X
erythroid	B-X
precursors	B-X
(	B-X
day	B-X
7	B-X
)	B-X
and	B-X
decreased	B-X
during	B-X
maturation	B-X
(	B-X
days	B-X
10	B-X
and	B-X
14	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
Bcl	B-X
-	B-X
3	B-X
is	B-X
involved	B-X
in	B-X
normal	B-X
erythroid	B-X
proliferation	B-X

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O

5-Lipoxygenase	B-protein
compartmentalization	O
in	O
granulocytic	O
cells	O
is	O
modulated	O
by	O
an	O
internal	B-protein
bipartite	I-protein
nuclear	I-protein
localizing	I-protein
sequence	I-protein
and	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
complex	I-protein
formation	O
.	O
<EOS>	B-X
5	B-X
-	B-X
Lipoxygenase	B-X
compartmentalization	B-X
in	B-X
granulocytic	B-X
cells	B-X
is	B-X
modulated	B-X
by	B-X
an	B-X
internal	B-X
bipartite	B-X
nuclear	B-X
localizing	B-X
sequence	B-X
and	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
complex	B-X
formation	B-X
.	B-X
<EOS>	B-X
A	B-X
synthetic	B-X
peptide	B-X
consisting	B-X
of	B-X
the	B-X
Kaposi	B-X
fibroblast	B-X
growth	B-X
factor	B-X
signal	B-X
sequence	B-X
fused	B-X
to	B-X
the	B-X
5	B-X
-	B-X
lipoxygenase639	B-X
-	B-X
656	B-X
bipartite	B-X
nuclear	B-X
localizing	B-X
sequence	B-X
has	B-X
a	B-X
prominent	B-X
inhibitory	B-X
effect	B-X
on	B-X
5	B-X
-	B-X
lipoxygenase	B-X
catalysis	B-X
in	B-X
granulocytic	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
activated	B-X
by	B-X
calcium	B-X
ionophor	B-X
A23187	B-X
<EOS>	B-X
5	B-X
-	B-X
Lipoxygenase	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
p65	B-X
subunit	B-X
immunoprecipitate	B-X
fractions	B-X
prepared	B-X
from	B-X
HL	B-X
-	B-X
60	B-X
cell	B-X
lysates	B-X
<EOS>	B-X
The	B-X
amount	B-X
of	B-X
5	B-X
-	B-X
lipoxygenase	B-X
protein	B-X
coimmunoprecipitated	B-X
by	B-X
NF	B-X
-	B-X
kappaB	B-X
antiserum	B-X
was	B-X
increased	B-X
following	B-X
A23187	B-X
stimulation	B-X

A	O
region	O
of	O
basic	O
amino	O
acids	O
spanning	O
residues	B-protein
639-656	I-protein
in	O
the	O
human	B-protein
5-lipoxygenase	I-protein
sequence	I-protein
resembles	O
a	O
consensus	B-protein
bipartite	I-protein
nuclear	I-protein
localizing	I-protein
sequence	I-protein
.	O
<EOS>	B-X
A	B-X
region	B-X
of	B-X
basic	B-X
amino	B-X
acids	B-X
spanning	B-X
residues	B-X
639	B-X
-	B-X
656	B-X
in	B-X
the	B-X
human	B-X
5	B-X
-	B-X
lipoxygenase	B-X
sequence	B-X
resembles	B-X
a	B-X
consensus	B-X
bipartite	B-X
nuclear	B-X
localizing	B-X
sequence	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
molecular	B-X
determinants	B-X
which	B-X
govern	B-X
5	B-X
-	B-X
lipoxygenase	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
redistribution	B-X
to	B-X
the	B-X
nucleus	B-X
may	B-X
be	B-X
coordinately	B-X
controlled	B-X
in	B-X
granulocytic	B-X
cells	B-X
<EOS>	B-X
In	B-X
cells	B-X
treated	B-X
with	B-X
agents	B-X
that	B-X
block	B-X
5	B-X
-	B-X
lipoxygenase	B-X
translocation	B-X
to	B-X
the	B-X
nucleus	B-X
,	B-X
5	B-X
-	B-X
lipoxygenase	B-X
protein	B-X
appearing	B-X
in	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
immunoprecipitate	B-X
was	B-X
diminished	B-X
<EOS>	B-X
A	B-X
synthetic	B-X
peptide	B-X
consisting	B-X
of	B-X
the	B-X
Kaposi	B-X
fibroblast	B-X
growth	B-X
factor	B-X
signal	B-X
sequence	B-X
fused	B-X
to	B-X
the	B-X
5	B-X
-	B-X
lipoxygenase639	B-X
-	B-X
656	B-X
bipartite	B-X
nuclear	B-X
localizing	B-X
sequence	B-X
has	B-X
a	B-X
prominent	B-X
inhibitory	B-X
effect	B-X
on	B-X
5	B-X
-	B-X
lipoxygenase	B-X
catalysis	B-X
in	B-X
granulocytic	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
activated	B-X
by	B-X
calcium	B-X
ionophor	B-X
A23187	B-X

A	O
synthetic	O
peptide	O
consisting	O
of	O
the	O
Kaposi	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
signal	I-protein
sequence	I-protein
fused	O
to	O
the	O
5-lipoxygenase639-656	B-protein
bipartite	I-protein
nuclear	I-protein
localizing	I-protein
sequence	I-protein
has	O
a	O
prominent	O
inhibitory	O
effect	O
on	O
5-lipoxygenase	B-protein
catalysis	O
in	O
granulocytic	O
HL-60	B-cell_line
cells	I-cell_line
activated	O
by	O
calcium	O
ionophor	O
A23187	O
.	O

Recombinant	O
5-lipoxygenase	B-protein
was	O
not	O
affected	O
by	O
the	O
peptide	O
.	O
<EOS>	B-X
Iron	B-X
-	B-X
Dependent	B-X
Trafficking	B-X
of	B-X
5	B-X
-	B-X
Lipoxygenase	B-X
and	B-X
Impact	B-X
on	B-X
Human	B-X
Macrophage	B-X
Activation	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
activity	B-X
assays	B-X
with	B-X
5	B-X
-	B-X
lipoxygenase	B-X
(	B-X
5	B-X
-	B-X
LO	B-X
)	B-X
and	B-X
recombinant	B-X
human	B-X
MMP9	B-X
and	B-X
KLK5	B-X
were	B-X
performed	B-X
<EOS>	B-X
Interactions	B-X
of	B-X
potato	B-X
-	B-X
derived	B-X
and	B-X
human	B-X
recombinant	B-X
5	B-X
-	B-X
lipoxygenase	B-X
with	B-X
sec	B-X
-	B-X
O	B-X
-	B-X
glucosylhamaudol	B-X
by	B-X
multi	B-X
-	B-X
spectroscopy	B-X
and	B-X
molecular	B-X
docking	B-X
.	B-X
<EOS>	B-X
Recombinant	B-X
5	B-X
-	B-X
LO	B-X
did	B-X
not	B-X
accept	B-X
the	B-X
precursors	B-X
for	B-X
SPM	B-X
formation	B-X
and	B-X
FLAP	B-X
inhibition	B-X
prevented	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
5	B-X
-	B-X
LO	B-X
-	B-X
dependent	B-X
SPMs	B-X

The	O
peptide	O
also	O
inhibited	O
redistribution	O
of	O
5-lipoxygenase	B-protein
from	O
the	O
cytosol	O
to	O
the	O
nuclear	O
membrane	O
of	O
HL-60	B-cell_line
cells	I-cell_line
stimulated	O
by	O
A23187	O
.	O

5-Lipoxygenase	B-protein
protein	I-protein
was	O
detected	O
in	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
p65	I-protein
subunit	I-protein
immunoprecipitate	O
fractions	O
prepared	O
from	O
HL-60	B-cell_line
cell	I-cell_line
lysates	O
.	O
<EOS>	B-X
5	B-X
-	B-X
Lipoxygenase	B-X
protein	B-X
was	B-X
detected	B-X
in	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
p65	B-X
subunit	B-X
immunoprecipitate	B-X
fractions	B-X
prepared	B-X
from	B-X
HL	B-X
-	B-X
60	B-X
cell	B-X
lysates	B-X
<EOS>	B-X
5	B-X
-	B-X
Lipoxygenase	B-X
compartmentalization	B-X
in	B-X
granulocytic	B-X
cells	B-X
is	B-X
modulated	B-X
by	B-X
an	B-X
internal	B-X
bipartite	B-X
nuclear	B-X
localizing	B-X
sequence	B-X
and	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
complex	B-X
formation	B-X
.	B-X
<EOS>	B-X
The	B-X
amount	B-X
of	B-X
5	B-X
-	B-X
lipoxygenase	B-X
protein	B-X
coimmunoprecipitated	B-X
by	B-X
NF	B-X
-	B-X
kappaB	B-X
antiserum	B-X
was	B-X
increased	B-X
following	B-X
A23187	B-X
stimulation	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
molecular	B-X
determinants	B-X
which	B-X
govern	B-X
5	B-X
-	B-X
lipoxygenase	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
redistribution	B-X
to	B-X
the	B-X
nucleus	B-X
may	B-X
be	B-X
coordinately	B-X
controlled	B-X
in	B-X
granulocytic	B-X
cells	B-X

The	O
amount	O
of	O
5-lipoxygenase	B-protein
protein	I-protein
coimmunoprecipitated	O
by	O
NF-kappaB	O
antiserum	O
was	O
increased	O
following	O
A23187	O
stimulation	O
.	O
<EOS>	B-X
The	B-X
amount	B-X
of	B-X
5	B-X
-	B-X
lipoxygenase	B-X
protein	B-X
coimmunoprecipitated	B-X
by	B-X
NF	B-X
-	B-X
kappaB	B-X
antiserum	B-X
was	B-X
increased	B-X
following	B-X
A23187	B-X
stimulation	B-X
<EOS>	B-X
Recombinant	B-X
5	B-X
-	B-X
lipoxygenase	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
peptide	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
molecular	B-X
determinants	B-X
which	B-X
govern	B-X
5	B-X
-	B-X
lipoxygenase	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
redistribution	B-X
to	B-X
the	B-X
nucleus	B-X
may	B-X
be	B-X
coordinately	B-X
controlled	B-X
in	B-X
granulocytic	B-X
cells	B-X
<EOS>	B-X
In	B-X
cells	B-X
treated	B-X
with	B-X
agents	B-X
that	B-X
block	B-X
5	B-X
-	B-X
lipoxygenase	B-X
translocation	B-X
to	B-X
the	B-X
nucleus	B-X
,	B-X
5	B-X
-	B-X
lipoxygenase	B-X
protein	B-X
appearing	B-X
in	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
immunoprecipitate	B-X
was	B-X
diminished	B-X

In	O
cells	O
treated	O
with	O
agents	O
that	O
block	O
5-lipoxygenase	B-protein
translocation	O
to	O
the	O
nucleus	O
,	O
5-lipoxygenase	B-protein
protein	O
appearing	O
in	O
the	O
NF-kappaB	B-protein
immunoprecipitate	O
was	O
diminished	O
.	O

Our	O
results	O
implicate	O
an	O
internal	B-protein
bipartite	I-protein
nuclear	I-protein
localizing	I-protein
sequence	I-protein
as	O
a	O
regulatory	O
domain	O
that	O
modulates	O
5-lipoxygenase	B-protein
redistribution	O
and	O
catalysis	O
in	O
granulocytic	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Our	B-X
results	B-X
implicate	B-X
an	B-X
internal	B-X
bipartite	B-X
nuclear	B-X
localizing	B-X
sequence	B-X
as	B-X
a	B-X
regulatory	B-X
domain	B-X
that	B-X
modulates	B-X
5	B-X
-	B-X
lipoxygenase	B-X
redistribution	B-X
and	B-X
catalysis	B-X
in	B-X
granulocytic	B-X
cells	B-X
<EOS>	B-X
A	B-X
synthetic	B-X
peptide	B-X
consisting	B-X
of	B-X
the	B-X
Kaposi	B-X
fibroblast	B-X
growth	B-X
factor	B-X
signal	B-X
sequence	B-X
fused	B-X
to	B-X
the	B-X
5	B-X
-	B-X
lipoxygenase639	B-X
-	B-X
656	B-X
bipartite	B-X
nuclear	B-X
localizing	B-X
sequence	B-X
has	B-X
a	B-X
prominent	B-X
inhibitory	B-X
effect	B-X
on	B-X
5	B-X
-	B-X
lipoxygenase	B-X
catalysis	B-X
in	B-X
granulocytic	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
activated	B-X
by	B-X
calcium	B-X
ionophor	B-X
A23187	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
molecular	B-X
determinants	B-X
which	B-X
govern	B-X
5	B-X
-	B-X
lipoxygenase	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
redistribution	B-X
to	B-X
the	B-X
nucleus	B-X
may	B-X
be	B-X
coordinately	B-X
controlled	B-X
in	B-X
granulocytic	B-X
cells	B-X
<EOS>	B-X
In	B-X
cells	B-X
treated	B-X
with	B-X
agents	B-X
that	B-X
block	B-X
5	B-X
-	B-X
lipoxygenase	B-X
translocation	B-X
to	B-X
the	B-X
nucleus	B-X
,	B-X
5	B-X
-	B-X
lipoxygenase	B-X
protein	B-X
appearing	B-X
in	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
immunoprecipitate	B-X
was	B-X
diminished	B-X

Additionally	O
,	O
our	O
results	O
suggest	O
that	O
molecular	O
determinants	O
which	O
govern	O
5-lipoxygenase	O
and	O
NF-kappaB	O
redistribution	O
to	O
the	O
nucleus	O
may	O
be	O
coordinately	O
controlled	O
in	O
granulocytic	B-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
CD28/CD3-mediated	O
costimulation	O
of	O
naive	B-cell_type
and	I-cell_type
memory	I-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
intracellular	O
incorporation	O
of	O
polyclonal	B-protein
antibodies	I-protein
specific	O
for	O
the	O
activator	B-protein
protein-1	I-protein
transcriptional	I-protein
complex	I-protein
.	O

A	O
number	O
of	O
indirect	O
methods	O
have	O
been	O
utilized	O
in	O
demonstrating	O
activator	B-protein
protein-1	I-protein
transcription	O
factor	O
function	O
in	O
IL-2	O
promoter	O
activity	O
.	O
<EOS>	B-X
A	B-X
number	B-X
of	B-X
indirect	B-X
methods	B-X
have	B-X
been	B-X
utilized	B-X
in	B-X
demonstrating	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
transcription	B-X
factor	B-X
function	B-X
in	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
T	B-X
cells	B-X
retained	B-X
their	B-X
physical	B-X
parameters	B-X
as	B-X
measured	B-X
by	B-X
forward	B-X
and	B-X
side	B-X
light	B-X
scatter	B-X
,	B-X
and	B-X
functional	B-X
activity	B-X
as	B-X
measured	B-X
by	B-X
costimulation	B-X
of	B-X
proliferation	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
after	B-X
being	B-X
scraped	B-X
off	B-X
this	B-X
substrate	B-X
<EOS>	B-X
However	B-X
,	B-X
there	B-X
has	B-X
been	B-X
no	B-X
direct	B-X
demonstration	B-X
that	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
is	B-X
involved	B-X
in	B-X
CD28	B-X
-	B-X
dependent	B-X
costimulation	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
transcription	B-X
in	B-X
freshly	B-X
isolated	B-X
naive	B-X
and	B-X
memory	B-X
human	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
CD28	B-X
/	B-X
CD3	B-X
-	B-X
mediated	B-X
costimulation	B-X
of	B-X
naive	B-X
and	B-X
memory	B-X
human	B-X
T	B-X
lymphocytes	B-X
by	B-X
intracellular	B-X
incorporation	B-X
of	B-X
polyclonal	B-X
antibodies	B-X
specific	B-X
for	B-X
the	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
transcriptional	B-X
complex	B-X
.	B-X

However	O
,	O
there	O
has	O
been	O
no	O
direct	O
demonstration	O
that	O
activator	B-protein
protein-1	I-protein
is	O
involved	O
in	O
CD28-dependent	O
costimulation	O
of	O
IL-2	B-DNA
gene	I-DNA
transcription	O
in	O
freshly	O
isolated	O
naive	B-cell_type
and	I-cell_type
memory	I-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

To	O
address	O
this	O
issue	O
,	O
the	O
method	O
of	O
scrape	O
loading	O
was	O
applied	O
to	O
purified	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Since	O
scrape	O
loading	O
relies	O
on	O
adherent	B-cell_type
cells	I-cell_type
,	O
peripheral	B-cell_type
blood	I-cell_type
human	I-cell_type
T	I-cell_type
(	I-cell_type
PB-T	I-cell_type
)	I-cell_type
cells	I-cell_type
were	O
immobilized	O
on	O
the	O
nonspecific	O
cell	O
attachment	O
factor	O
poly-L-lysine	O
.	O

Cells	O
scraped	O
off	O
poly-L-lysine	O
in	O
the	O
presence	O
of	O
Ig	B-protein
FITC	I-protein
efficiently	O
incorporated	O
Ig	O
,	O
with	O
relatively	O
uniform	O
fluorescence	O
.	O
<EOS>	B-X
Cells	B-X
scraped	B-X
off	B-X
poly	B-X
-	B-X
L	B-X
-	B-X
lysine	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ig	B-X
FITC	B-X
efficiently	B-X
incorporated	B-X
Ig	B-X
,	B-X
with	B-X
relatively	B-X
uniform	B-X
fluorescence	B-X
<EOS>	B-X
Since	B-X
scrape	B-X
loading	B-X
relies	B-X
on	B-X
adherent	B-X
cells	B-X
,	B-X
peripheral	B-X
blood	B-X
human	B-X
T	B-X
(	B-X
PB	B-X
-	B-X
T	B-X
)	B-X
cells	B-X
were	B-X
immobilized	B-X
on	B-X
the	B-X
nonspecific	B-X
cell	B-X
attachment	B-X
factor	B-X
poly	B-X
-	B-X
L	B-X
-	B-X
lysine	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
CD28	B-X
/	B-X
CD3	B-X
-	B-X
mediated	B-X
costimulation	B-X
of	B-X
naive	B-X
and	B-X
memory	B-X
human	B-X
T	B-X
lymphocytes	B-X
by	B-X
intracellular	B-X
incorporation	B-X
of	B-X
polyclonal	B-X
antibodies	B-X
specific	B-X
for	B-X
the	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
transcriptional	B-X
complex	B-X
.	B-X
<EOS>	B-X
To	B-X
address	B-X
this	B-X
issue	B-X
,	B-X
the	B-X
method	B-X
of	B-X
scrape	B-X
loading	B-X
was	B-X
applied	B-X
to	B-X
purified	B-X
peripheral	B-X
blood	B-X
T	B-X
lymphocytes	B-X

T	O
cells	O
retained	O
their	O
physical	O
parameters	O
as	O
measured	O
by	O
forward	O
and	O
side	O
light	O
scatter	O
,	O
and	O
functional	O
activity	O
as	O
measured	O
by	O
costimulation	O
of	O
proliferation	O
and	O
IL-2	B-protein
production	O
after	O
being	O
scraped	O
off	O
this	O
substrate	O
.	O
<EOS>	B-X
T	B-X
cells	B-X
retained	B-X
their	B-X
physical	B-X
parameters	B-X
as	B-X
measured	B-X
by	B-X
forward	B-X
and	B-X
side	B-X
light	B-X
scatter	B-X
,	B-X
and	B-X
functional	B-X
activity	B-X
as	B-X
measured	B-X
by	B-X
costimulation	B-X
of	B-X
proliferation	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
after	B-X
being	B-X
scraped	B-X
off	B-X
this	B-X
substrate	B-X
<EOS>	B-X
A	B-X
number	B-X
of	B-X
indirect	B-X
methods	B-X
have	B-X
been	B-X
utilized	B-X
in	B-X
demonstrating	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
transcription	B-X
factor	B-X
function	B-X
in	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Scrape	B-X
loading	B-X
thus	B-X
provides	B-X
an	B-X
efficient	B-X
mechanism	B-X
for	B-X
intracellular	B-X
incorporation	B-X
of	B-X
macromolecules	B-X
,	B-X
and	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
that	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
are	B-X
involved	B-X
in	B-X
transcription	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
within	B-X
its	B-X
correct	B-X
chromosomal	B-X
context	B-X
,	B-X
in	B-X
resting	B-X
human	B-X
T	B-X
lymphocyte	B-X
subpopulations	B-X
<EOS>	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
intracellular	B-X
accumulation	B-X
in	B-X
nonscraped	B-X
PB	B-X
-	B-X
T	B-X
cells	B-X
activated	B-X
with	B-X
CD28	B-X
/	B-X
CD3	B-X
coligation	B-X
were	B-X
skewed	B-X
favoring	B-X
CD45RO+	B-X
and	B-X
CD4+	B-X
subsets	B-X
,	B-X
as	B-X
was	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
in	B-X
scraped	B-X
PB	B-X
-	B-X
T	B-X
cells	B-X

CD28/CD3-costimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
produced	O
intracellular	O
IL-2	B-protein
from	O
all	O
subsets	O
measured	O
(	O
CD4+	B-cell_type
,	O
CD4-	B-cell_type
,	O
CD45RO+	B-cell_type
,	O
and	O
CD45RO-	B-cell_type
)	O
.	O
<EOS>	B-X
CD28	B-X
/	B-X
CD3	B-X
-	B-X
costimulated	B-X
T	B-X
cells	B-X
produced	B-X
intracellular	B-X
IL	B-X
-	B-X
2	B-X
from	B-X
all	B-X
subsets	B-X
measured	B-X
(	B-X
CD4+	B-X
,	B-X
CD4	B-X
-	B-X
	B-X
,	B-X
CD45RO+	B-X
,	B-X
and	B-X
CD45RO	B-X
-	B-X
	B-X
)	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
CD28	B-X
/	B-X
CD3	B-X
-	B-X
mediated	B-X
costimulation	B-X
of	B-X
naive	B-X
and	B-X
memory	B-X
human	B-X
T	B-X
lymphocytes	B-X
by	B-X
intracellular	B-X
incorporation	B-X
of	B-X
polyclonal	B-X
antibodies	B-X
specific	B-X
for	B-X
the	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
transcriptional	B-X
complex	B-X
.	B-X
<EOS>	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
intracellular	B-X
accumulation	B-X
in	B-X
nonscraped	B-X
PB	B-X
-	B-X
T	B-X
cells	B-X
activated	B-X
with	B-X
CD28	B-X
/	B-X
CD3	B-X
coligation	B-X
were	B-X
skewed	B-X
favoring	B-X
CD45RO+	B-X
and	B-X
CD4+	B-X
subsets	B-X
,	B-X
as	B-X
was	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
in	B-X
scraped	B-X
PB	B-X
-	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
intracellular	B-X
incorporation	B-X
of	B-X
Abs	B-X
specific	B-X
for	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
family	B-X
members	B-X
by	B-X
scrape	B-X
loading	B-X
inhibited	B-X
the	B-X
production	B-X
and	B-X
intracellular	B-X
accumulation	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
within	B-X
6	B-X
h	B-X
of	B-X
costimulation	B-X
with	B-X
PMA	B-X
/	B-X
ionomycin	B-X
,	B-X
or	B-X
costimulation	B-X
by	B-X
CD28	B-X
and	B-X
CD3	B-X
ligation	B-X

IL-2	B-protein
production	O
and	O
intracellular	O
accumulation	O
in	O
nonscraped	O
PB-T	B-cell_type
cells	I-cell_type
activated	O
with	O
CD28/CD3	O
coligation	O
were	O
skewed	O
favoring	O
CD45RO+	B-cell_type
and	I-cell_type
CD4+	I-cell_type
subsets	I-cell_type
,	O
as	O
was	O
IL-2	B-protein
production	O
in	O
scraped	O
PB-T	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
intracellular	B-X
accumulation	B-X
in	B-X
nonscraped	B-X
PB	B-X
-	B-X
T	B-X
cells	B-X
activated	B-X
with	B-X
CD28	B-X
/	B-X
CD3	B-X
coligation	B-X
were	B-X
skewed	B-X
favoring	B-X
CD45RO+	B-X
and	B-X
CD4+	B-X
subsets	B-X
,	B-X
as	B-X
was	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
in	B-X
scraped	B-X
PB	B-X
-	B-X
T	B-X
cells	B-X
<EOS>	B-X
Scrape	B-X
loading	B-X
thus	B-X
provides	B-X
an	B-X
efficient	B-X
mechanism	B-X
for	B-X
intracellular	B-X
incorporation	B-X
of	B-X
macromolecules	B-X
,	B-X
and	B-X
the	B-X
first	B-X
direct	B-X
evidence	B-X
that	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
are	B-X
involved	B-X
in	B-X
transcription	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
within	B-X
its	B-X
correct	B-X
chromosomal	B-X
context	B-X
,	B-X
in	B-X
resting	B-X
human	B-X
T	B-X
lymphocyte	B-X
subpopulations	B-X
<EOS>	B-X
T	B-X
cells	B-X
retained	B-X
their	B-X
physical	B-X
parameters	B-X
as	B-X
measured	B-X
by	B-X
forward	B-X
and	B-X
side	B-X
light	B-X
scatter	B-X
,	B-X
and	B-X
functional	B-X
activity	B-X
as	B-X
measured	B-X
by	B-X
costimulation	B-X
of	B-X
proliferation	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
after	B-X
being	B-X
scraped	B-X
off	B-X
this	B-X
substrate	B-X
<EOS>	B-X
A	B-X
number	B-X
of	B-X
indirect	B-X
methods	B-X
have	B-X
been	B-X
utilized	B-X
in	B-X
demonstrating	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
transcription	B-X
factor	B-X
function	B-X
in	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X

The	O
intracellular	O
incorporation	O
of	O
Abs	O
specific	O
for	O
c-Fos	B-protein
and	I-protein
c-Jun	I-protein
family	I-protein
members	I-protein
by	O
scrape	O
loading	O
inhibited	O
the	O
production	O
and	O
intracellular	O
accumulation	O
of	O
IL-2	B-protein
within	O
6	O
h	O
of	O
costimulation	O
with	O
PMA/ionomycin	O
,	O
or	O
costimulation	O
by	O
CD28	O
and	O
CD3	O
ligation	O
.	O
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
regions	B-X
of	B-X
the	B-X
viral	B-X
genome	B-X
outside	B-X
of	B-X
the	B-X
long	B-X
terminal	B-X
repeat	B-X
promoter	B-X
and	B-X
Tat	B-X
/	B-X
Rev	B-X
regulatory	B-X
genes	B-X
can	B-X
substantially	B-X
affect	B-X
both	B-X
the	B-X
basal	B-X
level	B-X
of	B-X
HIV	B-X
transcription	B-X
prior	B-X
to	B-X
stimulation	B-X
,	B-X
and	B-X
also	B-X
the	B-X
level	B-X
of	B-X
viral	B-X
expression	B-X
following	B-X
costimulation	B-X
via	B-X
CD3	B-X
and	B-X
CD28	B-X
ligation	B-X
<EOS>	B-X
Three	B-X
transcription	B-X
factors	B-X
,	B-X
namely	B-X
NF	B-X
-	B-X
κB	B-X
,	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
have	B-X
a	B-X
major	B-X
role	B-X
in	B-X
inducing	B-X
the	B-X
transcriptional	B-X
program	B-X
that	B-X
is	B-X
required	B-X
for	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
differentiation	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
BC12	B-X
on	B-X
IL	B-X
-	B-X
2	B-X
secretion	B-X
is	B-X
not	B-X
due	B-X
to	B-X
decreased	B-X
cell	B-X
viability	B-X
;	B-X
rather	B-X
,	B-X
BC12	B-X
blocks	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
transcription	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Proliferation	B-X
and	B-X
cytokine	B-X
production	B-X
assays	B-X
were	B-X
performed	B-X
using	B-X
CFSE	B-X
and	B-X
intracellular	B-X
IFN	B-X
-	B-X
γ	B-X
or	B-X
TNF	B-X
-	B-X
α	B-X
staining	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
flow	B-X
cytometry	B-X
analysis	B-X

Scrape	O
loading	O
thus	O
provides	O
an	O
efficient	O
mechanism	O
for	O
intracellular	O
incorporation	O
of	O
macromolecules	O
,	O
and	O
the	O
first	O
direct	O
evidence	O
that	O
c-Fos	B-protein
and	O
c-Jun	B-protein
are	O
involved	O
in	O
transcription	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
within	O
its	O
correct	O
chromosomal	O
context	O
,	O
in	O
resting	O
human	O
T	O
lymphocyte	O
subpopulations	O
.	O

Differential	O
expression	O
of	O
Nur77	B-protein
family	I-protein
members	I-protein
in	O
human	B-cell_type
T-lymphotropic	I-cell_type
virus	I-cell_type
type	I-cell_type
1-infected	I-cell_type
cells	I-cell_type
:	O
transactivation	O
of	O
the	O
TR3/nur77	B-DNA
gene	I-DNA
by	O
Tax	B-protein
protein	I-protein
.	O
<EOS>	B-X
Differential	B-X
expression	B-X
of	B-X
Nur77	B-X
family	B-X
members	B-X
in	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
:	B-X
transactivation	B-X
of	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
gene	B-X
by	B-X
Tax	B-X
protein	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
driven	B-X
by	B-X
the	B-X
NGFI	B-X
-	B-X
B	B-X
(	B-X
rat	B-X
homolog	B-X
of	B-X
TR3	B-X
/	B-X
Nur77	B-X
)	B-X
response	B-X
element	B-X
(	B-X
NBRE	B-X
)	B-X
provided	B-X
evidence	B-X
that	B-X
Tax	B-X
-	B-X
mediated	B-X
transactivation	B-X
resulted	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
functional	B-X
protein	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
differential	B-X
expression	B-X
and	B-X
regulation	B-X
of	B-X
three	B-X
members	B-X
of	B-X
the	B-X
Nur77	B-X
transcription	B-X
factor	B-X
family	B-X
by	B-X
the	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
Tax	B-X
protein	B-X
<EOS>	B-X
Cotransfection	B-X
assays	B-X
with	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
promoter	B-X
sequence	B-X
or	B-X
the	B-X
NBRE	B-X
binding	B-X
motif	B-X
together	B-X
with	B-X
a	B-X
series	B-X
of	B-X
Tax	B-X
mutants	B-X
have	B-X
shown	B-X
that	B-X
Tax	B-X
-	B-X
induced	B-X
TR3	B-X
/	B-X
nur77	B-X
expression	B-X
is	B-X
mediated	B-X
by	B-X
CREB	B-X
/	B-X
ATF	B-X
-	B-X
related	B-X
transcription	B-X
factors	B-X

We	O
analyzed	O
the	O
differential	O
expression	O
and	O
regulation	O
of	O
three	O
members	O
of	O
the	O
Nur77	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
by	O
the	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B-protein
protein	I-protein
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
differential	B-X
expression	B-X
and	B-X
regulation	B-X
of	B-X
three	B-X
members	B-X
of	B-X
the	B-X
Nur77	B-X
transcription	B-X
factor	B-X
family	B-X
by	B-X
the	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
Tax	B-X
protein	B-X
<EOS>	B-X
Differential	B-X
expression	B-X
of	B-X
Nur77	B-X
family	B-X
members	B-X
in	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
:	B-X
transactivation	B-X
of	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
gene	B-X
by	B-X
Tax	B-X
protein	B-X
.	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
analysis	B-X
further	B-X
confirmed	B-X
the	B-X
Tax	B-X
transactivation	B-X
of	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
promoter	B-X
but	B-X
not	B-X
the	B-X
NOR	B-X
-	B-X
1	B-X
promoter	B-X
in	B-X
different	B-X
cell	B-X
types	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
driven	B-X
by	B-X
the	B-X
NGFI	B-X
-	B-X
B	B-X
(	B-X
rat	B-X
homolog	B-X
of	B-X
TR3	B-X
/	B-X
Nur77	B-X
)	B-X
response	B-X
element	B-X
(	B-X
NBRE	B-X
)	B-X
provided	B-X
evidence	B-X
that	B-X
Tax	B-X
-	B-X
mediated	B-X
transactivation	B-X
resulted	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
functional	B-X
protein	B-X

We	O
have	O
demonstrated	O
that	O
in	O
both	O
HTLV-1-infected	B-cell_type
cells	I-cell_type
and	O
Tax-expressing	B-cell_line
JPX-9	I-cell_line
cells	I-cell_line
,	O
TR3/nur77	B-protein
is	O
highly	O
expressed	O
,	O
whereas	O
neither	O
NOR-1	O
nor	O
NOT	O
expression	O
is	O
detectable	O
.	O

Transient	O
transfection	O
analysis	O
further	O
confirmed	O
the	O
Tax	B-protein
transactivation	O
of	O
the	O
TR3/nur77	B-protein
promoter	O
but	O
not	O
the	O
NOR-1	B-DNA
promoter	I-DNA
in	O
different	O
cell	O
types	O
.	O

Furthermore	O
,	O
expression	O
of	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
driven	O
by	O
the	O
NGFI-B	B-DNA
(	I-DNA
rat	I-DNA
homolog	I-DNA
of	I-DNA
TR3/Nur77	I-DNA
)	I-DNA
response	I-DNA
element	I-DNA
(	O
NBRE	B-DNA
)	O
provided	O
evidence	O
that	O
Tax	B-protein
-mediated	O
transactivation	O
resulted	O
in	O
the	O
induction	O
of	O
a	O
functional	O
protein	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
driven	B-X
by	B-X
the	B-X
NGFI	B-X
-	B-X
B	B-X
(	B-X
rat	B-X
homolog	B-X
of	B-X
TR3	B-X
/	B-X
Nur77	B-X
)	B-X
response	B-X
element	B-X
(	B-X
NBRE	B-X
)	B-X
provided	B-X
evidence	B-X
that	B-X
Tax	B-X
-	B-X
mediated	B-X
transactivation	B-X
resulted	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
functional	B-X
protein	B-X
<EOS>	B-X
Differential	B-X
expression	B-X
of	B-X
Nur77	B-X
family	B-X
members	B-X
in	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
:	B-X
transactivation	B-X
of	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
gene	B-X
by	B-X
Tax	B-X
protein	B-X
.	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
analysis	B-X
further	B-X
confirmed	B-X
the	B-X
Tax	B-X
transactivation	B-X
of	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
promoter	B-X
but	B-X
not	B-X
the	B-X
NOR	B-X
-	B-X
1	B-X
promoter	B-X
in	B-X
different	B-X
cell	B-X
types	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
differential	B-X
expression	B-X
and	B-X
regulation	B-X
of	B-X
three	B-X
members	B-X
of	B-X
the	B-X
Nur77	B-X
transcription	B-X
factor	B-X
family	B-X
by	B-X
the	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
Tax	B-X
protein	B-X

Cotransfection	O
assays	O
with	O
the	O
TR3/nur77	B-DNA
promoter	I-DNA
sequence	I-DNA
or	O
the	O
NBRE	B-DNA
binding	O
motif	O
together	O
with	O
a	O
series	O
of	O
Tax	B-protein
mutants	O
have	O
shown	O
that	O
Tax	B-protein
-induced	O
TR3/nur77	B-protein
expression	O
is	O
mediated	O
by	O
CREB/ATF-related	B-protein
transcription	I-protein
factors	I-protein
.	O
<EOS>	B-X
Cotransfection	B-X
assays	B-X
with	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
promoter	B-X
sequence	B-X
or	B-X
the	B-X
NBRE	B-X
binding	B-X
motif	B-X
together	B-X
with	B-X
a	B-X
series	B-X
of	B-X
Tax	B-X
mutants	B-X
have	B-X
shown	B-X
that	B-X
Tax	B-X
-	B-X
induced	B-X
TR3	B-X
/	B-X
nur77	B-X
expression	B-X
is	B-X
mediated	B-X
by	B-X
CREB	B-X
/	B-X
ATF	B-X
-	B-X
related	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
analysis	B-X
further	B-X
confirmed	B-X
the	B-X
Tax	B-X
transactivation	B-X
of	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
promoter	B-X
but	B-X
not	B-X
the	B-X
NOR	B-X
-	B-X
1	B-X
promoter	B-X
in	B-X
different	B-X
cell	B-X
types	B-X
<EOS>	B-X
Differential	B-X
expression	B-X
of	B-X
Nur77	B-X
family	B-X
members	B-X
in	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
:	B-X
transactivation	B-X
of	B-X
the	B-X
TR3	B-X
/	B-X
nur77	B-X
gene	B-X
by	B-X
Tax	B-X
protein	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
in	B-X
both	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
and	B-X
Tax	B-X
-	B-X
expressing	B-X
JPX	B-X
-	B-X
9	B-X
cells	B-X
,	B-X
TR3	B-X
/	B-X
nur77	B-X
is	B-X
highly	B-X
expressed	B-X
,	B-X
whereas	B-X
neither	B-X
NOR	B-X
-	B-X
1	B-X
nor	B-X
NOT	B-X
expression	B-X
is	B-X
detectable	B-X

Negative	O
regulation	O
of	O
the	O
heat	O
shock	O
transcriptional	O
response	O
by	O
HSBP1	B-protein
.	O
<EOS>	B-X
Negative	B-X
regulation	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
transcriptional	B-X
response	B-X
by	B-X
HSBP1	B-X
.	B-X
<EOS>	B-X
Stress	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
heat	B-X
-	B-X
shock	B-X
response	B-X
:	B-X
cell	B-X
and	B-X
molecular	B-X
biology	B-X
of	B-X
heat	B-X
-	B-X
shock	B-X
factors	B-X
.	B-X
<EOS>	B-X
Alteration	B-X
in	B-X
the	B-X
level	B-X
of	B-X
HSBP1	B-X
expression	B-X
in	B-X
C	B-X
<EOS>	B-X
Identification	B-X
and	B-X
Characterization	B-X
of	B-X
a	B-X
Thermotolerant	B-X
TILLING	B-X
Allele	B-X
of	B-X
Heat	B-X
Shock	B-X
Binding	B-X
Protein	B-X
1	B-X
in	B-X
Tomato	B-X
.	B-X

In	O
response	O
to	O
stress	O
,	O
heat	B-protein
shock	I-protein
factor	I-protein
1	I-protein
(	O
HSF1	B-protein
)	O
acquires	O
rapid	O
DNA	O
binding	O
and	O
transient	O
transcriptional	O
activity	O
while	O
undergoing	O
conformational	O
transition	O
from	O
an	O
inert	O
non-DNA-binding	B-protein
monomer	I-protein
to	O
active	O
functional	O
trimers	O
.	O
<EOS>	B-X
In	B-X
response	B-X
to	B-X
stress	B-X
,	B-X
heat	B-X
shock	B-X
factor	B-X
1	B-X
(	B-X
HSF1	B-X
)	B-X
acquires	B-X
rapid	B-X
DNA	B-X
binding	B-X
and	B-X
transient	B-X
transcriptional	B-X
activity	B-X
while	B-X
undergoing	B-X
conformational	B-X
transition	B-X
from	B-X
an	B-X
inert	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
monomer	B-X
to	B-X
active	B-X
functional	B-X
trimers	B-X
<EOS>	B-X
elegans	B-X
has	B-X
severe	B-X
effects	B-X
on	B-X
survival	B-X
of	B-X
the	B-X
animals	B-X
after	B-X
thermal	B-X
and	B-X
chemical	B-X
stress	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
role	B-X
for	B-X
HSBP1	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
response	B-X
<EOS>	B-X
HSBP1	B-X
negatively	B-X
affects	B-X
HSF1	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
,	B-X
and	B-X
overexpression	B-X
of	B-X
HSBP1	B-X
in	B-X
mammalian	B-X
cells	B-X
represses	B-X
the	B-X
transactivation	B-X
activity	B-X
of	B-X
HSF1	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
the	B-X
hydrophobic	B-X
repeats	B-X
of	B-X
the	B-X
HSF1	B-X
trimerization	B-X
domain	B-X
in	B-X
the	B-X
yeast	B-X
two	B-X
-	B-X
hybrid	B-X
protein	B-X
interaction	B-X
assay	B-X
to	B-X
identify	B-X
heat	B-X
shock	B-X
factor	B-X
binding	B-X
protein	B-X
1	B-X
(	B-X
HSBP1	B-X
)	B-X
,	B-X
a	B-X
novel	B-X
,	B-X
conserved	B-X
,	B-X
76	B-X
-	B-X
amino	B-X
-	B-X
acid	B-X
protein	B-X
that	B-X
contains	B-X
two	B-X
extended	B-X
arrays	B-X
of	B-X
hydrophobic	B-X
repeats	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
HSF1	B-X
heptad	B-X
repeats	B-X

Attenuation	O
of	O
the	O
inducible	O
transcriptional	O
response	O
occurs	O
during	O
heat	O
shock	O
or	O
upon	O
recovery	O
at	O
non-stress	O
conditions	O
and	O
involves	O
dissociation	O
of	O
the	O
HSF1	B-protein
trimer	I-protein
and	O
loss	O
of	O
activity	O
.	O
<EOS>	B-X
Attenuation	B-X
of	B-X
mitochondrial	B-X
unfolded	B-X
protein	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
hepatic	B-X
dysfunction	B-X
in	B-X
septic	B-X
rats	B-X
.	B-X
<EOS>	B-X
Stressors	B-X
activate	B-X
heat	B-X
shock	B-X
transcription	B-X
factor	B-X
1	B-X
(	B-X
HSF1	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
heat	B-X
shock	B-X
elements	B-X
in	B-X
the	B-X
genes	B-X
for	B-X
heat	B-X
shock	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
rapid	B-X
induction	B-X
of	B-X
these	B-X
important	B-X
molecular	B-X
chaperones	B-X
<EOS>	B-X
Both	B-X
heat	B-X
and	B-X
noise	B-X
stress	B-X
are	B-X
known	B-X
to	B-X
activate	B-X
the	B-X
heat	B-X
shock	B-X
response	B-X
in	B-X
the	B-X
cochlea	B-X
and	B-X
protect	B-X
it	B-X
from	B-X
subsequent	B-X
noise	B-X
trauma	B-X
<EOS>	B-X
Apoptotic	B-X
cell	B-X
death	B-X
occurs	B-X
during	B-X
prolonged	B-X
period	B-X
of	B-X
stress	B-X
or	B-X
when	B-X
the	B-X
adaptive	B-X
response	B-X
fails	B-X

We	O
have	O
used	O
the	O
hydrophobic	B-protein
repeats	I-protein
of	O
the	O
HSF1	B-protein
trimerization	O
domain	O
in	O
the	O
yeast	O
two-hybrid	O
protein	O
interaction	O
assay	O
to	O
identify	O
heat	B-protein
shock	I-protein
factor	I-protein
binding	I-protein
protein	I-protein
1	I-protein
(	O
HSBP1	B-protein
)	O
,	O
a	O
novel	O
,	O
conserved	O
,	O
76-amino-acid	B-protein
protein	I-protein
that	O
contains	O
two	O
extended	O
arrays	O
of	O
hydrophobic	B-protein
repeats	I-protein
that	O
interact	O
with	O
the	O
HSF1	B-protein
heptad	I-protein
repeats	I-protein
.	O
<EOS>	B-X
We	B-X
have	B-X
used	B-X
the	B-X
hydrophobic	B-X
repeats	B-X
of	B-X
the	B-X
HSF1	B-X
trimerization	B-X
domain	B-X
in	B-X
the	B-X
yeast	B-X
two	B-X
-	B-X
hybrid	B-X
protein	B-X
interaction	B-X
assay	B-X
to	B-X
identify	B-X
heat	B-X
shock	B-X
factor	B-X
binding	B-X
protein	B-X
1	B-X
(	B-X
HSBP1	B-X
)	B-X
,	B-X
a	B-X
novel	B-X
,	B-X
conserved	B-X
,	B-X
76	B-X
-	B-X
amino	B-X
-	B-X
acid	B-X
protein	B-X
that	B-X
contains	B-X
two	B-X
extended	B-X
arrays	B-X
of	B-X
hydrophobic	B-X
repeats	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
HSF1	B-X
heptad	B-X
repeats	B-X
<EOS>	B-X
elegans	B-X
has	B-X
severe	B-X
effects	B-X
on	B-X
survival	B-X
of	B-X
the	B-X
animals	B-X
after	B-X
thermal	B-X
and	B-X
chemical	B-X
stress	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
role	B-X
for	B-X
HSBP1	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
response	B-X
<EOS>	B-X
Attenuation	B-X
of	B-X
the	B-X
inducible	B-X
transcriptional	B-X
response	B-X
occurs	B-X
during	B-X
heat	B-X
shock	B-X
or	B-X
upon	B-X
recovery	B-X
at	B-X
non	B-X
-	B-X
stress	B-X
conditions	B-X
and	B-X
involves	B-X
dissociation	B-X
of	B-X
the	B-X
HSF1	B-X
trimer	B-X
and	B-X
loss	B-X
of	B-X
activity	B-X
<EOS>	B-X
In	B-X
response	B-X
to	B-X
stress	B-X
,	B-X
heat	B-X
shock	B-X
factor	B-X
1	B-X
(	B-X
HSF1	B-X
)	B-X
acquires	B-X
rapid	B-X
DNA	B-X
binding	B-X
and	B-X
transient	B-X
transcriptional	B-X
activity	B-X
while	B-X
undergoing	B-X
conformational	B-X
transition	B-X
from	B-X
an	B-X
inert	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
monomer	B-X
to	B-X
active	B-X
functional	B-X
trimers	B-X

HSBP1	B-protein
is	O
nuclear-localized	O
and	O
interacts	O
in	O
vivo	O
with	O
the	O
active	O
trimeric	O
state	O
of	O
HSF1	B-protein
that	O
appears	O
during	O
heat	O
shock	O
.	O
<EOS>	B-X
HSBP1	B-X
is	B-X
nuclear	B-X
-	B-X
localized	B-X
and	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
the	B-X
active	B-X
trimeric	B-X
state	B-X
of	B-X
HSF1	B-X
that	B-X
appears	B-X
during	B-X
heat	B-X
shock	B-X
<EOS>	B-X
elegans	B-X
has	B-X
severe	B-X
effects	B-X
on	B-X
survival	B-X
of	B-X
the	B-X
animals	B-X
after	B-X
thermal	B-X
and	B-X
chemical	B-X
stress	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
role	B-X
for	B-X
HSBP1	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
response	B-X
<EOS>	B-X
During	B-X
attenuation	B-X
of	B-X
HSF1	B-X
to	B-X
the	B-X
inert	B-X
monomer	B-X
,	B-X
HSBP1	B-X
associates	B-X
with	B-X
Hsp70	B-X
<EOS>	B-X
To	B-X
establish	B-X
a	B-X
biological	B-X
role	B-X
for	B-X
HSBP1	B-X
,	B-X
the	B-X
homologous	B-X
Caenorhabditis	B-X
elegans	B-X
protein	B-X
was	B-X
overexpressed	B-X
in	B-X
body	B-X
wall	B-X
muscle	B-X
cells	B-X
and	B-X
was	B-X
shown	B-X
to	B-X
block	B-X
activation	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
response	B-X
from	B-X
a	B-X
heat	B-X
shock	B-X
promoter	B-X
-	B-X
reporter	B-X
construct	B-X

During	O
attenuation	O
of	O
HSF1	B-protein
to	O
the	O
inert	O
monomer	O
,	O
HSBP1	B-protein
associates	O
with	O
Hsp70	O
.	O

HSBP1	B-protein
negatively	O
affects	O
HSF1	B-protein
DNA-binding	O
activity	O
,	O
and	O
overexpression	O
of	O
HSBP1	B-protein
in	O
mammalian	B-cell_type
cells	I-cell_type
represses	O
the	O
transactivation	O
activity	O
of	O
HSF1	B-protein
.	O
<EOS>	B-X
HSBP1	B-X
negatively	B-X
affects	B-X
HSF1	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
,	B-X
and	B-X
overexpression	B-X
of	B-X
HSBP1	B-X
in	B-X
mammalian	B-X
cells	B-X
represses	B-X
the	B-X
transactivation	B-X
activity	B-X
of	B-X
HSF1	B-X
<EOS>	B-X
In	B-X
response	B-X
to	B-X
stress	B-X
,	B-X
heat	B-X
shock	B-X
factor	B-X
1	B-X
(	B-X
HSF1	B-X
)	B-X
acquires	B-X
rapid	B-X
DNA	B-X
binding	B-X
and	B-X
transient	B-X
transcriptional	B-X
activity	B-X
while	B-X
undergoing	B-X
conformational	B-X
transition	B-X
from	B-X
an	B-X
inert	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
monomer	B-X
to	B-X
active	B-X
functional	B-X
trimers	B-X
<EOS>	B-X
Negative	B-X
regulation	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
transcriptional	B-X
response	B-X
by	B-X
HSBP1	B-X
.	B-X
<EOS>	B-X
During	B-X
attenuation	B-X
of	B-X
HSF1	B-X
to	B-X
the	B-X
inert	B-X
monomer	B-X
,	B-X
HSBP1	B-X
associates	B-X
with	B-X
Hsp70	B-X

To	O
establish	O
a	O
biological	O
role	O
for	O
HSBP1	B-protein
,	O
the	O
homologous	O
Caenorhabditis	B-protein
elegans	I-protein
protein	I-protein
was	O
overexpressed	O
in	O
body	B-cell_type
wall	I-cell_type
muscle	I-cell_type
cells	I-cell_type
and	O
was	O
shown	O
to	O
block	O
activation	O
of	O
the	O
heat	O
shock	O
response	O
from	O
a	O
heat	B-DNA
shock	I-DNA
promoter-reporter	I-DNA
construct	I-DNA
.	O
<EOS>	B-X
To	B-X
establish	B-X
a	B-X
biological	B-X
role	B-X
for	B-X
HSBP1	B-X
,	B-X
the	B-X
homologous	B-X
Caenorhabditis	B-X
elegans	B-X
protein	B-X
was	B-X
overexpressed	B-X
in	B-X
body	B-X
wall	B-X
muscle	B-X
cells	B-X
and	B-X
was	B-X
shown	B-X
to	B-X
block	B-X
activation	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
response	B-X
from	B-X
a	B-X
heat	B-X
shock	B-X
promoter	B-X
-	B-X
reporter	B-X
construct	B-X
<EOS>	B-X
elegans	B-X
has	B-X
severe	B-X
effects	B-X
on	B-X
survival	B-X
of	B-X
the	B-X
animals	B-X
after	B-X
thermal	B-X
and	B-X
chemical	B-X
stress	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
role	B-X
for	B-X
HSBP1	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
response	B-X
<EOS>	B-X
Attenuation	B-X
of	B-X
the	B-X
inducible	B-X
transcriptional	B-X
response	B-X
occurs	B-X
during	B-X
heat	B-X
shock	B-X
or	B-X
upon	B-X
recovery	B-X
at	B-X
non	B-X
-	B-X
stress	B-X
conditions	B-X
and	B-X
involves	B-X
dissociation	B-X
of	B-X
the	B-X
HSF1	B-X
trimer	B-X
and	B-X
loss	B-X
of	B-X
activity	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
the	B-X
hydrophobic	B-X
repeats	B-X
of	B-X
the	B-X
HSF1	B-X
trimerization	B-X
domain	B-X
in	B-X
the	B-X
yeast	B-X
two	B-X
-	B-X
hybrid	B-X
protein	B-X
interaction	B-X
assay	B-X
to	B-X
identify	B-X
heat	B-X
shock	B-X
factor	B-X
binding	B-X
protein	B-X
1	B-X
(	B-X
HSBP1	B-X
)	B-X
,	B-X
a	B-X
novel	B-X
,	B-X
conserved	B-X
,	B-X
76	B-X
-	B-X
amino	B-X
-	B-X
acid	B-X
protein	B-X
that	B-X
contains	B-X
two	B-X
extended	B-X
arrays	B-X
of	B-X
hydrophobic	B-X
repeats	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
HSF1	B-X
heptad	B-X
repeats	B-X

Alteration	O
in	O
the	O
level	O
of	O
HSBP1	B-protein
expression	O
in	O
C.	O
elegans	O
has	O
severe	O
effects	O
on	O
survival	O
of	O
the	O
animals	O
after	O
thermal	O
and	O
chemical	O
stress	O
,	O
consistent	O
with	O
a	O
role	O
for	O
HSBP1	B-protein
as	O
a	O
negative	O
regulator	O
of	O
the	O
heat	O
shock	O
response	O
.	O

Long-range	O
transcriptional	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
.	O
<EOS>	B-X
Long	B-X
-	B-X
Range	B-X
Transcriptional	B-X
Control	B-X
of	B-X
the	B-X
Il2	B-X
Gene	B-X
by	B-X
an	B-X
Intergenic	B-X
Enhancer	B-X
.	B-X
<EOS>	B-X
Long	B-X
-	B-X
range	B-X
enhancers	B-X
of	B-X
transcription	B-X
are	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
genomic	B-X
regulatory	B-X
architecture	B-X
<EOS>	B-X
RHS6	B-X
-	B-X
mediated	B-X
chromosomal	B-X
looping	B-X
and	B-X
nuclear	B-X
substructure	B-X
binding	B-X
is	B-X
required	B-X
for	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
We	B-X
further	B-X
investigated	B-X
in	B-X
detail	B-X
AP	B-X
-	B-X
1	B-X
regulation	B-X
of	B-X
ZEB2	B-X
expression	B-X

Most	O
studies	O
on	O
the	O
control	O
of	O
cytokine	O
gene	O
expression	O
have	O
involved	O
the	O
functional	O
analysis	O
of	O
proximal	B-DNA
promoters	I-DNA
.	O
<EOS>	B-X
Most	B-X
studies	B-X
on	B-X
the	B-X
control	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
have	B-X
involved	B-X
the	B-X
functional	B-X
analysis	B-X
of	B-X
proximal	B-X
promoters	B-X
<EOS>	B-X
Recent	B-X
work	B-X
has	B-X
identified	B-X
distal	B-X
elements	B-X
that	B-X
mediate	B-X
long	B-X
-	B-X
range	B-X
cytokine	B-X
gene	B-X
regulation	B-X
and	B-X
has	B-X
implicated	B-X
chromatin	B-X
reorganization	B-X
in	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
loci	B-X
<EOS>	B-X
Functional	B-X
analysis	B-X
indicates	B-X
that	B-X
the	B-X
BRs	B-X
are	B-X
involved	B-X
in	B-X
control	B-X
of	B-X
hIL	B-X
-	B-X
5	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
We	B-X
identified	B-X
5	B-X
protein	B-X
binding	B-X
regions	B-X
(	B-X
BRs	B-X
)	B-X
located	B-X
within	B-X
the	B-X
proximal	B-X
hIL	B-X
-	B-X
5	B-X
promoter	B-X

Recent	O
work	O
has	O
identified	O
distal	B-DNA
elements	I-DNA
that	O
mediate	O
long-range	O
cytokine	O
gene	O
regulation	O
and	O
has	O
implicated	O
chromatin	O
reorganization	O
in	O
regulation	O
of	O
cytokine	B-DNA
gene	I-DNA
loci	I-DNA
.	O
<EOS>	B-X
Recent	B-X
work	B-X
has	B-X
identified	B-X
distal	B-X
elements	B-X
that	B-X
mediate	B-X
long	B-X
-	B-X
range	B-X
cytokine	B-X
gene	B-X
regulation	B-X
and	B-X
has	B-X
implicated	B-X
chromatin	B-X
reorganization	B-X
in	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
loci	B-X
<EOS>	B-X
Most	B-X
studies	B-X
on	B-X
the	B-X
control	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
have	B-X
involved	B-X
the	B-X
functional	B-X
analysis	B-X
of	B-X
proximal	B-X
promoters	B-X
<EOS>	B-X
These	B-X
studies	B-X
have	B-X
begun	B-X
to	B-X
elucidate	B-X
the	B-X
basis	B-X
for	B-X
cell	B-X
-	B-X
specificity	B-X
and	B-X
high	B-X
-	B-X
level	B-X
expression	B-X
of	B-X
cytokine	B-X
genes	B-X
<EOS>	B-X
Long	B-X
-	B-X
range	B-X
transcriptional	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X

These	O
studies	O
have	O
begun	O
to	O
elucidate	O
the	O
basis	O
for	O
cell-specificity	O
and	O
high-level	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
.	O
<EOS>	B-X
These	B-X
studies	B-X
have	B-X
begun	B-X
to	B-X
elucidate	B-X
the	B-X
basis	B-X
for	B-X
cell	B-X
-	B-X
specificity	B-X
and	B-X
high	B-X
-	B-X
level	B-X
expression	B-X
of	B-X
cytokine	B-X
genes	B-X
<EOS>	B-X
Recent	B-X
work	B-X
has	B-X
identified	B-X
distal	B-X
elements	B-X
that	B-X
mediate	B-X
long	B-X
-	B-X
range	B-X
cytokine	B-X
gene	B-X
regulation	B-X
and	B-X
has	B-X
implicated	B-X
chromatin	B-X
reorganization	B-X
in	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
loci	B-X
<EOS>	B-X
Long	B-X
-	B-X
range	B-X
transcriptional	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Most	B-X
studies	B-X
on	B-X
the	B-X
control	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
have	B-X
involved	B-X
the	B-X
functional	B-X
analysis	B-X
of	B-X
proximal	B-X
promoters	B-X

A	O
signaling	O
complex	O
of	O
Ca2+-calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
and	O
protein	B-protein
phosphatase	I-protein
2A	I-protein
[	O
see	O
comments	O
]	O
<EOS>	B-X
A	B-X
signaling	B-X
complex	B-X
of	B-X
Ca2+	B-X
-	B-X
calmodulin	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
IV	B-X
and	B-X
protein	B-X
phosphatase	B-X
2A	B-X
.	B-X
<EOS>	B-X
Activation	B-X
of	B-X
Ca2+	B-X
/	B-X
calmodulin	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
(	B-X
CaM	B-X
-	B-X
kinase	B-X
)	B-X
IV	B-X
by	B-X
CaM	B-X
-	B-X
kinase	B-X
kinase	B-X
in	B-X
Jurkat	B-X
T	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Identification	B-X
of	B-X
kinase	B-X
-	B-X
phosphatase	B-X
signaling	B-X
modules	B-X
composed	B-X
of	B-X
p70	B-X
S6	B-X
kinase	B-X
-	B-X
protein	B-X
phosphatase	B-X
2A	B-X
(	B-X
PP2A	B-X
)	B-X
and	B-X
p21	B-X
-	B-X
activated	B-X
kinase	B-X
-	B-X
PP2A	B-X
.	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
lymphocytes	B-X
results	B-X
in	B-X
a	B-X
rapid	B-X
increase	B-X
in	B-X
intracellular	B-X
calcium	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
that	B-X
parallels	B-X
the	B-X
activation	B-X
of	B-X
Ca2+	B-X
-	B-X
calmodulin	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
IV	B-X
(	B-X
CaMKIV	B-X
)	B-X
,	B-X
a	B-X
nuclear	B-X
enzyme	B-X
that	B-X
can	B-X
phosphorylate	B-X
and	B-X
activate	B-X
the	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
(	B-X
cAMP	B-X
)	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X

Stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
results	O
in	O
a	O
rapid	O
increase	O
in	O
intracellular	O
calcium	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
that	O
parallels	O
the	O
activation	O
of	O
Ca2+-calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
(	O
CaMKIV	B-protein
)	O
,	O
a	O
nuclear	B-protein
enzyme	I-protein
that	O
can	O
phosphorylate	O
and	O
activate	O
the	O
cyclic	B-protein
adenosine	I-protein
monophosphate	I-protein
(	I-protein
cAMP	I-protein
)	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O

However	O
,	O
inactivation	O
of	O
CaMKIV	B-protein
occurs	O
despite	O
the	O
sustained	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
that	O
is	O
required	O
for	O
T	O
cell	O
activation	O
.	O

A	O
stable	O
and	O
stoichiometric	O
complex	O
of	O
CaMKIV	B-protein
with	O
protein	B-protein
serine-threonine	I-protein
phosphatase	I-protein
2A	I-protein
(	O
PP2A	B-protein
)	O
was	O
identified	O
in	O
which	O
PP2A	B-protein
dephosphorylates	O
CaMKIV	B-protein
and	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
CaMKIV	B-protein
signaling	O
.	O
<EOS>	B-X
A	B-X
stable	B-X
and	B-X
stoichiometric	B-X
complex	B-X
of	B-X
CaMKIV	B-X
with	B-X
protein	B-X
serine	B-X
-	B-X
threonine	B-X
phosphatase	B-X
2A	B-X
(	B-X
PP2A	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
which	B-X
PP2A	B-X
dephosphorylates	B-X
CaMKIV	B-X
and	B-X
functions	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
CaMKIV	B-X
signaling	B-X
<EOS>	B-X
However	B-X
,	B-X
inactivation	B-X
of	B-X
CaMKIV	B-X
occurs	B-X
despite	B-X
the	B-X
sustained	B-X
increase	B-X
in	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
that	B-X
is	B-X
required	B-X
for	B-X
T	B-X
cell	B-X
activation	B-X
<EOS>	B-X
These	B-X
findings	B-X
reveal	B-X
an	B-X
intracellular	B-X
signaling	B-X
mechanism	B-X
whereby	B-X
a	B-X
protein	B-X
serine	B-X
-	B-X
threonine	B-X
kinase	B-X
(	B-X
CaMKIV	B-X
)	B-X
is	B-X
regulated	B-X
by	B-X
a	B-X
tightly	B-X
associated	B-X
protein	B-X
serine	B-X
-	B-X
threonine	B-X
phosphatase	B-X
(	B-X
PP2A	B-X
)	B-X
<EOS>	B-X
A	B-X
signaling	B-X
complex	B-X
of	B-X
Ca2+	B-X
-	B-X
calmodulin	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
IV	B-X
and	B-X
protein	B-X
phosphatase	B-X
2A	B-X
.	B-X

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
inhibition	O
of	O
PP2A	B-protein
activity	O
by	O
small	O
t	O
antigen	O
enhanced	O
activation	O
of	O
CREB	B-protein
-mediated	O
transcription	O
by	O
CaMKIV	B-protein
.	O

These	O
findings	O
reveal	O
an	O
intracellular	O
signaling	O
mechanism	O
whereby	O
a	O
protein	B-protein
serine-threonine	I-protein
kinase	I-protein
(	O
CaMKIV	B-protein
)	O
is	O
regulated	O
by	O
a	O
tightly	O
associated	O
protein	B-protein
serine-threonine	I-protein
phosphatase	I-protein
(	O
PP2A	B-protein
)	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
reveal	B-X
an	B-X
intracellular	B-X
signaling	B-X
mechanism	B-X
whereby	B-X
a	B-X
protein	B-X
serine	B-X
-	B-X
threonine	B-X
kinase	B-X
(	B-X
CaMKIV	B-X
)	B-X
is	B-X
regulated	B-X
by	B-X
a	B-X
tightly	B-X
associated	B-X
protein	B-X
serine	B-X
-	B-X
threonine	B-X
phosphatase	B-X
(	B-X
PP2A	B-X
)	B-X
<EOS>	B-X
A	B-X
signaling	B-X
complex	B-X
of	B-X
Ca2+	B-X
-	B-X
calmodulin	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
IV	B-X
and	B-X
protein	B-X
phosphatase	B-X
2A	B-X
.	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
lymphocytes	B-X
results	B-X
in	B-X
a	B-X
rapid	B-X
increase	B-X
in	B-X
intracellular	B-X
calcium	B-X
concentration	B-X
(	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
)	B-X
that	B-X
parallels	B-X
the	B-X
activation	B-X
of	B-X
Ca2+	B-X
-	B-X
calmodulin	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
IV	B-X
(	B-X
CaMKIV	B-X
)	B-X
,	B-X
a	B-X
nuclear	B-X
enzyme	B-X
that	B-X
can	B-X
phosphorylate	B-X
and	B-X
activate	B-X
the	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
(	B-X
cAMP	B-X
)	B-X
response	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
<EOS>	B-X
A	B-X
stable	B-X
and	B-X
stoichiometric	B-X
complex	B-X
of	B-X
CaMKIV	B-X
with	B-X
protein	B-X
serine	B-X
-	B-X
threonine	B-X
phosphatase	B-X
2A	B-X
(	B-X
PP2A	B-X
)	B-X
was	B-X
identified	B-X
in	B-X
which	B-X
PP2A	B-X
dephosphorylates	B-X
CaMKIV	B-X
and	B-X
functions	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
CaMKIV	B-X
signaling	B-X

Hypoxia	O
down-regulates	O
MCP-1	B-protein
expression	O
:	O
implications	O
for	O
macrophage	O
distribution	O
in	O
tumors	O
.	O
<EOS>	B-X
Hypoxia	B-X
down	B-X
-	B-X
regulates	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
:	B-X
implications	B-X
for	B-X
macrophage	B-X
distribution	B-X
in	B-X
tumors	B-X
.	B-X
<EOS>	B-X
Hypoxia	B-X
down	B-X
-	B-X
regulated	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
and	B-X
protein	B-X
production	B-X
by	B-X
ovarian	B-X
cancer	B-X
cells	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
monocyte	B-X
migration	B-X
are	B-X
independent	B-X
effects	B-X
of	B-X
hypoxia	B-X
that	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
distribution	B-X
of	B-X
macrophages	B-X
within	B-X
ovarian	B-X
tumors	B-X
<EOS>	B-X
Monocyte	B-X
chemoattractant	B-X
protein	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
likely	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
macrophage	B-X
infiltrate	B-X
in	B-X
human	B-X
ovarian	B-X
carcinomas	B-X

Monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
1	I-protein
(	O
MCP-1	B-protein
)	O
is	O
likely	O
to	O
contribute	O
to	O
the	O
macrophage	B-cell_type
infiltrate	I-cell_type
in	O
human	O
ovarian	O
carcinomas	O
.	O

Although	O
MCP-1	B-protein
is	O
predominantly	O
expressed	O
by	O
the	O
tumor	O
parenchyma	O
,	O
macrophages	O
accumulate	O
at	O
highest	O
density	O
in	O
necrotic	O
regions	O
,	O
which	O
are	O
associated	O
with	O
low	O
oxygen	O
tensions	O
.	O
<EOS>	B-X
Although	B-X
MCP	B-X
-	B-X
1	B-X
is	B-X
predominantly	B-X
expressed	B-X
by	B-X
the	B-X
tumor	B-X
parenchyma	B-X
,	B-X
macrophages	B-X
accumulate	B-X
at	B-X
highest	B-X
density	B-X
in	B-X
necrotic	B-X
regions	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
low	B-X
oxygen	B-X
tensions	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
can	B-X
stimulate	B-X
MCP	B-X
-	B-X
1	B-X
production	B-X
and	B-X
is	B-X
also	B-X
present	B-X
within	B-X
ovarian	B-X
carcinomas	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
hypoxia	B-X
both	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
monocyte	B-X
migration	B-X
<EOS>	B-X
The	B-X
effect	B-X
was	B-X
mimicked	B-X
by	B-X
cobalt	B-X
chloride	B-X
and	B-X
desferrioxamine	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
specific	B-X
oxygen	B-X
-	B-X
sensing	B-X
mechanism	B-X

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
can	O
stimulate	O
MCP-1	B-protein
production	O
and	O
is	O
also	O
present	O
within	O
ovarian	O
carcinomas	O
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
can	B-X
stimulate	B-X
MCP	B-X
-	B-X
1	B-X
production	B-X
and	B-X
is	B-X
also	B-X
present	B-X
within	B-X
ovarian	B-X
carcinomas	B-X
<EOS>	B-X
Hypoxia	B-X
down	B-X
-	B-X
regulated	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
and	B-X
protein	B-X
production	B-X
by	B-X
ovarian	B-X
cancer	B-X
cells	B-X
<EOS>	B-X
Monocyte	B-X
chemoattractant	B-X
protein	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
likely	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
macrophage	B-X
infiltrate	B-X
in	B-X
human	B-X
ovarian	B-X
carcinomas	B-X
<EOS>	B-X
Monocyte	B-X
migration	B-X
in	B-X
response	B-X
to	B-X
MCP	B-X
-	B-X
1	B-X
was	B-X
also	B-X
diminished	B-X
under	B-X
hypoxic	B-X
conditions	B-X

We	O
have	O
investigated	O
the	O
effect	O
of	O
hypoxia	O
both	O
on	O
MCP-1	B-protein
expression	O
in	O
ovarian	B-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
monocyte	O
migration	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
hypoxia	B-X
both	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
monocyte	B-X
migration	B-X
<EOS>	B-X
Unlike	B-X
antioxidants	B-X
,	B-X
hypoxia	B-X
did	B-X
not	B-X
inhibit	B-X
nuclear	B-X
factor	B-X
KB	B-X
mobilization	B-X
<EOS>	B-X
Monocyte	B-X
migration	B-X
in	B-X
response	B-X
to	B-X
MCP	B-X
-	B-X
1	B-X
was	B-X
also	B-X
diminished	B-X
under	B-X
hypoxic	B-X
conditions	B-X
<EOS>	B-X
Hypoxia	B-X
down	B-X
-	B-X
regulates	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
:	B-X
implications	B-X
for	B-X
macrophage	B-X
distribution	B-X
in	B-X
tumors	B-X
.	B-X

Hypoxia	O
down-regulated	O
TNF-alpha-induced	B-RNA
MCP-1	I-RNA
mRNA	I-RNA
and	O
protein	O
production	O
by	O
ovarian	B-cell_type
cancer	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Hypoxia	B-X
down	B-X
-	B-X
regulated	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
and	B-X
protein	B-X
production	B-X
by	B-X
ovarian	B-X
cancer	B-X
cells	B-X
<EOS>	B-X
Hypoxia	B-X
down	B-X
-	B-X
regulates	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
:	B-X
implications	B-X
for	B-X
macrophage	B-X
distribution	B-X
in	B-X
tumors	B-X
.	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
can	B-X
stimulate	B-X
MCP	B-X
-	B-X
1	B-X
production	B-X
and	B-X
is	B-X
also	B-X
present	B-X
within	B-X
ovarian	B-X
carcinomas	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
hypoxia	B-X
both	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
monocyte	B-X
migration	B-X

The	O
effect	O
was	O
mimicked	O
by	O
cobalt	O
chloride	O
and	O
desferrioxamine	O
,	O
consistent	O
with	O
a	O
specific	O
oxygen-sensing	O
mechanism	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
was	B-X
mimicked	B-X
by	B-X
cobalt	B-X
chloride	B-X
and	B-X
desferrioxamine	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
specific	B-X
oxygen	B-X
-	B-X
sensing	B-X
mechanism	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
the	B-X
inhibition	B-X
of	B-X
monocyte	B-X
migration	B-X
are	B-X
independent	B-X
effects	B-X
of	B-X
hypoxia	B-X
that	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
distribution	B-X
of	B-X
macrophages	B-X
within	B-X
ovarian	B-X
tumors	B-X
<EOS>	B-X
Although	B-X
MCP	B-X
-	B-X
1	B-X
is	B-X
predominantly	B-X
expressed	B-X
by	B-X
the	B-X
tumor	B-X
parenchyma	B-X
,	B-X
macrophages	B-X
accumulate	B-X
at	B-X
highest	B-X
density	B-X
in	B-X
necrotic	B-X
regions	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
low	B-X
oxygen	B-X
tensions	B-X
<EOS>	B-X
Unlike	B-X
antioxidants	B-X
,	B-X
hypoxia	B-X
did	B-X
not	B-X
inhibit	B-X
nuclear	B-X
factor	B-X
KB	B-X
mobilization	B-X

Unlike	O
antioxidants	O
,	O
hypoxia	O
did	O
not	O
inhibit	O
nuclear	O
factor	O
KB	O
mobilization	O
.	O
<EOS>	B-X
Unlike	B-X
4HR	B-X
,	B-X
silk	B-X
sericin	B-X
increased	B-X
the	B-X
expression	B-X
of	B-X
hypoxia	B-X
inducible	B-X
factor	B-X
-	B-X
1α	B-X
(	B-X
HIF	B-X
-	B-X
1α	B-X
)	B-X
and	B-X
HIF	B-X
-	B-X
2α	B-X
<EOS>	B-X
Hypoxia	B-X
adaptation	B-X
in	B-X
termites	B-X
:	B-X
hypoxic	B-X
conditions	B-X
enhance	B-X
survival	B-X
and	B-X
reproductive	B-X
activity	B-X
in	B-X
royals	B-X
.	B-X
<EOS>	B-X
Unlike	B-X
most	B-X
animals	B-X
,	B-X
humans	B-X
can	B-X
not	B-X
synthesize	B-X
ascorbic	B-X
acid	B-X
and	B-X
its	B-X
role	B-X
in	B-X
liver	B-X
fibrosis	B-X
remains	B-X
unclear	B-X
<EOS>	B-X
Nitric	B-X
oxide	B-X
homeostasis	B-X
is	B-X
maintained	B-X
during	B-X
acute	B-X
in	B-X
vitro	B-X
hypoxia	B-X
and	B-X
following	B-X
reoxygenation	B-X
in	B-X
naked	B-X
mole	B-X
-	B-X
rat	B-X
but	B-X
not	B-X
mouse	B-X
cortical	B-X
neurons	B-X
.	B-X

Monocyte	O
migration	O
in	O
response	O
to	O
MCP-1	B-protein
was	O
also	O
diminished	O
under	O
hypoxic	O
conditions	O
.	O
<EOS>	B-X
Monocyte	B-X
migration	B-X
in	B-X
response	B-X
to	B-X
MCP	B-X
-	B-X
1	B-X
was	B-X
also	B-X
diminished	B-X
under	B-X
hypoxic	B-X
conditions	B-X
<EOS>	B-X
Monocyte	B-X
chemoattractant	B-X
protein	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
likely	B-X
to	B-X
contribute	B-X
to	B-X
the	B-X
macrophage	B-X
infiltrate	B-X
in	B-X
human	B-X
ovarian	B-X
carcinomas	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
hypoxia	B-X
both	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
ovarian	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
monocyte	B-X
migration	B-X
<EOS>	B-X
Hypoxia	B-X
down	B-X
-	B-X
regulated	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
and	B-X
protein	B-X
production	B-X
by	B-X
ovarian	B-X
cancer	B-X
cells	B-X

Down-regulation	O
of	O
MCP-1	B-protein
expression	O
and	O
the	O
inhibition	O
of	O
monocyte	O
migration	O
are	O
independent	O
effects	O
of	O
hypoxia	O
that	O
may	O
contribute	O
to	O
the	O
distribution	O
of	O
macrophages	B-cell_type
within	O
ovarian	O
tumors	O
.	O

Activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
κB	B-X
)	B-X
pathway	B-X
-	B-X
related	B-X
proteins	B-X
in	B-X
colonic	B-X
tissues	B-X
was	B-X
detected	B-X
by	B-X
Western	B-X
-	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
Phytochemicals	B-X
and	B-X
Regulation	B-X
of	B-X
NF	B-X
-	B-X
kB	B-X
in	B-X
Inflammatory	B-X
Bowel	B-X
Diseases	B-X
:	B-X
An	B-X
Overview	B-X
of	B-X
In	B-X
Vitro	B-X
and	B-X
In	B-X
Vivo	B-X
Effects	B-X
.	B-X
<EOS>	B-X
Ulcerative	B-X
colitis	B-X
(	B-X
UC	B-X
)	B-X
is	B-X
a	B-X
persistent	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
that	B-X
is	B-X
regarded	B-X
as	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
cognitive	B-X
impairment	B-X
<EOS>	B-X
The	B-X
levels	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
nuclear	B-X
factor	B-X
kappa	B-X
-	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
κB	B-X
)	B-X
pathway	B-X
in	B-X
the	B-X
UC	B-X
were	B-X
investigated	B-X
by	B-X
western	B-X
blotting	B-X
and	B-X
RT	B-X
-	B-X
qPCR	B-X

BACKGROUND	O
:	O
Expression	O
of	O
pro-inflammatory	B-protein
cytokines	I-protein
is	O
increased	O
in	O
the	O
intestinal	O
lamina	O
propria	O
of	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
intestinal	B-X
lamina	B-X
propria	B-X
of	B-X
patients	B-X
with	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
<EOS>	B-X
Primary	B-X
cultures	B-X
of	B-X
human	B-X
CEC	B-X
were	B-X
established	B-X
from	B-X
the	B-X
mucosa	B-X
of	B-X
patients	B-X
without	B-X
inflammatory	B-X
disease	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
the	B-X
manipulation	B-X
of	B-X
the	B-X
gut	B-X
microbiome	B-X
represents	B-X
a	B-X
promising	B-X
treatment	B-X
for	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
<EOS>	B-X
Loss	B-X
-	B-X
of	B-X
-	B-X
function	B-X
variants	B-X
in	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
non	B-X
-	B-X
receptor	B-X
type	B-X
-	B-X
2	B-X
[	B-X
PTPN2	B-X
]	B-X
promote	B-X
susceptibility	B-X
to	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
[	B-X
IBD	B-X
]	B-X

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
controls	O
transcription	O
of	O
inflammation	B-DNA
genes	I-DNA
.	O

On	O
activation	O
,	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
rapidly	O
released	O
from	O
its	O
cytoplasmic	B-protein
inhibitor	I-protein
(	O
I	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
transmigrates	O
into	O
the	O
nucleus	O
,	O
and	O
binds	O
to	O
DNA	B-DNA
response	I-DNA
elements	I-DNA
in	O
gene	O
promoter	O
regions	O
.	O
<EOS>	B-X
On	B-X
activation	B-X
,	B-X
NF	B-X
kappa	B-X
B	B-X
is	B-X
rapidly	B-X
released	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
(	B-X
I	B-X
kappa	B-X
B	B-X
)	B-X
,	B-X
transmigrates	B-X
into	B-X
the	B-X
nucleus	B-X
,	B-X
and	B-X
binds	B-X
to	B-X
DNA	B-X
response	B-X
elements	B-X
in	B-X
gene	B-X
promoter	B-X
regions	B-X
<EOS>	B-X
On	B-X
activation	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
rapidly	B-X
released	B-X
from	B-X
its	B-X
cytoplasmatic	B-X
inhibitor	B-X
(	B-X
IKB	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
transmigrates	B-X
into	B-X
the	B-X
nucleus	B-X
and	B-X
binds	B-X
to	B-X
DNA	B-X
response	B-X
elements	B-X
in	B-X
gene	B-X
promoter	B-X
regions	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
stimulated	B-X
by	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
and	B-X
its	B-X
nuclear	B-X
translocation	B-X
together	B-X
with	B-X
the	B-X
degradation	B-X
of	B-X
IKB	B-X
-	B-X
alpha	B-X
were	B-X
blocked	B-X
by	B-X
TX	B-X
527	B-X
<EOS>	B-X
At	B-X
the	B-X
same	B-X
time	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
protein	B-X
levels	B-X
present	B-X
in	B-X
cytoplasmic	B-X
extracts	B-X
decreased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
and	B-X
increased	B-X
when	B-X
PBMC	B-X
were	B-X
incubated	B-X
with	B-X
TX	B-X
527	B-X

AIMS	O
:	O
To	O
investigate	O
whether	O
increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
important	O
in	O
IBD	O
and	O
may	O
be	O
down-regulated	O
by	O
anti-inflammatory	O
treatment	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
is	B-X
important	B-X
in	B-X
IBD	B-X
and	B-X
may	B-X
be	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
anti	B-X
-	B-X
inflammatory	B-X
treatment	B-X
<EOS>	B-X
In	B-X
both	B-X
IBDs	B-X
,	B-X
but	B-X
particularly	B-X
Crohn	B-X
's	B-X
disease	B-X
,	B-X
increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
may	B-X
represent	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
steroids	B-X
exert	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
in	B-X
IBD	B-X
<EOS>	B-X
Increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
was	B-X
detected	B-X
in	B-X
lamina	B-X
propria	B-X
mononuclear	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
IBD	B-X

METHODS	O
:	O
Activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
was	O
determined	O
by	O
western	O
blot	O
assessment	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
in	O
nuclear	O
extracts	O
of	O
colonic	O
biopsy	O
samples	O
as	O
well	O
as	O
lamina	B-cell_type
propria	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
was	B-X
determined	B-X
by	B-X
western	B-X
blot	B-X
assessment	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
colonic	B-X
biopsy	B-X
samples	B-X
as	B-X
well	B-X
as	B-X
lamina	B-X
propria	B-X
mononuclear	B-X
cells	B-X
<EOS>	B-X
Increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
was	B-X
detected	B-X
in	B-X
lamina	B-X
propria	B-X
mononuclear	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
IBD	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
may	B-X
represent	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
steroids	B-X
exert	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
in	B-X
IBD	B-X
<EOS>	B-X
On	B-X
activation	B-X
,	B-X
NF	B-X
kappa	B-X
B	B-X
is	B-X
rapidly	B-X
released	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
(	B-X
I	B-X
kappa	B-X
B	B-X
)	B-X
,	B-X
transmigrates	B-X
into	B-X
the	B-X
nucleus	B-X
,	B-X
and	B-X
binds	B-X
to	B-X
DNA	B-X
response	B-X
elements	B-X
in	B-X
gene	B-X
promoter	B-X
regions	B-X

RESULTS	O
:	O
Nuclear	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
p65	B-protein
are	O
increased	O
in	O
lamina	O
propria	O
biopsy	O
specimens	O
from	O
patients	O
with	O
Crohn	O
's	O
disease	O
in	O
comparison	O
with	O
patients	O
with	O
ulcerative	O
colitis	O
and	O
controls	O
.	O
<EOS>	B-X
Nuclear	B-X
levels	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
p65	B-X
are	B-X
increased	B-X
in	B-X
lamina	B-X
propria	B-X
biopsy	B-X
specimens	B-X
from	B-X
patients	B-X
with	B-X
Crohn	B-X
's	B-X
disease	B-X
in	B-X
comparison	B-X
with	B-X
patients	B-X
with	B-X
ulcerative	B-X
colitis	B-X
and	B-X
controls	B-X
<EOS>	B-X
Increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
was	B-X
detected	B-X
in	B-X
lamina	B-X
propria	B-X
mononuclear	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
IBD	B-X
<EOS>	B-X
Expression	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
intestinal	B-X
lamina	B-X
propria	B-X
of	B-X
patients	B-X
with	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
is	B-X
important	B-X
in	B-X
IBD	B-X
and	B-X
may	B-X
be	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
anti	B-X
-	B-X
inflammatory	B-X
treatment	B-X

Increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
was	O
detected	O
in	O
lamina	B-cell_type
propria	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
active	O
IBD	O
.	O
<EOS>	B-X
Increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
was	B-X
detected	B-X
in	B-X
lamina	B-X
propria	B-X
mononuclear	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
IBD	B-X
<EOS>	B-X
Nuclear	B-X
levels	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
p65	B-X
are	B-X
increased	B-X
in	B-X
lamina	B-X
propria	B-X
biopsy	B-X
specimens	B-X
from	B-X
patients	B-X
with	B-X
Crohn	B-X
's	B-X
disease	B-X
in	B-X
comparison	B-X
with	B-X
patients	B-X
with	B-X
ulcerative	B-X
colitis	B-X
and	B-X
controls	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
is	B-X
important	B-X
in	B-X
IBD	B-X
and	B-X
may	B-X
be	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
anti	B-X
-	B-X
inflammatory	B-X
treatment	B-X
<EOS>	B-X
Activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
was	B-X
determined	B-X
by	B-X
western	B-X
blot	B-X
assessment	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
colonic	B-X
biopsy	B-X
samples	B-X
as	B-X
well	B-X
as	B-X
lamina	B-X
propria	B-X
mononuclear	B-X
cells	B-X

Corticosteroids	O
strongly	O
inhibit	O
intestinal	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
in	O
IBD	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
stabilising	O
the	O
cytosolic	B-protein
inhibitor	I-protein
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
against	O
activation	O
induced	O
degradation	O
.	O
<EOS>	B-X
Corticosteroids	B-X
strongly	B-X
inhibit	B-X
intestinal	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
IBD	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
by	B-X
stabilising	B-X
the	B-X
cytosolic	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
against	B-X
activation	B-X
induced	B-X
degradation	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
may	B-X
represent	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
steroids	B-X
exert	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
in	B-X
IBD	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
is	B-X
important	B-X
in	B-X
IBD	B-X
and	B-X
may	B-X
be	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
anti	B-X
-	B-X
inflammatory	B-X
treatment	B-X
<EOS>	B-X
Expression	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
intestinal	B-X
lamina	B-X
propria	B-X
of	B-X
patients	B-X
with	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X

CONCLUSIONS	O
:	O
In	O
both	O
IBDs	O
,	O
but	O
particularly	O
Crohn	O
's	O
disease	O
,	O
increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
inflammatory	O
response	O
.	O
<EOS>	B-X
In	B-X
both	B-X
IBDs	B-X
,	B-X
but	B-X
particularly	B-X
Crohn	B-X
's	B-X
disease	B-X
,	B-X
increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
is	B-X
important	B-X
in	B-X
IBD	B-X
and	B-X
may	B-X
be	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
anti	B-X
-	B-X
inflammatory	B-X
treatment	B-X
<EOS>	B-X
Expression	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
intestinal	B-X
lamina	B-X
propria	B-X
of	B-X
patients	B-X
with	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
kappa	B-X
B	B-X
)	B-X
controls	B-X
transcription	B-X
of	B-X
inflammation	B-X
genes	B-X

Inhibition	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
may	O
represent	O
a	O
mechanism	O
by	O
which	O
steroids	O
exert	O
an	O
anti-inflammatory	O
effect	O
in	O
IBD	O
<EOS>	B-X
Inhibition	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
may	B-X
represent	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
steroids	B-X
exert	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
in	B-X
IBD	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
increased	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
is	B-X
important	B-X
in	B-X
IBD	B-X
and	B-X
may	B-X
be	B-X
down	B-X
-	B-X
regulated	B-X
by	B-X
anti	B-X
-	B-X
inflammatory	B-X
treatment	B-X
<EOS>	B-X
Expression	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X
is	B-X
increased	B-X
in	B-X
the	B-X
intestinal	B-X
lamina	B-X
propria	B-X
of	B-X
patients	B-X
with	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
<EOS>	B-X
Activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
was	B-X
determined	B-X
by	B-X
western	B-X
blot	B-X
assessment	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
colonic	B-X
biopsy	B-X
samples	B-X
as	B-X
well	B-X
as	B-X
lamina	B-X
propria	B-X
mononuclear	B-X
cells	B-X

Insufficient	O
glycemic	O
control	O
increases	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
binding	O
activity	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
isolated	O
from	O
patients	O
with	O
type	O
1	O
diabetes	O
.	O
<EOS>	B-X
Insufficient	B-X
glycemic	B-X
control	B-X
increases	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
isolated	B-X
from	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X
<EOS>	B-X
Hyperglycemia	B-X
induces	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
ex	B-X
vivo	B-X
-	B-X
isolated	B-X
PBMCs	B-X
of	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
<EOS>	B-X
Monocytes	B-X
of	B-X
patients	B-X
with	B-X
HbA1c	B-X
levels	B-X
>	B-X
10	B-X
%	B-X
demonstrated	B-X
significantly	B-X
higher	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
an	B-X
EMSA	B-X
and	B-X
a	B-X
stronger	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
staining	B-X
in	B-X
immunohistochemistry	B-X
than	B-X
monocytes	B-X
of	B-X
patients	B-X
with	B-X
HbA1c	B-X
levels	B-X
of	B-X
6	B-X
-	B-X
8	B-X
%	B-X
<EOS>	B-X
The	B-X
redox	B-X
-	B-X
sensitive	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
is	B-X
believed	B-X
to	B-X
contribute	B-X
to	B-X
late	B-X
diabetic	B-X
complications	B-X

OBJECTIVE	O
:	O
The	O
redox-sensitive	B-protein
transcription	I-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
believed	O
to	O
contribute	O
to	O
late	O
diabetic	O
complications	O
.	O
<EOS>	B-X
The	B-X
redox	B-X
-	B-X
sensitive	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
is	B-X
believed	B-X
to	B-X
contribute	B-X
to	B-X
late	B-X
diabetic	B-X
complications	B-X
<EOS>	B-X
Hyperglycemia	B-X
induces	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
ex	B-X
vivo	B-X
-	B-X
isolated	B-X
PBMCs	B-X
of	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
<EOS>	B-X
Insufficient	B-X
glycemic	B-X
control	B-X
increases	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
isolated	B-X
from	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
decreased	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X

It	O
is	O
unknown	O
whether	O
NF-kappa	B-protein
B	I-protein
is	O
influenced	O
by	O
glycemic	O
control	O
.	O
<EOS>	B-X
It	B-X
is	B-X
unknown	B-X
whether	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
influenced	B-X
by	B-X
glycemic	B-X
control	B-X
<EOS>	B-X
The	B-X
redox	B-X
-	B-X
sensitive	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
is	B-X
believed	B-X
to	B-X
contribute	B-X
to	B-X
late	B-X
diabetic	B-X
complications	B-X
<EOS>	B-X
Hyperglycemia	B-X
induces	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
ex	B-X
vivo	B-X
-	B-X
isolated	B-X
PBMCs	B-X
of	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
<EOS>	B-X
The	B-X
increase	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
correlated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
plasmatic	B-X
markers	B-X
of	B-X
lipid	B-X
peroxidation	B-X

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
To	O
determine	O
whether	O
NF-kappa	B-protein
B	I-protein
is	O
activated	O
in	O
patients	O
with	O
insufficient	O
glycemic	O
control	O
(	O
HbA1c	O
>	O
10	O
%	O
)	O
,	O
we	O
developed	O
a	O
tissue	O
culture-independent	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
-based	O
semiquantitative	O
detection	O
system	O
that	O
allowed	O
us	O
to	O
determine	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
ex	O
vivo-isolated	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
activated	B-X
in	B-X
patients	B-X
with	B-X
insufficient	B-X
glycemic	B-X
control	B-X
(	B-X
HbA1c	B-X
>	B-X
10	B-X
%	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
tissue	B-X
culture	B-X
-	B-X
independent	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
	B-X
-	B-X
based	B-X
semiquantitative	B-X
detection	B-X
system	B-X
that	B-X
allowed	B-X
us	B-X
to	B-X
determine	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
ex	B-X
vivo	B-X
-	B-X
isolated	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
is	B-X
at	B-X
least	B-X
partially	B-X
dependent	B-X
on	B-X
oxidative	B-X
stress	B-X
,	B-X
since	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
significantly	B-X
lowered	B-X
the	B-X
extent	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
<EOS>	B-X
Monocytes	B-X
of	B-X
patients	B-X
with	B-X
HbA1c	B-X
levels	B-X
>	B-X
10	B-X
%	B-X
demonstrated	B-X
significantly	B-X
higher	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
an	B-X
EMSA	B-X
and	B-X
a	B-X
stronger	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
staining	B-X
in	B-X
immunohistochemistry	B-X
than	B-X
monocytes	B-X
of	B-X
patients	B-X
with	B-X
HbA1c	B-X
levels	B-X
of	B-X
6	B-X
-	B-X
8	B-X
%	B-X
<EOS>	B-X
Insufficient	B-X
glycemic	B-X
control	B-X
increases	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
isolated	B-X
from	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X

We	O
included	O
43	O
patients	O
with	O
type	O
1	O
diabetes	O
in	O
this	O
cross-sectional	O
study	O
.	O
<EOS>	B-X
Results	B-X
We	B-X
included	B-X
332	B-X
patients	B-X
,	B-X
43	B-X
%	B-X
of	B-X
whom	B-X
had	B-X
type	B-X
1	B-X
diabetes	B-X
;	B-X
26	B-X
%	B-X
of	B-X
the	B-X
patients	B-X
had	B-X
previously	B-X
used	B-X
one	B-X
or	B-X
more	B-X
types	B-X
of	B-X
CAM	B-X
<EOS>	B-X
Dyslipidemia	B-X
Among	B-X
Patients	B-X
With	B-X
Type	B-X
1	B-X
Diabetes	B-X
and	B-X
Its	B-X
Associated	B-X
Factors	B-X
in	B-X
Saudi	B-X
Arabia	B-X
:	B-X
An	B-X
Analytical	B-X
Cross	B-X
-	B-X
Sectional	B-X
Study	B-X
.	B-X
<EOS>	B-X
In	B-X
total	B-X
,	B-X
56	B-X
patients	B-X
were	B-X
diagnosed	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
mellitus	B-X
during	B-X
the	B-X
pandemic	B-X
and	B-X
2	B-X
(	B-X
3	B-X
<EOS>	B-X
Accessibility	B-X
of	B-X
Low	B-X
-	B-X
cost	B-X
Insulin	B-X
From	B-X
Illegitimate	B-X
Internet	B-X
Pharmacies	B-X
:	B-X
Cross	B-X
-	B-X
sectional	B-X
Study	B-X
.	B-X

10	O
of	O
those	O
received	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
600	O
mg/day	O
p.o.	O
)	O
for	O
2	O
weeks	O
.	O
<EOS>	B-X
10	B-X
of	B-X
those	B-X
received	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
(	B-X
600	B-X
mg	B-X
/	B-X
day	B-X
p	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
decreased	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
is	B-X
at	B-X
least	B-X
partially	B-X
dependent	B-X
on	B-X
oxidative	B-X
stress	B-X
,	B-X
since	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
significantly	B-X
lowered	B-X
the	B-X
extent	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
<EOS>	B-X
Hyperglycemia	B-X
induces	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
ex	B-X
vivo	B-X
-	B-X
isolated	B-X
PBMCs	B-X
of	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X

RESULTS	O
:	O
Monocytes	O
of	O
patients	O
with	O
HbA1c	O
levels	O
>	O
10	O
%	O
demonstrated	O
significantly	O
higher	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
an	O
EMSA	O
and	O
a	O
stronger	O
NF-kappa	B-protein
B	I-protein
staining	O
in	O
immunohistochemistry	O
than	O
monocytes	B-cell_type
of	O
patients	O
with	O
HbA1c	O
levels	O
of	O
6-8	O
%	O
.	O

The	O
increase	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
correlated	O
with	O
an	O
increase	O
in	O
plasmatic	O
markers	O
of	O
lipid	O
peroxidation	O
.	O
<EOS>	B-X
The	B-X
increase	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
correlated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
plasmatic	B-X
markers	B-X
of	B-X
lipid	B-X
peroxidation	B-X
<EOS>	B-X
Insufficient	B-X
glycemic	B-X
control	B-X
increases	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
isolated	B-X
from	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X
<EOS>	B-X
The	B-X
redox	B-X
-	B-X
sensitive	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
is	B-X
believed	B-X
to	B-X
contribute	B-X
to	B-X
late	B-X
diabetic	B-X
complications	B-X
<EOS>	B-X
We	B-X
included	B-X
43	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
in	B-X
this	B-X
cross	B-X
-	B-X
sectional	B-X
study	B-X

Treatment	O
with	O
the	O
antioxidant	O
thioctic	O
acid	O
decreased	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
.	O
<EOS>	B-X
Treatment	B-X
with	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
decreased	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
is	B-X
at	B-X
least	B-X
partially	B-X
dependent	B-X
on	B-X
oxidative	B-X
stress	B-X
,	B-X
since	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
significantly	B-X
lowered	B-X
the	B-X
extent	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
<EOS>	B-X
10	B-X
of	B-X
those	B-X
received	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
(	B-X
600	B-X
mg	B-X
/	B-X
day	B-X
p	B-X
<EOS>	B-X
This	B-X
inhibition	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
EC	B-X
antioxidant	B-X
activity	B-X
,	B-X
with	B-X
changes	B-X
in	B-X
p65	B-X
phosphorylation	B-X
or	B-X
NF	B-X
-	B-X
kappaB	B-X
nuclear	B-X
translocation	B-X

CONCLUSIONS	O
:	O
Hyperglycemia	O
induces	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
in	O
ex	O
vivo-isolated	O
PBMCs	B-cell_type
of	O
patients	O
with	O
type	O
1	O
diabetes	O
.	O
<EOS>	B-X
Hyperglycemia	B-X
induces	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
ex	B-X
vivo	B-X
-	B-X
isolated	B-X
PBMCs	B-X
of	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
<EOS>	B-X
Insufficient	B-X
glycemic	B-X
control	B-X
increases	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
isolated	B-X
from	B-X
patients	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X
<EOS>	B-X
Monocytes	B-X
of	B-X
patients	B-X
with	B-X
HbA1c	B-X
levels	B-X
>	B-X
10	B-X
%	B-X
demonstrated	B-X
significantly	B-X
higher	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
an	B-X
EMSA	B-X
and	B-X
a	B-X
stronger	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
staining	B-X
in	B-X
immunohistochemistry	B-X
than	B-X
monocytes	B-X
of	B-X
patients	B-X
with	B-X
HbA1c	B-X
levels	B-X
of	B-X
6	B-X
-	B-X
8	B-X
%	B-X
<EOS>	B-X
The	B-X
increase	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
correlated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
plasmatic	B-X
markers	B-X
of	B-X
lipid	B-X
peroxidation	B-X

NF-kappa	B-protein
B	I-protein
activation	O
is	O
at	O
least	O
partially	O
dependent	O
on	O
oxidative	O
stress	O
,	O
since	O
the	O
antioxidant	O
thioctic	O
acid	O
significantly	O
lowered	O
the	O
extent	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
.	O
<EOS>	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
is	B-X
at	B-X
least	B-X
partially	B-X
dependent	B-X
on	B-X
oxidative	B-X
stress	B-X
,	B-X
since	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
significantly	B-X
lowered	B-X
the	B-X
extent	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
decreased	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
activated	B-X
in	B-X
patients	B-X
with	B-X
insufficient	B-X
glycemic	B-X
control	B-X
(	B-X
HbA1c	B-X
>	B-X
10	B-X
%	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
tissue	B-X
culture	B-X
-	B-X
independent	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
	B-X
-	B-X
based	B-X
semiquantitative	B-X
detection	B-X
system	B-X
that	B-X
allowed	B-X
us	B-X
to	B-X
determine	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
ex	B-X
vivo	B-X
-	B-X
isolated	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
<EOS>	B-X
10	B-X
of	B-X
those	B-X
received	B-X
the	B-X
antioxidant	B-X
thioctic	B-X
acid	B-X
(	B-X
600	B-X
mg	B-X
/	B-X
day	B-X
p	B-X

Synergistic	O
activation	O
of	O
MAP	B-protein
kinase	I-protein
(	O
ERK1/2	B-protein
)	O
by	O
erythropoietin	B-protein
and	O
stem	B-protein
cell	I-protein
factor	I-protein
is	O
essential	O
for	O
expanded	O
erythropoiesis	O
.	O
<EOS>	B-X
Synergistic	B-X
activation	B-X
of	B-X
MAP	B-X
kinase	B-X
(	B-X
ERK1	B-X
/	B-X
2	B-X
)	B-X
by	B-X
erythropoietin	B-X
and	B-X
stem	B-X
cell	B-X
factor	B-X
is	B-X
essential	B-X
for	B-X
expanded	B-X
erythropoiesis	B-X
.	B-X
<EOS>	B-X
Together	B-X
,	B-X
the	B-X
data	B-X
suggest	B-X
that	B-X
synergistic	B-X
activation	B-X
of	B-X
MAPK	B-X
by	B-X
SCF	B-X
and	B-X
EPO	B-X
is	B-X
essential	B-X
for	B-X
expanded	B-X
erythropoiesis	B-X
<EOS>	B-X
Wortmannin	B-X
only	B-X
inhibits	B-X
MAPK	B-X
activation	B-X
induced	B-X
by	B-X
EPO	B-X
but	B-X
not	B-X
that	B-X
by	B-X
SCF	B-X
,	B-X
suggesting	B-X
that	B-X
SCF	B-X
and	B-X
EPO	B-X
may	B-X
activate	B-X
MAPK	B-X
through	B-X
different	B-X
pathways	B-X
,	B-X
which	B-X
would	B-X
facilitate	B-X
synergy	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
EPO	B-X
,	B-X
but	B-X
not	B-X
SCF	B-X
,	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
STAT5	B-X
,	B-X
whereas	B-X
SCF	B-X
and	B-X
wortmannin	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
EPO	B-X
-	B-X
induced	B-X
STAT5	B-X
activation	B-X
,	B-X
suggesting	B-X
that	B-X
STAT5	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
the	B-X
synergistic	B-X
action	B-X
of	B-X
SCF	B-X
and	B-X
EPO	B-X

Stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
work	O
synergistically	O
to	O
support	O
erythropoiesis	O
,	O
but	O
the	O
mechanism	O
for	O
this	O
synergism	O
is	O
unknown	O
.	O
<EOS>	B-X
Stem	B-X
cell	B-X
factor	B-X
(	B-X
SCF	B-X
)	B-X
and	B-X
erythropoietin	B-X
(	B-X
EPO	B-X
)	B-X
work	B-X
synergistically	B-X
to	B-X
support	B-X
erythropoiesis	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
for	B-X
this	B-X
synergism	B-X
is	B-X
unknown	B-X
<EOS>	B-X
By	B-X
using	B-X
purified	B-X
human	B-X
erythroid	B-X
colony	B-X
-	B-X
forming	B-X
cells	B-X
(	B-X
ECFC	B-X
)	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
SCF	B-X
and	B-X
EPO	B-X
synergistically	B-X
activate	B-X
MAP	B-X
kinase	B-X
(	B-X
MAPK	B-X
,	B-X
ERK1	B-X
/	B-X
2	B-X
)	B-X
,	B-X
which	B-X
correlates	B-X
with	B-X
the	B-X
cell	B-X
growth	B-X
and	B-X
thus	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
synergistic	B-X
effects	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
EPO	B-X
,	B-X
but	B-X
not	B-X
SCF	B-X
,	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
STAT5	B-X
,	B-X
whereas	B-X
SCF	B-X
and	B-X
wortmannin	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
EPO	B-X
-	B-X
induced	B-X
STAT5	B-X
activation	B-X
,	B-X
suggesting	B-X
that	B-X
STAT5	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
the	B-X
synergistic	B-X
action	B-X
of	B-X
SCF	B-X
and	B-X
EPO	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
PD98059	B-X
and	B-X
wortmannin	B-X
,	B-X
inhibitors	B-X
of	B-X
MEK	B-X
and	B-X
PI	B-X
-	B-X
3	B-X
kinase	B-X
,	B-X
respectively	B-X
,	B-X
inhibited	B-X
the	B-X
synergistic	B-X
activation	B-X
of	B-X
MAPK	B-X
and	B-X
also	B-X
the	B-X
cell	B-X
growth	B-X
,	B-X
further	B-X
supporting	B-X
this	B-X
conclusion	B-X

By	O
using	O
purified	B-cell_line
human	I-cell_line
erythroid	I-cell_line
colony-forming	I-cell_line
cells	I-cell_line
(	O
ECFC	B-cell_line
)	O
,	O
we	O
have	O
found	O
that	O
SCF	B-protein
and	O
EPO	B-protein
synergistically	O
activate	O
MAP	B-protein
kinase	I-protein
(	O
MAPK	B-protein
,	O
ERK1/2	B-protein
)	O
,	O
which	O
correlates	O
with	O
the	O
cell	O
growth	O
and	O
thus	O
may	O
be	O
responsible	O
for	O
the	O
synergistic	O
effects	O
.	O
<EOS>	B-X
By	B-X
using	B-X
purified	B-X
human	B-X
erythroid	B-X
colony	B-X
-	B-X
forming	B-X
cells	B-X
(	B-X
ECFC	B-X
)	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
SCF	B-X
and	B-X
EPO	B-X
synergistically	B-X
activate	B-X
MAP	B-X
kinase	B-X
(	B-X
MAPK	B-X
,	B-X
ERK1	B-X
/	B-X
2	B-X
)	B-X
,	B-X
which	B-X
correlates	B-X
with	B-X
the	B-X
cell	B-X
growth	B-X
and	B-X
thus	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
synergistic	B-X
effects	B-X
<EOS>	B-X
Stem	B-X
cell	B-X
factor	B-X
(	B-X
SCF	B-X
)	B-X
and	B-X
erythropoietin	B-X
(	B-X
EPO	B-X
)	B-X
work	B-X
synergistically	B-X
to	B-X
support	B-X
erythropoiesis	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
for	B-X
this	B-X
synergism	B-X
is	B-X
unknown	B-X
<EOS>	B-X
Wortmannin	B-X
only	B-X
inhibits	B-X
MAPK	B-X
activation	B-X
induced	B-X
by	B-X
EPO	B-X
but	B-X
not	B-X
that	B-X
by	B-X
SCF	B-X
,	B-X
suggesting	B-X
that	B-X
SCF	B-X
and	B-X
EPO	B-X
may	B-X
activate	B-X
MAPK	B-X
through	B-X
different	B-X
pathways	B-X
,	B-X
which	B-X
would	B-X
facilitate	B-X
synergy	B-X
<EOS>	B-X
Together	B-X
,	B-X
the	B-X
data	B-X
suggest	B-X
that	B-X
synergistic	B-X
activation	B-X
of	B-X
MAPK	B-X
by	B-X
SCF	B-X
and	B-X
EPO	B-X
is	B-X
essential	B-X
for	B-X
expanded	B-X
erythropoiesis	B-X

Treatment	O
of	O
the	O
cells	O
with	O
PD98059	O
and	O
wortmannin	O
,	O
inhibitors	O
of	O
MEK	B-protein
and	O
PI-3	B-protein
kinase	I-protein
,	O
respectively	O
,	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
MAPK	B-protein
and	O
also	O
the	O
cell	O
growth	O
,	O
further	O
supporting	O
this	O
conclusion	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
PD98059	B-X
and	B-X
wortmannin	B-X
,	B-X
inhibitors	B-X
of	B-X
MEK	B-X
and	B-X
PI	B-X
-	B-X
3	B-X
kinase	B-X
,	B-X
respectively	B-X
,	B-X
inhibited	B-X
the	B-X
synergistic	B-X
activation	B-X
of	B-X
MAPK	B-X
and	B-X
also	B-X
the	B-X
cell	B-X
growth	B-X
,	B-X
further	B-X
supporting	B-X
this	B-X
conclusion	B-X
<EOS>	B-X
Together	B-X
,	B-X
the	B-X
data	B-X
suggest	B-X
that	B-X
synergistic	B-X
activation	B-X
of	B-X
MAPK	B-X
by	B-X
SCF	B-X
and	B-X
EPO	B-X
is	B-X
essential	B-X
for	B-X
expanded	B-X
erythropoiesis	B-X
<EOS>	B-X
Stem	B-X
cell	B-X
factor	B-X
(	B-X
SCF	B-X
)	B-X
and	B-X
erythropoietin	B-X
(	B-X
EPO	B-X
)	B-X
work	B-X
synergistically	B-X
to	B-X
support	B-X
erythropoiesis	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
for	B-X
this	B-X
synergism	B-X
is	B-X
unknown	B-X
<EOS>	B-X
By	B-X
using	B-X
purified	B-X
human	B-X
erythroid	B-X
colony	B-X
-	B-X
forming	B-X
cells	B-X
(	B-X
ECFC	B-X
)	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
SCF	B-X
and	B-X
EPO	B-X
synergistically	B-X
activate	B-X
MAP	B-X
kinase	B-X
(	B-X
MAPK	B-X
,	B-X
ERK1	B-X
/	B-X
2	B-X
)	B-X
,	B-X
which	B-X
correlates	B-X
with	B-X
the	B-X
cell	B-X
growth	B-X
and	B-X
thus	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
synergistic	B-X
effects	B-X

Wortmannin	O
only	O
inhibits	O
MAPK	B-protein
activation	O
induced	O
by	O
EPO	B-protein
but	O
not	O
that	O
by	O
SCF	B-protein
,	O
suggesting	O
that	O
SCF	B-protein
and	O
EPO	B-protein
may	O
activate	O
MAPK	B-protein
through	O
different	O
pathways	O
,	O
which	O
would	O
facilitate	O
synergy	O
.	O
<EOS>	B-X
We	B-X
can	B-X
conclude	B-X
EPO	B-X
increases	B-X
immediate	B-X
cardioprotection	B-X
through	B-X
the	B-X
activation	B-X
of	B-X
multiple	B-X
signal	B-X
transduction	B-X
pathways	B-X
<EOS>	B-X
Pretreatment	B-X
with	B-X
Wortmannin	B-X
abolished	B-X
EPO	B-X
-	B-X
induced	B-X
Akt	B-X
activation	B-X
and	B-X
phosphorylation	B-X
<EOS>	B-X
We	B-X
determined	B-X
the	B-X
role	B-X
of	B-X
JAK	B-X
/	B-X
STAT	B-X
and	B-X
Ras	B-X
/	B-X
Rac	B-X
/	B-X
MAPK	B-X
in	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
EPO	B-X
against	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injury	B-X
in	B-X
infant	B-X
rabbit	B-X
heart	B-X
<EOS>	B-X
The	B-X
immediate	B-X
protective	B-X
effect	B-X
of	B-X
erythropoietin	B-X
(	B-X
EPO	B-X
)	B-X
against	B-X
ischemia	B-X
in	B-X
heart	B-X
suggests	B-X
a	B-X
role	B-X
beyond	B-X
hematopoiesis	B-X
and	B-X
the	B-X
treatment	B-X
of	B-X
anemia	B-X

Furthermore	O
,	O
EPO	B-protein
,	O
but	O
not	O
SCF	B-protein
,	O
led	O
to	O
activation	O
of	O
STAT5	B-protein
,	O
whereas	O
SCF	B-protein
and	O
wortmannin	O
had	O
no	O
effect	O
on	O
the	O
EPO	B-protein
-induced	O
STAT5	B-protein
activation	O
,	O
suggesting	O
that	O
STAT5	B-protein
is	O
not	O
involved	O
in	O
the	O
synergistic	O
action	O
of	O
SCF	B-protein
and	O
EPO	B-protein
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
injected	B-X
mutant	B-X
SHP2	B-X
-	B-X
transformed	B-X
HCD	B-X
-	B-X
57	B-X
cells	B-X
into	B-X
immune	B-X
-	B-X
deficient	B-X
mice	B-X
intravenously	B-X
and	B-X
found	B-X
that	B-X
these	B-X
cells	B-X
rapidly	B-X
proliferated	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
bone	B-X
marrow	B-X
,	B-X
providing	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
in	B-X
vivo	B-X
testing	B-X
of	B-X
drugs	B-X
targeting	B-X
the	B-X
aberrant	B-X
signaling	B-X
of	B-X
mutant	B-X
SHP2	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
their	B-X
potential	B-X
inhibitory	B-X
activities	B-X
against	B-X
HIF	B-X
prolyl	B-X
hydroxylase	B-X
domain	B-X
(	B-X
PHD	B-X
)	B-X
revealed	B-X
their	B-X
function	B-X
as	B-X
PHD	B-X
inhibitors	B-X
in	B-X
PHD	B-X
-	B-X
HIF	B-X
pathway	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
LTP	B-X
in	B-X
the	B-X
injured	B-X
animals	B-X
that	B-X
received	B-X
EPO	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
healthy	B-X
control	B-X
animals	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
CRF	B-X
-	B-X
antagonists	B-X
directed	B-X
toward	B-X
alleviating	B-X
the	B-X
symptoms	B-X
of	B-X
the	B-X
withdrawal	B-X
stage	B-X
have	B-X
been	B-X
examined	B-X
with	B-X
interesting	B-X
resulting	B-X
changes	B-X
in	B-X
behaviour	B-X

Together	O
,	O
the	O
data	O
suggest	O
that	O
synergistic	O
activation	O
of	O
MAPK	B-protein
by	O
SCF	B-protein
and	O
EPO	B-protein
is	O
essential	O
for	O
expanded	O
erythropoiesis	O
.	O
<EOS>	B-X
Together	B-X
,	B-X
the	B-X
data	B-X
suggest	B-X
that	B-X
synergistic	B-X
activation	B-X
of	B-X
MAPK	B-X
by	B-X
SCF	B-X
and	B-X
EPO	B-X
is	B-X
essential	B-X
for	B-X
expanded	B-X
erythropoiesis	B-X
<EOS>	B-X
Synergistic	B-X
activation	B-X
of	B-X
MAP	B-X
kinase	B-X
(	B-X
ERK1	B-X
/	B-X
2	B-X
)	B-X
by	B-X
erythropoietin	B-X
and	B-X
stem	B-X
cell	B-X
factor	B-X
is	B-X
essential	B-X
for	B-X
expanded	B-X
erythropoiesis	B-X
.	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
PD98059	B-X
and	B-X
wortmannin	B-X
,	B-X
inhibitors	B-X
of	B-X
MEK	B-X
and	B-X
PI	B-X
-	B-X
3	B-X
kinase	B-X
,	B-X
respectively	B-X
,	B-X
inhibited	B-X
the	B-X
synergistic	B-X
activation	B-X
of	B-X
MAPK	B-X
and	B-X
also	B-X
the	B-X
cell	B-X
growth	B-X
,	B-X
further	B-X
supporting	B-X
this	B-X
conclusion	B-X
<EOS>	B-X
By	B-X
using	B-X
purified	B-X
human	B-X
erythroid	B-X
colony	B-X
-	B-X
forming	B-X
cells	B-X
(	B-X
ECFC	B-X
)	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
SCF	B-X
and	B-X
EPO	B-X
synergistically	B-X
activate	B-X
MAP	B-X
kinase	B-X
(	B-X
MAPK	B-X
,	B-X
ERK1	B-X
/	B-X
2	B-X
)	B-X
,	B-X
which	B-X
correlates	B-X
with	B-X
the	B-X
cell	B-X
growth	B-X
and	B-X
thus	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
synergistic	B-X
effects	B-X

The	O
molecular	O
and	O
phenotypic	O
profile	O
of	O
primary	O
central	O
nervous	O
system	O
lymphoma	O
identifies	O
distinct	O
categories	O
of	O
the	O
disease	O
and	O
is	O
consistent	O
with	O
histogenetic	O
derivation	O
from	O
germinal	B-cell_type
center-related	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
molecular	B-X
and	B-X
phenotypic	B-X
profile	B-X
of	B-X
primary	B-X
central	B-X
nervous	B-X
system	B-X
lymphoma	B-X
identifies	B-X
distinct	B-X
categories	B-X
of	B-X
the	B-X
disease	B-X
and	B-X
is	B-X
consistent	B-X
with	B-X
histogenetic	B-X
derivation	B-X
from	B-X
germinal	B-X
center	B-X
-	B-X
related	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
Primary	B-X
central	B-X
nervous	B-X
system	B-X
lymphoma	B-X
(	B-X
PCNSL	B-X
)	B-X
is	B-X
a	B-X
major	B-X
cause	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
among	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
	B-X
-	B-X
infected	B-X
individuals	B-X
<EOS>	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
clarify	B-X
the	B-X
histogenesis	B-X
and	B-X
pathogenesis	B-X
of	B-X
these	B-X
lymphomas	B-X
,	B-X
49	B-X
PCNSL	B-X
(	B-X
26	B-X
acquired	B-X
immunodeficiency	B-X
syndrome	B-X
[	B-X
AIDS	B-X
]	B-X
	B-X
-	B-X
related	B-X
and	B-X
23	B-X
AIDS	B-X
-	B-X
unrelated	B-X
)	B-X
were	B-X
analyzed	B-X
for	B-X
multiple	B-X
biologic	B-X
markers	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
bear	B-X
histogenetic	B-X
and	B-X
pathogenetic	B-X
significance	B-X
for	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
neoplasms	B-X
<EOS>	B-X
0	B-X
%	B-X
)	B-X
with	B-X
mutations	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
5	B-X
'	B-X
noncoding	B-X
regions	B-X
,	B-X
which	B-X
are	B-X
regarded	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
transition	B-X
through	B-X
the	B-X
germinal	B-X
center	B-X
(	B-X
GC	B-X
)	B-X

Primary	O
central	O
nervous	O
system	O
lymphoma	O
(	O
PCNSL	O
)	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
among	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-infected	O
individuals	O
.	O

The	O
precise	O
histogenetic	O
derivation	O
and	O
the	O
molecular	O
pathogenesis	O
of	O
PCNSL	O
is	O
poorly	O
understood	O
.	O
<EOS>	B-X
The	B-X
precise	B-X
histogenetic	B-X
derivation	B-X
and	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
PCNSL	B-X
is	B-X
poorly	B-X
understood	B-X
<EOS>	B-X
These	B-X
data	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
pathogenesis	B-X
and	B-X
histogenesis	B-X
of	B-X
PCNSL	B-X
and	B-X
may	B-X
be	B-X
helpful	B-X
to	B-X
segregate	B-X
distinct	B-X
biologic	B-X
and	B-X
prognostic	B-X
categories	B-X
of	B-X
these	B-X
lymphomas	B-X
<EOS>	B-X
The	B-X
molecular	B-X
and	B-X
phenotypic	B-X
profile	B-X
of	B-X
primary	B-X
central	B-X
nervous	B-X
system	B-X
lymphoma	B-X
identifies	B-X
distinct	B-X
categories	B-X
of	B-X
the	B-X
disease	B-X
and	B-X
is	B-X
consistent	B-X
with	B-X
histogenetic	B-X
derivation	B-X
from	B-X
germinal	B-X
center	B-X
-	B-X
related	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
PCNSL	B-X
may	B-X
be	B-X
frequently	B-X
related	B-X
to	B-X
GC	B-X
B	B-X
cells	B-X
and	B-X
may	B-X
be	B-X
segregated	B-X
into	B-X
two	B-X
major	B-X
biologic	B-X
categories	B-X
based	B-X
on	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
,	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
BCL	B-X
-	B-X
2	B-X

In	O
an	O
attempt	O
to	O
clarify	O
the	O
histogenesis	O
and	O
pathogenesis	O
of	O
these	O
lymphomas	O
,	O
49	O
PCNSL	O
(	O
26	O
acquired	O
immunodeficiency	O
syndrome	O
[	O
AIDS	O
]	O
-related	O
and	O
23	O
AIDS-unrelated	O
)	O
were	O
analyzed	O
for	O
multiple	O
biologic	O
markers	O
,	O
which	O
are	O
known	O
to	O
bear	O
histogenetic	O
and	O
pathogenetic	O
significance	O
for	O
mature	O
B-cell	O
neoplasms	O
.	O

PCNSL	O
associated	O
frequently	O
(	O
50.0	O
%	O
)	O
with	O
mutations	O
of	O
BCL-6	B-DNA
5	I-DNA
'	I-DNA
noncoding	I-DNA
regions	I-DNA
,	O
which	O
are	O
regarded	O
as	O
a	O
marker	O
of	O
B-cell	O
transition	O
through	O
the	O
germinal	O
center	O
(	O
GC	O
)	O
.	O
<EOS>	B-X
0	B-X
%	B-X
)	B-X
with	B-X
mutations	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
5	B-X
'	B-X
noncoding	B-X
regions	B-X
,	B-X
which	B-X
are	B-X
regarded	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
transition	B-X
through	B-X
the	B-X
germinal	B-X
center	B-X
(	B-X
GC	B-X
)	B-X
<EOS>	B-X
The	B-X
molecular	B-X
and	B-X
phenotypic	B-X
profile	B-X
of	B-X
primary	B-X
central	B-X
nervous	B-X
system	B-X
lymphoma	B-X
identifies	B-X
distinct	B-X
categories	B-X
of	B-X
the	B-X
disease	B-X
and	B-X
is	B-X
consistent	B-X
with	B-X
histogenetic	B-X
derivation	B-X
from	B-X
germinal	B-X
center	B-X
-	B-X
related	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
clarify	B-X
the	B-X
histogenesis	B-X
and	B-X
pathogenesis	B-X
of	B-X
these	B-X
lymphomas	B-X
,	B-X
49	B-X
PCNSL	B-X
(	B-X
26	B-X
acquired	B-X
immunodeficiency	B-X
syndrome	B-X
[	B-X
AIDS	B-X
]	B-X
	B-X
-	B-X
related	B-X
and	B-X
23	B-X
AIDS	B-X
-	B-X
unrelated	B-X
)	B-X
were	B-X
analyzed	B-X
for	B-X
multiple	B-X
biologic	B-X
markers	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
bear	B-X
histogenetic	B-X
and	B-X
pathogenetic	B-X
significance	B-X
for	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
neoplasms	B-X
<EOS>	B-X
All	B-X
but	B-X
one	B-X
PCNSL	B-X
expressed	B-X
hMSH2	B-X
,	B-X
which	B-X
among	B-X
mature	B-X
B	B-X
cells	B-X
selectively	B-X
stains	B-X
GC	B-X
B	B-X
cells	B-X

Expression	O
of	O
BCL-6	B-protein
protein	I-protein
,	O
which	O
is	O
restricted	O
to	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
throughout	O
physiologic	O
B-cell	O
maturation	O
,	O
was	O
detected	O
in	O
100	O
%	O
AIDS-unrelated	O
PCNSL	O
and	O
in	O
56.2	O
%	O
AIDS-related	O
cases	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
,	B-X
which	B-X
is	B-X
restricted	B-X
to	B-X
GC	B-X
B	B-X
cells	B-X
throughout	B-X
physiologic	B-X
B	B-X
-	B-X
cell	B-X
maturation	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
AIDS	B-X
-	B-X
unrelated	B-X
PCNSL	B-X
and	B-X
in	B-X
56	B-X
<EOS>	B-X
The	B-X
molecular	B-X
and	B-X
phenotypic	B-X
profile	B-X
of	B-X
primary	B-X
central	B-X
nervous	B-X
system	B-X
lymphoma	B-X
identifies	B-X
distinct	B-X
categories	B-X
of	B-X
the	B-X
disease	B-X
and	B-X
is	B-X
consistent	B-X
with	B-X
histogenetic	B-X
derivation	B-X
from	B-X
germinal	B-X
center	B-X
-	B-X
related	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
All	B-X
but	B-X
one	B-X
PCNSL	B-X
expressed	B-X
hMSH2	B-X
,	B-X
which	B-X
among	B-X
mature	B-X
B	B-X
cells	B-X
selectively	B-X
stains	B-X
GC	B-X
B	B-X
cells	B-X
<EOS>	B-X
The	B-X
precise	B-X
histogenetic	B-X
derivation	B-X
and	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
PCNSL	B-X
is	B-X
poorly	B-X
understood	B-X

Notably	O
,	O
among	O
AIDS-related	O
PCNSL	O
,	O
expression	O
of	O
BCL-6	B-protein
was	O
mutually	O
exclusive	O
with	O
expression	O
of	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
-encoded	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
(	I-protein
LMP	I-protein
)	I-protein
-1	I-protein
and	O
,	O
with	O
few	O
exceptions	O
,	O
also	O
of	O
BCL-2	B-protein
.	O
<EOS>	B-X
Notably	B-X
,	B-X
among	B-X
AIDS	B-X
-	B-X
related	B-X
PCNSL	B-X
,	B-X
expression	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
was	B-X
mutually	B-X
exclusive	B-X
with	B-X
expression	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
	B-X
-	B-X
encoded	B-X
latent	B-X
membrane	B-X
protein	B-X
(	B-X
LMP	B-X
)	B-X
	B-X
-	B-X
1	B-X
and	B-X
,	B-X
with	B-X
few	B-X
exceptions	B-X
,	B-X
also	B-X
of	B-X
BCL	B-X
-	B-X
2	B-X
<EOS>	B-X
0	B-X
%	B-X
)	B-X
with	B-X
mutations	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
5	B-X
'	B-X
noncoding	B-X
regions	B-X
,	B-X
which	B-X
are	B-X
regarded	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
transition	B-X
through	B-X
the	B-X
germinal	B-X
center	B-X
(	B-X
GC	B-X
)	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
PCNSL	B-X
may	B-X
be	B-X
frequently	B-X
related	B-X
to	B-X
GC	B-X
B	B-X
cells	B-X
and	B-X
may	B-X
be	B-X
segregated	B-X
into	B-X
two	B-X
major	B-X
biologic	B-X
categories	B-X
based	B-X
on	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
,	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
BCL	B-X
-	B-X
2	B-X
<EOS>	B-X
All	B-X
but	B-X
one	B-X
PCNSL	B-X
expressed	B-X
hMSH2	B-X
,	B-X
which	B-X
among	B-X
mature	B-X
B	B-X
cells	B-X
selectively	B-X
stains	B-X
GC	B-X
B	B-X
cells	B-X

All	O
but	O
one	O
PCNSL	O
expressed	O
hMSH2	O
,	O
which	O
among	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
selectively	O
stains	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
All	B-X
but	B-X
one	B-X
PCNSL	B-X
expressed	B-X
hMSH2	B-X
,	B-X
which	B-X
among	B-X
mature	B-X
B	B-X
cells	B-X
selectively	B-X
stains	B-X
GC	B-X
B	B-X
cells	B-X
<EOS>	B-X
0	B-X
%	B-X
)	B-X
with	B-X
mutations	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
5	B-X
'	B-X
noncoding	B-X
regions	B-X
,	B-X
which	B-X
are	B-X
regarded	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
transition	B-X
through	B-X
the	B-X
germinal	B-X
center	B-X
(	B-X
GC	B-X
)	B-X
<EOS>	B-X
Notably	B-X
,	B-X
among	B-X
AIDS	B-X
-	B-X
related	B-X
PCNSL	B-X
,	B-X
expression	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
was	B-X
mutually	B-X
exclusive	B-X
with	B-X
expression	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
	B-X
-	B-X
encoded	B-X
latent	B-X
membrane	B-X
protein	B-X
(	B-X
LMP	B-X
)	B-X
	B-X
-	B-X
1	B-X
and	B-X
,	B-X
with	B-X
few	B-X
exceptions	B-X
,	B-X
also	B-X
of	B-X
BCL	B-X
-	B-X
2	B-X
<EOS>	B-X
Expression	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
,	B-X
which	B-X
is	B-X
restricted	B-X
to	B-X
GC	B-X
B	B-X
cells	B-X
throughout	B-X
physiologic	B-X
B	B-X
-	B-X
cell	B-X
maturation	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
AIDS	B-X
-	B-X
unrelated	B-X
PCNSL	B-X
and	B-X
in	B-X
56	B-X

These	O
data	O
suggest	O
that	O
PCNSL	O
may	O
be	O
frequently	O
related	O
to	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
may	O
be	O
segregated	O
into	O
two	O
major	O
biologic	O
categories	O
based	O
on	O
the	O
expression	O
pattern	O
of	O
BCL-6	B-protein
,	O
LMP-1	B-protein
,	O
and	O
BCL-2	B-protein
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
PCNSL	B-X
may	B-X
be	B-X
frequently	B-X
related	B-X
to	B-X
GC	B-X
B	B-X
cells	B-X
and	B-X
may	B-X
be	B-X
segregated	B-X
into	B-X
two	B-X
major	B-X
biologic	B-X
categories	B-X
based	B-X
on	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
,	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
BCL	B-X
-	B-X
2	B-X
<EOS>	B-X
These	B-X
data	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
pathogenesis	B-X
and	B-X
histogenesis	B-X
of	B-X
PCNSL	B-X
and	B-X
may	B-X
be	B-X
helpful	B-X
to	B-X
segregate	B-X
distinct	B-X
biologic	B-X
and	B-X
prognostic	B-X
categories	B-X
of	B-X
these	B-X
lymphomas	B-X
<EOS>	B-X
Expression	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
,	B-X
which	B-X
is	B-X
restricted	B-X
to	B-X
GC	B-X
B	B-X
cells	B-X
throughout	B-X
physiologic	B-X
B	B-X
-	B-X
cell	B-X
maturation	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
100	B-X
%	B-X
AIDS	B-X
-	B-X
unrelated	B-X
PCNSL	B-X
and	B-X
in	B-X
56	B-X
<EOS>	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
clarify	B-X
the	B-X
histogenesis	B-X
and	B-X
pathogenesis	B-X
of	B-X
these	B-X
lymphomas	B-X
,	B-X
49	B-X
PCNSL	B-X
(	B-X
26	B-X
acquired	B-X
immunodeficiency	B-X
syndrome	B-X
[	B-X
AIDS	B-X
]	B-X
	B-X
-	B-X
related	B-X
and	B-X
23	B-X
AIDS	B-X
-	B-X
unrelated	B-X
)	B-X
were	B-X
analyzed	B-X
for	B-X
multiple	B-X
biologic	B-X
markers	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
bear	B-X
histogenetic	B-X
and	B-X
pathogenetic	B-X
significance	B-X
for	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
neoplasms	B-X

BCL-6	B-protein
(	O
+	O
)	O
/	O
LMP-1	B-protein
(	O
-	O
)	O
/	O
BCL-2	B-protein
(	O
-	O
)	O
PCNSL	O
occur	O
both	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
HIV	O
infection	O
and	O
consistently	O
display	O
a	O
large	O
noncleaved	O
cell	O
morphology	O
.	O
<EOS>	B-X
BCL	B-X
-	B-X
6	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
LMP	B-X
-	B-X
1	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
	B-X
/	B-X
BCL	B-X
-	B-X
2	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
PCNSL	B-X
occur	B-X
both	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
HIV	B-X
infection	B-X
and	B-X
consistently	B-X
display	B-X
a	B-X
large	B-X
noncleaved	B-X
cell	B-X
morphology	B-X
<EOS>	B-X
Conversely	B-X
,	B-X
BCL	B-X
-	B-X
6	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
	B-X
/	B-X
LMP	B-X
-	B-X
1	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
BCL	B-X
-	B-X
2	B-X
(	B-X
+	B-X
)	B-X
PCNSL	B-X
are	B-X
restricted	B-X
to	B-X
HIV	B-X
-	B-X
infected	B-X
hosts	B-X
and	B-X
are	B-X
represented	B-X
by	B-X
lymphomas	B-X
with	B-X
immunoblastic	B-X
features	B-X
<EOS>	B-X
The	B-X
molecular	B-X
and	B-X
phenotypic	B-X
profile	B-X
of	B-X
primary	B-X
central	B-X
nervous	B-X
system	B-X
lymphoma	B-X
identifies	B-X
distinct	B-X
categories	B-X
of	B-X
the	B-X
disease	B-X
and	B-X
is	B-X
consistent	B-X
with	B-X
histogenetic	B-X
derivation	B-X
from	B-X
germinal	B-X
center	B-X
-	B-X
related	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
0	B-X
%	B-X
)	B-X
with	B-X
mutations	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
5	B-X
'	B-X
noncoding	B-X
regions	B-X
,	B-X
which	B-X
are	B-X
regarded	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
transition	B-X
through	B-X
the	B-X
germinal	B-X
center	B-X
(	B-X
GC	B-X
)	B-X

Conversely	O
,	O
BCL-6	B-protein
(	O
-	O
)	O
/	O
LMP-1	B-protein
(	O
+	O
)	O
/	O
BCL-2	B-protein
(	O
+	O
)	O
PCNSL	O
are	O
restricted	O
to	O
HIV-infected	O
hosts	O
and	O
are	O
represented	O
by	O
lymphomas	O
with	O
immunoblastic	O
features	O
.	O
<EOS>	B-X
Conversely	B-X
,	B-X
BCL	B-X
-	B-X
6	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
	B-X
/	B-X
LMP	B-X
-	B-X
1	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
BCL	B-X
-	B-X
2	B-X
(	B-X
+	B-X
)	B-X
PCNSL	B-X
are	B-X
restricted	B-X
to	B-X
HIV	B-X
-	B-X
infected	B-X
hosts	B-X
and	B-X
are	B-X
represented	B-X
by	B-X
lymphomas	B-X
with	B-X
immunoblastic	B-X
features	B-X
<EOS>	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
clarify	B-X
the	B-X
histogenesis	B-X
and	B-X
pathogenesis	B-X
of	B-X
these	B-X
lymphomas	B-X
,	B-X
49	B-X
PCNSL	B-X
(	B-X
26	B-X
acquired	B-X
immunodeficiency	B-X
syndrome	B-X
[	B-X
AIDS	B-X
]	B-X
	B-X
-	B-X
related	B-X
and	B-X
23	B-X
AIDS	B-X
-	B-X
unrelated	B-X
)	B-X
were	B-X
analyzed	B-X
for	B-X
multiple	B-X
biologic	B-X
markers	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
bear	B-X
histogenetic	B-X
and	B-X
pathogenetic	B-X
significance	B-X
for	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
neoplasms	B-X
<EOS>	B-X
Notably	B-X
,	B-X
among	B-X
AIDS	B-X
-	B-X
related	B-X
PCNSL	B-X
,	B-X
expression	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
was	B-X
mutually	B-X
exclusive	B-X
with	B-X
expression	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
	B-X
-	B-X
encoded	B-X
latent	B-X
membrane	B-X
protein	B-X
(	B-X
LMP	B-X
)	B-X
	B-X
-	B-X
1	B-X
and	B-X
,	B-X
with	B-X
few	B-X
exceptions	B-X
,	B-X
also	B-X
of	B-X
BCL	B-X
-	B-X
2	B-X
<EOS>	B-X
0	B-X
%	B-X
)	B-X
with	B-X
mutations	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
5	B-X
'	B-X
noncoding	B-X
regions	B-X
,	B-X
which	B-X
are	B-X
regarded	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
transition	B-X
through	B-X
the	B-X
germinal	B-X
center	B-X
(	B-X
GC	B-X
)	B-X

These	O
data	O
are	O
relevant	O
for	O
the	O
pathogenesis	O
and	O
histogenesis	O
of	O
PCNSL	O
and	O
may	O
be	O
helpful	O
to	O
segregate	O
distinct	O
biologic	O
and	O
prognostic	O
categories	O
of	O
these	O
lymphomas	O
.	O
<EOS>	B-X
These	B-X
data	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
pathogenesis	B-X
and	B-X
histogenesis	B-X
of	B-X
PCNSL	B-X
and	B-X
may	B-X
be	B-X
helpful	B-X
to	B-X
segregate	B-X
distinct	B-X
biologic	B-X
and	B-X
prognostic	B-X
categories	B-X
of	B-X
these	B-X
lymphomas	B-X
<EOS>	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
clarify	B-X
the	B-X
histogenesis	B-X
and	B-X
pathogenesis	B-X
of	B-X
these	B-X
lymphomas	B-X
,	B-X
49	B-X
PCNSL	B-X
(	B-X
26	B-X
acquired	B-X
immunodeficiency	B-X
syndrome	B-X
[	B-X
AIDS	B-X
]	B-X
	B-X
-	B-X
related	B-X
and	B-X
23	B-X
AIDS	B-X
-	B-X
unrelated	B-X
)	B-X
were	B-X
analyzed	B-X
for	B-X
multiple	B-X
biologic	B-X
markers	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
bear	B-X
histogenetic	B-X
and	B-X
pathogenetic	B-X
significance	B-X
for	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
neoplasms	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
PCNSL	B-X
may	B-X
be	B-X
frequently	B-X
related	B-X
to	B-X
GC	B-X
B	B-X
cells	B-X
and	B-X
may	B-X
be	B-X
segregated	B-X
into	B-X
two	B-X
major	B-X
biologic	B-X
categories	B-X
based	B-X
on	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
,	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
BCL	B-X
-	B-X
2	B-X
<EOS>	B-X
The	B-X
precise	B-X
histogenetic	B-X
derivation	B-X
and	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
PCNSL	B-X
is	B-X
poorly	B-X
understood	B-X

Antioxidant	O
regulation	O
of	O
phorbol	O
ester-induced	O
adhesion	O
of	O
human	B-cell_line
Jurkat	I-cell_line
T-cells	I-cell_line
to	O
endothelial	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Antioxidant	B-X
regulation	B-X
of	B-X
phorbol	B-X
ester	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
endothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
clinically	B-X
safe	B-X
antioxidants	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion	B-X
molecule	B-X
expression	B-X
in	B-X
human	B-X
endothelial	B-X
cells	B-X
(	B-X
ECV	B-X
)	B-X
,	B-X
and	B-X
adherence	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
to	B-X
ECV	B-X
cells	B-X
were	B-X
investigated	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PMA	B-X
-	B-X
induced	B-X
ICAM	B-X
-	B-X
1	B-X
and	B-X
VCAM	B-X
-	B-X
1	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
ECV	B-X
cells	B-X
by	B-X
alpha	B-X
-	B-X
lipoate	B-X
was	B-X
dose	B-X
dependent	B-X
(	B-X
50	B-X
-	B-X
250	B-X
microM	B-X
)	B-X
<EOS>	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
by	B-X
post	B-X
-	B-X
transcriptional	B-X
stabilization	B-X
of	B-X
adhesion	B-X
molecule	B-X
mRNA	B-X

Regulation	O
of	O
adhesion	O
molecule	O
expression	O
and	O
function	O
by	O
reactive	O
oxygen	O
species	O
via	O
specific	O
redox	O
sensitive	O
mechanisms	O
have	O
been	O
reported	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
function	B-X
by	B-X
reactive	B-X
oxygen	B-X
species	B-X
via	B-X
specific	B-X
redox	B-X
sensitive	B-X
mechanisms	B-X
have	B-X
been	B-X
reported	B-X
<EOS>	B-X
The	B-X
regulation	B-X
of	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
function	B-X
by	B-X
low	B-X
concentration	B-X
of	B-X
antioxidants	B-X
investigated	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
NF	B-X
-	B-X
kappaB	B-X
regulated	B-X
or	B-X
transcription	B-X
dependent	B-X
because	B-X
no	B-X
change	B-X
in	B-X
the	B-X
mRNA	B-X
response	B-X
was	B-X
observed	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cell	B-X
-	B-X
cell	B-X
adhesion	B-X
was	B-X
more	B-X
pronounced	B-X
when	B-X
a	B-X
combination	B-X
of	B-X
antioxidants	B-X
,	B-X
alpha	B-X
-	B-X
lipoate	B-X
and	B-X
alpha	B-X
-	B-X
tocopherol	B-X
,	B-X
were	B-X
used	B-X
compared	B-X
to	B-X
the	B-X
use	B-X
of	B-X
either	B-X
of	B-X
these	B-X
antioxidant	B-X
alone	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
clinically	B-X
safe	B-X
antioxidants	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion	B-X
molecule	B-X
expression	B-X
in	B-X
human	B-X
endothelial	B-X
cells	B-X
(	B-X
ECV	B-X
)	B-X
,	B-X
and	B-X
adherence	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
to	B-X
ECV	B-X
cells	B-X
were	B-X
investigated	B-X

The	O
effects	O
of	O
clinically	O
safe	O
antioxidants	O
in	O
the	O
regulation	O
of	O
adhesion	O
molecule	O
expression	O
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
ECV	O
)	O
,	O
and	O
adherence	O
of	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
to	O
ECV	B-cell_type
cells	I-cell_type
were	O
investigated	O
.	O

The	O
thiol	O
antioxidant	O
,	O
alpha-lipoate	O
,	O
at	O
clinically	O
relevant	O
doses	O
down-regulated	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
adhesion	O
molecule	O
expression	O
and	O
cell-cell	O
adhesion	O
.	O
<EOS>	B-X
The	B-X
thiol	B-X
antioxidant	B-X
,	B-X
alpha	B-X
-	B-X
lipoate	B-X
,	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
down	B-X
-	B-X
regulated	B-X
phorbol	B-X
12	B-X
-	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cell	B-X
-	B-X
cell	B-X
adhesion	B-X
<EOS>	B-X
Antioxidant	B-X
regulation	B-X
of	B-X
phorbol	B-X
ester	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
endothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Alpha	B-X
-	B-X
lipoate	B-X
(	B-X
100	B-X
or	B-X
250	B-X
microM	B-X
)	B-X
treatment	B-X
decreased	B-X
PMA	B-X
-	B-X
induced	B-X
generation	B-X
of	B-X
intracellular	B-X
oxidants	B-X
<EOS>	B-X
Oxidants	B-X
are	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
adhesion	B-X
processes	B-X

Inhibition	O
of	O
PMA-induced	O
ICAM-1	O
and	O
VCAM-1	O
expression	O
as	O
well	O
as	O
PMA-induced	O
adhesion	O
of	O
Jurkat	B-cell_line
T-cells	I-cell_line
to	O
ECV	B-cell_type
cells	I-cell_type
by	O
alpha-lipoate	O
was	O
dose	O
dependent	O
(	O
50-250	O
microM	O
)	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
PMA	B-X
-	B-X
induced	B-X
ICAM	B-X
-	B-X
1	B-X
and	B-X
VCAM	B-X
-	B-X
1	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
ECV	B-X
cells	B-X
by	B-X
alpha	B-X
-	B-X
lipoate	B-X
was	B-X
dose	B-X
dependent	B-X
(	B-X
50	B-X
-	B-X
250	B-X
microM	B-X
)	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cell	B-X
-	B-X
cell	B-X
adhesion	B-X
was	B-X
more	B-X
pronounced	B-X
when	B-X
a	B-X
combination	B-X
of	B-X
antioxidants	B-X
,	B-X
alpha	B-X
-	B-X
lipoate	B-X
and	B-X
alpha	B-X
-	B-X
tocopherol	B-X
,	B-X
were	B-X
used	B-X
compared	B-X
to	B-X
the	B-X
use	B-X
of	B-X
either	B-X
of	B-X
these	B-X
antioxidant	B-X
alone	B-X
<EOS>	B-X
Antioxidant	B-X
regulation	B-X
of	B-X
phorbol	B-X
ester	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
endothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
by	B-X
post	B-X
-	B-X
transcriptional	B-X
stabilization	B-X
of	B-X
adhesion	B-X
molecule	B-X
mRNA	B-X

The	O
effect	O
was	O
significant	O
for	O
ICAM-1	B-protein
(	O
p	O
<	O
.01	O
)	O
and	O
VCAM-1	B-protein
(	O
p	O
<	O
.01	O
)	O
expression	O
in	O
cells	O
pretreated	O
with	O
100	O
microM	O
alpha-lipoate	O
compared	O
to	O
PMA-activated	B-cell_type
untreated	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
01	B-X
)	B-X
expression	B-X
in	B-X
cells	B-X
pretreated	B-X
with	B-X
100	B-X
microM	B-X
alpha	B-X
-	B-X
lipoate	B-X
compared	B-X
to	B-X
PMA	B-X
-	B-X
activated	B-X
untreated	B-X
cells	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
clinically	B-X
safe	B-X
antioxidants	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion	B-X
molecule	B-X
expression	B-X
in	B-X
human	B-X
endothelial	B-X
cells	B-X
(	B-X
ECV	B-X
)	B-X
,	B-X
and	B-X
adherence	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
to	B-X
ECV	B-X
cells	B-X
were	B-X
investigated	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cell	B-X
-	B-X
cell	B-X
adhesion	B-X
was	B-X
more	B-X
pronounced	B-X
when	B-X
a	B-X
combination	B-X
of	B-X
antioxidants	B-X
,	B-X
alpha	B-X
-	B-X
lipoate	B-X
and	B-X
alpha	B-X
-	B-X
tocopherol	B-X
,	B-X
were	B-X
used	B-X
compared	B-X
to	B-X
the	B-X
use	B-X
of	B-X
either	B-X
of	B-X
these	B-X
antioxidant	B-X
alone	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PMA	B-X
-	B-X
induced	B-X
ICAM	B-X
-	B-X
1	B-X
and	B-X
VCAM	B-X
-	B-X
1	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
ECV	B-X
cells	B-X
by	B-X
alpha	B-X
-	B-X
lipoate	B-X
was	B-X
dose	B-X
dependent	B-X
(	B-X
50	B-X
-	B-X
250	B-X
microM	B-X
)	B-X

Inhibition	O
of	O
PMA-induced	O
adhesion	O
molecule	O
expression	O
and	O
cell-cell	O
adhesion	O
was	O
more	O
pronounced	O
when	O
a	O
combination	O
of	O
antioxidants	O
,	O
alpha-lipoate	O
and	O
alpha-tocopherol	O
,	O
were	O
used	O
compared	O
to	O
the	O
use	O
of	O
either	O
of	O
these	O
antioxidant	O
alone	O
.	O

The	O
regulation	O
of	O
adhesion	O
molecule	O
expression	O
and	O
function	O
by	O
low	O
concentration	O
of	O
antioxidants	O
investigated	O
does	O
not	O
appear	O
to	O
be	O
NF-kappaB	B-protein
regulated	O
or	O
transcription	O
dependent	O
because	O
no	O
change	O
in	O
the	O
mRNA	O
response	O
was	O
observed	O
.	O
<EOS>	B-X
The	B-X
temporal	B-X
patterns	B-X
of	B-X
target	B-X
gene	B-X
expression	B-X
were	B-X
highly	B-X
variable	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
mRNA	B-X
transcripts	B-X
detected	B-X
was	B-X
largely	B-X
dependent	B-X
on	B-X
the	B-X
timing	B-X
of	B-X
muscle	B-X
sampling	B-X
<EOS>	B-X
N6	B-X
-	B-X
methyladenosine	B-X
modification	B-X
(	B-X
m6A	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
abundant	B-X
cellular	B-X
RNA	B-X
modifications	B-X
,	B-X
regulates	B-X
key	B-X
processes	B-X
in	B-X
RNA	B-X
metabolism	B-X
during	B-X
a	B-X
stress	B-X
response	B-X
<EOS>	B-X
Inhibin	B-X
suppresses	B-X
the	B-X
pituitary	B-X
secretion	B-X
of	B-X
follicle‑stimulating	B-X
hormone	B-X
and	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
act	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
in	B-X
the	B-X
gonad	B-X
in	B-X
mice	B-X
<EOS>	B-X
Whilst	B-X
regulation	B-X
of	B-X
GLUT	B-X
transcripts	B-X
was	B-X
cell	B-X
line	B-X
and	B-X
inhibitor	B-X
specific	B-X
,	B-X
GLUT3	B-X
was	B-X
consistently	B-X
upregulated	B-X
in	B-X
actively	B-X
proliferating	B-X
OSCC	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
not	B-X
in	B-X
OKF6	B-X
,	B-X
regardless	B-X
of	B-X
the	B-X
inhibitor	B-X
used	B-X
,	B-X
suggesting	B-X
that	B-X
modulation	B-X
of	B-X
this	B-X
transporter	B-X
may	B-X
act	B-X
as	B-X
one	B-X
of	B-X
the	B-X
primary	B-X
compensation	B-X
mechanisms	B-X
for	B-X
OSCC	B-X
cells	B-X
upon	B-X
inhibition	B-X
of	B-X
glucose	B-X
uptake	B-X

Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
has	O
been	O
suggested	O
to	O
regulate	O
PMA-induced	O
adhesion	O
molecule	O
expression	O
by	O
post-transcriptional	O
stabilization	O
of	O
adhesion	B-RNA
molecule	I-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
by	B-X
post	B-X
-	B-X
transcriptional	B-X
stabilization	B-X
of	B-X
adhesion	B-X
molecule	B-X
mRNA	B-X
<EOS>	B-X
Antioxidant	B-X
regulation	B-X
of	B-X
phorbol	B-X
ester	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
endothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
clinically	B-X
safe	B-X
antioxidants	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion	B-X
molecule	B-X
expression	B-X
in	B-X
human	B-X
endothelial	B-X
cells	B-X
(	B-X
ECV	B-X
)	B-X
,	B-X
and	B-X
adherence	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
to	B-X
ECV	B-X
cells	B-X
were	B-X
investigated	B-X
<EOS>	B-X
Alpha	B-X
-	B-X
lipoate	B-X
(	B-X
100	B-X
or	B-X
250	B-X
microM	B-X
)	B-X
treatment	B-X
decreased	B-X
PMA	B-X
-	B-X
induced	B-X
generation	B-X
of	B-X
intracellular	B-X
oxidants	B-X

Alpha-lipoate	O
pretreatment	O
did	O
not	O
influence	O
the	O
response	O
of	O
PKC	B-protein
activity	O
to	O
PMA	O
.	O
<EOS>	B-X
Alpha	B-X
-	B-X
lipoic	B-X
acid	B-X
protects	B-X
rat	B-X
cortical	B-X
neurons	B-X
against	B-X
cell	B-X
death	B-X
induced	B-X
by	B-X
amyloid	B-X
and	B-X
hydrogen	B-X
peroxide	B-X
through	B-X
the	B-X
Akt	B-X
signalling	B-X
pathway	B-X
.	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
treatment	B-X
with	B-X
LA	B-X
protected	B-X
cortical	B-X
neurons	B-X
against	B-X
cytotoxicity	B-X
induced	B-X
by	B-X
Abeta	B-X
or	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
antioxidant	B-X
alpha	B-X
-	B-X
lipoate	B-X
,	B-X
which	B-X
is	B-X
able	B-X
to	B-X
cross	B-X
the	B-X
blood	B-X
-	B-X
brain	B-X
barrier	B-X
,	B-X
would	B-X
seem	B-X
an	B-X
ideal	B-X
substance	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
AD	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
neuroprotective	B-X
effects	B-X
of	B-X
the	B-X
antioxidant	B-X
LA	B-X
are	B-X
partly	B-X
mediated	B-X
through	B-X
activation	B-X
of	B-X
the	B-X
PKB	B-X
/	B-X
Akt	B-X
signaling	B-X
pathway	B-X

Oxidants	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
adhesion	O
processes	O
.	O
<EOS>	B-X
Rac1	B-X
and	B-X
RhoA	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
cytoskeleton	B-X
assembly	B-X
process	B-X
<EOS>	B-X
Functional	B-X
investigations	B-X
displayed	B-X
that	B-X
miRNAs	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
control	B-X
of	B-X
apoptosis	B-X
through	B-X
disruption	B-X
of	B-X
cell	B-X
adhesion	B-X
in	B-X
response	B-X
to	B-X
cytotoxicity	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
lncRNAs	B-X
involved	B-X
in	B-X
cold	B-X
acclimation	B-X
of	B-X
zebrafish	B-X
ZF4	B-X
cells	B-X
.	B-X
<EOS>	B-X
Bioinformatics	B-X
analysis	B-X
showed	B-X
that	B-X
proteins	B-X
involved	B-X
in	B-X
sperm	B-X
-	B-X
egg	B-X
interaction	B-X
and	B-X
fertilization	B-X
processes	B-X
were	B-X
significantly	B-X
down	B-X
-	B-X
regulated	B-X

Treatment	O
of	O
ECV	B-cell_type
cells	I-cell_type
with	O
PMA	O
induced	O
generation	O
of	O
intracellular	O
oxidants	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
ECV	B-X
cells	B-X
with	B-X
PMA	B-X
induced	B-X
generation	B-X
of	B-X
intracellular	B-X
oxidants	B-X
<EOS>	B-X
Alpha	B-X
-	B-X
lipoate	B-X
(	B-X
100	B-X
or	B-X
250	B-X
microM	B-X
)	B-X
treatment	B-X
decreased	B-X
PMA	B-X
-	B-X
induced	B-X
generation	B-X
of	B-X
intracellular	B-X
oxidants	B-X
<EOS>	B-X
Antioxidant	B-X
regulation	B-X
of	B-X
phorbol	B-X
ester	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
endothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
by	B-X
post	B-X
-	B-X
transcriptional	B-X
stabilization	B-X
of	B-X
adhesion	B-X
molecule	B-X
mRNA	B-X

Alpha-lipoate	O
(	O
100	O
or	O
250	O
microM	O
)	O
treatment	O
decreased	O
PMA-induced	O
generation	O
of	O
intracellular	O
oxidants	O
.	O
<EOS>	B-X
Alpha	B-X
-	B-X
lipoate	B-X
(	B-X
100	B-X
or	B-X
250	B-X
microM	B-X
)	B-X
treatment	B-X
decreased	B-X
PMA	B-X
-	B-X
induced	B-X
generation	B-X
of	B-X
intracellular	B-X
oxidants	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
ECV	B-X
cells	B-X
with	B-X
PMA	B-X
induced	B-X
generation	B-X
of	B-X
intracellular	B-X
oxidants	B-X
<EOS>	B-X
Alpha	B-X
-	B-X
lipoate	B-X
pretreatment	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
response	B-X
of	B-X
PKC	B-X
activity	B-X
to	B-X
PMA	B-X
<EOS>	B-X
The	B-X
thiol	B-X
antioxidant	B-X
,	B-X
alpha	B-X
-	B-X
lipoate	B-X
,	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
down	B-X
-	B-X
regulated	B-X
phorbol	B-X
12	B-X
-	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cell	B-X
-	B-X
cell	B-X
adhesion	B-X

The	O
inhibitory	O
effect	O
of	O
low	O
concentration	O
of	O
alpha-lipaote	O
alone	O
or	O
in	O
combination	O
with	O
alpha-tocopherol	O
on	O
agonist-induced	O
adhesion	O
processes	O
observed	O
in	O
this	O
study	O
may	O
be	O
of	O
potential	O
therapeutic	O
value	O
.	O
<EOS>	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
low	B-X
concentration	B-X
of	B-X
alpha	B-X
-	B-X
lipaote	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
alpha	B-X
-	B-X
tocopherol	B-X
on	B-X
agonist	B-X
-	B-X
induced	B-X
adhesion	B-X
processes	B-X
observed	B-X
in	B-X
this	B-X
study	B-X
may	B-X
be	B-X
of	B-X
potential	B-X
therapeutic	B-X
value	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PMA	B-X
-	B-X
induced	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cell	B-X
-	B-X
cell	B-X
adhesion	B-X
was	B-X
more	B-X
pronounced	B-X
when	B-X
a	B-X
combination	B-X
of	B-X
antioxidants	B-X
,	B-X
alpha	B-X
-	B-X
lipoate	B-X
and	B-X
alpha	B-X
-	B-X
tocopherol	B-X
,	B-X
were	B-X
used	B-X
compared	B-X
to	B-X
the	B-X
use	B-X
of	B-X
either	B-X
of	B-X
these	B-X
antioxidant	B-X
alone	B-X
<EOS>	B-X
Antioxidant	B-X
regulation	B-X
of	B-X
phorbol	B-X
ester	B-X
-	B-X
induced	B-X
adhesion	B-X
of	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
to	B-X
endothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
function	B-X
by	B-X
reactive	B-X
oxygen	B-X
species	B-X
via	B-X
specific	B-X
redox	B-X
sensitive	B-X
mechanisms	B-X
have	B-X
been	B-X
reported	B-X

Binding	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
to	O
CD4	B-protein
and	I-protein
CXCR4	I-protein
receptors	I-protein
differentially	O
regulates	O
expression	O
of	O
inflammatory	B-DNA
genes	I-DNA
and	O
activates	O
the	O
MEK	B-protein
/ERK	O
signaling	O
pathway	O
.	O
<EOS>	B-X
Binding	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
to	B-X
CD4	B-X
and	B-X
CXCR4	B-X
receptors	B-X
differentially	B-X
regulates	B-X
expression	B-X
of	B-X
inflammatory	B-X
genes	B-X
and	B-X
activates	B-X
the	B-X
MEK	B-X
/	B-X
ERK	B-X
signaling	B-X
pathway	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
binding	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
virions	B-X
to	B-X
CD4	B-X
receptors	B-X
stimulates	B-X
association	B-X
of	B-X
Lck	B-X
with	B-X
Raf	B-X
-	B-X
1	B-X
and	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
Raf	B-X
-	B-X
1	B-X
kinase	B-X
in	B-X
a	B-X
Ras	B-X
-	B-X
independent	B-X
manner	B-X
<EOS>	B-X
Binding	B-X
of	B-X
the	B-X
natural	B-X
ligand	B-X
stromal	B-X
cell	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
(	B-X
SDF	B-X
-	B-X
1	B-X
)	B-X
to	B-X
CXCR4	B-X
,	B-X
which	B-X
inhibits	B-X
entry	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
tropic	B-X
HIV	B-X
-	B-X
1	B-X
,	B-X
activates	B-X
also	B-X
the	B-X
ERK	B-X
/	B-X
MAP	B-X
kinase	B-X
pathway	B-X
<EOS>	B-X
These	B-X
results	B-X
provide	B-X
firm	B-X
molecular	B-X
evidence	B-X
that	B-X
binding	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
envelope	B-X
glycoproteins	B-X
to	B-X
CD4	B-X
receptor	B-X
initiates	B-X
a	B-X
signaling	B-X
pathway	B-X
(	B-X
s	B-X
)	B-X
independent	B-X
of	B-X
the	B-X
binding	B-X
to	B-X
the	B-X
chemokine	B-X
receptor	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
aberrant	B-X
expression	B-X
of	B-X
inflammatory	B-X
genes	B-X
and	B-X
may	B-X
contribute	B-X
significantly	B-X
to	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
as	B-X
well	B-X
as	B-X
to	B-X
deregulation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X

We	O
have	O
previously	O
shown	O
that	O
binding	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
virions	O
to	O
CD4	B-protein
receptors	I-protein
stimulates	O
association	O
of	O
Lck	B-protein
with	O
Raf-1	B-protein
and	O
results	O
in	O
the	O
activation	O
of	O
Raf-1	B-protein
kinase	O
in	O
a	O
Ras-independent	O
manner	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
both	O
T-cell-tropic	O
and	O
macrophagetropic	O
strains	O
rapidly	O
activate	O
the	O
ERK/mitogen-activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
pathway	O
and	O
the	O
binding	O
of	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
(	O
AP-1	B-protein
,	O
NF-kappaB	B-protein
,	O
and	O
C/EBP	B-protein
)	O
and	O
stimulate	O
expression	O
of	O
cytokine	B-DNA
and	I-DNA
chemokine	I-DNA
genes	I-DNA
.	O

The	O
activation	O
of	O
this	O
signaling	O
pathway	O
requires	O
functional	O
CD4	B-protein
receptors	I-protein
and	O
is	O
independent	O
of	O
binding	O
to	O
CXCR4	B-protein
.	O
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
this	B-X
signaling	B-X
pathway	B-X
requires	B-X
functional	B-X
CD4	B-X
receptors	B-X
and	B-X
is	B-X
independent	B-X
of	B-X
binding	B-X
to	B-X
CXCR4	B-X
<EOS>	B-X
Identification	B-X
of	B-X
CXCR4	B-X
domains	B-X
that	B-X
support	B-X
coreceptor	B-X
and	B-X
chemokine	B-X
receptor	B-X
functions	B-X
.	B-X
<EOS>	B-X
Several	B-X
CXCR4	B-X
mutants	B-X
that	B-X
were	B-X
not	B-X
capable	B-X
of	B-X
binding	B-X
SDF	B-X
-	B-X
1	B-X
or	B-X
signaling	B-X
still	B-X
supported	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
CXCR4	B-X
to	B-X
function	B-X
as	B-X
a	B-X
coreceptor	B-X
is	B-X
independent	B-X
of	B-X
its	B-X
ability	B-X
to	B-X
signal	B-X
<EOS>	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
CXCR4	B-X
required	B-X
the	B-X
Asp	B-X
-	B-X
Arg	B-X
-	B-X
Tyr	B-X
motif	B-X
in	B-X
the	B-X
second	B-X
intracellular	B-X
loop	B-X
of	B-X
CXCR4	B-X
,	B-X
was	B-X
pertussis	B-X
toxin	B-X
sensitive	B-X
,	B-X
and	B-X
did	B-X
not	B-X
require	B-X
the	B-X
distal	B-X
C	B-X
-	B-X
terminal	B-X
tail	B-X
of	B-X
CXCR4	B-X

Binding	O
of	O
the	O
natural	O
ligand	O
stromal	B-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
(	O
SDF-1	B-protein
)	O
to	O
CXCR4	B-protein
,	O
which	O
inhibits	O
entry	O
of	O
T-cell-tropic	O
HIV-1	O
,	O
activates	O
also	O
the	O
ERK/	O
MAP	B-protein
kinase	I-protein
pathway	O
.	O
<EOS>	B-X
Binding	B-X
of	B-X
the	B-X
natural	B-X
ligand	B-X
stromal	B-X
cell	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
(	B-X
SDF	B-X
-	B-X
1	B-X
)	B-X
to	B-X
CXCR4	B-X
,	B-X
which	B-X
inhibits	B-X
entry	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
tropic	B-X
HIV	B-X
-	B-X
1	B-X
,	B-X
activates	B-X
also	B-X
the	B-X
ERK	B-X
/	B-X
MAP	B-X
kinase	B-X
pathway	B-X
<EOS>	B-X
Binding	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
to	B-X
CD4	B-X
and	B-X
CXCR4	B-X
receptors	B-X
differentially	B-X
regulates	B-X
expression	B-X
of	B-X
inflammatory	B-X
genes	B-X
and	B-X
activates	B-X
the	B-X
MEK	B-X
/	B-X
ERK	B-X
signaling	B-X
pathway	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
binding	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
virions	B-X
to	B-X
CD4	B-X
receptors	B-X
stimulates	B-X
association	B-X
of	B-X
Lck	B-X
with	B-X
Raf	B-X
-	B-X
1	B-X
and	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
Raf	B-X
-	B-X
1	B-X
kinase	B-X
in	B-X
a	B-X
Ras	B-X
-	B-X
independent	B-X
manner	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
HIV	B-X
-	B-X
1	B-X
envelope	B-X
glycoproteins	B-X
of	B-X
both	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
tropic	B-X
and	B-X
macrophagetropic	B-X
strains	B-X
rapidly	B-X
activate	B-X
the	B-X
ERK	B-X
/	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinase	B-X
pathway	B-X
and	B-X
the	B-X
binding	B-X
of	B-X
nuclear	B-X
transcription	B-X
factors	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
and	B-X
C	B-X
/	B-X
EBP	B-X
)	B-X
and	B-X
stimulate	B-X
expression	B-X
of	B-X
cytokine	B-X
and	B-X
chemokine	B-X
genes	B-X

However	O
,	O
SDF-1	B-protein
did	O
not	O
affect	O
the	O
CD4-mediated	O
expression	O
of	O
cytokine	B-DNA
and	I-DNA
chemokine	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
However	B-X
,	B-X
CoL1A1	B-X
was	B-X
increased	B-X
significantly	B-X
in	B-X
the	B-X
cryoinjured	B-X
group	B-X
<EOS>	B-X
Here	B-X
we	B-X
mapped	B-X
the	B-X
phosphorylation	B-X
patterns	B-X
and	B-X
determined	B-X
that	B-X
GRK5	B-X
phosphorylation	B-X
of	B-X
ACKR3	B-X
dominates	B-X
β	B-X
-	B-X
arrestin	B-X
recruitment	B-X
and	B-X
chemokine	B-X
scavenging	B-X
over	B-X
GRK2	B-X
<EOS>	B-X
While	B-X
TGM2	B-X
overexpression	B-X
exerts	B-X
the	B-X
opposite	B-X
impact	B-X
on	B-X
cell	B-X
migration	B-X
and	B-X
expression	B-X
levels	B-X
of	B-X
osteoblast	B-X
-	B-X
associated	B-X
genes	B-X
<EOS>	B-X
Structural	B-X
Basis	B-X
of	B-X
the	B-X
Binding	B-X
Mode	B-X
of	B-X
the	B-X
Antineoplastic	B-X
Compound	B-X
Motixafortide	B-X
(	B-X
BL	B-X
-	B-X
8040	B-X
)	B-X
in	B-X
the	B-X
CXCR4	B-X
Chemokine	B-X
Receptor	B-X
.	B-X

These	O
results	O
provide	O
firm	O
molecular	O
evidence	O
that	O
binding	O
of	O
HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
to	O
CD4	B-protein
receptor	I-protein
initiates	O
a	O
signaling	O
pathway	O
(	O
s	O
)	O
independent	O
of	O
the	O
binding	O
to	O
the	O
chemokine	B-protein
receptor	I-protein
that	O
leads	O
to	O
the	O
aberrant	O
expression	O
of	O
inflammatory	B-DNA
genes	I-DNA
and	O
may	O
contribute	O
significantly	O
to	O
HIV-1	O
replication	O
as	O
well	O
as	O
to	O
deregulation	O
of	O
the	O
immune	O
system	O
.	O

Antigen	O
receptor	O
signaling	O
induces	O
MAP	O
kinase-mediated	O
phosphorylation	O
and	O
degradation	O
of	O
the	O
BCL-6	B-protein
transcription	B-protein
factor	I-protein
.	O
<EOS>	B-X
Antigen	B-X
receptor	B-X
signaling	B-X
induces	B-X
MAP	B-X
kinase	B-X
-	B-X
mediated	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
transcription	B-X
factor	B-X
.	B-X
<EOS>	B-X
This	B-X
signaling	B-X
pathway	B-X
may	B-X
be	B-X
crucial	B-X
for	B-X
the	B-X
control	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
and	B-X
antibody	B-X
response	B-X
and	B-X
has	B-X
implications	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
other	B-X
POZ	B-X
/	B-X
zinc	B-X
finger	B-X
transcription	B-X
factors	B-X
in	B-X
other	B-X
tissues	B-X
<EOS>	B-X
Phosphorylation	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
targets	B-X
BCL	B-X
-	B-X
6	B-X
for	B-X
rapid	B-X
degradation	B-X
by	B-X
the	B-X
ubiquitin	B-X
/	B-X
proteasome	B-X
pathway	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
antigen	B-X
receptor	B-X
activation	B-X
leads	B-X
to	B-X
BCL	B-X
-	B-X
6	B-X
phosphorylation	B-X
by	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X

The	O
bcl-6	B-DNA
proto-oncogene	I-DNA
encodes	O
a	O
POZ/zinc	B-protein
finger	I-protein
transcriptional	I-protein
repressor	I-protein
expressed	O
in	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B	I-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
required	O
for	O
GC	O
formation	O
and	O
antibody	O
affinity	O
maturation	O
.	O

Deregulation	O
of	O
bcl-6	B-DNA
expression	O
by	O
chromosomal	O
rearrangements	O
and	O
point	O
mutations	O
of	O
the	O
bcl-6	B-DNA
promoter	I-DNA
region	I-DNA
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
B-cell	O
lymphoma	O
.	O
<EOS>	B-X
Deregulation	B-X
of	B-X
bcl	B-X
-	B-X
6	B-X
expression	B-X
by	B-X
chromosomal	B-X
rearrangements	B-X
and	B-X
point	B-X
mutations	B-X
of	B-X
the	B-X
bcl	B-X
-	B-X
6	B-X
promoter	B-X
region	B-X
are	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
antigen	B-X
receptor	B-X
activation	B-X
leads	B-X
to	B-X
BCL	B-X
-	B-X
6	B-X
phosphorylation	B-X
by	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
<EOS>	B-X
Antigen	B-X
receptor	B-X
signaling	B-X
induces	B-X
MAP	B-X
kinase	B-X
-	B-X
mediated	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
transcription	B-X
factor	B-X
.	B-X
<EOS>	B-X
This	B-X
signaling	B-X
pathway	B-X
may	B-X
be	B-X
crucial	B-X
for	B-X
the	B-X
control	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
and	B-X
antibody	B-X
response	B-X
and	B-X
has	B-X
implications	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
other	B-X
POZ	B-X
/	B-X
zinc	B-X
finger	B-X
transcription	B-X
factors	B-X
in	B-X
other	B-X
tissues	B-X

The	O
signals	O
regulating	O
bcl-6	B-DNA
expression	O
are	O
not	O
known	O
.	O
<EOS>	B-X
Critical	B-X
regulation	B-X
of	B-X
follicular	B-X
helper	B-X
T	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
by	B-X
Gα	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
AGR	B-X
suppressed	B-X
RANKL	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
NFATc1	B-X
<EOS>	B-X
A	B-X
novel	B-X
strategy	B-X
to	B-X
investigate	B-X
the	B-X
factors	B-X
regulating	B-X
the	B-X
Treg	B-X
to	B-X
Tfr	B-X
transition	B-X
during	B-X
acute	B-X
viral	B-X
infection	B-X
.	B-X
<EOS>	B-X
Then	B-X
,	B-X
HTR8	B-X
/	B-X
SVneo	B-X
cells	B-X
were	B-X
used	B-X
to	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
miR	B-X
-	B-X
187	B-X
on	B-X
BCL6	B-X
expression	B-X
and	B-X
biological	B-X
activity	B-X
of	B-X
trophoblasts	B-X

Here	O
we	O
show	O
that	O
antigen	O
receptor	O
activation	O
leads	O
to	O
BCL-6	B-protein
phosphorylation	O
by	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
antigen	B-X
receptor	B-X
activation	B-X
leads	B-X
to	B-X
BCL	B-X
-	B-X
6	B-X
phosphorylation	B-X
by	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
<EOS>	B-X
Phosphorylation	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
targets	B-X
BCL	B-X
-	B-X
6	B-X
for	B-X
rapid	B-X
degradation	B-X
by	B-X
the	B-X
ubiquitin	B-X
/	B-X
proteasome	B-X
pathway	B-X
<EOS>	B-X
Deregulation	B-X
of	B-X
bcl	B-X
-	B-X
6	B-X
expression	B-X
by	B-X
chromosomal	B-X
rearrangements	B-X
and	B-X
point	B-X
mutations	B-X
of	B-X
the	B-X
bcl	B-X
-	B-X
6	B-X
promoter	B-X
region	B-X
are	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
<EOS>	B-X
This	B-X
signaling	B-X
pathway	B-X
may	B-X
be	B-X
crucial	B-X
for	B-X
the	B-X
control	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
and	B-X
antibody	B-X
response	B-X
and	B-X
has	B-X
implications	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
other	B-X
POZ	B-X
/	B-X
zinc	B-X
finger	B-X
transcription	B-X
factors	B-X
in	B-X
other	B-X
tissues	B-X

Phosphorylation	O
,	O
in	O
turn	O
,	O
targets	O
BCL-6	B-protein
for	O
rapid	O
degradation	O
by	O
the	O
ubiquitin	B-protein
/	O
proteasome	B-protein
pathway	O
.	O
<EOS>	B-X
Phosphorylation	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
targets	B-X
BCL	B-X
-	B-X
6	B-X
for	B-X
rapid	B-X
degradation	B-X
by	B-X
the	B-X
ubiquitin	B-X
/	B-X
proteasome	B-X
pathway	B-X
<EOS>	B-X
Antigen	B-X
receptor	B-X
signaling	B-X
induces	B-X
MAP	B-X
kinase	B-X
-	B-X
mediated	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
transcription	B-X
factor	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
BCL	B-X
-	B-X
6	B-X
expression	B-X
is	B-X
directly	B-X
controlled	B-X
by	B-X
the	B-X
antigen	B-X
receptor	B-X
via	B-X
MAPK	B-X
activation	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
antigen	B-X
receptor	B-X
activation	B-X
leads	B-X
to	B-X
BCL	B-X
-	B-X
6	B-X
phosphorylation	B-X
by	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X

These	O
findings	O
indicate	O
that	O
BCL-6	B-protein
expression	O
is	O
directly	O
controlled	O
by	O
the	O
antigen	O
receptor	O
via	O
MAPK	B-protein
activation	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
BCL	B-X
-	B-X
6	B-X
expression	B-X
is	B-X
directly	B-X
controlled	B-X
by	B-X
the	B-X
antigen	B-X
receptor	B-X
via	B-X
MAPK	B-X
activation	B-X
<EOS>	B-X
The	B-X
signals	B-X
regulating	B-X
bcl	B-X
-	B-X
6	B-X
expression	B-X
are	B-X
not	B-X
known	B-X
<EOS>	B-X
Phosphorylation	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
targets	B-X
BCL	B-X
-	B-X
6	B-X
for	B-X
rapid	B-X
degradation	B-X
by	B-X
the	B-X
ubiquitin	B-X
/	B-X
proteasome	B-X
pathway	B-X
<EOS>	B-X
The	B-X
bcl	B-X
-	B-X
6	B-X
proto	B-X
-	B-X
oncogene	B-X
encodes	B-X
a	B-X
POZ	B-X
/	B-X
zinc	B-X
finger	B-X
transcriptional	B-X
repressor	B-X
expressed	B-X
in	B-X
germinal	B-X
center	B-X
(	B-X
GC	B-X
)	B-X
B	B-X
and	B-X
T	B-X
cells	B-X
and	B-X
required	B-X
for	B-X
GC	B-X
formation	B-X
and	B-X
antibody	B-X
affinity	B-X
maturation	B-X

This	O
signaling	O
pathway	O
may	O
be	O
crucial	O
for	O
the	O
control	O
of	O
B-cell	O
differentiation	O
and	O
antibody	O
response	O
and	O
has	O
implications	O
for	O
the	O
regulation	O
of	O
other	O
POZ/zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
other	O
tissues	O
.	O
<EOS>	B-X
This	B-X
signaling	B-X
pathway	B-X
may	B-X
be	B-X
crucial	B-X
for	B-X
the	B-X
control	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
differentiation	B-X
and	B-X
antibody	B-X
response	B-X
and	B-X
has	B-X
implications	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
other	B-X
POZ	B-X
/	B-X
zinc	B-X
finger	B-X
transcription	B-X
factors	B-X
in	B-X
other	B-X
tissues	B-X
<EOS>	B-X
Antigen	B-X
receptor	B-X
signaling	B-X
induces	B-X
MAP	B-X
kinase	B-X
-	B-X
mediated	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
transcription	B-X
factor	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
BCL	B-X
-	B-X
6	B-X
expression	B-X
is	B-X
directly	B-X
controlled	B-X
by	B-X
the	B-X
antigen	B-X
receptor	B-X
via	B-X
MAPK	B-X
activation	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
antigen	B-X
receptor	B-X
activation	B-X
leads	B-X
to	B-X
BCL	B-X
-	B-X
6	B-X
phosphorylation	B-X
by	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X

Glucocorticoid	B-protein
receptors	I-protein
are	O
differentially	O
expressed	O
in	O
the	O
cells	O
and	O
tissues	O
of	O
the	O
immune	O
system	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
are	B-X
differentially	B-X
expressed	B-X
in	B-X
the	B-X
cells	B-X
and	B-X
tissues	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
corticosensitivity	B-X
of	B-X
human	B-X
thymocytes	B-X
at	B-X
discrete	B-X
stages	B-X
of	B-X
intrathymic	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
represses	B-X
proinflammatory	B-X
genes	B-X
at	B-X
distinct	B-X
steps	B-X
of	B-X
the	B-X
transcription	B-X
cycle	B-X
.	B-X
<EOS>	B-X
Using	B-X
this	B-X
technique	B-X
we	B-X
have	B-X
isolated	B-X
several	B-X
differentially	B-X
expressed	B-X
sequence	B-X
tags	B-X
(	B-X
DESTs	B-X
)	B-X
from	B-X
the	B-X
mouse	B-X
thymocyte	B-X
cell	B-X
line	B-X
WEHI	B-X
7	B-X

Cytosolic	B-protein
glucocorticoid	I-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
studies	O
on	O
immune	O
tissues	O
demonstrate	O
that	O
the	O
thymus	O
exhibits	O
three	O
to	O
four	O
times	O
higher	O
levels	O
of	O
GR	B-protein
protein	I-protein
than	O
the	O
spleen	O
.	O

High	O
levels	O
of	O
GR	B-protein
are	O
consistent	O
with	O
the	O
exquisite	O
sensitivity	O
of	O
the	O
thymus	O
to	O
glucocorticoid	O
exposure	O
.	O
<EOS>	B-X
High	B-X
levels	B-X
of	B-X
GR	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
exquisite	B-X
sensitivity	B-X
of	B-X
the	B-X
thymus	B-X
to	B-X
glucocorticoid	B-X
exposure	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
a	B-X
meaningful	B-X
relationship	B-X
between	B-X
receptor	B-X
expression	B-X
and	B-X
known	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
<EOS>	B-X
Cytosolic	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
binding	B-X
studies	B-X
on	B-X
immune	B-X
tissues	B-X
demonstrate	B-X
that	B-X
the	B-X
thymus	B-X
exhibits	B-X
three	B-X
to	B-X
four	B-X
times	B-X
higher	B-X
levels	B-X
of	B-X
GR	B-X
protein	B-X
than	B-X
the	B-X
spleen	B-X
<EOS>	B-X
To	B-X
address	B-X
these	B-X
inconsistencies	B-X
,	B-X
GR	B-X
protein	B-X
was	B-X
assessed	B-X
in	B-X
immune	B-X
cells	B-X
and	B-X
tissues	B-X
using	B-X
cytosolic	B-X
radioligand	B-X
binding	B-X

Nevertheless	O
,	O
whole	O
cell	O
binding	O
studies	O
reveal	O
similar	O
levels	O
of	O
GR	B-protein
in	O
immature	B-cell_type
thymic	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
more	O
mature	O
,	O
splenic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
whole	B-X
cell	B-X
binding	B-X
studies	B-X
reveal	B-X
similar	B-X
levels	B-X
of	B-X
GR	B-X
in	B-X
immature	B-X
thymic	B-X
T	B-X
lymphocytes	B-X
and	B-X
more	B-X
mature	B-X
,	B-X
splenic	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
whole	B-X
cell	B-X
binding	B-X
techniques	B-X
indicate	B-X
that	B-X
neutrophils	B-X
(	B-X
which	B-X
represent	B-X
roughly	B-X
30	B-X
%	B-X
of	B-X
splenic	B-X
leukocytes	B-X
)	B-X
exhibit	B-X
higher	B-X
GR	B-X
than	B-X
both	B-X
T	B-X
and	B-X
B	B-X
lymphocytes	B-X
,	B-X
further	B-X
contradicting	B-X
results	B-X
from	B-X
cytosolic	B-X
binding	B-X
studies	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
previous	B-X
cytosolic	B-X
receptor	B-X
binding	B-X
studies	B-X
on	B-X
immune	B-X
tissue	B-X
homogenates	B-X
,	B-X
thymic	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
have	B-X
higher	B-X
levels	B-X
of	B-X
GR	B-X
than	B-X
T	B-X
cells	B-X
isolated	B-X
from	B-X
the	B-X
spleen	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
neutrophils	B-X
were	B-X
found	B-X
to	B-X
have	B-X
fewer	B-X
GR	B-X
than	B-X
lymphocytes	B-X
and	B-X
monocytes	B-X

Moreover	O
,	O
whole	O
cell	O
binding	O
techniques	O
indicate	O
that	O
neutrophils	B-cell_type
(	O
which	O
represent	O
roughly	O
30	O
%	O
of	O
splenic	B-cell_type
leukocytes	I-cell_type
)	O
exhibit	O
higher	O
GR	B-protein
than	O
both	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
further	O
contradicting	O
results	O
from	O
cytosolic	O
binding	O
studies	O
.	O

To	O
address	O
these	O
inconsistencies	O
,	O
GR	B-protein
protein	I-protein
was	O
assessed	O
in	O
immune	B-cell_type
cells	I-cell_type
and	I-cell_type
tissues	I-cell_type
using	O
cytosolic	O
radioligand	O
binding	O
.	O
<EOS>	B-X
To	B-X
address	B-X
these	B-X
inconsistencies	B-X
,	B-X
GR	B-X
protein	B-X
was	B-X
assessed	B-X
in	B-X
immune	B-X
cells	B-X
and	B-X
tissues	B-X
using	B-X
cytosolic	B-X
radioligand	B-X
binding	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
are	B-X
differentially	B-X
expressed	B-X
in	B-X
the	B-X
cells	B-X
and	B-X
tissues	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
neutrophils	B-X
were	B-X
found	B-X
to	B-X
have	B-X
fewer	B-X
GR	B-X
than	B-X
lymphocytes	B-X
and	B-X
monocytes	B-X
<EOS>	B-X
High	B-X
levels	B-X
of	B-X
GR	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
exquisite	B-X
sensitivity	B-X
of	B-X
the	B-X
thymus	B-X
to	B-X
glucocorticoid	B-X
exposure	B-X

Western	O
blot	O
analysis	O
,	O
and	O
immunocytochemistry	O
.	O
<EOS>	B-X
Angiogenesis	B-X
of	B-X
cerebral	B-X
tissue	B-X
was	B-X
analyzed	B-X
using	B-X
immunohistochemistry	B-X
<EOS>	B-X
Comprehensive	B-X
analysis	B-X
of	B-X
COMMD10	B-X
as	B-X
a	B-X
novel	B-X
prognostic	B-X
biomarker	B-X
for	B-X
gastric	B-X
cancer	B-X
.	B-X
<EOS>	B-X
We	B-X
analysed	B-X
the	B-X
prognostic	B-X
role	B-X
of	B-X
DSC2	B-X
at	B-X
mRNA	B-X
and	B-X
protein	B-X
level	B-X
using	B-X
microarray	B-X
data	B-X
,	B-X
western	B-X
blot	B-X
analysis	B-X
and	B-X
immunohistochemistry	B-X
<EOS>	B-X
Western	B-X
blotting	B-X
,	B-X
quantitative	B-X
real	B-X
-	B-X
time	B-X
PCR	B-X
(	B-X
RT	B-X
-	B-X
qPCR	B-X
)	B-X
and	B-X
immunocytochemistry	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
and	B-X
localization	B-X
of	B-X
different	B-X
proteins	B-X

Consistent	O
with	O
previous	O
cytosolic	O
receptor	O
binding	O
studies	O
on	O
immune	O
tissue	O
homogenates	O
,	O
thymic	O
T	B-cell_type
cells	I-cell_type
were	O
found	O
to	O
have	O
higher	O
levels	O
of	O
GR	B-protein
than	O
T	B-cell_type
cells	I-cell_type
isolated	O
from	O
the	O
spleen	O
.	O

In	O
addition	O
,	O
neutrophils	O
were	O
found	O
to	O
have	O
fewer	O
GR	B-protein
than	O
lymphocytes	B-cell_type
and	O
monocytes	B-cell_type
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
neutrophils	B-X
were	B-X
found	B-X
to	B-X
have	B-X
fewer	B-X
GR	B-X
than	B-X
lymphocytes	B-X
and	B-X
monocytes	B-X
<EOS>	B-X
Nevertheless	B-X
,	B-X
whole	B-X
cell	B-X
binding	B-X
studies	B-X
reveal	B-X
similar	B-X
levels	B-X
of	B-X
GR	B-X
in	B-X
immature	B-X
thymic	B-X
T	B-X
lymphocytes	B-X
and	B-X
more	B-X
mature	B-X
,	B-X
splenic	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
previous	B-X
cytosolic	B-X
receptor	B-X
binding	B-X
studies	B-X
on	B-X
immune	B-X
tissue	B-X
homogenates	B-X
,	B-X
thymic	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
have	B-X
higher	B-X
levels	B-X
of	B-X
GR	B-X
than	B-X
T	B-X
cells	B-X
isolated	B-X
from	B-X
the	B-X
spleen	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
whole	B-X
cell	B-X
binding	B-X
techniques	B-X
indicate	B-X
that	B-X
neutrophils	B-X
(	B-X
which	B-X
represent	B-X
roughly	B-X
30	B-X
%	B-X
of	B-X
splenic	B-X
leukocytes	B-X
)	B-X
exhibit	B-X
higher	B-X
GR	B-X
than	B-X
both	B-X
T	B-X
and	B-X
B	B-X
lymphocytes	B-X
,	B-X
further	B-X
contradicting	B-X
results	B-X
from	B-X
cytosolic	B-X
binding	B-X
studies	B-X

These	O
results	O
indicate	O
a	O
meaningful	O
relationship	O
between	O
receptor	O
expression	O
and	O
known	O
sensitivity	O
to	O
glucocorticoids	O
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
a	B-X
meaningful	B-X
relationship	B-X
between	B-X
receptor	B-X
expression	B-X
and	B-X
known	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
<EOS>	B-X
High	B-X
levels	B-X
of	B-X
GR	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
exquisite	B-X
sensitivity	B-X
of	B-X
the	B-X
thymus	B-X
to	B-X
glucocorticoid	B-X
exposure	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
whole	B-X
cell	B-X
binding	B-X
techniques	B-X
indicate	B-X
that	B-X
neutrophils	B-X
(	B-X
which	B-X
represent	B-X
roughly	B-X
30	B-X
%	B-X
of	B-X
splenic	B-X
leukocytes	B-X
)	B-X
exhibit	B-X
higher	B-X
GR	B-X
than	B-X
both	B-X
T	B-X
and	B-X
B	B-X
lymphocytes	B-X
,	B-X
further	B-X
contradicting	B-X
results	B-X
from	B-X
cytosolic	B-X
binding	B-X
studies	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
previous	B-X
cytosolic	B-X
receptor	B-X
binding	B-X
studies	B-X
on	B-X
immune	B-X
tissue	B-X
homogenates	B-X
,	B-X
thymic	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
have	B-X
higher	B-X
levels	B-X
of	B-X
GR	B-X
than	B-X
T	B-X
cells	B-X
isolated	B-X
from	B-X
the	B-X
spleen	B-X

Functional	O
replacement	O
of	O
the	O
mouse	B-DNA
E2A	I-DNA
gene	I-DNA
with	O
a	O
human	B-DNA
HEB	I-DNA
cDNA	I-DNA
.	O
<EOS>	B-X
Functional	B-X
replacement	B-X
of	B-X
the	B-X
mouse	B-X
E2A	B-X
gene	B-X
with	B-X
a	B-X
human	B-X
HEB	B-X
cDNA	B-X
.	B-X
<EOS>	B-X
We	B-X
find	B-X
that	B-X
the	B-X
alternatively	B-X
spliced	B-X
E12	B-X
and	B-X
E47	B-X
bHLH	B-X
proteins	B-X
of	B-X
the	B-X
E2A	B-X
gene	B-X
play	B-X
similar	B-X
and	B-X
additive	B-X
roles	B-X
in	B-X
supporting	B-X
B	B-X
lymphopoiesis	B-X
<EOS>	B-X
Finally	B-X
,	B-X
the	B-X
postnatal	B-X
lethality	B-X
associated	B-X
with	B-X
E2A	B-X
disruption	B-X
is	B-X
fully	B-X
rescued	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
HEB	B-X
<EOS>	B-X
Further	B-X
,	B-X
we	B-X
find	B-X
that	B-X
HEB	B-X
driven	B-X
by	B-X
the	B-X
endogenous	B-X
E2A	B-X
promoter	B-X
can	B-X
functionally	B-X
replace	B-X
E2A	B-X
in	B-X
supporting	B-X
B	B-X
-	B-X
cell	B-X
commitment	B-X
and	B-X
differentiation	B-X
toward	B-X
completion	B-X

The	O
mammalian	B-DNA
E2A	I-DNA
,	I-DNA
HEB	I-DNA
,	I-DNA
and	I-DNA
E2-2	I-DNA
genes	I-DNA
encode	O
a	O
unique	O
class	O
of	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
that	O
are	O
evolutionarily	O
conserved	O
and	O
essential	O
for	O
embryonic	O
and	O
postnatal	O
development	O
.	O
<EOS>	B-X
The	B-X
mammalian	B-X
E2A	B-X
,	B-X
HEB	B-X
,	B-X
and	B-X
E2	B-X
-	B-X
2	B-X
genes	B-X
encode	B-X
a	B-X
unique	B-X
class	B-X
of	B-X
basic	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
(	B-X
bHLH	B-X
)	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
essential	B-X
for	B-X
embryonic	B-X
and	B-X
postnatal	B-X
development	B-X
<EOS>	B-X
We	B-X
find	B-X
that	B-X
the	B-X
alternatively	B-X
spliced	B-X
E12	B-X
and	B-X
E47	B-X
bHLH	B-X
proteins	B-X
of	B-X
the	B-X
E2A	B-X
gene	B-X
play	B-X
similar	B-X
and	B-X
additive	B-X
roles	B-X
in	B-X
supporting	B-X
B	B-X
lymphopoiesis	B-X
<EOS>	B-X
Further	B-X
,	B-X
we	B-X
find	B-X
that	B-X
HEB	B-X
driven	B-X
by	B-X
the	B-X
endogenous	B-X
E2A	B-X
promoter	B-X
can	B-X
functionally	B-X
replace	B-X
E2A	B-X
in	B-X
supporting	B-X
B	B-X
-	B-X
cell	B-X
commitment	B-X
and	B-X
differentiation	B-X
toward	B-X
completion	B-X
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
functional	B-X
specificity	B-X
between	B-X
E2A	B-X
and	B-X
HEB	B-X
/	B-X
E2	B-X
-	B-X
2	B-X
in	B-X
mammalian	B-X
development	B-X
,	B-X
we	B-X
generated	B-X
and	B-X
tested	B-X
a	B-X
panel	B-X
of	B-X
E2A	B-X
knockin	B-X
mutations	B-X
including	B-X
subtle	B-X
mutations	B-X
in	B-X
the	B-X
E12	B-X
and	B-X
E47	B-X
exons	B-X
and	B-X
substitution	B-X
of	B-X
both	B-X
E12	B-X
and	B-X
E47	B-X
exons	B-X
with	B-X
a	B-X
human	B-X
HEB	B-X
cDNA	B-X

While	O
the	O
structural	O
and	O
functional	O
similarities	O
among	O
the	O
gene	B-protein
products	I-protein
are	O
well	O
demonstrated	O
,	O
it	O
is	O
not	O
clear	O
why	O
deletion	O
of	O
E2A	B-DNA
,	O
but	O
not	O
HEB	B-DNA
or	O
E2-2	B-DNA
,	O
leads	O
to	O
a	O
complete	O
arrest	O
in	O
B-lymphocyte	O
development	O
.	O
<EOS>	B-X
The	B-X
toxicological	B-X
information	B-X
obtained	B-X
from	B-X
this	B-X
model	B-X
can	B-X
be	B-X
utilized	B-X
for	B-X
identification	B-X
of	B-X
nephrotoxic	B-X
chemicals	B-X
and	B-X
hence	B-X
for	B-X
protection	B-X
of	B-X
public	B-X
health	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
retinoic	B-X
acid	B-X
stops	B-X
the	B-X
production	B-X
of	B-X
neural	B-X
crest	B-X
cells	B-X
by	B-X
repressing	B-X
BMP	B-X
activity	B-X
in	B-X
the	B-X
roof	B-X
plate	B-X
of	B-X
the	B-X
neural	B-X
tube	B-X
<EOS>	B-X
Five	B-X
classes	B-X
of	B-X
mutation	B-X
have	B-X
been	B-X
described	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
impact	B-X
of	B-X
the	B-X
mutation	B-X
on	B-X
the	B-X
processing	B-X
of	B-X
the	B-X
CFTR	B-X
protein	B-X
in	B-X
the	B-X
cell	B-X
<EOS>	B-X
The	B-X
division	B-X
between	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
–	B-X
formed	B-X
by	B-X
the	B-X
brain	B-X
and	B-X
spinal	B-X
cord	B-X
–	B-X
and	B-X
the	B-X
peripheral	B-X
nervous	B-X
system	B-X
–	B-X
which	B-X
consists	B-X
of	B-X
the	B-X
neurons	B-X
that	B-X
sense	B-X
and	B-X
relay	B-X
information	B-X
to	B-X
and	B-X
from	B-X
the	B-X
body	B-X
–	B-X
takes	B-X
place	B-X
early	B-X
during	B-X
embryonic	B-X
development	B-X

To	O
understand	O
the	O
molecular	O
basis	O
of	O
the	O
functional	O
specificity	O
between	O
E2A	B-DNA
and	O
HEB	B-DNA
/	O
E2-2	B-DNA
in	O
mammalian	O
development	O
,	O
we	O
generated	O
and	O
tested	O
a	O
panel	O
of	O
E2A	B-DNA
knockin	O
mutations	O
including	O
subtle	O
mutations	O
in	O
the	O
E12	B-DNA
and	I-DNA
E47	I-DNA
exons	I-DNA
and	O
substitution	O
of	O
both	O
E12	B-DNA
and	I-DNA
E47	I-DNA
exons	I-DNA
with	O
a	O
human	B-DNA
HEB	I-DNA
cDNA	I-DNA
.	O

We	O
find	O
that	O
the	O
alternatively	O
spliced	O
E12	B-protein
and	I-protein
E47	I-protein
bHLH	I-protein
proteins	I-protein
of	O
the	O
E2A	B-DNA
gene	I-DNA
play	O
similar	O
and	O
additive	O
roles	O
in	O
supporting	O
B	B-cell_type
lymphopoiesis	I-cell_type
.	O
<EOS>	B-X
We	B-X
find	B-X
that	B-X
the	B-X
alternatively	B-X
spliced	B-X
E12	B-X
and	B-X
E47	B-X
bHLH	B-X
proteins	B-X
of	B-X
the	B-X
E2A	B-X
gene	B-X
play	B-X
similar	B-X
and	B-X
additive	B-X
roles	B-X
in	B-X
supporting	B-X
B	B-X
lymphopoiesis	B-X
<EOS>	B-X
While	B-X
the	B-X
structural	B-X
and	B-X
functional	B-X
similarities	B-X
among	B-X
the	B-X
gene	B-X
products	B-X
are	B-X
well	B-X
demonstrated	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
why	B-X
deletion	B-X
of	B-X
E2A	B-X
,	B-X
but	B-X
not	B-X
HEB	B-X
or	B-X
E2	B-X
-	B-X
2	B-X
,	B-X
leads	B-X
to	B-X
a	B-X
complete	B-X
arrest	B-X
in	B-X
B	B-X
-	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
Finally	B-X
,	B-X
the	B-X
postnatal	B-X
lethality	B-X
associated	B-X
with	B-X
E2A	B-X
disruption	B-X
is	B-X
fully	B-X
rescued	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
HEB	B-X
<EOS>	B-X
The	B-X
mammalian	B-X
E2A	B-X
,	B-X
HEB	B-X
,	B-X
and	B-X
E2	B-X
-	B-X
2	B-X
genes	B-X
encode	B-X
a	B-X
unique	B-X
class	B-X
of	B-X
basic	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
(	B-X
bHLH	B-X
)	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
essential	B-X
for	B-X
embryonic	B-X
and	B-X
postnatal	B-X
development	B-X

Further	O
,	O
we	O
find	O
that	O
HEB	B-DNA
driven	O
by	O
the	O
endogenous	B-DNA
E2A	I-DNA
promoter	I-DNA
can	O
functionally	O
replace	O
E2A	B-DNA
in	O
supporting	O
B-cell	O
commitment	O
and	O
differentiation	O
toward	O
completion	O
.	O
<EOS>	B-X
Further	B-X
,	B-X
we	B-X
find	B-X
that	B-X
HEB	B-X
driven	B-X
by	B-X
the	B-X
endogenous	B-X
E2A	B-X
promoter	B-X
can	B-X
functionally	B-X
replace	B-X
E2A	B-X
in	B-X
supporting	B-X
B	B-X
-	B-X
cell	B-X
commitment	B-X
and	B-X
differentiation	B-X
toward	B-X
completion	B-X
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
functional	B-X
specificity	B-X
between	B-X
E2A	B-X
and	B-X
HEB	B-X
/	B-X
E2	B-X
-	B-X
2	B-X
in	B-X
mammalian	B-X
development	B-X
,	B-X
we	B-X
generated	B-X
and	B-X
tested	B-X
a	B-X
panel	B-X
of	B-X
E2A	B-X
knockin	B-X
mutations	B-X
including	B-X
subtle	B-X
mutations	B-X
in	B-X
the	B-X
E12	B-X
and	B-X
E47	B-X
exons	B-X
and	B-X
substitution	B-X
of	B-X
both	B-X
E12	B-X
and	B-X
E47	B-X
exons	B-X
with	B-X
a	B-X
human	B-X
HEB	B-X
cDNA	B-X
<EOS>	B-X
While	B-X
the	B-X
structural	B-X
and	B-X
functional	B-X
similarities	B-X
among	B-X
the	B-X
gene	B-X
products	B-X
are	B-X
well	B-X
demonstrated	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
why	B-X
deletion	B-X
of	B-X
E2A	B-X
,	B-X
but	B-X
not	B-X
HEB	B-X
or	B-X
E2	B-X
-	B-X
2	B-X
,	B-X
leads	B-X
to	B-X
a	B-X
complete	B-X
arrest	B-X
in	B-X
B	B-X
-	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
The	B-X
mammalian	B-X
E2A	B-X
,	B-X
HEB	B-X
,	B-X
and	B-X
E2	B-X
-	B-X
2	B-X
genes	B-X
encode	B-X
a	B-X
unique	B-X
class	B-X
of	B-X
basic	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
(	B-X
bHLH	B-X
)	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
essential	B-X
for	B-X
embryonic	B-X
and	B-X
postnatal	B-X
development	B-X

Finally	O
,	O
the	O
postnatal	O
lethality	O
associated	O
with	O
E2A	B-DNA
disruption	O
is	O
fully	O
rescued	O
by	O
the	O
addition	O
of	O
HEB	B-DNA
.	O
<EOS>	B-X
Finally	B-X
,	B-X
the	B-X
postnatal	B-X
lethality	B-X
associated	B-X
with	B-X
E2A	B-X
disruption	B-X
is	B-X
fully	B-X
rescued	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
HEB	B-X
<EOS>	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
the	B-X
functional	B-X
divergence	B-X
among	B-X
E12	B-X
,	B-X
E47	B-X
,	B-X
and	B-X
HEB	B-X
in	B-X
different	B-X
cell	B-X
types	B-X
is	B-X
partially	B-X
defined	B-X
by	B-X
the	B-X
context	B-X
of	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Functional	B-X
replacement	B-X
of	B-X
the	B-X
mouse	B-X
E2A	B-X
gene	B-X
with	B-X
a	B-X
human	B-X
HEB	B-X
cDNA	B-X
.	B-X
<EOS>	B-X
We	B-X
find	B-X
that	B-X
the	B-X
alternatively	B-X
spliced	B-X
E12	B-X
and	B-X
E47	B-X
bHLH	B-X
proteins	B-X
of	B-X
the	B-X
E2A	B-X
gene	B-X
play	B-X
similar	B-X
and	B-X
additive	B-X
roles	B-X
in	B-X
supporting	B-X
B	B-X
lymphopoiesis	B-X

This	O
study	O
suggests	O
that	O
the	O
functional	O
divergence	O
among	O
E12	B-DNA
,	O
E47	B-DNA
,	O
and	O
HEB	B-DNA
in	O
different	O
cell	O
types	O
is	O
partially	O
defined	O
by	O
the	O
context	O
of	O
gene	O
expression	O
.	O
<EOS>	B-X
This	B-X
study	B-X
suggests	B-X
that	B-X
the	B-X
functional	B-X
divergence	B-X
among	B-X
E12	B-X
,	B-X
E47	B-X
,	B-X
and	B-X
HEB	B-X
in	B-X
different	B-X
cell	B-X
types	B-X
is	B-X
partially	B-X
defined	B-X
by	B-X
the	B-X
context	B-X
of	B-X
gene	B-X
expression	B-X
<EOS>	B-X
While	B-X
the	B-X
structural	B-X
and	B-X
functional	B-X
similarities	B-X
among	B-X
the	B-X
gene	B-X
products	B-X
are	B-X
well	B-X
demonstrated	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
why	B-X
deletion	B-X
of	B-X
E2A	B-X
,	B-X
but	B-X
not	B-X
HEB	B-X
or	B-X
E2	B-X
-	B-X
2	B-X
,	B-X
leads	B-X
to	B-X
a	B-X
complete	B-X
arrest	B-X
in	B-X
B	B-X
-	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
Finally	B-X
,	B-X
the	B-X
postnatal	B-X
lethality	B-X
associated	B-X
with	B-X
E2A	B-X
disruption	B-X
is	B-X
fully	B-X
rescued	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
HEB	B-X
<EOS>	B-X
We	B-X
find	B-X
that	B-X
the	B-X
alternatively	B-X
spliced	B-X
E12	B-X
and	B-X
E47	B-X
bHLH	B-X
proteins	B-X
of	B-X
the	B-X
E2A	B-X
gene	B-X
play	B-X
similar	B-X
and	B-X
additive	B-X
roles	B-X
in	B-X
supporting	B-X
B	B-X
lymphopoiesis	B-X

Biased	O
dependency	O
of	O
CD80	B-protein
versus	O
CD86	B-protein
in	O
the	O
induction	O
of	O
transcription	B-protein
factors	I-protein
regulating	O
the	O
human	B-DNA
IL-2	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Biased	B-X
dependency	B-X
of	B-X
CD80	B-X
versus	B-X
CD86	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
transcription	B-X
factors	B-X
regulating	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
eventual	B-X
appearance	B-X
of	B-X
CD80	B-X
on	B-X
recently	B-X
activated	B-X
CD86+	B-X
APC	B-X
is	B-X
important	B-X
for	B-X
the	B-X
superinduction	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
to	B-X
support	B-X
vigorous	B-X
T	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
To	B-X
further	B-X
characterize	B-X
the	B-X
consequences	B-X
of	B-X
this	B-X
biased	B-X
co	B-X
-	B-X
stimulatory	B-X
dependency	B-X
,	B-X
we	B-X
employed	B-X
a	B-X
well	B-X
-	B-X
defined	B-X
system	B-X
of	B-X
transfected	B-X
CHO	B-X
cells	B-X
expressing	B-X
human	B-X
MHC	B-X
class	B-X
II	B-X
together	B-X
with	B-X
CD80	B-X
,	B-X
CD86	B-X
or	B-X
CD80	B-X
and	B-X
CD86	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
transcription	B-X
factors	B-X
regulating	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
enhancer	B-X
region	B-X
including	B-X
activation	B-X
protein	B-X
-	B-X
1	B-X
,	B-X
CD28	B-X
response	B-X
element	B-X
and	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
were	B-X
4	B-X
-	B-X
8	B-X
times	B-X
higher	B-X
after	B-X
CD80	B-X
compared	B-X
to	B-X
CD86	B-X
ligation	B-X

In	O
addition	O
to	O
the	O
signals	O
obtained	O
by	O
ligation	O
of	O
the	O
TCR	O
,	O
T	B-cell_type
cells	I-cell_type
need	O
additional	O
,	O
co-stimulatory	O
signals	O
to	O
be	O
activated	O
.	O

One	O
such	O
co-stimulatory	O
signal	O
is	O
delivered	O
when	O
CD28	B-protein
on	O
T	B-cell_type
cells	I-cell_type
binds	O
to	O
CD80	B-protein
or	O
CD86	B-protein
on	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
APC	B-cell_type
)	O
.	O
<EOS>	B-X
The	B-X
co	B-X
-	B-X
stimulatory	B-X
molecules	B-X
CD80	B-X
and	B-X
CD86	B-X
are	B-X
upregulated	B-X
on	B-X
activated	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
<EOS>	B-X
Treg	B-X
-	B-X
expressed	B-X
CTLA	B-X
-	B-X
4	B-X
depletes	B-X
CD80	B-X
/	B-X
CD86	B-X
by	B-X
trogocytosis	B-X
,	B-X
releasing	B-X
free	B-X
PD	B-X
-	B-X
L1	B-X
on	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
mice	B-X
,	B-X
different	B-X
types	B-X
of	B-X
peripheral	B-X
AIRE	B-X
expressing	B-X
cells	B-X
have	B-X
been	B-X
described	B-X
,	B-X
including	B-X
cells	B-X
with	B-X
an	B-X
innate	B-X
lymphoid	B-X
cell	B-X
-	B-X
like	B-X
phenotype	B-X
and	B-X
antigen	B-X
presenting	B-X
cell	B-X
(	B-X
APC	B-X
)	B-X
function	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
stimuli	B-X
that	B-X
control	B-X
CD80	B-X
and	B-X
CD86	B-X
expression	B-X
on	B-X
T	B-X
cells	B-X
and	B-X
show	B-X
that	B-X
in	B-X
APC	B-X
-	B-X
free	B-X
conditions	B-X
around	B-X
40	B-X
%	B-X
of	B-X
activated	B-X
,	B-X
proliferating	B-X
CD4	B-X

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
CD80	B-protein
and	O
CD86	B-protein
to	O
co-stimulate	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
activated	O
by	O
superantigen	O
.	O

Using	O
the	O
Raji	B-cell_line
B	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
,	O
which	O
express	O
similar	O
levels	O
of	O
CD80	B-protein
and	O
CD86	B-protein
,	O
it	O
was	O
found	O
that	O
T	O
cell	O
proliferation	O
was	O
mainly	O
co-stimulated	O
by	O
CD80	B-protein
.	O

To	O
further	O
characterize	O
the	O
consequences	O
of	O
this	O
biased	O
co-stimulatory	O
dependency	O
,	O
we	O
employed	O
a	O
well-defined	O
system	O
of	O
transfected	O
CHO	B-cell_line
cells	I-cell_line
expressing	O
human	B-protein
MHC	I-protein
class	I-protein
II	I-protein
together	O
with	O
CD80	B-protein
,	O
CD86	B-protein
or	O
CD80	B-protein
and	O
CD86	B-protein
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
AgNPs	B-X
inhibited	B-X
LPS	B-X
-	B-X
induced	B-X
toll	B-X
-	B-X
like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
4	B-X
signaling	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
decreased	B-X
expression	B-X
of	B-X
myeloid	B-X
differentiation	B-X
factor	B-X
88	B-X
(	B-X
MyD88	B-X
)	B-X
and	B-X
TLR4	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
effectiveness	B-X
of	B-X
the	B-X
vaccine	B-X
,	B-X
we	B-X
first	B-X
detected	B-X
the	B-X
expression	B-X
of	B-X
molecular	B-X
markers	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
antigen	B-X
presenting	B-X
cells	B-X
and	B-X
the	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Chimeric	B-X
antigen	B-X
receptor	B-X
Tregs	B-X
specific	B-X
for	B-X
an	B-X
insulin	B-X
B	B-X
-	B-X
chain	B-X
peptide	B-X
presented	B-X
by	B-X
MHC	B-X
class	B-X
II	B-X
prevent	B-X
autoimmune	B-X
diabetes	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
extracellular	B-X
ATP	B-X
on	B-X
mouse	B-X
bone	B-X
marrow	B-X
-	B-X
derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDCs	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
potential	B-X
for	B-X
subsequent	B-X
T	B-X
cell	B-X
activation	B-X

Proliferation	O
of	O
freshly	O
prepared	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
required	O
the	O
presence	O
of	O
either	O
CD80	B-protein
or	O
CD86	B-protein
.	O
<EOS>	B-X
Cooperative	B-X
stimulation	B-X
of	B-X
ATP	B-X
and	B-X
its	B-X
metabolite	B-X
adenosine	B-X
was	B-X
required	B-X
for	B-X
the	B-X
upregulation	B-X
of	B-X
MHC	B-X
-	B-X
I	B-X
and	B-X
MHC	B-X
-	B-X
II	B-X
<EOS>	B-X
The	B-X
interactions	B-X
of	B-X
APOC1	B-X
with	B-X
other	B-X
proteins	B-X
were	B-X
predicted	B-X
using	B-X
STRING	B-X
<EOS>	B-X
In	B-X
the	B-X
mixed	B-X
leukocyte	B-X
reaction	B-X
assay	B-X
,	B-X
ATP	B-X
-	B-X
stimulated	B-X
BMDCs	B-X
activated	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
and	B-X
induced	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
γ	B-X
)	B-X
production	B-X
by	B-X
these	B-X
T	B-X
cells	B-X
<EOS>	B-X
Upregulation	B-X
of	B-X
APOC1	B-X
Promotes	B-X
Colorectal	B-X
Cancer	B-X
Progression	B-X
and	B-X
Serves	B-X
as	B-X
a	B-X
Potential	B-X
Therapeutic	B-X
Target	B-X
Based	B-X
on	B-X
Bioinformatics	B-X
Analysis	B-X
.	B-X

However	O
,	O
IL-2	B-protein
production	O
reached	O
only	O
suboptimal	O
levels	O
in	O
the	O
presence	O
of	O
CD86	B-protein
but	O
optimal	O
levels	O
with	O
CD80	B-protein
.	O
<EOS>	B-X
However	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
reached	B-X
only	B-X
suboptimal	B-X
levels	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
CD86	B-X
but	B-X
optimal	B-X
levels	B-X
with	B-X
CD80	B-X
<EOS>	B-X
Proliferation	B-X
of	B-X
freshly	B-X
prepared	B-X
CD4+	B-X
T	B-X
cells	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
CD80	B-X
or	B-X
CD86	B-X
<EOS>	B-X
To	B-X
analyze	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
activity	B-X
in	B-X
CD80	B-X
and	B-X
CD86	B-X
co	B-X
-	B-X
stimulated	B-X
T	B-X
cells	B-X
we	B-X
used	B-X
Jurkat	B-X
T	B-X
cells	B-X
transfected	B-X
with	B-X
luciferase	B-X
reporter	B-X
gene	B-X
constructs	B-X
<EOS>	B-X
To	B-X
further	B-X
characterize	B-X
the	B-X
consequences	B-X
of	B-X
this	B-X
biased	B-X
co	B-X
-	B-X
stimulatory	B-X
dependency	B-X
,	B-X
we	B-X
employed	B-X
a	B-X
well	B-X
-	B-X
defined	B-X
system	B-X
of	B-X
transfected	B-X
CHO	B-X
cells	B-X
expressing	B-X
human	B-X
MHC	B-X
class	B-X
II	B-X
together	B-X
with	B-X
CD80	B-X
,	B-X
CD86	B-X
or	B-X
CD80	B-X
and	B-X
CD86	B-X

To	O
analyze	O
IL-2	B-protein
transcriptional	O
activity	O
in	O
CD80	B-protein
and	O
CD86	B-protein
co-stimulated	O
T	B-cell_type
cells	I-cell_type
we	O
used	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
transfected	O
with	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
.	O

CD80	B-protein
induced	O
higher	O
levels	O
of	O
IL-2	B-DNA
promoter	I-DNA
-enhancer	O
activity	O
compared	O
to	O
CD86	B-protein
.	O
<EOS>	B-X
CD80	B-X
induced	B-X
higher	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
enhancer	B-X
activity	B-X
compared	B-X
to	B-X
CD86	B-X
<EOS>	B-X
Using	B-X
the	B-X
Raji	B-X
B	B-X
cell	B-X
lymphoma	B-X
,	B-X
which	B-X
express	B-X
similar	B-X
levels	B-X
of	B-X
CD80	B-X
and	B-X
CD86	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
T	B-X
cell	B-X
proliferation	B-X
was	B-X
mainly	B-X
co	B-X
-	B-X
stimulated	B-X
by	B-X
CD80	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
signals	B-X
obtained	B-X
by	B-X
ligation	B-X
of	B-X
the	B-X
TCR	B-X
,	B-X
T	B-X
cells	B-X
need	B-X
additional	B-X
,	B-X
co	B-X
-	B-X
stimulatory	B-X
signals	B-X
to	B-X
be	B-X
activated	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
transcription	B-X
factors	B-X
regulating	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
enhancer	B-X
region	B-X
including	B-X
activation	B-X
protein	B-X
-	B-X
1	B-X
,	B-X
CD28	B-X
response	B-X
element	B-X
and	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
were	B-X
4	B-X
-	B-X
8	B-X
times	B-X
higher	B-X
after	B-X
CD80	B-X
compared	B-X
to	B-X
CD86	B-X
ligation	B-X

Furthermore	O
,	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
regulating	O
the	O
IL-2	B-DNA
promoter-enhancer	I-DNA
region	I-DNA
including	O
activation	B-protein
protein-1	I-protein
,	O
CD28	B-DNA
response	I-DNA
element	I-DNA
and	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
were	O
4-8	O
times	O
higher	O
after	O
CD80	B-protein
compared	O
to	O
CD86	B-protein
ligation	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
transcription	B-X
factors	B-X
regulating	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
enhancer	B-X
region	B-X
including	B-X
activation	B-X
protein	B-X
-	B-X
1	B-X
,	B-X
CD28	B-X
response	B-X
element	B-X
and	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
were	B-X
4	B-X
-	B-X
8	B-X
times	B-X
higher	B-X
after	B-X
CD80	B-X
compared	B-X
to	B-X
CD86	B-X
ligation	B-X
<EOS>	B-X
To	B-X
further	B-X
characterize	B-X
the	B-X
consequences	B-X
of	B-X
this	B-X
biased	B-X
co	B-X
-	B-X
stimulatory	B-X
dependency	B-X
,	B-X
we	B-X
employed	B-X
a	B-X
well	B-X
-	B-X
defined	B-X
system	B-X
of	B-X
transfected	B-X
CHO	B-X
cells	B-X
expressing	B-X
human	B-X
MHC	B-X
class	B-X
II	B-X
together	B-X
with	B-X
CD80	B-X
,	B-X
CD86	B-X
or	B-X
CD80	B-X
and	B-X
CD86	B-X
<EOS>	B-X
To	B-X
analyze	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
activity	B-X
in	B-X
CD80	B-X
and	B-X
CD86	B-X
co	B-X
-	B-X
stimulated	B-X
T	B-X
cells	B-X
we	B-X
used	B-X
Jurkat	B-X
T	B-X
cells	B-X
transfected	B-X
with	B-X
luciferase	B-X
reporter	B-X
gene	B-X
constructs	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
signals	B-X
obtained	B-X
by	B-X
ligation	B-X
of	B-X
the	B-X
TCR	B-X
,	B-X
T	B-X
cells	B-X
need	B-X
additional	B-X
,	B-X
co	B-X
-	B-X
stimulatory	B-X
signals	B-X
to	B-X
be	B-X
activated	B-X

Our	O
results	O
suggest	O
that	O
the	O
eventual	O
appearance	O
of	O
CD80	B-protein
on	O
recently	O
activated	O
CD86+	B-cell_type
APC	I-cell_type
is	O
important	O
for	O
the	O
superinduction	O
of	O
IL-2	B-protein
production	O
and	O
to	O
support	O
vigorous	O
T	O
cell	O
proliferation	O
.	O
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
eventual	B-X
appearance	B-X
of	B-X
CD80	B-X
on	B-X
recently	B-X
activated	B-X
CD86+	B-X
APC	B-X
is	B-X
important	B-X
for	B-X
the	B-X
superinduction	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
to	B-X
support	B-X
vigorous	B-X
T	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
Biased	B-X
dependency	B-X
of	B-X
CD80	B-X
versus	B-X
CD86	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
transcription	B-X
factors	B-X
regulating	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
signals	B-X
obtained	B-X
by	B-X
ligation	B-X
of	B-X
the	B-X
TCR	B-X
,	B-X
T	B-X
cells	B-X
need	B-X
additional	B-X
,	B-X
co	B-X
-	B-X
stimulatory	B-X
signals	B-X
to	B-X
be	B-X
activated	B-X
<EOS>	B-X
To	B-X
analyze	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
activity	B-X
in	B-X
CD80	B-X
and	B-X
CD86	B-X
co	B-X
-	B-X
stimulated	B-X
T	B-X
cells	B-X
we	B-X
used	B-X
Jurkat	B-X
T	B-X
cells	B-X
transfected	B-X
with	B-X
luciferase	B-X
reporter	B-X
gene	B-X
constructs	B-X

Duplication	O
of	O
the	O
DR3	B-DNA
gene	I-DNA
on	O
human	B-DNA
chromosome	I-DNA
1p36	I-DNA
and	O
its	O
deletion	O
in	O
human	B-cell_type
neuroblastoma	I-cell_type
.	O
<EOS>	B-X
Duplication	B-X
of	B-X
the	B-X
DR3	B-X
gene	B-X
on	B-X
human	B-X
chromosome	B-X
1p36	B-X
and	B-X
its	B-X
deletion	B-X
in	B-X
human	B-X
neuroblastoma	B-X
.	B-X
<EOS>	B-X
Duplication	B-X
of	B-X
at	B-X
least	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
DR3	B-X
gene	B-X
,	B-X
including	B-X
the	B-X
extracellular	B-X
and	B-X
transmembrane	B-X
regions	B-X
but	B-X
not	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
,	B-X
was	B-X
demonstrated	B-X
by	B-X
both	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
and	B-X
genomic	B-X
Southern	B-X
blotting	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
DR3	B-X
gene	B-X
locus	B-X
is	B-X
tandemly	B-X
duplicated	B-X
on	B-X
human	B-X
chromosome	B-X
band	B-X
1p36	B-X
<EOS>	B-X
In	B-X
most	B-X
NB	B-X
cell	B-X
lines	B-X
,	B-X
both	B-X
the	B-X
DR3	B-X
and	B-X
the	B-X
DR3L	B-X
sequences	B-X
are	B-X
simultaneously	B-X
deleted	B-X
and	B-X
/	B-X
or	B-X
translocated	B-X
to	B-X
another	B-X
chromosome	B-X

The	O
human	B-DNA
DR3	I-DNA
gene	I-DNA
,	O
whose	O
product	O
is	O
also	O
known	O
as	O
Wsl-1/APO-3/TRAMP/LARD	B-protein
,	O
encodes	O
a	O
tumor	B-protein
necrosis	I-protein
factor-related	I-protein
receptor	I-protein
that	O
is	O
expressed	O
primarily	O
on	O
the	O
surface	O
of	O
thymocytes	B-cell_type
and	O
lymphocytes	B-cell_type
.	O
<EOS>	B-X
The	B-X
human	B-X
DR3	B-X
gene	B-X
,	B-X
whose	B-X
product	B-X
is	B-X
also	B-X
known	B-X
as	B-X
Wsl	B-X
-	B-X
1	B-X
/	B-X
APO	B-X
-	B-X
3	B-X
/	B-X
TRAMP	B-X
/	B-X
LARD	B-X
,	B-X
encodes	B-X
a	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
related	B-X
receptor	B-X
that	B-X
is	B-X
expressed	B-X
primarily	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
thymocytes	B-X
and	B-X
lymphocytes	B-X
<EOS>	B-X
In	B-X
most	B-X
NB	B-X
cell	B-X
lines	B-X
,	B-X
both	B-X
the	B-X
DR3	B-X
and	B-X
the	B-X
DR3L	B-X
sequences	B-X
are	B-X
simultaneously	B-X
deleted	B-X
and	B-X
/	B-X
or	B-X
translocated	B-X
to	B-X
another	B-X
chromosome	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
DR3	B-X
gene	B-X
locus	B-X
is	B-X
tandemly	B-X
duplicated	B-X
on	B-X
human	B-X
chromosome	B-X
band	B-X
1p36	B-X
<EOS>	B-X
Finally	B-X
,	B-X
DR3	B-X
/	B-X
	B-X
Wsl	B-X
-	B-X
1	B-X
protein	B-X
expression	B-X
is	B-X
quite	B-X
variable	B-X
among	B-X
these	B-X
NB	B-X
cell	B-X
lines	B-X
,	B-X
with	B-X
very	B-X
low	B-X
or	B-X
undetectable	B-X
levels	B-X
in	B-X
7	B-X
of	B-X
17	B-X
NB	B-X
cell	B-X
lines	B-X

DR3	B-protein
is	O
capable	O
of	O
inducing	O
both	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
apoptosis	O
when	O
overexpressed	O
in	O
mammalian	B-cell_type
cells	I-cell_type
,	O
although	O
its	O
ligand	O
has	O
not	O
yet	O
been	O
identified	O
.	O

We	O
report	O
here	O
that	O
the	O
DR3	B-DNA
gene	I-DNA
locus	I-DNA
is	O
tandemly	O
duplicated	O
on	O
human	B-DNA
chromosome	I-DNA
band	I-DNA
1p36.2-p36.3	I-DNA
and	O
that	O
these	O
genes	O
are	O
hemizygously	O
deleted	O
and/or	O
translocated	O
to	O
another	O
chromosome	O
in	O
neuroblastoma	B-cell_line
(	I-cell_line
NB	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
with	O
amplified	O
MYCN	O
.	O
<EOS>	B-X
3	B-X
and	B-X
that	B-X
these	B-X
genes	B-X
are	B-X
hemizygously	B-X
deleted	B-X
and	B-X
/	B-X
or	B-X
translocated	B-X
to	B-X
another	B-X
chromosome	B-X
in	B-X
neuroblastoma	B-X
(	B-X
NB	B-X
)	B-X
cell	B-X
lines	B-X
with	B-X
amplified	B-X
MYCN	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
DR3	B-X
gene	B-X
locus	B-X
is	B-X
tandemly	B-X
duplicated	B-X
on	B-X
human	B-X
chromosome	B-X
band	B-X
1p36	B-X
<EOS>	B-X
In	B-X
most	B-X
NB	B-X
cell	B-X
lines	B-X
,	B-X
both	B-X
the	B-X
DR3	B-X
and	B-X
the	B-X
DR3L	B-X
sequences	B-X
are	B-X
simultaneously	B-X
deleted	B-X
and	B-X
/	B-X
or	B-X
translocated	B-X
to	B-X
another	B-X
chromosome	B-X
<EOS>	B-X
Duplication	B-X
of	B-X
the	B-X
DR3	B-X
gene	B-X
on	B-X
human	B-X
chromosome	B-X
1p36	B-X
and	B-X
its	B-X
deletion	B-X
in	B-X
human	B-X
neuroblastoma	B-X
.	B-X

Duplication	O
of	O
at	O
least	O
a	O
portion	O
of	O
the	O
DR3	B-DNA
gene	I-DNA
,	O
including	O
the	O
extracellular	B-protein
and	I-protein
transmembrane	I-protein
regions	I-protein
but	O
not	O
the	O
cytoplasmic	B-protein
domain	I-protein
,	O
was	O
demonstrated	O
by	O
both	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
genomic	O
Southern	O
blotting	O
.	O

In	O
most	O
NB	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
both	O
the	O
DR3	B-DNA
and	I-DNA
the	I-DNA
DR3L	I-DNA
sequences	I-DNA
are	O
simultaneously	O
deleted	O
and/or	O
translocated	O
to	O
another	O
chromosome	B-DNA
.	O
<EOS>	B-X
Genetic	B-X
mapping	B-X
of	B-X
the	B-X
powdery	B-X
mildew	B-X
resistance	B-X
gene	B-X
Pm7	B-X
on	B-X
oat	B-X
chromosome	B-X
5D	B-X
.	B-X
<EOS>	B-X
'	B-X
Markers	B-X
from	B-X
this	B-X
region	B-X
were	B-X
homologous	B-X
to	B-X
a	B-X
region	B-X
of	B-X
chromosome	B-X
2Ce	B-X
of	B-X
the	B-X
C	B-X
-	B-X
genome	B-X
species	B-X
,	B-X
Avena	B-X
eriantha	B-X
,	B-X
the	B-X
donor	B-X
of	B-X
Pm7	B-X
,	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
the	B-X
ancestral	B-X
source	B-X
of	B-X
a	B-X
translocated	B-X
region	B-X
on	B-X
the	B-X
hexaploid	B-X
chromosome	B-X
5D	B-X
<EOS>	B-X
Rice	B-X
is	B-X
an	B-X
important	B-X
food	B-X
crop	B-X
in	B-X
the	B-X
world	B-X
,	B-X
but	B-X
there	B-X
are	B-X
few	B-X
studies	B-X
on	B-X
the	B-X
uptake	B-X
and	B-X
translocation	B-X
of	B-X
Mg	B-X
<EOS>	B-X
The	B-X
storage	B-X
of	B-X
whole	B-X
blood	B-X
samples	B-X
can	B-X
affect	B-X
the	B-X
amount	B-X
and	B-X
integrity	B-X
of	B-X
genomic	B-X
DNA	B-X
,	B-X
and	B-X
it	B-X
can	B-X
distort	B-X
the	B-X
results	B-X
of	B-X
subsequent	B-X
analyses	B-X
if	B-X
the	B-X
storage	B-X
was	B-X
not	B-X
under	B-X
proper	B-X
conditions	B-X

Finally	O
,	O
DR3/	B-protein
Wsl-1	I-protein
protein	I-protein
expression	O
is	O
quite	O
variable	O
among	O
these	O
NB	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
with	O
very	O
low	O
or	O
undetectable	O
levels	O
in	O
7	O
of	O
17	O
NB	B-cell_line
cell	I-cell_line
lines	I-cell_line
<EOS>	B-X
Finally	B-X
,	B-X
DR3	B-X
/	B-X
	B-X
Wsl	B-X
-	B-X
1	B-X
protein	B-X
expression	B-X
is	B-X
quite	B-X
variable	B-X
among	B-X
these	B-X
NB	B-X
cell	B-X
lines	B-X
,	B-X
with	B-X
very	B-X
low	B-X
or	B-X
undetectable	B-X
levels	B-X
in	B-X
7	B-X
of	B-X
17	B-X
NB	B-X
cell	B-X
lines	B-X
<EOS>	B-X
The	B-X
SH	B-X
-	B-X
SY5Y	B-X
,	B-X
SK	B-X
-	B-X
N	B-X
-	B-X
AS	B-X
,	B-X
and	B-X
Lan	B-X
-	B-X
5	B-X
however	B-X
,	B-X
had	B-X
extremely	B-X
low	B-X
to	B-X
undetectable	B-X
levels	B-X
of	B-X
dimers	B-X
and	B-X
tetramers	B-X
<EOS>	B-X
Duplication	B-X
of	B-X
at	B-X
least	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
DR3	B-X
gene	B-X
,	B-X
including	B-X
the	B-X
extracellular	B-X
and	B-X
transmembrane	B-X
regions	B-X
but	B-X
not	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
,	B-X
was	B-X
demonstrated	B-X
by	B-X
both	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
and	B-X
genomic	B-X
Southern	B-X
blotting	B-X
<EOS>	B-X
Our	B-X
study	B-X
also	B-X
showed	B-X
no	B-X
cytoplasmic	B-X
accumulation	B-X
of	B-X
p53	B-X
in	B-X
these	B-X
cells	B-X
contrary	B-X
to	B-X
some	B-X
previous	B-X
reports	B-X

Differential	O
protection	O
of	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
human	I-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
(	O
CFU-GM	B-cell_type
)	O
from	O
Ara-C	O
toxicity	O
using	O
cycloheximide	O
.	O
<EOS>	B-X
Differential	B-X
protection	B-X
of	B-X
normal	B-X
and	B-X
malignant	B-X
human	B-X
myeloid	B-X
progenitors	B-X
(	B-X
CFU	B-X
-	B-X
GM	B-X
)	B-X
from	B-X
Ara	B-X
-	B-X
C	B-X
toxicity	B-X
using	B-X
cycloheximide	B-X
.	B-X
<EOS>	B-X
Similar	B-X
cycloheximide	B-X
pretreatment	B-X
of	B-X
CML	B-X
progenitors	B-X
and	B-X
clonogenic	B-X
HL	B-X
-	B-X
60	B-X
and	B-X
KG	B-X
-	B-X
1	B-X
cells	B-X
failed	B-X
to	B-X
protect	B-X
CFU	B-X
-	B-X
GM	B-X
from	B-X
Ara	B-X
-	B-X
C	B-X
-	B-X
induced	B-X
cytotoxicity	B-X
<EOS>	B-X
Mononuclear	B-X
or	B-X
clonogenic	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
one	B-X
hour	B-X
with	B-X
cycloheximide	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
addition	B-X
,	B-X
for	B-X
three	B-X
or	B-X
17	B-X
hours	B-X
,	B-X
of	B-X
Ara	B-X
-	B-X
C	B-X
before	B-X
being	B-X
plated	B-X
in	B-X
a	B-X
methylcellulose	B-X
culture	B-X
system	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
cycloheximide	B-X
on	B-X
granulocyte	B-X
/	B-X
macrophage	B-X
progenitors	B-X
(	B-X
CFU	B-X
-	B-X
GM	B-X
)	B-X
after	B-X
in	B-X
vitro	B-X
Ara	B-X
-	B-X
C	B-X
exposure	B-X
was	B-X
examined	B-X
using	B-X
normal	B-X
human	B-X
bone	B-X
marrow	B-X
,	B-X
malignant	B-X
progenitors	B-X
from	B-X
patients	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
and	B-X
clonogenic	B-X
cells	B-X
from	B-X
the	B-X
human	B-X
acute	B-X
nonlymphocytic	B-X
leukemia	B-X
cell	B-X
lines	B-X
HL	B-X
-	B-X
60	B-X
and	B-X
KG	B-X
-	B-X
1	B-X

Cycloheximide	O
,	O
a	O
reversible	O
protein	O
synthesis	O
inhibitor	O
,	O
is	O
thought	O
to	O
block	O
DNA	O
replication	O
in	O
normal	B-cell_type
cells	I-cell_type
by	O
preventing	O
synthesis	O
of	O
a	O
labile	B-protein
protein	I-protein
.	O
<EOS>	B-X
Cycloheximide	B-X
,	B-X
a	B-X
reversible	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
block	B-X
DNA	B-X
replication	B-X
in	B-X
normal	B-X
cells	B-X
by	B-X
preventing	B-X
synthesis	B-X
of	B-X
a	B-X
labile	B-X
protein	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
cycloheximide	B-X
on	B-X
granulocyte	B-X
/	B-X
macrophage	B-X
progenitors	B-X
(	B-X
CFU	B-X
-	B-X
GM	B-X
)	B-X
after	B-X
in	B-X
vitro	B-X
Ara	B-X
-	B-X
C	B-X
exposure	B-X
was	B-X
examined	B-X
using	B-X
normal	B-X
human	B-X
bone	B-X
marrow	B-X
,	B-X
malignant	B-X
progenitors	B-X
from	B-X
patients	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
and	B-X
clonogenic	B-X
cells	B-X
from	B-X
the	B-X
human	B-X
acute	B-X
nonlymphocytic	B-X
leukemia	B-X
cell	B-X
lines	B-X
HL	B-X
-	B-X
60	B-X
and	B-X
KG	B-X
-	B-X
1	B-X
<EOS>	B-X
CFU	B-X
-	B-X
GM	B-X
survival	B-X
was	B-X
significantly	B-X
increase	B-X
if	B-X
normal	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
cycloheximide	B-X
before	B-X
Ara	B-X
-	B-X
C	B-X
exposure	B-X
<EOS>	B-X
Mononuclear	B-X
or	B-X
clonogenic	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
one	B-X
hour	B-X
with	B-X
cycloheximide	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
addition	B-X
,	B-X
for	B-X
three	B-X
or	B-X
17	B-X
hours	B-X
,	B-X
of	B-X
Ara	B-X
-	B-X
C	B-X
before	B-X
being	B-X
plated	B-X
in	B-X
a	B-X
methylcellulose	B-X
culture	B-X
system	B-X

In	O
animal	O
systems	O
,	O
cycloheximide	O
protects	O
normal	B-cell_type
cells	I-cell_type
from	O
cytotoxic	O
S-phase	O
specific	O
agents	O
,	O
such	O
as	O
cytosine	O
arabinoside	O
(	O
Ara-C	O
)	O
.	O
<EOS>	B-X
In	B-X
animal	B-X
systems	B-X
,	B-X
cycloheximide	B-X
protects	B-X
normal	B-X
cells	B-X
from	B-X
cytotoxic	B-X
S	B-X
-	B-X
phase	B-X
specific	B-X
agents	B-X
,	B-X
such	B-X
as	B-X
cytosine	B-X
arabinoside	B-X
(	B-X
Ara	B-X
-	B-X
C	B-X
)	B-X
<EOS>	B-X
Similar	B-X
cycloheximide	B-X
pretreatment	B-X
of	B-X
CML	B-X
progenitors	B-X
and	B-X
clonogenic	B-X
HL	B-X
-	B-X
60	B-X
and	B-X
KG	B-X
-	B-X
1	B-X
cells	B-X
failed	B-X
to	B-X
protect	B-X
CFU	B-X
-	B-X
GM	B-X
from	B-X
Ara	B-X
-	B-X
C	B-X
-	B-X
induced	B-X
cytotoxicity	B-X
<EOS>	B-X
CFU	B-X
-	B-X
GM	B-X
survival	B-X
was	B-X
significantly	B-X
increase	B-X
if	B-X
normal	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
cycloheximide	B-X
before	B-X
Ara	B-X
-	B-X
C	B-X
exposure	B-X
<EOS>	B-X
Mononuclear	B-X
or	B-X
clonogenic	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
one	B-X
hour	B-X
with	B-X
cycloheximide	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
addition	B-X
,	B-X
for	B-X
three	B-X
or	B-X
17	B-X
hours	B-X
,	B-X
of	B-X
Ara	B-X
-	B-X
C	B-X
before	B-X
being	B-X
plated	B-X
in	B-X
a	B-X
methylcellulose	B-X
culture	B-X
system	B-X

Malignant	B-cell_type
cells	I-cell_type
appear	O
not	O
to	O
be	O
susceptible	O
to	O
cycloheximide-induced	O
cycle	O
arrest	O
and	O
,	O
subsequently	O
,	O
may	O
not	O
be	O
protected	O
from	O
Ara-C	O
cytotoxicity	O
.	O
<EOS>	B-X
Malignant	B-X
transformation	B-X
and	B-X
pulmonary	B-X
metastasis	B-X
were	B-X
exclusively	B-X
reported	B-X
for	B-X
giant	B-X
cell	B-X
tumors	B-X
<EOS>	B-X
BM	B-X
adipogenesis	B-X
appears	B-X
to	B-X
be	B-X
an	B-X
emergency	B-X
phenomenon	B-X
that	B-X
follows	B-X
the	B-X
production	B-X
of	B-X
hematopoietic	B-X
stem	B-X
and	B-X
progenitor	B-X
cell	B-X
niche	B-X
factors	B-X
,	B-X
thus	B-X
regulating	B-X
physiological	B-X
,	B-X
stressed	B-X
,	B-X
and	B-X
malignant	B-X
hematopoiesis	B-X
<EOS>	B-X
As	B-X
clinical	B-X
and	B-X
radiological	B-X
elements	B-X
are	B-X
not	B-X
sufficient	B-X
to	B-X
distinguish	B-X
between	B-X
these	B-X
two	B-X
entities	B-X
,	B-X
immunohistochemistry	B-X
and	B-X
molecular	B-X
genetics	B-X
can	B-X
be	B-X
represent	B-X
diagnostic	B-X
biomarkers	B-X
to	B-X
distinguish	B-X
giant	B-X
cell	B-X
granulomas	B-X
and	B-X
giant	B-X
cell	B-X
tumors	B-X
in	B-X
oral	B-X
cavity	B-X
<EOS>	B-X
However	B-X
,	B-X
limited	B-X
biopsy	B-X
material	B-X
or	B-X
fine	B-X
-	B-X
needle	B-X
aspiration	B-X
specimens	B-X
may	B-X
be	B-X
particularly	B-X
challenging	B-X

The	O
effect	O
of	O
cycloheximide	O
on	O
granulocyte/macrophage	B-cell_type
progenitors	I-cell_type
(	O
CFU-GM	B-cell_type
)	O
after	O
in	O
vitro	O
Ara-C	O
exposure	O
was	O
examined	O
using	O
normal	O
human	O
bone	O
marrow	O
,	O
malignant	B-cell_type
progenitors	I-cell_type
from	O
patients	O
with	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
,	O
and	O
clonogenic	B-cell_line
cells	I-cell_line
from	O
the	O
human	B-cell_line
acute	I-cell_line
nonlymphocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL-60	I-cell_line
and	I-cell_line
KG-1	I-cell_line
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
cycloheximide	B-X
on	B-X
granulocyte	B-X
/	B-X
macrophage	B-X
progenitors	B-X
(	B-X
CFU	B-X
-	B-X
GM	B-X
)	B-X
after	B-X
in	B-X
vitro	B-X
Ara	B-X
-	B-X
C	B-X
exposure	B-X
was	B-X
examined	B-X
using	B-X
normal	B-X
human	B-X
bone	B-X
marrow	B-X
,	B-X
malignant	B-X
progenitors	B-X
from	B-X
patients	B-X
with	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
and	B-X
clonogenic	B-X
cells	B-X
from	B-X
the	B-X
human	B-X
acute	B-X
nonlymphocytic	B-X
leukemia	B-X
cell	B-X
lines	B-X
HL	B-X
-	B-X
60	B-X
and	B-X
KG	B-X
-	B-X
1	B-X
<EOS>	B-X
Cycloheximide	B-X
,	B-X
a	B-X
reversible	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
block	B-X
DNA	B-X
replication	B-X
in	B-X
normal	B-X
cells	B-X
by	B-X
preventing	B-X
synthesis	B-X
of	B-X
a	B-X
labile	B-X
protein	B-X
<EOS>	B-X
Similar	B-X
cycloheximide	B-X
pretreatment	B-X
of	B-X
CML	B-X
progenitors	B-X
and	B-X
clonogenic	B-X
HL	B-X
-	B-X
60	B-X
and	B-X
KG	B-X
-	B-X
1	B-X
cells	B-X
failed	B-X
to	B-X
protect	B-X
CFU	B-X
-	B-X
GM	B-X
from	B-X
Ara	B-X
-	B-X
C	B-X
-	B-X
induced	B-X
cytotoxicity	B-X
<EOS>	B-X
Mononuclear	B-X
or	B-X
clonogenic	B-X
cells	B-X
were	B-X
incubated	B-X
for	B-X
one	B-X
hour	B-X
with	B-X
cycloheximide	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
addition	B-X
,	B-X
for	B-X
three	B-X
or	B-X
17	B-X
hours	B-X
,	B-X
of	B-X
Ara	B-X
-	B-X
C	B-X
before	B-X
being	B-X
plated	B-X
in	B-X
a	B-X
methylcellulose	B-X
culture	B-X
system	B-X

Mononuclear	B-cell_line
or	I-cell_line
clonogenic	I-cell_line
cells	I-cell_line
were	O
incubated	O
for	O
one	O
hour	O
with	O
cycloheximide	O
,	O
followed	O
by	O
the	O
addition	O
,	O
for	O
three	O
or	O
17	O
hours	O
,	O
of	O
Ara-C	O
before	O
being	O
plated	O
in	O
a	O
methylcellulose	O
culture	O
system	O
.	O
<EOS>	B-X
Mononuclear	B-X
phagocytes	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
innate	B-X
immune	B-X
responses	B-X
and	B-X
represent	B-X
a	B-X
first	B-X
line	B-X
of	B-X
defence	B-X
against	B-X
pathogens	B-X
<EOS>	B-X
The	B-X
number	B-X
of	B-X
cells	B-X
with	B-X
active	B-X
caspase	B-X
3	B-X
/	B-X
7	B-X
and	B-X
,	B-X
consecutively	B-X
,	B-X
the	B-X
amount	B-X
of	B-X
cells	B-X
undergoing	B-X
apoptosis	B-X
steadily	B-X
decreased	B-X
in	B-X
presence	B-X
of	B-X
zinc	B-X
aspartate	B-X
<EOS>	B-X
Zinc	B-X
aspartate	B-X
induces	B-X
proliferation	B-X
of	B-X
resting	B-X
and	B-X
antigen	B-X
-	B-X
stimulated	B-X
human	B-X
PBMC	B-X
under	B-X
high	B-X
-	B-X
density	B-X
cell	B-X
culture	B-X
condition	B-X
.	B-X
<EOS>	B-X
To	B-X
establish	B-X
a	B-X
procedure	B-X
allowing	B-X
the	B-X
isolation	B-X
of	B-X
such	B-X
cells	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
cell	B-X
line	B-X
BC	B-X
-	B-X
M1	B-X
established	B-X
from	B-X
DTCs	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
a	B-X
breast	B-X
cancer	B-X
patient	B-X
by	B-X
stable	B-X
isotope	B-X
labeling	B-X
by	B-X
amino	B-X
acids	B-X
in	B-X
cell	B-X
culture	B-X
(	B-X
SILAC	B-X
)	B-X
and	B-X
mass	B-X
spectrometry	B-X

CFU-GM	O
survival	O
was	O
significantly	O
increase	O
if	O
normal	O
cells	O
were	O
treated	O
with	O
cycloheximide	O
before	O
Ara-C	O
exposure	O
.	O
<EOS>	B-X
CFU	B-X
-	B-X
GM	B-X
survival	B-X
was	B-X
significantly	B-X
increase	B-X
if	B-X
normal	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
cycloheximide	B-X
before	B-X
Ara	B-X
-	B-X
C	B-X
exposure	B-X
<EOS>	B-X
Cycloheximide	B-X
,	B-X
a	B-X
reversible	B-X
protein	B-X
synthesis	B-X
inhibitor	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
block	B-X
DNA	B-X
replication	B-X
in	B-X
normal	B-X
cells	B-X
by	B-X
preventing	B-X
synthesis	B-X
of	B-X
a	B-X
labile	B-X
protein	B-X
<EOS>	B-X
Malignant	B-X
cells	B-X
appear	B-X
not	B-X
to	B-X
be	B-X
susceptible	B-X
to	B-X
cycloheximide	B-X
-	B-X
induced	B-X
cycle	B-X
arrest	B-X
and	B-X
,	B-X
subsequently	B-X
,	B-X
may	B-X
not	B-X
be	B-X
protected	B-X
from	B-X
Ara	B-X
-	B-X
C	B-X
cytotoxicity	B-X
<EOS>	B-X
In	B-X
animal	B-X
systems	B-X
,	B-X
cycloheximide	B-X
protects	B-X
normal	B-X
cells	B-X
from	B-X
cytotoxic	B-X
S	B-X
-	B-X
phase	B-X
specific	B-X
agents	B-X
,	B-X
such	B-X
as	B-X
cytosine	B-X
arabinoside	B-X
(	B-X
Ara	B-X
-	B-X
C	B-X
)	B-X

Similar	O
cycloheximide	O
pretreatment	O
of	O
CML	B-cell_type
progenitors	I-cell_type
and	O
clonogenic	B-cell_line
HL-60	I-cell_line
and	I-cell_line
KG-1	I-cell_line
cells	I-cell_line
failed	O
to	O
protect	O
CFU-GM	B-cell_type
from	O
Ara-C-induced	O
cytotoxicity	O
.	O
<EOS>	B-X
Similar	B-X
cycloheximide	B-X
pretreatment	B-X
of	B-X
CML	B-X
progenitors	B-X
and	B-X
clonogenic	B-X
HL	B-X
-	B-X
60	B-X
and	B-X
KG	B-X
-	B-X
1	B-X
cells	B-X
failed	B-X
to	B-X
protect	B-X
CFU	B-X
-	B-X
GM	B-X
from	B-X
Ara	B-X
-	B-X
C	B-X
-	B-X
induced	B-X
cytotoxicity	B-X
<EOS>	B-X
Differential	B-X
protection	B-X
of	B-X
normal	B-X
and	B-X
malignant	B-X
human	B-X
myeloid	B-X
progenitors	B-X
(	B-X
CFU	B-X
-	B-X
GM	B-X
)	B-X
from	B-X
Ara	B-X
-	B-X
C	B-X
toxicity	B-X
using	B-X
cycloheximide	B-X
.	B-X
<EOS>	B-X
Malignant	B-X
cells	B-X
appear	B-X
not	B-X
to	B-X
be	B-X
susceptible	B-X
to	B-X
cycloheximide	B-X
-	B-X
induced	B-X
cycle	B-X
arrest	B-X
and	B-X
,	B-X
subsequently	B-X
,	B-X
may	B-X
not	B-X
be	B-X
protected	B-X
from	B-X
Ara	B-X
-	B-X
C	B-X
cytotoxicity	B-X
<EOS>	B-X
In	B-X
animal	B-X
systems	B-X
,	B-X
cycloheximide	B-X
protects	B-X
normal	B-X
cells	B-X
from	B-X
cytotoxic	B-X
S	B-X
-	B-X
phase	B-X
specific	B-X
agents	B-X
,	B-X
such	B-X
as	B-X
cytosine	B-X
arabinoside	B-X
(	B-X
Ara	B-X
-	B-X
C	B-X
)	B-X

Primary	O
cortisol	O
resistance	O
accompanied	O
by	O
a	O
reduction	O
in	O
glucocorticoid	B-protein
receptors	I-protein
in	O
two	O
members	O
of	O
the	O
same	O
family	O
.	O
<EOS>	B-X
Primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
two	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
.	B-X
<EOS>	B-X
To	B-X
study	B-X
this	B-X
apparent	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
cells	B-X
<EOS>	B-X
This	B-X
conclusion	B-X
is	B-X
based	B-X
on	B-X
his	B-X
high	B-X
plasma	B-X
cortisol	B-X
levels	B-X
and	B-X
high	B-X
24	B-X
-	B-X
h	B-X
urinary	B-X
17	B-X
-	B-X
hydroxycorticosteroid	B-X
and	B-X
cortisol	B-X
excretion	B-X
,	B-X
plus	B-X
the	B-X
fact	B-X
that	B-X
he	B-X
had	B-X
no	B-X
manifestations	B-X
of	B-X
Cushing	B-X
's	B-X
syndrome	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
these	B-X
two	B-X
patients	B-X
,	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
,	B-X
have	B-X
primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduced	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X

This	O
report	O
describes	O
studies	O
of	O
a	O
man	O
suspected	O
of	O
having	O
primary	O
cortisol	O
resistance	O
.	O
<EOS>	B-X
This	B-X
report	B-X
describes	B-X
studies	B-X
of	B-X
a	B-X
man	B-X
suspected	B-X
of	B-X
having	B-X
primary	B-X
cortisol	B-X
resistance	B-X
<EOS>	B-X
Among	B-X
family	B-X
members	B-X
tested	B-X
,	B-X
his	B-X
mother	B-X
also	B-X
had	B-X
hypercortisolemia	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
these	B-X
two	B-X
patients	B-X
,	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
,	B-X
have	B-X
primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduced	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Both	B-X
were	B-X
partially	B-X
resistant	B-X
to	B-X
dexamethasone	B-X
adrenal	B-X
suppression	B-X
,	B-X
and	B-X
both	B-X
had	B-X
mild	B-X
hypertension	B-X
without	B-X
hypokalemia	B-X

This	O
conclusion	O
is	O
based	O
on	O
his	O
high	O
plasma	O
cortisol	O
levels	O
and	O
high	O
24-h	O
urinary	O
17-hydroxycorticosteroid	O
and	O
cortisol	O
excretion	O
,	O
plus	O
the	O
fact	O
that	O
he	O
had	O
no	O
manifestations	O
of	O
Cushing	O
's	O
syndrome	O
.	O
<EOS>	B-X
This	B-X
conclusion	B-X
is	B-X
based	B-X
on	B-X
his	B-X
high	B-X
plasma	B-X
cortisol	B-X
levels	B-X
and	B-X
high	B-X
24	B-X
-	B-X
h	B-X
urinary	B-X
17	B-X
-	B-X
hydroxycorticosteroid	B-X
and	B-X
cortisol	B-X
excretion	B-X
,	B-X
plus	B-X
the	B-X
fact	B-X
that	B-X
he	B-X
had	B-X
no	B-X
manifestations	B-X
of	B-X
Cushing	B-X
's	B-X
syndrome	B-X
<EOS>	B-X
Both	B-X
mother	B-X
and	B-X
son	B-X
had	B-X
high	B-X
levels	B-X
of	B-X
unbound	B-X
plasma	B-X
cortisol	B-X
,	B-X
but	B-X
their	B-X
plasma	B-X
ACTH	B-X
concentrations	B-X
were	B-X
within	B-X
the	B-X
normal	B-X
range	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
these	B-X
two	B-X
patients	B-X
,	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
,	B-X
have	B-X
primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduced	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
two	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
.	B-X

Among	O
family	O
members	O
tested	O
,	O
his	O
mother	O
also	O
had	O
hypercortisolemia	O
.	O
<EOS>	B-X
Among	B-X
family	B-X
members	B-X
tested	B-X
,	B-X
his	B-X
mother	B-X
also	B-X
had	B-X
hypercortisolemia	B-X
<EOS>	B-X
This	B-X
report	B-X
describes	B-X
studies	B-X
of	B-X
a	B-X
man	B-X
suspected	B-X
of	B-X
having	B-X
primary	B-X
cortisol	B-X
resistance	B-X
<EOS>	B-X
His	B-X
father	B-X
and	B-X
sister	B-X
did	B-X
not	B-X
carry	B-X
the	B-X
same	B-X
deletion	B-X
<EOS>	B-X
Genetic	B-X
testing	B-X
is	B-X
the	B-X
gold	B-X
standard	B-X

Both	O
mother	O
and	O
son	O
had	O
high	O
levels	O
of	O
unbound	O
plasma	O
cortisol	O
,	O
but	O
their	O
plasma	O
ACTH	O
concentrations	O
were	O
within	O
the	O
normal	O
range	O
.	O
<EOS>	B-X
Both	B-X
mother	B-X
and	B-X
son	B-X
had	B-X
high	B-X
levels	B-X
of	B-X
unbound	B-X
plasma	B-X
cortisol	B-X
,	B-X
but	B-X
their	B-X
plasma	B-X
ACTH	B-X
concentrations	B-X
were	B-X
within	B-X
the	B-X
normal	B-X
range	B-X
<EOS>	B-X
This	B-X
conclusion	B-X
is	B-X
based	B-X
on	B-X
his	B-X
high	B-X
plasma	B-X
cortisol	B-X
levels	B-X
and	B-X
high	B-X
24	B-X
-	B-X
h	B-X
urinary	B-X
17	B-X
-	B-X
hydroxycorticosteroid	B-X
and	B-X
cortisol	B-X
excretion	B-X
,	B-X
plus	B-X
the	B-X
fact	B-X
that	B-X
he	B-X
had	B-X
no	B-X
manifestations	B-X
of	B-X
Cushing	B-X
's	B-X
syndrome	B-X
<EOS>	B-X
This	B-X
report	B-X
describes	B-X
studies	B-X
of	B-X
a	B-X
man	B-X
suspected	B-X
of	B-X
having	B-X
primary	B-X
cortisol	B-X
resistance	B-X
<EOS>	B-X
Among	B-X
family	B-X
members	B-X
tested	B-X
,	B-X
his	B-X
mother	B-X
also	B-X
had	B-X
hypercortisolemia	B-X

Both	O
were	O
partially	O
resistant	O
to	O
dexamethasone	O
adrenal	O
suppression	O
,	O
and	O
both	O
had	O
mild	O
hypertension	O
without	O
hypokalemia	O
.	O
<EOS>	B-X
Both	B-X
were	B-X
partially	B-X
resistant	B-X
to	B-X
dexamethasone	B-X
adrenal	B-X
suppression	B-X
,	B-X
and	B-X
both	B-X
had	B-X
mild	B-X
hypertension	B-X
without	B-X
hypokalemia	B-X
<EOS>	B-X
Among	B-X
family	B-X
members	B-X
tested	B-X
,	B-X
his	B-X
mother	B-X
also	B-X
had	B-X
hypercortisolemia	B-X
<EOS>	B-X
This	B-X
report	B-X
describes	B-X
studies	B-X
of	B-X
a	B-X
man	B-X
suspected	B-X
of	B-X
having	B-X
primary	B-X
cortisol	B-X
resistance	B-X
<EOS>	B-X
Primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
two	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
.	B-X

To	O
study	O
this	O
apparent	O
end-organ	O
resistance	O
to	O
cortisol	O
,	O
we	O
examined	O
the	O
glucocorticoid	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
To	B-X
study	B-X
this	B-X
apparent	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
cells	B-X
<EOS>	B-X
Primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
two	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
.	B-X
<EOS>	B-X
This	B-X
report	B-X
describes	B-X
studies	B-X
of	B-X
a	B-X
man	B-X
suspected	B-X
of	B-X
having	B-X
primary	B-X
cortisol	B-X
resistance	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
these	B-X
two	B-X
patients	B-X
,	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
,	B-X
have	B-X
primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduced	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X

Using	O
whole	O
cell	O
assays	O
,	O
glucocorticoid	B-protein
receptors	I-protein
in	O
both	O
patients	O
were	O
found	O
to	O
have	O
reduced	O
total	O
binding	O
capacity	O
.	O
<EOS>	B-X
Using	B-X
whole	B-X
cell	B-X
assays	B-X
,	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
both	B-X
patients	B-X
were	B-X
found	B-X
to	B-X
have	B-X
reduced	B-X
total	B-X
binding	B-X
capacity	B-X
<EOS>	B-X
This	B-X
conclusion	B-X
is	B-X
based	B-X
on	B-X
his	B-X
high	B-X
plasma	B-X
cortisol	B-X
levels	B-X
and	B-X
high	B-X
24	B-X
-	B-X
h	B-X
urinary	B-X
17	B-X
-	B-X
hydroxycorticosteroid	B-X
and	B-X
cortisol	B-X
excretion	B-X
,	B-X
plus	B-X
the	B-X
fact	B-X
that	B-X
he	B-X
had	B-X
no	B-X
manifestations	B-X
of	B-X
Cushing	B-X
's	B-X
syndrome	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
these	B-X
two	B-X
patients	B-X
,	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
,	B-X
have	B-X
primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduced	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
two	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
.	B-X

We	O
conclude	O
that	O
these	O
two	O
patients	O
,	O
members	O
of	O
the	O
same	O
family	O
,	O
have	O
primary	O
cortisol	O
resistance	O
accompanied	O
by	O
a	O
reduced	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
these	B-X
two	B-X
patients	B-X
,	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
,	B-X
have	B-X
primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduced	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Primary	B-X
cortisol	B-X
resistance	B-X
accompanied	B-X
by	B-X
a	B-X
reduction	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
two	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
.	B-X
<EOS>	B-X
This	B-X
report	B-X
describes	B-X
studies	B-X
of	B-X
a	B-X
man	B-X
suspected	B-X
of	B-X
having	B-X
primary	B-X
cortisol	B-X
resistance	B-X
<EOS>	B-X
To	B-X
study	B-X
this	B-X
apparent	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
cortisol	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
cells	B-X

[	O
Glucocorticoid	B-protein
receptors	I-protein
and	O
response	O
to	O
polychemotherapy	O
in	O
acute	O
lymphatic	O
leukemia	O
]	O
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
response	B-X
to	B-X
polychemotherapy	B-X
in	B-X
acute	B-X
lymphatic	B-X
leukemia	B-X
]	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
predict	B-X
response	B-X
to	B-X
combination	B-X
chemotherapy	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
The	B-X
study	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
leukemic	B-X
cells	B-X
may	B-X
predict	B-X
response	B-X
to	B-X
combination	B-X
chemotherapy	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
patients	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
adult	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
.	B-X

Glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
levels	O
were	O
quantified	O
in	O
leukemic	B-cell_type
blasts	I-cell_type
from	O
peripheral	O
blood	O
of	O
86	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
levels	B-X
were	B-X
quantified	B-X
in	B-X
leukemic	B-X
blasts	B-X
from	B-X
peripheral	B-X
blood	B-X
of	B-X
86	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
<EOS>	B-X
The	B-X
study	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
leukemic	B-X
cells	B-X
may	B-X
predict	B-X
response	B-X
to	B-X
combination	B-X
chemotherapy	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
response	B-X
to	B-X
polychemotherapy	B-X
in	B-X
acute	B-X
lymphatic	B-X
leukemia	B-X
]	B-X
.	B-X
<EOS>	B-X
Forty	B-X
-	B-X
seven	B-X
of	B-X
50	B-X
patients	B-X
with	B-X
leukemic	B-X
cells	B-X
containing	B-X
more	B-X
than	B-X
6,000	B-X
receptor	B-X
sites	B-X
and	B-X
22	B-X
of	B-X
36	B-X
patients	B-X
with	B-X
cells	B-X
containing	B-X
less	B-X
than	B-X
6,000	B-X
receptor	B-X
sites	B-X
achieved	B-X
remission	B-X

The	O
subsequent	O
achievement	O
of	O
complete	O
remission	O
after	O
combination	O
chemotherapy	O
was	O
correlated	O
with	O
high	O
receptor	O
levels	O
.	O
<EOS>	B-X
The	B-X
subsequent	B-X
achievement	B-X
of	B-X
complete	B-X
remission	B-X
after	B-X
combination	B-X
chemotherapy	B-X
was	B-X
correlated	B-X
with	B-X
high	B-X
receptor	B-X
levels	B-X
<EOS>	B-X
The	B-X
study	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
leukemic	B-X
cells	B-X
may	B-X
predict	B-X
response	B-X
to	B-X
combination	B-X
chemotherapy	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
response	B-X
to	B-X
polychemotherapy	B-X
in	B-X
acute	B-X
lymphatic	B-X
leukemia	B-X
]	B-X
.	B-X
<EOS>	B-X
Forty	B-X
-	B-X
seven	B-X
of	B-X
50	B-X
patients	B-X
with	B-X
leukemic	B-X
cells	B-X
containing	B-X
more	B-X
than	B-X
6,000	B-X
receptor	B-X
sites	B-X
and	B-X
22	B-X
of	B-X
36	B-X
patients	B-X
with	B-X
cells	B-X
containing	B-X
less	B-X
than	B-X
6,000	B-X
receptor	B-X
sites	B-X
achieved	B-X
remission	B-X

Forty-seven	O
of	O
50	O
patients	O
with	O
leukemic	B-cell_type
cells	I-cell_type
containing	O
more	O
than	O
6	O
,	O
000	O
receptor	O
sites	O
and	O
22	O
of	O
36	O
patients	O
with	O
cells	O
containing	O
less	O
than	O
6	O
,	O
000	O
receptor	O
sites	O
achieved	O
remission	O
.	O
<EOS>	B-X
Forty	B-X
-	B-X
seven	B-X
of	B-X
50	B-X
patients	B-X
with	B-X
leukemic	B-X
cells	B-X
containing	B-X
more	B-X
than	B-X
6,000	B-X
receptor	B-X
sites	B-X
and	B-X
22	B-X
of	B-X
36	B-X
patients	B-X
with	B-X
cells	B-X
containing	B-X
less	B-X
than	B-X
6,000	B-X
receptor	B-X
sites	B-X
achieved	B-X
remission	B-X
<EOS>	B-X
The	B-X
study	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
leukemic	B-X
cells	B-X
may	B-X
predict	B-X
response	B-X
to	B-X
combination	B-X
chemotherapy	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
<EOS>	B-X
The	B-X
study	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
leukemic	B-X
cells	B-X
may	B-X
predict	B-X
response	B-X
to	B-X
combination	B-X
chemotherapy	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
patients	B-X
<EOS>	B-X
Subsequent	B-X
achievement	B-X
of	B-X
complete	B-X
remission	B-X
correlated	B-X
with	B-X
high	B-X
receptor	B-X
levels	B-X

The	O
study	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
leukemic	B-cell_type
cells	I-cell_type
may	O
predict	O
response	O
to	O
combination	O
chemotherapy	O
in	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Specific	O
uptake	O
of	O
1	O
,	O
25-dihydroxycholecalciferol	O
by	O
human	B-cell_type
chronic	I-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Specific	B-X
uptake	B-X
of	B-X
1,25	B-X
-	B-X
dihydroxycholecalciferol	B-X
by	B-X
human	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
cells	B-X
.	B-X
<EOS>	B-X
5	B-X
]	B-X
or	B-X
than	B-X
did	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
[	B-X
2	B-X
<EOS>	B-X
)	B-X
fmol	B-X
/	B-X
10	B-X
(	B-X
7	B-X
)	B-X
cells	B-X
]	B-X
than	B-X
did	B-X
those	B-X
in	B-X
acute	B-X
myeloid	B-X
transformation	B-X
[	B-X
7	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
cytosols	B-X
prepared	B-X
from	B-X
a	B-X
mixture	B-X
of	B-X
CML	B-X
cells	B-X
and	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptor	B-X
-	B-X
positive	B-X
T47D	B-X
(	B-X
human	B-X
breast	B-X
cancer	B-X
)	B-X
cells	B-X
had	B-X
less	B-X
than	B-X
10	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
measured	B-X
in	B-X
T47D	B-X
cytosol	B-X
alone	B-X

We	O
have	O
examined	O
mononuclear	B-cell_line
cell	I-cell_line
preparations	I-cell_line
from	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
[	O
CML	O
]	O
for	O
binding	O
of	O
and	O
response	O
to	O
1	O
,	O
25-dihydroxycholecalciferol	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
mononuclear	B-X
cell	B-X
preparations	B-X
from	B-X
patients	B-X
with	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
[	B-X
CML	B-X
]	B-X
for	B-X
binding	B-X
of	B-X
and	B-X
response	B-X
to	B-X
1,25	B-X
-	B-X
dihydroxycholecalciferol	B-X
[	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
]	B-X
<EOS>	B-X
Cells	B-X
from	B-X
patients	B-X
with	B-X
CML	B-X
in	B-X
the	B-X
chronic	B-X
phase	B-X
specifically	B-X
bound	B-X
more	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
[	B-X
18	B-X
<EOS>	B-X
5	B-X
]	B-X
or	B-X
than	B-X
did	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
[	B-X
2	B-X
<EOS>	B-X
Subcellular	B-X
fractionation	B-X
of	B-X
labeled	B-X
cells	B-X
showed	B-X
that	B-X
binding	B-X
was	B-X
restricted	B-X
to	B-X
cytosols	B-X
and	B-X
nuclei	B-X

Whole	O
cells	O
specifically	O
took	O
up	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
with	O
high	O
affinity	O
(	O
Kd	O
3.6	O
X	O
10	O
(	O
-11	O
)	O
M	O
)	O
and	O
low	O
capacity	O
.	O
<EOS>	B-X
Whole	B-X
cells	B-X
specifically	B-X
took	B-X
up	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
with	B-X
high	B-X
affinity	B-X
(	B-X
Kd	B-X
3	B-X
<EOS>	B-X
Thus	B-X
,	B-X
CML	B-X
cells	B-X
appear	B-X
to	B-X
contain	B-X
both	B-X
the	B-X
receptor	B-X
for	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
and	B-X
an	B-X
unknown	B-X
substance	B-X
which	B-X
prevents	B-X
its	B-X
detection	B-X
following	B-X
the	B-X
preparation	B-X
of	B-X
cytosol	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
cytosols	B-X
prepared	B-X
from	B-X
a	B-X
mixture	B-X
of	B-X
CML	B-X
cells	B-X
and	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptor	B-X
-	B-X
positive	B-X
T47D	B-X
(	B-X
human	B-X
breast	B-X
cancer	B-X
)	B-X
cells	B-X
had	B-X
less	B-X
than	B-X
10	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
measured	B-X
in	B-X
T47D	B-X
cytosol	B-X
alone	B-X
<EOS>	B-X
6	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
11	B-X
)	B-X
M	B-X
)	B-X
and	B-X
low	B-X
capacity	B-X

Subcellular	O
fractionation	O
of	O
labeled	B-cell_line
cells	I-cell_line
showed	O
that	O
binding	O
was	O
restricted	O
to	O
cytosols	O
and	O
nuclei	O
.	O
<EOS>	B-X
Subcellular	B-X
fractionation	B-X
of	B-X
labeled	B-X
cells	B-X
showed	B-X
that	B-X
binding	B-X
was	B-X
restricted	B-X
to	B-X
cytosols	B-X
and	B-X
nuclei	B-X
<EOS>	B-X
Direct	B-X
targeting	B-X
of	B-X
cis	B-X
-	B-X
Golgi	B-X
matrix	B-X
proteins	B-X
to	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
<EOS>	B-X
5	B-X
]	B-X
or	B-X
than	B-X
did	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
[	B-X
2	B-X
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
mononuclear	B-X
cell	B-X
preparations	B-X
from	B-X
patients	B-X
with	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
[	B-X
CML	B-X
]	B-X
for	B-X
binding	B-X
of	B-X
and	B-X
response	B-X
to	B-X
1,25	B-X
-	B-X
dihydroxycholecalciferol	B-X
[	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
]	B-X

Sucrose	O
gradient	O
centrifugation	O
of	O
cells	O
preincubated	O
with	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
revealed	O
a	O
single	O
3.6S	O
peak	O
which	O
was	O
totally	O
displaced	O
with	O
100-fold	O
excess	O
nonradioactive	O
hormone	O
.	O
<EOS>	B-X
Sucrose	B-X
gradient	B-X
centrifugation	B-X
of	B-X
cells	B-X
preincubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
revealed	B-X
a	B-X
single	B-X
3	B-X
<EOS>	B-X
6S	B-X
peak	B-X
which	B-X
was	B-X
totally	B-X
displaced	B-X
with	B-X
100	B-X
-	B-X
fold	B-X
excess	B-X
nonradioactive	B-X
hormone	B-X
<EOS>	B-X
However	B-X
,	B-X
we	B-X
were	B-X
unable	B-X
to	B-X
demonstrate	B-X
specific	B-X
binding	B-X
of	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
by	B-X
postlabeling	B-X
standard	B-X
cytosol	B-X
preparations	B-X
<EOS>	B-X
Thus	B-X
,	B-X
CML	B-X
cells	B-X
appear	B-X
to	B-X
contain	B-X
both	B-X
the	B-X
receptor	B-X
for	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
and	B-X
an	B-X
unknown	B-X
substance	B-X
which	B-X
prevents	B-X
its	B-X
detection	B-X
following	B-X
the	B-X
preparation	B-X
of	B-X
cytosol	B-X

However	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
specific	O
binding	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	O
postlabeling	O
standard	O
cytosol	O
preparations	O
.	O
<EOS>	B-X
However	B-X
,	B-X
we	B-X
were	B-X
unable	B-X
to	B-X
demonstrate	B-X
specific	B-X
binding	B-X
of	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
by	B-X
postlabeling	B-X
standard	B-X
cytosol	B-X
preparations	B-X
<EOS>	B-X
Only	B-X
cells	B-X
from	B-X
the	B-X
first	B-X
group	B-X
of	B-X
patients	B-X
responded	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
by	B-X
differentiating	B-X
along	B-X
the	B-X
monocyte	B-X
-	B-X
macrophage	B-X
pathway	B-X
<EOS>	B-X
Thus	B-X
,	B-X
CML	B-X
cells	B-X
appear	B-X
to	B-X
contain	B-X
both	B-X
the	B-X
receptor	B-X
for	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
and	B-X
an	B-X
unknown	B-X
substance	B-X
which	B-X
prevents	B-X
its	B-X
detection	B-X
following	B-X
the	B-X
preparation	B-X
of	B-X
cytosol	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
binding	B-X
in	B-X
T47D	B-X
cytosols	B-X
were	B-X
not	B-X
reduced	B-X
if	B-X
the	B-X
receptors	B-X
were	B-X
occupied	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
prior	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
CML	B-X
cytosols	B-X

In	O
addition	O
,	O
cytosols	O
prepared	O
from	O
a	O
mixture	O
of	O
CML	B-cell_line
cells	I-cell_line
and	O
1	B-cell_line
,	I-cell_line
25-	I-cell_line
(	I-cell_line
OH	I-cell_line
)	I-cell_line
2D3	I-cell_line
receptor-positive	I-cell_line
T47D	I-cell_line
(	O
human	O
breast	O
cancer	O
)	O
cells	O
had	O
less	O
than	O
10	O
%	O
of	O
the	O
binding	O
measured	O
in	O
T47D	B-cell_line
cytosol	O
alone	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
cytosols	B-X
prepared	B-X
from	B-X
a	B-X
mixture	B-X
of	B-X
CML	B-X
cells	B-X
and	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptor	B-X
-	B-X
positive	B-X
T47D	B-X
(	B-X
human	B-X
breast	B-X
cancer	B-X
)	B-X
cells	B-X
had	B-X
less	B-X
than	B-X
10	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
measured	B-X
in	B-X
T47D	B-X
cytosol	B-X
alone	B-X
<EOS>	B-X
Thus	B-X
,	B-X
CML	B-X
cells	B-X
appear	B-X
to	B-X
contain	B-X
both	B-X
the	B-X
receptor	B-X
for	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
and	B-X
an	B-X
unknown	B-X
substance	B-X
which	B-X
prevents	B-X
its	B-X
detection	B-X
following	B-X
the	B-X
preparation	B-X
of	B-X
cytosol	B-X
<EOS>	B-X
Subcellular	B-X
fractionation	B-X
of	B-X
labeled	B-X
cells	B-X
showed	B-X
that	B-X
binding	B-X
was	B-X
restricted	B-X
to	B-X
cytosols	B-X
and	B-X
nuclei	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
differentiation	B-X
-	B-X
induction	B-X
effect	B-X
of	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
is	B-X
likely	B-X
to	B-X
depend	B-X
on	B-X
adequate	B-X
levels	B-X
of	B-X
receptor	B-X
and	B-X
that	B-X
intact	B-X
cells	B-X
rather	B-X
than	B-X
cytosol	B-X
preparations	B-X
should	B-X
be	B-X
studied	B-X
before	B-X
cells	B-X
of	B-X
a	B-X
particular	B-X
tissue	B-X
are	B-X
designated	B-X
as	B-X
receptor	B-X
negative	B-X

However	O
,	O
the	O
levels	O
of	O
binding	O
in	O
T47D	B-cell_line
cytosols	O
were	O
not	O
reduced	O
if	O
the	O
receptors	O
were	O
occupied	O
with	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
prior	O
to	O
the	O
addition	O
of	O
the	O
CML	B-cell_line
cytosols	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
the	B-X
cyclosporin	B-X
A	B-X
-	B-X
binding	B-X
protein	B-X
,	B-X
CyP	B-X
-	B-X
40	B-X
,	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
isolated	B-X
chicken	B-X
PR	B-X
complexes	B-X
and	B-X
in	B-X
PR	B-X
complexes	B-X
that	B-X
were	B-X
reconstituted	B-X
in	B-X
vitro	B-X
,	B-X
but	B-X
this	B-X
protein	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
human	B-X
PR	B-X
complexes	B-X
,	B-X
which	B-X
are	B-X
less	B-X
stable	B-X
than	B-X
chicken	B-X
PR	B-X
complexes	B-X
in	B-X
cytosol	B-X
extracts	B-X
<EOS>	B-X
Overexpressing	B-X
GPR40	B-X
in	B-X
T47D	B-X
and	B-X
MCF	B-X
-	B-X
7	B-X
breast	B-X
cancer	B-X
cells	B-X
that	B-X
are	B-X
poorly	B-X
responsive	B-X
to	B-X
oleate	B-X
allowed	B-X
a	B-X
robust	B-X
proliferative	B-X
action	B-X
of	B-X
oleate	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
in	B-X
areas	B-X
with	B-X
abundant	B-X
endocytic	B-X
vesicles	B-X
the	B-X
labels	B-X
for	B-X
both	B-X
IT	B-X
moieties	B-X
were	B-X
also	B-X
found	B-X
in	B-X
the	B-X
cytosol	B-X
,	B-X
suggesting	B-X
that	B-X
intact	B-X
IT	B-X
is	B-X
translocated	B-X
from	B-X
the	B-X
vesicles	B-X
into	B-X
the	B-X
cytosol	B-X
<EOS>	B-X
Another	B-X
complex	B-X
identified	B-X
in	B-X
T47D	B-X
cytosol	B-X
contained	B-X
hsp90	B-X
and	B-X
the	B-X
cyclosporin	B-X
A	B-X
-	B-X
binding	B-X
cyclophilin	B-X
of	B-X
40	B-X
kDa	B-X
,	B-X
CYP40	B-X
,	B-X
but	B-X
not	B-X
hsp70	B-X
,	B-X
PR	B-X
,	B-X
or	B-X
GR	B-X

Thus	O
,	O
CML	B-cell_line
cells	I-cell_line
appear	O
to	O
contain	O
both	O
the	O
receptor	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
and	O
an	O
unknown	O
substance	O
which	O
prevents	O
its	O
detection	O
following	O
the	O
preparation	O
of	O
cytosol	O
.	O

Cells	O
from	O
patients	O
with	O
CML	O
in	O
the	O
chronic	O
phase	O
specifically	O
bound	O
more	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
[	O
18.0	O
+/-	O
3.2	O
(	O
S.E.	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
]	O
than	O
did	O
those	O
in	O
acute	O
myeloid	O
transformation	O
[	O
7.2	O
+/-	O
1.5	O
]	O
or	O
than	O
did	O
cells	O
from	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
[	O
2.6	O
+/-	O
0.8	O
]	O
.	O
<EOS>	B-X
Studies	B-X
have	B-X
not	B-X
systematically	B-X
compared	B-X
the	B-X
ability	B-X
to	B-X
verify	B-X
performance	B-X
of	B-X
prognostic	B-X
transcripts	B-X
in	B-X
paired	B-X
bulk	B-X
mononuclear	B-X
cells	B-X
versus	B-X
viable	B-X
CD34	B-X
-	B-X
expressing	B-X
leukemic	B-X
blasts	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
<EOS>	B-X
This	B-X
research	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanism	B-X
underlying	B-X
the	B-X
self	B-X
-	B-X
renewal	B-X
capacity	B-X
of	B-X
leukemic	B-X
stem	B-X
cells	B-X
(	B-X
LSCs	B-X
)	B-X
to	B-X
offer	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
treatment	B-X
of	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
<EOS>	B-X
Verification	B-X
of	B-X
prognostic	B-X
expression	B-X
biomarkers	B-X
is	B-X
improved	B-X
by	B-X
examining	B-X
enriched	B-X
leukemic	B-X
blasts	B-X
rather	B-X
than	B-X
mononuclear	B-X
cells	B-X
from	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
patients	B-X
.	B-X
<EOS>	B-X
Among	B-X
patients	B-X
≥	B-X
65	B-X
-	B-X
70	B-X
years	B-X
,	B-X
the	B-X
mortality	B-X
in	B-X
complete	B-X
remission	B-X
(	B-X
CR	B-X
)	B-X
is	B-X
still	B-X
high	B-X
and	B-X
is	B-X
multifactorial	B-X
(	B-X
old	B-X
age	B-X
,	B-X
death	B-X
in	B-X
CR	B-X
with	B-X
infections	B-X
,	B-X
development	B-X
of	B-X
myelodysplastic	B-X
syndrome	B-X
or	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
)	B-X

Only	O
cells	O
from	O
the	O
first	O
group	O
of	O
patients	O
responded	O
to	O
the	O
addition	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	O
differentiating	O
along	O
the	O
monocyte-macrophage	O
pathway	O
.	O

We	O
conclude	O
that	O
the	O
differentiation-induction	O
effect	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
is	O
likely	O
to	O
depend	O
on	O
adequate	O
levels	O
of	O
receptor	O
and	O
that	O
intact	B-cell_type
cells	I-cell_type
rather	O
than	O
cytosol	O
preparations	O
should	O
be	O
studied	O
before	O
cells	O
of	O
a	O
particular	O
tissue	O
are	O
designated	O
as	O
receptor	O
negative	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
differentiation	B-X
-	B-X
induction	B-X
effect	B-X
of	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
is	B-X
likely	B-X
to	B-X
depend	B-X
on	B-X
adequate	B-X
levels	B-X
of	B-X
receptor	B-X
and	B-X
that	B-X
intact	B-X
cells	B-X
rather	B-X
than	B-X
cytosol	B-X
preparations	B-X
should	B-X
be	B-X
studied	B-X
before	B-X
cells	B-X
of	B-X
a	B-X
particular	B-X
tissue	B-X
are	B-X
designated	B-X
as	B-X
receptor	B-X
negative	B-X
<EOS>	B-X
Thus	B-X
,	B-X
CML	B-X
cells	B-X
appear	B-X
to	B-X
contain	B-X
both	B-X
the	B-X
receptor	B-X
for	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
and	B-X
an	B-X
unknown	B-X
substance	B-X
which	B-X
prevents	B-X
its	B-X
detection	B-X
following	B-X
the	B-X
preparation	B-X
of	B-X
cytosol	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
cytosols	B-X
prepared	B-X
from	B-X
a	B-X
mixture	B-X
of	B-X
CML	B-X
cells	B-X
and	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptor	B-X
-	B-X
positive	B-X
T47D	B-X
(	B-X
human	B-X
breast	B-X
cancer	B-X
)	B-X
cells	B-X
had	B-X
less	B-X
than	B-X
10	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
measured	B-X
in	B-X
T47D	B-X
cytosol	B-X
alone	B-X
<EOS>	B-X
Subcellular	B-X
fractionation	B-X
of	B-X
labeled	B-X
cells	B-X
showed	B-X
that	B-X
binding	B-X
was	B-X
restricted	B-X
to	B-X
cytosols	B-X
and	B-X
nuclei	B-X

Effect	O
of	O
cell	O
cycle	O
position	O
on	O
dexamethasone	O
binding	O
by	O
mouse	B-cell_line
and	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
correlation	O
between	O
an	O
increase	O
in	O
dexamethasone	O
binding	O
during	O
S	O
phase	O
and	O
dexamethasone	O
sensitivity	O
.	O

We	O
determined	O
the	O
effect	O
of	O
cell	O
cycle	O
position	O
on	O
the	O
amount	O
of	O
dexamethasone	O
that	O
was	O
specifically	O
bound	O
by	O
mouse	B-cell_line
and	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
We	B-X
determined	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
cycle	B-X
position	B-X
on	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
that	B-X
was	B-X
specifically	B-X
bound	B-X
by	B-X
mouse	B-X
and	B-X
human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Results	B-X
were	B-X
the	B-X
same	B-X
when	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
milligram	B-X
of	B-X
cell	B-X
protein	B-X
was	B-X
measured	B-X
<EOS>	B-X
In	B-X
three	B-X
dexamethasone	B-X
-	B-X
sensitive	B-X
cell	B-X
lines	B-X
(	B-X
two	B-X
mouse	B-X
and	B-X
one	B-X
human	B-X
)	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
increased	B-X
2	B-X
-	B-X
4	B-X
-	B-X
fold	B-X
between	B-X
G1	B-X
phase	B-X
and	B-X
S	B-X
phase	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
during	B-X
G2	B-X
/	B-X
M	B-X
phase	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
by	B-X
three	B-X
dexamethasone	B-X
-	B-X
resistant	B-X
cell	B-X
lines	B-X
(	B-X
two	B-X
mouse	B-X
and	B-X
one	B-X
human	B-X
)	B-X
did	B-X
not	B-X
increase	B-X
during	B-X
S	B-X
phase	B-X

Cell	B-cell_line
lines	I-cell_line
that	O
were	O
either	O
sensitive	O
or	O
resistant	O
to	O
growth	O
inhibition	O
by	O
dexamethasone	O
were	O
compared	O
.	O
<EOS>	B-X
Therapeutically	B-X
,	B-X
NKX2	B-X
-	B-X
1	B-X
-	B-X
expressing	B-X
cancer	B-X
cells	B-X
are	B-X
more	B-X
sensitive	B-X
to	B-X
serine	B-X
/	B-X
glycine	B-X
conversion	B-X
inhibition	B-X
by	B-X
repurposed	B-X
anti	B-X
-	B-X
depressant	B-X
sertraline	B-X
,	B-X
and	B-X
to	B-X
etoposide	B-X
chemotherapy	B-X
<EOS>	B-X
CAR	B-X
T	B-X
cells	B-X
exert	B-X
their	B-X
cytotoxic	B-X
function	B-X
through	B-X
secretion	B-X
of	B-X
granzymes	B-X
and	B-X
perforin	B-X
<EOS>	B-X
RECs	B-X
might	B-X
serve	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
strategy	B-X
for	B-X
diseases	B-X
linked	B-X
to	B-X
mitochondrial	B-X
dysfunction	B-X
by	B-X
donating	B-X
healthy	B-X
mitochondria	B-X
<EOS>	B-X
Overall	B-X
,	B-X
the	B-X
data	B-X
indicate	B-X
that	B-X
serpin	B-X
B9	B-X
is	B-X
a	B-X
resistance	B-X
mediator	B-X
for	B-X
CAR	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
tumor	B-X
cell	B-X
killing	B-X
that	B-X
should	B-X
be	B-X
inhibited	B-X
or	B-X
bypassed	B-X
to	B-X
improve	B-X
CAR	B-X
T	B-X
-	B-X
cell	B-X
responses	B-X

Exponentially	B-cell_type
growing	I-cell_type
cells	I-cell_type
were	O
separated	O
by	O
centrifugal	O
elutriation	O
into	O
fractions	O
that	O
corresponded	O
to	O
different	O
positions	O
in	O
the	O
cell	O
cycle	O
.	O
<EOS>	B-X
Exponentially	B-X
growing	B-X
cells	B-X
were	B-X
separated	B-X
by	B-X
centrifugal	B-X
elutriation	B-X
into	B-X
fractions	B-X
that	B-X
corresponded	B-X
to	B-X
different	B-X
positions	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
cell	B-X
cycle	B-X
changes	B-X
in	B-X
dexamethasone	B-X
binding	B-X
are	B-X
not	B-X
simply	B-X
related	B-X
to	B-X
changes	B-X
in	B-X
cell	B-X
protein	B-X
or	B-X
cell	B-X
volume	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
Cell	B-X
lines	B-X
that	B-X
were	B-X
either	B-X
sensitive	B-X
or	B-X
resistant	B-X
to	B-X
growth	B-X
inhibition	B-X
by	B-X
dexamethasone	B-X
were	B-X
compared	B-X
<EOS>	B-X
The	B-X
cell	B-X
cycle	B-X
phase	B-X
distribution	B-X
of	B-X
each	B-X
fraction	B-X
was	B-X
estimated	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
autoradiography	B-X

The	O
cell	O
cycle	O
phase	O
distribution	O
of	O
each	O
fraction	O
was	O
estimated	O
by	O
flow	O
cytometry	O
and	O
autoradiography	O
.	O
<EOS>	B-X
The	B-X
cell	B-X
cycle	B-X
phase	B-X
distribution	B-X
of	B-X
each	B-X
fraction	B-X
was	B-X
estimated	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
autoradiography	B-X
<EOS>	B-X
The	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
in	B-X
each	B-X
fraction	B-X
was	B-X
measured	B-X
by	B-X
a	B-X
whole	B-X
cell	B-X
binding	B-X
assay	B-X
<EOS>	B-X
We	B-X
determined	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
cycle	B-X
position	B-X
on	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
that	B-X
was	B-X
specifically	B-X
bound	B-X
by	B-X
mouse	B-X
and	B-X
human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Binding	B-X
affinity	B-X
was	B-X
the	B-X
same	B-X
during	B-X
G1	B-X
phase	B-X
and	B-X
S	B-X
phase	B-X
,	B-X
but	B-X
the	B-X
proportion	B-X
of	B-X
bound	B-X
dexamethasone	B-X
that	B-X
translocated	B-X
to	B-X
the	B-X
nucleus	B-X
was	B-X
greater	B-X
during	B-X
S	B-X
phase	B-X

The	O
amount	O
of	O
dexamethasone	O
bound	O
per	O
cell	O
in	O
each	O
fraction	O
was	O
measured	O
by	O
a	O
whole	O
cell	O
binding	O
assay	O
.	O
<EOS>	B-X
The	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
in	B-X
each	B-X
fraction	B-X
was	B-X
measured	B-X
by	B-X
a	B-X
whole	B-X
cell	B-X
binding	B-X
assay	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
by	B-X
three	B-X
dexamethasone	B-X
-	B-X
resistant	B-X
cell	B-X
lines	B-X
(	B-X
two	B-X
mouse	B-X
and	B-X
one	B-X
human	B-X
)	B-X
did	B-X
not	B-X
increase	B-X
during	B-X
S	B-X
phase	B-X
<EOS>	B-X
The	B-X
cell	B-X
cycle	B-X
phase	B-X
distribution	B-X
of	B-X
each	B-X
fraction	B-X
was	B-X
estimated	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
autoradiography	B-X
<EOS>	B-X
Effect	B-X
of	B-X
cell	B-X
cycle	B-X
position	B-X
on	B-X
dexamethasone	B-X
binding	B-X
by	B-X
mouse	B-X
and	B-X
human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
:	B-X
correlation	B-X
between	B-X
an	B-X
increase	B-X
in	B-X
dexamethasone	B-X
binding	B-X
during	B-X
S	B-X
phase	B-X
and	B-X
dexamethasone	B-X
sensitivity	B-X
.	B-X

In	O
three	O
dexamethasone-sensitive	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
two	O
mouse	O
and	O
one	O
human	O
)	O
,	O
we	O
found	O
that	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
per	O
cell	O
increased	O
2-4-fold	O
between	O
G1	O
phase	O
and	O
S	O
phase	O
,	O
and	O
then	O
decreased	O
during	O
G2/M	O
phase	O
.	O
<EOS>	B-X
In	B-X
three	B-X
dexamethasone	B-X
-	B-X
sensitive	B-X
cell	B-X
lines	B-X
(	B-X
two	B-X
mouse	B-X
and	B-X
one	B-X
human	B-X
)	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
increased	B-X
2	B-X
-	B-X
4	B-X
-	B-X
fold	B-X
between	B-X
G1	B-X
phase	B-X
and	B-X
S	B-X
phase	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
during	B-X
G2	B-X
/	B-X
M	B-X
phase	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
by	B-X
three	B-X
dexamethasone	B-X
-	B-X
resistant	B-X
cell	B-X
lines	B-X
(	B-X
two	B-X
mouse	B-X
and	B-X
one	B-X
human	B-X
)	B-X
did	B-X
not	B-X
increase	B-X
during	B-X
S	B-X
phase	B-X
<EOS>	B-X
An	B-X
increase	B-X
in	B-X
dexamethasone	B-X
binding	B-X
during	B-X
S	B-X
phase	B-X
may	B-X
be	B-X
required	B-X
for	B-X
dexamethasone	B-X
to	B-X
inhibit	B-X
cell	B-X
growth	B-X
,	B-X
and	B-X
a	B-X
failure	B-X
of	B-X
dexamethasone	B-X
binding	B-X
to	B-X
increase	B-X
during	B-X
S	B-X
phase	B-X
might	B-X
represent	B-X
a	B-X
new	B-X
mechanism	B-X
of	B-X
dexamethasone	B-X
resistance	B-X
in	B-X
lymphoid	B-X
cells	B-X
<EOS>	B-X
Binding	B-X
affinity	B-X
was	B-X
the	B-X
same	B-X
during	B-X
G1	B-X
phase	B-X
and	B-X
S	B-X
phase	B-X
,	B-X
but	B-X
the	B-X
proportion	B-X
of	B-X
bound	B-X
dexamethasone	B-X
that	B-X
translocated	B-X
to	B-X
the	B-X
nucleus	B-X
was	B-X
greater	B-X
during	B-X
S	B-X
phase	B-X

Results	O
were	O
the	O
same	O
when	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
per	O
milligram	O
of	O
cell	B-protein
protein	I-protein
was	O
measured	O
.	O
<EOS>	B-X
Results	B-X
were	B-X
the	B-X
same	B-X
when	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
milligram	B-X
of	B-X
cell	B-X
protein	B-X
was	B-X
measured	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
by	B-X
three	B-X
dexamethasone	B-X
-	B-X
resistant	B-X
cell	B-X
lines	B-X
(	B-X
two	B-X
mouse	B-X
and	B-X
one	B-X
human	B-X
)	B-X
did	B-X
not	B-X
increase	B-X
during	B-X
S	B-X
phase	B-X
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
cell	B-X
cycle	B-X
changes	B-X
in	B-X
dexamethasone	B-X
binding	B-X
are	B-X
not	B-X
simply	B-X
related	B-X
to	B-X
changes	B-X
in	B-X
cell	B-X
protein	B-X
or	B-X
cell	B-X
volume	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
We	B-X
determined	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
cycle	B-X
position	B-X
on	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
that	B-X
was	B-X
specifically	B-X
bound	B-X
by	B-X
mouse	B-X
and	B-X
human	B-X
lymphoid	B-X
cell	B-X
lines	B-X

Binding	O
affinity	O
was	O
the	O
same	O
during	O
G1	O
phase	O
and	O
S	O
phase	O
,	O
but	O
the	O
proportion	O
of	O
bound	O
dexamethasone	O
that	O
translocated	O
to	O
the	O
nucleus	O
was	O
greater	O
during	O
S	O
phase	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
per	O
cell	O
by	O
three	O
dexamethasone-resistant	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
two	O
mouse	O
and	O
one	O
human	O
)	O
did	O
not	O
increase	O
during	O
S	O
phase	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
by	B-X
three	B-X
dexamethasone	B-X
-	B-X
resistant	B-X
cell	B-X
lines	B-X
(	B-X
two	B-X
mouse	B-X
and	B-X
one	B-X
human	B-X
)	B-X
did	B-X
not	B-X
increase	B-X
during	B-X
S	B-X
phase	B-X
<EOS>	B-X
In	B-X
three	B-X
dexamethasone	B-X
-	B-X
sensitive	B-X
cell	B-X
lines	B-X
(	B-X
two	B-X
mouse	B-X
and	B-X
one	B-X
human	B-X
)	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
increased	B-X
2	B-X
-	B-X
4	B-X
-	B-X
fold	B-X
between	B-X
G1	B-X
phase	B-X
and	B-X
S	B-X
phase	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
during	B-X
G2	B-X
/	B-X
M	B-X
phase	B-X
<EOS>	B-X
The	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
cell	B-X
in	B-X
each	B-X
fraction	B-X
was	B-X
measured	B-X
by	B-X
a	B-X
whole	B-X
cell	B-X
binding	B-X
assay	B-X
<EOS>	B-X
Results	B-X
were	B-X
the	B-X
same	B-X
when	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
per	B-X
milligram	B-X
of	B-X
cell	B-X
protein	B-X
was	B-X
measured	B-X

Our	O
results	O
indicate	O
that	O
cell	O
cycle	O
changes	O
in	O
dexamethasone	O
binding	O
are	O
not	O
simply	O
related	O
to	O
changes	O
in	O
cell	B-protein
protein	I-protein
or	O
cell	O
volume	O
during	O
the	O
cell	O
cycle	O
.	O
<EOS>	B-X
This	B-X
clearly	B-X
indicates	B-X
the	B-X
lacunae	B-X
in	B-X
the	B-X
study	B-X
of	B-X
the	B-X
nucleolar	B-X
proteins	B-X
pertaining	B-X
to	B-X
cancer	B-X
<EOS>	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
nitrogen	B-X
streamlining	B-X
in	B-X
both	B-X
cellular	B-X
and	B-X
viral	B-X
genomes	B-X
on	B-X
spatial	B-X
scales	B-X
of	B-X
meters	B-X
to	B-X
microns	B-X
<EOS>	B-X
The	B-X
results	B-X
of	B-X
this	B-X
phase	B-X
II	B-X
trial	B-X
will	B-X
be	B-X
helpful	B-X
to	B-X
clarify	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
the	B-X
sequential	B-X
addition	B-X
of	B-X
tislelizumab	B-X
after	B-X
neoadjuvant	B-X
chemoradiotherapy	B-X
for	B-X
locally	B-X
advanced	B-X
resectable	B-X
esophageal	B-X
carcinoma	B-X
<EOS>	B-X
How	B-X
cells	B-X
regulate	B-X
their	B-X
cell	B-X
cycles	B-X
is	B-X
a	B-X
central	B-X
question	B-X
for	B-X
cell	B-X
biology	B-X

An	O
increase	O
in	O
dexamethasone	O
binding	O
during	O
S	O
phase	O
may	O
be	O
required	O
for	O
dexamethasone	O
to	O
inhibit	O
cell	O
growth	O
,	O
and	O
a	O
failure	O
of	O
dexamethasone	O
binding	O
to	O
increase	O
during	O
S	O
phase	O
might	O
represent	O
a	O
new	O
mechanism	O
of	O
dexamethasone	O
resistance	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Presence	O
and	O
steroid	O
inducibility	O
of	O
glutamine	B-protein
synthetase	I-protein
in	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Presence	B-X
and	B-X
steroid	B-X
inducibility	B-X
of	B-X
glutamine	B-X
synthetase	B-X
in	B-X
human	B-X
leukemic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Glutamine	B-X
synthetase	B-X
induction	B-X
by	B-X
glucocorticoids	B-X
in	B-X
the	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
-	B-X
C7	B-X
.	B-X
<EOS>	B-X
5	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
GS	B-X
activity	B-X
,	B-X
ruling	B-X
out	B-X
inhibition	B-X
of	B-X
glutamine	B-X
uptake	B-X
as	B-X
a	B-X
mechanism	B-X
for	B-X
the	B-X
dex	B-X
-	B-X
induced	B-X
increase	B-X
<EOS>	B-X
Hybrids	B-X
were	B-X
analyzed	B-X
for	B-X
chromosome	B-X
content	B-X
,	B-X
steroid	B-X
-	B-X
induced	B-X
growth	B-X
inhibition	B-X
,	B-X
induction	B-X
of	B-X
the	B-X
enzyme	B-X
glutamine	B-X
synthetase	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X

Glutamine	B-protein
synthetase	I-protein
(	O
EC	O
6.3.1.2	O
;	O
GS	O
)	O
is	O
present	O
in	O
lymphoblasts	B-cell_type
from	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
as	O
well	O
as	O
in	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
16	O
out	O
of	O
20	O
ALL	O
patients	O
studied	O
exposure	O
of	O
the	O
cells	O
to	O
physiological	O
concentrations	O
of	O
dexamethasone	O
in	O
vitro	O
increased	O
enzyme	B-protein
activity	O
above	O
the	O
control	O
levels	O
.	O
<EOS>	B-X
In	B-X
16	B-X
out	B-X
of	B-X
20	B-X
ALL	B-X
patients	B-X
studied	B-X
exposure	B-X
of	B-X
the	B-X
cells	B-X
to	B-X
physiological	B-X
concentrations	B-X
of	B-X
dexamethasone	B-X
in	B-X
vitro	B-X
increased	B-X
enzyme	B-X
activity	B-X
above	B-X
the	B-X
control	B-X
levels	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
basal	B-X
levels	B-X
of	B-X
the	B-X
enzyme	B-X
measured	B-X
in	B-X
cells	B-X
prior	B-X
to	B-X
exposure	B-X
to	B-X
dexamethasone	B-X
correlated	B-X
negatively	B-X
with	B-X
receptor	B-X
density	B-X
<EOS>	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
steroid	B-X
-	B-X
inducible	B-X
GS	B-X
in	B-X
ALL	B-X
cells	B-X
may	B-X
prove	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
for	B-X
functional	B-X
receptor	B-X
sites	B-X
<EOS>	B-X
Presence	B-X
and	B-X
steroid	B-X
inducibility	B-X
of	B-X
glutamine	B-X
synthetase	B-X
in	B-X
human	B-X
leukemic	B-X
cells	B-X
.	B-X

The	O
increase	O
was	O
specific	O
for	O
glucocorticoid	B-protein
receptor	I-protein
ligands	O
.	O
<EOS>	B-X
Structural	B-X
and	B-X
molecular	B-X
determinants	B-X
of	B-X
mineralocorticoid	B-X
receptor	B-X
signalling	B-X
.	B-X
<EOS>	B-X
In	B-X
the	B-X
heart	B-X
,	B-X
GCs	B-X
exerts	B-X
physiological	B-X
and	B-X
pharmacological	B-X
effects	B-X
by	B-X
binding	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
,	B-X
NR3C1	B-X
)	B-X
<EOS>	B-X
A	B-X
specialized	B-X
Hsp90	B-X
co	B-X
-	B-X
chaperone	B-X
network	B-X
regulates	B-X
steroid	B-X
hormone	B-X
receptor	B-X
response	B-X
to	B-X
ligand	B-X
.	B-X
<EOS>	B-X
New	B-X
insights	B-X
into	B-X
the	B-X
roles	B-X
of	B-X
glucocorticoid	B-X
signaling	B-X
dysregulation	B-X
in	B-X
pathological	B-X
cardiac	B-X
hypertrophy	B-X
.	B-X

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
magnitude	O
of	O
glucocorticoid-mediated	O
increase	O
of	O
GS	O
activity	O
and	O
the	O
cellular	O
levels	O
of	O
specific	O
glucocorticoid	B-protein
receptors	I-protein
assayed	O
in	O
the	O
same	O
cell	B-cell_type
specimen	I-cell_type
.	O
<EOS>	B-X
A	B-X
direct	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
the	B-X
magnitude	B-X
of	B-X
glucocorticoid	B-X
-	B-X
mediated	B-X
increase	B-X
of	B-X
GS	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
specific	B-X
glucocorticoid	B-X
receptors	B-X
assayed	B-X
in	B-X
the	B-X
same	B-X
cell	B-X
specimen	B-X
<EOS>	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
steroid	B-X
-	B-X
inducible	B-X
GS	B-X
in	B-X
ALL	B-X
cells	B-X
may	B-X
prove	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
for	B-X
functional	B-X
receptor	B-X
sites	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
basal	B-X
levels	B-X
of	B-X
the	B-X
enzyme	B-X
measured	B-X
in	B-X
cells	B-X
prior	B-X
to	B-X
exposure	B-X
to	B-X
dexamethasone	B-X
correlated	B-X
negatively	B-X
with	B-X
receptor	B-X
density	B-X
<EOS>	B-X
The	B-X
increase	B-X
was	B-X
specific	B-X
for	B-X
glucocorticoid	B-X
receptor	B-X
ligands	B-X

Moreover	O
,	O
the	O
basal	O
levels	O
of	O
the	O
enzyme	B-protein
measured	O
in	O
cells	O
prior	O
to	O
exposure	O
to	O
dexamethasone	O
correlated	O
negatively	O
with	O
receptor	O
density	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
basal	B-X
levels	B-X
of	B-X
the	B-X
enzyme	B-X
measured	B-X
in	B-X
cells	B-X
prior	B-X
to	B-X
exposure	B-X
to	B-X
dexamethasone	B-X
correlated	B-X
negatively	B-X
with	B-X
receptor	B-X
density	B-X
<EOS>	B-X
In	B-X
16	B-X
out	B-X
of	B-X
20	B-X
ALL	B-X
patients	B-X
studied	B-X
exposure	B-X
of	B-X
the	B-X
cells	B-X
to	B-X
physiological	B-X
concentrations	B-X
of	B-X
dexamethasone	B-X
in	B-X
vitro	B-X
increased	B-X
enzyme	B-X
activity	B-X
above	B-X
the	B-X
control	B-X
levels	B-X
<EOS>	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
steroid	B-X
-	B-X
inducible	B-X
GS	B-X
in	B-X
ALL	B-X
cells	B-X
may	B-X
prove	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
for	B-X
functional	B-X
receptor	B-X
sites	B-X
<EOS>	B-X
A	B-X
direct	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
the	B-X
magnitude	B-X
of	B-X
glucocorticoid	B-X
-	B-X
mediated	B-X
increase	B-X
of	B-X
GS	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
specific	B-X
glucocorticoid	B-X
receptors	B-X
assayed	B-X
in	B-X
the	B-X
same	B-X
cell	B-X
specimen	B-X

It	O
is	O
suggested	O
that	O
the	O
presence	O
of	O
steroid-inducible	B-protein
GS	I-protein
in	O
ALL	B-cell_type
cells	I-cell_type
may	O
prove	O
to	O
be	O
a	O
marker	O
for	O
functional	B-protein
receptor	I-protein
sites	I-protein
.	O
<EOS>	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
steroid	B-X
-	B-X
inducible	B-X
GS	B-X
in	B-X
ALL	B-X
cells	B-X
may	B-X
prove	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
for	B-X
functional	B-X
receptor	B-X
sites	B-X
<EOS>	B-X
Presence	B-X
and	B-X
steroid	B-X
inducibility	B-X
of	B-X
glutamine	B-X
synthetase	B-X
in	B-X
human	B-X
leukemic	B-X
cells	B-X
.	B-X
<EOS>	B-X
A	B-X
direct	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
the	B-X
magnitude	B-X
of	B-X
glucocorticoid	B-X
-	B-X
mediated	B-X
increase	B-X
of	B-X
GS	B-X
activity	B-X
and	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
specific	B-X
glucocorticoid	B-X
receptors	B-X
assayed	B-X
in	B-X
the	B-X
same	B-X
cell	B-X
specimen	B-X
<EOS>	B-X
In	B-X
16	B-X
out	B-X
of	B-X
20	B-X
ALL	B-X
patients	B-X
studied	B-X
exposure	B-X
of	B-X
the	B-X
cells	B-X
to	B-X
physiological	B-X
concentrations	B-X
of	B-X
dexamethasone	B-X
in	B-X
vitro	B-X
increased	B-X
enzyme	B-X
activity	B-X
above	B-X
the	B-X
control	B-X
levels	B-X

Binding	O
of	O
progestins	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Correlation	O
to	O
their	O
glucocorticoid-like	O
effects	O
on	O
in	O
vitro	O
functions	O
of	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O
<EOS>	B-X
Binding	B-X
of	B-X
progestins	B-X
to	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
Correlation	B-X
to	B-X
their	B-X
glucocorticoid	B-X
-	B-X
like	B-X
effects	B-X
on	B-X
in	B-X
vitro	B-X
functions	B-X
of	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
.	B-X
<EOS>	B-X
A	B-X
number	B-X
of	B-X
physiological	B-X
and	B-X
synthetic	B-X
progestins	B-X
were	B-X
tested	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
compete	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
of	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
and	B-X
their	B-X
ability	B-X
to	B-X
elicit	B-X
glucocorticoid	B-X
-	B-X
like	B-X
effects	B-X
on	B-X
the	B-X
same	B-X
cells	B-X
<EOS>	B-X
The	B-X
effective	B-X
binding	B-X
of	B-X
medroxyprogesterone	B-X
acetate	B-X
to	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
was	B-X
confirmed	B-X
by	B-X
direct	B-X
binding	B-X
studies	B-X
utilizing	B-X
a	B-X
tritiated	B-X
derivative	B-X
of	B-X
this	B-X
steroid	B-X
<EOS>	B-X
suppression	B-X
of	B-X
the	B-X
pituitary	B-X
-	B-X
adrenal	B-X
axis	B-X
)	B-X
might	B-X
be	B-X
expected	B-X
when	B-X
these	B-X
compounds	B-X
are	B-X
used	B-X
in	B-X
pharmacological	B-X
doses	B-X

A	O
number	O
of	O
physiological	O
and	O
synthetic	O
progestins	O
were	O
tested	O
for	O
their	O
ability	O
to	O
compete	O
with	O
[	O
3H	O
]	O
dexamethasone	O
for	O
the	O
binding	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
of	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
and	O
their	O
ability	O
to	O
elicit	O
glucocorticoid-like	O
effects	O
on	O
the	O
same	O
cells	O
.	O

As	O
compared	O
to	O
the	O
reference	O
compound	O
dexamethasone	O
(	O
relative	O
receptor	O
binding	O
affinity	O
defined	O
as	O
100	O
%	O
)	O
,	O
two	O
potent	O
synthetic	O
progestins	O
with	O
a	O
pregnane-type	O
structure	O
,	O
megestrol	O
acetate	O
and	O
medroxyprogesterone	O
acetate	O
,	O
were	O
found	O
to	O
display	O
a	O
considerable	O
binding	O
affinity	O
towards	O
the	O
receptor	O
(	O
46	O
and	O
42	O
%	O
,	O
respectively	O
)	O
.	O

The	O
relative	O
binding	O
affinity	O
of	O
the	O
naturally	O
occurring	O
ligand	O
,	O
cortisol	O
,	O
to	O
the	O
receptor	O
was	O
clearly	O
lower	O
(	O
25	O
%	O
)	O
.	O

The	O
effective	O
binding	O
of	O
medroxyprogesterone	O
acetate	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
was	O
confirmed	O
by	O
direct	O
binding	O
studies	O
utilizing	O
a	O
tritiated	O
derivative	O
of	O
this	O
steroid	O
.	O

No	O
evidence	O
for	O
the	O
existence	O
of	O
a	O
specific	O
progesterone	B-protein
receptor	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
was	O
obtained	O
as	O
judged	O
by	O
the	O
results	O
of	O
competition	O
experiments	O
where	O
a	O
progesterone	O
receptor-specific	O
ligand	O
[	O
3H	O
]	O
Org	O
2058	O
was	O
used	O
.	O
<EOS>	B-X
No	B-X
evidence	B-X
for	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
specific	B-X
progesterone	B-X
receptor	B-X
in	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
was	B-X
obtained	B-X
as	B-X
judged	B-X
by	B-X
the	B-X
results	B-X
of	B-X
competition	B-X
experiments	B-X
where	B-X
a	B-X
progesterone	B-X
receptor	B-X
-	B-X
specific	B-X
ligand	B-X
[	B-X
3H	B-X
]	B-X
Org	B-X
2058	B-X
was	B-X
used	B-X
<EOS>	B-X
The	B-X
effective	B-X
binding	B-X
of	B-X
medroxyprogesterone	B-X
acetate	B-X
to	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
was	B-X
confirmed	B-X
by	B-X
direct	B-X
binding	B-X
studies	B-X
utilizing	B-X
a	B-X
tritiated	B-X
derivative	B-X
of	B-X
this	B-X
steroid	B-X
<EOS>	B-X
As	B-X
compared	B-X
to	B-X
the	B-X
reference	B-X
compound	B-X
dexamethasone	B-X
(	B-X
relative	B-X
receptor	B-X
binding	B-X
affinity	B-X
defined	B-X
as	B-X
100	B-X
%	B-X
)	B-X
,	B-X
two	B-X
potent	B-X
synthetic	B-X
progestins	B-X
with	B-X
a	B-X
pregnane	B-X
-	B-X
type	B-X
structure	B-X
,	B-X
megestrol	B-X
acetate	B-X
and	B-X
medroxyprogesterone	B-X
acetate	B-X
,	B-X
were	B-X
found	B-X
to	B-X
display	B-X
a	B-X
considerable	B-X
binding	B-X
affinity	B-X
towards	B-X
the	B-X
receptor	B-X
(	B-X
46	B-X
and	B-X
42	B-X
%	B-X
,	B-X
respectively	B-X
)	B-X
<EOS>	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
certain	B-X
progestins	B-X
in	B-X
common	B-X
clinical	B-X
use	B-X
probably	B-X
possess	B-X
inherent	B-X
glucocorticoid	B-X
activity	B-X
and	B-X
suggest	B-X
that	B-X
side	B-X
effects	B-X
attributable	B-X
to	B-X
this	B-X
character	B-X
(	B-X
e	B-X

Medroxyprogesterone	O
acetate	O
and	O
megestrol	O
acetate	O
also	O
induced	O
glucocorticoid-like	O
effects	O
on	O
the	O
lymphocyte	B-cell_type
functions	O
.	O
<EOS>	B-X
Medroxyprogesterone	B-X
acetate	B-X
and	B-X
megestrol	B-X
acetate	B-X
also	B-X
induced	B-X
glucocorticoid	B-X
-	B-X
like	B-X
effects	B-X
on	B-X
the	B-X
lymphocyte	B-X
functions	B-X
<EOS>	B-X
Binding	B-X
of	B-X
progestins	B-X
to	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
Correlation	B-X
to	B-X
their	B-X
glucocorticoid	B-X
-	B-X
like	B-X
effects	B-X
on	B-X
in	B-X
vitro	B-X
functions	B-X
of	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
synthetic	B-X
progestins	B-X
related	B-X
structurally	B-X
to	B-X
19	B-X
-	B-X
nortestosterone	B-X
,	B-X
norethisterone	B-X
and	B-X
d	B-X
-	B-X
norgestrel	B-X
,	B-X
were	B-X
virtually	B-X
devoid	B-X
of	B-X
binding	B-X
affinity	B-X
towards	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
nor	B-X
did	B-X
they	B-X
measurably	B-X
influence	B-X
the	B-X
in	B-X
vitro	B-X
lymphocyte	B-X
functions	B-X
<EOS>	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
certain	B-X
progestins	B-X
in	B-X
common	B-X
clinical	B-X
use	B-X
probably	B-X
possess	B-X
inherent	B-X
glucocorticoid	B-X
activity	B-X
and	B-X
suggest	B-X
that	B-X
side	B-X
effects	B-X
attributable	B-X
to	B-X
this	B-X
character	B-X
(	B-X
e	B-X

These	O
included	O
inhibition	O
of	O
the	O
proliferative	O
responses	O
to	O
the	O
T-cell	B-protein
mitogens	I-protein
concanavalin	B-protein
A	I-protein
and	O
phytohaemagglutinin	B-protein
and	O
an	O
enhanced	O
accumulation	O
of	O
immunoglobulin	B-cell_type
secreting	I-cell_type
cells	I-cell_type
in	O
pokeweed	B-cell_line
mitogen-stimulated	I-cell_line
cultures	I-cell_line
.	O

The	O
progestin	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
a	O
radiosensitive	O
(	O
suppressor	O
)	O
subpopulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
The	B-X
progestin	B-X
effect	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
through	B-X
a	B-X
radiosensitive	B-X
(	B-X
suppressor	B-X
)	B-X
subpopulation	B-X
of	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
Binding	B-X
of	B-X
progestins	B-X
to	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
Correlation	B-X
to	B-X
their	B-X
glucocorticoid	B-X
-	B-X
like	B-X
effects	B-X
on	B-X
in	B-X
vitro	B-X
functions	B-X
of	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
synthetic	B-X
progestins	B-X
related	B-X
structurally	B-X
to	B-X
19	B-X
-	B-X
nortestosterone	B-X
,	B-X
norethisterone	B-X
and	B-X
d	B-X
-	B-X
norgestrel	B-X
,	B-X
were	B-X
virtually	B-X
devoid	B-X
of	B-X
binding	B-X
affinity	B-X
towards	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
nor	B-X
did	B-X
they	B-X
measurably	B-X
influence	B-X
the	B-X
in	B-X
vitro	B-X
lymphocyte	B-X
functions	B-X
<EOS>	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
certain	B-X
progestins	B-X
in	B-X
common	B-X
clinical	B-X
use	B-X
probably	B-X
possess	B-X
inherent	B-X
glucocorticoid	B-X
activity	B-X
and	B-X
suggest	B-X
that	B-X
side	B-X
effects	B-X
attributable	B-X
to	B-X
this	B-X
character	B-X
(	B-X
e	B-X

In	O
contrast	O
,	O
the	O
synthetic	O
progestins	O
related	O
structurally	O
to	O
19-nortestosterone	O
,	O
norethisterone	O
and	O
d-norgestrel	O
,	O
were	O
virtually	O
devoid	O
of	O
binding	O
affinity	O
towards	O
the	O
glucocorticoid	B-protein
receptor	I-protein
nor	O
did	O
they	O
measurably	O
influence	O
the	O
in	O
vitro	O
lymphocyte	B-cell_type
functions	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
synthetic	B-X
progestins	B-X
related	B-X
structurally	B-X
to	B-X
19	B-X
-	B-X
nortestosterone	B-X
,	B-X
norethisterone	B-X
and	B-X
d	B-X
-	B-X
norgestrel	B-X
,	B-X
were	B-X
virtually	B-X
devoid	B-X
of	B-X
binding	B-X
affinity	B-X
towards	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
nor	B-X
did	B-X
they	B-X
measurably	B-X
influence	B-X
the	B-X
in	B-X
vitro	B-X
lymphocyte	B-X
functions	B-X
<EOS>	B-X
Medroxyprogesterone	B-X
acetate	B-X
and	B-X
megestrol	B-X
acetate	B-X
also	B-X
induced	B-X
glucocorticoid	B-X
-	B-X
like	B-X
effects	B-X
on	B-X
the	B-X
lymphocyte	B-X
functions	B-X
<EOS>	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
certain	B-X
progestins	B-X
in	B-X
common	B-X
clinical	B-X
use	B-X
probably	B-X
possess	B-X
inherent	B-X
glucocorticoid	B-X
activity	B-X
and	B-X
suggest	B-X
that	B-X
side	B-X
effects	B-X
attributable	B-X
to	B-X
this	B-X
character	B-X
(	B-X
e	B-X
<EOS>	B-X
Binding	B-X
of	B-X
progestins	B-X
to	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
Correlation	B-X
to	B-X
their	B-X
glucocorticoid	B-X
-	B-X
like	B-X
effects	B-X
on	B-X
in	B-X
vitro	B-X
functions	B-X
of	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
.	B-X

These	O
studies	O
demonstrate	O
that	O
certain	O
progestins	O
in	O
common	O
clinical	O
use	O
probably	O
possess	O
inherent	O
glucocorticoid	O
activity	O
and	O
suggest	O
that	O
side	O
effects	O
attributable	O
to	O
this	O
character	O
(	O
e.g.	O
suppression	O
of	O
the	O
pituitary-adrenal	O
axis	O
)	O
might	O
be	O
expected	O
when	O
these	O
compounds	O
are	O
used	O
in	O
pharmacological	O
doses	O
.	O
<EOS>	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
certain	B-X
progestins	B-X
in	B-X
common	B-X
clinical	B-X
use	B-X
probably	B-X
possess	B-X
inherent	B-X
glucocorticoid	B-X
activity	B-X
and	B-X
suggest	B-X
that	B-X
side	B-X
effects	B-X
attributable	B-X
to	B-X
this	B-X
character	B-X
(	B-X
e	B-X
<EOS>	B-X
suppression	B-X
of	B-X
the	B-X
pituitary	B-X
-	B-X
adrenal	B-X
axis	B-X
)	B-X
might	B-X
be	B-X
expected	B-X
when	B-X
these	B-X
compounds	B-X
are	B-X
used	B-X
in	B-X
pharmacological	B-X
doses	B-X
<EOS>	B-X
The	B-X
effective	B-X
binding	B-X
of	B-X
medroxyprogesterone	B-X
acetate	B-X
to	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
was	B-X
confirmed	B-X
by	B-X
direct	B-X
binding	B-X
studies	B-X
utilizing	B-X
a	B-X
tritiated	B-X
derivative	B-X
of	B-X
this	B-X
steroid	B-X
<EOS>	B-X
No	B-X
evidence	B-X
for	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
specific	B-X
progesterone	B-X
receptor	B-X
in	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
was	B-X
obtained	B-X
as	B-X
judged	B-X
by	B-X
the	B-X
results	B-X
of	B-X
competition	B-X
experiments	B-X
where	B-X
a	B-X
progesterone	B-X
receptor	B-X
-	B-X
specific	B-X
ligand	B-X
[	B-X
3H	B-X
]	B-X
Org	B-X
2058	B-X
was	B-X
used	B-X

Metabolic	O
and	O
ultrastructural	O
aspects	O
of	O
the	O
in	O
vitro	O
lysis	O
of	O
chronic	B-cell_type
lymphocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
by	O
glucocorticoids	O
.	O
<EOS>	B-X
Metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
lysis	B-X
of	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
killing	B-X
process	B-X
of	B-X
CLL	B-X
cells	B-X
are	B-X
recorded	B-X
<EOS>	B-X
The	B-X
large	B-X
holes	B-X
in	B-X
the	B-X
membrane	B-X
appearing	B-X
after	B-X
6	B-X
hr	B-X
of	B-X
incubation	B-X
with	B-X
the	B-X
hormone	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
for	B-X
the	B-X
penetration	B-X
of	B-X
the	B-X
viable	B-X
stain	B-X
into	B-X
the	B-X
dead	B-X
cells	B-X
,	B-X
as	B-X
seen	B-X
by	B-X
light	B-X
microscopy	B-X
<EOS>	B-X
In	B-X
vitro	B-X
lysis	B-X
was	B-X
found	B-X
to	B-X
be	B-X
temperature	B-X
dependent	B-X
and	B-X
was	B-X
detected	B-X
only	B-X
after	B-X
6	B-X
to	B-X
8	B-X
hr	B-X
incubation	B-X
with	B-X
cortisol	B-X
by	B-X
means	B-X
of	B-X
the	B-X
trypan	B-X
blue	B-X
exclusion	B-X
test	B-X

Human	B-cell_type
chronic	I-cell_type
lymphocytic	I-cell_type
leukemia	I-cell_type
(	I-cell_type
CLL	I-cell_type
)	I-cell_type
cells	I-cell_type
like	O
prothymocytes	B-cell_type
and	O
immunoactivated	B-cell_type
T-lymphocytes	I-cell_type
are	O
readily	O
lysed	O
in	O
vitro	O
by	O
pharmacological	O
concentrations	O
of	O
glucocorticoids	O
such	O
as	O
cortisol	O
,	O
whereas	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
thymocytes	B-cell_type
are	O
unaffected	O
by	O
the	O
hormone	B-protein
.	O
<EOS>	B-X
Human	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
cells	B-X
like	B-X
prothymocytes	B-X
and	B-X
immunoactivated	B-X
T	B-X
-	B-X
lymphocytes	B-X
are	B-X
readily	B-X
lysed	B-X
in	B-X
vitro	B-X
by	B-X
pharmacological	B-X
concentrations	B-X
of	B-X
glucocorticoids	B-X
such	B-X
as	B-X
cortisol	B-X
,	B-X
whereas	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
and	B-X
thymocytes	B-X
are	B-X
unaffected	B-X
by	B-X
the	B-X
hormone	B-X
<EOS>	B-X
In	B-X
vitro	B-X
lysis	B-X
was	B-X
found	B-X
to	B-X
be	B-X
temperature	B-X
dependent	B-X
and	B-X
was	B-X
detected	B-X
only	B-X
after	B-X
6	B-X
to	B-X
8	B-X
hr	B-X
incubation	B-X
with	B-X
cortisol	B-X
by	B-X
means	B-X
of	B-X
the	B-X
trypan	B-X
blue	B-X
exclusion	B-X
test	B-X
<EOS>	B-X
The	B-X
large	B-X
holes	B-X
in	B-X
the	B-X
membrane	B-X
appearing	B-X
after	B-X
6	B-X
hr	B-X
of	B-X
incubation	B-X
with	B-X
the	B-X
hormone	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
for	B-X
the	B-X
penetration	B-X
of	B-X
the	B-X
viable	B-X
stain	B-X
into	B-X
the	B-X
dead	B-X
cells	B-X
,	B-X
as	B-X
seen	B-X
by	B-X
light	B-X
microscopy	B-X
<EOS>	B-X
However	B-X
,	B-X
30	B-X
min	B-X
of	B-X
incubation	B-X
with	B-X
cortisol	B-X
at	B-X
either	B-X
37	B-X
degrees	B-X
or	B-X
4	B-X
degrees	B-X
followed	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
hormone	B-X
was	B-X
still	B-X
sufficient	B-X
to	B-X
induce	B-X
the	B-X
lytic	B-X
process	B-X

In	O
this	O
study	O
,	O
metabolic	O
and	O
ultrastructural	O
aspects	O
of	O
the	O
cortisol-induced	O
killing	O
process	O
of	O
CLL	B-cell_type
cells	I-cell_type
are	O
recorded	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
killing	B-X
process	B-X
of	B-X
CLL	B-X
cells	B-X
are	B-X
recorded	B-X
<EOS>	B-X
Metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
lysis	B-X
of	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
<EOS>	B-X
An	B-X
excess	B-X
of	B-X
an	B-X
antagonist	B-X
such	B-X
as	B-X
cortexolone	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
cytolysis	B-X
of	B-X
the	B-X
CLL	B-X
cells	B-X
<EOS>	B-X
In	B-X
vitro	B-X
lysis	B-X
was	B-X
found	B-X
to	B-X
be	B-X
temperature	B-X
dependent	B-X
and	B-X
was	B-X
detected	B-X
only	B-X
after	B-X
6	B-X
to	B-X
8	B-X
hr	B-X
incubation	B-X
with	B-X
cortisol	B-X
by	B-X
means	B-X
of	B-X
the	B-X
trypan	B-X
blue	B-X
exclusion	B-X
test	B-X

In	O
vitro	O
lysis	O
was	O
found	O
to	O
be	O
temperature	O
dependent	O
and	O
was	O
detected	O
only	O
after	O
6	O
to	O
8	O
hr	O
incubation	O
with	O
cortisol	O
by	O
means	O
of	O
the	O
trypan	O
blue	O
exclusion	O
test	O
.	O
<EOS>	B-X
In	B-X
vitro	B-X
lysis	B-X
was	B-X
found	B-X
to	B-X
be	B-X
temperature	B-X
dependent	B-X
and	B-X
was	B-X
detected	B-X
only	B-X
after	B-X
6	B-X
to	B-X
8	B-X
hr	B-X
incubation	B-X
with	B-X
cortisol	B-X
by	B-X
means	B-X
of	B-X
the	B-X
trypan	B-X
blue	B-X
exclusion	B-X
test	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
killing	B-X
process	B-X
of	B-X
CLL	B-X
cells	B-X
are	B-X
recorded	B-X
<EOS>	B-X
Metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
lysis	B-X
of	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
<EOS>	B-X
An	B-X
excess	B-X
of	B-X
an	B-X
antagonist	B-X
such	B-X
as	B-X
cortexolone	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
cytolysis	B-X
of	B-X
the	B-X
CLL	B-X
cells	B-X

However	O
,	O
30	O
min	O
of	O
incubation	O
with	O
cortisol	O
at	O
either	O
37	O
degrees	O
or	O
4	O
degrees	O
followed	O
by	O
the	O
removal	O
of	O
the	O
hormone	B-protein
was	O
still	O
sufficient	O
to	O
induce	O
the	O
lytic	O
process	O
.	O
<EOS>	B-X
However	B-X
,	B-X
30	B-X
min	B-X
of	B-X
incubation	B-X
with	B-X
cortisol	B-X
at	B-X
either	B-X
37	B-X
degrees	B-X
or	B-X
4	B-X
degrees	B-X
followed	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
hormone	B-X
was	B-X
still	B-X
sufficient	B-X
to	B-X
induce	B-X
the	B-X
lytic	B-X
process	B-X
<EOS>	B-X
The	B-X
data	B-X
are	B-X
given	B-X
indicating	B-X
that	B-X
the	B-X
incorporation	B-X
is	B-X
not	B-X
random	B-X
when	B-X
an	B-X
amino	B-X
acid	B-X
mixture	B-X
is	B-X
present	B-X
<EOS>	B-X
Preincubation	B-X
of	B-X
chromatin	B-X
with	B-X
NAD+	B-X
but	B-X
not	B-X
with	B-X
its	B-X
analogues	B-X
increases	B-X
the	B-X
polypeptide	B-X
-	B-X
synthesizing	B-X
activity	B-X
of	B-X
chromatin	B-X
<EOS>	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
hormone	B-X
treatment	B-X
was	B-X
not	B-X
due	B-X
to	B-X
a	B-X
direct	B-X
inactivation	B-X
of	B-X
bound	B-X
or	B-X
fluid	B-X
-	B-X
phase	B-X
complement	B-X
components	B-X
by	B-X
the	B-X
hormones	B-X
or	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
cells	B-X
to	B-X
bind	B-X
complement	B-X
-	B-X
fixing	B-X
antibody	B-X

Ultrastructural	O
studies	O
demonstrated	O
sequential	O
changes	O
in	O
the	O
cytoplasm	O
,	O
including	O
swelling	O
of	O
mitochondria	O
and	O
cytoplasmic	O
decompartmentalization	O
,	O
followed	O
by	O
loss	O
of	O
surface	O
microvilli	O
with	O
the	O
appearance	O
of	O
``	O
holes	O
''	O
in	O
the	O
cell	O
membrane	O
,	O
and	O
subsequent	O
condensation	O
of	O
nuclear	B-DNA
chromatin	I-DNA
.	O
<EOS>	B-X
Ultrastructural	B-X
studies	B-X
demonstrated	B-X
sequential	B-X
changes	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
including	B-X
swelling	B-X
of	B-X
mitochondria	B-X
and	B-X
cytoplasmic	B-X
decompartmentalization	B-X
,	B-X
followed	B-X
by	B-X
loss	B-X
of	B-X
surface	B-X
microvilli	B-X
with	B-X
the	B-X
appearance	B-X
of	B-X
``	B-X
holes	B-X
''	B-X
in	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
subsequent	B-X
condensation	B-X
of	B-X
nuclear	B-X
chromatin	B-X
<EOS>	B-X
Addition	B-X
of	B-X
metabolic	B-X
inhibitors	B-X
including	B-X
actinomycin	B-X
D	B-X
,	B-X
puromycin	B-X
,	B-X
and	B-X
cycloheximide	B-X
following	B-X
administration	B-X
of	B-X
cortisol	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
the	B-X
cell	B-X
lysis	B-X
<EOS>	B-X
The	B-X
large	B-X
holes	B-X
in	B-X
the	B-X
membrane	B-X
appearing	B-X
after	B-X
6	B-X
hr	B-X
of	B-X
incubation	B-X
with	B-X
the	B-X
hormone	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
for	B-X
the	B-X
penetration	B-X
of	B-X
the	B-X
viable	B-X
stain	B-X
into	B-X
the	B-X
dead	B-X
cells	B-X
,	B-X
as	B-X
seen	B-X
by	B-X
light	B-X
microscopy	B-X
<EOS>	B-X
In	B-X
vitro	B-X
lysis	B-X
was	B-X
found	B-X
to	B-X
be	B-X
temperature	B-X
dependent	B-X
and	B-X
was	B-X
detected	B-X
only	B-X
after	B-X
6	B-X
to	B-X
8	B-X
hr	B-X
incubation	B-X
with	B-X
cortisol	B-X
by	B-X
means	B-X
of	B-X
the	B-X
trypan	B-X
blue	B-X
exclusion	B-X
test	B-X

The	O
large	O
holes	O
in	O
the	O
membrane	O
appearing	O
after	O
6	O
hr	O
of	O
incubation	O
with	O
the	O
hormone	B-protein
may	O
be	O
the	O
cause	O
for	O
the	O
penetration	O
of	O
the	O
viable	O
stain	O
into	O
the	O
dead	B-cell_type
cells	I-cell_type
,	O
as	O
seen	O
by	O
light	O
microscopy	O
.	O
<EOS>	B-X
The	B-X
large	B-X
holes	B-X
in	B-X
the	B-X
membrane	B-X
appearing	B-X
after	B-X
6	B-X
hr	B-X
of	B-X
incubation	B-X
with	B-X
the	B-X
hormone	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
for	B-X
the	B-X
penetration	B-X
of	B-X
the	B-X
viable	B-X
stain	B-X
into	B-X
the	B-X
dead	B-X
cells	B-X
,	B-X
as	B-X
seen	B-X
by	B-X
light	B-X
microscopy	B-X
<EOS>	B-X
The	B-X
resulting	B-X
complex	B-X
appears	B-X
to	B-X
activate	B-X
specific	B-X
gene	B-X
(	B-X
s	B-X
)	B-X
the	B-X
products	B-X
of	B-X
which	B-X
eventually	B-X
cause	B-X
cytolysis	B-X
<EOS>	B-X
Metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
lysis	B-X
of	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
<EOS>	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
lysis	B-X
of	B-X
human	B-X
CLL	B-X
cells	B-X
is	B-X
similar	B-X
to	B-X
the	B-X
phenomenon	B-X
observed	B-X
in	B-X
rat	B-X
or	B-X
murine	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
interaction	B-X
of	B-X
the	B-X
steroid	B-X
molecule	B-X
with	B-X
the	B-X
cytoplasmic	B-X
receptor	B-X

Addition	O
of	O
metabolic	O
inhibitors	O
including	O
actinomycin	O
D	O
,	O
puromycin	O
,	O
and	O
cycloheximide	O
following	O
administration	O
of	O
cortisol	O
resulted	O
in	O
inhibition	O
of	O
the	O
cell	O
lysis	O
.	O
<EOS>	B-X
Addition	B-X
of	B-X
metabolic	B-X
inhibitors	B-X
including	B-X
actinomycin	B-X
D	B-X
,	B-X
puromycin	B-X
,	B-X
and	B-X
cycloheximide	B-X
following	B-X
administration	B-X
of	B-X
cortisol	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
the	B-X
cell	B-X
lysis	B-X
<EOS>	B-X
An	B-X
excess	B-X
of	B-X
an	B-X
antagonist	B-X
such	B-X
as	B-X
cortexolone	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
cytolysis	B-X
of	B-X
the	B-X
CLL	B-X
cells	B-X
<EOS>	B-X
Ultrastructural	B-X
studies	B-X
demonstrated	B-X
sequential	B-X
changes	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
including	B-X
swelling	B-X
of	B-X
mitochondria	B-X
and	B-X
cytoplasmic	B-X
decompartmentalization	B-X
,	B-X
followed	B-X
by	B-X
loss	B-X
of	B-X
surface	B-X
microvilli	B-X
with	B-X
the	B-X
appearance	B-X
of	B-X
``	B-X
holes	B-X
''	B-X
in	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
and	B-X
subsequent	B-X
condensation	B-X
of	B-X
nuclear	B-X
chromatin	B-X
<EOS>	B-X
Metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
lysis	B-X
of	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X

An	O
excess	O
of	O
an	O
antagonist	O
such	O
as	O
cortexolone	O
was	O
found	O
to	O
inhibit	O
the	O
cortisol-induced	O
cytolysis	O
of	O
the	O
CLL	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
An	B-X
excess	B-X
of	B-X
an	B-X
antagonist	B-X
such	B-X
as	B-X
cortexolone	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
cytolysis	B-X
of	B-X
the	B-X
CLL	B-X
cells	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
metabolic	B-X
and	B-X
ultrastructural	B-X
aspects	B-X
of	B-X
the	B-X
cortisol	B-X
-	B-X
induced	B-X
killing	B-X
process	B-X
of	B-X
CLL	B-X
cells	B-X
are	B-X
recorded	B-X
<EOS>	B-X
Addition	B-X
of	B-X
metabolic	B-X
inhibitors	B-X
including	B-X
actinomycin	B-X
D	B-X
,	B-X
puromycin	B-X
,	B-X
and	B-X
cycloheximide	B-X
following	B-X
administration	B-X
of	B-X
cortisol	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
the	B-X
cell	B-X
lysis	B-X
<EOS>	B-X
However	B-X
,	B-X
30	B-X
min	B-X
of	B-X
incubation	B-X
with	B-X
cortisol	B-X
at	B-X
either	B-X
37	B-X
degrees	B-X
or	B-X
4	B-X
degrees	B-X
followed	B-X
by	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
hormone	B-X
was	B-X
still	B-X
sufficient	B-X
to	B-X
induce	B-X
the	B-X
lytic	B-X
process	B-X

It	O
is	O
suggested	O
that	O
the	O
glucocorticoid-induced	O
lysis	O
of	O
human	B-cell_line
CLL	I-cell_line
cells	I-cell_line
is	O
similar	O
to	O
the	O
phenomenon	O
observed	O
in	O
rat	B-cell_type
or	I-cell_type
murine	I-cell_type
lymphocytes	I-cell_type
and	O
is	O
mediated	O
by	O
interaction	O
of	O
the	O
steroid	O
molecule	O
with	O
the	O
cytoplasmic	B-protein
receptor	I-protein
.	O
<EOS>	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
lysis	B-X
of	B-X
human	B-X
CLL	B-X
cells	B-X
is	B-X
similar	B-X
to	B-X
the	B-X
phenomenon	B-X
observed	B-X
in	B-X
rat	B-X
or	B-X
murine	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
interaction	B-X
of	B-X
the	B-X
steroid	B-X
molecule	B-X
with	B-X
the	B-X
cytoplasmic	B-X
receptor	B-X
<EOS>	B-X
Incubation	B-X
with	B-X
the	B-X
glucocorticoid	B-X
hormone	B-X
corticosterone	B-X
(	B-X
CORT	B-X
)	B-X
shifted	B-X
the	B-X
enhancement	B-X
of	B-X
CD4	B-X
expression	B-X
to	B-X
a	B-X
point	B-X
about	B-X
24	B-X
h	B-X
earlier	B-X
than	B-X
that	B-X
observed	B-X
in	B-X
control	B-X
cultures	B-X
<EOS>	B-X
The	B-X
large	B-X
holes	B-X
in	B-X
the	B-X
membrane	B-X
appearing	B-X
after	B-X
6	B-X
hr	B-X
of	B-X
incubation	B-X
with	B-X
the	B-X
hormone	B-X
may	B-X
be	B-X
the	B-X
cause	B-X
for	B-X
the	B-X
penetration	B-X
of	B-X
the	B-X
viable	B-X
stain	B-X
into	B-X
the	B-X
dead	B-X
cells	B-X
,	B-X
as	B-X
seen	B-X
by	B-X
light	B-X
microscopy	B-X
<EOS>	B-X
In	B-X
vitro	B-X
lysis	B-X
was	B-X
found	B-X
to	B-X
be	B-X
temperature	B-X
dependent	B-X
and	B-X
was	B-X
detected	B-X
only	B-X
after	B-X
6	B-X
to	B-X
8	B-X
hr	B-X
incubation	B-X
with	B-X
cortisol	B-X
by	B-X
means	B-X
of	B-X
the	B-X
trypan	B-X
blue	B-X
exclusion	B-X
test	B-X

The	O
resulting	O
complex	O
appears	O
to	O
activate	O
specific	O
gene	B-DNA
(	O
s	O
)	O
the	O
products	O
of	O
which	O
eventually	O
cause	O
cytolysis	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
lymphoid	O
tumors	O
.	O
<EOS>	B-X
Glucocorticoids	B-X
and	B-X
Cancer	B-X
.	B-X
<EOS>	B-X
Insight	B-X
into	B-X
glucocorticoid	B-X
receptor	B-X
signalling	B-X
through	B-X
interactome	B-X
model	B-X
analysis	B-X
.	B-X
<EOS>	B-X
GITR	B-X
deficiency	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
lymphoid	B-X
population	B-X
<EOS>	B-X
ESRRB	B-X
regulates	B-X
glucocorticoid	B-X
gene	B-X
expression	B-X
in	B-X
mice	B-X
and	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
.	B-X

There	O
is	O
a	O
range	O
of	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
seen	O
in	O
the	O
various	O
subclasses	O
of	O
acute	O
lymphatic	O
leukemia	O
(	O
ALL	O
)	O
.	O
<EOS>	B-X
There	B-X
is	B-X
a	B-X
range	B-X
of	B-X
levels	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
numbers	B-X
seen	B-X
in	B-X
the	B-X
various	B-X
subclasses	B-X
of	B-X
acute	B-X
lymphatic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
<EOS>	B-X
All	B-X
clinical	B-X
specimens	B-X
from	B-X
patients	B-X
with	B-X
lymphatic	B-X
leukemia	B-X
have	B-X
some	B-X
measurable	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
;	B-X
therefore	B-X
,	B-X
the	B-X
resistance	B-X
seen	B-X
in	B-X
vivo	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
receptors	B-X
<EOS>	B-X
,	B-X
common	B-X
ALL	B-X
of	B-X
childhood	B-X
)	B-X
have	B-X
relative	B-X
stability	B-X
of	B-X
their	B-X
genetic	B-X
material	B-X
making	B-X
glucocorticoid	B-X
-	B-X
resistant	B-X
mutations	B-X
less	B-X
likely	B-X
to	B-X
occur	B-X
in	B-X
patients	B-X
with	B-X
these	B-X
cells	B-X
than	B-X
in	B-X
low	B-X
-	B-X
receptor	B-X
cell	B-X
lines	B-X
(	B-X
i	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
lymphoid	B-X
tumors	B-X
.	B-X

This	O
variability	O
can	O
not	O
be	O
explained	O
by	O
the	O
known	O
correlation	O
between	O
active	O
cell	O
proliferation	O
and	O
an	O
increase	O
in	O
the	O
number	O
of	O
receptors	O
,	O
since	O
the	O
tumors	O
with	O
the	O
highest	O
growth	O
fraction	O
(	O
i.e.	O
,	O
Burkitt	O
's	O
lymphoma	O
and	O
T-cell	O
leukemia	O
)	O
tend	O
to	O
have	O
lower	O
average	O
receptor	O
numbers	O
than	O
do	O
tumors	O
with	O
lower	O
growth	O
fractions	O
such	O
as	O
common	O
ALL	O
.	O
<EOS>	B-X
Biomechanical	B-X
studies	B-X
on	B-X
PMFs	B-X
demonstrate	B-X
wide	B-X
variability	B-X
in	B-X
fragment	B-X
characteristics	B-X
and	B-X
mode	B-X
of	B-X
testing	B-X
,	B-X
which	B-X
makes	B-X
it	B-X
difficult	B-X
to	B-X
compare	B-X
studies	B-X
and	B-X
draw	B-X
conclusions	B-X
on	B-X
the	B-X
need	B-X
for	B-X
surgery	B-X
and	B-X
method	B-X
of	B-X
fixation	B-X
<EOS>	B-X
The	B-X
Izhikevich	B-X
single	B-X
neuron	B-X
model	B-X
can	B-X
account	B-X
for	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
different	B-X
neuron	B-X
types	B-X
and	B-X
spiking	B-X
patterns	B-X
,	B-X
thus	B-X
rendering	B-X
it	B-X
an	B-X
optimal	B-X
candidate	B-X
for	B-X
a	B-X
mean	B-X
-	B-X
field	B-X
theoretic	B-X
treatment	B-X
of	B-X
brain	B-X
dynamics	B-X
in	B-X
heterogeneous	B-X
networks	B-X
<EOS>	B-X
The	B-X
third	B-X
application	B-X
analyses	B-X
two	B-X
dimensions	B-X
of	B-X
childhood	B-X
undernutrition	B-X
in	B-X
Nigeria	B-X
as	B-X
a	B-X
bivariate	B-X
response	B-X
and	B-X
we	B-X
find	B-X
that	B-X
the	B-X
correlation	B-X
between	B-X
the	B-X
two	B-X
undernutrition	B-X
scores	B-X
is	B-X
considerably	B-X
different	B-X
depending	B-X
on	B-X
the	B-X
child	B-X
's	B-X
age	B-X
and	B-X
the	B-X
region	B-X
the	B-X
child	B-X
lives	B-X
in	B-X
<EOS>	B-X
Our	B-X
proposed	B-X
approach	B-X
widens	B-X
the	B-X
scope	B-X
of	B-X
hazard	B-X
shapes	B-X
including	B-X
non	B-X
-	B-X
proportional	B-X
hazards	B-X
,	B-X
can	B-X
be	B-X
scaled	B-X
up	B-X
to	B-X
large	B-X
sample	B-X
sizes	B-X
,	B-X
naturally	B-X
provides	B-X
estimates	B-X
of	B-X
uncertainty	B-X
via	B-X
the	B-X
posterior	B-X
and	B-X
can	B-X
be	B-X
seamlessly	B-X
employed	B-X
for	B-X
variable	B-X
selection	B-X

All	O
clinical	O
specimens	O
from	O
patients	O
with	O
lymphatic	O
leukemia	O
have	O
some	O
measurable	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
;	O
therefore	O
,	O
the	O
resistance	O
seen	O
in	O
vivo	O
can	O
not	O
be	O
explained	O
by	O
the	O
lack	O
of	O
receptors	O
.	O

However	O
,	O
there	O
has	O
been	O
a	O
positive	O
correlation	O
,	O
in	O
our	O
hands	O
,	O
with	O
receptor	O
level	O
and	O
prognosis	O
.	O
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
ING3	B-X
levels	B-X
positively	B-X
correlate	B-X
with	B-X
poor	B-X
survival	B-X
prognosis	B-X
of	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
patients	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
IL	B-X
-	B-X
17	B-X
negatively	B-X
correlated	B-X
with	B-X
neonatal	B-X
birth	B-X
weight	B-X
<EOS>	B-X
The	B-X
function	B-X
of	B-X
them	B-X
were	B-X
assessed	B-X
in	B-X
many	B-X
aspects	B-X
,	B-X
indicating	B-X
the	B-X
strong	B-X
potential	B-X
of	B-X
the	B-X
two	B-X
genes	B-X
to	B-X
serve	B-X
as	B-X
biomarkers	B-X
for	B-X
NSCLC	B-X
progression	B-X
and	B-X
prognosis	B-X
<EOS>	B-X
05	B-X
)	B-X
Post	B-X
-	B-X
treatment	B-X
in	B-X
dogs	B-X
infected	B-X
with	B-X
canine	B-X
distemper	B-X
and	B-X
there	B-X
was	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
the	B-X
upregulation	B-X
of	B-X
miR	B-X
-	B-X
155	B-X
and	B-X
the	B-X
upregulation	B-X
of	B-X
TLR8	B-X
in	B-X
the	B-X
same	B-X
period	B-X

On	O
the	O
basis	O
of	O
in	O
vitro	O
models	O
,	O
it	O
is	O
proposed	O
that	O
perhaps	O
the	O
high	B-cell_line
receptor	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
i.e.	O
,	O
common	O
ALL	O
of	O
childhood	O
)	O
have	O
relative	O
stability	O
of	O
their	O
genetic	O
material	O
making	O
glucocorticoid-resistant	O
mutations	O
less	O
likely	O
to	O
occur	O
in	O
patients	O
with	O
these	O
cells	O
than	O
in	O
low-receptor	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
i.e.	O
,	O
T-cell	O
leukemia	O
)	O
.	O

This	O
greater	O
genetic	O
variability	O
in	O
the	O
low-receptor	B-cell_line
lines	I-cell_line
could	O
account	O
for	O
the	O
earlier	O
emergence	O
of	O
clinical	O
glucocorticoid	O
resistance	O
in	O
these	O
patients	O
.	O
<EOS>	B-X
This	B-X
greater	B-X
genetic	B-X
variability	B-X
in	B-X
the	B-X
low	B-X
-	B-X
receptor	B-X
lines	B-X
could	B-X
account	B-X
for	B-X
the	B-X
earlier	B-X
emergence	B-X
of	B-X
clinical	B-X
glucocorticoid	B-X
resistance	B-X
in	B-X
these	B-X
patients	B-X
<EOS>	B-X
This	B-X
variability	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
the	B-X
known	B-X
correlation	B-X
between	B-X
active	B-X
cell	B-X
proliferation	B-X
and	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
receptors	B-X
,	B-X
since	B-X
the	B-X
tumors	B-X
with	B-X
the	B-X
highest	B-X
growth	B-X
fraction	B-X
(	B-X
i	B-X
<EOS>	B-X
There	B-X
is	B-X
a	B-X
range	B-X
of	B-X
levels	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
numbers	B-X
seen	B-X
in	B-X
the	B-X
various	B-X
subclasses	B-X
of	B-X
acute	B-X
lymphatic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
<EOS>	B-X
,	B-X
common	B-X
ALL	B-X
of	B-X
childhood	B-X
)	B-X
have	B-X
relative	B-X
stability	B-X
of	B-X
their	B-X
genetic	B-X
material	B-X
making	B-X
glucocorticoid	B-X
-	B-X
resistant	B-X
mutations	B-X
less	B-X
likely	B-X
to	B-X
occur	B-X
in	B-X
patients	B-X
with	B-X
these	B-X
cells	B-X
than	B-X
in	B-X
low	B-X
-	B-X
receptor	B-X
cell	B-X
lines	B-X
(	B-X
i	B-X

[	O
Tumor	O
histology	O
and	O
steroid	B-protein
receptors	I-protein
in	O
breast	O
carcinoma	O
]	O
<EOS>	B-X
Anticancer	B-X
or	B-X
carcinogenic	B-X
?	B-X
The	B-X
role	B-X
of	B-X
estrogen	B-X
receptor	B-X
β	B-X
in	B-X
breast	B-X
cancer	B-X
progression	B-X
.	B-X
<EOS>	B-X
8	B-X
%	B-X
)	B-X
ranged	B-X
between	B-X
2	B-X
and	B-X
5	B-X
cm	B-X
in	B-X
size	B-X
;	B-X
the	B-X
most	B-X
common	B-X
histological	B-X
type	B-X
of	B-X
breast	B-X
carcinoma	B-X
(	B-X
49	B-X
<EOS>	B-X
Prognostic	B-X
value	B-X
of	B-X
androgen	B-X
receptor	B-X
expression	B-X
in	B-X
different	B-X
molecular	B-X
types	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
women	B-X
.	B-X
<EOS>	B-X
001	B-X
)	B-X
and	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
	B-X
-	B-X
positive	B-X
(	B-X
p	B-X
<	B-X
0	B-X

In	O
Specimens	O
of	O
115	O
patients	O
with	O
breast	O
cancer	O
4	O
tumorparameters	O
(	O
tumorsize	O
,	O
tumorboder	O
,	O
nucleargrade	O
,	O
lymphocytic	O
stromal	O
reaction	O
)	O
3	O
features	O
of	O
regional	O
lymphnodes	O
(	O
sinushistiocytosis	O
,	O
T-cellreaction	O
,	O
lymphnode	O
metastases	O
)	O
and	O
estrogen	B-protein
and	I-protein
progesteron	I-protein
receptors	I-protein
were	O
determined	O
.	O
<EOS>	B-X
In	B-X
Specimens	B-X
of	B-X
115	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
4	B-X
tumorparameters	B-X
(	B-X
tumorsize	B-X
,	B-X
tumorboder	B-X
,	B-X
nucleargrade	B-X
,	B-X
lymphocytic	B-X
stromal	B-X
reaction	B-X
)	B-X
3	B-X
features	B-X
of	B-X
regional	B-X
lymphnodes	B-X
(	B-X
sinushistiocytosis	B-X
,	B-X
T	B-X
-	B-X
cellreaction	B-X
,	B-X
lymphnode	B-X
metastases	B-X
)	B-X
and	B-X
estrogen	B-X
and	B-X
progesteron	B-X
receptors	B-X
were	B-X
determined	B-X
<EOS>	B-X
A	B-X
strong	B-X
sinushistiocytosis	B-X
and	B-X
T	B-X
-	B-X
cellreaction	B-X
could	B-X
be	B-X
verified	B-X
mainly	B-X
in	B-X
metastases	B-X
in	B-X
free	B-X
lymphnodes	B-X
<EOS>	B-X
The	B-X
steroid	B-X
receptor	B-X
content	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
histological	B-X
parameters	B-X
<EOS>	B-X
[	B-X
Tumor	B-X
histology	B-X
and	B-X
steroid	B-X
receptors	B-X
in	B-X
breast	B-X
carcinoma	B-X
]	B-X
.	B-X

A	O
strong	O
sinushistiocytosis	O
and	O
T-cellreaction	O
could	O
be	O
verified	O
mainly	O
in	O
metastases	O
in	O
free	O
lymphnodes	O
.	O

The	O
steroid	B-protein
receptor	I-protein
content	O
does	O
not	O
correlate	O
with	O
histological	O
parameters	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
exercise	B-X
intensity	B-X
on	B-X
fatty	B-X
liver	B-X
in	B-X
rats	B-X
.	B-X
<EOS>	B-X
Breast	B-X
cancer	B-X
is	B-X
a	B-X
highly	B-X
heterogeneous	B-X
disease	B-X
with	B-X
various	B-X
molecular	B-X
subtypes	B-X
exhibiting	B-X
distinct	B-X
biological	B-X
behaviors	B-X
and	B-X
treatment	B-X
responsiveness	B-X
<EOS>	B-X
Such	B-X
alterations	B-X
could	B-X
either	B-X
contribute	B-X
to	B-X
increased	B-X
anxiety	B-X
or	B-X
be	B-X
a	B-X
compensatory	B-X
mechanism	B-X
for	B-X
reducing	B-X
anxiety	B-X
<EOS>	B-X
The	B-X
relationship	B-X
between	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
plaque	B-X
stability	B-X
in	B-X
the	B-X
postmenopausal	B-X
stage	B-X
remains	B-X
to	B-X
be	B-X
elucidated	B-X

Aldosterone-receptor	B-protein
deficiency	O
in	O
pseudohypoaldosteronism	O
.	O
<EOS>	B-X
Mechanisms	B-X
of	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
pseudohypoaldosteronism	B-X
.	B-X
<EOS>	B-X
Hyper	B-X
-	B-X
	B-X
and	B-X
hypoaldosteronism	B-X
.	B-X
<EOS>	B-X
In	B-X
conditions	B-X
of	B-X
resistance	B-X
,	B-X
aldosterone	B-X
levels	B-X
are	B-X
often	B-X
elevated	B-X
and	B-X
termed	B-X
pseudo	B-X
-	B-X
hypoaldosteronism	B-X
<EOS>	B-X
During	B-X
the	B-X
first	B-X
week	B-X
of	B-X
life	B-X
,	B-X
MR	B-X
-	B-X
deficient	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
developed	B-X
symptoms	B-X
of	B-X
pseudohypoaldosteronism	B-X

Pseudohypoaldosteronism	O
,	O
a	O
syndrome	O
characterized	O
by	O
salt	O
wasting	O
and	O
failure	O
to	O
thrive	O
,	O
usually	O
presents	O
in	O
infancy	O
as	O
high	O
urinary	O
levels	O
of	O
sodium	O
despite	O
hyponatremia	O
,	O
hyperkalemia	O
,	O
hyperreninemia	O
,	O
and	O
elevated	O
aldosterone	O
levels	O
.	O
<EOS>	B-X
Pseudohypoaldosteronism	B-X
,	B-X
a	B-X
syndrome	B-X
characterized	B-X
by	B-X
salt	B-X
wasting	B-X
and	B-X
failure	B-X
to	B-X
thrive	B-X
,	B-X
usually	B-X
presents	B-X
in	B-X
infancy	B-X
as	B-X
high	B-X
urinary	B-X
levels	B-X
of	B-X
sodium	B-X
despite	B-X
hyponatremia	B-X
,	B-X
hyperkalemia	B-X
,	B-X
hyperreninemia	B-X
,	B-X
and	B-X
elevated	B-X
aldosterone	B-X
levels	B-X
<EOS>	B-X
It	B-X
appears	B-X
that	B-X
pseudohypoaldosteronism	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
Type	B-X
I	B-X
receptor	B-X
defect	B-X
,	B-X
that	B-X
the	B-X
defect	B-X
may	B-X
be	B-X
complete	B-X
or	B-X
partial	B-X
,	B-X
that	B-X
transmission	B-X
may	B-X
be	B-X
autosomal	B-X
recessive	B-X
,	B-X
and	B-X
that	B-X
the	B-X
study	B-X
of	B-X
patients	B-X
with	B-X
pseudohypoaldosteronism	B-X
may	B-X
indicate	B-X
physiologic	B-X
roles	B-X
for	B-X
Type	B-X
I	B-X
receptors	B-X
in	B-X
nonepithelial	B-X
tissues	B-X
<EOS>	B-X
On	B-X
repeated	B-X
examination	B-X
,	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
binding	B-X
was	B-X
found	B-X
in	B-X
monocytes	B-X
from	B-X
Patients	B-X
1	B-X
and	B-X
2	B-X
;	B-X
in	B-X
Patient	B-X
3	B-X
,	B-X
the	B-X
levels	B-X
were	B-X
62	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
more	B-X
than	B-X
2	B-X
S	B-X
<EOS>	B-X
Percoll	B-X
-	B-X
separated	B-X
control	B-X
monocytes	B-X
bound	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
with	B-X
high	B-X
affinity	B-X
(	B-X
Kd	B-X
approximately	B-X
3	B-X
nM	B-X
)	B-X
and	B-X
limited	B-X
capacity	B-X
(	B-X
150	B-X
to	B-X
600	B-X
sites	B-X
per	B-X
cell	B-X
)	B-X

We	O
have	O
investigated	O
this	O
syndrome	O
for	O
the	O
possibility	O
of	O
abnormal	B-protein
Type	I-protein
I	I-protein
or	O
``	B-protein
mineralocorticoid-like	I-protein
''	I-protein
receptors	I-protein
,	O
which	O
have	O
intrinsic	O
steroid	O
specificity	O
indistinguishable	O
from	O
that	O
of	O
renal	B-protein
mineralocorticoid	I-protein
receptors	I-protein
and	O
are	O
found	O
in	O
many	O
tissues	O
and	O
cells	B-cell_type
,	O
including	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O
<EOS>	B-X
Disruption	B-X
of	B-X
any	B-X
of	B-X
the	B-X
ocular	B-X
development	B-X
steps	B-X
can	B-X
result	B-X
in	B-X
ocular	B-X
defects	B-X
such	B-X
as	B-X
microphthalmia	B-X
,	B-X
coloboma	B-X
and	B-X
anterior	B-X
segment	B-X
dysgeneses	B-X
including	B-X
aniridia	B-X
and	B-X
cataract	B-X
<EOS>	B-X
Decreased	B-X
diffusivity	B-X
was	B-X
predominantly	B-X
present	B-X
in	B-X
posterior	B-X
cortical	B-X
regions	B-X
of	B-X
the	B-X
DMN	B-X
,	B-X
but	B-X
also	B-X
outside	B-X
of	B-X
the	B-X
DMN	B-X
in	B-X
temporal	B-X
areas	B-X
and	B-X
in	B-X
a	B-X
few	B-X
limbic	B-X
and	B-X
frontal	B-X
areas	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
extensive	B-X
deep	B-X
nuclei	B-X
involvement	B-X
<EOS>	B-X
Nowadays	B-X
,	B-X
it	B-X
is	B-X
still	B-X
not	B-X
possible	B-X
to	B-X
clinically	B-X
distinguish	B-X
whether	B-X
an	B-X
increase	B-X
in	B-X
high	B-X
-	B-X
sensitivity	B-X
cardiac	B-X
troponin	B-X
(	B-X
hs	B-X
-	B-X
cTn	B-X
)	B-X
values	B-X
is	B-X
due	B-X
to	B-X
myocardial	B-X
injury	B-X
or	B-X
an	B-X
acute	B-X
coronary	B-X
syndrome	B-X
(	B-X
ACS	B-X
)	B-X
<EOS>	B-X
Cornelia	B-X
de	B-X
Lange	B-X
syndrome	B-X
(	B-X
CdLS	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
multisystem	B-X
genetic	B-X
disorder	B-X
which	B-X
is	B-X
caused	B-X
by	B-X
genetic	B-X
defects	B-X
involving	B-X
the	B-X
Nipped	B-X
-	B-X
B	B-X
-	B-X
like	B-X
protein	B-X
(	B-X
NIPBL	B-X
)	B-X
gene	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
clinical	B-X
cases	B-X
(	B-X
60	B-X
-	B-X
70	B-X
%	B-X
)	B-X

We	O
have	O
studied	O
three	O
patients	O
with	O
pseudohypoaldosteronism	O
:	O
the	O
28-year-old	O
index	O
case	O
in	O
Melbourne	O
(	O
Patient	O
1	O
)	O
and	O
two	O
siblings	O
in	O
Munich	O
,	O
eight	O
and	O
two	O
years	O
of	O
age	O
(	O
Patients	O
2	O
and	O
3	O
)	O
;	O
clinically	O
,	O
Patient	O
3	O
had	O
a	O
less	O
severe	O
case	O
than	O
his	O
sister	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
three	B-X
patients	B-X
with	B-X
pseudohypoaldosteronism	B-X
:	B-X
the	B-X
28	B-X
-	B-X
year	B-X
-	B-X
old	B-X
index	B-X
case	B-X
in	B-X
Melbourne	B-X
(	B-X
Patient	B-X
1	B-X
)	B-X
and	B-X
two	B-X
siblings	B-X
in	B-X
Munich	B-X
,	B-X
eight	B-X
and	B-X
two	B-X
years	B-X
of	B-X
age	B-X
(	B-X
Patients	B-X
2	B-X
and	B-X
3	B-X
)	B-X
;	B-X
clinically	B-X
,	B-X
Patient	B-X
3	B-X
had	B-X
a	B-X
less	B-X
severe	B-X
case	B-X
than	B-X
his	B-X
sister	B-X
<EOS>	B-X
On	B-X
repeated	B-X
examination	B-X
,	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
binding	B-X
was	B-X
found	B-X
in	B-X
monocytes	B-X
from	B-X
Patients	B-X
1	B-X
and	B-X
2	B-X
;	B-X
in	B-X
Patient	B-X
3	B-X
,	B-X
the	B-X
levels	B-X
were	B-X
62	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
more	B-X
than	B-X
2	B-X
S	B-X
<EOS>	B-X
It	B-X
appears	B-X
that	B-X
pseudohypoaldosteronism	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
Type	B-X
I	B-X
receptor	B-X
defect	B-X
,	B-X
that	B-X
the	B-X
defect	B-X
may	B-X
be	B-X
complete	B-X
or	B-X
partial	B-X
,	B-X
that	B-X
transmission	B-X
may	B-X
be	B-X
autosomal	B-X
recessive	B-X
,	B-X
and	B-X
that	B-X
the	B-X
study	B-X
of	B-X
patients	B-X
with	B-X
pseudohypoaldosteronism	B-X
may	B-X
indicate	B-X
physiologic	B-X
roles	B-X
for	B-X
Type	B-X
I	B-X
receptors	B-X
in	B-X
nonepithelial	B-X
tissues	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
this	B-X
syndrome	B-X
for	B-X
the	B-X
possibility	B-X
of	B-X
abnormal	B-X
Type	B-X
I	B-X
or	B-X
``	B-X
mineralocorticoid	B-X
-	B-X
like	B-X
''	B-X
receptors	B-X
,	B-X
which	B-X
have	B-X
intrinsic	B-X
steroid	B-X
specificity	B-X
indistinguishable	B-X
from	B-X
that	B-X
of	B-X
renal	B-X
mineralocorticoid	B-X
receptors	B-X
and	B-X
are	B-X
found	B-X
in	B-X
many	B-X
tissues	B-X
and	B-X
cells	B-X
,	B-X
including	B-X
mononuclear	B-X
leukocytes	B-X

Percoll-separated	B-cell_type
control	I-cell_type
monocytes	I-cell_type
bound	O
[	O
3H	O
]	O
aldosterone	O
with	O
high	O
affinity	O
(	O
Kd	O
approximately	O
3	O
nM	O
)	O
and	O
limited	O
capacity	O
(	O
150	O
to	O
600	O
sites	O
per	O
cell	O
)	O
.	O
<EOS>	B-X
Percoll	B-X
-	B-X
separated	B-X
control	B-X
monocytes	B-X
bound	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
with	B-X
high	B-X
affinity	B-X
(	B-X
Kd	B-X
approximately	B-X
3	B-X
nM	B-X
)	B-X
and	B-X
limited	B-X
capacity	B-X
(	B-X
150	B-X
to	B-X
600	B-X
sites	B-X
per	B-X
cell	B-X
)	B-X
<EOS>	B-X
On	B-X
repeated	B-X
examination	B-X
,	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
binding	B-X
was	B-X
found	B-X
in	B-X
monocytes	B-X
from	B-X
Patients	B-X
1	B-X
and	B-X
2	B-X
;	B-X
in	B-X
Patient	B-X
3	B-X
,	B-X
the	B-X
levels	B-X
were	B-X
62	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
more	B-X
than	B-X
2	B-X
S	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
three	B-X
patients	B-X
with	B-X
pseudohypoaldosteronism	B-X
:	B-X
the	B-X
28	B-X
-	B-X
year	B-X
-	B-X
old	B-X
index	B-X
case	B-X
in	B-X
Melbourne	B-X
(	B-X
Patient	B-X
1	B-X
)	B-X
and	B-X
two	B-X
siblings	B-X
in	B-X
Munich	B-X
,	B-X
eight	B-X
and	B-X
two	B-X
years	B-X
of	B-X
age	B-X
(	B-X
Patients	B-X
2	B-X
and	B-X
3	B-X
)	B-X
;	B-X
clinically	B-X
,	B-X
Patient	B-X
3	B-X
had	B-X
a	B-X
less	B-X
severe	B-X
case	B-X
than	B-X
his	B-X
sister	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
this	B-X
syndrome	B-X
for	B-X
the	B-X
possibility	B-X
of	B-X
abnormal	B-X
Type	B-X
I	B-X
or	B-X
``	B-X
mineralocorticoid	B-X
-	B-X
like	B-X
''	B-X
receptors	B-X
,	B-X
which	B-X
have	B-X
intrinsic	B-X
steroid	B-X
specificity	B-X
indistinguishable	B-X
from	B-X
that	B-X
of	B-X
renal	B-X
mineralocorticoid	B-X
receptors	B-X
and	B-X
are	B-X
found	B-X
in	B-X
many	B-X
tissues	B-X
and	B-X
cells	B-X
,	B-X
including	B-X
mononuclear	B-X
leukocytes	B-X

On	O
repeated	O
examination	O
,	O
no	O
[	O
3H	O
]	O
aldosterone	O
binding	O
was	O
found	O
in	O
monocytes	B-cell_type
from	O
Patients	O
1	O
and	O
2	O
;	O
in	O
Patient	O
3	O
,	O
the	O
levels	O
were	O
62	O
sites	O
per	O
cell	O
,	O
more	O
than	O
2	O
S.D.	O
below	O
those	O
of	O
the	O
control	O
.	O
<EOS>	B-X
On	B-X
repeated	B-X
examination	B-X
,	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
binding	B-X
was	B-X
found	B-X
in	B-X
monocytes	B-X
from	B-X
Patients	B-X
1	B-X
and	B-X
2	B-X
;	B-X
in	B-X
Patient	B-X
3	B-X
,	B-X
the	B-X
levels	B-X
were	B-X
62	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
more	B-X
than	B-X
2	B-X
S	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
three	B-X
patients	B-X
with	B-X
pseudohypoaldosteronism	B-X
:	B-X
the	B-X
28	B-X
-	B-X
year	B-X
-	B-X
old	B-X
index	B-X
case	B-X
in	B-X
Melbourne	B-X
(	B-X
Patient	B-X
1	B-X
)	B-X
and	B-X
two	B-X
siblings	B-X
in	B-X
Munich	B-X
,	B-X
eight	B-X
and	B-X
two	B-X
years	B-X
of	B-X
age	B-X
(	B-X
Patients	B-X
2	B-X
and	B-X
3	B-X
)	B-X
;	B-X
clinically	B-X
,	B-X
Patient	B-X
3	B-X
had	B-X
a	B-X
less	B-X
severe	B-X
case	B-X
than	B-X
his	B-X
sister	B-X
<EOS>	B-X
Pseudohypoaldosteronism	B-X
,	B-X
a	B-X
syndrome	B-X
characterized	B-X
by	B-X
salt	B-X
wasting	B-X
and	B-X
failure	B-X
to	B-X
thrive	B-X
,	B-X
usually	B-X
presents	B-X
in	B-X
infancy	B-X
as	B-X
high	B-X
urinary	B-X
levels	B-X
of	B-X
sodium	B-X
despite	B-X
hyponatremia	B-X
,	B-X
hyperkalemia	B-X
,	B-X
hyperreninemia	B-X
,	B-X
and	B-X
elevated	B-X
aldosterone	B-X
levels	B-X
<EOS>	B-X
It	B-X
appears	B-X
that	B-X
pseudohypoaldosteronism	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
Type	B-X
I	B-X
receptor	B-X
defect	B-X
,	B-X
that	B-X
the	B-X
defect	B-X
may	B-X
be	B-X
complete	B-X
or	B-X
partial	B-X
,	B-X
that	B-X
transmission	B-X
may	B-X
be	B-X
autosomal	B-X
recessive	B-X
,	B-X
and	B-X
that	B-X
the	B-X
study	B-X
of	B-X
patients	B-X
with	B-X
pseudohypoaldosteronism	B-X
may	B-X
indicate	B-X
physiologic	B-X
roles	B-X
for	B-X
Type	B-X
I	B-X
receptors	B-X
in	B-X
nonepithelial	B-X
tissues	B-X

Levels	O
in	O
the	O
parents	O
of	O
the	O
Munich	O
patients	O
(	O
first	O
cousins	O
)	O
were	O
normal	O
.	O
<EOS>	B-X
Levels	B-X
in	B-X
the	B-X
parents	B-X
of	B-X
the	B-X
Munich	B-X
patients	B-X
(	B-X
first	B-X
cousins	B-X
)	B-X
were	B-X
normal	B-X
<EOS>	B-X
below	B-X
those	B-X
of	B-X
the	B-X
control	B-X
<EOS>	B-X
On	B-X
repeated	B-X
examination	B-X
,	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
binding	B-X
was	B-X
found	B-X
in	B-X
monocytes	B-X
from	B-X
Patients	B-X
1	B-X
and	B-X
2	B-X
;	B-X
in	B-X
Patient	B-X
3	B-X
,	B-X
the	B-X
levels	B-X
were	B-X
62	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
more	B-X
than	B-X
2	B-X
S	B-X
<EOS>	B-X
Aldosterone	B-X
-	B-X
receptor	B-X
deficiency	B-X
in	B-X
pseudohypoaldosteronism	B-X
.	B-X

It	O
appears	O
that	O
pseudohypoaldosteronism	O
is	O
caused	O
by	O
a	O
Type	O
I	O
receptor	O
defect	O
,	O
that	O
the	O
defect	O
may	O
be	O
complete	O
or	O
partial	O
,	O
that	O
transmission	O
may	O
be	O
autosomal	O
recessive	O
,	O
and	O
that	O
the	O
study	O
of	O
patients	O
with	O
pseudohypoaldosteronism	O
may	O
indicate	O
physiologic	O
roles	O
for	O
Type	B-protein
I	I-protein
receptors	I-protein
in	O
nonepithelial	O
tissues	O
.	O
<EOS>	B-X
It	B-X
appears	B-X
that	B-X
pseudohypoaldosteronism	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
Type	B-X
I	B-X
receptor	B-X
defect	B-X
,	B-X
that	B-X
the	B-X
defect	B-X
may	B-X
be	B-X
complete	B-X
or	B-X
partial	B-X
,	B-X
that	B-X
transmission	B-X
may	B-X
be	B-X
autosomal	B-X
recessive	B-X
,	B-X
and	B-X
that	B-X
the	B-X
study	B-X
of	B-X
patients	B-X
with	B-X
pseudohypoaldosteronism	B-X
may	B-X
indicate	B-X
physiologic	B-X
roles	B-X
for	B-X
Type	B-X
I	B-X
receptors	B-X
in	B-X
nonepithelial	B-X
tissues	B-X
<EOS>	B-X
Pseudohypoaldosteronism	B-X
,	B-X
a	B-X
syndrome	B-X
characterized	B-X
by	B-X
salt	B-X
wasting	B-X
and	B-X
failure	B-X
to	B-X
thrive	B-X
,	B-X
usually	B-X
presents	B-X
in	B-X
infancy	B-X
as	B-X
high	B-X
urinary	B-X
levels	B-X
of	B-X
sodium	B-X
despite	B-X
hyponatremia	B-X
,	B-X
hyperkalemia	B-X
,	B-X
hyperreninemia	B-X
,	B-X
and	B-X
elevated	B-X
aldosterone	B-X
levels	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
three	B-X
patients	B-X
with	B-X
pseudohypoaldosteronism	B-X
:	B-X
the	B-X
28	B-X
-	B-X
year	B-X
-	B-X
old	B-X
index	B-X
case	B-X
in	B-X
Melbourne	B-X
(	B-X
Patient	B-X
1	B-X
)	B-X
and	B-X
two	B-X
siblings	B-X
in	B-X
Munich	B-X
,	B-X
eight	B-X
and	B-X
two	B-X
years	B-X
of	B-X
age	B-X
(	B-X
Patients	B-X
2	B-X
and	B-X
3	B-X
)	B-X
;	B-X
clinically	B-X
,	B-X
Patient	B-X
3	B-X
had	B-X
a	B-X
less	B-X
severe	B-X
case	B-X
than	B-X
his	B-X
sister	B-X
<EOS>	B-X
On	B-X
repeated	B-X
examination	B-X
,	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
binding	B-X
was	B-X
found	B-X
in	B-X
monocytes	B-X
from	B-X
Patients	B-X
1	B-X
and	B-X
2	B-X
;	B-X
in	B-X
Patient	B-X
3	B-X
,	B-X
the	B-X
levels	B-X
were	B-X
62	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
more	B-X
than	B-X
2	B-X
S	B-X

Glucocorticoid	O
inhibition	O
of	O
urokinase-like	B-protein
plasminogen	I-protein
activators	I-protein
in	O
cultured	B-cell_line
human	I-cell_line
lymphoblasts	I-cell_line
.	O
<EOS>	B-X
Glucocorticoid	B-X
inhibition	B-X
of	B-X
urokinase	B-X
-	B-X
like	B-X
plasminogen	B-X
activators	B-X
in	B-X
cultured	B-X
human	B-X
lymphoblasts	B-X
.	B-X
<EOS>	B-X
Both	B-X
cell	B-X
types	B-X
secrete	B-X
a	B-X
urokinase	B-X
(	B-X
UK	B-X
)	B-X
	B-X
-	B-X
like	B-X
plasminogen	B-X
activator	B-X
(	B-X
PA	B-X
)	B-X
<EOS>	B-X
Glucocorticoid	B-X
-	B-X
inducible	B-X
inhibitors	B-X
in	B-X
HMy2	B-X
cells	B-X
are	B-X
either	B-X
totally	B-X
absent	B-X
or	B-X
are	B-X
present	B-X
at	B-X
undetectable	B-X
levels	B-X
<EOS>	B-X
This	B-X
apparent	B-X
clinical	B-X
effect	B-X
of	B-X
hydroxyurea	B-X
led	B-X
to	B-X
an	B-X
examination	B-X
of	B-X
hydroxyurea	B-X
effects	B-X
on	B-X
GR	B-X
binding	B-X
and	B-X
sensitivity	B-X
in	B-X
the	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
human	B-X
lymphoblast	B-X
cell	B-X
line	B-X
GM4672A	B-X

Two	O
human	B-cell_line
lymphoblast	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
LICR-LON-HMy2	B-cell_line
(	O
HMy2	B-cell_line
cells	I-cell_line
)	O
and	O
GM4672A	B-cell_line
cells	I-cell_line
,	O
are	O
moderately	O
growth	O
inhibited	O
by	O
dexamethasone	O
(	O
1	O
,	O
4-pregnadien-9-fluoro-16	O
alpha-methyl-11	O
beta	O
,	O
17	O
alpha	O
,	O
21-triol-3	O
,	O
20-dione	O
)	O
(	O
Dex	O
)	O
.	O
<EOS>	B-X
Two	B-X
human	B-X
lymphoblast	B-X
cell	B-X
lines	B-X
,	B-X
LICR	B-X
-	B-X
LON	B-X
-	B-X
HMy2	B-X
(	B-X
HMy2	B-X
cells	B-X
)	B-X
and	B-X
GM4672A	B-X
cells	B-X
,	B-X
are	B-X
moderately	B-X
growth	B-X
inhibited	B-X
by	B-X
dexamethasone	B-X
(	B-X
1,4	B-X
-	B-X
pregnadien	B-X
-	B-X
9	B-X
-	B-X
fluoro	B-X
-	B-X
16	B-X
alpha	B-X
-	B-X
methyl	B-X
-	B-X
11	B-X
beta	B-X
,	B-X
17	B-X
alpha	B-X
,	B-X
21	B-X
-	B-X
triol	B-X
-	B-X
3,20	B-X
-	B-X
dione	B-X
)	B-X
(	B-X
Dex	B-X
)	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
both	B-X
HMy2	B-X
and	B-X
GM4672A	B-X
cells	B-X
with	B-X
Dex	B-X
for	B-X
1	B-X
-	B-X
4	B-X
days	B-X
inhibits	B-X
extracellular	B-X
PA	B-X
activity	B-X
in	B-X
a	B-X
concentration	B-X
-	B-X
dependent	B-X
manner	B-X
,	B-X
being	B-X
half	B-X
-	B-X
maximal	B-X
at	B-X
approximately	B-X
1	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
9	B-X
)	B-X
M	B-X
<EOS>	B-X
However	B-X
,	B-X
conditioned	B-X
media	B-X
from	B-X
Dex	B-X
-	B-X
treated	B-X
GM4672A	B-X
cells	B-X
inhibits	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
homologous	B-X
cellular	B-X
activator	B-X
in	B-X
conditioned	B-X
media	B-X
from	B-X
control	B-X
GM4672A	B-X
cells	B-X
<EOS>	B-X
Glucocorticoid	B-X
-	B-X
inducible	B-X
inhibitors	B-X
in	B-X
HMy2	B-X
cells	B-X
are	B-X
either	B-X
totally	B-X
absent	B-X
or	B-X
are	B-X
present	B-X
at	B-X
undetectable	B-X
levels	B-X

Both	O
cell	O
types	O
secrete	O
a	O
urokinase	B-protein
(	I-protein
UK	I-protein
)	I-protein
-like	I-protein
plasminogen	I-protein
activator	I-protein
(	O
PA	B-protein
)	O
.	O
<EOS>	B-X
Both	B-X
cell	B-X
types	B-X
secrete	B-X
a	B-X
urokinase	B-X
(	B-X
UK	B-X
)	B-X
	B-X
-	B-X
like	B-X
plasminogen	B-X
activator	B-X
(	B-X
PA	B-X
)	B-X
<EOS>	B-X
,	B-X
(	B-X
iv	B-X
)	B-X
cell	B-X
surface	B-X
pro	B-X
-	B-X
uPA	B-X
activation	B-X
by	B-X
plasmin	B-X
and	B-X
(	B-X
v	B-X
)	B-X
plasminogen	B-X
activation	B-X
by	B-X
cell	B-X
surface	B-X
uPA	B-X
<EOS>	B-X
Glucocorticoid	B-X
inhibition	B-X
of	B-X
urokinase	B-X
-	B-X
like	B-X
plasminogen	B-X
activators	B-X
in	B-X
cultured	B-X
human	B-X
lymphoblasts	B-X
.	B-X
<EOS>	B-X
Only	B-X
at	B-X
high	B-X
concentrations	B-X
of	B-X
pro	B-X
-	B-X
UK	B-X
(	B-X
scu	B-X
-	B-X
PA	B-X
)	B-X
(	B-X
greater	B-X
than	B-X
or	B-X
equal	B-X
to	B-X
250	B-X
IU	B-X
/	B-X
mL	B-X
)	B-X
did	B-X
plasminogen	B-X
activation	B-X
in	B-X
plasma	B-X
occur	B-X

Treatment	O
of	O
both	O
HMy2	B-cell_line
and	I-cell_line
GM4672A	I-cell_line
cells	I-cell_line
with	O
Dex	O
for	O
1-4	O
days	O
inhibits	O
extracellular	O
PA	B-protein
activity	O
in	O
a	O
concentration-dependent	O
manner	O
,	O
being	O
half-maximal	O
at	O
approximately	O
1	O
X	O
10	O
(	O
-9	O
)	O
M	O
.	O

Inhibition	O
of	O
PA	B-protein
in	O
both	O
cell	O
types	O
is	O
specific	O
for	O
active	O
glucocorticoids	O
,	O
and	O
this	O
specificity	O
parallels	O
the	O
ability	O
of	O
various	O
steroids	O
to	O
bind	O
to	O
glucocorticoid	B-protein
receptors	I-protein
.	O

HMy2	B-cell_line
cell	I-cell_line
PA	B-protein
is	O
fully	O
suppressible	O
by	O
Dex	O
,	O
whereas	O
up	O
to	O
one	O
third	O
of	O
the	O
activator	O
expressed	O
by	O
GM4672A	B-cell_line
cells	I-cell_line
is	O
resistant	O
to	O
glucocorticoid	O
inhibition	O
.	O
<EOS>	B-X
HMy2	B-X
cell	B-X
PA	B-X
is	B-X
fully	B-X
suppressible	B-X
by	B-X
Dex	B-X
,	B-X
whereas	B-X
up	B-X
to	B-X
one	B-X
third	B-X
of	B-X
the	B-X
activator	B-X
expressed	B-X
by	B-X
GM4672A	B-X
cells	B-X
is	B-X
resistant	B-X
to	B-X
glucocorticoid	B-X
inhibition	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PA	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
is	B-X
specific	B-X
for	B-X
active	B-X
glucocorticoids	B-X
,	B-X
and	B-X
this	B-X
specificity	B-X
parallels	B-X
the	B-X
ability	B-X
of	B-X
various	B-X
steroids	B-X
to	B-X
bind	B-X
to	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Thus	B-X
,	B-X
regulation	B-X
of	B-X
UK	B-X
-	B-X
like	B-X
PAs	B-X
in	B-X
HMy2	B-X
and	B-X
GM4672A	B-X
cells	B-X
differs	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
glucocorticoids	B-X
inhibit	B-X
constitutively	B-X
expressed	B-X
activator	B-X
levels	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
possible	B-X
contribution	B-X
of	B-X
glucocorticoid	B-X
-	B-X
inducible	B-X
inhibitors	B-X
to	B-X
the	B-X
regulatory	B-X
process	B-X
in	B-X
GM4672A	B-X
cells	B-X
<EOS>	B-X
Glucocorticoid	B-X
inhibition	B-X
of	B-X
urokinase	B-X
-	B-X
like	B-X
plasminogen	B-X
activators	B-X
in	B-X
cultured	B-X
human	B-X
lymphoblasts	B-X
.	B-X

Mixing	O
experiments	O
using	O
a	O
UK	O
standard	O
and	O
conditioned	O
media	O
from	O
Dex-treated	B-cell_line
cells	I-cell_line
suggest	O
an	O
absence	O
of	O
glucocorticoid-inducible	B-protein
inhibitors	I-protein
to	O
UK	B-protein
or	O
plasmin	B-protein
in	O
both	O
cell	O
types	O
.	O
<EOS>	B-X
Our	B-X
experiments	B-X
indicate	B-X
that	B-X
chiral	B-X
CQDs	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
plasmin	B-X
activity	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
relationship	B-X
between	B-X
plasmin	B-X
and	B-X
hypertension	B-X
as	B-X
well	B-X
as	B-X
podocyte	B-X
injury	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
plasmin	B-X
inhibitors	B-X
in	B-X
DS	B-X
rats	B-X
<EOS>	B-X
Distinguishing	B-X
Plasmin	B-X
-	B-X
Generating	B-X
Microvesicles	B-X
:	B-X
Tiny	B-X
Messengers	B-X
Involved	B-X
in	B-X
Fibrinolysis	B-X
and	B-X
Proteolysis	B-X
.	B-X
<EOS>	B-X
The	B-X
main	B-X
objective	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
provide	B-X
an	B-X
overview	B-X
on	B-X
the	B-X
mechanism	B-X
of	B-X
plasminogen	B-X
reception	B-X
and	B-X
activation	B-X
at	B-X
the	B-X
surface	B-X
of	B-X
cell	B-X
-	B-X
derived	B-X
microvesicles	B-X
,	B-X
new	B-X
actors	B-X
in	B-X
fibrinolysis	B-X
and	B-X
proteolysis	B-X

However	O
,	O
conditioned	O
media	O
from	O
Dex-treated	B-cell_line
GM4672A	I-cell_line
cells	I-cell_line
inhibits	O
a	O
portion	O
of	O
the	O
homologous	O
cellular	O
activator	O
in	O
conditioned	O
media	O
from	O
control	O
GM4672A	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
However	B-X
,	B-X
conditioned	B-X
media	B-X
from	B-X
Dex	B-X
-	B-X
treated	B-X
GM4672A	B-X
cells	B-X
inhibits	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
homologous	B-X
cellular	B-X
activator	B-X
in	B-X
conditioned	B-X
media	B-X
from	B-X
control	B-X
GM4672A	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
regulation	B-X
of	B-X
UK	B-X
-	B-X
like	B-X
PAs	B-X
in	B-X
HMy2	B-X
and	B-X
GM4672A	B-X
cells	B-X
differs	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
glucocorticoids	B-X
inhibit	B-X
constitutively	B-X
expressed	B-X
activator	B-X
levels	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
possible	B-X
contribution	B-X
of	B-X
glucocorticoid	B-X
-	B-X
inducible	B-X
inhibitors	B-X
to	B-X
the	B-X
regulatory	B-X
process	B-X
in	B-X
GM4672A	B-X
cells	B-X
<EOS>	B-X
Mixing	B-X
experiments	B-X
using	B-X
a	B-X
UK	B-X
standard	B-X
and	B-X
conditioned	B-X
media	B-X
from	B-X
Dex	B-X
-	B-X
treated	B-X
cells	B-X
suggest	B-X
an	B-X
absence	B-X
of	B-X
glucocorticoid	B-X
-	B-X
inducible	B-X
inhibitors	B-X
to	B-X
UK	B-X
or	B-X
plasmin	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
<EOS>	B-X
Thus	B-X
,	B-X
low	B-X
levels	B-X
of	B-X
glucocorticoid	B-X
-	B-X
inducible	B-X
inhibitors	B-X
may	B-X
contribute	B-X
to	B-X
,	B-X
but	B-X
can	B-X
not	B-X
fully	B-X
account	B-X
for	B-X
,	B-X
Dex	B-X
inhibition	B-X
of	B-X
GM4672A	B-X
PA	B-X
activity	B-X

Thus	O
,	O
low	O
levels	O
of	O
glucocorticoid-inducible	B-protein
inhibitors	I-protein
may	O
contribute	O
to	O
,	O
but	O
can	O
not	O
fully	O
account	O
for	O
,	O
Dex	O
inhibition	O
of	O
GM4672A	B-protein
PA	I-protein
activity	O
.	O
<EOS>	B-X
Our	B-X
preliminary	B-X
study	B-X
shows	B-X
that	B-X
oxidized	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
(	B-X
oxLDL	B-X
)	B-X
	B-X
-	B-X
induced	B-X
NET	B-X
formation	B-X
is	B-X
accompanied	B-X
by	B-X
an	B-X
elevated	B-X
intracellular	B-X
Cl	B-X
<EOS>	B-X
Neutrophil	B-X
extracellular	B-X
traps	B-X
(	B-X
NETs	B-X
)	B-X
play	B-X
crucial	B-X
roles	B-X
in	B-X
atherosclerotic	B-X
cardiovascular	B-X
diseases	B-X
such	B-X
as	B-X
acute	B-X
coronary	B-X
syndrome	B-X
(	B-X
ACS	B-X
)	B-X
<EOS>	B-X
Increased	B-X
intracellular	B-X
Cl	B-X

Glucocorticoid-inducible	B-protein
inhibitors	I-protein
in	O
HMy2	B-cell_line
cells	I-cell_line
are	O
either	O
totally	O
absent	O
or	O
are	O
present	O
at	O
undetectable	O
levels	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
CRC	B-X
cells	B-X
expressed	B-X
POSTN	B-X
at	B-X
almost	B-X
undetectable	B-X
levels	B-X
<EOS>	B-X
Due	B-X
to	B-X
refractory	B-X
potassium	B-X
depletion	B-X
and	B-X
hypertension	B-X
,	B-X
workup	B-X
for	B-X
hyperaldosteronism	B-X
revealed	B-X
renal	B-X
potassium	B-X
wasting	B-X
,	B-X
inappropriately	B-X
normal	B-X
plasma	B-X
renin	B-X
levels	B-X
,	B-X
and	B-X
almost	B-X
undetectable	B-X
aldosterone	B-X
levels	B-X
<EOS>	B-X
Off	B-X
-	B-X
season	B-X
circulation	B-X
and	B-X
characterization	B-X
of	B-X
enterovirus	B-X
D68	B-X
with	B-X
respiratory	B-X
and	B-X
neurological	B-X
presentation	B-X
using	B-X
whole	B-X
-	B-X
genome	B-X
sequencing	B-X
.	B-X
<EOS>	B-X
Combining	B-X
cytoreductive	B-X
therapy	B-X
with	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
(	B-X
TKIs	B-X
)	B-X
is	B-X
a	B-X
therapeutic	B-X
option	B-X
when	B-X
both	B-X
mutations	B-X
are	B-X
present	B-X
,	B-X
and	B-X
TKI	B-X
alone	B-X
is	B-X
not	B-X
sufficient	B-X
to	B-X
control	B-X
peripheral	B-X
blood	B-X
cell	B-X
counts	B-X

Thus	O
,	O
regulation	O
of	O
UK-like	B-protein
PAs	I-protein
in	O
HMy2	B-cell_line
and	I-cell_line
GM4672A	I-cell_line
cells	I-cell_line
differs	O
with	O
respect	O
to	O
the	O
extent	O
to	O
which	O
glucocorticoids	O
inhibit	O
constitutively	B-protein
expressed	I-protein
activator	I-protein
levels	O
,	O
as	O
well	O
as	O
the	O
possible	O
contribution	O
of	O
glucocorticoid-inducible	B-protein
inhibitors	I-protein
to	O
the	O
regulatory	O
process	O
in	O
GM4672A	B-cell_line
cells	I-cell_line
.	O

Characterization	O
of	O
aldosterone	O
binding	O
sites	O
in	O
circulating	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O
<EOS>	B-X
Characterization	B-X
of	B-X
aldosterone	B-X
binding	B-X
sites	B-X
in	B-X
circulating	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
.	B-X
<EOS>	B-X
Aldosterone	B-X
binds	B-X
to	B-X
a	B-X
single	B-X
class	B-X
of	B-X
receptors	B-X
with	B-X
an	B-X
affinity	B-X
of	B-X
2	B-X
<EOS>	B-X
The	B-X
specificity	B-X
data	B-X
show	B-X
a	B-X
hierarchy	B-X
of	B-X
affinity	B-X
of	B-X
desoxycorticosterone	B-X
=	B-X
corticosterone	B-X
=	B-X
aldosterone	B-X
greater	B-X
than	B-X
hydrocortisone	B-X
greater	B-X
than	B-X
dexamethasone	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
mononuclear	B-X
leukocytes	B-X
could	B-X
be	B-X
useful	B-X
for	B-X
studying	B-X
the	B-X
physiological	B-X
significance	B-X
of	B-X
these	B-X
mineralocorticoid	B-X
receptors	B-X
and	B-X
their	B-X
regulation	B-X
in	B-X
humans	B-X

Aldosterone	O
binding	O
sites	O
in	O
human	B-cell_line
mononuclear	I-cell_line
leukocytes	I-cell_line
were	O
characterized	O
after	O
separation	O
of	O
cells	O
from	O
blood	O
by	O
a	O
Percoll	O
gradient	O
.	O
<EOS>	B-X
Aldosterone	B-X
binding	B-X
sites	B-X
in	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
were	B-X
characterized	B-X
after	B-X
separation	B-X
of	B-X
cells	B-X
from	B-X
blood	B-X
by	B-X
a	B-X
Percoll	B-X
gradient	B-X
<EOS>	B-X
Aldosterone	B-X
binds	B-X
to	B-X
a	B-X
single	B-X
class	B-X
of	B-X
receptors	B-X
with	B-X
an	B-X
affinity	B-X
of	B-X
2	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
mononuclear	B-X
leukocytes	B-X
could	B-X
be	B-X
useful	B-X
for	B-X
studying	B-X
the	B-X
physiological	B-X
significance	B-X
of	B-X
these	B-X
mineralocorticoid	B-X
receptors	B-X
and	B-X
their	B-X
regulation	B-X
in	B-X
humans	B-X
<EOS>	B-X
The	B-X
specificity	B-X
data	B-X
show	B-X
a	B-X
hierarchy	B-X
of	B-X
affinity	B-X
of	B-X
desoxycorticosterone	B-X
=	B-X
corticosterone	B-X
=	B-X
aldosterone	B-X
greater	B-X
than	B-X
hydrocortisone	B-X
greater	B-X
than	B-X
dexamethasone	B-X

After	O
washing	O
and	O
resuspension	O
in	O
RPMI-1640	O
medium	O
,	O
cells	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
1	O
h	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
aldosterone	O
plus	O
a	O
100-fold	O
concentration	O
of	O
RU-26988	O
(	O
11	O
alpha	O
,	O
17	O
alpha-dihydroxy-17	O
beta-propynylandrost-1	O
,	O
4	O
,	O
6-trien-3-one	O
)	O
,	O
with	O
or	O
without	O
an	O
excess	O
of	O
unlabeled	O
aldosterone	O
.	O
<EOS>	B-X
After	B-X
washing	B-X
and	B-X
resuspension	B-X
in	B-X
RPMI	B-X
-	B-X
1640	B-X
medium	B-X
,	B-X
cells	B-X
were	B-X
incubated	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
for	B-X
1	B-X
h	B-X
with	B-X
different	B-X
concentrations	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
plus	B-X
a	B-X
100	B-X
-	B-X
fold	B-X
concentration	B-X
of	B-X
RU	B-X
-	B-X
26988	B-X
(	B-X
11	B-X
alpha	B-X
,	B-X
17	B-X
alpha	B-X
-	B-X
dihydroxy	B-X
-	B-X
17	B-X
beta	B-X
-	B-X
propynylandrost	B-X
-	B-X
1,4,6	B-X
-	B-X
trien	B-X
-	B-X
3	B-X
-	B-X
one	B-X
)	B-X
,	B-X
with	B-X
or	B-X
without	B-X
an	B-X
excess	B-X
of	B-X
unlabeled	B-X
aldosterone	B-X
<EOS>	B-X
Cells	B-X
were	B-X
separated	B-X
from	B-X
blood	B-X
samples	B-X
on	B-X
a	B-X
Ficoll	B-X
gradient	B-X
and	B-X
incubated	B-X
with	B-X
different	B-X
concentrations	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
testosterone	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
400	B-X
-	B-X
fold	B-X
excess	B-X
of	B-X
unlabelled	B-X
testosterone	B-X
<EOS>	B-X
Kidney	B-X
pyramids	B-X
were	B-X
incubated	B-X
in	B-X
vitro	B-X
before	B-X
microdissection	B-X
with	B-X
collagenase	B-X
and	B-X
2	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
9	B-X
)	B-X
M	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
an	B-X
excess	B-X
of	B-X
unlabeled	B-X
aldosterone	B-X
<EOS>	B-X
Autoradiographs	B-X
of	B-X
microdissected	B-X
tubular	B-X
segments	B-X
were	B-X
performed	B-X
on	B-X
dry	B-X
film	B-X
after	B-X
incubation	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
A	B-X
)	B-X
at	B-X
2	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
10	B-X
)	B-X
,	B-X
2	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
9	B-X
)	B-X
,	B-X
and	B-X
2	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
8	B-X
)	B-X
M	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
an	B-X
excess	B-X
unlabeled	B-X
hormone	B-X

Aldosterone	O
binds	O
to	O
a	O
single	O
class	O
of	O
receptors	O
with	O
an	O
affinity	O
of	O
2.7	O
+/-	O
0.5	O
nM	O
(	O
means	O
+/-	O
SD	O
,	O
n	O
=	O
14	O
)	O
and	O
a	O
capacity	O
of	O
290	O
+/-	O
108	O
sites/cell	O
(	O
n	O
=	O
14	O
)	O
.	O

The	O
specificity	O
data	O
show	O
a	O
hierarchy	O
of	O
affinity	O
of	O
desoxycorticosterone	O
=	O
corticosterone	O
=	O
aldosterone	O
greater	O
than	O
hydrocortisone	O
greater	O
than	O
dexamethasone	O
.	O
<EOS>	B-X
The	B-X
specificity	B-X
data	B-X
show	B-X
a	B-X
hierarchy	B-X
of	B-X
affinity	B-X
of	B-X
desoxycorticosterone	B-X
=	B-X
corticosterone	B-X
=	B-X
aldosterone	B-X
greater	B-X
than	B-X
hydrocortisone	B-X
greater	B-X
than	B-X
dexamethasone	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
mononuclear	B-X
leukocytes	B-X
could	B-X
be	B-X
useful	B-X
for	B-X
studying	B-X
the	B-X
physiological	B-X
significance	B-X
of	B-X
these	B-X
mineralocorticoid	B-X
receptors	B-X
and	B-X
their	B-X
regulation	B-X
in	B-X
humans	B-X
<EOS>	B-X
Aldosterone	B-X
binding	B-X
sites	B-X
in	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
were	B-X
characterized	B-X
after	B-X
separation	B-X
of	B-X
cells	B-X
from	B-X
blood	B-X
by	B-X
a	B-X
Percoll	B-X
gradient	B-X
<EOS>	B-X
After	B-X
washing	B-X
and	B-X
resuspension	B-X
in	B-X
RPMI	B-X
-	B-X
1640	B-X
medium	B-X
,	B-X
cells	B-X
were	B-X
incubated	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
for	B-X
1	B-X
h	B-X
with	B-X
different	B-X
concentrations	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
aldosterone	B-X
plus	B-X
a	B-X
100	B-X
-	B-X
fold	B-X
concentration	B-X
of	B-X
RU	B-X
-	B-X
26988	B-X
(	B-X
11	B-X
alpha	B-X
,	B-X
17	B-X
alpha	B-X
-	B-X
dihydroxy	B-X
-	B-X
17	B-X
beta	B-X
-	B-X
propynylandrost	B-X
-	B-X
1,4,6	B-X
-	B-X
trien	B-X
-	B-X
3	B-X
-	B-X
one	B-X
)	B-X
,	B-X
with	B-X
or	B-X
without	B-X
an	B-X
excess	B-X
of	B-X
unlabeled	B-X
aldosterone	B-X

The	O
results	O
indicate	O
that	O
mononuclear	B-cell_type
leukocytes	I-cell_type
could	O
be	O
useful	O
for	O
studying	O
the	O
physiological	O
significance	O
of	O
these	O
mineralocorticoid	B-protein
receptors	I-protein
and	O
their	O
regulation	O
in	O
humans	O
.	O
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
mononuclear	B-X
leukocytes	B-X
could	B-X
be	B-X
useful	B-X
for	B-X
studying	B-X
the	B-X
physiological	B-X
significance	B-X
of	B-X
these	B-X
mineralocorticoid	B-X
receptors	B-X
and	B-X
their	B-X
regulation	B-X
in	B-X
humans	B-X
<EOS>	B-X
Aldosterone	B-X
binding	B-X
sites	B-X
in	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
were	B-X
characterized	B-X
after	B-X
separation	B-X
of	B-X
cells	B-X
from	B-X
blood	B-X
by	B-X
a	B-X
Percoll	B-X
gradient	B-X
<EOS>	B-X
The	B-X
specificity	B-X
data	B-X
show	B-X
a	B-X
hierarchy	B-X
of	B-X
affinity	B-X
of	B-X
desoxycorticosterone	B-X
=	B-X
corticosterone	B-X
=	B-X
aldosterone	B-X
greater	B-X
than	B-X
hydrocortisone	B-X
greater	B-X
than	B-X
dexamethasone	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
aldosterone	B-X
binding	B-X
sites	B-X
in	B-X
circulating	B-X
human	B-X
mononuclear	B-X
leukocytes	B-X
.	B-X

Mineralocorticoid	B-protein
and	I-protein
glucocorticoid	I-protein
receptors	I-protein
in	O
circulating	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
primary	O
hyperaldosteronism	O
.	O
<EOS>	B-X
Mineralocorticoid	B-X
and	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
circulating	B-X
mononuclear	B-X
leukocytes	B-X
of	B-X
patients	B-X
with	B-X
primary	B-X
hyperaldosteronism	B-X
.	B-X
<EOS>	B-X
Mineralocorticoid	B-X
and	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
measured	B-X
in	B-X
circulating	B-X
mononuclear	B-X
leukocytes	B-X
in	B-X
5	B-X
patients	B-X
affected	B-X
by	B-X
Conn	B-X
's	B-X
syndrome	B-X
(	B-X
3	B-X
cases	B-X
of	B-X
bilateral	B-X
adrenal	B-X
hyperplasia	B-X
and	B-X
2	B-X
cases	B-X
of	B-X
adenoma	B-X
plus	B-X
unilateral	B-X
hyperplasia	B-X
)	B-X
<EOS>	B-X
The	B-X
affinity	B-X
of	B-X
aldosterone	B-X
for	B-X
the	B-X
receptor	B-X
was	B-X
found	B-X
to	B-X
be	B-X
not	B-X
different	B-X
than	B-X
that	B-X
of	B-X
healthy	B-X
control	B-X
subjects	B-X
<EOS>	B-X
The	B-X
capacity	B-X
and	B-X
the	B-X
affinity	B-X
of	B-X
dexamethasone	B-X
for	B-X
glucocorticoid	B-X
receptors	B-X
ranged	B-X
in	B-X
the	B-X
normal	B-X
values	B-X

Mineralocorticoid	B-protein
and	I-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
measured	O
in	O
circulating	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
in	O
5	O
patients	O
affected	O
by	O
Conn	O
's	O
syndrome	O
(	O
3	O
cases	O
of	O
bilateral	O
adrenal	O
hyperplasia	O
and	O
2	O
cases	O
of	O
adenoma	O
plus	O
unilateral	O
hyperplasia	O
)	O
.	O
<EOS>	B-X
Mineralocorticoid	B-X
and	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
measured	B-X
in	B-X
circulating	B-X
mononuclear	B-X
leukocytes	B-X
in	B-X
5	B-X
patients	B-X
affected	B-X
by	B-X
Conn	B-X
's	B-X
syndrome	B-X
(	B-X
3	B-X
cases	B-X
of	B-X
bilateral	B-X
adrenal	B-X
hyperplasia	B-X
and	B-X
2	B-X
cases	B-X
of	B-X
adenoma	B-X
plus	B-X
unilateral	B-X
hyperplasia	B-X
)	B-X
<EOS>	B-X
Mineralocorticoid	B-X
and	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
circulating	B-X
mononuclear	B-X
leukocytes	B-X
of	B-X
patients	B-X
with	B-X
primary	B-X
hyperaldosteronism	B-X
.	B-X
<EOS>	B-X
The	B-X
affinity	B-X
of	B-X
aldosterone	B-X
for	B-X
the	B-X
receptor	B-X
was	B-X
found	B-X
to	B-X
be	B-X
not	B-X
different	B-X
than	B-X
that	B-X
of	B-X
healthy	B-X
control	B-X
subjects	B-X
<EOS>	B-X
The	B-X
number	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
per	B-X
cell	B-X
resulted	B-X
significantly	B-X
lower	B-X
(	B-X
189	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
114	B-X
,	B-X
mean	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
SD	B-X
)	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
the	B-X
normal	B-X
controls	B-X
(	B-X
298	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
105	B-X
)	B-X

The	O
number	O
of	O
the	O
binding	O
sites	O
per	O
cell	O
resulted	O
significantly	O
lower	O
(	O
189	O
+/-	O
114	O
,	O
mean	O
+/-	O
SD	O
)	O
,	O
as	O
compared	O
with	O
the	O
normal	O
controls	O
(	O
298	O
+/-	O
105	O
)	O
.	O
<EOS>	B-X
The	B-X
number	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
per	B-X
cell	B-X
resulted	B-X
significantly	B-X
lower	B-X
(	B-X
189	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
114	B-X
,	B-X
mean	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
SD	B-X
)	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
the	B-X
normal	B-X
controls	B-X
(	B-X
298	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
105	B-X
)	B-X
<EOS>	B-X
The	B-X
capacity	B-X
and	B-X
the	B-X
affinity	B-X
of	B-X
dexamethasone	B-X
for	B-X
glucocorticoid	B-X
receptors	B-X
ranged	B-X
in	B-X
the	B-X
normal	B-X
values	B-X
<EOS>	B-X
The	B-X
affinity	B-X
of	B-X
aldosterone	B-X
for	B-X
the	B-X
receptor	B-X
was	B-X
found	B-X
to	B-X
be	B-X
not	B-X
different	B-X
than	B-X
that	B-X
of	B-X
healthy	B-X
control	B-X
subjects	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
possible	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
mineralocorticoid	B-X
receptors	B-X
in	B-X
humans	B-X

The	O
affinity	O
of	O
aldosterone	O
for	O
the	O
receptor	O
was	O
found	O
to	O
be	O
not	O
different	O
than	O
that	O
of	O
healthy	O
control	O
subjects	O
.	O
<EOS>	B-X
There	B-X
was	B-X
a	B-X
subsequent	B-X
increase	B-X
in	B-X
serum	B-X
potassium	B-X
level	B-X
,	B-X
which	B-X
was	B-X
followed	B-X
by	B-X
a	B-X
return	B-X
to	B-X
baseline	B-X
after	B-X
discontinuation	B-X
of	B-X
heparin	B-X
,	B-X
thereby	B-X
confirming	B-X
the	B-X
suspected	B-X
diagnosis	B-X
<EOS>	B-X
CK1	B-X
enhanced	B-X
the	B-X
binding	B-X
affinity	B-X
of	B-X
aldosterone	B-X
to	B-X
the	B-X
MR	B-X
,	B-X
facilitated	B-X
nuclear	B-X
translocation	B-X
and	B-X
DNA	B-X
interaction	B-X
of	B-X
the	B-X
MR	B-X
,	B-X
and	B-X
led	B-X
to	B-X
expression	B-X
changes	B-X
of	B-X
pathophysiologically	B-X
relevant	B-X
genes	B-X
like	B-X
Per	B-X
-	B-X
1	B-X
and	B-X
Phlda1	B-X
<EOS>	B-X
Beta	B-X
-	B-X
agonists	B-X
bind	B-X
to	B-X
the	B-X
beta	B-X
receptors	B-X
on	B-X
various	B-X
tissues	B-X
throughout	B-X
the	B-X
body	B-X
<EOS>	B-X
To	B-X
determine	B-X
if	B-X
aldosterone	B-X
binds	B-X
directly	B-X
to	B-X
GPER	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
ability	B-X
of	B-X
aldosterone	B-X
to	B-X
compete	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
[	B-X

The	O
capacity	O
and	O
the	O
affinity	O
of	O
dexamethasone	O
for	O
glucocorticoid	B-protein
receptors	I-protein
ranged	O
in	O
the	O
normal	O
values	O
.	O
<EOS>	B-X
The	B-X
capacity	B-X
and	B-X
the	B-X
affinity	B-X
of	B-X
dexamethasone	B-X
for	B-X
glucocorticoid	B-X
receptors	B-X
ranged	B-X
in	B-X
the	B-X
normal	B-X
values	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
possible	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
mineralocorticoid	B-X
receptors	B-X
in	B-X
humans	B-X
<EOS>	B-X
Our	B-X
objective	B-X
was	B-X
to	B-X
assess	B-X
concentrations	B-X
of	B-X
cortisol	B-X
and	B-X
its	B-X
predominant	B-X
metabolites	B-X
,	B-X
cortisol	B-X
production	B-X
rate	B-X
(	B-X
CPR	B-X
)	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
binding	B-X
characteristics	B-X
in	B-X
PTSD	B-X
compared	B-X
with	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
Matched	B-X
PTSD	B-X
patients	B-X
and	B-X
control	B-X
subjects	B-X
had	B-X
CPR	B-X
determined	B-X
by	B-X
a	B-X
stable	B-X
isotope	B-X
dilution	B-X
technique	B-X
after	B-X
infusion	B-X
of	B-X
deuterated	B-X
cortisol	B-X

These	O
data	O
suggest	O
a	O
possible	O
down-regulation	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
in	O
humans	O
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
possible	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
mineralocorticoid	B-X
receptors	B-X
in	B-X
humans	B-X
<EOS>	B-X
The	B-X
capacity	B-X
and	B-X
the	B-X
affinity	B-X
of	B-X
dexamethasone	B-X
for	B-X
glucocorticoid	B-X
receptors	B-X
ranged	B-X
in	B-X
the	B-X
normal	B-X
values	B-X
<EOS>	B-X
The	B-X
basal	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
is	B-X
regulated	B-X
by	B-X
interaction	B-X
with	B-X
coactivator	B-X
or	B-X
corepressor	B-X
proteins	B-X
<EOS>	B-X
The	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
is	B-X
a	B-X
ligand	B-X
-	B-X
dependent	B-X
transcriptional	B-X
regulator	B-X
which	B-X
belongs	B-X
to	B-X
the	B-X
nuclear	B-X
receptor	B-X
superfamily	B-X

Short-term	O
and	O
long-term	O
effects	O
of	O
estrogen	O
on	O
lymphoid	O
tissues	O
and	O
lymphoid	B-cell_type
cells	I-cell_type
with	O
some	O
remarks	O
on	O
the	O
significance	O
for	O
carcinogenesis	O
.	O
<EOS>	B-X
Short	B-X
-	B-X
term	B-X
and	B-X
long	B-X
-	B-X
term	B-X
effects	B-X
of	B-X
estrogen	B-X
on	B-X
lymphoid	B-X
tissues	B-X
and	B-X
lymphoid	B-X
cells	B-X
with	B-X
some	B-X
remarks	B-X
on	B-X
the	B-X
significance	B-X
for	B-X
carcinogenesis	B-X
.	B-X
<EOS>	B-X
A	B-X
broad	B-X
review	B-X
is	B-X
given	B-X
of	B-X
such	B-X
estrogen	B-X
effects	B-X
on	B-X
lymphoid	B-X
tissue	B-X
and	B-X
immune	B-X
response	B-X
<EOS>	B-X
Another	B-X
example	B-X
is	B-X
the	B-X
estrogen	B-X
effect	B-X
on	B-X
the	B-X
delayed	B-X
type	B-X
hypersensitivity	B-X
response	B-X
<EOS>	B-X
Lymphocytes	B-X
from	B-X
adult	B-X
,	B-X
neonatally	B-X
DES	B-X
-	B-X
treated	B-X
female	B-X
mice	B-X
have	B-X
a	B-X
reduced	B-X
mitogen	B-X
response	B-X
to	B-X
ConA	B-X
and	B-X
LPS	B-X
(	B-X
T	B-X
and	B-X
B	B-X
cell	B-X
mitogen	B-X
)	B-X
and	B-X
the	B-X
delayed	B-X
type	B-X
hypersensitivity	B-X
response	B-X
is	B-X
depressed	B-X

Estrogens	O
have	O
long	O
been	O
thought	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
immune	O
system	O
.	O
<EOS>	B-X
Estrogens	B-X
have	B-X
long	B-X
been	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
immune	B-X
system	B-X
<EOS>	B-X
Estrogen	B-X
effects	B-X
in	B-X
adults	B-X
are	B-X
reversible	B-X
<EOS>	B-X
Estrogens	B-X
stimulate	B-X
some	B-X
aspects	B-X
of	B-X
macrophage	B-X
activity	B-X
and	B-X
,	B-X
depending	B-X
on	B-X
dose	B-X
and	B-X
mitogen	B-X
,	B-X
inhibit	B-X
or	B-X
stimulate	B-X
lymphocyte	B-X
proliferative	B-X
response	B-X
in	B-X
vitro	B-X
<EOS>	B-X
A	B-X
broad	B-X
review	B-X
is	B-X
given	B-X
of	B-X
such	B-X
estrogen	B-X
effects	B-X
on	B-X
lymphoid	B-X
tissue	B-X
and	B-X
immune	B-X
response	B-X

The	O
difference	O
in	O
some	O
types	O
of	O
immune	O
responses	O
between	O
males	O
and	O
females	O
is	O
well-known	O
,	O
as	O
is	O
the	O
pronounced	O
thymic	O
involution	O
induced	O
by	O
exogenous	O
estrogens	O
.	O
<EOS>	B-X
The	B-X
difference	B-X
in	B-X
some	B-X
types	B-X
of	B-X
immune	B-X
responses	B-X
between	B-X
males	B-X
and	B-X
females	B-X
is	B-X
well	B-X
-	B-X
known	B-X
,	B-X
as	B-X
is	B-X
the	B-X
pronounced	B-X
thymic	B-X
involution	B-X
induced	B-X
by	B-X
exogenous	B-X
estrogens	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
recent	B-X
description	B-X
of	B-X
estrogen	B-X
receptors	B-X
in	B-X
the	B-X
thymus	B-X
and	B-X
in	B-X
some	B-X
lymphocyte	B-X
subpopulations	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
regulating	B-X
factors	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
open	B-X
the	B-X
possibility	B-X
of	B-X
a	B-X
more	B-X
detailed	B-X
understanding	B-X
of	B-X
the	B-X
estrogen	B-X
mechanism	B-X
of	B-X
interference	B-X
<EOS>	B-X
Short	B-X
-	B-X
term	B-X
and	B-X
long	B-X
-	B-X
term	B-X
effects	B-X
of	B-X
estrogen	B-X
on	B-X
lymphoid	B-X
tissues	B-X
and	B-X
lymphoid	B-X
cells	B-X
with	B-X
some	B-X
remarks	B-X
on	B-X
the	B-X
significance	B-X
for	B-X
carcinogenesis	B-X
.	B-X
<EOS>	B-X
The	B-X
association	B-X
between	B-X
estrogen	B-X
-	B-X
associated	B-X
malignancy	B-X
and	B-X
estrogen	B-X
effects	B-X
in	B-X
lymphocyte	B-X
functions	B-X
deserves	B-X
further	B-X
study	B-X

Estrogens	O
stimulate	O
some	O
aspects	O
of	O
macrophage	B-cell_type
activity	O
and	O
,	O
depending	O
on	O
dose	O
and	O
mitogen	B-protein
,	O
inhibit	O
or	O
stimulate	O
lymphocyte	O
proliferative	O
response	O
in	O
vitro	O
.	O
<EOS>	B-X
It	B-X
may	B-X
be	B-X
used	B-X
in	B-X
a	B-X
fast	B-X
,	B-X
efficient	B-X
and	B-X
specific	B-X
means	B-X
of	B-X
evaluating	B-X
cell	B-X
proliferation	B-X
via	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
The	B-X
comparison	B-X
between	B-X
healthy	B-X
and	B-X
diseased	B-X
cows	B-X
suggested	B-X
that	B-X
healthy	B-X
animals	B-X
seemed	B-X
to	B-X
better	B-X
control	B-X
the	B-X
response	B-X
to	B-X
LPS	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
aortic	B-X
IL	B-X
-	B-X
17A	B-X
-	B-X
expressing	B-X
T	B-X
cell	B-X
subsets	B-X
on	B-X
aortic	B-X
endothelial	B-X
cells	B-X
was	B-X
determined	B-X
in	B-X
vitro	B-X
<EOS>	B-X
However	B-X
,	B-X
insight	B-X
into	B-X
the	B-X
metabolism	B-X
of	B-X
LN	B-X
CLL	B-X
and	B-X
how	B-X
this	B-X
may	B-X
relate	B-X
to	B-X
therapeutic	B-X
response	B-X
is	B-X
lacking	B-X

Another	O
example	O
is	O
the	O
estrogen	O
effect	O
on	O
the	O
delayed	O
type	O
hypersensitivity	O
response	O
.	O
<EOS>	B-X
Another	B-X
example	B-X
is	B-X
the	B-X
estrogen	B-X
effect	B-X
on	B-X
the	B-X
delayed	B-X
type	B-X
hypersensitivity	B-X
response	B-X
<EOS>	B-X
Lymphocytes	B-X
from	B-X
adult	B-X
,	B-X
neonatally	B-X
DES	B-X
-	B-X
treated	B-X
female	B-X
mice	B-X
have	B-X
a	B-X
reduced	B-X
mitogen	B-X
response	B-X
to	B-X
ConA	B-X
and	B-X
LPS	B-X
(	B-X
T	B-X
and	B-X
B	B-X
cell	B-X
mitogen	B-X
)	B-X
and	B-X
the	B-X
delayed	B-X
type	B-X
hypersensitivity	B-X
response	B-X
is	B-X
depressed	B-X
<EOS>	B-X
A	B-X
broad	B-X
review	B-X
is	B-X
given	B-X
of	B-X
such	B-X
estrogen	B-X
effects	B-X
on	B-X
lymphoid	B-X
tissue	B-X
and	B-X
immune	B-X
response	B-X
<EOS>	B-X
Estrogen	B-X
effects	B-X
in	B-X
adults	B-X
are	B-X
reversible	B-X

A	O
broad	O
review	O
is	O
given	O
of	O
such	O
estrogen	O
effects	O
on	O
lymphoid	B-cell_type
tissue	I-cell_type
and	O
immune	O
response	O
.	O
<EOS>	B-X
A	B-X
broad	B-X
review	B-X
is	B-X
given	B-X
of	B-X
such	B-X
estrogen	B-X
effects	B-X
on	B-X
lymphoid	B-X
tissue	B-X
and	B-X
immune	B-X
response	B-X
<EOS>	B-X
Another	B-X
example	B-X
is	B-X
the	B-X
estrogen	B-X
effect	B-X
on	B-X
the	B-X
delayed	B-X
type	B-X
hypersensitivity	B-X
response	B-X
<EOS>	B-X
The	B-X
association	B-X
between	B-X
estrogen	B-X
-	B-X
associated	B-X
malignancy	B-X
and	B-X
estrogen	B-X
effects	B-X
in	B-X
lymphocyte	B-X
functions	B-X
deserves	B-X
further	B-X
study	B-X
<EOS>	B-X
Short	B-X
-	B-X
term	B-X
and	B-X
long	B-X
-	B-X
term	B-X
effects	B-X
of	B-X
estrogen	B-X
on	B-X
lymphoid	B-X
tissues	B-X
and	B-X
lymphoid	B-X
cells	B-X
with	B-X
some	B-X
remarks	B-X
on	B-X
the	B-X
significance	B-X
for	B-X
carcinogenesis	B-X
.	B-X

Most	O
of	O
the	O
studies	O
published	O
so	O
far	O
are	O
phenomenological	O
.	O
<EOS>	B-X
Most	B-X
of	B-X
the	B-X
studies	B-X
published	B-X
so	B-X
far	B-X
are	B-X
phenomenological	B-X
<EOS>	B-X
62	B-X
%	B-X
)	B-X
of	B-X
the	B-X
articles	B-X
were	B-X
published	B-X
in	B-X
local	B-X
South	B-X
African	B-X
journals	B-X
,	B-X
13	B-X
<EOS>	B-X
59	B-X
%	B-X
of	B-X
the	B-X
articles	B-X
were	B-X
published	B-X
in	B-X
international	B-X
journals	B-X
<EOS>	B-X
Socioeconomic	B-X
and	B-X
religious	B-X
differentials	B-X
in	B-X
contraceptive	B-X
uptake	B-X
in	B-X
western	B-X
Ethiopia	B-X
:	B-X
a	B-X
mixed	B-X
-	B-X
methods	B-X
phenomenological	B-X
study	B-X
.	B-X

However	O
,	O
the	O
recent	O
description	O
of	O
estrogen	B-protein
receptors	I-protein
in	O
the	O
thymus	O
and	O
in	O
some	O
lymphocyte	B-cell_line
subpopulations	I-cell_line
,	O
as	O
well	O
as	O
a	O
deeper	O
understanding	O
of	O
regulating	O
factors	O
in	O
the	O
immune	O
system	O
,	O
open	O
the	O
possibility	O
of	O
a	O
more	O
detailed	O
understanding	O
of	O
the	O
estrogen	O
mechanism	O
of	O
interference	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
recent	B-X
description	B-X
of	B-X
estrogen	B-X
receptors	B-X
in	B-X
the	B-X
thymus	B-X
and	B-X
in	B-X
some	B-X
lymphocyte	B-X
subpopulations	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
regulating	B-X
factors	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
open	B-X
the	B-X
possibility	B-X
of	B-X
a	B-X
more	B-X
detailed	B-X
understanding	B-X
of	B-X
the	B-X
estrogen	B-X
mechanism	B-X
of	B-X
interference	B-X
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
Natural	B-X
Killer	B-X
cells	B-X
is	B-X
permanently	B-X
reduced	B-X
and	B-X
this	B-X
functional	B-X
impairment	B-X
is	B-X
related	B-X
to	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
these	B-X
cells	B-X
,	B-X
in	B-X
turn	B-X
determined	B-X
at	B-X
the	B-X
bone	B-X
marrow	B-X
level	B-X
<EOS>	B-X
The	B-X
difference	B-X
in	B-X
some	B-X
types	B-X
of	B-X
immune	B-X
responses	B-X
between	B-X
males	B-X
and	B-X
females	B-X
is	B-X
well	B-X
-	B-X
known	B-X
,	B-X
as	B-X
is	B-X
the	B-X
pronounced	B-X
thymic	B-X
involution	B-X
induced	B-X
by	B-X
exogenous	B-X
estrogens	B-X
<EOS>	B-X
Short	B-X
-	B-X
term	B-X
and	B-X
long	B-X
-	B-X
term	B-X
effects	B-X
of	B-X
estrogen	B-X
on	B-X
lymphoid	B-X
tissues	B-X
and	B-X
lymphoid	B-X
cells	B-X
with	B-X
some	B-X
remarks	B-X
on	B-X
the	B-X
significance	B-X
for	B-X
carcinogenesis	B-X
.	B-X

Estrogen	O
effects	O
in	O
adults	O
are	O
reversible	O
.	O
<EOS>	B-X
Estrogen	B-X
-	B-X
related	B-X
regimen	B-X
reduced	B-X
CRC	B-X
risk	B-X
more	B-X
than	B-X
progestogen	B-X
-	B-X
only	B-X
<EOS>	B-X
Estrogen	B-X
therapy	B-X
reversed	B-X
these	B-X
changes	B-X
<EOS>	B-X
The	B-X
estrous	B-X
cycle	B-X
is	B-X
a	B-X
potent	B-X
modulator	B-X
of	B-X
neuron	B-X
physiology	B-X
<EOS>	B-X
Testicular	B-X
oocytes	B-X
in	B-X
wild	B-X
adult	B-X
bass	B-X
(	B-X
Micropterus	B-X
spp	B-X

After	O
treating	O
neonatal	O
mice	O
with	O
the	O
synthetic	O
estrogen	O
diethylstilbestrol	O
(	O
DES	O
)	O
,	O
disturbances	O
are	O
induced	O
in	O
lymphocyte	B-cell_line
populations	I-cell_line
and	O
lymphocyte	B-cell_type
functions	O
which	O
are	O
permanent	O
and	O
irreversible	O
.	O
<EOS>	B-X
After	B-X
treating	B-X
neonatal	B-X
mice	B-X
with	B-X
the	B-X
synthetic	B-X
estrogen	B-X
diethylstilbestrol	B-X
(	B-X
DES	B-X
)	B-X
,	B-X
disturbances	B-X
are	B-X
induced	B-X
in	B-X
lymphocyte	B-X
populations	B-X
and	B-X
lymphocyte	B-X
functions	B-X
which	B-X
are	B-X
permanent	B-X
and	B-X
irreversible	B-X
<EOS>	B-X
The	B-X
association	B-X
between	B-X
estrogen	B-X
-	B-X
associated	B-X
malignancy	B-X
and	B-X
estrogen	B-X
effects	B-X
in	B-X
lymphocyte	B-X
functions	B-X
deserves	B-X
further	B-X
study	B-X
<EOS>	B-X
Estrogens	B-X
stimulate	B-X
some	B-X
aspects	B-X
of	B-X
macrophage	B-X
activity	B-X
and	B-X
,	B-X
depending	B-X
on	B-X
dose	B-X
and	B-X
mitogen	B-X
,	B-X
inhibit	B-X
or	B-X
stimulate	B-X
lymphocyte	B-X
proliferative	B-X
response	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Short	B-X
-	B-X
term	B-X
and	B-X
long	B-X
-	B-X
term	B-X
effects	B-X
of	B-X
estrogen	B-X
on	B-X
lymphoid	B-X
tissues	B-X
and	B-X
lymphoid	B-X
cells	B-X
with	B-X
some	B-X
remarks	B-X
on	B-X
the	B-X
significance	B-X
for	B-X
carcinogenesis	B-X
.	B-X

Lymphocytes	B-cell_type
from	O
adult	O
,	O
neonatally	O
DES-treated	O
female	O
mice	O
have	O
a	O
reduced	O
mitogen	O
response	O
to	O
ConA	B-protein
and	O
LPS	B-protein
(	O
T	B-protein
and	I-protein
B	I-protein
cell	I-protein
mitogen	I-protein
)	O
and	O
the	O
delayed	O
type	O
hypersensitivity	O
response	O
is	O
depressed	O
.	O

A	O
detailed	O
analysis	O
demonstrated	O
a	O
decreased	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
population	O
.	O
<EOS>	B-X
A	B-X
detailed	B-X
analysis	B-X
demonstrated	B-X
a	B-X
decreased	B-X
T	B-X
helper	B-X
cell	B-X
population	B-X
<EOS>	B-X
The	B-X
elevated	B-X
CRP	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
levels	B-X
were	B-X
associated	B-X
with	B-X
decreases	B-X
in	B-X
the	B-X
percentages	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
helper	B-X
T	B-X
-	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
lymphocyte	B-X
populations	B-X
<EOS>	B-X
Another	B-X
example	B-X
is	B-X
the	B-X
estrogen	B-X
effect	B-X
on	B-X
the	B-X
delayed	B-X
type	B-X
hypersensitivity	B-X
response	B-X
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
Natural	B-X
Killer	B-X
cells	B-X
is	B-X
permanently	B-X
reduced	B-X
and	B-X
this	B-X
functional	B-X
impairment	B-X
is	B-X
related	B-X
to	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
these	B-X
cells	B-X
,	B-X
in	B-X
turn	B-X
determined	B-X
at	B-X
the	B-X
bone	B-X
marrow	B-X
level	B-X

The	O
activity	O
of	O
Natural	B-cell_type
Killer	I-cell_type
cells	I-cell_type
is	O
permanently	O
reduced	O
and	O
this	O
functional	O
impairment	O
is	O
related	O
to	O
a	O
decreased	O
number	O
of	O
these	O
cells	O
,	O
in	O
turn	O
determined	O
at	O
the	O
bone	O
marrow	O
level	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
Natural	B-X
Killer	B-X
cells	B-X
is	B-X
permanently	B-X
reduced	B-X
and	B-X
this	B-X
functional	B-X
impairment	B-X
is	B-X
related	B-X
to	B-X
a	B-X
decreased	B-X
number	B-X
of	B-X
these	B-X
cells	B-X
,	B-X
in	B-X
turn	B-X
determined	B-X
at	B-X
the	B-X
bone	B-X
marrow	B-X
level	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
recent	B-X
description	B-X
of	B-X
estrogen	B-X
receptors	B-X
in	B-X
the	B-X
thymus	B-X
and	B-X
in	B-X
some	B-X
lymphocyte	B-X
subpopulations	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
deeper	B-X
understanding	B-X
of	B-X
regulating	B-X
factors	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
open	B-X
the	B-X
possibility	B-X
of	B-X
a	B-X
more	B-X
detailed	B-X
understanding	B-X
of	B-X
the	B-X
estrogen	B-X
mechanism	B-X
of	B-X
interference	B-X
<EOS>	B-X
The	B-X
association	B-X
between	B-X
estrogen	B-X
-	B-X
associated	B-X
malignancy	B-X
and	B-X
estrogen	B-X
effects	B-X
in	B-X
lymphocyte	B-X
functions	B-X
deserves	B-X
further	B-X
study	B-X
<EOS>	B-X
Short	B-X
-	B-X
term	B-X
and	B-X
long	B-X
-	B-X
term	B-X
effects	B-X
of	B-X
estrogen	B-X
on	B-X
lymphoid	B-X
tissues	B-X
and	B-X
lymphoid	B-X
cells	B-X
with	B-X
some	B-X
remarks	B-X
on	B-X
the	B-X
significance	B-X
for	B-X
carcinogenesis	B-X
.	B-X

The	O
same	O
animals	O
have	O
an	O
increased	O
sensitivity	O
to	O
chemical	O
carcinogens	O
(	O
methylcholanthrene	O
)	O
and	O
they	O
spontaneously	O
develop	O
epithelial	O
changes	O
in	O
the	O
uterine	O
cervix	O
which	O
morphologically	O
are	O
similar	O
to	O
adenocarcinoma	O
.	O
<EOS>	B-X
The	B-X
same	B-X
animals	B-X
have	B-X
an	B-X
increased	B-X
sensitivity	B-X
to	B-X
chemical	B-X
carcinogens	B-X
(	B-X
methylcholanthrene	B-X
)	B-X
and	B-X
they	B-X
spontaneously	B-X
develop	B-X
epithelial	B-X
changes	B-X
in	B-X
the	B-X
uterine	B-X
cervix	B-X
which	B-X
morphologically	B-X
are	B-X
similar	B-X
to	B-X
adenocarcinoma	B-X
<EOS>	B-X
Short	B-X
-	B-X
term	B-X
and	B-X
long	B-X
-	B-X
term	B-X
effects	B-X
of	B-X
estrogen	B-X
on	B-X
lymphoid	B-X
tissues	B-X
and	B-X
lymphoid	B-X
cells	B-X
with	B-X
some	B-X
remarks	B-X
on	B-X
the	B-X
significance	B-X
for	B-X
carcinogenesis	B-X
.	B-X
<EOS>	B-X
The	B-X
difference	B-X
in	B-X
some	B-X
types	B-X
of	B-X
immune	B-X
responses	B-X
between	B-X
males	B-X
and	B-X
females	B-X
is	B-X
well	B-X
-	B-X
known	B-X
,	B-X
as	B-X
is	B-X
the	B-X
pronounced	B-X
thymic	B-X
involution	B-X
induced	B-X
by	B-X
exogenous	B-X
estrogens	B-X
<EOS>	B-X
The	B-X
association	B-X
between	B-X
estrogen	B-X
-	B-X
associated	B-X
malignancy	B-X
and	B-X
estrogen	B-X
effects	B-X
in	B-X
lymphocyte	B-X
functions	B-X
deserves	B-X
further	B-X
study	B-X

The	O
association	O
between	O
estrogen-associated	O
malignancy	O
and	O
estrogen	O
effects	O
in	O
lymphocyte	B-cell_type
functions	O
deserves	O
further	O
study	O
.	O
<EOS>	B-X
The	B-X
association	B-X
between	B-X
estrogen	B-X
-	B-X
associated	B-X
malignancy	B-X
and	B-X
estrogen	B-X
effects	B-X
in	B-X
lymphocyte	B-X
functions	B-X
deserves	B-X
further	B-X
study	B-X
<EOS>	B-X
A	B-X
broad	B-X
review	B-X
is	B-X
given	B-X
of	B-X
such	B-X
estrogen	B-X
effects	B-X
on	B-X
lymphoid	B-X
tissue	B-X
and	B-X
immune	B-X
response	B-X
<EOS>	B-X
After	B-X
treating	B-X
neonatal	B-X
mice	B-X
with	B-X
the	B-X
synthetic	B-X
estrogen	B-X
diethylstilbestrol	B-X
(	B-X
DES	B-X
)	B-X
,	B-X
disturbances	B-X
are	B-X
induced	B-X
in	B-X
lymphocyte	B-X
populations	B-X
and	B-X
lymphocyte	B-X
functions	B-X
which	B-X
are	B-X
permanent	B-X
and	B-X
irreversible	B-X
<EOS>	B-X
Another	B-X
example	B-X
is	B-X
the	B-X
estrogen	B-X
effect	B-X
on	B-X
the	B-X
delayed	B-X
type	B-X
hypersensitivity	B-X
response	B-X

Drugs	O
affecting	O
the	O
hormonal	O
receptors	O
of	O
normal	B-cell_type
and	I-cell_type
leukaemic	I-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
.	O
<EOS>	B-X
Drugs	B-X
affecting	B-X
the	B-X
hormonal	B-X
receptors	B-X
of	B-X
normal	B-X
and	B-X
leukaemic	B-X
peripheral	B-X
leucocytes	B-X
.	B-X
<EOS>	B-X
Differences	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
behavior	B-X
of	B-X
hormonal	B-X
uptake	B-X
of	B-X
CML	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
of	B-X
AML	B-X
,	B-X
CLL	B-X
and	B-X
ALL	B-X
peripheral	B-X
leucocytes	B-X
<EOS>	B-X
The	B-X
results	B-X
demonstrated	B-X
the	B-X
presence	B-X
in	B-X
leukaemic	B-X
cells	B-X
of	B-X
an	B-X
alteration	B-X
in	B-X
the	B-X
incorporation	B-X
of	B-X
steroid	B-X
hormones	B-X
<EOS>	B-X
This	B-X
alteration	B-X
was	B-X
scarcely	B-X
modified	B-X
by	B-X
incubation	B-X
with	B-X
theophylline	B-X
,	B-X
which	B-X
increases	B-X
cellular	B-X
concentration	B-X
of	B-X
cAMP	B-X

The	O
authors	O
investigated	O
the	O
behaviour	O
of	O
steroid	O
hormone	O
uptake	O
in	O
leukaemic	B-cell_type
cells	I-cell_type
(	O
CML	B-cell_line
,	O
CLL	B-cell_line
,	O
AML	B-cell_line
,	O
ALL	B-cell_line
)	O
,	O
in	O
basal	O
conditions	O
and	O
after	O
incubation	O
with	O
drugs	O
which	O
modify	O
the	O
cellular	O
concentration	O
of	O
cAMP	O
,	O
PGE	O
and	O
PGF	O
.	O

The	O
results	O
demonstrated	O
the	O
presence	O
in	O
leukaemic	B-cell_type
cells	I-cell_type
of	O
an	O
alteration	O
in	O
the	O
incorporation	O
of	O
steroid	O
hormones	O
.	O
<EOS>	B-X
The	B-X
results	B-X
demonstrated	B-X
the	B-X
presence	B-X
in	B-X
leukaemic	B-X
cells	B-X
of	B-X
an	B-X
alteration	B-X
in	B-X
the	B-X
incorporation	B-X
of	B-X
steroid	B-X
hormones	B-X
<EOS>	B-X
The	B-X
authors	B-X
investigated	B-X
the	B-X
behaviour	B-X
of	B-X
steroid	B-X
hormone	B-X
uptake	B-X
in	B-X
leukaemic	B-X
cells	B-X
(	B-X
CML	B-X
,	B-X
CLL	B-X
,	B-X
AML	B-X
,	B-X
ALL	B-X
)	B-X
,	B-X
in	B-X
basal	B-X
conditions	B-X
and	B-X
after	B-X
incubation	B-X
with	B-X
drugs	B-X
which	B-X
modify	B-X
the	B-X
cellular	B-X
concentration	B-X
of	B-X
cAMP	B-X
,	B-X
PGE	B-X
and	B-X
PGF	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
it	B-X
was	B-X
moderately	B-X
counteracted	B-X
by	B-X
thioproline	B-X
and	B-X
was	B-X
evidently	B-X
inhibited	B-X
by	B-X
flurbiprofen	B-X
,	B-X
which	B-X
also	B-X
reduced	B-X
cellular	B-X
concentrations	B-X
of	B-X
prostaglandins	B-X
,	B-X
particularly	B-X
PGE2	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
PGF2	B-X
which	B-X
showed	B-X
a	B-X
poor	B-X
response	B-X
<EOS>	B-X
Drugs	B-X
affecting	B-X
the	B-X
hormonal	B-X
receptors	B-X
of	B-X
normal	B-X
and	B-X
leukaemic	B-X
peripheral	B-X
leucocytes	B-X
.	B-X

This	O
alteration	O
was	O
scarcely	O
modified	O
by	O
incubation	O
with	O
theophylline	B-protein
,	O
which	O
increases	O
cellular	O
concentration	O
of	O
cAMP	O
.	O
<EOS>	B-X
This	B-X
alteration	B-X
was	B-X
scarcely	B-X
modified	B-X
by	B-X
incubation	B-X
with	B-X
theophylline	B-X
,	B-X
which	B-X
increases	B-X
cellular	B-X
concentration	B-X
of	B-X
cAMP	B-X
<EOS>	B-X
The	B-X
authors	B-X
investigated	B-X
the	B-X
behaviour	B-X
of	B-X
steroid	B-X
hormone	B-X
uptake	B-X
in	B-X
leukaemic	B-X
cells	B-X
(	B-X
CML	B-X
,	B-X
CLL	B-X
,	B-X
AML	B-X
,	B-X
ALL	B-X
)	B-X
,	B-X
in	B-X
basal	B-X
conditions	B-X
and	B-X
after	B-X
incubation	B-X
with	B-X
drugs	B-X
which	B-X
modify	B-X
the	B-X
cellular	B-X
concentration	B-X
of	B-X
cAMP	B-X
,	B-X
PGE	B-X
and	B-X
PGF	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
it	B-X
was	B-X
moderately	B-X
counteracted	B-X
by	B-X
thioproline	B-X
and	B-X
was	B-X
evidently	B-X
inhibited	B-X
by	B-X
flurbiprofen	B-X
,	B-X
which	B-X
also	B-X
reduced	B-X
cellular	B-X
concentrations	B-X
of	B-X
prostaglandins	B-X
,	B-X
particularly	B-X
PGE2	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
PGF2	B-X
which	B-X
showed	B-X
a	B-X
poor	B-X
response	B-X
<EOS>	B-X
Drugs	B-X
affecting	B-X
the	B-X
hormonal	B-X
receptors	B-X
of	B-X
normal	B-X
and	B-X
leukaemic	B-X
peripheral	B-X
leucocytes	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
it	O
was	O
moderately	O
counteracted	O
by	O
thioproline	O
and	O
was	O
evidently	O
inhibited	O
by	O
flurbiprofen	O
,	O
which	O
also	O
reduced	O
cellular	O
concentrations	O
of	O
prostaglandins	O
,	O
particularly	O
PGE2	O
,	O
with	O
the	O
exception	O
of	O
PGF2	O
which	O
showed	O
a	O
poor	O
response	O
.	O
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
it	B-X
was	B-X
moderately	B-X
counteracted	B-X
by	B-X
thioproline	B-X
and	B-X
was	B-X
evidently	B-X
inhibited	B-X
by	B-X
flurbiprofen	B-X
,	B-X
which	B-X
also	B-X
reduced	B-X
cellular	B-X
concentrations	B-X
of	B-X
prostaglandins	B-X
,	B-X
particularly	B-X
PGE2	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
PGF2	B-X
which	B-X
showed	B-X
a	B-X
poor	B-X
response	B-X
<EOS>	B-X
This	B-X
alteration	B-X
was	B-X
scarcely	B-X
modified	B-X
by	B-X
incubation	B-X
with	B-X
theophylline	B-X
,	B-X
which	B-X
increases	B-X
cellular	B-X
concentration	B-X
of	B-X
cAMP	B-X
<EOS>	B-X
The	B-X
results	B-X
demonstrated	B-X
the	B-X
presence	B-X
in	B-X
leukaemic	B-X
cells	B-X
of	B-X
an	B-X
alteration	B-X
in	B-X
the	B-X
incorporation	B-X
of	B-X
steroid	B-X
hormones	B-X
<EOS>	B-X
The	B-X
authors	B-X
investigated	B-X
the	B-X
behaviour	B-X
of	B-X
steroid	B-X
hormone	B-X
uptake	B-X
in	B-X
leukaemic	B-X
cells	B-X
(	B-X
CML	B-X
,	B-X
CLL	B-X
,	B-X
AML	B-X
,	B-X
ALL	B-X
)	B-X
,	B-X
in	B-X
basal	B-X
conditions	B-X
and	B-X
after	B-X
incubation	B-X
with	B-X
drugs	B-X
which	B-X
modify	B-X
the	B-X
cellular	B-X
concentration	B-X
of	B-X
cAMP	B-X
,	B-X
PGE	B-X
and	B-X
PGF	B-X

Differences	O
were	O
observed	O
in	O
the	O
behavior	O
of	O
hormonal	O
uptake	O
of	O
CML	B-cell_line
,	O
in	O
contrast	O
to	O
that	O
of	O
AML	B-cell_line
,	I-cell_line
CLL	I-cell_line
and	I-cell_line
ALL	I-cell_line
peripheral	I-cell_line
leucocytes	I-cell_line
.	O
<EOS>	B-X
Differences	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
behavior	B-X
of	B-X
hormonal	B-X
uptake	B-X
of	B-X
CML	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
of	B-X
AML	B-X
,	B-X
CLL	B-X
and	B-X
ALL	B-X
peripheral	B-X
leucocytes	B-X
<EOS>	B-X
Drugs	B-X
affecting	B-X
the	B-X
hormonal	B-X
receptors	B-X
of	B-X
normal	B-X
and	B-X
leukaemic	B-X
peripheral	B-X
leucocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
authors	B-X
investigated	B-X
the	B-X
behaviour	B-X
of	B-X
steroid	B-X
hormone	B-X
uptake	B-X
in	B-X
leukaemic	B-X
cells	B-X
(	B-X
CML	B-X
,	B-X
CLL	B-X
,	B-X
AML	B-X
,	B-X
ALL	B-X
)	B-X
,	B-X
in	B-X
basal	B-X
conditions	B-X
and	B-X
after	B-X
incubation	B-X
with	B-X
drugs	B-X
which	B-X
modify	B-X
the	B-X
cellular	B-X
concentration	B-X
of	B-X
cAMP	B-X
,	B-X
PGE	B-X
and	B-X
PGF	B-X
<EOS>	B-X
The	B-X
results	B-X
demonstrated	B-X
the	B-X
presence	B-X
in	B-X
leukaemic	B-X
cells	B-X
of	B-X
an	B-X
alteration	B-X
in	B-X
the	B-X
incorporation	B-X
of	B-X
steroid	B-X
hormones	B-X

Human	O
breast	O
cancer	O
and	O
impaired	O
NK	B-cell_type
cell	I-cell_type
function	O
.	O
<EOS>	B-X
For	B-X
breast	B-X
cancer	B-X
patients	B-X
,	B-X
surgery	B-X
remains	B-X
the	B-X
cornerstone	B-X
in	B-X
treatment	B-X
<EOS>	B-X
Tumors	B-X
,	B-X
however	B-X
,	B-X
can	B-X
create	B-X
a	B-X
suppressive	B-X
microenvironment	B-X
that	B-X
decreases	B-X
NK	B-X
function	B-X
<EOS>	B-X
Pharmaceutical	B-X
activation	B-X
of	B-X
STAT3	B-X
in	B-X
haNKs	B-X
led	B-X
to	B-X
reduced	B-X
killing	B-X
,	B-X
implicating	B-X
active	B-X
STAT3	B-X
in	B-X
reduced	B-X
NK	B-X
cell	B-X
function	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
sera	B-X
from	B-X
Trastuzumab	B-X
-	B-X
refractory	B-X
patients	B-X
could	B-X
inhibit	B-X
healthy	B-X
NK	B-X
cell	B-X
ADCC	B-X
in	B-X
vitro	B-X

Recent	O
advances	O
in	O
tumor	O
immunology	O
have	O
led	O
to	O
the	O
discovery	O
of	O
a	O
new	O
lymphoid	B-cell_type
cell	I-cell_type
with	O
unique	O
antitumor	O
activity	O
.	O

Natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
form	O
an	O
antitumor	O
surveillance	O
system	O
and	O
appear	O
to	O
be	O
vital	O
in	O
preventing	O
tumor	O
growth	O
and	O
metastasis	O
in	O
animal	O
models	O
.	O
<EOS>	B-X
Natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
form	B-X
an	B-X
antitumor	B-X
surveillance	B-X
system	B-X
and	B-X
appear	B-X
to	B-X
be	B-X
vital	B-X
in	B-X
preventing	B-X
tumor	B-X
growth	B-X
and	B-X
metastasis	B-X
in	B-X
animal	B-X
models	B-X
<EOS>	B-X
Positive	B-X
correlation	B-X
of	B-X
a	B-X
depressed	B-X
natural	B-X
killer	B-X
activity	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
tumor	B-X
spread	B-X
supports	B-X
the	B-X
concept	B-X
of	B-X
an	B-X
NK	B-X
cell	B-X
immune	B-X
surveillance	B-X
system	B-X
in	B-X
breast	B-X
cancer	B-X
and	B-X
emphasizes	B-X
its	B-X
importance	B-X
in	B-X
this	B-X
malignancy	B-X
<EOS>	B-X
NK	B-X
activity	B-X
was	B-X
not	B-X
correlated	B-X
to	B-X
estrogen	B-X
or	B-X
progesterone	B-X
receptor	B-X
states	B-X
<EOS>	B-X
Recent	B-X
advances	B-X
in	B-X
tumor	B-X
immunology	B-X
have	B-X
led	B-X
to	B-X
the	B-X
discovery	B-X
of	B-X
a	B-X
new	B-X
lymphoid	B-X
cell	B-X
with	B-X
unique	B-X
antitumor	B-X
activity	B-X

We	O
studied	O
NK	B-cell_type
activity	O
in	O
patients	O
with	O
benign	O
and	O
malignant	O
breast	O
disease	O
,	O
using	O
a	O
chromium-51	O
release	O
microtiter	O
cytotoxicity	O
assay	O
with	O
K562	B-cell_line
cells	I-cell_line
as	O
targets	O
.	O
<EOS>	B-X
We	B-X
studied	B-X
NK	B-X
activity	B-X
in	B-X
patients	B-X
with	B-X
benign	B-X
and	B-X
malignant	B-X
breast	B-X
disease	B-X
,	B-X
using	B-X
a	B-X
chromium	B-X
-	B-X
51	B-X
release	B-X
microtiter	B-X
cytotoxicity	B-X
assay	B-X
with	B-X
K562	B-X
cells	B-X
as	B-X
targets	B-X
<EOS>	B-X
Compared	B-X
with	B-X
benign	B-X
controls	B-X
,	B-X
patients	B-X
with	B-X
malignancies	B-X
had	B-X
significantly	B-X
depressed	B-X
NK	B-X
-	B-X
mediated	B-X
lysis	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
NK	B-X
activity	B-X
was	B-X
not	B-X
correlated	B-X
to	B-X
estrogen	B-X
or	B-X
progesterone	B-X
receptor	B-X
states	B-X
<EOS>	B-X
Positive	B-X
correlation	B-X
of	B-X
a	B-X
depressed	B-X
natural	B-X
killer	B-X
activity	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
tumor	B-X
spread	B-X
supports	B-X
the	B-X
concept	B-X
of	B-X
an	B-X
NK	B-X
cell	B-X
immune	B-X
surveillance	B-X
system	B-X
in	B-X
breast	B-X
cancer	B-X
and	B-X
emphasizes	B-X
its	B-X
importance	B-X
in	B-X
this	B-X
malignancy	B-X

Compared	O
with	O
benign	O
controls	O
,	O
patients	O
with	O
malignancies	O
had	O
significantly	O
depressed	O
NK	B-cell_type
-mediated	O
lysis	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O
<EOS>	B-X
Compared	B-X
with	B-X
benign	B-X
controls	B-X
,	B-X
patients	B-X
with	B-X
malignancies	B-X
had	B-X
significantly	B-X
depressed	B-X
NK	B-X
-	B-X
mediated	B-X
lysis	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
lysis	B-X
in	B-X
those	B-X
with	B-X
advanced	B-X
disease	B-X
(	B-X
stages	B-X
II	B-X
,	B-X
III	B-X
,	B-X
and	B-X
IV	B-X
)	B-X
was	B-X
significantly	B-X
less	B-X
than	B-X
in	B-X
those	B-X
with	B-X
limited	B-X
disease	B-X
(	B-X
stage	B-X
I	B-X
)	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
We	B-X
studied	B-X
NK	B-X
activity	B-X
in	B-X
patients	B-X
with	B-X
benign	B-X
and	B-X
malignant	B-X
breast	B-X
disease	B-X
,	B-X
using	B-X
a	B-X
chromium	B-X
-	B-X
51	B-X
release	B-X
microtiter	B-X
cytotoxicity	B-X
assay	B-X
with	B-X
K562	B-X
cells	B-X
as	B-X
targets	B-X
<EOS>	B-X
Positive	B-X
correlation	B-X
of	B-X
a	B-X
depressed	B-X
natural	B-X
killer	B-X
activity	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
tumor	B-X
spread	B-X
supports	B-X
the	B-X
concept	B-X
of	B-X
an	B-X
NK	B-X
cell	B-X
immune	B-X
surveillance	B-X
system	B-X
in	B-X
breast	B-X
cancer	B-X
and	B-X
emphasizes	B-X
its	B-X
importance	B-X
in	B-X
this	B-X
malignancy	B-X

Furthermore	O
,	O
lysis	O
in	O
those	O
with	O
advanced	O
disease	O
(	O
stages	O
II	O
,	O
III	O
,	O
and	O
IV	O
)	O
was	O
significantly	O
less	O
than	O
in	O
those	O
with	O
limited	O
disease	O
(	O
stage	O
I	O
)	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

NK	B-cell_type
activity	O
was	O
not	O
correlated	O
to	O
estrogen	O
or	O
progesterone	O
receptor	O
states	O
.	O
<EOS>	B-X
Variability	B-X
analysis	B-X
of	B-X
soil	B-X
properties	B-X
,	B-X
mapping	B-X
,	B-X
and	B-X
crop	B-X
test	B-X
responses	B-X
in	B-X
Southern	B-X
Ethiopia	B-X
.	B-X
<EOS>	B-X
Endometrial	B-X
samples	B-X
were	B-X
collected	B-X
ipsilateral	B-X
to	B-X
the	B-X
ovary	B-X
bearing	B-X
the	B-X
highest	B-X
number	B-X
of	B-X
corpora	B-X
lutea	B-X
<EOS>	B-X
Review	B-X
article	B-X
:	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
pharmacological	B-X
rationale	B-X
for	B-X
selecting	B-X
drugs	B-X
to	B-X
inhibit	B-X
vomiting	B-X
or	B-X
increase	B-X
gastric	B-X
emptying	B-X
during	B-X
treatment	B-X
of	B-X
gastroparesis	B-X
.	B-X
<EOS>	B-X
The	B-X
DSM	B-X
information	B-X
was	B-X
tested	B-X
under	B-X
field	B-X
conditions	B-X
using	B-X
haricot	B-X
bean	B-X
(	B-X
Phaseolus	B-X
vulgaris	B-X
)	B-X
with	B-X
lime	B-X
and	B-X
organic	B-X
fertilizers	B-X
as	B-X
treatments	B-X

Positive	O
correlation	O
of	O
a	O
depressed	O
natural	O
killer	O
activity	O
with	O
the	O
extent	O
of	O
tumor	O
spread	O
supports	O
the	O
concept	O
of	O
an	O
NK	B-cell_type
cell	I-cell_type
immune	O
surveillance	O
system	O
in	O
breast	O
cancer	O
and	O
emphasizes	O
its	O
importance	O
in	O
this	O
malignancy	O
.	O

Immunosuppressive	O
effect	O
of	O
serum	O
progesterone	O
during	O
pregnancy	O
depends	O
on	O
the	O
progesterone	O
binding	O
capacity	O
of	O
the	O
lymphocytes	B-cell_type
.	O
<EOS>	B-X
Immunosuppressive	B-X
effect	B-X
of	B-X
serum	B-X
progesterone	B-X
during	B-X
pregnancy	B-X
depends	B-X
on	B-X
the	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
001	B-X
)	B-X
and	B-X
significantly	B-X
lower	B-X
progesterone	B-X
binding	B-X
capacity	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
The	B-X
findings	B-X
indicate	B-X
that	B-X
intact	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
is	B-X
an	B-X
essential	B-X
factor	B-X
for	B-X
the	B-X
manifestation	B-X
of	B-X
the	B-X
blocking	B-X
effect	B-X
exerted	B-X
by	B-X
pregnancy	B-X
serum	B-X
on	B-X
lymphocyte	B-X
cytotoxicity	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Cytotoxic	B-X
activity	B-X
and	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
,	B-X
together	B-X
with	B-X
serum	B-X
progesterone	B-X
concentrations	B-X
,	B-X
were	B-X
determined	B-X
in	B-X
women	B-X
with	B-X
normal	B-X
pregnancy	B-X
or	B-X
with	B-X
a	B-X
clinical	B-X
diagnosis	B-X
of	B-X
threatened	B-X
abortion	B-X
or	B-X
threatened	B-X
premature	B-X
labour	B-X

Cytotoxic	O
activity	O
and	O
progesterone	O
binding	O
capacity	O
of	O
the	O
lymphocytes	B-cell_type
,	O
together	O
with	O
serum	O
progesterone	O
concentrations	O
,	O
were	O
determined	O
in	O
women	O
with	O
normal	O
pregnancy	O
or	O
with	O
a	O
clinical	O
diagnosis	O
of	O
threatened	O
abortion	O
or	O
threatened	O
premature	O
labour	O
.	O
<EOS>	B-X
Ultrasonographic	B-X
changes	B-X
in	B-X
quadriceps	B-X
femoris	B-X
thickness	B-X
in	B-X
women	B-X
with	B-X
normal	B-X
pregnancy	B-X
and	B-X
women	B-X
on	B-X
bed	B-X
rest	B-X
for	B-X
threatened	B-X
preterm	B-X
labor	B-X
.	B-X
<EOS>	B-X
With	B-X
a	B-X
moderate	B-X
certainty	B-X
of	B-X
evidence	B-X
,	B-X
17	B-X
-	B-X
HP	B-X
prevents	B-X
PTB	B-X
<	B-X
34	B-X
weeks	B-X
'	B-X
gestation	B-X
among	B-X
women	B-X
that	B-X
remained	B-X
undelivered	B-X
after	B-X
an	B-X
episode	B-X
of	B-X
threatened	B-X
preterm	B-X
labour	B-X
<EOS>	B-X
The	B-X
technology	B-X
-	B-X
free	B-X
factors	B-X
seems	B-X
to	B-X
have	B-X
moderate	B-X
power	B-X
in	B-X
preterm	B-X
birth	B-X
prediction	B-X
in	B-X
singleton	B-X
pregnant	B-X
women	B-X
hospitalized	B-X
for	B-X
threatened	B-X
preterm	B-X
labor	B-X
<EOS>	B-X
This	B-X
prospective	B-X
cohort	B-X
study	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
technology	B-X
-	B-X
free	B-X
predictors	B-X
of	B-X
preterm	B-X
birth	B-X
in	B-X
singleton	B-X
women	B-X
with	B-X
threatened	B-X
preterm	B-X
labor	B-X

The	O
lymphocytes	O
of	O
women	O
with	O
threatened	O
abortion	O
or	O
threatened	O
premature	O
labour	O
showed	O
significantly	O
higher	O
cytotoxic	O
activity	O
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
significantly	O
lower	O
progesterone	O
binding	O
capacity	O
(	O
P	O
less	O
than	O
0.001	O
)	O
than	O
did	O
lymphocytes	B-cell_type
obtained	O
from	O
the	O
healthy	O
pregnant	O
women	O
.	O
<EOS>	B-X
The	B-X
lymphocytes	B-X
of	B-X
women	B-X
with	B-X
threatened	B-X
abortion	B-X
or	B-X
threatened	B-X
premature	B-X
labour	B-X
showed	B-X
significantly	B-X
higher	B-X
cytotoxic	B-X
activity	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
Neither	B-X
cytotoxic	B-X
activity	B-X
nor	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
was	B-X
influenced	B-X
by	B-X
gestational	B-X
age	B-X
<EOS>	B-X
Cytotoxic	B-X
activity	B-X
and	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
lymphocytes	B-X
obtained	B-X
from	B-X
135	B-X
pregnant	B-X
women	B-X
was	B-X
tested	B-X
<EOS>	B-X
Immunosuppressive	B-X
effect	B-X
of	B-X
serum	B-X
progesterone	B-X
during	B-X
pregnancy	B-X
depends	B-X
on	B-X
the	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
.	B-X

Significant	O
inverse	O
correlation	O
was	O
found	O
between	O
progesterone	O
binding	O
capacity	O
and	O
cytotoxic	O
activity	O
of	O
the	O
lymphocytes	B-cell_type
(	O
P	O
less	O
than	O
0.001	O
)	O
,	O
but	O
the	O
progesterone	O
concentration	O
of	O
the	O
pregnancy	O
serum	O
appeared	O
to	O
have	O
no	O
influence	O
on	O
the	O
other	O
two	O
parameters	O
.	O
<EOS>	B-X
Significant	B-X
inverse	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
progesterone	B-X
binding	B-X
capacity	B-X
and	B-X
cytotoxic	B-X
activity	B-X
of	B-X
the	B-X
lymphocytes	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
001	B-X
)	B-X
,	B-X
but	B-X
the	B-X
progesterone	B-X
concentration	B-X
of	B-X
the	B-X
pregnancy	B-X
serum	B-X
appeared	B-X
to	B-X
have	B-X
no	B-X
influence	B-X
on	B-X
the	B-X
other	B-X
two	B-X
parameters	B-X
<EOS>	B-X
The	B-X
findings	B-X
indicate	B-X
that	B-X
intact	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
is	B-X
an	B-X
essential	B-X
factor	B-X
for	B-X
the	B-X
manifestation	B-X
of	B-X
the	B-X
blocking	B-X
effect	B-X
exerted	B-X
by	B-X
pregnancy	B-X
serum	B-X
on	B-X
lymphocyte	B-X
cytotoxicity	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Cytotoxic	B-X
activity	B-X
and	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
,	B-X
together	B-X
with	B-X
serum	B-X
progesterone	B-X
concentrations	B-X
,	B-X
were	B-X
determined	B-X
in	B-X
women	B-X
with	B-X
normal	B-X
pregnancy	B-X
or	B-X
with	B-X
a	B-X
clinical	B-X
diagnosis	B-X
of	B-X
threatened	B-X
abortion	B-X
or	B-X
threatened	B-X
premature	B-X
labour	B-X

The	O
findings	O
indicate	O
that	O
intact	O
progesterone	O
binding	O
capacity	O
of	O
the	O
lymphocytes	B-cell_type
is	O
an	O
essential	O
factor	O
for	O
the	O
manifestation	O
of	O
the	O
blocking	O
effect	O
exerted	O
by	O
pregnancy	O
serum	O
on	O
lymphocyte	B-cell_type
cytotoxicity	O
in	O
vitro	O
.	O
<EOS>	B-X
The	B-X
findings	B-X
indicate	B-X
that	B-X
intact	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
is	B-X
an	B-X
essential	B-X
factor	B-X
for	B-X
the	B-X
manifestation	B-X
of	B-X
the	B-X
blocking	B-X
effect	B-X
exerted	B-X
by	B-X
pregnancy	B-X
serum	B-X
on	B-X
lymphocyte	B-X
cytotoxicity	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Cytotoxic	B-X
activity	B-X
and	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
,	B-X
together	B-X
with	B-X
serum	B-X
progesterone	B-X
concentrations	B-X
,	B-X
were	B-X
determined	B-X
in	B-X
women	B-X
with	B-X
normal	B-X
pregnancy	B-X
or	B-X
with	B-X
a	B-X
clinical	B-X
diagnosis	B-X
of	B-X
threatened	B-X
abortion	B-X
or	B-X
threatened	B-X
premature	B-X
labour	B-X
<EOS>	B-X
Immunosuppressive	B-X
effect	B-X
of	B-X
serum	B-X
progesterone	B-X
during	B-X
pregnancy	B-X
depends	B-X
on	B-X
the	B-X
progesterone	B-X
binding	B-X
capacity	B-X
of	B-X
the	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
001	B-X
)	B-X
,	B-X
but	B-X
the	B-X
progesterone	B-X
concentration	B-X
of	B-X
the	B-X
pregnancy	B-X
serum	B-X
appeared	B-X
to	B-X
have	B-X
no	B-X
influence	B-X
on	B-X
the	B-X
other	B-X
two	B-X
parameters	B-X

Serum	O
sex	O
steroid	O
and	O
peptide	O
hormone	O
concentrations	O
,	O
and	O
endometrial	O
estrogen	O
and	O
progestin	O
receptor	O
levels	O
during	O
administration	O
of	O
human	B-protein
leukocyte	I-protein
interferon	I-protein
.	O
<EOS>	B-X
Serum	B-X
sex	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
,	B-X
and	B-X
endometrial	B-X
estrogen	B-X
and	B-X
progestin	B-X
receptor	B-X
levels	B-X
during	B-X
administration	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
.	B-X
<EOS>	B-X
No	B-X
significant	B-X
changes	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
serum	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
measured	B-X
(	B-X
FSH	B-X
,	B-X
LH	B-X
,	B-X
prolactin	B-X
,	B-X
insulin	B-X
,	B-X
growth	B-X
hormone	B-X
and	B-X
TSH	B-X
)	B-X
;	B-X
neither	B-X
were	B-X
the	B-X
levels	B-X
of	B-X
endometrial	B-X
ERC	B-X
,	B-X
ERN	B-X
,	B-X
PRC	B-X
and	B-X
PRN	B-X
affected	B-X
by	B-X
interferon	B-X
administration	B-X
<EOS>	B-X
Serum	B-X
estradiol	B-X
and	B-X
progesterone	B-X
concentrations	B-X
were	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
treatment	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
interferon	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
the	B-X
function	B-X
of	B-X
both	B-X
FSH	B-X
and	B-X
LH	B-X
<EOS>	B-X
Concentrations	B-X
of	B-X
cytosol	B-X
and	B-X
nuclear	B-X
estrogen	B-X
receptors	B-X
(	B-X
ERC	B-X
and	B-X
ERN	B-X
,	B-X
respectively	B-X
)	B-X
and	B-X
progestin	B-X
receptors	B-X
(	B-X
PRC	B-X
and	B-X
PRN	B-X
)	B-X
were	B-X
also	B-X
measured	B-X
from	B-X
endometrial	B-X
biopsies	B-X
taken	B-X
on	B-X
the	B-X
24th	B-X
day	B-X
of	B-X
the	B-X
control	B-X
and	B-X
treatment	B-X
cycle	B-X

Five	O
normally	O
cycling	O
healthy	O
women	O
were	O
given	O
daily	O
subcutaneous	O
injections	O
of	O
human	B-protein
leukocyte	I-protein
interferon	I-protein
(	O
3	O
X	O
10	O
(	O
6	O
)	O
units/day	O
)	O
from	O
the	O
3rd	O
through	O
23rd	O
day	O
of	O
the	O
menstrual	O
cycle	O
,	O
and	O
serum	O
steroid	O
and	O
peptide	O
hormone	O
concentrations	O
monitored	O
at	O
3-day	O
intervals	O
during	O
the	O
treatment	O
and	O
the	O
preceding	O
control	O
cycle	O
.	O

Concentrations	O
of	O
cytosol	B-protein
and	I-protein
nuclear	I-protein
estrogen	I-protein
receptors	I-protein
(	O
ERC	B-protein
and	O
ERN	B-protein
,	O
respectively	O
)	O
and	O
progestin	B-protein
receptors	I-protein
(	O
PRC	B-protein
and	O
PRN	B-protein
)	O
were	O
also	O
measured	O
from	O
endometrial	O
biopsies	O
taken	O
on	O
the	O
24th	O
day	O
of	O
the	O
control	O
and	O
treatment	O
cycle	O
.	O
<EOS>	B-X
Concentrations	B-X
of	B-X
cytosol	B-X
and	B-X
nuclear	B-X
estrogen	B-X
receptors	B-X
(	B-X
ERC	B-X
and	B-X
ERN	B-X
,	B-X
respectively	B-X
)	B-X
and	B-X
progestin	B-X
receptors	B-X
(	B-X
PRC	B-X
and	B-X
PRN	B-X
)	B-X
were	B-X
also	B-X
measured	B-X
from	B-X
endometrial	B-X
biopsies	B-X
taken	B-X
on	B-X
the	B-X
24th	B-X
day	B-X
of	B-X
the	B-X
control	B-X
and	B-X
treatment	B-X
cycle	B-X
<EOS>	B-X
Serum	B-X
sex	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
,	B-X
and	B-X
endometrial	B-X
estrogen	B-X
and	B-X
progestin	B-X
receptor	B-X
levels	B-X
during	B-X
administration	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
.	B-X
<EOS>	B-X
Five	B-X
normally	B-X
cycling	B-X
healthy	B-X
women	B-X
were	B-X
given	B-X
daily	B-X
subcutaneous	B-X
injections	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
(	B-X
3	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
units	B-X
/	B-X
day	B-X
)	B-X
from	B-X
the	B-X
3rd	B-X
through	B-X
23rd	B-X
day	B-X
of	B-X
the	B-X
menstrual	B-X
cycle	B-X
,	B-X
and	B-X
serum	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
monitored	B-X
at	B-X
3	B-X
-	B-X
day	B-X
intervals	B-X
during	B-X
the	B-X
treatment	B-X
and	B-X
the	B-X
preceding	B-X
control	B-X
cycle	B-X
<EOS>	B-X
Serum	B-X
estradiol	B-X
and	B-X
progesterone	B-X
concentrations	B-X
were	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
treatment	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
interferon	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
the	B-X
function	B-X
of	B-X
both	B-X
FSH	B-X
and	B-X
LH	B-X

In	O
addition	O
,	O
an	O
extensive	O
monitoring	O
of	O
clinical	O
chemical	O
and	O
hematological	O
tests	O
from	O
the	O
blood	O
samples	O
were	O
performed	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
an	B-X
extensive	B-X
monitoring	B-X
of	B-X
clinical	B-X
chemical	B-X
and	B-X
hematological	B-X
tests	B-X
from	B-X
the	B-X
blood	B-X
samples	B-X
were	B-X
performed	B-X
<EOS>	B-X
Serum	B-X
sex	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
,	B-X
and	B-X
endometrial	B-X
estrogen	B-X
and	B-X
progestin	B-X
receptor	B-X
levels	B-X
during	B-X
administration	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
.	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
an	B-X
increasing	B-X
tendency	B-X
in	B-X
the	B-X
activities	B-X
of	B-X
serum	B-X
alkaline	B-X
phosphatase	B-X
and	B-X
gamma	B-X
-	B-X
glutamyltransferase	B-X
during	B-X
the	B-X
interferon	B-X
therapy	B-X
shows	B-X
that	B-X
interferon	B-X
may	B-X
slightly	B-X
interfere	B-X
with	B-X
the	B-X
liver	B-X
function	B-X
<EOS>	B-X
Serum	B-X
estradiol	B-X
and	B-X
progesterone	B-X
concentrations	B-X
were	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
treatment	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
interferon	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
the	B-X
function	B-X
of	B-X
both	B-X
FSH	B-X
and	B-X
LH	B-X

Serum	O
estradiol	O
and	O
progesterone	O
concentrations	O
were	O
significantly	O
decreased	O
during	O
the	O
treatment	O
cycle	O
,	O
suggesting	O
that	O
interferon	B-protein
interacts	O
in	O
vivo	O
with	O
the	O
function	O
of	O
both	O
FSH	O
and	O
LH	O
.	O
<EOS>	B-X
Serum	B-X
estradiol	B-X
and	B-X
progesterone	B-X
concentrations	B-X
were	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
treatment	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
interferon	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
the	B-X
function	B-X
of	B-X
both	B-X
FSH	B-X
and	B-X
LH	B-X
<EOS>	B-X
Serum	B-X
sex	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
,	B-X
and	B-X
endometrial	B-X
estrogen	B-X
and	B-X
progestin	B-X
receptor	B-X
levels	B-X
during	B-X
administration	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
one	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
interferon	B-X
treatment	B-X
may	B-X
affect	B-X
the	B-X
growth	B-X
of	B-X
hormone	B-X
-	B-X
dependent	B-X
neoplasms	B-X
could	B-X
be	B-X
the	B-X
interaction	B-X
with	B-X
production	B-X
and	B-X
/	B-X
or	B-X
function	B-X
of	B-X
circulating	B-X
hormonal	B-X
compounds	B-X
<EOS>	B-X
Five	B-X
normally	B-X
cycling	B-X
healthy	B-X
women	B-X
were	B-X
given	B-X
daily	B-X
subcutaneous	B-X
injections	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
(	B-X
3	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
units	B-X
/	B-X
day	B-X
)	B-X
from	B-X
the	B-X
3rd	B-X
through	B-X
23rd	B-X
day	B-X
of	B-X
the	B-X
menstrual	B-X
cycle	B-X
,	B-X
and	B-X
serum	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
monitored	B-X
at	B-X
3	B-X
-	B-X
day	B-X
intervals	B-X
during	B-X
the	B-X
treatment	B-X
and	B-X
the	B-X
preceding	B-X
control	B-X
cycle	B-X

No	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
serum	O
peptide	O
hormone	O
concentrations	O
measured	O
(	O
FSH	O
,	O
LH	O
,	O
prolactin	O
,	O
insulin	O
,	O
growth	O
hormone	O
and	O
TSH	O
)	O
;	O
neither	O
were	O
the	O
levels	O
of	O
endometrial	B-protein
ERC	I-protein
,	I-protein
ERN	I-protein
,	I-protein
PRC	I-protein
and	I-protein
PRN	I-protein
affected	O
by	O
interferon	B-protein
administration	O
.	O
<EOS>	B-X
No	B-X
significant	B-X
changes	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
serum	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
measured	B-X
(	B-X
FSH	B-X
,	B-X
LH	B-X
,	B-X
prolactin	B-X
,	B-X
insulin	B-X
,	B-X
growth	B-X
hormone	B-X
and	B-X
TSH	B-X
)	B-X
;	B-X
neither	B-X
were	B-X
the	B-X
levels	B-X
of	B-X
endometrial	B-X
ERC	B-X
,	B-X
ERN	B-X
,	B-X
PRC	B-X
and	B-X
PRN	B-X
affected	B-X
by	B-X
interferon	B-X
administration	B-X
<EOS>	B-X
Serum	B-X
sex	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
,	B-X
and	B-X
endometrial	B-X
estrogen	B-X
and	B-X
progestin	B-X
receptor	B-X
levels	B-X
during	B-X
administration	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
.	B-X
<EOS>	B-X
Concentrations	B-X
of	B-X
cytosol	B-X
and	B-X
nuclear	B-X
estrogen	B-X
receptors	B-X
(	B-X
ERC	B-X
and	B-X
ERN	B-X
,	B-X
respectively	B-X
)	B-X
and	B-X
progestin	B-X
receptors	B-X
(	B-X
PRC	B-X
and	B-X
PRN	B-X
)	B-X
were	B-X
also	B-X
measured	B-X
from	B-X
endometrial	B-X
biopsies	B-X
taken	B-X
on	B-X
the	B-X
24th	B-X
day	B-X
of	B-X
the	B-X
control	B-X
and	B-X
treatment	B-X
cycle	B-X
<EOS>	B-X
Serum	B-X
estradiol	B-X
and	B-X
progesterone	B-X
concentrations	B-X
were	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
treatment	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
interferon	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
the	B-X
function	B-X
of	B-X
both	B-X
FSH	B-X
and	B-X
LH	B-X

As	O
expected	O
,	O
interferon	B-protein
administration	O
resulted	O
in	O
decreased	O
leukocyte	B-cell_type
counts	O
.	O
<EOS>	B-X
As	B-X
expected	B-X
,	B-X
interferon	B-X
administration	B-X
resulted	B-X
in	B-X
decreased	B-X
leukocyte	B-X
counts	B-X
<EOS>	B-X
Serum	B-X
sex	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
,	B-X
and	B-X
endometrial	B-X
estrogen	B-X
and	B-X
progestin	B-X
receptor	B-X
levels	B-X
during	B-X
administration	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
.	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
the	B-X
pharmacology	B-X
of	B-X
type	B-X
I	B-X
IFNs	B-X
,	B-X
PEG	B-X
-	B-X
IFN	B-X
β	B-X
-	B-X
1a	B-X
resulted	B-X
in	B-X
the	B-X
elevation	B-X
of	B-X
neopterin	B-X
concentration	B-X
,	B-X
a	B-X
transient	B-X
body	B-X
temperature	B-X
increase	B-X
,	B-X
and	B-X
a	B-X
reversible	B-X
lymphocyte	B-X
count	B-X
decrease	B-X
<EOS>	B-X
As	B-X
expected	B-X
,	B-X
neutralizing	B-X
antibodies	B-X
to	B-X
PEG	B-X
-	B-X
IFN	B-X
β	B-X
-	B-X
1a	B-X
formed	B-X
in	B-X
almost	B-X
all	B-X
monkeys	B-X
after	B-X
5	B-X
weeks	B-X
of	B-X
treatment	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
significantly	B-X
reduced	B-X
drug	B-X
exposure	B-X
and	B-X
abrogation	B-X
of	B-X
neopterin	B-X
induction	B-X

Moreover	O
,	O
an	O
increasing	O
tendency	O
in	O
the	O
activities	O
of	O
serum	B-protein
alkaline	I-protein
phosphatase	I-protein
and	O
gamma-glutamyltransferase	B-protein
during	O
the	O
interferon	B-protein
therapy	O
shows	O
that	O
interferon	B-protein
may	O
slightly	O
interfere	O
with	O
the	O
liver	O
function	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
an	B-X
increasing	B-X
tendency	B-X
in	B-X
the	B-X
activities	B-X
of	B-X
serum	B-X
alkaline	B-X
phosphatase	B-X
and	B-X
gamma	B-X
-	B-X
glutamyltransferase	B-X
during	B-X
the	B-X
interferon	B-X
therapy	B-X
shows	B-X
that	B-X
interferon	B-X
may	B-X
slightly	B-X
interfere	B-X
with	B-X
the	B-X
liver	B-X
function	B-X
<EOS>	B-X
Serum	B-X
estradiol	B-X
and	B-X
progesterone	B-X
concentrations	B-X
were	B-X
significantly	B-X
decreased	B-X
during	B-X
the	B-X
treatment	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
interferon	B-X
interacts	B-X
in	B-X
vivo	B-X
with	B-X
the	B-X
function	B-X
of	B-X
both	B-X
FSH	B-X
and	B-X
LH	B-X
<EOS>	B-X
Five	B-X
normally	B-X
cycling	B-X
healthy	B-X
women	B-X
were	B-X
given	B-X
daily	B-X
subcutaneous	B-X
injections	B-X
of	B-X
human	B-X
leukocyte	B-X
interferon	B-X
(	B-X
3	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
units	B-X
/	B-X
day	B-X
)	B-X
from	B-X
the	B-X
3rd	B-X
through	B-X
23rd	B-X
day	B-X
of	B-X
the	B-X
menstrual	B-X
cycle	B-X
,	B-X
and	B-X
serum	B-X
steroid	B-X
and	B-X
peptide	B-X
hormone	B-X
concentrations	B-X
monitored	B-X
at	B-X
3	B-X
-	B-X
day	B-X
intervals	B-X
during	B-X
the	B-X
treatment	B-X
and	B-X
the	B-X
preceding	B-X
control	B-X
cycle	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
an	B-X
extensive	B-X
monitoring	B-X
of	B-X
clinical	B-X
chemical	B-X
and	B-X
hematological	B-X
tests	B-X
from	B-X
the	B-X
blood	B-X
samples	B-X
were	B-X
performed	B-X

These	O
results	O
suggest	O
that	O
one	O
of	O
the	O
mechanisms	O
by	O
which	O
interferon	B-protein
treatment	O
may	O
affect	O
the	O
growth	O
of	O
hormone-dependent	O
neoplasms	O
could	O
be	O
the	O
interaction	O
with	O
production	O
and/or	O
function	O
of	O
circulating	O
hormonal	O
compounds	O
.	O
<EOS>	B-X
Testosterone	B-X
levels	B-X
have	B-X
also	B-X
been	B-X
studied	B-X
in	B-X
relation	B-X
to	B-X
the	B-X
impact	B-X
of	B-X
diseases	B-X
,	B-X
aging	B-X
,	B-X
nutrition	B-X
and	B-X
the	B-X
environment	B-X
on	B-X
its	B-X
circulating	B-X
levels	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
study	B-X
is	B-X
to	B-X
observe	B-X
the	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
Entresto	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
left	B-X
ventricular	B-X
ejection	B-X
fraction	B-X
heart	B-X
failure	B-X
(	B-X
HFpEF	B-X
)	B-X
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
intratesticular	B-X
administration	B-X
of	B-X
a	B-X
25	B-X
amino	B-X
acid	B-X
peptide	B-X
blocking	B-X
the	B-X
interaction	B-X
between	B-X
14	B-X
-	B-X
3	B-X
-	B-X
3ϵ	B-X
with	B-X
VDAC1	B-X
increased	B-X
circulating	B-X
levels	B-X
of	B-X
testosterone	B-X
<EOS>	B-X
This	B-X
work	B-X
unveils	B-X
a	B-X
new	B-X
physiological	B-X
role	B-X
for	B-X
NR	B-X
metabolism	B-X
in	B-X
the	B-X
maintenance	B-X
of	B-X
glucose	B-X
tolerance	B-X
and	B-X
pancreatic	B-X
β	B-X
-	B-X
cell	B-X
function	B-X
in	B-X
high	B-X
-	B-X
fat	B-X
feeding	B-X
or	B-X
aging	B-X
conditions	B-X

[	O
Glucocorticoid	B-protein
receptor	I-protein
level	O
in	O
the	O
blood	B-cell_type
leukocytes	I-cell_type
in	O
different	O
acute	O
diseases	O
]	O
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptor	B-X
level	B-X
in	B-X
the	B-X
blood	B-X
leukocytes	B-X
in	B-X
different	B-X
acute	B-X
diseases	B-X
]	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
effects	B-X
in	B-X
human	B-X
lymphoid	B-X
and	B-X
leukemic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
	B-X
-	B-X
binding	B-X
assay	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
was	B-X
performed	B-X
using	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
<EOS>	B-X
Glucocorticoids	B-X
are	B-X
the	B-X
standard	B-X
treatment	B-X
of	B-X
acute	B-X
attacks	B-X
of	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X

Content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
cytosol	O
of	O
blood	B-cell_type
leukocytes	I-cell_type
,	O
concentration	O
of	O
cortisol	O
and	O
amount	O
of	O
leukocytes	B-cell_type
in	O
blood	O
were	O
studied	O
in	O
20	O
patients	O
with	O
acute	O
impairments	O
within	O
the	O
second	O
day	O
of	O
the	O
disease	O
.	O
<EOS>	B-X
Content	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
cytosol	B-X
of	B-X
blood	B-X
leukocytes	B-X
,	B-X
concentration	B-X
of	B-X
cortisol	B-X
and	B-X
amount	B-X
of	B-X
leukocytes	B-X
in	B-X
blood	B-X
were	B-X
studied	B-X
in	B-X
20	B-X
patients	B-X
with	B-X
acute	B-X
impairments	B-X
within	B-X
the	B-X
second	B-X
day	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
immunological	B-X
processes	B-X
under	B-X
conditions	B-X
of	B-X
purulent	B-X
complications	B-X
and	B-X
possibility	B-X
to	B-X
regulate	B-X
the	B-X
metabolism	B-X
in	B-X
leukocytes	B-X
are	B-X
discussed	B-X
<EOS>	B-X
Content	B-X
of	B-X
receptors	B-X
in	B-X
cytosol	B-X
of	B-X
blood	B-X
leukocytes	B-X
was	B-X
studied	B-X
using	B-X
3H	B-X
-	B-X
triamcinolone	B-X
acetonide	B-X
<EOS>	B-X
Reverse	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
concentration	B-X
of	B-X
cortisol	B-X
in	B-X
blood	B-X
and	B-X
content	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
leukocytes	B-X

Content	O
of	O
receptors	O
in	O
cytosol	O
of	O
blood	O
leukocytes	O
was	O
studied	O
using	O
3H-triamcinolone	O
acetonide	O
.	O
<EOS>	B-X
Content	B-X
of	B-X
receptors	B-X
in	B-X
cytosol	B-X
of	B-X
blood	B-X
leukocytes	B-X
was	B-X
studied	B-X
using	B-X
3H	B-X
-	B-X
triamcinolone	B-X
acetonide	B-X
<EOS>	B-X
Content	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
cytosol	B-X
of	B-X
blood	B-X
leukocytes	B-X
,	B-X
concentration	B-X
of	B-X
cortisol	B-X
and	B-X
amount	B-X
of	B-X
leukocytes	B-X
in	B-X
blood	B-X
were	B-X
studied	B-X
in	B-X
20	B-X
patients	B-X
with	B-X
acute	B-X
impairments	B-X
within	B-X
the	B-X
second	B-X
day	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptor	B-X
level	B-X
in	B-X
the	B-X
blood	B-X
leukocytes	B-X
in	B-X
different	B-X
acute	B-X
diseases	B-X
]	B-X
.	B-X
<EOS>	B-X
Concentration	B-X
of	B-X
endogenous	B-X
cortisol	B-X
was	B-X
increased	B-X
in	B-X
blood	B-X
of	B-X
all	B-X
the	B-X
patients	B-X
,	B-X
except	B-X
of	B-X
the	B-X
cases	B-X
of	B-X
acetate	B-X
intoxication	B-X

Distinct	O
increase	O
in	O
amount	O
of	O
the	O
leukocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
was	O
found	O
in	O
patients	O
with	O
poisoning	O
by	O
dichlorethane	O
and	O
hypnotic	O
drugs	O
under	O
conditions	O
of	O
acute	O
myocardial	O
infarction	O
.	O
<EOS>	B-X
Distinct	B-X
increase	B-X
in	B-X
amount	B-X
of	B-X
the	B-X
leukocyte	B-X
glucocorticoid	B-X
receptors	B-X
was	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
poisoning	B-X
by	B-X
dichlorethane	B-X
and	B-X
hypnotic	B-X
drugs	B-X
under	B-X
conditions	B-X
of	B-X
acute	B-X
myocardial	B-X
infarction	B-X
<EOS>	B-X
In	B-X
acute	B-X
pancreatitis	B-X
content	B-X
of	B-X
the	B-X
leukocyte	B-X
receptors	B-X
was	B-X
not	B-X
altered	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
<EOS>	B-X
Concentration	B-X
of	B-X
endogenous	B-X
cortisol	B-X
was	B-X
increased	B-X
in	B-X
blood	B-X
of	B-X
all	B-X
the	B-X
patients	B-X
,	B-X
except	B-X
of	B-X
the	B-X
cases	B-X
of	B-X
acetate	B-X
intoxication	B-X
<EOS>	B-X
But	B-X
in	B-X
the	B-X
patients	B-X
with	B-X
acute	B-X
pancreatitis	B-X
the	B-X
decrease	B-X
in	B-X
content	B-X
of	B-X
leukocyte	B-X
glucocorticoid	B-X
receptors	B-X
was	B-X
not	B-X
observed	B-X
although	B-X
there	B-X
was	B-X
an	B-X
increase	B-X
in	B-X
cortisol	B-X
concentration	B-X
in	B-X
blood	B-X

In	O
acute	O
pancreatitis	O
content	O
of	O
the	O
leukocyte	B-protein
receptors	I-protein
was	O
not	O
altered	O
as	O
compared	O
with	O
controls	O
.	O
<EOS>	B-X
Acute	B-X
pancreatitis	B-X
is	B-X
a	B-X
common	B-X
gastrointestinal	B-X
disorder	B-X
burdened	B-X
with	B-X
a	B-X
high	B-X
mortality	B-X
<EOS>	B-X
Acute	B-X
pancreatitis	B-X
is	B-X
characterized	B-X
by	B-X
inflammatory	B-X
processes	B-X
affecting	B-X
not	B-X
only	B-X
the	B-X
pancreas	B-X
,	B-X
but	B-X
also	B-X
the	B-X
lung	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
pancreatitis	B-X
-	B-X
associated	B-X
lung	B-X
injury	B-X
appears	B-X
to	B-X
result	B-X
from	B-X
an	B-X
endogenous	B-X
inflammatory	B-X
response	B-X
in	B-X
which	B-X
PAF	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
<EOS>	B-X
Acute	B-X
pancreatitis	B-X
is	B-X
a	B-X
complex	B-X
disorder	B-X
involving	B-X
both	B-X
premature	B-X
intracellular	B-X
protease	B-X
activation	B-X
and	B-X
inflammatory	B-X
cell	B-X
invasion	B-X

Concentration	O
of	O
endogenous	O
cortisol	O
was	O
increased	O
in	O
blood	O
of	O
all	O
the	O
patients	O
,	O
except	O
of	O
the	O
cases	O
of	O
acetate	O
intoxication	O
.	O

Reverse	O
correlation	O
was	O
observed	O
between	O
concentration	O
of	O
cortisol	O
in	O
blood	O
and	O
content	O
of	O
glucocorticoid	O
receptors	O
in	O
leukocytes	B-cell_type
.	O
<EOS>	B-X
Reverse	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
concentration	B-X
of	B-X
cortisol	B-X
in	B-X
blood	B-X
and	B-X
content	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
leukocytes	B-X
<EOS>	B-X
Content	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
cytosol	B-X
of	B-X
blood	B-X
leukocytes	B-X
,	B-X
concentration	B-X
of	B-X
cortisol	B-X
and	B-X
amount	B-X
of	B-X
leukocytes	B-X
in	B-X
blood	B-X
were	B-X
studied	B-X
in	B-X
20	B-X
patients	B-X
with	B-X
acute	B-X
impairments	B-X
within	B-X
the	B-X
second	B-X
day	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
immunological	B-X
processes	B-X
under	B-X
conditions	B-X
of	B-X
purulent	B-X
complications	B-X
and	B-X
possibility	B-X
to	B-X
regulate	B-X
the	B-X
metabolism	B-X
in	B-X
leukocytes	B-X
are	B-X
discussed	B-X
<EOS>	B-X
Distinct	B-X
increase	B-X
in	B-X
amount	B-X
of	B-X
the	B-X
leukocyte	B-X
glucocorticoid	B-X
receptors	B-X
was	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
poisoning	B-X
by	B-X
dichlorethane	B-X
and	B-X
hypnotic	B-X
drugs	B-X
under	B-X
conditions	B-X
of	B-X
acute	B-X
myocardial	B-X
infarction	B-X

But	O
in	O
the	O
patients	O
with	O
acute	O
pancreatitis	O
the	O
decrease	O
in	O
content	O
of	O
leukocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
was	O
not	O
observed	O
although	O
there	O
was	O
an	O
increase	O
in	O
cortisol	O
concentration	O
in	O
blood	O
.	O

The	O
role	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
immunological	O
processes	O
under	O
conditions	O
of	O
purulent	O
complications	O
and	O
possibility	O
to	O
regulate	O
the	O
metabolism	O
in	O
leukocytes	B-cell_type

Therapeutic	O
concentrations	O
of	O
glucocorticoids	O
suppress	O
the	O
antimicrobial	O
activity	O
of	O
human	B-cell_type
macrophages	I-cell_type
without	O
impairing	O
their	O
responsiveness	O
to	O
gamma	B-protein
interferon	I-protein
.	O
<EOS>	B-X
Therapeutic	B-X
concentrations	B-X
of	B-X
glucocorticoids	B-X
suppress	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
human	B-X
macrophages	B-X
without	B-X
impairing	B-X
their	B-X
responsiveness	B-X
to	B-X
gamma	B-X
interferon	B-X
.	B-X
<EOS>	B-X
By	B-X
exposing	B-X
human	B-X
blood	B-X
-	B-X
derived	B-X
macrophages	B-X
and	B-X
alveolar	B-X
macrophages	B-X
in	B-X
vitro	B-X
to	B-X
dexamethasone	B-X
,	B-X
we	B-X
showed	B-X
in	B-X
these	B-X
studies	B-X
that	B-X
glucocorticoids	B-X
markedly	B-X
suppress	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
macrophages	B-X
but	B-X
not	B-X
macrophage	B-X
activation	B-X
by	B-X
lymphokines	B-X
<EOS>	B-X
Proliferating	B-X
lymphocytes	B-X
and	B-X
gamma	B-X
-	B-X
interferon	B-X
thus	B-X
increased	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
phagocytes	B-X
exposed	B-X
to	B-X
glucocorticoids	B-X
over	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
<EOS>	B-X
Dexamethasone	B-X
-	B-X
induced	B-X
damage	B-X
to	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
human	B-X
macrophages	B-X
in	B-X
vitro	B-X
parallels	B-X
observations	B-X
that	B-X
glucocorticoids	B-X
render	B-X
laboratory	B-X
animals	B-X
susceptible	B-X
to	B-X
listeriosis	B-X
and	B-X
aspergillosis	B-X
by	B-X
damaging	B-X
resident	B-X
macrophages	B-X

By	O
exposing	O
human	B-cell_type
blood-derived	I-cell_type
macrophages	I-cell_type
and	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
in	O
vitro	O
to	O
dexamethasone	O
,	O
we	O
showed	O
in	O
these	O
studies	O
that	O
glucocorticoids	O
markedly	O
suppress	O
the	O
antimicrobial	O
activity	O
of	O
macrophages	B-cell_type
but	O
not	O
macrophage	B-cell_type
activation	O
by	O
lymphokines	B-cell_type
.	O

As	O
little	O
as	O
2.5	O
X	O
10	O
(	O
-8	O
)	O
mol/liter	O
of	O
dexamethasone	O
prevented	O
macrophages	B-cell_type
from	O
inhibiting	O
germination	O
of	O
Aspergillus	O
spores	O
or	O
from	O
eliminating	O
ingested	O
bacteria	O
such	O
as	O
Listeria	O
,	O
Nocardia	O
,	O
or	O
Salmonella	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
if	B-X
diarrhoea	B-X
-	B-X
causing	B-X
bacteria	B-X
,	B-X
including	B-X
Yersinia	B-X
species	B-X
,	B-X
could	B-X
mimic	B-X
the	B-X
symptoms	B-X
of	B-X
appendicitis	B-X
and	B-X
lead	B-X
to	B-X
surgery	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
collected	B-X
a	B-X
total	B-X
of	B-X
160	B-X
boot	B-X
sock	B-X
samples	B-X
from	B-X
20	B-X
broiler	B-X
farms	B-X
across	B-X
four	B-X
different	B-X
integrators	B-X
with	B-X
different	B-X
antibiotic	B-X
management	B-X
programs	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
in	B-X
vitro	B-X
reconstitution	B-X
of	B-X
the	B-X
Dpd	B-X
modification	B-X
machinery	B-X
from	B-X
Salmonella	B-X
enterica	B-X
serovar	B-X
Montevideo	B-X
,	B-X
the	B-X
elucidation	B-X
of	B-X
the	B-X
roles	B-X
of	B-X
each	B-X
protein	B-X
and	B-X
the	B-X
X	B-X
-	B-X
ray	B-X
crystal	B-X
structure	B-X
of	B-X
DpdA	B-X
supported	B-X
by	B-X
small	B-X
-	B-X
angle	B-X
X	B-X
-	B-X
ray	B-X
scattering	B-X
analysis	B-X
of	B-X
DpdA	B-X
and	B-X
DpdB	B-X
,	B-X
the	B-X
former	B-X
bound	B-X
to	B-X
DNA	B-X
<EOS>	B-X
We	B-X
present	B-X
a	B-X
case	B-X
of	B-X
a	B-X
32	B-X
-	B-X
year	B-X
-	B-X
old	B-X
transgender	B-X
male	B-X
who	B-X
underwent	B-X
chest	B-X
masculinization	B-X
,	B-X
complicated	B-X
by	B-X
purulent	B-X
soft	B-X
tissue	B-X
infection	B-X
of	B-X
bilateral	B-X
chest	B-X
incisions	B-X

Damage	O
to	O
macrophage	B-cell_type
function	O
was	O
inhibited	O
by	O
progesterone	O
and	O
appeared	O
to	O
be	O
receptor-mediated	O
.	O
<EOS>	B-X
Damage	B-X
to	B-X
macrophage	B-X
function	B-X
was	B-X
inhibited	B-X
by	B-X
progesterone	B-X
and	B-X
appeared	B-X
to	B-X
be	B-X
receptor	B-X
-	B-X
mediated	B-X
<EOS>	B-X
Macrophage	B-X
activation	B-X
and	B-X
correction	B-X
of	B-X
the	B-X
dexamethasone	B-X
effect	B-X
by	B-X
gamma	B-X
-	B-X
interferon	B-X
,	B-X
however	B-X
,	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
pathogen	B-X
<EOS>	B-X
Therapeutic	B-X
concentrations	B-X
of	B-X
glucocorticoids	B-X
suppress	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
human	B-X
macrophages	B-X
without	B-X
impairing	B-X
their	B-X
responsiveness	B-X
to	B-X
gamma	B-X
interferon	B-X
.	B-X
<EOS>	B-X
5	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
8	B-X
)	B-X
mol	B-X
/	B-X
liter	B-X
of	B-X
dexamethasone	B-X
prevented	B-X
macrophages	B-X
from	B-X
inhibiting	B-X
germination	B-X
of	B-X
Aspergillus	B-X
spores	B-X
or	B-X
from	B-X
eliminating	B-X
ingested	B-X
bacteria	B-X
such	B-X
as	B-X
Listeria	B-X
,	B-X
Nocardia	B-X
,	B-X
or	B-X
Salmonella	B-X

In	O
accordance	O
with	O
in	O
vivo	O
observations	O
,	O
dexamethasone	O
required	O
24-36	O
h	O
to	O
suppress	O
antimicrobial	O
activity	O
.	O
<EOS>	B-X
In	B-X
accordance	B-X
with	B-X
in	B-X
vivo	B-X
observations	B-X
,	B-X
dexamethasone	B-X
required	B-X
24	B-X
-	B-X
36	B-X
h	B-X
to	B-X
suppress	B-X
antimicrobial	B-X
activity	B-X
<EOS>	B-X
While	B-X
glucocorticoids	B-X
interfered	B-X
with	B-X
base	B-X
-	B-X
line	B-X
activity	B-X
of	B-X
macrophages	B-X
,	B-X
dexamethasone	B-X
concentrations	B-X
comparable	B-X
to	B-X
drug	B-X
levels	B-X
in	B-X
patients	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
macrophage	B-X
activation	B-X
<EOS>	B-X
By	B-X
exposing	B-X
human	B-X
blood	B-X
-	B-X
derived	B-X
macrophages	B-X
and	B-X
alveolar	B-X
macrophages	B-X
in	B-X
vitro	B-X
to	B-X
dexamethasone	B-X
,	B-X
we	B-X
showed	B-X
in	B-X
these	B-X
studies	B-X
that	B-X
glucocorticoids	B-X
markedly	B-X
suppress	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
macrophages	B-X
but	B-X
not	B-X
macrophage	B-X
activation	B-X
by	B-X
lymphokines	B-X
<EOS>	B-X
Macrophage	B-X
activation	B-X
and	B-X
correction	B-X
of	B-X
the	B-X
dexamethasone	B-X
effect	B-X
by	B-X
gamma	B-X
-	B-X
interferon	B-X
,	B-X
however	B-X
,	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
pathogen	B-X

While	O
glucocorticoids	O
interfered	O
with	O
base-line	O
activity	O
of	O
macrophages	B-cell_type
,	O
dexamethasone	O
concentrations	O
comparable	O
to	O
drug	O
levels	O
in	O
patients	O
had	O
no	O
effect	O
on	O
macrophage	B-cell_type
activation	O
.	O
<EOS>	B-X
While	B-X
glucocorticoids	B-X
interfered	B-X
with	B-X
base	B-X
-	B-X
line	B-X
activity	B-X
of	B-X
macrophages	B-X
,	B-X
dexamethasone	B-X
concentrations	B-X
comparable	B-X
to	B-X
drug	B-X
levels	B-X
in	B-X
patients	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
macrophage	B-X
activation	B-X
<EOS>	B-X
In	B-X
accordance	B-X
with	B-X
in	B-X
vivo	B-X
observations	B-X
,	B-X
dexamethasone	B-X
required	B-X
24	B-X
-	B-X
36	B-X
h	B-X
to	B-X
suppress	B-X
antimicrobial	B-X
activity	B-X
<EOS>	B-X
By	B-X
exposing	B-X
human	B-X
blood	B-X
-	B-X
derived	B-X
macrophages	B-X
and	B-X
alveolar	B-X
macrophages	B-X
in	B-X
vitro	B-X
to	B-X
dexamethasone	B-X
,	B-X
we	B-X
showed	B-X
in	B-X
these	B-X
studies	B-X
that	B-X
glucocorticoids	B-X
markedly	B-X
suppress	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
macrophages	B-X
but	B-X
not	B-X
macrophage	B-X
activation	B-X
by	B-X
lymphokines	B-X
<EOS>	B-X
Macrophage	B-X
activation	B-X
and	B-X
correction	B-X
of	B-X
the	B-X
dexamethasone	B-X
effect	B-X
by	B-X
gamma	B-X
-	B-X
interferon	B-X
,	B-X
however	B-X
,	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
pathogen	B-X

Proliferating	O
lymphocytes	B-cell_type
and	O
gamma-interferon	B-protein
thus	O
increased	O
the	O
antimicrobial	O
activity	O
of	O
phagocytes	B-cell_type
exposed	O
to	O
glucocorticoids	O
over	O
that	O
of	O
control	O
cells	O
.	O
<EOS>	B-X
Proliferating	B-X
lymphocytes	B-X
and	B-X
gamma	B-X
-	B-X
interferon	B-X
thus	B-X
increased	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
phagocytes	B-X
exposed	B-X
to	B-X
glucocorticoids	B-X
over	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
<EOS>	B-X
Therapeutic	B-X
concentrations	B-X
of	B-X
glucocorticoids	B-X
suppress	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
human	B-X
macrophages	B-X
without	B-X
impairing	B-X
their	B-X
responsiveness	B-X
to	B-X
gamma	B-X
interferon	B-X
.	B-X
<EOS>	B-X
By	B-X
exposing	B-X
human	B-X
blood	B-X
-	B-X
derived	B-X
macrophages	B-X
and	B-X
alveolar	B-X
macrophages	B-X
in	B-X
vitro	B-X
to	B-X
dexamethasone	B-X
,	B-X
we	B-X
showed	B-X
in	B-X
these	B-X
studies	B-X
that	B-X
glucocorticoids	B-X
markedly	B-X
suppress	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
macrophages	B-X
but	B-X
not	B-X
macrophage	B-X
activation	B-X
by	B-X
lymphokines	B-X
<EOS>	B-X
Dexamethasone	B-X
-	B-X
induced	B-X
damage	B-X
to	B-X
the	B-X
antimicrobial	B-X
activity	B-X
of	B-X
human	B-X
macrophages	B-X
in	B-X
vitro	B-X
parallels	B-X
observations	B-X
that	B-X
glucocorticoids	B-X
render	B-X
laboratory	B-X
animals	B-X
susceptible	B-X
to	B-X
listeriosis	B-X
and	B-X
aspergillosis	B-X
by	B-X
damaging	B-X
resident	B-X
macrophages	B-X

Macrophage	O
activation	O
and	O
correction	O
of	O
the	O
dexamethasone	O
effect	O
by	O
gamma-interferon	B-protein
,	O
however	O
,	O
was	O
dependent	O
on	O
the	O
pathogen	O
.	O
<EOS>	B-X
Macrophage	B-X
activation	B-X
and	B-X
correction	B-X
of	B-X
the	B-X
dexamethasone	B-X
effect	B-X
by	B-X
gamma	B-X
-	B-X
interferon	B-X
,	B-X
however	B-X
,	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
pathogen	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
macrophage	B-X
antimicrobial	B-X
activity	B-X
should	B-X
thus	B-X
be	B-X
considered	B-X
when	B-X
treating	B-X
patients	B-X
with	B-X
glucocorticoids	B-X
;	B-X
its	B-X
prevention	B-X
by	B-X
gamma	B-X
-	B-X
interferon	B-X
might	B-X
be	B-X
beneficial	B-X
for	B-X
some	B-X
but	B-X
not	B-X
all	B-X
pathogens	B-X
<EOS>	B-X
While	B-X
glucocorticoids	B-X
interfered	B-X
with	B-X
base	B-X
-	B-X
line	B-X
activity	B-X
of	B-X
macrophages	B-X
,	B-X
dexamethasone	B-X
concentrations	B-X
comparable	B-X
to	B-X
drug	B-X
levels	B-X
in	B-X
patients	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
macrophage	B-X
activation	B-X
<EOS>	B-X
Damage	B-X
to	B-X
macrophage	B-X
function	B-X
was	B-X
inhibited	B-X
by	B-X
progesterone	B-X
and	B-X
appeared	B-X
to	B-X
be	B-X
receptor	B-X
-	B-X
mediated	B-X

The	O
lymphokine	B-protein
enhanced	O
the	O
antimicrobial	O
activity	O
of	O
dexamethasone-treated	B-cell_line
macrophages	I-cell_line
against	O
Listeria	O
and	O
Salmonella	O
but	O
not	O
against	O
Aspergillus	O
or	O
Nocardia	O
.	O
<EOS>	B-X
The	B-X
shortlisted	B-X
T	B-X
-	B-X
cell	B-X
and	B-X
B	B-X
-	B-X
cell	B-X
epitopes	B-X
were	B-X
fused	B-X
with	B-X
appropriate	B-X
adjuvants	B-X
and	B-X
linkers	B-X
to	B-X
construct	B-X
vaccines	B-X
<EOS>	B-X
We	B-X
have	B-X
collected	B-X
the	B-X
clinical	B-X
details	B-X
of	B-X
our	B-X
recent	B-X
cases	B-X
and	B-X
described	B-X
them	B-X
in	B-X
full	B-X
<EOS>	B-X
To	B-X
summarize	B-X
the	B-X
clinical	B-X
characteristics	B-X
and	B-X
management	B-X
of	B-X
nocardiosis	B-X
would	B-X
help	B-X
with	B-X
better	B-X
diagnosis	B-X
and	B-X
prognosis	B-X
of	B-X
nocardiosis	B-X
<EOS>	B-X
We	B-X
here	B-X
report	B-X
a	B-X
typical	B-X
case	B-X
of	B-X
newly	B-X
diagnosed	B-X
autoimmune	B-X
PAP	B-X
,	B-X
with	B-X
initial	B-X
indication	B-X
to	B-X
realize	B-X
a	B-X
whole	B-X
-	B-X
lung	B-X
lavage	B-X

Dexamethasone-induced	O
damage	O
to	O
the	O
antimicrobial	O
activity	O
of	O
human	B-cell_type
macrophages	I-cell_type
in	O
vitro	O
parallels	O
observations	O
that	O
glucocorticoids	O
render	O
laboratory	O
animals	O
susceptible	O
to	O
listeriosis	O
and	O
aspergillosis	O
by	O
damaging	O
resident	O
macrophages	B-cell_line
.	O

Suppression	O
of	O
macrophage	B-cell_type
antimicrobial	O
activity	O
should	O
thus	O
be	O
considered	O
when	O
treating	O
patients	O
with	O
glucocorticoids	O
;	O
its	O
prevention	O
by	O
gamma-interferon	B-protein
might	O
be	O
beneficial	O
for	O
some	O
but	O
not	O
all	O
pathogens	O
.	O

Interleukin	B-protein
2	I-protein
receptor	I-protein
(	O
Tac	B-protein
antigen	I-protein
)	O
expression	O
in	O
HTLV-I-associated	O
adult	O
T-cell	B-cell_type
leukemia	O
.	O
<EOS>	B-X
Interleukin	B-X
2	B-X
receptor	B-X
(	B-X
Tac	B-X
antigen	B-X
)	B-X
expression	B-X
in	B-X
HTLV	B-X
-	B-X
I	B-X
-	B-X
associated	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
Interleukin	B-X
-	B-X
2	B-X
receptor	B-X
expression	B-X
in	B-X
retrovirus	B-X
associated	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
The	B-X
constant	B-X
expression	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
which	B-X
may	B-X
be	B-X
aberrant	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
uncontrolled	B-X
growth	B-X
of	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
cells	B-X
<EOS>	B-X
Normal	B-X
resting	B-X
T	B-X
cells	B-X
and	B-X
most	B-X
leukemic	B-X
T	B-X
cell	B-X
populations	B-X
do	B-X
not	B-X
express	B-X
IL	B-X
2	B-X
receptors	B-X
;	B-X
however	B-X
,	B-X
the	B-X
leukemic	B-X
cells	B-X
of	B-X
all	B-X
patients	B-X
with	B-X
HTLV	B-X
-	B-X
I	B-X
-	B-X
associated	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
examined	B-X
expressed	B-X
the	B-X
Tac	B-X
antigen	B-X

Interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
is	O
a	O
lymphokine	B-protein
synthesized	O
by	O
some	O
T-cells	B-cell_type
following	O
activation	O
.	O
<EOS>	B-X
Autocrine	B-X
activation	B-X
by	B-X
interferon	B-X
-	B-X
gamma	B-X
of	B-X
STAT	B-X
factors	B-X
following	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
<EOS>	B-X
Interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
production	B-X
by	B-X
cord	B-X
blood	B-X
T	B-X
cells	B-X
following	B-X
activation	B-X
by	B-X
Con	B-X
A	B-X
or	B-X
PHA	B-X
was	B-X
also	B-X
strongly	B-X
reduced	B-X
<EOS>	B-X
Immunotoxic	B-X
effects	B-X
of	B-X
mercuric	B-X
compounds	B-X
on	B-X
human	B-X
lymphocytes	B-X
and	B-X
monocytes	B-X
.	B-X
I.	B-X
Suppression	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
.	B-X
<EOS>	B-X
Detection	B-X
of	B-X
activated	B-X
T	B-X
lymphocytes	B-X
in	B-X
the	B-X
human	B-X
atherosclerotic	B-X
plaque	B-X
.	B-X

Resting	O
T-cells	B-cell_type
do	O
not	O
express	O
IL-2	B-protein
receptors	I-protein
,	O
but	O
receptors	O
are	O
rapidly	O
expressed	O
on	O
T-cells	B-cell_type
following	O
interaction	O
of	O
antigens	O
,	O
mitogens	O
,	O
or	O
monoclonal	B-protein
antibodies	I-protein
with	O
the	O
antigen-specific	B-protein
T-cell	I-protein
receptor	I-protein
complex	I-protein
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
Treg	B-X
subsets	B-X
were	B-X
altered	B-X
in	B-X
the	B-X
endometrium	B-X
and	B-X
PF	B-X
of	B-X
patients	B-X
with	B-X
endometriosis	B-X
during	B-X
the	B-X
menstrual	B-X
cycle	B-X
<EOS>	B-X
C	B-X
-	B-X
type	B-X
lectin	B-X
receptors	B-X
(	B-X
CLRs	B-X
)	B-X
expressed	B-X
by	B-X
DCs	B-X
recognize	B-X
carbohydrate	B-X
structures	B-X
and	B-X
are	B-X
crucial	B-X
in	B-X
allergen	B-X
uptake	B-X
,	B-X
presentation	B-X
,	B-X
and	B-X
polarization	B-X
of	B-X
T	B-X
cell	B-X
responses	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
regulators	B-X
of	B-X
immune	B-X
inflammatory	B-X
functions	B-X
may	B-X
be	B-X
interesting	B-X
targets	B-X
to	B-X
modulate	B-X
to	B-X
improve	B-X
antitumor	B-X
responses	B-X
<EOS>	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
recent	B-X
literature	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
CLRs	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
type	B-X
2	B-X
immune	B-X
responses	B-X
to	B-X
allergens	B-X

Using	O
anti-Tac	B-protein
,	O
a	O
monoclonal	B-protein
antibody	I-protein
that	O
recognizes	O
the	O
IL-2	B-protein
receptor	I-protein
,	O
the	O
receptor	O
has	O
been	O
purified	O
and	O
shown	O
to	O
be	O
a	O
Mr	O
33	O
,	O
000	O
peptide	O
that	O
is	O
posttranslationally	O
glycosylated	O
to	O
a	O
Mr	O
55	O
,	O
000	O
mature	O
form	O
.	O
<EOS>	B-X
Using	B-X
anti	B-X
-	B-X
Tac	B-X
,	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
recognizes	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
,	B-X
the	B-X
receptor	B-X
has	B-X
been	B-X
purified	B-X
and	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
Mr	B-X
33,000	B-X
peptide	B-X
that	B-X
is	B-X
posttranslationally	B-X
glycosylated	B-X
to	B-X
a	B-X
Mr	B-X
55,000	B-X
mature	B-X
form	B-X
<EOS>	B-X
The	B-X
constant	B-X
expression	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
which	B-X
may	B-X
be	B-X
aberrant	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
uncontrolled	B-X
growth	B-X
of	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
cells	B-X
<EOS>	B-X
Normal	B-X
resting	B-X
T	B-X
-	B-X
cells	B-X
and	B-X
most	B-X
leukemic	B-X
T	B-X
-	B-X
cell	B-X
populations	B-X
do	B-X
not	B-X
express	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
;	B-X
however	B-X
,	B-X
the	B-X
leukemic	B-X
cells	B-X
of	B-X
the	B-X
11	B-X
patients	B-X
examined	B-X
who	B-X
had	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
-	B-X
associated	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
expressed	B-X
the	B-X
Tac	B-X
antigen	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
patients	B-X
had	B-X
6	B-X
-	B-X
	B-X
and	B-X
3	B-X
-	B-X
mo	B-X
remissions	B-X
of	B-X
his	B-X
leukemia	B-X
following	B-X
two	B-X
courses	B-X
of	B-X
therapy	B-X
with	B-X
this	B-X
monoclonal	B-X
antibody	B-X
directed	B-X
toward	B-X
this	B-X
growth	B-X
factor	B-X
receptor	B-X

Normal	O
resting	O
T-cells	B-cell_type
and	O
most	O
leukemic	B-cell_line
T-cell	I-cell_line
populations	I-cell_line
do	O
not	O
express	O
IL-2	B-protein
receptors	I-protein
;	O
however	O
,	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
the	O
11	O
patients	O
examined	O
who	O
had	O
human	O
T-cell	O
lymphotropic	O
virus-associated	O
adult	O
T-cell	O
leukemia	O
expressed	O
the	O
Tac	B-protein
antigen	I-protein
.	O
<EOS>	B-X
Normal	B-X
resting	B-X
T	B-X
cells	B-X
and	B-X
most	B-X
leukemic	B-X
T	B-X
-	B-X
cell	B-X
populations	B-X
examined	B-X
did	B-X
not	B-X
express	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
;	B-X
however	B-X
,	B-X
the	B-X
leukemic	B-X
cells	B-X
of	B-X
all	B-X
patients	B-X
with	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
lymphotrophic	B-X
virus	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
)	B-X
	B-X
-	B-X
associated	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
expressed	B-X
the	B-X
Tac	B-X
antigen	B-X
<EOS>	B-X
Normal	B-X
resting	B-X
T	B-X
cells	B-X
and	B-X
most	B-X
leukemic	B-X
T	B-X
-	B-X
cell	B-X
populations	B-X
do	B-X
not	B-X
express	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
however	B-X
the	B-X
leukemic	B-X
cells	B-X
of	B-X
all	B-X
patients	B-X
with	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
/	B-X
lymphoma	B-X
virus	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
)	B-X
associated	B-X
,	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
examined	B-X
expressed	B-X
the	B-X
Tac	B-X
antigen	B-X
<EOS>	B-X
Normal	B-X
resting	B-X
T	B-X
cells	B-X
and	B-X
most	B-X
leukemic	B-X
T	B-X
cell	B-X
populations	B-X
do	B-X
not	B-X
express	B-X
IL	B-X
2	B-X
receptors	B-X
;	B-X
however	B-X
,	B-X
the	B-X
leukemic	B-X
cells	B-X
of	B-X
all	B-X
patients	B-X
with	B-X
HTLV	B-X
-	B-X
I	B-X
-	B-X
associated	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
examined	B-X
expressed	B-X
the	B-X
Tac	B-X
antigen	B-X
<EOS>	B-X
Resting	B-X
T	B-X
cells	B-X
do	B-X
not	B-X
express	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
,	B-X
but	B-X
receptors	B-X
are	B-X
rapidly	B-X
expressed	B-X
on	B-X
T	B-X
cells	B-X
following	B-X
interaction	B-X
of	B-X
the	B-X
antigen	B-X
-	B-X
specific	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
complex	B-X
with	B-X
appropriately	B-X
processed	B-X
and	B-X
presented	B-X
antigens	B-X

In	O
human	B-cell_type
T-cell	I-cell_type
lymphotropic	I-cell_type
virus-I	I-cell_type
infected	I-cell_type
cells	I-cell_type
,	O
the	O
Mr	O
42	O
,	O
000	O
long	O
open	B-protein
reading	I-protein
frame	I-protein
protein	I-protein
encoded	O
in	O
part	O
by	O
the	O
pX	B-DNA
region	I-DNA
of	O
this	O
virus	O
may	O
act	O
as	O
a	O
transacting	B-protein
transcriptional	I-protein
activator	I-protein
that	O
induces	O
IL-2	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
,	O
thus	O
providing	O
an	O
explanation	O
for	O
the	O
constant	O
association	O
of	O
IL-2	B-protein
receptor	I-protein
expression	O
with	O
adult	O
T-cell	O
lymphotropic	O
virus-I	O
infection	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
In	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
-	B-X
I	B-X
infected	B-X
cells	B-X
,	B-X
the	B-X
Mr	B-X
42,000	B-X
long	B-X
open	B-X
reading	B-X
frame	B-X
protein	B-X
encoded	B-X
in	B-X
part	B-X
by	B-X
the	B-X
pX	B-X
region	B-X
of	B-X
this	B-X
virus	B-X
may	B-X
act	B-X
as	B-X
a	B-X
transacting	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
gene	B-X
transcription	B-X
,	B-X
thus	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
constant	B-X
association	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
expression	B-X
with	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
-	B-X
I	B-X
infection	B-X
of	B-X
lymphoid	B-X
cells	B-X
<EOS>	B-X
Resting	B-X
T	B-X
-	B-X
cells	B-X
do	B-X
not	B-X
express	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
,	B-X
but	B-X
receptors	B-X
are	B-X
rapidly	B-X
expressed	B-X
on	B-X
T	B-X
-	B-X
cells	B-X
following	B-X
interaction	B-X
of	B-X
antigens	B-X
,	B-X
mitogens	B-X
,	B-X
or	B-X
monoclonal	B-X
antibodies	B-X
with	B-X
the	B-X
antigen	B-X
-	B-X
specific	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
complex	B-X
<EOS>	B-X
Normal	B-X
resting	B-X
T	B-X
-	B-X
cells	B-X
and	B-X
most	B-X
leukemic	B-X
T	B-X
-	B-X
cell	B-X
populations	B-X
do	B-X
not	B-X
express	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
;	B-X
however	B-X
,	B-X
the	B-X
leukemic	B-X
cells	B-X
of	B-X
the	B-X
11	B-X
patients	B-X
examined	B-X
who	B-X
had	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
-	B-X
associated	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
expressed	B-X
the	B-X
Tac	B-X
antigen	B-X
<EOS>	B-X
Using	B-X
anti	B-X
-	B-X
Tac	B-X
,	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
recognizes	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
,	B-X
the	B-X
receptor	B-X
has	B-X
been	B-X
purified	B-X
and	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
Mr	B-X
33,000	B-X
peptide	B-X
that	B-X
is	B-X
posttranslationally	B-X
glycosylated	B-X
to	B-X
a	B-X
Mr	B-X
55,000	B-X
mature	B-X
form	B-X

The	O
constant	O
expression	O
of	O
large	O
numbers	O
of	O
IL-2	B-protein
receptors	I-protein
which	O
may	O
be	O
aberrant	O
may	O
play	O
a	O
role	O
in	O
the	O
uncontrolled	O
growth	O
of	O
adult	B-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
constant	B-X
expression	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
which	B-X
may	B-X
be	B-X
aberrant	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
uncontrolled	B-X
growth	B-X
of	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
cells	B-X
<EOS>	B-X
The	B-X
constant	B-X
display	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
IL	B-X
2	B-X
receptors	B-X
that	B-X
may	B-X
be	B-X
aberrant	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
uncontrolled	B-X
growth	B-X
of	B-X
these	B-X
leukemic	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
constant	B-X
display	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
which	B-X
may	B-X
be	B-X
aberrant	B-X
in	B-X
the	B-X
ATL	B-X
cells	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
uncontrolled	B-X
growth	B-X
of	B-X
these	B-X
leukemic	B-X
T	B-X
cells	B-X
<EOS>	B-X
Interleukin	B-X
2	B-X
receptor	B-X
(	B-X
Tac	B-X
antigen	B-X
)	B-X
expression	B-X
in	B-X
HTLV	B-X
-	B-X
I	B-X
-	B-X
associated	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
.	B-X

Two	O
patients	O
with	O
Tac-positive	O
adult	O
T-cell	O
leukemia	O
have	O
been	O
treated	O
with	O
the	O
anti-Tac	B-protein
.	O
<EOS>	B-X
Two	B-X
patients	B-X
with	B-X
Tac	B-X
-	B-X
positive	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
have	B-X
been	B-X
treated	B-X
with	B-X
the	B-X
anti	B-X
-	B-X
Tac	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
patients	B-X
had	B-X
6	B-X
-	B-X
	B-X
and	B-X
3	B-X
-	B-X
mo	B-X
remissions	B-X
of	B-X
his	B-X
leukemia	B-X
following	B-X
two	B-X
courses	B-X
of	B-X
therapy	B-X
with	B-X
this	B-X
monoclonal	B-X
antibody	B-X
directed	B-X
toward	B-X
this	B-X
growth	B-X
factor	B-X
receptor	B-X
<EOS>	B-X
Resting	B-X
T	B-X
-	B-X
cells	B-X
do	B-X
not	B-X
express	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
,	B-X
but	B-X
receptors	B-X
are	B-X
rapidly	B-X
expressed	B-X
on	B-X
T	B-X
-	B-X
cells	B-X
following	B-X
interaction	B-X
of	B-X
antigens	B-X
,	B-X
mitogens	B-X
,	B-X
or	B-X
monoclonal	B-X
antibodies	B-X
with	B-X
the	B-X
antigen	B-X
-	B-X
specific	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
complex	B-X
<EOS>	B-X
The	B-X
constant	B-X
expression	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
receptors	B-X
which	B-X
may	B-X
be	B-X
aberrant	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
uncontrolled	B-X
growth	B-X
of	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
cells	B-X

One	O
of	O
the	O
patients	O
had	O
6-	O
and	O
3-mo	O
remissions	O
of	O
his	O
leukemia	O
following	O
two	O
courses	O
of	O
therapy	O
with	O
this	O
monoclonal	B-protein
antibody	I-protein
directed	O
toward	O
this	O
growth	B-protein
factor	I-protein
receptor	I-protein
.	O

Lymphocyte	B-cell_type
glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
depressed	O
patients	O
with	O
hypercortisolemia	O
.	O
<EOS>	B-X
Lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
depressed	B-X
patients	B-X
with	B-X
hypercortisolemia	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
compared	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
to	B-X
lymphocytes	B-X
from	B-X
normal	B-X
subjects	B-X
and	B-X
depressed	B-X
patients	B-X
with	B-X
hypercortisolemia	B-X
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
a	B-X
change	B-X
in	B-X
lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cortisol	B-X
excess	B-X
suggests	B-X
the	B-X
possibility	B-X
that	B-X
hypercortisolemia	B-X
in	B-X
depressive	B-X
illness	B-X
represents	B-X
a	B-X
state	B-X
of	B-X
peripheral	B-X
glucocorticoid	B-X
resistance	B-X
<EOS>	B-X
Lymphocytes	B-X
from	B-X
normal	B-X
subjects	B-X
had	B-X
a	B-X
mean	B-X
receptor	B-X
concentration	B-X
of	B-X
10	B-X

Despite	O
elevated	O
levels	O
of	O
serum	O
and	O
urinary	O
cortisol	O
,	O
patients	O
with	O
depressive	O
illness	O
manifest	O
none	O
of	O
the	O
clinical	O
stigmata	O
of	O
glucocorticoid	O
excess	O
.	O
<EOS>	B-X
Despite	B-X
elevated	B-X
levels	B-X
of	B-X
serum	B-X
and	B-X
urinary	B-X
cortisol	B-X
,	B-X
patients	B-X
with	B-X
depressive	B-X
illness	B-X
manifest	B-X
none	B-X
of	B-X
the	B-X
clinical	B-X
stigmata	B-X
of	B-X
glucocorticoid	B-X
excess	B-X
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
a	B-X
change	B-X
in	B-X
lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cortisol	B-X
excess	B-X
suggests	B-X
the	B-X
possibility	B-X
that	B-X
hypercortisolemia	B-X
in	B-X
depressive	B-X
illness	B-X
represents	B-X
a	B-X
state	B-X
of	B-X
peripheral	B-X
glucocorticoid	B-X
resistance	B-X
<EOS>	B-X
This	B-X
hypercortisolemia	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
effects	B-X
suggests	B-X
a	B-X
state	B-X
of	B-X
hormone	B-X
resistance	B-X
and	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
alterations	B-X
in	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
<EOS>	B-X
Lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
depressed	B-X
patients	B-X
with	B-X
hypercortisolemia	B-X
.	B-X

This	O
hypercortisolemia	O
in	O
the	O
absence	O
of	O
clinical	O
effects	O
suggests	O
a	O
state	O
of	O
hormone	O
resistance	O
and	O
could	O
be	O
mediated	O
by	O
alterations	O
in	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O
<EOS>	B-X
This	B-X
hypercortisolemia	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
effects	B-X
suggests	B-X
a	B-X
state	B-X
of	B-X
hormone	B-X
resistance	B-X
and	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
alterations	B-X
in	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
a	B-X
change	B-X
in	B-X
lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cortisol	B-X
excess	B-X
suggests	B-X
the	B-X
possibility	B-X
that	B-X
hypercortisolemia	B-X
in	B-X
depressive	B-X
illness	B-X
represents	B-X
a	B-X
state	B-X
of	B-X
peripheral	B-X
glucocorticoid	B-X
resistance	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
compared	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
to	B-X
lymphocytes	B-X
from	B-X
normal	B-X
subjects	B-X
and	B-X
depressed	B-X
patients	B-X
with	B-X
hypercortisolemia	B-X
<EOS>	B-X
Despite	B-X
elevated	B-X
levels	B-X
of	B-X
serum	B-X
and	B-X
urinary	B-X
cortisol	B-X
,	B-X
patients	B-X
with	B-X
depressive	B-X
illness	B-X
manifest	B-X
none	B-X
of	B-X
the	B-X
clinical	B-X
stigmata	B-X
of	B-X
glucocorticoid	B-X
excess	B-X

Earlier	O
studies	O
have	O
shown	O
that	O
small	O
doses	O
of	O
glucocorticoids	O
cause	O
a	O
decrease	O
in	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
normal	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

White	O
cells	O
from	O
depressed	O
patients	O
with	O
significant	O
hypercortisolemia	O
would	O
be	O
expected	O
to	O
show	O
a	O
similar	O
change	O
in	O
receptor	O
concentration	O
if	O
peripheral	O
tissues	O
are	O
adequately	O
exposed	O
to	O
and	O
sensitive	O
to	O
the	O
hormone	O
.	O

In	O
this	O
study	O
we	O
compared	O
the	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
to	O
lymphocytes	B-cell_type
from	O
normal	O
subjects	O
and	O
depressed	O
patients	O
with	O
hypercortisolemia	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
compared	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
to	B-X
lymphocytes	B-X
from	B-X
normal	B-X
subjects	B-X
and	B-X
depressed	B-X
patients	B-X
with	B-X
hypercortisolemia	B-X
<EOS>	B-X
75	B-X
fm	B-X
/	B-X
10	B-X
(	B-X
6	B-X
)	B-X
cells	B-X
,	B-X
which	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
from	B-X
that	B-X
in	B-X
lymphocytes	B-X
from	B-X
normal	B-X
subjects	B-X
or	B-X
from	B-X
depressed	B-X
subjects	B-X
with	B-X
normal	B-X
post	B-X
-	B-X
dexamethasone	B-X
cortisol	B-X
levels	B-X
(	B-X
9	B-X
<EOS>	B-X
Lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
depressed	B-X
patients	B-X
with	B-X
hypercortisolemia	B-X
.	B-X
<EOS>	B-X
This	B-X
hypercortisolemia	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
effects	B-X
suggests	B-X
a	B-X
state	B-X
of	B-X
hormone	B-X
resistance	B-X
and	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
alterations	B-X
in	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X

Lymphocytes	B-cell_type
from	O
normal	O
subjects	O
had	O
a	O
mean	O
receptor	O
concentration	O
of	O
10.2	O
+/-	O
0.66	O
fm/10	O
(	O
6	O
)	O
cells	O
(	O
S.E.M.	O
)	O
and	O
a	O
dissociation	O
constant	O
of	O
4.8	O
+/-	O
0.47	O
nM	O
.	O

Lymphocytes	B-cell_type
from	O
depressed	O
patients	O
with	O
abnormal	O
0800	O
h	O
serum	O
cortisol	O
after	O
dexamethasone	O
had	O
a	O
mean	O
receptor	O
concentration	O
of	O
8.8	O
+/-	O
0.75	O
fm/10	O
(	O
6	O
)	O
cells	O
,	O
which	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
lymphocytes	B-cell_type
from	O
normal	O
subjects	O
or	O
from	O
depressed	O
subjects	O
with	O
normal	O
post-dexamethasone	O
cortisol	O
levels	O
(	O
9.4	O
+/-	O
0.95	O
fm/10	O
(	O
6	O
)	O
cells	O
)	O
.	O

Lymphocytes	B-cell_type
from	O
depressed	O
patients	O
with	O
elevated	O
urinary	O
free	O
cortisol	O
excretion	O
(	O
UFC	O
)	O
also	O
had	O
normal	O
receptor	O
concentration	O
and	O
binding	O
affinity	O
for	O
dexamethasone	O
.	O
<EOS>	B-X
Lymphocytes	B-X
from	B-X
depressed	B-X
patients	B-X
with	B-X
elevated	B-X
urinary	B-X
free	B-X
cortisol	B-X
excretion	B-X
(	B-X
UFC	B-X
)	B-X
also	B-X
had	B-X
normal	B-X
receptor	B-X
concentration	B-X
and	B-X
binding	B-X
affinity	B-X
for	B-X
dexamethasone	B-X
<EOS>	B-X
Lymphocytes	B-X
from	B-X
depressed	B-X
patients	B-X
with	B-X
abnormal	B-X
0800	B-X
h	B-X
serum	B-X
cortisol	B-X
after	B-X
dexamethasone	B-X
had	B-X
a	B-X
mean	B-X
receptor	B-X
concentration	B-X
of	B-X
8	B-X
<EOS>	B-X
White	B-X
cells	B-X
from	B-X
depressed	B-X
patients	B-X
with	B-X
significant	B-X
hypercortisolemia	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
show	B-X
a	B-X
similar	B-X
change	B-X
in	B-X
receptor	B-X
concentration	B-X
if	B-X
peripheral	B-X
tissues	B-X
are	B-X
adequately	B-X
exposed	B-X
to	B-X
and	B-X
sensitive	B-X
to	B-X
the	B-X
hormone	B-X
<EOS>	B-X
Lymphocytes	B-X
from	B-X
normal	B-X
subjects	B-X
had	B-X
a	B-X
mean	B-X
receptor	B-X
concentration	B-X
of	B-X
10	B-X

The	O
lack	O
of	O
a	O
change	O
in	O
lymphocyte	B-cell_type
glucocorticoid	B-protein
receptor	I-protein
concentration	O
in	O
the	O
presence	O
of	O
cortisol	O
excess	O
suggests	O
the	O
possibility	O
that	O
hypercortisolemia	O
in	O
depressive	O
illness	O
represents	O
a	O
state	O
of	O
peripheral	O
glucocorticoid	O
resistance	O
.	O
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
a	B-X
change	B-X
in	B-X
lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cortisol	B-X
excess	B-X
suggests	B-X
the	B-X
possibility	B-X
that	B-X
hypercortisolemia	B-X
in	B-X
depressive	B-X
illness	B-X
represents	B-X
a	B-X
state	B-X
of	B-X
peripheral	B-X
glucocorticoid	B-X
resistance	B-X
<EOS>	B-X
This	B-X
hypercortisolemia	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
effects	B-X
suggests	B-X
a	B-X
state	B-X
of	B-X
hormone	B-X
resistance	B-X
and	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
alterations	B-X
in	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
<EOS>	B-X
Lymphocyte	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
depressed	B-X
patients	B-X
with	B-X
hypercortisolemia	B-X
.	B-X
<EOS>	B-X
Despite	B-X
elevated	B-X
levels	B-X
of	B-X
serum	B-X
and	B-X
urinary	B-X
cortisol	B-X
,	B-X
patients	B-X
with	B-X
depressive	B-X
illness	B-X
manifest	B-X
none	B-X
of	B-X
the	B-X
clinical	B-X
stigmata	B-X
of	B-X
glucocorticoid	B-X
excess	B-X

Structure	O
and	O
regulation	O
of	O
the	O
glucocorticoid	B-protein
hormone	I-protein
receptor	I-protein
.	O
<EOS>	B-X
Structural	B-X
basis	B-X
of	B-X
signaling	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
melanocortin	B-X
-	B-X
2	B-X
receptor	B-X
by	B-X
MRAP1	B-X
.	B-X
<EOS>	B-X
A	B-X
specialized	B-X
Hsp90	B-X
co	B-X
-	B-X
chaperone	B-X
network	B-X
regulates	B-X
steroid	B-X
hormone	B-X
receptor	B-X
response	B-X
to	B-X
ligand	B-X
.	B-X
<EOS>	B-X
Designing	B-X
Selective	B-X
Drug	B-X
-	B-X
like	B-X
Molecular	B-X
Glues	B-X
for	B-X
the	B-X
Glucocorticoid	B-X
Receptor	B-X
/	B-X
14	B-X
-	B-X
3	B-X
-	B-X
3	B-X
Protein	B-X
-	B-X
Protein	B-X
Interaction	B-X
.	B-X
<EOS>	B-X
The	B-X
molecular	B-X
structures	B-X
and	B-X
applications	B-X
of	B-X
the	B-X
isoforms	B-X
of	B-X
GR	B-X
have	B-X
been	B-X
intensively	B-X
researched	B-X
in	B-X
the	B-X
past	B-X
60	B-X
years	B-X

The	O
glucocorticoid	B-protein
receptor	I-protein
is	O
an	O
intracellular	B-protein
protein	I-protein
which	O
possesses	O
three	O
distinct	O
domains	O
,	O
one	O
that	O
binds	O
agonist	O
and	O
antagonist	O
steroids	O
,	O
one	O
that	O
binds	O
DNA	O
,	O
and	O
one	O
that	O
binds	O
anti-receptor	B-protein
antibodies	I-protein
and	O
is	O
required	O
for	O
glucocorticoid	O
modulation	O
of	O
gene	O
expression	O
.	O
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
is	B-X
an	B-X
intracellular	B-X
protein	B-X
which	B-X
possesses	B-X
three	B-X
distinct	B-X
domains	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
agonist	B-X
and	B-X
antagonist	B-X
steroids	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
DNA	B-X
,	B-X
and	B-X
one	B-X
that	B-X
binds	B-X
anti	B-X
-	B-X
receptor	B-X
antibodies	B-X
and	B-X
is	B-X
required	B-X
for	B-X
glucocorticoid	B-X
modulation	B-X
of	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Glucocorticoid	B-X
agonists	B-X
promote	B-X
the	B-X
'transformation	B-X
'	B-X
of	B-X
the	B-X
receptor	B-X
into	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
state	B-X
,	B-X
which	B-X
is	B-X
competent	B-X
for	B-X
modulating	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Glucocorticoid	B-X
antagonists	B-X
are	B-X
steroids	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
receptor	B-X
but	B-X
either	B-X
fail	B-X
to	B-X
produce	B-X
a	B-X
stable	B-X
complex	B-X
or	B-X
produce	B-X
a	B-X
stable	B-X
but	B-X
inefficient	B-X
complex	B-X
<EOS>	B-X
Although	B-X
substituent	B-X
groups	B-X
that	B-X
confer	B-X
agonist	B-X
or	B-X
antagonist	B-X
activity	B-X
to	B-X
the	B-X
steroid	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
molecular	B-X
determinants	B-X
of	B-X
this	B-X
difference	B-X
at	B-X
the	B-X
receptor	B-X
level	B-X
remain	B-X
unknown	B-X

In	O
intact	O
cells	O
,	O
receptor	O
number	O
,	O
affinity	O
and	O
activity	O
can	O
change	O
in	O
response	O
to	O
factors	O
that	O
bind	O
to	O
the	O
receptor	O
,	O
or	O
that	O
act	O
indirectly	O
through	O
ill-defined	O
mechanisms	O
which	O
may	O
include	O
resumption	O
or	O
arrest	O
of	O
cell	O
cycling	O
and	O
variations	O
in	O
intracellular	O
calcium	O
ion	O
concentrations	O
.	O
<EOS>	B-X
In	B-X
intact	B-X
cells	B-X
,	B-X
receptor	B-X
number	B-X
,	B-X
affinity	B-X
and	B-X
activity	B-X
can	B-X
change	B-X
in	B-X
response	B-X
to	B-X
factors	B-X
that	B-X
bind	B-X
to	B-X
the	B-X
receptor	B-X
,	B-X
or	B-X
that	B-X
act	B-X
indirectly	B-X
through	B-X
ill	B-X
-	B-X
defined	B-X
mechanisms	B-X
which	B-X
may	B-X
include	B-X
resumption	B-X
or	B-X
arrest	B-X
of	B-X
cell	B-X
cycling	B-X
and	B-X
variations	B-X
in	B-X
intracellular	B-X
calcium	B-X
ion	B-X
concentrations	B-X
<EOS>	B-X
Glucocorticoid	B-X
antagonists	B-X
are	B-X
steroids	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
receptor	B-X
but	B-X
either	B-X
fail	B-X
to	B-X
produce	B-X
a	B-X
stable	B-X
complex	B-X
or	B-X
produce	B-X
a	B-X
stable	B-X
but	B-X
inefficient	B-X
complex	B-X
<EOS>	B-X
Some	B-X
of	B-X
these	B-X
factors	B-X
appear	B-X
to	B-X
exert	B-X
their	B-X
effect	B-X
by	B-X
controlling	B-X
critical	B-X
receptor	B-X
properties	B-X
such	B-X
as	B-X
ATP	B-X
-	B-X
dependent	B-X
phosphorylation	B-X
,	B-X
integrity	B-X
of	B-X
thiol	B-X
groups	B-X
,	B-X
and	B-X
exposure	B-X
of	B-X
key	B-X
amino	B-X
acid	B-X
residues	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
recent	B-X
finding	B-X
that	B-X
the	B-X
pHi	B-X
increase	B-X
at	B-X
fertilization	B-X
in	B-X
Xenopus	B-X
eggs	B-X
is	B-X
a	B-X
propagating	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
	B-X
-	B-X
dependent	B-X
pH	B-X
wave	B-X
which	B-X
closely	B-X
follows	B-X
the	B-X
Ca2+	B-X
wave	B-X
,	B-X
together	B-X
with	B-X
the	B-X
absence	B-X
in	B-X
the	B-X
egg	B-X
plasma	B-X
membrane	B-X
of	B-X
pHi	B-X
-	B-X
regulating	B-X
systems	B-X
responsible	B-X
for	B-X
that	B-X
pHi	B-X
increase	B-X
,	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
cortical	B-X
or	B-X
subcortical	B-X
vesicles	B-X
acidifying	B-X
in	B-X
the	B-X
wake	B-X
of	B-X
the	B-X
Ca2+	B-X
wave	B-X
,	B-X
thus	B-X
producing	B-X
the	B-X
pH	B-X
wave	B-X

Some	O
of	O
these	O
factors	O
appear	O
to	O
exert	O
their	O
effect	O
by	O
controlling	O
critical	O
receptor	O
properties	O
such	O
as	O
ATP-dependent	O
phosphorylation	O
,	O
integrity	O
of	O
thiol	B-protein
groups	I-protein
,	O
and	O
exposure	O
of	O
key	B-protein
amino	I-protein
acid	I-protein
residues	I-protein
.	O
<EOS>	B-X
Some	B-X
of	B-X
these	B-X
factors	B-X
appear	B-X
to	B-X
exert	B-X
their	B-X
effect	B-X
by	B-X
controlling	B-X
critical	B-X
receptor	B-X
properties	B-X
such	B-X
as	B-X
ATP	B-X
-	B-X
dependent	B-X
phosphorylation	B-X
,	B-X
integrity	B-X
of	B-X
thiol	B-X
groups	B-X
,	B-X
and	B-X
exposure	B-X
of	B-X
key	B-X
amino	B-X
acid	B-X
residues	B-X
<EOS>	B-X
Glucocorticoid	B-X
agonists	B-X
promote	B-X
the	B-X
'transformation	B-X
'	B-X
of	B-X
the	B-X
receptor	B-X
into	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
state	B-X
,	B-X
which	B-X
is	B-X
competent	B-X
for	B-X
modulating	B-X
gene	B-X
expression	B-X
<EOS>	B-X
The	B-X
active	B-X
free	B-X
receptor	B-X
is	B-X
phosphorylated	B-X
,	B-X
reduced	B-X
,	B-X
and	B-X
presumably	B-X
oligomeric	B-X
(	B-X
state	B-X
A	B-X
)	B-X
<EOS>	B-X
Following	B-X
binding	B-X
of	B-X
an	B-X
agonist	B-X
(	B-X
state	B-X
B	B-X
)	B-X
,	B-X
it	B-X
can	B-X
become	B-X
transformed	B-X
by	B-X
dissociation	B-X
into	B-X
its	B-X
subunits	B-X
and	B-X
dephosphorylation	B-X
(	B-X
state	B-X
C	B-X
)	B-X

Glucocorticoid	O
agonists	O
promote	O
the	O
'transformation	O
'	O
of	O
the	O
receptor	O
into	O
the	O
DNA-binding	O
state	O
,	O
which	O
is	O
competent	O
for	O
modulating	O
gene	O
expression	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
agonists	B-X
promote	B-X
the	B-X
'transformation	B-X
'	B-X
of	B-X
the	B-X
receptor	B-X
into	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
state	B-X
,	B-X
which	B-X
is	B-X
competent	B-X
for	B-X
modulating	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Glucocorticoid	B-X
antagonists	B-X
are	B-X
steroids	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
receptor	B-X
but	B-X
either	B-X
fail	B-X
to	B-X
produce	B-X
a	B-X
stable	B-X
complex	B-X
or	B-X
produce	B-X
a	B-X
stable	B-X
but	B-X
inefficient	B-X
complex	B-X
<EOS>	B-X
Reduction	B-X
and	B-X
rephosphorylation	B-X
of	B-X
the	B-X
receptor	B-X
enable	B-X
it	B-X
to	B-X
bind	B-X
steroids	B-X
again	B-X
so	B-X
that	B-X
the	B-X
cycle	B-X
is	B-X
closed	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
is	B-X
an	B-X
intracellular	B-X
protein	B-X
which	B-X
possesses	B-X
three	B-X
distinct	B-X
domains	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
agonist	B-X
and	B-X
antagonist	B-X
steroids	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
DNA	B-X
,	B-X
and	B-X
one	B-X
that	B-X
binds	B-X
anti	B-X
-	B-X
receptor	B-X
antibodies	B-X
and	B-X
is	B-X
required	B-X
for	B-X
glucocorticoid	B-X
modulation	B-X
of	B-X
gene	B-X
expression	B-X

Glucocorticoid	O
antagonists	O
are	O
steroids	O
that	O
interact	O
with	O
the	O
receptor	O
but	O
either	O
fail	O
to	O
produce	O
a	O
stable	B-protein
complex	I-protein
or	O
produce	O
a	O
stable	B-protein
but	I-protein
inefficient	I-protein
complex	I-protein
.	O
<EOS>	B-X
As	B-X
a	B-X
first	B-X
step	B-X
in	B-X
evaluating	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
use	B-X
of	B-X
the	B-X
alternative	B-X
cofactor	B-X
could	B-X
make	B-X
the	B-X
RNR	B-X
more	B-X
robust	B-X
to	B-X
reactive	B-X
oxygen	B-X
and	B-X
nitrogen	B-X
species	B-X
[	B-X
RO	B-X
(	B-X
N	B-X
)	B-X
S	B-X
]	B-X
produced	B-X
by	B-X
the	B-X
host	B-X
's	B-X
immune	B-X
system	B-X
[	B-X
Högbom	B-X
,	B-X
M	B-X
<EOS>	B-X
As	B-X
previously	B-X
observed	B-X
,	B-X
the	B-X
intermediate	B-X
decays	B-X
by	B-X
reduction	B-X
of	B-X
the	B-X
Fe	B-X
site	B-X
to	B-X
the	B-X
active	B-X
Mn	B-X
(	B-X
IV	B-X
)	B-X
	B-X
/	B-X
Fe	B-X
(	B-X
III	B-X
)	B-X
	B-X
-	B-X
R2	B-X
complex	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
pulse	B-X
-	B-X
chase	B-X
stable	B-X
isotope	B-X
labeling	B-X
with	B-X
amino	B-X
acids	B-X
in	B-X
cell	B-X
culture	B-X
(	B-X
SILAC	B-X
)	B-X
is	B-X
a	B-X
valuable	B-X
technique	B-X
to	B-X
study	B-X
RC	B-X
assembly	B-X
because	B-X
it	B-X
can	B-X
reveal	B-X
considerable	B-X
differences	B-X
in	B-X
the	B-X
assembly	B-X
rates	B-X
and	B-X
efficiencies	B-X
of	B-X
the	B-X
different	B-X
complexes	B-X
<EOS>	B-X
Quantitative	B-X
phosphoproteomic	B-X
analysis	B-X
of	B-X
T	B-X
cell	B-X
receptor	B-X
signaling	B-X
in	B-X
diabetes	B-X
prone	B-X
and	B-X
resistant	B-X
mice	B-X
.	B-X

Although	O
substituent	O
groups	O
that	O
confer	O
agonist	O
or	O
antagonist	O
activity	O
to	O
the	O
steroid	O
have	O
been	O
identified	O
,	O
the	O
molecular	O
determinants	O
of	O
this	O
difference	O
at	O
the	O
receptor	O
level	O
remain	O
unknown	O
.	O
<EOS>	B-X
Although	B-X
substituent	B-X
groups	B-X
that	B-X
confer	B-X
agonist	B-X
or	B-X
antagonist	B-X
activity	B-X
to	B-X
the	B-X
steroid	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
molecular	B-X
determinants	B-X
of	B-X
this	B-X
difference	B-X
at	B-X
the	B-X
receptor	B-X
level	B-X
remain	B-X
unknown	B-X
<EOS>	B-X
However	B-X
,	B-X
para	B-X
-	B-X
substitution	B-X
with	B-X
strong	B-X
electron	B-X
withdrawing	B-X
properties	B-X
on	B-X
the	B-X
5'	B-X
-	B-X
aryl	B-X
extension	B-X
is	B-X
important	B-X
for	B-X
antagonist	B-X
activity	B-X
,	B-X
and	B-X
antagonist	B-X
potency	B-X
-	B-X
but	B-X
not	B-X
ligand	B-X
receptor	B-X
binding	B-X
-	B-X
was	B-X
found	B-X
to	B-X
correlate	B-X
linearly	B-X
with	B-X
the	B-X
sigma	B-X
values	B-X
for	B-X
the	B-X
electron	B-X
withdrawing	B-X
substituents	B-X
<EOS>	B-X
Directed	B-X
screening	B-X
of	B-X
compounds	B-X
selected	B-X
from	B-X
the	B-X
Glaxo	B-X
registry	B-X
file	B-X
for	B-X
contractile	B-X
activity	B-X
on	B-X
the	B-X
isolated	B-X
guinea	B-X
pig	B-X
gallbladder	B-X
(	B-X
GPGB	B-X
)	B-X
identified	B-X
a	B-X
series	B-X
of	B-X
1,5	B-X
-	B-X
benzodiazepines	B-X
with	B-X
peripheral	B-X
cholecystokinin	B-X
(	B-X
CCK	B-X
)	B-X
receptor	B-X
agonist	B-X
activity	B-X
<EOS>	B-X
The	B-X
mineralocorticoid	B-X
activity	B-X
of	B-X
progesterone	B-X
derivatives	B-X
depends	B-X
on	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
C18	B-X
substituent	B-X
.	B-X

Most	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
on	O
receptor	O
regulation	O
can	O
be	O
accommodated	O
by	O
postulating	O
the	O
existence	O
of	O
an	O
intracellular	O
cycle	O
that	O
involves	O
five	O
states	O
of	O
the	O
receptor	O
.	O
<EOS>	B-X
Most	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
data	B-X
on	B-X
receptor	B-X
regulation	B-X
can	B-X
be	B-X
accommodated	B-X
by	B-X
postulating	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
intracellular	B-X
cycle	B-X
that	B-X
involves	B-X
five	B-X
states	B-X
of	B-X
the	B-X
receptor	B-X
<EOS>	B-X
Reduction	B-X
and	B-X
rephosphorylation	B-X
of	B-X
the	B-X
receptor	B-X
enable	B-X
it	B-X
to	B-X
bind	B-X
steroids	B-X
again	B-X
so	B-X
that	B-X
the	B-X
cycle	B-X
is	B-X
closed	B-X
<EOS>	B-X
Following	B-X
binding	B-X
of	B-X
an	B-X
agonist	B-X
(	B-X
state	B-X
B	B-X
)	B-X
,	B-X
it	B-X
can	B-X
become	B-X
transformed	B-X
by	B-X
dissociation	B-X
into	B-X
its	B-X
subunits	B-X
and	B-X
dephosphorylation	B-X
(	B-X
state	B-X
C	B-X
)	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
is	B-X
an	B-X
intracellular	B-X
protein	B-X
which	B-X
possesses	B-X
three	B-X
distinct	B-X
domains	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
agonist	B-X
and	B-X
antagonist	B-X
steroids	B-X
,	B-X
one	B-X
that	B-X
binds	B-X
DNA	B-X
,	B-X
and	B-X
one	B-X
that	B-X
binds	B-X
anti	B-X
-	B-X
receptor	B-X
antibodies	B-X
and	B-X
is	B-X
required	B-X
for	B-X
glucocorticoid	B-X
modulation	B-X
of	B-X
gene	B-X
expression	B-X

The	O
active	O
free	O
receptor	O
is	O
phosphorylated	O
,	O
reduced	O
,	O
and	O
presumably	O
oligomeric	O
(	O
state	O
A	O
)	O
.	O

Following	O
binding	O
of	O
an	O
agonist	O
(	O
state	O
B	O
)	O
,	O
it	O
can	O
become	O
transformed	O
by	O
dissociation	O
into	O
its	O
subunits	O
and	O
dephosphorylation	O
(	O
state	O
C	O
)	O
.	O

The	O
transformed	B-protein
receptor	I-protein
then	O
interacts	O
with	O
chromatin	B-DNA
(	O
state	O
D	O
)	O
.	O

Dissociation	O
of	O
the	O
steroid	O
and	O
oxidation	O
of	O
receptor	B-protein
thiol	I-protein
group	I-protein
(	O
s	O
)	O
lead	O
to	O
the	O
inactive	O
receptor	O
form	O
(	O
state	O
E	O
)	O
.	O

Reduction	O
and	O
rephosphorylation	O
of	O
the	O
receptor	O
enable	O
it	O
to	O
bind	O
steroids	O
again	O
so	O
that	O
the	O
cycle	O
is	O
closed	O
.	O
<EOS>	B-X
Reduction	B-X
and	B-X
rephosphorylation	B-X
of	B-X
the	B-X
receptor	B-X
enable	B-X
it	B-X
to	B-X
bind	B-X
steroids	B-X
again	B-X
so	B-X
that	B-X
the	B-X
cycle	B-X
is	B-X
closed	B-X
<EOS>	B-X
Glucocorticoid	B-X
agonists	B-X
promote	B-X
the	B-X
'transformation	B-X
'	B-X
of	B-X
the	B-X
receptor	B-X
into	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
state	B-X
,	B-X
which	B-X
is	B-X
competent	B-X
for	B-X
modulating	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Structure	B-X
and	B-X
regulation	B-X
of	B-X
the	B-X
glucocorticoid	B-X
hormone	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
antagonists	B-X
are	B-X
steroids	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
receptor	B-X
but	B-X
either	B-X
fail	B-X
to	B-X
produce	B-X
a	B-X
stable	B-X
complex	B-X
or	B-X
produce	B-X
a	B-X
stable	B-X
but	B-X
inefficient	B-X
complex	B-X

Thermodynamics	O
of	O
steroid	O
binding	O
to	O
the	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
.	O

The	O
thermodynamics	O
of	O
the	O
interaction	O
of	O
glucocorticoids	O
with	O
their	O
receptor	O
were	O
studied	O
in	O
cytosol	O
from	O
human	B-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
thermodynamics	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
glucocorticoids	B-X
with	B-X
their	B-X
receptor	B-X
were	B-X
studied	B-X
in	B-X
cytosol	B-X
from	B-X
human	B-X
lymphoblastoid	B-X
cells	B-X
<EOS>	B-X
Thermodynamics	B-X
of	B-X
steroid	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Thermodynamic	B-X
values	B-X
for	B-X
the	B-X
transition	B-X
state	B-X
were	B-X
calculated	B-X
from	B-X
the	B-X
rate	B-X
constants	B-X
<EOS>	B-X
The	B-X
rate	B-X
and	B-X
affinity	B-X
constants	B-X
of	B-X
dexamethasone	B-X
and	B-X
cortisol	B-X
between	B-X
0	B-X
degree	B-X
and	B-X
25	B-X
degrees	B-X
C	B-X
were	B-X
calculated	B-X
by	B-X
curve	B-X
-	B-X
fitting	B-X
from	B-X
time	B-X
-	B-X
course	B-X
and	B-X
equilibrium	B-X
kinetics	B-X

The	O
rate	O
and	O
affinity	O
constants	O
of	O
dexamethasone	O
and	O
cortisol	O
between	O
0	O
degree	O
and	O
25	O
degrees	O
C	O
were	O
calculated	O
by	O
curve-fitting	O
from	O
time-course	O
and	O
equilibrium	O
kinetics	O
.	O

The	O
data	O
were	O
consistent	O
with	O
a	O
simple	O
reversible	O
bimolecular	O
interaction	O
.	O
<EOS>	B-X
The	B-X
data	B-X
were	B-X
consistent	B-X
with	B-X
a	B-X
simple	B-X
reversible	B-X
bimolecular	B-X
interaction	B-X
<EOS>	B-X
Beta	B-X
nerve	B-X
growth	B-X
factor	B-X
binding	B-X
to	B-X
PC12	B-X
cells	B-X
.	B-X
Association	B-X
kinetics	B-X
and	B-X
cooperative	B-X
interactions	B-X
.	B-X
<EOS>	B-X
Computer	B-X
-	B-X
assisted	B-X
analysis	B-X
of	B-X
kinetic	B-X
data	B-X
revealed	B-X
association	B-X
and	B-X
dissociation	B-X
time	B-X
courses	B-X
consistent	B-X
with	B-X
a	B-X
simple	B-X
bimolecular	B-X
reaction	B-X
<EOS>	B-X
The	B-X
studies	B-X
presented	B-X
here	B-X
indicate	B-X
that	B-X
their	B-X
interactions	B-X
are	B-X
more	B-X
complex	B-X
than	B-X
previously	B-X
described	B-X

Arrhenius	O
and	O
Va	O
n't	O
Hoff	O
plots	O
were	O
curvilinear	O
for	O
both	O
steroids	O
.	O

At	O
equilibrium	O
,	O
the	O
solution	O
for	O
the	O
equation	O
delta	O
G	O
=	O
delta	O
H	O
-	O
T	O
X	O
delta	O
S	O
(	O
eqn.	O
1	O
)	O
was	O
(	O
in	O
kJ	O
X	O
mol-1	O
)	O
-47	O
=	O
36	O
-	O
83	O
(	O
dexamethasone	O
)	O
and	O
-42	O
=	O
-9	O
-	O
33	O
(	O
cortisol	O
)	O
at	O
0	O
degree	O
C	O
.	O

Enthalpy	O
and	O
entropy	O
changes	O
decreased	O
quasi-linearly	O
with	O
temperature	O
such	O
that	O
,	O
at	O
25	O
degrees	O
C	O
,	O
the	O
respective	O
values	O
were	O
-50	O
=	O
-75	O
+	O
25	O
and	O
-43	O
=	O
-48	O
+	O
5	O
.	O
<EOS>	B-X
Enthalpy	B-X
and	B-X
entropy	B-X
changes	B-X
decreased	B-X
quasi	B-X
-	B-X
linearly	B-X
with	B-X
temperature	B-X
such	B-X
that	B-X
,	B-X
at	B-X
25	B-X
degrees	B-X
C	B-X
,	B-X
the	B-X
respective	B-X
values	B-X
were	B-X
	B-X
-	B-X
50	B-X
=	B-X
	B-X
-	B-X
75	B-X
+	B-X
25	B-X
and	B-X
	B-X
-	B-X
43	B-X
=	B-X
	B-X
-	B-X
48	B-X
+	B-X
5	B-X
<EOS>	B-X
The	B-X
rate	B-X
and	B-X
affinity	B-X
constants	B-X
of	B-X
dexamethasone	B-X
and	B-X
cortisol	B-X
between	B-X
0	B-X
degree	B-X
and	B-X
25	B-X
degrees	B-X
C	B-X
were	B-X
calculated	B-X
by	B-X
curve	B-X
-	B-X
fitting	B-X
from	B-X
time	B-X
-	B-X
course	B-X
and	B-X
equilibrium	B-X
kinetics	B-X
<EOS>	B-X
Thermodynamic	B-X
values	B-X
for	B-X
the	B-X
transition	B-X
state	B-X
were	B-X
calculated	B-X
from	B-X
the	B-X
rate	B-X
constants	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
this	B-X
model	B-X
,	B-X
an	B-X
analysis	B-X
of	B-X
the	B-X
transition	B-X
-	B-X
state	B-X
thermodynamics	B-X
led	B-X
to	B-X
the	B-X
conclusion	B-X
that	B-X
no	B-X
more	B-X
than	B-X
half	B-X
of	B-X
the	B-X
steroid	B-X
molecular	B-X
area	B-X
is	B-X
engaged	B-X
in	B-X
the	B-X
binding	B-X
process	B-X

Thus	O
,	O
for	O
both	O
steroids	O
,	O
the	O
interaction	O
was	O
entropy-driven	O
at	O
low	O
temperature	O
and	O
became	O
entirely	O
enthalpy-driven	O
at	O
20	O
degrees	O
C	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
for	B-X
both	B-X
steroids	B-X
,	B-X
the	B-X
interaction	B-X
was	B-X
entropy	B-X
-	B-X
driven	B-X
at	B-X
low	B-X
temperature	B-X
and	B-X
became	B-X
entirely	B-X
enthalpy	B-X
-	B-X
driven	B-X
at	B-X
20	B-X
degrees	B-X
C	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
this	B-X
model	B-X
,	B-X
an	B-X
analysis	B-X
of	B-X
the	B-X
transition	B-X
-	B-X
state	B-X
thermodynamics	B-X
led	B-X
to	B-X
the	B-X
conclusion	B-X
that	B-X
no	B-X
more	B-X
than	B-X
half	B-X
of	B-X
the	B-X
steroid	B-X
molecular	B-X
area	B-X
is	B-X
engaged	B-X
in	B-X
the	B-X
binding	B-X
process	B-X
<EOS>	B-X
At	B-X
equilibrium	B-X
,	B-X
the	B-X
solution	B-X
for	B-X
the	B-X
equation	B-X
delta	B-X
G	B-X
=	B-X
delta	B-X
H	B-X
	B-X
-	B-X
	B-X
T	B-X
X	B-X
delta	B-X
S	B-X
(	B-X
eqn	B-X
<EOS>	B-X
The	B-X
thermodynamics	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
glucocorticoids	B-X
with	B-X
their	B-X
receptor	B-X
were	B-X
studied	B-X
in	B-X
cytosol	B-X
from	B-X
human	B-X
lymphoblastoid	B-X
cells	B-X

Thermodynamic	O
values	O
for	O
the	O
transition	O
state	O
were	O
calculated	O
from	O
the	O
rate	O
constants	O
.	O
<EOS>	B-X
The	B-X
defining	B-X
property	B-X
of	B-X
enzyme	B-X
catalysts	B-X
is	B-X
their	B-X
specificity	B-X
for	B-X
binding	B-X
the	B-X
transition	B-X
state	B-X
with	B-X
a	B-X
much	B-X
higher	B-X
affinity	B-X
than	B-X
the	B-X
substrate	B-X
<EOS>	B-X
Ab	B-X
initio	B-X
method	B-X
and	B-X
canonical	B-X
variational	B-X
transition	B-X
-	B-X
state	B-X
theory	B-X
are	B-X
employed	B-X
to	B-X
study	B-X
the	B-X
kinetic	B-X
nature	B-X
of	B-X
hydrogen	B-X
abstraction	B-X
reactions	B-X
of	B-X
CH	B-X
<EOS>	B-X
Four	B-X
reaction	B-X
pathways	B-X
were	B-X
identified	B-X
for	B-X
the	B-X
initial	B-X
reaction	B-X
<EOS>	B-X
A	B-X
Systematic	B-X
Theoretical	B-X
Kinetics	B-X
Analysis	B-X
for	B-X
the	B-X
Waddington	B-X
Mechanism	B-X
in	B-X
the	B-X
Low	B-X
-	B-X
Temperature	B-X
Oxidation	B-X
of	B-X
Butene	B-X
and	B-X
Butanol	B-X
Isomers	B-X
.	B-X

For	O
the	O
forward	O
reaction	O
,	O
eqn.	O
(	O
1	O
)	O
gave	O
45	O
=	O
84	O
-	O
39	O
(	O
dexamethasone	O
)	O
and	O
46	O
=	O
60	O
-	O
14	O
(	O
cortisol	O
)	O
at	O
0	O
degree	O
C	O
,	O
and	O
44	O
=	O
24	O
+	O
20	O
(	O
dexamethasone	O
)	O
and	O
46	O
=	O
28	O
+	O
18	O
(	O
cortisol	O
)	O
at	O
25	O
degrees	O
C	O
.	O

These	O
data	O
fit	O
quite	O
well	O
with	O
a	O
two-step	O
model	O
[	O
Ross	O
&	O
Subramanian	O
(	O
1981	O
)	O
Biochemistry	O
20	O
,	O
3096-3102	O
]	O
proposed	O
for	O
ligand-protein	O
interactions	O
,	O
which	O
involves	O
a	O
partial	O
immobilization	O
of	O
the	O
reacting	O
species	O
governed	O
by	O
hydrophobic	O
forces	O
,	O
followed	O
by	O
stabilization	O
of	O
the	O
complex	O
by	O
short-range	O
interactions	O
.	O
<EOS>	B-X
These	B-X
data	B-X
fit	B-X
quite	B-X
well	B-X
with	B-X
a	B-X
two	B-X
-	B-X
step	B-X
model	B-X
[	B-X
Ross	B-X
&	B-X
Subramanian	B-X
(	B-X
1981	B-X
)	B-X
Biochemistry	B-X
20	B-X
,	B-X
3096	B-X
-	B-X
3102	B-X
]	B-X
proposed	B-X
for	B-X
ligand	B-X
-	B-X
protein	B-X
interactions	B-X
,	B-X
which	B-X
involves	B-X
a	B-X
partial	B-X
immobilization	B-X
of	B-X
the	B-X
reacting	B-X
species	B-X
governed	B-X
by	B-X
hydrophobic	B-X
forces	B-X
,	B-X
followed	B-X
by	B-X
stabilization	B-X
of	B-X
the	B-X
complex	B-X
by	B-X
short	B-X
-	B-X
range	B-X
interactions	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
this	B-X
model	B-X
,	B-X
an	B-X
analysis	B-X
of	B-X
the	B-X
transition	B-X
-	B-X
state	B-X
thermodynamics	B-X
led	B-X
to	B-X
the	B-X
conclusion	B-X
that	B-X
no	B-X
more	B-X
than	B-X
half	B-X
of	B-X
the	B-X
steroid	B-X
molecular	B-X
area	B-X
is	B-X
engaged	B-X
in	B-X
the	B-X
binding	B-X
process	B-X
<EOS>	B-X
The	B-X
rate	B-X
and	B-X
affinity	B-X
constants	B-X
of	B-X
dexamethasone	B-X
and	B-X
cortisol	B-X
between	B-X
0	B-X
degree	B-X
and	B-X
25	B-X
degrees	B-X
C	B-X
were	B-X
calculated	B-X
by	B-X
curve	B-X
-	B-X
fitting	B-X
from	B-X
time	B-X
-	B-X
course	B-X
and	B-X
equilibrium	B-X
kinetics	B-X
<EOS>	B-X
The	B-X
thermodynamics	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
glucocorticoids	B-X
with	B-X
their	B-X
receptor	B-X
were	B-X
studied	B-X
in	B-X
cytosol	B-X
from	B-X
human	B-X
lymphoblastoid	B-X
cells	B-X

On	O
the	O
basis	O
of	O
this	O
model	O
,	O
an	O
analysis	O
of	O
the	O
transition-state	O
thermodynamics	O
led	O
to	O
the	O
conclusion	O
that	O
no	O
more	O
than	O
half	O
of	O
the	O
steroid	O
molecular	O
area	O
is	O
engaged	O
in	O
the	O
binding	O
process	O
.	O

Cell	O
cycle-related	O
changes	O
in	O
number	O
of	O
T-lymphocyte	B-protein
receptors	I-protein
for	O
glucocorticoids	O
and	O
insulin	O
.	O
<EOS>	B-X
Cell	B-X
cycle	B-X
-	B-X
related	B-X
changes	B-X
in	B-X
number	B-X
of	B-X
T	B-X
-	B-X
lymphocyte	B-X
receptors	B-X
for	B-X
glucocorticoids	B-X
and	B-X
insulin	B-X
.	B-X
<EOS>	B-X
Few	B-X
but	B-X
significant	B-X
numbers	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
2700	B-X
/	B-X
cell	B-X
)	B-X
and	B-X
no	B-X
insulin	B-X
receptors	B-X
(	B-X
	B-X
-	B-X
1	B-X
/	B-X
cell	B-X
)	B-X
were	B-X
found	B-X
in	B-X
the	B-X
resting	B-X
(	B-X
G0	B-X
)	B-X
phase	B-X
<EOS>	B-X
Enriched	B-X
human	B-X
peripheral	B-X
T	B-X
-	B-X
lymphocytes	B-X
were	B-X
stimulated	B-X
with	B-X
PHA	B-X
and	B-X
examined	B-X
for	B-X
variations	B-X
in	B-X
insulin	B-X
and	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
numbers	B-X
during	B-X
the	B-X
early	B-X
phases	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
As	B-X
cells	B-X
entered	B-X
the	B-X
G1a	B-X
phase	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
increased	B-X
and	B-X
of	B-X
insulin	B-X
took	B-X
place	B-X

Enriched	O
human	B-cell_type
peripheral	I-cell_type
T-lymphocytes	I-cell_type
were	O
stimulated	O
with	O
PHA	O
and	O
examined	O
for	O
variations	O
in	O
insulin	O
and	O
glucocorticoid	O
(	O
dexamethasone	O
)	O
receptor	O
numbers	O
during	O
the	O
early	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O
<EOS>	B-X
Enriched	B-X
human	B-X
peripheral	B-X
T	B-X
-	B-X
lymphocytes	B-X
were	B-X
stimulated	B-X
with	B-X
PHA	B-X
and	B-X
examined	B-X
for	B-X
variations	B-X
in	B-X
insulin	B-X
and	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
numbers	B-X
during	B-X
the	B-X
early	B-X
phases	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
Cells	B-X
in	B-X
G0	B-X
,	B-X
G1a	B-X
and	B-X
G1b	B-X
phases	B-X
,	B-X
where	B-X
the	B-X
G1a	B-X
	B-X
-	B-X
	B-X
G1b	B-X
transition	B-X
is	B-X
an	B-X
Interleukin	B-X
2	B-X
dependent	B-X
event	B-X
,	B-X
were	B-X
quantitated	B-X
by	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
As	B-X
cells	B-X
entered	B-X
the	B-X
G1a	B-X
phase	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
increased	B-X
and	B-X
of	B-X
insulin	B-X
took	B-X
place	B-X
<EOS>	B-X
Although	B-X
the	B-X
specific	B-X
binding	B-X
further	B-X
increased	B-X
as	B-X
T	B-X
-	B-X
cells	B-X
entered	B-X
the	B-X
G1b	B-X
phase	B-X
(	B-X
as	B-X
measured	B-X
at	B-X
44	B-X
h	B-X
of	B-X
incubation	B-X
and	B-X
using	B-X
hydroxyurea	B-X
-	B-X
treated	B-X
cells	B-X
)	B-X
,	B-X
the	B-X
major	B-X
changes	B-X
in	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
took	B-X
place	B-X
during	B-X
the	B-X
period	B-X
16	B-X
	B-X
-	B-X
	B-X
20	B-X
h	B-X
after	B-X
stimulation	B-X

Cells	O
in	O
G0	O
,	O
G1a	O
and	O
G1b	O
phases	O
,	O
where	O
the	O
G1a	O
-	O
G1b	O
transition	O
is	O
an	O
Interleukin	B-protein
2	I-protein
dependent	O
event	O
,	O
were	O
quantitated	O
by	O
flow	O
cytometry	O
.	O
<EOS>	B-X
Cells	B-X
in	B-X
G0	B-X
,	B-X
G1a	B-X
and	B-X
G1b	B-X
phases	B-X
,	B-X
where	B-X
the	B-X
G1a	B-X
	B-X
-	B-X
	B-X
G1b	B-X
transition	B-X
is	B-X
an	B-X
Interleukin	B-X
2	B-X
dependent	B-X
event	B-X
,	B-X
were	B-X
quantitated	B-X
by	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
As	B-X
cells	B-X
entered	B-X
the	B-X
G1a	B-X
phase	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
increased	B-X
and	B-X
of	B-X
insulin	B-X
took	B-X
place	B-X
<EOS>	B-X
Enriched	B-X
human	B-X
peripheral	B-X
T	B-X
-	B-X
lymphocytes	B-X
were	B-X
stimulated	B-X
with	B-X
PHA	B-X
and	B-X
examined	B-X
for	B-X
variations	B-X
in	B-X
insulin	B-X
and	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
numbers	B-X
during	B-X
the	B-X
early	B-X
phases	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
Although	B-X
the	B-X
specific	B-X
binding	B-X
further	B-X
increased	B-X
as	B-X
T	B-X
-	B-X
cells	B-X
entered	B-X
the	B-X
G1b	B-X
phase	B-X
(	B-X
as	B-X
measured	B-X
at	B-X
44	B-X
h	B-X
of	B-X
incubation	B-X
and	B-X
using	B-X
hydroxyurea	B-X
-	B-X
treated	B-X
cells	B-X
)	B-X
,	B-X
the	B-X
major	B-X
changes	B-X
in	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
took	B-X
place	B-X
during	B-X
the	B-X
period	B-X
16	B-X
	B-X
-	B-X
	B-X
20	B-X
h	B-X
after	B-X
stimulation	B-X

Few	O
but	O
significant	O
numbers	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
2700/cell	O
)	O
and	O
no	O
insulin	B-protein
receptors	I-protein
(	O
-1/cell	O
)	O
were	O
found	O
in	O
the	O
resting	O
(	O
G0	O
)	O
phase	O
.	O
<EOS>	B-X
Few	B-X
but	B-X
significant	B-X
numbers	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
2700	B-X
/	B-X
cell	B-X
)	B-X
and	B-X
no	B-X
insulin	B-X
receptors	B-X
(	B-X
	B-X
-	B-X
1	B-X
/	B-X
cell	B-X
)	B-X
were	B-X
found	B-X
in	B-X
the	B-X
resting	B-X
(	B-X
G0	B-X
)	B-X
phase	B-X
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
findings	B-X
,	B-X
it	B-X
is	B-X
concluded	B-X
that	B-X
both	B-X
receptor	B-X
types	B-X
(	B-X
cell	B-X
membrane	B-X
and	B-X
cytoplasmic	B-X
receptors	B-X
)	B-X
are	B-X
being	B-X
formed	B-X
and	B-X
increased	B-X
at	B-X
G1	B-X
phase	B-X
prior	B-X
to	B-X
cell	B-X
proliferation	B-X
,	B-X
indicating	B-X
the	B-X
importance	B-X
of	B-X
G1	B-X
phase	B-X
in	B-X
immunoregulation	B-X
<EOS>	B-X
Although	B-X
the	B-X
specific	B-X
binding	B-X
further	B-X
increased	B-X
as	B-X
T	B-X
-	B-X
cells	B-X
entered	B-X
the	B-X
G1b	B-X
phase	B-X
(	B-X
as	B-X
measured	B-X
at	B-X
44	B-X
h	B-X
of	B-X
incubation	B-X
and	B-X
using	B-X
hydroxyurea	B-X
-	B-X
treated	B-X
cells	B-X
)	B-X
,	B-X
the	B-X
major	B-X
changes	B-X
in	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
took	B-X
place	B-X
during	B-X
the	B-X
period	B-X
16	B-X
	B-X
-	B-X
	B-X
20	B-X
h	B-X
after	B-X
stimulation	B-X
<EOS>	B-X
Enriched	B-X
human	B-X
peripheral	B-X
T	B-X
-	B-X
lymphocytes	B-X
were	B-X
stimulated	B-X
with	B-X
PHA	B-X
and	B-X
examined	B-X
for	B-X
variations	B-X
in	B-X
insulin	B-X
and	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
numbers	B-X
during	B-X
the	B-X
early	B-X
phases	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X

As	O
cells	O
entered	O
the	O
G1a	O
phase	O
the	O
specific	O
binding	O
of	O
dexamethasone	O
increased	O
and	O
of	O
insulin	O
took	O
place	O
.	O
<EOS>	B-X
As	B-X
cells	B-X
entered	B-X
the	B-X
G1a	B-X
phase	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
increased	B-X
and	B-X
of	B-X
insulin	B-X
took	B-X
place	B-X
<EOS>	B-X
Although	B-X
the	B-X
specific	B-X
binding	B-X
further	B-X
increased	B-X
as	B-X
T	B-X
-	B-X
cells	B-X
entered	B-X
the	B-X
G1b	B-X
phase	B-X
(	B-X
as	B-X
measured	B-X
at	B-X
44	B-X
h	B-X
of	B-X
incubation	B-X
and	B-X
using	B-X
hydroxyurea	B-X
-	B-X
treated	B-X
cells	B-X
)	B-X
,	B-X
the	B-X
major	B-X
changes	B-X
in	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
took	B-X
place	B-X
during	B-X
the	B-X
period	B-X
16	B-X
	B-X
-	B-X
	B-X
20	B-X
h	B-X
after	B-X
stimulation	B-X
<EOS>	B-X
Cells	B-X
in	B-X
G0	B-X
,	B-X
G1a	B-X
and	B-X
G1b	B-X
phases	B-X
,	B-X
where	B-X
the	B-X
G1a	B-X
	B-X
-	B-X
	B-X
G1b	B-X
transition	B-X
is	B-X
an	B-X
Interleukin	B-X
2	B-X
dependent	B-X
event	B-X
,	B-X
were	B-X
quantitated	B-X
by	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
Enriched	B-X
human	B-X
peripheral	B-X
T	B-X
-	B-X
lymphocytes	B-X
were	B-X
stimulated	B-X
with	B-X
PHA	B-X
and	B-X
examined	B-X
for	B-X
variations	B-X
in	B-X
insulin	B-X
and	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
numbers	B-X
during	B-X
the	B-X
early	B-X
phases	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X

Although	O
the	O
specific	O
binding	O
further	O
increased	O
as	O
T-cells	B-cell_type
entered	O
the	O
G1b	O
phase	O
(	O
as	O
measured	O
at	O
44	O
h	O
of	O
incubation	O
and	O
using	O
hydroxyurea-treated	B-cell_line
cells	I-cell_line
)	O
,	O
the	O
major	O
changes	O
in	O
the	O
specific	O
binding	O
of	O
dexamethasone	O
took	O
place	O
during	O
the	O
period	O
16	O
-	O
20	O
h	O
after	O
stimulation	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
specific	B-X
binding	B-X
further	B-X
increased	B-X
as	B-X
T	B-X
-	B-X
cells	B-X
entered	B-X
the	B-X
G1b	B-X
phase	B-X
(	B-X
as	B-X
measured	B-X
at	B-X
44	B-X
h	B-X
of	B-X
incubation	B-X
and	B-X
using	B-X
hydroxyurea	B-X
-	B-X
treated	B-X
cells	B-X
)	B-X
,	B-X
the	B-X
major	B-X
changes	B-X
in	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
took	B-X
place	B-X
during	B-X
the	B-X
period	B-X
16	B-X
	B-X
-	B-X
	B-X
20	B-X
h	B-X
after	B-X
stimulation	B-X
<EOS>	B-X
As	B-X
cells	B-X
entered	B-X
the	B-X
G1a	B-X
phase	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
increased	B-X
and	B-X
of	B-X
insulin	B-X
took	B-X
place	B-X
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
findings	B-X
,	B-X
it	B-X
is	B-X
concluded	B-X
that	B-X
both	B-X
receptor	B-X
types	B-X
(	B-X
cell	B-X
membrane	B-X
and	B-X
cytoplasmic	B-X
receptors	B-X
)	B-X
are	B-X
being	B-X
formed	B-X
and	B-X
increased	B-X
at	B-X
G1	B-X
phase	B-X
prior	B-X
to	B-X
cell	B-X
proliferation	B-X
,	B-X
indicating	B-X
the	B-X
importance	B-X
of	B-X
G1	B-X
phase	B-X
in	B-X
immunoregulation	B-X
<EOS>	B-X
Enriched	B-X
human	B-X
peripheral	B-X
T	B-X
-	B-X
lymphocytes	B-X
were	B-X
stimulated	B-X
with	B-X
PHA	B-X
and	B-X
examined	B-X
for	B-X
variations	B-X
in	B-X
insulin	B-X
and	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
numbers	B-X
during	B-X
the	B-X
early	B-X
phases	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X

Based	O
on	O
these	O
findings	O
,	O
it	O
is	O
concluded	O
that	O
both	O
receptor	O
types	O
(	O
cell	B-protein
membrane	I-protein
and	I-protein
cytoplasmic	I-protein
receptors	I-protein
)	O
are	O
being	O
formed	O
and	O
increased	O
at	O
G1	O
phase	O
prior	O
to	O
cell	O
proliferation	O
,	O
indicating	O
the	O
importance	O
of	O
G1	O
phase	O
in	O
immunoregulation	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
findings	B-X
,	B-X
it	B-X
is	B-X
concluded	B-X
that	B-X
both	B-X
receptor	B-X
types	B-X
(	B-X
cell	B-X
membrane	B-X
and	B-X
cytoplasmic	B-X
receptors	B-X
)	B-X
are	B-X
being	B-X
formed	B-X
and	B-X
increased	B-X
at	B-X
G1	B-X
phase	B-X
prior	B-X
to	B-X
cell	B-X
proliferation	B-X
,	B-X
indicating	B-X
the	B-X
importance	B-X
of	B-X
G1	B-X
phase	B-X
in	B-X
immunoregulation	B-X
<EOS>	B-X
Few	B-X
but	B-X
significant	B-X
numbers	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
2700	B-X
/	B-X
cell	B-X
)	B-X
and	B-X
no	B-X
insulin	B-X
receptors	B-X
(	B-X
	B-X
-	B-X
1	B-X
/	B-X
cell	B-X
)	B-X
were	B-X
found	B-X
in	B-X
the	B-X
resting	B-X
(	B-X
G0	B-X
)	B-X
phase	B-X
<EOS>	B-X
Although	B-X
the	B-X
specific	B-X
binding	B-X
further	B-X
increased	B-X
as	B-X
T	B-X
-	B-X
cells	B-X
entered	B-X
the	B-X
G1b	B-X
phase	B-X
(	B-X
as	B-X
measured	B-X
at	B-X
44	B-X
h	B-X
of	B-X
incubation	B-X
and	B-X
using	B-X
hydroxyurea	B-X
-	B-X
treated	B-X
cells	B-X
)	B-X
,	B-X
the	B-X
major	B-X
changes	B-X
in	B-X
the	B-X
specific	B-X
binding	B-X
of	B-X
dexamethasone	B-X
took	B-X
place	B-X
during	B-X
the	B-X
period	B-X
16	B-X
	B-X
-	B-X
	B-X
20	B-X
h	B-X
after	B-X
stimulation	B-X
<EOS>	B-X
Cells	B-X
in	B-X
G0	B-X
,	B-X
G1a	B-X
and	B-X
G1b	B-X
phases	B-X
,	B-X
where	B-X
the	B-X
G1a	B-X
	B-X
-	B-X
	B-X
G1b	B-X
transition	B-X
is	B-X
an	B-X
Interleukin	B-X
2	B-X
dependent	B-X
event	B-X
,	B-X
were	B-X
quantitated	B-X
by	B-X
flow	B-X
cytometry	B-X

Glucocorticoid	B-protein
receptors	I-protein
and	O
cortico-sensitivity	O
in	O
a	O
human	B-cell_line
clonal	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
CM-SM	B-cell_line
.	O

CM-SM	B-cell_line
is	O
a	O
clonal	B-cell_line
line	I-cell_line
of	O
human	B-cell_type
precursor	I-cell_type
mononuclear	I-cell_type
phagocytes	I-cell_type
inducible	O
to	O
macrophage	B-cell_type
differentiation	O
in	O
response	O
to	O
the	O
tumor	O
promoter	O
phorbol	O
ester	O
12-O-tetradecanoyl-phorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Untreated	O
CM-SM	O
cells	O
contain	O
single	O
class	O
,	O
high-affinity	O
(	O
KD	O
=	O
4.0	O
X	O
10	O
(	O
-9	O
)	O
M	O
)	O
glucocorticoid-specific	O
receptor	O
sites	O
(	O
approximately	O
60	O
,	O
000	O
per	O
cell	O
)	O
,	O
as	O
measured	O
by	O
a	O
whole	O
cell	O
assay	O
,	O
at	O
37	O
degrees	O
C	O
,	O
using	O
[	O
3H	O
]	O
triamcinolone	O
acetonide	O
(	O
TA	O
)	O
.	O
<EOS>	B-X
0	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
9	B-X
)	B-X
M	B-X
)	B-X
glucocorticoid	B-X
-	B-X
specific	B-X
receptor	B-X
sites	B-X
(	B-X
approximately	B-X
60,000	B-X
per	B-X
cell	B-X
)	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
a	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
,	B-X
using	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
(	B-X
TA	B-X
)	B-X
<EOS>	B-X
0	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
viable	B-X
cells	B-X
/	B-X
ml	B-X
in	B-X
the	B-X
controls	B-X
)	B-X
,	B-X
while	B-X
the	B-X
modal	B-X
volume	B-X
of	B-X
the	B-X
resulting	B-X
cell	B-X
population	B-X
was	B-X
approximately	B-X
60	B-X
%	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
volume	B-X
of	B-X
untreated	B-X
cells	B-X
<EOS>	B-X
Untreated	B-X
CM	B-X
-	B-X
SM	B-X
cells	B-X
contain	B-X
single	B-X
class	B-X
,	B-X
high	B-X
-	B-X
affinity	B-X
(	B-X
KD	B-X
=	B-X
4	B-X
<EOS>	B-X
CM	B-X
-	B-X
SM	B-X
is	B-X
a	B-X
clonal	B-X
line	B-X
of	B-X
human	B-X
precursor	B-X
mononuclear	B-X
phagocytes	B-X
inducible	B-X
to	B-X
macrophage	B-X
differentiation	B-X
in	B-X
response	B-X
to	B-X
the	B-X
tumor	B-X
promoter	B-X
phorbol	B-X
ester	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoyl	B-X
-	B-X
phorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
TPA	B-X
)	B-X

Exposure	O
of	O
CM-SM	B-cell_line
to	O
dexamethasone	O
(	O
DEX	O
)	O
produced	O
a	O
progressive	O
,	O
dose-	O
and	O
time-related	O
series	O
of	O
changes	O
in	O
CM-SM	B-cell_line
cell	O
growth	O
,	O
saturation	O
density	O
,	O
morphology	O
,	O
and	O
functional	O
properties	O
,	O
with	O
half-maximal	O
effects	O
at	O
about	O
10	O
(	O
-9	O
)	O
M	O
for	O
DEX	O
.	O
<EOS>	B-X
Exposure	B-X
of	B-X
CM	B-X
-	B-X
SM	B-X
to	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
produced	B-X
a	B-X
progressive	B-X
,	B-X
dose	B-X
-	B-X
	B-X
and	B-X
time	B-X
-	B-X
related	B-X
series	B-X
of	B-X
changes	B-X
in	B-X
CM	B-X
-	B-X
SM	B-X
cell	B-X
growth	B-X
,	B-X
saturation	B-X
density	B-X
,	B-X
morphology	B-X
,	B-X
and	B-X
functional	B-X
properties	B-X
,	B-X
with	B-X
half	B-X
-	B-X
maximal	B-X
effects	B-X
at	B-X
about	B-X
10	B-X
(	B-X
	B-X
-	B-X
9	B-X
)	B-X
M	B-X
for	B-X
DEX	B-X
<EOS>	B-X
After	B-X
removal	B-X
of	B-X
DEX	B-X
,	B-X
the	B-X
cells	B-X
,	B-X
within	B-X
a	B-X
few	B-X
passages	B-X
,	B-X
returned	B-X
to	B-X
a	B-X
state	B-X
apparently	B-X
identical	B-X
to	B-X
the	B-X
untreated	B-X
controls	B-X
and	B-X
could	B-X
be	B-X
induced	B-X
to	B-X
macrophage	B-X
differentiation	B-X
in	B-X
response	B-X
to	B-X
TPA	B-X
<EOS>	B-X
DEX	B-X
-	B-X
treated	B-X
cells	B-X
appeared	B-X
less	B-X
differentiated	B-X
than	B-X
controls	B-X
,	B-X
as	B-X
assessed	B-X
by	B-X
combined	B-X
morphologic	B-X
,	B-X
antigenic	B-X
,	B-X
and	B-X
cytoenzymatic	B-X
analyses	B-X
<EOS>	B-X
0	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
viable	B-X
cells	B-X
/	B-X
ml	B-X
in	B-X
the	B-X
controls	B-X
)	B-X
,	B-X
while	B-X
the	B-X
modal	B-X
volume	B-X
of	B-X
the	B-X
resulting	B-X
cell	B-X
population	B-X
was	B-X
approximately	B-X
60	B-X
%	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
volume	B-X
of	B-X
untreated	B-X
cells	B-X

TA-receptor	O
sites	O
rapidly	O
decreased	O
(	O
about	O
70	O
%	O
)	O
after	O
DEX	O
treatment	O
,	O
without	O
any	O
apparent	O
change	O
in	O
steroid	O
specificity	O
and	O
affinity	O
.	O
<EOS>	B-X
TA	B-X
-	B-X
receptor	B-X
sites	B-X
rapidly	B-X
decreased	B-X
(	B-X
about	B-X
70	B-X
%	B-X
)	B-X
after	B-X
DEX	B-X
treatment	B-X
,	B-X
without	B-X
any	B-X
apparent	B-X
change	B-X
in	B-X
steroid	B-X
specificity	B-X
and	B-X
affinity	B-X
<EOS>	B-X
After	B-X
removal	B-X
of	B-X
DEX	B-X
,	B-X
the	B-X
cells	B-X
,	B-X
within	B-X
a	B-X
few	B-X
passages	B-X
,	B-X
returned	B-X
to	B-X
a	B-X
state	B-X
apparently	B-X
identical	B-X
to	B-X
the	B-X
untreated	B-X
controls	B-X
and	B-X
could	B-X
be	B-X
induced	B-X
to	B-X
macrophage	B-X
differentiation	B-X
in	B-X
response	B-X
to	B-X
TPA	B-X
<EOS>	B-X
0	B-X
X	B-X
10	B-X
(	B-X
	B-X
-	B-X
9	B-X
)	B-X
M	B-X
)	B-X
glucocorticoid	B-X
-	B-X
specific	B-X
receptor	B-X
sites	B-X
(	B-X
approximately	B-X
60,000	B-X
per	B-X
cell	B-X
)	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
a	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
,	B-X
using	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
(	B-X
TA	B-X
)	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
cortico	B-X
-	B-X
sensitivity	B-X
in	B-X
a	B-X
human	B-X
clonal	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
CM	B-X
-	B-X
SM	B-X
.	B-X

After	O
5	O
days	O
in	O
culture	O
with	O
a	O
saturating	O
concentration	O
(	O
3.6	O
X	O
10	O
(	O
-8	O
)	O
M	O
)	O
of	O
hormone	O
,	O
the	O
cells	O
reached	O
a	O
saturation	O
density	O
of	O
about	O
9.0	O
X	O
10	O
(	O
6	O
)	O
viable	O
cells/ml	O
(	O
about	O
4.0	O
X	O
10	O
(	O
6	O
)	O
viable	O
cells/ml	O
in	O
the	O
controls	O
)	O
,	O
while	O
the	O
modal	O
volume	O
of	O
the	O
resulting	O
cell	B-cell_line
population	I-cell_line
was	O
approximately	O
60	O
%	O
,	O
as	O
compared	O
to	O
the	O
volume	O
of	O
untreated	B-cell_line
cells	I-cell_line
.	O

DEX-treated	B-cell_line
cells	I-cell_line
appeared	O
less	O
differentiated	O
than	O
controls	O
,	O
as	O
assessed	O
by	O
combined	O
morphologic	O
,	O
antigenic	O
,	O
and	O
cytoenzymatic	O
analyses	O
.	O
<EOS>	B-X
DEX	B-X
-	B-X
treated	B-X
cells	B-X
appeared	B-X
less	B-X
differentiated	B-X
than	B-X
controls	B-X
,	B-X
as	B-X
assessed	B-X
by	B-X
combined	B-X
morphologic	B-X
,	B-X
antigenic	B-X
,	B-X
and	B-X
cytoenzymatic	B-X
analyses	B-X
<EOS>	B-X
After	B-X
removal	B-X
of	B-X
DEX	B-X
,	B-X
the	B-X
cells	B-X
,	B-X
within	B-X
a	B-X
few	B-X
passages	B-X
,	B-X
returned	B-X
to	B-X
a	B-X
state	B-X
apparently	B-X
identical	B-X
to	B-X
the	B-X
untreated	B-X
controls	B-X
and	B-X
could	B-X
be	B-X
induced	B-X
to	B-X
macrophage	B-X
differentiation	B-X
in	B-X
response	B-X
to	B-X
TPA	B-X
<EOS>	B-X
DEX	B-X
almost	B-X
completely	B-X
inhibited	B-X
TPA	B-X
activation	B-X
of	B-X
the	B-X
following	B-X
macrophage	B-X
functions	B-X
:	B-X
adherency	B-X
to	B-X
the	B-X
culture	B-X
plate	B-X
,	B-X
expression	B-X
of	B-X
lysosomal	B-X
enzymes	B-X
,	B-X
Fc	B-X
and	B-X
C3	B-X
receptors	B-X
,	B-X
and	B-X
stimulation	B-X
of	B-X
phagocytosis	B-X
<EOS>	B-X
Exposure	B-X
of	B-X
CM	B-X
-	B-X
SM	B-X
to	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
produced	B-X
a	B-X
progressive	B-X
,	B-X
dose	B-X
-	B-X
	B-X
and	B-X
time	B-X
-	B-X
related	B-X
series	B-X
of	B-X
changes	B-X
in	B-X
CM	B-X
-	B-X
SM	B-X
cell	B-X
growth	B-X
,	B-X
saturation	B-X
density	B-X
,	B-X
morphology	B-X
,	B-X
and	B-X
functional	B-X
properties	B-X
,	B-X
with	B-X
half	B-X
-	B-X
maximal	B-X
effects	B-X
at	B-X
about	B-X
10	B-X
(	B-X
	B-X
-	B-X
9	B-X
)	B-X
M	B-X
for	B-X
DEX	B-X

DEX	O
almost	O
completely	O
inhibited	O
TPA	O
activation	O
of	O
the	O
following	O
macrophage	B-cell_type
functions	O
:	O
adherency	O
to	O
the	O
culture	O
plate	O
,	O
expression	O
of	O
lysosomal	B-protein
enzymes	I-protein
,	O
Fc	B-protein
and	I-protein
C3	I-protein
receptors	I-protein
,	O
and	O
stimulation	O
of	O
phagocytosis	O
.	O

After	O
removal	O
of	O
DEX	O
,	O
the	O
cells	O
,	O
within	O
a	O
few	O
passages	O
,	O
returned	O
to	O
a	O
state	O
apparently	O
identical	O
to	O
the	O
untreated	O
controls	O
and	O
could	O
be	O
induced	O
to	O
macrophage	B-cell_type
differentiation	O
in	O
response	O
to	O
TPA	O
.	O

Acute	O
lymphoblastic	O
leukemia	O
in	O
children	O
:	O
current	O
status	O
,	O
controversies	O
,	O
and	O
future	O
perspective	O
.	O
<EOS>	B-X
Acute	B-X
lymphoblastic	B-X
leukemia	B-X
in	B-X
children	B-X
:	B-X
current	B-X
status	B-X
,	B-X
controversies	B-X
,	B-X
and	B-X
future	B-X
perspective	B-X
.	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
prognostic	B-X
factors	B-X
lose	B-X
their	B-X
significance	B-X
after	B-X
2	B-X
years	B-X
of	B-X
continuous	B-X
complete	B-X
remission	B-X
and	B-X
that	B-X
2	B-X
years	B-X
of	B-X
maintenance	B-X
therapy	B-X
is	B-X
adequate	B-X
<EOS>	B-X
A	B-X
unified	B-X
approach	B-X
to	B-X
children	B-X
with	B-X
leukemia	B-X
/	B-X
lymphoma	B-X
,	B-X
a	B-X
group	B-X
with	B-X
a	B-X
particularly	B-X
poor	B-X
prognosis	B-X
,	B-X
utilizing	B-X
NHL	B-X
-	B-X
type	B-X
therapy	B-X
may	B-X
be	B-X
more	B-X
effective	B-X
than	B-X
conventional	B-X
ALL	B-X
therapy	B-X
<EOS>	B-X
Disease	B-X
-	B-X
free	B-X
survival	B-X
(	B-X
DFS	B-X
)	B-X
in	B-X
childhood	B-X
ALL	B-X
is	B-X
60	B-X
%	B-X
,	B-X
and	B-X
survival	B-X
in	B-X
good	B-X
,	B-X
average	B-X
,	B-X
and	B-X
poor	B-X
prognostic	B-X
groups	B-X
defined	B-X
by	B-X
initial	B-X
WBC	B-X
and	B-X
age	B-X
is	B-X
90	B-X
,	B-X
60	B-X
,	B-X
and	B-X
45	B-X
%	B-X
,	B-X
respectively	B-X

Disease-free	O
survival	O
(	O
DFS	O
)	O
in	O
childhood	O
ALL	O
is	O
60	O
%	O
,	O
and	O
survival	O
in	O
good	O
,	O
average	O
,	O
and	O
poor	O
prognostic	O
groups	O
defined	O
by	O
initial	O
WBC	O
and	O
age	O
is	O
90	O
,	O
60	O
,	O
and	O
45	O
%	O
,	O
respectively	O
.	O
<EOS>	B-X
Disease	B-X
-	B-X
free	B-X
survival	B-X
(	B-X
DFS	B-X
)	B-X
in	B-X
childhood	B-X
ALL	B-X
is	B-X
60	B-X
%	B-X
,	B-X
and	B-X
survival	B-X
in	B-X
good	B-X
,	B-X
average	B-X
,	B-X
and	B-X
poor	B-X
prognostic	B-X
groups	B-X
defined	B-X
by	B-X
initial	B-X
WBC	B-X
and	B-X
age	B-X
is	B-X
90	B-X
,	B-X
60	B-X
,	B-X
and	B-X
45	B-X
%	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Other	B-X
issues	B-X
include	B-X
the	B-X
optimal	B-X
duration	B-X
of	B-X
therapy	B-X
,	B-X
the	B-X
role	B-X
of	B-X
testicular	B-X
biopsies	B-X
,	B-X
and	B-X
prophylactic	B-X
testicular	B-X
radiation	B-X
<EOS>	B-X
Additional	B-X
immunological	B-X
,	B-X
morphological	B-X
,	B-X
biochemical	B-X
,	B-X
cytokinetic	B-X
,	B-X
and	B-X
cytogenetic	B-X
factors	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
illustrating	B-X
the	B-X
heterogeneity	B-X
of	B-X
ALL	B-X
and	B-X
its	B-X
derivation	B-X
from	B-X
malignant	B-X
clones	B-X
at	B-X
various	B-X
stages	B-X
of	B-X
differentiation	B-X
and	B-X
with	B-X
varying	B-X
rates	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
Late	B-X
neuropsychological	B-X
defects	B-X
caused	B-X
by	B-X
cranial	B-X
XRT	B-X
and	B-X
IT	B-X
MTX	B-X
have	B-X
prompted	B-X
programs	B-X
designed	B-X
to	B-X
reduce	B-X
the	B-X
potential	B-X
late	B-X
toxicity	B-X
of	B-X
CNS	B-X
prophylaxis	B-X

Additional	O
immunological	O
,	O
morphological	O
,	O
biochemical	O
,	O
cytokinetic	O
,	O
and	O
cytogenetic	O
factors	O
have	O
been	O
identified	O
,	O
illustrating	O
the	O
heterogeneity	O
of	O
ALL	O
and	O
its	O
derivation	O
from	O
malignant	B-cell_line
clones	I-cell_line
at	O
various	O
stages	O
of	O
differentiation	O
and	O
with	O
varying	O
rates	O
of	O
proliferation	O
.	O
<EOS>	B-X
Additional	B-X
immunological	B-X
,	B-X
morphological	B-X
,	B-X
biochemical	B-X
,	B-X
cytokinetic	B-X
,	B-X
and	B-X
cytogenetic	B-X
factors	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
illustrating	B-X
the	B-X
heterogeneity	B-X
of	B-X
ALL	B-X
and	B-X
its	B-X
derivation	B-X
from	B-X
malignant	B-X
clones	B-X
at	B-X
various	B-X
stages	B-X
of	B-X
differentiation	B-X
and	B-X
with	B-X
varying	B-X
rates	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
prognostic	B-X
factors	B-X
lose	B-X
their	B-X
significance	B-X
after	B-X
2	B-X
years	B-X
of	B-X
continuous	B-X
complete	B-X
remission	B-X
and	B-X
that	B-X
2	B-X
years	B-X
of	B-X
maintenance	B-X
therapy	B-X
is	B-X
adequate	B-X
<EOS>	B-X
Of	B-X
biologic	B-X
importance	B-X
,	B-X
these	B-X
factors	B-X
may	B-X
refine	B-X
further	B-X
the	B-X
characteristic	B-X
features	B-X
of	B-X
clinically	B-X
-	B-X
determined	B-X
prognostic	B-X
groups	B-X
<EOS>	B-X
Multivariate	B-X
analysis	B-X
of	B-X
large	B-X
prospective	B-X
trials	B-X
with	B-X
homogeneous	B-X
therapy	B-X
will	B-X
be	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
independent	B-X
prognostic	B-X
importance	B-X
of	B-X
these	B-X
factors	B-X

Of	O
biologic	O
importance	O
,	O
these	O
factors	O
may	O
refine	O
further	O
the	O
characteristic	O
features	O
of	O
clinically-determined	O
prognostic	O
groups	O
.	O
<EOS>	B-X
Of	B-X
biologic	B-X
importance	B-X
,	B-X
these	B-X
factors	B-X
may	B-X
refine	B-X
further	B-X
the	B-X
characteristic	B-X
features	B-X
of	B-X
clinically	B-X
-	B-X
determined	B-X
prognostic	B-X
groups	B-X
<EOS>	B-X
Current	B-X
studies	B-X
show	B-X
a	B-X
CNS	B-X
relapse	B-X
rate	B-X
of	B-X
5	B-X
%	B-X
in	B-X
all	B-X
prognostic	B-X
groups	B-X
<EOS>	B-X
Additional	B-X
immunological	B-X
,	B-X
morphological	B-X
,	B-X
biochemical	B-X
,	B-X
cytokinetic	B-X
,	B-X
and	B-X
cytogenetic	B-X
factors	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
illustrating	B-X
the	B-X
heterogeneity	B-X
of	B-X
ALL	B-X
and	B-X
its	B-X
derivation	B-X
from	B-X
malignant	B-X
clones	B-X
at	B-X
various	B-X
stages	B-X
of	B-X
differentiation	B-X
and	B-X
with	B-X
varying	B-X
rates	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
Multivariate	B-X
analysis	B-X
of	B-X
large	B-X
prospective	B-X
trials	B-X
with	B-X
homogeneous	B-X
therapy	B-X
will	B-X
be	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
independent	B-X
prognostic	B-X
importance	B-X
of	B-X
these	B-X
factors	B-X

Multivariate	O
analysis	O
of	O
large	O
prospective	O
trials	O
with	O
homogeneous	O
therapy	O
will	O
be	O
required	O
to	O
determine	O
the	O
independent	O
prognostic	O
importance	O
of	O
these	O
factors	O
.	O

Current	O
treatment	O
strategies	O
in	O
ALL	O
include	O
(	O
1	O
)	O
tailoring	O
therapy	O
and	O
its	O
intensity	O
to	O
prognostic	O
groups	O
;	O
(	O
2	O
)	O
multiple-drug	O
combinations	O
in	O
induction	O
;	O
(	O
3	O
)	O
early	O
use	O
of	O
intrathecal	O
(	O
IT	O
)	O
methotrexate	O
(	O
MTX	O
)	O
;	O
(	O
4	O
)	O
CNS	O
prophylaxis	O
with	O
IT	O
MTX	O
alone	O
in	O
good	O
prognosis	O
patients	O
and	O
combined	O
cranial	O
radiation	O
(	O
CXRT	O
)	O
,	O
1800	O
rads	O
plus	O
IT	O
MTX	O
,	O
in	O
average	O
and	O
poor	O
prognosis	O
patients	O
.	O

Current	O
studies	O
show	O
a	O
CNS	O
relapse	O
rate	O
of	O
5	O
%	O
in	O
all	O
prognostic	O
groups	O
.	O
<EOS>	B-X
Current	B-X
studies	B-X
show	B-X
a	B-X
CNS	B-X
relapse	B-X
rate	B-X
of	B-X
5	B-X
%	B-X
in	B-X
all	B-X
prognostic	B-X
groups	B-X
<EOS>	B-X
Of	B-X
biologic	B-X
importance	B-X
,	B-X
these	B-X
factors	B-X
may	B-X
refine	B-X
further	B-X
the	B-X
characteristic	B-X
features	B-X
of	B-X
clinically	B-X
-	B-X
determined	B-X
prognostic	B-X
groups	B-X
<EOS>	B-X
The	B-X
current	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
prognosis	B-X
remains	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
metastatic	B-X
to	B-X
the	B-X
CNS	B-X
<EOS>	B-X
Logistic	B-X
regression	B-X
analysis	B-X
showed	B-X
that	B-X
LDH	B-X
>	B-X
2N	B-X
was	B-X
an	B-X
independent	B-X
unfavorable	B-X
prognostic	B-X
factors	B-X
(	B-X
OR	B-X
=	B-X
31	B-X

Late	O
neuropsychological	O
defects	O
caused	O
by	O
cranial	O
XRT	O
and	O
IT	O
MTX	O
have	O
prompted	O
programs	O
designed	O
to	O
reduce	O
the	O
potential	O
late	O
toxicity	O
of	O
CNS	O
prophylaxis	O
.	O
<EOS>	B-X
Late	B-X
neuropsychological	B-X
defects	B-X
caused	B-X
by	B-X
cranial	B-X
XRT	B-X
and	B-X
IT	B-X
MTX	B-X
have	B-X
prompted	B-X
programs	B-X
designed	B-X
to	B-X
reduce	B-X
the	B-X
potential	B-X
late	B-X
toxicity	B-X
of	B-X
CNS	B-X
prophylaxis	B-X
<EOS>	B-X
Additional	B-X
immunological	B-X
,	B-X
morphological	B-X
,	B-X
biochemical	B-X
,	B-X
cytokinetic	B-X
,	B-X
and	B-X
cytogenetic	B-X
factors	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
illustrating	B-X
the	B-X
heterogeneity	B-X
of	B-X
ALL	B-X
and	B-X
its	B-X
derivation	B-X
from	B-X
malignant	B-X
clones	B-X
at	B-X
various	B-X
stages	B-X
of	B-X
differentiation	B-X
and	B-X
with	B-X
varying	B-X
rates	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
Ultra	B-X
-	B-X
high	B-X
-	B-X
dose	B-X
MTX	B-X
,	B-X
without	B-X
cranial	B-X
radiation	B-X
,	B-X
is	B-X
also	B-X
showing	B-X
promise	B-X
in	B-X
poor	B-X
prognosis	B-X
patients	B-X
<EOS>	B-X
Bilateral	B-X
open	B-X
-	B-X
wedge	B-X
testicular	B-X
biopsies	B-X
have	B-X
identified	B-X
occult	B-X
testicular	B-X
disease	B-X
in	B-X
8	B-X
to	B-X
10	B-X
%	B-X
of	B-X
males	B-X

More	O
pronounced	O
in	O
younger	O
children	O
,	O
these	O
abnormalities	O
include	O
decreased	O
IQ	O
,	O
visual-motor	O
incoordination	O
,	O
poor	O
performance	O
in	O
mathematics	O
,	O
and	O
memory	O
dysfunction	O
.	O
<EOS>	B-X
More	B-X
pronounced	B-X
in	B-X
younger	B-X
children	B-X
,	B-X
these	B-X
abnormalities	B-X
include	B-X
decreased	B-X
IQ	B-X
,	B-X
visual	B-X
-	B-X
motor	B-X
incoordination	B-X
,	B-X
poor	B-X
performance	B-X
in	B-X
mathematics	B-X
,	B-X
and	B-X
memory	B-X
dysfunction	B-X
<EOS>	B-X
Other	B-X
issues	B-X
include	B-X
the	B-X
optimal	B-X
duration	B-X
of	B-X
therapy	B-X
,	B-X
the	B-X
role	B-X
of	B-X
testicular	B-X
biopsies	B-X
,	B-X
and	B-X
prophylactic	B-X
testicular	B-X
radiation	B-X
<EOS>	B-X
Of	B-X
biologic	B-X
importance	B-X
,	B-X
these	B-X
factors	B-X
may	B-X
refine	B-X
further	B-X
the	B-X
characteristic	B-X
features	B-X
of	B-X
clinically	B-X
-	B-X
determined	B-X
prognostic	B-X
groups	B-X
<EOS>	B-X
Ultra	B-X
-	B-X
high	B-X
-	B-X
dose	B-X
MTX	B-X
,	B-X
without	B-X
cranial	B-X
radiation	B-X
,	B-X
is	B-X
also	B-X
showing	B-X
promise	B-X
in	B-X
poor	B-X
prognosis	B-X
patients	B-X

Until	O
1980	O
,	O
more	O
intensive	O
induction	O
,	O
consolidation	O
,	O
and	O
maintenance	O
therapy	O
had	O
failed	O
to	O
prolong	O
DFS	O
in	O
children	O
with	O
a	O
poor	O
prognosis	O
.	O
<EOS>	B-X
Until	B-X
1980	B-X
,	B-X
more	B-X
intensive	B-X
induction	B-X
,	B-X
consolidation	B-X
,	B-X
and	B-X
maintenance	B-X
therapy	B-X
had	B-X
failed	B-X
to	B-X
prolong	B-X
DFS	B-X
in	B-X
children	B-X
with	B-X
a	B-X
poor	B-X
prognosis	B-X
<EOS>	B-X
Ultra	B-X
-	B-X
high	B-X
-	B-X
dose	B-X
MTX	B-X
,	B-X
without	B-X
cranial	B-X
radiation	B-X
,	B-X
is	B-X
also	B-X
showing	B-X
promise	B-X
in	B-X
poor	B-X
prognosis	B-X
patients	B-X
<EOS>	B-X
Additional	B-X
immunological	B-X
,	B-X
morphological	B-X
,	B-X
biochemical	B-X
,	B-X
cytokinetic	B-X
,	B-X
and	B-X
cytogenetic	B-X
factors	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
illustrating	B-X
the	B-X
heterogeneity	B-X
of	B-X
ALL	B-X
and	B-X
its	B-X
derivation	B-X
from	B-X
malignant	B-X
clones	B-X
at	B-X
various	B-X
stages	B-X
of	B-X
differentiation	B-X
and	B-X
with	B-X
varying	B-X
rates	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
West	B-X
Germany	B-X
(	B-X
Berlin	B-X
-	B-X
Frankfurt	B-X
-	B-X
Muenster	B-X
protocol	B-X
)	B-X
a	B-X
70	B-X
to	B-X
75	B-X
%	B-X
DFS	B-X
is	B-X
seen	B-X
in	B-X
all	B-X
patients	B-X
regardless	B-X
of	B-X
initial	B-X
WBC	B-X
,	B-X
suggesting	B-X
that	B-X
effective	B-X
therapy	B-X
will	B-X
override	B-X
prognostic	B-X
factors	B-X

In	O
West	O
Germany	O
(	O
Berlin-Frankfurt-Muenster	O
protocol	O
)	O
a	O
70	O
to	O
75	O
%	O
DFS	O
is	O
seen	O
in	O
all	O
patients	O
regardless	O
of	O
initial	O
WBC	O
,	O
suggesting	O
that	O
effective	O
therapy	O
will	O
override	O
prognostic	O
factors	O
.	O
<EOS>	B-X
In	B-X
West	B-X
Germany	B-X
(	B-X
Berlin	B-X
-	B-X
Frankfurt	B-X
-	B-X
Muenster	B-X
protocol	B-X
)	B-X
a	B-X
70	B-X
to	B-X
75	B-X
%	B-X
DFS	B-X
is	B-X
seen	B-X
in	B-X
all	B-X
patients	B-X
regardless	B-X
of	B-X
initial	B-X
WBC	B-X
,	B-X
suggesting	B-X
that	B-X
effective	B-X
therapy	B-X
will	B-X
override	B-X
prognostic	B-X
factors	B-X
<EOS>	B-X
Of	B-X
biologic	B-X
importance	B-X
,	B-X
these	B-X
factors	B-X
may	B-X
refine	B-X
further	B-X
the	B-X
characteristic	B-X
features	B-X
of	B-X
clinically	B-X
-	B-X
determined	B-X
prognostic	B-X
groups	B-X
<EOS>	B-X
Until	B-X
1980	B-X
,	B-X
more	B-X
intensive	B-X
induction	B-X
,	B-X
consolidation	B-X
,	B-X
and	B-X
maintenance	B-X
therapy	B-X
had	B-X
failed	B-X
to	B-X
prolong	B-X
DFS	B-X
in	B-X
children	B-X
with	B-X
a	B-X
poor	B-X
prognosis	B-X
<EOS>	B-X
Multivariate	B-X
analysis	B-X
of	B-X
large	B-X
prospective	B-X
trials	B-X
with	B-X
homogeneous	B-X
therapy	B-X
will	B-X
be	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
independent	B-X
prognostic	B-X
importance	B-X
of	B-X
these	B-X
factors	B-X

Ultra-high-dose	O
MTX	O
,	O
without	O
cranial	O
radiation	O
,	O
is	O
also	O
showing	O
promise	O
in	O
poor	O
prognosis	O
patients	O
.	O
<EOS>	B-X
Ultra	B-X
-	B-X
high	B-X
-	B-X
dose	B-X
MTX	B-X
,	B-X
without	B-X
cranial	B-X
radiation	B-X
,	B-X
is	B-X
also	B-X
showing	B-X
promise	B-X
in	B-X
poor	B-X
prognosis	B-X
patients	B-X
<EOS>	B-X
Current	B-X
studies	B-X
show	B-X
a	B-X
CNS	B-X
relapse	B-X
rate	B-X
of	B-X
5	B-X
%	B-X
in	B-X
all	B-X
prognostic	B-X
groups	B-X
<EOS>	B-X
Multivariate	B-X
analysis	B-X
of	B-X
large	B-X
prospective	B-X
trials	B-X
with	B-X
homogeneous	B-X
therapy	B-X
will	B-X
be	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
independent	B-X
prognostic	B-X
importance	B-X
of	B-X
these	B-X
factors	B-X
<EOS>	B-X
Until	B-X
1980	B-X
,	B-X
more	B-X
intensive	B-X
induction	B-X
,	B-X
consolidation	B-X
,	B-X
and	B-X
maintenance	B-X
therapy	B-X
had	B-X
failed	B-X
to	B-X
prolong	B-X
DFS	B-X
in	B-X
children	B-X
with	B-X
a	B-X
poor	B-X
prognosis	B-X

Other	O
issues	O
include	O
the	O
optimal	O
duration	O
of	O
therapy	O
,	O
the	O
role	O
of	O
testicular	O
biopsies	O
,	O
and	O
prophylactic	O
testicular	O
radiation	O
.	O
<EOS>	B-X
Other	B-X
issues	B-X
include	B-X
the	B-X
optimal	B-X
duration	B-X
of	B-X
therapy	B-X
,	B-X
the	B-X
role	B-X
of	B-X
testicular	B-X
biopsies	B-X
,	B-X
and	B-X
prophylactic	B-X
testicular	B-X
radiation	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
prognostic	B-X
factors	B-X
lose	B-X
their	B-X
significance	B-X
after	B-X
2	B-X
years	B-X
of	B-X
continuous	B-X
complete	B-X
remission	B-X
and	B-X
that	B-X
2	B-X
years	B-X
of	B-X
maintenance	B-X
therapy	B-X
is	B-X
adequate	B-X
<EOS>	B-X
Multivariate	B-X
analysis	B-X
of	B-X
large	B-X
prospective	B-X
trials	B-X
with	B-X
homogeneous	B-X
therapy	B-X
will	B-X
be	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
independent	B-X
prognostic	B-X
importance	B-X
of	B-X
these	B-X
factors	B-X
<EOS>	B-X
Bilateral	B-X
open	B-X
-	B-X
wedge	B-X
testicular	B-X
biopsies	B-X
have	B-X
identified	B-X
occult	B-X
testicular	B-X
disease	B-X
in	B-X
8	B-X
to	B-X
10	B-X
%	B-X
of	B-X
males	B-X

Recent	O
studies	O
suggest	O
that	O
prognostic	O
factors	O
lose	O
their	O
significance	O
after	O
2	O
years	O
of	O
continuous	O
complete	O
remission	O
and	O
that	O
2	O
years	O
of	O
maintenance	O
therapy	O
is	O
adequate	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
prognostic	B-X
factors	B-X
lose	B-X
their	B-X
significance	B-X
after	B-X
2	B-X
years	B-X
of	B-X
continuous	B-X
complete	B-X
remission	B-X
and	B-X
that	B-X
2	B-X
years	B-X
of	B-X
maintenance	B-X
therapy	B-X
is	B-X
adequate	B-X
<EOS>	B-X
Other	B-X
issues	B-X
include	B-X
the	B-X
optimal	B-X
duration	B-X
of	B-X
therapy	B-X
,	B-X
the	B-X
role	B-X
of	B-X
testicular	B-X
biopsies	B-X
,	B-X
and	B-X
prophylactic	B-X
testicular	B-X
radiation	B-X
<EOS>	B-X
Additional	B-X
immunological	B-X
,	B-X
morphological	B-X
,	B-X
biochemical	B-X
,	B-X
cytokinetic	B-X
,	B-X
and	B-X
cytogenetic	B-X
factors	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
illustrating	B-X
the	B-X
heterogeneity	B-X
of	B-X
ALL	B-X
and	B-X
its	B-X
derivation	B-X
from	B-X
malignant	B-X
clones	B-X
at	B-X
various	B-X
stages	B-X
of	B-X
differentiation	B-X
and	B-X
with	B-X
varying	B-X
rates	B-X
of	B-X
proliferation	B-X
<EOS>	B-X
Acute	B-X
lymphoblastic	B-X
leukemia	B-X
in	B-X
children	B-X
:	B-X
current	B-X
status	B-X
,	B-X
controversies	B-X
,	B-X
and	B-X
future	B-X
perspective	B-X
.	B-X

Bilateral	O
open-wedge	O
testicular	O
biopsies	O
have	O
identified	O
occult	O
testicular	O
disease	O
in	O
8	O
to	O
10	O
%	O
of	O
males	O
.	O
<EOS>	B-X
Bilateral	B-X
open	B-X
-	B-X
wedge	B-X
testicular	B-X
biopsies	B-X
have	B-X
identified	B-X
occult	B-X
testicular	B-X
disease	B-X
in	B-X
8	B-X
to	B-X
10	B-X
%	B-X
of	B-X
males	B-X
<EOS>	B-X
Other	B-X
issues	B-X
include	B-X
the	B-X
optimal	B-X
duration	B-X
of	B-X
therapy	B-X
,	B-X
the	B-X
role	B-X
of	B-X
testicular	B-X
biopsies	B-X
,	B-X
and	B-X
prophylactic	B-X
testicular	B-X
radiation	B-X
<EOS>	B-X
Multivariate	B-X
analysis	B-X
of	B-X
large	B-X
prospective	B-X
trials	B-X
with	B-X
homogeneous	B-X
therapy	B-X
will	B-X
be	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
independent	B-X
prognostic	B-X
importance	B-X
of	B-X
these	B-X
factors	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
prognostic	B-X
factors	B-X
lose	B-X
their	B-X
significance	B-X
after	B-X
2	B-X
years	B-X
of	B-X
continuous	B-X
complete	B-X
remission	B-X
and	B-X
that	B-X
2	B-X
years	B-X
of	B-X
maintenance	B-X
therapy	B-X
is	B-X
adequate	B-X

A	O
unified	O
approach	O
to	O
children	O
with	O
leukemia/lymphoma	O
,	O
a	O
group	O
with	O
a	O
particularly	O
poor	O
prognosis	O
,	O
utilizing	O
NHL-type	O
therapy	O
may	O
be	O
more	O
effective	O
than	O
conventional	O
ALL	O
therapy	O
.	O
<EOS>	B-X
A	B-X
unified	B-X
approach	B-X
to	B-X
children	B-X
with	B-X
leukemia	B-X
/	B-X
lymphoma	B-X
,	B-X
a	B-X
group	B-X
with	B-X
a	B-X
particularly	B-X
poor	B-X
prognosis	B-X
,	B-X
utilizing	B-X
NHL	B-X
-	B-X
type	B-X
therapy	B-X
may	B-X
be	B-X
more	B-X
effective	B-X
than	B-X
conventional	B-X
ALL	B-X
therapy	B-X
<EOS>	B-X
Acute	B-X
lymphoblastic	B-X
leukemia	B-X
in	B-X
children	B-X
:	B-X
current	B-X
status	B-X
,	B-X
controversies	B-X
,	B-X
and	B-X
future	B-X
perspective	B-X
.	B-X
<EOS>	B-X
Other	B-X
issues	B-X
include	B-X
the	B-X
optimal	B-X
duration	B-X
of	B-X
therapy	B-X
,	B-X
the	B-X
role	B-X
of	B-X
testicular	B-X
biopsies	B-X
,	B-X
and	B-X
prophylactic	B-X
testicular	B-X
radiation	B-X
<EOS>	B-X
Late	B-X
neuropsychological	B-X
defects	B-X
caused	B-X
by	B-X
cranial	B-X
XRT	B-X
and	B-X
IT	B-X
MTX	B-X
have	B-X
prompted	B-X
programs	B-X
designed	B-X
to	B-X
reduce	B-X
the	B-X
potential	B-X
late	B-X
toxicity	B-X
of	B-X
CNS	B-X
prophylaxis	B-X

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
<EOS>	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X
<EOS>	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
<EOS>	B-X
2poly	B-X
(	B-X
dT	B-X
)	B-X
DNA	B-X
triplex	B-X
and	B-X
to	B-X
the	B-X
poly	B-X
(	B-X
rA	B-X
)	B-X
<EOS>	B-X
7	B-X
JK	B-X
-	B-X
1	B-X
mol	B-X
-	B-X
1	B-X
at	B-X
pH	B-X
3	B-X

Glucocorticoid	B-protein
receptor	I-protein
and	O
in	O
vitro	O
sensitivity	O
to	O
steroid	O
hormones	O
in	O
human	O
lymphoproliferative	O
diseases	O
and	O
myeloid	O
leukemia	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
steroid	B-X
hormones	B-X
in	B-X
human	B-X
lymphoproliferative	B-X
diseases	B-X
and	B-X
myeloid	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
No	B-X
clear	B-X
relationship	B-X
among	B-X
GR	B-X
pattern	B-X
,	B-X
in	B-X
vitro	B-X
cell	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
,	B-X
and	B-X
clinicohematologic	B-X
parameters	B-X
was	B-X
observed	B-X
in	B-X
myeloid	B-X
leukemia	B-X
-	B-X
bearing	B-X
patients	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
quantitation	B-X
by	B-X
a	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
and	B-X
/	B-X
or	B-X
cytosol	B-X
technique	B-X
and	B-X
the	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
steroids	B-X
have	B-X
been	B-X
assessed	B-X
in	B-X
peripheral	B-X
blood	B-X
cells	B-X
from	B-X
normal	B-X
donors	B-X
and	B-X
patients	B-X
with	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
,	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
,	B-X
lymphosarcoma	B-X
cell	B-X
leukemia	B-X
(	B-X
LSCL	B-X
)	B-X
,	B-X
acute	B-X
nonlymphatic	B-X
leukemia	B-X
(	B-X
ANLL	B-X
)	B-X
,	B-X
and	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
<EOS>	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CLL	B-X
cells	B-X
presented	B-X
the	B-X
highest	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
in	B-X
PHA	B-X
-	B-X
stimulated	B-X
cell	B-X
cultures	B-X

The	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
quantitation	O
by	O
a	O
whole-cell	O
assay	O
and/or	O
cytosol	O
technique	O
and	O
the	O
in	O
vitro	O
sensitivity	O
to	O
steroids	O
have	O
been	O
assessed	O
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
from	O
normal	O
donors	O
and	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
(	O
CLL	O
)	O
,	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
lymphosarcoma	O
cell	O
leukemia	O
(	O
LSCL	O
)	O
,	O
acute	O
nonlymphatic	O
leukemia	O
(	O
ANLL	O
)	O
,	O
and	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O

Within	O
the	O
lymphoproliferative	O
diseases	O
,	O
ALL	B-cell_line
cells	I-cell_line
exhibited	O
the	O
highest	O
GR	B-protein
concentration	O
(	O
regardless	O
of	O
the	O
method	O
used	O
)	O
and	O
the	O
highest	O
in	O
vitro	O
inhibition	O
of	O
spontaneous	O
[	O
3H	O
]	O
thymidine	O
(	O
[	O
3H	O
]	O
TdR	O
)	O
uptake	O
by	O
glucocorticoids	O
.	O
<EOS>	B-X
Within	B-X
the	B-X
lymphoproliferative	B-X
diseases	B-X
,	B-X
ALL	B-X
cells	B-X
exhibited	B-X
the	B-X
highest	B-X
GR	B-X
concentration	B-X
(	B-X
regardless	B-X
of	B-X
the	B-X
method	B-X
used	B-X
)	B-X
and	B-X
the	B-X
highest	B-X
in	B-X
vitro	B-X
inhibition	B-X
of	B-X
spontaneous	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
(	B-X
[	B-X
3H	B-X
]	B-X
TdR	B-X
)	B-X
uptake	B-X
by	B-X
glucocorticoids	B-X
<EOS>	B-X
Concerning	B-X
myeloid	B-X
leukemia	B-X
,	B-X
ANLL	B-X
patients	B-X
had	B-X
GR	B-X
concentrations	B-X
slightly	B-X
higher	B-X
than	B-X
those	B-X
found	B-X
in	B-X
the	B-X
ALL	B-X
group	B-X
but	B-X
exhibited	B-X
the	B-X
lowest	B-X
degree	B-X
of	B-X
inhibition	B-X
of	B-X
spontaneous	B-X
[	B-X
3H	B-X
]	B-X
TdR	B-X
uptake	B-X
by	B-X
dexamethasone	B-X
(	B-X
stimulatory	B-X
effects	B-X
occurred	B-X
in	B-X
some	B-X
cases	B-X
)	B-X
<EOS>	B-X
A	B-X
significant	B-X
relationship	B-X
between	B-X
GR	B-X
concentration	B-X
(	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
)	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
dexamethasone	B-X
was	B-X
also	B-X
found	B-X
<EOS>	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CLL	B-X
cells	B-X
presented	B-X
the	B-X
highest	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
in	B-X
PHA	B-X
-	B-X
stimulated	B-X
cell	B-X
cultures	B-X

A	O
significant	O
relationship	O
between	O
GR	B-protein
concentration	O
(	O
whole-cell	O
assay	O
)	O
and	O
in	O
vitro	O
sensitivity	O
to	O
dexamethasone	O
was	O
also	O
found	O
.	O
<EOS>	B-X
A	B-X
significant	B-X
relationship	B-X
between	B-X
GR	B-X
concentration	B-X
(	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
)	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
dexamethasone	B-X
was	B-X
also	B-X
found	B-X
<EOS>	B-X
Cells	B-X
from	B-X
the	B-X
only	B-X
two	B-X
ALL	B-X
patients	B-X
who	B-X
did	B-X
not	B-X
undergo	B-X
a	B-X
remission	B-X
after	B-X
glucocorticoid	B-X
-	B-X
inclusive	B-X
chemotherapy	B-X
had	B-X
both	B-X
the	B-X
lowest	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
dexamethasone	B-X
and	B-X
the	B-X
lowest	B-X
GR	B-X
concentration	B-X
with	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
<EOS>	B-X
Within	B-X
the	B-X
lymphoproliferative	B-X
diseases	B-X
,	B-X
ALL	B-X
cells	B-X
exhibited	B-X
the	B-X
highest	B-X
GR	B-X
concentration	B-X
(	B-X
regardless	B-X
of	B-X
the	B-X
method	B-X
used	B-X
)	B-X
and	B-X
the	B-X
highest	B-X
in	B-X
vitro	B-X
inhibition	B-X
of	B-X
spontaneous	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
(	B-X
[	B-X
3H	B-X
]	B-X
TdR	B-X
)	B-X
uptake	B-X
by	B-X
glucocorticoids	B-X
<EOS>	B-X
Concerning	B-X
myeloid	B-X
leukemia	B-X
,	B-X
ANLL	B-X
patients	B-X
had	B-X
GR	B-X
concentrations	B-X
slightly	B-X
higher	B-X
than	B-X
those	B-X
found	B-X
in	B-X
the	B-X
ALL	B-X
group	B-X
but	B-X
exhibited	B-X
the	B-X
lowest	B-X
degree	B-X
of	B-X
inhibition	B-X
of	B-X
spontaneous	B-X
[	B-X
3H	B-X
]	B-X
TdR	B-X
uptake	B-X
by	B-X
dexamethasone	B-X
(	B-X
stimulatory	B-X
effects	B-X
occurred	B-X
in	B-X
some	B-X
cases	B-X
)	B-X

On	O
the	O
contrary	O
,	O
CLL	B-cell_line
cells	I-cell_line
presented	O
the	O
highest	O
sensitivity	O
to	O
glucocorticoids	O
in	O
PHA-stimulated	B-cell_line
cell	I-cell_line
cultures	I-cell_line
.	O
<EOS>	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CLL	B-X
cells	B-X
presented	B-X
the	B-X
highest	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
in	B-X
PHA	B-X
-	B-X
stimulated	B-X
cell	B-X
cultures	B-X
<EOS>	B-X
No	B-X
clear	B-X
relationship	B-X
among	B-X
GR	B-X
pattern	B-X
,	B-X
in	B-X
vitro	B-X
cell	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
,	B-X
and	B-X
clinicohematologic	B-X
parameters	B-X
was	B-X
observed	B-X
in	B-X
myeloid	B-X
leukemia	B-X
-	B-X
bearing	B-X
patients	B-X
<EOS>	B-X
Within	B-X
the	B-X
lymphoproliferative	B-X
diseases	B-X
,	B-X
ALL	B-X
cells	B-X
exhibited	B-X
the	B-X
highest	B-X
GR	B-X
concentration	B-X
(	B-X
regardless	B-X
of	B-X
the	B-X
method	B-X
used	B-X
)	B-X
and	B-X
the	B-X
highest	B-X
in	B-X
vitro	B-X
inhibition	B-X
of	B-X
spontaneous	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
(	B-X
[	B-X
3H	B-X
]	B-X
TdR	B-X
)	B-X
uptake	B-X
by	B-X
glucocorticoids	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
steroid	B-X
hormones	B-X
in	B-X
human	B-X
lymphoproliferative	B-X
diseases	B-X
and	B-X
myeloid	B-X
leukemia	B-X
.	B-X

Cells	O
from	O
the	O
only	O
two	O
ALL	O
patients	O
who	O
did	O
not	O
undergo	O
a	O
remission	O
after	O
glucocorticoid-inclusive	O
chemotherapy	O
had	O
both	O
the	O
lowest	O
in	O
vitro	O
sensitivity	O
to	O
dexamethasone	O
and	O
the	O
lowest	O
GR	O
concentration	O
with	O
whole-cell	O
assay	O
.	O
<EOS>	B-X
Dermoscopy	B-X
of	B-X
the	B-X
first	B-X
patient	B-X
revealed	B-X
a	B-X
red	B-X
structureless	B-X
area	B-X
in	B-X
the	B-X
central	B-X
part	B-X
of	B-X
the	B-X
lesion	B-X
,	B-X
consistent	B-X
with	B-X
ulceration	B-X
<EOS>	B-X
There	B-X
were	B-X
no	B-X
signs	B-X
that	B-X
the	B-X
drugs	B-X
were	B-X
toxic	B-X
in	B-X
mice	B-X
,	B-X
but	B-X
more	B-X
studies	B-X
must	B-X
prove	B-X
they	B-X
are	B-X
safe	B-X
and	B-X
effective	B-X
before	B-X
testing	B-X
the	B-X
drugs	B-X
in	B-X
humans	B-X
with	B-X
multiple	B-X
myeloma	B-X
<EOS>	B-X
Two	B-X
of	B-X
them	B-X
did	B-X
not	B-X
receive	B-X
second	B-X
line	B-X
anti	B-X
-	B-X
rejection	B-X
treatment	B-X
due	B-X
to	B-X
economic	B-X
reasons	B-X
,	B-X
and	B-X
three	B-X
of	B-X
them	B-X
were	B-X
treated	B-X
with	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
<EOS>	B-X
,	B-X
of	B-X
the	B-X
patients	B-X
with	B-X
stage	B-X
IA	B-X
ovarian	B-X
cancer	B-X
,	B-X
who	B-X
were	B-X
admitted	B-X
to	B-X
Nantong	B-X
tumor	B-X
Hospital	B-X
between	B-X
2013	B-X
and	B-X
2020	B-X
were	B-X
analyzed	B-X
retrospectively	B-X

Concerning	O
myeloid	O
leukemia	O
,	O
ANLL	O
patients	O
had	O
GR	B-protein
concentrations	O
slightly	O
higher	O
than	O
those	O
found	O
in	O
the	O
ALL	O
group	O
but	O
exhibited	O
the	O
lowest	O
degree	O
of	O
inhibition	O
of	O
spontaneous	O
[	O
3H	O
]	O
TdR	O
uptake	O
by	O
dexamethasone	O
(	O
stimulatory	O
effects	O
occurred	O
in	O
some	O
cases	O
)	O
.	O
<EOS>	B-X
Concerning	B-X
myeloid	B-X
leukemia	B-X
,	B-X
ANLL	B-X
patients	B-X
had	B-X
GR	B-X
concentrations	B-X
slightly	B-X
higher	B-X
than	B-X
those	B-X
found	B-X
in	B-X
the	B-X
ALL	B-X
group	B-X
but	B-X
exhibited	B-X
the	B-X
lowest	B-X
degree	B-X
of	B-X
inhibition	B-X
of	B-X
spontaneous	B-X
[	B-X
3H	B-X
]	B-X
TdR	B-X
uptake	B-X
by	B-X
dexamethasone	B-X
(	B-X
stimulatory	B-X
effects	B-X
occurred	B-X
in	B-X
some	B-X
cases	B-X
)	B-X
<EOS>	B-X
Within	B-X
the	B-X
lymphoproliferative	B-X
diseases	B-X
,	B-X
ALL	B-X
cells	B-X
exhibited	B-X
the	B-X
highest	B-X
GR	B-X
concentration	B-X
(	B-X
regardless	B-X
of	B-X
the	B-X
method	B-X
used	B-X
)	B-X
and	B-X
the	B-X
highest	B-X
in	B-X
vitro	B-X
inhibition	B-X
of	B-X
spontaneous	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
(	B-X
[	B-X
3H	B-X
]	B-X
TdR	B-X
)	B-X
uptake	B-X
by	B-X
glucocorticoids	B-X
<EOS>	B-X
Cells	B-X
from	B-X
the	B-X
only	B-X
two	B-X
ALL	B-X
patients	B-X
who	B-X
did	B-X
not	B-X
undergo	B-X
a	B-X
remission	B-X
after	B-X
glucocorticoid	B-X
-	B-X
inclusive	B-X
chemotherapy	B-X
had	B-X
both	B-X
the	B-X
lowest	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
dexamethasone	B-X
and	B-X
the	B-X
lowest	B-X
GR	B-X
concentration	B-X
with	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
<EOS>	B-X
A	B-X
significant	B-X
relationship	B-X
between	B-X
GR	B-X
concentration	B-X
(	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X
)	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
dexamethasone	B-X
was	B-X
also	B-X
found	B-X

CML	B-cell_line
cells	I-cell_line
exhibited	O
an	O
inhibition	O
degree	O
by	O
in	O
vitro	O
glucocorticoids	O
significantly	O
higher	O
than	O
that	O
of	O
ANLL	B-cell_line
cells	I-cell_line
but	O
not	O
different	O
from	O
that	O
of	O
lymphoproliferative	O
diseases	O
.	O

No	O
clear	O
relationship	O
among	O
GR	O
pattern	O
,	O
in	O
vitro	O
cell	O
sensitivity	O
to	O
glucocorticoids	O
,	O
and	O
clinicohematologic	O
parameters	O
was	O
observed	O
in	O
myeloid	O
leukemia-bearing	O
patients	O
.	O
<EOS>	B-X
No	B-X
clear	B-X
relationship	B-X
among	B-X
GR	B-X
pattern	B-X
,	B-X
in	B-X
vitro	B-X
cell	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
,	B-X
and	B-X
clinicohematologic	B-X
parameters	B-X
was	B-X
observed	B-X
in	B-X
myeloid	B-X
leukemia	B-X
-	B-X
bearing	B-X
patients	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
steroid	B-X
hormones	B-X
in	B-X
human	B-X
lymphoproliferative	B-X
diseases	B-X
and	B-X
myeloid	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
CLL	B-X
cells	B-X
presented	B-X
the	B-X
highest	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
in	B-X
PHA	B-X
-	B-X
stimulated	B-X
cell	B-X
cultures	B-X
<EOS>	B-X
Cells	B-X
from	B-X
the	B-X
only	B-X
two	B-X
ALL	B-X
patients	B-X
who	B-X
did	B-X
not	B-X
undergo	B-X
a	B-X
remission	B-X
after	B-X
glucocorticoid	B-X
-	B-X
inclusive	B-X
chemotherapy	B-X
had	B-X
both	B-X
the	B-X
lowest	B-X
in	B-X
vitro	B-X
sensitivity	B-X
to	B-X
dexamethasone	B-X
and	B-X
the	B-X
lowest	B-X
GR	B-X
concentration	B-X
with	B-X
whole	B-X
-	B-X
cell	B-X
assay	B-X

Glucocorticoid	B-protein
receptors	I-protein
and	O
in	O
vitro	O
corticosensitivity	O
of	O
peanut-positive	B-cell_line
and	I-cell_line
peanut-negative	I-cell_line
human	I-cell_line
thymocyte	I-cell_line
subpopulations	I-cell_line
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
in	B-X
vitro	B-X
corticosensitivity	B-X
of	B-X
peanut	B-X
-	B-X
positive	B-X
and	B-X
peanut	B-X
-	B-X
negative	B-X
human	B-X
thymocyte	B-X
subpopulations	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
density	B-X
and	B-X
corticosensitivity	B-X
are	B-X
not	B-X
directly	B-X
correlated	B-X
and	B-X
that	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
may	B-X
be	B-X
dependent	B-X
on	B-X
the	B-X
degree	B-X
of	B-X
immunologic	B-X
maturation	B-X
<EOS>	B-X
The	B-X
unagglutinated	B-X
thymocytes	B-X
(	B-X
peanut	B-X
negative	B-X
)	B-X
contained	B-X
about	B-X
2	B-X
times	B-X
more	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
than	B-X
agglutinated	B-X
(	B-X
peanut	B-X
positive	B-X
)	B-X
ones	B-X
(	B-X
7650	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
1550	B-X
S	B-X
<EOS>	B-X
Despite	B-X
the	B-X
greater	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
,	B-X
the	B-X
peanut	B-X
-	B-X
negative	B-X
thymocyte	B-X
subpopulation	B-X
did	B-X
not	B-X
differ	B-X
from	B-X
the	B-X
peanut	B-X
-	B-X
positive	B-X
one	B-X
in	B-X
its	B-X
sensitivity	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
triamcinolone	B-X
acetonide	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
measurements	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
radiolabeled	B-X
precursors	B-X
of	B-X
protein	B-X
and	B-X
DNA	B-X

In	O
6	O
human	O
thymus	O
glands	O
,	O
the	O
immature	O
subset	O
of	O
thymocytes	B-cell_type
was	O
separated	O
from	O
the	O
more	O
mature	O
one	O
,	O
by	O
differential	O
peanut	O
lectin	O
agglutination	O
.	O
<EOS>	B-X
In	B-X
6	B-X
human	B-X
thymus	B-X
glands	B-X
,	B-X
the	B-X
immature	B-X
subset	B-X
of	B-X
thymocytes	B-X
was	B-X
separated	B-X
from	B-X
the	B-X
more	B-X
mature	B-X
one	B-X
,	B-X
by	B-X
differential	B-X
peanut	B-X
lectin	B-X
agglutination	B-X
<EOS>	B-X
The	B-X
affinity	B-X
for	B-X
steroid	B-X
was	B-X
similar	B-X
in	B-X
both	B-X
cell	B-X
subsets	B-X
,	B-X
as	B-X
was	B-X
the	B-X
stereospecificity	B-X
for	B-X
glucocorticoids	B-X
,	B-X
the	B-X
time	B-X
-	B-X
course	B-X
of	B-X
steroid	B-X
-	B-X
receptor	B-X
association	B-X
,	B-X
and	B-X
cytoplasmic	B-X
to	B-X
nuclear	B-X
translocation	B-X
<EOS>	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
density	B-X
and	B-X
corticosensitivity	B-X
are	B-X
not	B-X
directly	B-X
correlated	B-X
and	B-X
that	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
may	B-X
be	B-X
dependent	B-X
on	B-X
the	B-X
degree	B-X
of	B-X
immunologic	B-X
maturation	B-X
<EOS>	B-X
Despite	B-X
the	B-X
greater	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
,	B-X
the	B-X
peanut	B-X
-	B-X
negative	B-X
thymocyte	B-X
subpopulation	B-X
did	B-X
not	B-X
differ	B-X
from	B-X
the	B-X
peanut	B-X
-	B-X
positive	B-X
one	B-X
in	B-X
its	B-X
sensitivity	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
triamcinolone	B-X
acetonide	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
measurements	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
radiolabeled	B-X
precursors	B-X
of	B-X
protein	B-X
and	B-X
DNA	B-X

These	O
2	O
cell	O
subpopulations	O
were	O
analyzed	O
for	O
glucocorticoid	B-protein
receptor	I-protein
content	O
by	O
using	O
a	O
whole	O
cell	O
assay	O
,	O
with	O
(	O
3H	O
)	O
-triamcinolone	O
acetonide	O
as	O
tracer	O
.	O
<EOS>	B-X
These	B-X
2	B-X
cell	B-X
subpopulations	B-X
were	B-X
analyzed	B-X
for	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
by	B-X
using	B-X
a	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
with	B-X
(	B-X
3H	B-X
)	B-X
	B-X
-	B-X
triamcinolone	B-X
acetonide	B-X
as	B-X
tracer	B-X
<EOS>	B-X
The	B-X
affinity	B-X
for	B-X
steroid	B-X
was	B-X
similar	B-X
in	B-X
both	B-X
cell	B-X
subsets	B-X
,	B-X
as	B-X
was	B-X
the	B-X
stereospecificity	B-X
for	B-X
glucocorticoids	B-X
,	B-X
the	B-X
time	B-X
-	B-X
course	B-X
of	B-X
steroid	B-X
-	B-X
receptor	B-X
association	B-X
,	B-X
and	B-X
cytoplasmic	B-X
to	B-X
nuclear	B-X
translocation	B-X
<EOS>	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
density	B-X
and	B-X
corticosensitivity	B-X
are	B-X
not	B-X
directly	B-X
correlated	B-X
and	B-X
that	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
may	B-X
be	B-X
dependent	B-X
on	B-X
the	B-X
degree	B-X
of	B-X
immunologic	B-X
maturation	B-X
<EOS>	B-X
Despite	B-X
the	B-X
greater	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
,	B-X
the	B-X
peanut	B-X
-	B-X
negative	B-X
thymocyte	B-X
subpopulation	B-X
did	B-X
not	B-X
differ	B-X
from	B-X
the	B-X
peanut	B-X
-	B-X
positive	B-X
one	B-X
in	B-X
its	B-X
sensitivity	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
triamcinolone	B-X
acetonide	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
measurements	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
radiolabeled	B-X
precursors	B-X
of	B-X
protein	B-X
and	B-X
DNA	B-X

The	O
unagglutinated	B-cell_type
thymocytes	I-cell_type
(	O
peanut	O
negative	O
)	O
contained	O
about	O
2	O
times	O
more	O
receptor	O
sites	O
per	O
cell	O
than	O
agglutinated	O
(	O
peanut	O
positive	O
)	O
ones	O
(	O
7650	O
+/-	O
1550	O
S.D.	O
verus	O
3195	O
+/-	O
896	O
S.D.	O
)	O
.	O
<EOS>	B-X
The	B-X
unagglutinated	B-X
thymocytes	B-X
(	B-X
peanut	B-X
negative	B-X
)	B-X
contained	B-X
about	B-X
2	B-X
times	B-X
more	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
than	B-X
agglutinated	B-X
(	B-X
peanut	B-X
positive	B-X
)	B-X
ones	B-X
(	B-X
7650	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
1550	B-X
S	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
peanut	B-X
-	B-X
negative	B-X
subset	B-X
appeared	B-X
more	B-X
resistant	B-X
in	B-X
vitro	B-X
to	B-X
the	B-X
steroid	B-X
-	B-X
induced	B-X
cell	B-X
lysis	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
peanut	B-X
-	B-X
positive	B-X
one	B-X
<EOS>	B-X
Despite	B-X
the	B-X
greater	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
,	B-X
the	B-X
peanut	B-X
-	B-X
negative	B-X
thymocyte	B-X
subpopulation	B-X
did	B-X
not	B-X
differ	B-X
from	B-X
the	B-X
peanut	B-X
-	B-X
positive	B-X
one	B-X
in	B-X
its	B-X
sensitivity	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
triamcinolone	B-X
acetonide	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
measurements	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
radiolabeled	B-X
precursors	B-X
of	B-X
protein	B-X
and	B-X
DNA	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
in	B-X
vitro	B-X
corticosensitivity	B-X
of	B-X
peanut	B-X
-	B-X
positive	B-X
and	B-X
peanut	B-X
-	B-X
negative	B-X
human	B-X
thymocyte	B-X
subpopulations	B-X
.	B-X

The	O
affinity	O
for	O
steroid	O
was	O
similar	O
in	O
both	O
cell	O
subsets	O
,	O
as	O
was	O
the	O
stereospecificity	O
for	O
glucocorticoids	O
,	O
the	O
time-course	O
of	O
steroid-receptor	O
association	O
,	O
and	O
cytoplasmic	O
to	O
nuclear	O
translocation	O
.	O
<EOS>	B-X
The	B-X
affinity	B-X
for	B-X
steroid	B-X
was	B-X
similar	B-X
in	B-X
both	B-X
cell	B-X
subsets	B-X
,	B-X
as	B-X
was	B-X
the	B-X
stereospecificity	B-X
for	B-X
glucocorticoids	B-X
,	B-X
the	B-X
time	B-X
-	B-X
course	B-X
of	B-X
steroid	B-X
-	B-X
receptor	B-X
association	B-X
,	B-X
and	B-X
cytoplasmic	B-X
to	B-X
nuclear	B-X
translocation	B-X
<EOS>	B-X
These	B-X
2	B-X
cell	B-X
subpopulations	B-X
were	B-X
analyzed	B-X
for	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
by	B-X
using	B-X
a	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
with	B-X
(	B-X
3H	B-X
)	B-X
	B-X
-	B-X
triamcinolone	B-X
acetonide	B-X
as	B-X
tracer	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
peanut	B-X
-	B-X
negative	B-X
subset	B-X
appeared	B-X
more	B-X
resistant	B-X
in	B-X
vitro	B-X
to	B-X
the	B-X
steroid	B-X
-	B-X
induced	B-X
cell	B-X
lysis	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
peanut	B-X
-	B-X
positive	B-X
one	B-X
<EOS>	B-X
In	B-X
6	B-X
human	B-X
thymus	B-X
glands	B-X
,	B-X
the	B-X
immature	B-X
subset	B-X
of	B-X
thymocytes	B-X
was	B-X
separated	B-X
from	B-X
the	B-X
more	B-X
mature	B-X
one	B-X
,	B-X
by	B-X
differential	B-X
peanut	B-X
lectin	B-X
agglutination	B-X

Despite	O
the	O
greater	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	O
,	O
the	O
peanut-negative	B-cell_line
thymocyte	I-cell_line
subpopulation	I-cell_line
did	O
not	O
differ	O
from	O
the	O
peanut-positive	B-cell_line
one	O
in	O
its	O
sensitivity	O
to	O
the	O
inhibitory	O
effects	O
of	O
triamcinolone	O
acetonide	O
,	O
as	O
determined	O
by	O
measurements	O
of	O
the	O
incorporation	O
of	O
radiolabeled	O
precursors	O
of	O
protein	O
and	O
DNA	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
greater	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
,	B-X
the	B-X
peanut	B-X
-	B-X
negative	B-X
thymocyte	B-X
subpopulation	B-X
did	B-X
not	B-X
differ	B-X
from	B-X
the	B-X
peanut	B-X
-	B-X
positive	B-X
one	B-X
in	B-X
its	B-X
sensitivity	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
triamcinolone	B-X
acetonide	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
measurements	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
radiolabeled	B-X
precursors	B-X
of	B-X
protein	B-X
and	B-X
DNA	B-X
<EOS>	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
density	B-X
and	B-X
corticosensitivity	B-X
are	B-X
not	B-X
directly	B-X
correlated	B-X
and	B-X
that	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
may	B-X
be	B-X
dependent	B-X
on	B-X
the	B-X
degree	B-X
of	B-X
immunologic	B-X
maturation	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
peanut	B-X
-	B-X
negative	B-X
subset	B-X
appeared	B-X
more	B-X
resistant	B-X
in	B-X
vitro	B-X
to	B-X
the	B-X
steroid	B-X
-	B-X
induced	B-X
cell	B-X
lysis	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
peanut	B-X
-	B-X
positive	B-X
one	B-X
<EOS>	B-X
The	B-X
unagglutinated	B-X
thymocytes	B-X
(	B-X
peanut	B-X
negative	B-X
)	B-X
contained	B-X
about	B-X
2	B-X
times	B-X
more	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
than	B-X
agglutinated	B-X
(	B-X
peanut	B-X
positive	B-X
)	B-X
ones	B-X
(	B-X
7650	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
1550	B-X
S	B-X

Moreover	O
,	O
the	O
peanut-negative	B-cell_line
subset	I-cell_line
appeared	O
more	O
resistant	O
in	O
vitro	O
to	O
the	O
steroid-induced	O
cell	O
lysis	O
as	O
compared	O
to	O
the	O
peanut-positive	B-cell_line
one	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
glucocorticoid	O
receptor	O
density	O
and	O
corticosensitivity	O
are	O
not	O
directly	O
correlated	O
and	O
that	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	O
may	O
be	O
dependent	O
on	O
the	O
degree	O
of	O
immunologic	O
maturation	O

Defective	O
binding	O
and	O
function	O
of	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
patients	O
with	O
end-organ	O
resistance	O
to	O
1	O
,	O
25-dihydroxyvitamin	O
D	O
.	O
<EOS>	B-X
Defective	B-X
binding	B-X
and	B-X
function	B-X
of	B-X
1,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
receptors	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
cells	B-X
of	B-X
patients	B-X
with	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
1,25	B-X
-	B-X
dihydroxyvitamin	B-X
D	B-X
.	B-X
<EOS>	B-X
The	B-X
conclusions	B-X
from	B-X
these	B-X
findings	B-X
are	B-X
:	B-X
(	B-X
a	B-X
)	B-X
the	B-X
inhibition	B-X
of	B-X
mitogenic	B-X
stimulation	B-X
by	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
is	B-X
mediated	B-X
by	B-X
specific	B-X
functional	B-X
receptors	B-X
to	B-X
the	B-X
hormone	B-X
;	B-X
and	B-X
(	B-X
b	B-X
)	B-X
the	B-X
receptors	B-X
for	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
in	B-X
mononuclear	B-X
cells	B-X
are	B-X
probably	B-X
controlled	B-X
genetically	B-X
by	B-X
the	B-X
same	B-X
mechanisms	B-X
as	B-X
the	B-X
effector	B-X
system	B-X
in	B-X
well	B-X
-	B-X
characterized	B-X
target	B-X
organs	B-X
of	B-X
the	B-X
hormone	B-X
,	B-X
such	B-X
as	B-X
intestine	B-X
and	B-X
kidney	B-X
<EOS>	B-X
We	B-X
studied	B-X
lymphocytes	B-X
from	B-X
six	B-X
patients	B-X
from	B-X
four	B-X
different	B-X
kindreds	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
hereditary	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D	B-X
(	B-X
the	B-X
so	B-X
-	B-X
called	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
rickets	B-X
type	B-X
II	B-X
)	B-X
<EOS>	B-X
A	B-X
similar	B-X
pattern	B-X
of	B-X
the	B-X
vitamin	B-X
D	B-X
effector	B-X
system	B-X
was	B-X
previously	B-X
observed	B-X
in	B-X
fibroblasts	B-X
cultured	B-X
from	B-X
skin	B-X
biopsies	B-X
of	B-X
the	B-X
same	B-X
group	B-X
of	B-X
patients	B-X

Lectin-induced	O
DNA	O
synthesis	O
by	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
17	O
normal	O
donors	O
was	O
inhibited	O
(	O
40-60	O
%	O
)	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
[	O
OH	O
]	O
2D3	O
)	O
at	O
physiological	O
concentrations	O
(	O
10	O
(	O
-10	O
)	O
-10	O
(	O
-9	O
)	O
M	O
)	O
.	O

The	O
lymphocytes	B-cell_type
acquire	O
specific	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
upon	O
activation	O
by	O
the	O
lectins	B-protein
.	O
<EOS>	B-X
The	B-X
lymphocytes	B-X
acquire	B-X
specific	B-X
receptors	B-X
for	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
upon	B-X
activation	B-X
by	B-X
the	B-X
lectins	B-X
<EOS>	B-X
In	B-X
five	B-X
patients	B-X
(	B-X
three	B-X
kindreds	B-X
)	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
did	B-X
not	B-X
acquire	B-X
receptors	B-X
for	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
upon	B-X
phytohemagglutinin	B-X
-	B-X
induced	B-X
activation	B-X
<EOS>	B-X
Activated	B-X
lymphocytes	B-X
of	B-X
the	B-X
sixth	B-X
patient	B-X
from	B-X
a	B-X
fourth	B-X
kindred	B-X
exhibited	B-X
normal	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
but	B-X
the	B-X
hormone	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
mitogenic	B-X
stimulation	B-X
<EOS>	B-X
We	B-X
studied	B-X
lymphocytes	B-X
from	B-X
six	B-X
patients	B-X
from	B-X
four	B-X
different	B-X
kindreds	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
hereditary	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D	B-X
(	B-X
the	B-X
so	B-X
-	B-X
called	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
rickets	B-X
type	B-X
II	B-X
)	B-X

This	O
process	O
precedes	O
the	O
inhibitory	O
effect	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
<EOS>	B-X
This	B-X
process	B-X
precedes	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
<EOS>	B-X
The	B-X
lymphocytes	B-X
acquire	B-X
specific	B-X
receptors	B-X
for	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
upon	B-X
activation	B-X
by	B-X
the	B-X
lectins	B-X
<EOS>	B-X
We	B-X
studied	B-X
lymphocytes	B-X
from	B-X
six	B-X
patients	B-X
from	B-X
four	B-X
different	B-X
kindreds	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
hereditary	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D	B-X
(	B-X
the	B-X
so	B-X
-	B-X
called	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
rickets	B-X
type	B-X
II	B-X
)	B-X
<EOS>	B-X
Activated	B-X
lymphocytes	B-X
of	B-X
the	B-X
sixth	B-X
patient	B-X
from	B-X
a	B-X
fourth	B-X
kindred	B-X
exhibited	B-X
normal	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
but	B-X
the	B-X
hormone	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
mitogenic	B-X
stimulation	B-X

We	O
studied	O
lymphocytes	B-cell_type
from	O
six	O
patients	O
from	O
four	O
different	O
kindreds	O
with	O
the	O
syndrome	O
of	O
hereditary	O
end-organ	O
resistance	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
(	O
the	O
so-called	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
)	O
.	O
<EOS>	B-X
We	B-X
studied	B-X
lymphocytes	B-X
from	B-X
six	B-X
patients	B-X
from	B-X
four	B-X
different	B-X
kindreds	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
hereditary	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D	B-X
(	B-X
the	B-X
so	B-X
-	B-X
called	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
rickets	B-X
type	B-X
II	B-X
)	B-X
<EOS>	B-X
Activated	B-X
lymphocytes	B-X
of	B-X
the	B-X
sixth	B-X
patient	B-X
from	B-X
a	B-X
fourth	B-X
kindred	B-X
exhibited	B-X
normal	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
but	B-X
the	B-X
hormone	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
mitogenic	B-X
stimulation	B-X
<EOS>	B-X
The	B-X
lymphocytes	B-X
acquire	B-X
specific	B-X
receptors	B-X
for	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
upon	B-X
activation	B-X
by	B-X
the	B-X
lectins	B-X
<EOS>	B-X
In	B-X
five	B-X
patients	B-X
(	B-X
three	B-X
kindreds	B-X
)	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
did	B-X
not	B-X
acquire	B-X
receptors	B-X
for	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
upon	B-X
phytohemagglutinin	B-X
-	B-X
induced	B-X
activation	B-X

In	O
five	O
patients	O
(	O
three	O
kindreds	O
)	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
did	O
not	O
acquire	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
upon	O
phytohemagglutinin-induced	O
activation	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
normal	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
mitogenic	O
stimulation	O
of	O
these	O
patients	O
'	O
lymphocytes	B-cell_type
by	O
phytohemagglutinin	B-protein
and	O
concanavalin	O
A	O
was	O
not	O
inhibited	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
when	B-X
individual	B-X
patients	B-X
were	B-X
followed	B-X
through	B-X
their	B-X
clinical	B-X
illness	B-X
,	B-X
LN	B-X
patients	B-X
had	B-X
high	B-X
levels	B-X
of	B-X
SI	B-X
,	B-X
particularly	B-X
in	B-X
the	B-X
beginning	B-X
of	B-X
acute	B-X
exacerbations	B-X
;	B-X
the	B-X
SI	B-X
levels	B-X
than	B-X
decreased	B-X
sharply	B-X
in	B-X
the	B-X
latter	B-X
phase	B-X
of	B-X
relapse	B-X
and	B-X
again	B-X
increased	B-X
to	B-X
relatively	B-X
normal	B-X
levels	B-X
with	B-X
the	B-X
onset	B-X
of	B-X
clinical	B-X
remission	B-X
<EOS>	B-X
These	B-X
in	B-X
vitro	B-X
findings	B-X
suggest	B-X
that	B-X
there	B-X
exists	B-X
an	B-X
alteration	B-X
in	B-X
Con	B-X
A	B-X
-	B-X
induced	B-X
SCA	B-X
in	B-X
a	B-X
group	B-X
of	B-X
patients	B-X
with	B-X
LN	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
mean	B-X
suppression	B-X
values	B-X
in	B-X
the	B-X
PBL	B-X
from	B-X
LN	B-X
patients	B-X
in	B-X
remission	B-X
and	B-X
CGN	B-X
patients	B-X
with	B-X
or	B-X
without	B-X
nephrotic	B-X
syndrome	B-X
,	B-X
whether	B-X
the	B-X
mitogen	B-X
used	B-X
was	B-X
Con	B-X
A	B-X
or	B-X
PHA	B-X
,	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
control	B-X
subjects	B-X
<EOS>	B-X
We	B-X
have	B-X
assessed	B-X
the	B-X
ability	B-X
of	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
(	B-X
PBL	B-X
)	B-X
stimulated	B-X
by	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
to	B-X
inhibit	B-X
the	B-X
proliferative	B-X
response	B-X
of	B-X
normal	B-X
allogeneic	B-X
lymphocytes	B-X
by	B-X
both	B-X
Con	B-X
A	B-X
and	B-X
phytohaemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X

Activated	O
lymphocytes	B-cell_type
of	O
the	O
sixth	O
patient	O
from	O
a	O
fourth	O
kindred	O
exhibited	O
normal	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
but	O
the	O
hormone	O
failed	O
to	O
inhibit	O
the	O
mitogenic	O
stimulation	O
.	O
<EOS>	B-X
Activated	B-X
lymphocytes	B-X
of	B-X
the	B-X
sixth	B-X
patient	B-X
from	B-X
a	B-X
fourth	B-X
kindred	B-X
exhibited	B-X
normal	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
but	B-X
the	B-X
hormone	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
mitogenic	B-X
stimulation	B-X
<EOS>	B-X
We	B-X
studied	B-X
lymphocytes	B-X
from	B-X
six	B-X
patients	B-X
from	B-X
four	B-X
different	B-X
kindreds	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
hereditary	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D	B-X
(	B-X
the	B-X
so	B-X
-	B-X
called	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
rickets	B-X
type	B-X
II	B-X
)	B-X
<EOS>	B-X
The	B-X
lymphocytes	B-X
acquire	B-X
specific	B-X
receptors	B-X
for	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
upon	B-X
activation	B-X
by	B-X
the	B-X
lectins	B-X
<EOS>	B-X
A	B-X
similar	B-X
pattern	B-X
of	B-X
the	B-X
vitamin	B-X
D	B-X
effector	B-X
system	B-X
was	B-X
previously	B-X
observed	B-X
in	B-X
fibroblasts	B-X
cultured	B-X
from	B-X
skin	B-X
biopsies	B-X
of	B-X
the	B-X
same	B-X
group	B-X
of	B-X
patients	B-X

A	O
similar	O
pattern	O
of	O
the	O
vitamin	O
D	O
effector	O
system	O
was	O
previously	O
observed	O
in	O
fibroblasts	O
cultured	O
from	O
skin	O
biopsies	O
of	O
the	O
same	O
group	O
of	O
patients	O
.	O
<EOS>	B-X
A	B-X
similar	B-X
pattern	B-X
of	B-X
the	B-X
vitamin	B-X
D	B-X
effector	B-X
system	B-X
was	B-X
previously	B-X
observed	B-X
in	B-X
fibroblasts	B-X
cultured	B-X
from	B-X
skin	B-X
biopsies	B-X
of	B-X
the	B-X
same	B-X
group	B-X
of	B-X
patients	B-X
<EOS>	B-X
Activated	B-X
lymphocytes	B-X
of	B-X
the	B-X
sixth	B-X
patient	B-X
from	B-X
a	B-X
fourth	B-X
kindred	B-X
exhibited	B-X
normal	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
but	B-X
the	B-X
hormone	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
mitogenic	B-X
stimulation	B-X
<EOS>	B-X
Defective	B-X
binding	B-X
and	B-X
function	B-X
of	B-X
1,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
receptors	B-X
in	B-X
peripheral	B-X
mononuclear	B-X
cells	B-X
of	B-X
patients	B-X
with	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
1,25	B-X
-	B-X
dihydroxyvitamin	B-X
D	B-X
.	B-X
<EOS>	B-X
We	B-X
studied	B-X
lymphocytes	B-X
from	B-X
six	B-X
patients	B-X
from	B-X
four	B-X
different	B-X
kindreds	B-X
with	B-X
the	B-X
syndrome	B-X
of	B-X
hereditary	B-X
end	B-X
-	B-X
organ	B-X
resistance	B-X
to	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D	B-X
(	B-X
the	B-X
so	B-X
-	B-X
called	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
rickets	B-X
type	B-X
II	B-X
)	B-X

The	O
conclusions	O
from	O
these	O
findings	O
are	O
:	O
(	O
a	O
)	O
the	O
inhibition	O
of	O
mitogenic	O
stimulation	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
mediated	O
by	O
specific	B-protein
functional	I-protein
receptors	I-protein
to	O
the	O
hormone	O
;	O
and	O
(	O
b	O
)	O
the	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
are	O
probably	O
controlled	O
genetically	O
by	O
the	O
same	O
mechanisms	O
as	O
the	O
effector	O
system	O
in	O
well-characterized	O
target	O
organs	O
of	O
the	O
hormone	O
,	O
such	O
as	O
intestine	O
and	O
kidney	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
of	O
mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
myasthenia	O
gravis	O
patients	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
of	B-X
mononuclear	B-X
leukocytes	B-X
from	B-X
myasthenia	B-X
gravis	B-X
patients	B-X
.	B-X
<EOS>	B-X
Altered	B-X
expression	B-X
of	B-X
chemokine	B-X
receptor	B-X
CXCR5	B-X
on	B-X
T	B-X
cells	B-X
of	B-X
myasthenia	B-X
gravis	B-X
patients	B-X
.	B-X
<EOS>	B-X
[	B-X
The	B-X
investigation	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
myasthenia	B-X
gravis	B-X
]	B-X
.	B-X
<EOS>	B-X
Clinical	B-X
implication	B-X
of	B-X
peripheral	B-X
CD4+CD25+	B-X
regulatory	B-X
T	B-X
cells	B-X
and	B-X
Th17	B-X
cells	B-X
in	B-X
myasthenia	B-X
gravis	B-X
patients	B-X
.	B-X

The	O
present	O
study	O
was	O
performed	O
to	O
analyse	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
from	O
39	O
myasthenia	O
gravis	O
(	O
MG	O
)	O
patients	O
(	O
unoperated	O
patients	O
(	O
n	O
=	O
13	O
)	O
,	O
thymectomized	O
patients	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
receiving	O
glucocorticoids	O
:	O
thymectomized	O
(	O
n	O
=	O
11	O
)	O
and	O
unoperated	O
(	O
n	O
=	O
6	O
]	O
.	O

A	O
whole	O
cell	O
binding	O
assay	O
with	O
3	O
(	O
H	O
)	O
dexamethasone	O
was	O
used	O
.	O
<EOS>	B-X
A	B-X
whole	B-X
cell	B-X
binding	B-X
assay	B-X
with	B-X
3	B-X
(	B-X
H	B-X
)	B-X
dexamethasone	B-X
was	B-X
used	B-X
<EOS>	B-X
The	B-X
increase	B-X
in	B-X
EGF	B-X
binding	B-X
depends	B-X
upon	B-X
the	B-X
dose	B-X
of	B-X
dexamethasone	B-X
,	B-X
being	B-X
raised	B-X
from	B-X
10	B-X
(	B-X
	B-X
-	B-X
11	B-X
)	B-X
to	B-X
10	B-X
(	B-X
	B-X
-	B-X
6	B-X
)	B-X
M	B-X
<EOS>	B-X
as	B-X
determined	B-X
by	B-X
inoculation	B-X
of	B-X
domestic	B-X
ducklings	B-X
with	B-X
blood	B-X
from	B-X
dexamethasone	B-X
-	B-X
immunosuppressed	B-X
pigeons	B-X
<EOS>	B-X
Scatchard	B-X
analysis	B-X
of	B-X
the	B-X
binding	B-X
after	B-X
15	B-X
min	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
demonstrates	B-X
a	B-X
single	B-X
class	B-X
of	B-X
binding	B-X
sites	B-X

GR	B-protein
mean	O
values	O
were	O
significantly	O
higher	O
in	O
the	O
MNL	B-cell_type
of	O
MG	O
patients	O
(	O
thymectomized	O
or	O
not	O
)	O
not	O
receiving	O
glucocorticoid	O
than	O
in	O
the	O
MNL	B-cell_type
of	O
healthy	O
donors	O
.	O

Affinity	O
was	O
within	O
the	O
normal	O
range	O
.	O
<EOS>	B-X
Under	B-X
the	B-X
optimum	B-X
conditions	B-X
,	B-X
wide	B-X
linear	B-X
range	B-X
(	B-X
0	B-X
<EOS>	B-X
High	B-X
selectivity	B-X
was	B-X
obtained	B-X
with	B-X
adsorption	B-X
efficiency	B-X
≥	B-X
86	B-X
<EOS>	B-X
3	B-X
in	B-X
the	B-X
Guizhou	B-X
Han	B-X
population	B-X
<EOS>	B-X
In	B-X
the	B-X
in	B-X
vitro	B-X
enzyme	B-X
assay	B-X
,	B-X
the	B-X
standard	B-X
drug	B-X
Sitagliptin	B-X
had	B-X
an	B-X
IC	B-X

Sex	O
,	O
age	O
or	O
clinical	O
forms	O
of	O
illness	O
did	O
not	O
influence	O
the	O
results	O
.	O
<EOS>	B-X
,	B-X
age	B-X
;	B-X
gender	B-X
;	B-X
condomless	B-X
vaginal	B-X
or	B-X
anal	B-X
sex	B-X
)	B-X
<EOS>	B-X
Serum	B-X
and	B-X
plasma	B-X
protein	B-X
biomarkers	B-X
associated	B-X
with	B-X
frailty	B-X
in	B-X
patients	B-X
with	B-X
cirrhosis	B-X
.	B-X
<EOS>	B-X
Sex	B-X
stratified	B-X
ordinal	B-X
regression	B-X
examined	B-X
the	B-X
social	B-X
gradient	B-X
in	B-X
having	B-X
less	B-X
favourable	B-X
CMRS	B-X
<EOS>	B-X
Preoperative	B-X
and	B-X
postoperative	B-X
spinal	B-X
parameters	B-X
were	B-X
measured	B-X
,	B-X
and	B-X
the	B-X
differences	B-X
between	B-X
these	B-X
parameters	B-X
were	B-X
calculated	B-X

In	O
patients	O
receiving	O
prednisone	O
(	O
Pd	O
)	O
the	O
GR	B-protein
values	O
were	O
significantly	O
lower	O
than	O
in	O
MG	O
patients	O
without	O
Pd	O
therapy	O
,	O
independent	O
of	O
Pd	O
dose	O
or	O
time	O
of	O
administration	O
.	O
<EOS>	B-X
Whether	B-X
amantadine	B-X
is	B-X
effective	B-X
and	B-X
safe	B-X
among	B-X
patients	B-X
with	B-X
different	B-X
COVID	B-X
-	B-X
19	B-X
severity	B-X
classifications	B-X
<EOS>	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
PM	B-X
-	B-X
HDOX	B-X
intensities	B-X
around	B-X
the	B-X
surgical	B-X
margins	B-X
of	B-X
the	B-X
preoperative	B-X
administration	B-X
group	B-X
were	B-X
more	B-X
than	B-X
twice	B-X
that	B-X
of	B-X
the	B-X
postoperative	B-X
administration	B-X
group	B-X
due	B-X
to	B-X
bypassing	B-X
the	B-X
thrombus	B-X
formed	B-X
in	B-X
the	B-X
broken	B-X
BBB	B-X
<EOS>	B-X
In	B-X
vitro	B-X
cell	B-X
based	B-X
assays	B-X
were	B-X
used	B-X
to	B-X
measure	B-X
cell	B-X
viability	B-X
and	B-X
survival	B-X
of	B-X
primary	B-X
patient	B-X
-	B-X
derived	B-X
GBM	B-X
cells	B-X
and	B-X
established	B-X
GBM	B-X
cell	B-X
lines	B-X
after	B-X
TMZ	B-X
±	B-X
calpain	B-X
inhibitor	B-X
administration	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
statistically	B-X
significant	B-X
difference	B-X
in	B-X
the	B-X
time	B-X
from	B-X
stroke	B-X
onset	B-X
to	B-X
arrival	B-X
at	B-X
the	B-X
hospital	B-X
(	B-X
97	B-X

No	O
differences	O
in	O
receptor	O
binding	O
between	O
normal	O
subjects	O
and	O
MG	O
patients	O
receiving	O
Pd	O
have	O
been	O
found	O
.	O
<EOS>	B-X
No	B-X
differences	B-X
in	B-X
receptor	B-X
binding	B-X
between	B-X
normal	B-X
subjects	B-X
and	B-X
MG	B-X
patients	B-X
receiving	B-X
Pd	B-X
have	B-X
been	B-X
found	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
transdermal	B-X
oestradiol	B-X
on	B-X
bleeding	B-X
pattern	B-X
,	B-X
hormonal	B-X
profiles	B-X
and	B-X
sex	B-X
steroid	B-X
receptor	B-X
distribution	B-X
in	B-X
the	B-X
endometrium	B-X
of	B-X
Norplant	B-X
users	B-X
.	B-X
<EOS>	B-X
The	B-X
doses	B-X
prescribed	B-X
for	B-X
these	B-X
types	B-X
of	B-X
patients	B-X
should	B-X
not	B-X
exceed	B-X
2	B-X
<EOS>	B-X
81	B-X
%	B-X
)	B-X
were	B-X
similar	B-X
for	B-X
mild	B-X
and	B-X
moderate	B-X
renally	B-X
impaired	B-X
subjects	B-X
and	B-X
matched	B-X
controls	B-X
with	B-X
normal	B-X
renal	B-X
function	B-X

Immunological	O
interference	O
of	O
high	O
dose	O
corticosteroids	O
.	O
<EOS>	B-X
Immunological	B-X
interference	B-X
of	B-X
high	B-X
dose	B-X
corticosteroids	B-X
.	B-X
<EOS>	B-X
All	B-X
patients	B-X
were	B-X
administered	B-X
lansoprazole	B-X
,	B-X
starting	B-X
the	B-X
night	B-X
before	B-X
corticosteroid	B-X
treatment	B-X
began	B-X
<EOS>	B-X
We	B-X
prospectively	B-X
recruited	B-X
30	B-X
patients	B-X
requiring	B-X
primary	B-X
high	B-X
-	B-X
dose	B-X
corticosteroid	B-X
treatment	B-X
for	B-X
immune	B-X
diseases	B-X
<EOS>	B-X
Lymphocyte	B-X
functions	B-X
will	B-X
be	B-X
impaired	B-X

High-dose	O
corticosteroids	O
(	O
HDC	O
)	O
will	O
influence	O
cellular	O
as	O
well	O
as	O
humoral	O
participants	O
of	O
the	O
immune	O
response	O
.	O
<EOS>	B-X
High	B-X
-	B-X
dose	B-X
corticosteroids	B-X
(	B-X
HDC	B-X
)	B-X
will	B-X
influence	B-X
cellular	B-X
as	B-X
well	B-X
as	B-X
humoral	B-X
participants	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
<EOS>	B-X
However	B-X
,	B-X
if	B-X
sepsis	B-X
or	B-X
rejection	B-X
is	B-X
not	B-X
rapidly	B-X
reversed	B-X
,	B-X
complications	B-X
such	B-X
as	B-X
multisystem	B-X
organ	B-X
failure	B-X
and	B-X
bacteremia	B-X
are	B-X
prone	B-X
to	B-X
appear	B-X
<EOS>	B-X
The	B-X
lymphoid	B-X
tissue	B-X
will	B-X
decrease	B-X
in	B-X
size	B-X
and	B-X
weight	B-X
after	B-X
prolonged	B-X
treatment	B-X
with	B-X
HDC	B-X
<EOS>	B-X
Reduced	B-X
T	B-X
-	B-X
cell	B-X
function	B-X
indicated	B-X
by	B-X
impaired	B-X
stimulation	B-X
by	B-X
PHA	B-X
and	B-X
porkweed	B-X
as	B-X
well	B-X
as	B-X
by	B-X
impaired	B-X
lymphokinin	B-X
effects	B-X
on	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
has	B-X
been	B-X
reported	B-X

The	O
lymphoid	O
tissue	O
will	O
decrease	O
in	O
size	O
and	O
weight	O
after	O
prolonged	O
treatment	O
with	O
HDC	O
.	O
<EOS>	B-X
The	B-X
lymphoid	B-X
tissue	B-X
will	B-X
decrease	B-X
in	B-X
size	B-X
and	B-X
weight	B-X
after	B-X
prolonged	B-X
treatment	B-X
with	B-X
HDC	B-X
<EOS>	B-X
This	B-X
can	B-X
be	B-X
explained	B-X
partly	B-X
by	B-X
the	B-X
observed	B-X
reduced	B-X
complement	B-X
activation	B-X
via	B-X
the	B-X
alternative	B-X
as	B-X
well	B-X
as	B-X
the	B-X
classical	B-X
pathway	B-X
in	B-X
association	B-X
with	B-X
HDC	B-X
therapy	B-X
<EOS>	B-X
High	B-X
-	B-X
dose	B-X
corticosteroids	B-X
(	B-X
HDC	B-X
)	B-X
will	B-X
influence	B-X
cellular	B-X
as	B-X
well	B-X
as	B-X
humoral	B-X
participants	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
<EOS>	B-X
Immunological	B-X
interference	B-X
of	B-X
high	B-X
dose	B-X
corticosteroids	B-X
.	B-X

Lymphocyte	O
functions	O
will	O
be	O
impaired	O
.	O

Reduced	O
synthesis	O
of	O
B-	B-cell_type
as	I-cell_type
well	I-cell_type
as	I-cell_type
T-lymphocytes	I-cell_type
will	O
be	O
seen	O
.	O

The	O
inhibitory	O
effect	O
on	O
B-cell	B-cell_type
function	O
can	O
be	O
observed	O
both	O
as	O
decreased	O
serum	O
levels	O
of	O
immunoglobulins	B-protein
and	O
as	O
impaired	O
binding	O
of	O
antibodies	B-protein
and	O
complement	O
to	O
the	O
cellular	O
surface	O
.	O

Reduced	O
T-cell	B-cell_type
function	O
indicated	O
by	O
impaired	O
stimulation	O
by	O
PHA	B-protein
and	O
porkweed	B-protein
as	O
well	O
as	O
by	O
impaired	O
lymphokinin	O
effects	O
on	O
leukocyte	B-cell_type
migration	O
inhibition	O
has	O
been	O
reported	O
.	O
<EOS>	B-X
Reduced	B-X
T	B-X
-	B-X
cell	B-X
function	B-X
indicated	B-X
by	B-X
impaired	B-X
stimulation	B-X
by	B-X
PHA	B-X
and	B-X
porkweed	B-X
as	B-X
well	B-X
as	B-X
by	B-X
impaired	B-X
lymphokinin	B-X
effects	B-X
on	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
has	B-X
been	B-X
reported	B-X
<EOS>	B-X
Reduced	B-X
lymphocyte	B-X
adherence	B-X
to	B-X
antigen	B-X
and	B-X
suppressed	B-X
lymphocyte	B-X
reaction	B-X
have	B-X
also	B-X
been	B-X
observed	B-X
<EOS>	B-X
High	B-X
-	B-X
dose	B-X
corticosteroids	B-X
(	B-X
HDC	B-X
)	B-X
will	B-X
influence	B-X
cellular	B-X
as	B-X
well	B-X
as	B-X
humoral	B-X
participants	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
<EOS>	B-X
Acute	B-X
processes	B-X
with	B-X
increased	B-X
vascular	B-X
permeability	B-X
and	B-X
accumulation	B-X
of	B-X
leukocytes	B-X
as	B-X
impairing	B-X
factors	B-X
could	B-X
be	B-X
influenced	B-X
beneficially	B-X
by	B-X
HDC	B-X
therapy	B-X

Reduced	O
lymphocyte	O
adherence	O
to	O
antigen	O
and	O
suppressed	O
lymphocyte	O
reaction	O
have	O
also	O
been	O
observed	O
.	O
<EOS>	B-X
Reduced	B-X
lymphocyte	B-X
adherence	B-X
to	B-X
antigen	B-X
and	B-X
suppressed	B-X
lymphocyte	B-X
reaction	B-X
have	B-X
also	B-X
been	B-X
observed	B-X
<EOS>	B-X
Second	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
human	B-X
UCMS	B-X
cells	B-X
on	B-X
one	B-X
-	B-X
way	B-X
and	B-X
two	B-X
-	B-X
way	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
(	B-X
MLR	B-X
)	B-X
assays	B-X
was	B-X
determined	B-X
<EOS>	B-X
Reduced	B-X
synthesis	B-X
of	B-X
B	B-X
-	B-X
	B-X
as	B-X
well	B-X
as	B-X
T	B-X
-	B-X
lymphocytes	B-X
will	B-X
be	B-X
seen	B-X
<EOS>	B-X
Reduced	B-X
T	B-X
-	B-X
cell	B-X
function	B-X
indicated	B-X
by	B-X
impaired	B-X
stimulation	B-X
by	B-X
PHA	B-X
and	B-X
porkweed	B-X
as	B-X
well	B-X
as	B-X
by	B-X
impaired	B-X
lymphokinin	B-X
effects	B-X
on	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
has	B-X
been	B-X
reported	B-X

Humoral	O
factors	O
involved	O
in	O
chemotaxis	O
,	O
opsonisation	O
,	O
phagocytosis	O
,	O
vascular	O
permeability	O
leading	O
to	O
leakage	O
of	O
fluid	O
and	O
cells	O
and	O
factors	O
involved	O
in	O
lysis	O
of	O
antigens	O
are	O
impaired	O
.	O
<EOS>	B-X
Humoral	B-X
factors	B-X
involved	B-X
in	B-X
chemotaxis	B-X
,	B-X
opsonisation	B-X
,	B-X
phagocytosis	B-X
,	B-X
vascular	B-X
permeability	B-X
leading	B-X
to	B-X
leakage	B-X
of	B-X
fluid	B-X
and	B-X
cells	B-X
and	B-X
factors	B-X
involved	B-X
in	B-X
lysis	B-X
of	B-X
antigens	B-X
are	B-X
impaired	B-X
<EOS>	B-X
Acute	B-X
processes	B-X
with	B-X
increased	B-X
vascular	B-X
permeability	B-X
and	B-X
accumulation	B-X
of	B-X
leukocytes	B-X
as	B-X
impairing	B-X
factors	B-X
could	B-X
be	B-X
influenced	B-X
beneficially	B-X
by	B-X
HDC	B-X
therapy	B-X
<EOS>	B-X
However	B-X
,	B-X
if	B-X
sepsis	B-X
or	B-X
rejection	B-X
is	B-X
not	B-X
rapidly	B-X
reversed	B-X
,	B-X
complications	B-X
such	B-X
as	B-X
multisystem	B-X
organ	B-X
failure	B-X
and	B-X
bacteremia	B-X
are	B-X
prone	B-X
to	B-X
appear	B-X
<EOS>	B-X
Reduced	B-X
T	B-X
-	B-X
cell	B-X
function	B-X
indicated	B-X
by	B-X
impaired	B-X
stimulation	B-X
by	B-X
PHA	B-X
and	B-X
porkweed	B-X
as	B-X
well	B-X
as	B-X
by	B-X
impaired	B-X
lymphokinin	B-X
effects	B-X
on	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
has	B-X
been	B-X
reported	B-X

This	O
can	O
be	O
explained	O
partly	O
by	O
the	O
observed	O
reduced	O
complement	O
activation	O
via	O
the	O
alternative	O
as	O
well	O
as	O
the	O
classical	O
pathway	O
in	O
association	O
with	O
HDC	O
therapy	O
.	O
<EOS>	B-X
This	B-X
can	B-X
be	B-X
explained	B-X
partly	B-X
by	B-X
the	B-X
observed	B-X
reduced	B-X
complement	B-X
activation	B-X
via	B-X
the	B-X
alternative	B-X
as	B-X
well	B-X
as	B-X
the	B-X
classical	B-X
pathway	B-X
in	B-X
association	B-X
with	B-X
HDC	B-X
therapy	B-X
<EOS>	B-X
This	B-X
positive	B-X
effect	B-X
can	B-X
be	B-X
seen	B-X
in	B-X
treatment	B-X
of	B-X
septic	B-X
shock	B-X
or	B-X
rejection	B-X
of	B-X
a	B-X
transplant	B-X
<EOS>	B-X
The	B-X
lymphoid	B-X
tissue	B-X
will	B-X
decrease	B-X
in	B-X
size	B-X
and	B-X
weight	B-X
after	B-X
prolonged	B-X
treatment	B-X
with	B-X
HDC	B-X
<EOS>	B-X
High	B-X
-	B-X
dose	B-X
corticosteroids	B-X
(	B-X
HDC	B-X
)	B-X
will	B-X
influence	B-X
cellular	B-X
as	B-X
well	B-X
as	B-X
humoral	B-X
participants	B-X
of	B-X
the	B-X
immune	B-X
response	B-X

Acute	O
processes	O
with	O
increased	O
vascular	O
permeability	O
and	O
accumulation	O
of	O
leukocytes	B-cell_type
as	O
impairing	O
factors	O
could	O
be	O
influenced	O
beneficially	O
by	O
HDC	O
therapy	O
.	O
<EOS>	B-X
Acute	B-X
processes	B-X
with	B-X
increased	B-X
vascular	B-X
permeability	B-X
and	B-X
accumulation	B-X
of	B-X
leukocytes	B-X
as	B-X
impairing	B-X
factors	B-X
could	B-X
be	B-X
influenced	B-X
beneficially	B-X
by	B-X
HDC	B-X
therapy	B-X
<EOS>	B-X
Humoral	B-X
factors	B-X
involved	B-X
in	B-X
chemotaxis	B-X
,	B-X
opsonisation	B-X
,	B-X
phagocytosis	B-X
,	B-X
vascular	B-X
permeability	B-X
leading	B-X
to	B-X
leakage	B-X
of	B-X
fluid	B-X
and	B-X
cells	B-X
and	B-X
factors	B-X
involved	B-X
in	B-X
lysis	B-X
of	B-X
antigens	B-X
are	B-X
impaired	B-X
<EOS>	B-X
Reduced	B-X
T	B-X
-	B-X
cell	B-X
function	B-X
indicated	B-X
by	B-X
impaired	B-X
stimulation	B-X
by	B-X
PHA	B-X
and	B-X
porkweed	B-X
as	B-X
well	B-X
as	B-X
by	B-X
impaired	B-X
lymphokinin	B-X
effects	B-X
on	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
has	B-X
been	B-X
reported	B-X
<EOS>	B-X
This	B-X
positive	B-X
effect	B-X
can	B-X
be	B-X
seen	B-X
in	B-X
treatment	B-X
of	B-X
septic	B-X
shock	B-X
or	B-X
rejection	B-X
of	B-X
a	B-X
transplant	B-X

This	O
positive	O
effect	O
can	O
be	O
seen	O
in	O
treatment	O
of	O
septic	O
shock	O
or	O
rejection	O
of	O
a	O
transplant	O
.	O
<EOS>	B-X
Macrophages	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
,	B-X
the	B-X
currently	B-X
uncurable	B-X
,	B-X
chronic	B-X
rejection	B-X
of	B-X
transplants	B-X
<EOS>	B-X
Still	B-X
,	B-X
none	B-X
had	B-X
been	B-X
tested	B-X
for	B-X
chronic	B-X
rejection	B-X
in	B-X
humans	B-X
<EOS>	B-X
thoracentesis	B-X
,	B-X
chest	B-X
tube	B-X
insertion	B-X
,	B-X
indwelling	B-X
pleural	B-X
catheters	B-X
)	B-X
may	B-X
be	B-X
useful	B-X
in	B-X
the	B-X
context	B-X
of	B-X
early	B-X
and	B-X
late	B-X
pleural	B-X
complications	B-X
occurring	B-X
after	B-X
lung	B-X
transplantation	B-X
<EOS>	B-X
Machine	B-X
perfusion	B-X
offers	B-X
the	B-X
option	B-X
to	B-X
evaluate	B-X
(	B-X
especially	B-X
marginal	B-X
)	B-X
donor	B-X
organs	B-X
and	B-X
to	B-X
better	B-X
decide	B-X
whether	B-X
a	B-X
graft	B-X
has	B-X
the	B-X
potential	B-X
of	B-X
being	B-X
transplanted	B-X
or	B-X
not	B-X

However	O
,	O
if	O
sepsis	O
or	O
rejection	O
is	O
not	O
rapidly	O
reversed	O
,	O
complications	O
such	O
as	O
multisystem	O
organ	O
failure	O
and	O
bacteremia	O
are	O
prone	O
to	O
appear	O
.	O
<EOS>	B-X
Pyroptosis	B-X
,	B-X
systemic	B-X
inflammation	B-X
,	B-X
and	B-X
mitochondrial	B-X
apoptosis	B-X
are	B-X
the	B-X
three	B-X
primary	B-X
contributors	B-X
to	B-X
sepsis	B-X
's	B-X
multiple	B-X
organ	B-X
failure	B-X
,	B-X
the	B-X
ultimate	B-X
cause	B-X
of	B-X
high	B-X
clinical	B-X
mortality	B-X
<EOS>	B-X
Pancreatic	B-X
injury	B-X
is	B-X
considered	B-X
an	B-X
organ	B-X
-	B-X
related	B-X
complication	B-X
in	B-X
patients	B-X
with	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID	B-X
-	B-X
19	B-X
)	B-X
<EOS>	B-X
Further	B-X
,	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
facilitators	B-X
and	B-X
barriers	B-X
to	B-X
RP	B-X
implementation	B-X
can	B-X
help	B-X
with	B-X
future	B-X
translatability	B-X
and	B-X
uptake	B-X
to	B-X
other	B-X
community	B-X
programs	B-X
<EOS>	B-X
According	B-X
to	B-X
available	B-X
studies	B-X
,	B-X
it	B-X
can	B-X
lead	B-X
to	B-X
benefits	B-X
in	B-X
term	B-X
of	B-X
metabolic	B-X
compensation	B-X
,	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
donor	B-X
-	B-X
specific	B-X
tolerance	B-X
and	B-X
many	B-X
others	B-X
,	B-X
with	B-X
an	B-X
overall	B-X
improvement	B-X
in	B-X
the	B-X
quality	B-X
of	B-X
patient	B-X
and	B-X
graft	B-X
survival	B-X

Identification	O
of	O
human	B-protein
leukemic	I-protein
glucocorticoid	I-protein
receptors	I-protein
using	O
affinity	O
labeling	O
and	O
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
.	O
<EOS>	B-X
Identification	B-X
of	B-X
human	B-X
leukemic	B-X
glucocorticoid	B-X
receptors	B-X
using	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
is	B-X
capable	B-X
of	B-X
providing	B-X
direct	B-X
physical	B-X
identification	B-X
of	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
These	B-X
antibodies	B-X
also	B-X
recognized	B-X
rat	B-X
liver	B-X
and	B-X
murine	B-X
S49	B-X
cell	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Antisera	B-X
raised	B-X
against	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
affinity	B-X
label	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
21	B-X
-	B-X
mesylate	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
DM	B-X
)	B-X
to	B-X
identify	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
of	B-X
the	B-X
human	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
line	B-X
IM	B-X
-	B-X
9	B-X
and	B-X
the	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
-	B-X
C7	B-X

Antisera	O
raised	O
against	O
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
used	O
in	O
combination	O
with	O
the	O
glucocorticoid	O
receptor	O
affinity	O
label	O
[	O
3H	O
]	O
dexamethasone	O
21-mesylate	O
[	O
(	O
3H	O
]	O
DM	O
)	O
to	O
identify	O
the	O
glucocorticoid	B-protein
receptors	I-protein
of	O
the	O
human	B-cell_line
B-lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
IM-9	B-cell_line
and	O
the	O
human	B-cell_line
T-cell	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
CEM-C7	B-cell_line
.	O
<EOS>	B-X
Antisera	B-X
raised	B-X
against	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
affinity	B-X
label	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
21	B-X
-	B-X
mesylate	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
DM	B-X
)	B-X
to	B-X
identify	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
of	B-X
the	B-X
human	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
line	B-X
IM	B-X
-	B-X
9	B-X
and	B-X
the	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
-	B-X
C7	B-X
<EOS>	B-X
Antisera	B-X
were	B-X
obtained	B-X
following	B-X
immunization	B-X
of	B-X
New	B-X
Zealand	B-X
White	B-X
rabbits	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
TA	B-X
)	B-X
	B-X
-	B-X
glucocorticoid	B-X
receptor	B-X
complexes	B-X
partially	B-X
purified	B-X
by	B-X
two	B-X
-	B-X
stage	B-X
DNA	B-X
-	B-X
cellulose	B-X
chromatography	B-X
<EOS>	B-X
Identification	B-X
of	B-X
human	B-X
leukemic	B-X
glucocorticoid	B-X
receptors	B-X
using	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
is	B-X
capable	B-X
of	B-X
providing	B-X
direct	B-X
physical	B-X
identification	B-X
of	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X

Antisera	O
were	O
obtained	O
following	O
immunization	O
of	O
New	O
Zealand	O
White	O
rabbits	O
with	O
[	B-protein
3H	I-protein
]	I-protein
triamcinolone	I-protein
acetonide	I-protein
[	I-protein
(	I-protein
3H	I-protein
]	I-protein
TA	I-protein
)	I-protein
-glucocorticoid	I-protein
receptor	I-protein
complexes	I-protein
partially	O
purified	O
by	O
two-stage	O
DNA-cellulose	O
chromatography	O
.	O
<EOS>	B-X
Antisera	B-X
were	B-X
obtained	B-X
following	B-X
immunization	B-X
of	B-X
New	B-X
Zealand	B-X
White	B-X
rabbits	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
TA	B-X
)	B-X
	B-X
-	B-X
glucocorticoid	B-X
receptor	B-X
complexes	B-X
partially	B-X
purified	B-X
by	B-X
two	B-X
-	B-X
stage	B-X
DNA	B-X
-	B-X
cellulose	B-X
chromatography	B-X
<EOS>	B-X
Antisera	B-X
raised	B-X
against	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
affinity	B-X
label	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
21	B-X
-	B-X
mesylate	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
DM	B-X
)	B-X
to	B-X
identify	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
of	B-X
the	B-X
human	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
line	B-X
IM	B-X
-	B-X
9	B-X
and	B-X
the	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
-	B-X
C7	B-X
<EOS>	B-X
This	B-X
component	B-X
was	B-X
markedly	B-X
diminished	B-X
when	B-X
cytosols	B-X
from	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
-	B-X
deficient	B-X
cell	B-X
line	B-X
ICR	B-X
-	B-X
27	B-X
were	B-X
used	B-X
<EOS>	B-X
Identification	B-X
of	B-X
human	B-X
leukemic	B-X
glucocorticoid	B-X
receptors	B-X
using	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
.	B-X

The	O
presence	O
of	O
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
was	O
verified	O
by	O
:	O
(	O
a	O
)	O
adsorption	O
of	O
[	B-protein
3H	I-protein
]	I-protein
TA-receptor-antibody	I-protein
complexes	I-protein
to	O
Protein	B-protein
A	I-protein
;	O
(	O
b	O
)	O
a	O
shift	O
to	O
higher	O
apparent	O
molecular	O
weight	O
in	O
the	O
elution	O
position	O
from	O
Sephacryl	O
S300	O
of	O
[	B-protein
3H	I-protein
]	I-protein
TA-receptor	I-protein
complexes	I-protein
incubated	O
with	O
immune	O
serum	O
;	O
and	O
(	O
c	O
)	O
the	O
ability	O
of	O
immune	O
serum	O
to	O
displace	O
[	B-protein
3H	I-protein
]	I-protein
TA-receptor	I-protein
complexes	I-protein
on	O
sucrose	O
gradients	O
.	O

These	O
antibodies	B-protein
also	O
recognized	O
rat	O
liver	O
and	O
murine	B-protein
S49	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O
<EOS>	B-X
These	B-X
antibodies	B-X
also	B-X
recognized	B-X
rat	B-X
liver	B-X
and	B-X
murine	B-X
S49	B-X
cell	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Identification	B-X
of	B-X
human	B-X
leukemic	B-X
glucocorticoid	B-X
receptors	B-X
using	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
is	B-X
capable	B-X
of	B-X
providing	B-X
direct	B-X
physical	B-X
identification	B-X
of	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
This	B-X
component	B-X
was	B-X
markedly	B-X
diminished	B-X
when	B-X
cytosols	B-X
from	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
-	B-X
deficient	B-X
cell	B-X
line	B-X
ICR	B-X
-	B-X
27	B-X
were	B-X
used	B-X

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
of	O
[	O
3H	O
]	O
DM-labeled	O
IM-9	O
cytosol	O
identified	O
a	O
major	O
competable	O
band	O
with	O
a	O
molecular	O
weight	O
of	O
approximately	O
90	O
,	O
000	O
,	O
three	O
minor	O
competable	O
components	O
with	O
molecular	O
weights	O
of	O
approximately	O
78	O
,	O
000	O
,	O
approximately	O
51	O
,	O
000	O
,	O
and	O
approximately	O
38	O
,	O
500	O
,	O
and	O
at	O
least	O
21	O
other	O
noncompetable	O
components	O
.	O

Following	O
immunoprecipitation	O
of	O
[	O
3H	O
]	O
DM-labeled	O
cytosol	O
with	O
immune	O
serum	O
,	O
only	O
the	O
Mr	O
90	O
,	O
000	O
and	O
78	O
,	O
000	O
components	O
were	O
seen	O
.	O
<EOS>	B-X
Following	B-X
immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
cytosol	B-X
with	B-X
immune	B-X
serum	B-X
,	B-X
only	B-X
the	B-X
Mr	B-X
90,000	B-X
and	B-X
78,000	B-X
components	B-X
were	B-X
seen	B-X
<EOS>	B-X
However	B-X
,	B-X
after	B-X
immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
CEM	B-X
-	B-X
C7	B-X
cytosol	B-X
,	B-X
a	B-X
predominant	B-X
competable	B-X
component	B-X
with	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
90,000	B-X
was	B-X
easily	B-X
identified	B-X
<EOS>	B-X
Sodium	B-X
dodecyl	B-X
sulfate	B-X
-	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
IM	B-X
-	B-X
9	B-X
cytosol	B-X
identified	B-X
a	B-X
major	B-X
competable	B-X
band	B-X
with	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
approximately	B-X
90,000	B-X
,	B-X
three	B-X
minor	B-X
competable	B-X
components	B-X
with	B-X
molecular	B-X
weights	B-X
of	B-X
approximately	B-X
78,000	B-X
,	B-X
approximately	B-X
51,000	B-X
,	B-X
and	B-X
approximately	B-X
38,500	B-X
,	B-X
and	B-X
at	B-X
least	B-X
21	B-X
other	B-X
noncompetable	B-X
components	B-X
<EOS>	B-X
Antisera	B-X
were	B-X
obtained	B-X
following	B-X
immunization	B-X
of	B-X
New	B-X
Zealand	B-X
White	B-X
rabbits	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
TA	B-X
)	B-X
	B-X
-	B-X
glucocorticoid	B-X
receptor	B-X
complexes	B-X
partially	B-X
purified	B-X
by	B-X
two	B-X
-	B-X
stage	B-X
DNA	B-X
-	B-X
cellulose	B-X
chromatography	B-X

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
of	O
[	O
3H	O
]	O
DM-labeled	O
CEM-C7	O
cytosol	O
revealed	O
a	O
larger	O
number	O
of	O
[	O
3H	O
]	O
DM-labeled	O
components	O
.	O
<EOS>	B-X
Sodium	B-X
dodecyl	B-X
sulfate	B-X
-	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
CEM	B-X
-	B-X
C7	B-X
cytosol	B-X
revealed	B-X
a	B-X
larger	B-X
number	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
components	B-X
<EOS>	B-X
Sodium	B-X
dodecyl	B-X
sulfate	B-X
-	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
IM	B-X
-	B-X
9	B-X
cytosol	B-X
identified	B-X
a	B-X
major	B-X
competable	B-X
band	B-X
with	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
approximately	B-X
90,000	B-X
,	B-X
three	B-X
minor	B-X
competable	B-X
components	B-X
with	B-X
molecular	B-X
weights	B-X
of	B-X
approximately	B-X
78,000	B-X
,	B-X
approximately	B-X
51,000	B-X
,	B-X
and	B-X
approximately	B-X
38,500	B-X
,	B-X
and	B-X
at	B-X
least	B-X
21	B-X
other	B-X
noncompetable	B-X
components	B-X
<EOS>	B-X
Following	B-X
immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
cytosol	B-X
with	B-X
immune	B-X
serum	B-X
,	B-X
only	B-X
the	B-X
Mr	B-X
90,000	B-X
and	B-X
78,000	B-X
components	B-X
were	B-X
seen	B-X
<EOS>	B-X
Antisera	B-X
were	B-X
obtained	B-X
following	B-X
immunization	B-X
of	B-X
New	B-X
Zealand	B-X
White	B-X
rabbits	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
TA	B-X
)	B-X
	B-X
-	B-X
glucocorticoid	B-X
receptor	B-X
complexes	B-X
partially	B-X
purified	B-X
by	B-X
two	B-X
-	B-X
stage	B-X
DNA	B-X
-	B-X
cellulose	B-X
chromatography	B-X

However	O
,	O
after	O
immunoprecipitation	O
of	O
[	O
3H	O
]	O
DM-labeled	O
CEM-C7	O
cytosol	O
,	O
a	O
predominant	O
competable	O
component	O
with	O
a	O
molecular	O
weight	O
of	O
90	O
,	O
000	O
was	O
easily	O
identified	O
.	O
<EOS>	B-X
However	B-X
,	B-X
after	B-X
immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
CEM	B-X
-	B-X
C7	B-X
cytosol	B-X
,	B-X
a	B-X
predominant	B-X
competable	B-X
component	B-X
with	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
90,000	B-X
was	B-X
easily	B-X
identified	B-X
<EOS>	B-X
Following	B-X
immunoprecipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
cytosol	B-X
with	B-X
immune	B-X
serum	B-X
,	B-X
only	B-X
the	B-X
Mr	B-X
90,000	B-X
and	B-X
78,000	B-X
components	B-X
were	B-X
seen	B-X
<EOS>	B-X
Sodium	B-X
dodecyl	B-X
sulfate	B-X
-	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
IM	B-X
-	B-X
9	B-X
cytosol	B-X
identified	B-X
a	B-X
major	B-X
competable	B-X
band	B-X
with	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
approximately	B-X
90,000	B-X
,	B-X
three	B-X
minor	B-X
competable	B-X
components	B-X
with	B-X
molecular	B-X
weights	B-X
of	B-X
approximately	B-X
78,000	B-X
,	B-X
approximately	B-X
51,000	B-X
,	B-X
and	B-X
approximately	B-X
38,500	B-X
,	B-X
and	B-X
at	B-X
least	B-X
21	B-X
other	B-X
noncompetable	B-X
components	B-X
<EOS>	B-X
Sodium	B-X
dodecyl	B-X
sulfate	B-X
-	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
CEM	B-X
-	B-X
C7	B-X
cytosol	B-X
revealed	B-X
a	B-X
larger	B-X
number	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DM	B-X
-	B-X
labeled	B-X
components	B-X

This	O
component	O
was	O
markedly	O
diminished	O
when	O
cytosols	O
from	O
the	O
glucocorticoid	B-cell_line
receptor-deficient	I-cell_line
cell	I-cell_line
line	I-cell_line
ICR-27	B-cell_line
were	O
used	O
.	O
<EOS>	B-X
This	B-X
component	B-X
was	B-X
markedly	B-X
diminished	B-X
when	B-X
cytosols	B-X
from	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
-	B-X
deficient	B-X
cell	B-X
line	B-X
ICR	B-X
-	B-X
27	B-X
were	B-X
used	B-X
<EOS>	B-X
Antisera	B-X
were	B-X
obtained	B-X
following	B-X
immunization	B-X
of	B-X
New	B-X
Zealand	B-X
White	B-X
rabbits	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
TA	B-X
)	B-X
	B-X
-	B-X
glucocorticoid	B-X
receptor	B-X
complexes	B-X
partially	B-X
purified	B-X
by	B-X
two	B-X
-	B-X
stage	B-X
DNA	B-X
-	B-X
cellulose	B-X
chromatography	B-X
<EOS>	B-X
These	B-X
antibodies	B-X
also	B-X
recognized	B-X
rat	B-X
liver	B-X
and	B-X
murine	B-X
S49	B-X
cell	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Antisera	B-X
raised	B-X
against	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
affinity	B-X
label	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
21	B-X
-	B-X
mesylate	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
DM	B-X
)	B-X
to	B-X
identify	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
of	B-X
the	B-X
human	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
line	B-X
IM	B-X
-	B-X
9	B-X
and	B-X
the	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
-	B-X
C7	B-X

Thus	O
,	O
the	O
combination	O
of	O
affinity	O
labeling	O
and	O
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
is	O
capable	O
of	O
providing	O
direct	O
physical	O
identification	O
of	O
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
is	B-X
capable	B-X
of	B-X
providing	B-X
direct	B-X
physical	B-X
identification	B-X
of	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Identification	B-X
of	B-X
human	B-X
leukemic	B-X
glucocorticoid	B-X
receptors	B-X
using	B-X
affinity	B-X
labeling	B-X
and	B-X
anti	B-X
-	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
antibodies	B-X
.	B-X
<EOS>	B-X
These	B-X
antibodies	B-X
also	B-X
recognized	B-X
rat	B-X
liver	B-X
and	B-X
murine	B-X
S49	B-X
cell	B-X
glucocorticoid	B-X
receptors	B-X
<EOS>	B-X
Antisera	B-X
raised	B-X
against	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
affinity	B-X
label	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
21	B-X
-	B-X
mesylate	B-X
[	B-X
(	B-X
3H	B-X
]	B-X
DM	B-X
)	B-X
to	B-X
identify	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
of	B-X
the	B-X
human	B-X
B	B-X
-	B-X
lymphoblastoid	B-X
cell	B-X
line	B-X
IM	B-X
-	B-X
9	B-X
and	B-X
the	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
-	B-X
C7	B-X

Effect	O
of	O
thymosin	O
on	O
glucocorticoid	B-protein
receptor	I-protein
activity	O
and	O
glucocorticoid	O
sensitivity	O
of	O
human	B-cell_type
thymocytes	I-cell_type
.	O
<EOS>	B-X
Effect	B-X
of	B-X
thymosin	B-X
on	B-X
glucocorticoid	B-X
receptor	B-X
activity	B-X
and	B-X
glucocorticoid	B-X
sensitivity	B-X
of	B-X
human	B-X
thymocytes	B-X
.	B-X
<EOS>	B-X
05	B-X
)	B-X
,	B-X
but	B-X
TMS	B-X
F5	B-X
did	B-X
not	B-X
significantly	B-X
reduce	B-X
the	B-X
glucocorticoid	B-X
sensitivity	B-X
of	B-X
MOLT	B-X
3	B-X
cells	B-X
<EOS>	B-X
Incubation	B-X
with	B-X
thymosin	B-X
fraction	B-X
5	B-X
,	B-X
(	B-X
TMS	B-X
F5	B-X
at	B-X
300	B-X
micrograms	B-X
/	B-X
ml	B-X
)	B-X
a	B-X
partially	B-X
purified	B-X
thymic	B-X
factor	B-X
,	B-X
reduced	B-X
the	B-X
steroid	B-X
binding	B-X
activity	B-X
of	B-X
human	B-X
infant	B-X
thymocytes	B-X
from	B-X
9	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
activity	B-X
in	B-X
normal	B-X
infant	B-X
thymocytes	B-X
was	B-X
found	B-X
to	B-X
be	B-X
2,146	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
726	B-X
(	B-X
s	B-X

Incubation	O
with	O
thymosin	O
fraction	O
5	O
,	O
(	O
TMS	O
F5	O
at	O
300	O
micrograms/ml	O
)	O
a	O
partially	O
purified	O
thymic	O
factor	O
,	O
reduced	O
the	O
steroid	O
binding	O
activity	O
of	O
human	B-cell_type
infant	I-cell_type
thymocytes	I-cell_type
from	O
9.6	O
+/-	O
2.1	O
fmole/ml	O
to	O
5.0	O
+/-	O
2.0	O
fmole/ml	O
.	O
<EOS>	B-X
Incubation	B-X
with	B-X
thymosin	B-X
fraction	B-X
5	B-X
,	B-X
(	B-X
TMS	B-X
F5	B-X
at	B-X
300	B-X
micrograms	B-X
/	B-X
ml	B-X
)	B-X
a	B-X
partially	B-X
purified	B-X
thymic	B-X
factor	B-X
,	B-X
reduced	B-X
the	B-X
steroid	B-X
binding	B-X
activity	B-X
of	B-X
human	B-X
infant	B-X
thymocytes	B-X
from	B-X
9	B-X
<EOS>	B-X
Effect	B-X
of	B-X
thymosin	B-X
on	B-X
glucocorticoid	B-X
receptor	B-X
activity	B-X
and	B-X
glucocorticoid	B-X
sensitivity	B-X
of	B-X
human	B-X
thymocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
activity	B-X
in	B-X
normal	B-X
infant	B-X
thymocytes	B-X
was	B-X
found	B-X
to	B-X
be	B-X
2,146	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
726	B-X
(	B-X
s	B-X
<EOS>	B-X
Incubation	B-X
of	B-X
a	B-X
human	B-X
malignant	B-X
thymus	B-X
derived	B-X
T	B-X
cell	B-X
line	B-X
(	B-X
MOLT	B-X
3	B-X
)	B-X
with	B-X
TMS	B-X
F5	B-X
also	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
reduction	B-X
of	B-X
the	B-X
number	B-X
of	B-X
steroid	B-X
binding	B-X
sites	B-X
to	B-X
44	B-X

The	O
glucocorticoid	B-protein
receptor	I-protein
activity	O
in	O
normal	O
infant	O
thymocytes	O
was	O
found	O
to	O
be	O
2	O
,	O
146	O
+/-	O
726	O
(	O
s.d.	O
)	O
sites	O
per	O
cell	O
with	O
dissociation	O
constant	O
of	O
1.4	O
+/-	O
0.6	O
X	O
10	O
(	O
-8	O
)	O
M	O
.	O
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
activity	B-X
in	B-X
normal	B-X
infant	B-X
thymocytes	B-X
was	B-X
found	B-X
to	B-X
be	B-X
2,146	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
726	B-X
(	B-X
s	B-X
<EOS>	B-X
)	B-X
sites	B-X
per	B-X
cell	B-X
with	B-X
dissociation	B-X
constant	B-X
of	B-X
1	B-X
<EOS>	B-X
The	B-X
results	B-X
show	B-X
that	B-X
thymosin	B-X
can	B-X
induce	B-X
changes	B-X
consistent	B-X
with	B-X
differentiation	B-X
in	B-X
human	B-X
thymocytes	B-X
<EOS>	B-X
TMS	B-X
F5	B-X
also	B-X
increased	B-X
the	B-X
resistance	B-X
of	B-X
human	B-X
thymocytes	B-X
to	B-X
the	B-X
cytolytic	B-X
effect	B-X
of	B-X
dexamethasone	B-X
(	B-X
2	B-X

TMS	O
F5	O
also	O
increased	O
the	O
resistance	O
of	O
human	O
thymocytes	O
to	O
the	O
cytolytic	O
effect	O
of	O
dexamethasone	O
(	O
2.5	O
X	O
10	O
(	O
-8	O
)	O
M	O
)	O
to	O
168.6	O
+/-	O
30.2	O
%	O
of	O
control	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

In	O
animals	O
,	O
medullary	B-cell_type
and	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
are	O
more	O
resistant	O
to	O
glucocorticoids	O
than	O
immature	B-cell_type
thymic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
results	O
show	O
that	O
thymosin	O
can	O
induce	O
changes	O
consistent	O
with	O
differentiation	O
in	O
human	B-cell_type
thymocytes	I-cell_type
.	O
<EOS>	B-X
The	B-X
results	B-X
show	B-X
that	B-X
thymosin	B-X
can	B-X
induce	B-X
changes	B-X
consistent	B-X
with	B-X
differentiation	B-X
in	B-X
human	B-X
thymocytes	B-X
<EOS>	B-X
Effect	B-X
of	B-X
thymosin	B-X
on	B-X
glucocorticoid	B-X
receptor	B-X
activity	B-X
and	B-X
glucocorticoid	B-X
sensitivity	B-X
of	B-X
human	B-X
thymocytes	B-X
.	B-X
<EOS>	B-X
Incubation	B-X
with	B-X
thymosin	B-X
fraction	B-X
5	B-X
,	B-X
(	B-X
TMS	B-X
F5	B-X
at	B-X
300	B-X
micrograms	B-X
/	B-X
ml	B-X
)	B-X
a	B-X
partially	B-X
purified	B-X
thymic	B-X
factor	B-X
,	B-X
reduced	B-X
the	B-X
steroid	B-X
binding	B-X
activity	B-X
of	B-X
human	B-X
infant	B-X
thymocytes	B-X
from	B-X
9	B-X
<EOS>	B-X
In	B-X
animals	B-X
,	B-X
medullary	B-X
and	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
are	B-X
more	B-X
resistant	B-X
to	B-X
glucocorticoids	B-X
than	B-X
immature	B-X
thymic	B-X
T	B-X
cells	B-X

These	O
in	O
vitro	O
results	O
are	O
consistent	O
with	O
a	O
physiological	O
role	O
of	O
thymosin	O
in	O
intrathymic	O
T	O
cell	O
maturation	O
in	O
man	O
.	O
<EOS>	B-X
These	B-X
in	B-X
vitro	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
physiological	B-X
role	B-X
of	B-X
thymosin	B-X
in	B-X
intrathymic	B-X
T	B-X
cell	B-X
maturation	B-X
in	B-X
man	B-X
<EOS>	B-X
The	B-X
results	B-X
show	B-X
that	B-X
thymosin	B-X
can	B-X
induce	B-X
changes	B-X
consistent	B-X
with	B-X
differentiation	B-X
in	B-X
human	B-X
thymocytes	B-X
<EOS>	B-X
TMS	B-X
F5	B-X
also	B-X
increased	B-X
the	B-X
resistance	B-X
of	B-X
human	B-X
thymocytes	B-X
to	B-X
the	B-X
cytolytic	B-X
effect	B-X
of	B-X
dexamethasone	B-X
(	B-X
2	B-X
<EOS>	B-X
Incubation	B-X
with	B-X
thymosin	B-X
fraction	B-X
5	B-X
,	B-X
(	B-X
TMS	B-X
F5	B-X
at	B-X
300	B-X
micrograms	B-X
/	B-X
ml	B-X
)	B-X
a	B-X
partially	B-X
purified	B-X
thymic	B-X
factor	B-X
,	B-X
reduced	B-X
the	B-X
steroid	B-X
binding	B-X
activity	B-X
of	B-X
human	B-X
infant	B-X
thymocytes	B-X
from	B-X
9	B-X

Incubation	O
of	O
a	O
human	B-cell_line
malignant	I-cell_line
thymus	I-cell_line
derived	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
MOLT	B-cell_line
3	I-cell_line
)	O
with	O
TMS	O
F5	O
also	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
number	O
of	O
steroid	O
binding	O
sites	O
to	O
44.2	O
+/-	O
15.3	O
%	O
of	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
,	O
but	O
TMS	O
F5	O
did	O
not	O
significantly	O
reduce	O
the	O
glucocorticoid	O
sensitivity	O
of	O
MOLT	B-cell_line
3	I-cell_line
cells	I-cell_line
.	O

Specific	B-protein
high-affinity	I-protein
receptors	I-protein
for	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
presence	O
in	O
monocytes	B-cell_type
and	O
induction	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
following	O
activation	O
.	O

Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
have	O
high	O
affinity	O
binding	O
sites	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
Kd	O
0.14	O
nM	O
,	O
sedimentation	O
coefficient	O
3.7S	O
)	O
.	O
<EOS>	B-X
Human	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
have	B-X
high	B-X
affinity	B-X
binding	B-X
sites	B-X
for	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
(	B-X
Kd	B-X
0	B-X
<EOS>	B-X
The	B-X
receptor	B-X
in	B-X
activated	B-X
T	B-X
lymphocytes	B-X
has	B-X
a	B-X
sedimentation	B-X
coefficient	B-X
of	B-X
3	B-X
<EOS>	B-X
Resting	B-X
human	B-X
peripheral	B-X
blood	B-X
T	B-X
lymphocytes	B-X
,	B-X
however	B-X
,	B-X
do	B-X
not	B-X
have	B-X
a	B-X
demonstrable	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptor	B-X
<EOS>	B-X
14	B-X
nM	B-X
,	B-X
sedimentation	B-X
coefficient	B-X
3	B-X

Resting	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
however	O
,	O
do	O
not	O
have	O
a	O
demonstrable	O
1	B-protein
,	I-protein
25-	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O

After	O
activation	O
with	O
phytohemagglutinin	B-protein
the	O
T	B-cell_type
cells	I-cell_type
exhibit	O
the	O
receptor	O
within	O
24	O
h	O
,	O
and	O
this	O
expression	O
is	O
blocked	O
by	O
cycloheximide	O
.	O

The	O
receptor	O
in	O
activated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
has	O
a	O
sedimentation	O
coefficient	O
of	O
3.7S	O
and	O
a	O
high	O
affinity	O
(	O
Kd	O
0.10	O
nM	O
)	O
for	O
the	O
ligand	O
.	O

Effects	O
of	O
chronic	O
glucocorticoid	O
excess	O
in	O
man	O
on	O
insulin	O
binding	O
to	O
circulating	B-cell_type
cells	I-cell_type
:	O
differences	O
between	O
endogenous	O
and	O
exogenous	O
hypercorticism	O
.	O

We	O
measured	O
[	O
125I	O
]	O
insulin	O
binding	O
to	O
circulating	B-cell_type
monocytes	I-cell_type
or	I-cell_type
erythrocytes	I-cell_type
from	O
16	O
patients	O
with	O
chronic	O
glucocorticoid	O
excess	O
,	O
9	O
chronically	O
treated	O
with	O
prednisone	O
and	O
7	O
with	O
adrenocortical	O
hyperfunction	O
.	O
<EOS>	B-X
Welters	B-X
P277	B-X
	B-X
-	B-X
	B-X
Risk	B-X
of	B-X
coronary	B-X
artery	B-X
disease	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
liver	B-X
disease	B-X
:	B-X
a	B-X
population	B-X
based	B-X
cohort	B-X
study	B-X
Y	B-X
<EOS>	B-X
Molokhia	B-X
P458	B-X
	B-X
-	B-X
	B-X
A	B-X
study	B-X
to	B-X
explore	B-X
the	B-X
experiences	B-X
of	B-X
patient	B-X
and	B-X
family	B-X
volunteers	B-X
in	B-X
a	B-X
critical	B-X
care	B-X
environment	B-X
:	B-X
a	B-X
phenomenological	B-X
analysis	B-X
J	B-X
<EOS>	B-X
Won	B-X
P326	B-X
Monitoring	B-X
of	B-X
cTroponin	B-X
I	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
ischemic	B-X
stroke	B-X
	B-X
-	B-X
	B-X
predictor	B-X
of	B-X
inhospital	B-X
mortality	B-X
S	B-X
<EOS>	B-X
Lee	B-X
P388	B-X
	B-X
-	B-X
	B-X
Comparison	B-X
of	B-X
mortality	B-X
prediction	B-X
scoring	B-X
systems	B-X
in	B-X
patients	B-X
with	B-X
cirrhosis	B-X
admitted	B-X
to	B-X
general	B-X
intensive	B-X
care	B-X
unit	B-X
M	B-X

With	O
monocytes	B-cell_type
,	O
[	O
125I	O
]	O
insulin	O
binding	O
was	O
iincreased	O
in	O
all	O
patients	O
.	O
<EOS>	B-X
With	B-X
monocytes	B-X
,	B-X
[	B-X
125I	B-X
]	B-X
insulin	B-X
binding	B-X
was	B-X
iincreased	B-X
in	B-X
all	B-X
patients	B-X
<EOS>	B-X
Effects	B-X
of	B-X
chronic	B-X
glucocorticoid	B-X
excess	B-X
in	B-X
man	B-X
on	B-X
insulin	B-X
binding	B-X
to	B-X
circulating	B-X
cells	B-X
:	B-X
differences	B-X
between	B-X
endogenous	B-X
and	B-X
exogenous	B-X
hypercorticism	B-X
.	B-X
<EOS>	B-X
With	B-X
erythrocytes	B-X
from	B-X
patients	B-X
with	B-X
adrenocortical	B-X
hyperfunction	B-X
there	B-X
was	B-X
an	B-X
increase	B-X
in	B-X
receptor	B-X
affinity	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
receptor	B-X
concentration	B-X
,	B-X
so	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
125I	B-X
]	B-X
insulin	B-X
was	B-X
normal	B-X
<EOS>	B-X
We	B-X
measured	B-X
[	B-X
125I	B-X
]	B-X
insulin	B-X
binding	B-X
to	B-X
circulating	B-X
monocytes	B-X
or	B-X
erythrocytes	B-X
from	B-X
16	B-X
patients	B-X
with	B-X
chronic	B-X
glucocorticoid	B-X
excess	B-X
,	B-X
9	B-X
chronically	B-X
treated	B-X
with	B-X
prednisone	B-X
and	B-X
7	B-X
with	B-X
adrenocortical	B-X
hyperfunction	B-X

Analysis	O
of	O
binding	O
data	O
indicated	O
that	O
increased	O
binding	O
in	O
patients	O
treated	O
with	O
prednisone	O
was	O
due	O
to	O
an	O
ncrease	O
in	O
receptor	O
concentration	O
,	O
whereas	O
in	O
patients	O
with	O
adrenocortical	O
hyperfunction	O
,	O
it	O
was	O
due	O
to	O
an	O
increase	O
in	O
receptor	O
affinity	O
.	O

With	O
erythrocytes	O
from	O
patients	O
with	O
adrenocortical	O
hyperfunction	O
there	O
was	O
an	O
increase	O
in	O
receptor	O
affinity	O
and	O
a	O
decrease	O
in	O
receptor	O
concentration	O
,	O
so	O
that	O
the	O
binding	O
of	O
[	O
125I	O
]	O
insulin	O
was	O
normal	O
.	O

The	O
disparity	O
of	O
results	O
between	O
endogenous	O
and	O
exogenous	O
hypercorticism	O
,	O
between	O
the	O
two	O
cell	O
types	O
,	O
and	O
between	O
the	O
present	O
studies	O
and	O
previous	O
studies	O
suggest	O
that	O
the	O
effects	O
of	O
glucocorticoid	O
excess	O
on	O
the	O
insulin	B-protein
receptor	I-protein
are	O
extremely	O
complex	O
and	O
wide-ranging	O
and	O
that	O
in	O
this	O
condition	O
,	O
extrapolations	O
in	O
humans	O
from	O
data	O
with	O
circulating	B-cell_type
cells	I-cell_type
to	O
liver	O
and	O
muscle	O
may	O
not	O
be	O
appropriate	O
.	O

Reduced	O
level	O
of	O
cellular	B-protein
glucocorticoid	I-protein
receptors	I-protein
in	O
patients	O
with	O
anorexia	O
nervosa	O
.	O
<EOS>	B-X
Reduced	B-X
level	B-X
of	B-X
cellular	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
.	B-X
<EOS>	B-X
A	B-X
partial	B-X
glucocorticoid	B-X
receptor	B-X
defect	B-X
may	B-X
well	B-X
explain	B-X
the	B-X
abnormal	B-X
cortisol	B-X
metabolism	B-X
and	B-X
glucocorticoid	B-X
resistance	B-X
commonly	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
<EOS>	B-X
001	B-X
)	B-X
and	B-X
was	B-X
diminished	B-X
by	B-X
dexamethasone	B-X
to	B-X
an	B-X
extent	B-X
similar	B-X
to	B-X
control	B-X
subjects	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
,	B-X
but	B-X
significantly	B-X
(	B-X
p	B-X
<	B-X
<EOS>	B-X
Specific	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
measured	B-X
in	B-X
circulating	B-X
mononuclear	B-X
leukocytes	B-X
from	B-X
12	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
and	B-X
21	B-X
healthy	B-X
control	B-X
subjects	B-X

Specific	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
in	O
circulating	O
mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
12	O
patients	O
with	O
anorexia	O
nervosa	O
and	O
21	O
healthy	O
control	O
subjects	O
.	O
<EOS>	B-X
Specific	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
measured	B-X
in	B-X
circulating	B-X
mononuclear	B-X
leukocytes	B-X
from	B-X
12	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
and	B-X
21	B-X
healthy	B-X
control	B-X
subjects	B-X
<EOS>	B-X
Reduced	B-X
level	B-X
of	B-X
cellular	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
.	B-X
<EOS>	B-X
A	B-X
partial	B-X
glucocorticoid	B-X
receptor	B-X
defect	B-X
may	B-X
well	B-X
explain	B-X
the	B-X
abnormal	B-X
cortisol	B-X
metabolism	B-X
and	B-X
glucocorticoid	B-X
resistance	B-X
commonly	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
<EOS>	B-X
01	B-X
)	B-X
lower	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
3830	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
210	B-X
sites	B-X
/	B-X
cell	B-X
,	B-X
mean	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
SE	B-X
)	B-X
than	B-X
those	B-X
from	B-X
controls	B-X
(	B-X
4930	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
250	B-X
sites	B-X
/	B-X
cell	B-X
)	B-X

Cells	O
from	O
patients	O
were	O
found	O
to	O
contain	O
a	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
lower	O
level	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
3830	O
+/-	O
210	O
sites/cell	O
,	O
mean	O
+/-	O
SE	O
)	O
than	O
those	O
from	O
controls	O
(	O
4930	O
+/-	O
250	O
sites/cell	O
)	O
.	O
<EOS>	B-X
01	B-X
)	B-X
lower	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
3830	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
210	B-X
sites	B-X
/	B-X
cell	B-X
,	B-X
mean	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
SE	B-X
)	B-X
than	B-X
those	B-X
from	B-X
controls	B-X
(	B-X
4930	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
250	B-X
sites	B-X
/	B-X
cell	B-X
)	B-X
<EOS>	B-X
Cells	B-X
from	B-X
patients	B-X
were	B-X
found	B-X
to	B-X
contain	B-X
a	B-X
significantly	B-X
(	B-X
p	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
Reduced	B-X
level	B-X
of	B-X
cellular	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
.	B-X
<EOS>	B-X
A	B-X
partial	B-X
glucocorticoid	B-X
receptor	B-X
defect	B-X
may	B-X
well	B-X
explain	B-X
the	B-X
abnormal	B-X
cortisol	B-X
metabolism	B-X
and	B-X
glucocorticoid	B-X
resistance	B-X
commonly	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X

A	O
partial	O
glucocorticoid	B-protein
receptor	I-protein
defect	O
may	O
well	O
explain	O
the	O
abnormal	O
cortisol	O
metabolism	O
and	O
glucocorticoid	O
resistance	O
commonly	O
found	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
.	O
<EOS>	B-X
A	B-X
partial	B-X
glucocorticoid	B-X
receptor	B-X
defect	B-X
may	B-X
well	B-X
explain	B-X
the	B-X
abnormal	B-X
cortisol	B-X
metabolism	B-X
and	B-X
glucocorticoid	B-X
resistance	B-X
commonly	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
<EOS>	B-X
Reduced	B-X
level	B-X
of	B-X
cellular	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
.	B-X
<EOS>	B-X
Specific	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
measured	B-X
in	B-X
circulating	B-X
mononuclear	B-X
leukocytes	B-X
from	B-X
12	B-X
patients	B-X
with	B-X
anorexia	B-X
nervosa	B-X
and	B-X
21	B-X
healthy	B-X
control	B-X
subjects	B-X
<EOS>	B-X
01	B-X
)	B-X
lower	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
3830	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
210	B-X
sites	B-X
/	B-X
cell	B-X
,	B-X
mean	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
SE	B-X
)	B-X
than	B-X
those	B-X
from	B-X
controls	B-X
(	B-X
4930	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
250	B-X
sites	B-X
/	B-X
cell	B-X
)	B-X

Regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
The	B-X
contribution	B-X
of	B-X
sleep	B-X
to	B-X
the	B-X
neuroendocrine	B-X
regulation	B-X
of	B-X
rhythms	B-X
in	B-X
human	B-X
leukocyte	B-X
traffic	B-X
.	B-X
<EOS>	B-X
Antenatal	B-X
Steroids	B-X
and	B-X
Cord	B-X
Blood	B-X
T	B-X
-	B-X
cell	B-X
Glucocorticoid	B-X
Receptor	B-X
DNA	B-X
Methylation	B-X
and	B-X
Exon	B-X
1	B-X
Splicing	B-X
.	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
Cyclooxygenase	B-X
-	B-X
2	B-X
Expression	B-X
in	B-X
Human	B-X
T	B-X
Cells	B-X
by	B-X
Glucocorticoid	B-X
Receptor	B-X
-	B-X
Mediated	B-X
Transrepression	B-X
of	B-X
Nuclear	B-X
Factor	B-X
of	B-X
Activated	B-X
T	B-X
Cells	B-X
.	B-X
<EOS>	B-X
Effects	B-X
of	B-X
glucocorticoids	B-X
on	B-X
leukocytes	B-X
:	B-X
Genomic	B-X
and	B-X
non	B-X
-	B-X
genomic	B-X
mechanisms	B-X
.	B-X

The	O
presence	O
of	O
a	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
is	O
well	O
established	O
,	O
but	O
factors	O
affecting	O
its	O
regulation	O
have	O
not	O
been	O
described	O
.	O

Using	O
a	O
competitive	O
binding	O
whole	O
cell	O
assay	O
,	O
we	O
have	O
examined	O
the	O
binding	O
of	O
[	O
3H	O
]	O
-dexamethasone	O
at	O
24	O
and	O
37	O
degrees	O
C	O
in	O
untreated	O
normal	O
subjects	O
and	O
in	O
healthy	O
subjects	O
taking	O
various	O
glucocorticoid	O
preparations	O
.	O
<EOS>	B-X
Using	B-X
a	B-X
competitive	B-X
binding	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
dexamethasone	B-X
at	B-X
24	B-X
and	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
untreated	B-X
normal	B-X
subjects	B-X
and	B-X
in	B-X
healthy	B-X
subjects	B-X
taking	B-X
various	B-X
glucocorticoid	B-X
preparations	B-X
<EOS>	B-X
No	B-X
changes	B-X
in	B-X
the	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
was	B-X
noted	B-X
before	B-X
1	B-X
week	B-X
and	B-X
the	B-X
diminished	B-X
number	B-X
persisted	B-X
for	B-X
1	B-X
week	B-X
after	B-X
discontinuation	B-X
of	B-X
glucocorticoid	B-X
treatment	B-X
<EOS>	B-X
Glucocorticoid	B-X
administration	B-X
results	B-X
in	B-X
a	B-X
time	B-X
-	B-X
dependent	B-X
decrease	B-X
in	B-X
the	B-X
number	B-X
of	B-X
lymphocyte	B-X
glucocorticoid	B-X
binding	B-X
sites	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
type	B-X
of	B-X
glucocorticoid	B-X
administered	B-X
<EOS>	B-X
Lymphocytes	B-X
from	B-X
hospitalized	B-X
patients	B-X
taking	B-X
40	B-X
-	B-X
60	B-X
mg	B-X
of	B-X
dexamethasone	B-X
daily	B-X
demonstrated	B-X
the	B-X
same	B-X
change	B-X
in	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
that	B-X
was	B-X
seen	B-X
in	B-X
normal	B-X
subjects	B-X
taking	B-X
1	B-X
mg	B-X
of	B-X
dexamethasone	B-X

At	O
24	O
degrees	O
C	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
had	O
6000	O
binding	O
sites/cell	O
and	O
a	O
dissociation	O
constant	O
of	O
4	O
x	O
10	O
(	O
-9	O
)	O
M	O
.	O

The	O
administration	O
of	O
1	O
mg	O
of	O
dexamethasone	O
,	O
5	O
mg	O
of	O
prednisone	O
,	O
and	O
37.5	O
mg	O
of	O
cortisone	O
acetate	O
resulted	O
in	O
a	O
30	O
%	O
decrease	O
in	O
binding	O
sites	O
after	O
1	O
week	O
with	O
no	O
change	O
in	O
binding	O
affinity	O
.	O

No	O
changes	O
in	O
the	O
number	O
of	O
binding	O
sites	O
was	O
noted	O
before	O
1	O
week	O
and	O
the	O
diminished	O
number	O
persisted	O
for	O
1	O
week	O
after	O
discontinuation	O
of	O
glucocorticoid	O
treatment	O
.	O
<EOS>	B-X
No	B-X
changes	B-X
in	B-X
the	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
was	B-X
noted	B-X
before	B-X
1	B-X
week	B-X
and	B-X
the	B-X
diminished	B-X
number	B-X
persisted	B-X
for	B-X
1	B-X
week	B-X
after	B-X
discontinuation	B-X
of	B-X
glucocorticoid	B-X
treatment	B-X
<EOS>	B-X
Using	B-X
a	B-X
competitive	B-X
binding	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
dexamethasone	B-X
at	B-X
24	B-X
and	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
untreated	B-X
normal	B-X
subjects	B-X
and	B-X
in	B-X
healthy	B-X
subjects	B-X
taking	B-X
various	B-X
glucocorticoid	B-X
preparations	B-X
<EOS>	B-X
5	B-X
mg	B-X
of	B-X
cortisone	B-X
acetate	B-X
resulted	B-X
in	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
binding	B-X
sites	B-X
after	B-X
1	B-X
week	B-X
with	B-X
no	B-X
change	B-X
in	B-X
binding	B-X
affinity	B-X
<EOS>	B-X
Glucocorticoid	B-X
administration	B-X
results	B-X
in	B-X
a	B-X
time	B-X
-	B-X
dependent	B-X
decrease	B-X
in	B-X
the	B-X
number	B-X
of	B-X
lymphocyte	B-X
glucocorticoid	B-X
binding	B-X
sites	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
type	B-X
of	B-X
glucocorticoid	B-X
administered	B-X

Lymphocytes	B-cell_type
from	O
hospitalized	O
patients	O
taking	O
40-60	O
mg	O
of	O
dexamethasone	O
daily	O
demonstrated	O
the	O
same	O
change	O
in	O
number	O
of	O
binding	O
sites	O
that	O
was	O
seen	O
in	O
normal	O
subjects	O
taking	O
1	O
mg	O
of	O
dexamethasone	O
.	O
<EOS>	B-X
Lymphocytes	B-X
from	B-X
hospitalized	B-X
patients	B-X
taking	B-X
40	B-X
-	B-X
60	B-X
mg	B-X
of	B-X
dexamethasone	B-X
daily	B-X
demonstrated	B-X
the	B-X
same	B-X
change	B-X
in	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
that	B-X
was	B-X
seen	B-X
in	B-X
normal	B-X
subjects	B-X
taking	B-X
1	B-X
mg	B-X
of	B-X
dexamethasone	B-X
<EOS>	B-X
5	B-X
mg	B-X
of	B-X
cortisone	B-X
acetate	B-X
resulted	B-X
in	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
binding	B-X
sites	B-X
after	B-X
1	B-X
week	B-X
with	B-X
no	B-X
change	B-X
in	B-X
binding	B-X
affinity	B-X
<EOS>	B-X
When	B-X
binding	B-X
assays	B-X
were	B-X
carried	B-X
out	B-X
at	B-X
physiologic	B-X
temperature	B-X
there	B-X
was	B-X
the	B-X
same	B-X
decrease	B-X
in	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
after	B-X
dexamethasone	B-X
administration	B-X
,	B-X
and	B-X
in	B-X
addition	B-X
,	B-X
there	B-X
was	B-X
a	B-X
two	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
binding	B-X
affinity	B-X
<EOS>	B-X
Glucocorticoid	B-X
administration	B-X
results	B-X
in	B-X
a	B-X
time	B-X
-	B-X
dependent	B-X
decrease	B-X
in	B-X
the	B-X
number	B-X
of	B-X
lymphocyte	B-X
glucocorticoid	B-X
binding	B-X
sites	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
type	B-X
of	B-X
glucocorticoid	B-X
administered	B-X

When	O
binding	O
assays	O
were	O
carried	O
out	O
at	O
physiologic	O
temperature	O
there	O
was	O
the	O
same	O
decrease	O
in	O
number	O
of	O
binding	O
sites	O
after	O
dexamethasone	O
administration	O
,	O
and	O
in	O
addition	O
,	O
there	O
was	O
a	O
two-fold	O
increase	O
in	O
binding	O
affinity	O
.	O
<EOS>	B-X
When	B-X
binding	B-X
assays	B-X
were	B-X
carried	B-X
out	B-X
at	B-X
physiologic	B-X
temperature	B-X
there	B-X
was	B-X
the	B-X
same	B-X
decrease	B-X
in	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
after	B-X
dexamethasone	B-X
administration	B-X
,	B-X
and	B-X
in	B-X
addition	B-X
,	B-X
there	B-X
was	B-X
a	B-X
two	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
binding	B-X
affinity	B-X
<EOS>	B-X
5	B-X
mg	B-X
of	B-X
cortisone	B-X
acetate	B-X
resulted	B-X
in	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
in	B-X
binding	B-X
sites	B-X
after	B-X
1	B-X
week	B-X
with	B-X
no	B-X
change	B-X
in	B-X
binding	B-X
affinity	B-X
<EOS>	B-X
No	B-X
changes	B-X
in	B-X
the	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
was	B-X
noted	B-X
before	B-X
1	B-X
week	B-X
and	B-X
the	B-X
diminished	B-X
number	B-X
persisted	B-X
for	B-X
1	B-X
week	B-X
after	B-X
discontinuation	B-X
of	B-X
glucocorticoid	B-X
treatment	B-X
<EOS>	B-X
Lymphocytes	B-X
from	B-X
hospitalized	B-X
patients	B-X
taking	B-X
40	B-X
-	B-X
60	B-X
mg	B-X
of	B-X
dexamethasone	B-X
daily	B-X
demonstrated	B-X
the	B-X
same	B-X
change	B-X
in	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
that	B-X
was	B-X
seen	B-X
in	B-X
normal	B-X
subjects	B-X
taking	B-X
1	B-X
mg	B-X
of	B-X
dexamethasone	B-X

Glucocorticoid	O
administration	O
results	O
in	O
a	O
time-dependent	O
decrease	O
in	O
the	O
number	O
of	O
lymphocyte	O
glucocorticoid	O
binding	O
sites	O
that	O
is	O
independent	O
of	O
the	O
type	O
of	O
glucocorticoid	O
administered	O
.	O

This	O
is	O
the	O
first	O
in	O
vivo	O
demonstration	O
that	O
glucocorticoids	O
modulate	O
their	O
own	O
receptors	O
in	O
man	O
.	O
<EOS>	B-X
This	B-X
is	B-X
the	B-X
first	B-X
in	B-X
vivo	B-X
demonstration	B-X
that	B-X
glucocorticoids	B-X
modulate	B-X
their	B-X
own	B-X
receptors	B-X
in	B-X
man	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
in	B-X
human	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
administration	B-X
results	B-X
in	B-X
a	B-X
time	B-X
-	B-X
dependent	B-X
decrease	B-X
in	B-X
the	B-X
number	B-X
of	B-X
lymphocyte	B-X
glucocorticoid	B-X
binding	B-X
sites	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
type	B-X
of	B-X
glucocorticoid	B-X
administered	B-X
<EOS>	B-X
The	B-X
administration	B-X
of	B-X
1	B-X
mg	B-X
of	B-X
dexamethasone	B-X
,	B-X
5	B-X
mg	B-X
of	B-X
prednisone	B-X
,	B-X
and	B-X
37	B-X

Immunoglobulin	O
localization	O
in	O
benign	O
and	O
malignant	O
lesions	O
of	O
the	O
human	O
mammary	O
gland	O
.	O
<EOS>	B-X
Immunoglobulin	B-X
localization	B-X
in	B-X
benign	B-X
and	B-X
malignant	B-X
lesions	B-X
of	B-X
the	B-X
human	B-X
mammary	B-X
gland	B-X
.	B-X
<EOS>	B-X
Differences	B-X
in	B-X
immunoglobulin	B-X
localization	B-X
(	B-X
IgG	B-X
,	B-X
IgM	B-X
,	B-X
IgA	B-X
)	B-X
in	B-X
benign	B-X
versus	B-X
malignant	B-X
lesions	B-X
of	B-X
the	B-X
human	B-X
mammary	B-X
gland	B-X
have	B-X
been	B-X
previously	B-X
demonstrated	B-X
<EOS>	B-X
Immunoglobulin	B-X
localization	B-X
in	B-X
the	B-X
normal	B-X
human	B-X
mammary	B-X
gland	B-X
:	B-X
variation	B-X
with	B-X
the	B-X
menstrual	B-X
cycle	B-X
.	B-X
<EOS>	B-X
Immunoglobulin	B-X
localization	B-X
in	B-X
the	B-X
tissue	B-X
section	B-X
was	B-X
determined	B-X
by	B-X
direct	B-X
immunofluorescence	B-X
with	B-X
antibodies	B-X
specific	B-X
for	B-X
IgG	B-X
,	B-X
IgA	B-X
,	B-X
IgM	B-X
,	B-X
and	B-X
IgA	B-X
secretory	B-X
component	B-X

Using	O
direct	O
imunofluorescence	O
,	O
lesions	O
from	O
266	O
human	O
breast	O
specimens	O
were	O
studied	O
for	O
the	O
presence	O
of	O
IgA	O
,	O
IgM	O
,	O
or	O
IgG	O
localization	O
.	O
<EOS>	B-X
Western	B-X
blot	B-X
analyses	B-X
using	B-X
IgG	B-X
eluted	B-X
from	B-X
frozen	B-X
biopsy	B-X
tissue	B-X
were	B-X
performed	B-X
to	B-X
detect	B-X
binding	B-X
to	B-X
target	B-X
antigen	B-X
<EOS>	B-X
After	B-X
combining	B-X
the	B-X
biopsy	B-X
results	B-X
with	B-X
immunohistochemistry	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
the	B-X
absolute	B-X
number	B-X
of	B-X
positive	B-X
IgG4+	B-X
cells	B-X
per	B-X
high	B-X
power	B-X
field	B-X
exceeded	B-X
10	B-X
,	B-X
and	B-X
the	B-X
ratio	B-X
of	B-X
IgG4	B-X
/	B-X
IgG	B-X
was	B-X
over	B-X
40	B-X
%	B-X
<EOS>	B-X
The	B-X
patient	B-X
presented	B-X
to	B-X
the	B-X
hospital	B-X
with	B-X
complaints	B-X
of	B-X
elevated	B-X
serum	B-X
creatinine	B-X
(	B-X
Cr	B-X
)	B-X
,	B-X
nausea	B-X
,	B-X
and	B-X
vomiting	B-X
<EOS>	B-X
Differences	B-X
in	B-X
AMPA	B-X
levels	B-X
corresponded	B-X
to	B-X
differences	B-X
in	B-X
total	B-X
serum	B-X
IgG	B-X
levels	B-X

The	O
lesions	O
included	O
benign	O
elements	O
from	O
66	O
subcutaneous	O
mastectomy	O
specimens	O
in	O
which	O
the	O
absence	O
of	O
simultaneous	O
breast	O
malignancy	O
was	O
documented	O
,	O
primary	O
breast	O
carcinomas	O
from	O
153	O
mastectomy	O
specimens	O
,	O
and	O
47	O
biopsies	O
containing	O
metastatic	O
breast	O
cancer	O
.	O
<EOS>	B-X
The	B-X
lesions	B-X
included	B-X
benign	B-X
elements	B-X
from	B-X
66	B-X
subcutaneous	B-X
mastectomy	B-X
specimens	B-X
in	B-X
which	B-X
the	B-X
absence	B-X
of	B-X
simultaneous	B-X
breast	B-X
malignancy	B-X
was	B-X
documented	B-X
,	B-X
primary	B-X
breast	B-X
carcinomas	B-X
from	B-X
153	B-X
mastectomy	B-X
specimens	B-X
,	B-X
and	B-X
47	B-X
biopsies	B-X
containing	B-X
metastatic	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
In	B-X
both	B-X
primary	B-X
and	B-X
metastatic	B-X
lesions	B-X
,	B-X
IgG	B-X
localization	B-X
was	B-X
associated	B-X
with	B-X
estrogen	B-X
-	B-X
receptor	B-X
-	B-X
poor	B-X
primary	B-X
cancers	B-X
as	B-X
compared	B-X
with	B-X
estrogen	B-X
-	B-X
receptor	B-X
-	B-X
rich	B-X
primary	B-X
cancers	B-X
<EOS>	B-X
A	B-X
statistically	B-X
significant	B-X
association	B-X
of	B-X
IgA	B-X
and	B-X
IgM	B-X
with	B-X
benign	B-X
lesions	B-X
was	B-X
contrasted	B-X
to	B-X
the	B-X
association	B-X
of	B-X
IgG	B-X
with	B-X
malignant	B-X
lesions	B-X
<EOS>	B-X
A	B-X
shorter	B-X
disease	B-X
-	B-X
free	B-X
interval	B-X
was	B-X
noted	B-X
in	B-X
association	B-X
with	B-X
IgG	B-X
localization	B-X
among	B-X
the	B-X
metastatic	B-X
breast	B-X
lesions	B-X

A	O
statistically	O
significant	O
association	O
of	O
IgA	B-protein
and	O
IgM	B-protein
with	O
benign	O
lesions	O
was	O
contrasted	O
to	O
the	O
association	O
of	O
IgG	B-protein
with	O
malignant	O
lesions	O
.	O

In	O
both	O
primary	O
and	O
metastatic	O
lesions	O
,	O
IgG	B-protein
localization	O
was	O
associated	O
with	O
estrogen-receptor-poor	O
primary	O
cancers	O
as	O
compared	O
with	O
estrogen-receptor-rich	O
primary	O
cancers	O
.	O
<EOS>	B-X
In	B-X
both	B-X
primary	B-X
and	B-X
metastatic	B-X
lesions	B-X
,	B-X
IgG	B-X
localization	B-X
was	B-X
associated	B-X
with	B-X
estrogen	B-X
-	B-X
receptor	B-X
-	B-X
poor	B-X
primary	B-X
cancers	B-X
as	B-X
compared	B-X
with	B-X
estrogen	B-X
-	B-X
receptor	B-X
-	B-X
rich	B-X
primary	B-X
cancers	B-X
<EOS>	B-X
Among	B-X
primary	B-X
breast	B-X
cancer	B-X
patients	B-X
,	B-X
IgG	B-X
localization	B-X
in	B-X
the	B-X
tumor	B-X
correlated	B-X
with	B-X
relative	B-X
lymphopenia	B-X
<EOS>	B-X
A	B-X
shorter	B-X
disease	B-X
-	B-X
free	B-X
interval	B-X
was	B-X
noted	B-X
in	B-X
association	B-X
with	B-X
IgG	B-X
localization	B-X
among	B-X
the	B-X
metastatic	B-X
breast	B-X
lesions	B-X
<EOS>	B-X
No	B-X
statistically	B-X
significant	B-X
association	B-X
between	B-X
stage	B-X
of	B-X
disease	B-X
and	B-X
immunoglobulin	B-X
presence	B-X
was	B-X
demonstrable	B-X

Among	O
primary	O
breast	O
cancer	O
patients	O
,	O
IgG	B-protein
localization	O
in	O
the	O
tumor	O
correlated	O
with	O
relative	O
lymphopenia	O
.	O
<EOS>	B-X
Among	B-X
primary	B-X
breast	B-X
cancer	B-X
patients	B-X
,	B-X
IgG	B-X
localization	B-X
in	B-X
the	B-X
tumor	B-X
correlated	B-X
with	B-X
relative	B-X
lymphopenia	B-X
<EOS>	B-X
In	B-X
both	B-X
primary	B-X
and	B-X
metastatic	B-X
lesions	B-X
,	B-X
IgG	B-X
localization	B-X
was	B-X
associated	B-X
with	B-X
estrogen	B-X
-	B-X
receptor	B-X
-	B-X
poor	B-X
primary	B-X
cancers	B-X
as	B-X
compared	B-X
with	B-X
estrogen	B-X
-	B-X
receptor	B-X
-	B-X
rich	B-X
primary	B-X
cancers	B-X
<EOS>	B-X
A	B-X
shorter	B-X
disease	B-X
-	B-X
free	B-X
interval	B-X
was	B-X
noted	B-X
in	B-X
association	B-X
with	B-X
IgG	B-X
localization	B-X
among	B-X
the	B-X
metastatic	B-X
breast	B-X
lesions	B-X
<EOS>	B-X
Using	B-X
direct	B-X
imunofluorescence	B-X
,	B-X
lesions	B-X
from	B-X
266	B-X
human	B-X
breast	B-X
specimens	B-X
were	B-X
studied	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
IgA	B-X
,	B-X
IgM	B-X
,	B-X
or	B-X
IgG	B-X
localization	B-X

A	O
shorter	O
disease-free	O
interval	O
was	O
noted	O
in	O
association	O
with	O
IgG	B-protein
localization	O
among	O
the	O
metastatic	O
breast	O
lesions	O
.	O
<EOS>	B-X
A	B-X
shorter	B-X
disease	B-X
-	B-X
free	B-X
interval	B-X
was	B-X
noted	B-X
in	B-X
association	B-X
with	B-X
IgG	B-X
localization	B-X
among	B-X
the	B-X
metastatic	B-X
breast	B-X
lesions	B-X
<EOS>	B-X
Moderate	B-X
-	B-X
to	B-X
-	B-X
severe	B-X
intraductal	B-X
epithelial	B-X
hyperplasias	B-X
were	B-X
more	B-X
often	B-X
associated	B-X
with	B-X
immunoglobulin	B-X
G	B-X
localization	B-X
that	B-X
were	B-X
other	B-X
benign	B-X
lesions	B-X
<EOS>	B-X
Among	B-X
primary	B-X
breast	B-X
cancer	B-X
patients	B-X
,	B-X
IgG	B-X
localization	B-X
in	B-X
the	B-X
tumor	B-X
correlated	B-X
with	B-X
relative	B-X
lymphopenia	B-X
<EOS>	B-X
In	B-X
both	B-X
primary	B-X
and	B-X
metastatic	B-X
lesions	B-X
,	B-X
IgG	B-X
localization	B-X
was	B-X
associated	B-X
with	B-X
estrogen	B-X
-	B-X
receptor	B-X
-	B-X
poor	B-X
primary	B-X
cancers	B-X
as	B-X
compared	B-X
with	B-X
estrogen	B-X
-	B-X
receptor	B-X
-	B-X
rich	B-X
primary	B-X
cancers	B-X

No	O
statistically	O
significant	O
association	O
between	O
stage	O
of	O
disease	O
and	O
immunoglobulin	O
presence	O
was	O
demonstrable	O
.	O
<EOS>	B-X
No	B-X
statistically	B-X
significant	B-X
association	B-X
between	B-X
stage	B-X
of	B-X
disease	B-X
and	B-X
immunoglobulin	B-X
presence	B-X
was	B-X
demonstrable	B-X
<EOS>	B-X
A	B-X
statistically	B-X
significant	B-X
association	B-X
of	B-X
IgA	B-X
and	B-X
IgM	B-X
with	B-X
benign	B-X
lesions	B-X
was	B-X
contrasted	B-X
to	B-X
the	B-X
association	B-X
of	B-X
IgG	B-X
with	B-X
malignant	B-X
lesions	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
statistically	B-X
significant	B-X
negative	B-X
association	B-X
between	B-X
the	B-X
presence	B-X
(	B-X
P	B-X
=	B-X
0	B-X
<EOS>	B-X
No	B-X
statistically	B-X
significant	B-X
difference	B-X
was	B-X
observed	B-X
when	B-X
serum	B-X
profile	B-X
of	B-X
GM1	B-X
IgM	B-X
antibodies	B-X
in	B-X
patients	B-X
with	B-X
localized	B-X
melanoma	B-X
was	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
other	B-X
study	B-X
subjects	B-X

Moderate-to-severe	O
intraductal	O
epithelial	O
hyperplasias	O
were	O
more	O
often	O
associated	O
with	O
immunoglobulin	B-protein
G	I-protein
localization	O
that	O
were	O
other	O
benign	O
lesions	O
<EOS>	B-X
Moderate	B-X
-	B-X
to	B-X
-	B-X
severe	B-X
intraductal	B-X
epithelial	B-X
hyperplasias	B-X
were	B-X
more	B-X
often	B-X
associated	B-X
with	B-X
immunoglobulin	B-X
G	B-X
localization	B-X
that	B-X
were	B-X
other	B-X
benign	B-X
lesions	B-X
<EOS>	B-X
A	B-X
shorter	B-X
disease	B-X
-	B-X
free	B-X
interval	B-X
was	B-X
noted	B-X
in	B-X
association	B-X
with	B-X
IgG	B-X
localization	B-X
among	B-X
the	B-X
metastatic	B-X
breast	B-X
lesions	B-X
<EOS>	B-X
No	B-X
statistically	B-X
significant	B-X
association	B-X
between	B-X
stage	B-X
of	B-X
disease	B-X
and	B-X
immunoglobulin	B-X
presence	B-X
was	B-X
demonstrable	B-X
<EOS>	B-X
A	B-X
statistically	B-X
significant	B-X
association	B-X
of	B-X
IgA	B-X
and	B-X
IgM	B-X
with	B-X
benign	B-X
lesions	B-X
was	B-X
contrasted	B-X
to	B-X
the	B-X
association	B-X
of	B-X
IgG	B-X
with	B-X
malignant	B-X
lesions	B-X

Correlation	O
of	O
steroid	B-protein
receptors	I-protein
with	O
histologic	O
differentiation	O
in	O
mammary	O
carcinoma	O
.	O
<EOS>	B-X
The	B-X
combined	B-X
use	B-X
of	B-X
these	B-X
3	B-X
markers	B-X
could	B-X
be	B-X
used	B-X
in	B-X
addition	B-X
to	B-X
histological	B-X
grade	B-X
to	B-X
predict	B-X
the	B-X
biological	B-X
behavior	B-X
of	B-X
canine	B-X
mammary	B-X
carcinomas	B-X
<EOS>	B-X
More	B-X
than	B-X
half	B-X
of	B-X
the	B-X
cases	B-X
were	B-X
poorly	B-X
differentiated	B-X
cancer	B-X
(	B-X
65	B-X
<EOS>	B-X
GATA3	B-X
immunohistochemistry	B-X
expression	B-X
in	B-X
histologic	B-X
subtypes	B-X
of	B-X
primary	B-X
breast	B-X
carcinoma	B-X
and	B-X
metastatic	B-X
breast	B-X
carcinoma	B-X
cytology	B-X
.	B-X
<EOS>	B-X
Metaplastic	B-X
breast	B-X
carcinoma	B-X
is	B-X
a	B-X
rare	B-X
entity	B-X
among	B-X
breast	B-X
carcinomas	B-X

A	O
Singapore	O
experience	O
.	O
<EOS>	B-X
51	B-X
)	B-X
,	B-X
waiting	B-X
time	B-X
in	B-X
the	B-X
office	B-X
(	B-X
ρ=0	B-X
<EOS>	B-X
A	B-X
total	B-X
of	B-X
86	B-X
responses	B-X
were	B-X
received	B-X
<EOS>	B-X
Ratings	B-X
were	B-X
missing	B-X
for	B-X
18	B-X
<EOS>	B-X
A	B-X
qualitative	B-X
systematic	B-X
review	B-X
was	B-X
carried	B-X
out	B-X

Cancer	O
of	O
the	O
breast	O
is	O
the	O
most	O
common	O
tumor	O
in	O
females	O
in	O
Singapore	O
,	O
with	O
the	O
rate	O
of	O
20.7	O
per	O
100	O
,	O
000	O
per	O
year	O
(	O
1977	O
estimate	O
)	O
,	O
which	O
is	O
predicted	O
to	O
increase	O
to	O
29.8	O
per	O
100	O
,	O
000	O
women	O
per	O
year	O
by	O
1995	O
.	O
<EOS>	B-X
Cancer	B-X
of	B-X
the	B-X
breast	B-X
is	B-X
the	B-X
most	B-X
common	B-X
tumor	B-X
in	B-X
females	B-X
in	B-X
Singapore	B-X
,	B-X
with	B-X
the	B-X
rate	B-X
of	B-X
20	B-X
<EOS>	B-X
7	B-X
per	B-X
100,000	B-X
per	B-X
year	B-X
(	B-X
1977	B-X
estimate	B-X
)	B-X
,	B-X
which	B-X
is	B-X
predicted	B-X
to	B-X
increase	B-X
to	B-X
29	B-X
<EOS>	B-X
A	B-X
detailed	B-X
histopathologic	B-X
review	B-X
of	B-X
50	B-X
primary	B-X
breast	B-X
cancer	B-X
tumors	B-X
analyzed	B-X
for	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
level	B-X
was	B-X
carried	B-X
out	B-X
and	B-X
a	B-X
variety	B-X
of	B-X
morphologic	B-X
features	B-X
correlated	B-X
with	B-X
ER	B-X
results	B-X
to	B-X
identify	B-X
any	B-X
factors	B-X
that	B-X
will	B-X
improve	B-X
the	B-X
management	B-X
and	B-X
prognosis	B-X
for	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Correlation	B-X
of	B-X
steroid	B-X
receptors	B-X
with	B-X
histologic	B-X
differentiation	B-X
in	B-X
mammary	B-X
carcinoma	B-X
.	B-X
A	B-X
Singapore	B-X
experience	B-X
.	B-X

A	O
detailed	O
histopathologic	O
review	O
of	O
50	O
primary	O
breast	O
cancer	O
tumors	O
analyzed	O
for	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
level	O
was	O
carried	O
out	O
and	O
a	O
variety	O
of	O
morphologic	O
features	O
correlated	O
with	O
ER	B-protein
results	O
to	O
identify	O
any	O
factors	O
that	O
will	O
improve	O
the	O
management	O
and	O
prognosis	O
for	O
breast	O
cancer	O
.	O

Cytosol	O
was	O
incubated	O
with	O
3H-estradiol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
cold	O
diethylstilbestrol	O
,	O
and	O
bound	O
and	O
free	O
hormone	O
were	O
separated	O
by	O
Dextran-coated	O
charcoal	O
method	O
.	O
<EOS>	B-X
Cytosol	B-X
was	B-X
incubated	B-X
with	B-X
3H	B-X
-	B-X
estradiol	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
cold	B-X
diethylstilbestrol	B-X
,	B-X
and	B-X
bound	B-X
and	B-X
free	B-X
hormone	B-X
were	B-X
separated	B-X
by	B-X
Dextran	B-X
-	B-X
coated	B-X
charcoal	B-X
method	B-X
<EOS>	B-X
Results	B-X
indicated	B-X
that	B-X
there	B-X
was	B-X
strong	B-X
correlation	B-X
between	B-X
ER	B-X
level	B-X
,	B-X
age	B-X
,	B-X
and	B-X
histologic	B-X
grade	B-X
of	B-X
the	B-X
tumors	B-X
<EOS>	B-X
No	B-X
correlation	B-X
existed	B-X
between	B-X
absence	B-X
or	B-X
presence	B-X
of	B-X
lymph	B-X
node	B-X
metastases	B-X
and	B-X
ER	B-X
<EOS>	B-X
Cancer	B-X
of	B-X
the	B-X
breast	B-X
is	B-X
the	B-X
most	B-X
common	B-X
tumor	B-X
in	B-X
females	B-X
in	B-X
Singapore	B-X
,	B-X
with	B-X
the	B-X
rate	B-X
of	B-X
20	B-X

Tumors	O
binding	O
more	O
than	O
5	O
fmol/mg	O
cytosol	B-protein
protein	I-protein
were	O
classified	O
as	O
ER	B-protein
-positive	O
.	O
<EOS>	B-X
Tumors	B-X
binding	B-X
more	B-X
than	B-X
5	B-X
fmol	B-X
/	B-X
mg	B-X
cytosol	B-X
protein	B-X
were	B-X
classified	B-X
as	B-X
ER	B-X
-	B-X
positive	B-X
<EOS>	B-X
Although	B-X
there	B-X
was	B-X
a	B-X
trend	B-X
for	B-X
ER	B-X
-	B-X
positive	B-X
tumors	B-X
to	B-X
have	B-X
a	B-X
low	B-X
-	B-X
grade	B-X
lymphocytic	B-X
infiltration	B-X
,	B-X
the	B-X
difference	B-X
was	B-X
not	B-X
statistically	B-X
significant	B-X
<EOS>	B-X
Results	B-X
indicated	B-X
that	B-X
there	B-X
was	B-X
strong	B-X
correlation	B-X
between	B-X
ER	B-X
level	B-X
,	B-X
age	B-X
,	B-X
and	B-X
histologic	B-X
grade	B-X
of	B-X
the	B-X
tumors	B-X
<EOS>	B-X
Most	B-X
of	B-X
the	B-X
patients	B-X
were	B-X
Chinese	B-X
(	B-X
90	B-X
%	B-X
)	B-X

Progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
level	O
was	O
analyzed	O
in	O
some	O
specimens	O
with	O
the	O
use	O
of	O
a	O
similar	O
method	O
.	O
<EOS>	B-X
Progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
level	B-X
was	B-X
analyzed	B-X
in	B-X
some	B-X
specimens	B-X
with	B-X
the	B-X
use	B-X
of	B-X
a	B-X
similar	B-X
method	B-X
<EOS>	B-X
IGFBPs	B-X
can	B-X
be	B-X
detected	B-X
in	B-X
breast	B-X
cancer	B-X
specimens	B-X
,	B-X
and	B-X
their	B-X
level	B-X
of	B-X
expression	B-X
correlates	B-X
with	B-X
other	B-X
known	B-X
biological	B-X
parameters	B-X
of	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Proteins	B-X
were	B-X
extracted	B-X
from	B-X
breast	B-X
cancer	B-X
specimens	B-X
and	B-X
analyzed	B-X
by	B-X
semiquantitative	B-X
IGF	B-X
-	B-X
I	B-X
ligand	B-X
blotting	B-X
for	B-X
IGFBP	B-X
expression	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
IGFBPs	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
breast	B-X
cancer	B-X
biology	B-X
and	B-X
that	B-X
BP	B-X
-	B-X
4	B-X
levels	B-X
,	B-X
analyzed	B-X
in	B-X
conjunction	B-X
with	B-X
tumor	B-X
size	B-X
,	B-X
may	B-X
have	B-X
prognostic	B-X
significance	B-X

Most	O
of	O
the	O
patients	O
were	O
Chinese	O
(	O
90	O
%	O
)	O
.	O

Three	O
patients	O
were	O
Malays	O
,	O
one	O
was	O
Indian	O
,	O
and	O
one	O
was	O
European	O
in	O
this	O
series	O
.	O
<EOS>	B-X
Three	B-X
patients	B-X
were	B-X
Malays	B-X
,	B-X
one	B-X
was	B-X
Indian	B-X
,	B-X
and	B-X
one	B-X
was	B-X
European	B-X
in	B-X
this	B-X
series	B-X
<EOS>	B-X
Correlation	B-X
of	B-X
steroid	B-X
receptors	B-X
with	B-X
histologic	B-X
differentiation	B-X
in	B-X
mammary	B-X
carcinoma	B-X
.	B-X
A	B-X
Singapore	B-X
experience	B-X
.	B-X
<EOS>	B-X
Progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
level	B-X
was	B-X
analyzed	B-X
in	B-X
some	B-X
specimens	B-X
with	B-X
the	B-X
use	B-X
of	B-X
a	B-X
similar	B-X
method	B-X
<EOS>	B-X
Although	B-X
there	B-X
was	B-X
a	B-X
trend	B-X
for	B-X
ER	B-X
-	B-X
positive	B-X
tumors	B-X
to	B-X
have	B-X
a	B-X
low	B-X
-	B-X
grade	B-X
lymphocytic	B-X
infiltration	B-X
,	B-X
the	B-X
difference	B-X
was	B-X
not	B-X
statistically	B-X
significant	B-X

Results	O
indicated	O
that	O
there	O
was	O
strong	O
correlation	O
between	O
ER	B-protein
level	O
,	O
age	O
,	O
and	O
histologic	O
grade	O
of	O
the	O
tumors	O
.	O
<EOS>	B-X
Results	B-X
indicated	B-X
that	B-X
there	B-X
was	B-X
strong	B-X
correlation	B-X
between	B-X
ER	B-X
level	B-X
,	B-X
age	B-X
,	B-X
and	B-X
histologic	B-X
grade	B-X
of	B-X
the	B-X
tumors	B-X
<EOS>	B-X
Cancer	B-X
of	B-X
the	B-X
breast	B-X
is	B-X
the	B-X
most	B-X
common	B-X
tumor	B-X
in	B-X
females	B-X
in	B-X
Singapore	B-X
,	B-X
with	B-X
the	B-X
rate	B-X
of	B-X
20	B-X
<EOS>	B-X
Cytosol	B-X
was	B-X
incubated	B-X
with	B-X
3H	B-X
-	B-X
estradiol	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
cold	B-X
diethylstilbestrol	B-X
,	B-X
and	B-X
bound	B-X
and	B-X
free	B-X
hormone	B-X
were	B-X
separated	B-X
by	B-X
Dextran	B-X
-	B-X
coated	B-X
charcoal	B-X
method	B-X
<EOS>	B-X
Three	B-X
patients	B-X
were	B-X
Malays	B-X
,	B-X
one	B-X
was	B-X
Indian	B-X
,	B-X
and	B-X
one	B-X
was	B-X
European	B-X
in	B-X
this	B-X
series	B-X

No	O
correlation	O
existed	O
between	O
absence	O
or	O
presence	O
of	O
lymph	O
node	O
metastases	O
and	O
ER	B-protein
.	O
<EOS>	B-X
015	B-X
)	B-X
as	B-X
well	B-X
as	B-X
with	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
pain	B-X
(	B-X
p=0	B-X
<EOS>	B-X
The	B-X
correlation	B-X
of	B-X
hub	B-X
genes	B-X
with	B-X
clinical	B-X
characteristics	B-X
was	B-X
analyzed	B-X
by	B-X
the	B-X
Nephroseq	B-X
v5	B-X
database	B-X
<EOS>	B-X
Visceral	B-X
fat	B-X
correlates	B-X
with	B-X
insulin	B-X
secretion	B-X
and	B-X
sensitivity	B-X
independent	B-X
of	B-X
BMI	B-X
and	B-X
subcutaneous	B-X
fat	B-X
in	B-X
Chinese	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
.	B-X
<EOS>	B-X
Spectral	B-X
characterization	B-X
and	B-X
severity	B-X
assessment	B-X
of	B-X
rice	B-X
blast	B-X
disease	B-X
using	B-X
univariate	B-X
and	B-X
multivariate	B-X
models	B-X
.	B-X

Although	O
there	O
was	O
a	O
trend	O
for	O
ER	B-protein
-positive	O
tumors	O
to	O
have	O
a	O
low-grade	O
lymphocytic	O
infiltration	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Mononuclear	B-cell_type
cells	I-cell_type
infiltrating	O
human	O
mammary	O
carcinomas	O
:	O
immunohistochemical	O
analysis	O
with	O
monoclonal	B-protein
antibodies	I-protein
.	O
<EOS>	B-X
Mononuclear	B-X
cells	B-X
infiltrating	B-X
human	B-X
mammary	B-X
carcinomas	B-X
:	B-X
immunohistochemical	B-X
analysis	B-X
with	B-X
monoclonal	B-X
antibodies	B-X
.	B-X
<EOS>	B-X
Lymphocyte	B-X
subsets	B-X
in	B-X
the	B-X
tumor	B-X
nests	B-X
of	B-X
breast	B-X
carcinoma	B-X
were	B-X
immunohistochemically	B-X
investigated	B-X
and	B-X
a	B-X
quantitative	B-X
analysis	B-X
was	B-X
added	B-X
<EOS>	B-X
HLA	B-X
-	B-X
DR	B-X
antigens	B-X
on	B-X
differentiating	B-X
human	B-X
mammary	B-X
gland	B-X
epithelium	B-X
and	B-X
breast	B-X
tumours	B-X
.	B-X
<EOS>	B-X
Detection	B-X
of	B-X
isolated	B-X
tumor	B-X
cells	B-X
in	B-X
bone	B-X
marrow	B-X
in	B-X
early	B-X
-	B-X
stage	B-X
breast	B-X
carcinoma	B-X
patients	B-X
:	B-X
comparison	B-X
with	B-X
preoperative	B-X
clinical	B-X
parameters	B-X
and	B-X
primary	B-X
tumor	B-X
characteristics	B-X
.	B-X

Breast	O
carcinomas	O
were	O
examined	O
by	O
the	O
immunoperoxidase	O
technique	O
using	O
antisera	O
specific	O
for	O
lymphocyte	B-cell_type
subsets	I-cell_type
,	O
monocytes	B-cell_type
,	O
NK	B-cell_type
cells	I-cell_type
and	O
major	B-protein
histocompatibility	I-protein
antigens	I-protein
(	O
HLA-A	B-protein
,	O
-B	B-protein
,	O
-C	O
;	O
Ia-like	B-protein
)	O
.	O

Sixty-four	O
per	O
cent	O
of	O
the	O
patients	O
had	O
a	O
moderate	O
or	O
strong	O
mononuclear	O
cell	O
infiltration	O
,	O
77	O
%	O
of	O
the	O
patients	O
without	O
mononuclear	B-cell_type
cell	I-cell_type
infiltration	O
had	O
receptors	O
for	O
estrogens	O
as	O
compared	O
to	O
51	O
%	O
of	O
the	O
patients	O
with	O
infiltration	O
.	O

The	O
majority	O
of	O
the	O
infiltrating	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
were	O
T	B-cell_type
cells	I-cell_type
;	O
generally	O
the	O
OKT8	B-cell_line
cells	I-cell_line
were	O
predominant	O
.	O

The	O
Leu	O
3A/OKT8	O
cell	O
ratio	O
was	O
not	O
related	O
to	O
histological	O
type	O
,	O
tumor	O
size	O
,	O
age	O
of	O
the	O
patient	O
or	O
presence	O
of	O
metastases	O
.	O
<EOS>	B-X
These	B-X
frequencies	B-X
are	B-X
generally	B-X
lower	B-X
than	B-X
was	B-X
observed	B-X
in	B-X
The	B-X
Cancer	B-X
Genome	B-X
Atlas	B-X
,	B-X
where	B-X
the	B-X
specimens	B-X
analyzed	B-X
were	B-X
predominantly	B-X
obtained	B-X
from	B-X
metastases	B-X
<EOS>	B-X
This	B-X
study	B-X
provides	B-X
important	B-X
insights	B-X
into	B-X
the	B-X
poor	B-X
prognosis	B-X
of	B-X
microcalcification	B-X
,	B-X
not	B-X
only	B-X
in	B-X
terms	B-X
of	B-X
poor	B-X
response	B-X
to	B-X
NACT	B-X
but	B-X
also	B-X
the	B-X
risk	B-X
factor	B-X
of	B-X
bone	B-X
metastases	B-X
<EOS>	B-X
Tumors	B-X
were	B-X
designated	B-X
``	B-X
positive	B-X
''	B-X
if	B-X
they	B-X
had	B-X
at	B-X
least	B-X
5	B-X
positive	B-X
lymph	B-X
node	B-X
metastases	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
laryngeal	B-X
cancer	B-X
mortality	B-X
is	B-X
related	B-X
to	B-X
the	B-X
extent	B-X
of	B-X
laryngeal	B-X
cancer	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
treatment	B-X
modalities	B-X
,	B-X
and	B-X
postoperative	B-X
lifestyle	B-X
habits	B-X

Some	O
of	O
the	O
T	O
cells	O
had	O
the	O
Ia	B-protein
antigen	I-protein
and	O
were	O
thus	O
probably	O
activated	O
.	O
<EOS>	B-X
So	B-X
far	B-X
,	B-X
most	B-X
efforts	B-X
to	B-X
intervene	B-X
in	B-X
the	B-X
immunopathogenesis	B-X
of	B-X
sepsis	B-X
have	B-X
been	B-X
directed	B-X
at	B-X
the	B-X
pro	B-X
-	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
The	B-X
central	B-X
role	B-X
of	B-X
monocytes	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
sepsis	B-X
:	B-X
consequences	B-X
for	B-X
immunomonitoring	B-X
and	B-X
treatment	B-X
.	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
sepsis	B-X
is	B-X
a	B-X
bimodal	B-X
entity	B-X
<EOS>	B-X
None	B-X
of	B-X
these	B-X
interventions	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
improve	B-X
the	B-X
prognosis	B-X
of	B-X
sepsis	B-X
,	B-X
possibly	B-X
because	B-X
many	B-X
patients	B-X
were	B-X
already	B-X
in	B-X
a	B-X
state	B-X
in	B-X
which	B-X
anti	B-X
-	B-X
inflammatory	B-X
responses	B-X
dominated	B-X

The	O
B	B-cell_type
cells	I-cell_type
were	O
either	O
absent	O
or	O
less	O
numerous	O
than	O
the	O
T	O
cells	O
.	O

There	O
was	O
no	O
relation	O
between	O
their	O
distribution	O
and	O
the	O
various	O
parameters	O
studied	O
.	O
<EOS>	B-X
The	B-X
relationship	B-X
between	B-X
the	B-X
distribution	B-X
of	B-X
reentrant	B-X
activity	B-X
and	B-X
the	B-X
clinical	B-X
outcome	B-X
after	B-X
PVI	B-X
was	B-X
studied	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
relationship	B-X
between	B-X
lumbar	B-X
disc	B-X
herniation	B-X
and	B-X
Goutallier	B-X
classification	B-X
(	B-X
GC	B-X
)	B-X
,	B-X
lumbar	B-X
indentation	B-X
value	B-X
,	B-X
and	B-X
subcutaneous	B-X
adipose	B-X
tissue	B-X
thickness	B-X
<EOS>	B-X
The	B-X
results	B-X
were	B-X
compared	B-X
to	B-X
human	B-X
data	B-X
from	B-X
the	B-X
literature	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
statistical	B-X
difference	B-X
between	B-X
herniated	B-X
and	B-X
non	B-X
-	B-X
herniated	B-X
groups	B-X
regarding	B-X
lumbar	B-X
indentation	B-X
value	B-X
(	B-X
LIV	B-X
)	B-X
and	B-X
subcutaneous	B-X
adipose	B-X
tissue	B-X
thickness	B-X
(	B-X
SATT	B-X
)	B-X

A	O
few	O
monocytes	B-cell_type
were	O
heterogeneous	O
according	O
to	O
their	O
markers	O
(	O
OKM	B-protein
I	I-protein
and	O
acid	O
phosphatase	O
)	O
.	O
<EOS>	B-X
A	B-X
few	B-X
monocytes	B-X
were	B-X
heterogeneous	B-X
according	B-X
to	B-X
their	B-X
markers	B-X
(	B-X
OKM	B-X
I	B-X
and	B-X
acid	B-X
phosphatase	B-X
)	B-X
<EOS>	B-X
In	B-X
6	B-X
cases	B-X
only	B-X
there	B-X
was	B-X
a	B-X
strong	B-X
infiltration	B-X
of	B-X
mononuclear	B-X
cells	B-X
positive	B-X
for	B-X
acid	B-X
phosphatase	B-X
<EOS>	B-X
The	B-X
B	B-X
cells	B-X
were	B-X
either	B-X
absent	B-X
or	B-X
less	B-X
numerous	B-X
than	B-X
the	B-X
T	B-X
cells	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
the	B-X
inflammatory	B-X
infiltration	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
HLA	B-X
class	B-X
-	B-X
I	B-X
antigens	B-X
on	B-X
tumor	B-X
cells	B-X

In	O
6	O
cases	O
only	O
there	O
was	O
a	O
strong	O
infiltration	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
positive	O
for	O
acid	B-protein
phosphatase	I-protein
.	O

The	O
number	O
of	O
the	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
was	O
also	O
low	O
.	O
<EOS>	B-X
The	B-X
numbers	B-X
of	B-X
neutrophils	B-X
and	B-X
of	B-X
T	B-X
-	B-X
	B-X
,	B-X
B	B-X
-	B-X
	B-X
,	B-X
and	B-X
NK	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
frequency	B-X
of	B-X
HLA	B-X
-	B-X
DR	B-X
<EOS>	B-X
Median	B-X
number	B-X
of	B-X
scIL2	B-X
cycles	B-X
was	B-X
3	B-X
(	B-X
1	B-X
-	B-X
6	B-X
)	B-X
<EOS>	B-X
The	B-X
immunophenotype	B-X
and	B-X
the	B-X
ex	B-X
-	B-X
vivo	B-X
killing	B-X
ability	B-X
of	B-X
CIK	B-X
cells	B-X
were	B-X
evaluated	B-X
<EOS>	B-X
Immunophenotype	B-X
and	B-X
antitumor	B-X
activity	B-X
of	B-X
cytokine	B-X
-	B-X
induced	B-X
killer	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X

Only	O
a	O
few	O
mononuclear	O
infiltrating	O
cells	O
had	O
receptors	O
for	O
transferrin	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
the	O
inflammatory	O
infiltration	O
and	O
the	O
presence	O
of	O
HLA	B-protein
class-I	I-protein
antigens	I-protein
on	O
tumor	B-cell_type
cell	I-cell_type
s	O
.	O

Some	O
of	O
the	O
antisera	O
specific	O
for	O
lymphocyte	B-cell_type
subsets	I-cell_type
also	O
stained	O
the	O
breast	B-cell_type
carcinoma	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Some	B-X
of	B-X
the	B-X
antisera	B-X
specific	B-X
for	B-X
lymphocyte	B-X
subsets	B-X
also	B-X
stained	B-X
the	B-X
breast	B-X
carcinoma	B-X
cells	B-X
<EOS>	B-X
Breast	B-X
carcinomas	B-X
were	B-X
examined	B-X
by	B-X
the	B-X
immunoperoxidase	B-X
technique	B-X
using	B-X
antisera	B-X
specific	B-X
for	B-X
lymphocyte	B-X
subsets	B-X
,	B-X
monocytes	B-X
,	B-X
NK	B-X
cells	B-X
and	B-X
major	B-X
histocompatibility	B-X
antigens	B-X
(	B-X
HLA	B-X
-	B-X
A	B-X
,	B-X
	B-X
-	B-X
B	B-X
,	B-X
	B-X
-	B-X
C	B-X
;	B-X
Ia	B-X
-	B-X
like	B-X
)	B-X
<EOS>	B-X
Some	B-X
of	B-X
the	B-X
T	B-X
cells	B-X
had	B-X
the	B-X
Ia	B-X
antigen	B-X
and	B-X
were	B-X
thus	B-X
probably	B-X
activated	B-X
<EOS>	B-X
The	B-X
B	B-X
cells	B-X
were	B-X
either	B-X
absent	B-X
or	B-X
less	B-X
numerous	B-X
than	B-X
the	B-X
T	B-X
cells	B-X

The	O
great	O
variations	O
in	O
the	O
subsets	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
in	O
breast	O
carcinomas	O
may	O
correspond	O
to	O
various	O
systems	O
of	O
defense	O
against	O
neoplasm	O
.	O
<EOS>	B-X
The	B-X
great	B-X
variations	B-X
in	B-X
the	B-X
subsets	B-X
of	B-X
mononuclear	B-X
cells	B-X
in	B-X
breast	B-X
carcinomas	B-X
may	B-X
correspond	B-X
to	B-X
various	B-X
systems	B-X
of	B-X
defense	B-X
against	B-X
neoplasm	B-X
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
the	B-X
infiltrating	B-X
mononuclear	B-X
cells	B-X
were	B-X
T	B-X
cells	B-X
;	B-X
generally	B-X
the	B-X
OKT8	B-X
cells	B-X
were	B-X
predominant	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
relation	B-X
between	B-X
their	B-X
distribution	B-X
and	B-X
the	B-X
various	B-X
parameters	B-X
studied	B-X
<EOS>	B-X
Sixty	B-X
-	B-X
four	B-X
per	B-X
cent	B-X
of	B-X
the	B-X
patients	B-X
had	B-X
a	B-X
moderate	B-X
or	B-X
strong	B-X
mononuclear	B-X
cell	B-X
infiltration	B-X
,	B-X
77	B-X
%	B-X
of	B-X
the	B-X
patients	B-X
without	B-X
mononuclear	B-X
cell	B-X
infiltration	B-X
had	B-X
receptors	B-X
for	B-X
estrogens	B-X
as	B-X
compared	B-X
to	B-X
51	B-X
%	B-X
of	B-X
the	B-X
patients	B-X
with	B-X
infiltration	B-X

A	O
case	O
of	O
male	O
pseudohermaphroditism	O
with	O
normal	O
androgen	B-protein
receptor	I-protein
binding	O
and	O
47	O
,	O
XYY	O
karyotype	O
.	O
<EOS>	B-X
A	B-X
case	B-X
of	B-X
male	B-X
pseudohermaphroditism	B-X
with	B-X
normal	B-X
androgen	B-X
receptor	B-X
binding	B-X
and	B-X
47	B-X
,	B-X
XYY	B-X
karyotype	B-X
.	B-X
<EOS>	B-X
A	B-X
case	B-X
of	B-X
male	B-X
pseudohermaphroditism	B-X
with	B-X
47	B-X
,	B-X
XYY	B-X
karyotype	B-X
in	B-X
blood	B-X
and	B-X
cutaneous	B-X
fibroblasts	B-X
is	B-X
described	B-X
<EOS>	B-X
The	B-X
plasma	B-X
testosterone	B-X
response	B-X
to	B-X
HCG	B-X
stimulation	B-X
was	B-X
slightly	B-X
below	B-X
the	B-X
normal	B-X
range	B-X
on	B-X
two	B-X
occasions	B-X
suggesting	B-X
a	B-X
deficit	B-X
of	B-X
gonadal	B-X
function	B-X
<EOS>	B-X
The	B-X
diagnostic	B-X
possibility	B-X
of	B-X
a	B-X
complete	B-X
testicular	B-X
feminization	B-X
syndrome	B-X
with	B-X
normal	B-X
receptors	B-X
for	B-X
dihydrotestosterone	B-X
is	B-X
commented	B-X
on	B-X

A	O
case	O
of	O
male	O
pseudohermaphroditism	O
with	O
47	O
,	O
XYY	O
karyotype	O
in	O
blood	O
and	O
cutaneous	B-cell_type
fibroblasts	I-cell_type
is	O
described	O
.	O
<EOS>	B-X
A	B-X
case	B-X
of	B-X
male	B-X
pseudohermaphroditism	B-X
with	B-X
47	B-X
,	B-X
XYY	B-X
karyotype	B-X
in	B-X
blood	B-X
and	B-X
cutaneous	B-X
fibroblasts	B-X
is	B-X
described	B-X
<EOS>	B-X
A	B-X
case	B-X
of	B-X
male	B-X
pseudohermaphroditism	B-X
with	B-X
normal	B-X
androgen	B-X
receptor	B-X
binding	B-X
and	B-X
47	B-X
,	B-X
XYY	B-X
karyotype	B-X
.	B-X
<EOS>	B-X
The	B-X
plasma	B-X
testosterone	B-X
response	B-X
to	B-X
HCG	B-X
stimulation	B-X
was	B-X
slightly	B-X
below	B-X
the	B-X
normal	B-X
range	B-X
on	B-X
two	B-X
occasions	B-X
suggesting	B-X
a	B-X
deficit	B-X
of	B-X
gonadal	B-X
function	B-X
<EOS>	B-X
The	B-X
diagnostic	B-X
possibility	B-X
of	B-X
a	B-X
complete	B-X
testicular	B-X
feminization	B-X
syndrome	B-X
with	B-X
normal	B-X
receptors	B-X
for	B-X
dihydrotestosterone	B-X
is	B-X
commented	B-X
on	B-X

The	O
plasma	O
testosterone	O
response	O
to	O
HCG	O
stimulation	O
was	O
slightly	O
below	O
the	O
normal	O
range	O
on	O
two	O
occasions	O
suggesting	O
a	O
deficit	O
of	O
gonadal	O
function	O
.	O
<EOS>	B-X
The	B-X
plasma	B-X
testosterone	B-X
response	B-X
to	B-X
HCG	B-X
stimulation	B-X
was	B-X
slightly	B-X
below	B-X
the	B-X
normal	B-X
range	B-X
on	B-X
two	B-X
occasions	B-X
suggesting	B-X
a	B-X
deficit	B-X
of	B-X
gonadal	B-X
function	B-X
<EOS>	B-X
A	B-X
case	B-X
of	B-X
male	B-X
pseudohermaphroditism	B-X
with	B-X
normal	B-X
androgen	B-X
receptor	B-X
binding	B-X
and	B-X
47	B-X
,	B-X
XYY	B-X
karyotype	B-X
.	B-X
<EOS>	B-X
A	B-X
study	B-X
of	B-X
the	B-X
receptors	B-X
for	B-X
dihydrotestosterone	B-X
in	B-X
fibroblasts	B-X
of	B-X
genital	B-X
and	B-X
nongenital	B-X
skin	B-X
showed	B-X
a	B-X
normal	B-X
concentration	B-X
of	B-X
receptors	B-X
in	B-X
genital	B-X
skin	B-X
;	B-X
5	B-X
-	B-X
alpha	B-X
-	B-X
reductase	B-X
activity	B-X
in	B-X
fibroblasts	B-X
of	B-X
the	B-X
genital	B-X
skin	B-X
was	B-X
low	B-X
,	B-X
but	B-X
the	B-X
plasma	B-X
relationship	B-X
testosterone	B-X
/	B-X
dihydrotestosterone	B-X
under	B-X
HCG	B-X
stimulation	B-X
was	B-X
normal	B-X
<EOS>	B-X
The	B-X
diagnostic	B-X
possibility	B-X
of	B-X
a	B-X
complete	B-X
testicular	B-X
feminization	B-X
syndrome	B-X
with	B-X
normal	B-X
receptors	B-X
for	B-X
dihydrotestosterone	B-X
is	B-X
commented	B-X
on	B-X

A	O
study	O
of	O
the	O
receptors	O
for	O
dihydrotestosterone	O
in	O
fibroblasts	B-cell_type
of	O
genital	O
and	O
nongenital	O
skin	O
showed	O
a	O
normal	O
concentration	O
of	O
receptors	O
in	O
genital	O
skin	O
;	O
5-alpha-reductase	B-protein
activity	O
in	O
fibroblasts	B-cell_type
of	O
the	O
genital	O
skin	O
was	O
low	O
,	O
but	O
the	O
plasma	O
relationship	O
testosterone/dihydrotestosterone	O
under	O
HCG	O
stimulation	O
was	O
normal	O
.	O
<EOS>	B-X
A	B-X
study	B-X
of	B-X
the	B-X
receptors	B-X
for	B-X
dihydrotestosterone	B-X
in	B-X
fibroblasts	B-X
of	B-X
genital	B-X
and	B-X
nongenital	B-X
skin	B-X
showed	B-X
a	B-X
normal	B-X
concentration	B-X
of	B-X
receptors	B-X
in	B-X
genital	B-X
skin	B-X
;	B-X
5	B-X
-	B-X
alpha	B-X
-	B-X
reductase	B-X
activity	B-X
in	B-X
fibroblasts	B-X
of	B-X
the	B-X
genital	B-X
skin	B-X
was	B-X
low	B-X
,	B-X
but	B-X
the	B-X
plasma	B-X
relationship	B-X
testosterone	B-X
/	B-X
dihydrotestosterone	B-X
under	B-X
HCG	B-X
stimulation	B-X
was	B-X
normal	B-X
<EOS>	B-X
The	B-X
diagnostic	B-X
possibility	B-X
of	B-X
a	B-X
complete	B-X
testicular	B-X
feminization	B-X
syndrome	B-X
with	B-X
normal	B-X
receptors	B-X
for	B-X
dihydrotestosterone	B-X
is	B-X
commented	B-X
on	B-X
<EOS>	B-X
The	B-X
plasma	B-X
testosterone	B-X
response	B-X
to	B-X
HCG	B-X
stimulation	B-X
was	B-X
slightly	B-X
below	B-X
the	B-X
normal	B-X
range	B-X
on	B-X
two	B-X
occasions	B-X
suggesting	B-X
a	B-X
deficit	B-X
of	B-X
gonadal	B-X
function	B-X
<EOS>	B-X
A	B-X
case	B-X
of	B-X
male	B-X
pseudohermaphroditism	B-X
with	B-X
47	B-X
,	B-X
XYY	B-X
karyotype	B-X
in	B-X
blood	B-X
and	B-X
cutaneous	B-X
fibroblasts	B-X
is	B-X
described	B-X

The	O
diagnostic	O
possibility	O
of	O
a	O
complete	O
testicular	O
feminization	O
syndrome	O
with	O
normal	O
receptors	O
for	O
dihydrotestosterone	O
is	O
commented	O
on	O
.	O
<EOS>	B-X
The	B-X
diagnostic	B-X
possibility	B-X
of	B-X
a	B-X
complete	B-X
testicular	B-X
feminization	B-X
syndrome	B-X
with	B-X
normal	B-X
receptors	B-X
for	B-X
dihydrotestosterone	B-X
is	B-X
commented	B-X
on	B-X
<EOS>	B-X
A	B-X
case	B-X
of	B-X
male	B-X
pseudohermaphroditism	B-X
with	B-X
normal	B-X
androgen	B-X
receptor	B-X
binding	B-X
and	B-X
47	B-X
,	B-X
XYY	B-X
karyotype	B-X
.	B-X
<EOS>	B-X
A	B-X
study	B-X
of	B-X
the	B-X
receptors	B-X
for	B-X
dihydrotestosterone	B-X
in	B-X
fibroblasts	B-X
of	B-X
genital	B-X
and	B-X
nongenital	B-X
skin	B-X
showed	B-X
a	B-X
normal	B-X
concentration	B-X
of	B-X
receptors	B-X
in	B-X
genital	B-X
skin	B-X
;	B-X
5	B-X
-	B-X
alpha	B-X
-	B-X
reductase	B-X
activity	B-X
in	B-X
fibroblasts	B-X
of	B-X
the	B-X
genital	B-X
skin	B-X
was	B-X
low	B-X
,	B-X
but	B-X
the	B-X
plasma	B-X
relationship	B-X
testosterone	B-X
/	B-X
dihydrotestosterone	B-X
under	B-X
HCG	B-X
stimulation	B-X
was	B-X
normal	B-X
<EOS>	B-X
The	B-X
plasma	B-X
testosterone	B-X
response	B-X
to	B-X
HCG	B-X
stimulation	B-X
was	B-X
slightly	B-X
below	B-X
the	B-X
normal	B-X
range	B-X
on	B-X
two	B-X
occasions	B-X
suggesting	B-X
a	B-X
deficit	B-X
of	B-X
gonadal	B-X
function	B-X

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
inhibits	O
antigen-induced	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O
<EOS>	B-X
1,25	B-X
-	B-X
Dihydroxyvitamin	B-X
D3	B-X
inhibits	B-X
antigen	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
<EOS>	B-X
1,25	B-X
-	B-X
Dihydroxyvitamin	B-X
D	B-X
inhibits	B-X
lipopolysaccharide	B-X
-	B-X
induced	B-X
immune	B-X
activation	B-X
in	B-X
human	B-X
endothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Constant	B-X
,	B-X
but	B-X
not	B-X
pulsed	B-X
calcitriol	B-X
suppresses	B-X
hemodialysis	B-X
patients	B-X
'	B-X
antigen	B-X
-	B-X
induced	B-X
lymphocyte	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2	B-X
D3	B-X
pretreatment	B-X
of	B-X
HMEC	B-X
did	B-X
not	B-X
block	B-X
MyD88	B-X
-	B-X
independent	B-X
LPS	B-X
-	B-X
induced	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
beta	B-X
promoter	B-X
activation	B-X

The	O
proliferative	O
response	O
of	O
murine	B-cell_type
spleen	I-cell_type
and	I-cell_type
thymus	I-cell_type
cells	I-cell_type
to	O
antigen	B-protein
but	O
not	O
to	O
lectin	B-protein
was	O
inhibited	O
by	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
the	B-X
proliferative	B-X
response	B-X
of	B-X
thymocytes	B-X
to	B-X
mitogens	B-X
and	B-X
peripheral	B-X
lymph	B-X
node	B-X
T	B-X
cells	B-X
to	B-X
male	B-X
H	B-X
-	B-X
Y	B-X
antigen	B-X
was	B-X
significantly	B-X
altered	B-X
in	B-X
female	B-X
and	B-X
male	B-X
mice	B-X
following	B-X
DES	B-X
treatment	B-X
<EOS>	B-X
The	B-X
proliferation	B-X
of	B-X
T	B-X
or	B-X
B	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
ConA	B-X
or	B-X
LPS	B-X
,	B-X
respectively	B-X
,	B-X
was	B-X
analyzed	B-X
by	B-X
3H	B-X
-	B-X
TdR	B-X
labeling	B-X
<EOS>	B-X
OVA	B-X
-	B-X
specific	B-X
proliferative	B-X
responses	B-X
and	B-X
interferon	B-X
-	B-X
gamma	B-X
production	B-X
levels	B-X
were	B-X
decreased	B-X
in	B-X
mice	B-X
administered	B-X
20	B-X
mg	B-X
/	B-X
kg	B-X
genistein	B-X
compared	B-X
with	B-X
those	B-X
in	B-X
control	B-X
mice	B-X
without	B-X
reduction	B-X
in	B-X
responses	B-X
to	B-X
anti	B-X
-	B-X
CD3	B-X
monoclonal	B-X
(	B-X
m	B-X
)	B-X
antibody	B-X
<EOS>	B-X
Gestational	B-X
exposure	B-X
to	B-X
mercury	B-X
leads	B-X
to	B-X
persistent	B-X
changes	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
function	B-X
in	B-X
adult	B-X
DBF1	B-X
mice	B-X
.	B-X

To	O
directly	O
examine	O
the	O
effect	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
on	O
T	B-cell_type
cell	I-cell_type
activation	O
in	O
the	O
absence	O
of	O
other	O
complicating	O
interactions	O
,	O
we	O
utilized	O
a	O
panel	O
of	O
cloned	O
Ia-restricted	B-cell_line
T	I-cell_line
cell	I-cell_line
hybridomas	I-cell_line
that	O
secrete	O
IL	B-protein
2	I-protein
on	O
activation	O
by	O
cloned	O
Ia-bearing	B-cell_type
stimulator	I-cell_type
cells	I-cell_type
(	O
TA3	B-cell_type
)	O
or	O
when	O
stimulated	O
by	O
mitogen	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
C	B-X
-	B-X
176	B-X
could	B-X
inhibit	B-X
STING	B-X
activation	B-X
in	B-X
osteoclast	B-X
precursor	B-X
cells	B-X
and	B-X
inhibit	B-X
osteoclast	B-X
activation	B-X
induced	B-X
by	B-X
nuclear	B-X
factor	B-X
κB	B-X
ligand	B-X
receptor	B-X
activator	B-X
in	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
7	B-X
as	B-X
a	B-X
model	B-X
in	B-X
experiments	B-X
aimed	B-X
at	B-X
investigating	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
effects	B-X
of	B-X
acenocoumarol	B-X
in	B-X
inhibiting	B-X
the	B-X
production	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
mediators	B-X
and	B-X
cytokines	B-X
<EOS>	B-X
Rutaecarpine	B-X
protected	B-X
against	B-X
HG	B-X
-	B-X
induced	B-X
cardiomyocyte	B-X
damage	B-X
by	B-X
enhancing	B-X
cell	B-X
viability	B-X
and	B-X
reducing	B-X
cell	B-X
spoptosis	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
activity	B-X
,	B-X
and	B-X
lactate	B-X
dehydrogenase	B-X
(	B-X
LDH	B-X
)	B-X
release	B-X
<EOS>	B-X
An	B-X
in	B-X
vitro	B-X
system	B-X
was	B-X
developed	B-X
to	B-X
detect	B-X
MBP	B-X
toxicity	B-X
to	B-X
the	B-X
Michigan	B-X
Cancer	B-X
Foundation	B-X
-	B-X
7	B-X
(	B-X
MCF	B-X
-	B-X
7	B-X
)	B-X
cells	B-X
that	B-X
had	B-X
been	B-X
repeatedly	B-X
exposed	B-X
to	B-X
a	B-X
low	B-X
dose	B-X
of	B-X
the	B-X
metabolite	B-X

Physiologic	O
concentrations	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
0.01	O
to	O
0.1	O
nm	O
)	O
inhibited	O
the	O
antigen-induced	O
secretion	O
of	O
IL	O
2	O
by	O
several	O
of	O
these	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
.	O
<EOS>	B-X
1	B-X
nm	B-X
)	B-X
inhibited	B-X
the	B-X
antigen	B-X
-	B-X
induced	B-X
secretion	B-X
of	B-X
IL	B-X
2	B-X
by	B-X
several	B-X
of	B-X
these	B-X
T	B-X
cell	B-X
hybridomas	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
may	B-X
be	B-X
interfering	B-X
with	B-X
early	B-X
events	B-X
of	B-X
antigen	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
perhaps	B-X
by	B-X
hindering	B-X
T	B-X
cell	B-X
recognition	B-X
of	B-X
the	B-X
relevant	B-X
antigen	B-X
on	B-X
stimulator	B-X
cell	B-X
surfaces	B-X
<EOS>	B-X
Physiologic	B-X
concentrations	B-X
of	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
(	B-X
0	B-X
<EOS>	B-X
1,25	B-X
-	B-X
Dihydroxyvitamin	B-X
D3	B-X
inhibits	B-X
antigen	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

This	O
inhibition	O
was	O
dependent	O
on	O
the	O
concentration	O
of	O
the	O
free	O
hormone	O
and	O
could	O
be	O
overcome	O
by	O
increasing	O
the	O
number	O
of	O
Ia-bearing	B-cell_line
stimulator	I-cell_line
cells	I-cell_line
used	O
.	O
<EOS>	B-X
This	B-X
inhibition	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
concentration	B-X
of	B-X
the	B-X
free	B-X
hormone	B-X
and	B-X
could	B-X
be	B-X
overcome	B-X
by	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
Ia	B-X
-	B-X
bearing	B-X
stimulator	B-X
cells	B-X
used	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
may	B-X
be	B-X
interfering	B-X
with	B-X
early	B-X
events	B-X
of	B-X
antigen	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
perhaps	B-X
by	B-X
hindering	B-X
T	B-X
cell	B-X
recognition	B-X
of	B-X
the	B-X
relevant	B-X
antigen	B-X
on	B-X
stimulator	B-X
cell	B-X
surfaces	B-X
<EOS>	B-X
To	B-X
directly	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
on	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
other	B-X
complicating	B-X
interactions	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
cloned	B-X
Ia	B-X
-	B-X
restricted	B-X
T	B-X
cell	B-X
hybridomas	B-X
that	B-X
secrete	B-X
IL	B-X
2	B-X
on	B-X
activation	B-X
by	B-X
cloned	B-X
Ia	B-X
-	B-X
bearing	B-X
stimulator	B-X
cells	B-X
(	B-X
TA3	B-X
)	B-X
or	B-X
when	B-X
stimulated	B-X
by	B-X
mitogen	B-X
<EOS>	B-X
1	B-X
nm	B-X
)	B-X
inhibited	B-X
the	B-X
antigen	B-X
-	B-X
induced	B-X
secretion	B-X
of	B-X
IL	B-X
2	B-X
by	B-X
several	B-X
of	B-X
these	B-X
T	B-X
cell	B-X
hybridomas	B-X

Pretreatment	O
of	O
the	O
T	B-cell_line
hybridoma	I-cell_line
but	O
not	O
the	O
TA3	B-cell_line
stimulator	I-cell_line
cell	I-cell_line
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
resulted	O
in	O
inhibition	O
of	O
activation	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
finding	O
that	O
specific	O
1	B-protein
,	I-protein
25-	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
are	O
present	O
on	O
the	O
T	O
cell	O
hybridomas	O
but	O
are	O
lacking	O
in	O
TA3	B-cell_line
cells	I-cell_line
.	O

1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
failed	O
,	O
however	O
,	O
to	O
inhibit	O
the	O
activation	O
of	O
the	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
by	O
lectin	B-protein
or	O
by	O
an	O
anti-Thy-1	B-protein
antibody	I-protein
.	O
<EOS>	B-X
Effect	B-X
of	B-X
Huaier	B-X
On	B-X
the	B-X
Proliferation	B-X
of	B-X
Mesangial	B-X
Cells	B-X
in	B-X
Anti	B-X
-	B-X
Thy	B-X
-	B-X
1	B-X
Nephritis	B-X
.	B-X
<EOS>	B-X
The	B-X
current	B-X
data	B-X
suggest	B-X
that	B-X
DBP	B-X
effectively	B-X
inhibits	B-X
the	B-X
proliferation	B-X
of	B-X
MCs	B-X
through	B-X
G1	B-X
phase	B-X
arrest	B-X
,	B-X
and	B-X
the	B-X
decrease	B-X
of	B-X
DBP	B-X
may	B-X
induce	B-X
mesangial	B-X
over	B-X
proliferation	B-X
in	B-X
rats	B-X
with	B-X
anti	B-X
-	B-X
Thy1N	B-X
<EOS>	B-X
We	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
proliferation	B-X
in	B-X
anti	B-X
-	B-X
Thy	B-X
-	B-X
1	B-X
nephritis	B-X
<EOS>	B-X
We	B-X
screened	B-X
for	B-X
genes	B-X
with	B-X
expression	B-X
levels	B-X
similar	B-X
to	B-X
CCL2	B-X
and	B-X
found	B-X
that	B-X
the	B-X
upregulation	B-X
of	B-X
the	B-X
circadian	B-X
gene	B-X
albumin	B-X
D	B-X
-	B-X
site	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
DBP	B-X
)	B-X
was	B-X
involved	B-X
in	B-X
CCL2	B-X
activation	B-X
in	B-X
mesangial	B-X
cells	B-X

These	O
findings	O
suggest	O
that	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
may	O
be	O
interfering	O
with	O
early	O
events	O
of	O
antigen-induced	O
T	B-cell_type
cell	I-cell_type
activation	O
,	O
perhaps	O
by	O
hindering	O
T	B-cell_type
cell	I-cell_type
recognition	O
of	O
the	O
relevant	O
antigen	O
on	O
stimulator	O
cell	O
surfaces	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
may	B-X
be	B-X
interfering	B-X
with	B-X
early	B-X
events	B-X
of	B-X
antigen	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
perhaps	B-X
by	B-X
hindering	B-X
T	B-X
cell	B-X
recognition	B-X
of	B-X
the	B-X
relevant	B-X
antigen	B-X
on	B-X
stimulator	B-X
cell	B-X
surfaces	B-X
<EOS>	B-X
This	B-X
inhibition	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
concentration	B-X
of	B-X
the	B-X
free	B-X
hormone	B-X
and	B-X
could	B-X
be	B-X
overcome	B-X
by	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
Ia	B-X
-	B-X
bearing	B-X
stimulator	B-X
cells	B-X
used	B-X
<EOS>	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
failed	B-X
,	B-X
however	B-X
,	B-X
to	B-X
inhibit	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
hybridomas	B-X
by	B-X
lectin	B-X
or	B-X
by	B-X
an	B-X
anti	B-X
-	B-X
Thy	B-X
-	B-X
1	B-X
antibody	B-X
<EOS>	B-X
To	B-X
directly	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
on	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
other	B-X
complicating	B-X
interactions	B-X
,	B-X
we	B-X
utilized	B-X
a	B-X
panel	B-X
of	B-X
cloned	B-X
Ia	B-X
-	B-X
restricted	B-X
T	B-X
cell	B-X
hybridomas	B-X
that	B-X
secrete	B-X
IL	B-X
2	B-X
on	B-X
activation	B-X
by	B-X
cloned	B-X
Ia	B-X
-	B-X
bearing	B-X
stimulator	B-X
cells	B-X
(	B-X
TA3	B-X
)	B-X
or	B-X
when	B-X
stimulated	B-X
by	B-X
mitogen	B-X

This	O
system	O
should	O
prove	O
useful	O
in	O
studying	O
the	O
molecular	O
mechanisms	O
by	O
which	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
acts	O
to	O
inhibit	O
T	O
cell	O
activation	O
and	O
subsequent	O
IL	B-protein
2	I-protein
production	O
.	O
<EOS>	B-X
This	B-X
system	B-X
should	B-X
prove	B-X
useful	B-X
in	B-X
studying	B-X
the	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
acts	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
subsequent	B-X
IL	B-X
2	B-X
production	B-X
<EOS>	B-X
Pretreatment	B-X
of	B-X
the	B-X
T	B-X
hybridoma	B-X
but	B-X
not	B-X
the	B-X
TA3	B-X
stimulator	B-X
cell	B-X
with	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
activation	B-X
<EOS>	B-X
These	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
finding	B-X
that	B-X
specific	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
receptors	B-X
are	B-X
present	B-X
on	B-X
the	B-X
T	B-X
cell	B-X
hybridomas	B-X
but	B-X
are	B-X
lacking	B-X
in	B-X
TA3	B-X
cells	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
1,25	B-X
-	B-X
	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
may	B-X
be	B-X
interfering	B-X
with	B-X
early	B-X
events	B-X
of	B-X
antigen	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
perhaps	B-X
by	B-X
hindering	B-X
T	B-X
cell	B-X
recognition	B-X
of	B-X
the	B-X
relevant	B-X
antigen	B-X
on	B-X
stimulator	B-X
cell	B-X
surfaces	B-X

Glucocorticoid	B-protein
receptors	I-protein
and	O
steroid	O
sensitivity	O
in	O
normal	O
and	O
neoplastic	O
human	O
lymphoid	O
tissues	O
:	O
a	O
review	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
steroid	B-X
sensitivity	B-X
in	B-X
normal	B-X
and	B-X
neoplastic	B-X
human	B-X
lymphoid	B-X
tissues	B-X
:	B-X
a	B-X
review	B-X
.	B-X
<EOS>	B-X
No	B-X
clear	B-X
correlation	B-X
could	B-X
be	B-X
established	B-X
between	B-X
the	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
the	B-X
in	B-X
vitro	B-X
action	B-X
of	B-X
steroids	B-X
in	B-X
normal	B-X
and	B-X
neoplastic	B-X
lymphoid	B-X
tissue	B-X
<EOS>	B-X
The	B-X
determination	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
receptors	B-X
in	B-X
breast	B-X
cancer	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
useful	B-X
in	B-X
predicting	B-X
the	B-X
response	B-X
to	B-X
endocrine	B-X
therapy	B-X
<EOS>	B-X
Given	B-X
these	B-X
facts	B-X
,	B-X
over	B-X
the	B-X
last	B-X
10	B-X
years	B-X
,	B-X
several	B-X
investigators	B-X
have	B-X
measured	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
normal	B-X
and	B-X
neoplastic	B-X
lymphoid	B-X
tissue	B-X
to	B-X
see	B-X
whether	B-X
their	B-X
number	B-X
correlated	B-X
with	B-X
glucocorticoid	B-X
responsiveness	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X

The	O
determination	O
of	O
estrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
in	O
breast	O
cancer	O
has	O
been	O
shown	O
to	O
be	O
useful	O
in	O
predicting	O
the	O
response	O
to	O
endocrine	O
therapy	O
.	O
<EOS>	B-X
Estrogen	B-X
receptor	B-X
alpha	B-X
(	B-X
ER	B-X
alpha	B-X
)	B-X
mediates	B-X
the	B-X
growth	B-X
stimulation	B-X
of	B-X
estrogen	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
and	B-X
is	B-X
a	B-X
useful	B-X
predictive	B-X
factor	B-X
for	B-X
response	B-X
to	B-X
endocrine	B-X
therapy	B-X
<EOS>	B-X
Accurate	B-X
assessment	B-X
of	B-X
estrogen	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
progesterone	B-X
(	B-X
PR	B-X
)	B-X
receptors	B-X
is	B-X
critical	B-X
in	B-X
predicting	B-X
the	B-X
response	B-X
to	B-X
endocrine	B-X
therapies	B-X
in	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
Breast	B-X
cancer	B-X
is	B-X
a	B-X
hormone	B-X
-	B-X
dependent	B-X
cancer	B-X
,	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
progesterone	B-X
receptor	B-X
(	B-X
PgR	B-X
)	B-X
in	B-X
tumors	B-X
is	B-X
used	B-X
clinically	B-X
to	B-X
predict	B-X
the	B-X
likelihood	B-X
of	B-X
response	B-X
to	B-X
hormonal	B-X
therapies	B-X
<EOS>	B-X
Progesterone	B-X
receptor	B-X
is	B-X
a	B-X
surrogate	B-X
marker	B-X
of	B-X
estrogen	B-X
receptor	B-X
activity	B-X
in	B-X
breast	B-X
cancer	B-X
and	B-X
its	B-X
utility	B-X
in	B-X
helping	B-X
predict	B-X
clinical	B-X
outcome	B-X
has	B-X
been	B-X
established	B-X
using	B-X
biochemical	B-X
assays	B-X

Given	O
their	O
well-known	O
inhibitory	O
effects	O
on	O
lymphoid	O
tissue	O
,	O
glucocorticoids	O
have	O
been	O
used	O
widely	O
in	O
the	O
treatment	O
of	O
leukemia	O
.	O
<EOS>	B-X
Given	B-X
their	B-X
well	B-X
-	B-X
known	B-X
inhibitory	B-X
effects	B-X
on	B-X
lymphoid	B-X
tissue	B-X
,	B-X
glucocorticoids	B-X
have	B-X
been	B-X
used	B-X
widely	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
leukemia	B-X
<EOS>	B-X
Given	B-X
these	B-X
facts	B-X
,	B-X
over	B-X
the	B-X
last	B-X
10	B-X
years	B-X
,	B-X
several	B-X
investigators	B-X
have	B-X
measured	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
normal	B-X
and	B-X
neoplastic	B-X
lymphoid	B-X
tissue	B-X
to	B-X
see	B-X
whether	B-X
their	B-X
number	B-X
correlated	B-X
with	B-X
glucocorticoid	B-X
responsiveness	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
<EOS>	B-X
No	B-X
clear	B-X
correlation	B-X
could	B-X
be	B-X
established	B-X
between	B-X
the	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
the	B-X
in	B-X
vitro	B-X
action	B-X
of	B-X
steroids	B-X
in	B-X
normal	B-X
and	B-X
neoplastic	B-X
lymphoid	B-X
tissue	B-X
<EOS>	B-X
The	B-X
determination	B-X
of	B-X
estrogen	B-X
and	B-X
progesterone	B-X
receptors	B-X
in	B-X
breast	B-X
cancer	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
useful	B-X
in	B-X
predicting	B-X
the	B-X
response	B-X
to	B-X
endocrine	B-X
therapy	B-X

Given	O
these	O
facts	O
,	O
over	O
the	O
last	O
10	O
years	O
,	O
several	O
investigators	O
have	O
measured	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
normal	O
and	O
neoplastic	O
lymphoid	O
tissue	O
to	O
see	O
whether	O
their	O
number	O
correlated	O
with	O
glucocorticoid	O
responsiveness	O
in	O
vitro	O
or	O
in	O
vivo	O
.	O
<EOS>	B-X
EGR1	B-X
was	B-X
highly	B-X
expressed	B-X
in	B-X
pancreatic	B-X
cancer	B-X
rather	B-X
than	B-X
normal	B-X
pancreatic	B-X
tissues	B-X
and	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
and	B-X
cancer	B-X
metastasis	B-X
<EOS>	B-X
Background	B-X
:	B-X
Recent	B-X
research	B-X
in	B-X
our	B-X
laboratory	B-X
shows	B-X
that	B-X
CD4+	B-X
T	B-X
cells	B-X
express	B-X
the	B-X
β2	B-X
adrenergic	B-X
receptor	B-X
(	B-X
β2	B-X
-	B-X
AR	B-X
)	B-X
,	B-X
and	B-X
the	B-X
sympathetic	B-X
neurotransmitter	B-X
norepinephrine	B-X
regulates	B-X
the	B-X
function	B-X
of	B-X
T	B-X
cells	B-X
via	B-X
β2	B-X
-	B-X
AR	B-X
signaling	B-X
<EOS>	B-X
Non	B-X
-	B-X
alcoholic	B-X
fatty	B-X
liver	B-X
(	B-X
NAFLD	B-X
)	B-X
and	B-X
its	B-X
related	B-X
metabolic	B-X
syndrome	B-X
have	B-X
become	B-X
major	B-X
threats	B-X
to	B-X
human	B-X
health	B-X
,	B-X
but	B-X
there	B-X
is	B-X
still	B-X
a	B-X
need	B-X
for	B-X
effective	B-X
and	B-X
safe	B-X
drugs	B-X
to	B-X
treat	B-X
these	B-X
conditions	B-X
<EOS>	B-X
We	B-X
systematically	B-X
examined	B-X
the	B-X
therapeutic	B-X
effect	B-X
of	B-X
honokiol	B-X
in	B-X
NAFLD	B-X
and	B-X
metabolic	B-X
syndrome	B-X
in	B-X
multiple	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
models	B-X

No	O
clear	O
correlation	O
could	O
be	O
established	O
between	O
the	O
level	O
of	O
glucocorticoid	B-protein
receptor	I-protein
and	O
the	O
in	O
vitro	O
action	O
of	O
steroids	O
in	O
normal	O
and	O
neoplastic	O
lymphoid	O
tissue	O
.	O
<EOS>	B-X
No	B-X
clear	B-X
correlation	B-X
could	B-X
be	B-X
established	B-X
between	B-X
the	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
the	B-X
in	B-X
vitro	B-X
action	B-X
of	B-X
steroids	B-X
in	B-X
normal	B-X
and	B-X
neoplastic	B-X
lymphoid	B-X
tissue	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
steroid	B-X
sensitivity	B-X
in	B-X
normal	B-X
and	B-X
neoplastic	B-X
human	B-X
lymphoid	B-X
tissues	B-X
:	B-X
a	B-X
review	B-X
.	B-X
<EOS>	B-X
Given	B-X
these	B-X
facts	B-X
,	B-X
over	B-X
the	B-X
last	B-X
10	B-X
years	B-X
,	B-X
several	B-X
investigators	B-X
have	B-X
measured	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
normal	B-X
and	B-X
neoplastic	B-X
lymphoid	B-X
tissue	B-X
to	B-X
see	B-X
whether	B-X
their	B-X
number	B-X
correlated	B-X
with	B-X
glucocorticoid	B-X
responsiveness	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
attempts	B-X
to	B-X
correlate	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
in	B-X
acute	B-X
lymphocytic	B-X
leukemia	B-X
to	B-X
in	B-X
vivo	B-X
steroid	B-X
responsiveness	B-X
and	B-X
immunological	B-X
type	B-X
using	B-X
the	B-X
whole	B-X
-	B-X
cell	B-X
-	B-X
binding	B-X
assay	B-X
for	B-X
receptor	B-X
determination	B-X
and	B-X
selecting	B-X
the	B-X
patients	B-X
according	B-X
to	B-X
age	B-X
and	B-X
immunological	B-X
criteria	B-X
have	B-X
been	B-X
more	B-X
successful	B-X

In	O
contrast	O
,	O
attempts	O
to	O
correlate	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
acute	O
lymphocytic	O
leukemia	O
to	O
in	O
vivo	O
steroid	O
responsiveness	O
and	O
immunological	O
type	O
using	O
the	O
whole-cell-binding	O
assay	O
for	O
receptor	O
determination	O
and	O
selecting	O
the	O
patients	O
according	O
to	O
age	O
and	O
immunological	O
criteria	O
have	O
been	O
more	O
successful	O
.	O

[	O
Glucocorticoid	B-protein
receptors	I-protein
in	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
]	O
<EOS>	B-X
Ibrutinib	B-X
reprograms	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
cells	B-X
.	B-X
<EOS>	B-X
Murine	B-X
Glucocorticoid	B-X
Receptors	B-X
Orchestrate	B-X
B	B-X
Cell	B-X
Migration	B-X
Selectively	B-X
between	B-X
Bone	B-X
Marrow	B-X
and	B-X
Blood	B-X
.	B-X
<EOS>	B-X
This	B-X
continued	B-X
for	B-X
a	B-X
total	B-X
of	B-X
3	B-X
months	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
administration	B-X
was	B-X
reduced	B-X
sequentially	B-X
,	B-X
followed	B-X
by	B-X
successful	B-X
termination	B-X

Glucocorticoid	B-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
receptors	I-cell_type
were	O
studied	O
in	O
intact	O
lymphocytes	B-cell_type
from	O
11	O
donors	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
(	B-X
GC	B-X
)	B-X
receptors	B-X
were	B-X
studied	B-X
in	B-X
intact	B-X
lymphocytes	B-X
from	B-X
11	B-X
donors	B-X
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
]	B-X
.	B-X
<EOS>	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
GC	B-X
receptors	B-X
in	B-X
donors	B-X
'	B-X
lymphocytes	B-X
could	B-X
be	B-X
distributed	B-X
into	B-X
two	B-X
different	B-X
classes	B-X
similarly	B-X
to	B-X
the	B-X
pattern	B-X
seen	B-X
in	B-X
skin	B-X
fibroblasts	B-X
<EOS>	B-X
Human	B-X
lymphocytes	B-X
are	B-X
an	B-X
adequate	B-X
object	B-X
for	B-X
studying	B-X
genetically	B-X
determined	B-X
variability	B-X
of	B-X
GC	B-X
receptors	B-X
and	B-X
its	B-X
clinical	B-X
importance	B-X

GC	O
binding	O
parameters	O
were	O
found	O
to	O
be	O
highly	O
reproducible	O
in	O
repeated	O
experiments	O
with	O
lymphocytes	B-cell_type
.	O
<EOS>	B-X
GC	B-X
binding	B-X
parameters	B-X
were	B-X
found	B-X
to	B-X
be	B-X
highly	B-X
reproducible	B-X
in	B-X
repeated	B-X
experiments	B-X
with	B-X
lymphocytes	B-X
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
]	B-X
.	B-X
<EOS>	B-X
Human	B-X
lymphocytes	B-X
are	B-X
an	B-X
adequate	B-X
object	B-X
for	B-X
studying	B-X
genetically	B-X
determined	B-X
variability	B-X
of	B-X
GC	B-X
receptors	B-X
and	B-X
its	B-X
clinical	B-X
importance	B-X
<EOS>	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
GC	B-X
receptors	B-X
in	B-X
donors	B-X
'	B-X
lymphocytes	B-X
could	B-X
be	B-X
distributed	B-X
into	B-X
two	B-X
different	B-X
classes	B-X
similarly	B-X
to	B-X
the	B-X
pattern	B-X
seen	B-X
in	B-X
skin	B-X
fibroblasts	B-X

It	O
was	O
shown	O
that	O
GC	B-protein
receptors	I-protein
in	O
donors	O
'	O
lymphocytes	B-cell_type
could	O
be	O
distributed	O
into	O
two	O
different	O
classes	O
similarly	O
to	O
the	O
pattern	O
seen	O
in	O
skin	B-cell_type
fibroblasts	I-cell_type
.	O

Human	B-cell_type
lymphocytes	I-cell_type
are	O
an	O
adequate	O
object	O
for	O
studying	O
genetically	O
determined	O
variability	O
of	O
GC	B-protein
receptors	I-protein
and	O
its	O
clinical	O
importance	O
.	O
<EOS>	B-X
Human	B-X
lymphocytes	B-X
are	B-X
an	B-X
adequate	B-X
object	B-X
for	B-X
studying	B-X
genetically	B-X
determined	B-X
variability	B-X
of	B-X
GC	B-X
receptors	B-X
and	B-X
its	B-X
clinical	B-X
importance	B-X
<EOS>	B-X
GC	B-X
binding	B-X
parameters	B-X
were	B-X
found	B-X
to	B-X
be	B-X
highly	B-X
reproducible	B-X
in	B-X
repeated	B-X
experiments	B-X
with	B-X
lymphocytes	B-X
<EOS>	B-X
Glucocorticoid	B-X
(	B-X
GC	B-X
)	B-X
receptors	B-X
were	B-X
studied	B-X
in	B-X
intact	B-X
lymphocytes	B-X
from	B-X
11	B-X
donors	B-X
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
]	B-X
.	B-X

Specific	O
estrogen	B-protein
binding	I-protein
sites	I-protein
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
thymic	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Specific	B-X
estrogen	B-X
binding	B-X
sites	B-X
in	B-X
human	B-X
lymphoid	B-X
cells	B-X
and	B-X
thymic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Scatchard	B-X
's	B-X
analysis	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
moxestrol	B-X
(	B-X
R2858	B-X
)	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
estradiol	B-X
binding	B-X
proves	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
single	B-X
class	B-X
of	B-X
receptor	B-X
sites	B-X
having	B-X
a	B-X
dissociation	B-X
constant	B-X
of	B-X
0	B-X
<EOS>	B-X
Physicochemical	B-X
properties	B-X
of	B-X
the	B-X
binder	B-X
,	B-X
including	B-X
binding	B-X
capacity	B-X
and	B-X
steroid	B-X
specificity	B-X
,	B-X
are	B-X
quite	B-X
similar	B-X
to	B-X
those	B-X
reported	B-X
for	B-X
the	B-X
thymus	B-X
of	B-X
small	B-X
mammalian	B-X
species	B-X
or	B-X
human	B-X
thymoma	B-X
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
estrogen	B-X
in	B-X
preparations	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
splenic	B-X
and	B-X
thymic	B-X
cells	B-X
is	B-X
demonstrated	B-X
by	B-X
three	B-X
different	B-X
approaches	B-X
(	B-X
Dextran	B-X
-	B-X
coated	B-X
charcoal	B-X
method	B-X
,	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
and	B-X
gel	B-X
filtration	B-X
on	B-X
a	B-X
sepharose	B-X
4B	B-X
column	B-X
)	B-X

The	O
binding	O
of	O
estrogen	O
in	O
preparations	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	I-cell_type
as	O
well	O
as	O
by	O
splenic	B-cell_type
and	I-cell_type
thymic	I-cell_type
cells	I-cell_type
is	O
demonstrated	O
by	O
three	O
different	O
approaches	O
(	O
Dextran-coated	O
charcoal	O
method	O
,	O
whole	O
cell	O
assay	O
,	O
and	O
gel	O
filtration	O
on	O
a	O
sepharose	O
4B	O
column	O
)	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
estrogen	B-X
in	B-X
preparations	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
splenic	B-X
and	B-X
thymic	B-X
cells	B-X
is	B-X
demonstrated	B-X
by	B-X
three	B-X
different	B-X
approaches	B-X
(	B-X
Dextran	B-X
-	B-X
coated	B-X
charcoal	B-X
method	B-X
,	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
and	B-X
gel	B-X
filtration	B-X
on	B-X
a	B-X
sepharose	B-X
4B	B-X
column	B-X
)	B-X
<EOS>	B-X
Physicochemical	B-X
properties	B-X
of	B-X
the	B-X
binder	B-X
,	B-X
including	B-X
binding	B-X
capacity	B-X
and	B-X
steroid	B-X
specificity	B-X
,	B-X
are	B-X
quite	B-X
similar	B-X
to	B-X
those	B-X
reported	B-X
for	B-X
the	B-X
thymus	B-X
of	B-X
small	B-X
mammalian	B-X
species	B-X
or	B-X
human	B-X
thymoma	B-X
<EOS>	B-X
Scatchard	B-X
's	B-X
analysis	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
moxestrol	B-X
(	B-X
R2858	B-X
)	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
estradiol	B-X
binding	B-X
proves	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
single	B-X
class	B-X
of	B-X
receptor	B-X
sites	B-X
having	B-X
a	B-X
dissociation	B-X
constant	B-X
of	B-X
0	B-X
<EOS>	B-X
Specific	B-X
estrogen	B-X
binding	B-X
sites	B-X
in	B-X
human	B-X
lymphoid	B-X
cells	B-X
and	B-X
thymic	B-X
cells	B-X
.	B-X

Scatchard	O
's	O
analysis	O
of	O
[	O
3H	O
]	O
-moxestrol	O
(	O
R2858	O
)	O
and	O
[	O
3H	O
]	O
-estradiol	O
binding	O
proves	O
the	O
existence	O
of	O
a	O
single	O
class	O
of	O
receptor	B-protein
sites	I-protein
having	O
a	O
dissociation	O
constant	O
of	O
0.18-2.4	O
X	O
10	O
(	O
-9	O
)	O
M	O
.	O
<EOS>	B-X
Scatchard	B-X
's	B-X
analysis	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
moxestrol	B-X
(	B-X
R2858	B-X
)	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
estradiol	B-X
binding	B-X
proves	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
single	B-X
class	B-X
of	B-X
receptor	B-X
sites	B-X
having	B-X
a	B-X
dissociation	B-X
constant	B-X
of	B-X
0	B-X
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
estrogen	B-X
in	B-X
preparations	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
splenic	B-X
and	B-X
thymic	B-X
cells	B-X
is	B-X
demonstrated	B-X
by	B-X
three	B-X
different	B-X
approaches	B-X
(	B-X
Dextran	B-X
-	B-X
coated	B-X
charcoal	B-X
method	B-X
,	B-X
whole	B-X
cell	B-X
assay	B-X
,	B-X
and	B-X
gel	B-X
filtration	B-X
on	B-X
a	B-X
sepharose	B-X
4B	B-X
column	B-X
)	B-X
<EOS>	B-X
Specific	B-X
estrogen	B-X
binding	B-X
sites	B-X
in	B-X
human	B-X
lymphoid	B-X
cells	B-X
and	B-X
thymic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Physicochemical	B-X
properties	B-X
of	B-X
the	B-X
binder	B-X
,	B-X
including	B-X
binding	B-X
capacity	B-X
and	B-X
steroid	B-X
specificity	B-X
,	B-X
are	B-X
quite	B-X
similar	B-X
to	B-X
those	B-X
reported	B-X
for	B-X
the	B-X
thymus	B-X
of	B-X
small	B-X
mammalian	B-X
species	B-X
or	B-X
human	B-X
thymoma	B-X

Physicochemical	O
properties	O
of	O
the	O
binder	O
,	O
including	O
binding	O
capacity	O
and	O
steroid	O
specificity	O
,	O
are	O
quite	O
similar	O
to	O
those	O
reported	O
for	O
the	O
thymus	O
of	O
small	O
mammalian	O
species	O
or	O
human	O
thymoma	O
.	O
<EOS>	B-X
Percentages	B-X
of	B-X
poor	B-X
outcome	B-X
and	B-X
patient	B-X
death	B-X
in	B-X
thymic	B-X
carcinomas	B-X
were	B-X
much	B-X
higher	B-X
than	B-X
those	B-X
in	B-X
patients	B-X
with	B-X
high	B-X
-	B-X
risk	B-X
and	B-X
low	B-X
-	B-X
risk	B-X
thymomas	B-X
<EOS>	B-X
The	B-X
clinicopathological	B-X
significance	B-X
of	B-X
thymic	B-X
epithelial	B-X
markers	B-X
expression	B-X
in	B-X
thymoma	B-X
and	B-X
thymic	B-X
carcinoma	B-X
.	B-X
<EOS>	B-X
She	B-X
initially	B-X
presented	B-X
with	B-X
a	B-X
memory	B-X
deficit	B-X
,	B-X
abnormal	B-X
movement	B-X
of	B-X
the	B-X
limbs	B-X
and	B-X
trunk	B-X
,	B-X
and	B-X
ataxia	B-X
<EOS>	B-X
In	B-X
this	B-X
cohort	B-X
,	B-X
CT	B-X
features	B-X
of	B-X
vessel	B-X
invasion	B-X
and	B-X
pericardial	B-X
mass	B-X
were	B-X
related	B-X
to	B-X
poorer	B-X
outcomes	B-X
in	B-X
those	B-X
with	B-X
thymic	B-X
carcinoma	B-X
and	B-X
pericardial	B-X
mass	B-X
in	B-X
those	B-X
with	B-X
high	B-X
-	B-X
risk	B-X
thymoma	B-X

Administration	O
of	O
fibroblast	B-protein
interferon	I-protein
to	O
patients	O
with	O
advanced	O
breast	O
cancer	O
:	O
possible	O
effects	O
on	O
skin	O
metastasis	O
and	O
on	O
hormone	B-protein
receptors	I-protein
.	O
<EOS>	B-X
Administration	B-X
of	B-X
fibroblast	B-X
interferon	B-X
to	B-X
patients	B-X
with	B-X
advanced	B-X
breast	B-X
cancer	B-X
:	B-X
possible	B-X
effects	B-X
on	B-X
skin	B-X
metastasis	B-X
and	B-X
on	B-X
hormone	B-X
receptors	B-X
.	B-X
<EOS>	B-X
Although	B-X
several	B-X
types	B-X
of	B-X
metastases	B-X
were	B-X
monitored	B-X
,	B-X
only	B-X
skin	B-X
nodules	B-X
consistently	B-X
(	B-X
10	B-X
out	B-X
of	B-X
11	B-X
patients	B-X
)	B-X
exhibited	B-X
changes	B-X
that	B-X
were	B-X
suggestive	B-X
of	B-X
a	B-X
therapeutic	B-X
effect	B-X
of	B-X
the	B-X
treatment	B-X
regimen	B-X
:	B-X
either	B-X
a	B-X
simple	B-X
decrease	B-X
in	B-X
size	B-X
of	B-X
some	B-X
nodules	B-X
or	B-X
central	B-X
necrosis	B-X
accompanied	B-X
by	B-X
an	B-X
inflammatory	B-X
reaction	B-X
<EOS>	B-X
Receptors	B-X
for	B-X
estrogens	B-X
and	B-X
progestogens	B-X
were	B-X
increased	B-X
in	B-X
the	B-X
tumor	B-X
biopsies	B-X
of	B-X
2	B-X
out	B-X
of	B-X
2	B-X
and	B-X
5	B-X
out	B-X
of	B-X
6	B-X
patients	B-X
tested	B-X
respectively	B-X
<EOS>	B-X
NK	B-X
-	B-X
activity	B-X
of	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
was	B-X
significantly	B-X
increased	B-X
after	B-X
administration	B-X
of	B-X
the	B-X
first	B-X
dose	B-X
;	B-X
the	B-X
effect	B-X
of	B-X
subsequent	B-X
injections	B-X
was	B-X
less	B-X
clear	B-X

Eleven	O
patients	O
with	O
metastasized	O
breast	O
cancer	O
received	O
8	O
intramuscular	O
injections	O
of	O
6	O
x	O
10	O
(	O
6	O
)	O
units	O
of	O
human	B-protein
fibroblast	I-protein
interferon	I-protein
over	O
a	O
period	O
of	O
40	O
days	O
.	O

The	O
injections	O
did	O
not	O
cause	O
local	O
irritation	O
or	O
inflammation	O
.	O
<EOS>	B-X
5	B-X
%	B-X
)	B-X
injections	B-X
of	B-X
vitamin	B-X
D	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
clinical	B-X
trial	B-X
is	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
different	B-X
physical	B-X
stimulation	B-X
after	B-X
PRP	B-X
treatment	B-X
for	B-X
KOA	B-X
<EOS>	B-X
Traditional	B-X
Chinese	B-X
medicine	B-X
(	B-X
TCM	B-X
)	B-X
has	B-X
been	B-X
used	B-X
clinically	B-X
for	B-X
cardiovascular	B-X
disease	B-X
for	B-X
a	B-X
long	B-X
time	B-X
<EOS>	B-X
There	B-X
were	B-X
no	B-X
intraoperative	B-X
or	B-X
postoperative	B-X
complications	B-X

Fever	O
occurred	O
in	O
only	O
1	O
of	O
the	O
11	O
patients	O
.	O
<EOS>	B-X
One	B-X
thousand	B-X
one	B-X
hundred	B-X
thirteen	B-X
patients	B-X
(	B-X
73	B-X
<EOS>	B-X
One	B-X
thousand	B-X
four	B-X
hundred	B-X
fifty	B-X
-	B-X
eight	B-X
patients	B-X
(	B-X
96	B-X
<EOS>	B-X
5	B-X
%	B-X
of	B-X
the	B-X
patients	B-X
<EOS>	B-X
Appendicitis	B-X
pathology	B-X
was	B-X
present	B-X
in	B-X
1,381	B-X
patients	B-X
(	B-X
91	B-X

Although	O
several	O
types	O
of	O
metastases	O
were	O
monitored	O
,	O
only	O
skin	O
nodules	O
consistently	O
(	O
10	O
out	O
of	O
11	O
patients	O
)	O
exhibited	O
changes	O
that	O
were	O
suggestive	O
of	O
a	O
therapeutic	O
effect	O
of	O
the	O
treatment	O
regimen	O
:	O
either	O
a	O
simple	O
decrease	O
in	O
size	O
of	O
some	O
nodules	O
or	O
central	O
necrosis	O
accompanied	O
by	O
an	O
inflammatory	O
reaction	O
.	O
<EOS>	B-X
Systemic	B-X
treatment	B-X
with	B-X
PARIN5	B-X
prevented	B-X
the	B-X
appearance	B-X
of	B-X
behavioral	B-X
changes	B-X
,	B-X
normalized	B-X
serum	B-X
NfL	B-X
and	B-X
prevented	B-X
the	B-X
increase	B-X
in	B-X
peripheral	B-X
but	B-X
not	B-X
central	B-X
thrombin	B-X
activity	B-X
<EOS>	B-X
Notably	B-X
,	B-X
the	B-X
significant	B-X
gut	B-X
microbiota	B-X
dysbiosis	B-X
observed	B-X
in	B-X
TBM	B-X
patients	B-X
was	B-X
associated	B-X
with	B-X
markedly	B-X
high	B-X
proportions	B-X
of	B-X
Escherichia	B-X
-	B-X
Shigella	B-X
species	B-X
as	B-X
well	B-X
as	B-X
increased	B-X
blood	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
α	B-X
)	B-X
and	B-X
interleukin	B-X
6	B-X
(	B-X
IL	B-X
-	B-X
6	B-X
)	B-X
<EOS>	B-X
Current	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
nerve	B-X
cells	B-X
die	B-X
of	B-X
ischemia	B-X
several	B-X
hours	B-X
after	B-X
ischemic	B-X
stroke	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
promotes	B-X
the	B-X
production	B-X
of	B-X
neurotoxic	B-X
substances	B-X
such	B-X
as	B-X
inflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
and	B-X
	B-X
-	B-X
	B-X
nitrogen	B-X
oxide	B-X
,	B-X
and	B-X
mediates	B-X
the	B-X
destruction	B-X
of	B-X
blood	B-X
-	B-X
brain	B-X
barrier	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
a	B-X
series	B-X
of	B-X
inflammatory	B-X
cascade	B-X
reactions	B-X
<EOS>	B-X
While	B-X
neither	B-X
blood	B-X
glucose	B-X
nor	B-X
serum	B-X
insulin	B-X
level	B-X
was	B-X
significantly	B-X
altered	B-X
in	B-X
the	B-X
experimental	B-X
or	B-X
control	B-X
group	B-X
,	B-X
we	B-X
found	B-X
that	B-X
injection	B-X
of	B-X
S961	B-X
but	B-X
not	B-X
buffer	B-X
solution	B-X
significantly	B-X
increased	B-X
intraocular	B-X
pressure	B-X
at	B-X
14	B-X
and	B-X
24	B-X
days	B-X
after	B-X
first	B-X
injection	B-X
,	B-X
along	B-X
with	B-X
reduced	B-X
porosity	B-X
and	B-X
aquaporin	B-X
4	B-X
expression	B-X
in	B-X
the	B-X
trabecular	B-X
meshwork	B-X
,	B-X
and	B-X
increased	B-X
tumor	B-X
necrosis	B-X
factor	B-X
α	B-X
and	B-X
aquaporin	B-X
4	B-X
expression	B-X
in	B-X
the	B-X
ciliary	B-X
body	B-X

NK-activity	O
of	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
was	O
significantly	O
increased	O
after	O
administration	O
of	O
the	O
first	O
dose	O
;	O
the	O
effect	O
of	O
subsequent	O
injections	O
was	O
less	O
clear	O
.	O
<EOS>	B-X
NK	B-X
-	B-X
activity	B-X
of	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
was	B-X
significantly	B-X
increased	B-X
after	B-X
administration	B-X
of	B-X
the	B-X
first	B-X
dose	B-X
;	B-X
the	B-X
effect	B-X
of	B-X
subsequent	B-X
injections	B-X
was	B-X
less	B-X
clear	B-X
<EOS>	B-X
Receptors	B-X
for	B-X
estrogens	B-X
and	B-X
progestogens	B-X
were	B-X
increased	B-X
in	B-X
the	B-X
tumor	B-X
biopsies	B-X
of	B-X
2	B-X
out	B-X
of	B-X
2	B-X
and	B-X
5	B-X
out	B-X
of	B-X
6	B-X
patients	B-X
tested	B-X
respectively	B-X
<EOS>	B-X
Although	B-X
several	B-X
types	B-X
of	B-X
metastases	B-X
were	B-X
monitored	B-X
,	B-X
only	B-X
skin	B-X
nodules	B-X
consistently	B-X
(	B-X
10	B-X
out	B-X
of	B-X
11	B-X
patients	B-X
)	B-X
exhibited	B-X
changes	B-X
that	B-X
were	B-X
suggestive	B-X
of	B-X
a	B-X
therapeutic	B-X
effect	B-X
of	B-X
the	B-X
treatment	B-X
regimen	B-X
:	B-X
either	B-X
a	B-X
simple	B-X
decrease	B-X
in	B-X
size	B-X
of	B-X
some	B-X
nodules	B-X
or	B-X
central	B-X
necrosis	B-X
accompanied	B-X
by	B-X
an	B-X
inflammatory	B-X
reaction	B-X
<EOS>	B-X
Administration	B-X
of	B-X
fibroblast	B-X
interferon	B-X
to	B-X
patients	B-X
with	B-X
advanced	B-X
breast	B-X
cancer	B-X
:	B-X
possible	B-X
effects	B-X
on	B-X
skin	B-X
metastasis	B-X
and	B-X
on	B-X
hormone	B-X
receptors	B-X
.	B-X

Receptors	O
for	O
estrogens	O
and	O
progestogens	O
were	O
increased	O
in	O
the	O
tumor	O
biopsies	O
of	O
2	O
out	O
of	O
2	O
and	O
5	O
out	O
of	O
6	O
patients	O
tested	O
respectively	O
.	O
<EOS>	B-X
Receptors	B-X
for	B-X
estrogens	B-X
and	B-X
progestogens	B-X
were	B-X
increased	B-X
in	B-X
the	B-X
tumor	B-X
biopsies	B-X
of	B-X
2	B-X
out	B-X
of	B-X
2	B-X
and	B-X
5	B-X
out	B-X
of	B-X
6	B-X
patients	B-X
tested	B-X
respectively	B-X
<EOS>	B-X
NK	B-X
-	B-X
activity	B-X
of	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
was	B-X
significantly	B-X
increased	B-X
after	B-X
administration	B-X
of	B-X
the	B-X
first	B-X
dose	B-X
;	B-X
the	B-X
effect	B-X
of	B-X
subsequent	B-X
injections	B-X
was	B-X
less	B-X
clear	B-X
<EOS>	B-X
Eleven	B-X
patients	B-X
with	B-X
metastasized	B-X
breast	B-X
cancer	B-X
received	B-X
8	B-X
intramuscular	B-X
injections	B-X
of	B-X
6	B-X
x	B-X
10	B-X
(	B-X
6	B-X
)	B-X
units	B-X
of	B-X
human	B-X
fibroblast	B-X
interferon	B-X
over	B-X
a	B-X
period	B-X
of	B-X
40	B-X
days	B-X
<EOS>	B-X
Although	B-X
several	B-X
types	B-X
of	B-X
metastases	B-X
were	B-X
monitored	B-X
,	B-X
only	B-X
skin	B-X
nodules	B-X
consistently	B-X
(	B-X
10	B-X
out	B-X
of	B-X
11	B-X
patients	B-X
)	B-X
exhibited	B-X
changes	B-X
that	B-X
were	B-X
suggestive	B-X
of	B-X
a	B-X
therapeutic	B-X
effect	B-X
of	B-X
the	B-X
treatment	B-X
regimen	B-X
:	B-X
either	B-X
a	B-X
simple	B-X
decrease	B-X
in	B-X
size	B-X
of	B-X
some	B-X
nodules	B-X
or	B-X
central	B-X
necrosis	B-X
accompanied	B-X
by	B-X
an	B-X
inflammatory	B-X
reaction	B-X

Decreased	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
adrenal	O
insufficiency	O
.	O
<EOS>	B-X
Decreased	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
adrenal	B-X
insufficiency	B-X
.	B-X
<EOS>	B-X
Novel	B-X
hyperactive	B-X
glucocorticoid	B-X
receptor	B-X
isoform	B-X
identified	B-X
within	B-X
a	B-X
human	B-X
population	B-X
.	B-X
<EOS>	B-X
The	B-X
affinity	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
Kd	B-X
)	B-X
was	B-X
strikingly	B-X
decreased	B-X
(	B-X
9	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
glucocorticoid	B-X
treatment	B-X
in	B-X
6	B-X
patients	B-X
with	B-X
adrenal	B-X
insufficiency	B-X
resulted	B-X
in	B-X
the	B-X
increase	B-X
of	B-X
insulin	B-X
binding	B-X

To	O
examine	O
the	O
effect	O
of	O
glucocorticoid	O
deficiency	O
on	O
the	O
glucocorticoid	B-protein
receptor	I-protein
,	O
we	O
examine	O
the	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
to	O
lymphocytes	B-cell_type
in	O
normal	O
subjects	O
and	O
patients	O
with	O
adrenal	O
insufficiency	O
before	O
and	O
after	O
glucocorticoid	O
replacement	O
therapy	O
.	O
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
glucocorticoid	B-X
deficiency	B-X
on	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
to	B-X
lymphocytes	B-X
in	B-X
normal	B-X
subjects	B-X
and	B-X
patients	B-X
with	B-X
adrenal	B-X
insufficiency	B-X
before	B-X
and	B-X
after	B-X
glucocorticoid	B-X
replacement	B-X
therapy	B-X
<EOS>	B-X
The	B-X
physiological	B-X
implications	B-X
of	B-X
the	B-X
decreased	B-X
receptor	B-X
number	B-X
and	B-X
increased	B-X
binding	B-X
affinity	B-X
in	B-X
adrenal	B-X
insufficiency	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
<EOS>	B-X
After	B-X
long	B-X
term	B-X
glucocorticoid	B-X
replacement	B-X
therapy	B-X
,	B-X
binding	B-X
parameters	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
in	B-X
patients	B-X
before	B-X
treatment	B-X
<EOS>	B-X
The	B-X
administration	B-X
of	B-X
conventional	B-X
replacement	B-X
doses	B-X
of	B-X
cortisone	B-X
acetate	B-X
for	B-X
6	B-X
months	B-X
caused	B-X
no	B-X
change	B-X
in	B-X
receptor	B-X
number	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
binding	B-X
affinity	B-X
toward	B-X
normal	B-X

Using	O
a	O
whole	O
cell	O
competitive	O
binding	O
assay	O
,	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
had	O
5977	O
+/-	O
1487	O
(	O
mean	O
+/-	O
SD	O
)	O
binding	O
sites/cell	O
and	O
a	O
dissociation	O
constant	O
of	O
10	O
+/-	O
2	O
nM	O
.	O

Lymphocytes	B-cell_type
from	O
patients	O
with	O
untreated	O
adrenal	O
insufficiency	O
had	O
fewer	O
binding	B-protein
sites	I-protein
(	O
3364	O
+/-322	O
)	O
and	O
a	O
2-fold	O
increase	O
in	O
binding	O
affinity	O
(	O
5.4	O
+/-	O
0.9	O
mM	O
)	O
.	O

The	O
administration	O
of	O
conventional	O
replacement	O
doses	O
of	O
cortisone	O
acetate	O
for	O
6	O
months	O
caused	O
no	O
change	O
in	O
receptor	O
number	O
,	O
but	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
affinity	O
toward	O
normal	O
.	O
<EOS>	B-X
The	B-X
administration	B-X
of	B-X
conventional	B-X
replacement	B-X
doses	B-X
of	B-X
cortisone	B-X
acetate	B-X
for	B-X
6	B-X
months	B-X
caused	B-X
no	B-X
change	B-X
in	B-X
receptor	B-X
number	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
binding	B-X
affinity	B-X
toward	B-X
normal	B-X
<EOS>	B-X
The	B-X
physiological	B-X
implications	B-X
of	B-X
the	B-X
decreased	B-X
receptor	B-X
number	B-X
and	B-X
increased	B-X
binding	B-X
affinity	B-X
in	B-X
adrenal	B-X
insufficiency	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
<EOS>	B-X
Lymphocytes	B-X
from	B-X
patients	B-X
with	B-X
untreated	B-X
adrenal	B-X
insufficiency	B-X
had	B-X
fewer	B-X
binding	B-X
sites	B-X
(	B-X
3364	B-X
+	B-X
/	B-X
	B-X
-	B-X
322	B-X
)	B-X
and	B-X
a	B-X
2	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
binding	B-X
affinity	B-X
(	B-X
5	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
glucocorticoid	B-X
deficiency	B-X
on	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
to	B-X
lymphocytes	B-X
in	B-X
normal	B-X
subjects	B-X
and	B-X
patients	B-X
with	B-X
adrenal	B-X
insufficiency	B-X
before	B-X
and	B-X
after	B-X
glucocorticoid	B-X
replacement	B-X
therapy	B-X

After	O
long	O
term	O
glucocorticoid	O
replacement	O
therapy	O
,	O
binding	O
parameters	O
were	O
similar	O
to	O
those	O
in	O
patients	O
before	O
treatment	O
.	O
<EOS>	B-X
After	B-X
long	B-X
term	B-X
glucocorticoid	B-X
replacement	B-X
therapy	B-X
,	B-X
binding	B-X
parameters	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
in	B-X
patients	B-X
before	B-X
treatment	B-X
<EOS>	B-X
Decreased	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
adrenal	B-X
insufficiency	B-X
.	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
glucocorticoid	B-X
deficiency	B-X
on	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
to	B-X
lymphocytes	B-X
in	B-X
normal	B-X
subjects	B-X
and	B-X
patients	B-X
with	B-X
adrenal	B-X
insufficiency	B-X
before	B-X
and	B-X
after	B-X
glucocorticoid	B-X
replacement	B-X
therapy	B-X
<EOS>	B-X
The	B-X
administration	B-X
of	B-X
conventional	B-X
replacement	B-X
doses	B-X
of	B-X
cortisone	B-X
acetate	B-X
for	B-X
6	B-X
months	B-X
caused	B-X
no	B-X
change	B-X
in	B-X
receptor	B-X
number	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
binding	B-X
affinity	B-X
toward	B-X
normal	B-X

The	O
physiological	O
implications	O
of	O
the	O
decreased	O
receptor	O
number	O
and	O
increased	O
binding	O
affinity	O
in	O
adrenal	O
insufficiency	O
remain	O
to	O
be	O
elucidated	O
.	O
<EOS>	B-X
The	B-X
physiological	B-X
implications	B-X
of	B-X
the	B-X
decreased	B-X
receptor	B-X
number	B-X
and	B-X
increased	B-X
binding	B-X
affinity	B-X
in	B-X
adrenal	B-X
insufficiency	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
<EOS>	B-X
Decreased	B-X
glucocorticoid	B-X
receptor	B-X
binding	B-X
in	B-X
adrenal	B-X
insufficiency	B-X
.	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
effect	B-X
of	B-X
glucocorticoid	B-X
deficiency	B-X
on	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
to	B-X
lymphocytes	B-X
in	B-X
normal	B-X
subjects	B-X
and	B-X
patients	B-X
with	B-X
adrenal	B-X
insufficiency	B-X
before	B-X
and	B-X
after	B-X
glucocorticoid	B-X
replacement	B-X
therapy	B-X
<EOS>	B-X
The	B-X
administration	B-X
of	B-X
conventional	B-X
replacement	B-X
doses	B-X
of	B-X
cortisone	B-X
acetate	B-X
for	B-X
6	B-X
months	B-X
caused	B-X
no	B-X
change	B-X
in	B-X
receptor	B-X
number	B-X
,	B-X
but	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
binding	B-X
affinity	B-X
toward	B-X
normal	B-X

Glucocorticoid	B-protein
receptor	I-protein
concentrations	O
and	O
terminal	O
transferase	B-protein
activity	O
as	O
indicators	O
of	O
prognosis	O
in	O
acute	O
non-lymphocytic	O
leukaemia	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
concentrations	B-X
and	B-X
terminal	B-X
transferase	B-X
activity	B-X
as	B-X
indicators	B-X
of	B-X
prognosis	B-X
in	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
measurements	B-X
of	B-X
TdT	B-X
activity	B-X
and	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
yield	B-X
valuable	B-X
prognostic	B-X
information	B-X
in	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
of	B-X
the	B-X
leukaemic	B-X
blast	B-X
cells	B-X
ranged	B-X
from	B-X
0	B-X
to	B-X
0	B-X
<EOS>	B-X
Activity	B-X
of	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
(	B-X
TdT	B-X
)	B-X
,	B-X
adenosine	B-X
deaminase	B-X
,	B-X
and	B-X
5'nucleotidase	B-X
and	B-X
the	B-X
cellular	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
were	B-X
determined	B-X
in	B-X
25	B-X
patients	B-X
with	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X

Activity	O
of	O
terminal	B-protein
deoxynucleotidyl	I-protein
transferase	I-protein
(	O
TdT	B-protein
)	O
,	O
adenosine	B-protein
deaminase	I-protein
,	O
and	O
5'nucleotidase	B-protein
and	O
the	O
cellular	O
concentration	O
of	O
glucocorticoid	B-protein
(	I-protein
dexamethasone	I-protein
)	I-protein
receptor	I-protein
were	O
determined	O
in	O
25	O
patients	O
with	O
acute	O
non-lymphocytic	O
leukaemia	O
.	O
<EOS>	B-X
Activity	B-X
of	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
(	B-X
TdT	B-X
)	B-X
,	B-X
adenosine	B-X
deaminase	B-X
,	B-X
and	B-X
5'nucleotidase	B-X
and	B-X
the	B-X
cellular	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
were	B-X
determined	B-X
in	B-X
25	B-X
patients	B-X
with	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
measurements	B-X
of	B-X
TdT	B-X
activity	B-X
and	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
yield	B-X
valuable	B-X
prognostic	B-X
information	B-X
in	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
concentrations	B-X
and	B-X
terminal	B-X
transferase	B-X
activity	B-X
as	B-X
indicators	B-X
of	B-X
prognosis	B-X
in	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
.	B-X
<EOS>	B-X
This	B-X
finding	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
difference	B-X
in	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
since	B-X
these	B-X
were	B-X
not	B-X
used	B-X
as	B-X
therapeutic	B-X
agents	B-X

All	O
patients	O
were	O
treated	O
according	O
to	O
a	O
common	O
protocol	O
.	O
<EOS>	B-X
Patients	B-X
were	B-X
treated	B-X
according	B-X
to	B-X
the	B-X
imaging	B-X
findings	B-X
and	B-X
hemodynamic	B-X
stability	B-X
<EOS>	B-X
Clinical	B-X
risk	B-X
stratification	B-X
was	B-X
performed	B-X
according	B-X
to	B-X
GOG	B-X
92	B-X
and	B-X
GOG	B-X
109	B-X
protocols	B-X
<EOS>	B-X
300	B-X
patients	B-X
were	B-X
identified	B-X
,	B-X
265	B-X
met	B-X
inclusion	B-X
criteria	B-X
<EOS>	B-X
The	B-X
patients	B-X
are	B-X
often	B-X
frail	B-X
and	B-X
susceptible	B-X
to	B-X
complications	B-X

Increased	O
activity	O
of	O
TdT	B-protein
(	O
greater	O
than	O
0.1	O
unit/microgram	O
DNA	O
)	O
was	O
found	O
in	O
11	O
patients	O
.	O
<EOS>	B-X
1	B-X
unit	B-X
/	B-X
microgram	B-X
DNA	B-X
)	B-X
was	B-X
found	B-X
in	B-X
11	B-X
patients	B-X
<EOS>	B-X
Increased	B-X
activity	B-X
of	B-X
TdT	B-X
(	B-X
greater	B-X
than	B-X
0	B-X
<EOS>	B-X
Patients	B-X
with	B-X
TdT	B-X
levels	B-X
of	B-X
greater	B-X
than	B-X
or	B-X
equal	B-X
to	B-X
0	B-X
<EOS>	B-X
These	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
remission	B-X
and	B-X
survival	B-X
rates	B-X
(	B-X
p	B-X
=	B-X
0	B-X

This	O
group	O
of	O
patients	O
was	O
shown	O
to	O
have	O
higher	O
remission	O
and	O
survival	O
rates	O
(	O
p	O
=	O
0.06	O
)	O
compared	O
with	O
patients	O
with	O
low	O
activity	O
of	O
TdT	O
.	O
<EOS>	B-X
This	B-X
group	B-X
of	B-X
patients	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
higher	B-X
remission	B-X
and	B-X
survival	B-X
rates	B-X
(	B-X
p	B-X
=	B-X
0	B-X
<EOS>	B-X
These	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
remission	B-X
and	B-X
survival	B-X
rates	B-X
(	B-X
p	B-X
=	B-X
0	B-X
<EOS>	B-X
06	B-X
)	B-X
compared	B-X
with	B-X
patients	B-X
with	B-X
low	B-X
activity	B-X
of	B-X
TdT	B-X
<EOS>	B-X
Thirteen	B-X
patients	B-X
had	B-X
blast	B-X
cells	B-X
with	B-X
a	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
over	B-X
0	B-X

The	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
of	O
the	O
leukaemic	B-cell_type
blast	I-cell_type
cells	I-cell_type
ranged	O
from	O
0	O
to	O
0.94	O
fmol/microgram	O
DNA	O
.	O

Thirteen	O
patients	O
had	O
blast	B-cell_type
cells	I-cell_type
with	O
a	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
over	O
0.22	O
fmol/microgram	O
DNA	O
.	O
<EOS>	B-X
Thirteen	B-X
patients	B-X
had	B-X
blast	B-X
cells	B-X
with	B-X
a	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
over	B-X
0	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
measurements	B-X
of	B-X
TdT	B-X
activity	B-X
and	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
yield	B-X
valuable	B-X
prognostic	B-X
information	B-X
in	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
<EOS>	B-X
006	B-X
)	B-X
compared	B-X
with	B-X
those	B-X
with	B-X
a	B-X
low	B-X
receptor	B-X
concentration	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
of	B-X
the	B-X
leukaemic	B-X
blast	B-X
cells	B-X
ranged	B-X
from	B-X
0	B-X
to	B-X
0	B-X

These	O
patients	O
had	O
significantly	O
increased	O
remission	O
and	O
survival	O
rates	O
(	O
p	O
=	O
0.006	O
)	O
compared	O
with	O
those	O
with	O
a	O
low	O
receptor	O
concentration	O
.	O
<EOS>	B-X
These	B-X
patients	B-X
had	B-X
significantly	B-X
increased	B-X
remission	B-X
and	B-X
survival	B-X
rates	B-X
(	B-X
p	B-X
=	B-X
0	B-X
<EOS>	B-X
006	B-X
)	B-X
compared	B-X
with	B-X
those	B-X
with	B-X
a	B-X
low	B-X
receptor	B-X
concentration	B-X
<EOS>	B-X
Thirteen	B-X
patients	B-X
had	B-X
blast	B-X
cells	B-X
with	B-X
a	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
over	B-X
0	B-X
<EOS>	B-X
This	B-X
group	B-X
of	B-X
patients	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
higher	B-X
remission	B-X
and	B-X
survival	B-X
rates	B-X
(	B-X
p	B-X
=	B-X
0	B-X

This	O
finding	O
can	O
not	O
be	O
explained	O
by	O
a	O
difference	O
in	O
sensitivity	O
to	O
glucocorticoids	O
since	O
these	O
were	O
not	O
used	O
as	O
therapeutic	O
agents	O
.	O
<EOS>	B-X
This	B-X
case	B-X
reinforces	B-X
the	B-X
idea	B-X
that	B-X
clinicians	B-X
should	B-X
have	B-X
a	B-X
wide	B-X
differential	B-X
diagnosis	B-X
in	B-X
mind	B-X
when	B-X
dealing	B-X
with	B-X
vague	B-X
symptoms	B-X
and	B-X
should	B-X
not	B-X
hesitate	B-X
to	B-X
use	B-X
different	B-X
diagnostic	B-X
modalities	B-X
to	B-X
help	B-X
confirm	B-X
a	B-X
diagnosis	B-X
<EOS>	B-X
These	B-X
findings	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
pattern	B-X
of	B-X
adaptation	B-X
to	B-X
a	B-X
narrow	B-X
spectrum	B-X
of	B-X
hostsin	B-X
oligophagous	B-X
parasitoids	B-X
<EOS>	B-X
These	B-X
findings	B-X
can	B-X
inform	B-X
strategies	B-X
to	B-X
meet	B-X
HCV	B-X
elimination	B-X
targets	B-X
<EOS>	B-X
Expanded	B-X
gene	B-X
families	B-X
highlight	B-X
the	B-X
difference	B-X
in	B-X
sensory	B-X
-	B-X
related	B-X
genes	B-X
between	B-X
the	B-X
two	B-X
species	B-X
,	B-X
reflecting	B-X
the	B-X
difference	B-X
in	B-X
their	B-X
hosts	B-X

Adenosine	B-protein
deaminase	I-protein
and	O
5'nucleotidase	B-protein
activities	O
both	O
varied	O
within	O
two	O
orders	O
of	O
magnitude	O
.	O
<EOS>	B-X
Adenosine	B-X
deaminase	B-X
and	B-X
5'nucleotidase	B-X
activities	B-X
both	B-X
varied	B-X
within	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
concentrations	B-X
and	B-X
terminal	B-X
transferase	B-X
activity	B-X
as	B-X
indicators	B-X
of	B-X
prognosis	B-X
in	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
.	B-X
<EOS>	B-X
Activity	B-X
of	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
(	B-X
TdT	B-X
)	B-X
,	B-X
adenosine	B-X
deaminase	B-X
,	B-X
and	B-X
5'nucleotidase	B-X
and	B-X
the	B-X
cellular	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
were	B-X
determined	B-X
in	B-X
25	B-X
patients	B-X
with	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
<EOS>	B-X
This	B-X
finding	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
difference	B-X
in	B-X
sensitivity	B-X
to	B-X
glucocorticoids	B-X
since	B-X
these	B-X
were	B-X
not	B-X
used	B-X
as	B-X
therapeutic	B-X
agents	B-X

No	O
correlation	O
could	O
be	O
found	O
between	O
activities	O
of	O
these	O
enzymes	O
and	O
remission	O
or	O
survival	O
rate	O
.	O
<EOS>	B-X
In	B-X
our	B-X
series	B-X
,	B-X
age	B-X
appeared	B-X
to	B-X
be	B-X
an	B-X
independent	B-X
prognostic	B-X
factor	B-X
for	B-X
overall	B-X
survival	B-X
,	B-X
with	B-X
no	B-X
differences	B-X
in	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
survival	B-X
rates	B-X
<EOS>	B-X
For	B-X
amputations	B-X
performed	B-X
for	B-X
infection	B-X
or	B-X
necrosis	B-X
,	B-X
the	B-X
revision	B-X
rate	B-X
was	B-X
47	B-X
<EOS>	B-X
Testicular	B-X
germ	B-X
cell	B-X
tumor	B-X
(	B-X
TGCT	B-X
)	B-X
is	B-X
the	B-X
most	B-X
frequent	B-X
neoplasia	B-X
in	B-X
men	B-X
of	B-X
reproductive	B-X
age	B-X
,	B-X
with	B-X
a	B-X
5	B-X
-	B-X
year	B-X
survival	B-X
rate	B-X
of	B-X
95	B-X
%	B-X
<EOS>	B-X
High	B-X
level	B-X
of	B-X
PHB2	B-X
was	B-X
found	B-X
in	B-X
RCC	B-X
tissues	B-X
,	B-X
and	B-X
this	B-X
overexpression	B-X
was	B-X
linked	B-X
to	B-X
a	B-X
worse	B-X
overall	B-X
survival	B-X
rate	B-X
for	B-X
RCC	B-X
patients	B-X

These	O
results	O
show	O
that	O
measurements	O
of	O
TdT	B-protein
activity	O
and	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
yield	O
valuable	O
prognostic	O
information	O
in	O
acute	O
non-lymphocytic	O
leukaemia	O
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
measurements	B-X
of	B-X
TdT	B-X
activity	B-X
and	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
yield	B-X
valuable	B-X
prognostic	B-X
information	B-X
in	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
<EOS>	B-X
Activity	B-X
of	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
(	B-X
TdT	B-X
)	B-X
,	B-X
adenosine	B-X
deaminase	B-X
,	B-X
and	B-X
5'nucleotidase	B-X
and	B-X
the	B-X
cellular	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
(	B-X
dexamethasone	B-X
)	B-X
receptor	B-X
were	B-X
determined	B-X
in	B-X
25	B-X
patients	B-X
with	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
concentrations	B-X
and	B-X
terminal	B-X
transferase	B-X
activity	B-X
as	B-X
indicators	B-X
of	B-X
prognosis	B-X
in	B-X
acute	B-X
non	B-X
-	B-X
lymphocytic	B-X
leukaemia	B-X
.	B-X
<EOS>	B-X
Thirteen	B-X
patients	B-X
had	B-X
blast	B-X
cells	B-X
with	B-X
a	B-X
glucocorticoid	B-X
receptor	B-X
concentration	B-X
over	B-X
0	B-X

[	O
3H	O
]	O
cortivazol	O
:	O
a	O
unique	O
high	O
affinity	O
ligand	O
for	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O
<EOS>	B-X
[	B-X
3H	B-X
]	B-X
cortivazol	B-X
:	B-X
a	B-X
unique	B-X
high	B-X
affinity	B-X
ligand	B-X
for	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
13	B-X
pmol	B-X
/	B-X
mg	B-X
protein	B-X
)	B-X
to	B-X
the	B-X
high	B-X
affinity	B-X
site	B-X
detected	B-X
in	B-X
the	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
cell	B-X
line	B-X
C7	B-X
<EOS>	B-X
Cortivazol	B-X
(	B-X
CVZ	B-X
)	B-X
and	B-X
deacylcortivazol	B-X
(	B-X
DAC	B-X
)	B-X
are	B-X
pyrazolosteroids	B-X
with	B-X
potent	B-X
glucocorticoid	B-X
activity	B-X
<EOS>	B-X
The	B-X
receptor	B-X
concentration	B-X
of	B-X
the	B-X
low	B-X
affinity	B-X
site	B-X
(	B-X
0	B-X

Cortivazol	O
(	O
CVZ	O
)	O
and	O
deacylcortivazol	O
(	O
DAC	O
)	O
are	O
pyrazolosteroids	O
with	O
potent	O
glucocorticoid	O
activity	O
.	O
<EOS>	B-X
Cortivazol	B-X
(	B-X
CVZ	B-X
)	B-X
and	B-X
deacylcortivazol	B-X
(	B-X
DAC	B-X
)	B-X
are	B-X
pyrazolosteroids	B-X
with	B-X
potent	B-X
glucocorticoid	B-X
activity	B-X
<EOS>	B-X
[	B-X
3H	B-X
]	B-X
cortivazol	B-X
:	B-X
a	B-X
unique	B-X
high	B-X
affinity	B-X
ligand	B-X
for	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Examination	B-X
of	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
using	B-X
10	B-X
(	B-X
	B-X
-	B-X
5	B-X
)	B-X
M	B-X
DEX	B-X
as	B-X
the	B-X
competing	B-X
ligand	B-X
showed	B-X
that	B-X
DEX	B-X
binds	B-X
only	B-X
to	B-X
the	B-X
low	B-X
affinity	B-X
site	B-X
detected	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
interaction	B-X
between	B-X
these	B-X
atypical	B-X
steroids	B-X
and	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
to	B-X
cytosol	B-X
from	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
variants	B-X
of	B-X
the	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
C7	B-X

In	O
previous	O
work	O
we	O
showed	O
that	O
DAC	O
is	O
40-fold	O
more	O
potent	O
than	O
dexamethasone	O
(	O
DEX	O
)	O
in	O
lysing	O
leukemic	B-cell_type
lymphoblasts	I-cell_type
.	O
<EOS>	B-X
In	B-X
previous	B-X
work	B-X
we	B-X
showed	B-X
that	B-X
DAC	B-X
is	B-X
40	B-X
-	B-X
fold	B-X
more	B-X
potent	B-X
than	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
in	B-X
lysing	B-X
leukemic	B-X
lymphoblasts	B-X
<EOS>	B-X
CVZ	B-X
competes	B-X
for	B-X
a	B-X
97,000	B-X
-	B-X
dalton	B-X
protein	B-X
labeled	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
mesylate	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DEX	B-X
to	B-X
C7	B-X
cytosol	B-X
revealed	B-X
a	B-X
single	B-X
class	B-X
of	B-X
binding	B-X
sites	B-X
(	B-X
Kd	B-X
=	B-X
1	B-X
<EOS>	B-X
In	B-X
cytosol	B-X
from	B-X
a	B-X
glucocorticoid	B-X
-	B-X
resistant	B-X
cell	B-X
line	B-X
with	B-X
virtually	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
DEX	B-X
binding	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
detected	B-X
a	B-X
single	B-X
high	B-X
affinity	B-X
binding	B-X
site	B-X
that	B-X
was	B-X
similar	B-X
in	B-X
dissociation	B-X
constant	B-X
(	B-X
0	B-X

To	O
assess	O
the	O
interaction	O
between	O
these	O
atypical	O
steroids	O
and	O
the	O
glucocorticoid	B-protein
receptor	I-protein
,	O
we	O
examined	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	O
to	O
cytosol	O
from	O
glucocorticoid-sensitive	B-cell_line
and	I-cell_line
-resistant	I-cell_line
variants	I-cell_line
of	O
the	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
CEM	B-cell_line
C7	I-cell_line
.	O
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
interaction	B-X
between	B-X
these	B-X
atypical	B-X
steroids	B-X
and	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
to	B-X
cytosol	B-X
from	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
variants	B-X
of	B-X
the	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
C7	B-X
<EOS>	B-X
Scatchard	B-X
analysis	B-X
of	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
in	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
cells	B-X
revealed	B-X
a	B-X
curvilinear	B-X
plot	B-X
which	B-X
resolved	B-X
into	B-X
high	B-X
(	B-X
0	B-X
<EOS>	B-X
13	B-X
pmol	B-X
/	B-X
mg	B-X
protein	B-X
)	B-X
to	B-X
the	B-X
high	B-X
affinity	B-X
site	B-X
detected	B-X
in	B-X
the	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
cell	B-X
line	B-X
C7	B-X
<EOS>	B-X
In	B-X
cytosol	B-X
from	B-X
a	B-X
glucocorticoid	B-X
-	B-X
resistant	B-X
cell	B-X
line	B-X
with	B-X
virtually	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
DEX	B-X
binding	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
detected	B-X
a	B-X
single	B-X
high	B-X
affinity	B-X
binding	B-X
site	B-X
that	B-X
was	B-X
similar	B-X
in	B-X
dissociation	B-X
constant	B-X
(	B-X
0	B-X

In	O
glucocorticoid-sensitive	B-cell_line
cells	I-cell_line
[	O
3H	O
]	O
CVZ	O
causes	O
a	O
2-fold	O
induction	O
of	O
glutamine	B-protein
synthetase	I-protein
and	O
binds	O
to	O
a	O
protein	O
in	O
the	O
4.6	O
S	O
region	O
of	O
high	O
salt	O
sucrose	O
gradients	O
.	O
<EOS>	B-X
In	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
cells	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
causes	B-X
a	B-X
2	B-X
-	B-X
fold	B-X
induction	B-X
of	B-X
glutamine	B-X
synthetase	B-X
and	B-X
binds	B-X
to	B-X
a	B-X
protein	B-X
in	B-X
the	B-X
4	B-X
<EOS>	B-X
In	B-X
cytosol	B-X
from	B-X
a	B-X
glucocorticoid	B-X
-	B-X
resistant	B-X
cell	B-X
line	B-X
with	B-X
virtually	B-X
no	B-X
[	B-X
3H	B-X
]	B-X
DEX	B-X
binding	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
detected	B-X
a	B-X
single	B-X
high	B-X
affinity	B-X
binding	B-X
site	B-X
that	B-X
was	B-X
similar	B-X
in	B-X
dissociation	B-X
constant	B-X
(	B-X
0	B-X
<EOS>	B-X
In	B-X
previous	B-X
work	B-X
we	B-X
showed	B-X
that	B-X
DAC	B-X
is	B-X
40	B-X
-	B-X
fold	B-X
more	B-X
potent	B-X
than	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
in	B-X
lysing	B-X
leukemic	B-X
lymphoblasts	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DEX	B-X
to	B-X
C7	B-X
cytosol	B-X
revealed	B-X
a	B-X
single	B-X
class	B-X
of	B-X
binding	B-X
sites	B-X
(	B-X
Kd	B-X
=	B-X
1	B-X

On	O
DEAE-cellulose	O
chromatography	O
,	O
[	B-protein
3H	I-protein
]	I-protein
CVZ-receptor	I-protein
complexes	I-protein
show	O
a	O
shift	O
from	O
high	O
(	O
0.25	O
M	O
KP	O
)	O
to	O
low	O
salt	O
(	O
0.09	O
M	O
KP	O
)	O
eluting	O
forms	O
upon	O
activation	O
.	O

CVZ	O
competes	O
for	O
a	O
97	O
,	O
000-dalton	O
protein	O
labeled	O
by	O
[	O
3H	O
]	O
dexamethasone	O
mesylate	O
.	O
<EOS>	B-X
CVZ	B-X
competes	B-X
for	B-X
a	B-X
97,000	B-X
-	B-X
dalton	B-X
protein	B-X
labeled	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
mesylate	B-X
<EOS>	B-X
Dissociation	B-X
experiments	B-X
with	B-X
dilution	B-X
and	B-X
/	B-X
or	B-X
excess	B-X
unlabeled	B-X
CVZ	B-X
supported	B-X
the	B-X
presence	B-X
of	B-X
independent	B-X
sites	B-X
<EOS>	B-X
In	B-X
previous	B-X
work	B-X
we	B-X
showed	B-X
that	B-X
DAC	B-X
is	B-X
40	B-X
-	B-X
fold	B-X
more	B-X
potent	B-X
than	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
in	B-X
lysing	B-X
leukemic	B-X
lymphoblasts	B-X
<EOS>	B-X
The	B-X
receptor	B-X
concentration	B-X
of	B-X
the	B-X
low	B-X
affinity	B-X
site	B-X
(	B-X
0	B-X

Scatchard	O
analysis	O
of	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	O
in	O
glucocorticoid-sensitive	B-cell_line
cells	I-cell_line
revealed	O
a	O
curvilinear	O
plot	O
which	O
resolved	O
into	O
high	O
(	O
0.4	O
nM	O
)	O
and	O
low	O
(	O
11	O
nM	O
)	O
affinity	O
components	O
.	O
<EOS>	B-X
Scatchard	B-X
analysis	B-X
of	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
in	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
cells	B-X
revealed	B-X
a	B-X
curvilinear	B-X
plot	B-X
which	B-X
resolved	B-X
into	B-X
high	B-X
(	B-X
0	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DEX	B-X
to	B-X
C7	B-X
cytosol	B-X
revealed	B-X
a	B-X
single	B-X
class	B-X
of	B-X
binding	B-X
sites	B-X
(	B-X
Kd	B-X
=	B-X
1	B-X
<EOS>	B-X
Examination	B-X
of	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
using	B-X
10	B-X
(	B-X
	B-X
-	B-X
5	B-X
)	B-X
M	B-X
DEX	B-X
as	B-X
the	B-X
competing	B-X
ligand	B-X
showed	B-X
that	B-X
DEX	B-X
binds	B-X
only	B-X
to	B-X
the	B-X
low	B-X
affinity	B-X
site	B-X
detected	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
<EOS>	B-X
In	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
cells	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
causes	B-X
a	B-X
2	B-X
-	B-X
fold	B-X
induction	B-X
of	B-X
glutamine	B-X
synthetase	B-X
and	B-X
binds	B-X
to	B-X
a	B-X
protein	B-X
in	B-X
the	B-X
4	B-X

The	O
receptor	O
concentration	O
of	O
the	O
low	O
affinity	O
site	O
(	O
0.30	O
pmol/mg	O
protein	O
)	O
was	O
approximately	O
twice	O
that	O
of	O
the	O
high	B-protein
affinity	I-protein
site	I-protein
(	O
0.14	O
pmol/mg	O
protein	O
)	O
.	O
<EOS>	B-X
30	B-X
pmol	B-X
/	B-X
mg	B-X
protein	B-X
)	B-X
was	B-X
approximately	B-X
twice	B-X
that	B-X
of	B-X
the	B-X
high	B-X
affinity	B-X
site	B-X
(	B-X
0	B-X
<EOS>	B-X
The	B-X
receptor	B-X
concentration	B-X
of	B-X
the	B-X
low	B-X
affinity	B-X
site	B-X
(	B-X
0	B-X
<EOS>	B-X
13	B-X
pmol	B-X
/	B-X
mg	B-X
protein	B-X
)	B-X
to	B-X
the	B-X
high	B-X
affinity	B-X
site	B-X
detected	B-X
in	B-X
the	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
cell	B-X
line	B-X
C7	B-X
<EOS>	B-X
In	B-X
previous	B-X
work	B-X
we	B-X
showed	B-X
that	B-X
DAC	B-X
is	B-X
40	B-X
-	B-X
fold	B-X
more	B-X
potent	B-X
than	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
in	B-X
lysing	B-X
leukemic	B-X
lymphoblasts	B-X

Dissociation	O
experiments	O
with	O
dilution	O
and/or	O
excess	O
unlabeled	O
CVZ	O
supported	O
the	O
presence	O
of	O
independent	O
sites	O
.	O
<EOS>	B-X
Dilution	B-X
experiments	B-X
were	B-X
performed	B-X
to	B-X
investigate	B-X
PCR	B-X
inhibition	B-X
<EOS>	B-X
The	B-X
dissociation	B-X
constant	B-X
of	B-X
the	B-X
circulating	B-X
IgG	B-X
antibodies	B-X
is	B-X
suggested	B-X
to	B-X
be	B-X
proportional	B-X
to	B-X
the	B-X
partial	B-X
concentrations	B-X
of	B-X
these	B-X
antibodies	B-X
in	B-X
blood	B-X
serum	B-X
in	B-X
equilibrium	B-X
<EOS>	B-X
In	B-X
these	B-X
experiments	B-X
,	B-X
the	B-X
ratio	B-X
of	B-X
the	B-X
concentration	B-X
of	B-X
palmitate	B-X
to	B-X
albumin	B-X
was	B-X
set	B-X
at	B-X
0	B-X
<EOS>	B-X
Extraction	B-X
with	B-X
or	B-X
without	B-X
proteinase	B-X
K	B-X
was	B-X
used	B-X
to	B-X
examine	B-X
protein	B-X
dissociation	B-X

In	O
contrast	O
,	O
the	O
binding	O
of	O
[	O
3H	O
]	O
DEX	O
to	O
C7	O
cytosol	O
revealed	O
a	O
single	O
class	O
of	O
binding	O
sites	O
(	O
Kd	O
=	O
1.9	O
nM	O
;	O
receptor	O
concentration	O
,	O
0.46	O
pmol/mg	O
protein	O
)	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
DEX	B-X
to	B-X
C7	B-X
cytosol	B-X
revealed	B-X
a	B-X
single	B-X
class	B-X
of	B-X
binding	B-X
sites	B-X
(	B-X
Kd	B-X
=	B-X
1	B-X
<EOS>	B-X
Examination	B-X
of	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
using	B-X
10	B-X
(	B-X
	B-X
-	B-X
5	B-X
)	B-X
M	B-X
DEX	B-X
as	B-X
the	B-X
competing	B-X
ligand	B-X
showed	B-X
that	B-X
DEX	B-X
binds	B-X
only	B-X
to	B-X
the	B-X
low	B-X
affinity	B-X
site	B-X
detected	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
<EOS>	B-X
Scatchard	B-X
analysis	B-X
of	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
in	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
cells	B-X
revealed	B-X
a	B-X
curvilinear	B-X
plot	B-X
which	B-X
resolved	B-X
into	B-X
high	B-X
(	B-X
0	B-X
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
interaction	B-X
between	B-X
these	B-X
atypical	B-X
steroids	B-X
and	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
binding	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
CVZ	B-X
to	B-X
cytosol	B-X
from	B-X
glucocorticoid	B-X
-	B-X
sensitive	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
variants	B-X
of	B-X
the	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
CEM	B-X
C7	B-X

Examination	O
of	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	O
using	O
10	O
(	O
-5	O
)	O
M	O
DEX	O
as	O
the	O
competing	O
ligand	O
showed	O
that	O
DEX	O
binds	O
only	O
to	O
the	O
low	O
affinity	O
site	O
detected	O
by	O
[	O
3H	O
]	O
CVZ	O
.	O

In	O
cytosol	O
from	O
a	O
glucocorticoid-resistant	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
virtually	O
no	O
[	O
3H	O
]	O
DEX	O
binding	O
,	O
[	O
3H	O
]	O
CVZ	O
detected	O
a	O
single	O
high	B-protein
affinity	I-protein
binding	I-protein
site	I-protein
that	O
was	O
similar	O
in	O
dissociation	O
constant	O
(	O
0.8	O
nM	O
)	O
and	O
receptor	O
concentration	O
(	O
0.13	O
pmol/mg	O
protein	O
)	O
to	O
the	O
high	B-protein
affinity	I-protein
site	I-protein
detected	O
in	O
the	O
glucocorticoid-sensitive	B-cell_line
cell	I-cell_line
line	I-cell_line
C7	B-cell_line
.	O

A	O
controlled	O
pore	O
glass	O
bead	O
assay	O
for	O
the	O
measurement	O
of	O
cytoplasmic	B-protein
and	I-protein
nuclear	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O
<EOS>	B-X
A	B-X
controlled	B-X
pore	B-X
glass	B-X
bead	B-X
assay	B-X
for	B-X
the	B-X
measurement	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
.	B-X
<EOS>	B-X
An	B-X
assay	B-X
for	B-X
the	B-X
quantitation	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
lymphoid	B-X
tissue	B-X
has	B-X
been	B-X
developed	B-X
using	B-X
controlled	B-X
pore	B-X
glass	B-X
(	B-X
CPG	B-X
)	B-X
beads	B-X
<EOS>	B-X
A	B-X
comparison	B-X
of	B-X
the	B-X
CPG	B-X
assay	B-X
to	B-X
dextran	B-X
coated	B-X
charcoal	B-X
and	B-X
a	B-X
whole	B-X
cell	B-X
assay	B-X
demonstrates	B-X
that	B-X
CPG	B-X
and	B-X
dextran	B-X
coated	B-X
charcoal	B-X
give	B-X
equivalent	B-X
measurements	B-X
of	B-X
cytosolic	B-X
receptor	B-X
concentration	B-X
,	B-X
while	B-X
the	B-X
CPG	B-X
and	B-X
whole	B-X
cell	B-X
assays	B-X
provide	B-X
equivalent	B-X
values	B-X
for	B-X
total	B-X
receptor	B-X
content	B-X
<EOS>	B-X
Excess	B-X
labeled	B-X
steroid	B-X
as	B-X
well	B-X
as	B-X
most	B-X
non	B-X
-	B-X
specifically	B-X
bound	B-X
steroid	B-X
is	B-X
easily	B-X
washed	B-X
away	B-X
,	B-X
leaving	B-X
the	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
retained	B-X
by	B-X
the	B-X
beads	B-X

An	O
assay	O
for	O
the	O
quantitation	O
of	O
cytoplasmic	B-protein
and	I-protein
nuclear	I-protein
glucocorticoid	I-protein
receptors	I-protein
in	O
lymphoid	O
tissue	O
has	O
been	O
developed	O
using	O
controlled	O
pore	O
glass	O
(	O
CPG	O
)	O
beads	O
.	O
<EOS>	B-X
An	B-X
assay	B-X
for	B-X
the	B-X
quantitation	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
lymphoid	B-X
tissue	B-X
has	B-X
been	B-X
developed	B-X
using	B-X
controlled	B-X
pore	B-X
glass	B-X
(	B-X
CPG	B-X
)	B-X
beads	B-X
<EOS>	B-X
Soluble	B-X
receptor	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
3H	B-X
-	B-X
steroid	B-X
complex	B-X
(	B-X
cytosol	B-X
or	B-X
nuclear	B-X
extract	B-X
)	B-X
is	B-X
adsorbed	B-X
quantitatively	B-X
within	B-X
the	B-X
crevasses	B-X
of	B-X
porous	B-X
glass	B-X
beads	B-X
<EOS>	B-X
A	B-X
controlled	B-X
pore	B-X
glass	B-X
bead	B-X
assay	B-X
for	B-X
the	B-X
measurement	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
.	B-X
<EOS>	B-X
A	B-X
comparison	B-X
of	B-X
the	B-X
CPG	B-X
assay	B-X
to	B-X
dextran	B-X
coated	B-X
charcoal	B-X
and	B-X
a	B-X
whole	B-X
cell	B-X
assay	B-X
demonstrates	B-X
that	B-X
CPG	B-X
and	B-X
dextran	B-X
coated	B-X
charcoal	B-X
give	B-X
equivalent	B-X
measurements	B-X
of	B-X
cytosolic	B-X
receptor	B-X
concentration	B-X
,	B-X
while	B-X
the	B-X
CPG	B-X
and	B-X
whole	B-X
cell	B-X
assays	B-X
provide	B-X
equivalent	B-X
values	B-X
for	B-X
total	B-X
receptor	B-X
content	B-X

Soluble	O
receptor	B-protein
--	I-protein
3H-steroid	I-protein
complex	I-protein
(	O
cytosol	O
or	O
nuclear	O
extract	O
)	O
is	O
adsorbed	O
quantitatively	O
within	O
the	O
crevasses	O
of	O
porous	O
glass	O
beads	O
.	O
<EOS>	B-X
Soluble	B-X
receptor	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
3H	B-X
-	B-X
steroid	B-X
complex	B-X
(	B-X
cytosol	B-X
or	B-X
nuclear	B-X
extract	B-X
)	B-X
is	B-X
adsorbed	B-X
quantitatively	B-X
within	B-X
the	B-X
crevasses	B-X
of	B-X
porous	B-X
glass	B-X
beads	B-X
<EOS>	B-X
An	B-X
assay	B-X
for	B-X
the	B-X
quantitation	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
lymphoid	B-X
tissue	B-X
has	B-X
been	B-X
developed	B-X
using	B-X
controlled	B-X
pore	B-X
glass	B-X
(	B-X
CPG	B-X
)	B-X
beads	B-X
<EOS>	B-X
Bound	B-X
3H	B-X
-	B-X
steroid	B-X
is	B-X
eluted	B-X
with	B-X
ethanol	B-X
and	B-X
measured	B-X
for	B-X
radioactivity	B-X
<EOS>	B-X
A	B-X
comparison	B-X
of	B-X
the	B-X
CPG	B-X
assay	B-X
to	B-X
dextran	B-X
coated	B-X
charcoal	B-X
and	B-X
a	B-X
whole	B-X
cell	B-X
assay	B-X
demonstrates	B-X
that	B-X
CPG	B-X
and	B-X
dextran	B-X
coated	B-X
charcoal	B-X
give	B-X
equivalent	B-X
measurements	B-X
of	B-X
cytosolic	B-X
receptor	B-X
concentration	B-X
,	B-X
while	B-X
the	B-X
CPG	B-X
and	B-X
whole	B-X
cell	B-X
assays	B-X
provide	B-X
equivalent	B-X
values	B-X
for	B-X
total	B-X
receptor	B-X
content	B-X

Excess	O
labeled	O
steroid	O
as	O
well	O
as	O
most	O
non-specifically	O
bound	O
steroid	O
is	O
easily	O
washed	O
away	O
,	O
leaving	O
the	O
hormone-receptor	B-protein
complex	I-protein
retained	O
by	O
the	O
beads	O
.	O
<EOS>	B-X
Excess	B-X
labeled	B-X
steroid	B-X
as	B-X
well	B-X
as	B-X
most	B-X
non	B-X
-	B-X
specifically	B-X
bound	B-X
steroid	B-X
is	B-X
easily	B-X
washed	B-X
away	B-X
,	B-X
leaving	B-X
the	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
retained	B-X
by	B-X
the	B-X
beads	B-X
<EOS>	B-X
A	B-X
controlled	B-X
pore	B-X
glass	B-X
bead	B-X
assay	B-X
for	B-X
the	B-X
measurement	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
.	B-X
<EOS>	B-X
A	B-X
comparison	B-X
of	B-X
the	B-X
CPG	B-X
assay	B-X
to	B-X
dextran	B-X
coated	B-X
charcoal	B-X
and	B-X
a	B-X
whole	B-X
cell	B-X
assay	B-X
demonstrates	B-X
that	B-X
CPG	B-X
and	B-X
dextran	B-X
coated	B-X
charcoal	B-X
give	B-X
equivalent	B-X
measurements	B-X
of	B-X
cytosolic	B-X
receptor	B-X
concentration	B-X
,	B-X
while	B-X
the	B-X
CPG	B-X
and	B-X
whole	B-X
cell	B-X
assays	B-X
provide	B-X
equivalent	B-X
values	B-X
for	B-X
total	B-X
receptor	B-X
content	B-X
<EOS>	B-X
Soluble	B-X
receptor	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
3H	B-X
-	B-X
steroid	B-X
complex	B-X
(	B-X
cytosol	B-X
or	B-X
nuclear	B-X
extract	B-X
)	B-X
is	B-X
adsorbed	B-X
quantitatively	B-X
within	B-X
the	B-X
crevasses	B-X
of	B-X
porous	B-X
glass	B-X
beads	B-X

Bound	O
3H-steroid	O
is	O
eluted	O
with	O
ethanol	O
and	O
measured	O
for	O
radioactivity	O
.	O
<EOS>	B-X
Bound	B-X
3H	B-X
-	B-X
steroid	B-X
is	B-X
eluted	B-X
with	B-X
ethanol	B-X
and	B-X
measured	B-X
for	B-X
radioactivity	B-X
<EOS>	B-X
Soluble	B-X
receptor	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
3H	B-X
-	B-X
steroid	B-X
complex	B-X
(	B-X
cytosol	B-X
or	B-X
nuclear	B-X
extract	B-X
)	B-X
is	B-X
adsorbed	B-X
quantitatively	B-X
within	B-X
the	B-X
crevasses	B-X
of	B-X
porous	B-X
glass	B-X
beads	B-X
<EOS>	B-X
A	B-X
controlled	B-X
pore	B-X
glass	B-X
bead	B-X
assay	B-X
for	B-X
the	B-X
measurement	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
.	B-X
<EOS>	B-X
Excess	B-X
labeled	B-X
steroid	B-X
as	B-X
well	B-X
as	B-X
most	B-X
non	B-X
-	B-X
specifically	B-X
bound	B-X
steroid	B-X
is	B-X
easily	B-X
washed	B-X
away	B-X
,	B-X
leaving	B-X
the	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
retained	B-X
by	B-X
the	B-X
beads	B-X

This	O
procedure	O
which	O
is	O
simple	O
,	O
rapid	O
,	O
and	O
highly	O
reproducible	O
is	O
carried	O
out	O
using	O
frozen	O
samples	O
(	O
stable	O
for	O
many	O
months	O
)	O
containing	O
as	O
few	O
as	O
1	O
X	O
10	O
(	O
7	O
)	O
cells	O
.	O

A	O
comparison	O
of	O
the	O
CPG	O
assay	O
to	O
dextran	O
coated	O
charcoal	O
and	O
a	O
whole	O
cell	O
assay	O
demonstrates	O
that	O
CPG	O
and	O
dextran	O
coated	O
charcoal	O
give	O
equivalent	O
measurements	O
of	O
cytosolic	B-protein
receptor	I-protein
concentration	O
,	O
while	O
the	O
CPG	O
and	O
whole	O
cell	O
assays	O
provide	O
equivalent	O
values	O
for	O
total	O
receptor	O
content	O
.	O

Plasmacytoid	O
blast	O
crisis	O
in	O
B-cell	B-cell_type
chronic	O
lymphocytic	O
leukemia	O
:	O
effect	O
of	O
estradiol	O
on	O
growth	O
and	O
differentiation	O
in	O
vitro	O
.	O
<EOS>	B-X
Plasmacytoid	B-X
blast	B-X
crisis	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
:	B-X
effect	B-X
of	B-X
estradiol	B-X
on	B-X
growth	B-X
and	B-X
differentiation	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Exposure	B-X
of	B-X
the	B-X
patient	B-X
's	B-X
blast	B-X
cells	B-X
to	B-X
E2	B-X
in	B-X
vitro	B-X
resulted	B-X
in	B-X
cessation	B-X
of	B-X
cell	B-X
growth	B-X
following	B-X
at	B-X
least	B-X
one	B-X
mitosis	B-X
after	B-X
addition	B-X
of	B-X
the	B-X
inducer	B-X
as	B-X
seen	B-X
from	B-X
the	B-X
replacement	B-X
of	B-X
the	B-X
large	B-X
blasts	B-X
by	B-X
small	B-X
CLL	B-X
-	B-X
like	B-X
cells	B-X
without	B-X
definite	B-X
signs	B-X
of	B-X
alteration	B-X
of	B-X
the	B-X
differentiation	B-X
status	B-X
<EOS>	B-X
This	B-X
suggests	B-X
the	B-X
association	B-X
of	B-X
E2	B-X
-	B-X
receptor	B-X
expression	B-X
with	B-X
control	B-X
of	B-X
growth	B-X
rather	B-X
than	B-X
cell	B-X
maturation	B-X
<EOS>	B-X
The	B-X
functional	B-X
status	B-X
of	B-X
the	B-X
steroid	B-X
receptors	B-X
was	B-X
confirmed	B-X
by	B-X
nuclear	B-X
transfer	B-X
of	B-X
the	B-X
cytoplasmic	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
upon	B-X
temperature	B-X
activation	B-X

Evolution	O
of	O
a	O
case	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
into	O
blast	O
crisis	O
was	O
found	O
to	O
be	O
characterized	O
by	O
three	O
unusual	O
features	O
(	O
1	O
)	O
the	O
phenotype	O
of	O
the	O
emerging	B-cell_type
blast	I-cell_type
cells	I-cell_type
was	O
that	O
of	O
pre-plasmacytoid	B-cell_type
cells	I-cell_type
as	O
shown	O
by	O
plasma	O
cell	O
morphology	O
and	O
an	O
immunological	O
phenotype	O
corresponding	O
partially	O
with	O
CLL-	B-cell_type
or	I-cell_type
intermediate	I-cell_type
B-cells	I-cell_type
,	O
partially	O
with	O
plasma	B-cell_type
cells	I-cell_type
(	O
terminal	B-protein
transferase	I-protein
-	O
,	O
common	O
acute	B-protein
lymphocytic	I-protein
leukemia	I-protein
antigen	I-protein
-	O
,	O
Ia+	B-protein
,	O
surface	B-protein
immunoglobulin	I-protein
heavy	I-protein
chains	I-protein
-	O
,	O
surface	B-protein
kappa	I-protein
light	I-protein
chains	I-protein
+	O
,	O
intracytoplasmic	B-protein
immunoglobulin	I-protein
A+	I-protein
and	I-protein
G+	I-protein
,	O
BA-1+	B-protein
,	O
polyclonal	O
gammaglobulin	O
production	O
)	O
;	O
(	O
2	O
)	O
cytogenetic	O
analysis	O
of	O
spontaneous	O
metaphases	O
revealed	O
that	O
in	O
addition	O
to	O
the	O
typical	O
CLL	O
abnormality	O
,	O
trisomy	O
12	O
,	O
in	O
all	O
of	O
the	O
cells	O
,	O
an	O
additional	O
translocation	O
between	O
chromosomes	B-DNA
14	I-DNA
and	I-DNA
17	I-DNA
was	O
present	O
in	O
40	O
%	O
with	O
a	O
presumptive	O
breakpoint	O
on	O
chromosome	B-DNA
14	I-DNA
(	O
q12-3	O
)	O
never	O
described	O
before	O
(	O
commonly	O
q32	O
)	O
and	O
(	O
3	O
)	O
the	O
progression	O
of	O
the	O
disease	O
was	O
associated	O
with	O
a	O
striking	O
increase	O
in	O
the	O
expression	O
by	O
the	O
transformed	B-cell_type
cells	I-cell_type
of	O
specific	O
binding	O
sites	O
for	O
estradiol	O
(	O
E2	O
)	O
due	O
to	O
an	O
actual	O
increase	O
in	O
total	O
cellular	B-protein
receptor	I-protein
proteins	I-protein
and	O
not	O
to	O
a	O
change	O
in	O
receptor	O
affinity	O
for	O
E2	O
.	O

The	O
functional	O
status	O
of	O
the	O
steroid	B-protein
receptors	I-protein
was	O
confirmed	O
by	O
nuclear	O
transfer	O
of	O
the	O
cytoplasmic	B-protein
hormone-receptor	I-protein
complex	I-protein
upon	O
temperature	O
activation	O
.	O
<EOS>	B-X
The	B-X
functional	B-X
status	B-X
of	B-X
the	B-X
steroid	B-X
receptors	B-X
was	B-X
confirmed	B-X
by	B-X
nuclear	B-X
transfer	B-X
of	B-X
the	B-X
cytoplasmic	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
upon	B-X
temperature	B-X
activation	B-X
<EOS>	B-X
This	B-X
suggests	B-X
the	B-X
association	B-X
of	B-X
E2	B-X
-	B-X
receptor	B-X
expression	B-X
with	B-X
control	B-X
of	B-X
growth	B-X
rather	B-X
than	B-X
cell	B-X
maturation	B-X
<EOS>	B-X
Exposure	B-X
of	B-X
the	B-X
patient	B-X
's	B-X
blast	B-X
cells	B-X
to	B-X
E2	B-X
in	B-X
vitro	B-X
resulted	B-X
in	B-X
cessation	B-X
of	B-X
cell	B-X
growth	B-X
following	B-X
at	B-X
least	B-X
one	B-X
mitosis	B-X
after	B-X
addition	B-X
of	B-X
the	B-X
inducer	B-X
as	B-X
seen	B-X
from	B-X
the	B-X
replacement	B-X
of	B-X
the	B-X
large	B-X
blasts	B-X
by	B-X
small	B-X
CLL	B-X
-	B-X
like	B-X
cells	B-X
without	B-X
definite	B-X
signs	B-X
of	B-X
alteration	B-X
of	B-X
the	B-X
differentiation	B-X
status	B-X
<EOS>	B-X
Since	B-X
the	B-X
rise	B-X
in	B-X
E2	B-X
-	B-X
receptor	B-X
display	B-X
paralleled	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
proliferative	B-X
activity	B-X
of	B-X
the	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
a	B-X
change	B-X
in	B-X
their	B-X
maturation	B-X
status	B-X
the	B-X
question	B-X
was	B-X
raised	B-X
as	B-X
to	B-X
whether	B-X
the	B-X
E2	B-X
-	B-X
receptor	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
physiological	B-X
marker	B-X
of	B-X
growth	B-X
rate	B-X
or	B-X
of	B-X
cellular	B-X
differentiation	B-X

Since	O
the	O
rise	O
in	O
E2-receptor	B-protein
display	O
paralleled	O
a	O
large	O
increase	O
in	O
the	O
proliferative	O
activity	O
of	O
the	O
cells	O
as	O
well	O
as	O
a	O
change	O
in	O
their	O
maturation	O
status	O
the	O
question	O
was	O
raised	O
as	O
to	O
whether	O
the	O
E2-receptor	B-protein
should	O
be	O
considered	O
as	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
of	O
cellular	O
differentiation	O
.	O
<EOS>	B-X
Cilia	B-X
ablation	B-X
in	B-X
keratine14	B-X
-	B-X
expressing	B-X
tissue	B-X
disrupted	B-X
the	B-X
accumulation	B-X
of	B-X
proliferative	B-X
cells	B-X
at	B-X
the	B-X
distal	B-X
tip	B-X
but	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
overall	B-X
rate	B-X
of	B-X
proliferation	B-X
or	B-X
apoptosis	B-X
<EOS>	B-X
Studies	B-X
revealed	B-X
that	B-X
photobiomodulation	B-X
(	B-X
PBM	B-X
)	B-X
can	B-X
change	B-X
the	B-X
polarization	B-X
state	B-X
of	B-X
macrophages	B-X
and	B-X
inflammation	B-X
reduction	B-X
,	B-X
although	B-X
the	B-X
cellular	B-X
mechanisms	B-X
are	B-X
not	B-X
fully	B-X
elucidated	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
local	B-X
contact	B-X
-	B-X
mediated	B-X
cell	B-X
-	B-X
cell	B-X
interactions	B-X
utilize	B-X
inherent	B-X
asymmetry	B-X
in	B-X
the	B-X
response	B-X
of	B-X
patterning	B-X
genes	B-X
to	B-X
the	B-X
global	B-X
morphogen	B-X
signal	B-X
yielding	B-X
a	B-X
bimodal	B-X
response	B-X
<EOS>	B-X
Generally	B-X
,	B-X
the	B-X
membrane	B-X
lipid	B-X
compositions	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
membrane	B-X
fusion	B-X
by	B-X
modulating	B-X
the	B-X
membrane	B-X
's	B-X
physical	B-X
properties	B-X
and	B-X
the	B-X
behavior	B-X
of	B-X
membrane	B-X
proteins	B-X
in	B-X
the	B-X
cellular	B-X
milieu	B-X

Exposure	O
of	O
the	O
patient	O
's	O
blast	B-cell_type
cells	I-cell_type
to	O
E2	O
in	O
vitro	O
resulted	O
in	O
cessation	O
of	O
cell	O
growth	O
following	O
at	O
least	O
one	O
mitosis	O
after	O
addition	O
of	O
the	O
inducer	O
as	O
seen	O
from	O
the	O
replacement	O
of	O
the	O
large	B-cell_type
blasts	I-cell_type
by	O
small	O
CLL-like	B-cell_type
cells	I-cell_type
without	O
definite	O
signs	O
of	O
alteration	O
of	O
the	O
differentiation	O
status	O
.	O
<EOS>	B-X
Exposure	B-X
of	B-X
the	B-X
patient	B-X
's	B-X
blast	B-X
cells	B-X
to	B-X
E2	B-X
in	B-X
vitro	B-X
resulted	B-X
in	B-X
cessation	B-X
of	B-X
cell	B-X
growth	B-X
following	B-X
at	B-X
least	B-X
one	B-X
mitosis	B-X
after	B-X
addition	B-X
of	B-X
the	B-X
inducer	B-X
as	B-X
seen	B-X
from	B-X
the	B-X
replacement	B-X
of	B-X
the	B-X
large	B-X
blasts	B-X
by	B-X
small	B-X
CLL	B-X
-	B-X
like	B-X
cells	B-X
without	B-X
definite	B-X
signs	B-X
of	B-X
alteration	B-X
of	B-X
the	B-X
differentiation	B-X
status	B-X
<EOS>	B-X
The	B-X
functional	B-X
status	B-X
of	B-X
the	B-X
steroid	B-X
receptors	B-X
was	B-X
confirmed	B-X
by	B-X
nuclear	B-X
transfer	B-X
of	B-X
the	B-X
cytoplasmic	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
upon	B-X
temperature	B-X
activation	B-X
<EOS>	B-X
Plasmacytoid	B-X
blast	B-X
crisis	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
:	B-X
effect	B-X
of	B-X
estradiol	B-X
on	B-X
growth	B-X
and	B-X
differentiation	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Since	B-X
the	B-X
rise	B-X
in	B-X
E2	B-X
-	B-X
receptor	B-X
display	B-X
paralleled	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
proliferative	B-X
activity	B-X
of	B-X
the	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
a	B-X
change	B-X
in	B-X
their	B-X
maturation	B-X
status	B-X
the	B-X
question	B-X
was	B-X
raised	B-X
as	B-X
to	B-X
whether	B-X
the	B-X
E2	B-X
-	B-X
receptor	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
physiological	B-X
marker	B-X
of	B-X
growth	B-X
rate	B-X
or	B-X
of	B-X
cellular	B-X
differentiation	B-X

This	O
suggests	O
the	O
association	O
of	O
E2-receptor	B-protein
expression	O
with	O
control	O
of	O
growth	O
rather	O
than	O
cell	O
maturation	O
.	O
<EOS>	B-X
This	B-X
suggests	B-X
the	B-X
association	B-X
of	B-X
E2	B-X
-	B-X
receptor	B-X
expression	B-X
with	B-X
control	B-X
of	B-X
growth	B-X
rather	B-X
than	B-X
cell	B-X
maturation	B-X
<EOS>	B-X
The	B-X
functional	B-X
status	B-X
of	B-X
the	B-X
steroid	B-X
receptors	B-X
was	B-X
confirmed	B-X
by	B-X
nuclear	B-X
transfer	B-X
of	B-X
the	B-X
cytoplasmic	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
upon	B-X
temperature	B-X
activation	B-X
<EOS>	B-X
Plasmacytoid	B-X
blast	B-X
crisis	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
:	B-X
effect	B-X
of	B-X
estradiol	B-X
on	B-X
growth	B-X
and	B-X
differentiation	B-X
in	B-X
vitro	B-X
.	B-X
<EOS>	B-X
Since	B-X
the	B-X
rise	B-X
in	B-X
E2	B-X
-	B-X
receptor	B-X
display	B-X
paralleled	B-X
a	B-X
large	B-X
increase	B-X
in	B-X
the	B-X
proliferative	B-X
activity	B-X
of	B-X
the	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
a	B-X
change	B-X
in	B-X
their	B-X
maturation	B-X
status	B-X
the	B-X
question	B-X
was	B-X
raised	B-X
as	B-X
to	B-X
whether	B-X
the	B-X
E2	B-X
-	B-X
receptor	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
physiological	B-X
marker	B-X
of	B-X
growth	B-X
rate	B-X
or	B-X
of	B-X
cellular	B-X
differentiation	B-X

Multiple	O
forms	O
and	O
fragments	O
of	O
cytosolic	B-protein
glucocorticoid	I-protein
receptors	I-protein
from	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
and	O
normal	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Multiple	B-X
forms	B-X
and	B-X
fragments	B-X
of	B-X
cytosolic	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
human	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
objectives	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
whether	B-X
there	B-X
are	B-X
intrinsic	B-X
structural	B-X
differences	B-X
among	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
various	B-X
types	B-X
of	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
peptidases	B-X
in	B-X
receptor	B-X
degradation	B-X
<EOS>	B-X
Agarose	B-X
filtration	B-X
and	B-X
ultracentrifugation	B-X
in	B-X
hypotonic	B-X
buffers	B-X
containing	B-X
20	B-X
mM	B-X
Na2MoO4	B-X
revealed	B-X
complexes	B-X
of	B-X
similar	B-X
size	B-X
and	B-X
shape	B-X
in	B-X
all	B-X
clinical	B-X
specimens	B-X
tested	B-X
and	B-X
two	B-X
established	B-X
leukemic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Fragmentation	B-X
of	B-X
the	B-X
oligomer	B-X
and	B-X
the	B-X
subunit	B-X
was	B-X
evident	B-X
in	B-X
some	B-X
cytosols	B-X

Therapy	O
with	O
glucocorticoids	O
is	O
generally	O
more	O
effective	O
in	O
acute	O
lymphoblastic	O
leukemia	O
than	O
in	O
other	O
types	O
of	O
human	O
leukemia	O
.	O
<EOS>	B-X
Therapy	B-X
with	B-X
glucocorticoids	B-X
is	B-X
generally	B-X
more	B-X
effective	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
than	B-X
in	B-X
other	B-X
types	B-X
of	B-X
human	B-X
leukemia	B-X
<EOS>	B-X
IGFBP	B-X
-	B-X
6	B-X
levels	B-X
in	B-X
plasma	B-X
samples	B-X
derived	B-X
both	B-X
from	B-X
children	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukaemia	B-X
and	B-X
from	B-X
patients	B-X
with	B-X
various	B-X
types	B-X
of	B-X
solid	B-X
neoplasms	B-X
were	B-X
generally	B-X
within	B-X
the	B-X
normal	B-X
range	B-X
<EOS>	B-X
Mean	B-X
and	B-X
median	B-X
cytosolic	B-X
receptor	B-X
concentrations	B-X
in	B-X
12	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
specimens	B-X
lacking	B-X
the	B-X
standard	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
T	B-X
-	B-X
cell	B-X
markers	B-X
(	B-X
``	B-X
null	B-X
cells	B-X
''	B-X
)	B-X
were	B-X
approximately	B-X
4	B-X
-	B-X
fold	B-X
higher	B-X
than	B-X
in	B-X
23	B-X
other	B-X
leukemic	B-X
cell	B-X
specimens	B-X
<EOS>	B-X
High	B-X
activities	B-X
of	B-X
peptidases	B-X
of	B-X
various	B-X
specificities	B-X
were	B-X
detected	B-X
in	B-X
leukemic	B-X
cell	B-X
cytosols	B-X
,	B-X
as	B-X
in	B-X
other	B-X
cytosols	B-X
,	B-X
by	B-X
fluorometric	B-X
assays	B-X
with	B-X
derivatives	B-X
of	B-X
7	B-X
-	B-X
amino	B-X
-	B-X
4	B-X
-	B-X
methylcoumarin	B-X

Previous	O
studies	O
,	O
however	O
,	O
have	O
not	O
revealed	O
any	O
consistent	O
relationship	O
between	O
clinical	O
responsiveness	O
and	O
the	O
cellular	O
or	O
cytosolic	O
concentration	O
of	O
glucocorticoid-binding	B-protein
sites	I-protein
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
in	B-X
headache	B-X
patients	B-X
measured	B-X
the	B-X
cerebrovascular	B-X
reactivity	B-X
(	B-X
CVR	B-X
)	B-X
in	B-X
response	B-X
to	B-X
photic	B-X
stimulation	B-X
but	B-X
they	B-X
have	B-X
yielded	B-X
contradictory	B-X
results	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
age	B-X
of	B-X
the	B-X
patients	B-X
at	B-X
the	B-X
time	B-X
of	B-X
pyeloplasty	B-X
performed	B-X
for	B-X
UPJO	B-X
and	B-X
parenchymal	B-X
recovery	B-X
<EOS>	B-X
Several	B-X
studies	B-X
have	B-X
indicated	B-X
that	B-X
intensive	B-X
care	B-X
patients	B-X
are	B-X
more	B-X
likely	B-X
than	B-X
general	B-X
patients	B-X
to	B-X
develop	B-X
pressure	B-X
injuries	B-X
<EOS>	B-X
Results	B-X
show	B-X
that	B-X
increasing	B-X
levels	B-X
of	B-X
individual	B-X
resilience	B-X
are	B-X
related	B-X
to	B-X
increasing	B-X
levels	B-X
of	B-X
managerial	B-X
identity	B-X

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
whether	O
there	O
are	O
intrinsic	O
structural	O
differences	O
among	O
the	O
glucocorticoid	B-protein
receptors	I-protein
in	O
various	O
types	O
of	O
leukemic	B-cell_type
cells	I-cell_type
and	O
normal	B-cell_type
lymphocytes	I-cell_type
and	O
to	O
investigate	O
the	O
role	O
of	O
endogenous	B-protein
peptidases	I-protein
in	O
receptor	O
degradation	O
.	O
<EOS>	B-X
The	B-X
objectives	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
whether	B-X
there	B-X
are	B-X
intrinsic	B-X
structural	B-X
differences	B-X
among	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
various	B-X
types	B-X
of	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
peptidases	B-X
in	B-X
receptor	B-X
degradation	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
intrinsic	B-X
structural	B-X
defects	B-X
in	B-X
the	B-X
receptors	B-X
are	B-X
unlikely	B-X
explanations	B-X
for	B-X
the	B-X
unresponsiveness	B-X
of	B-X
some	B-X
types	B-X
of	B-X
leukemia	B-X
to	B-X
steroid	B-X
therapy	B-X
<EOS>	B-X
Multiple	B-X
forms	B-X
and	B-X
fragments	B-X
of	B-X
cytosolic	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
human	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
,	B-X
however	B-X
,	B-X
have	B-X
not	B-X
revealed	B-X
any	B-X
consistent	B-X
relationship	B-X
between	B-X
clinical	B-X
responsiveness	B-X
and	B-X
the	B-X
cellular	B-X
or	B-X
cytosolic	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
-	B-X
binding	B-X
sites	B-X

Cytosols	O
were	O
prepared	O
from	O
fresh	B-cell_type
or	I-cell_type
rapidly	I-cell_type
frozen	I-cell_type
leukocytes	I-cell_type
from	O
6	O
healthy	O
adults	O
and	O
35	O
high-risk	O
leukemia	O
patients	O
(	O
median	O
white	O
blood	O
cell	O
count	O
,	O
150	O
,	O
000	O
cells/microliter	O
;	O
median	O
age	O
,	O
13	O
years	O
)	O
.	O
<EOS>	B-X
The	B-X
conditioned	B-X
medium	B-X
prepared	B-X
from	B-X
the	B-X
cells	B-X
cultured	B-X
in	B-X
a	B-X
fresh	B-X
medium	B-X
after	B-X
the	B-X
treatment	B-X
with	B-X
H2O2	B-X
had	B-X
the	B-X
FGF	B-X
-	B-X
1	B-X
-	B-X
like	B-X
activities	B-X
,	B-X
which	B-X
enhanced	B-X
cholesterol	B-X
synthesis	B-X
,	B-X
signalings	B-X
to	B-X
phosphorylate	B-X
Akt	B-X
and	B-X
ERK	B-X
,	B-X
and	B-X
apoE	B-X
secretion	B-X
<EOS>	B-X
This	B-X
simple	B-X
and	B-X
reproducible	B-X
protocol	B-X
yielded	B-X
nuclear	B-X
protein	B-X
extracts	B-X
that	B-X
were	B-X
highly	B-X
enriched	B-X
in	B-X
nuclear	B-X
proteins	B-X
with	B-X
almost	B-X
complete	B-X
removal	B-X
of	B-X
cytosolic	B-X
and	B-X
myofilament	B-X
proteins	B-X
<EOS>	B-X
Proteins	B-X
are	B-X
extracted	B-X
from	B-X
the	B-X
still	B-X
frozen	B-X
pulverised	B-X
tissue	B-X
by	B-X
addition	B-X
of	B-X
Tris	B-X
-	B-X
buffered	B-X
saline	B-X
to	B-X
obtain	B-X
the	B-X
cytosol	B-X
fraction	B-X
of	B-X
the	B-X
tumour	B-X
or	B-X
by	B-X
the	B-X
Tris	B-X
buffer	B-X
supplemented	B-X
with	B-X
the	B-X
non	B-X
-	B-X
ionic	B-X
detergent	B-X
Triton	B-X
X	B-X
-	B-X
100	B-X
,	B-X
and	B-X
,	B-X
after	B-X
high	B-X
-	B-X
speed	B-X
centrifugation	B-X
,	B-X
are	B-X
found	B-X
in	B-X
the	B-X
tissue	B-X
supernatant	B-X
<EOS>	B-X
As	B-X
the	B-X
field	B-X
of	B-X
tumour	B-X
-	B-X
associated	B-X
biomarkers	B-X
has	B-X
expanded	B-X
rapidly	B-X
over	B-X
the	B-X
last	B-X
years	B-X
,	B-X
it	B-X
has	B-X
become	B-X
increasingly	B-X
apparent	B-X
that	B-X
a	B-X
strong	B-X
need	B-X
exists	B-X
to	B-X
establish	B-X
guidelines	B-X
on	B-X
how	B-X
to	B-X
easily	B-X
disintegrate	B-X
the	B-X
tumour	B-X
tissue	B-X
for	B-X
assessment	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
tumour	B-X
tissue	B-X
-	B-X
associated	B-X
biomarkers	B-X

Receptors	O
were	O
labeled	O
with	O
[	O
3H	O
]	O
triamcinolone	O
acetonide	O
and	O
quantitated	O
by	O
charcoal-dextran	O
treatment	O
or	O
Sephadex	O
LH-20	O
chromatography	O
.	O
<EOS>	B-X
The	B-X
high	B-X
Fischer	B-X
(	B-X
F	B-X
)	B-X
ratio	B-X
hemp	B-X
peptide	B-X
(	B-X
HFHP	B-X
)	B-X
was	B-X
prepared	B-X
by	B-X
enrichment	B-X
using	B-X
activated	B-X
carbon	B-X
adsorption	B-X
,	B-X
ultrafiltration	B-X
,	B-X
and	B-X
Sephadex	B-X
G	B-X
-	B-X
25	B-X
gel	B-X
filtration	B-X
chromatography	B-X
<EOS>	B-X
Ten	B-X
lignans	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
ethanol	B-X
extract	B-X
of	B-X
stems	B-X
and	B-X
branches	B-X
of	B-X
Rhododendron	B-X
ovatum	B-X
through	B-X
column	B-X
chromatography	B-X
over	B-X
silica	B-X
gel	B-X
,	B-X
ODS	B-X
,	B-X
Sephadex	B-X
LH	B-X
-	B-X
20	B-X
,	B-X
and	B-X
MCI	B-X
-	B-X
gel	B-X
resin	B-X
and	B-X
semi	B-X
-	B-X
preparative	B-X
RP	B-X
-	B-X
HPLC	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
improve	B-X
the	B-X
antioxidant	B-X
activity	B-X
of	B-X
chestnut	B-X
polysaccharide	B-X
,	B-X
chestnut	B-X
polysaccharide	B-X
(	B-X
CP	B-X
)	B-X
was	B-X
extracted	B-X
by	B-X
ultrasonic	B-X
-	B-X
assisted	B-X
water	B-X
extraction	B-X
and	B-X
alcohol	B-X
precipitation	B-X
and	B-X
purified	B-X
by	B-X
cellulose	B-X
DEAE	B-X
-	B-X
52	B-X
exchange	B-X
and	B-X
Sephadex	B-X
G	B-X
-	B-X
100	B-X
chromatography	B-X
in	B-X
this	B-X
study	B-X
<EOS>	B-X
Antiproliferative	B-X
activity	B-X
of	B-X
antimicrobial	B-X
peptides	B-X
and	B-X
bioactive	B-X
compounds	B-X
from	B-X
the	B-X
mangrove	B-X

Mean	O
and	O
median	O
cytosolic	O
receptor	O
concentrations	O
in	O
12	O
acute	O
lymphoblastic	O
leukemia	O
specimens	O
lacking	O
the	O
standard	O
B-cell	O
or	O
T-cell	O
markers	O
(	O
``	O
null	O
cells	O
''	O
)	O
were	O
approximately	O
4-fold	O
higher	O
than	O
in	O
23	O
other	O
leukemic	B-cell_type
cell	I-cell_type
specimens	I-cell_type
.	O
<EOS>	B-X
Mean	B-X
and	B-X
median	B-X
cytosolic	B-X
receptor	B-X
concentrations	B-X
in	B-X
12	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
specimens	B-X
lacking	B-X
the	B-X
standard	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
T	B-X
-	B-X
cell	B-X
markers	B-X
(	B-X
``	B-X
null	B-X
cells	B-X
''	B-X
)	B-X
were	B-X
approximately	B-X
4	B-X
-	B-X
fold	B-X
higher	B-X
than	B-X
in	B-X
23	B-X
other	B-X
leukemic	B-X
cell	B-X
specimens	B-X
<EOS>	B-X
Receptor	B-X
cleavage	B-X
by	B-X
these	B-X
and	B-X
other	B-X
endogenous	B-X
enzymes	B-X
may	B-X
account	B-X
for	B-X
previous	B-X
observations	B-X
of	B-X
``	B-X
abnormal	B-X
''	B-X
receptors	B-X
in	B-X
cytosols	B-X
from	B-X
some	B-X
leukemic	B-X
specimens	B-X
<EOS>	B-X
Agarose	B-X
filtration	B-X
and	B-X
ultracentrifugation	B-X
in	B-X
hypotonic	B-X
buffers	B-X
containing	B-X
20	B-X
mM	B-X
Na2MoO4	B-X
revealed	B-X
complexes	B-X
of	B-X
similar	B-X
size	B-X
and	B-X
shape	B-X
in	B-X
all	B-X
clinical	B-X
specimens	B-X
tested	B-X
and	B-X
two	B-X
established	B-X
leukemic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Therapy	B-X
with	B-X
glucocorticoids	B-X
is	B-X
generally	B-X
more	B-X
effective	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
than	B-X
in	B-X
other	B-X
types	B-X
of	B-X
human	B-X
leukemia	B-X

No	O
other	O
consistent	O
differences	O
in	O
receptor	O
content	O
were	O
observed	O
.	O
<EOS>	B-X
These	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
role	B-X
for	B-X
CD23	B-X
in	B-X
many	B-X
species	B-X
as	B-X
a	B-X
receptor	B-X
for	B-X
potentially	B-X
pathogenic	B-X
microorganisms	B-X
as	B-X
well	B-X
as	B-X
IgE	B-X
<EOS>	B-X
These	B-X
mutant	B-X
-	B-X
specific	B-X
genes	B-X
showed	B-X
consistent	B-X
differential	B-X
expression	B-X
across	B-X
ER	B-X
-	B-X
mutant	B-X
lines	B-X
developed	B-X
in	B-X
other	B-X
laboratories	B-X
<EOS>	B-X
Global	B-X
NMR	B-X
metabolomics	B-X
was	B-X
used	B-X
to	B-X
elucidate	B-X
differences	B-X
in	B-X
the	B-X
metabolome	B-X
between	B-X
untreated	B-X
and	B-X
(	B-X
R	B-X
,	B-X
R	B-X
'	B-X
)	B-X
	B-X
-	B-X
MNF	B-X
-	B-X
treated	B-X
cells	B-X
<EOS>	B-X
However	B-X
,	B-X
much	B-X
is	B-X
still	B-X
unclear	B-X
regarding	B-X
the	B-X
effect	B-X
of	B-X
mutant	B-X
ER	B-X
beyond	B-X
its	B-X
estrogen	B-X
independence	B-X

Agarose	O
filtration	O
and	O
ultracentrifugation	O
in	O
hypotonic	O
buffers	O
containing	O
20	O
mM	O
Na2MoO4	O
revealed	O
complexes	O
of	O
similar	O
size	O
and	O
shape	O
in	O
all	O
clinical	O
specimens	O
tested	O
and	O
two	O
established	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
Agarose	B-X
filtration	B-X
and	B-X
ultracentrifugation	B-X
in	B-X
hypotonic	B-X
buffers	B-X
containing	B-X
20	B-X
mM	B-X
Na2MoO4	B-X
revealed	B-X
complexes	B-X
of	B-X
similar	B-X
size	B-X
and	B-X
shape	B-X
in	B-X
all	B-X
clinical	B-X
specimens	B-X
tested	B-X
and	B-X
two	B-X
established	B-X
leukemic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Multiple	B-X
forms	B-X
and	B-X
fragments	B-X
of	B-X
cytosolic	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
human	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
intrinsic	B-X
structural	B-X
defects	B-X
in	B-X
the	B-X
receptors	B-X
are	B-X
unlikely	B-X
explanations	B-X
for	B-X
the	B-X
unresponsiveness	B-X
of	B-X
some	B-X
types	B-X
of	B-X
leukemia	B-X
to	B-X
steroid	B-X
therapy	B-X
<EOS>	B-X
Mean	B-X
and	B-X
median	B-X
cytosolic	B-X
receptor	B-X
concentrations	B-X
in	B-X
12	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
specimens	B-X
lacking	B-X
the	B-X
standard	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
T	B-X
-	B-X
cell	B-X
markers	B-X
(	B-X
``	B-X
null	B-X
cells	B-X
''	B-X
)	B-X
were	B-X
approximately	B-X
4	B-X
-	B-X
fold	B-X
higher	B-X
than	B-X
in	B-X
23	B-X
other	B-X
leukemic	B-X
cell	B-X
specimens	B-X

They	O
had	O
Stokes	O
radii	O
(	O
Rs	O
)	O
of	O
8.1	O
+/-	O
0.5	O
(	O
S.D.	O
)	O
nm	O
(	O
n	O
=	O
50	O
)	O
,	O
sedimentation	O
coefficients	O
of	O
9.5	O
+/-	O
0.3S	O
(	O
n	O
=	O
40	O
)	O
,	O
molecular	O
weights	O
of	O
approximately	O
330	O
,	O
000	O
,	O
and	O
axial	O
ratios	O
(	O
a/b	O
)	O
of	O
approximately	O
12	O
.	O

In	O
hypertonic	O
,	O
molybdate-free	O
buffer	O
,	O
these	O
oligomeric	B-protein
complexes	I-protein
were	O
dissociated	O
into	O
subunits	O
with	O
Rs	O
of	O
5.9	O
+/-	O
0.3	O
nm	O
(	O
n	O
=	O
12	O
)	O
and	O
a/b	O
of	O
11	O
to	O
12	O
,	O
as	O
observed	O
previously	O
for	O
other	O
receptors	O
.	O

Fragmentation	O
of	O
the	O
oligomer	B-protein
and	O
the	O
subunit	B-protein
was	O
evident	O
in	O
some	O
cytosols	O
.	O
<EOS>	B-X
Fragmentation	B-X
of	B-X
the	B-X
oligomer	B-X
and	B-X
the	B-X
subunit	B-X
was	B-X
evident	B-X
in	B-X
some	B-X
cytosols	B-X
<EOS>	B-X
In	B-X
hypertonic	B-X
,	B-X
molybdate	B-X
-	B-X
free	B-X
buffer	B-X
,	B-X
these	B-X
oligomeric	B-X
complexes	B-X
were	B-X
dissociated	B-X
into	B-X
subunits	B-X
with	B-X
Rs	B-X
of	B-X
5	B-X
<EOS>	B-X
Multiple	B-X
forms	B-X
and	B-X
fragments	B-X
of	B-X
cytosolic	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
human	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Therapy	B-X
with	B-X
glucocorticoids	B-X
is	B-X
generally	B-X
more	B-X
effective	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
than	B-X
in	B-X
other	B-X
types	B-X
of	B-X
human	B-X
leukemia	B-X

High	O
activities	O
of	O
peptidases	B-protein
of	O
various	O
specificities	O
were	O
detected	O
in	O
leukemic	O
cell	O
cytosols	O
,	O
as	O
in	O
other	O
cytosols	O
,	O
by	O
fluorometric	O
assays	O
with	O
derivatives	O
of	O
7-amino-4-methylcoumarin	O
.	O
<EOS>	B-X
High	B-X
activities	B-X
of	B-X
peptidases	B-X
of	B-X
various	B-X
specificities	B-X
were	B-X
detected	B-X
in	B-X
leukemic	B-X
cell	B-X
cytosols	B-X
,	B-X
as	B-X
in	B-X
other	B-X
cytosols	B-X
,	B-X
by	B-X
fluorometric	B-X
assays	B-X
with	B-X
derivatives	B-X
of	B-X
7	B-X
-	B-X
amino	B-X
-	B-X
4	B-X
-	B-X
methylcoumarin	B-X
<EOS>	B-X
Therapy	B-X
with	B-X
glucocorticoids	B-X
is	B-X
generally	B-X
more	B-X
effective	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
than	B-X
in	B-X
other	B-X
types	B-X
of	B-X
human	B-X
leukemia	B-X
<EOS>	B-X
The	B-X
objectives	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
whether	B-X
there	B-X
are	B-X
intrinsic	B-X
structural	B-X
differences	B-X
among	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
various	B-X
types	B-X
of	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
peptidases	B-X
in	B-X
receptor	B-X
degradation	B-X
<EOS>	B-X
Multiple	B-X
forms	B-X
and	B-X
fragments	B-X
of	B-X
cytosolic	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
human	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
.	B-X

Receptor	O
cleavage	O
by	O
these	O
and	O
other	O
endogenous	B-protein
enzymes	I-protein
may	O
account	O
for	O
previous	O
observations	O
of	O
``	O
abnormal	O
''	O
receptors	O
in	O
cytosols	O
from	O
some	O
leukemic	B-cell_type
specimens	I-cell_type
.	O
<EOS>	B-X
Receptor	B-X
cleavage	B-X
by	B-X
these	B-X
and	B-X
other	B-X
endogenous	B-X
enzymes	B-X
may	B-X
account	B-X
for	B-X
previous	B-X
observations	B-X
of	B-X
``	B-X
abnormal	B-X
''	B-X
receptors	B-X
in	B-X
cytosols	B-X
from	B-X
some	B-X
leukemic	B-X
specimens	B-X
<EOS>	B-X
Multiple	B-X
forms	B-X
and	B-X
fragments	B-X
of	B-X
cytosolic	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
human	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
objectives	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
whether	B-X
there	B-X
are	B-X
intrinsic	B-X
structural	B-X
differences	B-X
among	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
various	B-X
types	B-X
of	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
peptidases	B-X
in	B-X
receptor	B-X
degradation	B-X
<EOS>	B-X
Mean	B-X
and	B-X
median	B-X
cytosolic	B-X
receptor	B-X
concentrations	B-X
in	B-X
12	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
specimens	B-X
lacking	B-X
the	B-X
standard	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
T	B-X
-	B-X
cell	B-X
markers	B-X
(	B-X
``	B-X
null	B-X
cells	B-X
''	B-X
)	B-X
were	B-X
approximately	B-X
4	B-X
-	B-X
fold	B-X
higher	B-X
than	B-X
in	B-X
23	B-X
other	B-X
leukemic	B-X
cell	B-X
specimens	B-X

We	O
conclude	O
that	O
intrinsic	O
structural	O
defects	O
in	O
the	O
receptors	O
are	O
unlikely	O
explanations	O
for	O
the	O
unresponsiveness	O
of	O
some	O
types	O
of	O
leukemia	O
to	O
steroid	O
therapy	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
intrinsic	B-X
structural	B-X
defects	B-X
in	B-X
the	B-X
receptors	B-X
are	B-X
unlikely	B-X
explanations	B-X
for	B-X
the	B-X
unresponsiveness	B-X
of	B-X
some	B-X
types	B-X
of	B-X
leukemia	B-X
to	B-X
steroid	B-X
therapy	B-X
<EOS>	B-X
The	B-X
objectives	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
whether	B-X
there	B-X
are	B-X
intrinsic	B-X
structural	B-X
differences	B-X
among	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
various	B-X
types	B-X
of	B-X
leukemic	B-X
cells	B-X
and	B-X
normal	B-X
lymphocytes	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
peptidases	B-X
in	B-X
receptor	B-X
degradation	B-X
<EOS>	B-X
No	B-X
other	B-X
consistent	B-X
differences	B-X
in	B-X
receptor	B-X
content	B-X
were	B-X
observed	B-X
<EOS>	B-X
Mean	B-X
and	B-X
median	B-X
cytosolic	B-X
receptor	B-X
concentrations	B-X
in	B-X
12	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
specimens	B-X
lacking	B-X
the	B-X
standard	B-X
B	B-X
-	B-X
cell	B-X
or	B-X
T	B-X
-	B-X
cell	B-X
markers	B-X
(	B-X
``	B-X
null	B-X
cells	B-X
''	B-X
)	B-X
were	B-X
approximately	B-X
4	B-X
-	B-X
fold	B-X
higher	B-X
than	B-X
in	B-X
23	B-X
other	B-X
leukemic	B-X
cell	B-X
specimens	B-X

Glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
intracellular	O
water	O
space	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
number	B-X
and	B-X
intracellular	B-X
water	B-X
space	B-X
.	B-X
<EOS>	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
comparisons	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
are	B-X
best	B-X
made	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
intracellular	B-X
receptor	B-X
concentrations	B-X
<EOS>	B-X
The	B-X
cellular	B-X
water	B-X
space	B-X
was	B-X
measured	B-X
with	B-X
3H2O	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
number	B-X
was	B-X
measured	B-X
in	B-X
a	B-X
whole	B-X
-	B-X
cell	B-X
binding	B-X
assay	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
at	B-X
30	B-X
and	B-X
37	B-X
degrees	B-X
C	B-X
<EOS>	B-X
The	B-X
intracellular	B-X
water	B-X
phase	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
around	B-X
40	B-X
nmol	B-X
/	B-X
l	B-X
cell	B-X
water	B-X
)	B-X
,	B-X
and	B-X
the	B-X
dependence	B-X
of	B-X
receptor	B-X
affinity	B-X
on	B-X
temperature	B-X
were	B-X
similar	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
rodent	B-X
and	B-X
human	B-X
cells	B-X

In	O
order	O
to	O
elucidate	O
the	O
relationship	O
between	O
cell	O
water	O
content	O
and	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
,	O
eleven	O
normal	O
and	O
malignant	B-cell_type
lymphoid	I-cell_type
or	I-cell_type
myelomonocytic	I-cell_type
cell	I-cell_type
types	I-cell_type
originating	O
from	O
mouse	O
,	O
rat	O
and	O
man	O
were	O
investigated	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
between	B-X
cell	B-X
water	B-X
content	B-X
and	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
,	B-X
eleven	B-X
normal	B-X
and	B-X
malignant	B-X
lymphoid	B-X
or	B-X
myelomonocytic	B-X
cell	B-X
types	B-X
originating	B-X
from	B-X
mouse	B-X
,	B-X
rat	B-X
and	B-X
man	B-X
were	B-X
investigated	B-X
<EOS>	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
comparisons	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
are	B-X
best	B-X
made	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
intracellular	B-X
receptor	B-X
concentrations	B-X
<EOS>	B-X
The	B-X
cellular	B-X
water	B-X
space	B-X
was	B-X
measured	B-X
with	B-X
3H2O	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
number	B-X
was	B-X
measured	B-X
in	B-X
a	B-X
whole	B-X
-	B-X
cell	B-X
binding	B-X
assay	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
at	B-X
30	B-X
and	B-X
37	B-X
degrees	B-X
C	B-X
<EOS>	B-X
The	B-X
intracellular	B-X
water	B-X
phase	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
around	B-X
40	B-X
nmol	B-X
/	B-X
l	B-X
cell	B-X
water	B-X
)	B-X
,	B-X
and	B-X
the	B-X
dependence	B-X
of	B-X
receptor	B-X
affinity	B-X
on	B-X
temperature	B-X
were	B-X
similar	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
rodent	B-X
and	B-X
human	B-X
cells	B-X

The	O
cellular	O
water	O
space	O
was	O
measured	O
with	O
3H2O	O
,	O
and	O
glucocorticoid	B-protein
receptor	I-protein
number	O
was	O
measured	O
in	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	O
at	O
30	O
and	O
37	O
degrees	O
C	O
.	O

The	O
intracellular	O
water	O
phase	O
concentration	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
around	O
40	O
nmol/l	O
cell	O
water	O
)	O
,	O
and	O
the	O
dependence	O
of	O
receptor	O
affinity	O
on	O
temperature	O
were	O
similar	O
in	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
rodent	I-cell_type
and	I-cell_type
human	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
intracellular	B-X
water	B-X
phase	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
around	B-X
40	B-X
nmol	B-X
/	B-X
l	B-X
cell	B-X
water	B-X
)	B-X
,	B-X
and	B-X
the	B-X
dependence	B-X
of	B-X
receptor	B-X
affinity	B-X
on	B-X
temperature	B-X
were	B-X
similar	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
rodent	B-X
and	B-X
human	B-X
cells	B-X
<EOS>	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
comparisons	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
are	B-X
best	B-X
made	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
intracellular	B-X
receptor	B-X
concentrations	B-X
<EOS>	B-X
The	B-X
cellular	B-X
water	B-X
space	B-X
was	B-X
measured	B-X
with	B-X
3H2O	B-X
,	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
number	B-X
was	B-X
measured	B-X
in	B-X
a	B-X
whole	B-X
-	B-X
cell	B-X
binding	B-X
assay	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
at	B-X
30	B-X
and	B-X
37	B-X
degrees	B-X
C	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
between	B-X
cell	B-X
water	B-X
content	B-X
and	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
,	B-X
eleven	B-X
normal	B-X
and	B-X
malignant	B-X
lymphoid	B-X
or	B-X
myelomonocytic	B-X
cell	B-X
types	B-X
originating	B-X
from	B-X
mouse	B-X
,	B-X
rat	B-X
and	B-X
man	B-X
were	B-X
investigated	B-X

It	O
is	O
concluded	O
that	O
comparisons	O
of	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
are	O
best	O
made	O
on	O
the	O
basis	O
of	O
intracellular	B-protein
receptor	I-protein
concentrations	O
.	O
<EOS>	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
comparisons	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
are	B-X
best	B-X
made	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
intracellular	B-X
receptor	B-X
concentrations	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
number	B-X
and	B-X
intracellular	B-X
water	B-X
space	B-X
.	B-X
<EOS>	B-X
The	B-X
intracellular	B-X
water	B-X
phase	B-X
concentration	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
around	B-X
40	B-X
nmol	B-X
/	B-X
l	B-X
cell	B-X
water	B-X
)	B-X
,	B-X
and	B-X
the	B-X
dependence	B-X
of	B-X
receptor	B-X
affinity	B-X
on	B-X
temperature	B-X
were	B-X
similar	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
rodent	B-X
and	B-X
human	B-X
cells	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
relationship	B-X
between	B-X
cell	B-X
water	B-X
content	B-X
and	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
,	B-X
eleven	B-X
normal	B-X
and	B-X
malignant	B-X
lymphoid	B-X
or	B-X
myelomonocytic	B-X
cell	B-X
types	B-X
originating	B-X
from	B-X
mouse	B-X
,	B-X
rat	B-X
and	B-X
man	B-X
were	B-X
investigated	B-X

Covalent	O
labeling	O
of	O
rat	B-cell_type
thymocyte	I-cell_type
and	O
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptor	I-protein
.	O
<EOS>	B-X
Covalent	B-X
labeling	B-X
of	B-X
rat	B-X
thymocyte	B-X
and	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
in	B-X
rat	B-X
and	B-X
human	B-X
lymphoid	B-X
cells	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
can	B-X
be	B-X
used	B-X
to	B-X
label	B-X
covalently	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
<EOS>	B-X
The	B-X
covalently	B-X
labeled	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
identified	B-X
by	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
0	B-X
<EOS>	B-X
Lymphoid	B-X
cells	B-X
contain	B-X
specific	B-X
receptors	B-X
for	B-X
glucocorticoids	B-X

Lymphoid	B-cell_type
cells	I-cell_type
contain	O
specific	O
receptors	B-protein
for	O
glucocorticoids	O
.	O
<EOS>	B-X
Noncoding	B-X
RNA	B-X
gas5	B-X
is	B-X
a	B-X
growth	B-X
arrest	B-X
-	B-X
	B-X
and	B-X
starvation	B-X
-	B-X
associated	B-X
repressor	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Cell	B-X
-	B-X
intrinsic	B-X
regulation	B-X
of	B-X
murine	B-X
dendritic	B-X
cell	B-X
function	B-X
and	B-X
survival	B-X
by	B-X
prereceptor	B-X
amplification	B-X
of	B-X
glucocorticoid	B-X
.	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
the	B-X
study	B-X
indicates	B-X
a	B-X
role	B-X
of	B-X
thymus	B-X
-	B-X
derived	B-X
glucocorticoids	B-X
in	B-X
this	B-X
modulation	B-X
<EOS>	B-X
Intracellular	B-X
molecular	B-X
signaling	B-X
.	B-X
Basis	B-X
for	B-X
specificity	B-X
to	B-X
glucocorticoid	B-X
anti	B-X
-	B-X
inflammatory	B-X
actions	B-X
.	B-X

We	O
have	O
used	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
to	O
label	O
covalently	O
glucocorticoid	B-protein
receptors	I-protein
in	O
rat	B-cell_type
thymic	I-cell_type
lymphocytes	I-cell_type
and	O
in	O
neoplastic	B-cell_type
cells	I-cell_type
obtained	O
from	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
and	O
malignant	O
lymphoma	O
.	O
<EOS>	B-X
We	B-X
have	B-X
used	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
to	B-X
label	B-X
covalently	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
rat	B-X
thymic	B-X
lymphocytes	B-X
and	B-X
in	B-X
neoplastic	B-X
cells	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
and	B-X
malignant	B-X
lymphoma	B-X
<EOS>	B-X
The	B-X
covalently	B-X
labeled	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
identified	B-X
by	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
0	B-X
<EOS>	B-X
Approximately	B-X
35	B-X
%	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
can	B-X
be	B-X
labeled	B-X
covalently	B-X
when	B-X
intact	B-X
thymocytes	B-X
are	B-X
treated	B-X
with	B-X
100	B-X
nM	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
for	B-X
30	B-X
min	B-X
at	B-X
4	B-X
degrees	B-X
<EOS>	B-X
In	B-X
cytosolic	B-X
fractions	B-X
prepared	B-X
from	B-X
rat	B-X
thymic	B-X
lymphocytes	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
labels	B-X
a	B-X
protein	B-X
(	B-X
Mr	B-X
approximately	B-X
equal	B-X
to	B-X
95,000	B-X
)	B-X
which	B-X
was	B-X
identified	B-X
as	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
by	B-X
the	B-X
following	B-X
criteria	B-X
:	B-X
(	B-X
a	B-X
)	B-X
labeling	B-X
of	B-X
this	B-X
moiety	B-X
is	B-X
inhibited	B-X
by	B-X
treatment	B-X
with	B-X
a	B-X
100	B-X
-	B-X
fold	B-X
molar	B-X
excess	B-X
of	B-X
glucocorticoids	B-X
,	B-X
such	B-X
as	B-X
dexamethasone	B-X
and	B-X
triamcinolone	B-X
acetonide	B-X
;	B-X
and	B-X
(	B-X
b	B-X
)	B-X
the	B-X
covalently	B-X
labeled	B-X
Mr	B-X
approximately	B-X
equal	B-X
to	B-X
95,000	B-X
protein	B-X
is	B-X
activated	B-X
(	B-X
by	B-X
heating	B-X
at	B-X
20	B-X
degrees	B-X
for	B-X
30	B-X
min	B-X
)	B-X
to	B-X
a	B-X
form	B-X
that	B-X
binds	B-X
to	B-X
DNA	B-X
-	B-X
cellulose	B-X

The	O
covalently	O
labeled	O
glucocorticoid	B-protein
receptors	I-protein
were	O
identified	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
in	O
the	O
presence	O
of	O
0.1	O
%	O
sodium	O
dodecyl	O
sulfate	O
)	O
.	O
<EOS>	B-X
The	B-X
covalently	B-X
labeled	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
identified	B-X
by	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
0	B-X
<EOS>	B-X
Approximately	B-X
35	B-X
%	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
can	B-X
be	B-X
labeled	B-X
covalently	B-X
when	B-X
intact	B-X
thymocytes	B-X
are	B-X
treated	B-X
with	B-X
100	B-X
nM	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
for	B-X
30	B-X
min	B-X
at	B-X
4	B-X
degrees	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
to	B-X
label	B-X
covalently	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
rat	B-X
thymic	B-X
lymphocytes	B-X
and	B-X
in	B-X
neoplastic	B-X
cells	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
and	B-X
malignant	B-X
lymphoma	B-X
<EOS>	B-X
Covalent	B-X
labeling	B-X
of	B-X
rat	B-X
thymocyte	B-X
and	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X

In	O
cytosolic	O
fractions	O
prepared	O
from	O
rat	B-cell_type
thymic	I-cell_type
lymphocytes	I-cell_type
,	O
[	O
3H	O
]	O
-dexamethasone-21-mesylate	O
labels	O
a	O
protein	O
(	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
)	O
which	O
was	O
identified	O
as	O
the	O
glucocorticoid	B-protein
receptor	I-protein
by	O
the	O
following	O
criteria	O
:	O
(	O
a	O
)	O
labeling	O
of	O
this	O
moiety	O
is	O
inhibited	O
by	O
treatment	O
with	O
a	O
100-fold	O
molar	O
excess	O
of	O
glucocorticoids	O
,	O
such	O
as	O
dexamethasone	O
and	O
triamcinolone	O
acetonide	O
;	O
and	O
(	O
b	O
)	O
the	O
covalently	O
labeled	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
protein	O
is	O
activated	O
(	O
by	O
heating	O
at	O
20	O
degrees	O
for	O
30	O
min	O
)	O
to	O
a	O
form	O
that	O
binds	O
to	O
DNA-cellulose	O
.	O

When	O
intact	B-cell_type
thymocytes	I-cell_type
are	O
treated	O
with	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
,	O
an	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
moiety	O
is	O
also	O
labeled	O
covalently	O
.	O

Approximately	O
35	O
%	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
labeled	O
covalently	O
when	O
intact	O
thymocytes	B-cell_type
are	O
treated	O
with	O
100	O
nM	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
for	O
30	O
min	O
at	O
4	O
degrees	O
.	O

Neoplastic	B-cell_type
cells	I-cell_type
from	O
acute	O
lymphoblastic	O
leukemia	O
and	O
malignant	O
lymphoma	O
were	O
treated	O
with	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
.	O
<EOS>	B-X
Neoplastic	B-X
cells	B-X
from	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
and	B-X
malignant	B-X
lymphoma	B-X
were	B-X
treated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
<EOS>	B-X
Approximately	B-X
35	B-X
%	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptors	B-X
can	B-X
be	B-X
labeled	B-X
covalently	B-X
when	B-X
intact	B-X
thymocytes	B-X
are	B-X
treated	B-X
with	B-X
100	B-X
nM	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
for	B-X
30	B-X
min	B-X
at	B-X
4	B-X
degrees	B-X
<EOS>	B-X
Covalent	B-X
labeling	B-X
of	B-X
rat	B-X
thymocyte	B-X
and	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
to	B-X
label	B-X
covalently	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
rat	B-X
thymic	B-X
lymphocytes	B-X
and	B-X
in	B-X
neoplastic	B-X
cells	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
and	B-X
malignant	B-X
lymphoma	B-X

In	O
all	O
samples	O
,	O
an	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
moiety	O
was	O
labeled	O
covalently	O
;	O
labeling	O
was	O
inhibited	O
by	O
excess	O
glucocorticoid	O
.	O

Smaller	B-protein
moieties	I-protein
were	O
also	O
identified	O
by	O
competition	O
experiments	O
;	O
these	O
may	O
represent	O
proteolytic	B-protein
fragments	I-protein
of	O
the	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
receptor	O
.	O
<EOS>	B-X
Smaller	B-X
moieties	B-X
were	B-X
also	B-X
identified	B-X
by	B-X
competition	B-X
experiments	B-X
;	B-X
these	B-X
may	B-X
represent	B-X
proteolytic	B-X
fragments	B-X
of	B-X
the	B-X
Mr	B-X
approximately	B-X
equal	B-X
to	B-X
95,000	B-X
receptor	B-X
<EOS>	B-X
The	B-X
covalently	B-X
labeled	B-X
glucocorticoid	B-X
receptors	B-X
were	B-X
identified	B-X
by	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
0	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
to	B-X
label	B-X
covalently	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
rat	B-X
thymic	B-X
lymphocytes	B-X
and	B-X
in	B-X
neoplastic	B-X
cells	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
and	B-X
malignant	B-X
lymphoma	B-X
<EOS>	B-X
Thus	B-X
,	B-X
in	B-X
rat	B-X
and	B-X
human	B-X
lymphoid	B-X
cells	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
can	B-X
be	B-X
used	B-X
to	B-X
label	B-X
covalently	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X

Thus	O
,	O
in	O
rat	B-cell_type
and	I-cell_type
human	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	O
can	O
be	O
used	O
to	O
label	O
covalently	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O
<EOS>	B-X
Thus	B-X
,	B-X
in	B-X
rat	B-X
and	B-X
human	B-X
lymphoid	B-X
cells	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
can	B-X
be	B-X
used	B-X
to	B-X
label	B-X
covalently	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
<EOS>	B-X
Covalent	B-X
labeling	B-X
of	B-X
rat	B-X
thymocyte	B-X
and	B-X
human	B-X
lymphoid	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
When	B-X
intact	B-X
thymocytes	B-X
are	B-X
treated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
-	B-X
21	B-X
-	B-X
mesylate	B-X
,	B-X
an	B-X
Mr	B-X
approximately	B-X
equal	B-X
to	B-X
95,000	B-X
moiety	B-X
is	B-X
also	B-X
labeled	B-X
covalently	B-X
<EOS>	B-X
Lymphoid	B-X
cells	B-X
contain	B-X
specific	B-X
receptors	B-X
for	B-X
glucocorticoids	B-X

The	O
association	O
of	O
cytosol	O
oestrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
with	O
histological	O
features	O
of	O
breast	O
cancer	O
and	O
early	O
recurrence	O
of	O
disease	O
.	O
<EOS>	B-X
The	B-X
association	B-X
of	B-X
cytosol	B-X
oestrogen	B-X
and	B-X
progesterone	B-X
receptors	B-X
with	B-X
histological	B-X
features	B-X
of	B-X
breast	B-X
cancer	B-X
and	B-X
early	B-X
recurrence	B-X
of	B-X
disease	B-X
.	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
nor	B-X
the	B-X
value	B-X
of	B-X
RPc	B-X
could	B-X
be	B-X
related	B-X
to	B-X
cellularity	B-X
or	B-X
fibrosis	B-X
<EOS>	B-X
Analysis	B-X
has	B-X
shown	B-X
a	B-X
relative	B-X
interdependence	B-X
between	B-X
the	B-X
steroid	B-X
receptor	B-X
status	B-X
of	B-X
primary	B-X
breast	B-X
cancer	B-X
and	B-X
other	B-X
prognostic	B-X
variables	B-X
such	B-X
as	B-X
histological	B-X
grade	B-X
,	B-X
lymphocytic	B-X
infiltration	B-X
and	B-X
tumour	B-X
elastosis	B-X
<EOS>	B-X
Cellularity	B-X
and	B-X
fibrosis	B-X
were	B-X
unrelated	B-X
to	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
oestrogen	B-X
receptor	B-X

Two	O
hundred	O
and	O
eighty-eight	O
primary	O
breast	O
tumours	O
were	O
examined	O
for	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	B-protein
(	I-protein
REc	I-protein
)	I-protein
and	I-protein
progesterone	I-protein
(	I-protein
RPc	I-protein
)	I-protein
receptors	I-protein
.	O
<EOS>	B-X
Two	B-X
hundred	B-X
and	B-X
eighty	B-X
-	B-X
eight	B-X
primary	B-X
breast	B-X
tumours	B-X
were	B-X
examined	B-X
for	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
oestrogen	B-X
(	B-X
REc	B-X
)	B-X
and	B-X
progesterone	B-X
(	B-X
RPc	B-X
)	B-X
receptors	B-X
<EOS>	B-X
Cellularity	B-X
and	B-X
fibrosis	B-X
were	B-X
unrelated	B-X
to	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
oestrogen	B-X
receptor	B-X
<EOS>	B-X
One	B-X
hundred	B-X
and	B-X
nineteen	B-X
patients	B-X
with	B-X
breast	B-X
cancer	B-X
had	B-X
2	B-X
or	B-X
more	B-X
lesions	B-X
removed	B-X
for	B-X
oestrogen	B-X
(	B-X
REc	B-X
)	B-X
or	B-X
progesterone	B-X
receptor	B-X
(	B-X
RPc	B-X
)	B-X
assay	B-X
,	B-X
either	B-X
synchronously	B-X
(	B-X
on	B-X
38	B-X
occasions	B-X
)	B-X
or	B-X
after	B-X
an	B-X
interval	B-X
(	B-X
on	B-X
91	B-X
occasions	B-X
)	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
nor	B-X
the	B-X
value	B-X
of	B-X
RPc	B-X
could	B-X
be	B-X
related	B-X
to	B-X
cellularity	B-X
or	B-X
fibrosis	B-X

Analysis	O
has	O
shown	O
a	O
relative	O
interdependence	O
between	O
the	O
steroid	B-protein
receptor	I-protein
status	O
of	O
primary	O
breast	O
cancer	O
and	O
other	O
prognostic	O
variables	O
such	O
as	O
histological	O
grade	O
,	O
lymphocytic	O
infiltration	O
and	O
tumour	O
elastosis	O
.	O
<EOS>	B-X
Analysis	B-X
has	B-X
shown	B-X
a	B-X
relative	B-X
interdependence	B-X
between	B-X
the	B-X
steroid	B-X
receptor	B-X
status	B-X
of	B-X
primary	B-X
breast	B-X
cancer	B-X
and	B-X
other	B-X
prognostic	B-X
variables	B-X
such	B-X
as	B-X
histological	B-X
grade	B-X
,	B-X
lymphocytic	B-X
infiltration	B-X
and	B-X
tumour	B-X
elastosis	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
RFS	B-X
of	B-X
receptor	B-X
positive	B-X
and	B-X
negative	B-X
tumours	B-X
when	B-X
the	B-X
axillary	B-X
node	B-X
status	B-X
was	B-X
taken	B-X
into	B-X
account	B-X
<EOS>	B-X
Two	B-X
hundred	B-X
and	B-X
eighty	B-X
-	B-X
eight	B-X
primary	B-X
breast	B-X
tumours	B-X
were	B-X
examined	B-X
for	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
oestrogen	B-X
(	B-X
REc	B-X
)	B-X
and	B-X
progesterone	B-X
(	B-X
RPc	B-X
)	B-X
receptors	B-X
<EOS>	B-X
The	B-X
association	B-X
of	B-X
cytosol	B-X
oestrogen	B-X
and	B-X
progesterone	B-X
receptors	B-X
with	B-X
histological	B-X
features	B-X
of	B-X
breast	B-X
cancer	B-X
and	B-X
early	B-X
recurrence	B-X
of	B-X
disease	B-X
.	B-X

There	O
were	O
significant	O
associations	O
between	O
epithelial	O
cellularity	O
,	O
stromal	O
fibrosis	O
and	O
the	O
value	O
of	O
REc	B-protein
in	O
those	O
tumours	O
in	O
which	O
the	O
receptor	O
was	O
present	O
.	O
<EOS>	B-X
There	B-X
were	B-X
significant	B-X
associations	B-X
between	B-X
epithelial	B-X
cellularity	B-X
,	B-X
stromal	B-X
fibrosis	B-X
and	B-X
the	B-X
value	B-X
of	B-X
REc	B-X
in	B-X
those	B-X
tumours	B-X
in	B-X
which	B-X
the	B-X
receptor	B-X
was	B-X
present	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
nor	B-X
the	B-X
value	B-X
of	B-X
RPc	B-X
could	B-X
be	B-X
related	B-X
to	B-X
cellularity	B-X
or	B-X
fibrosis	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
RFS	B-X
of	B-X
receptor	B-X
positive	B-X
and	B-X
negative	B-X
tumours	B-X
when	B-X
the	B-X
axillary	B-X
node	B-X
status	B-X
was	B-X
taken	B-X
into	B-X
account	B-X
<EOS>	B-X
The	B-X
association	B-X
of	B-X
cytosol	B-X
oestrogen	B-X
and	B-X
progesterone	B-X
receptors	B-X
with	B-X
histological	B-X
features	B-X
of	B-X
breast	B-X
cancer	B-X
and	B-X
early	B-X
recurrence	B-X
of	B-X
disease	B-X
.	B-X

Cellularity	O
and	O
fibrosis	O
were	O
unrelated	O
to	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	B-protein
receptor	I-protein
.	O
<EOS>	B-X
The	B-X
latter	B-X
observations	B-X
were	B-X
reversed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
exogenous	B-X
estrogen	B-X
<EOS>	B-X
Case	B-X
report	B-X
:	B-X
Response	B-X
to	B-X
endocrine	B-X
therapy	B-X
in	B-X
triple	B-X
-	B-X
negative	B-X
breast	B-X
cancer	B-X
metastases	B-X
with	B-X
altered	B-X
hormone	B-X
receptors	B-X
.	B-X
<EOS>	B-X
Three	B-X
principal	B-X
characteristics	B-X
of	B-X
TNBC	B-X
cells	B-X
are	B-X
(	B-X
i	B-X
)	B-X
extreme	B-X
aggressiveness	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
absence	B-X
of	B-X
hormones	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
growth	B-X
factor	B-X
receptors	B-X
<EOS>	B-X
BPA	B-X
exhibits	B-X
greater	B-X
binding	B-X
affinity	B-X
for	B-X
the	B-X
membrane	B-X
oestrogen	B-X
receptor	B-X
(	B-X
GPER	B-X
)	B-X
than	B-X
for	B-X
the	B-X
nuclear	B-X
oestrogen	B-X
receptors	B-X
(	B-X
ERα	B-X
and	B-X
ERβ	B-X
)	B-X

By	O
contrast	O
,	O
neither	O
the	O
presence	O
or	O
absence	O
nor	O
the	O
value	O
of	O
RPc	B-protein
could	O
be	O
related	O
to	O
cellularity	O
or	O
fibrosis	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
microstreaming	B-X
reported	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
nanoparticle	B-X
transport	B-X
,	B-X
the	B-X
formation	B-X
and	B-X
translation	B-X
of	B-X
bubble	B-X
clouds	B-X
were	B-X
found	B-X
to	B-X
be	B-X
primarily	B-X
responsible	B-X
for	B-X
the	B-X
motion	B-X
of	B-X
glass	B-X
microspheres	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
genetics	B-X
and	B-X
epigenetics	B-X
are	B-X
deeper	B-X
mechanisms	B-X
that	B-X
regulate	B-X
kidney	B-X
fibrosis	B-X
<EOS>	B-X
Echocardiography	B-X
data	B-X
indicated	B-X
that	B-X
the	B-X
values	B-X
of	B-X
LVEDd	B-X
and	B-X
LVEDs	B-X
were	B-X
reduced	B-X
and	B-X
the	B-X
values	B-X
of	B-X
FS	B-X
and	B-X
EF	B-X
were	B-X
improved	B-X
by	B-X
TE	B-X
and	B-X
RAF	B-X
significantly	B-X
<EOS>	B-X
The	B-X
bubble	B-X
clouds	B-X
were	B-X
seen	B-X
both	B-X
to	B-X
create	B-X
channels	B-X
in	B-X
the	B-X
phantom	B-X
and	B-X
to	B-X
travel	B-X
along	B-X
them	B-X
under	B-X
the	B-X
action	B-X
of	B-X
primary	B-X
acoustic	B-X
radiation	B-X
force	B-X
,	B-X
either	B-X
propelling	B-X
or	B-X
entraining	B-X
microspheres	B-X
with	B-X
them	B-X

The	O
value	O
of	O
REc	B-protein
and	O
RPc	B-protein
analysis	O
as	O
an	O
indicator	O
of	O
prognosis	O
was	O
examined	O
in	O
a	O
sub-group	O
of	O
175	O
patients	O
receiving	O
no	O
additional	O
treatment	O
following	O
mastectomy	O
.	O

Overall	O
relapse-free	O
survival	O
(	O
RFS	O
)	O
was	O
no	O
different	O
for	O
those	O
patients	O
with	O
receptors	O
compared	O
to	O
those	O
without	O
them	O
(	O
REc	B-protein
P	O
=	O
0.11	O
,	O
RPc	O
P	O
=	O
0.7	O
)	O
.	O
<EOS>	B-X
Overall	B-X
relapse	B-X
-	B-X
free	B-X
survival	B-X
(	B-X
RFS	B-X
)	B-X
was	B-X
no	B-X
different	B-X
for	B-X
those	B-X
patients	B-X
with	B-X
receptors	B-X
compared	B-X
to	B-X
those	B-X
without	B-X
them	B-X
(	B-X
REc	B-X
P	B-X
=	B-X
0	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
RFS	B-X
of	B-X
receptor	B-X
positive	B-X
and	B-X
negative	B-X
tumours	B-X
when	B-X
the	B-X
axillary	B-X
node	B-X
status	B-X
was	B-X
taken	B-X
into	B-X
account	B-X
<EOS>	B-X
Cellularity	B-X
and	B-X
fibrosis	B-X
were	B-X
unrelated	B-X
to	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
oestrogen	B-X
receptor	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
nor	B-X
the	B-X
value	B-X
of	B-X
RPc	B-X
could	B-X
be	B-X
related	B-X
to	B-X
cellularity	B-X
or	B-X
fibrosis	B-X

There	O
was	O
no	O
difference	O
in	O
RFS	O
of	O
receptor	O
positive	O
and	O
negative	O
tumours	O
when	O
the	O
axillary	O
node	O
status	O
was	O
taken	O
into	O
account	O
.	O
<EOS>	B-X
There	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
RFS	B-X
of	B-X
receptor	B-X
positive	B-X
and	B-X
negative	B-X
tumours	B-X
when	B-X
the	B-X
axillary	B-X
node	B-X
status	B-X
was	B-X
taken	B-X
into	B-X
account	B-X
<EOS>	B-X
There	B-X
were	B-X
significant	B-X
associations	B-X
between	B-X
epithelial	B-X
cellularity	B-X
,	B-X
stromal	B-X
fibrosis	B-X
and	B-X
the	B-X
value	B-X
of	B-X
REc	B-X
in	B-X
those	B-X
tumours	B-X
in	B-X
which	B-X
the	B-X
receptor	B-X
was	B-X
present	B-X
<EOS>	B-X
Analysis	B-X
has	B-X
shown	B-X
a	B-X
relative	B-X
interdependence	B-X
between	B-X
the	B-X
steroid	B-X
receptor	B-X
status	B-X
of	B-X
primary	B-X
breast	B-X
cancer	B-X
and	B-X
other	B-X
prognostic	B-X
variables	B-X
such	B-X
as	B-X
histological	B-X
grade	B-X
,	B-X
lymphocytic	B-X
infiltration	B-X
and	B-X
tumour	B-X
elastosis	B-X
<EOS>	B-X
The	B-X
value	B-X
of	B-X
REc	B-X
and	B-X
RPc	B-X
analysis	B-X
as	B-X
an	B-X
indicator	B-X
of	B-X
prognosis	B-X
was	B-X
examined	B-X
in	B-X
a	B-X
sub	B-X
-	B-X
group	B-X
of	B-X
175	B-X
patients	B-X
receiving	B-X
no	B-X
additional	B-X
treatment	B-X
following	B-X
mastectomy	B-X

Clinical	O
implications	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	O
leukemia	O
.	O
<EOS>	B-X
Clinical	B-X
implications	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
Clinical	B-X
implications	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
studies	B-X
in	B-X
childhood	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
Therapeutic	B-X
and	B-X
prognostic	B-X
implications	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
in	B-X
acute	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
The	B-X
molecular	B-X
basis	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
apoptosis	B-X
of	B-X
lymphoblastic	B-X
leukemia	B-X
cells	B-X
.	B-X

Normal	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
contain	O
glucocorticoid	B-protein
receptor	I-protein
.	O
<EOS>	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
during	B-X
thymic	B-X
reconstitution	B-X
after	B-X
glucocorticoid	B-X
treatment	B-X
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
murine	B-X
T	B-X
cells	B-X
contain	B-X
a	B-X
specific	B-X
DHEA	B-X
receptor	B-X
<EOS>	B-X
Reduced	B-X
signal	B-X
transduction	B-X
through	B-X
glucocorticoid	B-X
receptor	B-X
in	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
cell	B-X
lines	B-X
.	B-X
<EOS>	B-X
A	B-X
proportion	B-X
of	B-X
the	B-X
CD4+CD25high	B-X
T	B-X
cells	B-X
was	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
TNF	B-X
receptor	B-X
,	B-X
ICOS	B-X
,	B-X
and	B-X
FOXP3	B-X
positive	B-X

A	O
variety	O
of	O
stimuli	O
that	O
activate	O
these	O
cells	O
also	O
induce	O
increases	O
in	O
receptor	O
concentration	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
anergizing	B-X
stimuli	B-X
appear	B-X
to	B-X
activate	B-X
the	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
fyn	B-X
,	B-X
increase	B-X
intracellular	B-X
calcium	B-X
levels	B-X
,	B-X
and	B-X
activate	B-X
Rap1	B-X
<EOS>	B-X
An	B-X
amino	B-X
acid	B-X
transporter	B-X
involved	B-X
in	B-X
gastric	B-X
acid	B-X
secretion	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
transfection	B-X
of	B-X
the	B-X
bnip2	B-X
cDNA	B-X
results	B-X
in	B-X
massive	B-X
cell	B-X
death	B-X
and	B-X
Bcl	B-X
-	B-X
2	B-X
overexpression	B-X
counteracts	B-X
the	B-X
toxic	B-X
effect	B-X
of	B-X
bnip2	B-X
<EOS>	B-X
Whenever	B-X
studied	B-X
in	B-X
a	B-X
quantitative	B-X
fashion	B-X
the	B-X
hypertonic	B-X
activation	B-X
of	B-X
non	B-X
-	B-X
selective	B-X
cation	B-X
channels	B-X
is	B-X
found	B-X
to	B-X
be	B-X
the	B-X
main	B-X
mechanism	B-X
of	B-X
regulatory	B-X
volume	B-X
increase	B-X
(	B-X
RVI	B-X
)	B-X

Similar	O
glucocorticoid	B-protein
receptors	I-protein
can	O
be	O
detected	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O
<EOS>	B-X
Similar	B-X
glucocorticoid	B-X
receptors	B-X
can	B-X
be	B-X
detected	B-X
in	B-X
lymphoid	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
in	B-X
our	B-X
hands	B-X
,	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
correlate	B-X
with	B-X
the	B-X
duration	B-X
of	B-X
complete	B-X
remission	B-X
in	B-X
ALL	B-X
(	B-X
though	B-X
not	B-X
in	B-X
other	B-X
forms	B-X
of	B-X
leukemia	B-X
)	B-X
<EOS>	B-X
Absence	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
usually	B-X
found	B-X
in	B-X
treated	B-X
patients	B-X
)	B-X
predicts	B-X
lack	B-X
of	B-X
glucocorticoid	B-X
responsiveness	B-X
<EOS>	B-X
Clinical	B-X
implications	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X

Absence	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
usually	O
found	O
in	O
treated	O
patients	O
)	O
predicts	O
lack	O
of	O
glucocorticoid	O
responsiveness	O
.	O
<EOS>	B-X
Absence	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
usually	B-X
found	B-X
in	B-X
treated	B-X
patients	B-X
)	B-X
predicts	B-X
lack	B-X
of	B-X
glucocorticoid	B-X
responsiveness	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
in	B-X
our	B-X
hands	B-X
,	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
correlate	B-X
with	B-X
the	B-X
duration	B-X
of	B-X
complete	B-X
remission	B-X
in	B-X
ALL	B-X
(	B-X
though	B-X
not	B-X
in	B-X
other	B-X
forms	B-X
of	B-X
leukemia	B-X
)	B-X
<EOS>	B-X
Similar	B-X
glucocorticoid	B-X
receptors	B-X
can	B-X
be	B-X
detected	B-X
in	B-X
lymphoid	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
<EOS>	B-X
Normal	B-X
lymphoid	B-X
cells	B-X
contain	B-X
glucocorticoid	B-X
receptor	B-X

Furthermore	O
,	O
in	O
our	O
hands	O
,	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
correlate	O
with	O
the	O
duration	O
of	O
complete	O
remission	O
in	O
ALL	O
(	O
though	O
not	O
in	O
other	O
forms	O
of	O
leukemia	O
)	O
.	O

This	O
association	O
is	O
independent	O
of	O
cell	O
type	O
,	O
age	O
,	O
sex	O
,	O
or	O
initial	O
leukocyte	B-cell_type
count	O
.	O
<EOS>	B-X
The	B-X
condition	B-X
is	B-X
linked	B-X
to	B-X
sensorineural	B-X
hearing	B-X
loss	B-X
(	B-X
SNHL	B-X
)	B-X
<EOS>	B-X
AGEs	B-X
are	B-X
associated	B-X
with	B-X
some	B-X
pivotal	B-X
components	B-X
of	B-X
the	B-X
frailty	B-X
phenotype	B-X
,	B-X
although	B-X
they	B-X
are	B-X
not	B-X
associated	B-X
with	B-X
frailty	B-X
overall	B-X
<EOS>	B-X
HIV	B-X
status	B-X
was	B-X
independently	B-X
associated	B-X
with	B-X
approximately	B-X
1	B-X
<EOS>	B-X
DCX	B-X
and	B-X
GPC2	B-X
concentrations	B-X
independently	B-X
significantly	B-X
associated	B-X
with	B-X
age	B-X
,	B-X
and	B-X
their	B-X
concentration	B-X
declined	B-X
with	B-X
advancing	B-X
age	B-X
,	B-X
reaching	B-X
undetectable	B-X
levels	B-X
at	B-X
0	B-X

The	O
level	O
of	O
receptor	O
shows	O
a	O
negative	O
correlation	O
with	O
increasing	O
aggressiveness	O
of	O
the	O
tumor	O
(	O
null-cell	O
leukemia	O
greater	O
than	O
T-cell	O
leukemia	O
greater	O
than	O
Burkitt	O
's	O
lymphoma	O
)	O
.	O

Corticosteroid-mediated	O
immunoregulation	O
in	O
man	O
.	O
<EOS>	B-X
Corticosteroid	B-X
-	B-X
mediated	B-X
immunoregulation	B-X
in	B-X
man	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
mechanisms	B-X
of	B-X
the	B-X
corticosteroid	B-X
-	B-X
induced	B-X
immunoregulation	B-X
in	B-X
man	B-X
have	B-X
not	B-X
been	B-X
precisely	B-X
defined	B-X
<EOS>	B-X
Corticosteroid	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
monocyte	B-X
function	B-X
may	B-X
be	B-X
an	B-X
important	B-X
mechanism	B-X
of	B-X
drug	B-X
-	B-X
induced	B-X
immunoregulation	B-X
in	B-X
monocyte	B-X
-	B-X
dependent	B-X
responses	B-X
<EOS>	B-X
In	B-X
vitro	B-X
corticosteroids	B-X
appear	B-X
to	B-X
selectively	B-X
affect	B-X
early	B-X
immunoregulatory	B-X
events	B-X
as	B-X
opposed	B-X
to	B-X
altering	B-X
an	B-X
established	B-X
response	B-X

Glucocorticoids	O
have	O
profound	O
and	O
complex	O
effects	O
on	O
the	O
human	O
immune	O
response	O
.	O
<EOS>	B-X
Glucocorticoids	B-X
have	B-X
profound	B-X
and	B-X
complex	B-X
effects	B-X
on	B-X
the	B-X
human	B-X
immune	B-X
response	B-X
<EOS>	B-X
Glucocorticoids	B-X
induced	B-X
rapid	B-X
bone	B-X
marrow	B-X
homing	B-X
of	B-X
eosinophils	B-X
<EOS>	B-X
In	B-X
concert	B-X
with	B-X
GCs	B-X
,	B-X
elevated	B-X
levels	B-X
of	B-X
catecholamines	B-X
also	B-X
selectively	B-X
suppress	B-X
immune	B-X
response	B-X
mechanisms	B-X
<EOS>	B-X
Glucocorticoids	B-X
are	B-X
considered	B-X
first	B-X
-	B-X
line	B-X
therapy	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
eosinophilic	B-X
disorders	B-X

However	O
,	O
the	O
precise	O
mechanisms	O
of	O
the	O
corticosteroid-induced	O
immunoregulation	O
in	O
man	O
have	O
not	O
been	O
precisely	O
defined	O
.	O

Intracytoplasmic	B-protein
corticosteroid-specific	I-protein
receptors	I-protein
appear	O
to	O
be	O
an	O
important	O
common	O
pathway	O
for	O
steroid-induced	O
changes	O
,	O
but	O
variations	O
of	O
receptor	O
parameters	O
do	O
not	O
account	O
for	O
the	O
multifaceted	O
effects	O
on	O
the	O
immune	O
system	O
.	O

Human	B-cell_type
circulating	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
redistribute	O
out	O
of	O
the	O
intravascular	O
compartment	O
following	O
treatment	O
with	O
corticosteroids	O
.	O
<EOS>	B-X
Human	B-X
circulating	B-X
mononuclear	B-X
cells	B-X
redistribute	B-X
out	B-X
of	B-X
the	B-X
intravascular	B-X
compartment	B-X
following	B-X
treatment	B-X
with	B-X
corticosteroids	B-X
<EOS>	B-X
Although	B-X
certain	B-X
components	B-X
at	B-X
this	B-X
redistribution	B-X
phenomenon	B-X
have	B-X
been	B-X
well	B-X
-	B-X
characterized	B-X
,	B-X
the	B-X
importance	B-X
of	B-X
this	B-X
compartmental	B-X
cellular	B-X
shift	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
mechanisms	B-X
of	B-X
corticosteroid	B-X
-	B-X
induced	B-X
immunoregulation	B-X
are	B-X
less	B-X
well	B-X
-	B-X
defined	B-X
<EOS>	B-X
In	B-X
some	B-X
experimental	B-X
conditions	B-X
,	B-X
corticosteroids	B-X
inhibit	B-X
Interleukin	B-X
1	B-X
production	B-X
by	B-X
monocytes	B-X
<EOS>	B-X
Recent	B-X
observations	B-X
that	B-X
activated	B-X
lymphocytes	B-X
may	B-X
be	B-X
sensitive	B-X
to	B-X
the	B-X
lytic	B-X
effects	B-X
of	B-X
glucocorticoids	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
situations	B-X
the	B-X
elimination	B-X
of	B-X
selected	B-X
subsets	B-X
of	B-X
cells	B-X
may	B-X
be	B-X
a	B-X
relevant	B-X
mechanism	B-X
of	B-X
corticosteroid	B-X
-	B-X
mediated	B-X
immunoregulation	B-X
in	B-X
man	B-X

Although	O
certain	O
components	O
at	O
this	O
redistribution	O
phenomenon	O
have	O
been	O
well-characterized	O
,	O
the	O
importance	O
of	O
this	O
compartmental	O
cellular	O
shift	O
with	O
respect	O
to	O
the	O
mechanisms	O
of	O
corticosteroid-induced	O
immunoregulation	O
are	O
less	O
well-defined	O
.	O

Recent	O
observations	O
that	O
activated	B-cell_type
lymphocytes	I-cell_type
may	O
be	O
sensitive	O
to	O
the	O
lytic	O
effects	O
of	O
glucocorticoids	O
suggest	O
that	O
under	O
certain	O
situations	O
the	O
elimination	O
of	O
selected	O
subsets	O
of	O
cells	O
may	O
be	O
a	O
relevant	O
mechanism	O
of	O
corticosteroid-mediated	O
immunoregulation	O
in	O
man	O
.	O

Corticosteroid-mediated	O
effects	O
on	O
monocyte	B-cell_type
function	O
may	O
be	O
an	O
important	O
mechanism	O
of	O
drug-induced	B-cell_type
immunoregulation	I-cell_type
in	O
monocyte-dependent	B-cell_type
responses	I-cell_type
.	O
<EOS>	B-X
Corticosteroid	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
monocyte	B-X
function	B-X
may	B-X
be	B-X
an	B-X
important	B-X
mechanism	B-X
of	B-X
drug	B-X
-	B-X
induced	B-X
immunoregulation	B-X
in	B-X
monocyte	B-X
-	B-X
dependent	B-X
responses	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
mechanisms	B-X
of	B-X
the	B-X
corticosteroid	B-X
-	B-X
induced	B-X
immunoregulation	B-X
in	B-X
man	B-X
have	B-X
not	B-X
been	B-X
precisely	B-X
defined	B-X
<EOS>	B-X
Corticosteroid	B-X
-	B-X
mediated	B-X
immunoregulation	B-X
in	B-X
man	B-X
.	B-X
<EOS>	B-X
Although	B-X
certain	B-X
components	B-X
at	B-X
this	B-X
redistribution	B-X
phenomenon	B-X
have	B-X
been	B-X
well	B-X
-	B-X
characterized	B-X
,	B-X
the	B-X
importance	B-X
of	B-X
this	B-X
compartmental	B-X
cellular	B-X
shift	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
mechanisms	B-X
of	B-X
corticosteroid	B-X
-	B-X
induced	B-X
immunoregulation	B-X
are	B-X
less	B-X
well	B-X
-	B-X
defined	B-X

In	O
some	O
experimental	O
conditions	O
,	O
corticosteroids	O
inhibit	O
Interleukin	B-protein
1	I-protein
production	O
by	O
monocytes	B-cell_type
.	O
<EOS>	B-X
In	B-X
some	B-X
experimental	B-X
conditions	B-X
,	B-X
corticosteroids	B-X
inhibit	B-X
Interleukin	B-X
1	B-X
production	B-X
by	B-X
monocytes	B-X
<EOS>	B-X
The	B-X
immunoregulatory	B-X
effects	B-X
of	B-X
corticosteroids	B-X
on	B-X
lymphocyte	B-X
immune	B-X
responses	B-X
are	B-X
complex	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
mechanisms	B-X
of	B-X
the	B-X
corticosteroid	B-X
-	B-X
induced	B-X
immunoregulation	B-X
in	B-X
man	B-X
have	B-X
not	B-X
been	B-X
precisely	B-X
defined	B-X
<EOS>	B-X
interleukin	B-X
-	B-X
2	B-X
,	B-X
	B-X
-	B-X
4	B-X
,	B-X
	B-X
-	B-X
6	B-X
and	B-X
gamma	B-X
-	B-X
interferon	B-X
)	B-X
and	B-X
monocytes	B-X
(	B-X
e	B-X

The	O
immunoregulatory	O
effects	O
of	O
corticosteroids	O
on	O
lymphocyte	B-cell_type
immune	O
responses	O
are	O
complex	O
.	O
<EOS>	B-X
The	B-X
immunoregulatory	B-X
effects	B-X
of	B-X
corticosteroids	B-X
on	B-X
lymphocyte	B-X
immune	B-X
responses	B-X
are	B-X
complex	B-X
<EOS>	B-X
The	B-X
immunoregulatory	B-X
effects	B-X
of	B-X
in	B-X
vivo	B-X
CS	B-X
on	B-X
mitogen	B-X
-	B-X
induced	B-X
Ig	B-X
production	B-X
are	B-X
more	B-X
complex	B-X
<EOS>	B-X
Additive	B-X
effects	B-X
of	B-X
suboptimal	B-X
doses	B-X
of	B-X
estrogen	B-X
and	B-X
cortisone	B-X
on	B-X
the	B-X
suppression	B-X
of	B-X
T	B-X
lymphocyte	B-X
dependent	B-X
inflammatory	B-X
responses	B-X
in	B-X
mice	B-X
.	B-X
<EOS>	B-X
The	B-X
results	B-X
could	B-X
indicate	B-X
the	B-X
potential	B-X
to	B-X
use	B-X
combinations	B-X
of	B-X
corticosteroids	B-X
and	B-X
estrogen	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
T	B-X
lymphocyte	B-X
dependent	B-X
rheumatic	B-X
diseases	B-X
such	B-X
as	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X

In	O
vitro	O
corticosteroids	O
appear	O
to	O
selectively	O
affect	O
early	O
immunoregulatory	O
events	O
as	O
opposed	O
to	O
altering	O
an	O
established	O
response	O
.	O
<EOS>	B-X
In	B-X
vitro	B-X
corticosteroids	B-X
appear	B-X
to	B-X
selectively	B-X
affect	B-X
early	B-X
immunoregulatory	B-X
events	B-X
as	B-X
opposed	B-X
to	B-X
altering	B-X
an	B-X
established	B-X
response	B-X
<EOS>	B-X
Glucocorticoids	B-X
have	B-X
profound	B-X
and	B-X
complex	B-X
effects	B-X
on	B-X
the	B-X
human	B-X
immune	B-X
response	B-X
<EOS>	B-X
Intracytoplasmic	B-X
corticosteroid	B-X
-	B-X
specific	B-X
receptors	B-X
appear	B-X
to	B-X
be	B-X
an	B-X
important	B-X
common	B-X
pathway	B-X
for	B-X
steroid	B-X
-	B-X
induced	B-X
changes	B-X
,	B-X
but	B-X
variations	B-X
of	B-X
receptor	B-X
parameters	B-X
do	B-X
not	B-X
account	B-X
for	B-X
the	B-X
multifaceted	B-X
effects	B-X
on	B-X
the	B-X
immune	B-X
system	B-X
<EOS>	B-X
Corticosteroid	B-X
-	B-X
mediated	B-X
immunoregulation	B-X
in	B-X
man	B-X
.	B-X

Multiple	O
sites	O
of	O
steroid-induced	O
modulations	O
of	O
human	B-cell_type
B	I-cell_type
cell	I-cell_type
responses	O
have	O
been	O
defined	O
.	O

Human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
glucocorticoids	O
:	O
II	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
human	B-X
MC	B-X
lines	B-X
and	B-X
CB	B-X
-	B-X
MCs	B-X
constitutively	B-X
produce	B-X
GILZ	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
multiple	B-X
myeloma	B-X
survival	B-X
and	B-X
progression	B-X
by	B-X
CD1d	B-X
.	B-X
<EOS>	B-X
11β	B-X
-	B-X
hydroxysteroid	B-X
dehydrogenase	B-X
enzymes	B-X
modulate	B-X
effects	B-X
of	B-X
glucocorticoids	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
synovial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
gene	B-X
mutations	B-X
in	B-X
leukemic	B-X
cells	B-X
acquired	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

Whole	O
cell	O
and	O
cytoplasmic	O
binding	O
properties	O
of	O
lymphoblastoid	B-cell_line
,	I-cell_line
leukaemia	I-cell_line
and	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
Human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
and	B-X
glucocorticoids	B-X
:	B-X
II	B-X
.	B-X
Whole	B-X
cell	B-X
and	B-X
cytoplasmic	B-X
binding	B-X
properties	B-X
of	B-X
lymphoblastoid	B-X
,	B-X
leukaemia	B-X
and	B-X
lymphoma	B-X
lines	B-X
.	B-X
<EOS>	B-X
A	B-X
gradation	B-X
in	B-X
whole	B-X
cell	B-X
and	B-X
cytoplasmic	B-X
glucocorticoid	B-X
binding	B-X
capacity	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
different	B-X
cell	B-X
line	B-X
types	B-X
:	B-X
lymphoblastoid	B-X
greater	B-X
than	B-X
lymphoma	B-X
greater	B-X
than	B-X
leukaemia	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
binding	B-X
properties	B-X
of	B-X
18	B-X
human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
(	B-X
HLCL	B-X
)	B-X
have	B-X
been	B-X
investigated	B-X
<EOS>	B-X
The	B-X
cytoplasmic	B-X
receptors	B-X
of	B-X
leukaemia	B-X
and	B-X
lymphoblastoid	B-X
lines	B-X
appeared	B-X
to	B-X
contain	B-X
both	B-X
proteinaceous	B-X
and	B-X
phospholipid	B-X
components	B-X

The	O
glucocorticoid	O
binding	O
properties	O
of	O
18	O
human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
HLCL	B-cell_line
)	O
have	O
been	O
investigated	O
.	O
<EOS>	B-X
The	B-X
glucocorticoid	B-X
binding	B-X
properties	B-X
of	B-X
18	B-X
human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
(	B-X
HLCL	B-X
)	B-X
have	B-X
been	B-X
investigated	B-X
<EOS>	B-X
The	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
glucocorticoids	B-X
achieve	B-X
cytolethal	B-X
responses	B-X
in	B-X
human	B-X
lymphoid	B-X
cells	B-X
has	B-X
still	B-X
to	B-X
be	B-X
resolved	B-X
<EOS>	B-X
A	B-X
gradation	B-X
in	B-X
whole	B-X
cell	B-X
and	B-X
cytoplasmic	B-X
glucocorticoid	B-X
binding	B-X
capacity	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
different	B-X
cell	B-X
line	B-X
types	B-X
:	B-X
lymphoblastoid	B-X
greater	B-X
than	B-X
lymphoma	B-X
greater	B-X
than	B-X
leukaemia	B-X
<EOS>	B-X
No	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
the	B-X
level	B-X
or	B-X
nature	B-X
of	B-X
glucocorticoid	B-X
binding	B-X
and	B-X
the	B-X
cytolethal	B-X
or	B-X
cytostatic	B-X
responsiveness	B-X
of	B-X
HLCL	B-X
to	B-X
glucocorticoid	B-X
treatment	B-X
in	B-X
vitro	B-X

The	O
specificity	O
of	O
steroid	O
binding	O
was	O
confirmed	O
with	O
various	O
glucocorticoid	O
agonists	O
and	O
antagonists	O
.	O
<EOS>	B-X
The	B-X
specificity	B-X
of	B-X
steroid	B-X
binding	B-X
was	B-X
confirmed	B-X
with	B-X
various	B-X
glucocorticoid	B-X
agonists	B-X
and	B-X
antagonists	B-X
<EOS>	B-X
These	B-X
methods	B-X
may	B-X
guide	B-X
the	B-X
design	B-X
of	B-X
new	B-X
corticosteroid	B-X
agonists	B-X
and	B-X
antagonists	B-X
<EOS>	B-X
This	B-X
difference	B-X
of	B-X
activation	B-X
was	B-X
confirmed	B-X
in	B-X
a	B-X
DNA	B-X
-	B-X
cellulose	B-X
binding	B-X
assay	B-X
<EOS>	B-X
Antiprogestins	B-X
without	B-X
glucocorticoid	B-X
activity	B-X
are	B-X
being	B-X
sought	B-X

A	O
gradation	O
in	O
whole	O
cell	O
and	O
cytoplasmic	O
glucocorticoid	O
binding	O
capacity	O
was	O
observed	O
in	O
the	O
different	O
cell	O
line	O
types	O
:	O
lymphoblastoid	B-cell_line
greater	O
than	O
lymphoma	B-cell_line
greater	O
than	O
leukaemia	B-cell_line
.	O
<EOS>	B-X
A	B-X
gradation	B-X
in	B-X
whole	B-X
cell	B-X
and	B-X
cytoplasmic	B-X
glucocorticoid	B-X
binding	B-X
capacity	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
different	B-X
cell	B-X
line	B-X
types	B-X
:	B-X
lymphoblastoid	B-X
greater	B-X
than	B-X
lymphoma	B-X
greater	B-X
than	B-X
leukaemia	B-X
<EOS>	B-X
Human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
and	B-X
glucocorticoids	B-X
:	B-X
II	B-X
.	B-X
Whole	B-X
cell	B-X
and	B-X
cytoplasmic	B-X
binding	B-X
properties	B-X
of	B-X
lymphoblastoid	B-X
,	B-X
leukaemia	B-X
and	B-X
lymphoma	B-X
lines	B-X
.	B-X
<EOS>	B-X
The	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
glucocorticoids	B-X
achieve	B-X
cytolethal	B-X
responses	B-X
in	B-X
human	B-X
lymphoid	B-X
cells	B-X
has	B-X
still	B-X
to	B-X
be	B-X
resolved	B-X
<EOS>	B-X
The	B-X
glucocorticoid	B-X
binding	B-X
properties	B-X
of	B-X
18	B-X
human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
(	B-X
HLCL	B-X
)	B-X
have	B-X
been	B-X
investigated	B-X

The	O
cytoplasmic	B-protein
receptors	I-protein
of	O
leukaemia	B-cell_line
and	I-cell_line
lymphoblastoid	I-cell_line
lines	I-cell_line
appeared	O
to	O
contain	O
both	O
proteinaceous	O
and	O
phospholipid	O
components	O
.	O
<EOS>	B-X
The	B-X
cytoplasmic	B-X
receptors	B-X
of	B-X
leukaemia	B-X
and	B-X
lymphoblastoid	B-X
lines	B-X
appeared	B-X
to	B-X
contain	B-X
both	B-X
proteinaceous	B-X
and	B-X
phospholipid	B-X
components	B-X
<EOS>	B-X
Cytoplasmic	B-X
steroid	B-X
-	B-X
receptor	B-X
complexes	B-X
exhibited	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
sedimentation	B-X
coefficients	B-X
(	B-X
8	B-X
<EOS>	B-X
The	B-X
specificity	B-X
of	B-X
steroid	B-X
binding	B-X
was	B-X
confirmed	B-X
with	B-X
various	B-X
glucocorticoid	B-X
agonists	B-X
and	B-X
antagonists	B-X
<EOS>	B-X
The	B-X
resistance	B-X
to	B-X
cytolethal	B-X
effects	B-X
can	B-X
not	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
failure	B-X
of	B-X
cells	B-X
to	B-X
take	B-X
up	B-X
and	B-X
bind	B-X
steroid	B-X
or	B-X
to	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
molecular	B-X
species	B-X
of	B-X
cytoplasmic	B-X
receptors	B-X
present	B-X

Cytoplasmic	B-protein
steroid-receptor	I-protein
complexes	I-protein
exhibited	O
a	O
wide	O
range	O
of	O
sedimentation	O
coefficients	O
(	O
8.5-11.3S	O
)	O
in	O
low	O
ionic	O
strength	O
buffer	O
but	O
there	O
was	O
no	O
correlation	O
with	O
cell	O
line	O
type	O
or	O
glucocorticoid	O
sensitivity	O
.	O
<EOS>	B-X
Maternal	B-X
sensitivity	B-X
and	B-X
child	B-X
internalizing	B-X
and	B-X
externalizing	B-X
behavior	B-X
:	B-X
a	B-X
mediating	B-X
role	B-X
for	B-X
glucocorticoid	B-X
receptor	B-X
gene	B-X
(	B-X
<EOS>	B-X
However	B-X
,	B-X
this	B-X
resilience	B-X
is	B-X
lost	B-X
after	B-X
exposure	B-X
to	B-X
chronic	B-X
stress	B-X
in	B-X
adulthood	B-X
leading	B-X
to	B-X
an	B-X
exacerbation	B-X
of	B-X
visceral	B-X
hypersensitivity	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
co	B-X
-	B-X
administration	B-X
of	B-X
AZD4017	B-X
with	B-X
prednisolone	B-X
in	B-X
men	B-X
is	B-X
a	B-X
potential	B-X
strategy	B-X
to	B-X
limit	B-X
adverse	B-X
glucocorticoid	B-X
effects	B-X
<EOS>	B-X
The	B-X
prediction	B-X
model	B-X
constructed	B-X
by	B-X
the	B-X
above	B-X
mentioned	B-X
risk	B-X
factors	B-X
has	B-X
certain	B-X
predictive	B-X
value	B-X
for	B-X
the	B-X
occurrence	B-X
of	B-X
pulmonary	B-X
infection	B-X
in	B-X
elderly	B-X
neurocritical	B-X
patients	B-X

Activation	O
of	O
these	O
complexes	O
by	O
heat	O
(	O
37	O
degrees	O
C	O
)	O
or	O
exposure	O
to	O
high	O
ionic	O
strength	O
buffer	O
(	O
0.3	O
M	O
NaCl	O
)	O
induced	O
nuclear	O
binding	O
of	O
steroid	O
but	O
only	O
complexes	O
in	O
high	O
ionic	O
strength	O
buffer	O
manifested	O
changes	O
in	O
sedimentation	O
coefficient	O
.	O
<EOS>	B-X
3	B-X
M	B-X
NaCl	B-X
)	B-X
induced	B-X
nuclear	B-X
binding	B-X
of	B-X
steroid	B-X
but	B-X
only	B-X
complexes	B-X
in	B-X
high	B-X
ionic	B-X
strength	B-X
buffer	B-X
manifested	B-X
changes	B-X
in	B-X
sedimentation	B-X
coefficient	B-X
<EOS>	B-X
Activation	B-X
of	B-X
these	B-X
complexes	B-X
by	B-X
heat	B-X
(	B-X
37	B-X
degrees	B-X
C	B-X
)	B-X
or	B-X
exposure	B-X
to	B-X
high	B-X
ionic	B-X
strength	B-X
buffer	B-X
(	B-X
0	B-X
<EOS>	B-X
Cytoplasmic	B-X
steroid	B-X
-	B-X
receptor	B-X
complexes	B-X
exhibited	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
sedimentation	B-X
coefficients	B-X
(	B-X
8	B-X
<EOS>	B-X
The	B-X
resistance	B-X
to	B-X
cytolethal	B-X
effects	B-X
can	B-X
not	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
failure	B-X
of	B-X
cells	B-X
to	B-X
take	B-X
up	B-X
and	B-X
bind	B-X
steroid	B-X
or	B-X
to	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
molecular	B-X
species	B-X
of	B-X
cytoplasmic	B-X
receptors	B-X
present	B-X

No	O
correlation	O
was	O
observed	O
between	O
the	O
level	O
or	O
nature	O
of	O
glucocorticoid	O
binding	O
and	O
the	O
cytolethal	O
or	O
cytostatic	O
responsiveness	O
of	O
HLCL	B-cell_line
to	O
glucocorticoid	O
treatment	O
in	O
vitro	O
.	O
<EOS>	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
observed	B-X
between	B-X
number	B-X
of	B-X
deviations	B-X
and	B-X
type	B-X
of	B-X
study	B-X
by	B-X
investigational	B-X
product	B-X
category	B-X
<EOS>	B-X
Relationships	B-X
between	B-X
hormone	B-X
levels	B-X
,	B-X
metabolism	B-X
and	B-X
immune	B-X
response	B-X
in	B-X
toads	B-X
from	B-X
a	B-X
semi	B-X
-	B-X
arid	B-X
region	B-X
.	B-X
<EOS>	B-X
Exploring	B-X
relationships	B-X
between	B-X
exposure	B-X
to	B-X
fast	B-X
food	B-X
outlets	B-X
and	B-X
childhood	B-X
obesity	B-X
at	B-X
differing	B-X
spatial	B-X
resolutions	B-X
:	B-X
results	B-X
from	B-X
the	B-X
Born	B-X
in	B-X
Bradford	B-X
cohort	B-X
study	B-X
.	B-X
<EOS>	B-X
In	B-X
the	B-X
same	B-X
cohort	B-X
,	B-X
we	B-X
observed	B-X
the	B-X
two	B-X
main	B-X
coronary	B-X
arteries	B-X
(	B-X
common	B-X
trunk	B-X
,	B-X
circumflex	B-X
,	B-X
anterior	B-X
interventricular	B-X
and	B-X
right	B-X
coronary	B-X
heart	B-X
)	B-X
using	B-X
a	B-X
visual	B-X
score	B-X
,	B-X
so	B-X
patients	B-X
were	B-X
divided	B-X
into	B-X
four	B-X
groups	B-X
based	B-X
on	B-X
Ordinal	B-X
CAC	B-X
Score	B-X
(	B-X
OCS	B-X
)	B-X
levels	B-X

The	O
resistance	O
to	O
cytolethal	O
effects	O
can	O
not	O
be	O
ascribed	O
to	O
a	O
failure	O
of	O
cells	O
to	O
take	O
up	O
and	O
bind	O
steroid	O
or	O
to	O
significant	O
differences	O
in	O
the	O
molecular	O
species	O
of	O
cytoplasmic	B-protein
receptors	I-protein
present	O
.	O
<EOS>	B-X
The	B-X
innate	B-X
immunity	B-X
response	B-X
,	B-X
which	B-X
has	B-X
a	B-X
broad	B-X
spectrum	B-X
and	B-X
a	B-X
persistent	B-X
effect	B-X
,	B-X
is	B-X
the	B-X
basal	B-X
defence	B-X
of	B-X
plants	B-X
in	B-X
response	B-X
to	B-X
pathogens	B-X
<EOS>	B-X
In	B-X
-	B-X
vitro	B-X
assessment	B-X
of	B-X
DNase	B-X
activity	B-X
of	B-X
cloned	B-X
and	B-X
purified	B-X
CdtB	B-X
protein	B-X
showed	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
band	B-X
intensity	B-X
of	B-X
DNA	B-X
<EOS>	B-X
Kynurenine	B-X
inhibits	B-X
autophagy	B-X
and	B-X
promotes	B-X
senescence	B-X
in	B-X
aged	B-X
bone	B-X
marrow	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
through	B-X
the	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
pathway	B-X
.	B-X
<EOS>	B-X
The	B-X
different	B-X
mechanisms	B-X
and	B-X
signaling	B-X
pathways	B-X
that	B-X
change	B-X
with	B-X
age	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
development	B-X
of	B-X
osteoporosis	B-X
are	B-X
being	B-X
identified	B-X

The	O
molecular	O
mechanisms	O
by	O
which	O
glucocorticoids	O
achieve	O
cytolethal	O
responses	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
<EOS>	B-X
The	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
glucocorticoids	B-X
achieve	B-X
cytolethal	B-X
responses	B-X
in	B-X
human	B-X
lymphoid	B-X
cells	B-X
has	B-X
still	B-X
to	B-X
be	B-X
resolved	B-X
<EOS>	B-X
Human	B-X
lymphoid	B-X
cell	B-X
lines	B-X
and	B-X
glucocorticoids	B-X
:	B-X
II	B-X
.	B-X
Whole	B-X
cell	B-X
and	B-X
cytoplasmic	B-X
binding	B-X
properties	B-X
of	B-X
lymphoblastoid	B-X
,	B-X
leukaemia	B-X
and	B-X
lymphoma	B-X
lines	B-X
.	B-X
<EOS>	B-X
No	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
the	B-X
level	B-X
or	B-X
nature	B-X
of	B-X
glucocorticoid	B-X
binding	B-X
and	B-X
the	B-X
cytolethal	B-X
or	B-X
cytostatic	B-X
responsiveness	B-X
of	B-X
HLCL	B-X
to	B-X
glucocorticoid	B-X
treatment	B-X
in	B-X
vitro	B-X
<EOS>	B-X
The	B-X
cytoplasmic	B-X
receptors	B-X
of	B-X
leukaemia	B-X
and	B-X
lymphoblastoid	B-X
lines	B-X
appeared	B-X
to	B-X
contain	B-X
both	B-X
proteinaceous	B-X
and	B-X
phospholipid	B-X
components	B-X

CD28	B-protein
-mediated	O
activation	O
in	O
CD45RA+	B-cell_type
and	I-cell_type
CD45RO+	I-cell_type
T	I-cell_type
cells	I-cell_type
:	O
enhanced	O
levels	O
of	O
reactive	O
oxygen	O
intermediates	O
and	O
c-Rel	B-protein
nuclear	O
translocation	O
in	O
CD45RA+	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
CD28	B-X
-	B-X
mediated	B-X
activation	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
T	B-X
cells	B-X
:	B-X
enhanced	B-X
levels	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
nuclear	B-X
translocation	B-X
in	B-X
CD45RA+	B-X
cells	B-X
.	B-X
<EOS>	B-X
Because	B-X
the	B-X
CD28	B-X
costimulus	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
(	B-X
ROIs	B-X
)	B-X
,	B-X
the	B-X
intracellular	B-X
ROI	B-X
levels	B-X
in	B-X
CD45RA+	B-X
and	B-X
CD45RO+	B-X
cells	B-X
were	B-X
compared	B-X
by	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
Long	B-X
exposure	B-X
(	B-X
24	B-X
h	B-X
)	B-X
induced	B-X
stronger	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
in	B-X
CD45RA+	B-X
cells	B-X
than	B-X
in	B-X
CD45RO+	B-X
cells	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
nuclear	B-X
c	B-X
-	B-X
Rel	B-X
protein	B-X
indicated	B-X
that	B-X
after	B-X
anti	B-X
-	B-X
CD3+anti	B-X
-	B-X
CD28	B-X
stimulation	B-X
the	B-X
level	B-X
of	B-X
c	B-X
-	B-X
Rel	B-X
was	B-X
higher	B-X
in	B-X
CD45RA+	B-X
cells	B-X

In	O
addition	O
a	O
comparative	O
analysis	O
of	O
the	O
hemopoietic	B-cell_type
stem	I-cell_type
cell	I-cell_type
and	O
precursor	O
compartment	O
resulting	O
from	O
the	O
two	O
Ikaros	B-protein
mutations	O
reveals	O
a	O
profound	O
yet	O
not	O
absolute	O
requirement	O
for	O
Ikaros	B-protein
in	O
the	O
production	O
and	O
differentiation	O
of	O
these	O
populations	O
.	O

Overexpression	O
of	O
p65	O
and	O
c-Jun	O
substitutes	O
for	O
B7-1	O
costimulation	O
by	O
targeting	O
the	O
CD28RE	B-DNA
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Overexpression	B-X
of	B-X
p65	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
substitutes	B-X
for	B-X
B7	B-X
-	B-X
1	B-X
costimulation	B-X
by	B-X
targeting	B-X
the	B-X
CD28RE	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Cotransfection	B-X
of	B-X
both	B-X
c	B-X
-	B-X
Jun	B-X
and	B-X
c	B-X
-	B-X
Fos	B-X
substitutes	B-X
for	B-X
B7	B-X
-	B-X
1	B-X
costimulation	B-X
in	B-X
driving	B-X
an	B-X
activation	B-X
protein	B-X
-	B-X
1	B-X
response	B-X
element	B-X
but	B-X
not	B-X
for	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
The	B-X
results	B-X
implicates	B-X
a	B-X
major	B-X
role	B-X
of	B-X
the	B-X
CD28RE	B-X
in	B-X
the	B-X
integration	B-X
of	B-X
p65	B-X
/	B-X
c	B-X
-	B-X
Jun	B-X
-	B-X
mediated	B-X
transcription	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
the	B-X
transition	B-X
from	B-X
an	B-X
autocrine	B-X
LFA	B-X
-	B-X
3	B-X
-	B-X
driven	B-X
immune	B-X
response	B-X
to	B-X
a	B-X
B7	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
induced	B-X
paracrine	B-X
immune	B-X
response	B-X
involves	B-X
the	B-X
activation	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
and	B-X
p65	B-X
,	B-X
which	B-X
target	B-X
the	B-X
CD28RE	B-X
region	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X

The	O
role	O
of	O
Rel	B-protein
and	O
activation	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
B7-1-	B-cell_type
and	I-cell_type
leukocyte	I-cell_type
function-associated	I-cell_type
Ag-3	I-cell_type
(	I-cell_type
LFA.	I-cell_type
3	I-cell_type
)	I-cell_type
-costimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
has	O
been	O
evaluated	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
Rel	B-X
and	B-X
activation	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
in	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
in	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
leukocyte	B-X
function	B-X
-	B-X
associated	B-X
Ag	B-X
-	B-X
3	B-X
(	B-X
LFA	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
overexpression	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
but	B-X
not	B-X
c	B-X
-	B-X
Fos	B-X
increases	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
in	B-X
both	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
LFA	B-X
-	B-X
3	B-X
-	B-X
costimulated	B-X
Jurkat	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
results	B-X
implicates	B-X
a	B-X
major	B-X
role	B-X
of	B-X
the	B-X
CD28RE	B-X
in	B-X
the	B-X
integration	B-X
of	B-X
p65	B-X
/	B-X
c	B-X
-	B-X
Jun	B-X
-	B-X
mediated	B-X
transcription	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
Combined	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
and	B-X
p65	B-X
induced	B-X
vigorous	B-X
transcription	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
	B-X
and	B-X
CD28RE	B-X
-	B-X
driven	B-X
reporter	B-X
constructs	B-X
in	B-X
both	B-X
LFA	B-X
-	B-X
3	B-X
-	B-X
	B-X
and	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
costimulated	B-X
Jurkat	B-X
cells	B-X

We	O
demonstrate	O
that	O
overexpression	O
of	O
c-Jun	B-protein
but	O
not	O
c-Fos	B-protein
increases	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
both	O
B7-1-	B-cell_type
and	I-cell_type
LFA-3-costimulated	I-cell_type
Jurkat	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Firstly	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
aberrant	B-X
expression	B-X
of	B-X
LAD1	B-X
in	B-X
LUAD	B-X
and	B-X
its	B-X
correlation	B-X
with	B-X
patient	B-X
survival	B-X
,	B-X
tumor	B-X
immune	B-X
infiltration	B-X
,	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
cancer	B-X
signaling	B-X
pathways	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
LAD1	B-X
depletion	B-X
significantly	B-X
inhibited	B-X
the	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
cell	B-X
-	B-X
cycle	B-X
progression	B-X
of	B-X
LUAD	B-X
cells	B-X
and	B-X
promoted	B-X
sensitivity	B-X
to	B-X
Gefitinib	B-X
,	B-X
K	B-X
-	B-X
Ras	B-X
inhibitor	B-X
,	B-X
and	B-X
paclitaxel	B-X
treatments	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
GTSE1	B-X
was	B-X
verified	B-X
in	B-X
ESCC	B-X
patients	B-X
'	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
progression	B-X
and	B-X
metastasis	B-X
of	B-X
lung	B-X
cancer	B-X
were	B-X
associated	B-X
with	B-X
human	B-X
antigen	B-X
R	B-X
(	B-X
HuR	B-X
)	B-X
,	B-X
a	B-X
post	B-X
-	B-X
transcriptional	B-X
RNA	B-X
-	B-X
binding	B-X
protein	B-X
that	B-X
stabilize	B-X
and	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
many	B-X
tumor	B-X
-	B-X
related	B-X
genes	B-X

Cotransfection	O
of	O
both	O
c-Jun	O
and	O
c-Fos	O
substitutes	O
for	O
B7-1	O
costimulation	O
in	O
driving	O
an	O
activation	B-DNA
protein-1	I-DNA
response	I-DNA
element	I-DNA
but	O
not	O
for	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

Overexpression	O
of	O
Rel	B-protein
proteins	I-protein
demonstrated	O
that	O
p65-expressing	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
transcribed	O
equally	O
well	O
a	O
nuclear	B-DNA
factor	I-DNA
kappabeta	I-DNA
reporter	I-DNA
construct	I-DNA
when	O
costimulated	O
with	O
B7-1	B-protein
or	O
LFA-3	B-protein
,	O
but	O
transcription	O
of	O
IL-2	B-DNA
promoter	I-DNA
or	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CD28RE	I-DNA
)	I-DNA
-driven	I-DNA
reporters	I-DNA
was	O
superior	O
in	O
B7-1-costimulated	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Overexpression	B-X
of	B-X
Rel	B-X
proteins	B-X
demonstrated	B-X
that	B-X
p65	B-X
-	B-X
expressing	B-X
Jurkat	B-X
cells	B-X
transcribed	B-X
equally	B-X
well	B-X
a	B-X
nuclear	B-X
factor	B-X
kappabeta	B-X
reporter	B-X
construct	B-X
when	B-X
costimulated	B-X
with	B-X
B7	B-X
-	B-X
1	B-X
or	B-X
LFA	B-X
-	B-X
3	B-X
,	B-X
but	B-X
transcription	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
or	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
	B-X
-	B-X
driven	B-X
reporters	B-X
was	B-X
superior	B-X
in	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
costimulated	B-X
cells	B-X
<EOS>	B-X
Combined	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
and	B-X
p65	B-X
induced	B-X
vigorous	B-X
transcription	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
	B-X
and	B-X
CD28RE	B-X
-	B-X
driven	B-X
reporter	B-X
constructs	B-X
in	B-X
both	B-X
LFA	B-X
-	B-X
3	B-X
-	B-X
	B-X
and	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
costimulated	B-X
Jurkat	B-X
cells	B-X
<EOS>	B-X
Overexpression	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
proteins	B-X
in	B-X
T	B-X
cells	B-X
augments	B-X
the	B-X
activity	B-X
of	B-X
an	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
luciferase	B-X
reporter	B-X
gene	B-X
equally	B-X
in	B-X
the	B-X
absence	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
EC	B-X
costimulation	B-X
<EOS>	B-X
Deletion	B-X
analysis	B-X
demonstrated	B-X
that	B-X
the	B-X
transcriptional	B-X
elements	B-X
mediating	B-X
this	B-X
effect	B-X
were	B-X
located	B-X
within	B-X
a	B-X
300	B-X
-	B-X
bp	B-X
region	B-X
upstream	B-X
of	B-X
the	B-X
start	B-X
site	B-X

Combined	O
expression	O
of	O
c-Jun	B-protein
and	O
p65	B-protein
induced	O
vigorous	O
transcription	O
of	O
IL-2	B-DNA
promoter-	I-DNA
and	I-DNA
CD28RE-driven	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
both	O
LFA-3-	B-cell_type
and	I-cell_type
B7-1-costimulated	I-cell_type
Jurkat	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Combined	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
and	B-X
p65	B-X
induced	B-X
vigorous	B-X
transcription	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
	B-X
and	B-X
CD28RE	B-X
-	B-X
driven	B-X
reporter	B-X
constructs	B-X
in	B-X
both	B-X
LFA	B-X
-	B-X
3	B-X
-	B-X
	B-X
and	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
costimulated	B-X
Jurkat	B-X
cells	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
overexpression	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
but	B-X
not	B-X
c	B-X
-	B-X
Fos	B-X
increases	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
in	B-X
both	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
LFA	B-X
-	B-X
3	B-X
-	B-X
costimulated	B-X
Jurkat	B-X
T	B-X
cells	B-X
<EOS>	B-X
Overexpression	B-X
of	B-X
Rel	B-X
proteins	B-X
demonstrated	B-X
that	B-X
p65	B-X
-	B-X
expressing	B-X
Jurkat	B-X
cells	B-X
transcribed	B-X
equally	B-X
well	B-X
a	B-X
nuclear	B-X
factor	B-X
kappabeta	B-X
reporter	B-X
construct	B-X
when	B-X
costimulated	B-X
with	B-X
B7	B-X
-	B-X
1	B-X
or	B-X
LFA	B-X
-	B-X
3	B-X
,	B-X
but	B-X
transcription	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
or	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
	B-X
-	B-X
driven	B-X
reporters	B-X
was	B-X
superior	B-X
in	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
costimulated	B-X
cells	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
Rel	B-X
and	B-X
activation	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
in	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
in	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
leukocyte	B-X
function	B-X
-	B-X
associated	B-X
Ag	B-X
-	B-X
3	B-X
(	B-X
LFA	B-X

Mutating	O
the	O
CD28RE	B-DNA
but	O
not	O
the	O
upstream	B-DNA
nuclear	I-DNA
factor	I-DNA
kappabeta-binding	I-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
reduced	O
B7-1	B-protein
-driven	O
transcription	O
>	O
90	O
%	O
.	O
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
functional	B-X
regulation	B-X
of	B-X
the	B-X
CD28RE	B-X
,	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
by	B-X
Rel	B-X
/	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
sequence	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
6	B-X
promoter	B-X
functions	B-X
as	B-X
a	B-X
CD28	B-X
response	B-X
element	B-X
<EOS>	B-X
Mutations	B-X
in	B-X
this	B-X
sequence	B-X
rendered	B-X
the	B-X
IL	B-X
-	B-X
6	B-X
promoter	B-X
unresponsive	B-X
to	B-X
CD28	B-X
costimulation	B-X
<EOS>	B-X
This	B-X
response	B-X
element	B-X
is	B-X
homologous	B-X
to	B-X
the	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
previously	B-X
identified	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
and	B-X
bears	B-X
structural	B-X
similarities	B-X
to	B-X
a	B-X
newly	B-X
identified	B-X
CD28RE	B-X
in	B-X
the	B-X
CD154	B-X
promoter	B-X

The	O
results	O
implicates	O
a	O
major	O
role	O
of	O
the	O
CD28RE	B-DNA
in	O
the	O
integration	O
of	O
p65	B-protein
/	O
c-Jun	B-protein
-mediated	O
transcription	O
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

We	O
suggest	O
that	O
the	O
transition	O
from	O
an	O
autocrine	O
LFA-3	B-protein
-driven	O
immune	O
response	O
to	O
a	O
B7	O
--	O
induced	O
paracrine	O
immune	O
response	O
involves	O
the	O
activation	O
of	O
c-Jun	B-protein
and	O
p65	B-protein
,	O
which	O
target	O
the	O
CD28RE	B-DNA
region	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
the	B-X
transition	B-X
from	B-X
an	B-X
autocrine	B-X
LFA	B-X
-	B-X
3	B-X
-	B-X
driven	B-X
immune	B-X
response	B-X
to	B-X
a	B-X
B7	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
induced	B-X
paracrine	B-X
immune	B-X
response	B-X
involves	B-X
the	B-X
activation	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
and	B-X
p65	B-X
,	B-X
which	B-X
target	B-X
the	B-X
CD28RE	B-X
region	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
Overexpression	B-X
of	B-X
p65	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
substitutes	B-X
for	B-X
B7	B-X
-	B-X
1	B-X
costimulation	B-X
by	B-X
targeting	B-X
the	B-X
CD28RE	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Cotransfection	B-X
of	B-X
both	B-X
c	B-X
-	B-X
Jun	B-X
and	B-X
c	B-X
-	B-X
Fos	B-X
substitutes	B-X
for	B-X
B7	B-X
-	B-X
1	B-X
costimulation	B-X
in	B-X
driving	B-X
an	B-X
activation	B-X
protein	B-X
-	B-X
1	B-X
response	B-X
element	B-X
but	B-X
not	B-X
for	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
The	B-X
results	B-X
implicates	B-X
a	B-X
major	B-X
role	B-X
of	B-X
the	B-X
CD28RE	B-X
in	B-X
the	B-X
integration	B-X
of	B-X
p65	B-X
/	B-X
c	B-X
-	B-X
Jun	B-X
-	B-X
mediated	B-X
transcription	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X

Defects	O
in	O
actin-cap	O
formation	O
in	O
Vav-deficient	O
mice	O
implicate	O
an	O
actin	O
requirement	O
for	O
lymphocyte	O
signal	O
transduction	O
.	O
<EOS>	B-X
Defects	B-X
in	B-X
actin	B-X
-	B-X
cap	B-X
formation	B-X
in	B-X
Vav	B-X
-	B-X
deficient	B-X
mice	B-X
implicate	B-X
an	B-X
actin	B-X
requirement	B-X
for	B-X
lymphocyte	B-X
signal	B-X
transduction	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
cap	B-X
formation	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
proliferation	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
an	B-X
actin	B-X
-	B-X
dependent	B-X
pathway	B-X
is	B-X
a	B-X
source	B-X
of	B-X
specialized	B-X
growth	B-X
regulatory	B-X
signals	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Vav	B-X
is	B-X
required	B-X
for	B-X
cap	B-X
formation	B-X
in	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
events	B-X
underlying	B-X
cap	B-X
formation	B-X
using	B-X
mice	B-X
bearing	B-X
a	B-X
null	B-X
mutation	B-X
in	B-X
vav	B-X
(	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
,	B-X
a	B-X
gene	B-X
that	B-X
encodes	B-X
a	B-X
guanine	B-X
-	B-X
nucleotide	B-X
exchange	B-X
factor	B-X
for	B-X
the	B-X
GTPase	B-X
Rac	B-X

BACKGROUND	O
:	O
Antigen-receptor	O
interactions	O
on	O
lymphocytes	B-cell_type
result	O
in	O
local	O
clustering	O
of	O
actin	B-protein
,	O
receptors	O
and	O
signaling	O
molecules	O
into	O
an	O
asymmetric	O
membrane	O
structure	O
termed	O
a	O
cap	O
.	O
<EOS>	B-X
Antigen	B-X
-	B-X
receptor	B-X
interactions	B-X
on	B-X
lymphocytes	B-X
result	B-X
in	B-X
local	B-X
clustering	B-X
of	B-X
actin	B-X
,	B-X
receptors	B-X
and	B-X
signaling	B-X
molecules	B-X
into	B-X
an	B-X
asymmetric	B-X
membrane	B-X
structure	B-X
termed	B-X
a	B-X
cap	B-X
<EOS>	B-X
Defects	B-X
in	B-X
actin	B-X
-	B-X
cap	B-X
formation	B-X
in	B-X
Vav	B-X
-	B-X
deficient	B-X
mice	B-X
implicate	B-X
an	B-X
actin	B-X
requirement	B-X
for	B-X
lymphocyte	B-X
signal	B-X
transduction	B-X
.	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
lymphocytes	B-X
with	B-X
cytochalasin	B-X
D	B-X
,	B-X
which	B-X
blocks	B-X
actin	B-X
polymerization	B-X
,	B-X
inhibited	B-X
cap	B-X
formation	B-X
and	B-X
produced	B-X
defects	B-X
in	B-X
signaling	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
-	B-X
receptor	B-X
signaling	B-X
that	B-X
were	B-X
nearly	B-X
identical	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
cells	B-X
<EOS>	B-X
Although	B-X
actin	B-X
polymerization	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
,	B-X
the	B-X
mechanisms	B-X
underlying	B-X
cap	B-X
formation	B-X
are	B-X
unclear	B-X

Although	O
actin	O
polymerization	O
is	O
known	O
to	O
be	O
required	O
,	O
the	O
mechanisms	O
underlying	O
cap	O
formation	O
are	O
unclear	O
.	O
<EOS>	B-X
Although	B-X
actin	B-X
polymerization	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
,	B-X
the	B-X
mechanisms	B-X
underlying	B-X
cap	B-X
formation	B-X
are	B-X
unclear	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Vav	B-X
is	B-X
required	B-X
for	B-X
cap	B-X
formation	B-X
in	B-X
lymphocytes	B-X
<EOS>	B-X
Antigen	B-X
-	B-X
receptor	B-X
interactions	B-X
on	B-X
lymphocytes	B-X
result	B-X
in	B-X
local	B-X
clustering	B-X
of	B-X
actin	B-X
,	B-X
receptors	B-X
and	B-X
signaling	B-X
molecules	B-X
into	B-X
an	B-X
asymmetric	B-X
membrane	B-X
structure	B-X
termed	B-X
a	B-X
cap	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
cap	B-X
formation	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
proliferation	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
an	B-X
actin	B-X
-	B-X
dependent	B-X
pathway	B-X
is	B-X
a	B-X
source	B-X
of	B-X
specialized	B-X
growth	B-X
regulatory	B-X
signals	B-X

We	O
have	O
studied	O
the	O
events	O
underlying	O
cap	O
formation	O
using	O
mice	O
bearing	O
a	O
null	O
mutation	O
in	O
vav	B-DNA
(	O
vav	B-DNA
-/-	O
)	O
,	O
a	O
gene	O
that	O
encodes	O
a	O
guanine-nucleotide	B-protein
exchange	I-protein
factor	I-protein
for	O
the	O
GTPase	B-protein
Rac	I-protein
.	O

RESULTS	O
:	O
Lymphocytes	B-cell_type
from	O
vav	B-DNA
-/-	O
mice	O
failed	O
to	O
form	O
T-cell	O
receptor	O
caps	O
following	O
activation	O
and	O
had	O
a	O
defective	O
actin	O
cytoskeleton	O
.	O
<EOS>	B-X
Lymphocytes	B-X
from	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
mice	B-X
failed	B-X
to	B-X
form	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
caps	B-X
following	B-X
activation	B-X
and	B-X
had	B-X
a	B-X
defective	B-X
actin	B-X
cytoskeleton	B-X
<EOS>	B-X
Antigen	B-X
-	B-X
receptor	B-X
interactions	B-X
on	B-X
lymphocytes	B-X
result	B-X
in	B-X
local	B-X
clustering	B-X
of	B-X
actin	B-X
,	B-X
receptors	B-X
and	B-X
signaling	B-X
molecules	B-X
into	B-X
an	B-X
asymmetric	B-X
membrane	B-X
structure	B-X
termed	B-X
a	B-X
cap	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
lymphocytes	B-X
with	B-X
cytochalasin	B-X
D	B-X
,	B-X
which	B-X
blocks	B-X
actin	B-X
polymerization	B-X
,	B-X
inhibited	B-X
cap	B-X
formation	B-X
and	B-X
produced	B-X
defects	B-X
in	B-X
signaling	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
-	B-X
receptor	B-X
signaling	B-X
that	B-X
were	B-X
nearly	B-X
identical	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Vav	B-X
is	B-X
required	B-X
for	B-X
cap	B-X
formation	B-X
in	B-X
lymphocytes	B-X

The	O
vav-/-	B-cell_type
T	I-cell_type
cells	I-cell_type
were	O
deficient	O
in	O
interleukin-2	O
(	O
IL-2	O
)	O
production	O
and	O
proliferation	O
,	O
and	O
the	O
peak	O
of	O
Ca2+	O
mobilization	O
was	O
reduced	O
although	O
of	O
normal	O
duration	O
.	O
<EOS>	B-X
The	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
T	B-X
cells	B-X
were	B-X
deficient	B-X
in	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
production	B-X
and	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
peak	B-X
of	B-X
Ca2+	B-X
mobilization	B-X
was	B-X
reduced	B-X
although	B-X
of	B-X
normal	B-X
duration	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
cap	B-X
formation	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
proliferation	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
an	B-X
actin	B-X
-	B-X
dependent	B-X
pathway	B-X
is	B-X
a	B-X
source	B-X
of	B-X
specialized	B-X
growth	B-X
regulatory	B-X
signals	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
lymphocytes	B-X
with	B-X
cytochalasin	B-X
D	B-X
,	B-X
which	B-X
blocks	B-X
actin	B-X
polymerization	B-X
,	B-X
inhibited	B-X
cap	B-X
formation	B-X
and	B-X
produced	B-X
defects	B-X
in	B-X
signaling	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
-	B-X
receptor	B-X
signaling	B-X
that	B-X
were	B-X
nearly	B-X
identical	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
cells	B-X
<EOS>	B-X
Activation	B-X
of	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
kinase	B-X
or	B-X
stress	B-X
-	B-X
activated	B-X
kinase	B-X
(	B-X
JNK	B-X
or	B-X
SAPK	B-X
)	B-X
and	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
ATc1	B-X
and	B-X
egr	B-X
-	B-X
1	B-X
genes	B-X
was	B-X
normal	B-X

Activation	O
of	O
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
or	O
stress-activated	B-protein
kinase	I-protein
(	O
JNK	B-protein
or	O
SAPK	B-protein
)	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
and	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-ATc1	B-DNA
and	I-DNA
egr-1	I-DNA
genes	I-DNA
was	O
normal	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
kinase	B-X
or	B-X
stress	B-X
-	B-X
activated	B-X
kinase	B-X
(	B-X
JNK	B-X
or	B-X
SAPK	B-X
)	B-X
and	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
ATc1	B-X
and	B-X
egr	B-X
-	B-X
1	B-X
genes	B-X
was	B-X
normal	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
lymphocytes	B-X
with	B-X
cytochalasin	B-X
D	B-X
,	B-X
which	B-X
blocks	B-X
actin	B-X
polymerization	B-X
,	B-X
inhibited	B-X
cap	B-X
formation	B-X
and	B-X
produced	B-X
defects	B-X
in	B-X
signaling	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
-	B-X
receptor	B-X
signaling	B-X
that	B-X
were	B-X
nearly	B-X
identical	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
cells	B-X
<EOS>	B-X
In	B-X
transfection	B-X
studies	B-X
,	B-X
either	B-X
constitutively	B-X
active	B-X
Vav	B-X
or	B-X
Rac	B-X
could	B-X
complement	B-X
constitutively	B-X
active	B-X
calcineurin	B-X
to	B-X
activate	B-X
NF	B-X
-	B-X
AT	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
The	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
T	B-X
cells	B-X
were	B-X
deficient	B-X
in	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
production	B-X
and	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
peak	B-X
of	B-X
Ca2+	B-X
mobilization	B-X
was	B-X
reduced	B-X
although	B-X
of	B-X
normal	B-X
duration	B-X

Despite	O
the	O
reduced	O
Ca2+	O
mobilization	O
,	O
translocation	O
of	O
cytoplasmic	B-protein
NF-ATc	I-protein
to	O
the	O
nucleus	O
was	O
normal	O
,	O
reflecting	O
that	O
the	O
lower	O
levels	O
of	O
Ca2+	O
in	O
vav-/-	B-cell_type
cells	I-cell_type
were	O
still	O
sufficient	O
to	O
activate	O
calcineurin	B-protein
.	O

Treatment	O
of	O
lymphocytes	B-cell_type
with	O
cytochalasin	O
D	O
,	O
which	O
blocks	O
actin	O
polymerization	O
,	O
inhibited	O
cap	O
formation	O
and	O
produced	O
defects	O
in	O
signaling	O
and	O
IL-2	O
transcriptional	O
induction	O
in	O
response	O
to	O
antigen-receptor	O
signaling	O
that	O
were	O
nearly	O
identical	O
to	O
those	O
seen	O
in	O
vav-/-	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
lymphocytes	B-X
with	B-X
cytochalasin	B-X
D	B-X
,	B-X
which	B-X
blocks	B-X
actin	B-X
polymerization	B-X
,	B-X
inhibited	B-X
cap	B-X
formation	B-X
and	B-X
produced	B-X
defects	B-X
in	B-X
signaling	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
-	B-X
receptor	B-X
signaling	B-X
that	B-X
were	B-X
nearly	B-X
identical	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
cap	B-X
formation	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
proliferation	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
an	B-X
actin	B-X
-	B-X
dependent	B-X
pathway	B-X
is	B-X
a	B-X
source	B-X
of	B-X
specialized	B-X
growth	B-X
regulatory	B-X
signals	B-X
<EOS>	B-X
Activation	B-X
of	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
kinase	B-X
or	B-X
stress	B-X
-	B-X
activated	B-X
kinase	B-X
(	B-X
JNK	B-X
or	B-X
SAPK	B-X
)	B-X
and	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
ATc1	B-X
and	B-X
egr	B-X
-	B-X
1	B-X
genes	B-X
was	B-X
normal	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
events	B-X
underlying	B-X
cap	B-X
formation	B-X
using	B-X
mice	B-X
bearing	B-X
a	B-X
null	B-X
mutation	B-X
in	B-X
vav	B-X
(	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
,	B-X
a	B-X
gene	B-X
that	B-X
encodes	B-X
a	B-X
guanine	B-X
-	B-X
nucleotide	B-X
exchange	B-X
factor	B-X
for	B-X
the	B-X
GTPase	B-X
Rac	B-X

In	O
transfection	O
studies	O
,	O
either	O
constitutively	O
active	O
Vav	B-protein
or	O
Rac	B-protein
could	O
complement	O
constitutively	O
active	O
calcineurin	B-protein
to	O
activate	O
NF-AT-dependent	O
transcription	O
.	O
<EOS>	B-X
In	B-X
transfection	B-X
studies	B-X
,	B-X
either	B-X
constitutively	B-X
active	B-X
Vav	B-X
or	B-X
Rac	B-X
could	B-X
complement	B-X
constitutively	B-X
active	B-X
calcineurin	B-X
to	B-X
activate	B-X
NF	B-X
-	B-X
AT	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
Vav1	B-X
cells	B-X
with	B-X
constitutively	B-X
active	B-X
Rac1	B-X
or	B-X
Rac2	B-X
stabilized	B-X
a	B-X
labile	B-X
β	B-X
-	B-X
globin	B-X
reporter	B-X
mRNA	B-X
,	B-X
in	B-X
a	B-X
HuR	B-X
-	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
constitutively	B-X
activated	B-X
Rac1	B-X
efficiently	B-X
stimulated	B-X
JNK1	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
under	B-X
the	B-X
same	B-X
conditions	B-X
<EOS>	B-X
Vav	B-X
overexpression	B-X
resulted	B-X
in	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
JNK1	B-X
with	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
on	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
and	B-X
ERK2	B-X

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
Vav	B-protein
is	O
required	O
for	O
cap	O
formation	O
in	O
lymphocytes	B-cell_type
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Vav	B-X
is	B-X
required	B-X
for	B-X
cap	B-X
formation	B-X
in	B-X
lymphocytes	B-X
<EOS>	B-X
Defects	B-X
in	B-X
actin	B-X
-	B-X
cap	B-X
formation	B-X
in	B-X
Vav	B-X
-	B-X
deficient	B-X
mice	B-X
implicate	B-X
an	B-X
actin	B-X
requirement	B-X
for	B-X
lymphocyte	B-X
signal	B-X
transduction	B-X
.	B-X
<EOS>	B-X
Although	B-X
actin	B-X
polymerization	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
,	B-X
the	B-X
mechanisms	B-X
underlying	B-X
cap	B-X
formation	B-X
are	B-X
unclear	B-X
<EOS>	B-X
Antigen	B-X
-	B-X
receptor	B-X
interactions	B-X
on	B-X
lymphocytes	B-X
result	B-X
in	B-X
local	B-X
clustering	B-X
of	B-X
actin	B-X
,	B-X
receptors	B-X
and	B-X
signaling	B-X
molecules	B-X
into	B-X
an	B-X
asymmetric	B-X
membrane	B-X
structure	B-X
termed	B-X
a	B-X
cap	B-X

Furthermore	O
,	O
the	O
correlation	O
between	O
cap	O
formation	O
,	O
IL-2	O
production	O
and	O
proliferation	O
supports	O
the	O
hypothesis	O
that	O
an	O
actin-dependent	O
pathway	O
is	O
a	O
source	O
of	O
specialized	O
growth	O
regulatory	O
signals	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
cap	B-X
formation	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
proliferation	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
an	B-X
actin	B-X
-	B-X
dependent	B-X
pathway	B-X
is	B-X
a	B-X
source	B-X
of	B-X
specialized	B-X
growth	B-X
regulatory	B-X
signals	B-X
<EOS>	B-X
The	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
T	B-X
cells	B-X
were	B-X
deficient	B-X
in	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
production	B-X
and	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
peak	B-X
of	B-X
Ca2+	B-X
mobilization	B-X
was	B-X
reduced	B-X
although	B-X
of	B-X
normal	B-X
duration	B-X
<EOS>	B-X
Defects	B-X
in	B-X
actin	B-X
-	B-X
cap	B-X
formation	B-X
in	B-X
Vav	B-X
-	B-X
deficient	B-X
mice	B-X
implicate	B-X
an	B-X
actin	B-X
requirement	B-X
for	B-X
lymphocyte	B-X
signal	B-X
transduction	B-X
.	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
lymphocytes	B-X
with	B-X
cytochalasin	B-X
D	B-X
,	B-X
which	B-X
blocks	B-X
actin	B-X
polymerization	B-X
,	B-X
inhibited	B-X
cap	B-X
formation	B-X
and	B-X
produced	B-X
defects	B-X
in	B-X
signaling	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
transcriptional	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
-	B-X
receptor	B-X
signaling	B-X
that	B-X
were	B-X
nearly	B-X
identical	B-X
to	B-X
those	B-X
seen	B-X
in	B-X
vav	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
cells	B-X

CD14	B-protein
-dependent	O
activation	O
of	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
by	O
Bacteroides	O
fragilis	O
outer	O
membrane	O
.	O
<EOS>	B-X
CD14	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
human	B-X
endothelial	B-X
cells	B-X
by	B-X
Bacteroides	B-X
fragilis	B-X
outer	B-X
membrane	B-X
.	B-X
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
capacity	B-X
of	B-X
isolated	B-X
Bacteriodes	B-X
fragilis	B-X
outer	B-X
membrane	B-X
,	B-X
B	B-X
<EOS>	B-X
fragilis	B-X
cell	B-X
wall	B-X
contains	B-X
a	B-X
proinflammatory	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
,	B-X
that	B-X
is	B-X
not	B-X
LPS	B-X
,	B-X
which	B-X
induces	B-X
human	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
CD14	B-X
-	B-X
dependent	B-X
mechanism	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
outer	B-X
membrane	B-X
component	B-X
of	B-X
the	B-X
B	B-X

We	O
studied	O
the	O
capacity	O
of	O
isolated	O
Bacteriodes	O
fragilis	O
outer	O
membrane	O
,	O
B.	O
fragilis	O
NCTC9343	O
lipopolysaccharide	O
(	O
LPS	O
;	O
endotoxin	O
)	O
,	O
and	O
B.	O
fragilis	O
NCTC9343	O
capsular	O
polysaccharides	O
to	O
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
monolayers	O
.	O

To	O
assess	O
HUVEC	O
activation	O
,	O
E-selectin	B-protein
expression	O
was	O
measured	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
Northern	O
blot	O
analysis	O
for	O
E-selectin-specific	B-RNA
mRNA	I-RNA
,	O
and	O
electrophoretic	O
gel	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
for	O
NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
necessary	O
for	O
E-selectin	B-DNA
gene	I-DNA
activation	O
.	O
<EOS>	B-X
To	B-X
assess	B-X
HUVEC	B-X
activation	B-X
,	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
was	B-X
measured	B-X
by	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
,	B-X
Northern	B-X
blot	B-X
analysis	B-X
for	B-X
E	B-X
-	B-X
selectin	B-X
-	B-X
specific	B-X
mRNA	B-X
,	B-X
and	B-X
electrophoretic	B-X
gel	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
necessary	B-X
for	B-X
E	B-X
-	B-X
selectin	B-X
gene	B-X
activation	B-X
<EOS>	B-X
fragilis	B-X
cell	B-X
wall	B-X
contains	B-X
a	B-X
proinflammatory	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
,	B-X
that	B-X
is	B-X
not	B-X
LPS	B-X
,	B-X
which	B-X
induces	B-X
human	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
CD14	B-X
-	B-X
dependent	B-X
mechanism	B-X
<EOS>	B-X
fragilis	B-X
cell	B-X
wall	B-X
by	B-X
isopycnic	B-X
,	B-X
sucrose	B-X
gradient	B-X
centrifugation	B-X
,	B-X
significantly	B-X
increased	B-X
surface	B-X
expression	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
and	B-X
induced	B-X
functional	B-X
endothelial	B-X
cell	B-X
-	B-X
dependent	B-X
leukocyte	B-X
adhesion	B-X
<EOS>	B-X
fragilis	B-X
outer	B-X
membrane	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
,	B-X
E	B-X
-	B-X
selectin	B-X
transcription	B-X
,	B-X
and	B-X
E	B-X
-	B-X
selectin	B-X
surface	B-X
expression	B-X

Exposure	O
of	O
HUVECs	B-cell_type
to	O
B.	O
fragilis	O
outer	O
membrane	O
fractions	O
,	O
separated	O
from	O
other	O
components	O
of	O
the	O
B.	O
fragilis	O
cell	O
wall	O
by	O
isopycnic	O
,	O
sucrose	O
gradient	O
centrifugation	O
,	O
significantly	O
increased	O
surface	O
expression	O
of	O
E-selectin	B-protein
and	O
induced	O
functional	O
endothelial	B-cell_type
cell	I-cell_type
-dependent	O
leukocyte	O
adhesion	O
.	O

B.	O
fragilis	O
outer	O
membranes	O
induced	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
to	O
HUVEC	O
nuclei	O
and	O
accumulation	O
of	O
E-selectin	B-RNA
mRNA	I-RNA
in	O
HUVEC	O
cytoplasm	O
.	O
<EOS>	B-X
fragilis	B-X
outer	B-X
membranes	B-X
induced	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
to	B-X
HUVEC	B-X
nuclei	B-X
and	B-X
accumulation	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
mRNA	B-X
in	B-X
HUVEC	B-X
cytoplasm	B-X
<EOS>	B-X
fragilis	B-X
outer	B-X
membrane	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
,	B-X
E	B-X
-	B-X
selectin	B-X
transcription	B-X
,	B-X
and	B-X
E	B-X
-	B-X
selectin	B-X
surface	B-X
expression	B-X
<EOS>	B-X
fragilis	B-X
outer	B-X
membrane	B-X
fractions	B-X
,	B-X
separated	B-X
from	B-X
other	B-X
components	B-X
of	B-X
the	B-X
B	B-X
<EOS>	B-X
fragilis	B-X
outer	B-X
membranes	B-X
was	B-X
not	B-X
blocked	B-X
by	B-X
polymixin	B-X
B	B-X

E-selectin	O
expression	O
induced	O
by	O
B.	O
fragilis	O
outer	O
membranes	O
was	O
not	O
blocked	O
by	O
polymixin	O
B	O
.	O

In	O
contrast	O
,	O
E-selectin	O
expression	O
induced	O
by	O
outer	O
membrane	O
fractions	O
purified	O
from	O
E.	O
coli	O
was	O
competitively	O
inhibited	O
by	O
polymixin	O
B	O
.	O

Neither	O
purified	O
B.	O
fragilis	O
LPS	O
,	O
a	O
prominent	O
constituent	O
of	O
the	O
outer	O
membrane	O
,	O
nor	O
purified	O
B.	O
fragilis	O
capsular	O
polysaccharides	O
induced	O
HUVEC	O
activation	O
.	O
<EOS>	B-X
fragilis	B-X
LPS	B-X
,	B-X
a	B-X
prominent	B-X
constituent	B-X
of	B-X
the	B-X
outer	B-X
membrane	B-X
,	B-X
nor	B-X
purified	B-X
B	B-X
<EOS>	B-X
fragilis	B-X
capsular	B-X
polysaccharides	B-X
induced	B-X
HUVEC	B-X
activation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
induced	B-X
by	B-X
outer	B-X
membrane	B-X
fractions	B-X
purified	B-X
from	B-X
E	B-X
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
capacity	B-X
of	B-X
isolated	B-X
Bacteriodes	B-X
fragilis	B-X
outer	B-X
membrane	B-X
,	B-X
B	B-X

Two	O
different	O
monoclonal	B-protein
antibodies	I-protein
directed	O
against	O
human	B-protein
CD14	I-protein
completely	O
inhibited	O
B.	O
fragilis	O
outer	O
membrane-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
E-selectin	O
transcription	O
,	O
and	O
E-selectin	O
surface	O
expression	O
.	O
<EOS>	B-X
fragilis	B-X
outer	B-X
membrane	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
,	B-X
E	B-X
-	B-X
selectin	B-X
transcription	B-X
,	B-X
and	B-X
E	B-X
-	B-X
selectin	B-X
surface	B-X
expression	B-X
<EOS>	B-X
Two	B-X
different	B-X
monoclonal	B-X
antibodies	B-X
directed	B-X
against	B-X
human	B-X
CD14	B-X
completely	B-X
inhibited	B-X
B	B-X
<EOS>	B-X
fragilis	B-X
outer	B-X
membranes	B-X
induced	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
to	B-X
HUVEC	B-X
nuclei	B-X
and	B-X
accumulation	B-X
of	B-X
E	B-X
-	B-X
selectin	B-X
mRNA	B-X
in	B-X
HUVEC	B-X
cytoplasm	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
induced	B-X
by	B-X
outer	B-X
membrane	B-X
fractions	B-X
purified	B-X
from	B-X
E	B-X

We	O
conclude	O
that	O
the	O
outer	O
membrane	O
component	O
of	O
the	O
B.	O
fragilis	O
cell	O
wall	O
contains	O
a	O
proinflammatory	O
factor	O
(	O
s	O
)	O
,	O
that	O
is	O
not	O
LPS	O
,	O
which	O
induces	O
human	B-cell_type
endothelial	I-cell_type
cell	I-cell_type
activation	O
by	O
a	O
soluble	O
CD14	B-protein
-dependent	O
mechanism	O
.	O

NF-kappaB	B-protein
protects	O
HIV-1-infected	O
myeloid	B-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
protects	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
myeloid	B-X
cells	B-X
from	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
Recently	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
induction	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
from	B-X
programmed	B-X
cell	B-X
death	B-X
<EOS>	B-X
TNFalpha	B-X
and	B-X
cycloheximide	B-X
caused	B-X
infected	B-X
cells	B-X
to	B-X
undergo	B-X
apoptosis	B-X
more	B-X
rapidly	B-X
than	B-X
parental	B-X
U937	B-X
and	B-X
PLB	B-X
-	B-X
985	B-X
cells	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
investigate	B-X
whether	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
chronically	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
promonocytic	B-X
U937	B-X
(	B-X
U9	B-X
-	B-X
IIIB	B-X
)	B-X
and	B-X
myeloblastic	B-X
PLB	B-X
-	B-X
985	B-X
(	B-X
PLB	B-X
-	B-X
IIIB	B-X
)	B-X
cells	B-X
affects	B-X
apoptotic	B-X
signaling	B-X

HIV-1	O
infection	O
of	O
primary	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
and	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
results	O
in	O
sustained	O
NF-kappaB	O
activation	O
.	O
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
primary	B-X
monocytic	B-X
cells	B-X
and	B-X
myeloid	B-X
cell	B-X
lines	B-X
results	B-X
in	B-X
sustained	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
U9	B-X
-	B-X
IIIB	B-X
and	B-X
PLB	B-X
-	B-X
IIIB	B-X
cells	B-X
also	B-X
induced	B-X
apoptosis	B-X
,	B-X
suggesting	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
protects	B-X
cells	B-X
from	B-X
a	B-X
persistent	B-X
apoptotic	B-X
signal	B-X
<EOS>	B-X
As	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
,	B-X
TNFalpha	B-X
treatment	B-X
also	B-X
induced	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
Bcl	B-X
-	B-X
2	B-X
protein	B-X
levels	B-X
in	B-X
TD	B-X
-	B-X
IkappaB	B-X
expressing	B-X
cells	B-X
<EOS>	B-X
Cells	B-X
underwent	B-X
apoptosis	B-X
in	B-X
response	B-X
to	B-X
TNFalpha	B-X
only	B-X
when	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
TD	B-X
-	B-X
IkappaB	B-X
expression	B-X

Recently	O
,	O
NF-kappaB	O
induction	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
induction	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
from	B-X
programmed	B-X
cell	B-X
death	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
renders	B-X
human	B-X
juvenile	B-X
costal	B-X
chondrocyte	B-X
cell	B-X
lines	B-X
sensitive	B-X
to	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
mediated	B-X
cell	B-X
death	B-X
.	B-X
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
Pim	B-X
kinases	B-X
play	B-X
a	B-X
role	B-X
in	B-X
immune	B-X
regulation	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
They	B-X
also	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
promoting	B-X
cell	B-X
survival	B-X

In	O
the	O
present	O
study	O
,	O
we	O
sought	O
to	O
investigate	O
whether	O
constitutive	O
NF-kappaB	B-protein
activity	O
in	O
chronically	O
HIV-1-infected	O
promonocytic	B-cell_line
U937	I-cell_line
(	I-cell_line
U9-IIIB	I-cell_line
)	I-cell_line
and	I-cell_line
myeloblastic	I-cell_line
PLB-985	I-cell_line
(	I-cell_line
PLB-IIIB	I-cell_line
)	I-cell_line
cells	I-cell_line
affects	O
apoptotic	O
signaling	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
investigate	B-X
whether	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
chronically	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
promonocytic	B-X
U937	B-X
(	B-X
U9	B-X
-	B-X
IIIB	B-X
)	B-X
and	B-X
myeloblastic	B-X
PLB	B-X
-	B-X
985	B-X
(	B-X
PLB	B-X
-	B-X
IIIB	B-X
)	B-X
cells	B-X
affects	B-X
apoptotic	B-X
signaling	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
U9	B-X
-	B-X
IIIB	B-X
and	B-X
PLB	B-X
-	B-X
IIIB	B-X
cells	B-X
also	B-X
induced	B-X
apoptosis	B-X
,	B-X
suggesting	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
protects	B-X
cells	B-X
from	B-X
a	B-X
persistent	B-X
apoptotic	B-X
signal	B-X
<EOS>	B-X
TNFalpha	B-X
plus	B-X
NAC	B-X
treatment	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
Bcl	B-X
-	B-X
2	B-X
protein	B-X
levels	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
coupled	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
Bax	B-X
protein	B-X
compared	B-X
to	B-X
uninfected	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
difference	B-X
in	B-X
susceptibility	B-X
to	B-X
TNFalpha	B-X
-	B-X
induced	B-X
apoptosis	B-X
may	B-X
relate	B-X
to	B-X
the	B-X
differences	B-X
in	B-X
relative	B-X
levels	B-X
of	B-X
Bcl	B-X
-	B-X
2	B-X
and	B-X
Bax	B-X
<EOS>	B-X
Cells	B-X
underwent	B-X
apoptosis	B-X
in	B-X
response	B-X
to	B-X
TNFalpha	B-X
only	B-X
when	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
TD	B-X
-	B-X
IkappaB	B-X
expression	B-X

TNFalpha	B-protein
and	O
cycloheximide	O
caused	O
infected	O
cells	O
to	O
undergo	O
apoptosis	O
more	O
rapidly	O
than	O
parental	B-cell_line
U937	I-cell_line
and	O
PLB-985	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
TNFalpha	B-X
and	B-X
cycloheximide	B-X
caused	B-X
infected	B-X
cells	B-X
to	B-X
undergo	B-X
apoptosis	B-X
more	B-X
rapidly	B-X
than	B-X
parental	B-X
U937	B-X
and	B-X
PLB	B-X
-	B-X
985	B-X
cells	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
U9	B-X
-	B-X
IIIB	B-X
and	B-X
PLB	B-X
-	B-X
IIIB	B-X
cells	B-X
also	B-X
induced	B-X
apoptosis	B-X
,	B-X
suggesting	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
protects	B-X
cells	B-X
from	B-X
a	B-X
persistent	B-X
apoptotic	B-X
signal	B-X
<EOS>	B-X
These	B-X
experiments	B-X
demonstrate	B-X
that	B-X
apoptotic	B-X
signaling	B-X
is	B-X
perturbed	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
and	B-X
indicate	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
may	B-X
play	B-X
an	B-X
additional	B-X
protective	B-X
role	B-X
against	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
myeloid	B-X
cells	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
investigate	B-X
whether	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
chronically	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
promonocytic	B-X
U937	B-X
(	B-X
U9	B-X
-	B-X
IIIB	B-X
)	B-X
and	B-X
myeloblastic	B-X
PLB	B-X
-	B-X
985	B-X
(	B-X
PLB	B-X
-	B-X
IIIB	B-X
)	B-X
cells	B-X
affects	B-X
apoptotic	B-X
signaling	B-X

Inhibition	O
of	O
TNFalpha	B-protein
-induced	O
NF-kappaB	O
activation	O
using	O
the	O
antioxidant	O
N-acetylcysteine	O
(	O
NAC	O
)	O
resulted	O
in	O
increased	O
apoptosis	O
in	O
both	O
U937	B-cell_line
and	I-cell_line
U9-IIIB	I-cell_line
cells	I-cell_line
,	O
while	O
preactivation	O
of	O
NF-kappaB	B-protein
with	O
the	O
non-apoptotic	B-protein
inducer	I-protein
IL-1beta	I-protein
caused	O
a	O
relative	O
decrease	O
in	O
apoptosis	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
TNFalpha	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
using	B-X
the	B-X
antioxidant	B-X
N	B-X
-	B-X
acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
resulted	B-X
in	B-X
increased	B-X
apoptosis	B-X
in	B-X
both	B-X
U937	B-X
and	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
,	B-X
while	B-X
preactivation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
with	B-X
the	B-X
non	B-X
-	B-X
apoptotic	B-X
inducer	B-X
IL	B-X
-	B-X
1beta	B-X
caused	B-X
a	B-X
relative	B-X
decrease	B-X
in	B-X
apoptosis	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
U9	B-X
-	B-X
IIIB	B-X
and	B-X
PLB	B-X
-	B-X
IIIB	B-X
cells	B-X
also	B-X
induced	B-X
apoptosis	B-X
,	B-X
suggesting	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
protects	B-X
cells	B-X
from	B-X
a	B-X
persistent	B-X
apoptotic	B-X
signal	B-X
<EOS>	B-X
TNFalpha	B-X
plus	B-X
NAC	B-X
treatment	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
Bcl	B-X
-	B-X
2	B-X
protein	B-X
levels	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
coupled	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
Bax	B-X
protein	B-X
compared	B-X
to	B-X
uninfected	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
difference	B-X
in	B-X
susceptibility	B-X
to	B-X
TNFalpha	B-X
-	B-X
induced	B-X
apoptosis	B-X
may	B-X
relate	B-X
to	B-X
the	B-X
differences	B-X
in	B-X
relative	B-X
levels	B-X
of	B-X
Bcl	B-X
-	B-X
2	B-X
and	B-X
Bax	B-X
<EOS>	B-X
These	B-X
experiments	B-X
demonstrate	B-X
that	B-X
apoptotic	B-X
signaling	B-X
is	B-X
perturbed	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
and	B-X
indicate	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
may	B-X
play	B-X
an	B-X
additional	B-X
protective	B-X
role	B-X
against	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
myeloid	B-X
cells	B-X

Inhibition	O
of	O
constitutive	O
NF-kappaB	B-protein
activity	O
in	O
U9-IIIB	B-cell_line
and	I-cell_line
PLB-IIIB	I-cell_line
cells	I-cell_line
also	O
induced	O
apoptosis	O
,	O
suggesting	O
that	O
NF-kappaB	B-cell_type
protects	I-cell_type
cells	I-cell_type
from	O
a	O
persistent	O
apoptotic	O
signal	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
U9	B-X
-	B-X
IIIB	B-X
and	B-X
PLB	B-X
-	B-X
IIIB	B-X
cells	B-X
also	B-X
induced	B-X
apoptosis	B-X
,	B-X
suggesting	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
protects	B-X
cells	B-X
from	B-X
a	B-X
persistent	B-X
apoptotic	B-X
signal	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
TNFalpha	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
using	B-X
the	B-X
antioxidant	B-X
N	B-X
-	B-X
acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
resulted	B-X
in	B-X
increased	B-X
apoptosis	B-X
in	B-X
both	B-X
U937	B-X
and	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
,	B-X
while	B-X
preactivation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
with	B-X
the	B-X
non	B-X
-	B-X
apoptotic	B-X
inducer	B-X
IL	B-X
-	B-X
1beta	B-X
caused	B-X
a	B-X
relative	B-X
decrease	B-X
in	B-X
apoptosis	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
investigate	B-X
whether	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
chronically	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
promonocytic	B-X
U937	B-X
(	B-X
U9	B-X
-	B-X
IIIB	B-X
)	B-X
and	B-X
myeloblastic	B-X
PLB	B-X
-	B-X
985	B-X
(	B-X
PLB	B-X
-	B-X
IIIB	B-X
)	B-X
cells	B-X
affects	B-X
apoptotic	B-X
signaling	B-X
<EOS>	B-X
These	B-X
experiments	B-X
demonstrate	B-X
that	B-X
apoptotic	B-X
signaling	B-X
is	B-X
perturbed	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
and	B-X
indicate	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
may	B-X
play	B-X
an	B-X
additional	B-X
protective	B-X
role	B-X
against	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
myeloid	B-X
cells	B-X

TNFalpha	B-protein
plus	O
NAC	O
treatment	O
resulted	O
in	O
a	O
marked	O
decrease	O
in	O
Bcl-2	B-protein
protein	I-protein
levels	O
in	O
HIV-1-infected	B-cell_type
cells	I-cell_type
,	O
coupled	O
with	O
an	O
increase	O
in	O
Bax	B-protein
protein	I-protein
compared	O
to	O
uninfected	O
cells	O
,	O
suggesting	O
that	O
the	O
difference	O
in	O
susceptibility	O
to	O
TNFalpha	B-protein
-induced	O
apoptosis	O
may	O
relate	O
to	O
the	O
differences	O
in	O
relative	O
levels	O
of	O
Bcl-2	B-protein
and	O
Bax	B-protein
.	O

The	O
protective	O
role	O
of	O
NF-kappaB	B-protein
in	O
blocking	O
TNFalpha-	O
and	O
HIV-1-induced	O
apoptosis	O
was	O
supported	O
by	O
studies	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
engineered	O
to	O
express	O
IkappaB	B-protein
alpha	I-protein
repressor	I-protein
mutants	I-protein
(	O
TD-IkappaB	B-protein
)	O
under	O
the	O
control	O
of	O
a	O
tetracycline-responsive	B-DNA
promoter	I-DNA
.	O

Cells	O
underwent	O
apoptosis	O
in	O
response	O
to	O
TNFalpha	B-protein
only	O
when	O
NF-kappaB	O
activation	O
was	O
inhibited	O
by	O
TD-IkappaB	B-protein
expression	O
.	O
<EOS>	B-X
Cells	B-X
underwent	B-X
apoptosis	B-X
in	B-X
response	B-X
to	B-X
TNFalpha	B-X
only	B-X
when	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
TD	B-X
-	B-X
IkappaB	B-X
expression	B-X
<EOS>	B-X
As	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
,	B-X
TNFalpha	B-X
treatment	B-X
also	B-X
induced	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
Bcl	B-X
-	B-X
2	B-X
protein	B-X
levels	B-X
in	B-X
TD	B-X
-	B-X
IkappaB	B-X
expressing	B-X
cells	B-X
<EOS>	B-X
These	B-X
experiments	B-X
demonstrate	B-X
that	B-X
apoptotic	B-X
signaling	B-X
is	B-X
perturbed	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
and	B-X
indicate	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
may	B-X
play	B-X
an	B-X
additional	B-X
protective	B-X
role	B-X
against	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
myeloid	B-X
cells	B-X
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
primary	B-X
monocytic	B-X
cells	B-X
and	B-X
myeloid	B-X
cell	B-X
lines	B-X
results	B-X
in	B-X
sustained	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X

As	O
was	O
observed	O
for	O
the	O
U9-IIIB	B-cell_line
cells	I-cell_line
,	O
TNFalpha	B-protein
treatment	O
also	O
induced	O
a	O
marked	O
decrease	O
in	O
Bcl-2	B-protein
protein	I-protein
levels	O
in	O
TD-IkappaB	B-cell_type
expressing	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
As	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
,	B-X
TNFalpha	B-X
treatment	B-X
also	B-X
induced	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
Bcl	B-X
-	B-X
2	B-X
protein	B-X
levels	B-X
in	B-X
TD	B-X
-	B-X
IkappaB	B-X
expressing	B-X
cells	B-X
<EOS>	B-X
Cells	B-X
underwent	B-X
apoptosis	B-X
in	B-X
response	B-X
to	B-X
TNFalpha	B-X
only	B-X
when	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
TD	B-X
-	B-X
IkappaB	B-X
expression	B-X
<EOS>	B-X
The	B-X
protective	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
blocking	B-X
TNFalpha	B-X
-	B-X
	B-X
and	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
induced	B-X
apoptosis	B-X
was	B-X
supported	B-X
by	B-X
studies	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
engineered	B-X
to	B-X
express	B-X
IkappaB	B-X
alpha	B-X
repressor	B-X
mutants	B-X
(	B-X
TD	B-X
-	B-X
IkappaB	B-X
)	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
tetracycline	B-X
-	B-X
responsive	B-X
promoter	B-X
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
primary	B-X
monocytic	B-X
cells	B-X
and	B-X
myeloid	B-X
cell	B-X
lines	B-X
results	B-X
in	B-X
sustained	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X

These	O
experiments	O
demonstrate	O
that	O
apoptotic	O
signaling	O
is	O
perturbed	O
in	O
HIV-1-infected	O
U9-IIIB	B-cell_line
cells	I-cell_line
and	O
indicate	O
that	O
NF-kappaB	O
activation	O
may	O
play	O
an	O
additional	O
protective	O
role	O
against	O
HIV-1-induced	O
apoptosis	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
These	B-X
experiments	B-X
demonstrate	B-X
that	B-X
apoptotic	B-X
signaling	B-X
is	B-X
perturbed	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
U9	B-X
-	B-X
IIIB	B-X
cells	B-X
and	B-X
indicate	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
may	B-X
play	B-X
an	B-X
additional	B-X
protective	B-X
role	B-X
against	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
myeloid	B-X
cells	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
constitutive	B-X
NF	B-X
-	B-X
kappaB	B-X
activity	B-X
in	B-X
U9	B-X
-	B-X
IIIB	B-X
and	B-X
PLB	B-X
-	B-X
IIIB	B-X
cells	B-X
also	B-X
induced	B-X
apoptosis	B-X
,	B-X
suggesting	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
protects	B-X
cells	B-X
from	B-X
a	B-X
persistent	B-X
apoptotic	B-X
signal	B-X
<EOS>	B-X
Cells	B-X
underwent	B-X
apoptosis	B-X
in	B-X
response	B-X
to	B-X
TNFalpha	B-X
only	B-X
when	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
TD	B-X
-	B-X
IkappaB	B-X
expression	B-X
<EOS>	B-X
TNFalpha	B-X
plus	B-X
NAC	B-X
treatment	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
Bcl	B-X
-	B-X
2	B-X
protein	B-X
levels	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
coupled	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
Bax	B-X
protein	B-X
compared	B-X
to	B-X
uninfected	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
difference	B-X
in	B-X
susceptibility	B-X
to	B-X
TNFalpha	B-X
-	B-X
induced	B-X
apoptosis	B-X
may	B-X
relate	B-X
to	B-X
the	B-X
differences	B-X
in	B-X
relative	B-X
levels	B-X
of	B-X
Bcl	B-X
-	B-X
2	B-X
and	B-X
Bax	B-X

Human	B-cell_type
normal	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
B-lymphocytes	I-cell_type
are	O
deficient	O
in	O
DNA-dependent	O
protein	O
kinase	O
activity	O
due	O
to	O
the	O
expression	O
of	O
a	O
variant	O
form	O
of	O
the	O
Ku86	B-protein
protein	I-protein
.	O

The	O
heterodimeric	O
Ku	B-protein
protein	I-protein
,	O
which	O
comprises	O
a	O
86	B-protein
kDa	I-protein
(	I-protein
Ku86	I-protein
)	I-protein
amd	O
a	O
70	B-protein
kDa	I-protein
(	I-protein
Ku70	I-protein
)	I-protein
subunits	I-protein
,	O
is	O
an	O
abundant	O
nuclear	B-protein
DNA-binding	I-protein
protein	I-protein
which	O
binds	O
in	O
vitro	O
to	O
DNA	B-DNA
termini	I-DNA
without	O
sequence	O
specificity	O
.	O
<EOS>	B-X
The	B-X
heterodimeric	B-X
Ku	B-X
protein	B-X
,	B-X
which	B-X
comprises	B-X
a	B-X
86	B-X
kDa	B-X
(	B-X
Ku86	B-X
)	B-X
amd	B-X
a	B-X
70	B-X
kDa	B-X
(	B-X
Ku70	B-X
)	B-X
subunits	B-X
,	B-X
is	B-X
an	B-X
abundant	B-X
nuclear	B-X
DNA	B-X
-	B-X
binding	B-X
protein	B-X
which	B-X
binds	B-X
in	B-X
vitro	B-X
to	B-X
DNA	B-X
termini	B-X
without	B-X
sequence	B-X
specificity	B-X
<EOS>	B-X
Although	B-X
the	B-X
heterodimer	B-X
Ku70	B-X
/	B-X
variant	B-X
-	B-X
Ku86	B-X
binds	B-X
to	B-X
DNA	B-X
-	B-X
ends	B-X
,	B-X
this	B-X
altered	B-X
form	B-X
of	B-X
the	B-X
Ku	B-X
heterodimer	B-X
has	B-X
a	B-X
decreased	B-X
ability	B-X
to	B-X
recruit	B-X
the	B-X
catalytic	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
,	B-X
DNA	B-X
-	B-X
PK	B-X
(	B-X
CS	B-X
)	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
an	B-X
absence	B-X
of	B-X
detectable	B-X
DNA	B-X
-	B-X
PK	B-X
activity	B-X
in	B-X
B	B-X
cells	B-X
<EOS>	B-X
Western	B-X
blot	B-X
analysis	B-X
revealed	B-X
that	B-X
B	B-X
cells	B-X
express	B-X
a	B-X
variant	B-X
form	B-X
of	B-X
the	B-X
Ku86	B-X
protein	B-X
with	B-X
an	B-X
apparent	B-X
molecular	B-X
weight	B-X
of	B-X
69	B-X
kDa	B-X
,	B-X
and	B-X
not	B-X
the	B-X
86	B-X
kDa	B-X
-	B-X
	B-X
full	B-X
-	B-X
length	B-X
protein	B-X
<EOS>	B-X
These	B-X
data	B-X
provide	B-X
a	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
increased	B-X
sensitivity	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
ionizing	B-X
radiation	B-X
and	B-X
identify	B-X
a	B-X
new	B-X
mechanism	B-X
of	B-X
regulation	B-X
of	B-X
DNA	B-X
-	B-X
PK	B-X
activity	B-X
that	B-X
operates	B-X
in	B-X
vivo	B-X

Ku	B-protein
is	O
the	O
DNA-targeting	B-protein
component	I-protein
of	O
the	O
large	O
catalytic	B-protein
sub-unit	I-protein
of	O
the	O
DNA-dependent	B-protein
protein	I-protein
kinase	I-protein
complex	I-protein
(	O
DNA-PK	B-protein
[	I-protein
CS	I-protein
]	I-protein
)	O
,	O
that	O
plays	O
a	O
critical	O
role	O
in	O
mammalian	O
double-strand	O
break	O
repair	O
and	O
lymphoid	O
V	O
(	O
D	O
)	O
J	O
recombination	O
.	O

By	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
demonstrated	O
that	O
in	O
addition	O
to	O
the	O
major	B-protein
Ku	I-protein
x	I-protein
DNA	I-protein
complex	I-protein
usually	O
detected	O
in	O
cell	O
line	O
extracts	O
,	O
a	O
second	O
complex	O
with	O
faster	O
electrophoretic	O
mobility	O
was	O
observed	O
in	O
normal	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
extracts	O
.	O

The	O
presence	O
of	O
this	O
faster	B-protein
migrating	I-protein
complex	I-protein
was	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
among	O
the	O
circulating	B-cell_type
lymphocyte	I-cell_type
population	I-cell_type
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
B	B-cell_type
cells	I-cell_type
express	O
a	O
variant	O
form	O
of	O
the	O
Ku86	B-protein
protein	I-protein
with	O
an	O
apparent	O
molecular	O
weight	O
of	O
69	O
kDa	O
,	O
and	O
not	O
the	O
86	B-protein
kDa-	I-protein
full-length	I-protein
protein	I-protein
.	O

Although	O
the	O
heterodimer	B-protein
Ku70/variant-Ku86	I-protein
binds	O
to	O
DNA-ends	B-DNA
,	O
this	O
altered	O
form	O
of	O
the	O
Ku	B-protein
heterodimer	I-protein
has	O
a	O
decreased	O
ability	O
to	O
recruit	O
the	O
catalytic	B-protein
component	I-protein
of	O
the	O
complex	O
,	O
DNA-PK	B-protein
(	I-protein
CS	I-protein
)	I-protein
,	O
which	O
contributes	O
to	O
an	O
absence	O
of	O
detectable	O
DNA-PK	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

These	O
data	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
increased	O
sensitivity	O
of	O
B	B-cell_type
cells	I-cell_type
to	O
ionizing	O
radiation	O
and	O
identify	O
a	O
new	O
mechanism	O
of	O
regulation	O
of	O
DNA-PK	O
activity	O
that	O
operates	O
in	O
vivo	O
.	O
<EOS>	B-X
These	B-X
data	B-X
provide	B-X
a	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
increased	B-X
sensitivity	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
ionizing	B-X
radiation	B-X
and	B-X
identify	B-X
a	B-X
new	B-X
mechanism	B-X
of	B-X
regulation	B-X
of	B-X
DNA	B-X
-	B-X
PK	B-X
activity	B-X
that	B-X
operates	B-X
in	B-X
vivo	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
this	B-X
faster	B-X
migrating	B-X
complex	B-X
was	B-X
restricted	B-X
to	B-X
B	B-X
cells	B-X
among	B-X
the	B-X
circulating	B-X
lymphocyte	B-X
population	B-X
<EOS>	B-X
Human	B-X
normal	B-X
peripheral	B-X
blood	B-X
B	B-X
-	B-X
lymphocytes	B-X
are	B-X
deficient	B-X
in	B-X
DNA	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
activity	B-X
due	B-X
to	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
variant	B-X
form	B-X
of	B-X
the	B-X
Ku86	B-X
protein	B-X
.	B-X
<EOS>	B-X
By	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
major	B-X
Ku	B-X
x	B-X
DNA	B-X
complex	B-X
usually	B-X
detected	B-X
in	B-X
cell	B-X
line	B-X
extracts	B-X
,	B-X
a	B-X
second	B-X
complex	B-X
with	B-X
faster	B-X
electrophoretic	B-X
mobility	B-X
was	B-X
observed	B-X
in	B-X
normal	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
(	B-X
PBL	B-X
)	B-X
extracts	B-X

Co-stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
with	O
IL-2	B-protein
and	O
anti-CD3	B-protein
monoclonal	I-protein
antibodies	I-protein
induces	O
phosphorylation	O
of	O
CREB	B-protein
.	O
<EOS>	B-X
Co	B-X
-	B-X
stimulation	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
anti	B-X
-	B-X
CD3	B-X
monoclonal	B-X
antibodies	B-X
induces	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
.	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
signal	B-X
transduction	B-X
through	B-X
p56lck	B-X
or	B-X
p59fyn	B-X
,	B-X
inhibition	B-X
of	B-X
PTK	B-X
signaling	B-X
reduced	B-X
phosphorylation	B-X
50	B-X
%	B-X
<EOS>	B-X
Due	B-X
to	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
being	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
independent	B-X
,	B-X
it	B-X
was	B-X
postulated	B-X
that	B-X
IL	B-X
-	B-X
2	B-X
might	B-X
provide	B-X
a	B-X
necessary	B-X
co	B-X
-	B-X
stimulus	B-X
for	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
in	B-X
primary	B-X
lymphocytes	B-X
<EOS>	B-X
Phosphorylation	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
cAMP	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
PKA	B-X
signaling	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
P	B-X
-	B-X
CREB	B-X

Phosphorylation	O
of	O
the	O
cAMP-response	B-protein
element	I-protein
binding	I-protein
protein	I-protein
CREB	I-protein
within	O
1	O
h	O
of	O
CD2	B-protein
but	O
not	O
CD3	B-protein
cross-linking	O
of	O
human	B-cell_type
PBMC	I-cell_type
was	O
recently	O
demonstrated	O
.	O

The	O
absence	O
of	O
P-CREB	B-protein
following	O
CD3	O
cross-linking	O
was	O
unexpected	O
,	O
as	O
other	O
laboratories	O
reported	O
increased	O
phosphorylation	O
of	O
CREB	B-protein
following	O
CD3	O
cross-linking	O
of	O
the	O
Jurkat	B-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
P	B-X
-	B-X
CREB	B-X
following	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
was	B-X
unexpected	B-X
,	B-X
as	B-X
other	B-X
laboratories	B-X
reported	B-X
increased	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
Jurkat	B-X
lymphocyte	B-X
cell	B-X
line	B-X
<EOS>	B-X
IL	B-X
-	B-X
2	B-X
did	B-X
not	B-X
further	B-X
augment	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
CD2	B-X
cross	B-X
-	B-X
linking	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
CD3	B-X
signaling	B-X
pathways	B-X
provide	B-X
a	B-X
necessary	B-X
and	B-X
co	B-X
-	B-X
operative	B-X
stimulus	B-X
promoting	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
receptor	B-X
cross	B-X
-	B-X
linking	B-X
<EOS>	B-X
Due	B-X
to	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
being	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
independent	B-X
,	B-X
it	B-X
was	B-X
postulated	B-X
that	B-X
IL	B-X
-	B-X
2	B-X
might	B-X
provide	B-X
a	B-X
necessary	B-X
co	B-X
-	B-X
stimulus	B-X
for	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
in	B-X
primary	B-X
lymphocytes	B-X

Due	O
to	O
Jurkat	B-cell_line
T-cells	I-cell_line
being	O
IL-2-independent	O
,	O
it	O
was	O
postulated	O
that	O
IL-2	B-protein
might	O
provide	O
a	O
necessary	O
co-stimulus	O
for	O
phosphorylation	O
of	O
CREB	B-protein
in	O
primary	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Due	B-X
to	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
being	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
independent	B-X
,	B-X
it	B-X
was	B-X
postulated	B-X
that	B-X
IL	B-X
-	B-X
2	B-X
might	B-X
provide	B-X
a	B-X
necessary	B-X
co	B-X
-	B-X
stimulus	B-X
for	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
in	B-X
primary	B-X
lymphocytes	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
CD3	B-X
signaling	B-X
pathways	B-X
provide	B-X
a	B-X
necessary	B-X
and	B-X
co	B-X
-	B-X
operative	B-X
stimulus	B-X
promoting	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
receptor	B-X
cross	B-X
-	B-X
linking	B-X
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
P	B-X
-	B-X
CREB	B-X
following	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
was	B-X
unexpected	B-X
,	B-X
as	B-X
other	B-X
laboratories	B-X
reported	B-X
increased	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
Jurkat	B-X
lymphocyte	B-X
cell	B-X
line	B-X
<EOS>	B-X
Co	B-X
-	B-X
stimulation	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
anti	B-X
-	B-X
CD3	B-X
monoclonal	B-X
antibodies	B-X
induces	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
.	B-X

Therefore	O
,	O
P-CREB	B-protein
was	O
evaluated	O
following	O
co-stimulation	O
of	O
human	B-cell_type
PBMC	I-cell_type
through	O
the	O
IL-2	B-protein
and	I-protein
CD2	I-protein
or	I-protein
CD3	I-protein
receptors	I-protein
.	O
<EOS>	B-X
The	B-X
skin	B-X
at	B-X
the	B-X
injection	B-X
site	B-X
was	B-X
evaluated	B-X
for	B-X
local	B-X
inflammation	B-X
,	B-X
histopathology	B-X
,	B-X
immune	B-X
cell	B-X
infiltration	B-X
,	B-X
and	B-X
gene	B-X
expression	B-X
<EOS>	B-X
These	B-X
results	B-X
are	B-X
useful	B-X
for	B-X
the	B-X
development	B-X
of	B-X
tumor	B-X
immunotherapy	B-X
based	B-X
on	B-X
γδ	B-X
T	B-X
cells	B-X
<EOS>	B-X
Biodistribution	B-X
was	B-X
evaluated	B-X
in	B-X
CD34	B-X
-	B-X
humanized	B-X
mice	B-X
and	B-X
in	B-X
canines	B-X
<EOS>	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
explore	B-X
the	B-X
clinical	B-X
value	B-X
of	B-X
TSH	B-X
in	B-X
regulating	B-X
the	B-X
progression	B-X
of	B-X
TC	B-X
,	B-X
so	B-X
as	B-X
to	B-X
find	B-X
a	B-X
breakthrough	B-X
for	B-X
the	B-X
early	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
TC	B-X

IL-2	B-protein
did	O
not	O
further	O
augment	O
phosphorylation	O
of	O
CREB	B-protein
following	O
CD2	O
cross-linking	O
.	O
<EOS>	B-X
Sulfated	B-X
polysaccharides	B-X
are	B-X
effective	B-X
immunostimulating	B-X
agents	B-X
by	B-X
activating	B-X
several	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
<EOS>	B-X
Preclinical	B-X
proof	B-X
of	B-X
concept	B-X
for	B-X
VivoVec	B-X
,	B-X
a	B-X
lentiviral	B-X
-	B-X
based	B-X
platform	B-X
for	B-X
in	B-X
vivo	B-X
CAR	B-X
T	B-X
-	B-X
cell	B-X
engineering	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
CM	B-X
and	B-X
HJ	B-X
may	B-X
benefit	B-X
specific	B-X
metabolic	B-X
functions	B-X
of	B-X
gut	B-X
microbiota	B-X
,	B-X
such	B-X
as	B-X
starch	B-X
,	B-X
sucrose	B-X
,	B-X
and	B-X
tyrosine	B-X
metabolism	B-X
<EOS>	B-X
There	B-X
is	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
response	B-X
and	B-X
a	B-X
significant	B-X
correlation	B-X
between	B-X
binding	B-X
and	B-X
neutralizing	B-X
antibody	B-X
activity	B-X

However	O
,	O
while	O
neither	O
IL-2	B-protein
nor	O
CD3	O
cross-linking	O
alone	O
induced	O
P-CREB	B-protein
,	O
a	O
4.5-fold	O
increase	O
in	O
phosphorylation	O
of	O
CREB	B-protein
within	O
1	O
h	O
of	O
IL-2/CD3	O
co-stimulation	O
was	O
observed	O
.	O
<EOS>	B-X
5	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
within	B-X
1	B-X
h	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
CD3	B-X
co	B-X
-	B-X
stimulation	B-X
was	B-X
observed	B-X
<EOS>	B-X
However	B-X
,	B-X
while	B-X
neither	B-X
IL	B-X
-	B-X
2	B-X
nor	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
alone	B-X
induced	B-X
P	B-X
-	B-X
CREB	B-X
,	B-X
a	B-X
4	B-X
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
P	B-X
-	B-X
CREB	B-X
following	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
was	B-X
unexpected	B-X
,	B-X
as	B-X
other	B-X
laboratories	B-X
reported	B-X
increased	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
Jurkat	B-X
lymphocyte	B-X
cell	B-X
line	B-X
<EOS>	B-X
IL	B-X
-	B-X
2	B-X
did	B-X
not	B-X
further	B-X
augment	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
CD2	B-X
cross	B-X
-	B-X
linking	B-X

Phosphorylation	O
was	O
not	O
associated	O
with	O
the	O
induction	O
of	O
cAMP	O
,	O
and	O
inhibition	O
of	O
PKA	O
signaling	O
had	O
no	O
effect	O
on	O
P-CREB	B-protein
.	O
<EOS>	B-X
This	B-X
down	B-X
-	B-X
regulation	B-X
is	B-X
related	B-X
to	B-X
the	B-X
activity	B-X
of	B-X
EGFR	B-X
signaling	B-X
pathway	B-X
<EOS>	B-X
SP1	B-X
is	B-X
an	B-X
upstream	B-X
transcription	B-X
factor	B-X
of	B-X
PSRC1	B-X
and	B-X
inhibits	B-X
the	B-X
transcription	B-X
of	B-X
PSRC1	B-X
<EOS>	B-X
Under	B-X
low	B-X
-	B-X
concentration	B-X
cadmium	B-X
stress	B-X
,	B-X
the	B-X
body	B-X
improved	B-X
immunity	B-X
by	B-X
enhancing	B-X
the	B-X
expression	B-X
of	B-X
ShACP	B-X
,	B-X
while	B-X
high	B-X
-	B-X
concentration	B-X
cadmium	B-X
stress	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
ShACP	B-X
<EOS>	B-X
M2	B-X
polarized	B-X
tumor	B-X
-	B-X
associated	B-X
macrophages	B-X
(	B-X
TAMs	B-X
)	B-X
have	B-X
a	B-X
multifunctional	B-X
role	B-X
in	B-X
cancer	B-X
initiation	B-X
,	B-X
progression	B-X
,	B-X
metastasis	B-X
,	B-X
and	B-X
contribute	B-X
to	B-X
chemotherapeutic	B-X
resistance	B-X

Consistent	O
with	O
signal	O
transduction	O
through	O
p56lck	B-protein
or	O
p59fyn	B-protein
,	O
inhibition	O
of	O
PTK	O
signaling	O
reduced	O
phosphorylation	O
50	O
%	O
.	O
<EOS>	B-X
Consistent	B-X
with	B-X
signal	B-X
transduction	B-X
through	B-X
p56lck	B-X
or	B-X
p59fyn	B-X
,	B-X
inhibition	B-X
of	B-X
PTK	B-X
signaling	B-X
reduced	B-X
phosphorylation	B-X
50	B-X
%	B-X
<EOS>	B-X
Phosphorylation	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
cAMP	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
PKA	B-X
signaling	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
P	B-X
-	B-X
CREB	B-X
<EOS>	B-X
Co	B-X
-	B-X
stimulation	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
anti	B-X
-	B-X
CD3	B-X
monoclonal	B-X
antibodies	B-X
induces	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
.	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
depletion	B-X
of	B-X
the	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
by	B-X
preincubation	B-X
of	B-X
S15	B-X
CTL	B-X
with	B-X
herbimycin	B-X
A	B-X
severely	B-X
impaired	B-X
perforin	B-X
-	B-X
	B-X
but	B-X
not	B-X
Fas	B-X
-	B-X
dependent	B-X
cytotoxicity	B-X

Interestingly	O
,	O
inhibiting	O
PKC	O
signaling	O
with	O
calphostin	O
C	O
further	O
increased	O
P-CREB	O
levels	O
3-fold	O
over	O
that	O
observed	O
in	O
IL-2/CD3	B-cell_type
co-stimulated	I-cell_type
cells	I-cell_type
not	O
pretreated	O
with	O
a	O
PKC	O
inhibitor	O
.	O

In	O
contrast	O
to	O
previous	O
studies	O
performed	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
IL-2	I-protein
,	O
no	O
increase	O
in	O
binding	O
of	O
CREB	B-protein
to	O
a	O
32P-labeled	O
oligonucleotide	O
probe	O
was	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
previous	B-X
studies	B-X
performed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
exogenous	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
no	B-X
increase	B-X
in	B-X
binding	B-X
of	B-X
CREB	B-X
to	B-X
a	B-X
32P	B-X
-	B-X
labeled	B-X
oligonucleotide	B-X
probe	B-X
was	B-X
observed	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
signal	B-X
transduction	B-X
through	B-X
p56lck	B-X
or	B-X
p59fyn	B-X
,	B-X
inhibition	B-X
of	B-X
PTK	B-X
signaling	B-X
reduced	B-X
phosphorylation	B-X
50	B-X
%	B-X
<EOS>	B-X
Phosphorylation	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
cAMP	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
PKA	B-X
signaling	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
P	B-X
-	B-X
CREB	B-X
<EOS>	B-X
Co	B-X
-	B-X
stimulation	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
anti	B-X
-	B-X
CD3	B-X
monoclonal	B-X
antibodies	B-X
induces	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
.	B-X

These	O
data	O
suggest	O
that	O
the	O
IL-2	B-protein
and	O
CD3	B-protein
signaling	O
pathways	O
provide	O
a	O
necessary	O
and	O
co-operative	O
stimulus	O
promoting	O
phosphorylation	O
of	O
CREB	B-protein
following	O
receptor	O
cross-linking	O
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
CD3	B-X
signaling	B-X
pathways	B-X
provide	B-X
a	B-X
necessary	B-X
and	B-X
co	B-X
-	B-X
operative	B-X
stimulus	B-X
promoting	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
receptor	B-X
cross	B-X
-	B-X
linking	B-X
<EOS>	B-X
IL	B-X
-	B-X
2	B-X
did	B-X
not	B-X
further	B-X
augment	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
CD2	B-X
cross	B-X
-	B-X
linking	B-X
<EOS>	B-X
Due	B-X
to	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
being	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
independent	B-X
,	B-X
it	B-X
was	B-X
postulated	B-X
that	B-X
IL	B-X
-	B-X
2	B-X
might	B-X
provide	B-X
a	B-X
necessary	B-X
co	B-X
-	B-X
stimulus	B-X
for	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
in	B-X
primary	B-X
lymphocytes	B-X
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
P	B-X
-	B-X
CREB	B-X
following	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
was	B-X
unexpected	B-X
,	B-X
as	B-X
other	B-X
laboratories	B-X
reported	B-X
increased	B-X
phosphorylation	B-X
of	B-X
CREB	B-X
following	B-X
CD3	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
Jurkat	B-X
lymphocyte	B-X
cell	B-X
line	B-X

HIV-1	O
infection	O
induces	O
a	O
selective	O
reduction	O
in	O
STAT5	O
protein	O
expression	O
.	O
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
induces	B-X
a	B-X
selective	B-X
reduction	B-X
in	B-X
STAT5	B-X
protein	B-X
expression	B-X
.	B-X
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
is	B-X
accompanied	B-X
by	B-X
qualitative	B-X
and	B-X
quantitative	B-X
defects	B-X
in	B-X
CD4+	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
Loss	B-X
of	B-X
immune	B-X
function	B-X
in	B-X
HIV	B-X
patients	B-X
is	B-X
usually	B-X
associated	B-X
with	B-X
a	B-X
profound	B-X
dysregulation	B-X
of	B-X
cytokine	B-X
production	B-X
<EOS>	B-X
The	B-X
reduction	B-X
in	B-X
STATs	B-X
seen	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
after	B-X
HIV	B-X
infection	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
T	B-X
cell	B-X
function	B-X
in	B-X
HIV	B-X
disease	B-X

HIV-1	O
infection	O
is	O
accompanied	O
by	O
qualitative	O
and	O
quantitative	O
defects	O
in	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
is	B-X
accompanied	B-X
by	B-X
qualitative	B-X
and	B-X
quantitative	B-X
defects	B-X
in	B-X
CD4+	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
induces	B-X
a	B-X
selective	B-X
reduction	B-X
in	B-X
STAT5	B-X
protein	B-X
expression	B-X
.	B-X
<EOS>	B-X
Loss	B-X
of	B-X
immune	B-X
function	B-X
in	B-X
HIV	B-X
patients	B-X
is	B-X
usually	B-X
associated	B-X
with	B-X
a	B-X
profound	B-X
dysregulation	B-X
of	B-X
cytokine	B-X
production	B-X
<EOS>	B-X
The	B-X
reduction	B-X
in	B-X
STATs	B-X
seen	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
after	B-X
HIV	B-X
infection	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
T	B-X
cell	B-X
function	B-X
in	B-X
HIV	B-X
disease	B-X

Loss	O
of	O
immune	O
function	O
in	O
HIV	O
patients	O
is	O
usually	O
associated	O
with	O
a	O
profound	O
dysregulation	O
of	O
cytokine	B-protein
production	O
.	O
<EOS>	B-X
Loss	B-X
of	B-X
immune	B-X
function	B-X
in	B-X
HIV	B-X
patients	B-X
is	B-X
usually	B-X
associated	B-X
with	B-X
a	B-X
profound	B-X
dysregulation	B-X
of	B-X
cytokine	B-X
production	B-X
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
is	B-X
accompanied	B-X
by	B-X
qualitative	B-X
and	B-X
quantitative	B-X
defects	B-X
in	B-X
CD4+	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
induces	B-X
a	B-X
selective	B-X
reduction	B-X
in	B-X
STAT5	B-X
protein	B-X
expression	B-X
.	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
cytokine	B-X
signaling	B-X
defects	B-X
occur	B-X
during	B-X
HIV	B-X
infection	B-X
,	B-X
PHA	B-X
blasts	B-X
from	B-X
healthy	B-X
human	B-X
donors	B-X
were	B-X
infected	B-X
with	B-X
two	B-X
strains	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
and	B-X
screened	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
STAT	B-X
proteins	B-X
used	B-X
in	B-X
cytokine	B-X
signaling	B-X

To	O
investigate	O
whether	O
cytokine	B-protein
signaling	O
defects	O
occur	O
during	O
HIV	O
infection	O
,	O
PHA	B-cell_type
blasts	I-cell_type
from	O
healthy	O
human	O
donors	O
were	O
infected	O
with	O
two	O
strains	O
of	O
HIV-1	O
and	O
screened	O
for	O
the	O
expression	O
of	O
STAT	B-protein
proteins	I-protein
used	O
in	O
cytokine	B-protein
signaling	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
cytokine	B-X
signaling	B-X
defects	B-X
occur	B-X
during	B-X
HIV	B-X
infection	B-X
,	B-X
PHA	B-X
blasts	B-X
from	B-X
healthy	B-X
human	B-X
donors	B-X
were	B-X
infected	B-X
with	B-X
two	B-X
strains	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
and	B-X
screened	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
STAT	B-X
proteins	B-X
used	B-X
in	B-X
cytokine	B-X
signaling	B-X
<EOS>	B-X
Loss	B-X
of	B-X
immune	B-X
function	B-X
in	B-X
HIV	B-X
patients	B-X
is	B-X
usually	B-X
associated	B-X
with	B-X
a	B-X
profound	B-X
dysregulation	B-X
of	B-X
cytokine	B-X
production	B-X
<EOS>	B-X
The	B-X
reduction	B-X
in	B-X
STATs	B-X
seen	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
after	B-X
HIV	B-X
infection	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
T	B-X
cell	B-X
function	B-X
in	B-X
HIV	B-X
disease	B-X
<EOS>	B-X
A	B-X
selective	B-X
decrease	B-X
in	B-X
STAT5B	B-X
was	B-X
seen	B-X
8	B-X
days	B-X
after	B-X
infection	B-X
with	B-X
the	B-X
BZ167	B-X
dual	B-X
-	B-X
tropic	B-X
HIV	B-X
isolate	B-X
,	B-X
but	B-X
not	B-X
with	B-X
the	B-X
Ba	B-X
-	B-X
L	B-X
,	B-X
M	B-X
-	B-X
tropic	B-X
strain	B-X

A	O
selective	O
decrease	O
in	O
STAT5B	B-protein
was	O
seen	O
8	O
days	O
after	O
infection	O
with	O
the	O
BZ167	O
dual-tropic	O
HIV	O
isolate	O
,	O
but	O
not	O
with	O
the	O
Ba-L	O
,	O
M-tropic	O
strain	O
.	O

Based	O
on	O
these	O
findings	O
,	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
HIV-infected	O
patients	O
in	O
different	O
stages	O
of	O
disease	O
were	O
also	O
tested	O
for	O
STAT	O
expression	O
;	O
decreases	O
in	O
STAT5A	B-protein
,	O
STAT5B	B-protein
,	O
and	O
STAT1alpha	B-protein
were	O
observed	O
in	O
all	O
patients	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
findings	B-X
,	B-X
purified	B-X
T	B-X
cells	B-X
from	B-X
HIV	B-X
-	B-X
infected	B-X
patients	B-X
in	B-X
different	B-X
stages	B-X
of	B-X
disease	B-X
were	B-X
also	B-X
tested	B-X
for	B-X
STAT	B-X
expression	B-X
;	B-X
decreases	B-X
in	B-X
STAT5A	B-X
,	B-X
STAT5B	B-X
,	B-X
and	B-X
STAT1alpha	B-X
were	B-X
observed	B-X
in	B-X
all	B-X
patients	B-X
<EOS>	B-X
Loss	B-X
of	B-X
immune	B-X
function	B-X
in	B-X
HIV	B-X
patients	B-X
is	B-X
usually	B-X
associated	B-X
with	B-X
a	B-X
profound	B-X
dysregulation	B-X
of	B-X
cytokine	B-X
production	B-X
<EOS>	B-X
The	B-X
reduction	B-X
in	B-X
STATs	B-X
seen	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
after	B-X
HIV	B-X
infection	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
T	B-X
cell	B-X
function	B-X
in	B-X
HIV	B-X
disease	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
cytokine	B-X
signaling	B-X
defects	B-X
occur	B-X
during	B-X
HIV	B-X
infection	B-X
,	B-X
PHA	B-X
blasts	B-X
from	B-X
healthy	B-X
human	B-X
donors	B-X
were	B-X
infected	B-X
with	B-X
two	B-X
strains	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
and	B-X
screened	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
STAT	B-X
proteins	B-X
used	B-X
in	B-X
cytokine	B-X
signaling	B-X

The	O
reduction	O
in	O
STATs	B-protein
seen	O
in	O
vivo	O
and	O
in	O
vitro	O
after	O
HIV	O
infection	O
may	O
contribute	O
to	O
the	O
loss	O
of	O
T	B-cell_type
cell	I-cell_type
function	O
in	O
HIV	O
disease	O
.	O

Transcription	B-protein
factors	I-protein
that	O
regulate	O
monocyte	B-cell_type
/	O
macrophage	B-cell_type
differentiation	O
.	O
<EOS>	B-X
p38	B-X
MAPK	B-X
-	B-X
dependent	B-X
phosphorylation	B-X
of	B-X
TFEB	B-X
promotes	B-X
monocyte	B-X
-	B-X
to	B-X
-	B-X
macrophage	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
Activating	B-X
transcription	B-X
factor	B-X
4	B-X
(	B-X
ATF4	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
immune	B-X
cell	B-X
differentiation	B-X
<EOS>	B-X
RNA	B-X
-	B-X
sequencing	B-X
(	B-X
RNA	B-X
-	B-X
seq	B-X
)	B-X
analysis	B-X
revealed	B-X
the	B-X
effect	B-X
of	B-X
ASGR1	B-X
on	B-X
monocyte	B-X
-	B-X
to	B-X
-	B-X
macrophage	B-X
differentiation	B-X
<EOS>	B-X
ASGR1	B-X
promotes	B-X
liver	B-X
injury	B-X
in	B-X
sepsis	B-X
by	B-X
modulating	B-X
monocyte	B-X
-	B-X
to	B-X
-	B-X
macrophage	B-X
differentiation	B-X
via	B-X
NF	B-X
-	B-X
κB	B-X
/	B-X
ATF5	B-X
pathway	B-X
.	B-X

Although	O
all	O
the	O
cells	O
in	O
an	O
organism	O
contain	O
the	O
same	O
genetic	O
information	O
,	O
differences	O
in	O
the	O
cell	O
phenotype	O
arise	O
from	O
the	O
expression	O
of	O
lineage-specific	B-DNA
genes	I-DNA
.	O

During	O
myelopoiesis	O
,	O
external	O
differentiating	O
signals	O
regulate	O
the	O
expression	O
of	O
a	O
set	O
of	O
transcription	B-protein
factors	I-protein
.	O
<EOS>	B-X
During	B-X
myelopoiesis	B-X
,	B-X
external	B-X
differentiating	B-X
signals	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
set	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
transcription	B-X
factor	B-X
PU	B-X
<EOS>	B-X
Transcription	B-X
factors	B-X
that	B-X
regulate	B-X
monocyte	B-X
/	B-X
macrophage	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
The	B-X
combined	B-X
action	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
subsequently	B-X
determines	B-X
the	B-X
expression	B-X
of	B-X
myeloid	B-X
-	B-X
specific	B-X
genes	B-X
and	B-X
the	B-X
generation	B-X
of	B-X
monocytes	B-X
and	B-X
macrophages	B-X

The	O
combined	O
action	O
of	O
these	O
transcription	B-protein
factors	I-protein
subsequently	O
determines	O
the	O
expression	O
of	O
myeloid-specific	B-DNA
genes	I-DNA
and	O
the	O
generation	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
.	O
<EOS>	B-X
The	B-X
combined	B-X
action	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
subsequently	B-X
determines	B-X
the	B-X
expression	B-X
of	B-X
myeloid	B-X
-	B-X
specific	B-X
genes	B-X
and	B-X
the	B-X
generation	B-X
of	B-X
monocytes	B-X
and	B-X
macrophages	B-X
<EOS>	B-X
We	B-X
review	B-X
the	B-X
contribution	B-X
of	B-X
several	B-X
transcription	B-X
factors	B-X
to	B-X
the	B-X
control	B-X
of	B-X
macrophage	B-X
development	B-X
<EOS>	B-X
During	B-X
myelopoiesis	B-X
,	B-X
external	B-X
differentiating	B-X
signals	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
set	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Transcription	B-X
factors	B-X
that	B-X
regulate	B-X
monocyte	B-X
/	B-X
macrophage	B-X
differentiation	B-X
.	B-X

In	O
particular	O
,	O
the	O
transcription	B-protein
factor	I-protein
PU.1	I-protein
has	O
a	O
critical	O
role	O
in	O
this	O
process	O
.	O

We	O
review	O
the	O
contribution	O
of	O
several	O
transcription	B-protein
factors	I-protein
to	O
the	O
control	O
of	O
macrophage	B-cell_type
development	O

Transcription	B-protein
factor	I-protein
LKLF	I-protein
is	O
sufficient	O
to	O
program	O
T	O
cell	O
quiescence	O
via	O
a	O
c-Myc	O
--	O
dependent	O
pathway	O
.	O

T	B-cell_type
lymphocytes	I-cell_type
circulate	O
in	O
a	O
quiescent	O
state	O
until	O
they	O
encounter	O
cognate	B-protein
antigen	I-protein
bound	O
to	O
the	O
surface	O
of	O
an	O
antigen-presenting	B-cell_type
cell	I-cell_type
.	O

The	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
quiescence	O
remain	O
largely	O
unknown	O
.	O
<EOS>	B-X
The	B-X
molecular	B-X
pathways	B-X
that	B-X
regulate	B-X
T	B-X
cell	B-X
quiescence	B-X
remain	B-X
largely	B-X
unknown	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
LKLF	B-X
is	B-X
sufficient	B-X
to	B-X
program	B-X
T	B-X
cell	B-X
quiescence	B-X
via	B-X
a	B-X
c	B-X
-	B-X
Myc	B-X
-	B-X
dependent	B-X
pathway	B-X
.	B-X
<EOS>	B-X
T	B-X
lymphocytes	B-X
circulate	B-X
in	B-X
a	B-X
quiescent	B-X
state	B-X
until	B-X
they	B-X
encounter	B-X
cognate	B-X
antigen	B-X
bound	B-X
to	B-X
the	B-X
surface	B-X
of	B-X
an	B-X
antigen	B-X
-	B-X
presenting	B-X
cell	B-X
<EOS>	B-X
Thus	B-X
,	B-X
LKLF	B-X
is	B-X
both	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
program	B-X
quiescence	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
functions	B-X
,	B-X
in	B-X
part	B-X
,	B-X
by	B-X
negatively	B-X
regulating	B-X
a	B-X
c	B-X
-	B-X
Myc	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
dependent	B-X
pathway	B-X

Here	O
we	O
show	O
that	O
forced	O
expression	O
of	O
the	O
lung	B-protein
Kruppel-like	I-protein
transcription	I-protein
factor	I-protein
(	O
LKLF	B-protein
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
is	O
sufficient	O
to	O
program	O
a	O
quiescent	O
phenotype	O
characterized	O
by	O
decreased	O
proliferation	O
,	O
reduced	O
cell	O
size	O
and	O
protein	O
synthesis	O
and	O
decreased	O
surface	O
expression	O
of	O
activation	O
markers	O
.	O

Conversely	O
,	O
LKLF-deficient	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
produced	O
by	O
gene	O
targeting	O
showed	O
increased	O
proliferation	O
,	O
increased	O
cell	O
size	O
and	O
enhanced	O
expression	O
of	O
surface	O
activation	O
markers	O
in	O
vivo	O
.	O
<EOS>	B-X
Conversely	B-X
,	B-X
LKLF	B-X
-	B-X
deficient	B-X
peripheral	B-X
T	B-X
cells	B-X
produced	B-X
by	B-X
gene	B-X
targeting	B-X
showed	B-X
increased	B-X
proliferation	B-X
,	B-X
increased	B-X
cell	B-X
size	B-X
and	B-X
enhanced	B-X
expression	B-X
of	B-X
surface	B-X
activation	B-X
markers	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
forced	B-X
expression	B-X
of	B-X
the	B-X
lung	B-X
Krüppel	B-X
-	B-X
like	B-X
transcription	B-X
factor	B-X
(	B-X
LKLF	B-X
)	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
is	B-X
sufficient	B-X
to	B-X
program	B-X
a	B-X
quiescent	B-X
phenotype	B-X
characterized	B-X
by	B-X
decreased	B-X
proliferation	B-X
,	B-X
reduced	B-X
cell	B-X
size	B-X
and	B-X
protein	B-X
synthesis	B-X
and	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
activation	B-X
markers	B-X
<EOS>	B-X
LKLF	B-X
appeared	B-X
to	B-X
function	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
decreasing	B-X
expression	B-X
of	B-X
the	B-X
proto	B-X
-	B-X
oncogene	B-X
encoding	B-X
c	B-X
-	B-X
Myc	B-X
<EOS>	B-X
T	B-X
lymphocytes	B-X
circulate	B-X
in	B-X
a	B-X
quiescent	B-X
state	B-X
until	B-X
they	B-X
encounter	B-X
cognate	B-X
antigen	B-X
bound	B-X
to	B-X
the	B-X
surface	B-X
of	B-X
an	B-X
antigen	B-X
-	B-X
presenting	B-X
cell	B-X

LKLF	B-protein
appeared	O
to	O
function	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
decreasing	O
expression	O
of	O
the	O
proto-oncogene	B-DNA
encoding	O
c-Myc	B-protein
.	O
<EOS>	B-X
LKLF	B-X
appeared	B-X
to	B-X
function	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
decreasing	B-X
expression	B-X
of	B-X
the	B-X
proto	B-X
-	B-X
oncogene	B-X
encoding	B-X
c	B-X
-	B-X
Myc	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
effects	B-X
of	B-X
LKLF	B-X
expression	B-X
were	B-X
mimicked	B-X
by	B-X
expression	B-X
of	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
MadMyc	B-X
protein	B-X
and	B-X
rescued	B-X
by	B-X
overexpression	B-X
of	B-X
c	B-X
-	B-X
Myc	B-X
<EOS>	B-X
T	B-X
lymphocytes	B-X
circulate	B-X
in	B-X
a	B-X
quiescent	B-X
state	B-X
until	B-X
they	B-X
encounter	B-X
cognate	B-X
antigen	B-X
bound	B-X
to	B-X
the	B-X
surface	B-X
of	B-X
an	B-X
antigen	B-X
-	B-X
presenting	B-X
cell	B-X
<EOS>	B-X
Conversely	B-X
,	B-X
LKLF	B-X
-	B-X
deficient	B-X
peripheral	B-X
T	B-X
cells	B-X
produced	B-X
by	B-X
gene	B-X
targeting	B-X
showed	B-X
increased	B-X
proliferation	B-X
,	B-X
increased	B-X
cell	B-X
size	B-X
and	B-X
enhanced	B-X
expression	B-X
of	B-X
surface	B-X
activation	B-X
markers	B-X
in	B-X
vivo	B-X

Forced	O
expression	O
of	O
LKLF	B-protein
was	O
associated	O
with	O
markedly	O
decreased	O
c-Myc	B-protein
expression	O
.	O
<EOS>	B-X
Forced	B-X
expression	B-X
of	B-X
LKLF	B-X
was	B-X
associated	B-X
with	B-X
markedly	B-X
decreased	B-X
c	B-X
-	B-X
Myc	B-X
expression	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
effects	B-X
of	B-X
LKLF	B-X
expression	B-X
were	B-X
mimicked	B-X
by	B-X
expression	B-X
of	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
MadMyc	B-X
protein	B-X
and	B-X
rescued	B-X
by	B-X
overexpression	B-X
of	B-X
c	B-X
-	B-X
Myc	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
LKLF	B-X
is	B-X
sufficient	B-X
to	B-X
program	B-X
T	B-X
cell	B-X
quiescence	B-X
via	B-X
a	B-X
c	B-X
-	B-X
Myc	B-X
-	B-X
dependent	B-X
pathway	B-X
.	B-X
<EOS>	B-X
Conversely	B-X
,	B-X
LKLF	B-X
-	B-X
deficient	B-X
peripheral	B-X
T	B-X
cells	B-X
produced	B-X
by	B-X
gene	B-X
targeting	B-X
showed	B-X
increased	B-X
proliferation	B-X
,	B-X
increased	B-X
cell	B-X
size	B-X
and	B-X
enhanced	B-X
expression	B-X
of	B-X
surface	B-X
activation	B-X
markers	B-X
in	B-X
vivo	B-X

In	O
addition	O
,	O
many	O
effects	O
of	O
LKLF	B-protein
expression	O
were	O
mimicked	O
by	O
expression	O
of	O
the	O
dominant-negative	B-protein
MadMyc	I-protein
protein	I-protein
and	O
rescued	O
by	O
overexpression	O
of	O
c-Myc	B-protein
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
effects	B-X
of	B-X
LKLF	B-X
expression	B-X
were	B-X
mimicked	B-X
by	B-X
expression	B-X
of	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
MadMyc	B-X
protein	B-X
and	B-X
rescued	B-X
by	B-X
overexpression	B-X
of	B-X
c	B-X
-	B-X
Myc	B-X
<EOS>	B-X
LKLF	B-X
appeared	B-X
to	B-X
function	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
decreasing	B-X
expression	B-X
of	B-X
the	B-X
proto	B-X
-	B-X
oncogene	B-X
encoding	B-X
c	B-X
-	B-X
Myc	B-X
<EOS>	B-X
Forced	B-X
expression	B-X
of	B-X
LKLF	B-X
was	B-X
associated	B-X
with	B-X
markedly	B-X
decreased	B-X
c	B-X
-	B-X
Myc	B-X
expression	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
forced	B-X
expression	B-X
of	B-X
the	B-X
lung	B-X
Krüppel	B-X
-	B-X
like	B-X
transcription	B-X
factor	B-X
(	B-X
LKLF	B-X
)	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
is	B-X
sufficient	B-X
to	B-X
program	B-X
a	B-X
quiescent	B-X
phenotype	B-X
characterized	B-X
by	B-X
decreased	B-X
proliferation	B-X
,	B-X
reduced	B-X
cell	B-X
size	B-X
and	B-X
protein	B-X
synthesis	B-X
and	B-X
decreased	B-X
surface	B-X
expression	B-X
of	B-X
activation	B-X
markers	B-X

Thus	O
,	O
LKLF	B-protein
is	O
both	O
necessary	O
and	O
sufficient	O
to	O
program	O
quiescence	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
functions	O
,	O
in	O
part	O
,	O
by	O
negatively	O
regulating	O
a	O
c-Myc	O
--	O
dependent	O
pathway	O
.	O

HTLV-1	B-protein
p12	I-protein
(	I-protein
I	I-protein
)	I-protein
protein	I-protein
enhances	O
STAT5	O
activation	O
and	O
decreases	O
the	O
interleukin-2	B-protein
requirement	O
for	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
HTLV	B-X
-	B-X
1	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
protein	B-X
enhances	B-X
STAT5	B-X
activation	B-X
and	B-X
decreases	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
requirement	B-X
for	B-X
proliferation	B-X
of	B-X
primary	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
.	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
may	B-X
confer	B-X
a	B-X
proliferative	B-X
advantage	B-X
on	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
suboptimal	B-X
antigen	B-X
stimulation	B-X
and	B-X
that	B-X
this	B-X
event	B-X
may	B-X
account	B-X
for	B-X
the	B-X
clonal	B-X
proliferation	B-X
of	B-X
infected	B-X
T	B-X
cells	B-X
in	B-X
vivo	B-X
<EOS>	B-X
This	B-X
study	B-X
demonstrated	B-X
that	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
binds	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
beta	B-X
chain	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
the	B-X
Jak1	B-X
and	B-X
Jak3	B-X
kinases	B-X
<EOS>	B-X
The	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
protein	B-X
,	B-X
encoded	B-X
by	B-X
the	B-X
pX	B-X
open	B-X
reading	B-X
frame	B-X
I	B-X
of	B-X
the	B-X
human	B-X
T	B-X
-	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
,	B-X
is	B-X
a	B-X
hydrophobic	B-X
protein	B-X
that	B-X
localizes	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
the	B-X
Golgi	B-X

The	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
protein	I-protein
,	O
encoded	O
by	O
the	O
pX	B-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
I	I-DNA
of	O
the	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
,	O
is	O
a	O
hydrophobic	B-protein
protein	I-protein
that	O
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
Golgi	O
.	O

Although	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
contains	O
4	O
minimal	O
proline-rich	O
,	O
src	B-protein
homology	I-protein
3-binding	I-protein
motifs	I-protein
(	O
PXXP	B-protein
)	O
,	O
a	O
characteristic	O
commonly	O
found	O
in	O
proteins	O
involved	O
in	O
signaling	O
pathways	O
,	O
it	O
has	O
not	O
been	O
known	O
whether	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
has	O
a	O
role	O
in	O
modulating	O
intracellular	O
signaling	O
pathways	O
.	O

This	O
study	O
demonstrated	O
that	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
binds	O
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
interleukin-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
beta	I-protein
chain	I-protein
that	O
is	O
involved	O
in	O
the	O
recruitment	O
of	O
the	O
Jak1	B-protein
and	I-protein
Jak3	I-protein
kinases	I-protein
.	O

As	O
a	O
result	O
of	O
this	O
interaction	O
,	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
increases	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
5	I-protein
(	O
STAT5	B-protein
)	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
and	O
this	O
effect	O
depends	O
on	O
the	O
presence	O
of	O
both	O
IL-2R	B-protein
beta	I-protein
and	I-protein
gamma	I-protein
(	I-protein
c	I-protein
)	I-protein
chains	I-protein
and	O
Jak3	B-protein
.	O

Transduction	O
of	O
primary	B-cell_line
human	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
(	O
PBMCs	B-cell_type
)	O
with	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1-based	I-DNA
retroviral	I-DNA
vector	I-DNA
expressing	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
also	O
resulted	O
in	O
increased	O
STAT5	B-protein
phosphorylation	O
and	O
DNA	O
binding	O
.	O

However	O
,	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
could	O
increase	O
proliferation	O
of	O
human	B-cell_type
PBMCs	I-cell_type
only	O
after	O
stimulation	O
of	O
T-cell	B-protein
receptors	I-protein
by	O
treatment	O
of	O
cells	O
with	O
low	O
concentrations	O
of	O
alphaCD3	B-protein
and	I-protein
alphaCD28	I-protein
antibodies	I-protein
.	O
<EOS>	B-X
However	B-X
,	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
could	B-X
increase	B-X
proliferation	B-X
of	B-X
human	B-X
PBMCs	B-X
only	B-X
after	B-X
stimulation	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
receptors	B-X
by	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
low	B-X
concentrations	B-X
of	B-X
alphaCD3	B-X
and	B-X
alphaCD28	B-X
antibodies	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
proliferative	B-X
advantage	B-X
of	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
	B-X
-	B-X
transduced	B-X
PBMCs	B-X
was	B-X
evident	B-X
mainly	B-X
at	B-X
low	B-X
concentrations	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
may	B-X
confer	B-X
a	B-X
proliferative	B-X
advantage	B-X
on	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
suboptimal	B-X
antigen	B-X
stimulation	B-X
and	B-X
that	B-X
this	B-X
event	B-X
may	B-X
account	B-X
for	B-X
the	B-X
clonal	B-X
proliferation	B-X
of	B-X
infected	B-X
T	B-X
cells	B-X
in	B-X
vivo	B-X
<EOS>	B-X
HTLV	B-X
-	B-X
1	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
protein	B-X
enhances	B-X
STAT5	B-X
activation	B-X
and	B-X
decreases	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
requirement	B-X
for	B-X
proliferation	B-X
of	B-X
primary	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
.	B-X

In	O
addition	O
,	O
the	O
proliferative	O
advantage	O
of	O
p12	B-cell_type
(	I-cell_type
I	I-cell_type
)	I-cell_type
-transduced	I-cell_type
PBMCs	I-cell_type
was	O
evident	O
mainly	O
at	O
low	O
concentrations	O
of	O
IL-2	B-protein
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
proliferative	B-X
advantage	B-X
of	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
	B-X
-	B-X
transduced	B-X
PBMCs	B-X
was	B-X
evident	B-X
mainly	B-X
at	B-X
low	B-X
concentrations	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
However	B-X
,	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
could	B-X
increase	B-X
proliferation	B-X
of	B-X
human	B-X
PBMCs	B-X
only	B-X
after	B-X
stimulation	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
receptors	B-X
by	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
low	B-X
concentrations	B-X
of	B-X
alphaCD3	B-X
and	B-X
alphaCD28	B-X
antibodies	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
may	B-X
confer	B-X
a	B-X
proliferative	B-X
advantage	B-X
on	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
suboptimal	B-X
antigen	B-X
stimulation	B-X
and	B-X
that	B-X
this	B-X
event	B-X
may	B-X
account	B-X
for	B-X
the	B-X
clonal	B-X
proliferation	B-X
of	B-X
infected	B-X
T	B-X
cells	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Transduction	B-X
of	B-X
primary	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
with	B-X
a	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
-	B-X
based	B-X
retroviral	B-X
vector	B-X
expressing	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
also	B-X
resulted	B-X
in	B-X
increased	B-X
STAT5	B-X
phosphorylation	B-X
and	B-X
DNA	B-X
binding	B-X

Together	O
,	O
these	O
data	O
indicate	O
that	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
may	O
confer	O
a	O
proliferative	O
advantage	O
on	O
HTLV-1-infected	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
suboptimal	O
antigen	O
stimulation	O
and	O
that	O
this	O
event	O
may	O
account	O
for	O
the	O
clonal	O
proliferation	O
of	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O

(	O
Blood.	O
2001	O
;	O
98	O
:	O
823-829	O
)	O
<EOS>	B-X
2001	B-X
;	B-X
98:823	B-X
-	B-X
829	B-X
)	B-X
<EOS>	B-X
(	B-X
Blood	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
proliferative	B-X
advantage	B-X
of	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
	B-X
-	B-X
transduced	B-X
PBMCs	B-X
was	B-X
evident	B-X
mainly	B-X
at	B-X
low	B-X
concentrations	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
However	B-X
,	B-X
p12	B-X
(	B-X
I	B-X
)	B-X
could	B-X
increase	B-X
proliferation	B-X
of	B-X
human	B-X
PBMCs	B-X
only	B-X
after	B-X
stimulation	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
receptors	B-X
by	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
low	B-X
concentrations	B-X
of	B-X
alphaCD3	B-X
and	B-X
alphaCD28	B-X
antibodies	B-X

Single	O
dose	O
intranasal	O
administration	O
of	O
retinal	B-protein
autoantigen	I-protein
generates	O
a	O
rapid	O
accumulation	O
and	O
cell	O
activation	O
in	O
draining	O
lymph	O
node	O
and	O
spleen	O
:	O
implications	O
for	O
tolerance	O
therapy	O
.	O
<EOS>	B-X
Single	B-X
dose	B-X
intranasal	B-X
administration	B-X
of	B-X
retinal	B-X
autoantigen	B-X
generates	B-X
a	B-X
rapid	B-X
accumulation	B-X
and	B-X
cell	B-X
activation	B-X
in	B-X
draining	B-X
lymph	B-X
node	B-X
and	B-X
spleen	B-X
:	B-X
implications	B-X
for	B-X
tolerance	B-X
therapy	B-X
.	B-X
<EOS>	B-X
A	B-X
single	B-X
intranasal	B-X
delivery	B-X
of	B-X
retinal	B-X
autoantigen	B-X
suppresses	B-X
effectively	B-X
experimental	B-X
autoimmune	B-X
uveoretinitis	B-X
(	B-X
EAU	B-X
)	B-X
<EOS>	B-X
Further	B-X
understanding	B-X
of	B-X
these	B-X
underlying	B-X
cellular	B-X
mechanisms	B-X
,	B-X
in	B-X
particular	B-X
as	B-X
is	B-X
inferred	B-X
by	B-X
the	B-X
results	B-X
the	B-X
contribution	B-X
of	B-X
local	B-X
versus	B-X
systemic	B-X
tolerance	B-X
induction	B-X
,	B-X
may	B-X
assist	B-X
in	B-X
strategies	B-X
to	B-X
clinically	B-X
apply	B-X
mucosal	B-X
tolerance	B-X
therapy	B-X
successfully	B-X
<EOS>	B-X
A	B-X
rapid	B-X
accumulation	B-X
of	B-X
antigen	B-X
within	B-X
both	B-X
superficial	B-X
cervical	B-X
lymph	B-X
nodes	B-X
(	B-X
SCLN	B-X
)	B-X
and	B-X
spleen	B-X
was	B-X
observed	B-X
after	B-X
30	B-X
minutes	B-X

BACKGROUND/AIMS	O
:	O
A	O
single	O
intranasal	O
delivery	O
of	O
retinal	B-protein
autoantigen	I-protein
suppresses	O
effectively	O
experimental	O
autoimmune	O
uveoretinitis	O
(	O
EAU	O
)	O
.	O
<EOS>	B-X
A	B-X
single	B-X
intranasal	B-X
delivery	B-X
of	B-X
retinal	B-X
autoantigen	B-X
suppresses	B-X
effectively	B-X
experimental	B-X
autoimmune	B-X
uveoretinitis	B-X
(	B-X
EAU	B-X
)	B-X
<EOS>	B-X
Single	B-X
dose	B-X
intranasal	B-X
administration	B-X
of	B-X
retinal	B-X
autoantigen	B-X
generates	B-X
a	B-X
rapid	B-X
accumulation	B-X
and	B-X
cell	B-X
activation	B-X
in	B-X
draining	B-X
lymph	B-X
node	B-X
and	B-X
spleen	B-X
:	B-X
implications	B-X
for	B-X
tolerance	B-X
therapy	B-X
.	B-X
<EOS>	B-X
To	B-X
further	B-X
unravel	B-X
underlying	B-X
mechanisms	B-X
the	B-X
authors	B-X
wished	B-X
to	B-X
determine	B-X
,	B-X
firstly	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
antigen	B-X
delivery	B-X
and	B-X
,	B-X
secondly	B-X
,	B-X
the	B-X
early	B-X
cellular	B-X
responses	B-X
involved	B-X
in	B-X
the	B-X
initial	B-X
stages	B-X
of	B-X
nasal	B-X
mucosal	B-X
tolerance	B-X
induction	B-X
<EOS>	B-X
Resulting	B-X
T	B-X
cell	B-X
proliferation	B-X
develops	B-X
consequent	B-X
to	B-X
differential	B-X
cell	B-X
signalling	B-X
in	B-X
SCLN	B-X
and	B-X
spleen	B-X

To	O
further	O
unravel	O
underlying	O
mechanisms	O
the	O
authors	O
wished	O
to	O
determine	O
,	O
firstly	O
,	O
the	O
kinetics	O
of	O
antigen	O
delivery	O
and	O
,	O
secondly	O
,	O
the	O
early	O
cellular	O
responses	O
involved	O
in	O
the	O
initial	O
stages	O
of	O
nasal	O
mucosal	O
tolerance	O
induction	O
.	O

METHODS	O
:	O
Flow	O
cytometry	O
,	O
cell	O
proliferation	O
assays	O
,	O
and	O
microscopy	O
were	O
used	O
to	O
track	O
antigen	B-protein
following	O
a	O
single	O
,	O
intranasal	O
dose	O
of	O
Alexa-488	B-protein
labelled	I-protein
retinal	I-protein
antigen	I-protein
.	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
,	B-X
cell	B-X
proliferation	B-X
assays	B-X
,	B-X
and	B-X
microscopy	B-X
were	B-X
used	B-X
to	B-X
track	B-X
antigen	B-X
following	B-X
a	B-X
single	B-X
,	B-X
intranasal	B-X
dose	B-X
of	B-X
Alexa	B-X
-	B-X
488	B-X
labelled	B-X
retinal	B-X
antigen	B-X
<EOS>	B-X
The	B-X
results	B-X
provide	B-X
novel	B-X
evidence	B-X
that	B-X
following	B-X
a	B-X
single	B-X
intranasal	B-X
application	B-X
rapid	B-X
transfer	B-X
of	B-X
antigen	B-X
occurs	B-X
<EOS>	B-X
Resulting	B-X
T	B-X
cell	B-X
proliferation	B-X
develops	B-X
consequent	B-X
to	B-X
differential	B-X
cell	B-X
signalling	B-X
in	B-X
SCLN	B-X
and	B-X
spleen	B-X
<EOS>	B-X
Significant	B-X
proliferative	B-X
responses	B-X
to	B-X
IRBP	B-X
were	B-X
elicited	B-X
by	B-X
48	B-X
hours	B-X
indicating	B-X
that	B-X
systemic	B-X
priming	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
to	B-X
retinal	B-X
antigen	B-X
had	B-X
occurred	B-X

RESULTS	O
:	O
A	O
rapid	O
accumulation	O
of	O
antigen	B-protein
within	O
both	O
superficial	O
cervical	O
lymph	O
nodes	O
(	O
SCLN	O
)	O
and	O
spleen	O
was	O
observed	O
after	O
30	O
minutes	O
.	O
<EOS>	B-X
A	B-X
rapid	B-X
accumulation	B-X
of	B-X
antigen	B-X
within	B-X
both	B-X
superficial	B-X
cervical	B-X
lymph	B-X
nodes	B-X
(	B-X
SCLN	B-X
)	B-X
and	B-X
spleen	B-X
was	B-X
observed	B-X
after	B-X
30	B-X
minutes	B-X
<EOS>	B-X
Single	B-X
dose	B-X
intranasal	B-X
administration	B-X
of	B-X
retinal	B-X
autoantigen	B-X
generates	B-X
a	B-X
rapid	B-X
accumulation	B-X
and	B-X
cell	B-X
activation	B-X
in	B-X
draining	B-X
lymph	B-X
node	B-X
and	B-X
spleen	B-X
:	B-X
implications	B-X
for	B-X
tolerance	B-X
therapy	B-X
.	B-X
<EOS>	B-X
Resulting	B-X
T	B-X
cell	B-X
proliferation	B-X
develops	B-X
consequent	B-X
to	B-X
differential	B-X
cell	B-X
signalling	B-X
in	B-X
SCLN	B-X
and	B-X
spleen	B-X
<EOS>	B-X
However	B-X
,	B-X
at	B-X
24	B-X
hours	B-X
,	B-X
STAT4	B-X
heterodimerisation	B-X
with	B-X
STAT	B-X
3	B-X
was	B-X
only	B-X
observed	B-X
in	B-X
spleen	B-X

Significant	O
proliferative	O
responses	O
to	O
IRBP	O
were	O
elicited	O
by	O
48	O
hours	O
indicating	O
that	O
systemic	O
priming	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
retinal	B-protein
antigen	I-protein
had	O
occurred	O
.	O
<EOS>	B-X
Significant	B-X
proliferative	B-X
responses	B-X
to	B-X
IRBP	B-X
were	B-X
elicited	B-X
by	B-X
48	B-X
hours	B-X
indicating	B-X
that	B-X
systemic	B-X
priming	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
to	B-X
retinal	B-X
antigen	B-X
had	B-X
occurred	B-X
<EOS>	B-X
The	B-X
results	B-X
provide	B-X
novel	B-X
evidence	B-X
that	B-X
following	B-X
a	B-X
single	B-X
intranasal	B-X
application	B-X
rapid	B-X
transfer	B-X
of	B-X
antigen	B-X
occurs	B-X
<EOS>	B-X
Further	B-X
understanding	B-X
of	B-X
these	B-X
underlying	B-X
cellular	B-X
mechanisms	B-X
,	B-X
in	B-X
particular	B-X
as	B-X
is	B-X
inferred	B-X
by	B-X
the	B-X
results	B-X
the	B-X
contribution	B-X
of	B-X
local	B-X
versus	B-X
systemic	B-X
tolerance	B-X
induction	B-X
,	B-X
may	B-X
assist	B-X
in	B-X
strategies	B-X
to	B-X
clinically	B-X
apply	B-X
mucosal	B-X
tolerance	B-X
therapy	B-X
successfully	B-X
<EOS>	B-X
Resulting	B-X
T	B-X
cell	B-X
proliferation	B-X
develops	B-X
consequent	B-X
to	B-X
differential	B-X
cell	B-X
signalling	B-X
in	B-X
SCLN	B-X
and	B-X
spleen	B-X

Cell	O
activation	O
was	O
further	O
confirmed	O
by	O
immunoprecipitation	O
studies	O
,	O
which	O
demonstrated	O
phosphorylation	O
of	O
STAT4	B-protein
but	O
not	O
STAT6	B-protein
in	O
both	O
lymph	O
nodes	O
and	O
spleen	O
.	O

However	O
,	O
at	O
24	O
hours	O
,	O
STAT4	O
heterodimerisation	O
with	O
STAT	B-protein
3	I-protein
was	O
only	O
observed	O
in	O
spleen	O
.	O
<EOS>	B-X
However	B-X
,	B-X
at	B-X
24	B-X
hours	B-X
,	B-X
STAT4	B-X
heterodimerisation	B-X
with	B-X
STAT	B-X
3	B-X
was	B-X
only	B-X
observed	B-X
in	B-X
spleen	B-X
<EOS>	B-X
A	B-X
rapid	B-X
accumulation	B-X
of	B-X
antigen	B-X
within	B-X
both	B-X
superficial	B-X
cervical	B-X
lymph	B-X
nodes	B-X
(	B-X
SCLN	B-X
)	B-X
and	B-X
spleen	B-X
was	B-X
observed	B-X
after	B-X
30	B-X
minutes	B-X
<EOS>	B-X
Cell	B-X
activation	B-X
was	B-X
further	B-X
confirmed	B-X
by	B-X
immunoprecipitation	B-X
studies	B-X
,	B-X
which	B-X
demonstrated	B-X
phosphorylation	B-X
of	B-X
STAT4	B-X
but	B-X
not	B-X
STAT6	B-X
in	B-X
both	B-X
lymph	B-X
nodes	B-X
and	B-X
spleen	B-X
<EOS>	B-X
Flow	B-X
cytometry	B-X
,	B-X
cell	B-X
proliferation	B-X
assays	B-X
,	B-X
and	B-X
microscopy	B-X
were	B-X
used	B-X
to	B-X
track	B-X
antigen	B-X
following	B-X
a	B-X
single	B-X
,	B-X
intranasal	B-X
dose	B-X
of	B-X
Alexa	B-X
-	B-X
488	B-X
labelled	B-X
retinal	B-X
antigen	B-X

CONCLUSIONS	O
:	O
The	O
results	O
provide	O
novel	O
evidence	O
that	O
following	O
a	O
single	O
intranasal	O
application	O
rapid	O
transfer	O
of	O
antigen	B-protein
occurs	O
.	O
<EOS>	B-X
The	B-X
results	B-X
provide	B-X
novel	B-X
evidence	B-X
that	B-X
following	B-X
a	B-X
single	B-X
intranasal	B-X
application	B-X
rapid	B-X
transfer	B-X
of	B-X
antigen	B-X
occurs	B-X
<EOS>	B-X
Flow	B-X
cytometry	B-X
,	B-X
cell	B-X
proliferation	B-X
assays	B-X
,	B-X
and	B-X
microscopy	B-X
were	B-X
used	B-X
to	B-X
track	B-X
antigen	B-X
following	B-X
a	B-X
single	B-X
,	B-X
intranasal	B-X
dose	B-X
of	B-X
Alexa	B-X
-	B-X
488	B-X
labelled	B-X
retinal	B-X
antigen	B-X
<EOS>	B-X
Significant	B-X
proliferative	B-X
responses	B-X
to	B-X
IRBP	B-X
were	B-X
elicited	B-X
by	B-X
48	B-X
hours	B-X
indicating	B-X
that	B-X
systemic	B-X
priming	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
to	B-X
retinal	B-X
antigen	B-X
had	B-X
occurred	B-X
<EOS>	B-X
Resulting	B-X
T	B-X
cell	B-X
proliferation	B-X
develops	B-X
consequent	B-X
to	B-X
differential	B-X
cell	B-X
signalling	B-X
in	B-X
SCLN	B-X
and	B-X
spleen	B-X

Resulting	O
T	O
cell	O
proliferation	O
develops	O
consequent	O
to	O
differential	O
cell	O
signalling	O
in	O
SCLN	O
and	O
spleen	O
.	O
<EOS>	B-X
Resulting	B-X
T	B-X
cell	B-X
proliferation	B-X
develops	B-X
consequent	B-X
to	B-X
differential	B-X
cell	B-X
signalling	B-X
in	B-X
SCLN	B-X
and	B-X
spleen	B-X
<EOS>	B-X
Flow	B-X
cytometry	B-X
,	B-X
cell	B-X
proliferation	B-X
assays	B-X
,	B-X
and	B-X
microscopy	B-X
were	B-X
used	B-X
to	B-X
track	B-X
antigen	B-X
following	B-X
a	B-X
single	B-X
,	B-X
intranasal	B-X
dose	B-X
of	B-X
Alexa	B-X
-	B-X
488	B-X
labelled	B-X
retinal	B-X
antigen	B-X
<EOS>	B-X
Single	B-X
dose	B-X
intranasal	B-X
administration	B-X
of	B-X
retinal	B-X
autoantigen	B-X
generates	B-X
a	B-X
rapid	B-X
accumulation	B-X
and	B-X
cell	B-X
activation	B-X
in	B-X
draining	B-X
lymph	B-X
node	B-X
and	B-X
spleen	B-X
:	B-X
implications	B-X
for	B-X
tolerance	B-X
therapy	B-X
.	B-X
<EOS>	B-X
Cell	B-X
activation	B-X
was	B-X
further	B-X
confirmed	B-X
by	B-X
immunoprecipitation	B-X
studies	B-X
,	B-X
which	B-X
demonstrated	B-X
phosphorylation	B-X
of	B-X
STAT4	B-X
but	B-X
not	B-X
STAT6	B-X
in	B-X
both	B-X
lymph	B-X
nodes	B-X
and	B-X
spleen	B-X

Further	O
understanding	O
of	O
these	O
underlying	O
cellular	O
mechanisms	O
,	O
in	O
particular	O
as	O
is	O
inferred	O
by	O
the	O
results	O
the	O
contribution	O
of	O
local	O
versus	O
systemic	O
tolerance	O
induction	O
,	O
may	O
assist	O
in	O
strategies	O
to	O
clinically	O
apply	O
mucosal	O
tolerance	O
therapy	O
successfully	O
.	O
<EOS>	B-X
Further	B-X
understanding	B-X
of	B-X
these	B-X
underlying	B-X
cellular	B-X
mechanisms	B-X
,	B-X
in	B-X
particular	B-X
as	B-X
is	B-X
inferred	B-X
by	B-X
the	B-X
results	B-X
the	B-X
contribution	B-X
of	B-X
local	B-X
versus	B-X
systemic	B-X
tolerance	B-X
induction	B-X
,	B-X
may	B-X
assist	B-X
in	B-X
strategies	B-X
to	B-X
clinically	B-X
apply	B-X
mucosal	B-X
tolerance	B-X
therapy	B-X
successfully	B-X
<EOS>	B-X
To	B-X
further	B-X
unravel	B-X
underlying	B-X
mechanisms	B-X
the	B-X
authors	B-X
wished	B-X
to	B-X
determine	B-X
,	B-X
firstly	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
antigen	B-X
delivery	B-X
and	B-X
,	B-X
secondly	B-X
,	B-X
the	B-X
early	B-X
cellular	B-X
responses	B-X
involved	B-X
in	B-X
the	B-X
initial	B-X
stages	B-X
of	B-X
nasal	B-X
mucosal	B-X
tolerance	B-X
induction	B-X
<EOS>	B-X
Single	B-X
dose	B-X
intranasal	B-X
administration	B-X
of	B-X
retinal	B-X
autoantigen	B-X
generates	B-X
a	B-X
rapid	B-X
accumulation	B-X
and	B-X
cell	B-X
activation	B-X
in	B-X
draining	B-X
lymph	B-X
node	B-X
and	B-X
spleen	B-X
:	B-X
implications	B-X
for	B-X
tolerance	B-X
therapy	B-X
.	B-X
<EOS>	B-X
Significant	B-X
proliferative	B-X
responses	B-X
to	B-X
IRBP	B-X
were	B-X
elicited	B-X
by	B-X
48	B-X
hours	B-X
indicating	B-X
that	B-X
systemic	B-X
priming	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
to	B-X
retinal	B-X
antigen	B-X
had	B-X
occurred	B-X

Regulation	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-18	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
expression	O
on	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
during	O
T	O
helper	O
(	O
Th	O
)	O
1/Th2	O
differentiation	O
.	O

Critical	O
downregulatory	O
role	O
of	O
IL-4	B-protein
.	O
<EOS>	B-X
IL	B-X
-	B-X
12	B-X
-	B-X
mediated	B-X
upregulation	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
required	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
peripheral	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
constitutively	B-X
expressed	B-X
the	B-X
IL	B-X
-	B-X
18Ralpha	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
18	B-X
receptor	B-X
alpha	B-X
chain	B-X
expression	B-X
on	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
during	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
1	B-X
/	B-X
Th2	B-X
differentiation	B-X
.	B-X
Critical	B-X
downregulatory	B-X
role	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
.	B-X
<EOS>	B-X
Surviving	B-X
mice	B-X
remained	B-X
moribund	B-X
until	B-X
termination	B-X
of	B-X
the	B-X
experiments	B-X

Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-18	I-protein
has	O
been	O
well	O
characterized	O
as	O
a	O
costimulatory	B-protein
factor	I-protein
for	O
the	O
induction	O
of	O
IL-12-mediated	B-protein
interferon	I-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
production	O
by	O
T	B-cell_type
helper	I-cell_type
(	I-cell_type
Th	I-cell_type
)	I-cell_type
1	I-cell_type
cells	I-cell_type
,	O
but	O
also	O
can	O
induce	O
IL-4	O
production	O
and	O
thus	O
facilitate	O
the	O
differentiation	O
of	O
Th2	B-cell_type
cells	I-cell_type
.	O

To	O
determine	O
the	O
mechanisms	O
by	O
which	O
IL-18	B-protein
might	O
regulate	O
these	O
diametrically	O
distinct	O
immune	O
responses	O
,	O
we	O
have	O
analyzed	O
the	O
role	O
of	O
cytokines	B-protein
in	O
the	O
regulation	O
of	O
IL-18	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-18Ralpha	B-protein
)	O
expression	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
IL	B-X
-	B-X
18	B-X
might	B-X
regulate	B-X
these	B-X
diametrically	B-X
distinct	B-X
immune	B-X
responses	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
cytokines	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL	B-X
-	B-X
18	B-X
receptor	B-X
alpha	B-X
chain	B-X
(	B-X
IL	B-X
-	B-X
18Ralpha	B-X
)	B-X
expression	B-X
<EOS>	B-X
Thus	B-X
,	B-X
positive	B-X
/	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
18Ralpha	B-X
by	B-X
the	B-X
major	B-X
inductive	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
)	B-X
determines	B-X
the	B-X
capacity	B-X
of	B-X
IL	B-X
-	B-X
18	B-X
to	B-X
polarize	B-X
an	B-X
immune	B-X
response	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
T	B-X
cell	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
resulted	B-X
in	B-X
a	B-X
downregulation	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
expression	B-X
<EOS>	B-X
Both	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
and	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
Stat	B-X
)	B-X
6	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
T	B-X
cells	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
after	B-X
TCR	B-X
stimulation	B-X

The	O
majority	O
of	O
peripheral	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
constitutively	O
expressed	O
the	O
IL-18Ralpha	B-protein
.	O
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
peripheral	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
constitutively	B-X
expressed	B-X
the	B-X
IL	B-X
-	B-X
18Ralpha	B-X
<EOS>	B-X
Both	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
and	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
Stat	B-X
)	B-X
6	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
T	B-X
cells	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
after	B-X
TCR	B-X
stimulation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
T	B-X
cell	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
resulted	B-X
in	B-X
a	B-X
downregulation	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
expression	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
activated	B-X
T	B-X
cells	B-X
from	B-X
Stat6	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
mice	B-X
produced	B-X
more	B-X
IFN	B-X
-	B-X
gamma	B-X
in	B-X
response	B-X
to	B-X
IL	B-X
-	B-X
18	B-X
than	B-X
wild	B-X
-	B-X
type	B-X
controls	B-X

Upon	O
antigen	O
stimulation	O
in	O
the	O
presence	O
of	O
IL-12	B-protein
,	O
marked	O
enhancement	O
of	O
IL-18Ralpha	B-protein
expression	O
was	O
observed	O
.	O
<EOS>	B-X
Upon	B-X
antigen	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
marked	B-X
enhancement	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
expression	B-X
was	B-X
observed	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
T	B-X
cell	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
resulted	B-X
in	B-X
a	B-X
downregulation	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
expression	B-X
<EOS>	B-X
Thus	B-X
,	B-X
positive	B-X
/	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
18Ralpha	B-X
by	B-X
the	B-X
major	B-X
inductive	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
)	B-X
determines	B-X
the	B-X
capacity	B-X
of	B-X
IL	B-X
-	B-X
18	B-X
to	B-X
polarize	B-X
an	B-X
immune	B-X
response	B-X
<EOS>	B-X
Both	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
and	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
Stat	B-X
)	B-X
6	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
T	B-X
cells	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
after	B-X
TCR	B-X
stimulation	B-X

IL-12	B-protein
-mediated	O
upregulation	O
of	O
IL-18Ralpha	B-protein
required	O
IFN-gamma	B-protein
.	O
<EOS>	B-X
IL	B-X
-	B-X
12	B-X
-	B-X
mediated	B-X
upregulation	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
required	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
Upon	B-X
antigen	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
marked	B-X
enhancement	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
expression	B-X
was	B-X
observed	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
IL	B-X
-	B-X
12	B-X
together	B-X
with	B-X
IL	B-X
-	B-X
18	B-X
-	B-X
induced	B-X
secretion	B-X
of	B-X
IFN	B-X
-	B-X
gamma	B-X
in	B-X
both	B-X
populations	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
T	B-X
cell	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
resulted	B-X
in	B-X
a	B-X
downregulation	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
expression	B-X

Activated	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
expressed	O
low	O
levels	O
of	O
IL-18Ralpha	B-protein
could	O
produce	O
IFN-gamma	B-protein
when	O
stimulated	O
with	O
the	O
combination	O
of	O
IL-12	B-protein
and	O
IL-18	B-protein
,	O
while	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
which	O
expressed	O
high	O
levels	O
of	O
IL-18Ralpha	B-protein
could	O
respond	O
to	O
IL-18	B-protein
alone	O
.	O
<EOS>	B-X
Activated	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
that	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
could	B-X
produce	B-X
IFN	B-X
-	B-X
gamma	B-X
when	B-X
stimulated	B-X
with	B-X
the	B-X
combination	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
18	B-X
,	B-X
while	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
which	B-X
expressed	B-X
high	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
could	B-X
respond	B-X
to	B-X
IL	B-X
-	B-X
18	B-X
alone	B-X
<EOS>	B-X
Both	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
and	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
Stat	B-X
)	B-X
6	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
T	B-X
cells	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
after	B-X
TCR	B-X
stimulation	B-X
<EOS>	B-X
Thus	B-X
,	B-X
positive	B-X
/	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
18Ralpha	B-X
by	B-X
the	B-X
major	B-X
inductive	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
)	B-X
determines	B-X
the	B-X
capacity	B-X
of	B-X
IL	B-X
-	B-X
18	B-X
to	B-X
polarize	B-X
an	B-X
immune	B-X
response	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
T	B-X
cell	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
resulted	B-X
in	B-X
a	B-X
downregulation	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
expression	B-X

In	O
contrast	O
,	O
T	O
cell	O
stimulation	O
in	O
the	O
presence	O
of	O
IL-4	B-protein
resulted	O
in	O
a	O
downregulation	O
of	O
IL-18Ralpha	B-protein
expression	O
.	O

Both	O
IL-4	B-cell_type
(	I-cell_type
-/	I-cell_type
)	I-cell_type
-	I-cell_type
and	I-cell_type
signal	I-cell_type
transducer	I-cell_type
and	I-cell_type
activator	I-cell_type
of	I-cell_type
transcription	I-cell_type
(	I-cell_type
Stat	I-cell_type
)	I-cell_type
6	I-cell_type
(	I-cell_type
-/	I-cell_type
)	I-cell_type
-	I-cell_type
T	I-cell_type
cells	I-cell_type
expressed	O
higher	O
levels	O
of	O
IL-18Ralpha	B-protein
after	O
TCR	O
stimulation	O
.	O

Furthermore	O
,	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
Stat6	O
(	O
-/	O
)	O
-	O
mice	O
produced	O
more	O
IFN-gamma	B-protein
in	O
response	O
to	O
IL-18	B-protein
than	O
wild-type	O
controls	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
activated	B-X
T	B-X
cells	B-X
from	B-X
Stat6	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
)	B-X
	B-X
-	B-X
	B-X
mice	B-X
produced	B-X
more	B-X
IFN	B-X
-	B-X
gamma	B-X
in	B-X
response	B-X
to	B-X
IL	B-X
-	B-X
18	B-X
than	B-X
wild	B-X
-	B-X
type	B-X
controls	B-X
<EOS>	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
18	B-X
has	B-X
been	B-X
well	B-X
characterized	B-X
as	B-X
a	B-X
costimulatory	B-X
factor	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
-	B-X
mediated	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
gamma	B-X
production	B-X
by	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
1	B-X
cells	B-X
,	B-X
but	B-X
also	B-X
can	B-X
induce	B-X
IL	B-X
-	B-X
4	B-X
production	B-X
and	B-X
thus	B-X
facilitate	B-X
the	B-X
differentiation	B-X
of	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
peripheral	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
constitutively	B-X
expressed	B-X
the	B-X
IL	B-X
-	B-X
18Ralpha	B-X
<EOS>	B-X
Thus	B-X
,	B-X
positive	B-X
/	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
18Ralpha	B-X
by	B-X
the	B-X
major	B-X
inductive	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
)	B-X
determines	B-X
the	B-X
capacity	B-X
of	B-X
IL	B-X
-	B-X
18	B-X
to	B-X
polarize	B-X
an	B-X
immune	B-X
response	B-X

Thus	O
,	O
positive/negative	O
regulation	O
of	O
the	O
IL-18Ralpha	B-protein
by	O
the	O
major	O
inductive	O
cytokines	B-protein
(	O
IL-12	B-protein
and	O
IL-4	B-protein
)	O
determines	O
the	O
capacity	O
of	O
IL-18	B-protein
to	O
polarize	O
an	O
immune	O
response	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
positive	B-X
/	B-X
negative	B-X
regulation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
18Ralpha	B-X
by	B-X
the	B-X
major	B-X
inductive	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
)	B-X
determines	B-X
the	B-X
capacity	B-X
of	B-X
IL	B-X
-	B-X
18	B-X
to	B-X
polarize	B-X
an	B-X
immune	B-X
response	B-X
<EOS>	B-X
Upon	B-X
antigen	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
marked	B-X
enhancement	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
expression	B-X
was	B-X
observed	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
IL	B-X
-	B-X
18	B-X
might	B-X
regulate	B-X
these	B-X
diametrically	B-X
distinct	B-X
immune	B-X
responses	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
cytokines	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL	B-X
-	B-X
18	B-X
receptor	B-X
alpha	B-X
chain	B-X
(	B-X
IL	B-X
-	B-X
18Ralpha	B-X
)	B-X
expression	B-X
<EOS>	B-X
Activated	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
that	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
could	B-X
produce	B-X
IFN	B-X
-	B-X
gamma	B-X
when	B-X
stimulated	B-X
with	B-X
the	B-X
combination	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
18	B-X
,	B-X
while	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
which	B-X
expressed	B-X
high	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
18Ralpha	B-X
could	B-X
respond	B-X
to	B-X
IL	B-X
-	B-X
18	B-X
alone	B-X

Glucocorticoid-regulated	B-protein
transcription	I-protein
factors	I-protein
.	O
<EOS>	B-X
Coregulators	B-X
are	B-X
recruited	B-X
to	B-X
regulate	B-X
the	B-X
activation	B-X
of	B-X
steroid	B-X
hormone	B-X
receptors	B-X
<EOS>	B-X
Identification	B-X
of	B-X
serum	B-X
and	B-X
glucocorticoid	B-X
-	B-X
regulated	B-X
kinase	B-X
1	B-X
as	B-X
a	B-X
regulator	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
signaling	B-X
.	B-X
<EOS>	B-X
Cross	B-X
-	B-X
regulation	B-X
of	B-X
notch	B-X
/	B-X
AKT	B-X
and	B-X
serum	B-X
/	B-X
glucocorticoid	B-X
regulated	B-X
kinase	B-X
1	B-X
(	B-X
SGK1	B-X
)	B-X
in	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
stimulated	B-X
human	B-X
macrophages	B-X
.	B-X
<EOS>	B-X
Serum	B-X
and	B-X
glucocorticoid	B-X
-	B-X
regulated	B-X
kinase	B-X
3	B-X
(	B-X
SGK3	B-X
)	B-X
promotes	B-X
the	B-X
progression	B-X
and	B-X
drug	B-X
resistance	B-X
of	B-X
estrogen	B-X
receptor	B-X
-	B-X
positive	B-X
(	B-X
ER+	B-X
)	B-X
breast	B-X
cancer	B-X

Glucocorticoids	O
are	O
the	O
most	O
effective	O
antiinflammatory	O
drugs	O
used	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O
<EOS>	B-X
Asthma	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
inflammatory	B-X
diseases	B-X
of	B-X
the	B-X
lung	B-X
worldwide	B-X
<EOS>	B-X
Leaves	B-X
of	B-X
Quercus	B-X
leucotrichophora	B-X
are	B-X
traditionally	B-X
used	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
asthma	B-X
<EOS>	B-X
7	B-X
billion	B-X
rubles	B-X
,	B-X
while	B-X
direct	B-X
non	B-X
-	B-X
drug	B-X
costs	B-X
associated	B-X
with	B-X
the	B-X
treatment	B-X
of	B-X
complications	B-X
that	B-X
developed	B-X
during	B-X
the	B-X
treatment	B-X
of	B-X
asthma	B-X
decreased	B-X
by	B-X
8	B-X
<EOS>	B-X
Indirect	B-X
costs	B-X
considered	B-X
the	B-X
loss	B-X
of	B-X
GDP	B-X
due	B-X
to	B-X
hospitalization	B-X
of	B-X
patients	B-X
against	B-X
the	B-X
background	B-X
of	B-X
asthma	B-X
exacerbations	B-X

They	O
act	O
by	O
binding	O
to	O
a	O
specific	O
receptor	O
(	O
GR	B-protein
)	O
that	O
,	O
upon	O
activation	O
,	O
translocates	O
to	O
the	O
nucleus	O
and	O
either	O
increases	O
(	O
transactivates	O
)	O
or	O
decreases	O
(	O
transrepresses	O
)	O
gene	O
expression	O
.	O
<EOS>	B-X
GCs	B-X
act	B-X
through	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
,	B-X
and	B-X
the	B-X
GR	B-X
regulates	B-X
transcription	B-X
both	B-X
through	B-X
transactivation	B-X
and	B-X
transrepression	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
repressor	B-X
GATAD2B	B-X
mediates	B-X
progesterone	B-X
receptor	B-X
suppression	B-X
of	B-X
myometrial	B-X
contractile	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Dermatopontin	B-X
expression	B-X
was	B-X
found	B-X
increased	B-X
in	B-X
fibrosis	B-X
,	B-X
and	B-X
reversal	B-X
of	B-X
fibrosis	B-X
after	B-X
gastric	B-X
bypass	B-X
correlated	B-X
with	B-X
decreased	B-X
dermatopontin	B-X
expression	B-X
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
sex	B-X
-	B-X
specific	B-X
differences	B-X
in	B-X
OGT	B-X
levels	B-X
and	B-X
O	B-X
-	B-X
GlcNAcylation	B-X
during	B-X
Cort	B-X
exposure	B-X
which	B-X
impacts	B-X
on	B-X
key	B-X
mediators	B-X
of	B-X
cell	B-X
survival	B-X
,	B-X
in	B-X
particular	B-X
AKT	B-X
as	B-X
well	B-X
as	B-X
the	B-X
stress	B-X
responsive	B-X
OGT	B-X
/	B-X
GR	B-X
transrepression	B-X
complex	B-X

Inhibition	O
of	O
pro-inflammatory	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
activator	B-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
,	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
,	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
is	O
thought	O
to	O
be	O
a	O
major	O
action	O
of	O
glucocorticoids	O
.	O

Acetylation	O
of	O
histones	B-protein
allows	O
unwinding	O
of	O
the	O
local	B-DNA
DNA	I-DNA
structure	I-DNA
and	O
enables	O
RNA	B-protein
polymerase	I-protein
II	I-protein
to	O
enhance	O
gene	O
transcription	O
.	O
<EOS>	B-X
Acetylation	B-X
of	B-X
histones	B-X
allows	B-X
unwinding	B-X
of	B-X
the	B-X
local	B-X
DNA	B-X
structure	B-X
and	B-X
enables	B-X
RNA	B-X
polymerase	B-X
II	B-X
to	B-X
enhance	B-X
gene	B-X
transcription	B-X
<EOS>	B-X
They	B-X
act	B-X
by	B-X
binding	B-X
to	B-X
a	B-X
specific	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
that	B-X
,	B-X
upon	B-X
activation	B-X
,	B-X
translocates	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
either	B-X
increases	B-X
(	B-X
transactivates	B-X
)	B-X
or	B-X
decreases	B-X
(	B-X
transrepresses	B-X
)	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Glucocorticoids	B-X
are	B-X
the	B-X
most	B-X
effective	B-X
antiinflammatory	B-X
drugs	B-X
used	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
asthma	B-X
<EOS>	B-X
A	B-X
sub	B-X
-	B-X
group	B-X
of	B-X
patients	B-X
with	B-X
glucocorticoid	B-X
-	B-X
insensitive	B-X
asthma	B-X
have	B-X
an	B-X
inability	B-X
to	B-X
induce	B-X
histone	B-X
acetylation	B-X
in	B-X
response	B-X
to	B-X
dexamethasone	B-X
suggesting	B-X
reduced	B-X
expression	B-X
of	B-X
a	B-X
GR	B-X
-	B-X
specific	B-X
HAT	B-X

Histone	O
acetylation	O
is	O
regulated	O
by	O
a	O
balance	O
between	O
the	O
activity	O
of	O
histone	B-protein
acetyltransferases	I-protein
(	O
HATs	B-protein
)	O
and	O
histone	B-protein
deacetylases	I-protein
(	O
HDACs	B-protein
)	O
.	O
<EOS>	B-X
Histone	B-X
acetylation	B-X
levels	B-X
are	B-X
balanced	B-X
through	B-X
the	B-X
opposing	B-X
activities	B-X
of	B-X
histone	B-X
acetyltransferases	B-X
(	B-X
HATs	B-X
)	B-X
and	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
<EOS>	B-X
Histone	B-X
acetylation	B-X
-	B-X
a	B-X
balance	B-X
between	B-X
the	B-X
activities	B-X
of	B-X
histone	B-X
acetyltransferases	B-X
(	B-X
HATs	B-X
)	B-X
and	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
	B-X
-	B-X
is	B-X
one	B-X
of	B-X
the	B-X
key	B-X
epigenetic	B-X
events	B-X
<EOS>	B-X
Histone	B-X
acetylation	B-X
is	B-X
a	B-X
dynamic	B-X
process	B-X
regulated	B-X
by	B-X
the	B-X
antagonistic	B-X
actions	B-X
of	B-X
2	B-X
families	B-X
of	B-X
enzymes	B-X
	B-X
-	B-X
	B-X
the	B-X
histone	B-X
acetyltransferases	B-X
(	B-X
HATs	B-X
)	B-X
and	B-X
the	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
<EOS>	B-X
The	B-X
acetylation	B-X
process	B-X
is	B-X
homeostatically	B-X
balanced	B-X
by	B-X
two	B-X
groups	B-X
of	B-X
cellular	B-X
enzymes	B-X
,	B-X
histone	B-X
acetyltransferases	B-X
(	B-X
HATs	B-X
)	B-X
and	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X

GR	B-protein
acts	O
as	O
a	O
direct	O
inhibitor	O
of	O
NF-kappa	O
B-induced	O
HAT	O
activity	O
and	O
also	O
by	O
recruiting	O
HDAC2	B-protein
to	O
the	O
NF-kappa	B-protein
B/HAT	I-protein
complex	I-protein
.	O

A	O
sub-group	O
of	O
patients	O
with	O
glucocorticoid-insensitive	O
asthma	O
have	O
an	O
inability	O
to	O
induce	O
histone	O
acetylation	O
in	O
response	O
to	O
dexamethasone	O
suggesting	O
reduced	O
expression	O
of	O
a	O
GR-specific	B-protein
HAT	I-protein
.	O
<EOS>	B-X
A	B-X
sub	B-X
-	B-X
group	B-X
of	B-X
patients	B-X
with	B-X
glucocorticoid	B-X
-	B-X
insensitive	B-X
asthma	B-X
have	B-X
an	B-X
inability	B-X
to	B-X
induce	B-X
histone	B-X
acetylation	B-X
in	B-X
response	B-X
to	B-X
dexamethasone	B-X
suggesting	B-X
reduced	B-X
expression	B-X
of	B-X
a	B-X
GR	B-X
-	B-X
specific	B-X
HAT	B-X
<EOS>	B-X
Histone	B-X
acetylation	B-X
is	B-X
regulated	B-X
by	B-X
a	B-X
balance	B-X
between	B-X
the	B-X
activity	B-X
of	B-X
histone	B-X
acetyltransferases	B-X
(	B-X
HATs	B-X
)	B-X
and	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
pharmacological	B-X
manipulation	B-X
of	B-X
specific	B-X
histone	B-X
acetylation	B-X
status	B-X
is	B-X
a	B-X
potentially	B-X
useful	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
diseases	B-X
<EOS>	B-X
Glucocorticoids	B-X
are	B-X
the	B-X
most	B-X
effective	B-X
antiinflammatory	B-X
drugs	B-X
used	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
asthma	B-X

This	O
suggests	O
that	O
pharmacological	O
manipulation	O
of	O
specific	O
histone	O
acetylation	O
status	O
is	O
a	O
potentially	O
useful	O
approach	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
.	O
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
pharmacological	B-X
manipulation	B-X
of	B-X
specific	B-X
histone	B-X
acetylation	B-X
status	B-X
is	B-X
a	B-X
potentially	B-X
useful	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
diseases	B-X
<EOS>	B-X
This	B-X
further	B-X
suggests	B-X
that	B-X
pharmacological	B-X
manipulation	B-X
of	B-X
of	B-X
specific	B-X
histone	B-X
acetylation	B-X
status	B-X
is	B-X
a	B-X
potentially	B-X
useful	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
diseases	B-X
<EOS>	B-X
These	B-X
data	B-X
also	B-X
suggest	B-X
that	B-X
pharmacological	B-X
manipulation	B-X
of	B-X
specific	B-X
histone	B-X
acetylation	B-X
status	B-X
is	B-X
a	B-X
potentially	B-X
useful	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
diseases	B-X
<EOS>	B-X
This	B-X
mechanism	B-X
for	B-X
glucocorticoid	B-X
repression	B-X
is	B-X
novel	B-X
and	B-X
establishes	B-X
that	B-X
inhibition	B-X
of	B-X
histone	B-X
acetylation	B-X
is	B-X
an	B-X
additional	B-X
level	B-X
of	B-X
control	B-X
of	B-X
inflammatory	B-X
gene	B-X
expression	B-X

Identification	O
of	O
the	O
precise	O
mechanism	O
by	O
which	O
activated	B-protein
GR	I-protein
recruits	O
HDAC2	B-protein
may	O
reveal	O
new	O
targets	O
for	O
the	O
development	O
of	O
drugs	O
that	O
may	O
dissociate	O
the	O
antiinflammatory	O
actions	O
of	O
glucocorticoids	O
from	O
their	O
side	O
effects	O
that	O
are	O
largely	O
due	O
to	O
gene	O
induction	O
.	O
<EOS>	B-X
Identification	B-X
of	B-X
the	B-X
precise	B-X
mechanism	B-X
by	B-X
which	B-X
activated	B-X
GR	B-X
recruits	B-X
HDAC2	B-X
may	B-X
reveal	B-X
new	B-X
targets	B-X
for	B-X
the	B-X
development	B-X
of	B-X
drugs	B-X
that	B-X
may	B-X
dissociate	B-X
the	B-X
antiinflammatory	B-X
actions	B-X
of	B-X
glucocorticoids	B-X
from	B-X
their	B-X
side	B-X
effects	B-X
that	B-X
are	B-X
largely	B-X
due	B-X
to	B-X
gene	B-X
induction	B-X
<EOS>	B-X
They	B-X
act	B-X
by	B-X
binding	B-X
to	B-X
a	B-X
specific	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
that	B-X
,	B-X
upon	B-X
activation	B-X
,	B-X
translocates	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
either	B-X
increases	B-X
(	B-X
transactivates	B-X
)	B-X
or	B-X
decreases	B-X
(	B-X
transrepresses	B-X
)	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Acetylation	B-X
of	B-X
histones	B-X
allows	B-X
unwinding	B-X
of	B-X
the	B-X
local	B-X
DNA	B-X
structure	B-X
and	B-X
enables	B-X
RNA	B-X
polymerase	B-X
II	B-X
to	B-X
enhance	B-X
gene	B-X
transcription	B-X
<EOS>	B-X
This	B-X
suggests	B-X
that	B-X
pharmacological	B-X
manipulation	B-X
of	B-X
specific	B-X
histone	B-X
acetylation	B-X
status	B-X
is	B-X
a	B-X
potentially	B-X
useful	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
diseases	B-X

Copyright	O
Academic	O
Press	O
.	O
<EOS>	B-X
,	B-X
MCI	B-X
due	B-X
to	B-X
AD	B-X
and	B-X
mild	B-X
AD	B-X
dementia	B-X
)	B-X
<EOS>	B-X
6	B-X
]	B-X
)	B-X
,	B-X
and	B-X
loneliness	B-X
(	B-X
0	B-X
<EOS>	B-X
To	B-X
reach	B-X
the	B-X
consensus	B-X
on	B-X
an	B-X
evidence	B-X
summarization	B-X
process	B-X
for	B-X
PDAs	B-X
<EOS>	B-X
Further	B-X
original	B-X
studies	B-X
are	B-X
needed	B-X

Differential	O
ultraviolet-B-induced	O
immunomodulation	O
in	O
XPA	O
,	O
XPC	O
,	O
and	O
CSB	O
DNA	O
repair-deficient	O
mice	O
.	O
<EOS>	B-X
Differential	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
immunomodulation	B-X
in	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
DNA	B-X
repair	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
cellular	B-X
immune	B-X
parameters	B-X
in	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
mice	B-X
are	B-X
normal	B-X
compared	B-X
with	B-X
their	B-X
wild	B-X
-	B-X
type	B-X
(	B-X
control	B-X
)	B-X
littermates	B-X
<EOS>	B-X
Ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
DNA	B-X
damage	B-X
is	B-X
repaired	B-X
by	B-X
the	B-X
nucleotide	B-X
excision	B-X
repair	B-X
mechanism	B-X
very	B-X
efficiently	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
the	B-X
immunologic	B-X
consequences	B-X
of	B-X
specific	B-X
nucleotide	B-X
excision	B-X
repair	B-X
defects	B-X
in	B-X
three	B-X
mouse	B-X
models	B-X
,	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
mutant	B-X
mice	B-X
,	B-X
were	B-X
investigated	B-X

Ultraviolet	O
B	O
irradiation	O
has	O
serious	O
consequences	O
for	O
cellular	O
immunity	O
and	O
can	O
suppress	O
the	O
rejection	O
of	O
skin	O
tumors	O
and	O
the	O
resistance	O
to	O
infectious	O
diseases	O
.	O
<EOS>	B-X
Ultraviolet	B-X
B	B-X
irradiation	B-X
has	B-X
serious	B-X
consequences	B-X
for	B-X
cellular	B-X
immunity	B-X
and	B-X
can	B-X
suppress	B-X
the	B-X
rejection	B-X
of	B-X
skin	B-X
tumors	B-X
and	B-X
the	B-X
resistance	B-X
to	B-X
infectious	B-X
diseases	B-X
<EOS>	B-X
Ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
DNA	B-X
damage	B-X
is	B-X
repaired	B-X
by	B-X
the	B-X
nucleotide	B-X
excision	B-X
repair	B-X
mechanism	B-X
very	B-X
efficiently	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
both	B-X
global	B-X
genome	B-X
repair	B-X
and	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
are	B-X
needed	B-X
to	B-X
prevent	B-X
immunomodulation	B-X
by	B-X
ultraviolet	B-X
B	B-X
,	B-X
whereas	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
is	B-X
the	B-X
major	B-X
DNA	B-X
repair	B-X
subpathway	B-X
of	B-X
nucleotide	B-X
excision	B-X
repair	B-X
that	B-X
prevents	B-X
the	B-X
acute	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
effects	B-X
such	B-X
as	B-X
erythema	B-X
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
cellular	B-X
immune	B-X
parameters	B-X
in	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
mice	B-X
are	B-X
normal	B-X
compared	B-X
with	B-X
their	B-X
wild	B-X
-	B-X
type	B-X
(	B-X
control	B-X
)	B-X
littermates	B-X

DNA	O
damage	O
plays	O
a	O
crucial	O
role	O
in	O
these	O
immunomodulatory	O
effects	O
of	O
ultraviolet	O
B	O
,	O
as	O
impaired	O
repair	O
of	O
ultraviolet-B-induced	O
DNA	O
damage	O
has	O
been	O
shown	O
to	O
cause	O
suppression	O
of	O
cellular	O
immunity	O
.	O

Ultraviolet-B-induced	O
DNA	O
damage	O
is	O
repaired	O
by	O
the	O
nucleotide	O
excision	O
repair	O
mechanism	O
very	O
efficiently	O
.	O
<EOS>	B-X
Ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
DNA	B-X
damage	B-X
is	B-X
repaired	B-X
by	B-X
the	B-X
nucleotide	B-X
excision	B-X
repair	B-X
mechanism	B-X
very	B-X
efficiently	B-X
<EOS>	B-X
Ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
cyclobutane	B-X
-	B-X
pyrimidine	B-X
dimer	B-X
formation	B-X
and	B-X
repair	B-X
in	B-X
Arctic	B-X
marine	B-X
macrophytes	B-X
.	B-X
<EOS>	B-X
Ultraviolet	B-X
B	B-X
irradiation	B-X
has	B-X
serious	B-X
consequences	B-X
for	B-X
cellular	B-X
immunity	B-X
and	B-X
can	B-X
suppress	B-X
the	B-X
rejection	B-X
of	B-X
skin	B-X
tumors	B-X
and	B-X
the	B-X
resistance	B-X
to	B-X
infectious	B-X
diseases	B-X
<EOS>	B-X
The	B-X
significance	B-X
of	B-X
ultraviolet	B-X
-	B-X
B	B-X
radiation	B-X
(	B-X
UVBR	B-X
:	B-X
280	B-X
-	B-X
315	B-X
nm	B-X
)	B-X
	B-X
-	B-X
induced	B-X
DNA	B-X
damage	B-X
as	B-X
a	B-X
stress	B-X
factor	B-X
for	B-X
Arctic	B-X
marine	B-X
macrophytes	B-X
was	B-X
examined	B-X
in	B-X
the	B-X
Kongsfjord	B-X
(	B-X
Spitsbergen	B-X
,	B-X
78	B-X
degrees	B-X
55	B-X

Nucleotide	O
excision	O
repair	O
comprises	O
two	O
subpathways	O
:	O
transcription-coupled	O
and	O
global	O
genome	O
repair	O
.	O
<EOS>	B-X
Nucleotide	B-X
excision	B-X
repair	B-X
comprises	B-X
two	B-X
subpathways	B-X
:	B-X
transcription	B-X
-	B-X
coupled	B-X
and	B-X
global	B-X
genome	B-X
repair	B-X
<EOS>	B-X
The	B-X
nucleotide	B-X
excision	B-X
repair	B-X
(	B-X
NER	B-X
)	B-X
pathway	B-X
comprises	B-X
two	B-X
sub	B-X
-	B-X
pathways	B-X
,	B-X
transcription	B-X
coupled	B-X
repair	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
global	B-X
genome	B-X
repair	B-X
(	B-X
GGR	B-X
)	B-X
<EOS>	B-X
NER	B-X
comprises	B-X
two	B-X
subpathways	B-X
:	B-X
transcription	B-X
-	B-X
coupled	B-X
NER	B-X
(	B-X
TC	B-X
-	B-X
NER	B-X
)	B-X
and	B-X
global	B-X
genome	B-X
NER	B-X
<EOS>	B-X
Nucleotide	B-X
excision	B-X
repair	B-X
(	B-X
NER	B-X
)	B-X
eliminates	B-X
a	B-X
broad	B-X
variety	B-X
of	B-X
helix	B-X
-	B-X
distorting	B-X
DNA	B-X
lesions	B-X
that	B-X
can	B-X
otherwise	B-X
cause	B-X
genomic	B-X
instability	B-X

In	O
this	O
study	O
the	O
immunologic	O
consequences	O
of	O
specific	O
nucleotide	O
excision	O
repair	O
defects	O
in	O
three	O
mouse	O
models	O
,	O
XPA	O
,	O
XPC	O
,	O
and	O
CSB	O
mutant	O
mice	O
,	O
were	O
investigated	O
.	O

XPA	O
mice	O
carry	O
a	O
total	O
nucleotide	O
excision	O
repair	O
defect	O
,	O
whereas	O
XPC	O
and	O
CSB	O
mice	O
only	O
lack	O
global	O
genome	O
and	O
transcription-coupled	O
nucleotide	O
excision	O
repair	O
,	O
respectively	O
.	O
<EOS>	B-X
XPA	B-X
mice	B-X
carry	B-X
a	B-X
total	B-X
nucleotide	B-X
excision	B-X
repair	B-X
defect	B-X
,	B-X
whereas	B-X
XPC	B-X
and	B-X
CSB	B-X
mice	B-X
only	B-X
lack	B-X
global	B-X
genome	B-X
and	B-X
transcription	B-X
-	B-X
coupled	B-X
nucleotide	B-X
excision	B-X
repair	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Nucleotide	B-X
excision	B-X
repair	B-X
comprises	B-X
two	B-X
subpathways	B-X
:	B-X
transcription	B-X
-	B-X
coupled	B-X
and	B-X
global	B-X
genome	B-X
repair	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
both	B-X
global	B-X
genome	B-X
repair	B-X
and	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
are	B-X
needed	B-X
to	B-X
prevent	B-X
immunomodulation	B-X
by	B-X
ultraviolet	B-X
B	B-X
,	B-X
whereas	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
is	B-X
the	B-X
major	B-X
DNA	B-X
repair	B-X
subpathway	B-X
of	B-X
nucleotide	B-X
excision	B-X
repair	B-X
that	B-X
prevents	B-X
the	B-X
acute	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
effects	B-X
such	B-X
as	B-X
erythema	B-X
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
cellular	B-X
immune	B-X
parameters	B-X
in	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
mice	B-X
are	B-X
normal	B-X
compared	B-X
with	B-X
their	B-X
wild	B-X
-	B-X
type	B-X
(	B-X
control	B-X
)	B-X
littermates	B-X

Our	O
data	O
demonstrate	O
that	O
cellular	O
immune	O
parameters	O
in	O
XPA	O
,	O
XPC	O
,	O
and	O
CSB	O
mice	O
are	O
normal	O
compared	O
with	O
their	O
wild-type	O
(	O
control	O
)	O
littermates	O
.	O
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
cellular	B-X
immune	B-X
parameters	B-X
in	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
mice	B-X
are	B-X
normal	B-X
compared	B-X
with	B-X
their	B-X
wild	B-X
-	B-X
type	B-X
(	B-X
control	B-X
)	B-X
littermates	B-X
<EOS>	B-X
Differential	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
immunomodulation	B-X
in	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
DNA	B-X
repair	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X
<EOS>	B-X
XPA	B-X
mice	B-X
carry	B-X
a	B-X
total	B-X
nucleotide	B-X
excision	B-X
repair	B-X
defect	B-X
,	B-X
whereas	B-X
XPC	B-X
and	B-X
CSB	B-X
mice	B-X
only	B-X
lack	B-X
global	B-X
genome	B-X
and	B-X
transcription	B-X
-	B-X
coupled	B-X
nucleotide	B-X
excision	B-X
repair	B-X
,	B-X
respectively	B-X
<EOS>	B-X
This	B-X
may	B-X
indicate	B-X
that	B-X
the	B-X
reported	B-X
altered	B-X
cellular	B-X
responses	B-X
in	B-X
xeroderma	B-X
pigmentosum	B-X
patients	B-X
are	B-X
not	B-X
constitutive	B-X
but	B-X
could	B-X
be	B-X
due	B-X
to	B-X
external	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
ultraviolet	B-X
B	B-X

This	O
may	O
indicate	O
that	O
the	O
reported	O
altered	O
cellular	O
responses	O
in	O
xeroderma	O
pigmentosum	O
patients	O
are	O
not	O
constitutive	O
but	O
could	O
be	O
due	O
to	O
external	O
factors	O
,	O
such	O
as	O
ultraviolet	O
B	O
.	O
<EOS>	B-X
We	B-X
explored	B-X
the	B-X
prevalence	B-X
of	B-X
NER	B-X
gene	B-X
alterations	B-X
across	B-X
cancers	B-X
and	B-X
putative	B-X
therapeutic	B-X
strategies	B-X
targeting	B-X
these	B-X
vulnerabilities	B-X
<EOS>	B-X
Nucleotide	B-X
excision	B-X
repair	B-X
(	B-X
NER	B-X
)	B-X
gene	B-X
alterations	B-X
constitute	B-X
potential	B-X
cancer	B-X
therapeutic	B-X
targets	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
putative	B-X
damaging	B-X
germline	B-X
and	B-X
somatic	B-X
alterations	B-X
in	B-X
NER	B-X
genes	B-X
were	B-X
present	B-X
with	B-X
frequencies	B-X
up	B-X
to	B-X
10	B-X
%	B-X
across	B-X
multiple	B-X
cancer	B-X
types	B-X
<EOS>	B-X
These	B-X
findings	B-X
provide	B-X
novel	B-X
insights	B-X
into	B-X
a	B-X
synthetic	B-X
lethal	B-X
relationship	B-X
between	B-X
clinically	B-X
observed	B-X
NER	B-X
gene	B-X
deficiencies	B-X
and	B-X
sensitivity	B-X
to	B-X
irofulven	B-X
and	B-X
its	B-X
potential	B-X
synergistic	B-X
combination	B-X
with	B-X
other	B-X
drugs	B-X

Upon	O
exposure	O
to	O
ultraviolet	O
B	O
,	O
only	O
XPA	O
mice	O
are	O
very	O
sensitive	O
to	O
ultraviolet-B-induced	O
inhibition	O
of	O
Th1-mediated	O
contact	O
hypersensitivity	O
responses	O
and	O
interferon-gamma	B-protein
production	O
in	O
skin	O
draining	O
lymph	O
nodes	O
.	O
<EOS>	B-X
Upon	B-X
exposure	B-X
to	B-X
ultraviolet	B-X
B	B-X
,	B-X
only	B-X
XPA	B-X
mice	B-X
are	B-X
very	B-X
sensitive	B-X
to	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
Th1	B-X
-	B-X
mediated	B-X
contact	B-X
hypersensitivity	B-X
responses	B-X
and	B-X
interferon	B-X
-	B-X
gamma	B-X
production	B-X
in	B-X
skin	B-X
draining	B-X
lymph	B-X
nodes	B-X
<EOS>	B-X
In	B-X
general	B-X
XPC	B-X
mice	B-X
do	B-X
not	B-X
exhibit	B-X
any	B-X
indication	B-X
of	B-X
enhanced	B-X
ultraviolet	B-X
B	B-X
susceptibility	B-X
with	B-X
regard	B-X
to	B-X
the	B-X
immune	B-X
parameters	B-X
analyzed	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
both	B-X
global	B-X
genome	B-X
repair	B-X
and	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
are	B-X
needed	B-X
to	B-X
prevent	B-X
immunomodulation	B-X
by	B-X
ultraviolet	B-X
B	B-X
,	B-X
whereas	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
is	B-X
the	B-X
major	B-X
DNA	B-X
repair	B-X
subpathway	B-X
of	B-X
nucleotide	B-X
excision	B-X
repair	B-X
that	B-X
prevents	B-X
the	B-X
acute	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
effects	B-X
such	B-X
as	B-X
erythema	B-X
<EOS>	B-X
Differential	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
immunomodulation	B-X
in	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
DNA	B-X
repair	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X

Lipopolysaccharide-stimulated	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
interleukin-10	B-protein
production	O
are	O
significantly	O
augmented	O
in	O
both	O
XPA	O
and	O
CSB	O
mice	O
after	O
ultraviolet	O
B	O
exposure	O
.	O
<EOS>	B-X
Lipopolysaccharide	B-X
-	B-X
stimulated	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
and	B-X
interleukin	B-X
-	B-X
10	B-X
production	B-X
are	B-X
significantly	B-X
augmented	B-X
in	B-X
both	B-X
XPA	B-X
and	B-X
CSB	B-X
mice	B-X
after	B-X
ultraviolet	B-X
B	B-X
exposure	B-X
<EOS>	B-X
Lymph	B-X
node	B-X
cell	B-X
numbers	B-X
were	B-X
increased	B-X
very	B-X
significantly	B-X
in	B-X
XPA	B-X
,	B-X
mildly	B-X
increased	B-X
in	B-X
CSB	B-X
,	B-X
and	B-X
not	B-X
in	B-X
XPC	B-X
mice	B-X
<EOS>	B-X
Differential	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
immunomodulation	B-X
in	B-X
XPA	B-X
,	B-X
XPC	B-X
,	B-X
and	B-X
CSB	B-X
DNA	B-X
repair	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
both	B-X
global	B-X
genome	B-X
repair	B-X
and	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
are	B-X
needed	B-X
to	B-X
prevent	B-X
immunomodulation	B-X
by	B-X
ultraviolet	B-X
B	B-X
,	B-X
whereas	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
is	B-X
the	B-X
major	B-X
DNA	B-X
repair	B-X
subpathway	B-X
of	B-X
nucleotide	B-X
excision	B-X
repair	B-X
that	B-X
prevents	B-X
the	B-X
acute	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
effects	B-X
such	B-X
as	B-X
erythema	B-X

Lymph	O
node	O
cell	O
numbers	O
were	O
increased	O
very	O
significantly	O
in	O
XPA	O
,	O
mildly	O
increased	O
in	O
CSB	O
,	O
and	O
not	O
in	O
XPC	O
mice	O
.	O

In	O
general	O
XPC	O
mice	O
do	O
not	O
exhibit	O
any	O
indication	O
of	O
enhanced	O
ultraviolet	O
B	O
susceptibility	O
with	O
regard	O
to	O
the	O
immune	O
parameters	O
analyzed	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
PSMD7	B-X
silencing	B-X
inhibited	B-X
tumor	B-X
growth	B-X
and	B-X
enhanced	B-X
the	B-X
sensitivity	B-X
of	B-X
GC	B-X
cells	B-X
to	B-X
DDP	B-X
treatment	B-X
in	B-X
mice	B-X
<EOS>	B-X
XPC	B-X
is	B-X
involved	B-X
in	B-X
genome	B-X
maintenance	B-X
through	B-X
multiple	B-X
pathways	B-X
in	B-X
different	B-X
tissues	B-X
.	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
UVB	B-X
irradiation	B-X
increased	B-X
HDAC4	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
replication	B-X
checkpoint	B-X
inhibition	B-X
on	B-X
carcinogenesis	B-X
,	B-X
we	B-X
generated	B-X
transgenic	B-X
mice	B-X
with	B-X
diminished	B-X
ATR	B-X
function	B-X
in	B-X
skin	B-X
and	B-X
crossed	B-X
them	B-X
into	B-X
a	B-X
UV	B-X
-	B-X
sensitive	B-X
background	B-X
,	B-X
Xpc	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X

These	O
data	O
suggest	O
that	O
both	O
global	O
genome	O
repair	O
and	O
transcription-coupled	O
repair	O
are	O
needed	O
to	O
prevent	O
immunomodulation	O
by	O
ultraviolet	O
B	O
,	O
whereas	O
transcription-coupled	O
repair	O
is	O
the	O
major	O
DNA	O
repair	O
subpathway	O
of	O
nucleotide	O
excision	O
repair	O
that	O
prevents	O
the	O
acute	O
ultraviolet-B-induced	O
effects	O
such	O
as	O
erythema	O
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
both	B-X
global	B-X
genome	B-X
repair	B-X
and	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
are	B-X
needed	B-X
to	B-X
prevent	B-X
immunomodulation	B-X
by	B-X
ultraviolet	B-X
B	B-X
,	B-X
whereas	B-X
transcription	B-X
-	B-X
coupled	B-X
repair	B-X
is	B-X
the	B-X
major	B-X
DNA	B-X
repair	B-X
subpathway	B-X
of	B-X
nucleotide	B-X
excision	B-X
repair	B-X
that	B-X
prevents	B-X
the	B-X
acute	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
effects	B-X
such	B-X
as	B-X
erythema	B-X
<EOS>	B-X
XPA	B-X
mice	B-X
carry	B-X
a	B-X
total	B-X
nucleotide	B-X
excision	B-X
repair	B-X
defect	B-X
,	B-X
whereas	B-X
XPC	B-X
and	B-X
CSB	B-X
mice	B-X
only	B-X
lack	B-X
global	B-X
genome	B-X
and	B-X
transcription	B-X
-	B-X
coupled	B-X
nucleotide	B-X
excision	B-X
repair	B-X
,	B-X
respectively	B-X
<EOS>	B-X
DNA	B-X
damage	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
these	B-X
immunomodulatory	B-X
effects	B-X
of	B-X
ultraviolet	B-X
B	B-X
,	B-X
as	B-X
impaired	B-X
repair	B-X
of	B-X
ultraviolet	B-X
-	B-X
B	B-X
-	B-X
induced	B-X
DNA	B-X
damage	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
cause	B-X
suppression	B-X
of	B-X
cellular	B-X
immunity	B-X
<EOS>	B-X
This	B-X
may	B-X
indicate	B-X
that	B-X
the	B-X
reported	B-X
altered	B-X
cellular	B-X
responses	B-X
in	B-X
xeroderma	B-X
pigmentosum	B-X
patients	B-X
are	B-X
not	B-X
constitutive	B-X
but	B-X
could	B-X
be	B-X
due	B-X
to	B-X
external	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
ultraviolet	B-X
B	B-X

Biomechanical	O
strain	O
induces	O
class	O
a	O
scavenger	B-protein
receptor	I-protein
expression	O
in	O
human	B-cell_type
monocyte/macrophages	I-cell_type
and	O
THP-1	B-cell_type
cells	I-cell_type
:	O
a	O
potential	O
mechanism	O
of	O
increased	O
atherosclerosis	O
in	O
hypertension	O
.	O

BACKGROUND	O
:	O
Although	O
hypertension	O
is	O
an	O
important	O
risk	O
factor	O
for	O
the	O
development	O
of	O
atherosclerosis	O
,	O
the	O
mechanisms	O
for	O
this	O
interaction	O
are	O
incompletely	O
described	O
.	O
<EOS>	B-X
Although	B-X
hypertension	B-X
is	B-X
an	B-X
important	B-X
risk	B-X
factor	B-X
for	B-X
the	B-X
development	B-X
of	B-X
atherosclerosis	B-X
,	B-X
the	B-X
mechanisms	B-X
for	B-X
this	B-X
interaction	B-X
are	B-X
incompletely	B-X
described	B-X
<EOS>	B-X
This	B-X
induction	B-X
was	B-X
accompanied	B-X
by	B-X
augmented	B-X
expression	B-X
of	B-X
the	B-X
class	B-X
B	B-X
scavenger	B-X
receptor	B-X
CD36	B-X
(	B-X
2	B-X
<EOS>	B-X
Immunohistochemistry	B-X
revealed	B-X
that	B-X
among	B-X
macrophages	B-X
in	B-X
atherosclerotic	B-X
lesions	B-X
of	B-X
the	B-X
aorta	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
macrophages	B-X
with	B-X
SRA	B-X
expression	B-X
was	B-X
highest	B-X
in	B-X
hypertensive	B-X
animals	B-X
on	B-X
a	B-X
high	B-X
-	B-X
cholesterol	B-X
diet	B-X
(	B-X
43	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
this	B-X
effect	B-X
in	B-X
vivo	B-X
,	B-X
apolipoprotein	B-X
E	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
were	B-X
randomly	B-X
assigned	B-X
to	B-X
receive	B-X
standard	B-X
chow	B-X
,	B-X
a	B-X
high	B-X
-	B-X
cholesterol	B-X
diet	B-X
,	B-X
or	B-X
a	B-X
high	B-X
-	B-X
cholesterol	B-X
diet	B-X
with	B-X
hypertension	B-X
induced	B-X
by	B-X
angiotensin	B-X
II	B-X
infusion	B-X
for	B-X
8	B-X
weeks	B-X

Previous	O
studies	O
have	O
suggested	O
that	O
biomechanical	O
strain	O
regulates	O
macrophage	O
phenotype	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
biomechanical	B-X
strain	B-X
regulates	B-X
macrophage	B-X
phenotype	B-X
<EOS>	B-X
We	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
biomechanical	B-X
strain	B-X
can	B-X
induce	B-X
expression	B-X
of	B-X
the	B-X
class	B-X
A	B-X
scavenger	B-X
receptor	B-X
(	B-X
SRA	B-X
)	B-X
,	B-X
an	B-X
important	B-X
lipoprotein	B-X
receptor	B-X
in	B-X
atherogenesis	B-X
<EOS>	B-X
Biomechanical	B-X
strain	B-X
induces	B-X
SRA	B-X
expression	B-X
by	B-X
monocyte	B-X
/	B-X
macrophages	B-X
,	B-X
suggesting	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
promotion	B-X
of	B-X
atherosclerosis	B-X
in	B-X
hypertensive	B-X
patients	B-X
<EOS>	B-X
Biomechanical	B-X
strain	B-X
induces	B-X
class	B-X
a	B-X
scavenger	B-X
receptor	B-X
expression	B-X
in	B-X
human	B-X
monocyte	B-X
/	B-X
macrophages	B-X
and	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
:	B-X
a	B-X
potential	B-X
mechanism	B-X
of	B-X
increased	B-X
atherosclerosis	B-X
in	B-X
hypertension	B-X
.	B-X

We	O
tested	O
the	O
hypothesis	O
that	O
biomechanical	O
strain	O
can	O
induce	O
expression	O
of	O
the	O
class	B-protein
A	I-protein
scavenger	I-protein
receptor	I-protein
(	O
SRA	B-protein
)	O
,	O
an	O
important	O
lipoprotein	B-protein
receptor	I-protein
in	O
atherogenesis	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Human	B-cell_type
monocyte/macrophages	I-cell_type
or	O
THP-1	B-cell_type
cells	I-cell_type
were	O
cultured	O
in	O
a	O
device	O
that	O
imposes	O
uniform	O
biaxial	O
cyclic	O
1-Hz	O
strains	O
of	O
0	O
%	O
,	O
1	O
%	O
,	O
2	O
%	O
,	O
or	O
3	O
%	O
,	O
and	O
SRA	B-protein
expression	O
was	O
analyzed	O
.	O
<EOS>	B-X
Ex	B-X
vivo	B-X
cultures	B-X
of	B-X
monocyte	B-X
/	B-X
macrophages	B-X
from	B-X
the	B-X
murine	B-X
models	B-X
were	B-X
used	B-X
to	B-X
verify	B-X
the	B-X
molecular	B-X
pathways	B-X
<EOS>	B-X
The	B-X
frequency	B-X
of	B-X
TF	B-X
-	B-X
positive	B-X
monocyte	B-X
/	B-X
macrophages	B-X
in	B-X
thrombi	B-X
was	B-X
higher	B-X
in	B-X
cancer	B-X
-	B-X
associated	B-X
VTE	B-X
than	B-X
that	B-X
in	B-X
VTE	B-X
without	B-X
cancer	B-X
<EOS>	B-X
We	B-X
show	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
of	B-X
the	B-X
pathway	B-X
through	B-X
which	B-X
platelets	B-X
expressing	B-X
MMP	B-X
-	B-X
2	B-X
trigger	B-X
the	B-X
initial	B-X
phases	B-X
of	B-X
atherosclerosis	B-X
and	B-X
provide	B-X
a	B-X
mechanism	B-X
showing	B-X
that	B-X
they	B-X
activate	B-X
endothelial	B-X
PAR	B-X
-	B-X
1	B-X
triggering	B-X
endothelial	B-X
p38MAPK	B-X
signalling	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
adhesion	B-X
molecules	B-X
<EOS>	B-X
Monocytes	B-X
/	B-X
macrophages	B-X
initiate	B-X
innate	B-X
immune	B-X
response	B-X
,	B-X
and	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
the	B-X
cell	B-X
that	B-X
first	B-X
comes	B-X
into	B-X
contact	B-X
with	B-X
the	B-X
pathogen	B-X

Mechanical	O
strains	O
induced	O
SRA	B-RNA
mRNA	I-RNA
(	O
3.5+/-0.6-fold	O
at	O
3	O
%	O
strain	O
for	O
48	O
hours	O
,	O
P	O
<	O
0.01	O
)	O
and	O
SRA	B-protein
protein	I-protein
in	O
THP-1	B-cell_type
cells	I-cell_type
in	O
an	O
amplitude-dependent	O
manner	O
.	O

This	O
induction	O
was	O
accompanied	O
by	O
augmented	O
expression	O
of	O
the	O
class	B-protein
B	I-protein
scavenger	I-protein
receptor	I-protein
CD36	I-protein
(	O
2.8+/-0.3-fold	O
,	O
P	O
<	O
0.001	O
)	O
but	O
not	O
by	O
increased	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
expression	O
.	O

To	O
evaluate	O
this	O
effect	O
in	O
vivo	O
,	O
apolipoprotein	O
E	O
(	O
-/-	O
)	O
mice	O
were	O
randomly	O
assigned	O
to	O
receive	O
standard	O
chow	O
,	O
a	O
high-cholesterol	O
diet	O
,	O
or	O
a	O
high-cholesterol	O
diet	O
with	O
hypertension	O
induced	O
by	O
angiotensin	O
II	O
infusion	O
for	O
8	O
weeks	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
this	B-X
effect	B-X
in	B-X
vivo	B-X
,	B-X
apolipoprotein	B-X
E	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
were	B-X
randomly	B-X
assigned	B-X
to	B-X
receive	B-X
standard	B-X
chow	B-X
,	B-X
a	B-X
high	B-X
-	B-X
cholesterol	B-X
diet	B-X
,	B-X
or	B-X
a	B-X
high	B-X
-	B-X
cholesterol	B-X
diet	B-X
with	B-X
hypertension	B-X
induced	B-X
by	B-X
angiotensin	B-X
II	B-X
infusion	B-X
for	B-X
8	B-X
weeks	B-X
<EOS>	B-X
Despite	B-X
the	B-X
larger	B-X
increase	B-X
in	B-X
TPR	B-X
and	B-X
the	B-X
reduced	B-X
baroreceptor	B-X
reflex	B-X
sensitivity	B-X
in	B-X
the	B-X
high	B-X
-	B-X
cholesterol	B-X
group	B-X
,	B-X
maximum	B-X
blood	B-X
pressure	B-X
response	B-X
to	B-X
angiotensin	B-X
II	B-X
was	B-X
similar	B-X
in	B-X
both	B-X
groups	B-X
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
a	B-X
greater	B-X
blood	B-X
pressure	B-X
response	B-X
to	B-X
angiotensin	B-X
II	B-X
in	B-X
the	B-X
high	B-X
-	B-X
cholesterol	B-X
group	B-X
could	B-X
be	B-X
the	B-X
result	B-X
of	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
heart	B-X
failure	B-X
<EOS>	B-X
Rabbits	B-X
were	B-X
fed	B-X
a	B-X
high	B-X
-	B-X
cholesterol	B-X
diet	B-X
(	B-X
n	B-X
=	B-X
10	B-X
)	B-X
for	B-X
12	B-X
weeks	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
standard	B-X
diet	B-X
for	B-X
another	B-X
6	B-X
weeks	B-X

Immunohistochemistry	O
revealed	O
that	O
among	O
macrophages	B-cell_type
in	O
atherosclerotic	O
lesions	O
of	O
the	O
aorta	O
,	O
the	O
proportion	O
of	O
macrophages	B-cell_type
with	O
SRA	B-protein
expression	O
was	O
highest	O
in	O
hypertensive	O
animals	O
on	O
a	O
high-cholesterol	O
diet	O
(	O
43.9+/-0.7	O
%	O
,	O
versus	O
12.0+/-2.0	O
%	O
for	O
normotensive	O
animals	O
on	O
a	O
high-cholesterol	O
diet	O
and	O
4.7+/-4.7	O
%	O
for	O
animals	O
on	O
standard	O
chow	O
;	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Biomechanical	O
strain	O
induces	O
SRA	B-protein
expression	O
by	O
monocyte/macrophages	B-cell_type
,	O
suggesting	O
a	O
novel	O
mechanism	O
for	O
promotion	O
of	O
atherosclerosis	O
in	O
hypertensive	O
patients	O
.	O
<EOS>	B-X
Biomechanical	B-X
strain	B-X
induces	B-X
SRA	B-X
expression	B-X
by	B-X
monocyte	B-X
/	B-X
macrophages	B-X
,	B-X
suggesting	B-X
a	B-X
novel	B-X
mechanism	B-X
for	B-X
promotion	B-X
of	B-X
atherosclerosis	B-X
in	B-X
hypertensive	B-X
patients	B-X
<EOS>	B-X
Biomechanical	B-X
strain	B-X
induces	B-X
class	B-X
a	B-X
scavenger	B-X
receptor	B-X
expression	B-X
in	B-X
human	B-X
monocyte	B-X
/	B-X
macrophages	B-X
and	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
:	B-X
a	B-X
potential	B-X
mechanism	B-X
of	B-X
increased	B-X
atherosclerosis	B-X
in	B-X
hypertension	B-X
.	B-X
<EOS>	B-X
We	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
biomechanical	B-X
strain	B-X
can	B-X
induce	B-X
expression	B-X
of	B-X
the	B-X
class	B-X
A	B-X
scavenger	B-X
receptor	B-X
(	B-X
SRA	B-X
)	B-X
,	B-X
an	B-X
important	B-X
lipoprotein	B-X
receptor	B-X
in	B-X
atherogenesis	B-X
<EOS>	B-X
This	B-X
induction	B-X
was	B-X
accompanied	B-X
by	B-X
augmented	B-X
expression	B-X
of	B-X
the	B-X
class	B-X
B	B-X
scavenger	B-X
receptor	B-X
CD36	B-X
(	B-X
2	B-X

High	O
glucose	O
induces	O
MCP-1	O
expression	O
partly	O
via	O
tyrosine	O
kinase-AP-1	O
pathway	O
in	O
peritoneal	B-cell_type
mesothelial	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
High	B-X
glucose	B-X
induces	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
in	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
:	B-X
High	B-X
glucose	B-X
induced	B-X
mesothelial	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
<EOS>	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
its	B-X
signal	B-X
transduction	B-X
pathway	B-X
in	B-X
human	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X
<EOS>	B-X
Glucose	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
in	B-X
a	B-X
time	B-X
-	B-X
	B-X
and	B-X
dose	B-X
-	B-X
dependent	B-X
manner	B-X

BACKGROUND	O
:	O
High	O
glucose	O
in	O
peritoneal	O
dialysis	O
solutions	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
peritoneal	O
fibrosis	O
in	O
chronic	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
patients	O
.	O
<EOS>	B-X
High	B-X
glucose	B-X
in	B-X
peritoneal	B-X
dialysis	B-X
solutions	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
peritoneal	B-X
fibrosis	B-X
in	B-X
chronic	B-X
ambulatory	B-X
peritoneal	B-X
dialysis	B-X
(	B-X
CAPD	B-X
)	B-X
patients	B-X
<EOS>	B-X
VEGF	B-X
expression	B-X
in	B-X
stromal	B-X
cells	B-X
,	B-X
retaining	B-X
mesothelial	B-X
markers	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
peritoneal	B-X
biopsy	B-X
specimens	B-X
from	B-X
high	B-X
-	B-X
transporter	B-X
patients	B-X
<EOS>	B-X
:	B-X
High	B-X
glucose	B-X
induced	B-X
mesothelial	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
<EOS>	B-X
High	B-X
glucose	B-X
induces	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
in	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X
.	B-X

However	O
,	O
the	O
mechanisms	O
are	O
not	O
very	O
clear	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
in	B-X
HCMV	B-X
infection	B-X
still	B-X
remains	B-X
unclear	B-X
<EOS>	B-X
Deciphering	B-X
the	B-X
mechanism	B-X
of	B-X
fungal	B-X
pathogen	B-X
-	B-X
induced	B-X
disease	B-X
-	B-X
suppressive	B-X
soil	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
exact	B-X
molecular	B-X
mechanism	B-X
responsible	B-X
for	B-X
salinity	B-X
-	B-X
induced	B-X
malate	B-X
accumulation	B-X
remains	B-X
unclear	B-X
<EOS>	B-X
To	B-X
identify	B-X
the	B-X
mechanism	B-X
of	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
Lewis	B-X
Y	B-X
antigen	B-X
caused	B-X
by	B-X
X	B-X
-	B-X
ray	B-X
irradiation	B-X

Peritoneal	B-cell_type
macrophages	I-cell_type
seem	O
to	O
participate	O
in	O
the	O
process	O
of	O
peritoneal	O
fibrosis	O
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
recruitment	O
of	O
monocytes	B-cell_type
toward	O
the	O
peritoneal	O
cavity	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effect	O
of	O
high	O
glucose	O
on	O
MCP-1	B-protein
expression	O
and	O
its	O
signal	O
transduction	O
pathway	O
in	O
human	B-cell_type
peritoneal	I-cell_type
mesothelial	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
its	B-X
signal	B-X
transduction	B-X
pathway	B-X
in	B-X
human	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X
<EOS>	B-X
High	B-X
glucose	B-X
induces	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
in	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Chemotactic	B-X
activity	B-X
of	B-X
high	B-X
-	B-X
glucose	B-X
-	B-X
conditioned	B-X
culture	B-X
supernatant	B-X
was	B-X
measured	B-X
by	B-X
chemotactic	B-X
assay	B-X
<EOS>	B-X
:	B-X
High	B-X
glucose	B-X
induced	B-X
mesothelial	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X

METHODS	O
:	O
Mesothelial	B-cell_type
cells	I-cell_type
were	O
cultured	O
with	O
glucose	O
(	O
5	O
to	O
100	O
mmol/L	O
)	O
or	O
mannitol	O
chronically	O
for	O
up	O
to	O
seven	O
days	O
.	O
<EOS>	B-X
Mesothelial	B-X
cells	B-X
were	B-X
cultured	B-X
with	B-X
glucose	B-X
(	B-X
5	B-X
to	B-X
100	B-X
mmol	B-X
/	B-X
L	B-X
)	B-X
or	B-X
mannitol	B-X
chronically	B-X
for	B-X
up	B-X
to	B-X
seven	B-X
days	B-X
<EOS>	B-X
HMCs	B-X
were	B-X
cultured	B-X
in	B-X
5	B-X
mmol	B-X
/	B-X
L	B-X
D	B-X
-	B-X
glucose	B-X
[	B-X
normal	B-X
glucose	B-X
(	B-X
NG	B-X
)	B-X
]	B-X
or	B-X
30	B-X
mmol	B-X
/	B-X
L	B-X
D	B-X
-	B-X
glucose	B-X
(	B-X
HG	B-X
)	B-X
for	B-X
seven	B-X
days	B-X
<EOS>	B-X
Absorptive	B-X
epithelial	B-X
cells	B-X
were	B-X
not	B-X
damaged	B-X
and	B-X
the	B-X
microvilli	B-X
were	B-X
normal	B-X
in	B-X
height	B-X
and	B-X
appearance	B-X
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
osmotic	B-X
stress	B-X
in	B-X
HG	B-X
activation	B-X
of	B-X
p38	B-X
MAPK	B-X
,	B-X
cells	B-X
were	B-X
acutely	B-X
treated	B-X
with	B-X
mannitol	B-X
(	B-X
25	B-X
to	B-X
250	B-X
mOsm	B-X
/	B-X
L	B-X
x	B-X
5	B-X
to	B-X
60	B-X
min	B-X
)	B-X
or	B-X
were	B-X
grown	B-X
seven	B-X
days	B-X
in	B-X
media	B-X
supplemented	B-X
with	B-X
mannitol	B-X
at	B-X
concentrations	B-X
iso	B-X
-	B-X
osmotic	B-X
to	B-X
HG	B-X
media	B-X

MCP-1	B-protein
expression	O
of	O
mRNA	O
and	O
protein	O
was	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O
<EOS>	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
of	B-X
mRNA	B-X
and	B-X
protein	B-X
was	B-X
measured	B-X
by	B-X
Northern	B-X
blot	B-X
analysis	B-X
and	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
<EOS>	B-X
MCP	B-X
-	B-X
1	B-X
in	B-X
culture	B-X
media	B-X
was	B-X
quantified	B-X
using	B-X
an	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
<EOS>	B-X
MCP	B-X
-	B-X
1	B-X
was	B-X
measured	B-X
in	B-X
the	B-X
plasma	B-X
or	B-X
culture	B-X
medium	B-X
by	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
<EOS>	B-X
MCP	B-X
-	B-X
1	B-X
gene	B-X
expression	B-X
was	B-X
detected	B-X
by	B-X
Northern	B-X
blot	B-X
analysis	B-X
of	B-X
buffy	B-X
coat	B-X
or	B-X
mononuclear	B-X
cell	B-X
total	B-X
RNA	B-X

Chemotactic	O
activity	O
of	O
high-glucose-conditioned	O
culture	O
supernatant	O
was	O
measured	O
by	O
chemotactic	O
assay	O
.	O

To	O
examine	O
the	O
roles	O
of	O
the	O
transcription	B-protein
factors	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
was	O
performed	O
.	O
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
,	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
was	B-X
performed	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
were	B-X
performed	B-X
in	B-X
order	B-X
to	B-X
examine	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
and	B-X
activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
	B-X
-	B-X
1	B-X
binding	B-X
activities	B-X
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
bile	B-X
and	B-X
acid	B-X
in	B-X
the	B-X
causation	B-X
of	B-X
esophageal	B-X
cancer	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
bile	B-X
acids	B-X
and	B-X
acid	B-X
on	B-X
NF	B-X
-	B-X
κB	B-X
activation	B-X
in	B-X
the	B-X
esophageal	B-X
epithelial	B-X
cells	B-X
OE33	B-X
and	B-X
SKGT	B-X
-	B-X
4	B-X
qualitatively	B-X
and	B-X
quantitatively	B-X
<EOS>	B-X
Factors	B-X
regulating	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
esophageal	B-X
cancer	B-X
cells	B-X
:	B-X
Role	B-X
of	B-X
bile	B-X
acids	B-X
and	B-X
acid	B-X
.	B-X

RESULTS	O
:	O
Glucose	O
induced	O
MCP-1	B-RNA
mRNA	I-RNA
expression	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
.	O

MCP-1	B-protein
protein	I-protein
in	O
cell	O
culture	O
supernant	O
was	O
also	O
increased	O
.	O
<EOS>	B-X
MCP	B-X
-	B-X
1	B-X
protein	B-X
in	B-X
cell	B-X
culture	B-X
supernant	B-X
was	B-X
also	B-X
increased	B-X
<EOS>	B-X
Chemotactic	B-X
activity	B-X
of	B-X
high	B-X
-	B-X
glucose	B-X
-	B-X
conditioned	B-X
culture	B-X
supernatant	B-X
was	B-X
measured	B-X
by	B-X
chemotactic	B-X
assay	B-X
<EOS>	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
of	B-X
mRNA	B-X
and	B-X
protein	B-X
was	B-X
measured	B-X
by	B-X
Northern	B-X
blot	B-X
analysis	B-X
and	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
<EOS>	B-X
Tyrosine	B-X
kinase	B-X
inhibitors	B-X
such	B-X
as	B-X
genistein	B-X
(	B-X
12	B-X

Equivalent	O
concentrations	O
of	O
mannitol	O
had	O
no	O
significant	O
effect	O
.	O
<EOS>	B-X
Equivalent	B-X
concentrations	B-X
of	B-X
mannitol	B-X
had	B-X
no	B-X
significant	B-X
effect	B-X
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
equivalent	B-X
osmolalities	B-X
of	B-X
mannitol	B-X
,	B-X
NaCl	B-X
,	B-X
or	B-X
glycerol	B-X
failed	B-X
to	B-X
exhibit	B-X
this	B-X
response	B-X
<EOS>	B-X
coli	B-X
cells	B-X
were	B-X
able	B-X
to	B-X
form	B-X
D	B-X
-	B-X
mannitol	B-X
from	B-X
D	B-X
-	B-X
fructose	B-X
in	B-X
a	B-X
low	B-X
but	B-X
significant	B-X
quantity	B-X
(	B-X
15	B-X
mM	B-X
)	B-X
<EOS>	B-X
Administration	B-X
of	B-X
2,5	B-X
-	B-X
AM	B-X
at	B-X
rest	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
0	B-X

High-glucose-conditioned	O
supernatant	O
possessed	O
an	O
increased	O
chemotactic	O
activity	O
for	O
monocytes	B-cell_type
,	O
which	O
was	O
neutralized	O
by	O
anti-MCP-1	B-protein
antibody	I-protein
.	O
<EOS>	B-X
High	B-X
-	B-X
glucose	B-X
-	B-X
conditioned	B-X
supernatant	B-X
possessed	B-X
an	B-X
increased	B-X
chemotactic	B-X
activity	B-X
for	B-X
monocytes	B-X
,	B-X
which	B-X
was	B-X
neutralized	B-X
by	B-X
anti	B-X
-	B-X
MCP	B-X
-	B-X
1	B-X
antibody	B-X
<EOS>	B-X
High	B-X
glucose	B-X
in	B-X
peritoneal	B-X
dialysis	B-X
solutions	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
peritoneal	B-X
fibrosis	B-X
in	B-X
chronic	B-X
ambulatory	B-X
peritoneal	B-X
dialysis	B-X
(	B-X
CAPD	B-X
)	B-X
patients	B-X
<EOS>	B-X
:	B-X
High	B-X
glucose	B-X
induced	B-X
mesothelial	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
<EOS>	B-X
High	B-X
glucose	B-X
induces	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
in	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X
.	B-X

EMSA	O
revealed	O
that	O
glucose	O
increased	O
the	O
AP-1	B-protein
binding	O
activity	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
,	O
but	O
not	O
NF-kappaB	B-protein
.	O

Curcumin	O
,	O
an	O
inhibitor	O
of	O
AP-1	B-protein
,	O
dose-dependently	O
suppressed	O
the	O
induction	O
of	O
MCP-1	B-RNA
mRNA	I-RNA
by	O
high	O
glucose	O
.	O
<EOS>	B-X
Curcumin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
dose	B-X
-	B-X
dependently	B-X
suppressed	B-X
the	B-X
induction	B-X
of	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
by	B-X
high	B-X
glucose	B-X
<EOS>	B-X
1	B-X
to	B-X
1	B-X
micromol	B-X
/	B-X
L	B-X
)	B-X
inhibited	B-X
the	B-X
high	B-X
-	B-X
glucose	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
in	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
manner	B-X
,	B-X
and	B-X
also	B-X
suppressed	B-X
the	B-X
high	B-X
-	B-X
glucose	B-X
-	B-X
induced	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
activity	B-X
<EOS>	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
its	B-X
signal	B-X
transduction	B-X
pathway	B-X
in	B-X
human	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X
<EOS>	B-X
Chemotactic	B-X
activity	B-X
of	B-X
high	B-X
-	B-X
glucose	B-X
-	B-X
conditioned	B-X
culture	B-X
supernatant	B-X
was	B-X
measured	B-X
by	B-X
chemotactic	B-X
assay	B-X

Tyrosine	O
kinase	O
inhibitors	O
such	O
as	O
genistein	O
(	O
12.5	O
to	O
50	O
micromol/L	O
)	O
and	O
herbimycin	O
A	O
(	O
0.1	O
to	O
1	O
micromol/L	O
)	O
inhibited	O
the	O
high-glucose-induced	O
MCP-1	B-RNA
mRNA	I-RNA
expression	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
also	O
suppressed	O
the	O
high-glucose-induced	O
AP-1	B-protein
binding	O
activity	O
.	O

CONCLUSIONS	O
:	O
:	O
High	O
glucose	O
induced	O
mesothelial	O
MCP-1	B-protein
expression	O
partly	O
via	O
the	O
tyrosine	O
kinase-	O
AP-1	B-protein
pathway	O
.	O
<EOS>	B-X
:	B-X
High	B-X
glucose	B-X
induced	B-X
mesothelial	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
the	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
<EOS>	B-X
High	B-X
glucose	B-X
induces	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
partly	B-X
via	B-X
tyrosine	B-X
kinase	B-X
-	B-X
AP	B-X
-	B-X
1	B-X
pathway	B-X
in	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Glucose	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
in	B-X
a	B-X
time	B-X
-	B-X
	B-X
and	B-X
dose	B-X
-	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
its	B-X
signal	B-X
transduction	B-X
pathway	B-X
in	B-X
human	B-X
peritoneal	B-X
mesothelial	B-X
cells	B-X

Signal	O
thresholds	O
and	O
modular	O
synergy	O
during	O
expression	O
of	O
costimulatory	O
molecules	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
analyzed	O
intracellular	O
pathways	O
modulating	O
surface	O
densities	O
of	O
CD80	B-protein
and	O
CD86	B-protein
in	O
B	B-cell_type
cells	I-cell_type
activated	O
through	O
ligation	O
of	O
the	O
Ag	B-protein
receptor	I-protein
,	O
and	O
the	O
adhesion	B-protein
molecule	I-protein
CD54	B-protein
.	O

Whereas	O
B	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
cross-linking	O
alone	O
stimulated	O
increased	O
expression	O
of	O
CD86	B-protein
,	O
up-regulation	O
of	O
CD80	B-protein
required	O
dual	O
stimulation	O
with	O
anti-IgM	B-protein
and	O
anti-CD54	B-protein
.	O
<EOS>	B-X
Whereas	B-X
B	B-X
cell	B-X
Ag	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
cross	B-X
-	B-X
linking	B-X
alone	B-X
stimulated	B-X
increased	B-X
expression	B-X
of	B-X
CD86	B-X
,	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
CD80	B-X
required	B-X
dual	B-X
stimulation	B-X
with	B-X
anti	B-X
-	B-X
IgM	B-X
and	B-X
anti	B-X
-	B-X
CD54	B-X
<EOS>	B-X
Signal	B-X
thresholds	B-X
and	B-X
modular	B-X
synergy	B-X
during	B-X
expression	B-X
of	B-X
costimulatory	B-X
molecules	B-X
in	B-X
B	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
nexus	B-X
between	B-X
anti	B-X
-	B-X
IgM	B-X
and	B-X
anti	B-X
-	B-X
CD54	B-X
stimulation	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
CD80	B-X
regulation	B-X
,	B-X
was	B-X
identified	B-X
to	B-X
involve	B-X
a	B-X
self	B-X
-	B-X
propagating	B-X
process	B-X
of	B-X
sequential	B-X
synergy	B-X
<EOS>	B-X
However	B-X
,	B-X
CD80	B-X
enhancement	B-X
required	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
both	B-X
intracellular	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
concentration	B-X
and	B-X
CD54	B-X
-	B-X
initiated	B-X
pathways	B-X

The	O
principal	O
downstream	O
component	O
contributed	O
by	O
BCR	B-protein
signaling	O
,	O
toward	O
both	O
CD80	B-protein
and	O
CD86	B-protein
induction	O
,	O
was	O
the	O
elevated	O
concentration	O
of	O
free	O
cytoplasmic	O
Ca	O
(	O
2+	O
)	O
,	O
recruited	O
by	O
way	O
of	O
capacitative	O
influx	O
.	O
<EOS>	B-X
The	B-X
principal	B-X
downstream	B-X
component	B-X
contributed	B-X
by	B-X
BCR	B-X
signaling	B-X
,	B-X
toward	B-X
both	B-X
CD80	B-X
and	B-X
CD86	B-X
induction	B-X
,	B-X
was	B-X
the	B-X
elevated	B-X
concentration	B-X
of	B-X
free	B-X
cytoplasmic	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
recruited	B-X
by	B-X
way	B-X
of	B-X
capacitative	B-X
influx	B-X
<EOS>	B-X
The	B-X
nexus	B-X
between	B-X
anti	B-X
-	B-X
IgM	B-X
and	B-X
anti	B-X
-	B-X
CD54	B-X
stimulation	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
CD80	B-X
regulation	B-X
,	B-X
was	B-X
identified	B-X
to	B-X
involve	B-X
a	B-X
self	B-X
-	B-X
propagating	B-X
process	B-X
of	B-X
sequential	B-X
synergy	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
intracellular	B-X
pathways	B-X
modulating	B-X
surface	B-X
densities	B-X
of	B-X
CD80	B-X
and	B-X
CD86	B-X
in	B-X
B	B-X
cells	B-X
activated	B-X
through	B-X
ligation	B-X
of	B-X
the	B-X
Ag	B-X
receptor	B-X
,	B-X
and	B-X
the	B-X
adhesion	B-X
molecule	B-X
CD54	B-X
<EOS>	B-X
However	B-X
,	B-X
CD80	B-X
enhancement	B-X
required	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
both	B-X
intracellular	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
concentration	B-X
and	B-X
CD54	B-X
-	B-X
initiated	B-X
pathways	B-X

This	O
alone	O
was	O
sufficient	O
to	O
generate	O
an	O
increase	O
in	O
CD86	B-protein
levels	O
.	O
<EOS>	B-X
This	B-X
alone	B-X
was	B-X
sufficient	B-X
to	B-X
generate	B-X
an	B-X
increase	B-X
in	B-X
CD86	B-X
levels	B-X
<EOS>	B-X
This	B-X
then	B-X
facilitated	B-X
a	B-X
second	B-X
synergistic	B-X
interaction	B-X
between	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
cAMP	B-X
,	B-X
culminating	B-X
in	B-X
CD80	B-X
expression	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
level	B-X
of	B-X
costimulation	B-X
is	B-X
important	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
and	B-X
for	B-X
host	B-X
survival	B-X
<EOS>	B-X
B7	B-X
-	B-X
2	B-X
expression	B-X
above	B-X
a	B-X
threshold	B-X
elicits	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
as	B-X
effective	B-X
as	B-X
interleukin	B-X
-	B-X
12	B-X
and	B-X
prolongs	B-X
survival	B-X
in	B-X
murine	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
.	B-X

However	O
,	O
CD80	B-protein
enhancement	O
required	O
the	O
concerted	O
action	O
of	O
both	O
intracellular	O
Ca	O
(	O
2+	O
)	O
concentration	O
and	O
CD54-initiated	O
pathways	O
.	O
<EOS>	B-X
However	B-X
,	B-X
CD80	B-X
enhancement	B-X
required	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
both	B-X
intracellular	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
concentration	B-X
and	B-X
CD54	B-X
-	B-X
initiated	B-X
pathways	B-X
<EOS>	B-X
The	B-X
principal	B-X
downstream	B-X
component	B-X
contributed	B-X
by	B-X
BCR	B-X
signaling	B-X
,	B-X
toward	B-X
both	B-X
CD80	B-X
and	B-X
CD86	B-X
induction	B-X
,	B-X
was	B-X
the	B-X
elevated	B-X
concentration	B-X
of	B-X
free	B-X
cytoplasmic	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
recruited	B-X
by	B-X
way	B-X
of	B-X
capacitative	B-X
influx	B-X
<EOS>	B-X
The	B-X
first	B-X
step	B-X
involved	B-X
amplified	B-X
accumulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
BCR	B-X
-	B-X
mobilized	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
CD54	B-X
-	B-X
derived	B-X
signals	B-X
<EOS>	B-X
This	B-X
then	B-X
facilitated	B-X
a	B-X
second	B-X
synergistic	B-X
interaction	B-X
between	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
cAMP	B-X
,	B-X
culminating	B-X
in	B-X
CD80	B-X
expression	B-X

The	O
nexus	O
between	O
anti-IgM	O
and	O
anti-CD54	O
stimulation	O
,	O
in	O
the	O
context	O
of	O
CD80	B-protein
regulation	O
,	O
was	O
identified	O
to	O
involve	O
a	O
self-propagating	O
process	O
of	O
sequential	O
synergy	O
.	O
<EOS>	B-X
The	B-X
nexus	B-X
between	B-X
anti	B-X
-	B-X
IgM	B-X
and	B-X
anti	B-X
-	B-X
CD54	B-X
stimulation	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
CD80	B-X
regulation	B-X
,	B-X
was	B-X
identified	B-X
to	B-X
involve	B-X
a	B-X
self	B-X
-	B-X
propagating	B-X
process	B-X
of	B-X
sequential	B-X
synergy	B-X
<EOS>	B-X
The	B-X
principal	B-X
downstream	B-X
component	B-X
contributed	B-X
by	B-X
BCR	B-X
signaling	B-X
,	B-X
toward	B-X
both	B-X
CD80	B-X
and	B-X
CD86	B-X
induction	B-X
,	B-X
was	B-X
the	B-X
elevated	B-X
concentration	B-X
of	B-X
free	B-X
cytoplasmic	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
recruited	B-X
by	B-X
way	B-X
of	B-X
capacitative	B-X
influx	B-X
<EOS>	B-X
Our	B-X
findings	B-X
of	B-X
distinct	B-X
signal	B-X
transducer	B-X
requirements	B-X
,	B-X
with	B-X
the	B-X
added	B-X
consequences	B-X
of	B-X
cross	B-X
-	B-X
talk	B-X
,	B-X
offers	B-X
an	B-X
explanation	B-X
for	B-X
variable	B-X
modulation	B-X
of	B-X
costimulatory	B-X
molecule	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
physiological	B-X
stimuli	B-X
<EOS>	B-X
This	B-X
then	B-X
facilitated	B-X
a	B-X
second	B-X
synergistic	B-X
interaction	B-X
between	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
cAMP	B-X
,	B-X
culminating	B-X
in	B-X
CD80	B-X
expression	B-X

The	O
first	O
step	O
involved	O
amplified	O
accumulation	O
of	O
intracellular	O
cAMP	O
,	O
as	O
a	O
result	O
of	O
cross-talk	O
between	O
BCR	B-protein
-mobilized	O
Ca	O
(	O
2+	O
)	O
and	O
CD54-derived	O
signals	O
.	O

This	O
then	O
facilitated	O
a	O
second	O
synergistic	O
interaction	O
between	O
Ca	O
(	O
2+	O
)	O
and	O
cAMP	O
,	O
culminating	O
in	O
CD80	B-protein
expression	O
.	O
<EOS>	B-X
This	B-X
then	B-X
facilitated	B-X
a	B-X
second	B-X
synergistic	B-X
interaction	B-X
between	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
cAMP	B-X
,	B-X
culminating	B-X
in	B-X
CD80	B-X
expression	B-X
<EOS>	B-X
This	B-X
alone	B-X
was	B-X
sufficient	B-X
to	B-X
generate	B-X
an	B-X
increase	B-X
in	B-X
CD86	B-X
levels	B-X
<EOS>	B-X
The	B-X
first	B-X
step	B-X
involved	B-X
amplified	B-X
accumulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
BCR	B-X
-	B-X
mobilized	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
CD54	B-X
-	B-X
derived	B-X
signals	B-X
<EOS>	B-X
The	B-X
nexus	B-X
between	B-X
anti	B-X
-	B-X
IgM	B-X
and	B-X
anti	B-X
-	B-X
CD54	B-X
stimulation	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
CD80	B-X
regulation	B-X
,	B-X
was	B-X
identified	B-X
to	B-X
involve	B-X
a	B-X
self	B-X
-	B-X
propagating	B-X
process	B-X
of	B-X
sequential	B-X
synergy	B-X

Our	O
findings	O
of	O
distinct	O
signal	O
transducer	O
requirements	O
,	O
with	O
the	O
added	O
consequences	O
of	O
cross-talk	O
,	O
offers	O
an	O
explanation	O
for	O
variable	O
modulation	O
of	O
costimulatory	O
molecule	O
expression	O
in	O
response	O
to	O
diverse	O
physiological	O
stimuli	O
.	O
<EOS>	B-X
Our	B-X
findings	B-X
of	B-X
distinct	B-X
signal	B-X
transducer	B-X
requirements	B-X
,	B-X
with	B-X
the	B-X
added	B-X
consequences	B-X
of	B-X
cross	B-X
-	B-X
talk	B-X
,	B-X
offers	B-X
an	B-X
explanation	B-X
for	B-X
variable	B-X
modulation	B-X
of	B-X
costimulatory	B-X
molecule	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
physiological	B-X
stimuli	B-X
<EOS>	B-X
Signal	B-X
thresholds	B-X
and	B-X
modular	B-X
synergy	B-X
during	B-X
expression	B-X
of	B-X
costimulatory	B-X
molecules	B-X
in	B-X
B	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
intracellular	B-X
pathways	B-X
modulating	B-X
surface	B-X
densities	B-X
of	B-X
CD80	B-X
and	B-X
CD86	B-X
in	B-X
B	B-X
cells	B-X
activated	B-X
through	B-X
ligation	B-X
of	B-X
the	B-X
Ag	B-X
receptor	B-X
,	B-X
and	B-X
the	B-X
adhesion	B-X
molecule	B-X
CD54	B-X
<EOS>	B-X
The	B-X
nexus	B-X
between	B-X
anti	B-X
-	B-X
IgM	B-X
and	B-X
anti	B-X
-	B-X
CD54	B-X
stimulation	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
CD80	B-X
regulation	B-X
,	B-X
was	B-X
identified	B-X
to	B-X
involve	B-X
a	B-X
self	B-X
-	B-X
propagating	B-X
process	B-X
of	B-X
sequential	B-X
synergy	B-X

Importantly	O
,	O
these	O
results	O
also	O
reveal	O
how	O
concentration	O
threshold	O
barriers	O
for	O
recruitment	O
of	O
individual	O
second	O
messengers	O
can	O
be	O
overcome	O
by	O
constructive	O
convergence	O
of	O
signaling	O
modules	O
.	O
<EOS>	B-X
Importantly	B-X
,	B-X
these	B-X
results	B-X
also	B-X
reveal	B-X
how	B-X
concentration	B-X
threshold	B-X
barriers	B-X
for	B-X
recruitment	B-X
of	B-X
individual	B-X
second	B-X
messengers	B-X
can	B-X
be	B-X
overcome	B-X
by	B-X
constructive	B-X
convergence	B-X
of	B-X
signaling	B-X
modules	B-X
<EOS>	B-X
Signal	B-X
thresholds	B-X
and	B-X
modular	B-X
synergy	B-X
during	B-X
expression	B-X
of	B-X
costimulatory	B-X
molecules	B-X
in	B-X
B	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
CD80	B-X
enhancement	B-X
required	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
both	B-X
intracellular	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
concentration	B-X
and	B-X
CD54	B-X
-	B-X
initiated	B-X
pathways	B-X
<EOS>	B-X
The	B-X
first	B-X
step	B-X
involved	B-X
amplified	B-X
accumulation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
BCR	B-X
-	B-X
mobilized	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
CD54	B-X
-	B-X
derived	B-X
signals	B-X

The	O
role	O
of	O
Epstein-Barr	O
virus	O
in	O
neoplastic	O
transformation	O
.	O
<EOS>	B-X
Pathogenic	B-X
Role	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
Virus	B-X
in	B-X
Lung	B-X
Cancers	B-X
.	B-X
<EOS>	B-X
A	B-X
central	B-X
role	B-X
of	B-X
IKK2	B-X
and	B-X
TPL2	B-X
in	B-X
JNK	B-X
activation	B-X
and	B-X
viral	B-X
B	B-X
-	B-X
cell	B-X
transformation	B-X
.	B-X
<EOS>	B-X
Development	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
-	B-X
associated	B-X
gastric	B-X
cancer	B-X
:	B-X
Infection	B-X
,	B-X
inflammation	B-X
,	B-X
and	B-X
oncogenesis	B-X
.	B-X
<EOS>	B-X
01	B-X
)	B-X
;	B-X
and	B-X
Epstein	B-X
Barr	B-X
virus	B-X
infection	B-X
(	B-X
p	B-X
<	B-X
0	B-X

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
new	O
data	O
from	O
basic	O
,	O
translational	O
and	O
clinical	O
research	O
relating	O
to	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

Beside	O
its	O
well-known	O
tropism	O
for	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
,	O
EBV	O
also	O
infects	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
monocytes	B-cell_type
and	O
granulocytes	B-cell_type
.	O
<EOS>	B-X
Beside	B-X
its	B-X
well	B-X
-	B-X
known	B-X
tropism	B-X
for	B-X
B	B-X
lymphocytes	B-X
and	B-X
epithelial	B-X
cells	B-X
,	B-X
EBV	B-X
also	B-X
infects	B-X
T	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
and	B-X
granulocytes	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
LMP1	B-X
to	B-X
suppress	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
its	B-X
capacity	B-X
to	B-X
mediate	B-X
its	B-X
own	B-X
transcriptional	B-X
activation	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
EBV	B-X
-	B-X
associated	B-X
latency	B-X
type	B-X
II	B-X
lymphoproliferations	B-X
like	B-X
Hodgkin	B-X
's	B-X
disease	B-X
and	B-X
angioimmunoblastic	B-X
lymphadenopathy	B-X
<EOS>	B-X
Cytotoxic	B-X
T	B-X
lymphocytes	B-X
directed	B-X
against	B-X
well	B-X
-	B-X
characterized	B-X
epitopes	B-X
of	B-X
EBV	B-X
latency	B-X
genes	B-X
represent	B-X
an	B-X
already	B-X
successful	B-X
and	B-X
promising	B-X
therapeutic	B-X
approach	B-X
to	B-X
EBV	B-X
-	B-X
associated	B-X
lymphomas	B-X
,	B-X
in	B-X
particular	B-X
PTLDs	B-X
<EOS>	B-X
LMP1	B-X
acts	B-X
like	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
family	B-X
and	B-X
allows	B-X
the	B-X
amplification	B-X
or	B-X
bypassing	B-X
of	B-X
physiological	B-X
regulatory	B-X
signals	B-X
through	B-X
direct	B-X
and	B-X
indirect	B-X
interactions	B-X
with	B-X
proteins	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X

After	O
primary	O
infection	O
,	O
EBV	O
persists	O
throughout	O
the	O
life	O
span	O
in	O
resting	B-cell_type
memory	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
from	O
where	O
it	O
is	O
reactivated	O
upon	O
breakdown	O
of	O
cellular	O
immunity	O
.	O
<EOS>	B-X
After	B-X
primary	B-X
infection	B-X
,	B-X
EBV	B-X
persists	B-X
throughout	B-X
the	B-X
life	B-X
span	B-X
in	B-X
resting	B-X
memory	B-X
B	B-X
cells	B-X
,	B-X
from	B-X
where	B-X
it	B-X
is	B-X
reactivated	B-X
upon	B-X
breakdown	B-X
of	B-X
cellular	B-X
immunity	B-X
<EOS>	B-X
LMP1	B-X
acts	B-X
like	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
family	B-X
and	B-X
allows	B-X
the	B-X
amplification	B-X
or	B-X
bypassing	B-X
of	B-X
physiological	B-X
regulatory	B-X
signals	B-X
through	B-X
direct	B-X
and	B-X
indirect	B-X
interactions	B-X
with	B-X
proteins	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
<EOS>	B-X
Cytotoxic	B-X
T	B-X
lymphocytes	B-X
directed	B-X
against	B-X
well	B-X
-	B-X
characterized	B-X
epitopes	B-X
of	B-X
EBV	B-X
latency	B-X
genes	B-X
represent	B-X
an	B-X
already	B-X
successful	B-X
and	B-X
promising	B-X
therapeutic	B-X
approach	B-X
to	B-X
EBV	B-X
-	B-X
associated	B-X
lymphomas	B-X
,	B-X
in	B-X
particular	B-X
PTLDs	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
LMP1	B-X
to	B-X
suppress	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
its	B-X
capacity	B-X
to	B-X
mediate	B-X
its	B-X
own	B-X
transcriptional	B-X
activation	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
EBV	B-X
-	B-X
associated	B-X
latency	B-X
type	B-X
II	B-X
lymphoproliferations	B-X
like	B-X
Hodgkin	B-X
's	B-X
disease	B-X
and	B-X
angioimmunoblastic	B-X
lymphadenopathy	B-X

In	O
the	O
process	O
of	O
neoplastic	O
transformation	O
,	O
the	O
EBV-encoded	B-DNA
latent	I-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
LMP1	I-DNA
)	I-DNA
oncogene	I-DNA
represents	O
the	O
major	O
driving	O
force	O
.	O
<EOS>	B-X
In	B-X
the	B-X
process	B-X
of	B-X
neoplastic	B-X
transformation	B-X
,	B-X
the	B-X
EBV	B-X
-	B-X
encoded	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
oncogene	B-X
represents	B-X
the	B-X
major	B-X
driving	B-X
force	B-X
<EOS>	B-X
The	B-X
carboxy	B-X
terminus	B-X
of	B-X
LMP1	B-X
is	B-X
also	B-X
a	B-X
reliable	B-X
marker	B-X
for	B-X
individual	B-X
EBV	B-X
strain	B-X
identification	B-X
and	B-X
thus	B-X
offers	B-X
new	B-X
possibilities	B-X
in	B-X
tracing	B-X
the	B-X
molecular	B-X
events	B-X
leading	B-X
to	B-X
posttransplant	B-X
lymphoproliferative	B-X
disorders	B-X
(	B-X
PTLDs	B-X
)	B-X
<EOS>	B-X
Cytotoxic	B-X
T	B-X
lymphocytes	B-X
directed	B-X
against	B-X
well	B-X
-	B-X
characterized	B-X
epitopes	B-X
of	B-X
EBV	B-X
latency	B-X
genes	B-X
represent	B-X
an	B-X
already	B-X
successful	B-X
and	B-X
promising	B-X
therapeutic	B-X
approach	B-X
to	B-X
EBV	B-X
-	B-X
associated	B-X
lymphomas	B-X
,	B-X
in	B-X
particular	B-X
PTLDs	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
LMP1	B-X
to	B-X
suppress	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
its	B-X
capacity	B-X
to	B-X
mediate	B-X
its	B-X
own	B-X
transcriptional	B-X
activation	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
EBV	B-X
-	B-X
associated	B-X
latency	B-X
type	B-X
II	B-X
lymphoproliferations	B-X
like	B-X
Hodgkin	B-X
's	B-X
disease	B-X
and	B-X
angioimmunoblastic	B-X
lymphadenopathy	B-X

LMP1	B-protein
acts	O
like	O
a	O
constitutively	B-protein
activated	I-protein
receptor	I-protein
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
family	I-protein
and	O
allows	O
the	O
amplification	O
or	O
bypassing	O
of	O
physiological	O
regulatory	O
signals	O
through	O
direct	O
and	O
indirect	O
interactions	O
with	O
proteins	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
(	I-protein
TRAF	I-protein
)	I-protein
family	I-protein
.	O
<EOS>	B-X
LMP1	B-X
acts	B-X
like	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
family	B-X
and	B-X
allows	B-X
the	B-X
amplification	B-X
or	B-X
bypassing	B-X
of	B-X
physiological	B-X
regulatory	B-X
signals	B-X
through	B-X
direct	B-X
and	B-X
indirect	B-X
interactions	B-X
with	B-X
proteins	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
<EOS>	B-X
The	B-X
carboxy	B-X
terminus	B-X
of	B-X
LMP1	B-X
is	B-X
also	B-X
a	B-X
reliable	B-X
marker	B-X
for	B-X
individual	B-X
EBV	B-X
strain	B-X
identification	B-X
and	B-X
thus	B-X
offers	B-X
new	B-X
possibilities	B-X
in	B-X
tracing	B-X
the	B-X
molecular	B-X
events	B-X
leading	B-X
to	B-X
posttransplant	B-X
lymphoproliferative	B-X
disorders	B-X
(	B-X
PTLDs	B-X
)	B-X
<EOS>	B-X
Cytotoxic	B-X
T	B-X
lymphocytes	B-X
directed	B-X
against	B-X
well	B-X
-	B-X
characterized	B-X
epitopes	B-X
of	B-X
EBV	B-X
latency	B-X
genes	B-X
represent	B-X
an	B-X
already	B-X
successful	B-X
and	B-X
promising	B-X
therapeutic	B-X
approach	B-X
to	B-X
EBV	B-X
-	B-X
associated	B-X
lymphomas	B-X
,	B-X
in	B-X
particular	B-X
PTLDs	B-X
<EOS>	B-X
After	B-X
primary	B-X
infection	B-X
,	B-X
EBV	B-X
persists	B-X
throughout	B-X
the	B-X
life	B-X
span	B-X
in	B-X
resting	B-X
memory	B-X
B	B-X
cells	B-X
,	B-X
from	B-X
where	B-X
it	B-X
is	B-X
reactivated	B-X
upon	B-X
breakdown	B-X
of	B-X
cellular	B-X
immunity	B-X

TRAF2	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
,	O
AP-1	B-protein
induction	O
and	O
JAK3	B-protein
/	O
STAT	B-protein
activation	O
may	O
result	O
in	O
sustained	O
proliferation	O
leading	O
to	O
lymphoma	B-cell_line
.	O
<EOS>	B-X
TRAF2	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
induction	B-X
and	B-X
JAK3	B-X
/	B-X
STAT	B-X
activation	B-X
may	B-X
result	B-X
in	B-X
sustained	B-X
proliferation	B-X
leading	B-X
to	B-X
lymphoma	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
LMP1	B-X
to	B-X
suppress	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
its	B-X
capacity	B-X
to	B-X
mediate	B-X
its	B-X
own	B-X
transcriptional	B-X
activation	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
EBV	B-X
-	B-X
associated	B-X
latency	B-X
type	B-X
II	B-X
lymphoproliferations	B-X
like	B-X
Hodgkin	B-X
's	B-X
disease	B-X
and	B-X
angioimmunoblastic	B-X
lymphadenopathy	B-X
<EOS>	B-X
The	B-X
carboxy	B-X
terminus	B-X
of	B-X
LMP1	B-X
is	B-X
also	B-X
a	B-X
reliable	B-X
marker	B-X
for	B-X
individual	B-X
EBV	B-X
strain	B-X
identification	B-X
and	B-X
thus	B-X
offers	B-X
new	B-X
possibilities	B-X
in	B-X
tracing	B-X
the	B-X
molecular	B-X
events	B-X
leading	B-X
to	B-X
posttransplant	B-X
lymphoproliferative	B-X
disorders	B-X
(	B-X
PTLDs	B-X
)	B-X
<EOS>	B-X
Cytotoxic	B-X
T	B-X
lymphocytes	B-X
directed	B-X
against	B-X
well	B-X
-	B-X
characterized	B-X
epitopes	B-X
of	B-X
EBV	B-X
latency	B-X
genes	B-X
represent	B-X
an	B-X
already	B-X
successful	B-X
and	B-X
promising	B-X
therapeutic	B-X
approach	B-X
to	B-X
EBV	B-X
-	B-X
associated	B-X
lymphomas	B-X
,	B-X
in	B-X
particular	B-X
PTLDs	B-X

The	O
ability	O
of	O
LMP1	B-protein
to	O
suppress	O
germinal	O
center	O
formation	O
and	O
its	O
capacity	O
to	O
mediate	O
its	O
own	O
transcriptional	O
activation	O
shed	O
new	O
light	O
on	O
the	O
pathogenesis	O
of	O
EBV-associated	O
latency	O
type	O
II	O
lymphoproliferations	O
like	O
Hodgkin	O
's	O
disease	O
and	O
angioimmunoblastic	O
lymphadenopathy	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
LMP1	B-X
to	B-X
suppress	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
its	B-X
capacity	B-X
to	B-X
mediate	B-X
its	B-X
own	B-X
transcriptional	B-X
activation	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
EBV	B-X
-	B-X
associated	B-X
latency	B-X
type	B-X
II	B-X
lymphoproliferations	B-X
like	B-X
Hodgkin	B-X
's	B-X
disease	B-X
and	B-X
angioimmunoblastic	B-X
lymphadenopathy	B-X
<EOS>	B-X
TRAF2	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
induction	B-X
and	B-X
JAK3	B-X
/	B-X
STAT	B-X
activation	B-X
may	B-X
result	B-X
in	B-X
sustained	B-X
proliferation	B-X
leading	B-X
to	B-X
lymphoma	B-X
<EOS>	B-X
The	B-X
carboxy	B-X
terminus	B-X
of	B-X
LMP1	B-X
is	B-X
also	B-X
a	B-X
reliable	B-X
marker	B-X
for	B-X
individual	B-X
EBV	B-X
strain	B-X
identification	B-X
and	B-X
thus	B-X
offers	B-X
new	B-X
possibilities	B-X
in	B-X
tracing	B-X
the	B-X
molecular	B-X
events	B-X
leading	B-X
to	B-X
posttransplant	B-X
lymphoproliferative	B-X
disorders	B-X
(	B-X
PTLDs	B-X
)	B-X
<EOS>	B-X
Beside	B-X
its	B-X
well	B-X
-	B-X
known	B-X
tropism	B-X
for	B-X
B	B-X
lymphocytes	B-X
and	B-X
epithelial	B-X
cells	B-X
,	B-X
EBV	B-X
also	B-X
infects	B-X
T	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
and	B-X
granulocytes	B-X

The	O
carboxy	B-protein
terminus	I-protein
of	O
LMP1	B-protein
is	O
also	O
a	O
reliable	O
marker	O
for	O
individual	O
EBV	O
strain	O
identification	O
and	O
thus	O
offers	O
new	O
possibilities	O
in	O
tracing	O
the	O
molecular	O
events	O
leading	O
to	O
posttransplant	O
lymphoproliferative	O
disorders	O
(	O
PTLDs	O
)	O
.	O
<EOS>	B-X
The	B-X
carboxy	B-X
terminus	B-X
of	B-X
LMP1	B-X
is	B-X
also	B-X
a	B-X
reliable	B-X
marker	B-X
for	B-X
individual	B-X
EBV	B-X
strain	B-X
identification	B-X
and	B-X
thus	B-X
offers	B-X
new	B-X
possibilities	B-X
in	B-X
tracing	B-X
the	B-X
molecular	B-X
events	B-X
leading	B-X
to	B-X
posttransplant	B-X
lymphoproliferative	B-X
disorders	B-X
(	B-X
PTLDs	B-X
)	B-X
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
new	B-X
data	B-X
from	B-X
basic	B-X
,	B-X
translational	B-X
and	B-X
clinical	B-X
research	B-X
relating	B-X
to	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
LMP1	B-X
to	B-X
suppress	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
its	B-X
capacity	B-X
to	B-X
mediate	B-X
its	B-X
own	B-X
transcriptional	B-X
activation	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
the	B-X
pathogenesis	B-X
of	B-X
EBV	B-X
-	B-X
associated	B-X
latency	B-X
type	B-X
II	B-X
lymphoproliferations	B-X
like	B-X
Hodgkin	B-X
's	B-X
disease	B-X
and	B-X
angioimmunoblastic	B-X
lymphadenopathy	B-X
<EOS>	B-X
LMP1	B-X
acts	B-X
like	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
family	B-X
and	B-X
allows	B-X
the	B-X
amplification	B-X
or	B-X
bypassing	B-X
of	B-X
physiological	B-X
regulatory	B-X
signals	B-X
through	B-X
direct	B-X
and	B-X
indirect	B-X
interactions	B-X
with	B-X
proteins	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X

Cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
directed	O
against	O
well-characterized	O
epitopes	O
of	O
EBV	B-DNA
latency	I-DNA
genes	I-DNA
represent	O
an	O
already	O
successful	O
and	O
promising	O
therapeutic	O
approach	O
to	O
EBV-associated	B-cell_line
lymphomas	I-cell_line
,	O
in	O
particular	O
PTLDs	O
<EOS>	B-X
Cytotoxic	B-X
T	B-X
lymphocytes	B-X
directed	B-X
against	B-X
well	B-X
-	B-X
characterized	B-X
epitopes	B-X
of	B-X
EBV	B-X
latency	B-X
genes	B-X
represent	B-X
an	B-X
already	B-X
successful	B-X
and	B-X
promising	B-X
therapeutic	B-X
approach	B-X
to	B-X
EBV	B-X
-	B-X
associated	B-X
lymphomas	B-X
,	B-X
in	B-X
particular	B-X
PTLDs	B-X
<EOS>	B-X
LMP1	B-X
acts	B-X
like	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
family	B-X
and	B-X
allows	B-X
the	B-X
amplification	B-X
or	B-X
bypassing	B-X
of	B-X
physiological	B-X
regulatory	B-X
signals	B-X
through	B-X
direct	B-X
and	B-X
indirect	B-X
interactions	B-X
with	B-X
proteins	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
<EOS>	B-X
Beside	B-X
its	B-X
well	B-X
-	B-X
known	B-X
tropism	B-X
for	B-X
B	B-X
lymphocytes	B-X
and	B-X
epithelial	B-X
cells	B-X
,	B-X
EBV	B-X
also	B-X
infects	B-X
T	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
and	B-X
granulocytes	B-X
<EOS>	B-X
After	B-X
primary	B-X
infection	B-X
,	B-X
EBV	B-X
persists	B-X
throughout	B-X
the	B-X
life	B-X
span	B-X
in	B-X
resting	B-X
memory	B-X
B	B-X
cells	B-X
,	B-X
from	B-X
where	B-X
it	B-X
is	B-X
reactivated	B-X
upon	B-X
breakdown	B-X
of	B-X
cellular	B-X
immunity	B-X

Interferon-alpha	B-protein
drives	O
T	O
cell-mediated	O
immunopathology	O
in	O
the	O
intestine	O
.	O
<EOS>	B-X
Interferon	B-X
-	B-X
alpha	B-X
drives	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
immunopathology	B-X
in	B-X
the	B-X
intestine	B-X
.	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
alpha	B-X
to	B-X
induce	B-X
autoimmunity	B-X
and	B-X
exacerbate	B-X
Th1	B-X
diseases	B-X
is	B-X
well	B-X
known	B-X
<EOS>	B-X
Together	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
IFN	B-X
-	B-X
alpha	B-X
can	B-X
facilitate	B-X
activation	B-X
of	B-X
Th1	B-X
-	B-X
reactive	B-X
cells	B-X
in	B-X
the	B-X
gut	B-X
and	B-X
drive	B-X
immunopathology	B-X
<EOS>	B-X
However	B-X
,	B-X
addition	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
results	B-X
in	B-X
enhanced	B-X
Th1	B-X
response	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X

The	O
ability	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-alpha	I-protein
to	O
induce	O
autoimmunity	O
and	O
exacerbate	O
Th1	O
diseases	O
is	O
well	O
known	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
alpha	B-X
to	B-X
induce	B-X
autoimmunity	B-X
and	B-X
exacerbate	B-X
Th1	B-X
diseases	B-X
is	B-X
well	B-X
known	B-X
<EOS>	B-X
Interferon	B-X
-	B-X
alpha	B-X
drives	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
immunopathology	B-X
in	B-X
the	B-X
intestine	B-X
.	B-X
<EOS>	B-X
Together	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
IFN	B-X
-	B-X
alpha	B-X
can	B-X
facilitate	B-X
activation	B-X
of	B-X
Th1	B-X
-	B-X
reactive	B-X
cells	B-X
in	B-X
the	B-X
gut	B-X
and	B-X
drive	B-X
immunopathology	B-X
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
described	B-X
enhanced	B-X
expression	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
in	B-X
the	B-X
mucosa	B-X
of	B-X
patients	B-X
with	B-X
celiac	B-X
disease	B-X
(	B-X
CD	B-X
)	B-X
,	B-X
a	B-X
gluten	B-X
-	B-X
sensitive	B-X
Th1	B-X
-	B-X
mediated	B-X
enteropathy	B-X
,	B-X
characterized	B-X
by	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X

We	O
have	O
recently	O
described	O
enhanced	O
expression	O
of	O
IFN-alpha	B-protein
in	O
the	O
mucosa	O
of	O
patients	O
with	O
celiac	O
disease	O
(	O
CD	O
)	O
,	O
a	O
gluten-sensitive	O
Th1-mediated	O
enteropathy	O
,	O
characterized	O
by	O
villous	O
atrophy	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
described	B-X
enhanced	B-X
expression	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
in	B-X
the	B-X
mucosa	B-X
of	B-X
patients	B-X
with	B-X
celiac	B-X
disease	B-X
(	B-X
CD	B-X
)	B-X
,	B-X
a	B-X
gluten	B-X
-	B-X
sensitive	B-X
Th1	B-X
-	B-X
mediated	B-X
enteropathy	B-X
,	B-X
characterized	B-X
by	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
from	B-X
this	B-X
laboratory	B-X
have	B-X
shown	B-X
that	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
can	B-X
also	B-X
result	B-X
in	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
However	B-X
,	B-X
addition	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
results	B-X
in	B-X
enhanced	B-X
Th1	B-X
response	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
We	B-X
have	B-X
,	B-X
therefore	B-X
,	B-X
examined	B-X
changes	B-X
that	B-X
take	B-X
place	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
and	B-X
/	B-X
or	B-X
IFN	B-X
-	B-X
alpha	B-X

Previous	O
studies	O
from	O
this	O
laboratory	O
have	O
shown	O
that	O
T	B-cell_type
cell	I-cell_type
activation	O
in	O
explant	O
cultures	O
of	O
human	O
fetal	O
gut	O
can	O
also	O
result	O
in	O
villous	O
atrophy	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O

We	O
have	O
,	O
therefore	O
,	O
examined	O
changes	O
that	O
take	O
place	O
in	O
explant	O
cultures	O
of	O
human	O
fetal	O
gut	O
after	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
anti-CD3	B-protein
and/or	O
IFN-alpha	B-protein
.	O
<EOS>	B-X
Thereafter	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
genetic	B-X
background	B-X
on	B-X
IFN	B-X
α	B-X
/	B-X
β	B-X
receptor	B-X
expression	B-X
in	B-X
lung	B-X
organ	B-X
cultures	B-X
and	B-X
whether	B-X
,	B-X
it	B-X
has	B-X
any	B-X
effect	B-X
on	B-X
transcription	B-X
factors	B-X
STAT1	B-X
and	B-X
STAT2	B-X
involved	B-X
in	B-X
IFN	B-X
signaling	B-X
<EOS>	B-X
We	B-X
retrieved	B-X
studies	B-X
that	B-X
were	B-X
published	B-X
from	B-X
the	B-X
start	B-X
of	B-X
each	B-X
database	B-X
until	B-X
August	B-X
2021	B-X
<EOS>	B-X
We	B-X
aim	B-X
to	B-X
examine	B-X
the	B-X
immune	B-X
biomarker	B-X
and	B-X
coagulation	B-X
profiles	B-X
in	B-X
association	B-X
with	B-X
the	B-X
clinical	B-X
presentation	B-X
and	B-X
course	B-X
of	B-X
MIS	B-X
-	B-X
A	B-X
<EOS>	B-X
Mechanistic	B-X
analyses	B-X
of	B-X
the	B-X
cytokine	B-X
modulation	B-X
by	B-X
ANP	B-X
revealed	B-X
that	B-X
ANP	B-X
blocked	B-X
the	B-X
mammalian	B-X
target	B-X
of	B-X
the	B-X
rapamycin	B-X
(	B-X
mTOR	B-X
)	B-X
pathway	B-X
by	B-X
inhibiting	B-X
Akt	B-X
translocation	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
thereby	B-X
inhibiting	B-X
Akt	B-X
phosphorylation	B-X

We	O
show	O
that	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
anti-CD3	B-protein
alone	O
elicits	O
a	O
small	O
IFN-gamma	B-protein
and	O
TNF-alpha	B-protein
response	O
with	O
no	O
tissue	O
injury	O
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
alone	B-X
elicits	B-X
a	B-X
small	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
response	B-X
with	B-X
no	B-X
tissue	B-X
injury	B-X
<EOS>	B-X
However	B-X
,	B-X
addition	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
results	B-X
in	B-X
enhanced	B-X
Th1	B-X
response	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
from	B-X
this	B-X
laboratory	B-X
have	B-X
shown	B-X
that	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
can	B-X
also	B-X
result	B-X
in	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
We	B-X
have	B-X
,	B-X
therefore	B-X
,	B-X
examined	B-X
changes	B-X
that	B-X
take	B-X
place	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
and	B-X
/	B-X
or	B-X
IFN	B-X
-	B-X
alpha	B-X

Similarly	O
,	O
no	O
changes	O
are	O
seen	O
in	O
explants	O
cultured	O
with	O
IFN-alpha	B-protein
alone	O
.	O
<EOS>	B-X
Similarly	B-X
,	B-X
no	B-X
changes	B-X
are	B-X
seen	B-X
in	B-X
explants	B-X
cultured	B-X
with	B-X
IFN	B-X
-	B-X
alpha	B-X
alone	B-X
<EOS>	B-X
We	B-X
have	B-X
,	B-X
therefore	B-X
,	B-X
examined	B-X
changes	B-X
that	B-X
take	B-X
place	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
and	B-X
/	B-X
or	B-X
IFN	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
from	B-X
this	B-X
laboratory	B-X
have	B-X
shown	B-X
that	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
can	B-X
also	B-X
result	B-X
in	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
This	B-X
is	B-X
associated	B-X
with	B-X
enhanced	B-X
phosphorylation	B-X
of	B-X
STAT1	B-X
,	B-X
STAT3	B-X
,	B-X
and	B-X
Fyn	B-X
,	B-X
a	B-X
Src	B-X
homology	B-X
tyrosine	B-X
kinase	B-X
,	B-X
which	B-X
interacts	B-X
with	B-X
both	B-X
TCR	B-X
and	B-X
IFN	B-X
-	B-X
alpha	B-X
signal	B-X
components	B-X

However	O
,	O
addition	O
of	O
IFN-alpha	B-protein
with	O
anti-CD3	B-protein
results	O
in	O
enhanced	O
Th1	O
response	O
and	O
crypt	O
cell	O
hyperplasia	O
.	O
<EOS>	B-X
However	B-X
,	B-X
addition	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
results	B-X
in	B-X
enhanced	B-X
Th1	B-X
response	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
from	B-X
this	B-X
laboratory	B-X
have	B-X
shown	B-X
that	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
can	B-X
also	B-X
result	B-X
in	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
described	B-X
enhanced	B-X
expression	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
in	B-X
the	B-X
mucosa	B-X
of	B-X
patients	B-X
with	B-X
celiac	B-X
disease	B-X
(	B-X
CD	B-X
)	B-X
,	B-X
a	B-X
gluten	B-X
-	B-X
sensitive	B-X
Th1	B-X
-	B-X
mediated	B-X
enteropathy	B-X
,	B-X
characterized	B-X
by	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
alone	B-X
elicits	B-X
a	B-X
small	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
response	B-X
with	B-X
no	B-X
tissue	B-X
injury	B-X

This	O
is	O
associated	O
with	O
enhanced	O
phosphorylation	O
of	O
STAT1	B-protein
,	O
STAT3	B-protein
,	O
and	O
Fyn	B-protein
,	I-protein
a	I-protein
Src	I-protein
homology	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
which	O
interacts	O
with	O
both	O
TCR	O
and	O
IFN-alpha	O
signal	O
components	O
.	O
<EOS>	B-X
This	B-X
is	B-X
associated	B-X
with	B-X
enhanced	B-X
phosphorylation	B-X
of	B-X
STAT1	B-X
,	B-X
STAT3	B-X
,	B-X
and	B-X
Fyn	B-X
,	B-X
a	B-X
Src	B-X
homology	B-X
tyrosine	B-X
kinase	B-X
,	B-X
which	B-X
interacts	B-X
with	B-X
both	B-X
TCR	B-X
and	B-X
IFN	B-X
-	B-X
alpha	B-X
signal	B-X
components	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
no	B-X
changes	B-X
are	B-X
seen	B-X
in	B-X
explants	B-X
cultured	B-X
with	B-X
IFN	B-X
-	B-X
alpha	B-X
alone	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
alone	B-X
elicits	B-X
a	B-X
small	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
response	B-X
with	B-X
no	B-X
tissue	B-X
injury	B-X
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
described	B-X
enhanced	B-X
expression	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
in	B-X
the	B-X
mucosa	B-X
of	B-X
patients	B-X
with	B-X
celiac	B-X
disease	B-X
(	B-X
CD	B-X
)	B-X
,	B-X
a	B-X
gluten	B-X
-	B-X
sensitive	B-X
Th1	B-X
-	B-X
mediated	B-X
enteropathy	B-X
,	B-X
characterized	B-X
by	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X

Together	O
these	O
data	O
indicate	O
that	O
IFN-alpha	B-protein
can	O
facilitate	O
activation	O
of	O
Th1-reactive	B-cell_type
cells	I-cell_type
in	O
the	O
gut	O
and	O
drive	O
immunopathology	O
.	O
<EOS>	B-X
Together	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
IFN	B-X
-	B-X
alpha	B-X
can	B-X
facilitate	B-X
activation	B-X
of	B-X
Th1	B-X
-	B-X
reactive	B-X
cells	B-X
in	B-X
the	B-X
gut	B-X
and	B-X
drive	B-X
immunopathology	B-X
<EOS>	B-X
However	B-X
,	B-X
addition	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
results	B-X
in	B-X
enhanced	B-X
Th1	B-X
response	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X
<EOS>	B-X
We	B-X
have	B-X
,	B-X
therefore	B-X
,	B-X
examined	B-X
changes	B-X
that	B-X
take	B-X
place	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
and	B-X
/	B-X
or	B-X
IFN	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
from	B-X
this	B-X
laboratory	B-X
have	B-X
shown	B-X
that	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
explant	B-X
cultures	B-X
of	B-X
human	B-X
fetal	B-X
gut	B-X
can	B-X
also	B-X
result	B-X
in	B-X
villous	B-X
atrophy	B-X
and	B-X
crypt	B-X
cell	B-X
hyperplasia	B-X

Suppression	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
production	O
by	O
cAMP	O
in	O
human	B-cell_type
monocytes	I-cell_type
:	O
dissociation	O
with	O
mRNA	O
level	O
and	O
independent	O
of	O
interleukin-10	B-protein
.	O
<EOS>	B-X
Suppression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
production	B-X
by	B-X
cAMP	B-X
in	B-X
human	B-X
monocytes	B-X
:	B-X
dissociation	B-X
with	B-X
mRNA	B-X
level	B-X
and	B-X
independent	B-X
of	B-X
interleukin	B-X
-	B-X
10	B-X
.	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
cAMP	B-X
inhibits	B-X
LPS	B-X
-	B-X
stimulated	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
through	B-X
a	B-X
posttranscriptional	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
endogenous	B-X
IL	B-X
-	B-X
10	B-X
<EOS>	B-X
Elevation	B-X
of	B-X
cellular	B-X
cAMP	B-X
inhibits	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
	B-X
-	B-X
stimulated	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
production	B-X
and	B-X
increases	B-X
the	B-X
expression	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
10	B-X
in	B-X
mononuclear	B-X
cells	B-X
<EOS>	B-X
Exogenous	B-X
IL	B-X
-	B-X
10	B-X
inhibits	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
monocytes	B-X
and	B-X
thus	B-X
attenuates	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X

BACKGROUND	O
:	O
Elevation	O
of	O
cellular	O
cAMP	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
production	O
and	O
increases	O
the	O
expression	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
in	O
mononuclear	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Elevation	B-X
of	B-X
cellular	B-X
cAMP	B-X
inhibits	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
	B-X
-	B-X
stimulated	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
production	B-X
and	B-X
increases	B-X
the	B-X
expression	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
10	B-X
in	B-X
mononuclear	B-X
cells	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
cAMP	B-X
inhibits	B-X
LPS	B-X
-	B-X
stimulated	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
through	B-X
a	B-X
posttranscriptional	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
endogenous	B-X
IL	B-X
-	B-X
10	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
production	B-X
by	B-X
cAMP	B-X
in	B-X
human	B-X
monocytes	B-X
:	B-X
dissociation	B-X
with	B-X
mRNA	B-X
level	B-X
and	B-X
independent	B-X
of	B-X
interleukin	B-X
-	B-X
10	B-X
.	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
by	B-X
cAMP	B-X

TNF-alpha	B-DNA
gene	I-DNA
expression	O
obligates	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
gene	B-X
expression	B-X
obligates	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
<EOS>	B-X
Proinflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
TNFα	B-X
activate	B-X
the	B-X
canonical	B-X
nuclear	B-X
factor	B-X
-	B-X
κB	B-X
(	B-X
NF	B-X
-	B-X
κB	B-X
)	B-X
pathway	B-X
<EOS>	B-X
1	B-X
-	B-X
fold	B-X
within	B-X
1	B-X
day	B-X
)	B-X
rise	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
obligate	B-X
osteoclastogenic	B-X
cytokine	B-X
,	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa	B-X
-	B-X
B	B-X
ligand	B-X
(	B-X
Rankl	B-X
)	B-X
,	B-X
within	B-X
marrow	B-X
cells	B-X
over	B-X
controls	B-X
<EOS>	B-X
Neither	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
expression	B-X
nor	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
stimulated	B-X
by	B-X
LPS	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
cAMP	B-X
-	B-X
elevating	B-X
agents	B-X

Exogenous	O
IL-10	B-protein
inhibits	O
NF-kappaB	B-protein
in	O
monocytes	B-cell_type
and	O
thus	O
attenuates	O
TNF-alpha	B-protein
production	O
.	O
<EOS>	B-X
Exogenous	B-X
IL	B-X
-	B-X
10	B-X
inhibits	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
monocytes	B-X
and	B-X
thus	B-X
attenuates	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
<EOS>	B-X
Neutralization	B-X
of	B-X
IL	B-X
-	B-X
10	B-X
with	B-X
a	B-X
specific	B-X
antibody	B-X
did	B-X
not	B-X
attenuate	B-X
the	B-X
effect	B-X
of	B-X
cAMP	B-X
-	B-X
elevating	B-X
agents	B-X
on	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
by	B-X
cAMP	B-X
<EOS>	B-X
cAMP	B-X
-	B-X
elevating	B-X
agents	B-X
inhibited	B-X
LPS	B-X
-	B-X
stimulated	B-X
TNF	B-X
-	B-X
alpha	B-X
release	B-X
(	B-X
0	B-X

We	O
examined	O
the	O
role	O
of	O
endogenous	O
IL-10	B-protein
in	O
the	O
regulation	O
of	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
cAMP	O
.	O
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
by	B-X
cAMP	B-X
<EOS>	B-X
Exogenous	B-X
IL	B-X
-	B-X
10	B-X
inhibits	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
monocytes	B-X
and	B-X
thus	B-X
attenuates	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
<EOS>	B-X
Neither	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
expression	B-X
nor	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
stimulated	B-X
by	B-X
LPS	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
cAMP	B-X
-	B-X
elevating	B-X
agents	B-X
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
gene	B-X
expression	B-X
obligates	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X

METHODS	O
:	O
Human	B-cell_type
monocytes	I-cell_type
were	O
stimulated	O
with	O
Escherichia	O
coli	O
LPS	O
(	O
100	O
ng/ml	O
)	O
with	O
and	O
without	O
forskolin	O
(	O
FSK	O
,	O
50	O
microM	O
)	O
or	O
dibutyryl	O
cyclic	O
AMP	O
(	O
dbcAMP	O
,	O
100	O
microM	O
)	O
.	O
<EOS>	B-X
Confocal	B-X
microscopy	B-X
experiments	B-X
with	B-X
Fluo	B-X
-	B-X
3	B-X
loaded	B-X
cells	B-X
reveal	B-X
that	B-X
both	B-X
LH	B-X
and	B-X
dibutyryl	B-X
-	B-X
cAMP	B-X
(	B-X
db	B-X
-	B-X
cAMP	B-X
)	B-X
increase	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
<EOS>	B-X
Further	B-X
,	B-X
LPS	B-X
(	B-X
1	B-X
microgml	B-X
(	B-X
	B-X
-	B-X
1	B-X
)	B-X
)	B-X
	B-X
-	B-X
induced	B-X
decrease	B-X
in	B-X
Bcl	B-X
-	B-X
2	B-X
and	B-X
increase	B-X
in	B-X
Bax	B-X
protein	B-X
expression	B-X
were	B-X
fully	B-X
reversed	B-X
by	B-X
cilostazol	B-X
(	B-X
10	B-X
microM	B-X
)	B-X
and	B-X
dibutyryl	B-X
cAMP	B-X
(	B-X
100	B-X
microM	B-X
)	B-X
,	B-X
all	B-X
of	B-X
which	B-X
were	B-X
antagonized	B-X
by	B-X
Rp	B-X
-	B-X
cAMPs	B-X
(	B-X
200	B-X
microM	B-X
)	B-X
<EOS>	B-X
Oocytes	B-X
were	B-X
not	B-X
penetrated	B-X
by	B-X
frozen	B-X
-	B-X
thawed	B-X
sperm	B-X
when	B-X
cocultured	B-X
with	B-X
cumulus	B-X
-	B-X
oocyte	B-X
complexes	B-X
in	B-X
a	B-X
medium	B-X
without	B-X
ATP	B-X
and	B-X
dbcAMP	B-X
<EOS>	B-X
In	B-X
fat	B-X
cells	B-X
incubated	B-X
for	B-X
90	B-X
min	B-X
with	B-X
125	B-X
and	B-X
250	B-X
microM	B-X
resveratrol	B-X
(	B-X
but	B-X
not	B-X
with	B-X
62	B-X

Cytokine	B-protein
(	O
TNF-alpha	B-protein
and	O
IL-10	B-protein
)	O
release	O
was	O
measured	O
by	O
immunoassay	O
.	O
<EOS>	B-X
Cytokine	B-X
release	B-X
was	B-X
measured	B-X
by	B-X
an	B-X
enzyme	B-X
immunoassay	B-X
<EOS>	B-X
Cytokines	B-X
were	B-X
measured	B-X
in	B-X
supernatant	B-X
using	B-X
an	B-X
equine	B-X
-	B-X
specific	B-X
multiplex	B-X
bead	B-X
immunoassay	B-X
<EOS>	B-X
Cytokines	B-X
(	B-X
interleukin	B-X
[	B-X
IL	B-X
]	B-X
	B-X
-	B-X
6	B-X
,	B-X
IL	B-X
-	B-X
10	B-X
,	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
α	B-X
[	B-X
TNF	B-X
-	B-X
α	B-X
]	B-X
)	B-X
were	B-X
measured	B-X
by	B-X
enzyme	B-X
-	B-X
linked	B-X
immuno	B-X
sorbent	B-X
assay	B-X
<EOS>	B-X
The	B-X
release	B-X
of	B-X
NO	B-X
was	B-X
measured	B-X
by	B-X
Griess	B-X
method	B-X

TNF-alpha	B-RNA
mRNA	I-RNA
was	O
measured	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
and	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
was	O
assessed	O
by	O
gel	O
mobility	O
shift	O
assay	O
.	O
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
was	B-X
measured	B-X
by	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
was	B-X
assessed	B-X
by	B-X
gel	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
NHE2	B-X
regulation	B-X
was	B-X
examined	B-X
in	B-X
TNF	B-X
-	B-X
α	B-X
-	B-X
treated	B-X
C2BBe1	B-X
cells	B-X
by	B-X
reverse	B-X
-	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT	B-X
-	B-X
PCR	B-X
)	B-X
,	B-X
reporter	B-X
gene	B-X
assays	B-X
,	B-X
and	B-X
Western	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
TNF	B-X
-	B-X
α	B-X
activated	B-X
NF	B-X
-	B-X
κB	B-X
subunits	B-X
,	B-X
p50	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
their	B-X
DNA	B-X
-	B-X
binding	B-X
to	B-X
a	B-X
putative	B-X
NF	B-X
-	B-X
κB	B-X
motif	B-X
within	B-X
TNF	B-X
-	B-X
RE	B-X
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
gene	B-X
expression	B-X
obligates	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X

RESULTS	O
:	O
cAMP-elevating	O
agents	O
inhibited	O
LPS-stimulated	O
TNF-alpha	B-protein
release	O
(	O
0.77	O
+/-	O
0.13	O
ng/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
+	O
dbcAMP	O
and	O
0.68	O
+/-	O
0.19	O
ng/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
+	O
FSK	O
,	O
both	O
P	O
<	O
0.05	O
vs	O
1.61	O
+/-	O
0.34	O
ng/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
alone	O
)	O
.	O

Conversely	O
,	O
cAMP	O
enhanced	O
LPS-stimulated	O
IL-10	B-protein
release	O
(	O
100	O
+/-	O
21.5	O
pg/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
+	O
dbcAMP	O
and	O
110	O
+/-	O
25.2	O
pg/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
+	O
FSK	O
,	O
both	O
P	O
<	O
0.05	O
vs	O
53.3	O
+/-	O
12.8	O
pg/10	O
(	O
6	O
)	O
cells	O
in	O
LPS	O
alone	O
)	O
.	O

Neither	O
TNF-alpha	B-RNA
mRNA	I-RNA
expression	O
nor	O
NF-kappaB	B-protein
activation	O
stimulated	O
by	O
LPS	O
was	O
inhibited	O
by	O
the	O
cAMP-elevating	O
agents	O
.	O
<EOS>	B-X
Neither	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
expression	B-X
nor	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
stimulated	B-X
by	B-X
LPS	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
cAMP	B-X
-	B-X
elevating	B-X
agents	B-X
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
gene	B-X
expression	B-X
obligates	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
by	B-X
cAMP	B-X
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
was	B-X
measured	B-X
by	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
was	B-X
assessed	B-X
by	B-X
gel	B-X
mobility	B-X
shift	B-X
assay	B-X

Neutralization	O
of	O
IL-10	B-protein
with	O
a	O
specific	O
antibody	B-protein
did	O
not	O
attenuate	O
the	O
effect	O
of	O
cAMP-elevating	O
agents	O
on	O
TNF-alpha	B-protein
production	O
.	O
<EOS>	B-X
Neutralising	B-X
the	B-X
effects	B-X
of	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
human	B-X
CRLM	B-X
has	B-X
therapeutic	B-X
potential	B-X
as	B-X
a	B-X
stand	B-X
-	B-X
alone	B-X
treatment	B-X
and	B-X
to	B-X
augment	B-X
the	B-X
function	B-X
of	B-X
adoptively	B-X
transferred	B-X
CAR	B-X
-	B-X
T	B-X
cells	B-X
<EOS>	B-X
Neutralizing	B-X
antibodies	B-X
were	B-X
induced	B-X
without	B-X
affecting	B-X
the	B-X
health	B-X
of	B-X
immunized	B-X
mice	B-X
<EOS>	B-X
The	B-X
CD4	B-X
T	B-X
-	B-X
cell	B-X
responses	B-X
did	B-X
not	B-X
differ	B-X
between	B-X
COPD	B-X
patients	B-X
and	B-X
healthy	B-X
control	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
both	B-X
experimental	B-X
groups	B-X
with	B-X
different	B-X
doses	B-X
of	B-X
inactive	B-X
virus	B-X
enhanced	B-X
the	B-X
secretion	B-X
of	B-X
specific	B-X
antibodies	B-X
in	B-X
the	B-X
serum	B-X
and	B-X
intestinal	B-X
mucus	B-X
,	B-X
which	B-X
caused	B-X
the	B-X
effective	B-X
neutralization	B-X
against	B-X
PEDV	B-X
in	B-X
the	B-X
Vero	B-X
cell	B-X
by	B-X
both	B-X
IgG	B-X
and	B-X
IgA	B-X
,	B-X
respectively	B-X

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
cAMP	O
inhibits	O
LPS-stimulated	O
TNF-alpha	B-protein
production	O
through	O
a	O
posttranscriptional	O
mechanism	O
that	O
is	O
independent	O
of	O
endogenous	O
IL-10	B-protein
.	O
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
cAMP	B-X
inhibits	B-X
LPS	B-X
-	B-X
stimulated	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
through	B-X
a	B-X
posttranscriptional	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
endogenous	B-X
IL	B-X
-	B-X
10	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
production	B-X
by	B-X
cAMP	B-X
in	B-X
human	B-X
monocytes	B-X
:	B-X
dissociation	B-X
with	B-X
mRNA	B-X
level	B-X
and	B-X
independent	B-X
of	B-X
interleukin	B-X
-	B-X
10	B-X
.	B-X
<EOS>	B-X
cAMP	B-X
-	B-X
elevating	B-X
agents	B-X
inhibited	B-X
LPS	B-X
-	B-X
stimulated	B-X
TNF	B-X
-	B-X
alpha	B-X
release	B-X
(	B-X
0	B-X
<EOS>	B-X
Elevation	B-X
of	B-X
cellular	B-X
cAMP	B-X
inhibits	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
	B-X
-	B-X
stimulated	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
production	B-X
and	B-X
increases	B-X
the	B-X
expression	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
10	B-X
in	B-X
mononuclear	B-X
cells	B-X

Copyright	O
2001	O
Academic	O
Press	O
.	O
<EOS>	B-X
Copyright	B-X
2001	B-X
Academic	B-X
Press	B-X
<EOS>	B-X
Fictitious	B-X
Academic	B-X
Expertise	B-X
and	B-X
Processing	B-X
Resources	B-X
.	B-X
<EOS>	B-X
1	B-X
,	B-X
indicating	B-X
an	B-X
increase	B-X
in	B-X
fractal	B-X
dimension	B-X
<EOS>	B-X
Implications	B-X
for	B-X
teaching	B-X
are	B-X
discussed	B-X

Activation	O
of	O
the	O
p21	B-DNA
(	I-DNA
CIP1/WAF1	I-DNA
)	I-DNA
promoter	I-DNA
by	O
bone	B-protein
morphogenetic	I-protein
protein-2	I-protein
in	O
mouse	O
B	B-cell_line
lineage	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
p21	B-X
(	B-X
CIP1	B-X
/	B-X
WAF1	B-X
)	B-X
promoter	B-X
by	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
-	B-X
2	B-X
in	B-X
mouse	B-X
B	B-X
lineage	B-X
cells	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
BMP	B-X
-	B-X
2	B-X
might	B-X
activate	B-X
p21	B-X
(	B-X
CIP1	B-X
/	B-X
WAF1	B-X
)	B-X
transcription	B-X
by	B-X
inducing	B-X
a	B-X
binding	B-X
of	B-X
Smad4	B-X
and	B-X
Smad1	B-X
to	B-X
the	B-X
29	B-X
-	B-X
b	B-X
region	B-X
in	B-X
HS	B-X
-	B-X
72	B-X
cells	B-X
<EOS>	B-X
BMPs	B-X
exert	B-X
a	B-X
negative	B-X
growth	B-X
effect	B-X
on	B-X
various	B-X
types	B-X
of	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
an	B-X
oligonucleotide	B-X
containing	B-X
the	B-X
29	B-X
-	B-X
b	B-X
region	B-X
was	B-X
found	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
Smad4	B-X
and	B-X
phosphorylated	B-X
Smad1	B-X
in	B-X
the	B-X
nuclear	B-X
extract	B-X
of	B-X
BMP	B-X
-	B-X
2	B-X
-	B-X
stimulated	B-X
HS	B-X
-	B-X
72	B-X
cells	B-X

BMPs	B-protein
exert	O
a	O
negative	O
growth	O
effect	O
on	O
various	O
types	O
of	O
cells	O
.	O
<EOS>	B-X
BMPs	B-X
exert	B-X
a	B-X
negative	B-X
growth	B-X
effect	B-X
on	B-X
various	B-X
types	B-X
of	B-X
cells	B-X
<EOS>	B-X
Here	B-X
we	B-X
tested	B-X
the	B-X
anti	B-X
-	B-X
glucocorticoid	B-X
potential	B-X
of	B-X
BMP	B-X
-	B-X
2	B-X
in	B-X
cultured	B-X
osteoblasts	B-X
<EOS>	B-X
The	B-X
rhBMP	B-X
-	B-X
2	B-X
-	B-X
rescued	B-X
mineral	B-X
was	B-X
bone	B-X
-	B-X
like	B-X
apatite	B-X
nearly	B-X
identical	B-X
to	B-X
the	B-X
mineral	B-X
of	B-X
control	B-X
cultures	B-X
<EOS>	B-X
BMP	B-X
-	B-X
2	B-X
exerts	B-X
both	B-X
positive	B-X
and	B-X
negative	B-X
effects	B-X
on	B-X
osteoblasts	B-X
,	B-X
possibly	B-X
depending	B-X
on	B-X
the	B-X
differentiation	B-X
stage	B-X
and	B-X
/	B-X
or	B-X
the	B-X
existing	B-X
BMP	B-X
signaling	B-X

We	O
have	O
previously	O
reported	O
that	O
BMP-2	B-protein
inhibited	O
the	O
growth	O
of	O
HS-72	B-cell_line
mouse	I-cell_line
hybridoma	I-cell_line
cells	I-cell_line
by	O
inducing	O
p21	O
(	O
CIP1/WAF1	O
)	O
expression	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
BMP	B-X
-	B-X
2	B-X
inhibited	B-X
the	B-X
growth	B-X
of	B-X
HS	B-X
-	B-X
72	B-X
mouse	B-X
hybridoma	B-X
cells	B-X
by	B-X
inducing	B-X
p21	B-X
(	B-X
CIP1	B-X
/	B-X
WAF1	B-X
)	B-X
expression	B-X
<EOS>	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
BMP	B-X
-	B-X
2	B-X
might	B-X
activate	B-X
p21	B-X
(	B-X
CIP1	B-X
/	B-X
WAF1	B-X
)	B-X
transcription	B-X
by	B-X
inducing	B-X
a	B-X
binding	B-X
of	B-X
Smad4	B-X
and	B-X
Smad1	B-X
to	B-X
the	B-X
29	B-X
-	B-X
b	B-X
region	B-X
in	B-X
HS	B-X
-	B-X
72	B-X
cells	B-X
<EOS>	B-X
BMPs	B-X
exert	B-X
a	B-X
negative	B-X
growth	B-X
effect	B-X
on	B-X
various	B-X
types	B-X
of	B-X
cells	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
BMP	B-X
-	B-X
2	B-X
activated	B-X
the	B-X
mouse	B-X
p21	B-X
(	B-X
CIP1	B-X
/	B-X
WAF1	B-X
)	B-X
promoter	B-X
in	B-X
HS	B-X
-	B-X
72	B-X
cells	B-X
,	B-X
and	B-X
that	B-X
a	B-X
29	B-X
-	B-X
base	B-X
pair	B-X
(	B-X
b	B-X
)	B-X
region	B-X
of	B-X
the	B-X
promoter	B-X
(	B-X
	B-X
-	B-X
1928	B-X
/	B-X
	B-X
-	B-X
1900	B-X
relative	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
)	B-X
,	B-X
conserved	B-X
between	B-X
mice	B-X
and	B-X
humans	B-X
,	B-X
was	B-X
responsive	B-X
to	B-X
BMP	B-X
-	B-X
2	B-X
as	B-X
well	B-X
as	B-X
expression	B-X
of	B-X
Smad1	B-X
,	B-X
Smad4	B-X
,	B-X
and	B-X
constitutively	B-X
active	B-X
mutants	B-X
of	B-X
BMP	B-X
type	B-X
I	B-X
receptors	B-X

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
BMP-2	B-protein
activated	O
the	O
mouse	O
p21	B-DNA
(	I-DNA
CIP1/WAF1	I-DNA
)	I-DNA
promoter	I-DNA
in	O
HS-72	B-cell_line
cells	I-cell_line
,	O
and	O
that	O
a	O
29-base	B-DNA
pair	I-DNA
(	I-DNA
b	I-DNA
)	I-DNA
region	I-DNA
of	O
the	O
promoter	O
(	O
-1928/-1900	O
relative	O
to	O
the	O
TATA	B-DNA
box	I-DNA
)	O
,	O
conserved	O
between	O
mice	O
and	O
humans	O
,	O
was	O
responsive	O
to	O
BMP-2	B-protein
as	O
well	O
as	O
expression	O
of	O
Smad1	B-protein
,	O
Smad4	B-protein
,	O
and	O
constitutively	O
active	O
mutants	O
of	O
BMP	B-protein
type	I-protein
I	I-protein
receptors	I-protein
.	O

Furthermore	O
,	O
an	O
oligonucleotide	O
containing	O
the	O
29-b	B-DNA
region	I-DNA
was	O
found	O
to	O
be	O
associated	O
with	O
Smad4	B-protein
and	O
phosphorylated	B-protein
Smad1	I-protein
in	O
the	O
nuclear	O
extract	O
of	O
BMP-2	B-protein
-stimulated	O
HS-72	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
an	B-X
oligonucleotide	B-X
containing	B-X
the	B-X
29	B-X
-	B-X
b	B-X
region	B-X
was	B-X
found	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
Smad4	B-X
and	B-X
phosphorylated	B-X
Smad1	B-X
in	B-X
the	B-X
nuclear	B-X
extract	B-X
of	B-X
BMP	B-X
-	B-X
2	B-X
-	B-X
stimulated	B-X
HS	B-X
-	B-X
72	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
BMP	B-X
-	B-X
2	B-X
might	B-X
activate	B-X
p21	B-X
(	B-X
CIP1	B-X
/	B-X
WAF1	B-X
)	B-X
transcription	B-X
by	B-X
inducing	B-X
a	B-X
binding	B-X
of	B-X
Smad4	B-X
and	B-X
Smad1	B-X
to	B-X
the	B-X
29	B-X
-	B-X
b	B-X
region	B-X
in	B-X
HS	B-X
-	B-X
72	B-X
cells	B-X
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
p21	B-X
(	B-X
CIP1	B-X
/	B-X
WAF1	B-X
)	B-X
promoter	B-X
by	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
-	B-X
2	B-X
in	B-X
mouse	B-X
B	B-X
lineage	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
BMP	B-X
-	B-X
2	B-X
activated	B-X
the	B-X
mouse	B-X
p21	B-X
(	B-X
CIP1	B-X
/	B-X
WAF1	B-X
)	B-X
promoter	B-X
in	B-X
HS	B-X
-	B-X
72	B-X
cells	B-X
,	B-X
and	B-X
that	B-X
a	B-X
29	B-X
-	B-X
base	B-X
pair	B-X
(	B-X
b	B-X
)	B-X
region	B-X
of	B-X
the	B-X
promoter	B-X
(	B-X
	B-X
-	B-X
1928	B-X
/	B-X
	B-X
-	B-X
1900	B-X
relative	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
)	B-X
,	B-X
conserved	B-X
between	B-X
mice	B-X
and	B-X
humans	B-X
,	B-X
was	B-X
responsive	B-X
to	B-X
BMP	B-X
-	B-X
2	B-X
as	B-X
well	B-X
as	B-X
expression	B-X
of	B-X
Smad1	B-X
,	B-X
Smad4	B-X
,	B-X
and	B-X
constitutively	B-X
active	B-X
mutants	B-X
of	B-X
BMP	B-X
type	B-X
I	B-X
receptors	B-X

These	O
results	O
suggested	O
that	O
BMP-2	B-protein
might	O
activate	O
p21	O
(	O
CIP1/WAF1	O
)	O
transcription	O
by	O
inducing	O
a	O
binding	O
of	O
Smad4	B-protein
and	O
Smad1	B-protein
to	O
the	O
29-b	B-DNA
region	I-DNA
in	O
HS-72	B-cell_line
cells	I-cell_line
.	O

Dendritic	B-cell_type
cell	I-cell_type
development	O
from	O
common	O
myeloid	B-cell_type
progenitors	I-cell_type
.	O
<EOS>	B-X
In	B-X
Vitro	B-X
Generation	B-X
of	B-X
Murine	B-X
Dendritic	B-X
Cells	B-X
from	B-X
Hoxb8	B-X
-	B-X
Immortalized	B-X
Hematopoietic	B-X
Progenitors	B-X
.	B-X
<EOS>	B-X
Ablation	B-X
of	B-X
cDC2	B-X
development	B-X
by	B-X
triple	B-X
mutations	B-X
within	B-X
the	B-X
Zeb2	B-X
enhancer	B-X
.	B-X
<EOS>	B-X
The	B-X
divergence	B-X
of	B-X
the	B-X
common	B-X
dendritic	B-X
cell	B-X
progenitor	B-X
<EOS>	B-X
Erythropoietin	B-X
directly	B-X
remodels	B-X
the	B-X
clonal	B-X
composition	B-X
of	B-X
murine	B-X
hematopoietic	B-X
multipotent	B-X
progenitor	B-X
cells	B-X
.	B-X

Dendritic	B-cell_type
cells	I-cell_type
(	O
DCs	B-cell_type
)	O
are	O
professional	O
antigen-presenting	B-cell_type
cells	I-cell_type
which	O
both	O
initiate	O
adaptive	O
immune	O
responses	O
and	O
control	O
tolerance	O
to	O
self-antigens	B-protein
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
are	B-X
professional	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
which	B-X
both	B-X
initiate	B-X
adaptive	B-X
immune	B-X
responses	B-X
and	B-X
control	B-X
tolerance	B-X
to	B-X
self	B-X
-	B-X
antigens	B-X
<EOS>	B-X
Dendritic	B-X
cell	B-X
development	B-X
from	B-X
common	B-X
myeloid	B-X
progenitors	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
model	B-X
,	B-X
CD8	B-X
alpha+	B-X
Mac	B-X
-	B-X
1	B-X
-	B-X
	B-X
DCs	B-X
are	B-X
supposed	B-X
to	B-X
be	B-X
of	B-X
lymphoid	B-X
while	B-X
CD8	B-X
alpha	B-X
-	B-X
	B-X
Mac	B-X
-	B-X
1+	B-X
DCs	B-X
are	B-X
supposed	B-X
to	B-X
be	B-X
of	B-X
myeloid	B-X
origin	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
these	B-X
different	B-X
effects	B-X
on	B-X
responder	B-X
cells	B-X
depend	B-X
on	B-X
subsets	B-X
of	B-X
DCs	B-X
arising	B-X
from	B-X
either	B-X
myeloid	B-X
or	B-X
lymphoid	B-X
hematopoietic	B-X
origins	B-X

It	O
has	O
been	O
suggested	O
that	O
these	O
different	O
effects	O
on	O
responder	O
cells	O
depend	O
on	O
subsets	O
of	O
DCs	B-cell_type
arising	O
from	O
either	O
myeloid	O
or	O
lymphoid	O
hematopoietic	O
origins	O
.	O
<EOS>	B-X
CD38	B-X
is	B-X
expressed	B-X
also	B-X
at	B-X
relatively	B-X
low	B-X
levels	B-X
on	B-X
normal	B-X
lymphoid	B-X
and	B-X
myeloid	B-X
cells	B-X
,	B-X
and	B-X
in	B-X
some	B-X
tissues	B-X
of	B-X
non	B-X
-	B-X
hematopoietic	B-X
origin	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
EP	B-X
-	B-X
derived	B-X
VE	B-X
-	B-X
cad+	B-X
cells	B-X
generate	B-X
MCs	B-X
independently	B-X
of	B-X
HSC	B-X
development	B-X
in	B-X
vitro	B-X
and	B-X
possess	B-X
the	B-X
potential	B-X
of	B-X
generating	B-X
connective	B-X
tissue	B-X
MCs	B-X
in	B-X
vivo	B-X
,	B-X
although	B-X
the	B-X
exact	B-X
differentiation	B-X
program	B-X
remains	B-X
unsolved	B-X
<EOS>	B-X
Inflammasomes	B-X
are	B-X
intracellular	B-X
multimeric	B-X
complexes	B-X
that	B-X
cleave	B-X
the	B-X
precursors	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
1	B-X
family	B-X
of	B-X
cytokines	B-X
and	B-X
various	B-X
proteins	B-X
,	B-X
found	B-X
predominantly	B-X
in	B-X
cells	B-X
of	B-X
hematopoietic	B-X
origin	B-X
<EOS>	B-X
Hematopoietic	B-X
stem	B-X
cell	B-X
(	B-X
HSC	B-X
)	B-X
	B-X
-	B-X
independent	B-X
hematopoiesis	B-X
from	B-X
hemogenic	B-X
endothelial	B-X
cells	B-X
(	B-X
HECs	B-X
)	B-X
in	B-X
the	B-X
mouse	B-X
embryo	B-X
has	B-X
been	B-X
recognized	B-X
as	B-X
a	B-X
source	B-X
of	B-X
tissue	B-X
-	B-X
resident	B-X
hematopoietic	B-X
cells	B-X
in	B-X
adult	B-X
mice	B-X

In	O
this	O
model	O
,	O
CD8	B-cell_type
alpha+	I-cell_type
Mac-1-	I-cell_type
DCs	I-cell_type
are	O
supposed	O
to	O
be	O
of	O
lymphoid	O
while	O
CD8	B-cell_type
alpha-	I-cell_type
Mac-1+	I-cell_type
DCs	I-cell_type
are	O
supposed	O
to	O
be	O
of	O
myeloid	O
origin	O
.	O
<EOS>	B-X
In	B-X
this	B-X
model	B-X
,	B-X
CD8	B-X
alpha+	B-X
Mac	B-X
-	B-X
1	B-X
-	B-X
	B-X
DCs	B-X
are	B-X
supposed	B-X
to	B-X
be	B-X
of	B-X
lymphoid	B-X
while	B-X
CD8	B-X
alpha	B-X
-	B-X
	B-X
Mac	B-X
-	B-X
1+	B-X
DCs	B-X
are	B-X
supposed	B-X
to	B-X
be	B-X
of	B-X
myeloid	B-X
origin	B-X
<EOS>	B-X
Therefore	B-X
CD8	B-X
alpha	B-X
expression	B-X
DCs	B-X
does	B-X
not	B-X
indicate	B-X
a	B-X
lymphoid	B-X
origin	B-X
and	B-X
differences	B-X
among	B-X
CD8	B-X
alpha+	B-X
and	B-X
CD8	B-X
alpha	B-X
-	B-X
	B-X
DCs	B-X
might	B-X
rather	B-X
reflect	B-X
maturation	B-X
status	B-X
than	B-X
ontogeny	B-X
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
transplantation	B-X
studies	B-X
,	B-X
it	B-X
seems	B-X
likely	B-X
that	B-X
most	B-X
of	B-X
the	B-X
DCs	B-X
in	B-X
secondary	B-X
lymphoid	B-X
organs	B-X
and	B-X
a	B-X
substantial	B-X
fraction	B-X
of	B-X
thymic	B-X
DCs	B-X
are	B-X
myeloid	B-X
-	B-X
derived	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
these	B-X
different	B-X
effects	B-X
on	B-X
responder	B-X
cells	B-X
depend	B-X
on	B-X
subsets	B-X
of	B-X
DCs	B-X
arising	B-X
from	B-X
either	B-X
myeloid	B-X
or	B-X
lymphoid	B-X
hematopoietic	B-X
origins	B-X

Here	O
we	O
summarize	O
our	O
findings	O
that	O
both	O
CD8	B-cell_type
alpha+	I-cell_type
and	I-cell_type
CD8	I-cell_type
alpha-	I-cell_type
DCs	I-cell_type
can	O
arise	O
from	O
clonogenic	B-cell_type
common	I-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
(	O
CMPs	B-cell_type
)	O
in	O
both	O
thymus	O
and	O
spleen	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
summarize	B-X
our	B-X
findings	B-X
that	B-X
both	B-X
CD8	B-X
alpha+	B-X
and	B-X
CD8	B-X
alpha	B-X
-	B-X
	B-X
DCs	B-X
can	B-X
arise	B-X
from	B-X
clonogenic	B-X
common	B-X
myeloid	B-X
progenitors	B-X
(	B-X
CMPs	B-X
)	B-X
in	B-X
both	B-X
thymus	B-X
and	B-X
spleen	B-X
<EOS>	B-X
Dendritic	B-X
cell	B-X
development	B-X
from	B-X
common	B-X
myeloid	B-X
progenitors	B-X
.	B-X
<EOS>	B-X
Therefore	B-X
CD8	B-X
alpha	B-X
expression	B-X
DCs	B-X
does	B-X
not	B-X
indicate	B-X
a	B-X
lymphoid	B-X
origin	B-X
and	B-X
differences	B-X
among	B-X
CD8	B-X
alpha+	B-X
and	B-X
CD8	B-X
alpha	B-X
-	B-X
	B-X
DCs	B-X
might	B-X
rather	B-X
reflect	B-X
maturation	B-X
status	B-X
than	B-X
ontogeny	B-X
<EOS>	B-X
In	B-X
this	B-X
model	B-X
,	B-X
CD8	B-X
alpha+	B-X
Mac	B-X
-	B-X
1	B-X
-	B-X
	B-X
DCs	B-X
are	B-X
supposed	B-X
to	B-X
be	B-X
of	B-X
lymphoid	B-X
while	B-X
CD8	B-X
alpha	B-X
-	B-X
	B-X
Mac	B-X
-	B-X
1+	B-X
DCs	B-X
are	B-X
supposed	B-X
to	B-X
be	B-X
of	B-X
myeloid	B-X
origin	B-X

Therefore	O
CD8	B-protein
alpha	I-protein
expression	O
DCs	B-cell_type
does	O
not	O
indicate	O
a	O
lymphoid	O
origin	O
and	O
differences	O
among	O
CD8	B-cell_type
alpha+	I-cell_type
and	I-cell_type
CD8	I-cell_type
alpha-	I-cell_type
DCs	I-cell_type
might	O
rather	O
reflect	O
maturation	O
status	O
than	O
ontogeny	O
.	O
<EOS>	B-X
Viperin	B-X
deficiency	B-X
promotes	B-X
dendritic	B-X
cell	B-X
activation	B-X
and	B-X
function	B-X
via	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
during	B-X
Mycobacterium	B-X
tuberculosis	B-X
infection	B-X
.	B-X
<EOS>	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
Dio	B-X
upregulated	B-X
connexin	B-X
43	B-X
(	B-X
Cx43	B-X
)	B-X
expression	B-X
and	B-X
improved	B-X
gap	B-X
junction	B-X
intercellular	B-X
communication	B-X
(	B-X
GJIC	B-X
)	B-X
in	B-X
B16	B-X
cells	B-X
while	B-X
increasing	B-X
the	B-X
cross	B-X
-	B-X
presentation	B-X
of	B-X
antigens	B-X
by	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
,	B-X
eventually	B-X
promoting	B-X
the	B-X
activation	B-X
and	B-X
antitumor	B-X
immune	B-X
killing	B-X
effects	B-X
of	B-X
CD8	B-X
<EOS>	B-X
During	B-X
SARS	B-X
-	B-X
CoV	B-X
-	B-X
2	B-X
infection	B-X
,	B-X
dialysis	B-X
and	B-X
kidney	B-X
transplant	B-X
patients	B-X
manifest	B-X
immunophenotype	B-X
abnormalities	B-X
;	B-X
these	B-X
are	B-X
similar	B-X
in	B-X
the	B-X
two	B-X
groups	B-X
,	B-X
however	B-X
kidney	B-X
transplant	B-X
recipients	B-X
show	B-X
more	B-X
profound	B-X
alterations	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
and	B-X
lower	B-X
anti	B-X
-	B-X
spike	B-X
antibody	B-X
response	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
transient	B-X
Treg	B-X
-	B-X
cell	B-X
depletion	B-X
resulted	B-X
in	B-X
maturation	B-X
of	B-X
both	B-X
migratory	B-X
and	B-X
resident	B-X
DCs	B-X
in	B-X
draining	B-X
lymph	B-X
nodes	B-X
that	B-X
captured	B-X
S1	B-X
-	B-X
antigen	B-X

On	O
the	O
basis	O
of	O
transplantation	O
studies	O
,	O
it	O
seems	O
likely	O
that	O
most	O
of	O
the	O
DCs	B-cell_type
in	O
secondary	O
lymphoid	O
organs	O
and	O
a	O
substantial	O
fraction	O
of	O
thymic	B-cell_type
DCs	I-cell_type
are	O
myeloid-derived	O
.	O

Macrophage	O
stimulation	O
with	O
Murabutide	O
,	O
an	O
HIV-suppressive	O
muramyl	O
peptide	O
derivative	O
,	O
selectively	O
activates	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
1	I-protein
and	I-protein
2	I-protein
,	O
C/EBPbeta	B-protein
and	O
STAT1	B-protein
:	O
role	O
of	O
CD14	B-protein
and	O
Toll-like	B-protein
receptors	I-protein
2	I-protein
and	I-protein
4	I-protein
.	O
<EOS>	B-X
Macrophage	B-X
stimulation	B-X
with	B-X
Murabutide	B-X
,	B-X
an	B-X
HIV	B-X
-	B-X
suppressive	B-X
muramyl	B-X
peptide	B-X
derivative	B-X
,	B-X
selectively	B-X
activates	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinases	B-X
1	B-X
and	B-X
2	B-X
,	B-X
C	B-X
/	B-X
EBPbeta	B-X
and	B-X
STAT1	B-X
:	B-X
role	B-X
of	B-X
CD14	B-X
and	B-X
Toll	B-X
-	B-X
like	B-X
receptors	B-X
2	B-X
and	B-X
4	B-X
.	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
,	B-X
unlike	B-X
LPS	B-X
,	B-X
the	B-X
safe	B-X
immunomodulator	B-X
MB	B-X
selectively	B-X
activates	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinases	B-X
(	B-X
Erk	B-X
)	B-X
1	B-X
/	B-X
2	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
detectable	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
or	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
kinase	B-X
activation	B-X
<EOS>	B-X
These	B-X
findings	B-X
present	B-X
major	B-X
differences	B-X
in	B-X
the	B-X
early	B-X
cell	B-X
activation	B-X
process	B-X
between	B-X
LPS	B-X
and	B-X
muramyl	B-X
peptides	B-X
,	B-X
and	B-X
strongly	B-X
argue	B-X
for	B-X
the	B-X
implication	B-X
of	B-X
co	B-X
-	B-X
receptors	B-X
other	B-X
than	B-X
TLR2	B-X
and	B-X
TLR4	B-X
in	B-X
mediating	B-X
the	B-X
signaling	B-X
events	B-X
induced	B-X
by	B-X
defined	B-X
subunits	B-X
of	B-X
bacterial	B-X
peptidoglycans	B-X
<EOS>	B-X
We	B-X
have	B-X
addressed	B-X
the	B-X
signaling	B-X
events	B-X
activated	B-X
in	B-X
MDM	B-X
following	B-X
stimulation	B-X
with	B-X
either	B-X
MB	B-X
or	B-X
the	B-X
potent	B-X
immunostimulant	B-X
LPS	B-X

The	O
smallest	O
unit	O
of	O
bacterial	O
peptidoglycans	O
known	O
to	O
be	O
endowed	O
with	O
biological	O
activities	O
is	O
muramyl	O
dipeptide	O
(	O
MDP	O
)	O
.	O
<EOS>	B-X
The	B-X
smallest	B-X
unit	B-X
of	B-X
bacterial	B-X
peptidoglycans	B-X
known	B-X
to	B-X
be	B-X
endowed	B-X
with	B-X
biological	B-X
activities	B-X
is	B-X
muramyl	B-X
dipeptide	B-X
(	B-X
MDP	B-X
)	B-X
<EOS>	B-X
A	B-X
clinically	B-X
acceptable	B-X
synthetic	B-X
derivative	B-X
of	B-X
MDP	B-X
,	B-X
namely	B-X
murabutide	B-X
(	B-X
MB	B-X
)	B-X
,	B-X
has	B-X
been	B-X
found	B-X
to	B-X
present	B-X
interesting	B-X
pharmacological	B-X
properties	B-X
and	B-X
to	B-X
suppress	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
in	B-X
monocyte	B-X
-	B-X
derived	B-X
macrophages	B-X
(	B-X
MDM	B-X
)	B-X
<EOS>	B-X
Macrophage	B-X
stimulation	B-X
with	B-X
Murabutide	B-X
,	B-X
an	B-X
HIV	B-X
-	B-X
suppressive	B-X
muramyl	B-X
peptide	B-X
derivative	B-X
,	B-X
selectively	B-X
activates	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinases	B-X
1	B-X
and	B-X
2	B-X
,	B-X
C	B-X
/	B-X
EBPbeta	B-X
and	B-X
STAT1	B-X
:	B-X
role	B-X
of	B-X
CD14	B-X
and	B-X
Toll	B-X
-	B-X
like	B-X
receptors	B-X
2	B-X
and	B-X
4	B-X
.	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
truncated	B-X
form	B-X
of	B-X
C	B-X
/	B-X
EBPbeta	B-X
,	B-X
known	B-X
to	B-X
repress	B-X
HIV	B-X
-	B-X
1	B-X
transcription	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
extracts	B-X
from	B-X
MB	B-X
-	B-X
treated	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X

A	O
clinically	O
acceptable	O
synthetic	O
derivative	O
of	O
MDP	O
,	O
namely	O
murabutide	O
(	O
MB	O
)	O
,	O
has	O
been	O
found	O
to	O
present	O
interesting	O
pharmacological	O
properties	O
and	O
to	O
suppress	O
HIV-1	O
replication	O
in	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
(	O
MDM	B-cell_type
)	O
.	O
<EOS>	B-X
A	B-X
clinically	B-X
acceptable	B-X
synthetic	B-X
derivative	B-X
of	B-X
MDP	B-X
,	B-X
namely	B-X
murabutide	B-X
(	B-X
MB	B-X
)	B-X
,	B-X
has	B-X
been	B-X
found	B-X
to	B-X
present	B-X
interesting	B-X
pharmacological	B-X
properties	B-X
and	B-X
to	B-X
suppress	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
in	B-X
monocyte	B-X
-	B-X
derived	B-X
macrophages	B-X
(	B-X
MDM	B-X
)	B-X
<EOS>	B-X
The	B-X
smallest	B-X
unit	B-X
of	B-X
bacterial	B-X
peptidoglycans	B-X
known	B-X
to	B-X
be	B-X
endowed	B-X
with	B-X
biological	B-X
activities	B-X
is	B-X
muramyl	B-X
dipeptide	B-X
(	B-X
MDP	B-X
)	B-X
<EOS>	B-X
We	B-X
have	B-X
addressed	B-X
the	B-X
signaling	B-X
events	B-X
activated	B-X
in	B-X
MDM	B-X
following	B-X
stimulation	B-X
with	B-X
either	B-X
MB	B-X
or	B-X
the	B-X
potent	B-X
immunostimulant	B-X
LPS	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
STAT1	B-X
activation	B-X
but	B-X
weak	B-X
or	B-X
no	B-X
activation	B-X
of	B-X
STAT3	B-X
or	B-X
STAT5	B-X
respectively	B-X
,	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
MB	B-X
-	B-X
stimulated	B-X
MDM	B-X

We	O
have	O
addressed	O
the	O
signaling	O
events	O
activated	O
in	O
MDM	B-cell_type
following	O
stimulation	O
with	O
either	O
MB	O
or	O
the	O
potent	O
immunostimulant	O
LPS	O
.	O
<EOS>	B-X
Mononuclear	B-X
bone	B-X
marrow	B-X
cells	B-X
of	B-X
pigs	B-X
,	B-X
aged	B-X
5	B-X
-	B-X
6	B-X
months	B-X
,	B-X
were	B-X
cultured	B-X
into	B-X
M1	B-X
or	B-X
M2	B-X
macrophages	B-X
and	B-X
stimulated	B-X
with	B-X
LPS	B-X
or	B-X
whole	B-X
bacteria	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
host	B-X
defence	B-X
peptides	B-X
(	B-X
HDPs	B-X
)	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
MPLA	B-X
appeared	B-X
to	B-X
present	B-X
a	B-X
more	B-X
informative	B-X
stratification	B-X
potential	B-X
within	B-X
the	B-X
septic	B-X
population	B-X
<EOS>	B-X
GF	B-X
(	B-X
IL	B-X
-	B-X
17	B-X
)	B-X
up	B-X
-	B-X
regulated	B-X
the	B-X
expression	B-X
of	B-X
chemokines	B-X
and	B-X
other	B-X
molecules	B-X
for	B-X
neutrophil	B-X
infiltration	B-X
and	B-X
activation	B-X
,	B-X
the	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokine	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
C3	B-X
<EOS>	B-X
However	B-X
,	B-X
on	B-X
the	B-X
seventh	B-X
day	B-X
of	B-X
the	B-X
study	B-X
combination	B-X
of	B-X
an	B-X
inactivated	B-X
P	B-X

We	O
also	O
examined	O
whether	O
signaling	O
by	O
muramyl	O
peptides	O
involves	O
the	O
use	O
of	O
cell	B-protein
surface	I-protein
receptors	I-protein
,	O
including	O
CD14	B-protein
and	O
Toll-like	B-protein
receptor	I-protein
2	I-protein
(	O
TLR2	B-protein
)	O
or	O
TLR4	B-protein
that	O
are	O
known	O
to	O
be	O
signal-transducing	B-protein
receptors	I-protein
for	O
other	O
bacterial	O
cell	O
wall	O
components	O
.	O
<EOS>	B-X
We	B-X
also	B-X
examined	B-X
whether	B-X
signaling	B-X
by	B-X
muramyl	B-X
peptides	B-X
involves	B-X
the	B-X
use	B-X
of	B-X
cell	B-X
surface	B-X
receptors	B-X
,	B-X
including	B-X
CD14	B-X
and	B-X
Toll	B-X
-	B-X
like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
or	B-X
TLR4	B-X
that	B-X
are	B-X
known	B-X
to	B-X
be	B-X
signal	B-X
-	B-X
transducing	B-X
receptors	B-X
for	B-X
other	B-X
bacterial	B-X
cell	B-X
wall	B-X
components	B-X
<EOS>	B-X
These	B-X
findings	B-X
present	B-X
major	B-X
differences	B-X
in	B-X
the	B-X
early	B-X
cell	B-X
activation	B-X
process	B-X
between	B-X
LPS	B-X
and	B-X
muramyl	B-X
peptides	B-X
,	B-X
and	B-X
strongly	B-X
argue	B-X
for	B-X
the	B-X
implication	B-X
of	B-X
co	B-X
-	B-X
receptors	B-X
other	B-X
than	B-X
TLR2	B-X
and	B-X
TLR4	B-X
in	B-X
mediating	B-X
the	B-X
signaling	B-X
events	B-X
induced	B-X
by	B-X
defined	B-X
subunits	B-X
of	B-X
bacterial	B-X
peptidoglycans	B-X
<EOS>	B-X
We	B-X
have	B-X
addressed	B-X
the	B-X
signaling	B-X
events	B-X
activated	B-X
in	B-X
MDM	B-X
following	B-X
stimulation	B-X
with	B-X
either	B-X
MB	B-X
or	B-X
the	B-X
potent	B-X
immunostimulant	B-X
LPS	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
truncated	B-X
form	B-X
of	B-X
C	B-X
/	B-X
EBPbeta	B-X
,	B-X
known	B-X
to	B-X
repress	B-X
HIV	B-X
-	B-X
1	B-X
transcription	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
extracts	B-X
from	B-X
MB	B-X
-	B-X
treated	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X

We	O
demonstrate	O
that	O
,	O
unlike	O
LPS	O
,	O
the	O
safe	O
immunomodulator	O
MB	O
selectively	O
activates	O
extracellular	B-protein
signal-regulated	I-protein
kinases	I-protein
(	I-protein
Erk	I-protein
)	I-protein
1/2	I-protein
,	O
in	O
the	O
absence	O
of	O
detectable	O
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
or	O
p38	B-protein
mitogen-activated	I-protein
kinase	I-protein
activation	O
.	O
<EOS>	B-X
In	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
phosphorylated	B-X
protein	B-X
levels	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
Kinase	B-X
1	B-X
/	B-X
2	B-X
(	B-X
JNK1	B-X
/	B-X
2	B-X
)	B-X
,	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
(	B-X
ERK1	B-X
/	B-X
2	B-X
)	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPK	B-X
)	B-X
were	B-X
decreased	B-X
in	B-X
PPE	B-X
-	B-X
induced	B-X
mice	B-X
treated	B-X
PTD	B-X
-	B-X
FGF2	B-X
<EOS>	B-X
AA	B-X
elevates	B-X
the	B-X
activity	B-X
of	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
,	B-X
in	B-X
which	B-X
the	B-X
activation	B-X
of	B-X
ERK	B-X
and	B-X
JNK	B-X
improves	B-X
cell	B-X
survival	B-X
<EOS>	B-X
Consequently	B-X
,	B-X
studying	B-X
immunomodulatory	B-X
ingredients	B-X
present	B-X
in	B-X
natural	B-X
products	B-X
,	B-X
such	B-X
as	B-X
ginseng	B-X
,	B-X
is	B-X
important	B-X
for	B-X
developing	B-X
new	B-X
treatment	B-X
options	B-X
<EOS>	B-X
We	B-X
detected	B-X
the	B-X
lactate	B-X
dehydrogenase	B-X
(	B-X
LDH	B-X
)	B-X
and	B-X
creatine	B-X
kinase	B-X
-	B-X
MB	B-X
(	B-X
CK	B-X
-	B-X
MB	B-X
)	B-X
in	B-X
the	B-X
serum	B-X
and	B-X
the	B-X
plasma	B-X
level	B-X
of	B-X
angiotensin	B-X
II	B-X
(	B-X
AngII	B-X
)	B-X

Furthermore	O
,	O
STAT1	B-protein
activation	O
but	O
weak	O
or	O
no	O
activation	O
of	O
STAT3	B-protein
or	O
STAT5	B-protein
respectively	O
,	O
could	O
be	O
detected	O
in	O
MB-stimulated	B-cell_type
MDM	I-cell_type
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
intraperitoneal	B-X
administration	B-X
of	B-X
IS	B-X
in	B-X
mice	B-X
promoted	B-X
tumor	B-X
growth	B-X
and	B-X
metastasis	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
keratinocytes	B-X
by	B-X
Th2	B-X
cytokines	B-X
in	B-X
cAD	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
demonstrated	B-X
<EOS>	B-X
Further	B-X
investigation	B-X
revealed	B-X
increased	B-X
STAT3	B-X
activation	B-X
occurred	B-X
a	B-X
result	B-X
of	B-X
increased	B-X
MET	B-X
activity	B-X
<EOS>	B-X
The	B-X
abnormal	B-X
activation	B-X
of	B-X
STAT3	B-X
renders	B-X
the	B-X
tumor	B-X
microenvironment	B-X
of	B-X
GBM	B-X
immunosuppression	B-X

Using	O
MonoMac6	B-cell_line
cells	I-cell_line
,	O
we	O
observed	O
high	O
C/EBPbeta	B-protein
and	O
AP-1	B-protein
but	O
weaker	O
and	O
transient	O
NF-kappaB	B-protein
activation	O
by	O
MB	O
.	O

Moreover	O
,	O
the	O
truncated	O
form	O
of	O
C/EBPbeta	B-protein
,	O
known	O
to	O
repress	O
HIV-1	O
transcription	O
,	O
was	O
detected	O
in	O
extracts	O
from	O
MB-treated	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
truncated	B-X
form	B-X
of	B-X
C	B-X
/	B-X
EBPbeta	B-X
,	B-X
known	B-X
to	B-X
repress	B-X
HIV	B-X
-	B-X
1	B-X
transcription	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
extracts	B-X
from	B-X
MB	B-X
-	B-X
treated	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
,	B-X
unlike	B-X
LPS	B-X
,	B-X
the	B-X
safe	B-X
immunomodulator	B-X
MB	B-X
selectively	B-X
activates	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinases	B-X
(	B-X
Erk	B-X
)	B-X
1	B-X
/	B-X
2	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
detectable	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
or	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
kinase	B-X
activation	B-X
<EOS>	B-X
Surprisingly	B-X
,	B-X
neither	B-X
MB	B-X
nor	B-X
MDP	B-X
were	B-X
able	B-X
to	B-X
transduce	B-X
signals	B-X
via	B-X
CD14	B-X
and	B-X
TLR2	B-X
or	B-X
4	B-X
<EOS>	B-X
We	B-X
also	B-X
examined	B-X
whether	B-X
signaling	B-X
by	B-X
muramyl	B-X
peptides	B-X
involves	B-X
the	B-X
use	B-X
of	B-X
cell	B-X
surface	B-X
receptors	B-X
,	B-X
including	B-X
CD14	B-X
and	B-X
Toll	B-X
-	B-X
like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
or	B-X
TLR4	B-X
that	B-X
are	B-X
known	B-X
to	B-X
be	B-X
signal	B-X
-	B-X
transducing	B-X
receptors	B-X
for	B-X
other	B-X
bacterial	B-X
cell	B-X
wall	B-X
components	B-X

Surprisingly	O
,	O
neither	O
MB	O
nor	O
MDP	O
were	O
able	O
to	O
transduce	O
signals	O
via	O
CD14	B-protein
and	O
TLR2	B-protein
or	I-protein
4	I-protein
.	O
<EOS>	B-X
Surprisingly	B-X
,	B-X
neither	B-X
MB	B-X
nor	B-X
MDP	B-X
were	B-X
able	B-X
to	B-X
transduce	B-X
signals	B-X
via	B-X
CD14	B-X
and	B-X
TLR2	B-X
or	B-X
4	B-X
<EOS>	B-X
Macrophage	B-X
stimulation	B-X
with	B-X
Murabutide	B-X
,	B-X
an	B-X
HIV	B-X
-	B-X
suppressive	B-X
muramyl	B-X
peptide	B-X
derivative	B-X
,	B-X
selectively	B-X
activates	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinases	B-X
1	B-X
and	B-X
2	B-X
,	B-X
C	B-X
/	B-X
EBPbeta	B-X
and	B-X
STAT1	B-X
:	B-X
role	B-X
of	B-X
CD14	B-X
and	B-X
Toll	B-X
-	B-X
like	B-X
receptors	B-X
2	B-X
and	B-X
4	B-X
.	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
truncated	B-X
form	B-X
of	B-X
C	B-X
/	B-X
EBPbeta	B-X
,	B-X
known	B-X
to	B-X
repress	B-X
HIV	B-X
-	B-X
1	B-X
transcription	B-X
,	B-X
was	B-X
detected	B-X
in	B-X
extracts	B-X
from	B-X
MB	B-X
-	B-X
treated	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
A	B-X
clinically	B-X
acceptable	B-X
synthetic	B-X
derivative	B-X
of	B-X
MDP	B-X
,	B-X
namely	B-X
murabutide	B-X
(	B-X
MB	B-X
)	B-X
,	B-X
has	B-X
been	B-X
found	B-X
to	B-X
present	B-X
interesting	B-X
pharmacological	B-X
properties	B-X
and	B-X
to	B-X
suppress	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
in	B-X
monocyte	B-X
-	B-X
derived	B-X
macrophages	B-X
(	B-X
MDM	B-X
)	B-X

These	O
findings	O
present	O
major	O
differences	O
in	O
the	O
early	O
cell	O
activation	O
process	O
between	O
LPS	O
and	O
muramyl	O
peptides	O
,	O
and	O
strongly	O
argue	O
for	O
the	O
implication	O
of	O
co-receptors	B-protein
other	O
than	O
TLR2	B-protein
and	O
TLR4	B-protein
in	O
mediating	O
the	O
signaling	O
events	O
induced	O
by	O
defined	O
subunits	O
of	O
bacterial	O
peptidoglycans	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
present	B-X
major	B-X
differences	B-X
in	B-X
the	B-X
early	B-X
cell	B-X
activation	B-X
process	B-X
between	B-X
LPS	B-X
and	B-X
muramyl	B-X
peptides	B-X
,	B-X
and	B-X
strongly	B-X
argue	B-X
for	B-X
the	B-X
implication	B-X
of	B-X
co	B-X
-	B-X
receptors	B-X
other	B-X
than	B-X
TLR2	B-X
and	B-X
TLR4	B-X
in	B-X
mediating	B-X
the	B-X
signaling	B-X
events	B-X
induced	B-X
by	B-X
defined	B-X
subunits	B-X
of	B-X
bacterial	B-X
peptidoglycans	B-X
<EOS>	B-X
We	B-X
also	B-X
examined	B-X
whether	B-X
signaling	B-X
by	B-X
muramyl	B-X
peptides	B-X
involves	B-X
the	B-X
use	B-X
of	B-X
cell	B-X
surface	B-X
receptors	B-X
,	B-X
including	B-X
CD14	B-X
and	B-X
Toll	B-X
-	B-X
like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
or	B-X
TLR4	B-X
that	B-X
are	B-X
known	B-X
to	B-X
be	B-X
signal	B-X
-	B-X
transducing	B-X
receptors	B-X
for	B-X
other	B-X
bacterial	B-X
cell	B-X
wall	B-X
components	B-X
<EOS>	B-X
Macrophage	B-X
stimulation	B-X
with	B-X
Murabutide	B-X
,	B-X
an	B-X
HIV	B-X
-	B-X
suppressive	B-X
muramyl	B-X
peptide	B-X
derivative	B-X
,	B-X
selectively	B-X
activates	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinases	B-X
1	B-X
and	B-X
2	B-X
,	B-X
C	B-X
/	B-X
EBPbeta	B-X
and	B-X
STAT1	B-X
:	B-X
role	B-X
of	B-X
CD14	B-X
and	B-X
Toll	B-X
-	B-X
like	B-X
receptors	B-X
2	B-X
and	B-X
4	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
STAT1	B-X
activation	B-X
but	B-X
weak	B-X
or	B-X
no	B-X
activation	B-X
of	B-X
STAT3	B-X
or	B-X
STAT5	B-X
respectively	B-X
,	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
MB	B-X
-	B-X
stimulated	B-X
MDM	B-X

Nuclear	B-protein
peroxisome	I-protein
proliferator-activated	I-protein
receptors	I-protein
alpha	I-protein
and	I-protein
gamma	I-protein
have	O
opposing	O
effects	O
on	O
monocyte	O
chemotaxis	O
in	O
endometriosis	O
.	O
<EOS>	B-X
Nuclear	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptors	B-X
alpha	B-X
and	B-X
gamma	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
monocyte	B-X
chemotaxis	B-X
in	B-X
endometriosis	B-X
.	B-X
<EOS>	B-X
The	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptors	B-X
(	B-X
PPARs	B-X
)	B-X
alpha	B-X
and	B-X
gamma	B-X
are	B-X
nuclear	B-X
receptors	B-X
that	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
inflammatory	B-X
diseases	B-X
like	B-X
ulcerative	B-X
colitis	B-X
and	B-X
arthritis	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
PPARs	B-X
in	B-X
macrophage	B-X
attraction	B-X
into	B-X
the	B-X
peritoneal	B-X
cavity	B-X
of	B-X
patients	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
The	B-X
U937	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
a	B-X
PPAR	B-X
response	B-X
element	B-X
luciferase	B-X
reporter	B-X
showed	B-X
disease	B-X
stage	B-X
-	B-X
dependent	B-X
up	B-X
-	B-X
regulation	B-X
when	B-X
treated	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X

The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
(	I-protein
PPARs	I-protein
)	I-protein
alpha	I-protein
and	I-protein
gamma	I-protein
are	O
nuclear	B-protein
receptors	I-protein
that	O
play	O
important	O
roles	O
in	O
inflammatory	O
diseases	O
like	O
ulcerative	O
colitis	O
and	O
arthritis	O
.	O
<EOS>	B-X
The	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptors	B-X
(	B-X
PPARs	B-X
)	B-X
alpha	B-X
and	B-X
gamma	B-X
are	B-X
nuclear	B-X
receptors	B-X
that	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
inflammatory	B-X
diseases	B-X
like	B-X
ulcerative	B-X
colitis	B-X
and	B-X
arthritis	B-X
<EOS>	B-X
Nuclear	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptors	B-X
alpha	B-X
and	B-X
gamma	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
monocyte	B-X
chemotaxis	B-X
in	B-X
endometriosis	B-X
.	B-X
<EOS>	B-X
Inhibitors	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
or	B-X
activators	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
could	B-X
be	B-X
developed	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammation	B-X
associated	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
PPARs	B-X
in	B-X
macrophage	B-X
attraction	B-X
into	B-X
the	B-X
peritoneal	B-X
cavity	B-X
of	B-X
patients	B-X
with	B-X
endometriosis	B-X

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
possible	O
role	O
of	O
PPARs	B-protein
in	O
macrophage	O
attraction	O
into	O
the	O
peritoneal	O
cavity	O
of	O
patients	O
with	O
endometriosis	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
PPARs	B-X
in	B-X
macrophage	B-X
attraction	B-X
into	B-X
the	B-X
peritoneal	B-X
cavity	B-X
of	B-X
patients	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
The	B-X
U937	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
a	B-X
PPAR	B-X
response	B-X
element	B-X
luciferase	B-X
reporter	B-X
showed	B-X
disease	B-X
stage	B-X
-	B-X
dependent	B-X
up	B-X
-	B-X
regulation	B-X
when	B-X
treated	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
Inhibitors	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
or	B-X
activators	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
could	B-X
be	B-X
developed	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammation	B-X
associated	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
Nuclear	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptors	B-X
alpha	B-X
and	B-X
gamma	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
monocyte	B-X
chemotaxis	B-X
in	B-X
endometriosis	B-X
.	B-X

We	O
identified	O
PPAR-alpha	B-RNA
and	I-RNA
-gamma	I-RNA
messenger	O
RNA	O
by	O
RT-PCR	O
and	O
protein	O
by	O
immunoblotting	O
of	O
lysates	O
of	O
peritoneal	B-cell_type
macrophages	I-cell_type
and	O
monocytic	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
We	B-X
identified	B-X
PPAR	B-X
-	B-X
alpha	B-X
and	B-X
	B-X
-	B-X
gamma	B-X
messenger	B-X
RNA	B-X
by	B-X
RT	B-X
-	B-X
PCR	B-X
and	B-X
protein	B-X
by	B-X
immunoblotting	B-X
of	B-X
lysates	B-X
of	B-X
peritoneal	B-X
macrophages	B-X
and	B-X
monocytic	B-X
U937	B-X
cells	B-X
<EOS>	B-X
Inhibitors	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
or	B-X
activators	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
could	B-X
be	B-X
developed	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammation	B-X
associated	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
The	B-X
U937	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
a	B-X
PPAR	B-X
response	B-X
element	B-X
luciferase	B-X
reporter	B-X
showed	B-X
disease	B-X
stage	B-X
-	B-X
dependent	B-X
up	B-X
-	B-X
regulation	B-X
when	B-X
treated	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
PPARs	B-X
in	B-X
macrophage	B-X
attraction	B-X
into	B-X
the	B-X
peritoneal	B-X
cavity	B-X
of	B-X
patients	B-X
with	B-X
endometriosis	B-X

Using	O
immunocytochemistry	O
,	O
we	O
localized	O
PPAR-alpha	B-protein
and	I-protein
-gamma	I-protein
within	O
the	O
nuclei	O
of	O
both	O
cell	O
types	O
.	O
<EOS>	B-X
Using	B-X
immunocytochemistry	B-X
,	B-X
we	B-X
localized	B-X
PPAR	B-X
-	B-X
alpha	B-X
and	B-X
	B-X
-	B-X
gamma	B-X
within	B-X
the	B-X
nuclei	B-X
of	B-X
both	B-X
cell	B-X
types	B-X
<EOS>	B-X
Immunocytochemistry	B-X
revealed	B-X
that	B-X
PPARalpha	B-X
and	B-X
gamma	B-X
were	B-X
localized	B-X
in	B-X
cell	B-X
nuclei	B-X
<EOS>	B-X
Immunoblot	B-X
analyses	B-X
demonstrated	B-X
protein	B-X
expression	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
and	B-X
	B-X
-	B-X
gamma1	B-X
,	B-X
but	B-X
not	B-X
of	B-X
	B-X
-	B-X
gamma2	B-X
,	B-X
in	B-X
the	B-X
kidney	B-X
nuclear	B-X
extracts	B-X
<EOS>	B-X
Finally	B-X
,	B-X
our	B-X
demonstration	B-X
of	B-X
a	B-X
nuclear	B-X
localization	B-X
supports	B-X
that	B-X
the	B-X
Egr	B-X
-	B-X
1	B-X
induced	B-X
by	B-X
PPAR	B-X
alpha	B-X
and	B-X
PPAR	B-X
gamma	B-X
coactivation	B-X
in	B-X
the	B-X
rat	B-X
urothelium	B-X
may	B-X
be	B-X
biologically	B-X
active	B-X

Monocyte	O
chemotactic	O
activity	O
of	O
peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
was	O
quantified	O
in	O
Boyden	O
chambers	O
.	O
<EOS>	B-X
Monocyte	B-X
chemotactic	B-X
activity	B-X
of	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X
was	B-X
quantified	B-X
in	B-X
Boyden	B-X
chambers	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
peritoneal	B-X
fluid	B-X
of	B-X
endometriosis	B-X
patients	B-X
contains	B-X
activators	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
that	B-X
stimulate	B-X
macrophage	B-X
chemotaxis	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
peritoneal	B-X
fluid	B-X
did	B-X
not	B-X
cause	B-X
significant	B-X
activation	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
/	B-X
GAL4	B-X
constructs	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
healthy	B-X
controls	B-X
down	B-X
-	B-X
regulated	B-X
PPAR	B-X
response	B-X
element	B-X
transactivation	B-X

Migration	O
of	O
U937	B-cell_line
cells	I-cell_line
was	O
increased	O
by	O
WY	O
14643	O
and	O
reduced	O
by	O
rosiglitazone	O
.	O
<EOS>	B-X
Migration	B-X
of	B-X
U937	B-X
cells	B-X
was	B-X
increased	B-X
by	B-X
WY	B-X
14643	B-X
and	B-X
reduced	B-X
by	B-X
rosiglitazone	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
healthy	B-X
controls	B-X
down	B-X
-	B-X
regulated	B-X
PPAR	B-X
response	B-X
element	B-X
transactivation	B-X
<EOS>	B-X
Peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X
activated	B-X
U937	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
a	B-X
PPAR	B-X
-	B-X
alpha	B-X
/	B-X
GAL4	B-X
luciferase	B-X
reporter	B-X
<EOS>	B-X
Monocyte	B-X
chemotactic	B-X
activity	B-X
of	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X
was	B-X
quantified	B-X
in	B-X
Boyden	B-X
chambers	B-X

Peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
activated	O
U937	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
a	O
PPAR-alpha/GAL4	B-DNA
luciferase	I-DNA
reporter	I-DNA
.	O
<EOS>	B-X
Peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X
activated	B-X
U937	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
a	B-X
PPAR	B-X
-	B-X
alpha	B-X
/	B-X
GAL4	B-X
luciferase	B-X
reporter	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
peritoneal	B-X
fluid	B-X
of	B-X
endometriosis	B-X
patients	B-X
contains	B-X
activators	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
that	B-X
stimulate	B-X
macrophage	B-X
chemotaxis	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
peritoneal	B-X
fluid	B-X
did	B-X
not	B-X
cause	B-X
significant	B-X
activation	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
/	B-X
GAL4	B-X
constructs	B-X
<EOS>	B-X
The	B-X
U937	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
a	B-X
PPAR	B-X
response	B-X
element	B-X
luciferase	B-X
reporter	B-X
showed	B-X
disease	B-X
stage	B-X
-	B-X
dependent	B-X
up	B-X
-	B-X
regulation	B-X
when	B-X
treated	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X

By	O
contrast	O
,	O
peritoneal	O
fluid	O
did	O
not	O
cause	O
significant	O
activation	O
of	O
PPAR-gamma/GAL4	B-DNA
constructs	I-DNA
.	O
<EOS>	B-X
Lactoferrin	B-X
in	B-X
peritoneal	B-X
fluid	B-X
correlated	B-X
with	B-X
lactoferrin	B-X
,	B-X
iron	B-X
and	B-X
transferrin	B-X
of	B-X
plasma	B-X
in	B-X
patients	B-X
without	B-X
endometriosis	B-X
<EOS>	B-X
The	B-X
implementation	B-X
of	B-X
point	B-X
of	B-X
care	B-X
ultrasound	B-X
has	B-X
significantly	B-X
impacted	B-X
the	B-X
evaluation	B-X
and	B-X
treatment	B-X
of	B-X
patients	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
heart	B-X
failure	B-X
is	B-X
a	B-X
very	B-X
late	B-X
consequence	B-X
of	B-X
a	B-X
long	B-X
-	B-X
standing	B-X
overworked	B-X
heart	B-X
<EOS>	B-X
After	B-X
peritoneal	B-X
lavage	B-X
,	B-X
the	B-X
perforation	B-X
was	B-X
repaired	B-X
over	B-X
a	B-X
T	B-X
-	B-X
tube	B-X

The	O
U937	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
a	O
PPAR	B-DNA
response	I-DNA
element	I-DNA
luciferase	I-DNA
reporter	I-DNA
showed	O
disease	O
stage-dependent	O
up-regulation	O
when	O
treated	O
with	O
peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	O
.	O
<EOS>	B-X
The	B-X
U937	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
a	B-X
PPAR	B-X
response	B-X
element	B-X
luciferase	B-X
reporter	B-X
showed	B-X
disease	B-X
stage	B-X
-	B-X
dependent	B-X
up	B-X
-	B-X
regulation	B-X
when	B-X
treated	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
PPARs	B-X
in	B-X
macrophage	B-X
attraction	B-X
into	B-X
the	B-X
peritoneal	B-X
cavity	B-X
of	B-X
patients	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
Inhibitors	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
or	B-X
activators	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
could	B-X
be	B-X
developed	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammation	B-X
associated	B-X
with	B-X
endometriosis	B-X
<EOS>	B-X
Nuclear	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptors	B-X
alpha	B-X
and	B-X
gamma	B-X
have	B-X
opposing	B-X
effects	B-X
on	B-X
monocyte	B-X
chemotaxis	B-X
in	B-X
endometriosis	B-X
.	B-X

Treatment	O
with	O
peritoneal	O
fluid	O
from	O
healthy	O
controls	O
down-regulated	O
PPAR	O
response	O
element	O
transactivation	O
.	O
<EOS>	B-X
Treatment	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
healthy	B-X
controls	B-X
down	B-X
-	B-X
regulated	B-X
PPAR	B-X
response	B-X
element	B-X
transactivation	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
peritoneal	B-X
fluid	B-X
of	B-X
endometriosis	B-X
patients	B-X
contains	B-X
activators	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
that	B-X
stimulate	B-X
macrophage	B-X
chemotaxis	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
peritoneal	B-X
fluid	B-X
did	B-X
not	B-X
cause	B-X
significant	B-X
activation	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
/	B-X
GAL4	B-X
constructs	B-X
<EOS>	B-X
The	B-X
U937	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
a	B-X
PPAR	B-X
response	B-X
element	B-X
luciferase	B-X
reporter	B-X
showed	B-X
disease	B-X
stage	B-X
-	B-X
dependent	B-X
up	B-X
-	B-X
regulation	B-X
when	B-X
treated	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X

We	O
conclude	O
that	O
peritoneal	O
fluid	O
of	O
endometriosis	O
patients	O
contains	O
activators	O
of	O
PPAR-alpha	B-protein
that	O
stimulate	O
macrophage	O
chemotaxis	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
peritoneal	B-X
fluid	B-X
of	B-X
endometriosis	B-X
patients	B-X
contains	B-X
activators	B-X
of	B-X
PPAR	B-X
-	B-X
alpha	B-X
that	B-X
stimulate	B-X
macrophage	B-X
chemotaxis	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
peritoneal	B-X
fluid	B-X
did	B-X
not	B-X
cause	B-X
significant	B-X
activation	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
/	B-X
GAL4	B-X
constructs	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
peritoneal	B-X
fluid	B-X
from	B-X
healthy	B-X
controls	B-X
down	B-X
-	B-X
regulated	B-X
PPAR	B-X
response	B-X
element	B-X
transactivation	B-X
<EOS>	B-X
Monocyte	B-X
chemotactic	B-X
activity	B-X
of	B-X
peritoneal	B-X
fluid	B-X
from	B-X
patients	B-X
with	B-X
endometriosis	B-X
was	B-X
quantified	B-X
in	B-X
Boyden	B-X
chambers	B-X

Inhibitors	O
of	O
PPAR-alpha	B-protein
or	O
activators	O
of	O
PPAR-gamma	B-protein
could	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
inflammation	O
associated	O
with	O
endometriosis	O
.	O
<EOS>	B-X
To	B-X
date	B-X
,	B-X
numerous	B-X
activators	B-X
and	B-X
inhibitors	B-X
of	B-X
SIRT6	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
translational	B-X
research	B-X
<EOS>	B-X
Pharmacological	B-X
Utility	B-X
of	B-X
PPAR	B-X
Modulation	B-X
for	B-X
Angiogenesis	B-X
in	B-X
Cardiovascular	B-X
Disease	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
implications	B-X
of	B-X
PPARs	B-X
in	B-X
vascular	B-X
biology	B-X
regarding	B-X
cardiac	B-X
pathology	B-X
and	B-X
focus	B-X
on	B-X
the	B-X
outcomes	B-X
of	B-X
clinical	B-X
studies	B-X
evaluating	B-X
their	B-X
benefits	B-X
in	B-X
cardiovascular	B-X
diseases	B-X
<EOS>	B-X
MG	B-X
binds	B-X
PPAR	B-X
-	B-X
γ	B-X
and	B-X
excites	B-X
this	B-X
signaling	B-X
to	B-X
initiate	B-X
ligand	B-X
-	B-X
dependent	B-X
anti	B-X
-	B-X
inflammatory	B-X
activity	B-X

Long-term-impaired	O
expression	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
trauma	O
patients	O
.	O
<EOS>	B-X
Long	B-X
-	B-X
term	B-X
-	B-X
impaired	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
of	B-X
trauma	B-X
patients	B-X
.	B-X
<EOS>	B-X
The	B-X
ex	B-X
vivo	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
higher	B-X
in	B-X
PBMCs	B-X
of	B-X
controls	B-X
than	B-X
of	B-X
trauma	B-X
patients	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
expression	B-X
and	B-X
dimer	B-X
characteristics	B-X
were	B-X
studied	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
major	B-X
-	B-X
trauma	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
The	B-X
long	B-X
-	B-X
term	B-X
low	B-X
-	B-X
basal	B-X
and	B-X
LPS	B-X
-	B-X
induced	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
recalled	B-X
long	B-X
-	B-X
term	B-X
immunoparalysis	B-X
observed	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
inflammatory	B-X
stress	B-X
such	B-X
as	B-X
trauma	B-X

Nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
expression	O
and	O
dimer	O
characteristics	O
were	O
studied	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
of	O
major-trauma	O
patients	O
and	O
healthy	O
controls	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
expression	B-X
and	B-X
dimer	B-X
characteristics	B-X
were	B-X
studied	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
major	B-X
-	B-X
trauma	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
Long	B-X
-	B-X
term	B-X
-	B-X
impaired	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
of	B-X
trauma	B-X
patients	B-X
.	B-X
<EOS>	B-X
After	B-X
LPS	B-X
stimulation	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
p65p50	B-X
/	B-X
p50p50	B-X
ratio	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
PBMCs	B-X
from	B-X
trauma	B-X
patients	B-X
than	B-X
from	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
However	B-X
,	B-X
throughout	B-X
the	B-X
survey	B-X
,	B-X
p65p50	B-X
activation	B-X
remained	B-X
significantly	B-X
lower	B-X
in	B-X
trauma	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X

Analysis	O
of	O
PBMCs	B-cell_type
on	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
and	O
10	O
after	O
trauma	O
revealed	O
that	O
expression	O
of	O
both	O
p65p50	B-protein
heterodimers	I-protein
and	O
p50p50	B-protein
homodimers	I-protein
was	O
significantly	O
reduced	O
compared	O
with	O
that	O
in	O
controls	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
PBMCs	B-X
on	B-X
days	B-X
1	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
10	B-X
after	B-X
trauma	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
both	B-X
p65p50	B-X
heterodimers	B-X
and	B-X
p50p50	B-X
homodimers	B-X
was	B-X
significantly	B-X
reduced	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
controls	B-X
<EOS>	B-X
However	B-X
,	B-X
throughout	B-X
the	B-X
survey	B-X
,	B-X
p65p50	B-X
activation	B-X
remained	B-X
significantly	B-X
lower	B-X
in	B-X
trauma	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
<EOS>	B-X
Although	B-X
no	B-X
direct	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
levels	B-X
of	B-X
interleukin	B-X
-	B-X
10	B-X
or	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
these	B-X
immunosuppressive	B-X
cytokines	B-X
were	B-X
significantly	B-X
elevated	B-X
in	B-X
trauma	B-X
patients	B-X
by	B-X
10	B-X
days	B-X
after	B-X
admission	B-X
<EOS>	B-X
After	B-X
LPS	B-X
stimulation	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
p65p50	B-X
/	B-X
p50p50	B-X
ratio	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
PBMCs	B-X
from	B-X
trauma	B-X
patients	B-X
than	B-X
from	B-X
healthy	B-X
controls	B-X

In	O
vitro	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
PBMCs	B-cell_type
induced	O
NF-kappa	O
B	O
translocation	O
.	O
<EOS>	B-X
In	B-X
vitro	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
of	B-X
PBMCs	B-X
induced	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
translocation	B-X
<EOS>	B-X
The	B-X
ex	B-X
vivo	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
higher	B-X
in	B-X
PBMCs	B-X
of	B-X
controls	B-X
than	B-X
of	B-X
trauma	B-X
patients	B-X
<EOS>	B-X
Our	B-X
study	B-X
indicates	B-X
that	B-X
OmpU	B-X
-	B-X
pretreatment	B-X
followed	B-X
by	B-X
LPS	B-X
-	B-X
activation	B-X
does	B-X
not	B-X
induce	B-X
M2	B-X
-	B-X
polarization	B-X
of	B-X
macrophages	B-X
/	B-X
monocytes	B-X
<EOS>	B-X
However	B-X
,	B-X
throughout	B-X
the	B-X
survey	B-X
,	B-X
p65p50	B-X
activation	B-X
remained	B-X
significantly	B-X
lower	B-X
in	B-X
trauma	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X

However	O
,	O
throughout	O
the	O
survey	O
,	O
p65p50	O
activation	O
remained	O
significantly	O
lower	O
in	O
trauma	O
patients	O
than	O
in	O
controls	O
.	O
<EOS>	B-X
However	B-X
,	B-X
throughout	B-X
the	B-X
survey	B-X
,	B-X
p65p50	B-X
activation	B-X
remained	B-X
significantly	B-X
lower	B-X
in	B-X
trauma	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
<EOS>	B-X
After	B-X
LPS	B-X
stimulation	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
p65p50	B-X
/	B-X
p50p50	B-X
ratio	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
PBMCs	B-X
from	B-X
trauma	B-X
patients	B-X
than	B-X
from	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
expression	B-X
and	B-X
dimer	B-X
characteristics	B-X
were	B-X
studied	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
major	B-X
-	B-X
trauma	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
PBMCs	B-X
on	B-X
days	B-X
1	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
10	B-X
after	B-X
trauma	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
both	B-X
p65p50	B-X
heterodimers	B-X
and	B-X
p50p50	B-X
homodimers	B-X
was	B-X
significantly	B-X
reduced	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
controls	B-X

After	O
LPS	O
stimulation	O
in	O
vitro	O
,	O
the	O
p65p50/p50p50	O
ratio	O
was	O
significantly	O
lower	O
in	O
PBMCs	B-cell_type
from	O
trauma	O
patients	O
than	O
from	O
healthy	O
controls	O
.	O
<EOS>	B-X
After	B-X
LPS	B-X
stimulation	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
p65p50	B-X
/	B-X
p50p50	B-X
ratio	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
PBMCs	B-X
from	B-X
trauma	B-X
patients	B-X
than	B-X
from	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
However	B-X
,	B-X
throughout	B-X
the	B-X
survey	B-X
,	B-X
p65p50	B-X
activation	B-X
remained	B-X
significantly	B-X
lower	B-X
in	B-X
trauma	B-X
patients	B-X
than	B-X
in	B-X
controls	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
expression	B-X
and	B-X
dimer	B-X
characteristics	B-X
were	B-X
studied	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
major	B-X
-	B-X
trauma	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
The	B-X
ex	B-X
vivo	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
higher	B-X
in	B-X
PBMCs	B-X
of	B-X
controls	B-X
than	B-X
of	B-X
trauma	B-X
patients	B-X

The	O
ex	O
vivo	O
expression	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
was	O
higher	O
in	O
PBMCs	B-cell_type
of	O
controls	O
than	O
of	O
trauma	O
patients	O
.	O
<EOS>	B-X
The	B-X
ex	B-X
vivo	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
higher	B-X
in	B-X
PBMCs	B-X
of	B-X
controls	B-X
than	B-X
of	B-X
trauma	B-X
patients	B-X
<EOS>	B-X
Long	B-X
-	B-X
term	B-X
-	B-X
impaired	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
of	B-X
trauma	B-X
patients	B-X
.	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
expression	B-X
and	B-X
dimer	B-X
characteristics	B-X
were	B-X
studied	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
major	B-X
-	B-X
trauma	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
After	B-X
LPS	B-X
stimulation	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
p65p50	B-X
/	B-X
p50p50	B-X
ratio	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
PBMCs	B-X
from	B-X
trauma	B-X
patients	B-X
than	B-X
from	B-X
healthy	B-X
controls	B-X

LPS	O
did	O
not	O
induce	O
I	O
kappa	O
B	O
expression	O
in	O
PBMCs	B-cell_type
from	O
trauma	O
patients	O
,	O
but	O
strong	O
induction	O
was	O
obtained	O
with	O
staphylococci	O
,	O
suggesting	O
that	O
this	O
defect	O
is	O
not	O
universal	O
and	O
depends	O
on	O
the	O
nature	O
of	O
the	O
activating	O
signal	O
.	O
<EOS>	B-X
We	B-X
found	B-X
here	B-X
that	B-X
exploratory	B-X
laparotomy	B-X
induced	B-X
cognitive	B-X
function	B-X
decline	B-X
in	B-X
aged	B-X
mice	B-X
but	B-X
not	B-X
in	B-X
young	B-X
mice	B-X
and	B-X
that	B-X
this	B-X
decline	B-X
was	B-X
accompanied	B-X
by	B-X
inflammatory	B-X
activation	B-X
of	B-X
microglia	B-X
in	B-X
the	B-X
hippocampus	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
expression	B-X
of	B-X
HDAC3	B-X
in	B-X
diabetic	B-X
mice	B-X
wounds	B-X
,	B-X
hyperglycemia	B-X
was	B-X
induced	B-X
in	B-X
C57BL	B-X
/	B-X
6	B-X
mice	B-X
with	B-X
streptozotocin	B-X
followed	B-X
by	B-X
induction	B-X
of	B-X
6	B-X
mm	B-X
wounds	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
inhibition	B-X
associated	B-X
with	B-X
macrophage	B-X
activation	B-X
,	B-X
IL	B-X
-	B-X
1β	B-X
expression	B-X
,	B-X
angiogenesis	B-X
and	B-X
wound	B-X
healing	B-X
in	B-X
diabetic	B-X
mice	B-X
<EOS>	B-X
Depression	B-X
might	B-X
manifest	B-X
itself	B-X
with	B-X
a	B-X
chronic	B-X
inflammation	B-X
in	B-X
different	B-X
tissues	B-X
and	B-X
organs	B-X
independent	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X

Although	O
no	O
direct	O
correlation	O
was	O
found	O
between	O
levels	O
of	O
interleukin-10	B-protein
or	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	O
NF-kappa	B-protein
B	I-protein
,	O
these	O
immunosuppressive	B-protein
cytokines	I-protein
were	O
significantly	O
elevated	O
in	O
trauma	O
patients	O
by	O
10	O
days	O
after	O
admission	O
.	O
<EOS>	B-X
Serum	B-X
levels	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
6	B-X
,	B-X
IL	B-X
-	B-X
10	B-X
,	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNFα	B-X
)	B-X
in	B-X
non	B-X
-	B-X
survivors	B-X
were	B-X
consistently	B-X
elevated	B-X
compared	B-X
to	B-X
those	B-X
in	B-X
the	B-X
survivors	B-X
<EOS>	B-X
GAS5	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
mRNA	B-X
levels	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
were	B-X
significantly	B-X
lower	B-X
in	B-X
MG	B-X
patients	B-X
than	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
We	B-X
found	B-X
several	B-X
correlations	B-X
between	B-X
basal	B-X
mRNA	B-X
expression	B-X
levels	B-X
of	B-X
CCL3	B-X
,	B-X
CCL4	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
CLL	B-X
B	B-X
cells	B-X
and	B-X
their	B-X
sensitivity	B-X
to	B-X
chemotherapeutic	B-X
drugs	B-X
ex	B-X
vivo	B-X
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
GAS5	B-X
and	B-X
interleukin	B-X
10	B-X
(	B-X
IL	B-X
-	B-X
10	B-X
)	B-X
was	B-X
explored	B-X
in	B-X
overexpressed	B-X
cells	B-X
using	B-X
real	B-X
time	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reactions	B-X
(	B-X
RT	B-X
-	B-X
qPCRs	B-X
)	B-X
and	B-X
western	B-X
blot	B-X

The	O
long-term	O
low-basal	O
and	O
LPS-induced	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
recalled	O
long-term	O
immunoparalysis	O
observed	O
in	O
patients	O
with	O
severe	O
inflammatory	O
stress	O
such	O
as	O
trauma	O
.	O
<EOS>	B-X
The	B-X
long	B-X
-	B-X
term	B-X
low	B-X
-	B-X
basal	B-X
and	B-X
LPS	B-X
-	B-X
induced	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
recalled	B-X
long	B-X
-	B-X
term	B-X
immunoparalysis	B-X
observed	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
inflammatory	B-X
stress	B-X
such	B-X
as	B-X
trauma	B-X
<EOS>	B-X
Long	B-X
-	B-X
term	B-X
-	B-X
impaired	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
of	B-X
trauma	B-X
patients	B-X
.	B-X
<EOS>	B-X
Although	B-X
no	B-X
direct	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
levels	B-X
of	B-X
interleukin	B-X
-	B-X
10	B-X
or	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
these	B-X
immunosuppressive	B-X
cytokines	B-X
were	B-X
significantly	B-X
elevated	B-X
in	B-X
trauma	B-X
patients	B-X
by	B-X
10	B-X
days	B-X
after	B-X
admission	B-X
<EOS>	B-X
The	B-X
ex	B-X
vivo	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
higher	B-X
in	B-X
PBMCs	B-X
of	B-X
controls	B-X
than	B-X
of	B-X
trauma	B-X
patients	B-X

Hepatic	O
ischemia-reperfusion	O
injury	O
.	O
<EOS>	B-X
Hepatic	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
(	B-X
I	B-X
/	B-X
R	B-X
)	B-X
injury	B-X
is	B-X
a	B-X
common	B-X
complication	B-X
in	B-X
liver	B-X
transplantation	B-X
<EOS>	B-X
Identify	B-X
Key	B-X
Genes	B-X
Correlated	B-X
to	B-X
Ischemia	B-X
-	B-X
Reperfusion	B-X
Injury	B-X
in	B-X
Aging	B-X
Livers	B-X
.	B-X
<EOS>	B-X
Hepatic	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
(	B-X
IR	B-X
)	B-X
injury	B-X
occurs	B-X
in	B-X
liver	B-X
surgery	B-X
,	B-X
resection	B-X
,	B-X
and	B-X
transplantation	B-X
<EOS>	B-X
Neutrophil	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
recruitment	B-X
contribute	B-X
to	B-X
hepatic	B-X
ischemia	B-X
/	B-X
reperfusion	B-X
injury	B-X

BACKGROUND	O
:	O
The	O
morbidity	O
associated	O
with	O
liver	O
transplantation	O
and	O
major	O
hepatic	O
resections	O
is	O
partly	O
a	O
result	O
of	O
ischemia-reperfusion	O
injury	O
.	O
<EOS>	B-X
The	B-X
morbidity	B-X
associated	B-X
with	B-X
liver	B-X
transplantation	B-X
and	B-X
major	B-X
hepatic	B-X
resections	B-X
is	B-X
partly	B-X
a	B-X
result	B-X
of	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injury	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
demonstrated	B-X
that	B-X
treatment	B-X
with	B-X
follistatin	B-X
reduced	B-X
the	B-X
expression	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
activin	B-X
resulting	B-X
in	B-X
beneficial	B-X
support	B-X
for	B-X
hepatic	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injuries	B-X
<EOS>	B-X
This	B-X
study	B-X
was	B-X
conducted	B-X
to	B-X
investigate	B-X
the	B-X
involvement	B-X
of	B-X
the	B-X
activin	B-X
-	B-X
follistatin	B-X
system	B-X
in	B-X
hepatic	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injury	B-X
<EOS>	B-X
Beneficial	B-X
effects	B-X
of	B-X
follistatin	B-X
in	B-X
hepatic	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injuries	B-X
in	B-X
rats	B-X
.	B-X

DATA	O
SOURCES	O
:	O
The	O
entire	O
world	O
literature	O
on	O
the	O
subject	O
was	O
searched	O
via	O
Medline	O
.	O
<EOS>	B-X
The	B-X
entire	B-X
world	B-X
literature	B-X
on	B-X
the	B-X
subject	B-X
was	B-X
searched	B-X
via	B-X
Medline	B-X
<EOS>	B-X
An	B-X
imbalance	B-X
between	B-X
endothelin	B-X
and	B-X
nitric	B-X
oxide	B-X
levels	B-X
results	B-X
in	B-X
failure	B-X
of	B-X
the	B-X
hepatic	B-X
microcirculation	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
reperfusion	B-X
<EOS>	B-X
Application	B-X
of	B-X
the	B-X
knowledge	B-X
gained	B-X
from	B-X
animal	B-X
models	B-X
of	B-X
hepatic	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
to	B-X
the	B-X
clinical	B-X
setting	B-X
will	B-X
improve	B-X
the	B-X
outcome	B-X
of	B-X
hepatic	B-X
surgery	B-X
<EOS>	B-X
These	B-X
result	B-X
in	B-X
oxygen	B-X
-	B-X
derived	B-X
free	B-X
radical	B-X
production	B-X
and	B-X
neutrophil	B-X
recruitment	B-X
,	B-X
further	B-X
contributing	B-X
to	B-X
cellular	B-X
injury	B-X

Keywords	O
included	O
reperfusion	O
injury	O
,	O
transplantation	O
,	O
liver	O
resection	O
,	O
nitric	O
oxide	O
,	O
endothelin	O
,	O
cytokines	B-protein
,	O
Kupffer	B-cell_type
cells	I-cell_type
,	O
ischemic/ischaemic	O
preconditioning	O
,	O
and	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O
<EOS>	B-X
Keywords	B-X
included	B-X
reperfusion	B-X
injury	B-X
,	B-X
transplantation	B-X
,	B-X
liver	B-X
resection	B-X
,	B-X
nitric	B-X
oxide	B-X
,	B-X
endothelin	B-X
,	B-X
cytokines	B-X
,	B-X
Kupffer	B-X
cells	B-X
,	B-X
ischemic	B-X
/	B-X
ischaemic	B-X
preconditioning	B-X
,	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
The	B-X
morbidity	B-X
associated	B-X
with	B-X
liver	B-X
transplantation	B-X
and	B-X
major	B-X
hepatic	B-X
resections	B-X
is	B-X
partly	B-X
a	B-X
result	B-X
of	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injury	B-X
<EOS>	B-X
An	B-X
imbalance	B-X
between	B-X
endothelin	B-X
and	B-X
nitric	B-X
oxide	B-X
levels	B-X
results	B-X
in	B-X
failure	B-X
of	B-X
the	B-X
hepatic	B-X
microcirculation	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
reperfusion	B-X
<EOS>	B-X
These	B-X
result	B-X
in	B-X
oxygen	B-X
-	B-X
derived	B-X
free	B-X
radical	B-X
production	B-X
and	B-X
neutrophil	B-X
recruitment	B-X
,	B-X
further	B-X
contributing	B-X
to	B-X
cellular	B-X
injury	B-X

CONCLUSIONS	O
:	O
An	O
imbalance	O
between	O
endothelin	O
and	O
nitric	O
oxide	O
levels	O
results	O
in	O
failure	O
of	O
the	O
hepatic	O
microcirculation	O
at	O
the	O
onset	O
of	O
reperfusion	O
.	O
<EOS>	B-X
An	B-X
imbalance	B-X
between	B-X
endothelin	B-X
and	B-X
nitric	B-X
oxide	B-X
levels	B-X
results	B-X
in	B-X
failure	B-X
of	B-X
the	B-X
hepatic	B-X
microcirculation	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
reperfusion	B-X
<EOS>	B-X
Keywords	B-X
included	B-X
reperfusion	B-X
injury	B-X
,	B-X
transplantation	B-X
,	B-X
liver	B-X
resection	B-X
,	B-X
nitric	B-X
oxide	B-X
,	B-X
endothelin	B-X
,	B-X
cytokines	B-X
,	B-X
Kupffer	B-X
cells	B-X
,	B-X
ischemic	B-X
/	B-X
ischaemic	B-X
preconditioning	B-X
,	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
Various	B-X
therapeutic	B-X
modalities	B-X
acting	B-X
on	B-X
the	B-X
above	B-X
mediators	B-X
have	B-X
been	B-X
successfully	B-X
used	B-X
to	B-X
attenuate	B-X
reperfusion	B-X
injury	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
hepatic	B-X
transplantation	B-X
and	B-X
resection	B-X
<EOS>	B-X
The	B-X
morbidity	B-X
associated	B-X
with	B-X
liver	B-X
transplantation	B-X
and	B-X
major	B-X
hepatic	B-X
resections	B-X
is	B-X
partly	B-X
a	B-X
result	B-X
of	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injury	B-X

Activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
in	O
the	O
liver	O
promotes	O
proinflammatory	B-protein
cytokine	I-protein
and	O
adhesion	B-protein
molecule	I-protein
synthesis	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
the	B-X
liver	B-X
promotes	B-X
proinflammatory	B-X
cytokine	B-X
and	B-X
adhesion	B-X
molecule	B-X
synthesis	B-X
<EOS>	B-X
LPS	B-X
administration	B-X
to	B-X
mouse	B-X
lungs	B-X
resulted	B-X
in	B-X
an	B-X
increased	B-X
release	B-X
of	B-X
inflammation	B-X
-	B-X
relevant	B-X
cytokines	B-X
and	B-X
chemokines	B-X
into	B-X
the	B-X
perfusate	B-X
(	B-X
Luminex	B-X
assay	B-X
)	B-X
compared	B-X
with	B-X
the	B-X
saline	B-X
-	B-X
controls	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
lung	B-X
-	B-X
derived	B-X
inflammatory	B-X
mediators	B-X
in	B-X
induction	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
remote	B-X
organs	B-X
is	B-X
poorly	B-X
understood	B-X
<EOS>	B-X
A	B-X
microenvironment	B-X
including	B-X
active	B-X
immune	B-X
cells	B-X
releasing	B-X
high	B-X
amounts	B-X
of	B-X
inflammatory	B-X
signaling	B-X
molecules	B-X
can	B-X
favor	B-X
the	B-X
carcinogenic	B-X
transformation	B-X
of	B-X
host	B-X
cells	B-X

These	O
result	O
in	O
oxygen-derived	O
free	O
radical	O
production	O
and	O
neutrophil	O
recruitment	O
,	O
further	O
contributing	O
to	O
cellular	O
injury	O
.	O
<EOS>	B-X
These	B-X
result	B-X
in	B-X
oxygen	B-X
-	B-X
derived	B-X
free	B-X
radical	B-X
production	B-X
and	B-X
neutrophil	B-X
recruitment	B-X
,	B-X
further	B-X
contributing	B-X
to	B-X
cellular	B-X
injury	B-X
<EOS>	B-X
The	B-X
morbidity	B-X
associated	B-X
with	B-X
liver	B-X
transplantation	B-X
and	B-X
major	B-X
hepatic	B-X
resections	B-X
is	B-X
partly	B-X
a	B-X
result	B-X
of	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injury	B-X
<EOS>	B-X
The	B-X
entire	B-X
world	B-X
literature	B-X
on	B-X
the	B-X
subject	B-X
was	B-X
searched	B-X
via	B-X
Medline	B-X
<EOS>	B-X
Application	B-X
of	B-X
the	B-X
knowledge	B-X
gained	B-X
from	B-X
animal	B-X
models	B-X
of	B-X
hepatic	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
to	B-X
the	B-X
clinical	B-X
setting	B-X
will	B-X
improve	B-X
the	B-X
outcome	B-X
of	B-X
hepatic	B-X
surgery	B-X

Various	O
therapeutic	O
modalities	O
acting	O
on	O
the	O
above	O
mediators	O
have	O
been	O
successfully	O
used	O
to	O
attenuate	O
reperfusion	O
injury	O
in	O
animal	O
models	O
of	O
hepatic	O
transplantation	O
and	O
resection	O
.	O
<EOS>	B-X
Various	B-X
therapeutic	B-X
modalities	B-X
acting	B-X
on	B-X
the	B-X
above	B-X
mediators	B-X
have	B-X
been	B-X
successfully	B-X
used	B-X
to	B-X
attenuate	B-X
reperfusion	B-X
injury	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
hepatic	B-X
transplantation	B-X
and	B-X
resection	B-X
<EOS>	B-X
The	B-X
morbidity	B-X
associated	B-X
with	B-X
liver	B-X
transplantation	B-X
and	B-X
major	B-X
hepatic	B-X
resections	B-X
is	B-X
partly	B-X
a	B-X
result	B-X
of	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injury	B-X
<EOS>	B-X
Application	B-X
of	B-X
the	B-X
knowledge	B-X
gained	B-X
from	B-X
animal	B-X
models	B-X
of	B-X
hepatic	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
to	B-X
the	B-X
clinical	B-X
setting	B-X
will	B-X
improve	B-X
the	B-X
outcome	B-X
of	B-X
hepatic	B-X
surgery	B-X
<EOS>	B-X
An	B-X
imbalance	B-X
between	B-X
endothelin	B-X
and	B-X
nitric	B-X
oxide	B-X
levels	B-X
results	B-X
in	B-X
failure	B-X
of	B-X
the	B-X
hepatic	B-X
microcirculation	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
reperfusion	B-X

Application	O
of	O
the	O
knowledge	O
gained	O
from	O
animal	O
models	O
of	O
hepatic	O
ischemia-reperfusion	O
to	O
the	O
clinical	O
setting	O
will	O
improve	O
the	O
outcome	O
of	O
hepatic	O
surgery	O
.	O

Down-regulation	O
of	O
IL-12	B-DNA
p40	I-DNA
gene	I-DNA
in	O
Plasmodium	O
berghei-infected	O
mice	O
.	O
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
in	B-X
Plasmodium	B-X
berghei	B-X
-	B-X
infected	B-X
mice	B-X
.	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
mechanism	B-X
that	B-X
causes	B-X
suppression	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
induction	B-X
during	B-X
Plasmodium	B-X
berghei	B-X
infection	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
induction	B-X
appeared	B-X
to	B-X
be	B-X
regulated	B-X
at	B-X
transcriptional	B-X
regulation	B-X
level	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
We	B-X
showed	B-X
in	B-X
the	B-X
present	B-X
study	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
but	B-X
not	B-X
IL	B-X
-	B-X
12	B-X
p35	B-X
gene	B-X
in	B-X
macrophages	B-X
of	B-X
P	B-X

We	O
analyzed	O
the	O
mechanism	O
that	O
causes	O
suppression	O
of	O
IL-12	B-DNA
p40	I-DNA
gene	I-DNA
induction	O
during	O
Plasmodium	O
berghei	O
infection	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
mechanism	B-X
that	B-X
causes	B-X
suppression	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
induction	B-X
during	B-X
Plasmodium	B-X
berghei	B-X
infection	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
in	B-X
Plasmodium	B-X
berghei	B-X
-	B-X
infected	B-X
mice	B-X
.	B-X
<EOS>	B-X
We	B-X
showed	B-X
in	B-X
the	B-X
present	B-X
study	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
but	B-X
not	B-X
IL	B-X
-	B-X
12	B-X
p35	B-X
gene	B-X
in	B-X
macrophages	B-X
of	B-X
P	B-X
<EOS>	B-X
Although	B-X
IL	B-X
-	B-X
12	B-X
together	B-X
with	B-X
IFN	B-X
-	B-X
gamma	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
protection	B-X
against	B-X
pathogenic	B-X
infection	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
12	B-X
p70	B-X
protein	B-X
production	B-X
of	B-X
infected	B-X
macrophages	B-X
is	B-X
lower	B-X
than	B-X
that	B-X
by	B-X
the	B-X
uninfected	B-X
macrophages	B-X

Although	O
IL-12	B-protein
together	O
with	O
IFN-gamma	B-protein
plays	O
an	O
important	O
role	O
in	O
protection	O
against	O
pathogenic	O
infection	O
,	O
the	O
IL-12	B-protein
p70	I-protein
protein	I-protein
production	O
of	O
infected	B-cell_type
macrophages	I-cell_type
is	O
lower	O
than	O
that	O
by	O
the	O
uninfected	B-cell_type
macrophages	I-cell_type
.	O
<EOS>	B-X
Although	B-X
IL	B-X
-	B-X
12	B-X
together	B-X
with	B-X
IFN	B-X
-	B-X
gamma	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
protection	B-X
against	B-X
pathogenic	B-X
infection	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
12	B-X
p70	B-X
protein	B-X
production	B-X
of	B-X
infected	B-X
macrophages	B-X
is	B-X
lower	B-X
than	B-X
that	B-X
by	B-X
the	B-X
uninfected	B-X
macrophages	B-X
<EOS>	B-X
We	B-X
showed	B-X
in	B-X
the	B-X
present	B-X
study	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
but	B-X
not	B-X
IL	B-X
-	B-X
12	B-X
p35	B-X
gene	B-X
in	B-X
macrophages	B-X
of	B-X
P	B-X
<EOS>	B-X
The	B-X
inhibition	B-X
was	B-X
induced	B-X
by	B-X
interaction	B-X
with	B-X
macrophages	B-X
that	B-X
had	B-X
contacted	B-X
with	B-X
P	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
mechanism	B-X
that	B-X
causes	B-X
suppression	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
induction	B-X
during	B-X
Plasmodium	B-X
berghei	B-X
infection	B-X

We	O
showed	O
in	O
the	O
present	O
study	O
that	O
the	O
induction	O
of	O
IL-12	B-DNA
p40	I-DNA
gene	I-DNA
but	O
not	O
IL-12	B-DNA
p35	I-DNA
gene	I-DNA
in	O
macrophages	B-cell_type
of	O
P.	O
berghei-infected	O
mice	O
was	O
profoundly	O
inhibited	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
cloned	B-X
two	B-X
types	B-X
of	B-X
IL	B-X
-	B-X
12p35	B-X
and	B-X
three	B-X
types	B-X
of	B-X
IL	B-X
-	B-X
12p40	B-X
genes	B-X
in	B-X
amberjack	B-X
and	B-X
yellowtail	B-X
,	B-X
and	B-X
analyzed	B-X
their	B-X
expressions	B-X
in	B-X
response	B-X
to	B-X
stimulation	B-X
with	B-X
Nocardia	B-X
seriolae	B-X
in	B-X
amberjack	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
EBSS	B-X
and	B-X
rapamycin	B-X
on	B-X
the	B-X
maturation	B-X
of	B-X
DCs	B-X
infected	B-X
with	B-X
BCG	B-X
<EOS>	B-X
However	B-X
,	B-X
no	B-X
such	B-X
induction	B-X
in	B-X
IL	B-X
-	B-X
10	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
gene	B-X
expression	B-X
was	B-X
observed	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
if	B-X
chicken	B-X
melanoma	B-X
-	B-X
differentiation	B-X
-	B-X
associated	B-X
gene	B-X
5	B-X
(	B-X
MDA5	B-X
)	B-X
senses	B-X
infectious	B-X
bursal	B-X
disease	B-X
virus	B-X
infection	B-X
to	B-X
induce	B-X
innate	B-X
immunity	B-X
that	B-X
bridges	B-X
to	B-X
adaptive	B-X
immunity	B-X

The	O
inhibition	O
was	O
induced	O
by	O
interaction	O
with	O
macrophages	B-cell_type
that	O
had	O
contacted	O
with	O
P.	B-cell_type
berghei-infected	I-cell_type
erythrocytes	I-cell_type
and	O
was	O
mediated	O
by	O
a	O
soluble	O
factor	O
,	O
IL-10	B-protein
.	O

There	O
was	O
comparable	O
activation	O
of	O
NF-kappaB	B-protein
in	O
uninfected	B-cell_type
and	I-cell_type
infected	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Innate	B-X
immune	B-X
pathway	B-X
activation	B-X
was	B-X
interfered	B-X
by	B-X
injecting	B-X
S	B-X
layer	B-X
protein	B-X
-	B-X
deficient	B-X
(	B-X
∆slpA	B-X
)	B-X
B	B-X
<EOS>	B-X
Also	B-X
,	B-X
similar	B-X
levels	B-X
of	B-X
Casp	B-X
-	B-X
1	B-X
,	B-X
phosphorylated	B-X
NF	B-X
-	B-X
κB	B-X
(	B-X
p65	B-X
)	B-X
and	B-X
NLRP3	B-X
proteins	B-X
were	B-X
found	B-X
in	B-X
uninfected	B-X
and	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
macrophages	B-X
<EOS>	B-X
A	B-X
NanoString	B-X
murine	B-X
inflammation	B-X
panel	B-X
was	B-X
used	B-X
to	B-X
compare	B-X
gene	B-X
expression	B-X
in	B-X
WT	B-X
-	B-X
infected	B-X
,	B-X
WT+OxPAPC	B-X
,	B-X
∆slpA	B-X
-	B-X
infected	B-X
,	B-X
and	B-X
uninfected	B-X
eyes	B-X
<EOS>	B-X
Chlamydia	B-X
suis	B-X
is	B-X
associated	B-X
with	B-X
intestinal	B-X
NF	B-X
-	B-X
κB	B-X
activation	B-X
in	B-X
experimentally	B-X
infected	B-X
gnotobiotic	B-X
piglets	B-X
.	B-X

The	O
induction	O
of	O
IFN-regulatory	B-DNA
factor-1	I-DNA
gene	I-DNA
was	O
comparable	O
in	O
transcription	O
level	O
in	O
uninfected	B-cell_type
and	I-cell_type
infected	I-cell_type
cells	I-cell_type
,	O
while	O
the	O
unidentified	O
complex	O
formation	O
of	O
IFN-regulatory	B-protein
factor-1	I-protein
was	O
observed	O
in	O
infected	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
IFN	B-X
-	B-X
regulatory	B-X
factor	B-X
-	B-X
1	B-X
gene	B-X
was	B-X
comparable	B-X
in	B-X
transcription	B-X
level	B-X
in	B-X
uninfected	B-X
and	B-X
infected	B-X
cells	B-X
,	B-X
while	B-X
the	B-X
unidentified	B-X
complex	B-X
formation	B-X
of	B-X
IFN	B-X
-	B-X
regulatory	B-X
factor	B-X
-	B-X
1	B-X
was	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
induction	B-X
appeared	B-X
to	B-X
be	B-X
regulated	B-X
at	B-X
transcriptional	B-X
regulation	B-X
level	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
There	B-X
was	B-X
comparable	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
uninfected	B-X
and	B-X
infected	B-X
cells	B-X
<EOS>	B-X
The	B-X
inhibition	B-X
was	B-X
induced	B-X
by	B-X
interaction	B-X
with	B-X
macrophages	B-X
that	B-X
had	B-X
contacted	B-X
with	B-X
P	B-X

Therefore	O
,	O
the	O
inhibition	O
of	O
the	O
IL-12	B-DNA
p40	I-DNA
gene	I-DNA
induction	O
appeared	O
to	O
be	O
regulated	O
at	O
transcriptional	O
regulation	O
level	O
of	O
the	O
gene	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
induction	B-X
appeared	B-X
to	B-X
be	B-X
regulated	B-X
at	B-X
transcriptional	B-X
regulation	B-X
level	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
in	B-X
Plasmodium	B-X
berghei	B-X
-	B-X
infected	B-X
mice	B-X
.	B-X
<EOS>	B-X
The	B-X
inhibition	B-X
was	B-X
induced	B-X
by	B-X
interaction	B-X
with	B-X
macrophages	B-X
that	B-X
had	B-X
contacted	B-X
with	B-X
P	B-X
<EOS>	B-X
We	B-X
showed	B-X
in	B-X
the	B-X
present	B-X
study	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
gene	B-X
but	B-X
not	B-X
IL	B-X
-	B-X
12	B-X
p35	B-X
gene	B-X
in	B-X
macrophages	B-X
of	B-X
P	B-X

The	O
Friend	B-protein
of	I-protein
GATA	I-protein
proteins	I-protein
U-shaped	O
,	O
FOG-1	B-protein
,	O
and	O
FOG-2	B-protein
function	O
as	O
negative	O
regulators	O
of	O
blood	O
,	O
heart	O
,	O
and	O
eye	O
development	O
in	O
Drosophila	O
.	O
<EOS>	B-X
The	B-X
Friend	B-X
of	B-X
GATA	B-X
proteins	B-X
U	B-X
-	B-X
shaped	B-X
,	B-X
FOG	B-X
-	B-X
1	B-X
,	B-X
and	B-X
FOG	B-X
-	B-X
2	B-X
function	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
blood	B-X
,	B-X
heart	B-X
,	B-X
and	B-X
eye	B-X
development	B-X
in	B-X
Drosophila	B-X
.	B-X
<EOS>	B-X
The	B-X
GATA	B-X
factor	B-X
Pannier	B-X
(	B-X
Pnr	B-X
)	B-X
is	B-X
required	B-X
for	B-X
eye	B-X
and	B-X
heart	B-X
development	B-X
in	B-X
Drosophila	B-X
<EOS>	B-X
Friend	B-X
of	B-X
GATA	B-X
(	B-X
FOG	B-X
)	B-X
proteins	B-X
regulate	B-X
GATA	B-X
factor	B-X
-	B-X
activated	B-X
gene	B-X
transcription	B-X
<EOS>	B-X
The	B-X
Drosophila	B-X
FOG	B-X
homologue	B-X
U	B-X
-	B-X
shaped	B-X
(	B-X
Ush	B-X
)	B-X
is	B-X
expressed	B-X
similarly	B-X
in	B-X
the	B-X
blood	B-X
cell	B-X
anlage	B-X
during	B-X
embryogenesis	B-X

Friend	B-protein
of	I-protein
GATA	I-protein
(	I-protein
FOG	I-protein
)	I-protein
proteins	I-protein
regulate	O
GATA	O
factor-activated	O
gene	O
transcription	O
.	O
<EOS>	B-X
Friend	B-X
of	B-X
GATA	B-X
(	B-X
FOG	B-X
)	B-X
proteins	B-X
regulate	B-X
GATA	B-X
factor	B-X
-	B-X
activated	B-X
gene	B-X
transcription	B-X
<EOS>	B-X
The	B-X
Friend	B-X
of	B-X
GATA	B-X
proteins	B-X
U	B-X
-	B-X
shaped	B-X
,	B-X
FOG	B-X
-	B-X
1	B-X
,	B-X
and	B-X
FOG	B-X
-	B-X
2	B-X
function	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
blood	B-X
,	B-X
heart	B-X
,	B-X
and	B-X
eye	B-X
development	B-X
in	B-X
Drosophila	B-X
.	B-X
<EOS>	B-X
During	B-X
vertebrate	B-X
hematopoiesis	B-X
,	B-X
FOG	B-X
and	B-X
GATA	B-X
proteins	B-X
cooperate	B-X
to	B-X
promote	B-X
erythrocyte	B-X
and	B-X
megakaryocyte	B-X
differentiation	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
loss	B-X
of	B-X
ush	B-X
function	B-X
results	B-X
in	B-X
an	B-X
overproduction	B-X
of	B-X
crystal	B-X
cells	B-X
,	B-X
whereas	B-X
forced	B-X
expression	B-X
of	B-X
Ush	B-X
reduces	B-X
this	B-X
cell	B-X
population	B-X

During	O
vertebrate	O
hematopoiesis	O
,	O
FOG	B-protein
and	I-protein
GATA	I-protein
proteins	I-protein
cooperate	O
to	O
promote	O
erythrocyte	O
and	O
megakaryocyte	O
differentiation	O
.	O
<EOS>	B-X
During	B-X
vertebrate	B-X
hematopoiesis	B-X
,	B-X
FOG	B-X
and	B-X
GATA	B-X
proteins	B-X
cooperate	B-X
to	B-X
promote	B-X
erythrocyte	B-X
and	B-X
megakaryocyte	B-X
differentiation	B-X
<EOS>	B-X
In	B-X
cell	B-X
culture	B-X
,	B-X
FOG	B-X
cooperates	B-X
with	B-X
the	B-X
hematopoietic	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
1	B-X
to	B-X
promote	B-X
erythroid	B-X
and	B-X
megakaryocytic	B-X
differentiation	B-X
<EOS>	B-X
GATA	B-X
-	B-X
1	B-X
and	B-X
FOG	B-X
(	B-X
Friend	B-X
of	B-X
GATA	B-X
-	B-X
1	B-X
)	B-X
are	B-X
each	B-X
essential	B-X
for	B-X
erythroid	B-X
and	B-X
megakaryocyte	B-X
development	B-X
<EOS>	B-X
Thus	B-X
,	B-X
interaction	B-X
of	B-X
FOG	B-X
with	B-X
GATA	B-X
-	B-X
1	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
function	B-X
of	B-X
GATA	B-X
-	B-X
1	B-X
in	B-X
erythroid	B-X
differentiation	B-X

The	O
Drosophila	B-protein
FOG	I-protein
homologue	I-protein
U-shaped	I-protein
(	O
Ush	B-protein
)	O
is	O
expressed	O
similarly	O
in	O
the	O
blood	O
cell	O
anlage	O
during	O
embryogenesis	O
.	O
<EOS>	B-X
The	B-X
Drosophila	B-X
FOG	B-X
homologue	B-X
U	B-X
-	B-X
shaped	B-X
(	B-X
Ush	B-X
)	B-X
is	B-X
expressed	B-X
similarly	B-X
in	B-X
the	B-X
blood	B-X
cell	B-X
anlage	B-X
during	B-X
embryogenesis	B-X
<EOS>	B-X
The	B-X
Friend	B-X
of	B-X
GATA	B-X
proteins	B-X
U	B-X
-	B-X
shaped	B-X
,	B-X
FOG	B-X
-	B-X
1	B-X
,	B-X
and	B-X
FOG	B-X
-	B-X
2	B-X
function	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
blood	B-X
,	B-X
heart	B-X
,	B-X
and	B-X
eye	B-X
development	B-X
in	B-X
Drosophila	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
fly	B-X
and	B-X
mouse	B-X
FOG	B-X
proteins	B-X
function	B-X
similarly	B-X
in	B-X
three	B-X
distinct	B-X
cellular	B-X
contexts	B-X
in	B-X
Drosophila	B-X
,	B-X
but	B-X
may	B-X
use	B-X
different	B-X
mechanisms	B-X
to	B-X
regulate	B-X
genetic	B-X
events	B-X
in	B-X
blood	B-X
vs	B-X
<EOS>	B-X
The	B-X
GATA	B-X
factor	B-X
Pannier	B-X
(	B-X
Pnr	B-X
)	B-X
is	B-X
required	B-X
for	B-X
eye	B-X
and	B-X
heart	B-X
development	B-X
in	B-X
Drosophila	B-X

During	O
hematopoiesis	O
,	O
the	O
acute	O
myeloid	O
leukemia	O
1	O
homologue	O
Lozenge	B-cell_type
and	I-cell_type
Glial	I-cell_type
cells	I-cell_type
missing	O
are	O
required	O
for	O
the	O
production	O
of	O
crystal	B-cell_type
cells	I-cell_type
and	O
plasmatocytes	B-cell_type
,	O
respectively	O
.	O
<EOS>	B-X
During	B-X
hematopoiesis	B-X
,	B-X
the	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
1	B-X
homologue	B-X
Lozenge	B-X
and	B-X
Glial	B-X
cells	B-X
missing	B-X
are	B-X
required	B-X
for	B-X
the	B-X
production	B-X
of	B-X
crystal	B-X
cells	B-X
and	B-X
plasmatocytes	B-X
,	B-X
respectively	B-X
<EOS>	B-X
During	B-X
vertebrate	B-X
hematopoiesis	B-X
,	B-X
FOG	B-X
and	B-X
GATA	B-X
proteins	B-X
cooperate	B-X
to	B-X
promote	B-X
erythrocyte	B-X
and	B-X
megakaryocyte	B-X
differentiation	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
loss	B-X
of	B-X
ush	B-X
function	B-X
results	B-X
in	B-X
an	B-X
overproduction	B-X
of	B-X
crystal	B-X
cells	B-X
,	B-X
whereas	B-X
forced	B-X
expression	B-X
of	B-X
Ush	B-X
reduces	B-X
this	B-X
cell	B-X
population	B-X
<EOS>	B-X
The	B-X
Drosophila	B-X
FOG	B-X
homologue	B-X
U	B-X
-	B-X
shaped	B-X
(	B-X
Ush	B-X
)	B-X
is	B-X
expressed	B-X
similarly	B-X
in	B-X
the	B-X
blood	B-X
cell	B-X
anlage	B-X
during	B-X
embryogenesis	B-X

However	O
,	O
additional	O
factors	O
have	O
been	O
predicted	O
to	O
control	O
crystal	O
cell	O
proliferation	O
.	O
<EOS>	B-X
However	B-X
,	B-X
additional	B-X
factors	B-X
have	B-X
been	B-X
predicted	B-X
to	B-X
control	B-X
crystal	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
During	B-X
vertebrate	B-X
hematopoiesis	B-X
,	B-X
FOG	B-X
and	B-X
GATA	B-X
proteins	B-X
cooperate	B-X
to	B-X
promote	B-X
erythrocyte	B-X
and	B-X
megakaryocyte	B-X
differentiation	B-X
<EOS>	B-X
During	B-X
hematopoiesis	B-X
,	B-X
the	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
1	B-X
homologue	B-X
Lozenge	B-X
and	B-X
Glial	B-X
cells	B-X
missing	B-X
are	B-X
required	B-X
for	B-X
the	B-X
production	B-X
of	B-X
crystal	B-X
cells	B-X
and	B-X
plasmatocytes	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
loss	B-X
of	B-X
ush	B-X
function	B-X
results	B-X
in	B-X
an	B-X
overproduction	B-X
of	B-X
crystal	B-X
cells	B-X
,	B-X
whereas	B-X
forced	B-X
expression	B-X
of	B-X
Ush	B-X
reduces	B-X
this	B-X
cell	B-X
population	B-X

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Ush	B-protein
is	O
expressed	O
in	O
hemocyte	B-cell_type
precursors	I-cell_type
and	O
plasmatocytes	B-cell_type
throughout	O
embryogenesis	O
and	O
larval	O
development	O
,	O
and	O
the	O
GATA	B-protein
factor	I-protein
Serpent	I-protein
is	O
essential	O
for	O
Ush	B-protein
embryonic	O
expression	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Ush	B-X
is	B-X
expressed	B-X
in	B-X
hemocyte	B-X
precursors	B-X
and	B-X
plasmatocytes	B-X
throughout	B-X
embryogenesis	B-X
and	B-X
larval	B-X
development	B-X
,	B-X
and	B-X
the	B-X
GATA	B-X
factor	B-X
Serpent	B-X
is	B-X
essential	B-X
for	B-X
Ush	B-X
embryonic	B-X
expression	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
loss	B-X
of	B-X
ush	B-X
function	B-X
results	B-X
in	B-X
an	B-X
overproduction	B-X
of	B-X
crystal	B-X
cells	B-X
,	B-X
whereas	B-X
forced	B-X
expression	B-X
of	B-X
Ush	B-X
reduces	B-X
this	B-X
cell	B-X
population	B-X
<EOS>	B-X
The	B-X
Friend	B-X
of	B-X
GATA	B-X
proteins	B-X
U	B-X
-	B-X
shaped	B-X
,	B-X
FOG	B-X
-	B-X
1	B-X
,	B-X
and	B-X
FOG	B-X
-	B-X
2	B-X
function	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
blood	B-X
,	B-X
heart	B-X
,	B-X
and	B-X
eye	B-X
development	B-X
in	B-X
Drosophila	B-X
.	B-X
<EOS>	B-X
The	B-X
Drosophila	B-X
FOG	B-X
homologue	B-X
U	B-X
-	B-X
shaped	B-X
(	B-X
Ush	B-X
)	B-X
is	B-X
expressed	B-X
similarly	B-X
in	B-X
the	B-X
blood	B-X
cell	B-X
anlage	B-X
during	B-X
embryogenesis	B-X

Furthermore	O
,	O
loss	O
of	O
ush	O
function	O
results	O
in	O
an	O
overproduction	O
of	O
crystal	B-cell_type
cells	I-cell_type
,	O
whereas	O
forced	O
expression	O
of	O
Ush	B-protein
reduces	O
this	O
cell	O
population	O
.	O

Murine	B-protein
FOG-1	I-protein
and	I-protein
FOG-2	I-protein
also	O
can	O
repress	O
crystal	O
cell	O
production	O
,	O
but	O
a	O
mutant	O
version	O
of	O
FOG-2	B-protein
lacking	O
a	O
conserved	O
motif	O
that	O
binds	O
the	O
corepressor	B-protein
C-terminal	I-protein
binding	I-protein
protein	I-protein
fails	O
to	O
affect	O
the	O
cell	O
lineage	O
.	O
<EOS>	B-X
Murine	B-X
FOG	B-X
-	B-X
1	B-X
and	B-X
FOG	B-X
-	B-X
2	B-X
also	B-X
can	B-X
repress	B-X
crystal	B-X
cell	B-X
production	B-X
,	B-X
but	B-X
a	B-X
mutant	B-X
version	B-X
of	B-X
FOG	B-X
-	B-X
2	B-X
lacking	B-X
a	B-X
conserved	B-X
motif	B-X
that	B-X
binds	B-X
the	B-X
corepressor	B-X
C	B-X
-	B-X
terminal	B-X
binding	B-X
protein	B-X
fails	B-X
to	B-X
affect	B-X
the	B-X
cell	B-X
lineage	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
loss	B-X
of	B-X
ush	B-X
function	B-X
results	B-X
in	B-X
an	B-X
overproduction	B-X
of	B-X
crystal	B-X
cells	B-X
,	B-X
whereas	B-X
forced	B-X
expression	B-X
of	B-X
Ush	B-X
reduces	B-X
this	B-X
cell	B-X
population	B-X
<EOS>	B-X
The	B-X
Friend	B-X
of	B-X
GATA	B-X
proteins	B-X
U	B-X
-	B-X
shaped	B-X
,	B-X
FOG	B-X
-	B-X
1	B-X
,	B-X
and	B-X
FOG	B-X
-	B-X
2	B-X
function	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
blood	B-X
,	B-X
heart	B-X
,	B-X
and	B-X
eye	B-X
development	B-X
in	B-X
Drosophila	B-X
.	B-X
<EOS>	B-X
During	B-X
hematopoiesis	B-X
,	B-X
the	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
1	B-X
homologue	B-X
Lozenge	B-X
and	B-X
Glial	B-X
cells	B-X
missing	B-X
are	B-X
required	B-X
for	B-X
the	B-X
production	B-X
of	B-X
crystal	B-X
cells	B-X
and	B-X
plasmatocytes	B-X
,	B-X
respectively	B-X

The	O
GATA	B-protein
factor	I-protein
Pannier	I-protein
(	O
Pnr	B-protein
)	O
is	O
required	O
for	O
eye	O
and	O
heart	O
development	O
in	O
Drosophila	O
.	O
<EOS>	B-X
The	B-X
GATA	B-X
factor	B-X
Pannier	B-X
(	B-X
Pnr	B-X
)	B-X
is	B-X
required	B-X
for	B-X
eye	B-X
and	B-X
heart	B-X
development	B-X
in	B-X
Drosophila	B-X
<EOS>	B-X
The	B-X
Iroquois	B-X
complex	B-X
is	B-X
required	B-X
in	B-X
the	B-X
dorsal	B-X
mesoderm	B-X
to	B-X
ensure	B-X
normal	B-X
heart	B-X
development	B-X
in	B-X
Drosophila	B-X
.	B-X
<EOS>	B-X
The	B-X
Friend	B-X
of	B-X
GATA	B-X
proteins	B-X
U	B-X
-	B-X
shaped	B-X
,	B-X
FOG	B-X
-	B-X
1	B-X
,	B-X
and	B-X
FOG	B-X
-	B-X
2	B-X
function	B-X
as	B-X
negative	B-X
regulators	B-X
of	B-X
blood	B-X
,	B-X
heart	B-X
,	B-X
and	B-X
eye	B-X
development	B-X
in	B-X
Drosophila	B-X
.	B-X
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
the	B-X
whole	B-X
Iro	B-X
complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
loss	B-X
of	B-X
either	B-X
ara	B-X
/	B-X
caup	B-X
or	B-X
mirr	B-X
only	B-X
,	B-X
affect	B-X
heart	B-X
development	B-X
in	B-X
Drosophila	B-X

When	O
Ush	B-protein
,	O
FOG-1	B-protein
,	O
FOG-2	B-protein
,	O
or	O
mutant	B-protein
FOG-2	I-protein
is	O
coexpressed	O
with	O
Pnr	B-protein
during	O
these	O
developmental	O
processes	O
,	O
severe	O
eye	O
and	O
heart	O
phenotypes	O
result	O
,	O
consistent	O
with	O
a	O
conserved	O
negative	O
regulation	O
of	O
Pnr	B-protein
function	O
.	O
<EOS>	B-X
When	B-X
Ush	B-X
,	B-X
FOG	B-X
-	B-X
1	B-X
,	B-X
FOG	B-X
-	B-X
2	B-X
,	B-X
or	B-X
mutant	B-X
FOG	B-X
-	B-X
2	B-X
is	B-X
coexpressed	B-X
with	B-X
Pnr	B-X
during	B-X
these	B-X
developmental	B-X
processes	B-X
,	B-X
severe	B-X
eye	B-X
and	B-X
heart	B-X
phenotypes	B-X
result	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
conserved	B-X
negative	B-X
regulation	B-X
of	B-X
Pnr	B-X
function	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
loss	B-X
of	B-X
ush	B-X
function	B-X
results	B-X
in	B-X
an	B-X
overproduction	B-X
of	B-X
crystal	B-X
cells	B-X
,	B-X
whereas	B-X
forced	B-X
expression	B-X
of	B-X
Ush	B-X
reduces	B-X
this	B-X
cell	B-X
population	B-X
<EOS>	B-X
The	B-X
GATA	B-X
factor	B-X
Pannier	B-X
(	B-X
Pnr	B-X
)	B-X
is	B-X
required	B-X
for	B-X
eye	B-X
and	B-X
heart	B-X
development	B-X
in	B-X
Drosophila	B-X
<EOS>	B-X
The	B-X
Drosophila	B-X
FOG	B-X
homologue	B-X
U	B-X
-	B-X
shaped	B-X
(	B-X
Ush	B-X
)	B-X
is	B-X
expressed	B-X
similarly	B-X
in	B-X
the	B-X
blood	B-X
cell	B-X
anlage	B-X
during	B-X
embryogenesis	B-X

These	O
results	O
indicate	O
that	O
the	O
fly	O
and	O
mouse	O
FOG	B-protein
proteins	I-protein
function	O
similarly	O
in	O
three	O
distinct	O
cellular	O
contexts	O
in	O
Drosophila	O
,	O
but	O
may	O
use	O
different	O
mechanisms	O
to	O
regulate	O
genetic	O
events	O
in	O
blood	O
vs	O
.	O
cardial	B-cell_line
or	I-cell_line
eye	I-cell_line
cell	I-cell_line
lineages	I-cell_line
<EOS>	B-X
These	B-X
findings	B-X
indicated	B-X
that	B-X
A	B-X
/	B-X
G	B-X
substrate	B-X
induced	B-X
neural	B-X
retinal	B-X
cell	B-X
propagation	B-X
in	B-X
cultures	B-X
and	B-X
would	B-X
therefore	B-X
be	B-X
promising	B-X
for	B-X
RPE	B-X
-	B-X
based	B-X
tissue	B-X
engineering	B-X
studies	B-X
<EOS>	B-X
These	B-X
findings	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
persistent	B-X
changes	B-X
in	B-X
the	B-X
local	B-X
immune	B-X
population	B-X
that	B-X
occur	B-X
in	B-X
response	B-X
to	B-X
cell	B-X
loss	B-X
in	B-X
aging	B-X
and	B-X
progressive	B-X
retinal	B-X
diseases	B-X
may	B-X
include	B-X
the	B-X
establishment	B-X
of	B-X
subpopulations	B-X
of	B-X
bone	B-X
marrow	B-X
-	B-X
derived	B-X
cells	B-X
whose	B-X
ability	B-X
to	B-X
respond	B-X
to	B-X
subsequent	B-X
insults	B-X
wanes	B-X
over	B-X
time	B-X
<EOS>	B-X
The	B-X
tumor	B-X
microenvironment	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
deconvolution	B-X
analysis	B-X
,	B-X
was	B-X
mainly	B-X
composed	B-X
of	B-X
multiple	B-X
B	B-X
cell	B-X
subtypes	B-X
which	B-X
reflects	B-X
the	B-X
tumor	B-X
's	B-X
B	B-X
cell	B-X
lineage	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicated	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
NOTCH2	B-X
inhibition	B-X
in	B-X
lens	B-X
overgrowth	B-X
of	B-X
highly	B-X
myopic	B-X
eyes	B-X
,	B-X
suggesting	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
future	B-X
interventions	B-X

The	O
RING	B-protein
finger	I-protein
protein	I-protein
Siah-1	B-protein
regulates	O
the	O
level	O
of	O
the	O
transcriptional	B-protein
coactivator	I-protein
OBF-1	B-protein
.	O
<EOS>	B-X
The	B-X
RING	B-X
finger	B-X
protein	B-X
Siah	B-X
-	B-X
1	B-X
regulates	B-X
the	B-X
level	B-X
of	B-X
the	B-X
transcriptional	B-X
coactivator	B-X
OBF	B-X
-	B-X
1	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
identified	B-X
the	B-X
RING	B-X
finger	B-X
protein	B-X
Siah	B-X
-	B-X
1	B-X
as	B-X
a	B-X
protein	B-X
interacting	B-X
specifically	B-X
with	B-X
OBF	B-X
-	B-X
1	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
in	B-X
immunized	B-X
mice	B-X
,	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X
amounts	B-X
are	B-X
dramatically	B-X
increased	B-X
in	B-X
primary	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
without	B-X
concomitant	B-X
increase	B-X
in	B-X
OBF	B-X
-	B-X
1	B-X
mRNA	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Siah	B-X
-	B-X
1	B-X
is	B-X
part	B-X
of	B-X
a	B-X
novel	B-X
regulatory	B-X
loop	B-X
controlling	B-X
the	B-X
level	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X
in	B-X
B	B-X
cells	B-X

The	O
transcriptional	B-protein
coactivator	I-protein
OBF-1	B-protein
,	O
which	O
interacts	O
with	O
Oct-1	B-protein
and	O
Oct-2	B-protein
and	O
the	O
octamer	B-DNA
site	I-DNA
DNA	I-DNA
,	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
development	O
of	O
a	O
normal	O
immune	O
response	O
and	O
the	O
formation	O
of	O
germinal	O
centers	O
in	O
secondary	O
lymphoid	O
organs	O
.	O
<EOS>	B-X
The	B-X
transcriptional	B-X
coactivator	B-X
OBF	B-X
-	B-X
1	B-X
,	B-X
which	B-X
interacts	B-X
with	B-X
Oct	B-X
-	B-X
1	B-X
and	B-X
Oct	B-X
-	B-X
2	B-X
and	B-X
the	B-X
octamer	B-X
site	B-X
DNA	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
development	B-X
of	B-X
a	B-X
normal	B-X
immune	B-X
response	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
germinal	B-X
centers	B-X
in	B-X
secondary	B-X
lymphoid	B-X
organs	B-X
<EOS>	B-X
This	B-X
interaction	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
part	B-X
of	B-X
Siah	B-X
-	B-X
1	B-X
and	B-X
by	B-X
residues	B-X
in	B-X
the	B-X
N	B-X
-	B-X
terminus	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
,	B-X
partly	B-X
distinct	B-X
from	B-X
the	B-X
residues	B-X
required	B-X
for	B-X
formation	B-X
of	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
Oct	B-X
POU	B-X
domains	B-X
and	B-X
the	B-X
DNA	B-X
<EOS>	B-X
Interaction	B-X
between	B-X
Siah	B-X
-	B-X
1	B-X
and	B-X
OBF	B-X
-	B-X
1	B-X
leads	B-X
to	B-X
downregulation	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X
level	B-X
but	B-X
not	B-X
mRNA	B-X
,	B-X
and	B-X
to	B-X
a	B-X
corresponding	B-X
reduction	B-X
in	B-X
octamer	B-X
site	B-X
-	B-X
dependent	B-X
transcription	B-X
activation	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Siah	B-X
-	B-X
1	B-X
is	B-X
part	B-X
of	B-X
a	B-X
novel	B-X
regulatory	B-X
loop	B-X
controlling	B-X
the	B-X
level	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X
in	B-X
B	B-X
cells	B-X

Here	O
we	O
have	O
identified	O
the	O
RING	B-protein
finger	I-protein
protein	I-protein
Siah-1	B-protein
as	O
a	O
protein	O
interacting	O
specifically	O
with	O
OBF-1	B-protein
.	O
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
identified	B-X
the	B-X
RING	B-X
finger	B-X
protein	B-X
Siah	B-X
-	B-X
1	B-X
as	B-X
a	B-X
protein	B-X
interacting	B-X
specifically	B-X
with	B-X
OBF	B-X
-	B-X
1	B-X
<EOS>	B-X
The	B-X
RING	B-X
finger	B-X
protein	B-X
Siah	B-X
-	B-X
1	B-X
regulates	B-X
the	B-X
level	B-X
of	B-X
the	B-X
transcriptional	B-X
coactivator	B-X
OBF	B-X
-	B-X
1	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
in	B-X
immunized	B-X
mice	B-X
,	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X
amounts	B-X
are	B-X
dramatically	B-X
increased	B-X
in	B-X
primary	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
without	B-X
concomitant	B-X
increase	B-X
in	B-X
OBF	B-X
-	B-X
1	B-X
mRNA	B-X
<EOS>	B-X
This	B-X
interaction	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
part	B-X
of	B-X
Siah	B-X
-	B-X
1	B-X
and	B-X
by	B-X
residues	B-X
in	B-X
the	B-X
N	B-X
-	B-X
terminus	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
,	B-X
partly	B-X
distinct	B-X
from	B-X
the	B-X
residues	B-X
required	B-X
for	B-X
formation	B-X
of	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
Oct	B-X
POU	B-X
domains	B-X
and	B-X
the	B-X
DNA	B-X

This	O
interaction	O
is	O
mediated	O
by	O
the	O
C-terminal	B-protein
part	O
of	O
Siah-1	B-protein
and	O
by	O
residues	O
in	O
the	O
N-terminus	B-protein
of	O
OBF-1	B-protein
,	O
partly	O
distinct	O
from	O
the	O
residues	O
required	O
for	O
formation	O
of	O
a	O
complex	O
with	O
the	O
Oct	B-protein
POU	I-protein
domains	I-protein
and	O
the	O
DNA	O
.	O
<EOS>	B-X
This	B-X
interaction	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
part	B-X
of	B-X
Siah	B-X
-	B-X
1	B-X
and	B-X
by	B-X
residues	B-X
in	B-X
the	B-X
N	B-X
-	B-X
terminus	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
,	B-X
partly	B-X
distinct	B-X
from	B-X
the	B-X
residues	B-X
required	B-X
for	B-X
formation	B-X
of	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
Oct	B-X
POU	B-X
domains	B-X
and	B-X
the	B-X
DNA	B-X
<EOS>	B-X
Interaction	B-X
between	B-X
Siah	B-X
-	B-X
1	B-X
and	B-X
OBF	B-X
-	B-X
1	B-X
leads	B-X
to	B-X
downregulation	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X
level	B-X
but	B-X
not	B-X
mRNA	B-X
,	B-X
and	B-X
to	B-X
a	B-X
corresponding	B-X
reduction	B-X
in	B-X
octamer	B-X
site	B-X
-	B-X
dependent	B-X
transcription	B-X
activation	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
coactivator	B-X
OBF	B-X
-	B-X
1	B-X
,	B-X
which	B-X
interacts	B-X
with	B-X
Oct	B-X
-	B-X
1	B-X
and	B-X
Oct	B-X
-	B-X
2	B-X
and	B-X
the	B-X
octamer	B-X
site	B-X
DNA	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
development	B-X
of	B-X
a	B-X
normal	B-X
immune	B-X
response	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
germinal	B-X
centers	B-X
in	B-X
secondary	B-X
lymphoid	B-X
organs	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Siah	B-X
-	B-X
1	B-X
is	B-X
part	B-X
of	B-X
a	B-X
novel	B-X
regulatory	B-X
loop	B-X
controlling	B-X
the	B-X
level	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X
in	B-X
B	B-X
cells	B-X

Interaction	O
between	O
Siah-1	B-protein
and	O
OBF-1	B-protein
leads	O
to	O
downregulation	O
of	O
OBF-1	O
protein	O
level	O
but	O
not	O
mRNA	O
,	O
and	O
to	O
a	O
corresponding	O
reduction	O
in	O
octamer	O
site-dependent	O
transcription	O
activation	O
.	O

Inhibition	O
of	O
the	O
ubiquitin-proteasome	O
pathway	O
in	O
B	B-cell_type
cells	I-cell_type
leads	O
to	O
elevated	O
levels	O
of	O
OBF-1	B-protein
protein	I-protein
.	O

Furthermore	O
,	O
in	O
immunized	O
mice	O
,	O
OBF-1	B-protein
protein	I-protein
amounts	O
are	O
dramatically	O
increased	O
in	O
primary	B-cell_type
activated	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
without	O
concomitant	O
increase	O
in	O
OBF-1	B-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
in	B-X
immunized	B-X
mice	B-X
,	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X
amounts	B-X
are	B-X
dramatically	B-X
increased	B-X
in	B-X
primary	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
without	B-X
concomitant	B-X
increase	B-X
in	B-X
OBF	B-X
-	B-X
1	B-X
mRNA	B-X
<EOS>	B-X
The	B-X
RING	B-X
finger	B-X
protein	B-X
Siah	B-X
-	B-X
1	B-X
regulates	B-X
the	B-X
level	B-X
of	B-X
the	B-X
transcriptional	B-X
coactivator	B-X
OBF	B-X
-	B-X
1	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
have	B-X
identified	B-X
the	B-X
RING	B-X
finger	B-X
protein	B-X
Siah	B-X
-	B-X
1	B-X
as	B-X
a	B-X
protein	B-X
interacting	B-X
specifically	B-X
with	B-X
OBF	B-X
-	B-X
1	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
the	B-X
ubiquitin	B-X
-	B-X
proteasome	B-X
pathway	B-X
in	B-X
B	B-X
cells	B-X
leads	B-X
to	B-X
elevated	B-X
levels	B-X
of	B-X
OBF	B-X
-	B-X
1	B-X
protein	B-X

These	O
data	O
suggest	O
that	O
Siah-1	B-protein
is	O
part	O
of	O
a	O
novel	O
regulatory	O
loop	O
controlling	O
the	O
level	O
of	O
OBF-1	B-protein
protein	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
beta-catenin	O
--	O
TCF-1	O
pathway	O
ensures	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocyte	I-cell_type
survival	O
.	O
<EOS>	B-X
The	B-X
beta	B-X
-	B-X
catenin	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
TCF	B-X
-	B-X
1	B-X
pathway	B-X
ensures	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocyte	B-X
survival	B-X
.	B-X
<EOS>	B-X
Increasing	B-X
anti	B-X
-	B-X
apoptotic	B-X
effectors	B-X
in	B-X
thymocytes	B-X
by	B-X
the	B-X
use	B-X
of	B-X
a	B-X
Bcl	B-X
-	B-X
2	B-X
transgene	B-X
rescued	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
deficient	B-X
DP	B-X
thymocytes	B-X
from	B-X
apoptosis	B-X
<EOS>	B-X
Accelerated	B-X
spontaneous	B-X
thymocyte	B-X
death	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
correlates	B-X
with	B-X
aberrantly	B-X
low	B-X
expression	B-X
of	B-X
the	B-X
anti	B-X
-	B-X
apoptotic	B-X
protein	B-X
Bcl	B-X
-	B-X
x	B-X
(	B-X
L	B-X
)	B-X
<EOS>	B-X
This	B-X
domain	B-X
is	B-X
necessary	B-X
to	B-X
mediate	B-X
the	B-X
survival	B-X
of	B-X
immature	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
double	B-X
-	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X

The	O
association	O
of	O
trans-acting	B-protein
T	I-protein
cell	I-protein
factors	I-protein
(	O
TCFs	B-protein
)	O
or	O
lymphoid	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
(	O
LEF-1	B-protein
)	O
with	O
their	O
coactivator	O
beta-catenin	O
mediates	O
transient	O
transcriptional	O
responses	O
to	O
extracellular	O
Wnt	O
signals	O
.	O
<EOS>	B-X
The	B-X
association	B-X
of	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factors	B-X
(	B-X
TCFs	B-X
)	B-X
or	B-X
lymphoid	B-X
enhancer	B-X
factor	B-X
1	B-X
(	B-X
LEF	B-X
-	B-X
1	B-X
)	B-X
with	B-X
their	B-X
coactivator	B-X
beta	B-X
-	B-X
catenin	B-X
mediates	B-X
transient	B-X
transcriptional	B-X
responses	B-X
to	B-X
extracellular	B-X
Wnt	B-X
signals	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
T	B-X
cell	B-X
maturation	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
beta	B-X
-	B-X
catenin	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
binding	B-X
domain	B-X
in	B-X
TCF	B-X
-	B-X
1	B-X
<EOS>	B-X
Increasing	B-X
anti	B-X
-	B-X
apoptotic	B-X
effectors	B-X
in	B-X
thymocytes	B-X
by	B-X
the	B-X
use	B-X
of	B-X
a	B-X
Bcl	B-X
-	B-X
2	B-X
transgene	B-X
rescued	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
deficient	B-X
DP	B-X
thymocytes	B-X
from	B-X
apoptosis	B-X
<EOS>	B-X
Accelerated	B-X
spontaneous	B-X
thymocyte	B-X
death	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
correlates	B-X
with	B-X
aberrantly	B-X
low	B-X
expression	B-X
of	B-X
the	B-X
anti	B-X
-	B-X
apoptotic	B-X
protein	B-X
Bcl	B-X
-	B-X
x	B-X
(	B-X
L	B-X
)	B-X

We	O
show	O
here	O
that	O
T	O
cell	O
maturation	O
depends	O
on	O
the	O
presence	O
of	O
the	O
beta-catenin	B-protein
--	I-protein
binding	I-protein
domain	I-protein
in	O
TCF-1	B-protein
.	O

This	O
domain	O
is	O
necessary	O
to	O
mediate	O
the	O
survival	O
of	O
immature	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
double-positive	I-cell_type
(	I-cell_type
DP	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
.	O
<EOS>	B-X
This	B-X
domain	B-X
is	B-X
necessary	B-X
to	B-X
mediate	B-X
the	B-X
survival	B-X
of	B-X
immature	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
double	B-X
-	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X
<EOS>	B-X
Thus	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
,	B-X
upon	B-X
association	B-X
with	B-X
beta	B-X
-	B-X
catenin	B-X
,	B-X
transiently	B-X
ensures	B-X
the	B-X
survival	B-X
of	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
enables	B-X
them	B-X
to	B-X
generate	B-X
and	B-X
edit	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
alpha	B-X
chains	B-X
and	B-X
attempt	B-X
TCR	B-X
-	B-X
mediated	B-X
positive	B-X
selection	B-X
<EOS>	B-X
The	B-X
beta	B-X
-	B-X
catenin	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
TCF	B-X
-	B-X
1	B-X
pathway	B-X
ensures	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocyte	B-X
survival	B-X
.	B-X
<EOS>	B-X
Increasing	B-X
anti	B-X
-	B-X
apoptotic	B-X
effectors	B-X
in	B-X
thymocytes	B-X
by	B-X
the	B-X
use	B-X
of	B-X
a	B-X
Bcl	B-X
-	B-X
2	B-X
transgene	B-X
rescued	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
deficient	B-X
DP	B-X
thymocytes	B-X
from	B-X
apoptosis	B-X

Accelerated	O
spontaneous	O
thymocyte	O
death	O
in	O
the	O
absence	O
of	O
TCF-1	B-protein
correlates	O
with	O
aberrantly	O
low	O
expression	O
of	O
the	O
anti-apoptotic	B-protein
protein	I-protein
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
.	O
<EOS>	B-X
Accelerated	B-X
spontaneous	B-X
thymocyte	B-X
death	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
correlates	B-X
with	B-X
aberrantly	B-X
low	B-X
expression	B-X
of	B-X
the	B-X
anti	B-X
-	B-X
apoptotic	B-X
protein	B-X
Bcl	B-X
-	B-X
x	B-X
(	B-X
L	B-X
)	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
T	B-X
cell	B-X
maturation	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
beta	B-X
-	B-X
catenin	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
binding	B-X
domain	B-X
in	B-X
TCF	B-X
-	B-X
1	B-X
<EOS>	B-X
Thus	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
,	B-X
upon	B-X
association	B-X
with	B-X
beta	B-X
-	B-X
catenin	B-X
,	B-X
transiently	B-X
ensures	B-X
the	B-X
survival	B-X
of	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
enables	B-X
them	B-X
to	B-X
generate	B-X
and	B-X
edit	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
alpha	B-X
chains	B-X
and	B-X
attempt	B-X
TCR	B-X
-	B-X
mediated	B-X
positive	B-X
selection	B-X
<EOS>	B-X
The	B-X
association	B-X
of	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factors	B-X
(	B-X
TCFs	B-X
)	B-X
or	B-X
lymphoid	B-X
enhancer	B-X
factor	B-X
1	B-X
(	B-X
LEF	B-X
-	B-X
1	B-X
)	B-X
with	B-X
their	B-X
coactivator	B-X
beta	B-X
-	B-X
catenin	B-X
mediates	B-X
transient	B-X
transcriptional	B-X
responses	B-X
to	B-X
extracellular	B-X
Wnt	B-X
signals	B-X

Increasing	O
anti-apoptotic	O
effectors	O
in	O
thymocytes	B-cell_type
by	O
the	O
use	O
of	O
a	O
Bcl-2	B-DNA
transgene	I-DNA
rescued	O
TCF-1-deficient	B-cell_type
DP	I-cell_type
thymocytes	I-cell_type
from	O
apoptosis	O
.	O
<EOS>	B-X
Increasing	B-X
anti	B-X
-	B-X
apoptotic	B-X
effectors	B-X
in	B-X
thymocytes	B-X
by	B-X
the	B-X
use	B-X
of	B-X
a	B-X
Bcl	B-X
-	B-X
2	B-X
transgene	B-X
rescued	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
deficient	B-X
DP	B-X
thymocytes	B-X
from	B-X
apoptosis	B-X
<EOS>	B-X
This	B-X
domain	B-X
is	B-X
necessary	B-X
to	B-X
mediate	B-X
the	B-X
survival	B-X
of	B-X
immature	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
double	B-X
-	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X
<EOS>	B-X
Thus	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
,	B-X
upon	B-X
association	B-X
with	B-X
beta	B-X
-	B-X
catenin	B-X
,	B-X
transiently	B-X
ensures	B-X
the	B-X
survival	B-X
of	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
enables	B-X
them	B-X
to	B-X
generate	B-X
and	B-X
edit	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
alpha	B-X
chains	B-X
and	B-X
attempt	B-X
TCR	B-X
-	B-X
mediated	B-X
positive	B-X
selection	B-X
<EOS>	B-X
The	B-X
association	B-X
of	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factors	B-X
(	B-X
TCFs	B-X
)	B-X
or	B-X
lymphoid	B-X
enhancer	B-X
factor	B-X
1	B-X
(	B-X
LEF	B-X
-	B-X
1	B-X
)	B-X
with	B-X
their	B-X
coactivator	B-X
beta	B-X
-	B-X
catenin	B-X
mediates	B-X
transient	B-X
transcriptional	B-X
responses	B-X
to	B-X
extracellular	B-X
Wnt	B-X
signals	B-X

Thus	O
,	O
TCF-1	B-protein
,	O
upon	O
association	O
with	O
beta-catenin	O
,	O
transiently	O
ensures	O
the	O
survival	O
of	O
immature	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
which	O
enables	O
them	O
to	O
generate	O
and	O
edit	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
alpha	I-protein
chains	I-protein
and	O
attempt	O
TCR	B-protein
-mediated	O
positive	O
selection	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
,	B-X
upon	B-X
association	B-X
with	B-X
beta	B-X
-	B-X
catenin	B-X
,	B-X
transiently	B-X
ensures	B-X
the	B-X
survival	B-X
of	B-X
immature	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
enables	B-X
them	B-X
to	B-X
generate	B-X
and	B-X
edit	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
alpha	B-X
chains	B-X
and	B-X
attempt	B-X
TCR	B-X
-	B-X
mediated	B-X
positive	B-X
selection	B-X
<EOS>	B-X
This	B-X
domain	B-X
is	B-X
necessary	B-X
to	B-X
mediate	B-X
the	B-X
survival	B-X
of	B-X
immature	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
double	B-X
-	B-X
positive	B-X
(	B-X
DP	B-X
)	B-X
thymocytes	B-X
<EOS>	B-X
Accelerated	B-X
spontaneous	B-X
thymocyte	B-X
death	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
correlates	B-X
with	B-X
aberrantly	B-X
low	B-X
expression	B-X
of	B-X
the	B-X
anti	B-X
-	B-X
apoptotic	B-X
protein	B-X
Bcl	B-X
-	B-X
x	B-X
(	B-X
L	B-X
)	B-X
<EOS>	B-X
Increasing	B-X
anti	B-X
-	B-X
apoptotic	B-X
effectors	B-X
in	B-X
thymocytes	B-X
by	B-X
the	B-X
use	B-X
of	B-X
a	B-X
Bcl	B-X
-	B-X
2	B-X
transgene	B-X
rescued	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
deficient	B-X
DP	B-X
thymocytes	B-X
from	B-X
apoptosis	B-X

TRAIL/Apo2L	B-protein
ligand	I-protein
selectively	O
induces	O
apoptosis	O
and	O
overcomes	O
drug	O
resistance	O
in	O
multiple	O
myeloma	O
:	O
therapeutic	O
applications	O
.	O
<EOS>	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
ligand	B-X
selectively	B-X
induces	B-X
apoptosis	B-X
and	B-X
overcomes	B-X
drug	B-X
resistance	B-X
in	B-X
multiple	B-X
myeloma	B-X
:	B-X
therapeutic	B-X
applications	B-X
.	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
selectively	B-X
induced	B-X
apoptosis	B-X
of	B-X
patient	B-X
MM	B-X
tumour	B-X
cells	B-X
while	B-X
sparing	B-X
non	B-X
-	B-X
malignant	B-X
bone	B-X
marrow	B-X
and	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
<EOS>	B-X
Concepts	B-X
in	B-X
the	B-X
use	B-X
of	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
:	B-X
an	B-X
emerging	B-X
biotherapy	B-X
for	B-X
myeloma	B-X
and	B-X
other	B-X
neoplasias	B-X
.	B-X
<EOS>	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
potently	B-X
induced	B-X
apoptosis	B-X
of	B-X
MM	B-X
cells	B-X
from	B-X
patients	B-X
and	B-X
the	B-X
majority	B-X
of	B-X
MM	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
cells	B-X
sensitive	B-X
or	B-X
resistant	B-X
to	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
,	B-X
doxorubicin	B-X
(	B-X
Dox	B-X
)	B-X
,	B-X
melphalan	B-X
,	B-X
and	B-X
mitoxantrone	B-X

Multiple	O
myeloma	O
(	O
MM	O
)	O
remains	O
incurable	O
and	O
novel	O
treatments	O
are	O
urgently	O
needed	O
.	O
<EOS>	B-X
Multiple	B-X
myeloma	B-X
(	B-X
MM	B-X
)	B-X
remains	B-X
incurable	B-X
and	B-X
novel	B-X
treatments	B-X
are	B-X
urgently	B-X
needed	B-X
<EOS>	B-X
Multiple	B-X
myeloma	B-X
(	B-X
MM	B-X
)	B-X
remains	B-X
an	B-X
incurable	B-X
disease	B-X
and	B-X
novel	B-X
therapeutic	B-X
agents	B-X
/	B-X
approaches	B-X
are	B-X
urgently	B-X
needed	B-X
<EOS>	B-X
Multiple	B-X
myeloma	B-X
(	B-X
MM	B-X
)	B-X
remains	B-X
incurable	B-X
with	B-X
current	B-X
therapies	B-X
,	B-X
and	B-X
novel	B-X
biologically	B-X
based	B-X
therapies	B-X
are	B-X
urgently	B-X
needed	B-X
<EOS>	B-X
However	B-X
,	B-X
this	B-X
plasma	B-X
cell	B-X
malignancy	B-X
remains	B-X
incurable	B-X
,	B-X
and	B-X
novel	B-X
therapies	B-X
are	B-X
therefore	B-X
urgently	B-X
needed	B-X

Preclinical	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluations	O
were	O
performed	O
to	O
assess	O
the	O
potential	O
therapeutic	O
applications	O
of	O
human	O
recombinant	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-related	I-protein
apoptosis-inducing	I-protein
ligand/Apo2	I-protein
ligand	I-protein
(	O
TRAIL/Apo2L	B-protein
)	O
in	O
MM	O
.	O

TRAIL/Apo2L	B-protein
potently	O
induced	O
apoptosis	O
of	O
MM	B-cell_type
cells	I-cell_type
from	O
patients	O
and	O
the	O
majority	O
of	O
MM	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
including	O
cells	O
sensitive	O
or	O
resistant	O
to	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
doxorubicin	O
(	O
Dox	O
)	O
,	O
melphalan	O
,	O
and	O
mitoxantrone	O
.	O
<EOS>	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
potently	B-X
induced	B-X
apoptosis	B-X
of	B-X
MM	B-X
cells	B-X
from	B-X
patients	B-X
and	B-X
the	B-X
majority	B-X
of	B-X
MM	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
cells	B-X
sensitive	B-X
or	B-X
resistant	B-X
to	B-X
dexamethasone	B-X
(	B-X
Dex	B-X
)	B-X
,	B-X
doxorubicin	B-X
(	B-X
Dox	B-X
)	B-X
,	B-X
melphalan	B-X
,	B-X
and	B-X
mitoxantrone	B-X
<EOS>	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
ligand	B-X
selectively	B-X
induces	B-X
apoptosis	B-X
and	B-X
overcomes	B-X
drug	B-X
resistance	B-X
in	B-X
multiple	B-X
myeloma	B-X
:	B-X
therapeutic	B-X
applications	B-X
.	B-X
<EOS>	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
also	B-X
overcame	B-X
the	B-X
survival	B-X
effect	B-X
of	B-X
interleukin	B-X
6	B-X
on	B-X
MM	B-X
cells	B-X
and	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
survival	B-X
of	B-X
peripheral	B-X
blood	B-X
and	B-X
bone	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
and	B-X
purified	B-X
B	B-X
cells	B-X
from	B-X
healthy	B-X
donors	B-X
<EOS>	B-X
Importantly	B-X
,	B-X
normal	B-X
B	B-X
lymphocytes	B-X
were	B-X
not	B-X
sensitized	B-X
to	B-X
TRAIL	B-X
by	B-X
either	B-X
Dox	B-X
,	B-X
SN50	B-X
,	B-X
or	B-X
PS	B-X
-	B-X
341	B-X

TRAIL/Apo2L	B-protein
also	O
overcame	O
the	O
survival	O
effect	O
of	O
interleukin	B-protein
6	I-protein
on	O
MM	B-cell_type
cells	I-cell_type
and	O
did	O
not	O
affect	O
the	O
survival	O
of	O
peripheral	B-cell_type
blood	I-cell_type
and	I-cell_type
bone	I-cell_type
marrow	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
purified	B-cell_type
B	I-cell_type
cells	I-cell_type
from	O
healthy	O
donors	O
.	O

The	O
status	O
of	O
the	O
TRAIL	B-protein
receptors	I-protein
(	O
assessed	O
by	O
immunoblotting	O
and	O
flow	O
cytometry	O
)	O
could	O
not	O
predict	O
TRAIL	O
sensitivity	O
of	O
MM	B-cell_type
cells	I-cell_type
.	O

The	O
anti-MM	O
activity	O
of	O
TRAIL/Apo2L	B-protein
was	O
confirmed	O
in	O
nu/xid/bg	O
mice	O
xenografted	O
with	O
human	B-cell_type
MM	I-cell_type
cells	I-cell_type
;	O
TRAIL	B-protein
(	O
500	O
microg	O
intraperitoneally	O
daily	O
for	O
14	O
days	O
)	O
was	O
well	O
tolerated	O
and	O
significantly	O
suppressed	O
the	O
growth	O
of	O
plasmacytomas	B-cell_type
.	O
<EOS>	B-X
The	B-X
anti	B-X
-	B-X
MM	B-X
activity	B-X
of	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
was	B-X
confirmed	B-X
in	B-X
nu	B-X
/	B-X
xid	B-X
/	B-X
bg	B-X
mice	B-X
xenografted	B-X
with	B-X
human	B-X
MM	B-X
cells	B-X
;	B-X
TRAIL	B-X
(	B-X
500	B-X
microg	B-X
intraperitoneally	B-X
daily	B-X
for	B-X
14	B-X
days	B-X
)	B-X
was	B-X
well	B-X
tolerated	B-X
and	B-X
significantly	B-X
suppressed	B-X
the	B-X
growth	B-X
of	B-X
plasmacytomas	B-X
<EOS>	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
also	B-X
overcame	B-X
the	B-X
survival	B-X
effect	B-X
of	B-X
interleukin	B-X
6	B-X
on	B-X
MM	B-X
cells	B-X
and	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
survival	B-X
of	B-X
peripheral	B-X
blood	B-X
and	B-X
bone	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
and	B-X
purified	B-X
B	B-X
cells	B-X
from	B-X
healthy	B-X
donors	B-X
<EOS>	B-X
These	B-X
preclinical	B-X
studies	B-X
suggest	B-X
that	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
can	B-X
overcome	B-X
conventional	B-X
drug	B-X
resistance	B-X
and	B-X
provide	B-X
the	B-X
basis	B-X
for	B-X
clinical	B-X
trials	B-X
of	B-X
TRAIL	B-X
-	B-X
based	B-X
treatment	B-X
regimens	B-X
to	B-X
improve	B-X
outcome	B-X
in	B-X
patients	B-X
with	B-X
MM	B-X
<EOS>	B-X
The	B-X
status	B-X
of	B-X
the	B-X
TRAIL	B-X
receptors	B-X
(	B-X
assessed	B-X
by	B-X
immunoblotting	B-X
and	B-X
flow	B-X
cytometry	B-X
)	B-X
could	B-X
not	B-X
predict	B-X
TRAIL	B-X
sensitivity	B-X
of	B-X
MM	B-X
cells	B-X

Dox	O
up-regulated	O
the	O
expression	O
of	O
the	O
TRAIL	B-protein
receptor	I-protein
death	B-protein
receptor	I-protein
5	I-protein
(	O
DR5	B-protein
)	O
and	O
synergistically	O
enhanced	O
the	O
effect	O
of	O
TRAIL	B-protein
not	O
only	O
against	O
MM	B-cell_type
cells	I-cell_type
sensitive	O
to	O
,	O
but	O
also	O
against	O
those	O
resistant	O
to	O
,	O
Dex-	O
or	O
Dox-induced	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
SGK1	B-X
was	B-X
evaluated	B-X
in	B-X
blood	B-X
samples	B-X
of	B-X
heart	B-X
failure	B-X
children	B-X
,	B-X
and	B-X
in	B-X
myocardial	B-X
tissues	B-X
and	B-X
blood	B-X
samples	B-X
of	B-X
Dox	B-X
-	B-X
induced	B-X
rats	B-X
<EOS>	B-X
NSUN2	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
Nrf2	B-X
by	B-X
promoting	B-X
Nrf2	B-X
mRNA	B-X
m5C	B-X
modification	B-X
and	B-X
enhances	B-X
its	B-X
antioxidative	B-X
stress	B-X
effect	B-X
to	B-X
alleviate	B-X
DOX	B-X
-	B-X
induced	B-X
myocardial	B-X
injury	B-X
<EOS>	B-X
Also	B-X
,	B-X
DOX	B-X
remarkably	B-X
increased	B-X
the	B-X
expression	B-X
of	B-X
dynamin	B-X
1	B-X
like	B-X
(	B-X
DRP1	B-X
)	B-X
and	B-X
decreased	B-X
the	B-X
expression	B-X
of	B-X
mitofusin	B-X
1	B-X
(	B-X
MFN1	B-X
)	B-X
and	B-X
mitofusin	B-X
2	B-X
(	B-X
MFN2	B-X
)	B-X
genes	B-X
,	B-X
which	B-X
are	B-X
related	B-X
to	B-X
mitochondrial	B-X
dynamics	B-X
<EOS>	B-X
The	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
evaluate	B-X
the	B-X
therapeutic	B-X
potential	B-X
of	B-X
Pleurotus	B-X
eryngii	B-X
extract	B-X
(	B-X
PEE	B-X
)	B-X
,	B-X
an	B-X
extract	B-X
of	B-X
a	B-X
fungus	B-X
with	B-X
antioxidant	B-X
properties	B-X
,	B-X
against	B-X
DOX	B-X
-	B-X
induced	B-X
lung	B-X
damage	B-X

Nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
inhibitors	O
,	O
such	O
as	O
SN50	O
(	O
a	O
cell-permeable	O
inhibitor	O
of	O
the	O
nuclear	O
translocation	O
and	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-protein
)	O
or	O
the	O
proteasome	O
inhibitor	O
PS-341	O
,	O
enhanced	O
the	O
proapoptotic	O
activity	O
of	O
TRAIL/Apo2L	B-protein
against	O
TRAIL-sensitive	B-cell_type
MM	I-cell_type
cells	I-cell_type
,	O
whereas	O
SN50	O
reversed	O
the	O
TRAIL	O
resistance	O
of	O
ARH-77	B-cell_type
and	I-cell_type
IM-9	I-cell_type
MM	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
SN50	B-X
(	B-X
a	B-X
cell	B-X
-	B-X
permeable	B-X
inhibitor	B-X
of	B-X
the	B-X
nuclear	B-X
translocation	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
or	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
PS	B-X
-	B-X
341	B-X
,	B-X
enhanced	B-X
the	B-X
proapoptotic	B-X
activity	B-X
of	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
against	B-X
TRAIL	B-X
-	B-X
sensitive	B-X
MM	B-X
cells	B-X
,	B-X
whereas	B-X
SN50	B-X
reversed	B-X
the	B-X
TRAIL	B-X
resistance	B-X
of	B-X
ARH	B-X
-	B-X
77	B-X
and	B-X
IM	B-X
-	B-X
9	B-X
MM	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
SN	B-X
-	B-X
50	B-X
,	B-X
a	B-X
cell	B-X
-	B-X
permeable	B-X
peptide	B-X
capable	B-X
of	B-X
inhibiting	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
complexes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
ammonium	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
exhibited	B-X
a	B-X
similar	B-X
profile	B-X
of	B-X
activity	B-X
of	B-X
decoy	B-X
ODN	B-X
<EOS>	B-X
Our	B-X
study	B-X
implies	B-X
that	B-X
reversible	B-X
inhibitors	B-X
of	B-X
stress	B-X
-	B-X
responsive	B-X
transcription	B-X
factors	B-X
like	B-X
NF	B-X
-	B-X
kappaB	B-X
might	B-X
be	B-X
clinically	B-X
useful	B-X
for	B-X
the	B-X
suppression	B-X
of	B-X
the	B-X
severity	B-X
of	B-X
acute	B-X
pancreatitis	B-X
<EOS>	B-X
Dox	B-X
up	B-X
-	B-X
regulated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
TRAIL	B-X
receptor	B-X
death	B-X
receptor	B-X
5	B-X
(	B-X
DR5	B-X
)	B-X
and	B-X
synergistically	B-X
enhanced	B-X
the	B-X
effect	B-X
of	B-X
TRAIL	B-X
not	B-X
only	B-X
against	B-X
MM	B-X
cells	B-X
sensitive	B-X
to	B-X
,	B-X
but	B-X
also	B-X
against	B-X
those	B-X
resistant	B-X
to	B-X
,	B-X
Dex	B-X
-	B-X
	B-X
or	B-X
Dox	B-X
-	B-X
induced	B-X
apoptosis	B-X

Importantly	O
,	O
normal	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
were	O
not	O
sensitized	O
to	O
TRAIL	B-protein
by	O
either	O
Dox	O
,	O
SN50	O
,	O
or	O
PS-341	O
.	O
<EOS>	B-X
Importantly	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
the	B-X
RNA	B-X
expression	B-X
levels	B-X
of	B-X
several	B-X
players	B-X
in	B-X
pyruvate	B-X
metabolism	B-X
were	B-X
altered	B-X
in	B-X
advanced	B-X
stages	B-X
of	B-X
MM	B-X
wherein	B-X
they	B-X
correlated	B-X
with	B-X
poor	B-X
prognosis	B-X
for	B-X
MM	B-X
patients	B-X
<EOS>	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
bortezomib	B-X
has	B-X
been	B-X
used	B-X
to	B-X
treat	B-X
patients	B-X
with	B-X
refractory	B-X
TTP	B-X
<EOS>	B-X
CCK	B-X
-	B-X
8	B-X
assay	B-X
and	B-X
flow	B-X
cytometry	B-X
assay	B-X
were	B-X
conducted	B-X
to	B-X
analyze	B-X
the	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
of	B-X
T	B-X
-	B-X
ALL	B-X
cells	B-X
<EOS>	B-X
Upregulation	B-X
of	B-X
CD80	B-X
may	B-X
interact	B-X
with	B-X
cytotoxic	B-X
T	B-X
lymphocyte	B-X
antigen	B-X
4	B-X
(	B-X
CTLA4	B-X
)	B-X
to	B-X
promote	B-X
tumor	B-X
progression	B-X
and	B-X
provide	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
biological	B-X
antitumor	B-X
therapy	B-X

These	O
preclinical	O
studies	O
suggest	O
that	O
TRAIL/Apo2L	B-protein
can	O
overcome	O
conventional	O
drug	O
resistance	O
and	O
provide	O
the	O
basis	O
for	O
clinical	O
trials	O
of	O
TRAIL	B-protein
-based	O
treatment	O
regimens	O
to	O
improve	O
outcome	O
in	O
patients	O
with	O
MM	O
.	O
<EOS>	B-X
These	B-X
preclinical	B-X
studies	B-X
suggest	B-X
that	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
can	B-X
overcome	B-X
conventional	B-X
drug	B-X
resistance	B-X
and	B-X
provide	B-X
the	B-X
basis	B-X
for	B-X
clinical	B-X
trials	B-X
of	B-X
TRAIL	B-X
-	B-X
based	B-X
treatment	B-X
regimens	B-X
to	B-X
improve	B-X
outcome	B-X
in	B-X
patients	B-X
with	B-X
MM	B-X
<EOS>	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
ligand	B-X
selectively	B-X
induces	B-X
apoptosis	B-X
and	B-X
overcomes	B-X
drug	B-X
resistance	B-X
in	B-X
multiple	B-X
myeloma	B-X
:	B-X
therapeutic	B-X
applications	B-X
.	B-X
<EOS>	B-X
The	B-X
status	B-X
of	B-X
the	B-X
TRAIL	B-X
receptors	B-X
(	B-X
assessed	B-X
by	B-X
immunoblotting	B-X
and	B-X
flow	B-X
cytometry	B-X
)	B-X
could	B-X
not	B-X
predict	B-X
TRAIL	B-X
sensitivity	B-X
of	B-X
MM	B-X
cells	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
SN50	B-X
(	B-X
a	B-X
cell	B-X
-	B-X
permeable	B-X
inhibitor	B-X
of	B-X
the	B-X
nuclear	B-X
translocation	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
or	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
PS	B-X
-	B-X
341	B-X
,	B-X
enhanced	B-X
the	B-X
proapoptotic	B-X
activity	B-X
of	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
against	B-X
TRAIL	B-X
-	B-X
sensitive	B-X
MM	B-X
cells	B-X
,	B-X
whereas	B-X
SN50	B-X
reversed	B-X
the	B-X
TRAIL	B-X
resistance	B-X
of	B-X
ARH	B-X
-	B-X
77	B-X
and	B-X
IM	B-X
-	B-X
9	B-X
MM	B-X
cells	B-X

(	O
Blood.	O
2001	O
;	O
98	O
:	O
795-804	O
)	O
<EOS>	B-X
2001	B-X
;	B-X
98:795	B-X
-	B-X
804	B-X
)	B-X
<EOS>	B-X
(	B-X
Blood	B-X
<EOS>	B-X
Importantly	B-X
,	B-X
normal	B-X
B	B-X
lymphocytes	B-X
were	B-X
not	B-X
sensitized	B-X
to	B-X
TRAIL	B-X
by	B-X
either	B-X
Dox	B-X
,	B-X
SN50	B-X
,	B-X
or	B-X
PS	B-X
-	B-X
341	B-X
<EOS>	B-X
Multiple	B-X
myeloma	B-X
(	B-X
MM	B-X
)	B-X
remains	B-X
incurable	B-X
and	B-X
novel	B-X
treatments	B-X
are	B-X
urgently	B-X
needed	B-X

CD28	B-protein
costimulation	O
is	O
required	O
not	O
only	O
to	O
induce	O
IL-12	B-protein
receptor	I-protein
but	O
also	O
to	O
render	O
janus	B-protein
kinases/STAT4	I-protein
responsive	O
to	O
IL-12	B-protein
stimulation	O
in	O
TCR-triggered	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Costimulatory	B-X
interactions	B-X
can	B-X
be	B-X
critical	B-X
in	B-X
developing	B-X
immune	B-X
responses	B-X
to	B-X
infectious	B-X
agents	B-X
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
B7	B-X
-	B-X
CD28	B-X
co	B-X
-	B-X
stimulation	B-X
is	B-X
required	B-X
for	B-X
thymic	B-X
iNKT	B-X
cell	B-X
development	B-X
,	B-X
but	B-X
the	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
this	B-X
co	B-X
-	B-X
stimulatory	B-X
requirement	B-X
are	B-X
not	B-X
understood	B-X
<EOS>	B-X
CD137	B-X
costimulation	B-X
is	B-X
associated	B-X
with	B-X
reduced	B-X
herpetic	B-X
stromal	B-X
keratitis	B-X
and	B-X
with	B-X
developing	B-X
normal	B-X
CD8	B-X
<EOS>	B-X
Costimulation	B-X
blockade	B-X
in	B-X
combination	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
permits	B-X
regulatory	B-X
T	B-X
cell	B-X
sparing	B-X
immunomodulation	B-X
that	B-X
inhibits	B-X
autoimmunity	B-X
.	B-X

The	O
activation	O
of	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
for	O
the	O
acquisition	O
of	O
various	O
functions	O
depends	O
on	O
whether	O
CD28	O
costimulatory	O
signals	O
are	O
provided	O
upon	O
T	O
cell	O
receptor	O
stimulation	O
.	O
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
various	B-X
functions	B-X
depends	B-X
on	B-X
whether	B-X
CD28	B-X
costimulatory	B-X
signals	B-X
are	B-X
provided	B-X
upon	B-X
T	B-X
cell	B-X
receptor	B-X
stimulation	B-X
<EOS>	B-X
However	B-X
,	B-X
stimulation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
high	B-X
doses	B-X
of	B-X
anti	B-X
-	B-X
CD3	B-X
alone	B-X
induced	B-X
comparable	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
12R	B-X
expression	B-X
to	B-X
those	B-X
induced	B-X
upon	B-X
CD28	B-X
costimulation	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
how	B-X
CD28	B-X
costimulation	B-X
functions	B-X
to	B-X
allow	B-X
TCR	B-X
-	B-X
triggered	B-X
resting	B-X
T	B-X
cells	B-X
to	B-X
acquire	B-X
IL	B-X
-	B-X
12	B-X
responsiveness	B-X
<EOS>	B-X
When	B-X
T	B-X
cells	B-X
are	B-X
stimulated	B-X
with	B-X
low	B-X
doses	B-X
of	B-X
anti	B-X
-	B-X
CD3	B-X
mAb	B-X
,	B-X
CD28	B-X
costimulation	B-X
was	B-X
required	B-X
for	B-X
the	B-X
optimal	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
12R	B-X
)	B-X
expression	B-X

Here	O
,	O
we	O
investigated	O
how	O
CD28	O
costimulation	O
functions	O
to	O
allow	O
TCR	B-protein
-triggered	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
acquire	O
IL-12	B-protein
responsiveness	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
how	B-X
CD28	B-X
costimulation	B-X
functions	B-X
to	B-X
allow	B-X
TCR	B-X
-	B-X
triggered	B-X
resting	B-X
T	B-X
cells	B-X
to	B-X
acquire	B-X
IL	B-X
-	B-X
12	B-X
responsiveness	B-X
<EOS>	B-X
These	B-X
resutls	B-X
indicate	B-X
that	B-X
CD28	B-X
costimulation	B-X
not	B-X
only	B-X
contributes	B-X
to	B-X
up	B-X
-	B-X
regulating	B-X
IL	B-X
-	B-X
12R	B-X
expression	B-X
but	B-X
is	B-X
also	B-X
required	B-X
to	B-X
render	B-X
JAKs	B-X
/	B-X
STAT4	B-X
responsive	B-X
to	B-X
IL	B-X
-	B-X
12	B-X
stimulation	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
various	B-X
functions	B-X
depends	B-X
on	B-X
whether	B-X
CD28	B-X
costimulatory	B-X
signals	B-X
are	B-X
provided	B-X
upon	B-X
T	B-X
cell	B-X
receptor	B-X
stimulation	B-X
<EOS>	B-X
When	B-X
T	B-X
cells	B-X
are	B-X
stimulated	B-X
with	B-X
low	B-X
doses	B-X
of	B-X
anti	B-X
-	B-X
CD3	B-X
mAb	B-X
,	B-X
CD28	B-X
costimulation	B-X
was	B-X
required	B-X
for	B-X
the	B-X
optimal	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
12R	B-X
)	B-X
expression	B-X

When	O
T	B-cell_type
cells	I-cell_type
are	O
stimulated	O
with	O
low	O
doses	O
of	O
anti-CD3	B-protein
mAb	I-protein
,	O
CD28	O
costimulation	O
was	O
required	O
for	O
the	O
optimal	O
levels	O
of	O
IL-12	B-protein
receptor	I-protein
(	O
IL-12R	B-protein
)	O
expression	O
.	O
<EOS>	B-X
When	B-X
T	B-X
cells	B-X
are	B-X
stimulated	B-X
with	B-X
low	B-X
doses	B-X
of	B-X
anti	B-X
-	B-X
CD3	B-X
mAb	B-X
,	B-X
CD28	B-X
costimulation	B-X
was	B-X
required	B-X
for	B-X
the	B-X
optimal	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
12R	B-X
)	B-X
expression	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
how	B-X
CD28	B-X
costimulation	B-X
functions	B-X
to	B-X
allow	B-X
TCR	B-X
-	B-X
triggered	B-X
resting	B-X
T	B-X
cells	B-X
to	B-X
acquire	B-X
IL	B-X
-	B-X
12	B-X
responsiveness	B-X
<EOS>	B-X
These	B-X
resutls	B-X
indicate	B-X
that	B-X
CD28	B-X
costimulation	B-X
not	B-X
only	B-X
contributes	B-X
to	B-X
up	B-X
-	B-X
regulating	B-X
IL	B-X
-	B-X
12R	B-X
expression	B-X
but	B-X
is	B-X
also	B-X
required	B-X
to	B-X
render	B-X
JAKs	B-X
/	B-X
STAT4	B-X
responsive	B-X
to	B-X
IL	B-X
-	B-X
12	B-X
stimulation	B-X
<EOS>	B-X
However	B-X
,	B-X
stimulation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
high	B-X
doses	B-X
of	B-X
anti	B-X
-	B-X
CD3	B-X
alone	B-X
induced	B-X
comparable	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
12R	B-X
expression	B-X
to	B-X
those	B-X
induced	B-X
upon	B-X
CD28	B-X
costimulation	B-X

However	O
,	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
high	O
doses	O
of	O
anti-CD3	B-protein
alone	O
induced	O
comparable	O
levels	O
of	O
IL-12R	B-protein
expression	O
to	O
those	O
induced	O
upon	O
CD28	O
costimulation	O
.	O
<EOS>	B-X
However	B-X
,	B-X
stimulation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
high	B-X
doses	B-X
of	B-X
anti	B-X
-	B-X
CD3	B-X
alone	B-X
induced	B-X
comparable	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
12R	B-X
expression	B-X
to	B-X
those	B-X
induced	B-X
upon	B-X
CD28	B-X
costimulation	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
various	B-X
functions	B-X
depends	B-X
on	B-X
whether	B-X
CD28	B-X
costimulatory	B-X
signals	B-X
are	B-X
provided	B-X
upon	B-X
T	B-X
cell	B-X
receptor	B-X
stimulation	B-X
<EOS>	B-X
These	B-X
resutls	B-X
indicate	B-X
that	B-X
CD28	B-X
costimulation	B-X
not	B-X
only	B-X
contributes	B-X
to	B-X
up	B-X
-	B-X
regulating	B-X
IL	B-X
-	B-X
12R	B-X
expression	B-X
but	B-X
is	B-X
also	B-X
required	B-X
to	B-X
render	B-X
JAKs	B-X
/	B-X
STAT4	B-X
responsive	B-X
to	B-X
IL	B-X
-	B-X
12	B-X
stimulation	B-X
<EOS>	B-X
When	B-X
T	B-X
cells	B-X
are	B-X
stimulated	B-X
with	B-X
low	B-X
doses	B-X
of	B-X
anti	B-X
-	B-X
CD3	B-X
mAb	B-X
,	B-X
CD28	B-X
costimulation	B-X
was	B-X
required	B-X
for	B-X
the	B-X
optimal	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
12R	B-X
)	B-X
expression	B-X

Nevertheless	O
,	O
there	O
was	O
a	O
substantial	O
difference	O
in	O
IL-12	B-protein
responsiveness	O
between	O
these	O
two	O
groups	O
of	O
T	B-cell_type
cells	I-cell_type
:	O
compared	O
to	O
anti-CD28-costimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cells	I-cell_type
that	O
were	O
not	O
costimulated	O
with	O
anti-CD28	B-protein
exhibited	O
decreased	O
levels	O
of	O
Janus	B-protein
kinases	I-protein
(	O
JAK	B-protein
)	O
JAK2/TYK2	B-protein
and	O
STAT4	B-protein
phosphorylation	O
and	O
IFN-y	O
production	O
following	O
IL-12	B-protein
stimulation	O
.	O

Importantly	O
,	O
STAT6	O
phosphorylation	O
following	O
IL-4	O
stimulation	O
was	O
not	O
decreased	O
in	O
anti-CD28-uncostimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
resutls	O
indicate	O
that	O
CD28	O
costimulation	O
not	O
only	O
contributes	O
to	O
up-regulating	O
IL-12R	B-protein
expression	O
but	O
is	O
also	O
required	O
to	O
render	O
JAKs/STAT4	B-protein
responsive	O
to	O
IL-12	B-protein
stimulation	O
.	O

Constitutively	O
activated	O
Akt-1	B-protein
is	O
vital	O
for	O
the	O
survival	O
of	O
human	B-cell_type
monocyte-differentiated	I-cell_type
macrophages	I-cell_type
.	O
<EOS>	B-X
Constitutively	B-X
activated	B-X
Akt	B-X
-	B-X
1	B-X
is	B-X
vital	B-X
for	B-X
the	B-X
survival	B-X
of	B-X
human	B-X
monocyte	B-X
-	B-X
differentiated	B-X
macrophages	B-X
.	B-X
Role	B-X
of	B-X
Mcl	B-X
-	B-X
1	B-X
,	B-X
independent	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
,	B-X
Bad	B-X
,	B-X
or	B-X
caspase	B-X
activation	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
that	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
Akt	B-X
-	B-X
1	B-X
regulates	B-X
macrophage	B-X
survival	B-X
through	B-X
Mcl	B-X
-	B-X
1	B-X
,	B-X
which	B-X
is	B-X
independent	B-X
of	B-X
caspases	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
or	B-X
Bad	B-X
<EOS>	B-X
Akt	B-X
-	B-X
1	B-X
was	B-X
constitutively	B-X
activated	B-X
in	B-X
human	B-X
macrophages	B-X
and	B-X
addition	B-X
of	B-X
the	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
,	B-X
suppressed	B-X
the	B-X
activation	B-X
of	B-X
Akt	B-X
-	B-X
1	B-X
and	B-X
induced	B-X
cell	B-X
death	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PI3K	B-X
/	B-X
Akt	B-X
-	B-X
1	B-X
pathway	B-X
either	B-X
by	B-X
LY294002	B-X
or	B-X
DN	B-X
Akt	B-X
-	B-X
1	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
constitutive	B-X
or	B-X
inducible	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
in	B-X
human	B-X
macrophages	B-X

Role	O
of	O
Mcl-1	B-protein
,	O
independent	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
,	O
Bad	B-protein
,	O
or	O
caspase	O
activation	O
.	O
<EOS>	B-X
Knockdown	B-X
of	B-X
TFAM	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
mtDNA	B-X
copy	B-X
number	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
resulted	B-X
in	B-X
elevated	B-X
NLRP3	B-X
expression	B-X
,	B-X
active	B-X
caspase	B-X
-	B-X
1	B-X
and	B-X
mature	B-X
IL	B-X
-	B-X
1β	B-X
<EOS>	B-X
The	B-X
dose	B-X
and	B-X
time	B-X
-	B-X
dependent	B-X
increase	B-X
of	B-X
3	B-X
-	B-X
NPA	B-X
revealed	B-X
its	B-X
neurotoxic	B-X
dose	B-X
as	B-X
0	B-X
<EOS>	B-X
Processing	B-X
and	B-X
release	B-X
of	B-X
the	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X
interleukin	B-X
-	B-X
1β	B-X
(	B-X
IL	B-X
-	B-X
1β	B-X
)	B-X
and	B-X
IL	B-X
-	B-X
18	B-X
depend	B-X
on	B-X
caspase	B-X
-	B-X
1	B-X
activation	B-X
within	B-X
inflammasomes	B-X
<EOS>	B-X
Over	B-X
time	B-X
,	B-X
the	B-X
use	B-X
of	B-X
plant	B-X
-	B-X
derived	B-X
agents	B-X
in	B-X
the	B-X
management	B-X
of	B-X
various	B-X
human	B-X
health	B-X
conditions	B-X
has	B-X
gained	B-X
a	B-X
lot	B-X
of	B-X
attention	B-X

Recent	O
data	O
from	O
mice	O
deficient	O
for	O
phosphatase	B-protein
and	O
tensin	B-DNA
homologue	I-DNA
deleted	O
from	O
chromosome	B-DNA
10	I-DNA
or	O
src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
5	I-protein
'	I-protein
inositol	I-protein
phosphatase	I-protein
,	O
phosphatases	B-protein
that	O
negatively	O
regulate	O
the	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3K	B-protein
)	O
pathway	O
,	O
revealed	O
an	O
increased	O
number	O
of	O
macrophages	B-cell_type
in	O
these	O
animals	O
,	O
suggesting	O
an	O
essential	O
role	O
for	O
the	O
PI3K	B-protein
pathway	O
for	O
macro-phage	B-cell_type
survival	O
.	O
<EOS>	B-X
Recent	B-X
data	B-X
from	B-X
mice	B-X
deficient	B-X
for	B-X
phosphatase	B-X
and	B-X
tensin	B-X
homologue	B-X
deleted	B-X
from	B-X
chromosome	B-X
10	B-X
or	B-X
src	B-X
homology	B-X
2	B-X
domain	B-X
-	B-X
containing	B-X
5	B-X
'	B-X
inositol	B-X
phosphatase	B-X
,	B-X
phosphatases	B-X
that	B-X
negatively	B-X
regulate	B-X
the	B-X
phosphatidylinositol	B-X
3	B-X
-	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
,	B-X
revealed	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
macrophages	B-X
in	B-X
these	B-X
animals	B-X
,	B-X
suggesting	B-X
an	B-X
essential	B-X
role	B-X
for	B-X
the	B-X
PI3K	B-X
pathway	B-X
for	B-X
macro	B-X
-	B-X
phage	B-X
survival	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
suppression	B-X
of	B-X
Akt	B-X
-	B-X
1	B-X
by	B-X
inhibition	B-X
of	B-X
PI3K	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
Akt	B-X
-	B-X
1	B-X
resulted	B-X
in	B-X
loss	B-X
of	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
,	B-X
activation	B-X
of	B-X
caspases	B-X
-	B-X
9	B-X
and	B-X
	B-X
-	B-X
3	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
<EOS>	B-X
However	B-X
,	B-X
after	B-X
inhibition	B-X
of	B-X
the	B-X
PI3K	B-X
/	B-X
Akt	B-X
-	B-X
1	B-X
pathway	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
antiapoptotic	B-X
molecule	B-X
Mcl	B-X
-	B-X
1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
Bcl	B-X
-	B-X
2	B-X
family	B-X
members	B-X
was	B-X
observed	B-X
,	B-X
and	B-X
Mcl	B-X
-	B-X
1	B-X
rescued	B-X
macrophages	B-X
from	B-X
LY294002	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
<EOS>	B-X
Constitutively	B-X
activated	B-X
Akt	B-X
-	B-X
1	B-X
is	B-X
vital	B-X
for	B-X
the	B-X
survival	B-X
of	B-X
human	B-X
monocyte	B-X
-	B-X
differentiated	B-X
macrophages	B-X
.	B-X
Role	B-X
of	B-X
Mcl	B-X
-	B-X
1	B-X
,	B-X
independent	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
,	B-X
Bad	B-X
,	B-X
or	B-X
caspase	B-X
activation	B-X
.	B-X

Here	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
the	O
PI3K-regulated	B-protein
serine/threonine	I-protein
kinase	I-protein
Akt-1	B-protein
in	O
modulating	O
macrophage	B-cell_type
survival	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
focused	B-X
on	B-X
the	B-X
role	B-X
of	B-X
the	B-X
PI3K	B-X
-	B-X
regulated	B-X
serine	B-X
/	B-X
threonine	B-X
kinase	B-X
Akt	B-X
-	B-X
1	B-X
in	B-X
modulating	B-X
macrophage	B-X
survival	B-X
<EOS>	B-X
Further	B-X
,	B-X
inhibition	B-X
of	B-X
Mcl	B-X
-	B-X
1	B-X
by	B-X
antisense	B-X
oligonucleotides	B-X
,	B-X
also	B-X
resulted	B-X
in	B-X
macrophage	B-X
apoptosis	B-X
<EOS>	B-X
Thus	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
that	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
Akt	B-X
-	B-X
1	B-X
regulates	B-X
macrophage	B-X
survival	B-X
through	B-X
Mcl	B-X
-	B-X
1	B-X
,	B-X
which	B-X
is	B-X
independent	B-X
of	B-X
caspases	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
or	B-X
Bad	B-X
<EOS>	B-X
Constitutively	B-X
activated	B-X
Akt	B-X
-	B-X
1	B-X
is	B-X
vital	B-X
for	B-X
the	B-X
survival	B-X
of	B-X
human	B-X
monocyte	B-X
-	B-X
differentiated	B-X
macrophages	B-X
.	B-X
Role	B-X
of	B-X
Mcl	B-X
-	B-X
1	B-X
,	B-X
independent	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
,	B-X
Bad	B-X
,	B-X
or	B-X
caspase	B-X
activation	B-X
.	B-X

Akt-1	B-protein
was	O
constitutively	O
activated	O
in	O
human	B-cell_type
macrophages	I-cell_type
and	O
addition	O
of	O
the	O
PI3K	B-protein
inhibitor	O
,	O
LY294002	O
,	O
suppressed	O
the	O
activation	O
of	O
Akt-1	B-protein
and	O
induced	O
cell	O
death	O
.	O
<EOS>	B-X
Akt	B-X
-	B-X
1	B-X
was	B-X
constitutively	B-X
activated	B-X
in	B-X
human	B-X
macrophages	B-X
and	B-X
addition	B-X
of	B-X
the	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
,	B-X
suppressed	B-X
the	B-X
activation	B-X
of	B-X
Akt	B-X
-	B-X
1	B-X
and	B-X
induced	B-X
cell	B-X
death	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
suppression	B-X
of	B-X
Akt	B-X
-	B-X
1	B-X
by	B-X
inhibition	B-X
of	B-X
PI3K	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
Akt	B-X
-	B-X
1	B-X
resulted	B-X
in	B-X
loss	B-X
of	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
,	B-X
activation	B-X
of	B-X
caspases	B-X
-	B-X
9	B-X
and	B-X
	B-X
-	B-X
3	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
<EOS>	B-X
However	B-X
,	B-X
after	B-X
inhibition	B-X
of	B-X
the	B-X
PI3K	B-X
/	B-X
Akt	B-X
-	B-X
1	B-X
pathway	B-X
,	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
antiapoptotic	B-X
molecule	B-X
Mcl	B-X
-	B-X
1	B-X
,	B-X
but	B-X
not	B-X
other	B-X
Bcl	B-X
-	B-X
2	B-X
family	B-X
members	B-X
was	B-X
observed	B-X
,	B-X
and	B-X
Mcl	B-X
-	B-X
1	B-X
rescued	B-X
macrophages	B-X
from	B-X
LY294002	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
PI3K	B-X
inhibition	B-X
were	B-X
reversed	B-X
by	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
constitutively	B-X
activated	B-X
Akt	B-X
-	B-X
1	B-X
or	B-X
Bcl	B-X
-	B-X
x	B-X
(	B-X
L	B-X
)	B-X

Furthermore	O
,	O
suppression	O
of	O
Akt-1	B-protein
by	O
inhibition	O
of	O
PI3K	B-protein
or	O
a	O
dominant	B-protein
negative	I-protein
(	I-protein
DN	I-protein
)	I-protein
Akt-1	I-protein
resulted	O
in	O
loss	O
of	O
mitochondrial	O
transmembrane	O
potential	O
,	O
activation	O
of	O
caspases-9	B-protein
and	I-protein
-3	I-protein
,	O
and	O
DNA	O
fragmentation	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
suppression	B-X
of	B-X
Akt	B-X
-	B-X
1	B-X
by	B-X
inhibition	B-X
of	B-X
PI3K	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
Akt	B-X
-	B-X
1	B-X
resulted	B-X
in	B-X
loss	B-X
of	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
,	B-X
activation	B-X
of	B-X
caspases	B-X
-	B-X
9	B-X
and	B-X
	B-X
-	B-X
3	B-X
,	B-X
and	B-X
DNA	B-X
fragmentation	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
PI3K	B-X
/	B-X
Akt	B-X
/	B-X
MMP	B-X
-	B-X
9	B-X
by	B-X
LY294002	B-X
and	B-X
SB	B-X
-	B-X
3CT	B-X
enhanced	B-X
the	B-X
anticancer	B-X
effects	B-X
of	B-X
fentanyl	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
Cbl	B-X
-	B-X
b	B-X
increased	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IRS	B-X
-	B-X
1	B-X
in	B-X
primary	B-X
Cbl	B-X
-	B-X
b	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
osteoblastic	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
impaired	B-X
mitogenic	B-X
response	B-X
to	B-X
IGF	B-X
-	B-X
I	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
SLB	B-X
suppressed	B-X
the	B-X
activation	B-X
of	B-X
autophagy	B-X
by	B-X
decreasing	B-X
microtubule	B-X
-	B-X
associated	B-X
protein	B-X
1	B-X
light	B-X
chain	B-X
3	B-X
(	B-X
LC3	B-X
-	B-X
II	B-X
)	B-X
and	B-X
Beclin	B-X
-	B-X
1	B-X
levels	B-X
under	B-X
oxidative	B-X
stress	B-X
accordingly	B-X

The	O
effects	O
of	O
PI3K	B-protein
inhibition	O
were	O
reversed	O
by	O
the	O
ectopic	O
expression	O
of	O
constitutively	O
activated	O
Akt-1	B-protein
or	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
.	O
<EOS>	B-X
Among	B-X
the	B-X
mechanisms	B-X
mediating	B-X
resistance	B-X
,	B-X
overexpression	B-X
of	B-X
anti	B-X
-	B-X
apoptotic	B-X
Bcl	B-X
-	B-X
2	B-X
proteins	B-X
(	B-X
Bcl	B-X
-	B-X
2	B-X
,	B-X
Bcl	B-X
-	B-X
x	B-X
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
SphK	B-X
inhibition	B-X
enhances	B-X
ICD	B-X
,	B-X
we	B-X
focused	B-X
on	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
leading	B-X
to	B-X
cell	B-X
surface	B-X
exposure	B-X
of	B-X
calreticulin	B-X
(	B-X
ectoCRT	B-X
)	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
inhibition	B-X
of	B-X
PDGFRβ	B-X
or	B-X
STAT3	B-X
/	B-X
5	B-X
improve	B-X
existing	B-X
therapies	B-X
for	B-X
both	B-X
previously	B-X
untreated	B-X
and	B-X
relapsed	B-X
/	B-X
refractory	B-X
ALK	B-X
<EOS>	B-X
The	B-X
dismal	B-X
prognosis	B-X
in	B-X
SCLC	B-X
is	B-X
in	B-X
part	B-X
associated	B-X
with	B-X
an	B-X
upregulation	B-X
of	B-X
BCL	B-X
-	B-X
2	B-X
family	B-X
anti	B-X
-	B-X
apoptotic	B-X
proteins	B-X
,	B-X
including	B-X
BCL	B-X
-	B-X
X	B-X

Inhibition	O
of	O
PI3K	B-protein
/Akt-1	O
pathway	O
either	O
by	O
LY294002	O
or	O
DN	B-protein
Akt-1	I-protein
had	O
no	O
effect	O
on	O
the	O
constitutive	O
or	O
inducible	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
in	O
human	B-cell_type
macrophages	I-cell_type
.	O
<EOS>	B-X
Deficiency	B-X
in	B-X
DCLK1	B-X
,	B-X
achieved	B-X
by	B-X
silencing	B-X
or	B-X
through	B-X
pharmacological	B-X
inhibition	B-X
,	B-X
prevented	B-X
LPS	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
κB	B-X
activation	B-X
and	B-X
cytokine	B-X
production	B-X
in	B-X
macrophages	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
a	B-X
novel	B-X
humanized	B-X
AAA	B-X
model	B-X
was	B-X
established	B-X
to	B-X
test	B-X
the	B-X
role	B-X
of	B-X
human	B-X
macrophages	B-X
in	B-X
aneurysm	B-X
formation	B-X
in	B-X
human	B-X
arteries	B-X
<EOS>	B-X
Eckmaxol	B-X
attenuated	B-X
the	B-X
expression	B-X
of	B-X
cyclooxygenase	B-X
-	B-X
2	B-X
(	B-X
COX	B-X
-	B-X
2	B-X
)	B-X
and	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
in	B-X
PM	B-X
-	B-X
induced	B-X
lung	B-X
macrophages	B-X
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
CDDO	B-X
-	B-X
EA	B-X
protects	B-X
skeletal	B-X
muscle	B-X
from	B-X
LPS	B-X
-	B-X
induced	B-X
inflammation	B-X
by	B-X
blocking	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
κB	B-X
)	B-X
signaling	B-X

However	O
,	O
after	O
inhibition	O
of	O
the	O
PI3K	B-protein
/	O
Akt-1	B-protein
pathway	O
,	O
a	O
marked	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
antiapoptotic	B-protein
molecule	I-protein
Mcl-1	B-protein
,	O
but	O
not	O
other	O
Bcl-2	B-protein
family	I-protein
members	I-protein
was	O
observed	O
,	O
and	O
Mcl-1	B-protein
rescued	O
macrophages	B-cell_type
from	O
LY294002-induced	O
cell	O
death	O
.	O

Further	O
,	O
inhibition	O
of	O
Mcl-1	B-protein
by	O
antisense	O
oligonucleotides	O
,	O
also	O
resulted	O
in	O
macrophage	B-cell_type
apoptosis	O
.	O
<EOS>	B-X
Further	B-X
,	B-X
inhibition	B-X
of	B-X
Mcl	B-X
-	B-X
1	B-X
by	B-X
antisense	B-X
oligonucleotides	B-X
,	B-X
also	B-X
resulted	B-X
in	B-X
macrophage	B-X
apoptosis	B-X
<EOS>	B-X
Exposure	B-X
of	B-X
PMN	B-X
to	B-X
GM	B-X
-	B-X
CSF	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
AG	B-X
-	B-X
490	B-X
,	B-X
antisense	B-X
STAT3	B-X
oligonucleotides	B-X
,	B-X
or	B-X
wortmannin	B-X
resulted	B-X
in	B-X
a	B-X
partial	B-X
inhibition	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
-	B-X
mediated	B-X
pro	B-X
-	B-X
survival	B-X
activity	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
cooperative	B-X
regulation	B-X
of	B-X
Mcl	B-X
-	B-X
1	B-X
by	B-X
the	B-X
Janus	B-X
kinase	B-X
/	B-X
STAT	B-X
and	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
pathways	B-X
contribute	B-X
to	B-X
GM	B-X
-	B-X
CSF	B-X
-	B-X
delayed	B-X
apoptosis	B-X
<EOS>	B-X
Cooperative	B-X
regulation	B-X
of	B-X
Mcl	B-X
-	B-X
1	B-X
by	B-X
Janus	B-X
kinase	B-X
/	B-X
stat	B-X
and	B-X
phosphatidylinositol	B-X
3	B-X
-	B-X
kinase	B-X
contribute	B-X
to	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
-	B-X
delayed	B-X
apoptosis	B-X
in	B-X
human	B-X
neutrophils	B-X
.	B-X

Thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
the	O
constitutive	O
activation	O
of	O
Akt-1	B-protein
regulates	O
macrophage	B-cell_type
survival	O
through	O
Mcl-1	B-protein
,	O
which	O
is	O
independent	O
of	O
caspases	B-protein
,	O
NF-kappaB	B-protein
,	O
or	O
Bad	B-protein
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
position	B-X
of	B-X
the	B-X
IAS	B-X
in	B-X
the	B-X
infra	B-X
-	B-X
acetabular	B-X
corridor	B-X
after	B-X
navigated	B-X
placement	B-X
and	B-X
after	B-X
freehand	B-X
placement	B-X
<EOS>	B-X
The	B-X
insulin	B-X
/	B-X
insulin	B-X
-	B-X
like	B-X
growth	B-X
factor	B-X
1	B-X
(	B-X
IGF1	B-X
)	B-X
pathway	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
crucial	B-X
component	B-X
of	B-X
prostate	B-X
cancer	B-X
progression	B-X
<EOS>	B-X
Nonetheless	B-X
,	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
contribution	B-X
of	B-X
maltreatment	B-X
to	B-X
the	B-X
neuroanatomical	B-X
alterations	B-X
observed	B-X
in	B-X
CD	B-X
remains	B-X
limited	B-X
<EOS>	B-X
Although	B-X
previous	B-X
before	B-X
and	B-X
after	B-X
quantitative	B-X
assessments	B-X
have	B-X
found	B-X
the	B-X
intervention	B-X
to	B-X
be	B-X
effective	B-X
,	B-X
this	B-X
realist	B-X
evaluation	B-X
aimed	B-X
to	B-X
qualitatively	B-X
develop	B-X
the	B-X
theory	B-X
of	B-X
change	B-X
,	B-X
exploring	B-X
how	B-X
the	B-X
mechanisms	B-X
played	B-X
out	B-X
in	B-X
different	B-X
contexts	B-X
to	B-X
achieve	B-X
the	B-X
desired	B-X
outcomes	B-X

GRbeta	O
expression	O
in	O
nasal	B-cell_type
polyp	I-cell_type
inflammatory	I-cell_type
cells	I-cell_type
and	O
its	O
relationship	O
to	O
the	O
anti-inflammatory	O
effects	O
of	O
intranasal	O
fluticasone	O
.	O

BACKGROUND	O
:	O
Nasal	O
polyposis	O
disease	O
is	O
an	O
inflammatory	O
disorder	O
with	O
intense	O
eosinophilic	O
infiltration	O
of	O
respiratory	O
mucosa	O
that	O
is	O
often	O
difficult	O
to	O
control	O
with	O
topical	O
steroids	O
.	O
<EOS>	B-X
Nasal	B-X
polyposis	B-X
disease	B-X
is	B-X
an	B-X
inflammatory	B-X
disorder	B-X
with	B-X
intense	B-X
eosinophilic	B-X
infiltration	B-X
of	B-X
respiratory	B-X
mucosa	B-X
that	B-X
is	B-X
often	B-X
difficult	B-X
to	B-X
control	B-X
with	B-X
topical	B-X
steroids	B-X
<EOS>	B-X
GRbeta	B-X
expression	B-X
in	B-X
nasal	B-X
polyp	B-X
inflammatory	B-X
cells	B-X
and	B-X
its	B-X
relationship	B-X
to	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
effects	B-X
of	B-X
intranasal	B-X
fluticasone	B-X
.	B-X
<EOS>	B-X
The	B-X
purposes	B-X
of	B-X
this	B-X
investigation	B-X
were	B-X
to	B-X
determine	B-X
whether	B-X
nasal	B-X
polyp	B-X
(	B-X
NP	B-X
)	B-X
inflammatory	B-X
cells	B-X
overexpress	B-X
GRbeta	B-X
and	B-X
to	B-X
examine	B-X
whether	B-X
GRbeta	B-X
overexpression	B-X
is	B-X
associated	B-X
with	B-X
insensitivity	B-X
to	B-X
the	B-X
potent	B-X
topical	B-X
steroid	B-X
fluticasone	B-X
propionate	B-X
(	B-X
FP	B-X
)	B-X
<EOS>	B-X
The	B-X
anti	B-X
-	B-X
inflammatory	B-X
response	B-X
to	B-X
FP	B-X
was	B-X
examined	B-X
in	B-X
relation	B-X
to	B-X
pretreatment	B-X
levels	B-X
of	B-X
GRbeta	B-X
expression	B-X

Recent	O
evidence	O
suggests	O
that	O
overexpression	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
splice	I-protein
variant	I-protein
GRbeta	B-protein
in	O
inflammatory	B-cell_type
cells	I-cell_type
might	O
contribute	O
to	O
steroid	O
insensitivity	O
in	O
diseases	O
such	O
as	O
asthma	O
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
overexpression	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
splice	B-X
variant	B-X
GRbeta	B-X
in	B-X
inflammatory	B-X
cells	B-X
might	B-X
contribute	B-X
to	B-X
steroid	B-X
insensitivity	B-X
in	B-X
diseases	B-X
such	B-X
as	B-X
asthma	B-X
<EOS>	B-X
NPs	B-X
that	B-X
were	B-X
``	B-X
FP	B-X
-	B-X
insensitive	B-X
''	B-X
in	B-X
terms	B-X
of	B-X
suppression	B-X
of	B-X
eosinophil	B-X
numbers	B-X
(	B-X
major	B-X
basic	B-X
protein	B-X
-	B-X
positive	B-X
)	B-X
had	B-X
a	B-X
significantly	B-X
greater	B-X
percentage	B-X
of	B-X
GRbeta	B-X
-	B-X
positive	B-X
inflammatory	B-X
cells	B-X
,	B-X
a	B-X
higher	B-X
ratio	B-X
of	B-X
GRbeta	B-X
-	B-X
positive	B-X
/	B-X
GRalpha	B-X
-	B-X
positive	B-X
cells	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
GRbeta	B-X
-	B-X
positive	B-X
eosinophils	B-X
and	B-X
macrophages	B-X
in	B-X
comparison	B-X
with	B-X
those	B-X
that	B-X
were	B-X
``	B-X
FP	B-X
-	B-X
sensitive	B-X
<EOS>	B-X
GRbeta	B-X
expression	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
steroid	B-X
insensitivity	B-X
in	B-X
NPs	B-X
<EOS>	B-X
The	B-X
purposes	B-X
of	B-X
this	B-X
investigation	B-X
were	B-X
to	B-X
determine	B-X
whether	B-X
nasal	B-X
polyp	B-X
(	B-X
NP	B-X
)	B-X
inflammatory	B-X
cells	B-X
overexpress	B-X
GRbeta	B-X
and	B-X
to	B-X
examine	B-X
whether	B-X
GRbeta	B-X
overexpression	B-X
is	B-X
associated	B-X
with	B-X
insensitivity	B-X
to	B-X
the	B-X
potent	B-X
topical	B-X
steroid	B-X
fluticasone	B-X
propionate	B-X
(	B-X
FP	B-X
)	B-X

OBJECTIVE	O
:	O
The	O
purposes	O
of	O
this	O
investigation	O
were	O
to	O
determine	O
whether	O
nasal	B-cell_type
polyp	I-cell_type
(	I-cell_type
NP	I-cell_type
)	I-cell_type
inflammatory	I-cell_type
cells	I-cell_type
overexpress	O
GRbeta	B-protein
and	O
to	O
examine	O
whether	O
GRbeta	B-protein
overexpression	O
is	O
associated	O
with	O
insensitivity	O
to	O
the	O
potent	O
topical	O
steroid	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
.	O

METHODS	O
:	O
Biopsies	O
were	O
obtained	O
from	O
10	O
subjects	O
with	O
NPs	O
before	O
and	O
4	O
weeks	O
after	O
treatment	O
with	O
intranasal	O
FP	O
.	O
<EOS>	B-X
Biopsies	B-X
were	B-X
obtained	B-X
from	B-X
10	B-X
subjects	B-X
with	B-X
NPs	B-X
before	B-X
and	B-X
4	B-X
weeks	B-X
after	B-X
treatment	B-X
with	B-X
intranasal	B-X
FP	B-X
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
inflammatory	B-X
cells	B-X
expressing	B-X
GRbeta	B-X
was	B-X
also	B-X
increased	B-X
(	B-X
40	B-X
<EOS>	B-X
Middle	B-X
turbinates	B-X
biopsies	B-X
from	B-X
6	B-X
healthy	B-X
,	B-X
nonallergic	B-X
subjects	B-X
served	B-X
as	B-X
normal	B-X
controls	B-X
<EOS>	B-X
GRbeta	B-X
expression	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
steroid	B-X
insensitivity	B-X
in	B-X
NPs	B-X

Middle	O
turbinates	O
biopsies	O
from	O
6	O
healthy	O
,	O
nonallergic	O
subjects	O
served	O
as	O
normal	O
controls	O
.	O
<EOS>	B-X
Middle	B-X
turbinates	B-X
biopsies	B-X
from	B-X
6	B-X
healthy	B-X
,	B-X
nonallergic	B-X
subjects	B-X
served	B-X
as	B-X
normal	B-X
controls	B-X
<EOS>	B-X
The	B-X
total	B-X
numbers	B-X
of	B-X
inflammatory	B-X
cells	B-X
were	B-X
increased	B-X
in	B-X
NPs	B-X
<EOS>	B-X
Biopsies	B-X
were	B-X
immunostained	B-X
for	B-X
inflammatory	B-X
cell	B-X
markers	B-X
as	B-X
well	B-X
as	B-X
GRbeta	B-X
and	B-X
probed	B-X
for	B-X
various	B-X
cytokine	B-X
mRNA	B-X
<EOS>	B-X
GRbeta	B-X
expression	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
steroid	B-X
insensitivity	B-X
in	B-X
NPs	B-X

Biopsies	O
were	O
immunostained	O
for	O
inflammatory	O
cell	O
markers	O
as	O
well	O
as	O
GRbeta	B-protein
and	O
probed	O
for	O
various	O
cytokine	B-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
Biopsies	B-X
were	B-X
immunostained	B-X
for	B-X
inflammatory	B-X
cell	B-X
markers	B-X
as	B-X
well	B-X
as	B-X
GRbeta	B-X
and	B-X
probed	B-X
for	B-X
various	B-X
cytokine	B-X
mRNA	B-X
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
inflammatory	B-X
cells	B-X
expressing	B-X
GRbeta	B-X
was	B-X
also	B-X
increased	B-X
(	B-X
40	B-X
<EOS>	B-X
Biopsies	B-X
were	B-X
obtained	B-X
from	B-X
10	B-X
subjects	B-X
with	B-X
NPs	B-X
before	B-X
and	B-X
4	B-X
weeks	B-X
after	B-X
treatment	B-X
with	B-X
intranasal	B-X
FP	B-X
<EOS>	B-X
The	B-X
total	B-X
numbers	B-X
of	B-X
inflammatory	B-X
cells	B-X
were	B-X
increased	B-X
in	B-X
NPs	B-X

The	O
anti-inflammatory	O
response	O
to	O
FP	O
was	O
examined	O
in	O
relation	O
to	O
pretreatment	O
levels	O
of	O
GRbeta	O
expression	O
.	O

RESULTS	O
:	O
The	O
total	O
numbers	O
of	O
inflammatory	B-cell_type
cells	I-cell_type
were	O
increased	O
in	O
NPs	B-cell_type
.	O
<EOS>	B-X
The	B-X
total	B-X
numbers	B-X
of	B-X
inflammatory	B-X
cells	B-X
were	B-X
increased	B-X
in	B-X
NPs	B-X
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
inflammatory	B-X
cells	B-X
expressing	B-X
GRbeta	B-X
was	B-X
also	B-X
increased	B-X
(	B-X
40	B-X
<EOS>	B-X
Biopsies	B-X
were	B-X
immunostained	B-X
for	B-X
inflammatory	B-X
cell	B-X
markers	B-X
as	B-X
well	B-X
as	B-X
GRbeta	B-X
and	B-X
probed	B-X
for	B-X
various	B-X
cytokine	B-X
mRNA	B-X
<EOS>	B-X
The	B-X
current	B-X
study	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
Nrf2	B-X
deletion	B-X
on	B-X
the	B-X
lung	B-X
inflammatory	B-X
response	B-X
in	B-X
female	B-X
mice	B-X
exposed	B-X
to	B-X
ZnO	B-X
-	B-X
NPs	B-X

The	O
percentage	O
of	O
inflammatory	B-cell_type
cells	I-cell_type
expressing	O
GRbeta	B-protein
was	O
also	O
increased	O
(	O
40.5	O
%	O
+/-	O
19.2	O
%	O
vs	O
16.1	O
%	O
+/-	O
4.0	O
%	O
,	O
P	O
=.009	O
)	O
.	O
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
inflammatory	B-X
cells	B-X
expressing	B-X
GRbeta	B-X
was	B-X
also	B-X
increased	B-X
(	B-X
40	B-X
<EOS>	B-X
The	B-X
total	B-X
numbers	B-X
of	B-X
inflammatory	B-X
cells	B-X
were	B-X
increased	B-X
in	B-X
NPs	B-X
<EOS>	B-X
The	B-X
anti	B-X
-	B-X
inflammatory	B-X
response	B-X
to	B-X
FP	B-X
was	B-X
examined	B-X
in	B-X
relation	B-X
to	B-X
pretreatment	B-X
levels	B-X
of	B-X
GRbeta	B-X
expression	B-X
<EOS>	B-X
Expression	B-X
of	B-X
GRbeta	B-X
by	B-X
NP	B-X
inflammatory	B-X
cells	B-X
,	B-X
particularly	B-X
T	B-X
cells	B-X
and	B-X
eosinophils	B-X
,	B-X
might	B-X
render	B-X
them	B-X
resistant	B-X
to	B-X
suppression	B-X
by	B-X
topical	B-X
steroids	B-X
and	B-X
thereby	B-X
contribute	B-X
to	B-X
persistent	B-X
NP	B-X
inflammation	B-X

GRbeta	B-protein
expression	O
in	O
NPs	B-cell_type
was	O
almost	O
exclusive	O
to	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
eosinophils	B-cell_type
,	O
and	O
macrophages	B-cell_type
.	O

An	O
inverse	O
correlation	O
was	O
observed	O
between	O
the	O
baseline	O
inflammatory	O
cell	O
GRbeta	B-protein
expression	O
and	O
the	O
reduction	O
after	O
FP	O
treatment	O
in	O
EG2-positive	B-cell_type
eosinophils	I-cell_type
,	O
CD4-positive	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
endothelial	O
VCAM-1	B-protein
expression	O
,	O
and	O
IL-4	B-cell_type
mRNA-positive	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
An	B-X
inverse	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
the	B-X
baseline	B-X
inflammatory	B-X
cell	B-X
GRbeta	B-X
expression	B-X
and	B-X
the	B-X
reduction	B-X
after	B-X
FP	B-X
treatment	B-X
in	B-X
EG2	B-X
-	B-X
positive	B-X
eosinophils	B-X
,	B-X
CD4	B-X
-	B-X
positive	B-X
T	B-X
lymphocytes	B-X
,	B-X
endothelial	B-X
VCAM	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
mRNA	B-X
-	B-X
positive	B-X
cells	B-X
<EOS>	B-X
GRbeta	B-X
expression	B-X
in	B-X
nasal	B-X
polyp	B-X
inflammatory	B-X
cells	B-X
and	B-X
its	B-X
relationship	B-X
to	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
effects	B-X
of	B-X
intranasal	B-X
fluticasone	B-X
.	B-X
<EOS>	B-X
The	B-X
anti	B-X
-	B-X
inflammatory	B-X
response	B-X
to	B-X
FP	B-X
was	B-X
examined	B-X
in	B-X
relation	B-X
to	B-X
pretreatment	B-X
levels	B-X
of	B-X
GRbeta	B-X
expression	B-X
<EOS>	B-X
Nasal	B-X
polyposis	B-X
disease	B-X
is	B-X
an	B-X
inflammatory	B-X
disorder	B-X
with	B-X
intense	B-X
eosinophilic	B-X
infiltration	B-X
of	B-X
respiratory	B-X
mucosa	B-X
that	B-X
is	B-X
often	B-X
difficult	B-X
to	B-X
control	B-X
with	B-X
topical	B-X
steroids	B-X

NPs	B-cell_type
that	O
were	O
``	O
FP-insensitive	O
''	O
in	O
terms	O
of	O
suppression	O
of	O
eosinophil	B-cell_type
numbers	O
(	O
major	B-protein
basic	I-protein
protein	I-protein
-positive	O
)	O
had	O
a	O
significantly	O
greater	O
percentage	O
of	O
GRbeta-positive	B-cell_type
inflammatory	I-cell_type
cells	I-cell_type
,	O
a	O
higher	O
ratio	O
of	O
GRbeta-positive/GRalpha-positive	B-cell_type
cells	I-cell_type
,	O
and	O
increased	O
numbers	O
of	O
GRbeta-positive	B-cell_type
eosinophils	I-cell_type
and	O
macrophages	B-cell_type
in	O
comparison	O
with	O
those	O
that	O
were	O
``	O
FP-sensitive.	O
''	O

``	B-cell_type
FP-insensitive	I-cell_type
''	I-cell_type
NPs	I-cell_type
also	O
demonstrated	O
a	O
higher	O
percentage	O
of	O
IL-5-positive	B-cell_type
inflammatory	I-cell_type
cells	I-cell_type
expressing	O
GRbeta	B-protein
before	O
and	O
after	O
FP	O
treatment	O
.	O
<EOS>	B-X
``	B-X
``	B-X
FP	B-X
-	B-X
insensitive	B-X
''	B-X
NPs	B-X
also	B-X
demonstrated	B-X
a	B-X
higher	B-X
percentage	B-X
of	B-X
IL	B-X
-	B-X
5	B-X
-	B-X
positive	B-X
inflammatory	B-X
cells	B-X
expressing	B-X
GRbeta	B-X
before	B-X
and	B-X
after	B-X
FP	B-X
treatment	B-X
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
inflammatory	B-X
cells	B-X
expressing	B-X
GRbeta	B-X
was	B-X
also	B-X
increased	B-X
(	B-X
40	B-X
<EOS>	B-X
NPs	B-X
that	B-X
were	B-X
``	B-X
FP	B-X
-	B-X
insensitive	B-X
''	B-X
in	B-X
terms	B-X
of	B-X
suppression	B-X
of	B-X
eosinophil	B-X
numbers	B-X
(	B-X
major	B-X
basic	B-X
protein	B-X
-	B-X
positive	B-X
)	B-X
had	B-X
a	B-X
significantly	B-X
greater	B-X
percentage	B-X
of	B-X
GRbeta	B-X
-	B-X
positive	B-X
inflammatory	B-X
cells	B-X
,	B-X
a	B-X
higher	B-X
ratio	B-X
of	B-X
GRbeta	B-X
-	B-X
positive	B-X
/	B-X
GRalpha	B-X
-	B-X
positive	B-X
cells	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
GRbeta	B-X
-	B-X
positive	B-X
eosinophils	B-X
and	B-X
macrophages	B-X
in	B-X
comparison	B-X
with	B-X
those	B-X
that	B-X
were	B-X
``	B-X
FP	B-X
-	B-X
sensitive	B-X
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
overexpression	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
splice	B-X
variant	B-X
GRbeta	B-X
in	B-X
inflammatory	B-X
cells	B-X
might	B-X
contribute	B-X
to	B-X
steroid	B-X
insensitivity	B-X
in	B-X
diseases	B-X
such	B-X
as	B-X
asthma	B-X

CONCLUSION	O
:	O
GRbeta	B-protein
expression	O
appears	O
to	O
be	O
a	O
marker	O
of	O
steroid	O
insensitivity	O
in	O
NPs	B-cell_type
.	O
<EOS>	B-X
GRbeta	B-X
expression	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
steroid	B-X
insensitivity	B-X
in	B-X
NPs	B-X
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
overexpression	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
splice	B-X
variant	B-X
GRbeta	B-X
in	B-X
inflammatory	B-X
cells	B-X
might	B-X
contribute	B-X
to	B-X
steroid	B-X
insensitivity	B-X
in	B-X
diseases	B-X
such	B-X
as	B-X
asthma	B-X
<EOS>	B-X
The	B-X
total	B-X
numbers	B-X
of	B-X
inflammatory	B-X
cells	B-X
were	B-X
increased	B-X
in	B-X
NPs	B-X
<EOS>	B-X
Biopsies	B-X
were	B-X
obtained	B-X
from	B-X
10	B-X
subjects	B-X
with	B-X
NPs	B-X
before	B-X
and	B-X
4	B-X
weeks	B-X
after	B-X
treatment	B-X
with	B-X
intranasal	B-X
FP	B-X

Expression	O
of	O
GRbeta	B-protein
by	O
NP	B-cell_type
inflammatory	I-cell_type
cells	I-cell_type
,	O
particularly	O
T	B-cell_type
cells	I-cell_type
and	O
eosinophils	B-cell_type
,	O
might	O
render	O
them	O
resistant	O
to	O
suppression	O
by	O
topical	O
steroids	O
and	O
thereby	O
contribute	O
to	O
persistent	O
NP	B-cell_type
inflammation	O
.	O

Transcriptional	O
regulation	O
of	O
galectin-10	B-protein
(	O
eosinophil	B-protein
Charcot-Leyden	I-protein
crystal	I-protein
protein	I-protein
)	O
:	O
a	O
GC	B-DNA
box	I-DNA
(	O
-44	O
to	O
-50	O
)	O
controls	O
butyric	O
acid	O
induction	O
of	O
gene	O
expression	O
.	O

Galectin-10	B-protein
(	O
gal-10	B-protein
,	O
also	O
known	O
as	O
Charcot-Leyden	B-protein
crystal	I-protein
protein	I-protein
)	O
is	O
a	O
member	O
of	O
the	O
galectin	B-protein
family	I-protein
of	O
beta-galactoside	B-protein
binding	I-protein
proteins	I-protein
that	O
is	O
expressed	O
uniquely	O
in	O
eosinophilic	B-cell_type
and	I-cell_type
basophilic	I-cell_type
leukocytes	I-cell_type
.	O
<EOS>	B-X
Galectin	B-X
-	B-X
10	B-X
(	B-X
gal	B-X
-	B-X
10	B-X
,	B-X
also	B-X
known	B-X
as	B-X
Charcot	B-X
-	B-X
Leyden	B-X
crystal	B-X
protein	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
galectin	B-X
family	B-X
of	B-X
beta	B-X
-	B-X
galactoside	B-X
binding	B-X
proteins	B-X
that	B-X
is	B-X
expressed	B-X
uniquely	B-X
in	B-X
eosinophilic	B-X
and	B-X
basophilic	B-X
leukocytes	B-X
<EOS>	B-X
Transcriptional	B-X
regulation	B-X
of	B-X
galectin	B-X
-	B-X
10	B-X
(	B-X
eosinophil	B-X
Charcot	B-X
-	B-X
Leyden	B-X
crystal	B-X
protein	B-X
)	B-X
:	B-X
a	B-X
GC	B-X
box	B-X
(	B-X
	B-X
-	B-X
44	B-X
to	B-X
	B-X
-	B-X
50	B-X
)	B-X
controls	B-X
butyric	B-X
acid	B-X
induction	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Similar	B-X
to	B-X
gal	B-X
-	B-X
1	B-X
,	B-X
gal	B-X
-	B-X
10	B-X
expression	B-X
is	B-X
induced	B-X
by	B-X
butyric	B-X
acid	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
is	B-X
lost	B-X
upon	B-X
ablation	B-X
of	B-X
the	B-X
GC	B-X
box	B-X
<EOS>	B-X
By	B-X
supershift	B-X
analysis	B-X
,	B-X
we	B-X
demonstrate	B-X
binding	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
Sp1	B-X
and	B-X
Oct1	B-X
to	B-X
the	B-X
consensus	B-X
GC	B-X
box	B-X
and	B-X
the	B-X
Oct	B-X
site	B-X
,	B-X
respectively	B-X

To	O
gain	O
a	O
better	O
understanding	O
of	O
galectin	O
gene	O
expression	O
,	O
we	O
present	O
an	O
analysis	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
gal-10	B-protein
.	O

Analysis	O
of	O
the	O
minimal	B-DNA
promoter	I-DNA
revealed	O
nine	O
consensus-binding	B-DNA
sites	I-DNA
for	O
transcription	B-protein
factors	I-protein
,	O
including	O
several	O
that	O
are	O
also	O
found	O
in	O
the	O
minimal	B-DNA
promoters	I-DNA
of	O
galectins	B-DNA
-1	I-DNA
,	I-DNA
-2	I-DNA
,	I-DNA
and	I-DNA
-3	I-DNA
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
minimal	B-X
promoter	B-X
revealed	B-X
nine	B-X
consensus	B-X
-	B-X
binding	B-X
sites	B-X
for	B-X
transcription	B-X
factors	B-X
,	B-X
including	B-X
several	B-X
that	B-X
are	B-X
also	B-X
found	B-X
in	B-X
the	B-X
minimal	B-X
promoters	B-X
of	B-X
galectins	B-X
	B-X
-	B-X
1	B-X
,	B-X
	B-X
-	B-X
2	B-X
,	B-X
and	B-X
	B-X
-	B-X
3	B-X
<EOS>	B-X
By	B-X
supershift	B-X
analysis	B-X
,	B-X
we	B-X
demonstrate	B-X
binding	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
Sp1	B-X
and	B-X
Oct1	B-X
to	B-X
the	B-X
consensus	B-X
GC	B-X
box	B-X
and	B-X
the	B-X
Oct	B-X
site	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
we	B-X
demonstrate	B-X
AML3	B-X
binding	B-X
to	B-X
the	B-X
consensus	B-X
AML	B-X
site	B-X
and	B-X
YY1	B-X
binding	B-X
to	B-X
the	B-X
Inr	B-X
sequence	B-X
,	B-X
both	B-X
elements	B-X
functioning	B-X
as	B-X
silencers	B-X
in	B-X
the	B-X
gal	B-X
-	B-X
10	B-X
promoter	B-X
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
galectin	B-X
gene	B-X
expression	B-X
,	B-X
we	B-X
present	B-X
an	B-X
analysis	B-X
of	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
gal	B-X
-	B-X
10	B-X

The	O
decrease	O
in	O
gal-10	O
promoter	O
activity	O
after	O
disruption	O
of	O
either	O
the	O
GC	B-DNA
box	I-DNA
(	O
-44	O
to	O
-50	O
)	O
or	O
the	O
Oct	B-DNA
site	I-DNA
(	O
-255	O
to	O
-261	O
)	O
suggests	O
that	O
these	O
sites	O
,	O
along	O
with	O
the	O
previously	O
characterized	O
GATA	B-DNA
and	I-DNA
EoTF	I-DNA
sites	I-DNA
,	O
are	O
necessary	O
for	O
full	O
promoter	O
activity	O
.	O
<EOS>	B-X
The	B-X
decrease	B-X
in	B-X
gal	B-X
-	B-X
10	B-X
promoter	B-X
activity	B-X
after	B-X
disruption	B-X
of	B-X
either	B-X
the	B-X
GC	B-X
box	B-X
(	B-X
	B-X
-	B-X
44	B-X
to	B-X
	B-X
-	B-X
50	B-X
)	B-X
or	B-X
the	B-X
Oct	B-X
site	B-X
(	B-X
	B-X
-	B-X
255	B-X
to	B-X
	B-X
-	B-X
261	B-X
)	B-X
suggests	B-X
that	B-X
these	B-X
sites	B-X
,	B-X
along	B-X
with	B-X
the	B-X
previously	B-X
characterized	B-X
GATA	B-X
and	B-X
EoTF	B-X
sites	B-X
,	B-X
are	B-X
necessary	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
we	B-X
demonstrate	B-X
AML3	B-X
binding	B-X
to	B-X
the	B-X
consensus	B-X
AML	B-X
site	B-X
and	B-X
YY1	B-X
binding	B-X
to	B-X
the	B-X
Inr	B-X
sequence	B-X
,	B-X
both	B-X
elements	B-X
functioning	B-X
as	B-X
silencers	B-X
in	B-X
the	B-X
gal	B-X
-	B-X
10	B-X
promoter	B-X
<EOS>	B-X
By	B-X
supershift	B-X
analysis	B-X
,	B-X
we	B-X
demonstrate	B-X
binding	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
Sp1	B-X
and	B-X
Oct1	B-X
to	B-X
the	B-X
consensus	B-X
GC	B-X
box	B-X
and	B-X
the	B-X
Oct	B-X
site	B-X
,	B-X
respectively	B-X
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
galectin	B-X
gene	B-X
expression	B-X
,	B-X
we	B-X
present	B-X
an	B-X
analysis	B-X
of	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
gal	B-X
-	B-X
10	B-X

By	O
supershift	O
analysis	O
,	O
we	O
demonstrate	O
binding	O
of	O
the	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
Oct1	B-protein
to	O
the	O
consensus	B-DNA
GC	I-DNA
box	I-DNA
and	O
the	O
Oct	B-DNA
site	I-DNA
,	O
respectively	O
.	O

Similar	O
to	O
gal-1	B-DNA
,	O
gal-10	O
expression	O
is	O
induced	O
by	O
butyric	O
acid	O
,	O
an	O
effect	O
that	O
is	O
lost	O
upon	O
ablation	O
of	O
the	O
GC	B-DNA
box	I-DNA
.	O

Additionally	O
,	O
we	O
demonstrate	O
AML3	O
binding	O
to	O
the	O
consensus	B-DNA
AML	I-DNA
site	I-DNA
and	O
YY1	B-protein
binding	I-protein
to	O
the	O
Inr	B-DNA
sequence	I-DNA
,	O
both	O
elements	O
functioning	O
as	O
silencers	O
in	O
the	O
gal-10	B-DNA
promoter	I-DNA
.	O

Tumour-stromal	O
interactions	O
.	O
<EOS>	B-X
The	B-X
molecular	B-X
players	B-X
of	B-X
such	B-X
interplay	B-X
remain	B-X
partially	B-X
understood	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
emerging	B-X
role	B-X
of	B-X
YAP	B-X
and	B-X
TAZ	B-X
in	B-X
choreographing	B-X
tumour	B-X
-	B-X
stromal	B-X
interactions	B-X
<EOS>	B-X
Silencing	B-X
YAP1	B-X
in	B-X
tumour	B-X
stromal	B-X
cells	B-X
can	B-X
effectively	B-X
inhibit	B-X
tumour	B-X
growth	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
tumour	B-X
microenvironment	B-X
:	B-X
a	B-X
new	B-X
vision	B-X
for	B-X
cholangiocarcinoma	B-X
.	B-X

Role	O
of	O
the	O
stroma	O
in	O
mammary	O
development	O
.	O
<EOS>	B-X
Mesenchymal	B-X
stem	B-X
/	B-X
stromal	B-X
cells	B-X
in	B-X
breast	B-X
cancer	B-X
development	B-X
and	B-X
management	B-X
.	B-X
<EOS>	B-X
After	B-X
lactation	B-X
,	B-X
the	B-X
mammary	B-X
gland	B-X
involutes	B-X
to	B-X
a	B-X
pre	B-X
-	B-X
pregnant	B-X
state	B-X
<EOS>	B-X
A	B-X
prominent	B-X
cell	B-X
type	B-X
within	B-X
the	B-X
stroma	B-X
is	B-X
cancer	B-X
-	B-X
associated	B-X
fibroblasts	B-X
(	B-X
CAFs	B-X
)	B-X
<EOS>	B-X
The	B-X
Prognostic	B-X
Role	B-X
of	B-X
Intratumoral	B-X
Stromal	B-X
Content	B-X
in	B-X
Lobular	B-X
Breast	B-X
Cancer	B-X
.	B-X

Mammary	O
development	O
depends	O
on	O
branching	O
morphogenesis	O
,	O
namely	O
the	O
bifurcation	O
and	O
extension	O
of	O
ductal	O
growth	O
points	O
(	O
end	O
buds	O
)	O
and	O
secretory	O
lobules	O
into	O
a	O
more	O
or	O
less	O
fatty	O
stroma	O
.	O
<EOS>	B-X
Mammary	B-X
development	B-X
depends	B-X
on	B-X
branching	B-X
morphogenesis	B-X
,	B-X
namely	B-X
the	B-X
bifurcation	B-X
and	B-X
extension	B-X
of	B-X
ductal	B-X
growth	B-X
points	B-X
(	B-X
end	B-X
buds	B-X
)	B-X
and	B-X
secretory	B-X
lobules	B-X
into	B-X
a	B-X
more	B-X
or	B-X
less	B-X
fatty	B-X
stroma	B-X
<EOS>	B-X
Resolved	B-X
protein	B-X
interactions	B-X
are	B-X
discussed	B-X
and	B-X
compared	B-X
with	B-X
an	B-X
extensive	B-X
collection	B-X
of	B-X
native	B-X
mass	B-X
data	B-X
of	B-X
orthologues	B-X
in	B-X
other	B-X
plants	B-X
and	B-X
bacteria	B-X
<EOS>	B-X
The	B-X
histopathological	B-X
analysis	B-X
showed	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
collagen	B-X
fibres	B-X
and	B-X
in	B-X
the	B-X
inflammatory	B-X
cells	B-X
in	B-X
the	B-X
connective	B-X
tissue	B-X
stroma	B-X
<EOS>	B-X
thaliana	B-X
confirmed	B-X
the	B-X
accuracy	B-X
of	B-X
the	B-X
native	B-X
mass	B-X
determination	B-X
,	B-X
and	B-X
by	B-X
extension	B-X
,	B-X
the	B-X
usefulness	B-X
of	B-X
the	B-X
native	B-X
mass	B-X
data	B-X
for	B-X
future	B-X
in	B-X
-	B-X
depth	B-X
protein	B-X
interaction	B-X
studies	B-X

Because	O
breast	O
carcinomas	O
are	O
overwhelmingly	O
ductal	O
in	O
origin	O
,	O
this	O
review	O
focuses	O
on	O
stromal	O
influences	O
guiding	O
postnatal	O
ductal	O
development	O
and	O
there	O
is	O
only	O
the	O
briefest	O
account	O
of	O
the	O
role	O
of	O
embryonic	O
stroma	O
(	O
mesenchyme	O
)	O
.	O
<EOS>	B-X
Because	B-X
breast	B-X
carcinomas	B-X
are	B-X
overwhelmingly	B-X
ductal	B-X
in	B-X
origin	B-X
,	B-X
this	B-X
review	B-X
focuses	B-X
on	B-X
stromal	B-X
influences	B-X
guiding	B-X
postnatal	B-X
ductal	B-X
development	B-X
and	B-X
there	B-X
is	B-X
only	B-X
the	B-X
briefest	B-X
account	B-X
of	B-X
the	B-X
role	B-X
of	B-X
embryonic	B-X
stroma	B-X
(	B-X
mesenchyme	B-X
)	B-X
<EOS>	B-X
Mammary	B-X
development	B-X
depends	B-X
on	B-X
branching	B-X
morphogenesis	B-X
,	B-X
namely	B-X
the	B-X
bifurcation	B-X
and	B-X
extension	B-X
of	B-X
ductal	B-X
growth	B-X
points	B-X
(	B-X
end	B-X
buds	B-X
)	B-X
and	B-X
secretory	B-X
lobules	B-X
into	B-X
a	B-X
more	B-X
or	B-X
less	B-X
fatty	B-X
stroma	B-X
<EOS>	B-X
Evidence	B-X
is	B-X
presented	B-X
that	B-X
if	B-X
they	B-X
are	B-X
to	B-X
grow	B-X
,	B-X
end	B-X
buds	B-X
must	B-X
condition	B-X
proximal	B-X
fatty	B-X
stroma	B-X
by	B-X
recruiting	B-X
white	B-X
blood	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
inducing	B-X
stromal	B-X
cell	B-X
division	B-X
and	B-X
,	B-X
possibly	B-X
,	B-X
estrogen	B-X
receptors	B-X
<EOS>	B-X
Although	B-X
the	B-X
signals	B-X
governing	B-X
fibrotic	B-X
induction	B-X
,	B-X
ductal	B-X
morphogenesis	B-X
,	B-X
and	B-X
growth	B-X
inhibition	B-X
are	B-X
unknown	B-X
,	B-X
a	B-X
role	B-X
for	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
is	B-X
highly	B-X
likely	B-X
and	B-X
is	B-X
discussed	B-X

The	O
stroma	O
as	O
the	O
necessary	O
target	O
for	O
endocrine	O
mammogens	O
and	O
the	O
source	O
of	O
stimulatory	O
growth	O
factors	O
is	O
described	O
and	O
the	O
importance	O
of	O
mammary	O
epithelium-induced	O
modifications	O
of	O
the	O
periductal	O
stroma	O
is	O
emphasized	O
.	O
<EOS>	B-X
The	B-X
stroma	B-X
as	B-X
the	B-X
necessary	B-X
target	B-X
for	B-X
endocrine	B-X
mammogens	B-X
and	B-X
the	B-X
source	B-X
of	B-X
stimulatory	B-X
growth	B-X
factors	B-X
is	B-X
described	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
mammary	B-X
epithelium	B-X
-	B-X
induced	B-X
modifications	B-X
of	B-X
the	B-X
periductal	B-X
stroma	B-X
is	B-X
emphasized	B-X
<EOS>	B-X
Finally	B-X
,	B-X
a	B-X
need	B-X
for	B-X
new	B-X
conceptual	B-X
and	B-X
experimental	B-X
approaches	B-X
to	B-X
understanding	B-X
stromal	B-X
-	B-X
epithelial	B-X
signaling	B-X
is	B-X
discussed	B-X
<EOS>	B-X
Although	B-X
the	B-X
signals	B-X
governing	B-X
fibrotic	B-X
induction	B-X
,	B-X
ductal	B-X
morphogenesis	B-X
,	B-X
and	B-X
growth	B-X
inhibition	B-X
are	B-X
unknown	B-X
,	B-X
a	B-X
role	B-X
for	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
is	B-X
highly	B-X
likely	B-X
and	B-X
is	B-X
discussed	B-X
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
a	B-X
fibrous	B-X
stromal	B-X
tunic	B-X
around	B-X
the	B-X
end	B-X
bud	B-X
is	B-X
described	B-X
and	B-X
its	B-X
likely	B-X
role	B-X
as	B-X
a	B-X
complex	B-X
ductal	B-X
morphogen	B-X
is	B-X
discussed	B-X
;	B-X
a	B-X
possible	B-X
role	B-X
in	B-X
growth	B-X
inhibition	B-X
is	B-X
also	B-X
considered	B-X

Evidence	O
is	O
presented	O
that	O
if	O
they	O
are	O
to	O
grow	O
,	O
end	O
buds	O
must	O
condition	O
proximal	O
fatty	O
stroma	O
by	O
recruiting	O
white	B-cell_type
blood	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
inducing	O
stromal	O
cell	O
division	O
and	O
,	O
possibly	O
,	O
estrogen	B-protein
receptors	I-protein
.	O
<EOS>	B-X
Evidence	B-X
is	B-X
presented	B-X
that	B-X
if	B-X
they	B-X
are	B-X
to	B-X
grow	B-X
,	B-X
end	B-X
buds	B-X
must	B-X
condition	B-X
proximal	B-X
fatty	B-X
stroma	B-X
by	B-X
recruiting	B-X
white	B-X
blood	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
inducing	B-X
stromal	B-X
cell	B-X
division	B-X
and	B-X
,	B-X
possibly	B-X
,	B-X
estrogen	B-X
receptors	B-X
<EOS>	B-X
Finally	B-X
,	B-X
a	B-X
need	B-X
for	B-X
new	B-X
conceptual	B-X
and	B-X
experimental	B-X
approaches	B-X
to	B-X
understanding	B-X
stromal	B-X
-	B-X
epithelial	B-X
signaling	B-X
is	B-X
discussed	B-X
<EOS>	B-X
Because	B-X
breast	B-X
carcinomas	B-X
are	B-X
overwhelmingly	B-X
ductal	B-X
in	B-X
origin	B-X
,	B-X
this	B-X
review	B-X
focuses	B-X
on	B-X
stromal	B-X
influences	B-X
guiding	B-X
postnatal	B-X
ductal	B-X
development	B-X
and	B-X
there	B-X
is	B-X
only	B-X
the	B-X
briefest	B-X
account	B-X
of	B-X
the	B-X
role	B-X
of	B-X
embryonic	B-X
stroma	B-X
(	B-X
mesenchyme	B-X
)	B-X
<EOS>	B-X
The	B-X
stroma	B-X
as	B-X
the	B-X
necessary	B-X
target	B-X
for	B-X
endocrine	B-X
mammogens	B-X
and	B-X
the	B-X
source	B-X
of	B-X
stimulatory	B-X
growth	B-X
factors	B-X
is	B-X
described	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
mammary	B-X
epithelium	B-X
-	B-X
induced	B-X
modifications	B-X
of	B-X
the	B-X
periductal	B-X
stroma	B-X
is	B-X
emphasized	B-X

The	O
induction	O
of	O
a	O
fibrous	O
stromal	O
tunic	O
around	O
the	O
end	O
bud	O
is	O
described	O
and	O
its	O
likely	O
role	O
as	O
a	O
complex	O
ductal	O
morphogen	O
is	O
discussed	O
;	O
a	O
possible	O
role	O
in	O
growth	O
inhibition	O
is	O
also	O
considered	O
.	O
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
a	B-X
fibrous	B-X
stromal	B-X
tunic	B-X
around	B-X
the	B-X
end	B-X
bud	B-X
is	B-X
described	B-X
and	B-X
its	B-X
likely	B-X
role	B-X
as	B-X
a	B-X
complex	B-X
ductal	B-X
morphogen	B-X
is	B-X
discussed	B-X
;	B-X
a	B-X
possible	B-X
role	B-X
in	B-X
growth	B-X
inhibition	B-X
is	B-X
also	B-X
considered	B-X
<EOS>	B-X
Finally	B-X
,	B-X
a	B-X
need	B-X
for	B-X
new	B-X
conceptual	B-X
and	B-X
experimental	B-X
approaches	B-X
to	B-X
understanding	B-X
stromal	B-X
-	B-X
epithelial	B-X
signaling	B-X
is	B-X
discussed	B-X
<EOS>	B-X
Because	B-X
breast	B-X
carcinomas	B-X
are	B-X
overwhelmingly	B-X
ductal	B-X
in	B-X
origin	B-X
,	B-X
this	B-X
review	B-X
focuses	B-X
on	B-X
stromal	B-X
influences	B-X
guiding	B-X
postnatal	B-X
ductal	B-X
development	B-X
and	B-X
there	B-X
is	B-X
only	B-X
the	B-X
briefest	B-X
account	B-X
of	B-X
the	B-X
role	B-X
of	B-X
embryonic	B-X
stroma	B-X
(	B-X
mesenchyme	B-X
)	B-X
<EOS>	B-X
The	B-X
stroma	B-X
as	B-X
the	B-X
necessary	B-X
target	B-X
for	B-X
endocrine	B-X
mammogens	B-X
and	B-X
the	B-X
source	B-X
of	B-X
stimulatory	B-X
growth	B-X
factors	B-X
is	B-X
described	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
mammary	B-X
epithelium	B-X
-	B-X
induced	B-X
modifications	B-X
of	B-X
the	B-X
periductal	B-X
stroma	B-X
is	B-X
emphasized	B-X

Although	O
the	O
signals	O
governing	O
fibrotic	O
induction	O
,	O
ductal	O
morphogenesis	O
,	O
and	O
growth	O
inhibition	O
are	O
unknown	O
,	O
a	O
role	O
for	O
transforming	O
growth	B-protein
factor-beta	I-protein
is	O
highly	O
likely	O
and	O
is	O
discussed	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
signals	B-X
governing	B-X
fibrotic	B-X
induction	B-X
,	B-X
ductal	B-X
morphogenesis	B-X
,	B-X
and	B-X
growth	B-X
inhibition	B-X
are	B-X
unknown	B-X
,	B-X
a	B-X
role	B-X
for	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
is	B-X
highly	B-X
likely	B-X
and	B-X
is	B-X
discussed	B-X
<EOS>	B-X
Finally	B-X
,	B-X
a	B-X
need	B-X
for	B-X
new	B-X
conceptual	B-X
and	B-X
experimental	B-X
approaches	B-X
to	B-X
understanding	B-X
stromal	B-X
-	B-X
epithelial	B-X
signaling	B-X
is	B-X
discussed	B-X
<EOS>	B-X
The	B-X
stroma	B-X
as	B-X
the	B-X
necessary	B-X
target	B-X
for	B-X
endocrine	B-X
mammogens	B-X
and	B-X
the	B-X
source	B-X
of	B-X
stimulatory	B-X
growth	B-X
factors	B-X
is	B-X
described	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
mammary	B-X
epithelium	B-X
-	B-X
induced	B-X
modifications	B-X
of	B-X
the	B-X
periductal	B-X
stroma	B-X
is	B-X
emphasized	B-X
<EOS>	B-X
Mammary	B-X
development	B-X
depends	B-X
on	B-X
branching	B-X
morphogenesis	B-X
,	B-X
namely	B-X
the	B-X
bifurcation	B-X
and	B-X
extension	B-X
of	B-X
ductal	B-X
growth	B-X
points	B-X
(	B-X
end	B-X
buds	B-X
)	B-X
and	B-X
secretory	B-X
lobules	B-X
into	B-X
a	B-X
more	B-X
or	B-X
less	B-X
fatty	B-X
stroma	B-X

Finally	O
,	O
a	O
need	O
for	O
new	O
conceptual	O
and	O
experimental	O
approaches	O
to	O
understanding	O
stromal-epithelial	O
signaling	O
is	O
discussed	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
a	B-X
need	B-X
for	B-X
new	B-X
conceptual	B-X
and	B-X
experimental	B-X
approaches	B-X
to	B-X
understanding	B-X
stromal	B-X
-	B-X
epithelial	B-X
signaling	B-X
is	B-X
discussed	B-X
<EOS>	B-X
Although	B-X
the	B-X
signals	B-X
governing	B-X
fibrotic	B-X
induction	B-X
,	B-X
ductal	B-X
morphogenesis	B-X
,	B-X
and	B-X
growth	B-X
inhibition	B-X
are	B-X
unknown	B-X
,	B-X
a	B-X
role	B-X
for	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
is	B-X
highly	B-X
likely	B-X
and	B-X
is	B-X
discussed	B-X
<EOS>	B-X
The	B-X
stroma	B-X
as	B-X
the	B-X
necessary	B-X
target	B-X
for	B-X
endocrine	B-X
mammogens	B-X
and	B-X
the	B-X
source	B-X
of	B-X
stimulatory	B-X
growth	B-X
factors	B-X
is	B-X
described	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
mammary	B-X
epithelium	B-X
-	B-X
induced	B-X
modifications	B-X
of	B-X
the	B-X
periductal	B-X
stroma	B-X
is	B-X
emphasized	B-X
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
a	B-X
fibrous	B-X
stromal	B-X
tunic	B-X
around	B-X
the	B-X
end	B-X
bud	B-X
is	B-X
described	B-X
and	B-X
its	B-X
likely	B-X
role	B-X
as	B-X
a	B-X
complex	B-X
ductal	B-X
morphogen	B-X
is	B-X
discussed	B-X
;	B-X
a	B-X
possible	B-X
role	B-X
in	B-X
growth	B-X
inhibition	B-X
is	B-X
also	B-X
considered	B-X

Adipophilin	B-protein
is	O
a	O
sensitive	O
marker	O
for	O
lipid	O
loading	O
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
Adipophilin	B-X
is	B-X
a	B-X
sensitive	B-X
marker	B-X
for	B-X
lipid	B-X
loading	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Adipophilin	B-X
facilitates	B-X
the	B-X
uptake	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
,	B-X
and	B-X
here	B-X
we	B-X
demonstrate	B-X
that	B-X
free	B-X
fatty	B-X
acids	B-X
increase	B-X
is	B-X
related	B-X
to	B-X
the	B-X
early	B-X
upregulation	B-X
of	B-X
adipophilin	B-X
expression	B-X
in	B-X
blood	B-X
monocytes	B-X
<EOS>	B-X
Adipophilin	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
lipid	B-X
accumulation	B-X
initially	B-X
described	B-X
in	B-X
adipocytes	B-X
,	B-X
was	B-X
recently	B-X
shown	B-X
to	B-X
be	B-X
induced	B-X
in	B-X
macrophage	B-X
foam	B-X
cells	B-X
<EOS>	B-X
This	B-X
rapid	B-X
induction	B-X
of	B-X
adipophilin	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
in	B-X
monocytes	B-X
incubated	B-X
with	B-X
E	B-X
-	B-X
LDL	B-X

Adipophilin	B-protein
,	O
a	O
marker	O
of	O
lipid	O
accumulation	O
initially	O
described	O
in	O
adipocytes	B-cell_type
,	O
was	O
recently	O
shown	O
to	O
be	O
induced	O
in	O
macrophage	B-cell_type
foam	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Adipophilin	B-X
,	B-X
a	B-X
marker	B-X
of	B-X
lipid	B-X
accumulation	B-X
initially	B-X
described	B-X
in	B-X
adipocytes	B-X
,	B-X
was	B-X
recently	B-X
shown	B-X
to	B-X
be	B-X
induced	B-X
in	B-X
macrophage	B-X
foam	B-X
cells	B-X
<EOS>	B-X
Adipophilin	B-X
is	B-X
a	B-X
sensitive	B-X
marker	B-X
for	B-X
lipid	B-X
loading	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Adipophilin	B-X
facilitates	B-X
the	B-X
uptake	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
,	B-X
and	B-X
here	B-X
we	B-X
demonstrate	B-X
that	B-X
free	B-X
fatty	B-X
acids	B-X
increase	B-X
is	B-X
related	B-X
to	B-X
the	B-X
early	B-X
upregulation	B-X
of	B-X
adipophilin	B-X
expression	B-X
in	B-X
blood	B-X
monocytes	B-X
<EOS>	B-X
This	B-X
rapid	B-X
induction	B-X
of	B-X
adipophilin	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
in	B-X
monocytes	B-X
incubated	B-X
with	B-X
E	B-X
-	B-X
LDL	B-X

We	O
found	O
that	O
even	O
freshly	B-cell_type
isolated	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
express	O
adipophilin	B-protein
and	O
that	O
the	O
amount	O
of	O
adipophilin	B-protein
protein	I-protein
is	O
variable	O
in	O
monocytes	B-cell_type
from	O
different	O
healthy	O
individuals	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
even	B-X
freshly	B-X
isolated	B-X
blood	B-X
monocytes	B-X
express	B-X
adipophilin	B-X
and	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
adipophilin	B-X
protein	B-X
is	B-X
variable	B-X
in	B-X
monocytes	B-X
from	B-X
different	B-X
healthy	B-X
individuals	B-X
<EOS>	B-X
Fatty	B-X
acids	B-X
are	B-X
ligands	B-X
for	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
-	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
,	B-X
and	B-X
the	B-X
upregulation	B-X
of	B-X
adipophilin	B-X
mRNA	B-X
by	B-X
PPARgamma	B-X
agonists	B-X
like	B-X
15d	B-X
-	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
and	B-X
ciglitazone	B-X
indicates	B-X
that	B-X
PPARgamma	B-X
may	B-X
mediate	B-X
the	B-X
induction	B-X
of	B-X
adipophilin	B-X
expression	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
<EOS>	B-X
This	B-X
rapid	B-X
induction	B-X
of	B-X
adipophilin	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
in	B-X
monocytes	B-X
incubated	B-X
with	B-X
E	B-X
-	B-X
LDL	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
physiological	B-X
expression	B-X
of	B-X
adipophilin	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
levels	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
,	B-X
cholesterylesters	B-X
or	B-X
free	B-X
cholesterol	B-X

However	O
,	O
the	O
physiological	O
expression	O
of	O
adipophilin	B-protein
does	O
not	O
correlate	O
with	O
the	O
levels	O
of	O
free	O
fatty	O
acids	O
,	O
cholesterylesters	O
or	O
free	O
cholesterol	O
.	O
<EOS>	B-X
The	B-X
inhibitor	B-X
-	B-X
associated	B-X
oxylipin	B-X
changes	B-X
were	B-X
unrelated	B-X
to	B-X
serum	B-X
insulin	B-X
,	B-X
glucose	B-X
,	B-X
cholesterol	B-X
,	B-X
or	B-X
female	B-X
estrous	B-X
cycle	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
influence	B-X
of	B-X
MetS	B-X
on	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
HCC	B-X
is	B-X
still	B-X
unclear	B-X
<EOS>	B-X
Further	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
stability	B-X
of	B-X
the	B-X
liposomes	B-X
and	B-X
the	B-X
changes	B-X
in	B-X
the	B-X
simulated	B-X
reducing	B-X
environment	B-X
were	B-X
determined	B-X
<EOS>	B-X
CPAP	B-X
did	B-X
not	B-X
affect	B-X
expression	B-X
of	B-X
CD59	B-X
or	B-X
complement	B-X
deposition	B-X
on	B-X
endothelial	B-X
cells	B-X
in	B-X
OSA	B-X
patients	B-X
regardless	B-X
of	B-X
adherence	B-X

Enzymatically	B-protein
modified	I-protein
low-density	I-protein
lipoprotein	I-protein
(	O
E-LDL	B-protein
)	O
induces	O
rapid	O
foam	O
cell	O
formation	O
in	O
monocytes	B-cell_type
and	O
upregulates	O
adipophilin	B-protein
mRNA	O
and	O
protein	O
within	O
2	O
h	O
of	O
incubation	O
.	O
<EOS>	B-X
Enzymatically	B-X
modified	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
(	B-X
E	B-X
-	B-X
LDL	B-X
)	B-X
induces	B-X
rapid	B-X
foam	B-X
cell	B-X
formation	B-X
in	B-X
monocytes	B-X
and	B-X
upregulates	B-X
adipophilin	B-X
mRNA	B-X
and	B-X
protein	B-X
within	B-X
2	B-X
h	B-X
of	B-X
incubation	B-X
<EOS>	B-X
This	B-X
rapid	B-X
induction	B-X
of	B-X
adipophilin	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
in	B-X
monocytes	B-X
incubated	B-X
with	B-X
E	B-X
-	B-X
LDL	B-X
<EOS>	B-X
Fatty	B-X
acids	B-X
are	B-X
ligands	B-X
for	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
-	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
,	B-X
and	B-X
the	B-X
upregulation	B-X
of	B-X
adipophilin	B-X
mRNA	B-X
by	B-X
PPARgamma	B-X
agonists	B-X
like	B-X
15d	B-X
-	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
and	B-X
ciglitazone	B-X
indicates	B-X
that	B-X
PPARgamma	B-X
may	B-X
mediate	B-X
the	B-X
induction	B-X
of	B-X
adipophilin	B-X
expression	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
<EOS>	B-X
Adipophilin	B-X
facilitates	B-X
the	B-X
uptake	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
,	B-X
and	B-X
here	B-X
we	B-X
demonstrate	B-X
that	B-X
free	B-X
fatty	B-X
acids	B-X
increase	B-X
is	B-X
related	B-X
to	B-X
the	B-X
early	B-X
upregulation	B-X
of	B-X
adipophilin	B-X
expression	B-X
in	B-X
blood	B-X
monocytes	B-X

This	O
rapid	O
induction	O
of	O
adipophilin	B-protein
is	O
accompanied	O
by	O
a	O
significant	O
increase	O
of	O
free	O
fatty	O
acids	O
in	O
monocytes	B-cell_type
incubated	O
with	O
E-LDL	B-protein
.	O
<EOS>	B-X
This	B-X
rapid	B-X
induction	B-X
of	B-X
adipophilin	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
in	B-X
monocytes	B-X
incubated	B-X
with	B-X
E	B-X
-	B-X
LDL	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
physiological	B-X
expression	B-X
of	B-X
adipophilin	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
levels	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
,	B-X
cholesterylesters	B-X
or	B-X
free	B-X
cholesterol	B-X
<EOS>	B-X
Adipophilin	B-X
is	B-X
a	B-X
sensitive	B-X
marker	B-X
for	B-X
lipid	B-X
loading	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
even	B-X
freshly	B-X
isolated	B-X
blood	B-X
monocytes	B-X
express	B-X
adipophilin	B-X
and	B-X
that	B-X
the	B-X
amount	B-X
of	B-X
adipophilin	B-X
protein	B-X
is	B-X
variable	B-X
in	B-X
monocytes	B-X
from	B-X
different	B-X
healthy	B-X
individuals	B-X

Adipophilin	B-protein
facilitates	O
the	O
uptake	O
of	O
free	O
fatty	O
acids	O
,	O
and	O
here	O
we	O
demonstrate	O
that	O
free	O
fatty	O
acids	O
increase	O
is	O
related	O
to	O
the	O
early	O
upregulation	O
of	O
adipophilin	O
expression	O
in	O
blood	B-cell_type
monocytes	I-cell_type
.	O

Fatty	O
acids	O
are	O
ligands	O
for	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
and	O
the	O
upregulation	O
of	O
adipophilin	B-RNA
mRNA	I-RNA
by	O
PPARgamma	B-protein
agonists	O
like	O
15d-PGJ	O
(	O
2	O
)	O
and	O
ciglitazone	O
indicates	O
that	O
PPARgamma	B-protein
may	O
mediate	O
the	O
induction	O
of	O
adipophilin	O
expression	O
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

Constitutive	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
melanoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
results	O
from	O
the	O
transcription	O
of	O
class	B-DNA
II	I-DNA
transactivator	I-DNA
abnormally	O
initiated	O
from	O
its	O
B	B-DNA
cell-specific	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
melanoma	B-X
cell	B-X
lines	B-X
results	B-X
from	B-X
the	B-X
transcription	B-X
of	B-X
class	B-X
II	B-X
transactivator	B-X
abnormally	B-X
initiated	B-X
from	B-X
its	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Constitutive	B-X
transcription	B-X
of	B-X
CIITA	B-X
from	B-X
promoter	B-X
III	B-X
having	B-X
been	B-X
observed	B-X
in	B-X
unrelated	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
propose	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
phenomenon	B-X
might	B-X
not	B-X
be	B-X
a	B-X
random	B-X
event	B-X
,	B-X
but	B-X
could	B-X
be	B-X
linked	B-X
to	B-X
the	B-X
neoplasic	B-X
state	B-X
of	B-X
the	B-X
melanoma	B-X
cells	B-X
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
a	B-X
coordinate	B-X
transcription	B-X
of	B-X
the	B-X
HLA	B-X
-	B-X
D	B-X
genes	B-X
in	B-X
these	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
CIITA	B-X
(	B-X
class	B-X
II	B-X
transactivator	B-X
)	B-X
transcripts	B-X
,	B-X
CIITA	B-X
being	B-X
known	B-X
as	B-X
the	B-X
master	B-X
switch	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
<EOS>	B-X
In	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
two	B-X
different	B-X
patterns	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
have	B-X
been	B-X
described	B-X
,	B-X
either	B-X
an	B-X
IFN	B-X
gamma	B-X
-	B-X
inducible	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
DR	B-X
and	B-X
HLA	B-X
-	B-X
DP	B-X
,	B-X
with	B-X
a	B-X
faint	B-X
or	B-X
null	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
DQ	B-X
,	B-X
resembling	B-X
that	B-X
described	B-X
for	B-X
melanocytes	B-X
,	B-X
or	B-X
a	B-X
constitutive	B-X
expression	B-X
,	B-X
i	B-X

In	O
melanoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
two	O
different	O
patterns	O
of	O
MHC	O
class	O
II	O
expression	O
have	O
been	O
described	O
,	O
either	O
an	O
IFN	O
gamma-inducible	O
expression	O
of	O
HLA-DR	B-DNA
and	O
HLA-DP	B-DNA
,	O
with	O
a	O
faint	O
or	O
null	O
expression	O
of	O
HLA-DQ	B-DNA
,	O
resembling	O
that	O
described	O
for	O
melanocytes	B-cell_type
,	O
or	O
a	O
constitutive	O
expression	O
,	O
i.e.	O
,	O
IFN-gamma	O
independent	O
,	O
of	O
all	O
three	O
HLA-D	B-DNA
isotypes	I-DNA
.	O
<EOS>	B-X
In	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
two	B-X
different	B-X
patterns	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
have	B-X
been	B-X
described	B-X
,	B-X
either	B-X
an	B-X
IFN	B-X
gamma	B-X
-	B-X
inducible	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
DR	B-X
and	B-X
HLA	B-X
-	B-X
DP	B-X
,	B-X
with	B-X
a	B-X
faint	B-X
or	B-X
null	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
DQ	B-X
,	B-X
resembling	B-X
that	B-X
described	B-X
for	B-X
melanocytes	B-X
,	B-X
or	B-X
a	B-X
constitutive	B-X
expression	B-X
,	B-X
i	B-X
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
a	B-X
coordinate	B-X
transcription	B-X
of	B-X
the	B-X
HLA	B-X
-	B-X
D	B-X
genes	B-X
in	B-X
these	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
CIITA	B-X
(	B-X
class	B-X
II	B-X
transactivator	B-X
)	B-X
transcripts	B-X
,	B-X
CIITA	B-X
being	B-X
known	B-X
as	B-X
the	B-X
master	B-X
switch	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
<EOS>	B-X
As	B-X
this	B-X
latter	B-X
phenotype	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
more	B-X
rapid	B-X
progression	B-X
of	B-X
melanoma	B-X
tumors	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
in	B-X
different	B-X
melanoma	B-X
cell	B-X
lines	B-X
the	B-X
molecular	B-X
mechanisms	B-X
leading	B-X
to	B-X
this	B-X
abnormal	B-X
pattern	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
melanoma	B-X
cell	B-X
lines	B-X
results	B-X
from	B-X
the	B-X
transcription	B-X
of	B-X
class	B-X
II	B-X
transactivator	B-X
abnormally	B-X
initiated	B-X
from	B-X
its	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
promoter	B-X
.	B-X

As	O
this	O
latter	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
more	O
rapid	O
progression	O
of	O
melanoma	O
tumors	O
,	O
we	O
have	O
analyzed	O
in	O
different	O
melanoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
the	O
molecular	O
mechanisms	O
leading	O
to	O
this	O
abnormal	O
pattern	O
of	O
MHC	O
class	O
II	O
expression	O
.	O
<EOS>	B-X
As	B-X
this	B-X
latter	B-X
phenotype	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
more	B-X
rapid	B-X
progression	B-X
of	B-X
melanoma	B-X
tumors	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
in	B-X
different	B-X
melanoma	B-X
cell	B-X
lines	B-X
the	B-X
molecular	B-X
mechanisms	B-X
leading	B-X
to	B-X
this	B-X
abnormal	B-X
pattern	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
a	B-X
coordinate	B-X
transcription	B-X
of	B-X
the	B-X
HLA	B-X
-	B-X
D	B-X
genes	B-X
in	B-X
these	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
CIITA	B-X
(	B-X
class	B-X
II	B-X
transactivator	B-X
)	B-X
transcripts	B-X
,	B-X
CIITA	B-X
being	B-X
known	B-X
as	B-X
the	B-X
master	B-X
switch	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
<EOS>	B-X
In	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
two	B-X
different	B-X
patterns	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
have	B-X
been	B-X
described	B-X
,	B-X
either	B-X
an	B-X
IFN	B-X
gamma	B-X
-	B-X
inducible	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
DR	B-X
and	B-X
HLA	B-X
-	B-X
DP	B-X
,	B-X
with	B-X
a	B-X
faint	B-X
or	B-X
null	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
DQ	B-X
,	B-X
resembling	B-X
that	B-X
described	B-X
for	B-X
melanocytes	B-X
,	B-X
or	B-X
a	B-X
constitutive	B-X
expression	B-X
,	B-X
i	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
melanoma	B-X
cell	B-X
lines	B-X
results	B-X
from	B-X
the	B-X
transcription	B-X
of	B-X
class	B-X
II	B-X
transactivator	B-X
abnormally	B-X
initiated	B-X
from	B-X
its	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
promoter	B-X
.	B-X

In	O
agreement	O
with	O
the	O
evidence	O
of	O
a	O
coordinate	O
transcription	O
of	O
the	O
HLA-D	B-DNA
genes	I-DNA
in	O
these	O
cell	O
lines	O
,	O
we	O
have	O
shown	O
the	O
constitutive	O
expression	O
of	O
CIITA	B-RNA
(	I-RNA
class	I-RNA
II	I-RNA
transactivator	I-RNA
)	I-RNA
transcripts	I-RNA
,	O
CIITA	B-protein
being	O
known	O
as	O
the	O
master	O
switch	O
of	O
MHC	O
class	O
II	O
expression	O
.	O
<EOS>	B-X
In	B-X
agreement	B-X
with	B-X
the	B-X
evidence	B-X
of	B-X
a	B-X
coordinate	B-X
transcription	B-X
of	B-X
the	B-X
HLA	B-X
-	B-X
D	B-X
genes	B-X
in	B-X
these	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
CIITA	B-X
(	B-X
class	B-X
II	B-X
transactivator	B-X
)	B-X
transcripts	B-X
,	B-X
CIITA	B-X
being	B-X
known	B-X
as	B-X
the	B-X
master	B-X
switch	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
melanoma	B-X
cell	B-X
lines	B-X
results	B-X
from	B-X
the	B-X
transcription	B-X
of	B-X
class	B-X
II	B-X
transactivator	B-X
abnormally	B-X
initiated	B-X
from	B-X
its	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
promoter	B-X
.	B-X
<EOS>	B-X
As	B-X
this	B-X
latter	B-X
phenotype	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
more	B-X
rapid	B-X
progression	B-X
of	B-X
melanoma	B-X
tumors	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
in	B-X
different	B-X
melanoma	B-X
cell	B-X
lines	B-X
the	B-X
molecular	B-X
mechanisms	B-X
leading	B-X
to	B-X
this	B-X
abnormal	B-X
pattern	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
<EOS>	B-X
In	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
two	B-X
different	B-X
patterns	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
have	B-X
been	B-X
described	B-X
,	B-X
either	B-X
an	B-X
IFN	B-X
gamma	B-X
-	B-X
inducible	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
DR	B-X
and	B-X
HLA	B-X
-	B-X
DP	B-X
,	B-X
with	B-X
a	B-X
faint	B-X
or	B-X
null	B-X
expression	B-X
of	B-X
HLA	B-X
-	B-X
DQ	B-X
,	B-X
resembling	B-X
that	B-X
described	B-X
for	B-X
melanocytes	B-X
,	B-X
or	B-X
a	B-X
constitutive	B-X
expression	B-X
,	B-X
i	B-X

Unexpectedly	O
,	O
these	O
transcripts	O
initiate	O
from	O
promoter	B-DNA
III	I-DNA
of	O
the	O
CIITA	B-DNA
gene	I-DNA
,	O
a	O
promoter	O
that	O
is	O
mainly	O
used	O
constitutively	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

This	O
expression	O
was	O
further	O
shown	O
to	O
occur	O
through	O
factor	O
(	O
s	O
)	O
acting	O
on	O
the	O
enhancer	O
located	O
upstream	O
of	O
CIITA	B-DNA
promoter	I-DNA
III	I-DNA
,	O
which	O
was	O
previously	O
described	O
in	O
epithelioid	B-cell_type
cells	I-cell_type
as	O
an	O
IFN-gamma-response	O
sequence	O
.	O

The	O
hypothesis	O
of	O
a	O
general	O
abnormality	O
of	O
the	O
IFN-gamma	O
transduction	O
pathway	O
was	O
dismissed	O
.	O
<EOS>	B-X
The	B-X
hypothesis	B-X
of	B-X
a	B-X
general	B-X
abnormality	B-X
of	B-X
the	B-X
IFN	B-X
-	B-X
gamma	B-X
transduction	B-X
pathway	B-X
was	B-X
dismissed	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
melanoma	B-X
cell	B-X
lines	B-X
results	B-X
from	B-X
the	B-X
transcription	B-X
of	B-X
class	B-X
II	B-X
transactivator	B-X
abnormally	B-X
initiated	B-X
from	B-X
its	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Unexpectedly	B-X
,	B-X
these	B-X
transcripts	B-X
initiate	B-X
from	B-X
promoter	B-X
III	B-X
of	B-X
the	B-X
CIITA	B-X
gene	B-X
,	B-X
a	B-X
promoter	B-X
that	B-X
is	B-X
mainly	B-X
used	B-X
constitutively	B-X
in	B-X
B	B-X
lymphocytes	B-X
<EOS>	B-X
This	B-X
expression	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
occur	B-X
through	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
acting	B-X
on	B-X
the	B-X
enhancer	B-X
located	B-X
upstream	B-X
of	B-X
CIITA	B-X
promoter	B-X
III	B-X
,	B-X
which	B-X
was	B-X
previously	B-X
described	B-X
in	B-X
epithelioid	B-X
cells	B-X
as	B-X
an	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
response	B-X
sequence	B-X

Constitutive	O
transcription	O
of	O
CIITA	B-DNA
from	O
promoter	B-DNA
III	I-DNA
having	O
been	O
observed	O
in	O
unrelated	O
melanoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
we	O
propose	O
the	O
hypothesis	O
that	O
this	O
phenomenon	O
might	O
not	O
be	O
a	O
random	O
event	O
,	O
but	O
could	O
be	O
linked	O
to	O
the	O
neoplasic	O
state	O
of	O
the	O
melanoma	B-cell_type
cells	I-cell_type
<EOS>	B-X
Constitutive	B-X
transcription	B-X
of	B-X
CIITA	B-X
from	B-X
promoter	B-X
III	B-X
having	B-X
been	B-X
observed	B-X
in	B-X
unrelated	B-X
melanoma	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
propose	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
phenomenon	B-X
might	B-X
not	B-X
be	B-X
a	B-X
random	B-X
event	B-X
,	B-X
but	B-X
could	B-X
be	B-X
linked	B-X
to	B-X
the	B-X
neoplasic	B-X
state	B-X
of	B-X
the	B-X
melanoma	B-X
cells	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
melanoma	B-X
cell	B-X
lines	B-X
results	B-X
from	B-X
the	B-X
transcription	B-X
of	B-X
class	B-X
II	B-X
transactivator	B-X
abnormally	B-X
initiated	B-X
from	B-X
its	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Unexpectedly	B-X
,	B-X
these	B-X
transcripts	B-X
initiate	B-X
from	B-X
promoter	B-X
III	B-X
of	B-X
the	B-X
CIITA	B-X
gene	B-X
,	B-X
a	B-X
promoter	B-X
that	B-X
is	B-X
mainly	B-X
used	B-X
constitutively	B-X
in	B-X
B	B-X
lymphocytes	B-X
<EOS>	B-X
As	B-X
this	B-X
latter	B-X
phenotype	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
more	B-X
rapid	B-X
progression	B-X
of	B-X
melanoma	B-X
tumors	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
in	B-X
different	B-X
melanoma	B-X
cell	B-X
lines	B-X
the	B-X
molecular	B-X
mechanisms	B-X
leading	B-X
to	B-X
this	B-X
abnormal	B-X
pattern	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X

Caspase	B-protein
-mediated	O
calcineurin	O
activation	O
contributes	O
to	O
IL-2	B-protein
release	O
during	O
T	O
cell	O
activation	O
.	O

Calcineurin	B-protein
,	O
a	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
/calmodulin-dependent	I-protein
Ser/Thr	I-protein
phosphatase	I-protein
(	I-protein
protein	I-protein
phosphatase	I-protein
2B	I-protein
)	I-protein
,	O
plays	O
a	O
critical	O
role	O
in	O
IL-2	O
production	O
during	O
T	O
cell	O
activation	O
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
IL-2	B-protein
release	O
in	O
activated	O
Jurkat	B-cell_line
T	I-cell_line
requires	O
caspase-like	O
activity	O
(	O
Posmantur	O
et	O
al.	O
(	O
1998	O
)	O
Exp.	O
Cell.	O
Res.	O
244	O
,	O
302-309	O
)	O
.	O

We	O
report	O
here	O
that	O
the	O
60-kDa	B-protein
catalytic	I-protein
subunit	I-protein
of	O
calcineurin	B-protein
A	I-protein
(	O
Cn	B-protein
A	I-protein
)	O
was	O
partially	O
cleaved	O
to	O
a	O
45-kDa	B-protein
form	O
in	O
phytohemagglutinin	O
A	O
(	O
PHA	O
)	O
or	O
phorbol	O
ester	O
+	O
ionomycin	O
(	O
P	O
+	O
I	O
)	O
-activated	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

In	O
parallel	O
,	O
proteolytic	O
activation	O
of	O
upstream	O
caspases	B-protein
(	O
caspase-8	O
and	O
-9	O
)	O
as	O
well	O
as	O
effector	B-protein
caspase-3	I-protein
was	O
also	O
observed	O
.	O
<EOS>	B-X
In	B-X
parallel	B-X
,	B-X
proteolytic	B-X
activation	B-X
of	B-X
upstream	B-X
caspases	B-X
(	B-X
caspase	B-X
-	B-X
8	B-X
and	B-X
	B-X
-	B-X
9	B-X
)	B-X
as	B-X
well	B-X
as	B-X
effector	B-X
caspase	B-X
-	B-X
3	B-X
was	B-X
also	B-X
observed	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
in	B-X
PHA	B-X
or	B-X
P	B-X
+	B-X
I	B-X
-	B-X
activated	B-X
Jurkat	B-X
cells	B-X
,	B-X
dephosphorylation	B-X
of	B-X
calcineurin	B-X
substrate	B-X
NFATc	B-X
(	B-X
a	B-X
transcription	B-X
factor	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
transactivation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
)	B-X
,	B-X
was	B-X
also	B-X
suppressed	B-X
by	B-X
Z	B-X
-	B-X
D	B-X
-	B-X
DCB	B-X
<EOS>	B-X
Caspase	B-X
-	B-X
mediated	B-X
calcineurin	B-X
activation	B-X
contributes	B-X
to	B-X
IL	B-X
-	B-X
2	B-X
release	B-X
during	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
previously	B-X
reported	B-X
that	B-X
IL	B-X
-	B-X
2	B-X
release	B-X
in	B-X
activated	B-X
Jurkat	B-X
T	B-X
requires	B-X
caspase	B-X
-	B-X
like	B-X
activity	B-X
(	B-X
Posmantur	B-X
et	B-X
al	B-X

Cn	B-protein
A	I-protein
cleavage	O
was	O
caspase	O
mediated	O
,	O
since	O
it	O
was	O
inhibitable	O
by	O
pan-caspase	O
inhibitor	O
Cbz-Asp-CH	O
(	O
2	O
)	O
OC	O
(	O
O	O
)	O
-2	O
,	O
6-dichlorobenzene	O
(	O
Z-D-DCB	O
)	O
.	O

Cn	B-protein
A	I-protein
cleavage	O
was	O
also	O
observed	O
when	O
purified	O
calcineurin	B-protein
was	O
digested	O
in	O
vitro	O
with	O
caspase-3	B-protein
.	O

Truncated	B-protein
Cn	I-protein
A	I-protein
was	O
associated	O
with	O
enhanced	O
phosphatase	O
activity	O
and	O
reduced	O
calmodulin	O
sensitivity	O
.	O

Furthermore	O
,	O
in	O
PHA	O
or	O
P	O
+	O
I-activated	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
dephosphorylation	O
of	O
calcineurin	B-protein
substrate	O
NFATc	B-protein
(	O
a	O
transcription	B-protein
factor	I-protein
known	O
to	O
be	O
involved	O
in	O
transactivation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
)	O
,	O
was	O
also	O
suppressed	O
by	O
Z-D-DCB	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
glutamatergic	B-X
PHa	B-X
theta	B-X
rhythm	B-X
recorded	B-X
extracellularly	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
activity	B-X
of	B-X
specific	B-X
subtypes	B-X
of	B-X
theta	B-X
-	B-X
related	B-X
neurons	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
there	B-X
are	B-X
differences	B-X
in	B-X
the	B-X
profile	B-X
of	B-X
the	B-X
participants	B-X
regarding	B-X
socioeconomic	B-X
and	B-X
anxiety	B-X
levels	B-X
,	B-X
treatment	B-X
time	B-X
,	B-X
ethnicity	B-X
,	B-X
and	B-X
city	B-X
where	B-X
they	B-X
live	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
an	B-X
important	B-X
aspect	B-X
in	B-X
the	B-X
implementation	B-X
of	B-X
any	B-X
additives	B-X
and	B-X
formulations	B-X
is	B-X
their	B-X
environmental	B-X
impact	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
differences	B-X
in	B-X
the	B-X
dosing	B-X
time	B-X
of	B-X
cisplatin	B-X
caused	B-X
differences	B-X
in	B-X
oxidative	B-X
stress	B-X
which	B-X
were	B-X
correlated	B-X
with	B-X
cisplatin	B-X
-	B-X
induced	B-X
hypoalgesia	B-X

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
caspase-mediated	O
cleavage	O
of	O
Cn	B-protein
A	I-protein
contributes	O
to	O
IL-2	O
production	O
during	O
T	O
cell	O
activation	O
.	O

Maturation	O
of	O
human	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
as	O
sulfasalazine	O
target	O
.	O
<EOS>	B-X
Maturation	B-X
of	B-X
human	B-X
dendritic	B-X
cells	B-X
as	B-X
sulfasalazine	B-X
target	B-X
.	B-X
<EOS>	B-X
Dendritic	B-X
cells	B-X
treated	B-X
with	B-X
sulfasalazine	B-X
(	B-X
1	B-X
<EOS>	B-X
5	B-X
micromol	B-X
/	B-X
L	B-X
sulfasalazine	B-X
<EOS>	B-X
Maturing	B-X
human	B-X
dendritic	B-X
cells	B-X
are	B-X
hundred	B-X
-	B-X
fold	B-X
more	B-X
sensitive	B-X
to	B-X
sulfasalazine	B-X
than	B-X
T	B-X
cells	B-X
and	B-X
NK	B-X
cells	B-X
and	B-X
the	B-X
most	B-X
sensitive	B-X
human	B-X
cells	B-X
described	B-X
so	B-X
far	B-X

AIM	O
:	O
Sulfasalazine	O
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
,	O
is	O
effective	O
in	O
treating	O
some	O
autoimmune	O
diseases	O
,	O
but	O
its	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O
<EOS>	B-X
Sulfasalazine	B-X
,	B-X
a	B-X
nonsteroidal	B-X
anti	B-X
-	B-X
inflammatory	B-X
drug	B-X
,	B-X
is	B-X
effective	B-X
in	B-X
treating	B-X
some	B-X
autoimmune	B-X
diseases	B-X
,	B-X
but	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
is	B-X
unclear	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
dendritic	B-X
cells	B-X
could	B-X
be	B-X
a	B-X
possible	B-X
target	B-X
of	B-X
the	B-X
drug	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
sulfasalazine	B-X
and	B-X
its	B-X
metabolites	B-X
,	B-X
aminosalicylate	B-X
and	B-X
sulfapyridine	B-X
,	B-X
on	B-X
in	B-X
vitro	B-X
maturation	B-X
(	B-X
terminal	B-X
differentiation	B-X
)	B-X
of	B-X
human	B-X
myeloid	B-X
dendritic	B-X
cells	B-X
<EOS>	B-X
We	B-X
quantified	B-X
the	B-X
effect	B-X
of	B-X
drugs	B-X
on	B-X
the	B-X
dendritic	B-X
cell	B-X
characteristics	B-X
,	B-X
such	B-X
as	B-X
stimulation	B-X
of	B-X
autologous	B-X
and	B-X
allogeneic	B-X
pan	B-X
-	B-X
T	B-X
cell	B-X
proliferation	B-X
,	B-X
surface	B-X
marker	B-X
phenotype	B-X
,	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
subunit	B-X
secretion	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
03	B-X
for	B-X
difference	B-X
between	B-X
measurements	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
sulfasalazine	B-X
)	B-X

To	O
determine	O
whether	O
dendritic	B-cell_type
cells	I-cell_type
could	O
be	O
a	O
possible	O
target	O
of	O
the	O
drug	O
,	O
we	O
studied	O
the	O
effects	O
of	O
sulfasalazine	O
and	O
its	O
metabolites	O
,	O
aminosalicylate	O
and	O
sulfapyridine	O
,	O
on	O
in	O
vitro	O
maturation	O
(	O
terminal	O
differentiation	O
)	O
of	O
human	B-cell_type
myeloid	I-cell_type
dendritic	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
dendritic	B-X
cells	B-X
could	B-X
be	B-X
a	B-X
possible	B-X
target	B-X
of	B-X
the	B-X
drug	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
sulfasalazine	B-X
and	B-X
its	B-X
metabolites	B-X
,	B-X
aminosalicylate	B-X
and	B-X
sulfapyridine	B-X
,	B-X
on	B-X
in	B-X
vitro	B-X
maturation	B-X
(	B-X
terminal	B-X
differentiation	B-X
)	B-X
of	B-X
human	B-X
myeloid	B-X
dendritic	B-X
cells	B-X
<EOS>	B-X
The	B-X
cells	B-X
were	B-X
matured	B-X
by	B-X
addition	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
a	B-X
,	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
and	B-X
prostaglandin	B-X
E2	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sulfasalazine	B-X
or	B-X
its	B-X
metabolites	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
aminosalicylate	B-X
and	B-X
sulfapyridine	B-X
,	B-X
or	B-X
their	B-X
combinations	B-X
<EOS>	B-X
Maturing	B-X
human	B-X
dendritic	B-X
cells	B-X
are	B-X
hundred	B-X
-	B-X
fold	B-X
more	B-X
sensitive	B-X
to	B-X
sulfasalazine	B-X
than	B-X
T	B-X
cells	B-X
and	B-X
NK	B-X
cells	B-X
and	B-X
the	B-X
most	B-X
sensitive	B-X
human	B-X
cells	B-X
described	B-X
so	B-X
far	B-X
<EOS>	B-X
We	B-X
prepared	B-X
immature	B-X
dendritic	B-X
cells	B-X
by	B-X
incubating	B-X
CD14	B-X
-	B-X
positive	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
granulocyte	B-X
-	B-X
	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
4	B-X

METHODS	O
:	O
We	O
prepared	O
immature	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
by	O
incubating	O
CD14-positive	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
granulocyte-	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
.	O
<EOS>	B-X
We	B-X
prepared	B-X
immature	B-X
dendritic	B-X
cells	B-X
by	B-X
incubating	B-X
CD14	B-X
-	B-X
positive	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
granulocyte	B-X
-	B-X
	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
4	B-X
<EOS>	B-X
We	B-X
quantified	B-X
the	B-X
effect	B-X
of	B-X
drugs	B-X
on	B-X
the	B-X
dendritic	B-X
cell	B-X
characteristics	B-X
,	B-X
such	B-X
as	B-X
stimulation	B-X
of	B-X
autologous	B-X
and	B-X
allogeneic	B-X
pan	B-X
-	B-X
T	B-X
cell	B-X
proliferation	B-X
,	B-X
surface	B-X
marker	B-X
phenotype	B-X
,	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
subunit	B-X
secretion	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
The	B-X
cells	B-X
were	B-X
matured	B-X
by	B-X
addition	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
a	B-X
,	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
and	B-X
prostaglandin	B-X
E2	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sulfasalazine	B-X
or	B-X
its	B-X
metabolites	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
aminosalicylate	B-X
and	B-X
sulfapyridine	B-X
,	B-X
or	B-X
their	B-X
combinations	B-X
<EOS>	B-X
03	B-X
for	B-X
difference	B-X
between	B-X
measurements	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
sulfasalazine	B-X
)	B-X

The	O
cells	O
were	O
matured	O
by	O
addition	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-a	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
and	O
prostaglandin	B-protein
E2	I-protein
in	O
the	O
presence	O
of	O
sulfasalazine	O
or	O
its	O
metabolites	O
--	O
aminosalicylate	O
and	O
sulfapyridine	O
,	O
or	O
their	O
combinations	O
.	O
<EOS>	B-X
The	B-X
optical	B-X
sensor	B-X
is	B-X
based	B-X
on	B-X
the	B-X
smart	B-X
integration	B-X
of	B-X
(	B-X
i	B-X
)	B-X
miniatuirized	B-X
organic	B-X
optoelectronic	B-X
devices	B-X
used	B-X
as	B-X
light	B-X
-	B-X
emitting	B-X
and	B-X
	B-X
-	B-X
sensing	B-X
elements	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
functionalized	B-X
nanostructured	B-X
plasmonic	B-X
grating	B-X
for	B-X
highly	B-X
sensitive	B-X
and	B-X
specific	B-X
localized	B-X
surface	B-X
plasmon	B-X
resonance	B-X
(	B-X
SPR	B-X
)	B-X
detection	B-X
<EOS>	B-X
Model	B-X
-	B-X
based	B-X
reconstruction	B-X
is	B-X
feasible	B-X
for	B-X
IVIM	B-X
and	B-X
IVIM	B-X
-	B-X
DTI	B-X
and	B-X
improves	B-X
the	B-X
precision	B-X
of	B-X
the	B-X
parameter	B-X
estimates	B-X
,	B-X
particularly	B-X
for	B-X
f	B-X
and	B-X
D	B-X
*	B-X
maps	B-X
<EOS>	B-X
Life	B-X
history	B-X
parameters	B-X
of	B-X
Bemisia	B-X
tabaci	B-X
MED	B-X
(	B-X
Hemiptera	B-X
:	B-X
Aleyrodidae	B-X
)	B-X
in	B-X
the	B-X
present	B-X
and	B-X
future	B-X
climate	B-X
of	B-X
central	B-X
Europe	B-X
,	B-X
predicted	B-X
by	B-X
physically	B-X
realistic	B-X
climatic	B-X
chamber	B-X
simulation	B-X
.	B-X
<EOS>	B-X
This	B-X
process	B-X
relies	B-X
on	B-X
the	B-X
partitioning	B-X
of	B-X
RBCs	B-X
at	B-X
successive	B-X
bifurcations	B-X
throughout	B-X
the	B-X
microvascular	B-X
network	B-X
and	B-X
it	B-X
is	B-X
known	B-X
since	B-X
the	B-X
last	B-X
century	B-X
that	B-X
RBCs	B-X
partition	B-X
disproportionately	B-X
to	B-X
the	B-X
fractional	B-X
blood	B-X
flow	B-X
rate	B-X
,	B-X
therefore	B-X
leading	B-X
to	B-X
heterogeneity	B-X
of	B-X
the	B-X
hematocrit	B-X
(	B-X
i	B-X

We	O
quantified	O
the	O
effect	O
of	O
drugs	O
on	O
the	O
dendritic	O
cell	O
characteristics	O
,	O
such	O
as	O
stimulation	O
of	O
autologous	O
and	O
allogeneic	O
pan-T	O
cell	O
proliferation	O
,	O
surface	O
marker	O
phenotype	O
,	O
IL-12	O
p40	O
subunit	O
secretion	O
,	O
and	O
activation	O
of	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O
<EOS>	B-X
We	B-X
quantified	B-X
the	B-X
effect	B-X
of	B-X
drugs	B-X
on	B-X
the	B-X
dendritic	B-X
cell	B-X
characteristics	B-X
,	B-X
such	B-X
as	B-X
stimulation	B-X
of	B-X
autologous	B-X
and	B-X
allogeneic	B-X
pan	B-X
-	B-X
T	B-X
cell	B-X
proliferation	B-X
,	B-X
surface	B-X
marker	B-X
phenotype	B-X
,	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
subunit	B-X
secretion	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
Because	B-X
of	B-X
the	B-X
role	B-X
of	B-X
dendritic	B-X
cells	B-X
in	B-X
(	B-X
auto	B-X
)	B-X
immunity	B-X
,	B-X
inhibition	B-X
of	B-X
their	B-X
maturation	B-X
might	B-X
provide	B-X
a	B-X
target	B-X
for	B-X
further	B-X
optimization	B-X
of	B-X
sulfasalazine	B-X
therapy	B-X
<EOS>	B-X
We	B-X
prepared	B-X
immature	B-X
dendritic	B-X
cells	B-X
by	B-X
incubating	B-X
CD14	B-X
-	B-X
positive	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
granulocyte	B-X
-	B-X
	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
4	B-X
<EOS>	B-X
Maturing	B-X
human	B-X
dendritic	B-X
cells	B-X
are	B-X
hundred	B-X
-	B-X
fold	B-X
more	B-X
sensitive	B-X
to	B-X
sulfasalazine	B-X
than	B-X
T	B-X
cells	B-X
and	B-X
NK	B-X
cells	B-X
and	B-X
the	B-X
most	B-X
sensitive	B-X
human	B-X
cells	B-X
described	B-X
so	B-X
far	B-X

RESULTS	O
:	O
Dendritic	B-cell_type
cells	I-cell_type
treated	O
with	O
sulfasalazine	O
(	O
1.25	O
micromol/L	O
or	O
2.5	O
micromol/L	O
)	O
could	O
not	O
stimulate	O
T	B-cell_type
cells	I-cell_type
(	O
p	O
<	O
0.028	O
,	O
two-sided	O
paired	O
t-test	O
)	O
.	O

In	O
distinction	O
to	O
drug-free	O
maturing	O
dendritic	B-cell_type
cells	I-cell_type
,	O
2.5	O
micromol/L	O
sulfasalazine	O
upregulated	O
the	O
levels	O
of	O
CD14	B-protein
and	O
CD68	B-protein
and	O
downregulated	O
the	O
levels	O
of	O
CD40	B-protein
,	O
CD80	B-protein
,	O
and	O
CD83	B-protein
(	O
for	O
all	O
CD	O
markers	O
,	O
p	O
<	O
0.03	O
for	O
difference	O
between	O
measurements	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
sulfasalazine	O
)	O
.	O

From	O
concentration-dependent	O
changes	O
in	O
CD83	O
expression	O
,	O
we	O
found	O
an	O
apparent	O
ID50	O
>	O
>	O
1.5	O
micromol/L	O
sulfasalazine	O
.	O
<EOS>	B-X
From	B-X
concentration	B-X
-	B-X
dependent	B-X
changes	B-X
in	B-X
CD83	B-X
expression	B-X
,	B-X
we	B-X
found	B-X
an	B-X
apparent	B-X
ID50	B-X
>	B-X
>	B-X
1	B-X
<EOS>	B-X
03	B-X
for	B-X
difference	B-X
between	B-X
measurements	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
sulfasalazine	B-X
)	B-X
<EOS>	B-X
Thus	B-X
,	B-X
dendritic	B-X
cell	B-X
maturation	B-X
is	B-X
an	B-X
important	B-X
target	B-X
of	B-X
sulfasalazine	B-X
<EOS>	B-X
Because	B-X
of	B-X
the	B-X
role	B-X
of	B-X
dendritic	B-X
cells	B-X
in	B-X
(	B-X
auto	B-X
)	B-X
immunity	B-X
,	B-X
inhibition	B-X
of	B-X
their	B-X
maturation	B-X
might	B-X
provide	B-X
a	B-X
target	B-X
for	B-X
further	B-X
optimization	B-X
of	B-X
sulfasalazine	B-X
therapy	B-X

The	O
apparent	O
ID50	O
value	O
for	O
aminosalicylate-inhibited	O
maturation	O
was	O
4	O
micromol/L	O
.	O
<EOS>	B-X
The	B-X
apparent	B-X
ID50	B-X
value	B-X
for	B-X
aminosalicylate	B-X
-	B-X
inhibited	B-X
maturation	B-X
was	B-X
4	B-X
micromol	B-X
/	B-X
L	B-X
<EOS>	B-X
Because	B-X
of	B-X
the	B-X
role	B-X
of	B-X
dendritic	B-X
cells	B-X
in	B-X
(	B-X
auto	B-X
)	B-X
immunity	B-X
,	B-X
inhibition	B-X
of	B-X
their	B-X
maturation	B-X
might	B-X
provide	B-X
a	B-X
target	B-X
for	B-X
further	B-X
optimization	B-X
of	B-X
sulfasalazine	B-X
therapy	B-X
<EOS>	B-X
25	B-X
micromol	B-X
/	B-X
L	B-X
,	B-X
sulfasalazine	B-X
largely	B-X
inhibited	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
in	B-X
dendritic	B-X
cells	B-X
<EOS>	B-X
Maturing	B-X
human	B-X
dendritic	B-X
cells	B-X
are	B-X
hundred	B-X
-	B-X
fold	B-X
more	B-X
sensitive	B-X
to	B-X
sulfasalazine	B-X
than	B-X
T	B-X
cells	B-X
and	B-X
NK	B-X
cells	B-X
and	B-X
the	B-X
most	B-X
sensitive	B-X
human	B-X
cells	B-X
described	B-X
so	B-X
far	B-X

Sulfapyridine	O
had	O
no	O
effect	O
.	O
<EOS>	B-X
2	B-X
,	B-X
with	B-X
estrogen	B-X
and	B-X
sulfapyridine	B-X
highest	B-X
among	B-X
the	B-X
twenty	B-X
pharmaceuticals	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
higher	B-X
O	B-X
<EOS>	B-X
Hydrolysis	B-X
appeared	B-X
to	B-X
be	B-X
significant	B-X
only	B-X
for	B-X
tetracyclines	B-X
(	B-X
12	B-X
<EOS>	B-X
For	B-X
the	B-X
sulfonamides	B-X
,	B-X
biodegradation	B-X
was	B-X
the	B-X
most	B-X
frequent	B-X
process	B-X
(	B-X
50	B-X

At	O
1.25	O
micromol/L	O
,	O
sulfasalazine	O
largely	O
inhibited	O
NF-kB	O
activation	O
in	O
dendritic	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
25	B-X
micromol	B-X
/	B-X
L	B-X
,	B-X
sulfasalazine	B-X
largely	B-X
inhibited	B-X
NF	B-X
-	B-X
kB	B-X
activation	B-X
in	B-X
dendritic	B-X
cells	B-X
<EOS>	B-X
In	B-X
distinction	B-X
to	B-X
drug	B-X
-	B-X
free	B-X
maturing	B-X
dendritic	B-X
cells	B-X
,	B-X
2	B-X
<EOS>	B-X
The	B-X
apparent	B-X
ID50	B-X
value	B-X
for	B-X
aminosalicylate	B-X
-	B-X
inhibited	B-X
maturation	B-X
was	B-X
4	B-X
micromol	B-X
/	B-X
L	B-X
<EOS>	B-X
5	B-X
micromol	B-X
/	B-X
L	B-X
sulfasalazine	B-X

CONCLUSION	O
:	O
Maturing	B-cell_type
human	I-cell_type
dendritic	I-cell_type
cells	I-cell_type
are	O
hundred-fold	O
more	O
sensitive	O
to	O
sulfasalazine	O
than	O
T	B-cell_type
cells	I-cell_type
and	O
NK	B-cell_type
cells	I-cell_type
and	O
the	O
most	O
sensitive	O
human	O
cells	O
described	O
so	O
far	O
.	O

Thus	O
,	O
dendritic	O
cell	O
maturation	O
is	O
an	O
important	O
target	O
of	O
sulfasalazine	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
dendritic	B-X
cell	B-X
maturation	B-X
is	B-X
an	B-X
important	B-X
target	B-X
of	B-X
sulfasalazine	B-X
<EOS>	B-X
Dendritic	B-X
cells	B-X
treated	B-X
with	B-X
sulfasalazine	B-X
(	B-X
1	B-X
<EOS>	B-X
03	B-X
for	B-X
difference	B-X
between	B-X
measurements	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
sulfasalazine	B-X
)	B-X
<EOS>	B-X
Because	B-X
of	B-X
the	B-X
role	B-X
of	B-X
dendritic	B-X
cells	B-X
in	B-X
(	B-X
auto	B-X
)	B-X
immunity	B-X
,	B-X
inhibition	B-X
of	B-X
their	B-X
maturation	B-X
might	B-X
provide	B-X
a	B-X
target	B-X
for	B-X
further	B-X
optimization	B-X
of	B-X
sulfasalazine	B-X
therapy	B-X

Because	O
of	O
the	O
role	O
of	O
dendritic	B-cell_type
cells	I-cell_type
in	O
(	O
auto	O
)	O
immunity	O
,	O
inhibition	O
of	O
their	O
maturation	O
might	O
provide	O
a	O
target	O
for	O
further	O
optimization	O
of	O
sulfasalazine	O
therapy	O
.	O
<EOS>	B-X
Because	B-X
of	B-X
the	B-X
role	B-X
of	B-X
dendritic	B-X
cells	B-X
in	B-X
(	B-X
auto	B-X
)	B-X
immunity	B-X
,	B-X
inhibition	B-X
of	B-X
their	B-X
maturation	B-X
might	B-X
provide	B-X
a	B-X
target	B-X
for	B-X
further	B-X
optimization	B-X
of	B-X
sulfasalazine	B-X
therapy	B-X
<EOS>	B-X
Thus	B-X
,	B-X
dendritic	B-X
cell	B-X
maturation	B-X
is	B-X
an	B-X
important	B-X
target	B-X
of	B-X
sulfasalazine	B-X
<EOS>	B-X
We	B-X
quantified	B-X
the	B-X
effect	B-X
of	B-X
drugs	B-X
on	B-X
the	B-X
dendritic	B-X
cell	B-X
characteristics	B-X
,	B-X
such	B-X
as	B-X
stimulation	B-X
of	B-X
autologous	B-X
and	B-X
allogeneic	B-X
pan	B-X
-	B-X
T	B-X
cell	B-X
proliferation	B-X
,	B-X
surface	B-X
marker	B-X
phenotype	B-X
,	B-X
IL	B-X
-	B-X
12	B-X
p40	B-X
subunit	B-X
secretion	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
nuclear	B-X
transcription	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
03	B-X
for	B-X
difference	B-X
between	B-X
measurements	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
sulfasalazine	B-X
)	B-X

Defective	O
function	O
of	O
the	O
proteasome	B-protein
in	O
autoimmunity	O
:	O
involvement	O
of	O
impaired	O
NF-kappaB	O
activation	O
.	O
<EOS>	B-X
Defective	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
in	B-X
autoimmunity	B-X
:	B-X
involvement	B-X
of	B-X
impaired	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
.	B-X
<EOS>	B-X
The	B-X
novel	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
in	B-X
dysfunction	B-X
in	B-X
autoimmunity	B-X
is	B-X
presented	B-X
and	B-X
documented	B-X
to	B-X
be	B-X
both	B-X
tissue	B-X
and	B-X
developmental	B-X
stage	B-X
specific	B-X
<EOS>	B-X
We	B-X
propose	B-X
a	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
as	B-X
a	B-X
step	B-X
in	B-X
disease	B-X
pathogenesis	B-X
and	B-X
tissue	B-X
targeting	B-X
<EOS>	B-X
However	B-X
,	B-X
transmission	B-X
is	B-X
dominant	B-X
,	B-X
symptom	B-X
onset	B-X
occurs	B-X
at	B-X
a	B-X
younger	B-X
age	B-X
,	B-X
and	B-X
severe	B-X
gastrointestinal	B-X
involvement	B-X
is	B-X
at	B-X
the	B-X
forefront	B-X
of	B-X
the	B-X
clinical	B-X
picture	B-X

Type	O
1	O
diabetes	O
(	O
also	O
known	O
as	O
insulin-dependent	O
diabetes	O
mellitus	O
or	O
juvenile-onset	O
diabetes	O
)	O
is	O
usually	O
caused	O
by	O
T	O
cell-mediated	O
autoimmunity	O
,	O
with	O
a	O
prediabetic	O
state	O
characterized	O
by	O
the	O
production	O
of	O
autoantibodies	B-protein
specific	O
for	O
proteins	O
expressed	O
by	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Type	B-X
1	B-X
diabetes	B-X
(	B-X
also	B-X
known	B-X
as	B-X
insulin	B-X
-	B-X
dependent	B-X
diabetes	B-X
mellitus	B-X
or	B-X
juvenile	B-X
-	B-X
onset	B-X
diabetes	B-X
)	B-X
is	B-X
usually	B-X
caused	B-X
by	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
autoimmunity	B-X
,	B-X
with	B-X
a	B-X
prediabetic	B-X
state	B-X
characterized	B-X
by	B-X
the	B-X
production	B-X
of	B-X
autoantibodies	B-X
specific	B-X
for	B-X
proteins	B-X
expressed	B-X
by	B-X
pancreatic	B-X
beta	B-X
cells	B-X
<EOS>	B-X
The	B-X
nonobese	B-X
patient	B-X
with	B-X
diabetes	B-X
(	B-X
NOD	B-X
)	B-X
mouse	B-X
is	B-X
a	B-X
spontaneous	B-X
model	B-X
of	B-X
type	B-X
1	B-X
diabetes	B-X
with	B-X
a	B-X
strong	B-X
genetic	B-X
component	B-X
that	B-X
maps	B-X
to	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
region	B-X
of	B-X
the	B-X
genome	B-X
<EOS>	B-X
The	B-X
non	B-X
-	B-X
obese	B-X
diabetic	B-X
(	B-X
NOD	B-X
)	B-X
mouse	B-X
is	B-X
a	B-X
spontaneous	B-X
model	B-X
of	B-X
type	B-X
1	B-X
diabetes	B-X
with	B-X
a	B-X
strong	B-X
genetic	B-X
component	B-X
that	B-X
maps	B-X
to	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
region	B-X
of	B-X
the	B-X
genome	B-X
<EOS>	B-X
The	B-X
novel	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
in	B-X
dysfunction	B-X
in	B-X
autoimmunity	B-X
is	B-X
presented	B-X
and	B-X
documented	B-X
to	B-X
be	B-X
both	B-X
tissue	B-X
and	B-X
developmental	B-X
stage	B-X
specific	B-X

The	O
nonobese	O
patient	O
with	O
diabetes	O
(	O
NOD	O
)	O
mouse	O
is	O
a	O
spontaneous	O
model	O
of	O
type	O
1	O
diabetes	O
with	O
a	O
strong	O
genetic	O
component	O
that	O
maps	O
to	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
region	I-DNA
of	O
the	O
genome	B-DNA
.	O

A	O
specific	O
proteasome	B-protein
defect	O
has	O
been	O
identified	O
in	O
NOD	O
mouse	O
in	O
select	O
lymphocytic	B-cell_line
and	I-cell_line
monocytic	I-cell_line
lineages	I-cell_line
that	O
results	O
from	O
down-regulation	O
of	O
expression	O
of	O
the	O
proteasome	B-protein
subunit	I-protein
LMP2	I-protein
,	O
which	O
is	O
encoded	O
by	O
a	O
gene	O
in	O
the	O
MHC	B-DNA
genomic	I-DNA
region	I-DNA
.	O
<EOS>	B-X
A	B-X
specific	B-X
proteasome	B-X
defect	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
NOD	B-X
mouse	B-X
in	B-X
select	B-X
lymphocytic	B-X
and	B-X
monocytic	B-X
lineages	B-X
that	B-X
results	B-X
from	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
proteasome	B-X
subunit	B-X
LMP2	B-X
,	B-X
which	B-X
is	B-X
encoded	B-X
by	B-X
a	B-X
gene	B-X
in	B-X
the	B-X
MHC	B-X
genomic	B-X
region	B-X
<EOS>	B-X
The	B-X
nonobese	B-X
patient	B-X
with	B-X
diabetes	B-X
(	B-X
NOD	B-X
)	B-X
mouse	B-X
is	B-X
a	B-X
spontaneous	B-X
model	B-X
of	B-X
type	B-X
1	B-X
diabetes	B-X
with	B-X
a	B-X
strong	B-X
genetic	B-X
component	B-X
that	B-X
maps	B-X
to	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
region	B-X
of	B-X
the	B-X
genome	B-X
<EOS>	B-X
The	B-X
novel	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
in	B-X
dysfunction	B-X
in	B-X
autoimmunity	B-X
is	B-X
presented	B-X
and	B-X
documented	B-X
to	B-X
be	B-X
both	B-X
tissue	B-X
and	B-X
developmental	B-X
stage	B-X
specific	B-X
<EOS>	B-X
This	B-X
defect	B-X
prevents	B-X
the	B-X
proteolytic	B-X
processing	B-X
required	B-X
for	B-X
the	B-X
production	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
,	B-X
which	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
as	B-X
well	B-X
as	B-X
increases	B-X
the	B-X
susceptibility	B-X
of	B-X
the	B-X
affected	B-X
cells	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X

This	O
defect	O
prevents	O
the	O
proteolytic	O
processing	O
required	O
for	O
the	O
production	O
and	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
which	O
plays	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
as	O
well	O
as	O
increases	O
the	O
susceptibility	O
of	O
the	O
affected	O
cells	O
to	O
apoptosis	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O
<EOS>	B-X
This	B-X
defect	B-X
prevents	B-X
the	B-X
proteolytic	B-X
processing	B-X
required	B-X
for	B-X
the	B-X
production	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
,	B-X
which	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
as	B-X
well	B-X
as	B-X
increases	B-X
the	B-X
susceptibility	B-X
of	B-X
the	B-X
affected	B-X
cells	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
<EOS>	B-X
This	B-X
defect	B-X
both	B-X
prevents	B-X
the	B-X
proteolytic	B-X
processing	B-X
required	B-X
for	B-X
the	B-X
production	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
,	B-X
which	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
as	B-X
well	B-X
as	B-X
increases	B-X
the	B-X
susceptibility	B-X
of	B-X
the	B-X
affected	B-X
cells	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
<EOS>	B-X
The	B-X
nonobese	B-X
patient	B-X
with	B-X
diabetes	B-X
(	B-X
NOD	B-X
)	B-X
mouse	B-X
is	B-X
a	B-X
spontaneous	B-X
model	B-X
of	B-X
type	B-X
1	B-X
diabetes	B-X
with	B-X
a	B-X
strong	B-X
genetic	B-X
component	B-X
that	B-X
maps	B-X
to	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
region	B-X
of	B-X
the	B-X
genome	B-X
<EOS>	B-X
A	B-X
specific	B-X
proteasome	B-X
defect	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
NOD	B-X
mouse	B-X
in	B-X
select	B-X
lymphocytic	B-X
and	B-X
monocytic	B-X
lineages	B-X
that	B-X
results	B-X
from	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
proteasome	B-X
subunit	B-X
LMP2	B-X
,	B-X
which	B-X
is	B-X
encoded	B-X
by	B-X
a	B-X
gene	B-X
in	B-X
the	B-X
MHC	B-X
genomic	B-X
region	B-X

The	O
novel	O
role	O
of	O
the	O
proteasome	B-protein
in	O
dysfunction	O
in	O
autoimmunity	O
is	O
presented	O
and	O
documented	O
to	O
be	O
both	O
tissue	O
and	O
developmental	O
stage	O
specific	O
.	O
<EOS>	B-X
The	B-X
novel	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
in	B-X
dysfunction	B-X
in	B-X
autoimmunity	B-X
is	B-X
presented	B-X
and	B-X
documented	B-X
to	B-X
be	B-X
both	B-X
tissue	B-X
and	B-X
developmental	B-X
stage	B-X
specific	B-X
<EOS>	B-X
We	B-X
propose	B-X
a	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
as	B-X
a	B-X
step	B-X
in	B-X
disease	B-X
pathogenesis	B-X
and	B-X
tissue	B-X
targeting	B-X
<EOS>	B-X
Defective	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
in	B-X
autoimmunity	B-X
:	B-X
involvement	B-X
of	B-X
impaired	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
.	B-X
<EOS>	B-X
The	B-X
nonobese	B-X
patient	B-X
with	B-X
diabetes	B-X
(	B-X
NOD	B-X
)	B-X
mouse	B-X
is	B-X
a	B-X
spontaneous	B-X
model	B-X
of	B-X
type	B-X
1	B-X
diabetes	B-X
with	B-X
a	B-X
strong	B-X
genetic	B-X
component	B-X
that	B-X
maps	B-X
to	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
region	B-X
of	B-X
the	B-X
genome	B-X

We	O
propose	O
a	O
role	O
of	O
the	O
proteasome	B-protein
as	O
a	O
step	O
in	O
disease	O
pathogenesis	O
and	O
tissue	O
targeting	O
.	O
<EOS>	B-X
We	B-X
propose	B-X
a	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
as	B-X
a	B-X
step	B-X
in	B-X
disease	B-X
pathogenesis	B-X
and	B-X
tissue	B-X
targeting	B-X
<EOS>	B-X
The	B-X
novel	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
in	B-X
dysfunction	B-X
in	B-X
autoimmunity	B-X
is	B-X
presented	B-X
and	B-X
documented	B-X
to	B-X
be	B-X
both	B-X
tissue	B-X
and	B-X
developmental	B-X
stage	B-X
specific	B-X
<EOS>	B-X
Defective	B-X
function	B-X
of	B-X
the	B-X
proteasome	B-X
in	B-X
autoimmunity	B-X
:	B-X
involvement	B-X
of	B-X
impaired	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
.	B-X
<EOS>	B-X
The	B-X
nonobese	B-X
patient	B-X
with	B-X
diabetes	B-X
(	B-X
NOD	B-X
)	B-X
mouse	B-X
is	B-X
a	B-X
spontaneous	B-X
model	B-X
of	B-X
type	B-X
1	B-X
diabetes	B-X
with	B-X
a	B-X
strong	B-X
genetic	B-X
component	B-X
that	B-X
maps	B-X
to	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
region	B-X
of	B-X
the	B-X
genome	B-X

Down-regulation	O
of	O
TDT	O
transcription	O
in	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
by	O
Ikaros	B-protein
proteins	I-protein
in	O
direct	O
competition	O
with	O
an	O
Ets	B-protein
activator	I-protein
.	O
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
TDT	B-X
transcription	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
by	B-X
Ikaros	B-X
proteins	B-X
in	B-X
direct	B-X
competition	B-X
with	B-X
an	B-X
Ets	B-X
activator	B-X
.	B-X
<EOS>	B-X
The	B-X
capacity	B-X
for	B-X
in	B-X
vivo	B-X
multimer	B-X
formation	B-X
suggests	B-X
that	B-X
interactions	B-X
between	B-X
Ikaros	B-X
dimers	B-X
bound	B-X
to	B-X
the	B-X
TdT	B-X
promoter	B-X
and	B-X
those	B-X
bound	B-X
to	B-X
pericentromeric	B-X
repeat	B-X
sequences	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pericentromeric	B-X
repositioning	B-X
of	B-X
the	B-X
inactive	B-X
gene	B-X
<EOS>	B-X
Reduced	B-X
access	B-X
to	B-X
restriction	B-X
enzyme	B-X
cleavage	B-X
suggested	B-X
that	B-X
chromatin	B-X
alterations	B-X
accompany	B-X
down	B-X
-	B-X
regulation	B-X
<EOS>	B-X
Ikaros	B-X
is	B-X
a	B-X
unique	B-X
regulator	B-X
of	B-X
lymphopoiesis	B-X
that	B-X
associates	B-X
with	B-X
pericentromeric	B-X
heterochromatin	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
heritable	B-X
gene	B-X
inactivation	B-X

Ikaros	B-protein
is	O
a	O
unique	O
regulator	O
of	O
lymphopoiesis	O
that	O
associates	O
with	O
pericentromeric	B-DNA
heterochromatin	I-DNA
and	O
has	O
been	O
implicated	O
in	O
heritable	O
gene	O
inactivation	O
.	O
<EOS>	B-X
Ikaros	B-X
is	B-X
a	B-X
unique	B-X
regulator	B-X
of	B-X
lymphopoiesis	B-X
that	B-X
associates	B-X
with	B-X
pericentromeric	B-X
heterochromatin	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
heritable	B-X
gene	B-X
inactivation	B-X
<EOS>	B-X
The	B-X
capacity	B-X
for	B-X
in	B-X
vivo	B-X
multimer	B-X
formation	B-X
suggests	B-X
that	B-X
interactions	B-X
between	B-X
Ikaros	B-X
dimers	B-X
bound	B-X
to	B-X
the	B-X
TdT	B-X
promoter	B-X
and	B-X
those	B-X
bound	B-X
to	B-X
pericentromeric	B-X
repeat	B-X
sequences	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pericentromeric	B-X
repositioning	B-X
of	B-X
the	B-X
inactive	B-X
gene	B-X
<EOS>	B-X
The	B-X
Ikaros	B-X
-	B-X
dependent	B-X
down	B-X
-	B-X
regulation	B-X
event	B-X
and	B-X
the	B-X
observed	B-X
chromatin	B-X
alterations	B-X
appear	B-X
to	B-X
precede	B-X
pericentromeric	B-X
repositioning	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
TDT	B-X
transcription	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
by	B-X
Ikaros	B-X
proteins	B-X
in	B-X
direct	B-X
competition	B-X
with	B-X
an	B-X
Ets	B-X
activator	B-X
.	B-X

Binding	O
and	O
competition	O
experiments	O
demonstrate	O
that	O
Ikaros	B-protein
dimers	I-protein
compete	O
with	O
an	O
Ets	B-protein
activator	I-protein
for	O
occupancy	O
of	O
the	O
lymphocyte-specific	B-DNA
TdT	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Binding	B-X
and	B-X
competition	B-X
experiments	B-X
demonstrate	B-X
that	B-X
Ikaros	B-X
dimers	B-X
compete	B-X
with	B-X
an	B-X
Ets	B-X
activator	B-X
for	B-X
occupancy	B-X
of	B-X
the	B-X
lymphocyte	B-X
-	B-X
specific	B-X
TdT	B-X
promoter	B-X
<EOS>	B-X
The	B-X
capacity	B-X
for	B-X
in	B-X
vivo	B-X
multimer	B-X
formation	B-X
suggests	B-X
that	B-X
interactions	B-X
between	B-X
Ikaros	B-X
dimers	B-X
bound	B-X
to	B-X
the	B-X
TdT	B-X
promoter	B-X
and	B-X
those	B-X
bound	B-X
to	B-X
pericentromeric	B-X
repeat	B-X
sequences	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pericentromeric	B-X
repositioning	B-X
of	B-X
the	B-X
inactive	B-X
gene	B-X
<EOS>	B-X
Rather	B-X
,	B-X
the	B-X
small	B-X
isoform	B-X
assembled	B-X
into	B-X
multimeric	B-X
complexes	B-X
with	B-X
DNA	B-X
-	B-X
bound	B-X
Ikaros	B-X
at	B-X
the	B-X
pericentromeric	B-X
foci	B-X
<EOS>	B-X
Surprisingly	B-X
,	B-X
in	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocyte	B-X
line	B-X
,	B-X
overexpression	B-X
of	B-X
a	B-X
small	B-X
Ikaros	B-X
isoform	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
differentiation	B-X
or	B-X
on	B-X
the	B-X
pericentromeric	B-X
targeting	B-X
and	B-X
DNA	B-X
-	B-X
binding	B-X
properties	B-X
of	B-X
Ikaros	B-X

Mutations	O
that	O
selectively	O
disrupt	O
Ikaros	O
binding	O
to	O
an	O
integrated	B-DNA
TdT	I-DNA
promoter	I-DNA
had	O
no	O
effect	O
on	O
promoter	O
function	O
in	O
a	O
CD4	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
thymocyte	I-cell_line
line	I-cell_line
.	O

However	O
,	O
these	O
mutations	O
abolished	O
down-regulation	O
on	O
differentiation	O
,	O
providing	O
evidence	O
that	O
Ikaros	B-protein
plays	O
a	O
direct	O
role	O
in	O
repression	O
.	O

Reduced	O
access	O
to	O
restriction	O
enzyme	O
cleavage	O
suggested	O
that	O
chromatin	O
alterations	O
accompany	O
down-regulation	O
.	O
<EOS>	B-X
Reduced	B-X
access	B-X
to	B-X
restriction	B-X
enzyme	B-X
cleavage	B-X
suggested	B-X
that	B-X
chromatin	B-X
alterations	B-X
accompany	B-X
down	B-X
-	B-X
regulation	B-X
<EOS>	B-X
The	B-X
Ikaros	B-X
-	B-X
dependent	B-X
down	B-X
-	B-X
regulation	B-X
event	B-X
and	B-X
the	B-X
observed	B-X
chromatin	B-X
alterations	B-X
appear	B-X
to	B-X
precede	B-X
pericentromeric	B-X
repositioning	B-X
<EOS>	B-X
Current	B-X
models	B-X
propose	B-X
that	B-X
the	B-X
functions	B-X
of	B-X
Ikaros	B-X
should	B-X
be	B-X
disrupted	B-X
by	B-X
a	B-X
small	B-X
isoform	B-X
that	B-X
retains	B-X
the	B-X
dimerization	B-X
domain	B-X
and	B-X
lacks	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
domain	B-X
<EOS>	B-X
Ikaros	B-X
is	B-X
a	B-X
unique	B-X
regulator	B-X
of	B-X
lymphopoiesis	B-X
that	B-X
associates	B-X
with	B-X
pericentromeric	B-X
heterochromatin	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
heritable	B-X
gene	B-X
inactivation	B-X

The	O
Ikaros-dependent	O
down-regulation	O
event	O
and	O
the	O
observed	O
chromatin	O
alterations	O
appear	O
to	O
precede	O
pericentromeric	O
repositioning	O
.	O
<EOS>	B-X
The	B-X
Ikaros	B-X
-	B-X
dependent	B-X
down	B-X
-	B-X
regulation	B-X
event	B-X
and	B-X
the	B-X
observed	B-X
chromatin	B-X
alterations	B-X
appear	B-X
to	B-X
precede	B-X
pericentromeric	B-X
repositioning	B-X
<EOS>	B-X
Reduced	B-X
access	B-X
to	B-X
restriction	B-X
enzyme	B-X
cleavage	B-X
suggested	B-X
that	B-X
chromatin	B-X
alterations	B-X
accompany	B-X
down	B-X
-	B-X
regulation	B-X
<EOS>	B-X
The	B-X
capacity	B-X
for	B-X
in	B-X
vivo	B-X
multimer	B-X
formation	B-X
suggests	B-X
that	B-X
interactions	B-X
between	B-X
Ikaros	B-X
dimers	B-X
bound	B-X
to	B-X
the	B-X
TdT	B-X
promoter	B-X
and	B-X
those	B-X
bound	B-X
to	B-X
pericentromeric	B-X
repeat	B-X
sequences	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pericentromeric	B-X
repositioning	B-X
of	B-X
the	B-X
inactive	B-X
gene	B-X
<EOS>	B-X
However	B-X
,	B-X
these	B-X
mutations	B-X
abolished	B-X
down	B-X
-	B-X
regulation	B-X
on	B-X
differentiation	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
Ikaros	B-X
plays	B-X
a	B-X
direct	B-X
role	B-X
in	B-X
repression	B-X

Current	O
models	O
propose	O
that	O
the	O
functions	O
of	O
Ikaros	B-protein
should	O
be	O
disrupted	O
by	O
a	O
small	O
isoform	B-protein
that	O
retains	O
the	O
dimerization	B-protein
domain	I-protein
and	O
lacks	O
the	O
DNA-binding	B-protein
domain	I-protein
.	O
<EOS>	B-X
Current	B-X
models	B-X
propose	B-X
that	B-X
the	B-X
functions	B-X
of	B-X
Ikaros	B-X
should	B-X
be	B-X
disrupted	B-X
by	B-X
a	B-X
small	B-X
isoform	B-X
that	B-X
retains	B-X
the	B-X
dimerization	B-X
domain	B-X
and	B-X
lacks	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
domain	B-X
<EOS>	B-X
Surprisingly	B-X
,	B-X
in	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocyte	B-X
line	B-X
,	B-X
overexpression	B-X
of	B-X
a	B-X
small	B-X
Ikaros	B-X
isoform	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
differentiation	B-X
or	B-X
on	B-X
the	B-X
pericentromeric	B-X
targeting	B-X
and	B-X
DNA	B-X
-	B-X
binding	B-X
properties	B-X
of	B-X
Ikaros	B-X
<EOS>	B-X
The	B-X
capacity	B-X
for	B-X
in	B-X
vivo	B-X
multimer	B-X
formation	B-X
suggests	B-X
that	B-X
interactions	B-X
between	B-X
Ikaros	B-X
dimers	B-X
bound	B-X
to	B-X
the	B-X
TdT	B-X
promoter	B-X
and	B-X
those	B-X
bound	B-X
to	B-X
pericentromeric	B-X
repeat	B-X
sequences	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pericentromeric	B-X
repositioning	B-X
of	B-X
the	B-X
inactive	B-X
gene	B-X
<EOS>	B-X
Reduced	B-X
access	B-X
to	B-X
restriction	B-X
enzyme	B-X
cleavage	B-X
suggested	B-X
that	B-X
chromatin	B-X
alterations	B-X
accompany	B-X
down	B-X
-	B-X
regulation	B-X

Surprisingly	O
,	O
in	O
the	O
CD4	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
thymocyte	I-cell_line
line	I-cell_line
,	O
overexpression	O
of	O
a	O
small	B-protein
Ikaros	I-protein
isoform	I-protein
had	O
no	O
effect	O
on	O
differentiation	O
or	O
on	O
the	O
pericentromeric	O
targeting	O
and	O
DNA-binding	O
properties	O
of	O
Ikaros	B-protein
.	O
<EOS>	B-X
Surprisingly	B-X
,	B-X
in	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocyte	B-X
line	B-X
,	B-X
overexpression	B-X
of	B-X
a	B-X
small	B-X
Ikaros	B-X
isoform	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
differentiation	B-X
or	B-X
on	B-X
the	B-X
pericentromeric	B-X
targeting	B-X
and	B-X
DNA	B-X
-	B-X
binding	B-X
properties	B-X
of	B-X
Ikaros	B-X
<EOS>	B-X
Current	B-X
models	B-X
propose	B-X
that	B-X
the	B-X
functions	B-X
of	B-X
Ikaros	B-X
should	B-X
be	B-X
disrupted	B-X
by	B-X
a	B-X
small	B-X
isoform	B-X
that	B-X
retains	B-X
the	B-X
dimerization	B-X
domain	B-X
and	B-X
lacks	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
domain	B-X
<EOS>	B-X
The	B-X
DNA	B-X
binding	B-X
and	B-X
dimerization	B-X
properties	B-X
of	B-X
Ikaros	B-X
are	B-X
also	B-X
responsible	B-X
for	B-X
its	B-X
targeting	B-X
to	B-X
pericentromeric	B-X
heterochromatin	B-X
(	B-X
PC	B-X
-	B-X
HC	B-X
)	B-X
<EOS>	B-X
The	B-X
capacity	B-X
for	B-X
in	B-X
vivo	B-X
multimer	B-X
formation	B-X
suggests	B-X
that	B-X
interactions	B-X
between	B-X
Ikaros	B-X
dimers	B-X
bound	B-X
to	B-X
the	B-X
TdT	B-X
promoter	B-X
and	B-X
those	B-X
bound	B-X
to	B-X
pericentromeric	B-X
repeat	B-X
sequences	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pericentromeric	B-X
repositioning	B-X
of	B-X
the	B-X
inactive	B-X
gene	B-X

Rather	O
,	O
the	O
small	O
isoform	B-protein
assembled	O
into	O
multimeric	B-protein
complexes	I-protein
with	O
DNA-bound	B-protein
Ikaros	I-protein
at	O
the	O
pericentromeric	O
foci	O
.	O
<EOS>	B-X
Rather	B-X
,	B-X
the	B-X
small	B-X
isoform	B-X
assembled	B-X
into	B-X
multimeric	B-X
complexes	B-X
with	B-X
DNA	B-X
-	B-X
bound	B-X
Ikaros	B-X
at	B-X
the	B-X
pericentromeric	B-X
foci	B-X
<EOS>	B-X
However	B-X
,	B-X
these	B-X
mutations	B-X
abolished	B-X
down	B-X
-	B-X
regulation	B-X
on	B-X
differentiation	B-X
,	B-X
providing	B-X
evidence	B-X
that	B-X
Ikaros	B-X
plays	B-X
a	B-X
direct	B-X
role	B-X
in	B-X
repression	B-X
<EOS>	B-X
The	B-X
Ikaros	B-X
-	B-X
dependent	B-X
down	B-X
-	B-X
regulation	B-X
event	B-X
and	B-X
the	B-X
observed	B-X
chromatin	B-X
alterations	B-X
appear	B-X
to	B-X
precede	B-X
pericentromeric	B-X
repositioning	B-X
<EOS>	B-X
The	B-X
capacity	B-X
for	B-X
in	B-X
vivo	B-X
multimer	B-X
formation	B-X
suggests	B-X
that	B-X
interactions	B-X
between	B-X
Ikaros	B-X
dimers	B-X
bound	B-X
to	B-X
the	B-X
TdT	B-X
promoter	B-X
and	B-X
those	B-X
bound	B-X
to	B-X
pericentromeric	B-X
repeat	B-X
sequences	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pericentromeric	B-X
repositioning	B-X
of	B-X
the	B-X
inactive	B-X
gene	B-X

The	O
capacity	O
for	O
in	O
vivo	O
multimer	O
formation	O
suggests	O
that	O
interactions	O
between	O
Ikaros	B-protein
dimers	I-protein
bound	O
to	O
the	O
TdT	B-DNA
promoter	I-DNA
and	O
those	O
bound	O
to	O
pericentromeric	B-DNA
repeat	I-DNA
sequences	I-DNA
may	O
contribute	O
to	O
the	O
pericentromeric	O
repositioning	O
of	O
the	O
inactive	B-DNA
gene	I-DNA
.	O

Type	B-protein
I	I-protein
interferons	I-protein
and	O
IL-12	B-protein
:	O
convergence	O
and	O
cross-regulation	O
among	O
mediators	O
of	O
cellular	O
immunity	O
.	O
<EOS>	B-X
Type	B-X
I	B-X
interferons	B-X
and	B-X
IL	B-X
-	B-X
12	B-X
:	B-X
convergence	B-X
and	B-X
cross	B-X
-	B-X
regulation	B-X
among	B-X
mediators	B-X
of	B-X
cellular	B-X
immunity	B-X
.	B-X
<EOS>	B-X
We	B-X
characterized	B-X
the	B-X
effects	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
on	B-X
the	B-X
production	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
the	B-X
central	B-X
immunoregulatory	B-X
cytokine	B-X
of	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
arm	B-X
of	B-X
CMI	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
to	B-X
suppress	B-X
IL	B-X
-	B-X
12	B-X
production	B-X
while	B-X
up	B-X
-	B-X
regulating	B-X
IFN	B-X
-	B-X
gamma	B-X
production	B-X
suggests	B-X
a	B-X
possible	B-X
mechanistic	B-X
basis	B-X
for	B-X
the	B-X
difficulties	B-X
of	B-X
employing	B-X
these	B-X
cytokines	B-X
in	B-X
diseases	B-X
involving	B-X
abnormalities	B-X
of	B-X
CMI	B-X
<EOS>	B-X
Type	B-X
I	B-X
IFN	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
able	B-X
to	B-X
substitute	B-X
for	B-X
IL	B-X
-	B-X
12	B-X
in	B-X
driving	B-X
IFN	B-X
-	B-X
gamma	B-X
production	B-X
from	B-X
T	B-X
and	B-X
NK	B-X
cells	B-X

Therapeutic	O
use	O
of	O
type	B-protein
I	I-protein
IFN	I-protein
(	O
IFN-alpha/beta	B-protein
)	O
has	O
become	O
common	O
.	O
<EOS>	B-X
Therapeutic	B-X
use	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
)	B-X
has	B-X
become	B-X
common	B-X
<EOS>	B-X
We	B-X
characterized	B-X
the	B-X
effects	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
on	B-X
the	B-X
production	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
the	B-X
central	B-X
immunoregulatory	B-X
cytokine	B-X
of	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
arm	B-X
of	B-X
CMI	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
type	B-X
I	B-X
IFN	B-X
are	B-X
potent	B-X
inhibitors	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
production	B-X
by	B-X
human	B-X
monocytes	B-X
/	B-X
macrophages	B-X
<EOS>	B-X
It	B-X
is	B-X
thus	B-X
notable	B-X
that	B-X
the	B-X
pleiotropic	B-X
effects	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
on	B-X
CMI	B-X
remain	B-X
poorly	B-X
understood	B-X

Many	O
of	O
the	O
diverse	O
diseases	O
targeted	O
are	O
marked	O
by	O
pathogenetic	O
abnormalities	O
in	O
cell-mediated	O
immunity	O
(	O
CMI	O
)	O
,	O
these	O
cellular	O
immune	O
responses	O
either	O
causing	O
injury	O
to	O
the	O
host	O
,	O
lacking	O
sufficient	O
vigor	O
for	O
virus	O
or	O
tumor	O
clearance	O
,	O
or	O
both	O
.	O
<EOS>	B-X
Most	B-X
of	B-X
the	B-X
literature	B-X
on	B-X
the	B-X
topic	B-X
comprises	B-X
case	B-X
reports	B-X
and	B-X
series	B-X
that	B-X
have	B-X
not	B-X
been	B-X
reviewed	B-X
in	B-X
a	B-X
systematic	B-X
manner	B-X
<EOS>	B-X
Included	B-X
studies	B-X
reported	B-X
on	B-X
patients	B-X
of	B-X
any	B-X
sex	B-X
or	B-X
age	B-X
who	B-X
received	B-X
TNFis	B-X
whose	B-X
treatment	B-X
was	B-X
followed	B-X
by	B-X
resolution	B-X
or	B-X
occurrence	B-X
of	B-X
acne	B-X
<EOS>	B-X
However	B-X
,	B-X
immune	B-X
escape	B-X
variants	B-X
were	B-X
reported	B-X
in	B-X
the	B-X
trial	B-X
,	B-X
suggesting	B-X
that	B-X
multivalent	B-X
approaches	B-X
targeting	B-X
GBM	B-X
-	B-X
associated	B-X
antigens	B-X
may	B-X
be	B-X
of	B-X
importance	B-X
<EOS>	B-X
The	B-X
objective	B-X
was	B-X
to	B-X
investigate	B-X
if	B-X
metformin	B-X
pharmacokinetics	B-X
is	B-X
modulated	B-X
by	B-X
time	B-X
-	B-X
of	B-X
-	B-X
day	B-X
in	B-X
humans	B-X
using	B-X
empirical	B-X
and	B-X
mechanistic	B-X
pharmacokinetic	B-X
modelling	B-X
techniques	B-X
on	B-X
a	B-X
large	B-X
clinical	B-X
dataset	B-X

In	O
general	O
,	O
therapeutic	O
efficacy	O
is	O
limited	O
.	O
<EOS>	B-X
We	B-X
conducted	B-X
ROC	B-X
analysis	B-X
to	B-X
assess	B-X
the	B-X
diagnostic	B-X
efficacy	B-X
of	B-X
hub	B-X
genes	B-X
<EOS>	B-X
In	B-X
several	B-X
domains	B-X
,	B-X
the	B-X
research	B-X
is	B-X
still	B-X
in	B-X
an	B-X
early	B-X
phase	B-X
of	B-X
development	B-X
,	B-X
e	B-X
<EOS>	B-X
Nevertheless	B-X
,	B-X
the	B-X
therapeutic	B-X
outcomes	B-X
were	B-X
greatly	B-X
limited	B-X
because	B-X
of	B-X
insufficient	B-X
endogenous	B-X
H	B-X
<EOS>	B-X
The	B-X
decorated	B-X
Au	B-X
nanoparticles	B-X
could	B-X
not	B-X
only	B-X
produce	B-X
O	B-X

It	O
is	O
thus	O
notable	O
that	O
the	O
pleiotropic	O
effects	O
of	O
type	B-protein
I	I-protein
IFN	I-protein
on	O
CMI	O
remain	O
poorly	O
understood	O
.	O
<EOS>	B-X
It	B-X
is	B-X
thus	B-X
notable	B-X
that	B-X
the	B-X
pleiotropic	B-X
effects	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
on	B-X
CMI	B-X
remain	B-X
poorly	B-X
understood	B-X
<EOS>	B-X
1	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
upstream	B-X
Ets	B-X
site	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
12p40	B-X
promoter	B-X
<EOS>	B-X
Therapeutic	B-X
use	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
)	B-X
has	B-X
become	B-X
common	B-X
<EOS>	B-X
In	B-X
general	B-X
,	B-X
therapeutic	B-X
efficacy	B-X
is	B-X
limited	B-X

We	O
characterized	O
the	O
effects	O
of	O
type	B-protein
I	I-protein
IFN	I-protein
on	O
the	O
production	O
of	O
IL-12	B-protein
,	O
the	O
central	B-protein
immunoregulatory	I-protein
cytokine	I-protein
of	O
the	O
CD4	B-protein
(	I-protein
+	I-protein
)	I-protein
T	I-protein
cell	I-protein
arm	I-protein
of	O
CMI	O
.	O
<EOS>	B-X
We	B-X
characterized	B-X
the	B-X
effects	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
on	B-X
the	B-X
production	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
the	B-X
central	B-X
immunoregulatory	B-X
cytokine	B-X
of	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
arm	B-X
of	B-X
CMI	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
type	B-X
I	B-X
IFN	B-X
are	B-X
potent	B-X
inhibitors	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
production	B-X
by	B-X
human	B-X
monocytes	B-X
/	B-X
macrophages	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
to	B-X
suppress	B-X
IL	B-X
-	B-X
12	B-X
production	B-X
while	B-X
up	B-X
-	B-X
regulating	B-X
IFN	B-X
-	B-X
gamma	B-X
production	B-X
suggests	B-X
a	B-X
possible	B-X
mechanistic	B-X
basis	B-X
for	B-X
the	B-X
difficulties	B-X
of	B-X
employing	B-X
these	B-X
cytokines	B-X
in	B-X
diseases	B-X
involving	B-X
abnormalities	B-X
of	B-X
CMI	B-X
<EOS>	B-X
Type	B-X
I	B-X
interferons	B-X
and	B-X
IL	B-X
-	B-X
12	B-X
:	B-X
convergence	B-X
and	B-X
cross	B-X
-	B-X
regulation	B-X
among	B-X
mediators	B-X
of	B-X
cellular	B-X
immunity	B-X
.	B-X

We	O
show	O
that	O
type	B-protein
I	I-protein
IFN	I-protein
are	O
potent	O
inhibitors	O
of	O
IL-12	O
production	O
by	O
human	B-cell_type
monocytes/macrophages	I-cell_type
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
type	B-X
I	B-X
IFN	B-X
are	B-X
potent	B-X
inhibitors	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
production	B-X
by	B-X
human	B-X
monocytes	B-X
/	B-X
macrophages	B-X
<EOS>	B-X
We	B-X
characterized	B-X
the	B-X
effects	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
on	B-X
the	B-X
production	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
the	B-X
central	B-X
immunoregulatory	B-X
cytokine	B-X
of	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
arm	B-X
of	B-X
CMI	B-X
<EOS>	B-X
Type	B-X
I	B-X
IFN	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
able	B-X
to	B-X
substitute	B-X
for	B-X
IL	B-X
-	B-X
12	B-X
in	B-X
driving	B-X
IFN	B-X
-	B-X
gamma	B-X
production	B-X
from	B-X
T	B-X
and	B-X
NK	B-X
cells	B-X
<EOS>	B-X
The	B-X
underlying	B-X
mechanism	B-X
involves	B-X
transcriptional	B-X
inhibition	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
12p40	B-X
gene	B-X
,	B-X
marked	B-X
by	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
PU	B-X

The	O
underlying	O
mechanism	O
involves	O
transcriptional	O
inhibition	O
of	O
the	O
IL-12p40	B-DNA
gene	I-DNA
,	O
marked	O
by	O
down-regulation	O
of	O
PU.1	O
binding	O
activity	O
at	O
the	O
upstream	B-DNA
Ets	I-DNA
site	I-DNA
of	O
the	O
IL-12p40	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
The	B-X
underlying	B-X
mechanism	B-X
involves	B-X
transcriptional	B-X
inhibition	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
12p40	B-X
gene	B-X
,	B-X
marked	B-X
by	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
PU	B-X
<EOS>	B-X
1	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
upstream	B-X
Ets	B-X
site	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
12p40	B-X
promoter	B-X
<EOS>	B-X
Type	B-X
I	B-X
interferons	B-X
and	B-X
IL	B-X
-	B-X
12	B-X
:	B-X
convergence	B-X
and	B-X
cross	B-X
-	B-X
regulation	B-X
among	B-X
mediators	B-X
of	B-X
cellular	B-X
immunity	B-X
.	B-X
<EOS>	B-X
We	B-X
characterized	B-X
the	B-X
effects	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
on	B-X
the	B-X
production	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
the	B-X
central	B-X
immunoregulatory	B-X
cytokine	B-X
of	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
arm	B-X
of	B-X
CMI	B-X

Type	B-protein
I	I-protein
IFN	I-protein
have	O
previously	O
been	O
shown	O
to	O
be	O
able	O
to	O
substitute	O
for	O
IL-12	B-protein
in	O
driving	O
IFN-gamma	O
production	O
from	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

The	O
ability	O
of	O
IFN-alpha/beta	B-protein
to	O
suppress	O
IL-12	O
production	O
while	O
up-regulating	O
IFN-gamma	O
production	O
suggests	O
a	O
possible	O
mechanistic	O
basis	O
for	O
the	O
difficulties	O
of	O
employing	O
these	O
cytokines	B-protein
in	O
diseases	O
involving	O
abnormalities	O
of	O
CMI	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
to	B-X
suppress	B-X
IL	B-X
-	B-X
12	B-X
production	B-X
while	B-X
up	B-X
-	B-X
regulating	B-X
IFN	B-X
-	B-X
gamma	B-X
production	B-X
suggests	B-X
a	B-X
possible	B-X
mechanistic	B-X
basis	B-X
for	B-X
the	B-X
difficulties	B-X
of	B-X
employing	B-X
these	B-X
cytokines	B-X
in	B-X
diseases	B-X
involving	B-X
abnormalities	B-X
of	B-X
CMI	B-X
<EOS>	B-X
We	B-X
characterized	B-X
the	B-X
effects	B-X
of	B-X
type	B-X
I	B-X
IFN	B-X
on	B-X
the	B-X
production	B-X
of	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
the	B-X
central	B-X
immunoregulatory	B-X
cytokine	B-X
of	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
arm	B-X
of	B-X
CMI	B-X
<EOS>	B-X
Type	B-X
I	B-X
IFN	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
able	B-X
to	B-X
substitute	B-X
for	B-X
IL	B-X
-	B-X
12	B-X
in	B-X
driving	B-X
IFN	B-X
-	B-X
gamma	B-X
production	B-X
from	B-X
T	B-X
and	B-X
NK	B-X
cells	B-X
<EOS>	B-X
Type	B-X
I	B-X
interferons	B-X
and	B-X
IL	B-X
-	B-X
12	B-X
:	B-X
convergence	B-X
and	B-X
cross	B-X
-	B-X
regulation	B-X
among	B-X
mediators	B-X
of	B-X
cellular	B-X
immunity	B-X
.	B-X

Nuclear	B-protein
factor-kappaB	I-protein
suppressive	O
and	O
inhibitor-kappaB	B-protein
stimulatory	O
effects	O
of	O
troglitazone	O
in	O
obese	O
patients	O
with	O
type	O
2	O
diabetes	O
:	O
evidence	O
of	O
an	O
antiinflammatory	O
action	O
?	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
suppressive	B-X
and	B-X
inhibitor	B-X
-	B-X
kappaB	B-X
stimulatory	B-X
effects	B-X
of	B-X
troglitazone	B-X
in	B-X
obese	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
:	B-X
evidence	B-X
of	B-X
an	B-X
antiinflammatory	B-X
action	B-X
?	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
binding	B-X
activity	B-X
in	B-X
MNC	B-X
nuclear	B-X
extracts	B-X
was	B-X
significantly	B-X
inhibited	B-X
after	B-X
troglitazone	B-X
treatment	B-X
at	B-X
week	B-X
1	B-X
and	B-X
continued	B-X
to	B-X
be	B-X
inhibited	B-X
up	B-X
to	B-X
week	B-X
4	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
IkappaB	B-X
protein	B-X
levels	B-X
increased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
treatment	B-X
at	B-X
week	B-X
1	B-X
,	B-X
and	B-X
this	B-X
increase	B-X
persisted	B-X
throughout	B-X
the	B-X
study	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
troglitazone	B-X
has	B-X
profound	B-X
antiinflammatory	B-X
effects	B-X
in	B-X
addition	B-X
to	B-X
antioxidant	B-X
effects	B-X
in	B-X
obese	B-X
type	B-X
2	B-X
diabetics	B-X
;	B-X
these	B-X
effects	B-X
may	B-X
be	B-X
relevant	B-X
to	B-X
the	B-X
recently	B-X
described	B-X
beneficial	B-X
antiatherosclerotic	B-X
effects	B-X
of	B-X
troglitazone	B-X
at	B-X
the	B-X
vascular	B-X
level	B-X

It	O
has	O
been	O
shown	O
recently	O
that	O
troglitazone	O
exerts	O
an	O
anti-inflammatory	O
effect	O
,	O
in	O
vitro	O
,	O
and	O
in	O
experimental	O
animals	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
recently	B-X
that	B-X
troglitazone	B-X
exerts	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
,	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
animals	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
troglitazone	B-X
has	B-X
profound	B-X
antiinflammatory	B-X
effects	B-X
in	B-X
addition	B-X
to	B-X
antioxidant	B-X
effects	B-X
in	B-X
obese	B-X
type	B-X
2	B-X
diabetics	B-X
;	B-X
these	B-X
effects	B-X
may	B-X
be	B-X
relevant	B-X
to	B-X
the	B-X
recently	B-X
described	B-X
beneficial	B-X
antiatherosclerotic	B-X
effects	B-X
of	B-X
troglitazone	B-X
at	B-X
the	B-X
vascular	B-X
level	B-X
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
by	B-X
polymorphonuclear	B-X
cells	B-X
and	B-X
MNC	B-X
,	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
protein	B-X
quantities	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
-	B-X
1	B-X
,	B-X
and	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
levels	B-X
decreased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
intake	B-X
<EOS>	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
troglitazone	B-X
on	B-X
reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
,	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
expression	B-X
,	B-X
9	B-X
-	B-X
hydroxyoctadecadienoic	B-X
acid	B-X
(	B-X
9	B-X
-	B-X
HODE	B-X
)	B-X
,	B-X
13	B-X
-	B-X
HODE	B-X
,	B-X
o	B-X
-	B-X
tyrosine	B-X
,	B-X
and	B-X
m	B-X
-	B-X
tyrosine	B-X
in	B-X
obese	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X

To	O
test	O
these	O
properties	O
in	O
humans	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
troglitazone	O
on	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
and	O
its	O
inhibitory	B-protein
protein	I-protein
IkappaB	I-protein
in	O
mononuclear	B-cell_type
cells	I-cell_type
(	O
MNC	B-cell_type
)	O
and	O
plasma	B-protein
soluble	I-protein
intracellular	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
,	O
plasminogen	B-protein
activator	I-protein
inhibitor-1	I-protein
,	O
and	O
C-reactive	B-protein
protein	I-protein
.	O
<EOS>	B-X
To	B-X
test	B-X
these	B-X
properties	B-X
in	B-X
humans	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
troglitazone	B-X
on	B-X
the	B-X
proinflammatory	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
its	B-X
inhibitory	B-X
protein	B-X
IkappaB	B-X
in	B-X
mononuclear	B-X
cells	B-X
(	B-X
MNC	B-X
)	B-X
and	B-X
plasma	B-X
soluble	B-X
intracellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
-	B-X
1	B-X
,	B-X
and	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
<EOS>	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
troglitazone	B-X
on	B-X
reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
,	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
expression	B-X
,	B-X
9	B-X
-	B-X
hydroxyoctadecadienoic	B-X
acid	B-X
(	B-X
9	B-X
-	B-X
HODE	B-X
)	B-X
,	B-X
13	B-X
-	B-X
HODE	B-X
,	B-X
o	B-X
-	B-X
tyrosine	B-X
,	B-X
and	B-X
m	B-X
-	B-X
tyrosine	B-X
in	B-X
obese	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
troglitazone	B-X
has	B-X
profound	B-X
antiinflammatory	B-X
effects	B-X
in	B-X
addition	B-X
to	B-X
antioxidant	B-X
effects	B-X
in	B-X
obese	B-X
type	B-X
2	B-X
diabetics	B-X
;	B-X
these	B-X
effects	B-X
may	B-X
be	B-X
relevant	B-X
to	B-X
the	B-X
recently	B-X
described	B-X
beneficial	B-X
antiatherosclerotic	B-X
effects	B-X
of	B-X
troglitazone	B-X
at	B-X
the	B-X
vascular	B-X
level	B-X
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
by	B-X
polymorphonuclear	B-X
cells	B-X
and	B-X
MNC	B-X
,	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
protein	B-X
quantities	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
-	B-X
1	B-X
,	B-X
and	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
levels	B-X
decreased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
intake	B-X

We	O
also	O
examined	O
the	O
effect	O
of	O
troglitazone	O
on	O
reactive	O
oxygen	O
species	O
generation	O
,	O
p47	O
(	O
phox	O
)	O
subunit	O
expression	O
,	O
9-hydroxyoctadecadienoic	O
acid	O
(	O
9-HODE	O
)	O
,	O
13-HODE	O
,	O
o-tyrosine	O
,	O
and	O
m-tyrosine	O
in	O
obese	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O
<EOS>	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
troglitazone	B-X
on	B-X
reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
,	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
expression	B-X
,	B-X
9	B-X
-	B-X
hydroxyoctadecadienoic	B-X
acid	B-X
(	B-X
9	B-X
-	B-X
HODE	B-X
)	B-X
,	B-X
13	B-X
-	B-X
HODE	B-X
,	B-X
o	B-X
-	B-X
tyrosine	B-X
,	B-X
and	B-X
m	B-X
-	B-X
tyrosine	B-X
in	B-X
obese	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
<EOS>	B-X
To	B-X
test	B-X
these	B-X
properties	B-X
in	B-X
humans	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
troglitazone	B-X
on	B-X
the	B-X
proinflammatory	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
its	B-X
inhibitory	B-X
protein	B-X
IkappaB	B-X
in	B-X
mononuclear	B-X
cells	B-X
(	B-X
MNC	B-X
)	B-X
and	B-X
plasma	B-X
soluble	B-X
intracellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
-	B-X
1	B-X
,	B-X
and	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
by	B-X
polymorphonuclear	B-X
cells	B-X
and	B-X
MNC	B-X
,	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
protein	B-X
quantities	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
-	B-X
1	B-X
,	B-X
and	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
levels	B-X
decreased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
intake	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
recently	B-X
that	B-X
troglitazone	B-X
exerts	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
,	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
in	B-X
experimental	B-X
animals	B-X

Seven	O
obese	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
treated	O
with	O
troglitazone	O
(	O
400	O
mg/day	O
)	O
for	O
4	O
weeks	O
.	O
<EOS>	B-X
Seven	B-X
obese	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
were	B-X
treated	B-X
with	B-X
troglitazone	B-X
(	B-X
400	B-X
mg	B-X
/	B-X
day	B-X
)	B-X
for	B-X
4	B-X
weeks	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
binding	B-X
activity	B-X
in	B-X
MNC	B-X
nuclear	B-X
extracts	B-X
was	B-X
significantly	B-X
inhibited	B-X
after	B-X
troglitazone	B-X
treatment	B-X
at	B-X
week	B-X
1	B-X
and	B-X
continued	B-X
to	B-X
be	B-X
inhibited	B-X
up	B-X
to	B-X
week	B-X
4	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
IkappaB	B-X
protein	B-X
levels	B-X
increased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
treatment	B-X
at	B-X
week	B-X
1	B-X
,	B-X
and	B-X
this	B-X
increase	B-X
persisted	B-X
throughout	B-X
the	B-X
study	B-X
<EOS>	B-X
Plasma	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
and	B-X
soluble	B-X
intracellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
concentrations	B-X
did	B-X
not	B-X
decrease	B-X
significantly	B-X
after	B-X
troglitazone	B-X
treatment	B-X
,	B-X
although	B-X
there	B-X
was	B-X
a	B-X
trend	B-X
toward	B-X
inhibition	B-X

Blood	O
samples	O
were	O
obtained	O
at	O
weekly	O
intervals	O
.	O
<EOS>	B-X
All	B-X
PK	B-X
exposures	B-X
were	B-X
within	B-X
expected	B-X
ranges	B-X
based	B-X
on	B-X
historical	B-X
studies	B-X
<EOS>	B-X
Blood	B-X
samples	B-X
were	B-X
drawn	B-X
to	B-X
determine	B-X
plasma	B-X
concentrations	B-X
of	B-X
the	B-X
parent	B-X
drug	B-X
and	B-X
its	B-X
two	B-X
main	B-X
metabolites	B-X
<EOS>	B-X
15	B-X
;	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
:	B-X
1	B-X
<EOS>	B-X
Blood	B-X
samples	B-X
were	B-X
collected	B-X
to	B-X
determine	B-X
tirzepatide	B-X
plasma	B-X
concentrations	B-X
to	B-X
estimate	B-X
pharmacokinetic	B-X
parameters	B-X

Nuclear	B-protein
factor-kappaB	I-protein
binding	O
activity	O
in	O
MNC	B-cell_type
nuclear	O
extracts	O
was	O
significantly	O
inhibited	O
after	O
troglitazone	O
treatment	O
at	O
week	O
1	O
and	O
continued	O
to	O
be	O
inhibited	O
up	O
to	O
week	O
4	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
binding	B-X
activity	B-X
in	B-X
MNC	B-X
nuclear	B-X
extracts	B-X
was	B-X
significantly	B-X
inhibited	B-X
after	B-X
troglitazone	B-X
treatment	B-X
at	B-X
week	B-X
1	B-X
and	B-X
continued	B-X
to	B-X
be	B-X
inhibited	B-X
up	B-X
to	B-X
week	B-X
4	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
IkappaB	B-X
protein	B-X
levels	B-X
increased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
treatment	B-X
at	B-X
week	B-X
1	B-X
,	B-X
and	B-X
this	B-X
increase	B-X
persisted	B-X
throughout	B-X
the	B-X
study	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
suppressive	B-X
and	B-X
inhibitor	B-X
-	B-X
kappaB	B-X
stimulatory	B-X
effects	B-X
of	B-X
troglitazone	B-X
in	B-X
obese	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
:	B-X
evidence	B-X
of	B-X
an	B-X
antiinflammatory	B-X
action	B-X
?	B-X
<EOS>	B-X
Plasma	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
and	B-X
soluble	B-X
intracellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
concentrations	B-X
did	B-X
not	B-X
decrease	B-X
significantly	B-X
after	B-X
troglitazone	B-X
treatment	B-X
,	B-X
although	B-X
there	B-X
was	B-X
a	B-X
trend	B-X
toward	B-X
inhibition	B-X

On	O
the	O
other	O
hand	O
,	O
IkappaB	O
protein	O
levels	O
increased	O
significantly	O
after	O
troglitazone	O
treatment	O
at	O
week	O
1	O
,	O
and	O
this	O
increase	O
persisted	O
throughout	O
the	O
study	O
.	O

Plasma	B-protein
monocyte	I-protein
chemoattractant	I-protein
protein-1	I-protein
and	O
soluble	B-protein
intracellular	I-protein
adhesion	I-protein
molecule-1	I-protein
concentrations	O
did	O
not	O
decrease	O
significantly	O
after	O
troglitazone	O
treatment	O
,	O
although	O
there	O
was	O
a	O
trend	O
toward	O
inhibition	O
.	O
<EOS>	B-X
Plasma	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
alpha	B-X
,	B-X
soluble	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
(	B-X
sICAM	B-X
-	B-X
1	B-X
)	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
1	B-X
(	B-X
PAI	B-X
-	B-X
1	B-X
)	B-X
,	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
(	B-X
CRP	B-X
)	B-X
,	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
10	B-X
(	B-X
antiinflammatory	B-X
cytokine	B-X
)	B-X
concentrations	B-X
were	B-X
also	B-X
measured	B-X
as	B-X
mediators	B-X
of	B-X
inflammatory	B-X
activity	B-X
that	B-X
are	B-X
regulated	B-X
by	B-X
the	B-X
proinflammatory	B-X
transcription	B-X
factor	B-X
NFkappaB	B-X
<EOS>	B-X
The	B-X
present	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
overweight	B-X
and	B-X
obese	B-X
subjects	B-X
,	B-X
low	B-X
-	B-X
fat	B-X
dairy	B-X
consumption	B-X
for	B-X
8	B-X
weeks	B-X
may	B-X
increase	B-X
concentrations	B-X
of	B-X
s	B-X
-	B-X
TNFR	B-X
compared	B-X
with	B-X
carbohydrate	B-X
-	B-X
rich	B-X
product	B-X
consumption	B-X
,	B-X
but	B-X
that	B-X
it	B-X
has	B-X
no	B-X
effects	B-X
on	B-X
other	B-X
markers	B-X
of	B-X
chronic	B-X
inflammation	B-X
and	B-X
endothelial	B-X
function	B-X
<EOS>	B-X
Plasma	B-X
IL	B-X
-	B-X
10	B-X
concentration	B-X
increased	B-X
significantly	B-X
,	B-X
whereas	B-X
plasma	B-X
CRP	B-X
concentrations	B-X
decreased	B-X
<EOS>	B-X
Low	B-X
-	B-X
fat	B-X
dairy	B-X
consumption	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
,	B-X
intracellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
concentrations	B-X

Reactive	O
oxygen	O
species	O
generation	O
by	O
polymorphonuclear	B-cell_type
cells	I-cell_type
and	O
MNC	B-cell_type
,	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
protein	I-protein
quantities	O
,	O
plasminogen	B-protein
activator	I-protein
inhibitor-1	I-protein
,	O
and	O
C-reactive	B-protein
protein	I-protein
levels	O
decreased	O
significantly	O
after	O
troglitazone	O
intake	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
by	B-X
polymorphonuclear	B-X
cells	B-X
and	B-X
MNC	B-X
,	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
protein	B-X
quantities	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
-	B-X
1	B-X
,	B-X
and	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
levels	B-X
decreased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
intake	B-X
<EOS>	B-X
13	B-X
-	B-X
HODE	B-X
/	B-X
linoleic	B-X
acid	B-X
and	B-X
9	B-X
-	B-X
HODE	B-X
/	B-X
linoleic	B-X
acid	B-X
ratios	B-X
also	B-X
decreased	B-X
after	B-X
troglitazone	B-X
intake	B-X
<EOS>	B-X
To	B-X
test	B-X
these	B-X
properties	B-X
in	B-X
humans	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
troglitazone	B-X
on	B-X
the	B-X
proinflammatory	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
its	B-X
inhibitory	B-X
protein	B-X
IkappaB	B-X
in	B-X
mononuclear	B-X
cells	B-X
(	B-X
MNC	B-X
)	B-X
and	B-X
plasma	B-X
soluble	B-X
intracellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
-	B-X
1	B-X
,	B-X
and	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
IkappaB	B-X
protein	B-X
levels	B-X
increased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
treatment	B-X
at	B-X
week	B-X
1	B-X
,	B-X
and	B-X
this	B-X
increase	B-X
persisted	B-X
throughout	B-X
the	B-X
study	B-X

13-HODE/linoleic	O
acid	O
and	O
9-HODE/linoleic	O
acid	O
ratios	O
also	O
decreased	O
after	O
troglitazone	O
intake	O
.	O
<EOS>	B-X
13	B-X
-	B-X
HODE	B-X
/	B-X
linoleic	B-X
acid	B-X
and	B-X
9	B-X
-	B-X
HODE	B-X
/	B-X
linoleic	B-X
acid	B-X
ratios	B-X
also	B-X
decreased	B-X
after	B-X
troglitazone	B-X
intake	B-X
<EOS>	B-X
Plasma	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
and	B-X
soluble	B-X
intracellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
concentrations	B-X
did	B-X
not	B-X
decrease	B-X
significantly	B-X
after	B-X
troglitazone	B-X
treatment	B-X
,	B-X
although	B-X
there	B-X
was	B-X
a	B-X
trend	B-X
toward	B-X
inhibition	B-X
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
by	B-X
polymorphonuclear	B-X
cells	B-X
and	B-X
MNC	B-X
,	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
protein	B-X
quantities	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
-	B-X
1	B-X
,	B-X
and	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
levels	B-X
decreased	B-X
significantly	B-X
after	B-X
troglitazone	B-X
intake	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
binding	B-X
activity	B-X
in	B-X
MNC	B-X
nuclear	B-X
extracts	B-X
was	B-X
significantly	B-X
inhibited	B-X
after	B-X
troglitazone	B-X
treatment	B-X
at	B-X
week	B-X
1	B-X
and	B-X
continued	B-X
to	B-X
be	B-X
inhibited	B-X
up	B-X
to	B-X
week	B-X
4	B-X

However	O
,	O
o-tyrosine/phenylalanine	O
and	O
m-tyrosine/phenylalanine	O
ratios	O
did	O
not	O
change	O
significantly	O
.	O
<EOS>	B-X
Plasma	B-X
o	B-X
-	B-X
tyrosine	B-X
/	B-X
phenylalanine	B-X
ratio	B-X
fell	B-X
significantly	B-X
from	B-X
0	B-X
<EOS>	B-X
055	B-X
mmol	B-X
/	B-X
mol	B-X
at	B-X
48h	B-X
and	B-X
m	B-X
-	B-X
tyrosine	B-X
/	B-X
phenylalanine	B-X
ratio	B-X
fell	B-X
from	B-X
0	B-X
<EOS>	B-X
Inhibitory	B-X
effect	B-X
of	B-X
a	B-X
two	B-X
day	B-X
fast	B-X
on	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
generation	B-X
by	B-X
leucocytes	B-X
and	B-X
plasma	B-X
ortho	B-X
-	B-X
tyrosine	B-X
and	B-X
meta	B-X
-	B-X
tyrosine	B-X
concentrations	B-X
.	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
,	B-X
an	B-X
index	B-X
of	B-X
NADPH	B-X
oxidase	B-X
,	B-X
the	B-X
enzyme	B-X
converting	B-X
molecular	B-X
oxygen	B-X
to	B-X
superoxide	B-X
(	B-X
O	B-X
(	B-X

These	O
data	O
show	O
that	O
troglitazone	O
has	O
profound	O
antiinflammatory	O
effects	O
in	O
addition	O
to	O
antioxidant	O
effects	O
in	O
obese	O
type	O
2	O
diabetics	O
;	O
these	O
effects	O
may	O
be	O
relevant	O
to	O
the	O
recently	O
described	O
beneficial	O
antiatherosclerotic	O
effects	O
of	O
troglitazone	O
at	O
the	O
vascular	O
level	O
.	O

OX40	O
stimulation	O
by	O
gp34/OX40	B-protein
ligand	I-protein
enhances	O
productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
.	O
<EOS>	B-X
OX40	B-X
stimulation	B-X
by	B-X
gp34	B-X
/	B-X
OX40	B-X
ligand	B-X
enhances	B-X
productive	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
infection	B-X
.	B-X
<EOS>	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
HIV	B-X
-	B-X
1	B-X
production	B-X
was	B-X
strongly	B-X
induced	B-X
<EOS>	B-X
OX40	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
receptor	B-X
superfamily	B-X
and	B-X
known	B-X
to	B-X
be	B-X
an	B-X
important	B-X
costimulatory	B-X
molecule	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
This	B-X
was	B-X
followed	B-X
by	B-X
apparent	B-X
apoptosis	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
specifically	B-X
inhibited	B-X
by	B-X
the	B-X
gp34	B-X
-	B-X
specific	B-X
neutralizing	B-X
monoclonal	B-X
antibody	B-X
5A8	B-X

OX40	B-protein
is	O
a	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
receptor	I-protein
superfamily	I-protein
and	O
known	O
to	O
be	O
an	O
important	O
costimulatory	B-protein
molecule	I-protein
expressed	O
on	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
OX40	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
receptor	B-X
superfamily	B-X
and	B-X
known	B-X
to	B-X
be	B-X
an	B-X
important	B-X
costimulatory	B-X
molecule	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
OX40	B-X
ligand	B-X
(	B-X
OX40L	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
TNF	B-X
superfamily	B-X
,	B-X
is	B-X
expressed	B-X
on	B-X
several	B-X
APC	B-X
such	B-X
as	B-X
splenic	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
and	B-X
activated	B-X
B	B-X
cells	B-X
<EOS>	B-X
These	B-X
responses	B-X
are	B-X
mediated	B-X
by	B-X
several	B-X
costimulatory	B-X
molecules	B-X
after	B-X
antigenic	B-X
challenge	B-X
<EOS>	B-X
Langerhans	B-X
cells	B-X
(	B-X
LC	B-X
)	B-X
represent	B-X
the	B-X
dominant	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
in	B-X
the	B-X
epidermis	B-X
and	B-X
thus	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
cutaneous	B-X
immune	B-X
responses	B-X
to	B-X
approaching	B-X
pathogens	B-X

To	O
investigate	O
the	O
role	O
of	O
costimulation	O
of	O
OX40	B-protein
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
by	O
its	O
natural	O
ligand	O
,	O
gp34	B-protein
,	O
the	O
OX40-transfected	B-cell_line
ACH-2	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
ACH-2/OX40	I-cell_line
,	O
chronically	O
infected	O
with	O
HIV-1	O
,	O
was	O
cocultured	O
with	O
paraformaldehyde	O
(	O
PFA	O
)	O
-fixed	O
gp34-transfected	B-cell_line
mouse	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
SV-T2/gp34	I-cell_line
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
costimulation	B-X
of	B-X
OX40	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
infection	B-X
by	B-X
its	B-X
natural	B-X
ligand	B-X
,	B-X
gp34	B-X
,	B-X
the	B-X
OX40	B-X
-	B-X
transfected	B-X
ACH	B-X
-	B-X
2	B-X
cell	B-X
line	B-X
,	B-X
ACH	B-X
-	B-X
2	B-X
/	B-X
OX40	B-X
,	B-X
chronically	B-X
infected	B-X
with	B-X
HIV	B-X
-	B-X
1	B-X
,	B-X
was	B-X
cocultured	B-X
with	B-X
paraformaldehyde	B-X
(	B-X
PFA	B-X
)	B-X
	B-X
-	B-X
fixed	B-X
gp34	B-X
-	B-X
transfected	B-X
mouse	B-X
cell	B-X
line	B-X
,	B-X
SV	B-X
-	B-X
T2	B-X
/	B-X
gp34	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
first	B-X
shows	B-X
that	B-X
OX40	B-X
-	B-X
gp34	B-X
interaction	B-X
stimulates	B-X
HIV	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
suggests	B-X
that	B-X
OX40	B-X
triggering	B-X
by	B-X
gp34	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
enhancing	B-X
HIV	B-X
-	B-X
1	B-X
production	B-X
in	B-X
both	B-X
acutely	B-X
and	B-X
latently	B-X
infected	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
vivo	B-X
<EOS>	B-X
OX40	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
receptor	B-X
superfamily	B-X
and	B-X
known	B-X
to	B-X
be	B-X
an	B-X
important	B-X
costimulatory	B-X
molecule	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
enhanced	B-X
HIV	B-X
-	B-X
1	B-X
transcription	B-X
in	B-X
gp34	B-X
-	B-X
stimulated	B-X
ACH	B-X
-	B-X
2	B-X
/	B-X
OX40	B-X
cells	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
kappa	B-X
B	B-X
site	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
long	B-X
terminal	B-X
repeat	B-X
,	B-X
and	B-X
the	B-X
OX40	B-X
-	B-X
gp34	B-X
interaction	B-X
activated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
subunits	B-X

The	O
results	O
showed	O
that	O
HIV-1	O
production	O
was	O
strongly	O
induced	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Tat	B-X
and	B-X
IFN	B-X
-	B-X
γ	B-X
act	B-X
probably	B-X
by	B-X
two	B-X
distinct	B-X
mechanisms	B-X
to	B-X
induce	B-X
the	B-X
production	B-X
of	B-X
IDO	B-X
-	B-X
1	B-X
<EOS>	B-X
As	B-X
a	B-X
result	B-X
,	B-X
IMB	B-X
-	B-X
301	B-X
strongly	B-X
inhibits	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
in	B-X
a	B-X
hA3G	B-X
-	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
HIV	B-X
-	B-X
1	B-X
Gag	B-X
multimerization	B-X
promotes	B-X
PIP2	B-X
clustering	B-X
<EOS>	B-X
Toll	B-X
-	B-X
like	B-X
receptor	B-X
7	B-X
-	B-X
adapter	B-X
complex	B-X
modulates	B-X
interferon	B-X
-	B-X
α	B-X
production	B-X
in	B-X
HIV	B-X
-	B-X
stimulated	B-X
plasmacytoid	B-X
dendritic	B-X
cells	B-X
.	B-X

This	O
was	O
followed	O
by	O
apparent	O
apoptosis	O
,	O
and	O
both	O
processes	O
were	O
specifically	O
inhibited	O
by	O
the	O
gp34	B-protein
-specific	O
neutralizing	B-protein
monoclonal	I-protein
antibody	I-protein
5A8	I-protein
.	O
<EOS>	B-X
This	B-X
was	B-X
followed	B-X
by	B-X
apparent	B-X
apoptosis	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
specifically	B-X
inhibited	B-X
by	B-X
the	B-X
gp34	B-X
-	B-X
specific	B-X
neutralizing	B-X
monoclonal	B-X
antibody	B-X
5A8	B-X
<EOS>	B-X
The	B-X
enhancement	B-X
was	B-X
again	B-X
significantly	B-X
inhibited	B-X
by	B-X
5A8	B-X
<EOS>	B-X
Endogenous	B-X
TNF	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
TNF	B-X
-	B-X
beta	B-X
production	B-X
were	B-X
not	B-X
involved	B-X
in	B-X
the	B-X
enhanced	B-X
HIV	B-X
-	B-X
1	B-X
production	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
enhanced	B-X
HIV	B-X
-	B-X
1	B-X
transcription	B-X
in	B-X
gp34	B-X
-	B-X
stimulated	B-X
ACH	B-X
-	B-X
2	B-X
/	B-X
OX40	B-X
cells	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
kappa	B-X
B	B-X
site	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
long	B-X
terminal	B-X
repeat	B-X
,	B-X
and	B-X
the	B-X
OX40	B-X
-	B-X
gp34	B-X
interaction	B-X
activated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
subunits	B-X

Endogenous	O
TNF	B-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
TNF-beta	B-protein
production	O
were	O
not	O
involved	O
in	O
the	O
enhanced	O
HIV-1	O
production	O
.	O
<EOS>	B-X
Exogenous	B-X
treatment	B-X
with	B-X
recombinant	B-X
SNCA	B-X
(	B-X
rSNCA	B-X
)	B-X
activated	B-X
the	B-X
Akt	B-X
-	B-X
eNOS	B-X
axis	B-X
and	B-X
increased	B-X
nitric	B-X
oxide	B-X
production	B-X
in	B-X
ECs	B-X
<EOS>	B-X
First	B-X
,	B-X
targets	B-X
and	B-X
target	B-X
pathways	B-X
are	B-X
predicted	B-X
and	B-X
prioritized	B-X
by	B-X
computational	B-X
means	B-X
to	B-X
increase	B-X
the	B-X
specificity	B-X
and	B-X
positive	B-X
predictive	B-X
value	B-X
<EOS>	B-X
As	B-X
for	B-X
endogenous	B-X
SNCA	B-X
expression	B-X
,	B-X
replicative	B-X
senescence	B-X
resulted	B-X
in	B-X
the	B-X
attenuation	B-X
of	B-X
SNCA	B-X
expression	B-X
in	B-X
cultured	B-X
ECs	B-X
,	B-X
similar	B-X
to	B-X
the	B-X
effects	B-X
of	B-X
physiological	B-X
aging	B-X
on	B-X
mice	B-X
aortas	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
rSNCA	B-X
also	B-X
suppressed	B-X
TNF	B-X
-	B-X
α	B-X
-	B-X
	B-X
and	B-X
palmitic	B-X
acid	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
κB	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
suppression	B-X
of	B-X
VCAM	B-X
-	B-X
1	B-X
upregulation	B-X
and	B-X
restoration	B-X
of	B-X
eNOS	B-X
downregulation	B-X
in	B-X
ECs	B-X

Furthermore	O
,	O
enhanced	O
HIV-1	O
transcription	O
in	O
gp34	B-protein
-stimulated	O
ACH-2/OX40	B-cell_line
cells	I-cell_line
was	O
dependent	O
on	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
and	O
the	O
OX40-gp34	O
interaction	O
activated	O
NF-kappa	B-protein
B	I-protein
consisting	O
of	O
p50	B-protein
and	I-protein
p65	I-protein
subunits	I-protein
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
enhanced	B-X
HIV	B-X
-	B-X
1	B-X
transcription	B-X
in	B-X
gp34	B-X
-	B-X
stimulated	B-X
ACH	B-X
-	B-X
2	B-X
/	B-X
OX40	B-X
cells	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
kappa	B-X
B	B-X
site	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
long	B-X
terminal	B-X
repeat	B-X
,	B-X
and	B-X
the	B-X
OX40	B-X
-	B-X
gp34	B-X
interaction	B-X
activated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
subunits	B-X
<EOS>	B-X
This	B-X
was	B-X
followed	B-X
by	B-X
apparent	B-X
apoptosis	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
specifically	B-X
inhibited	B-X
by	B-X
the	B-X
gp34	B-X
-	B-X
specific	B-X
neutralizing	B-X
monoclonal	B-X
antibody	B-X
5A8	B-X
<EOS>	B-X
OX40	B-X
stimulation	B-X
by	B-X
gp34	B-X
/	B-X
OX40	B-X
ligand	B-X
enhances	B-X
productive	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
infection	B-X
.	B-X
<EOS>	B-X
OX40	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
receptor	B-X
superfamily	B-X
and	B-X
known	B-X
to	B-X
be	B-X
an	B-X
important	B-X
costimulatory	B-X
molecule	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X

When	O
primary	O
activated	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
acutely	O
infected	O
with	O
HIV-1	O
(	O
NL4-3	O
)	O
(	O
CXCR4-using	B-cell_line
T-cell-line-tropic	I-cell_line
)	O
were	O
cocultured	O
with	O
PFA-fixed	O
gp34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
human	I-cell_type
T-cell	I-cell_type
leukemia	O
virus	O
type	O
1-bearing	O
MT-2	B-cell_line
cells	I-cell_line
or	O
SV-T2/gp34	B-cell_line
cells	I-cell_line
,	O
HIV-1	O
production	O
was	O
also	O
markedly	O
enhanced	O
.	O
<EOS>	B-X
When	B-X
primary	B-X
activated	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
acutely	B-X
infected	B-X
with	B-X
HIV	B-X
-	B-X
1	B-X
(	B-X
NL4	B-X
-	B-X
3	B-X
)	B-X
(	B-X
CXCR4	B-X
-	B-X
using	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
line	B-X
-	B-X
tropic	B-X
)	B-X
were	B-X
cocultured	B-X
with	B-X
PFA	B-X
-	B-X
fixed	B-X
gp34	B-X
(	B-X
+	B-X
)	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
-	B-X
bearing	B-X
MT	B-X
-	B-X
2	B-X
cells	B-X
or	B-X
SV	B-X
-	B-X
T2	B-X
/	B-X
gp34	B-X
cells	B-X
,	B-X
HIV	B-X
-	B-X
1	B-X
production	B-X
was	B-X
also	B-X
markedly	B-X
enhanced	B-X
<EOS>	B-X
OX40	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
receptor	B-X
superfamily	B-X
and	B-X
known	B-X
to	B-X
be	B-X
an	B-X
important	B-X
costimulatory	B-X
molecule	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Endogenous	B-X
TNF	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
TNF	B-X
-	B-X
beta	B-X
production	B-X
were	B-X
not	B-X
involved	B-X
in	B-X
the	B-X
enhanced	B-X
HIV	B-X
-	B-X
1	B-X
production	B-X
<EOS>	B-X
This	B-X
was	B-X
followed	B-X
by	B-X
apparent	B-X
apoptosis	B-X
,	B-X
and	B-X
both	B-X
processes	B-X
were	B-X
specifically	B-X
inhibited	B-X
by	B-X
the	B-X
gp34	B-X
-	B-X
specific	B-X
neutralizing	B-X
monoclonal	B-X
antibody	B-X
5A8	B-X

The	O
enhancement	O
was	O
again	O
significantly	O
inhibited	O
by	O
5A8	B-protein
.	O
<EOS>	B-X
The	B-X
enhancement	B-X
was	B-X
again	B-X
significantly	B-X
inhibited	B-X
by	B-X
5A8	B-X
<EOS>	B-X
The	B-X
anti	B-X
-	B-X
V3	B-X
loop	B-X
antibodies	B-X
0	B-X
<EOS>	B-X
The	B-X
anti	B-X
-	B-X
CD4	B-X
MAb	B-X
5A8	B-X
is	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
CD4	B-X
-	B-X
mediated	B-X
infection	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
<EOS>	B-X
The	B-X
antibody	B-X
did	B-X
not	B-X
cross	B-X
react	B-X
with	B-X
other	B-X
tissues	B-X

The	O
present	O
study	O
first	O
shows	O
that	O
OX40-gp34	O
interaction	O
stimulates	O
HIV-1	O
expression	O
and	O
suggests	O
that	O
OX40	O
triggering	O
by	O
gp34	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
enhancing	O
HIV-1	O
production	O
in	O
both	O
acutely	O
and	O
latently	O
infected	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
first	B-X
shows	B-X
that	B-X
OX40	B-X
-	B-X
gp34	B-X
interaction	B-X
stimulates	B-X
HIV	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
suggests	B-X
that	B-X
OX40	B-X
triggering	B-X
by	B-X
gp34	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
enhancing	B-X
HIV	B-X
-	B-X
1	B-X
production	B-X
in	B-X
both	B-X
acutely	B-X
and	B-X
latently	B-X
infected	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
vivo	B-X
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
costimulation	B-X
of	B-X
OX40	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
infection	B-X
by	B-X
its	B-X
natural	B-X
ligand	B-X
,	B-X
gp34	B-X
,	B-X
the	B-X
OX40	B-X
-	B-X
transfected	B-X
ACH	B-X
-	B-X
2	B-X
cell	B-X
line	B-X
,	B-X
ACH	B-X
-	B-X
2	B-X
/	B-X
OX40	B-X
,	B-X
chronically	B-X
infected	B-X
with	B-X
HIV	B-X
-	B-X
1	B-X
,	B-X
was	B-X
cocultured	B-X
with	B-X
paraformaldehyde	B-X
(	B-X
PFA	B-X
)	B-X
	B-X
-	B-X
fixed	B-X
gp34	B-X
-	B-X
transfected	B-X
mouse	B-X
cell	B-X
line	B-X
,	B-X
SV	B-X
-	B-X
T2	B-X
/	B-X
gp34	B-X
<EOS>	B-X
OX40	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
receptor	B-X
superfamily	B-X
and	B-X
known	B-X
to	B-X
be	B-X
an	B-X
important	B-X
costimulatory	B-X
molecule	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
OX40	B-X
stimulation	B-X
by	B-X
gp34	B-X
/	B-X
OX40	B-X
ligand	B-X
enhances	B-X
productive	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
infection	B-X
.	B-X

Troglitazone	O
,	O
a	O
PPARgamma	O
ligand	O
,	O
inhibits	O
osteopontin	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes/macrophage	I-cell_type
THP-1	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Troglitazone	B-X
,	B-X
a	B-X
PPARgamma	B-X
ligand	B-X
,	B-X
inhibits	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytes	B-X
/	B-X
macrophage	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
.	B-X
<EOS>	B-X
Troglitazone	B-X
,	B-X
a	B-X
PPARgamma	B-X
ligand	B-X
,	B-X
dramatically	B-X
attenuated	B-X
the	B-X
PMA	B-X
-	B-X
induced	B-X
osteopontin	B-X
expression	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
PPARgamma	B-X
ligand	B-X
regulates	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
a	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cells	B-X
which	B-X
can	B-X
differentiate	B-X
to	B-X
macrophage	B-X
upon	B-X
stimulation	B-X
with	B-X
phorbol	B-X
ester	B-X
PMA	B-X
<EOS>	B-X
Northern	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
osteopontin	B-X
expression	B-X
is	B-X
markedly	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
PMA	B-X

Peroxizome	B-protein
proliferator-activated	I-protein
receptor-gamma	I-protein
(	O
PPARgamma	B-protein
)	O
is	O
a	O
member	O
of	O
the	O
nuclear	B-protein
receptor	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
adipocyte	O
differentiation	O
.	O
<EOS>	B-X
Peroxizome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
-	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
nuclear	B-X
receptor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
regulate	B-X
adipocyte	B-X
differentiation	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
indicate	B-X
that	B-X
liganded	B-X
PPARgamma	B-X
not	B-X
only	B-X
promotes	B-X
differentiation	B-X
but	B-X
also	B-X
inhibits	B-X
the	B-X
activation	B-X
of	B-X
macrophages	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
troglitazone	B-X
reduces	B-X
osteopontin	B-X
gene	B-X
expression	B-X
at	B-X
transcriptional	B-X
level	B-X
through	B-X
PPARgamma	B-X
activation	B-X
,	B-X
and	B-X
suggest	B-X
the	B-X
role	B-X
of	B-X
troglitazone	B-X
in	B-X
inhibiting	B-X
the	B-X
ability	B-X
of	B-X
macrophages	B-X
to	B-X
produce	B-X
extracellular	B-X
matrix	B-X
,	B-X
which	B-X
is	B-X
particularly	B-X
relevant	B-X
to	B-X
atherosclerotic	B-X
plaque	B-X
formation	B-X
<EOS>	B-X
Troglitazone	B-X
,	B-X
a	B-X
PPARgamma	B-X
ligand	B-X
,	B-X
dramatically	B-X
attenuated	B-X
the	B-X
PMA	B-X
-	B-X
induced	B-X
osteopontin	B-X
expression	B-X

Recent	O
studies	O
indicate	O
that	O
liganded	B-protein
PPARgamma	I-protein
not	O
only	O
promotes	O
differentiation	O
but	O
also	O
inhibits	O
the	O
activation	O
of	O
macrophages	B-cell_type
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
indicate	B-X
that	B-X
tissue	B-X
cells	B-X
and	B-X
macrophages	B-X
interact	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
demonstrated	B-X
a	B-X
considerable	B-X
link	B-X
between	B-X
risk	B-X
of	B-X
PC	B-X
and	B-X
diabetes	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
AhR	B-X
also	B-X
plays	B-X
essential	B-X
roles	B-X
in	B-X
energy	B-X
metabolism	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
reveal	B-X
that	B-X
CSIs	B-X
may	B-X
affect	B-X
non	B-X
-	B-X
target	B-X
organisms	B-X
at	B-X
sublethal	B-X
concentrations	B-X
,	B-X
highlighting	B-X
the	B-X
need	B-X
for	B-X
further	B-X
ecological	B-X
and	B-X
health	B-X
risk	B-X
investigations	B-X
of	B-X
these	B-X
compounds	B-X

Osteopontin	B-protein
,	O
a	O
component	O
of	O
extracellular	O
matrix	O
,	O
is	O
synthesized	O
by	O
macrophages	B-cell_type
in	O
atherosclerotic	O
plaques	O
.	O
<EOS>	B-X
Osteopontin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
extracellular	B-X
matrix	B-X
,	B-X
is	B-X
synthesized	B-X
by	B-X
macrophages	B-X
in	B-X
atherosclerotic	B-X
plaques	B-X
<EOS>	B-X
Osteopontin	B-X
(	B-X
OPN	B-X
)	B-X
,	B-X
a	B-X
component	B-X
of	B-X
extracellular	B-X
matrix	B-X
,	B-X
is	B-X
elevated	B-X
during	B-X
neointimal	B-X
formation	B-X
in	B-X
the	B-X
vessel	B-X
wall	B-X
and	B-X
is	B-X
synthesized	B-X
by	B-X
macrophages	B-X
in	B-X
atherosclerotic	B-X
plaques	B-X
<EOS>	B-X
Osteopontin	B-X
is	B-X
synthesized	B-X
by	B-X
macrophage	B-X
,	B-X
smooth	B-X
muscle	B-X
,	B-X
and	B-X
endothelial	B-X
cells	B-X
in	B-X
primary	B-X
and	B-X
restenotic	B-X
human	B-X
coronary	B-X
atherosclerotic	B-X
plaques	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
,	B-X
combined	B-X
with	B-X
studies	B-X
showing	B-X
that	B-X
OPN	B-X
has	B-X
adhesive	B-X
,	B-X
chemotactic	B-X
,	B-X
and	B-X
calcium	B-X
-	B-X
binding	B-X
properties	B-X
,	B-X
suggest	B-X
that	B-X
OPN	B-X
may	B-X
contribute	B-X
to	B-X
cellular	B-X
accumulations	B-X
and	B-X
dystrophic	B-X
calcification	B-X
in	B-X
atherosclerotic	B-X
plaques	B-X

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
PPARgamma	B-protein
ligand	O
regulates	O
osteopontin	O
gene	O
expression	O
in	O
THP-1	B-cell_line
cells	I-cell_line
,	O
a	O
cell	O
line	O
derived	O
from	O
human	B-cell_type
monocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
which	O
can	O
differentiate	O
to	O
macrophage	B-cell_type
upon	O
stimulation	O
with	O
phorbol	O
ester	O
PMA	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
PPARgamma	B-X
ligand	B-X
regulates	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
a	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cells	B-X
which	B-X
can	B-X
differentiate	B-X
to	B-X
macrophage	B-X
upon	B-X
stimulation	B-X
with	B-X
phorbol	B-X
ester	B-X
PMA	B-X
<EOS>	B-X
Troglitazone	B-X
,	B-X
a	B-X
PPARgamma	B-X
ligand	B-X
,	B-X
inhibits	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytes	B-X
/	B-X
macrophage	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
troglitazone	B-X
reduces	B-X
osteopontin	B-X
gene	B-X
expression	B-X
at	B-X
transcriptional	B-X
level	B-X
through	B-X
PPARgamma	B-X
activation	B-X
,	B-X
and	B-X
suggest	B-X
the	B-X
role	B-X
of	B-X
troglitazone	B-X
in	B-X
inhibiting	B-X
the	B-X
ability	B-X
of	B-X
macrophages	B-X
to	B-X
produce	B-X
extracellular	B-X
matrix	B-X
,	B-X
which	B-X
is	B-X
particularly	B-X
relevant	B-X
to	B-X
atherosclerotic	B-X
plaque	B-X
formation	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
indicate	B-X
that	B-X
liganded	B-X
PPARgamma	B-X
not	B-X
only	B-X
promotes	B-X
differentiation	B-X
but	B-X
also	B-X
inhibits	B-X
the	B-X
activation	B-X
of	B-X
macrophages	B-X

Northern	O
blot	O
analysis	O
showed	O
that	O
osteopontin	O
expression	O
is	O
markedly	O
induced	O
in	O
response	O
to	O
PMA	O
.	O
<EOS>	B-X
Northern	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
osteopontin	B-X
expression	B-X
is	B-X
markedly	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
PMA	B-X
<EOS>	B-X
Troglitazone	B-X
,	B-X
a	B-X
PPARgamma	B-X
ligand	B-X
,	B-X
inhibits	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytes	B-X
/	B-X
macrophage	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
PPARgamma	B-X
ligand	B-X
regulates	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
a	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cells	B-X
which	B-X
can	B-X
differentiate	B-X
to	B-X
macrophage	B-X
upon	B-X
stimulation	B-X
with	B-X
phorbol	B-X
ester	B-X
PMA	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
indicate	B-X
that	B-X
liganded	B-X
PPARgamma	B-X
not	B-X
only	B-X
promotes	B-X
differentiation	B-X
but	B-X
also	B-X
inhibits	B-X
the	B-X
activation	B-X
of	B-X
macrophages	B-X

Troglitazone	O
,	O
a	O
PPARgamma	B-protein
ligand	O
,	O
dramatically	O
attenuated	O
the	O
PMA-induced	O
osteopontin	O
expression	O
.	O
<EOS>	B-X
Troglitazone	B-X
,	B-X
a	B-X
PPARgamma	B-X
ligand	B-X
,	B-X
dramatically	B-X
attenuated	B-X
the	B-X
PMA	B-X
-	B-X
induced	B-X
osteopontin	B-X
expression	B-X
<EOS>	B-X
Troglitazone	B-X
,	B-X
a	B-X
PPARgamma	B-X
ligand	B-X
,	B-X
inhibits	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytes	B-X
/	B-X
macrophage	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
.	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
indicate	B-X
that	B-X
liganded	B-X
PPARgamma	B-X
not	B-X
only	B-X
promotes	B-X
differentiation	B-X
but	B-X
also	B-X
inhibits	B-X
the	B-X
activation	B-X
of	B-X
macrophages	B-X
<EOS>	B-X
Peroxizome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
-	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
nuclear	B-X
receptor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
regulate	B-X
adipocyte	B-X
differentiation	B-X

Transient	O
transfection	O
assays	O
of	O
the	O
human	B-DNA
osteopontin	I-DNA
promoter/luciferase	I-DNA
construct	I-DNA
which	O
contains	O
a	O
5'-flanking	B-DNA
region	I-DNA
between	O
-1500	O
and	O
+87	O
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
demonstrate	O
that	O
either	O
treatment	O
with	O
troglitazone	O
or	O
cotransfection	O
of	O
PPARgamma	B-DNA
expression	I-DNA
vector	I-DNA
inhibits	O
osteopontin	O
promoter	O
activity	O
.	O
<EOS>	B-X
Transient	B-X
transfection	B-X
assays	B-X
of	B-X
the	B-X
human	B-X
osteopontin	B-X
promoter	B-X
/	B-X
luciferase	B-X
construct	B-X
which	B-X
contains	B-X
a	B-X
5'	B-X
-	B-X
flanking	B-X
region	B-X
between	B-X
	B-X
-	B-X
1500	B-X
and	B-X
+87	B-X
relative	B-X
to	B-X
the	B-X
transcription	B-X
start	B-X
site	B-X
demonstrate	B-X
that	B-X
either	B-X
treatment	B-X
with	B-X
troglitazone	B-X
or	B-X
cotransfection	B-X
of	B-X
PPARgamma	B-X
expression	B-X
vector	B-X
inhibits	B-X
osteopontin	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Peroxizome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
-	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
nuclear	B-X
receptor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
regulate	B-X
adipocyte	B-X
differentiation	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
PPARgamma	B-X
ligand	B-X
regulates	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
a	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cells	B-X
which	B-X
can	B-X
differentiate	B-X
to	B-X
macrophage	B-X
upon	B-X
stimulation	B-X
with	B-X
phorbol	B-X
ester	B-X
PMA	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
troglitazone	B-X
reduces	B-X
osteopontin	B-X
gene	B-X
expression	B-X
at	B-X
transcriptional	B-X
level	B-X
through	B-X
PPARgamma	B-X
activation	B-X
,	B-X
and	B-X
suggest	B-X
the	B-X
role	B-X
of	B-X
troglitazone	B-X
in	B-X
inhibiting	B-X
the	B-X
ability	B-X
of	B-X
macrophages	B-X
to	B-X
produce	B-X
extracellular	B-X
matrix	B-X
,	B-X
which	B-X
is	B-X
particularly	B-X
relevant	B-X
to	B-X
atherosclerotic	B-X
plaque	B-X
formation	B-X

These	O
data	O
indicate	O
that	O
troglitazone	O
reduces	O
osteopontin	O
gene	O
expression	O
at	O
transcriptional	O
level	O
through	O
PPARgamma	B-protein
activation	O
,	O
and	O
suggest	O
the	O
role	O
of	O
troglitazone	O
in	O
inhibiting	O
the	O
ability	O
of	O
macrophages	B-cell_type
to	O
produce	O
extracellular	O
matrix	O
,	O
which	O
is	O
particularly	O
relevant	O
to	O
atherosclerotic	O
plaque	O
formation	O
.	O
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
troglitazone	B-X
reduces	B-X
osteopontin	B-X
gene	B-X
expression	B-X
at	B-X
transcriptional	B-X
level	B-X
through	B-X
PPARgamma	B-X
activation	B-X
,	B-X
and	B-X
suggest	B-X
the	B-X
role	B-X
of	B-X
troglitazone	B-X
in	B-X
inhibiting	B-X
the	B-X
ability	B-X
of	B-X
macrophages	B-X
to	B-X
produce	B-X
extracellular	B-X
matrix	B-X
,	B-X
which	B-X
is	B-X
particularly	B-X
relevant	B-X
to	B-X
atherosclerotic	B-X
plaque	B-X
formation	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
PPARgamma	B-X
ligand	B-X
regulates	B-X
osteopontin	B-X
gene	B-X
expression	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
,	B-X
a	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cells	B-X
which	B-X
can	B-X
differentiate	B-X
to	B-X
macrophage	B-X
upon	B-X
stimulation	B-X
with	B-X
phorbol	B-X
ester	B-X
PMA	B-X
<EOS>	B-X
Peroxizome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
-	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
nuclear	B-X
receptor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
regulate	B-X
adipocyte	B-X
differentiation	B-X
<EOS>	B-X
Osteopontin	B-X
,	B-X
a	B-X
component	B-X
of	B-X
extracellular	B-X
matrix	B-X
,	B-X
is	B-X
synthesized	B-X
by	B-X
macrophages	B-X
in	B-X
atherosclerotic	B-X
plaques	B-X

Transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
regulates	O
Ig	B-protein
lambda	I-protein
light	O
chain	O
gene	O
rearrangement	O
.	O
<EOS>	B-X
Transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
regulates	B-X
Ig	B-X
lambda	B-X
light	B-X
chain	B-X
gene	B-X
rearrangement	B-X
.	B-X
<EOS>	B-X
Molecular	B-X
analyses	B-X
indicate	B-X
that	B-X
the	B-X
block	B-X
in	B-X
NF	B-X
-	B-X
kappaB	B-X
impairs	B-X
Iglambda	B-X
rearrangement	B-X
at	B-X
the	B-X
level	B-X
of	B-X
recombinase	B-X
accessibility	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
assembled	B-X
Iglambda	B-X
genes	B-X
in	B-X
mature	B-X
B	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
NF	B-X
-	B-X
kappaB	B-X
independent	B-X
<EOS>	B-X
As	B-X
demonstrated	B-X
in	B-X
our	B-X
prior	B-X
studies	B-X
,	B-X
rearrangement	B-X
of	B-X
the	B-X
Igkappa	B-X
locus	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
inducible	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X

The	O
tissue-	O
and	O
stage-specific	O
assembly	O
of	O
Ig	B-DNA
and	I-DNA
TCR	I-DNA
genes	I-DNA
is	O
mediated	O
by	O
a	O
common	O
V	B-protein
(	I-protein
D	I-protein
)	I-protein
J	I-protein
recombinase	I-protein
complex	I-protein
in	O
precursor	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
The	B-X
tissue	B-X
-	B-X
	B-X
and	B-X
stage	B-X
-	B-X
specific	B-X
assembly	B-X
of	B-X
Ig	B-X
and	B-X
TCR	B-X
genes	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
common	B-X
V	B-X
(	B-X
D	B-X
)	B-X
J	B-X
recombinase	B-X
complex	B-X
in	B-X
precursor	B-X
lymphocytes	B-X
<EOS>	B-X
Directed	B-X
alterations	B-X
in	B-X
the	B-X
accessibility	B-X
of	B-X
V	B-X
,	B-X
D	B-X
,	B-X
and	B-X
J	B-X
gene	B-X
segments	B-X
target	B-X
the	B-X
recombinase	B-X
to	B-X
specific	B-X
Ag	B-X
receptor	B-X
loci	B-X
<EOS>	B-X
Nonetheless	B-X
,	B-X
we	B-X
now	B-X
show	B-X
that	B-X
specific	B-X
repression	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibits	B-X
germline	B-X
transcription	B-X
and	B-X
recombination	B-X
of	B-X
Iglambda	B-X
gene	B-X
segments	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
<EOS>	B-X
These	B-X
findings	B-X
expand	B-X
the	B-X
range	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
action	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
beyond	B-X
Igkappa	B-X
to	B-X
include	B-X
the	B-X
control	B-X
of	B-X
recombinational	B-X
accessibility	B-X
at	B-X
both	B-X
L	B-X
chain	B-X
loci	B-X

Directed	O
alterations	O
in	O
the	O
accessibility	O
of	O
V	B-DNA
,	I-DNA
D	I-DNA
,	I-DNA
and	I-DNA
J	I-DNA
gene	I-DNA
segments	I-DNA
target	O
the	O
recombinase	B-protein
to	O
specific	O
Ag	B-DNA
receptor	I-DNA
loci	I-DNA
.	O

Accessibility	O
within	O
a	O
given	O
locus	B-DNA
is	O
regulated	O
by	O
the	O
functional	O
interaction	O
of	O
transcription	B-protein
factors	I-protein
with	O
cognate	B-DNA
enhancer	I-DNA
elements	I-DNA
and	O
correlates	O
with	O
the	O
transcriptional	O
activity	O
of	O
unrearranged	O
gene	B-DNA
segments	I-DNA
.	O
<EOS>	B-X
Accessibility	B-X
within	B-X
a	B-X
given	B-X
locus	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
functional	B-X
interaction	B-X
of	B-X
transcription	B-X
factors	B-X
with	B-X
cognate	B-X
enhancer	B-X
elements	B-X
and	B-X
correlates	B-X
with	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
unrearranged	B-X
gene	B-X
segments	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
Igkappa	B-X
locus	B-X
,	B-X
known	B-X
transcriptional	B-X
control	B-X
elements	B-X
in	B-X
the	B-X
Iglambda	B-X
locus	B-X
lack	B-X
functional	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
sites	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
activities	B-X
of	B-X
known	B-X
Iglambda	B-X
promoter	B-X
and	B-X
enhancer	B-X
elements	B-X
are	B-X
unaffected	B-X
in	B-X
the	B-X
same	B-X
cellular	B-X
background	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
assembled	B-X
Iglambda	B-X
genes	B-X
in	B-X
mature	B-X
B	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
NF	B-X
-	B-X
kappaB	B-X
independent	B-X

As	O
demonstrated	O
in	O
our	O
prior	O
studies	O
,	O
rearrangement	O
of	O
the	O
Igkappa	B-DNA
locus	I-DNA
is	O
regulated	O
by	O
the	O
inducible	B-protein
transcription	I-protein
factor	I-protein
NF-kappaB	B-protein
.	O
<EOS>	B-X
As	B-X
demonstrated	B-X
in	B-X
our	B-X
prior	B-X
studies	B-X
,	B-X
rearrangement	B-X
of	B-X
the	B-X
Igkappa	B-X
locus	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
inducible	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
<EOS>	B-X
Accessibility	B-X
within	B-X
a	B-X
given	B-X
locus	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
functional	B-X
interaction	B-X
of	B-X
transcription	B-X
factors	B-X
with	B-X
cognate	B-X
enhancer	B-X
elements	B-X
and	B-X
correlates	B-X
with	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
unrearranged	B-X
gene	B-X
segments	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
our	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
novel	B-X
Iglambda	B-X
regulatory	B-X
element	B-X
that	B-X
is	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
activated	B-X
by	B-X
NF	B-X
-	B-X
kappaB	B-X
during	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
B	B-X
cell	B-X
development	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
regulates	B-X
Ig	B-X
lambda	B-X
light	B-X
chain	B-X
gene	B-X
rearrangement	B-X
.	B-X

In	O
contrast	O
to	O
the	O
Igkappa	B-DNA
locus	I-DNA
,	O
known	O
transcriptional	B-DNA
control	I-DNA
elements	I-DNA
in	O
the	O
Iglambda	B-DNA
locus	I-DNA
lack	O
functional	O
NF-kappaB	B-DNA
binding	I-DNA
sites	I-DNA
.	O

Consistent	O
with	O
this	O
observation	O
,	O
the	O
expression	O
of	O
assembled	O
Iglambda	B-DNA
genes	I-DNA
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
has	O
been	O
shown	O
to	O
be	O
NF-kappaB	B-protein
independent	O
.	O
<EOS>	B-X
Consistent	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
assembled	B-X
Iglambda	B-X
genes	B-X
in	B-X
mature	B-X
B	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
NF	B-X
-	B-X
kappaB	B-X
independent	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
Igkappa	B-X
locus	B-X
,	B-X
known	B-X
transcriptional	B-X
control	B-X
elements	B-X
in	B-X
the	B-X
Iglambda	B-X
locus	B-X
lack	B-X
functional	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
our	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
novel	B-X
Iglambda	B-X
regulatory	B-X
element	B-X
that	B-X
is	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
activated	B-X
by	B-X
NF	B-X
-	B-X
kappaB	B-X
during	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
B	B-X
cell	B-X
development	B-X
<EOS>	B-X
Accessibility	B-X
within	B-X
a	B-X
given	B-X
locus	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
functional	B-X
interaction	B-X
of	B-X
transcription	B-X
factors	B-X
with	B-X
cognate	B-X
enhancer	B-X
elements	B-X
and	B-X
correlates	B-X
with	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
unrearranged	B-X
gene	B-X
segments	B-X

Nonetheless	O
,	O
we	O
now	O
show	O
that	O
specific	O
repression	O
of	O
NF-kappaB	B-protein
inhibits	O
germline	O
transcription	O
and	O
recombination	O
of	O
Iglambda	B-DNA
gene	I-DNA
segments	I-DNA
in	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Nonetheless	B-X
,	B-X
we	B-X
now	B-X
show	B-X
that	B-X
specific	B-X
repression	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibits	B-X
germline	B-X
transcription	B-X
and	B-X
recombination	B-X
of	B-X
Iglambda	B-X
gene	B-X
segments	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
<EOS>	B-X
The	B-X
tissue	B-X
-	B-X
	B-X
and	B-X
stage	B-X
-	B-X
specific	B-X
assembly	B-X
of	B-X
Ig	B-X
and	B-X
TCR	B-X
genes	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
common	B-X
V	B-X
(	B-X
D	B-X
)	B-X
J	B-X
recombinase	B-X
complex	B-X
in	B-X
precursor	B-X
lymphocytes	B-X
<EOS>	B-X
Molecular	B-X
analyses	B-X
indicate	B-X
that	B-X
the	B-X
block	B-X
in	B-X
NF	B-X
-	B-X
kappaB	B-X
impairs	B-X
Iglambda	B-X
rearrangement	B-X
at	B-X
the	B-X
level	B-X
of	B-X
recombinase	B-X
accessibility	B-X
<EOS>	B-X
Directed	B-X
alterations	B-X
in	B-X
the	B-X
accessibility	B-X
of	B-X
V	B-X
,	B-X
D	B-X
,	B-X
and	B-X
J	B-X
gene	B-X
segments	B-X
target	B-X
the	B-X
recombinase	B-X
to	B-X
specific	B-X
Ag	B-X
receptor	B-X
loci	B-X

Molecular	O
analyses	O
indicate	O
that	O
the	O
block	O
in	O
NF-kappaB	B-protein
impairs	O
Iglambda	O
rearrangement	O
at	O
the	O
level	O
of	O
recombinase	B-protein
accessibility	O
.	O
<EOS>	B-X
Molecular	B-X
analyses	B-X
indicate	B-X
that	B-X
the	B-X
block	B-X
in	B-X
NF	B-X
-	B-X
kappaB	B-X
impairs	B-X
Iglambda	B-X
rearrangement	B-X
at	B-X
the	B-X
level	B-X
of	B-X
recombinase	B-X
accessibility	B-X
<EOS>	B-X
These	B-X
findings	B-X
expand	B-X
the	B-X
range	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
action	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
beyond	B-X
Igkappa	B-X
to	B-X
include	B-X
the	B-X
control	B-X
of	B-X
recombinational	B-X
accessibility	B-X
at	B-X
both	B-X
L	B-X
chain	B-X
loci	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
regulates	B-X
Ig	B-X
lambda	B-X
light	B-X
chain	B-X
gene	B-X
rearrangement	B-X
.	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
our	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
novel	B-X
Iglambda	B-X
regulatory	B-X
element	B-X
that	B-X
is	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
activated	B-X
by	B-X
NF	B-X
-	B-X
kappaB	B-X
during	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
B	B-X
cell	B-X
development	B-X

In	O
contrast	O
,	O
the	O
activities	O
of	O
known	O
Iglambda	B-DNA
promoter	I-DNA
and	O
enhancer	B-DNA
elements	I-DNA
are	O
unaffected	O
in	O
the	O
same	O
cellular	O
background	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
activities	B-X
of	B-X
known	B-X
Iglambda	B-X
promoter	B-X
and	B-X
enhancer	B-X
elements	B-X
are	B-X
unaffected	B-X
in	B-X
the	B-X
same	B-X
cellular	B-X
background	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
Igkappa	B-X
locus	B-X
,	B-X
known	B-X
transcriptional	B-X
control	B-X
elements	B-X
in	B-X
the	B-X
Iglambda	B-X
locus	B-X
lack	B-X
functional	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Accessibility	B-X
within	B-X
a	B-X
given	B-X
locus	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
functional	B-X
interaction	B-X
of	B-X
transcription	B-X
factors	B-X
with	B-X
cognate	B-X
enhancer	B-X
elements	B-X
and	B-X
correlates	B-X
with	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
unrearranged	B-X
gene	B-X
segments	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
our	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
novel	B-X
Iglambda	B-X
regulatory	B-X
element	B-X
that	B-X
is	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
activated	B-X
by	B-X
NF	B-X
-	B-X
kappaB	B-X
during	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
B	B-X
cell	B-X
development	B-X

These	O
findings	O
expand	O
the	O
range	O
of	O
NF-kappaB	B-protein
action	O
in	O
precursor	B-cell_type
B	I-cell_type
cells	I-cell_type
beyond	O
Igkappa	B-protein
to	O
include	O
the	O
control	O
of	O
recombinational	O
accessibility	O
at	O
both	O
L	B-DNA
chain	I-DNA
loci	I-DNA
.	O

Moreover	O
,	O
our	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
Iglambda	B-DNA
regulatory	I-DNA
element	I-DNA
that	O
is	O
either	O
directly	O
or	O
indirectly	O
activated	O
by	O
NF-kappaB	B-protein
during	O
the	O
early	O
stages	O
of	O
B	O
cell	O
development	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
our	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
novel	B-X
Iglambda	B-X
regulatory	B-X
element	B-X
that	B-X
is	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
activated	B-X
by	B-X
NF	B-X
-	B-X
kappaB	B-X
during	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
B	B-X
cell	B-X
development	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
activities	B-X
of	B-X
known	B-X
Iglambda	B-X
promoter	B-X
and	B-X
enhancer	B-X
elements	B-X
are	B-X
unaffected	B-X
in	B-X
the	B-X
same	B-X
cellular	B-X
background	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
assembled	B-X
Iglambda	B-X
genes	B-X
in	B-X
mature	B-X
B	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
NF	B-X
-	B-X
kappaB	B-X
independent	B-X
<EOS>	B-X
Molecular	B-X
analyses	B-X
indicate	B-X
that	B-X
the	B-X
block	B-X
in	B-X
NF	B-X
-	B-X
kappaB	B-X
impairs	B-X
Iglambda	B-X
rearrangement	B-X
at	B-X
the	B-X
level	B-X
of	B-X
recombinase	B-X
accessibility	B-X

Transcription	B-protein
factor	I-protein
STAT5A	B-protein
is	O
a	O
substrate	O
of	O
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

STAT5A	B-protein
is	O
a	O
molecular	O
regulator	O
of	O
proliferation	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
in	O
lymphohematopoietic	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
STAT5A	B-X
is	B-X
a	B-X
molecular	B-X
regulator	B-X
of	B-X
proliferation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
apoptosis	B-X
in	B-X
lymphohematopoietic	B-X
cells	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
anti	B-X
-	B-X
IgM	B-X
stimulation	B-X
resulted	B-X
in	B-X
enhanced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
STAT5A	B-X
in	B-X
BTK	B-X
-	B-X
competent	B-X
B	B-X
cells	B-X
from	B-X
wild	B-X
type	B-X
mice	B-X
but	B-X
not	B-X
in	B-X
BTK	B-X
-	B-X
deficient	B-X
B	B-X
cells	B-X
from	B-X
XID	B-X
mice	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
STAT5A	B-X
is	B-X
a	B-X
substrate	B-X
of	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
provide	B-X
unprecedented	B-X
experimental	B-X
evidence	B-X
that	B-X
BTK	B-X
plays	B-X
a	B-X
nonredundant	B-X
and	B-X
pivotal	B-X
role	B-X
in	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
-	B-X
mediated	B-X
STAT5A	B-X
activation	B-X
in	B-X
B	B-X
cells	B-X

Here	O
we	O
show	O
that	O
STAT5A	B-protein
can	O
serve	O
as	O
a	O
functional	O
substrate	O
of	O
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
BTK	B-protein
)	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
STAT5A	B-X
can	B-X
serve	B-X
as	B-X
a	B-X
functional	B-X
substrate	B-X
of	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
(	B-X
BTK	B-X
)	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
STAT5A	B-X
is	B-X
a	B-X
substrate	B-X
of	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
STAT5A	B-X
mutations	B-X
in	B-X
the	B-X
Src	B-X
homology	B-X
2	B-X
(	B-X
SH2	B-X
)	B-X
and	B-X
SH3	B-X
domains	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
BTK	B-X
-	B-X
mediated	B-X
tyrosine	B-X
phosphorylation	B-X
<EOS>	B-X
These	B-X
findings	B-X
provide	B-X
unprecedented	B-X
experimental	B-X
evidence	B-X
that	B-X
BTK	B-X
plays	B-X
a	B-X
nonredundant	B-X
and	B-X
pivotal	B-X
role	B-X
in	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
-	B-X
mediated	B-X
STAT5A	B-X
activation	B-X
in	B-X
B	B-X
cells	B-X

Purified	B-protein
recombinant	I-protein
BTK	I-protein
was	O
capable	O
of	O
directly	O
binding	O
purified	B-protein
recombinant	I-protein
STAT5A	I-protein
with	O
high	O
affinity	O
(	O
K	O
(	O
d	O
)	O
=	O
44	O
nm	O
)	O
,	O
as	O
determined	O
by	O
surface	O
plasmon	O
resonance	O
using	O
a	O
BIAcore	O
biosensor	O
system	O
.	O
<EOS>	B-X
Purified	B-X
recombinant	B-X
BTK	B-X
was	B-X
capable	B-X
of	B-X
directly	B-X
binding	B-X
purified	B-X
recombinant	B-X
STAT5A	B-X
with	B-X
high	B-X
affinity	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
=	B-X
44	B-X
nm	B-X
)	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
surface	B-X
plasmon	B-X
resonance	B-X
using	B-X
a	B-X
BIAcore	B-X
biosensor	B-X
system	B-X
<EOS>	B-X
BTK	B-X
was	B-X
also	B-X
capable	B-X
of	B-X
tyrosine	B-X
-	B-X
phosphorylating	B-X
ectopically	B-X
expressed	B-X
recombinant	B-X
STAT5A	B-X
on	B-X
Tyr	B-X
(	B-X
694	B-X
)	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
in	B-X
a	B-X
Janus	B-X
kinase	B-X
3	B-X
-	B-X
independent	B-X
fashion	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
anti	B-X
-	B-X
IgM	B-X
stimulation	B-X
resulted	B-X
in	B-X
enhanced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
STAT5A	B-X
in	B-X
BTK	B-X
-	B-X
competent	B-X
B	B-X
cells	B-X
from	B-X
wild	B-X
type	B-X
mice	B-X
but	B-X
not	B-X
in	B-X
BTK	B-X
-	B-X
deficient	B-X
B	B-X
cells	B-X
from	B-X
XID	B-X
mice	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
B	B-X
cells	B-X
from	B-X
XID	B-X
mice	B-X
,	B-X
B	B-X
cells	B-X
from	B-X
JAK3	B-X
knockout	B-X
mice	B-X
showed	B-X
a	B-X
normal	B-X
STAT5A	B-X
phosphorylation	B-X
response	B-X
to	B-X
anti	B-X
-	B-X
IgM	B-X
stimulation	B-X

BTK	B-protein
was	O
also	O
capable	O
of	O
tyrosine-phosphorylating	O
ectopically	O
expressed	O
recombinant	B-protein
STAT5A	I-protein
on	O
Tyr	O
(	O
694	O
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
a	O
Janus	B-protein
kinase	I-protein
3	I-protein
-independent	O
fashion	O
.	O

BTK	B-protein
phosphorylated	O
the	O
Y665F	B-protein
,	I-protein
Y668F	I-protein
,	I-protein
and	I-protein
Y682F	I-protein
,	I-protein
Y683F	I-protein
mutants	I-protein
but	O
not	O
the	O
Y694F	B-protein
mutant	I-protein
of	O
STAT5A	B-protein
.	O

STAT5A	O
mutations	O
in	O
the	O
Src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
and	I-protein
SH3	I-protein
domains	I-protein
did	O
not	O
alter	O
the	O
BTK	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
.	O
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
STAP	B-X
-	B-X
2	B-X
/	B-X
BKS	B-X
is	B-X
an	B-X
additional	B-X
modulator	B-X
of	B-X
STAT5	B-X
-	B-X
mediated	B-X
signaling	B-X
<EOS>	B-X
STAP	B-X
-	B-X
1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
STAT5	B-X
and	B-X
the	B-X
tyrosine	B-X
kinase	B-X
Tec	B-X
<EOS>	B-X
The	B-X
physiological	B-X
role	B-X
of	B-X
these	B-X
interactions	B-X
is	B-X
not	B-X
fully	B-X
understood	B-X
,	B-X
but	B-X
in	B-X
studies	B-X
of	B-X
overexpression	B-X
of	B-X
STAP	B-X
-	B-X
2	B-X
/	B-X
BKS	B-X
,	B-X
cytokine	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
and	B-X
transcriptional	B-X
activation	B-X
of	B-X
STAT5	B-X
was	B-X
diminished	B-X
<EOS>	B-X
STAP	B-X
-	B-X
2	B-X
/	B-X
BKS	B-X
and	B-X
STAT5	B-X
were	B-X
found	B-X
to	B-X
constitutively	B-X
co	B-X
-	B-X
localize	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
resting	B-X
cells	B-X
,	B-X
but	B-X
STAP	B-X
-	B-X
2	B-X
/	B-X
BKS	B-X
was	B-X
found	B-X
to	B-X
dissociate	B-X
upon	B-X
STAT5	B-X
phosphorylation	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
signaling	B-X
of	B-X
STAT5	B-X

Recombinant	B-protein
BTK	I-protein
proteins	I-protein
with	O
mutant	O
pleckstrin	O
homology	O
,	O
SH2	B-protein
,	I-protein
or	I-protein
SH3	I-protein
domains	I-protein
were	O
capable	O
of	O
phosphorylating	O
STAT5A	B-protein
,	O
whereas	O
recombinant	B-protein
BTK	I-protein
proteins	I-protein
with	O
SH1/kinase	O
domain	O
mutations	O
were	O
not	O
.	O
<EOS>	B-X
Recombinant	B-X
BTK	B-X
proteins	B-X
with	B-X
mutant	B-X
pleckstrin	B-X
homology	B-X
,	B-X
SH2	B-X
,	B-X
or	B-X
SH3	B-X
domains	B-X
were	B-X
capable	B-X
of	B-X
phosphorylating	B-X
STAT5A	B-X
,	B-X
whereas	B-X
recombinant	B-X
BTK	B-X
proteins	B-X
with	B-X
SH1	B-X
/	B-X
kinase	B-X
domain	B-X
mutations	B-X
were	B-X
not	B-X
<EOS>	B-X
Ectopically	B-X
expressed	B-X
BTK	B-X
kinase	B-X
domain	B-X
was	B-X
capable	B-X
of	B-X
tyrosine	B-X
-	B-X
phosphorylating	B-X
STAT5A	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
STAT5A	B-X
mutations	B-X
in	B-X
the	B-X
Src	B-X
homology	B-X
2	B-X
(	B-X
SH2	B-X
)	B-X
and	B-X
SH3	B-X
domains	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
BTK	B-X
-	B-X
mediated	B-X
tyrosine	B-X
phosphorylation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
B	B-X
cells	B-X
from	B-X
XID	B-X
mice	B-X
,	B-X
B	B-X
cells	B-X
from	B-X
JAK3	B-X
knockout	B-X
mice	B-X
showed	B-X
a	B-X
normal	B-X
STAT5A	B-X
phosphorylation	B-X
response	B-X
to	B-X
anti	B-X
-	B-X
IgM	B-X
stimulation	B-X

In	O
pull-down	O
experiments	O
,	O
only	O
full-length	B-protein
BTK	I-protein
and	O
its	O
SH1/kinase	B-protein
domain	I-protein
(	O
but	O
not	O
the	O
pleckstrin	O
homology	O
,	O
SH2	B-protein
,	I-protein
or	I-protein
SH3	I-protein
domains	I-protein
)	O
were	O
capable	O
of	O
binding	O
STAT5A	B-protein
.	O
<EOS>	B-X
In	B-X
pull	B-X
-	B-X
down	B-X
experiments	B-X
,	B-X
only	B-X
full	B-X
-	B-X
length	B-X
BTK	B-X
and	B-X
its	B-X
SH1	B-X
/	B-X
kinase	B-X
domain	B-X
(	B-X
but	B-X
not	B-X
the	B-X
pleckstrin	B-X
homology	B-X
,	B-X
SH2	B-X
,	B-X
or	B-X
SH3	B-X
domains	B-X
)	B-X
were	B-X
capable	B-X
of	B-X
binding	B-X
STAT5A	B-X
<EOS>	B-X
Ectopically	B-X
expressed	B-X
BTK	B-X
kinase	B-X
domain	B-X
was	B-X
capable	B-X
of	B-X
tyrosine	B-X
-	B-X
phosphorylating	B-X
STAT5A	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
BTK	B-X
phosphorylated	B-X
the	B-X
Y665F	B-X
,	B-X
Y668F	B-X
,	B-X
and	B-X
Y682F	B-X
,	B-X
Y683F	B-X
mutants	B-X
but	B-X
not	B-X
the	B-X
Y694F	B-X
mutant	B-X
of	B-X
STAT5A	B-X
<EOS>	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
ligation	B-X
resulted	B-X
in	B-X
enhanced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
STAT5	B-X
in	B-X
BTK	B-X
-	B-X
deficient	B-X
chicken	B-X
B	B-X
cells	B-X
reconstituted	B-X
with	B-X
wild	B-X
type	B-X
human	B-X
BTK	B-X
but	B-X
not	B-X
in	B-X
BTK	B-X
-	B-X
deficient	B-X
chicken	B-X
B	B-X
cells	B-X
reconstituted	B-X
with	B-X
kinase	B-X
-	B-X
inactive	B-X
mutant	B-X
BTK	B-X

Ectopically	O
expressed	O
BTK	B-protein
kinase	I-protein
domain	I-protein
was	O
capable	O
of	O
tyrosine-phosphorylating	O
STAT5A	B-protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
Ectopically	B-X
expressed	B-X
BTK	B-X
kinase	B-X
domain	B-X
was	B-X
capable	B-X
of	B-X
tyrosine	B-X
-	B-X
phosphorylating	B-X
STAT5A	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Recombinant	B-X
BTK	B-X
proteins	B-X
with	B-X
mutant	B-X
pleckstrin	B-X
homology	B-X
,	B-X
SH2	B-X
,	B-X
or	B-X
SH3	B-X
domains	B-X
were	B-X
capable	B-X
of	B-X
phosphorylating	B-X
STAT5A	B-X
,	B-X
whereas	B-X
recombinant	B-X
BTK	B-X
proteins	B-X
with	B-X
SH1	B-X
/	B-X
kinase	B-X
domain	B-X
mutations	B-X
were	B-X
not	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
anti	B-X
-	B-X
IgM	B-X
stimulation	B-X
resulted	B-X
in	B-X
enhanced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
STAT5A	B-X
in	B-X
BTK	B-X
-	B-X
competent	B-X
B	B-X
cells	B-X
from	B-X
wild	B-X
type	B-X
mice	B-X
but	B-X
not	B-X
in	B-X
BTK	B-X
-	B-X
deficient	B-X
B	B-X
cells	B-X
from	B-X
XID	B-X
mice	B-X
<EOS>	B-X
BTK	B-X
was	B-X
also	B-X
capable	B-X
of	B-X
tyrosine	B-X
-	B-X
phosphorylating	B-X
ectopically	B-X
expressed	B-X
recombinant	B-X
STAT5A	B-X
on	B-X
Tyr	B-X
(	B-X
694	B-X
)	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
in	B-X
a	B-X
Janus	B-X
kinase	B-X
3	B-X
-	B-X
independent	B-X
fashion	B-X

BTK	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
of	O
ectopically	O
expressed	O
wild	O
type	O
(	O
but	O
not	O
Tyr	B-protein
(	I-protein
694	I-protein
)	I-protein
mutant	I-protein
)	O
STAT5A	B-protein
enhanced	O
its	O
DNA	O
binding	O
activity	O
.	O

In	O
BTK	B-protein
-competent	O
chicken	O
B	B-cell_type
cells	I-cell_type
,	O
anti-IgM-stimulated	O
tyrosine	O
phosphorylation	O
of	O
STAT5	B-protein
protein	I-protein
was	O
prevented	O
by	O
pretreatment	O
with	O
the	O
BTK	B-protein
inhibitor	O
LFM-A13	O
but	O
not	O
by	O
pretreatment	O
with	O
the	O
JAK3	O
inhibitor	O
HI-P131	O
.	O

B	O
cell	O
antigen	O
receptor	O
ligation	O
resulted	O
in	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT5	B-protein
in	O
BTK	B-protein
-deficient	O
chicken	O
B	B-cell_type
cells	I-cell_type
reconstituted	O
with	O
wild	B-protein
type	I-protein
human	I-protein
BTK	I-protein
but	O
not	O
in	O
BTK	B-protein
-deficient	O
chicken	O
B	B-cell_type
cells	I-cell_type
reconstituted	O
with	O
kinase-inactive	B-protein
mutant	I-protein
BTK	I-protein
.	O

Similarly	O
,	O
anti-IgM	O
stimulation	O
resulted	O
in	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B-protein
in	O
BTK	B-protein
-competent	O
B	B-cell_type
cells	I-cell_type
from	O
wild	O
type	O
mice	O
but	O
not	O
in	O
BTK	B-protein
-deficient	O
B	B-cell_type
cells	I-cell_type
from	O
XID	O
mice	O
.	O

In	O
contrast	O
to	O
B	B-cell_type
cells	I-cell_type
from	O
XID	O
mice	O
,	O
B	B-cell_type
cells	I-cell_type
from	O
JAK3	O
knockout	O
mice	O
showed	O
a	O
normal	O
STAT5A	O
phosphorylation	O
response	O
to	O
anti-IgM	O
stimulation	O
.	O

These	O
findings	O
provide	O
unprecedented	O
experimental	O
evidence	O
that	O
BTK	B-protein
plays	O
a	O
nonredundant	O
and	O
pivotal	O
role	O
in	O
B	O
cell	O
antigen	O
receptor-mediated	O
STAT5A	O
activation	O
in	O
B	B-cell_type
cells	I-cell_type

Role	O
of	O
T-bet	B-protein
in	O
commitment	O
of	O
TH1	B-cell_type
cells	I-cell_type
before	O
IL-12	B-protein
-dependent	O
selection	O
.	O
<EOS>	B-X
Role	B-X
of	B-X
T	B-X
-	B-X
bet	B-X
in	B-X
commitment	B-X
of	B-X
TH1	B-X
cells	B-X
before	B-X
IL	B-X
-	B-X
12	B-X
-	B-X
dependent	B-X
selection	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
cytokine	B-X
does	B-X
not	B-X
simply	B-X
induce	B-X
TH	B-X
fate	B-X
choice	B-X
but	B-X
instead	B-X
may	B-X
act	B-X
as	B-X
an	B-X
essential	B-X
secondary	B-X
stimulus	B-X
that	B-X
mediates	B-X
selective	B-X
survival	B-X
of	B-X
a	B-X
lineage	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
T	B-X
-	B-X
bet	B-X
,	B-X
without	B-X
apparent	B-X
assistance	B-X
from	B-X
interleukin	B-X
12	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
)	B-X
	B-X
/	B-X
STAT4	B-X
,	B-X
specifies	B-X
TH1	B-X
effector	B-X
fate	B-X
by	B-X
targeting	B-X
chromatin	B-X
remodeling	B-X
to	B-X
individual	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
alleles	B-X
and	B-X
by	B-X
inducing	B-X
IL	B-X
-	B-X
12	B-X
receptor	B-X
beta2	B-X
expression	B-X
<EOS>	B-X
Subsequently	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
IL	B-X
-	B-X
12	B-X
/	B-X
STAT4	B-X
serves	B-X
two	B-X
essential	B-X
functions	B-X
in	B-X
the	B-X
development	B-X
of	B-X
TH1	B-X
cells	B-X
:	B-X
as	B-X
growth	B-X
signal	B-X
,	B-X
inducing	B-X
survival	B-X
and	B-X
cell	B-X
division	B-X
;	B-X
and	B-X
as	B-X
trans	B-X
-	B-X
activator	B-X
,	B-X
prolonging	B-X
IFN	B-X
-	B-X
gamma	B-X
synthesis	B-X
through	B-X
a	B-X
genetic	B-X
interaction	B-X
with	B-X
the	B-X
coactivator	B-X
,	B-X
CREB	B-X
-	B-X
binding	B-X
protein	B-X

How	O
cytokines	B-protein
control	O
differentiation	O
of	O
helper	B-cell_type
T	I-cell_type
(	I-cell_type
TH	I-cell_type
)	I-cell_type
cells	I-cell_type
is	O
controversial	O
.	O
<EOS>	B-X
How	B-X
cytokines	B-X
control	B-X
differentiation	B-X
of	B-X
helper	B-X
T	B-X
(	B-X
TH	B-X
)	B-X
cells	B-X
is	B-X
controversial	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
is	B-X
still	B-X
controversial	B-X
to	B-X
what	B-X
extent	B-X
TGF	B-X
-	B-X
β	B-X
signaling	B-X
in	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
regulatory	B-X
T	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
contributes	B-X
to	B-X
immune	B-X
homeostasis	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
effectiveness	B-X
of	B-X
ILC	B-X
in	B-X
anti	B-X
-	B-X
tumor	B-X
defenses	B-X
is	B-X
controversial	B-X
<EOS>	B-X
Vitamin	B-X
C	B-X
is	B-X
traditionally	B-X
regarded	B-X
to	B-X
be	B-X
beneficial	B-X
for	B-X
asthma	B-X
,	B-X
however	B-X
the	B-X
benefit	B-X
is	B-X
still	B-X
controversial	B-X

We	O
show	O
that	O
T-bet	B-protein
,	O
without	O
apparent	O
assistance	O
from	O
interleukin	B-protein
12	I-protein
(	I-protein
IL-12	I-protein
)	I-protein
/	O
STAT4	B-protein
,	O
specifies	O
TH1	B-cell_type
effector	O
fate	O
by	O
targeting	O
chromatin	O
remodeling	O
to	O
individual	O
interferon-gamma	B-DNA
(	I-DNA
IFN-gamma	I-DNA
)	I-DNA
alleles	I-DNA
and	O
by	O
inducing	O
IL-12	B-DNA
receptor	I-DNA
beta2	I-DNA
expression	O
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
T	B-X
-	B-X
bet	B-X
,	B-X
without	B-X
apparent	B-X
assistance	B-X
from	B-X
interleukin	B-X
12	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
)	B-X
	B-X
/	B-X
STAT4	B-X
,	B-X
specifies	B-X
TH1	B-X
effector	B-X
fate	B-X
by	B-X
targeting	B-X
chromatin	B-X
remodeling	B-X
to	B-X
individual	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
alleles	B-X
and	B-X
by	B-X
inducing	B-X
IL	B-X
-	B-X
12	B-X
receptor	B-X
beta2	B-X
expression	B-X
<EOS>	B-X
Subsequently	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
IL	B-X
-	B-X
12	B-X
/	B-X
STAT4	B-X
serves	B-X
two	B-X
essential	B-X
functions	B-X
in	B-X
the	B-X
development	B-X
of	B-X
TH1	B-X
cells	B-X
:	B-X
as	B-X
growth	B-X
signal	B-X
,	B-X
inducing	B-X
survival	B-X
and	B-X
cell	B-X
division	B-X
;	B-X
and	B-X
as	B-X
trans	B-X
-	B-X
activator	B-X
,	B-X
prolonging	B-X
IFN	B-X
-	B-X
gamma	B-X
synthesis	B-X
through	B-X
a	B-X
genetic	B-X
interaction	B-X
with	B-X
the	B-X
coactivator	B-X
,	B-X
CREB	B-X
-	B-X
binding	B-X
protein	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
cytokine	B-X
does	B-X
not	B-X
simply	B-X
induce	B-X
TH	B-X
fate	B-X
choice	B-X
but	B-X
instead	B-X
may	B-X
act	B-X
as	B-X
an	B-X
essential	B-X
secondary	B-X
stimulus	B-X
that	B-X
mediates	B-X
selective	B-X
survival	B-X
of	B-X
a	B-X
lineage	B-X
<EOS>	B-X
How	B-X
cytokines	B-X
control	B-X
differentiation	B-X
of	B-X
helper	B-X
T	B-X
(	B-X
TH	B-X
)	B-X
cells	B-X
is	B-X
controversial	B-X

Subsequently	O
,	O
it	O
appears	O
that	O
IL-12	B-protein
/	O
STAT4	B-protein
serves	O
two	O
essential	O
functions	O
in	O
the	O
development	O
of	O
TH1	B-cell_type
cells	I-cell_type
:	O
as	O
growth	B-protein
signal	I-protein
,	O
inducing	O
survival	O
and	O
cell	O
division	O
;	O
and	O
as	O
trans-activator	B-protein
,	O
prolonging	O
IFN-gamma	B-protein
synthesis	O
through	O
a	O
genetic	O
interaction	O
with	O
the	O
coactivator	B-protein
,	O
CREB-binding	B-protein
protein	I-protein
.	O
<EOS>	B-X
Subsequently	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
IL	B-X
-	B-X
12	B-X
/	B-X
STAT4	B-X
serves	B-X
two	B-X
essential	B-X
functions	B-X
in	B-X
the	B-X
development	B-X
of	B-X
TH1	B-X
cells	B-X
:	B-X
as	B-X
growth	B-X
signal	B-X
,	B-X
inducing	B-X
survival	B-X
and	B-X
cell	B-X
division	B-X
;	B-X
and	B-X
as	B-X
trans	B-X
-	B-X
activator	B-X
,	B-X
prolonging	B-X
IFN	B-X
-	B-X
gamma	B-X
synthesis	B-X
through	B-X
a	B-X
genetic	B-X
interaction	B-X
with	B-X
the	B-X
coactivator	B-X
,	B-X
CREB	B-X
-	B-X
binding	B-X
protein	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
a	B-X
cytokine	B-X
does	B-X
not	B-X
simply	B-X
induce	B-X
TH	B-X
fate	B-X
choice	B-X
but	B-X
instead	B-X
may	B-X
act	B-X
as	B-X
an	B-X
essential	B-X
secondary	B-X
stimulus	B-X
that	B-X
mediates	B-X
selective	B-X
survival	B-X
of	B-X
a	B-X
lineage	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
T	B-X
-	B-X
bet	B-X
,	B-X
without	B-X
apparent	B-X
assistance	B-X
from	B-X
interleukin	B-X
12	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
)	B-X
	B-X
/	B-X
STAT4	B-X
,	B-X
specifies	B-X
TH1	B-X
effector	B-X
fate	B-X
by	B-X
targeting	B-X
chromatin	B-X
remodeling	B-X
to	B-X
individual	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
alleles	B-X
and	B-X
by	B-X
inducing	B-X
IL	B-X
-	B-X
12	B-X
receptor	B-X
beta2	B-X
expression	B-X
<EOS>	B-X
Role	B-X
of	B-X
T	B-X
-	B-X
bet	B-X
in	B-X
commitment	B-X
of	B-X
TH1	B-X
cells	B-X
before	B-X
IL	B-X
-	B-X
12	B-X
-	B-X
dependent	B-X
selection	B-X
.	B-X

These	O
results	O
suggest	O
that	O
a	O
cytokine	B-protein
does	O
not	O
simply	O
induce	O
TH	O
fate	O
choice	O
but	O
instead	O
may	O
act	O
as	O
an	O
essential	O
secondary	O
stimulus	O
that	O
mediates	O
selective	O
survival	O
of	O
a	O
lineage	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
KMT2D	B-X
could	B-X
be	B-X
regarded	B-X
as	B-X
a	B-X
potential	B-X
new	B-X
target	B-X
for	B-X
PCa	B-X
therapy	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
the	B-X
potential	B-X
of	B-X
not	B-X
only	B-X
JAK1	B-X
,	B-X
but	B-X
also	B-X
of	B-X
STAT6	B-X
as	B-X
therapeutic	B-X
targets	B-X
for	B-X
cAD	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
cytokine	B-X
and	B-X
chemokine	B-X
levels	B-X
reflect	B-X
a	B-X
perpetual	B-X
,	B-X
potent	B-X
and	B-X
pan	B-X
-	B-X
cerebebral	B-X
inflammatory	B-X
response	B-X
that	B-X
persists	B-X
beyond	B-X
15	B-X
days	B-X
following	B-X
TBI	B-X
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
bupropion	B-X
had	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
on	B-X
the	B-X
activated	B-X
macrophages	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
was	B-X
partially	B-X
dependent	B-X
on	B-X
p38	B-X
but	B-X
independent	B-X
of	B-X
PI3K	B-X
pathways	B-X

Stat6	B-protein
is	O
necessary	O
and	O
sufficient	O
for	O
IL-4	O
's	O
role	O
in	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
.	O
<EOS>	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
IL	B-X
-	B-X
4	B-X
's	B-X
role	B-X
in	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activated	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
mediate	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
signal	B-X
pathway	B-X
mediated	B-X
by	B-X
Y497	B-X
is	B-X
dispensable	B-X
for	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
<EOS>	B-X
A	B-X
constitutively	B-X
activated	B-X
form	B-X
of	B-X
Stat6	B-X
introduced	B-X
into	B-X
CD4	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
both	B-X
Th2	B-X
differentiation	B-X
and	B-X
enhanced	B-X
cell	B-X
expansion	B-X

IL-4	B-protein
plays	O
a	O
critical	O
role	O
in	O
the	O
differentiation	O
of	O
T	O
CR-stimulated	B-cell_type
naive	I-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
the	O
Th2	O
phenotype	O
.	O

In	O
response	O
to	O
IL-4	B-protein
,	O
the	O
IL-4R	B-protein
activates	O
a	O
set	O
of	O
phosphotyrosine	B-protein
binding	I-protein
domain-containing	I-protein
proteins	I-protein
,	O
including	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
1/2	I-protein
,	O
Shc	B-protein
,	O
and	O
IL-4R	B-protein
interacting	I-protein
protein	I-protein
,	O
as	O
well	O
as	O
Stat6	B-protein
.	O
<EOS>	B-X
In	B-X
response	B-X
to	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
4R	B-X
activates	B-X
a	B-X
set	B-X
of	B-X
phosphotyrosine	B-X
binding	B-X
domain	B-X
-	B-X
containing	B-X
proteins	B-X
,	B-X
including	B-X
insulin	B-X
receptor	B-X
substrate	B-X
1	B-X
/	B-X
2	B-X
,	B-X
Shc	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
4R	B-X
interacting	B-X
protein	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Stat6	B-X
<EOS>	B-X
A	B-X
constitutively	B-X
activated	B-X
form	B-X
of	B-X
Stat6	B-X
introduced	B-X
into	B-X
CD4	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
both	B-X
Th2	B-X
differentiation	B-X
and	B-X
enhanced	B-X
cell	B-X
expansion	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
phosphotyrosine	B-X
binding	B-X
adaptors	B-X
in	B-X
Th2	B-X
differentiation	B-X
,	B-X
we	B-X
prepared	B-X
a	B-X
retrovirus	B-X
containing	B-X
a	B-X
mutant	B-X
of	B-X
the	B-X
human	B-X
(	B-X
h	B-X
)	B-X
IL	B-X
-	B-X
4R	B-X
alpha	B-X
-	B-X
chain	B-X
,	B-X
Y497F	B-X
,	B-X
which	B-X
is	B-X
unable	B-X
to	B-X
recruit	B-X
these	B-X
adaptors	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
signal	B-X
pathway	B-X
mediated	B-X
by	B-X
Y497	B-X
is	B-X
dispensable	B-X
for	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X

Stat6	B-protein
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
Th2	O
differentiation	O
.	O
<EOS>	B-X
Similarly	B-X
to	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
counterpart	B-X
,	B-X
Tc9	B-X
cells	B-X
required	B-X
for	B-X
their	B-X
differentiation	B-X
STAT6	B-X
and	B-X
IRF4	B-X
<EOS>	B-X
The	B-X
Metabolic	B-X
Requirements	B-X
of	B-X
Th2	B-X
Cell	B-X
Differentiation	B-X
.	B-X
<EOS>	B-X
Homeostatic	B-X
IL	B-X
-	B-X
13	B-X
in	B-X
healthy	B-X
skin	B-X
directs	B-X
dendritic	B-X
cell	B-X
differentiation	B-X
to	B-X
promote	B-X
T	B-X
<EOS>	B-X
Tc9	B-X
cells	B-X
,	B-X
a	B-X
new	B-X
subset	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
support	B-X
Th2	B-X
-	B-X
mediated	B-X
airway	B-X
inflammation	B-X
.	B-X

To	O
determine	O
the	O
roles	O
of	O
the	O
phosphotyrosine	B-protein
binding	I-protein
adaptors	I-protein
in	O
Th2	O
differentiation	O
,	O
we	O
prepared	O
a	O
retrovirus	O
containing	O
a	O
mutant	O
of	O
the	O
human	B-protein
(	I-protein
h	I-protein
)	I-protein
IL-4R	I-protein
alpha-chain	I-protein
,	O
Y497F	B-protein
,	O
which	O
is	O
unable	O
to	O
recruit	O
these	O
adaptors	O
.	O

The	O
mutant	B-protein
hIL-4Ralpha	I-protein
,	O
as	O
well	O
as	O
the	O
wild-type	B-protein
(	I-protein
WT	I-protein
)	I-protein
hIL-4Ralpha	I-protein
,	O
was	O
introduced	O
into	O
naive	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
mutant	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
(	B-X
WT	B-X
)	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
,	B-X
was	B-X
introduced	B-X
into	B-X
naive	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
Both	B-X
WT	B-X
and	B-X
Y497F	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
lose	B-X
the	B-X
ability	B-X
to	B-X
drive	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
Stat6	B-X
-	B-X
knockout	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activated	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
mediate	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
Upon	B-X
hIL	B-X
-	B-X
4	B-X
stimulation	B-X
,	B-X
Y497F	B-X
worked	B-X
as	B-X
well	B-X
as	B-X
the	B-X
WT	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
in	B-X
driving	B-X
Th2	B-X
differentiation	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
Gata3	B-X
up	B-X
-	B-X
regulation	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
production	B-X

Upon	O
hIL-4	O
stimulation	O
,	O
Y497F	B-protein
worked	O
as	O
well	O
as	O
the	O
WT	B-protein
hIL-4Ralpha	I-protein
in	O
driving	O
Th2	O
differentiation	O
,	O
as	O
measured	O
by	O
Gata3	O
up-regulation	O
and	O
IL-4	O
production	O
.	O
<EOS>	B-X
Upon	B-X
hIL	B-X
-	B-X
4	B-X
stimulation	B-X
,	B-X
Y497F	B-X
worked	B-X
as	B-X
well	B-X
as	B-X
the	B-X
WT	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
in	B-X
driving	B-X
Th2	B-X
differentiation	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
Gata3	B-X
up	B-X
-	B-X
regulation	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
production	B-X
<EOS>	B-X
Both	B-X
WT	B-X
and	B-X
Y497F	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
lose	B-X
the	B-X
ability	B-X
to	B-X
drive	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
Stat6	B-X
-	B-X
knockout	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
IL	B-X
-	B-X
4	B-X
's	B-X
role	B-X
in	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activated	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
mediate	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X

Furthermore	O
,	O
IL-4-driven	O
cell	O
expansion	O
was	O
also	O
normal	O
in	O
the	O
cells	O
infected	O
with	O
Y497F	B-protein
,	O
although	O
cells	O
infected	O
with	O
Y497F	B-protein
were	O
not	O
capable	O
of	O
phosphorylating	O
insulin	B-protein
receptor	I-protein
substrate	I-protein
2	I-protein
.	O

These	O
results	O
suggest	O
that	O
the	O
signal	O
pathway	O
mediated	O
by	O
Y497	B-protein
is	O
dispensable	O
for	O
both	O
IL-4	B-protein
-driven	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
signal	B-X
pathway	B-X
mediated	B-X
by	B-X
Y497	B-X
is	B-X
dispensable	B-X
for	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
<EOS>	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
IL	B-X
-	B-X
4	B-X
's	B-X
role	B-X
in	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activated	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
mediate	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
A	B-X
constitutively	B-X
activated	B-X
form	B-X
of	B-X
Stat6	B-X
introduced	B-X
into	B-X
CD4	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
both	B-X
Th2	B-X
differentiation	B-X
and	B-X
enhanced	B-X
cell	B-X
expansion	B-X

Both	O
WT	B-protein
and	I-protein
Y497F	I-protein
hIL-4Ralpha	I-protein
lose	O
the	O
ability	O
to	O
drive	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
in	O
Stat6-knockout	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Both	B-X
WT	B-X
and	B-X
Y497F	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
lose	B-X
the	B-X
ability	B-X
to	B-X
drive	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
Stat6	B-X
-	B-X
knockout	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activated	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
mediate	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
IL	B-X
-	B-X
4	B-X
's	B-X
role	B-X
in	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
.	B-X
<EOS>	B-X
Upon	B-X
hIL	B-X
-	B-X
4	B-X
stimulation	B-X
,	B-X
Y497F	B-X
worked	B-X
as	B-X
well	B-X
as	B-X
the	B-X
WT	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
in	B-X
driving	B-X
Th2	B-X
differentiation	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
Gata3	B-X
up	B-X
-	B-X
regulation	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
production	B-X

A	O
constitutively	O
activated	O
form	O
of	O
Stat6	B-protein
introduced	O
into	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
resulted	O
in	O
both	O
Th2	O
differentiation	O
and	O
enhanced	O
cell	O
expansion	O
.	O
<EOS>	B-X
A	B-X
constitutively	B-X
activated	B-X
form	B-X
of	B-X
Stat6	B-X
introduced	B-X
into	B-X
CD4	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
both	B-X
Th2	B-X
differentiation	B-X
and	B-X
enhanced	B-X
cell	B-X
expansion	B-X
<EOS>	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
IL	B-X
-	B-X
4	B-X
's	B-X
role	B-X
in	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
signal	B-X
pathway	B-X
mediated	B-X
by	B-X
Y497	B-X
is	B-X
dispensable	B-X
for	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
<EOS>	B-X
Thus	B-X
,	B-X
activated	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
mediate	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X

Thus	O
,	O
activated	B-protein
Stat6	I-protein
is	O
necessary	O
and	O
sufficient	O
to	O
mediate	O
both	O
IL-4	B-protein
-driven	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
in	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Thus	B-X
,	B-X
activated	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
to	B-X
mediate	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
Stat6	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
IL	B-X
-	B-X
4	B-X
's	B-X
role	B-X
in	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
.	B-X
<EOS>	B-X
Both	B-X
WT	B-X
and	B-X
Y497F	B-X
hIL	B-X
-	B-X
4Ralpha	B-X
lose	B-X
the	B-X
ability	B-X
to	B-X
drive	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X
in	B-X
Stat6	B-X
-	B-X
knockout	B-X
CD4	B-X
T	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
signal	B-X
pathway	B-X
mediated	B-X
by	B-X
Y497	B-X
is	B-X
dispensable	B-X
for	B-X
both	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
driven	B-X
Th2	B-X
differentiation	B-X
and	B-X
cell	B-X
expansion	B-X

The	O
effect	O
of	O
HIV-1	B-protein
regulatory	I-protein
proteins	I-protein
on	O
cellular	O
genes	O
:	O
derepression	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tat	B-protein
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
regulatory	B-X
proteins	B-X
on	B-X
cellular	B-X
genes	B-X
:	B-X
derepression	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
by	B-X
Tat	B-X
.	B-X
<EOS>	B-X
In	B-X
HIV	B-X
-	B-X
infected	B-X
individuals	B-X
dysregulation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
characterized	B-X
by	B-X
severe	B-X
disorders	B-X
of	B-X
the	B-X
cytokine	B-X
network	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
increased	B-X
IL	B-X
-	B-X
2	B-X
secretion	B-X
is	B-X
due	B-X
to	B-X
Tat	B-X
-	B-X
enhanced	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activation	B-X
<EOS>	B-X
In	B-X
nonstimulated	B-X
T	B-X
cells	B-X
a	B-X
repressor	B-X
complex	B-X
containing	B-X
NF	B-X
-	B-X
IL6	B-X
,	B-X
JunB	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
Fra	B-X
-	B-X
1	B-X
is	B-X
formed	B-X
on	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
d	B-X
)	B-X
site	B-X
and	B-X
represses	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X

In	O
HIV-infected	O
individuals	O
dysregulation	O
of	O
the	O
immune	O
system	O
is	O
characterized	O
by	O
severe	O
disorders	O
of	O
the	O
cytokine	O
network	O
.	O
<EOS>	B-X
In	B-X
HIV	B-X
-	B-X
infected	B-X
individuals	B-X
dysregulation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
characterized	B-X
by	B-X
severe	B-X
disorders	B-X
of	B-X
the	B-X
cytokine	B-X
network	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
regulatory	B-X
proteins	B-X
on	B-X
cellular	B-X
genes	B-X
:	B-X
derepression	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
by	B-X
Tat	B-X
.	B-X
<EOS>	B-X
HIV	B-X
Tat	B-X
enhances	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
consequently	B-X
,	B-X
activates	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
d	B-X
)	B-X
site	B-X
<EOS>	B-X
Our	B-X
data	B-X
provide	B-X
evidence	B-X
for	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
HIV	B-X
Tat	B-X
dysregulates	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
therefore	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
in	B-X
a	B-X
way	B-X
yet	B-X
to	B-X
be	B-X
clarified	B-X

Increase	O
secretion	O
of	O
IL-2	B-protein
,	O
the	O
major	O
T	B-cell_type
cell	I-cell_type
growth	O
and	O
differentiation	O
cytokine	B-protein
,	O
may	O
play	O
a	O
decisive	O
role	O
in	O
sensitization	O
of	O
T	B-cell_type
cells	I-cell_type
for	O
activation	O
induced	O
apoptosis	O
and	O
indirect	O
death	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
through	O
augmented	O
virus	O
replication	O
.	O

We	O
investigated	O
the	O
cause	O
of	O
enhanced	O
IL-2	O
secretion	O
and	O
found	O
that	O
the	O
HIV	B-protein
Tat	I-protein
induces	O
this	O
effect	O
.	O

We	O
demonstrate	O
that	O
increased	O
IL-2	O
secretion	O
is	O
due	O
to	O
Tat	B-protein
-enhanced	O
IL-2	B-DNA
promoter	I-DNA
activation	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
increased	B-X
IL	B-X
-	B-X
2	B-X
secretion	B-X
is	B-X
due	B-X
to	B-X
Tat	B-X
-	B-X
enhanced	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activation	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
cause	B-X
of	B-X
enhanced	B-X
IL	B-X
-	B-X
2	B-X
secretion	B-X
and	B-X
found	B-X
that	B-X
the	B-X
HIV	B-X
Tat	B-X
induces	B-X
this	B-X
effect	B-X
<EOS>	B-X
In	B-X
nonstimulated	B-X
T	B-X
cells	B-X
a	B-X
repressor	B-X
complex	B-X
containing	B-X
NF	B-X
-	B-X
IL6	B-X
,	B-X
JunB	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
Fra	B-X
-	B-X
1	B-X
is	B-X
formed	B-X
on	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
d	B-X
)	B-X
site	B-X
and	B-X
represses	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Coexpression	B-X
of	B-X
tat	B-X
-	B-X
III	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
the	B-X
steady	B-X
state	B-X
level	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
mRNAs	B-X
transcribed	B-X
from	B-X
the	B-X
HIV	B-X
LTR	B-X
,	B-X
and	B-X
these	B-X
mRNAs	B-X
also	B-X
demonstrated	B-X
a	B-X
specific	B-X
enhancement	B-X
of	B-X
their	B-X
translational	B-X
efficiency	B-X

Tat	B-protein
derepresses	O
and	O
activates	O
the	O
distal	B-DNA
AP-1	I-DNA
site	I-DNA
(	O
position	B-DNA
-185	I-DNA
to	I-DNA
-177	I-DNA
)	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Tat	B-X
derepresses	B-X
and	B-X
activates	B-X
the	B-X
distal	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
(	B-X
position	B-X
	B-X
-	B-X
185	B-X
to	B-X
	B-X
-	B-X
177	B-X
)	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
increased	B-X
IL	B-X
-	B-X
2	B-X
secretion	B-X
is	B-X
due	B-X
to	B-X
Tat	B-X
-	B-X
enhanced	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activation	B-X
<EOS>	B-X
In	B-X
nonstimulated	B-X
T	B-X
cells	B-X
a	B-X
repressor	B-X
complex	B-X
containing	B-X
NF	B-X
-	B-X
IL6	B-X
,	B-X
JunB	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
Fra	B-X
-	B-X
1	B-X
is	B-X
formed	B-X
on	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
d	B-X
)	B-X
site	B-X
and	B-X
represses	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
regulatory	B-X
proteins	B-X
on	B-X
cellular	B-X
genes	B-X
:	B-X
derepression	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
by	B-X
Tat	B-X
.	B-X

In	O
nonstimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
a	O
repressor	O
complex	O
containing	O
NF-IL6	B-protein
,	O
JunB	B-protein
,	O
c-Fos	B-protein
and	O
Fra-1	B-protein
is	O
formed	O
on	O
the	O
AP-1	B-DNA
(	I-DNA
IL-2/d	I-DNA
)	I-DNA
site	I-DNA
and	O
represses	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O
<EOS>	B-X
In	B-X
nonstimulated	B-X
T	B-X
cells	B-X
a	B-X
repressor	B-X
complex	B-X
containing	B-X
NF	B-X
-	B-X
IL6	B-X
,	B-X
JunB	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
Fra	B-X
-	B-X
1	B-X
is	B-X
formed	B-X
on	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
d	B-X
)	B-X
site	B-X
and	B-X
represses	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
increased	B-X
IL	B-X
-	B-X
2	B-X
secretion	B-X
is	B-X
due	B-X
to	B-X
Tat	B-X
-	B-X
enhanced	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activation	B-X
<EOS>	B-X
Tat	B-X
derepresses	B-X
and	B-X
activates	B-X
the	B-X
distal	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
(	B-X
position	B-X
	B-X
-	B-X
185	B-X
to	B-X
	B-X
-	B-X
177	B-X
)	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
cause	B-X
of	B-X
enhanced	B-X
IL	B-X
-	B-X
2	B-X
secretion	B-X
and	B-X
found	B-X
that	B-X
the	B-X
HIV	B-X
Tat	B-X
induces	B-X
this	B-X
effect	B-X

After	O
T	O
cell	O
activation	O
,	O
a	O
heterodimeric	B-protein
activator	I-protein
containing	O
p65	B-protein
and	O
c-Jun	B-protein
binds	O
to	O
the	O
AP-1	B-DNA
(	I-DNA
IL-2/d	I-DNA
)	I-DNA
site	I-DNA
.	O

HIV	B-protein
Tat	I-protein
enhances	O
activation	O
of	O
NF-kappaB	B-protein
and	O
consequently	O
,	O
activates	O
the	O
AP-1	B-DNA
(	I-DNA
IL-2/d	I-DNA
)	I-DNA
site	I-DNA
.	O
<EOS>	B-X
HIV	B-X
Tat	B-X
enhances	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
consequently	B-X
,	B-X
activates	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
d	B-X
)	B-X
site	B-X
<EOS>	B-X
After	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
a	B-X
heterodimeric	B-X
activator	B-X
containing	B-X
p65	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
binds	B-X
to	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
d	B-X
)	B-X
site	B-X
<EOS>	B-X
In	B-X
nonstimulated	B-X
T	B-X
cells	B-X
a	B-X
repressor	B-X
complex	B-X
containing	B-X
NF	B-X
-	B-X
IL6	B-X
,	B-X
JunB	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
Fra	B-X
-	B-X
1	B-X
is	B-X
formed	B-X
on	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
/	B-X
d	B-X
)	B-X
site	B-X
and	B-X
represses	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Our	B-X
data	B-X
provide	B-X
evidence	B-X
for	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
HIV	B-X
Tat	B-X
dysregulates	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
and	B-X
therefore	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
in	B-X
a	B-X
way	B-X
yet	B-X
to	B-X
be	B-X
clarified	B-X

Our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
mechanism	O
by	O
which	O
HIV	B-protein
Tat	I-protein
dysregulates	O
IL-2	O
production	O
and	O
therefore	O
may	O
contribute	O
to	O
the	O
HIV-1	O
infection	O
in	O
a	O
way	O
yet	O
to	O
be	O
clarified	O
.	O

Transforming	B-protein
growth	I-protein
factor-beta1	I-protein
interferes	O
with	O
thrombopoietin-induced	O
signal	O
transduction	O
in	O
megakaryoblastic	B-cell_type
and	I-cell_type
erythroleukemic	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
interferes	B-X
with	B-X
thrombopoietin	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
megakaryoblastic	B-X
and	B-X
erythroleukemic	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
interferes	B-X
directly	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
regulatory	B-X
effects	B-X
in	B-X
the	B-X
TPO	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X
<EOS>	B-X
Thrombopoietin	B-X
(	B-X
TPO	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
(	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
opposite	B-X
effects	B-X
on	B-X
proliferation	B-X
and	B-X
megakaryocytic	B-X
differentiation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
modulates	B-X
TPO	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
megakaryocytic	B-X
proliferation	B-X
by	B-X
interfering	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
,	B-X
particularly	B-X
by	B-X
reducing	B-X
the	B-X
activities	B-X
of	B-X
MAPK	B-X
ERK1	B-X
/	B-X
ERK2	B-X
and	B-X
STAT5	B-X

OBJECTIVE	O
:	O
Thrombopoietin	B-protein
(	O
TPO	B-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	I-protein
1	I-protein
)	I-protein
(	O
TGF-beta	B-protein
(	I-protein
1	I-protein
)	I-protein
)	O
have	O
been	O
shown	O
to	O
exert	O
opposite	O
effects	O
on	O
proliferation	O
and	O
megakaryocytic	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

To	O
determine	O
whether	O
TGF-beta	B-protein
(	I-protein
1	I-protein
)	I-protein
interferes	O
directly	O
with	O
TPO	B-protein
-induced	O
signal	O
transduction	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
we	O
compared	O
the	O
regulatory	O
effects	O
in	O
the	O
TPO	B-protein
-responsive	O
cell	O
lines	O
Mo-7e	O
and	O
HEL	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
interferes	B-X
directly	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
regulatory	B-X
effects	B-X
in	B-X
the	B-X
TPO	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
interferes	B-X
with	B-X
thrombopoietin	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
megakaryoblastic	B-X
and	B-X
erythroleukemic	B-X
cells	B-X
.	B-X
<EOS>	B-X
As	B-X
demonstrated	B-X
by	B-X
Western	B-X
blotting	B-X
,	B-X
TGF	B-X
-	B-X
beta1	B-X
reduced	B-X
the	B-X
TPO	B-X
-	B-X
stimulated	B-X
ERK1	B-X
/	B-X
ERK2	B-X
and	B-X
STAT5	B-X
phosphorylation	B-X
in	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X
cells	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
modulates	B-X
TPO	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
megakaryocytic	B-X
proliferation	B-X
by	B-X
interfering	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
,	B-X
particularly	B-X
by	B-X
reducing	B-X
the	B-X
activities	B-X
of	B-X
MAPK	B-X
ERK1	B-X
/	B-X
ERK2	B-X
and	B-X
STAT5	B-X

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
cells	O
were	O
stimulated	O
by	O
100	O
ng/mL	O
TPO	B-protein
and/or	O
100	O
ng/mL	O
TGF-beta1	B-protein
and	O
analyzed	O
for	O
proliferation	O
(	O
3H	O
thymidine	O
incorporation	O
)	O
,	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
,	O
and	O
protein	O
expression	O
and	O
phosphorylation	O
(	O
Western	O
blot	O
)	O
.	O
<EOS>	B-X
The	B-X
cells	B-X
were	B-X
stimulated	B-X
by	B-X
100	B-X
ng	B-X
/	B-X
mL	B-X
TPO	B-X
and	B-X
/	B-X
or	B-X
100	B-X
ng	B-X
/	B-X
mL	B-X
TGF	B-X
-	B-X
beta1	B-X
and	B-X
analyzed	B-X
for	B-X
proliferation	B-X
(	B-X
3H	B-X
thymidine	B-X
incorporation	B-X
)	B-X
,	B-X
viability	B-X
(	B-X
trypan	B-X
blue	B-X
exclusion	B-X
)	B-X
,	B-X
and	B-X
protein	B-X
expression	B-X
and	B-X
phosphorylation	B-X
(	B-X
Western	B-X
blot	B-X
)	B-X
<EOS>	B-X
TPO	B-X
enhanced	B-X
the	B-X
proliferation	B-X
of	B-X
Mo	B-X
-	B-X
7e	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
3H	B-X
-	B-X
thymidine	B-X
incorporation	B-X
,	B-X
whereas	B-X
TGF	B-X
-	B-X
beta1	B-X
suppressed	B-X
baseline	B-X
cell	B-X
growth	B-X
and	B-X
antagonized	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
TPO	B-X
<EOS>	B-X
As	B-X
demonstrated	B-X
by	B-X
Western	B-X
blotting	B-X
,	B-X
TGF	B-X
-	B-X
beta1	B-X
reduced	B-X
the	B-X
TPO	B-X
-	B-X
stimulated	B-X
ERK1	B-X
/	B-X
ERK2	B-X
and	B-X
STAT5	B-X
phosphorylation	B-X
in	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X
cells	B-X
<EOS>	B-X
This	B-X
effect	B-X
was	B-X
completely	B-X
reversed	B-X
by	B-X
preincubation	B-X
with	B-X
a	B-X
tyrosine	B-X
phosphatase	B-X
inhibitor	B-X
(	B-X
Na3VO4	B-X
)	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
activated	B-X
a	B-X
phosphatase	B-X

RESULTS	O
:	O
TPO	B-protein
enhanced	O
the	O
proliferation	O
of	O
Mo-7e	B-cell_line
cells	I-cell_line
as	O
determined	O
by	O
3H-thymidine	O
incorporation	O
,	O
whereas	O
TGF-beta1	B-protein
suppressed	O
baseline	O
cell	O
growth	O
and	O
antagonized	O
the	O
proliferative	O
effect	O
of	O
TPO	B-protein
.	O
<EOS>	B-X
TPO	B-X
enhanced	B-X
the	B-X
proliferation	B-X
of	B-X
Mo	B-X
-	B-X
7e	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
3H	B-X
-	B-X
thymidine	B-X
incorporation	B-X
,	B-X
whereas	B-X
TGF	B-X
-	B-X
beta1	B-X
suppressed	B-X
baseline	B-X
cell	B-X
growth	B-X
and	B-X
antagonized	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
TPO	B-X
<EOS>	B-X
The	B-X
cells	B-X
were	B-X
stimulated	B-X
by	B-X
100	B-X
ng	B-X
/	B-X
mL	B-X
TPO	B-X
and	B-X
/	B-X
or	B-X
100	B-X
ng	B-X
/	B-X
mL	B-X
TGF	B-X
-	B-X
beta1	B-X
and	B-X
analyzed	B-X
for	B-X
proliferation	B-X
(	B-X
3H	B-X
thymidine	B-X
incorporation	B-X
)	B-X
,	B-X
viability	B-X
(	B-X
trypan	B-X
blue	B-X
exclusion	B-X
)	B-X
,	B-X
and	B-X
protein	B-X
expression	B-X
and	B-X
phosphorylation	B-X
(	B-X
Western	B-X
blot	B-X
)	B-X
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
interferes	B-X
with	B-X
thrombopoietin	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
megakaryoblastic	B-X
and	B-X
erythroleukemic	B-X
cells	B-X
.	B-X
<EOS>	B-X
TPO	B-X
-	B-X
induced	B-X
proliferation	B-X
also	B-X
was	B-X
reduced	B-X
by	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathway	B-X
(	B-X
PD098059	B-X
)	B-X
,	B-X
which	B-X
inhibits	B-X
activation	B-X
of	B-X
the	B-X
MAPK	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinases	B-X
(	B-X
ERK	B-X
)	B-X
ERK1	B-X
and	B-X
ERK2	B-X
,	B-X
and	B-X
AG490	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Janus	B-X
kinase	B-X
-	B-X
2	B-X
,	B-X
which	B-X
completely	B-X
blocked	B-X
TPO	B-X
-	B-X
induced	B-X
proliferation	B-X

TPO	B-protein
-induced	O
proliferation	O
also	O
was	O
reduced	O
by	O
a	O
specific	O
inhibitor	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathway	O
(	O
PD098059	O
)	O
,	O
which	O
inhibits	O
activation	O
of	O
the	O
MAPK	B-protein
extracellular	I-protein
signal-regulated	I-protein
kinases	I-protein
(	O
ERK	B-protein
)	O
ERK1	B-protein
and	O
ERK2	B-protein
,	O
and	O
AG490	O
,	O
an	O
inhibitor	O
of	O
Janus	B-protein
kinase-2	I-protein
,	O
which	O
completely	O
blocked	O
TPO	B-protein
-induced	O
proliferation	O
.	O
<EOS>	B-X
TPO	B-X
-	B-X
induced	B-X
proliferation	B-X
also	B-X
was	B-X
reduced	B-X
by	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathway	B-X
(	B-X
PD098059	B-X
)	B-X
,	B-X
which	B-X
inhibits	B-X
activation	B-X
of	B-X
the	B-X
MAPK	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinases	B-X
(	B-X
ERK	B-X
)	B-X
ERK1	B-X
and	B-X
ERK2	B-X
,	B-X
and	B-X
AG490	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Janus	B-X
kinase	B-X
-	B-X
2	B-X
,	B-X
which	B-X
completely	B-X
blocked	B-X
TPO	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
TPO	B-X
enhanced	B-X
the	B-X
proliferation	B-X
of	B-X
Mo	B-X
-	B-X
7e	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
3H	B-X
-	B-X
thymidine	B-X
incorporation	B-X
,	B-X
whereas	B-X
TGF	B-X
-	B-X
beta1	B-X
suppressed	B-X
baseline	B-X
cell	B-X
growth	B-X
and	B-X
antagonized	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
TPO	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
interferes	B-X
directly	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
regulatory	B-X
effects	B-X
in	B-X
the	B-X
TPO	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X
<EOS>	B-X
Thrombopoietin	B-X
(	B-X
TPO	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
(	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
opposite	B-X
effects	B-X
on	B-X
proliferation	B-X
and	B-X
megakaryocytic	B-X
differentiation	B-X
of	B-X
hematopoietic	B-X
cells	B-X

As	O
demonstrated	O
by	O
Western	O
blotting	O
,	O
TGF-beta1	B-protein
reduced	O
the	O
TPO	B-protein
-stimulated	O
ERK1	B-protein
/	O
ERK2	B-protein
and	O
STAT5	O
phosphorylation	O
in	O
Mo-7e	B-cell_line
and	I-cell_line
HEL	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
As	B-X
demonstrated	B-X
by	B-X
Western	B-X
blotting	B-X
,	B-X
TGF	B-X
-	B-X
beta1	B-X
reduced	B-X
the	B-X
TPO	B-X
-	B-X
stimulated	B-X
ERK1	B-X
/	B-X
ERK2	B-X
and	B-X
STAT5	B-X
phosphorylation	B-X
in	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X
cells	B-X
<EOS>	B-X
The	B-X
cells	B-X
were	B-X
stimulated	B-X
by	B-X
100	B-X
ng	B-X
/	B-X
mL	B-X
TPO	B-X
and	B-X
/	B-X
or	B-X
100	B-X
ng	B-X
/	B-X
mL	B-X
TGF	B-X
-	B-X
beta1	B-X
and	B-X
analyzed	B-X
for	B-X
proliferation	B-X
(	B-X
3H	B-X
thymidine	B-X
incorporation	B-X
)	B-X
,	B-X
viability	B-X
(	B-X
trypan	B-X
blue	B-X
exclusion	B-X
)	B-X
,	B-X
and	B-X
protein	B-X
expression	B-X
and	B-X
phosphorylation	B-X
(	B-X
Western	B-X
blot	B-X
)	B-X
<EOS>	B-X
Thrombopoietin	B-X
(	B-X
TPO	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
(	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
opposite	B-X
effects	B-X
on	B-X
proliferation	B-X
and	B-X
megakaryocytic	B-X
differentiation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
interferes	B-X
directly	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
regulatory	B-X
effects	B-X
in	B-X
the	B-X
TPO	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X

This	O
effect	O
was	O
completely	O
reversed	O
by	O
preincubation	O
with	O
a	O
tyrosine	O
phosphatase	O
inhibitor	O
(	O
Na3VO4	O
)	O
,	O
which	O
suggests	O
that	O
TGF-beta1	B-protein
activated	O
a	O
phosphatase	B-protein
.	O
<EOS>	B-X
This	B-X
effect	B-X
was	B-X
completely	B-X
reversed	B-X
by	B-X
preincubation	B-X
with	B-X
a	B-X
tyrosine	B-X
phosphatase	B-X
inhibitor	B-X
(	B-X
Na3VO4	B-X
)	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
activated	B-X
a	B-X
phosphatase	B-X
<EOS>	B-X
The	B-X
cells	B-X
were	B-X
stimulated	B-X
by	B-X
100	B-X
ng	B-X
/	B-X
mL	B-X
TPO	B-X
and	B-X
/	B-X
or	B-X
100	B-X
ng	B-X
/	B-X
mL	B-X
TGF	B-X
-	B-X
beta1	B-X
and	B-X
analyzed	B-X
for	B-X
proliferation	B-X
(	B-X
3H	B-X
thymidine	B-X
incorporation	B-X
)	B-X
,	B-X
viability	B-X
(	B-X
trypan	B-X
blue	B-X
exclusion	B-X
)	B-X
,	B-X
and	B-X
protein	B-X
expression	B-X
and	B-X
phosphorylation	B-X
(	B-X
Western	B-X
blot	B-X
)	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
interferes	B-X
directly	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
regulatory	B-X
effects	B-X
in	B-X
the	B-X
TPO	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
modulates	B-X
TPO	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
megakaryocytic	B-X
proliferation	B-X
by	B-X
interfering	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
,	B-X
particularly	B-X
by	B-X
reducing	B-X
the	B-X
activities	B-X
of	B-X
MAPK	B-X
ERK1	B-X
/	B-X
ERK2	B-X
and	B-X
STAT5	B-X

Although	O
STAT3	B-protein
also	O
was	O
activated	O
by	O
TPO	B-protein
,	O
STAT3	B-protein
activation	O
remained	O
unaltered	O
by	O
TGF-beta1	B-protein
.	O
<EOS>	B-X
Although	B-X
STAT3	B-X
also	B-X
was	B-X
activated	B-X
by	B-X
TPO	B-X
,	B-X
STAT3	B-X
activation	B-X
remained	B-X
unaltered	B-X
by	B-X
TGF	B-X
-	B-X
beta1	B-X
<EOS>	B-X
Thrombopoietin	B-X
(	B-X
TPO	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
(	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
opposite	B-X
effects	B-X
on	B-X
proliferation	B-X
and	B-X
megakaryocytic	B-X
differentiation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
<EOS>	B-X
TPO	B-X
enhanced	B-X
the	B-X
proliferation	B-X
of	B-X
Mo	B-X
-	B-X
7e	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
3H	B-X
-	B-X
thymidine	B-X
incorporation	B-X
,	B-X
whereas	B-X
TGF	B-X
-	B-X
beta1	B-X
suppressed	B-X
baseline	B-X
cell	B-X
growth	B-X
and	B-X
antagonized	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
TPO	B-X
<EOS>	B-X
This	B-X
effect	B-X
was	B-X
completely	B-X
reversed	B-X
by	B-X
preincubation	B-X
with	B-X
a	B-X
tyrosine	B-X
phosphatase	B-X
inhibitor	B-X
(	B-X
Na3VO4	B-X
)	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
activated	B-X
a	B-X
phosphatase	B-X

CONCLUSION	O
:	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
TGF-beta1	B-protein
modulates	O
TPO	B-protein
-mediated	O
effects	O
on	O
megakaryocytic	O
proliferation	O
by	O
interfering	O
with	O
TPO	B-protein
-induced	O
signal	O
transduction	O
,	O
particularly	O
by	O
reducing	O
the	O
activities	O
of	O
MAPK	B-protein
ERK1/ERK2	I-protein
and	I-protein
STAT5	I-protein
.	O
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
modulates	B-X
TPO	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
megakaryocytic	B-X
proliferation	B-X
by	B-X
interfering	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
,	B-X
particularly	B-X
by	B-X
reducing	B-X
the	B-X
activities	B-X
of	B-X
MAPK	B-X
ERK1	B-X
/	B-X
ERK2	B-X
and	B-X
STAT5	B-X
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
interferes	B-X
with	B-X
thrombopoietin	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
megakaryoblastic	B-X
and	B-X
erythroleukemic	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
TGF	B-X
-	B-X
beta	B-X
(	B-X
1	B-X
)	B-X
interferes	B-X
directly	B-X
with	B-X
TPO	B-X
-	B-X
induced	B-X
signal	B-X
transduction	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
regulatory	B-X
effects	B-X
in	B-X
the	B-X
TPO	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
Mo	B-X
-	B-X
7e	B-X
and	B-X
HEL	B-X
<EOS>	B-X
TPO	B-X
enhanced	B-X
the	B-X
proliferation	B-X
of	B-X
Mo	B-X
-	B-X
7e	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
3H	B-X
-	B-X
thymidine	B-X
incorporation	B-X
,	B-X
whereas	B-X
TGF	B-X
-	B-X
beta1	B-X
suppressed	B-X
baseline	B-X
cell	B-X
growth	B-X
and	B-X
antagonized	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
TPO	B-X

Invariant	B-protein
chain	I-protein
induces	O
B	O
cell	O
maturation	O
by	O
activating	O
a	O
TAF	B-protein
(	I-protein
II	I-protein
)	I-protein
105-NF-kappaB	I-protein
-dependent	O
transcription	O
program	O
.	O
<EOS>	B-X
Invariant	B-X
chain	B-X
induces	B-X
B	B-X
cell	B-X
maturation	B-X
by	B-X
activating	B-X
a	B-X
TAF	B-X
(	B-X
II	B-X
)	B-X
105	B-X
-	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
transcription	B-X
program	B-X
.	B-X
<EOS>	B-X
Our	B-X
studies	B-X
indicate	B-X
that	B-X
Ii	B-X
-	B-X
induced	B-X
B	B-X
cell	B-X
maturation	B-X
involves	B-X
activation	B-X
of	B-X
transcription	B-X
mediated	B-X
by	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
p65	B-X
/	B-X
RelA	B-X
homodimer	B-X
and	B-X
requires	B-X
the	B-X
B	B-X
cell	B-X
-	B-X
enriched	B-X
coactivator	B-X
TBP	B-X
-	B-X
associated	B-X
factor	B-X
(	B-X
II	B-X
)	B-X
105	B-X
<EOS>	B-X
Recently	B-X
,	B-X
invariant	B-X
chain	B-X
(	B-X
Ii	B-X
)	B-X
,	B-X
a	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
chaperone	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
transcription	B-X
factors	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
p65	B-X
/	B-X
RelA	B-X
,	B-X
were	B-X
found	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
final	B-X
antigen	B-X
-	B-X
independent	B-X
differentiation	B-X
stage	B-X
of	B-X
B	B-X
cells	B-X
in	B-X
the	B-X
spleen	B-X
<EOS>	B-X
From	B-X
there	B-X
these	B-X
immature	B-X
cells	B-X
migrate	B-X
to	B-X
the	B-X
spleen	B-X
where	B-X
they	B-X
differentiate	B-X
to	B-X
mature	B-X
cells	B-X

Early	O
stages	O
of	O
B	O
cell	O
development	O
occur	O
in	O
the	O
bone	O
marrow	O
,	O
resulting	O
in	O
formation	O
of	O
immature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Early	B-X
stages	B-X
of	B-X
B	B-X
cell	B-X
development	B-X
occur	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
,	B-X
resulting	B-X
in	B-X
formation	B-X
of	B-X
immature	B-X
B	B-X
cells	B-X
<EOS>	B-X
Mesenchymal	B-X
lineage	B-X
cells	B-X
arise	B-X
from	B-X
pluripotent	B-X
stem	B-X
cells	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
and	B-X
transition	B-X
through	B-X
a	B-X
series	B-X
of	B-X
developmental	B-X
stages	B-X
resulting	B-X
in	B-X
mature	B-X
functional	B-X
cells	B-X
<EOS>	B-X
From	B-X
there	B-X
these	B-X
immature	B-X
cells	B-X
migrate	B-X
to	B-X
the	B-X
spleen	B-X
where	B-X
they	B-X
differentiate	B-X
to	B-X
mature	B-X
cells	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Id2	B-X
expression	B-X
is	B-X
down	B-X
-	B-X
regulated	B-X
during	B-X
differentiation	B-X
of	B-X
immature	B-X
B	B-X
cells	B-X
into	B-X
mature	B-X
B2	B-X
and	B-X
MZ	B-X
B	B-X
cells	B-X

From	O
there	O
these	O
immature	B-cell_type
cells	I-cell_type
migrate	O
to	O
the	O
spleen	O
where	O
they	O
differentiate	O
to	O
mature	B-cell_type
cells	I-cell_type
.	O

This	O
final	O
maturation	O
step	O
is	O
crucial	O
for	O
the	O
B	B-cell_type
cells	I-cell_type
to	O
become	O
responsive	O
to	O
antigens	B-protein
and	O
to	O
participate	O
in	O
the	O
immune	O
response	O
.	O

Recently	O
,	O
invariant	B-protein
chain	I-protein
(	O
Ii	B-protein
)	O
,	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
chaperone	I-protein
,	O
as	O
well	O
as	O
the	O
transcription	B-protein
factors	I-protein
c-Rel	B-protein
and	O
p65/RelA	B-protein
,	O
were	O
found	O
to	O
play	O
a	O
role	O
in	O
the	O
final	O
antigen-independent	O
differentiation	O
stage	O
of	O
B	B-cell_type
cells	I-cell_type
in	O
the	O
spleen	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
possible	O
link	O
between	O
Ii	B-protein
-dependent	O
B	O
cell	O
maturation	O
and	O
the	O
NF-kappaB	O
pathway	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
a	B-X
possible	B-X
link	B-X
between	B-X
Ii	B-X
-	B-X
dependent	B-X
B	B-X
cell	B-X
maturation	B-X
and	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
pathway	B-X
<EOS>	B-X
Our	B-X
studies	B-X
indicate	B-X
that	B-X
Ii	B-X
-	B-X
induced	B-X
B	B-X
cell	B-X
maturation	B-X
involves	B-X
activation	B-X
of	B-X
transcription	B-X
mediated	B-X
by	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
p65	B-X
/	B-X
RelA	B-X
homodimer	B-X
and	B-X
requires	B-X
the	B-X
B	B-X
cell	B-X
-	B-X
enriched	B-X
coactivator	B-X
TBP	B-X
-	B-X
associated	B-X
factor	B-X
(	B-X
II	B-X
)	B-X
105	B-X
<EOS>	B-X
Recently	B-X
,	B-X
invariant	B-X
chain	B-X
(	B-X
Ii	B-X
)	B-X
,	B-X
a	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
chaperone	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
transcription	B-X
factors	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
p65	B-X
/	B-X
RelA	B-X
,	B-X
were	B-X
found	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
final	B-X
antigen	B-X
-	B-X
independent	B-X
differentiation	B-X
stage	B-X
of	B-X
B	B-X
cells	B-X
in	B-X
the	B-X
spleen	B-X
<EOS>	B-X
This	B-X
final	B-X
maturation	B-X
step	B-X
is	B-X
crucial	B-X
for	B-X
the	B-X
B	B-X
cells	B-X
to	B-X
become	B-X
responsive	B-X
to	B-X
antigens	B-X
and	B-X
to	B-X
participate	B-X
in	B-X
the	B-X
immune	B-X
response	B-X

Our	O
studies	O
indicate	O
that	O
Ii	B-protein
-induced	O
B	O
cell	O
maturation	O
involves	O
activation	O
of	O
transcription	O
mediated	O
by	O
the	O
NF-kappaB	B-protein
p65/RelA	I-protein
homodimer	I-protein
and	O
requires	O
the	O
B	B-protein
cell-enriched	I-protein
coactivator	I-protein
TBP-associated	B-protein
factor	I-protein
(	I-protein
II	I-protein
)	I-protein
105	I-protein
.	O

Androgens	O
indirectly	O
accelerate	O
thymocyte	B-cell_type
apoptosis	O
.	O
<EOS>	B-X
Androgens	B-X
indirectly	B-X
accelerate	B-X
thymocyte	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
concluded	B-X
that	B-X
androgens	B-X
indirectly	B-X
accelerate	B-X
thymocyte	B-X
apoptosis	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Using	B-X
the	B-X
very	B-X
sensitive	B-X
TUNEL	B-X
assay	B-X
,	B-X
no	B-X
direct	B-X
effect	B-X
of	B-X
androgens	B-X
on	B-X
thymocytes	B-X
in	B-X
vitro	B-X
could	B-X
be	B-X
observed	B-X
<EOS>	B-X
Several	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
thymocyte	B-X
apoptosis	B-X
in	B-X
vitro	B-X
,	B-X
but	B-X
no	B-X
enhanced	B-X
apoptotic	B-X
signal	B-X
was	B-X
observed	B-X

Apoptotic	O
processes	O
,	O
or	O
the	O
disturbance	O
of	O
the	O
natural	O
regulation	O
of	O
these	O
processes	O
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
diseases	O
(	O
AID	O
)	O
.	O
<EOS>	B-X
Mitochondrial	B-X
impairment	B-X
,	B-X
energetic	B-X
crisis	B-X
and	B-X
elevated	B-X
oxidative	B-X
stress	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
pathological	B-X
processes	B-X
of	B-X
Huntington	B-X
's	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
<EOS>	B-X
Thus	B-X
,	B-X
a	B-X
comprehensive	B-X
analysis	B-X
focusing	B-X
on	B-X
the	B-X
biological	B-X
function	B-X
and	B-X
interaction	B-X
of	B-X
EA	B-X
genes	B-X
would	B-X
provide	B-X
valuable	B-X
information	B-X
for	B-X
understanding	B-X
the	B-X
pathogenesis	B-X
of	B-X
EA	B-X
,	B-X
which	B-X
may	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
gene	B-X
function	B-X
as	B-X
well	B-X
as	B-X
potential	B-X
therapy	B-X
targets	B-X
<EOS>	B-X
The	B-X
research	B-X
trends	B-X
included	B-X
the	B-X
cellular	B-X
players	B-X
of	B-X
the	B-X
efferocytosis	B-X
process	B-X
and	B-X
the	B-X
role	B-X
of	B-X
efferocytosis	B-X
in	B-X
inflammation	B-X
resolution	B-X
<EOS>	B-X
Current	B-X
efferocytosis	B-X
studies	B-X
focus	B-X
on	B-X
three	B-X
main	B-X
aspects	B-X
:	B-X
mechanisms	B-X
,	B-X
basic	B-X
biology	B-X
,	B-X
and	B-X
potential	B-X
role	B-X
in	B-X
disease	B-X

Women	O
are	O
,	O
in	O
general	O
,	O
more	O
susceptible	O
than	O
men	O
to	O
develop	O
AID	O
like	O
rheumatoid	O
arthritis	O
.	O
<EOS>	B-X
Women	B-X
are	B-X
,	B-X
in	B-X
general	B-X
,	B-X
more	B-X
susceptible	B-X
than	B-X
men	B-X
to	B-X
develop	B-X
AID	B-X
like	B-X
rheumatoid	B-X
arthritis	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
upon	B-X
in	B-X
vivo	B-X
androgen	B-X
treatment	B-X
,	B-X
other	B-X
cells	B-X
containing	B-X
androgen	B-X
receptors	B-X
than	B-X
thymocytes	B-X
are	B-X
probably	B-X
involved	B-X
in	B-X
inducing	B-X
the	B-X
increase	B-X
in	B-X
thymic	B-X
apoptosis	B-X
<EOS>	B-X
Androgens	B-X
indirectly	B-X
accelerate	B-X
thymocyte	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
on	B-X
thymocyte	B-X
apoptosis	B-X
,	B-X
androgen	B-X
receptor	B-X
mutant	B-X
(	B-X
Tfm	B-X
/	B-X
Y	B-X
)	B-X
mice	B-X
were	B-X
treated	B-X
with	B-X
androgens	B-X

Androgens	O
and	O
glucocorticoids	O
,	O
in	O
contrast	O
to	O
oestrogens	O
,	O
have	O
favourable	O
effects	O
in	O
AID	O
models	O
as	O
well	O
as	O
in	O
human	O
AID	O
.	O
<EOS>	B-X
Androgens	B-X
and	B-X
glucocorticoids	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
oestrogens	B-X
,	B-X
have	B-X
favourable	B-X
effects	B-X
in	B-X
AID	B-X
models	B-X
as	B-X
well	B-X
as	B-X
in	B-X
human	B-X
AID	B-X
<EOS>	B-X
It	B-X
was	B-X
asked	B-X
whether	B-X
androgens	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
oestrogens	B-X
,	B-X
exert	B-X
their	B-X
favourable	B-X
effects	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
AID	B-X
by	B-X
a	B-X
mechanism	B-X
comparable	B-X
to	B-X
that	B-X
described	B-X
for	B-X
GC	B-X
by	B-X
eliminating	B-X
the	B-X
apoptosis	B-X
prone	B-X
CD4+	B-X
CD8+	B-X
population	B-X
in	B-X
the	B-X
thymus	B-X
<EOS>	B-X
It	B-X
is	B-X
known	B-X
that	B-X
glucocorticoids	B-X
(	B-X
GC	B-X
)	B-X
,	B-X
used	B-X
for	B-X
treatment	B-X
of	B-X
AID	B-X
,	B-X
increase	B-X
apoptosis	B-X
in	B-X
the	B-X
thymus	B-X
resulting	B-X
in	B-X
decreased	B-X
numbers	B-X
of	B-X
CD4+	B-X
CD8+	B-X
thymocytes	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
upon	B-X
in	B-X
vivo	B-X
androgen	B-X
treatment	B-X
,	B-X
other	B-X
cells	B-X
containing	B-X
androgen	B-X
receptors	B-X
than	B-X
thymocytes	B-X
are	B-X
probably	B-X
involved	B-X
in	B-X
inducing	B-X
the	B-X
increase	B-X
in	B-X
thymic	B-X
apoptosis	B-X

It	O
is	O
known	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
,	O
used	O
for	O
treatment	O
of	O
AID	O
,	O
increase	O
apoptosis	O
in	O
the	O
thymus	O
resulting	O
in	O
decreased	O
numbers	O
of	O
CD4+	B-cell_type
CD8+	I-cell_type
thymocytes	I-cell_type
.	O
<EOS>	B-X
It	B-X
is	B-X
known	B-X
that	B-X
glucocorticoids	B-X
(	B-X
GC	B-X
)	B-X
,	B-X
used	B-X
for	B-X
treatment	B-X
of	B-X
AID	B-X
,	B-X
increase	B-X
apoptosis	B-X
in	B-X
the	B-X
thymus	B-X
resulting	B-X
in	B-X
decreased	B-X
numbers	B-X
of	B-X
CD4+	B-X
CD8+	B-X
thymocytes	B-X
<EOS>	B-X
It	B-X
was	B-X
asked	B-X
whether	B-X
androgens	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
oestrogens	B-X
,	B-X
exert	B-X
their	B-X
favourable	B-X
effects	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
AID	B-X
by	B-X
a	B-X
mechanism	B-X
comparable	B-X
to	B-X
that	B-X
described	B-X
for	B-X
GC	B-X
by	B-X
eliminating	B-X
the	B-X
apoptosis	B-X
prone	B-X
CD4+	B-X
CD8+	B-X
population	B-X
in	B-X
the	B-X
thymus	B-X
<EOS>	B-X
Androgens	B-X
and	B-X
glucocorticoids	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
oestrogens	B-X
,	B-X
have	B-X
favourable	B-X
effects	B-X
in	B-X
AID	B-X
models	B-X
as	B-X
well	B-X
as	B-X
in	B-X
human	B-X
AID	B-X
<EOS>	B-X
Several	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
thymocyte	B-X
apoptosis	B-X
in	B-X
vitro	B-X
,	B-X
but	B-X
no	B-X
enhanced	B-X
apoptotic	B-X
signal	B-X
was	B-X
observed	B-X

It	O
was	O
asked	O
whether	O
androgens	O
,	O
in	O
contrast	O
to	O
oestrogens	O
,	O
exert	O
their	O
favourable	O
effects	O
in	O
the	O
treatment	O
of	O
AID	O
by	O
a	O
mechanism	O
comparable	O
to	O
that	O
described	O
for	O
GC	O
by	O
eliminating	O
the	O
apoptosis	O
prone	O
CD4+	B-cell_type
CD8+	I-cell_type
population	I-cell_type
in	O
the	O
thymus	O
.	O
<EOS>	B-X
It	B-X
was	B-X
asked	B-X
whether	B-X
androgens	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
oestrogens	B-X
,	B-X
exert	B-X
their	B-X
favourable	B-X
effects	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
AID	B-X
by	B-X
a	B-X
mechanism	B-X
comparable	B-X
to	B-X
that	B-X
described	B-X
for	B-X
GC	B-X
by	B-X
eliminating	B-X
the	B-X
apoptosis	B-X
prone	B-X
CD4+	B-X
CD8+	B-X
population	B-X
in	B-X
the	B-X
thymus	B-X
<EOS>	B-X
Androgens	B-X
and	B-X
glucocorticoids	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
oestrogens	B-X
,	B-X
have	B-X
favourable	B-X
effects	B-X
in	B-X
AID	B-X
models	B-X
as	B-X
well	B-X
as	B-X
in	B-X
human	B-X
AID	B-X
<EOS>	B-X
It	B-X
is	B-X
known	B-X
that	B-X
glucocorticoids	B-X
(	B-X
GC	B-X
)	B-X
,	B-X
used	B-X
for	B-X
treatment	B-X
of	B-X
AID	B-X
,	B-X
increase	B-X
apoptosis	B-X
in	B-X
the	B-X
thymus	B-X
resulting	B-X
in	B-X
decreased	B-X
numbers	B-X
of	B-X
CD4+	B-X
CD8+	B-X
thymocytes	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
upon	B-X
in	B-X
vivo	B-X
androgen	B-X
treatment	B-X
,	B-X
other	B-X
cells	B-X
containing	B-X
androgen	B-X
receptors	B-X
than	B-X
thymocytes	B-X
are	B-X
probably	B-X
involved	B-X
in	B-X
inducing	B-X
the	B-X
increase	B-X
in	B-X
thymic	B-X
apoptosis	B-X

Although	O
both	O
androgens	O
and	O
oestrogens	O
proved	O
thymolytic	O
,	O
a	O
significantly	O
decreased	O
percentage	O
of	O
CD4+	B-cell_type
CD8+	I-cell_type
thymocytes	I-cell_type
was	O
observed	O
by	O
flow	O
cytometry	O
after	O
treatment	O
of	O
mice	O
with	O
the	O
androgen	O
methyltestosterone	O
,	O
but	O
not	O
with	O
the	O
oestrogen	O
ethinylestradiol	O
.	O

To	O
investigate	O
whether	O
the	O
observed	O
thymolytic	O
effects	O
were	O
due	O
to	O
the	O
presence	O
of	O
hormone	B-protein
receptors	I-protein
on	O
thymocytes	B-cell_type
,	O
cells	O
were	O
isolated	O
from	O
the	O
thymus	O
and	O
incubated	O
with	O
androgens	O
or	O
oestrogens	O
to	O
measure	O
apoptosis	O
.	O
<EOS>	B-X
Shortened	B-X
AGD	B-X
,	B-X
as	B-X
related	B-X
to	B-X
previous	B-X
exposure	B-X
to	B-X
endocrine	B-X
disruptors	B-X
,	B-X
and	B-X
male	B-X
infertility	B-X
are	B-X
accompanied	B-X
by	B-X
increased	B-X
presence	B-X
of	B-X
hormonal	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
differentially	B-X
methylated	B-X
regulatory	B-X
sequences	B-X
of	B-X
the	B-X
genome	B-X
of	B-X
sperm	B-X
fractions	B-X
characterized	B-X
by	B-X
chromatin	B-X
decondensation	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
present	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
existence	B-X
of	B-X
LPS	B-X
in	B-X
developing	B-X
follicles	B-X
is	B-X
one	B-X
of	B-X
the	B-X
causes	B-X
of	B-X
ovarian	B-X
quiescence	B-X
in	B-X
cows	B-X
<EOS>	B-X
The	B-X
underlying	B-X
hypothesis	B-X
is	B-X
that	B-X
bisphenols	B-X
disrupt	B-X
the	B-X
granulosa	B-X
cell	B-X
environment	B-X
surrounding	B-X
the	B-X
oocyte	B-X
inducing	B-X
excessive	B-X
apoptosis	B-X
<EOS>	B-X
Adding	B-X
letrozole	B-X
to	B-X
testosterone	B-X
resulted	B-X
in	B-X
decreased	B-X
cellular	B-X
proliferation	B-X
and	B-X
even	B-X
induced	B-X
apoptosis	B-X

Several	O
techniques	O
were	O
used	O
to	O
determine	O
thymocyte	B-cell_type
apoptosis	O
in	O
vitro	O
,	O
but	O
no	O
enhanced	O
apoptotic	O
signal	O
was	O
observed	O
.	O
<EOS>	B-X
Several	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
thymocyte	B-X
apoptosis	B-X
in	B-X
vitro	B-X
,	B-X
but	B-X
no	B-X
enhanced	B-X
apoptotic	B-X
signal	B-X
was	B-X
observed	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
on	B-X
thymocyte	B-X
apoptosis	B-X
,	B-X
androgen	B-X
receptor	B-X
mutant	B-X
(	B-X
Tfm	B-X
/	B-X
Y	B-X
)	B-X
mice	B-X
were	B-X
treated	B-X
with	B-X
androgens	B-X
<EOS>	B-X
It	B-X
is	B-X
known	B-X
that	B-X
glucocorticoids	B-X
(	B-X
GC	B-X
)	B-X
,	B-X
used	B-X
for	B-X
treatment	B-X
of	B-X
AID	B-X
,	B-X
increase	B-X
apoptosis	B-X
in	B-X
the	B-X
thymus	B-X
resulting	B-X
in	B-X
decreased	B-X
numbers	B-X
of	B-X
CD4+	B-X
CD8+	B-X
thymocytes	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
the	B-X
observed	B-X
thymolytic	B-X
effects	B-X
were	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
hormone	B-X
receptors	B-X
on	B-X
thymocytes	B-X
,	B-X
cells	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
thymus	B-X
and	B-X
incubated	B-X
with	B-X
androgens	B-X
or	B-X
oestrogens	B-X
to	B-X
measure	B-X
apoptosis	B-X

Using	O
the	O
very	O
sensitive	O
TUNEL	O
assay	O
,	O
no	O
direct	O
effect	O
of	O
androgens	O
on	O
thymocytes	B-cell_type
in	O
vitro	O
could	O
be	O
observed	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
very	B-X
sensitive	B-X
TUNEL	B-X
assay	B-X
,	B-X
no	B-X
direct	B-X
effect	B-X
of	B-X
androgens	B-X
on	B-X
thymocytes	B-X
in	B-X
vitro	B-X
could	B-X
be	B-X
observed	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
the	B-X
observed	B-X
thymolytic	B-X
effects	B-X
were	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
hormone	B-X
receptors	B-X
on	B-X
thymocytes	B-X
,	B-X
cells	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
thymus	B-X
and	B-X
incubated	B-X
with	B-X
androgens	B-X
or	B-X
oestrogens	B-X
to	B-X
measure	B-X
apoptosis	B-X
<EOS>	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
concluded	B-X
that	B-X
androgens	B-X
indirectly	B-X
accelerate	B-X
thymocyte	B-X
apoptosis	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
upon	B-X
in	B-X
vivo	B-X
androgen	B-X
treatment	B-X
,	B-X
other	B-X
cells	B-X
containing	B-X
androgen	B-X
receptors	B-X
than	B-X
thymocytes	B-X
are	B-X
probably	B-X
involved	B-X
in	B-X
inducing	B-X
the	B-X
increase	B-X
in	B-X
thymic	B-X
apoptosis	B-X

This	O
is	O
in	O
sharp	O
contrast	O
to	O
the	O
high	O
signal	O
observed	O
with	O
GC	O
.	O

Therefore	O
,	O
upon	O
in	O
vivo	O
androgen	O
treatment	O
,	O
other	O
cells	O
containing	O
androgen	B-protein
receptors	I-protein
than	O
thymocytes	B-cell_type
are	O
probably	O
involved	O
in	O
inducing	O
the	O
increase	O
in	O
thymic	O
apoptosis	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
upon	B-X
in	B-X
vivo	B-X
androgen	B-X
treatment	B-X
,	B-X
other	B-X
cells	B-X
containing	B-X
androgen	B-X
receptors	B-X
than	B-X
thymocytes	B-X
are	B-X
probably	B-X
involved	B-X
in	B-X
inducing	B-X
the	B-X
increase	B-X
in	B-X
thymic	B-X
apoptosis	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
on	B-X
thymocyte	B-X
apoptosis	B-X
,	B-X
androgen	B-X
receptor	B-X
mutant	B-X
(	B-X
Tfm	B-X
/	B-X
Y	B-X
)	B-X
mice	B-X
were	B-X
treated	B-X
with	B-X
androgens	B-X
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
the	B-X
observed	B-X
thymolytic	B-X
effects	B-X
were	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
hormone	B-X
receptors	B-X
on	B-X
thymocytes	B-X
,	B-X
cells	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
thymus	B-X
and	B-X
incubated	B-X
with	B-X
androgens	B-X
or	B-X
oestrogens	B-X
to	B-X
measure	B-X
apoptosis	B-X
<EOS>	B-X
No	B-X
alterations	B-X
of	B-X
thymocyte	B-X
subpopulations	B-X
were	B-X
seen	B-X
,	B-X
suggesting	B-X
that	B-X
changes	B-X
in	B-X
the	B-X
percentage	B-X
of	B-X
CD4+	B-X
CD8+	B-X
thymocytes	B-X
after	B-X
administration	B-X
of	B-X
androgens	B-X
depend	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
functional	B-X
androgen	B-X
receptors	B-X

To	O
study	O
the	O
role	O
of	O
the	O
androgen	B-protein
receptor	I-protein
on	O
thymocyte	B-cell_type
apoptosis	O
,	O
androgen	B-protein
receptor	I-protein
mutant	O
(	O
Tfm/Y	O
)	O
mice	O
were	O
treated	O
with	O
androgens	O
.	O

No	O
alterations	O
of	O
thymocyte	B-cell_type
subpopulations	I-cell_type
were	O
seen	O
,	O
suggesting	O
that	O
changes	O
in	O
the	O
percentage	O
of	O
CD4+	B-cell_type
CD8+	I-cell_type
thymocytes	I-cell_type
after	O
administration	O
of	O
androgens	O
depend	O
on	O
the	O
presence	O
of	O
functional	O
androgen	B-protein
receptors	I-protein
.	O
<EOS>	B-X
No	B-X
alterations	B-X
of	B-X
thymocyte	B-X
subpopulations	B-X
were	B-X
seen	B-X
,	B-X
suggesting	B-X
that	B-X
changes	B-X
in	B-X
the	B-X
percentage	B-X
of	B-X
CD4+	B-X
CD8+	B-X
thymocytes	B-X
after	B-X
administration	B-X
of	B-X
androgens	B-X
depend	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
functional	B-X
androgen	B-X
receptors	B-X
<EOS>	B-X
Although	B-X
both	B-X
androgens	B-X
and	B-X
oestrogens	B-X
proved	B-X
thymolytic	B-X
,	B-X
a	B-X
significantly	B-X
decreased	B-X
percentage	B-X
of	B-X
CD4+	B-X
CD8+	B-X
thymocytes	B-X
was	B-X
observed	B-X
by	B-X
flow	B-X
cytometry	B-X
after	B-X
treatment	B-X
of	B-X
mice	B-X
with	B-X
the	B-X
androgen	B-X
methyltestosterone	B-X
,	B-X
but	B-X
not	B-X
with	B-X
the	B-X
oestrogen	B-X
ethinylestradiol	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
upon	B-X
in	B-X
vivo	B-X
androgen	B-X
treatment	B-X
,	B-X
other	B-X
cells	B-X
containing	B-X
androgen	B-X
receptors	B-X
than	B-X
thymocytes	B-X
are	B-X
probably	B-X
involved	B-X
in	B-X
inducing	B-X
the	B-X
increase	B-X
in	B-X
thymic	B-X
apoptosis	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
on	B-X
thymocyte	B-X
apoptosis	B-X
,	B-X
androgen	B-X
receptor	B-X
mutant	B-X
(	B-X
Tfm	B-X
/	B-X
Y	B-X
)	B-X
mice	B-X
were	B-X
treated	B-X
with	B-X
androgens	B-X

Thus	O
,	O
it	O
is	O
concluded	O
that	O
androgens	O
indirectly	O
accelerate	O
thymocyte	B-cell_type
apoptosis	O
in	O
vivo	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
concluded	B-X
that	B-X
androgens	B-X
indirectly	B-X
accelerate	B-X
thymocyte	B-X
apoptosis	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Androgens	B-X
indirectly	B-X
accelerate	B-X
thymocyte	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
upon	B-X
in	B-X
vivo	B-X
androgen	B-X
treatment	B-X
,	B-X
other	B-X
cells	B-X
containing	B-X
androgen	B-X
receptors	B-X
than	B-X
thymocytes	B-X
are	B-X
probably	B-X
involved	B-X
in	B-X
inducing	B-X
the	B-X
increase	B-X
in	B-X
thymic	B-X
apoptosis	B-X
<EOS>	B-X
Using	B-X
the	B-X
very	B-X
sensitive	B-X
TUNEL	B-X
assay	B-X
,	B-X
no	B-X
direct	B-X
effect	B-X
of	B-X
androgens	B-X
on	B-X
thymocytes	B-X
in	B-X
vitro	B-X
could	B-X
be	B-X
observed	B-X

Inhibition	O
of	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
NF-kappaB	B-protein
in	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
ligands	I-protein
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
by	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
ligands	B-X
.	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
both	B-X
the	B-X
proliferative	B-X
response	B-X
and	B-X
inflammatory	B-X
cytokine	B-X
expression	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
was	B-X
correlated	B-X
with	B-X
suppression	B-X
of	B-X
the	B-X
activated	B-X
transcription	B-X
factors	B-X
AP1	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
the	B-X
PPARgamma	B-X
ligand	B-X
ciglitizone	B-X
to	B-X
attenuate	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
inhibiting	B-X
cytokine	B-X
gene	B-X
expression	B-X
and	B-X
anti	B-X
-	B-X
CD3	B-X
and	B-X
anti	B-X
-	B-X
CD28	B-X
or	B-X
PMA	B-X
-	B-X
induced	B-X
proliferative	B-X
responses	B-X
<EOS>	B-X
These	B-X
results	B-X
,	B-X
together	B-X
with	B-X
previous	B-X
findings	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
PPARgamma	B-X
ligands	B-X
on	B-X
activated	B-X
macrophages	B-X
,	B-X
provide	B-X
clear	B-X
evidence	B-X
for	B-X
PPARgamma	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
inflammatory	B-X
activation	B-X
of	B-X
both	B-X
macrophage	B-X
and	B-X
T	B-X
cells	B-X

The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
,	O
is	O
essential	O
for	O
adipocyte	O
differentiation	O
and	O
glucose	O
homeostasis	O
.	O
<EOS>	B-X
The	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
(	B-X
PPARgamma	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
nuclear	B-X
hormone	B-X
receptor	B-X
superfamily	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
adipocyte	B-X
differentiation	B-X
and	B-X
glucose	B-X
homeostasis	B-X
<EOS>	B-X
TDs	B-X
bind	B-X
to	B-X
peroxisome	B-X
proliferator	B-X
activating	B-X
receptors	B-X
gamma	B-X
(	B-X
PPAR	B-X
gamma	B-X
)	B-X
,	B-X
members	B-X
of	B-X
the	B-X
steroid	B-X
/	B-X
thyroid	B-X
hormone	B-X
nuclear	B-X
receptor	B-X
superfamily	B-X
of	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
adipocyte	B-X
differentiation	B-X
and	B-X
glucose	B-X
and	B-X
lipid	B-X
homeostasis	B-X
<EOS>	B-X
These	B-X
results	B-X
,	B-X
together	B-X
with	B-X
previous	B-X
findings	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
PPARgamma	B-X
ligands	B-X
on	B-X
activated	B-X
macrophages	B-X
,	B-X
provide	B-X
clear	B-X
evidence	B-X
for	B-X
PPARgamma	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
inflammatory	B-X
activation	B-X
of	B-X
both	B-X
macrophage	B-X
and	B-X
T	B-X
cells	B-X
<EOS>	B-X
These	B-X
processes	B-X
are	B-X
considered	B-X
to	B-X
be	B-X
crucial	B-X
in	B-X
the	B-X
development	B-X
of	B-X
vascular	B-X
remodelling	B-X
,	B-X
atherosclerosis	B-X
and	B-X
diabetic	B-X
organ	B-X
complications	B-X

PPARgamma	B-protein
has	O
been	O
found	O
recently	O
to	O
regulate	O
macrophage	O
activation	O
in	O
response	O
to	O
mitogens	B-protein
and	O
inflammation	O
.	O
<EOS>	B-X
PPARgamma	B-X
has	B-X
been	B-X
found	B-X
recently	B-X
to	B-X
regulate	B-X
macrophage	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
mitogens	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
PPARgamma	B-X
may	B-X
thus	B-X
be	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
autoimmunity	B-X
<EOS>	B-X
Our	B-X
study	B-X
shows	B-X
PPARgamma	B-X
to	B-X
be	B-X
preferentially	B-X
expressed	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
and	B-X
to	B-X
increase	B-X
upon	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
either	B-X
anti	B-X
-	B-X
CD3	B-X
and	B-X
anti	B-X
-	B-X
CD28	B-X
or	B-X
phorbol	B-X
myristyl	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
<EOS>	B-X
PPARgamma	B-X
ligands	B-X
also	B-X
strongly	B-X
inhibited	B-X
SEA	B-X
-	B-X
induced	B-X
Vbeta3	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
vivo	B-X

Our	O
study	O
shows	O
PPARgamma	B-protein
to	O
be	O
preferentially	O
expressed	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
to	O
increase	O
upon	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
either	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
or	O
phorbol	O
myristyl	O
acetate	O
(	O
PMA	O
)	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
blood	B-X
cells	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
and	B-X
P	B-X
-	B-X
selectin	B-X
in	B-X
platelets	B-X
and	B-X
microparticles	B-X
from	B-X
blood	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
with	B-X
or	B-X
without	B-X
the	B-X
further	B-X
addition	B-X
of	B-X
phorbol	B-X
myristyl	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
<EOS>	B-X
Eugenosedin	B-X
-	B-X
A	B-X
reversed	B-X
the	B-X
inhibition	B-X
of	B-X
BK	B-X
(	B-X
Ca	B-X
)	B-X
current	B-X
induced	B-X
by	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
activator	B-X
,	B-X
phorbol	B-X
myristyl	B-X
acetate	B-X
(	B-X
PMA	B-X
,	B-X
0	B-X
<EOS>	B-X
This	B-X
is	B-X
the	B-X
first	B-X
study	B-X
to	B-X
demonstrate	B-X
that	B-X
the	B-X
interaction	B-X
between	B-X
beta	B-X
-	B-X
adrenoceptor	B-X
activation	B-X
,	B-X
and	B-X
the	B-X
production	B-X
of	B-X
inflammatory	B-X
mediators	B-X
can	B-X
be	B-X
modulated	B-X
in	B-X
opposite	B-X
ways	B-X
by	B-X
two	B-X
inflammatory	B-X
stimuli	B-X
,	B-X
namely	B-X
,	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
	B-X
-	B-X
activating	B-X
phorbol	B-X
myristyl	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
<EOS>	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
from	B-X
women	B-X
at	B-X
28	B-X
weeks	B-X
,	B-X
term	B-X
pre	B-X
-	B-X
labour	B-X
,	B-X
term	B-X
labour	B-X
as	B-X
well	B-X
as	B-X
non	B-X
-	B-X
pregnant	B-X
female	B-X
controls	B-X
were	B-X
cultured	B-X
with	B-X
15dPGJ	B-X
(	B-X
2	B-X
)	B-X
or	B-X
vehicle	B-X
control	B-X
and	B-X
stimulated	B-X
with	B-X
phorbol	B-X
myristyl	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
	B-X
/	B-X
ionomycin	B-X

We	O
also	O
found	O
the	O
PPARgamma	B-protein
ligand	I-protein
ciglitizone	O
to	O
attenuate	O
the	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
inhibiting	O
cytokine	O
gene	O
expression	O
and	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
or	O
PMA-induced	O
proliferative	O
responses	O
.	O
<EOS>	B-X
We	B-X
also	B-X
found	B-X
the	B-X
PPARgamma	B-X
ligand	B-X
ciglitizone	B-X
to	B-X
attenuate	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
inhibiting	B-X
cytokine	B-X
gene	B-X
expression	B-X
and	B-X
anti	B-X
-	B-X
CD3	B-X
and	B-X
anti	B-X
-	B-X
CD28	B-X
or	B-X
PMA	B-X
-	B-X
induced	B-X
proliferative	B-X
responses	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
inhibiting	B-X
CD28	B-X
expression	B-X
on	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
T	B-X
cell	B-X
responses	B-X
<EOS>	B-X
Blocking	B-X
CD28	B-X
ligation	B-X
can	B-X
inhibit	B-X
cytokine	B-X
expression	B-X
and	B-X
elicits	B-X
a	B-X
state	B-X
of	B-X
T	B-X
cell	B-X
hyporesponsiveness	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
rosiglitazone	B-X
quenches	B-X
inflammation	B-X
in	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
by	B-X
counteracting	B-X
PMA	B-X
-	B-X
induced	B-X
phosphorylation	B-X
of	B-X
ERK1	B-X
/	B-X
2	B-X

Inhibition	O
of	O
both	O
the	O
proliferative	O
response	O
and	O
inflammatory	O
cytokine	O
expression	O
in	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
correlated	O
with	O
suppression	O
of	O
the	O
activated	O
transcription	B-protein
factors	I-protein
AP1	B-protein
and	O
NF-kappaB	B-protein
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
both	B-X
the	B-X
proliferative	B-X
response	B-X
and	B-X
inflammatory	B-X
cytokine	B-X
expression	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
was	B-X
correlated	B-X
with	B-X
suppression	B-X
of	B-X
the	B-X
activated	B-X
transcription	B-X
factors	B-X
AP1	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
by	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
ligands	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
,	B-X
together	B-X
with	B-X
previous	B-X
findings	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
PPARgamma	B-X
ligands	B-X
on	B-X
activated	B-X
macrophages	B-X
,	B-X
provide	B-X
clear	B-X
evidence	B-X
for	B-X
PPARgamma	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
inflammatory	B-X
activation	B-X
of	B-X
both	B-X
macrophage	B-X
and	B-X
T	B-X
cells	B-X
<EOS>	B-X
PPARgamma	B-X
has	B-X
been	B-X
found	B-X
recently	B-X
to	B-X
regulate	B-X
macrophage	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
mitogens	B-X
and	B-X
inflammation	B-X

PPARgamma	B-protein
ligands	I-protein
also	O
strongly	O
inhibited	O
SEA-induced	O
Vbeta3	O
T	O
cell	O
activation	O
in	O
vivo	O
.	O
<EOS>	B-X
PPARgamma	B-X
ligands	B-X
also	B-X
strongly	B-X
inhibited	B-X
SEA	B-X
-	B-X
induced	B-X
Vbeta3	B-X
T	B-X
cell	B-X
activation	B-X
in	B-X
vivo	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
the	B-X
PPARgamma	B-X
ligand	B-X
ciglitizone	B-X
to	B-X
attenuate	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
inhibiting	B-X
cytokine	B-X
gene	B-X
expression	B-X
and	B-X
anti	B-X
-	B-X
CD3	B-X
and	B-X
anti	B-X
-	B-X
CD28	B-X
or	B-X
PMA	B-X
-	B-X
induced	B-X
proliferative	B-X
responses	B-X
<EOS>	B-X
PPARgamma	B-X
has	B-X
been	B-X
found	B-X
recently	B-X
to	B-X
regulate	B-X
macrophage	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
mitogens	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
PPARgamma	B-X
may	B-X
thus	B-X
be	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
autoimmunity	B-X

These	O
results	O
,	O
together	O
with	O
previous	O
findings	O
of	O
the	O
inhibitory	O
effect	O
of	O
PPARgamma	B-protein
ligands	I-protein
on	O
activated	B-cell_type
macrophages	I-cell_type
,	O
provide	O
clear	O
evidence	O
for	O
PPARgamma	B-protein
as	O
a	O
negative	B-protein
regulator	I-protein
of	O
the	O
inflammatory	O
activation	O
of	O
both	O
macrophage	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

PPARgamma	B-protein
may	O
thus	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmunity	O
.	O
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
new	B-X
compound	B-X
which	B-X
displays	B-X
a	B-X
potential	B-X
therapeutic	B-X
benefit	B-X
for	B-X
treatment	B-X
of	B-X
MS	B-X
by	B-X
targeting	B-X
E	B-X
-	B-X
FABP	B-X
<EOS>	B-X
Virgin	B-X
olive	B-X
oil	B-X
and	B-X
its	B-X
phenol	B-X
fraction	B-X
modulate	B-X
monocyte	B-X
/	B-X
macrophage	B-X
functionality	B-X
:	B-X
a	B-X
potential	B-X
therapeutic	B-X
strategy	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
.	B-X
<EOS>	B-X
This	B-X
study	B-X
highlights	B-X
the	B-X
therapeutic	B-X
potential	B-X
of	B-X
VCE	B-X
-	B-X
003	B-X
as	B-X
an	B-X
agent	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
human	B-X
immune	B-X
diseases	B-X
with	B-X
both	B-X
inflammatory	B-X
and	B-X
autoimmune	B-X
components	B-X
<EOS>	B-X
Proposed	B-X
as	B-X
immunomodulatory	B-X
and	B-X
neuroprotective	B-X
,	B-X
the	B-X
therapeutic	B-X
use	B-X
of	B-X
PGC	B-X
-	B-X
1α	B-X
activation	B-X
needs	B-X
to	B-X
be	B-X
assessed	B-X
in	B-X
EAE	B-X
/	B-X
MS	B-X

A	O
prominent	O
role	O
for	O
activator	B-protein
protein-1	I-protein
in	O
the	O
transcription	O
of	O
the	O
human	B-DNA
2B4	I-DNA
(	I-DNA
CD244	I-DNA
)	I-DNA
gene	I-DNA
in	O
NK	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
A	B-X
prominent	B-X
role	B-X
for	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
2B4	B-X
(	B-X
CD244	B-X
)	B-X
gene	B-X
in	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
Through	B-X
primer	B-X
extension	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
initiates	B-X
at	B-X
multiple	B-X
start	B-X
sites	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
report	B-X
the	B-X
molecular	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
the	B-X
human	B-X
2B4	B-X
(	B-X
h2B4	B-X
)	B-X
promoter	B-X
<EOS>	B-X
EMSAs	B-X
with	B-X
Abs	B-X
specific	B-X
for	B-X
various	B-X
protein	B-X
factors	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
family	B-X
revealed	B-X
that	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
Jun	B-X
family	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X

The	O
cell	B-protein
surface	I-protein
glycoprotein	I-protein
2B4	I-protein
(	O
CD244	B-protein
)	O
of	O
the	O
Ig	B-protein
superfamily	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
NK	B-cell_type
and	O
T	B-cell_type
lymphocyte	I-cell_type
functions	O
.	O

We	O
have	O
recently	O
identified	O
CD48	B-protein
as	O
the	O
high	B-protein
affinity	I-protein
counterreceptor	I-protein
for	O
2B4	B-protein
in	O
both	O
mice	O
and	O
humans	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
identified	B-X
CD48	B-X
as	B-X
the	B-X
high	B-X
affinity	B-X
counterreceptor	B-X
for	B-X
2B4	B-X
in	B-X
both	B-X
mice	B-X
and	B-X
humans	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
functional	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
that	B-X
lies	B-X
between	B-X
(	B-X
	B-X
-	B-X
106	B-X
to	B-X
	B-X
-	B-X
100	B-X
)	B-X
through	B-X
transient	B-X
transfection	B-X
analysis	B-X
in	B-X
YT	B-X
cells	B-X
,	B-X
a	B-X
human	B-X
NK	B-X
cell	B-X
line	B-X
<EOS>	B-X
The	B-X
cell	B-X
surface	B-X
glycoprotein	B-X
2B4	B-X
(	B-X
CD244	B-X
)	B-X
of	B-X
the	B-X
Ig	B-X
superfamily	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NK	B-X
and	B-X
T	B-X
lymphocyte	B-X
functions	B-X
<EOS>	B-X
We	B-X
isolated	B-X
h2B4	B-X
genomic	B-X
clones	B-X
and	B-X
PCR	B-X
amplified	B-X
the	B-X
5	B-X
'	B-X
untranslated	B-X
region	B-X
containing	B-X
the	B-X
promoter	B-X
elements	B-X

The	O
cytoplasmic	B-protein
domain	I-protein
of	O
2B4	B-protein
associates	O
with	O
src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
protein	I-protein
or	O
signaling	B-protein
lymphocyte	I-protein
activation	I-protein
molecule-associated	I-protein
protein	I-protein
,	O
whose	O
mutation	O
is	O
the	O
underlying	O
genetic	O
defect	O
in	O
the	O
X-linked	O
lymphoproliferative	O
syndrome	O
.	O
<EOS>	B-X
The	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
2B4	B-X
associates	B-X
with	B-X
src	B-X
homology	B-X
2	B-X
domain	B-X
-	B-X
containing	B-X
protein	B-X
or	B-X
signaling	B-X
lymphocyte	B-X
activation	B-X
molecule	B-X
-	B-X
associated	B-X
protein	B-X
,	B-X
whose	B-X
mutation	B-X
is	B-X
the	B-X
underlying	B-X
genetic	B-X
defect	B-X
in	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
lymphoproliferative	B-X
syndrome	B-X
<EOS>	B-X
The	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
2B4	B-X
contains	B-X
unique	B-X
tyrosine	B-X
motifs	B-X
(	B-X
TxYxxV	B-X
/	B-X
I	B-X
)	B-X
that	B-X
associate	B-X
with	B-X
src	B-X
homology	B-X
2	B-X
domain	B-X
-	B-X
containing	B-X
protein	B-X
or	B-X
signaling	B-X
lymphocyte	B-X
activation	B-X
molecule	B-X
(	B-X
SLAM	B-X
)	B-X
	B-X
-	B-X
associated	B-X
protein	B-X
,	B-X
whose	B-X
mutation	B-X
is	B-X
the	B-X
underlying	B-X
genetic	B-X
defect	B-X
in	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
lymphoproliferative	B-X
disease	B-X
(	B-X
XLPD	B-X
)	B-X
<EOS>	B-X
The	B-X
gene	B-X
mutated	B-X
in	B-X
XLP	B-X
encodes	B-X
SLAM	B-X
(	B-X
signaling	B-X
lymphocytic	B-X
activation	B-X
molecule	B-X
-	B-X
associated	B-X
protein	B-X
)	B-X
	B-X
-	B-X
associated	B-X
protein	B-X
(	B-X
SAP	B-X
)	B-X
,	B-X
a	B-X
small	B-X
SH2	B-X
domain	B-X
-	B-X
containing	B-X
protein	B-X
<EOS>	B-X
Functional	B-X
requirement	B-X
for	B-X
SAP	B-X
in	B-X
2B4	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
human	B-X
natural	B-X
killer	B-X
cells	B-X
as	B-X
revealed	B-X
by	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
lymphoproliferative	B-X
syndrome	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
the	O
human	B-DNA
2B4	I-DNA
(	I-DNA
h2B4	I-DNA
)	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
report	B-X
the	B-X
molecular	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
the	B-X
human	B-X
2B4	B-X
(	B-X
h2B4	B-X
)	B-X
promoter	B-X
<EOS>	B-X
A	B-X
prominent	B-X
role	B-X
for	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
2B4	B-X
(	B-X
CD244	B-X
)	B-X
gene	B-X
in	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
EMSAs	B-X
with	B-X
Abs	B-X
specific	B-X
for	B-X
various	B-X
protein	B-X
factors	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
family	B-X
revealed	B-X
that	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
Jun	B-X
family	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
<EOS>	B-X
Through	B-X
primer	B-X
extension	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
initiates	B-X
at	B-X
multiple	B-X
start	B-X
sites	B-X

Through	O
primer	O
extension	O
analysis	O
,	O
we	O
found	O
that	O
the	O
transcription	O
of	O
the	O
h2B4	B-DNA
gene	I-DNA
initiates	O
at	O
multiple	O
start	O
sites	O
.	O
<EOS>	B-X
Through	B-X
primer	B-X
extension	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
initiates	B-X
at	B-X
multiple	B-X
start	B-X
sites	B-X
<EOS>	B-X
A	B-X
prominent	B-X
role	B-X
for	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
2B4	B-X
(	B-X
CD244	B-X
)	B-X
gene	B-X
in	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
significant	B-X
role	B-X
for	B-X
AP	B-X
-	B-X
1	B-X
in	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
report	B-X
the	B-X
molecular	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
the	B-X
human	B-X
2B4	B-X
(	B-X
h2B4	B-X
)	B-X
promoter	B-X

We	O
isolated	O
h2B4	B-DNA
genomic	I-DNA
clones	I-DNA
and	O
PCR	O
amplified	O
the	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
containing	O
the	O
promoter	B-DNA
elements	I-DNA
.	O
<EOS>	B-X
We	B-X
isolated	B-X
h2B4	B-X
genomic	B-X
clones	B-X
and	B-X
PCR	B-X
amplified	B-X
the	B-X
5	B-X
'	B-X
untranslated	B-X
region	B-X
containing	B-X
the	B-X
promoter	B-X
elements	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
not	B-X
only	B-X
abolishes	B-X
protein	B-X
/	B-X
DNA	B-X
interactions	B-X
but	B-X
also	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
identified	B-X
CD48	B-X
as	B-X
the	B-X
high	B-X
affinity	B-X
counterreceptor	B-X
for	B-X
2B4	B-X
in	B-X
both	B-X
mice	B-X
and	B-X
humans	B-X
<EOS>	B-X
The	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
2B4	B-X
associates	B-X
with	B-X
src	B-X
homology	B-X
2	B-X
domain	B-X
-	B-X
containing	B-X
protein	B-X
or	B-X
signaling	B-X
lymphocyte	B-X
activation	B-X
molecule	B-X
-	B-X
associated	B-X
protein	B-X
,	B-X
whose	B-X
mutation	B-X
is	B-X
the	B-X
underlying	B-X
genetic	B-X
defect	B-X
in	B-X
the	B-X
X	B-X
-	B-X
linked	B-X
lymphoproliferative	B-X
syndrome	B-X

We	O
have	O
identified	O
a	O
functional	O
AP-1	B-DNA
site	I-DNA
that	O
lies	O
between	O
(	O
-106	O
to	O
-100	O
)	O
through	O
transient	O
transfection	O
analysis	O
in	O
YT	B-cell_line
cells	I-cell_line
,	O
a	O
human	B-cell_line
NK	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

EMSAs	O
with	O
Abs	B-protein
specific	O
for	O
various	O
protein	B-protein
factors	I-protein
of	O
the	O
AP-1	B-protein
family	I-protein
revealed	O
that	O
multiple	O
members	O
of	O
the	O
Jun	B-protein
family	I-protein
are	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
h2B4	B-DNA
gene	I-DNA
.	O
<EOS>	B-X
EMSAs	B-X
with	B-X
Abs	B-X
specific	B-X
for	B-X
various	B-X
protein	B-X
factors	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
family	B-X
revealed	B-X
that	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
Jun	B-X
family	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
significant	B-X
role	B-X
for	B-X
AP	B-X
-	B-X
1	B-X
in	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
<EOS>	B-X
The	B-X
cell	B-X
surface	B-X
glycoprotein	B-X
2B4	B-X
(	B-X
CD244	B-X
)	B-X
of	B-X
the	B-X
Ig	B-X
superfamily	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NK	B-X
and	B-X
T	B-X
lymphocyte	B-X
functions	B-X
<EOS>	B-X
A	B-X
prominent	B-X
role	B-X
for	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
2B4	B-X
(	B-X
CD244	B-X
)	B-X
gene	B-X
in	B-X
NK	B-X
cells	B-X
.	B-X

Mutation	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
not	O
only	O
abolishes	O
protein/DNA	O
interactions	O
but	O
also	O
promoter	O
activity	O
.	O
<EOS>	B-X
Mutation	B-X
of	B-X
the	B-X
DNA	B-X
binding	B-X
site	B-X
for	B-X
STAT	B-X
had	B-X
no	B-X
or	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
c	B-X
-	B-X
Fos	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
TPA	B-X
increased	B-X
both	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
κB	B-X
activities	B-X
<EOS>	B-X
Mutations	B-X
affecting	B-X
the	B-X
binding	B-X
site	B-X
of	B-X
one	B-X
transcription	B-X
factor	B-X
within	B-X
an	B-X
enhancer	B-X
can	B-X
indirectly	B-X
affect	B-X
the	B-X
binding	B-X
of	B-X
other	B-X
types	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Multi	B-X
-	B-X
omics	B-X
analyses	B-X
of	B-X
MEN1	B-X
missense	B-X
mutations	B-X
identify	B-X
disruption	B-X
of	B-X
menin	B-X
-	B-X
MLL	B-X
and	B-X
menin	B-X
-	B-X
JunD	B-X
interactions	B-X
as	B-X
critical	B-X
requirements	B-X
for	B-X
molecular	B-X
pathogenicity	B-X
.	B-X

These	O
results	O
demonstrate	O
a	O
significant	O
role	O
for	O
AP-1	B-protein
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
h2B4	B-DNA
gene	I-DNA
.	O
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
significant	B-X
role	B-X
for	B-X
AP	B-X
-	B-X
1	B-X
in	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
<EOS>	B-X
EMSAs	B-X
with	B-X
Abs	B-X
specific	B-X
for	B-X
various	B-X
protein	B-X
factors	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
family	B-X
revealed	B-X
that	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
Jun	B-X
family	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
<EOS>	B-X
A	B-X
prominent	B-X
role	B-X
for	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
in	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
2B4	B-X
(	B-X
CD244	B-X
)	B-X
gene	B-X
in	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
Through	B-X
primer	B-X
extension	B-X
analysis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
h2B4	B-X
gene	B-X
initiates	B-X
at	B-X
multiple	B-X
start	B-X
sites	B-X

Functional	O
correction	O
of	O
FA-C	B-cell_type
cells	I-cell_type
with	O
FANCC	B-protein
suppresses	O
the	O
expression	O
of	O
interferon	B-DNA
gamma-inducible	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
Functional	B-X
correction	B-X
of	B-X
FA	B-X
-	B-X
C	B-X
cells	B-X
with	B-X
FANCC	B-X
suppresses	B-X
the	B-X
expression	B-X
of	B-X
interferon	B-X
gamma	B-X
-	B-X
inducible	B-X
genes	B-X
.	B-X
<EOS>	B-X
Levels	B-X
of	B-X
the	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
factor	B-X
IFN	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
(	B-X
ICSBP	B-X
)	B-X
,	B-X
a	B-X
negative	B-X
trans	B-X
-	B-X
acting	B-X
regulator	B-X
of	B-X
some	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
,	B-X
were	B-X
quantified	B-X
<EOS>	B-X
Because	B-X
hematopoietic	B-X
cells	B-X
derived	B-X
from	B-X
Fanconi	B-X
anemia	B-X
(	B-X
FA	B-X
)	B-X
patients	B-X
of	B-X
the	B-X
C	B-X
-	B-X
complementation	B-X
group	B-X
(	B-X
FA	B-X
-	B-X
C	B-X
)	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNgamma	B-X
)	B-X
,	B-X
the	B-X
products	B-X
of	B-X
certain	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
known	B-X
to	B-X
influence	B-X
hematopoietic	B-X
cell	B-X
survival	B-X
were	B-X
quantified	B-X
<EOS>	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
clarify	B-X
mechanisms	B-X
by	B-X
which	B-X
FA	B-X
-	B-X
C	B-X
cells	B-X
overexpress	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
in	B-X
the	B-X
face	B-X
of	B-X
defective	B-X
STAT1	B-X
phosphorylation	B-X
,	B-X
it	B-X
was	B-X
reasoned	B-X
that	B-X
decreased	B-X
levels	B-X
of	B-X
activated	B-X
STAT1	B-X
might	B-X
result	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
a	B-X
hematopoietic	B-X
IFNgamma	B-X
-	B-X
responsive	B-X
protein	B-X
that	B-X
normally	B-X
modulates	B-X
expression	B-X
of	B-X
other	B-X
IFNgamma	B-X
-	B-X
responsive	B-X
genes	B-X

Because	O
hematopoietic	B-cell_type
cells	I-cell_type
derived	O
from	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
patients	O
of	O
the	O
C-complementation	O
group	O
(	O
FA-C	O
)	O
are	O
hypersensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
,	O
the	O
products	O
of	O
certain	O
IFNgamma-inducible	B-DNA
genes	I-DNA
known	O
to	O
influence	O
hematopoietic	O
cell	O
survival	O
were	O
quantified	O
.	O

High	O
constitutive	O
expression	O
of	O
the	O
IFNgamma-inducible	B-DNA
genes	I-DNA
,	O
IFN-stimulated	B-protein
gene	I-protein
factor	I-protein
3	I-protein
gamma	I-protein
subunit	I-protein
(	O
ISGF3gamma	B-protein
)	O
,	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	O
IRF-1	B-protein
)	O
,	O
and	O
the	O
cyclin-dependent	B-protein
kinase	I-protein
inhibitor	I-protein
p21	I-protein
(	O
WAF1	B-protein
)	O
was	O
found	O
in	O
FANCC	B-protein
mutant	O
B	B-cell_type
lymphoblasts	I-cell_type
,	O
low-density	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
and	O
murine	B-cell_type
embryonic	I-cell_type
fibroblasts	I-cell_type
.	O
<EOS>	B-X
High	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
,	B-X
IFN	B-X
-	B-X
stimulated	B-X
gene	B-X
factor	B-X
3	B-X
gamma	B-X
subunit	B-X
(	B-X
ISGF3gamma	B-X
)	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
-	B-X
1	B-X
(	B-X
IRF	B-X
-	B-X
1	B-X
)	B-X
,	B-X
and	B-X
the	B-X
cyclin	B-X
-	B-X
dependent	B-X
kinase	B-X
inhibitor	B-X
p21	B-X
(	B-X
WAF1	B-X
)	B-X
was	B-X
found	B-X
in	B-X
FANCC	B-X
mutant	B-X
B	B-X
lymphoblasts	B-X
,	B-X
low	B-X
-	B-X
density	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
and	B-X
murine	B-X
embryonic	B-X
fibroblasts	B-X
<EOS>	B-X
Levels	B-X
of	B-X
the	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
factor	B-X
IFN	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
(	B-X
ICSBP	B-X
)	B-X
,	B-X
a	B-X
negative	B-X
trans	B-X
-	B-X
acting	B-X
regulator	B-X
of	B-X
some	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
,	B-X
were	B-X
quantified	B-X
<EOS>	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
clarify	B-X
mechanisms	B-X
by	B-X
which	B-X
FA	B-X
-	B-X
C	B-X
cells	B-X
overexpress	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
in	B-X
the	B-X
face	B-X
of	B-X
defective	B-X
STAT1	B-X
phosphorylation	B-X
,	B-X
it	B-X
was	B-X
reasoned	B-X
that	B-X
decreased	B-X
levels	B-X
of	B-X
activated	B-X
STAT1	B-X
might	B-X
result	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
a	B-X
hematopoietic	B-X
IFNgamma	B-X
-	B-X
responsive	B-X
protein	B-X
that	B-X
normally	B-X
modulates	B-X
expression	B-X
of	B-X
other	B-X
IFNgamma	B-X
-	B-X
responsive	B-X
genes	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
FANCC	B-X
protein	B-X
functions	B-X
to	B-X
modulate	B-X
expression	B-X
of	B-X
a	B-X
family	B-X
of	B-X
genes	B-X
that	B-X
in	B-X
normal	B-X
cells	B-X
are	B-X
inducible	B-X
only	B-X
by	B-X
specific	B-X
environmental	B-X
cues	B-X
for	B-X
apoptosis	B-X
or	B-X
mitogenic	B-X
inhibition	B-X
,	B-X
but	B-X
it	B-X
does	B-X
so	B-X
independently	B-X
of	B-X
the	B-X
classic	B-X
IFN	B-X
-	B-X
STAT1	B-X
pathway	B-X
and	B-X
is	B-X
not	B-X
the	B-X
direct	B-X
result	B-X
of	B-X
reduced	B-X
ICSBP	B-X
expression	B-X

Paradoxically	O
,	O
these	O
cells	O
do	O
not	O
activate	B-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
1	I-protein
properly	O
.	O
<EOS>	B-X
IS	B-X
induced	B-X
the	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
in	B-X
an	B-X
AhR	B-X
-	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
Paradoxically	B-X
,	B-X
the	B-X
numbers	B-X
of	B-X
antiviral	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
are	B-X
increased	B-X
in	B-X
males	B-X
<EOS>	B-X
Paradoxically	B-X
,	B-X
both	B-X
cancer	B-X
cells	B-X
and	B-X
activated	B-X
T	B-X
cells	B-X
are	B-X
metabolically	B-X
dependent	B-X
on	B-X
glycolysis	B-X
,	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
oxygen	B-X
,	B-X
a	B-X
metabolic	B-X
process	B-X
known	B-X
as	B-X
the	B-X
Warburg	B-X
effect	B-X
<EOS>	B-X
Paradoxically	B-X
,	B-X
they	B-X
are	B-X
also	B-X
seen	B-X
as	B-X
having	B-X
potential	B-X
protective	B-X
effects	B-X
in	B-X
tissue	B-X
remodeling	B-X
post	B-X
-	B-X
injury	B-X

In	O
an	O
attempt	O
to	O
clarify	O
mechanisms	O
by	O
which	O
FA-C	B-cell_type
cells	I-cell_type
overexpress	O
IFNgamma-inducible	B-DNA
genes	I-DNA
in	O
the	O
face	O
of	O
defective	O
STAT1	O
phosphorylation	O
,	O
it	O
was	O
reasoned	O
that	O
decreased	O
levels	O
of	O
activated	B-protein
STAT1	I-protein
might	O
result	O
in	O
reduced	O
expression	O
of	O
a	O
hematopoietic	B-protein
IFNgamma-responsive	I-protein
protein	I-protein
that	O
normally	O
modulates	O
expression	O
of	O
other	O
IFNgamma-responsive	B-DNA
genes	I-DNA
.	O

Levels	O
of	O
the	O
IFNgamma	B-protein
-inducible	O
factor	O
IFN	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
,	O
a	O
negative	B-protein
trans-acting	I-protein
regulator	I-protein
of	O
some	O
IFNgamma-inducible	B-DNA
genes	I-DNA
,	O
were	O
quantified	O
.	O
<EOS>	B-X
Levels	B-X
of	B-X
the	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
factor	B-X
IFN	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
(	B-X
ICSBP	B-X
)	B-X
,	B-X
a	B-X
negative	B-X
trans	B-X
-	B-X
acting	B-X
regulator	B-X
of	B-X
some	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
,	B-X
were	B-X
quantified	B-X
<EOS>	B-X
Because	B-X
hematopoietic	B-X
cells	B-X
derived	B-X
from	B-X
Fanconi	B-X
anemia	B-X
(	B-X
FA	B-X
)	B-X
patients	B-X
of	B-X
the	B-X
C	B-X
-	B-X
complementation	B-X
group	B-X
(	B-X
FA	B-X
-	B-X
C	B-X
)	B-X
are	B-X
hypersensitive	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNgamma	B-X
)	B-X
,	B-X
the	B-X
products	B-X
of	B-X
certain	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
known	B-X
to	B-X
influence	B-X
hematopoietic	B-X
cell	B-X
survival	B-X
were	B-X
quantified	B-X
<EOS>	B-X
High	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
,	B-X
IFN	B-X
-	B-X
stimulated	B-X
gene	B-X
factor	B-X
3	B-X
gamma	B-X
subunit	B-X
(	B-X
ISGF3gamma	B-X
)	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
-	B-X
1	B-X
(	B-X
IRF	B-X
-	B-X
1	B-X
)	B-X
,	B-X
and	B-X
the	B-X
cyclin	B-X
-	B-X
dependent	B-X
kinase	B-X
inhibitor	B-X
p21	B-X
(	B-X
WAF1	B-X
)	B-X
was	B-X
found	B-X
in	B-X
FANCC	B-X
mutant	B-X
B	B-X
lymphoblasts	B-X
,	B-X
low	B-X
-	B-X
density	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
and	B-X
murine	B-X
embryonic	B-X
fibroblasts	B-X
<EOS>	B-X
Functional	B-X
correction	B-X
of	B-X
FA	B-X
-	B-X
C	B-X
cells	B-X
with	B-X
FANCC	B-X
suppresses	B-X
the	B-X
expression	B-X
of	B-X
interferon	B-X
gamma	B-X
-	B-X
inducible	B-X
genes	B-X
.	B-X

ICSBP	B-protein
levels	O
were	O
reduced	O
in	O
FA-C	B-cell_type
B	I-cell_type
lymphoblasts	I-cell_type
and	O
MEFs	B-cell_type
.	O
<EOS>	B-X
ICSBP	B-X
levels	B-X
were	B-X
reduced	B-X
in	B-X
FA	B-X
-	B-X
C	B-X
B	B-X
lymphoblasts	B-X
and	B-X
MEFs	B-X
<EOS>	B-X
However	B-X
,	B-X
enforced	B-X
expression	B-X
of	B-X
ICSBP	B-X
failed	B-X
to	B-X
down	B-X
-	B-X
regulate	B-X
IRF	B-X
-	B-X
1	B-X
,	B-X
ISGF3gamma	B-X
,	B-X
and	B-X
p21	B-X
(	B-X
WAF1	B-X
)	B-X
<EOS>	B-X
Functional	B-X
correction	B-X
of	B-X
FA	B-X
-	B-X
C	B-X
cells	B-X
with	B-X
FANCC	B-X
suppresses	B-X
the	B-X
expression	B-X
of	B-X
interferon	B-X
gamma	B-X
-	B-X
inducible	B-X
genes	B-X
.	B-X
<EOS>	B-X
Paradoxically	B-X
,	B-X
these	B-X
cells	B-X
do	B-X
not	B-X
activate	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
)	B-X
1	B-X
properly	B-X

However	O
,	O
enforced	O
expression	O
of	O
ICSBP	B-protein
failed	O
to	O
down-regulate	O
IRF-1	B-protein
,	O
ISGF3gamma	B-protein
,	O
and	O
p21	B-protein
(	I-protein
WAF1	I-protein
)	I-protein
.	O
<EOS>	B-X
However	B-X
,	B-X
enforced	B-X
expression	B-X
of	B-X
ICSBP	B-X
failed	B-X
to	B-X
down	B-X
-	B-X
regulate	B-X
IRF	B-X
-	B-X
1	B-X
,	B-X
ISGF3gamma	B-X
,	B-X
and	B-X
p21	B-X
(	B-X
WAF1	B-X
)	B-X
<EOS>	B-X
Levels	B-X
of	B-X
the	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
factor	B-X
IFN	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
(	B-X
ICSBP	B-X
)	B-X
,	B-X
a	B-X
negative	B-X
trans	B-X
-	B-X
acting	B-X
regulator	B-X
of	B-X
some	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
,	B-X
were	B-X
quantified	B-X
<EOS>	B-X
ICSBP	B-X
levels	B-X
were	B-X
reduced	B-X
in	B-X
FA	B-X
-	B-X
C	B-X
B	B-X
lymphoblasts	B-X
and	B-X
MEFs	B-X
<EOS>	B-X
High	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
IFNgamma	B-X
-	B-X
inducible	B-X
genes	B-X
,	B-X
IFN	B-X
-	B-X
stimulated	B-X
gene	B-X
factor	B-X
3	B-X
gamma	B-X
subunit	B-X
(	B-X
ISGF3gamma	B-X
)	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
-	B-X
1	B-X
(	B-X
IRF	B-X
-	B-X
1	B-X
)	B-X
,	B-X
and	B-X
the	B-X
cyclin	B-X
-	B-X
dependent	B-X
kinase	B-X
inhibitor	B-X
p21	B-X
(	B-X
WAF1	B-X
)	B-X
was	B-X
found	B-X
in	B-X
FANCC	B-X
mutant	B-X
B	B-X
lymphoblasts	B-X
,	B-X
low	B-X
-	B-X
density	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
and	B-X
murine	B-X
embryonic	B-X
fibroblasts	B-X

Thus	O
,	O
the	O
FANCC	B-protein
protein	I-protein
functions	O
to	O
modulate	O
expression	O
of	O
a	O
family	O
of	O
genes	O
that	O
in	O
normal	O
cells	O
are	O
inducible	O
only	O
by	O
specific	O
environmental	O
cues	O
for	O
apoptosis	O
or	O
mitogenic	O
inhibition	O
,	O
but	O
it	O
does	O
so	O
independently	O
of	O
the	O
classic	O
IFN-STAT1	O
pathway	O
and	O
is	O
not	O
the	O
direct	O
result	O
of	O
reduced	O
ICSBP	B-protein
expression	O
.	O

A	O
genetic	O
investigation	O
of	O
E2A	O
function	O
in	O
lymphocyte	O
development	O
.	O
<EOS>	B-X
A	B-X
genetic	B-X
investigation	B-X
of	B-X
E2A	B-X
function	B-X
in	B-X
lymphocyte	B-X
development	B-X
.	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
E2A	B-X
activities	B-X
by	B-X
histone	B-X
acetyltransferases	B-X
in	B-X
B	B-X
lymphocyte	B-X
development	B-X
.	B-X
<EOS>	B-X
This	B-X
work	B-X
establishes	B-X
a	B-X
new	B-X
model	B-X
for	B-X
further	B-X
investigating	B-X
E2A	B-X
function	B-X
in	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
leukemiogenesis	B-X
<EOS>	B-X
Several	B-X
recent	B-X
reviews	B-X
have	B-X
provided	B-X
a	B-X
comprehensive	B-X
discussion	B-X
of	B-X
biochemical	B-X
,	B-X
cellular	B-X
,	B-X
and	B-X
genetic	B-X
research	B-X
on	B-X
E2A	B-X
function	B-X
in	B-X
lymphocyte	B-X
development	B-X
(	B-X
1,2	B-X
)	B-X

Lymphocytes	B-cell_type
are	O
derived	O
from	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
(	O
HSC	B-cell_type
)	O
following	O
a	O
series	O
of	O
regulated	O
differentiation	O
events	O
.	O
<EOS>	B-X
Lymphocytes	B-X
are	B-X
derived	B-X
from	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSC	B-X
)	B-X
following	B-X
a	B-X
series	B-X
of	B-X
regulated	B-X
differentiation	B-X
events	B-X
<EOS>	B-X
Lymphocyte	B-X
commitment	B-X
and	B-X
differentiation	B-X
are	B-X
accompanied	B-X
by	B-X
programmed	B-X
gene	B-X
expression	B-X
or	B-X
repression	B-X
events	B-X
which	B-X
are	B-X
driven	B-X
by	B-X
lineage	B-X
and	B-X
stage	B-X
specific	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Multipotent	B-X
HSCs	B-X
become	B-X
committed	B-X
to	B-X
the	B-X
B	B-X
cell	B-X
lineage	B-X
in	B-X
bone	B-X
marrow	B-X
and	B-X
the	B-X
T	B-X
cell	B-X
lineage	B-X
in	B-X
the	B-X
thymus	B-X
after	B-X
receiving	B-X
appropriate	B-X
signals	B-X
from	B-X
the	B-X
corresponding	B-X
microenvironment	B-X
<EOS>	B-X
Several	B-X
recent	B-X
reviews	B-X
have	B-X
provided	B-X
a	B-X
comprehensive	B-X
discussion	B-X
of	B-X
biochemical	B-X
,	B-X
cellular	B-X
,	B-X
and	B-X
genetic	B-X
research	B-X
on	B-X
E2A	B-X
function	B-X
in	B-X
lymphocyte	B-X
development	B-X
(	B-X
1,2	B-X
)	B-X

Multipotent	B-cell_type
HSCs	I-cell_type
become	O
committed	O
to	O
the	O
B	B-cell_line
cell	I-cell_line
lineage	I-cell_line
in	O
bone	O
marrow	O
and	O
the	O
T	B-cell_line
cell	I-cell_line
lineage	I-cell_line
in	O
the	O
thymus	O
after	O
receiving	O
appropriate	O
signals	O
from	O
the	O
corresponding	O
microenvironment	O
.	O

These	O
committed	O
lymphoid	B-cell_type
cells	I-cell_type
must	O
then	O
undergo	O
V	O
(	O
D	O
)	O
J	O
recombination	O
at	O
the	O
immunoglobulin	B-DNA
gene	I-DNA
or	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
gene	I-DNA
locus	I-DNA
resulting	O
in	O
clonal	O
production	O
of	O
functional	O
B	B-cell_type
or	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
mRNA	B-X
expression	B-X
of	B-X
Bcl	B-X
-	B-X
2	B-X
,	B-X
Bax	B-X
and	B-X
protein	B-X
expression	B-X
of	B-X
Bcl	B-X
-	B-X
2	B-X
,	B-X
Bax	B-X
,	B-X
p	B-X
-	B-X
ERK	B-X
,	B-X
and	B-X
p	B-X
-	B-X
JNK	B-X
in	B-X
NK	B-X
cells	B-X
were	B-X
evaluated	B-X
by	B-X
qRT	B-X
-	B-X
PCR	B-X
and	B-X
western	B-X
blotting	B-X
analysis	B-X
,	B-X
respectively	B-X
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
explore	B-X
the	B-X
correlation	B-X
between	B-X
the	B-X
absolute	B-X
lymphocyte	B-X
and	B-X
T	B-X
-	B-X
lymphocyte	B-X
subpopulation	B-X
counts	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
pneumonia	B-X
after	B-X
lung	B-X
transplantation	B-X
and	B-X
to	B-X
predict	B-X
the	B-X
risk	B-X
of	B-X
pneumonia	B-X
development	B-X
after	B-X
lung	B-X
transplantation	B-X
<EOS>	B-X
The	B-X
adoptive	B-X
transfer	B-X
of	B-X
itaconate	B-X
-	B-X
treated	B-X
Th17	B-X
-	B-X
polarizing	B-X
T	B-X
cells	B-X
ameliorates	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
<EOS>	B-X
Recombinant	B-X
Pichinde	B-X
viral	B-X
vector	B-X
expressing	B-X
tuberculosis	B-X
antigens	B-X
elicits	B-X
strong	B-X
T	B-X
cell	B-X
responses	B-X
and	B-X
protection	B-X
in	B-X
mice	B-X
.	B-X

Lymphocyte	O
commitment	O
and	O
differentiation	O
are	O
accompanied	O
by	O
programmed	O
gene	O
expression	O
or	O
repression	O
events	O
which	O
are	O
driven	O
by	O
lineage	B-protein
and	I-protein
stage	I-protein
specific	I-protein
transcription	I-protein
factors	I-protein
.	O
<EOS>	B-X
Lymphocyte	B-X
commitment	B-X
and	B-X
differentiation	B-X
are	B-X
accompanied	B-X
by	B-X
programmed	B-X
gene	B-X
expression	B-X
or	B-X
repression	B-X
events	B-X
which	B-X
are	B-X
driven	B-X
by	B-X
lineage	B-X
and	B-X
stage	B-X
specific	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
B	B-X
cells	B-X
in	B-X
the	B-X
germinal	B-X
center	B-X
(	B-X
GC	B-X
)	B-X
are	B-X
programmed	B-X
to	B-X
form	B-X
plasma	B-X
cells	B-X
(	B-X
PCs	B-X
)	B-X
or	B-X
memory	B-X
B	B-X
cells	B-X
according	B-X
to	B-X
signals	B-X
received	B-X
by	B-X
receptors	B-X
that	B-X
are	B-X
translated	B-X
to	B-X
carry	B-X
out	B-X
appropriate	B-X
activities	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Lymphocytes	B-X
are	B-X
derived	B-X
from	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSC	B-X
)	B-X
following	B-X
a	B-X
series	B-X
of	B-X
regulated	B-X
differentiation	B-X
events	B-X
<EOS>	B-X
Single	B-X
cell	B-X
characterization	B-X
of	B-X
B	B-X
-	B-X
lymphoid	B-X
differentiation	B-X
and	B-X
leukemic	B-X
cell	B-X
states	B-X
during	B-X
chemotherapy	B-X
in	B-X
ETV6	B-X
-	B-X
RUNX1	B-X
-	B-X
positive	B-X
pediatric	B-X
leukemia	B-X
identifies	B-X
drug	B-X
-	B-X
targetable	B-X
transcription	B-X
factor	B-X
activities	B-X
.	B-X

The	O
basic-helix-loop-helix	B-protein
(	I-protein
bHLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
encoded	O
by	O
the	O
E2A	B-DNA
gene	I-DNA
are	O
involved	O
in	O
several	O
differentiation	O
events	O
during	O
B	O
and	O
T	O
cell	O
development	O
,	O
including	O
lineage	O
commitment	O
,	O
initiation	O
of	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
and	O
antigen	O
receptor	O
mediated	O
proliferation	O
and	O
differentiation	O
.	O

Several	O
recent	O
reviews	O
have	O
provided	O
a	O
comprehensive	O
discussion	O
of	O
biochemical	O
,	O
cellular	O
,	O
and	O
genetic	O
research	O
on	O
E2A	O
function	O
in	O
lymphocyte	O
development	O
(	O
1	O
,	O
2	O
)	O
.	O
<EOS>	B-X
Several	B-X
recent	B-X
reviews	B-X
have	B-X
provided	B-X
a	B-X
comprehensive	B-X
discussion	B-X
of	B-X
biochemical	B-X
,	B-X
cellular	B-X
,	B-X
and	B-X
genetic	B-X
research	B-X
on	B-X
E2A	B-X
function	B-X
in	B-X
lymphocyte	B-X
development	B-X
(	B-X
1,2	B-X
)	B-X
<EOS>	B-X
A	B-X
genetic	B-X
investigation	B-X
of	B-X
E2A	B-X
function	B-X
in	B-X
lymphocyte	B-X
development	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
only	B-X
discuss	B-X
some	B-X
of	B-X
the	B-X
genetic	B-X
approaches	B-X
our	B-X
laboratory	B-X
(	B-X
except	B-X
where	B-X
it	B-X
is	B-X
noted	B-X
)	B-X
has	B-X
undertaken	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
pathways	B-X
mediated	B-X
by	B-X
E2A	B-X
transcription	B-X
factors	B-X
in	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
These	B-X
committed	B-X
lymphoid	B-X
cells	B-X
must	B-X
then	B-X
undergo	B-X
V	B-X
(	B-X
D	B-X
)	B-X
J	B-X
recombination	B-X
at	B-X
the	B-X
immunoglobulin	B-X
gene	B-X
or	B-X
T	B-X
cell	B-X
receptor	B-X
gene	B-X
locus	B-X
resulting	B-X
in	B-X
clonal	B-X
production	B-X
of	B-X
functional	B-X
B	B-X
or	B-X
T	B-X
lymphocytes	B-X
,	B-X
respectively	B-X

Here	O
,	O
we	O
only	O
discuss	O
some	O
of	O
the	O
genetic	O
approaches	O
our	O
laboratory	O
(	O
except	O
where	O
it	O
is	O
noted	O
)	O
has	O
undertaken	O
to	O
investigate	O
the	O
molecular	O
pathways	O
mediated	O
by	O
E2A	B-protein
transcription	I-protein
factors	I-protein
in	O
lymphocyte	O
development	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
only	B-X
discuss	B-X
some	B-X
of	B-X
the	B-X
genetic	B-X
approaches	B-X
our	B-X
laboratory	B-X
(	B-X
except	B-X
where	B-X
it	B-X
is	B-X
noted	B-X
)	B-X
has	B-X
undertaken	B-X
to	B-X
investigate	B-X
the	B-X
molecular	B-X
pathways	B-X
mediated	B-X
by	B-X
E2A	B-X
transcription	B-X
factors	B-X
in	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
Several	B-X
recent	B-X
reviews	B-X
have	B-X
provided	B-X
a	B-X
comprehensive	B-X
discussion	B-X
of	B-X
biochemical	B-X
,	B-X
cellular	B-X
,	B-X
and	B-X
genetic	B-X
research	B-X
on	B-X
E2A	B-X
function	B-X
in	B-X
lymphocyte	B-X
development	B-X
(	B-X
1,2	B-X
)	B-X
<EOS>	B-X
A	B-X
genetic	B-X
investigation	B-X
of	B-X
E2A	B-X
function	B-X
in	B-X
lymphocyte	B-X
development	B-X
.	B-X
<EOS>	B-X
Lymphocyte	B-X
commitment	B-X
and	B-X
differentiation	B-X
are	B-X
accompanied	B-X
by	B-X
programmed	B-X
gene	B-X
expression	B-X
or	B-X
repression	B-X
events	B-X
which	B-X
are	B-X
driven	B-X
by	B-X
lineage	B-X
and	B-X
stage	B-X
specific	B-X
transcription	B-X
factors	B-X

D609	O
inhibits	O
ionizing	O
radiation-induced	O
oxidative	O
damage	O
by	O
acting	O
as	O
a	O
potent	O
antioxidant	O
.	O
<EOS>	B-X
D609	B-X
inhibits	B-X
ionizing	B-X
radiation	B-X
-	B-X
induced	B-X
oxidative	B-X
damage	B-X
by	B-X
acting	B-X
as	B-X
a	B-X
potent	B-X
antioxidant	B-X
.	B-X
<EOS>	B-X
This	B-X
implies	B-X
that	B-X
D609	B-X
and	B-X
other	B-X
xanthate	B-X
derivatives	B-X
may	B-X
function	B-X
as	B-X
potent	B-X
antioxidants	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
we	B-X
found	B-X
that	B-X
D609	B-X
inhibited	B-X
the	B-X
Fenton	B-X
reaction	B-X
-	B-X
induced	B-X
oxidation	B-X
of	B-X
dihydrorhodamine	B-X
123	B-X
in	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
manner	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
pyrrolidinedithiocarbamate	B-X
,	B-X
a	B-X
well	B-X
known	B-X
antioxidant	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
D609	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
alpha	B-X
-	B-X
phenyl	B-X
-	B-X
tert	B-X
-	B-X
butylnitrone	B-X
-	B-X
free	B-X
radical	B-X
spin	B-X
adducts	B-X
and	B-X
lipid	B-X
peroxidation	B-X
of	B-X
synaptosomal	B-X
membranes	B-X
by	B-X
the	B-X
Fenton	B-X
reagents	B-X

Tricyclodecan-9-yl-xanthogenate	O
(	O
D609	O
)	O
has	O
been	O
extensively	O
studied	O
in	O
biological	O
systems	O
and	O
exhibits	O
a	O
variety	O
of	O
biological	O
functions	O
,	O
including	O
antiviral	O
,	O
antitumor	O
,	O
and	O
anti-inflammatory	O
activities	O
.	O
<EOS>	B-X
Tricyclodecan	B-X
-	B-X
9	B-X
-	B-X
yl	B-X
-	B-X
xanthogenate	B-X
(	B-X
D609	B-X
)	B-X
has	B-X
been	B-X
extensively	B-X
studied	B-X
in	B-X
biological	B-X
systems	B-X
and	B-X
exhibits	B-X
a	B-X
variety	B-X
of	B-X
biological	B-X
functions	B-X
,	B-X
including	B-X
antiviral	B-X
,	B-X
antitumor	B-X
,	B-X
and	B-X
anti	B-X
-	B-X
inflammatory	B-X
activities	B-X
<EOS>	B-X
Thus	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
D609	B-X
is	B-X
a	B-X
potent	B-X
antioxidant	B-X
and	B-X
has	B-X
the	B-X
ability	B-X
to	B-X
inhibit	B-X
IR	B-X
-	B-X
induced	B-X
cellular	B-X
oxidative	B-X
stress	B-X
<EOS>	B-X
However	B-X
,	B-X
as	B-X
a	B-X
xanthate	B-X
derivative	B-X
,	B-X
D609	B-X
is	B-X
a	B-X
strong	B-X
electrolyte	B-X
and	B-X
readily	B-X
dissociates	B-X
to	B-X
xanthate	B-X
anions	B-X
and	B-X
cations	B-X
of	B-X
alkali	B-X
metals	B-X
in	B-X
solution	B-X
<EOS>	B-X
Xanthate	B-X
anions	B-X
and	B-X
protonated	B-X
xanthic	B-X
acid	B-X
contain	B-X
a	B-X
free	B-X
thiol	B-X
moiety	B-X
and	B-X
are	B-X
highly	B-X
reductive	B-X

Most	O
of	O
these	O
activities	O
have	O
been	O
largely	O
attributed	O
to	O
the	O
inhibitory	O
effect	O
of	O
D609	O
on	O
phosphatidylcholine-specific	O
phospholipase	B-protein
C	I-protein
.	O

However	O
,	O
as	O
a	O
xanthate	O
derivative	O
,	O
D609	O
is	O
a	O
strong	O
electrolyte	O
and	O
readily	O
dissociates	O
to	O
xanthate	O
anions	O
and	O
cations	O
of	O
alkali	O
metals	O
in	O
solution	O
.	O

Xanthate	O
anions	O
and	O
protonated	O
xanthic	O
acid	O
contain	O
a	O
free	O
thiol	O
moiety	O
and	O
are	O
highly	O
reductive	O
.	O
<EOS>	B-X
Xanthate	B-X
anions	B-X
and	B-X
protonated	B-X
xanthic	B-X
acid	B-X
contain	B-X
a	B-X
free	B-X
thiol	B-X
moiety	B-X
and	B-X
are	B-X
highly	B-X
reductive	B-X
<EOS>	B-X
Thus	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
D609	B-X
is	B-X
a	B-X
potent	B-X
antioxidant	B-X
and	B-X
has	B-X
the	B-X
ability	B-X
to	B-X
inhibit	B-X
IR	B-X
-	B-X
induced	B-X
cellular	B-X
oxidative	B-X
stress	B-X
<EOS>	B-X
5	B-X
Gy	B-X
)	B-X
,	B-X
it	B-X
protected	B-X
the	B-X
mice	B-X
from	B-X
IR	B-X
-	B-X
induced	B-X
lethality	B-X
<EOS>	B-X
However	B-X
,	B-X
as	B-X
a	B-X
xanthate	B-X
derivative	B-X
,	B-X
D609	B-X
is	B-X
a	B-X
strong	B-X
electrolyte	B-X
and	B-X
readily	B-X
dissociates	B-X
to	B-X
xanthate	B-X
anions	B-X
and	B-X
cations	B-X
of	B-X
alkali	B-X
metals	B-X
in	B-X
solution	B-X

This	O
implies	O
that	O
D609	O
and	O
other	O
xanthate	O
derivatives	O
may	O
function	O
as	O
potent	O
antioxidants	O
.	O
<EOS>	B-X
This	B-X
implies	B-X
that	B-X
D609	B-X
and	B-X
other	B-X
xanthate	B-X
derivatives	B-X
may	B-X
function	B-X
as	B-X
potent	B-X
antioxidants	B-X
<EOS>	B-X
D609	B-X
inhibits	B-X
ionizing	B-X
radiation	B-X
-	B-X
induced	B-X
oxidative	B-X
damage	B-X
by	B-X
acting	B-X
as	B-X
a	B-X
potent	B-X
antioxidant	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
D609	B-X
is	B-X
a	B-X
potent	B-X
antioxidant	B-X
and	B-X
has	B-X
the	B-X
ability	B-X
to	B-X
inhibit	B-X
IR	B-X
-	B-X
induced	B-X
cellular	B-X
oxidative	B-X
stress	B-X
<EOS>	B-X
However	B-X
,	B-X
as	B-X
a	B-X
xanthate	B-X
derivative	B-X
,	B-X
D609	B-X
is	B-X
a	B-X
strong	B-X
electrolyte	B-X
and	B-X
readily	B-X
dissociates	B-X
to	B-X
xanthate	B-X
anions	B-X
and	B-X
cations	B-X
of	B-X
alkali	B-X
metals	B-X
in	B-X
solution	B-X

Indeed	O
,	O
we	O
found	O
that	O
D609	O
inhibited	O
the	O
Fenton	O
reaction-induced	O
oxidation	O
of	O
dihydrorhodamine	O
123	O
in	O
a	O
dose-dependent	O
manner	O
similar	O
to	O
that	O
of	O
pyrrolidinedithiocarbamate	O
,	O
a	O
well	O
known	O
antioxidant	O
.	O

In	O
addition	O
,	O
D609	O
inhibited	O
the	O
formation	O
of	O
the	O
alpha-phenyl-tert-butylnitrone-free	O
radical	O
spin	O
adducts	O
and	O
lipid	O
peroxidation	O
of	O
synaptosomal	O
membranes	O
by	O
the	O
Fenton	O
reagents	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
D609	B-X
inhibited	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
alpha	B-X
-	B-X
phenyl	B-X
-	B-X
tert	B-X
-	B-X
butylnitrone	B-X
-	B-X
free	B-X
radical	B-X
spin	B-X
adducts	B-X
and	B-X
lipid	B-X
peroxidation	B-X
of	B-X
synaptosomal	B-X
membranes	B-X
by	B-X
the	B-X
Fenton	B-X
reagents	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
we	B-X
found	B-X
that	B-X
D609	B-X
inhibited	B-X
the	B-X
Fenton	B-X
reaction	B-X
-	B-X
induced	B-X
oxidation	B-X
of	B-X
dihydrorhodamine	B-X
123	B-X
in	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
manner	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
pyrrolidinedithiocarbamate	B-X
,	B-X
a	B-X
well	B-X
known	B-X
antioxidant	B-X
<EOS>	B-X
D609	B-X
inhibits	B-X
ionizing	B-X
radiation	B-X
-	B-X
induced	B-X
oxidative	B-X
damage	B-X
by	B-X
acting	B-X
as	B-X
a	B-X
potent	B-X
antioxidant	B-X
.	B-X
<EOS>	B-X
Xanthate	B-X
anions	B-X
and	B-X
protonated	B-X
xanthic	B-X
acid	B-X
contain	B-X
a	B-X
free	B-X
thiol	B-X
moiety	B-X
and	B-X
are	B-X
highly	B-X
reductive	B-X

Furthermore	O
,	O
preincubation	O
of	O
lymphocytes	B-cell_type
with	O
D609	O
resulted	O
in	O
a	O
significant	O
diminution	O
of	O
ionizing	O
radiation	O
(	O
IR	O
)	O
-induced	O
1	O
)	O
production	O
of	O
reactive	O
oxygen	O
species	O
;	O
2	O
)	O
decrease	O
in	O
intracellular	O
reduced	O
glutathione	O
;	O
3	O
)	O
oxidative	O
damage	O
to	O
proteins	O
and	O
lipids	O
;	O
and	O
4	O
)	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
.	O

Moreover	O
,	O
when	O
D609	O
(	O
50	O
mg/kg	O
i.v.	O
)	O
was	O
administered	O
to	O
mice	O
10	O
min	O
prior	O
to	O
total	O
body	O
IR	O
(	O
6.5	O
and	O
8.5	O
Gy	O
)	O
,	O
it	O
protected	O
the	O
mice	O
from	O
IR-induced	O
lethality	O
.	O
<EOS>	B-X
)	B-X
was	B-X
administered	B-X
to	B-X
mice	B-X
10	B-X
min	B-X
prior	B-X
to	B-X
total	B-X
body	B-X
IR	B-X
(	B-X
6	B-X
<EOS>	B-X
5	B-X
Gy	B-X
)	B-X
,	B-X
it	B-X
protected	B-X
the	B-X
mice	B-X
from	B-X
IR	B-X
-	B-X
induced	B-X
lethality	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
we	B-X
found	B-X
that	B-X
D609	B-X
inhibited	B-X
the	B-X
Fenton	B-X
reaction	B-X
-	B-X
induced	B-X
oxidation	B-X
of	B-X
dihydrorhodamine	B-X
123	B-X
in	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
manner	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
pyrrolidinedithiocarbamate	B-X
,	B-X
a	B-X
well	B-X
known	B-X
antioxidant	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
preincubation	B-X
of	B-X
lymphocytes	B-X
with	B-X
D609	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
diminution	B-X
of	B-X
ionizing	B-X
radiation	B-X
(	B-X
IR	B-X
)	B-X
	B-X
-	B-X
induced	B-X
1	B-X
)	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
;	B-X
2	B-X
)	B-X
decrease	B-X
in	B-X
intracellular	B-X
reduced	B-X
glutathione	B-X
;	B-X
3	B-X
)	B-X
oxidative	B-X
damage	B-X
to	B-X
proteins	B-X
and	B-X
lipids	B-X
;	B-X
and	B-X
4	B-X
)	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X

Thus	O
,	O
these	O
results	O
indicate	O
that	O
D609	O
is	O
a	O
potent	O
antioxidant	O
and	O
has	O
the	O
ability	O
to	O
inhibit	O
IR-induced	O
cellular	O
oxidative	O
stress	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
D609	B-X
is	B-X
a	B-X
potent	B-X
antioxidant	B-X
and	B-X
has	B-X
the	B-X
ability	B-X
to	B-X
inhibit	B-X
IR	B-X
-	B-X
induced	B-X
cellular	B-X
oxidative	B-X
stress	B-X
<EOS>	B-X
This	B-X
implies	B-X
that	B-X
D609	B-X
and	B-X
other	B-X
xanthate	B-X
derivatives	B-X
may	B-X
function	B-X
as	B-X
potent	B-X
antioxidants	B-X
<EOS>	B-X
However	B-X
,	B-X
as	B-X
a	B-X
xanthate	B-X
derivative	B-X
,	B-X
D609	B-X
is	B-X
a	B-X
strong	B-X
electrolyte	B-X
and	B-X
readily	B-X
dissociates	B-X
to	B-X
xanthate	B-X
anions	B-X
and	B-X
cations	B-X
of	B-X
alkali	B-X
metals	B-X
in	B-X
solution	B-X
<EOS>	B-X
Xanthate	B-X
anions	B-X
and	B-X
protonated	B-X
xanthic	B-X
acid	B-X
contain	B-X
a	B-X
free	B-X
thiol	B-X
moiety	B-X
and	B-X
are	B-X
highly	B-X
reductive	B-X

Inhibition	O
of	O
AP-1	B-protein
by	O
the	O
glucocorticoid-inducible	O
protein	B-protein
GILZ	I-protein
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
by	B-X
the	B-X
glucocorticoid	B-X
-	B-X
inducible	B-X
protein	B-X
GILZ	B-X
.	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
transient	B-X
expression	B-X
of	B-X
GILZ	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
blocked	B-X
induction	B-X
of	B-X
a	B-X
reporter	B-X
construct	B-X
driven	B-X
by	B-X
the	B-X
FasL	B-X
promoter	B-X
<EOS>	B-X
Whereas	B-X
homodimerization	B-X
of	B-X
GILZ	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
its	B-X
leucine	B-X
zipper	B-X
,	B-X
the	B-X
interaction	B-X
with	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
occurred	B-X
through	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
60	B-X
-	B-X
amino	B-X
acid	B-X
region	B-X
of	B-X
GILZ	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
prominent	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
genes	B-X
is	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
leucine	B-X
zipper	B-X
(	B-X
GILZ	B-X
)	B-X
,	B-X
which	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
activation	B-X
-	B-X
induced	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
mRNA	B-X

The	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	O
arise	O
largely	O
by	O
inhibition	O
of	O
cytokine	O
gene	O
expression	O
,	O
which	O
has	O
been	O
ascribed	O
to	O
interference	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
as	O
well	O
as	O
by	O
competition	O
for	O
common	O
coactivators	O
.	O
<EOS>	B-X
The	B-X
immunosuppressive	B-X
effects	B-X
of	B-X
glucocorticoids	B-X
arise	B-X
largely	B-X
by	B-X
inhibition	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
,	B-X
which	B-X
has	B-X
been	B-X
ascribed	B-X
to	B-X
interference	B-X
between	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
as	B-X
well	B-X
as	B-X
by	B-X
competition	B-X
for	B-X
common	B-X
coactivators	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
mRNA	B-X
expression	B-X
in	B-X
activated	B-X
normal	B-X
T	B-X
cells	B-X
required	B-X
new	B-X
protein	B-X
synthesis	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
phenomenon	B-X
is	B-X
secondary	B-X
to	B-X
expression	B-X
of	B-X
glucocorticoid	B-X
-	B-X
regulated	B-X
genes	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
prominent	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
genes	B-X
is	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
leucine	B-X
zipper	B-X
(	B-X
GILZ	B-X
)	B-X
,	B-X
which	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
activation	B-X
-	B-X
induced	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
mRNA	B-X
<EOS>	B-X
Thus	B-X
,	B-X
GILZ	B-X
represents	B-X
a	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
gene	B-X
product	B-X
that	B-X
can	B-X
inhibit	B-X
a	B-X
variety	B-X
of	B-X
activation	B-X
-	B-X
induced	B-X
events	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
direct	B-X
interference	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
candidate	B-X
for	B-X
a	B-X
mediator	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
immunosuppression	B-X

Here	O
we	O
show	O
that	O
glucocorticoid-induced	O
inhibition	O
of	O
interleukin-2	O
mRNA	O
expression	O
in	O
activated	B-cell_type
normal	I-cell_type
T	I-cell_type
cells	I-cell_type
required	O
new	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
this	O
phenomenon	O
is	O
secondary	O
to	O
expression	O
of	O
glucocorticoid-regulated	O
genes	B-DNA
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
mRNA	B-X
expression	B-X
in	B-X
activated	B-X
normal	B-X
T	B-X
cells	B-X
required	B-X
new	B-X
protein	B-X
synthesis	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
phenomenon	B-X
is	B-X
secondary	B-X
to	B-X
expression	B-X
of	B-X
glucocorticoid	B-X
-	B-X
regulated	B-X
genes	B-X
<EOS>	B-X
Thus	B-X
,	B-X
GILZ	B-X
represents	B-X
a	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
gene	B-X
product	B-X
that	B-X
can	B-X
inhibit	B-X
a	B-X
variety	B-X
of	B-X
activation	B-X
-	B-X
induced	B-X
events	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
direct	B-X
interference	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
candidate	B-X
for	B-X
a	B-X
mediator	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
immunosuppression	B-X
<EOS>	B-X
The	B-X
immunosuppressive	B-X
effects	B-X
of	B-X
glucocorticoids	B-X
arise	B-X
largely	B-X
by	B-X
inhibition	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
,	B-X
which	B-X
has	B-X
been	B-X
ascribed	B-X
to	B-X
interference	B-X
between	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
as	B-X
well	B-X
as	B-X
by	B-X
competition	B-X
for	B-X
common	B-X
coactivators	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
prominent	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
genes	B-X
is	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
leucine	B-X
zipper	B-X
(	B-X
GILZ	B-X
)	B-X
,	B-X
which	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
activation	B-X
-	B-X
induced	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
mRNA	B-X

One	O
of	O
the	O
most	O
prominent	O
glucocorticoid-induced	O
genes	B-DNA
is	O
glucocorticoid-induced	B-DNA
leucine	I-DNA
zipper	I-DNA
(	O
GILZ	B-DNA
)	O
,	O
which	O
has	O
been	O
reported	O
to	O
inhibit	O
activation-induced	O
up-regulation	O
of	O
Fas	B-RNA
ligand	I-RNA
(	I-RNA
FasL	I-RNA
)	I-RNA
mRNA	I-RNA
.	O

Indeed	O
,	O
transient	O
expression	O
of	O
GILZ	B-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
blocked	O
induction	O
of	O
a	O
reporter	B-DNA
construct	I-DNA
driven	O
by	O
the	O
FasL	B-DNA
promoter	I-DNA
.	O

This	O
could	O
be	O
accounted	O
for	O
by	O
GILZ	B-protein
-mediated	O
inhibition	O
of	O
Egr-2	B-protein
and	O
Egr-3	B-protein
,	O
NFAT/AP-1	B-protein
-inducible	O
transcription	B-protein
factors	I-protein
that	O
bind	O
a	O
regulatory	B-DNA
element	I-DNA
in	O
the	O
FasL	B-DNA
promoter	I-DNA
and	O
up-regulate	O
FasL	O
expression	O
.	O
<EOS>	B-X
This	B-X
could	B-X
be	B-X
accounted	B-X
for	B-X
by	B-X
GILZ	B-X
-	B-X
mediated	B-X
inhibition	B-X
of	B-X
Egr	B-X
-	B-X
2	B-X
and	B-X
Egr	B-X
-	B-X
3	B-X
,	B-X
NFAT	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
inducible	B-X
transcription	B-X
factors	B-X
that	B-X
bind	B-X
a	B-X
regulatory	B-X
element	B-X
in	B-X
the	B-X
FasL	B-X
promoter	B-X
and	B-X
up	B-X
-	B-X
regulate	B-X
FasL	B-X
expression	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
transient	B-X
expression	B-X
of	B-X
GILZ	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
blocked	B-X
induction	B-X
of	B-X
a	B-X
reporter	B-X
construct	B-X
driven	B-X
by	B-X
the	B-X
FasL	B-X
promoter	B-X
<EOS>	B-X
The	B-X
immunosuppressive	B-X
effects	B-X
of	B-X
glucocorticoids	B-X
arise	B-X
largely	B-X
by	B-X
inhibition	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
,	B-X
which	B-X
has	B-X
been	B-X
ascribed	B-X
to	B-X
interference	B-X
between	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
as	B-X
well	B-X
as	B-X
by	B-X
competition	B-X
for	B-X
common	B-X
coactivators	B-X
<EOS>	B-X
Thus	B-X
,	B-X
GILZ	B-X
represents	B-X
a	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
gene	B-X
product	B-X
that	B-X
can	B-X
inhibit	B-X
a	B-X
variety	B-X
of	B-X
activation	B-X
-	B-X
induced	B-X
events	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
direct	B-X
interference	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
candidate	B-X
for	B-X
a	B-X
mediator	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
immunosuppression	B-X

GILZ	B-protein
also	O
potently	O
inhibited	O
AP-1-driven	B-DNA
and	I-DNA
IL-2	I-DNA
promoter-driven	I-DNA
reporter	I-DNA
constructs	I-DNA
,	O
and	O
recombinant	O
GILZ	B-protein
specifically	O
interacted	O
with	O
c-Fos	B-protein
and	O
c-Jun	B-protein
in	O
vitro	O
and	O
inhibited	O
the	O
binding	O
of	O
active	B-protein
AP-1	I-protein
to	O
its	O
target	O
DNA	O
.	O
<EOS>	B-X
GILZ	B-X
also	B-X
potently	B-X
inhibited	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
driven	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
driven	B-X
reporter	B-X
constructs	B-X
,	B-X
and	B-X
recombinant	B-X
GILZ	B-X
specifically	B-X
interacted	B-X
with	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
in	B-X
vitro	B-X
and	B-X
inhibited	B-X
the	B-X
binding	B-X
of	B-X
active	B-X
AP	B-X
-	B-X
1	B-X
to	B-X
its	B-X
target	B-X
DNA	B-X
<EOS>	B-X
Whereas	B-X
homodimerization	B-X
of	B-X
GILZ	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
its	B-X
leucine	B-X
zipper	B-X
,	B-X
the	B-X
interaction	B-X
with	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
occurred	B-X
through	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
60	B-X
-	B-X
amino	B-X
acid	B-X
region	B-X
of	B-X
GILZ	B-X
<EOS>	B-X
Thus	B-X
,	B-X
GILZ	B-X
represents	B-X
a	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
gene	B-X
product	B-X
that	B-X
can	B-X
inhibit	B-X
a	B-X
variety	B-X
of	B-X
activation	B-X
-	B-X
induced	B-X
events	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
direct	B-X
interference	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
candidate	B-X
for	B-X
a	B-X
mediator	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
immunosuppression	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
transient	B-X
expression	B-X
of	B-X
GILZ	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
blocked	B-X
induction	B-X
of	B-X
a	B-X
reporter	B-X
construct	B-X
driven	B-X
by	B-X
the	B-X
FasL	B-X
promoter	B-X

Whereas	O
homodimerization	O
of	O
GILZ	B-protein
required	O
the	O
presence	O
of	O
its	O
leucine	B-protein
zipper	I-protein
,	O
the	O
interaction	O
with	O
c-Fos	B-protein
and	O
c-Jun	B-protein
occurred	O
through	O
the	O
N-terminal	B-protein
60-amino	B-protein
acid	I-protein
region	I-protein
of	O
GILZ	B-protein
.	O
<EOS>	B-X
Whereas	B-X
homodimerization	B-X
of	B-X
GILZ	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
its	B-X
leucine	B-X
zipper	B-X
,	B-X
the	B-X
interaction	B-X
with	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
occurred	B-X
through	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
60	B-X
-	B-X
amino	B-X
acid	B-X
region	B-X
of	B-X
GILZ	B-X
<EOS>	B-X
GILZ	B-X
also	B-X
potently	B-X
inhibited	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
driven	B-X
and	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
driven	B-X
reporter	B-X
constructs	B-X
,	B-X
and	B-X
recombinant	B-X
GILZ	B-X
specifically	B-X
interacted	B-X
with	B-X
c	B-X
-	B-X
Fos	B-X
and	B-X
c	B-X
-	B-X
Jun	B-X
in	B-X
vitro	B-X
and	B-X
inhibited	B-X
the	B-X
binding	B-X
of	B-X
active	B-X
AP	B-X
-	B-X
1	B-X
to	B-X
its	B-X
target	B-X
DNA	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
transient	B-X
expression	B-X
of	B-X
GILZ	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
blocked	B-X
induction	B-X
of	B-X
a	B-X
reporter	B-X
construct	B-X
driven	B-X
by	B-X
the	B-X
FasL	B-X
promoter	B-X
<EOS>	B-X
Thus	B-X
,	B-X
GILZ	B-X
represents	B-X
a	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
gene	B-X
product	B-X
that	B-X
can	B-X
inhibit	B-X
a	B-X
variety	B-X
of	B-X
activation	B-X
-	B-X
induced	B-X
events	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
direct	B-X
interference	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
candidate	B-X
for	B-X
a	B-X
mediator	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
immunosuppression	B-X

Thus	O
,	O
GILZ	B-protein
represents	O
a	O
glucocorticoid-induced	O
gene	O
product	O
that	O
can	O
inhibit	O
a	O
variety	O
of	O
activation-induced	O
events	O
,	O
at	O
least	O
in	O
part	O
by	O
direct	O
interference	O
with	O
AP-1	B-protein
,	O
and	O
is	O
therefore	O
a	O
candidate	O
for	O
a	O
mediator	O
of	O
glucocorticoid-induced	O
immunosuppression	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
GILZ	B-X
represents	B-X
a	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
gene	B-X
product	B-X
that	B-X
can	B-X
inhibit	B-X
a	B-X
variety	B-X
of	B-X
activation	B-X
-	B-X
induced	B-X
events	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
by	B-X
direct	B-X
interference	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
candidate	B-X
for	B-X
a	B-X
mediator	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
immunosuppression	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
mRNA	B-X
expression	B-X
in	B-X
activated	B-X
normal	B-X
T	B-X
cells	B-X
required	B-X
new	B-X
protein	B-X
synthesis	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
phenomenon	B-X
is	B-X
secondary	B-X
to	B-X
expression	B-X
of	B-X
glucocorticoid	B-X
-	B-X
regulated	B-X
genes	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
prominent	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
genes	B-X
is	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
leucine	B-X
zipper	B-X
(	B-X
GILZ	B-X
)	B-X
,	B-X
which	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
activation	B-X
-	B-X
induced	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
mRNA	B-X
<EOS>	B-X
The	B-X
immunosuppressive	B-X
effects	B-X
of	B-X
glucocorticoids	B-X
arise	B-X
largely	B-X
by	B-X
inhibition	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
,	B-X
which	B-X
has	B-X
been	B-X
ascribed	B-X
to	B-X
interference	B-X
between	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
as	B-X
well	B-X
as	B-X
by	B-X
competition	B-X
for	B-X
common	B-X
coactivators	B-X

Pharmacokinetic	O
differences	O
between	O
a	O
T	O
cell-tolerizing	O
and	O
a	O
T	O
cell-activating	O
peptide	O
.	O

Vaccination	O
with	O
a	O
peptide	O
representing	O
a	O
CTL	O
epitope	O
from	O
the	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
16	O
E7	B-protein
protein	I-protein
induces	O
a	O
specific	O
CTL	O
response	O
that	O
prevents	O
the	O
outgrowth	O
of	O
HPV16	O
E7-expressing	O
tumors	O
.	O
<EOS>	B-X
Vaccination	B-X
with	B-X
a	B-X
peptide	B-X
representing	B-X
a	B-X
CTL	B-X
epitope	B-X
from	B-X
the	B-X
human	B-X
papillomavirus	B-X
(	B-X
HPV	B-X
)	B-X
16	B-X
E7	B-X
protein	B-X
induces	B-X
a	B-X
specific	B-X
CTL	B-X
response	B-X
that	B-X
prevents	B-X
the	B-X
outgrowth	B-X
of	B-X
HPV16	B-X
E7	B-X
-	B-X
expressing	B-X
tumors	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
vaccination	B-X
with	B-X
a	B-X
peptide	B-X
encoding	B-X
an	B-X
adenovirus	B-X
type	B-X
5	B-X
(	B-X
Ad5	B-X
)	B-X
E1A	B-X
CTL	B-X
epitope	B-X
results	B-X
in	B-X
CTL	B-X
tolerance	B-X
and	B-X
enhanced	B-X
growth	B-X
of	B-X
an	B-X
Ad5	B-X
E1A	B-X
-	B-X
expressing	B-X
tumor	B-X
<EOS>	B-X
This	B-X
demonstrates	B-X
that	B-X
CVLPs	B-X
induce	B-X
an	B-X
E7	B-X
-	B-X
specific	B-X
CTL	B-X
response	B-X
in	B-X
mice	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
adjuvant	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
Ad5	B-X
E1A	B-X
peptide	B-X
injection	B-X
resulted	B-X
in	B-X
physical	B-X
deletion	B-X
of	B-X
preexisting	B-X
Ad5	B-X
E1A	B-X
-	B-X
specific	B-X
CTLs	B-X
within	B-X
24	B-X
h	B-X
after	B-X
injection	B-X

In	O
contrast	O
,	O
vaccination	O
with	O
a	O
peptide	O
encoding	O
an	O
adenovirus	O
type	O
5	O
(	O
Ad5	O
)	O
E1A	O
CTL	O
epitope	O
results	O
in	O
CTL	O
tolerance	O
and	O
enhanced	O
growth	O
of	O
an	O
Ad5	O
E1A-expressing	O
tumor	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
vaccination	B-X
with	B-X
a	B-X
peptide	B-X
encoding	B-X
an	B-X
adenovirus	B-X
type	B-X
5	B-X
(	B-X
Ad5	B-X
)	B-X
E1A	B-X
CTL	B-X
epitope	B-X
results	B-X
in	B-X
CTL	B-X
tolerance	B-X
and	B-X
enhanced	B-X
growth	B-X
of	B-X
an	B-X
Ad5	B-X
E1A	B-X
-	B-X
expressing	B-X
tumor	B-X
<EOS>	B-X
Vaccination	B-X
with	B-X
a	B-X
peptide	B-X
representing	B-X
a	B-X
CTL	B-X
epitope	B-X
from	B-X
the	B-X
human	B-X
papillomavirus	B-X
(	B-X
HPV	B-X
)	B-X
16	B-X
E7	B-X
protein	B-X
induces	B-X
a	B-X
specific	B-X
CTL	B-X
response	B-X
that	B-X
prevents	B-X
the	B-X
outgrowth	B-X
of	B-X
HPV16	B-X
E7	B-X
-	B-X
expressing	B-X
tumors	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
Ad5	B-X
E1A	B-X
peptide	B-X
injection	B-X
resulted	B-X
in	B-X
physical	B-X
deletion	B-X
of	B-X
preexisting	B-X
Ad5	B-X
E1A	B-X
-	B-X
specific	B-X
CTLs	B-X
within	B-X
24	B-X
h	B-X
after	B-X
injection	B-X
<EOS>	B-X
This	B-X
tolerization	B-X
occurred	B-X
at	B-X
the	B-X
time	B-X
when	B-X
the	B-X
peptide	B-X
reached	B-X
its	B-X
maximum	B-X
peptide	B-X
concentration	B-X
in	B-X
the	B-X
organs	B-X

It	O
is	O
unclear	O
why	O
these	O
peptides	O
induce	O
such	O
opposite	O
effects	O
.	O
<EOS>	B-X
It	B-X
is	B-X
unclear	B-X
why	B-X
these	B-X
peptides	B-X
induce	B-X
such	B-X
opposite	B-X
effects	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aim	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
insulin	B-X
in	B-X
high	B-X
concentration	B-X
in	B-X
AEC	B-X
cellular	B-X
senescence	B-X
<EOS>	B-X
This	B-X
period	B-X
was	B-X
chosen	B-X
in	B-X
order	B-X
to	B-X
study	B-X
stress	B-X
response	B-X
adaptations	B-X
<EOS>	B-X
This	B-X
tolerization	B-X
occurred	B-X
at	B-X
the	B-X
time	B-X
when	B-X
the	B-X
peptide	B-X
reached	B-X
its	B-X
maximum	B-X
peptide	B-X
concentration	B-X
in	B-X
the	B-X
organs	B-X

To	O
determine	O
whether	O
a	O
difference	O
in	O
pharmacokinetics	O
can	O
explain	O
the	O
functional	O
contrasts	O
,	O
tritiated	O
Ad5	O
E1A	O
and	O
HPV16	O
E7	O
peptides	O
were	O
injected	O
into	O
mice	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
a	B-X
difference	B-X
in	B-X
pharmacokinetics	B-X
can	B-X
explain	B-X
the	B-X
functional	B-X
contrasts	B-X
,	B-X
tritiated	B-X
Ad5	B-X
E1A	B-X
and	B-X
HPV16	B-X
E7	B-X
peptides	B-X
were	B-X
injected	B-X
into	B-X
mice	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
information	B-X
on	B-X
the	B-X
pharmacokinetics	B-X
of	B-X
peptides	B-X
is	B-X
vital	B-X
for	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
peptide	B-X
-	B-X
based	B-X
vaccines	B-X
<EOS>	B-X
The	B-X
HPV16	B-X
E7	B-X
peptide	B-X
kinetics	B-X
correlated	B-X
with	B-X
the	B-X
kinetics	B-X
of	B-X
HPV16	B-X
E7	B-X
-	B-X
specific	B-X
CTL	B-X
induction	B-X
<EOS>	B-X
Pharmacokinetic	B-X
differences	B-X
between	B-X
a	B-X
T	B-X
cell	B-X
-	B-X
tolerizing	B-X
and	B-X
a	B-X
T	B-X
cell	B-X
-	B-X
activating	B-X
peptide	B-X
.	B-X

Results	O
show	O
that	O
the	O
tolerizing	O
peptide	O
spread	O
through	O
the	O
body	O
16	O
times	O
faster	O
than	O
the	O
activating	O
peptide	O
and	O
was	O
cleared	O
at	O
least	O
2	O
times	O
faster	O
.	O

The	O
HPV16	O
E7	O
peptide	O
kinetics	O
correlated	O
with	O
the	O
kinetics	O
of	O
HPV16	B-protein
E7	I-protein
-specific	O
CTL	O
induction	O
.	O
<EOS>	B-X
The	B-X
HPV16	B-X
E7	B-X
peptide	B-X
kinetics	B-X
correlated	B-X
with	B-X
the	B-X
kinetics	B-X
of	B-X
HPV16	B-X
E7	B-X
-	B-X
specific	B-X
CTL	B-X
induction	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
Ad5	B-X
E1A	B-X
peptide	B-X
injection	B-X
resulted	B-X
in	B-X
physical	B-X
deletion	B-X
of	B-X
preexisting	B-X
Ad5	B-X
E1A	B-X
-	B-X
specific	B-X
CTLs	B-X
within	B-X
24	B-X
h	B-X
after	B-X
injection	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
a	B-X
difference	B-X
in	B-X
pharmacokinetics	B-X
can	B-X
explain	B-X
the	B-X
functional	B-X
contrasts	B-X
,	B-X
tritiated	B-X
Ad5	B-X
E1A	B-X
and	B-X
HPV16	B-X
E7	B-X
peptides	B-X
were	B-X
injected	B-X
into	B-X
mice	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
information	B-X
on	B-X
the	B-X
pharmacokinetics	B-X
of	B-X
peptides	B-X
is	B-X
vital	B-X
for	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
peptide	B-X
-	B-X
based	B-X
vaccines	B-X

In	O
contrast	O
,	O
Ad5	O
E1A	O
peptide	O
injection	O
resulted	O
in	O
physical	O
deletion	O
of	O
preexisting	O
Ad5	B-protein
E1A	I-protein
-specific	O
CTLs	B-protein
within	O
24	O
h	O
after	O
injection	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
Ad5	B-X
E1A	B-X
peptide	B-X
injection	B-X
resulted	B-X
in	B-X
physical	B-X
deletion	B-X
of	B-X
preexisting	B-X
Ad5	B-X
E1A	B-X
-	B-X
specific	B-X
CTLs	B-X
within	B-X
24	B-X
h	B-X
after	B-X
injection	B-X
<EOS>	B-X
The	B-X
HPV16	B-X
E7	B-X
peptide	B-X
kinetics	B-X
correlated	B-X
with	B-X
the	B-X
kinetics	B-X
of	B-X
HPV16	B-X
E7	B-X
-	B-X
specific	B-X
CTL	B-X
induction	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
vaccination	B-X
with	B-X
a	B-X
peptide	B-X
encoding	B-X
an	B-X
adenovirus	B-X
type	B-X
5	B-X
(	B-X
Ad5	B-X
)	B-X
E1A	B-X
CTL	B-X
epitope	B-X
results	B-X
in	B-X
CTL	B-X
tolerance	B-X
and	B-X
enhanced	B-X
growth	B-X
of	B-X
an	B-X
Ad5	B-X
E1A	B-X
-	B-X
expressing	B-X
tumor	B-X
<EOS>	B-X
Vaccination	B-X
with	B-X
a	B-X
peptide	B-X
representing	B-X
a	B-X
CTL	B-X
epitope	B-X
from	B-X
the	B-X
human	B-X
papillomavirus	B-X
(	B-X
HPV	B-X
)	B-X
16	B-X
E7	B-X
protein	B-X
induces	B-X
a	B-X
specific	B-X
CTL	B-X
response	B-X
that	B-X
prevents	B-X
the	B-X
outgrowth	B-X
of	B-X
HPV16	B-X
E7	B-X
-	B-X
expressing	B-X
tumors	B-X

This	O
tolerization	O
occurred	O
at	O
the	O
time	O
when	O
the	O
peptide	O
reached	O
its	O
maximum	O
peptide	O
concentration	O
in	O
the	O
organs	O
.	O
<EOS>	B-X
This	B-X
tolerization	B-X
occurred	B-X
at	B-X
the	B-X
time	B-X
when	B-X
the	B-X
peptide	B-X
reached	B-X
its	B-X
maximum	B-X
peptide	B-X
concentration	B-X
in	B-X
the	B-X
organs	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
ubiquitous	B-X
expression	B-X
of	B-X
the	B-X
tolerizing	B-X
Ad5	B-X
E1A	B-X
peptide	B-X
within	B-X
a	B-X
short	B-X
period	B-X
of	B-X
time	B-X
causes	B-X
activation	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
of	B-X
Ad5	B-X
E1A	B-X
-	B-X
specific	B-X
CTLs	B-X
<EOS>	B-X
Results	B-X
show	B-X
that	B-X
the	B-X
tolerizing	B-X
peptide	B-X
spread	B-X
through	B-X
the	B-X
body	B-X
16	B-X
times	B-X
faster	B-X
than	B-X
the	B-X
activating	B-X
peptide	B-X
and	B-X
was	B-X
cleared	B-X
at	B-X
least	B-X
2	B-X
times	B-X
faster	B-X
<EOS>	B-X
It	B-X
is	B-X
unclear	B-X
why	B-X
these	B-X
peptides	B-X
induce	B-X
such	B-X
opposite	B-X
effects	B-X

These	O
data	O
suggest	O
that	O
ubiquitous	O
expression	O
of	O
the	O
tolerizing	O
Ad5	O
E1A	O
peptide	O
within	O
a	O
short	O
period	O
of	O
time	O
causes	O
activation-induced	O
cell	O
death	O
of	O
Ad5	B-protein
E1A	I-protein
-specific	O
CTLs	B-protein
.	O

Therefore	O
,	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
peptides	O
is	O
vital	O
for	O
the	O
safety	O
and	O
efficacy	O
of	O
peptide-based	O
vaccines	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
information	B-X
on	B-X
the	B-X
pharmacokinetics	B-X
of	B-X
peptides	B-X
is	B-X
vital	B-X
for	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
peptide	B-X
-	B-X
based	B-X
vaccines	B-X
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
a	B-X
difference	B-X
in	B-X
pharmacokinetics	B-X
can	B-X
explain	B-X
the	B-X
functional	B-X
contrasts	B-X
,	B-X
tritiated	B-X
Ad5	B-X
E1A	B-X
and	B-X
HPV16	B-X
E7	B-X
peptides	B-X
were	B-X
injected	B-X
into	B-X
mice	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
ubiquitous	B-X
expression	B-X
of	B-X
the	B-X
tolerizing	B-X
Ad5	B-X
E1A	B-X
peptide	B-X
within	B-X
a	B-X
short	B-X
period	B-X
of	B-X
time	B-X
causes	B-X
activation	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
of	B-X
Ad5	B-X
E1A	B-X
-	B-X
specific	B-X
CTLs	B-X
<EOS>	B-X
The	B-X
HPV16	B-X
E7	B-X
peptide	B-X
kinetics	B-X
correlated	B-X
with	B-X
the	B-X
kinetics	B-X
of	B-X
HPV16	B-X
E7	B-X
-	B-X
specific	B-X
CTL	B-X
induction	B-X

Smad3	B-protein
and	O
Smad4	B-protein
mediate	O
transforming	B-protein
growth	I-protein
factor-beta1	I-protein
-induced	O
IgA	O
expression	O
in	O
murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Smad3	B-X
and	B-X
Smad4	B-X
mediate	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
in	B-X
murine	B-X
B	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
involvement	B-X
of	B-X
Smad	B-X
proteins	B-X
in	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
<EOS>	B-X
Similar	B-X
to	B-X
endogenous	B-X
GLalpha	B-X
transcripts	B-X
,	B-X
TGF	B-X
-	B-X
beta1	B-X
induces	B-X
GLalpha	B-X
promoter	B-X
activity	B-X
and	B-X
overexpression	B-X
of	B-X
Smad3	B-X
markedly	B-X
enhances	B-X
the	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Instead	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
overexpression	B-X
increased	B-X
the	B-X
expression	B-X
of	B-X
Smad7	B-X
transcripts	B-X

Transforming	B-protein
growth	I-protein
factor	I-protein
(	I-protein
TGF	I-protein
)	I-protein
-beta1	I-protein
is	O
well	O
established	O
as	O
a	O
critical	O
IgA	B-protein
isotype	I-protein
switching	I-protein
factor	I-protein
and	O
Smad	B-protein
molecules	I-protein
have	O
been	O
reported	O
to	O
act	O
as	O
transducers	B-protein
and	O
transcriptional	B-protein
factors	I-protein
in	O
the	O
expression	O
of	O
TGF-beta1	B-protein
-targeted	O
genes	B-DNA
.	O
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
	B-X
-	B-X
beta1	B-X
is	B-X
well	B-X
established	B-X
as	B-X
a	B-X
critical	B-X
IgA	B-X
isotype	B-X
switching	B-X
factor	B-X
and	B-X
Smad	B-X
molecules	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
act	B-X
as	B-X
transducers	B-X
and	B-X
transcriptional	B-X
factors	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
targeted	B-X
genes	B-X
<EOS>	B-X
First	B-X
,	B-X
we	B-X
found	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
significantly	B-X
increases	B-X
endogenous	B-X
germ	B-X
-	B-X
line	B-X
(	B-X
GL	B-X
)	B-X
alpha	B-X
transcripts	B-X
by	B-X
LPS	B-X
-	B-X
stimulated	B-X
CH12	B-X
<EOS>	B-X
Finally	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
TGF	B-X
-	B-X
beta1	B-X
,	B-X
overexpression	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
selectively	B-X
increases	B-X
both	B-X
surface	B-X
IgA	B-X
expression	B-X
and	B-X
IgA	B-X
production	B-X
<EOS>	B-X
To	B-X
investigate	B-X
its	B-X
signaling	B-X
mechanisms	B-X
,	B-X
the	B-X
lymphoma	B-X
cell	B-X
line	B-X
was	B-X
transfected	B-X
with	B-X
pFL3	B-X
that	B-X
contains	B-X
the	B-X
TGF	B-X
-	B-X
beta	B-X
-	B-X
responsive	B-X
element	B-X
of	B-X
the	B-X
GLalpha	B-X
promoter	B-X
,	B-X
and	B-X
stimulated	B-X
with	B-X
TGF	B-X
-	B-X
beta1	B-X

We	O
examined	O
the	O
involvement	O
of	O
Smad	B-protein
proteins	I-protein
in	O
TGF-beta1	B-protein
-induced	O
IgA	O
expression	O
.	O
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
involvement	B-X
of	B-X
Smad	B-X
proteins	B-X
in	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
previously	B-X
that	B-X
Smad3	B-X
and	B-X
Smad4	B-X
mediate	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
<EOS>	B-X
p300	B-X
cooperates	B-X
with	B-X
Smad3	B-X
/	B-X
4	B-X
and	B-X
Runx3	B-X
in	B-X
TGFbeta1	B-X
-	B-X
induced	B-X
IgA	B-X
isotype	B-X
expression	B-X
.	B-X
<EOS>	B-X
Smad3	B-X
and	B-X
Smad4	B-X
mediate	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
in	B-X
murine	B-X
B	B-X
lymphocytes	B-X
.	B-X

First	O
,	O
we	O
found	O
that	O
TGF-beta1	B-protein
significantly	O
increases	O
endogenous	B-RNA
germ-line	I-RNA
(	I-RNA
GL	I-RNA
)	I-RNA
alpha	I-RNA
transcripts	I-RNA
by	O
LPS-stimulated	O
CH12.LX.4933	B-cell_line
(	I-cell_line
mu	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
)	I-cell_line
B	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
First	B-X
,	B-X
we	B-X
found	B-X
that	B-X
TGF	B-X
-	B-X
beta1	B-X
significantly	B-X
increases	B-X
endogenous	B-X
germ	B-X
-	B-X
line	B-X
(	B-X
GL	B-X
)	B-X
alpha	B-X
transcripts	B-X
by	B-X
LPS	B-X
-	B-X
stimulated	B-X
CH12	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
overexpression	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
enhances	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
endogenous	B-X
GLalpha	B-X
transcripts	B-X
in	B-X
normal	B-X
spleen	B-X
B	B-X
cells	B-X
<EOS>	B-X
Smad3	B-X
and	B-X
Smad4	B-X
mediate	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
in	B-X
murine	B-X
B	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
results	B-X
from	B-X
the	B-X
present	B-X
study	B-X
indicate	B-X
that	B-X
Smad3	B-X
,	B-X
Smad4	B-X
,	B-X
and	B-X
Smad7	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
serve	B-X
as	B-X
mediators	B-X
linking	B-X
TGF	B-X
-	B-X
beta1	B-X
to	B-X
transcriptional	B-X
regulation	B-X
of	B-X
IgA	B-X
switching	B-X
related	B-X
gene	B-X
and	B-X
regulation	B-X
of	B-X
IgA	B-X
class	B-X
switching	B-X

To	O
investigate	O
its	O
signaling	O
mechanisms	O
,	O
the	O
lymphoma	B-cell_line
cell	I-cell_line
line	I-cell_line
was	O
transfected	O
with	O
pFL3	B-DNA
that	O
contains	O
the	O
TGF-beta-responsive	B-DNA
element	I-DNA
of	O
the	O
GLalpha	B-DNA
promoter	I-DNA
,	O
and	O
stimulated	O
with	O
TGF-beta1	B-protein
.	O
<EOS>	B-X
To	B-X
investigate	B-X
its	B-X
signaling	B-X
mechanisms	B-X
,	B-X
the	B-X
lymphoma	B-X
cell	B-X
line	B-X
was	B-X
transfected	B-X
with	B-X
pFL3	B-X
that	B-X
contains	B-X
the	B-X
TGF	B-X
-	B-X
beta	B-X
-	B-X
responsive	B-X
element	B-X
of	B-X
the	B-X
GLalpha	B-X
promoter	B-X
,	B-X
and	B-X
stimulated	B-X
with	B-X
TGF	B-X
-	B-X
beta1	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
Smad7	B-X
substantially	B-X
abrogates	B-X
the	B-X
synergistic	B-X
effect	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
onGLalpha	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
The	B-X
results	B-X
from	B-X
the	B-X
present	B-X
study	B-X
indicate	B-X
that	B-X
Smad3	B-X
,	B-X
Smad4	B-X
,	B-X
and	B-X
Smad7	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
serve	B-X
as	B-X
mediators	B-X
linking	B-X
TGF	B-X
-	B-X
beta1	B-X
to	B-X
transcriptional	B-X
regulation	B-X
of	B-X
IgA	B-X
switching	B-X
related	B-X
gene	B-X
and	B-X
regulation	B-X
of	B-X
IgA	B-X
class	B-X
switching	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
overexpression	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
enhances	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
endogenous	B-X
GLalpha	B-X
transcripts	B-X
in	B-X
normal	B-X
spleen	B-X
B	B-X
cells	B-X

Similar	O
to	O
endogenous	B-RNA
GLalpha	I-RNA
transcripts	I-RNA
,	O
TGF-beta1	B-protein
induces	O
GLalpha	B-DNA
promoter	I-DNA
activity	O
and	O
overexpression	O
of	O
Smad3	B-protein
markedly	O
enhances	O
the	O
promoter	O
activity	O
.	O
<EOS>	B-X
Similar	B-X
to	B-X
endogenous	B-X
GLalpha	B-X
transcripts	B-X
,	B-X
TGF	B-X
-	B-X
beta1	B-X
induces	B-X
GLalpha	B-X
promoter	B-X
activity	B-X
and	B-X
overexpression	B-X
of	B-X
Smad3	B-X
markedly	B-X
enhances	B-X
the	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
Smad7	B-X
substantially	B-X
abrogates	B-X
the	B-X
synergistic	B-X
effect	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
onGLalpha	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Smad3	B-X
and	B-X
Smad4	B-X
mediate	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
in	B-X
murine	B-X
B	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Finally	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
TGF	B-X
-	B-X
beta1	B-X
,	B-X
overexpression	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
selectively	B-X
increases	B-X
both	B-X
surface	B-X
IgA	B-X
expression	B-X
and	B-X
IgA	B-X
production	B-X

This	O
activity	O
is	O
further	O
augmented	O
by	O
cotransfected	B-protein
Smad4	I-protein
.	O
<EOS>	B-X
This	B-X
activity	B-X
is	B-X
further	B-X
augmented	B-X
by	B-X
cotransfected	B-X
Smad4	B-X
<EOS>	B-X
p300	B-X
,	B-X
which	B-X
has	B-X
histone	B-X
acetyltransferase	B-X
activity	B-X
,	B-X
further	B-X
augmented	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
GLalpha	B-X
transcription	B-X
promoted	B-X
by	B-X
Smad3	B-X
/	B-X
4	B-X
and	B-X
Runx3	B-X
<EOS>	B-X
The	B-X
activin	B-X
signaling	B-X
pathway	B-X
is	B-X
conserved	B-X
in	B-X
a	B-X
number	B-X
of	B-X
cells	B-X
,	B-X
but	B-X
FSHbeta	B-X
expression	B-X
is	B-X
restricted	B-X
to	B-X
gonadotropes	B-X
<EOS>	B-X
The	B-X
relevance	B-X
of	B-X
these	B-X
elements	B-X
was	B-X
confirmed	B-X
by	B-X
chromatin	B-X
immunoprecipitation	B-X
assay	B-X

On	O
the	O
other	O
hand	O
,	O
Smad7	B-protein
substantially	O
abrogates	O
the	O
synergistic	O
effect	O
of	O
Smad3/4	B-protein
on	O
GLalpha	B-DNA
promoter	I-DNA
activity	O
.	O
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
Smad7	B-X
substantially	B-X
abrogates	B-X
the	B-X
synergistic	B-X
effect	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
onGLalpha	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Similar	B-X
to	B-X
endogenous	B-X
GLalpha	B-X
transcripts	B-X
,	B-X
TGF	B-X
-	B-X
beta1	B-X
induces	B-X
GLalpha	B-X
promoter	B-X
activity	B-X
and	B-X
overexpression	B-X
of	B-X
Smad3	B-X
markedly	B-X
enhances	B-X
the	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
To	B-X
investigate	B-X
its	B-X
signaling	B-X
mechanisms	B-X
,	B-X
the	B-X
lymphoma	B-X
cell	B-X
line	B-X
was	B-X
transfected	B-X
with	B-X
pFL3	B-X
that	B-X
contains	B-X
the	B-X
TGF	B-X
-	B-X
beta	B-X
-	B-X
responsive	B-X
element	B-X
of	B-X
the	B-X
GLalpha	B-X
promoter	B-X
,	B-X
and	B-X
stimulated	B-X
with	B-X
TGF	B-X
-	B-X
beta1	B-X
<EOS>	B-X
The	B-X
results	B-X
from	B-X
the	B-X
present	B-X
study	B-X
indicate	B-X
that	B-X
Smad3	B-X
,	B-X
Smad4	B-X
,	B-X
and	B-X
Smad7	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
serve	B-X
as	B-X
mediators	B-X
linking	B-X
TGF	B-X
-	B-X
beta1	B-X
to	B-X
transcriptional	B-X
regulation	B-X
of	B-X
IgA	B-X
switching	B-X
related	B-X
gene	B-X
and	B-X
regulation	B-X
of	B-X
IgA	B-X
class	B-X
switching	B-X

In	O
addition	O
,	O
overexpression	O
of	O
Smad3/4	B-protein
enhances	O
TGF-beta1	B-protein
-induced	O
endogenous	B-RNA
GLalpha	I-RNA
transcripts	I-RNA
in	O
normal	B-cell_type
spleen	I-cell_type
B	I-cell_type
cell	I-cell_type
s	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
overexpression	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
enhances	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
endogenous	B-X
GLalpha	B-X
transcripts	B-X
in	B-X
normal	B-X
spleen	B-X
B	B-X
cells	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
involvement	B-X
of	B-X
Smad	B-X
proteins	B-X
in	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
<EOS>	B-X
Smad3	B-X
and	B-X
Smad4	B-X
mediate	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
in	B-X
murine	B-X
B	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
To	B-X
investigate	B-X
its	B-X
signaling	B-X
mechanisms	B-X
,	B-X
the	B-X
lymphoma	B-X
cell	B-X
line	B-X
was	B-X
transfected	B-X
with	B-X
pFL3	B-X
that	B-X
contains	B-X
the	B-X
TGF	B-X
-	B-X
beta	B-X
-	B-X
responsive	B-X
element	B-X
of	B-X
the	B-X
GLalpha	B-X
promoter	B-X
,	B-X
and	B-X
stimulated	B-X
with	B-X
TGF	B-X
-	B-X
beta1	B-X

Finally	O
,	O
in	O
the	O
presence	O
of	O
TGF-beta1	B-protein
,	O
overexpression	O
of	O
Smad3/4	B-protein
selectively	O
increases	O
both	O
surface	O
IgA	O
expression	O
and	O
IgA	O
production	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
TGF	B-X
-	B-X
beta1	B-X
,	B-X
overexpression	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
selectively	B-X
increases	B-X
both	B-X
surface	B-X
IgA	B-X
expression	B-X
and	B-X
IgA	B-X
production	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
involvement	B-X
of	B-X
Smad	B-X
proteins	B-X
in	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
IgA	B-X
expression	B-X
<EOS>	B-X
Similar	B-X
to	B-X
endogenous	B-X
GLalpha	B-X
transcripts	B-X
,	B-X
TGF	B-X
-	B-X
beta1	B-X
induces	B-X
GLalpha	B-X
promoter	B-X
activity	B-X
and	B-X
overexpression	B-X
of	B-X
Smad3	B-X
markedly	B-X
enhances	B-X
the	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
	B-X
-	B-X
beta1	B-X
is	B-X
well	B-X
established	B-X
as	B-X
a	B-X
critical	B-X
IgA	B-X
isotype	B-X
switching	B-X
factor	B-X
and	B-X
Smad	B-X
molecules	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
act	B-X
as	B-X
transducers	B-X
and	B-X
transcriptional	B-X
factors	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
targeted	B-X
genes	B-X

The	O
results	O
from	O
the	O
present	O
study	O
indicate	O
that	O
Smad3	B-protein
,	O
Smad4	B-protein
,	O
and	O
Smad7	B-protein
,	O
at	O
least	O
in	O
part	O
,	O
serve	O
as	O
mediators	O
linking	O
TGF-beta1	B-protein
to	O
transcriptional	O
regulation	O
of	O
IgA	B-DNA
switching	I-DNA
related	I-DNA
gene	I-DNA
and	O
regulation	O
of	O
IgA	O
class	O
switching	O
.	O
<EOS>	B-X
The	B-X
results	B-X
from	B-X
the	B-X
present	B-X
study	B-X
indicate	B-X
that	B-X
Smad3	B-X
,	B-X
Smad4	B-X
,	B-X
and	B-X
Smad7	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
serve	B-X
as	B-X
mediators	B-X
linking	B-X
TGF	B-X
-	B-X
beta1	B-X
to	B-X
transcriptional	B-X
regulation	B-X
of	B-X
IgA	B-X
switching	B-X
related	B-X
gene	B-X
and	B-X
regulation	B-X
of	B-X
IgA	B-X
class	B-X
switching	B-X
<EOS>	B-X
To	B-X
investigate	B-X
its	B-X
signaling	B-X
mechanisms	B-X
,	B-X
the	B-X
lymphoma	B-X
cell	B-X
line	B-X
was	B-X
transfected	B-X
with	B-X
pFL3	B-X
that	B-X
contains	B-X
the	B-X
TGF	B-X
-	B-X
beta	B-X
-	B-X
responsive	B-X
element	B-X
of	B-X
the	B-X
GLalpha	B-X
promoter	B-X
,	B-X
and	B-X
stimulated	B-X
with	B-X
TGF	B-X
-	B-X
beta1	B-X
<EOS>	B-X
Finally	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
TGF	B-X
-	B-X
beta1	B-X
,	B-X
overexpression	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
selectively	B-X
increases	B-X
both	B-X
surface	B-X
IgA	B-X
expression	B-X
and	B-X
IgA	B-X
production	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
overexpression	B-X
of	B-X
Smad3	B-X
/	B-X
4	B-X
enhances	B-X
TGF	B-X
-	B-X
beta1	B-X
-	B-X
induced	B-X
endogenous	B-X
GLalpha	B-X
transcripts	B-X
in	B-X
normal	B-X
spleen	B-X
B	B-X
cells	B-X

The	O
translesion	B-protein
DNA	I-protein
polymerase	I-protein
zeta	I-protein
plays	O
a	O
major	O
role	O
in	O
Ig	O
and	O
bcl-6	O
somatic	O
hypermutation	O
.	O

Ig	O
somatic	O
mutations	O
would	O
be	O
introduced	O
by	O
a	O
polymerase	B-protein
(	O
pol	B-protein
)	O
while	O
repairing	O
DNA	O
outside	O
main	O
DNA	O
replication	O
.	O
<EOS>	B-X
Ig	B-X
somatic	B-X
mutations	B-X
would	B-X
be	B-X
introduced	B-X
by	B-X
a	B-X
polymerase	B-X
(	B-X
pol	B-X
)	B-X
while	B-X
repairing	B-X
DNA	B-X
outside	B-X
main	B-X
DNA	B-X
replication	B-X
<EOS>	B-X
The	B-X
translesion	B-X
DNA	B-X
polymerase	B-X
zeta	B-X
plays	B-X
a	B-X
major	B-X
role	B-X
in	B-X
Ig	B-X
and	B-X
bcl	B-X
-	B-X
6	B-X
somatic	B-X
hypermutation	B-X
.	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
human	B-X
B	B-X
cells	B-X
constitutively	B-X
express	B-X
the	B-X
translesion	B-X
pol	B-X
zeta	B-X
,	B-X
which	B-X
effectively	B-X
extends	B-X
DNA	B-X
past	B-X
mismatched	B-X
bases	B-X
(	B-X
mispair	B-X
extender	B-X
)	B-X
,	B-X
and	B-X
pol	B-X
eta	B-X
,	B-X
which	B-X
bypasses	B-X
DNA	B-X
lesions	B-X
in	B-X
an	B-X
error	B-X
-	B-X
free	B-X
fashion	B-X
<EOS>	B-X
Upon	B-X
B	B-X
cell	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
engagement	B-X
and	B-X
coculture	B-X
with	B-X
activated	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
these	B-X
lymphocytes	B-X
upregulated	B-X
pol	B-X
zeta	B-X
,	B-X
downregulated	B-X
pol	B-X
eta	B-X
,	B-X
and	B-X
mutated	B-X
the	B-X
Ig	B-X
and	B-X
bcl	B-X
-	B-X
6	B-X
genes	B-X

We	O
show	O
that	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
constitutively	O
express	O
the	O
translesion	B-protein
pol	I-protein
zeta	I-protein
,	O
which	O
effectively	O
extends	O
DNA	O
past	O
mismatched	O
bases	O
(	O
mispair	O
extender	O
)	O
,	O
and	O
pol	B-protein
eta	I-protein
,	O
which	O
bypasses	O
DNA	O
lesions	O
in	O
an	O
error-free	O
fashion	O
.	O

Upon	O
B	B-protein
cell	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
engagement	O
and	O
coculture	O
with	O
activated	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
these	O
lymphocytes	B-cell_type
upregulated	O
pol	B-protein
zeta	I-protein
,	O
downregulated	O
pol	B-protein
eta	I-protein
,	O
and	O
mutated	O
the	O
Ig	B-DNA
and	I-DNA
bcl-6	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
Upon	B-X
B	B-X
cell	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
engagement	B-X
and	B-X
coculture	B-X
with	B-X
activated	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
these	B-X
lymphocytes	B-X
upregulated	B-X
pol	B-X
zeta	B-X
,	B-X
downregulated	B-X
pol	B-X
eta	B-X
,	B-X
and	B-X
mutated	B-X
the	B-X
Ig	B-X
and	B-X
bcl	B-X
-	B-X
6	B-X
genes	B-X
<EOS>	B-X
Thus	B-X
,	B-X
pol	B-X
zeta	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
Ig	B-X
and	B-X
bcl	B-X
-	B-X
6	B-X
hypermutation	B-X
,	B-X
perhaps	B-X
facilitated	B-X
by	B-X
the	B-X
downregulation	B-X
of	B-X
pol	B-X
eta	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
human	B-X
B	B-X
cells	B-X
constitutively	B-X
express	B-X
the	B-X
translesion	B-X
pol	B-X
zeta	B-X
,	B-X
which	B-X
effectively	B-X
extends	B-X
DNA	B-X
past	B-X
mismatched	B-X
bases	B-X
(	B-X
mispair	B-X
extender	B-X
)	B-X
,	B-X
and	B-X
pol	B-X
eta	B-X
,	B-X
which	B-X
bypasses	B-X
DNA	B-X
lesions	B-X
in	B-X
an	B-X
error	B-X
-	B-X
free	B-X
fashion	B-X
<EOS>	B-X
Ig	B-X
somatic	B-X
mutations	B-X
would	B-X
be	B-X
introduced	B-X
by	B-X
a	B-X
polymerase	B-X
(	B-X
pol	B-X
)	B-X
while	B-X
repairing	B-X
DNA	B-X
outside	B-X
main	B-X
DNA	B-X
replication	B-X

Inhibition	O
of	O
the	O
pol	B-protein
zeta	I-protein
REV3	B-protein
catalytic	I-protein
subunit	I-protein
by	O
specific	O
phosphorothioate-modified	O
oligonucleotides	O
impaired	O
Ig	O
and	O
bcl-6	O
hypermutation	O
and	O
UV	O
damage-induced	O
DNA	O
mutagenesis	O
,	O
without	O
affecting	O
cell	O
cycle	O
or	O
viability	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
step	B-X
-	B-X
by	B-X
-	B-X
step	B-X
workflow	B-X
for	B-X
tissue	B-X
acquisition	B-X
,	B-X
dissection	B-X
,	B-X
and	B-X
sectioning	B-X
of	B-X
300	B-X
-	B-X
μm	B-X
tumor	B-X
slices	B-X
maintaining	B-X
cell	B-X
viability	B-X
<EOS>	B-X
We	B-X
hypothesize	B-X
that	B-X
calpain	B-X
-	B-X
2	B-X
causes	B-X
desensitization	B-X
of	B-X
tumor	B-X
cells	B-X
against	B-X
TMZ	B-X
by	B-X
preventing	B-X
strong	B-X
DNA	B-X
damage	B-X
and	B-X
subsequent	B-X
apoptosis	B-X
via	B-X
post	B-X
-	B-X
translational	B-X
TP53	B-X
inhibition	B-X
<EOS>	B-X
In	B-X
the	B-X
mouse	B-X
AS	B-X
model	B-X
,	B-X
restoration	B-X
of	B-X
miR	B-X
-	B-X
202	B-X
-	B-X
5p	B-X
stimulated	B-X
atherosclerotic	B-X
plaque	B-X
formation	B-X
,	B-X
but	B-X
reduced	B-X
collagen	B-X
synthesis	B-X
and	B-X
fiber	B-X
cap	B-X
thickness	B-X
<EOS>	B-X
It	B-X
also	B-X
offered	B-X
features	B-X
such	B-X
as	B-X
pain	B-X
relief	B-X
,	B-X
good	B-X
attachment	B-X
and	B-X
adhesiveness	B-X
,	B-X
improved	B-X
wound	B-X
healing	B-X
and	B-X
suppressed	B-X
scar	B-X
formation	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
ACC	B-X
skin	B-X
defects	B-X

Thus	O
,	O
pol	B-protein
zeta	I-protein
plays	O
a	O
critical	O
role	O
in	O
Ig	O
and	O
bcl-6	O
hypermutation	O
,	O
perhaps	O
facilitated	O
by	O
the	O
downregulation	O
of	O
pol	B-protein
eta	I-protein
.	O

Molecular	O
mechanism	O
of	O
cell	O
cycle	O
progression	O
induced	O
by	O
the	O
oncogene	B-protein
product	I-protein
Tax	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O
<EOS>	B-X
Molecular	B-X
mechanism	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
induced	B-X
by	B-X
the	B-X
oncogene	B-X
product	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
Cell	B-X
type	B-X
-	B-X
specific	B-X
E2F	B-X
activation	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
induced	B-X
by	B-X
the	B-X
oncogene	B-X
product	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
Direct	B-X
trans	B-X
-	B-X
activation	B-X
of	B-X
the	B-X
human	B-X
cyclin	B-X
D2	B-X
gene	B-X
by	B-X
the	B-X
oncogene	B-X
product	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
The	B-X
molecular	B-X
mechanism	B-X
of	B-X
leukemogenesis	B-X
induced	B-X
by	B-X
Tax	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
elucidated	B-X

The	O
trans-activator	B-protein
protein	I-protein
Tax	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
adult	O
T-cell	O
leukemia	O
through	O
,	O
at	O
least	O
in	O
part	O
,	O
its	O
ability	O
to	O
stimulate	O
cell	O
growth	O
.	O
<EOS>	B-X
The	B-X
trans	B-X
-	B-X
activator	B-X
protein	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
through	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
its	B-X
ability	B-X
to	B-X
stimulate	B-X
cell	B-X
growth	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
the	B-X
important	B-X
role	B-X
of	B-X
Tax	B-X
-	B-X
mediated	B-X
trans	B-X
-	B-X
activation	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
cell	B-X
cycle	B-X
regulatory	B-X
molecules	B-X
in	B-X
Tax	B-X
-	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
Molecular	B-X
mechanism	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
induced	B-X
by	B-X
the	B-X
oncogene	B-X
product	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
Tax	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
from	B-X
G0	B-X
/	B-X
G1	B-X
phase	B-X
to	B-X
S	B-X
and	B-X
G2	B-X
/	B-X
M	B-X
phases	B-X
in	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
Kit	B-X
225	B-X
cells	B-X

We	O
previously	O
reported	O
that	O
Tax	B-protein
induced	O
cell	O
cycle	O
progression	O
from	O
G0/G1	O
phase	O
to	O
S	O
and	O
G2/M	O
phases	O
in	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
Kit	I-cell_line
225	I-cell_line
cells	I-cell_line
.	O

To	O
elucidate	O
molecular	O
mechanism	O
of	O
Tax	B-protein
-induced	O
cell	O
cycle	O
progression	O
,	O
we	O
systematically	O
examined	O
the	O
effects	O
of	O
Tax	B-protein
on	O
biochemical	O
events	O
associated	O
with	O
cell	O
cycle	O
progression	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
molecular	B-X
mechanism	B-X
of	B-X
Tax	B-X
-	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
we	B-X
systematically	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
Tax	B-X
on	B-X
biochemical	B-X
events	B-X
associated	B-X
with	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
Molecular	B-X
mechanism	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
induced	B-X
by	B-X
the	B-X
oncogene	B-X
product	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
.	B-X
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
Tax	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
from	B-X
G0	B-X
/	B-X
G1	B-X
phase	B-X
to	B-X
S	B-X
and	B-X
G2	B-X
/	B-X
M	B-X
phases	B-X
in	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
Kit	B-X
225	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
the	B-X
important	B-X
role	B-X
of	B-X
Tax	B-X
-	B-X
mediated	B-X
trans	B-X
-	B-X
activation	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
cell	B-X
cycle	B-X
regulatory	B-X
molecules	B-X
in	B-X
Tax	B-X
-	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X

Introduction	O
of	O
Tax	B-protein
into	O
resting	B-cell_line
Kit	I-cell_line
225	I-cell_line
cells	I-cell_line
induced	O
activation	O
of	O
the	O
G1/S	O
transition	O
regulation	O
cascade	O
consisting	O
of	O
activation	O
of	O
cyclin	B-protein
dependent	I-protein
kinase	I-protein
2	I-protein
(	O
CDK2	B-protein
)	O
and	O
CDK4	B-protein
,	O
phosphorylation	O
of	O
the	O
Rb	B-protein
family	I-protein
proteins	I-protein
and	O
an	O
increase	O
in	O
free	O
E2F	B-protein
.	O

The	O
kinase	O
activation	O
was	O
found	O
to	O
result	O
from	O
Tax	B-protein
-induced	O
expression	O
of	O
genes	O
for	O
cell	B-protein
cycle	I-protein
regulatory	I-protein
molecules	I-protein
including	O
cyclin	B-protein
D2	I-protein
,	O
cyclin	B-protein
E	I-protein
,	O
E2F1	B-protein
,	O
CDK2	B-protein
,	O
CDK4	B-protein
and	O
CDK6	B-protein
,	O
and	O
Tax	B-protein
-induced	O
reduction	O
of	O
CDK	B-protein
inhibitors	I-protein
p19	I-protein
(	O
INK4d	B-protein
)	O
and	O
p27	B-protein
(	I-protein
Kip1	I-protein
)	I-protein
.	O
<EOS>	B-X
The	B-X
kinase	B-X
activation	B-X
was	B-X
found	B-X
to	B-X
result	B-X
from	B-X
Tax	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
genes	B-X
for	B-X
cell	B-X
cycle	B-X
regulatory	B-X
molecules	B-X
including	B-X
cyclin	B-X
D2	B-X
,	B-X
cyclin	B-X
E	B-X
,	B-X
E2F1	B-X
,	B-X
CDK2	B-X
,	B-X
CDK4	B-X
and	B-X
CDK6	B-X
,	B-X
and	B-X
Tax	B-X
-	B-X
induced	B-X
reduction	B-X
of	B-X
CDK	B-X
inhibitors	B-X
p19	B-X
(	B-X
INK4d	B-X
)	B-X
and	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
the	B-X
important	B-X
role	B-X
of	B-X
Tax	B-X
-	B-X
mediated	B-X
trans	B-X
-	B-X
activation	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
cell	B-X
cycle	B-X
regulatory	B-X
molecules	B-X
in	B-X
Tax	B-X
-	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
Introduction	B-X
of	B-X
Tax	B-X
into	B-X
resting	B-X
Kit	B-X
225	B-X
cells	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
G1	B-X
/	B-X
S	B-X
transition	B-X
regulation	B-X
cascade	B-X
consisting	B-X
of	B-X
activation	B-X
of	B-X
cyclin	B-X
dependent	B-X
kinase	B-X
2	B-X
(	B-X
CDK2	B-X
)	B-X
and	B-X
CDK4	B-X
,	B-X
phosphorylation	B-X
of	B-X
the	B-X
Rb	B-X
family	B-X
proteins	B-X
and	B-X
an	B-X
increase	B-X
in	B-X
free	B-X
E2F	B-X
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
Tax	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
from	B-X
G0	B-X
/	B-X
G1	B-X
phase	B-X
to	B-X
S	B-X
and	B-X
G2	B-X
/	B-X
M	B-X
phases	B-X
in	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
Kit	B-X
225	B-X
cells	B-X

These	O
modulations	O
by	O
Tax	B-protein
always	O
paralleled	O
the	O
ability	O
of	O
Tax	B-protein
to	O
activate	O
the	O
NF-kappaB	O
transcription	O
pathway	O
.	O
<EOS>	B-X
These	B-X
modulations	B-X
by	B-X
Tax	B-X
always	B-X
paralleled	B-X
the	B-X
ability	B-X
of	B-X
Tax	B-X
to	B-X
activate	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
pathway	B-X
<EOS>	B-X
To	B-X
elucidate	B-X
molecular	B-X
mechanism	B-X
of	B-X
Tax	B-X
-	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
we	B-X
systematically	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
Tax	B-X
on	B-X
biochemical	B-X
events	B-X
associated	B-X
with	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
The	B-X
trans	B-X
-	B-X
activator	B-X
protein	B-X
Tax	B-X
of	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
through	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
its	B-X
ability	B-X
to	B-X
stimulate	B-X
cell	B-X
growth	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
the	B-X
important	B-X
role	B-X
of	B-X
Tax	B-X
-	B-X
mediated	B-X
trans	B-X
-	B-X
activation	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
cell	B-X
cycle	B-X
regulatory	B-X
molecules	B-X
in	B-X
Tax	B-X
-	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X

These	O
results	O
indicate	O
the	O
important	O
role	O
of	O
Tax	B-protein
-mediated	O
trans-activation	O
of	O
the	O
genes	O
for	O
cell	B-protein
cycle	I-protein
regulatory	I-protein
molecules	I-protein
in	O
Tax	B-protein
-induced	O
cell	O
cycle	O
progression	O
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
the	B-X
important	B-X
role	B-X
of	B-X
Tax	B-X
-	B-X
mediated	B-X
trans	B-X
-	B-X
activation	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
cell	B-X
cycle	B-X
regulatory	B-X
molecules	B-X
in	B-X
Tax	B-X
-	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
The	B-X
kinase	B-X
activation	B-X
was	B-X
found	B-X
to	B-X
result	B-X
from	B-X
Tax	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
genes	B-X
for	B-X
cell	B-X
cycle	B-X
regulatory	B-X
molecules	B-X
including	B-X
cyclin	B-X
D2	B-X
,	B-X
cyclin	B-X
E	B-X
,	B-X
E2F1	B-X
,	B-X
CDK2	B-X
,	B-X
CDK4	B-X
and	B-X
CDK6	B-X
,	B-X
and	B-X
Tax	B-X
-	B-X
induced	B-X
reduction	B-X
of	B-X
CDK	B-X
inhibitors	B-X
p19	B-X
(	B-X
INK4d	B-X
)	B-X
and	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
<EOS>	B-X
To	B-X
elucidate	B-X
molecular	B-X
mechanism	B-X
of	B-X
Tax	B-X
-	B-X
induced	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
we	B-X
systematically	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
Tax	B-X
on	B-X
biochemical	B-X
events	B-X
associated	B-X
with	B-X
cell	B-X
cycle	B-X
progression	B-X
<EOS>	B-X
Introduction	B-X
of	B-X
Tax	B-X
into	B-X
resting	B-X
Kit	B-X
225	B-X
cells	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
G1	B-X
/	B-X
S	B-X
transition	B-X
regulation	B-X
cascade	B-X
consisting	B-X
of	B-X
activation	B-X
of	B-X
cyclin	B-X
dependent	B-X
kinase	B-X
2	B-X
(	B-X
CDK2	B-X
)	B-X
and	B-X
CDK4	B-X
,	B-X
phosphorylation	B-X
of	B-X
the	B-X
Rb	B-X
family	B-X
proteins	B-X
and	B-X
an	B-X
increase	B-X
in	B-X
free	B-X
E2F	B-X

Cot	B-protein
kinase	I-protein
induces	O
cyclooxygenase-2	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
through	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

Cyclooxygenase-2	B-protein
(	O
COX-2	B-protein
)	O
is	O
induced	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
triggering	O
.	O

Here	O
we	O
report	O
that	O
Cot	B-protein
kinase	I-protein
,	O
a	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
kinase	I-protein
kinase	I-protein
involved	O
in	O
T	O
cell	O
activation	O
,	O
up-regulates	O
COX-2	B-DNA
gene	I-DNA
expression	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Induction	O
of	O
COX-2	O
promoter	O
activity	O
by	O
Cot	B-protein
kinase	I-protein
occurred	O
mainly	O
through	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
by	B-X
Cot	B-X
kinase	B-X
occurred	B-X
mainly	B-X
through	B-X
activation	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
<EOS>	B-X
Cot	B-X
kinase	B-X
induces	B-X
cyclooxygenase	B-X
-	B-X
2	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
through	B-X
activation	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
phorbol	B-X
ester	B-X
plus	B-X
calcium	B-X
ionophore	B-X
A23187	B-X
,	B-X
Cot	B-X
kinase	B-X
increases	B-X
both	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
and	B-X
NFAT	B-X
-	B-X
mediated	B-X
transactivation	B-X
in	B-X
a	B-X
cyclosporin	B-X
A	B-X
-	B-X
independent	B-X
manner	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Cot	B-X
kinase	B-X
up	B-X
-	B-X
regulates	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
driven	B-X
transcription	B-X
through	B-X
the	B-X
NFAT	B-X
response	B-X
elements	B-X
,	B-X
being	B-X
the	B-X
Cot	B-X
kinase	B-X
-	B-X
induced	B-X
NFAT	B-X
-	B-X
dependent	B-X
transactivation	B-X
presumably	B-X
implicated	B-X
in	B-X
this	B-X
up	B-X
-	B-X
regulation	B-X

Mutation	O
of	O
the	O
distal	B-DNA
(	I-DNA
-105/-97	I-DNA
)	I-DNA
and	O
proximal	B-DNA
(	I-DNA
-76/-61	I-DNA
)	I-DNA
NFAT	B-DNA
response	I-DNA
elements	I-DNA
in	O
the	O
COX-2	B-DNA
promoter	I-DNA
abolished	O
the	O
activation	O
induced	O
by	O
Cot	B-protein
kinase	I-protein
.	O
<EOS>	B-X
Mutation	B-X
of	B-X
the	B-X
distal	B-X
(	B-X
	B-X
-	B-X
105	B-X
/	B-X
	B-X
-	B-X
97	B-X
)	B-X
and	B-X
proximal	B-X
(	B-X
	B-X
-	B-X
76	B-X
/	B-X
	B-X
-	B-X
61	B-X
)	B-X
NFAT	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
abolished	B-X
the	B-X
activation	B-X
induced	B-X
by	B-X
Cot	B-X
kinase	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Cot	B-X
kinase	B-X
up	B-X
-	B-X
regulates	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
driven	B-X
transcription	B-X
through	B-X
the	B-X
NFAT	B-X
response	B-X
elements	B-X
,	B-X
being	B-X
the	B-X
Cot	B-X
kinase	B-X
-	B-X
induced	B-X
NFAT	B-X
-	B-X
dependent	B-X
transactivation	B-X
presumably	B-X
implicated	B-X
in	B-X
this	B-X
up	B-X
-	B-X
regulation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
phorbol	B-X
ester	B-X
plus	B-X
calcium	B-X
ionophore	B-X
A23187	B-X
,	B-X
Cot	B-X
kinase	B-X
increases	B-X
both	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
and	B-X
NFAT	B-X
-	B-X
mediated	B-X
transactivation	B-X
in	B-X
a	B-X
cyclosporin	B-X
A	B-X
-	B-X
independent	B-X
manner	B-X
<EOS>	B-X
Strikingly	B-X
,	B-X
Cot	B-X
kinase	B-X
increased	B-X
transactivation	B-X
mediated	B-X
by	B-X
a	B-X
GAL4	B-X
-	B-X
NFAT	B-X
fusion	B-X
protein	B-X
containing	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
transactivation	B-X
domain	B-X
of	B-X
NFATp	B-X

Even	O
more	O
,	O
coexpression	O
of	O
a	O
dominant	O
negative	O
version	O
of	O
NFAT	B-protein
inhibited	O
Cot	B-protein
kinase	I-protein
-mediated	O
COX-2	B-DNA
promoter	I-DNA
activation	O
,	O
whereas	O
cotransfection	O
of	O
a	O
constitutively	O
active	O
version	O
of	O
the	O
calcium-dependent	B-protein
phosphatase	I-protein
calcineurin	I-protein
synergizes	O
with	O
Cot	B-protein
kinase	I-protein
in	O
the	O
up-regulation	O
of	O
COX-2	B-DNA
promoter	I-DNA
-driven	O
transcription	O
.	O
<EOS>	B-X
Even	B-X
more	B-X
,	B-X
coexpression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
version	B-X
of	B-X
NFAT	B-X
inhibited	B-X
Cot	B-X
kinase	B-X
-	B-X
mediated	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
activation	B-X
,	B-X
whereas	B-X
cotransfection	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
version	B-X
of	B-X
the	B-X
calcium	B-X
-	B-X
dependent	B-X
phosphatase	B-X
calcineurin	B-X
synergizes	B-X
with	B-X
Cot	B-X
kinase	B-X
in	B-X
the	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
driven	B-X
transcription	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Cot	B-X
kinase	B-X
up	B-X
-	B-X
regulates	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
driven	B-X
transcription	B-X
through	B-X
the	B-X
NFAT	B-X
response	B-X
elements	B-X
,	B-X
being	B-X
the	B-X
Cot	B-X
kinase	B-X
-	B-X
induced	B-X
NFAT	B-X
-	B-X
dependent	B-X
transactivation	B-X
presumably	B-X
implicated	B-X
in	B-X
this	B-X
up	B-X
-	B-X
regulation	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Cot	B-X
kinase	B-X
,	B-X
a	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
kinase	B-X
kinase	B-X
involved	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
up	B-X
-	B-X
regulates	B-X
COX	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
phorbol	B-X
ester	B-X
plus	B-X
calcium	B-X
ionophore	B-X
A23187	B-X
,	B-X
Cot	B-X
kinase	B-X
increases	B-X
both	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
and	B-X
NFAT	B-X
-	B-X
mediated	B-X
transactivation	B-X
in	B-X
a	B-X
cyclosporin	B-X
A	B-X
-	B-X
independent	B-X
manner	B-X

Strikingly	O
,	O
Cot	B-protein
kinase	I-protein
increased	O
transactivation	O
mediated	O
by	O
a	O
GAL4-NFAT	B-protein
fusion	I-protein
protein	I-protein
containing	O
the	O
N-terminal	B-protein
transactivation	I-protein
domain	I-protein
of	O
NFATp	B-protein
.	O
<EOS>	B-X
Strikingly	B-X
,	B-X
Cot	B-X
kinase	B-X
increased	B-X
transactivation	B-X
mediated	B-X
by	B-X
a	B-X
GAL4	B-X
-	B-X
NFAT	B-X
fusion	B-X
protein	B-X
containing	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
transactivation	B-X
domain	B-X
of	B-X
NFATp	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Cot	B-X
kinase	B-X
up	B-X
-	B-X
regulates	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
driven	B-X
transcription	B-X
through	B-X
the	B-X
NFAT	B-X
response	B-X
elements	B-X
,	B-X
being	B-X
the	B-X
Cot	B-X
kinase	B-X
-	B-X
induced	B-X
NFAT	B-X
-	B-X
dependent	B-X
transactivation	B-X
presumably	B-X
implicated	B-X
in	B-X
this	B-X
up	B-X
-	B-X
regulation	B-X
<EOS>	B-X
Cot	B-X
kinase	B-X
induces	B-X
cyclooxygenase	B-X
-	B-X
2	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
through	B-X
activation	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
phorbol	B-X
ester	B-X
plus	B-X
calcium	B-X
ionophore	B-X
A23187	B-X
,	B-X
Cot	B-X
kinase	B-X
increases	B-X
both	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
and	B-X
NFAT	B-X
-	B-X
mediated	B-X
transactivation	B-X
in	B-X
a	B-X
cyclosporin	B-X
A	B-X
-	B-X
independent	B-X
manner	B-X

In	O
contrast	O
to	O
phorbol	O
ester	O
plus	O
calcium	O
ionophore	O
A23187	O
,	O
Cot	B-protein
kinase	I-protein
increases	O
both	O
COX-2	B-DNA
promoter	I-DNA
activity	O
and	O
NFAT	B-protein
-mediated	O
transactivation	O
in	O
a	O
cyclosporin	O
A-independent	O
manner	O
.	O

These	O
data	O
indicate	O
that	O
Cot	B-protein
kinase	I-protein
up-regulates	O
COX-2	B-DNA
promoter	I-DNA
-driven	O
transcription	O
through	O
the	O
NFAT	B-DNA
response	I-DNA
elements	I-DNA
,	O
being	O
the	O
Cot	B-protein
kinase	I-protein
-induced	O
NFAT	B-protein
-dependent	O
transactivation	O
presumably	O
implicated	O
in	O
this	O
up-regulation	O
.	O
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Cot	B-X
kinase	B-X
up	B-X
-	B-X
regulates	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
-	B-X
driven	B-X
transcription	B-X
through	B-X
the	B-X
NFAT	B-X
response	B-X
elements	B-X
,	B-X
being	B-X
the	B-X
Cot	B-X
kinase	B-X
-	B-X
induced	B-X
NFAT	B-X
-	B-X
dependent	B-X
transactivation	B-X
presumably	B-X
implicated	B-X
in	B-X
this	B-X
up	B-X
-	B-X
regulation	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
the	B-X
distal	B-X
(	B-X
	B-X
-	B-X
105	B-X
/	B-X
	B-X
-	B-X
97	B-X
)	B-X
and	B-X
proximal	B-X
(	B-X
	B-X
-	B-X
76	B-X
/	B-X
	B-X
-	B-X
61	B-X
)	B-X
NFAT	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
COX	B-X
-	B-X
2	B-X
promoter	B-X
abolished	B-X
the	B-X
activation	B-X
induced	B-X
by	B-X
Cot	B-X
kinase	B-X
<EOS>	B-X
Strikingly	B-X
,	B-X
Cot	B-X
kinase	B-X
increased	B-X
transactivation	B-X
mediated	B-X
by	B-X
a	B-X
GAL4	B-X
-	B-X
NFAT	B-X
fusion	B-X
protein	B-X
containing	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
transactivation	B-X
domain	B-X
of	B-X
NFATp	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Cot	B-X
kinase	B-X
,	B-X
a	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
kinase	B-X
kinase	B-X
involved	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
up	B-X
-	B-X
regulates	B-X
COX	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X

Positive	O
and	O
negative	O
roles	O
of	O
the	O
trans-acting	B-protein
T	I-protein
cell	I-protein
factor-1	I-protein
for	O
the	O
acquisition	O
of	O
distinct	O
Ly-49	B-protein
MHC	I-protein
class	I-protein
I	I-protein
receptors	I-protein
by	O
NK	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Positive	B-X
and	B-X
negative	B-X
roles	B-X
of	B-X
the	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
distinct	B-X
Ly	B-X
-	B-X
49	B-X
MHC	B-X
class	B-X
I	B-X
receptors	B-X
by	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
Our	B-X
findings	B-X
rather	B-X
suggest	B-X
a	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
,	B-X
cell	B-X
autonomous	B-X
effect	B-X
on	B-X
the	B-X
acquisition	B-X
of	B-X
multiple	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
<EOS>	B-X
These	B-X
findings	B-X
reveal	B-X
an	B-X
important	B-X
role	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
NK	B-X
cell	B-X
receptor	B-X
repertoire	B-X
<EOS>	B-X
TCF	B-X
-	B-X
1	B-X
deficiency	B-X
resulted	B-X
in	B-X
the	B-X
altered	B-X
usage	B-X
of	B-X
additional	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X

Members	O
of	O
the	O
Ly-49	B-DNA
gene	I-DNA
family	I-DNA
code	O
for	O
class	B-protein
I	I-protein
MHC-specific	I-protein
receptors	I-protein
that	O
regulate	O
NK	O
cell	O
function	O
.	O

Due	O
to	O
a	O
combinatorial	O
distribution	O
of	O
Ly-49	B-protein
receptors	I-protein
,	O
NK	B-cell_type
cells	I-cell_type
display	O
considerable	O
clonal	O
heterogeneity	O
.	O
<EOS>	B-X
Due	B-X
to	B-X
a	B-X
combinatorial	B-X
distribution	B-X
of	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
,	B-X
NK	B-X
cells	B-X
display	B-X
considerable	B-X
clonal	B-X
heterogeneity	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
the	B-X
observed	B-X
differential	B-X
,	B-X
positive	B-X
or	B-X
negative	B-X
role	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
for	B-X
Ly	B-X
-	B-X
49	B-X
receptor	B-X
acquisition	B-X
,	B-X
reporter	B-X
gene	B-X
assays	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
inducing	B-X
as	B-X
well	B-X
as	B-X
a	B-X
repressing	B-X
TCF	B-X
site	B-X
in	B-X
certain	B-X
proximal	B-X
Ly	B-X
-	B-X
49	B-X
promoters	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
binds	B-X
to	B-X
two	B-X
sites	B-X
in	B-X
the	B-X
Ly	B-X
-	B-X
49a	B-X
promoter	B-X
and	B-X
regulates	B-X
its	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Ly	B-X
-	B-X
49a	B-X
gene	B-X
is	B-X
a	B-X
direct	B-X
TCF	B-X
-	B-X
1	B-X
target	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
besides	B-X
TCF	B-X
-	B-X
1	B-X
binding	B-X
to	B-X
the	B-X
proximal	B-X
promoter	B-X
,	B-X
Ly	B-X
-	B-X
49	B-X
acquisition	B-X
may	B-X
also	B-X
be	B-X
regulated	B-X
by	B-X
TCF	B-X
-	B-X
1	B-X
binding	B-X
to	B-X
more	B-X
distant	B-X
cis	B-X
-	B-X
acting	B-X
elements	B-X
and	B-X
/	B-X
or	B-X
by	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
additional	B-X
trans	B-X
-	B-X
acting	B-X
factors	B-X

The	O
acquisition	O
of	O
one	O
Ly-49	B-protein
receptor	I-protein
,	O
Ly-49A	B-protein
is	O
strictly	O
dependent	O
on	O
the	O
transcriptional	B-protein
trans-acting	I-protein
factor	I-protein
T	B-protein
cell-specific	I-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
.	O
<EOS>	B-X
The	B-X
acquisition	B-X
of	B-X
one	B-X
Ly	B-X
-	B-X
49	B-X
receptor	B-X
,	B-X
Ly	B-X
-	B-X
49A	B-X
is	B-X
strictly	B-X
dependent	B-X
on	B-X
the	B-X
transcriptional	B-X
trans	B-X
-	B-X
acting	B-X
factor	B-X
T	B-X
cell	B-X
-	B-X
specific	B-X
factor	B-X
-	B-X
1	B-X
(	B-X
TCF	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
These	B-X
findings	B-X
reveal	B-X
an	B-X
important	B-X
role	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
NK	B-X
cell	B-X
receptor	B-X
repertoire	B-X
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
Ly	B-X
-	B-X
49	B-X
gene	B-X
family	B-X
code	B-X
for	B-X
class	B-X
I	B-X
MHC	B-X
-	B-X
specific	B-X
receptors	B-X
that	B-X
regulate	B-X
NK	B-X
cell	B-X
function	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
besides	B-X
TCF	B-X
-	B-X
1	B-X
binding	B-X
to	B-X
the	B-X
proximal	B-X
promoter	B-X
,	B-X
Ly	B-X
-	B-X
49	B-X
acquisition	B-X
may	B-X
also	B-X
be	B-X
regulated	B-X
by	B-X
TCF	B-X
-	B-X
1	B-X
binding	B-X
to	B-X
more	B-X
distant	B-X
cis	B-X
-	B-X
acting	B-X
elements	B-X
and	B-X
/	B-X
or	B-X
by	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
additional	B-X
trans	B-X
-	B-X
acting	B-X
factors	B-X

Indeed	O
,	O
TCF-1	B-protein
binds	O
to	O
two	O
sites	O
in	O
the	O
Ly-49a	B-DNA
promoter	I-DNA
and	O
regulates	O
its	O
activity	O
,	O
suggesting	O
that	O
the	O
Ly-49a	B-DNA
gene	I-DNA
is	O
a	O
direct	O
TCF-1	B-protein
target	O
.	O
<EOS>	B-X
Indeed	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
binds	B-X
to	B-X
two	B-X
sites	B-X
in	B-X
the	B-X
Ly	B-X
-	B-X
49a	B-X
promoter	B-X
and	B-X
regulates	B-X
its	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Ly	B-X
-	B-X
49a	B-X
gene	B-X
is	B-X
a	B-X
direct	B-X
TCF	B-X
-	B-X
1	B-X
target	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
besides	B-X
TCF	B-X
-	B-X
1	B-X
binding	B-X
to	B-X
the	B-X
proximal	B-X
promoter	B-X
,	B-X
Ly	B-X
-	B-X
49	B-X
acquisition	B-X
may	B-X
also	B-X
be	B-X
regulated	B-X
by	B-X
TCF	B-X
-	B-X
1	B-X
binding	B-X
to	B-X
more	B-X
distant	B-X
cis	B-X
-	B-X
acting	B-X
elements	B-X
and	B-X
/	B-X
or	B-X
by	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
additional	B-X
trans	B-X
-	B-X
acting	B-X
factors	B-X
<EOS>	B-X
TCF	B-X
-	B-X
1	B-X
deficiency	B-X
resulted	B-X
in	B-X
the	B-X
altered	B-X
usage	B-X
of	B-X
additional	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
<EOS>	B-X
Positive	B-X
and	B-X
negative	B-X
roles	B-X
of	B-X
the	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
distinct	B-X
Ly	B-X
-	B-X
49	B-X
MHC	B-X
class	B-X
I	B-X
receptors	B-X
by	B-X
NK	B-X
cells	B-X
.	B-X

TCF-1	B-protein
deficiency	O
resulted	O
in	O
the	O
altered	O
usage	O
of	O
additional	O
Ly-49	B-protein
receptors	I-protein
.	O
<EOS>	B-X
TCF	B-X
-	B-X
1	B-X
deficiency	B-X
resulted	B-X
in	B-X
the	B-X
altered	B-X
usage	B-X
of	B-X
additional	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
<EOS>	B-X
Our	B-X
findings	B-X
rather	B-X
suggest	B-X
a	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
,	B-X
cell	B-X
autonomous	B-X
effect	B-X
on	B-X
the	B-X
acquisition	B-X
of	B-X
multiple	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
<EOS>	B-X
Positive	B-X
and	B-X
negative	B-X
roles	B-X
of	B-X
the	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
distinct	B-X
Ly	B-X
-	B-X
49	B-X
MHC	B-X
class	B-X
I	B-X
receptors	B-X
by	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
binds	B-X
to	B-X
two	B-X
sites	B-X
in	B-X
the	B-X
Ly	B-X
-	B-X
49a	B-X
promoter	B-X
and	B-X
regulates	B-X
its	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Ly	B-X
-	B-X
49a	B-X
gene	B-X
is	B-X
a	B-X
direct	B-X
TCF	B-X
-	B-X
1	B-X
target	B-X

We	O
show	O
in	O
this	O
study	O
,	O
using	O
TCF-1	B-protein
beta	I-protein
(	I-protein
2	I-protein
)	I-protein
-microglobulin	I-protein
double-deficient	O
mice	O
,	O
that	O
these	O
repertoire	O
alterations	O
are	O
not	O
due	O
to	O
Ly-49/MHC	O
class	O
I	O
interactions	O
.	O
<EOS>	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
,	B-X
using	B-X
TCF	B-X
-	B-X
1	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
	B-X
-	B-X
microglobulin	B-X
double	B-X
-	B-X
deficient	B-X
mice	B-X
,	B-X
that	B-X
these	B-X
repertoire	B-X
alterations	B-X
are	B-X
not	B-X
due	B-X
to	B-X
Ly	B-X
-	B-X
49	B-X
/	B-X
MHC	B-X
class	B-X
I	B-X
interactions	B-X
<EOS>	B-X
Our	B-X
findings	B-X
rather	B-X
suggest	B-X
a	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
,	B-X
cell	B-X
autonomous	B-X
effect	B-X
on	B-X
the	B-X
acquisition	B-X
of	B-X
multiple	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
<EOS>	B-X
Positive	B-X
and	B-X
negative	B-X
roles	B-X
of	B-X
the	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
distinct	B-X
Ly	B-X
-	B-X
49	B-X
MHC	B-X
class	B-X
I	B-X
receptors	B-X
by	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
Ly	B-X
-	B-X
49	B-X
gene	B-X
family	B-X
code	B-X
for	B-X
class	B-X
I	B-X
MHC	B-X
-	B-X
specific	B-X
receptors	B-X
that	B-X
regulate	B-X
NK	B-X
cell	B-X
function	B-X

Our	O
findings	O
rather	O
suggest	O
a	O
TCF-1	B-protein
-dependent	O
,	O
cell	O
autonomous	O
effect	O
on	O
the	O
acquisition	O
of	O
multiple	O
Ly-49	B-protein
receptors	I-protein
.	O
<EOS>	B-X
Our	B-X
findings	B-X
rather	B-X
suggest	B-X
a	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
,	B-X
cell	B-X
autonomous	B-X
effect	B-X
on	B-X
the	B-X
acquisition	B-X
of	B-X
multiple	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
<EOS>	B-X
Positive	B-X
and	B-X
negative	B-X
roles	B-X
of	B-X
the	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
distinct	B-X
Ly	B-X
-	B-X
49	B-X
MHC	B-X
class	B-X
I	B-X
receptors	B-X
by	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
TCF	B-X
-	B-X
1	B-X
deficiency	B-X
resulted	B-X
in	B-X
the	B-X
altered	B-X
usage	B-X
of	B-X
additional	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
<EOS>	B-X
These	B-X
findings	B-X
reveal	B-X
an	B-X
important	B-X
role	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
NK	B-X
cell	B-X
receptor	B-X
repertoire	B-X

Besides	O
reduced	O
receptor	O
usage	O
(	O
Ly-49A	B-protein
and	I-protein
D	I-protein
)	O
,	O
we	O
also	O
observed	O
no	O
effect	O
(	O
Ly-49C	B-protein
)	O
and	O
significantly	O
expanded	O
(	O
Ly-49G	B-protein
and	I-protein
I	I-protein
)	O
receptor	O
usage	O
in	O
the	O
absence	O
of	O
TCF-1	B-protein
.	O

These	O
effects	O
did	O
not	O
in	O
all	O
cases	O
correlate	O
with	O
the	O
presence	O
of	O
TCF	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
respective	O
proximal	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Advanced	B-X
hybrid	B-X
closed	B-X
loop	B-X
system	B-X
use	B-X
in	B-X
elderly	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
:	B-X
effectiveness	B-X
and	B-X
safety	B-X
in	B-X
a	B-X
prospective	B-X
,	B-X
observational	B-X
,	B-X
one	B-X
year	B-X
follow	B-X
-	B-X
up	B-X
real	B-X
-	B-X
world	B-X
study	B-X
.	B-X
<EOS>	B-X
The	B-X
risk	B-X
of	B-X
developing	B-X
a	B-X
post	B-X
-	B-X
operative	B-X
infection	B-X
after	B-X
craniotomy	B-X
is	B-X
the	B-X
highest	B-X
in	B-X
GBM	B-X
patients	B-X
<EOS>	B-X
Results	B-X
from	B-X
this	B-X
study	B-X
can	B-X
be	B-X
used	B-X
by	B-X
health	B-X
care	B-X
providers	B-X
to	B-X
better	B-X
formulate	B-X
therapeutic	B-X
interventions	B-X
for	B-X
a	B-X
timely	B-X
diagnosis	B-X
and	B-X
effective	B-X
treatment	B-X
of	B-X
epilepsy	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
child	B-X
race	B-X
,	B-X
perpetrator	B-X
race	B-X
,	B-X
and	B-X
abuse	B-X
disclosure	B-X
status	B-X
(	B-X
within	B-X
the	B-X
context	B-X
of	B-X
a	B-X
formal	B-X
forensic	B-X
interview	B-X
)	B-X
on	B-X
abuse	B-X
substantiation	B-X
outcomes	B-X

Therefore	O
,	O
besides	O
TCF-1	B-protein
binding	O
to	O
the	O
proximal	B-DNA
promoter	I-DNA
,	O
Ly-49	O
acquisition	O
may	O
also	O
be	O
regulated	O
by	O
TCF-1	B-protein
binding	O
to	O
more	O
distant	O
cis-acting	B-DNA
elements	I-DNA
and/or	O
by	O
regulating	O
the	O
expression	O
of	O
additional	O
trans-acting	B-DNA
factors	I-DNA
.	O
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
genes	B-X
was	B-X
evaluated	B-X
using	B-X
qRT	B-X
-	B-X
PCR	B-X
;	B-X
this	B-X
was	B-X
also	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
cascade	B-X
of	B-X
additional	B-X
transcriptional	B-X
regulators	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrated	B-X
that	B-X
PHF5A	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
progression	B-X
of	B-X
NSCLC	B-X
by	B-X
regulating	B-X
the	B-X
PI3K	B-X
/	B-X
AKT	B-X
signaling	B-X
pathway	B-X
<EOS>	B-X
In	B-X
the	B-X
study	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
HBX	B-X
promoted	B-X
HER2	B-X
expression	B-X
to	B-X
facilitate	B-X
the	B-X
sensitization	B-X
of	B-X
the	B-X
insulin	B-X
signaling	B-X
pathway	B-X
and	B-X
enhance	B-X
the	B-X
growth	B-X
and	B-X
migration	B-X
of	B-X
HCC	B-X
cells	B-X
<EOS>	B-X
The	B-X
downregulation	B-X
of	B-X
the	B-X
SHh	B-X
signaling	B-X
promotes	B-X
HPV	B-X
replication	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
warts	B-X
by	B-X
inducing	B-X
G2	B-X
/	B-X
M	B-X
arrest	B-X
in	B-X
the	B-X
keratinocytes	B-X
of	B-X
CA	B-X

Consistent	O
with	O
the	O
observed	O
differential	O
,	O
positive	O
or	O
negative	O
role	O
of	O
TCF-1	B-protein
for	O
Ly-49	B-protein
receptor	I-protein
acquisition	O
,	O
reporter	O
gene	O
assays	O
revealed	O
the	O
presence	O
of	O
an	O
inducing	O
as	O
well	O
as	O
a	O
repressing	O
TCF	B-DNA
site	I-DNA
in	O
certain	O
proximal	O
Ly-49	B-DNA
promoters	I-DNA
.	O
<EOS>	B-X
Epigenetic	B-X
analysis	B-X
revealed	B-X
that	B-X
a	B-X
5	B-X
-	B-X
day	B-X
treatment	B-X
of	B-X
4F	B-X
upregulated	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
hepatic	B-X
differentiation	B-X
,	B-X
and	B-X
repressed	B-X
genes	B-X
related	B-X
to	B-X
pluripotency	B-X
of	B-X
MSCs	B-X
<EOS>	B-X
First	B-X
,	B-X
the	B-X
current	B-X
work	B-X
provides	B-X
an	B-X
integrated	B-X
theoretical	B-X
framework	B-X
to	B-X
compare	B-X
popular	B-X
mobile	B-X
wallet	B-X
service	B-X
providers	B-X
based	B-X
on	B-X
users	B-X
'	B-X
views	B-X
in	B-X
the	B-X
Indian	B-X
context	B-X
<EOS>	B-X
We	B-X
find	B-X
that	B-X
user	B-X
-	B-X
friendliness	B-X
,	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
use	B-X
,	B-X
and	B-X
familiarity	B-X
and	B-X
awareness	B-X
about	B-X
the	B-X
products	B-X
help	B-X
reduce	B-X
the	B-X
uncertainty	B-X
factors	B-X
and	B-X
obtain	B-X
positive	B-X
impressions	B-X
from	B-X
the	B-X
users	B-X
<EOS>	B-X
Results	B-X
highlighted	B-X
that	B-X
Trait	B-X
EI	B-X
was	B-X
positively	B-X
related	B-X
to	B-X
Self	B-X
-	B-X
Esteem	B-X
and	B-X
negatively	B-X
related	B-X
to	B-X
Social	B-X
Phobia	B-X
and	B-X
General	B-X
Distress	B-X

These	O
findings	O
reveal	O
an	O
important	O
role	O
of	O
TCF-1	B-protein
for	O
the	O
formation	O
of	O
the	O
NK	B-protein
cell	I-protein
receptor	I-protein
repertoire	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
reveal	B-X
an	B-X
important	B-X
role	B-X
of	B-X
TCF	B-X
-	B-X
1	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
NK	B-X
cell	B-X
receptor	B-X
repertoire	B-X
<EOS>	B-X
Positive	B-X
and	B-X
negative	B-X
roles	B-X
of	B-X
the	B-X
trans	B-X
-	B-X
acting	B-X
T	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
for	B-X
the	B-X
acquisition	B-X
of	B-X
distinct	B-X
Ly	B-X
-	B-X
49	B-X
MHC	B-X
class	B-X
I	B-X
receptors	B-X
by	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
Our	B-X
findings	B-X
rather	B-X
suggest	B-X
a	B-X
TCF	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
,	B-X
cell	B-X
autonomous	B-X
effect	B-X
on	B-X
the	B-X
acquisition	B-X
of	B-X
multiple	B-X
Ly	B-X
-	B-X
49	B-X
receptors	B-X
<EOS>	B-X
These	B-X
effects	B-X
did	B-X
not	B-X
in	B-X
all	B-X
cases	B-X
correlate	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
TCF	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
respective	B-X
proximal	B-X
promoter	B-X

Ligation	O
of	O
CD11b	B-protein
and	O
CD11c	B-protein
beta	I-protein
(	I-protein
2	I-protein
)	I-protein
integrins	B-protein
by	O
antibodies	B-protein
or	O
soluble	B-protein
CD23	I-protein
induces	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
1alpha	I-protein
(	O
MIP-1alpha	B-protein
)	O
and	O
MIP-1beta	B-protein
production	O
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
through	O
a	O
pathway	O
dependent	O
on	O
nuclear	B-protein
factor-kappaB	I-protein
.	O
<EOS>	B-X
Ligation	B-X
of	B-X
CD11b	B-X
and	B-X
CD11c	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrins	B-X
by	B-X
antibodies	B-X
or	B-X
soluble	B-X
CD23	B-X
induces	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1alpha	B-X
(	B-X
MIP	B-X
-	B-X
1alpha	B-X
)	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
production	B-X
in	B-X
primary	B-X
human	B-X
monocytes	B-X
through	B-X
a	B-X
pathway	B-X
dependent	B-X
on	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
triggering	B-X
of	B-X
CD11b	B-X
or	B-X
CD11c	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrin	B-X
on	B-X
primary	B-X
human	B-X
monocytes	B-X
provides	B-X
activation	B-X
signals	B-X
leading	B-X
to	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
subsequent	B-X
secretion	B-X
of	B-X
MIP	B-X
-	B-X
1alpha	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
that	B-X
may	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
recruitment	B-X
of	B-X
other	B-X
inflammatory	B-X
cells	B-X
during	B-X
initiation	B-X
of	B-X
an	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
ligation	B-X
of	B-X
CD11b	B-X
or	B-X
CD11c	B-X
but	B-X
not	B-X
CD11a	B-X
alpha	B-X
chains	B-X
of	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrins	B-X
by	B-X
antibodies	B-X
or	B-X
soluble	B-X
CD23	B-X
(	B-X
sCD23	B-X
)	B-X
fusion	B-X
proteins	B-X
rapidly	B-X
induced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
interleukin	B-X
8	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
(	B-X
MIP	B-X
)	B-X
1alpha	B-X
,	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
<EOS>	B-X
Chemokines	B-X
and	B-X
adhesion	B-X
molecules	B-X
such	B-X
as	B-X
integrins	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
trafficking	B-X
,	B-X
extravasation	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
leukocytes	B-X
to	B-X
inflammatory	B-X
sites	B-X

Chemokines	B-protein
and	O
adhesion	B-protein
molecules	I-protein
such	O
as	O
integrins	B-protein
play	O
a	O
major	O
part	O
in	O
the	O
trafficking	O
,	O
extravasation	O
,	O
and	O
recruitment	O
of	O
leukocytes	B-cell_type
to	O
inflammatory	O
sites	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
beta	O
(	O
2	O
)	O
integrin	O
engagement	O
on	O
chemokine	O
production	O
by	O
freshly	B-cell_type
isolated	I-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrin	B-X
engagement	B-X
on	B-X
chemokine	B-X
production	B-X
by	B-X
freshly	B-X
isolated	B-X
human	B-X
monocytes	B-X
<EOS>	B-X
Chemokines	B-X
and	B-X
adhesion	B-X
molecules	B-X
such	B-X
as	B-X
integrins	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
trafficking	B-X
,	B-X
extravasation	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
leukocytes	B-X
to	B-X
inflammatory	B-X
sites	B-X
<EOS>	B-X
Ligation	B-X
of	B-X
CD11b	B-X
and	B-X
CD11c	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrins	B-X
by	B-X
antibodies	B-X
or	B-X
soluble	B-X
CD23	B-X
induces	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1alpha	B-X
(	B-X
MIP	B-X
-	B-X
1alpha	B-X
)	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
production	B-X
in	B-X
primary	B-X
human	B-X
monocytes	B-X
through	B-X
a	B-X
pathway	B-X
dependent	B-X
on	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
.	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
ligation	B-X
of	B-X
CD11b	B-X
or	B-X
CD11c	B-X
but	B-X
not	B-X
CD11a	B-X
alpha	B-X
chains	B-X
of	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrins	B-X
by	B-X
antibodies	B-X
or	B-X
soluble	B-X
CD23	B-X
(	B-X
sCD23	B-X
)	B-X
fusion	B-X
proteins	B-X
rapidly	B-X
induced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
interleukin	B-X
8	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
(	B-X
MIP	B-X
)	B-X
1alpha	B-X
,	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X

We	O
found	O
that	O
ligation	O
of	O
CD11b	B-protein
or	O
CD11c	B-protein
but	O
not	O
CD11a	B-protein
alpha	I-protein
chains	I-protein
of	O
beta	B-protein
(	I-protein
2	I-protein
)	I-protein
integrins	I-protein
by	O
antibodies	B-protein
or	O
soluble	B-protein
CD23	I-protein
(	I-protein
sCD23	I-protein
)	I-protein
fusion	I-protein
proteins	I-protein
rapidly	O
induced	O
transcription	O
and	O
secretion	O
of	O
interleukin	B-protein
8	I-protein
,	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
(	I-protein
MIP	I-protein
)	I-protein
1alpha	I-protein
,	O
and	O
MIP-1beta	B-protein
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
ligation	B-X
of	B-X
CD11b	B-X
or	B-X
CD11c	B-X
but	B-X
not	B-X
CD11a	B-X
alpha	B-X
chains	B-X
of	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrins	B-X
by	B-X
antibodies	B-X
or	B-X
soluble	B-X
CD23	B-X
(	B-X
sCD23	B-X
)	B-X
fusion	B-X
proteins	B-X
rapidly	B-X
induced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
interleukin	B-X
8	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
(	B-X
MIP	B-X
)	B-X
1alpha	B-X
,	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
<EOS>	B-X
Ligation	B-X
of	B-X
CD11b	B-X
and	B-X
CD11c	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrins	B-X
by	B-X
antibodies	B-X
or	B-X
soluble	B-X
CD23	B-X
induces	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1alpha	B-X
(	B-X
MIP	B-X
-	B-X
1alpha	B-X
)	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
production	B-X
in	B-X
primary	B-X
human	B-X
monocytes	B-X
through	B-X
a	B-X
pathway	B-X
dependent	B-X
on	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
triggering	B-X
of	B-X
CD11b	B-X
or	B-X
CD11c	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
integrin	B-X
on	B-X
primary	B-X
human	B-X
monocytes	B-X
provides	B-X
activation	B-X
signals	B-X
leading	B-X
to	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
subsequent	B-X
secretion	B-X
of	B-X
MIP	B-X
-	B-X
1alpha	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
that	B-X
may	B-X
have	B-X
an	B-X
important	B-X
role	B-X
in	B-X
recruitment	B-X
of	B-X
other	B-X
inflammatory	B-X
cells	B-X
during	B-X
initiation	B-X
of	B-X
an	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
Chemokines	B-X
and	B-X
adhesion	B-X
molecules	B-X
such	B-X
as	B-X
integrins	B-X
play	B-X
a	B-X
major	B-X
part	B-X
in	B-X
the	B-X
trafficking	B-X
,	B-X
extravasation	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
leukocytes	B-X
to	B-X
inflammatory	B-X
sites	B-X

Because	O
the	O
promoters	B-DNA
of	O
these	O
chemokine	B-DNA
genes	I-DNA
contain	O
kappaB	B-DNA
binding	I-DNA
sites	I-DNA
,	O
we	O
assessed	O
the	O
possible	O
role	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
in	O
controlling	O
induction	O
of	O
the	O
genes	O
through	O
beta	O
(	O
2	O
)	O
integrin	O
engagement	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
sCD23	B-protein
or	O
antibodies	B-protein
to	O
CD11b	B-protein
or	O
to	O
CD11c	B-protein
up-regulated	O
DNA-binding	O
activity	O
of	O
NF-kappaB	B-protein
.	O
<EOS>	B-X
There	B-X
were	B-X
no	B-X
differences	B-X
in	B-X
serum	B-X
anti	B-X
-	B-X
dsDNA	B-X
antibodies	B-X
and	B-X
renal	B-X
C3	B-X
and	B-X
IgG2a	B-X
deposit	B-X
in	B-X
these	B-X
mice	B-X
<EOS>	B-X
Neutrophil	B-X
activation	B-X
,	B-X
including	B-X
NET	B-X
formation	B-X
,	B-X
is	B-X
increased	B-X
in	B-X
PMR	B-X
,	B-X
through	B-X
IC	B-X
-	B-X
mediated	B-X
engagement	B-X
of	B-X
FcγRIIA	B-X
<EOS>	B-X
The	B-X
in	B-X
vitro	B-X
release	B-X
experiment	B-X
of	B-X
microcapsules	B-X
showed	B-X
that	B-X
inactive	B-X
PEDV	B-X
was	B-X
not	B-X
only	B-X
easily	B-X
released	B-X
in	B-X
saline	B-X
and	B-X
acid	B-X
solutions	B-X
but	B-X
also	B-X
had	B-X
an	B-X
excellent	B-X
storage	B-X
tolerance	B-X
,	B-X
and	B-X
was	B-X
suitable	B-X
for	B-X
use	B-X
as	B-X
an	B-X
oral	B-X
vaccine	B-X
<EOS>	B-X
Phagocytosis	B-X
via	B-X
complement	B-X
receptor	B-X
3	B-X
enables	B-X
microbes	B-X
to	B-X
evade	B-X
killing	B-X
by	B-X
neutrophils	B-X
.	B-X

Activation	O
of	O
NF-kappaB	B-protein
was	O
accompanied	O
by	O
degradation	O
of	O
its	O
cytosolic	B-protein
inhibitor	I-protein
IkappaB-alpha	I-protein
.	O
<EOS>	B-X
FC	B-X
-	B-X
77	B-X
also	B-X
attenuated	B-X
the	B-X
LPS	B-X
-	B-X
induced	B-X
PGE2	B-X
formation	B-X
accompanied	B-X
by	B-X
suppressing	B-X
COX	B-X
-	B-X
2	B-X
expression	B-X
,	B-X
the	B-X
degradation	B-X
of	B-X
cytosolic	B-X
inhibitor	B-X
of	B-X
kappaB	B-X
-	B-X
alpha	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
<EOS>	B-X
LY	B-X
/	B-X
Api	B-X
-	B-X
induced	B-X
apoptosis	B-X
was	B-X
accompanied	B-X
by	B-X
activation	B-X
of	B-X
caspase	B-X
cascades	B-X
and	B-X
disruption	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
STING	B-X
pathway	B-X
induces	B-X
peripheral	B-X
sensitization	B-X
via	B-X
neuroinflammation	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
of	B-X
bone	B-X
cancer	B-X
pain	B-X
.	B-X
<EOS>	B-X
Preconditioning	B-X
with	B-X
HSP	B-X
-	B-X
70	B-X
attenuated	B-X
cytosolic	B-X
degradation	B-X
of	B-X
inhibitor	B-X
kappaB	B-X
-	B-X
alpha	B-X
and	B-X
inhibited	B-X
activation	B-X
of	B-X
inhibitor	B-X
kappaB	B-X
kinase	B-X
following	B-X
LPS	B-X
stimulation	B-X

Blockade	O
of	O
depletion	O
of	O
IkappaB-alpha	B-protein
by	O
proteasome	O
inhibitors	O
(	O
proteasome	O
inhibitor	O
I	O
or	O
acetyl-leucinyl-leucinyl-norleucinal	O
)	O
led	O
to	O
concomitant	O
inhibition	O
of	O
NF-kappaB	O
DNA-binding	O
activity	O
and	O
expression	O
of	O
MIP-1alpha	B-RNA
and	I-RNA
MIP-1beta	I-RNA
messenger	I-RNA
RNA	I-RNA
induced	O
by	O
beta	O
(	O
2	O
)	O
integrin	O
ligation	O
.	O

These	O
results	O
suggest	O
that	O
triggering	O
of	O
CD11b	B-protein
or	O
CD11c	B-protein
beta	I-protein
(	I-protein
2	I-protein
)	I-protein
integrin	O
on	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
provides	O
activation	O
signals	O
leading	O
to	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
and	O
subsequent	O
secretion	O
of	O
MIP-1alpha	B-protein
and	O
MIP-1beta	B-protein
that	O
may	O
have	O
an	O
important	O
role	O
in	O
recruitment	O
of	O
other	O
inflammatory	B-cell_type
cells	I-cell_type
during	O
initiation	O
of	O
an	O
inflammatory	O
response	O
<EOS>	B-X
Considering	B-X
the	B-X
role	B-X
of	B-X
CD11b	B-X
and	B-X
CD14	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
innate	B-X
immunity	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
this	B-X
subpopulation	B-X
of	B-X
sheep	B-X
γδ	B-X
T	B-X
cells	B-X
may	B-X
function	B-X
as	B-X
innate	B-X
antigen	B-X
presenting	B-X
and	B-X
pro	B-X
-	B-X
inflammatory	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
profile	B-X
of	B-X
circulating	B-X
and	B-X
renal	B-X
cytokines	B-X
after	B-X
Stx2	B-X
differed	B-X
between	B-X
strains	B-X
suggesting	B-X
that	B-X
balance	B-X
of	B-X
these	B-X
factors	B-X
could	B-X
participate	B-X
in	B-X
renal	B-X
protection	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
clearance	B-X
of	B-X
PHx	B-X
-	B-X
induced	B-X
aEVs	B-X
leads	B-X
to	B-X
a	B-X
population	B-X
of	B-X
non	B-X
-	B-X
inflammatory	B-X
but	B-X
regenerative	B-X
neutrophils	B-X
,	B-X
which	B-X
may	B-X
support	B-X
human	B-X
liver	B-X
regeneration	B-X
<EOS>	B-X
The	B-X
results	B-X
suggested	B-X
that	B-X
antineoplastic	B-X
-	B-X
agent	B-X
treatment	B-X
augmented	B-X
the	B-X
tumor	B-X
microenvironment	B-X
by	B-X
mobilizing	B-X
proangiogenic	B-X
BMDCs	B-X
,	B-X
enhancing	B-X
BMDC	B-X
recruitment	B-X
and	B-X
angiogenesis	B-X
,	B-X
and	B-X
increasing	B-X
BMDC	B-X
-	B-X
mediated	B-X
tumor	B-X
and	B-X
EC	B-X
functions	B-X

Synergistic	O
transcriptional	O
activation	O
of	O
human	B-DNA
Acyl-coenzyme	I-DNA
A	I-DNA
:	I-DNA
cholesterol	I-DNA
acyltransterase-1	I-DNA
gene	I-DNA
by	O
interferon-gamma	B-protein
and	O
all-trans-retinoic	O
acid	O
THP-1	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Synergistic	B-X
transcriptional	B-X
activation	B-X
of	B-X
human	B-X
Acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
:	B-X
cholesterol	B-X
acyltransterase	B-X
-	B-X
1	B-X
gene	B-X
by	B-X
interferon	B-X
-	B-X
gamma	B-X
and	B-X
all	B-X
-	B-X
trans	B-X
-	B-X
retinoic	B-X
acid	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
.	B-X
<EOS>	B-X
Interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
,	B-X
a	B-X
cytokine	B-X
that	B-X
exerts	B-X
many	B-X
pro	B-X
-	B-X
atherosclerotic	B-X
effects	B-X
in	B-X
vivo	B-X
,	B-X
causes	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
ACAT	B-X
-	B-X
1	B-X
mRNA	B-X
in	B-X
human	B-X
blood	B-X
monocyte	B-X
-	B-X
derived	B-X
macrophages	B-X
and	B-X
macrophage	B-X
-	B-X
like	B-X
cells	B-X
but	B-X
not	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
<EOS>	B-X
This	B-X
region	B-X
contains	B-X
4	B-X
Sp1	B-X
elements	B-X
and	B-X
an	B-X
IFN	B-X
-	B-X
gamma	B-X
activated	B-X
sequence	B-X
(	B-X
GAS	B-X
)	B-X
that	B-X
overlaps	B-X
with	B-X
the	B-X
second	B-X
Sp1	B-X
element	B-X
<EOS>	B-X
Additional	B-X
experiments	B-X
showed	B-X
that	B-X
all	B-X
-	B-X
trans	B-X
-	B-X
retinoic	B-X
acid	B-X
causes	B-X
large	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
STAT1	B-X
,	B-X
while	B-X
IFN	B-X
-	B-X
gamma	B-X
causes	B-X
activation	B-X
of	B-X
STAT1	B-X
such	B-X
that	B-X
it	B-X
binds	B-X
to	B-X
the	B-X
GAS	B-X
/	B-X
Sp1	B-X
site	B-X
in	B-X
the	B-X
ACAT	B-X
-	B-X
1	B-X
P1	B-X
promoter	B-X

Acyl-coenzyme	B-protein
A	I-protein
:	I-protein
cholesterol	I-protein
acyltransferase	I-protein
(	O
ACAT	B-protein
)	O
is	O
an	O
intracellular	B-protein
enzyme	I-protein
involved	O
in	O
cellular	O
cholesterol	O
homeostasis	O
and	O
in	O
atherosclerotic	O
foam	O
cell	O
formation	O
.	O
<EOS>	B-X
Acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
:	B-X
cholesterol	B-X
acyltransferase	B-X
(	B-X
ACAT	B-X
)	B-X
is	B-X
an	B-X
intracellular	B-X
enzyme	B-X
involved	B-X
in	B-X
cellular	B-X
cholesterol	B-X
homeostasis	B-X
and	B-X
in	B-X
atherosclerotic	B-X
foam	B-X
cell	B-X
formation	B-X
<EOS>	B-X
Acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
:	B-X
cholesterol	B-X
acyltransferase	B-X
(	B-X
ACAT	B-X
)	B-X
is	B-X
an	B-X
intracellular	B-X
enzyme	B-X
involved	B-X
in	B-X
cellular	B-X
cholesterol	B-X
homeostasis	B-X
and	B-X
in	B-X
atherosclerotic	B-X
foam	B-X
cell	B-X
formation	B-X
<EOS>	B-X
Insulin	B-X
induces	B-X
human	B-X
acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
:	B-X
cholesterol	B-X
acyltransferase1	B-X
gene	B-X
expression	B-X
via	B-X
MAP	B-X
kinases	B-X
and	B-X
CCAAT	B-X
/	B-X
enhancer	B-X
-	B-X
binding	B-X
protein	B-X
α	B-X
.	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
molecular	B-X
nature	B-X
of	B-X
this	B-X
observation	B-X
,	B-X
we	B-X
identified	B-X
within	B-X
the	B-X
ACAT	B-X
-	B-X
1	B-X
P1	B-X
promoter	B-X
a	B-X
159	B-X
-	B-X
base	B-X
pair	B-X
core	B-X
region	B-X

Human	B-DNA
ACAT-1	I-DNA
gene	I-DNA
contains	O
two	O
promoters	B-DNA
(	O
P1	B-DNA
and	O
P7	B-DNA
)	O
,	O
each	O
located	O
in	O
a	O
different	O
chromosome	B-DNA
(	I-DNA
1	I-DNA
and	I-DNA
7	I-DNA
)	I-DNA
(	O
Li	O
,	O
B.	O
L.	O
,	O
Li	O
,	O
X.	O
L.	O
,	O
Duan	O
,	O
Z.	O
J.	O
,	O
Lee	O
,	O
O.	O
,	O
Lin	O
,	O
S.	O
,	O
Ma	O
,	O
Z.	O
M.	O
,	O
Chang	O
,	O
C.	O
C.	O
,	O
Yang	O
,	O
X.	O
Y.	O
,	O
Park	O
,	O
J.	O
P.	O
,	O
Mohandas	O
,	O
T.	O
K.	O
,	O
Noll	O
,	O
W.	O
,	O
Chan	O
,	O
L.	O
,	O
and	O
Chang	O
,	O
T.	O
Y.	O
(	O
1999	O
)	O
J.	O
Biol	O
Chem.	O
274	O
,	O
11060-11071	O
)	O
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
,	O
a	O
cytokine	B-protein
that	O
exerts	O
many	O
pro-atherosclerotic	O
effects	O
in	O
vivo	O
,	O
causes	O
up-regulation	O
of	O
ACAT-1	B-RNA
mRNA	I-RNA
in	O
human	B-cell_type
blood	I-cell_type
monocyte-derived	I-cell_type
macrophages	I-cell_type
and	O
macrophage-like	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
other	O
cell	O
types	O
.	O

To	O
examine	O
the	O
molecular	O
nature	O
of	O
this	O
observation	O
,	O
we	O
identified	O
within	O
the	O
ACAT-1	B-DNA
P1	I-DNA
promoter	I-DNA
a	O
159-base	B-DNA
pair	I-DNA
core	I-DNA
region	I-DNA
.	O
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
molecular	B-X
nature	B-X
of	B-X
this	B-X
observation	B-X
,	B-X
we	B-X
identified	B-X
within	B-X
the	B-X
ACAT	B-X
-	B-X
1	B-X
P1	B-X
promoter	B-X
a	B-X
159	B-X
-	B-X
base	B-X
pair	B-X
core	B-X
region	B-X
<EOS>	B-X
In	B-X
the	B-X
monocytic	B-X
cell	B-X
line	B-X
THP	B-X
-	B-X
1	B-X
cell	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
all	B-X
-	B-X
trans	B-X
-	B-X
retinoic	B-X
acid	B-X
(	B-X
a	B-X
known	B-X
differentiation	B-X
agent	B-X
)	B-X
enhances	B-X
the	B-X
ACAT	B-X
-	B-X
1	B-X
P1	B-X
promoter	B-X
but	B-X
not	B-X
the	B-X
P7	B-X
promoter	B-X
<EOS>	B-X
Additional	B-X
experiments	B-X
showed	B-X
that	B-X
all	B-X
-	B-X
trans	B-X
-	B-X
retinoic	B-X
acid	B-X
causes	B-X
large	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
STAT1	B-X
,	B-X
while	B-X
IFN	B-X
-	B-X
gamma	B-X
causes	B-X
activation	B-X
of	B-X
STAT1	B-X
such	B-X
that	B-X
it	B-X
binds	B-X
to	B-X
the	B-X
GAS	B-X
/	B-X
Sp1	B-X
site	B-X
in	B-X
the	B-X
ACAT	B-X
-	B-X
1	B-X
P1	B-X
promoter	B-X
<EOS>	B-X
Acyl	B-X
-	B-X
coenzyme	B-X
A	B-X
:	B-X
cholesterol	B-X
acyltransferase	B-X
(	B-X
ACAT	B-X
)	B-X
is	B-X
an	B-X
intracellular	B-X
enzyme	B-X
involved	B-X
in	B-X
cellular	B-X
cholesterol	B-X
homeostasis	B-X
and	B-X
in	B-X
atherosclerotic	B-X
foam	B-X
cell	B-X
formation	B-X

This	O
region	O
contains	O
4	O
Sp1	B-DNA
elements	I-DNA
and	O
an	O
IFN-gamma	B-DNA
activated	I-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
that	O
overlaps	O
with	O
the	O
second	O
Sp1	B-DNA
element	I-DNA
.	O

In	O
the	O
monocytic	B-cell_type
cell	I-cell_type
line	I-cell_type
THP-1	I-cell_type
cell	I-cell_type
,	O
the	O
combination	O
of	O
IFN-gamma	B-protein
and	O
all-trans-retinoic	O
acid	O
(	O
a	O
known	O
differentiation	O
agent	O
)	O
enhances	O
the	O
ACAT-1	B-DNA
P1	I-DNA
promoter	I-DNA
but	O
not	O
the	O
P7	B-DNA
promoter	I-DNA
.	O

Additional	O
experiments	O
showed	O
that	O
all-trans-retinoic	O
acid	O
causes	O
large	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
STAT1	I-protein
,	O
while	O
IFN-gamma	B-protein
causes	O
activation	O
of	O
STAT1	B-protein
such	O
that	O
it	O
binds	O
to	O
the	O
GAS/Sp1	B-DNA
site	I-DNA
in	O
the	O
ACAT-1	B-DNA
P1	I-DNA
promoter	I-DNA
.	O

Our	O
work	O
provides	O
a	O
molecular	O
mechanism	O
to	O
account	O
for	O
the	O
effect	O
of	O
IFN-gamma	B-protein
in	O
causing	O
transcriptional	O
activation	O
of	O
ACAT-1	B-protein
in	O
macrophage-like	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Our	B-X
work	B-X
provides	B-X
a	B-X
molecular	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
effect	B-X
of	B-X
IFN	B-X
-	B-X
gamma	B-X
in	B-X
causing	B-X
transcriptional	B-X
activation	B-X
of	B-X
ACAT	B-X
-	B-X
1	B-X
in	B-X
macrophage	B-X
-	B-X
like	B-X
cells	B-X
<EOS>	B-X
Interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
,	B-X
a	B-X
cytokine	B-X
that	B-X
exerts	B-X
many	B-X
pro	B-X
-	B-X
atherosclerotic	B-X
effects	B-X
in	B-X
vivo	B-X
,	B-X
causes	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
ACAT	B-X
-	B-X
1	B-X
mRNA	B-X
in	B-X
human	B-X
blood	B-X
monocyte	B-X
-	B-X
derived	B-X
macrophages	B-X
and	B-X
macrophage	B-X
-	B-X
like	B-X
cells	B-X
but	B-X
not	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
<EOS>	B-X
Additional	B-X
experiments	B-X
showed	B-X
that	B-X
all	B-X
-	B-X
trans	B-X
-	B-X
retinoic	B-X
acid	B-X
causes	B-X
large	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
STAT1	B-X
,	B-X
while	B-X
IFN	B-X
-	B-X
gamma	B-X
causes	B-X
activation	B-X
of	B-X
STAT1	B-X
such	B-X
that	B-X
it	B-X
binds	B-X
to	B-X
the	B-X
GAS	B-X
/	B-X
Sp1	B-X
site	B-X
in	B-X
the	B-X
ACAT	B-X
-	B-X
1	B-X
P1	B-X
promoter	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
molecular	B-X
nature	B-X
of	B-X
this	B-X
observation	B-X
,	B-X
we	B-X
identified	B-X
within	B-X
the	B-X
ACAT	B-X
-	B-X
1	B-X
P1	B-X
promoter	B-X
a	B-X
159	B-X
-	B-X
base	B-X
pair	B-X
core	B-X
region	B-X

Inhaled	O
nitric	O
oxide	O
down-regulates	O
intrapulmonary	O
nitric	O
oxide	O
production	O
in	O
lipopolysaccharide-induced	O
acute	O
lung	O
injury	O
.	O
<EOS>	B-X
Inhaled	B-X
nitric	B-X
oxide	B-X
down	B-X
-	B-X
regulates	B-X
intrapulmonary	B-X
nitric	B-X
oxide	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
-	B-X
induced	B-X
acute	B-X
lung	B-X
injury	B-X
.	B-X
<EOS>	B-X
To	B-X
examine	B-X
whether	B-X
inhaled	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
affected	B-X
the	B-X
intrapulmonary	B-X
production	B-X
of	B-X
NO	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
,	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
a	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
	B-X
-	B-X
induced	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
attenuates	B-X
LPS	B-X
-	B-X
induced	B-X
acute	B-X
lung	B-X
injury	B-X
,	B-X
possibly	B-X
by	B-X
decreasing	B-X
NO	B-X
production	B-X
in	B-X
the	B-X
lungs	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
decreased	B-X
the	B-X
lung	B-X
leak	B-X
index	B-X
,	B-X
the	B-X
neutrophils	B-X
and	B-X
NO	B-X
levels	B-X
as	B-X
measured	B-X
by	B-X
nitrite	B-X
levels	B-X
in	B-X
the	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
NO	B-X
produced	B-X
by	B-X
the	B-X
resting	B-X
and	B-X
stimulated	B-X
alveolar	B-X
macrophages	B-X

OBJECTIVE	O
:	O
To	O
examine	O
whether	O
inhaled	O
nitric	O
oxide	O
(	O
NO	O
)	O
affected	O
the	O
intrapulmonary	O
production	O
of	O
NO	O
,	O
reactive	O
oxygen	O
species	O
,	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
in	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
model	O
of	O
acute	O
lung	O
injury	O
.	O

DESIGN	O
:	O
Prospective	O
,	O
randomized	O
,	O
laboratory	O
study	O
.	O
<EOS>	B-X
Prospective	B-X
randomized	B-X
controlled	B-X
trial	B-X
<EOS>	B-X
Prospective	B-X
,	B-X
block	B-X
-	B-X
randomized	B-X
,	B-X
clinical	B-X
trial	B-X
<EOS>	B-X
Prospectively	B-X
registered	B-X
on	B-X
July	B-X
1	B-X
<EOS>	B-X
To	B-X
date	B-X
,	B-X
no	B-X
prospective	B-X
trials	B-X
have	B-X
been	B-X
published	B-X
on	B-X
this	B-X
subject	B-X

SETTING	O
:	O
Experimental	O
laboratory	O
at	O
a	O
biomedical	O
institute	O
.	O

SUBJECTS	O
:	O
Twenty	O
male	O
rabbits	O
weighing	O
2.5-3.5	O
kg	O
.	O
<EOS>	B-X
Twenty	B-X
male	B-X
rabbits	B-X
weighing	B-X
2	B-X
<EOS>	B-X
Saline	B-X
or	B-X
LPS	B-X
(	B-X
5	B-X
mg	B-X
/	B-X
kg	B-X
of	B-X
body	B-X
weight	B-X
)	B-X
was	B-X
administered	B-X
intravenously	B-X
with	B-X
or	B-X
without	B-X
NO	B-X
inhalation	B-X
(	B-X
10	B-X
ppm	B-X
)	B-X
in	B-X
each	B-X
group	B-X
of	B-X
five	B-X
rabbits	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
attenuates	B-X
LPS	B-X
-	B-X
induced	B-X
acute	B-X
lung	B-X
injury	B-X
,	B-X
possibly	B-X
by	B-X
decreasing	B-X
NO	B-X
production	B-X
in	B-X
the	B-X
lungs	B-X
<EOS>	B-X
Inhaled	B-X
nitric	B-X
oxide	B-X
down	B-X
-	B-X
regulates	B-X
intrapulmonary	B-X
nitric	B-X
oxide	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
-	B-X
induced	B-X
acute	B-X
lung	B-X
injury	B-X
.	B-X

INTERVENTIONS	O
:	O
Saline	O
or	O
LPS	O
(	O
5	O
mg/kg	O
of	O
body	O
weight	O
)	O
was	O
administered	O
intravenously	O
with	O
or	O
without	O
NO	O
inhalation	O
(	O
10	O
ppm	O
)	O
in	O
each	O
group	O
of	O
five	O
rabbits	O
.	O
<EOS>	B-X
Saline	B-X
or	B-X
LPS	B-X
(	B-X
5	B-X
mg	B-X
/	B-X
kg	B-X
of	B-X
body	B-X
weight	B-X
)	B-X
was	B-X
administered	B-X
intravenously	B-X
with	B-X
or	B-X
without	B-X
NO	B-X
inhalation	B-X
(	B-X
10	B-X
ppm	B-X
)	B-X
in	B-X
each	B-X
group	B-X
of	B-X
five	B-X
rabbits	B-X
<EOS>	B-X
EGPE	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
feed	B-X
consumption	B-X
or	B-X
body	B-X
weight	B-X
gain	B-X
,	B-X
while	B-X
body	B-X
weight	B-X
gain	B-X
was	B-X
reduced	B-X
in	B-X
the	B-X
two	B-X
high	B-X
dose	B-X
groups	B-X
exposed	B-X
to	B-X
EGPEA	B-X
and	B-X
feed	B-X
consumption	B-X
was	B-X
reduced	B-X
at	B-X
all	B-X
dose	B-X
levels	B-X
<EOS>	B-X
EGPE	B-X
produced	B-X
a	B-X
very	B-X
weak	B-X
positive	B-X
sensitization	B-X
response	B-X
in	B-X
one	B-X
of	B-X
five	B-X
guinea	B-X
pigs	B-X
<EOS>	B-X
Effects	B-X
relatable	B-X
to	B-X
exposure	B-X
to	B-X
NM	B-X
were	B-X
decreased	B-X
body	B-X
weight	B-X
gain	B-X
in	B-X
rats	B-X
following	B-X
8	B-X
weeks	B-X
of	B-X
exposure	B-X
to	B-X
745	B-X
ppm	B-X
,	B-X
and	B-X
a	B-X
thyroid	B-X
effect	B-X
evidenced	B-X
by	B-X
an	B-X
increased	B-X
thyroid	B-X
weight	B-X
and	B-X
decreased	B-X
serum	B-X
thyroxin	B-X
levels	B-X
,	B-X
most	B-X
notable	B-X
in	B-X
rabbits	B-X

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
LPS	O
increased	O
the	O
lung	O
leak	O
index	O
,	O
the	O
neutrophils	B-cell_type
and	O
NO	O
levels	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
and	O
NO	O
levels	O
produced	O
by	O
resting	O
and	O
stimulated	O
alveolar	B-cell_type
macrophages	I-cell_type
.	O
<EOS>	B-X
LPS	B-X
increased	B-X
the	B-X
lung	B-X
leak	B-X
index	B-X
,	B-X
the	B-X
neutrophils	B-X
and	B-X
NO	B-X
levels	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
NO	B-X
levels	B-X
produced	B-X
by	B-X
resting	B-X
and	B-X
stimulated	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
decreased	B-X
the	B-X
lung	B-X
leak	B-X
index	B-X
,	B-X
the	B-X
neutrophils	B-X
and	B-X
NO	B-X
levels	B-X
as	B-X
measured	B-X
by	B-X
nitrite	B-X
levels	B-X
in	B-X
the	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
NO	B-X
produced	B-X
by	B-X
the	B-X
resting	B-X
and	B-X
stimulated	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
also	B-X
blocked	B-X
the	B-X
activities	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
binding	B-X
to	B-X
DNA	B-X
in	B-X
lavage	B-X
cells	B-X
and	B-X
in	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
attenuates	B-X
LPS	B-X
-	B-X
induced	B-X
acute	B-X
lung	B-X
injury	B-X
,	B-X
possibly	B-X
by	B-X
decreasing	B-X
NO	B-X
production	B-X
in	B-X
the	B-X
lungs	B-X

Inhaled	O
NO	O
decreased	O
the	O
lung	O
leak	O
index	O
,	O
the	O
neutrophils	B-cell_type
and	O
NO	O
levels	O
as	O
measured	O
by	O
nitrite	O
levels	O
in	O
the	O
lavage	O
fluid	O
,	O
and	O
NO	O
produced	O
by	O
the	O
resting	O
and	O
stimulated	O
alveolar	B-cell_type
macrophages	I-cell_type
.	O
<EOS>	B-X
Inhaled	B-X
NO	B-X
decreased	B-X
the	B-X
lung	B-X
leak	B-X
index	B-X
,	B-X
the	B-X
neutrophils	B-X
and	B-X
NO	B-X
levels	B-X
as	B-X
measured	B-X
by	B-X
nitrite	B-X
levels	B-X
in	B-X
the	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
NO	B-X
produced	B-X
by	B-X
the	B-X
resting	B-X
and	B-X
stimulated	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
LPS	B-X
increased	B-X
the	B-X
lung	B-X
leak	B-X
index	B-X
,	B-X
the	B-X
neutrophils	B-X
and	B-X
NO	B-X
levels	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
NO	B-X
levels	B-X
produced	B-X
by	B-X
resting	B-X
and	B-X
stimulated	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
also	B-X
blocked	B-X
the	B-X
activities	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
binding	B-X
to	B-X
DNA	B-X
in	B-X
lavage	B-X
cells	B-X
and	B-X
in	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
attenuates	B-X
LPS	B-X
-	B-X
induced	B-X
acute	B-X
lung	B-X
injury	B-X
,	B-X
possibly	B-X
by	B-X
decreasing	B-X
NO	B-X
production	B-X
in	B-X
the	B-X
lungs	B-X

Inhaled	O
NO	O
also	O
blocked	O
the	O
activities	O
of	O
reactive	O
oxygen	O
species	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
binding	O
to	O
DNA	O
in	O
lavage	B-cell_type
cells	I-cell_type
and	O
in	O
alveolar	B-cell_type
macrophages	I-cell_type
.	O
<EOS>	B-X
Inhaled	B-X
NO	B-X
also	B-X
blocked	B-X
the	B-X
activities	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
binding	B-X
to	B-X
DNA	B-X
in	B-X
lavage	B-X
cells	B-X
and	B-X
in	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
To	B-X
examine	B-X
whether	B-X
inhaled	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
affected	B-X
the	B-X
intrapulmonary	B-X
production	B-X
of	B-X
NO	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
,	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
a	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
	B-X
-	B-X
induced	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
decreased	B-X
the	B-X
lung	B-X
leak	B-X
index	B-X
,	B-X
the	B-X
neutrophils	B-X
and	B-X
NO	B-X
levels	B-X
as	B-X
measured	B-X
by	B-X
nitrite	B-X
levels	B-X
in	B-X
the	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
NO	B-X
produced	B-X
by	B-X
the	B-X
resting	B-X
and	B-X
stimulated	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
LPS	B-X
increased	B-X
the	B-X
lung	B-X
leak	B-X
index	B-X
,	B-X
the	B-X
neutrophils	B-X
and	B-X
NO	B-X
levels	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
NO	B-X
levels	B-X
produced	B-X
by	B-X
resting	B-X
and	B-X
stimulated	B-X
alveolar	B-X
macrophages	B-X

CONCLUSION	O
:	O
Inhaled	O
NO	O
attenuates	O
LPS-induced	O
acute	O
lung	O
injury	O
,	O
possibly	O
by	O
decreasing	O
NO	O
production	O
in	O
the	O
lungs	O
.	O
<EOS>	B-X
Inhaled	B-X
NO	B-X
attenuates	B-X
LPS	B-X
-	B-X
induced	B-X
acute	B-X
lung	B-X
injury	B-X
,	B-X
possibly	B-X
by	B-X
decreasing	B-X
NO	B-X
production	B-X
in	B-X
the	B-X
lungs	B-X
<EOS>	B-X
Inhaled	B-X
NO	B-X
decreased	B-X
the	B-X
lung	B-X
leak	B-X
index	B-X
,	B-X
the	B-X
neutrophils	B-X
and	B-X
NO	B-X
levels	B-X
as	B-X
measured	B-X
by	B-X
nitrite	B-X
levels	B-X
in	B-X
the	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
NO	B-X
produced	B-X
by	B-X
the	B-X
resting	B-X
and	B-X
stimulated	B-X
alveolar	B-X
macrophages	B-X
<EOS>	B-X
To	B-X
examine	B-X
whether	B-X
inhaled	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
affected	B-X
the	B-X
intrapulmonary	B-X
production	B-X
of	B-X
NO	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
,	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
a	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
	B-X
-	B-X
induced	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
reducing	B-X
NO	B-X
production	B-X
resulting	B-X
from	B-X
inhaled	B-X
NO	B-X
may	B-X
involve	B-X
,	B-X
in	B-X
part	B-X
,	B-X
the	B-X
activities	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
and	B-X
/	B-X
or	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X

The	O
mechanism	O
of	O
reducing	O
NO	O
production	O
resulting	O
from	O
inhaled	O
NO	O
may	O
involve	O
,	O
in	O
part	O
,	O
the	O
activities	O
of	O
reactive	O
oxygen	O
species	O
and/or	O
nuclear	B-protein
factor-kappaB	I-protein
.	O
<EOS>	B-X
The	B-X
mechanisms	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
regulating	B-X
placental	B-X
inflammatory	B-X
response	B-X
were	B-X
elucidated	B-X
by	B-X
western	B-X
blotting	B-X
<EOS>	B-X
The	B-X
platycodin	B-X
D	B-X
content	B-X
in	B-X
the	B-X
aqueous	B-X
extract	B-X
of	B-X
the	B-X
roots	B-X
in	B-X
descending	B-X
order	B-X
was	B-X
24	B-X
<EOS>	B-X
It	B-X
is	B-X
involved	B-X
in	B-X
regulating	B-X
inflammation	B-X
in	B-X
AD	B-X
and	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
AD	B-X
treatment	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
LPS	B-X
challenge	B-X
resulted	B-X
in	B-X
inflammatory	B-X
intestinal	B-X
damage	B-X
,	B-X
by	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
the	B-X
protein	B-X
or	B-X
mRNA	B-X
abundances	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
α	B-X
(	B-X
TNF	B-X
-	B-X
α	B-X
)	B-X
,	B-X
IL	B-X
-	B-X
1β	B-X
,	B-X
toll	B-X
-	B-X
like	B-X
receptors	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
and	B-X
phosphor	B-X
-	B-X
nuclear	B-X
factor	B-X
-	B-X
κB	B-X
-	B-X
p65	B-X
(	B-X
p	B-X
-	B-X
NFκB	B-X
-	B-X
p65	B-X
)	B-X
(	B-X
P	B-X
<	B-X
0	B-X

Treatment	O
of	O
allergic	O
airway	O
inflammation	O
and	O
hyperresponsiveness	O
by	O
antisense-induced	O
local	O
blockade	O
of	O
GATA-3	B-DNA
expression	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
hyperresponsiveness	B-X
by	B-X
antisense	B-X
-	B-X
induced	B-X
local	B-X
blockade	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
.	B-X
<EOS>	B-X
In	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
asthma	B-X
associated	B-X
with	B-X
allergic	B-X
pulmonary	B-X
inflammation	B-X
and	B-X
hyperresponsiveness	B-X
in	B-X
ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
	B-X
-	B-X
sensitized	B-X
mice	B-X
,	B-X
local	B-X
intranasal	B-X
administration	B-X
of	B-X
fluorescein	B-X
isothiocyanate	B-X
-	B-X
labeled	B-X
GATA	B-X
-	B-X
3	B-X
antisense	B-X
oligonucleotides	B-X
led	B-X
to	B-X
DNA	B-X
uptake	B-X
in	B-X
lung	B-X
cells	B-X
associated	B-X
with	B-X
a	B-X
reduction	B-X
of	B-X
intracellular	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
unclear	B-X
whether	B-X
GATA	B-X
-	B-X
3	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
effector	B-X
phase	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
whether	B-X
antagonizing	B-X
the	B-X
expression	B-X
and	B-X
/	B-X
or	B-X
function	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
can	B-X
be	B-X
used	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
hyperresponsiveness	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
the	B-X
effector	B-X
phase	B-X
of	B-X
a	B-X
murine	B-X
asthma	B-X
model	B-X
and	B-X
suggest	B-X
that	B-X
local	B-X
delivery	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
antisense	B-X
oligonucleotides	B-X
may	B-X
be	B-X
a	B-X
novel	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
airway	B-X
hyperresponsiveness	B-X
such	B-X
as	B-X
in	B-X
asthma	B-X

Recent	O
studies	O
in	O
transgenic	O
mice	O
have	O
revealed	O
that	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
in	O
T	B-cell_type
cells	I-cell_type
can	O
prevent	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
type	I-cell_type
2	I-cell_type
(	O
Th2	B-cell_type
)	O
-mediated	O
allergic	O
airway	O
inflammation	O
in	O
mice	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
GATA-3	B-protein
plays	O
a	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
airway	O
inflammation	O
and	O
whether	O
antagonizing	O
the	O
expression	O
and/or	O
function	O
of	O
GATA-3	B-DNA
can	O
be	O
used	O
for	O
the	O
therapy	O
of	O
allergic	O
airway	O
inflammation	O
and	O
hyperresponsiveness	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
whether	B-X
IVIG	B-X
is	B-X
able	B-X
to	B-X
attenuate	B-X
bronchial	B-X
reactivity	B-X
,	B-X
pulmonary	B-X
inflammation	B-X
and	B-X
T	B-X
cell	B-X
function	B-X
using	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
allergic	B-X
airways	B-X
disease	B-X
<EOS>	B-X
We	B-X
employed	B-X
acute	B-X
ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
and	B-X
house	B-X
dust	B-X
mite	B-X
(	B-X
HDM	B-X
)	B-X
sensitization	B-X
and	B-X
challenge	B-X
models	B-X
to	B-X
establish	B-X
allergic	B-X
airway	B-X
inflammation	B-X
in	B-X
mice	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
analysis	B-X
of	B-X
lungs	B-X
and	B-X
draining	B-X
lymph	B-X
node	B-X
(	B-X
DLN	B-X
)	B-X
cell	B-X
infiltrates	B-X
,	B-X
immunoglobulin	B-X
E	B-X
(	B-X
IgE	B-X
)	B-X
production	B-X
,	B-X
and	B-X
airway	B-X
hyper	B-X
-	B-X
responsiveness	B-X
(	B-X
AHR	B-X
)	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
chrysin	B-X
on	B-X
airway	B-X
inflammation	B-X
and	B-X
the	B-X
possible	B-X
mechanisms	B-X
through	B-X
which	B-X
it	B-X
acts	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
allergic	B-X
asthma	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
an	B-X
important	B-X
role	B-X
for	B-X
LAPCs	B-X
in	B-X
polarizing	B-X
the	B-X
Th2	B-X
response	B-X
in	B-X
mouse	B-X
models	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X

Here	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
locally	O
antagonizing	O
GATA-3	B-protein
function	O
in	O
a	O
murine	O
model	O
of	O
asthma	O
.	O

We	O
could	O
suppress	O
GATA-3	O
expression	O
in	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
-producing	O
T	B-cell_type
cells	I-cell_type
in	O
vitro	O
and	O
in	O
vivo	O
by	O
an	O
antisense	O
phosphorothioate	O
oligonucleotide	O
overlapping	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
of	O
GATA-3	B-DNA
,	O
whereas	O
nonsense	O
control	O
oligonucleotides	O
were	O
virtually	O
inactive	O
.	O
<EOS>	B-X
We	B-X
could	B-X
suppress	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
in	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
4	B-X
-	B-X
producing	B-X
T	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
by	B-X
an	B-X
antisense	B-X
phosphorothioate	B-X
oligonucleotide	B-X
overlapping	B-X
the	B-X
translation	B-X
start	B-X
site	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
,	B-X
whereas	B-X
nonsense	B-X
control	B-X
oligonucleotides	B-X
were	B-X
virtually	B-X
inactive	B-X
<EOS>	B-X
Such	B-X
intrapulmonary	B-X
blockade	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
caused	B-X
an	B-X
abrogation	B-X
of	B-X
signs	B-X
of	B-X
lung	B-X
inflammation	B-X
including	B-X
infiltration	B-X
of	B-X
eosinophils	B-X
and	B-X
Th2	B-X
cytokine	B-X
production	B-X
<EOS>	B-X
This	B-X
approach	B-X
has	B-X
the	B-X
potential	B-X
advantage	B-X
of	B-X
suppressing	B-X
the	B-X
expression	B-X
of	B-X
various	B-X
proinflammatory	B-X
Th2	B-X
cytokines	B-X
simultaneously	B-X
rather	B-X
than	B-X
suppressing	B-X
the	B-X
activity	B-X
of	B-X
a	B-X
single	B-X
cytokine	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
in	B-X
transgenic	B-X
mice	B-X
have	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
form	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
T	B-X
cells	B-X
can	B-X
prevent	B-X
T	B-X
helper	B-X
cell	B-X
type	B-X
2	B-X
(	B-X
Th2	B-X
)	B-X
	B-X
-	B-X
mediated	B-X
allergic	B-X
airway	B-X
inflammation	B-X
in	B-X
mice	B-X

In	O
a	O
murine	O
model	O
of	O
asthma	O
associated	O
with	O
allergic	O
pulmonary	O
inflammation	O
and	O
hyperresponsiveness	O
in	O
ovalbumin	O
(	O
OVA	O
)	O
-sensitized	O
mice	O
,	O
local	O
intranasal	O
administration	O
of	O
fluorescein	O
isothiocyanate-labeled	O
GATA-3	O
antisense	O
oligonucleotides	O
led	O
to	O
DNA	O
uptake	O
in	O
lung	B-cell_type
cells	I-cell_type
associated	O
with	O
a	O
reduction	O
of	O
intracellular	O
GATA-3	O
expression	O
.	O

Such	O
intrapulmonary	O
blockade	O
of	O
GATA-3	O
expression	O
caused	O
an	O
abrogation	O
of	O
signs	O
of	O
lung	O
inflammation	O
including	O
infiltration	O
of	O
eosinophils	B-cell_type
and	O
Th2	B-cell_type
cytokine	O
production	O
.	O
<EOS>	B-X
Such	B-X
intrapulmonary	B-X
blockade	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
caused	B-X
an	B-X
abrogation	B-X
of	B-X
signs	B-X
of	B-X
lung	B-X
inflammation	B-X
including	B-X
infiltration	B-X
of	B-X
eosinophils	B-X
and	B-X
Th2	B-X
cytokine	B-X
production	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
the	B-X
effector	B-X
phase	B-X
of	B-X
a	B-X
murine	B-X
asthma	B-X
model	B-X
and	B-X
suggest	B-X
that	B-X
local	B-X
delivery	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
antisense	B-X
oligonucleotides	B-X
may	B-X
be	B-X
a	B-X
novel	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
airway	B-X
hyperresponsiveness	B-X
such	B-X
as	B-X
in	B-X
asthma	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
in	B-X
transgenic	B-X
mice	B-X
have	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
form	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
T	B-X
cells	B-X
can	B-X
prevent	B-X
T	B-X
helper	B-X
cell	B-X
type	B-X
2	B-X
(	B-X
Th2	B-X
)	B-X
	B-X
-	B-X
mediated	B-X
allergic	B-X
airway	B-X
inflammation	B-X
in	B-X
mice	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
unclear	B-X
whether	B-X
GATA	B-X
-	B-X
3	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
effector	B-X
phase	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
whether	B-X
antagonizing	B-X
the	B-X
expression	B-X
and	B-X
/	B-X
or	B-X
function	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
can	B-X
be	B-X
used	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
hyperresponsiveness	B-X

Furthermore	O
,	O
treatment	O
with	O
antisense	O
but	O
not	O
nonsense	O
oligonucleotides	O
induced	O
a	O
significant	O
reduction	O
of	O
airway	O
hyperresponsiveness	O
in	O
OVA-sensitized	O
mice	O
to	O
levels	O
comparable	O
to	O
saline-treated	O
control	O
mice	O
,	O
as	O
assessed	O
by	O
both	O
enhanced	O
pause	O
(	O
PenH	O
)	O
responses	O
and	O
pulmonary	O
resistance	O
determined	O
by	O
body	O
plethysmography	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
transient	B-X
modulation	B-X
of	B-X
protein	B-X
function	B-X
,	B-X
such	B-X
as	B-X
altering	B-X
the	B-X
active	B-X
sites	B-X
of	B-X
enzymes	B-X
or	B-X
the	B-X
interface	B-X
of	B-X
protein	B-X
-	B-X
protein	B-X
interactions	B-X
,	B-X
opens	B-X
the	B-X
door	B-X
to	B-X
therapeutic	B-X
avenues	B-X
ranging	B-X
from	B-X
regenerative	B-X
medicine	B-X
to	B-X
oncology	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
designed	B-X
a	B-X
series	B-X
of	B-X
antisense	B-X
oligonucleotides	B-X
(	B-X
ASOs	B-X
)	B-X
to	B-X
screen	B-X
drug	B-X
candidates	B-X
,	B-X
and	B-X
ASOs	B-X
targeting	B-X
S	B-X
-	B-X
3	B-X
'	B-X
SS	B-X
and	B-X
its	B-X
PPT	B-X
region	B-X
or	B-X
the	B-X
exonic	B-X
region	B-X
of	B-X
exon	B-X
3	B-X
turned	B-X
out	B-X
to	B-X
be	B-X
most	B-X
effective	B-X
in	B-X
rescuing	B-X
exon	B-X
3a	B-X
splicing	B-X
<EOS>	B-X
Combinatorial	B-X
gene	B-X
-	B-X
	B-X
and	B-X
chemotherapies	B-X
using	B-X
antisense	B-X
oligonucleotides	B-X
(	B-X
ASOs	B-X
)	B-X
to	B-X
suppress	B-X
the	B-X
expression	B-X
of	B-X
Bcl	B-X
-	B-X
2	B-X
-	B-X
family	B-X
mRNA	B-X
and	B-X
restore	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
chemodrugs	B-X
provide	B-X
a	B-X
promising	B-X
pathway	B-X
for	B-X
anticancer	B-X
treatment	B-X
<EOS>	B-X
Currently	B-X
,	B-X
four	B-X
antisense	B-X
oligonucleotides	B-X
(	B-X
AONs	B-X
)	B-X
based	B-X
on	B-X
phosphorodiamidate	B-X
morpholino	B-X
oligomer	B-X
(	B-X
PMO	B-X
)	B-X
chemistry	B-X
are	B-X
approved	B-X
by	B-X
US	B-X
Food	B-X
and	B-X
Drug	B-X
Administration	B-X
for	B-X
exon	B-X
skipping	B-X
therapy	B-X
of	B-X
eligible	B-X
DMD	B-X
patients	B-X

These	O
data	O
indicate	O
a	O
critical	O
role	O
for	O
GATA-3	B-DNA
in	O
the	O
effector	O
phase	O
of	O
a	O
murine	O
asthma	O
model	O
and	O
suggest	O
that	O
local	O
delivery	O
of	O
GATA-3	O
antisense	O
oligonucleotides	O
may	O
be	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
airway	O
hyperresponsiveness	O
such	O
as	O
in	O
asthma	O
.	O
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
the	B-X
effector	B-X
phase	B-X
of	B-X
a	B-X
murine	B-X
asthma	B-X
model	B-X
and	B-X
suggest	B-X
that	B-X
local	B-X
delivery	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
antisense	B-X
oligonucleotides	B-X
may	B-X
be	B-X
a	B-X
novel	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
airway	B-X
hyperresponsiveness	B-X
such	B-X
as	B-X
in	B-X
asthma	B-X
<EOS>	B-X
In	B-X
a	B-X
murine	B-X
model	B-X
of	B-X
asthma	B-X
associated	B-X
with	B-X
allergic	B-X
pulmonary	B-X
inflammation	B-X
and	B-X
hyperresponsiveness	B-X
in	B-X
ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
	B-X
-	B-X
sensitized	B-X
mice	B-X
,	B-X
local	B-X
intranasal	B-X
administration	B-X
of	B-X
fluorescein	B-X
isothiocyanate	B-X
-	B-X
labeled	B-X
GATA	B-X
-	B-X
3	B-X
antisense	B-X
oligonucleotides	B-X
led	B-X
to	B-X
DNA	B-X
uptake	B-X
in	B-X
lung	B-X
cells	B-X
associated	B-X
with	B-X
a	B-X
reduction	B-X
of	B-X
intracellular	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
unclear	B-X
whether	B-X
GATA	B-X
-	B-X
3	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
effector	B-X
phase	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
whether	B-X
antagonizing	B-X
the	B-X
expression	B-X
and	B-X
/	B-X
or	B-X
function	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
can	B-X
be	B-X
used	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
hyperresponsiveness	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
hyperresponsiveness	B-X
by	B-X
antisense	B-X
-	B-X
induced	B-X
local	B-X
blockade	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
.	B-X

This	O
approach	O
has	O
the	O
potential	O
advantage	O
of	O
suppressing	O
the	O
expression	O
of	O
various	O
proinflammatory	B-protein
Th2	I-protein
cytokines	I-protein
simultaneously	O
rather	O
than	O
suppressing	O
the	O
activity	O
of	O
a	O
single	O
cytokine	B-protein
.	O
<EOS>	B-X
This	B-X
approach	B-X
has	B-X
the	B-X
potential	B-X
advantage	B-X
of	B-X
suppressing	B-X
the	B-X
expression	B-X
of	B-X
various	B-X
proinflammatory	B-X
Th2	B-X
cytokines	B-X
simultaneously	B-X
rather	B-X
than	B-X
suppressing	B-X
the	B-X
activity	B-X
of	B-X
a	B-X
single	B-X
cytokine	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
unclear	B-X
whether	B-X
GATA	B-X
-	B-X
3	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
effector	B-X
phase	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
whether	B-X
antagonizing	B-X
the	B-X
expression	B-X
and	B-X
/	B-X
or	B-X
function	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
can	B-X
be	B-X
used	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
hyperresponsiveness	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
the	B-X
effector	B-X
phase	B-X
of	B-X
a	B-X
murine	B-X
asthma	B-X
model	B-X
and	B-X
suggest	B-X
that	B-X
local	B-X
delivery	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
antisense	B-X
oligonucleotides	B-X
may	B-X
be	B-X
a	B-X
novel	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
airway	B-X
hyperresponsiveness	B-X
such	B-X
as	B-X
in	B-X
asthma	B-X
<EOS>	B-X
Such	B-X
intrapulmonary	B-X
blockade	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
caused	B-X
an	B-X
abrogation	B-X
of	B-X
signs	B-X
of	B-X
lung	B-X
inflammation	B-X
including	B-X
infiltration	B-X
of	B-X
eosinophils	B-X
and	B-X
Th2	B-X
cytokine	B-X
production	B-X

T	O
helper-cell	O
phenotype	O
regulates	O
atherosclerosis	O
in	O
mice	O
under	O
conditions	O
of	O
mild	O
hypercholesterolemia	O
.	O
<EOS>	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
regulates	B-X
atherosclerosis	B-X
in	B-X
mice	B-X
under	B-X
conditions	B-X
of	B-X
mild	B-X
hypercholesterolemia	B-X
.	B-X
<EOS>	B-X
T	B-X
cells	B-X
are	B-X
implicated	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
genetic	B-X
control	B-X
or	B-X
molecular	B-X
pathways	B-X
,	B-X
especially	B-X
under	B-X
conditions	B-X
of	B-X
mild	B-X
hypercholesterolemia	B-X
<EOS>	B-X
In	B-X
mildly	B-X
hypercholesterolemic	B-X
C57Bl	B-X
/	B-X
6	B-X
mice	B-X
,	B-X
presence	B-X
of	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
and	B-X
absence	B-X
of	B-X
IE	B-X
regulated	B-X
CD4+	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
;	B-X
fatty	B-X
lesions	B-X
were	B-X
proportional	B-X
to	B-X
IFNgamma+	B-X
Th1	B-X
cells	B-X
in	B-X
both	B-X
C57Bl	B-X
/	B-X
6	B-X
and	B-X
BALB	B-X
/	B-X
c	B-X
strains	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
in	B-X
fatty	B-X
streak	B-X
formation	B-X
,	B-X
wild	B-X
-	B-X
type	B-X
C57Bl	B-X
/	B-X
6	B-X
mice	B-X
(	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
+IE	B-X
-	B-X
	B-X
)	B-X
and	B-X
transgenic	B-X
mice	B-X
,	B-X
either	B-X
AB	B-X
(	B-X
o	B-X
)	B-X
,	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
	B-X
-	B-X
IE	B-X
-	B-X
	B-X
;	B-X
ABEalpha	B-X
,	B-X
IA	B-X
-	B-X
IE	B-X
(	B-X
k	B-X
)	B-X
+	B-X
;	B-X
or	B-X
BL	B-X
:	B-X
TG	B-X
:	B-X
Ealpha	B-X
,	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
+IE	B-X
(	B-X
k	B-X
)	B-X
+	B-X
,	B-X
were	B-X
fed	B-X
a	B-X
high	B-X
-	B-X
cholesterol	B-X
diet	B-X
for	B-X
16	B-X
weeks	B-X
and	B-X
evaluated	B-X
histomorphometrically	B-X
for	B-X
aortic	B-X
lesions	B-X

BACKGROUND	O
:	O
T	B-cell_type
cells	I-cell_type
are	O
implicated	O
in	O
atherosclerosis	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
genetic	O
control	O
or	O
molecular	O
pathways	O
,	O
especially	O
under	O
conditions	O
of	O
mild	O
hypercholesterolemia	O
.	O
<EOS>	B-X
T	B-X
cells	B-X
are	B-X
implicated	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
genetic	B-X
control	B-X
or	B-X
molecular	B-X
pathways	B-X
,	B-X
especially	B-X
under	B-X
conditions	B-X
of	B-X
mild	B-X
hypercholesterolemia	B-X
<EOS>	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
regulates	B-X
atherosclerosis	B-X
in	B-X
mice	B-X
under	B-X
conditions	B-X
of	B-X
mild	B-X
hypercholesterolemia	B-X
.	B-X
<EOS>	B-X
Atorvastatin	B-X
,	B-X
the	B-X
most	B-X
prescribed	B-X
statin	B-X
,	B-X
is	B-X
currently	B-X
used	B-X
to	B-X
treat	B-X
conditions	B-X
such	B-X
as	B-X
hypercholesterolaemia	B-X
and	B-X
dyslipidaemia	B-X
<EOS>	B-X
Two	B-X
review	B-X
authors	B-X
independently	B-X
screened	B-X
the	B-X
citations	B-X
,	B-X
extracted	B-X
the	B-X
data	B-X
and	B-X
assessed	B-X
the	B-X
risk	B-X
of	B-X
bias	B-X
of	B-X
the	B-X
included	B-X
studies	B-X

METHODS	O
AND	O
RESULTS	O
:	O
BALB/c	O
mice	O
,	O
making	O
a	O
CD4+	O
Th2	O
(	O
IL-4+	O
)	O
cell	O
response	O
,	O
express	O
both	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
(	O
IA	B-protein
(	I-protein
d	I-protein
)	I-protein
,	O
IE	B-protein
(	I-protein
d	I-protein
)	I-protein
)	O
and	O
are	O
atherosclerosis-resistant	O
.	O

C57Bl/6	O
mice	O
produce	O
a	O
CD4+	O
Th1	O
(	O
interferon	O
[	O
IFN	O
]	O
gamma+	O
)	O
response	O
,	O
express	O
IA	B-protein
(	I-protein
b	I-protein
)	I-protein
but	O
no	O
IE	B-protein
,	O
and	O
are	O
atherosclerosis-prone	O
.	O
<EOS>	B-X
C57Bl	B-X
/	B-X
6	B-X
mice	B-X
produce	B-X
a	B-X
CD4+	B-X
Th1	B-X
(	B-X
interferon	B-X
[	B-X
IFN	B-X
]	B-X
gamma+	B-X
)	B-X
response	B-X
,	B-X
express	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
but	B-X
no	B-X
IE	B-X
,	B-X
and	B-X
are	B-X
atherosclerosis	B-X
-	B-X
prone	B-X
<EOS>	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
,	B-X
making	B-X
a	B-X
CD4+	B-X
Th2	B-X
(	B-X
IL	B-X
-	B-X
4+	B-X
)	B-X
cell	B-X
response	B-X
,	B-X
express	B-X
both	B-X
MHC	B-X
class	B-X
II	B-X
antigens	B-X
(	B-X
IA	B-X
(	B-X
d	B-X
)	B-X
,	B-X
IE	B-X
(	B-X
d	B-X
)	B-X
)	B-X
and	B-X
are	B-X
atherosclerosis	B-X
-	B-X
resistant	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
may	B-X
participate	B-X
through	B-X
macrophage	B-X
activation	B-X
,	B-X
whereas	B-X
IL	B-X
-	B-X
4	B-X
may	B-X
act	B-X
to	B-X
limit	B-X
Th1	B-X
-	B-X
cell	B-X
response	B-X
<EOS>	B-X
In	B-X
mildly	B-X
hypercholesterolemic	B-X
C57Bl	B-X
/	B-X
6	B-X
mice	B-X
,	B-X
presence	B-X
of	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
and	B-X
absence	B-X
of	B-X
IE	B-X
regulated	B-X
CD4+	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
;	B-X
fatty	B-X
lesions	B-X
were	B-X
proportional	B-X
to	B-X
IFNgamma+	B-X
Th1	B-X
cells	B-X
in	B-X
both	B-X
C57Bl	B-X
/	B-X
6	B-X
and	B-X
BALB	B-X
/	B-X
c	B-X
strains	B-X

To	O
evaluate	O
T	O
helper-cell	O
phenotype	O
in	O
fatty	O
streak	O
formation	O
,	O
wild-type	O
C57Bl/6	O
mice	O
(	O
IA	O
(	O
b	O
)	O
+IE-	O
)	O
and	O
transgenic	O
mice	O
,	O
either	O
AB	O
(	O
o	O
)	O
,	O
IA	O
(	O
b	O
)	O
-IE-	O
;	O
ABEalpha	O
,	O
IA-IE	O
(	O
k	O
)	O
+	O
;	O
or	O
BL	O
:	O
TG	O
:	O
Ealpha	O
,	O
IA	O
(	O
b	O
)	O
+IE	O
(	O
k	O
)	O
+	O
,	O
were	O
fed	O
a	O
high-cholesterol	O
diet	O
for	O
16	O
weeks	O
and	O
evaluated	O
histomorphometrically	O
for	O
aortic	O
lesions	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
in	B-X
fatty	B-X
streak	B-X
formation	B-X
,	B-X
wild	B-X
-	B-X
type	B-X
C57Bl	B-X
/	B-X
6	B-X
mice	B-X
(	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
+IE	B-X
-	B-X
	B-X
)	B-X
and	B-X
transgenic	B-X
mice	B-X
,	B-X
either	B-X
AB	B-X
(	B-X
o	B-X
)	B-X
,	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
	B-X
-	B-X
IE	B-X
-	B-X
	B-X
;	B-X
ABEalpha	B-X
,	B-X
IA	B-X
-	B-X
IE	B-X
(	B-X
k	B-X
)	B-X
+	B-X
;	B-X
or	B-X
BL	B-X
:	B-X
TG	B-X
:	B-X
Ealpha	B-X
,	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
+IE	B-X
(	B-X
k	B-X
)	B-X
+	B-X
,	B-X
were	B-X
fed	B-X
a	B-X
high	B-X
-	B-X
cholesterol	B-X
diet	B-X
for	B-X
16	B-X
weeks	B-X
and	B-X
evaluated	B-X
histomorphometrically	B-X
for	B-X
aortic	B-X
lesions	B-X
<EOS>	B-X
In	B-X
mildly	B-X
hypercholesterolemic	B-X
C57Bl	B-X
/	B-X
6	B-X
mice	B-X
,	B-X
presence	B-X
of	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
and	B-X
absence	B-X
of	B-X
IE	B-X
regulated	B-X
CD4+	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
;	B-X
fatty	B-X
lesions	B-X
were	B-X
proportional	B-X
to	B-X
IFNgamma+	B-X
Th1	B-X
cells	B-X
in	B-X
both	B-X
C57Bl	B-X
/	B-X
6	B-X
and	B-X
BALB	B-X
/	B-X
c	B-X
strains	B-X
<EOS>	B-X
T	B-X
cells	B-X
are	B-X
implicated	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
genetic	B-X
control	B-X
or	B-X
molecular	B-X
pathways	B-X
,	B-X
especially	B-X
under	B-X
conditions	B-X
of	B-X
mild	B-X
hypercholesterolemia	B-X
<EOS>	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
regulates	B-X
atherosclerosis	B-X
in	B-X
mice	B-X
under	B-X
conditions	B-X
of	B-X
mild	B-X
hypercholesterolemia	B-X
.	B-X

Lesion	O
size	O
in	O
AB	O
(	O
o	O
)	O
,	O
ABEalpha	O
,	O
and	O
BL	O
:	O
TG	O
:	O
Ealpha	O
strains	O
was	O
decreased	O
by	O
54	O
%	O
,	O
79	O
%	O
,	O
and	O
82	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
wild-type	O
,	O
correlating	O
with	O
decreased	O
Th1	B-cell_type
and	O
increased	O
Th2	B-cell_type
expression	O
and	O
suggesting	O
that	O
T	O
helper-cell	O
phenotype	O
is	O
important	O
in	O
fatty	O
lesion	O
development	O
.	O

Decreasing	O
Th1	B-cell_type
cells	I-cell_type
by	O
antibodies	B-protein
(	O
alpha-CD4	B-protein
)	O
or	O
cytokines	B-protein
(	O
IL-4	B-protein
)	O
also	O
caused	O
>	O
/=80	O
%	O
reductions	O
in	O
lesion	O
size	O
.	O
<EOS>	B-X
Decreasing	B-X
Th1	B-X
cells	B-X
by	B-X
antibodies	B-X
(	B-X
alpha	B-X
-	B-X
CD4	B-X
)	B-X
or	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
)	B-X
also	B-X
caused	B-X
>	B-X
	B-X
/	B-X
=80	B-X
%	B-X
reductions	B-X
in	B-X
lesion	B-X
size	B-X
<EOS>	B-X
Compared	B-X
to	B-X
CL	B-X
patients	B-X
,	B-X
the	B-X
LST	B-X
induration	B-X
size	B-X
was	B-X
larger	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
all	B-X
cytokine	B-X
mRNAs	B-X
but	B-X
IL	B-X
-	B-X
10	B-X
were	B-X
higher	B-X
,	B-X
T	B-X
-	B-X
cell	B-X
mRNA	B-X
was	B-X
similar	B-X
,	B-X
and	B-X
macrophage	B-X
mRNA	B-X
was	B-X
lower	B-X
in	B-X
ML	B-X
patients	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
per	B-X
T	B-X
cell	B-X
and	B-X
macrophage	B-X
decreased	B-X
with	B-X
treatment	B-X
but	B-X
IL	B-X
-	B-X
10	B-X
production	B-X
remained	B-X
high	B-X
in	B-X
nonresponders	B-X
<EOS>	B-X
T	B-X
cells	B-X
are	B-X
implicated	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
genetic	B-X
control	B-X
or	B-X
molecular	B-X
pathways	B-X
,	B-X
especially	B-X
under	B-X
conditions	B-X
of	B-X
mild	B-X
hypercholesterolemia	B-X

Immunohistology	O
revealed	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-4	B-protein
,	O
colocalized	O
with	O
activated	O
macrophages	B-cell_type
.	O
<EOS>	B-X
Immunohistology	B-X
revealed	B-X
a	B-X
monocytic	B-X
and	B-X
dense	B-X
T	B-X
-	B-X
cell	B-X
infiltrate	B-X
<EOS>	B-X
Immunohistology	B-X
showed	B-X
dermal	B-X
B	B-X
cells	B-X
with	B-X
intracytoplasmic	B-X
IgE	B-X
<EOS>	B-X
Immunohistology	B-X
also	B-X
revealed	B-X
no	B-X
evidence	B-X
of	B-X
a	B-X
number	B-X
of	B-X
placental	B-X
infections	B-X
<EOS>	B-X
Immunohistology	B-X
revealed	B-X
IL	B-X
-	B-X
18	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
villi	B-X
and	B-X
crypt	B-X
enterocytes	B-X
and	B-X
IL	B-X
-	B-X
12	B-X
-	B-X
positive	B-X
monocytes	B-X
/	B-X
macrophages	B-X
were	B-X
increased	B-X
with	B-X
disease	B-X
progression	B-X
(	B-X
r	B-X
=	B-X
0	B-X

Confirming	O
these	O
findings	O
in	O
a	O
different	O
mouse	O
strain	O
,	O
BALB/c	O
Stat	O
6	O
knockout	O
mice	O
(	O
Th2	O
cell-deficient	O
)	O
developed	O
aortic	O
lesions	O
comparable	O
to	O
C57Bl/6	O
mice	O
on	O
the	O
same	O
diet	O
.	O

CONCLUSIONS	O
:	O
In	O
mildly	O
hypercholesterolemic	O
C57Bl/6	O
mice	O
,	O
presence	O
of	O
IA	B-protein
(	I-protein
b	I-protein
)	I-protein
and	O
absence	O
of	O
IE	B-protein
regulated	O
CD4+	O
T	O
helper-cell	O
phenotype	O
;	O
fatty	O
lesions	O
were	O
proportional	O
to	O
IFNgamma+	B-cell_type
Th1	I-cell_type
cells	I-cell_type
in	O
both	O
C57Bl/6	O
and	O
BALB/c	O
strains	O
.	O

IFN-gamma	B-protein
may	O
participate	O
through	O
macrophage	O
activation	O
,	O
whereas	O
IL-4	B-protein
may	O
act	O
to	O
limit	O
Th1-cell	O
response	O
.	O
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
may	B-X
participate	B-X
through	B-X
macrophage	B-X
activation	B-X
,	B-X
whereas	B-X
IL	B-X
-	B-X
4	B-X
may	B-X
act	B-X
to	B-X
limit	B-X
Th1	B-X
-	B-X
cell	B-X
response	B-X
<EOS>	B-X
T	B-X
cells	B-X
are	B-X
implicated	B-X
in	B-X
atherosclerosis	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
genetic	B-X
control	B-X
or	B-X
molecular	B-X
pathways	B-X
,	B-X
especially	B-X
under	B-X
conditions	B-X
of	B-X
mild	B-X
hypercholesterolemia	B-X
<EOS>	B-X
C57Bl	B-X
/	B-X
6	B-X
mice	B-X
produce	B-X
a	B-X
CD4+	B-X
Th1	B-X
(	B-X
interferon	B-X
[	B-X
IFN	B-X
]	B-X
gamma+	B-X
)	B-X
response	B-X
,	B-X
express	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
but	B-X
no	B-X
IE	B-X
,	B-X
and	B-X
are	B-X
atherosclerosis	B-X
-	B-X
prone	B-X
<EOS>	B-X
In	B-X
mildly	B-X
hypercholesterolemic	B-X
C57Bl	B-X
/	B-X
6	B-X
mice	B-X
,	B-X
presence	B-X
of	B-X
IA	B-X
(	B-X
b	B-X
)	B-X
and	B-X
absence	B-X
of	B-X
IE	B-X
regulated	B-X
CD4+	B-X
T	B-X
helper	B-X
-	B-X
cell	B-X
phenotype	B-X
;	B-X
fatty	B-X
lesions	B-X
were	B-X
proportional	B-X
to	B-X
IFNgamma+	B-X
Th1	B-X
cells	B-X
in	B-X
both	B-X
C57Bl	B-X
/	B-X
6	B-X
and	B-X
BALB	B-X
/	B-X
c	B-X
strains	B-X

Requirement	O
for	O
p38	B-protein
and	O
p44/p42	B-protein
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
in	O
RAGE	B-protein
-mediated	O
nuclear	B-protein
factor-kappaB	I-protein
transcriptional	O
activation	O
and	O
cytokine	O
secretion	O
.	O
<EOS>	B-X
Requirement	B-X
for	B-X
p38	B-X
and	B-X
p44	B-X
/	B-X
p42	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
in	B-X
RAGE	B-X
-	B-X
mediated	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
transcriptional	B-X
activation	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
p38	B-X
MAPK	B-X
activation	B-X
mediates	B-X
RAGE	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
suggest	B-X
that	B-X
accelerated	B-X
inflammation	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
cellular	B-X
activation	B-X
induced	B-X
by	B-X
this	B-X
receptor	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
human	B-X
serum	B-X
albumin	B-X
modified	B-X
with	B-X
N	B-X
(	B-X
epsilon	B-X
)	B-X
	B-X
-	B-X
	B-X
(	B-X
carboxymethyl	B-X
)	B-X
lysine	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
a	B-X
major	B-X
AGE	B-X
adduct	B-X
that	B-X
progressively	B-X
accumulates	B-X
with	B-X
aging	B-X
,	B-X
diabetes	B-X
,	B-X
and	B-X
renal	B-X
failure	B-X
,	B-X
induced	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
-	B-X
driven	B-X
reporter	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytic	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
CML	B-X
-	B-X
modified	B-X
albumin	B-X
produced	B-X
rapid	B-X
transient	B-X
activation	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
1	B-X
and	B-X
2	B-X
,	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
but	B-X
not	B-X
c	B-X
-	B-X
Jun	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
	B-X
-	B-X
terminal	B-X
kinase	B-X

Advanced	O
glycation	O
end	O
product	O
(	O
AGE	O
)	O
activation	O
of	O
the	O
signal-transducing	B-protein
receptor	I-protein
for	I-protein
AGE	I-protein
(	O
RAGE	B-protein
)	O
has	O
been	O
linked	O
to	O
a	O
proinflammatory	O
phenotypic	O
change	O
within	O
cells	O
.	O
<EOS>	B-X
Advanced	B-X
glycation	B-X
end	B-X
product	B-X
(	B-X
AGE	B-X
)	B-X
activation	B-X
of	B-X
the	B-X
signal	B-X
-	B-X
transducing	B-X
receptor	B-X
for	B-X
AGE	B-X
(	B-X
RAGE	B-X
)	B-X
has	B-X
been	B-X
linked	B-X
to	B-X
a	B-X
proinflammatory	B-X
phenotypic	B-X
change	B-X
within	B-X
cells	B-X
<EOS>	B-X
CML	B-X
-	B-X
modified	B-X
albumin	B-X
produced	B-X
rapid	B-X
transient	B-X
activation	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
1	B-X
and	B-X
2	B-X
,	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
but	B-X
not	B-X
c	B-X
-	B-X
Jun	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
	B-X
-	B-X
terminal	B-X
kinase	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
p38	B-X
MAPK	B-X
activation	B-X
mediates	B-X
RAGE	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
suggest	B-X
that	B-X
accelerated	B-X
inflammation	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
cellular	B-X
activation	B-X
induced	B-X
by	B-X
this	B-X
receptor	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
kappaB	B-X
response	B-X
was	B-X
blocked	B-X
with	B-X
a	B-X
synthetic	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
putative	B-X
ligand	B-X
-	B-X
binding	B-X
domain	B-X
of	B-X
RAGE	B-X
,	B-X
with	B-X
anti	B-X
-	B-X
RAGE	B-X
antiserum	B-X
,	B-X
and	B-X
by	B-X
coexpression	B-X
of	B-X
truncated	B-X
receptors	B-X
lacking	B-X
the	B-X
intracellular	B-X
domain	B-X

However	O
,	O
the	O
precise	O
intracellular	O
signaling	O
pathways	O
involved	O
have	O
not	O
been	O
elucidated	O
.	O
<EOS>	B-X
However	B-X
,	B-X
concerns	B-X
surrounding	B-X
the	B-X
pleiotropic	B-X
and	B-X
ubiquitous	B-X
nature	B-X
of	B-X
these	B-X
signaling	B-X
pathways	B-X
have	B-X
limited	B-X
the	B-X
translation	B-X
of	B-X
inhibitory	B-X
drugs	B-X
<EOS>	B-X
Autophagy	B-X
is	B-X
an	B-X
intracellular	B-X
degradation	B-X
pathway	B-X
conserved	B-X
in	B-X
all	B-X
eukaryotes	B-X
from	B-X
yeast	B-X
to	B-X
humans	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
molecular	B-X
mechanism	B-X
by	B-X
which	B-X
eCIRP	B-X
regulates	B-X
calcium	B-X
signaling	B-X
and	B-X
calpain	B-X
remains	B-X
to	B-X
be	B-X
addressed	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
function	B-X
of	B-X
GS28	B-X
in	B-X
different	B-X
disease	B-X
models	B-X
and	B-X
the	B-X
regulatory	B-X
network	B-X
remains	B-X
unclear	B-X

We	O
demonstrate	O
here	O
that	O
human	O
serum	O
albumin	O
modified	O
with	O
N	O
(	O
varepsilon	O
)	O
-	O
(	O
carboxymethyl	O
)	O
lysine	O
(	O
CML	O
)	O
,	O
a	O
major	O
AGE	O
adduct	O
that	O
progressively	O
accumulates	O
with	O
aging	O
,	O
diabetes	O
,	O
and	O
renal	O
failure	O
,	O
induced	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
-driven	O
reporter	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
THP-1	I-cell_type
cells	I-cell_type
.	O

The	O
NF-kappaB	O
response	O
was	O
blocked	O
with	O
a	O
synthetic	O
peptide	O
corresponding	O
to	O
the	O
putative	B-protein
ligand-binding	I-protein
domain	I-protein
of	O
RAGE	B-protein
,	O
with	O
anti-	O
RAGE	B-protein
antiserum	O
,	O
and	O
by	O
coexpression	O
of	O
truncated	B-protein
receptors	I-protein
lacking	O
the	O
intracellular	B-protein
domain	I-protein
.	O

Signal	O
transduction	O
from	O
RAGE	B-protein
to	O
NF-kappaB	B-protein
involved	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
,	O
since	O
reporter	O
gene	O
expression	O
was	O
blocked	O
with	O
the	O
antioxidant	O
N-acetyl-L-cysteine	O
.	O
<EOS>	B-X
Signal	B-X
transduction	B-X
from	B-X
RAGE	B-X
to	B-X
NF	B-X
-	B-X
kappaB	B-X
involved	B-X
the	B-X
generation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
,	B-X
since	B-X
reporter	B-X
gene	B-X
expression	B-X
was	B-X
blocked	B-X
with	B-X
the	B-X
antioxidant	B-X
N	B-X
-	B-X
acetyl	B-X
-	B-X
L	B-X
-	B-X
cysteine	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
p38	B-X
MAPK	B-X
activation	B-X
mediates	B-X
RAGE	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
suggest	B-X
that	B-X
accelerated	B-X
inflammation	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
cellular	B-X
activation	B-X
induced	B-X
by	B-X
this	B-X
receptor	B-X
<EOS>	B-X
RAGE	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
suppressed	B-X
by	B-X
the	B-X
selective	B-X
p38	B-X
MAPK	B-X
inhibitor	B-X
SB203580	B-X
and	B-X
by	B-X
coexpression	B-X
of	B-X
a	B-X
kinase	B-X
-	B-X
dead	B-X
p38	B-X
dominant	B-X
-	B-X
negative	B-X
mutant	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
kappaB	B-X
response	B-X
was	B-X
blocked	B-X
with	B-X
a	B-X
synthetic	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
putative	B-X
ligand	B-X
-	B-X
binding	B-X
domain	B-X
of	B-X
RAGE	B-X
,	B-X
with	B-X
anti	B-X
-	B-X
RAGE	B-X
antiserum	B-X
,	B-X
and	B-X
by	B-X
coexpression	B-X
of	B-X
truncated	B-X
receptors	B-X
lacking	B-X
the	B-X
intracellular	B-X
domain	B-X

CML-modified	B-protein
albumin	I-protein
produced	O
rapid	O
transient	O
activation	O
of	O
tyrosine	O
phosphorylation	O
,	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
1	I-protein
and	I-protein
2	I-protein
,	O
and	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
,	O
but	O
not	O
c-Jun	B-protein
NH	I-protein
(	I-protein
2	I-protein
)	I-protein
-terminal	I-protein
kinase	I-protein
.	O

RAGE	B-protein
-mediated	O
NF-kappaB	O
activation	O
was	O
suppressed	O
by	O
the	O
selective	O
p38	B-protein
MAPK	I-protein
inhibitor	O
SB203580	O
and	O
by	O
coexpression	O
of	O
a	O
kinase-dead	O
p38	O
dominant-negative	O
mutant	O
.	O
<EOS>	B-X
RAGE	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
suppressed	B-X
by	B-X
the	B-X
selective	B-X
p38	B-X
MAPK	B-X
inhibitor	B-X
SB203580	B-X
and	B-X
by	B-X
coexpression	B-X
of	B-X
a	B-X
kinase	B-X
-	B-X
dead	B-X
p38	B-X
dominant	B-X
-	B-X
negative	B-X
mutant	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
kappaB	B-X
response	B-X
was	B-X
blocked	B-X
with	B-X
a	B-X
synthetic	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
putative	B-X
ligand	B-X
-	B-X
binding	B-X
domain	B-X
of	B-X
RAGE	B-X
,	B-X
with	B-X
anti	B-X
-	B-X
RAGE	B-X
antiserum	B-X
,	B-X
and	B-X
by	B-X
coexpression	B-X
of	B-X
truncated	B-X
receptors	B-X
lacking	B-X
the	B-X
intracellular	B-X
domain	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
p38	B-X
MAPK	B-X
activation	B-X
mediates	B-X
RAGE	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
suggest	B-X
that	B-X
accelerated	B-X
inflammation	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
cellular	B-X
activation	B-X
induced	B-X
by	B-X
this	B-X
receptor	B-X
<EOS>	B-X
CML	B-X
-	B-X
modified	B-X
albumin	B-X
produced	B-X
rapid	B-X
transient	B-X
activation	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
1	B-X
and	B-X
2	B-X
,	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
but	B-X
not	B-X
c	B-X
-	B-X
Jun	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
	B-X
-	B-X
terminal	B-X
kinase	B-X

Activation	O
of	O
NF-kappaB	B-protein
by	O
CML-modified	B-protein
albumin	I-protein
increased	O
secretion	O
of	O
proinflammatory	B-protein
cytokines	I-protein
(	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-1beta	B-protein
,	O
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
)	O
severalfold	O
,	O
and	O
inhibition	O
of	O
p38	B-protein
MAPK	I-protein
blocked	O
these	O
increases	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
by	B-X
CML	B-X
-	B-X
modified	B-X
albumin	B-X
increased	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
(	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
,	B-X
interleukin	B-X
-	B-X
1beta	B-X
,	B-X
and	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
)	B-X
severalfold	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
p38	B-X
MAPK	B-X
blocked	B-X
these	B-X
increases	B-X
<EOS>	B-X
CML	B-X
-	B-X
modified	B-X
albumin	B-X
produced	B-X
rapid	B-X
transient	B-X
activation	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
1	B-X
and	B-X
2	B-X
,	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
but	B-X
not	B-X
c	B-X
-	B-X
Jun	B-X
NH	B-X
(	B-X
2	B-X
)	B-X
	B-X
-	B-X
terminal	B-X
kinase	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
p38	B-X
MAPK	B-X
activation	B-X
mediates	B-X
RAGE	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
suggest	B-X
that	B-X
accelerated	B-X
inflammation	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
cellular	B-X
activation	B-X
induced	B-X
by	B-X
this	B-X
receptor	B-X
<EOS>	B-X
Requirement	B-X
for	B-X
p38	B-X
and	B-X
p44	B-X
/	B-X
p42	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
in	B-X
RAGE	B-X
-	B-X
mediated	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
transcriptional	B-X
activation	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X

These	O
results	O
indicate	O
that	O
p38	B-protein
MAPK	I-protein
activation	O
mediates	O
RAGE	B-protein
-induced	O
NF-kappaB	B-protein
-dependent	O
secretion	O
of	O
proinflammatory	B-protein
cytokines	I-protein
and	O
suggest	O
that	O
accelerated	O
inflammation	O
may	O
be	O
a	O
consequence	O
of	O
cellular	O
activation	O
induced	O
by	O
this	O
receptor	O
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
p38	B-X
MAPK	B-X
activation	B-X
mediates	B-X
RAGE	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
suggest	B-X
that	B-X
accelerated	B-X
inflammation	B-X
may	B-X
be	B-X
a	B-X
consequence	B-X
of	B-X
cellular	B-X
activation	B-X
induced	B-X
by	B-X
this	B-X
receptor	B-X
<EOS>	B-X
Signal	B-X
transduction	B-X
from	B-X
RAGE	B-X
to	B-X
NF	B-X
-	B-X
kappaB	B-X
involved	B-X
the	B-X
generation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
,	B-X
since	B-X
reporter	B-X
gene	B-X
expression	B-X
was	B-X
blocked	B-X
with	B-X
the	B-X
antioxidant	B-X
N	B-X
-	B-X
acetyl	B-X
-	B-X
L	B-X
-	B-X
cysteine	B-X
<EOS>	B-X
Requirement	B-X
for	B-X
p38	B-X
and	B-X
p44	B-X
/	B-X
p42	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
in	B-X
RAGE	B-X
-	B-X
mediated	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
transcriptional	B-X
activation	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
<EOS>	B-X
RAGE	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
was	B-X
suppressed	B-X
by	B-X
the	B-X
selective	B-X
p38	B-X
MAPK	B-X
inhibitor	B-X
SB203580	B-X
and	B-X
by	B-X
coexpression	B-X
of	B-X
a	B-X
kinase	B-X
-	B-X
dead	B-X
p38	B-X
dominant	B-X
-	B-X
negative	B-X
mutant	B-X

Antigen-receptor	O
cross-linking	O
and	O
lipopolysaccharide	O
trigger	O
distinct	O
phosphoinositide	B-protein
3-kinase	I-protein
-dependent	O
pathways	O
to	O
NF-kappa	O
B	O
activation	O
in	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Antigen	B-X
-	B-X
receptor	B-X
cross	B-X
-	B-X
linking	B-X
and	B-X
lipopolysaccharide	B-X
trigger	B-X
distinct	B-X
phosphoinositide	B-X
3	B-X
-	B-X
kinase	B-X
-	B-X
dependent	B-X
pathways	B-X
to	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
we	B-X
address	B-X
the	B-X
role	B-X
of	B-X
phosphoinositide	B-X
3'	B-X
-	B-X
kinase	B-X
(	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
)	B-X
in	B-X
BCR	B-X
-	B-X
	B-X
and	B-X
LPS	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
using	B-X
populations	B-X
of	B-X
primary	B-X
murine	B-X
resting	B-X
B	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
this	B-X
is	B-X
achieved	B-X
via	B-X
protein	B-X
kinase	B-X
C	B-X
-	B-X
dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
the	B-X
involvement	B-X
of	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
in	B-X
at	B-X
least	B-X
two	B-X
distinct	B-X
signaling	B-X
pathways	B-X
leading	B-X
to	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
B	B-X
cells	B-X

The	O
NF-kappaB/Rel	B-protein
transcription	I-protein
factors	I-protein
play	O
an	O
important	O
role	O
in	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
B	O
cell	O
development	O
,	O
differentiation	O
and	O
function	O
.	O

Nuclear	B-protein
NF-kappaB	I-protein
is	O
induced	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
engagement	O
of	O
either	O
the	O
BCR	B-protein
or	O
CD40	B-protein
or	O
by	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
<EOS>	B-X
In	B-X
vitro	B-X
,	B-X
BV2	B-X
cells	B-X
lacking	B-X
Mef2C	B-X
released	B-X
higher	B-X
levels	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
upon	B-X
stimulation	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
,	B-X
a	B-X
bacterial	B-X
toxin	B-X
)	B-X
than	B-X
Mef2C	B-X
-	B-X
sufficient	B-X
cells	B-X
<EOS>	B-X
AKT	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
effect	B-X
of	B-X
LPS	B-X
on	B-X
the	B-X
inhibition	B-X
of	B-X
O	B-X
-	B-X
GlcNAc	B-X
modification	B-X
<EOS>	B-X
We	B-X
found	B-X
here	B-X
that	B-X
exploratory	B-X
laparotomy	B-X
induced	B-X
cognitive	B-X
function	B-X
decline	B-X
in	B-X
aged	B-X
mice	B-X
but	B-X
not	B-X
in	B-X
young	B-X
mice	B-X
and	B-X
that	B-X
this	B-X
decline	B-X
was	B-X
accompanied	B-X
by	B-X
inflammatory	B-X
activation	B-X
of	B-X
microglia	B-X
in	B-X
the	B-X
hippocampus	B-X
<EOS>	B-X
Piceatannol	B-X
induces	B-X
regulatory	B-X
T	B-X
cells	B-X
and	B-X
modulates	B-X
the	B-X
inflammatory	B-X
response	B-X
and	B-X
adipogenesis	B-X
.	B-X

Despite	O
the	O
importance	O
of	O
NF-kappaB	B-protein
to	O
B	O
cell	O
function	O
,	O
little	O
is	O
known	O
about	O
the	O
signaling	O
pathways	O
leading	O
to	O
NF-kappaB	O
activation	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
role	O
of	O
phosphoinositide	B-protein
3'-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
in	O
BCR	B-protein
-	O
and	O
LPS-induced	O
NF-kappaB	O
activation	O
using	O
populations	O
of	O
primary	B-cell_type
murine	I-cell_type
resting	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
we	B-X
address	B-X
the	B-X
role	B-X
of	B-X
phosphoinositide	B-X
3'	B-X
-	B-X
kinase	B-X
(	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
)	B-X
in	B-X
BCR	B-X
-	B-X
	B-X
and	B-X
LPS	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
using	B-X
populations	B-X
of	B-X
primary	B-X
murine	B-X
resting	B-X
B	B-X
cells	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
the	B-X
involvement	B-X
of	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
in	B-X
at	B-X
least	B-X
two	B-X
distinct	B-X
signaling	B-X
pathways	B-X
leading	B-X
to	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
B	B-X
cells	B-X
<EOS>	B-X
Antigen	B-X
-	B-X
receptor	B-X
cross	B-X
-	B-X
linking	B-X
and	B-X
lipopolysaccharide	B-X
trigger	B-X
distinct	B-X
phosphoinositide	B-X
3	B-X
-	B-X
kinase	B-X
-	B-X
dependent	B-X
pathways	B-X
to	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
this	B-X
is	B-X
achieved	B-X
via	B-X
protein	B-X
kinase	B-X
C	B-X
-	B-X
dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X

Using	O
the	O
specific	O
pharmacological	O
inhibitors	O
of	O
PI	B-protein
3-kinase	I-protein
,	O
Wortmannin	O
and	O
LY294002	O
,	O
we	O
demonstrate	O
that	O
PI	B-protein
3-kinase	I-protein
activity	O
is	O
vital	O
for	O
BCR	B-protein
-induced	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
specific	B-X
pharmacological	B-X
inhibitors	B-X
of	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
,	B-X
Wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
activity	B-X
is	B-X
vital	B-X
for	B-X
BCR	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
the	B-X
involvement	B-X
of	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
in	B-X
at	B-X
least	B-X
two	B-X
distinct	B-X
signaling	B-X
pathways	B-X
leading	B-X
to	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
B	B-X
cells	B-X
<EOS>	B-X
Despite	B-X
the	B-X
importance	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
to	B-X
B	B-X
cell	B-X
function	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
signaling	B-X
pathways	B-X
leading	B-X
to	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
<EOS>	B-X
Similar	B-X
analyses	B-X
reveal	B-X
that	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
is	B-X
also	B-X
critical	B-X
in	B-X
triggering	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
and	B-X
IkappaBalpha	B-X
degradation	B-X
following	B-X
LPS	B-X
stimulation	B-X

Furthermore	O
,	O
we	O
show	O
that	O
this	O
is	O
achieved	O
via	O
protein	B-protein
kinase	I-protein
C	I-protein
-dependent	O
degradation	O
of	O
IkappaBalpha	B-protein
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
this	B-X
is	B-X
achieved	B-X
via	B-X
protein	B-X
kinase	B-X
C	B-X
-	B-X
dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
a	B-X
PKC	B-X
inhibitor	B-X
which	B-X
blocked	B-X
the	B-X
BCR	B-X
-	B-X
induced	B-X
IkappaBalpha	B-X
degradation	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
after	B-X
LPS	B-X
stimulation	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
the	B-X
involvement	B-X
of	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
in	B-X
at	B-X
least	B-X
two	B-X
distinct	B-X
signaling	B-X
pathways	B-X
leading	B-X
to	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
B	B-X
cells	B-X
<EOS>	B-X
Similar	B-X
analyses	B-X
reveal	B-X
that	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
is	B-X
also	B-X
critical	B-X
in	B-X
triggering	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
and	B-X
IkappaBalpha	B-X
degradation	B-X
following	B-X
LPS	B-X
stimulation	B-X

Similar	O
analyses	O
reveal	O
that	O
PI	B-protein
3-kinase	I-protein
is	O
also	O
critical	O
in	O
triggering	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
and	O
IkappaBalpha	B-protein
degradation	O
following	O
LPS	O
stimulation	O
.	O
<EOS>	B-X
Similar	B-X
analyses	B-X
reveal	B-X
that	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
is	B-X
also	B-X
critical	B-X
in	B-X
triggering	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
and	B-X
IkappaBalpha	B-X
degradation	B-X
following	B-X
LPS	B-X
stimulation	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
this	B-X
is	B-X
achieved	B-X
via	B-X
protein	B-X
kinase	B-X
C	B-X
-	B-X
dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
a	B-X
PKC	B-X
inhibitor	B-X
which	B-X
blocked	B-X
the	B-X
BCR	B-X
-	B-X
induced	B-X
IkappaBalpha	B-X
degradation	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
after	B-X
LPS	B-X
stimulation	B-X
<EOS>	B-X
Using	B-X
the	B-X
specific	B-X
pharmacological	B-X
inhibitors	B-X
of	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
,	B-X
Wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
activity	B-X
is	B-X
vital	B-X
for	B-X
BCR	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X

Interestingly	O
,	O
a	O
PKC	O
inhibitor	O
which	O
blocked	O
the	O
BCR	B-protein
-induced	O
IkappaBalpha	B-protein
degradation	O
had	O
no	O
effect	O
on	O
the	O
degradation	O
of	O
IkappaBalpha	B-protein
after	O
LPS	O
stimulation	O
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
a	B-X
PKC	B-X
inhibitor	B-X
which	B-X
blocked	B-X
the	B-X
BCR	B-X
-	B-X
induced	B-X
IkappaBalpha	B-X
degradation	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
after	B-X
LPS	B-X
stimulation	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
this	B-X
is	B-X
achieved	B-X
via	B-X
protein	B-X
kinase	B-X
C	B-X
-	B-X
dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
<EOS>	B-X
Similar	B-X
analyses	B-X
reveal	B-X
that	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
is	B-X
also	B-X
critical	B-X
in	B-X
triggering	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
and	B-X
IkappaBalpha	B-X
degradation	B-X
following	B-X
LPS	B-X
stimulation	B-X
<EOS>	B-X
Using	B-X
the	B-X
specific	B-X
pharmacological	B-X
inhibitors	B-X
of	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
,	B-X
Wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
PI	B-X
3	B-X
-	B-X
kinase	B-X
activity	B-X
is	B-X
vital	B-X
for	B-X
BCR	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X

Taken	O
together	O
,	O
our	O
results	O
indicate	O
the	O
involvement	O
of	O
PI	B-protein
3-kinase	I-protein
in	O
at	O
least	O
two	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
activation	O
of	O
NF-kappaB	B-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

Tetramer-guided	O
epitope	O
mapping	O
:	O
rapid	O
identification	O
and	O
characterization	O
of	O
immunodominant	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cell	I-cell_type
epitopes	I-cell_type
from	O
complex	O
antigens	B-protein
.	O
<EOS>	B-X
Tetramer	B-X
-	B-X
guided	B-X
epitope	B-X
mapping	B-X
:	B-X
rapid	B-X
identification	B-X
and	B-X
characterization	B-X
of	B-X
immunodominant	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
from	B-X
complex	B-X
antigens	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
new	B-X
approach	B-X
for	B-X
direct	B-X
identification	B-X
of	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
of	B-X
complex	B-X
Ags	B-X
that	B-X
uses	B-X
human	B-X
class	B-X
II	B-X
tetramers	B-X
to	B-X
identify	B-X
reactive	B-X
cells	B-X
<EOS>	B-X
T	B-X
cell	B-X
responses	B-X
to	B-X
Ags	B-X
involve	B-X
recognition	B-X
of	B-X
selected	B-X
peptide	B-X
epitopes	B-X
contained	B-X
within	B-X
the	B-X
antigenic	B-X
protein	B-X
<EOS>	B-X
By	B-X
using	B-X
tetramers	B-X
to	B-X
sort	B-X
individual	B-X
cells	B-X
,	B-X
we	B-X
easily	B-X
obtained	B-X
a	B-X
large	B-X
number	B-X
of	B-X
clones	B-X
specific	B-X
to	B-X
these	B-X
epitopes	B-X

T	O
cell	O
responses	O
to	O
Ags	B-protein
involve	O
recognition	O
of	O
selected	O
peptide	B-protein
epitopes	I-protein
contained	O
within	O
the	O
antigenic	B-protein
protein	I-protein
.	O
<EOS>	B-X
T	B-X
cell	B-X
responses	B-X
to	B-X
Ags	B-X
involve	B-X
recognition	B-X
of	B-X
selected	B-X
peptide	B-X
epitopes	B-X
contained	B-X
within	B-X
the	B-X
antigenic	B-X
protein	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
new	B-X
approach	B-X
for	B-X
direct	B-X
identification	B-X
of	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
of	B-X
complex	B-X
Ags	B-X
that	B-X
uses	B-X
human	B-X
class	B-X
II	B-X
tetramers	B-X
to	B-X
identify	B-X
reactive	B-X
cells	B-X
<EOS>	B-X
This	B-X
rapid	B-X
approach	B-X
to	B-X
detecting	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
from	B-X
complex	B-X
Ags	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
any	B-X
known	B-X
Ag	B-X
that	B-X
gives	B-X
a	B-X
T	B-X
cell	B-X
response	B-X
<EOS>	B-X
Tetramer	B-X
-	B-X
guided	B-X
epitope	B-X
mapping	B-X
:	B-X
rapid	B-X
identification	B-X
and	B-X
characterization	B-X
of	B-X
immunodominant	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
from	B-X
complex	B-X
antigens	B-X
.	B-X

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
new	O
approach	O
for	O
direct	O
identification	O
of	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
epitopes	I-cell_type
of	O
complex	O
Ags	B-protein
that	O
uses	O
human	B-protein
class	I-protein
II	I-protein
tetramers	I-protein
to	O
identify	O
reactive	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
new	B-X
approach	B-X
for	B-X
direct	B-X
identification	B-X
of	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
of	B-X
complex	B-X
Ags	B-X
that	B-X
uses	B-X
human	B-X
class	B-X
II	B-X
tetramers	B-X
to	B-X
identify	B-X
reactive	B-X
cells	B-X
<EOS>	B-X
This	B-X
rapid	B-X
approach	B-X
to	B-X
detecting	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
from	B-X
complex	B-X
Ags	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
any	B-X
known	B-X
Ag	B-X
that	B-X
gives	B-X
a	B-X
T	B-X
cell	B-X
response	B-X
<EOS>	B-X
Tetramer	B-X
-	B-X
guided	B-X
epitope	B-X
mapping	B-X
:	B-X
rapid	B-X
identification	B-X
and	B-X
characterization	B-X
of	B-X
immunodominant	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
from	B-X
complex	B-X
antigens	B-X
.	B-X
<EOS>	B-X
T	B-X
cell	B-X
responses	B-X
to	B-X
Ags	B-X
involve	B-X
recognition	B-X
of	B-X
selected	B-X
peptide	B-X
epitopes	B-X
contained	B-X
within	B-X
the	B-X
antigenic	B-X
protein	B-X

With	O
a	O
panel	O
of	O
60	O
overlapping	O
peptides	O
covering	O
the	O
entire	O
sequence	O
of	O
the	O
VP16	B-protein
protein	I-protein
,	O
a	O
major	O
Ag	B-protein
for	O
HSV-2	O
,	O
we	O
generated	O
a	O
panel	O
of	O
class	B-protein
II	I-protein
MHC	I-protein
tetramers	I-protein
loaded	O
with	O
peptide	O
pools	O
that	O
were	O
used	O
to	O
stain	O
peripheral	B-cell_type
lymphocytes	I-cell_type
of	O
an	O
HSV-2	O
infected	O
individual	O
.	O

With	O
this	O
approach	O
,	O
we	O
identified	O
four	O
new	O
DRA1*0101/DRB1*0401-	O
and	O
two	O
DRA1*0101/DRB1*0404-restricted	O
,	O
VP16-specific	B-protein
epitopes	I-protein
.	O
<EOS>	B-X
With	B-X
this	B-X
approach	B-X
,	B-X
we	B-X
identified	B-X
four	B-X
new	B-X
DRA1	B-X
*	B-X
0101	B-X
/	B-X
DRB1	B-X
*	B-X
0401	B-X
-	B-X
	B-X
and	B-X
two	B-X
DRA1	B-X
*	B-X
0101	B-X
/	B-X
DRB1	B-X
*	B-X
0404	B-X
-	B-X
restricted	B-X
,	B-X
VP16	B-X
-	B-X
specific	B-X
epitopes	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
new	B-X
approach	B-X
for	B-X
direct	B-X
identification	B-X
of	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
of	B-X
complex	B-X
Ags	B-X
that	B-X
uses	B-X
human	B-X
class	B-X
II	B-X
tetramers	B-X
to	B-X
identify	B-X
reactive	B-X
cells	B-X
<EOS>	B-X
By	B-X
using	B-X
tetramers	B-X
to	B-X
sort	B-X
individual	B-X
cells	B-X
,	B-X
we	B-X
easily	B-X
obtained	B-X
a	B-X
large	B-X
number	B-X
of	B-X
clones	B-X
specific	B-X
to	B-X
these	B-X
epitopes	B-X
<EOS>	B-X
Although	B-X
DRA1	B-X
*	B-X
0101	B-X
/	B-X
DRB1	B-X
*	B-X
0401	B-X
and	B-X
DRA1	B-X
*	B-X
0101	B-X
/	B-X
DRB1	B-X
*	B-X
0404	B-X
are	B-X
structurally	B-X
very	B-X
similar	B-X
,	B-X
nonoverlapping	B-X
VP16	B-X
epitopes	B-X
were	B-X
identified	B-X
,	B-X
illustrating	B-X
high	B-X
selectivity	B-X
of	B-X
individual	B-X
allele	B-X
polymorphisms	B-X
within	B-X
common	B-X
MHC	B-X
variants	B-X

By	O
using	O
tetramers	B-protein
to	O
sort	O
individual	O
cells	O
,	O
we	O
easily	O
obtained	O
a	O
large	O
number	O
of	O
clones	O
specific	O
to	O
these	O
epitopes	B-protein
.	O
<EOS>	B-X
By	B-X
using	B-X
tetramers	B-X
to	B-X
sort	B-X
individual	B-X
cells	B-X
,	B-X
we	B-X
easily	B-X
obtained	B-X
a	B-X
large	B-X
number	B-X
of	B-X
clones	B-X
specific	B-X
to	B-X
these	B-X
epitopes	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
new	B-X
approach	B-X
for	B-X
direct	B-X
identification	B-X
of	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
of	B-X
complex	B-X
Ags	B-X
that	B-X
uses	B-X
human	B-X
class	B-X
II	B-X
tetramers	B-X
to	B-X
identify	B-X
reactive	B-X
cells	B-X
<EOS>	B-X
T	B-X
cell	B-X
responses	B-X
to	B-X
Ags	B-X
involve	B-X
recognition	B-X
of	B-X
selected	B-X
peptide	B-X
epitopes	B-X
contained	B-X
within	B-X
the	B-X
antigenic	B-X
protein	B-X
<EOS>	B-X
This	B-X
rapid	B-X
approach	B-X
to	B-X
detecting	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
from	B-X
complex	B-X
Ags	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
any	B-X
known	B-X
Ag	B-X
that	B-X
gives	B-X
a	B-X
T	B-X
cell	B-X
response	B-X

Although	O
DRA1*0101/DRB1*0401	O
and	O
DRA1*0101/DRB1*0404	O
are	O
structurally	O
very	O
similar	O
,	O
nonoverlapping	O
VP16	B-protein
epitopes	I-protein
were	O
identified	O
,	O
illustrating	O
high	O
selectivity	O
of	O
individual	O
allele	O
polymorphisms	O
within	O
common	O
MHC	O
variants	O
.	O
<EOS>	B-X
Although	B-X
DRA1	B-X
*	B-X
0101	B-X
/	B-X
DRB1	B-X
*	B-X
0401	B-X
and	B-X
DRA1	B-X
*	B-X
0101	B-X
/	B-X
DRB1	B-X
*	B-X
0404	B-X
are	B-X
structurally	B-X
very	B-X
similar	B-X
,	B-X
nonoverlapping	B-X
VP16	B-X
epitopes	B-X
were	B-X
identified	B-X
,	B-X
illustrating	B-X
high	B-X
selectivity	B-X
of	B-X
individual	B-X
allele	B-X
polymorphisms	B-X
within	B-X
common	B-X
MHC	B-X
variants	B-X
<EOS>	B-X
Tetramer	B-X
-	B-X
guided	B-X
epitope	B-X
mapping	B-X
:	B-X
rapid	B-X
identification	B-X
and	B-X
characterization	B-X
of	B-X
immunodominant	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
from	B-X
complex	B-X
antigens	B-X
.	B-X
<EOS>	B-X
T	B-X
cell	B-X
responses	B-X
to	B-X
Ags	B-X
involve	B-X
recognition	B-X
of	B-X
selected	B-X
peptide	B-X
epitopes	B-X
contained	B-X
within	B-X
the	B-X
antigenic	B-X
protein	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
new	B-X
approach	B-X
for	B-X
direct	B-X
identification	B-X
of	B-X
CD4+	B-X
T	B-X
cell	B-X
epitopes	B-X
of	B-X
complex	B-X
Ags	B-X
that	B-X
uses	B-X
human	B-X
class	B-X
II	B-X
tetramers	B-X
to	B-X
identify	B-X
reactive	B-X
cells	B-X

This	O
rapid	O
approach	O
to	O
detecting	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
epitopes	I-cell_type
from	O
complex	O
Ags	B-protein
can	O
be	O
applied	O
to	O
any	O
known	O
Ag	B-protein
that	O
gives	O
a	O
T	O
cell	O
response	O
.	O

Localized	O
pancreatic	O
NF-kappaB	O
activation	O
and	O
inflammatory	O
response	O
in	O
taurocholate-induced	O
pancreatitis	O
.	O
<EOS>	B-X
Localized	B-X
pancreatic	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
inflammatory	B-X
response	B-X
in	B-X
taurocholate	B-X
-	B-X
induced	B-X
pancreatitis	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
upregulation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
inflammatory	B-X
molecules	B-X
,	B-X
and	B-X
their	B-X
correlation	B-X
with	B-X
local	B-X
pancreatic	B-X
injury	B-X
,	B-X
in	B-X
a	B-X
model	B-X
of	B-X
severe	B-X
pancreatitis	B-X
<EOS>	B-X
Correlation	B-X
between	B-X
localized	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
cytokine	B-X
upregulation	B-X
,	B-X
and	B-X
tissue	B-X
damage	B-X
suggests	B-X
a	B-X
key	B-X
role	B-X
for	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
of	B-X
acute	B-X
pancreatitis	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
transcription	B-X
factor	B-X
activation	B-X
in	B-X
other	B-X
models	B-X
of	B-X
pancreatitis	B-X
has	B-X
not	B-X
been	B-X
established	B-X

Transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
is	O
activated	O
in	O
cerulein	O
pancreatitis	O
and	O
mediates	O
cytokine	O
expression	O
.	O
<EOS>	B-X
Inhibitory	B-X
κB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
	B-X
/	B-X
nuclear	B-X
factor	B-X
κB	B-X
(	B-X
NF	B-X
-	B-X
κB	B-X
)	B-X
signalling	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
pancreatitis	B-X
,	B-X
but	B-X
its	B-X
precise	B-X
function	B-X
has	B-X
remained	B-X
controversial	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
-	B-X
κB	B-X
p65	B-X
(	B-X
NF	B-X
-	B-X
κBp65	B-X
)	B-X
activation	B-X
has	B-X
been	B-X
observed	B-X
early	B-X
in	B-X
the	B-X
onset	B-X
of	B-X
pancreatitis	B-X
<EOS>	B-X
The	B-X
co	B-X
-	B-X
localization	B-X
and	B-X
nuclear	B-X
accumulation	B-X
of	B-X
KPNA2	B-X
and	B-X
p65	B-X
were	B-X
detected	B-X
in	B-X
cerulein	B-X
-	B-X
treated	B-X
cells	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
indicated	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
activation	B-X
by	B-X
apelin	B-X
was	B-X
a	B-X
mechanism	B-X
behind	B-X
the	B-X
reduced	B-X
pancreatic	B-X
levels	B-X
of	B-X
inflammatory	B-X
mediators	B-X
in	B-X
CP	B-X
mice	B-X
exposed	B-X
to	B-X
apelin	B-X

The	O
role	O
of	O
transcription	O
factor	O
activation	O
in	O
other	O
models	O
of	O
pancreatitis	O
has	O
not	O
been	O
established	O
.	O
<EOS>	B-X
1	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
that	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
pancreatic	B-X
β	B-X
cell	B-X
function	B-X
and	B-X
proliferation	B-X
<EOS>	B-X
RFXAP	B-X
is	B-X
a	B-X
critical	B-X
transcription	B-X
factor	B-X
for	B-X
MHC	B-X
II	B-X
molecules	B-X
,	B-X
however	B-X
,	B-X
its	B-X
transcriptional	B-X
role	B-X
in	B-X
PDAC	B-X
is	B-X
poorly	B-X
understood	B-X
<EOS>	B-X
NKX6.1	B-X
transcription	B-X
factor	B-X
:	B-X
a	B-X
crucial	B-X
regulator	B-X
of	B-X
pancreatic	B-X
β	B-X
cell	B-X
development	B-X
,	B-X
identity	B-X
,	B-X
and	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
While	B-X
the	B-X
cells	B-X
of	B-X
this	B-X
particular	B-X
cancer	B-X
display	B-X
distinct	B-X
features	B-X
that	B-X
separate	B-X
them	B-X
from	B-X
other	B-X
forms	B-X
of	B-X
pancreatic	B-X
cancer	B-X
,	B-X
the	B-X
genetic	B-X
causes	B-X
of	B-X
these	B-X
features	B-X
are	B-X
unclear	B-X

Here	O
we	O
report	O
upregulation	O
of	O
NF-kappaB	B-protein
and	O
inflammatory	B-protein
molecules	I-protein
,	O
and	O
their	O
correlation	O
with	O
local	O
pancreatic	O
injury	O
,	O
in	O
a	O
model	O
of	O
severe	O
pancreatitis	O
.	O

Rats	O
received	O
intraductal	O
infusion	O
of	O
taurocholate	O
or	O
saline	O
,	O
and	O
the	O
pancreatic	O
head	O
and	O
tail	O
were	O
analyzed	O
separately	O
.	O
<EOS>	B-X
Rats	B-X
received	B-X
intraductal	B-X
infusion	B-X
of	B-X
taurocholate	B-X
or	B-X
saline	B-X
,	B-X
and	B-X
the	B-X
pancreatic	B-X
head	B-X
and	B-X
tail	B-X
were	B-X
analyzed	B-X
separately	B-X
<EOS>	B-X
AP	B-X
was	B-X
induced	B-X
via	B-X
intraductal	B-X
taurocholate	B-X
infusion	B-X
in	B-X
the	B-X
remaining	B-X
seventy	B-X
rats	B-X
<EOS>	B-X
The	B-X
liver	B-X
ultrastructure	B-X
in	B-X
caerulein	B-X
and	B-X
taurocholate	B-X
acute	B-X
pancreatitis	B-X
in	B-X
the	B-X
rats	B-X
.	B-X
<EOS>	B-X
Rats	B-X
that	B-X
survived	B-X
to	B-X
induction	B-X
of	B-X
acute	B-X
necrotizing	B-X
pancreatitis	B-X
were	B-X
randomized	B-X
into	B-X
four	B-X
groups	B-X

NF-kappaB	B-protein
and	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
activation	O
were	O
assessed	O
by	O
gel	O
shift	O
assay	O
,	O
and	O
mRNA	O
expression	O
of	O
interleukin-6	B-RNA
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
KC	O
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
,	O
and	O
inducible	B-protein
nitric	I-protein
oxide	I-protein
synthase	I-protein
was	O
assessed	O
by	O
semiquantitative	O
RT-PCR	O
.	O
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
activation	B-X
were	B-X
assessed	B-X
by	B-X
gel	B-X
shift	B-X
assay	B-X
,	B-X
and	B-X
mRNA	B-X
expression	B-X
of	B-X
interleukin	B-X
-	B-X
6	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
,	B-X
KC	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
,	B-X
and	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
was	B-X
assessed	B-X
by	B-X
semiquantitative	B-X
RT	B-X
-	B-X
PCR	B-X
<EOS>	B-X
Morphological	B-X
damage	B-X
and	B-X
trypsin	B-X
activation	B-X
were	B-X
much	B-X
greater	B-X
in	B-X
the	B-X
pancreatic	B-X
head	B-X
than	B-X
tail	B-X
,	B-X
in	B-X
parallel	B-X
with	B-X
a	B-X
stronger	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
cytokine	B-X
mRNA	B-X
<EOS>	B-X
Correlation	B-X
between	B-X
localized	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
cytokine	B-X
upregulation	B-X
,	B-X
and	B-X
tissue	B-X
damage	B-X
suggests	B-X
a	B-X
key	B-X
role	B-X
for	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
of	B-X
acute	B-X
pancreatitis	B-X
<EOS>	B-X
Rats	B-X
received	B-X
intraductal	B-X
infusion	B-X
of	B-X
taurocholate	B-X
or	B-X
saline	B-X
,	B-X
and	B-X
the	B-X
pancreatic	B-X
head	B-X
and	B-X
tail	B-X
were	B-X
analyzed	B-X
separately	B-X

Morphological	O
damage	O
and	O
trypsin	O
activation	O
were	O
much	O
greater	O
in	O
the	O
pancreatic	O
head	O
than	O
tail	O
,	O
in	O
parallel	O
with	O
a	O
stronger	O
activation	O
of	O
NF-kappaB	B-RNA
and	I-RNA
cytokine	I-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
Morphological	B-X
damage	B-X
and	B-X
trypsin	B-X
activation	B-X
were	B-X
much	B-X
greater	B-X
in	B-X
the	B-X
pancreatic	B-X
head	B-X
than	B-X
tail	B-X
,	B-X
in	B-X
parallel	B-X
with	B-X
a	B-X
stronger	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
cytokine	B-X
mRNA	B-X
<EOS>	B-X
AP	B-X
-	B-X
1	B-X
was	B-X
strongly	B-X
activated	B-X
in	B-X
both	B-X
pancreatic	B-X
segments	B-X
after	B-X
either	B-X
taurocholate	B-X
or	B-X
saline	B-X
infusion	B-X
<EOS>	B-X
Rats	B-X
received	B-X
intraductal	B-X
infusion	B-X
of	B-X
taurocholate	B-X
or	B-X
saline	B-X
,	B-X
and	B-X
the	B-X
pancreatic	B-X
head	B-X
and	B-X
tail	B-X
were	B-X
analyzed	B-X
separately	B-X
<EOS>	B-X
Localized	B-X
pancreatic	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
inflammatory	B-X
response	B-X
in	B-X
taurocholate	B-X
-	B-X
induced	B-X
pancreatitis	B-X
.	B-X

Saline	O
infusion	O
mildly	O
affected	O
these	O
parameters	O
.	O
<EOS>	B-X
Saline	B-X
infusion	B-X
mildly	B-X
affected	B-X
these	B-X
parameters	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
saline	B-X
infusion	B-X
did	B-X
not	B-X
affect	B-X
any	B-X
of	B-X
these	B-X
parameters	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibition	B-X
with	B-X
N	B-X
-	B-X
acetylcysteine	B-X
ameliorated	B-X
the	B-X
local	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
Rats	B-X
received	B-X
intraductal	B-X
infusion	B-X
of	B-X
taurocholate	B-X
or	B-X
saline	B-X
,	B-X
and	B-X
the	B-X
pancreatic	B-X
head	B-X
and	B-X
tail	B-X
were	B-X
analyzed	B-X
separately	B-X

AP-1	B-protein
was	O
strongly	O
activated	O
in	O
both	O
pancreatic	O
segments	O
after	O
either	O
taurocholate	O
or	O
saline	O
infusion	O
.	O
<EOS>	B-X
001	B-X
)	B-X
for	B-X
worst	B-X
pain	B-X
in	B-X
patients	B-X
given	B-X
a	B-X
placebo	B-X
infusion	B-X
<EOS>	B-X
Group	B-X
N	B-X
received	B-X
erector	B-X
spinae	B-X
plane	B-X
block	B-X
+	B-X
general	B-X
anesthesia	B-X
+	B-X
20ml	B-X
of	B-X
normal	B-X
saline	B-X
infusion	B-X
<EOS>	B-X
Regional	B-X
techniques	B-X
minimize	B-X
anesthetic	B-X
requirements	B-X
and	B-X
their	B-X
effects	B-X
may	B-X
be	B-X
beneficial	B-X
<EOS>	B-X
For	B-X
a	B-X
full	B-X
description	B-X
of	B-X
these	B-X
Evidence	B-X
-	B-X
Based	B-X
Medicine	B-X
ratings	B-X
,	B-X
please	B-X
refer	B-X
to	B-X
the	B-X
Table	B-X
of	B-X
Contents	B-X
or	B-X
the	B-X
online	B-X
Instructions	B-X
to	B-X
Authors	B-X
www	B-X

NF-kappaB	B-protein
inhibition	O
with	O
N-acetylcysteine	O
ameliorated	O
the	O
local	O
inflammatory	O
response	O
.	O
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibition	B-X
with	B-X
N	B-X
-	B-X
acetylcysteine	B-X
ameliorated	B-X
the	B-X
local	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
Correlation	B-X
between	B-X
localized	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
cytokine	B-X
upregulation	B-X
,	B-X
and	B-X
tissue	B-X
damage	B-X
suggests	B-X
a	B-X
key	B-X
role	B-X
for	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
of	B-X
acute	B-X
pancreatitis	B-X
<EOS>	B-X
Saline	B-X
infusion	B-X
mildly	B-X
affected	B-X
these	B-X
parameters	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
upregulation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
inflammatory	B-X
molecules	B-X
,	B-X
and	B-X
their	B-X
correlation	B-X
with	B-X
local	B-X
pancreatic	B-X
injury	B-X
,	B-X
in	B-X
a	B-X
model	B-X
of	B-X
severe	B-X
pancreatitis	B-X

Correlation	O
between	O
localized	O
NF-kappaB	B-protein
activation	O
,	O
cytokine	O
upregulation	O
,	O
and	O
tissue	O
damage	O
suggests	O
a	O
key	O
role	O
for	O
NF-kappaB	B-protein
in	O
the	O
development	O
of	O
the	O
inflammatory	O
response	O
of	O
acute	O
pancreatitis	O
.	O
<EOS>	B-X
Correlation	B-X
between	B-X
localized	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
cytokine	B-X
upregulation	B-X
,	B-X
and	B-X
tissue	B-X
damage	B-X
suggests	B-X
a	B-X
key	B-X
role	B-X
for	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
of	B-X
acute	B-X
pancreatitis	B-X
<EOS>	B-X
Localized	B-X
pancreatic	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
inflammatory	B-X
response	B-X
in	B-X
taurocholate	B-X
-	B-X
induced	B-X
pancreatitis	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
upregulation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
inflammatory	B-X
molecules	B-X
,	B-X
and	B-X
their	B-X
correlation	B-X
with	B-X
local	B-X
pancreatic	B-X
injury	B-X
,	B-X
in	B-X
a	B-X
model	B-X
of	B-X
severe	B-X
pancreatitis	B-X
<EOS>	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibition	B-X
with	B-X
N	B-X
-	B-X
acetylcysteine	B-X
ameliorated	B-X
the	B-X
local	B-X
inflammatory	B-X
response	B-X

CD45	B-protein
tyrosine	I-protein
phosphatase	I-protein
controls	O
common	O
gamma-chain	B-protein
cytokine	I-protein
-mediated	O
STAT	B-protein
and	O
extracellular	O
signal-related	O
kinase	O
phosphorylation	O
in	O
activated	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
:	O
inhibition	O
of	O
proliferation	O
without	O
induction	O
of	O
apoptosis	O
.	O
<EOS>	B-X
CD45	B-X
tyrosine	B-X
phosphatase	B-X
controls	B-X
common	B-X
gamma	B-X
-	B-X
chain	B-X
cytokine	B-X
-	B-X
mediated	B-X
STAT	B-X
and	B-X
extracellular	B-X
signal	B-X
-	B-X
related	B-X
kinase	B-X
phosphorylation	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
:	B-X
inhibition	B-X
of	B-X
proliferation	B-X
without	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
In	B-X
Western	B-X
blots	B-X
using	B-X
mAbs	B-X
detecting	B-X
phosphorylated	B-X
STAT	B-X
-	B-X
3	B-X
,	B-X
STAT	B-X
-	B-X
5	B-X
,	B-X
STAT	B-X
-	B-X
6	B-X
,	B-X
or	B-X
extracellular	B-X
signal	B-X
-	B-X
related	B-X
kinase	B-X
1	B-X
/	B-X
2	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CD45R0	B-X
signaling	B-X
could	B-X
effectively	B-X
diminish	B-X
phosphorylation	B-X
of	B-X
these	B-X
intracellular	B-X
signaling	B-X
components	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
test	B-X
whether	B-X
CD45	B-X
signals	B-X
can	B-X
influence	B-X
signaling	B-X
processes	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
3	B-X
,	B-X
which	B-X
is	B-X
most	B-X
effective	B-X
in	B-X
inhibition	B-X
of	B-X
OKT	B-X
-	B-X
3	B-X
-	B-X
mediated	B-X
proliferation	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
was	B-X
ineffective	B-X
in	B-X
lymphoblasts	B-X

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
CD45	O
signals	O
can	O
influence	O
signaling	O
processes	O
in	O
activated	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
test	B-X
whether	B-X
CD45	B-X
signals	B-X
can	B-X
influence	B-X
signaling	B-X
processes	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
illustrate	B-X
that	B-X
CD45R0	B-X
signals	B-X
control	B-X
early	B-X
cytokine	B-X
receptor	B-X
-	B-X
associated	B-X
signaling	B-X
processes	B-X
and	B-X
mRNA	B-X
and	B-X
DNA	B-X
synthesis	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
3	B-X
)	B-X
,	B-X
which	B-X
are	B-X
active	B-X
and	B-X
critical	B-X
for	B-X
signaling	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
but	B-X
are	B-X
nonfunctional	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
3	B-X
,	B-X
which	B-X
is	B-X
most	B-X
effective	B-X
in	B-X
inhibition	B-X
of	B-X
OKT	B-X
-	B-X
3	B-X
-	B-X
mediated	B-X
proliferation	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
was	B-X
ineffective	B-X
in	B-X
lymphoblasts	B-X

To	O
this	O
end	O
,	O
we	O
generated	O
lymphoblasts	B-cell_type
which	O
proliferate	O
in	O
response	O
to	O
common	O
gamma-chain	B-protein
cytokines	I-protein
,	O
but	O
readily	O
undergo	O
apoptosis	O
after	O
cytokine	O
withdrawal	O
.	O
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
generated	B-X
lymphoblasts	B-X
which	B-X
proliferate	B-X
in	B-X
response	B-X
to	B-X
common	B-X
gamma	B-X
-	B-X
chain	B-X
cytokines	B-X
,	B-X
but	B-X
readily	B-X
undergo	B-X
apoptosis	B-X
after	B-X
cytokine	B-X
withdrawal	B-X
<EOS>	B-X
3	B-X
)	B-X
,	B-X
which	B-X
are	B-X
active	B-X
and	B-X
critical	B-X
for	B-X
signaling	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
but	B-X
are	B-X
nonfunctional	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
CD45	B-X
tyrosine	B-X
phosphatase	B-X
controls	B-X
common	B-X
gamma	B-X
-	B-X
chain	B-X
cytokine	B-X
-	B-X
mediated	B-X
STAT	B-X
and	B-X
extracellular	B-X
signal	B-X
-	B-X
related	B-X
kinase	B-X
phosphorylation	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
:	B-X
inhibition	B-X
of	B-X
proliferation	B-X
without	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
In	B-X
Western	B-X
blots	B-X
using	B-X
mAbs	B-X
detecting	B-X
phosphorylated	B-X
STAT	B-X
-	B-X
3	B-X
,	B-X
STAT	B-X
-	B-X
5	B-X
,	B-X
STAT	B-X
-	B-X
6	B-X
,	B-X
or	B-X
extracellular	B-X
signal	B-X
-	B-X
related	B-X
kinase	B-X
1	B-X
/	B-X
2	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CD45R0	B-X
signaling	B-X
could	B-X
effectively	B-X
diminish	B-X
phosphorylation	B-X
of	B-X
these	B-X
intracellular	B-X
signaling	B-X
components	B-X

In	O
experiments	O
with	O
the	O
CD45R0	B-protein
mAb	I-protein
UCHL-1	I-protein
,	O
but	O
not	O
control	B-protein
CD45	I-protein
mAbs	I-protein
,	O
we	O
found	O
significant	O
inhibition	O
of	O
proliferation	O
.	O

Interestingly	O
,	O
the	O
pan-CD45	B-protein
mAb	I-protein
GAP8.3	I-protein
,	O
which	O
is	O
most	O
effective	O
in	O
inhibition	O
of	O
OKT-3-mediated	O
proliferation	O
in	O
quiescent	B-cell_type
lymphocytes	I-cell_type
,	O
was	O
ineffective	O
in	O
lymphoblasts	B-cell_type
.	O
<EOS>	B-X
3	B-X
,	B-X
which	B-X
is	B-X
most	B-X
effective	B-X
in	B-X
inhibition	B-X
of	B-X
OKT	B-X
-	B-X
3	B-X
-	B-X
mediated	B-X
proliferation	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
was	B-X
ineffective	B-X
in	B-X
lymphoblasts	B-X
<EOS>	B-X
Addition	B-X
of	B-X
CD3	B-X
mAb	B-X
OKT	B-X
-	B-X
3	B-X
had	B-X
no	B-X
influence	B-X
on	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
mediated	B-X
proliferation	B-X
(	B-X
with	B-X
or	B-X
without	B-X
UCHL	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
3	B-X
)	B-X
,	B-X
which	B-X
are	B-X
active	B-X
and	B-X
critical	B-X
for	B-X
signaling	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
but	B-X
are	B-X
nonfunctional	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
test	B-X
whether	B-X
CD45	B-X
signals	B-X
can	B-X
influence	B-X
signaling	B-X
processes	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X

Addition	O
of	O
CD3	B-protein
mAb	I-protein
OKT-3	I-protein
had	O
no	O
influence	O
on	O
IL-2-mediated	O
proliferation	O
(	O
with	O
or	O
without	O
UCHL-1	B-protein
)	O
.	O
<EOS>	B-X
Addition	B-X
of	B-X
CD3	B-X
mAb	B-X
OKT	B-X
-	B-X
3	B-X
had	B-X
no	B-X
influence	B-X
on	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
mediated	B-X
proliferation	B-X
(	B-X
with	B-X
or	B-X
without	B-X
UCHL	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
3	B-X
,	B-X
which	B-X
is	B-X
most	B-X
effective	B-X
in	B-X
inhibition	B-X
of	B-X
OKT	B-X
-	B-X
3	B-X
-	B-X
mediated	B-X
proliferation	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
was	B-X
ineffective	B-X
in	B-X
lymphoblasts	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
after	B-X
addition	B-X
of	B-X
OKT	B-X
-	B-X
3	B-X
to	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
	B-X
and	B-X
IL	B-X
-	B-X
7	B-X
-	B-X
stimulated	B-X
proliferation	B-X
assays	B-X
,	B-X
UCHL	B-X
-	B-X
1	B-X
signals	B-X
could	B-X
not	B-X
significantly	B-X
alter	B-X
cellular	B-X
proliferation	B-X
<EOS>	B-X
CD45	B-X
tyrosine	B-X
phosphatase	B-X
controls	B-X
common	B-X
gamma	B-X
-	B-X
chain	B-X
cytokine	B-X
-	B-X
mediated	B-X
STAT	B-X
and	B-X
extracellular	B-X
signal	B-X
-	B-X
related	B-X
kinase	B-X
phosphorylation	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
:	B-X
inhibition	B-X
of	B-X
proliferation	B-X
without	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X

In	O
contrast	O
,	O
after	O
addition	O
of	O
OKT-3	B-protein
to	O
IL-4	B-protein
-	O
and	O
IL-7	B-protein
-stimulated	O
proliferation	O
assays	O
,	O
UCHL-1	B-protein
signals	O
could	O
not	O
significantly	O
alter	O
cellular	O
proliferation	O
.	O

We	O
did	O
not	O
find	O
induction	O
of	O
apoptosis	O
following	O
CD45R0	O
signaling	O
.	O

In	O
Western	O
blots	O
using	O
mAbs	B-protein
detecting	O
phosphorylated	B-protein
STAT-3	I-protein
,	I-protein
STAT-5	I-protein
,	I-protein
STAT-6	I-protein
,	O
or	O
extracellular	B-protein
signal-related	I-protein
kinase	I-protein
1/2	I-protein
,	O
we	O
found	O
that	O
CD45R0	O
signaling	O
could	O
effectively	O
diminish	O
phosphorylation	O
of	O
these	O
intracellular	O
signaling	O
components	O
.	O
<EOS>	B-X
In	B-X
Western	B-X
blots	B-X
using	B-X
mAbs	B-X
detecting	B-X
phosphorylated	B-X
STAT	B-X
-	B-X
3	B-X
,	B-X
STAT	B-X
-	B-X
5	B-X
,	B-X
STAT	B-X
-	B-X
6	B-X
,	B-X
or	B-X
extracellular	B-X
signal	B-X
-	B-X
related	B-X
kinase	B-X
1	B-X
/	B-X
2	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CD45R0	B-X
signaling	B-X
could	B-X
effectively	B-X
diminish	B-X
phosphorylation	B-X
of	B-X
these	B-X
intracellular	B-X
signaling	B-X
components	B-X
<EOS>	B-X
CD45	B-X
tyrosine	B-X
phosphatase	B-X
controls	B-X
common	B-X
gamma	B-X
-	B-X
chain	B-X
cytokine	B-X
-	B-X
mediated	B-X
STAT	B-X
and	B-X
extracellular	B-X
signal	B-X
-	B-X
related	B-X
kinase	B-X
phosphorylation	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
:	B-X
inhibition	B-X
of	B-X
proliferation	B-X
without	B-X
induction	B-X
of	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
after	B-X
addition	B-X
of	B-X
OKT	B-X
-	B-X
3	B-X
to	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
	B-X
and	B-X
IL	B-X
-	B-X
7	B-X
-	B-X
stimulated	B-X
proliferation	B-X
assays	B-X
,	B-X
UCHL	B-X
-	B-X
1	B-X
signals	B-X
could	B-X
not	B-X
significantly	B-X
alter	B-X
cellular	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
illustrate	B-X
that	B-X
CD45R0	B-X
signals	B-X
control	B-X
early	B-X
cytokine	B-X
receptor	B-X
-	B-X
associated	B-X
signaling	B-X
processes	B-X
and	B-X
mRNA	B-X
and	B-X
DNA	B-X
synthesis	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X

Using	O
RT-PCR	O
,	O
we	O
found	O
that	O
CD45R0	O
signaling	O
inhibited	O
IL-2	O
mRNA	O
production	O
without	O
major	O
influence	O
on	O
IL-13	B-protein
,	O
IL-5	B-protein
,	O
or	O
IFN-gamma	B-RNA
mRNA	I-RNA
levels	O
.	O
<EOS>	B-X
Whole	B-X
milk	B-X
digested	B-X
samples	B-X
induced	B-X
higher	B-X
mRNA	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
p65	B-X
and	B-X
IL	B-X
-	B-X
1β	B-X
than	B-X
fat	B-X
-	B-X
free	B-X
milk	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
Production	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
LPS	B-X
activation	B-X
,	B-X
but	B-X
was	B-X
increased	B-X
upon	B-X
stimulation	B-X
with	B-X
IFN	B-X
-	B-X
γ	B-X
or	B-X
CD40L	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
IL	B-X
-	B-X
27β	B-X
(	B-X
defined	B-X
as	B-X
OnIL	B-X
-	B-X
27β	B-X
)	B-X
from	B-X
Nile	B-X
tilapia	B-X
(	B-X
<EOS>	B-X
MCP	B-X
-	B-X
1	B-X
/	B-X
IL	B-X
-	B-X
12	B-X
ratio	B-X
expressions	B-X
correlated	B-X
with	B-X
adventitial	B-X
collagen	B-X
depositions	B-X
in	B-X
renal	B-X
vessels	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
/	B-X
IFN	B-X
-	B-X
γ	B-X
expression	B-X
correlated	B-X
with	B-X
interstitial	B-X
collagen	B-X
depositions	B-X
in	B-X
the	B-X
kidneys	B-X
of	B-X
dogs	B-X
with	B-X
canine	B-X
leishmaniasis	B-X
.	B-X

Costimulation	O
with	O
OKT-3	B-protein
and	O
IL-2	B-protein
optimally	O
induced	O
secretion	O
of	O
IFN-gamma	B-protein
,	O
TNF-alpha	B-protein
,	O
and	O
IL-5	B-protein
,	O
which	O
was	O
not	O
decreased	O
by	O
CD45	O
signals	O
.	O

In	O
conclusion	O
,	O
we	O
illustrate	O
that	O
CD45R0	O
signals	O
control	O
early	O
cytokine	O
receptor-associated	O
signaling	O
processes	O
and	O
mRNA	O
and	O
DNA	O
synthesis	O
in	O
activated	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
.	O
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
illustrate	B-X
that	B-X
CD45R0	B-X
signals	B-X
control	B-X
early	B-X
cytokine	B-X
receptor	B-X
-	B-X
associated	B-X
signaling	B-X
processes	B-X
and	B-X
mRNA	B-X
and	B-X
DNA	B-X
synthesis	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
test	B-X
whether	B-X
CD45	B-X
signals	B-X
can	B-X
influence	B-X
signaling	B-X
processes	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
3	B-X
)	B-X
,	B-X
which	B-X
are	B-X
active	B-X
and	B-X
critical	B-X
for	B-X
signaling	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
but	B-X
are	B-X
nonfunctional	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
3	B-X
,	B-X
which	B-X
is	B-X
most	B-X
effective	B-X
in	B-X
inhibition	B-X
of	B-X
OKT	B-X
-	B-X
3	B-X
-	B-X
mediated	B-X
proliferation	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
was	B-X
ineffective	B-X
in	B-X
lymphoblasts	B-X

Furthermore	O
,	O
we	O
show	O
the	O
existence	O
of	O
CD45	B-protein
epitopes	I-protein
(	O
GAP8.3	B-protein
)	O
,	O
which	O
are	O
active	O
and	O
critical	O
for	O
signaling	O
in	O
quiescent	B-cell_type
lymphocytes	I-cell_type
,	O
but	O
are	O
nonfunctional	O
in	O
activated	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
.	O
<EOS>	B-X
3	B-X
)	B-X
,	B-X
which	B-X
are	B-X
active	B-X
and	B-X
critical	B-X
for	B-X
signaling	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
but	B-X
are	B-X
nonfunctional	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
3	B-X
,	B-X
which	B-X
is	B-X
most	B-X
effective	B-X
in	B-X
inhibition	B-X
of	B-X
OKT	B-X
-	B-X
3	B-X
-	B-X
mediated	B-X
proliferation	B-X
in	B-X
quiescent	B-X
lymphocytes	B-X
,	B-X
was	B-X
ineffective	B-X
in	B-X
lymphoblasts	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
test	B-X
whether	B-X
CD45	B-X
signals	B-X
can	B-X
influence	B-X
signaling	B-X
processes	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
illustrate	B-X
that	B-X
CD45R0	B-X
signals	B-X
control	B-X
early	B-X
cytokine	B-X
receptor	B-X
-	B-X
associated	B-X
signaling	B-X
processes	B-X
and	B-X
mRNA	B-X
and	B-X
DNA	B-X
synthesis	B-X
in	B-X
activated	B-X
human	B-X
lymphoblasts	B-X

Pax5	B-DNA
determines	O
the	O
identity	O
of	O
B	B-cell_type
cells	I-cell_type
from	O
the	O
beginning	O
to	O
the	O
end	O
of	O
B-lymphopoiesis	O
.	O

Despite	O
being	O
one	O
of	O
the	O
most	O
intensively	O
studied	O
cell	O
types	O
,	O
the	O
molecular	O
basis	O
of	O
B	O
cell	O
specification	O
is	O
largely	O
unknown	O
.	O
<EOS>	B-X
Despite	B-X
being	B-X
one	B-X
of	B-X
the	B-X
most	B-X
intensively	B-X
studied	B-X
cell	B-X
types	B-X
,	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
B	B-X
cell	B-X
specification	B-X
is	B-X
largely	B-X
unknown	B-X
<EOS>	B-X
Pax5	B-X
determines	B-X
the	B-X
identity	B-X
of	B-X
B	B-X
cells	B-X
from	B-X
the	B-X
beginning	B-X
to	B-X
the	B-X
end	B-X
of	B-X
B	B-X
-	B-X
lymphopoiesis	B-X
.	B-X
<EOS>	B-X
Pax5	B-X
thus	B-X
functions	B-X
both	B-X
as	B-X
a	B-X
transcriptional	B-X
repressor	B-X
and	B-X
activator	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
interactions	B-X
with	B-X
corepressors	B-X
of	B-X
the	B-X
Groucho	B-X
protein	B-X
family	B-X
or	B-X
with	B-X
positive	B-X
regulators	B-X
such	B-X
as	B-X
the	B-X
TATA	B-X
-	B-X
binding	B-X
protein	B-X
<EOS>	B-X
Pax5	B-X
-	B-X
deficient	B-X
pro	B-X
-	B-X
B	B-X
cells	B-X
are	B-X
,	B-X
however	B-X
,	B-X
not	B-X
yet	B-X
committed	B-X
to	B-X
the	B-X
B	B-X
-	B-X
lymphoid	B-X
lineage	B-X
,	B-X
but	B-X
instead	B-X
have	B-X
a	B-X
broad	B-X
lymphomyeloid	B-X
developmental	B-X
potential	B-X

The	O
Pax5	B-DNA
gene	I-DNA
encoding	O
the	O
transcription	B-protein
factor	I-protein
BSAP	I-protein
is	O
required	O
for	O
progression	O
of	O
B-lymphopoiesis	O
beyond	O
the	O
pro-B	O
cell	O
stage	O
.	O
<EOS>	B-X
The	B-X
Pax5	B-X
gene	B-X
encoding	B-X
the	B-X
transcription	B-X
factor	B-X
BSAP	B-X
is	B-X
required	B-X
for	B-X
progression	B-X
of	B-X
B	B-X
-	B-X
lymphopoiesis	B-X
beyond	B-X
the	B-X
pro	B-X
-	B-X
B	B-X
cell	B-X
stage	B-X
<EOS>	B-X
Pax5	B-X
determines	B-X
the	B-X
identity	B-X
of	B-X
B	B-X
cells	B-X
from	B-X
the	B-X
beginning	B-X
to	B-X
the	B-X
end	B-X
of	B-X
B	B-X
-	B-X
lymphopoiesis	B-X
.	B-X
<EOS>	B-X
Pax5	B-X
thus	B-X
functions	B-X
both	B-X
as	B-X
a	B-X
transcriptional	B-X
repressor	B-X
and	B-X
activator	B-X
,	B-X
depending	B-X
on	B-X
its	B-X
interactions	B-X
with	B-X
corepressors	B-X
of	B-X
the	B-X
Groucho	B-X
protein	B-X
family	B-X
or	B-X
with	B-X
positive	B-X
regulators	B-X
such	B-X
as	B-X
the	B-X
TATA	B-X
-	B-X
binding	B-X
protein	B-X
<EOS>	B-X
Pax5	B-X
appears	B-X
to	B-X
mediate	B-X
B	B-X
-	B-X
lineage	B-X
commitment	B-X
by	B-X
repressing	B-X
the	B-X
transcription	B-X
of	B-X
non	B-X
-	B-X
B	B-X
-	B-X
lymphoid	B-X
genes	B-X
and	B-X
by	B-X
simultaneously	B-X
activating	B-X
the	B-X
expression	B-X
of	B-X
B	B-X
-	B-X
lineage	B-X
-	B-X
specific	B-X
genes	B-X

Pax5-deficient	B-cell_type
pro-B	I-cell_type
cells	I-cell_type
are	O
,	O
however	O
,	O
not	O
yet	O
committed	O
to	O
the	O
B-lymphoid	B-cell_type
lineage	I-cell_type
,	O
but	O
instead	O
have	O
a	O
broad	O
lymphomyeloid	O
developmental	O
potential	O
.	O
<EOS>	B-X
Pax5	B-X
-	B-X
deficient	B-X
pro	B-X
-	B-X
B	B-X
cells	B-X
are	B-X
,	B-X
however	B-X
,	B-X
not	B-X
yet	B-X
committed	B-X
to	B-X
the	B-X
B	B-X
-	B-X
lymphoid	B-X
lineage	B-X
,	B-X
but	B-X
instead	B-X
have	B-X
a	B-X
broad	B-X
lymphomyeloid	B-X
developmental	B-X
potential	B-X
<EOS>	B-X
Pax5	B-X
-	B-X
deficient	B-X
progenitor	B-X
B	B-X
(	B-X
pro	B-X
-	B-X
B	B-X
)	B-X
cells	B-X
are	B-X
thought	B-X
to	B-X
be	B-X
severely	B-X
defective	B-X
for	B-X
recombination	B-X
of	B-X
all	B-X
immunoglobulin	B-X
heavy	B-X
chain	B-X
(	B-X
IgH	B-X
)	B-X
V	B-X
gene	B-X
segments	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
Pax5	B-X
regulates	B-X
this	B-X
process	B-X
has	B-X
not	B-X
been	B-X
defined	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
Pax5	B-X
commits	B-X
common	B-X
lymphoid	B-X
progenitor	B-X
cells	B-X
to	B-X
B	B-X
-	B-X
lymphoid	B-X
lineage	B-X
differentiation	B-X
<EOS>	B-X
Pax5	B-X
deficient	B-X
pro	B-X
-	B-X
B	B-X
cells	B-X
that	B-X
can	B-X
give	B-X
rise	B-X
to	B-X
different	B-X
hematopoietic	B-X
cells	B-X
like	B-X
T	B-X
cells	B-X
,	B-X
were	B-X
retrovirally	B-X
transduced	B-X
with	B-X
this	B-X
double	B-X
-	B-X
reporter	B-X
cassette	B-X
and	B-X
were	B-X
used	B-X
to	B-X
reconstitute	B-X
the	B-X
T	B-X
cell	B-X
pool	B-X
in	B-X
RAG1	B-X
deficient	B-X
mice	B-X
that	B-X
lack	B-X
T	B-X
and	B-X
B	B-X
cells	B-X

Pax5	B-DNA
appears	O
to	O
mediate	O
B-lineage	O
commitment	O
by	O
repressing	O
the	O
transcription	O
of	O
non-B-lymphoid	B-DNA
genes	I-DNA
and	O
by	O
simultaneously	O
activating	O
the	O
expression	O
of	O
B-lineage-specific	B-DNA
genes	I-DNA
.	O
<EOS>	B-X
Pax5	B-X
appears	B-X
to	B-X
mediate	B-X
B	B-X
-	B-X
lineage	B-X
commitment	B-X
by	B-X
repressing	B-X
the	B-X
transcription	B-X
of	B-X
non	B-X
-	B-X
B	B-X
-	B-X
lymphoid	B-X
genes	B-X
and	B-X
by	B-X
simultaneously	B-X
activating	B-X
the	B-X
expression	B-X
of	B-X
B	B-X
-	B-X
lineage	B-X
-	B-X
specific	B-X
genes	B-X
<EOS>	B-X
Pax5	B-X
determines	B-X
the	B-X
identity	B-X
of	B-X
B	B-X
cells	B-X
from	B-X
the	B-X
beginning	B-X
to	B-X
the	B-X
end	B-X
of	B-X
B	B-X
-	B-X
lymphopoiesis	B-X
.	B-X
<EOS>	B-X
Once	B-X
committed	B-X
to	B-X
the	B-X
B	B-X
-	B-X
lineage	B-X
,	B-X
B	B-X
cells	B-X
require	B-X
Pax5	B-X
function	B-X
to	B-X
maintain	B-X
their	B-X
B	B-X
-	B-X
lymphoid	B-X
identity	B-X
throughout	B-X
B	B-X
cell	B-X
development	B-X
<EOS>	B-X
Pax5	B-X
-	B-X
deficient	B-X
pro	B-X
-	B-X
B	B-X
cells	B-X
are	B-X
,	B-X
however	B-X
,	B-X
not	B-X
yet	B-X
committed	B-X
to	B-X
the	B-X
B	B-X
-	B-X
lymphoid	B-X
lineage	B-X
,	B-X
but	B-X
instead	B-X
have	B-X
a	B-X
broad	B-X
lymphomyeloid	B-X
developmental	B-X
potential	B-X

Pax5	B-DNA
thus	O
functions	O
both	O
as	O
a	O
transcriptional	O
repressor	O
and	O
activator	O
,	O
depending	O
on	O
its	O
interactions	O
with	O
corepressors	B-protein
of	O
the	O
Groucho	B-protein
protein	I-protein
family	I-protein
or	O
with	O
positive	O
regulators	O
such	O
as	O
the	O
TATA-binding	B-protein
protein	I-protein
.	O
<EOS>	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
indicates	B-X
that	B-X
the	B-X
use	B-X
of	B-X
principal	B-X
component	B-X
analysis	B-X
in	B-X
GWAS	B-X
is	B-X
statistically	B-X
more	B-X
robust	B-X
in	B-X
terms	B-X
of	B-X
identifying	B-X
genes	B-X
and	B-X
FarmCPU	B-X
is	B-X
a	B-X
better	B-X
choice	B-X
compared	B-X
to	B-X
the	B-X
other	B-X
aforementioned	B-X
models	B-X
in	B-X
dealing	B-X
with	B-X
both	B-X
false	B-X
positive	B-X
and	B-X
negative	B-X
associations	B-X
and	B-X
thus	B-X
can	B-X
be	B-X
used	B-X
for	B-X
traits	B-X
with	B-X
complex	B-X
inheritance	B-X
<EOS>	B-X
Following	B-X
this	B-X
track	B-X
,	B-X
a	B-X
potential	B-X
treatment	B-X
to	B-X
eliminate	B-X
these	B-X
fusion	B-X
proteins	B-X
,	B-X
which	B-X
may	B-X
ultimately	B-X
cure	B-X
the	B-X
disease	B-X
,	B-X
is	B-X
proposed	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
BRF1	B-X
modulates	B-X
Pol	B-X
I	B-X
-	B-X
directed	B-X
transcription	B-X
by	B-X
controlling	B-X
the	B-X
expression	B-X
of	B-X
selective	B-X
factor	B-X
1	B-X
subunits	B-X
<EOS>	B-X
Our	B-X
goal	B-X
in	B-X
the	B-X
current	B-X
study	B-X
was	B-X
to	B-X
use	B-X
genome	B-X
wide	B-X
association	B-X
strategy	B-X
to	B-X
discover	B-X
the	B-X
loci	B-X
that	B-X
regulate	B-X
days	B-X
to	B-X
flowering	B-X
in	B-X
pigeonpea	B-X

Once	O
committed	O
to	O
the	O
B-lineage	B-cell_type
,	O
B	B-cell_type
cells	I-cell_type
require	O
Pax5	B-DNA
function	O
to	O
maintain	O
their	O
B-lymphoid	O
identity	O
throughout	O
B	O
cell	O
development	O

Partners	O
in	O
transcription	O
:	O
NFAT	B-protein
and	O
AP-1	B-protein
.	O
<EOS>	B-X
Partners	B-X
in	B-X
transcription	B-X
:	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
define	B-X
a	B-X
transcriptional	B-X
network	B-X
that	B-X
mediates	B-X
CD8	B-X
<EOS>	B-X
Transcriptional	B-X
partners	B-X
in	B-X
regulatory	B-X
T	B-X
cells	B-X
:	B-X
Foxp3	B-X
,	B-X
Runx	B-X
and	B-X
NFAT	B-X
.	B-X
<EOS>	B-X
A	B-X
general	B-X
theme	B-X
in	B-X
gene	B-X
regulation	B-X
is	B-X
that	B-X
transcription	B-X
factors	B-X
never	B-X
function	B-X
alone	B-X

Combinatorial	O
regulation	O
is	O
a	O
powerful	O
mechanism	O
that	O
enables	O
tight	O
control	O
of	O
gene	O
expression	O
,	O
via	O
integration	O
of	O
multiple	O
signaling	O
pathways	O
that	O
induce	O
different	O
transcription	B-protein
factors	I-protein
required	O
for	O
enhanceosome	O
assembly	O
.	O
<EOS>	B-X
Combinatorial	B-X
regulation	B-X
is	B-X
a	B-X
powerful	B-X
mechanism	B-X
that	B-X
enables	B-X
tight	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
via	B-X
integration	B-X
of	B-X
multiple	B-X
signaling	B-X
pathways	B-X
that	B-X
induce	B-X
different	B-X
transcription	B-X
factors	B-X
required	B-X
for	B-X
enhanceosome	B-X
assembly	B-X
<EOS>	B-X
Pharmacological	B-X
interference	B-X
with	B-X
theNFAT	B-X
:	B-X
AP	B-X
-	B-X
1	B-X
interaction	B-X
may	B-X
be	B-X
useful	B-X
in	B-X
selective	B-X
manipulation	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
<EOS>	B-X
Concomitant	B-X
induction	B-X
of	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
requires	B-X
concerted	B-X
activation	B-X
of	B-X
two	B-X
different	B-X
signaling	B-X
pathways	B-X
:	B-X
calcium	B-X
/	B-X
calcineurin	B-X
,	B-X
which	B-X
promotes	B-X
NFAT	B-X
dephosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
and	B-X
activation	B-X
;	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
	B-X
/	B-X
Ras	B-X
,	B-X
which	B-X
promotes	B-X
the	B-X
synthesis	B-X
,	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Fos	B-X
and	B-X
Jun	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
The	B-X
four	B-X
calcium	B-X
-	B-X
regulated	B-X
transcription	B-X
factors	B-X
of	B-X
the	B-X
NFAT	B-X
family	B-X
act	B-X
synergistically	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
Fos	B-X
/	B-X
Jun	B-X
)	B-X
proteins	B-X
on	B-X
composite	B-X
DNA	B-X
elements	B-X
which	B-X
contain	B-X
adjacent	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
,	B-X
where	B-X
they	B-X
form	B-X
highly	B-X
stable	B-X
ternary	B-X
complexes	B-X
to	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
diverse	B-X
inducible	B-X
genes	B-X

The	O
four	O
calcium-regulated	O
transcription	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
act	O
synergistically	O
with	O
AP-1	B-protein
(	I-protein
Fos/Jun	I-protein
)	I-protein
proteins	I-protein
on	O
composite	O
DNA	O
elements	O
which	O
contain	O
adjacent	O
NFAT	B-DNA
and	I-DNA
AP-1	I-DNA
binding	I-DNA
sites	I-DNA
,	O
where	O
they	O
form	O
highly	O
stable	O
ternary	O
complexes	O
to	O
regulate	O
the	O
expression	O
of	O
diverse	O
inducible	O
genes	O
.	O
<EOS>	B-X
The	B-X
four	B-X
calcium	B-X
-	B-X
regulated	B-X
transcription	B-X
factors	B-X
of	B-X
the	B-X
NFAT	B-X
family	B-X
act	B-X
synergistically	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
Fos	B-X
/	B-X
Jun	B-X
)	B-X
proteins	B-X
on	B-X
composite	B-X
DNA	B-X
elements	B-X
which	B-X
contain	B-X
adjacent	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
,	B-X
where	B-X
they	B-X
form	B-X
highly	B-X
stable	B-X
ternary	B-X
complexes	B-X
to	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
diverse	B-X
inducible	B-X
genes	B-X
<EOS>	B-X
A	B-X
fifth	B-X
member	B-X
of	B-X
the	B-X
NFAT	B-X
family	B-X
,	B-X
NFAT5	B-X
,	B-X
controls	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
osmotic	B-X
stress	B-X
,	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
requires	B-X
dimer	B-X
formation	B-X
and	B-X
is	B-X
independent	B-X
of	B-X
calcineurin	B-X
or	B-X
of	B-X
interaction	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
<EOS>	B-X
Balanced	B-X
activation	B-X
of	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
productive	B-X
immune	B-X
responses	B-X
,	B-X
but	B-X
the	B-X
role	B-X
of	B-X
NFAT	B-X
:	B-X
AP	B-X
-	B-X
1	B-X
interactions	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
and	B-X
biological	B-X
processes	B-X
remains	B-X
to	B-X
be	B-X
understood	B-X
<EOS>	B-X
Combinatorial	B-X
regulation	B-X
is	B-X
a	B-X
powerful	B-X
mechanism	B-X
that	B-X
enables	B-X
tight	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
via	B-X
integration	B-X
of	B-X
multiple	B-X
signaling	B-X
pathways	B-X
that	B-X
induce	B-X
different	B-X
transcription	B-X
factors	B-X
required	B-X
for	B-X
enhanceosome	B-X
assembly	B-X

Concomitant	O
induction	O
of	O
NFAT	B-protein
and	O
AP-1	B-protein
requires	O
concerted	O
activation	O
of	O
two	O
different	O
signaling	O
pathways	O
:	O
calcium/calcineurin	O
,	O
which	O
promotes	O
NFAT	O
dephosphorylation	O
,	O
nuclear	O
translocation	O
and	O
activation	O
;	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
/Ras	I-protein
,	O
which	O
promotes	O
the	O
synthesis	O
,	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Fos	B-protein
and	I-protein
Jun	I-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
<EOS>	B-X
Concomitant	B-X
induction	B-X
of	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
requires	B-X
concerted	B-X
activation	B-X
of	B-X
two	B-X
different	B-X
signaling	B-X
pathways	B-X
:	B-X
calcium	B-X
/	B-X
calcineurin	B-X
,	B-X
which	B-X
promotes	B-X
NFAT	B-X
dephosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
and	B-X
activation	B-X
;	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
	B-X
/	B-X
Ras	B-X
,	B-X
which	B-X
promotes	B-X
the	B-X
synthesis	B-X
,	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Fos	B-X
and	B-X
Jun	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Balanced	B-X
activation	B-X
of	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
productive	B-X
immune	B-X
responses	B-X
,	B-X
but	B-X
the	B-X
role	B-X
of	B-X
NFAT	B-X
:	B-X
AP	B-X
-	B-X
1	B-X
interactions	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
and	B-X
biological	B-X
processes	B-X
remains	B-X
to	B-X
be	B-X
understood	B-X
<EOS>	B-X
Combinatorial	B-X
regulation	B-X
is	B-X
a	B-X
powerful	B-X
mechanism	B-X
that	B-X
enables	B-X
tight	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
via	B-X
integration	B-X
of	B-X
multiple	B-X
signaling	B-X
pathways	B-X
that	B-X
induce	B-X
different	B-X
transcription	B-X
factors	B-X
required	B-X
for	B-X
enhanceosome	B-X
assembly	B-X
<EOS>	B-X
A	B-X
fifth	B-X
member	B-X
of	B-X
the	B-X
NFAT	B-X
family	B-X
,	B-X
NFAT5	B-X
,	B-X
controls	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
osmotic	B-X
stress	B-X
,	B-X
by	B-X
a	B-X
mechanism	B-X
that	B-X
requires	B-X
dimer	B-X
formation	B-X
and	B-X
is	B-X
independent	B-X
of	B-X
calcineurin	B-X
or	B-X
of	B-X
interaction	B-X
with	B-X
AP	B-X
-	B-X
1	B-X

A	O
fifth	O
member	O
of	O
the	O
NFAT	B-protein
family	I-protein
,	O
NFAT5	B-protein
,	O
controls	O
the	O
cellular	O
response	O
to	O
osmotic	O
stress	O
,	O
by	O
a	O
mechanism	O
that	O
requires	O
dimer	O
formation	O
and	O
is	O
independent	O
of	O
calcineurin	B-protein
or	O
of	O
interaction	O
with	O
AP-1	B-protein
.	O
<EOS>	B-X
Using	B-X
network	B-X
pharmacology	B-X
and	B-X
molecular	B-X
docking	B-X
verification	B-X
to	B-X
explore	B-X
the	B-X
mechanism	B-X
of	B-X
ursolic	B-X
acid	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
osteoporosis	B-X
.	B-X
<EOS>	B-X
To	B-X
verify	B-X
the	B-X
role	B-X
of	B-X
clathrin	B-X
in	B-X
the	B-X
insect	B-X
colonization	B-X
by	B-X
phytoplasmas	B-X
,	B-X
RNAi	B-X
was	B-X
performed	B-X
via	B-X
artificial	B-X
feeding	B-X
of	B-X
chc	B-X
dsRNA	B-X
by	B-X
the	B-X
vector	B-X
E	B-X
<EOS>	B-X
As	B-X
a	B-X
complement	B-X
to	B-X
the	B-X
integrated	B-X
analysis	B-X
,	B-X
the	B-X
results	B-X
of	B-X
molecular	B-X
docking	B-X
indicated	B-X
the	B-X
potential	B-X
binding	B-X
interactions	B-X
between	B-X
eugenol	B-X
and	B-X
four	B-X
proteins	B-X
relating	B-X
to	B-X
cytokine	B-X
production	B-X
/	B-X
release	B-X
and	B-X
the	B-X
function	B-X
of	B-X
T	B-X
type	B-X
lymphocytes	B-X
,	B-X
including	B-X
human	B-X
TLR	B-X
-	B-X
4	B-X
,	B-X
TCR	B-X
,	B-X
NF	B-X
-	B-X
κB	B-X
,	B-X
JNK	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
<EOS>	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
prevention	B-X
of	B-X
DNA	B-X
mutation	B-X
and	B-X
cellular	B-X
apoptosis	B-X
,	B-X
especially	B-X
in	B-X
relation	B-X
to	B-X
cancer	B-X
cells	B-X
is	B-X
controversial	B-X

Pharmacological	O
interference	O
with	O
theNFAT	O
:	O
AP-1	O
interaction	O
may	O
be	O
useful	O
in	O
selective	O
manipulation	O
of	O
the	O
immune	O
response	O
.	O
<EOS>	B-X
Pharmacological	B-X
interference	B-X
with	B-X
theNFAT	B-X
:	B-X
AP	B-X
-	B-X
1	B-X
interaction	B-X
may	B-X
be	B-X
useful	B-X
in	B-X
selective	B-X
manipulation	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
<EOS>	B-X
Combinatorial	B-X
regulation	B-X
is	B-X
a	B-X
powerful	B-X
mechanism	B-X
that	B-X
enables	B-X
tight	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
via	B-X
integration	B-X
of	B-X
multiple	B-X
signaling	B-X
pathways	B-X
that	B-X
induce	B-X
different	B-X
transcription	B-X
factors	B-X
required	B-X
for	B-X
enhanceosome	B-X
assembly	B-X
<EOS>	B-X
Balanced	B-X
activation	B-X
of	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
productive	B-X
immune	B-X
responses	B-X
,	B-X
but	B-X
the	B-X
role	B-X
of	B-X
NFAT	B-X
:	B-X
AP	B-X
-	B-X
1	B-X
interactions	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
and	B-X
biological	B-X
processes	B-X
remains	B-X
to	B-X
be	B-X
understood	B-X
<EOS>	B-X
The	B-X
four	B-X
calcium	B-X
-	B-X
regulated	B-X
transcription	B-X
factors	B-X
of	B-X
the	B-X
NFAT	B-X
family	B-X
act	B-X
synergistically	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
Fos	B-X
/	B-X
Jun	B-X
)	B-X
proteins	B-X
on	B-X
composite	B-X
DNA	B-X
elements	B-X
which	B-X
contain	B-X
adjacent	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
,	B-X
where	B-X
they	B-X
form	B-X
highly	B-X
stable	B-X
ternary	B-X
complexes	B-X
to	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
diverse	B-X
inducible	B-X
genes	B-X

Balanced	O
activation	O
of	O
NFAT	B-protein
and	O
AP-1	B-protein
is	O
known	O
to	O
be	O
required	O
for	O
productive	O
immune	O
responses	O
,	O
but	O
the	O
role	O
of	O
NFAT	O
:	O
AP-1	O
interactions	O
in	O
other	O
cell	O
types	O
and	O
biological	O
processes	O
remains	O
to	O
be	O
understood	O
.	O
<EOS>	B-X
Balanced	B-X
activation	B-X
of	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
productive	B-X
immune	B-X
responses	B-X
,	B-X
but	B-X
the	B-X
role	B-X
of	B-X
NFAT	B-X
:	B-X
AP	B-X
-	B-X
1	B-X
interactions	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
and	B-X
biological	B-X
processes	B-X
remains	B-X
to	B-X
be	B-X
understood	B-X
<EOS>	B-X
Pharmacological	B-X
interference	B-X
with	B-X
theNFAT	B-X
:	B-X
AP	B-X
-	B-X
1	B-X
interaction	B-X
may	B-X
be	B-X
useful	B-X
in	B-X
selective	B-X
manipulation	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
<EOS>	B-X
Concomitant	B-X
induction	B-X
of	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
requires	B-X
concerted	B-X
activation	B-X
of	B-X
two	B-X
different	B-X
signaling	B-X
pathways	B-X
:	B-X
calcium	B-X
/	B-X
calcineurin	B-X
,	B-X
which	B-X
promotes	B-X
NFAT	B-X
dephosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
and	B-X
activation	B-X
;	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
	B-X
/	B-X
Ras	B-X
,	B-X
which	B-X
promotes	B-X
the	B-X
synthesis	B-X
,	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Fos	B-X
and	B-X
Jun	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
The	B-X
four	B-X
calcium	B-X
-	B-X
regulated	B-X
transcription	B-X
factors	B-X
of	B-X
the	B-X
NFAT	B-X
family	B-X
act	B-X
synergistically	B-X
with	B-X
AP	B-X
-	B-X
1	B-X
(	B-X
Fos	B-X
/	B-X
Jun	B-X
)	B-X
proteins	B-X
on	B-X
composite	B-X
DNA	B-X
elements	B-X
which	B-X
contain	B-X
adjacent	B-X
NFAT	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
,	B-X
where	B-X
they	B-X
form	B-X
highly	B-X
stable	B-X
ternary	B-X
complexes	B-X
to	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
diverse	B-X
inducible	B-X
genes	B-X

Cytokine	O
production	O
by	O
Vgamma	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
-T-cell	I-cell_type
subsets	I-cell_type
is	O
an	O
important	O
factor	O
determining	O
CD4	O
(	O
+	O
)	O
-Th-cell	O
phenotype	O
and	O
susceptibility	O
of	O
BALB/c	O
mice	O
to	O
coxsackievirus	O
B3-induced	O
myocarditis	O
.	O
<EOS>	B-X
Cytokine	B-X
production	B-X
by	B-X
Vgamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
is	B-X
an	B-X
important	B-X
factor	B-X
determining	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
susceptibility	B-X
of	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
to	B-X
coxsackievirus	B-X
B3	B-X
-	B-X
induced	B-X
myocarditis	B-X
.	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
cytokine	B-X
production	B-X
by	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
and	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
was	B-X
investigated	B-X
by	B-X
adoptively	B-X
transferring	B-X
these	B-X
cells	B-X
isolated	B-X
from	B-X
H3	B-X
-	B-X
infected	B-X
BALB	B-X
/	B-X
c	B-X
Stat4	B-X
knockout	B-X
(	B-X
Stat4ko	B-X
)	B-X
(	B-X
defective	B-X
in	B-X
IFN	B-X
-	B-X
gamma	B-X
expression	B-X
)	B-X
or	B-X
BALB	B-X
/	B-X
c	B-X
Stat6ko	B-X
(	B-X
defective	B-X
in	B-X
IL	B-X
-	B-X
4	B-X
expression	B-X
)	B-X
mice	B-X
into	B-X
H3	B-X
virus	B-X
-	B-X
infected	B-X
wild	B-X
-	B-X
type	B-X
BALB	B-X
/	B-X
c	B-X
recipients	B-X
<EOS>	B-X
Depleting	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
suppressed	B-X
myocarditis	B-X
and	B-X
reduced	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
but	B-X
increased	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
cytokines	B-X
produced	B-X
by	B-X
the	B-X
Vgamma	B-X
subpopulation	B-X
have	B-X
a	B-X
significant	B-X
influence	B-X
on	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X

Two	O
coxsackievirus	O
B3	O
(	O
CVB3	O
)	O
variants	O
(	O
H3	O
and	O
H310A1	O
)	O
differ	O
by	O
a	O
single	O
amino	O
acid	O
mutation	O
in	O
the	O
VP2	B-protein
capsid	I-protein
protein	I-protein
.	O
<EOS>	B-X
Two	B-X
coxsackievirus	B-X
B3	B-X
(	B-X
CVB3	B-X
)	B-X
variants	B-X
(	B-X
H3	B-X
and	B-X
H310A1	B-X
)	B-X
differ	B-X
by	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
mutation	B-X
in	B-X
the	B-X
VP2	B-X
capsid	B-X
protein	B-X
<EOS>	B-X
H3	B-X
induces	B-X
severe	B-X
myocarditis	B-X
in	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
,	B-X
but	B-X
H310A1	B-X
is	B-X
amyocarditic	B-X
<EOS>	B-X
Cytokine	B-X
production	B-X
by	B-X
Vgamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
is	B-X
an	B-X
important	B-X
factor	B-X
determining	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
susceptibility	B-X
of	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
to	B-X
coxsackievirus	B-X
B3	B-X
-	B-X
induced	B-X
myocarditis	B-X
.	B-X
<EOS>	B-X
The	B-X
cytokines	B-X
produced	B-X
by	B-X
the	B-X
Vgamma	B-X
subpopulation	B-X
have	B-X
a	B-X
significant	B-X
influence	B-X
on	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X

H3	O
induces	O
severe	O
myocarditis	O
in	O
BALB/c	O
mice	O
,	O
but	O
H310A1	O
is	O
amyocarditic	O
.	O
<EOS>	B-X
H3	B-X
induces	B-X
severe	B-X
myocarditis	B-X
in	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
,	B-X
but	B-X
H310A1	B-X
is	B-X
amyocarditic	B-X
<EOS>	B-X
Depleting	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
suppressed	B-X
myocarditis	B-X
and	B-X
reduced	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
but	B-X
increased	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
Cytokine	B-X
production	B-X
by	B-X
Vgamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
is	B-X
an	B-X
important	B-X
factor	B-X
determining	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
susceptibility	B-X
of	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
to	B-X
coxsackievirus	B-X
B3	B-X
-	B-X
induced	B-X
myocarditis	B-X
.	B-X
<EOS>	B-X
Stat4ko	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
)	B-X
suppress	B-X
myocarditis	B-X

Infection	O
with	O
H3	O
,	O
but	O
not	O
H310A1	O
,	O
preferentially	O
activates	O
Vgamma4	B-cell_type
Vdelta4	I-cell_type
cells	I-cell_type
,	O
which	O
are	O
strongly	O
positive	O
for	O
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
,	O
whereas	O
Vgamma1	B-cell_type
Vdelta4	I-cell_type
cells	I-cell_type
are	O
increased	O
in	O
both	O
H3	O
and	O
H310A1	O
virus-infected	O
animals	O
.	O
<EOS>	B-X
If	B-X
a	B-X
variant	B-X
virus	B-X
is	B-X
antigenically	B-X
drifted	B-X
from	B-X
current	B-X
human	B-X
seasonal	B-X
vaccine	B-X
(	B-X
HuVac	B-X
)	B-X
strains	B-X
,	B-X
it	B-X
may	B-X
be	B-X
chosen	B-X
as	B-X
a	B-X
candidate	B-X
virus	B-X
vaccine	B-X
(	B-X
CVV	B-X
)	B-X
for	B-X
pandemic	B-X
preparedness	B-X
purposes	B-X
<EOS>	B-X
Functional	B-X
HA	B-X
-	B-X
specific	B-X
antibody	B-X
titers	B-X
against	B-X
all	B-X
four	B-X
homologous	B-X
vaccine	B-X
strains	B-X
were	B-X
enhanced	B-X
by	B-X
AF03	B-X
,	B-X
indicating	B-X
potential	B-X
increase	B-X
in	B-X
protective	B-X
immunity	B-X
<EOS>	B-X
Endothelial	B-X
cell	B-X
formation	B-X
was	B-X
initially	B-X
more	B-X
active	B-X
on	B-X
the	B-X
VS	B-X
than	B-X
on	B-X
the	B-X
AS	B-X
,	B-X
but	B-X
these	B-X
cells	B-X
subsequently	B-X
increased	B-X
in	B-X
number	B-X
across	B-X
the	B-X
luminal	B-X
surface	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
these	B-X
strains	B-X
yielded	B-X
negative	B-X
results	B-X
for	B-X
the	B-X
three	B-X
-	B-X
human	B-X
seasonal	B-X
IAV	B-X
(	B-X
H1	B-X
,	B-X
H3	B-X
and	B-X
H1N1	B-X
pandemic	B-X
)	B-X
assays	B-X

Depletion	O
of	O
Vgamma1	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
using	O
monoclonal	B-protein
anti-Vgamma1	I-protein
antibody	I-protein
enhanced	O
myocarditis	O
and	O
CD4	O
(	O
+	O
)	O
-	O
,	O
IFN-gamma	B-protein
(	O
+	O
)	O
-cell	O
responses	O
in	O
both	O
H3-	O
and	O
H310A1-infected	O
mice	O
yet	O
decreased	O
the	O
CD4	O
(	O
+	O
)	O
-	O
,	O
IL-4	O
(	O
+	O
)	O
-cell	O
response	O
.	O
<EOS>	B-X
Depletion	B-X
of	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
using	B-X
monoclonal	B-X
anti	B-X
-	B-X
Vgamma1	B-X
antibody	B-X
enhanced	B-X
myocarditis	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
responses	B-X
in	B-X
both	B-X
H3	B-X
-	B-X
	B-X
and	B-X
H310A1	B-X
-	B-X
infected	B-X
mice	B-X
yet	B-X
decreased	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
response	B-X
<EOS>	B-X
Depleting	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
suppressed	B-X
myocarditis	B-X
and	B-X
reduced	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
but	B-X
increased	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
distinct	B-X
gammadelta	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
control	B-X
myocarditis	B-X
susceptibility	B-X
and	B-X
bias	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
response	B-X
<EOS>	B-X
Vgamma4	B-X
and	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
Stat4ko	B-X
mice	B-X
expressed	B-X
IL	B-X
-	B-X
4	B-X
but	B-X
no	B-X
or	B-X
minimal	B-X
IFN	B-X
-	B-X
gamma	B-X
,	B-X
whereas	B-X
these	B-X
cell	B-X
populations	B-X
derived	B-X
from	B-X
Stat6ko	B-X
mice	B-X
expressed	B-X
IFN	B-X
-	B-X
gamma	B-X
but	B-X
no	B-X
IL	B-X
-	B-X
4	B-X

Depleting	O
Vgamma4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
suppressed	O
myocarditis	O
and	O
reduced	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
IFN-gamma	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
but	O
increased	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
IL-4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Depleting	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
suppressed	B-X
myocarditis	B-X
and	B-X
reduced	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
but	B-X
increased	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
Depletion	B-X
of	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
using	B-X
monoclonal	B-X
anti	B-X
-	B-X
Vgamma1	B-X
antibody	B-X
enhanced	B-X
myocarditis	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
responses	B-X
in	B-X
both	B-X
H3	B-X
-	B-X
	B-X
and	B-X
H310A1	B-X
-	B-X
infected	B-X
mice	B-X
yet	B-X
decreased	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
response	B-X
<EOS>	B-X
Vgamma4	B-X
and	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
Stat4ko	B-X
mice	B-X
expressed	B-X
IL	B-X
-	B-X
4	B-X
but	B-X
no	B-X
or	B-X
minimal	B-X
IFN	B-X
-	B-X
gamma	B-X
,	B-X
whereas	B-X
these	B-X
cell	B-X
populations	B-X
derived	B-X
from	B-X
Stat6ko	B-X
mice	B-X
expressed	B-X
IFN	B-X
-	B-X
gamma	B-X
but	B-X
no	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
Stat6ko	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
)	B-X
significantly	B-X
enhanced	B-X
myocarditis	B-X

The	O
role	O
of	O
cytokine	O
production	O
by	O
Vgamma1	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
and	I-cell_type
Vgamma4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
investigated	O
by	O
adoptively	O
transferring	O
these	O
cells	O
isolated	O
from	O
H3-infected	O
BALB/c	O
Stat4	O
knockout	O
(	O
Stat4ko	O
)	O
(	O
defective	O
in	O
IFN-gamma	B-protein
expression	O
)	O
or	O
BALB/c	O
Stat6ko	O
(	O
defective	O
in	O
IL-4	O
expression	O
)	O
mice	O
into	O
H3	O
virus-infected	O
wild-type	O
BALB/c	O
recipients	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
cytokine	B-X
production	B-X
by	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
and	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
was	B-X
investigated	B-X
by	B-X
adoptively	B-X
transferring	B-X
these	B-X
cells	B-X
isolated	B-X
from	B-X
H3	B-X
-	B-X
infected	B-X
BALB	B-X
/	B-X
c	B-X
Stat4	B-X
knockout	B-X
(	B-X
Stat4ko	B-X
)	B-X
(	B-X
defective	B-X
in	B-X
IFN	B-X
-	B-X
gamma	B-X
expression	B-X
)	B-X
or	B-X
BALB	B-X
/	B-X
c	B-X
Stat6ko	B-X
(	B-X
defective	B-X
in	B-X
IL	B-X
-	B-X
4	B-X
expression	B-X
)	B-X
mice	B-X
into	B-X
H3	B-X
virus	B-X
-	B-X
infected	B-X
wild	B-X
-	B-X
type	B-X
BALB	B-X
/	B-X
c	B-X
recipients	B-X
<EOS>	B-X
Cytokine	B-X
production	B-X
by	B-X
Vgamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
is	B-X
an	B-X
important	B-X
factor	B-X
determining	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
susceptibility	B-X
of	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
to	B-X
coxsackievirus	B-X
B3	B-X
-	B-X
induced	B-X
myocarditis	B-X
.	B-X
<EOS>	B-X
Vgamma4	B-X
and	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
Stat4ko	B-X
mice	B-X
expressed	B-X
IL	B-X
-	B-X
4	B-X
but	B-X
no	B-X
or	B-X
minimal	B-X
IFN	B-X
-	B-X
gamma	B-X
,	B-X
whereas	B-X
these	B-X
cell	B-X
populations	B-X
derived	B-X
from	B-X
Stat6ko	B-X
mice	B-X
expressed	B-X
IFN	B-X
-	B-X
gamma	B-X
but	B-X
no	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
Infection	B-X
with	B-X
H3	B-X
,	B-X
but	B-X
not	B-X
H310A1	B-X
,	B-X
preferentially	B-X
activates	B-X
Vgamma4	B-X
Vdelta4	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
strongly	B-X
positive	B-X
for	B-X
gamma	B-X
interferon	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
,	B-X
whereas	B-X
Vgamma1	B-X
Vdelta4	B-X
cells	B-X
are	B-X
increased	B-X
in	B-X
both	B-X
H3	B-X
and	B-X
H310A1	B-X
virus	B-X
-	B-X
infected	B-X
animals	B-X

Vgamma4	B-cell_type
and	I-cell_type
Vgamma1	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
Stat4ko	O
mice	O
expressed	O
IL-4	B-protein
but	O
no	O
or	O
minimal	O
IFN-gamma	B-protein
,	O
whereas	O
these	O
cell	O
populations	O
derived	O
from	O
Stat6ko	O
mice	O
expressed	O
IFN-gamma	B-protein
but	O
no	O
IL-4	B-protein
.	O
<EOS>	B-X
Vgamma4	B-X
and	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
Stat4ko	B-X
mice	B-X
expressed	B-X
IL	B-X
-	B-X
4	B-X
but	B-X
no	B-X
or	B-X
minimal	B-X
IFN	B-X
-	B-X
gamma	B-X
,	B-X
whereas	B-X
these	B-X
cell	B-X
populations	B-X
derived	B-X
from	B-X
Stat6ko	B-X
mice	B-X
expressed	B-X
IFN	B-X
-	B-X
gamma	B-X
but	B-X
no	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
Depleting	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
suppressed	B-X
myocarditis	B-X
and	B-X
reduced	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
but	B-X
increased	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
cytokine	B-X
production	B-X
by	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
and	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
was	B-X
investigated	B-X
by	B-X
adoptively	B-X
transferring	B-X
these	B-X
cells	B-X
isolated	B-X
from	B-X
H3	B-X
-	B-X
infected	B-X
BALB	B-X
/	B-X
c	B-X
Stat4	B-X
knockout	B-X
(	B-X
Stat4ko	B-X
)	B-X
(	B-X
defective	B-X
in	B-X
IFN	B-X
-	B-X
gamma	B-X
expression	B-X
)	B-X
or	B-X
BALB	B-X
/	B-X
c	B-X
Stat6ko	B-X
(	B-X
defective	B-X
in	B-X
IL	B-X
-	B-X
4	B-X
expression	B-X
)	B-X
mice	B-X
into	B-X
H3	B-X
virus	B-X
-	B-X
infected	B-X
wild	B-X
-	B-X
type	B-X
BALB	B-X
/	B-X
c	B-X
recipients	B-X
<EOS>	B-X
Depletion	B-X
of	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
using	B-X
monoclonal	B-X
anti	B-X
-	B-X
Vgamma1	B-X
antibody	B-X
enhanced	B-X
myocarditis	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
responses	B-X
in	B-X
both	B-X
H3	B-X
-	B-X
	B-X
and	B-X
H310A1	B-X
-	B-X
infected	B-X
mice	B-X
yet	B-X
decreased	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
response	B-X

Stat4ko	B-cell_type
Vgamma1	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
(	I-cell_type
IL-4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	O
suppress	O
myocarditis	O
.	O
<EOS>	B-X
Stat4ko	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
)	B-X
suppress	B-X
myocarditis	B-X
<EOS>	B-X
Stat6ko	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
)	B-X
were	B-X
not	B-X
inhibitory	B-X
<EOS>	B-X
Stat6ko	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
)	B-X
significantly	B-X
enhanced	B-X
myocarditis	B-X
<EOS>	B-X
Stat4ko	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
)	B-X
neither	B-X
inhibited	B-X
nor	B-X
enhanced	B-X
disease	B-X

Stat6ko	B-cell_type
Vgamma1	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
(	I-cell_type
IFN-gamma	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	I-cell_type
were	O
not	O
inhibitory	O
.	O

Stat6ko	B-cell_type
Vgamma4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
(	I-cell_type
IFN-gamma	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	I-cell_type
significantly	O
enhanced	O
myocarditis	O
.	O
<EOS>	B-X
Stat6ko	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
)	B-X
significantly	B-X
enhanced	B-X
myocarditis	B-X
<EOS>	B-X
Stat6ko	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
)	B-X
were	B-X
not	B-X
inhibitory	B-X
<EOS>	B-X
Stat4ko	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
)	B-X
suppress	B-X
myocarditis	B-X
<EOS>	B-X
Stat4ko	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
)	B-X
neither	B-X
inhibited	B-X
nor	B-X
enhanced	B-X
disease	B-X

Stat4ko	B-cell_type
Vgamma4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
(	I-cell_type
IL-4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	I-cell_type
neither	O
inhibited	O
nor	O
enhanced	O
disease	O
.	O
<EOS>	B-X
Stat4ko	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
)	B-X
neither	B-X
inhibited	B-X
nor	B-X
enhanced	B-X
disease	B-X
<EOS>	B-X
Stat6ko	B-X
Vgamma4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
)	B-X
significantly	B-X
enhanced	B-X
myocarditis	B-X
<EOS>	B-X
Stat4ko	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
)	B-X
suppress	B-X
myocarditis	B-X
<EOS>	B-X
Stat6ko	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
)	B-X
were	B-X
not	B-X
inhibitory	B-X

These	O
results	O
show	O
that	O
distinct	O
gammadelta-T-cell	B-cell_type
subsets	I-cell_type
control	O
myocarditis	O
susceptibility	O
and	O
bias	O
the	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
-Th-cell	I-cell_type
response	O
.	O
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
distinct	B-X
gammadelta	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
control	B-X
myocarditis	B-X
susceptibility	B-X
and	B-X
bias	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
response	B-X
<EOS>	B-X
The	B-X
cytokines	B-X
produced	B-X
by	B-X
the	B-X
Vgamma	B-X
subpopulation	B-X
have	B-X
a	B-X
significant	B-X
influence	B-X
on	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X
<EOS>	B-X
Depletion	B-X
of	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
using	B-X
monoclonal	B-X
anti	B-X
-	B-X
Vgamma1	B-X
antibody	B-X
enhanced	B-X
myocarditis	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
responses	B-X
in	B-X
both	B-X
H3	B-X
-	B-X
	B-X
and	B-X
H310A1	B-X
-	B-X
infected	B-X
mice	B-X
yet	B-X
decreased	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
response	B-X
<EOS>	B-X
Cytokine	B-X
production	B-X
by	B-X
Vgamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
is	B-X
an	B-X
important	B-X
factor	B-X
determining	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
susceptibility	B-X
of	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
to	B-X
coxsackievirus	B-X
B3	B-X
-	B-X
induced	B-X
myocarditis	B-X
.	B-X

The	O
cytokines	B-protein
produced	O
by	O
the	O
Vgamma	B-cell_type
subpopulation	I-cell_type
have	O
a	O
significant	O
influence	O
on	O
the	O
CD4	B-protein
(	O
+	O
)	O
-Th-cell	O
phenotype	O
.	O
<EOS>	B-X
The	B-X
cytokines	B-X
produced	B-X
by	B-X
the	B-X
Vgamma	B-X
subpopulation	B-X
have	B-X
a	B-X
significant	B-X
influence	B-X
on	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
distinct	B-X
gammadelta	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
control	B-X
myocarditis	B-X
susceptibility	B-X
and	B-X
bias	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
response	B-X
<EOS>	B-X
Cytokine	B-X
production	B-X
by	B-X
Vgamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
is	B-X
an	B-X
important	B-X
factor	B-X
determining	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
Th	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
susceptibility	B-X
of	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
to	B-X
coxsackievirus	B-X
B3	B-X
-	B-X
induced	B-X
myocarditis	B-X
.	B-X
<EOS>	B-X
Depletion	B-X
of	B-X
Vgamma1	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
using	B-X
monoclonal	B-X
anti	B-X
-	B-X
Vgamma1	B-X
antibody	B-X
enhanced	B-X
myocarditis	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IFN	B-X
-	B-X
gamma	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
responses	B-X
in	B-X
both	B-X
H3	B-X
-	B-X
	B-X
and	B-X
H310A1	B-X
-	B-X
infected	B-X
mice	B-X
yet	B-X
decreased	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
cell	B-X
response	B-X

Plasmin	B-protein
-induced	O
expression	O
of	O
cytokines	B-protein
and	O
tissue	B-protein
factor	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
involves	O
AP-1	B-protein
and	O
IKKbeta	B-protein
-mediated	O
NF-kappaB	O
activation	O
.	O
<EOS>	B-X
Plasmin	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
tissue	B-X
factor	B-X
in	B-X
human	B-X
monocytes	B-X
involves	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
IKKbeta	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
further	B-X
substantiate	B-X
the	B-X
role	B-X
of	B-X
plasmin	B-X
as	B-X
a	B-X
proinflammatory	B-X
activator	B-X
of	B-X
human	B-X
monocytes	B-X
and	B-X
reveal	B-X
an	B-X
important	B-X
new	B-X
link	B-X
between	B-X
the	B-X
plasminogen	B-X
-	B-X
plasmin	B-X
system	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
Plasmin	B-X
-	B-X
mediated	B-X
mRNA	B-X
expression	B-X
was	B-X
inhibited	B-X
in	B-X
a	B-X
concentration	B-X
-	B-X
dependent	B-X
manner	B-X
by	B-X
the	B-X
lysine	B-X
analogue	B-X
trans	B-X
-	B-X
4	B-X
-	B-X
	B-X
(	B-X
aminomethyl	B-X
)	B-X
cyclohexane	B-X
-	B-X
1	B-X
-	B-X
carboxylic	B-X
acid	B-X
(	B-X
t	B-X
-	B-X
AMCA	B-X
)	B-X
<EOS>	B-X
It	B-X
was	B-X
previously	B-X
shown	B-X
that	B-X
plasmin	B-X
activates	B-X
human	B-X
peripheral	B-X
monocytes	B-X
in	B-X
terms	B-X
of	B-X
lipid	B-X
mediator	B-X
release	B-X
and	B-X
chemotactic	B-X
migration	B-X

It	O
was	O
previously	O
shown	O
that	O
plasmin	B-protein
activates	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
in	O
terms	O
of	O
lipid	O
mediator	O
release	O
and	O
chemotactic	O
migration	O
.	O
<EOS>	B-X
It	B-X
was	B-X
previously	B-X
shown	B-X
that	B-X
plasmin	B-X
activates	B-X
human	B-X
peripheral	B-X
monocytes	B-X
in	B-X
terms	B-X
of	B-X
lipid	B-X
mediator	B-X
release	B-X
and	B-X
chemotactic	B-X
migration	B-X
<EOS>	B-X
These	B-X
findings	B-X
further	B-X
substantiate	B-X
the	B-X
role	B-X
of	B-X
plasmin	B-X
as	B-X
a	B-X
proinflammatory	B-X
activator	B-X
of	B-X
human	B-X
monocytes	B-X
and	B-X
reveal	B-X
an	B-X
important	B-X
new	B-X
link	B-X
between	B-X
the	B-X
plasminogen	B-X
-	B-X
plasmin	B-X
system	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
Plasmin	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
tissue	B-X
factor	B-X
in	B-X
human	B-X
monocytes	B-X
involves	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
IKKbeta	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
.	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
indicated	B-X
plasmin	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
;	B-X
DNA	B-X
-	B-X
binding	B-X
complexes	B-X
were	B-X
composed	B-X
of	B-X
p50	B-X
,	B-X
p65	B-X
,	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
supershift	B-X
experiments	B-X

Here	O
it	O
is	O
demonstrated	O
that	O
plasmin	B-protein
induces	O
proinflammatory	B-protein
cytokine	I-protein
release	O
and	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
expression	O
by	O
monocytes	B-cell_type
.	O
<EOS>	B-X
Here	B-X
it	B-X
is	B-X
demonstrated	B-X
that	B-X
plasmin	B-X
induces	B-X
proinflammatory	B-X
cytokine	B-X
release	B-X
and	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
expression	B-X
by	B-X
monocytes	B-X
<EOS>	B-X
These	B-X
findings	B-X
further	B-X
substantiate	B-X
the	B-X
role	B-X
of	B-X
plasmin	B-X
as	B-X
a	B-X
proinflammatory	B-X
activator	B-X
of	B-X
human	B-X
monocytes	B-X
and	B-X
reveal	B-X
an	B-X
important	B-X
new	B-X
link	B-X
between	B-X
the	B-X
plasminogen	B-X
-	B-X
plasmin	B-X
system	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
Increases	B-X
in	B-X
mRNA	B-X
levels	B-X
were	B-X
followed	B-X
by	B-X
concentration	B-X
-	B-X
	B-X
and	B-X
time	B-X
-	B-X
dependent	B-X
release	B-X
of	B-X
IL	B-X
-	B-X
1alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
and	B-X
by	B-X
TF	B-X
expression	B-X
on	B-X
monocyte	B-X
surfaces	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
indicated	B-X
plasmin	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
;	B-X
DNA	B-X
-	B-X
binding	B-X
complexes	B-X
were	B-X
composed	B-X
of	B-X
p50	B-X
,	B-X
p65	B-X
,	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
supershift	B-X
experiments	B-X

Plasmin	B-protein
0.043	O
to	O
1.43	O
CTA	O
U/mL	O
,	O
but	O
not	O
active	B-protein
site-blocked	I-protein
plasmin	I-protein
,	O
triggered	O
concentration-dependent	O
expression	O
of	O
mRNA	O
for	O
interleukin-1alpha	B-protein
(	O
IL-1alpha	B-protein
)	O
,	O
IL-1beta	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
and	O
TF	B-protein
with	O
maximum	O
responses	O
after	O
4	O
hours	O
.	O

Plasmin	B-protein
-mediated	O
mRNA	O
expression	O
was	O
inhibited	O
in	O
a	O
concentration-dependent	O
manner	O
by	O
the	O
lysine	O
analogue	O
trans-4-	O
(	O
aminomethyl	O
)	O
cyclohexane-1-carboxylic	O
acid	O
(	O
t-AMCA	O
)	O
.	O

Increases	O
in	O
mRNA	O
levels	O
were	O
followed	O
by	O
concentration-	O
and	O
time-dependent	O
release	O
of	O
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
and	O
TNF-alpha	B-protein
and	O
by	O
TF	B-protein
expression	O
on	O
monocyte	O
surfaces	O
.	O
<EOS>	B-X
Increases	B-X
in	B-X
mRNA	B-X
levels	B-X
were	B-X
followed	B-X
by	B-X
concentration	B-X
-	B-X
	B-X
and	B-X
time	B-X
-	B-X
dependent	B-X
release	B-X
of	B-X
IL	B-X
-	B-X
1alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
and	B-X
by	B-X
TF	B-X
expression	B-X
on	B-X
monocyte	B-X
surfaces	B-X
<EOS>	B-X
Here	B-X
it	B-X
is	B-X
demonstrated	B-X
that	B-X
plasmin	B-X
induces	B-X
proinflammatory	B-X
cytokine	B-X
release	B-X
and	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
expression	B-X
by	B-X
monocytes	B-X
<EOS>	B-X
43	B-X
CTA	B-X
U	B-X
/	B-X
mL	B-X
,	B-X
but	B-X
not	B-X
active	B-X
site	B-X
-	B-X
blocked	B-X
plasmin	B-X
,	B-X
triggered	B-X
concentration	B-X
-	B-X
dependent	B-X
expression	B-X
of	B-X
mRNA	B-X
for	B-X
interleukin	B-X
-	B-X
1alpha	B-X
(	B-X
IL	B-X
-	B-X
1alpha	B-X
)	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
and	B-X
TF	B-X
with	B-X
maximum	B-X
responses	B-X
after	B-X
4	B-X
hours	B-X
<EOS>	B-X
Plasmin	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
tissue	B-X
factor	B-X
in	B-X
human	B-X
monocytes	B-X
involves	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
IKKbeta	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
.	B-X

Neither	O
cytokines	B-protein
nor	O
TF	B-protein
could	O
be	O
detected	O
when	O
monocytes	B-cell_type
were	O
preincubated	O
with	O
actinomycin	O
D	O
or	O
cycloheximide	O
.	O
<EOS>	B-X
Nitrovin	B-X
showed	B-X
significant	B-X
cytotoxicity	B-X
to	B-X
a	B-X
panel	B-X
of	B-X
cancer	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Next	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
potential	B-X
molecular	B-X
mechanisms	B-X
of	B-X
which	B-X
RASGRP3	B-X
high	B-X
expression	B-X
driven	B-X
by	B-X
NPM1	B-X
mutations	B-X
through	B-X
utilizing	B-X
immunoprecipitation	B-X
,	B-X
WB	B-X
and	B-X
Cycloheximide	B-X
(	B-X
CHX	B-X
)	B-X
assay	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
nitrovin	B-X
might	B-X
be	B-X
a	B-X
potential	B-X
anticancer	B-X
lead	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
nitrovin	B-X
interacted	B-X
with	B-X
TrxR1	B-X
and	B-X
significantly	B-X
inhibited	B-X
its	B-X
activity	B-X

Electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
plasmin	B-protein
-induced	O
activation	O
of	O
NF-kappaB	B-protein
;	O
DNA-binding	B-protein
complexes	I-protein
were	O
composed	O
of	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
c-Rel	B-protein
,	O
as	O
shown	O
by	O
supershift	O
experiments	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
indicated	B-X
plasmin	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
;	B-X
DNA	B-X
-	B-X
binding	B-X
complexes	B-X
were	B-X
composed	B-X
of	B-X
p50	B-X
,	B-X
p65	B-X
,	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
supershift	B-X
experiments	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
was	B-X
increased	B-X
in	B-X
plasmin	B-X
-	B-X
treated	B-X
monocytes	B-X
,	B-X
with	B-X
most	B-X
complexes	B-X
composed	B-X
of	B-X
JunD	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
,	B-X
and	B-X
FosB	B-X
<EOS>	B-X
Here	B-X
it	B-X
is	B-X
demonstrated	B-X
that	B-X
plasmin	B-X
induces	B-X
proinflammatory	B-X
cytokine	B-X
release	B-X
and	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
expression	B-X
by	B-X
monocytes	B-X
<EOS>	B-X
It	B-X
was	B-X
previously	B-X
shown	B-X
that	B-X
plasmin	B-X
activates	B-X
human	B-X
peripheral	B-X
monocytes	B-X
in	B-X
terms	B-X
of	B-X
lipid	B-X
mediator	B-X
release	B-X
and	B-X
chemotactic	B-X
migration	B-X

Nuclear	O
translocation	O
of	O
NF-kappaB/Rel	B-protein
proteins	I-protein
coincided	O
with	O
IkappaBalpha	O
degradation	O
.	O
<EOS>	B-X
Nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
proteins	B-X
coincided	B-X
with	B-X
IkappaBalpha	B-X
degradation	B-X
<EOS>	B-X
Mononuclear	B-X
phagocytes	B-X
play	B-X
a	B-X
major	B-X
role	B-X
in	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
<EOS>	B-X
Neither	B-X
cytokines	B-X
nor	B-X
TF	B-X
could	B-X
be	B-X
detected	B-X
when	B-X
monocytes	B-X
were	B-X
preincubated	B-X
with	B-X
actinomycin	B-X
D	B-X
or	B-X
cycloheximide	B-X
<EOS>	B-X
It	B-X
was	B-X
previously	B-X
shown	B-X
that	B-X
plasmin	B-X
activates	B-X
human	B-X
peripheral	B-X
monocytes	B-X
in	B-X
terms	B-X
of	B-X
lipid	B-X
mediator	B-X
release	B-X
and	B-X
chemotactic	B-X
migration	B-X

At	O
variance	O
with	O
endotoxic	O
lipopolysaccharide	O
,	O
plasmin	B-protein
elicited	O
the	O
rapid	O
degradation	O
of	O
another	O
cytoplasmic	B-protein
NF-kappaB	I-protein
inhibitor	I-protein
,	I-protein
p105	I-protein
.	O
<EOS>	B-X
At	B-X
variance	B-X
with	B-X
endotoxic	B-X
lipopolysaccharide	B-X
,	B-X
plasmin	B-X
elicited	B-X
the	B-X
rapid	B-X
degradation	B-X
of	B-X
another	B-X
cytoplasmic	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibitor	B-X
,	B-X
p105	B-X
<EOS>	B-X
These	B-X
findings	B-X
further	B-X
substantiate	B-X
the	B-X
role	B-X
of	B-X
plasmin	B-X
as	B-X
a	B-X
proinflammatory	B-X
activator	B-X
of	B-X
human	B-X
monocytes	B-X
and	B-X
reveal	B-X
an	B-X
important	B-X
new	B-X
link	B-X
between	B-X
the	B-X
plasminogen	B-X
-	B-X
plasmin	B-X
system	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
43	B-X
CTA	B-X
U	B-X
/	B-X
mL	B-X
,	B-X
but	B-X
not	B-X
active	B-X
site	B-X
-	B-X
blocked	B-X
plasmin	B-X
,	B-X
triggered	B-X
concentration	B-X
-	B-X
dependent	B-X
expression	B-X
of	B-X
mRNA	B-X
for	B-X
interleukin	B-X
-	B-X
1alpha	B-X
(	B-X
IL	B-X
-	B-X
1alpha	B-X
)	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
and	B-X
TF	B-X
with	B-X
maximum	B-X
responses	B-X
after	B-X
4	B-X
hours	B-X
<EOS>	B-X
Nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
proteins	B-X
coincided	B-X
with	B-X
IkappaBalpha	B-X
degradation	B-X

Proteolysis	O
of	O
NF-kappaB	O
inhibitors	O
was	O
apparently	O
due	O
to	O
transient	O
activation	O
of	O
IkappaB	B-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
beta	I-protein
that	O
reached	O
maximum	O
activity	O
at	O
1	O
hour	O
after	O
plasmin	B-protein
stimulation	O
.	O
<EOS>	B-X
Proteolysis	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibitors	B-X
was	B-X
apparently	B-X
due	B-X
to	B-X
transient	B-X
activation	B-X
of	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
beta	B-X
that	B-X
reached	B-X
maximum	B-X
activity	B-X
at	B-X
1	B-X
hour	B-X
after	B-X
plasmin	B-X
stimulation	B-X
<EOS>	B-X
These	B-X
findings	B-X
further	B-X
substantiate	B-X
the	B-X
role	B-X
of	B-X
plasmin	B-X
as	B-X
a	B-X
proinflammatory	B-X
activator	B-X
of	B-X
human	B-X
monocytes	B-X
and	B-X
reveal	B-X
an	B-X
important	B-X
new	B-X
link	B-X
between	B-X
the	B-X
plasminogen	B-X
-	B-X
plasmin	B-X
system	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
It	B-X
was	B-X
previously	B-X
shown	B-X
that	B-X
plasmin	B-X
activates	B-X
human	B-X
peripheral	B-X
monocytes	B-X
in	B-X
terms	B-X
of	B-X
lipid	B-X
mediator	B-X
release	B-X
and	B-X
chemotactic	B-X
migration	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
indicated	B-X
plasmin	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
;	B-X
DNA	B-X
-	B-X
binding	B-X
complexes	B-X
were	B-X
composed	B-X
of	B-X
p50	B-X
,	B-X
p65	B-X
,	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
supershift	B-X
experiments	B-X

In	O
addition	O
,	O
AP-1	O
binding	O
was	O
increased	O
in	O
plasmin	B-protein
-treated	O
monocytes	B-cell_type
,	O
with	O
most	O
complexes	O
composed	O
of	O
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	O
FosB	B-protein
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
was	B-X
increased	B-X
in	B-X
plasmin	B-X
-	B-X
treated	B-X
monocytes	B-X
,	B-X
with	B-X
most	B-X
complexes	B-X
composed	B-X
of	B-X
JunD	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
,	B-X
and	B-X
FosB	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
indicated	B-X
plasmin	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
;	B-X
DNA	B-X
-	B-X
binding	B-X
complexes	B-X
were	B-X
composed	B-X
of	B-X
p50	B-X
,	B-X
p65	B-X
,	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
supershift	B-X
experiments	B-X
<EOS>	B-X
Plasmin	B-X
-	B-X
mediated	B-X
mRNA	B-X
expression	B-X
was	B-X
inhibited	B-X
in	B-X
a	B-X
concentration	B-X
-	B-X
dependent	B-X
manner	B-X
by	B-X
the	B-X
lysine	B-X
analogue	B-X
trans	B-X
-	B-X
4	B-X
-	B-X
	B-X
(	B-X
aminomethyl	B-X
)	B-X
cyclohexane	B-X
-	B-X
1	B-X
-	B-X
carboxylic	B-X
acid	B-X
(	B-X
t	B-X
-	B-X
AMCA	B-X
)	B-X
<EOS>	B-X
These	B-X
findings	B-X
further	B-X
substantiate	B-X
the	B-X
role	B-X
of	B-X
plasmin	B-X
as	B-X
a	B-X
proinflammatory	B-X
activator	B-X
of	B-X
human	B-X
monocytes	B-X
and	B-X
reveal	B-X
an	B-X
important	B-X
new	B-X
link	B-X
between	B-X
the	B-X
plasminogen	B-X
-	B-X
plasmin	B-X
system	B-X
and	B-X
inflammation	B-X

These	O
findings	O
further	O
substantiate	O
the	O
role	O
of	O
plasmin	B-protein
as	O
a	O
proinflammatory	O
activator	O
of	O
human	B-cell_type
monocytes	I-cell_type
and	O
reveal	O
an	O
important	O
new	O
link	O
between	O
the	O
plasminogen-plasmin	O
system	O
and	O
inflammation	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
further	B-X
substantiate	B-X
the	B-X
role	B-X
of	B-X
plasmin	B-X
as	B-X
a	B-X
proinflammatory	B-X
activator	B-X
of	B-X
human	B-X
monocytes	B-X
and	B-X
reveal	B-X
an	B-X
important	B-X
new	B-X
link	B-X
between	B-X
the	B-X
plasminogen	B-X
-	B-X
plasmin	B-X
system	B-X
and	B-X
inflammation	B-X
<EOS>	B-X
Plasmin	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
tissue	B-X
factor	B-X
in	B-X
human	B-X
monocytes	B-X
involves	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
IKKbeta	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
.	B-X
<EOS>	B-X
Here	B-X
it	B-X
is	B-X
demonstrated	B-X
that	B-X
plasmin	B-X
induces	B-X
proinflammatory	B-X
cytokine	B-X
release	B-X
and	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
expression	B-X
by	B-X
monocytes	B-X
<EOS>	B-X
It	B-X
was	B-X
previously	B-X
shown	B-X
that	B-X
plasmin	B-X
activates	B-X
human	B-X
peripheral	B-X
monocytes	B-X
in	B-X
terms	B-X
of	B-X
lipid	B-X
mediator	B-X
release	B-X
and	B-X
chemotactic	B-X
migration	B-X

(	O
Blood.	O
2001	O
;	O
97	O
:	O
3941-3950	O
)	O
<EOS>	B-X
2001	B-X
;	B-X
97:3941	B-X
-	B-X
3950	B-X
)	B-X
<EOS>	B-X
(	B-X
Blood	B-X
<EOS>	B-X
043	B-X
to	B-X
1	B-X
<EOS>	B-X
Nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
proteins	B-X
coincided	B-X
with	B-X
IkappaBalpha	B-X
degradation	B-X

STAT3	B-protein
is	O
constitutively	O
active	O
in	O
some	O
patients	O
with	O
Polycythemia	O
rubra	O
vera	O
.	O
<EOS>	B-X
STAT3	B-X
is	B-X
constitutively	B-X
active	B-X
in	B-X
some	B-X
patients	B-X
with	B-X
Polycythemia	B-X
rubra	B-X
vera	B-X
.	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
constitutive	B-X
STAT3	B-X
activity	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
duration	B-X
of	B-X
disease	B-X
or	B-X
the	B-X
treatment	B-X
regimen	B-X
<EOS>	B-X
A	B-X
constitutive	B-X
activation	B-X
of	B-X
STAT	B-X
factors	B-X
could	B-X
explain	B-X
the	B-X
increased	B-X
proliferation	B-X
of	B-X
P	B-X
<EOS>	B-X
Constitutively	B-X
active	B-X
STAT3	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
growth	B-X
factor	B-X
hypersensitivity	B-X
of	B-X
P	B-X

OBJECTIVE	O
:	O
Polycythemia	O
vera	O
is	O
a	O
clonal	O
stem	O
cell	O
disorder	O
characterized	O
by	O
hyperproliferation	O
of	O
the	O
erythroid	B-cell_type
,	I-cell_type
myeloid	I-cell_type
,	I-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
.	O
<EOS>	B-X
Polycythemia	B-X
vera	B-X
is	B-X
a	B-X
clonal	B-X
stem	B-X
cell	B-X
disorder	B-X
characterized	B-X
by	B-X
hyperproliferation	B-X
of	B-X
the	B-X
erythroid	B-X
,	B-X
myeloid	B-X
,	B-X
and	B-X
megakaryocytic	B-X
lineages	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
constitutive	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
STAT3	B-X
is	B-X
not	B-X
a	B-X
secondary	B-X
event	B-X
induced	B-X
by	B-X
mutagenizing	B-X
agents	B-X
or	B-X
by	B-X
prolonged	B-X
hyperproliferation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
,	B-X
but	B-X
rather	B-X
represents	B-X
a	B-X
primary	B-X
molecular	B-X
aberration	B-X
<EOS>	B-X
A	B-X
constitutive	B-X
activation	B-X
of	B-X
STAT	B-X
factors	B-X
could	B-X
explain	B-X
the	B-X
increased	B-X
proliferation	B-X
of	B-X
P	B-X
<EOS>	B-X
STAT3	B-X
is	B-X
constitutively	B-X
active	B-X
in	B-X
some	B-X
patients	B-X
with	B-X
Polycythemia	B-X
rubra	B-X
vera	B-X
.	B-X

While	O
it	O
has	O
been	O
shown	O
that	O
progenitor	B-cell_type
cells	I-cell_type
of	O
P.	O
vera	O
patients	O
are	O
hypersensitive	O
to	O
several	O
growth	O
factors	O
including	O
erythropoietin	B-protein
,	O
insulin-like	B-protein
growth	I-protein
factor-1	I-protein
,	O
thrombopoietin	B-protein
,	O
interleukin-3	B-protein
,	O
and	O
granulocyte/monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
the	O
molecular	O
pathogenesis	O
of	O
this	O
disease	O
remains	O
unknown	O
.	O
<EOS>	B-X
vera	B-X
patients	B-X
are	B-X
hypersensitive	B-X
to	B-X
several	B-X
growth	B-X
factors	B-X
including	B-X
erythropoietin	B-X
,	B-X
insulin	B-X
-	B-X
like	B-X
growth	B-X
factor	B-X
-	B-X
1	B-X
,	B-X
thrombopoietin	B-X
,	B-X
interleukin	B-X
-	B-X
3	B-X
,	B-X
and	B-X
granulocyte	B-X
/	B-X
monocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
,	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
this	B-X
disease	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
Western	B-X
blotting	B-X
demonstrated	B-X
that	B-X
,	B-X
in	B-X
the	B-X
three	B-X
patients	B-X
,	B-X
STAT3	B-X
is	B-X
constitutively	B-X
phosphorylated	B-X
on	B-X
Tyr	B-X
705	B-X
,	B-X
whereas	B-X
it	B-X
is	B-X
unphosphorylated	B-X
in	B-X
the	B-X
other	B-X
patients	B-X
and	B-X
in	B-X
controls	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
constitutive	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
STAT3	B-X
is	B-X
not	B-X
a	B-X
secondary	B-X
event	B-X
induced	B-X
by	B-X
mutagenizing	B-X
agents	B-X
or	B-X
by	B-X
prolonged	B-X
hyperproliferation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
,	B-X
but	B-X
rather	B-X
represents	B-X
a	B-X
primary	B-X
molecular	B-X
aberration	B-X
<EOS>	B-X
vera	B-X
patients	B-X
analyzed	B-X
showed	B-X
constitutive	B-X
STAT3	B-X
DNA	B-X
binding	B-X
in	B-X
unstimulated	B-X
peripheral	B-X
granulocytes	B-X
,	B-X
while	B-X
none	B-X
of	B-X
the	B-X
17	B-X
healthy	B-X
volunteers	B-X
tested	B-X
did	B-X

Growth	O
factor	O
hypersensitivity	O
could	O
be	O
mediated	O
by	O
changes	O
in	O
signal	O
transduction	O
pathways	O
.	O
<EOS>	B-X
Food	B-X
hypersensitivity	B-X
is	B-X
a	B-X
group	B-X
of	B-X
diseases	B-X
arising	B-X
from	B-X
a	B-X
specific	B-X
immune	B-X
response	B-X
that	B-X
reproduces	B-X
on	B-X
exposure	B-X
to	B-X
a	B-X
given	B-X
food	B-X
<EOS>	B-X
Alterations	B-X
produced	B-X
by	B-X
overactivation	B-X
of	B-X
some	B-X
cytokine	B-X
signaling	B-X
pathways	B-X
,	B-X
e	B-X
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
are	B-X
found	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
AD	B-X
,	B-X
and	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
immunological	B-X
abnormalities	B-X
and	B-X
dysfunctional	B-X
skin	B-X
barrier	B-X
<EOS>	B-X
Further	B-X
,	B-X
inflammatory	B-X
factors	B-X
,	B-X
epidermal	B-X
differentiation	B-X
-	B-X
related	B-X
genes	B-X
,	B-X
oxidative	B-X
stress	B-X
indicators	B-X
and	B-X
JAK2	B-X
/	B-X
STAT5	B-X
signaling	B-X
pathway	B-X
were	B-X
evaluated	B-X

We	O
therefore	O
investigated	O
a	O
common	O
downstream	O
effector	O
of	O
cytokines	B-protein
,	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
.	O
<EOS>	B-X
We	B-X
therefore	B-X
investigated	B-X
a	B-X
common	B-X
downstream	B-X
effector	B-X
of	B-X
cytokines	B-X
,	B-X
the	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
(	B-X
STATs	B-X
)	B-X
<EOS>	B-X
Growth	B-X
factor	B-X
hypersensitivity	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
changes	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
<EOS>	B-X
A	B-X
constitutive	B-X
activation	B-X
of	B-X
STAT	B-X
factors	B-X
could	B-X
explain	B-X
the	B-X
increased	B-X
proliferation	B-X
of	B-X
P	B-X
<EOS>	B-X
Western	B-X
blotting	B-X
demonstrated	B-X
that	B-X
,	B-X
in	B-X
the	B-X
three	B-X
patients	B-X
,	B-X
STAT3	B-X
is	B-X
constitutively	B-X
phosphorylated	B-X
on	B-X
Tyr	B-X
705	B-X
,	B-X
whereas	B-X
it	B-X
is	B-X
unphosphorylated	B-X
in	B-X
the	B-X
other	B-X
patients	B-X
and	B-X
in	B-X
controls	B-X

A	O
constitutive	O
activation	O
of	O
STAT	B-protein
factors	I-protein
could	O
explain	O
the	O
increased	O
proliferation	O
of	O
P.	B-cell_type
vera	I-cell_type
cells	I-cell_type
even	O
in	O
the	O
absence	O
of	O
growth	O
factor	O
stimulation	O
.	O
<EOS>	B-X
A	B-X
constitutive	B-X
activation	B-X
of	B-X
STAT	B-X
factors	B-X
could	B-X
explain	B-X
the	B-X
increased	B-X
proliferation	B-X
of	B-X
P	B-X
<EOS>	B-X
vera	B-X
cells	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
growth	B-X
factor	B-X
stimulation	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
constitutive	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
STAT3	B-X
is	B-X
not	B-X
a	B-X
secondary	B-X
event	B-X
induced	B-X
by	B-X
mutagenizing	B-X
agents	B-X
or	B-X
by	B-X
prolonged	B-X
hyperproliferation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
,	B-X
but	B-X
rather	B-X
represents	B-X
a	B-X
primary	B-X
molecular	B-X
aberration	B-X
<EOS>	B-X
Constitutively	B-X
active	B-X
STAT3	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
growth	B-X
factor	B-X
hypersensitivity	B-X
of	B-X
P	B-X

METHODS	O
:	O
Peripheral	B-cell_type
granulocytes	I-cell_type
from	O
patients	O
with	O
P.	O
vera	O
and	O
from	O
healthy	O
volunteers	O
were	O
assayed	O
for	O
STAT1	B-protein
,	I-protein
3	I-protein
,	I-protein
and	I-protein
5	I-protein
DNA	O
binding	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Four	O
of	O
14	O
P.	O
vera	O
patients	O
analyzed	O
showed	O
constitutive	O
STAT3	O
DNA	O
binding	O
in	O
unstimulated	B-cell_type
peripheral	I-cell_type
granulocytes	I-cell_type
,	O
while	O
none	O
of	O
the	O
17	O
healthy	O
volunteers	O
tested	O
did	O
.	O
<EOS>	B-X
vera	B-X
patients	B-X
analyzed	B-X
showed	B-X
constitutive	B-X
STAT3	B-X
DNA	B-X
binding	B-X
in	B-X
unstimulated	B-X
peripheral	B-X
granulocytes	B-X
,	B-X
while	B-X
none	B-X
of	B-X
the	B-X
17	B-X
healthy	B-X
volunteers	B-X
tested	B-X
did	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
constitutive	B-X
STAT3	B-X
activity	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
duration	B-X
of	B-X
disease	B-X
or	B-X
the	B-X
treatment	B-X
regimen	B-X
<EOS>	B-X
STAT3	B-X
is	B-X
constitutively	B-X
active	B-X
in	B-X
some	B-X
patients	B-X
with	B-X
Polycythemia	B-X
rubra	B-X
vera	B-X
.	B-X
<EOS>	B-X
vera	B-X
patients	B-X
are	B-X
hypersensitive	B-X
to	B-X
several	B-X
growth	B-X
factors	B-X
including	B-X
erythropoietin	B-X
,	B-X
insulin	B-X
-	B-X
like	B-X
growth	B-X
factor	B-X
-	B-X
1	B-X
,	B-X
thrombopoietin	B-X
,	B-X
interleukin	B-X
-	B-X
3	B-X
,	B-X
and	B-X
granulocyte	B-X
/	B-X
monocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
,	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
this	B-X
disease	B-X
remains	B-X
unknown	B-X

None	O
of	O
the	O
subjects	O
showed	O
constitutive	O
STAT1	B-protein
or	O
STAT5	B-protein
activity	O
.	O
<EOS>	B-X
Emerging	B-X
evidences	B-X
showed	B-X
that	B-X
methylation	B-X
of	B-X
SHP	B-X
-	B-X
1	B-X
contributed	B-X
to	B-X
Imatinib	B-X
(	B-X
IM	B-X
)	B-X
resistance	B-X
<EOS>	B-X
This	B-X
was	B-X
stronger	B-X
when	B-X
tumors	B-X
were	B-X
positive	B-X
for	B-X
both	B-X
pSTAT5	B-X
-	B-X
N	B-X
and	B-X
pSTAT5	B-X
-	B-X
C	B-X
(	B-X
OR	B-X
2	B-X
<EOS>	B-X
Cannabinoid	B-X
Mixture	B-X
Affects	B-X
the	B-X
Fate	B-X
and	B-X
Functions	B-X
of	B-X
B	B-X
Cells	B-X
through	B-X
the	B-X
Modulation	B-X
of	B-X
the	B-X
Caspase	B-X
and	B-X
MAP	B-X
Kinase	B-X
Pathways	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
exposure	B-X
to	B-X
the	B-X
CM	B-X
significantly	B-X
altered	B-X
the	B-X
cytokine	B-X
profile	B-X
of	B-X
the	B-X
B	B-X
cells	B-X

Western	O
blotting	O
demonstrated	O
that	O
,	O
in	O
the	O
three	O
patients	O
,	O
STAT3	B-protein
is	O
constitutively	O
phosphorylated	O
on	O
Tyr	O
705	O
,	O
whereas	O
it	O
is	O
unphosphorylated	O
in	O
the	O
other	O
patients	O
and	O
in	O
controls	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
demonstrated	B-X
that	B-X
,	B-X
in	B-X
the	B-X
three	B-X
patients	B-X
,	B-X
STAT3	B-X
is	B-X
constitutively	B-X
phosphorylated	B-X
on	B-X
Tyr	B-X
705	B-X
,	B-X
whereas	B-X
it	B-X
is	B-X
unphosphorylated	B-X
in	B-X
the	B-X
other	B-X
patients	B-X
and	B-X
in	B-X
controls	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
constitutive	B-X
STAT3	B-X
activity	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
duration	B-X
of	B-X
disease	B-X
or	B-X
the	B-X
treatment	B-X
regimen	B-X
<EOS>	B-X
vera	B-X
patients	B-X
analyzed	B-X
showed	B-X
constitutive	B-X
STAT3	B-X
DNA	B-X
binding	B-X
in	B-X
unstimulated	B-X
peripheral	B-X
granulocytes	B-X
,	B-X
while	B-X
none	B-X
of	B-X
the	B-X
17	B-X
healthy	B-X
volunteers	B-X
tested	B-X
did	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
constitutive	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
STAT3	B-X
is	B-X
not	B-X
a	B-X
secondary	B-X
event	B-X
induced	B-X
by	B-X
mutagenizing	B-X
agents	B-X
or	B-X
by	B-X
prolonged	B-X
hyperproliferation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
,	B-X
but	B-X
rather	B-X
represents	B-X
a	B-X
primary	B-X
molecular	B-X
aberration	B-X

Interestingly	O
,	O
constitutive	O
STAT3	B-protein
activity	O
did	O
not	O
correlate	O
with	O
the	O
duration	O
of	O
disease	O
or	O
the	O
treatment	O
regimen	O
.	O
<EOS>	B-X
No	B-X
trials	B-X
included	B-X
ROV	B-X
items	B-X
in	B-X
ancestry	B-X
,	B-X
how	B-X
to	B-X
connect	B-X
with	B-X
other	B-X
participants	B-X
,	B-X
or	B-X
remuneration	B-X
<EOS>	B-X
This	B-X
study	B-X
is	B-X
being	B-X
conducted	B-X
in	B-X
accordance	B-X
with	B-X
the	B-X
Declaration	B-X
of	B-X
Helsinki	B-X
<EOS>	B-X
Orthopedic	B-X
trauma	B-X
patients	B-X
may	B-X
have	B-X
poor	B-X
recall	B-X
of	B-X
their	B-X
injuries	B-X
and	B-X
treatment	B-X
<EOS>	B-X
A	B-X
fractioned	B-X
bleaching	B-X
protocol	B-X
with	B-X
4	B-X
%	B-X
HP	B-X
(	B-X
30	B-X
minutes	B-X
twice	B-X
daily	B-X
)	B-X
did	B-X
not	B-X
increase	B-X
the	B-X
whitening	B-X
degree	B-X
nor	B-X
affect	B-X
the	B-X
risk	B-X
and	B-X
intensity	B-X
of	B-X
TS	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
one	B-X
-	B-X
hour	B-X
continuous	B-X
protocol	B-X

It	O
was	O
observed	O
in	O
a	O
recently	O
diagnosed	O
patient	O
and	O
in	O
two	O
patients	O
treated	O
only	O
with	O
phlebotomy	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
constitutive	O
phosphorylation	O
and	O
activation	O
of	O
STAT3	B-protein
is	O
not	O
a	O
secondary	O
event	O
induced	O
by	O
mutagenizing	O
agents	O
or	O
by	O
prolonged	O
hyperproliferation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
but	O
rather	O
represents	O
a	O
primary	O
molecular	O
aberration	O
.	O
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
constitutive	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
STAT3	B-X
is	B-X
not	B-X
a	B-X
secondary	B-X
event	B-X
induced	B-X
by	B-X
mutagenizing	B-X
agents	B-X
or	B-X
by	B-X
prolonged	B-X
hyperproliferation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
,	B-X
but	B-X
rather	B-X
represents	B-X
a	B-X
primary	B-X
molecular	B-X
aberration	B-X
<EOS>	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
constitutive	B-X
activation	B-X
of	B-X
STAT3	B-X
is	B-X
present	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
canine	B-X
OSA	B-X
tumors	B-X
and	B-X
human	B-X
and	B-X
canine	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
not	B-X
normal	B-X
canine	B-X
osteoblasts	B-X
<EOS>	B-X
Our	B-X
data	B-X
suggest	B-X
constitutively	B-X
activated	B-X
STAT3	B-X
monocytes	B-X
promote	B-X
liver	B-X
tumorigenesis	B-X
in	B-X
clinical	B-X
patients	B-X
and	B-X
animal	B-X
experiments	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
STAT3	B-X
activation	B-X
contributes	B-X
to	B-X
the	B-X
survival	B-X
and	B-X
proliferation	B-X
of	B-X
human	B-X
and	B-X
canine	B-X
OSA	B-X
cells	B-X
,	B-X
thereby	B-X
providing	B-X
a	B-X
potentially	B-X
promising	B-X
target	B-X
for	B-X
therapeutic	B-X
intervention	B-X

Constitutively	B-protein
active	I-protein
STAT3	I-protein
may	O
contribute	O
to	O
the	O
growth	O
factor	O
hypersensitivity	O
of	O
P.	B-cell_type
vera	I-cell_type
cells	I-cell_type
.	O

Identification	O
of	O
phosphorylation	B-protein
sites	I-protein
for	O
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
within	O
the	O
transcriptional	B-protein
regulator	I-protein
BAP/TFII-I	I-protein
.	O
<EOS>	B-X
Identification	B-X
of	B-X
phosphorylation	B-X
sites	B-X
for	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
within	B-X
the	B-X
transcriptional	B-X
regulator	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
.	B-X
<EOS>	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
understand	B-X
the	B-X
physiologic	B-X
consequences	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
tyrosine	B-X
phosphorylation	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
stimulation	B-X
,	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
and	B-X
phosphopeptide	B-X
mapping	B-X
were	B-X
used	B-X
to	B-X
locate	B-X
the	B-X
predominant	B-X
sites	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
phosphorylation	B-X
by	B-X
Btk	B-X
in	B-X
vitro	B-X
<EOS>	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
,	B-X
a	B-X
protein	B-X
implicated	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
Btk	B-X
in	B-X
B	B-X
cells	B-X
and	B-X
is	B-X
transiently	B-X
phosphorylated	B-X
on	B-X
tyrosine	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
engagement	B-X
<EOS>	B-X
These	B-X
residues	B-X
,	B-X
Tyr248	B-X
,	B-X
Tyr357	B-X
,	B-X
and	B-X
Tyr462	B-X
,	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
the	B-X
major	B-X
sites	B-X
for	B-X
Btk	B-X
-	B-X
dependent	B-X
phosphorylation	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
in	B-X
vivo	B-X

Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
Btk	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
Tec	B-protein
family	I-protein
of	I-protein
cytosolic	I-protein
kinases	I-protein
,	O
is	O
essential	O
for	O
B	B-cell_type
cell	I-cell_type
development	O
and	O
function	O
.	O
<EOS>	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
(	B-X
Btk	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Tec	B-X
family	B-X
of	B-X
cytosolic	B-X
kinases	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
B	B-X
cell	B-X
development	B-X
and	B-X
function	B-X
<EOS>	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
,	B-X
a	B-X
protein	B-X
implicated	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
Btk	B-X
in	B-X
B	B-X
cells	B-X
and	B-X
is	B-X
transiently	B-X
phosphorylated	B-X
on	B-X
tyrosine	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
engagement	B-X
<EOS>	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
understand	B-X
the	B-X
physiologic	B-X
consequences	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
tyrosine	B-X
phosphorylation	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
stimulation	B-X
,	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
and	B-X
phosphopeptide	B-X
mapping	B-X
were	B-X
used	B-X
to	B-X
locate	B-X
the	B-X
predominant	B-X
sites	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
phosphorylation	B-X
by	B-X
Btk	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Identification	B-X
of	B-X
phosphorylation	B-X
sites	B-X
for	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
within	B-X
the	B-X
transcriptional	B-X
regulator	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
.	B-X

BAP/TFII-I	B-protein
,	O
a	O
protein	O
implicated	O
in	O
transcriptional	O
regulation	O
,	O
is	O
associated	O
with	O
Btk	B-protein
in	O
B	B-cell_type
cells	I-cell_type
and	O
is	O
transiently	O
phosphorylated	O
on	O
tyrosine	O
following	O
B	B-cell_type
cell	I-cell_type
receptor	O
engagement	O
.	O

BAP/TFII-I	B-protein
is	O
a	O
substrate	O
for	O
Btk	B-protein
in	O
vitro	O
and	O
is	O
hyperphosphorylated	O
on	O
tyrosine	O
upon	O
coexpression	O
with	O
Btk	B-protein
in	O
mammalian	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
is	B-X
a	B-X
substrate	B-X
for	B-X
Btk	B-X
in	B-X
vitro	B-X
and	B-X
is	B-X
hyperphosphorylated	B-X
on	B-X
tyrosine	B-X
upon	B-X
coexpression	B-X
with	B-X
Btk	B-X
in	B-X
mammalian	B-X
cells	B-X
<EOS>	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
,	B-X
a	B-X
protein	B-X
implicated	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
Btk	B-X
in	B-X
B	B-X
cells	B-X
and	B-X
is	B-X
transiently	B-X
phosphorylated	B-X
on	B-X
tyrosine	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
engagement	B-X
<EOS>	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
understand	B-X
the	B-X
physiologic	B-X
consequences	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
tyrosine	B-X
phosphorylation	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
stimulation	B-X
,	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
and	B-X
phosphopeptide	B-X
mapping	B-X
were	B-X
used	B-X
to	B-X
locate	B-X
the	B-X
predominant	B-X
sites	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
phosphorylation	B-X
by	B-X
Btk	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
either	B-X
Tyr248	B-X
,	B-X
Tyr357	B-X
,	B-X
or	B-X
Tyr462	B-X
to	B-X
phenylalanine	B-X
reduced	B-X
transcription	B-X
from	B-X
a	B-X
c	B-X
-	B-X
fos	B-X
promoter	B-X
relative	B-X
to	B-X
wild	B-X
-	B-X
type	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
in	B-X
transfected	B-X
COS	B-X
-	B-X
7	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
interpretation	B-X
that	B-X
phosphorylation	B-X
at	B-X
these	B-X
sites	B-X
contributes	B-X
to	B-X
transcriptional	B-X
activation	B-X

In	O
an	O
effort	O
to	O
understand	O
the	O
physiologic	O
consequences	O
of	O
BAP/TFII-I	B-protein
tyrosine	O
phosphorylation	O
following	O
B	O
cell	O
receptor	O
stimulation	O
,	O
site-directed	O
mutagenesis	O
and	O
phosphopeptide	O
mapping	O
were	O
used	O
to	O
locate	O
the	O
predominant	O
sites	O
of	O
BAP/TFII-I	B-protein
phosphorylation	O
by	O
Btk	B-protein
in	O
vitro	O
.	O

These	O
residues	O
,	O
Tyr248	O
,	O
Tyr357	O
,	O
and	O
Tyr462	O
,	O
were	O
also	O
found	O
to	O
be	O
the	O
major	O
sites	O
for	O
Btk	B-protein
-dependent	O
phosphorylation	O
of	O
BAP/TFII-I	B-protein
in	O
vivo	O
.	O
<EOS>	B-X
These	B-X
residues	B-X
,	B-X
Tyr248	B-X
,	B-X
Tyr357	B-X
,	B-X
and	B-X
Tyr462	B-X
,	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
the	B-X
major	B-X
sites	B-X
for	B-X
Btk	B-X
-	B-X
dependent	B-X
phosphorylation	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Residues	B-X
Tyr357	B-X
and	B-X
Tyr462	B-X
are	B-X
contained	B-X
within	B-X
the	B-X
loop	B-X
regions	B-X
of	B-X
adjacent	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
-	B-X
like	B-X
repeats	B-X
within	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
either	B-X
Tyr248	B-X
,	B-X
Tyr357	B-X
,	B-X
or	B-X
Tyr462	B-X
to	B-X
phenylalanine	B-X
reduced	B-X
transcription	B-X
from	B-X
a	B-X
c	B-X
-	B-X
fos	B-X
promoter	B-X
relative	B-X
to	B-X
wild	B-X
-	B-X
type	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
in	B-X
transfected	B-X
COS	B-X
-	B-X
7	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
interpretation	B-X
that	B-X
phosphorylation	B-X
at	B-X
these	B-X
sites	B-X
contributes	B-X
to	B-X
transcriptional	B-X
activation	B-X
<EOS>	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
understand	B-X
the	B-X
physiologic	B-X
consequences	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
tyrosine	B-X
phosphorylation	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
stimulation	B-X
,	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
and	B-X
phosphopeptide	B-X
mapping	B-X
were	B-X
used	B-X
to	B-X
locate	B-X
the	B-X
predominant	B-X
sites	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
phosphorylation	B-X
by	B-X
Btk	B-X
in	B-X
vitro	B-X

Residues	O
Tyr357	O
and	O
Tyr462	O
are	O
contained	O
within	O
the	O
loop	B-protein
regions	I-protein
of	O
adjacent	O
helix-loop-helix-like	B-protein
repeats	I-protein
within	O
BAP/TFII-I	B-protein
.	O
<EOS>	B-X
Residues	B-X
Tyr357	B-X
and	B-X
Tyr462	B-X
are	B-X
contained	B-X
within	B-X
the	B-X
loop	B-X
regions	B-X
of	B-X
adjacent	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
-	B-X
like	B-X
repeats	B-X
within	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
<EOS>	B-X
These	B-X
residues	B-X
,	B-X
Tyr248	B-X
,	B-X
Tyr357	B-X
,	B-X
and	B-X
Tyr462	B-X
,	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
the	B-X
major	B-X
sites	B-X
for	B-X
Btk	B-X
-	B-X
dependent	B-X
phosphorylation	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Identification	B-X
of	B-X
phosphorylation	B-X
sites	B-X
for	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
within	B-X
the	B-X
transcriptional	B-X
regulator	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
.	B-X
<EOS>	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
understand	B-X
the	B-X
physiologic	B-X
consequences	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
tyrosine	B-X
phosphorylation	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
stimulation	B-X
,	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
and	B-X
phosphopeptide	B-X
mapping	B-X
were	B-X
used	B-X
to	B-X
locate	B-X
the	B-X
predominant	B-X
sites	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
phosphorylation	B-X
by	B-X
Btk	B-X
in	B-X
vitro	B-X

Mutation	O
of	O
either	O
Tyr248	O
,	O
Tyr357	O
,	O
or	O
Tyr462	O
to	O
phenylalanine	O
reduced	O
transcription	O
from	O
a	O
c-fos	B-DNA
promoter	I-DNA
relative	O
to	O
wild-type	B-DNA
BAP/TFII-I	I-DNA
in	O
transfected	O
COS-7	B-cell_line
cells	I-cell_line
,	O
consistent	O
with	O
the	O
interpretation	O
that	O
phosphorylation	O
at	O
these	O
sites	O
contributes	O
to	O
transcriptional	O
activation	O
.	O
<EOS>	B-X
Mutation	B-X
of	B-X
either	B-X
Tyr248	B-X
,	B-X
Tyr357	B-X
,	B-X
or	B-X
Tyr462	B-X
to	B-X
phenylalanine	B-X
reduced	B-X
transcription	B-X
from	B-X
a	B-X
c	B-X
-	B-X
fos	B-X
promoter	B-X
relative	B-X
to	B-X
wild	B-X
-	B-X
type	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
in	B-X
transfected	B-X
COS	B-X
-	B-X
7	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
interpretation	B-X
that	B-X
phosphorylation	B-X
at	B-X
these	B-X
sites	B-X
contributes	B-X
to	B-X
transcriptional	B-X
activation	B-X
<EOS>	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
,	B-X
a	B-X
protein	B-X
implicated	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
Btk	B-X
in	B-X
B	B-X
cells	B-X
and	B-X
is	B-X
transiently	B-X
phosphorylated	B-X
on	B-X
tyrosine	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
engagement	B-X
<EOS>	B-X
These	B-X
residues	B-X
,	B-X
Tyr248	B-X
,	B-X
Tyr357	B-X
,	B-X
and	B-X
Tyr462	B-X
,	B-X
were	B-X
also	B-X
found	B-X
to	B-X
be	B-X
the	B-X
major	B-X
sites	B-X
for	B-X
Btk	B-X
-	B-X
dependent	B-X
phosphorylation	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Residues	B-X
Tyr357	B-X
and	B-X
Tyr462	B-X
are	B-X
contained	B-X
within	B-X
the	B-X
loop	B-X
regions	B-X
of	B-X
adjacent	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
-	B-X
like	B-X
repeats	B-X
within	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X

Phosphorylation	O
of	O
BAP/TFII-I	B-protein
by	O
Btk	B-protein
may	O
link	O
engagement	O
of	O
receptors	O
such	O
as	O
surface	O
immunoglobulin	B-protein
to	O
modulation	O
of	O
gene	O
expression	O
.	O
<EOS>	B-X
Phosphorylation	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
by	B-X
Btk	B-X
may	B-X
link	B-X
engagement	B-X
of	B-X
receptors	B-X
such	B-X
as	B-X
surface	B-X
immunoglobulin	B-X
to	B-X
modulation	B-X
of	B-X
gene	B-X
expression	B-X
<EOS>	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
understand	B-X
the	B-X
physiologic	B-X
consequences	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
tyrosine	B-X
phosphorylation	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
stimulation	B-X
,	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
and	B-X
phosphopeptide	B-X
mapping	B-X
were	B-X
used	B-X
to	B-X
locate	B-X
the	B-X
predominant	B-X
sites	B-X
of	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
phosphorylation	B-X
by	B-X
Btk	B-X
in	B-X
vitro	B-X
<EOS>	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
,	B-X
a	B-X
protein	B-X
implicated	B-X
in	B-X
transcriptional	B-X
regulation	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
Btk	B-X
in	B-X
B	B-X
cells	B-X
and	B-X
is	B-X
transiently	B-X
phosphorylated	B-X
on	B-X
tyrosine	B-X
following	B-X
B	B-X
cell	B-X
receptor	B-X
engagement	B-X
<EOS>	B-X
Identification	B-X
of	B-X
phosphorylation	B-X
sites	B-X
for	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
within	B-X
the	B-X
transcriptional	B-X
regulator	B-X
BAP	B-X
/	B-X
TFII	B-X
-	B-X
I	B-X
.	B-X

Expression	O
of	O
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
induces	O
potent	O
immunity	O
against	O
BCR/ABL-induced	O
leukemia	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
interferon	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
induces	B-X
potent	B-X
immunity	B-X
against	B-X
BCR	B-X
/	B-X
ABL	B-X
-	B-X
induced	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
Mice	B-X
deficient	B-X
in	B-X
the	B-X
interferon	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
(	B-X
ICSBP	B-X
)	B-X
develop	B-X
a	B-X
disease	B-X
resembling	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
which	B-X
in	B-X
humans	B-X
is	B-X
caused	B-X
by	B-X
the	B-X
BCR	B-X
/	B-X
ABL	B-X
oncoprotein	B-X
<EOS>	B-X
This	B-X
study	B-X
examined	B-X
whether	B-X
enforced	B-X
expression	B-X
of	B-X
ICSBP	B-X
might	B-X
antagonize	B-X
BCR	B-X
/	B-X
ABL	B-X
-	B-X
induced	B-X
leukemia	B-X
;	B-X
results	B-X
demonstrated	B-X
that	B-X
ICSBP	B-X
-	B-X
modified	B-X
cells	B-X
generated	B-X
a	B-X
protective	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
-	B-X
cell	B-X
response	B-X
against	B-X
BCR	B-X
/	B-X
ABL	B-X
-	B-X
transformed	B-X
BaF3	B-X
cells	B-X
in	B-X
a	B-X
murine	B-X
leukemia	B-X
model	B-X
<EOS>	B-X
ICSBP	B-X
expression	B-X
represents	B-X
a	B-X
novel	B-X
means	B-X
of	B-X
stimulating	B-X
a	B-X
host	B-X
immune	B-X
response	B-X
to	B-X
BCR	B-X
/	B-X
ABL	B-X
(	B-X
+	B-X
)	B-X
leukemia	B-X
cells	B-X
and	B-X
a	B-X
potential	B-X
strategy	B-X
for	B-X
immunotherapy	B-X
of	B-X
CML	B-X

Mice	O
deficient	O
in	O
the	O
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
develop	O
a	O
disease	O
resembling	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
,	O
which	O
in	O
humans	O
is	O
caused	O
by	O
the	O
BCR/ABL	B-protein
oncoprotein	I-protein
.	O
<EOS>	B-X
Mice	B-X
deficient	B-X
in	B-X
the	B-X
interferon	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
(	B-X
ICSBP	B-X
)	B-X
develop	B-X
a	B-X
disease	B-X
resembling	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
which	B-X
in	B-X
humans	B-X
is	B-X
caused	B-X
by	B-X
the	B-X
BCR	B-X
/	B-X
ABL	B-X
oncoprotein	B-X
<EOS>	B-X
Expression	B-X
of	B-X
interferon	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
induces	B-X
potent	B-X
immunity	B-X
against	B-X
BCR	B-X
/	B-X
ABL	B-X
-	B-X
induced	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
ICSBP	B-X
expression	B-X
represents	B-X
a	B-X
novel	B-X
means	B-X
of	B-X
stimulating	B-X
a	B-X
host	B-X
immune	B-X
response	B-X
to	B-X
BCR	B-X
/	B-X
ABL	B-X
(	B-X
+	B-X
)	B-X
leukemia	B-X
cells	B-X
and	B-X
a	B-X
potential	B-X
strategy	B-X
for	B-X
immunotherapy	B-X
of	B-X
CML	B-X
<EOS>	B-X
This	B-X
study	B-X
examined	B-X
whether	B-X
enforced	B-X
expression	B-X
of	B-X
ICSBP	B-X
might	B-X
antagonize	B-X
BCR	B-X
/	B-X
ABL	B-X
-	B-X
induced	B-X
leukemia	B-X
;	B-X
results	B-X
demonstrated	B-X
that	B-X
ICSBP	B-X
-	B-X
modified	B-X
cells	B-X
generated	B-X
a	B-X
protective	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
-	B-X
cell	B-X
response	B-X
against	B-X
BCR	B-X
/	B-X
ABL	B-X
-	B-X
transformed	B-X
BaF3	B-X
cells	B-X
in	B-X
a	B-X
murine	B-X
leukemia	B-X
model	B-X

Interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
induces	O
ICSBP	B-protein
expression	O
and	O
is	O
an	O
effective	O
therapy	O
for	O
CML	O
.	O
<EOS>	B-X
Interferon	B-X
-	B-X
alpha	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
induces	B-X
ICSBP	B-X
expression	B-X
and	B-X
is	B-X
an	B-X
effective	B-X
therapy	B-X
for	B-X
CML	B-X
<EOS>	B-X
Alpha	B-X
interferon	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
treatment	B-X
induces	B-X
hematological	B-X
remission	B-X
and	B-X
prolongs	B-X
life	B-X
in	B-X
75	B-X
%	B-X
of	B-X
CML	B-X
patients	B-X
in	B-X
the	B-X
chronic	B-X
phase	B-X
<EOS>	B-X
ICSBP	B-X
expression	B-X
represents	B-X
a	B-X
novel	B-X
means	B-X
of	B-X
stimulating	B-X
a	B-X
host	B-X
immune	B-X
response	B-X
to	B-X
BCR	B-X
/	B-X
ABL	B-X
(	B-X
+	B-X
)	B-X
leukemia	B-X
cells	B-X
and	B-X
a	B-X
potential	B-X
strategy	B-X
for	B-X
immunotherapy	B-X
of	B-X
CML	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
coexpression	B-X
of	B-X
ICSBP	B-X
and	B-X
Bcr	B-X
-	B-X
Abl	B-X
induced	B-X
a	B-X
transient	B-X
B	B-X
-	B-X
lymphoproliferative	B-X
disorder	B-X
in	B-X
the	B-X
murine	B-X
model	B-X
of	B-X
Bcr	B-X
-	B-X
Abl	B-X
-	B-X
induced	B-X
CML	B-X
-	B-X
like	B-X
disease	B-X

This	O
study	O
examined	O
whether	O
enforced	O
expression	O
of	O
ICSBP	B-protein
might	O
antagonize	O
BCR/ABL-induced	O
leukemia	O
;	O
results	O
demonstrated	O
that	O
ICSBP-modified	B-cell_type
cells	I-cell_type
generated	O
a	O
protective	O
CD8	O
(	O
+	O
)	O
cytotoxic	O
T-cell	O
response	O
against	O
BCR/ABL-transformed	B-cell_type
BaF3	I-cell_type
cells	I-cell_type
in	O
a	O
murine	O
leukemia	O
model	O
.	O

ICSBP	B-protein
expression	O
represents	O
a	O
novel	O
means	O
of	O
stimulating	O
a	O
host	O
immune	O
response	O
to	O
BCR/ABL	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
a	O
potential	O
strategy	O
for	O
immunotherapy	O
of	O
CML	O
.	O

(	O
Blood.	O
2001	O
;	O
97	O
:	O
3491-3497	O
)	O
<EOS>	B-X
2001	B-X
;	B-X
97:3491	B-X
-	B-X
3497	B-X
)	B-X
<EOS>	B-X
(	B-X
Blood	B-X
<EOS>	B-X
Interferon	B-X
-	B-X
alpha	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
induces	B-X
ICSBP	B-X
expression	B-X
and	B-X
is	B-X
an	B-X
effective	B-X
therapy	B-X
for	B-X
CML	B-X
<EOS>	B-X
Expression	B-X
of	B-X
interferon	B-X
consensus	B-X
sequence	B-X
binding	B-X
protein	B-X
induces	B-X
potent	B-X
immunity	B-X
against	B-X
BCR	B-X
/	B-X
ABL	B-X
-	B-X
induced	B-X
leukemia	B-X
.	B-X

A	O
transcriptional	O
block	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
at	O
the	O
-150	B-DNA
AP-1	I-DNA
site	I-DNA
in	O
effector	B-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
A	B-X
transcriptional	B-X
block	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
at	B-X
the	B-X
	B-X
-	B-X
150	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
effector	B-X
CD8+	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
CD8+	B-X
T	B-X
cells	B-X
,	B-X
we	B-X
stably	B-X
transfected	B-X
reporter	B-X
genes	B-X
into	B-X
Ag	B-X
-	B-X
specific	B-X
CD8+	B-X
T	B-X
cell	B-X
clones	B-X
<EOS>	B-X
IL	B-X
-	B-X
2	B-X
expression	B-X
in	B-X
CD4+	B-X
T	B-X
cells	B-X
is	B-X
primarily	B-X
controlled	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
but	B-X
mechanisms	B-X
restricting	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
in	B-X
CD8+	B-X
T	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
elucidated	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
defect	B-X
at	B-X
the	B-X
	B-X
-	B-X
150	B-X
site	B-X
may	B-X
reflect	B-X
the	B-X
absence	B-X
or	B-X
inactivity	B-X
of	B-X
a	B-X
required	B-X
factor	B-X
rather	B-X
than	B-X
repression	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X

Both	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
produce	O
IL-2	B-protein
in	O
response	O
to	O
Ag	O
recognition	O
have	O
been	O
isolated	O
.	O

However	O
,	O
most	O
effector	B-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
recovered	O
after	O
exposure	O
to	O
Ag	B-protein
do	O
not	O
produce	O
sufficient	O
IL-2	B-protein
to	O
sustain	O
growth	O
,	O
and	O
depend	O
on	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
cells	I-cell_type
for	O
this	O
obligate	O
growth	O
factor	O
.	O

IL-2	O
expression	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
primarily	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
,	O
but	O
mechanisms	O
restricting	O
IL-2	O
production	O
in	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
elucidated	O
.	O

To	O
evaluate	O
transcriptional	O
regulation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
in	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
stably	O
transfected	O
reporter	B-DNA
genes	I-DNA
into	O
Ag	B-protein
-specific	O
CD8+	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
CD8+	B-X
T	B-X
cells	B-X
,	B-X
we	B-X
stably	B-X
transfected	B-X
reporter	B-X
genes	B-X
into	B-X
Ag	B-X
-	B-X
specific	B-X
CD8+	B-X
T	B-X
cell	B-X
clones	B-X
<EOS>	B-X
A	B-X
transcriptional	B-X
block	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
at	B-X
the	B-X
	B-X
-	B-X
150	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
effector	B-X
CD8+	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
Both	B-X
CD4+	B-X
and	B-X
CD8+	B-X
T	B-X
cells	B-X
that	B-X
produce	B-X
IL	B-X
-	B-X
2	B-X
in	B-X
response	B-X
to	B-X
Ag	B-X
recognition	B-X
have	B-X
been	B-X
isolated	B-X
<EOS>	B-X
CD28+	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
unable	B-X
to	B-X
transcribe	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
antigenic	B-X
stimulation	B-X
had	B-X
a	B-X
block	B-X
in	B-X
transactivation	B-X
of	B-X
the	B-X
	B-X
-	B-X
150	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
but	B-X
did	B-X
transactivate	B-X
the	B-X
composite	B-X
NFAT	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
OCT	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
sites	B-X
,	B-X
and	B-X
a	B-X
consensus	B-X
AP	B-X
-	B-X
1	B-X
motif	B-X

CD28+	B-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
unable	O
to	O
transcribe	O
the	O
IL-2	B-DNA
gene	I-DNA
in	O
response	O
to	O
antigenic	O
stimulation	O
had	O
a	O
block	O
in	O
transactivation	O
of	O
the	O
-150	B-DNA
CD28	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CD28RE	I-DNA
)	I-DNA
/AP-1	I-DNA
site	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
but	O
did	O
transactivate	O
the	O
composite	O
NFAT/AP-1	B-DNA
and	I-DNA
OCT/AP-1	I-DNA
sites	I-DNA
,	O
and	O
a	O
consensus	B-DNA
AP-1	I-DNA
motif	I-DNA
.	O

Mutation	O
of	O
the	O
nonconsensus	B-DNA
-150	I-DNA
AP-1	I-DNA
site	I-DNA
to	O
a	O
consensus	B-DNA
AP-1	I-DNA
site	I-DNA
,	O
or	O
insertion	O
of	O
a	O
CD28RE/AP-1	B-DNA
consensus	I-DNA
site	I-DNA
upstream	O
of	O
the	O
native	O
-150	B-DNA
CD28RE/AP-1	I-DNA
site	I-DNA
restored	O
transactivation	O
of	O
the	O
altered	O
promoter	B-DNA
.	O
<EOS>	B-X
Mutation	B-X
of	B-X
the	B-X
nonconsensus	B-X
	B-X
-	B-X
150	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
to	B-X
a	B-X
consensus	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
,	B-X
or	B-X
insertion	B-X
of	B-X
a	B-X
CD28RE	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
consensus	B-X
site	B-X
upstream	B-X
of	B-X
the	B-X
native	B-X
	B-X
-	B-X
150	B-X
CD28RE	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
restored	B-X
transactivation	B-X
of	B-X
the	B-X
altered	B-X
promoter	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
defect	B-X
at	B-X
the	B-X
	B-X
-	B-X
150	B-X
site	B-X
may	B-X
reflect	B-X
the	B-X
absence	B-X
or	B-X
inactivity	B-X
of	B-X
a	B-X
required	B-X
factor	B-X
rather	B-X
than	B-X
repression	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
CD28+	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
unable	B-X
to	B-X
transcribe	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
antigenic	B-X
stimulation	B-X
had	B-X
a	B-X
block	B-X
in	B-X
transactivation	B-X
of	B-X
the	B-X
	B-X
-	B-X
150	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
but	B-X
did	B-X
transactivate	B-X
the	B-X
composite	B-X
NFAT	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
OCT	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
sites	B-X
,	B-X
and	B-X
a	B-X
consensus	B-X
AP	B-X
-	B-X
1	B-X
motif	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
CD8+	B-X
T	B-X
cells	B-X
,	B-X
we	B-X
stably	B-X
transfected	B-X
reporter	B-X
genes	B-X
into	B-X
Ag	B-X
-	B-X
specific	B-X
CD8+	B-X
T	B-X
cell	B-X
clones	B-X

These	O
results	O
suggest	O
that	O
the	O
defect	O
at	O
the	O
-150	B-DNA
site	I-DNA
may	O
reflect	O
the	O
absence	O
or	O
inactivity	O
of	O
a	O
required	O
factor	O
rather	O
than	O
repression	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
defect	B-X
at	B-X
the	B-X
	B-X
-	B-X
150	B-X
site	B-X
may	B-X
reflect	B-X
the	B-X
absence	B-X
or	B-X
inactivity	B-X
of	B-X
a	B-X
required	B-X
factor	B-X
rather	B-X
than	B-X
repression	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
the	B-X
nonconsensus	B-X
	B-X
-	B-X
150	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
to	B-X
a	B-X
consensus	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
,	B-X
or	B-X
insertion	B-X
of	B-X
a	B-X
CD28RE	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
consensus	B-X
site	B-X
upstream	B-X
of	B-X
the	B-X
native	B-X
	B-X
-	B-X
150	B-X
CD28RE	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
restored	B-X
transactivation	B-X
of	B-X
the	B-X
altered	B-X
promoter	B-X
<EOS>	B-X
A	B-X
transcriptional	B-X
block	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
at	B-X
the	B-X
	B-X
-	B-X
150	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
effector	B-X
CD8+	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
CD28+	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
unable	B-X
to	B-X
transcribe	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
antigenic	B-X
stimulation	B-X
had	B-X
a	B-X
block	B-X
in	B-X
transactivation	B-X
of	B-X
the	B-X
	B-X
-	B-X
150	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
but	B-X
did	B-X
transactivate	B-X
the	B-X
composite	B-X
NFAT	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
OCT	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
sites	B-X
,	B-X
and	B-X
a	B-X
consensus	B-X
AP	B-X
-	B-X
1	B-X
motif	B-X

Stem	B-protein
cell	I-protein
factor	I-protein
and	O
interleukin-3	B-protein
induce	O
stepwise	O
generation	O
of	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
from	O
a	O
basic	O
fibroblast	B-protein
growth	I-protein
factor	I-protein
-dependent	O
hematopoietic	B-cell_line
stem	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
A-6	I-cell_line
.	O
<EOS>	B-X
Stem	B-X
cell	B-X
factor	B-X
and	B-X
interleukin	B-X
-	B-X
3	B-X
induce	B-X
stepwise	B-X
generation	B-X
of	B-X
erythroid	B-X
precursor	B-X
cells	B-X
from	B-X
a	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
-	B-X
dependent	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X
,	B-X
A	B-X
-	B-X
6	B-X
.	B-X
<EOS>	B-X
SCF	B-X
and	B-X
IL	B-X
-	B-X
3	B-X
induced	B-X
stepwise	B-X
generation	B-X
of	B-X
erythroid	B-X
precursor	B-X
cells	B-X
from	B-X
an	B-X
A	B-X
-	B-X
6	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X
<EOS>	B-X
A	B-X
multipotent	B-X
immature	B-X
myeloid	B-X
cell	B-X
population	B-X
was	B-X
produced	B-X
from	B-X
a	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
bFGF	B-X
)	B-X
	B-X
-	B-X
dependent	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X
,	B-X
A	B-X
-	B-X
6	B-X
,	B-X
when	B-X
cultured	B-X
with	B-X
stem	B-X
cell	B-X
factor	B-X
(	B-X
SCF	B-X
)	B-X
replacing	B-X
bFGF	B-X
<EOS>	B-X
The	B-X
quantitative	B-X
analysis	B-X
showed	B-X
that	B-X
erythroid	B-X
precursor	B-X
cells	B-X
were	B-X
newly	B-X
produced	B-X
from	B-X
the	B-X
immature	B-X
myeloid	B-X
cells	B-X
by	B-X
cultivation	B-X
with	B-X
IL	B-X
-	B-X
3	B-X

A	O
m	O
ultipotent	B-cell_type
immature	I-cell_type
myeloid	I-cell_type
cell	I-cell_type
population	I-cell_type
was	O
produced	O
from	O
a	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
(	O
bFGF	B-protein
)	O
-dependent	O
hematopoietic	B-cell_line
stem	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
A-6	I-cell_line
,	O
when	O
cultured	O
with	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
replacing	O
bFGF	B-protein
.	O

Those	O
cells	O
were	O
positive	O
for	O
stem	B-protein
cell	I-protein
markers	I-protein
,	O
c-kit	B-protein
and	O
CD34	B-protein
,	O
and	O
a	O
myeloid	B-protein
cell	I-protein
marker	I-protein
,	I-protein
F4/80	I-protein
.	O

Some	O
cell	O
fractions	O
were	O
also	O
positive	O
for	O
Mac-1	B-protein
,	I-protein
a	I-protein
macrophage	I-protein
marker	I-protein
or	O
Gr-1	B-protein
,	I-protein
a	I-protein
granulocytic	I-protein
maker	I-protein
,	O
but	O
negative	O
for	O
an	O
erythroid	B-protein
marker	I-protein
TER119	I-protein
.	O
<EOS>	B-X
Some	B-X
cell	B-X
fractions	B-X
were	B-X
also	B-X
positive	B-X
for	B-X
Mac	B-X
-	B-X
1	B-X
,	B-X
a	B-X
macrophage	B-X
marker	B-X
or	B-X
Gr	B-X
-	B-X
1	B-X
,	B-X
a	B-X
granulocytic	B-X
maker	B-X
,	B-X
but	B-X
negative	B-X
for	B-X
an	B-X
erythroid	B-X
marker	B-X
TER119	B-X
<EOS>	B-X
Motile	B-X
HML	B-X
were	B-X
positive	B-X
for	B-X
a	B-X
specific	B-X
macrophage	B-X
marker	B-X
(	B-X
cathepsin	B-X
B	B-X
)	B-X
and	B-X
a	B-X
neutrophil	B-X
and	B-X
monocyte	B-X
marker	B-X
(	B-X
Mac	B-X
-	B-X
1	B-X
)	B-X
but	B-X
were	B-X
negative	B-X
for	B-X
specific	B-X
neutrophil	B-X
(	B-X
cathepsin	B-X
G	B-X
)	B-X
or	B-X
lymphocyte	B-X
markers	B-X
(	B-X
CD3	B-X
and	B-X
CD5	B-X
)	B-X
<EOS>	B-X
Those	B-X
cells	B-X
were	B-X
positive	B-X
for	B-X
stem	B-X
cell	B-X
markers	B-X
,	B-X
c	B-X
-	B-X
kit	B-X
and	B-X
CD34	B-X
,	B-X
and	B-X
a	B-X
myeloid	B-X
cell	B-X
marker	B-X
,	B-X
F4	B-X
/	B-X
80	B-X
<EOS>	B-X
KUP5	B-X
cells	B-X
are	B-X
immunocytochemically	B-X
positive	B-X
for	B-X
mouse	B-X
macrophage	B-X
markers	B-X
,	B-X
such	B-X
as	B-X
Mac	B-X
-	B-X
1	B-X
,	B-X
F4	B-X
/	B-X
80	B-X

They	O
also	O
showed	O
the	O
expression	O
of	O
mRNA	O
for	O
the	O
myeloid-specific	B-protein
PU.1	I-protein
but	O
did	O
not	O
that	O
for	O
the	O
erythroid-specific	B-protein
GATA-1	I-protein
.	O
<EOS>	B-X
1	B-X
and	B-X
C	B-X
/	B-X
EBP	B-X
alpha	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
myeloid	B-X
-	B-X
specific	B-X
genes	B-X
and	B-X
neutrophil	B-X
development	B-X
<EOS>	B-X
The	B-X
proto	B-X
-	B-X
oncogene	B-X
PU.1	B-X
regulates	B-X
expression	B-X
of	B-X
the	B-X
myeloid	B-X
-	B-X
specific	B-X
CD11b	B-X
promoter	B-X
.	B-X
<EOS>	B-X
1	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
ets	B-X
family	B-X
of	B-X
genes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
sequences	B-X
described	B-X
in	B-X
other	B-X
myeloid	B-X
-	B-X
specific	B-X
promoters	B-X
<EOS>	B-X
The	B-X
Sp1	B-X
transcription	B-X
factor	B-X
binds	B-X
the	B-X
CD11b	B-X
promoter	B-X
specifically	B-X
in	B-X
myeloid	B-X
cells	B-X
in	B-X
vivo	B-X
and	B-X
is	B-X
essential	B-X
for	B-X
myeloid	B-X
-	B-X
specific	B-X
promoter	B-X
activity	B-X
.	B-X

Among	O
various	O
cytokines	B-protein
,	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
induced	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
that	O
expressed	O
the	O
erythroid-specific	B-protein
GATA-1	I-protein
and	O
beta-major	B-protein
globin	I-protein
.	O
<EOS>	B-X
Among	B-X
various	B-X
cytokines	B-X
,	B-X
interleukin	B-X
-	B-X
3	B-X
(	B-X
IL	B-X
-	B-X
3	B-X
)	B-X
induced	B-X
erythroid	B-X
precursor	B-X
cells	B-X
that	B-X
expressed	B-X
the	B-X
erythroid	B-X
-	B-X
specific	B-X
GATA	B-X
-	B-X
1	B-X
and	B-X
beta	B-X
-	B-X
major	B-X
globin	B-X
<EOS>	B-X
SCF	B-X
and	B-X
IL	B-X
-	B-X
3	B-X
induced	B-X
stepwise	B-X
generation	B-X
of	B-X
erythroid	B-X
precursor	B-X
cells	B-X
from	B-X
an	B-X
A	B-X
-	B-X
6	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X
<EOS>	B-X
Stem	B-X
cell	B-X
factor	B-X
and	B-X
interleukin	B-X
-	B-X
3	B-X
induce	B-X
stepwise	B-X
generation	B-X
of	B-X
erythroid	B-X
precursor	B-X
cells	B-X
from	B-X
a	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
-	B-X
dependent	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X
,	B-X
A	B-X
-	B-X
6	B-X
.	B-X
<EOS>	B-X
The	B-X
quantitative	B-X
analysis	B-X
showed	B-X
that	B-X
erythroid	B-X
precursor	B-X
cells	B-X
were	B-X
newly	B-X
produced	B-X
from	B-X
the	B-X
immature	B-X
myeloid	B-X
cells	B-X
by	B-X
cultivation	B-X
with	B-X
IL	B-X
-	B-X
3	B-X

The	O
quantitative	O
analysis	O
showed	O
that	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
were	O
newly	O
produced	O
from	O
the	O
immature	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
by	O
cultivation	O
with	O
IL-3	B-protein
.	O
<EOS>	B-X
The	B-X
quantitative	B-X
analysis	B-X
showed	B-X
that	B-X
erythroid	B-X
precursor	B-X
cells	B-X
were	B-X
newly	B-X
produced	B-X
from	B-X
the	B-X
immature	B-X
myeloid	B-X
cells	B-X
by	B-X
cultivation	B-X
with	B-X
IL	B-X
-	B-X
3	B-X
<EOS>	B-X
Stem	B-X
cell	B-X
factor	B-X
and	B-X
interleukin	B-X
-	B-X
3	B-X
induce	B-X
stepwise	B-X
generation	B-X
of	B-X
erythroid	B-X
precursor	B-X
cells	B-X
from	B-X
a	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
-	B-X
dependent	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X
,	B-X
A	B-X
-	B-X
6	B-X
.	B-X
<EOS>	B-X
They	B-X
also	B-X
showed	B-X
the	B-X
expression	B-X
of	B-X
mRNA	B-X
for	B-X
the	B-X
myeloid	B-X
-	B-X
specific	B-X
PU	B-X
<EOS>	B-X
SCF	B-X
and	B-X
IL	B-X
-	B-X
3	B-X
induced	B-X
stepwise	B-X
generation	B-X
of	B-X
erythroid	B-X
precursor	B-X
cells	B-X
from	B-X
an	B-X
A	B-X
-	B-X
6	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X

SCF	B-protein
and	O
IL-3	B-protein
induced	O
stepwise	O
generation	O
of	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
from	O
an	O
A-6	B-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
<EOS>	B-X
SCF	B-X
and	B-X
IL	B-X
-	B-X
3	B-X
induced	B-X
stepwise	B-X
generation	B-X
of	B-X
erythroid	B-X
precursor	B-X
cells	B-X
from	B-X
an	B-X
A	B-X
-	B-X
6	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X
<EOS>	B-X
Stem	B-X
cell	B-X
factor	B-X
and	B-X
interleukin	B-X
-	B-X
3	B-X
induce	B-X
stepwise	B-X
generation	B-X
of	B-X
erythroid	B-X
precursor	B-X
cells	B-X
from	B-X
a	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
-	B-X
dependent	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
line	B-X
,	B-X
A	B-X
-	B-X
6	B-X
.	B-X
<EOS>	B-X
Among	B-X
various	B-X
cytokines	B-X
,	B-X
interleukin	B-X
-	B-X
3	B-X
(	B-X
IL	B-X
-	B-X
3	B-X
)	B-X
induced	B-X
erythroid	B-X
precursor	B-X
cells	B-X
that	B-X
expressed	B-X
the	B-X
erythroid	B-X
-	B-X
specific	B-X
GATA	B-X
-	B-X
1	B-X
and	B-X
beta	B-X
-	B-X
major	B-X
globin	B-X
<EOS>	B-X
The	B-X
quantitative	B-X
analysis	B-X
showed	B-X
that	B-X
erythroid	B-X
precursor	B-X
cells	B-X
were	B-X
newly	B-X
produced	B-X
from	B-X
the	B-X
immature	B-X
myeloid	B-X
cells	B-X
by	B-X
cultivation	B-X
with	B-X
IL	B-X
-	B-X
3	B-X

Distinct	O
BMI-1	B-protein
and	O
EZH2	B-protein
expression	O
patterns	O
in	O
thymocytes	B-cell_type
and	O
mature	B-cell_type
T	I-cell_type
cells	I-cell_type
suggest	O
a	O
role	O
for	O
Polycomb	B-DNA
genes	I-DNA
in	O
human	O
T	O
cell	O
differentiation	O
.	O

BMI-1	B-protein
and	O
EZH2	B-protein
Polycomb-group	B-protein
(	I-protein
PcG	I-protein
)	I-protein
proteins	I-protein
belong	O
to	O
two	O
distinct	O
protein	O
complexes	O
involved	O
in	O
the	O
regulation	O
of	O
hematopoiesis	O
.	O
<EOS>	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
Polycomb	B-X
-	B-X
group	B-X
(	B-X
PcG	B-X
)	B-X
proteins	B-X
belong	B-X
to	B-X
two	B-X
distinct	B-X
protein	B-X
complexes	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
hematopoiesis	B-X
<EOS>	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
in	B-X
mature	B-X
peripheral	B-X
T	B-X
cells	B-X
is	B-X
mutually	B-X
exclusive	B-X
and	B-X
linked	B-X
to	B-X
proliferation	B-X
status	B-X
,	B-X
and	B-X
that	B-X
this	B-X
pattern	B-X
is	B-X
not	B-X
yet	B-X
established	B-X
in	B-X
thymocytes	B-X
of	B-X
the	B-X
cortex	B-X
and	B-X
medulla	B-X
<EOS>	B-X
Distinct	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
patterns	B-X
in	B-X
thymocytes	B-X
and	B-X
mature	B-X
T	B-X
cells	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
Polycomb	B-X
genes	B-X
in	B-X
human	B-X
T	B-X
cell	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
T	B-X
cell	B-X
stage	B-X
-	B-X
specific	B-X
PcG	B-X
expression	B-X
profiles	B-X
suggest	B-X
that	B-X
PcG	B-X
genes	B-X
contribute	B-X
to	B-X
regulation	B-X
of	B-X
T	B-X
cell	B-X
differentiation	B-X

Using	O
unique	O
PcG-specific	O
antisera	O
and	O
triple	O
immunofluorescence	O
,	O
we	O
found	O
that	O
mature	B-cell_type
resting	I-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
expressed	O
BMI-1	B-protein
,	O
whereas	O
dividing	B-cell_type
blasts	I-cell_type
were	O
EZH2	O
(	O
+	O
)	O
.	O
<EOS>	B-X
Using	B-X
unique	B-X
PcG	B-X
-	B-X
specific	B-X
antisera	B-X
and	B-X
triple	B-X
immunofluorescence	B-X
,	B-X
we	B-X
found	B-X
that	B-X
mature	B-X
resting	B-X
peripheral	B-X
T	B-X
cells	B-X
expressed	B-X
BMI	B-X
-	B-X
1	B-X
,	B-X
whereas	B-X
dividing	B-X
blasts	B-X
were	B-X
EZH2	B-X
(	B-X
+	B-X
)	B-X
<EOS>	B-X
They	B-X
probably	B-X
reflect	B-X
stabilization	B-X
of	B-X
cell	B-X
type	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
and	B-X
irreversibility	B-X
of	B-X
lineage	B-X
choice	B-X
<EOS>	B-X
T	B-X
cell	B-X
stage	B-X
-	B-X
specific	B-X
PcG	B-X
expression	B-X
profiles	B-X
suggest	B-X
that	B-X
PcG	B-X
genes	B-X
contribute	B-X
to	B-X
regulation	B-X
of	B-X
T	B-X
cell	B-X
differentiation	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
subcapsular	B-X
immature	B-X
double	B-X
-	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
(	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
thymus	B-X
coexpressed	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
or	B-X
were	B-X
BMI	B-X
-	B-X
1	B-X
single	B-X
positive	B-X

By	O
contrast	O
,	O
subcapsular	B-cell_type
immature	I-cell_type
double-negative	I-cell_type
(	I-cell_type
DN	I-cell_type
)	I-cell_type
(	I-cell_type
CD4	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
/CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
coexpressed	O
BMI-1	B-protein
and	O
EZH2	B-protein
or	O
were	O
BMI-1	O
single	O
positive	O
.	O
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
subcapsular	B-X
immature	B-X
double	B-X
-	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
(	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
thymus	B-X
coexpressed	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
or	B-X
were	B-X
BMI	B-X
-	B-X
1	B-X
single	B-X
positive	B-X
<EOS>	B-X
Their	B-X
descendants	B-X
,	B-X
double	B-X
-	B-X
positive	B-X
(	B-X
DP	B-X
;	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
)	B-X
cortical	B-X
thymocytes	B-X
,	B-X
expressed	B-X
EZH2	B-X
without	B-X
BMI	B-X
-	B-X
1	B-X
<EOS>	B-X
Maturation	B-X
of	B-X
DP	B-X
cortical	B-X
thymocytes	B-X
to	B-X
single	B-X
-	B-X
positive	B-X
(	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
or	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
medullar	B-X
thymocytes	B-X
correlated	B-X
with	B-X
decreased	B-X
detectability	B-X
of	B-X
EZH2	B-X
and	B-X
continued	B-X
relative	B-X
absence	B-X
of	B-X
BMI	B-X
-	B-X
1	B-X
<EOS>	B-X
The	B-X
SPISE	B-X
index	B-X
correlated	B-X
positively	B-X
with	B-X
the	B-X
insulin	B-X
sensitivity	B-X
index	B-X
(	B-X
ISI	B-X
)	B-X
and	B-X
the	B-X
disposition	B-X
index	B-X
(	B-X
DI	B-X
)	B-X
,	B-X
negatively	B-X
with	B-X
age	B-X
,	B-X
blood	B-X
pressure	B-X
,	B-X
HOMA	B-X
-	B-X
IR	B-X
,	B-X
basal	B-X
and	B-X
120	B-X
min	B-X
blood	B-X
glucose	B-X
and	B-X
insulin	B-X
(	B-X
all	B-X
p	B-X
values	B-X
<	B-X
0	B-X

Their	O
descendants	O
,	O
double-positive	B-cell_type
(	I-cell_type
DP	I-cell_type
;	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
/CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	I-cell_type
cortical	I-cell_type
thymocytes	I-cell_type
,	O
expressed	O
EZH2	B-protein
without	O
BMI-1	B-protein
.	O
<EOS>	B-X
Their	B-X
descendants	B-X
,	B-X
double	B-X
-	B-X
positive	B-X
(	B-X
DP	B-X
;	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
)	B-X
cortical	B-X
thymocytes	B-X
,	B-X
expressed	B-X
EZH2	B-X
without	B-X
BMI	B-X
-	B-X
1	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
subcapsular	B-X
immature	B-X
double	B-X
-	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
(	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
thymus	B-X
coexpressed	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
or	B-X
were	B-X
BMI	B-X
-	B-X
1	B-X
single	B-X
positive	B-X
<EOS>	B-X
Maturation	B-X
of	B-X
DP	B-X
cortical	B-X
thymocytes	B-X
to	B-X
single	B-X
-	B-X
positive	B-X
(	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
or	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
medullar	B-X
thymocytes	B-X
correlated	B-X
with	B-X
decreased	B-X
detectability	B-X
of	B-X
EZH2	B-X
and	B-X
continued	B-X
relative	B-X
absence	B-X
of	B-X
BMI	B-X
-	B-X
1	B-X
<EOS>	B-X
Using	B-X
unique	B-X
PcG	B-X
-	B-X
specific	B-X
antisera	B-X
and	B-X
triple	B-X
immunofluorescence	B-X
,	B-X
we	B-X
found	B-X
that	B-X
mature	B-X
resting	B-X
peripheral	B-X
T	B-X
cells	B-X
expressed	B-X
BMI	B-X
-	B-X
1	B-X
,	B-X
whereas	B-X
dividing	B-X
blasts	B-X
were	B-X
EZH2	B-X
(	B-X
+	B-X
)	B-X

Most	O
EZH2	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
DN	I-cell_type
and	I-cell_type
DP	I-cell_type
thymocytes	I-cell_type
were	O
dividing	O
,	O
while	O
DN	B-cell_type
BMI-1	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
/EZH2	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
were	O
resting	O
and	O
proliferation	O
was	O
occasionally	O
noted	O
in	O
DN	B-cell_type
BMI-1	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
/EZH2	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Most	B-X
EZH2	B-X
(	B-X
+	B-X
)	B-X
DN	B-X
and	B-X
DP	B-X
thymocytes	B-X
were	B-X
dividing	B-X
,	B-X
while	B-X
DN	B-X
BMI	B-X
-	B-X
1	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
EZH2	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
thymocytes	B-X
were	B-X
resting	B-X
and	B-X
proliferation	B-X
was	B-X
occasionally	B-X
noted	B-X
in	B-X
DN	B-X
BMI	B-X
-	B-X
1	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
EZH2	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
<EOS>	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
in	B-X
mature	B-X
peripheral	B-X
T	B-X
cells	B-X
is	B-X
mutually	B-X
exclusive	B-X
and	B-X
linked	B-X
to	B-X
proliferation	B-X
status	B-X
,	B-X
and	B-X
that	B-X
this	B-X
pattern	B-X
is	B-X
not	B-X
yet	B-X
established	B-X
in	B-X
thymocytes	B-X
of	B-X
the	B-X
cortex	B-X
and	B-X
medulla	B-X
<EOS>	B-X
Distinct	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
patterns	B-X
in	B-X
thymocytes	B-X
and	B-X
mature	B-X
T	B-X
cells	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
Polycomb	B-X
genes	B-X
in	B-X
human	B-X
T	B-X
cell	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
Maturation	B-X
of	B-X
DP	B-X
cortical	B-X
thymocytes	B-X
to	B-X
single	B-X
-	B-X
positive	B-X
(	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
or	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
medullar	B-X
thymocytes	B-X
correlated	B-X
with	B-X
decreased	B-X
detectability	B-X
of	B-X
EZH2	B-X
and	B-X
continued	B-X
relative	B-X
absence	B-X
of	B-X
BMI	B-X
-	B-X
1	B-X

Maturation	O
of	O
DP	B-cell_type
cortical	I-cell_type
thymocytes	I-cell_type
to	O
single-positive	B-cell_type
(	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
/CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
or	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
/CD4	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
)	I-cell_type
medullar	I-cell_type
thymocytes	I-cell_type
correlated	O
with	O
decreased	O
detectability	O
of	O
EZH2	B-protein
and	O
continued	O
relative	O
absence	O
of	O
BMI-1	B-protein
.	O
<EOS>	B-X
Maturation	B-X
of	B-X
DP	B-X
cortical	B-X
thymocytes	B-X
to	B-X
single	B-X
-	B-X
positive	B-X
(	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
or	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
medullar	B-X
thymocytes	B-X
correlated	B-X
with	B-X
decreased	B-X
detectability	B-X
of	B-X
EZH2	B-X
and	B-X
continued	B-X
relative	B-X
absence	B-X
of	B-X
BMI	B-X
-	B-X
1	B-X
<EOS>	B-X
Their	B-X
descendants	B-X
,	B-X
double	B-X
-	B-X
positive	B-X
(	B-X
DP	B-X
;	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
)	B-X
cortical	B-X
thymocytes	B-X
,	B-X
expressed	B-X
EZH2	B-X
without	B-X
BMI	B-X
-	B-X
1	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
subcapsular	B-X
immature	B-X
double	B-X
-	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
(	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
thymus	B-X
coexpressed	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
or	B-X
were	B-X
BMI	B-X
-	B-X
1	B-X
single	B-X
positive	B-X
<EOS>	B-X
Most	B-X
EZH2	B-X
(	B-X
+	B-X
)	B-X
DN	B-X
and	B-X
DP	B-X
thymocytes	B-X
were	B-X
dividing	B-X
,	B-X
while	B-X
DN	B-X
BMI	B-X
-	B-X
1	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
EZH2	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
thymocytes	B-X
were	B-X
resting	B-X
and	B-X
proliferation	B-X
was	B-X
occasionally	B-X
noted	B-X
in	B-X
DN	B-X
BMI	B-X
-	B-X
1	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
EZH2	B-X
(	B-X
+	B-X
)	B-X
cells	B-X

Our	O
data	O
show	O
that	O
BMI-1	B-protein
and	O
EZH2	B-protein
expression	O
in	O
mature	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
mutually	O
exclusive	O
and	O
linked	O
to	O
proliferation	O
status	O
,	O
and	O
that	O
this	O
pattern	O
is	O
not	O
yet	O
established	O
in	O
thymocytes	B-cell_type
of	O
the	O
cortex	O
and	O
medulla	O
.	O

T	B-cell_type
cell	I-cell_type
stage-specific	O
PcG	O
expression	O
profiles	O
suggest	O
that	O
PcG	B-DNA
genes	I-DNA
contribute	O
to	O
regulation	O
of	O
T	O
cell	O
differentiation	O
.	O
<EOS>	B-X
T	B-X
cell	B-X
stage	B-X
-	B-X
specific	B-X
PcG	B-X
expression	B-X
profiles	B-X
suggest	B-X
that	B-X
PcG	B-X
genes	B-X
contribute	B-X
to	B-X
regulation	B-X
of	B-X
T	B-X
cell	B-X
differentiation	B-X
<EOS>	B-X
Distinct	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
patterns	B-X
in	B-X
thymocytes	B-X
and	B-X
mature	B-X
T	B-X
cells	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
Polycomb	B-X
genes	B-X
in	B-X
human	B-X
T	B-X
cell	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
The	B-X
difference	B-X
in	B-X
PcG	B-X
expression	B-X
between	B-X
medullar	B-X
thymocytes	B-X
and	B-X
mature	B-X
interfollicular	B-X
T	B-X
cells	B-X
indicates	B-X
that	B-X
additional	B-X
maturation	B-X
processes	B-X
occur	B-X
after	B-X
thymocyte	B-X
transportation	B-X
from	B-X
the	B-X
thymus	B-X
<EOS>	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
in	B-X
mature	B-X
peripheral	B-X
T	B-X
cells	B-X
is	B-X
mutually	B-X
exclusive	B-X
and	B-X
linked	B-X
to	B-X
proliferation	B-X
status	B-X
,	B-X
and	B-X
that	B-X
this	B-X
pattern	B-X
is	B-X
not	B-X
yet	B-X
established	B-X
in	B-X
thymocytes	B-X
of	B-X
the	B-X
cortex	B-X
and	B-X
medulla	B-X

They	O
probably	O
reflect	O
stabilization	O
of	O
cell	O
type-specific	O
gene	O
expression	O
and	O
irreversibility	O
of	O
lineage	O
choice	O
.	O
<EOS>	B-X
They	B-X
probably	B-X
reflect	B-X
stabilization	B-X
of	B-X
cell	B-X
type	B-X
-	B-X
specific	B-X
gene	B-X
expression	B-X
and	B-X
irreversibility	B-X
of	B-X
lineage	B-X
choice	B-X
<EOS>	B-X
By	B-X
contrast	B-X
,	B-X
subcapsular	B-X
immature	B-X
double	B-X
-	B-X
negative	B-X
(	B-X
DN	B-X
)	B-X
(	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
thymus	B-X
coexpressed	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
or	B-X
were	B-X
BMI	B-X
-	B-X
1	B-X
single	B-X
positive	B-X
<EOS>	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
in	B-X
mature	B-X
peripheral	B-X
T	B-X
cells	B-X
is	B-X
mutually	B-X
exclusive	B-X
and	B-X
linked	B-X
to	B-X
proliferation	B-X
status	B-X
,	B-X
and	B-X
that	B-X
this	B-X
pattern	B-X
is	B-X
not	B-X
yet	B-X
established	B-X
in	B-X
thymocytes	B-X
of	B-X
the	B-X
cortex	B-X
and	B-X
medulla	B-X
<EOS>	B-X
Maturation	B-X
of	B-X
DP	B-X
cortical	B-X
thymocytes	B-X
to	B-X
single	B-X
-	B-X
positive	B-X
(	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD8	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
or	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
	B-X
/	B-X
CD4	B-X
(	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
medullar	B-X
thymocytes	B-X
correlated	B-X
with	B-X
decreased	B-X
detectability	B-X
of	B-X
EZH2	B-X
and	B-X
continued	B-X
relative	B-X
absence	B-X
of	B-X
BMI	B-X
-	B-X
1	B-X

The	O
difference	O
in	O
PcG	O
expression	O
between	O
medullar	B-cell_type
thymocytes	I-cell_type
and	O
mature	B-cell_type
interfollicular	I-cell_type
T	I-cell_type
cells	I-cell_type
indicates	O
that	O
additional	O
maturation	O
processes	O
occur	O
after	O
thymocyte	O
transportation	O
from	O
the	O
thymus	O
.	O
<EOS>	B-X
The	B-X
difference	B-X
in	B-X
PcG	B-X
expression	B-X
between	B-X
medullar	B-X
thymocytes	B-X
and	B-X
mature	B-X
interfollicular	B-X
T	B-X
cells	B-X
indicates	B-X
that	B-X
additional	B-X
maturation	B-X
processes	B-X
occur	B-X
after	B-X
thymocyte	B-X
transportation	B-X
from	B-X
the	B-X
thymus	B-X
<EOS>	B-X
Distinct	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
patterns	B-X
in	B-X
thymocytes	B-X
and	B-X
mature	B-X
T	B-X
cells	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
Polycomb	B-X
genes	B-X
in	B-X
human	B-X
T	B-X
cell	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
T	B-X
cell	B-X
stage	B-X
-	B-X
specific	B-X
PcG	B-X
expression	B-X
profiles	B-X
suggest	B-X
that	B-X
PcG	B-X
genes	B-X
contribute	B-X
to	B-X
regulation	B-X
of	B-X
T	B-X
cell	B-X
differentiation	B-X
<EOS>	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
BMI	B-X
-	B-X
1	B-X
and	B-X
EZH2	B-X
expression	B-X
in	B-X
mature	B-X
peripheral	B-X
T	B-X
cells	B-X
is	B-X
mutually	B-X
exclusive	B-X
and	B-X
linked	B-X
to	B-X
proliferation	B-X
status	B-X
,	B-X
and	B-X
that	B-X
this	B-X
pattern	B-X
is	B-X
not	B-X
yet	B-X
established	B-X
in	B-X
thymocytes	B-X
of	B-X
the	B-X
cortex	B-X
and	B-X
medulla	B-X

Stepwise	O
lineage	O
restriction	O
of	O
progenitors	B-cell_type
in	O
lympho-myelopoiesis	O
.	O
<EOS>	B-X
Stepwise	B-X
lineage	B-X
restriction	B-X
of	B-X
progenitors	B-X
in	B-X
lympho	B-X
-	B-X
myelopoiesis	B-X
.	B-X
<EOS>	B-X
By	B-X
extending	B-X
the	B-X
area	B-X
of	B-X
investigation	B-X
to	B-X
include	B-X
the	B-X
erythroid	B-X
lineage	B-X
,	B-X
more	B-X
convincing	B-X
evidence	B-X
for	B-X
the	B-X
ordered	B-X
process	B-X
was	B-X
obtained	B-X
<EOS>	B-X
Among	B-X
these	B-X
seven	B-X
types	B-X
,	B-X
the	B-X
p	B-X
-	B-X
TB	B-X
type	B-X
progenitor	B-X
was	B-X
found	B-X
to	B-X
be	B-X
absent	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
process	B-X
of	B-X
lineage	B-X
commitment	B-X
proceeds	B-X
through	B-X
an	B-X
ordered	B-X
but	B-X
not	B-X
random	B-X
process	B-X

It	O
has	O
long	O
been	O
controversial	O
whether	O
hematopoiesis	O
progresses	O
through	O
ordered	O
stages	O
of	O
determination	O
as	O
in	O
embryonic	O
development	O
.	O
<EOS>	B-X
It	B-X
has	B-X
long	B-X
been	B-X
controversial	B-X
whether	B-X
hematopoiesis	B-X
progresses	B-X
through	B-X
ordered	B-X
stages	B-X
of	B-X
determination	B-X
as	B-X
in	B-X
embryonic	B-X
development	B-X
<EOS>	B-X
Detailed	B-X
and	B-X
exact	B-X
illustration	B-X
of	B-X
the	B-X
process	B-X
of	B-X
hematopoiesis	B-X
will	B-X
provide	B-X
an	B-X
opportunity	B-X
to	B-X
revive	B-X
hematopoiesis	B-X
as	B-X
one	B-X
of	B-X
the	B-X
most	B-X
fascinating	B-X
targets	B-X
of	B-X
research	B-X
in	B-X
developmental	B-X
biology	B-X
<EOS>	B-X
Among	B-X
these	B-X
seven	B-X
types	B-X
,	B-X
the	B-X
p	B-X
-	B-X
TB	B-X
type	B-X
progenitor	B-X
was	B-X
found	B-X
to	B-X
be	B-X
absent	B-X
<EOS>	B-X
The	B-X
multilineage	B-X
progenitor	B-X
(	B-X
MLP	B-X
)	B-X
assay	B-X
enabled	B-X
us	B-X
to	B-X
discriminate	B-X
among	B-X
seven	B-X
types	B-X
of	B-X
hematopoietic	B-X
progenitors	B-X
,	B-X
which	B-X
are	B-X
multipotent	B-X
progenitor	B-X
p	B-X
-	B-X
MTB	B-X
(	B-X
capable	B-X
of	B-X
generating	B-X
myeloid	B-X
,	B-X
T	B-X
and	B-X
B	B-X
cells	B-X
)	B-X
,	B-X
bipotent	B-X
progenitors	B-X
p	B-X
-	B-X
MT	B-X
,	B-X
p	B-X
-	B-X
MB	B-X
and	B-X
p	B-X
-	B-X
TB	B-X
,	B-X
and	B-X
unipotent	B-X
progenitors	B-X
p	B-X
-	B-X
M	B-X
,	B-X
p	B-X
-	B-X
T	B-X
and	B-X
p	B-X
-	B-X
B	B-X

This	O
is	O
due	O
to	O
the	O
absence	O
of	O
a	O
methodology	O
capable	O
of	O
exactly	O
determining	O
the	O
developmental	O
potential	O
of	O
hematopoietic	B-cell_type
stem/progenitor	I-cell_type
cells	I-cell_type
.	O

The	O
multilineage	O
progenitor	O
(	O
MLP	O
)	O
assay	O
enabled	O
us	O
to	O
discriminate	O
among	O
seven	O
types	O
of	O
hematopoietic	O
progenitors	O
,	O
which	O
are	O
multipotent	O
progenitor	O
p-MTB	O
(	O
capable	O
of	O
generating	O
myeloid	B-cell_type
,	I-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
)	O
,	O
bipotent	O
progenitors	O
p-MT	O
,	O
p-MB	O
and	O
p-TB	O
,	O
and	O
unipotent	O
progenitors	O
p-M	O
,	O
p-T	O
and	O
p-B	O
.	O

Among	O
these	O
seven	O
types	O
,	O
the	O
p-TB	O
type	O
progenitor	O
was	O
found	O
to	O
be	O
absent	O
.	O
<EOS>	B-X
Among	B-X
these	B-X
seven	B-X
types	B-X
,	B-X
the	B-X
p	B-X
-	B-X
TB	B-X
type	B-X
progenitor	B-X
was	B-X
found	B-X
to	B-X
be	B-X
absent	B-X
<EOS>	B-X
Stepwise	B-X
lineage	B-X
restriction	B-X
of	B-X
progenitors	B-X
in	B-X
lympho	B-X
-	B-X
myelopoiesis	B-X
.	B-X
<EOS>	B-X
By	B-X
extending	B-X
the	B-X
area	B-X
of	B-X
investigation	B-X
to	B-X
include	B-X
the	B-X
erythroid	B-X
lineage	B-X
,	B-X
more	B-X
convincing	B-X
evidence	B-X
for	B-X
the	B-X
ordered	B-X
process	B-X
was	B-X
obtained	B-X
<EOS>	B-X
It	B-X
has	B-X
long	B-X
been	B-X
controversial	B-X
whether	B-X
hematopoiesis	B-X
progresses	B-X
through	B-X
ordered	B-X
stages	B-X
of	B-X
determination	B-X
as	B-X
in	B-X
embryonic	B-X
development	B-X

These	O
findings	O
indicate	O
that	O
the	O
process	O
of	O
lineage	O
commitment	O
proceeds	O
through	O
an	O
ordered	O
but	O
not	O
random	O
process	O
.	O

By	O
extending	O
the	O
area	O
of	O
investigation	O
to	O
include	O
the	O
erythroid	B-cell_type
lineage	I-cell_type
,	O
more	O
convincing	O
evidence	O
for	O
the	O
ordered	O
process	O
was	O
obtained	O
.	O
<EOS>	B-X
By	B-X
extending	B-X
the	B-X
area	B-X
of	B-X
investigation	B-X
to	B-X
include	B-X
the	B-X
erythroid	B-X
lineage	B-X
,	B-X
more	B-X
convincing	B-X
evidence	B-X
for	B-X
the	B-X
ordered	B-X
process	B-X
was	B-X
obtained	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
process	B-X
of	B-X
lineage	B-X
commitment	B-X
proceeds	B-X
through	B-X
an	B-X
ordered	B-X
but	B-X
not	B-X
random	B-X
process	B-X
<EOS>	B-X
Detailed	B-X
and	B-X
exact	B-X
illustration	B-X
of	B-X
the	B-X
process	B-X
of	B-X
hematopoiesis	B-X
will	B-X
provide	B-X
an	B-X
opportunity	B-X
to	B-X
revive	B-X
hematopoiesis	B-X
as	B-X
one	B-X
of	B-X
the	B-X
most	B-X
fascinating	B-X
targets	B-X
of	B-X
research	B-X
in	B-X
developmental	B-X
biology	B-X
<EOS>	B-X
Among	B-X
these	B-X
seven	B-X
types	B-X
,	B-X
the	B-X
p	B-X
-	B-X
TB	B-X
type	B-X
progenitor	B-X
was	B-X
found	B-X
to	B-X
be	B-X
absent	B-X

Detailed	O
and	O
exact	O
illustration	O
of	O
the	O
process	O
of	O
hematopoiesis	O
will	O
provide	O
an	O
opportunity	O
to	O
revive	O
hematopoiesis	O
as	O
one	O
of	O
the	O
most	O
fascinating	O
targets	O
of	O
research	O
in	O
developmental	O
biology	O
<EOS>	B-X
Detailed	B-X
and	B-X
exact	B-X
illustration	B-X
of	B-X
the	B-X
process	B-X
of	B-X
hematopoiesis	B-X
will	B-X
provide	B-X
an	B-X
opportunity	B-X
to	B-X
revive	B-X
hematopoiesis	B-X
as	B-X
one	B-X
of	B-X
the	B-X
most	B-X
fascinating	B-X
targets	B-X
of	B-X
research	B-X
in	B-X
developmental	B-X
biology	B-X
<EOS>	B-X
It	B-X
has	B-X
long	B-X
been	B-X
controversial	B-X
whether	B-X
hematopoiesis	B-X
progresses	B-X
through	B-X
ordered	B-X
stages	B-X
of	B-X
determination	B-X
as	B-X
in	B-X
embryonic	B-X
development	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
process	B-X
of	B-X
lineage	B-X
commitment	B-X
proceeds	B-X
through	B-X
an	B-X
ordered	B-X
but	B-X
not	B-X
random	B-X
process	B-X
<EOS>	B-X
By	B-X
extending	B-X
the	B-X
area	B-X
of	B-X
investigation	B-X
to	B-X
include	B-X
the	B-X
erythroid	B-X
lineage	B-X
,	B-X
more	B-X
convincing	B-X
evidence	B-X
for	B-X
the	B-X
ordered	B-X
process	B-X
was	B-X
obtained	B-X

Epstein-Barr	O
Virus	O
and	O
its	O
glycoprotein-350	B-protein
upregulate	O
IL-6	B-protein
in	O
human	B-cell_type
B-lymphocytes	I-cell_type
via	O
CD21	B-protein
,	O
involving	O
activation	O
of	O
NF-kappaB	B-protein
and	O
different	O
signaling	O
pathways	O
.	O
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
Virus	B-X
and	B-X
its	B-X
glycoprotein	B-X
-	B-X
350	B-X
upregulate	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
human	B-X
B	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD21	B-X
,	B-X
involving	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
different	B-X
signaling	B-X
pathways	B-X
.	B-X
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
a	B-X
ubiquitous	B-X
and	B-X
highly	B-X
immunotropic	B-X
gamma	B-X
herpesvirus	B-X
that	B-X
infects	B-X
more	B-X
than	B-X
90	B-X
%	B-X
of	B-X
humans	B-X
worldwide	B-X
<EOS>	B-X
To	B-X
our	B-X
knowledge	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
showing	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
herpesvirus	B-X
envelope	B-X
glycoprotein	B-X
to	B-X
CR2	B-X
on	B-X
human	B-X
B	B-X
cells	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
leading	B-X
to	B-X
the	B-X
upregulation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
in	B-X
these	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
now	B-X
show	B-X
that	B-X
while	B-X
both	B-X
purified	B-X
recombinant	B-X
gp350	B-X
(	B-X
rgp350	B-X
)	B-X
and	B-X
EBV	B-X
upregulate	B-X
IL	B-X
-	B-X
6	B-X
mRNA	B-X
synthesis	B-X
in	B-X
B	B-X
cells	B-X
,	B-X
EBV	B-X
-	B-X
induced	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
activation	B-X
occurs	B-X
for	B-X
a	B-X
significantly	B-X
longer	B-X
period	B-X
of	B-X
time	B-X
(	B-X
i	B-X

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
ubiquitous	O
and	O
highly	O
immunotropic	O
gamma	O
herpesvirus	O
that	O
infects	O
more	O
than	O
90	O
%	O
of	O
humans	O
worldwide	O
.	O
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
a	B-X
ubiquitous	B-X
and	B-X
highly	B-X
immunotropic	B-X
gamma	B-X
herpesvirus	B-X
that	B-X
infects	B-X
more	B-X
than	B-X
90	B-X
%	B-X
of	B-X
humans	B-X
worldwide	B-X
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
Virus	B-X
and	B-X
its	B-X
glycoprotein	B-X
-	B-X
350	B-X
upregulate	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
human	B-X
B	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD21	B-X
,	B-X
involving	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
different	B-X
signaling	B-X
pathways	B-X
.	B-X
<EOS>	B-X
We	B-X
had	B-X
previously	B-X
shown	B-X
that	B-X
EBV	B-X
is	B-X
capable	B-X
of	B-X
modulating	B-X
the	B-X
synthesis	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cytokines	B-X
<EOS>	B-X
EBV	B-X
utilizes	B-X
CD21	B-X
/	B-X
CR2	B-X
as	B-X
its	B-X
receptor	B-X
on	B-X
B	B-X
cells	B-X
to	B-X
initiate	B-X
the	B-X
infection	B-X
process	B-X

Its	O
pathogenicity	O
leads	O
to	O
a	O
number	O
of	O
diseases	O
including	O
tumors	O
that	O
result	O
from	O
EBV	O
's	O
ability	O
to	O
readily	O
transform	O
B-lymphocytes	B-cell_type
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
epithelial	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Its	B-X
pathogenicity	B-X
leads	B-X
to	B-X
a	B-X
number	B-X
of	B-X
diseases	B-X
including	B-X
tumors	B-X
that	B-X
result	B-X
from	B-X
EBV	B-X
's	B-X
ability	B-X
to	B-X
readily	B-X
transform	B-X
B	B-X
-	B-X
lymphocytes	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
epithelial	B-X
cells	B-X
<EOS>	B-X
We	B-X
had	B-X
previously	B-X
shown	B-X
that	B-X
EBV	B-X
is	B-X
capable	B-X
of	B-X
modulating	B-X
the	B-X
synthesis	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cytokines	B-X
<EOS>	B-X
To	B-X
our	B-X
knowledge	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
showing	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
herpesvirus	B-X
envelope	B-X
glycoprotein	B-X
to	B-X
CR2	B-X
on	B-X
human	B-X
B	B-X
cells	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
leading	B-X
to	B-X
the	B-X
upregulation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
in	B-X
these	B-X
lymphocytes	B-X
<EOS>	B-X
EBV	B-X
utilizes	B-X
CD21	B-X
/	B-X
CR2	B-X
as	B-X
its	B-X
receptor	B-X
on	B-X
B	B-X
cells	B-X
to	B-X
initiate	B-X
the	B-X
infection	B-X
process	B-X

EBV	O
utilizes	O
CD21/CR2	B-protein
as	O
its	O
receptor	O
on	O
B	B-cell_type
cells	I-cell_type
to	O
initiate	O
the	O
infection	O
process	O
.	O

EBV	O
binds	O
to	O
CR2	B-protein
through	O
its	O
major	B-protein
envelope	I-protein
glycoprotein-350	I-protein
(	O
gp350	B-protein
)	O
and	O
is	O
also	O
a	O
remarkable	O
immunomodulating	O
agent	O
.	O
<EOS>	B-X
EBV	B-X
binds	B-X
to	B-X
CR2	B-X
through	B-X
its	B-X
major	B-X
envelope	B-X
glycoprotein	B-X
-	B-X
350	B-X
(	B-X
gp350	B-X
)	B-X
and	B-X
is	B-X
also	B-X
a	B-X
remarkable	B-X
immunomodulating	B-X
agent	B-X
<EOS>	B-X
EBV	B-X
utilizes	B-X
CD21	B-X
/	B-X
CR2	B-X
as	B-X
its	B-X
receptor	B-X
on	B-X
B	B-X
cells	B-X
to	B-X
initiate	B-X
the	B-X
infection	B-X
process	B-X
<EOS>	B-X
To	B-X
our	B-X
knowledge	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
showing	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
herpesvirus	B-X
envelope	B-X
glycoprotein	B-X
to	B-X
CR2	B-X
on	B-X
human	B-X
B	B-X
cells	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
leading	B-X
to	B-X
the	B-X
upregulation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
in	B-X
these	B-X
lymphocytes	B-X
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
Virus	B-X
and	B-X
its	B-X
glycoprotein	B-X
-	B-X
350	B-X
upregulate	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
human	B-X
B	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD21	B-X
,	B-X
involving	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
different	B-X
signaling	B-X
pathways	B-X
.	B-X

We	O
had	O
previously	O
shown	O
that	O
EBV	O
is	O
capable	O
of	O
modulating	O
the	O
synthesis	O
of	O
a	O
number	O
of	O
cytokines	B-protein
.	O
<EOS>	B-X
We	B-X
had	B-X
previously	B-X
shown	B-X
that	B-X
EBV	B-X
is	B-X
capable	B-X
of	B-X
modulating	B-X
the	B-X
synthesis	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cytokines	B-X
<EOS>	B-X
12	B-X
hours	B-X
for	B-X
EBV	B-X
as	B-X
compared	B-X
to	B-X
6	B-X
hours	B-X
for	B-X
rgp350	B-X
)	B-X
<EOS>	B-X
Its	B-X
pathogenicity	B-X
leads	B-X
to	B-X
a	B-X
number	B-X
of	B-X
diseases	B-X
including	B-X
tumors	B-X
that	B-X
result	B-X
from	B-X
EBV	B-X
's	B-X
ability	B-X
to	B-X
readily	B-X
transform	B-X
B	B-X
-	B-X
lymphocytes	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
epithelial	B-X
cells	B-X
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
a	B-X
ubiquitous	B-X
and	B-X
highly	B-X
immunotropic	B-X
gamma	B-X
herpesvirus	B-X
that	B-X
infects	B-X
more	B-X
than	B-X
90	B-X
%	B-X
of	B-X
humans	B-X
worldwide	B-X

We	O
now	O
show	O
that	O
while	O
both	O
purified	O
recombinant	B-protein
gp350	I-protein
(	O
rgp350	B-protein
)	O
and	O
EBV	O
upregulate	O
IL-6	B-RNA
mRNA	I-RNA
synthesis	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
EBV-induced	O
IL-6	O
gene	O
activation	O
occurs	O
for	O
a	O
significantly	O
longer	O
period	O
of	O
time	O
(	O
i.e.	O
12	O
hours	O
for	O
EBV	O
as	O
compared	O
to	O
6	O
hours	O
for	O
rgp350	B-protein
)	O
.	O

Moreover	O
,	O
the	O
half-life	O
of	O
EBV-induced	O
IL-6	B-RNA
mRNA	I-RNA
was	O
also	O
significantly	O
longer	O
(	O
10	O
hours	O
)	O
than	O
that	O
of	O
mRNA	O
induced	O
by	O
rgp350	B-protein
(	O
about	O
6	O
hours	O
)	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
half	B-X
-	B-X
life	B-X
of	B-X
EBV	B-X
-	B-X
induced	B-X
IL	B-X
-	B-X
6	B-X
mRNA	B-X
was	B-X
also	B-X
significantly	B-X
longer	B-X
(	B-X
10	B-X
hours	B-X
)	B-X
than	B-X
that	B-X
of	B-X
mRNA	B-X
induced	B-X
by	B-X
rgp350	B-X
(	B-X
about	B-X
6	B-X
hours	B-X
)	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
while	B-X
the	B-X
activation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
by	B-X
gp350	B-X
is	B-X
mediated	B-X
primarily	B-X
by	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
pathway	B-X
,	B-X
EBV	B-X
can	B-X
mediate	B-X
its	B-X
effects	B-X
through	B-X
multiple	B-X
signaling	B-X
pathways	B-X
<EOS>	B-X
We	B-X
now	B-X
show	B-X
that	B-X
while	B-X
both	B-X
purified	B-X
recombinant	B-X
gp350	B-X
(	B-X
rgp350	B-X
)	B-X
and	B-X
EBV	B-X
upregulate	B-X
IL	B-X
-	B-X
6	B-X
mRNA	B-X
synthesis	B-X
in	B-X
B	B-X
cells	B-X
,	B-X
EBV	B-X
-	B-X
induced	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
activation	B-X
occurs	B-X
for	B-X
a	B-X
significantly	B-X
longer	B-X
period	B-X
of	B-X
time	B-X
(	B-X
i	B-X
<EOS>	B-X
EBV	B-X
utilizes	B-X
CD21	B-X
/	B-X
CR2	B-X
as	B-X
its	B-X
receptor	B-X
on	B-X
B	B-X
cells	B-X
to	B-X
initiate	B-X
the	B-X
infection	B-X
process	B-X

Both	O
EBV	O
and	O
gp350	B-protein
enhance	O
the	O
binding	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
,	O
as	O
determined	O
by	O
band-shift	O
and	O
augment	O
NF-kappaB	B-protein
-mediated	O
activation	O
of	O
a	O
CAT	B-DNA
reporter	I-DNA
plasmid	I-DNA
.	O
<EOS>	B-X
Both	B-X
EBV	B-X
and	B-X
gp350	B-X
enhance	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
band	B-X
-	B-X
shift	B-X
and	B-X
augment	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
a	B-X
CAT	B-X
reporter	B-X
plasmid	B-X
<EOS>	B-X
To	B-X
our	B-X
knowledge	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
showing	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
herpesvirus	B-X
envelope	B-X
glycoprotein	B-X
to	B-X
CR2	B-X
on	B-X
human	B-X
B	B-X
cells	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
leading	B-X
to	B-X
the	B-X
upregulation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
in	B-X
these	B-X
lymphocytes	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
while	B-X
the	B-X
activation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
by	B-X
gp350	B-X
is	B-X
mediated	B-X
primarily	B-X
by	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
pathway	B-X
,	B-X
EBV	B-X
can	B-X
mediate	B-X
its	B-X
effects	B-X
through	B-X
multiple	B-X
signaling	B-X
pathways	B-X
<EOS>	B-X
EBV	B-X
binds	B-X
to	B-X
CR2	B-X
through	B-X
its	B-X
major	B-X
envelope	B-X
glycoprotein	B-X
-	B-X
350	B-X
(	B-X
gp350	B-X
)	B-X
and	B-X
is	B-X
also	B-X
a	B-X
remarkable	B-X
immunomodulating	B-X
agent	B-X

Furthermore	O
,	O
we	O
demonstrate	O
that	O
while	O
the	O
activation	O
of	O
IL-6	O
gene	O
expression	O
by	O
gp350	B-protein
is	O
mediated	O
primarily	O
by	O
the	O
protein	O
kinase	O
C	O
pathway	O
,	O
EBV	O
can	O
mediate	O
its	O
effects	O
through	O
multiple	O
signaling	O
pathways	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
while	B-X
the	B-X
activation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
by	B-X
gp350	B-X
is	B-X
mediated	B-X
primarily	B-X
by	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
pathway	B-X
,	B-X
EBV	B-X
can	B-X
mediate	B-X
its	B-X
effects	B-X
through	B-X
multiple	B-X
signaling	B-X
pathways	B-X
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
Virus	B-X
and	B-X
its	B-X
glycoprotein	B-X
-	B-X
350	B-X
upregulate	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
human	B-X
B	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD21	B-X
,	B-X
involving	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
different	B-X
signaling	B-X
pathways	B-X
.	B-X
<EOS>	B-X
To	B-X
our	B-X
knowledge	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
showing	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
herpesvirus	B-X
envelope	B-X
glycoprotein	B-X
to	B-X
CR2	B-X
on	B-X
human	B-X
B	B-X
cells	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
leading	B-X
to	B-X
the	B-X
upregulation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
in	B-X
these	B-X
lymphocytes	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
half	B-X
-	B-X
life	B-X
of	B-X
EBV	B-X
-	B-X
induced	B-X
IL	B-X
-	B-X
6	B-X
mRNA	B-X
was	B-X
also	B-X
significantly	B-X
longer	B-X
(	B-X
10	B-X
hours	B-X
)	B-X
than	B-X
that	B-X
of	B-X
mRNA	B-X
induced	B-X
by	B-X
rgp350	B-X
(	B-X
about	B-X
6	B-X
hours	B-X
)	B-X

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
showing	O
that	O
the	O
binding	O
of	O
a	O
herpesvirus	B-protein
envelope	I-protein
glycoprotein	I-protein
to	O
CR2	B-protein
on	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
results	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
leading	O
to	O
the	O
upregulation	O
of	O
IL-6	O
gene	O
expression	O
in	O
these	O
lymphocytes	B-cell_type
.	O

Gene-	O
and	O
tissue-specificity	O
of	O
mutation	O
in	O
Big	O
Blue	O
rats	O
treated	O
with	O
the	O
hepatocarcinogen	O
N-hydroxy-2-acetylaminofluorene	O
.	O
<EOS>	B-X
Gene	B-X
-	B-X
	B-X
and	B-X
tissue	B-X
-	B-X
specificity	B-X
of	B-X
mutation	B-X
in	B-X
Big	B-X
Blue	B-X
rats	B-X
treated	B-X
with	B-X
the	B-X
hepatocarcinogen	B-X
N	B-X
-	B-X
hydroxy	B-X
-	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
.	B-X
<EOS>	B-X
The	B-X
tissue	B-X
-	B-X
specificity	B-X
of	B-X
the	B-X
mutation	B-X
spectra	B-X
may	B-X
contribute	B-X
to	B-X
targeting	B-X
tumor	B-X
formation	B-X
to	B-X
the	B-X
liver	B-X
<EOS>	B-X
,	B-X
G	B-X
:	B-X
C	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
T	B-X
:	B-X
A	B-X
transversion	B-X
was	B-X
the	B-X
most	B-X
common	B-X
mutation	B-X
in	B-X
all	B-X
mutation	B-X
sets	B-X
)	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
patterns	B-X
of	B-X
basepair	B-X
substitution	B-X
and	B-X
frameshift	B-X
mutation	B-X
between	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
lymphocyte	B-X
lacI	B-X
mutants	B-X
(	B-X
P	B-X
=	B-X
0	B-X
<EOS>	B-X
Also	B-X
,	B-X
multiplex	B-X
PCR	B-X
analysis	B-X
of	B-X
genomic	B-X
DNA	B-X
from	B-X
the	B-X
hprt	B-X
mutants	B-X
indicated	B-X
that	B-X
12	B-X
%	B-X
of	B-X
mutants	B-X
from	B-X
treated	B-X
rats	B-X
had	B-X
major	B-X
deletions	B-X
in	B-X
the	B-X
hprt	B-X
gene	B-X
;	B-X
no	B-X
corresponding	B-X
incidence	B-X
of	B-X
large	B-X
deletions	B-X
was	B-X
evident	B-X
among	B-X
lacI	B-X
mutations	B-X

In	O
a	O
previous	O
study	O
,	O
we	O
found	O
that	O
treating	O
transgenic	O
Big	O
Blue	O
rats	O
with	O
the	O
hepatocarcinogen	O
N-hydroxy-2-acetylaminofluorene	O
(	O
N-OH-AAF	O
)	O
produced	O
the	O
same	O
major	O
DNA	O
adduct	O
in	O
the	O
target	O
liver	O
and	O
the	O
nontarget	B-cell_type
spleen	I-cell_type
lymphocytes	I-cell_type
and	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
induced	O
lacI	B-cell_type
mutants	I-cell_type
in	O
the	O
liver	O
,	O
and	O
induced	O
much	O
lower	O
frequencies	O
of	O
l	O
acI	B-cell_type
and	I-cell_type
hprt	I-cell_type
mutants	I-cell_type
in	O
spleen	B-cell_type
lymphocytes	I-cell_type
.	O

In	O
the	O
present	O
study	O
,	O
sequence	O
analysis	O
was	O
conducted	O
on	O
lacI	B-DNA
DNA	I-DNA
and	O
hprt	B-DNA
cDNA	I-DNA
from	O
the	O
mutants	O
,	O
to	O
determine	O
the	O
mutational	O
specificity	O
of	O
N-OH-AAF	O
in	O
the	O
rat	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
sequence	B-X
analysis	B-X
was	B-X
conducted	B-X
on	B-X
lacI	B-X
DNA	B-X
and	B-X
hprt	B-X
cDNA	B-X
from	B-X
the	B-X
mutants	B-X
,	B-X
to	B-X
determine	B-X
the	B-X
mutational	B-X
specificity	B-X
of	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
in	B-X
the	B-X
rat	B-X
<EOS>	B-X
Although	B-X
there	B-X
were	B-X
similarities	B-X
among	B-X
the	B-X
mutational	B-X
patterns	B-X
derived	B-X
from	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
-	B-X
treated	B-X
rats	B-X
(	B-X
e	B-X
<EOS>	B-X
The	B-X
tissue	B-X
-	B-X
specificity	B-X
of	B-X
the	B-X
mutation	B-X
spectra	B-X
may	B-X
contribute	B-X
to	B-X
targeting	B-X
tumor	B-X
formation	B-X
to	B-X
the	B-X
liver	B-X
<EOS>	B-X
Also	B-X
,	B-X
multiplex	B-X
PCR	B-X
analysis	B-X
of	B-X
genomic	B-X
DNA	B-X
from	B-X
the	B-X
hprt	B-X
mutants	B-X
indicated	B-X
that	B-X
12	B-X
%	B-X
of	B-X
mutants	B-X
from	B-X
treated	B-X
rats	B-X
had	B-X
major	B-X
deletions	B-X
in	B-X
the	B-X
hprt	B-X
gene	B-X
;	B-X
no	B-X
corresponding	B-X
incidence	B-X
of	B-X
large	B-X
deletions	B-X
was	B-X
evident	B-X
among	B-X
lacI	B-X
mutations	B-X

All	O
the	O
mutation	O
spectra	O
from	O
N-OH-AAF-treated	O
rats	O
differed	O
significantly	O
from	O
corresponding	O
mutation	O
profiles	O
from	O
untreated	O
animals	O
(	O
P	O
=	O
0.02	O
to	O
P	O
<	O
0.0001	O
)	O
.	O

Although	O
there	O
were	O
similarities	O
among	O
the	O
mutational	O
patterns	O
derived	O
from	O
N-OH-AAF-treated	O
rats	O
(	O
e.g.	O
,	O
G	O
:	O
C	O
--	O
>	O
T	O
:	O
A	O
transversion	O
was	O
the	O
most	O
common	O
mutation	O
in	O
all	O
mutation	O
sets	O
)	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
patterns	O
of	O
basepair	O
substitution	O
and	O
frameshift	O
mutation	O
between	O
the	O
liver	O
and	O
spleen	B-cell_type
lymphocyte	I-cell_type
lacI	I-cell_type
mutants	I-cell_type
(	O
P	O
=	O
0.02	O
)	O
and	O
between	O
the	O
spleen	B-cell_type
lymphocyte	I-cell_type
lacI	B-cell_type
and	I-cell_type
hprt	I-cell_type
mutants	I-cell_type
(	O
P	O
=	O
0.04	O
)	O
.	O

Also	O
,	O
multiplex	O
PCR	O
analysis	O
of	O
genomic	B-DNA
DNA	I-DNA
from	O
the	O
hprt	B-cell_type
mutants	I-cell_type
indicated	O
that	O
12	O
%	O
of	O
mutants	O
from	O
treated	O
rats	O
had	O
major	O
deletions	O
in	O
the	O
hprt	B-DNA
gene	I-DNA
;	O
no	O
corresponding	O
incidence	O
of	O
large	O
deletions	O
was	O
evident	O
among	O
lacI	O
mutations	O
.	O
<EOS>	B-X
Also	B-X
,	B-X
multiplex	B-X
PCR	B-X
analysis	B-X
of	B-X
genomic	B-X
DNA	B-X
from	B-X
the	B-X
hprt	B-X
mutants	B-X
indicated	B-X
that	B-X
12	B-X
%	B-X
of	B-X
mutants	B-X
from	B-X
treated	B-X
rats	B-X
had	B-X
major	B-X
deletions	B-X
in	B-X
the	B-X
hprt	B-X
gene	B-X
;	B-X
no	B-X
corresponding	B-X
incidence	B-X
of	B-X
large	B-X
deletions	B-X
was	B-X
evident	B-X
among	B-X
lacI	B-X
mutations	B-X
<EOS>	B-X
All	B-X
the	B-X
mutation	B-X
spectra	B-X
from	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
-	B-X
treated	B-X
rats	B-X
differed	B-X
significantly	B-X
from	B-X
corresponding	B-X
mutation	B-X
profiles	B-X
from	B-X
untreated	B-X
animals	B-X
(	B-X
P	B-X
=	B-X
0	B-X
<EOS>	B-X
In	B-X
a	B-X
previous	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
treating	B-X
transgenic	B-X
Big	B-X
Blue	B-X
rats	B-X
with	B-X
the	B-X
hepatocarcinogen	B-X
N	B-X
-	B-X
hydroxy	B-X
-	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
(	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
)	B-X
produced	B-X
the	B-X
same	B-X
major	B-X
DNA	B-X
adduct	B-X
in	B-X
the	B-X
target	B-X
liver	B-X
and	B-X
the	B-X
nontarget	B-X
spleen	B-X
lymphocytes	B-X
and	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
induced	B-X
lacI	B-X
mutants	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
and	B-X
induced	B-X
much	B-X
lower	B-X
frequencies	B-X
of	B-X
lacI	B-X
and	B-X
hprt	B-X
mutants	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
<EOS>	B-X
Gene	B-X
-	B-X
	B-X
and	B-X
tissue	B-X
-	B-X
specificity	B-X
of	B-X
mutation	B-X
in	B-X
Big	B-X
Blue	B-X
rats	B-X
treated	B-X
with	B-X
the	B-X
hepatocarcinogen	B-X
N	B-X
-	B-X
hydroxy	B-X
-	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
.	B-X

All	O
the	O
mutation	O
profiles	O
reflect	O
the	O
general	O
mutational	O
specificity	O
of	O
the	O
major	O
DNA	O
adduct	O
formed	O
by	O
N-OH-AAF	O
.	O
<EOS>	B-X
All	B-X
the	B-X
mutation	B-X
profiles	B-X
reflect	B-X
the	B-X
general	B-X
mutational	B-X
specificity	B-X
of	B-X
the	B-X
major	B-X
DNA	B-X
adduct	B-X
formed	B-X
by	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
<EOS>	B-X
All	B-X
the	B-X
mutation	B-X
spectra	B-X
from	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
-	B-X
treated	B-X
rats	B-X
differed	B-X
significantly	B-X
from	B-X
corresponding	B-X
mutation	B-X
profiles	B-X
from	B-X
untreated	B-X
animals	B-X
(	B-X
P	B-X
=	B-X
0	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
sequence	B-X
analysis	B-X
was	B-X
conducted	B-X
on	B-X
lacI	B-X
DNA	B-X
and	B-X
hprt	B-X
cDNA	B-X
from	B-X
the	B-X
mutants	B-X
,	B-X
to	B-X
determine	B-X
the	B-X
mutational	B-X
specificity	B-X
of	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
in	B-X
the	B-X
rat	B-X
<EOS>	B-X
Although	B-X
there	B-X
were	B-X
similarities	B-X
among	B-X
the	B-X
mutational	B-X
patterns	B-X
derived	B-X
from	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
-	B-X
treated	B-X
rats	B-X
(	B-X
e	B-X

The	O
differences	O
between	O
N-OH-AAF	O
mutation	O
in	O
the	O
endogenous	B-DNA
gene	I-DNA
and	O
transgene	B-DNA
can	O
be	O
partially	O
explained	O
by	O
the	O
structures	O
of	O
the	O
two	O
genes	O
.	O
<EOS>	B-X
The	B-X
differences	B-X
between	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
mutation	B-X
in	B-X
the	B-X
endogenous	B-X
gene	B-X
and	B-X
transgene	B-X
can	B-X
be	B-X
partially	B-X
explained	B-X
by	B-X
the	B-X
structures	B-X
of	B-X
the	B-X
two	B-X
genes	B-X
<EOS>	B-X
The	B-X
tissue	B-X
-	B-X
specificity	B-X
of	B-X
the	B-X
mutation	B-X
spectra	B-X
may	B-X
contribute	B-X
to	B-X
targeting	B-X
tumor	B-X
formation	B-X
to	B-X
the	B-X
liver	B-X
<EOS>	B-X
,	B-X
G	B-X
:	B-X
C	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
>	B-X
T	B-X
:	B-X
A	B-X
transversion	B-X
was	B-X
the	B-X
most	B-X
common	B-X
mutation	B-X
in	B-X
all	B-X
mutation	B-X
sets	B-X
)	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
patterns	B-X
of	B-X
basepair	B-X
substitution	B-X
and	B-X
frameshift	B-X
mutation	B-X
between	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
lymphocyte	B-X
lacI	B-X
mutants	B-X
(	B-X
P	B-X
=	B-X
0	B-X
<EOS>	B-X
Gene	B-X
-	B-X
	B-X
and	B-X
tissue	B-X
-	B-X
specificity	B-X
of	B-X
mutation	B-X
in	B-X
Big	B-X
Blue	B-X
rats	B-X
treated	B-X
with	B-X
the	B-X
hepatocarcinogen	B-X
N	B-X
-	B-X
hydroxy	B-X
-	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
.	B-X

The	O
tissue-specificity	O
of	O
the	O
mutation	O
spectra	O
may	O
contribute	O
to	O
targeting	O
tumor	O
formation	O
to	O
the	O
liver	O
.	O

Environ.	O
Mol.	O
Mutagen.	O
37	O
:	O
203-214	O
,	O
2001	O
.	O
<EOS>	B-X
37:203	B-X
-	B-X
214	B-X
,	B-X
2001	B-X
<EOS>	B-X
Although	B-X
there	B-X
were	B-X
similarities	B-X
among	B-X
the	B-X
mutational	B-X
patterns	B-X
derived	B-X
from	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
-	B-X
treated	B-X
rats	B-X
(	B-X
e	B-X
<EOS>	B-X
Mutagen	B-X
<EOS>	B-X
Environ	B-X

Published	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O
<EOS>	B-X
Published	B-X
2001	B-X
Wiley	B-X
-	B-X
Liss	B-X
,	B-X
Inc	B-X
<EOS>	B-X
Published	B-X
2002	B-X
Wiley	B-X
-	B-X
Liss	B-X
,	B-X
Inc	B-X
<EOS>	B-X
Correlations	B-X
of	B-X
the	B-X
bead	B-X
assays	B-X
and	B-X
the	B-X
ELISAs	B-X
were	B-X
0	B-X
<EOS>	B-X
The	B-X
study	B-X
population	B-X
included	B-X
20,032	B-X
adults	B-X
aged	B-X
17	B-X
years	B-X
and	B-X
older	B-X

Caspase	B-protein
-dependent	O
cleavage	O
of	O
the	O
hematopoietic	B-protein
specific	I-protein
adaptor	I-protein
protein	I-protein
Gads	I-protein
alters	O
signalling	O
from	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
.	O

Gads	B-protein
is	O
a	O
SH2	B-protein
and	I-protein
SH3	I-protein
domain	I-protein
-containing	O
,	O
hematopoietic-specific	B-protein
adaptor	I-protein
protein	I-protein
that	O
functions	O
in	O
signalling	O
from	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
.	O

Gads	B-protein
acts	O
by	O
linking	O
SLP-76	B-protein
,	O
bound	O
by	O
the	O
carboxy-terminal	B-protein
Gads	I-protein
SH3	I-protein
domain	I-protein
,	O
to	O
tyrosine	B-protein
phosphorylated	I-protein
LAT	I-protein
which	O
contains	O
binding	O
sites	O
for	O
the	O
Gads	B-protein
SH2	I-protein
domain	I-protein
.	O
<EOS>	B-X
Gads	B-X
acts	B-X
by	B-X
linking	B-X
SLP	B-X
-	B-X
76	B-X
,	B-X
bound	B-X
by	B-X
the	B-X
carboxy	B-X
-	B-X
terminal	B-X
Gads	B-X
SH3	B-X
domain	B-X
,	B-X
to	B-X
tyrosine	B-X
phosphorylated	B-X
LAT	B-X
which	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
Gads	B-X
SH2	B-X
domain	B-X
<EOS>	B-X
Gads	B-X
is	B-X
distinguished	B-X
from	B-X
Grb2	B-X
and	B-X
the	B-X
closely	B-X
related	B-X
Grap	B-X
protein	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
120	B-X
amino	B-X
acid	B-X
unique	B-X
region	B-X
between	B-X
the	B-X
SH2	B-X
domain	B-X
and	B-X
the	B-X
carboxy	B-X
terminal	B-X
SH3	B-X
domain	B-X
<EOS>	B-X
Gads	B-X
is	B-X
a	B-X
SH2	B-X
and	B-X
SH3	B-X
domain	B-X
-	B-X
containing	B-X
,	B-X
hematopoietic	B-X
-	B-X
specific	B-X
adaptor	B-X
protein	B-X
that	B-X
functions	B-X
in	B-X
signalling	B-X
from	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
<EOS>	B-X
Caspase	B-X
-	B-X
dependent	B-X
cleavage	B-X
of	B-X
the	B-X
hematopoietic	B-X
specific	B-X
adaptor	B-X
protein	B-X
Gads	B-X
alters	B-X
signalling	B-X
from	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
.	B-X

Gads	B-protein
is	O
distinguished	O
from	O
Grb2	B-protein
and	O
the	O
closely	O
related	O
Grap	B-protein
protein	I-protein
by	O
the	O
presence	O
of	O
a	O
120	B-protein
amino	I-protein
acid	I-protein
unique	I-protein
region	I-protein
between	O
the	O
SH2	B-protein
domain	I-protein
and	O
the	O
carboxy	B-protein
terminal	I-protein
SH3	I-protein
domain	I-protein
.	O
<EOS>	B-X
Gads	B-X
is	B-X
distinguished	B-X
from	B-X
Grb2	B-X
and	B-X
the	B-X
closely	B-X
related	B-X
Grap	B-X
protein	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
120	B-X
amino	B-X
acid	B-X
unique	B-X
region	B-X
between	B-X
the	B-X
SH2	B-X
domain	B-X
and	B-X
the	B-X
carboxy	B-X
terminal	B-X
SH3	B-X
domain	B-X
<EOS>	B-X
Gads	B-X
acts	B-X
by	B-X
linking	B-X
SLP	B-X
-	B-X
76	B-X
,	B-X
bound	B-X
by	B-X
the	B-X
carboxy	B-X
-	B-X
terminal	B-X
Gads	B-X
SH3	B-X
domain	B-X
,	B-X
to	B-X
tyrosine	B-X
phosphorylated	B-X
LAT	B-X
which	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
Gads	B-X
SH2	B-X
domain	B-X
<EOS>	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
unique	B-X
region	B-X
of	B-X
Gads	B-X
contains	B-X
a	B-X
capase	B-X
cleavage	B-X
site	B-X
<EOS>	B-X
Gads	B-X
is	B-X
a	B-X
SH2	B-X
and	B-X
SH3	B-X
domain	B-X
-	B-X
containing	B-X
,	B-X
hematopoietic	B-X
-	B-X
specific	B-X
adaptor	B-X
protein	B-X
that	B-X
functions	B-X
in	B-X
signalling	B-X
from	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X

Here	O
we	O
demonstrate	O
that	O
the	O
unique	O
region	O
of	O
Gads	B-protein
contains	O
a	O
capase	B-protein
cleavage	I-protein
site	I-protein
.	O
<EOS>	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
unique	B-X
region	B-X
of	B-X
Gads	B-X
contains	B-X
a	B-X
capase	B-X
cleavage	B-X
site	B-X
<EOS>	B-X
A	B-X
putative	B-X
caspase	B-X
3	B-X
cleavage	B-X
site	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
unique	B-X
region	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
prevented	B-X
Gads	B-X
cleavage	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Caspase	B-X
-	B-X
dependent	B-X
cleavage	B-X
of	B-X
the	B-X
hematopoietic	B-X
specific	B-X
adaptor	B-X
protein	B-X
Gads	B-X
alters	B-X
signalling	B-X
from	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
cleavage	B-X
of	B-X
Gads	B-X
in	B-X
vivo	B-X
could	B-X
function	B-X
to	B-X
alter	B-X
signalling	B-X
downstream	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
by	B-X
disrupting	B-X
cross	B-X
talk	B-X
between	B-X
SLP	B-X
-	B-X
76	B-X
and	B-X
LAT	B-X

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	B-cell_type
results	O
in	O
detectable	O
Gads	B-protein
cleavage	O
by	O
60	O
min	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
apoptosis	B-X
in	B-X
lymphocytes	B-X
results	B-X
in	B-X
detectable	B-X
Gads	B-X
cleavage	B-X
by	B-X
60	B-X
min	B-X
<EOS>	B-X
A	B-X
putative	B-X
caspase	B-X
3	B-X
cleavage	B-X
site	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
unique	B-X
region	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
prevented	B-X
Gads	B-X
cleavage	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
Gads	B-X
cleavage	B-X
products	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
inhibited	B-X
NFAT	B-X
activation	B-X
following	B-X
TCR	B-X
cross	B-X
linking	B-X
<EOS>	B-X
Gads	B-X
cleavage	B-X
is	B-X
blocked	B-X
in	B-X
vivo	B-X
by	B-X
treating	B-X
cells	B-X
with	B-X
a	B-X
caspase	B-X
3	B-X
inhibitor	B-X

Gads	B-protein
cleavage	O
is	O
blocked	O
in	O
vivo	O
by	O
treating	O
cells	O
with	O
a	O
caspase	O
3	O
inhibitor	O
.	O
<EOS>	B-X
Gads	B-X
cleavage	B-X
is	B-X
blocked	B-X
in	B-X
vivo	B-X
by	B-X
treating	B-X
cells	B-X
with	B-X
a	B-X
caspase	B-X
3	B-X
inhibitor	B-X
<EOS>	B-X
A	B-X
putative	B-X
caspase	B-X
3	B-X
cleavage	B-X
site	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
unique	B-X
region	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
prevented	B-X
Gads	B-X
cleavage	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
Gads	B-X
cleavage	B-X
products	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
inhibited	B-X
NFAT	B-X
activation	B-X
following	B-X
TCR	B-X
cross	B-X
linking	B-X
<EOS>	B-X
The	B-X
Gads	B-X
cleavage	B-X
products	B-X
retained	B-X
the	B-X
predicted	B-X
binding	B-X
specificity	B-X
for	B-X
SLP	B-X
-	B-X
76	B-X
and	B-X
LAT	B-X

A	O
putative	B-protein
caspase	I-protein
3	I-protein
cleavage	I-protein
site	I-protein
was	O
identified	O
within	O
the	O
unique	O
region	O
and	O
mutation	O
of	O
this	O
site	O
prevented	O
Gads	B-protein
cleavage	O
in	O
vitro	O
,	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
A	B-X
putative	B-X
caspase	B-X
3	B-X
cleavage	B-X
site	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
unique	B-X
region	B-X
and	B-X
mutation	B-X
of	B-X
this	B-X
site	B-X
prevented	B-X
Gads	B-X
cleavage	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
unique	B-X
region	B-X
of	B-X
Gads	B-X
contains	B-X
a	B-X
capase	B-X
cleavage	B-X
site	B-X
<EOS>	B-X
Gads	B-X
cleavage	B-X
is	B-X
blocked	B-X
in	B-X
vivo	B-X
by	B-X
treating	B-X
cells	B-X
with	B-X
a	B-X
caspase	B-X
3	B-X
inhibitor	B-X
<EOS>	B-X
Induction	B-X
of	B-X
apoptosis	B-X
in	B-X
lymphocytes	B-X
results	B-X
in	B-X
detectable	B-X
Gads	B-X
cleavage	B-X
by	B-X
60	B-X
min	B-X

The	O
Gads	B-protein
cleavage	O
products	O
retained	O
the	O
predicted	O
binding	O
specificity	O
for	O
SLP-76	B-protein
and	O
LAT	B-protein
.	O
<EOS>	B-X
The	B-X
Gads	B-X
cleavage	B-X
products	B-X
retained	B-X
the	B-X
predicted	B-X
binding	B-X
specificity	B-X
for	B-X
SLP	B-X
-	B-X
76	B-X
and	B-X
LAT	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
Gads	B-X
cleavage	B-X
products	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
inhibited	B-X
NFAT	B-X
activation	B-X
following	B-X
TCR	B-X
cross	B-X
linking	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
cleavage	B-X
of	B-X
Gads	B-X
in	B-X
vivo	B-X
could	B-X
function	B-X
to	B-X
alter	B-X
signalling	B-X
downstream	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
by	B-X
disrupting	B-X
cross	B-X
talk	B-X
between	B-X
SLP	B-X
-	B-X
76	B-X
and	B-X
LAT	B-X
<EOS>	B-X
Gads	B-X
cleavage	B-X
is	B-X
blocked	B-X
in	B-X
vivo	B-X
by	B-X
treating	B-X
cells	B-X
with	B-X
a	B-X
caspase	B-X
3	B-X
inhibitor	B-X

Expression	O
of	O
the	O
Gads	B-protein
cleavage	O
products	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
inhibited	O
NFAT	O
activation	O
following	O
TCR	O
cross	O
linking	O
.	O

These	O
findings	O
indicate	O
that	O
cleavage	O
of	O
Gads	B-protein
in	O
vivo	O
could	O
function	O
to	O
alter	O
signalling	O
downstream	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
by	O
disrupting	O
cross	O
talk	O
between	O
SLP-76	B-protein
and	O
LAT	B-protein
.	O

Targeting	O
of	O
p300	B-protein
to	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
via	O
CREB-Rel	O
cross-talk	O
during	O
mitogen	B-protein
and	O
oncogenic	O
molecular	O
signaling	O
in	O
activated	B-cell_type
T-cells	I-cell_type
.	O

In	O
this	O
report	O
,	O
we	O
explore	O
the	O
mechanisms	O
of	O
targeting	O
of	O
p300	B-protein
to	O
the	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
in	O
response	O
to	O
mitogenic	O
and	O
oncogenic	O
molecular	O
signals	O
.	O

Recruitment	O
of	O
p300	B-protein
by	O
cAMP-responsive	B-protein
element-binding	I-protein
protein-Rel	I-protein
cross-talk	O
at	O
the	O
composite	B-protein
CD28	I-protein
response	I-protein
element	I-protein
(	O
CD28RE	B-protein
)	O
-	O
TRE	B-DNA
element	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
essential	O
for	O
promoter	O
inducibility	O
during	O
T-cell	O
activation	O
,	O
and	O
CD28RE-TRE	B-DNA
is	O
the	O
exclusive	O
target	O
of	O
the	O
human	B-cell_type
T-cell	I-cell_type
lymphotropic	O
virus	O
type	O
I	O
oncoprotein	B-protein
Tax	I-protein
.	O
<EOS>	B-X
Recruitment	B-X
of	B-X
p300	B-X
by	B-X
cAMP	B-X
-	B-X
responsive	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
-	B-X
Rel	B-X
cross	B-X
-	B-X
talk	B-X
at	B-X
the	B-X
composite	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
	B-X
-	B-X
TRE	B-X
element	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
is	B-X
essential	B-X
for	B-X
promoter	B-X
inducibility	B-X
during	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
,	B-X
and	B-X
CD28RE	B-X
-	B-X
TRE	B-X
is	B-X
the	B-X
exclusive	B-X
target	B-X
of	B-X
the	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
I	B-X
oncoprotein	B-X
Tax	B-X
<EOS>	B-X
The	B-X
intrinsic	B-X
histone	B-X
acetyltransferase	B-X
activity	B-X
of	B-X
p300	B-X
is	B-X
dispensable	B-X
for	B-X
activation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
and	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
743	B-X
residues	B-X
contain	B-X
the	B-X
minimal	B-X
structural	B-X
requirements	B-X
for	B-X
synergistic	B-X
transactivation	B-X
of	B-X
the	B-X
CD28RE	B-X
-	B-X
TRE	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
and	B-X
endogenous	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Targeting	B-X
of	B-X
p300	B-X
to	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
promoter	B-X
via	B-X
CREB	B-X
-	B-X
Rel	B-X
cross	B-X
-	B-X
talk	B-X
during	B-X
mitogen	B-X
and	B-X
oncogenic	B-X
molecular	B-X
signaling	B-X
in	B-X
activated	B-X
T	B-X
-	B-X
cells	B-X
.	B-X
<EOS>	B-X
Mutational	B-X
analysis	B-X
of	B-X
p300	B-X
reveals	B-X
differential	B-X
structural	B-X
requirements	B-X
for	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
p300	B-X
module	B-X
by	B-X
individual	B-X
cis	B-X
-	B-X
elements	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X

The	O
intrinsic	O
histone	O
acetyltransferase	O
activity	O
of	O
p300	B-protein
is	O
dispensable	O
for	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
the	O
N-terminal	B-protein
743	I-protein
residues	I-protein
contain	O
the	O
minimal	O
structural	O
requirements	O
for	O
synergistic	O
transactivation	O
of	O
the	O
CD28RE-TRE	B-DNA
,	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
endogenous	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O
<EOS>	B-X
The	B-X
intrinsic	B-X
histone	B-X
acetyltransferase	B-X
activity	B-X
of	B-X
p300	B-X
is	B-X
dispensable	B-X
for	B-X
activation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
and	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
743	B-X
residues	B-X
contain	B-X
the	B-X
minimal	B-X
structural	B-X
requirements	B-X
for	B-X
synergistic	B-X
transactivation	B-X
of	B-X
the	B-X
CD28RE	B-X
-	B-X
TRE	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
and	B-X
endogenous	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Mutational	B-X
analysis	B-X
of	B-X
p300	B-X
reveals	B-X
differential	B-X
structural	B-X
requirements	B-X
for	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
p300	B-X
module	B-X
by	B-X
individual	B-X
cis	B-X
-	B-X
elements	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
These	B-X
findings	B-X
provide	B-X
evidence	B-X
that	B-X
p300	B-X
assembles	B-X
at	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
to	B-X
form	B-X
an	B-X
enhanceosome	B-X
-	B-X
like	B-X
signal	B-X
transduction	B-X
target	B-X
that	B-X
is	B-X
centrally	B-X
integrated	B-X
at	B-X
the	B-X
CD28RE	B-X
-	B-X
TRE	B-X
element	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
through	B-X
specific	B-X
protein	B-X
module	B-X
-	B-X
targeted	B-X
associations	B-X
in	B-X
activated	B-X
T	B-X
-	B-X
cells	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
mechanisms	B-X
of	B-X
targeting	B-X
of	B-X
p300	B-X
to	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
promoter	B-X
in	B-X
response	B-X
to	B-X
mitogenic	B-X
and	B-X
oncogenic	B-X
molecular	B-X
signals	B-X

Mutational	O
analysis	O
of	O
p300	B-protein
reveals	O
differential	O
structural	O
requirements	O
for	O
the	O
N-terminal	O
p300	O
module	O
by	O
individual	O
cis-elements	B-DNA
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Mutational	B-X
analysis	B-X
of	B-X
p300	B-X
reveals	B-X
differential	B-X
structural	B-X
requirements	B-X
for	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
p300	B-X
module	B-X
by	B-X
individual	B-X
cis	B-X
-	B-X
elements	B-X
within	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
The	B-X
intrinsic	B-X
histone	B-X
acetyltransferase	B-X
activity	B-X
of	B-X
p300	B-X
is	B-X
dispensable	B-X
for	B-X
activation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
and	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
743	B-X
residues	B-X
contain	B-X
the	B-X
minimal	B-X
structural	B-X
requirements	B-X
for	B-X
synergistic	B-X
transactivation	B-X
of	B-X
the	B-X
CD28RE	B-X
-	B-X
TRE	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
and	B-X
endogenous	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Recruitment	B-X
of	B-X
p300	B-X
by	B-X
cAMP	B-X
-	B-X
responsive	B-X
element	B-X
-	B-X
binding	B-X
protein	B-X
-	B-X
Rel	B-X
cross	B-X
-	B-X
talk	B-X
at	B-X
the	B-X
composite	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
	B-X
-	B-X
TRE	B-X
element	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
is	B-X
essential	B-X
for	B-X
promoter	B-X
inducibility	B-X
during	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
,	B-X
and	B-X
CD28RE	B-X
-	B-X
TRE	B-X
is	B-X
the	B-X
exclusive	B-X
target	B-X
of	B-X
the	B-X
human	B-X
T	B-X
-	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
I	B-X
oncoprotein	B-X
Tax	B-X
<EOS>	B-X
These	B-X
findings	B-X
provide	B-X
evidence	B-X
that	B-X
p300	B-X
assembles	B-X
at	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
to	B-X
form	B-X
an	B-X
enhanceosome	B-X
-	B-X
like	B-X
signal	B-X
transduction	B-X
target	B-X
that	B-X
is	B-X
centrally	B-X
integrated	B-X
at	B-X
the	B-X
CD28RE	B-X
-	B-X
TRE	B-X
element	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
through	B-X
specific	B-X
protein	B-X
module	B-X
-	B-X
targeted	B-X
associations	B-X
in	B-X
activated	B-X
T	B-X
-	B-X
cells	B-X

These	O
findings	O
provide	O
evidence	O
that	O
p300	B-protein
assembles	O
at	O
the	O
IL-2	B-DNA
promoter	I-DNA
to	O
form	O
an	O
enhanceosome-like	O
signal	O
transduction	O
target	O
that	O
is	O
centrally	O
integrated	O
at	O
the	O
CD28RE-TRE	B-DNA
element	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
through	O
specific	O
protein	O
module-targeted	O
associations	O
in	O
activated	B-cell_type
T-cells	I-cell_type
.	O
<EOS>	B-X
These	B-X
findings	B-X
provide	B-X
evidence	B-X
that	B-X
p300	B-X
assembles	B-X
at	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
to	B-X
form	B-X
an	B-X
enhanceosome	B-X
-	B-X
like	B-X
signal	B-X
transduction	B-X
target	B-X
that	B-X
is	B-X
centrally	B-X
integrated	B-X
at	B-X
the	B-X
CD28RE	B-X
-	B-X
TRE	B-X
element	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
through	B-X
specific	B-X
protein	B-X
module	B-X
-	B-X
targeted	B-X
associations	B-X
in	B-X
activated	B-X
T	B-X
-	B-X
cells	B-X
<EOS>	B-X
Targeting	B-X
of	B-X
p300	B-X
to	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
promoter	B-X
via	B-X
CREB	B-X
-	B-X
Rel	B-X
cross	B-X
-	B-X
talk	B-X
during	B-X
mitogen	B-X
and	B-X
oncogenic	B-X
molecular	B-X
signaling	B-X
in	B-X
activated	B-X
T	B-X
-	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
mechanisms	B-X
of	B-X
targeting	B-X
of	B-X
p300	B-X
to	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
promoter	B-X
in	B-X
response	B-X
to	B-X
mitogenic	B-X
and	B-X
oncogenic	B-X
molecular	B-X
signals	B-X
<EOS>	B-X
The	B-X
intrinsic	B-X
histone	B-X
acetyltransferase	B-X
activity	B-X
of	B-X
p300	B-X
is	B-X
dispensable	B-X
for	B-X
activation	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
and	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
743	B-X
residues	B-X
contain	B-X
the	B-X
minimal	B-X
structural	B-X
requirements	B-X
for	B-X
synergistic	B-X
transactivation	B-X
of	B-X
the	B-X
CD28RE	B-X
-	B-X
TRE	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
,	B-X
and	B-X
endogenous	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
expression	B-X

Regulation	O
of	O
cytokine	O
production	O
in	O
T-cell	B-cell_type
responses	O
to	O
inhalant	O
allergen	O
:	O
GATA-3	B-protein
expression	O
distinguishes	O
between	O
Th1-	O
and	O
Th2-polarized	O
immunity	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
responses	B-X
to	B-X
inhalant	B-X
allergen	B-X
:	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
distinguishes	B-X
between	B-X
Th1	B-X
-	B-X
	B-X
and	B-X
Th2	B-X
-	B-X
polarized	B-X
immunity	B-X
.	B-X
<EOS>	B-X
Cytokine	B-X
-	B-X
driven	B-X
Th2	B-X
polarization	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
whereas	B-X
a	B-X
reciprocal	B-X
expression	B-X
pattern	B-X
accompanies	B-X
differentiation	B-X
towards	B-X
the	B-X
Th1	B-X
cytokine	B-X
phenotype	B-X
<EOS>	B-X
Upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
in	B-X
PBMC	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
Th2	B-X
recall	B-X
responses	B-X
to	B-X
specific	B-X
allergen	B-X
in	B-X
atopics	B-X
<EOS>	B-X
The	B-X
reciprocal	B-X
expression	B-X
pattern	B-X
observed	B-X
in	B-X
HDM	B-X
-	B-X
specific	B-X
recall	B-X
responses	B-X
of	B-X
non	B-X
-	B-X
atopics	B-X
provides	B-X
independent	B-X
confirmation	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
underlying	B-X
Th1	B-X
-	B-X
like	B-X
immunity	B-X
in	B-X
these	B-X
subjects	B-X

BACKGROUND	O
:	O
The	O
precise	O
nature	O
of	O
allergen-specific	O
cytokine	O
responses	O
in	O
atopics	O
versus	O
non-atopics	O
,	O
in	O
particular	O
the	O
'Th1	O
polarity	O
'	O
of	O
responses	O
in	O
non-atopics	O
,	O
remains	O
controversial	O
.	O
<EOS>	B-X
The	B-X
precise	B-X
nature	B-X
of	B-X
allergen	B-X
-	B-X
specific	B-X
cytokine	B-X
responses	B-X
in	B-X
atopics	B-X
versus	B-X
non	B-X
-	B-X
atopics	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
'Th1	B-X
polarity	B-X
'	B-X
of	B-X
responses	B-X
in	B-X
non	B-X
-	B-X
atopics	B-X
,	B-X
remains	B-X
controversial	B-X
<EOS>	B-X
The	B-X
reciprocal	B-X
expression	B-X
pattern	B-X
observed	B-X
in	B-X
HDM	B-X
-	B-X
specific	B-X
recall	B-X
responses	B-X
of	B-X
non	B-X
-	B-X
atopics	B-X
provides	B-X
independent	B-X
confirmation	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
underlying	B-X
Th1	B-X
-	B-X
like	B-X
immunity	B-X
in	B-X
these	B-X
subjects	B-X
<EOS>	B-X
Upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
in	B-X
PBMC	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
Th2	B-X
recall	B-X
responses	B-X
to	B-X
specific	B-X
allergen	B-X
in	B-X
atopics	B-X
<EOS>	B-X
This	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
the	B-X
relative	B-X
insensitivity	B-X
of	B-X
cytokine	B-X
detection	B-X
systems	B-X
,	B-X
and	B-X
associated	B-X
variations	B-X
in	B-X
kinetics	B-X
of	B-X
cytokine	B-X
production	B-X
and	B-X
catabolism	B-X
in	B-X
in	B-X
vitro	B-X
culture	B-X
systems	B-X

This	O
is	O
due	O
in	O
part	O
to	O
the	O
relative	O
insensitivity	O
of	O
cytokine	O
detection	O
systems	O
,	O
and	O
associated	O
variations	O
in	O
kinetics	O
of	O
cytokine	O
production	O
and	O
catabolism	O
in	O
in	O
vitro	O
culture	O
systems	O
.	O

As	O
an	O
alternative	O
to	O
cytokine	O
measurement	O
,	O
this	O
study	O
focuses	O
on	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
for	O
analysis	O
of	O
allergen-specific	O
Th	O
cell	O
responses	O
.	O
<EOS>	B-X
As	B-X
an	B-X
alternative	B-X
to	B-X
cytokine	B-X
measurement	B-X
,	B-X
this	B-X
study	B-X
focuses	B-X
on	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
3	B-X
for	B-X
analysis	B-X
of	B-X
allergen	B-X
-	B-X
specific	B-X
Th	B-X
cell	B-X
responses	B-X
<EOS>	B-X
Upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
in	B-X
PBMC	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
Th2	B-X
recall	B-X
responses	B-X
to	B-X
specific	B-X
allergen	B-X
in	B-X
atopics	B-X
<EOS>	B-X
In	B-X
T	B-X
cells	B-X
from	B-X
HDM	B-X
skin	B-X
prick	B-X
test	B-X
-	B-X
positive	B-X
(	B-X
HDM	B-X
-	B-X
SPT+	B-X
/	B-X
HDM	B-X
-	B-X
IgE+	B-X
)	B-X
volunteers	B-X
,	B-X
overnight	B-X
stimulation	B-X
results	B-X
in	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
compared	B-X
to	B-X
an	B-X
equally	B-X
marked	B-X
downregulation	B-X
of	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
SPT	B-X
-	B-X
	B-X
/	B-X
IgE	B-X
-	B-X
	B-X
subjects	B-X
<EOS>	B-X
The	B-X
parallel	B-X
findings	B-X
in	B-X
neonatal	B-X
T	B-X
cells	B-X
suggest	B-X
that	B-X
the	B-X
same	B-X
approach	B-X
may	B-X
be	B-X
utilized	B-X
for	B-X
monitoring	B-X
the	B-X
progress	B-X
of	B-X
allergen	B-X
-	B-X
specific	B-X
Th1	B-X
/	B-X
Th2	B-X
memory	B-X
development	B-X
during	B-X
early	B-X
childhood	B-X
,	B-X
and	B-X
hence	B-X
in	B-X
assessment	B-X
of	B-X
risk	B-X
for	B-X
future	B-X
allergic	B-X
disease	B-X

METHODS	O
:	O
Cord	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
were	O
Th1-	O
or	O
Th2-polarized	O
by	O
culture	O
in	O
IL-12-	O
or	O
IL-4-employing	O
established	O
methods	O
;	O
PBMC	B-cell_type
from	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
-sensitive	O
atopics	O
and	O
controls	O
were	O
stimulated	O
overnight	O
with	O
HDM	O
;	O
cytokine	O
production	O
was	O
measured	O
by	O
ELISA	O
and	O
GATA-3	B-RNA
mRNA	I-RNA
expression	O
by	O
PCR	O
.	O
<EOS>	B-X
Cord	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
CBMCs	B-X
)	B-X
from	B-X
offspring	B-X
with	B-X
allergic	B-X
mothers	B-X
showed	B-X
fewer	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
FOXP3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
lower	B-X
expression	B-X
levels	B-X
of	B-X
associated	B-X
genes	B-X
,	B-X
and	B-X
reduced	B-X
cytokine	B-X
production	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
10	B-X
and	B-X
interferon	B-X
-	B-X
γ	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
levels	B-X
of	B-X
MaR1	B-X
and	B-X
other	B-X
SPMs	B-X
were	B-X
below	B-X
the	B-X
limit	B-X
of	B-X
detection	B-X
or	B-X
not	B-X
increased	B-X
in	B-X
the	B-X
spinal	B-X
cord	B-X
of	B-X
EAE	B-X
mice	B-X
,	B-X
whereas	B-X
the	B-X
production	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
eicosanoids	B-X
was	B-X
induced	B-X
during	B-X
disease	B-X
progression	B-X
<EOS>	B-X
Cord	B-X
blood	B-X
samples	B-X
obtained	B-X
at	B-X
the	B-X
time	B-X
of	B-X
birth	B-X
were	B-X
analysed	B-X
for	B-X
Treg	B-X
counts	B-X
,	B-X
as	B-X
well	B-X
Treg	B-X
activity	B-X
,	B-X
based	B-X
on	B-X
their	B-X
response	B-X
to	B-X
Toll	B-X
-	B-X
like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
stimuli	B-X
such	B-X
as	B-X
lipid	B-X
A	B-X
(	B-X
LPA	B-X
)	B-X
and	B-X
peptidoglycans	B-X
(	B-X
PPG	B-X
)	B-X
<EOS>	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
from	B-X
10	B-X
wAIHA	B-X
patients	B-X
and	B-X
8	B-X
healthy	B-X
controls	B-X
were	B-X
isolated	B-X
from	B-X
peripheral	B-X
blood	B-X
and	B-X
cultured	B-X
for	B-X
3	B-X
days	B-X
with	B-X
or	B-X
without	B-X
the	B-X
presence	B-X
of	B-X
hUC	B-X
-	B-X
MSCs	B-X
;	B-X
PBMCs	B-X
were	B-X
co	B-X
-	B-X
cultured	B-X
with	B-X
hUC	B-X
-	B-X
MSCs	B-X
using	B-X
Transwell	B-X
assays	B-X

RESULTS	O
:	O
Cytokine	B-protein
-driven	O
Th2	O
polarization	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
associated	O
with	O
marked	O
upregulation	O
of	O
GATA-3	B-protein
expression	O
,	O
whereas	O
a	O
reciprocal	O
expression	O
pattern	O
accompanies	O
differentiation	O
towards	O
the	O
Th1	O
cytokine	O
phenotype	O
.	O
<EOS>	B-X
Cytokine	B-X
-	B-X
driven	B-X
Th2	B-X
polarization	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
whereas	B-X
a	B-X
reciprocal	B-X
expression	B-X
pattern	B-X
accompanies	B-X
differentiation	B-X
towards	B-X
the	B-X
Th1	B-X
cytokine	B-X
phenotype	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
responses	B-X
to	B-X
inhalant	B-X
allergen	B-X
:	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
distinguishes	B-X
between	B-X
Th1	B-X
-	B-X
	B-X
and	B-X
Th2	B-X
-	B-X
polarized	B-X
immunity	B-X
.	B-X
<EOS>	B-X
In	B-X
T	B-X
cells	B-X
from	B-X
HDM	B-X
skin	B-X
prick	B-X
test	B-X
-	B-X
positive	B-X
(	B-X
HDM	B-X
-	B-X
SPT+	B-X
/	B-X
HDM	B-X
-	B-X
IgE+	B-X
)	B-X
volunteers	B-X
,	B-X
overnight	B-X
stimulation	B-X
results	B-X
in	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
compared	B-X
to	B-X
an	B-X
equally	B-X
marked	B-X
downregulation	B-X
of	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
SPT	B-X
-	B-X
	B-X
/	B-X
IgE	B-X
-	B-X
	B-X
subjects	B-X
<EOS>	B-X
Upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
in	B-X
PBMC	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
Th2	B-X
recall	B-X
responses	B-X
to	B-X
specific	B-X
allergen	B-X
in	B-X
atopics	B-X

In	O
T	B-cell_type
cells	I-cell_type
from	O
HDM	O
skin	O
prick	O
test-positive	O
(	O
HDM-SPT+/HDM-IgE+	O
)	O
volunteers	O
,	O
overnight	O
stimulation	O
results	O
in	O
marked	O
upregulation	O
of	O
GATA-3	B-protein
expression	O
,	O
compared	O
to	O
an	O
equally	O
marked	O
downregulation	O
of	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
SPT-/IgE-	O
subjects	O
.	O

In	O
subjects	O
who	O
are	O
HDM-SPT+	O
but	O
IgE-	O
,	O
GATA-3	B-protein
expression	O
levels	O
remained	O
relatively	O
stable	O
during	O
culture	O
with	O
HDM	O
.	O
<EOS>	B-X
In	B-X
subjects	B-X
who	B-X
are	B-X
HDM	B-X
-	B-X
SPT+	B-X
but	B-X
IgE	B-X
-	B-X
	B-X
,	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
levels	B-X
remained	B-X
relatively	B-X
stable	B-X
during	B-X
culture	B-X
with	B-X
HDM	B-X
<EOS>	B-X
In	B-X
T	B-X
cells	B-X
from	B-X
HDM	B-X
skin	B-X
prick	B-X
test	B-X
-	B-X
positive	B-X
(	B-X
HDM	B-X
-	B-X
SPT+	B-X
/	B-X
HDM	B-X
-	B-X
IgE+	B-X
)	B-X
volunteers	B-X
,	B-X
overnight	B-X
stimulation	B-X
results	B-X
in	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
compared	B-X
to	B-X
an	B-X
equally	B-X
marked	B-X
downregulation	B-X
of	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
SPT	B-X
-	B-X
	B-X
/	B-X
IgE	B-X
-	B-X
	B-X
subjects	B-X
<EOS>	B-X
Cytokine	B-X
-	B-X
driven	B-X
Th2	B-X
polarization	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
whereas	B-X
a	B-X
reciprocal	B-X
expression	B-X
pattern	B-X
accompanies	B-X
differentiation	B-X
towards	B-X
the	B-X
Th1	B-X
cytokine	B-X
phenotype	B-X
<EOS>	B-X
This	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
the	B-X
relative	B-X
insensitivity	B-X
of	B-X
cytokine	B-X
detection	B-X
systems	B-X
,	B-X
and	B-X
associated	B-X
variations	B-X
in	B-X
kinetics	B-X
of	B-X
cytokine	B-X
production	B-X
and	B-X
catabolism	B-X
in	B-X
in	B-X
vitro	B-X
culture	B-X
systems	B-X

CONCLUSIONS	O
:	O
Upregulation	O
of	O
GATA-3	B-protein
expression	O
in	O
PBMC	B-cell_type
is	O
a	O
hallmark	O
of	O
the	O
early	O
phase	O
of	O
Th2	O
recall	O
responses	O
to	O
specific	O
allergen	O
in	O
atopics	O
.	O
<EOS>	B-X
Upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
in	B-X
PBMC	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
Th2	B-X
recall	B-X
responses	B-X
to	B-X
specific	B-X
allergen	B-X
in	B-X
atopics	B-X
<EOS>	B-X
The	B-X
precise	B-X
nature	B-X
of	B-X
allergen	B-X
-	B-X
specific	B-X
cytokine	B-X
responses	B-X
in	B-X
atopics	B-X
versus	B-X
non	B-X
-	B-X
atopics	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
'Th1	B-X
polarity	B-X
'	B-X
of	B-X
responses	B-X
in	B-X
non	B-X
-	B-X
atopics	B-X
,	B-X
remains	B-X
controversial	B-X
<EOS>	B-X
Cytokine	B-X
-	B-X
driven	B-X
Th2	B-X
polarization	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
whereas	B-X
a	B-X
reciprocal	B-X
expression	B-X
pattern	B-X
accompanies	B-X
differentiation	B-X
towards	B-X
the	B-X
Th1	B-X
cytokine	B-X
phenotype	B-X
<EOS>	B-X
In	B-X
T	B-X
cells	B-X
from	B-X
HDM	B-X
skin	B-X
prick	B-X
test	B-X
-	B-X
positive	B-X
(	B-X
HDM	B-X
-	B-X
SPT+	B-X
/	B-X
HDM	B-X
-	B-X
IgE+	B-X
)	B-X
volunteers	B-X
,	B-X
overnight	B-X
stimulation	B-X
results	B-X
in	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
compared	B-X
to	B-X
an	B-X
equally	B-X
marked	B-X
downregulation	B-X
of	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
SPT	B-X
-	B-X
	B-X
/	B-X
IgE	B-X
-	B-X
	B-X
subjects	B-X

The	O
reciprocal	O
expression	O
pattern	O
observed	O
in	O
HDM-specific	O
recall	O
responses	O
of	O
non-atopics	O
provides	O
independent	O
confirmation	O
of	O
the	O
presence	O
of	O
underlying	O
Th1-like	O
immunity	O
in	O
these	O
subjects	O
.	O
<EOS>	B-X
The	B-X
reciprocal	B-X
expression	B-X
pattern	B-X
observed	B-X
in	B-X
HDM	B-X
-	B-X
specific	B-X
recall	B-X
responses	B-X
of	B-X
non	B-X
-	B-X
atopics	B-X
provides	B-X
independent	B-X
confirmation	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
underlying	B-X
Th1	B-X
-	B-X
like	B-X
immunity	B-X
in	B-X
these	B-X
subjects	B-X
<EOS>	B-X
The	B-X
precise	B-X
nature	B-X
of	B-X
allergen	B-X
-	B-X
specific	B-X
cytokine	B-X
responses	B-X
in	B-X
atopics	B-X
versus	B-X
non	B-X
-	B-X
atopics	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
'Th1	B-X
polarity	B-X
'	B-X
of	B-X
responses	B-X
in	B-X
non	B-X
-	B-X
atopics	B-X
,	B-X
remains	B-X
controversial	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
responses	B-X
to	B-X
inhalant	B-X
allergen	B-X
:	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
distinguishes	B-X
between	B-X
Th1	B-X
-	B-X
	B-X
and	B-X
Th2	B-X
-	B-X
polarized	B-X
immunity	B-X
.	B-X
<EOS>	B-X
In	B-X
T	B-X
cells	B-X
from	B-X
HDM	B-X
skin	B-X
prick	B-X
test	B-X
-	B-X
positive	B-X
(	B-X
HDM	B-X
-	B-X
SPT+	B-X
/	B-X
HDM	B-X
-	B-X
IgE+	B-X
)	B-X
volunteers	B-X
,	B-X
overnight	B-X
stimulation	B-X
results	B-X
in	B-X
marked	B-X
upregulation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
,	B-X
compared	B-X
to	B-X
an	B-X
equally	B-X
marked	B-X
downregulation	B-X
of	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
SPT	B-X
-	B-X
	B-X
/	B-X
IgE	B-X
-	B-X
	B-X
subjects	B-X

The	O
parallel	O
findings	O
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
suggest	O
that	O
the	O
same	O
approach	O
may	O
be	O
utilized	O
for	O
monitoring	O
the	O
progress	O
of	O
allergen-specific	O
Th1/Th2	O
memory	O
development	O
during	O
early	O
childhood	O
,	O
and	O
hence	O
in	O
assessment	O
of	O
risk	O
for	O
future	O
allergic	O
disease	O
.	O
<EOS>	B-X
The	B-X
parallel	B-X
findings	B-X
in	B-X
neonatal	B-X
T	B-X
cells	B-X
suggest	B-X
that	B-X
the	B-X
same	B-X
approach	B-X
may	B-X
be	B-X
utilized	B-X
for	B-X
monitoring	B-X
the	B-X
progress	B-X
of	B-X
allergen	B-X
-	B-X
specific	B-X
Th1	B-X
/	B-X
Th2	B-X
memory	B-X
development	B-X
during	B-X
early	B-X
childhood	B-X
,	B-X
and	B-X
hence	B-X
in	B-X
assessment	B-X
of	B-X
risk	B-X
for	B-X
future	B-X
allergic	B-X
disease	B-X
<EOS>	B-X
This	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
the	B-X
relative	B-X
insensitivity	B-X
of	B-X
cytokine	B-X
detection	B-X
systems	B-X
,	B-X
and	B-X
associated	B-X
variations	B-X
in	B-X
kinetics	B-X
of	B-X
cytokine	B-X
production	B-X
and	B-X
catabolism	B-X
in	B-X
in	B-X
vitro	B-X
culture	B-X
systems	B-X
<EOS>	B-X
The	B-X
reciprocal	B-X
expression	B-X
pattern	B-X
observed	B-X
in	B-X
HDM	B-X
-	B-X
specific	B-X
recall	B-X
responses	B-X
of	B-X
non	B-X
-	B-X
atopics	B-X
provides	B-X
independent	B-X
confirmation	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
underlying	B-X
Th1	B-X
-	B-X
like	B-X
immunity	B-X
in	B-X
these	B-X
subjects	B-X
<EOS>	B-X
As	B-X
an	B-X
alternative	B-X
to	B-X
cytokine	B-X
measurement	B-X
,	B-X
this	B-X
study	B-X
focuses	B-X
on	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
3	B-X
for	B-X
analysis	B-X
of	B-X
allergen	B-X
-	B-X
specific	B-X
Th	B-X
cell	B-X
responses	B-X

Copyright	O
2001	O
S.	O
Karger	O
AG	O
,	O
Basel	O
<EOS>	B-X
Karger	B-X
AG	B-X
,	B-X
Basel	B-X
<EOS>	B-X
Copyright	B-X
2001	B-X
S	B-X
<EOS>	B-X
Copyright	B-X
2002	B-X
S	B-X
<EOS>	B-X
Termination	B-X
of	B-X
pregnancy	B-X
was	B-X
performed	B-X
in	B-X
1,657	B-X
cases	B-X
(	B-X
21	B-X

The	O
heat	O
shock	O
response	O
reduces	O
myelin	B-protein
oligodendrocyte	I-protein
glycoprotein	I-protein
-induced	O
experimental	O
autoimmune	O
encephalomyelitis	O
in	O
mice	O
.	O
<EOS>	B-X
The	B-X
heat	B-X
shock	B-X
response	B-X
reduces	B-X
myelin	B-X
oligodendrocyte	B-X
glycoprotein	B-X
-	B-X
induced	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
in	B-X
mice	B-X
.	B-X
<EOS>	B-X
Hsp70	B-X
regulates	B-X
immune	B-X
response	B-X
in	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
<EOS>	B-X
The	B-X
heat	B-X
-	B-X
shock	B-X
protein	B-X
90	B-X
inhibitor	B-X
17	B-X
-	B-X
allylamino	B-X
-	B-X
17	B-X
-	B-X
demethoxygeldanamycin	B-X
suppresses	B-X
glial	B-X
inflammatory	B-X
responses	B-X
and	B-X
ameliorates	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
.	B-X
<EOS>	B-X
17	B-X
-	B-X
AAG	B-X
administration	B-X
to	B-X
mice	B-X
immunized	B-X
with	B-X
myelin	B-X
oligodendrocyte	B-X
glycoprotein	B-X
peptide	B-X
prevented	B-X
disease	B-X
onset	B-X
when	B-X
given	B-X
at	B-X
an	B-X
early	B-X
time	B-X
,	B-X
and	B-X
reduced	B-X
clinical	B-X
symptoms	B-X
when	B-X
given	B-X
during	B-X
ongoing	B-X
disease	B-X

The	O
stress	O
response	O
(	O
SR	O
)	O
can	O
block	O
inflammatory	O
gene	O
expression	O
by	O
preventing	O
activation	O
of	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O
<EOS>	B-X
The	B-X
stress	B-X
response	B-X
(	B-X
SR	B-X
)	B-X
can	B-X
block	B-X
inflammatory	B-X
gene	B-X
expression	B-X
by	B-X
preventing	B-X
activation	B-X
of	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
<EOS>	B-X
The	B-X
early	B-X
activation	B-X
of	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
was	B-X
also	B-X
blocked	B-X
by	B-X
the	B-X
HSR	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
brain	B-X
that	B-X
normally	B-X
occurs	B-X
during	B-X
EAE	B-X
,	B-X
including	B-X
the	B-X
early	B-X
increase	B-X
in	B-X
RANTES	B-X
(	B-X
regulated	B-X
on	B-X
activation	B-X
of	B-X
normal	B-X
T	B-X
-	B-X
cell	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
the	B-X
later	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
form	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X
<EOS>	B-X
The	B-X
heat	B-X
shock	B-X
response	B-X
reduces	B-X
myelin	B-X
oligodendrocyte	B-X
glycoprotein	B-X
-	B-X
induced	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
in	B-X
mice	B-X
.	B-X

As	O
inflammatory	O
gene	O
expression	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
demyelinating	O
diseases	O
,	O
we	O
tested	O
the	O
effects	O
of	O
the	O
SR	O
on	O
the	O
progression	O
of	O
the	O
demyelinating	O
disease	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
.	O

EAE	O
was	O
actively	O
induced	O
in	O
C57BL/6	O
mice	O
using	O
an	O
encephalitogenic	O
myelin	B-protein
oligodendrocyte	I-protein
glycoprotein	I-protein
(	O
MOG	B-protein
(	I-protein
35-55	I-protein
)	I-protein
)	O
peptide	O
.	O
<EOS>	B-X
EAE	B-X
was	B-X
actively	B-X
induced	B-X
in	B-X
C57BL	B-X
/	B-X
6	B-X
mice	B-X
using	B-X
an	B-X
encephalitogenic	B-X
myelin	B-X
oligodendrocyte	B-X
glycoprotein	B-X
(	B-X
MOG	B-X
(	B-X
35	B-X
-	B-X
55	B-X
)	B-X
)	B-X
peptide	B-X
<EOS>	B-X
Female	B-X
C57BL	B-X
/	B-X
6	B-X
mice	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
were	B-X
induced	B-X
by	B-X
myelin	B-X
oligodendrocyte	B-X
glycoprotein	B-X
(	B-X
MOG	B-X
)	B-X
35	B-X
-	B-X
55	B-X
peptide	B-X
<EOS>	B-X
EAE	B-X
was	B-X
induced	B-X
by	B-X
immunization	B-X
with	B-X
myelin	B-X
oligodendrocyte	B-X
glycoprotein	B-X
(	B-X
MOG	B-X
(	B-X
35	B-X
-	B-X
55	B-X
)	B-X
)	B-X
in	B-X
C57BL	B-X
/	B-X
6	B-X
female	B-X
mice	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
oral	B-X
administration	B-X
of	B-X
the	B-X
selective	B-X
PPARdelta	B-X
agonist	B-X
GW0742	B-X
reduced	B-X
clinical	B-X
symptoms	B-X
in	B-X
C57BL	B-X
/	B-X
6	B-X
mice	B-X
that	B-X
had	B-X
been	B-X
immunized	B-X
with	B-X
encephalitogenic	B-X
myelin	B-X
oligodendrocyte	B-X
glycoprotein	B-X
(	B-X
MOG	B-X
)	B-X
peptide	B-X

Whole	O
body	O
hyperthermia	O
was	O
used	O
to	O
induce	O
a	O
heat	O
shock	O
response	O
(	O
HSR	O
)	O
in	O
immunized	O
mice	O
2	O
days	O
after	O
the	O
booster	O
MOG	O
(	O
35-55	O
)	O
peptide	O
injection	O
.	O
<EOS>	B-X
Whole	B-X
body	B-X
hyperthermia	B-X
was	B-X
used	B-X
to	B-X
induce	B-X
a	B-X
heat	B-X
shock	B-X
response	B-X
(	B-X
HSR	B-X
)	B-X
in	B-X
immunized	B-X
mice	B-X
2	B-X
days	B-X
after	B-X
the	B-X
booster	B-X
MOG	B-X
(	B-X
35	B-X
-	B-X
55	B-X
)	B-X
peptide	B-X
injection	B-X
<EOS>	B-X
EAE	B-X
was	B-X
actively	B-X
induced	B-X
in	B-X
C57BL	B-X
/	B-X
6	B-X
mice	B-X
using	B-X
an	B-X
encephalitogenic	B-X
myelin	B-X
oligodendrocyte	B-X
glycoprotein	B-X
(	B-X
MOG	B-X
(	B-X
35	B-X
-	B-X
55	B-X
)	B-X
)	B-X
peptide	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
the	B-X
incidence	B-X
of	B-X
EAE	B-X
by	B-X
70	B-X
%	B-X
,	B-X
delayed	B-X
disease	B-X
onset	B-X
by	B-X
6	B-X
days	B-X
,	B-X
and	B-X
attenuated	B-X
disease	B-X
severity	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
brain	B-X
that	B-X
normally	B-X
occurs	B-X
during	B-X
EAE	B-X
,	B-X
including	B-X
the	B-X
early	B-X
increase	B-X
in	B-X
RANTES	B-X
(	B-X
regulated	B-X
on	B-X
activation	B-X
of	B-X
normal	B-X
T	B-X
-	B-X
cell	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
the	B-X
later	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
form	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X

The	O
HSR	O
reduced	O
the	O
incidence	O
of	O
EAE	O
by	O
70	O
%	O
,	O
delayed	O
disease	O
onset	O
by	O
6	O
days	O
,	O
and	O
attenuated	O
disease	O
severity	O
.	O
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
the	B-X
incidence	B-X
of	B-X
EAE	B-X
by	B-X
70	B-X
%	B-X
,	B-X
delayed	B-X
disease	B-X
onset	B-X
by	B-X
6	B-X
days	B-X
,	B-X
and	B-X
attenuated	B-X
disease	B-X
severity	B-X
<EOS>	B-X
The	B-X
HSR	B-X
attenuated	B-X
leukocyte	B-X
infiltration	B-X
into	B-X
CNS	B-X
assessed	B-X
by	B-X
quantitation	B-X
of	B-X
perivascular	B-X
infiltrates	B-X
,	B-X
and	B-X
by	B-X
reduced	B-X
staining	B-X
for	B-X
CD4	B-X
and	B-X
CD25	B-X
immunopositive	B-X
T	B-X
-	B-X
cells	B-X
<EOS>	B-X
The	B-X
finding	B-X
that	B-X
the	B-X
SR	B-X
reduces	B-X
inflammation	B-X
in	B-X
the	B-X
brain	B-X
and	B-X
the	B-X
clinical	B-X
severity	B-X
of	B-X
EAE	B-X
opens	B-X
a	B-X
novel	B-X
therapeutic	B-X
approach	B-X
for	B-X
prevention	B-X
of	B-X
autoimmune	B-X
diseases	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
brain	B-X
that	B-X
normally	B-X
occurs	B-X
during	B-X
EAE	B-X
,	B-X
including	B-X
the	B-X
early	B-X
increase	B-X
in	B-X
RANTES	B-X
(	B-X
regulated	B-X
on	B-X
activation	B-X
of	B-X
normal	B-X
T	B-X
-	B-X
cell	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
the	B-X
later	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
form	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X

The	O
HSR	O
attenuated	O
leukocyte	B-cell_type
infiltration	O
into	O
CNS	O
assessed	O
by	O
quantitation	O
of	O
perivascular	O
infiltrates	O
,	O
and	O
by	O
reduced	O
staining	O
for	O
CD4	B-protein
and	O
CD25	B-protein
immunopositive	O
T-cells	B-cell_type
.	O
<EOS>	B-X
The	B-X
HSR	B-X
attenuated	B-X
leukocyte	B-X
infiltration	B-X
into	B-X
CNS	B-X
assessed	B-X
by	B-X
quantitation	B-X
of	B-X
perivascular	B-X
infiltrates	B-X
,	B-X
and	B-X
by	B-X
reduced	B-X
staining	B-X
for	B-X
CD4	B-X
and	B-X
CD25	B-X
immunopositive	B-X
T	B-X
-	B-X
cells	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
brain	B-X
that	B-X
normally	B-X
occurs	B-X
during	B-X
EAE	B-X
,	B-X
including	B-X
the	B-X
early	B-X
increase	B-X
in	B-X
RANTES	B-X
(	B-X
regulated	B-X
on	B-X
activation	B-X
of	B-X
normal	B-X
T	B-X
-	B-X
cell	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
the	B-X
later	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
form	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
the	B-X
incidence	B-X
of	B-X
EAE	B-X
by	B-X
70	B-X
%	B-X
,	B-X
delayed	B-X
disease	B-X
onset	B-X
by	B-X
6	B-X
days	B-X
,	B-X
and	B-X
attenuated	B-X
disease	B-X
severity	B-X
<EOS>	B-X
The	B-X
finding	B-X
that	B-X
the	B-X
SR	B-X
reduces	B-X
inflammation	B-X
in	B-X
the	B-X
brain	B-X
and	B-X
the	B-X
clinical	B-X
severity	B-X
of	B-X
EAE	B-X
opens	B-X
a	B-X
novel	B-X
therapeutic	B-X
approach	B-X
for	B-X
prevention	B-X
of	B-X
autoimmune	B-X
diseases	B-X

T-cell	O
activation	O
,	O
assessed	O
by	O
the	O
production	O
of	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
in	O
response	O
to	O
MOG	B-protein
(	I-protein
35-55	I-protein
)	I-protein
,	O
was	O
also	O
decreased	O
by	O
the	O
HSR	O
.	O
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
,	B-X
assessed	B-X
by	B-X
the	B-X
production	B-X
of	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNgamma	B-X
)	B-X
in	B-X
response	B-X
to	B-X
MOG	B-X
(	B-X
35	B-X
-	B-X
55	B-X
)	B-X
,	B-X
was	B-X
also	B-X
decreased	B-X
by	B-X
the	B-X
HSR	B-X
<EOS>	B-X
The	B-X
early	B-X
activation	B-X
of	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
was	B-X
also	B-X
blocked	B-X
by	B-X
the	B-X
HSR	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
the	B-X
incidence	B-X
of	B-X
EAE	B-X
by	B-X
70	B-X
%	B-X
,	B-X
delayed	B-X
disease	B-X
onset	B-X
by	B-X
6	B-X
days	B-X
,	B-X
and	B-X
attenuated	B-X
disease	B-X
severity	B-X
<EOS>	B-X
The	B-X
HSR	B-X
attenuated	B-X
leukocyte	B-X
infiltration	B-X
into	B-X
CNS	B-X
assessed	B-X
by	B-X
quantitation	B-X
of	B-X
perivascular	B-X
infiltrates	B-X
,	B-X
and	B-X
by	B-X
reduced	B-X
staining	B-X
for	B-X
CD4	B-X
and	B-X
CD25	B-X
immunopositive	B-X
T	B-X
-	B-X
cells	B-X

The	O
HSR	O
reduced	O
inflammatory	O
gene	O
expression	O
in	O
the	O
brain	O
that	O
normally	O
occurs	O
during	O
EAE	O
,	O
including	O
the	O
early	O
increase	O
in	O
RANTES	B-protein
(	O
regulated	B-protein
on	I-protein
activation	I-protein
of	I-protein
normal	I-protein
T-cell	I-protein
expressed	I-protein
and	I-protein
secreted	I-protein
)	O
expression	O
,	O
and	O
the	O
later	O
expression	O
of	O
the	O
inducible	O
form	O
of	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
.	O
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
brain	B-X
that	B-X
normally	B-X
occurs	B-X
during	B-X
EAE	B-X
,	B-X
including	B-X
the	B-X
early	B-X
increase	B-X
in	B-X
RANTES	B-X
(	B-X
regulated	B-X
on	B-X
activation	B-X
of	B-X
normal	B-X
T	B-X
-	B-X
cell	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
the	B-X
later	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
form	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X
<EOS>	B-X
As	B-X
inflammatory	B-X
gene	B-X
expression	B-X
contributes	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
demyelinating	B-X
diseases	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
SR	B-X
on	B-X
the	B-X
progression	B-X
of	B-X
the	B-X
demyelinating	B-X
disease	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
<EOS>	B-X
The	B-X
finding	B-X
that	B-X
the	B-X
SR	B-X
reduces	B-X
inflammation	B-X
in	B-X
the	B-X
brain	B-X
and	B-X
the	B-X
clinical	B-X
severity	B-X
of	B-X
EAE	B-X
opens	B-X
a	B-X
novel	B-X
therapeutic	B-X
approach	B-X
for	B-X
prevention	B-X
of	B-X
autoimmune	B-X
diseases	B-X
<EOS>	B-X
The	B-X
HSR	B-X
attenuated	B-X
leukocyte	B-X
infiltration	B-X
into	B-X
CNS	B-X
assessed	B-X
by	B-X
quantitation	B-X
of	B-X
perivascular	B-X
infiltrates	B-X
,	B-X
and	B-X
by	B-X
reduced	B-X
staining	B-X
for	B-X
CD4	B-X
and	B-X
CD25	B-X
immunopositive	B-X
T	B-X
-	B-X
cells	B-X

The	O
early	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
was	O
also	O
blocked	O
by	O
the	O
HSR	O
.	O
<EOS>	B-X
The	B-X
early	B-X
activation	B-X
of	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
was	B-X
also	B-X
blocked	B-X
by	B-X
the	B-X
HSR	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
,	B-X
assessed	B-X
by	B-X
the	B-X
production	B-X
of	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNgamma	B-X
)	B-X
in	B-X
response	B-X
to	B-X
MOG	B-X
(	B-X
35	B-X
-	B-X
55	B-X
)	B-X
,	B-X
was	B-X
also	B-X
decreased	B-X
by	B-X
the	B-X
HSR	B-X
<EOS>	B-X
The	B-X
stress	B-X
response	B-X
(	B-X
SR	B-X
)	B-X
can	B-X
block	B-X
inflammatory	B-X
gene	B-X
expression	B-X
by	B-X
preventing	B-X
activation	B-X
of	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
<EOS>	B-X
The	B-X
HSR	B-X
attenuated	B-X
leukocyte	B-X
infiltration	B-X
into	B-X
CNS	B-X
assessed	B-X
by	B-X
quantitation	B-X
of	B-X
perivascular	B-X
infiltrates	B-X
,	B-X
and	B-X
by	B-X
reduced	B-X
staining	B-X
for	B-X
CD4	B-X
and	B-X
CD25	B-X
immunopositive	B-X
T	B-X
-	B-X
cells	B-X

The	O
finding	O
that	O
the	O
SR	O
reduces	O
inflammation	O
in	O
the	O
brain	O
and	O
the	O
clinical	O
severity	O
of	O
EAE	O
opens	O
a	O
novel	O
therapeutic	O
approach	O
for	O
prevention	O
of	O
autoimmune	O
diseases	O
.	O
<EOS>	B-X
The	B-X
finding	B-X
that	B-X
the	B-X
SR	B-X
reduces	B-X
inflammation	B-X
in	B-X
the	B-X
brain	B-X
and	B-X
the	B-X
clinical	B-X
severity	B-X
of	B-X
EAE	B-X
opens	B-X
a	B-X
novel	B-X
therapeutic	B-X
approach	B-X
for	B-X
prevention	B-X
of	B-X
autoimmune	B-X
diseases	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
the	B-X
incidence	B-X
of	B-X
EAE	B-X
by	B-X
70	B-X
%	B-X
,	B-X
delayed	B-X
disease	B-X
onset	B-X
by	B-X
6	B-X
days	B-X
,	B-X
and	B-X
attenuated	B-X
disease	B-X
severity	B-X
<EOS>	B-X
The	B-X
HSR	B-X
reduced	B-X
inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
brain	B-X
that	B-X
normally	B-X
occurs	B-X
during	B-X
EAE	B-X
,	B-X
including	B-X
the	B-X
early	B-X
increase	B-X
in	B-X
RANTES	B-X
(	B-X
regulated	B-X
on	B-X
activation	B-X
of	B-X
normal	B-X
T	B-X
-	B-X
cell	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
the	B-X
later	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
form	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X
<EOS>	B-X
As	B-X
inflammatory	B-X
gene	B-X
expression	B-X
contributes	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
demyelinating	B-X
diseases	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
SR	B-X
on	B-X
the	B-X
progression	B-X
of	B-X
the	B-X
demyelinating	B-X
disease	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X

In	O
vivo	O
detection	O
of	O
intracellular	O
signaling	O
pathways	O
in	O
developing	O
thymocytes	B-cell_type
.	O
<EOS>	B-X
In	B-X
vivo	B-X
detection	B-X
of	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
in	B-X
developing	B-X
thymocytes	B-X
.	B-X
<EOS>	B-X
This	B-X
approach	B-X
uses	B-X
reporter	B-X
-	B-X
plasmids	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
intracellular	B-X
signals	B-X
mediated	B-X
by	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
or	B-X
cyclic	B-X
AMP	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
novel	B-X
system	B-X
that	B-X
facilitates	B-X
the	B-X
in	B-X
vivo	B-X
analysis	B-X
of	B-X
signal	B-X
transduction	B-X
pathways	B-X
during	B-X
T	B-X
-	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
A	B-X
systematic	B-X
observation	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
apoptosis	B-X
related	B-X
markers	B-X
(	B-X
especially	B-X
FasR	B-X
)	B-X
and	B-X
cells	B-X
in	B-X
PCD	B-X
was	B-X
carried	B-X
out	B-X

Information	O
regarding	O
the	O
intracellular	O
signaling	O
processes	O
that	O
occur	O
during	O
the	O
development	O
of	O
T	B-cell_type
cells	I-cell_type
has	O
largely	O
been	O
obtained	O
with	O
the	O
use	O
of	O
transgenic	O
mouse	O
models	O
,	O
which	O
although	O
providing	O
invaluable	O
information	O
are	O
time	O
consuming	O
and	O
costly	O
.	O
<EOS>	B-X
Information	B-X
regarding	B-X
the	B-X
intracellular	B-X
signaling	B-X
processes	B-X
that	B-X
occur	B-X
during	B-X
the	B-X
development	B-X
of	B-X
T	B-X
cells	B-X
has	B-X
largely	B-X
been	B-X
obtained	B-X
with	B-X
the	B-X
use	B-X
of	B-X
transgenic	B-X
mouse	B-X
models	B-X
,	B-X
which	B-X
although	B-X
providing	B-X
invaluable	B-X
information	B-X
are	B-X
time	B-X
consuming	B-X
and	B-X
costly	B-X
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
method	B-X
allows	B-X
for	B-X
the	B-X
monitoring	B-X
of	B-X
signals	B-X
that	B-X
occur	B-X
in	B-X
a	B-X
biological	B-X
time	B-X
frame	B-X
,	B-X
such	B-X
as	B-X
during	B-X
differentiation	B-X
,	B-X
and	B-X
within	B-X
the	B-X
natural	B-X
environment	B-X
of	B-X
differentiating	B-X
cells	B-X
<EOS>	B-X
This	B-X
approach	B-X
uses	B-X
reporter	B-X
-	B-X
plasmids	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
intracellular	B-X
signals	B-X
mediated	B-X
by	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
or	B-X
cyclic	B-X
AMP	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
novel	B-X
system	B-X
that	B-X
facilitates	B-X
the	B-X
in	B-X
vivo	B-X
analysis	B-X
of	B-X
signal	B-X
transduction	B-X
pathways	B-X
during	B-X
T	B-X
-	B-X
lymphocyte	B-X
development	B-X

To	O
this	O
end	O
,	O
we	O
have	O
developed	O
a	O
novel	O
system	O
that	O
facilitates	O
the	O
in	O
vivo	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
during	O
T-lymphocyte	B-cell_type
development	O
.	O
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
novel	B-X
system	B-X
that	B-X
facilitates	B-X
the	B-X
in	B-X
vivo	B-X
analysis	B-X
of	B-X
signal	B-X
transduction	B-X
pathways	B-X
during	B-X
T	B-X
-	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
method	B-X
allows	B-X
for	B-X
the	B-X
monitoring	B-X
of	B-X
signals	B-X
that	B-X
occur	B-X
in	B-X
a	B-X
biological	B-X
time	B-X
frame	B-X
,	B-X
such	B-X
as	B-X
during	B-X
differentiation	B-X
,	B-X
and	B-X
within	B-X
the	B-X
natural	B-X
environment	B-X
of	B-X
differentiating	B-X
cells	B-X
<EOS>	B-X
In	B-X
vivo	B-X
detection	B-X
of	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
in	B-X
developing	B-X
thymocytes	B-X
.	B-X
<EOS>	B-X
Reporter	B-X
-	B-X
plasmids	B-X
are	B-X
transfected	B-X
into	B-X
thymocytes	B-X
in	B-X
fetal	B-X
thymic	B-X
organ	B-X
culture	B-X
by	B-X
accelerated	B-X
DNA	B-X
/	B-X
particle	B-X
bombardment	B-X
(	B-X
gene	B-X
gun	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
signaling	B-X
pathway	B-X
is	B-X
determined	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
standard	B-X
luciferase	B-X
assay	B-X

This	O
approach	O
uses	O
reporter-plasmids	B-DNA
for	O
the	O
detection	O
of	O
intracellular	O
signals	O
mediated	O
by	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
or	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinase	I-protein
.	O
<EOS>	B-X
These	B-X
effects	B-X
were	B-X
associated	B-X
with	B-X
lower	B-X
protein	B-X
amounts	B-X
and	B-X
activity	B-X
of	B-X
the	B-X
protein	B-X
deacetylase	B-X
sirtuin	B-X
1	B-X
(	B-X
SIRT1	B-X
)	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
adenosine	B-X
monophosphate	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
(	B-X
AMPK	B-X
)	B-X
<EOS>	B-X
In	B-X
this	B-X
case	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
exenatide	B-X
was	B-X
dependent	B-X
on	B-X
a	B-X
protein	B-X
kinase	B-X
A	B-X
pathway	B-X
<EOS>	B-X
The	B-X
same	B-X
epigenetic	B-X
mechanism	B-X
in	B-X
the	B-X
context	B-X
of	B-X
CREB	B-X
binding	B-X
site	B-X
was	B-X
identified	B-X
in	B-X
other	B-X
genes	B-X
involved	B-X
in	B-X
neuronal	B-X
differentiation	B-X
and	B-X
LTP	B-X
<EOS>	B-X
Enhanced	B-X
secretory	B-X
function	B-X
in	B-X
pentoxifylline	B-X
-	B-X
treated	B-X
cells	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
stability	B-X
of	B-X
PDX1	B-X
-	B-X
SERCA2B	B-X
protein	B-X
levels	B-X

Reporter-plasmids	B-DNA
are	O
transfected	O
into	O
thymocytes	B-cell_type
in	O
fetal	O
thymic	O
organ	O
culture	O
by	O
accelerated	O
DNA/particle	O
bombardment	O
(	O
gene	O
gun	O
)	O
,	O
and	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
is	O
determined	O
in	O
the	O
form	O
of	O
a	O
standard	O
luciferase	O
assay	O
.	O
<EOS>	B-X
Reporter	B-X
-	B-X
plasmids	B-X
are	B-X
transfected	B-X
into	B-X
thymocytes	B-X
in	B-X
fetal	B-X
thymic	B-X
organ	B-X
culture	B-X
by	B-X
accelerated	B-X
DNA	B-X
/	B-X
particle	B-X
bombardment	B-X
(	B-X
gene	B-X
gun	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
signaling	B-X
pathway	B-X
is	B-X
determined	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
standard	B-X
luciferase	B-X
assay	B-X
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
method	B-X
allows	B-X
for	B-X
the	B-X
monitoring	B-X
of	B-X
signals	B-X
that	B-X
occur	B-X
in	B-X
a	B-X
biological	B-X
time	B-X
frame	B-X
,	B-X
such	B-X
as	B-X
during	B-X
differentiation	B-X
,	B-X
and	B-X
within	B-X
the	B-X
natural	B-X
environment	B-X
of	B-X
differentiating	B-X
cells	B-X
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
novel	B-X
system	B-X
that	B-X
facilitates	B-X
the	B-X
in	B-X
vivo	B-X
analysis	B-X
of	B-X
signal	B-X
transduction	B-X
pathways	B-X
during	B-X
T	B-X
-	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
This	B-X
approach	B-X
uses	B-X
reporter	B-X
-	B-X
plasmids	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
intracellular	B-X
signals	B-X
mediated	B-X
by	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
or	B-X
cyclic	B-X
AMP	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X

Importantly	O
,	O
this	O
powerful	O
technique	O
preserves	O
the	O
structural	O
integrity	O
of	O
the	O
thymus	O
,	O
and	O
will	O
provide	O
an	O
invaluable	O
tool	O
to	O
study	O
how	O
thymocytes	B-cell_type
respond	O
to	O
normal	O
environmental	O
stimuli	O
encountered	O
during	O
differentiation	O
within	O
the	O
thymic	O
milieu	O
.	O
<EOS>	B-X
Importantly	B-X
,	B-X
this	B-X
powerful	B-X
technique	B-X
preserves	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
thymus	B-X
,	B-X
and	B-X
will	B-X
provide	B-X
an	B-X
invaluable	B-X
tool	B-X
to	B-X
study	B-X
how	B-X
thymocytes	B-X
respond	B-X
to	B-X
normal	B-X
environmental	B-X
stimuli	B-X
encountered	B-X
during	B-X
differentiation	B-X
within	B-X
the	B-X
thymic	B-X
milieu	B-X
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
method	B-X
allows	B-X
for	B-X
the	B-X
monitoring	B-X
of	B-X
signals	B-X
that	B-X
occur	B-X
in	B-X
a	B-X
biological	B-X
time	B-X
frame	B-X
,	B-X
such	B-X
as	B-X
during	B-X
differentiation	B-X
,	B-X
and	B-X
within	B-X
the	B-X
natural	B-X
environment	B-X
of	B-X
differentiating	B-X
cells	B-X
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
novel	B-X
system	B-X
that	B-X
facilitates	B-X
the	B-X
in	B-X
vivo	B-X
analysis	B-X
of	B-X
signal	B-X
transduction	B-X
pathways	B-X
during	B-X
T	B-X
-	B-X
lymphocyte	B-X
development	B-X
<EOS>	B-X
This	B-X
approach	B-X
uses	B-X
reporter	B-X
-	B-X
plasmids	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
intracellular	B-X
signals	B-X
mediated	B-X
by	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
or	B-X
cyclic	B-X
AMP	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X

Thus	O
,	O
this	O
method	O
allows	O
for	O
the	O
monitoring	O
of	O
signals	O
that	O
occur	O
in	O
a	O
biological	O
time	O
frame	O
,	O
such	O
as	O
during	O
differentiation	O
,	O
and	O
within	O
the	O
natural	O
environment	O
of	O
differentiating	B-cell_type
cells	I-cell_type
.	O

Core-binding	B-protein
factor	I-protein
beta	I-protein
(	O
CBFbeta	B-protein
)	O
,	O
but	O
not	O
CBFbeta-smooth	B-protein
muscle	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
,	O
rescues	O
definitive	O
hematopoiesis	O
in	O
CBFbeta	B-protein
-deficient	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Core	B-X
-	B-X
binding	B-X
factors	B-X
-	B-X
beta	B-X
(	B-X
CBFβ	B-X
)	B-X
is	B-X
a	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
factor	B-X
that	B-X
combines	B-X
with	B-X
the	B-X
runt	B-X
-	B-X
related	B-X
transcription	B-X
factor	B-X
family	B-X
transcription	B-X
factors	B-X
to	B-X
mediate	B-X
their	B-X
DNA	B-X
-	B-X
binding	B-X
affinities	B-X
,	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
osteogenic	B-X
differentiation	B-X
<EOS>	B-X
Core	B-X
binding	B-X
factor	B-X
β	B-X
(	B-X
Cbfβ	B-X
)	B-X
is	B-X
a	B-X
non	B-X
-	B-X
DNA	B-X
binding	B-X
cofactor	B-X
of	B-X
Runx2	B-X
that	B-X
potentiates	B-X
DNA	B-X
binding	B-X
<EOS>	B-X
Folic	B-X
acid	B-X
was	B-X
reported	B-X
to	B-X
significantly	B-X
improve	B-X
chondrogenic	B-X
differentiation	B-X
of	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
<EOS>	B-X
Core	B-X
-	B-X
binding	B-X
factor	B-X
(	B-X
CBF	B-X
)	B-X
fusions	B-X
RUNX1	B-X
-	B-X
ETO	B-X
and	B-X
CBFβ	B-X
-	B-X
MYH11	B-X
in	B-X
t	B-X
(	B-X
8	B-X
;	B-X
21	B-X
)	B-X
and	B-X
inv	B-X
(	B-X
16	B-X
)	B-X
AML	B-X
,	B-X
respectively	B-X
,	B-X
activate	B-X
the	B-X
PU	B-X

Core-binding	B-protein
factor	I-protein
beta	I-protein
(	O
CBFbeta	B-protein
)	O
is	O
the	O
non-DNA-binding	B-protein
subunit	I-protein
of	O
the	O
heterodimeric	B-protein
CBFs	I-protein
.	O
<EOS>	B-X
Core	B-X
-	B-X
binding	B-X
factor	B-X
beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
is	B-X
the	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
subunit	B-X
of	B-X
the	B-X
heterodimeric	B-X
CBFs	B-X
<EOS>	B-X
Core	B-X
-	B-X
binding	B-X
factor	B-X
beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
,	B-X
but	B-X
not	B-X
CBFbeta	B-X
-	B-X
smooth	B-X
muscle	B-X
myosin	B-X
heavy	B-X
chain	B-X
,	B-X
rescues	B-X
definitive	B-X
hematopoiesis	B-X
in	B-X
CBFbeta	B-X
-	B-X
deficient	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
<EOS>	B-X
Sequences	B-X
C	B-X
terminal	B-X
to	B-X
amino	B-X
acid	B-X
214	B-X
also	B-X
inhibit	B-X
heterodimerization	B-X
with	B-X
the	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
CBFbeta	B-X
subunit	B-X
,	B-X
particularly	B-X
heterodimerization	B-X
off	B-X
DNA	B-X
<EOS>	B-X
Energetic	B-X
and	B-X
functional	B-X
contribution	B-X
of	B-X
residues	B-X
in	B-X
the	B-X
core	B-X
binding	B-X
factor	B-X
beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
subunit	B-X
to	B-X
heterodimerization	B-X
with	B-X
CBFalpha	B-X
.	B-X

Genes	B-DNA
encoding	I-DNA
CBFbeta	I-DNA
(	O
CBFB	B-DNA
)	O
,	O
and	O
one	O
of	O
the	O
DNA-binding	B-protein
CBFalpha	I-protein
subunits	I-protein
,	I-protein
Runx1	I-protein
(	O
also	O
known	O
as	O
CBFalpha2	B-protein
,	O
AML1	B-protein
,	O
and	O
PEBP2alphaB	B-protein
)	O
,	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
and	O
are	O
also	O
frequent	O
targets	O
of	O
chromosomal	O
translocations	O
in	O
acute	O
leukemias	O
in	O
humans	O
.	O
<EOS>	B-X
Genes	B-X
encoding	B-X
CBFbeta	B-X
(	B-X
CBFB	B-X
)	B-X
,	B-X
and	B-X
one	B-X
of	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
CBFalpha	B-X
subunits	B-X
,	B-X
Runx1	B-X
(	B-X
also	B-X
known	B-X
as	B-X
CBFalpha2	B-X
,	B-X
AML1	B-X
,	B-X
and	B-X
PEBP2alphaB	B-X
)	B-X
,	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
and	B-X
are	B-X
also	B-X
frequent	B-X
targets	B-X
of	B-X
chromosomal	B-X
translocations	B-X
in	B-X
acute	B-X
leukemias	B-X
in	B-X
humans	B-X
<EOS>	B-X
Core	B-X
-	B-X
binding	B-X
factor	B-X
beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
,	B-X
but	B-X
not	B-X
CBFbeta	B-X
-	B-X
smooth	B-X
muscle	B-X
myosin	B-X
heavy	B-X
chain	B-X
,	B-X
rescues	B-X
definitive	B-X
hematopoiesis	B-X
in	B-X
CBFbeta	B-X
-	B-X
deficient	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
<EOS>	B-X
Sequences	B-X
responsible	B-X
for	B-X
the	B-X
inability	B-X
of	B-X
CBFbeta	B-X
-	B-X
SMMHC	B-X
to	B-X
rescue	B-X
definitive	B-X
hematopoiesis	B-X
reside	B-X
in	B-X
the	B-X
SMMHC	B-X
portion	B-X
of	B-X
the	B-X
fusion	B-X
protein	B-X
<EOS>	B-X
Results	B-X
also	B-X
show	B-X
that	B-X
the	B-X
CBFbeta	B-X
-	B-X
SMMHC	B-X
fusion	B-X
protein	B-X
transdominantly	B-X
inhibits	B-X
definitive	B-X
hematopoiesis	B-X
,	B-X
but	B-X
not	B-X
to	B-X
the	B-X
same	B-X
extent	B-X
as	B-X
homozygous	B-X
loss	B-X
of	B-X
Runx1	B-X
or	B-X
Cbfb	B-X

Homozygous	O
disruption	O
of	O
either	O
the	O
Runx1	B-DNA
or	I-DNA
Cbfb	I-DNA
gene	I-DNA
in	O
mice	O
results	O
in	O
embryonic	O
lethality	O
at	O
midgestation	O
due	O
to	O
hemorrhaging	O
in	O
the	O
central	O
nervous	O
system	O
,	O
and	O
severely	O
impairs	O
fetal	O
liver	O
hematopoiesis	O
.	O
<EOS>	B-X
Homozygous	B-X
disruption	B-X
of	B-X
either	B-X
the	B-X
Runx1	B-X
or	B-X
Cbfb	B-X
gene	B-X
in	B-X
mice	B-X
results	B-X
in	B-X
embryonic	B-X
lethality	B-X
at	B-X
midgestation	B-X
due	B-X
to	B-X
hemorrhaging	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
and	B-X
severely	B-X
impairs	B-X
fetal	B-X
liver	B-X
hematopoiesis	B-X
<EOS>	B-X
We	B-X
and	B-X
others	B-X
previously	B-X
demonstrated	B-X
that	B-X
homozygous	B-X
disruption	B-X
of	B-X
the	B-X
mouse	B-X
Cbfa2	B-X
(	B-X
AML1	B-X
)	B-X
gene	B-X
results	B-X
in	B-X
embryonic	B-X
lethality	B-X
at	B-X
midgestation	B-X
due	B-X
to	B-X
hemorrhaging	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
blocks	B-X
fetal	B-X
liver	B-X
hematopoiesis	B-X
<EOS>	B-X
Mice	B-X
heterozygous	B-X
for	B-X
an	B-X
AML1	B-X
-	B-X
ETO	B-X
allele	B-X
(	B-X
AML1	B-X
-	B-X
ETO	B-X
/	B-X
+	B-X
)	B-X
die	B-X
in	B-X
midgestation	B-X
from	B-X
haemorrhaging	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
exhibit	B-X
a	B-X
severe	B-X
block	B-X
in	B-X
fetal	B-X
liver	B-X
haematopoiesis	B-X
<EOS>	B-X
Reduced	B-X
expression	B-X
of	B-X
rad21	B-X
in	B-X
zebrafish	B-X
,	B-X
and	B-X
dysregulation	B-X
of	B-X
these	B-X
target	B-X
genes	B-X
,	B-X
disrupts	B-X
intestinal	B-X
transit	B-X
and	B-X
the	B-X
development	B-X
of	B-X
enteric	B-X
neurons	B-X

Results	O
of	O
this	O
study	O
show	O
that	O
Cbfb-deficient	O
mouse	O
embryonic	B-cell_type
stem	I-cell_type
(	I-cell_type
ES	I-cell_type
)	I-cell_type
cells	I-cell_type
can	O
differentiate	O
into	O
primitive	B-cell_type
erythroid	I-cell_type
colonies	I-cell_type
in	O
vitro	O
,	O
but	O
are	O
impaired	O
in	O
their	O
ability	O
to	O
produce	O
definitive	O
erythroid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
colonies	I-cell_type
,	O
mimicking	O
the	O
in	O
vivo	O
defect	O
.	O

Definitive	O
hematopoiesis	O
is	O
restored	O
by	O
ectopic	O
expression	O
of	O
full-length	B-DNA
Cbfb	I-DNA
transgenes	I-DNA
,	O
as	O
well	O
as	O
by	O
a	O
transgene	O
encoding	O
only	O
the	O
heterodimerization	B-protein
domain	I-protein
of	O
CBFbeta	B-protein
.	O
<EOS>	B-X
Definitive	B-X
hematopoiesis	B-X
is	B-X
restored	B-X
by	B-X
ectopic	B-X
expression	B-X
of	B-X
full	B-X
-	B-X
length	B-X
Cbfb	B-X
transgenes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
a	B-X
transgene	B-X
encoding	B-X
only	B-X
the	B-X
heterodimerization	B-X
domain	B-X
of	B-X
CBFbeta	B-X
<EOS>	B-X
Core	B-X
-	B-X
binding	B-X
factor	B-X
beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
is	B-X
the	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
subunit	B-X
of	B-X
the	B-X
heterodimeric	B-X
CBFs	B-X
<EOS>	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
Cbfb	B-X
-	B-X
deficient	B-X
mouse	B-X
embryonic	B-X
stem	B-X
(	B-X
ES	B-X
)	B-X
cells	B-X
can	B-X
differentiate	B-X
into	B-X
primitive	B-X
erythroid	B-X
colonies	B-X
in	B-X
vitro	B-X
,	B-X
but	B-X
are	B-X
impaired	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
produce	B-X
definitive	B-X
erythroid	B-X
and	B-X
myeloid	B-X
colonies	B-X
,	B-X
mimicking	B-X
the	B-X
in	B-X
vivo	B-X
defect	B-X
<EOS>	B-X
Sequences	B-X
responsible	B-X
for	B-X
the	B-X
inability	B-X
of	B-X
CBFbeta	B-X
-	B-X
SMMHC	B-X
to	B-X
rescue	B-X
definitive	B-X
hematopoiesis	B-X
reside	B-X
in	B-X
the	B-X
SMMHC	B-X
portion	B-X
of	B-X
the	B-X
fusion	B-X
protein	B-X

In	O
contrast	O
,	O
the	O
CBFbeta	B-protein
-	O
smooth	B-protein
muscle	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
(	I-protein
SMMHC	I-protein
)	I-protein
fusion	I-protein
protein	I-protein
generated	O
by	O
the	O
inv	B-protein
(	I-protein
16	I-protein
)	I-protein
associated	O
with	O
acute	B-cell_line
myeloid	I-cell_line
leukemias	I-cell_line
(	O
M4Eo	B-cell_line
)	O
can	O
not	O
rescue	O
definitive	O
hematopoiesis	O
by	O
Cbfb-deficient	B-cell_type
ES	I-cell_type
cells	I-cell_type
.	O

Sequences	O
responsible	O
for	O
the	O
inability	O
of	O
CBFbeta	B-protein
-SMMHC	O
to	O
rescue	O
definitive	O
hematopoiesis	O
reside	O
in	O
the	O
SMMHC	B-protein
portion	I-protein
of	O
the	O
fusion	B-protein
protein	I-protein
.	O
<EOS>	B-X
Sequences	B-X
responsible	B-X
for	B-X
the	B-X
inability	B-X
of	B-X
CBFbeta	B-X
-	B-X
SMMHC	B-X
to	B-X
rescue	B-X
definitive	B-X
hematopoiesis	B-X
reside	B-X
in	B-X
the	B-X
SMMHC	B-X
portion	B-X
of	B-X
the	B-X
fusion	B-X
protein	B-X
<EOS>	B-X
Results	B-X
also	B-X
show	B-X
that	B-X
the	B-X
CBFbeta	B-X
-	B-X
SMMHC	B-X
fusion	B-X
protein	B-X
transdominantly	B-X
inhibits	B-X
definitive	B-X
hematopoiesis	B-X
,	B-X
but	B-X
not	B-X
to	B-X
the	B-X
same	B-X
extent	B-X
as	B-X
homozygous	B-X
loss	B-X
of	B-X
Runx1	B-X
or	B-X
Cbfb	B-X
<EOS>	B-X
Core	B-X
-	B-X
binding	B-X
factor	B-X
beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
,	B-X
but	B-X
not	B-X
CBFbeta	B-X
-	B-X
smooth	B-X
muscle	B-X
myosin	B-X
heavy	B-X
chain	B-X
,	B-X
rescues	B-X
definitive	B-X
hematopoiesis	B-X
in	B-X
CBFbeta	B-X
-	B-X
deficient	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
<EOS>	B-X
Genes	B-X
encoding	B-X
CBFbeta	B-X
(	B-X
CBFB	B-X
)	B-X
,	B-X
and	B-X
one	B-X
of	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
CBFalpha	B-X
subunits	B-X
,	B-X
Runx1	B-X
(	B-X
also	B-X
known	B-X
as	B-X
CBFalpha2	B-X
,	B-X
AML1	B-X
,	B-X
and	B-X
PEBP2alphaB	B-X
)	B-X
,	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
and	B-X
are	B-X
also	B-X
frequent	B-X
targets	B-X
of	B-X
chromosomal	B-X
translocations	B-X
in	B-X
acute	B-X
leukemias	B-X
in	B-X
humans	B-X

Results	O
also	O
show	O
that	O
the	O
CBFbeta-SMMHC	B-protein
fusion	I-protein
protein	I-protein
transdominantly	O
inhibits	O
definitive	O
hematopoiesis	O
,	O
but	O
not	O
to	O
the	O
same	O
extent	O
as	O
homozygous	O
loss	O
of	O
Runx1	B-protein
or	O
Cbfb	B-protein
.	O
<EOS>	B-X
Variants	B-X
that	B-X
upregulate	B-X
ATM	B-X
expression	B-X
were	B-X
associated	B-X
with	B-X
a	B-X
decreased	B-X
risk	B-X
of	B-X
somatic	B-X
ATM	B-X
mutations	B-X
across	B-X
8	B-X
cancer	B-X
types	B-X
<EOS>	B-X
This	B-X
study	B-X
highlights	B-X
the	B-X
importance	B-X
of	B-X
extended	B-X
molecular	B-X
testing	B-X
at	B-X
the	B-X
initial	B-X
diagnosis	B-X
of	B-X
CML	B-X
-	B-X
CP	B-X
at	B-X
TKI	B-X
resistance	B-X
and	B-X
/	B-X
or	B-X
disease	B-X
transformation	B-X
<EOS>	B-X
A	B-X
lung	B-X
biopsy	B-X
showed	B-X
increased	B-X
eosinophils	B-X
within	B-X
vessels	B-X
and	B-X
pleural	B-X
fibrosis	B-X
but	B-X
no	B-X
interstitial	B-X
fibrosis	B-X
or	B-X
vasculitis	B-X
<EOS>	B-X
As	B-X
with	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
,	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
minimal	B-X
residual	B-X
disease	B-X
is	B-X
an	B-X
important	B-X
factor	B-X
in	B-X
determining	B-X
the	B-X
success	B-X
of	B-X
treatment	B-X
against	B-X
AML	B-X
,	B-X
and	B-X
it	B-X
is	B-X
important	B-X
to	B-X
predict	B-X
prognosis	B-X
and	B-X
formulate	B-X
treatment	B-X
strategies	B-X
considering	B-X
the	B-X
genetic	B-X
abnormalities	B-X

CBFbeta-SMMHC	B-protein
preferentially	O
inhibits	O
the	O
differentiation	O
of	O
myeloid	B-cell_type
lineage	I-cell_type
cells	I-cell_type
,	O
while	O
increasing	O
the	O
number	O
of	O
blastlike	B-cell_type
cells	I-cell_type
in	O
culture	O
.	O
<EOS>	B-X
CBFbeta	B-X
-	B-X
SMMHC	B-X
preferentially	B-X
inhibits	B-X
the	B-X
differentiation	B-X
of	B-X
myeloid	B-X
lineage	B-X
cells	B-X
,	B-X
while	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
blastlike	B-X
cells	B-X
in	B-X
culture	B-X
<EOS>	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
show	B-X
that	B-X
Cbfb	B-X
-	B-X
deficient	B-X
mouse	B-X
embryonic	B-X
stem	B-X
(	B-X
ES	B-X
)	B-X
cells	B-X
can	B-X
differentiate	B-X
into	B-X
primitive	B-X
erythroid	B-X
colonies	B-X
in	B-X
vitro	B-X
,	B-X
but	B-X
are	B-X
impaired	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
produce	B-X
definitive	B-X
erythroid	B-X
and	B-X
myeloid	B-X
colonies	B-X
,	B-X
mimicking	B-X
the	B-X
in	B-X
vivo	B-X
defect	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
CBFbeta	B-X
-	B-X
smooth	B-X
muscle	B-X
myosin	B-X
heavy	B-X
chain	B-X
(	B-X
SMMHC	B-X
)	B-X
fusion	B-X
protein	B-X
generated	B-X
by	B-X
the	B-X
inv	B-X
(	B-X
16	B-X
)	B-X
associated	B-X
with	B-X
acute	B-X
myeloid	B-X
leukemias	B-X
(	B-X
M4Eo	B-X
)	B-X
can	B-X
not	B-X
rescue	B-X
definitive	B-X
hematopoiesis	B-X
by	B-X
Cbfb	B-X
-	B-X
deficient	B-X
ES	B-X
cells	B-X
<EOS>	B-X
Genes	B-X
encoding	B-X
CBFbeta	B-X
(	B-X
CBFB	B-X
)	B-X
,	B-X
and	B-X
one	B-X
of	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
CBFalpha	B-X
subunits	B-X
,	B-X
Runx1	B-X
(	B-X
also	B-X
known	B-X
as	B-X
CBFalpha2	B-X
,	B-X
AML1	B-X
,	B-X
and	B-X
PEBP2alphaB	B-X
)	B-X
,	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
and	B-X
are	B-X
also	B-X
frequent	B-X
targets	B-X
of	B-X
chromosomal	B-X
translocations	B-X
in	B-X
acute	B-X
leukemias	B-X
in	B-X
humans	B-X

The	O
latency	O
pattern	O
of	O
Epstein-Barr	O
virus	O
infection	O
and	O
viral	O
IL-10	B-protein
expression	O
in	O
cutaneous	B-cell_type
natural	I-cell_type
killer/T-cell	I-cell_type
lymphomas	I-cell_type
.	O
<EOS>	B-X
The	B-X
latency	B-X
pattern	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
infection	B-X
and	B-X
viral	B-X
IL	B-X
-	B-X
10	B-X
expression	B-X
in	B-X
cutaneous	B-X
natural	B-X
killer	B-X
/	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
.	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
EBV	B-X
gene	B-X
expression	B-X
patterns	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
examined	B-X
eight	B-X
patients	B-X
with	B-X
cutaneous	B-X
EBV	B-X
-	B-X
related	B-X
NK	B-X
/	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
,	B-X
including	B-X
six	B-X
patients	B-X
with	B-X
a	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
two	B-X
patients	B-X
with	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
phenotype	B-X
<EOS>	B-X
Latent	B-X
BHRF1	B-X
transcripts	B-X
encoding	B-X
bcl	B-X
-	B-X
2	B-X
homologue	B-X
and	B-X
BCRF1	B-X
transcripts	B-X
encoding	B-X
viral	B-X
interleukin	B-X
(	B-X
vIL	B-X
)	B-X
	B-X
-	B-X
10	B-X
were	B-X
detected	B-X
in	B-X
one	B-X
and	B-X
two	B-X
of	B-X
eight	B-X
patients	B-X
,	B-X
respectively	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
EBV	B-X
-	B-X
related	B-X
antigens	B-X
was	B-X
examined	B-X
by	B-X
immunostaining	B-X
using	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
and	B-X
cell	B-X
pellets	B-X
of	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X

The	O
nasal	B-cell_type
type	I-cell_type
,	I-cell_type
extranodal	I-cell_type
natural	I-cell_type
killer	I-cell_type
or	I-cell_type
T	I-cell_type
(	I-cell_type
NK/T	I-cell_type
)	I-cell_type
-cell	I-cell_type
lymphoma	I-cell_type
is	O
usually	O
associated	O
with	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
.	O
<EOS>	B-X
The	B-X
nasal	B-X
type	B-X
,	B-X
extranodal	B-X
natural	B-X
killer	B-X
or	B-X
T	B-X
(	B-X
NK	B-X
/	B-X
T	B-X
)	B-X
	B-X
-	B-X
cell	B-X
lymphoma	B-X
is	B-X
usually	B-X
associated	B-X
with	B-X
latent	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
infection	B-X
<EOS>	B-X
A	B-X
novel	B-X
,	B-X
noninvasive	B-X
diagnostic	B-X
probe	B-X
for	B-X
hydroa	B-X
vacciniforme	B-X
and	B-X
related	B-X
disorders	B-X
:	B-X
detection	B-X
of	B-X
latency	B-X
-	B-X
associated	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
transcripts	B-X
in	B-X
the	B-X
crusts	B-X
.	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
EBV	B-X
gene	B-X
expression	B-X
patterns	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
examined	B-X
eight	B-X
patients	B-X
with	B-X
cutaneous	B-X
EBV	B-X
-	B-X
related	B-X
NK	B-X
/	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
,	B-X
including	B-X
six	B-X
patients	B-X
with	B-X
a	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
two	B-X
patients	B-X
with	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
phenotype	B-X
<EOS>	B-X
Uncommonly	B-X
,	B-X
EBV	B-X
can	B-X
infect	B-X
T	B-X
or	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
in	B-X
a	B-X
person	B-X
with	B-X
a	B-X
defect	B-X
in	B-X
innate	B-X
immunity	B-X
,	B-X
and	B-X
EBV	B-X
infection	B-X
can	B-X
cause	B-X
unique	B-X
systemic	B-X
lymphoproliferative	B-X
diseases	B-X
(	B-X
LPD	B-X
)	B-X
of	B-X
childhood	B-X

In	O
order	O
to	O
elucidate	O
the	O
EBV	O
gene	O
expression	O
patterns	O
in	O
vivo	O
,	O
we	O
examined	O
eight	O
patients	O
with	O
cutaneous	O
EBV-related	O
NK/T-cell	O
lymphomas	O
,	O
including	O
six	O
patients	O
with	O
a	O
NK-cell	O
phenotype	O
and	O
two	O
patients	O
with	O
a	O
T-cell	O
phenotype	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
EBV	B-X
gene	B-X
expression	B-X
patterns	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
examined	B-X
eight	B-X
patients	B-X
with	B-X
cutaneous	B-X
EBV	B-X
-	B-X
related	B-X
NK	B-X
/	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
,	B-X
including	B-X
six	B-X
patients	B-X
with	B-X
a	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
two	B-X
patients	B-X
with	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
phenotype	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
EBV	B-X
-	B-X
related	B-X
antigens	B-X
was	B-X
examined	B-X
by	B-X
immunostaining	B-X
using	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
and	B-X
cell	B-X
pellets	B-X
of	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
LMP	B-X
-	B-X
1	B-X
)	B-X
mRNA	B-X
was	B-X
detected	B-X
in	B-X
seven	B-X
of	B-X
eight	B-X
patients	B-X
and	B-X
all	B-X
cell	B-X
lines	B-X
,	B-X
whereas	B-X
EBNA	B-X
-	B-X
2	B-X
transcripts	B-X
were	B-X
found	B-X
only	B-X
in	B-X
the	B-X
cell	B-X
lines	B-X
<EOS>	B-X
The	B-X
implication	B-X
of	B-X
EBV	B-X
in	B-X
the	B-X
skin	B-X
lesions	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
EBV	B-X
-	B-X
DNA	B-X
,	B-X
EBV	B-X
-	B-X
encoded	B-X
nuclear	B-X
RNA	B-X
(	B-X
EBER	B-X
)	B-X
and	B-X
a	B-X
clonality	B-X
of	B-X
EBV	B-X
-	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
terminal	B-X
repeats	B-X

The	O
implication	O
of	O
EBV	O
in	O
the	O
skin	O
lesions	O
was	O
determined	O
by	O
the	O
presence	O
of	O
EBV-DNA	B-DNA
,	O
EBV-encoded	B-RNA
nuclear	I-RNA
RNA	I-RNA
(	O
EBER	B-RNA
)	O
and	O
a	O
clonality	O
of	O
EBV-DNA	B-DNA
fragments	I-DNA
containing	O
the	O
terminal	B-DNA
repeats	I-DNA
.	O

Transcripts	O
of	O
EBV-encoded	B-DNA
genes	I-DNA
were	O
screened	O
by	O
reverse	O
transcription-	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
,	O
and	O
confirmed	O
by	O
Southern	O
blot	O
hybridization	O
.	O
<EOS>	B-X
Transcripts	B-X
of	B-X
EBV	B-X
-	B-X
encoded	B-X
genes	B-X
were	B-X
screened	B-X
by	B-X
reverse	B-X
transcription	B-X
-	B-X
	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT	B-X
-	B-X
PCR	B-X
)	B-X
,	B-X
and	B-X
confirmed	B-X
by	B-X
Southern	B-X
blot	B-X
hybridization	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
EBV	B-X
-	B-X
related	B-X
antigens	B-X
was	B-X
examined	B-X
by	B-X
immunostaining	B-X
using	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
and	B-X
cell	B-X
pellets	B-X
of	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
<EOS>	B-X
The	B-X
implication	B-X
of	B-X
EBV	B-X
in	B-X
the	B-X
skin	B-X
lesions	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
EBV	B-X
-	B-X
DNA	B-X
,	B-X
EBV	B-X
-	B-X
encoded	B-X
nuclear	B-X
RNA	B-X
(	B-X
EBER	B-X
)	B-X
and	B-X
a	B-X
clonality	B-X
of	B-X
EBV	B-X
-	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
terminal	B-X
repeats	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
EBV	B-X
gene	B-X
expression	B-X
patterns	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
examined	B-X
eight	B-X
patients	B-X
with	B-X
cutaneous	B-X
EBV	B-X
-	B-X
related	B-X
NK	B-X
/	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
,	B-X
including	B-X
six	B-X
patients	B-X
with	B-X
a	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
two	B-X
patients	B-X
with	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
phenotype	B-X

The	O
expression	O
of	O
EBV-related	B-protein
antigens	I-protein
was	O
examined	O
by	O
immunostaining	O
using	O
paraffin-embedded	O
tissue	O
sections	O
and	O
cell	O
pellets	O
of	O
EBV-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
EBV	B-X
-	B-X
related	B-X
antigens	B-X
was	B-X
examined	B-X
by	B-X
immunostaining	B-X
using	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
and	B-X
cell	B-X
pellets	B-X
of	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Immunostaining	B-X
showed	B-X
no	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
EBNA	B-X
-	B-X
2	B-X
or	B-X
ZEBRA	B-X
antigens	B-X
in	B-X
the	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
,	B-X
although	B-X
they	B-X
were	B-X
positive	B-X
in	B-X
the	B-X
cell	B-X
line	B-X
cells	B-X
<EOS>	B-X
The	B-X
implication	B-X
of	B-X
EBV	B-X
in	B-X
the	B-X
skin	B-X
lesions	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
EBV	B-X
-	B-X
DNA	B-X
,	B-X
EBV	B-X
-	B-X
encoded	B-X
nuclear	B-X
RNA	B-X
(	B-X
EBER	B-X
)	B-X
and	B-X
a	B-X
clonality	B-X
of	B-X
EBV	B-X
-	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
terminal	B-X
repeats	B-X
<EOS>	B-X
Our	B-X
study	B-X
demonstrated	B-X
that	B-X
all	B-X
samples	B-X
from	B-X
the	B-X
patients	B-X
contained	B-X
EBV	B-X
nuclear	B-X
antigen	B-X
(	B-X
EBNA	B-X
)	B-X
	B-X
-	B-X
1	B-X
mRNA	B-X
which	B-X
was	B-X
transcribed	B-X
using	B-X
the	B-X
Q	B-X
promoter	B-X
,	B-X
whereas	B-X
both	B-X
the	B-X
Q	B-X
promoter	B-X
and	B-X
another	B-X
upstream	B-X
promoter	B-X
(	B-X
Cp	B-X
/	B-X
Wp	B-X
)	B-X
were	B-X
used	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
,	B-X
B95	B-X

Our	O
study	O
demonstrated	O
that	O
all	O
samples	O
from	O
the	O
patients	O
contained	O
EBV	B-RNA
nuclear	I-RNA
antigen	I-RNA
(	I-RNA
EBNA	I-RNA
)	I-RNA
-1	I-RNA
mRNA	I-RNA
which	O
was	O
transcribed	O
using	O
the	O
Q	B-DNA
promoter	I-DNA
,	O
whereas	O
both	O
the	O
Q	B-DNA
promoter	I-DNA
and	O
another	O
upstream	B-DNA
promoter	I-DNA
(	O
Cp/Wp	B-DNA
)	O
were	O
used	O
in	O
EBV-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
B95.8	B-cell_line
,	O
Raji	B-cell_line
and	O
Jiyoye	B-cell_line
.	O

Latent	B-RNA
membrane	I-RNA
protein-1	I-RNA
(	I-RNA
LMP-1	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
detected	O
in	O
seven	O
of	O
eight	O
patients	O
and	O
all	O
cell	B-cell_line
lines	I-cell_line
,	O
whereas	O
EBNA-2	B-RNA
transcripts	I-RNA
were	O
found	O
only	O
in	O
the	O
cell	B-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
LMP	B-X
-	B-X
1	B-X
)	B-X
mRNA	B-X
was	B-X
detected	B-X
in	B-X
seven	B-X
of	B-X
eight	B-X
patients	B-X
and	B-X
all	B-X
cell	B-X
lines	B-X
,	B-X
whereas	B-X
EBNA	B-X
-	B-X
2	B-X
transcripts	B-X
were	B-X
found	B-X
only	B-X
in	B-X
the	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Immunostaining	B-X
showed	B-X
no	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
EBNA	B-X
-	B-X
2	B-X
or	B-X
ZEBRA	B-X
antigens	B-X
in	B-X
the	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
,	B-X
although	B-X
they	B-X
were	B-X
positive	B-X
in	B-X
the	B-X
cell	B-X
line	B-X
cells	B-X
<EOS>	B-X
Our	B-X
study	B-X
demonstrated	B-X
that	B-X
all	B-X
samples	B-X
from	B-X
the	B-X
patients	B-X
contained	B-X
EBV	B-X
nuclear	B-X
antigen	B-X
(	B-X
EBNA	B-X
)	B-X
	B-X
-	B-X
1	B-X
mRNA	B-X
which	B-X
was	B-X
transcribed	B-X
using	B-X
the	B-X
Q	B-X
promoter	B-X
,	B-X
whereas	B-X
both	B-X
the	B-X
Q	B-X
promoter	B-X
and	B-X
another	B-X
upstream	B-X
promoter	B-X
(	B-X
Cp	B-X
/	B-X
Wp	B-X
)	B-X
were	B-X
used	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
,	B-X
B95	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
the	B-X
EBV	B-X
gene	B-X
expression	B-X
patterns	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
examined	B-X
eight	B-X
patients	B-X
with	B-X
cutaneous	B-X
EBV	B-X
-	B-X
related	B-X
NK	B-X
/	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
,	B-X
including	B-X
six	B-X
patients	B-X
with	B-X
a	B-X
NK	B-X
-	B-X
cell	B-X
phenotype	B-X
and	B-X
two	B-X
patients	B-X
with	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
phenotype	B-X

Immunostaining	O
showed	O
no	O
LMP-1	B-protein
,	I-protein
EBNA-2	I-protein
or	I-protein
ZEBRA	I-protein
antigens	I-protein
in	O
the	O
paraffin-embedded	O
tissue	O
sections	O
,	O
although	O
they	O
were	O
positive	O
in	O
the	O
cell	B-cell_line
line	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Immunostaining	B-X
showed	B-X
no	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
EBNA	B-X
-	B-X
2	B-X
or	B-X
ZEBRA	B-X
antigens	B-X
in	B-X
the	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
,	B-X
although	B-X
they	B-X
were	B-X
positive	B-X
in	B-X
the	B-X
cell	B-X
line	B-X
cells	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
EBV	B-X
-	B-X
related	B-X
antigens	B-X
was	B-X
examined	B-X
by	B-X
immunostaining	B-X
using	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
and	B-X
cell	B-X
pellets	B-X
of	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Cytotoxic	B-X
injury	B-X
granule	B-X
-	B-X
related	B-X
antigens	B-X
of	B-X
TIA	B-X
-	B-X
1	B-X
and	B-X
granzyme	B-X
B	B-X
were	B-X
positive	B-X
in	B-X
tumor	B-X
cells	B-X
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
LMP	B-X
-	B-X
1	B-X
)	B-X
mRNA	B-X
was	B-X
detected	B-X
in	B-X
seven	B-X
of	B-X
eight	B-X
patients	B-X
and	B-X
all	B-X
cell	B-X
lines	B-X
,	B-X
whereas	B-X
EBNA	B-X
-	B-X
2	B-X
transcripts	B-X
were	B-X
found	B-X
only	B-X
in	B-X
the	B-X
cell	B-X
lines	B-X

Latent	B-RNA
BHRF1	I-RNA
transcripts	I-RNA
encoding	O
bcl-2	B-RNA
homologue	I-RNA
and	O
BCRF1	B-RNA
transcripts	I-RNA
encoding	O
viral	B-protein
interleukin	I-protein
(	I-protein
vIL	I-protein
)	I-protein
-10	I-protein
were	O
detected	O
in	O
one	O
and	O
two	O
of	O
eight	O
patients	O
,	O
respectively	O
.	O
<EOS>	B-X
Latent	B-X
BHRF1	B-X
transcripts	B-X
encoding	B-X
bcl	B-X
-	B-X
2	B-X
homologue	B-X
and	B-X
BCRF1	B-X
transcripts	B-X
encoding	B-X
viral	B-X
interleukin	B-X
(	B-X
vIL	B-X
)	B-X
	B-X
-	B-X
10	B-X
were	B-X
detected	B-X
in	B-X
one	B-X
and	B-X
two	B-X
of	B-X
eight	B-X
patients	B-X
,	B-X
respectively	B-X
<EOS>	B-X
A	B-X
patient	B-X
with	B-X
NK	B-X
-	B-X
cell	B-X
lymphoma	B-X
expressing	B-X
both	B-X
transcripts	B-X
died	B-X
of	B-X
rapid	B-X
progression	B-X
of	B-X
the	B-X
illness	B-X
<EOS>	B-X
Our	B-X
study	B-X
demonstrated	B-X
that	B-X
all	B-X
samples	B-X
from	B-X
the	B-X
patients	B-X
contained	B-X
EBV	B-X
nuclear	B-X
antigen	B-X
(	B-X
EBNA	B-X
)	B-X
	B-X
-	B-X
1	B-X
mRNA	B-X
which	B-X
was	B-X
transcribed	B-X
using	B-X
the	B-X
Q	B-X
promoter	B-X
,	B-X
whereas	B-X
both	B-X
the	B-X
Q	B-X
promoter	B-X
and	B-X
another	B-X
upstream	B-X
promoter	B-X
(	B-X
Cp	B-X
/	B-X
Wp	B-X
)	B-X
were	B-X
used	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
,	B-X
B95	B-X
<EOS>	B-X
The	B-X
latency	B-X
pattern	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
infection	B-X
and	B-X
viral	B-X
IL	B-X
-	B-X
10	B-X
expression	B-X
in	B-X
cutaneous	B-X
natural	B-X
killer	B-X
/	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
.	B-X

A	O
patient	O
with	O
NK-cell	O
lymphoma	O
expressing	O
both	O
transcripts	O
died	O
of	O
rapid	O
progression	O
of	O
the	O
illness	O
.	O
<EOS>	B-X
A	B-X
patient	B-X
with	B-X
NK	B-X
-	B-X
cell	B-X
lymphoma	B-X
expressing	B-X
both	B-X
transcripts	B-X
died	B-X
of	B-X
rapid	B-X
progression	B-X
of	B-X
the	B-X
illness	B-X
<EOS>	B-X
Latent	B-X
BHRF1	B-X
transcripts	B-X
encoding	B-X
bcl	B-X
-	B-X
2	B-X
homologue	B-X
and	B-X
BCRF1	B-X
transcripts	B-X
encoding	B-X
viral	B-X
interleukin	B-X
(	B-X
vIL	B-X
)	B-X
	B-X
-	B-X
10	B-X
were	B-X
detected	B-X
in	B-X
one	B-X
and	B-X
two	B-X
of	B-X
eight	B-X
patients	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Immunostaining	B-X
showed	B-X
no	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
EBNA	B-X
-	B-X
2	B-X
or	B-X
ZEBRA	B-X
antigens	B-X
in	B-X
the	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
,	B-X
although	B-X
they	B-X
were	B-X
positive	B-X
in	B-X
the	B-X
cell	B-X
line	B-X
cells	B-X
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
LMP	B-X
-	B-X
1	B-X
)	B-X
mRNA	B-X
was	B-X
detected	B-X
in	B-X
seven	B-X
of	B-X
eight	B-X
patients	B-X
and	B-X
all	B-X
cell	B-X
lines	B-X
,	B-X
whereas	B-X
EBNA	B-X
-	B-X
2	B-X
transcripts	B-X
were	B-X
found	B-X
only	B-X
in	B-X
the	B-X
cell	B-X
lines	B-X

Our	O
results	O
indicate	O
that	O
the	O
restricted	O
expression	O
of	O
the	O
latency-associated	B-DNA
EBV	I-DNA
genes	I-DNA
and	O
the	O
production	O
of	O
vIL-10	B-RNA
and	I-RNA
bcl-2	I-RNA
homologue	I-RNA
may	O
favour	O
tumour	O
growth	O
,	O
evading	O
the	O
host	O
immune	O
surveillance	O
.	O
<EOS>	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
restricted	B-X
expression	B-X
of	B-X
the	B-X
latency	B-X
-	B-X
associated	B-X
EBV	B-X
genes	B-X
and	B-X
the	B-X
production	B-X
of	B-X
vIL	B-X
-	B-X
10	B-X
and	B-X
bcl	B-X
-	B-X
2	B-X
homologue	B-X
may	B-X
favour	B-X
tumour	B-X
growth	B-X
,	B-X
evading	B-X
the	B-X
host	B-X
immune	B-X
surveillance	B-X
<EOS>	B-X
Our	B-X
study	B-X
demonstrated	B-X
that	B-X
all	B-X
samples	B-X
from	B-X
the	B-X
patients	B-X
contained	B-X
EBV	B-X
nuclear	B-X
antigen	B-X
(	B-X
EBNA	B-X
)	B-X
	B-X
-	B-X
1	B-X
mRNA	B-X
which	B-X
was	B-X
transcribed	B-X
using	B-X
the	B-X
Q	B-X
promoter	B-X
,	B-X
whereas	B-X
both	B-X
the	B-X
Q	B-X
promoter	B-X
and	B-X
another	B-X
upstream	B-X
promoter	B-X
(	B-X
Cp	B-X
/	B-X
Wp	B-X
)	B-X
were	B-X
used	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
,	B-X
B95	B-X
<EOS>	B-X
Immunostaining	B-X
showed	B-X
no	B-X
LMP	B-X
-	B-X
1	B-X
,	B-X
EBNA	B-X
-	B-X
2	B-X
or	B-X
ZEBRA	B-X
antigens	B-X
in	B-X
the	B-X
paraffin	B-X
-	B-X
embedded	B-X
tissue	B-X
sections	B-X
,	B-X
although	B-X
they	B-X
were	B-X
positive	B-X
in	B-X
the	B-X
cell	B-X
line	B-X
cells	B-X
<EOS>	B-X
Transcripts	B-X
of	B-X
EBV	B-X
-	B-X
encoded	B-X
genes	B-X
were	B-X
screened	B-X
by	B-X
reverse	B-X
transcription	B-X
-	B-X
	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT	B-X
-	B-X
PCR	B-X
)	B-X
,	B-X
and	B-X
confirmed	B-X
by	B-X
Southern	B-X
blot	B-X
hybridization	B-X

Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O

Oxidized	O
alkyl	O
phospholipids	O
are	O
specific	O
,	O
high	O
affinity	O
peroxisome	O
proliferator-activated	O
receptor	O
gamma	O
ligands	O
and	O
agonists	O
.	O
<EOS>	B-X
Oxidized	B-X
alkyl	B-X
phospholipids	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
ligands	B-X
and	B-X
agonists	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
certain	B-X
alkyl	B-X
phospholipid	B-X
oxidation	B-X
products	B-X
in	B-X
oxLDL	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
extracellular	B-X
ligands	B-X
and	B-X
agonists	B-X
for	B-X
PPARgamma	B-X
that	B-X
induce	B-X
PPAR	B-X
-	B-X
responsive	B-X
genes	B-X
<EOS>	B-X
Synthetic	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
(	B-X
PPAR	B-X
)	B-X
agonists	B-X
are	B-X
known	B-X
,	B-X
but	B-X
biologic	B-X
ligands	B-X
are	B-X
of	B-X
low	B-X
affinity	B-X
<EOS>	B-X
We	B-X
identified	B-X
an	B-X
abundant	B-X
oxidatively	B-X
fragmented	B-X
alkyl	B-X
phospholipid	B-X
in	B-X
oxLDL	B-X
,	B-X
hexadecyl	B-X
azelaoyl	B-X
phosphatidylcholine	B-X
(	B-X
azPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
high	B-X
affinity	B-X
ligand	B-X
and	B-X
agonist	B-X
for	B-X
PPARgamma	B-X

Synthetic	O
high	O
affinity	O
peroxisome	O
proliferator-activated	O
receptor	O
(	O
PPAR	O
)	O
agonists	O
are	O
known	O
,	O
but	O
biologic	O
ligands	O
are	O
of	O
low	O
affinity	O
.	O
<EOS>	B-X
Synthetic	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
(	B-X
PPAR	B-X
)	B-X
agonists	B-X
are	B-X
known	B-X
,	B-X
but	B-X
biologic	B-X
ligands	B-X
are	B-X
of	B-X
low	B-X
affinity	B-X
<EOS>	B-X
Oxidized	B-X
alkyl	B-X
phospholipids	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
ligands	B-X
and	B-X
agonists	B-X
.	B-X
<EOS>	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
azPC	B-X
bound	B-X
recombinant	B-X
PPARgamma	B-X
with	B-X
an	B-X
affinity	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
(	B-X
(	B-X
app	B-X
)	B-X
)	B-X
approximately	B-X
40	B-X
nm	B-X
)	B-X
that	B-X
was	B-X
equivalent	B-X
to	B-X
rosiglitazone	B-X
(	B-X
BRL49653	B-X
)	B-X
,	B-X
and	B-X
competition	B-X
with	B-X
rosiglitazone	B-X
showed	B-X
that	B-X
binding	B-X
occurred	B-X
in	B-X
the	B-X
ligand	B-X
-	B-X
binding	B-X
pocket	B-X
<EOS>	B-X
We	B-X
identified	B-X
an	B-X
abundant	B-X
oxidatively	B-X
fragmented	B-X
alkyl	B-X
phospholipid	B-X
in	B-X
oxLDL	B-X
,	B-X
hexadecyl	B-X
azelaoyl	B-X
phosphatidylcholine	B-X
(	B-X
azPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
high	B-X
affinity	B-X
ligand	B-X
and	B-X
agonist	B-X
for	B-X
PPARgamma	B-X

Oxidized	B-protein
low	I-protein
density	I-protein
lipoprotein	I-protein
(	O
oxLDL	B-protein
)	O
is	O
inflammatory	O
and	O
signals	O
through	O
PPARs	B-protein
.	O
<EOS>	B-X
Oxidized	B-X
Low	B-X
-	B-X
Density	B-X
Lipoprotein	B-X
Loading	B-X
of	B-X
Macrophages	B-X
Downregulates	B-X
TLR	B-X
-	B-X
Induced	B-X
Proinflammatory	B-X
Responses	B-X
in	B-X
a	B-X
Gene	B-X
-	B-X
Specific	B-X
and	B-X
Temporal	B-X
Manner	B-X
through	B-X
Transcriptional	B-X
Control	B-X
.	B-X
<EOS>	B-X
In	B-X
vitro	B-X
,	B-X
baicalin	B-X
restricted	B-X
oxidized	B-X
-	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
ox	B-X
-	B-X
LDL	B-X
)	B-X
	B-X
-	B-X
induced	B-X
intracellular	B-X
lipid	B-X
accumulation	B-X
and	B-X
foam	B-X
cell	B-X
formation	B-X
in	B-X
THP	B-X
-	B-X
1	B-X
macrophages	B-X
<EOS>	B-X
7	B-X
foam	B-X
cell	B-X
formation	B-X
and	B-X
anti	B-X
-	B-X
inflammatory	B-X
in	B-X
vitro	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
oxidized	B-X
low	B-X
-	B-X
density	B-X
lipoprotein	B-X
(	B-X
ox	B-X
-	B-X
LDL	B-X
)	B-X
markedly	B-X
decreased	B-X
lncRNA	B-X
AC096664	B-X

We	O
showed	O
,	O
by	O
phospholipase	O
A	O
(	O
1	O
)	O
digestion	O
,	O
that	O
PPARgamma	O
agonists	O
in	O
oxLDL	B-protein
arise	O
from	O
the	O
small	O
pool	O
of	O
alkyl	O
phosphatidylcholines	O
in	O
LDL	B-protein
.	O
<EOS>	B-X
We	B-X
showed	B-X
,	B-X
by	B-X
phospholipase	B-X
A	B-X
(	B-X
1	B-X
)	B-X
digestion	B-X
,	B-X
that	B-X
PPARgamma	B-X
agonists	B-X
in	B-X
oxLDL	B-X
arise	B-X
from	B-X
the	B-X
small	B-X
pool	B-X
of	B-X
alkyl	B-X
phosphatidylcholines	B-X
in	B-X
LDL	B-X
<EOS>	B-X
Oxidized	B-X
alkyl	B-X
phospholipids	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
ligands	B-X
and	B-X
agonists	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
certain	B-X
alkyl	B-X
phospholipid	B-X
oxidation	B-X
products	B-X
in	B-X
oxLDL	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
extracellular	B-X
ligands	B-X
and	B-X
agonists	B-X
for	B-X
PPARgamma	B-X
that	B-X
induce	B-X
PPAR	B-X
-	B-X
responsive	B-X
genes	B-X
<EOS>	B-X
The	B-X
scavenger	B-X
receptor	B-X
CD36	B-X
is	B-X
encoded	B-X
by	B-X
a	B-X
PPRE	B-X
-	B-X
responsive	B-X
gene	B-X
,	B-X
and	B-X
azPC	B-X
enhanced	B-X
expression	B-X
of	B-X
CD36	B-X
in	B-X
primary	B-X
human	B-X
monocytes	B-X

We	O
identified	O
an	O
abundant	O
oxidatively	O
fragmented	O
alkyl	O
phospholipid	O
in	O
oxLDL	B-protein
,	O
hexadecyl	O
azelaoyl	O
phosphatidylcholine	O
(	O
azPC	O
)	O
,	O
as	O
a	O
high	O
affinity	O
ligand	O
and	O
agonist	O
for	O
PPARgamma	B-protein
.	O
<EOS>	B-X
We	B-X
identified	B-X
an	B-X
abundant	B-X
oxidatively	B-X
fragmented	B-X
alkyl	B-X
phospholipid	B-X
in	B-X
oxLDL	B-X
,	B-X
hexadecyl	B-X
azelaoyl	B-X
phosphatidylcholine	B-X
(	B-X
azPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
high	B-X
affinity	B-X
ligand	B-X
and	B-X
agonist	B-X
for	B-X
PPARgamma	B-X
<EOS>	B-X
Oxidized	B-X
alkyl	B-X
phospholipids	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
ligands	B-X
and	B-X
agonists	B-X
.	B-X
<EOS>	B-X
Oxidized	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
oxLDL	B-X
)	B-X
is	B-X
inflammatory	B-X
and	B-X
signals	B-X
through	B-X
PPARs	B-X
<EOS>	B-X
Overexpression	B-X
of	B-X
PPARalpha	B-X
or	B-X
PPARgamma	B-X
revealed	B-X
that	B-X
azPC	B-X
was	B-X
a	B-X
specific	B-X
PPARgamma	B-X
agonist	B-X

[	O
(	O
3	O
)	O
H	O
]	O
azPC	O
bound	O
recombinant	B-protein
PPARgamma	I-protein
with	O
an	O
affinity	O
(	O
K	O
(	O
d	O
)	O
(	O
(	O
app	O
)	O
)	O
approximately	O
40	O
nm	O
)	O
that	O
was	O
equivalent	O
to	O
rosiglitazone	O
(	O
BRL49653	O
)	O
,	O
and	O
competition	O
with	O
rosiglitazone	O
showed	O
that	O
binding	O
occurred	O
in	O
the	O
ligand-binding	B-protein
pocket	I-protein
.	O

azPC	O
induced	O
PPRE	O
reporter	O
gene	O
expression	O
,	O
as	O
did	O
rosiglitazone	O
,	O
with	O
a	O
half-maximal	O
effect	O
at	O
100	O
nm	O
.	O
<EOS>	B-X
azPC	B-X
induced	B-X
PPRE	B-X
reporter	B-X
gene	B-X
expression	B-X
,	B-X
as	B-X
did	B-X
rosiglitazone	B-X
,	B-X
with	B-X
a	B-X
half	B-X
-	B-X
maximal	B-X
effect	B-X
at	B-X
100	B-X
nm	B-X
<EOS>	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
azPC	B-X
bound	B-X
recombinant	B-X
PPARgamma	B-X
with	B-X
an	B-X
affinity	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
(	B-X
(	B-X
app	B-X
)	B-X
)	B-X
approximately	B-X
40	B-X
nm	B-X
)	B-X
that	B-X
was	B-X
equivalent	B-X
to	B-X
rosiglitazone	B-X
(	B-X
BRL49653	B-X
)	B-X
,	B-X
and	B-X
competition	B-X
with	B-X
rosiglitazone	B-X
showed	B-X
that	B-X
binding	B-X
occurred	B-X
in	B-X
the	B-X
ligand	B-X
-	B-X
binding	B-X
pocket	B-X
<EOS>	B-X
We	B-X
identified	B-X
an	B-X
abundant	B-X
oxidatively	B-X
fragmented	B-X
alkyl	B-X
phospholipid	B-X
in	B-X
oxLDL	B-X
,	B-X
hexadecyl	B-X
azelaoyl	B-X
phosphatidylcholine	B-X
(	B-X
azPC	B-X
)	B-X
,	B-X
as	B-X
a	B-X
high	B-X
affinity	B-X
ligand	B-X
and	B-X
agonist	B-X
for	B-X
PPARgamma	B-X
<EOS>	B-X
Oxidized	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
oxLDL	B-X
)	B-X
is	B-X
inflammatory	B-X
and	B-X
signals	B-X
through	B-X
PPARs	B-X

Overexpression	O
of	O
PPARalpha	B-protein
or	O
PPARgamma	B-protein
revealed	O
that	O
azPC	O
was	O
a	O
specific	O
PPARgamma	O
agonist	O
.	O
<EOS>	B-X
Overexpression	B-X
of	B-X
C	B-X
/	B-X
EBPα	B-X
significantly	B-X
increased	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
TAG	B-X
synthesis	B-X
(	B-X
AGPAT6	B-X
,	B-X
DGAT2	B-X
,	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
Overexpression	B-X
of	B-X
phosphatidylserine	B-X
decarboxylase	B-X
(	B-X
PISD	B-X
)	B-X
alleviated	B-X
the	B-X
NASH	B-X
-	B-X
like	B-X
phenotype	B-X
in	B-X
Cds2	B-X
<EOS>	B-X
The	B-X
modulation	B-X
of	B-X
PPARGC1B	B-X
by	B-X
miR136	B-X
may	B-X
provide	B-X
a	B-X
new	B-X
potential	B-X
target	B-X
for	B-X
increasing	B-X
intramuscular	B-X
fat	B-X
<EOS>	B-X
The	B-X
overexpression	B-X
of	B-X
the	B-X
RXRA	B-X
gene	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
double	B-X
-	B-X
luciferase	B-X
reporter	B-X
gene	B-X
of	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
CD36	B-X
promoter	B-X
was	B-X
higher	B-X
than	B-X
that	B-X
of	B-X
the	B-X
mutant	B-X
type	B-X

The	O
scavenger	B-protein
receptor	I-protein
CD36	I-protein
is	O
encoded	O
by	O
a	O
PPRE-responsive	B-DNA
gene	I-DNA
,	O
and	O
azPC	O
enhanced	O
expression	O
of	O
CD36	B-protein
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
The	B-X
scavenger	B-X
receptor	B-X
CD36	B-X
is	B-X
encoded	B-X
by	B-X
a	B-X
PPRE	B-X
-	B-X
responsive	B-X
gene	B-X
,	B-X
and	B-X
azPC	B-X
enhanced	B-X
expression	B-X
of	B-X
CD36	B-X
in	B-X
primary	B-X
human	B-X
monocytes	B-X
<EOS>	B-X
Overexpression	B-X
of	B-X
PPARalpha	B-X
or	B-X
PPARgamma	B-X
revealed	B-X
that	B-X
azPC	B-X
was	B-X
a	B-X
specific	B-X
PPARgamma	B-X
agonist	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
anti	B-X
-	B-X
CD36	B-X
inhibited	B-X
azPC	B-X
uptake	B-X
,	B-X
and	B-X
it	B-X
inhibited	B-X
PPRE	B-X
reporter	B-X
induction	B-X
<EOS>	B-X
Thus	B-X
,	B-X
certain	B-X
alkyl	B-X
phospholipid	B-X
oxidation	B-X
products	B-X
in	B-X
oxLDL	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
extracellular	B-X
ligands	B-X
and	B-X
agonists	B-X
for	B-X
PPARgamma	B-X
that	B-X
induce	B-X
PPAR	B-X
-	B-X
responsive	B-X
genes	B-X

We	O
found	O
that	O
anti-CD36	B-protein
inhibited	O
azPC	O
uptake	O
,	O
and	O
it	O
inhibited	O
PPRE	O
reporter	O
induction	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
anti	B-X
-	B-X
CD36	B-X
inhibited	B-X
azPC	B-X
uptake	B-X
,	B-X
and	B-X
it	B-X
inhibited	B-X
PPRE	B-X
reporter	B-X
induction	B-X
<EOS>	B-X
The	B-X
scavenger	B-X
receptor	B-X
CD36	B-X
is	B-X
encoded	B-X
by	B-X
a	B-X
PPRE	B-X
-	B-X
responsive	B-X
gene	B-X
,	B-X
and	B-X
azPC	B-X
enhanced	B-X
expression	B-X
of	B-X
CD36	B-X
in	B-X
primary	B-X
human	B-X
monocytes	B-X
<EOS>	B-X
Thus	B-X
,	B-X
certain	B-X
alkyl	B-X
phospholipid	B-X
oxidation	B-X
products	B-X
in	B-X
oxLDL	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
extracellular	B-X
ligands	B-X
and	B-X
agonists	B-X
for	B-X
PPARgamma	B-X
that	B-X
induce	B-X
PPAR	B-X
-	B-X
responsive	B-X
genes	B-X
<EOS>	B-X
We	B-X
showed	B-X
,	B-X
by	B-X
phospholipase	B-X
A	B-X
(	B-X
1	B-X
)	B-X
digestion	B-X
,	B-X
that	B-X
PPARgamma	B-X
agonists	B-X
in	B-X
oxLDL	B-X
arise	B-X
from	B-X
the	B-X
small	B-X
pool	B-X
of	B-X
alkyl	B-X
phosphatidylcholines	B-X
in	B-X
LDL	B-X

Results	O
with	O
a	O
small	O
molecule	O
phospholipid	B-protein
flippase	I-protein
mimetic	I-protein
suggest	O
azPC	O
acts	O
intracellularly	O
and	O
that	O
cellular	O
azPC	O
accumulation	O
was	O
efficient	O
.	O
<EOS>	B-X
Results	B-X
with	B-X
a	B-X
small	B-X
molecule	B-X
phospholipid	B-X
flippase	B-X
mimetic	B-X
suggest	B-X
azPC	B-X
acts	B-X
intracellularly	B-X
and	B-X
that	B-X
cellular	B-X
azPC	B-X
accumulation	B-X
was	B-X
efficient	B-X
<EOS>	B-X
Thus	B-X
,	B-X
certain	B-X
alkyl	B-X
phospholipid	B-X
oxidation	B-X
products	B-X
in	B-X
oxLDL	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
extracellular	B-X
ligands	B-X
and	B-X
agonists	B-X
for	B-X
PPARgamma	B-X
that	B-X
induce	B-X
PPAR	B-X
-	B-X
responsive	B-X
genes	B-X
<EOS>	B-X
Oxidized	B-X
alkyl	B-X
phospholipids	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
ligands	B-X
and	B-X
agonists	B-X
.	B-X
<EOS>	B-X
Synthetic	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
(	B-X
PPAR	B-X
)	B-X
agonists	B-X
are	B-X
known	B-X
,	B-X
but	B-X
biologic	B-X
ligands	B-X
are	B-X
of	B-X
low	B-X
affinity	B-X

Thus	O
,	O
certain	O
alkyl	O
phospholipid	O
oxidation	O
products	O
in	O
oxLDL	B-protein
are	O
specific	O
,	O
high	O
affinity	O
extracellular	O
ligands	O
and	O
agonists	O
for	O
PPARgamma	B-protein
that	O
induce	O
PPAR-responsive	B-DNA
genes	I-DNA
<EOS>	B-X
Thus	B-X
,	B-X
certain	B-X
alkyl	B-X
phospholipid	B-X
oxidation	B-X
products	B-X
in	B-X
oxLDL	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
extracellular	B-X
ligands	B-X
and	B-X
agonists	B-X
for	B-X
PPARgamma	B-X
that	B-X
induce	B-X
PPAR	B-X
-	B-X
responsive	B-X
genes	B-X
<EOS>	B-X
Oxidized	B-X
alkyl	B-X
phospholipids	B-X
are	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
gamma	B-X
ligands	B-X
and	B-X
agonists	B-X
.	B-X
<EOS>	B-X
Results	B-X
with	B-X
a	B-X
small	B-X
molecule	B-X
phospholipid	B-X
flippase	B-X
mimetic	B-X
suggest	B-X
azPC	B-X
acts	B-X
intracellularly	B-X
and	B-X
that	B-X
cellular	B-X
azPC	B-X
accumulation	B-X
was	B-X
efficient	B-X
<EOS>	B-X
Oxidized	B-X
low	B-X
density	B-X
lipoprotein	B-X
(	B-X
oxLDL	B-X
)	B-X
is	B-X
inflammatory	B-X
and	B-X
signals	B-X
through	B-X
PPARs	B-X

Regulation	O
of	O
the	O
human	B-DNA
MAT2B	I-DNA
gene	I-DNA
encoding	O
the	O
regulatory	B-protein
beta	I-protein
subunit	I-protein
of	O
methionine	B-protein
adenosyltransferase	I-protein
,	O
MAT	B-protein
II	I-protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
human	B-X
MAT2B	B-X
gene	B-X
encoding	B-X
the	B-X
regulatory	B-X
beta	B-X
subunit	B-X
of	B-X
methionine	B-X
adenosyltransferase	B-X
,	B-X
MAT	B-X
II	B-X
.	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
the	B-X
MAT2B	B-X
gene	B-X
initiates	B-X
at	B-X
position	B-X
	B-X
-	B-X
203	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
both	B-X
the	B-X
Sp1	B-X
site	B-X
at	B-X
+9	B-X
and	B-X
the	B-X
TATA	B-X
at	B-X
	B-X
-	B-X
32	B-X
reduced	B-X
promoter	B-X
activity	B-X
to	B-X
its	B-X
minimal	B-X
level	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
the	B-X
MAT	B-X
II	B-X
beta	B-X
subunit	B-X
expression	B-X
causes	B-X
a	B-X
6	B-X
-	B-X
10	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
intracellular	B-X
AdoMet	B-X
levels	B-X

Methionine	B-protein
adenosyltransferase	I-protein
(	O
MAT	B-protein
)	O
catalyzes	O
the	O
biosynthesis	O
of	O
S-adenosylmethionine	B-protein
(	O
AdoMet	B-protein
)	O
,	O
a	O
key	O
molecule	O
in	O
transmethylation	O
reactions	O
and	O
polyamine	O
biosynthesis	O
.	O
<EOS>	B-X
Methionine	B-X
adenosyltransferase	B-X
(	B-X
MAT	B-X
)	B-X
catalyzes	B-X
the	B-X
biosynthesis	B-X
of	B-X
S	B-X
-	B-X
adenosylmethionine	B-X
(	B-X
AdoMet	B-X
)	B-X
,	B-X
a	B-X
key	B-X
molecule	B-X
in	B-X
transmethylation	B-X
reactions	B-X
and	B-X
polyamine	B-X
biosynthesis	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
the	B-X
MAT2B	B-X
gene	B-X
initiates	B-X
at	B-X
position	B-X
	B-X
-	B-X
203	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
human	B-X
MAT2B	B-X
gene	B-X
encoding	B-X
the	B-X
regulatory	B-X
beta	B-X
subunit	B-X
of	B-X
methionine	B-X
adenosyltransferase	B-X
,	B-X
MAT	B-X
II	B-X
.	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
both	B-X
the	B-X
Sp1	B-X
site	B-X
at	B-X
+9	B-X
and	B-X
the	B-X
TATA	B-X
at	B-X
	B-X
-	B-X
32	B-X
reduced	B-X
promoter	B-X
activity	B-X
to	B-X
its	B-X
minimal	B-X
level	B-X

The	O
MAT	B-protein
II	I-protein
isozyme	I-protein
consists	O
of	O
a	O
catalytic	B-protein
alpha2	I-protein
and	I-protein
a	I-protein
regulatory	I-protein
beta	I-protein
subunit	I-protein
.	O

Down-regulation	O
of	O
the	O
MAT	B-protein
II	I-protein
beta	I-protein
subunit	I-protein
expression	O
causes	O
a	O
6-10-fold	O
increase	O
in	O
intracellular	O
AdoMet	B-protein
levels	O
.	O
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
the	B-X
MAT	B-X
II	B-X
beta	B-X
subunit	B-X
expression	B-X
causes	B-X
a	B-X
6	B-X
-	B-X
10	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
intracellular	B-X
AdoMet	B-X
levels	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
the	B-X
MAT2B	B-X
gene	B-X
initiates	B-X
at	B-X
position	B-X
	B-X
-	B-X
203	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X
<EOS>	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
5'	B-X
-	B-X
untranslated	B-X
sequences	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
MAT2B	B-X
gene	B-X
and	B-X
identifies	B-X
the	B-X
Sp1	B-X
site	B-X
at	B-X
+9	B-X
as	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
modulating	B-X
MAT2B	B-X
expression	B-X
,	B-X
a	B-X
process	B-X
that	B-X
can	B-X
have	B-X
a	B-X
major	B-X
effect	B-X
on	B-X
intracellular	B-X
AdoMet	B-X
levels	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
human	B-X
MAT2B	B-X
gene	B-X
encoding	B-X
the	B-X
regulatory	B-X
beta	B-X
subunit	B-X
of	B-X
methionine	B-X
adenosyltransferase	B-X
,	B-X
MAT	B-X
II	B-X
.	B-X

To	O
understand	O
the	O
mechanism	O
by	O
which	O
the	O
beta	B-protein
subunit	I-protein
expression	O
is	O
regulated	O
,	O
we	O
cloned	O
the	O
MAT2B	B-DNA
gene	I-DNA
,	O
determined	O
its	O
organization	O
,	O
characterized	O
its	O
5'-flanking	B-DNA
sequences	I-DNA
,	O
and	O
elucidated	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
regulation	O
of	O
its	O
promoter	B-DNA
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
beta	B-X
subunit	B-X
expression	B-X
is	B-X
regulated	B-X
,	B-X
we	B-X
cloned	B-X
the	B-X
MAT2B	B-X
gene	B-X
,	B-X
determined	B-X
its	B-X
organization	B-X
,	B-X
characterized	B-X
its	B-X
5'	B-X
-	B-X
flanking	B-X
sequences	B-X
,	B-X
and	B-X
elucidated	B-X
the	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
regulation	B-X
of	B-X
its	B-X
promoter	B-X
<EOS>	B-X
Supershift	B-X
assays	B-X
showed	B-X
no	B-X
effect	B-X
of	B-X
the	B-X
anti	B-X
-	B-X
Sp1	B-X
antibody	B-X
on	B-X
complex	B-X
formation	B-X
,	B-X
whereas	B-X
the	B-X
anti	B-X
-	B-X
Sp3	B-X
antibody	B-X
had	B-X
a	B-X
strong	B-X
effect	B-X
on	B-X
protein	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
the	B-X
MAT2B	B-X
gene	B-X
initiates	B-X
at	B-X
position	B-X
	B-X
-	B-X
203	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X
<EOS>	B-X
The	B-X
data	B-X
show	B-X
that	B-X
the	B-X
5'	B-X
-	B-X
untranslated	B-X
sequences	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
MAT2B	B-X
gene	B-X
and	B-X
identifies	B-X
the	B-X
Sp1	B-X
site	B-X
at	B-X
+9	B-X
as	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
modulating	B-X
MAT2B	B-X
expression	B-X
,	B-X
a	B-X
process	B-X
that	B-X
can	B-X
have	B-X
a	B-X
major	B-X
effect	B-X
on	B-X
intracellular	B-X
AdoMet	B-X
levels	B-X

Transcription	O
of	O
the	O
MAT2B	B-DNA
gene	I-DNA
initiates	O
at	O
position	O
-203	O
relative	O
to	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
.	O

Promoter	B-DNA
deletion	I-DNA
analysis	I-DNA
defined	O
a	O
minimal	B-DNA
promoter	I-DNA
between	O
positions	B-DNA
+52	I-DNA
and	I-DNA
+93	I-DNA
base	O
pairs	O
,	O
a	O
GC-rich	B-DNA
region	I-DNA
.	O
<EOS>	B-X
Promoter	B-X
deletion	B-X
analysis	B-X
defined	B-X
a	B-X
minimal	B-X
promoter	B-X
between	B-X
positions	B-X
+52	B-X
and	B-X
+93	B-X
base	B-X
pairs	B-X
,	B-X
a	B-X
GC	B-X
-	B-X
rich	B-X
region	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
the	B-X
MAT2B	B-X
gene	B-X
initiates	B-X
at	B-X
position	B-X
	B-X
-	B-X
203	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X
<EOS>	B-X
Inclusion	B-X
of	B-X
the	B-X
sequences	B-X
between	B-X
	B-X
-	B-X
4	B-X
and	B-X
+52	B-X
enhanced	B-X
promoter	B-X
activity	B-X
;	B-X
this	B-X
was	B-X
primarily	B-X
because	B-X
of	B-X
an	B-X
Sp1	B-X
recognition	B-X
site	B-X
at	B-X
+9	B-X
/	B-X
+15	B-X
<EOS>	B-X
Methionine	B-X
adenosyltransferase	B-X
(	B-X
MAT	B-X
)	B-X
catalyzes	B-X
the	B-X
biosynthesis	B-X
of	B-X
S	B-X
-	B-X
adenosylmethionine	B-X
(	B-X
AdoMet	B-X
)	B-X
,	B-X
a	B-X
key	B-X
molecule	B-X
in	B-X
transmethylation	B-X
reactions	B-X
and	B-X
polyamine	B-X
biosynthesis	B-X

Inclusion	O
of	O
the	O
sequences	O
between	O
-4	O
and	O
+52	O
enhanced	O
promoter	O
activity	O
;	O
this	O
was	O
primarily	O
because	O
of	O
an	O
Sp1	B-DNA
recognition	I-DNA
site	I-DNA
at	O
+9/+15	O
.	O
<EOS>	B-X
Inclusion	B-X
of	B-X
the	B-X
sequences	B-X
between	B-X
	B-X
-	B-X
4	B-X
and	B-X
+52	B-X
enhanced	B-X
promoter	B-X
activity	B-X
;	B-X
this	B-X
was	B-X
primarily	B-X
because	B-X
of	B-X
an	B-X
Sp1	B-X
recognition	B-X
site	B-X
at	B-X
+9	B-X
/	B-X
+15	B-X
<EOS>	B-X
The	B-X
inclusion	B-X
of	B-X
sequences	B-X
up	B-X
to	B-X
position	B-X
	B-X
-	B-X
115	B-X
provided	B-X
full	B-X
activity	B-X
;	B-X
this	B-X
was	B-X
attributed	B-X
to	B-X
a	B-X
TATA	B-X
at	B-X
	B-X
-	B-X
32	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
the	B-X
MAT2B	B-X
gene	B-X
initiates	B-X
at	B-X
position	B-X
	B-X
-	B-X
203	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
both	B-X
the	B-X
Sp1	B-X
site	B-X
at	B-X
+9	B-X
and	B-X
the	B-X
TATA	B-X
at	B-X
	B-X
-	B-X
32	B-X
reduced	B-X
promoter	B-X
activity	B-X
to	B-X
its	B-X
minimal	B-X
level	B-X

The	O
inclusion	O
of	O
sequences	O
up	O
to	O
position	O
-115	O
provided	O
full	O
activity	O
;	O
this	O
was	O
attributed	O
to	O
a	O
TATA	B-DNA
at	O
-32	O
.	O
<EOS>	B-X
The	B-X
inclusion	B-X
of	B-X
sequences	B-X
up	B-X
to	B-X
position	B-X
	B-X
-	B-X
115	B-X
provided	B-X
full	B-X
activity	B-X
;	B-X
this	B-X
was	B-X
attributed	B-X
to	B-X
a	B-X
TATA	B-X
at	B-X
	B-X
-	B-X
32	B-X
<EOS>	B-X
Inclusion	B-X
of	B-X
the	B-X
sequences	B-X
between	B-X
	B-X
-	B-X
4	B-X
and	B-X
+52	B-X
enhanced	B-X
promoter	B-X
activity	B-X
;	B-X
this	B-X
was	B-X
primarily	B-X
because	B-X
of	B-X
an	B-X
Sp1	B-X
recognition	B-X
site	B-X
at	B-X
+9	B-X
/	B-X
+15	B-X
<EOS>	B-X
The	B-X
Sp1	B-X
site	B-X
at	B-X
position	B-X
+9	B-X
was	B-X
key	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
protein	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
the	B-X
MAT2B	B-X
gene	B-X
initiates	B-X
at	B-X
position	B-X
	B-X
-	B-X
203	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X

The	O
Sp1	B-DNA
site	I-DNA
at	O
position	O
+9	O
was	O
key	O
for	O
the	O
formation	O
of	O
protein.DNA	O
complexes	O
.	O
<EOS>	B-X
The	B-X
Sp1	B-X
site	B-X
at	B-X
position	B-X
+9	B-X
was	B-X
key	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
protein	B-X
<EOS>	B-X
The	B-X
inclusion	B-X
of	B-X
sequences	B-X
up	B-X
to	B-X
position	B-X
	B-X
-	B-X
115	B-X
provided	B-X
full	B-X
activity	B-X
;	B-X
this	B-X
was	B-X
attributed	B-X
to	B-X
a	B-X
TATA	B-X
at	B-X
	B-X
-	B-X
32	B-X
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
supported	B-X
the	B-X
involvement	B-X
of	B-X
both	B-X
Sp1	B-X
and	B-X
Sp3	B-X
in	B-X
complexes	B-X
formed	B-X
on	B-X
the	B-X
MAT2B	B-X
promoter	B-X
<EOS>	B-X
Mutation	B-X
of	B-X
both	B-X
the	B-X
Sp1	B-X
site	B-X
at	B-X
+9	B-X
and	B-X
the	B-X
TATA	B-X
at	B-X
	B-X
-	B-X
32	B-X
reduced	B-X
promoter	B-X
activity	B-X
to	B-X
its	B-X
minimal	B-X
level	B-X

Mutation	O
of	O
both	O
the	O
Sp1	B-DNA
site	I-DNA
at	O
+9	O
and	O
the	O
TATA	B-DNA
at	O
-32	O
reduced	O
promoter	O
activity	O
to	O
its	O
minimal	O
level	O
.	O
<EOS>	B-X
Mutation	B-X
of	B-X
both	B-X
the	B-X
Sp1	B-X
site	B-X
at	B-X
+9	B-X
and	B-X
the	B-X
TATA	B-X
at	B-X
	B-X
-	B-X
32	B-X
reduced	B-X
promoter	B-X
activity	B-X
to	B-X
its	B-X
minimal	B-X
level	B-X
<EOS>	B-X
Inclusion	B-X
of	B-X
the	B-X
sequences	B-X
between	B-X
	B-X
-	B-X
4	B-X
and	B-X
+52	B-X
enhanced	B-X
promoter	B-X
activity	B-X
;	B-X
this	B-X
was	B-X
primarily	B-X
because	B-X
of	B-X
an	B-X
Sp1	B-X
recognition	B-X
site	B-X
at	B-X
+9	B-X
/	B-X
+15	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
human	B-X
MAT2B	B-X
gene	B-X
encoding	B-X
the	B-X
regulatory	B-X
beta	B-X
subunit	B-X
of	B-X
methionine	B-X
adenosyltransferase	B-X
,	B-X
MAT	B-X
II	B-X
.	B-X
<EOS>	B-X
The	B-X
Sp1	B-X
site	B-X
at	B-X
position	B-X
+9	B-X
was	B-X
key	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
protein	B-X

Supershift	O
assays	O
showed	O
no	O
effect	O
of	O
the	O
anti-Sp1	B-protein
antibody	I-protein
on	O
complex	O
formation	O
,	O
whereas	O
the	O
anti-Sp3	B-protein
antibody	I-protein
had	O
a	O
strong	O
effect	O
on	O
protein.DNA	O
complex	O
formation	O
,	O
suggesting	O
that	O
Sp3	B-protein
is	O
one	O
of	O
the	O
main	O
factors	O
binding	O
to	O
this	O
Sp1	B-DNA
site	I-DNA
.	O

Chromatin	O
immunoprecipitation	O
assays	O
supported	O
the	O
involvement	O
of	O
both	O
Sp1	B-protein
and	O
Sp3	B-protein
in	O
complexes	O
formed	O
on	O
the	O
MAT2B	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
supported	B-X
the	B-X
involvement	B-X
of	B-X
both	B-X
Sp1	B-X
and	B-X
Sp3	B-X
in	B-X
complexes	B-X
formed	B-X
on	B-X
the	B-X
MAT2B	B-X
promoter	B-X
<EOS>	B-X
The	B-X
Sp1	B-X
site	B-X
at	B-X
position	B-X
+9	B-X
was	B-X
key	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
protein	B-X
<EOS>	B-X
DNA	B-X
complex	B-X
formation	B-X
,	B-X
suggesting	B-X
that	B-X
Sp3	B-X
is	B-X
one	B-X
of	B-X
the	B-X
main	B-X
factors	B-X
binding	B-X
to	B-X
this	B-X
Sp1	B-X
site	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
the	B-X
MAT2B	B-X
gene	B-X
initiates	B-X
at	B-X
position	B-X
	B-X
-	B-X
203	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X

The	O
data	O
show	O
that	O
the	O
5'-untranslated	B-DNA
sequences	I-DNA
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
MAT2B	B-DNA
gene	I-DNA
and	O
identifies	O
the	O
Sp1	B-DNA
site	I-DNA
at	O
+9	O
as	O
a	O
potential	O
target	O
for	O
modulating	O
MAT2B	O
expression	O
,	O
a	O
process	O
that	O
can	O
have	O
a	O
major	O
effect	O
on	O
intracellular	O
AdoMet	B-protein
levels	O
.	O

Molecular	O
pathogenesis	O
of	O
influenza	O
A	O
virus	O
infection	O
and	O
virus-induced	O
regulation	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O
<EOS>	B-X
RIG	B-X
-	B-X
I	B-X
Signaling	B-X
Is	B-X
Essential	B-X
for	B-X
Influenza	B-X
B	B-X
Virus	B-X
-	B-X
Induced	B-X
Rapid	B-X
Interferon	B-X
Gene	B-X
Expression	B-X
.	B-X
<EOS>	B-X
Small	B-X
RNA	B-X
profiling	B-X
of	B-X
influenza	B-X
A	B-X
virus	B-X
-	B-X
infected	B-X
cells	B-X
identifies	B-X
miR	B-X
-	B-X
449b	B-X
as	B-X
a	B-X
regulator	B-X
of	B-X
histone	B-X
deacetylase	B-X
1	B-X
and	B-X
interferon	B-X
beta	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
analyzed	B-X
the	B-X
early	B-X
events	B-X
in	B-X
influenza	B-X
B	B-X
virus	B-X
infection	B-X
and	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocyte	B-X
-	B-X
derived	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
<EOS>	B-X
The	B-X
pathogenesis	B-X
of	B-X
the	B-X
2009	B-X
pH1N1	B-X
virus	B-X
infection	B-X
is	B-X
associated	B-X
with	B-X
viral	B-X
replication	B-X
and	B-X
production	B-X
of	B-X
proinflammatory	B-X
mediators	B-X

Despite	O
vaccines	O
and	O
antiviral	O
substances	O
influenza	O
still	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
world	O
wide	O
.	O
<EOS>	B-X
Despite	B-X
vaccines	B-X
and	B-X
antiviral	B-X
substances	B-X
influenza	B-X
still	B-X
causes	B-X
significant	B-X
morbidity	B-X
and	B-X
mortality	B-X
world	B-X
wide	B-X
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
-	B-X
induced	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
is	B-X
essential	B-X
in	B-X
host	B-X
's	B-X
antiviral	B-X
defence	B-X
by	B-X
activating	B-X
the	B-X
expression	B-X
of	B-X
antiviral	B-X
Mx	B-X
,	B-X
PKR	B-X
and	B-X
oligoadenylate	B-X
synthetase	B-X
genes	B-X
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
,	B-X
which	B-X
replicates	B-X
in	B-X
epithelial	B-X
cells	B-X
and	B-X
leukocytes	B-X
,	B-X
regulates	B-X
host	B-X
cell	B-X
transcriptional	B-X
and	B-X
translational	B-X
systems	B-X
and	B-X
activates	B-X
,	B-X
as	B-X
well	B-X
as	B-X
downregulates	B-X
apoptotic	B-X
pathways	B-X
<EOS>	B-X
In	B-X
addition	B-X
of	B-X
upregulating	B-X
cytokine	B-X
gene	B-X
expression	B-X
,	B-X
influenza	B-X
A	B-X
virus	B-X
infection	B-X
activates	B-X
caspase	B-X
-	B-X
1	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
proIL	B-X
-	B-X
1	B-X
beta	B-X
and	B-X
proIL	B-X
-	B-X
18	B-X
into	B-X
their	B-X
biologically	B-X
active	B-X
forms	B-X

Better	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
of	O
influenza	O
virus	O
replication	O
,	O
pathogenesis	O
and	O
host	O
immune	O
responses	O
is	O
required	O
for	O
the	O
development	O
of	O
more	O
efficient	O
means	O
of	O
prevention	O
and	O
treatment	O
of	O
influenza	O
.	O
<EOS>	B-X
Better	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
influenza	B-X
virus	B-X
replication	B-X
,	B-X
pathogenesis	B-X
and	B-X
host	B-X
immune	B-X
responses	B-X
is	B-X
required	B-X
for	B-X
the	B-X
development	B-X
of	B-X
more	B-X
efficient	B-X
means	B-X
of	B-X
prevention	B-X
and	B-X
treatment	B-X
of	B-X
influenza	B-X
<EOS>	B-X
Molecular	B-X
pathogenesis	B-X
of	B-X
influenza	B-X
A	B-X
virus	B-X
infection	B-X
and	B-X
virus	B-X
-	B-X
induced	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
of	B-X
upregulating	B-X
cytokine	B-X
gene	B-X
expression	B-X
,	B-X
influenza	B-X
A	B-X
virus	B-X
infection	B-X
activates	B-X
caspase	B-X
-	B-X
1	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
proIL	B-X
-	B-X
1	B-X
beta	B-X
and	B-X
proIL	B-X
-	B-X
18	B-X
into	B-X
their	B-X
biologically	B-X
active	B-X
forms	B-X
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
-	B-X
induced	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
is	B-X
essential	B-X
in	B-X
host	B-X
's	B-X
antiviral	B-X
defence	B-X
by	B-X
activating	B-X
the	B-X
expression	B-X
of	B-X
antiviral	B-X
Mx	B-X
,	B-X
PKR	B-X
and	B-X
oligoadenylate	B-X
synthetase	B-X
genes	B-X

Influenza	O
A	O
virus	O
,	O
which	O
replicates	O
in	O
epithelial	B-cell_type
cells	I-cell_type
and	O
leukocytes	B-cell_type
,	O
regulates	O
host	O
cell	O
transcriptional	O
and	O
translational	O
systems	O
and	O
activates	O
,	O
as	O
well	O
as	O
downregulates	O
apoptotic	O
pathways	O
.	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
,	B-X
which	B-X
replicates	B-X
in	B-X
epithelial	B-X
cells	B-X
and	B-X
leukocytes	B-X
,	B-X
regulates	B-X
host	B-X
cell	B-X
transcriptional	B-X
and	B-X
translational	B-X
systems	B-X
and	B-X
activates	B-X
,	B-X
as	B-X
well	B-X
as	B-X
downregulates	B-X
apoptotic	B-X
pathways	B-X
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
-	B-X
induced	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
is	B-X
essential	B-X
in	B-X
host	B-X
's	B-X
antiviral	B-X
defence	B-X
by	B-X
activating	B-X
the	B-X
expression	B-X
of	B-X
antiviral	B-X
Mx	B-X
,	B-X
PKR	B-X
and	B-X
oligoadenylate	B-X
synthetase	B-X
genes	B-X
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
infection	B-X
results	B-X
in	B-X
the	B-X
production	B-X
of	B-X
chemotactic	B-X
(	B-X
RANTES	B-X
,	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
,	B-X
MCP	B-X
-	B-X
1	B-X
,	B-X
MCP	B-X
-	B-X
3	B-X
,	B-X
and	B-X
IP	B-X
-	B-X
10	B-X
)	B-X
,	B-X
pro	B-X
-	B-X
inflammatory	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
IL	B-X
-	B-X
18	B-X
,	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
and	B-X
antiviral	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
)	B-X
cytokines	B-X
<EOS>	B-X
Despite	B-X
vaccines	B-X
and	B-X
antiviral	B-X
substances	B-X
influenza	B-X
still	B-X
causes	B-X
significant	B-X
morbidity	B-X
and	B-X
mortality	B-X
world	B-X
wide	B-X

Influenza	O
A	O
virus	O
infection	O
results	O
in	O
the	O
production	O
of	O
chemotactic	O
(	O
RANTES	B-protein
,	O
MIP-1	B-protein
alpha	I-protein
,	O
MCP-1	B-protein
,	O
MCP-3	B-protein
,	O
and	O
IP-10	B-protein
)	O
,	O
pro-inflammatory	O
(	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
,	O
IL-18	B-protein
,	O
and	O
TNF-alpha	B-protein
)	O
,	O
and	O
antiviral	B-protein
(	I-protein
IFN-alpha/beta	I-protein
)	I-protein
cytokines	I-protein
.	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
infection	B-X
results	B-X
in	B-X
the	B-X
production	B-X
of	B-X
chemotactic	B-X
(	B-X
RANTES	B-X
,	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
,	B-X
MCP	B-X
-	B-X
1	B-X
,	B-X
MCP	B-X
-	B-X
3	B-X
,	B-X
and	B-X
IP	B-X
-	B-X
10	B-X
)	B-X
,	B-X
pro	B-X
-	B-X
inflammatory	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
IL	B-X
-	B-X
18	B-X
,	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
and	B-X
antiviral	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
)	B-X
cytokines	B-X
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
-	B-X
induced	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
is	B-X
essential	B-X
in	B-X
host	B-X
's	B-X
antiviral	B-X
defence	B-X
by	B-X
activating	B-X
the	B-X
expression	B-X
of	B-X
antiviral	B-X
Mx	B-X
,	B-X
PKR	B-X
and	B-X
oligoadenylate	B-X
synthetase	B-X
genes	B-X
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
,	B-X
which	B-X
replicates	B-X
in	B-X
epithelial	B-X
cells	B-X
and	B-X
leukocytes	B-X
,	B-X
regulates	B-X
host	B-X
cell	B-X
transcriptional	B-X
and	B-X
translational	B-X
systems	B-X
and	B-X
activates	B-X
,	B-X
as	B-X
well	B-X
as	B-X
downregulates	B-X
apoptotic	B-X
pathways	B-X
<EOS>	B-X
Cytokine	B-X
gene	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
STAT	B-X
and	B-X
IRF	B-X
signal	B-X
transducing	B-X
molecules	B-X
in	B-X
influenza	B-X
A	B-X
virus	B-X
-	B-X
infected	B-X
cells	B-X

Cytokine	O
gene	O
expression	O
is	O
associated	O
with	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
STAT	B-protein
and	O
IRF	B-protein
signal	I-protein
transducing	I-protein
molecules	I-protein
in	O
influenza	O
A	O
virus-infected	O
cells	O
.	O
<EOS>	B-X
Cytokine	B-X
gene	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
STAT	B-X
and	B-X
IRF	B-X
signal	B-X
transducing	B-X
molecules	B-X
in	B-X
influenza	B-X
A	B-X
virus	B-X
-	B-X
infected	B-X
cells	B-X
<EOS>	B-X
In	B-X
addition	B-X
of	B-X
upregulating	B-X
cytokine	B-X
gene	B-X
expression	B-X
,	B-X
influenza	B-X
A	B-X
virus	B-X
infection	B-X
activates	B-X
caspase	B-X
-	B-X
1	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
proIL	B-X
-	B-X
1	B-X
beta	B-X
and	B-X
proIL	B-X
-	B-X
18	B-X
into	B-X
their	B-X
biologically	B-X
active	B-X
forms	B-X
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
infection	B-X
results	B-X
in	B-X
the	B-X
production	B-X
of	B-X
chemotactic	B-X
(	B-X
RANTES	B-X
,	B-X
MIP	B-X
-	B-X
1	B-X
alpha	B-X
,	B-X
MCP	B-X
-	B-X
1	B-X
,	B-X
MCP	B-X
-	B-X
3	B-X
,	B-X
and	B-X
IP	B-X
-	B-X
10	B-X
)	B-X
,	B-X
pro	B-X
-	B-X
inflammatory	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
IL	B-X
-	B-X
18	B-X
,	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
and	B-X
antiviral	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
/	B-X
beta	B-X
)	B-X
cytokines	B-X
<EOS>	B-X
Molecular	B-X
pathogenesis	B-X
of	B-X
influenza	B-X
A	B-X
virus	B-X
infection	B-X
and	B-X
virus	B-X
-	B-X
induced	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X

In	O
addition	O
of	O
upregulating	O
cytokine	B-DNA
gene	I-DNA
expression	O
,	O
influenza	O
A	O
virus	O
infection	O
activates	O
caspase-1	B-protein
enzyme	I-protein
,	O
which	O
is	O
involved	O
in	O
the	O
proteolytic	O
processing	O
of	O
proIL-1	B-protein
beta	I-protein
and	O
proIL-18	B-protein
into	O
their	O
biologically	O
active	O
forms	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
of	B-X
upregulating	B-X
cytokine	B-X
gene	B-X
expression	B-X
,	B-X
influenza	B-X
A	B-X
virus	B-X
infection	B-X
activates	B-X
caspase	B-X
-	B-X
1	B-X
enzyme	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
proIL	B-X
-	B-X
1	B-X
beta	B-X
and	B-X
proIL	B-X
-	B-X
18	B-X
into	B-X
their	B-X
biologically	B-X
active	B-X
forms	B-X
<EOS>	B-X
Molecular	B-X
pathogenesis	B-X
of	B-X
influenza	B-X
A	B-X
virus	B-X
infection	B-X
and	B-X
virus	B-X
-	B-X
induced	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Cytokine	B-X
gene	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
STAT	B-X
and	B-X
IRF	B-X
signal	B-X
transducing	B-X
molecules	B-X
in	B-X
influenza	B-X
A	B-X
virus	B-X
-	B-X
infected	B-X
cells	B-X
<EOS>	B-X
Better	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
influenza	B-X
virus	B-X
replication	B-X
,	B-X
pathogenesis	B-X
and	B-X
host	B-X
immune	B-X
responses	B-X
is	B-X
required	B-X
for	B-X
the	B-X
development	B-X
of	B-X
more	B-X
efficient	B-X
means	B-X
of	B-X
prevention	B-X
and	B-X
treatment	B-X
of	B-X
influenza	B-X

Influenza	O
A	O
virus-induced	O
IFN-alpha/beta	B-protein
is	O
essential	O
in	O
host	O
's	O
antiviral	O
defence	O
by	O
activating	O
the	O
expression	O
of	O
antiviral	B-DNA
Mx	I-DNA
,	O
PKR	B-DNA
and	I-DNA
oligoadenylate	I-DNA
synthetase	I-DNA
genes	I-DNA
.	O

IFN-alpha/beta	B-protein
also	O
prolongs	O
T	O
cell	O
survival	O
,	O
upregulates	O
IL-12	O
and	O
IL-18	O
receptor	O
gene	O
expression	O
and	O
together	O
with	O
IL-18	B-protein
stimulates	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cell	I-cell_type
IFN-gamma	O
production	O
and	O
the	O
development	O
of	O
Th1-type	O
immune	O
response	O
.	O

Comparison	O
of	O
hprt	O
and	O
lacI	O
mutant	O
frequency	O
with	O
DNA	O
adduct	O
formation	O
in	O
N-hydroxy-2-acetylaminofluorene-treated	O
Big	O
Blue	O
rats	O
.	O
<EOS>	B-X
Comparison	B-X
of	B-X
hprt	B-X
and	B-X
lacI	B-X
mutant	B-X
frequency	B-X
with	B-X
DNA	B-X
adduct	B-X
formation	B-X
in	B-X
N	B-X
-	B-X
hydroxy	B-X
-	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
-	B-X
treated	B-X
Big	B-X
Blue	B-X
rats	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
transgenic	B-X
Big	B-X
Blue	B-X
(	B-X
R	B-X
)	B-X
rats	B-X
were	B-X
used	B-X
to	B-X
examine	B-X
the	B-X
relationship	B-X
between	B-X
in	B-X
vivo	B-X
mutagenicity	B-X
and	B-X
DNA	B-X
adduct	B-X
formation	B-X
by	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
in	B-X
the	B-X
target	B-X
liver	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
nontarget	B-X
tissues	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
both	B-X
DNA	B-X
adduct	B-X
formation	B-X
and	B-X
mutant	B-X
induction	B-X
correlates	B-X
with	B-X
the	B-X
organ	B-X
specificity	B-X
for	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
carcinogenesis	B-X
in	B-X
the	B-X
rat	B-X
<EOS>	B-X
Additional	B-X
rats	B-X
were	B-X
evaluated	B-X
for	B-X
DNA	B-X
adduct	B-X
formation	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
by	B-X
(	B-X
32	B-X
)	B-X
P	B-X
-	B-X
postlabeling	B-X

N-Hydroxy-2-acetylaminofluorene	O
(	O
N-OH-AAF	O
)	O
is	O
the	O
proximate	O
carcinogenic	O
metabolite	O
of	O
the	O
powerful	O
rat	O
liver	O
carcinogen	O
2-acetylaminofluorene	O
.	O
<EOS>	B-X
N	B-X
-	B-X
Hydroxy	B-X
-	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
(	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
)	B-X
is	B-X
the	B-X
proximate	B-X
carcinogenic	B-X
metabolite	B-X
of	B-X
the	B-X
powerful	B-X
rat	B-X
liver	B-X
carcinogen	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
<EOS>	B-X
N	B-X
-	B-X
	B-X
(	B-X
Deoxyguanosin	B-X
-	B-X
8	B-X
-	B-X
yl	B-X
)	B-X
	B-X
-	B-X
2	B-X
-	B-X
aminofluorene	B-X
was	B-X
the	B-X
major	B-X
DNA	B-X
adduct	B-X
identified	B-X
in	B-X
all	B-X
the	B-X
tissues	B-X
examined	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
transgenic	B-X
Big	B-X
Blue	B-X
(	B-X
R	B-X
)	B-X
rats	B-X
were	B-X
used	B-X
to	B-X
examine	B-X
the	B-X
relationship	B-X
between	B-X
in	B-X
vivo	B-X
mutagenicity	B-X
and	B-X
DNA	B-X
adduct	B-X
formation	B-X
by	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
in	B-X
the	B-X
target	B-X
liver	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
nontarget	B-X
tissues	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
both	B-X
DNA	B-X
adduct	B-X
formation	B-X
and	B-X
mutant	B-X
induction	B-X
correlates	B-X
with	B-X
the	B-X
organ	B-X
specificity	B-X
for	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
carcinogenesis	B-X
in	B-X
the	B-X
rat	B-X

In	O
this	O
study	O
,	O
transgenic	O
Big	O
Blue	O
(	O
R	O
)	O
rats	O
were	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
in	O
vivo	O
mutagenicity	O
and	O
DNA	O
adduct	O
formation	O
by	O
N-OH-AAF	O
in	O
the	O
target	O
liver	O
compared	O
with	O
that	O
in	O
nontarget	O
tissues	O
.	O

Male	O
rats	O
were	O
given	O
one	O
,	O
two	O
,	O
or	O
four	O
doses	O
of	O
25	O
mg	O
N-OH-AAF/kg	O
body	O
weight	O
by	O
i.p.	O
injection	O
at	O
4-day	O
intervals	O
,	O
and	O
groups	O
of	O
treated	O
and	O
control	O
rats	O
were	O
euthanized	O
up	O
to	O
10	O
weeks	O
after	O
beginning	O
the	O
dosing	O
.	O
<EOS>	B-X
Berberine	B-X
at	B-X
a	B-X
dose	B-X
of	B-X
100	B-X
mg	B-X
kg	B-X
-	B-X
1	B-X
had	B-X
the	B-X
best	B-X
impact	B-X
and	B-X
reached	B-X
the	B-X
values	B-X
of	B-X
oxidative	B-X
stress	B-X
parameters	B-X
to	B-X
the	B-X
normal	B-X
level	B-X
<EOS>	B-X
One	B-X
hour	B-X
after	B-X
administration	B-X
of	B-X
taxifolin	B-X
or	B-X
distilled	B-X
water	B-X
,	B-X
animals	B-X
in	B-X
the	B-X
T+C	B-X
and	B-X
CIS	B-X
groups	B-X
were	B-X
injected	B-X
with	B-X
cisplatin	B-X
at	B-X
a	B-X
dose	B-X
of	B-X
2	B-X
<EOS>	B-X
In	B-X
a	B-X
fifth	B-X
week	B-X
of	B-X
intermittent	B-X
access	B-X
drinking	B-X
,	B-X
increasing	B-X
concentrations	B-X
of	B-X
quinine	B-X
(	B-X
10	B-X
mg	B-X
/	B-X
L	B-X
,	B-X
100	B-X
mg	B-X
/	B-X
L	B-X
,	B-X
and	B-X
200	B-X
mg	B-X
/	B-X
L	B-X
)	B-X
were	B-X
added	B-X
to	B-X
the	B-X
ethanol	B-X
to	B-X
test	B-X
aversion	B-X
-	B-X
resistant	B-X
drinking	B-X
<EOS>	B-X
The	B-X
goal	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
see	B-X
how	B-X
effective	B-X
subcutaneous	B-X
(	B-X
SC	B-X
)	B-X
insulin	B-X
is	B-X
and	B-X
two	B-X
different	B-X
types	B-X
of	B-X
oral	B-X
insulin	B-X
-	B-X
loaded	B-X
nanoparticles	B-X
(	B-X
INS	B-X
)	B-X
including	B-X
carboxymethyl	B-X
chitosan	B-X
nanoparticles	B-X
(	B-X
CMCNPs	B-X
)	B-X
and	B-X
gold	B-X
nanoparticles	B-X
(	B-X
AuNPs	B-X
)	B-X
separately	B-X
and	B-X
compare	B-X
their	B-X
effects	B-X
on	B-X
glucokinase	B-X
,	B-X
pyruvate	B-X
kinase	B-X
gene	B-X
expressions	B-X
,	B-X
and	B-X
other	B-X
parameters	B-X
in	B-X
diabetes	B-X
type	B-X
one	B-X
male	B-X
Wistar	B-X
rats	B-X

Mutant	O
frequencies	O
were	O
measured	O
in	O
the	O
spleen	B-DNA
lymphocyte	I-DNA
hprt	I-DNA
gene	I-DNA
,	O
and	O
lacI	O
mutant	O
frequencies	O
were	O
determined	O
in	O
the	O
liver	O
and	O
spleen	O
lymphocytes	B-cell_type
.	O
<EOS>	B-X
Mutant	B-X
frequencies	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
spleen	B-X
lymphocyte	B-X
hprt	B-X
gene	B-X
,	B-X
and	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
were	B-X
determined	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
lymphocytes	B-X
<EOS>	B-X
One	B-X
month	B-X
after	B-X
the	B-X
last	B-X
treatment	B-X
,	B-X
the	B-X
mutant	B-X
frequency	B-X
in	B-X
the	B-X
lacI	B-X
transgene	B-X
was	B-X
determined	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
uterus	B-X
<EOS>	B-X
7	B-X
x	B-X
10	B-X
(	B-X
	B-X
-	B-X
6	B-X
)	B-X
;	B-X
rats	B-X
given	B-X
four	B-X
doses	B-X
had	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
of	B-X
55	B-X
<EOS>	B-X
Neither	B-X
tamoxifen	B-X
nor	B-X
alpha	B-X
-	B-X
hydroxytamoxifen	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
mutant	B-X
frequency	B-X
in	B-X
the	B-X
lacI	B-X
gene	B-X
of	B-X
the	B-X
uterus	B-X
or	B-X
in	B-X
the	B-X
Hprt	B-X
gene	B-X
of	B-X
spleen	B-X
lymphocytes	B-X

At	O
6	O
weeks	O
after	O
beginning	O
the	O
dosing	O
,	O
the	O
hprt	O
mutant	O
frequency	O
in	O
spleen	B-cell_type
lymphocytes	I-cell_type
from	O
the	O
four-dose	O
group	O
was	O
16.5	O
x	O
10	O
(	O
-6	O
)	O
compared	O
with	O
3.2	O
x	O
10	O
(	O
-6	O
)	O
in	O
control	O
animals	O
.	O
<EOS>	B-X
At	B-X
6	B-X
weeks	B-X
after	B-X
beginning	B-X
the	B-X
dosing	B-X
,	B-X
the	B-X
hprt	B-X
mutant	B-X
frequency	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
from	B-X
the	B-X
four	B-X
-	B-X
dose	B-X
group	B-X
was	B-X
16	B-X
<EOS>	B-X
7	B-X
x	B-X
10	B-X
(	B-X
	B-X
-	B-X
6	B-X
)	B-X
;	B-X
rats	B-X
given	B-X
four	B-X
doses	B-X
had	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
of	B-X
55	B-X
<EOS>	B-X
Mutant	B-X
frequencies	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
spleen	B-X
lymphocyte	B-X
hprt	B-X
gene	B-X
,	B-X
and	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
were	B-X
determined	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
lymphocytes	B-X
<EOS>	B-X
Additional	B-X
rats	B-X
were	B-X
evaluated	B-X
for	B-X
DNA	B-X
adduct	B-X
formation	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
by	B-X
(	B-X
32	B-X
)	B-X
P	B-X
-	B-X
postlabeling	B-X

Also	O
at	O
6	O
weeks	O
,	O
rats	O
given	O
one	O
,	O
two	O
,	O
or	O
four	O
doses	O
of	O
N-OH-AAF	O
had	O
lacI	O
mutant	O
frequencies	O
in	O
the	O
liver	O
of	O
97.6	O
,	O
155.6	O
,	O
and	O
406.8	O
x	O
10	O
(	O
-6	O
)	O
,	O
respectively	O
,	O
compared	O
with	O
a	O
control	O
frequency	O
of	O
25.7	O
x	O
10	O
(	O
-6	O
)	O
;	O
rats	O
given	O
four	O
doses	O
had	O
lacI	O
mutant	O
frequencies	O
in	O
spleen	B-cell_type
lymphocytes	I-cell_type
of	O
55.8	O
x	O
10	O
(	O
-6	O
)	O
compared	O
with	O
a	O
control	O
frequency	O
of	O
20.4	O
x	O
10	O
(	O
-6	O
)	O
.	O
<EOS>	B-X
Also	B-X
at	B-X
6	B-X
weeks	B-X
,	B-X
rats	B-X
given	B-X
one	B-X
,	B-X
two	B-X
,	B-X
or	B-X
four	B-X
doses	B-X
of	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
had	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
97	B-X
<EOS>	B-X
In	B-X
samples	B-X
taken	B-X
after	B-X
four	B-X
doses	B-X
,	B-X
adduct	B-X
levels	B-X
were	B-X
103	B-X
,	B-X
28	B-X
,	B-X
and	B-X
7	B-X
fmol	B-X
/	B-X
microg	B-X
of	B-X
DNA	B-X
in	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
,	B-X
respectively	B-X
<EOS>	B-X
7	B-X
x	B-X
10	B-X
(	B-X
	B-X
-	B-X
6	B-X
)	B-X
;	B-X
rats	B-X
given	B-X
four	B-X
doses	B-X
had	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
of	B-X
55	B-X
<EOS>	B-X
At	B-X
6	B-X
weeks	B-X
after	B-X
beginning	B-X
the	B-X
dosing	B-X
,	B-X
the	B-X
hprt	B-X
mutant	B-X
frequency	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
from	B-X
the	B-X
four	B-X
-	B-X
dose	B-X
group	B-X
was	B-X
16	B-X

Additional	O
rats	O
were	O
evaluated	O
for	O
DNA	O
adduct	O
formation	O
in	O
the	O
liver	O
,	O
spleen	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
bone	O
marrow	O
by	O
(	O
32	O
)	O
P-postlabeling	O
.	O
<EOS>	B-X
Additional	B-X
rats	B-X
were	B-X
evaluated	B-X
for	B-X
DNA	B-X
adduct	B-X
formation	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
by	B-X
(	B-X
32	B-X
)	B-X
P	B-X
-	B-X
postlabeling	B-X
<EOS>	B-X
In	B-X
samples	B-X
taken	B-X
after	B-X
four	B-X
doses	B-X
,	B-X
adduct	B-X
levels	B-X
were	B-X
103	B-X
,	B-X
28	B-X
,	B-X
and	B-X
7	B-X
fmol	B-X
/	B-X
microg	B-X
of	B-X
DNA	B-X
in	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
,	B-X
respectively	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
both	B-X
DNA	B-X
adduct	B-X
formation	B-X
and	B-X
mutant	B-X
induction	B-X
correlates	B-X
with	B-X
the	B-X
organ	B-X
specificity	B-X
for	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
carcinogenesis	B-X
in	B-X
the	B-X
rat	B-X
<EOS>	B-X
At	B-X
6	B-X
weeks	B-X
after	B-X
beginning	B-X
the	B-X
dosing	B-X
,	B-X
the	B-X
hprt	B-X
mutant	B-X
frequency	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
from	B-X
the	B-X
four	B-X
-	B-X
dose	B-X
group	B-X
was	B-X
16	B-X

Adduct	O
analysis	O
was	O
conducted	O
1	O
day	O
after	O
one	O
,	O
two	O
,	O
and	O
four	O
treatments	O
with	O
N-OH-AAF	O
,	O
5	O
days	O
after	O
one	O
treatment	O
,	O
and	O
9	O
days	O
after	O
two	O
treatments	O
.	O
<EOS>	B-X
Adduct	B-X
analysis	B-X
was	B-X
conducted	B-X
1	B-X
day	B-X
after	B-X
one	B-X
,	B-X
two	B-X
,	B-X
and	B-X
four	B-X
treatments	B-X
with	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
,	B-X
5	B-X
days	B-X
after	B-X
one	B-X
treatment	B-X
,	B-X
and	B-X
9	B-X
days	B-X
after	B-X
two	B-X
treatments	B-X
<EOS>	B-X
Also	B-X
at	B-X
6	B-X
weeks	B-X
,	B-X
rats	B-X
given	B-X
one	B-X
,	B-X
two	B-X
,	B-X
or	B-X
four	B-X
doses	B-X
of	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
had	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
97	B-X
<EOS>	B-X
injection	B-X
at	B-X
4	B-X
-	B-X
day	B-X
intervals	B-X
,	B-X
and	B-X
groups	B-X
of	B-X
treated	B-X
and	B-X
control	B-X
rats	B-X
were	B-X
euthanized	B-X
up	B-X
to	B-X
10	B-X
weeks	B-X
after	B-X
beginning	B-X
the	B-X
dosing	B-X
<EOS>	B-X
Adduct	B-X
concentrations	B-X
increased	B-X
with	B-X
total	B-X
dose	B-X
to	B-X
maximum	B-X
values	B-X
in	B-X
samples	B-X
taken	B-X
1	B-X
day	B-X
after	B-X
two	B-X
doses	B-X
,	B-X
and	B-X
remained	B-X
essentially	B-X
the	B-X
same	B-X
after	B-X
four	B-X
doses	B-X

N-	O
(	O
Deoxyguanosin-8-yl	O
)	O
-2-aminofluorene	O
was	O
the	O
major	O
DNA	O
adduct	O
identified	O
in	O
all	O
the	O
tissues	O
examined	O
.	O
<EOS>	B-X
N	B-X
-	B-X
	B-X
(	B-X
Deoxyguanosin	B-X
-	B-X
8	B-X
-	B-X
yl	B-X
)	B-X
	B-X
-	B-X
2	B-X
-	B-X
aminofluorene	B-X
was	B-X
the	B-X
major	B-X
DNA	B-X
adduct	B-X
identified	B-X
in	B-X
all	B-X
the	B-X
tissues	B-X
examined	B-X
<EOS>	B-X
Adduct	B-X
concentrations	B-X
increased	B-X
with	B-X
total	B-X
dose	B-X
to	B-X
maximum	B-X
values	B-X
in	B-X
samples	B-X
taken	B-X
1	B-X
day	B-X
after	B-X
two	B-X
doses	B-X
,	B-X
and	B-X
remained	B-X
essentially	B-X
the	B-X
same	B-X
after	B-X
four	B-X
doses	B-X
<EOS>	B-X
N	B-X
-	B-X
Hydroxy	B-X
-	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
(	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
)	B-X
is	B-X
the	B-X
proximate	B-X
carcinogenic	B-X
metabolite	B-X
of	B-X
the	B-X
powerful	B-X
rat	B-X
liver	B-X
carcinogen	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
transgenic	B-X
Big	B-X
Blue	B-X
(	B-X
R	B-X
)	B-X
rats	B-X
were	B-X
used	B-X
to	B-X
examine	B-X
the	B-X
relationship	B-X
between	B-X
in	B-X
vivo	B-X
mutagenicity	B-X
and	B-X
DNA	B-X
adduct	B-X
formation	B-X
by	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
in	B-X
the	B-X
target	B-X
liver	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
nontarget	B-X
tissues	B-X

Adduct	O
concentrations	O
increased	O
with	O
total	O
dose	O
to	O
maximum	O
values	O
in	O
samples	O
taken	O
1	O
day	O
after	O
two	O
doses	O
,	O
and	O
remained	O
essentially	O
the	O
same	O
after	O
four	O
doses	O
.	O
<EOS>	B-X
Adduct	B-X
concentrations	B-X
increased	B-X
with	B-X
total	B-X
dose	B-X
to	B-X
maximum	B-X
values	B-X
in	B-X
samples	B-X
taken	B-X
1	B-X
day	B-X
after	B-X
two	B-X
doses	B-X
,	B-X
and	B-X
remained	B-X
essentially	B-X
the	B-X
same	B-X
after	B-X
four	B-X
doses	B-X
<EOS>	B-X
Adduct	B-X
analysis	B-X
was	B-X
conducted	B-X
1	B-X
day	B-X
after	B-X
one	B-X
,	B-X
two	B-X
,	B-X
and	B-X
four	B-X
treatments	B-X
with	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
,	B-X
5	B-X
days	B-X
after	B-X
one	B-X
treatment	B-X
,	B-X
and	B-X
9	B-X
days	B-X
after	B-X
two	B-X
treatments	B-X
<EOS>	B-X
Additional	B-X
rats	B-X
were	B-X
evaluated	B-X
for	B-X
DNA	B-X
adduct	B-X
formation	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
by	B-X
(	B-X
32	B-X
)	B-X
P	B-X
-	B-X
postlabeling	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
transgenic	B-X
Big	B-X
Blue	B-X
(	B-X
R	B-X
)	B-X
rats	B-X
were	B-X
used	B-X
to	B-X
examine	B-X
the	B-X
relationship	B-X
between	B-X
in	B-X
vivo	B-X
mutagenicity	B-X
and	B-X
DNA	B-X
adduct	B-X
formation	B-X
by	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
in	B-X
the	B-X
target	B-X
liver	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
nontarget	B-X
tissues	B-X

In	O
samples	O
taken	O
after	O
four	O
doses	O
,	O
adduct	O
levels	O
were	O
103	O
,	O
28	O
,	O
and	O
7	O
fmol/microg	O
of	O
DNA	O
in	O
liver	O
,	O
spleen	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
bone	O
marrow	O
,	O
respectively	O
.	O
<EOS>	B-X
In	B-X
samples	B-X
taken	B-X
after	B-X
four	B-X
doses	B-X
,	B-X
adduct	B-X
levels	B-X
were	B-X
103	B-X
,	B-X
28	B-X
,	B-X
and	B-X
7	B-X
fmol	B-X
/	B-X
microg	B-X
of	B-X
DNA	B-X
in	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Additional	B-X
rats	B-X
were	B-X
evaluated	B-X
for	B-X
DNA	B-X
adduct	B-X
formation	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
by	B-X
(	B-X
32	B-X
)	B-X
P	B-X
-	B-X
postlabeling	B-X
<EOS>	B-X
7	B-X
x	B-X
10	B-X
(	B-X
	B-X
-	B-X
6	B-X
)	B-X
;	B-X
rats	B-X
given	B-X
four	B-X
doses	B-X
had	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
of	B-X
55	B-X
<EOS>	B-X
At	B-X
6	B-X
weeks	B-X
after	B-X
beginning	B-X
the	B-X
dosing	B-X
,	B-X
the	B-X
hprt	B-X
mutant	B-X
frequency	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
from	B-X
the	B-X
four	B-X
-	B-X
dose	B-X
group	B-X
was	B-X
16	B-X

The	O
results	O
indicate	O
that	O
the	O
extent	O
of	O
both	O
DNA	O
adduct	O
formation	O
and	O
mutant	O
induction	O
correlates	O
with	O
the	O
organ	O
specificity	O
for	O
N-OH-AAF	O
carcinogenesis	O
in	O
the	O
rat	O
.	O
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
extent	B-X
of	B-X
both	B-X
DNA	B-X
adduct	B-X
formation	B-X
and	B-X
mutant	B-X
induction	B-X
correlates	B-X
with	B-X
the	B-X
organ	B-X
specificity	B-X
for	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
carcinogenesis	B-X
in	B-X
the	B-X
rat	B-X
<EOS>	B-X
Comparison	B-X
of	B-X
hprt	B-X
and	B-X
lacI	B-X
mutant	B-X
frequency	B-X
with	B-X
DNA	B-X
adduct	B-X
formation	B-X
in	B-X
N	B-X
-	B-X
hydroxy	B-X
-	B-X
2	B-X
-	B-X
acetylaminofluorene	B-X
-	B-X
treated	B-X
Big	B-X
Blue	B-X
rats	B-X
.	B-X
<EOS>	B-X
Additional	B-X
rats	B-X
were	B-X
evaluated	B-X
for	B-X
DNA	B-X
adduct	B-X
formation	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
spleen	B-X
lymphocytes	B-X
,	B-X
and	B-X
bone	B-X
marrow	B-X
by	B-X
(	B-X
32	B-X
)	B-X
P	B-X
-	B-X
postlabeling	B-X
<EOS>	B-X
injection	B-X
at	B-X
4	B-X
-	B-X
day	B-X
intervals	B-X
,	B-X
and	B-X
groups	B-X
of	B-X
treated	B-X
and	B-X
control	B-X
rats	B-X
were	B-X
euthanized	B-X
up	B-X
to	B-X
10	B-X
weeks	B-X
after	B-X
beginning	B-X
the	B-X
dosing	B-X

Environ.	O
Mol.	O
Mutagen.	O
37	O
:	O
195-202	O
,	O
2001	O
.	O
<EOS>	B-X
37:195	B-X
-	B-X
202	B-X
,	B-X
2001	B-X
<EOS>	B-X
Male	B-X
rats	B-X
were	B-X
given	B-X
one	B-X
,	B-X
two	B-X
,	B-X
or	B-X
four	B-X
doses	B-X
of	B-X
25	B-X
mg	B-X
N	B-X
-	B-X
OH	B-X
-	B-X
AAF	B-X
/	B-X
kg	B-X
body	B-X
weight	B-X
by	B-X
i	B-X
<EOS>	B-X
7	B-X
x	B-X
10	B-X
(	B-X
	B-X
-	B-X
6	B-X
)	B-X
;	B-X
rats	B-X
given	B-X
four	B-X
doses	B-X
had	B-X
lacI	B-X
mutant	B-X
frequencies	B-X
in	B-X
spleen	B-X
lymphocytes	B-X
of	B-X
55	B-X
<EOS>	B-X
Mutagen	B-X

Expression	O
of	O
Mad1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
leads	O
to	O
reduced	O
thymic	O
cellularity	O
and	O
impaired	O
mitogen-induced	O
proliferation	O
.	O

To	O
investigate	O
Mad1	B-protein
function	O
in	O
vivo	O
,	O
transgenic	O
mice	O
were	O
generated	O
that	O
express	O
a	O
Mad1	B-DNA
transgene	I-DNA
in	O
T	B-cell_type
lineage	I-cell_type
cells	I-cell_type
under	O
the	O
control	O
of	O
the	O
proximal	B-DNA
lck	I-DNA
promoter	I-DNA
.	O

Thymus	O
size	O
in	O
lck-Mad1	O
transgenic	O
mice	O
is	O
drastically	O
reduced	O
although	O
representation	O
of	O
the	O
various	O
thymocyte	B-cell_type
sub	I-cell_type
populations	I-cell_type
appears	O
normal	O
.	O
<EOS>	B-X
Thymus	B-X
size	B-X
in	B-X
lck	B-X
-	B-X
Mad1	B-X
transgenic	B-X
mice	B-X
is	B-X
drastically	B-X
reduced	B-X
although	B-X
representation	B-X
of	B-X
the	B-X
various	B-X
thymocyte	B-X
sub	B-X
populations	B-X
appears	B-X
normal	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
thymocytes	B-X
and	B-X
splenic	B-X
T	B-X
cells	B-X
from	B-X
lck	B-X
-	B-X
Mad1	B-X
transgenic	B-X
mice	B-X
display	B-X
a	B-X
profound	B-X
proliferative	B-X
defect	B-X
in	B-X
response	B-X
to	B-X
activation	B-X
with	B-X
either	B-X
PMA	B-X
/	B-X
Ionomycin	B-X
or	B-X
immobilized	B-X
anti	B-X
-	B-X
CD3	B-X
/	B-X
CD28	B-X
antibody	B-X
<EOS>	B-X
Expression	B-X
of	B-X
Mad1	B-X
in	B-X
T	B-X
cells	B-X
leads	B-X
to	B-X
reduced	B-X
thymic	B-X
cellularity	B-X
and	B-X
impaired	B-X
mitogen	B-X
-	B-X
induced	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
This	B-X
proliferative	B-X
defect	B-X
is	B-X
not	B-X
reversed	B-X
by	B-X
addition	B-X
of	B-X
exogenous	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
is	B-X
p53	B-X
-	B-X
independent	B-X

To	O
investigate	O
more	O
closely	O
any	O
effects	O
of	O
Mad1	O
expression	O
on	O
thymocytes	B-cell_type
,	O
we	O
examined	O
thymic	O
selection	O
using	O
MHC	O
class	O
I-restricted	O
H-Y-TCR	O
transgenic	O
mice	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
more	B-X
closely	B-X
any	B-X
effects	B-X
of	B-X
Mad1	B-X
expression	B-X
on	B-X
thymocytes	B-X
,	B-X
we	B-X
examined	B-X
thymic	B-X
selection	B-X
using	B-X
MHC	B-X
class	B-X
I	B-X
-	B-X
restricted	B-X
H	B-X
-	B-X
Y	B-X
-	B-X
TCR	B-X
transgenic	B-X
mice	B-X
<EOS>	B-X
Expression	B-X
of	B-X
Mad1	B-X
in	B-X
T	B-X
cells	B-X
leads	B-X
to	B-X
reduced	B-X
thymic	B-X
cellularity	B-X
and	B-X
impaired	B-X
mitogen	B-X
-	B-X
induced	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
To	B-X
investigate	B-X
Mad1	B-X
function	B-X
in	B-X
vivo	B-X
,	B-X
transgenic	B-X
mice	B-X
were	B-X
generated	B-X
that	B-X
express	B-X
a	B-X
Mad1	B-X
transgene	B-X
in	B-X
T	B-X
lineage	B-X
cells	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
proximal	B-X
lck	B-X
promoter	B-X
<EOS>	B-X
This	B-X
proliferative	B-X
defect	B-X
is	B-X
not	B-X
reversed	B-X
by	B-X
addition	B-X
of	B-X
exogenous	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
is	B-X
p53	B-X
-	B-X
independent	B-X

Mad1	O
expression	O
in	O
vivo	O
reduces	O
the	O
efficiency	O
of	O
positive	O
selection	O
.	O
<EOS>	B-X
Mad1	B-X
expression	B-X
in	B-X
vivo	B-X
reduces	B-X
the	B-X
efficiency	B-X
of	B-X
positive	B-X
selection	B-X
<EOS>	B-X
Expression	B-X
of	B-X
Mad1	B-X
in	B-X
T	B-X
cells	B-X
leads	B-X
to	B-X
reduced	B-X
thymic	B-X
cellularity	B-X
and	B-X
impaired	B-X
mitogen	B-X
-	B-X
induced	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
Thymus	B-X
size	B-X
in	B-X
lck	B-X
-	B-X
Mad1	B-X
transgenic	B-X
mice	B-X
is	B-X
drastically	B-X
reduced	B-X
although	B-X
representation	B-X
of	B-X
the	B-X
various	B-X
thymocyte	B-X
sub	B-X
populations	B-X
appears	B-X
normal	B-X
<EOS>	B-X
To	B-X
investigate	B-X
more	B-X
closely	B-X
any	B-X
effects	B-X
of	B-X
Mad1	B-X
expression	B-X
on	B-X
thymocytes	B-X
,	B-X
we	B-X
examined	B-X
thymic	B-X
selection	B-X
using	B-X
MHC	B-X
class	B-X
I	B-X
-	B-X
restricted	B-X
H	B-X
-	B-X
Y	B-X
-	B-X
TCR	B-X
transgenic	B-X
mice	B-X

Furthermore	O
,	O
thymocytes	B-cell_type
and	O
splenic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
lck-Mad1	O
transgenic	O
mice	O
display	O
a	O
profound	O
proliferative	O
defect	O
in	O
response	O
to	O
activation	O
with	O
either	O
PMA/Ionomycin	O
or	O
immobilized	B-protein
anti-CD3/CD28	I-protein
antibody	I-protein
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
thymocytes	B-X
and	B-X
splenic	B-X
T	B-X
cells	B-X
from	B-X
lck	B-X
-	B-X
Mad1	B-X
transgenic	B-X
mice	B-X
display	B-X
a	B-X
profound	B-X
proliferative	B-X
defect	B-X
in	B-X
response	B-X
to	B-X
activation	B-X
with	B-X
either	B-X
PMA	B-X
/	B-X
Ionomycin	B-X
or	B-X
immobilized	B-X
anti	B-X
-	B-X
CD3	B-X
/	B-X
CD28	B-X
antibody	B-X
<EOS>	B-X
Thymus	B-X
size	B-X
in	B-X
lck	B-X
-	B-X
Mad1	B-X
transgenic	B-X
mice	B-X
is	B-X
drastically	B-X
reduced	B-X
although	B-X
representation	B-X
of	B-X
the	B-X
various	B-X
thymocyte	B-X
sub	B-X
populations	B-X
appears	B-X
normal	B-X
<EOS>	B-X
Optimization	B-X
of	B-X
lentiviral	B-X
vector	B-X
transduction	B-X
into	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
combination	B-X
with	B-X
the	B-X
fibronectin	B-X
fragment	B-X
CH	B-X
-	B-X
296	B-X
stimulation	B-X
.	B-X
<EOS>	B-X
Development	B-X
of	B-X
an	B-X
animal	B-X
model	B-X
for	B-X
autotransfusion	B-X
therapy	B-X
:	B-X
in	B-X
vitro	B-X
characterization	B-X
and	B-X
analysis	B-X
of	B-X
anti	B-X
-	B-X
CD3	B-X
/	B-X
CD28	B-X
expanded	B-X
cells	B-X
.	B-X

This	O
proliferative	O
defect	O
is	O
not	O
reversed	O
by	O
addition	O
of	O
exogenous	B-protein
IL-2	I-protein
and	O
is	O
p53-independent	O
.	O
<EOS>	B-X
The	B-X
underlying	B-X
mechanisms	B-X
range	B-X
from	B-X
the	B-X
attenuation	B-X
of	B-X
the	B-X
p53	B-X
-	B-X
dependent	B-X
G	B-X
<EOS>	B-X
The	B-X
anti	B-X
-	B-X
proliferative	B-X
effects	B-X
of	B-X
GSE	B-X
,	B-X
MTE	B-X
and	B-X
combinations	B-X
were	B-X
evaluated	B-X
in	B-X
lung	B-X
neoplastic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Proliferative	B-X
diabetic	B-X
retinopathy	B-X
(	B-X
PDR	B-X
)	B-X
is	B-X
a	B-X
vision	B-X
-	B-X
threatening	B-X
complication	B-X
of	B-X
diabetes	B-X
<EOS>	B-X
A	B-X
32	B-X
-	B-X
year	B-X
-	B-X
old	B-X
Caucasian	B-X
male	B-X
diagnosed	B-X
with	B-X
PDR	B-X
in	B-X
the	B-X
right	B-X
eye	B-X
was	B-X
treated	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
PRP	B-X
and	B-X
multiple	B-X
anti	B-X
-	B-X
VEGF	B-X
treatments	B-X
over	B-X
a	B-X
12	B-X
-	B-X
month	B-X
period	B-X

The	O
growth	O
inhibition	O
caused	O
by	O
Mad1	B-protein
is	O
overcome	O
by	O
expression	O
of	O
active	B-protein
c-Myc	I-protein
.	O
<EOS>	B-X
The	B-X
growth	B-X
inhibition	B-X
caused	B-X
by	B-X
Mad1	B-X
is	B-X
overcome	B-X
by	B-X
expression	B-X
of	B-X
active	B-X
c	B-X
-	B-X
Myc	B-X
<EOS>	B-X
This	B-X
proliferative	B-X
defect	B-X
is	B-X
not	B-X
reversed	B-X
by	B-X
addition	B-X
of	B-X
exogenous	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
is	B-X
p53	B-X
-	B-X
independent	B-X
<EOS>	B-X
Thymus	B-X
size	B-X
in	B-X
lck	B-X
-	B-X
Mad1	B-X
transgenic	B-X
mice	B-X
is	B-X
drastically	B-X
reduced	B-X
although	B-X
representation	B-X
of	B-X
the	B-X
various	B-X
thymocyte	B-X
sub	B-X
populations	B-X
appears	B-X
normal	B-X
<EOS>	B-X
To	B-X
investigate	B-X
more	B-X
closely	B-X
any	B-X
effects	B-X
of	B-X
Mad1	B-X
expression	B-X
on	B-X
thymocytes	B-X
,	B-X
we	B-X
examined	B-X
thymic	B-X
selection	B-X
using	B-X
MHC	B-X
class	B-X
I	B-X
-	B-X
restricted	B-X
H	B-X
-	B-X
Y	B-X
-	B-X
TCR	B-X
transgenic	B-X
mice	B-X

Differential	O
requirement	O
for	O
the	O
transcription	B-protein
factor	I-protein
PU.1	I-protein
in	O
the	O
generation	O
of	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
versus	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

PU.1	B-protein
is	O
a	O
member	O
of	O
the	O
Ets	B-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
required	O
for	O
the	O
development	O
of	O
various	O
lymphoid	B-cell_line
and	I-cell_line
myeloid	I-cell_line
cell	I-cell_line
lineages	I-cell_line
,	O
but	O
its	O
role	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
development	O
is	O
not	O
known	O
.	O

The	O
study	O
shows	O
that	O
PU.1	B-protein
is	O
expressed	O
in	O
NK	B-cell_type
cells	I-cell_type
and	O
that	O
,	O
on	O
cell	O
transfer	O
into	O
alymphoid	O
Rag2/gammac	O
(	O
-/-	O
)	O
mice	O
,	O
hematopoietic	B-cell_type
progenitors	I-cell_type
of	O
PU.1	B-cell_type
(	I-cell_type
-/-	I-cell_type
)	I-cell_type
fetal	I-cell_type
liver	I-cell_type
cells	I-cell_type
could	O
generate	O
functional	O
NK	B-cell_type
cells	I-cell_type
but	O
not	O
B	B-cell_type
or	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
underlying	B-X
causes	B-X
is	B-X
the	B-X
resistance	B-X
mechanisms	B-X
in	B-X
cancer	B-X
cells	B-X
that	B-X
limit	B-X
effective	B-X
killing	B-X
by	B-X
CAR	B-X
T	B-X
cells	B-X
<EOS>	B-X
Coculture	B-X
killing	B-X
experiments	B-X
were	B-X
performed	B-X
with	B-X
melanoma	B-X
cell	B-X
line	B-X
MeWo	B-X
,	B-X
diffuse	B-X
large	B-X
B	B-X
cell	B-X
lymphoma	B-X
(	B-X
DLBCL	B-X
)	B-X
cell	B-X
line	B-X
OCI	B-X
-	B-X
Ly7	B-X
or	B-X
primary	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
cells	B-X
as	B-X
target	B-X
cells	B-X
and	B-X
natural	B-X
killer	B-X
cell	B-X
line	B-X
YT	B-X
-	B-X
Indy	B-X
,	B-X
CD20	B-X
CAR	B-X
T	B-X
cells	B-X
or	B-X
CD19	B-X
CAR	B-X
T	B-X
cells	B-X
as	B-X
effector	B-X
cells	B-X
and	B-X
analyzed	B-X
by	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
The	B-X
panel	B-X
presented	B-X
here	B-X
first	B-X
identify	B-X
the	B-X
main	B-X
cell	B-X
subsets	B-X
including	B-X
myeloid	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
NKT	B-X
cells	B-X
,	B-X
γδ	B-X
T	B-X
cells	B-X
,	B-X
CD4	B-X
<EOS>	B-X
Acute	B-X
graft	B-X
-	B-X
versus	B-X
-	B-X
host	B-X
disease	B-X
(	B-X
aGVHD	B-X
)	B-X
is	B-X
a	B-X
prominent	B-X
barrier	B-X
to	B-X
allogeneic	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
transplantation	B-X
(	B-X
allo	B-X
-	B-X
HSCT	B-X
)	B-X
and	B-X
even	B-X
leads	B-X
to	B-X
death	B-X
after	B-X
HSCT	B-X

Nevertheless	O
,	O
the	O
numbers	O
of	O
bone	B-cell_type
marrow	I-cell_type
NK	I-cell_type
cell	I-cell_type
precursors	I-cell_type
and	O
splenic	B-cell_type
mature	I-cell_type
NK	I-cell_type
cells	I-cell_type
were	O
reduced	O
compared	O
to	O
controls	O
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
the	B-X
numbers	B-X
of	B-X
bone	B-X
marrow	B-X
NK	B-X
cell	B-X
precursors	B-X
and	B-X
splenic	B-X
mature	B-X
NK	B-X
cells	B-X
were	B-X
reduced	B-X
compared	B-X
to	B-X
controls	B-X
<EOS>	B-X
1	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
these	B-X
cytokine	B-X
receptor	B-X
genes	B-X
during	B-X
NK	B-X
cell	B-X
development	B-X
<EOS>	B-X
1	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
fetal	B-X
liver	B-X
cells	B-X
could	B-X
generate	B-X
functional	B-X
NK	B-X
cells	B-X
but	B-X
not	B-X
B	B-X
or	B-X
T	B-X
cells	B-X
<EOS>	B-X
1	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Ets	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
required	B-X
for	B-X
the	B-X
development	B-X
of	B-X
various	B-X
lymphoid	B-X
and	B-X
myeloid	B-X
cell	B-X
lineages	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
development	B-X
is	B-X
not	B-X
known	B-X

Moreover	O
,	O
PU.1	B-cell_type
(	I-cell_type
-/-	I-cell_type
)	I-cell_type
NK	I-cell_type
cells	I-cell_type
displayed	O
reduced	O
expression	O
of	O
the	O
receptors	O
for	O
stem	B-protein
cell	I-protein
factor	I-protein
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-7	I-protein
,	O
suggesting	O
a	O
nonredundant	O
role	O
for	O
PU.1	B-protein
in	O
regulating	O
the	O
expression	O
of	O
these	O
cytokine	B-DNA
receptor	I-DNA
genes	I-DNA
during	O
NK	O
cell	O
development	O
.	O

PU.1	B-cell_type
(	I-cell_type
-/-	I-cell_type
)	I-cell_type
NK	I-cell_type
cells	I-cell_type
also	O
showed	O
defective	O
expression	O
of	O
inhibitory	O
and	O
activating	O
members	O
of	O
the	O
Ly49	B-protein
family	I-protein
and	O
failed	O
to	O
proliferate	O
in	O
response	O
to	O
IL-2	B-protein
and	O
IL-12	B-protein
.	O
<EOS>	B-X
1	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
NK	B-X
cells	B-X
also	B-X
showed	B-X
defective	B-X
expression	B-X
of	B-X
inhibitory	B-X
and	B-X
activating	B-X
members	B-X
of	B-X
the	B-X
Ly49	B-X
family	B-X
and	B-X
failed	B-X
to	B-X
proliferate	B-X
in	B-X
response	B-X
to	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
12	B-X
<EOS>	B-X
1	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
NK	B-X
cells	B-X
displayed	B-X
reduced	B-X
expression	B-X
of	B-X
the	B-X
receptors	B-X
for	B-X
stem	B-X
cell	B-X
factor	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
7	B-X
,	B-X
suggesting	B-X
a	B-X
nonredundant	B-X
role	B-X
for	B-X
PU	B-X
<EOS>	B-X
1	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
these	B-X
cytokine	B-X
receptor	B-X
genes	B-X
during	B-X
NK	B-X
cell	B-X
development	B-X
<EOS>	B-X
1	B-X
is	B-X
expressed	B-X
in	B-X
NK	B-X
cells	B-X
and	B-X
that	B-X
,	B-X
on	B-X
cell	B-X
transfer	B-X
into	B-X
alymphoid	B-X
Rag2	B-X
/	B-X
gammac	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
,	B-X
hematopoietic	B-X
progenitors	B-X
of	B-X
PU	B-X

Thus	O
,	O
despite	O
the	O
less	O
stringent	O
requirement	O
for	O
PU.1	B-protein
in	O
NK	O
cell	O
development	O
compared	O
to	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
PU.1	B-protein
regulates	O
NK	O
cell	O
differentiation	O
and	O
homeostasis	O
.	O

Benzene-extracted	O
components	O
are	O
important	O
for	O
the	O
major	O
activity	O
of	O
diesel	O
exhaust	O
particles	O
:	O
effect	O
on	O
interleukin-8	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
bronchial	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
are	B-X
important	B-X
for	B-X
the	B-X
major	B-X
activity	B-X
of	B-X
diesel	B-X
exhaust	B-X
particles	B-X
:	B-X
effect	B-X
on	B-X
interleukin	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
DEPs	B-X
augmented	B-X
the	B-X
production	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
by	B-X
human	B-X
airway	B-X
epithelial	B-X
cells	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Epidemiologic	B-X
and	B-X
experimental	B-X
studies	B-X
suggest	B-X
that	B-X
diesel	B-X
exhaust	B-X
particles	B-X
(	B-X
DEPs	B-X
)	B-X
may	B-X
be	B-X
related	B-X
to	B-X
increasing	B-X
respiratory	B-X
mortality	B-X
and	B-X
morbidity	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
showed	B-X
effects	B-X
mimicking	B-X
DEPs	B-X
on	B-X
IL	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
,	B-X
release	B-X
of	B-X
several	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
8	B-X
;	B-X
granulocyte	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
;	B-X
and	B-X
regulated	B-X
on	B-X
activation	B-X
,	B-X
normal	B-X
T	B-X
cells	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X

Epidemiologic	O
and	O
experimental	O
studies	O
suggest	O
that	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
may	O
be	O
related	O
to	O
increasing	O
respiratory	O
mortality	O
and	O
morbidity	O
.	O
<EOS>	B-X
Epidemiologic	B-X
and	B-X
experimental	B-X
studies	B-X
suggest	B-X
that	B-X
diesel	B-X
exhaust	B-X
particles	B-X
(	B-X
DEPs	B-X
)	B-X
may	B-X
be	B-X
related	B-X
to	B-X
increasing	B-X
respiratory	B-X
mortality	B-X
and	B-X
morbidity	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
are	B-X
important	B-X
for	B-X
the	B-X
major	B-X
activity	B-X
of	B-X
diesel	B-X
exhaust	B-X
particles	B-X
:	B-X
effect	B-X
on	B-X
interleukin	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
NAC	B-X
,	B-X
PDTC	B-X
,	B-X
and	B-X
SB203580	B-X
suppressed	B-X
the	B-X
activities	B-X
of	B-X
DEPs	B-X
and	B-X
their	B-X
benzene	B-X
extracts	B-X
,	B-X
suggesting	B-X
the	B-X
roles	B-X
of	B-X
oxidants	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
and	B-X
p38MAPK	B-X
pathways	B-X
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
proinflammatory	B-X
activities	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
several	B-X
components	B-X
extracted	B-X
from	B-X
DEPs	B-X
on	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
8	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
line	B-X
BEAS	B-X
-	B-X
2B	B-X
and	B-X
normal	B-X
human	B-X
airway	B-X
epithelial	B-X
cells	B-X
obtained	B-X
from	B-X
very	B-X
peripheral	B-X
airways	B-X
by	B-X
an	B-X
ultrathin	B-X
bronchoscope	B-X

We	O
have	O
shown	O
that	O
DEPs	O
augmented	O
the	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
by	O
human	B-cell_type
airway	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
in	O
vitro	O
.	O
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
DEPs	B-X
augmented	B-X
the	B-X
production	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
by	B-X
human	B-X
airway	B-X
epithelial	B-X
cells	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
are	B-X
important	B-X
for	B-X
the	B-X
major	B-X
activity	B-X
of	B-X
diesel	B-X
exhaust	B-X
particles	B-X
:	B-X
effect	B-X
on	B-X
interleukin	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
NAC	B-X
,	B-X
PDTC	B-X
,	B-X
and	B-X
SB203580	B-X
suppressed	B-X
the	B-X
activities	B-X
of	B-X
DEPs	B-X
and	B-X
their	B-X
benzene	B-X
extracts	B-X
,	B-X
suggesting	B-X
the	B-X
roles	B-X
of	B-X
oxidants	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
and	B-X
p38MAPK	B-X
pathways	B-X
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
proinflammatory	B-X
activities	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
several	B-X
components	B-X
extracted	B-X
from	B-X
DEPs	B-X
on	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
8	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
line	B-X
BEAS	B-X
-	B-X
2B	B-X
and	B-X
normal	B-X
human	B-X
airway	B-X
epithelial	B-X
cells	B-X
obtained	B-X
from	B-X
very	B-X
peripheral	B-X
airways	B-X
by	B-X
an	B-X
ultrathin	B-X
bronchoscope	B-X

To	O
better	O
understand	O
the	O
mechanisms	O
of	O
their	O
proinflammatory	O
activities	O
,	O
we	O
studied	O
the	O
effects	O
of	O
several	O
components	O
extracted	O
from	O
DEPs	O
on	O
interleukin	O
(	O
IL	O
)	O
-8	O
expression	O
in	O
human	B-cell_line
bronchial	I-cell_line
epithelial	I-cell_line
cell	I-cell_line
line	I-cell_line
BEAS-2B	I-cell_line
and	O
normal	B-cell_type
human	I-cell_type
airway	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
obtained	O
from	O
very	O
peripheral	O
airways	O
by	O
an	O
ultrathin	O
bronchoscope	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
proinflammatory	B-X
activities	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
several	B-X
components	B-X
extracted	B-X
from	B-X
DEPs	B-X
on	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
8	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
line	B-X
BEAS	B-X
-	B-X
2B	B-X
and	B-X
normal	B-X
human	B-X
airway	B-X
epithelial	B-X
cells	B-X
obtained	B-X
from	B-X
very	B-X
peripheral	B-X
airways	B-X
by	B-X
an	B-X
ultrathin	B-X
bronchoscope	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
are	B-X
important	B-X
for	B-X
the	B-X
major	B-X
activity	B-X
of	B-X
diesel	B-X
exhaust	B-X
particles	B-X
:	B-X
effect	B-X
on	B-X
interleukin	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
DEPs	B-X
augmented	B-X
the	B-X
production	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
by	B-X
human	B-X
airway	B-X
epithelial	B-X
cells	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
showed	B-X
effects	B-X
mimicking	B-X
DEPs	B-X
on	B-X
IL	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
,	B-X
release	B-X
of	B-X
several	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
8	B-X
;	B-X
granulocyte	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
;	B-X
and	B-X
regulated	B-X
on	B-X
activation	B-X
,	B-X
normal	B-X
T	B-X
cells	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X

We	O
used	O
several	O
agents	O
active	O
on	O
signal	O
transduction	O
pathways	O
in	O
cytokine	O
expression	O
,	O
such	O
as	O
the	O
protein	O
kinase	O
C	O
inhibitor	O
staurosporin	O
,	O
antioxidant	O
agents	O
including	O
N-acetyl	O
cysteine	O
(	O
NAC	O
)	O
and	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
and	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
inhibitor	O
SB203580	O
.	O
<EOS>	B-X
We	B-X
used	B-X
several	B-X
agents	B-X
active	B-X
on	B-X
signal	B-X
transduction	B-X
pathways	B-X
in	B-X
cytokine	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitor	B-X
staurosporin	B-X
,	B-X
antioxidant	B-X
agents	B-X
including	B-X
N	B-X
-	B-X
acetyl	B-X
cysteine	B-X
(	B-X
NAC	B-X
)	B-X
and	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
(	B-X
PDTC	B-X
)	B-X
,	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
inhibitor	B-X
SB203580	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
NAC	B-X
,	B-X
PDTC	B-X
,	B-X
and	B-X
SB203580	B-X
suppressed	B-X
the	B-X
activities	B-X
of	B-X
DEPs	B-X
and	B-X
their	B-X
benzene	B-X
extracts	B-X
,	B-X
suggesting	B-X
the	B-X
roles	B-X
of	B-X
oxidants	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
and	B-X
p38MAPK	B-X
pathways	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
showed	B-X
effects	B-X
mimicking	B-X
DEPs	B-X
on	B-X
IL	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
,	B-X
release	B-X
of	B-X
several	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
8	B-X
;	B-X
granulocyte	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
;	B-X
and	B-X
regulated	B-X
on	B-X
activation	B-X
,	B-X
normal	B-X
T	B-X
cells	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
are	B-X
important	B-X
for	B-X
the	B-X
major	B-X
activity	B-X
of	B-X
diesel	B-X
exhaust	B-X
particles	B-X
:	B-X
effect	B-X
on	B-X
interleukin	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
.	B-X

Benzene-extracted	O
components	O
showed	O
effects	O
mimicking	O
DEPs	O
on	O
IL-8	O
gene	O
expression	O
,	O
release	O
of	O
several	O
cytokines	B-protein
(	O
IL-8	B-protein
;	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
;	O
and	O
regulated	O
on	O
activation	O
,	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
expressed	O
and	O
secreted	O
)	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
activation	O
.	O
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
showed	B-X
effects	B-X
mimicking	B-X
DEPs	B-X
on	B-X
IL	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
,	B-X
release	B-X
of	B-X
several	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
8	B-X
;	B-X
granulocyte	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
;	B-X
and	B-X
regulated	B-X
on	B-X
activation	B-X
,	B-X
normal	B-X
T	B-X
cells	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
are	B-X
important	B-X
for	B-X
the	B-X
major	B-X
activity	B-X
of	B-X
diesel	B-X
exhaust	B-X
particles	B-X
:	B-X
effect	B-X
on	B-X
interleukin	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
mechanisms	B-X
of	B-X
their	B-X
proinflammatory	B-X
activities	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
several	B-X
components	B-X
extracted	B-X
from	B-X
DEPs	B-X
on	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
8	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
line	B-X
BEAS	B-X
-	B-X
2B	B-X
and	B-X
normal	B-X
human	B-X
airway	B-X
epithelial	B-X
cells	B-X
obtained	B-X
from	B-X
very	B-X
peripheral	B-X
airways	B-X
by	B-X
an	B-X
ultrathin	B-X
bronchoscope	B-X
<EOS>	B-X
We	B-X
used	B-X
several	B-X
agents	B-X
active	B-X
on	B-X
signal	B-X
transduction	B-X
pathways	B-X
in	B-X
cytokine	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitor	B-X
staurosporin	B-X
,	B-X
antioxidant	B-X
agents	B-X
including	B-X
N	B-X
-	B-X
acetyl	B-X
cysteine	B-X
(	B-X
NAC	B-X
)	B-X
and	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
(	B-X
PDTC	B-X
)	B-X
,	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
inhibitor	B-X
SB203580	B-X

We	O
also	O
found	O
that	O
NAC	O
,	O
PDTC	O
,	O
and	O
SB203580	O
suppressed	O
the	O
activities	O
of	O
DEPs	O
and	O
their	O
benzene	O
extracts	O
,	O
suggesting	O
the	O
roles	O
of	O
oxidants-mediated	O
NF-kappa	O
B	O
activation	O
and	O
p38MAPK	B-protein
pathways	O
.	O
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
NAC	B-X
,	B-X
PDTC	B-X
,	B-X
and	B-X
SB203580	B-X
suppressed	B-X
the	B-X
activities	B-X
of	B-X
DEPs	B-X
and	B-X
their	B-X
benzene	B-X
extracts	B-X
,	B-X
suggesting	B-X
the	B-X
roles	B-X
of	B-X
oxidants	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
and	B-X
p38MAPK	B-X
pathways	B-X
<EOS>	B-X
Finally	B-X
,	B-X
benzo	B-X
[	B-X
a	B-X
]	B-X
pyrene	B-X
,	B-X
one	B-X
of	B-X
the	B-X
important	B-X
compounds	B-X
included	B-X
in	B-X
the	B-X
benzene	B-X
component	B-X
,	B-X
replicated	B-X
the	B-X
activities	B-X
shown	B-X
by	B-X
DEPs	B-X
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
DEPs	B-X
augmented	B-X
the	B-X
production	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
by	B-X
human	B-X
airway	B-X
epithelial	B-X
cells	B-X
in	B-X
vitro	B-X
<EOS>	B-X
We	B-X
used	B-X
several	B-X
agents	B-X
active	B-X
on	B-X
signal	B-X
transduction	B-X
pathways	B-X
in	B-X
cytokine	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitor	B-X
staurosporin	B-X
,	B-X
antioxidant	B-X
agents	B-X
including	B-X
N	B-X
-	B-X
acetyl	B-X
cysteine	B-X
(	B-X
NAC	B-X
)	B-X
and	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
(	B-X
PDTC	B-X
)	B-X
,	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
inhibitor	B-X
SB203580	B-X

Finally	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
,	O
one	O
of	O
the	O
important	O
compounds	O
included	O
in	O
the	O
benzene	O
component	O
,	O
replicated	O
the	O
activities	O
shown	O
by	O
DEPs	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
benzo	B-X
[	B-X
a	B-X
]	B-X
pyrene	B-X
,	B-X
one	B-X
of	B-X
the	B-X
important	B-X
compounds	B-X
included	B-X
in	B-X
the	B-X
benzene	B-X
component	B-X
,	B-X
replicated	B-X
the	B-X
activities	B-X
shown	B-X
by	B-X
DEPs	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
NAC	B-X
,	B-X
PDTC	B-X
,	B-X
and	B-X
SB203580	B-X
suppressed	B-X
the	B-X
activities	B-X
of	B-X
DEPs	B-X
and	B-X
their	B-X
benzene	B-X
extracts	B-X
,	B-X
suggesting	B-X
the	B-X
roles	B-X
of	B-X
oxidants	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
and	B-X
p38MAPK	B-X
pathways	B-X
<EOS>	B-X
Benzene	B-X
-	B-X
extracted	B-X
components	B-X
are	B-X
important	B-X
for	B-X
the	B-X
major	B-X
activity	B-X
of	B-X
diesel	B-X
exhaust	B-X
particles	B-X
:	B-X
effect	B-X
on	B-X
interleukin	B-X
-	B-X
8	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
used	B-X
several	B-X
agents	B-X
active	B-X
on	B-X
signal	B-X
transduction	B-X
pathways	B-X
in	B-X
cytokine	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitor	B-X
staurosporin	B-X
,	B-X
antioxidant	B-X
agents	B-X
including	B-X
N	B-X
-	B-X
acetyl	B-X
cysteine	B-X
(	B-X
NAC	B-X
)	B-X
and	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
(	B-X
PDTC	B-X
)	B-X
,	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
inhibitor	B-X
SB203580	B-X

The	O
nuclear	B-protein
receptor	I-protein
PPAR	I-protein
gamma	I-protein
is	O
expressed	O
by	O
mouse	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
PPAR	O
gamma	O
agonists	O
induce	O
apoptosis	O
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
(	I-protein
PPAR	I-protein
)	I-protein
-gamma	I-protein
is	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
that	O
serves	O
as	O
a	O
trans	O
factor	O
to	O
regulate	O
lipid	O
metabolism	O
.	O
<EOS>	B-X
Peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
(	B-X
PPAR	B-X
)	B-X
	B-X
-	B-X
gamma	B-X
is	B-X
a	B-X
nuclear	B-X
hormone	B-X
receptor	B-X
that	B-X
serves	B-X
as	B-X
a	B-X
trans	B-X
factor	B-X
to	B-X
regulate	B-X
lipid	B-X
metabolism	B-X
<EOS>	B-X
Peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptors	B-X
(	B-X
PPAR	B-X
alpha	B-X
,	B-X
beta	B-X
,	B-X
and	B-X
gamma	B-X
)	B-X
are	B-X
nuclear	B-X
hormone	B-X
receptors	B-X
that	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
regulating	B-X
lipid	B-X
metabolism	B-X
<EOS>	B-X
The	B-X
nuclear	B-X
receptor	B-X
PPAR	B-X
gamma	B-X
is	B-X
expressed	B-X
by	B-X
mouse	B-X
T	B-X
lymphocytes	B-X
and	B-X
PPAR	B-X
gamma	B-X
agonists	B-X
induce	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
1	B-X
co	B-X
-	B-X
binding	B-X
to	B-X
PPARG	B-X
sites	B-X
appears	B-X
to	B-X
be	B-X
important	B-X
for	B-X
possible	B-X
PPARG	B-X
ancestral	B-X
functions	B-X
such	B-X
as	B-X
lipid	B-X
metabolism	B-X

Intense	O
interest	O
is	O
focused	O
on	O
PPAR-gamma	B-protein
and	O
its	O
ligands	O
owing	O
to	O
its	O
putative	O
role	O
in	O
adipocyte	O
differentiation	O
.	O
<EOS>	B-X
Intense	B-X
interest	B-X
is	B-X
focused	B-X
on	B-X
PPAR	B-X
-	B-X
gamma	B-X
and	B-X
its	B-X
ligands	B-X
owing	B-X
to	B-X
its	B-X
putative	B-X
role	B-X
in	B-X
adipocyte	B-X
differentiation	B-X
<EOS>	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
PPAR	B-X
-	B-X
gamma	B-X
agonists	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
immune	B-X
responses	B-X
by	B-X
inducing	B-X
apoptosis	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
function	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
,	B-X
T	B-X
cells	B-X
were	B-X
stimulated	B-X
with	B-X
phorbol	B-X
12	B-X
-	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
and	B-X
ionomycin	B-X
or	B-X
antigen	B-X
and	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
<EOS>	B-X
T	B-X
cell	B-X
death	B-X
via	B-X
PPAR	B-X
-	B-X
gamma	B-X
ligation	B-X
may	B-X
act	B-X
as	B-X
a	B-X
potent	B-X
anti	B-X
-	B-X
inflammatory	B-X
signal	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
and	B-X
ligands	B-X
could	B-X
possibly	B-X
be	B-X
used	B-X
to	B-X
control	B-X
disorders	B-X
in	B-X
which	B-X
excessive	B-X
inflammation	B-X
occurs	B-X

Little	O
is	O
known	O
,	O
however	O
,	O
about	O
the	O
functions	O
of	O
PPAR-gamma	B-protein
in	O
the	O
immune	O
system	O
,	O
especially	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
demonstrate	O
that	O
both	O
naive	B-cell_type
and	I-cell_type
activated	I-cell_type
ovalbumin-specific	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
DO11.10-transgenic	O
mice	O
express	O
PPAR-gamma	B-RNA
mRNA	O
and	O
protein	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
both	B-X
naive	B-X
and	B-X
activated	B-X
ovalbumin	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
from	B-X
DO11	B-X
<EOS>	B-X
10	B-X
-	B-X
transgenic	B-X
mice	B-X
express	B-X
PPAR	B-X
-	B-X
gamma	B-X
mRNA	B-X
and	B-X
protein	B-X
<EOS>	B-X
The	B-X
decrease	B-X
in	B-X
cell	B-X
viability	B-X
was	B-X
due	B-X
to	B-X
apoptosis	B-X
of	B-X
the	B-X
T	B-X
lymphocytes	B-X
,	B-X
and	B-X
occurred	B-X
only	B-X
when	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
PPAR	B-X
-	B-X
gamma	B-X
,	B-X
and	B-X
not	B-X
PPAR	B-X
-	B-X
alpha	B-X
agonists	B-X
,	B-X
revealing	B-X
specificity	B-X
of	B-X
this	B-X
response	B-X
for	B-X
PPAR	B-X
-	B-X
gamma	B-X
<EOS>	B-X
The	B-X
nuclear	B-X
receptor	B-X
PPAR	B-X
gamma	B-X
is	B-X
expressed	B-X
by	B-X
mouse	B-X
T	B-X
lymphocytes	B-X
and	B-X
PPAR	B-X
gamma	B-X
agonists	B-X
induce	B-X
apoptosis	B-X
.	B-X

In	O
order	O
to	O
determine	O
the	O
function	O
of	O
PPAR-gamma	B-protein
,	O
T	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
or	O
antigen	O
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
introduced	B-X
the	B-X
ectodomain	B-X
of	B-X
NA	B-X
into	B-X
DNA	B-X
vaccines	B-X
that	B-X
as	B-X
translated	B-X
dimeric	B-X
vaccine	B-X
proteins	B-X
target	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
(	B-X
APCs	B-X
)	B-X
<EOS>	B-X
How	B-X
I	B-X
treat	B-X
refractory	B-X
/	B-X
relapsed	B-X
diffuse	B-X
large	B-X
B	B-X
-	B-X
cell	B-X
lymphomas	B-X
with	B-X
CD19	B-X
-	B-X
directed	B-X
chimeric	B-X
antigen	B-X
receptor	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
a	B-X
fourth	B-X
new	B-X
mechanism	B-X
,	B-X
preformed	B-X
peptide	B-X
-	B-X
MHC	B-X
complexes	B-X
can	B-X
be	B-X
directly	B-X
transferred	B-X
from	B-X
the	B-X
surface	B-X
of	B-X
antigen	B-X
donor	B-X
cells	B-X
(	B-X
i	B-X
<EOS>	B-X
Dendritic	B-X
cells	B-X
orient	B-X
T	B-X
cell	B-X
responses	B-X
via	B-X
antigen	B-X
presentation	B-X
and	B-X
provision	B-X
of	B-X
polarizing	B-X
signals	B-X

Simultaneous	O
exposure	O
to	O
PPAR-gamma	O
ligands	O
(	O
e.g.	O
15-deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
-prostaglandin	O
J	O
(	O
2	O
)	O
,	O
troglitazone	O
)	O
showed	O
drastic	O
inhibition	O
of	O
proliferation	O
and	O
significant	O
decreases	O
in	O
cell	O
viability	O
.	O

The	O
decrease	O
in	O
cell	O
viability	O
was	O
due	O
to	O
apoptosis	O
of	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
occurred	O
only	O
when	O
cells	O
were	O
treated	O
with	O
PPAR-gamma	B-protein
,	O
and	O
not	O
PPAR-alpha	O
agonists	O
,	O
revealing	O
specificity	O
of	O
this	O
response	O
for	O
PPAR-gamma	B-protein
.	O

These	O
observations	O
suggest	O
that	O
PPAR-gamma	O
agonists	O
play	O
an	O
important	O
role	O
in	O
regulating	O
T	O
cell-mediated	O
immune	O
responses	O
by	O
inducing	O
apoptosis	O
.	O
<EOS>	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
PPAR	B-X
-	B-X
gamma	B-X
agonists	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
immune	B-X
responses	B-X
by	B-X
inducing	B-X
apoptosis	B-X
<EOS>	B-X
The	B-X
nuclear	B-X
receptor	B-X
PPAR	B-X
gamma	B-X
is	B-X
expressed	B-X
by	B-X
mouse	B-X
T	B-X
lymphocytes	B-X
and	B-X
PPAR	B-X
gamma	B-X
agonists	B-X
induce	B-X
apoptosis	B-X
.	B-X
<EOS>	B-X
Intense	B-X
interest	B-X
is	B-X
focused	B-X
on	B-X
PPAR	B-X
-	B-X
gamma	B-X
and	B-X
its	B-X
ligands	B-X
owing	B-X
to	B-X
its	B-X
putative	B-X
role	B-X
in	B-X
adipocyte	B-X
differentiation	B-X
<EOS>	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
function	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
,	B-X
T	B-X
cells	B-X
were	B-X
stimulated	B-X
with	B-X
phorbol	B-X
12	B-X
-	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
and	B-X
ionomycin	B-X
or	B-X
antigen	B-X
and	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X

T	O
cell	O
death	O
via	O
PPAR-gamma	O
ligation	O
may	O
act	O
as	O
a	O
potent	O
anti-inflammatory	O
signal	O
in	O
the	O
immune	O
system	O
,	O
and	O
ligands	O
could	O
possibly	O
be	O
used	O
to	O
control	O
disorders	O
in	O
which	O
excessive	O
inflammation	O
occurs	O
.	O
<EOS>	B-X
T	B-X
cell	B-X
death	B-X
via	B-X
PPAR	B-X
-	B-X
gamma	B-X
ligation	B-X
may	B-X
act	B-X
as	B-X
a	B-X
potent	B-X
anti	B-X
-	B-X
inflammatory	B-X
signal	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
and	B-X
ligands	B-X
could	B-X
possibly	B-X
be	B-X
used	B-X
to	B-X
control	B-X
disorders	B-X
in	B-X
which	B-X
excessive	B-X
inflammation	B-X
occurs	B-X
<EOS>	B-X
Intense	B-X
interest	B-X
is	B-X
focused	B-X
on	B-X
PPAR	B-X
-	B-X
gamma	B-X
and	B-X
its	B-X
ligands	B-X
owing	B-X
to	B-X
its	B-X
putative	B-X
role	B-X
in	B-X
adipocyte	B-X
differentiation	B-X
<EOS>	B-X
Little	B-X
is	B-X
known	B-X
,	B-X
however	B-X
,	B-X
about	B-X
the	B-X
functions	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
especially	B-X
in	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
PPAR	B-X
-	B-X
gamma	B-X
agonists	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
immune	B-X
responses	B-X
by	B-X
inducing	B-X
apoptosis	B-X

Suppression	O
of	O
lung	O
inflammation	O
in	O
rats	O
by	O
prevention	O
of	O
NF-kappaB	O
activation	O
in	O
the	O
liver	O
.	O
<EOS>	B-X
Suppression	B-X
of	B-X
lung	B-X
inflammation	B-X
in	B-X
rats	B-X
by	B-X
prevention	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
proteasome	B-X
function	B-X
with	B-X
CI	B-X
-	B-X
1	B-X
would	B-X
block	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
vivo	B-X
after	B-X
intraperitoneal	B-X
(	B-X
i	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
Cl	B-X
-	B-X
1	B-X
prevented	B-X
degradation	B-X
of	B-X
IkappaB	B-X
-	B-X
alpha	B-X
and	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
liver	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
;	B-X
however	B-X
,	B-X
Cl	B-X
-	B-X
1	B-X
treatment	B-X
had	B-X
no	B-X
detected	B-X
effect	B-X
on	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
lung	B-X
tissue	B-X
<EOS>	B-X
Calpain	B-X
-	B-X
1	B-X
inhibitor	B-X
(	B-X
CI	B-X
-	B-X
1	B-X
)	B-X
blocks	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
by	B-X
preventing	B-X
proteolysis	B-X
of	B-X
the	B-X
inhibitory	B-X
protein	B-X
IkappaB	B-X
-	B-X
alpha	B-X
by	B-X
the	B-X
ubiquitin	B-X
/	B-X
proteasome	B-X
pathway	B-X

Activation	O
of	O
NF-kappaB	B-protein
and	O
production	O
of	O
NF-kappaB	B-protein
-dependent	O
chemokines	B-protein
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neutrophilic	O
lung	O
inflammation	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
production	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
chemokines	B-X
are	B-X
thought	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
neutrophilic	B-X
lung	B-X
inflammation	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
Cl	B-X
-	B-X
1	B-X
prevented	B-X
degradation	B-X
of	B-X
IkappaB	B-X
-	B-X
alpha	B-X
and	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
liver	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
;	B-X
however	B-X
,	B-X
Cl	B-X
-	B-X
1	B-X
treatment	B-X
had	B-X
no	B-X
detected	B-X
effect	B-X
on	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
lung	B-X
tissue	B-X
<EOS>	B-X
)	B-X
treatment	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
and	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibition	B-X
would	B-X
be	B-X
associated	B-X
with	B-X
suppression	B-X
of	B-X
chemokine	B-X
gene	B-X
expression	B-X
and	B-X
attenuation	B-X
of	B-X
neutrophilic	B-X
alveolitis	B-X
<EOS>	B-X
Activation	B-X
of	B-X
NR8383	B-X
cells	B-X
with	B-X
LPS	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
resulted	B-X
in	B-X
accumulation	B-X
of	B-X
MCP	B-X
-	B-X
1	B-X
and	B-X
MIP	B-X
-	B-X
2	B-X
in	B-X
the	B-X
conditioned	B-X
media	B-X
over	B-X
the	B-X
following	B-X
24	B-X
-	B-X
h	B-X
and	B-X
this	B-X
was	B-X
inhibited	B-X
by	B-X
Tau	B-X
-	B-X
Cl	B-X
in	B-X
a	B-X
concentration	B-X
dependent	B-X
fashion	B-X

Calpain-1	O
inhibitor	O
(	O
CI-1	O
)	O
blocks	O
activation	O
of	O
NF-kappaB	B-protein
by	O
preventing	O
proteolysis	O
of	O
the	O
inhibitory	O
protein	O
IkappaB-alpha	B-protein
by	O
the	O
ubiquitin/proteasome	O
pathway	O
.	O
<EOS>	B-X
Calpain	B-X
-	B-X
1	B-X
inhibitor	B-X
(	B-X
CI	B-X
-	B-X
1	B-X
)	B-X
blocks	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
by	B-X
preventing	B-X
proteolysis	B-X
of	B-X
the	B-X
inhibitory	B-X
protein	B-X
IkappaB	B-X
-	B-X
alpha	B-X
by	B-X
the	B-X
ubiquitin	B-X
/	B-X
proteasome	B-X
pathway	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
lung	B-X
inflammation	B-X
in	B-X
rats	B-X
by	B-X
prevention	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
<EOS>	B-X
Treatment	B-X
with	B-X
Cl	B-X
-	B-X
1	B-X
prevented	B-X
degradation	B-X
of	B-X
IkappaB	B-X
-	B-X
alpha	B-X
and	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
liver	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
;	B-X
however	B-X
,	B-X
Cl	B-X
-	B-X
1	B-X
treatment	B-X
had	B-X
no	B-X
detected	B-X
effect	B-X
on	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
lung	B-X
tissue	B-X
<EOS>	B-X
Activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
production	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
chemokines	B-X
are	B-X
thought	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
neutrophilic	B-X
lung	B-X
inflammation	B-X

We	O
hypothesized	O
that	O
inhibition	O
of	O
proteasome	O
function	O
with	O
CI-1	O
would	O
block	O
NF-kappaB	O
activation	O
in	O
vivo	O
after	O
intraperitoneal	O
(	O
i.p.	O
)	O
treatment	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
and	O
that	O
NF-kappaB	O
inhibition	O
would	O
be	O
associated	O
with	O
suppression	O
of	O
chemokine	O
gene	O
expression	O
and	O
attenuation	O
of	O
neutrophilic	O
alveolitis	O
.	O
<EOS>	B-X
)	B-X
treatment	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
and	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibition	B-X
would	B-X
be	B-X
associated	B-X
with	B-X
suppression	B-X
of	B-X
chemokine	B-X
gene	B-X
expression	B-X
and	B-X
attenuation	B-X
of	B-X
neutrophilic	B-X
alveolitis	B-X
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
proteasome	B-X
function	B-X
with	B-X
CI	B-X
-	B-X
1	B-X
would	B-X
block	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
vivo	B-X
after	B-X
intraperitoneal	B-X
(	B-X
i	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibition	B-X
in	B-X
the	B-X
liver	B-X
can	B-X
alter	B-X
lung	B-X
inflammation	B-X
induced	B-X
by	B-X
systemic	B-X
LPS	B-X
treatment	B-X
and	B-X
suggest	B-X
that	B-X
a	B-X
liver	B-X
-	B-X
lung	B-X
interaction	B-X
contributes	B-X
to	B-X
the	B-X
inflammatory	B-X
response	B-X
of	B-X
the	B-X
lung	B-X
<EOS>	B-X
Calpain	B-X
-	B-X
1	B-X
inhibitor	B-X
(	B-X
CI	B-X
-	B-X
1	B-X
)	B-X
blocks	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
by	B-X
preventing	B-X
proteolysis	B-X
of	B-X
the	B-X
inhibitory	B-X
protein	B-X
IkappaB	B-X
-	B-X
alpha	B-X
by	B-X
the	B-X
ubiquitin	B-X
/	B-X
proteasome	B-X
pathway	B-X

We	O
treated	O
rats	O
with	O
a	O
single	O
i.p.	O
injection	O
of	O
CI-1	O
(	O
10	O
mg/kg	O
)	O
two	O
hours	O
prior	O
to	O
i.p.	O
LPS	O
(	O
7	O
mg/kg	O
)	O
.	O
<EOS>	B-X
injection	B-X
of	B-X
CI	B-X
-	B-X
1	B-X
(	B-X
10	B-X
mg	B-X
/	B-X
kg	B-X
)	B-X
two	B-X
hours	B-X
prior	B-X
to	B-X
i	B-X
<EOS>	B-X
CI	B-X
-	B-X
1	B-X
treatment	B-X
prior	B-X
to	B-X
LPS	B-X
resulted	B-X
in	B-X
40	B-X
%	B-X
lower	B-X
MIP	B-X
-	B-X
2	B-X
concentration	B-X
in	B-X
lung	B-X
lavage	B-X
fluid	B-X
compared	B-X
to	B-X
rats	B-X
treated	B-X
with	B-X
vehicle	B-X
prior	B-X
to	B-X
LPS	B-X
(	B-X
502	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
112	B-X
pg	B-X
/	B-X
ml	B-X
vs	B-X
<EOS>	B-X
We	B-X
treated	B-X
rats	B-X
with	B-X
a	B-X
single	B-X
i	B-X
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
proteasome	B-X
function	B-X
with	B-X
CI	B-X
-	B-X
1	B-X
would	B-X
block	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
vivo	B-X
after	B-X
intraperitoneal	B-X
(	B-X
i	B-X

Treatment	O
with	O
Cl-1	O
prevented	O
degradation	O
of	O
IkappaB-alpha	B-protein
and	O
activation	O
of	O
NF-kappaB	B-protein
in	O
the	O
liver	O
in	O
response	O
to	O
LPS	O
;	O
however	O
,	O
Cl-1	O
treatment	O
had	O
no	O
detected	O
effect	O
on	O
NF-kappaB	O
activation	O
in	O
lung	O
tissue	O
.	O
<EOS>	B-X
Treatment	B-X
with	B-X
Cl	B-X
-	B-X
1	B-X
prevented	B-X
degradation	B-X
of	B-X
IkappaB	B-X
-	B-X
alpha	B-X
and	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
in	B-X
the	B-X
liver	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
;	B-X
however	B-X
,	B-X
Cl	B-X
-	B-X
1	B-X
treatment	B-X
had	B-X
no	B-X
detected	B-X
effect	B-X
on	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
lung	B-X
tissue	B-X
<EOS>	B-X
Activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
production	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
chemokines	B-X
are	B-X
thought	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
neutrophilic	B-X
lung	B-X
inflammation	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
lung	B-X
inflammation	B-X
in	B-X
rats	B-X
by	B-X
prevention	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
<EOS>	B-X
Calpain	B-X
-	B-X
1	B-X
inhibitor	B-X
(	B-X
CI	B-X
-	B-X
1	B-X
)	B-X
blocks	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
by	B-X
preventing	B-X
proteolysis	B-X
of	B-X
the	B-X
inhibitory	B-X
protein	B-X
IkappaB	B-X
-	B-X
alpha	B-X
by	B-X
the	B-X
ubiquitin	B-X
/	B-X
proteasome	B-X
pathway	B-X

CI-1	O
treatment	O
prior	O
to	O
LPS	O
resulted	O
in	O
40	O
%	O
lower	O
MIP-2	O
concentration	O
in	O
lung	O
lavage	O
fluid	O
compared	O
to	O
rats	O
treated	O
with	O
vehicle	O
prior	O
to	O
LPS	O
(	O
502	O
+/-	O
112	O
pg/ml	O
vs.	O
859	O
+/-144	O
pg/ml	O
,	O
P	O
<	O
0.05	O
)	O
.	O
<EOS>	B-X
CI	B-X
-	B-X
1	B-X
treatment	B-X
prior	B-X
to	B-X
LPS	B-X
resulted	B-X
in	B-X
40	B-X
%	B-X
lower	B-X
MIP	B-X
-	B-X
2	B-X
concentration	B-X
in	B-X
lung	B-X
lavage	B-X
fluid	B-X
compared	B-X
to	B-X
rats	B-X
treated	B-X
with	B-X
vehicle	B-X
prior	B-X
to	B-X
LPS	B-X
(	B-X
502	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
112	B-X
pg	B-X
/	B-X
ml	B-X
vs	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
lung	B-X
inflammation	B-X
in	B-X
rats	B-X
by	B-X
prevention	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
<EOS>	B-X
Activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
production	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
dependent	B-X
chemokines	B-X
are	B-X
thought	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
neutrophilic	B-X
lung	B-X
inflammation	B-X
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
proteasome	B-X
function	B-X
with	B-X
CI	B-X
-	B-X
1	B-X
would	B-X
block	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
vivo	B-X
after	B-X
intraperitoneal	B-X
(	B-X
i	B-X

In	O
addition	O
,	O
CI-1	O
treatment	O
substantially	O
inhibited	O
LPS-induced	O
neutrophilic	O
alveolitis	O
(	O
2.7+	O
/-	O
1.2	O
x	O
10	O
(	O
5	O
)	O
vs.	O
43.7	O
+/-	O
12.2	O
x	O
10	O
(	O
5	O
)	O
lung	B-cell_type
lavage	I-cell_type
neutrophils	I-cell_type
,	O
P	O
<	O
0.01	O
)	O
.	O

These	O
data	O
indicate	O
that	O
NF-kappaB	O
inhibition	O
in	O
the	O
liver	O
can	O
alter	O
lung	O
inflammation	O
induced	O
by	O
systemic	O
LPS	O
treatment	O
and	O
suggest	O
that	O
a	O
liver-lung	O
interaction	O
contributes	O
to	O
the	O
inflammatory	O
response	O
of	O
the	O
lung	O
.	O

Notch1	B-protein
regulates	O
maturation	O
of	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
thymocytes	I-cell_type
by	O
modulating	O
TCR	O
signal	O
strength	O
.	O
<EOS>	B-X
Notch1	B-X
regulates	B-X
maturation	B-X
of	B-X
CD4+	B-X
and	B-X
CD8+	B-X
thymocytes	B-X
by	B-X
modulating	B-X
TCR	B-X
signal	B-X
strength	B-X
.	B-X
<EOS>	B-X
Notch	B-X
signaling	B-X
regulates	B-X
cell	B-X
fate	B-X
decisions	B-X
in	B-X
multiple	B-X
lineages	B-X
<EOS>	B-X
Notch1	B-X
-	B-X
mediated	B-X
developmental	B-X
arrest	B-X
was	B-X
dose	B-X
dependent	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
impaired	B-X
thymocyte	B-X
responses	B-X
to	B-X
TCR	B-X
stimulation	B-X
<EOS>	B-X
Notch1	B-X
also	B-X
inhibited	B-X
TCR	B-X
-	B-X
mediated	B-X
signaling	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X

Notch	O
signaling	O
regulates	O
cell	O
fate	O
decisions	O
in	O
multiple	O
lineages	O
.	O
<EOS>	B-X
Notch	B-X
signaling	B-X
regulates	B-X
multiple	B-X
cell	B-X
fate	B-X
decisions	B-X
by	B-X
hematopoietic	B-X
precursors	B-X
<EOS>	B-X
The	B-X
Notch	B-X
receptor	B-X
mediates	B-X
cell	B-X
fate	B-X
decision	B-X
in	B-X
multiple	B-X
organs	B-X
<EOS>	B-X
Notch	B-X
proteins	B-X
are	B-X
used	B-X
repeatedly	B-X
to	B-X
direct	B-X
developmental	B-X
cell	B-X
fate	B-X
decisions	B-X
in	B-X
multiple	B-X
organs	B-X
<EOS>	B-X
In	B-X
multiple	B-X
cell	B-X
lineages	B-X
,	B-X
Delta	B-X
-	B-X
Notch	B-X
signalling	B-X
regulates	B-X
cell	B-X
fate	B-X
decisions	B-X
owing	B-X
to	B-X
unidirectional	B-X
signalling	B-X
between	B-X
daughter	B-X
cells	B-X

We	O
demonstrate	O
in	O
this	O
report	O
that	O
retroviral	O
expression	O
of	O
activated	O
Notch1	B-protein
in	O
mouse	B-cell_type
thymocytes	I-cell_type
abrogates	O
differentiation	O
of	O
immature	B-cell_type
CD4+CD8+	I-cell_type
thymocytes	I-cell_type
into	O
both	O
CD4	B-cell_type
and	I-cell_type
CD8	I-cell_type
mature	I-cell_type
single-positive	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
in	B-X
this	B-X
report	B-X
that	B-X
retroviral	B-X
expression	B-X
of	B-X
activated	B-X
Notch1	B-X
in	B-X
mouse	B-X
thymocytes	B-X
abrogates	B-X
differentiation	B-X
of	B-X
immature	B-X
CD4+CD8+	B-X
thymocytes	B-X
into	B-X
both	B-X
CD4	B-X
and	B-X
CD8	B-X
mature	B-X
single	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
Notch1	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
development	B-X
was	B-X
observed	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
with	B-X
both	B-X
normal	B-X
and	B-X
TCR	B-X
transgenic	B-X
thymocytes	B-X
<EOS>	B-X
Notch1	B-X
-	B-X
mediated	B-X
developmental	B-X
arrest	B-X
was	B-X
dose	B-X
dependent	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
impaired	B-X
thymocyte	B-X
responses	B-X
to	B-X
TCR	B-X
stimulation	B-X
<EOS>	B-X
Notch1	B-X
regulates	B-X
maturation	B-X
of	B-X
CD4+	B-X
and	B-X
CD8+	B-X
thymocytes	B-X
by	B-X
modulating	B-X
TCR	B-X
signal	B-X
strength	B-X
.	B-X

The	O
ability	O
of	O
Notch1	B-protein
to	O
inhibit	O
T	O
cell	O
development	O
was	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
both	O
normal	B-cell_type
and	I-cell_type
TCR	I-cell_type
transgenic	I-cell_type
thymocytes	I-cell_type
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
Notch1	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
development	B-X
was	B-X
observed	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
with	B-X
both	B-X
normal	B-X
and	B-X
TCR	B-X
transgenic	B-X
thymocytes	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
constitutively	B-X
active	B-X
Notch1	B-X
abrogates	B-X
CD4+	B-X
and	B-X
CD8+	B-X
maturation	B-X
by	B-X
interfering	B-X
with	B-X
TCR	B-X
signal	B-X
strength	B-X
and	B-X
provide	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
physiological	B-X
regulation	B-X
of	B-X
Notch	B-X
expression	B-X
during	B-X
thymocyte	B-X
development	B-X
<EOS>	B-X
Notch1	B-X
also	B-X
inhibited	B-X
TCR	B-X
-	B-X
mediated	B-X
signaling	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
<EOS>	B-X
Notch1	B-X
regulates	B-X
maturation	B-X
of	B-X
CD4+	B-X
and	B-X
CD8+	B-X
thymocytes	B-X
by	B-X
modulating	B-X
TCR	B-X
signal	B-X
strength	B-X
.	B-X

Notch1	B-protein
-mediated	O
developmental	O
arrest	O
was	O
dose	O
dependent	O
and	O
was	O
associated	O
with	O
impaired	O
thymocyte	O
responses	O
to	O
TCR	O
stimulation	O
.	O
<EOS>	B-X
Notch1	B-X
-	B-X
mediated	B-X
developmental	B-X
arrest	B-X
was	B-X
dose	B-X
dependent	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
impaired	B-X
thymocyte	B-X
responses	B-X
to	B-X
TCR	B-X
stimulation	B-X
<EOS>	B-X
Notch1	B-X
regulates	B-X
maturation	B-X
of	B-X
CD4+	B-X
and	B-X
CD8+	B-X
thymocytes	B-X
by	B-X
modulating	B-X
TCR	B-X
signal	B-X
strength	B-X
.	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
in	B-X
this	B-X
report	B-X
that	B-X
retroviral	B-X
expression	B-X
of	B-X
activated	B-X
Notch1	B-X
in	B-X
mouse	B-X
thymocytes	B-X
abrogates	B-X
differentiation	B-X
of	B-X
immature	B-X
CD4+CD8+	B-X
thymocytes	B-X
into	B-X
both	B-X
CD4	B-X
and	B-X
CD8	B-X
mature	B-X
single	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
<EOS>	B-X
Notch	B-X
signaling	B-X
regulates	B-X
cell	B-X
fate	B-X
decisions	B-X
in	B-X
multiple	B-X
lineages	B-X

Notch1	B-protein
also	O
inhibited	O
TCR-mediated	O
signaling	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

These	O
data	O
indicate	O
that	O
constitutively	O
active	O
Notch1	B-protein
abrogates	O
CD4+	O
and	O
CD8+	O
maturation	O
by	O
interfering	O
with	O
TCR	O
signal	O
strength	O
and	O
provide	O
an	O
explanation	O
for	O
the	O
physiological	O
regulation	O
of	O
Notch	O
expression	O
during	O
thymocyte	O
development	O
.	O
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
constitutively	B-X
active	B-X
Notch1	B-X
abrogates	B-X
CD4+	B-X
and	B-X
CD8+	B-X
maturation	B-X
by	B-X
interfering	B-X
with	B-X
TCR	B-X
signal	B-X
strength	B-X
and	B-X
provide	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
physiological	B-X
regulation	B-X
of	B-X
Notch	B-X
expression	B-X
during	B-X
thymocyte	B-X
development	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
Notch1	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
development	B-X
was	B-X
observed	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
with	B-X
both	B-X
normal	B-X
and	B-X
TCR	B-X
transgenic	B-X
thymocytes	B-X
<EOS>	B-X
Notch1	B-X
regulates	B-X
maturation	B-X
of	B-X
CD4+	B-X
and	B-X
CD8+	B-X
thymocytes	B-X
by	B-X
modulating	B-X
TCR	B-X
signal	B-X
strength	B-X
.	B-X
<EOS>	B-X
Notch1	B-X
-	B-X
mediated	B-X
developmental	B-X
arrest	B-X
was	B-X
dose	B-X
dependent	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
impaired	B-X
thymocyte	B-X
responses	B-X
to	B-X
TCR	B-X
stimulation	B-X

Expression	O
of	O
SART3	B-protein
antigen	I-protein
and	O
induction	O
of	O
CTLs	B-cell_type
by	O
SART3-derived	O
peptides	O
in	O
breast	O
cancer	O
patients	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
SART3	B-X
antigen	B-X
and	B-X
induction	B-X
of	B-X
CTLs	B-X
by	B-X
SART3	B-X
-	B-X
derived	B-X
peptides	B-X
in	B-X
breast	B-X
cancer	B-X
patients	B-X
.	B-X
<EOS>	B-X
This	B-X
study	B-X
investigated	B-X
expression	B-X
of	B-X
the	B-X
SART3	B-X
antigen	B-X
in	B-X
breast	B-X
cancer	B-X
to	B-X
explore	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
SART3	B-X
antigen	B-X
and	B-X
its	B-X
peptides	B-X
could	B-X
be	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
HLA	B-X
-	B-X
A24	B-X
-	B-X
positive	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
SART3	B-X
derived	B-X
peptides	B-X
at	B-X
positions	B-X
109	B-X
-	B-X
118	B-X
and	B-X
315	B-X
-	B-X
323	B-X
induced	B-X
HLA	B-X
-	B-X
A24	B-X
restricted	B-X
CTLs	B-X
that	B-X
reacted	B-X
to	B-X
breast	B-X
cancer	B-X
cells	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X

We	O
recently	O
reported	O
the	O
SART3	B-protein
tumour-rejection	I-protein
antigen	I-protein
as	O
possessing	O
tumour	O
epitopes	O
capable	O
of	O
inducing	O
HLA-class	B-cell_type
I-restricted	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
CTLs	B-cell_type
)	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
the	B-X
SART3	B-X
tumour	B-X
-	B-X
rejection	B-X
antigen	B-X
as	B-X
possessing	B-X
tumour	B-X
epitopes	B-X
capable	B-X
of	B-X
inducing	B-X
HLA	B-X
-	B-X
class	B-X
I	B-X
-	B-X
restricted	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X
(	B-X
CTLs	B-X
)	B-X
<EOS>	B-X
Expression	B-X
of	B-X
SART3	B-X
antigen	B-X
and	B-X
induction	B-X
of	B-X
CTLs	B-X
by	B-X
SART3	B-X
-	B-X
derived	B-X
peptides	B-X
in	B-X
breast	B-X
cancer	B-X
patients	B-X
.	B-X
<EOS>	B-X
This	B-X
study	B-X
investigated	B-X
expression	B-X
of	B-X
the	B-X
SART3	B-X
antigen	B-X
in	B-X
breast	B-X
cancer	B-X
to	B-X
explore	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
SART3	B-X
antigen	B-X
and	B-X
its	B-X
peptides	B-X
could	B-X
be	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
HLA	B-X
-	B-X
A24	B-X
-	B-X
positive	B-X
breast	B-X
cancer	B-X
patients	B-X

This	O
study	O
investigated	O
expression	O
of	O
the	O
SART3	B-protein
antigen	I-protein
in	O
breast	O
cancer	O
to	O
explore	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
breast	O
cancer	O
patients	O
.	O
<EOS>	B-X
This	B-X
study	B-X
investigated	B-X
expression	B-X
of	B-X
the	B-X
SART3	B-X
antigen	B-X
in	B-X
breast	B-X
cancer	B-X
to	B-X
explore	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
SART3	B-X
antigen	B-X
and	B-X
its	B-X
peptides	B-X
could	B-X
be	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
HLA	B-X
-	B-X
A24	B-X
-	B-X
positive	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Expression	B-X
of	B-X
SART3	B-X
antigen	B-X
and	B-X
induction	B-X
of	B-X
CTLs	B-X
by	B-X
SART3	B-X
-	B-X
derived	B-X
peptides	B-X
in	B-X
breast	B-X
cancer	B-X
patients	B-X
.	B-X
<EOS>	B-X
SART3	B-X
derived	B-X
peptides	B-X
at	B-X
positions	B-X
109	B-X
-	B-X
118	B-X
and	B-X
315	B-X
-	B-X
323	B-X
induced	B-X
HLA	B-X
-	B-X
A24	B-X
restricted	B-X
CTLs	B-X
that	B-X
reacted	B-X
to	B-X
breast	B-X
cancer	B-X
cells	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X

The	O
SART3	B-protein
antigen	I-protein
was	O
detected	O
in	O
all	O
of	O
the	O
breast	B-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
tested	O
,	O
30	O
of	O
40	O
(	O
75	O
%	O
)	O
breast	O
cancer	O
tissue	O
samples	O
,	O
and	O
0	O
of	O
3	O
non-tumourous	O
breast	O
tissue	O
samples	O
.	O

SART3	O
derived	O
peptides	O
at	O
positions	B-DNA
109-118	I-DNA
and	I-DNA
315-323	I-DNA
induced	O
HLA-A24	O
restricted	O
CTLs	B-cell_type
that	O
reacted	O
to	O
breast	B-cell_type
cancer	I-cell_type
cells	I-cell_type
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
of	O
breast	O
cancer	O
patients	O
.	O
<EOS>	B-X
SART3	B-X
derived	B-X
peptides	B-X
at	B-X
positions	B-X
109	B-X
-	B-X
118	B-X
and	B-X
315	B-X
-	B-X
323	B-X
induced	B-X
HLA	B-X
-	B-X
A24	B-X
restricted	B-X
CTLs	B-X
that	B-X
reacted	B-X
to	B-X
breast	B-X
cancer	B-X
cells	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
This	B-X
study	B-X
investigated	B-X
expression	B-X
of	B-X
the	B-X
SART3	B-X
antigen	B-X
in	B-X
breast	B-X
cancer	B-X
to	B-X
explore	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
SART3	B-X
antigen	B-X
and	B-X
its	B-X
peptides	B-X
could	B-X
be	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
HLA	B-X
-	B-X
A24	B-X
-	B-X
positive	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
The	B-X
SART3	B-X
antigen	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
of	B-X
the	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
tested	B-X
,	B-X
30	B-X
of	B-X
40	B-X
(	B-X
75	B-X
%	B-X
)	B-X
breast	B-X
cancer	B-X
tissue	B-X
samples	B-X
,	B-X
and	B-X
0	B-X
of	B-X
3	B-X
non	B-X
-	B-X
tumourous	B-X
breast	B-X
tissue	B-X
samples	B-X

Therefore	O
,	O
the	O
SART3	B-protein
antigen	I-protein
and	O
its	O
peptides	O
could	O
be	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
the	O
majority	O
of	O
HLA-A24-positive	O
breast	O
cancer	O
patients	O
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
SART3	B-X
antigen	B-X
and	B-X
its	B-X
peptides	B-X
could	B-X
be	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
HLA	B-X
-	B-X
A24	B-X
-	B-X
positive	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
This	B-X
study	B-X
investigated	B-X
expression	B-X
of	B-X
the	B-X
SART3	B-X
antigen	B-X
in	B-X
breast	B-X
cancer	B-X
to	B-X
explore	B-X
an	B-X
appropriate	B-X
molecule	B-X
for	B-X
use	B-X
in	B-X
specific	B-X
immunotherapy	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
<EOS>	B-X
Expression	B-X
of	B-X
SART3	B-X
antigen	B-X
and	B-X
induction	B-X
of	B-X
CTLs	B-X
by	B-X
SART3	B-X
-	B-X
derived	B-X
peptides	B-X
in	B-X
breast	B-X
cancer	B-X
patients	B-X
.	B-X
<EOS>	B-X
SART3	B-X
derived	B-X
peptides	B-X
at	B-X
positions	B-X
109	B-X
-	B-X
118	B-X
and	B-X
315	B-X
-	B-X
323	B-X
induced	B-X
HLA	B-X
-	B-X
A24	B-X
restricted	B-X
CTLs	B-X
that	B-X
reacted	B-X
to	B-X
breast	B-X
cancer	B-X
cells	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X

Autostimulation	O
of	O
the	O
Epstein-Barr	O
virus	O
BRLF1	B-DNA
promoter	I-DNA
is	O
mediated	O
through	O
consensus	O
Sp1	B-DNA
and	I-DNA
Sp3	I-DNA
binding	I-DNA
sites	I-DNA
.	O
<EOS>	B-X
Autostimulation	B-X
of	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
BRLF1	B-X
promoter	B-X
is	B-X
mediated	B-X
through	B-X
consensus	B-X
Sp1	B-X
and	B-X
Sp3	B-X
binding	B-X
sites	B-X
.	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
this	B-X
biologic	B-X
function	B-X
,	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
Rta	B-X
protein	B-X
powerfully	B-X
stimulates	B-X
the	B-X
promoter	B-X
of	B-X
its	B-X
own	B-X
gene	B-X
,	B-X
Rp	B-X
,	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
B	B-X
cells	B-X
in	B-X
transient	B-X
-	B-X
transfection	B-X
reporter	B-X
-	B-X
based	B-X
assays	B-X
<EOS>	B-X
During	B-X
the	B-X
lytic	B-X
cycle	B-X
,	B-X
ZEBRA	B-X
bound	B-X
Rp	B-X
near	B-X
the	B-X
Sp1	B-X
/	B-X
Sp3	B-X
site	B-X
<EOS>	B-X
Gel	B-X
shift	B-X
analysis	B-X
,	B-X
using	B-X
extracts	B-X
of	B-X
B	B-X
cells	B-X
in	B-X
latency	B-X
or	B-X
induced	B-X
into	B-X
the	B-X
lytic	B-X
cycle	B-X
,	B-X
identified	B-X
Sp1	B-X
and	B-X
Sp3	B-X
as	B-X
the	B-X
predominant	B-X
cellular	B-X
proteins	B-X
bound	B-X
to	B-X
Rp	B-X
near	B-X
	B-X
-	B-X
45	B-X

As	O
an	O
essential	O
step	O
in	O
the	O
lytic	O
cascade	O
,	O
the	O
Rta	O
homologues	O
of	O
gammaherpesviruses	O
all	O
activate	O
their	O
own	O
expression	O
.	O
<EOS>	B-X
As	B-X
an	B-X
essential	B-X
step	B-X
in	B-X
the	B-X
lytic	B-X
cascade	B-X
,	B-X
the	B-X
Rta	B-X
homologues	B-X
of	B-X
gammaherpesviruses	B-X
all	B-X
activate	B-X
their	B-X
own	B-X
expression	B-X
<EOS>	B-X
During	B-X
the	B-X
lytic	B-X
cycle	B-X
,	B-X
ZEBRA	B-X
bound	B-X
Rp	B-X
near	B-X
the	B-X
Sp1	B-X
/	B-X
Sp3	B-X
site	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
RpCAT	B-X
in	B-X
response	B-X
to	B-X
Rta	B-X
by	B-X
deletional	B-X
and	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
<EOS>	B-X
The	B-X
relative	B-X
abundance	B-X
or	B-X
functional	B-X
state	B-X
of	B-X
the	B-X
cellular	B-X
Sp1	B-X
and	B-X
Sp3	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
altered	B-X
in	B-X
response	B-X
to	B-X
stimuli	B-X
that	B-X
induce	B-X
the	B-X
BRLF1	B-X
promoter	B-X
and	B-X
thereby	B-X
contribute	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
viral	B-X
lytic	B-X
cycle	B-X

Consistent	O
with	O
this	O
biologic	O
function	O
,	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
Rta	B-protein
protein	I-protein
powerfully	O
stimulates	O
the	O
promoter	B-DNA
of	O
its	O
own	O
gene	O
,	O
Rp	B-DNA
,	O
in	O
EBV-positive	B-cell_type
B	I-cell_type
cells	I-cell_type
in	O
transient-transfection	O
reporter-based	O
assays	O
.	O
<EOS>	B-X
Consistent	B-X
with	B-X
this	B-X
biologic	B-X
function	B-X
,	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
Rta	B-X
protein	B-X
powerfully	B-X
stimulates	B-X
the	B-X
promoter	B-X
of	B-X
its	B-X
own	B-X
gene	B-X
,	B-X
Rp	B-X
,	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
B	B-X
cells	B-X
in	B-X
transient	B-X
-	B-X
transfection	B-X
reporter	B-X
-	B-X
based	B-X
assays	B-X
<EOS>	B-X
Autostimulation	B-X
of	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
BRLF1	B-X
promoter	B-X
is	B-X
mediated	B-X
through	B-X
consensus	B-X
Sp1	B-X
and	B-X
Sp3	B-X
binding	B-X
sites	B-X
.	B-X
<EOS>	B-X
As	B-X
an	B-X
essential	B-X
step	B-X
in	B-X
the	B-X
lytic	B-X
cascade	B-X
,	B-X
the	B-X
Rta	B-X
homologues	B-X
of	B-X
gammaherpesviruses	B-X
all	B-X
activate	B-X
their	B-X
own	B-X
expression	B-X
<EOS>	B-X
Gel	B-X
shift	B-X
analysis	B-X
,	B-X
using	B-X
extracts	B-X
of	B-X
B	B-X
cells	B-X
in	B-X
latency	B-X
or	B-X
induced	B-X
into	B-X
the	B-X
lytic	B-X
cycle	B-X
,	B-X
identified	B-X
Sp1	B-X
and	B-X
Sp3	B-X
as	B-X
the	B-X
predominant	B-X
cellular	B-X
proteins	B-X
bound	B-X
to	B-X
Rp	B-X
near	B-X
	B-X
-	B-X
45	B-X

We	O
analyzed	O
the	O
activity	O
of	O
RpCAT	B-DNA
in	O
response	O
to	O
Rta	B-protein
by	O
deletional	O
and	O
site-directed	O
mutagenesis	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
RpCAT	B-X
in	B-X
response	B-X
to	B-X
Rta	B-X
by	B-X
deletional	B-X
and	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
<EOS>	B-X
Gel	B-X
shift	B-X
analysis	B-X
,	B-X
using	B-X
extracts	B-X
of	B-X
B	B-X
cells	B-X
in	B-X
latency	B-X
or	B-X
induced	B-X
into	B-X
the	B-X
lytic	B-X
cycle	B-X
,	B-X
identified	B-X
Sp1	B-X
and	B-X
Sp3	B-X
as	B-X
the	B-X
predominant	B-X
cellular	B-X
proteins	B-X
bound	B-X
to	B-X
Rp	B-X
near	B-X
	B-X
-	B-X
45	B-X
<EOS>	B-X
Two	B-X
cognate	B-X
Sp1	B-X
binding	B-X
sites	B-X
located	B-X
at	B-X
	B-X
-	B-X
279	B-X
and	B-X
	B-X
-	B-X
45	B-X
relative	B-X
to	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
proved	B-X
crucial	B-X
for	B-X
Rta	B-X
-	B-X
mediated	B-X
activation	B-X
<EOS>	B-X
The	B-X
relative	B-X
abundance	B-X
or	B-X
functional	B-X
state	B-X
of	B-X
the	B-X
cellular	B-X
Sp1	B-X
and	B-X
Sp3	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
altered	B-X
in	B-X
response	B-X
to	B-X
stimuli	B-X
that	B-X
induce	B-X
the	B-X
BRLF1	B-X
promoter	B-X
and	B-X
thereby	B-X
contribute	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
viral	B-X
lytic	B-X
cycle	B-X

Two	O
cognate	B-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
-279	O
and	O
-45	O
relative	O
to	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
proved	O
crucial	O
for	O
Rta-mediated	O
activation	O
.	O

Previously	O
described	O
binding	O
sites	O
for	O
the	O
cellular	O
transcription	B-protein
factor	I-protein
Zif268	I-protein
and	O
the	O
viral	B-protein
transactivator	I-protein
ZEBRA	I-protein
were	O
found	O
to	O
be	O
dispensable	O
for	O
activation	O
of	O
RpCAT	B-DNA
by	O
Rta	B-protein
.	O
<EOS>	B-X
Previously	B-X
described	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
cellular	B-X
transcription	B-X
factor	B-X
Zif268	B-X
and	B-X
the	B-X
viral	B-X
transactivator	B-X
ZEBRA	B-X
were	B-X
found	B-X
to	B-X
be	B-X
dispensable	B-X
for	B-X
activation	B-X
of	B-X
RpCAT	B-X
by	B-X
Rta	B-X
<EOS>	B-X
The	B-X
relative	B-X
abundance	B-X
or	B-X
functional	B-X
state	B-X
of	B-X
the	B-X
cellular	B-X
Sp1	B-X
and	B-X
Sp3	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
altered	B-X
in	B-X
response	B-X
to	B-X
stimuli	B-X
that	B-X
induce	B-X
the	B-X
BRLF1	B-X
promoter	B-X
and	B-X
thereby	B-X
contribute	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
viral	B-X
lytic	B-X
cycle	B-X
<EOS>	B-X
Two	B-X
cognate	B-X
Sp1	B-X
binding	B-X
sites	B-X
located	B-X
at	B-X
	B-X
-	B-X
279	B-X
and	B-X
	B-X
-	B-X
45	B-X
relative	B-X
to	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
proved	B-X
crucial	B-X
for	B-X
Rta	B-X
-	B-X
mediated	B-X
activation	B-X
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
Sp3	B-X
to	B-X
Rp	B-X
correlated	B-X
with	B-X
the	B-X
reporter	B-X
activities	B-X
in	B-X
the	B-X
mutagenesis	B-X
study	B-X
,	B-X
establishing	B-X
a	B-X
direct	B-X
link	B-X
between	B-X
transcriptional	B-X
activation	B-X
of	B-X
Rp	B-X
by	B-X
Rta	B-X
and	B-X
DNA	B-X
binding	B-X
by	B-X
Sp1	B-X
and	B-X
/	B-X
or	B-X
Sp3	B-X

Gel	O
shift	O
analysis	O
,	O
using	O
extracts	O
of	O
B	B-cell_type
cells	I-cell_type
in	O
latency	O
or	O
induced	O
into	O
the	O
lytic	O
cycle	O
,	O
identified	O
Sp1	B-protein
and	O
Sp3	B-protein
as	O
the	O
predominant	O
cellular	B-protein
proteins	I-protein
bound	O
to	O
Rp	B-DNA
near	O
-45	O
.	O
<EOS>	B-X
Gel	B-X
shift	B-X
analysis	B-X
,	B-X
using	B-X
extracts	B-X
of	B-X
B	B-X
cells	B-X
in	B-X
latency	B-X
or	B-X
induced	B-X
into	B-X
the	B-X
lytic	B-X
cycle	B-X
,	B-X
identified	B-X
Sp1	B-X
and	B-X
Sp3	B-X
as	B-X
the	B-X
predominant	B-X
cellular	B-X
proteins	B-X
bound	B-X
to	B-X
Rp	B-X
near	B-X
	B-X
-	B-X
45	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
RpCAT	B-X
in	B-X
response	B-X
to	B-X
Rta	B-X
by	B-X
deletional	B-X
and	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
<EOS>	B-X
We	B-X
used	B-X
a	B-X
fractionated	B-X
extract	B-X
of	B-X
CA46	B-X
lymphoblastoid	B-X
cells	B-X
and	B-X
bacterially	B-X
expressed	B-X
EBNA	B-X
-	B-X
2	B-X
polypeptides	B-X
to	B-X
demonstrate	B-X
that	B-X
EBNA	B-X
-	B-X
2	B-X
is	B-X
targeted	B-X
to	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
latency	B-X
C	B-X
promoter	B-X
(	B-X
Cp	B-X
)	B-X
through	B-X
interaction	B-X
with	B-X
a	B-X
cellular	B-X
DNA	B-X
binding	B-X
protein	B-X
designated	B-X
Cp	B-X
binding	B-X
factor	B-X
1	B-X
(	B-X
CBF1	B-X
)	B-X
<EOS>	B-X
The	B-X
reactivation	B-X
of	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
from	B-X
latency	B-X
requires	B-X
the	B-X
transcriptional	B-X
induction	B-X
of	B-X
the	B-X
viral	B-X
encoded	B-X
lytic	B-X
cycle	B-X
initiator	B-X
gene	B-X
,	B-X
BZLF1	B-X
,	B-X
and	B-X
a	B-X
concomitant	B-X
switch	B-X
from	B-X
OriP	B-X
to	B-X
OriLyt	B-X
directed	B-X
viral	B-X
DNA	B-X
replication	B-X

During	O
the	O
lytic	O
cycle	O
,	O
ZEBRA	B-protein
bound	O
Rp	B-DNA
near	O
the	O
Sp1/Sp3	B-DNA
site	I-DNA
.	O
<EOS>	B-X
During	B-X
the	B-X
lytic	B-X
cycle	B-X
,	B-X
ZEBRA	B-X
bound	B-X
Rp	B-X
near	B-X
the	B-X
Sp1	B-X
/	B-X
Sp3	B-X
site	B-X
<EOS>	B-X
Autostimulation	B-X
of	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
BRLF1	B-X
promoter	B-X
is	B-X
mediated	B-X
through	B-X
consensus	B-X
Sp1	B-X
and	B-X
Sp3	B-X
binding	B-X
sites	B-X
.	B-X
<EOS>	B-X
As	B-X
an	B-X
essential	B-X
step	B-X
in	B-X
the	B-X
lytic	B-X
cascade	B-X
,	B-X
the	B-X
Rta	B-X
homologues	B-X
of	B-X
gammaherpesviruses	B-X
all	B-X
activate	B-X
their	B-X
own	B-X
expression	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
RpCAT	B-X
in	B-X
response	B-X
to	B-X
Rta	B-X
by	B-X
deletional	B-X
and	B-X
site	B-X
-	B-X
directed	B-X
mutagenesis	B-X

The	O
binding	O
of	O
Sp1	B-protein
and	O
Sp3	B-protein
to	O
Rp	B-DNA
correlated	O
with	O
the	O
reporter	O
activities	O
in	O
the	O
mutagenesis	O
study	O
,	O
establishing	O
a	O
direct	O
link	O
between	O
transcriptional	O
activation	O
of	O
Rp	B-DNA
by	O
Rta	B-protein
and	O
DNA	O
binding	O
by	O
Sp1	B-protein
and/or	O
Sp3	B-protein
.	O
<EOS>	B-X
Through	B-X
a	B-X
combination	B-X
of	B-X
DFT	B-X
calculations	B-X
,	B-X
spectroscopic	B-X
studies	B-X
and	B-X
kinetic	B-X
measurement	B-X
we	B-X
show	B-X
the	B-X
origins	B-X
of	B-X
this	B-X
is	B-X
electronic	B-X
in	B-X
nature	B-X
and	B-X
can	B-X
be	B-X
influenced	B-X
through	B-X
the	B-X
addition	B-X
of	B-X
hydrogen	B-X
bond	B-X
donors	B-X
(	B-X
HBD	B-X
)	B-X
and	B-X
hydrogen	B-X
bond	B-X
acceptors	B-X
(	B-X
HBA	B-X
)	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
SP2	B-X
model	B-X
peptide	B-X
is	B-X
involved	B-X
in	B-X
silver	B-X
binding	B-X
through	B-X
its	B-X
histidine	B-X
and	B-X
methionine	B-X
residues	B-X
in	B-X
the	B-X
two	B-X
HXXM	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
more	B-X
detailed	B-X
understanding	B-X
of	B-X
the	B-X
potential	B-X
mechanism	B-X
and	B-X
identification	B-X
of	B-X
potential	B-X
targets	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
is	B-X
needed	B-X
<EOS>	B-X
The	B-X
ensuing	B-X
enantiospecific	B-X
and	B-X
diastereoselective	B-X
catalytic	B-X
oxidation	B-X
to	B-X
a	B-X
threefold	B-X
stereogenic	B-X
sulfone	B-X
provided	B-X
overall	B-X
control	B-X
over	B-X
the	B-X
stereogenic	B-X
C	B-X
-	B-X
S	B-X
axis	B-X

The	O
relative	O
abundance	O
or	O
functional	O
state	O
of	O
the	O
cellular	O
Sp1	B-protein
and	O
Sp3	B-protein
transcription	B-protein
factors	I-protein
may	O
be	O
altered	O
in	O
response	O
to	O
stimuli	O
that	O
induce	O
the	O
BRLF1	B-DNA
promoter	I-DNA
and	O
thereby	O
contribute	O
to	O
the	O
activation	O
of	O
the	O
viral	O
lytic	O
cycle	O
.	O
<EOS>	B-X
These	B-X
results	B-X
could	B-X
improve	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
function	B-X
of	B-X
LEA	B-X
proteins	B-X
in	B-X
the	B-X
response	B-X
of	B-X
dehydration	B-X
stress	B-X
and	B-X
their	B-X
contributions	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
seed	B-X
recalcitrance	B-X
<EOS>	B-X
The	B-X
relative	B-X
magnitudes	B-X
of	B-X
the	B-X
latent	B-X
variable	B-X
correlations	B-X
determine	B-X
whether	B-X
or	B-X
not	B-X
mediation	B-X
analysis	B-X
will	B-X
tend	B-X
to	B-X
infer	B-X
the	B-X
correct	B-X
causal	B-X
relationship	B-X
in	B-X
large	B-X
samples	B-X
<EOS>	B-X
We	B-X
will	B-X
perform	B-X
a	B-X
genome	B-X
-	B-X
wide	B-X
analysis	B-X
of	B-X
the	B-X
LEA	B-X
gene	B-X
family	B-X
and	B-X
their	B-X
transcriptional	B-X
responses	B-X
to	B-X
dehydration	B-X
stress	B-X
in	B-X
recalcitrant	B-X
P	B-X
<EOS>	B-X
We	B-X
examine	B-X
case	B-X
studies	B-X
that	B-X
illustrate	B-X
the	B-X
common	B-X
failure	B-X
modes	B-X
of	B-X
genetic	B-X
mediation	B-X
analysis	B-X
and	B-X
demonstrate	B-X
how	B-X
to	B-X
evaluate	B-X
the	B-X
effects	B-X
of	B-X
measurement	B-X
error	B-X

Gene	O
transfer	O
of	O
antisense	O
hypoxia	B-protein
inducible	I-protein
factor-1	I-protein
alpha	I-protein
enhances	O
the	O
therapeutic	O
efficacy	O
of	O
cancer	O
immunotherapy	O
.	O
<EOS>	B-X
Gene	B-X
transfer	B-X
of	B-X
antisense	B-X
hypoxia	B-X
inducible	B-X
factor	B-X
-	B-X
1	B-X
alpha	B-X
enhances	B-X
the	B-X
therapeutic	B-X
efficacy	B-X
of	B-X
cancer	B-X
immunotherapy	B-X
.	B-X
<EOS>	B-X
Antisense	B-X
hypoxia	B-X
-	B-X
inducible	B-X
factor	B-X
1alpha	B-X
gene	B-X
therapy	B-X
enhances	B-X
the	B-X
therapeutic	B-X
efficacy	B-X
of	B-X
doxorubicin	B-X
to	B-X
combat	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
gene	B-X
transfer	B-X
of	B-X
antisense	B-X
HIF	B-X
-	B-X
1alpha	B-X
could	B-X
enhance	B-X
the	B-X
therapeutic	B-X
efficacy	B-X
of	B-X
doxorubicin	B-X
to	B-X
combat	B-X
HCC	B-X
<EOS>	B-X
Gene	B-X
transfer	B-X
of	B-X
antisense	B-X
HIF	B-X
-	B-X
1alpha	B-X
downregulated	B-X
the	B-X
expression	B-X
of	B-X
both	B-X
HIF	B-X
-	B-X
1alpha	B-X
and	B-X
VEGF	B-X
,	B-X
whereas	B-X
doxorubicin	B-X
only	B-X
downregulated	B-X
VEGF	B-X
expression	B-X

Solid	O
tumors	O
meet	O
their	O
demands	O
for	O
nascent	O
blood	O
vessels	O
and	O
increased	O
glycolysis	O
,	O
to	O
combat	O
hypoxia	O
,	O
by	O
activating	O
multiple	O
genes	O
involved	O
in	O
angiogenesis	O
and	O
glucose	O
metabolism	O
.	O
<EOS>	B-X
Solid	B-X
tumors	B-X
meet	B-X
their	B-X
demands	B-X
for	B-X
nascent	B-X
blood	B-X
vessels	B-X
and	B-X
increased	B-X
glycolysis	B-X
,	B-X
to	B-X
combat	B-X
hypoxia	B-X
,	B-X
by	B-X
activating	B-X
multiple	B-X
genes	B-X
involved	B-X
in	B-X
angiogenesis	B-X
and	B-X
glucose	B-X
metabolism	B-X
<EOS>	B-X
Mice	B-X
cured	B-X
of	B-X
their	B-X
tumors	B-X
by	B-X
combination	B-X
therapy	B-X
resisted	B-X
a	B-X
rechallenge	B-X
with	B-X
parental	B-X
tumor	B-X
cells	B-X
,	B-X
indicating	B-X
systemic	B-X
antitumor	B-X
immunity	B-X
had	B-X
been	B-X
achieved	B-X
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
whilst	B-X
intensive	B-X
investigations	B-X
are	B-X
in	B-X
progress	B-X
to	B-X
target	B-X
the	B-X
many	B-X
HIF	B-X
-	B-X
1	B-X
effectors	B-X
,	B-X
the	B-X
results	B-X
herein	B-X
indicate	B-X
that	B-X
blocking	B-X
hypoxia	B-X
-	B-X
inducible	B-X
pathways	B-X
and	B-X
enhancing	B-X
NK	B-X
-	B-X
mediated	B-X
antitumor	B-X
immunity	B-X
by	B-X
targeting	B-X
HIF	B-X
-	B-X
1	B-X
itself	B-X
may	B-X
be	B-X
advantageous	B-X
,	B-X
especially	B-X
when	B-X
combined	B-X
with	B-X
cancer	B-X
immunotherapy	B-X
<EOS>	B-X
It	B-X
activates	B-X
the	B-X
transcription	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
maintaining	B-X
oxygen	B-X
homeostasis	B-X

Hypoxia	B-protein
inducible	I-protein
factor-1	I-protein
(	O
HIF-1	B-protein
)	O
is	O
a	O
constitutively	O
expressed	O
basic	O
helix-loop-helix	B-protein
transcription	I-protein
factor	I-protein
,	O
formed	O
by	O
the	O
assembly	O
of	O
HIF-1alpha	B-protein
and	O
HIF-1beta	B-protein
(	O
Arnt	B-protein
)	O
,	O
that	O
is	O
stablized	O
in	O
response	O
to	O
hypoxia	O
,	O
and	O
rapidly	O
degraded	O
under	O
normoxic	O
conditions	O
.	O
<EOS>	B-X
Hypoxia	B-X
inducible	B-X
factor	B-X
-	B-X
1	B-X
(	B-X
HIF	B-X
-	B-X
1	B-X
)	B-X
is	B-X
a	B-X
constitutively	B-X
expressed	B-X
basic	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
transcription	B-X
factor	B-X
,	B-X
formed	B-X
by	B-X
the	B-X
assembly	B-X
of	B-X
HIF	B-X
-	B-X
1alpha	B-X
and	B-X
HIF	B-X
-	B-X
1beta	B-X
(	B-X
Arnt	B-X
)	B-X
,	B-X
that	B-X
is	B-X
stablized	B-X
in	B-X
response	B-X
to	B-X
hypoxia	B-X
,	B-X
and	B-X
rapidly	B-X
degraded	B-X
under	B-X
normoxic	B-X
conditions	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
engineered	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
HIF	B-X
-	B-X
1alpha	B-X
by	B-X
intratumoral	B-X
gene	B-X
transfer	B-X
of	B-X
an	B-X
antisense	B-X
HIF	B-X
-	B-X
1alpha	B-X
plasmid	B-X
leads	B-X
to	B-X
the	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
VEGF	B-X
,	B-X
and	B-X
decreased	B-X
tumor	B-X
microvessel	B-X
density	B-X
<EOS>	B-X
Solid	B-X
tumors	B-X
meet	B-X
their	B-X
demands	B-X
for	B-X
nascent	B-X
blood	B-X
vessels	B-X
and	B-X
increased	B-X
glycolysis	B-X
,	B-X
to	B-X
combat	B-X
hypoxia	B-X
,	B-X
by	B-X
activating	B-X
multiple	B-X
genes	B-X
involved	B-X
in	B-X
angiogenesis	B-X
and	B-X
glucose	B-X
metabolism	B-X
<EOS>	B-X
Mice	B-X
cured	B-X
of	B-X
their	B-X
tumors	B-X
by	B-X
combination	B-X
therapy	B-X
resisted	B-X
a	B-X
rechallenge	B-X
with	B-X
parental	B-X
tumor	B-X
cells	B-X
,	B-X
indicating	B-X
systemic	B-X
antitumor	B-X
immunity	B-X
had	B-X
been	B-X
achieved	B-X

It	O
activates	O
the	O
transcription	O
of	O
genes	O
important	O
for	O
maintaining	O
oxygen	O
homeostasis	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
transcriptional	B-X
mechanisms	B-X
of	B-X
β	B-X
-	B-X
cell	B-X
proliferation	B-X
in	B-X
response	B-X
to	B-X
fatty	B-X
acids	B-X
<EOS>	B-X
Jasmonic	B-X
acid	B-X
limits	B-X
Rhizoctonia	B-X
solani	B-X
AG1	B-X
-	B-X
IA	B-X
infection	B-X
in	B-X
rice	B-X
by	B-X
modulating	B-X
reactive	B-X
oxygen	B-X
species	B-X
homeostasis	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
transcriptional	B-X
and	B-X
ultrastructural	B-X
ER	B-X
and	B-X
mitochondrial	B-X
modifications	B-X
induced	B-X
by	B-X
sleep	B-X
loss	B-X
<EOS>	B-X
Both	B-X
fatty	B-X
acids	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
energy	B-X
metabolism	B-X
and	B-X
mitochondrial	B-X
activity	B-X

Here	O
,	O
we	O
demonstrate	O
that	O
engineered	O
down-regulation	O
of	O
HIF-1alpha	B-protein
by	O
intratumoral	O
gene	O
transfer	O
of	O
an	O
antisense	B-DNA
HIF-1alpha	I-DNA
plasmid	I-DNA
leads	O
to	O
the	O
down-regulation	O
of	O
VEGF	B-DNA
,	O
and	O
decreased	O
tumor	O
microvessel	O
density	O
.	O

Antisense	O
HIF-1alpha	O
monotherapy	O
resulted	O
in	O
the	O
complete	O
and	O
permanent	O
rejection	O
of	O
small	O
(	O
0.1	O
cm	O
in	O
diameter	O
)	O
EL-4	O
tumors	O
,	O
which	O
is	O
unusual	O
for	O
an	O
anti-angiogenic	O
agent	O
where	O
transient	O
suppression	O
of	O
tumor	O
growth	O
is	O
the	O
norm	O
.	O
<EOS>	B-X
1	B-X
cm	B-X
in	B-X
diameter	B-X
)	B-X
EL	B-X
-	B-X
4	B-X
tumors	B-X
,	B-X
which	B-X
is	B-X
unusual	B-X
for	B-X
an	B-X
anti	B-X
-	B-X
angiogenic	B-X
agent	B-X
where	B-X
transient	B-X
suppression	B-X
of	B-X
tumor	B-X
growth	B-X
is	B-X
the	B-X
norm	B-X
<EOS>	B-X
Antisense	B-X
HIF	B-X
-	B-X
1alpha	B-X
monotherapy	B-X
resulted	B-X
in	B-X
the	B-X
complete	B-X
and	B-X
permanent	B-X
rejection	B-X
of	B-X
small	B-X
(	B-X
0	B-X
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
whilst	B-X
intensive	B-X
investigations	B-X
are	B-X
in	B-X
progress	B-X
to	B-X
target	B-X
the	B-X
many	B-X
HIF	B-X
-	B-X
1	B-X
effectors	B-X
,	B-X
the	B-X
results	B-X
herein	B-X
indicate	B-X
that	B-X
blocking	B-X
hypoxia	B-X
-	B-X
inducible	B-X
pathways	B-X
and	B-X
enhancing	B-X
NK	B-X
-	B-X
mediated	B-X
antitumor	B-X
immunity	B-X
by	B-X
targeting	B-X
HIF	B-X
-	B-X
1	B-X
itself	B-X
may	B-X
be	B-X
advantageous	B-X
,	B-X
especially	B-X
when	B-X
combined	B-X
with	B-X
cancer	B-X
immunotherapy	B-X
<EOS>	B-X
Mice	B-X
cured	B-X
of	B-X
their	B-X
tumors	B-X
by	B-X
combination	B-X
therapy	B-X
resisted	B-X
a	B-X
rechallenge	B-X
with	B-X
parental	B-X
tumor	B-X
cells	B-X
,	B-X
indicating	B-X
systemic	B-X
antitumor	B-X
immunity	B-X
had	B-X
been	B-X
achieved	B-X

It	O
induced	O
NK	B-cell_type
cell	I-cell_type
-dependent	O
rejection	O
of	O
tumors	O
,	O
but	O
failed	O
to	O
stimulate	O
systemic	O
T	B-cell_type
cell	I-cell_type
-mediated	O
anti-tumor	O
immunity	O
,	O
and	O
synergized	O
with	O
B7-1-mediated	O
immunotherapy	O
to	O
cause	O
the	O
NK	B-cell_type
cell	I-cell_type
and	O
CD8	B-cell_type
T	I-cell_type
cell	I-cell_type
-dependent	O
rejection	O
of	O
larger	O
EL-4	O
tumors	O
(	O
0.4	O
cm	O
in	O
diameter	O
)	O
that	O
were	O
refractory	O
to	O
monotherapies	O
.	O
<EOS>	B-X
It	B-X
induced	B-X
NK	B-X
cell	B-X
-	B-X
dependent	B-X
rejection	B-X
of	B-X
tumors	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
stimulate	B-X
systemic	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
,	B-X
and	B-X
synergized	B-X
with	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
immunotherapy	B-X
to	B-X
cause	B-X
the	B-X
NK	B-X
cell	B-X
and	B-X
CD8	B-X
T	B-X
cell	B-X
-	B-X
dependent	B-X
rejection	B-X
of	B-X
larger	B-X
EL	B-X
-	B-X
4	B-X
tumors	B-X
(	B-X
0	B-X
<EOS>	B-X
Mice	B-X
cured	B-X
of	B-X
their	B-X
tumors	B-X
by	B-X
combination	B-X
therapy	B-X
resisted	B-X
a	B-X
rechallenge	B-X
with	B-X
parental	B-X
tumor	B-X
cells	B-X
,	B-X
indicating	B-X
systemic	B-X
antitumor	B-X
immunity	B-X
had	B-X
been	B-X
achieved	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
engineered	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
HIF	B-X
-	B-X
1alpha	B-X
by	B-X
intratumoral	B-X
gene	B-X
transfer	B-X
of	B-X
an	B-X
antisense	B-X
HIF	B-X
-	B-X
1alpha	B-X
plasmid	B-X
leads	B-X
to	B-X
the	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
VEGF	B-X
,	B-X
and	B-X
decreased	B-X
tumor	B-X
microvessel	B-X
density	B-X
<EOS>	B-X
1	B-X
cm	B-X
in	B-X
diameter	B-X
)	B-X
EL	B-X
-	B-X
4	B-X
tumors	B-X
,	B-X
which	B-X
is	B-X
unusual	B-X
for	B-X
an	B-X
anti	B-X
-	B-X
angiogenic	B-X
agent	B-X
where	B-X
transient	B-X
suppression	B-X
of	B-X
tumor	B-X
growth	B-X
is	B-X
the	B-X
norm	B-X

Mice	O
cured	O
of	O
their	O
tumors	O
by	O
combination	O
therapy	O
resisted	O
a	O
rechallenge	O
with	O
parental	B-cell_type
tumor	I-cell_type
cells	I-cell_type
,	O
indicating	O
systemic	O
antitumor	O
immunity	O
had	O
been	O
achieved	O
.	O
<EOS>	B-X
Mice	B-X
cured	B-X
of	B-X
their	B-X
tumors	B-X
by	B-X
combination	B-X
therapy	B-X
resisted	B-X
a	B-X
rechallenge	B-X
with	B-X
parental	B-X
tumor	B-X
cells	B-X
,	B-X
indicating	B-X
systemic	B-X
antitumor	B-X
immunity	B-X
had	B-X
been	B-X
achieved	B-X
<EOS>	B-X
Gene	B-X
transfer	B-X
of	B-X
antisense	B-X
hypoxia	B-X
inducible	B-X
factor	B-X
-	B-X
1	B-X
alpha	B-X
enhances	B-X
the	B-X
therapeutic	B-X
efficacy	B-X
of	B-X
cancer	B-X
immunotherapy	B-X
.	B-X
<EOS>	B-X
1	B-X
cm	B-X
in	B-X
diameter	B-X
)	B-X
EL	B-X
-	B-X
4	B-X
tumors	B-X
,	B-X
which	B-X
is	B-X
unusual	B-X
for	B-X
an	B-X
anti	B-X
-	B-X
angiogenic	B-X
agent	B-X
where	B-X
transient	B-X
suppression	B-X
of	B-X
tumor	B-X
growth	B-X
is	B-X
the	B-X
norm	B-X
<EOS>	B-X
It	B-X
activates	B-X
the	B-X
transcription	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
maintaining	B-X
oxygen	B-X
homeostasis	B-X

In	O
summary	O
,	O
whilst	O
intensive	O
investigations	O
are	O
in	O
progress	O
to	O
target	O
the	O
many	O
HIF-1	B-protein
effectors	O
,	O
the	O
results	O
herein	O
indicate	O
that	O
blocking	O
hypoxia-inducible	O
pathways	O
and	O
enhancing	O
NK-mediated	O
antitumor	O
immunity	O
by	O
targeting	O
HIF-1	B-protein
itself	O
may	O
be	O
advantageous	O
,	O
especially	O
when	O
combined	O
with	O
cancer	O
immunotherapy	O
.	O
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
whilst	B-X
intensive	B-X
investigations	B-X
are	B-X
in	B-X
progress	B-X
to	B-X
target	B-X
the	B-X
many	B-X
HIF	B-X
-	B-X
1	B-X
effectors	B-X
,	B-X
the	B-X
results	B-X
herein	B-X
indicate	B-X
that	B-X
blocking	B-X
hypoxia	B-X
-	B-X
inducible	B-X
pathways	B-X
and	B-X
enhancing	B-X
NK	B-X
-	B-X
mediated	B-X
antitumor	B-X
immunity	B-X
by	B-X
targeting	B-X
HIF	B-X
-	B-X
1	B-X
itself	B-X
may	B-X
be	B-X
advantageous	B-X
,	B-X
especially	B-X
when	B-X
combined	B-X
with	B-X
cancer	B-X
immunotherapy	B-X
<EOS>	B-X
Gene	B-X
transfer	B-X
of	B-X
antisense	B-X
hypoxia	B-X
inducible	B-X
factor	B-X
-	B-X
1	B-X
alpha	B-X
enhances	B-X
the	B-X
therapeutic	B-X
efficacy	B-X
of	B-X
cancer	B-X
immunotherapy	B-X
.	B-X
<EOS>	B-X
It	B-X
induced	B-X
NK	B-X
cell	B-X
-	B-X
dependent	B-X
rejection	B-X
of	B-X
tumors	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
stimulate	B-X
systemic	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
,	B-X
and	B-X
synergized	B-X
with	B-X
B7	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
immunotherapy	B-X
to	B-X
cause	B-X
the	B-X
NK	B-X
cell	B-X
and	B-X
CD8	B-X
T	B-X
cell	B-X
-	B-X
dependent	B-X
rejection	B-X
of	B-X
larger	B-X
EL	B-X
-	B-X
4	B-X
tumors	B-X
(	B-X
0	B-X
<EOS>	B-X
Mice	B-X
cured	B-X
of	B-X
their	B-X
tumors	B-X
by	B-X
combination	B-X
therapy	B-X
resisted	B-X
a	B-X
rechallenge	B-X
with	B-X
parental	B-X
tumor	B-X
cells	B-X
,	B-X
indicating	B-X
systemic	B-X
antitumor	B-X
immunity	B-X
had	B-X
been	B-X
achieved	B-X

Runx2	B-DNA
:	O
a	O
novel	O
oncogenic	O
effector	O
revealed	O
by	O
in	O
vivo	O
complementation	O
and	O
retroviral	O
tagging	O
.	O
<EOS>	B-X
Runx2	B-X
:	B-X
a	B-X
novel	B-X
oncogenic	B-X
effector	B-X
revealed	B-X
by	B-X
in	B-X
vivo	B-X
complementation	B-X
and	B-X
retroviral	B-X
tagging	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Runx2	B-X
makes	B-X
a	B-X
distinct	B-X
contribution	B-X
to	B-X
T	B-X
-	B-X
cell	B-X
lymphoma	B-X
development	B-X
which	B-X
does	B-X
not	B-X
coincide	B-X
with	B-X
any	B-X
of	B-X
the	B-X
oncogene	B-X
complementation	B-X
groups	B-X
previously	B-X
identified	B-X
by	B-X
retroviral	B-X
tagging	B-X
<EOS>	B-X
The	B-X
Runx2	B-X
(	B-X
Cbfa1	B-X
,	B-X
Pebp2alphaA	B-X
,	B-X
Aml3	B-X
)	B-X
gene	B-X
was	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
frequent	B-X
target	B-X
for	B-X
transcriptional	B-X
activation	B-X
by	B-X
proviral	B-X
insertion	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
of	B-X
CD2	B-X
-	B-X
MYC	B-X
transgenic	B-X
mice	B-X
<EOS>	B-X
However	B-X
,	B-X
Runx2	B-X
appeared	B-X
to	B-X
have	B-X
a	B-X
dominant	B-X
effect	B-X
on	B-X
the	B-X
tumour	B-X
phenotype	B-X
in	B-X
each	B-X
case	B-X
,	B-X
with	B-X
most	B-X
tumours	B-X
conforming	B-X
to	B-X
the	B-X
CD3	B-X
(	B-X
+	B-X
)	B-X
,	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
phenotype	B-X
seen	B-X
in	B-X
CD2	B-X
-	B-X
Runx2	B-X
mice	B-X

The	O
Runx2	B-DNA
(	O
Cbfa1	B-DNA
,	O
Pebp2alphaA	B-DNA
,	O
Aml3	B-DNA
)	O
gene	O
was	O
previously	O
identified	O
as	O
a	O
frequent	O
target	O
for	O
transcriptional	O
activation	O
by	O
proviral	O
insertion	O
in	O
T-cell	O
lymphomas	O
of	O
CD2-MYC	O
transgenic	O
mice	O
.	O
<EOS>	B-X
The	B-X
Runx2	B-X
(	B-X
Cbfa1	B-X
,	B-X
Pebp2alphaA	B-X
,	B-X
Aml3	B-X
)	B-X
gene	B-X
was	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
frequent	B-X
target	B-X
for	B-X
transcriptional	B-X
activation	B-X
by	B-X
proviral	B-X
insertion	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
lymphomas	B-X
of	B-X
CD2	B-X
-	B-X
MYC	B-X
transgenic	B-X
mice	B-X
<EOS>	B-X
Runx2	B-X
:	B-X
a	B-X
novel	B-X
oncogenic	B-X
effector	B-X
revealed	B-X
by	B-X
in	B-X
vivo	B-X
complementation	B-X
and	B-X
retroviral	B-X
tagging	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
over	B-X
-	B-X
expression	B-X
of	B-X
the	B-X
full	B-X
-	B-X
length	B-X
,	B-X
most	B-X
highly	B-X
expressed	B-X
Runx2	B-X
isoform	B-X
in	B-X
the	B-X
thymus	B-X
perturbs	B-X
T	B-X
-	B-X
cell	B-X
development	B-X
,	B-X
leads	B-X
to	B-X
development	B-X
of	B-X
spontaneous	B-X
lymphomas	B-X
at	B-X
low	B-X
frequency	B-X
and	B-X
is	B-X
strongly	B-X
synergistic	B-X
with	B-X
Myc	B-X
<EOS>	B-X
Neonatal	B-X
infection	B-X
of	B-X
CD2	B-X
-	B-X
Runx2	B-X
mice	B-X
with	B-X
Moloney	B-X
murine	B-X
leukaemia	B-X
virus	B-X
(	B-X
Moloney	B-X
MLV	B-X
)	B-X
also	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
acceleration	B-X
of	B-X
tumour	B-X
onset	B-X

We	O
have	O
recently	O
shown	O
that	O
over-expression	O
of	O
the	O
full-length	O
,	O
most	O
highly	O
expressed	O
Runx2	B-DNA
isoform	O
in	O
the	O
thymus	O
perturbs	O
T-cell	O
development	O
,	O
leads	O
to	O
development	O
of	O
spontaneous	O
lymphomas	O
at	O
low	O
frequency	O
and	O
is	O
strongly	O
synergistic	O
with	O
Myc	B-protein
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
over	B-X
-	B-X
expression	B-X
of	B-X
the	B-X
full	B-X
-	B-X
length	B-X
,	B-X
most	B-X
highly	B-X
expressed	B-X
Runx2	B-X
isoform	B-X
in	B-X
the	B-X
thymus	B-X
perturbs	B-X
T	B-X
-	B-X
cell	B-X
development	B-X
,	B-X
leads	B-X
to	B-X
development	B-X
of	B-X
spontaneous	B-X
lymphomas	B-X
at	B-X
low	B-X
frequency	B-X
and	B-X
is	B-X
strongly	B-X
synergistic	B-X
with	B-X
Myc	B-X
<EOS>	B-X
To	B-X
gain	B-X
further	B-X
insight	B-X
into	B-X
the	B-X
relationship	B-X
of	B-X
Runx2	B-X
to	B-X
other	B-X
lymphomagenic	B-X
pathways	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effect	B-X
of	B-X
combining	B-X
the	B-X
CD2	B-X
-	B-X
Runx2	B-X
transgene	B-X
either	B-X
with	B-X
a	B-X
Pim1	B-X
transgene	B-X
(	B-X
E	B-X
(	B-X
mu	B-X
)	B-X
	B-X
-	B-X
Pim1	B-X
)	B-X
or	B-X
with	B-X
the	B-X
p53	B-X
null	B-X
genotype	B-X
,	B-X
as	B-X
each	B-X
of	B-X
these	B-X
displays	B-X
independent	B-X
synergy	B-X
with	B-X
Myc	B-X
<EOS>	B-X
Neonatal	B-X
infection	B-X
of	B-X
CD2	B-X
-	B-X
Runx2	B-X
mice	B-X
with	B-X
Moloney	B-X
murine	B-X
leukaemia	B-X
virus	B-X
(	B-X
Moloney	B-X
MLV	B-X
)	B-X
also	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
acceleration	B-X
of	B-X
tumour	B-X
onset	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Runx2	B-X
makes	B-X
a	B-X
distinct	B-X
contribution	B-X
to	B-X
T	B-X
-	B-X
cell	B-X
lymphoma	B-X
development	B-X
which	B-X
does	B-X
not	B-X
coincide	B-X
with	B-X
any	B-X
of	B-X
the	B-X
oncogene	B-X
complementation	B-X
groups	B-X
previously	B-X
identified	B-X
by	B-X
retroviral	B-X
tagging	B-X

To	O
gain	O
further	O
insight	O
into	O
the	O
relationship	O
of	O
Runx2	B-DNA
to	O
other	O
lymphomagenic	O
pathways	O
,	O
we	O
tested	O
the	O
effect	O
of	O
combining	O
the	O
CD2-Runx2	B-DNA
transgene	I-DNA
either	O
with	O
a	O
Pim1	B-DNA
transgene	I-DNA
(	O
E	B-DNA
(	I-DNA
mu	I-DNA
)	I-DNA
-Pim1	I-DNA
)	O
or	O
with	O
the	O
p53	B-DNA
null	O
genotype	O
,	O
as	O
each	O
of	O
these	O
displays	O
independent	O
synergy	O
with	O
Myc	B-protein
.	O
<EOS>	B-X
To	B-X
gain	B-X
further	B-X
insight	B-X
into	B-X
the	B-X
relationship	B-X
of	B-X
Runx2	B-X
to	B-X
other	B-X
lymphomagenic	B-X
pathways	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
effect	B-X
of	B-X
combining	B-X
the	B-X
CD2	B-X
-	B-X
Runx2	B-X
transgene	B-X
either	B-X
with	B-X
a	B-X
Pim1	B-X
transgene	B-X
(	B-X
E	B-X
(	B-X
mu	B-X
)	B-X
	B-X
-	B-X
Pim1	B-X
)	B-X
or	B-X
with	B-X
the	B-X
p53	B-X
null	B-X
genotype	B-X
,	B-X
as	B-X
each	B-X
of	B-X
these	B-X
displays	B-X
independent	B-X
synergy	B-X
with	B-X
Myc	B-X
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
over	B-X
-	B-X
expression	B-X
of	B-X
the	B-X
full	B-X
-	B-X
length	B-X
,	B-X
most	B-X
highly	B-X
expressed	B-X
Runx2	B-X
isoform	B-X
in	B-X
the	B-X
thymus	B-X
perturbs	B-X
T	B-X
-	B-X
cell	B-X
development	B-X
,	B-X
leads	B-X
to	B-X
development	B-X
of	B-X
spontaneous	B-X
lymphomas	B-X
at	B-X
low	B-X
frequency	B-X
and	B-X
is	B-X
strongly	B-X
synergistic	B-X
with	B-X
Myc	B-X
<EOS>	B-X
However	B-X
,	B-X
Runx2	B-X
appeared	B-X
to	B-X
have	B-X
a	B-X
dominant	B-X
effect	B-X
on	B-X
the	B-X
tumour	B-X
phenotype	B-X
in	B-X
each	B-X
case	B-X
,	B-X
with	B-X
most	B-X
tumours	B-X
conforming	B-X
to	B-X
the	B-X
CD3	B-X
(	B-X
+	B-X
)	B-X
,	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
phenotype	B-X
seen	B-X
in	B-X
CD2	B-X
-	B-X
Runx2	B-X
mice	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
known	B-X
Moloney	B-X
MLV	B-X
target	B-X
genes	B-X
in	B-X
these	B-X
lymphomas	B-X
showed	B-X
a	B-X
high	B-X
frequency	B-X
of	B-X
rearrangement	B-X
at	B-X
c	B-X
-	B-X
Myc	B-X
or	B-X
N	B-X
-	B-X
Myc	B-X
(	B-X
82	B-X
%	B-X
)	B-X
,	B-X
and	B-X
a	B-X
significant	B-X
number	B-X
at	B-X
Pim1	B-X
or	B-X
Pim2	B-X
(	B-X
23	B-X
%	B-X
)	B-X
,	B-X
and	B-X
at	B-X
Pal1	B-X
/	B-X
Gfi1	B-X
(	B-X
18	B-X
%	B-X
)	B-X

In	O
both	O
cases	O
we	O
observed	O
synergistic	O
tumour	O
development	O
.	O
<EOS>	B-X
Alcohol	B-X
intake	B-X
and	B-X
smoking	B-X
had	B-X
a	B-X
synergistic	B-X
effect	B-X
on	B-X
EC	B-X
development	B-X
<EOS>	B-X
In	B-X
BV	B-X
-	B-X
173	B-X
cells	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
cell	B-X
viability	B-X
to	B-X
only	B-X
1	B-X
<EOS>	B-X
Lorlatinib	B-X
in	B-X
combination	B-X
with	B-X
chemotherapy	B-X
was	B-X
synergistic	B-X
in	B-X
immunocompetent	B-X
neuroblastoma	B-X
GEMM	B-X
<EOS>	B-X
The	B-X
combination	B-X
showed	B-X
a	B-X
synergistic	B-X
inhibitory	B-X
activity	B-X

However	O
,	O
Runx2	B-protein
appeared	O
to	O
have	O
a	O
dominant	O
effect	O
on	O
the	O
tumour	O
phenotype	O
in	O
each	O
case	O
,	O
with	O
most	O
tumours	O
conforming	O
to	O
the	O
CD3	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
,	O
CD4	O
(	O
+/-	O
)	O
phenotype	O
seen	O
in	O
CD2-Runx2	O
mice	O
.	O

Neonatal	O
infection	O
of	O
CD2-Runx2	O
mice	O
with	O
Moloney	O
murine	O
leukaemia	O
virus	O
(	O
Moloney	O
MLV	O
)	O
also	O
led	O
to	O
a	O
dramatic	O
acceleration	O
of	O
tumour	O
onset	O
.	O
<EOS>	B-X
Neonatal	B-X
infection	B-X
of	B-X
CD2	B-X
-	B-X
Runx2	B-X
mice	B-X
with	B-X
Moloney	B-X
murine	B-X
leukaemia	B-X
virus	B-X
(	B-X
Moloney	B-X
MLV	B-X
)	B-X
also	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
acceleration	B-X
of	B-X
tumour	B-X
onset	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Runx2	B-X
makes	B-X
a	B-X
distinct	B-X
contribution	B-X
to	B-X
T	B-X
-	B-X
cell	B-X
lymphoma	B-X
development	B-X
which	B-X
does	B-X
not	B-X
coincide	B-X
with	B-X
any	B-X
of	B-X
the	B-X
oncogene	B-X
complementation	B-X
groups	B-X
previously	B-X
identified	B-X
by	B-X
retroviral	B-X
tagging	B-X
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
over	B-X
-	B-X
expression	B-X
of	B-X
the	B-X
full	B-X
-	B-X
length	B-X
,	B-X
most	B-X
highly	B-X
expressed	B-X
Runx2	B-X
isoform	B-X
in	B-X
the	B-X
thymus	B-X
perturbs	B-X
T	B-X
-	B-X
cell	B-X
development	B-X
,	B-X
leads	B-X
to	B-X
development	B-X
of	B-X
spontaneous	B-X
lymphomas	B-X
at	B-X
low	B-X
frequency	B-X
and	B-X
is	B-X
strongly	B-X
synergistic	B-X
with	B-X
Myc	B-X
<EOS>	B-X
Runx2	B-X
:	B-X
a	B-X
novel	B-X
oncogenic	B-X
effector	B-X
revealed	B-X
by	B-X
in	B-X
vivo	B-X
complementation	B-X
and	B-X
retroviral	B-X
tagging	B-X
.	B-X

Analysis	O
of	O
known	O
Moloney	B-DNA
MLV	I-DNA
target	I-DNA
genes	I-DNA
in	O
these	O
lymphomas	O
showed	O
a	O
high	O
frequency	O
of	O
rearrangement	O
at	O
c-Myc	B-DNA
or	O
N-Myc	B-DNA
(	O
82	O
%	O
)	O
,	O
and	O
a	O
significant	O
number	O
at	O
Pim1	B-DNA
or	O
Pim2	B-DNA
(	O
23	O
%	O
)	O
,	O
and	O
at	O
Pal1/Gfi1	B-DNA
(	O
18	O
%	O
)	O
.	O

These	O
results	O
indicate	O
that	O
Runx2	B-protein
makes	O
a	O
distinct	O
contribution	O
to	O
T-cell	O
lymphoma	O
development	O
which	O
does	O
not	O
coincide	O
with	O
any	O
of	O
the	O
oncogene	O
complementation	O
groups	O
previously	O
identified	O
by	O
retroviral	O
tagging	O
.	O

The	O
involvement	O
of	O
TNF-alpha	B-protein
-related	O
apoptosis-inducing	O
ligand	O
in	O
the	O
enhanced	O
cytotoxicity	O
of	O
IFN-beta	B-protein
-stimulated	O
human	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
to	O
tumor	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
involvement	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
in	B-X
the	B-X
enhanced	B-X
cytotoxicity	B-X
of	B-X
IFN	B-X
-	B-X
beta	B-X
-	B-X
stimulated	B-X
human	B-X
dendritic	B-X
cells	B-X
to	B-X
tumor	B-X
cells	B-X
.	B-X
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
(	B-X
TRAIL	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
its	B-X
preferential	B-X
induction	B-X
of	B-X
apoptosis	B-X
of	B-X
tumor	B-X
cells	B-X
but	B-X
not	B-X
normal	B-X
cells	B-X
<EOS>	B-X
Dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
,	B-X
besides	B-X
their	B-X
role	B-X
as	B-X
APCs	B-X
,	B-X
now	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
exert	B-X
cytotoxicity	B-X
or	B-X
cytostasis	B-X
on	B-X
some	B-X
tumor	B-X
cells	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
TRAIL	B-X
expression	B-X
remained	B-X
constant	B-X
until	B-X
DC	B-X
maturation	B-X

TNF-alpha	B-protein
-related	O
apoptosis-inducing	O
ligand	O
(	O
TRAIL	O
)	O
is	O
characterized	O
by	O
its	O
preferential	O
induction	O
of	O
apoptosis	O
of	O
tumor	B-cell_type
cells	I-cell_type
but	O
not	O
normal	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
(	B-X
TRAIL	B-X
)	B-X
has	B-X
emerged	B-X
as	B-X
an	B-X
attractive	B-X
cytokine	B-X
that	B-X
selectively	B-X
targets	B-X
cancer	B-X
cells	B-X
,	B-X
however	B-X
its	B-X
efficacy	B-X
has	B-X
been	B-X
challenged	B-X
by	B-X
a	B-X
number	B-X
of	B-X
resistance	B-X
mechanisms	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
/	B-X
Apo2	B-X
ligand	B-X
(	B-X
TRAIL	B-X
/	B-X
Apo2L	B-X
)	B-X
mRNA	B-X
was	B-X
induced	B-X
preferentially	B-X
by	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
beta	B-X
but	B-X
not	B-X
IFN	B-X
-	B-X
alpha	B-X
in	B-X
human	B-X
fibrosarcoma	B-X
and	B-X
primary	B-X
fibroblast	B-X
cells	B-X
<EOS>	B-X
Importantly	B-X
,	B-X
dipyridamole	B-X
-	B-X
induced	B-X
enhancement	B-X
of	B-X
TRAIL	B-X
efficacy	B-X
and	B-X
alterations	B-X
of	B-X
protein	B-X
expression	B-X
were	B-X
independent	B-X
of	B-X
either	B-X
protein	B-X
kinase	B-X
A	B-X
or	B-X
protein	B-X
kinase	B-X
G	B-X
<EOS>	B-X
Requirement	B-X
of	B-X
catalytically	B-X
active	B-X
Tyk2	B-X
and	B-X
accessory	B-X
signals	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
TRAIL	B-X
mRNA	B-X
by	B-X
IFN	B-X
-	B-X
beta	B-X
.	B-X

Dendritic	B-cell_type
cells	I-cell_type
(	O
DCs	B-cell_type
)	O
,	O
besides	O
their	O
role	O
as	O
APCs	O
,	O
now	O
have	O
been	O
demonstrated	O
to	O
exert	O
cytotoxicity	O
or	O
cytostasis	O
on	O
some	O
tumor	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Comparison	B-X
across	B-X
a	B-X
panel	B-X
of	B-X
cell	B-X
lines	B-X
demonstrated	B-X
that	B-X
sensitive	B-X
cells	B-X
died	B-X
upon	B-X
incubation	B-X
with	B-X
LY2606368	B-X
,	B-X
whereas	B-X
resistant	B-X
cells	B-X
underwent	B-X
growth	B-X
inhibition	B-X
and	B-X
/	B-X
or	B-X
cytostasis	B-X
but	B-X
failed	B-X
to	B-X
die	B-X
<EOS>	B-X
Three	B-X
cell	B-X
lines	B-X
had	B-X
lost	B-X
the	B-X
expression	B-X
of	B-X
cytostatic	B-X
effector	B-X
genes	B-X
<EOS>	B-X
Our	B-X
recent	B-X
comparison	B-X
of	B-X
three	B-X
CHK1i	B-X
demonstrated	B-X
that	B-X
they	B-X
all	B-X
inhibited	B-X
protein	B-X
synthesis	B-X
only	B-X
in	B-X
sensitive	B-X
cells	B-X
<EOS>	B-X
A	B-X
series	B-X
of	B-X
in	B-X
vitro	B-X
assays	B-X
demonstrated	B-X
that	B-X
ABT	B-X
-	B-X
751	B-X
induced	B-X
G	B-X

Here	O
,	O
we	O
report	O
that	O
both	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
stem	I-cell_type
cell	I-cell_type
-derived	O
DCs	B-cell_type
(	O
CD34DCs	B-cell_type
)	O
and	O
human	B-cell_type
CD14	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
monocyte	I-cell_type
-derived	O
DCs	B-cell_type
(	O
MoDCs	B-cell_type
)	O
express	O
TRAIL	O
and	O
exhibit	O
cytotoxicity	O
to	O
some	O
types	O
of	O
tumor	B-cell_type
cells	I-cell_type
partially	O
through	O
TRAIL	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
both	B-X
human	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
stem	B-X
cell	B-X
-	B-X
derived	B-X
DCs	B-X
(	B-X
CD34DCs	B-X
)	B-X
and	B-X
human	B-X
CD14	B-X
(	B-X
+	B-X
)	B-X
monocyte	B-X
-	B-X
derived	B-X
DCs	B-X
(	B-X
MoDCs	B-X
)	B-X
express	B-X
TRAIL	B-X
and	B-X
exhibit	B-X
cytotoxicity	B-X
to	B-X
some	B-X
types	B-X
of	B-X
tumor	B-X
cells	B-X
partially	B-X
through	B-X
TRAIL	B-X
<EOS>	B-X
Thus	B-X
,	B-X
an	B-X
innate	B-X
mechanism	B-X
of	B-X
DC	B-X
-	B-X
mediated	B-X
antitumor	B-X
immunity	B-X
might	B-X
exist	B-X
in	B-X
vivo	B-X
in	B-X
which	B-X
DCs	B-X
act	B-X
as	B-X
effectors	B-X
to	B-X
directly	B-X
kill	B-X
tumor	B-X
cells	B-X
partially	B-X
via	B-X
TRAIL	B-X
<EOS>	B-X
Dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
,	B-X
besides	B-X
their	B-X
role	B-X
as	B-X
APCs	B-X
,	B-X
now	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
exert	B-X
cytotoxicity	B-X
or	B-X
cytostasis	B-X
on	B-X
some	B-X
tumor	B-X
cells	B-X
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
(	B-X
TRAIL	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
its	B-X
preferential	B-X
induction	B-X
of	B-X
apoptosis	B-X
of	B-X
tumor	B-X
cells	B-X
but	B-X
not	B-X
normal	B-X
cells	B-X

Moderate	O
expression	O
of	O
TRAIL	O
appeared	O
on	O
CD34DCs	B-cell_type
from	O
the	O
8th	O
day	O
of	O
culture	O
and	O
was	O
also	O
seen	O
on	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
Moderate	B-X
expression	B-X
of	B-X
TRAIL	B-X
appeared	B-X
on	B-X
CD34DCs	B-X
from	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
culture	B-X
and	B-X
was	B-X
also	B-X
seen	B-X
on	B-X
freshly	B-X
isolated	B-X
monocytes	B-X
<EOS>	B-X
TRAIL	B-X
expression	B-X
on	B-X
immature	B-X
CD34DCs	B-X
or	B-X
MoDCs	B-X
was	B-X
greatly	B-X
up	B-X
-	B-X
regulated	B-X
after	B-X
IFN	B-X
-	B-X
beta	B-X
stimulation	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
TRAIL	B-X
expression	B-X
remained	B-X
constant	B-X
until	B-X
DC	B-X
maturation	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
IFN	B-X
-	B-X
beta	B-X
could	B-X
strikingly	B-X
enhance	B-X
the	B-X
ability	B-X
of	B-X
CD34DCs	B-X
or	B-X
MoDCs	B-X
to	B-X
kill	B-X
TRAIL	B-X
-	B-X
sensitive	B-X
tumor	B-X
cells	B-X
,	B-X
but	B-X
LPS	B-X
did	B-X
not	B-X
have	B-X
such	B-X
an	B-X
effect	B-X

The	O
level	O
of	O
TRAIL	O
expression	O
remained	O
constant	O
until	O
DC	O
maturation	O
.	O
<EOS>	B-X
The	B-X
level	B-X
of	B-X
TRAIL	B-X
expression	B-X
remained	B-X
constant	B-X
until	B-X
DC	B-X
maturation	B-X
<EOS>	B-X
Moderate	B-X
expression	B-X
of	B-X
TRAIL	B-X
appeared	B-X
on	B-X
CD34DCs	B-X
from	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
culture	B-X
and	B-X
was	B-X
also	B-X
seen	B-X
on	B-X
freshly	B-X
isolated	B-X
monocytes	B-X
<EOS>	B-X
The	B-X
involvement	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
in	B-X
the	B-X
enhanced	B-X
cytotoxicity	B-X
of	B-X
IFN	B-X
-	B-X
beta	B-X
-	B-X
stimulated	B-X
human	B-X
dendritic	B-X
cells	B-X
to	B-X
tumor	B-X
cells	B-X
.	B-X
<EOS>	B-X
Dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
,	B-X
besides	B-X
their	B-X
role	B-X
as	B-X
APCs	B-X
,	B-X
now	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
exert	B-X
cytotoxicity	B-X
or	B-X
cytostasis	B-X
on	B-X
some	B-X
tumor	B-X
cells	B-X

TRAIL	O
expression	O
on	O
immature	B-cell_type
CD34DCs	I-cell_type
or	O
MoDCs	B-cell_type
was	O
greatly	O
up-regulated	O
after	O
IFN-beta	B-protein
stimulation	O
.	O
<EOS>	B-X
TRAIL	B-X
expression	B-X
on	B-X
immature	B-X
CD34DCs	B-X
or	B-X
MoDCs	B-X
was	B-X
greatly	B-X
up	B-X
-	B-X
regulated	B-X
after	B-X
IFN	B-X
-	B-X
beta	B-X
stimulation	B-X
<EOS>	B-X
Moderate	B-X
expression	B-X
of	B-X
TRAIL	B-X
appeared	B-X
on	B-X
CD34DCs	B-X
from	B-X
the	B-X
8th	B-X
day	B-X
of	B-X
culture	B-X
and	B-X
was	B-X
also	B-X
seen	B-X
on	B-X
freshly	B-X
isolated	B-X
monocytes	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
IFN	B-X
-	B-X
beta	B-X
could	B-X
strikingly	B-X
enhance	B-X
the	B-X
ability	B-X
of	B-X
CD34DCs	B-X
or	B-X
MoDCs	B-X
to	B-X
kill	B-X
TRAIL	B-X
-	B-X
sensitive	B-X
tumor	B-X
cells	B-X
,	B-X
but	B-X
LPS	B-X
did	B-X
not	B-X
have	B-X
such	B-X
an	B-X
effect	B-X
<EOS>	B-X
The	B-X
level	B-X
of	B-X
TRAIL	B-X
expression	B-X
remained	B-X
constant	B-X
until	B-X
DC	B-X
maturation	B-X

Moreover	O
,	O
IFN-beta	B-protein
could	O
strikingly	O
enhance	O
the	O
ability	O
of	O
CD34DCs	B-cell_type
or	O
MoDCs	B-cell_type
to	O
kill	O
TRAIL-sensitive	O
tumor	B-cell_type
cells	I-cell_type
,	O
but	O
LPS	O
did	O
not	O
have	O
such	O
an	O
effect	O
.	O

The	O
up-regulation	O
of	O
TRAIL	O
on	O
IFN-beta	B-protein
-stimulated	O
DCs	B-cell_type
partially	O
contributed	O
to	O
the	O
increased	O
cytotoxicity	O
of	O
DCS	B-cell_type
:	O
Pretreatment	O
of	O
TRAIL-sensitive	O
tumor	B-cell_type
cells	I-cell_type
with	O
caspase-3	O
inhibitor	O
could	O
significantly	O
increase	O
their	O
resistance	O
to	O
the	O
cytotoxicity	O
of	O
IFN-beta	B-protein
-stimulated	O
DCS	B-cell_type
:	O
In	O
contrast	O
,	O
NF-kappaB	O
inhibitor	O
could	O
significantly	O
increase	O
the	O
sensitivity	O
of	O
tumor	B-cell_type
cells	I-cell_type
to	O
the	O
killing	O
by	O
nonstimulated	O
or	O
LPS-stimulated	O
DCS	B-cell_type
:	O
Our	O
studies	O
demonstrate	O
that	O
IFN-beta	B-protein
-stimulated	O
DCs	B-cell_type
are	O
functionally	O
cytotoxic	O
.	O
<EOS>	B-X
The	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
TRAIL	B-X
on	B-X
IFN	B-X
-	B-X
beta	B-X
-	B-X
stimulated	B-X
DCs	B-X
partially	B-X
contributed	B-X
to	B-X
the	B-X
increased	B-X
cytotoxicity	B-X
of	B-X
DCS	B-X
:	B-X
Pretreatment	B-X
of	B-X
TRAIL	B-X
-	B-X
sensitive	B-X
tumor	B-X
cells	B-X
with	B-X
caspase	B-X
-	B-X
3	B-X
inhibitor	B-X
could	B-X
significantly	B-X
increase	B-X
their	B-X
resistance	B-X
to	B-X
the	B-X
cytotoxicity	B-X
of	B-X
IFN	B-X
-	B-X
beta	B-X
-	B-X
stimulated	B-X
DCS	B-X
:	B-X
In	B-X
contrast	B-X
,	B-X
NF	B-X
-	B-X
kappaB	B-X
inhibitor	B-X
could	B-X
significantly	B-X
increase	B-X
the	B-X
sensitivity	B-X
of	B-X
tumor	B-X
cells	B-X
to	B-X
the	B-X
killing	B-X
by	B-X
nonstimulated	B-X
or	B-X
LPS	B-X
-	B-X
stimulated	B-X
DCS	B-X
:	B-X
Our	B-X
studies	B-X
demonstrate	B-X
that	B-X
IFN	B-X
-	B-X
beta	B-X
-	B-X
stimulated	B-X
DCs	B-X
are	B-X
functionally	B-X
cytotoxic	B-X
<EOS>	B-X
The	B-X
involvement	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
in	B-X
the	B-X
enhanced	B-X
cytotoxicity	B-X
of	B-X
IFN	B-X
-	B-X
beta	B-X
-	B-X
stimulated	B-X
human	B-X
dendritic	B-X
cells	B-X
to	B-X
tumor	B-X
cells	B-X
.	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
IFN	B-X
-	B-X
beta	B-X
could	B-X
strikingly	B-X
enhance	B-X
the	B-X
ability	B-X
of	B-X
CD34DCs	B-X
or	B-X
MoDCs	B-X
to	B-X
kill	B-X
TRAIL	B-X
-	B-X
sensitive	B-X
tumor	B-X
cells	B-X
,	B-X
but	B-X
LPS	B-X
did	B-X
not	B-X
have	B-X
such	B-X
an	B-X
effect	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
both	B-X
human	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
stem	B-X
cell	B-X
-	B-X
derived	B-X
DCs	B-X
(	B-X
CD34DCs	B-X
)	B-X
and	B-X
human	B-X
CD14	B-X
(	B-X
+	B-X
)	B-X
monocyte	B-X
-	B-X
derived	B-X
DCs	B-X
(	B-X
MoDCs	B-X
)	B-X
express	B-X
TRAIL	B-X
and	B-X
exhibit	B-X
cytotoxicity	B-X
to	B-X
some	B-X
types	B-X
of	B-X
tumor	B-X
cells	B-X
partially	B-X
through	B-X
TRAIL	B-X

Thus	O
,	O
an	O
innate	O
mechanism	O
of	O
DC-mediated	O
antitumor	O
immunity	O
might	O
exist	O
in	O
vivo	O
in	O
which	O
DCs	B-cell_type
act	O
as	O
effectors	O
to	O
directly	O
kill	O
tumor	B-cell_type
cells	I-cell_type
partially	O
via	O
TRAIL	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
an	B-X
innate	B-X
mechanism	B-X
of	B-X
DC	B-X
-	B-X
mediated	B-X
antitumor	B-X
immunity	B-X
might	B-X
exist	B-X
in	B-X
vivo	B-X
in	B-X
which	B-X
DCs	B-X
act	B-X
as	B-X
effectors	B-X
to	B-X
directly	B-X
kill	B-X
tumor	B-X
cells	B-X
partially	B-X
via	B-X
TRAIL	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
both	B-X
human	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
stem	B-X
cell	B-X
-	B-X
derived	B-X
DCs	B-X
(	B-X
CD34DCs	B-X
)	B-X
and	B-X
human	B-X
CD14	B-X
(	B-X
+	B-X
)	B-X
monocyte	B-X
-	B-X
derived	B-X
DCs	B-X
(	B-X
MoDCs	B-X
)	B-X
express	B-X
TRAIL	B-X
and	B-X
exhibit	B-X
cytotoxicity	B-X
to	B-X
some	B-X
types	B-X
of	B-X
tumor	B-X
cells	B-X
partially	B-X
through	B-X
TRAIL	B-X
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
(	B-X
TRAIL	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
its	B-X
preferential	B-X
induction	B-X
of	B-X
apoptosis	B-X
of	B-X
tumor	B-X
cells	B-X
but	B-X
not	B-X
normal	B-X
cells	B-X
<EOS>	B-X
The	B-X
involvement	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
in	B-X
the	B-X
enhanced	B-X
cytotoxicity	B-X
of	B-X
IFN	B-X
-	B-X
beta	B-X
-	B-X
stimulated	B-X
human	B-X
dendritic	B-X
cells	B-X
to	B-X
tumor	B-X
cells	B-X
.	B-X

Subsequently	O
,	O
DCs	B-cell_type
act	O
as	O
APCs	O
involved	O
in	O
the	O
uptake	O
,	O
processing	O
,	O
and	O
presentation	O
of	O
apoptotic	B-protein
tumor	I-protein
Ags	I-protein
to	O
cross-prime	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CTL	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Subsequently	B-X
,	B-X
DCs	B-X
act	B-X
as	B-X
APCs	B-X
involved	B-X
in	B-X
the	B-X
uptake	B-X
,	B-X
processing	B-X
,	B-X
and	B-X
presentation	B-X
of	B-X
apoptotic	B-X
tumor	B-X
Ags	B-X
to	B-X
cross	B-X
-	B-X
prime	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
CTL	B-X
cells	B-X
<EOS>	B-X
Dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
,	B-X
besides	B-X
their	B-X
role	B-X
as	B-X
APCs	B-X
,	B-X
now	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
exert	B-X
cytotoxicity	B-X
or	B-X
cytostasis	B-X
on	B-X
some	B-X
tumor	B-X
cells	B-X
<EOS>	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
(	B-X
TRAIL	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
its	B-X
preferential	B-X
induction	B-X
of	B-X
apoptosis	B-X
of	B-X
tumor	B-X
cells	B-X
but	B-X
not	B-X
normal	B-X
cells	B-X
<EOS>	B-X
The	B-X
involvement	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
related	B-X
apoptosis	B-X
-	B-X
inducing	B-X
ligand	B-X
in	B-X
the	B-X
enhanced	B-X
cytotoxicity	B-X
of	B-X
IFN	B-X
-	B-X
beta	B-X
-	B-X
stimulated	B-X
human	B-X
dendritic	B-X
cells	B-X
to	B-X
tumor	B-X
cells	B-X
.	B-X

Tumor	B-cell_type
cells	I-cell_type
regulate	O
the	O
lytic	O
activity	O
of	O
tumor-specific	B-cell_type
cytotoxic	I-cell_type
t	I-cell_type
lymphocytes	I-cell_type
by	O
modulating	O
the	O
inhibitory	O
natural	O
killer	O
receptor	O
function	O
.	O
<EOS>	B-X
Tumor	B-X
cells	B-X
regulate	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
tumor	B-X
-	B-X
specific	B-X
cytotoxic	B-X
t	B-X
lymphocytes	B-X
by	B-X
modulating	B-X
the	B-X
inhibitory	B-X
natural	B-X
killer	B-X
receptor	B-X
function	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
this	B-X
lytic	B-X
activity	B-X
was	B-X
significantly	B-X
increased	B-X
after	B-X
blockade	B-X
of	B-X
p58	B-X
with	B-X
specific	B-X
monoclonal	B-X
antibodies	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
stimulation	B-X
by	B-X
tumor	B-X
cells	B-X
was	B-X
required	B-X
to	B-X
trigger	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
p58	B-X
on	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
antigen	B-X
-	B-X
specific	B-X
CTLs	B-X
and	B-X
that	B-X
stimulation	B-X
of	B-X
the	B-X
inhibitory	B-X
function	B-X
of	B-X
p58	B-X
by	B-X
tumor	B-X
cells	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
p58+	B-X
tumor	B-X
-	B-X
specific	B-X
CTLS	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
infiltrating	B-X
p58+	B-X
T	B-X
cells	B-X
from	B-X
a	B-X
renal	B-X
tumor	B-X
were	B-X
specifically	B-X
expanded	B-X
in	B-X
response	B-X
to	B-X
tumor	B-X
cell	B-X
stimulation	B-X
and	B-X
cloned	B-X

Tumor-infiltrating	B-cell_type
p58+	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
a	O
renal	O
tumor	O
were	O
specifically	O
expanded	O
in	O
response	O
to	O
tumor	O
cell	O
stimulation	O
and	O
cloned	O
.	O
<EOS>	B-X
Tumor	B-X
-	B-X
infiltrating	B-X
p58+	B-X
T	B-X
cells	B-X
from	B-X
a	B-X
renal	B-X
tumor	B-X
were	B-X
specifically	B-X
expanded	B-X
in	B-X
response	B-X
to	B-X
tumor	B-X
cell	B-X
stimulation	B-X
and	B-X
cloned	B-X
<EOS>	B-X
These	B-X
p58+	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
express	B-X
a	B-X
memory	B-X
phenotype	B-X
and	B-X
corresponded	B-X
to	B-X
clonal	B-X
TCRBV3	B-X
T	B-X
-	B-X
cell	B-X
expansion	B-X
<EOS>	B-X
Functionally	B-X
,	B-X
p58	B-X
(	B-X
+	B-X
)	B-X
CTLs	B-X
displayed	B-X
a	B-X
low	B-X
lytic	B-X
activity	B-X
for	B-X
HLA	B-X
-	B-X
A2	B-X
tumor	B-X
and	B-X
normal	B-X
cells	B-X
<EOS>	B-X
Tumor	B-X
cells	B-X
regulate	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
tumor	B-X
-	B-X
specific	B-X
cytotoxic	B-X
t	B-X
lymphocytes	B-X
by	B-X
modulating	B-X
the	B-X
inhibitory	B-X
natural	B-X
killer	B-X
receptor	B-X
function	B-X
.	B-X

These	O
p58+	B-cell_type
T	I-cell_type
cells	I-cell_type
were	O
found	O
to	O
express	O
a	O
memory	B-cell_type
phenotype	I-cell_type
and	O
corresponded	O
to	O
clonal	O
TCRBV3	O
T-cell	O
expansion	O
.	O
<EOS>	B-X
These	B-X
p58+	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
express	B-X
a	B-X
memory	B-X
phenotype	B-X
and	B-X
corresponded	B-X
to	B-X
clonal	B-X
TCRBV3	B-X
T	B-X
-	B-X
cell	B-X
expansion	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
infiltrating	B-X
p58+	B-X
T	B-X
cells	B-X
from	B-X
a	B-X
renal	B-X
tumor	B-X
were	B-X
specifically	B-X
expanded	B-X
in	B-X
response	B-X
to	B-X
tumor	B-X
cell	B-X
stimulation	B-X
and	B-X
cloned	B-X
<EOS>	B-X
Tumor	B-X
cells	B-X
regulate	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
tumor	B-X
-	B-X
specific	B-X
cytotoxic	B-X
t	B-X
lymphocytes	B-X
by	B-X
modulating	B-X
the	B-X
inhibitory	B-X
natural	B-X
killer	B-X
receptor	B-X
function	B-X
.	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
stimulation	B-X
by	B-X
tumor	B-X
cells	B-X
was	B-X
required	B-X
to	B-X
trigger	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
p58	B-X
on	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
antigen	B-X
-	B-X
specific	B-X
CTLs	B-X
and	B-X
that	B-X
stimulation	B-X
of	B-X
the	B-X
inhibitory	B-X
function	B-X
of	B-X
p58	B-X
by	B-X
tumor	B-X
cells	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
p58+	B-X
tumor	B-X
-	B-X
specific	B-X
CTLS	B-X

Functionally	O
,	O
p58	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CTLs	I-cell_type
displayed	O
a	O
low	O
lytic	O
activity	O
for	O
HLA-A2	B-cell_type
tumor	I-cell_type
and	I-cell_type
normal	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Functionally	B-X
,	B-X
p58	B-X
(	B-X
+	B-X
)	B-X
CTLs	B-X
displayed	B-X
a	B-X
low	B-X
lytic	B-X
activity	B-X
for	B-X
HLA	B-X
-	B-X
A2	B-X
tumor	B-X
and	B-X
normal	B-X
cells	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
infiltrating	B-X
p58+	B-X
T	B-X
cells	B-X
from	B-X
a	B-X
renal	B-X
tumor	B-X
were	B-X
specifically	B-X
expanded	B-X
in	B-X
response	B-X
to	B-X
tumor	B-X
cell	B-X
stimulation	B-X
and	B-X
cloned	B-X
<EOS>	B-X
Tumor	B-X
cells	B-X
regulate	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
tumor	B-X
-	B-X
specific	B-X
cytotoxic	B-X
t	B-X
lymphocytes	B-X
by	B-X
modulating	B-X
the	B-X
inhibitory	B-X
natural	B-X
killer	B-X
receptor	B-X
function	B-X
.	B-X
<EOS>	B-X
These	B-X
p58+	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
express	B-X
a	B-X
memory	B-X
phenotype	B-X
and	B-X
corresponded	B-X
to	B-X
clonal	B-X
TCRBV3	B-X
T	B-X
-	B-X
cell	B-X
expansion	B-X

However	O
,	O
this	O
lytic	O
activity	O
was	O
significantly	O
increased	O
after	O
blockade	O
of	O
p58	B-protein
with	O
specific	O
monoclonal	B-protein
antibodies	I-protein
.	O
<EOS>	B-X
However	B-X
,	B-X
this	B-X
lytic	B-X
activity	B-X
was	B-X
significantly	B-X
increased	B-X
after	B-X
blockade	B-X
of	B-X
p58	B-X
with	B-X
specific	B-X
monoclonal	B-X
antibodies	B-X
<EOS>	B-X
Tumor	B-X
cells	B-X
regulate	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
tumor	B-X
-	B-X
specific	B-X
cytotoxic	B-X
t	B-X
lymphocytes	B-X
by	B-X
modulating	B-X
the	B-X
inhibitory	B-X
natural	B-X
killer	B-X
receptor	B-X
function	B-X
.	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
stimulation	B-X
by	B-X
tumor	B-X
cells	B-X
was	B-X
required	B-X
to	B-X
trigger	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
p58	B-X
on	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
antigen	B-X
-	B-X
specific	B-X
CTLs	B-X
and	B-X
that	B-X
stimulation	B-X
of	B-X
the	B-X
inhibitory	B-X
function	B-X
of	B-X
p58	B-X
by	B-X
tumor	B-X
cells	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
p58+	B-X
tumor	B-X
-	B-X
specific	B-X
CTLS	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
infiltrating	B-X
p58+	B-X
T	B-X
cells	B-X
from	B-X
a	B-X
renal	B-X
tumor	B-X
were	B-X
specifically	B-X
expanded	B-X
in	B-X
response	B-X
to	B-X
tumor	B-X
cell	B-X
stimulation	B-X
and	B-X
cloned	B-X

Interestingly	O
,	O
we	O
demonstrated	O
that	O
stimulation	O
by	O
tumor	B-cell_type
cells	I-cell_type
was	O
required	O
to	O
trigger	O
the	O
inhibitory	O
effect	O
of	O
p58	B-protein
on	O
the	O
lytic	O
activity	O
of	O
antigen-specific	B-cell_type
CTLs	I-cell_type
and	O
that	O
stimulation	O
of	O
the	O
inhibitory	O
function	O
of	O
p58	B-protein
by	O
tumor	B-cell_type
cells	I-cell_type
correlated	O
with	O
an	O
inhibition	O
of	O
nuclear	O
factor-kappaB	O
activation	O
in	O
p58+	B-cell_type
tumor-specific	I-cell_type
CTLS	I-cell_type
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
stimulation	B-X
by	B-X
tumor	B-X
cells	B-X
was	B-X
required	B-X
to	B-X
trigger	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
p58	B-X
on	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
antigen	B-X
-	B-X
specific	B-X
CTLs	B-X
and	B-X
that	B-X
stimulation	B-X
of	B-X
the	B-X
inhibitory	B-X
function	B-X
of	B-X
p58	B-X
by	B-X
tumor	B-X
cells	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
in	B-X
p58+	B-X
tumor	B-X
-	B-X
specific	B-X
CTLS	B-X
<EOS>	B-X
Tumor	B-X
cells	B-X
regulate	B-X
the	B-X
lytic	B-X
activity	B-X
of	B-X
tumor	B-X
-	B-X
specific	B-X
cytotoxic	B-X
t	B-X
lymphocytes	B-X
by	B-X
modulating	B-X
the	B-X
inhibitory	B-X
natural	B-X
killer	B-X
receptor	B-X
function	B-X
.	B-X
<EOS>	B-X
Tumor	B-X
-	B-X
infiltrating	B-X
p58+	B-X
T	B-X
cells	B-X
from	B-X
a	B-X
renal	B-X
tumor	B-X
were	B-X
specifically	B-X
expanded	B-X
in	B-X
response	B-X
to	B-X
tumor	B-X
cell	B-X
stimulation	B-X
and	B-X
cloned	B-X
<EOS>	B-X
However	B-X
,	B-X
this	B-X
lytic	B-X
activity	B-X
was	B-X
significantly	B-X
increased	B-X
after	B-X
blockade	B-X
of	B-X
p58	B-X
with	B-X
specific	B-X
monoclonal	B-X
antibodies	B-X

T-cell	B-protein
factor-1	I-protein
expression	O
during	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cell	I-cell_type
development	O
and	O
in	O
circulating	O
CD56	B-protein
(	I-protein
+	I-protein
)	I-protein
bright	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
human	B-X
natural	B-X
killer	B-X
cell	B-X
development	B-X
and	B-X
in	B-X
circulating	B-X
CD56	B-X
(	B-X
+	B-X
)	B-X
bright	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
expression	B-X
in	B-X
fresh	B-X
and	B-X
cultured	B-X
adult	B-X
human	B-X
bone	B-X
marrow	B-X
and	B-X
umbilical	B-X
cord	B-X
blood	B-X
progenitors	B-X
was	B-X
evaluated	B-X
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
developmental	B-X
link	B-X
between	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
derived	B-X
from	B-X
progenitors	B-X
,	B-X
we	B-X
studied	B-X
NK	B-X
cell	B-X
subsets	B-X
circulating	B-X
in	B-X
blood	B-X
<EOS>	B-X
Culture	B-X
with	B-X
the	B-X
murine	B-X
fetal	B-X
liver	B-X
cell	B-X
line	B-X
AFT024	B-X
and	B-X
defined	B-X
cytokines	B-X
was	B-X
capable	B-X
of	B-X
inducing	B-X
TCF	B-X
-	B-X
1	B-X
mRNA	B-X

Transcription	B-protein
factors	I-protein
are	O
essential	O
to	O
govern	O
differentiation	O
along	O
the	O
lymphoid	B-cell_type
lineage	I-cell_type
from	O
uncommitted	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Transcription	B-X
factors	B-X
are	B-X
essential	B-X
to	B-X
govern	B-X
differentiation	B-X
along	B-X
the	B-X
lymphoid	B-X
lineage	B-X
from	B-X
uncommitted	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
<EOS>	B-X
Id	B-X
-	B-X
3	B-X
,	B-X
a	B-X
basic	B-X
helix	B-X
loop	B-X
helix	B-X
factor	B-X
with	B-X
dominant	B-X
negative	B-X
function	B-X
for	B-X
T	B-X
-	B-X
cell	B-X
differentiation	B-X
transcription	B-X
factors	B-X
,	B-X
also	B-X
was	B-X
upregulated	B-X
and	B-X
may	B-X
explain	B-X
unsuccessful	B-X
T	B-X
-	B-X
cell	B-X
maturation	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
expression	B-X
in	B-X
fresh	B-X
and	B-X
cultured	B-X
adult	B-X
human	B-X
bone	B-X
marrow	B-X
and	B-X
umbilical	B-X
cord	B-X
blood	B-X
progenitors	B-X
was	B-X
evaluated	B-X
<EOS>	B-X
Although	B-X
many	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
have	B-X
putative	B-X
roles	B-X
based	B-X
on	B-X
murine	B-X
knockout	B-X
experiments	B-X
,	B-X
their	B-X
function	B-X
in	B-X
human	B-X
lymphoid	B-X
development	B-X
is	B-X
less	B-X
known	B-X
and	B-X
was	B-X
studied	B-X
further	B-X

Although	O
many	O
of	O
these	O
transcription	B-protein
factors	I-protein
have	O
putative	O
roles	O
based	O
on	O
murine	O
knockout	O
experiments	O
,	O
their	O
function	O
in	O
human	O
lymphoid	O
development	O
is	O
less	O
known	O
and	O
was	O
studied	O
further	O
.	O
<EOS>	B-X
Although	B-X
many	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
have	B-X
putative	B-X
roles	B-X
based	B-X
on	B-X
murine	B-X
knockout	B-X
experiments	B-X
,	B-X
their	B-X
function	B-X
in	B-X
human	B-X
lymphoid	B-X
development	B-X
is	B-X
less	B-X
known	B-X
and	B-X
was	B-X
studied	B-X
further	B-X
<EOS>	B-X
Transcription	B-X
factors	B-X
are	B-X
essential	B-X
to	B-X
govern	B-X
differentiation	B-X
along	B-X
the	B-X
lymphoid	B-X
lineage	B-X
from	B-X
uncommitted	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
expression	B-X
in	B-X
fresh	B-X
and	B-X
cultured	B-X
adult	B-X
human	B-X
bone	B-X
marrow	B-X
and	B-X
umbilical	B-X
cord	B-X
blood	B-X
progenitors	B-X
was	B-X
evaluated	B-X
<EOS>	B-X
Culture	B-X
with	B-X
the	B-X
murine	B-X
fetal	B-X
liver	B-X
cell	B-X
line	B-X
AFT024	B-X
and	B-X
defined	B-X
cytokines	B-X
was	B-X
capable	B-X
of	B-X
inducing	B-X
TCF	B-X
-	B-X
1	B-X
mRNA	B-X

Transcription	O
factor	O
expression	O
in	O
fresh	O
and	O
cultured	O
adult	B-cell_type
human	I-cell_type
bone	I-cell_type
marrow	I-cell_type
and	I-cell_type
umbilical	I-cell_type
cord	I-cell_type
blood	I-cell_type
progenitors	I-cell_type
was	O
evaluated	O
.	O
<EOS>	B-X
Transcription	B-X
factor	B-X
expression	B-X
in	B-X
fresh	B-X
and	B-X
cultured	B-X
adult	B-X
human	B-X
bone	B-X
marrow	B-X
and	B-X
umbilical	B-X
cord	B-X
blood	B-X
progenitors	B-X
was	B-X
evaluated	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
human	B-X
natural	B-X
killer	B-X
cell	B-X
development	B-X
and	B-X
in	B-X
circulating	B-X
CD56	B-X
(	B-X
+	B-X
)	B-X
bright	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X
<EOS>	B-X
Transcription	B-X
factors	B-X
are	B-X
essential	B-X
to	B-X
govern	B-X
differentiation	B-X
along	B-X
the	B-X
lymphoid	B-X
lineage	B-X
from	B-X
uncommitted	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
<EOS>	B-X
Although	B-X
many	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
have	B-X
putative	B-X
roles	B-X
based	B-X
on	B-X
murine	B-X
knockout	B-X
experiments	B-X
,	B-X
their	B-X
function	B-X
in	B-X
human	B-X
lymphoid	B-X
development	B-X
is	B-X
less	B-X
known	B-X
and	B-X
was	B-X
studied	B-X
further	B-X

We	O
found	O
that	O
fresh	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
Lin	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
cells	I-cell_type
that	O
are	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
-DR	O
(	O
-	O
)	O
or	O
CD38	O
(	O
-	O
)	O
constitutively	O
express	O
GATA-3	B-protein
but	O
not	O
T-cell	B-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
or	O
Id-3	B-protein
.	O
<EOS>	B-X
Compound	B-X
15	B-X
could	B-X
prolong	B-X
the	B-X
latent	B-X
time	B-X
of	B-X
PTZ	B-X
-	B-X
induced	B-X
seizures	B-X
at	B-X
medium	B-X
and	B-X
high	B-X
doses	B-X
,	B-X
improve	B-X
the	B-X
anxiety	B-X
-	B-X
and	B-X
depression	B-X
-	B-X
like	B-X
behaviors	B-X
induced	B-X
by	B-X
PTZ	B-X
,	B-X
reduce	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
COX	B-X
-	B-X
2	B-X
,	B-X
and	B-X
decrease	B-X
the	B-X
number	B-X
of	B-X
COX	B-X
-	B-X
2	B-X
immuno	B-X
-	B-X
posi	B-X
-	B-X
tive	B-X
cells	B-X
in	B-X
the	B-X
hippocampal	B-X
CA1	B-X
region	B-X
<EOS>	B-X
The	B-X
use	B-X
of	B-X
a	B-X
reference	B-X
method	B-X
by	B-X
a	B-X
single	B-X
laboratory	B-X
is	B-X
one	B-X
of	B-X
the	B-X
options	B-X
for	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
candidate	B-X
CRM	B-X
according	B-X
to	B-X
ISO	B-X
17034	B-X
[	B-X
39	B-X
]	B-X
<EOS>	B-X
A	B-X
certified	B-X
reference	B-X
seawater	B-X
material	B-X
(	B-X
CRM	B-X
)	B-X
,	B-X
UME	B-X
CRM	B-X
1206	B-X
which	B-X
was	B-X
sampled	B-X
from	B-X
the	B-X
Marmara	B-X
Sea	B-X
(	B-X
40	B-X
31,423	B-X
N	B-X
;	B-X
027	B-X
11	B-X
,	B-X
333	B-X
E	B-X
)	B-X
with	B-X
27	B-X
psu	B-X
of	B-X
salinity	B-X
is	B-X
about	B-X
to	B-X
be	B-X
released	B-X
by	B-X
Inorganic	B-X
Analysis	B-X
Laboratory	B-X
of	B-X
TÜBİTAK	B-X
National	B-X
Metrology	B-X
Institute	B-X
(	B-X
UME	B-X
)	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
MR	B-X
features	B-X
of	B-X
the	B-X
traumatic	B-X
injury	B-X
of	B-X
the	B-X
triangular	B-X
fibrocartilage	B-X
complex	B-X
(	B-X
TFCC	B-X
)	B-X
by	B-X
using	B-X
high	B-X
-	B-X
resolution	B-X
3	B-X
-	B-X
T	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
and	B-X
to	B-X
refine	B-X
the	B-X
Palmer	B-X
classification	B-X
system	B-X

Culture	O
with	O
the	O
murine	B-cell_line
fetal	I-cell_line
liver	I-cell_line
cell	I-cell_line
line	I-cell_line
AFT024	I-cell_line
and	O
defined	O
cytokines	B-protein
was	O
capable	O
of	O
inducing	O
TCF-1	B-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
Culture	B-X
with	B-X
the	B-X
murine	B-X
fetal	B-X
liver	B-X
cell	B-X
line	B-X
AFT024	B-X
and	B-X
defined	B-X
cytokines	B-X
was	B-X
capable	B-X
of	B-X
inducing	B-X
TCF	B-X
-	B-X
1	B-X
mRNA	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
human	B-X
natural	B-X
killer	B-X
cell	B-X
development	B-X
and	B-X
in	B-X
circulating	B-X
CD56	B-X
(	B-X
+	B-X
)	B-X
bright	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
developmental	B-X
link	B-X
between	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
derived	B-X
from	B-X
progenitors	B-X
,	B-X
we	B-X
studied	B-X
NK	B-X
cell	B-X
subsets	B-X
circulating	B-X
in	B-X
blood	B-X
<EOS>	B-X
Id	B-X
-	B-X
3	B-X
,	B-X
a	B-X
basic	B-X
helix	B-X
loop	B-X
helix	B-X
factor	B-X
with	B-X
dominant	B-X
negative	B-X
function	B-X
for	B-X
T	B-X
-	B-X
cell	B-X
differentiation	B-X
transcription	B-X
factors	B-X
,	B-X
also	B-X
was	B-X
upregulated	B-X
and	B-X
may	B-X
explain	B-X
unsuccessful	B-X
T	B-X
-	B-X
cell	B-X
maturation	B-X

However	O
,	O
no	O
T-cell	B-DNA
receptor	I-DNA
gene	I-DNA
rearrangement	O
was	O
identified	O
in	O
cultured	O
progeny	O
.	O
<EOS>	B-X
However	B-X
,	B-X
no	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
gene	B-X
rearrangement	B-X
was	B-X
identified	B-X
in	B-X
cultured	B-X
progeny	B-X
<EOS>	B-X
Immunoglobulin	B-X
mu	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
beta	B-X
-	B-X
genes	B-X
in	B-X
the	B-X
leukemic	B-X
cells	B-X
were	B-X
in	B-X
germline	B-X
configuration	B-X
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
developmental	B-X
link	B-X
between	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
derived	B-X
from	B-X
progenitors	B-X
,	B-X
we	B-X
studied	B-X
NK	B-X
cell	B-X
subsets	B-X
circulating	B-X
in	B-X
blood	B-X
<EOS>	B-X
Transcription	B-X
factor	B-X
expression	B-X
in	B-X
fresh	B-X
and	B-X
cultured	B-X
adult	B-X
human	B-X
bone	B-X
marrow	B-X
and	B-X
umbilical	B-X
cord	B-X
blood	B-X
progenitors	B-X
was	B-X
evaluated	B-X

Id-3	B-protein
,	O
a	O
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
factor	I-protein
with	O
dominant	O
negative	O
function	O
for	O
T-cell	O
differentiation	O
transcription	B-protein
factors	I-protein
,	O
also	O
was	O
upregulated	O
and	O
may	O
explain	O
unsuccessful	O
T-cell	O
maturation	O
.	O
<EOS>	B-X
Id	B-X
-	B-X
3	B-X
,	B-X
a	B-X
basic	B-X
helix	B-X
loop	B-X
helix	B-X
factor	B-X
with	B-X
dominant	B-X
negative	B-X
function	B-X
for	B-X
T	B-X
-	B-X
cell	B-X
differentiation	B-X
transcription	B-X
factors	B-X
,	B-X
also	B-X
was	B-X
upregulated	B-X
and	B-X
may	B-X
explain	B-X
unsuccessful	B-X
T	B-X
-	B-X
cell	B-X
maturation	B-X
<EOS>	B-X
Transcription	B-X
factors	B-X
are	B-X
essential	B-X
to	B-X
govern	B-X
differentiation	B-X
along	B-X
the	B-X
lymphoid	B-X
lineage	B-X
from	B-X
uncommitted	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
human	B-X
natural	B-X
killer	B-X
cell	B-X
development	B-X
and	B-X
in	B-X
circulating	B-X
CD56	B-X
(	B-X
+	B-X
)	B-X
bright	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X
<EOS>	B-X
Culture	B-X
with	B-X
the	B-X
murine	B-X
fetal	B-X
liver	B-X
cell	B-X
line	B-X
AFT024	B-X
and	B-X
defined	B-X
cytokines	B-X
was	B-X
capable	B-X
of	B-X
inducing	B-X
TCF	B-X
-	B-X
1	B-X
mRNA	B-X

To	O
better	O
understand	O
the	O
developmental	O
link	O
between	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
derived	O
from	O
progenitors	B-cell_type
,	O
we	O
studied	O
NK	B-cell_type
cell	I-cell_type
subsets	I-cell_type
circulating	O
in	O
blood	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
developmental	B-X
link	B-X
between	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
derived	B-X
from	B-X
progenitors	B-X
,	B-X
we	B-X
studied	B-X
NK	B-X
cell	B-X
subsets	B-X
circulating	B-X
in	B-X
blood	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
human	B-X
natural	B-X
killer	B-X
cell	B-X
development	B-X
and	B-X
in	B-X
circulating	B-X
CD56	B-X
(	B-X
+	B-X
)	B-X
bright	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X
<EOS>	B-X
Culture	B-X
with	B-X
the	B-X
murine	B-X
fetal	B-X
liver	B-X
cell	B-X
line	B-X
AFT024	B-X
and	B-X
defined	B-X
cytokines	B-X
was	B-X
capable	B-X
of	B-X
inducing	B-X
TCF	B-X
-	B-X
1	B-X
mRNA	B-X
<EOS>	B-X
The	B-X
TCF	B-X
-	B-X
1	B-X
isoform	B-X
found	B-X
in	B-X
CD56	B-X
(	B-X
+bright	B-X
)	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
lectin	B-X
but	B-X
not	B-X
immunoglobulin	B-X
class	B-X
I	B-X
recognizing	B-X
inhibitory	B-X
receptors	B-X
,	B-X
was	B-X
identical	B-X
to	B-X
that	B-X
induced	B-X
in	B-X
NK	B-X
cell	B-X
differentiation	B-X
culture	B-X
and	B-X
was	B-X
distinctly	B-X
different	B-X
from	B-X
isoforms	B-X
in	B-X
T	B-X
cells	B-X

CD56	B-cell_type
(	I-cell_type
+bright	I-cell_type
)	I-cell_type
,	O
but	O
not	O
CD56	B-cell_type
(	I-cell_type
+dim	I-cell_type
)	I-cell_type
,	O
NK	B-cell_type
cells	I-cell_type
constitutively	O
express	O
TCF-1	B-protein
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
analysis	O
.	O

The	O
TCF-1	B-protein
isoform	I-protein
found	O
in	O
CD56	B-cell_type
(	I-cell_type
+bright	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
which	O
express	O
lectin	B-protein
but	O
not	O
immunoglobulin	B-protein
class	I-protein
I	I-protein
recognizing	O
inhibitory	B-protein
receptors	I-protein
,	O
was	O
identical	O
to	O
that	O
induced	O
in	O
NK	O
cell	O
differentiation	O
culture	O
and	O
was	O
distinctly	O
different	O
from	O
isoforms	O
in	O
T	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
TCF	B-X
-	B-X
1	B-X
isoform	B-X
found	B-X
in	B-X
CD56	B-X
(	B-X
+bright	B-X
)	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
lectin	B-X
but	B-X
not	B-X
immunoglobulin	B-X
class	B-X
I	B-X
recognizing	B-X
inhibitory	B-X
receptors	B-X
,	B-X
was	B-X
identical	B-X
to	B-X
that	B-X
induced	B-X
in	B-X
NK	B-X
cell	B-X
differentiation	B-X
culture	B-X
and	B-X
was	B-X
distinctly	B-X
different	B-X
from	B-X
isoforms	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
CD56	B-X
(	B-X
+bright	B-X
)	B-X
,	B-X
but	B-X
not	B-X
CD56	B-X
(	B-X
+dim	B-X
)	B-X
,	B-X
NK	B-X
cells	B-X
constitutively	B-X
express	B-X
TCF	B-X
-	B-X
1	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
and	B-X
Western	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
factor	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
human	B-X
natural	B-X
killer	B-X
cell	B-X
development	B-X
and	B-X
in	B-X
circulating	B-X
CD56	B-X
(	B-X
+	B-X
)	B-X
bright	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
the	B-X
developmental	B-X
link	B-X
between	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
derived	B-X
from	B-X
progenitors	B-X
,	B-X
we	B-X
studied	B-X
NK	B-X
cell	B-X
subsets	B-X
circulating	B-X
in	B-X
blood	B-X

These	O
results	O
suggest	O
that	O
TCF-1	B-protein
does	O
not	O
target	O
human	B-DNA
killer	I-DNA
immunoglobulin	I-DNA
receptor	I-DNA
genes	I-DNA
,	O
TCF-1	B-protein
is	O
uniquely	O
expressed	O
in	O
circulating	O
CD56	B-cell_type
(	I-cell_type
+bright	I-cell_type
)	I-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
and	O
specific	O
TCF-1	B-protein
isoforms	I-protein
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
NK	O
differentiation	O
from	O
a	O
common	O
NK/T-cell	B-cell_type
progenitor	I-cell_type
.	O
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
apoptosing	B-X
INS	B-X
-	B-X
1	B-X
cells	B-X
shed	B-X
microparticles	B-X
that	B-X
may	B-X
stimulate	B-X
PSP	B-X
/	B-X
reg	B-X
induction	B-X
in	B-X
neighboring	B-X
cells	B-X
,	B-X
a	B-X
mechanism	B-X
that	B-X
may	B-X
facilitate	B-X
the	B-X
recovery	B-X
of	B-X
β	B-X
-	B-X
cell	B-X
mass	B-X
in	B-X
HNF1A	B-X
-	B-X
MODY	B-X
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
NISCH	B-X
downregulation	B-X
may	B-X
protect	B-X
cells	B-X
against	B-X
oxidative	B-X
stress	B-X
-	B-X
induced	B-X
injury	B-X
through	B-X
regulating	B-X
the	B-X
transduction	B-X
of	B-X
Wnt	B-X
signaling	B-X
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
multipotency	B-X
of	B-X
progenitor	B-X
cells	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
cells	B-X
epigenetically	B-X
primed	B-X
for	B-X
distinct	B-X
downstream	B-X
lineages	B-X
,	B-X
which	B-X
are	B-X
regulated	B-X
by	B-X
key	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
EBV	B-X
infection	B-X
primes	B-X
PD	B-X
-	B-X
1	B-X
positive	B-X
CD8+	B-X
T	B-X
cell	B-X
populations	B-X
that	B-X
rely	B-X
on	B-X
this	B-X
receptor	B-X
axis	B-X
for	B-X
the	B-X
efficient	B-X
immune	B-X
control	B-X
of	B-X
this	B-X
ubiquitous	B-X
human	B-X
tumor	B-X
virus	B-X

Transcriptional	O
activation	O
by	O
a	O
matrix	B-protein
associating	I-protein
region-binding	I-protein
protein	I-protein
.	O
<EOS>	B-X
Post	B-X
-	B-X
translational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
are	B-X
important	B-X
regulators	B-X
of	B-X
functional	B-X
activities	B-X
of	B-X
proteins	B-X
<EOS>	B-X
Satb2	B-X
is	B-X
critical	B-X
for	B-X
osteoblast	B-X
differentiation	B-X
as	B-X
a	B-X
special	B-X
AT	B-X
-	B-X
rich	B-X
binding	B-X
transcription	B-X
factor	B-X
<EOS>	B-X
Since	B-X
CDP	B-X
is	B-X
known	B-X
as	B-X
a	B-X
transcription	B-X
repressor	B-X
and	B-X
a	B-X
nuclear	B-X
matrix	B-X
-	B-X
associated	B-X
region	B-X
binding	B-X
protein	B-X
,	B-X
CDP	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
human	B-X
CMV	B-X
transcription	B-X
<EOS>	B-X
Osteoblast	B-X
-	B-X
specific	B-X
transcription	B-X
factor	B-X
Osterix	B-X
(	B-X
Osx	B-X
)	B-X
is	B-X
an	B-X
upstream	B-X
regulator	B-X
of	B-X
Satb2	B-X
during	B-X
bone	B-X
formation	B-X
.	B-X

contextual	O
requirements	O
for	O
the	O
function	O
of	O
bright	B-protein
.	O
<EOS>	B-X
Transcriptional	B-X
activation	B-X
by	B-X
a	B-X
matrix	B-X
associating	B-X
region	B-X
-	B-X
binding	B-X
protein	B-X
.	B-X
contextual	B-X
requirements	B-X
for	B-X
the	B-X
function	B-X
of	B-X
bright	B-X
.	B-X
<EOS>	B-X
Contextual	B-X
processing	B-X
of	B-X
brightness	B-X
and	B-X
color	B-X
in	B-X
Mongolian	B-X
gerbils	B-X
.	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
Bright	B-X
has	B-X
multiple	B-X
contextual	B-X
requirements	B-X
to	B-X
function	B-X
as	B-X
a	B-X
transcriptional	B-X
activator	B-X
<EOS>	B-X
Neural	B-X
mechanisms	B-X
of	B-X
contextual	B-X
modulation	B-X
in	B-X
the	B-X
retinal	B-X
direction	B-X
selective	B-X
circuit	B-X
.	B-X

Bright	B-protein
(	O
B	B-protein
cell	I-protein
regulator	I-protein
of	I-protein
IgH	I-protein
transcription	I-protein
)	O
is	O
a	O
B	B-cell_type
cell	I-cell_type
-specific	O
,	O
matrix	B-protein
associating	I-protein
region-binding	I-protein
protein	I-protein
that	O
transactivates	O
gene	O
expression	O
from	O
the	O
IgH	B-DNA
intronic	I-DNA
enhancer	I-DNA
(	O
E	B-DNA
mu	I-DNA
)	O
.	O

We	O
show	O
here	O
that	O
Bright	B-protein
has	O
multiple	O
contextual	O
requirements	O
to	O
function	O
as	O
a	O
transcriptional	B-protein
activator	I-protein
.	O
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
Bright	B-X
has	B-X
multiple	B-X
contextual	B-X
requirements	B-X
to	B-X
function	B-X
as	B-X
a	B-X
transcriptional	B-X
activator	B-X
<EOS>	B-X
These	B-X
data	B-X
further	B-X
suggest	B-X
that	B-X
Bright	B-X
may	B-X
contribute	B-X
to	B-X
increased	B-X
gene	B-X
expression	B-X
by	B-X
remodeling	B-X
the	B-X
immunoglobulin	B-X
locus	B-X
during	B-X
B	B-X
cell	B-X
development	B-X
<EOS>	B-X
Transfection	B-X
studies	B-X
further	B-X
implicate	B-X
Bright	B-X
in	B-X
facilitating	B-X
spatially	B-X
separated	B-X
promoter	B-X
-	B-X
enhancer	B-X
interactions	B-X
in	B-X
both	B-X
transient	B-X
and	B-X
stable	B-X
assays	B-X
<EOS>	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
Bright	B-X
leads	B-X
to	B-X
enhanced	B-X
DNase	B-X
I	B-X
sensitivity	B-X
of	B-X
the	B-X
endogenous	B-X
E	B-X
mu	B-X
matrix	B-X
associating	B-X
regions	B-X

Bright	B-protein
can	O
not	O
transactivate	O
via	O
out	O
of	O
context	O
,	O
concatenated	B-protein
binding	I-protein
sites	I-protein
.	O
<EOS>	B-X
Carbon	B-X
Quantum	B-X
Dots	B-X
with	B-X
Near	B-X
-	B-X
Unity	B-X
Quantum	B-X
Yield	B-X
Bandgap	B-X
Emission	B-X
for	B-X
Electroluminescent	B-X
Light	B-X
-	B-X
Emitting	B-X
Diodes	B-X
.	B-X
<EOS>	B-X
Perovskite	B-X
light	B-X
-	B-X
emitting	B-X
diodes	B-X
(	B-X
LEDs	B-X
)	B-X
have	B-X
attracted	B-X
broad	B-X
attention	B-X
due	B-X
to	B-X
their	B-X
rapidly	B-X
increasing	B-X
external	B-X
quantum	B-X
efficiencies	B-X
(	B-X
EQEs	B-X
)	B-X
<EOS>	B-X
The	B-X
use	B-X
and	B-X
reporting	B-X
of	B-X
a	B-X
detailed	B-X
SOP	B-X
can	B-X
significantly	B-X
reduce	B-X
the	B-X
potential	B-X
for	B-X
such	B-X
inconsistencies	B-X
<EOS>	B-X
There	B-X
are	B-X
many	B-X
more	B-X
targeted	B-X
treatments	B-X
that	B-X
will	B-X
undergo	B-X
trials	B-X
in	B-X
FXS	B-X
,	B-X
so	B-X
the	B-X
future	B-X
looks	B-X
bright	B-X
for	B-X
new	B-X
treatments	B-X

Transactivation	O
is	O
maximal	O
on	O
integrated	O
substrates	O
.	O
<EOS>	B-X
Transactivation	B-X
is	B-X
maximal	B-X
on	B-X
integrated	B-X
substrates	B-X
<EOS>	B-X
Bright	B-X
can	B-X
not	B-X
transactivate	B-X
via	B-X
out	B-X
of	B-X
context	B-X
,	B-X
concatenated	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Transcriptional	B-X
activation	B-X
by	B-X
a	B-X
matrix	B-X
associating	B-X
region	B-X
-	B-X
binding	B-X
protein	B-X
.	B-X
contextual	B-X
requirements	B-X
for	B-X
the	B-X
function	B-X
of	B-X
bright	B-X
.	B-X
<EOS>	B-X
The	B-X
potential	B-X
of	B-X
this	B-X
metabolic	B-X
and	B-X
engineering	B-X
integrated	B-X
approach	B-X
was	B-X
proven	B-X
in	B-X
fed	B-X
-	B-X
batch	B-X
cultivation	B-X
experiments	B-X
using	B-X
E	B-X

Two	O
of	O
the	O
three	O
previously	O
identified	O
binding	B-DNA
sites	I-DNA
in	O
E	B-DNA
mu	I-DNA
are	O
required	O
for	O
full	O
Bright	B-protein
transactivation	O
.	O

The	O
Bright	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
defined	O
a	O
new	O
family	O
,	O
which	O
includes	O
SWI1	B-protein
,	O
a	O
component	O
of	O
the	O
SWI.SNF	B-protein
complex	I-protein
shown	O
to	O
have	O
high	O
mobility	O
group-like	O
DNA	O
binding	O
characteristics	O
.	O
<EOS>	B-X
The	B-X
Bright	B-X
DNA	B-X
binding	B-X
domain	B-X
defined	B-X
a	B-X
new	B-X
family	B-X
,	B-X
which	B-X
includes	B-X
SWI1	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
SWI	B-X
<EOS>	B-X
SNF	B-X
complex	B-X
shown	B-X
to	B-X
have	B-X
high	B-X
mobility	B-X
group	B-X
-	B-X
like	B-X
DNA	B-X
binding	B-X
characteristics	B-X
<EOS>	B-X
Bright	B-X
can	B-X
not	B-X
transactivate	B-X
via	B-X
out	B-X
of	B-X
context	B-X
,	B-X
concatenated	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
overexpression	B-X
of	B-X
Bright	B-X
leads	B-X
to	B-X
enhanced	B-X
DNase	B-X
I	B-X
sensitivity	B-X
of	B-X
the	B-X
endogenous	B-X
E	B-X
mu	B-X
matrix	B-X
associating	B-X
regions	B-X

Similar	O
to	O
one	O
group	O
of	O
high	B-protein
mobility	I-protein
group	I-protein
box	I-protein
proteins	I-protein
,	O
Bright	B-protein
distorts	O
E	B-DNA
mu	I-DNA
binding	I-DNA
site	I-DNA
-containing	O
DNA	O
on	O
binding	O
,	O
supporting	O
the	O
concept	O
that	O
it	O
mediates	O
E	B-DNA
mu	I-DNA
remodeling	O
.	O

Transfection	O
studies	O
further	O
implicate	O
Bright	B-protein
in	O
facilitating	O
spatially	O
separated	O
promoter-enhancer	O
interactions	O
in	O
both	O
transient	O
and	O
stable	O
assays	O
.	O
<EOS>	B-X
Transfection	B-X
studies	B-X
further	B-X
implicate	B-X
Bright	B-X
in	B-X
facilitating	B-X
spatially	B-X
separated	B-X
promoter	B-X
-	B-X
enhancer	B-X
interactions	B-X
in	B-X
both	B-X
transient	B-X
and	B-X
stable	B-X
assays	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
Bright	B-X
has	B-X
multiple	B-X
contextual	B-X
requirements	B-X
to	B-X
function	B-X
as	B-X
a	B-X
transcriptional	B-X
activator	B-X
<EOS>	B-X
Transcriptional	B-X
activation	B-X
by	B-X
a	B-X
matrix	B-X
associating	B-X
region	B-X
-	B-X
binding	B-X
protein	B-X
.	B-X
contextual	B-X
requirements	B-X
for	B-X
the	B-X
function	B-X
of	B-X
bright	B-X
.	B-X
<EOS>	B-X
Two	B-X
of	B-X
the	B-X
three	B-X
previously	B-X
identified	B-X
binding	B-X
sites	B-X
in	B-X
E	B-X
mu	B-X
are	B-X
required	B-X
for	B-X
full	B-X
Bright	B-X
transactivation	B-X

Finally	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
Bright	B-protein
leads	O
to	O
enhanced	O
DNase	O
I	O
sensitivity	O
of	O
the	O
endogenous	O
E	B-DNA
mu	I-DNA
matrix	O
associating	O
regions	O
.	O

These	O
data	O
further	O
suggest	O
that	O
Bright	B-protein
may	O
contribute	O
to	O
increased	O
gene	O
expression	O
by	O
remodeling	O
the	O
immunoglobulin	B-DNA
locus	I-DNA
during	O
B	B-cell_type
cell	I-cell_type
development	O
.	O

Analysis	O
of	O
BCL-6	O
mutations	O
in	O
classic	O
Hodgkin	O
disease	O
of	O
the	O
B-	B-cell_type
and	I-cell_type
T-cell	I-cell_type
type	I-cell_type
.	O

BCL-6	B-DNA
is	O
essential	O
for	O
germinal	O
center	O
formation	O
and	O
thus	O
for	O
affinity	O
maturation	O
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
genes	I-DNA
by	O
somatic	O
mutations	O
.	O
<EOS>	B-X
BCL	B-X
-	B-X
6	B-X
is	B-X
essential	B-X
for	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
thus	B-X
for	B-X
affinity	B-X
maturation	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
genes	B-X
by	B-X
somatic	B-X
mutations	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
both	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
derived	B-X
HD	B-X
cases	B-X
and	B-X
cell	B-X
lines	B-X
were	B-X
devoid	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
Classic	B-X
Hodgkin	B-X
disease	B-X
(	B-X
cHD	B-X
)	B-X
is	B-X
also	B-X
derived	B-X
from	B-X
B	B-X
cells	B-X
with	B-X
high	B-X
loads	B-X
of	B-X
somatic	B-X
mutations	B-X
and	B-X
thus	B-X
a	B-X
further	B-X
candidate	B-X
for	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
(	B-X
1	B-X
)	B-X
somatic	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
are	B-X
restricted	B-X
to	B-X
cHD	B-X
cases	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
origin	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
represent	B-X
mostly	B-X
irrelevant	B-X
somatic	B-X
base	B-X
substitutions	B-X
without	B-X
consequences	B-X
for	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
expression	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
cHD	B-X

The	O
5'-noncoding	B-DNA
region	I-DNA
of	O
the	O
BCL-6	B-DNA
gene	I-DNA
is	O
even	O
a	O
target	O
for	O
the	O
mutation	O
machinery	O
.	O

Translocations	O
of	O
the	O
BCL-6	B-DNA
gene	I-DNA
to	O
heterologous	B-DNA
promoters	I-DNA
and	O
mutations	O
of	O
its	O
5'-noncoding	B-DNA
regulatory	I-DNA
region	I-DNA
were	O
reported	O
to	O
be	O
potential	O
mechanisms	O
for	O
deregulating	O
BCL-6	B-DNA
expression	O
and	O
for	O
playing	O
a	O
role	O
in	O
the	O
genesis	O
of	O
non-Hodgkin	O
lymphoma	O
.	O
<EOS>	B-X
Translocations	B-X
of	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
gene	B-X
to	B-X
heterologous	B-X
promoters	B-X
and	B-X
mutations	B-X
of	B-X
its	B-X
5'	B-X
-	B-X
noncoding	B-X
regulatory	B-X
region	B-X
were	B-X
reported	B-X
to	B-X
be	B-X
potential	B-X
mechanisms	B-X
for	B-X
deregulating	B-X
BCL	B-X
-	B-X
6	B-X
expression	B-X
and	B-X
for	B-X
playing	B-X
a	B-X
role	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
non	B-X
-	B-X
Hodgkin	B-X
lymphoma	B-X
<EOS>	B-X
With	B-X
only	B-X
one	B-X
exception	B-X
,	B-X
there	B-X
were	B-X
no	B-X
lymphoma	B-X
-	B-X
specific	B-X
recurrent	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
detected	B-X
,	B-X
and	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
was	B-X
absent	B-X
from	B-X
the	B-X
HRS	B-X
cells	B-X
of	B-X
most	B-X
cases	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
presence	B-X
and	B-X
potential	B-X
role	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
in	B-X
cHD	B-X
,	B-X
the	B-X
5'	B-X
-	B-X
noncoding	B-X
BCL	B-X
-	B-X
6	B-X
proportion	B-X
of	B-X
single	B-X
Hodgkin	B-X
and	B-X
Reed	B-X
-	B-X
Sternberg	B-X
(	B-X
HRS	B-X
)	B-X
cells	B-X
from	B-X
6	B-X
cases	B-X
of	B-X
cHD	B-X
and	B-X
6	B-X
cases	B-X
of	B-X
HD	B-X
-	B-X
derived	B-X
cell	B-X
lines	B-X
was	B-X
analyzed	B-X
<EOS>	B-X
BCL	B-X
-	B-X
6	B-X
is	B-X
essential	B-X
for	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
thus	B-X
for	B-X
affinity	B-X
maturation	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
genes	B-X
by	B-X
somatic	B-X
mutations	B-X

In	O
line	O
with	O
this	O
hypothesis	O
is	O
the	O
observation	O
that	O
B-cell	O
lymphoma	O
with	O
somatic	O
mutations	O
,	O
such	O
as	O
diffuse	O
large	O
B-cell	O
lymphoma	O
and	O
follicular	O
lymphoma	O
,	O
also	O
carry	O
BCL-6	O
mutations	O
,	O
some	O
of	O
which	O
are	O
recurrently	O
detectable	O
.	O
<EOS>	B-X
In	B-X
line	B-X
with	B-X
this	B-X
hypothesis	B-X
is	B-X
the	B-X
observation	B-X
that	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
with	B-X
somatic	B-X
mutations	B-X
,	B-X
such	B-X
as	B-X
diffuse	B-X
large	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
and	B-X
follicular	B-X
lymphoma	B-X
,	B-X
also	B-X
carry	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
,	B-X
some	B-X
of	B-X
which	B-X
are	B-X
recurrently	B-X
detectable	B-X
<EOS>	B-X
Classic	B-X
Hodgkin	B-X
disease	B-X
(	B-X
cHD	B-X
)	B-X
is	B-X
also	B-X
derived	B-X
from	B-X
B	B-X
cells	B-X
with	B-X
high	B-X
loads	B-X
of	B-X
somatic	B-X
mutations	B-X
and	B-X
thus	B-X
a	B-X
further	B-X
candidate	B-X
for	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
With	B-X
only	B-X
one	B-X
exception	B-X
,	B-X
there	B-X
were	B-X
no	B-X
lymphoma	B-X
-	B-X
specific	B-X
recurrent	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
detected	B-X
,	B-X
and	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
was	B-X
absent	B-X
from	B-X
the	B-X
HRS	B-X
cells	B-X
of	B-X
most	B-X
cases	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
(	B-X
1	B-X
)	B-X
somatic	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
are	B-X
restricted	B-X
to	B-X
cHD	B-X
cases	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
origin	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
represent	B-X
mostly	B-X
irrelevant	B-X
somatic	B-X
base	B-X
substitutions	B-X
without	B-X
consequences	B-X
for	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
expression	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
cHD	B-X

Classic	O
Hodgkin	O
disease	O
(	O
cHD	O
)	O
is	O
also	O
derived	O
from	O
B	B-cell_type
cells	I-cell_type
with	O
high	O
loads	O
of	O
somatic	O
mutations	O
and	O
thus	O
a	O
further	O
candidate	O
for	O
BCL-6	O
mutations	O
.	O

To	O
determine	O
the	O
presence	O
and	O
potential	O
role	O
of	O
BCL-6	O
mutations	O
in	O
cHD	O
,	O
the	O
5'-noncoding	B-DNA
BCL-6	I-DNA
proportion	O
of	O
single	B-cell_type
Hodgkin	I-cell_type
and	I-cell_type
Reed-Sternberg	I-cell_type
(	I-cell_type
HRS	I-cell_type
)	I-cell_type
cells	I-cell_type
from	O
6	O
cases	O
of	O
cHD	O
and	O
6	O
cases	O
of	O
HD-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
analyzed	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
presence	B-X
and	B-X
potential	B-X
role	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
in	B-X
cHD	B-X
,	B-X
the	B-X
5'	B-X
-	B-X
noncoding	B-X
BCL	B-X
-	B-X
6	B-X
proportion	B-X
of	B-X
single	B-X
Hodgkin	B-X
and	B-X
Reed	B-X
-	B-X
Sternberg	B-X
(	B-X
HRS	B-X
)	B-X
cells	B-X
from	B-X
6	B-X
cases	B-X
of	B-X
cHD	B-X
and	B-X
6	B-X
cases	B-X
of	B-X
HD	B-X
-	B-X
derived	B-X
cell	B-X
lines	B-X
was	B-X
analyzed	B-X
<EOS>	B-X
With	B-X
only	B-X
one	B-X
exception	B-X
,	B-X
there	B-X
were	B-X
no	B-X
lymphoma	B-X
-	B-X
specific	B-X
recurrent	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
detected	B-X
,	B-X
and	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
was	B-X
absent	B-X
from	B-X
the	B-X
HRS	B-X
cells	B-X
of	B-X
most	B-X
cases	B-X
<EOS>	B-X
Translocations	B-X
of	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
gene	B-X
to	B-X
heterologous	B-X
promoters	B-X
and	B-X
mutations	B-X
of	B-X
its	B-X
5'	B-X
-	B-X
noncoding	B-X
regulatory	B-X
region	B-X
were	B-X
reported	B-X
to	B-X
be	B-X
potential	B-X
mechanisms	B-X
for	B-X
deregulating	B-X
BCL	B-X
-	B-X
6	B-X
expression	B-X
and	B-X
for	B-X
playing	B-X
a	B-X
role	B-X
in	B-X
the	B-X
genesis	B-X
of	B-X
non	B-X
-	B-X
Hodgkin	B-X
lymphoma	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
in	B-X
classic	B-X
Hodgkin	B-X
disease	B-X
of	B-X
the	B-X
B	B-X
-	B-X
	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
type	B-X
.	B-X

All	O
B-cell-derived	O
HD	O
cases	O
and	O
cell	O
lines	O
harbored	O
BCL-6	O
mutations	O
.	O
<EOS>	B-X
All	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
derived	B-X
HD	B-X
cases	B-X
and	B-X
cell	B-X
lines	B-X
harbored	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
both	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
derived	B-X
HD	B-X
cases	B-X
and	B-X
cell	B-X
lines	B-X
were	B-X
devoid	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
Classic	B-X
Hodgkin	B-X
disease	B-X
(	B-X
cHD	B-X
)	B-X
is	B-X
also	B-X
derived	B-X
from	B-X
B	B-X
cells	B-X
with	B-X
high	B-X
loads	B-X
of	B-X
somatic	B-X
mutations	B-X
and	B-X
thus	B-X
a	B-X
further	B-X
candidate	B-X
for	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
The	B-X
5'	B-X
-	B-X
noncoding	B-X
region	B-X
of	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
gene	B-X
is	B-X
even	B-X
a	B-X
target	B-X
for	B-X
the	B-X
mutation	B-X
machinery	B-X

In	O
contrast	O
,	O
both	O
T-cell-derived	O
HD	O
cases	O
and	O
cell	O
lines	O
were	O
devoid	O
of	O
BCL-6	O
mutations	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
both	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
derived	B-X
HD	B-X
cases	B-X
and	B-X
cell	B-X
lines	B-X
were	B-X
devoid	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
All	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
derived	B-X
HD	B-X
cases	B-X
and	B-X
cell	B-X
lines	B-X
harbored	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
Classic	B-X
Hodgkin	B-X
disease	B-X
(	B-X
cHD	B-X
)	B-X
is	B-X
also	B-X
derived	B-X
from	B-X
B	B-X
cells	B-X
with	B-X
high	B-X
loads	B-X
of	B-X
somatic	B-X
mutations	B-X
and	B-X
thus	B-X
a	B-X
further	B-X
candidate	B-X
for	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
<EOS>	B-X
In	B-X
line	B-X
with	B-X
this	B-X
hypothesis	B-X
is	B-X
the	B-X
observation	B-X
that	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
with	B-X
somatic	B-X
mutations	B-X
,	B-X
such	B-X
as	B-X
diffuse	B-X
large	B-X
B	B-X
-	B-X
cell	B-X
lymphoma	B-X
and	B-X
follicular	B-X
lymphoma	B-X
,	B-X
also	B-X
carry	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
,	B-X
some	B-X
of	B-X
which	B-X
are	B-X
recurrently	B-X
detectable	B-X

With	O
only	O
one	O
exception	O
,	O
there	O
were	O
no	O
lymphoma-specific	O
recurrent	O
BCL-6	O
mutations	O
detected	O
,	O
and	O
BCL-6	B-protein
protein	I-protein
was	O
absent	O
from	O
the	O
HRS	B-cell_type
cells	I-cell_type
of	O
most	O
cases	O
.	O
<EOS>	B-X
With	B-X
only	B-X
one	B-X
exception	B-X
,	B-X
there	B-X
were	B-X
no	B-X
lymphoma	B-X
-	B-X
specific	B-X
recurrent	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
detected	B-X
,	B-X
and	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
was	B-X
absent	B-X
from	B-X
the	B-X
HRS	B-X
cells	B-X
of	B-X
most	B-X
cases	B-X
<EOS>	B-X
The	B-X
5'	B-X
-	B-X
noncoding	B-X
region	B-X
of	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
gene	B-X
is	B-X
even	B-X
a	B-X
target	B-X
for	B-X
the	B-X
mutation	B-X
machinery	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
(	B-X
1	B-X
)	B-X
somatic	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
are	B-X
restricted	B-X
to	B-X
cHD	B-X
cases	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
origin	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
the	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
represent	B-X
mostly	B-X
irrelevant	B-X
somatic	B-X
base	B-X
substitutions	B-X
without	B-X
consequences	B-X
for	B-X
BCL	B-X
-	B-X
6	B-X
protein	B-X
expression	B-X
and	B-X
the	B-X
pathogenesis	B-X
of	B-X
cHD	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
presence	B-X
and	B-X
potential	B-X
role	B-X
of	B-X
BCL	B-X
-	B-X
6	B-X
mutations	B-X
in	B-X
cHD	B-X
,	B-X
the	B-X
5'	B-X
-	B-X
noncoding	B-X
BCL	B-X
-	B-X
6	B-X
proportion	B-X
of	B-X
single	B-X
Hodgkin	B-X
and	B-X
Reed	B-X
-	B-X
Sternberg	B-X
(	B-X
HRS	B-X
)	B-X
cells	B-X
from	B-X
6	B-X
cases	B-X
of	B-X
cHD	B-X
and	B-X
6	B-X
cases	B-X
of	B-X
HD	B-X
-	B-X
derived	B-X
cell	B-X
lines	B-X
was	B-X
analyzed	B-X

In	O
conclusion	O
,	O
(	O
1	O
)	O
somatic	O
BCL-6	O
mutations	O
are	O
restricted	O
to	O
cHD	O
cases	O
of	O
B-cell	B-cell_type
origin	O
,	O
and	O
(	O
2	O
)	O
the	O
BCL-6	O
mutations	O
represent	O
mostly	O
irrelevant	O
somatic	O
base	O
substitutions	O
without	O
consequences	O
for	O
BCL-6	B-protein
protein	I-protein
expression	O
and	O
the	O
pathogenesis	O
of	O
cHD	O
.	O

Gadd45gamma	B-DNA
is	O
dispensable	O
for	O
normal	O
mouse	O
development	O
and	O
T-cell	O
proliferation	O
.	O
<EOS>	B-X
Gadd45gamma	B-X
is	B-X
dispensable	B-X
for	B-X
normal	B-X
mouse	B-X
development	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
Gadd45gamma	B-X
is	B-X
also	B-X
dispensable	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
induced	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
Gadd45gamma	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
normal	B-X
mouse	B-X
development	B-X
and	B-X
hematopoiesis	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
functional	B-X
redundancy	B-X
among	B-X
the	B-X
Gadd45	B-X
family	B-X
members	B-X
<EOS>	B-X
Gadd45gamma	B-X
-	B-X
deficient	B-X
mice	B-X
develop	B-X
normally	B-X
,	B-X
are	B-X
indistinguishable	B-X
from	B-X
their	B-X
littermates	B-X
,	B-X
and	B-X
are	B-X
fertile	B-X

Gadd45gamma	B-DNA
,	O
a	O
family	O
member	O
of	O
the	O
growth	B-DNA
arrest	I-DNA
and	I-DNA
DNA	I-DNA
damage-inducible	I-DNA
gene	I-DNA
family	I-DNA
45	I-DNA
(	O
Gadd45	B-DNA
)	O
,	O
is	O
strongly	O
induced	O
by	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Gadd45gamma	B-X
,	B-X
a	B-X
family	B-X
member	B-X
of	B-X
the	B-X
growth	B-X
arrest	B-X
and	B-X
DNA	B-X
damage	B-X
-	B-X
inducible	B-X
gene	B-X
family	B-X
45	B-X
(	B-X
Gadd45	B-X
)	B-X
,	B-X
is	B-X
strongly	B-X
induced	B-X
by	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X
<EOS>	B-X
Gadd45gamma	B-X
-	B-X
deficient	B-X
mice	B-X
develop	B-X
normally	B-X
,	B-X
are	B-X
indistinguishable	B-X
from	B-X
their	B-X
littermates	B-X
,	B-X
and	B-X
are	B-X
fertile	B-X
<EOS>	B-X
Gadd45gamma	B-X
is	B-X
dispensable	B-X
for	B-X
normal	B-X
mouse	B-X
development	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
While	B-X
in	B-X
most	B-X
tissues	B-X
all	B-X
Gadd45	B-X
family	B-X
members	B-X
are	B-X
expressed	B-X
,	B-X
Gadd45gamma	B-X
is	B-X
the	B-X
only	B-X
member	B-X
that	B-X
is	B-X
induced	B-X
by	B-X
IL	B-X
-	B-X
2	B-X

While	O
in	O
most	O
tissues	O
all	O
Gadd45	B-DNA
family	I-DNA
members	I-DNA
are	O
expressed	O
,	O
Gadd45gamma	B-DNA
is	O
the	O
only	O
member	O
that	O
is	O
induced	O
by	O
IL-2	B-protein
.	O
<EOS>	B-X
While	B-X
in	B-X
most	B-X
tissues	B-X
all	B-X
Gadd45	B-X
family	B-X
members	B-X
are	B-X
expressed	B-X
,	B-X
Gadd45gamma	B-X
is	B-X
the	B-X
only	B-X
member	B-X
that	B-X
is	B-X
induced	B-X
by	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
hematopoiesis	B-X
in	B-X
mice	B-X
lacking	B-X
Gadd45gamma	B-X
is	B-X
not	B-X
impaired	B-X
and	B-X
Gadd45gamma	B-X
-	B-X
deficient	B-X
T	B-X
lymphocytes	B-X
show	B-X
normal	B-X
responses	B-X
to	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
with	B-X
ectopically	B-X
overexpressed	B-X
Gadd45gamma	B-X
in	B-X
various	B-X
cell	B-X
lines	B-X
implicated	B-X
its	B-X
function	B-X
in	B-X
negative	B-X
growth	B-X
control	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
Gadd45gamma	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
normal	B-X
mouse	B-X
development	B-X
and	B-X
hematopoiesis	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
functional	B-X
redundancy	B-X
among	B-X
the	B-X
Gadd45	B-X
family	B-X
members	B-X

Here	O
we	O
show	O
that	O
the	O
IL-2	B-protein
-induced	O
expression	O
of	O
Gadd45gamma	B-DNA
is	O
dependent	O
on	O
a	O
signaling	O
pathway	O
mediated	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
Jak3	I-protein
and	O
the	O
transcription	B-protein
factors	I-protein
Stat5a	B-protein
and	O
Stat5b	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
Gadd45gamma	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
signaling	B-X
pathway	B-X
mediated	B-X
by	B-X
the	B-X
tyrosine	B-X
kinase	B-X
Jak3	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
Stat5a	B-X
and	B-X
Stat5b	B-X
(	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
)	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
Gadd45gamma	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
normal	B-X
mouse	B-X
development	B-X
and	B-X
hematopoiesis	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
functional	B-X
redundancy	B-X
among	B-X
the	B-X
Gadd45	B-X
family	B-X
members	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
with	B-X
ectopically	B-X
overexpressed	B-X
Gadd45gamma	B-X
in	B-X
various	B-X
cell	B-X
lines	B-X
implicated	B-X
its	B-X
function	B-X
in	B-X
negative	B-X
growth	B-X
control	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
hematopoiesis	B-X
in	B-X
mice	B-X
lacking	B-X
Gadd45gamma	B-X
is	B-X
not	B-X
impaired	B-X
and	B-X
Gadd45gamma	B-X
-	B-X
deficient	B-X
T	B-X
lymphocytes	B-X
show	B-X
normal	B-X
responses	B-X
to	B-X
IL	B-X
-	B-X
2	B-X

Previous	O
studies	O
with	O
ectopically	O
overexpressed	O
Gadd45gamma	B-DNA
in	O
various	O
cell	O
lines	O
implicated	O
its	O
function	O
in	O
negative	O
growth	O
control	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
with	B-X
ectopically	B-X
overexpressed	B-X
Gadd45gamma	B-X
in	B-X
various	B-X
cell	B-X
lines	B-X
implicated	B-X
its	B-X
function	B-X
in	B-X
negative	B-X
growth	B-X
control	B-X
<EOS>	B-X
While	B-X
in	B-X
most	B-X
tissues	B-X
all	B-X
Gadd45	B-X
family	B-X
members	B-X
are	B-X
expressed	B-X
,	B-X
Gadd45gamma	B-X
is	B-X
the	B-X
only	B-X
member	B-X
that	B-X
is	B-X
induced	B-X
by	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
To	B-X
analyze	B-X
the	B-X
physiological	B-X
role	B-X
of	B-X
Gadd45gamma	B-X
we	B-X
used	B-X
homologous	B-X
recombination	B-X
to	B-X
generate	B-X
mice	B-X
lacking	B-X
Gadd45gamma	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
Gadd45gamma	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
signaling	B-X
pathway	B-X
mediated	B-X
by	B-X
the	B-X
tyrosine	B-X
kinase	B-X
Jak3	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
Stat5a	B-X
and	B-X
Stat5b	B-X
(	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
)	B-X

To	O
analyze	O
the	O
physiological	O
role	O
of	O
Gadd45gamma	B-DNA
we	O
used	O
homologous	O
recombination	O
to	O
generate	O
mice	O
lacking	O
Gadd45gamma	B-DNA
.	O
<EOS>	B-X
To	B-X
analyze	B-X
the	B-X
physiological	B-X
role	B-X
of	B-X
Gadd45gamma	B-X
we	B-X
used	B-X
homologous	B-X
recombination	B-X
to	B-X
generate	B-X
mice	B-X
lacking	B-X
Gadd45gamma	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
Gadd45gamma	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
normal	B-X
mouse	B-X
development	B-X
and	B-X
hematopoiesis	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
functional	B-X
redundancy	B-X
among	B-X
the	B-X
Gadd45	B-X
family	B-X
members	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
with	B-X
ectopically	B-X
overexpressed	B-X
Gadd45gamma	B-X
in	B-X
various	B-X
cell	B-X
lines	B-X
implicated	B-X
its	B-X
function	B-X
in	B-X
negative	B-X
growth	B-X
control	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
Gadd45gamma	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
signaling	B-X
pathway	B-X
mediated	B-X
by	B-X
the	B-X
tyrosine	B-X
kinase	B-X
Jak3	B-X
and	B-X
the	B-X
transcription	B-X
factors	B-X
Stat5a	B-X
and	B-X
Stat5b	B-X
(	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
)	B-X

Gadd45gamma	B-DNA
-deficient	O
mice	O
develop	O
normally	O
,	O
are	O
indistinguishable	O
from	O
their	O
littermates	O
,	O
and	O
are	O
fertile	O
.	O
<EOS>	B-X
Gadd45gamma	B-X
-	B-X
deficient	B-X
mice	B-X
develop	B-X
normally	B-X
,	B-X
are	B-X
indistinguishable	B-X
from	B-X
their	B-X
littermates	B-X
,	B-X
and	B-X
are	B-X
fertile	B-X
<EOS>	B-X
Gadd45gamma	B-X
is	B-X
dispensable	B-X
for	B-X
normal	B-X
mouse	B-X
development	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
Gadd45gamma	B-X
is	B-X
also	B-X
dispensable	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
induced	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
Gadd45gamma	B-X
,	B-X
a	B-X
family	B-X
member	B-X
of	B-X
the	B-X
growth	B-X
arrest	B-X
and	B-X
DNA	B-X
damage	B-X
-	B-X
inducible	B-X
gene	B-X
family	B-X
45	B-X
(	B-X
Gadd45	B-X
)	B-X
,	B-X
is	B-X
strongly	B-X
induced	B-X
by	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X

Furthermore	O
,	O
hematopoiesis	O
in	O
mice	O
lacking	O
Gadd45gamma	B-DNA
is	O
not	O
impaired	O
and	O
Gadd45gamma	B-DNA
-deficient	O
T	B-cell_type
lymphocytes	I-cell_type
show	O
normal	O
responses	O
to	O
IL-2	B-protein
.	O

These	O
data	O
demonstrate	O
that	O
Gadd45gamma	B-DNA
is	O
not	O
essential	O
for	O
normal	O
mouse	O
development	O
and	O
hematopoiesis	O
,	O
possibly	O
due	O
to	O
functional	O
redundancy	O
among	O
the	O
Gadd45	B-DNA
family	I-DNA
members	I-DNA
.	O
<EOS>	B-X
We	B-X
further	B-X
demonstrated	B-X
that	B-X
,	B-X
following	B-X
Ol	B-X
-	B-X
Gadd45gamma	B-X
overexpression	B-X
,	B-X
cells	B-X
are	B-X
proliferation	B-X
-	B-X
arrested	B-X
before	B-X
both	B-X
G1	B-X
/	B-X
S	B-X
and	B-X
G2	B-X
/	B-X
M	B-X
cell	B-X
cycle	B-X
checkpoints	B-X
,	B-X
while	B-X
in	B-X
the	B-X
MO	B-X
-	B-X
Ol	B-X
-	B-X
Gadd45	B-X
loss	B-X
-	B-X
of	B-X
-	B-X
function	B-X
experiments	B-X
cells	B-X
are	B-X
engaged	B-X
in	B-X
apoptosis	B-X
rather	B-X
than	B-X
prevented	B-X
from	B-X
proliferating	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
Ol	B-X
-	B-X
Gadd45gamma	B-X
is	B-X
likely	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
coordinating	B-X
cell	B-X
fate	B-X
decisions	B-X
during	B-X
neurogenesis	B-X
;	B-X
they	B-X
also	B-X
demonstrate	B-X
that	B-X
the	B-X
medakafish	B-X
is	B-X
a	B-X
promising	B-X
model	B-X
to	B-X
analyse	B-X
in	B-X
vivo	B-X
the	B-X
developmental	B-X
control	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
study	B-X
demonstrates	B-X
that	B-X
²¹²Pb	B-X
-	B-X
trastuzumab	B-X
potentiation	B-X
of	B-X
cell	B-X
killing	B-X
efficacy	B-X
results	B-X
from	B-X
the	B-X
perturbation	B-X
of	B-X
genes	B-X
related	B-X
to	B-X
the	B-X
mitotic	B-X
spindle	B-X
checkpoint	B-X
and	B-X
BASC	B-X
(	B-X
BRCA1	B-X
-	B-X
associated	B-X
genome	B-X
surveillance	B-X
complex	B-X
)	B-X
,	B-X
suggesting	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
DNA	B-X
damage	B-X
repair	B-X
and	B-X
the	B-X
spindle	B-X
damage	B-X
response	B-X
<EOS>	B-X
However	B-X
,	B-X
while	B-X
various	B-X
'	B-X
data	B-X
demonstrate	B-X
the	B-X
response	B-X
of	B-X
the	B-X
working	B-X
skeletal	B-X
muscle	B-X
to	B-X
acute	B-X
exercise	B-X
and	B-X
training	B-X
,	B-X
considerably	B-X
less	B-X
is	B-X
known	B-X
about	B-X
the	B-X
molecular	B-X
events	B-X
in	B-X
the	B-X
liver	B-X
during	B-X
and	B-X
after	B-X
increased	B-X
physical	B-X
activity	B-X

Gadd45gamma	B-DNA
is	O
also	O
dispensable	O
for	O
IL-2	B-protein
-induced	O
T-cell	O
proliferation	O
.	O
<EOS>	B-X
Gadd45gamma	B-X
is	B-X
also	B-X
dispensable	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
induced	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
Gadd45gamma	B-X
is	B-X
dispensable	B-X
for	B-X
normal	B-X
mouse	B-X
development	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
.	B-X
<EOS>	B-X
Gadd45gamma	B-X
-	B-X
deficient	B-X
mice	B-X
develop	B-X
normally	B-X
,	B-X
are	B-X
indistinguishable	B-X
from	B-X
their	B-X
littermates	B-X
,	B-X
and	B-X
are	B-X
fertile	B-X
<EOS>	B-X
Gadd45gamma	B-X
,	B-X
a	B-X
family	B-X
member	B-X
of	B-X
the	B-X
growth	B-X
arrest	B-X
and	B-X
DNA	B-X
damage	B-X
-	B-X
inducible	B-X
gene	B-X
family	B-X
45	B-X
(	B-X
Gadd45	B-X
)	B-X
,	B-X
is	B-X
strongly	B-X
induced	B-X
by	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X

Decreased	O
expression	O
of	O
c-myc	B-DNA
family	I-DNA
genes	I-DNA
in	O
thymuses	O
from	O
myasthenia	O
gravis	O
patients	O
.	O
<EOS>	B-X
Decreased	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
thymuses	B-X
from	B-X
myasthenia	B-X
gravis	B-X
patients	B-X
.	B-X
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
apoptosis	B-X
-	B-X
associated	B-X
genes	B-X
,	B-X
bcl	B-X
-	B-X
xL	B-X
,	B-X
bad	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
,	B-X
and	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
myasthenia	B-X
gravis	B-X
(	B-X
MG	B-X
)	B-X
thymuses	B-X
<EOS>	B-X
We	B-X
observed	B-X
that	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
myc	B-X
family	B-X
genes	B-X
,	B-X
c	B-X
-	B-X
myc	B-X
and	B-X
max	B-X
,	B-X
were	B-X
markedly	B-X
reduced	B-X
in	B-X
MG	B-X
thymuses	B-X
<EOS>	B-X
The	B-X
levels	B-X
of	B-X
molecules	B-X
whose	B-X
expressions	B-X
are	B-X
associated	B-X
with	B-X
myc	B-X
,	B-X
such	B-X
as	B-X
STAM	B-X
,	B-X
prothymosin	B-X
-	B-X
alpha	B-X
,	B-X
and	B-X
NFkappaB	B-X
,	B-X
were	B-X
also	B-X
analyzed	B-X

The	O
thymus	O
is	O
a	O
critical	O
organ	O
for	O
the	O
elimination	O
of	O
autoreactive	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
thymus	B-X
is	B-X
a	B-X
critical	B-X
organ	B-X
for	B-X
the	B-X
elimination	B-X
of	B-X
autoreactive	B-X
T	B-X
cells	B-X
by	B-X
apoptosis	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
c	B-X
-	B-X
myc	B-X
-	B-X
mediated	B-X
signaling	B-X
is	B-X
abnormal	B-X
in	B-X
MG	B-X
thymuses	B-X
<EOS>	B-X
The	B-X
levels	B-X
of	B-X
molecules	B-X
whose	B-X
expressions	B-X
are	B-X
associated	B-X
with	B-X
myc	B-X
,	B-X
such	B-X
as	B-X
STAM	B-X
,	B-X
prothymosin	B-X
-	B-X
alpha	B-X
,	B-X
and	B-X
NFkappaB	B-X
,	B-X
were	B-X
also	B-X
analyzed	B-X
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
apoptosis	B-X
-	B-X
associated	B-X
genes	B-X
,	B-X
bcl	B-X
-	B-X
xL	B-X
,	B-X
bad	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
,	B-X
and	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
myasthenia	B-X
gravis	B-X
(	B-X
MG	B-X
)	B-X
thymuses	B-X

We	O
studied	O
the	O
expression	O
of	O
apoptosis-associated	O
genes	O
,	O
bcl-xL	B-DNA
,	O
bad	B-DNA
,	O
caspase-3	B-DNA
,	O
and	O
c-myc	B-DNA
family	I-DNA
genes	I-DNA
in	O
myasthenia	O
gravis	O
(	O
MG	O
)	O
thymuses	O
.	O
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
apoptosis	B-X
-	B-X
associated	B-X
genes	B-X
,	B-X
bcl	B-X
-	B-X
xL	B-X
,	B-X
bad	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
,	B-X
and	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
myasthenia	B-X
gravis	B-X
(	B-X
MG	B-X
)	B-X
thymuses	B-X
<EOS>	B-X
Decreased	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
thymuses	B-X
from	B-X
myasthenia	B-X
gravis	B-X
patients	B-X
.	B-X
<EOS>	B-X
We	B-X
observed	B-X
that	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
myc	B-X
family	B-X
genes	B-X
,	B-X
c	B-X
-	B-X
myc	B-X
and	B-X
max	B-X
,	B-X
were	B-X
markedly	B-X
reduced	B-X
in	B-X
MG	B-X
thymuses	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
c	B-X
-	B-X
myc	B-X
-	B-X
mediated	B-X
signaling	B-X
is	B-X
abnormal	B-X
in	B-X
MG	B-X
thymuses	B-X

We	O
observed	O
that	O
the	O
mRNA	O
levels	O
of	O
myc	B-DNA
family	I-DNA
genes	I-DNA
,	O
c-myc	B-DNA
and	O
max	B-DNA
,	O
were	O
markedly	O
reduced	O
in	O
MG	O
thymuses	O
.	O
<EOS>	B-X
We	B-X
observed	B-X
that	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
myc	B-X
family	B-X
genes	B-X
,	B-X
c	B-X
-	B-X
myc	B-X
and	B-X
max	B-X
,	B-X
were	B-X
markedly	B-X
reduced	B-X
in	B-X
MG	B-X
thymuses	B-X
<EOS>	B-X
Decreased	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
thymuses	B-X
from	B-X
myasthenia	B-X
gravis	B-X
patients	B-X
.	B-X
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
apoptosis	B-X
-	B-X
associated	B-X
genes	B-X
,	B-X
bcl	B-X
-	B-X
xL	B-X
,	B-X
bad	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
,	B-X
and	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
myasthenia	B-X
gravis	B-X
(	B-X
MG	B-X
)	B-X
thymuses	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
c	B-X
-	B-X
myc	B-X
-	B-X
mediated	B-X
signaling	B-X
is	B-X
abnormal	B-X
in	B-X
MG	B-X
thymuses	B-X

These	O
results	O
indicate	O
that	O
c-myc	B-DNA
-mediated	O
signaling	O
is	O
abnormal	O
in	O
MG	O
thymuses	O
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
c	B-X
-	B-X
myc	B-X
-	B-X
mediated	B-X
signaling	B-X
is	B-X
abnormal	B-X
in	B-X
MG	B-X
thymuses	B-X
<EOS>	B-X
We	B-X
observed	B-X
that	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
myc	B-X
family	B-X
genes	B-X
,	B-X
c	B-X
-	B-X
myc	B-X
and	B-X
max	B-X
,	B-X
were	B-X
markedly	B-X
reduced	B-X
in	B-X
MG	B-X
thymuses	B-X
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
apoptosis	B-X
-	B-X
associated	B-X
genes	B-X
,	B-X
bcl	B-X
-	B-X
xL	B-X
,	B-X
bad	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
,	B-X
and	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
myasthenia	B-X
gravis	B-X
(	B-X
MG	B-X
)	B-X
thymuses	B-X
<EOS>	B-X
The	B-X
levels	B-X
of	B-X
molecules	B-X
whose	B-X
expressions	B-X
are	B-X
associated	B-X
with	B-X
myc	B-X
,	B-X
such	B-X
as	B-X
STAM	B-X
,	B-X
prothymosin	B-X
-	B-X
alpha	B-X
,	B-X
and	B-X
NFkappaB	B-X
,	B-X
were	B-X
also	B-X
analyzed	B-X

The	O
levels	O
of	O
molecules	O
whose	O
expressions	O
are	O
associated	O
with	O
myc	B-DNA
,	O
such	O
as	O
STAM	B-protein
,	O
prothymosin-alpha	B-protein
,	O
and	O
NFkappaB	B-protein
<EOS>	B-X
The	B-X
levels	B-X
of	B-X
molecules	B-X
whose	B-X
expressions	B-X
are	B-X
associated	B-X
with	B-X
myc	B-X
,	B-X
such	B-X
as	B-X
STAM	B-X
,	B-X
prothymosin	B-X
-	B-X
alpha	B-X
,	B-X
and	B-X
NFkappaB	B-X
,	B-X
were	B-X
also	B-X
analyzed	B-X
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
expression	B-X
of	B-X
apoptosis	B-X
-	B-X
associated	B-X
genes	B-X
,	B-X
bcl	B-X
-	B-X
xL	B-X
,	B-X
bad	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
,	B-X
and	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
myasthenia	B-X
gravis	B-X
(	B-X
MG	B-X
)	B-X
thymuses	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
c	B-X
-	B-X
myc	B-X
-	B-X
mediated	B-X
signaling	B-X
is	B-X
abnormal	B-X
in	B-X
MG	B-X
thymuses	B-X
<EOS>	B-X
Decreased	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
myc	B-X
family	B-X
genes	B-X
in	B-X
thymuses	B-X
from	B-X
myasthenia	B-X
gravis	B-X
patients	B-X
.	B-X

Immunohistochemical	O
detection	O
of	O
interferon-gamma-producing	B-cell_type
cells	I-cell_type
in	O
dermatophytosis	O
.	O
<EOS>	B-X
Immunohistochemical	B-X
detection	B-X
of	B-X
interferon	B-X
-	B-X
gamma	B-X
-	B-X
producing	B-X
cells	B-X
in	B-X
dermatophytosis	B-X
.	B-X
<EOS>	B-X
Th1	B-X
response	B-X
,	B-X
which	B-X
is	B-X
characterized	B-X
by	B-X
IFN	B-X
-	B-X
gamma	B-X
release	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
host	B-X
defense	B-X
against	B-X
dermatophytes	B-X
and	B-X
to	B-X
reflect	B-X
cutaneous	B-X
reaction	B-X
in	B-X
dermatophytosis	B-X
<EOS>	B-X
We	B-X
examined	B-X
whether	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
(	B-X
as	B-X
expression	B-X
of	B-X
Th1	B-X
response	B-X
)	B-X
were	B-X
present	B-X
in	B-X
the	B-X
skin	B-X
lesions	B-X
of	B-X
dermatophytosis	B-X
in	B-X
situ	B-X
by	B-X
immunohistochemical	B-X
techniques	B-X
<EOS>	B-X
Mixtures	B-X
of	B-X
CD4	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
and	B-X
CD8	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
dermal	B-X
infiltrates	B-X
of	B-X
the	B-X
lesions	B-X

Skin	O
lesions	O
of	O
dermatophytosis	O
are	O
thought	O
to	O
be	O
a	O
result	O
of	O
a	O
T	B-cell_type
cell	I-cell_type
-dependent	O
inflammatory	O
response	O
that	O
is	O
mediated	O
by	O
various	O
cytokines	B-protein
.	O

We	O
examined	O
whether	O
IFN-gamma-positive	B-cell_type
cells	I-cell_type
(	O
as	O
expression	O
of	O
Th1	B-cell_type
response	O
)	O
were	O
present	O
in	O
the	O
skin	O
lesions	O
of	O
dermatophytosis	O
in	O
situ	O
by	O
immunohistochemical	O
techniques	O
.	O
<EOS>	B-X
We	B-X
examined	B-X
whether	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
(	B-X
as	B-X
expression	B-X
of	B-X
Th1	B-X
response	B-X
)	B-X
were	B-X
present	B-X
in	B-X
the	B-X
skin	B-X
lesions	B-X
of	B-X
dermatophytosis	B-X
in	B-X
situ	B-X
by	B-X
immunohistochemical	B-X
techniques	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
present	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
of	B-X
the	B-X
lesions	B-X
<EOS>	B-X
Our	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
skin	B-X
lesions	B-X
of	B-X
dermatophytosis	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
Th1	B-X
response	B-X
<EOS>	B-X
Mixtures	B-X
of	B-X
CD4	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
and	B-X
CD8	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
dermal	B-X
infiltrates	B-X
of	B-X
the	B-X
lesions	B-X

Mixtures	O
of	O
CD4-positive	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
CD8-positive	B-cell_type
T	I-cell_type
cells	I-cell_type
were	O
found	O
to	O
be	O
present	O
in	O
the	O
dermal	O
infiltrates	O
of	O
the	O
lesions	O
.	O
<EOS>	B-X
Mixtures	B-X
of	B-X
CD4	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
and	B-X
CD8	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
dermal	B-X
infiltrates	B-X
of	B-X
the	B-X
lesions	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
present	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
of	B-X
the	B-X
lesions	B-X
<EOS>	B-X
Considerable	B-X
numbers	B-X
of	B-X
CD1a	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
and	B-X
epidermis	B-X
<EOS>	B-X
A	B-X
marked	B-X
accumulation	B-X
of	B-X
CD68	B-X
-	B-X
positive	B-X
cells	B-X
was	B-X
found	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X

Considerable	O
numbers	O
of	O
CD1a-positive	B-cell_type
cells	I-cell_type
were	O
detected	O
in	O
the	O
upper	O
dermis	O
and	O
epidermis	O
.	O
<EOS>	B-X
Considerable	B-X
numbers	B-X
of	B-X
CD1a	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
and	B-X
epidermis	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
present	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
of	B-X
the	B-X
lesions	B-X
<EOS>	B-X
A	B-X
marked	B-X
accumulation	B-X
of	B-X
CD68	B-X
-	B-X
positive	B-X
cells	B-X
was	B-X
found	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
<EOS>	B-X
Mixtures	B-X
of	B-X
CD4	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
and	B-X
CD8	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
dermal	B-X
infiltrates	B-X
of	B-X
the	B-X
lesions	B-X

A	O
marked	O
accumulation	O
of	O
CD68-positive	B-cell_type
cells	I-cell_type
was	O
found	O
in	O
the	O
upper	O
dermis	O
.	O
<EOS>	B-X
A	B-X
marked	B-X
accumulation	B-X
of	B-X
CD68	B-X
-	B-X
positive	B-X
cells	B-X
was	B-X
found	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
<EOS>	B-X
Considerable	B-X
numbers	B-X
of	B-X
CD1a	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
and	B-X
epidermis	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
present	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
of	B-X
the	B-X
lesions	B-X
<EOS>	B-X
Mixtures	B-X
of	B-X
CD4	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
and	B-X
CD8	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
dermal	B-X
infiltrates	B-X
of	B-X
the	B-X
lesions	B-X

IFN-gamma-positive	B-cell_type
cells	I-cell_type
were	O
present	O
in	O
the	O
upper	O
dermis	O
of	O
the	O
lesions	O
.	O
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
present	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
of	B-X
the	B-X
lesions	B-X
<EOS>	B-X
Considerable	B-X
numbers	B-X
of	B-X
CD1a	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
and	B-X
epidermis	B-X
<EOS>	B-X
Mixtures	B-X
of	B-X
CD4	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
and	B-X
CD8	B-X
-	B-X
positive	B-X
T	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
dermal	B-X
infiltrates	B-X
of	B-X
the	B-X
lesions	B-X
<EOS>	B-X
We	B-X
examined	B-X
whether	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
(	B-X
as	B-X
expression	B-X
of	B-X
Th1	B-X
response	B-X
)	B-X
were	B-X
present	B-X
in	B-X
the	B-X
skin	B-X
lesions	B-X
of	B-X
dermatophytosis	B-X
in	B-X
situ	B-X
by	B-X
immunohistochemical	B-X
techniques	B-X

The	O
pattern	O
of	O
IFN-gamma	B-protein
staining	O
appeared	O
to	O
be	O
intracellular	O
in	O
mononuclear	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
pattern	B-X
of	B-X
IFN	B-X
-	B-X
gamma	B-X
staining	B-X
appeared	B-X
to	B-X
be	B-X
intracellular	B-X
in	B-X
mononuclear	B-X
lymphoid	B-X
cells	B-X
<EOS>	B-X
The	B-X
pattern	B-X
of	B-X
IFN	B-X
-	B-X
gamma	B-X
staining	B-X
appeared	B-X
to	B-X
be	B-X
a	B-X
combination	B-X
of	B-X
intracellular	B-X
staining	B-X
in	B-X
mononuclear	B-X
lymphoid	B-X
cells	B-X
and	B-X
extracellular	B-X
deposition	B-X
in	B-X
the	B-X
surrounding	B-X
areas	B-X
<EOS>	B-X
The	B-X
pattern	B-X
of	B-X
IFN	B-X
-	B-X
gamma	B-X
staining	B-X
appeared	B-X
to	B-X
be	B-X
a	B-X
combination	B-X
of	B-X
intracellular	B-X
staining	B-X
in	B-X
mononuclear	B-X
lymphoid	B-X
cells	B-X
and	B-X
extracellular	B-X
deposition	B-X
in	B-X
the	B-X
surrounding	B-X
tissue	B-X
<EOS>	B-X
The	B-X
involvement	B-X
of	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
and	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
in	B-X
the	B-X
granuloma	B-X
formation	B-X
of	B-X
sporotrichosis	B-X
is	B-X
less	B-X
known	B-X

The	O
staining	O
was	O
considered	O
to	O
be	O
highly	O
specific	O
because	O
it	O
could	O
be	O
completely	O
blocked	O
by	O
preabsorption	O
with	O
recombinant	B-protein
IFN-gamma	I-protein
.	O
<EOS>	B-X
The	B-X
staining	B-X
was	B-X
considered	B-X
to	B-X
be	B-X
highly	B-X
specific	B-X
because	B-X
it	B-X
could	B-X
be	B-X
completely	B-X
blocked	B-X
by	B-X
preabsorption	B-X
with	B-X
recombinant	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
The	B-X
pattern	B-X
of	B-X
IFN	B-X
-	B-X
gamma	B-X
staining	B-X
appeared	B-X
to	B-X
be	B-X
a	B-X
combination	B-X
of	B-X
intracellular	B-X
staining	B-X
in	B-X
mononuclear	B-X
lymphoid	B-X
cells	B-X
and	B-X
extracellular	B-X
deposition	B-X
in	B-X
the	B-X
surrounding	B-X
areas	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
epidermis	B-X
<EOS>	B-X
Considerable	B-X
numbers	B-X
of	B-X
CD1a	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
and	B-X
epidermis	B-X

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
skin	O
lesions	O
of	O
dermatophytosis	O
may	O
be	O
associated	O
with	O
a	O
Th1	B-cell_type
response	O
.	O
<EOS>	B-X
Our	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
skin	B-X
lesions	B-X
of	B-X
dermatophytosis	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
Th1	B-X
response	B-X
<EOS>	B-X
We	B-X
examined	B-X
whether	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
(	B-X
as	B-X
expression	B-X
of	B-X
Th1	B-X
response	B-X
)	B-X
were	B-X
present	B-X
in	B-X
the	B-X
skin	B-X
lesions	B-X
of	B-X
dermatophytosis	B-X
in	B-X
situ	B-X
by	B-X
immunohistochemical	B-X
techniques	B-X
<EOS>	B-X
Th1	B-X
response	B-X
,	B-X
which	B-X
is	B-X
characterized	B-X
by	B-X
IFN	B-X
-	B-X
gamma	B-X
release	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
host	B-X
defense	B-X
against	B-X
dermatophytes	B-X
and	B-X
to	B-X
reflect	B-X
cutaneous	B-X
reaction	B-X
in	B-X
dermatophytosis	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
positive	B-X
cells	B-X
were	B-X
present	B-X
in	B-X
the	B-X
upper	B-X
dermis	B-X
of	B-X
the	B-X
lesions	B-X

Th1	B-cell_type
response	O
,	O
which	O
is	O
characterized	O
by	O
IFN-gamma	B-protein
release	O
,	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
host	O
defense	O
against	O
dermatophytes	O
and	O
to	O
reflect	O
cutaneous	O
reaction	O
in	O
dermatophytosis	O
.	O
<EOS>	B-X
Th1	B-X
response	B-X
,	B-X
which	B-X
is	B-X
characterized	B-X
by	B-X
IFN	B-X
-	B-X
gamma	B-X
release	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
host	B-X
defense	B-X
against	B-X
dermatophytes	B-X
and	B-X
to	B-X
reflect	B-X
cutaneous	B-X
reaction	B-X
in	B-X
dermatophytosis	B-X
<EOS>	B-X
The	B-X
Th1	B-X
response	B-X
,	B-X
which	B-X
is	B-X
characterized	B-X
by	B-X
IFN	B-X
-	B-X
gamma	B-X
release	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
host	B-X
defense	B-X
against	B-X
dermatophytes	B-X
and	B-X
to	B-X
reflect	B-X
cutaneous	B-X
reaction	B-X
in	B-X
dermatophytosis	B-X
<EOS>	B-X
These	B-X
findings	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
skin	B-X
lesions	B-X
of	B-X
dermatophytosis	B-X
are	B-X
associated	B-X
with	B-X
a	B-X
Th1	B-X
response	B-X
<EOS>	B-X
Skin	B-X
lesions	B-X
of	B-X
dermatophytosis	B-X
are	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
result	B-X
of	B-X
a	B-X
T	B-X
cell	B-X
-	B-X
dependent	B-X
inflammatory	B-X
response	B-X
that	B-X
is	B-X
mediated	B-X
by	B-X
various	B-X
cytokines	B-X

Regulation	O
of	O
the	O
helix-loop-helix	B-protein
proteins	I-protein
,	O
E2A	B-protein
and	O
Id3	B-protein
,	O
by	O
the	O
Ras	B-protein
-	O
ERK	B-protein
MAPK	B-protein
cascade	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
proteins	B-X
,	B-X
E2A	B-X
and	B-X
Id3	B-X
,	B-X
by	B-X
the	B-X
Ras	B-X
-	B-X
ERK	B-X
MAPK	B-X
cascade	B-X
.	B-X
<EOS>	B-X
The	B-X
basic	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
(	B-X
bHLH	B-X
)	B-X
proteins	B-X
E12	B-X
and	B-X
E47	B-X
and	B-X
an	B-X
inhibitor	B-X
HLH	B-X
protein	B-X
,	B-X
Id3	B-X
,	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
thymocyte	B-X
differentiation	B-X
<EOS>	B-X
Activation	B-X
of	B-X
Id3	B-X
transcription	B-X
is	B-X
regulated	B-X
in	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
manner	B-X
by	B-X
the	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
MAPK	B-X
module	B-X
<EOS>	B-X
Whereas	B-X
expression	B-X
of	B-X
E2A	B-X
mRNA	B-X
and	B-X
protein	B-X
are	B-X
unaltered	B-X
,	B-X
Id3	B-X
transcripts	B-X
are	B-X
rapidly	B-X
induced	B-X
upon	B-X
signaling	B-X
from	B-X
the	B-X
TCR	B-X

Activation	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathways	O
leads	O
to	O
cellular	O
differentiation	O
and/or	O
proliferation	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
,	O
including	O
developing	B-cell_type
thymocytes	I-cell_type
.	O
<EOS>	B-X
Mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathways	B-X
represent	B-X
ubiquitous	B-X
cellular	B-X
signal	B-X
transduction	B-X
pathways	B-X
that	B-X
regulate	B-X
all	B-X
aspects	B-X
of	B-X
life	B-X
and	B-X
are	B-X
frequently	B-X
altered	B-X
in	B-X
disease	B-X
<EOS>	B-X
Despite	B-X
extensive	B-X
studies	B-X
showing	B-X
the	B-X
function	B-X
of	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
in	B-X
osteoblast	B-X
differentiation	B-X
,	B-X
none	B-X
of	B-X
these	B-X
studies	B-X
show	B-X
in	B-X
vivo	B-X
evidence	B-X
of	B-X
a	B-X
role	B-X
for	B-X
MAPKs	B-X
in	B-X
osteoblast	B-X
maturation	B-X
subsequent	B-X
to	B-X
lineage	B-X
commitment	B-X
<EOS>	B-X
Mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
kinase	B-X
(	B-X
MEK	B-X
)	B-X
inhibitors	B-X
show	B-X
limited	B-X
benefit	B-X
in	B-X
Kirsten	B-X
rat	B-X
sarcoma	B-X
(	B-X
<EOS>	B-X
Genes	B-X
associated	B-X
with	B-X
the	B-X
mitogen	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathways	B-X
comprised	B-X
the	B-X
largest	B-X
functional	B-X
group	B-X
identified	B-X

The	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
proteins	I-protein
E12	B-protein
and	O
E47	B-protein
and	O
an	O
inhibitor	B-protein
HLH	I-protein
protein	I-protein
,	O
Id3	B-protein
,	O
play	O
key	O
roles	O
in	O
thymocyte	O
differentiation	O
.	O

We	O
show	O
here	O
that	O
E2A	B-protein
DNA	O
binding	O
is	O
lowered	O
in	O
primary	B-cell_type
immature	I-cell_type
thymocytes	I-cell_type
consequent	O
to	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
-mediated	O
ligation	O
.	O

Whereas	O
expression	O
of	O
E2A	O
mRNA	O
and	O
protein	O
are	O
unaltered	O
,	O
Id3	B-RNA
transcripts	I-RNA
are	O
rapidly	O
induced	O
upon	O
signaling	O
from	O
the	O
TCR	B-protein
.	O
<EOS>	B-X
Whereas	B-X
expression	B-X
of	B-X
E2A	B-X
mRNA	B-X
and	B-X
protein	B-X
are	B-X
unaltered	B-X
,	B-X
Id3	B-X
transcripts	B-X
are	B-X
rapidly	B-X
induced	B-X
upon	B-X
signaling	B-X
from	B-X
the	B-X
TCR	B-X
<EOS>	B-X
Activation	B-X
of	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathways	B-X
leads	B-X
to	B-X
cellular	B-X
differentiation	B-X
and	B-X
/	B-X
or	B-X
proliferation	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
,	B-X
including	B-X
developing	B-X
thymocytes	B-X
<EOS>	B-X
These	B-X
observations	B-X
directly	B-X
connect	B-X
the	B-X
ERK	B-X
MAPK	B-X
cascade	B-X
and	B-X
HLH	B-X
proteins	B-X
in	B-X
a	B-X
linear	B-X
pathway	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
helix	B-X
-	B-X
loop	B-X
-	B-X
helix	B-X
proteins	B-X
,	B-X
E2A	B-X
and	B-X
Id3	B-X
,	B-X
by	B-X
the	B-X
Ras	B-X
-	B-X
ERK	B-X
MAPK	B-X
cascade	B-X
.	B-X

Activation	O
of	O
Id3	O
transcription	O
is	O
regulated	O
in	O
a	O
dose-dependent	O
manner	O
by	O
the	O
extracellular	O
signal-regulated	O
kinase	O
(	O
ERK	B-protein
)	O
MAPK	B-protein
module	O
.	O

These	O
observations	O
directly	O
connect	O
the	O
ERK	B-protein
MAPK	B-protein
cascade	O
and	O
HLH	B-protein
proteins	I-protein
in	O
a	O
linear	O
pathway	O
.	O

Retinoic	O
acid	O
up-regulates	O
myeloid	O
ICAM-3	O
expression	O
and	O
function	O
in	O
a	O
cell-specific	O
fashion	O
--	O
evidence	O
for	O
retinoid	O
signaling	O
pathways	O
in	O
the	O
mast	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O

Investigation	O
of	O
mast	O
cell	O
responsiveness	O
toward	O
retinoic	O
acid	O
(	O
RA	O
)	O
revealed	O
selective	O
promotion	O
of	O
ICAM-3	B-protein
expression	O
in	O
the	O
human	B-cell_line
mast	I-cell_line
cell	I-cell_line
line	I-cell_line
HMC-1	I-cell_line
.	O
<EOS>	B-X
Investigation	B-X
of	B-X
mast	B-X
cell	B-X
responsiveness	B-X
toward	B-X
retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
revealed	B-X
selective	B-X
promotion	B-X
of	B-X
ICAM	B-X
-	B-X
3	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
mast	B-X
cell	B-X
line	B-X
HMC	B-X
-	B-X
1	B-X
<EOS>	B-X
Investigation	B-X
of	B-X
retinoid	B-X
receptor	B-X
expression	B-X
,	B-X
known	B-X
to	B-X
mediate	B-X
intracellular	B-X
RA	B-X
signaling	B-X
,	B-X
revealed	B-X
presence	B-X
of	B-X
RAR	B-X
alpha	B-X
,	B-X
RAR	B-X
gamma	B-X
,	B-X
RXR	B-X
beta	B-X
,	B-X
and	B-X
RXR	B-X
gamma	B-X
transcripts	B-X
in	B-X
all	B-X
cell	B-X
lines	B-X
studied	B-X
,	B-X
and	B-X
HMC	B-X
-	B-X
1	B-X
cells	B-X
were	B-X
the	B-X
only	B-X
line	B-X
lacking	B-X
RXR	B-X
alpha	B-X
<EOS>	B-X
Retinoic	B-X
acid	B-X
up	B-X
-	B-X
regulates	B-X
myeloid	B-X
ICAM	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
function	B-X
in	B-X
a	B-X
cell	B-X
-	B-X
specific	B-X
fashion	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
evidence	B-X
for	B-X
retinoid	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
mast	B-X
cell	B-X
lineage	B-X
.	B-X
<EOS>	B-X
RAR	B-X
beta	B-X
,	B-X
not	B-X
expressed	B-X
at	B-X
baseline	B-X
,	B-X
was	B-X
induced	B-X
by	B-X
RA	B-X
in	B-X
a	B-X
fashion	B-X
obviously	B-X
correlating	B-X
with	B-X
ICAM	B-X
-	B-X
3	B-X
up	B-X
-	B-X
regulation	B-X

This	O
process	O
was	O
dose-	O
and	O
time-dependent	O
and	O
detectable	O
by	O
flow	O
cytometry	O
,	O
Western	O
blot	O
analysis	O
,	O
ELISA	O
,	O
and	O
Northern	O
blot	O
analysis	O
.	O
<EOS>	B-X
This	B-X
process	B-X
was	B-X
dose	B-X
-	B-X
	B-X
and	B-X
time	B-X
-	B-X
dependent	B-X
and	B-X
detectable	B-X
by	B-X
flow	B-X
cytometry	B-X
,	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
ELISA	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
ICAM	B-X
-	B-X
3	B-X
modulation	B-X
was	B-X
found	B-X
to	B-X
be	B-X
cell	B-X
-	B-X
type	B-X
dependent	B-X
,	B-X
detectable	B-X
also	B-X
for	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
and	B-X
monocytes	B-X
but	B-X
not	B-X
U	B-X
-	B-X
937	B-X
and	B-X
only	B-X
weakly	B-X
for	B-X
KU812	B-X
cells	B-X
<EOS>	B-X
Investigation	B-X
of	B-X
retinoid	B-X
receptor	B-X
expression	B-X
,	B-X
known	B-X
to	B-X
mediate	B-X
intracellular	B-X
RA	B-X
signaling	B-X
,	B-X
revealed	B-X
presence	B-X
of	B-X
RAR	B-X
alpha	B-X
,	B-X
RAR	B-X
gamma	B-X
,	B-X
RXR	B-X
beta	B-X
,	B-X
and	B-X
RXR	B-X
gamma	B-X
transcripts	B-X
in	B-X
all	B-X
cell	B-X
lines	B-X
studied	B-X
,	B-X
and	B-X
HMC	B-X
-	B-X
1	B-X
cells	B-X
were	B-X
the	B-X
only	B-X
line	B-X
lacking	B-X
RXR	B-X
alpha	B-X
<EOS>	B-X
RA	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
ICAM	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
studied	B-X
in	B-X
parallel	B-X
,	B-X
were	B-X
clearly	B-X
distinct	B-X
from	B-X
those	B-X
on	B-X
ICAM	B-X
-	B-X
3	B-X

ICAM-3	B-protein
modulation	O
was	O
found	O
to	O
be	O
cell-type	O
dependent	O
,	O
detectable	O
also	O
for	O
HL-60	B-cell_line
cells	I-cell_line
and	O
monocytes	B-cell_type
but	O
not	O
U-937	B-cell_line
and	O
only	O
weakly	O
for	O
KU812	B-cell_line
cells	I-cell_line
.	O

Terminally	B-cell_type
differentiated	I-cell_type
skin	I-cell_type
mast	I-cell_type
cells	I-cell_type
also	O
failed	O
to	O
up-modulate	O
their	O
ICAM-3	B-protein
,	O
suggesting	O
the	O
requirement	O
for	O
some	O
degree	O
of	O
immaturity	O
for	O
the	O
process	O
.	O
<EOS>	B-X
Terminally	B-X
differentiated	B-X
skin	B-X
mast	B-X
cells	B-X
also	B-X
failed	B-X
to	B-X
up	B-X
-	B-X
modulate	B-X
their	B-X
ICAM	B-X
-	B-X
3	B-X
,	B-X
suggesting	B-X
the	B-X
requirement	B-X
for	B-X
some	B-X
degree	B-X
of	B-X
immaturity	B-X
for	B-X
the	B-X
process	B-X
<EOS>	B-X
Increased	B-X
ICAM	B-X
-	B-X
3	B-X
expression	B-X
was	B-X
of	B-X
functional	B-X
significance	B-X
,	B-X
such	B-X
that	B-X
processes	B-X
stimulated	B-X
or	B-X
co	B-X
-	B-X
stimulated	B-X
via	B-X
ICAM	B-X
-	B-X
3	B-X
(	B-X
homotypic	B-X
aggregation	B-X
,	B-X
IL	B-X
-	B-X
8	B-X
secretion	B-X
)	B-X
were	B-X
clearly	B-X
enhanced	B-X
upon	B-X
RA	B-X
pretreatment	B-X
,	B-X
suggesting	B-X
that	B-X
RA	B-X
may	B-X
contribute	B-X
via	B-X
hitherto	B-X
unrecognized	B-X
pathways	B-X
to	B-X
immune	B-X
function	B-X
and	B-X
host	B-X
defense	B-X
<EOS>	B-X
RA	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
ICAM	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
studied	B-X
in	B-X
parallel	B-X
,	B-X
were	B-X
clearly	B-X
distinct	B-X
from	B-X
those	B-X
on	B-X
ICAM	B-X
-	B-X
3	B-X
<EOS>	B-X
Investigation	B-X
of	B-X
retinoid	B-X
receptor	B-X
expression	B-X
,	B-X
known	B-X
to	B-X
mediate	B-X
intracellular	B-X
RA	B-X
signaling	B-X
,	B-X
revealed	B-X
presence	B-X
of	B-X
RAR	B-X
alpha	B-X
,	B-X
RAR	B-X
gamma	B-X
,	B-X
RXR	B-X
beta	B-X
,	B-X
and	B-X
RXR	B-X
gamma	B-X
transcripts	B-X
in	B-X
all	B-X
cell	B-X
lines	B-X
studied	B-X
,	B-X
and	B-X
HMC	B-X
-	B-X
1	B-X
cells	B-X
were	B-X
the	B-X
only	B-X
line	B-X
lacking	B-X
RXR	B-X
alpha	B-X

RA-mediated	O
effects	O
on	O
ICAM-1	B-protein
expression	O
,	O
studied	O
in	O
parallel	O
,	O
were	O
clearly	O
distinct	O
from	O
those	O
on	O
ICAM-3	B-protein
.	O
<EOS>	B-X
RA	B-X
-	B-X
mediated	B-X
effects	B-X
on	B-X
ICAM	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
studied	B-X
in	B-X
parallel	B-X
,	B-X
were	B-X
clearly	B-X
distinct	B-X
from	B-X
those	B-X
on	B-X
ICAM	B-X
-	B-X
3	B-X
<EOS>	B-X
Retinoic	B-X
acid	B-X
up	B-X
-	B-X
regulates	B-X
myeloid	B-X
ICAM	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
function	B-X
in	B-X
a	B-X
cell	B-X
-	B-X
specific	B-X
fashion	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
evidence	B-X
for	B-X
retinoid	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
mast	B-X
cell	B-X
lineage	B-X
.	B-X
<EOS>	B-X
Investigation	B-X
of	B-X
retinoid	B-X
receptor	B-X
expression	B-X
,	B-X
known	B-X
to	B-X
mediate	B-X
intracellular	B-X
RA	B-X
signaling	B-X
,	B-X
revealed	B-X
presence	B-X
of	B-X
RAR	B-X
alpha	B-X
,	B-X
RAR	B-X
gamma	B-X
,	B-X
RXR	B-X
beta	B-X
,	B-X
and	B-X
RXR	B-X
gamma	B-X
transcripts	B-X
in	B-X
all	B-X
cell	B-X
lines	B-X
studied	B-X
,	B-X
and	B-X
HMC	B-X
-	B-X
1	B-X
cells	B-X
were	B-X
the	B-X
only	B-X
line	B-X
lacking	B-X
RXR	B-X
alpha	B-X
<EOS>	B-X
This	B-X
process	B-X
was	B-X
dose	B-X
-	B-X
	B-X
and	B-X
time	B-X
-	B-X
dependent	B-X
and	B-X
detectable	B-X
by	B-X
flow	B-X
cytometry	B-X
,	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
ELISA	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
analysis	B-X

Investigation	O
of	O
retinoid	B-protein
receptor	I-protein
expression	O
,	O
known	O
to	O
mediate	O
intracellular	O
RA	O
signaling	O
,	O
revealed	O
presence	O
of	O
RAR	B-RNA
alpha	I-RNA
,	I-RNA
RAR	I-RNA
gamma	I-RNA
,	I-RNA
RXR	I-RNA
beta	I-RNA
,	I-RNA
and	I-RNA
RXR	I-RNA
gamma	I-RNA
transcripts	I-RNA
in	O
all	O
cell	O
lines	O
studied	O
,	O
and	O
HMC-1	B-cell_line
cells	I-cell_line
were	O
the	O
only	O
line	O
lacking	O
RXR	B-protein
alpha	I-protein
.	O
<EOS>	B-X
Investigation	B-X
of	B-X
retinoid	B-X
receptor	B-X
expression	B-X
,	B-X
known	B-X
to	B-X
mediate	B-X
intracellular	B-X
RA	B-X
signaling	B-X
,	B-X
revealed	B-X
presence	B-X
of	B-X
RAR	B-X
alpha	B-X
,	B-X
RAR	B-X
gamma	B-X
,	B-X
RXR	B-X
beta	B-X
,	B-X
and	B-X
RXR	B-X
gamma	B-X
transcripts	B-X
in	B-X
all	B-X
cell	B-X
lines	B-X
studied	B-X
,	B-X
and	B-X
HMC	B-X
-	B-X
1	B-X
cells	B-X
were	B-X
the	B-X
only	B-X
line	B-X
lacking	B-X
RXR	B-X
alpha	B-X
<EOS>	B-X
Investigation	B-X
of	B-X
mast	B-X
cell	B-X
responsiveness	B-X
toward	B-X
retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
revealed	B-X
selective	B-X
promotion	B-X
of	B-X
ICAM	B-X
-	B-X
3	B-X
expression	B-X
in	B-X
the	B-X
human	B-X
mast	B-X
cell	B-X
line	B-X
HMC	B-X
-	B-X
1	B-X
<EOS>	B-X
Retinoic	B-X
acid	B-X
up	B-X
-	B-X
regulates	B-X
myeloid	B-X
ICAM	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
function	B-X
in	B-X
a	B-X
cell	B-X
-	B-X
specific	B-X
fashion	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
evidence	B-X
for	B-X
retinoid	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
mast	B-X
cell	B-X
lineage	B-X
.	B-X
<EOS>	B-X
ICAM	B-X
-	B-X
3	B-X
modulation	B-X
was	B-X
found	B-X
to	B-X
be	B-X
cell	B-X
-	B-X
type	B-X
dependent	B-X
,	B-X
detectable	B-X
also	B-X
for	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
and	B-X
monocytes	B-X
but	B-X
not	B-X
U	B-X
-	B-X
937	B-X
and	B-X
only	B-X
weakly	B-X
for	B-X
KU812	B-X
cells	B-X

RAR	B-protein
beta	I-protein
,	O
not	O
expressed	O
at	O
baseline	O
,	O
was	O
induced	O
by	O
RA	O
in	O
a	O
fashion	O
obviously	O
correlating	O
with	O
ICAM-3	B-protein
up-regulation	O
.	O
<EOS>	B-X
RARβ	B-X
is	B-X
a	B-X
tumor	B-X
-	B-X
suppressor	B-X
gene	B-X
silenced	B-X
by	B-X
epigenetic	B-X
mechanisms	B-X
such	B-X
as	B-X
DNA	B-X
methylation	B-X
in	B-X
breast	B-X
,	B-X
cervical	B-X
and	B-X
non	B-X
-	B-X
small	B-X
cell	B-X
lung	B-X
cancers	B-X
<EOS>	B-X
DLEU2	B-X
was	B-X
highly	B-X
expressed	B-X
in	B-X
CRC	B-X
according	B-X
to	B-X
the	B-X
bioinformatic	B-X
analysis	B-X
and	B-X
its	B-X
high	B-X
expression	B-X
was	B-X
detected	B-X
in	B-X
CRC	B-X
cells	B-X
compared	B-X
to	B-X
the	B-X
normal	B-X
colon	B-X
epithelial	B-X
cells	B-X
(	B-X
FHC	B-X
)	B-X
<EOS>	B-X
Transcriptomic	B-X
and	B-X
immunoblotting	B-X
results	B-X
showed	B-X
that	B-X
these	B-X
NR	B-X
modulators	B-X
may	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
osteosarcoma	B-X
cells	B-X
by	B-X
regulating	B-X
the	B-X
PI3K	B-X
/	B-X
AKT	B-X
/	B-X
mTOR	B-X
and	B-X
ERK	B-X
/	B-X
mTOR	B-X
pathways	B-X
<EOS>	B-X
The	B-X
treatment	B-X
in	B-X
this	B-X
case	B-X
demonstrated	B-X
effective	B-X
response	B-X
to	B-X
Venetoclax	B-X
,	B-X
which	B-X
suggested	B-X
its	B-X
possible	B-X
role	B-X
for	B-X
the	B-X
patient	B-X
with	B-X
acute	B-X
promyelocytic	B-X
-	B-X
like	B-X
leukemias	B-X
(	B-X
APLL	B-X
)	B-X

Increased	O
ICAM-3	B-protein
expression	O
was	O
of	O
functional	O
significance	O
,	O
such	O
that	O
processes	O
stimulated	O
or	O
co-stimulated	O
via	O
ICAM-3	B-protein
(	O
homotypic	O
aggregation	O
,	O
IL-8	O
secretion	O
)	O
were	O
clearly	O
enhanced	O
upon	O
RA	O
pretreatment	O
,	O
suggesting	O
that	O
RA	O
may	O
contribute	O
via	O
hitherto	O
unrecognized	O
pathways	O
to	O
immune	O
function	O
and	O
host	O
defense	O
.	O
<EOS>	B-X
Increased	B-X
ICAM	B-X
-	B-X
3	B-X
expression	B-X
was	B-X
of	B-X
functional	B-X
significance	B-X
,	B-X
such	B-X
that	B-X
processes	B-X
stimulated	B-X
or	B-X
co	B-X
-	B-X
stimulated	B-X
via	B-X
ICAM	B-X
-	B-X
3	B-X
(	B-X
homotypic	B-X
aggregation	B-X
,	B-X
IL	B-X
-	B-X
8	B-X
secretion	B-X
)	B-X
were	B-X
clearly	B-X
enhanced	B-X
upon	B-X
RA	B-X
pretreatment	B-X
,	B-X
suggesting	B-X
that	B-X
RA	B-X
may	B-X
contribute	B-X
via	B-X
hitherto	B-X
unrecognized	B-X
pathways	B-X
to	B-X
immune	B-X
function	B-X
and	B-X
host	B-X
defense	B-X
<EOS>	B-X
Increased	B-X
expressions	B-X
of	B-X
interleukin	B-X
-	B-X
8	B-X
and	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
measured	B-X
as	B-X
protein	B-X
as	B-X
well	B-X
as	B-X
mRNA	B-X
by	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
were	B-X
detected	B-X
after	B-X
exposure	B-X
to	B-X
BLM	B-X
<EOS>	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
HUVEC	B-X
were	B-X
stimulated	B-X
to	B-X
secrete	B-X
cytokines	B-X
and	B-X
express	B-X
adhesion	B-X
molecules	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
low	B-X
concentrations	B-X
of	B-X
BLM	B-X
which	B-X
have	B-X
a	B-X
mildly	B-X
inhibitory	B-X
effect	B-X
on	B-X
cellular	B-X
proliferation	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
although	B-X
inhibitable	B-X
by	B-X
two	B-X
of	B-X
six	B-X
mAbs	B-X
against	B-X
LFA	B-X
-	B-X
1	B-X
,	B-X
HMC	B-X
-	B-X
1	B-X
aggregation	B-X
induced	B-X
via	B-X
ICAM	B-X
-	B-X
3	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
an	B-X
adhesive	B-X
pathway	B-X
independent	B-X
of	B-X
LFA	B-X
-	B-X
1	B-X

CD28	B-protein
and	O
T	B-cell_type
cell	I-cell_type
co-stimulation	O
.	O

Over	O
the	O
last	O
decade	O
the	O
concept	O
of	O
T	B-cell_type
cell	I-cell_type
co-stimulation	O
has	O
emerged	O
to	O
take	O
a	O
central	O
role	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
.	O

However	O
,	O
the	O
exact	O
definition	O
of	O
co-stimulation	O
is	O
still	O
unclear	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
exact	B-X
definition	B-X
of	B-X
co	B-X
-	B-X
stimulation	B-X
is	B-X
still	B-X
unclear	B-X
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
while	B-X
co	B-X
-	B-X
stimulation	B-X
is	B-X
important	B-X
,	B-X
there	B-X
is	B-X
little	B-X
evidence	B-X
to	B-X
link	B-X
co	B-X
-	B-X
stimulation	B-X
with	B-X
T	B-X
cell	B-X
anergy	B-X
<EOS>	B-X
Over	B-X
the	B-X
last	B-X
decade	B-X
the	B-X
concept	B-X
of	B-X
T	B-X
cell	B-X
co	B-X
-	B-X
stimulation	B-X
has	B-X
emerged	B-X
to	B-X
take	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
<EOS>	B-X
CD28	B-X
and	B-X
T	B-X
cell	B-X
co	B-X
-	B-X
stimulation	B-X
.	B-X

In	O
this	O
review	O
,	O
we	O
re-examine	O
the	O
concept	O
of	O
co-stimulation	O
.	O
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
re	B-X
-	B-X
examine	B-X
the	B-X
concept	B-X
of	B-X
co	B-X
-	B-X
stimulation	B-X
<EOS>	B-X
We	B-X
then	B-X
suggest	B-X
a	B-X
framework	B-X
for	B-X
studying	B-X
co	B-X
-	B-X
stimulation	B-X
<EOS>	B-X
CD28	B-X
and	B-X
T	B-X
cell	B-X
co	B-X
-	B-X
stimulation	B-X
.	B-X
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
while	B-X
co	B-X
-	B-X
stimulation	B-X
is	B-X
important	B-X
,	B-X
there	B-X
is	B-X
little	B-X
evidence	B-X
to	B-X
link	B-X
co	B-X
-	B-X
stimulation	B-X
with	B-X
T	B-X
cell	B-X
anergy	B-X

We	O
suggest	O
that	O
while	O
co-stimulation	O
is	O
important	O
,	O
there	O
is	O
little	O
evidence	O
to	O
link	O
co-stimulation	O
with	O
T	B-cell_type
cell	I-cell_type
anergy	O
.	O

We	O
then	O
suggest	O
a	O
framework	O
for	O
studying	O
co-stimulation	O
.	O
<EOS>	B-X
We	B-X
then	B-X
suggest	B-X
a	B-X
framework	B-X
for	B-X
studying	B-X
co	B-X
-	B-X
stimulation	B-X
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
re	B-X
-	B-X
examine	B-X
the	B-X
concept	B-X
of	B-X
co	B-X
-	B-X
stimulation	B-X
<EOS>	B-X
CD28	B-X
and	B-X
T	B-X
cell	B-X
co	B-X
-	B-X
stimulation	B-X
.	B-X
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
while	B-X
co	B-X
-	B-X
stimulation	B-X
is	B-X
important	B-X
,	B-X
there	B-X
is	B-X
little	B-X
evidence	B-X
to	B-X
link	B-X
co	B-X
-	B-X
stimulation	B-X
with	B-X
T	B-X
cell	B-X
anergy	B-X

Focusing	O
on	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
CD28	B-protein
,	O
we	O
discuss	O
four	O
areas	O
of	O
T	B-cell_type
cell	I-cell_type
activation	O
where	O
co-stimulation	O
may	O
play	O
a	O
role	O
.	O
<EOS>	B-X
Focusing	B-X
on	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
CD28	B-X
,	B-X
we	B-X
discuss	B-X
four	B-X
areas	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
where	B-X
co	B-X
-	B-X
stimulation	B-X
may	B-X
play	B-X
a	B-X
role	B-X
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
while	B-X
co	B-X
-	B-X
stimulation	B-X
is	B-X
important	B-X
,	B-X
there	B-X
is	B-X
little	B-X
evidence	B-X
to	B-X
link	B-X
co	B-X
-	B-X
stimulation	B-X
with	B-X
T	B-X
cell	B-X
anergy	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
exact	B-X
definition	B-X
of	B-X
co	B-X
-	B-X
stimulation	B-X
is	B-X
still	B-X
unclear	B-X
<EOS>	B-X
We	B-X
then	B-X
suggest	B-X
a	B-X
framework	B-X
for	B-X
studying	B-X
co	B-X
-	B-X
stimulation	B-X

Regulation	O
of	O
activator	B-protein
protein-1	I-protein
and	O
NF-kappa	B-protein
B	I-protein
in	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
exposed	O
to	O
peripheral	B-protein
self-antigens	I-protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
CD8+	B-X
T	B-X
cells	B-X
exposed	B-X
to	B-X
peripheral	B-X
self	B-X
-	B-X
antigens	B-X
.	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
events	B-X
that	B-X
control	B-X
T	B-X
cell	B-X
tolerance	B-X
to	B-X
peripheral	B-X
self	B-X
Ags	B-X
are	B-X
still	B-X
unknown	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
activated	B-X
in	B-X
vivo	B-X
with	B-X
APCs	B-X
,	B-X
which	B-X
express	B-X
high	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
high	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
,	B-X
the	B-X
unresponsive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
expressed	B-X
no	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
only	B-X
weak	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
regulation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
mediated	B-X
transcription	B-X
during	B-X
in	B-X
vivo	B-X
induction	B-X
of	B-X
tolerance	B-X
to	B-X
a	B-X
self	B-X
Ag	B-X
expressed	B-X
exclusively	B-X
on	B-X
hepatocytes	B-X

The	O
transcriptional	O
events	O
that	O
control	O
T	B-cell_type
cell	I-cell_type
tolerance	O
to	O
peripheral	B-protein
self	I-protein
Ags	I-protein
are	O
still	O
unknown	O
.	O
<EOS>	B-X
The	B-X
transcriptional	B-X
events	B-X
that	B-X
control	B-X
T	B-X
cell	B-X
tolerance	B-X
to	B-X
peripheral	B-X
self	B-X
Ags	B-X
are	B-X
still	B-X
unknown	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
CD8+	B-X
T	B-X
cells	B-X
exposed	B-X
to	B-X
peripheral	B-X
self	B-X
-	B-X
antigens	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
regulation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
mediated	B-X
transcription	B-X
during	B-X
in	B-X
vivo	B-X
induction	B-X
of	B-X
tolerance	B-X
to	B-X
a	B-X
self	B-X
Ag	B-X
expressed	B-X
exclusively	B-X
on	B-X
hepatocytes	B-X
<EOS>	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
fine	B-X
regulation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complex	B-X
formation	B-X
may	B-X
determine	B-X
T	B-X
cell	B-X
fate	B-X

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
regulation	O
of	O
AP-1	B-protein
-	O
and	O
NF-kappa	B-protein
B	I-protein
-mediated	O
transcription	O
during	O
in	O
vivo	O
induction	O
of	O
tolerance	O
to	O
a	O
self	B-protein
Ag	I-protein
expressed	O
exclusively	O
on	O
hepatocytes	B-cell_type
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
regulation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
mediated	B-X
transcription	B-X
during	B-X
in	B-X
vivo	B-X
induction	B-X
of	B-X
tolerance	B-X
to	B-X
a	B-X
self	B-X
Ag	B-X
expressed	B-X
exclusively	B-X
on	B-X
hepatocytes	B-X
<EOS>	B-X
The	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
distinct	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complexes	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
activated	B-X
in	B-X
vivo	B-X
with	B-X
APCs	B-X
,	B-X
which	B-X
express	B-X
high	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
high	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
,	B-X
the	B-X
unresponsive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
expressed	B-X
no	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
only	B-X
weak	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
Naive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Désiré	B-X
(	B-X
Des	B-X
)	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
isolated	B-X
from	B-X
the	B-X
Des	B-X
TCR	B-X
-	B-X
transgenic	B-X
mice	B-X
that	B-X
are	B-X
specific	B-X
for	B-X
the	B-X
H	B-X
-	B-X
2K	B-X
(	B-X
b	B-X
)	B-X
class	B-X
I	B-X
Ag	B-X
were	B-X
transferred	B-X
into	B-X
Alb	B-X
-	B-X
K	B-X
(	B-X
b	B-X
)	B-X
	B-X
-	B-X
transgenic	B-X
mice	B-X
that	B-X
express	B-X
the	B-X
H	B-X
-	B-X
2K	B-X
(	B-X
b	B-X
)	B-X
Ag	B-X
on	B-X
hepatocytes	B-X
only	B-X

Naive	B-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
Desire	I-cell_type
(	I-cell_type
Des	I-cell_type
)	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
isolated	O
from	O
the	O
Des	O
TCR-transgenic	O
mice	O
that	O
are	O
specific	O
for	O
the	O
H-2K	B-protein
(	I-protein
b	I-protein
)	I-protein
class	I-protein
I	I-protein
Ag	I-protein
were	O
transferred	O
into	O
Alb-K	O
(	O
b	O
)	O
-transgenic	O
mice	O
that	O
express	O
the	O
H-2K	B-protein
(	I-protein
b	I-protein
)	I-protein
Ag	I-protein
on	O
hepatocytes	B-cell_type
only	O
.	O

Tolerance	O
develops	O
in	O
these	O
mice	O
.	O
<EOS>	B-X
CTLs	B-X
,	B-X
NK	B-X
cells	B-X
and	B-X
NK	B-X
-	B-X
derived	B-X
EVs	B-X
against	B-X
breast	B-X
cancer	B-X
.	B-X
<EOS>	B-X
These	B-X
will	B-X
segregate	B-X
through	B-X
cell	B-X
divisions	B-X
and	B-X
be	B-X
present	B-X
in	B-X
cells	B-X
'	B-X
progeny	B-X
<EOS>	B-X
VSG	B-X
improved	B-X
glucose	B-X
tolerance	B-X
in	B-X
both	B-X
saline	B-X
and	B-X
HDM	B-X
-	B-X
challenged	B-X
mice	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
Tet3	B-X
selectively	B-X
controls	B-X
the	B-X
development	B-X
of	B-X
CD25	B-X

We	O
found	O
that	O
the	O
self-reactive	B-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
Des	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
transiently	O
activated	O
,	O
then	O
became	O
unresponsive	O
and	O
were	O
further	O
deleted	O
.	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
self	B-X
-	B-X
reactive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
were	B-X
transiently	B-X
activated	B-X
,	B-X
then	B-X
became	B-X
unresponsive	B-X
and	B-X
were	B-X
further	B-X
deleted	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
activated	B-X
in	B-X
vivo	B-X
with	B-X
APCs	B-X
,	B-X
which	B-X
express	B-X
high	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
high	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
,	B-X
the	B-X
unresponsive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
expressed	B-X
no	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
only	B-X
weak	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
events	B-X
that	B-X
control	B-X
T	B-X
cell	B-X
tolerance	B-X
to	B-X
peripheral	B-X
self	B-X
Ags	B-X
are	B-X
still	B-X
unknown	B-X
<EOS>	B-X
Naive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Désiré	B-X
(	B-X
Des	B-X
)	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
isolated	B-X
from	B-X
the	B-X
Des	B-X
TCR	B-X
-	B-X
transgenic	B-X
mice	B-X
that	B-X
are	B-X
specific	B-X
for	B-X
the	B-X
H	B-X
-	B-X
2K	B-X
(	B-X
b	B-X
)	B-X
class	B-X
I	B-X
Ag	B-X
were	B-X
transferred	B-X
into	B-X
Alb	B-X
-	B-X
K	B-X
(	B-X
b	B-X
)	B-X
	B-X
-	B-X
transgenic	B-X
mice	B-X
that	B-X
express	B-X
the	B-X
H	B-X
-	B-X
2K	B-X
(	B-X
b	B-X
)	B-X
Ag	B-X
on	B-X
hepatocytes	B-X
only	B-X

In	O
contrast	O
to	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
Des	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
activated	O
in	O
vivo	O
with	O
APCs	O
,	O
which	O
express	O
high	O
AP-1	B-protein
and	O
high	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	O
,	O
the	O
unresponsive	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
Des	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
expressed	O
no	O
AP-1	B-protein
and	O
only	O
weak	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
activated	B-X
in	B-X
vivo	B-X
with	B-X
APCs	B-X
,	B-X
which	B-X
express	B-X
high	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
high	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
,	B-X
the	B-X
unresponsive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
expressed	B-X
no	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
only	B-X
weak	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
The	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
distinct	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complexes	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
regulation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
mediated	B-X
transcription	B-X
during	B-X
in	B-X
vivo	B-X
induction	B-X
of	B-X
tolerance	B-X
to	B-X
a	B-X
self	B-X
Ag	B-X
expressed	B-X
exclusively	B-X
on	B-X
hepatocytes	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
CD8+	B-X
T	B-X
cells	B-X
exposed	B-X
to	B-X
peripheral	B-X
self	B-X
-	B-X
antigens	B-X
.	B-X

The	O
differences	O
in	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	O
correlated	O
with	O
the	O
generation	O
of	O
distinct	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
.	O
<EOS>	B-X
The	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
distinct	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complexes	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
activated	B-X
in	B-X
vivo	B-X
with	B-X
APCs	B-X
,	B-X
which	B-X
express	B-X
high	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
high	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
,	B-X
the	B-X
unresponsive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
expressed	B-X
no	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
only	B-X
weak	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
RelA	B-X
-	B-X
deficient	B-X
cell	B-X
lines	B-X
appear	B-X
to	B-X
have	B-X
distinct	B-X
alterations	B-X
in	B-X
the	B-X
p53	B-X
pathway	B-X
,	B-X
which	B-X
correlate	B-X
with	B-X
the	B-X
normal	B-X
vs	B-X
transformed	B-X
status	B-X
of	B-X
individual	B-X
cell	B-X
lines	B-X
<EOS>	B-X
In	B-X
clones	B-X
stably	B-X
overexpressing	B-X
hIRAK	B-X
a	B-X
weak	B-X
constitutive	B-X
activation	B-X
of	B-X
NFkappaB	B-X
correlated	B-X
with	B-X
a	B-X
low	B-X
basal	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
which	B-X
was	B-X
enhanced	B-X
in	B-X
an	B-X
IL	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
manner	B-X

Indeed	O
,	O
in	O
vivo	O
primed	B-cell_type
T	I-cell_type
cells	I-cell_type
predominantly	O
express	O
p50/p50	B-protein
and	I-protein
p65/p50	I-protein
dimers	I-protein
,	O
whereas	O
these	O
p50-containing	B-protein
complexes	I-protein
are	O
barely	O
detectable	O
in	O
tolerant	B-cell_type
T	I-cell_type
cells	I-cell_type
that	O
express	O
p65-	B-protein
and	I-protein
c-Rel-containing	I-protein
complexes	I-protein
.	O
<EOS>	B-X
Indeed	B-X
,	B-X
in	B-X
vivo	B-X
primed	B-X
T	B-X
cells	B-X
predominantly	B-X
express	B-X
p50	B-X
/	B-X
p50	B-X
and	B-X
p65	B-X
/	B-X
p50	B-X
dimers	B-X
,	B-X
whereas	B-X
these	B-X
p50	B-X
-	B-X
containing	B-X
complexes	B-X
are	B-X
barely	B-X
detectable	B-X
in	B-X
tolerant	B-X
T	B-X
cells	B-X
that	B-X
express	B-X
p65	B-X
-	B-X
	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
-	B-X
containing	B-X
complexes	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
regulation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
mediated	B-X
transcription	B-X
during	B-X
in	B-X
vivo	B-X
induction	B-X
of	B-X
tolerance	B-X
to	B-X
a	B-X
self	B-X
Ag	B-X
expressed	B-X
exclusively	B-X
on	B-X
hepatocytes	B-X
<EOS>	B-X
The	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcriptional	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
distinct	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complexes	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
the	B-X
self	B-X
-	B-X
reactive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
Des	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
were	B-X
transiently	B-X
activated	B-X
,	B-X
then	B-X
became	B-X
unresponsive	B-X
and	B-X
were	B-X
further	B-X
deleted	B-X

These	O
observations	O
suggest	O
that	O
fine	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
formation	O
may	O
determine	O
T	B-cell_type
cell	I-cell_type
fate	O
.	O
<EOS>	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
fine	B-X
regulation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complex	B-X
formation	B-X
may	B-X
determine	B-X
T	B-X
cell	B-X
fate	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
events	B-X
that	B-X
control	B-X
T	B-X
cell	B-X
tolerance	B-X
to	B-X
peripheral	B-X
self	B-X
Ags	B-X
are	B-X
still	B-X
unknown	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
CD8+	B-X
T	B-X
cells	B-X
exposed	B-X
to	B-X
peripheral	B-X
self	B-X
-	B-X
antigens	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
regulation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
mediated	B-X
transcription	B-X
during	B-X
in	B-X
vivo	B-X
induction	B-X
of	B-X
tolerance	B-X
to	B-X
a	B-X
self	B-X
Ag	B-X
expressed	B-X
exclusively	B-X
on	B-X
hepatocytes	B-X

Transcriptional	O
regulation	O
in	O
lymphocytes	B-cell_type
.	O
<EOS>	B-X
Transcriptional	B-X
and	B-X
Epigenetic	B-X
Regulation	B-X
of	B-X
Context	B-X
-	B-X
Dependent	B-X
Plasticity	B-X
in	B-X
T	B-X
-	B-X
Helper	B-X
Lineages	B-X
.	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
regulator	B-X
Sin3A	B-X
balances	B-X
IL	B-X
-	B-X
17A	B-X
and	B-X
Foxp3	B-X
expression	B-X
in	B-X
primary	B-X
CD4	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
Lymphoma	B-X
represents	B-X
a	B-X
myriad	B-X
collection	B-X
of	B-X
neoplasms	B-X
that	B-X
impact	B-X
lymphocytes	B-X
<EOS>	B-X
The	B-X
Sin3	B-X
transcriptional	B-X
regulator	B-X
homolog	B-X
A	B-X
(	B-X
Sin3A	B-X
)	B-X
is	B-X
the	B-X
core	B-X
member	B-X
of	B-X
a	B-X
multiprotein	B-X
chromatin	B-X
-	B-X
modifying	B-X
complex	B-X

Lymphocytes	B-cell_type
have	O
been	O
used	O
to	O
investigate	O
many	O
cellular	O
processes	O
,	O
including	O
lineage	O
commitment	O
,	O
differentiation	O
,	O
proliferation	O
and	O
apoptosis	O
.	O
<EOS>	B-X
Lymphocytes	B-X
have	B-X
been	B-X
used	B-X
to	B-X
investigate	B-X
many	B-X
cellular	B-X
processes	B-X
,	B-X
including	B-X
lineage	B-X
commitment	B-X
,	B-X
differentiation	B-X
,	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
that	B-X
mediate	B-X
these	B-X
processes	B-X
are	B-X
often	B-X
expressed	B-X
broadly	B-X
in	B-X
many	B-X
cell	B-X
types	B-X
<EOS>	B-X
The	B-X
emerging	B-X
theme	B-X
is	B-X
one	B-X
of	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
regulation	B-X
,	B-X
affecting	B-X
not	B-X
only	B-X
the	B-X
functional	B-X
activation	B-X
of	B-X
transcription	B-X
factors	B-X
but	B-X
also	B-X
their	B-X
access	B-X
to	B-X
appropriate	B-X
regions	B-X
of	B-X
DNA	B-X
<EOS>	B-X
Transcriptional	B-X
regulation	B-X
in	B-X
lymphocytes	B-X
.	B-X

The	O
transcription	B-protein
factors	I-protein
that	O
mediate	O
these	O
processes	O
are	O
often	O
expressed	O
broadly	O
in	O
many	O
cell	O
types	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
that	B-X
mediate	B-X
these	B-X
processes	B-X
are	B-X
often	B-X
expressed	B-X
broadly	B-X
in	B-X
many	B-X
cell	B-X
types	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
transcriptional	B-X
reporters	B-X
,	B-X
such	B-X
as	B-X
promoters	B-X
of	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
genes	B-X
,	B-X
are	B-X
broadly	B-X
used	B-X
as	B-X
cell	B-X
identity	B-X
markers	B-X
in	B-X
developmental	B-X
biology	B-X
<EOS>	B-X
As	B-X
gene	B-X
-	B-X
specific	B-X
transcription	B-X
factors	B-X
,	B-X
nuclear	B-X
receptors	B-X
are	B-X
broadly	B-X
involved	B-X
in	B-X
many	B-X
important	B-X
biological	B-X
processes	B-X
<EOS>	B-X
GLD	B-X
-	B-X
4	B-X
-	B-X
mediated	B-X
translational	B-X
activation	B-X
regulates	B-X
the	B-X
size	B-X
of	B-X
the	B-X
proliferative	B-X
germ	B-X
cell	B-X
pool	B-X
in	B-X
the	B-X
adult	B-X
C.	B-X
elegans	B-X
germ	B-X
line	B-X
.	B-X

The	O
emerging	O
theme	O
is	O
one	O
of	O
cell-type-specific	O
regulation	O
,	O
affecting	O
not	O
only	O
the	O
functional	O
activation	O
of	O
transcription	B-protein
factors	I-protein
but	O
also	O
their	O
access	O
to	O
appropriate	O
regions	O
of	O
DNA	O
.	O

Existence	O
of	O
retinoic	B-protein
acid-receptor	I-protein
-independent	O
retinoid	B-protein
X-receptor	I-protein
-dependent	O
pathway	O
in	O
myeloid	B-cell_type
cell	I-cell_type
function	O
.	O
<EOS>	B-X
Existence	B-X
of	B-X
retinoic	B-X
acid	B-X
-	B-X
receptor	B-X
-	B-X
independent	B-X
retinoid	B-X
X	B-X
-	B-X
receptor	B-X
-	B-X
dependent	B-X
pathway	B-X
in	B-X
myeloid	B-X
cell	B-X
function	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
pharmacological	B-X
RXR	B-X
-	B-X
dependent	B-X
pathway	B-X
that	B-X
is	B-X
activated	B-X
by	B-X
a	B-X
ligand	B-X
that	B-X
can	B-X
bind	B-X
to	B-X
RXR	B-X
<EOS>	B-X
By	B-X
using	B-X
these	B-X
compounds	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
RAR	B-X
-	B-X
dependent	B-X
and	B-X
RXR	B-X
-	B-X
dependent	B-X
pathways	B-X
operate	B-X
to	B-X
mediate	B-X
the	B-X
diverse	B-X
activities	B-X
of	B-X
retinoids	B-X
,	B-X
particularly	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
RXR	B-X
pathway	B-X
on	B-X
cellular	B-X
function	B-X
<EOS>	B-X
Although	B-X
several	B-X
members	B-X
of	B-X
the	B-X
nuclear	B-X
hormone	B-X
receptor	B-X
superfamily	B-X
have	B-X
emerged	B-X
as	B-X
important	B-X
regulators	B-X
of	B-X
macrophage	B-X
gene	B-X
expression	B-X
,	B-X
the	B-X
existence	B-X
in	B-X
vivo	B-X
of	B-X
an	B-X
RXR	B-X
signaling	B-X
pathway	B-X
in	B-X
macrophages	B-X
has	B-X
not	B-X
been	B-X
established	B-X

We	O
previously	O
reported	O
that	O
ER-27191	O
(	O
4-	O
[	O
4	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10-hexahydro-7	O
,	O
7	O
,	O
10	O
,	O
10-tetramethyl-1-	O
(	O
3-pyridylmethyl	O
)	O
anthra	O
[	O
1	O
,	O
2-b	O
]	O
pyrrol-3-yl	O
]	O
benzoic	O
acid	O
)	O
is	O
a	O
potent	O
antagonist	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
,	O
and	O
ER-35795	O
(	O
(	O
2E	O
,	O
4E	O
,	O
6E	O
)	O
-7-	O
[	O
1-	O
(	O
1-methylethyl	O
)	O
-8-chloro-1	O
,	O
2	O
,	O
3	O
,	O
4-tetrahydroquinolin-6-yl	O
]	O
-6-fluoro-3-methyl-2	O
,	O
4	O
,	O
6-nonatrienoic	O
acid	O
)	O
is	O
a	O
novel	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	O
RXR	B-protein
)	O
-specific	O
agonist	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
ER	B-X
-	B-X
27191	B-X
(	B-X
4	B-X
-	B-X
	B-X
[	B-X
4,5,7,8,9,10	B-X
-	B-X
hexahydro	B-X
-	B-X
7,7,10,10	B-X
-	B-X
tetramethyl	B-X
-	B-X
1	B-X
-	B-X
	B-X
(	B-X
3	B-X
-	B-X
pyridylmethyl	B-X
)	B-X
anthra	B-X
[	B-X
1,2	B-X
-	B-X
b	B-X
]	B-X
pyrrol	B-X
-	B-X
3	B-X
-	B-X
yl	B-X
]	B-X
benzoic	B-X
acid	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
antagonist	B-X
of	B-X
retinoic	B-X
acid	B-X
receptor	B-X
(	B-X
RAR	B-X
)	B-X
,	B-X
and	B-X
ER	B-X
-	B-X
35795	B-X
(	B-X
(	B-X
2E,4E,6E	B-X
)	B-X
	B-X
-	B-X
7	B-X
-	B-X
	B-X
[	B-X
1	B-X
-	B-X
	B-X
(	B-X
1	B-X
-	B-X
methylethyl	B-X
)	B-X
	B-X
-	B-X
8	B-X
-	B-X
chloro	B-X
-	B-X
1,2,3,4	B-X
-	B-X
tetrahydroquinolin	B-X
-	B-X
6	B-X
-	B-X
yl	B-X
]	B-X
	B-X
-	B-X
6	B-X
-	B-X
fluoro	B-X
-	B-X
3	B-X
-	B-X
methyl	B-X
-	B-X
2,4,6	B-X
-	B-X
nonatrienoic	B-X
acid	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
retinoid	B-X
X	B-X
receptor	B-X
(	B-X
RXR	B-X
)	B-X
	B-X
-	B-X
specific	B-X
agonist	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
differentiation	B-X
induced	B-X
by	B-X
the	B-X
ER	B-X
-	B-X
35795	B-X
was	B-X
not	B-X
antagonized	B-X
at	B-X
all	B-X
by	B-X
the	B-X
RAR	B-X
antagonist	B-X
,	B-X
but	B-X
was	B-X
inhibited	B-X
by	B-X
an	B-X
RXR	B-X
homodimer	B-X
antagonist	B-X
(	B-X
LGD100754	B-X
,	B-X
(	B-X
2E,4E,6Z	B-X
)	B-X
	B-X
-	B-X
7	B-X
-	B-X
	B-X
(	B-X
3	B-X
-	B-X
n	B-X
-	B-X
propoxy	B-X
-	B-X
5,6,7,8	B-X
-	B-X
tetrahydro	B-X
-	B-X
5,5,8,8	B-X
-	B-X
tetramethylnaphthalen	B-X
-	B-X
2	B-X
-	B-X
yl	B-X
)	B-X
	B-X
-	B-X
3	B-X
-	B-X
methylocta	B-X
-	B-X
2,4,6	B-X
-	B-X
trienoic	B-X
acid	B-X
)	B-X
<EOS>	B-X
By	B-X
using	B-X
these	B-X
compounds	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
RAR	B-X
-	B-X
dependent	B-X
and	B-X
RXR	B-X
-	B-X
dependent	B-X
pathways	B-X
operate	B-X
to	B-X
mediate	B-X
the	B-X
diverse	B-X
activities	B-X
of	B-X
retinoids	B-X
,	B-X
particularly	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
RXR	B-X
pathway	B-X
on	B-X
cellular	B-X
function	B-X
<EOS>	B-X
These	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
pharmacological	B-X
RXR	B-X
-	B-X
dependent	B-X
pathway	B-X
that	B-X
is	B-X
activated	B-X
by	B-X
a	B-X
ligand	B-X
that	B-X
can	B-X
bind	B-X
to	B-X
RXR	B-X

By	O
using	O
these	O
compounds	O
,	O
we	O
investigated	O
whether	O
distinct	O
RAR	B-protein
-dependent	O
and	O
RXR	B-protein
-dependent	O
pathways	O
operate	O
to	O
mediate	O
the	O
diverse	O
activities	O
of	O
retinoids	O
,	O
particularly	O
,	O
the	O
effects	O
of	O
the	O
RXR	B-protein
pathway	O
on	O
cellular	O
function	O
.	O
<EOS>	B-X
By	B-X
using	B-X
these	B-X
compounds	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
RAR	B-X
-	B-X
dependent	B-X
and	B-X
RXR	B-X
-	B-X
dependent	B-X
pathways	B-X
operate	B-X
to	B-X
mediate	B-X
the	B-X
diverse	B-X
activities	B-X
of	B-X
retinoids	B-X
,	B-X
particularly	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
RXR	B-X
pathway	B-X
on	B-X
cellular	B-X
function	B-X
<EOS>	B-X
These	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
pharmacological	B-X
RXR	B-X
-	B-X
dependent	B-X
pathway	B-X
that	B-X
is	B-X
activated	B-X
by	B-X
a	B-X
ligand	B-X
that	B-X
can	B-X
bind	B-X
to	B-X
RXR	B-X
<EOS>	B-X
Existence	B-X
of	B-X
retinoic	B-X
acid	B-X
-	B-X
receptor	B-X
-	B-X
independent	B-X
retinoid	B-X
X	B-X
-	B-X
receptor	B-X
-	B-X
dependent	B-X
pathway	B-X
in	B-X
myeloid	B-X
cell	B-X
function	B-X
.	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
a	B-X
functional	B-X
RXR	B-X
-	B-X
pathway	B-X
was	B-X
also	B-X
seen	B-X
in	B-X
lipopolysaccharide	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
mouse	B-X
splenocyte	B-X
proliferation	B-X

ER-27191	O
completely	O
antagonized	O
HL60	B-cell_line
cell	I-cell_line
differentiation	O
induced	O
by	O
all-trans-retinoic	O
acid	O
(	O
atRA	O
)	O
.	O
<EOS>	B-X
ER	B-X
-	B-X
27191	B-X
completely	B-X
antagonized	B-X
HL60	B-X
cell	B-X
differentiation	B-X
induced	B-X
by	B-X
all	B-X
-	B-X
trans	B-X
-	B-X
retinoic	B-X
acid	B-X
(	B-X
atRA	B-X
)	B-X
<EOS>	B-X
During	B-X
HL60	B-X
cell	B-X
differentiation	B-X
,	B-X
atRA	B-X
induced	B-X
RARbeta	B-X
mRNA	B-X
,	B-X
while	B-X
the	B-X
RXR	B-X
had	B-X
no	B-X
effect	B-X
<EOS>	B-X
These	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
pharmacological	B-X
RXR	B-X
-	B-X
dependent	B-X
pathway	B-X
that	B-X
is	B-X
activated	B-X
by	B-X
a	B-X
ligand	B-X
that	B-X
can	B-X
bind	B-X
to	B-X
RXR	B-X
<EOS>	B-X
Existence	B-X
of	B-X
retinoic	B-X
acid	B-X
-	B-X
receptor	B-X
-	B-X
independent	B-X
retinoid	B-X
X	B-X
-	B-X
receptor	B-X
-	B-X
dependent	B-X
pathway	B-X
in	B-X
myeloid	B-X
cell	B-X
function	B-X
.	B-X

However	O
,	O
the	O
differentiation	O
induced	O
by	O
the	O
ER-35795	O
was	O
not	O
antagonized	O
at	O
all	O
by	O
the	O
RAR	B-protein
antagonist	O
,	O
but	O
was	O
inhibited	O
by	O
an	O
RXR	B-protein
homodimer	I-protein
antagonist	O
(	O
LGD100754	O
,	O
(	O
2E	O
,	O
4E	O
,	O
6Z	O
)	O
-7-	O
(	O
3-n-propoxy-5	O
,	O
6	O
,	O
7	O
,	O
8-tetrahydro-5	O
,	O
5	O
,	O
8	O
,	O
8-tetramethylnaphthalen-2-yl	O
)	O
-3-methylocta-2	O
,	O
4	O
,	O
6-trienoic	O
acid	O
)	O
.	O

Its	O
agonistic	O
action	O
on	O
RXR/RAR	B-protein
heterodimer	I-protein
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
neutralized	O
by	O
the	O
RAR	B-protein
antagonist	O
.	O
<EOS>	B-X
Its	B-X
agonistic	B-X
action	B-X
on	B-X
RXR	B-X
/	B-X
RAR	B-X
heterodimer	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
was	B-X
neutralized	B-X
by	B-X
the	B-X
RAR	B-X
antagonist	B-X
<EOS>	B-X
These	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
pharmacological	B-X
RXR	B-X
-	B-X
dependent	B-X
pathway	B-X
that	B-X
is	B-X
activated	B-X
by	B-X
a	B-X
ligand	B-X
that	B-X
can	B-X
bind	B-X
to	B-X
RXR	B-X
<EOS>	B-X
By	B-X
using	B-X
these	B-X
compounds	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
RAR	B-X
-	B-X
dependent	B-X
and	B-X
RXR	B-X
-	B-X
dependent	B-X
pathways	B-X
operate	B-X
to	B-X
mediate	B-X
the	B-X
diverse	B-X
activities	B-X
of	B-X
retinoids	B-X
,	B-X
particularly	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
RXR	B-X
pathway	B-X
on	B-X
cellular	B-X
function	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
a	B-X
functional	B-X
RXR	B-X
-	B-X
pathway	B-X
was	B-X
also	B-X
seen	B-X
in	B-X
lipopolysaccharide	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
mouse	B-X
splenocyte	B-X
proliferation	B-X

During	O
HL60	B-cell_line
cell	I-cell_line
differentiation	O
,	O
atRA	O
induced	O
RARbeta	B-RNA
mRNA	I-RNA
,	O
while	O
the	O
RXR	B-protein
had	O
no	O
effect	O
.	O
<EOS>	B-X
During	B-X
HL60	B-X
cell	B-X
differentiation	B-X
,	B-X
atRA	B-X
induced	B-X
RARbeta	B-X
mRNA	B-X
,	B-X
while	B-X
the	B-X
RXR	B-X
had	B-X
no	B-X
effect	B-X
<EOS>	B-X
ER	B-X
-	B-X
27191	B-X
completely	B-X
antagonized	B-X
HL60	B-X
cell	B-X
differentiation	B-X
induced	B-X
by	B-X
all	B-X
-	B-X
trans	B-X
-	B-X
retinoic	B-X
acid	B-X
(	B-X
atRA	B-X
)	B-X
<EOS>	B-X
FR	B-X
-	B-X
β	B-X
mRNA	B-X
expression	B-X
in	B-X
KG	B-X
-	B-X
1	B-X
cells	B-X
was	B-X
higher	B-X
when	B-X
ATRA	B-X
was	B-X
present	B-X
in	B-X
culture	B-X
medium	B-X
at	B-X
10⁻⁶	B-X
mol	B-X
/	B-X
L	B-X
for	B-X
5	B-X
days	B-X
,	B-X
and	B-X
it	B-X
went	B-X
down	B-X
to	B-X
baseline	B-X
when	B-X
ATRA	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
medium	B-X
,	B-X
vice	B-X
versa	B-X
<EOS>	B-X
These	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
pharmacological	B-X
RXR	B-X
-	B-X
dependent	B-X
pathway	B-X
that	B-X
is	B-X
activated	B-X
by	B-X
a	B-X
ligand	B-X
that	B-X
can	B-X
bind	B-X
to	B-X
RXR	B-X

Interestingly	O
,	O
a	O
functional	O
RXR	B-protein
-pathway	O
was	O
also	O
seen	O
in	O
lipopolysaccharide-induced	O
inhibition	O
of	O
mouse	B-cell_type
splenocyte	I-cell_type
proliferation	O
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
a	B-X
functional	B-X
RXR	B-X
-	B-X
pathway	B-X
was	B-X
also	B-X
seen	B-X
in	B-X
lipopolysaccharide	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
mouse	B-X
splenocyte	B-X
proliferation	B-X
<EOS>	B-X
Existence	B-X
of	B-X
retinoic	B-X
acid	B-X
-	B-X
receptor	B-X
-	B-X
independent	B-X
retinoid	B-X
X	B-X
-	B-X
receptor	B-X
-	B-X
dependent	B-X
pathway	B-X
in	B-X
myeloid	B-X
cell	B-X
function	B-X
.	B-X
<EOS>	B-X
By	B-X
using	B-X
these	B-X
compounds	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
RAR	B-X
-	B-X
dependent	B-X
and	B-X
RXR	B-X
-	B-X
dependent	B-X
pathways	B-X
operate	B-X
to	B-X
mediate	B-X
the	B-X
diverse	B-X
activities	B-X
of	B-X
retinoids	B-X
,	B-X
particularly	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
RXR	B-X
pathway	B-X
on	B-X
cellular	B-X
function	B-X
<EOS>	B-X
Its	B-X
agonistic	B-X
action	B-X
on	B-X
RXR	B-X
/	B-X
RAR	B-X
heterodimer	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
was	B-X
neutralized	B-X
by	B-X
the	B-X
RAR	B-X
antagonist	B-X

These	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
pharmacological	O
RXR	B-protein
-dependent	O
pathway	O
that	O
is	O
activated	O
by	O
a	O
ligand	O
that	O
can	O
bind	O
to	O
RXR	B-protein
.	O
<EOS>	B-X
These	B-X
results	B-X
strongly	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
pharmacological	B-X
RXR	B-X
-	B-X
dependent	B-X
pathway	B-X
that	B-X
is	B-X
activated	B-X
by	B-X
a	B-X
ligand	B-X
that	B-X
can	B-X
bind	B-X
to	B-X
RXR	B-X
<EOS>	B-X
By	B-X
using	B-X
these	B-X
compounds	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
RAR	B-X
-	B-X
dependent	B-X
and	B-X
RXR	B-X
-	B-X
dependent	B-X
pathways	B-X
operate	B-X
to	B-X
mediate	B-X
the	B-X
diverse	B-X
activities	B-X
of	B-X
retinoids	B-X
,	B-X
particularly	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
RXR	B-X
pathway	B-X
on	B-X
cellular	B-X
function	B-X
<EOS>	B-X
Existence	B-X
of	B-X
retinoic	B-X
acid	B-X
-	B-X
receptor	B-X
-	B-X
independent	B-X
retinoid	B-X
X	B-X
-	B-X
receptor	B-X
-	B-X
dependent	B-X
pathway	B-X
in	B-X
myeloid	B-X
cell	B-X
function	B-X
.	B-X
<EOS>	B-X
Its	B-X
agonistic	B-X
action	B-X
on	B-X
RXR	B-X
/	B-X
RAR	B-X
heterodimer	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
was	B-X
neutralized	B-X
by	B-X
the	B-X
RAR	B-X
antagonist	B-X

Targeting	O
Src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
SHP-1	B-protein
)	O
into	O
lipid	O
rafts	O
inhibits	O
CD3	B-protein
-induced	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O
<EOS>	B-X
Targeting	B-X
Src	B-X
homology	B-X
2	B-X
domain	B-X
-	B-X
containing	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
SHP	B-X
-	B-X
1	B-X
)	B-X
into	B-X
lipid	B-X
rafts	B-X
inhibits	B-X
CD3	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
<EOS>	B-X
In	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
approximately	B-X
5	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
10	B-X
%	B-X
of	B-X
Src	B-X
homology	B-X
2	B-X
domain	B-X
-	B-X
containing	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
SHP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
constitutively	B-X
associated	B-X
with	B-X
plasma	B-X
membrane	B-X
,	B-X
and	B-X
nearly	B-X
50	B-X
%	B-X
of	B-X
SHP	B-X
-	B-X
2	B-X
is	B-X
translocated	B-X
to	B-X
plasma	B-X
membrane	B-X
after	B-X
vanadate	B-X
treatment	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
protein	B-X
tyrosine	B-X
phosphatases	B-X
(	B-X
PTPs	B-X
)	B-X
regulate	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
distribution	B-X
of	B-X
PTPs	B-X
in	B-X
subdomains	B-X
of	B-X
plasma	B-X
membrane	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
bulk	B-X
PTP	B-X
activity	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
membrane	B-X
is	B-X
present	B-X
outside	B-X
the	B-X
lipid	B-X
rafts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
sucrose	B-X
density	B-X
gradient	B-X
sedimentation	B-X

To	O
study	O
the	O
mechanism	O
by	O
which	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
(	O
PTPs	B-protein
)	O
regulate	O
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	O
,	O
we	O
investigated	O
the	O
distribution	O
of	O
PTPs	B-protein
in	O
subdomains	O
of	O
plasma	O
membrane	O
.	O

We	O
report	O
here	O
that	O
the	O
bulk	O
PTP	B-protein
activity	O
associated	O
with	O
T	B-cell_type
cell	I-cell_type
membrane	O
is	O
present	O
outside	O
the	O
lipid	O
rafts	O
,	O
as	O
determined	O
by	O
sucrose	O
density	O
gradient	O
sedimentation	O
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
approximately	O
5	O
--	O
10	O
%	O
of	O
Src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
SHP-1	B-protein
)	O
is	O
constitutively	O
associated	O
with	O
plasma	O
membrane	O
,	O
and	O
nearly	O
50	O
%	O
of	O
SHP-2	B-protein
is	O
translocated	O
to	O
plasma	O
membrane	O
after	O
vanadate	O
treatment	O
.	O

Similar	O
to	O
transmembrane	B-protein
PTP	I-protein
,	O
CD45	B-protein
,	O
the	O
membrane-associated	O
populations	O
of	O
SHP-1	B-protein
and	O
SHP-2	B-protein
are	O
essentially	O
excluded	O
from	O
lipid	O
rafts	O
,	O
where	O
other	O
signaling	B-protein
molecules	I-protein
such	O
as	O
Lck	B-protein
,	I-protein
linker	I-protein
for	I-protein
activation	I-protein
of	I-protein
T	I-protein
cells	I-protein
,	O
and	O
CD3	B-protein
zeta	I-protein
are	O
enriched	O
.	O
<EOS>	B-X
Similar	B-X
to	B-X
transmembrane	B-X
PTP	B-X
,	B-X
CD45	B-X
,	B-X
the	B-X
membrane	B-X
-	B-X
associated	B-X
populations	B-X
of	B-X
SHP	B-X
-	B-X
1	B-X
and	B-X
SHP	B-X
-	B-X
2	B-X
are	B-X
essentially	B-X
excluded	B-X
from	B-X
lipid	B-X
rafts	B-X
,	B-X
where	B-X
other	B-X
signaling	B-X
molecules	B-X
such	B-X
as	B-X
Lck	B-X
,	B-X
linker	B-X
for	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
CD3	B-X
zeta	B-X
are	B-X
enriched	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
bulk	B-X
PTP	B-X
activity	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
membrane	B-X
is	B-X
present	B-X
outside	B-X
the	B-X
lipid	B-X
rafts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
sucrose	B-X
density	B-X
gradient	B-X
sedimentation	B-X
<EOS>	B-X
It	B-X
suggests	B-X
that	B-X
a	B-X
restricted	B-X
partition	B-X
of	B-X
PTPs	B-X
among	B-X
membrane	B-X
subdomains	B-X
may	B-X
regulate	B-X
protein	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
T	B-X
cell	B-X
membrane	B-X
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
exclusion	B-X
of	B-X
PTPs	B-X
from	B-X
lipid	B-X
rafts	B-X
may	B-X
be	B-X
a	B-X
mechanism	B-X
that	B-X
potentiates	B-X
TCR	B-X
/	B-X
CD3	B-X
activation	B-X

We	O
further	O
demonstrated	O
that	O
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
these	O
substrates	O
is	O
largely	O
restricted	O
to	O
lipid	O
rafts	O
,	O
unless	O
PTPs	B-protein
are	O
inhibited	O
.	O
<EOS>	B-X
We	B-X
further	B-X
demonstrated	B-X
that	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
these	B-X
substrates	B-X
is	B-X
largely	B-X
restricted	B-X
to	B-X
lipid	B-X
rafts	B-X
,	B-X
unless	B-X
PTPs	B-X
are	B-X
inhibited	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
protein	B-X
tyrosine	B-X
phosphatases	B-X
(	B-X
PTPs	B-X
)	B-X
regulate	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
distribution	B-X
of	B-X
PTPs	B-X
in	B-X
subdomains	B-X
of	B-X
plasma	B-X
membrane	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
Lck	B-X
/	B-X
SHP	B-X
-	B-X
1	B-X
chimera	B-X
inside	B-X
lipid	B-X
rafts	B-X
profoundly	B-X
inhibits	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
CD3	B-X
zeta	B-X
/	B-X
epsilon	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
generation	B-X
,	B-X
and	B-X
nuclear	B-X
mobilization	B-X
of	B-X
NF	B-X
-	B-X
AT	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
bulk	B-X
PTP	B-X
activity	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
membrane	B-X
is	B-X
present	B-X
outside	B-X
the	B-X
lipid	B-X
rafts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
sucrose	B-X
density	B-X
gradient	B-X
sedimentation	B-X

It	O
suggests	O
that	O
a	O
restricted	O
partition	O
of	O
PTPs	B-protein
among	O
membrane	O
subdomains	O
may	O
regulate	O
protein	O
tyrosine	O
phosphorylation	O
in	O
T	B-cell_type
cell	I-cell_type
membrane	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
targeted	O
SHP-1	B-protein
into	O
lipid	O
rafts	O
by	O
using	O
the	O
N-terminal	B-protein
region	I-protein
of	I-protein
Lck	I-protein
(	O
residues	B-protein
1	I-protein
--	I-protein
14	I-protein
)	O
.	O
<EOS>	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
targeted	B-X
SHP	B-X
-	B-X
1	B-X
into	B-X
lipid	B-X
rafts	B-X
by	B-X
using	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
region	B-X
of	B-X
Lck	B-X
(	B-X
residues	B-X
1	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
14	B-X
)	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
Lck	B-X
/	B-X
SHP	B-X
-	B-X
1	B-X
chimera	B-X
inside	B-X
lipid	B-X
rafts	B-X
profoundly	B-X
inhibits	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
CD3	B-X
zeta	B-X
/	B-X
epsilon	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
generation	B-X
,	B-X
and	B-X
nuclear	B-X
mobilization	B-X
of	B-X
NF	B-X
-	B-X
AT	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
bulk	B-X
PTP	B-X
activity	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
membrane	B-X
is	B-X
present	B-X
outside	B-X
the	B-X
lipid	B-X
rafts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
sucrose	B-X
density	B-X
gradient	B-X
sedimentation	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
protein	B-X
tyrosine	B-X
phosphatases	B-X
(	B-X
PTPs	B-X
)	B-X
regulate	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
distribution	B-X
of	B-X
PTPs	B-X
in	B-X
subdomains	B-X
of	B-X
plasma	B-X
membrane	B-X

The	O
results	O
indicate	O
that	O
the	O
expression	O
of	O
Lck/SHP-1	B-protein
chimera	I-protein
inside	O
lipid	O
rafts	O
profoundly	O
inhibits	O
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
CD3	B-protein
zeta/epsilon	I-protein
,	O
IL-2	O
generation	O
,	O
and	O
nuclear	O
mobilization	O
of	O
NF-AT	B-protein
.	O
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
Lck	B-X
/	B-X
SHP	B-X
-	B-X
1	B-X
chimera	B-X
inside	B-X
lipid	B-X
rafts	B-X
profoundly	B-X
inhibits	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
CD3	B-X
zeta	B-X
/	B-X
epsilon	B-X
,	B-X
IL	B-X
-	B-X
2	B-X
generation	B-X
,	B-X
and	B-X
nuclear	B-X
mobilization	B-X
of	B-X
NF	B-X
-	B-X
AT	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
protein	B-X
tyrosine	B-X
phosphatases	B-X
(	B-X
PTPs	B-X
)	B-X
regulate	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
distribution	B-X
of	B-X
PTPs	B-X
in	B-X
subdomains	B-X
of	B-X
plasma	B-X
membrane	B-X
<EOS>	B-X
It	B-X
suggests	B-X
that	B-X
a	B-X
restricted	B-X
partition	B-X
of	B-X
PTPs	B-X
among	B-X
membrane	B-X
subdomains	B-X
may	B-X
regulate	B-X
protein	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
T	B-X
cell	B-X
membrane	B-X
<EOS>	B-X
We	B-X
further	B-X
demonstrated	B-X
that	B-X
CD3	B-X
-	B-X
induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
these	B-X
substrates	B-X
is	B-X
largely	B-X
restricted	B-X
to	B-X
lipid	B-X
rafts	B-X
,	B-X
unless	B-X
PTPs	B-X
are	B-X
inhibited	B-X

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
exclusion	O
of	O
PTPs	B-protein
from	O
lipid	O
rafts	O
may	O
be	O
a	O
mechanism	O
that	O
potentiates	O
TCR	B-protein
/	O
CD3	B-protein
activation	O
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
exclusion	B-X
of	B-X
PTPs	B-X
from	B-X
lipid	B-X
rafts	B-X
may	B-X
be	B-X
a	B-X
mechanism	B-X
that	B-X
potentiates	B-X
TCR	B-X
/	B-X
CD3	B-X
activation	B-X
<EOS>	B-X
Similar	B-X
to	B-X
transmembrane	B-X
PTP	B-X
,	B-X
CD45	B-X
,	B-X
the	B-X
membrane	B-X
-	B-X
associated	B-X
populations	B-X
of	B-X
SHP	B-X
-	B-X
1	B-X
and	B-X
SHP	B-X
-	B-X
2	B-X
are	B-X
essentially	B-X
excluded	B-X
from	B-X
lipid	B-X
rafts	B-X
,	B-X
where	B-X
other	B-X
signaling	B-X
molecules	B-X
such	B-X
as	B-X
Lck	B-X
,	B-X
linker	B-X
for	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
CD3	B-X
zeta	B-X
are	B-X
enriched	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
bulk	B-X
PTP	B-X
activity	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
membrane	B-X
is	B-X
present	B-X
outside	B-X
the	B-X
lipid	B-X
rafts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
sucrose	B-X
density	B-X
gradient	B-X
sedimentation	B-X
<EOS>	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
targeted	B-X
SHP	B-X
-	B-X
1	B-X
into	B-X
lipid	B-X
rafts	B-X
by	B-X
using	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
region	B-X
of	B-X
Lck	B-X
(	B-X
residues	B-X
1	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
14	B-X
)	B-X

An	O
instructive	O
component	O
in	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
type	I-cell_type
2	I-cell_type
(	O
Th2	B-cell_type
)	O
development	O
mediated	O
by	O
GATA-3	B-protein
.	O

Although	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-12	I-protein
and	O
IL-4	B-protein
polarize	O
naive	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
toward	O
T	O
helper	O
cell	O
type	O
1	O
(	O
Th1	O
)	O
or	O
Th2	O
phenotypes	O
,	O
it	O
is	O
not	O
known	O
whether	O
cytokines	B-protein
instruct	O
the	O
developmental	O
fate	O
in	O
uncommitted	B-cell_type
progenitors	I-cell_type
or	O
select	O
for	O
outgrowth	O
of	O
cells	O
that	O
have	O
stochastically	O
committed	O
to	O
a	O
particular	O
fate	O
.	O
<EOS>	B-X
This	B-X
review	B-X
examines	B-X
the	B-X
role	B-X
of	B-X
the	B-X
CD4	B-X
T	B-X
-	B-X
cells	B-X
most	B-X
relevant	B-X
to	B-X
IBD	B-X
,	B-X
highlighting	B-X
how	B-X
these	B-X
cells	B-X
adapt	B-X
to	B-X
the	B-X
environment	B-X
and	B-X
interact	B-X
with	B-X
other	B-X
cell	B-X
populations	B-X
to	B-X
promote	B-X
or	B-X
inhibit	B-X
the	B-X
development	B-X
of	B-X
IBD	B-X
<EOS>	B-X
Although	B-X
poly	B-X
(	B-X
I	B-X
:	B-X
C	B-X
)	B-X
is	B-X
a	B-X
representative	B-X
dsRNA	B-X
with	B-X
potent	B-X
adjuvanticity	B-X
,	B-X
its	B-X
clinical	B-X
application	B-X
has	B-X
been	B-X
limited	B-X
due	B-X
to	B-X
heterogeneous	B-X
molecular	B-X
size	B-X
,	B-X
inconsistent	B-X
activity	B-X
,	B-X
poor	B-X
stability	B-X
,	B-X
and	B-X
toxicity	B-X
<EOS>	B-X
The	B-X
balance	B-X
between	B-X
lung	B-X
regulatory	B-X
T	B-X
cells	B-X
and	B-X
Th17	B-X
cells	B-X
is	B-X
a	B-X
risk	B-X
indicator	B-X
for	B-X
the	B-X
acute	B-X
exacerbation	B-X
of	B-X
interstitial	B-X
lung	B-X
disease	B-X
after	B-X
surgery	B-X
:	B-X
a	B-X
case	B-X
-	B-X
control	B-X
study	B-X
.	B-X
<EOS>	B-X
For	B-X
instance	B-X
,	B-X
in	B-X
Th1	B-X
-	B-X
biased	B-X
mice	B-X
,	B-X
adipose	B-X
tissue	B-X
fat	B-X
content	B-X
was	B-X
high	B-X
both	B-X
in	B-X
the	B-X
baseline	B-X
as	B-X
well	B-X
as	B-X
in	B-X
response	B-X
to	B-X
a	B-X
high	B-X
-	B-X
fat	B-X
diet	B-X
whereas	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
it	B-X
was	B-X
found	B-X
to	B-X
be	B-X
less	B-X

To	O
distinguish	O
these	O
instructive	O
and	O
selective	O
models	O
,	O
we	O
used	O
surface	O
affinity	O
matrix	O
technology	O
to	O
isolate	O
committed	B-cell_type
progenitors	I-cell_type
based	O
on	O
cytokine	O
secretion	O
phenotype	O
and	O
developed	O
retroviral-based	O
tagging	O
approaches	O
to	O
directly	O
monitor	O
individual	O
progenitor	O
fate	O
decisions	O
at	O
the	O
clonal	O
and	O
population	O
levels	O
.	O
<EOS>	B-X
To	B-X
distinguish	B-X
these	B-X
instructive	B-X
and	B-X
selective	B-X
models	B-X
,	B-X
we	B-X
used	B-X
surface	B-X
affinity	B-X
matrix	B-X
technology	B-X
to	B-X
isolate	B-X
committed	B-X
progenitors	B-X
based	B-X
on	B-X
cytokine	B-X
secretion	B-X
phenotype	B-X
and	B-X
developed	B-X
retroviral	B-X
-	B-X
based	B-X
tagging	B-X
approaches	B-X
to	B-X
directly	B-X
monitor	B-X
individual	B-X
progenitor	B-X
fate	B-X
decisions	B-X
at	B-X
the	B-X
clonal	B-X
and	B-X
population	B-X
levels	B-X
<EOS>	B-X
These	B-X
data	B-X
would	B-X
seem	B-X
to	B-X
exclude	B-X
selection	B-X
as	B-X
an	B-X
exclusive	B-X
mechanism	B-X
in	B-X
Th1	B-X
/	B-X
Th2	B-X
differentiation	B-X
,	B-X
and	B-X
support	B-X
an	B-X
instructive	B-X
model	B-X
of	B-X
cytokine	B-X
-	B-X
driven	B-X
transcriptional	B-X
programming	B-X
of	B-X
cell	B-X
fate	B-X
decisions	B-X
<EOS>	B-X
We	B-X
observe	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
dependent	B-X
redirection	B-X
of	B-X
phenotype	B-X
in	B-X
cells	B-X
that	B-X
have	B-X
already	B-X
committed	B-X
to	B-X
a	B-X
non	B-X
-	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
producing	B-X
fate	B-X
,	B-X
inconsistent	B-X
with	B-X
predictions	B-X
of	B-X
the	B-X
selective	B-X
model	B-X
<EOS>	B-X
Further	B-X
,	B-X
retroviral	B-X
tagging	B-X
of	B-X
naive	B-X
progenitors	B-X
with	B-X
the	B-X
Th2	B-X
-	B-X
specific	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
3	B-X
provided	B-X
direct	B-X
evidence	B-X
for	B-X
instructive	B-X
differentiation	B-X
,	B-X
and	B-X
no	B-X
evidence	B-X
for	B-X
the	B-X
selective	B-X
outgrowth	B-X
of	B-X
cells	B-X
committed	B-X
to	B-X
either	B-X
the	B-X
Th1	B-X
or	B-X
Th2	B-X
fate	B-X

We	O
observe	O
IL-4	B-protein
-dependent	O
redirection	O
of	O
phenotype	O
in	O
cells	O
that	O
have	O
already	O
committed	O
to	O
a	O
non-IL-4-producing	O
fate	O
,	O
inconsistent	O
with	O
predictions	O
of	O
the	O
selective	O
model	O
.	O
<EOS>	B-X
We	B-X
observe	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
dependent	B-X
redirection	B-X
of	B-X
phenotype	B-X
in	B-X
cells	B-X
that	B-X
have	B-X
already	B-X
committed	B-X
to	B-X
a	B-X
non	B-X
-	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
producing	B-X
fate	B-X
,	B-X
inconsistent	B-X
with	B-X
predictions	B-X
of	B-X
the	B-X
selective	B-X
model	B-X
<EOS>	B-X
To	B-X
distinguish	B-X
these	B-X
instructive	B-X
and	B-X
selective	B-X
models	B-X
,	B-X
we	B-X
used	B-X
surface	B-X
affinity	B-X
matrix	B-X
technology	B-X
to	B-X
isolate	B-X
committed	B-X
progenitors	B-X
based	B-X
on	B-X
cytokine	B-X
secretion	B-X
phenotype	B-X
and	B-X
developed	B-X
retroviral	B-X
-	B-X
based	B-X
tagging	B-X
approaches	B-X
to	B-X
directly	B-X
monitor	B-X
individual	B-X
progenitor	B-X
fate	B-X
decisions	B-X
at	B-X
the	B-X
clonal	B-X
and	B-X
population	B-X
levels	B-X
<EOS>	B-X
Although	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
polarize	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
toward	B-X
T	B-X
helper	B-X
cell	B-X
type	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
or	B-X
Th2	B-X
phenotypes	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
cytokines	B-X
instruct	B-X
the	B-X
developmental	B-X
fate	B-X
in	B-X
uncommitted	B-X
progenitors	B-X
or	B-X
select	B-X
for	B-X
outgrowth	B-X
of	B-X
cells	B-X
that	B-X
have	B-X
stochastically	B-X
committed	B-X
to	B-X
a	B-X
particular	B-X
fate	B-X
<EOS>	B-X
An	B-X
instructive	B-X
component	B-X
in	B-X
T	B-X
helper	B-X
cell	B-X
type	B-X
2	B-X
(	B-X
Th2	B-X
)	B-X
development	B-X
mediated	B-X
by	B-X
GATA	B-X
-	B-X
3	B-X
.	B-X

Further	O
,	O
retroviral	O
tagging	O
of	O
naive	B-cell_type
progenitors	I-cell_type
with	O
the	O
Th2-specific	B-protein
transcription	I-protein
factor	I-protein
GATA-3	I-protein
provided	O
direct	O
evidence	O
for	O
instructive	O
differentiation	O
,	O
and	O
no	O
evidence	O
for	O
the	O
selective	O
outgrowth	O
of	O
cells	O
committed	O
to	O
either	O
the	O
Th1	O
or	O
Th2	O
fate	O
.	O
<EOS>	B-X
Lineage	B-X
-	B-X
determining	B-X
transcription	B-X
factors	B-X
(	B-X
LD	B-X
-	B-X
TFs	B-X
)	B-X
drive	B-X
the	B-X
differentiation	B-X
of	B-X
progenitor	B-X
cells	B-X
into	B-X
a	B-X
specific	B-X
lineage	B-X
<EOS>	B-X
Decades	B-X
of	B-X
research	B-X
have	B-X
revealed	B-X
that	B-X
the	B-X
fate	B-X
decision	B-X
processes	B-X
are	B-X
controlled	B-X
by	B-X
cytokines	B-X
,	B-X
cytokine	B-X
receptor	B-X
signaling	B-X
,	B-X
and	B-X
master	B-X
transcription	B-X
factors	B-X
that	B-X
drive	B-X
the	B-X
differentiation	B-X
programs	B-X
<EOS>	B-X
In	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
T	B-X
-	B-X
bet	B-X
dictates	B-X
differentiation	B-X
of	B-X
the	B-X
TH1	B-X
lineage	B-X
,	B-X
whereas	B-X
GATA3	B-X
drives	B-X
differentiation	B-X
of	B-X
the	B-X
alternative	B-X
TH2	B-X
lineage	B-X
<EOS>	B-X
The	B-X
TH1	B-X
cell	B-X
lineage	B-X
-	B-X
determining	B-X
transcription	B-X
factor	B-X
T	B-X
-	B-X
bet	B-X
suppresses	B-X
TH2	B-X
gene	B-X
expression	B-X
by	B-X
redistributing	B-X
GATA3	B-X
away	B-X
from	B-X
TH2	B-X
genes	B-X
.	B-X

These	O
data	O
would	O
seem	O
to	O
exclude	O
selection	O
as	O
an	O
exclusive	O
mechanism	O
in	O
Th1	B-cell_type
/	O
Th2	B-cell_type
differentiation	O
,	O
and	O
support	O
an	O
instructive	O
model	O
of	O
cytokine-driven	O
transcriptional	O
programming	O
of	O
cell	O
fate	O
decisions	O
.	O
<EOS>	B-X
These	B-X
data	B-X
would	B-X
seem	B-X
to	B-X
exclude	B-X
selection	B-X
as	B-X
an	B-X
exclusive	B-X
mechanism	B-X
in	B-X
Th1	B-X
/	B-X
Th2	B-X
differentiation	B-X
,	B-X
and	B-X
support	B-X
an	B-X
instructive	B-X
model	B-X
of	B-X
cytokine	B-X
-	B-X
driven	B-X
transcriptional	B-X
programming	B-X
of	B-X
cell	B-X
fate	B-X
decisions	B-X
<EOS>	B-X
To	B-X
distinguish	B-X
these	B-X
instructive	B-X
and	B-X
selective	B-X
models	B-X
,	B-X
we	B-X
used	B-X
surface	B-X
affinity	B-X
matrix	B-X
technology	B-X
to	B-X
isolate	B-X
committed	B-X
progenitors	B-X
based	B-X
on	B-X
cytokine	B-X
secretion	B-X
phenotype	B-X
and	B-X
developed	B-X
retroviral	B-X
-	B-X
based	B-X
tagging	B-X
approaches	B-X
to	B-X
directly	B-X
monitor	B-X
individual	B-X
progenitor	B-X
fate	B-X
decisions	B-X
at	B-X
the	B-X
clonal	B-X
and	B-X
population	B-X
levels	B-X
<EOS>	B-X
Although	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
12	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
polarize	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
toward	B-X
T	B-X
helper	B-X
cell	B-X
type	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
or	B-X
Th2	B-X
phenotypes	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
whether	B-X
cytokines	B-X
instruct	B-X
the	B-X
developmental	B-X
fate	B-X
in	B-X
uncommitted	B-X
progenitors	B-X
or	B-X
select	B-X
for	B-X
outgrowth	B-X
of	B-X
cells	B-X
that	B-X
have	B-X
stochastically	B-X
committed	B-X
to	B-X
a	B-X
particular	B-X
fate	B-X
<EOS>	B-X
We	B-X
observe	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
dependent	B-X
redirection	B-X
of	B-X
phenotype	B-X
in	B-X
cells	B-X
that	B-X
have	B-X
already	B-X
committed	B-X
to	B-X
a	B-X
non	B-X
-	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
producing	B-X
fate	B-X
,	B-X
inconsistent	B-X
with	B-X
predictions	B-X
of	B-X
the	B-X
selective	B-X
model	B-X

In	O
vitro-activated	O
human	B-cell_type
lupus	I-cell_type
T	I-cell_type
cells	I-cell_type
express	O
normal	O
estrogen	B-protein
receptor	I-protein
proteins	I-protein
which	O
bind	O
to	O
the	O
estrogen	B-protein
response	I-protein
element	I-protein
.	O

We	O
have	O
shown	O
that	O
estrogen	B-protein
receptor	I-protein
(	O
ERalpha	B-protein
,	O
ERbeta	B-protein
)	O
transcripts	O
are	O
expressed	O
in	O
SLE	B-cell_type
and	I-cell_type
normal	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
estrogen	B-X
receptor	B-X
(	B-X
ERalpha	B-X
,	B-X
ERbeta	B-X
)	B-X
transcripts	B-X
are	B-X
expressed	B-X
in	B-X
SLE	B-X
and	B-X
normal	B-X
T	B-X
cells	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
estrogen	B-X
,	B-X
bound	B-X
to	B-X
the	B-X
ER	B-X
,	B-X
evokes	B-X
a	B-X
direct	B-X
increase	B-X
in	B-X
calcineurin	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
female	B-X
lupus	B-X
patients	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
notable	B-X
difference	B-X
in	B-X
the	B-X
migration	B-X
pattern	B-X
of	B-X
ERE	B-X
-	B-X
binding	B-X
proteins	B-X
between	B-X
the	B-X
SLE	B-X
and	B-X
normal	B-X
T	B-X
cell	B-X
extracts	B-X
<EOS>	B-X
Reverse	B-X
transcription	B-X
and	B-X
polymerase	B-X
chain	B-X
amplification	B-X
indicate	B-X
that	B-X
estrogen	B-X
receptor	B-X
-	B-X
alpha	B-X
and	B-X
estrogen	B-X
-	B-X
beta	B-X
are	B-X
expressed	B-X
in	B-X
human	B-X
T	B-X
cells	B-X

In	O
this	O
study	O
,	O
T	O
cell	O
nuclear	O
extracts	O
from	O
female	O
lupus	O
patients	O
and	O
normal	O
donors	O
were	O
tested	O
for	O
biologically	O
active	O
ER	B-protein
proteins	I-protein
capable	O
of	O
binding	O
to	O
the	O
human	B-DNA
estrogen	I-DNA
response	I-DNA
element	I-DNA
(	O
hERE	B-DNA
)	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

When	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
17beta-estradiol	O
(	O
E2	O
)	O
,	O
PMA	O
and	O
ionomycin	O
,	O
two	O
major	O
retarded	O
bands	O
in	O
T	O
cell	O
nuclear	O
extracts	O
exhibited	O
a	O
migration	O
pattern	O
similar	O
to	O
slow	O
migrating	O
protein-ERE	B-protein
complexes	I-protein
in	O
human	O
breast	O
cancer	O
cell	O
extracts	O
.	O

T	B-cell_type
cells	I-cell_type
cultured	O
only	O
with	O
E2	O
did	O
not	O
have	O
these	O
complexes	O
.	O
<EOS>	B-X
MAIT	B-X
cell	B-X
activation	B-X
is	B-X
reduced	B-X
by	B-X
direct	B-X
and	B-X
microbiota	B-X
-	B-X
mediated	B-X
exposure	B-X
to	B-X
bisphenols	B-X
.	B-X
<EOS>	B-X
T	B-X
-	B-X
cells	B-X
and	B-X
hepatocytes	B-X
containing	B-X
HCV	B-X
E2	B-X
RNA	B-X
had	B-X
reduced	B-X
PTPRE	B-X
protein	B-X
levels	B-X
<EOS>	B-X
All	B-X
experiments	B-X
were	B-X
performed	B-X
at	B-X
least	B-X
three	B-X
times	B-X
<EOS>	B-X
Many	B-X
studies	B-X
correlating	B-X
the	B-X
reduction	B-X
in	B-X
the	B-X
incidence	B-X
of	B-X
AD	B-X
with	B-X
the	B-X
diet	B-X
consumed	B-X
have	B-X
been	B-X
published	B-X

The	O
formation	O
of	O
the	O
complexes	O
was	O
inhibited	O
by	O
competition	O
with	O
the	O
hERE	O
cold	O
oligonucleotide	O
and	O
partially	O
with	O
anti-ERalpha	B-protein
antibodies	I-protein
.	O
<EOS>	B-X
The	B-X
formation	B-X
of	B-X
the	B-X
complexes	B-X
was	B-X
inhibited	B-X
by	B-X
competition	B-X
with	B-X
the	B-X
hERE	B-X
cold	B-X
oligonucleotide	B-X
and	B-X
partially	B-X
with	B-X
anti	B-X
-	B-X
ERalpha	B-X
antibodies	B-X
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
activated	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
whether	B-X
lupus	B-X
-	B-X
derived	B-X
or	B-X
normal	B-X
-	B-X
derived	B-X
,	B-X
contain	B-X
biologically	B-X
active	B-X
ERalpha	B-X
proteins	B-X
<EOS>	B-X
When	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
were	B-X
stimulated	B-X
with	B-X
17beta	B-X
-	B-X
estradiol	B-X
(	B-X
E2	B-X
)	B-X
,	B-X
PMA	B-X
and	B-X
ionomycin	B-X
,	B-X
two	B-X
major	B-X
retarded	B-X
bands	B-X
in	B-X
T	B-X
cell	B-X
nuclear	B-X
extracts	B-X
exhibited	B-X
a	B-X
migration	B-X
pattern	B-X
similar	B-X
to	B-X
slow	B-X
migrating	B-X
protein	B-X
-	B-X
ERE	B-X
complexes	B-X
in	B-X
human	B-X
breast	B-X
cancer	B-X
cell	B-X
extracts	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
notable	B-X
difference	B-X
in	B-X
the	B-X
migration	B-X
pattern	B-X
of	B-X
ERE	B-X
-	B-X
binding	B-X
proteins	B-X
between	B-X
the	B-X
SLE	B-X
and	B-X
normal	B-X
T	B-X
cell	B-X
extracts	B-X

There	O
was	O
no	O
notable	O
difference	O
in	O
the	O
migration	O
pattern	O
of	O
ERE-binding	B-protein
proteins	I-protein
between	O
the	O
SLE	O
and	O
normal	O
T	O
cell	O
extracts	O
.	O
<EOS>	B-X
There	B-X
was	B-X
no	B-X
notable	B-X
difference	B-X
in	B-X
the	B-X
migration	B-X
pattern	B-X
of	B-X
ERE	B-X
-	B-X
binding	B-X
proteins	B-X
between	B-X
the	B-X
SLE	B-X
and	B-X
normal	B-X
T	B-X
cell	B-X
extracts	B-X
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
estrogen	B-X
receptor	B-X
(	B-X
ERalpha	B-X
,	B-X
ERbeta	B-X
)	B-X
transcripts	B-X
are	B-X
expressed	B-X
in	B-X
SLE	B-X
and	B-X
normal	B-X
T	B-X
cells	B-X
<EOS>	B-X
When	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
were	B-X
stimulated	B-X
with	B-X
17beta	B-X
-	B-X
estradiol	B-X
(	B-X
E2	B-X
)	B-X
,	B-X
PMA	B-X
and	B-X
ionomycin	B-X
,	B-X
two	B-X
major	B-X
retarded	B-X
bands	B-X
in	B-X
T	B-X
cell	B-X
nuclear	B-X
extracts	B-X
exhibited	B-X
a	B-X
migration	B-X
pattern	B-X
similar	B-X
to	B-X
slow	B-X
migrating	B-X
protein	B-X
-	B-X
ERE	B-X
complexes	B-X
in	B-X
human	B-X
breast	B-X
cancer	B-X
cell	B-X
extracts	B-X
<EOS>	B-X
T	B-X
cells	B-X
cultured	B-X
only	B-X
with	B-X
E2	B-X
did	B-X
not	B-X
have	B-X
these	B-X
complexes	B-X

Together	O
,	O
these	O
results	O
suggest	O
that	O
activated	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whether	O
lupus-derived	O
or	O
normal-derived	O
,	O
contain	O
biologically	O
active	O
ERalpha	B-protein
proteins	I-protein
.	O
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
activated	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
whether	B-X
lupus	B-X
-	B-X
derived	B-X
or	B-X
normal	B-X
-	B-X
derived	B-X
,	B-X
contain	B-X
biologically	B-X
active	B-X
ERalpha	B-X
proteins	B-X
<EOS>	B-X
The	B-X
formation	B-X
of	B-X
the	B-X
complexes	B-X
was	B-X
inhibited	B-X
by	B-X
competition	B-X
with	B-X
the	B-X
hERE	B-X
cold	B-X
oligonucleotide	B-X
and	B-X
partially	B-X
with	B-X
anti	B-X
-	B-X
ERalpha	B-X
antibodies	B-X
<EOS>	B-X
When	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
were	B-X
stimulated	B-X
with	B-X
17beta	B-X
-	B-X
estradiol	B-X
(	B-X
E2	B-X
)	B-X
,	B-X
PMA	B-X
and	B-X
ionomycin	B-X
,	B-X
two	B-X
major	B-X
retarded	B-X
bands	B-X
in	B-X
T	B-X
cell	B-X
nuclear	B-X
extracts	B-X
exhibited	B-X
a	B-X
migration	B-X
pattern	B-X
similar	B-X
to	B-X
slow	B-X
migrating	B-X
protein	B-X
-	B-X
ERE	B-X
complexes	B-X
in	B-X
human	B-X
breast	B-X
cancer	B-X
cell	B-X
extracts	B-X
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
estrogen	B-X
receptor	B-X
(	B-X
ERalpha	B-X
,	B-X
ERbeta	B-X
)	B-X
transcripts	B-X
are	B-X
expressed	B-X
in	B-X
SLE	B-X
and	B-X
normal	B-X
T	B-X
cells	B-X

Other	O
factors	O
may	O
be	O
responsible	O
for	O
differential	O
sensitivity	O
of	O
lupus	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
estrogen	O
.	O
<EOS>	B-X
Other	B-X
factors	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
differential	B-X
sensitivity	B-X
of	B-X
lupus	B-X
T	B-X
cells	B-X
to	B-X
estrogen	B-X
<EOS>	B-X
In	B-X
vitro	B-X
-	B-X
activated	B-X
human	B-X
lupus	B-X
T	B-X
cells	B-X
express	B-X
normal	B-X
estrogen	B-X
receptor	B-X
proteins	B-X
which	B-X
bind	B-X
to	B-X
the	B-X
estrogen	B-X
response	B-X
element	B-X
.	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
notable	B-X
difference	B-X
in	B-X
the	B-X
migration	B-X
pattern	B-X
of	B-X
ERE	B-X
-	B-X
binding	B-X
proteins	B-X
between	B-X
the	B-X
SLE	B-X
and	B-X
normal	B-X
T	B-X
cell	B-X
extracts	B-X
<EOS>	B-X
The	B-X
formation	B-X
of	B-X
the	B-X
complexes	B-X
was	B-X
inhibited	B-X
by	B-X
competition	B-X
with	B-X
the	B-X
hERE	B-X
cold	B-X
oligonucleotide	B-X
and	B-X
partially	B-X
with	B-X
anti	B-X
-	B-X
ERalpha	B-X
antibodies	B-X

Mechanism	O
of	O
the	O
inhibitory	O
effect	O
of	O
protease	O
inhibitor	O
on	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
production	O
of	O
monocytes	B-cell_type
.	O
<EOS>	B-X
Mechanism	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitor	B-X
on	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
production	B-X
of	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
mechanism	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitors	B-X
on	B-X
the	B-X
proinflammatory	B-X
cytokine	B-X
production	B-X
of	B-X
lipopolysaccharide	B-X
-	B-X
	B-X
(	B-X
LPS	B-X
)	B-X
stimulated	B-X
monocytes	B-X
<EOS>	B-X
Urinary	B-X
trypsin	B-X
inhibitor	B-X
reduces	B-X
LPS	B-X
-	B-X
induced	B-X
hypotension	B-X
by	B-X
suppressing	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
production	B-X
through	B-X
inhibition	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
.	B-X
<EOS>	B-X
Although	B-X
urinary	B-X
trypsin	B-X
inhibitor	B-X
(	B-X
UTI	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
alpha	B-X
-	B-X
	B-X
production	B-X
,	B-X
the	B-X
detailed	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
remains	B-X
unclear	B-X

If	O
the	O
inflammatory	O
response	O
becomes	O
excessive	O
or	O
uncontrolled	O
by	O
some	O
stimuli	O
,	O
inappropriate	O
inflammatory	O
responses	O
occur	O
.	O
<EOS>	B-X
Inflammatory	B-X
response	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
early	B-X
stage	B-X
of	B-X
fracture	B-X
healing	B-X
<EOS>	B-X
Antiviral	B-X
drugs	B-X
and	B-X
respiratory	B-X
support	B-X
are	B-X
often	B-X
used	B-X
clinically	B-X
as	B-X
needed	B-X
,	B-X
but	B-X
are	B-X
not	B-X
yet	B-X
sufficient	B-X
to	B-X
alleviate	B-X
the	B-X
cytokine	B-X
storm	B-X
(	B-X
CS	B-X
)	B-X
and	B-X
systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
<EOS>	B-X
How	B-X
is	B-X
then	B-X
an	B-X
inflammatory	B-X
signal	B-X
thought	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
these	B-X
pregnancy	B-X
complications	B-X
?	B-X
It	B-X
is	B-X
not	B-X
clear	B-X
what	B-X
type	B-X
of	B-X
inflammation	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
onset	B-X
of	B-X
PE	B-X
-	B-X
like	B-X
features	B-X
<EOS>	B-X
If	B-X
inflammation	B-X
becomes	B-X
pathological	B-X
,	B-X
it	B-X
reduces	B-X
feed	B-X
intake	B-X
and	B-X
causes	B-X
hypocalcemia	B-X

Monocytes	B-cell_type
are	O
extremely	O
important	O
cells	O
for	O
regulating	O
the	O
cytokine	O
network	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
and	O
interleukin-	B-protein
(	I-protein
IL	I-protein
)	I-protein
10	I-protein
,	O
which	O
are	O
mainly	O
synthesized	O
by	O
monocytes	B-cell_type
,	O
are	O
representative	O
cytokines	B-protein
that	O
play	O
a	O
central	O
role	O
in	O
the	O
cytokine	O
network	O
.	O
<EOS>	B-X
Monocytes	B-X
are	B-X
extremely	B-X
important	B-X
cells	B-X
for	B-X
regulating	B-X
the	B-X
cytokine	B-X
network	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNFalpha	B-X
)	B-X
and	B-X
interleukin	B-X
-	B-X
	B-X
(	B-X
IL	B-X
)	B-X
10	B-X
,	B-X
which	B-X
are	B-X
mainly	B-X
synthesized	B-X
by	B-X
monocytes	B-X
,	B-X
are	B-X
representative	B-X
cytokines	B-X
that	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
cytokine	B-X
network	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
GM	B-X
on	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
activated	B-X
human	B-X
monocytes	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
suppression	B-X
of	B-X
NFkappaB	B-X
activation	B-X
,	B-X
while	B-X
the	B-X
mechanism	B-X
of	B-X
UTI	B-X
inhibiting	B-X
TNFalpha	B-X
production	B-X
of	B-X
human	B-X
monocytes	B-X
may	B-X
be	B-X
due	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
either	B-X
the	B-X
translation	B-X
or	B-X
secretion	B-X
of	B-X
TNFalpha	B-X
<EOS>	B-X
Protease	B-X
inhibitors	B-X
such	B-X
as	B-X
gabexate	B-X
mesilate	B-X
(	B-X
GM	B-X
)	B-X
and	B-X
ulinastatin	B-X
(	B-X
UTI	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
have	B-X
various	B-X
beneficial	B-X
effects	B-X
by	B-X
inhibiting	B-X
the	B-X
activation	B-X
of	B-X
leukocytes	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
for	B-X
this	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
fully	B-X
elucidated	B-X
<EOS>	B-X
Mechanism	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitor	B-X
on	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
production	B-X
of	B-X
monocytes	B-X
.	B-X

Protease	O
inhibitors	O
such	O
as	O
gabexate	O
mesilate	O
(	O
GM	O
)	O
and	O
ulinastatin	O
(	O
UTI	O
)	O
have	O
been	O
shown	O
to	O
have	O
various	O
beneficial	O
effects	O
by	O
inhibiting	O
the	O
activation	O
of	O
leukocytes	B-cell_type
,	O
but	O
the	O
mechanism	O
for	O
this	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O
<EOS>	B-X
Protease	B-X
inhibitors	B-X
such	B-X
as	B-X
gabexate	B-X
mesilate	B-X
(	B-X
GM	B-X
)	B-X
and	B-X
ulinastatin	B-X
(	B-X
UTI	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
have	B-X
various	B-X
beneficial	B-X
effects	B-X
by	B-X
inhibiting	B-X
the	B-X
activation	B-X
of	B-X
leukocytes	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
for	B-X
this	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
fully	B-X
elucidated	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
GM	B-X
on	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
activated	B-X
human	B-X
monocytes	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
suppression	B-X
of	B-X
NFkappaB	B-X
activation	B-X
,	B-X
while	B-X
the	B-X
mechanism	B-X
of	B-X
UTI	B-X
inhibiting	B-X
TNFalpha	B-X
production	B-X
of	B-X
human	B-X
monocytes	B-X
may	B-X
be	B-X
due	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
either	B-X
the	B-X
translation	B-X
or	B-X
secretion	B-X
of	B-X
TNFalpha	B-X
<EOS>	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitors	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
intracellular	B-X
signal	B-X
transduction	B-X
pathways	B-X
such	B-X
as	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NFkappaB	B-X
)	B-X
were	B-X
also	B-X
evaluated	B-X
<EOS>	B-X
Monocytes	B-X
are	B-X
extremely	B-X
important	B-X
cells	B-X
for	B-X
regulating	B-X
the	B-X
cytokine	B-X
network	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNFalpha	B-X
)	B-X
and	B-X
interleukin	B-X
-	B-X
	B-X
(	B-X
IL	B-X
)	B-X
10	B-X
,	B-X
which	B-X
are	B-X
mainly	B-X
synthesized	B-X
by	B-X
monocytes	B-X
,	B-X
are	B-X
representative	B-X
cytokines	B-X
that	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
cytokine	B-X
network	B-X

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
of	O
protease	O
inhibitors	O
on	O
the	O
proinflammatory	O
cytokine	O
production	O
of	O
lipopolysaccharide-	O
(	O
LPS	O
)	O
stimulated	O
monocytes	B-cell_type
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
mechanism	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitors	B-X
on	B-X
the	B-X
proinflammatory	B-X
cytokine	B-X
production	B-X
of	B-X
lipopolysaccharide	B-X
-	B-X
	B-X
(	B-X
LPS	B-X
)	B-X
stimulated	B-X
monocytes	B-X
<EOS>	B-X
Mechanism	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitor	B-X
on	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
production	B-X
of	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
GM	B-X
decreased	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
inhibition	B-X
of	B-X
mRNA	B-X
expression	B-X
and	B-X
increased	B-X
the	B-X
IL	B-X
-	B-X
10	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
GM	B-X
on	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
activated	B-X
human	B-X
monocytes	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
suppression	B-X
of	B-X
NFkappaB	B-X
activation	B-X
,	B-X
while	B-X
the	B-X
mechanism	B-X
of	B-X
UTI	B-X
inhibiting	B-X
TNFalpha	B-X
production	B-X
of	B-X
human	B-X
monocytes	B-X
may	B-X
be	B-X
due	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
either	B-X
the	B-X
translation	B-X
or	B-X
secretion	B-X
of	B-X
TNFalpha	B-X

LPS-stimulated	O
monocytes	B-cell_type
were	O
treated	O
with	O
GM	O
or	O
UTI	O
.	O
<EOS>	B-X
Cardiovascular	B-X
-	B-X
related	B-X
conditions	B-X
were	B-X
most	B-X
prominent	B-X
for	B-X
men	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
Postoperative	B-X
,	B-X
and	B-X
overall	B-X
complications	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
group	B-X
1	B-X
(	B-X
15	B-X
<EOS>	B-X
The	B-X
sensitivity	B-X
and	B-X
specificity	B-X
of	B-X
WBC	B-X
were	B-X
relatively	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
BACT	B-X
<EOS>	B-X
Virtual	B-X
encounters	B-X
increased	B-X
from	B-X
13	B-X

The	O
value	O
of	O
TNFalpha	B-protein
and	O
IL-10	B-protein
in	O
the	O
culture	O
medium	O
of	O
monocytes	B-cell_type
was	O
measured	O
and	O
each	O
mRNA	O
expression	O
was	O
assayed	O
.	O
<EOS>	B-X
The	B-X
value	B-X
of	B-X
TNFalpha	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
of	B-X
monocytes	B-X
was	B-X
measured	B-X
and	B-X
each	B-X
mRNA	B-X
expression	B-X
was	B-X
assayed	B-X
<EOS>	B-X
GM	B-X
decreased	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
inhibition	B-X
of	B-X
mRNA	B-X
expression	B-X
and	B-X
increased	B-X
the	B-X
IL	B-X
-	B-X
10	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
<EOS>	B-X
UTI	B-X
decreased	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
,	B-X
but	B-X
did	B-X
not	B-X
inhibit	B-X
the	B-X
TNFalpha	B-X
mRNA	B-X
expression	B-X
<EOS>	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitors	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
intracellular	B-X
signal	B-X
transduction	B-X
pathways	B-X
such	B-X
as	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NFkappaB	B-X
)	B-X
were	B-X
also	B-X
evaluated	B-X

The	O
inhibitory	O
effect	O
of	O
protease	O
inhibitors	O
on	O
the	O
activity	O
of	O
intracellular	O
signal	O
transduction	O
pathways	O
such	O
as	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NFkappaB	B-protein
)	O
were	O
also	O
evaluated	O
.	O
<EOS>	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitors	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
intracellular	B-X
signal	B-X
transduction	B-X
pathways	B-X
such	B-X
as	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NFkappaB	B-X
)	B-X
were	B-X
also	B-X
evaluated	B-X
<EOS>	B-X
Mechanism	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitor	B-X
on	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
production	B-X
of	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
GM	B-X
on	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
activated	B-X
human	B-X
monocytes	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
suppression	B-X
of	B-X
NFkappaB	B-X
activation	B-X
,	B-X
while	B-X
the	B-X
mechanism	B-X
of	B-X
UTI	B-X
inhibiting	B-X
TNFalpha	B-X
production	B-X
of	B-X
human	B-X
monocytes	B-X
may	B-X
be	B-X
due	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
either	B-X
the	B-X
translation	B-X
or	B-X
secretion	B-X
of	B-X
TNFalpha	B-X
<EOS>	B-X
The	B-X
value	B-X
of	B-X
TNFalpha	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
of	B-X
monocytes	B-X
was	B-X
measured	B-X
and	B-X
each	B-X
mRNA	B-X
expression	B-X
was	B-X
assayed	B-X

GM	O
decreased	O
the	O
TNFalpha	B-protein
production	O
of	O
LPS-stimulated	O
monocytes	B-cell_type
as	O
shown	O
by	O
the	O
inhibition	O
of	O
mRNA	O
expression	O
and	O
increased	O
the	O
IL-10	B-protein
production	O
of	O
LPS-stimulated	O
monocytes	B-cell_type
.	O
<EOS>	B-X
GM	B-X
decreased	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
as	B-X
shown	B-X
by	B-X
the	B-X
inhibition	B-X
of	B-X
mRNA	B-X
expression	B-X
and	B-X
increased	B-X
the	B-X
IL	B-X
-	B-X
10	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
<EOS>	B-X
UTI	B-X
decreased	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
,	B-X
but	B-X
did	B-X
not	B-X
inhibit	B-X
the	B-X
TNFalpha	B-X
mRNA	B-X
expression	B-X
<EOS>	B-X
Mechanism	B-X
of	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
protease	B-X
inhibitor	B-X
on	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
production	B-X
of	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
GM	B-X
on	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
activated	B-X
human	B-X
monocytes	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
suppression	B-X
of	B-X
NFkappaB	B-X
activation	B-X
,	B-X
while	B-X
the	B-X
mechanism	B-X
of	B-X
UTI	B-X
inhibiting	B-X
TNFalpha	B-X
production	B-X
of	B-X
human	B-X
monocytes	B-X
may	B-X
be	B-X
due	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
either	B-X
the	B-X
translation	B-X
or	B-X
secretion	B-X
of	B-X
TNFalpha	B-X

GM	O
also	O
suppressed	O
the	O
NFkappaB	B-protein
activity	O
of	O
LPS-stimulated	O
monocytes	B-cell_type
.	O
<EOS>	B-X
GM	B-X
also	B-X
suppressed	B-X
the	B-X
NFkappaB	B-X
activity	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
<EOS>	B-X
UTI	B-X
decreased	B-X
the	B-X
TNFalpha	B-X
production	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
monocytes	B-X
,	B-X
but	B-X
did	B-X
not	B-X
inhibit	B-X
the	B-X
TNFalpha	B-X
mRNA	B-X
expression	B-X
<EOS>	B-X
Neither	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
expression	B-X
nor	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
stimulated	B-X
by	B-X
LPS	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
cAMP	B-X
-	B-X
elevating	B-X
agents	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
IL	B-X
-	B-X
10	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
by	B-X
cAMP	B-X

UTI	O
decreased	O
the	O
TNFalpha	B-protein
production	O
of	O
LPS-stimulated	O
monocytes	B-cell_type
,	O
but	O
did	O
not	O
inhibit	O
the	O
TNFalpha	B-RNA
mRNA	I-RNA
expression	O
.	O

The	O
present	O
study	O
shows	O
that	O
the	O
inhibitory	O
effect	O
of	O
GM	O
on	O
the	O
TNFalpha	B-protein
production	O
of	O
activated	O
human	B-cell_type
monocytes	I-cell_type
is	O
mediated	O
by	O
the	O
suppression	O
of	O
NFkappaB	B-protein
activation	O
,	O
while	O
the	O
mechanism	O
of	O
UTI	O
inhibiting	O
TNFalpha	B-protein
production	O
of	O
human	B-cell_type
monocytes	I-cell_type
may	O
be	O
due	O
to	O
the	O
inhibition	O
of	O
either	O
the	O
translation	O
or	O
secretion	O
of	O
TNFalpha	B-protein
.	O
<EOS>	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
EEP	B-X
and	B-X
MET	B-X
reduce	B-X
fasting	B-X
blood	B-X
glucose	B-X
in	B-X
T2DM	B-X
mice	B-X
,	B-X
followed	B-X
by	B-X
alleviating	B-X
insulin	B-X
resistance	B-X
,	B-X
improving	B-X
the	B-X
inflammatory	B-X
reaction	B-X
of	B-X
mice	B-X
,	B-X
regulating	B-X
the	B-X
metabolism	B-X
of	B-X
mice	B-X
,	B-X
and	B-X
affecting	B-X
the	B-X
steady	B-X
state	B-X
of	B-X
gut	B-X
microbiota	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
aimed	B-X
to	B-X
clarify	B-X
the	B-X
effect	B-X
of	B-X
SeNPs	B-X
on	B-X
androgen	B-X
synthesis	B-X
and	B-X
action	B-X
in	B-X
the	B-X
PCOS	B-X
model	B-X
and	B-X
the	B-X
resulting	B-X
effect	B-X
on	B-X
ovarian	B-X
function	B-X
<EOS>	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
GLP	B-X
effectively	B-X
promoted	B-X
the	B-X
expression	B-X
of	B-X
AQP5	B-X
,	B-X
AQP4	B-X
,	B-X
and	B-X
AQP1	B-X
,	B-X
inhibited	B-X
the	B-X
release	B-X
of	B-X
TNF	B-X
-	B-X
α	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
and	B-X
reduced	B-X
inflammation	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
We	B-X
aimed	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
MIF	B-X
-	B-X
CD74	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
lung	B-X
adenocarcinoma	B-X
and	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
tumor	B-X
necrosis	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
α	B-X
-	B-X
mediated	B-X
inflammation	B-X
regulates	B-X
CD74	B-X
and	B-X
MIF	B-X
expression	B-X
in	B-X
IDLA	B-X

Homocysteine	O
stimulates	O
the	O
expression	O
of	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
leading	O
to	O
enhanced	O
monocyte	O
chemotaxis	O
.	O
<EOS>	B-X
Homocysteine	B-X
stimulates	B-X
the	B-X
expression	B-X
of	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
in	B-X
endothelial	B-X
cells	B-X
leading	B-X
to	B-X
enhanced	B-X
monocyte	B-X
chemotaxis	B-X
.	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
homocysteine	B-X
stimulates	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
endothelial	B-X
cells	B-X
leading	B-X
to	B-X
enhanced	B-X
monocyte	B-X
chemotaxis	B-X
<EOS>	B-X
Such	B-X
effect	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
increased	B-X
expression	B-X
of	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
(	B-X
176	B-X
%	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
control	B-X
)	B-X
in	B-X
endothelial	B-X
cells	B-X
which	B-X
resulted	B-X
in	B-X
enhanced	B-X
monocyte	B-X
chemotaxis	B-X
<EOS>	B-X
The	B-X
infiltration	B-X
of	B-X
monocytes	B-X
into	B-X
the	B-X
arterial	B-X
wall	B-X
is	B-X
one	B-X
of	B-X
the	B-X
key	B-X
events	B-X
during	B-X
atherogenesis	B-X

Hyperhomocysteinemia	O
has	O
been	O
identified	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O
<EOS>	B-X
Elevated	B-X
plasma	B-X
levels	B-X
of	B-X
homocysteine	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
an	B-X
independent	B-X
risk	B-X
factor	B-X
for	B-X
atherosclerosis	B-X
<EOS>	B-X
Hyperhomocysteinemia	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
an	B-X
important	B-X
and	B-X
independent	B-X
risk	B-X
factor	B-X
for	B-X
cerebral	B-X
,	B-X
coronary	B-X
and	B-X
peripheral	B-X
atherosclerosis	B-X
<EOS>	B-X
Hyperhomocysteinemia	B-X
is	B-X
a	B-X
common	B-X
independent	B-X
risk	B-X
factor	B-X
for	B-X
cardiovascular	B-X
diseases	B-X
<EOS>	B-X
Hyperhomocysteinemia	B-X
is	B-X
another	B-X
independent	B-X
risk	B-X
factor	B-X
for	B-X
atherosclerosis	B-X
and	B-X
arterial	B-X
thrombosis	B-X

The	O
infiltration	O
of	O
monocytes	B-cell_type
into	O
the	O
arterial	O
wall	O
is	O
one	O
of	O
the	O
key	O
events	O
during	O
atherogenesis	O
.	O
<EOS>	B-X
The	B-X
infiltration	B-X
of	B-X
monocytes	B-X
into	B-X
the	B-X
arterial	B-X
wall	B-X
is	B-X
one	B-X
of	B-X
the	B-X
key	B-X
events	B-X
during	B-X
atherogenesis	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
molecules	B-X
in	B-X
the	B-X
development	B-X
of	B-X
atherosclerosis	B-X
.	B-X
<EOS>	B-X
In	B-X
atherosclerosis	B-X
,	B-X
the	B-X
adhesion	B-X
of	B-X
monocytes	B-X
and	B-X
T	B-X
cells	B-X
to	B-X
the	B-X
endothelium	B-X
is	B-X
a	B-X
key	B-X
event	B-X
triggered	B-X
by	B-X
some	B-X
form	B-X
of	B-X
insult	B-X
<EOS>	B-X
In	B-X
atherosclerosis	B-X
,	B-X
the	B-X
adhesion	B-X
of	B-X
monocytes	B-X
(	B-X
and	B-X
T	B-X
cells	B-X
)	B-X
to	B-X
the	B-X
endothelium	B-X
is	B-X
a	B-X
key	B-X
event	B-X
triggered	B-X
by	B-X
some	B-X
form	B-X
of	B-X
insult	B-X

Monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
is	O
a	O
potent	O
chemokine	B-protein
that	O
stimulates	O
the	O
migration	O
of	O
monocytes	B-cell_type
into	O
the	O
intima	O
of	O
the	O
arterial	O
wall	O
.	O
<EOS>	B-X
Monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
chemokine	B-X
that	B-X
stimulates	B-X
the	B-X
migration	B-X
of	B-X
monocytes	B-X
into	B-X
the	B-X
intima	B-X
of	B-X
the	B-X
arterial	B-X
wall	B-X
<EOS>	B-X
Monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
l	B-X
(	B-X
MCP	B-X
-	B-X
l	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
chemokine	B-X
that	B-X
stimulates	B-X
the	B-X
migration	B-X
of	B-X
monocytes	B-X
into	B-X
the	B-X
intima	B-X
of	B-X
the	B-X
arterial	B-X
wall	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
homocysteine	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
production	B-X
in	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
Intracellular	B-X
redox	B-X
status	B-X
modulates	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
expression	B-X
stimulated	B-X
by	B-X
homocysteine	B-X
in	B-X
endothelial	B-X
cells	B-X
.	B-X

The	O
mechanism	O
by	O
which	O
increased	O
monocyte	O
infiltration	O
occurs	O
in	O
atherosclerotic	O
lesions	O
in	O
patients	O
with	O
hyperhomocysteinemia	O
has	O
not	O
been	O
delineated	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
homocysteine	O
on	O
MCP-1	B-protein
production	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
homocysteine	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
production	B-X
in	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
Homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
subsequent	B-X
monocyte	B-X
chemotaxis	B-X
were	B-X
blocked	B-X
by	B-X
a	B-X
p38	B-X
MAP	B-X
kinase	B-X
inhibitor	B-X
(	B-X
SB203580	B-X
)	B-X
suggesting	B-X
that	B-X
the	B-X
p38	B-X
MAP	B-X
kinase	B-X
pathway	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
The	B-X
infiltration	B-X
of	B-X
monocytes	B-X
into	B-X
the	B-X
arterial	B-X
wall	B-X
is	B-X
one	B-X
of	B-X
the	B-X
key	B-X
events	B-X
during	B-X
atherogenesis	B-X
<EOS>	B-X
Monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
chemokine	B-X
that	B-X
stimulates	B-X
the	B-X
migration	B-X
of	B-X
monocytes	B-X
into	B-X
the	B-X
intima	B-X
of	B-X
the	B-X
arterial	B-X
wall	B-X

Cells	O
were	O
incubated	O
with	O
homocysteine	O
.	O
<EOS>	B-X
H9c2	B-X
cells	B-X
and	B-X
neonatal	B-X
rat	B-X
cardiomyocytes	B-X
were	B-X
incubated	B-X
with	B-X
homocysteine	B-X
<EOS>	B-X
H9C2	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
Hcy	B-X
to	B-X
induce	B-X
a	B-X
cell	B-X
model	B-X
of	B-X
Hcy	B-X
-	B-X
injured	B-X
cardiomyocytes	B-X
<EOS>	B-X
Rats	B-X
were	B-X
fed	B-X
methionine	B-X
-	B-X
enriched	B-X
diet	B-X
to	B-X
induce	B-X
hyperhomocysteinemia	B-X
<EOS>	B-X
Rats	B-X
were	B-X
fed	B-X
a	B-X
methionine	B-X
diet	B-X
to	B-X
establish	B-X
the	B-X
animal	B-X
model	B-X
of	B-X
hyperhomocysteinemia	B-X
(	B-X
HHcy	B-X
)	B-X

The	O
secretion	O
of	O
MCP-1	B-protein
protein	I-protein
was	O
significantly	O
increased	O
(	O
195	O
%	O
as	O
compared	O
to	O
the	O
control	O
)	O
in	O
cells	O
treated	O
with	O
pathological	O
concentrations	O
of	O
homocysteine	O
.	O

Such	O
effect	O
was	O
accompanied	O
by	O
an	O
increased	O
expression	O
of	O
MCP-1	B-RNA
mRNA	I-RNA
(	O
176	O
%	O
as	O
compared	O
to	O
the	O
control	O
)	O
in	O
endothelial	B-cell_type
cells	I-cell_type
which	O
resulted	O
in	O
enhanced	O
monocyte	O
chemotaxis	O
.	O

The	O
p38	B-protein
MAP	I-protein
kinase	I-protein
as	O
well	O
as	O
other	O
members	O
of	O
the	O
p38	O
MAP	O
kinase	O
pathway	O
,	O
including	O
MKK3	B-protein
,	O
MKK6	B-protein
,	O
ATF-2	B-protein
and	O
Elk-1	B-protein
,	O
were	O
activated	O
in	O
homocysteine-treated	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
p38	B-X
MAP	B-X
kinase	B-X
as	B-X
well	B-X
as	B-X
other	B-X
members	B-X
of	B-X
the	B-X
p38	B-X
MAP	B-X
kinase	B-X
pathway	B-X
,	B-X
including	B-X
MKK3	B-X
,	B-X
MKK6	B-X
,	B-X
ATF	B-X
-	B-X
2	B-X
and	B-X
Elk	B-X
-	B-X
1	B-X
,	B-X
were	B-X
activated	B-X
in	B-X
homocysteine	B-X
-	B-X
treated	B-X
cells	B-X
<EOS>	B-X
Homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
subsequent	B-X
monocyte	B-X
chemotaxis	B-X
were	B-X
blocked	B-X
by	B-X
a	B-X
p38	B-X
MAP	B-X
kinase	B-X
inhibitor	B-X
(	B-X
SB203580	B-X
)	B-X
suggesting	B-X
that	B-X
the	B-X
p38	B-X
MAP	B-X
kinase	B-X
pathway	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
homocysteine	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
production	B-X
in	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
staurosporine	B-X
,	B-X
a	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitor	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X

Homocysteine-induced	O
MCP-1	B-protein
expression	O
and	O
subsequent	O
monocyte	O
chemotaxis	O
were	O
blocked	O
by	O
a	O
p38	B-protein
MAP	I-protein
kinase	I-protein
inhibitor	O
(	O
SB203580	O
)	O
suggesting	O
that	O
the	O
p38	B-protein
MAP	I-protein
kinase	I-protein
pathway	O
might	O
be	O
involved	O
in	O
homocysteine-induced	O
MCP-1	B-protein
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
subsequent	B-X
monocyte	B-X
chemotaxis	B-X
were	B-X
blocked	B-X
by	B-X
a	B-X
p38	B-X
MAP	B-X
kinase	B-X
inhibitor	B-X
(	B-X
SB203580	B-X
)	B-X
suggesting	B-X
that	B-X
the	B-X
p38	B-X
MAP	B-X
kinase	B-X
pathway	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
homocysteine	B-X
on	B-X
MCP	B-X
-	B-X
1	B-X
production	B-X
in	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
The	B-X
p38	B-X
MAP	B-X
kinase	B-X
as	B-X
well	B-X
as	B-X
other	B-X
members	B-X
of	B-X
the	B-X
p38	B-X
MAP	B-X
kinase	B-X
pathway	B-X
,	B-X
including	B-X
MKK3	B-X
,	B-X
MKK6	B-X
,	B-X
ATF	B-X
-	B-X
2	B-X
and	B-X
Elk	B-X
-	B-X
1	B-X
,	B-X
were	B-X
activated	B-X
in	B-X
homocysteine	B-X
-	B-X
treated	B-X
cells	B-X
<EOS>	B-X
Homocysteine	B-X
stimulates	B-X
the	B-X
expression	B-X
of	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
in	B-X
endothelial	B-X
cells	B-X
leading	B-X
to	B-X
enhanced	B-X
monocyte	B-X
chemotaxis	B-X
.	B-X

In	O
contrast	O
,	O
staurosporine	O
,	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitor	O
,	O
had	O
no	O
effect	O
on	O
homocysteine-induced	O
MCP-1	B-protein
expression	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
staurosporine	B-X
,	B-X
a	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitor	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
<EOS>	B-X
Homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
subsequent	B-X
monocyte	B-X
chemotaxis	B-X
were	B-X
blocked	B-X
by	B-X
a	B-X
p38	B-X
MAP	B-X
kinase	B-X
inhibitor	B-X
(	B-X
SB203580	B-X
)	B-X
suggesting	B-X
that	B-X
the	B-X
p38	B-X
MAP	B-X
kinase	B-X
pathway	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
homocysteine	B-X
stimulates	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
endothelial	B-X
cells	B-X
leading	B-X
to	B-X
enhanced	B-X
monocyte	B-X
chemotaxis	B-X
<EOS>	B-X
Monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
chemokine	B-X
that	B-X
stimulates	B-X
the	B-X
migration	B-X
of	B-X
monocytes	B-X
into	B-X
the	B-X
intima	B-X
of	B-X
the	B-X
arterial	B-X
wall	B-X

In	O
conclusion	O
,	O
our	O
results	O
indicate	O
that	O
homocysteine	O
stimulates	O
MCP-1	B-protein
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
leading	O
to	O
enhanced	O
monocyte	O
chemotaxis	O
.	O
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
homocysteine	B-X
stimulates	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
endothelial	B-X
cells	B-X
leading	B-X
to	B-X
enhanced	B-X
monocyte	B-X
chemotaxis	B-X
<EOS>	B-X
Homocysteine	B-X
stimulates	B-X
the	B-X
expression	B-X
of	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
in	B-X
endothelial	B-X
cells	B-X
leading	B-X
to	B-X
enhanced	B-X
monocyte	B-X
chemotaxis	B-X
.	B-X
<EOS>	B-X
Such	B-X
effect	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
increased	B-X
expression	B-X
of	B-X
MCP	B-X
-	B-X
1	B-X
mRNA	B-X
(	B-X
176	B-X
%	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
control	B-X
)	B-X
in	B-X
endothelial	B-X
cells	B-X
which	B-X
resulted	B-X
in	B-X
enhanced	B-X
monocyte	B-X
chemotaxis	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
staurosporine	B-X
,	B-X
a	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitor	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
homocysteine	B-X
-	B-X
induced	B-X
MCP	B-X
-	B-X
1	B-X
expression	B-X

Inducible	O
resistance	O
to	O
Fas-mediated	O
apoptosis	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Apoptosis	O
produced	O
in	O
B	B-cell_type
cells	I-cell_type
through	O
Fas	B-protein
(	O
APO-1	B-protein
,	O
CD95	B-protein
)	O
triggering	O
is	O
regulated	O
by	O
signals	O
derived	O
from	O
other	O
surface	O
receptors	O
:	O
CD40	O
engagement	O
produces	O
upregulation	O
of	O
Fas	B-protein
expression	O
and	O
marked	O
susceptibility	O
to	O
Fas	B-protein
-induced	O
cell	O
death	O
,	O
whereas	O
antigen	O
receptor	O
engagement	O
,	O
or	O
IL-4R	O
engagement	O
,	O
inhibits	O
Fas	B-protein
killing	O
and	O
in	O
so	O
doing	O
induces	O
a	O
state	O
of	O
Fas	B-protein
-resistance	O
,	O
even	O
in	O
otherwise	O
sensitive	O
,	O
CD40	B-protein
-stimulated	O
targets	O
.	O
<EOS>	B-X
Apoptosis	B-X
produced	B-X
in	B-X
B	B-X
cells	B-X
through	B-X
Fas	B-X
(	B-X
APO	B-X
-	B-X
1	B-X
,	B-X
CD95	B-X
)	B-X
triggering	B-X
is	B-X
regulated	B-X
by	B-X
signals	B-X
derived	B-X
from	B-X
other	B-X
surface	B-X
receptors	B-X
:	B-X
CD40	B-X
engagement	B-X
produces	B-X
upregulation	B-X
of	B-X
Fas	B-X
expression	B-X
and	B-X
marked	B-X
susceptibility	B-X
to	B-X
Fas	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
antigen	B-X
receptor	B-X
engagement	B-X
,	B-X
or	B-X
IL	B-X
-	B-X
4R	B-X
engagement	B-X
,	B-X
inhibits	B-X
Fas	B-X
killing	B-X
and	B-X
in	B-X
so	B-X
doing	B-X
induces	B-X
a	B-X
state	B-X
of	B-X
Fas	B-X
-	B-X
resistance	B-X
,	B-X
even	B-X
in	B-X
otherwise	B-X
sensitive	B-X
,	B-X
CD40	B-X
-	B-X
stimulated	B-X
targets	B-X
<EOS>	B-X
Inducible	B-X
resistance	B-X
to	B-X
Fas	B-X
killing	B-X
is	B-X
hypothesized	B-X
to	B-X
protect	B-X
foreign	B-X
antigen	B-X
-	B-X
specific	B-X
B	B-X
cells	B-X
during	B-X
potentially	B-X
hazardous	B-X
interactions	B-X
with	B-X
FasL	B-X
-	B-X
bearing	B-X
T	B-X
cells	B-X
,	B-X
whereas	B-X
autoreactive	B-X
B	B-X
cells	B-X
fail	B-X
to	B-X
become	B-X
Fas	B-X
-	B-X
resistant	B-X
and	B-X
are	B-X
deleted	B-X
via	B-X
Fas	B-X
-	B-X
dependent	B-X
cytotoxicity	B-X
<EOS>	B-X
Terminal	B-X
effectors	B-X
of	B-X
B	B-X
cell	B-X
Fas	B-X
-	B-X
resistance	B-X
include	B-X
the	B-X
known	B-X
anti	B-X
-	B-X
apoptotic	B-X
gene	B-X
products	B-X
,	B-X
Bcl	B-X
-	B-X
xL	B-X
and	B-X
FLIP	B-X
,	B-X
and	B-X
a	B-X
novel	B-X
anti	B-X
-	B-X
apoptotic	B-X
gene	B-X
that	B-X
encodes	B-X
FAIM	B-X
(	B-X
Fas	B-X
Apoptosis	B-X
Inhibitory	B-X
Molecule	B-X
)	B-X
<EOS>	B-X
Inadvertent	B-X
or	B-X
aberrant	B-X
acquisition	B-X
of	B-X
Fas	B-X
-	B-X
resistance	B-X
may	B-X
permit	B-X
autoreactive	B-X
B	B-X
cells	B-X
to	B-X
escape	B-X
Fas	B-X
deletion	B-X
,	B-X
and	B-X
malignant	B-X
lymphocytes	B-X
to	B-X
impede	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X

Surface	B-protein
immunoglobulin	I-protein
and	O
IL-4R	B-protein
utilize	O
at	O
least	O
partially	O
distinct	O
pathways	O
to	O
produce	O
Fas	B-protein
-resistance	O
that	O
differentially	O
depend	O
on	O
PKC	B-protein
and	O
STAT6	B-protein
,	O
respectively	O
.	O
<EOS>	B-X
Surface	B-X
immunoglobulin	B-X
and	B-X
IL	B-X
-	B-X
4R	B-X
utilize	B-X
at	B-X
least	B-X
partially	B-X
distinct	B-X
pathways	B-X
to	B-X
produce	B-X
Fas	B-X
-	B-X
resistance	B-X
that	B-X
differentially	B-X
depend	B-X
on	B-X
PKC	B-X
and	B-X
STAT6	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Further	B-X
,	B-X
surface	B-X
immunoglobulin	B-X
signaling	B-X
for	B-X
inducible	B-X
Fas	B-X
-	B-X
resistance	B-X
bypasses	B-X
Btk	B-X
,	B-X
requires	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
and	B-X
entails	B-X
new	B-X
macromolecular	B-X
synthesis	B-X
<EOS>	B-X
Inducible	B-X
resistance	B-X
to	B-X
Fas	B-X
killing	B-X
is	B-X
hypothesized	B-X
to	B-X
protect	B-X
foreign	B-X
antigen	B-X
-	B-X
specific	B-X
B	B-X
cells	B-X
during	B-X
potentially	B-X
hazardous	B-X
interactions	B-X
with	B-X
FasL	B-X
-	B-X
bearing	B-X
T	B-X
cells	B-X
,	B-X
whereas	B-X
autoreactive	B-X
B	B-X
cells	B-X
fail	B-X
to	B-X
become	B-X
Fas	B-X
-	B-X
resistant	B-X
and	B-X
are	B-X
deleted	B-X
via	B-X
Fas	B-X
-	B-X
dependent	B-X
cytotoxicity	B-X
<EOS>	B-X
Inducible	B-X
resistance	B-X
to	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
in	B-X
B	B-X
cells	B-X
.	B-X

Further	O
,	O
surface	O
immunoglobulin	O
signaling	O
for	O
inducible	O
Fas	B-protein
-resistance	O
bypasses	O
Btk	B-protein
,	O
requires	O
NF-kappaB	B-protein
,	O
and	O
entails	O
new	O
macromolecular	O
synthesis	O
.	O
<EOS>	B-X
Further	B-X
,	B-X
surface	B-X
immunoglobulin	B-X
signaling	B-X
for	B-X
inducible	B-X
Fas	B-X
-	B-X
resistance	B-X
bypasses	B-X
Btk	B-X
,	B-X
requires	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
and	B-X
entails	B-X
new	B-X
macromolecular	B-X
synthesis	B-X
<EOS>	B-X
Surface	B-X
immunoglobulin	B-X
and	B-X
IL	B-X
-	B-X
4R	B-X
utilize	B-X
at	B-X
least	B-X
partially	B-X
distinct	B-X
pathways	B-X
to	B-X
produce	B-X
Fas	B-X
-	B-X
resistance	B-X
that	B-X
differentially	B-X
depend	B-X
on	B-X
PKC	B-X
and	B-X
STAT6	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Inducible	B-X
resistance	B-X
to	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
The	B-X
FAIM	B-X
sequence	B-X
is	B-X
highly	B-X
evolu	B-X
-	B-X
	B-X
tionarily	B-X
conserved	B-X
,	B-X
suggesting	B-X
an	B-X
important	B-X
role	B-X
for	B-X
this	B-X
molecule	B-X
throughout	B-X
phylogeny	B-X

Terminal	O
effectors	O
of	O
B	B-cell_type
cell	I-cell_type
Fas	B-protein
-resistance	O
include	O
the	O
known	O
anti-apoptotic	B-protein
gene	I-protein
products	I-protein
,	O
Bcl-xL	B-protein
and	O
FLIP	B-protein
,	O
and	O
a	O
novel	O
anti-apoptotic	B-DNA
gene	I-DNA
that	O
encodes	O
FAIM	B-protein
(	O
Fas	B-protein
Apoptosis	I-protein
Inhibitory	I-protein
Molecule	I-protein
)	O
.	O

faim	B-protein
was	O
identified	O
by	O
differential	O
display	O
and	O
exists	O
in	O
two	O
alternatively	O
spliced	O
forms	O
;	O
faim-S	B-protein
is	O
broadly	O
expressed	O
,	O
but	O
faim-L	O
expression	O
is	O
tissue-specific	O
.	O
<EOS>	B-X
faim	B-X
was	B-X
identified	B-X
by	B-X
differential	B-X
display	B-X
and	B-X
exists	B-X
in	B-X
two	B-X
alternatively	B-X
spliced	B-X
forms	B-X
;	B-X
faim	B-X
-	B-X
S	B-X
is	B-X
broadly	B-X
expressed	B-X
,	B-X
but	B-X
faim	B-X
-	B-X
L	B-X
expression	B-X
is	B-X
tissue	B-X
-	B-X
specific	B-X
<EOS>	B-X
Inducible	B-X
resistance	B-X
to	B-X
Fas	B-X
killing	B-X
is	B-X
hypothesized	B-X
to	B-X
protect	B-X
foreign	B-X
antigen	B-X
-	B-X
specific	B-X
B	B-X
cells	B-X
during	B-X
potentially	B-X
hazardous	B-X
interactions	B-X
with	B-X
FasL	B-X
-	B-X
bearing	B-X
T	B-X
cells	B-X
,	B-X
whereas	B-X
autoreactive	B-X
B	B-X
cells	B-X
fail	B-X
to	B-X
become	B-X
Fas	B-X
-	B-X
resistant	B-X
and	B-X
are	B-X
deleted	B-X
via	B-X
Fas	B-X
-	B-X
dependent	B-X
cytotoxicity	B-X
<EOS>	B-X
The	B-X
FAIM	B-X
sequence	B-X
is	B-X
highly	B-X
evolu	B-X
-	B-X
	B-X
tionarily	B-X
conserved	B-X
,	B-X
suggesting	B-X
an	B-X
important	B-X
role	B-X
for	B-X
this	B-X
molecule	B-X
throughout	B-X
phylogeny	B-X
<EOS>	B-X
Apoptosis	B-X
produced	B-X
in	B-X
B	B-X
cells	B-X
through	B-X
Fas	B-X
(	B-X
APO	B-X
-	B-X
1	B-X
,	B-X
CD95	B-X
)	B-X
triggering	B-X
is	B-X
regulated	B-X
by	B-X
signals	B-X
derived	B-X
from	B-X
other	B-X
surface	B-X
receptors	B-X
:	B-X
CD40	B-X
engagement	B-X
produces	B-X
upregulation	B-X
of	B-X
Fas	B-X
expression	B-X
and	B-X
marked	B-X
susceptibility	B-X
to	B-X
Fas	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
antigen	B-X
receptor	B-X
engagement	B-X
,	B-X
or	B-X
IL	B-X
-	B-X
4R	B-X
engagement	B-X
,	B-X
inhibits	B-X
Fas	B-X
killing	B-X
and	B-X
in	B-X
so	B-X
doing	B-X
induces	B-X
a	B-X
state	B-X
of	B-X
Fas	B-X
-	B-X
resistance	B-X
,	B-X
even	B-X
in	B-X
otherwise	B-X
sensitive	B-X
,	B-X
CD40	B-X
-	B-X
stimulated	B-X
targets	B-X

The	O
FAIM	B-DNA
sequence	I-DNA
is	O
highly	O
evolu-	O
tionarily	O
conserved	O
,	O
suggesting	O
an	O
important	O
role	O
for	O
this	O
molecule	O
throughout	O
phylogeny	O
.	O
<EOS>	B-X
The	B-X
FAIM	B-X
sequence	B-X
is	B-X
highly	B-X
evolu	B-X
-	B-X
	B-X
tionarily	B-X
conserved	B-X
,	B-X
suggesting	B-X
an	B-X
important	B-X
role	B-X
for	B-X
this	B-X
molecule	B-X
throughout	B-X
phylogeny	B-X
<EOS>	B-X
Terminal	B-X
effectors	B-X
of	B-X
B	B-X
cell	B-X
Fas	B-X
-	B-X
resistance	B-X
include	B-X
the	B-X
known	B-X
anti	B-X
-	B-X
apoptotic	B-X
gene	B-X
products	B-X
,	B-X
Bcl	B-X
-	B-X
xL	B-X
and	B-X
FLIP	B-X
,	B-X
and	B-X
a	B-X
novel	B-X
anti	B-X
-	B-X
apoptotic	B-X
gene	B-X
that	B-X
encodes	B-X
FAIM	B-X
(	B-X
Fas	B-X
Apoptosis	B-X
Inhibitory	B-X
Molecule	B-X
)	B-X
<EOS>	B-X
Further	B-X
,	B-X
surface	B-X
immunoglobulin	B-X
signaling	B-X
for	B-X
inducible	B-X
Fas	B-X
-	B-X
resistance	B-X
bypasses	B-X
Btk	B-X
,	B-X
requires	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
and	B-X
entails	B-X
new	B-X
macromolecular	B-X
synthesis	B-X
<EOS>	B-X
Inadvertent	B-X
or	B-X
aberrant	B-X
acquisition	B-X
of	B-X
Fas	B-X
-	B-X
resistance	B-X
may	B-X
permit	B-X
autoreactive	B-X
B	B-X
cells	B-X
to	B-X
escape	B-X
Fas	B-X
deletion	B-X
,	B-X
and	B-X
malignant	B-X
lymphocytes	B-X
to	B-X
impede	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X

Inducible	O
resistance	O
to	O
Fas	B-protein
killing	O
is	O
hypothesized	O
to	O
protect	O
foreign	O
antigen-specific	O
B	B-cell_type
cells	I-cell_type
during	O
potentially	O
hazardous	O
interactions	O
with	O
FasL-bearing	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
autoreactive	B-cell_type
B	I-cell_type
cells	I-cell_type
fail	O
to	O
become	O
Fas	B-protein
-resistant	O
and	O
are	O
deleted	O
via	O
Fas	B-protein
-dependent	O
cytotoxicity	O
.	O
<EOS>	B-X
Inducible	B-X
resistance	B-X
to	B-X
Fas	B-X
killing	B-X
is	B-X
hypothesized	B-X
to	B-X
protect	B-X
foreign	B-X
antigen	B-X
-	B-X
specific	B-X
B	B-X
cells	B-X
during	B-X
potentially	B-X
hazardous	B-X
interactions	B-X
with	B-X
FasL	B-X
-	B-X
bearing	B-X
T	B-X
cells	B-X
,	B-X
whereas	B-X
autoreactive	B-X
B	B-X
cells	B-X
fail	B-X
to	B-X
become	B-X
Fas	B-X
-	B-X
resistant	B-X
and	B-X
are	B-X
deleted	B-X
via	B-X
Fas	B-X
-	B-X
dependent	B-X
cytotoxicity	B-X
<EOS>	B-X
Inadvertent	B-X
or	B-X
aberrant	B-X
acquisition	B-X
of	B-X
Fas	B-X
-	B-X
resistance	B-X
may	B-X
permit	B-X
autoreactive	B-X
B	B-X
cells	B-X
to	B-X
escape	B-X
Fas	B-X
deletion	B-X
,	B-X
and	B-X
malignant	B-X
lymphocytes	B-X
to	B-X
impede	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
<EOS>	B-X
Apoptosis	B-X
produced	B-X
in	B-X
B	B-X
cells	B-X
through	B-X
Fas	B-X
(	B-X
APO	B-X
-	B-X
1	B-X
,	B-X
CD95	B-X
)	B-X
triggering	B-X
is	B-X
regulated	B-X
by	B-X
signals	B-X
derived	B-X
from	B-X
other	B-X
surface	B-X
receptors	B-X
:	B-X
CD40	B-X
engagement	B-X
produces	B-X
upregulation	B-X
of	B-X
Fas	B-X
expression	B-X
and	B-X
marked	B-X
susceptibility	B-X
to	B-X
Fas	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
whereas	B-X
antigen	B-X
receptor	B-X
engagement	B-X
,	B-X
or	B-X
IL	B-X
-	B-X
4R	B-X
engagement	B-X
,	B-X
inhibits	B-X
Fas	B-X
killing	B-X
and	B-X
in	B-X
so	B-X
doing	B-X
induces	B-X
a	B-X
state	B-X
of	B-X
Fas	B-X
-	B-X
resistance	B-X
,	B-X
even	B-X
in	B-X
otherwise	B-X
sensitive	B-X
,	B-X
CD40	B-X
-	B-X
stimulated	B-X
targets	B-X
<EOS>	B-X
Surface	B-X
immunoglobulin	B-X
and	B-X
IL	B-X
-	B-X
4R	B-X
utilize	B-X
at	B-X
least	B-X
partially	B-X
distinct	B-X
pathways	B-X
to	B-X
produce	B-X
Fas	B-X
-	B-X
resistance	B-X
that	B-X
differentially	B-X
depend	B-X
on	B-X
PKC	B-X
and	B-X
STAT6	B-X
,	B-X
respectively	B-X

Inadvertent	O
or	O
aberrant	O
acquisition	O
of	O
Fas	B-protein
-resistance	O
may	O
permit	O
autoreactive	B-cell_type
B	I-cell_type
cells	I-cell_type
to	O
escape	O
Fas	B-protein
deletion	O
,	O
and	O
malignant	B-cell_type
lymphocytes	I-cell_type
to	O
impede	O
anti-tumor	O
immunity	O
.	O
<EOS>	B-X
The	B-X
omicron	B-X
variants	B-X
of	B-X
SARS	B-X
-	B-X
CoV	B-X
-	B-X
2	B-X
have	B-X
substantial	B-X
ability	B-X
to	B-X
escape	B-X
infection	B-X
-	B-X
	B-X
and	B-X
vaccine	B-X
-	B-X
elicited	B-X
antibody	B-X
immunity	B-X
<EOS>	B-X
Subsequently	B-X
to	B-X
the	B-X
publication	B-X
of	B-X
this	B-X
paper	B-X
,	B-X
the	B-X
authors	B-X
have	B-X
realized	B-X
that	B-X
an	B-X
error	B-X
was	B-X
made	B-X
during	B-X
the	B-X
compilation	B-X
of	B-X
Fig	B-X
<EOS>	B-X
The	B-X
inadvertent	B-X
intra	B-X
-	B-X
arterial	B-X
injection	B-X
of	B-X
ropivacaine	B-X
was	B-X
suspected	B-X
to	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
the	B-X
spread	B-X
into	B-X
the	B-X
brainstem	B-X
<EOS>	B-X
Infected	B-X
patients	B-X
requiring	B-X
surgery	B-X
can	B-X
increase	B-X
the	B-X
exposure	B-X
of	B-X
health	B-X
care	B-X
professionals	B-X
and	B-X
other	B-X
patients	B-X
to	B-X
the	B-X
virus	B-X

Stromal	B-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
alpha	I-protein
-induced	O
chemotaxis	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
nitric	O
oxide	O
signaling	O
pathways	O
.	O

Stromal	B-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
alpha	I-protein
(	O
SDF1	B-protein
alpha	I-protein
)	O
and	O
its	O
cognate	O
chemokine	B-protein
receptor	I-protein
CXCR4	I-protein
act	O
as	O
potent	O
chemoattractants	O
and	O
regulate	O
trafficking	O
and	O
homing	O
of	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
lymphocytes	B-cell_type
.	O
<EOS>	B-X
Stromal	B-X
cell	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
alpha	B-X
(	B-X
SDF1	B-X
alpha	B-X
)	B-X
and	B-X
its	B-X
cognate	B-X
chemokine	B-X
receptor	B-X
CXCR4	B-X
act	B-X
as	B-X
potent	B-X
chemoattractants	B-X
and	B-X
regulate	B-X
trafficking	B-X
and	B-X
homing	B-X
of	B-X
hematopoietic	B-X
progenitor	B-X
cells	B-X
and	B-X
lymphocytes	B-X
<EOS>	B-X
Stromal	B-X
cell	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
alpha	B-X
-	B-X
induced	B-X
chemotaxis	B-X
in	B-X
T	B-X
cells	B-X
is	B-X
mediated	B-X
by	B-X
nitric	B-X
oxide	B-X
signaling	B-X
pathways	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
explored	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
second	B-X
messenger	B-X
NO	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
migration	B-X
<EOS>	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
NO	B-X
-	B-X
related	B-X
signaling	B-X
pathways	B-X
may	B-X
mediate	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
chemotaxis	B-X
,	B-X
but	B-X
not	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
activation	B-X

However	O
,	O
the	O
molecular	O
mechanisms	O
regulating	O
SDF1	B-protein
alpha	I-protein
-driven	O
cell	O
migration	O
are	O
not	O
well	O
defined	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	O
roles	O
of	O
the	O
second	O
messenger	O
NO	O
and	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
SDF1	B-protein
alpha	I-protein
-induced	O
T	O
cell	O
migration	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
explored	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
second	B-X
messenger	B-X
NO	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
migration	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MAP	B-X
/	B-X
Erk	B-X
kinase	B-X
kinase	B-X
inhibitor	B-X
PD98059	B-X
did	B-X
not	B-X
abrogate	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
chemotaxis	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
inhibitors	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
linked	B-X
to	B-X
NO	B-X
signaling	B-X
pathways	B-X
,	B-X
also	B-X
significantly	B-X
blocked	B-X
the	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
chemotactic	B-X
response	B-X
<EOS>	B-X
AKT	B-X
,	B-X
which	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
mediate	B-X
NO	B-X
production	B-X
,	B-X
was	B-X
also	B-X
phosphorylated	B-X
upon	B-X
SDF1	B-X
alpha	B-X
stimulation	B-X

SDF1	B-protein
alpha	I-protein
treatment	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
increased	O
the	O
activity	O
of	O
NO	B-protein
synthase	I-protein
,	O
which	O
catalyzes	O
the	O
generation	O
of	O
NO	O
.	O

We	O
observed	O
that	O
pretreatment	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
or	O
activated	O
PBLs	B-cell_type
with	O
several	O
NO	O
donors	O
significantly	O
enhanced	O
the	O
SDF1	B-protein
alpha	I-protein
-induced	O
migration	O
,	O
whereas	O
various	O
inhibitors	O
of	O
NO	B-protein
synthase	I-protein
markedly	O
abrogated	O
the	O
chemotactic	O
response	O
in	O
a	O
concentration-dependent	O
manner	O
.	O
<EOS>	B-X
Pretreatment	B-X
of	B-X
Jurkat	B-X
T	B-X
cells	B-X
with	B-X
tBHQ	B-X
,	B-X
prior	B-X
to	B-X
activation	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
/	B-X
anti	B-X
-	B-X
CD28	B-X
,	B-X
diminished	B-X
the	B-X
production	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
at	B-X
both	B-X
the	B-X
transcript	B-X
and	B-X
protein	B-X
levels	B-X
<EOS>	B-X
We	B-X
then	B-X
showed	B-X
that	B-X
pre	B-X
-	B-X
treating	B-X
Jurkat	B-X
cells	B-X
with	B-X
low	B-X
concentration	B-X
of	B-X
cyclosporine	B-X
A	B-X
,	B-X
a	B-X
blocker	B-X
of	B-X
the	B-X
mitochondrial	B-X
transition	B-X
pore	B-X
,	B-X
attenuates	B-X
AT38	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
suppresses	B-X
cell	B-X
death	B-X
<EOS>	B-X
Further	B-X
estimation	B-X
of	B-X
ROS	B-X
and	B-X
GSH	B-X
have	B-X
shown	B-X
the	B-X
significant	B-X
oxidative	B-X
stress	B-X
induced	B-X
by	B-X
DLM	B-X
in	B-X
concentration	B-X
-	B-X
time	B-X
dependent	B-X
manner	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
exposure	B-X
of	B-X
each	B-X
cell	B-X
line	B-X
to	B-X
100	B-X
,	B-X
10	B-X
ns	B-X
pulses	B-X
at	B-X
50	B-X
kV	B-X
/	B-X
cm	B-X
caused	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
expression	B-X
of	B-X
cFLIP	B-X
(	B-X
extrinsic	B-X
apoptosis	B-X
inhibitor	B-X
)	B-X
in	B-X
U937	B-X
and	B-X
FasL	B-X
(	B-X
extrinsic	B-X
apoptosis	B-X
activator	B-X
)	B-X
in	B-X
Jurkat	B-X
,	B-X
respectively	B-X

Furthermore	O
,	O
we	O
observed	O
that	O
inhibitors	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
is	O
linked	O
to	O
NO	O
signaling	O
pathways	O
,	O
also	O
significantly	O
blocked	O
the	O
SDF1	B-protein
alpha	I-protein
-induced	O
chemotactic	O
response	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
inhibitors	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
linked	B-X
to	B-X
NO	B-X
signaling	B-X
pathways	B-X
,	B-X
also	B-X
significantly	B-X
blocked	B-X
the	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
chemotactic	B-X
response	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
explored	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
second	B-X
messenger	B-X
NO	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
migration	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
MAP	B-X
/	B-X
Erk	B-X
kinase	B-X
kinase	B-X
inhibitor	B-X
PD98059	B-X
did	B-X
not	B-X
abrogate	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
chemotaxis	B-X
<EOS>	B-X
AKT	B-X
,	B-X
which	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
mediate	B-X
NO	B-X
production	B-X
,	B-X
was	B-X
also	B-X
phosphorylated	B-X
upon	B-X
SDF1	B-X
alpha	B-X
stimulation	B-X

However	O
,	O
these	O
compounds	O
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
SDF1	B-protein
alpha	I-protein
-induced	O
mitogen-activated	O
protein	O
kinase	O
activity	O
.	O
<EOS>	B-X
Together	B-X
,	B-X
this	B-X
study	B-X
uncovered	B-X
the	B-X
covalently	B-X
modified	B-X
targets	B-X
of	B-X
these	B-X
natural	B-X
products	B-X
and	B-X
potential	B-X
molecular	B-X
mechanisms	B-X
of	B-X
their	B-X
antitumor	B-X
activities	B-X
<EOS>	B-X
However	B-X
,	B-X
there	B-X
remain	B-X
challenges	B-X
in	B-X
designing	B-X
2e	B-X
-	B-X
	B-X
ORR	B-X
catalysts	B-X
that	B-X
meet	B-X
the	B-X
application	B-X
criteria	B-X
<EOS>	B-X
Bioactive	B-X
compounds	B-X
generally	B-X
need	B-X
to	B-X
cross	B-X
membranes	B-X
to	B-X
arrive	B-X
at	B-X
their	B-X
site	B-X
of	B-X
action	B-X
<EOS>	B-X
However	B-X
,	B-X
more	B-X
information	B-X
is	B-X
need	B-X
to	B-X
be	B-X
deciphered	B-X
regarding	B-X
which	B-X
beneficial	B-X
microbes	B-X
become	B-X
enriched	B-X
,	B-X
and	B-X
how	B-X
the	B-X
disease	B-X
suppression	B-X
is	B-X
achieved	B-X

In	O
addition	O
,	O
the	O
MAP/Erk	O
kinase	O
kinase	O
inhibitor	O
PD98059	O
did	O
not	O
abrogate	O
SDF1	B-protein
alpha	I-protein
-induced	O
chemotaxis	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
MAPK	B-X
kinase	B-X
(	B-X
MEK	B-X
)	B-X
inhibitor	B-X
,	B-X
PD98059	B-X
reduced	B-X
the	B-X
C	B-X
/	B-X
EBPβ	B-X
and	B-X
C	B-X
/	B-X
EBPδ	B-X
gene	B-X
expression	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
MEK	B-X
inhibitor	B-X
impaired	B-X
UDCA	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
bile	B-X
duct	B-X
cancer	B-X
cells	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
MEK	B-X
by	B-X
its	B-X
specific	B-X
inhibitor	B-X
,	B-X
PD98059	B-X
,	B-X
altered	B-X
the	B-X
effect	B-X
of	B-X
OxLDL	B-X
on	B-X
ABCA1	B-X
transcription	B-X
and	B-X
activation	B-X
of	B-X
ERK	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
overexpression	B-X
of	B-X
IL	B-X
-	B-X
1β	B-X
in	B-X
HeLa	B-X
cells	B-X
promoted	B-X
cell	B-X
proliferation	B-X

AKT	B-protein
,	O
which	O
has	O
been	O
shown	O
to	O
mediate	O
NO	O
production	O
,	O
was	O
also	O
phosphorylated	O
upon	O
SDF1	B-protein
alpha	I-protein
stimulation	O
.	O
<EOS>	B-X
AKT	B-X
,	B-X
which	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
mediate	B-X
NO	B-X
production	B-X
,	B-X
was	B-X
also	B-X
phosphorylated	B-X
upon	B-X
SDF1	B-X
alpha	B-X
stimulation	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
explored	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
second	B-X
messenger	B-X
NO	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
T	B-X
cell	B-X
migration	B-X
<EOS>	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
NO	B-X
-	B-X
related	B-X
signaling	B-X
pathways	B-X
may	B-X
mediate	B-X
SDF1	B-X
alpha	B-X
-	B-X
induced	B-X
chemotaxis	B-X
,	B-X
but	B-X
not	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
activation	B-X
<EOS>	B-X
SDF	B-X
-	B-X
1alpha	B-X
increased	B-X
IL	B-X
-	B-X
6	B-X
production	B-X
in	B-X
both	B-X
protein	B-X
and	B-X
mRNA	B-X
levels	B-X

These	O
studies	O
suggest	O
that	O
NO-related	O
signaling	O
pathways	O
may	O
mediate	O
SDF1	B-protein
alpha	I-protein
-induced	O
chemotaxis	O
,	O
but	O
not	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
.	O

The	O
lack	O
of	O
NF-kappa	O
B	O
transactivation	O
and	O
PKC	O
epsilon	O
expression	O
in	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
correlates	O
with	O
negative	O
selection	O
.	O
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transactivation	B-X
and	B-X
PKC	B-X
epsilon	B-X
expression	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
correlates	B-X
with	B-X
negative	B-X
selection	B-X
.	B-X
<EOS>	B-X
Lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
induction	B-X
correlated	B-X
with	B-X
increased	B-X
death	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
<EOS>	B-X
Taken	B-X
together	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
lack	B-X
of	B-X
PKC	B-X
epsilon	B-X
in	B-X
DP	B-X
thymocytes	B-X
could	B-X
lead	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activity	B-X
after	B-X
antigenic	B-X
stimulation	B-X
contributing	B-X
to	B-X
negative	B-X
selection	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
a	B-X
complete	B-X
lack	B-X
of	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
epsilon	B-X
isoform	B-X
of	B-X
Protein	B-X
Kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
in	B-X
DP	B-X
thymocytes	B-X
,	B-X
although	B-X
it	B-X
was	B-X
present	B-X
in	B-X
mature	B-X
thymocytes	B-X
and	B-X
peripheral	B-X
T	B-X
cells	B-X

Deletion	O
of	O
autoreactive	B-cell_type
thymocytes	I-cell_type
at	O
the	O
DP	O
stage	O
is	O
the	O
basis	O
for	O
tolerance	O
to	O
thymus-expressed	B-protein
self	I-protein
antigens	I-protein
.	O
<EOS>	B-X
Deletion	B-X
of	B-X
autoreactive	B-X
thymocytes	B-X
at	B-X
the	B-X
DP	B-X
stage	B-X
is	B-X
the	B-X
basis	B-X
for	B-X
tolerance	B-X
to	B-X
thymus	B-X
-	B-X
expressed	B-X
self	B-X
antigens	B-X
<EOS>	B-X
Lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
induction	B-X
correlated	B-X
with	B-X
increased	B-X
death	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
signalling	B-X
pathways	B-X
are	B-X
induced	B-X
in	B-X
DP	B-X
thymocytes	B-X
as	B-X
compared	B-X
to	B-X
mature	B-X
T	B-X
cells	B-X
upon	B-X
stimulation	B-X
with	B-X
antigen	B-X
<EOS>	B-X
Taken	B-X
together	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
lack	B-X
of	B-X
PKC	B-X
epsilon	B-X
in	B-X
DP	B-X
thymocytes	B-X
could	B-X
lead	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activity	B-X
after	B-X
antigenic	B-X
stimulation	B-X
contributing	B-X
to	B-X
negative	B-X
selection	B-X

In	O
this	O
study	O
we	O
investigated	O
whether	O
distinct	O
signalling	O
pathways	O
are	O
induced	O
in	O
DP	B-cell_type
thymocytes	I-cell_type
as	O
compared	O
to	O
mature	B-cell_type
T	I-cell_type
cells	I-cell_type
upon	O
stimulation	O
with	O
antigen	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
signalling	B-X
pathways	B-X
are	B-X
induced	B-X
in	B-X
DP	B-X
thymocytes	B-X
as	B-X
compared	B-X
to	B-X
mature	B-X
T	B-X
cells	B-X
upon	B-X
stimulation	B-X
with	B-X
antigen	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
a	B-X
complete	B-X
lack	B-X
of	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
epsilon	B-X
isoform	B-X
of	B-X
Protein	B-X
Kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
in	B-X
DP	B-X
thymocytes	B-X
,	B-X
although	B-X
it	B-X
was	B-X
present	B-X
in	B-X
mature	B-X
thymocytes	B-X
and	B-X
peripheral	B-X
T	B-X
cells	B-X
<EOS>	B-X
Lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
induction	B-X
correlated	B-X
with	B-X
increased	B-X
death	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
<EOS>	B-X
Deletion	B-X
of	B-X
autoreactive	B-X
thymocytes	B-X
at	B-X
the	B-X
DP	B-X
stage	B-X
is	B-X
the	B-X
basis	B-X
for	B-X
tolerance	B-X
to	B-X
thymus	B-X
-	B-X
expressed	B-X
self	B-X
antigens	B-X

Using	O
triple	O
transgenic	O
mice	O
expressing	O
a	O
TCR	B-DNA
transgene	I-DNA
,	O
dominant	B-protein
negative	I-protein
ras/Mek	I-protein
proteins	I-protein
and	O
a	O
reporter	B-DNA
gene	I-DNA
construct	I-DNA
with	O
AP-1	B-DNA
or	I-DNA
NF-kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
,	O
we	O
showed	O
a	O
complete	O
lack	O
of	O
transcriptional	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
but	O
not	O
AP-1	B-protein
in	O
DP	B-cell_type
thymocytes	I-cell_type
,	O
whereas	O
both	O
were	O
transcriptionally	O
active	O
in	O
mature	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
antigenic	O
stimulation	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
tumor	B-X
suppressor	B-X
gene	B-X
product	B-X
,	B-X
a	B-X
sequence	B-X
-	B-X
specific	B-X
DNA	B-X
-	B-X
binding	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
act	B-X
as	B-X
a	B-X
transcriptional	B-X
activator	B-X
and	B-X
repressor	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
In	B-X
several	B-X
exceptions	B-X
,	B-X
such	B-X
as	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcriptional	B-X
regulator	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
the	B-X
substrate	B-X
,	B-X
the	B-X
precursor	B-X
protein	B-X
p105	B-X
,	B-X
is	B-X
processed	B-X
in	B-X
a	B-X
limited	B-X
manner	B-X
to	B-X
yield	B-X
the	B-X
active	B-X
subunit	B-X
p50	B-X
<EOS>	B-X
Following	B-X
stimulation	B-X
,	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
domain	B-X
is	B-X
involved	B-X
in	B-X
rapid	B-X
processing	B-X
/	B-X
degradation	B-X
of	B-X
p105	B-X
with	B-X
release	B-X
of	B-X
a	B-X
large	B-X
amount	B-X
of	B-X
the	B-X
stored	B-X
subunits	B-X
that	B-X
now	B-X
become	B-X
transcriptionally	B-X
active	B-X
<EOS>	B-X
The	B-X
upstream	B-X
elements	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
,	B-X
including	B-X
the	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
binding	B-X
sites	B-X
,	B-X
decrease	B-X
the	B-X
p53	B-X
-	B-X
induced	B-X
inhibitory	B-X
effects	B-X
on	B-X
viral	B-X
transcription	B-X

Lack	O
of	O
NF-kappa	B-protein
B	I-protein
induction	O
correlated	O
with	O
increased	O
death	O
in	O
response	O
to	O
antigen	B-protein
.	O
<EOS>	B-X
Lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
induction	B-X
correlated	B-X
with	B-X
increased	B-X
death	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transactivation	B-X
and	B-X
PKC	B-X
epsilon	B-X
expression	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
correlates	B-X
with	B-X
negative	B-X
selection	B-X
.	B-X
<EOS>	B-X
Deletion	B-X
of	B-X
autoreactive	B-X
thymocytes	B-X
at	B-X
the	B-X
DP	B-X
stage	B-X
is	B-X
the	B-X
basis	B-X
for	B-X
tolerance	B-X
to	B-X
thymus	B-X
-	B-X
expressed	B-X
self	B-X
antigens	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
signalling	B-X
pathways	B-X
are	B-X
induced	B-X
in	B-X
DP	B-X
thymocytes	B-X
as	B-X
compared	B-X
to	B-X
mature	B-X
T	B-X
cells	B-X
upon	B-X
stimulation	B-X
with	B-X
antigen	B-X

AP-1	B-protein
induction	O
was	O
dependent	O
on	O
the	O
integrity	O
of	O
the	O
ras/Mek	O
pathway	O
indicating	O
that	O
this	O
pathway	O
was	O
activated	O
in	O
the	O
DP	B-cell_type
thymocytes	I-cell_type
.	O
<EOS>	B-X
AP	B-X
-	B-X
1	B-X
induction	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
ras	B-X
/	B-X
Mek	B-X
pathway	B-X
indicating	B-X
that	B-X
this	B-X
pathway	B-X
was	B-X
activated	B-X
in	B-X
the	B-X
DP	B-X
thymocytes	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
a	B-X
complete	B-X
lack	B-X
of	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
epsilon	B-X
isoform	B-X
of	B-X
Protein	B-X
Kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
in	B-X
DP	B-X
thymocytes	B-X
,	B-X
although	B-X
it	B-X
was	B-X
present	B-X
in	B-X
mature	B-X
thymocytes	B-X
and	B-X
peripheral	B-X
T	B-X
cells	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
signalling	B-X
pathways	B-X
are	B-X
induced	B-X
in	B-X
DP	B-X
thymocytes	B-X
as	B-X
compared	B-X
to	B-X
mature	B-X
T	B-X
cells	B-X
upon	B-X
stimulation	B-X
with	B-X
antigen	B-X
<EOS>	B-X
Lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
induction	B-X
correlated	B-X
with	B-X
increased	B-X
death	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X

In	O
contrast	O
,	O
we	O
found	O
a	O
complete	O
lack	O
of	O
constitutive	O
expression	O
of	O
the	O
epsilon	B-protein
isoform	I-protein
of	I-protein
Protein	I-protein
Kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
in	O
DP	B-cell_type
thymocytes	I-cell_type
,	O
although	O
it	O
was	O
present	O
in	O
mature	B-cell_type
thymocytes	I-cell_type
and	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
found	B-X
a	B-X
complete	B-X
lack	B-X
of	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
epsilon	B-X
isoform	B-X
of	B-X
Protein	B-X
Kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
in	B-X
DP	B-X
thymocytes	B-X
,	B-X
although	B-X
it	B-X
was	B-X
present	B-X
in	B-X
mature	B-X
thymocytes	B-X
and	B-X
peripheral	B-X
T	B-X
cells	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
whether	B-X
distinct	B-X
signalling	B-X
pathways	B-X
are	B-X
induced	B-X
in	B-X
DP	B-X
thymocytes	B-X
as	B-X
compared	B-X
to	B-X
mature	B-X
T	B-X
cells	B-X
upon	B-X
stimulation	B-X
with	B-X
antigen	B-X
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transactivation	B-X
and	B-X
PKC	B-X
epsilon	B-X
expression	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
correlates	B-X
with	B-X
negative	B-X
selection	B-X
.	B-X
<EOS>	B-X
AP	B-X
-	B-X
1	B-X
induction	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
ras	B-X
/	B-X
Mek	B-X
pathway	B-X
indicating	B-X
that	B-X
this	B-X
pathway	B-X
was	B-X
activated	B-X
in	B-X
the	B-X
DP	B-X
thymocytes	B-X

Taken	O
together	O
the	O
results	O
suggest	O
that	O
the	O
lack	O
of	O
PKC	B-protein
epsilon	I-protein
in	O
DP	B-cell_type
thymocytes	I-cell_type
could	O
lead	O
to	O
the	O
absence	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
after	O
antigenic	O
stimulation	O
contributing	O
to	O
negative	O
selection	O
.	O

Cell	O
Death	O
and	O
Differentiation	O
(	O
2000	O
)	O
7	O
,	O
1253	O
-	O
1262	O
.	O
<EOS>	B-X
Cell	B-X
Death	B-X
and	B-X
Differentiation	B-X
(	B-X
2000	B-X
)	B-X
7	B-X
,	B-X
1253	B-X
	B-X
-	B-X
	B-X
1262	B-X
<EOS>	B-X
The	B-X
lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transactivation	B-X
and	B-X
PKC	B-X
epsilon	B-X
expression	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
correlates	B-X
with	B-X
negative	B-X
selection	B-X
.	B-X
<EOS>	B-X
Lack	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
induction	B-X
correlated	B-X
with	B-X
increased	B-X
death	B-X
in	B-X
response	B-X
to	B-X
antigen	B-X
<EOS>	B-X
AP	B-X
-	B-X
1	B-X
induction	B-X
was	B-X
dependent	B-X
on	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
ras	B-X
/	B-X
Mek	B-X
pathway	B-X
indicating	B-X
that	B-X
this	B-X
pathway	B-X
was	B-X
activated	B-X
in	B-X
the	B-X
DP	B-X
thymocytes	B-X

CD2	O
stimulation	O
leads	O
to	O
the	O
delayed	O
and	O
prolonged	O
activation	O
of	O
STAT1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
but	O
not	O
NK	B-cell_type
cells	I-cell_type
.	O

OBJECTIVE	O
:	O
T	B-cell_type
lymphocytes	I-cell_type
can	O
be	O
activated	O
by	O
soluble	O
factors	O
such	O
as	O
cytokines	B-protein
or	O
through	O
direct	O
cell-cell	O
interactions	O
.	O
<EOS>	B-X
Neonatal	B-X
platelets	B-X
likely	B-X
have	B-X
multifaceted	B-X
roles	B-X
during	B-X
ductal	B-X
closure	B-X
,	B-X
such	B-X
as	B-X
secretion	B-X
of	B-X
several	B-X
signaling	B-X
molecules	B-X
and	B-X
facilitation	B-X
of	B-X
specific	B-X
cell	B-X
-	B-X
cell	B-X
interactions	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
cardiac	B-X
fibroblasts	B-X
(	B-X
CFs	B-X
)	B-X
protect	B-X
cardiomyocytes	B-X
from	B-X
ferroptosis	B-X
through	B-X
paracrine	B-X
factors	B-X
and	B-X
direct	B-X
cell	B-X
-	B-X
cell	B-X
interaction	B-X
<EOS>	B-X
This	B-X
review	B-X
outlines	B-X
recent	B-X
discoveries	B-X
into	B-X
germ	B-X
cell	B-X
development	B-X
and	B-X
subtypes	B-X
,	B-X
somatic	B-X
cell	B-X
development	B-X
,	B-X
and	B-X
cell	B-X
-	B-X
cell	B-X
interactions	B-X
<EOS>	B-X
``	B-X
Among	B-X
the	B-X
various	B-X
factors	B-X
in	B-X
the	B-X
microenvironment	B-X
,	B-X
the	B-X
cell	B-X
-	B-X
surface	B-X
glycan	B-X
acts	B-X
as	B-X
a	B-X
mediator	B-X
of	B-X
cell	B-X
-	B-X
matrix	B-X
and	B-X
cell	B-X
-	B-X
cell	B-X
interactions	B-X
and	B-X
manipulates	B-X
the	B-X
behavior	B-X
of	B-X
cells	B-X

Although	O
cytokine	B-protein
receptors	I-protein
are	O
known	O
to	O
signal	O
through	O
STAT	B-protein
family	I-protein
transcription	I-protein
factors	I-protein
,	O
the	O
mechanisms	O
by	O
which	O
other	O
cell-surface	B-protein
molecules	I-protein
,	O
such	O
as	O
CD2	B-protein
,	O
transduce	O
signals	O
is	O
unclear	O
.	O
<EOS>	B-X
Although	B-X
cytokine	B-X
receptors	B-X
are	B-X
known	B-X
to	B-X
signal	B-X
through	B-X
STAT	B-X
family	B-X
transcription	B-X
factors	B-X
,	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
other	B-X
cell	B-X
-	B-X
surface	B-X
molecules	B-X
,	B-X
such	B-X
as	B-X
CD2	B-X
,	B-X
transduce	B-X
signals	B-X
is	B-X
unclear	B-X
<EOS>	B-X
This	B-X
pathway	B-X
appears	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
stimulation	B-X
of	B-X
CD2	B-X
on	B-X
NK	B-X
cells	B-X
does	B-X
not	B-X
lead	B-X
to	B-X
STAT1	B-X
activation	B-X
<EOS>	B-X
T	B-X
lymphocytes	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
soluble	B-X
factors	B-X
such	B-X
as	B-X
cytokines	B-X
or	B-X
through	B-X
direct	B-X
cell	B-X
-	B-X
cell	B-X
interactions	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
CD2	B-X
on	B-X
primary	B-X
T	B-X
lymphocytes	B-X
leads	B-X
to	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
and	B-X
DNA	B-X
binding	B-X
of	B-X
STAT1	B-X

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
through	O
CD2	B-protein
recapitulates	O
aspects	O
of	O
cytokine	B-protein
-induced	O
T-cell	O
activation	O
by	O
use	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O
<EOS>	B-X
The	B-X
goal	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
stimulation	B-X
of	B-X
T	B-X
cells	B-X
through	B-X
CD2	B-X
recapitulates	B-X
aspects	B-X
of	B-X
cytokine	B-X
-	B-X
induced	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
by	B-X
use	B-X
of	B-X
STAT	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
This	B-X
pathway	B-X
appears	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
stimulation	B-X
of	B-X
CD2	B-X
on	B-X
NK	B-X
cells	B-X
does	B-X
not	B-X
lead	B-X
to	B-X
STAT1	B-X
activation	B-X
<EOS>	B-X
T	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
anti	B-X
-	B-X
CD2	B-X
antibodies	B-X
or	B-X
cells	B-X
bearing	B-X
the	B-X
natural	B-X
CD2	B-X
ligand	B-X
CD58	B-X
,	B-X
after	B-X
which	B-X
signaling	B-X
through	B-X
STAT	B-X
transcription	B-X
factors	B-X
was	B-X
assessed	B-X
<EOS>	B-X
T	B-X
lymphocytes	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
soluble	B-X
factors	B-X
such	B-X
as	B-X
cytokines	B-X
or	B-X
through	B-X
direct	B-X
cell	B-X
-	B-X
cell	B-X
interactions	B-X

MATERIALS	O
AND	O
METHODS	O
:	O
T	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
anti-CD2	B-protein
antibodies	I-protein
or	O
cells	O
bearing	O
the	O
natural	O
CD2	B-protein
ligand	I-protein
CD58	I-protein
,	O
after	O
which	O
signaling	O
through	O
STAT	B-protein
transcription	I-protein
factors	I-protein
was	O
assessed	O
.	O
<EOS>	B-X
T	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
anti	B-X
-	B-X
CD2	B-X
antibodies	B-X
or	B-X
cells	B-X
bearing	B-X
the	B-X
natural	B-X
CD2	B-X
ligand	B-X
CD58	B-X
,	B-X
after	B-X
which	B-X
signaling	B-X
through	B-X
STAT	B-X
transcription	B-X
factors	B-X
was	B-X
assessed	B-X
<EOS>	B-X
The	B-X
goal	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
stimulation	B-X
of	B-X
T	B-X
cells	B-X
through	B-X
CD2	B-X
recapitulates	B-X
aspects	B-X
of	B-X
cytokine	B-X
-	B-X
induced	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
by	B-X
use	B-X
of	B-X
STAT	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
This	B-X
pathway	B-X
appears	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
stimulation	B-X
of	B-X
CD2	B-X
on	B-X
NK	B-X
cells	B-X
does	B-X
not	B-X
lead	B-X
to	B-X
STAT1	B-X
activation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
stimulation	B-X
by	B-X
cytokines	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
STAT1	B-X
in	B-X
response	B-X
to	B-X
CD2	B-X
ligation	B-X
is	B-X
delayed	B-X
and	B-X
does	B-X
not	B-X
involve	B-X
Jak	B-X
kinases	B-X

RESULTS	O
:	O
Stimulation	O
of	O
CD2	B-protein
on	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
leads	O
to	O
the	O
tyrosine	O
phosphorylation	O
,	O
nuclear	O
translocation	O
,	O
and	O
DNA	O
binding	O
of	O
STAT1	B-protein
.	O

In	O
contrast	O
to	O
stimulation	O
by	O
cytokines	B-protein
,	O
the	O
activation	O
of	O
STAT1	B-protein
in	O
response	O
to	O
CD2	O
ligation	O
is	O
delayed	O
and	O
does	O
not	O
involve	O
Jak	B-protein
kinases	I-protein
.	O

Furthermore	O
,	O
while	O
STAT	O
phosphorylation	O
induced	O
by	O
cytokines	B-protein
is	O
generally	O
transient	O
,	O
STAT1	O
phosphorylation	O
following	O
CD2	O
stimulation	O
persists	O
for	O
a	O
period	O
of	O
days	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
while	B-X
STAT	B-X
phosphorylation	B-X
induced	B-X
by	B-X
cytokines	B-X
is	B-X
generally	B-X
transient	B-X
,	B-X
STAT1	B-X
phosphorylation	B-X
following	B-X
CD2	B-X
stimulation	B-X
persists	B-X
for	B-X
a	B-X
period	B-X
of	B-X
days	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
CD2	B-X
on	B-X
primary	B-X
T	B-X
lymphocytes	B-X
leads	B-X
to	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
and	B-X
DNA	B-X
binding	B-X
of	B-X
STAT1	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
stimulation	B-X
by	B-X
cytokines	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
STAT1	B-X
in	B-X
response	B-X
to	B-X
CD2	B-X
ligation	B-X
is	B-X
delayed	B-X
and	B-X
does	B-X
not	B-X
involve	B-X
Jak	B-X
kinases	B-X
<EOS>	B-X
This	B-X
pathway	B-X
appears	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
stimulation	B-X
of	B-X
CD2	B-X
on	B-X
NK	B-X
cells	B-X
does	B-X
not	B-X
lead	B-X
to	B-X
STAT1	B-X
activation	B-X

Transcription	O
of	O
key	O
target	O
genes	O
such	O
as	O
IRF1	B-DNA
and	O
c-fos	B-DNA
proceeds	O
with	O
delayed	O
kinetics	O
following	O
CD2	O
stimulation	O
,	O
suggesting	O
that	O
this	O
unique	O
pattern	O
of	O
STAT	O
activation	O
may	O
lead	O
to	O
a	O
distinct	O
cellular	O
response	O
following	O
CD2	O
ligation	O
.	O
<EOS>	B-X
Transcription	B-X
of	B-X
key	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
IRF1	B-X
and	B-X
c	B-X
-	B-X
fos	B-X
proceeds	B-X
with	B-X
delayed	B-X
kinetics	B-X
following	B-X
CD2	B-X
stimulation	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
unique	B-X
pattern	B-X
of	B-X
STAT	B-X
activation	B-X
may	B-X
lead	B-X
to	B-X
a	B-X
distinct	B-X
cellular	B-X
response	B-X
following	B-X
CD2	B-X
ligation	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
cells	B-X
through	B-X
cell	B-X
-	B-X
surface	B-X
molecules	B-X
such	B-X
as	B-X
CD2	B-X
involves	B-X
activation	B-X
of	B-X
STAT	B-X
transcription	B-X
factors	B-X
,	B-X
thus	B-X
recapitulating	B-X
elements	B-X
of	B-X
cytokine	B-X
signaling	B-X
<EOS>	B-X
This	B-X
pathway	B-X
appears	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
stimulation	B-X
of	B-X
CD2	B-X
on	B-X
NK	B-X
cells	B-X
does	B-X
not	B-X
lead	B-X
to	B-X
STAT1	B-X
activation	B-X
<EOS>	B-X
T	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
anti	B-X
-	B-X
CD2	B-X
antibodies	B-X
or	B-X
cells	B-X
bearing	B-X
the	B-X
natural	B-X
CD2	B-X
ligand	B-X
CD58	B-X
,	B-X
after	B-X
which	B-X
signaling	B-X
through	B-X
STAT	B-X
transcription	B-X
factors	B-X
was	B-X
assessed	B-X

This	O
pathway	O
appears	O
to	O
be	O
restricted	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
as	O
stimulation	O
of	O
CD2	B-protein
on	O
NK	B-cell_type
cells	I-cell_type
does	O
not	O
lead	O
to	O
STAT1	O
activation	O
.	O

CONCLUSION	O
:	O
Stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
through	O
cell-surface	B-protein
molecules	I-protein
such	O
as	O
CD2	B-protein
involves	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
,	O
thus	O
recapitulating	O
elements	O
of	O
cytokine	O
signaling	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
cells	B-X
through	B-X
cell	B-X
-	B-X
surface	B-X
molecules	B-X
such	B-X
as	B-X
CD2	B-X
involves	B-X
activation	B-X
of	B-X
STAT	B-X
transcription	B-X
factors	B-X
,	B-X
thus	B-X
recapitulating	B-X
elements	B-X
of	B-X
cytokine	B-X
signaling	B-X
<EOS>	B-X
CD2	B-X
stimulation	B-X
leads	B-X
to	B-X
the	B-X
delayed	B-X
and	B-X
prolonged	B-X
activation	B-X
of	B-X
STAT1	B-X
in	B-X
T	B-X
cells	B-X
but	B-X
not	B-X
NK	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
stimulation	B-X
by	B-X
cytokines	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
STAT1	B-X
in	B-X
response	B-X
to	B-X
CD2	B-X
ligation	B-X
is	B-X
delayed	B-X
and	B-X
does	B-X
not	B-X
involve	B-X
Jak	B-X
kinases	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
CD2	B-X
on	B-X
primary	B-X
T	B-X
lymphocytes	B-X
leads	B-X
to	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
nuclear	B-X
translocation	B-X
,	B-X
and	B-X
DNA	B-X
binding	B-X
of	B-X
STAT1	B-X

NFATc1	B-protein
and	O
NFATc2	B-protein
together	O
control	O
both	O
T	O
and	O
B	O
cell	O
activation	O
and	O
differentiation	O
.	O

NFAT	B-protein
transcription	I-protein
factors	I-protein
play	O
critical	O
roles	O
in	O
gene	O
transcription	O
during	O
immune	O
responses	O
.	O
<EOS>	B-X
NFAT	B-X
transcription	B-X
factors	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
gene	B-X
transcription	B-X
during	B-X
immune	B-X
responses	B-X
<EOS>	B-X
NFAT	B-X
transcription	B-X
factors	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
both	B-X
the	B-X
activation	B-X
and	B-X
repression	B-X
of	B-X
T	B-X
and	B-X
B	B-X
lymphocyte	B-X
responses	B-X
<EOS>	B-X
Innate	B-X
immune	B-X
pattern	B-X
recognition	B-X
receptors	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
pathogen	B-X
detection	B-X
and	B-X
initiation	B-X
of	B-X
antimicrobial	B-X
responses	B-X
<EOS>	B-X
Transcription	B-X
factors	B-X
of	B-X
the	B-X
NFAT	B-X
family	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
response	B-X
by	B-X
activating	B-X
the	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
other	B-X
inducible	B-X
genes	B-X
in	B-X
antigen	B-X
-	B-X
stimulated	B-X
cells	B-X

To	O
investigate	O
further	O
the	O
two	O
most	O
prominent	O
NFAT	B-protein
family	I-protein
members	I-protein
,	O
NFATc1	B-protein
and	O
NFATc2	B-protein
,	O
we	O
generated	O
mice	O
bearing	O
lymphoid	O
systems	O
devoid	O
of	O
both	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
further	B-X
the	B-X
two	B-X
most	B-X
prominent	B-X
NFAT	B-X
family	B-X
members	B-X
,	B-X
NFATc1	B-X
and	B-X
NFATc2	B-X
,	B-X
we	B-X
generated	B-X
mice	B-X
bearing	B-X
lymphoid	B-X
systems	B-X
devoid	B-X
of	B-X
both	B-X
<EOS>	B-X
NFATc1	B-X
and	B-X
NFATc2	B-X
together	B-X
control	B-X
both	B-X
T	B-X
and	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
Doubly	B-X
deficient	B-X
T	B-X
cells	B-X
displayed	B-X
cell	B-X
surface	B-X
markers	B-X
of	B-X
activation	B-X
yet	B-X
were	B-X
significantly	B-X
deficient	B-X
in	B-X
the	B-X
development	B-X
of	B-X
multiple	B-X
effector	B-X
functions	B-X
,	B-X
including	B-X
Th	B-X
cytokine	B-X
production	B-X
,	B-X
surface	B-X
effector	B-X
molecule	B-X
expression	B-X
,	B-X
and	B-X
cytolytic	B-X
activity	B-X
<EOS>	B-X
Nevertheless	B-X
,	B-X
doubly	B-X
deficient	B-X
B	B-X
cells	B-X
were	B-X
hyperactivated	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
extremely	B-X
elevated	B-X
serum	B-X
IgG1	B-X
and	B-X
IgE	B-X
,	B-X
as	B-X
well	B-X
as	B-X
plasma	B-X
cell	B-X
expansion	B-X
and	B-X
infiltration	B-X
of	B-X
end	B-X
organs	B-X

Doubly	O
deficient	O
T	B-cell_type
cells	I-cell_type
displayed	O
cell	O
surface	O
markers	O
of	O
activation	O
yet	O
were	O
significantly	O
deficient	O
in	O
the	O
development	O
of	O
multiple	O
effector	O
functions	O
,	O
including	O
Th	B-protein
cytokine	I-protein
production	O
,	O
surface	B-protein
effector	I-protein
molecule	I-protein
expression	O
,	O
and	O
cytolytic	O
activity	O
.	O
<EOS>	B-X
Doubly	B-X
deficient	B-X
T	B-X
cells	B-X
displayed	B-X
cell	B-X
surface	B-X
markers	B-X
of	B-X
activation	B-X
yet	B-X
were	B-X
significantly	B-X
deficient	B-X
in	B-X
the	B-X
development	B-X
of	B-X
multiple	B-X
effector	B-X
functions	B-X
,	B-X
including	B-X
Th	B-X
cytokine	B-X
production	B-X
,	B-X
surface	B-X
effector	B-X
molecule	B-X
expression	B-X
,	B-X
and	B-X
cytolytic	B-X
activity	B-X
<EOS>	B-X
Thus	B-X
,	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
NFATc1	B-X
and	B-X
NFATc2	B-X
are	B-X
dispensable	B-X
for	B-X
inflammatory	B-X
reactivity	B-X
but	B-X
are	B-X
required	B-X
for	B-X
effector	B-X
differentiation	B-X
,	B-X
while	B-X
in	B-X
B	B-X
cells	B-X
,	B-X
NFATs	B-X
regulate	B-X
both	B-X
normal	B-X
homeostasis	B-X
and	B-X
differentiation	B-X
<EOS>	B-X
Nevertheless	B-X
,	B-X
doubly	B-X
deficient	B-X
B	B-X
cells	B-X
were	B-X
hyperactivated	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
extremely	B-X
elevated	B-X
serum	B-X
IgG1	B-X
and	B-X
IgE	B-X
,	B-X
as	B-X
well	B-X
as	B-X
plasma	B-X
cell	B-X
expansion	B-X
and	B-X
infiltration	B-X
of	B-X
end	B-X
organs	B-X
<EOS>	B-X
To	B-X
investigate	B-X
further	B-X
the	B-X
two	B-X
most	B-X
prominent	B-X
NFAT	B-X
family	B-X
members	B-X
,	B-X
NFATc1	B-X
and	B-X
NFATc2	B-X
,	B-X
we	B-X
generated	B-X
mice	B-X
bearing	B-X
lymphoid	B-X
systems	B-X
devoid	B-X
of	B-X
both	B-X

Nevertheless	O
,	O
doubly	B-cell_type
deficient	I-cell_type
B	I-cell_type
cells	I-cell_type
were	O
hyperactivated	O
,	O
as	O
evidenced	O
by	O
extremely	O
elevated	O
serum	O
IgG1	B-protein
and	O
IgE	B-protein
,	O
as	O
well	O
as	O
plasma	B-cell_type
cell	I-cell_type
expansion	O
and	O
infiltration	O
of	O
end	O
organs	O
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
doubly	B-X
deficient	B-X
B	B-X
cells	B-X
were	B-X
hyperactivated	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
extremely	B-X
elevated	B-X
serum	B-X
IgG1	B-X
and	B-X
IgE	B-X
,	B-X
as	B-X
well	B-X
as	B-X
plasma	B-X
cell	B-X
expansion	B-X
and	B-X
infiltration	B-X
of	B-X
end	B-X
organs	B-X
<EOS>	B-X
Doubly	B-X
deficient	B-X
T	B-X
cells	B-X
displayed	B-X
cell	B-X
surface	B-X
markers	B-X
of	B-X
activation	B-X
yet	B-X
were	B-X
significantly	B-X
deficient	B-X
in	B-X
the	B-X
development	B-X
of	B-X
multiple	B-X
effector	B-X
functions	B-X
,	B-X
including	B-X
Th	B-X
cytokine	B-X
production	B-X
,	B-X
surface	B-X
effector	B-X
molecule	B-X
expression	B-X
,	B-X
and	B-X
cytolytic	B-X
activity	B-X
<EOS>	B-X
To	B-X
investigate	B-X
further	B-X
the	B-X
two	B-X
most	B-X
prominent	B-X
NFAT	B-X
family	B-X
members	B-X
,	B-X
NFATc1	B-X
and	B-X
NFATc2	B-X
,	B-X
we	B-X
generated	B-X
mice	B-X
bearing	B-X
lymphoid	B-X
systems	B-X
devoid	B-X
of	B-X
both	B-X
<EOS>	B-X
NFATc1	B-X
and	B-X
NFATc2	B-X
together	B-X
control	B-X
both	B-X
T	B-X
and	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
differentiation	B-X
.	B-X

Thus	O
,	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
NFATc1	B-protein
and	O
NFATc2	B-protein
are	O
dispensable	O
for	O
inflammatory	O
reactivity	O
but	O
are	O
required	O
for	O
effector	O
differentiation	O
,	O
while	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
NFATs	B-protein
regulate	O
both	O
normal	O
homeostasis	O
and	O
differentiation	O
.	O

Epstein-barr	O
virus	O
immediate-early	B-protein
protein	I-protein
BZLF1	I-protein
is	O
SUMO-1	O
modified	O
and	O
disrupts	O
promyelocytic	O
leukemia	O
bodies	O
.	O
<EOS>	B-X
Epstein	B-X
-	B-X
barr	B-X
virus	B-X
immediate	B-X
-	B-X
early	B-X
protein	B-X
BZLF1	B-X
is	B-X
SUMO	B-X
-	B-X
1	B-X
modified	B-X
and	B-X
disrupts	B-X
promyelocytic	B-X
leukemia	B-X
bodies	B-X
.	B-X
<EOS>	B-X
SUMO	B-X
-	B-X
1	B-X
modification	B-X
of	B-X
PML	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PML	B-X
bodies	B-X
<EOS>	B-X
To	B-X
examine	B-X
whether	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
lytic	B-X
replication	B-X
interferes	B-X
with	B-X
PML	B-X
bodies	B-X
,	B-X
we	B-X
expressed	B-X
the	B-X
EBV	B-X
immediate	B-X
-	B-X
early	B-X
genes	B-X
BZLF1	B-X
(	B-X
Z	B-X
)	B-X
and	B-X
BRLF1	B-X
(	B-X
R	B-X
)	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
and	B-X
examined	B-X
PML	B-X
localization	B-X
<EOS>	B-X
The	B-X
PML	B-X
protein	B-X
is	B-X
induced	B-X
by	B-X
interferon	B-X
,	B-X
involved	B-X
in	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
I	B-X
presentation	B-X
,	B-X
and	B-X
necessary	B-X
for	B-X
certain	B-X
types	B-X
of	B-X
apoptosis	B-X

Although	O
the	O
immediate-early	B-protein
proteins	I-protein
of	O
both	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
are	O
known	O
to	O
modify	O
promyelocytic	O
leukemia	O
(	O
PML	O
)	O
(	O
ND10	O
)	O
bodies	O
in	O
the	O
nucleus	O
of	O
the	O
host	O
cell	O
,	O
it	O
has	O
been	O
unclear	O
whether	O
lytic	O
infection	O
with	O
gamma	O
herpesviruses	O
induces	O
a	O
similar	O
effect	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
immediate	B-X
-	B-X
early	B-X
proteins	B-X
of	B-X
both	B-X
herpes	B-X
simplex	B-X
virus	B-X
(	B-X
HSV	B-X
)	B-X
and	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
are	B-X
known	B-X
to	B-X
modify	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
PML	B-X
)	B-X
(	B-X
ND10	B-X
)	B-X
bodies	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
,	B-X
it	B-X
has	B-X
been	B-X
unclear	B-X
whether	B-X
lytic	B-X
infection	B-X
with	B-X
gamma	B-X
herpesviruses	B-X
induces	B-X
a	B-X
similar	B-X
effect	B-X
<EOS>	B-X
To	B-X
examine	B-X
whether	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
lytic	B-X
replication	B-X
interferes	B-X
with	B-X
PML	B-X
bodies	B-X
,	B-X
we	B-X
expressed	B-X
the	B-X
EBV	B-X
immediate	B-X
-	B-X
early	B-X
genes	B-X
BZLF1	B-X
(	B-X
Z	B-X
)	B-X
and	B-X
BRLF1	B-X
(	B-X
R	B-X
)	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
and	B-X
examined	B-X
PML	B-X
localization	B-X
<EOS>	B-X
The	B-X
PML	B-X
protein	B-X
is	B-X
induced	B-X
by	B-X
interferon	B-X
,	B-X
involved	B-X
in	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
I	B-X
presentation	B-X
,	B-X
and	B-X
necessary	B-X
for	B-X
certain	B-X
types	B-X
of	B-X
apoptosis	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
dispersion	B-X
of	B-X
PML	B-X
bodies	B-X
by	B-X
Z	B-X
requires	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Z	B-X
but	B-X
not	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
function	B-X

The	O
PML	B-protein
protein	I-protein
is	O
induced	O
by	O
interferon	B-protein
,	O
involved	O
in	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
presentation	O
,	O
and	O
necessary	O
for	O
certain	O
types	O
of	O
apoptosis	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
PML	O
bodies	O
function	O
in	O
an	O
antiviral	O
capacity	O
.	O

SUMO-1	O
modification	O
of	O
PML	B-protein
is	O
known	O
to	O
be	O
required	O
for	O
the	O
formation	O
of	O
PML	O
bodies	O
.	O
<EOS>	B-X
SUMO	B-X
-	B-X
1	B-X
modification	B-X
of	B-X
PML	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PML	B-X
bodies	B-X
<EOS>	B-X
PML	B-X
NB	B-X
formation	B-X
requires	B-X
the	B-X
covalent	B-X
modification	B-X
of	B-X
PML	B-X
to	B-X
SUMO	B-X
<EOS>	B-X
Reduction	B-X
of	B-X
PML	B-X
was	B-X
carried	B-X
out	B-X
by	B-X
the	B-X
EMCV	B-X
3C	B-X
protease	B-X
<EOS>	B-X
The	B-X
noncovalent	B-X
interactions	B-X
of	B-X
SUMO	B-X
with	B-X
PML	B-X
based	B-X
on	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
SUMO	B-X
-	B-X
interacting	B-X
motif	B-X
within	B-X
PML	B-X
seem	B-X
to	B-X
be	B-X
required	B-X
for	B-X
further	B-X
recruitment	B-X
within	B-X
PML	B-X
NBs	B-X
of	B-X
SUMOylated	B-X
proteins	B-X

To	O
examine	O
whether	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
lytic	O
replication	O
interferes	O
with	O
PML	O
bodies	O
,	O
we	O
expressed	O
the	O
EBV	B-DNA
immediate-early	I-DNA
genes	I-DNA
BZLF1	B-DNA
(	I-DNA
Z	I-DNA
)	I-DNA
and	O
BRLF1	B-DNA
(	I-DNA
R	I-DNA
)	I-DNA
in	O
EBV-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
examined	O
PML	B-protein
localization	O
.	O
<EOS>	B-X
To	B-X
examine	B-X
whether	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
lytic	B-X
replication	B-X
interferes	B-X
with	B-X
PML	B-X
bodies	B-X
,	B-X
we	B-X
expressed	B-X
the	B-X
EBV	B-X
immediate	B-X
-	B-X
early	B-X
genes	B-X
BZLF1	B-X
(	B-X
Z	B-X
)	B-X
and	B-X
BRLF1	B-X
(	B-X
R	B-X
)	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
and	B-X
examined	B-X
PML	B-X
localization	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
dispersion	B-X
of	B-X
PML	B-X
bodies	B-X
by	B-X
Z	B-X
requires	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Z	B-X
but	B-X
not	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
function	B-X
<EOS>	B-X
Epstein	B-X
-	B-X
barr	B-X
virus	B-X
immediate	B-X
-	B-X
early	B-X
protein	B-X
BZLF1	B-X
is	B-X
SUMO	B-X
-	B-X
1	B-X
modified	B-X
and	B-X
disrupts	B-X
promyelocytic	B-X
leukemia	B-X
bodies	B-X
.	B-X
<EOS>	B-X
Although	B-X
the	B-X
immediate	B-X
-	B-X
early	B-X
proteins	B-X
of	B-X
both	B-X
herpes	B-X
simplex	B-X
virus	B-X
(	B-X
HSV	B-X
)	B-X
and	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
are	B-X
known	B-X
to	B-X
modify	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
PML	B-X
)	B-X
(	B-X
ND10	B-X
)	B-X
bodies	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
,	B-X
it	B-X
has	B-X
been	B-X
unclear	B-X
whether	B-X
lytic	B-X
infection	B-X
with	B-X
gamma	B-X
herpesviruses	B-X
induces	B-X
a	B-X
similar	B-X
effect	B-X

Both	O
Z	O
and	O
R	O
expression	O
resulted	O
in	O
PML	B-protein
dispersion	O
in	O
EBV-positive	B-cell_type
cells	I-cell_type
.	O

Z	O
but	O
not	O
R	O
expression	O
is	O
sufficient	O
to	O
disrupt	O
PML	O
bodies	O
in	O
EBV-negative	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
Osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
is	B-X
a	B-X
chronic	B-X
progressive	B-X
degenerative	B-X
joint	B-X
disease	B-X
<EOS>	B-X
Mosaic	B-X
loss	B-X
of	B-X
Y	B-X
chromosome	B-X
in	B-X
monocytes	B-X
is	B-X
associated	B-X
with	B-X
lower	B-X
survival	B-X
after	B-X
transcatheter	B-X
aortic	B-X
valve	B-X
replacement	B-X
.	B-X
<EOS>	B-X
In	B-X
many	B-X
-	B-X
particle	B-X
diffusions	B-X
,	B-X
particles	B-X
that	B-X
move	B-X
the	B-X
furthest	B-X
and	B-X
fastest	B-X
can	B-X
play	B-X
an	B-X
outsized	B-X
role	B-X
in	B-X
physical	B-X
phenomena	B-X
<EOS>	B-X
Subsequent	B-X
post	B-X
-	B-X
hoc	B-X
t	B-X
-	B-X
tests	B-X
on	B-X
change	B-X
scores	B-X
were	B-X
limited	B-X
to	B-X
patients	B-X
who	B-X
had	B-X
provided	B-X
pre	B-X
-	B-X
	B-X
and	B-X
post	B-X
-	B-X
transplant	B-X
assessments	B-X

We	O
show	O
that	O
dispersion	O
of	O
PML	O
bodies	O
by	O
Z	B-DNA
requires	O
a	O
portion	O
of	O
the	O
transcriptional	B-DNA
activation	I-DNA
domain	I-DNA
of	O
Z	B-DNA
but	O
not	O
the	O
DNA-binding	O
function	O
.	O

As	O
was	O
previously	O
reported	O
for	O
the	O
HSV-1	B-protein
ICP0	I-protein
and	I-protein
CMV	I-protein
IE1	I-protein
proteins	I-protein
,	O
Z	B-DNA
reduces	O
the	O
amount	O
of	O
SUMO-1-modified	B-protein
PML	I-protein
.	O
<EOS>	B-X
As	B-X
was	B-X
previously	B-X
reported	B-X
for	B-X
the	B-X
HSV	B-X
-	B-X
1	B-X
ICP0	B-X
and	B-X
CMV	B-X
IE1	B-X
proteins	B-X
,	B-X
Z	B-X
reduces	B-X
the	B-X
amount	B-X
of	B-X
SUMO	B-X
-	B-X
1	B-X
-	B-X
modified	B-X
PML	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
Z	B-X
may	B-X
potentially	B-X
alter	B-X
the	B-X
function	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
by	B-X
inhibiting	B-X
SUMO	B-X
-	B-X
1	B-X
modification	B-X
<EOS>	B-X
SUMO	B-X
-	B-X
1	B-X
modification	B-X
of	B-X
PML	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PML	B-X
bodies	B-X
<EOS>	B-X
To	B-X
examine	B-X
whether	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
lytic	B-X
replication	B-X
interferes	B-X
with	B-X
PML	B-X
bodies	B-X
,	B-X
we	B-X
expressed	B-X
the	B-X
EBV	B-X
immediate	B-X
-	B-X
early	B-X
genes	B-X
BZLF1	B-X
(	B-X
Z	B-X
)	B-X
and	B-X
BRLF1	B-X
(	B-X
R	B-X
)	B-X
in	B-X
EBV	B-X
-	B-X
positive	B-X
cell	B-X
lines	B-X
and	B-X
examined	B-X
PML	B-X
localization	B-X

We	O
also	O
found	O
that	O
Z	B-DNA
itself	O
is	O
SUMO-1	O
modified	O
(	O
through	O
amino	O
acid	O
12	O
)	O
and	O
that	O
Z	B-DNA
competes	O
with	O
PML	B-protein
for	O
limiting	O
amounts	O
of	O
SUMO-1	B-protein
.	O
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
Z	B-X
itself	B-X
is	B-X
SUMO	B-X
-	B-X
1	B-X
modified	B-X
(	B-X
through	B-X
amino	B-X
acid	B-X
12	B-X
)	B-X
and	B-X
that	B-X
Z	B-X
competes	B-X
with	B-X
PML	B-X
for	B-X
limiting	B-X
amounts	B-X
of	B-X
SUMO	B-X
-	B-X
1	B-X
<EOS>	B-X
SUMO	B-X
-	B-X
1	B-X
modification	B-X
of	B-X
PML	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PML	B-X
bodies	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
disruption	B-X
of	B-X
PML	B-X
bodies	B-X
is	B-X
important	B-X
for	B-X
efficient	B-X
lytic	B-X
replication	B-X
of	B-X
EBV	B-X
<EOS>	B-X
As	B-X
was	B-X
previously	B-X
reported	B-X
for	B-X
the	B-X
HSV	B-X
-	B-X
1	B-X
ICP0	B-X
and	B-X
CMV	B-X
IE1	B-X
proteins	B-X
,	B-X
Z	B-X
reduces	B-X
the	B-X
amount	B-X
of	B-X
SUMO	B-X
-	B-X
1	B-X
-	B-X
modified	B-X
PML	B-X

These	O
results	O
suggest	O
that	O
disruption	O
of	O
PML	O
bodies	O
is	O
important	O
for	O
efficient	O
lytic	O
replication	O
of	O
EBV	O
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
disruption	B-X
of	B-X
PML	B-X
bodies	B-X
is	B-X
important	B-X
for	B-X
efficient	B-X
lytic	B-X
replication	B-X
of	B-X
EBV	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
likely	B-X
that	B-X
PML	B-X
bodies	B-X
function	B-X
in	B-X
an	B-X
antiviral	B-X
capacity	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
dispersion	B-X
of	B-X
PML	B-X
bodies	B-X
by	B-X
Z	B-X
requires	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Z	B-X
but	B-X
not	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
function	B-X
<EOS>	B-X
SUMO	B-X
-	B-X
1	B-X
modification	B-X
of	B-X
PML	B-X
is	B-X
known	B-X
to	B-X
be	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
PML	B-X
bodies	B-X

Furthermore	O
,	O
Z	B-DNA
may	O
potentially	O
alter	O
the	O
function	O
of	O
a	O
variety	O
of	O
cellular	O
proteins	O
by	O
inhibiting	O
SUMO-1	O
modification	O
<EOS>	B-X
Furthermore	B-X
,	B-X
Z	B-X
may	B-X
potentially	B-X
alter	B-X
the	B-X
function	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
proteins	B-X
by	B-X
inhibiting	B-X
SUMO	B-X
-	B-X
1	B-X
modification	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
likely	B-X
that	B-X
PML	B-X
bodies	B-X
function	B-X
in	B-X
an	B-X
antiviral	B-X
capacity	B-X
<EOS>	B-X
As	B-X
was	B-X
previously	B-X
reported	B-X
for	B-X
the	B-X
HSV	B-X
-	B-X
1	B-X
ICP0	B-X
and	B-X
CMV	B-X
IE1	B-X
proteins	B-X
,	B-X
Z	B-X
reduces	B-X
the	B-X
amount	B-X
of	B-X
SUMO	B-X
-	B-X
1	B-X
-	B-X
modified	B-X
PML	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
dispersion	B-X
of	B-X
PML	B-X
bodies	B-X
by	B-X
Z	B-X
requires	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Z	B-X
but	B-X
not	B-X
the	B-X
DNA	B-X
-	B-X
binding	B-X
function	B-X

Suppression	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
stimulation	O
of	O
inhibitor	B-protein
kappaB	I-protein
by	O
troglitazone	O
:	O
evidence	O
for	O
an	O
anti-inflammatory	O
effect	O
and	O
a	O
potential	O
antiatherosclerotic	O
effect	O
in	O
the	O
obese	O
.	O

To	O
elucidate	O
whether	O
troglitazone	O
exerts	O
an	O
antiinflammatory	O
effect	O
in	O
humans	O
,	O
in	O
vivo	O
,	O
we	O
investigated	O
the	O
suppression	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NFkappaB	B-protein
)	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
(	I-cell_type
MNC	I-cell_type
)	I-cell_type
by	O
this	O
drug	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
whether	B-X
troglitazone	B-X
exerts	B-X
an	B-X
antiinflammatory	B-X
effect	B-X
in	B-X
humans	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
suppression	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
in	B-X
mononuclear	B-X
cells	B-X
(	B-X
MNC	B-X
)	B-X
by	B-X
this	B-X
drug	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
troglitazone	B-X
has	B-X
an	B-X
antiinflammatory	B-X
action	B-X
that	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
putative	B-X
antiatherosclerotic	B-X
effects	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
fall	B-X
in	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
,	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
IkappaBalpha	B-X
at	B-X
week	B-X
2	B-X
,	B-X
which	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X
<EOS>	B-X
Plasma	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
alpha	B-X
,	B-X
soluble	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
(	B-X
sICAM	B-X
-	B-X
1	B-X
)	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
1	B-X
(	B-X
PAI	B-X
-	B-X
1	B-X
)	B-X
,	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
(	B-X
CRP	B-X
)	B-X
,	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
10	B-X
(	B-X
antiinflammatory	B-X
cytokine	B-X
)	B-X
concentrations	B-X
were	B-X
also	B-X
measured	B-X
as	B-X
mediators	B-X
of	B-X
inflammatory	B-X
activity	B-X
that	B-X
are	B-X
regulated	B-X
by	B-X
the	B-X
proinflammatory	B-X
transcription	B-X
factor	B-X
NFkappaB	B-X

We	O
measured	O
intranuclear	B-protein
NFkappaB	I-protein
,	O
total	O
cellular	B-protein
NFkappaB	I-protein
,	O
inhibitor	B-protein
kappaB	I-protein
(	I-protein
IkappaB	I-protein
)	I-protein
alpha	I-protein
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
,	O
and	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
(	O
a	O
key	O
component	O
protein	O
of	O
nicotinamide	B-protein
adenine	I-protein
dinucleotide	I-protein
phosphate	I-protein
oxidase	I-protein
)	O
in	O
MNC	B-cell_type
.	O
<EOS>	B-X
We	B-X
measured	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
inhibitor	B-X
kappaB	B-X
(	B-X
IkappaB	B-X
)	B-X
alpha	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
generation	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
(	B-X
a	B-X
key	B-X
component	B-X
protein	B-X
of	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
phosphate	B-X
oxidase	B-X
)	B-X
in	B-X
MNC	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
fall	B-X
in	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
,	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
IkappaBalpha	B-X
at	B-X
week	B-X
2	B-X
,	B-X
which	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X
<EOS>	B-X
MNC	B-X
were	B-X
separated	B-X
;	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
IkappaBalpha	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
and	B-X
ROS	B-X
generation	B-X
were	B-X
determined	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
stimulation	B-X
of	B-X
inhibitor	B-X
kappaB	B-X
by	B-X
troglitazone	B-X
:	B-X
evidence	B-X
for	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
and	B-X
a	B-X
potential	B-X
antiatherosclerotic	B-X
effect	B-X
in	B-X
the	B-X
obese	B-X
.	B-X

Plasma	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
,	O
soluble	B-protein
intercellular	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
sICAM-1	B-protein
)	O
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	I-protein
MCP-1	I-protein
)	I-protein
,	O
plasminogen	B-protein
activator	I-protein
inhibitor	I-protein
type	I-protein
1	I-protein
(	O
PAI-1	B-protein
)	O
,	O
C-reactive	B-protein
protein	I-protein
(	I-protein
CRP	I-protein
)	I-protein
,	O
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
(	O
antiinflammatory	B-protein
cytokine	I-protein
)	O
concentrations	O
were	O
also	O
measured	O
as	O
mediators	O
of	O
inflammatory	O
activity	O
that	O
are	O
regulated	O
by	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
NFkappaB	I-protein
.	O
<EOS>	B-X
Plasma	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
alpha	B-X
,	B-X
soluble	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
(	B-X
sICAM	B-X
-	B-X
1	B-X
)	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
MCP	B-X
-	B-X
1	B-X
)	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
1	B-X
(	B-X
PAI	B-X
-	B-X
1	B-X
)	B-X
,	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
(	B-X
CRP	B-X
)	B-X
,	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
10	B-X
(	B-X
antiinflammatory	B-X
cytokine	B-X
)	B-X
concentrations	B-X
were	B-X
also	B-X
measured	B-X
as	B-X
mediators	B-X
of	B-X
inflammatory	B-X
activity	B-X
that	B-X
are	B-X
regulated	B-X
by	B-X
the	B-X
proinflammatory	B-X
transcription	B-X
factor	B-X
NFkappaB	B-X
<EOS>	B-X
We	B-X
measured	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
inhibitor	B-X
kappaB	B-X
(	B-X
IkappaB	B-X
)	B-X
alpha	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
generation	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
(	B-X
a	B-X
key	B-X
component	B-X
protein	B-X
of	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
phosphate	B-X
oxidase	B-X
)	B-X
in	B-X
MNC	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
stimulation	B-X
of	B-X
inhibitor	B-X
kappaB	B-X
by	B-X
troglitazone	B-X
:	B-X
evidence	B-X
for	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
and	B-X
a	B-X
potential	B-X
antiatherosclerotic	B-X
effect	B-X
in	B-X
the	B-X
obese	B-X
.	B-X
<EOS>	B-X
To	B-X
elucidate	B-X
whether	B-X
troglitazone	B-X
exerts	B-X
an	B-X
antiinflammatory	B-X
effect	B-X
in	B-X
humans	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
suppression	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
in	B-X
mononuclear	B-X
cells	B-X
(	B-X
MNC	B-X
)	B-X
by	B-X
this	B-X
drug	B-X

Seven	O
nondiabetic	O
obese	O
patients	O
were	O
given	O
400	O
mg	O
troglitazone	O
daily	O
for	O
4	O
weeks	O
.	O
<EOS>	B-X
Seven	B-X
nondiabetic	B-X
obese	B-X
patients	B-X
were	B-X
given	B-X
400	B-X
mg	B-X
troglitazone	B-X
daily	B-X
for	B-X
4	B-X
weeks	B-X
<EOS>	B-X
01	B-X
)	B-X
and	B-X
remained	B-X
low	B-X
throughout	B-X
4	B-X
weeks	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
parallel	B-X
fall	B-X
in	B-X
ROS	B-X
generation	B-X
by	B-X
MNC	B-X
at	B-X
week	B-X
1	B-X
;	B-X
this	B-X
progressed	B-X
and	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
Plasma	B-X
insulin	B-X
concentrations	B-X
fell	B-X
significantly	B-X
at	B-X
week	B-X
1	B-X
,	B-X
from	B-X
31	B-X

Blood	O
samples	O
were	O
collected	O
before	O
and	O
at	O
weekly	O
intervals	O
thereafter	O
.	O
<EOS>	B-X
Blood	B-X
samples	B-X
were	B-X
collected	B-X
weekly	B-X
precalving	B-X
,	B-X
at	B-X
parturition	B-X
,	B-X
and	B-X
twice	B-X
weekly	B-X
thereafter	B-X
<EOS>	B-X
Blood	B-X
samples	B-X
were	B-X
collected	B-X
every	B-X
other	B-X
day	B-X
from	B-X
d	B-X
0	B-X
to	B-X
14	B-X
then	B-X
3	B-X
times	B-X
weekly	B-X
thereafter	B-X
<EOS>	B-X
Blood	B-X
samples	B-X
collected	B-X
weekly	B-X
for	B-X
six	B-X
consecutive	B-X
weeks	B-X
were	B-X
assayed	B-X
for	B-X
GH	B-X
<EOS>	B-X
The	B-X
blood	B-X
samples	B-X
were	B-X
collected	B-X
by	B-X
cardiac	B-X
puncture	B-X
before	B-X
the	B-X
start	B-X
of	B-X
iron	B-X
dosing	B-X
and	B-X
thereafter	B-X
,	B-X
at	B-X
weekly	B-X
intervals	B-X
for	B-X
28	B-X
days	B-X

MNC	B-cell_type
were	O
separated	O
;	O
and	O
the	O
levels	O
of	O
intranuclear	B-protein
NFkappaB	I-protein
,	O
total	O
cellular	B-protein
NFkappaB	I-protein
,	O
IkappaBalpha	B-protein
,	O
and	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
and	O
ROS	O
generation	O
were	O
determined	O
.	O
<EOS>	B-X
MNC	B-X
were	B-X
separated	B-X
;	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
IkappaBalpha	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
and	B-X
ROS	B-X
generation	B-X
were	B-X
determined	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
fall	B-X
in	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
,	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
IkappaBalpha	B-X
at	B-X
week	B-X
2	B-X
,	B-X
which	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X
<EOS>	B-X
We	B-X
measured	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
inhibitor	B-X
kappaB	B-X
(	B-X
IkappaB	B-X
)	B-X
alpha	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
generation	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
(	B-X
a	B-X
key	B-X
component	B-X
protein	B-X
of	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
phosphate	B-X
oxidase	B-X
)	B-X
in	B-X
MNC	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
stimulation	B-X
of	B-X
inhibitor	B-X
kappaB	B-X
by	B-X
troglitazone	B-X
:	B-X
evidence	B-X
for	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
and	B-X
a	B-X
potential	B-X
antiatherosclerotic	B-X
effect	B-X
in	B-X
the	B-X
obese	B-X
.	B-X

Plasma	O
was	O
used	O
to	O
measure	O
insulin	O
glucose	O
,	O
TNFalpha	B-protein
,	O
sICAM	B-protein
,	O
MCP-1	B-protein
,	O
PAI-1	B-protein
,	O
CRP	B-protein
,	O
and	O
IL-10	B-protein
.	O
<EOS>	B-X
Plasma	B-X
was	B-X
used	B-X
to	B-X
measure	B-X
insulin	B-X
glucose	B-X
,	B-X
TNFalpha	B-X
,	B-X
sICAM	B-X
,	B-X
MCP	B-X
-	B-X
1	B-X
,	B-X
PAI	B-X
-	B-X
1	B-X
,	B-X
CRP	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
<EOS>	B-X
Plasma	B-X
insulin	B-X
concentrations	B-X
fell	B-X
significantly	B-X
at	B-X
week	B-X
1	B-X
,	B-X
from	B-X
31	B-X
<EOS>	B-X
Plasma	B-X
glucose	B-X
concentrations	B-X
did	B-X
not	B-X
alter	B-X
significantly	B-X
<EOS>	B-X
MNC	B-X
were	B-X
separated	B-X
;	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
IkappaBalpha	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
and	B-X
ROS	B-X
generation	B-X
were	B-X
determined	B-X

Plasma	O
insulin	O
concentrations	O
fell	O
significantly	O
at	O
week	O
1	O
,	O
from	O
31.2	O
+/-	O
29.1	O
to	O
14.2	O
+/-	O
11.4	O
mU/L	O
(	O
P	O
<	O
0.01	O
)	O
and	O
remained	O
low	O
throughout	O
4	O
weeks	O
.	O

Plasma	O
glucose	O
concentrations	O
did	O
not	O
alter	O
significantly	O
.	O
<EOS>	B-X
Plasma	B-X
adiponectin	B-X
concentrations	B-X
were	B-X
measured	B-X
with	B-X
a	B-X
commercially	B-X
available	B-X
human	B-X
enzyme	B-X
immunoassay	B-X
kit	B-X
<EOS>	B-X
Plasma	B-X
glucose	B-X
,	B-X
insulin	B-X
,	B-X
and	B-X
triglyceride	B-X
concentrations	B-X
were	B-X
measured	B-X
in	B-X
response	B-X
to	B-X
two	B-X
meals	B-X
fed	B-X
at	B-X
baseline	B-X
and	B-X
120	B-X
min	B-X
<EOS>	B-X
Determinants	B-X
of	B-X
blood	B-X
glucose	B-X
concentrations	B-X
following	B-X
a	B-X
high	B-X
carbohydrate	B-X
meal	B-X
in	B-X
type	B-X
2	B-X
diabetes	B-X
:	B-X
A	B-X
multiple	B-X
linear	B-X
regression	B-X
analysis	B-X
.	B-X
<EOS>	B-X
Ghrelin	B-X
concentrations	B-X
were	B-X
estimated	B-X
by	B-X
specific	B-X
commercial	B-X
methods	B-X

There	O
was	O
a	O
fall	O
in	O
intranuclear	B-protein
NFkappaB	I-protein
,	O
total	O
cellular	B-protein
NFkappaB	I-protein
,	O
and	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
,	O
with	O
an	O
increase	O
in	O
cellular	O
IkappaBalpha	B-protein
at	O
week	O
2	O
,	O
which	O
persisted	O
until	O
week	O
4	O
.	O
<EOS>	B-X
There	B-X
was	B-X
a	B-X
fall	B-X
in	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
,	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
IkappaBalpha	B-X
at	B-X
week	B-X
2	B-X
,	B-X
which	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X
<EOS>	B-X
MNC	B-X
were	B-X
separated	B-X
;	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
IkappaBalpha	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
and	B-X
ROS	B-X
generation	B-X
were	B-X
determined	B-X
<EOS>	B-X
We	B-X
measured	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
inhibitor	B-X
kappaB	B-X
(	B-X
IkappaB	B-X
)	B-X
alpha	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
generation	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
(	B-X
a	B-X
key	B-X
component	B-X
protein	B-X
of	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
phosphate	B-X
oxidase	B-X
)	B-X
in	B-X
MNC	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
parallel	B-X
fall	B-X
in	B-X
ROS	B-X
generation	B-X
by	B-X
MNC	B-X
at	B-X
week	B-X
1	B-X
;	B-X
this	B-X
progressed	B-X
and	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X
(	B-X
P	B-X
<	B-X
0	B-X

There	O
was	O
a	O
parallel	O
fall	O
in	O
ROS	O
generation	O
by	O
MNC	B-cell_type
at	O
week	O
1	O
;	O
this	O
progressed	O
and	O
persisted	O
until	O
week	O
4	O
(	O
P	O
<	O
0.001	O
)	O
.	O
<EOS>	B-X
There	B-X
was	B-X
a	B-X
parallel	B-X
fall	B-X
in	B-X
ROS	B-X
generation	B-X
by	B-X
MNC	B-X
at	B-X
week	B-X
1	B-X
;	B-X
this	B-X
progressed	B-X
and	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
fall	B-X
in	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
,	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
IkappaBalpha	B-X
at	B-X
week	B-X
2	B-X
,	B-X
which	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X
<EOS>	B-X
Plasma	B-X
insulin	B-X
concentrations	B-X
fell	B-X
significantly	B-X
at	B-X
week	B-X
1	B-X
,	B-X
from	B-X
31	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
stimulation	B-X
of	B-X
inhibitor	B-X
kappaB	B-X
by	B-X
troglitazone	B-X
:	B-X
evidence	B-X
for	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
and	B-X
a	B-X
potential	B-X
antiatherosclerotic	B-X
effect	B-X
in	B-X
the	B-X
obese	B-X
.	B-X

Plasma	O
TNF-alpha	B-protein
,	O
sICAM-1	B-protein
,	O
MCP-1	B-protein
,	O
and	O
PAI-1	B-protein
concentrations	O
fell	O
significantly	O
at	O
week	O
4	O
.	O
<EOS>	B-X
Plasma	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
sICAM	B-X
-	B-X
1	B-X
,	B-X
MCP	B-X
-	B-X
1	B-X
,	B-X
and	B-X
PAI	B-X
-	B-X
1	B-X
concentrations	B-X
fell	B-X
significantly	B-X
at	B-X
week	B-X
4	B-X
<EOS>	B-X
Plasma	B-X
insulin	B-X
concentrations	B-X
fell	B-X
significantly	B-X
at	B-X
week	B-X
1	B-X
,	B-X
from	B-X
31	B-X
<EOS>	B-X
Plasma	B-X
glucose	B-X
concentrations	B-X
did	B-X
not	B-X
alter	B-X
significantly	B-X
<EOS>	B-X
There	B-X
was	B-X
a	B-X
fall	B-X
in	B-X
intranuclear	B-X
NFkappaB	B-X
,	B-X
total	B-X
cellular	B-X
NFkappaB	B-X
,	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
subunit	B-X
,	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
cellular	B-X
IkappaBalpha	B-X
at	B-X
week	B-X
2	B-X
,	B-X
which	B-X
persisted	B-X
until	B-X
week	B-X
4	B-X

Plasma	O
IL-10	B-protein
concentration	O
increased	O
significantly	O
,	O
whereas	O
plasma	B-protein
CRP	I-protein
concentrations	O
decreased	O
.	O
<EOS>	B-X
Plasma	B-X
IL	B-X
-	B-X
10	B-X
concentration	B-X
increased	B-X
significantly	B-X
,	B-X
whereas	B-X
plasma	B-X
CRP	B-X
concentrations	B-X
decreased	B-X
<EOS>	B-X
The	B-X
levels	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
OSI	B-X
in	B-X
saliva	B-X
decreased	B-X
following	B-X
NSPT	B-X
in	B-X
both	B-X
groups	B-X
,	B-X
whereas	B-X
salivary	B-X
TAC	B-X
concentrations	B-X
increased	B-X
<EOS>	B-X
Plasma	B-X
insulin	B-X
concentrations	B-X
fell	B-X
significantly	B-X
at	B-X
week	B-X
1	B-X
,	B-X
from	B-X
31	B-X
<EOS>	B-X
Plasma	B-X
glucose	B-X
concentrations	B-X
did	B-X
not	B-X
alter	B-X
significantly	B-X

We	O
conclude	O
that	O
troglitazone	O
has	O
an	O
antiinflammatory	O
action	O
that	O
may	O
contribute	O
to	O
its	O
putative	O
antiatherosclerotic	O
effects	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
troglitazone	B-X
has	B-X
an	B-X
antiinflammatory	B-X
action	B-X
that	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
putative	B-X
antiatherosclerotic	B-X
effects	B-X
<EOS>	B-X
To	B-X
elucidate	B-X
whether	B-X
troglitazone	B-X
exerts	B-X
an	B-X
antiinflammatory	B-X
effect	B-X
in	B-X
humans	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
suppression	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
in	B-X
mononuclear	B-X
cells	B-X
(	B-X
MNC	B-X
)	B-X
by	B-X
this	B-X
drug	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
stimulation	B-X
of	B-X
inhibitor	B-X
kappaB	B-X
by	B-X
troglitazone	B-X
:	B-X
evidence	B-X
for	B-X
an	B-X
anti	B-X
-	B-X
inflammatory	B-X
effect	B-X
and	B-X
a	B-X
potential	B-X
antiatherosclerotic	B-X
effect	B-X
in	B-X
the	B-X
obese	B-X
.	B-X
<EOS>	B-X
Seven	B-X
nondiabetic	B-X
obese	B-X
patients	B-X
were	B-X
given	B-X
400	B-X
mg	B-X
troglitazone	B-X
daily	B-X
for	B-X
4	B-X
weeks	B-X

Tyrosine	O
phosphorylation-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
<EOS>	B-X
Tyrosine	B-X
phosphorylation	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
NFkappaB	B-X
is	B-X
compromised	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
the	B-X
elderly	B-X
.	B-X
<EOS>	B-X
Oxidant	B-X
-	B-X
sensitive	B-X
and	B-X
phosphorylation	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
AP	B-X
-	B-X
1	B-X
in	B-X
endothelial	B-X
cells	B-X
.	B-X
<EOS>	B-X
Tyrosine	B-X
phosphorylation	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
.	B-X
Requirement	B-X
for	B-X
p56	B-X
LCK	B-X
and	B-X
ZAP	B-X
-	B-X
70	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
.	B-X
<EOS>	B-X
Tyrosine	B-X
phosphorylation	B-X
is	B-X
decreased	B-X
in	B-X
CD28	B-X
where	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
PxxP	B-X
motif	B-X
is	B-X
mutated	B-X
(	B-X
nPA	B-X
)	B-X

Requirement	O
for	O
p56	B-protein
LCK	I-protein
and	I-protein
ZAP-70	I-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
.	O
<EOS>	B-X
Regulatory	B-X
mechanisms	B-X
in	B-X
T	B-X
cell	B-X
receptor	B-X
signalling	B-X
.	B-X
<EOS>	B-X
T	B-X
cell	B-X
-	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
signaling	B-X
requires	B-X
the	B-X
sequential	B-X
activities	B-X
of	B-X
the	B-X
kinases	B-X
Lck	B-X
and	B-X
Zap70	B-X
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
loss	B-X
of	B-X
LAT	B-X
adaptor	B-X
expression	B-X
found	B-X
in	B-X
a	B-X
subline	B-X
of	B-X
J	B-X
<EOS>	B-X
Lck	B-X
promotes	B-X
Zap70	B-X
-	B-X
dependent	B-X
LAT	B-X
phosphorylation	B-X
by	B-X
bridging	B-X
Zap70	B-X
to	B-X
LAT	B-X
.	B-X

Phosphorylation	O
of	O
the	O
N-terminal	B-protein
domain	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
inhibitory	I-protein
subunits	I-protein
induces	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O
<EOS>	B-X
Phosphorylation	B-X
of	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
inhibitory	B-X
subunits	B-X
induces	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
Specifically	B-X
,	B-X
removal	B-X
of	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
36	B-X
amino	B-X
acids	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
failed	B-X
to	B-X
disrupt	B-X
its	B-X
ability	B-X
to	B-X
form	B-X
latent	B-X
complexes	B-X
with	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
the	B-X
cytoplasm	B-X
<EOS>	B-X
Coupling	B-X
of	B-X
a	B-X
signal	B-X
response	B-X
domain	B-X
in	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
multiple	B-X
pathways	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
.	B-X
<EOS>	B-X
Genetic	B-X
deletion	B-X
of	B-X
PKR	B-X
abrogates	B-X
TNF	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
IkappaBalpha	B-X
kinase	B-X
,	B-X
JNK	B-X
,	B-X
Akt	B-X
and	B-X
cell	B-X
proliferation	B-X
but	B-X
potentiates	B-X
p44	B-X
/	B-X
p42	B-X
MAPK	B-X
and	B-X
p38	B-X
MAPK	B-X
activation	B-X
.	B-X

Although	O
serine	O
phosphorylation	O
has	O
been	O
shown	O
to	O
induce	O
ubiquitination	O
and	O
subsequent	O
proteasome-mediated	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
that	O
lead	O
to	O
release	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
in	O
T	B-cell_type
cells	I-cell_type
as	O
a	O
consequence	O
of	O
tyrosine	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
[	O
Imbert	O
,	O
V.	O
,	O
Rupec	O
,	O
R.A.	O
,	O
Livolsi	O
,	O
A.	O
,	O
Pahl	O
,	O
H.L.	O
,	O
Traenckner	O
,	O
B.M.	O
,	O
Mueller-Dieckmann	O
,	O
C.	O
,	O
Farahifar	O
,	O
D.	O
,	O
Rossi	O
,	O
B.	O
,	O
Auberger	O
,	O
P.	O
,	O
Baeuerle	O
,	O
P.	O
&	O
Peyron	O
,	O
J.F.	O
(	O
1996	O
)	O
Cell	O
86	O
,	O
787	O
--	O
798	O
]	O
.	O

The	O
involvement	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
ZAP-70	B-protein
in	O
this	O
reaction	O
is	O
demonstrated	O
here	O
using	O
specific	O
pharmacological	O
inhibitors	O
and	O
Jurkat	B-cell_line
mutants	I-cell_line
unable	O
to	O
express	O
these	O
kinases	B-protein
.	O
<EOS>	B-X
The	B-X
involvement	B-X
of	B-X
the	B-X
tyrosine	B-X
kinases	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
and	B-X
ZAP	B-X
-	B-X
70	B-X
in	B-X
this	B-X
reaction	B-X
is	B-X
demonstrated	B-X
here	B-X
using	B-X
specific	B-X
pharmacological	B-X
inhibitors	B-X
and	B-X
Jurkat	B-X
mutants	B-X
unable	B-X
to	B-X
express	B-X
these	B-X
kinases	B-X
<EOS>	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
,	B-X
which	B-X
stimulates	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
and	B-X
ZAP	B-X
-	B-X
70	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
is	B-X
an	B-X
activator	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
through	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Phosphorylation	B-X
of	B-X
the	B-X
N	B-X
-	B-X
terminal	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
inhibitory	B-X
subunits	B-X
induces	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
Tyrosine	B-X
phosphorylation	B-X
-	B-X
dependent	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
.	B-X
Requirement	B-X
for	B-X
p56	B-X
LCK	B-X
and	B-X
ZAP	B-X
-	B-X
70	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
.	B-X

Although	O
the	O
inhibitors	O
prevented	O
both	O
pervanadate-induced	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
on	O
Tyr42	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
we	O
observed	O
that	O
,	O
in	O
p56	B-cell_line
(	I-cell_line
lck	I-cell_line
)	I-cell_line
-deficient	I-cell_line
Jurkat	I-cell_line
mutants	I-cell_line
,	O
NF-kappa	B-protein
B	I-protein
could	O
still	O
associate	O
with	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
despite	O
phosphorylation	O
on	O
Tyr42	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
inhibitors	B-X
prevented	B-X
both	B-X
pervanadate	B-X
-	B-X
induced	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
-	B-X
alpha	B-X
on	B-X
Tyr42	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
,	B-X
in	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
	B-X
-	B-X
deficient	B-X
Jurkat	B-X
mutants	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
could	B-X
still	B-X
associate	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
-	B-X
alpha	B-X
despite	B-X
phosphorylation	B-X
on	B-X
Tyr42	B-X
<EOS>	B-X
Although	B-X
serine	B-X
phosphorylation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
ubiquitination	B-X
and	B-X
subsequent	B-X
proteasome	B-X
-	B-X
mediated	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
-	B-X
alpha	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanisms	B-X
that	B-X
lead	B-X
to	B-X
release	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
T	B-X
cells	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
-	B-X
alpha	B-X
[	B-X
Imbert	B-X
,	B-X
V	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
SH2	B-X
domain	B-X
of	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
appeared	B-X
to	B-X
be	B-X
required	B-X
for	B-X
pervanadate	B-X
-	B-X
induced	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
but	B-X
not	B-X
for	B-X
Tyr42	B-X
phosphorylation	B-X
<EOS>	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
,	B-X
which	B-X
stimulates	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
and	B-X
ZAP	B-X
-	B-X
70	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
is	B-X
an	B-X
activator	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
through	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
-	B-X
alpha	B-X

Furthermore	O
,	O
the	O
SH2	B-protein
domain	I-protein
of	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
appeared	O
to	O
be	O
required	O
for	O
pervanadate-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
but	O
not	O
for	O
Tyr42	O
phosphorylation	O
.	O

These	O
results	O
show	O
that	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
ZAP-70	B-protein
are	O
key	O
components	O
of	O
the	O
signaling	O
pathway	O
that	O
leads	O
to	O
phosphotyrosine-dependent	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
confirm	O
that	O
tyrosine	B-protein
kinases	I-protein
must	O
control	O
at	O
least	O
two	O
different	O
steps	O
to	O
induce	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Finally	O
,	O
we	O
show	O
that	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
,	O
which	O
stimulates	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
ZAP-70	B-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
is	O
an	O
activator	O
of	O
NF-kappa	B-protein
B	I-protein
through	O
tyrosine	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O

Specific	O
missense	O
mutations	O
in	O
NEMO	B-DNA
result	O
in	O
hyper-IgM	O
syndrome	O
with	O
hypohydrotic	O
ectodermal	O
dysplasia	O
.	O
<EOS>	B-X
Specific	B-X
missense	B-X
mutations	B-X
in	B-X
NEMO	B-X
result	B-X
in	B-X
hyper	B-X
-	B-X
IgM	B-X
syndrome	B-X
with	B-X
hypohydrotic	B-X
ectodermal	B-X
dysplasia	B-X
.	B-X
<EOS>	B-X
We	B-X
describe	B-X
mutations	B-X
in	B-X
the	B-X
putative	B-X
zinc	B-X
-	B-X
finger	B-X
domain	B-X
of	B-X
NEMO	B-X
that	B-X
result	B-X
in	B-X
an	B-X
X	B-X
-	B-X
linked	B-X
primary	B-X
immunodeficiency	B-X
characterized	B-X
by	B-X
hyper	B-X
-	B-X
IgM	B-X
syndrome	B-X
and	B-X
hypohydrotic	B-X
ectodermal	B-X
dysplasia	B-X
(	B-X
XHM	B-X
-	B-X
ED	B-X
)	B-X
<EOS>	B-X
Nevertheless	B-X
,	B-X
innate	B-X
immunity	B-X
is	B-X
preserved	B-X
in	B-X
XHM	B-X
-	B-X
ED	B-X
patients	B-X
because	B-X
APCs	B-X
retain	B-X
the	B-X
capacity	B-X
to	B-X
respond	B-X
to	B-X
stimulation	B-X
by	B-X
lipopolysaccharide	B-X
or	B-X
Staphylococcus	B-X
aureus	B-X
Cowan	B-X
's	B-X
antigen	B-X
(	B-X
SAC	B-X
)	B-X
<EOS>	B-X
Overall	B-X
,	B-X
the	B-X
phenotype	B-X
observed	B-X
in	B-X
XHM	B-X
-	B-X
ED	B-X
patients	B-X
shows	B-X
that	B-X
the	B-X
putative	B-X
zinc	B-X
-	B-X
finger	B-X
domain	B-X
of	B-X
NEMO	B-X
has	B-X
a	B-X
regulatory	B-X
function	B-X
and	B-X
demonstrates	B-X
the	B-X
definite	B-X
requirement	B-X
of	B-X
CD40	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
for	B-X
B	B-X
cell	B-X
immunoglobulin	B-X
class	B-X
-	B-X
switching	B-X

The	O
gene	O
that	O
encodes	O
nuclear	B-DNA
factor	I-DNA
kappaB	I-DNA
(	I-DNA
NF-kappaB	I-DNA
)	I-DNA
essential	I-DNA
modulator	I-DNA
(	O
or	O
NEMO	B-DNA
,	O
also	O
known	O
as	O
IKKgamma	B-DNA
)	O
is	O
required	O
for	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	I-protein
.	O
<EOS>	B-X
The	B-X
gene	B-X
that	B-X
encodes	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
essential	B-X
modulator	B-X
(	B-X
or	B-X
NEMO	B-X
,	B-X
also	B-X
known	B-X
as	B-X
IKKgamma	B-X
)	B-X
is	B-X
required	B-X
for	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
a	B-X
novel	B-X
pathway	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
activation	B-X
involving	B-X
IKKalpha	B-X
and	B-X
IKKgamma	B-X
/	B-X
Nemo	B-X
,	B-X
which	B-X
together	B-X
mediate	B-X
the	B-X
expression	B-X
of	B-X
downstream	B-X
proapoptotic	B-X
genes	B-X
in	B-X
reovirus	B-X
-	B-X
infected	B-X
cells	B-X
<EOS>	B-X
Overall	B-X
,	B-X
the	B-X
phenotype	B-X
observed	B-X
in	B-X
XHM	B-X
-	B-X
ED	B-X
patients	B-X
shows	B-X
that	B-X
the	B-X
putative	B-X
zinc	B-X
-	B-X
finger	B-X
domain	B-X
of	B-X
NEMO	B-X
has	B-X
a	B-X
regulatory	B-X
function	B-X
and	B-X
demonstrates	B-X
the	B-X
definite	B-X
requirement	B-X
of	B-X
CD40	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
for	B-X
B	B-X
cell	B-X
immunoglobulin	B-X
class	B-X
-	B-X
switching	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
reovirus	B-X
infection	B-X
leads	B-X
initially	B-X
to	B-X
nuclear	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
RelA	B-X
,	B-X
followed	B-X
by	B-X
delayed	B-X
mobilization	B-X
of	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
p52	B-X

We	O
describe	O
mutations	O
in	O
the	O
putative	B-protein
zinc-finger	I-protein
domain	I-protein
of	O
NEMO	B-protein
that	O
result	O
in	O
an	O
X-linked	O
primary	O
immunodeficiency	O
characterized	O
by	O
hyper-IgM	O
syndrome	O
and	O
hypohydrotic	O
ectodermal	O
dysplasia	O
(	O
XHM-ED	O
)	O
.	O

These	O
mutations	O
prevent	O
CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
-mediated	O
degradation	O
of	O
inhibitor	O
of	O
NF-kappaB	B-protein
alpha	I-protein
(	O
IkappaB-alpha	B-protein
)	O
and	O
account	O
for	O
the	O
following	O
observations	O
:	O
B	B-cell_type
cells	I-cell_type
from	O
XHM-ED	O
patients	O
are	O
unable	O
to	O
undergo	O
immunoglobulin	O
class-switch	O
recombination	O
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
APCs	B-cell_type
)	O
are	O
unable	O
to	O
synthesize	O
the	O
NF-kappaB-regulated	B-protein
cytokines	I-protein
interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
when	O
stimulated	O
with	O
CD40L	B-protein
.	O
<EOS>	B-X
Cell	B-X
detachment	B-X
results	B-X
in	B-X
reduced	B-X
basal	B-X
levels	B-X
of	B-X
the	B-X
MEK	B-X
kinase	B-X
TPL2	B-X
,	B-X
compromises	B-X
TPL2	B-X
activation	B-X
and	B-X
sensitizes	B-X
carcinoma	B-X
cells	B-X
to	B-X
death	B-X
-	B-X
inducing	B-X
receptor	B-X
ligands	B-X
,	B-X
mimicking	B-X
the	B-X
synthetic	B-X
lethal	B-X
interactions	B-X
between	B-X
TPL2	B-X
inactivation	B-X
and	B-X
TNF	B-X
or	B-X
CD40L	B-X
stimulation	B-X
<EOS>	B-X
Finally	B-X
,	B-X
zDCs	B-X
were	B-X
also	B-X
superior	B-X
in	B-X
their	B-X
capacity	B-X
to	B-X
induce	B-X
melanoma	B-X
-	B-X
specific	B-X
CD8+	B-X
T	B-X
cells	B-X
,	B-X
CD8+	B-X
T	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
cytotoxic	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
produced	B-X
approximately	B-X
two	B-X
times	B-X
more	B-X
IFN	B-X
-	B-X
γ	B-X
and	B-X
more	B-X
granzyme	B-X
B	B-X
,	B-X
than	B-X
those	B-X
stimulated	B-X
with	B-X
αDCs	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
use	B-X
of	B-X
tofacitinib	B-X
exerts	B-X
a	B-X
rapid	B-X
regulatory	B-X
effect	B-X
on	B-X
B	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
following	B-X
stimulation	B-X
with	B-X
collagen	B-X
epitopes	B-X
while	B-X
not	B-X
reducing	B-X
inflammatory	B-X
cytokine	B-X
production	B-X
by	B-X
lymphocytes	B-X
<EOS>	B-X
Despite	B-X
the	B-X
relevance	B-X
of	B-X
adaptive	B-X
immunity	B-X
against	B-X
equine	B-X
pathogens	B-X
antigen	B-X
-	B-X
specific	B-X
T	B-X
cell	B-X
responses	B-X
of	B-X
horses	B-X
are	B-X
not	B-X
well	B-X
characterized	B-X
and	B-X
the	B-X
lack	B-X
of	B-X
insight	B-X
into	B-X
T	B-X
cell	B-X
responses	B-X
hampers	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
pathogeneses	B-X
of	B-X
important	B-X
diseases	B-X

Nevertheless	O
,	O
innate	O
immunity	O
is	O
preserved	O
in	O
XHM-ED	O
patients	O
because	O
APCs	B-cell_type
retain	O
the	O
capacity	O
to	O
respond	O
to	O
stimulation	O
by	O
lipopolysaccharide	O
or	O
Staphylococcus	B-protein
aureus	I-protein
Cowan	I-protein
's	I-protein
antigen	I-protein
(	O
SAC	B-protein
)	O
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
innate	B-X
immunity	B-X
is	B-X
preserved	B-X
in	B-X
XHM	B-X
-	B-X
ED	B-X
patients	B-X
because	B-X
APCs	B-X
retain	B-X
the	B-X
capacity	B-X
to	B-X
respond	B-X
to	B-X
stimulation	B-X
by	B-X
lipopolysaccharide	B-X
or	B-X
Staphylococcus	B-X
aureus	B-X
Cowan	B-X
's	B-X
antigen	B-X
(	B-X
SAC	B-X
)	B-X
<EOS>	B-X
Overall	B-X
,	B-X
the	B-X
phenotype	B-X
observed	B-X
in	B-X
XHM	B-X
-	B-X
ED	B-X
patients	B-X
shows	B-X
that	B-X
the	B-X
putative	B-X
zinc	B-X
-	B-X
finger	B-X
domain	B-X
of	B-X
NEMO	B-X
has	B-X
a	B-X
regulatory	B-X
function	B-X
and	B-X
demonstrates	B-X
the	B-X
definite	B-X
requirement	B-X
of	B-X
CD40	B-X
-	B-X
mediated	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
for	B-X
B	B-X
cell	B-X
immunoglobulin	B-X
class	B-X
-	B-X
switching	B-X
<EOS>	B-X
Specific	B-X
missense	B-X
mutations	B-X
in	B-X
NEMO	B-X
result	B-X
in	B-X
hyper	B-X
-	B-X
IgM	B-X
syndrome	B-X
with	B-X
hypohydrotic	B-X
ectodermal	B-X
dysplasia	B-X
.	B-X
<EOS>	B-X
These	B-X
mutations	B-X
prevent	B-X
CD40	B-X
ligand	B-X
(	B-X
CD40L	B-X
)	B-X
	B-X
-	B-X
mediated	B-X
degradation	B-X
of	B-X
inhibitor	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
alpha	B-X
(	B-X
IkappaB	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
account	B-X
for	B-X
the	B-X
following	B-X
observations	B-X
:	B-X
B	B-X
cells	B-X
from	B-X
XHM	B-X
-	B-X
ED	B-X
patients	B-X
are	B-X
unable	B-X
to	B-X
undergo	B-X
immunoglobulin	B-X
class	B-X
-	B-X
switch	B-X
recombination	B-X
and	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
(	B-X
APCs	B-X
)	B-X
are	B-X
unable	B-X
to	B-X
synthesize	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
regulated	B-X
cytokines	B-X
interleukin	B-X
12	B-X
(	B-X
IL	B-X
-	B-X
12	B-X
)	B-X
or	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
when	B-X
stimulated	B-X
with	B-X
CD40L	B-X

Overall	O
,	O
the	O
phenotype	O
observed	O
in	O
XHM-ED	O
patients	O
shows	O
that	O
the	O
putative	B-protein
zinc-finger	I-protein
domain	I-protein
of	O
NEMO	B-protein
has	O
a	O
regulatory	O
function	O
and	O
demonstrates	O
the	O
definite	O
requirement	O
of	O
CD40	B-protein
-mediated	O
NF-kappaB	O
activation	O
for	O
B	B-cell_type
cell	I-cell_type
immunoglobulin	O
class-switching	O
.	O

Granulocytic	O
differentiation	O
of	O
human	B-cell_type
NB4	I-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
induced	O
by	O
all-trans	O
retinoic	O
acid	O
metabolites	O
.	O
<EOS>	B-X
Granulocytic	B-X
differentiation	B-X
of	B-X
human	B-X
NB4	B-X
promyelocytic	B-X
leukemia	B-X
cells	B-X
induced	B-X
by	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
metabolites	B-X
.	B-X
<EOS>	B-X
4	B-X
-	B-X
Oxoretinol	B-X
,	B-X
a	B-X
metabolite	B-X
of	B-X
retinol	B-X
in	B-X
the	B-X
human	B-X
promyelocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
NB4	B-X
,	B-X
induces	B-X
cell	B-X
growth	B-X
arrest	B-X
and	B-X
granulocytic	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
Acute	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
APL	B-X
)	B-X
was	B-X
considered	B-X
to	B-X
be	B-X
one	B-X
of	B-X
the	B-X
most	B-X
lethal	B-X
forms	B-X
of	B-X
leukemia	B-X
in	B-X
adults	B-X
before	B-X
the	B-X
introduction	B-X
of	B-X
the	B-X
vitamin	B-X
A	B-X
metabolite	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
<EOS>	B-X
These	B-X
unique	B-X
properties	B-X
of	B-X
4	B-X
-	B-X
oxoROL	B-X
may	B-X
provide	B-X
advantages	B-X
over	B-X
RA	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
promyelocytic	B-X
leukemia	B-X
cells	B-X
because	B-X
it	B-X
may	B-X
be	B-X
possible	B-X
to	B-X
maintain	B-X
cytodifferentiating	B-X
concentrations	B-X
of	B-X
4	B-X
-	B-X
oxoROL	B-X
in	B-X
the	B-X
cells	B-X
for	B-X
extended	B-X
periods	B-X
of	B-X
time	B-X

The	O
metabolism	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
has	O
been	O
reported	O
to	O
be	O
partly	O
responsible	O
for	O
the	O
in	O
vivo	O
resistance	O
to	O
ATRA	O
seen	O
in	O
the	O
treatment	O
of	O
human	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

However	O
,	O
ATRA	O
metabolism	O
appears	O
to	O
be	O
involved	O
in	O
the	O
growth	O
inhibition	O
of	O
several	O
cancer	B-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
vitro	O
.	O
<EOS>	B-X
However	B-X
,	B-X
ATRA	B-X
metabolism	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
growth	B-X
inhibition	B-X
of	B-X
several	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
<EOS>	B-X
We	B-X
established	B-X
that	B-X
the	B-X
four	B-X
ATRA	B-X
metabolites	B-X
were	B-X
indeed	B-X
formed	B-X
by	B-X
the	B-X
NB4	B-X
cells	B-X
in	B-X
vitro	B-X
<EOS>	B-X
0	B-X
-	B-X
fold	B-X
more	B-X
growth	B-X
inhibition	B-X
in	B-X
most	B-X
cancer	B-X
cells	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
gynecologic	B-X
cancer	B-X
cells	B-X
<EOS>	B-X
Subsequent	B-X
studies	B-X
in	B-X
other	B-X
cancer	B-X
cell	B-X
lines	B-X
indicated	B-X
that	B-X
ABPN	B-X
was	B-X
much	B-X
more	B-X
growth	B-X
-	B-X
inhibitory	B-X
than	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
or	B-X
4	B-X
-	B-X
HPR	B-X

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
in	O
vitro	O
activity	O
of	O
the	O
principal	O
metabolites	O
of	O
ATRA	O
[	O
4-hydroxy-retinoic	O
acid	O
(	O
4-OH-RA	O
)	O
,	O
18-hydroxy-retinoic	O
acid	O
(	O
18-OH-RA	O
)	O
,	O
4-oxo-retinoic	O
acid	O
(	O
4-oxo-RA	O
)	O
,	O
and	O
5	O
,	O
6-epoxy-retinoic	O
acid	O
(	O
5	O
,	O
6-epoxy-RA	O
)	O
]	O
in	O
NB4	B-cell_line
,	I-cell_line
a	I-cell_line
human	I-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
exhibits	O
the	O
APL	O
diagnostic	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
and	O
expresses	O
the	O
PML-RAR	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
.	O

We	O
established	O
that	O
the	O
four	O
ATRA	O
metabolites	O
were	O
indeed	O
formed	O
by	O
the	O
NB4	B-cell_line
cells	I-cell_line
in	O
vitro	O
.	O
<EOS>	B-X
We	B-X
established	B-X
that	B-X
the	B-X
four	B-X
ATRA	B-X
metabolites	B-X
were	B-X
indeed	B-X
formed	B-X
by	B-X
the	B-X
NB4	B-X
cells	B-X
in	B-X
vitro	B-X
<EOS>	B-X
However	B-X
,	B-X
ATRA	B-X
metabolism	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
growth	B-X
inhibition	B-X
of	B-X
several	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Comparison	B-X
of	B-X
the	B-X
relative	B-X
potency	B-X
of	B-X
the	B-X
retinoids	B-X
using	B-X
the	B-X
nitroblue	B-X
tetrazolium	B-X
reduction	B-X
test	B-X
showed	B-X
effective	B-X
concentrations	B-X
required	B-X
to	B-X
differentiate	B-X
50	B-X
%	B-X
of	B-X
cells	B-X
in	B-X
72	B-X
h	B-X
as	B-X
follows	B-X
:	B-X
ATRA	B-X
,	B-X
15	B-X
<EOS>	B-X
Granulocytic	B-X
differentiation	B-X
of	B-X
human	B-X
NB4	B-X
promyelocytic	B-X
leukemia	B-X
cells	B-X
induced	B-X
by	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
metabolites	B-X
.	B-X

NB4	O
cell	O
growth	O
was	O
inhibited	O
(	O
69-78	O
%	O
at	O
120	O
h	O
)	O
and	O
cell	O
cycle	O
progression	O
in	O
the	O
G1	O
phase	O
(	O
82-85	O
%	O
at	O
120	O
h	O
)	O
was	O
blocked	O
by	O
ATRA	O
and	O
all	O
of	O
the	O
metabolites	O
at	O
1	O
microM	O
concentration	O
.	O
<EOS>	B-X
NB4	B-X
cell	B-X
growth	B-X
was	B-X
inhibited	B-X
(	B-X
69	B-X
-	B-X
78	B-X
%	B-X
at	B-X
120	B-X
h	B-X
)	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
the	B-X
G1	B-X
phase	B-X
(	B-X
82	B-X
-	B-X
85	B-X
%	B-X
at	B-X
120	B-X
h	B-X
)	B-X
was	B-X
blocked	B-X
by	B-X
ATRA	B-X
and	B-X
all	B-X
of	B-X
the	B-X
metabolites	B-X
at	B-X
1	B-X
microM	B-X
concentration	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
principal	B-X
ATRA	B-X
Phase	B-X
1	B-X
metabolites	B-X
can	B-X
elicit	B-X
leukemia	B-X
cell	B-X
growth	B-X
inhibition	B-X
and	B-X
differentiation	B-X
in	B-X
vitro	B-X
through	B-X
the	B-X
RAR	B-X
alpha	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
they	B-X
suggest	B-X
that	B-X
these	B-X
metabolites	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
ATRA	B-X
antileukemic	B-X
activity	B-X
in	B-X
vivo	B-X
<EOS>	B-X
ATRA	B-X
and	B-X
its	B-X
metabolites	B-X
could	B-X
induce	B-X
NB4	B-X
cells	B-X
differentiation	B-X
with	B-X
similar	B-X
activity	B-X
,	B-X
as	B-X
evaluated	B-X
by	B-X
cell	B-X
morphology	B-X
,	B-X
by	B-X
the	B-X
nitroblue	B-X
tetrazolium	B-X
reduction	B-X
test	B-X
(	B-X
82	B-X
-	B-X
88	B-X
%	B-X
at	B-X
120	B-X
h	B-X
)	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
maturation	B-X
specific	B-X
cell	B-X
surface	B-X
marker	B-X
CD11c	B-X
<EOS>	B-X
Granulocytic	B-X
differentiation	B-X
of	B-X
human	B-X
NB4	B-X
promyelocytic	B-X
leukemia	B-X
cells	B-X
induced	B-X
by	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
metabolites	B-X
.	B-X

ATRA	O
and	O
its	O
metabolites	O
could	O
induce	O
NB4	B-cell_line
cells	I-cell_line
differentiation	O
with	O
similar	O
activity	O
,	O
as	O
evaluated	O
by	O
cell	O
morphology	O
,	O
by	O
the	O
nitroblue	O
tetrazolium	O
reduction	O
test	O
(	O
82-88	O
%	O
at	O
120	O
h	O
)	O
or	O
by	O
the	O
expression	O
of	O
the	O
maturation	B-protein
specific	I-protein
cell	I-protein
surface	I-protein
marker	I-protein
CD11c	I-protein
.	O
<EOS>	B-X
The	B-X
main	B-X
feature	B-X
of	B-X
these	B-X
cells	B-X
is	B-X
their	B-X
ability	B-X
to	B-X
suppress	B-X
the	B-X
T	B-X
cell	B-X
response	B-X
in	B-X
antigen	B-X
specific	B-X
or	B-X
nonspecific	B-X
manners	B-X
depending	B-X
on	B-X
the	B-X
condition	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
established	B-X
a	B-X
mouse	B-X
model	B-X
and	B-X
flow	B-X
cytometry	B-X
was	B-X
used	B-X
to	B-X
detect	B-X
the	B-X
expression	B-X
of	B-X
mature	B-X
DC	B-X
surface	B-X
molecules	B-X
in	B-X
activated	B-X
microglia	B-X
<EOS>	B-X
Sinomenine	B-X
promotes	B-X
differentiation	B-X
of	B-X
induced	B-X
pluripotent	B-X
stem	B-X
cells	B-X
into	B-X
immature	B-X
dendritic	B-X
cells	B-X
with	B-X
high	B-X
induction	B-X
of	B-X
immune	B-X
tolerance	B-X
.	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
activation	B-X
of	B-X
AhR	B-X
by	B-X
2,3,7,8	B-X
-	B-X
tetrachlorodibenzo	B-X
-	B-X
p	B-X
-	B-X
dioxin	B-X
(	B-X
TCDD	B-X
)	B-X
caused	B-X
enhanced	B-X
differentiation	B-X
from	B-X
immature	B-X
DCs	B-X
(	B-X
IDCs	B-X
)	B-X
to	B-X
mature	B-X
DCs	B-X
(	B-X
MDCs	B-X
)	B-X
in	B-X
the	B-X
bone	B-X
-	B-X
marrow	B-X
-	B-X
derived	B-X
DCs	B-X
(	B-X
BMDC	B-X
)	B-X
from	B-X
B6	B-X
wild	B-X
-	B-X
type	B-X
mice	B-X
but	B-X
not	B-X
in	B-X
the	B-X
BMDCs	B-X
from	B-X
AhR	B-X
-	B-X
null	B-X
mice	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
CD11c	B-X
and	B-X
class	B-X
II	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X

In	O
addition	O
,	O
nuclear	O
body	O
reorganization	O
to	O
macropunctated	O
structures	O
,	O
as	O
well	O
as	O
the	O
degradation	O
of	O
PML-RAR	B-protein
alpha	I-protein
,	O
was	O
found	O
to	O
be	O
similar	O
for	O
ATRA	O
and	O
all	O
of	O
its	O
metabolites	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
nuclear	B-X
body	B-X
reorganization	B-X
to	B-X
macropunctated	B-X
structures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
degradation	B-X
of	B-X
PML	B-X
-	B-X
RAR	B-X
alpha	B-X
,	B-X
was	B-X
found	B-X
to	B-X
be	B-X
similar	B-X
for	B-X
ATRA	B-X
and	B-X
all	B-X
of	B-X
its	B-X
metabolites	B-X
<EOS>	B-X
Granulocytic	B-X
differentiation	B-X
of	B-X
human	B-X
NB4	B-X
promyelocytic	B-X
leukemia	B-X
cells	B-X
induced	B-X
by	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
metabolites	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
principal	B-X
ATRA	B-X
Phase	B-X
1	B-X
metabolites	B-X
can	B-X
elicit	B-X
leukemia	B-X
cell	B-X
growth	B-X
inhibition	B-X
and	B-X
differentiation	B-X
in	B-X
vitro	B-X
through	B-X
the	B-X
RAR	B-X
alpha	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
they	B-X
suggest	B-X
that	B-X
these	B-X
metabolites	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
ATRA	B-X
antileukemic	B-X
activity	B-X
in	B-X
vivo	B-X
<EOS>	B-X
ATRA	B-X
and	B-X
its	B-X
metabolites	B-X
could	B-X
induce	B-X
NB4	B-X
cells	B-X
differentiation	B-X
with	B-X
similar	B-X
activity	B-X
,	B-X
as	B-X
evaluated	B-X
by	B-X
cell	B-X
morphology	B-X
,	B-X
by	B-X
the	B-X
nitroblue	B-X
tetrazolium	B-X
reduction	B-X
test	B-X
(	B-X
82	B-X
-	B-X
88	B-X
%	B-X
at	B-X
120	B-X
h	B-X
)	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
maturation	B-X
specific	B-X
cell	B-X
surface	B-X
marker	B-X
CD11c	B-X

Comparison	O
of	O
the	O
relative	O
potency	O
of	O
the	O
retinoids	O
using	O
the	O
nitroblue	O
tetrazolium	O
reduction	O
test	O
showed	O
effective	O
concentrations	O
required	O
to	O
differentiate	O
50	O
%	O
of	O
cells	O
in	O
72	O
h	O
as	O
follows	O
:	O
ATRA	O
,	O
15.8	O
+/-	O
1.7	O
nM	O
;	O
4-oxo-RA	O
,	O
38.3	O
+/-	O
1.3	O
nM	O
;	O
18-OH-RA	O
,	O
55.5	O
+/-	O
1.8	O
nM	O
;	O
4-OH-RA	O
,	O
79.8	O
+/-	O
1.8	O
nM	O
;	O
and	O
5	O
,	O
6-epoxy-RA	O
,	O
99.5	O
+/-	O
1.5	O
nM	O
.	O
<EOS>	B-X
Comparison	B-X
of	B-X
the	B-X
relative	B-X
potency	B-X
of	B-X
the	B-X
retinoids	B-X
using	B-X
the	B-X
nitroblue	B-X
tetrazolium	B-X
reduction	B-X
test	B-X
showed	B-X
effective	B-X
concentrations	B-X
required	B-X
to	B-X
differentiate	B-X
50	B-X
%	B-X
of	B-X
cells	B-X
in	B-X
72	B-X
h	B-X
as	B-X
follows	B-X
:	B-X
ATRA	B-X
,	B-X
15	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
principal	B-X
ATRA	B-X
Phase	B-X
1	B-X
metabolites	B-X
can	B-X
elicit	B-X
leukemia	B-X
cell	B-X
growth	B-X
inhibition	B-X
and	B-X
differentiation	B-X
in	B-X
vitro	B-X
through	B-X
the	B-X
RAR	B-X
alpha	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
they	B-X
suggest	B-X
that	B-X
these	B-X
metabolites	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
ATRA	B-X
antileukemic	B-X
activity	B-X
in	B-X
vivo	B-X
<EOS>	B-X
The	B-X
ATRA	B-X
metabolites	B-X
were	B-X
found	B-X
to	B-X
exert	B-X
their	B-X
differentiation	B-X
effects	B-X
via	B-X
the	B-X
RAR	B-X
alpha	B-X
nuclear	B-X
receptors	B-X
,	B-X
because	B-X
the	B-X
RAR	B-X
alpha	B-X
-	B-X
specific	B-X
antagonist	B-X
BMS614	B-X
blocked	B-X
metabolite	B-X
-	B-X
induced	B-X
CD11c	B-X
expression	B-X
in	B-X
NB4	B-X
cells	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
nuclear	B-X
body	B-X
reorganization	B-X
to	B-X
macropunctated	B-X
structures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
degradation	B-X
of	B-X
PML	B-X
-	B-X
RAR	B-X
alpha	B-X
,	B-X
was	B-X
found	B-X
to	B-X
be	B-X
similar	B-X
for	B-X
ATRA	B-X
and	B-X
all	B-X
of	B-X
its	B-X
metabolites	B-X

The	O
ATRA	O
metabolites	O
were	O
found	O
to	O
exert	O
their	O
differentiation	O
effects	O
via	O
the	O
RAR	B-protein
alpha	I-protein
nuclear	I-protein
receptors	I-protein
,	O
because	O
the	O
RAR	O
alpha-specific	O
antagonist	O
BMS614	O
blocked	O
metabolite-induced	O
CD11c	O
expression	O
in	O
NB4	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
The	B-X
ATRA	B-X
metabolites	B-X
were	B-X
found	B-X
to	B-X
exert	B-X
their	B-X
differentiation	B-X
effects	B-X
via	B-X
the	B-X
RAR	B-X
alpha	B-X
nuclear	B-X
receptors	B-X
,	B-X
because	B-X
the	B-X
RAR	B-X
alpha	B-X
-	B-X
specific	B-X
antagonist	B-X
BMS614	B-X
blocked	B-X
metabolite	B-X
-	B-X
induced	B-X
CD11c	B-X
expression	B-X
in	B-X
NB4	B-X
cells	B-X
<EOS>	B-X
ATRA	B-X
and	B-X
its	B-X
metabolites	B-X
could	B-X
induce	B-X
NB4	B-X
cells	B-X
differentiation	B-X
with	B-X
similar	B-X
activity	B-X
,	B-X
as	B-X
evaluated	B-X
by	B-X
cell	B-X
morphology	B-X
,	B-X
by	B-X
the	B-X
nitroblue	B-X
tetrazolium	B-X
reduction	B-X
test	B-X
(	B-X
82	B-X
-	B-X
88	B-X
%	B-X
at	B-X
120	B-X
h	B-X
)	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
maturation	B-X
specific	B-X
cell	B-X
surface	B-X
marker	B-X
CD11c	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
principal	B-X
ATRA	B-X
Phase	B-X
1	B-X
metabolites	B-X
can	B-X
elicit	B-X
leukemia	B-X
cell	B-X
growth	B-X
inhibition	B-X
and	B-X
differentiation	B-X
in	B-X
vitro	B-X
through	B-X
the	B-X
RAR	B-X
alpha	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
they	B-X
suggest	B-X
that	B-X
these	B-X
metabolites	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
ATRA	B-X
antileukemic	B-X
activity	B-X
in	B-X
vivo	B-X
<EOS>	B-X
However	B-X
,	B-X
ATRA	B-X
metabolism	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
growth	B-X
inhibition	B-X
of	B-X
several	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X

These	O
data	O
demonstrate	O
that	O
the	O
principal	O
ATRA	O
Phase	O
1	O
metabolites	O
can	O
elicit	O
leukemia	B-cell_type
cell	I-cell_type
growth	O
inhibition	O
and	O
differentiation	O
in	O
vitro	O
through	O
the	O
RAR	O
alpha	O
signaling	O
pathway	O
,	O
and	O
they	O
suggest	O
that	O
these	O
metabolites	O
may	O
play	O
a	O
role	O
in	O
ATRA	O
antileukemic	O
activity	O
in	O
vivo	O
.	O
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
principal	B-X
ATRA	B-X
Phase	B-X
1	B-X
metabolites	B-X
can	B-X
elicit	B-X
leukemia	B-X
cell	B-X
growth	B-X
inhibition	B-X
and	B-X
differentiation	B-X
in	B-X
vitro	B-X
through	B-X
the	B-X
RAR	B-X
alpha	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
they	B-X
suggest	B-X
that	B-X
these	B-X
metabolites	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
ATRA	B-X
antileukemic	B-X
activity	B-X
in	B-X
vivo	B-X
<EOS>	B-X
The	B-X
ATRA	B-X
metabolites	B-X
were	B-X
found	B-X
to	B-X
exert	B-X
their	B-X
differentiation	B-X
effects	B-X
via	B-X
the	B-X
RAR	B-X
alpha	B-X
nuclear	B-X
receptors	B-X
,	B-X
because	B-X
the	B-X
RAR	B-X
alpha	B-X
-	B-X
specific	B-X
antagonist	B-X
BMS614	B-X
blocked	B-X
metabolite	B-X
-	B-X
induced	B-X
CD11c	B-X
expression	B-X
in	B-X
NB4	B-X
cells	B-X
<EOS>	B-X
The	B-X
metabolism	B-X
of	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
(	B-X
ATRA	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
partly	B-X
responsible	B-X
for	B-X
the	B-X
in	B-X
vivo	B-X
resistance	B-X
to	B-X
ATRA	B-X
seen	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
human	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
APL	B-X
)	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
nuclear	B-X
body	B-X
reorganization	B-X
to	B-X
macropunctated	B-X
structures	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
degradation	B-X
of	B-X
PML	B-X
-	B-X
RAR	B-X
alpha	B-X
,	B-X
was	B-X
found	B-X
to	B-X
be	B-X
similar	B-X
for	B-X
ATRA	B-X
and	B-X
all	B-X
of	B-X
its	B-X
metabolites	B-X

Expression	O
of	O
oestrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
by	O
mast	B-cell_type
cells	I-cell_type
alone	O
,	O
but	O
not	O
lymphocytes	B-cell_type
,	O
macrophages	B-cell_type
or	O
other	O
immune	B-cell_type
cells	I-cell_type
in	O
human	O
upper	O
airways	O
.	O
<EOS>	B-X
Cell	B-X
type	B-X
deconvolution	B-X
confirms	B-X
greater	B-X
recruitment	B-X
of	B-X
B	B-X
cells	B-X
,	B-X
and	B-X
to	B-X
a	B-X
lesser	B-X
degree	B-X
macrophages	B-X
,	B-X
to	B-X
the	B-X
upper	B-X
airway	B-X
of	B-X
children	B-X
<EOS>	B-X
Intramuscular	B-X
(	B-X
IM	B-X
)	B-X
	B-X
-	B-X
immunized	B-X
hamsters	B-X
are	B-X
strongly	B-X
protected	B-X
from	B-X
weight	B-X
loss	B-X
and	B-X
other	B-X
clinical	B-X
symptoms	B-X
after	B-X
the	B-X
Beta	B-X
challenge	B-X
but	B-X
show	B-X
delayed	B-X
viral	B-X
clearance	B-X
in	B-X
the	B-X
upper	B-X
airway	B-X
<EOS>	B-X
Many	B-X
micronutrients	B-X
(	B-X
vitamins	B-X
and	B-X
minerals	B-X
)	B-X
act	B-X
as	B-X
regulators	B-X
of	B-X
molecular	B-X
responses	B-X
of	B-X
immune	B-X
cells	B-X
to	B-X
infection	B-X
<EOS>	B-X
Viral	B-X
infection	B-X
that	B-X
causes	B-X
CRS	B-X
is	B-X
frequently	B-X
associated	B-X
with	B-X
type	B-X
1	B-X
and	B-X
type	B-X
2	B-X
immune	B-X
responses	B-X

BACKGROUND	O
:	O
Nasal	O
polyposis	O
often	O
coexists	O
with	O
asthma	O
in	O
airway	O
inflammatory	O
conditions	O
characterised	O
by	O
the	O
infiltration	O
of	O
a	O
range	O
of	O
immune	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Nasal	B-X
polyposis	B-X
often	B-X
coexists	B-X
with	B-X
asthma	B-X
in	B-X
airway	B-X
inflammatory	B-X
conditions	B-X
characterised	B-X
by	B-X
the	B-X
infiltration	B-X
of	B-X
a	B-X
range	B-X
of	B-X
immune	B-X
cells	B-X
<EOS>	B-X
Numerous	B-X
ER	B-X
/	B-X
PR	B-X
positive	B-X
mast	B-X
cells	B-X
exist	B-X
in	B-X
nasal	B-X
polyps	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
may	B-X
be	B-X
a	B-X
major	B-X
route	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
sex	B-X
hormones	B-X
in	B-X
airway	B-X
inflammation	B-X
when	B-X
exposed	B-X
to	B-X
the	B-X
higher	B-X
and	B-X
varying	B-X
concentration	B-X
of	B-X
oestrogen	B-X
and	B-X
progesterone	B-X
characteristic	B-X
of	B-X
females	B-X
<EOS>	B-X
A	B-X
potentially	B-X
important	B-X
role	B-X
for	B-X
ovarian	B-X
hormones	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
airway	B-X
inflammation	B-X
but	B-X
the	B-X
cellular	B-X
target	B-X
for	B-X
such	B-X
action	B-X
is	B-X
not	B-X
known	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
ER	B-X
/	B-X
PR	B-X
was	B-X
independent	B-X
of	B-X
patient	B-X
sex	B-X
and	B-X
age	B-X
but	B-X
was	B-X
highly	B-X
correlated	B-X
with	B-X
the	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
(	B-X
r	B-X
=	B-X
0	B-X

A	O
potentially	O
important	O
role	O
for	O
ovarian	O
hormones	O
has	O
been	O
implicated	O
in	O
airway	O
inflammation	O
but	O
the	O
cellular	O
target	O
for	O
such	O
action	O
is	O
not	O
known	O
.	O

METHODS	O
:	O
Expression	O
of	O
oestrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
and	O
progesterone	B-protein
receptors	I-protein
(	O
PR	B-protein
)	O
was	O
examined	O
using	O
immunohistochemistry	O
in	O
formalin	O
fixed	O
nasal	O
polyp	O
tissues	O
from	O
47	O
subjects	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
oestrogen	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
and	B-X
progesterone	B-X
receptors	B-X
(	B-X
PR	B-X
)	B-X
was	B-X
examined	B-X
using	B-X
immunohistochemistry	B-X
in	B-X
formalin	B-X
fixed	B-X
nasal	B-X
polyp	B-X
tissues	B-X
from	B-X
47	B-X
subjects	B-X
<EOS>	B-X
Expression	B-X
of	B-X
oestrogen	B-X
and	B-X
progesterone	B-X
receptors	B-X
by	B-X
mast	B-X
cells	B-X
alone	B-X
,	B-X
but	B-X
not	B-X
lymphocytes	B-X
,	B-X
macrophages	B-X
or	B-X
other	B-X
immune	B-X
cells	B-X
in	B-X
human	B-X
upper	B-X
airways	B-X
.	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
ER	B-X
/	B-X
PR	B-X
was	B-X
independent	B-X
of	B-X
patient	B-X
sex	B-X
and	B-X
age	B-X
but	B-X
was	B-X
highly	B-X
correlated	B-X
with	B-X
the	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
Nasal	B-X
polyposis	B-X
often	B-X
coexists	B-X
with	B-X
asthma	B-X
in	B-X
airway	B-X
inflammatory	B-X
conditions	B-X
characterised	B-X
by	B-X
the	B-X
infiltration	B-X
of	B-X
a	B-X
range	B-X
of	B-X
immune	B-X
cells	B-X

The	O
cells	O
positive	O
for	O
ER	B-protein
or	O
PR	B-protein
were	O
confirmed	O
by	O
spatial	O
location	O
,	O
dual	O
immunolabelling	O
,	O
and	O
histochemical	O
staining	O
.	O
<EOS>	B-X
The	B-X
tumor	B-X
cells	B-X
were	B-X
positive	B-X
for	B-X
Forkhead	B-X
Box	B-X
L2	B-X
(	B-X
FOXL2	B-X
)	B-X
,	B-X
inhibin	B-X
,	B-X
Wilms	B-X
tumor	B-X
protein	B-X
1	B-X
(	B-X
WT	B-X
-	B-X
1	B-X
)	B-X
,	B-X
steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF1	B-X
)	B-X
,	B-X
vimentin	B-X
,	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
,	B-X
and	B-X
smooth	B-X
muscle	B-X
actin	B-X
(	B-X
SMA	B-X
)	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
a	B-X
positive	B-X
correlation	B-X
was	B-X
observed	B-X
between	B-X
BRIP1	B-X
expression	B-X
and	B-X
the	B-X
immune	B-X
infiltration	B-X
levels	B-X
of	B-X
cancer	B-X
-	B-X
associated	B-X
fibroblasts	B-X
and	B-X
CD8+	B-X
T	B-X
cells	B-X
in	B-X
lung	B-X
adenocarcinoma	B-X
<EOS>	B-X
The	B-X
tumor	B-X
cells	B-X
were	B-X
positive	B-X
for	B-X
AE1	B-X
/	B-X
AE2	B-X
,	B-X
calretinin	B-X
,	B-X
WT	B-X
-	B-X
1	B-X
,	B-X
D2	B-X
-	B-X
40	B-X
,	B-X
HEG1	B-X
,	B-X
EMA	B-X
,	B-X
BAP1	B-X
,	B-X
and	B-X
MTAP	B-X
and	B-X
negative	B-X
for	B-X
carcinoembryonic	B-X
antigen	B-X
,	B-X
MOC	B-X
-	B-X
31	B-X
,	B-X
Ber	B-X
-	B-X
Ep4	B-X
,	B-X
ER	B-X
,	B-X
PgR	B-X
,	B-X
TTF	B-X
-	B-X
1	B-X
,	B-X
claudin	B-X
4	B-X
,	B-X
and	B-X
desmin	B-X
<EOS>	B-X
Then	B-X
,	B-X
the	B-X
MAM	B-X
score	B-X
was	B-X
constructed	B-X
using	B-X
the	B-X
lasso	B-X
algorithm	B-X

RESULTS	O
:	O
Consistent	O
with	O
the	O
known	O
features	O
of	O
nasal	O
polyps	O
,	O
CD4+	B-cell_type
(	I-cell_type
T	I-cell_type
helper/inducer	I-cell_type
)	I-cell_type
,	O
CD8+	B-cell_type
(	I-cell_type
cytotoxic/suppressor	I-cell_type
)	I-cell_type
,	O
CD68+	B-cell_type
(	O
macrophages	B-cell_type
)	O
,	O
mast	B-cell_type
cells	I-cell_type
,	O
eosinophils	B-cell_type
and	O
neutrophils	B-cell_type
were	O
all	O
clearly	O
detected	O
by	O
their	O
relevant	O
monoclonal	B-protein
antibodies	I-protein
or	O
appropriate	O
histochemical	O
staining	O
,	O
but	O
only	O
mast	B-cell_type
cells	I-cell_type
tested	O
positive	O
for	O
ER	B-protein
/PR	O
labelling	O
with	O
their	O
polyclonal	B-protein
and	I-protein
monoclonal	I-protein
antibodies	I-protein
.	O
<EOS>	B-X
Consistent	B-X
with	B-X
the	B-X
known	B-X
features	B-X
of	B-X
nasal	B-X
polyps	B-X
,	B-X
CD4+	B-X
(	B-X
T	B-X
helper	B-X
/	B-X
inducer	B-X
)	B-X
,	B-X
CD8+	B-X
(	B-X
cytotoxic	B-X
/	B-X
suppressor	B-X
)	B-X
,	B-X
CD68+	B-X
(	B-X
macrophages	B-X
)	B-X
,	B-X
mast	B-X
cells	B-X
,	B-X
eosinophils	B-X
and	B-X
neutrophils	B-X
were	B-X
all	B-X
clearly	B-X
detected	B-X
by	B-X
their	B-X
relevant	B-X
monoclonal	B-X
antibodies	B-X
or	B-X
appropriate	B-X
histochemical	B-X
staining	B-X
,	B-X
but	B-X
only	B-X
mast	B-X
cells	B-X
tested	B-X
positive	B-X
for	B-X
ER	B-X
/	B-X
PR	B-X
labelling	B-X
with	B-X
their	B-X
polyclonal	B-X
and	B-X
monoclonal	B-X
antibodies	B-X
<EOS>	B-X
Numerous	B-X
ER	B-X
/	B-X
PR	B-X
positive	B-X
mast	B-X
cells	B-X
exist	B-X
in	B-X
nasal	B-X
polyps	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
may	B-X
be	B-X
a	B-X
major	B-X
route	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
sex	B-X
hormones	B-X
in	B-X
airway	B-X
inflammation	B-X
when	B-X
exposed	B-X
to	B-X
the	B-X
higher	B-X
and	B-X
varying	B-X
concentration	B-X
of	B-X
oestrogen	B-X
and	B-X
progesterone	B-X
characteristic	B-X
of	B-X
females	B-X
<EOS>	B-X
Expression	B-X
of	B-X
oestrogen	B-X
and	B-X
progesterone	B-X
receptors	B-X
by	B-X
mast	B-X
cells	B-X
alone	B-X
,	B-X
but	B-X
not	B-X
lymphocytes	B-X
,	B-X
macrophages	B-X
or	B-X
other	B-X
immune	B-X
cells	B-X
in	B-X
human	B-X
upper	B-X
airways	B-X
.	B-X
<EOS>	B-X
A	B-X
potentially	B-X
important	B-X
role	B-X
for	B-X
ovarian	B-X
hormones	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
airway	B-X
inflammation	B-X
but	B-X
the	B-X
cellular	B-X
target	B-X
for	B-X
such	B-X
action	B-X
is	B-X
not	B-X
known	B-X

The	O
frequencies	O
for	O
expression	O
were	O
61.7	O
%	O
for	O
ER	B-cell_type
positive	I-cell_type
and	O
59.6	O
%	O
for	O
PR	B-cell_type
positive	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
frequencies	B-X
for	B-X
expression	B-X
were	B-X
61	B-X
<EOS>	B-X
Fewer	B-X
than	B-X
5	B-X
%	B-X
of	B-X
mast	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
negative	B-X
for	B-X
ER	B-X
/	B-X
PR	B-X
expression	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
ER	B-X
/	B-X
PR	B-X
was	B-X
independent	B-X
of	B-X
patient	B-X
sex	B-X
and	B-X
age	B-X
but	B-X
was	B-X
highly	B-X
correlated	B-X
with	B-X
the	B-X
numbers	B-X
of	B-X
mast	B-X
cells	B-X
(	B-X
r	B-X
=	B-X
0	B-X
<EOS>	B-X
7	B-X
%	B-X
for	B-X
ER	B-X
positive	B-X
and	B-X
59	B-X

The	O
expression	O
of	O
ER	B-protein
/	O
PR	B-protein
was	O
independent	O
of	O
patient	O
sex	O
and	O
age	O
but	O
was	O
highly	O
correlated	O
with	O
the	O
numbers	O
of	O
mast	B-cell_type
cells	I-cell_type
(	O
r	O
=	O
0.973	O
,	O
p	O
<	O
0.001	O
for	O
ER	B-protein
;	O
r	O
=	O
0.955	O
,	O
p	O
<	O
0.001	O
for	O
PR	B-protein
)	O
.	O

Fewer	O
than	O
5	O
%	O
of	O
mast	B-cell_type
cells	I-cell_type
were	O
found	O
to	O
be	O
negative	O
for	O
ER	B-protein
/	O
PR	B-protein
expression	O
.	O
<EOS>	B-X
Fewer	B-X
than	B-X
5	B-X
%	B-X
of	B-X
mast	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
be	B-X
negative	B-X
for	B-X
ER	B-X
/	B-X
PR	B-X
expression	B-X
<EOS>	B-X
A	B-X
potentially	B-X
important	B-X
role	B-X
for	B-X
ovarian	B-X
hormones	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
airway	B-X
inflammation	B-X
but	B-X
the	B-X
cellular	B-X
target	B-X
for	B-X
such	B-X
action	B-X
is	B-X
not	B-X
known	B-X
<EOS>	B-X
Expression	B-X
of	B-X
oestrogen	B-X
and	B-X
progesterone	B-X
receptors	B-X
by	B-X
mast	B-X
cells	B-X
alone	B-X
,	B-X
but	B-X
not	B-X
lymphocytes	B-X
,	B-X
macrophages	B-X
or	B-X
other	B-X
immune	B-X
cells	B-X
in	B-X
human	B-X
upper	B-X
airways	B-X
.	B-X
<EOS>	B-X
Mast	B-X
cells	B-X
alone	B-X
,	B-X
but	B-X
not	B-X
lymphocytes	B-X
,	B-X
macrophages	B-X
,	B-X
or	B-X
other	B-X
immune	B-X
cells	B-X
,	B-X
express	B-X
ER	B-X
/	B-X
PR	B-X
in	B-X
human	B-X
upper	B-X
airways	B-X

CONCLUSIONS	O
:	O
Mast	B-cell_type
cells	I-cell_type
alone	O
,	O
but	O
not	O
lymphocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
or	O
other	O
immune	B-cell_type
cells	I-cell_type
,	O
express	O
ER	B-protein
/	O
PR	B-protein
in	O
human	O
upper	O
airways	O
.	O
<EOS>	B-X
Total	B-X
mast	B-X
cells	B-X
and	B-X
tryptase	B-X
-	B-X
positive	B-X
mast	B-X
cells	B-X
counts	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
Group	B-X
R	B-X
than	B-X
in	B-X
all	B-X
other	B-X
groups	B-X
<EOS>	B-X
Serum	B-X
mouse	B-X
mast	B-X
cell	B-X
protease	B-X
1	B-X
level	B-X
was	B-X
used	B-X
to	B-X
measure	B-X
extent	B-X
of	B-X
mast	B-X
cell	B-X
degranulation	B-X
<EOS>	B-X
Mast	B-X
cells	B-X
contribute	B-X
to	B-X
the	B-X
resolution	B-X
of	B-X
allergic	B-X
inflammation	B-X
by	B-X
releasing	B-X
resolvin	B-X
D1	B-X
.	B-X
<EOS>	B-X
BALF	B-X
mast	B-X
cell	B-X
proportions	B-X
increased	B-X
with	B-X
increasing	B-X
TNF	B-X
-	B-X
α	B-X
gene	B-X
expression	B-X
in	B-X
post	B-X
-	B-X
race	B-X
blood	B-X
(	B-X
p	B-X
=	B-X
0	B-X

Numerous	O
ER/PR	B-cell_type
positive	I-cell_type
mast	I-cell_type
cells	I-cell_type
exist	O
in	O
nasal	O
polyps	O
,	O
indicating	O
that	O
this	O
may	O
be	O
a	O
major	O
route	O
for	O
the	O
involvement	O
of	O
sex	O
hormones	O
in	O
airway	O
inflammation	O
when	O
exposed	O
to	O
the	O
higher	O
and	O
varying	O
concentration	O
of	O
oestrogen	O
and	O
progesterone	O
characteristic	O
of	O
females	O
.	O

NF	O
kappa	O
b	O
signaling	O
in	O
posthypoxic	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
:	O
relevance	O
to	O
E-selectin	O
expression	O
and	O
neutrophil	O
adhesion	O
.	O
<EOS>	B-X
NF	B-X
kappa	B-X
b	B-X
signaling	B-X
in	B-X
posthypoxic	B-X
endothelial	B-X
cells	B-X
:	B-X
relevance	B-X
to	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
adhesion	B-X
.	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
-	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
were	B-X
blocked	B-X
by	B-X
inhibition	B-X
of	B-X
PKC	B-X
or	B-X
PTK	B-X
,	B-X
while	B-X
only	B-X
PTK	B-X
inhibited	B-X
the	B-X
redox	B-X
-	B-X
induced	B-X
adhesion	B-X
response	B-X
<EOS>	B-X
Pretreatment	B-X
of	B-X
cells	B-X
with	B-X
N	B-X
-	B-X
acetyl	B-X
cysteine	B-X
effectively	B-X
blocked	B-X
A	B-X
/	B-X
R	B-X
-	B-X
	B-X
or	B-X
redox	B-X
-	B-X
induced	B-X
I	B-X
kappa	B-X
B	B-X
degradation	B-X
and	B-X
significantly	B-X
attenuated	B-X
the	B-X
respective	B-X
neutrophil	B-X
adhesion	B-X
responses	B-X
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
-	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
are	B-X
mediated	B-X
by	B-X
both	B-X
PKC	B-X
and	B-X
PTK	B-X
,	B-X
which	B-X
signal	B-X
rapid	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X

Our	O
previous	O
studies	O
have	O
implicated	O
the	O
nuclear	O
transcription	O
factor	O
kappa	O
B	O
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
in	O
the	O
regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
exposed	O
to	O
anoxia-reoxygenation	O
(	O
A/R	O
)	O
or	O
a	O
redox	O
imbalance	O
.	O
<EOS>	B-X
Oxidative	B-X
stress	B-X
is	B-X
the	B-X
result	B-X
of	B-X
an	B-X
imbalance	B-X
between	B-X
the	B-X
formation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
enzymatic	B-X
and	B-X
non	B-X
-	B-X
enzymatic	B-X
antioxidants	B-X
<EOS>	B-X
Numerous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
oxidative	B-X
stress	B-X
resulting	B-X
from	B-X
an	B-X
imbalance	B-X
between	B-X
the	B-X
production	B-X
of	B-X
free	B-X
radicals	B-X
and	B-X
their	B-X
neutralization	B-X
by	B-X
antioxidant	B-X
enzymes	B-X
is	B-X
one	B-X
of	B-X
the	B-X
major	B-X
pathological	B-X
disorders	B-X
underlying	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
type	B-X
2	B-X
diabetes	B-X
(	B-X
T2D	B-X
)	B-X
<EOS>	B-X
Drastic	B-X
surges	B-X
in	B-X
intracellular	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
induce	B-X
cell	B-X
apoptosis	B-X
,	B-X
while	B-X
most	B-X
chemotherapy	B-X
drugs	B-X
lead	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
ROS	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
we	B-X
have	B-X
highlighted	B-X
the	B-X
pathological	B-X
mechanisms	B-X
of	B-X
ROS	B-X
in	B-X
ovarian	B-X
diseases	B-X
and	B-X
potential	B-X
antioxidant	B-X
strategies	B-X
for	B-X
treatment	B-X

The	O
objectives	O
of	O
this	O
study	O
were	O
(	O
1	O
)	O
to	O
define	O
the	O
kinetics	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
by	O
examining	O
I	O
kappa	O
B	O
alpha	O
degradation	O
and	O
the	O
nuclear	O
translocation	O
of	O
p65	B-protein
in	O
response	O
to	O
A/R	O
or	O
redox	O
imbalance	O
(	O
induced	O
by	O
treatment	O
of	O
cells	O
with	O
diamide	O
and	O
buthionine	O
sulfoximine	O
)	O
and	O
(	O
2	O
)	O
to	O
determine	O
whether	O
the	O
signal	O
for	O
I	O
kappa	O
B	O
alpha	O
degradation	O
,	O
nuclear	O
translocation	O
of	O
p65	B-protein
,	O
and	O
E-selectin	B-protein
-mediated	O
neutrophil	O
adhesion	O
is	O
related	O
to	O
the	O
activity	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
,	O
protein	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
PTPase	B-protein
)	O
and/or	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
also	B-X
indicate	B-X
a	B-X
potential	B-X
mechanism	B-X
of	B-X
clinical	B-X
cardiac	B-X
dysfunction	B-X
in	B-X
sepsis	B-X
and	B-X
other	B-X
critical	B-X
illnesses	B-X
with	B-X
high	B-X
levels	B-X
of	B-X
circulating	B-X
histones	B-X
,	B-X
which	B-X
holds	B-X
the	B-X
potential	B-X
translational	B-X
benefit	B-X
to	B-X
these	B-X
patients	B-X
by	B-X
targeting	B-X
circulating	B-X
histones	B-X
and	B-X
downstream	B-X
pathways	B-X
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
using	B-X
cultured	B-X
cardiomyocytes	B-X
and	B-X
a	B-X
histone	B-X
infusion	B-X
mouse	B-X
model	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
clinically	B-X
relevant	B-X
histone	B-X
concentrations	B-X
cause	B-X
significant	B-X
increases	B-X
in	B-X
intracellular	B-X
calcium	B-X
concentrations	B-X
with	B-X
subsequent	B-X
activation	B-X
and	B-X
enriched	B-X
localization	B-X
of	B-X
calcium	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
α	B-X
and	B-X
βII	B-X
into	B-X
the	B-X
myofilament	B-X
fraction	B-X
of	B-X
cardiomyocytes	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
significantly	B-X
regulated	B-X
signatures	B-X
were	B-X
involved	B-X
in	B-X
overlapping	B-X
pathways	B-X
at	B-X
metabolic	B-X
and	B-X
transcriptomic	B-X
levels	B-X
,	B-X
including	B-X
ROS	B-X
response	B-X
and	B-X
metabolism	B-X
,	B-X
fatty	B-X
acid	B-X
transport	B-X
and	B-X
metabolism	B-X
,	B-X
glucose	B-X
response	B-X
and	B-X
metabolism	B-X
,	B-X
mitochondrial	B-X
transport	B-X
and	B-X
respiratory	B-X
chain	B-X
complex	B-X
,	B-X
one	B-X
-	B-X
carbon	B-X
metabolism	B-X
,	B-X
amino	B-X
acid	B-X
transport	B-X
and	B-X
metabolism	B-X
,	B-X
and	B-X
glutaminolysis	B-X
,	B-X
which	B-X
are	B-X
directly	B-X
or	B-X
indirectly	B-X
linked	B-X
to	B-X
ROS	B-X
production	B-X
<EOS>	B-X
The	B-X
protein	B-X
expression	B-X
or	B-X
phosphorylation	B-X
of	B-X
OGT	B-X
,	B-X
O	B-X
-	B-X
GlcNAc	B-X
,	B-X
Akt	B-X
,	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
,	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
p38MAPK	B-X
)	B-X
,	B-X
nuclear	B-X
factor	B-X
-	B-X
κB	B-X
p65	B-X
(	B-X
NF	B-X
-	B-X
κB	B-X
p65	B-X
)	B-X
,	B-X
and	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
were	B-X
determined	B-X
by	B-X
Western	B-X
blotting	B-X

The	O
results	O
demonstrate	O
that	O
both	O
A/R	O
and	O
redox	O
imbalance	O
led	O
to	O
I	O
kappa	O
B	O
alpha	O
degradation	O
within	O
30	O
min	O
and	O
the	O
concomitant	O
appearance	O
of	O
p65	B-protein
in	O
the	O
nucleus	O
,	O
consistent	O
with	O
rapid	O
cytosolic	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
subsequent	O
nuclear	O
translocation	O
of	O
the	O
activated	B-protein
p65	I-protein
subunit	I-protein
.	O
<EOS>	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
both	B-X
A	B-X
/	B-X
R	B-X
and	B-X
redox	B-X
imbalance	B-X
led	B-X
to	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
within	B-X
30	B-X
min	B-X
and	B-X
the	B-X
concomitant	B-X
appearance	B-X
of	B-X
p65	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
consistent	B-X
with	B-X
rapid	B-X
cytosolic	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
of	B-X
the	B-X
activated	B-X
p65	B-X
subunit	B-X
<EOS>	B-X
The	B-X
objectives	B-X
of	B-X
this	B-X
study	B-X
were	B-X
(	B-X
1	B-X
)	B-X
to	B-X
define	B-X
the	B-X
kinetics	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
by	B-X
examining	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
and	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
p65	B-X
in	B-X
response	B-X
to	B-X
A	B-X
/	B-X
R	B-X
or	B-X
redox	B-X
imbalance	B-X
(	B-X
induced	B-X
by	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
diamide	B-X
and	B-X
buthionine	B-X
sulfoximine	B-X
)	B-X
and	B-X
(	B-X
2	B-X
)	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
signal	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
,	B-X
nuclear	B-X
translocation	B-X
of	B-X
p65	B-X
,	B-X
and	B-X
E	B-X
-	B-X
selectin	B-X
-	B-X
mediated	B-X
neutrophil	B-X
adhesion	B-X
is	B-X
related	B-X
to	B-X
the	B-X
activity	B-X
of	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
(	B-X
PTK	B-X
)	B-X
,	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
PTPase	B-X
)	B-X
and	B-X
/	B-X
or	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
PKC	B-X
blocked	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
and	B-X
p65	B-X
translocation	B-X
in	B-X
A	B-X
/	B-X
R	B-X
-	B-X
challenged	B-X
,	B-X
but	B-X
not	B-X
redox	B-X
-	B-X
altered	B-X
,	B-X
endothelial	B-X
cells	B-X
<EOS>	B-X
Our	B-X
previous	B-X
studies	B-X
have	B-X
implicated	B-X
the	B-X
nuclear	B-X
transcription	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
kappa	B-X
B	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adhesion	B-X
molecule	B-X
expression	B-X
in	B-X
endothelial	B-X
cells	B-X
exposed	B-X
to	B-X
anoxia	B-X
-	B-X
reoxygenation	B-X
(	B-X
A	B-X
/	B-X
R	B-X
)	B-X
or	B-X
a	B-X
redox	B-X
imbalance	B-X

Inhibition	O
of	O
PKC	B-protein
blocked	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
and	O
p65	B-protein
translocation	O
in	O
A/R-challenged	O
,	O
but	O
not	O
redox-altered	O
,	O
endothelial	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
both	O
A/R-	O
and	O
redox-induced	O
NF	O
kappa	O
B	O
activation	O
was	O
blocked	O
by	O
inhibition	O
of	O
PTK	B-protein
.	O
<EOS>	B-X
However	B-X
,	B-X
both	B-X
A	B-X
/	B-X
R	B-X
-	B-X
	B-X
and	B-X
redox	B-X
-	B-X
induced	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
was	B-X
blocked	B-X
by	B-X
inhibition	B-X
of	B-X
PTK	B-X
<EOS>	B-X
Pretreatment	B-X
of	B-X
cells	B-X
with	B-X
N	B-X
-	B-X
acetyl	B-X
cysteine	B-X
effectively	B-X
blocked	B-X
A	B-X
/	B-X
R	B-X
-	B-X
	B-X
or	B-X
redox	B-X
-	B-X
induced	B-X
I	B-X
kappa	B-X
B	B-X
degradation	B-X
and	B-X
significantly	B-X
attenuated	B-X
the	B-X
respective	B-X
neutrophil	B-X
adhesion	B-X
responses	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
-	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
were	B-X
blocked	B-X
by	B-X
inhibition	B-X
of	B-X
PKC	B-X
or	B-X
PTK	B-X
,	B-X
while	B-X
only	B-X
PTK	B-X
inhibited	B-X
the	B-X
redox	B-X
-	B-X
induced	B-X
adhesion	B-X
response	B-X
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
-	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
are	B-X
mediated	B-X
by	B-X
both	B-X
PKC	B-X
and	B-X
PTK	B-X
,	B-X
which	B-X
signal	B-X
rapid	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X

Similarly	O
,	O
A/R-induced	O
E-selectin	O
expression	O
and	O
neutrophil-endothelial	O
cell	O
adhesion	O
were	O
blocked	O
by	O
inhibition	O
of	O
PKC	B-protein
or	O
PTK	B-protein
,	O
while	O
only	O
PTK	B-protein
inhibited	O
the	O
redox-induced	O
adhesion	O
response	O
.	O
<EOS>	B-X
Similarly	B-X
,	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
-	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
were	B-X
blocked	B-X
by	B-X
inhibition	B-X
of	B-X
PKC	B-X
or	B-X
PTK	B-X
,	B-X
while	B-X
only	B-X
PTK	B-X
inhibited	B-X
the	B-X
redox	B-X
-	B-X
induced	B-X
adhesion	B-X
response	B-X
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
-	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
are	B-X
mediated	B-X
by	B-X
both	B-X
PKC	B-X
and	B-X
PTK	B-X
,	B-X
which	B-X
signal	B-X
rapid	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
<EOS>	B-X
NF	B-X
kappa	B-X
b	B-X
signaling	B-X
in	B-X
posthypoxic	B-X
endothelial	B-X
cells	B-X
:	B-X
relevance	B-X
to	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
adhesion	B-X
.	B-X
<EOS>	B-X
This	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
NF	B-X
kappa	B-X
B	B-X
signaling	B-X
response	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
intracellular	B-X
redox	B-X
imbalance	B-X

Pretreatment	O
of	O
cells	O
with	O
N-acetyl	O
cysteine	O
effectively	O
blocked	O
A/R-	O
or	O
redox-induced	O
I	O
kappa	O
B	O
degradation	O
and	O
significantly	O
attenuated	O
the	O
respective	O
neutrophil	O
adhesion	O
responses	O
.	O
<EOS>	B-X
Pretreatment	B-X
of	B-X
cells	B-X
with	B-X
N	B-X
-	B-X
acetyl	B-X
cysteine	B-X
effectively	B-X
blocked	B-X
A	B-X
/	B-X
R	B-X
-	B-X
	B-X
or	B-X
redox	B-X
-	B-X
induced	B-X
I	B-X
kappa	B-X
B	B-X
degradation	B-X
and	B-X
significantly	B-X
attenuated	B-X
the	B-X
respective	B-X
neutrophil	B-X
adhesion	B-X
responses	B-X
<EOS>	B-X
However	B-X
,	B-X
both	B-X
A	B-X
/	B-X
R	B-X
-	B-X
	B-X
and	B-X
redox	B-X
-	B-X
induced	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
was	B-X
blocked	B-X
by	B-X
inhibition	B-X
of	B-X
PTK	B-X
<EOS>	B-X
Pretreatment	B-X
with	B-X
SYA	B-X
(	B-X
40	B-X
,	B-X
60	B-X
and	B-X
80	B-X
nmol	B-X
/	B-X
L	B-X
)	B-X
concentration	B-X
-	B-X
dependently	B-X
blocked	B-X
the	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
changes	B-X
in	B-X
the	B-X
cardiomyocytes	B-X
<EOS>	B-X
NF	B-X
kappa	B-X
b	B-X
signaling	B-X
in	B-X
posthypoxic	B-X
endothelial	B-X
cells	B-X
:	B-X
relevance	B-X
to	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
adhesion	B-X
.	B-X

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R-induced	O
E-selectin	O
expression	O
and	O
neutrophil-endothelial	O
cell	O
adhesion	O
are	O
mediated	O
by	O
both	O
PKC	B-protein
and	O
PTK	B-protein
,	O
which	O
signal	O
rapid	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
-	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
are	B-X
mediated	B-X
by	B-X
both	B-X
PKC	B-X
and	B-X
PTK	B-X
,	B-X
which	B-X
signal	B-X
rapid	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
-	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
were	B-X
blocked	B-X
by	B-X
inhibition	B-X
of	B-X
PKC	B-X
or	B-X
PTK	B-X
,	B-X
while	B-X
only	B-X
PTK	B-X
inhibited	B-X
the	B-X
redox	B-X
-	B-X
induced	B-X
adhesion	B-X
response	B-X
<EOS>	B-X
This	B-X
A	B-X
/	B-X
R	B-X
-	B-X
induced	B-X
NF	B-X
kappa	B-X
B	B-X
signaling	B-X
response	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
intracellular	B-X
redox	B-X
imbalance	B-X
<EOS>	B-X
NF	B-X
kappa	B-X
b	B-X
signaling	B-X
in	B-X
posthypoxic	B-X
endothelial	B-X
cells	B-X
:	B-X
relevance	B-X
to	B-X
E	B-X
-	B-X
selectin	B-X
expression	B-X
and	B-X
neutrophil	B-X
adhesion	B-X
.	B-X

This	O
A/R-induced	O
NF	B-protein
kappa	I-protein
B	I-protein
signaling	O
response	O
appears	O
to	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
intracellular	O
redox	O
imbalance	O
.	O

Induction	O
of	O
apoptosis	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
by	O
the	O
herbicide	O
2	O
,	O
4-dichlorophenoxyacetic	O
acid	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
apoptosis	B-X
in	B-X
human	B-X
lymphocytes	B-X
by	B-X
the	B-X
herbicide	B-X
2,4	B-X
-	B-X
dichlorophenoxyacetic	B-X
acid	B-X
.	B-X
<EOS>	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
kills	B-X
human	B-X
lymphocytes	B-X
by	B-X
initiating	B-X
apoptosis	B-X
via	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
mitochondria	B-X
<EOS>	B-X
The	B-X
phases	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
were	B-X
determined	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
and	B-X
necrosis	B-X
was	B-X
demonstrated	B-X
by	B-X
annexin	B-X
binding	B-X
,	B-X
analysis	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
and	B-X
DNA	B-X
strand	B-X
breaks	B-X
<EOS>	B-X
Aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
suitability	B-X
of	B-X
flow	B-X
cytometry	B-X
for	B-X
the	B-X
determination	B-X
of	B-X
cytotoxicity	B-X
of	B-X
test	B-X
chemicals	B-X

Dimethylammonium	O
salt	O
of	O
2	O
,	O
4-dichlorophenoxyacetic	O
acid	O
(	O
DMA-2	O
,	O
4-D	O
)	O
is	O
a	O
widely	O
used	O
herbicide	O
that	O
is	O
considered	O
moderately	O
toxic	O
.	O
<EOS>	B-X
Dimethylammonium	B-X
salt	B-X
of	B-X
2,4	B-X
-	B-X
dichlorophenoxyacetic	B-X
acid	B-X
(	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
)	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
herbicide	B-X
that	B-X
is	B-X
considered	B-X
moderately	B-X
toxic	B-X
<EOS>	B-X
Induction	B-X
of	B-X
apoptosis	B-X
in	B-X
human	B-X
lymphocytes	B-X
by	B-X
the	B-X
herbicide	B-X
2,4	B-X
-	B-X
dichlorophenoxyacetic	B-X
acid	B-X
.	B-X
<EOS>	B-X
ZVAD	B-X
-	B-X
FMK	B-X
,	B-X
a	B-X
broad	B-X
-	B-X
spectrum	B-X
inhibitor	B-X
of	B-X
caspases	B-X
,	B-X
blocked	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
completely	B-X
<EOS>	B-X
While	B-X
an	B-X
inhibitor	B-X
of	B-X
caspase	B-X
-	B-X
9	B-X
,	B-X
as	B-X
well	B-X
as	B-X
caspase	B-X
-	B-X
9	B-X
and	B-X
caspase	B-X
-	B-X
3	B-X
inhibitors	B-X
in	B-X
combination	B-X
,	B-X
strongly	B-X
blocked	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
caspase	B-X
-	B-X
3	B-X
had	B-X
a	B-X
moderate	B-X
inhibitory	B-X
effect	B-X

In	O
the	O
present	O
study	O
we	O
found	O
that	O
DMA-2	O
,	O
4-D	O
is	O
able	O
to	O
cause	O
apoptosis	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
healthy	O
individuals	O
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Apoptosis	O
induced	O
by	O
DMA-2	O
,	O
4-D	O
was	O
dose	O
and	O
time	O
dependent	O
,	O
independent	O
of	O
Fas	B-protein
,	O
TNF	B-protein
receptor	I-protein
1	I-protein
or	O
the	O
aromatic	B-protein
hydrocarbon	I-protein
receptor	I-protein
,	O
and	O
involved	O
disruption	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
activation	O
of	O
caspase-9	B-protein
.	O
<EOS>	B-X
Apoptosis	B-X
induced	B-X
by	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
was	B-X
dose	B-X
and	B-X
time	B-X
dependent	B-X
,	B-X
independent	B-X
of	B-X
Fas	B-X
,	B-X
TNF	B-X
receptor	B-X
1	B-X
or	B-X
the	B-X
aromatic	B-X
hydrocarbon	B-X
receptor	B-X
,	B-X
and	B-X
involved	B-X
disruption	B-X
of	B-X
the	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
and	B-X
activation	B-X
of	B-X
caspase	B-X
-	B-X
9	B-X
<EOS>	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
Bcl	B-X
-	B-X
2	B-X
prevented	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
disruption	B-X
of	B-X
the	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
and	B-X
led	B-X
to	B-X
a	B-X
complete	B-X
blockage	B-X
of	B-X
apoptosis	B-X
<EOS>	B-X
Cell	B-X
death	B-X
was	B-X
accompanied	B-X
by	B-X
plasma	B-X
-	B-X
membrane	B-X
disruption	B-X
,	B-X
loss	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
-	B-X
potential	B-X
and	B-X
caspase	B-X
-	B-X
9	B-X
/	B-X
caspase	B-X
-	B-X
3	B-X
activation	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
NFD	B-X
treatment	B-X
disrupted	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
(	B-X
DeltaPsim	B-X
)	B-X
and	B-X
resulted	B-X
in	B-X
release	B-X
of	B-X
mitochondrial	B-X
cytochrome	B-X
c	B-X
and	B-X
activation	B-X
of	B-X
both	B-X
caspases	B-X
-	B-X
9	B-X
and	B-X
caspase	B-X
-	B-X
3	B-X

ZVAD-FMK	O
,	O
a	O
broad-spectrum	O
inhibitor	O
of	O
caspases	B-protein
,	O
blocked	O
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
completely	O
.	O
<EOS>	B-X
ZVAD	B-X
-	B-X
FMK	B-X
,	B-X
a	B-X
broad	B-X
-	B-X
spectrum	B-X
inhibitor	B-X
of	B-X
caspases	B-X
,	B-X
blocked	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
completely	B-X
<EOS>	B-X
Unlike	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
,	B-X
the	B-X
initiator	B-X
caspase	B-X
,	B-X
caspase	B-X
-	B-X
8	B-X
,	B-X
was	B-X
not	B-X
involved	B-X
in	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
<EOS>	B-X
While	B-X
an	B-X
inhibitor	B-X
of	B-X
caspase	B-X
-	B-X
9	B-X
,	B-X
as	B-X
well	B-X
as	B-X
caspase	B-X
-	B-X
9	B-X
and	B-X
caspase	B-X
-	B-X
3	B-X
inhibitors	B-X
in	B-X
combination	B-X
,	B-X
strongly	B-X
blocked	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
caspase	B-X
-	B-X
3	B-X
had	B-X
a	B-X
moderate	B-X
inhibitory	B-X
effect	B-X
<EOS>	B-X
Dimethylammonium	B-X
salt	B-X
of	B-X
2,4	B-X
-	B-X
dichlorophenoxyacetic	B-X
acid	B-X
(	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
)	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
herbicide	B-X
that	B-X
is	B-X
considered	B-X
moderately	B-X
toxic	B-X

While	O
an	O
inhibitor	O
of	O
caspase-9	B-protein
,	O
as	O
well	O
as	O
caspase-9	B-protein
and	O
caspase-3	O
inhibitors	O
in	O
combination	O
,	O
strongly	O
blocked	O
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
,	O
an	O
inhibitor	O
of	O
caspase-3	B-protein
had	O
a	O
moderate	O
inhibitory	O
effect	O
.	O
<EOS>	B-X
While	B-X
an	B-X
inhibitor	B-X
of	B-X
caspase	B-X
-	B-X
9	B-X
,	B-X
as	B-X
well	B-X
as	B-X
caspase	B-X
-	B-X
9	B-X
and	B-X
caspase	B-X
-	B-X
3	B-X
inhibitors	B-X
in	B-X
combination	B-X
,	B-X
strongly	B-X
blocked	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
caspase	B-X
-	B-X
3	B-X
had	B-X
a	B-X
moderate	B-X
inhibitory	B-X
effect	B-X
<EOS>	B-X
ZVAD	B-X
-	B-X
FMK	B-X
,	B-X
a	B-X
broad	B-X
-	B-X
spectrum	B-X
inhibitor	B-X
of	B-X
caspases	B-X
,	B-X
blocked	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
completely	B-X
<EOS>	B-X
Unlike	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
,	B-X
the	B-X
initiator	B-X
caspase	B-X
,	B-X
caspase	B-X
-	B-X
8	B-X
,	B-X
was	B-X
not	B-X
involved	B-X
in	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
<EOS>	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
kills	B-X
human	B-X
lymphocytes	B-X
by	B-X
initiating	B-X
apoptosis	B-X
via	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
mitochondria	B-X

Unlike	O
Fas	B-protein
-mediated	O
apoptosis	O
,	O
the	O
initiator	B-protein
caspase	I-protein
,	O
caspase-8	B-protein
,	O
was	O
not	O
involved	O
in	O
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
.	O
<EOS>	B-X
suis	B-X
strain	B-X
VTRS1	B-X
induces	B-X
a	B-X
caspase	B-X
-	B-X
2	B-X
-	B-X
mediated	B-X
and	B-X
caspase	B-X
-	B-X
1	B-X
-	B-X
independent	B-X
proinflammatory	B-X
cell	B-X
death	B-X
in	B-X
infected	B-X
macrophages	B-X
,	B-X
which	B-X
was	B-X
tentatively	B-X
coined	B-X
``	B-X
caspase	B-X
-	B-X
2	B-X
-	B-X
mediated	B-X
pyroptosis	B-X
''	B-X
<EOS>	B-X
Anti	B-X
-	B-X
apoptotic	B-X
effects	B-X
of	B-X
caspase	B-X
inhibitors	B-X
on	B-X
rat	B-X
intervertebral	B-X
disc	B-X
cells	B-X
.	B-X
<EOS>	B-X
Two	B-X
main	B-X
pathways	B-X
of	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
have	B-X
been	B-X
identified	B-X
:	B-X
Type	B-X
I	B-X
,	B-X
which	B-X
is	B-X
the	B-X
death	B-X
-	B-X
inducing	B-X
signaling	B-X
complex	B-X
pathway	B-X
,	B-X
and	B-X
Type	B-X
II	B-X
,	B-X
which	B-X
is	B-X
the	B-X
mitochondrial	B-X
pathway	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
apoptosis	B-X
of	B-X
intervertebral	B-X
disc	B-X
cells	B-X
can	B-X
be	B-X
attenuated	B-X
by	B-X
caspase	B-X
inhibitors	B-X

Transfection	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
Bcl-2	B-protein
prevented	O
DMA-2	O
,	O
4-D-induced	O
disruption	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
led	O
to	O
a	O
complete	O
blockage	O
of	O
apoptosis	O
.	O
<EOS>	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
Bcl	B-X
-	B-X
2	B-X
prevented	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
disruption	B-X
of	B-X
the	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
and	B-X
led	B-X
to	B-X
a	B-X
complete	B-X
blockage	B-X
of	B-X
apoptosis	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
caspases	B-X
occurs	B-X
downstream	B-X
of	B-X
mitochondrial	B-X
damage	B-X
,	B-X
and	B-X
the	B-X
dysfunction	B-X
of	B-X
mitochondria	B-X
appears	B-X
to	B-X
be	B-X
sufficient	B-X
for	B-X
triggering	B-X
all	B-X
downstream	B-X
events	B-X
leading	B-X
to	B-X
apoptosis	B-X
<EOS>	B-X
Apoptosis	B-X
induced	B-X
by	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
was	B-X
dose	B-X
and	B-X
time	B-X
dependent	B-X
,	B-X
independent	B-X
of	B-X
Fas	B-X
,	B-X
TNF	B-X
receptor	B-X
1	B-X
or	B-X
the	B-X
aromatic	B-X
hydrocarbon	B-X
receptor	B-X
,	B-X
and	B-X
involved	B-X
disruption	B-X
of	B-X
the	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
and	B-X
activation	B-X
of	B-X
caspase	B-X
-	B-X
9	B-X
<EOS>	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
kills	B-X
human	B-X
lymphocytes	B-X
by	B-X
initiating	B-X
apoptosis	B-X
via	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
mitochondria	B-X

Our	O
data	O
indicate	O
that	O
DMA-2	O
,	O
4-D	O
kills	O
human	B-cell_type
lymphocytes	I-cell_type
by	O
initiating	O
apoptosis	O
via	O
a	O
direct	O
effect	O
on	O
mitochondria	O
.	O

The	O
activation	O
of	O
caspases	B-protein
occurs	O
downstream	O
of	O
mitochondrial	O
damage	O
,	O
and	O
the	O
dysfunction	O
of	O
mitochondria	O
appears	O
to	O
be	O
sufficient	O
for	O
triggering	O
all	O
downstream	O
events	O
leading	O
to	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
caspases	B-X
occurs	B-X
downstream	B-X
of	B-X
mitochondrial	B-X
damage	B-X
,	B-X
and	B-X
the	B-X
dysfunction	B-X
of	B-X
mitochondria	B-X
appears	B-X
to	B-X
be	B-X
sufficient	B-X
for	B-X
triggering	B-X
all	B-X
downstream	B-X
events	B-X
leading	B-X
to	B-X
apoptosis	B-X
<EOS>	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
Bcl	B-X
-	B-X
2	B-X
prevented	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
disruption	B-X
of	B-X
the	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
and	B-X
led	B-X
to	B-X
a	B-X
complete	B-X
blockage	B-X
of	B-X
apoptosis	B-X
<EOS>	B-X
Unlike	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
,	B-X
the	B-X
initiator	B-X
caspase	B-X
,	B-X
caspase	B-X
-	B-X
8	B-X
,	B-X
was	B-X
not	B-X
involved	B-X
in	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
-	B-X
induced	B-X
apoptosis	B-X
<EOS>	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
DMA	B-X
-	B-X
2,4	B-X
-	B-X
D	B-X
kills	B-X
human	B-X
lymphocytes	B-X
by	B-X
initiating	B-X
apoptosis	B-X
via	B-X
a	B-X
direct	B-X
effect	B-X
on	B-X
mitochondria	B-X

Inhibition	O
of	O
Th1	O
differentiation	O
by	O
IL-6	B-protein
is	O
mediated	O
by	O
SOCS1	B-protein
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
is	B-X
mediated	B-X
by	B-X
SOCS1	B-X
.	B-X
<EOS>	B-X
Suppression	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
TGF	B-X
-	B-X
beta	B-X
was	B-X
impaired	B-X
in	B-X
SOCS1	B-X
-	B-X
deficient	B-X
T	B-X
cells	B-X
<EOS>	B-X
While	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
directed	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
is	B-X
mediated	B-X
by	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
inhibition	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
is	B-X
independent	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
Thus	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
promotes	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
and	B-X
inhibits	B-X
Th1	B-X
differentiation	B-X
by	B-X
two	B-X
independent	B-X
molecular	B-X
mechanisms	B-X

Interleukin	B-protein
6	I-protein
(	O
IL-6	B-protein
)	O
is	O
a	O
cytokine	B-protein
produced	O
by	O
immune	B-cell_type
and	I-cell_type
nonimmune	I-cell_type
cells	I-cell_type
and	O
exhibits	O
functional	O
pleiotropy	O
and	O
redundancy	O
.	O
<EOS>	B-X
Interleukin	B-X
6	B-X
(	B-X
IL	B-X
-	B-X
6	B-X
)	B-X
is	B-X
a	B-X
cytokine	B-X
produced	B-X
by	B-X
immune	B-X
and	B-X
nonimmune	B-X
cells	B-X
and	B-X
exhibits	B-X
functional	B-X
pleiotropy	B-X
and	B-X
redundancy	B-X
<EOS>	B-X
IL	B-X
-	B-X
6	B-X
upregulates	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
(	B-X
SOCS1	B-X
)	B-X
expression	B-X
in	B-X
activated	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
thereby	B-X
interfering	B-X
with	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
1	B-X
(	B-X
STAT1	B-X
)	B-X
phosphorylation	B-X
induced	B-X
by	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNgamma	B-X
)	B-X
<EOS>	B-X
IL	B-X
-	B-X
6	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
several	B-X
cell	B-X
types	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
IFNgamma	B-X
receptor	B-X
-	B-X
mediated	B-X
signals	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
prevents	B-X
autoregulation	B-X
of	B-X
IFNgamma	B-X
gene	B-X
expression	B-X
by	B-X
IFNgamma	B-X
during	B-X
CD4+	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
thereby	B-X
preventing	B-X
Th1	B-X
differentiation	B-X

IL-6	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O
<EOS>	B-X
SOST	B-X
/	B-X
sclerostin	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
mutual	B-X
cell	B-X
interaction	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
κB	B-X
pathway	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
inflammatory	B-X
process	B-X
and	B-X
is	B-X
activated	B-X
in	B-X
OA	B-X
<EOS>	B-X
Notch	B-X
signaling	B-X
pathway	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
cellular	B-X
fate	B-X
across	B-X
species	B-X
,	B-X
being	B-X
important	B-X
for	B-X
the	B-X
differentiation	B-X
and	B-X
development	B-X
of	B-X
several	B-X
cell	B-X
types	B-X
<EOS>	B-X
B	B-X
cell	B-X
activating	B-X
factor	B-X
(	B-X
BAFF	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
antibody	B-X
production	B-X
through	B-X
differentiation	B-X
and	B-X
maturation	B-X
of	B-X
B	B-X
cells	B-X
mainly	B-X
in	B-X
secondary	B-X
lymphoid	B-X
organs	B-X

Here	O
,	O
we	O
describe	O
a	O
novel	O
function	O
of	O
IL-6	B-protein
:	O
the	O
negative	O
regulation	O
of	O
CD4	B-protein
+	O
Th1	O
cell	O
differentiation	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
novel	B-X
function	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
:	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
CD4+	B-X
Th1	B-X
cell	B-X
differentiation	B-X
<EOS>	B-X
IL	B-X
-	B-X
6	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
several	B-X
cell	B-X
types	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
IFNgamma	B-X
receptor	B-X
-	B-X
mediated	B-X
signals	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
prevents	B-X
autoregulation	B-X
of	B-X
IFNgamma	B-X
gene	B-X
expression	B-X
by	B-X
IFNgamma	B-X
during	B-X
CD4+	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
thereby	B-X
preventing	B-X
Th1	B-X
differentiation	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
is	B-X
mediated	B-X
by	B-X
SOCS1	B-X
.	B-X

While	O
IL-6	B-protein
-directed	O
CD4	B-protein
+	O
Th2	O
differentiation	O
is	O
mediated	O
by	O
IL-4	B-protein
,	O
inhibition	O
of	O
Th1	O
differentiation	O
by	O
IL-6	B-protein
is	O
independent	O
of	O
IL-4	B-protein
.	O
<EOS>	B-X
While	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
directed	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
is	B-X
mediated	B-X
by	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
inhibition	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
is	B-X
independent	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
Thus	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
promotes	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
and	B-X
inhibits	B-X
Th1	B-X
differentiation	B-X
by	B-X
two	B-X
independent	B-X
molecular	B-X
mechanisms	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
is	B-X
mediated	B-X
by	B-X
SOCS1	B-X
.	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
human	B-X
Th9	B-X
differentiation	B-X
by	B-X
type	B-X
I	B-X
interferons	B-X
and	B-X
IL	B-X
-	B-X
21	B-X
.	B-X

IL-6	B-protein
upregulates	O
suppressor	B-protein
of	I-protein
cytokine	I-protein
signaling	I-protein
1	I-protein
(	O
SOCS1	B-protein
)	O
expression	O
in	O
activated	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
thereby	O
interfering	O
with	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
1	I-protein
(	O
STAT1	B-protein
)	O
phosphorylation	O
induced	O
by	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
.	O
<EOS>	B-X
IL	B-X
-	B-X
6	B-X
upregulates	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
(	B-X
SOCS1	B-X
)	B-X
expression	B-X
in	B-X
activated	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
thereby	B-X
interfering	B-X
with	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
1	B-X
(	B-X
STAT1	B-X
)	B-X
phosphorylation	B-X
induced	B-X
by	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNgamma	B-X
)	B-X
<EOS>	B-X
While	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
directed	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
is	B-X
mediated	B-X
by	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
inhibition	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
is	B-X
independent	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
Interleukin	B-X
6	B-X
(	B-X
IL	B-X
-	B-X
6	B-X
)	B-X
is	B-X
a	B-X
cytokine	B-X
produced	B-X
by	B-X
immune	B-X
and	B-X
nonimmune	B-X
cells	B-X
and	B-X
exhibits	B-X
functional	B-X
pleiotropy	B-X
and	B-X
redundancy	B-X
<EOS>	B-X
Thus	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
promotes	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
and	B-X
inhibits	B-X
Th1	B-X
differentiation	B-X
by	B-X
two	B-X
independent	B-X
molecular	B-X
mechanisms	B-X

Inhibition	O
of	O
IFNgamma	B-protein
receptor-mediated	O
signals	O
by	O
IL-6	B-protein
prevents	O
autoregulation	O
of	O
IFNgamma	B-DNA
gene	I-DNA
expression	O
by	O
IFNgamma	B-protein
during	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
activation	O
,	O
thereby	O
preventing	O
Th1	O
differentiation	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
IFNgamma	B-X
receptor	B-X
-	B-X
mediated	B-X
signals	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
prevents	B-X
autoregulation	B-X
of	B-X
IFNgamma	B-X
gene	B-X
expression	B-X
by	B-X
IFNgamma	B-X
during	B-X
CD4+	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
thereby	B-X
preventing	B-X
Th1	B-X
differentiation	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
novel	B-X
function	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
:	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
CD4+	B-X
Th1	B-X
cell	B-X
differentiation	B-X
<EOS>	B-X
While	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
directed	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
is	B-X
mediated	B-X
by	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
inhibition	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
is	B-X
independent	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
Thus	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
promotes	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
and	B-X
inhibits	B-X
Th1	B-X
differentiation	B-X
by	B-X
two	B-X
independent	B-X
molecular	B-X
mechanisms	B-X

Thus	O
,	O
IL-6	B-protein
promotes	O
CD4	B-protein
+	O
Th2	O
differentiation	O
and	O
inhibits	O
Th1	O
differentiation	O
by	O
two	O
independent	O
molecular	O
mechanisms	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
promotes	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
and	B-X
inhibits	B-X
Th1	B-X
differentiation	B-X
by	B-X
two	B-X
independent	B-X
molecular	B-X
mechanisms	B-X
<EOS>	B-X
IL	B-X
-	B-X
6	B-X
promotes	B-X
Th2	B-X
differentiation	B-X
and	B-X
simultaneously	B-X
inhibits	B-X
Th1	B-X
polarization	B-X
through	B-X
two	B-X
independent	B-X
molecular	B-X
mechanisms	B-X
<EOS>	B-X
While	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
directed	B-X
CD4+	B-X
Th2	B-X
differentiation	B-X
is	B-X
mediated	B-X
by	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
inhibition	B-X
of	B-X
Th1	B-X
differentiation	B-X
by	B-X
IL	B-X
-	B-X
6	B-X
is	B-X
independent	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
IL	B-X
-	B-X
6	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
several	B-X
cell	B-X
types	B-X

Interaction	O
between	O
CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
and	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
1	I-protein
regulates	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
cells	O
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
CCAAT	B-X
/	B-X
enhancer	B-X
binding	B-X
protein	B-X
and	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
binding	B-X
protein	B-X
1	B-X
regulates	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
transcription	B-X
in	B-X
cells	B-X
of	B-X
the	B-X
monocyte	B-X
/	B-X
macrophage	B-X
lineage	B-X
.	B-X
<EOS>	B-X
Recent	B-X
observations	B-X
have	B-X
shown	B-X
two	B-X
CCAAT	B-X
/	B-X
enhancer	B-X
binding	B-X
protein	B-X
(	B-X
C	B-X
/	B-X
EBP	B-X
)	B-X
binding	B-X
sites	B-X
to	B-X
be	B-X
critically	B-X
important	B-X
for	B-X
efficient	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
replication	B-X
within	B-X
cells	B-X
of	B-X
the	B-X
monocyte	B-X
/	B-X
macrophage	B-X
lineage	B-X
,	B-X
a	B-X
cell	B-X
type	B-X
likely	B-X
involved	B-X
in	B-X
transport	B-X
of	B-X
the	B-X
virus	B-X
to	B-X
the	B-X
brain	B-X
<EOS>	B-X
Thus	B-X
,	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
ATF	B-X
/	B-X
CREB	B-X
binding	B-X
site	B-X
sequence	B-X
variation	B-X
may	B-X
modulate	B-X
cellular	B-X
signaling	B-X
at	B-X
the	B-X
viral	B-X
promoter	B-X
through	B-X
the	B-X
C	B-X
/	B-X
EBP	B-X
pathway	B-X
<EOS>	B-X
Sequence	B-X
variation	B-X
at	B-X
both	B-X
C	B-X
/	B-X
EBP	B-X
and	B-X
ATF	B-X
/	B-X
CREB	B-X
sites	B-X
affects	B-X
the	B-X
molecular	B-X
interactions	B-X
involved	B-X
in	B-X
mediating	B-X
both	B-X
of	B-X
these	B-X
mechanisms	B-X

Recent	O
observations	O
have	O
shown	O
two	O
CCAAT/enhancer	B-DNA
binding	I-DNA
protein	I-DNA
(	I-DNA
C/EBP	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
to	O
be	O
critically	O
important	O
for	O
efficient	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
within	O
cells	O
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
,	O
a	O
cell	O
type	O
likely	O
involved	O
in	O
transport	O
of	O
the	O
virus	O
to	O
the	O
brain	O
.	O

Additionally	O
,	O
sequence	O
variation	O
at	O
C/EBP	B-DNA
site	I-DNA
I	I-DNA
,	O
which	O
lies	O
immediately	O
upstream	O
of	O
the	O
distal	B-DNA
nuclear	I-DNA
factor	I-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
and	O
immediately	O
downstream	O
of	O
a	O
binding	O
site	O
for	O
activating	B-protein
transcription	I-protein
factor	I-protein
(	O
ATF	B-protein
)	O
/	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
has	O
been	O
shown	O
to	O
affect	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
activity	O
.	O

Given	O
that	O
C/EBP	B-protein
proteins	I-protein
have	O
been	O
shown	O
to	O
interact	O
with	O
many	O
other	O
transcription	B-protein
factors	I-protein
including	O
members	O
of	O
the	O
ATF/CREB	B-protein
family	I-protein
,	O
we	O
proceeded	O
to	O
determine	O
whether	O
an	O
adjacent	O
ATF/CREB	B-DNA
binding	I-DNA
site	I-DNA
could	O
affect	O
C/EBP	B-protein
protein	I-protein
binding	O
to	O
C/EBP	B-DNA
site	I-DNA
I	I-DNA
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
indicated	O
that	O
selected	O
ATF/CREB	B-DNA
site	I-DNA
variants	I-DNA
assisted	O
in	O
the	O
recruitment	O
of	O
C/EBP	B-protein
proteins	I-protein
to	O
an	O
adjacent	O
,	O
naturally	O
occurring	O
,	O
low-affinity	O
C/EBP	B-DNA
site	I-DNA
.	O

This	O
biophysical	O
interaction	O
appears	O
to	O
occur	O
via	O
at	O
least	O
two	O
mechanisms	O
.	O
<EOS>	B-X
This	B-X
biophysical	B-X
interaction	B-X
appears	B-X
to	B-X
occur	B-X
via	B-X
at	B-X
least	B-X
two	B-X
mechanisms	B-X
<EOS>	B-X
There	B-X
are	B-X
at	B-X
least	B-X
two	B-X
distinct	B-X
gating	B-X
mechanisms	B-X
<EOS>	B-X
This	B-X
process	B-X
has	B-X
yet	B-X
to	B-X
be	B-X
studied	B-X
at	B-X
the	B-X
single	B-X
-	B-X
channel	B-X
level	B-X
<EOS>	B-X
This	B-X
has	B-X
a	B-X
functional	B-X
resemblance	B-X
to	B-X
the	B-X
particle	B-X
-	B-X
receptor	B-X
mechanism	B-X
for	B-X
N	B-X
-	B-X
type	B-X
inactivation	B-X
of	B-X
Shaker	B-X
channels	B-X

First	O
,	O
low	O
amounts	O
of	O
CREB-1	B-protein
and	O
C/EBP	B-protein
appear	O
to	O
heterodimerize	O
and	O
bind	O
to	O
a	O
site	O
consisting	O
of	O
a	O
half	O
site	O
from	O
both	O
the	O
ATF/CREB	B-DNA
and	I-DNA
C/EBP	I-DNA
binding	I-DNA
sites	I-DNA
.	O

In	O
addition	O
,	O
CREB-1	B-protein
homodimers	I-protein
bind	O
to	O
the	O
ATF/CREB	B-DNA
site	I-DNA
and	O
recruit	O
C/EBP	B-protein
dimers	I-protein
to	O
their	O
cognate	O
weak	B-DNA
binding	I-DNA
sites	I-DNA
.	O

This	O
interaction	O
is	O
reciprocal	O
,	O
since	O
C/EBP	B-protein
dimer	I-protein
binding	O
to	O
a	O
strong	O
C/EBP	B-DNA
site	I-DNA
leads	O
to	O
enhanced	O
CREB-1	B-protein
recruitment	O
to	O
ATF/CREB	B-DNA
sites	I-DNA
that	O
are	O
weakly	O
bound	O
by	O
CREB	B-protein
.	O

Sequence	O
variation	O
at	O
both	O
C/EBP	B-DNA
and	I-DNA
ATF/CREB	I-DNA
sites	I-DNA
affects	O
the	O
molecular	O
interactions	O
involved	O
in	O
mediating	O
both	O
of	O
these	O
mechanisms	O
.	O

Most	O
importantly	O
,	O
sequence	O
variation	O
at	O
the	O
ATF/CREB	B-DNA
binding	I-DNA
site	I-DNA
affected	O
basal	O
LTR	B-DNA
activity	O
as	O
well	O
as	O
LTR	B-DNA
function	O
following	O
interleukin-6	B-protein
stimulation	O
,	O
a	O
treatment	O
that	O
leads	O
to	O
increases	O
in	O
C/EBP	O
activation	O
.	O

Thus	O
,	O
HIV-1	B-DNA
LTR	I-DNA
ATF/CREB	B-DNA
binding	I-DNA
site	I-DNA
sequence	O
variation	O
may	O
modulate	O
cellular	O
signaling	O
at	O
the	O
viral	B-DNA
promoter	I-DNA
through	O
the	O
C/EBP	O
pathway	O

Selective	O
inhibition	O
of	O
interleukin-4	O
gene	O
expression	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
aspirin	O
.	O

Previous	O
studies	O
indicated	O
that	O
aspirin	O
(	O
acetylsalicylic	O
acid	O
[	O
ASA	O
]	O
)	O
can	O
have	O
profound	O
immunomodulatory	O
effects	O
by	O
regulating	O
cytokine	O
gene	O
expression	O
in	O
several	O
types	O
of	O
cells	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
indicated	B-X
that	B-X
aspirin	B-X
(	B-X
acetylsalicylic	B-X
acid	B-X
[	B-X
ASA	B-X
]	B-X
)	B-X
can	B-X
have	B-X
profound	B-X
immunomodulatory	B-X
effects	B-X
by	B-X
regulating	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
several	B-X
types	B-X
of	B-X
cells	B-X
<EOS>	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
in	B-X
which	B-X
concentrations	B-X
of	B-X
ASA	B-X
in	B-X
the	B-X
therapeutic	B-X
range	B-X
were	B-X
found	B-X
to	B-X
significantly	B-X
reduce	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
4	B-X
secretion	B-X
and	B-X
RNA	B-X
expression	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
mitogen	B-X
-	B-X
primed	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
<EOS>	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
anti	B-X
-	B-X
inflammatory	B-X
salicylates	B-X
,	B-X
by	B-X
means	B-X
of	B-X
a	B-X
previously	B-X
unrecognized	B-X
mechanism	B-X
of	B-X
action	B-X
,	B-X
can	B-X
influence	B-X
the	B-X
nature	B-X
of	B-X
adaptive	B-X
immune	B-X
responses	B-X
by	B-X
selectively	B-X
inhibiting	B-X
the	B-X
expression	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
a	B-X
critical	B-X
effector	B-X
of	B-X
these	B-X
responses	B-X
,	B-X
in	B-X
CD4+	B-X
T	B-X
cells	B-X
<EOS>	B-X
Selective	B-X
inhibition	B-X
of	B-X
interleukin	B-X
-	B-X
4	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
by	B-X
aspirin	B-X
.	B-X

This	O
study	O
is	O
the	O
first	O
in	O
which	O
concentrations	O
of	O
ASA	O
in	O
the	O
therapeutic	O
range	O
were	O
found	O
to	O
significantly	O
reduce	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
secretion	O
and	O
RNA	O
expression	O
in	O
freshly	B-cell_type
isolated	I-cell_type
and	I-cell_type
mitogen-primed	I-cell_type
human	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
ASA	O
did	O
not	O
affect	O
IL-13	B-protein
,	O
interferon-gamma	B-protein
,	O
and	O
IL-2	B-protein
expression	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
risk	B-X
for	B-X
major	B-X
bleeding	B-X
is	B-X
increased	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
polymerization	B-X
to	B-X
harmless	B-X
insoluble	B-X
polymers	B-X
was	B-X
favored	B-X
at	B-X
neutral	B-X
conditions	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
polymicrobial	B-X
infections	B-X
with	B-X
gram	B-X
-	B-X
negative	B-X
bacilli	B-X
were	B-X
more	B-X
common	B-X
in	B-X
contaminated	B-X
foot	B-X
surgeries	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
worse	B-X
ASA	B-X
physical	B-X
classification	B-X
was	B-X
more	B-X
strongly	B-X
associated	B-X
with	B-X
postoperative	B-X
cardiac	B-X
events	B-X
in	B-X
urgent	B-X
and	B-X
emergent	B-X
patients	B-X

ASA	O
inhibited	O
IL-4	B-protein
,	O
but	O
not	O
IL-2	B-protein
,	O
promoter-driven	O
chloramphenicol	O
acetyltransferase	O
expression	O
in	O
transiently	O
transfected	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Avenanthramide	B-X
C	B-X
from	B-X
germinated	B-X
oats	B-X
exhibits	B-X
anti	B-X
-	B-X
allergic	B-X
inflammatory	B-X
effects	B-X
in	B-X
mast	B-X
cells	B-X
.	B-X
<EOS>	B-X
For	B-X
the	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
RBL	B-X
-	B-X
2H3	B-X
,	B-X
mouse	B-X
bone	B-X
marrow	B-X
-	B-X
derived	B-X
mast	B-X
cells	B-X
and	B-X
rat	B-X
peritoneal	B-X
mast	B-X
cells	B-X
were	B-X
used	B-X
<EOS>	B-X
ASA	B-X
and	B-X
SHL	B-X
co	B-X
-	B-X
administration	B-X
induced	B-X
inflammatory	B-X
responses	B-X
in	B-X
HaCat	B-X
cells	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
marked	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
TNF	B-X
-	B-X
α	B-X
,	B-X
and	B-X
the	B-X
level	B-X
of	B-X
apoptosis	B-X
<EOS>	B-X
ASA	B-X
VI	B-X
inhibits	B-X
local	B-X
vascular	B-X
hyperproliferation	B-X
and	B-X
downregulates	B-X
the	B-X
HIF	B-X
-	B-X
1α	B-X
/	B-X
Hh	B-X
pathway	B-X
to	B-X
promote	B-X
the	B-X
tendinous	B-X
differentiation	B-X
of	B-X
tendon	B-X
stem	B-X
/	B-X
progenitor	B-X
cells	B-X
and	B-X
the	B-X
repair	B-X
of	B-X
tendinopathy	B-X

The	O
structurally	O
unrelated	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
indomethacin	O
and	O
flurbiprofen	O
did	O
not	O
affect	O
cytokine	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
whereas	O
the	O
weak	O
cyclo-oxygenase	O
inhibitor	O
salicylic	O
acid	O
was	O
at	O
least	O
as	O
effective	O
as	O
ASA	O
in	O
inhibiting	O
IL-4	B-protein
expression	O
and	O
promoter	O
activity	O
.	O
<EOS>	B-X
The	B-X
structurally	B-X
unrelated	B-X
nonsteroidal	B-X
anti	B-X
-	B-X
inflammatory	B-X
drugs	B-X
indomethacin	B-X
and	B-X
flurbiprofen	B-X
did	B-X
not	B-X
affect	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
whereas	B-X
the	B-X
weak	B-X
cyclo	B-X
-	B-X
oxygenase	B-X
inhibitor	B-X
salicylic	B-X
acid	B-X
was	B-X
at	B-X
least	B-X
as	B-X
effective	B-X
as	B-X
ASA	B-X
in	B-X
inhibiting	B-X
IL	B-X
-	B-X
4	B-X
expression	B-X
and	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
Several	B-X
structurally	B-X
unrelated	B-X
inhibitors	B-X
of	B-X
arachidonic	B-X
acid	B-X
metabolism	B-X
via	B-X
the	B-X
cyclooxygenase	B-X
pathway	B-X
totally	B-X
abolished	B-X
the	B-X
PGE2	B-X
response	B-X
to	B-X
bradykinin	B-X
<EOS>	B-X
The	B-X
stimulatory	B-X
effect	B-X
on	B-X
3H	B-X
-	B-X
arachidonic	B-X
acid	B-X
release	B-X
by	B-X
bradykinin	B-X
was	B-X
seen	B-X
at	B-X
and	B-X
above	B-X
10	B-X
nmol	B-X
/	B-X
l	B-X
,	B-X
whereas	B-X
des	B-X
-	B-X
Arg9	B-X
-	B-X
bradykinin	B-X
was	B-X
without	B-X
effect	B-X
up	B-X
to	B-X
a	B-X
concentration	B-X
of	B-X
1	B-X
mumol	B-X
/	B-X
l	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factors	B-X
alpha	B-X
and	B-X
beta	B-X
can	B-X
stimulate	B-X
bone	B-X
resorption	B-X
in	B-X
cultured	B-X
mouse	B-X
calvariae	B-X
by	B-X
a	B-X
prostaglandin	B-X
-	B-X
independent	B-X
mechanism	B-X
.	B-X

The	O
inhibitory	O
effect	O
of	O
ASA	O
on	O
IL-4	O
transcription	O
was	O
not	O
mediated	O
by	O
decreased	O
nuclear	O
expression	O
of	O
the	O
known	O
salicylate	B-protein
target	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
and	O
was	O
accompanied	O
by	O
reduced	O
binding	O
of	O
an	O
inducible	O
factor	O
to	O
an	O
IL-4	B-DNA
promoter	I-DNA
region	I-DNA
upstream	O
of	O
,	O
but	O
not	O
overlapping	O
,	O
the	O
NF	B-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells-	I-DNA
and	I-DNA
NF-kappaB-binding	I-DNA
P1	I-DNA
element	I-DNA
.	O
<EOS>	B-X
TMB	B-X
decreased	B-X
the	B-X
expression	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
α	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
4	B-X
at	B-X
both	B-X
the	B-X
transcriptional	B-X
and	B-X
translational	B-X
levels	B-X
<EOS>	B-X
Increased	B-X
expression	B-X
of	B-X
these	B-X
cytokines	B-X
was	B-X
caused	B-X
by	B-X
translocation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
κB	B-X
into	B-X
the	B-X
nucleus	B-X
,	B-X
and	B-X
it	B-X
was	B-X
hindered	B-X
by	B-X
suppressing	B-X
activation	B-X
of	B-X
IκB	B-X
kinase	B-X
complex	B-X
<EOS>	B-X
Mast	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
as	B-X
initiators	B-X
of	B-X
allergic	B-X
responses	B-X
through	B-X
the	B-X
release	B-X
of	B-X
histamine	B-X
;	B-X
therefore	B-X
,	B-X
they	B-X
should	B-X
be	B-X
the	B-X
target	B-X
of	B-X
pharmaceutical	B-X
development	B-X
for	B-X
the	B-X
management	B-X
of	B-X
allergic	B-X
inflammation	B-X
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
TMB	B-X
is	B-X
a	B-X
possible	B-X
therapeutic	B-X
candidate	B-X
for	B-X
allergic	B-X
inflammatory	B-X
diseases	B-X
that	B-X
acts	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
mast	B-X
cell	B-X
degranulation	B-X
and	B-X
expression	B-X
of	B-X
pro	B-X
-	B-X
inflammatory	B-X
cytokines	B-X

It	O
is	O
concluded	O
that	O
anti-inflammatory	O
salicylates	O
,	O
by	O
means	O
of	O
a	O
previously	O
unrecognized	O
mechanism	O
of	O
action	O
,	O
can	O
influence	O
the	O
nature	O
of	O
adaptive	O
immune	O
responses	O
by	O
selectively	O
inhibiting	O
the	O
expression	O
of	O
IL-4	B-protein
,	O
a	O
critical	O
effector	O
of	O
these	O
responses	O
,	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
anti	B-X
-	B-X
inflammatory	B-X
salicylates	B-X
,	B-X
by	B-X
means	B-X
of	B-X
a	B-X
previously	B-X
unrecognized	B-X
mechanism	B-X
of	B-X
action	B-X
,	B-X
can	B-X
influence	B-X
the	B-X
nature	B-X
of	B-X
adaptive	B-X
immune	B-X
responses	B-X
by	B-X
selectively	B-X
inhibiting	B-X
the	B-X
expression	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
a	B-X
critical	B-X
effector	B-X
of	B-X
these	B-X
responses	B-X
,	B-X
in	B-X
CD4+	B-X
T	B-X
cells	B-X
<EOS>	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
in	B-X
which	B-X
concentrations	B-X
of	B-X
ASA	B-X
in	B-X
the	B-X
therapeutic	B-X
range	B-X
were	B-X
found	B-X
to	B-X
significantly	B-X
reduce	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
4	B-X
secretion	B-X
and	B-X
RNA	B-X
expression	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
mitogen	B-X
-	B-X
primed	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
indicated	B-X
that	B-X
aspirin	B-X
(	B-X
acetylsalicylic	B-X
acid	B-X
[	B-X
ASA	B-X
]	B-X
)	B-X
can	B-X
have	B-X
profound	B-X
immunomodulatory	B-X
effects	B-X
by	B-X
regulating	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
several	B-X
types	B-X
of	B-X
cells	B-X
<EOS>	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
ASA	B-X
on	B-X
IL	B-X
-	B-X
4	B-X
transcription	B-X
was	B-X
not	B-X
mediated	B-X
by	B-X
decreased	B-X
nuclear	B-X
expression	B-X
of	B-X
the	B-X
known	B-X
salicylate	B-X
target	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
and	B-X
was	B-X
accompanied	B-X
by	B-X
reduced	B-X
binding	B-X
of	B-X
an	B-X
inducible	B-X
factor	B-X
to	B-X
an	B-X
IL	B-X
-	B-X
4	B-X
promoter	B-X
region	B-X
upstream	B-X
of	B-X
,	B-X
but	B-X
not	B-X
overlapping	B-X
,	B-X
the	B-X
NF	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
binding	B-X
P1	B-X
element	B-X

Molecular	O
and	O
cellular	O
mediators	O
of	O
interleukin-1	B-protein
-dependent	O
acute	O
inflammatory	O
arthritis	O
.	O
<EOS>	B-X
Molecular	B-X
and	B-X
cellular	B-X
mediators	B-X
of	B-X
interleukin	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
acute	B-X
inflammatory	B-X
arthritis	B-X
.	B-X
<EOS>	B-X
stamineus	B-X
could	B-X
be	B-X
beneficial	B-X
for	B-X
prevention	B-X
and	B-X
management	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
and	B-X
other	B-X
chronic	B-X
inflammatory	B-X
disorders	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
in	B-X
a	B-X
model	B-X
of	B-X
acute	B-X
inflammatory	B-X
monarticular	B-X
arthritis	B-X
induced	B-X
by	B-X
methylated	B-X
bovine	B-X
serum	B-X
albumin	B-X
(	B-X
mBSA	B-X
)	B-X
and	B-X
interleukin	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
stamineus	B-X
(	B-X
EOS	B-X
)	B-X
to	B-X
treat	B-X
rheumatoid	B-X
arthritis	B-X

OBJECTIVE	O
:	O
To	O
examine	O
the	O
molecular	O
and	O
cellular	O
mechanisms	O
in	O
a	O
model	O
of	O
acute	O
inflammatory	O
monarticular	O
arthritis	O
induced	O
by	O
methylated	B-protein
bovine	I-protein
serum	I-protein
albumin	I-protein
(	O
mBSA	B-protein
)	O
and	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
.	O

METHODS	O
:	O
Mice	O
were	O
injected	O
intraarticularly	O
with	O
mBSA	B-protein
on	O
day	O
0	O
and	O
subcutaneously	O
with	O
recombinant	B-protein
human	I-protein
IL-1beta	I-protein
on	O
days	O
0-2	O
.	O

At	O
day	O
7	O
,	O
knee	O
joints	O
were	O
removed	O
and	O
assessed	O
histologically	O
.	O
<EOS>	B-X
At	B-X
day	B-X
7	B-X
,	B-X
knee	B-X
joints	B-X
were	B-X
removed	B-X
and	B-X
assessed	B-X
histologically	B-X
<EOS>	B-X
In	B-X
Plg	B-X
(	B-X
+	B-X
/	B-X
+	B-X
)	B-X
mice	B-X
,	B-X
S	B-X
aureus	B-X
counts	B-X
had	B-X
declined	B-X
within	B-X
2	B-X
days	B-X
,	B-X
and	B-X
by	B-X
day	B-X
28	B-X
the	B-X
bacteria	B-X
had	B-X
been	B-X
completely	B-X
eliminated	B-X
<EOS>	B-X
However	B-X
,	B-X
S	B-X
aureus	B-X
was	B-X
still	B-X
detectable	B-X
in	B-X
all	B-X
injected	B-X
joints	B-X
from	B-X
Plg	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
,	B-X
and	B-X
bacteria	B-X
counts	B-X
were	B-X
27	B-X
times	B-X
higher	B-X
than	B-X
the	B-X
amount	B-X
injected	B-X
on	B-X
day	B-X
0	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
B	B-X
cell	B-X
-	B-X
deficient	B-X
(	B-X
muMT	B-X
/	B-X
	B-X
muMT	B-X
)	B-X
mice	B-X
developed	B-X
arthritis	B-X
at	B-X
an	B-X
incidence	B-X
and	B-X
severity	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
controls	B-X

Flow	O
cytometry	O
and	O
RNase	O
protection	O
were	O
used	O
to	O
analyze	O
IL-1	B-protein
-dependent	O
events	O
.	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
and	B-X
RNase	B-X
protection	B-X
were	B-X
used	B-X
to	B-X
analyze	B-X
IL	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
events	B-X
<EOS>	B-X
RelB	B-X
-	B-X
deficient	B-X
(	B-X
RelB	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
had	B-X
arthritis	B-X
that	B-X
was	B-X
significantly	B-X
reduced	B-X
in	B-X
incidence	B-X
and	B-X
severity	B-X
<EOS>	B-X
Molecular	B-X
and	B-X
cellular	B-X
mediators	B-X
of	B-X
interleukin	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
acute	B-X
inflammatory	B-X
arthritis	B-X
.	B-X
<EOS>	B-X
At	B-X
day	B-X
7	B-X
,	B-X
knee	B-X
joints	B-X
were	B-X
removed	B-X
and	B-X
assessed	B-X
histologically	B-X

RESULTS	O
:	O
C57BL/6	O
(	O
B6	O
)	O
,	O
129/Sv	O
,	O
and	O
(	O
B6	O
x	O
129/	O
Sv	O
)	O
F1	O
hybrid	O
mice	O
,	O
all	O
H-2b	O
strains	O
,	O
were	O
susceptible	O
to	O
mBSA	B-protein
/IL-1-induced	O
arthritis	O
,	O
whereas	O
C3H/HeJ	O
(	O
H-2k	O
)	O
mice	O
were	O
not	O
.	O
<EOS>	B-X
C57BL	B-X
/	B-X
6	B-X
(	B-X
B6	B-X
)	B-X
,	B-X
129	B-X
/	B-X
Sv	B-X
,	B-X
and	B-X
(	B-X
B6	B-X
x	B-X
129	B-X
/	B-X
	B-X
Sv	B-X
)	B-X
F1	B-X
hybrid	B-X
mice	B-X
,	B-X
all	B-X
H	B-X
-	B-X
2b	B-X
strains	B-X
,	B-X
were	B-X
susceptible	B-X
to	B-X
mBSA	B-X
/	B-X
IL	B-X
-	B-X
1	B-X
-	B-X
induced	B-X
arthritis	B-X
,	B-X
whereas	B-X
C3H	B-X
/	B-X
HeJ	B-X
(	B-X
H	B-X
-	B-X
2k	B-X
)	B-X
mice	B-X
were	B-X
not	B-X
<EOS>	B-X
RelB	B-X
-	B-X
deficient	B-X
(	B-X
RelB	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
had	B-X
arthritis	B-X
that	B-X
was	B-X
significantly	B-X
reduced	B-X
in	B-X
incidence	B-X
and	B-X
severity	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
B	B-X
cell	B-X
-	B-X
deficient	B-X
(	B-X
muMT	B-X
/	B-X
	B-X
muMT	B-X
)	B-X
mice	B-X
developed	B-X
arthritis	B-X
at	B-X
an	B-X
incidence	B-X
and	B-X
severity	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
controls	B-X
<EOS>	B-X
Flow	B-X
cytometry	B-X
and	B-X
RNase	B-X
protection	B-X
were	B-X
used	B-X
to	B-X
analyze	B-X
IL	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
events	B-X

B6	O
mice	O
lacking	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
(	O
RAG1-/-	O
)	O
or	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
(	O
MHCII-/-	O
)	O
,	O
and	O
B6	O
mice	O
treated	O
with	O
a	O
CD4+	B-protein
T	I-protein
cell-depleting	I-protein
monoclonal	I-protein
antibody	I-protein
,	O
were	O
resistant	O
to	O
disease	O
.	O
<EOS>	B-X
B6	B-X
mice	B-X
lacking	B-X
T	B-X
and	B-X
B	B-X
cells	B-X
(	B-X
RAG1	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
or	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
II	B-X
antigens	B-X
(	B-X
MHCII	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
,	B-X
and	B-X
B6	B-X
mice	B-X
treated	B-X
with	B-X
a	B-X
CD4+	B-X
T	B-X
cell	B-X
-	B-X
depleting	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
disease	B-X
<EOS>	B-X
RelB	B-X
-	B-X
deficient	B-X
(	B-X
RelB	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
had	B-X
arthritis	B-X
that	B-X
was	B-X
significantly	B-X
reduced	B-X
in	B-X
incidence	B-X
and	B-X
severity	B-X
<EOS>	B-X
In	B-X
B6	B-X
mice	B-X
,	B-X
flow	B-X
cytometry	B-X
demonstrated	B-X
an	B-X
IL	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
leukocyte	B-X
infiltration	B-X
into	B-X
the	B-X
synovial	B-X
compartment	B-X
and	B-X
RNase	B-X
protection	B-X
assays	B-X
revealed	B-X
induction	B-X
of	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
for	B-X
the	B-X
chemokines	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
1	B-X
,	B-X
macrophage	B-X
inhibitory	B-X
protein	B-X
2	B-X
(	B-X
MIP	B-X
-	B-X
2	B-X
)	B-X
,	B-X
RANTES	B-X
,	B-X
MIP	B-X
-	B-X
1alpha	B-X
,	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
,	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Molecular	B-X
and	B-X
cellular	B-X
mediators	B-X
of	B-X
interleukin	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
acute	B-X
inflammatory	B-X
arthritis	B-X
.	B-X

In	O
contrast	O
,	O
B	O
cell-deficient	O
(	O
muMT/	O
muMT	O
)	O
mice	O
developed	O
arthritis	O
at	O
an	O
incidence	O
and	O
severity	O
similar	O
to	O
that	O
of	O
controls	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
B	B-X
cell	B-X
-	B-X
deficient	B-X
(	B-X
muMT	B-X
/	B-X
	B-X
muMT	B-X
)	B-X
mice	B-X
developed	B-X
arthritis	B-X
at	B-X
an	B-X
incidence	B-X
and	B-X
severity	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
controls	B-X
<EOS>	B-X
RelB	B-X
-	B-X
deficient	B-X
(	B-X
RelB	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
had	B-X
arthritis	B-X
that	B-X
was	B-X
significantly	B-X
reduced	B-X
in	B-X
incidence	B-X
and	B-X
severity	B-X
<EOS>	B-X
This	B-X
model	B-X
of	B-X
acute	B-X
monarticular	B-X
arthritis	B-X
is	B-X
particularly	B-X
suitable	B-X
for	B-X
further	B-X
investigations	B-X
into	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
in	B-X
arthritis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
IL	B-X
-	B-X
1	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
in	B-X
a	B-X
model	B-X
of	B-X
acute	B-X
inflammatory	B-X
monarticular	B-X
arthritis	B-X
induced	B-X
by	B-X
methylated	B-X
bovine	B-X
serum	B-X
albumin	B-X
(	B-X
mBSA	B-X
)	B-X
and	B-X
interleukin	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
)	B-X

RelB-deficient	O
(	O
RelB-/-	O
)	O
bone	O
marrow	O
chimeric	O
mice	O
had	O
arthritis	O
that	O
was	O
significantly	O
reduced	O
in	O
incidence	O
and	O
severity	O
.	O
<EOS>	B-X
RelB	B-X
-	B-X
deficient	B-X
(	B-X
RelB	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
had	B-X
arthritis	B-X
that	B-X
was	B-X
significantly	B-X
reduced	B-X
in	B-X
incidence	B-X
and	B-X
severity	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
B	B-X
cell	B-X
-	B-X
deficient	B-X
(	B-X
muMT	B-X
/	B-X
	B-X
muMT	B-X
)	B-X
mice	B-X
developed	B-X
arthritis	B-X
at	B-X
an	B-X
incidence	B-X
and	B-X
severity	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
controls	B-X
<EOS>	B-X
Flow	B-X
cytometry	B-X
and	B-X
RNase	B-X
protection	B-X
were	B-X
used	B-X
to	B-X
analyze	B-X
IL	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
events	B-X
<EOS>	B-X
This	B-X
model	B-X
of	B-X
acute	B-X
monarticular	B-X
arthritis	B-X
is	B-X
particularly	B-X
suitable	B-X
for	B-X
further	B-X
investigations	B-X
into	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
in	B-X
arthritis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
IL	B-X
-	B-X
1	B-X

In	O
B6	O
mice	O
,	O
flow	O
cytometry	O
demonstrated	O
an	O
IL-1-dependent	B-cell_type
leukocyte	I-cell_type
infiltration	O
into	O
the	O
synovial	O
compartment	O
and	O
RNase	O
protection	O
assays	O
revealed	O
induction	O
of	O
messenger	B-RNA
RNA	I-RNA
(	O
mRNA	B-RNA
)	O
for	O
the	O
chemokines	B-protein
monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
1	I-protein
,	O
macrophage	B-protein
inhibitory	I-protein
protein	I-protein
2	I-protein
(	O
MIP-2	B-protein
)	O
,	O
RANTES	B-protein
,	O
MIP-1alpha	B-protein
,	O
and	O
MIP-1beta	B-protein
,	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
<EOS>	B-X
In	B-X
B6	B-X
mice	B-X
,	B-X
flow	B-X
cytometry	B-X
demonstrated	B-X
an	B-X
IL	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
leukocyte	B-X
infiltration	B-X
into	B-X
the	B-X
synovial	B-X
compartment	B-X
and	B-X
RNase	B-X
protection	B-X
assays	B-X
revealed	B-X
induction	B-X
of	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
for	B-X
the	B-X
chemokines	B-X
monocyte	B-X
chemoattractant	B-X
protein	B-X
1	B-X
,	B-X
macrophage	B-X
inhibitory	B-X
protein	B-X
2	B-X
(	B-X
MIP	B-X
-	B-X
2	B-X
)	B-X
,	B-X
RANTES	B-X
,	B-X
MIP	B-X
-	B-X
1alpha	B-X
,	B-X
and	B-X
MIP	B-X
-	B-X
1beta	B-X
,	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
<EOS>	B-X
IL	B-X
-	B-X
1	B-X
contributes	B-X
to	B-X
leukocyte	B-X
recruitment	B-X
to	B-X
the	B-X
synovium	B-X
and	B-X
directly	B-X
induces	B-X
chemokine	B-X
mRNA	B-X
production	B-X
by	B-X
synovial	B-X
cells	B-X
<EOS>	B-X
B6	B-X
mice	B-X
lacking	B-X
T	B-X
and	B-X
B	B-X
cells	B-X
(	B-X
RAG1	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
or	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
II	B-X
antigens	B-X
(	B-X
MHCII	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
,	B-X
and	B-X
B6	B-X
mice	B-X
treated	B-X
with	B-X
a	B-X
CD4+	B-X
T	B-X
cell	B-X
-	B-X
depleting	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
disease	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
in	B-X
a	B-X
model	B-X
of	B-X
acute	B-X
inflammatory	B-X
monarticular	B-X
arthritis	B-X
induced	B-X
by	B-X
methylated	B-X
bovine	B-X
serum	B-X
albumin	B-X
(	B-X
mBSA	B-X
)	B-X
and	B-X
interleukin	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
)	B-X

CONCLUSION	O
:	O
Arthritis	O
induced	O
by	O
mBSA	B-protein
/	O
IL-1	B-protein
is	O
strain	O
specific	O
and	O
dependent	O
on	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
at	O
least	O
partially	O
on	O
RelB	B-protein
,	O
but	O
not	O
on	O
B	B-cell_type
lymphocytes	I-cell_type
or	O
antibody	B-protein
.	O
<EOS>	B-X
Hairy	B-X
cell	B-X
leukemia	B-X
(	B-X
HCL	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
subtype	B-X
of	B-X
indolent	B-X
lymphoid	B-X
leukemia	B-X
originating	B-X
from	B-X
a	B-X
mature	B-X
B	B-X
lymphocyte	B-X
<EOS>	B-X
One	B-X
hundred	B-X
percent	B-X
of	B-X
CVID	B-X
seroresponders	B-X
and	B-X
83	B-X
%	B-X
of	B-X
non	B-X
-	B-X
seroresponders	B-X
had	B-X
a	B-X
detectable	B-X
polyfunctional	B-X
T	B-X
cell	B-X
response	B-X
<EOS>	B-X
Novel	B-X
multivalent	B-X
S100A8	B-X
inhibitory	B-X
peptides	B-X
attenuate	B-X
tumor	B-X
progression	B-X
and	B-X
metastasis	B-X
by	B-X
inhibiting	B-X
the	B-X
TLR4	B-X
-	B-X
dependent	B-X
pathway	B-X
.	B-X
<EOS>	B-X
A	B-X
method	B-X
development	B-X
aimed	B-X
for	B-X
high	B-X
-	B-X
throughput	B-X
and	B-X
automated	B-X
antibody	B-X
screening	B-X
holds	B-X
great	B-X
potential	B-X
for	B-X
areas	B-X
ranging	B-X
from	B-X
fundamental	B-X
molecular	B-X
interactions	B-X
to	B-X
the	B-X
discovery	B-X
of	B-X
novel	B-X
disease	B-X
markers	B-X
,	B-X
therapeutic	B-X
targets	B-X
and	B-X
monoclonal	B-X
antibody	B-X
engineering	B-X

IL-1	B-protein
contributes	O
to	O
leukocyte	O
recruitment	O
to	O
the	O
synovium	O
and	O
directly	O
induces	O
chemokine	O
mRNA	O
production	O
by	O
synovial	B-cell_type
cells	I-cell_type
.	O

This	O
model	O
of	O
acute	O
monarticular	O
arthritis	O
is	O
particularly	O
suitable	O
for	O
further	O
investigations	O
into	O
cell-mediated	O
immunity	O
in	O
arthritis	O
and	O
the	O
role	O
of	O
IL-1	B-protein
.	O
<EOS>	B-X
This	B-X
model	B-X
of	B-X
acute	B-X
monarticular	B-X
arthritis	B-X
is	B-X
particularly	B-X
suitable	B-X
for	B-X
further	B-X
investigations	B-X
into	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
in	B-X
arthritis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
IL	B-X
-	B-X
1	B-X
<EOS>	B-X
To	B-X
examine	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
in	B-X
a	B-X
model	B-X
of	B-X
acute	B-X
inflammatory	B-X
monarticular	B-X
arthritis	B-X
induced	B-X
by	B-X
methylated	B-X
bovine	B-X
serum	B-X
albumin	B-X
(	B-X
mBSA	B-X
)	B-X
and	B-X
interleukin	B-X
-	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
Mice	B-X
were	B-X
injected	B-X
intraarticularly	B-X
with	B-X
mBSA	B-X
on	B-X
day	B-X
0	B-X
and	B-X
subcutaneously	B-X
with	B-X
recombinant	B-X
human	B-X
IL	B-X
-	B-X
1beta	B-X
on	B-X
days	B-X
0	B-X
-	B-X
2	B-X
<EOS>	B-X
Molecular	B-X
and	B-X
cellular	B-X
mediators	B-X
of	B-X
interleukin	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
acute	B-X
inflammatory	B-X
arthritis	B-X
.	B-X

Positive	O
and	O
negative	O
regulation	O
of	O
granulopoiesis	O
by	O
endogenous	B-protein
RARalpha	I-protein
.	O
<EOS>	B-X
Positive	B-X
and	B-X
negative	B-X
regulation	B-X
of	B-X
granulopoiesis	B-X
by	B-X
endogenous	B-X
RARalpha	B-X
.	B-X
<EOS>	B-X
RARalpha	B-X
stimulates	B-X
differentiation	B-X
in	B-X
response	B-X
to	B-X
exogenous	B-X
retinoic	B-X
acid	B-X
<EOS>	B-X
Acute	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
APL	B-X
)	B-X
is	B-X
always	B-X
associated	B-X
with	B-X
chromosomal	B-X
translocations	B-X
that	B-X
disrupt	B-X
the	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
(	B-X
RARalpha	B-X
)	B-X
gene	B-X
<EOS>	B-X
Conversely	B-X
,	B-X
RARalpha	B-X
acts	B-X
to	B-X
limit	B-X
differentiation	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ligand	B-X
because	B-X
granulocyte	B-X
precursors	B-X
from	B-X
RARalpha	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
differentiate	B-X
earlier	B-X
in	B-X
culture	B-X

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
always	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
RARalpha	I-DNA
)	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
Acute	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
APL	B-X
)	B-X
is	B-X
always	B-X
associated	B-X
with	B-X
chromosomal	B-X
translocations	B-X
that	B-X
disrupt	B-X
the	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
(	B-X
RARalpha	B-X
)	B-X
gene	B-X
<EOS>	B-X
Acute	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
APL	B-X
)	B-X
is	B-X
typified	B-X
by	B-X
the	B-X
reciprocal	B-X
translocation	B-X
,	B-X
t	B-X
(	B-X
15	B-X
;	B-X
17	B-X
)	B-X
(	B-X
q22	B-X
;	B-X
q21	B-X
)	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
PML	B-X
-	B-X
RARalpha	B-X
and	B-X
RARalpha	B-X
-	B-X
PML	B-X
fusion	B-X
genes	B-X
<EOS>	B-X
The	B-X
translocation	B-X
results	B-X
in	B-X
a	B-X
fusion	B-X
gene	B-X
product	B-X
,	B-X
PML	B-X
-	B-X
RARalpha	B-X
,	B-X
in	B-X
which	B-X
the	B-X
PML	B-X
gene	B-X
fuses	B-X
to	B-X
the	B-X
retinoic	B-X
acid	B-X
receptor	B-X
alpha	B-X
(	B-X
RARalpha	B-X
)	B-X
gene	B-X
<EOS>	B-X
Acute	B-X
promyelocytic	B-X
leukemia	B-X
(	B-X
APL	B-X
)	B-X
has	B-X
been	B-X
recognized	B-X
as	B-X
a	B-X
distinct	B-X
clinical	B-X
entity	B-X
for	B-X
over	B-X
40	B-X
years	B-X

Whether	O
these	O
translocations	O
relate	O
to	O
a	O
role	O
for	O
endogenous	B-protein
RARalpha	I-protein
in	O
normal	O
granulopoiesis	O
remains	O
uncertain	O
because	O
most	O
studies	O
addressing	O
this	O
question	O
have	O
used	O
non-physiological	O
overexpression	O
systems	O
.	O
<EOS>	B-X
Whether	B-X
these	B-X
translocations	B-X
relate	B-X
to	B-X
a	B-X
role	B-X
for	B-X
endogenous	B-X
RARalpha	B-X
in	B-X
normal	B-X
granulopoiesis	B-X
remains	B-X
uncertain	B-X
because	B-X
most	B-X
studies	B-X
addressing	B-X
this	B-X
question	B-X
have	B-X
used	B-X
non	B-X
-	B-X
physiological	B-X
overexpression	B-X
systems	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
block	B-X
in	B-X
granulopoiesis	B-X
exerted	B-X
by	B-X
RARalpha	B-X
fusion	B-X
proteins	B-X
expressed	B-X
in	B-X
APL	B-X
cells	B-X
may	B-X
correspond	B-X
to	B-X
an	B-X
amplification	B-X
of	B-X
a	B-X
normal	B-X
function	B-X
of	B-X
unliganded	B-X
RARalpha	B-X
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
RARalpha	B-X
is	B-X
dispensable	B-X
for	B-X
granulopoiesis	B-X
,	B-X
as	B-X
RARalpha	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
have	B-X
a	B-X
normal	B-X
granulocyte	B-X
population	B-X
despite	B-X
an	B-X
impaired	B-X
ability	B-X
to	B-X
respond	B-X
to	B-X
retinoids	B-X
<EOS>	B-X
Granulocyte	B-X
differentiation	B-X
in	B-X
cells	B-X
derived	B-X
from	B-X
RARalpha	B-X
-	B-X
deficient	B-X
(	B-X
RARalpha	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
mice	B-X
was	B-X
studied	B-X
and	B-X
evaluated	B-X
in	B-X
the	B-X
context	B-X
of	B-X
agonist	B-X
-	B-X
bound	B-X
and	B-X
ligand	B-X
-	B-X
free	B-X
RARalpha	B-X

Granulocyte	O
differentiation	O
in	O
cells	O
derived	O
from	O
RARalpha-deficient	O
(	O
RARalpha	O
(	O
-/-	O
)	O
)	O
mice	O
was	O
studied	O
and	O
evaluated	O
in	O
the	O
context	O
of	O
agonist-bound	B-protein
and	I-protein
ligand-free	I-protein
RARalpha	I-protein
.	O

Our	O
results	O
demonstrate	O
that	O
RARalpha	B-protein
is	O
dispensable	O
for	O
granulopoiesis	O
,	O
as	O
RARalpha	O
(	O
-/-	O
)	O
mice	O
have	O
a	O
normal	B-cell_type
granulocyte	I-cell_type
population	I-cell_type
despite	O
an	O
impaired	O
ability	O
to	O
respond	O
to	O
retinoids	O
.	O
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
RARalpha	B-X
is	B-X
dispensable	B-X
for	B-X
granulopoiesis	B-X
,	B-X
as	B-X
RARalpha	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
have	B-X
a	B-X
normal	B-X
granulocyte	B-X
population	B-X
despite	B-X
an	B-X
impaired	B-X
ability	B-X
to	B-X
respond	B-X
to	B-X
retinoids	B-X
<EOS>	B-X
Granulocyte	B-X
differentiation	B-X
in	B-X
cells	B-X
derived	B-X
from	B-X
RARalpha	B-X
-	B-X
deficient	B-X
(	B-X
RARalpha	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
mice	B-X
was	B-X
studied	B-X
and	B-X
evaluated	B-X
in	B-X
the	B-X
context	B-X
of	B-X
agonist	B-X
-	B-X
bound	B-X
and	B-X
ligand	B-X
-	B-X
free	B-X
RARalpha	B-X
<EOS>	B-X
Whether	B-X
these	B-X
translocations	B-X
relate	B-X
to	B-X
a	B-X
role	B-X
for	B-X
endogenous	B-X
RARalpha	B-X
in	B-X
normal	B-X
granulopoiesis	B-X
remains	B-X
uncertain	B-X
because	B-X
most	B-X
studies	B-X
addressing	B-X
this	B-X
question	B-X
have	B-X
used	B-X
non	B-X
-	B-X
physiological	B-X
overexpression	B-X
systems	B-X
<EOS>	B-X
However	B-X
,	B-X
although	B-X
it	B-X
is	B-X
not	B-X
absolutely	B-X
required	B-X
,	B-X
RARalpha	B-X
can	B-X
bidirectionally	B-X
modulate	B-X
granulopoiesis	B-X

However	O
,	O
although	O
it	O
is	O
not	O
absolutely	O
required	O
,	O
RARalpha	B-protein
can	O
bidirectionally	O
modulate	O
granulopoiesis	O
.	O

RARalpha	B-protein
stimulates	O
differentiation	O
in	O
response	O
to	O
exogenous	O
retinoic	O
acid	O
.	O
<EOS>	B-X
RARalpha	B-X
stimulates	B-X
differentiation	B-X
in	B-X
response	B-X
to	B-X
exogenous	B-X
retinoic	B-X
acid	B-X
<EOS>	B-X
Conversely	B-X
,	B-X
RARalpha	B-X
acts	B-X
to	B-X
limit	B-X
differentiation	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ligand	B-X
because	B-X
granulocyte	B-X
precursors	B-X
from	B-X
RARalpha	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
differentiate	B-X
earlier	B-X
in	B-X
culture	B-X
<EOS>	B-X
Retinoids	B-X
stimulate	B-X
periosteal	B-X
bone	B-X
resorption	B-X
by	B-X
enhancing	B-X
the	B-X
protein	B-X
RANKL	B-X
,	B-X
a	B-X
response	B-X
inhibited	B-X
by	B-X
monomeric	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
Positive	B-X
and	B-X
negative	B-X
regulation	B-X
of	B-X
granulopoiesis	B-X
by	B-X
endogenous	B-X
RARalpha	B-X
.	B-X

Furthermore	O
,	O
endogenous	O
retinoids	O
control	O
granulopoiesis	O
in	O
vivo	O
,	O
as	O
either	O
vitamin	O
A-deficient	O
mice	O
or	O
animals	O
treated	O
with	O
an	O
RAR	O
antagonist	O
accumulate	O
more	O
immature	B-cell_type
granulocytes	I-cell_type
in	O
their	O
bone	O
marrow	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
endogenous	B-X
retinoids	B-X
control	B-X
granulopoiesis	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
either	B-X
vitamin	B-X
A	B-X
-	B-X
deficient	B-X
mice	B-X
or	B-X
animals	B-X
treated	B-X
with	B-X
an	B-X
RAR	B-X
antagonist	B-X
accumulate	B-X
more	B-X
immature	B-X
granulocytes	B-X
in	B-X
their	B-X
bone	B-X
marrow	B-X
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
RARalpha	B-X
is	B-X
dispensable	B-X
for	B-X
granulopoiesis	B-X
,	B-X
as	B-X
RARalpha	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
have	B-X
a	B-X
normal	B-X
granulocyte	B-X
population	B-X
despite	B-X
an	B-X
impaired	B-X
ability	B-X
to	B-X
respond	B-X
to	B-X
retinoids	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
block	B-X
in	B-X
granulopoiesis	B-X
exerted	B-X
by	B-X
RARalpha	B-X
fusion	B-X
proteins	B-X
expressed	B-X
in	B-X
APL	B-X
cells	B-X
may	B-X
correspond	B-X
to	B-X
an	B-X
amplification	B-X
of	B-X
a	B-X
normal	B-X
function	B-X
of	B-X
unliganded	B-X
RARalpha	B-X
<EOS>	B-X
However	B-X
,	B-X
although	B-X
it	B-X
is	B-X
not	B-X
absolutely	B-X
required	B-X
,	B-X
RARalpha	B-X
can	B-X
bidirectionally	B-X
modulate	B-X
granulopoiesis	B-X

Conversely	O
,	O
RARalpha	B-protein
acts	O
to	O
limit	O
differentiation	O
in	O
the	O
absence	O
of	O
ligand	B-protein
because	O
granulocyte	B-cell_type
precursors	I-cell_type
from	O
RARalpha	O
(	O
-/-	O
)	O
mice	O
differentiate	O
earlier	O
in	O
culture	O
.	O
<EOS>	B-X
Conversely	B-X
,	B-X
RARalpha	B-X
acts	B-X
to	B-X
limit	B-X
differentiation	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ligand	B-X
because	B-X
granulocyte	B-X
precursors	B-X
from	B-X
RARalpha	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
differentiate	B-X
earlier	B-X
in	B-X
culture	B-X
<EOS>	B-X
RARalpha	B-X
stimulates	B-X
differentiation	B-X
in	B-X
response	B-X
to	B-X
exogenous	B-X
retinoic	B-X
acid	B-X
<EOS>	B-X
However	B-X
,	B-X
although	B-X
it	B-X
is	B-X
not	B-X
absolutely	B-X
required	B-X
,	B-X
RARalpha	B-X
can	B-X
bidirectionally	B-X
modulate	B-X
granulopoiesis	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
endogenous	B-X
retinoids	B-X
control	B-X
granulopoiesis	B-X
in	B-X
vivo	B-X
,	B-X
as	B-X
either	B-X
vitamin	B-X
A	B-X
-	B-X
deficient	B-X
mice	B-X
or	B-X
animals	B-X
treated	B-X
with	B-X
an	B-X
RAR	B-X
antagonist	B-X
accumulate	B-X
more	B-X
immature	B-X
granulocytes	B-X
in	B-X
their	B-X
bone	B-X
marrow	B-X

Thus	O
,	O
the	O
block	O
in	O
granulopoiesis	O
exerted	O
by	O
RARalpha	B-protein
fusion	B-protein
proteins	I-protein
expressed	O
in	O
APL	B-cell_type
cells	I-cell_type
may	O
correspond	O
to	O
an	O
amplification	O
of	O
a	O
normal	O
function	O
of	O
unliganded	B-protein
RARalpha	I-protein
.	O

Expression	O
and	O
function	O
of	O
a	O
stem	B-DNA
cell	I-DNA
promoter	I-DNA
for	O
the	O
murine	B-DNA
CBFalpha2	I-DNA
gene	I-DNA
:	O
distinct	O
roles	O
and	O
regulation	O
in	O
natural	B-cell_type
killer	I-cell_type
and	I-cell_type
T	I-cell_type
cell	I-cell_type
development	O
.	O

The	O
Runt	B-protein
family	I-protein
transcription	I-protein
factor	I-protein
CBFalpha2	B-protein
(	O
AML1	B-protein
,	O
PEBP2alphaB	B-protein
,	O
or	O
Runx1	B-protein
)	O
is	O
required	O
by	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
expressed	O
at	O
high	O
levels	O
in	O
T-lineage	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
Runt	B-X
family	B-X
transcription	B-X
factor	B-X
CBFalpha2	B-X
(	B-X
AML1	B-X
,	B-X
PEBP2alphaB	B-X
,	B-X
or	B-X
Runx1	B-X
)	B-X
is	B-X
required	B-X
by	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
expressed	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
T	B-X
-	B-X
lineage	B-X
cells	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
both	B-X
coding	B-X
and	B-X
noncoding	B-X
sequences	B-X
of	B-X
the	B-X
distal	B-X
5	B-X
'	B-X
end	B-X
are	B-X
highly	B-X
conserved	B-X
between	B-X
the	B-X
human	B-X
and	B-X
the	B-X
murine	B-X
genes	B-X
,	B-X
and	B-X
the	B-X
distal	B-X
promoter	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
overwhelming	B-X
majority	B-X
of	B-X
CBFalpha2	B-X
expression	B-X
in	B-X
murine	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
Neither	B-X
full	B-X
-	B-X
length	B-X
isoform	B-X
alters	B-X
growth	B-X
of	B-X
a	B-X
myeloid	B-X
cell	B-X
line	B-X
under	B-X
nondifferentiating	B-X
conditions	B-X
,	B-X
but	B-X
the	B-X
proximal	B-X
isoform	B-X
selectively	B-X
delays	B-X
mitotic	B-X
arrest	B-X
of	B-X
the	B-X
cell	B-X
line	B-X
under	B-X
differentiating	B-X
conditions	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
generation	B-X
of	B-X
greater	B-X
numbers	B-X
of	B-X
neutrophils	B-X
<EOS>	B-X
In	B-X
human	B-X
T	B-X
cells	B-X
CBFalpha2	B-X
is	B-X
usually	B-X
transcribed	B-X
from	B-X
a	B-X
different	B-X
promoter	B-X
(	B-X
distal	B-X
promoter	B-X
)	B-X
than	B-X
in	B-X
myeloid	B-X
cells	B-X
(	B-X
proximal	B-X
promoter	B-X
)	B-X
,	B-X
but	B-X
the	B-X
developmental	B-X
and	B-X
functional	B-X
significance	B-X
of	B-X
this	B-X
promoter	B-X
switch	B-X
has	B-X
not	B-X
been	B-X
known	B-X

In	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
CBFalpha2	B-protein
is	O
usually	O
transcribed	O
from	O
a	O
different	B-DNA
promoter	I-DNA
(	O
distal	B-DNA
promoter	I-DNA
)	O
than	O
in	O
myeloid	B-cell_type
cells	I-cell_type
(	O
proximal	B-DNA
promoter	I-DNA
)	O
,	O
but	O
the	O
developmental	O
and	O
functional	O
significance	O
of	O
this	O
promoter	O
switch	O
has	O
not	O
been	O
known	O
.	O

Here	O
,	O
we	O
report	O
that	O
both	O
coding	B-DNA
and	I-DNA
noncoding	I-DNA
sequences	I-DNA
of	O
the	O
distal	B-DNA
5	I-DNA
'	I-DNA
end	I-DNA
are	O
highly	O
conserved	O
between	O
the	O
human	B-DNA
and	I-DNA
the	I-DNA
murine	I-DNA
genes	I-DNA
,	O
and	O
the	O
distal	B-DNA
promoter	I-DNA
is	O
responsible	O
for	O
the	O
overwhelming	O
majority	O
of	O
CBFalpha2	O
expression	O
in	O
murine	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Distal	O
promoter	O
activity	O
is	O
maintained	O
throughout	O
T	O
cell	O
development	O
and	O
at	O
lower	O
levels	O
in	O
B	O
cell	O
development	O
,	O
but	O
downregulated	O
in	O
natural	O
killer	O
cell	O
development	O
.	O

The	O
distal	B-DNA
N-terminal	I-DNA
isoform	I-DNA
binds	O
to	O
functionally	O
important	O
regulatory	B-DNA
sites	I-DNA
from	O
known	O
target	B-DNA
genes	I-DNA
with	O
two-	O
to	O
threefold	O
higher	O
affinity	O
than	O
the	O
proximal	B-DNA
N-terminal	I-DNA
isoform	I-DNA
.	O

Neither	O
full-length	B-DNA
isoform	I-DNA
alters	O
growth	O
of	O
a	O
myeloid	B-cell_line
cell	I-cell_line
line	I-cell_line
under	O
nondifferentiating	O
conditions	O
,	O
but	O
the	O
proximal	B-DNA
isoform	I-DNA
selectively	O
delays	O
mitotic	O
arrest	O
of	O
the	O
cell	O
line	O
under	O
differentiating	O
conditions	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
greater	O
numbers	O
of	O
neutrophils	B-cell_type
.	O
<EOS>	B-X
Neither	B-X
full	B-X
-	B-X
length	B-X
isoform	B-X
alters	B-X
growth	B-X
of	B-X
a	B-X
myeloid	B-X
cell	B-X
line	B-X
under	B-X
nondifferentiating	B-X
conditions	B-X
,	B-X
but	B-X
the	B-X
proximal	B-X
isoform	B-X
selectively	B-X
delays	B-X
mitotic	B-X
arrest	B-X
of	B-X
the	B-X
cell	B-X
line	B-X
under	B-X
differentiating	B-X
conditions	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
generation	B-X
of	B-X
greater	B-X
numbers	B-X
of	B-X
neutrophils	B-X
<EOS>	B-X
The	B-X
distal	B-X
N	B-X
-	B-X
terminal	B-X
isoform	B-X
binds	B-X
to	B-X
functionally	B-X
important	B-X
regulatory	B-X
sites	B-X
from	B-X
known	B-X
target	B-X
genes	B-X
with	B-X
two	B-X
-	B-X
	B-X
to	B-X
threefold	B-X
higher	B-X
affinity	B-X
than	B-X
the	B-X
proximal	B-X
N	B-X
-	B-X
terminal	B-X
isoform	B-X
<EOS>	B-X
Distal	B-X
promoter	B-X
activity	B-X
is	B-X
maintained	B-X
throughout	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
at	B-X
lower	B-X
levels	B-X
in	B-X
B	B-X
cell	B-X
development	B-X
,	B-X
but	B-X
downregulated	B-X
in	B-X
natural	B-X
killer	B-X
cell	B-X
development	B-X
<EOS>	B-X
In	B-X
human	B-X
T	B-X
cells	B-X
CBFalpha2	B-X
is	B-X
usually	B-X
transcribed	B-X
from	B-X
a	B-X
different	B-X
promoter	B-X
(	B-X
distal	B-X
promoter	B-X
)	B-X
than	B-X
in	B-X
myeloid	B-X
cells	B-X
(	B-X
proximal	B-X
promoter	B-X
)	B-X
,	B-X
but	B-X
the	B-X
developmental	B-X
and	B-X
functional	B-X
significance	B-X
of	B-X
this	B-X
promoter	B-X
switch	B-X
has	B-X
not	B-X
been	B-X
known	B-X

Constitutive	O
PI3-K	O
activity	O
is	O
essential	O
for	O
proliferation	O
,	O
but	O
not	O
survival	O
,	O
of	O
Theileria	B-cell_type
parva-transformed	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Rac	B-X
is	B-X
essential	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
endothelial	B-X
cells	B-X
by	B-X
polyoma	B-X
middle	B-X
T	B-X
.	B-X
<EOS>	B-X
The	B-X
downstream	B-X
Rac	B-X
effectors	B-X
,	B-X
P13	B-X
-	B-X
K	B-X
and	B-X
p70S6k	B-X
,	B-X
mediate	B-X
PyMT	B-X
/	B-X
Rac	B-X
effects	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
cyst	B-X
formation	B-X
,	B-X
but	B-X
other	B-X
unknown	B-X
effectors	B-X
of	B-X
PyMT	B-X
are	B-X
required	B-X
for	B-X
the	B-X
cytoskeletal	B-X
changes	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
PA	B-X
/	B-X
plasmin	B-X
system	B-X
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
N17	B-X
Rac	B-X
action	B-X
in	B-X
blocking	B-X
the	B-X
endothelial	B-X
cell	B-X
transformant	B-X
,	B-X
PyMT	B-X
,	B-X
did	B-X
not	B-X
involve	B-X
effects	B-X
of	B-X
Rac	B-X
on	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
since	B-X
this	B-X
component	B-X
of	B-X
the	B-X
bEND	B-X
<EOS>	B-X
3	B-X
,	B-X
expressing	B-X
constitutively	B-X
active	B-X
and	B-X
dominant	B-X
negative	B-X
mutants	B-X
of	B-X
the	B-X
small	B-X
GTPase	B-X
Rac	B-X

Theileria	O
is	O
an	O
intracellular	O
parasite	O
that	O
causes	O
lymphoproliferative	O
disorders	O
in	O
cattle	O
,	O
and	O
infection	O
of	O
leucocytes	B-cell_type
induces	O
a	O
transformed	O
phenotype	O
similar	O
to	O
tumour	B-cell_type
cells	I-cell_type
,	O
but	O
the	O
mechanisms	O
by	O
which	O
the	O
parasite	O
induces	O
this	O
phenotype	O
are	O
not	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
infected	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
display	O
constitutive	O
phosphoinositide	O
3-kinase	O
(	O
PI3-K	O
)	O
activity	O
,	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
proliferation	O
,	O
but	O
not	O
survival	O
.	O

Importantly	O
,	O
we	O
demonstrate	O
that	O
one	O
mechanism	O
by	O
which	O
PI3-K	B-protein
mediates	O
the	O
proliferation	O
of	O
infected	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
is	O
through	O
the	O
induction	O
of	O
a	O
granulocyte-monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
-dependent	O
autocrine	O
loop	O
.	O
<EOS>	B-X
Importantly	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
one	B-X
mechanism	B-X
by	B-X
which	B-X
PI3	B-X
-	B-X
K	B-X
mediates	B-X
the	B-X
proliferation	B-X
of	B-X
infected	B-X
B	B-X
lymphocytes	B-X
is	B-X
through	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
granulocyte	B-X
-	B-X
monocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
	B-X
-	B-X
dependent	B-X
autocrine	B-X
loop	B-X
<EOS>	B-X
Constitutive	B-X
PI3	B-X
-	B-X
K	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
proliferation	B-X
,	B-X
but	B-X
not	B-X
survival	B-X
,	B-X
of	B-X
Theileria	B-X
parva	B-X
-	B-X
transformed	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
Theileria	B-X
is	B-X
an	B-X
intracellular	B-X
parasite	B-X
that	B-X
causes	B-X
lymphoproliferative	B-X
disorders	B-X
in	B-X
cattle	B-X
,	B-X
and	B-X
infection	B-X
of	B-X
leucocytes	B-X
induces	B-X
a	B-X
transformed	B-X
phenotype	B-X
similar	B-X
to	B-X
tumour	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
parasite	B-X
induces	B-X
this	B-X
phenotype	B-X
are	B-X
not	B-X
understood	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
highlight	B-X
a	B-X
novel	B-X
strategy	B-X
exploited	B-X
by	B-X
the	B-X
intracellular	B-X
parasite	B-X
Theileria	B-X
to	B-X
induce	B-X
continued	B-X
proliferation	B-X
of	B-X
its	B-X
host	B-X
leucocyte	B-X

PI3-K	B-protein
induction	O
of	O
GM-CSF	B-protein
appears	O
to	O
be	O
at	O
the	O
transcriptional	O
level	O
and	O
,	O
consistently	O
,	O
we	O
demonstrate	O
that	O
PI3-K	B-protein
is	O
also	O
involved	O
in	O
the	O
constitutive	O
induction	O
of	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
,	O
which	O
characterizes	O
Theileria-infected	O
leucocytes	B-cell_type
.	O
<EOS>	B-X
PI3	B-X
-	B-X
K	B-X
induction	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
appears	B-X
to	B-X
be	B-X
at	B-X
the	B-X
transcriptional	B-X
level	B-X
and	B-X
,	B-X
consistently	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
PI3	B-X
-	B-X
K	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
the	B-X
constitutive	B-X
induction	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
which	B-X
characterizes	B-X
Theileria	B-X
-	B-X
infected	B-X
leucocytes	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
highlight	B-X
a	B-X
novel	B-X
strategy	B-X
exploited	B-X
by	B-X
the	B-X
intracellular	B-X
parasite	B-X
Theileria	B-X
to	B-X
induce	B-X
continued	B-X
proliferation	B-X
of	B-X
its	B-X
host	B-X
leucocyte	B-X
<EOS>	B-X
Theileria	B-X
is	B-X
an	B-X
intracellular	B-X
parasite	B-X
that	B-X
causes	B-X
lymphoproliferative	B-X
disorders	B-X
in	B-X
cattle	B-X
,	B-X
and	B-X
infection	B-X
of	B-X
leucocytes	B-X
induces	B-X
a	B-X
transformed	B-X
phenotype	B-X
similar	B-X
to	B-X
tumour	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
parasite	B-X
induces	B-X
this	B-X
phenotype	B-X
are	B-X
not	B-X
understood	B-X
<EOS>	B-X
Constitutive	B-X
PI3	B-X
-	B-X
K	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
proliferation	B-X
,	B-X
but	B-X
not	B-X
survival	B-X
,	B-X
of	B-X
Theileria	B-X
parva	B-X
-	B-X
transformed	B-X
B	B-X
cells	B-X
.	B-X

Taken	O
together	O
,	O
our	O
results	O
highlight	O
a	O
novel	O
strategy	O
exploited	O
by	O
the	O
intracellular	O
parasite	O
Theileria	O
to	O
induce	O
continued	O
proliferation	O
of	O
its	O
host	B-cell_type
leucocyte	I-cell_type
.	O
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
highlight	B-X
a	B-X
novel	B-X
strategy	B-X
exploited	B-X
by	B-X
the	B-X
intracellular	B-X
parasite	B-X
Theileria	B-X
to	B-X
induce	B-X
continued	B-X
proliferation	B-X
of	B-X
its	B-X
host	B-X
leucocyte	B-X
<EOS>	B-X
PI3	B-X
-	B-X
K	B-X
induction	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
appears	B-X
to	B-X
be	B-X
at	B-X
the	B-X
transcriptional	B-X
level	B-X
and	B-X
,	B-X
consistently	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
PI3	B-X
-	B-X
K	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
the	B-X
constitutive	B-X
induction	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
which	B-X
characterizes	B-X
Theileria	B-X
-	B-X
infected	B-X
leucocytes	B-X
<EOS>	B-X
Theileria	B-X
is	B-X
an	B-X
intracellular	B-X
parasite	B-X
that	B-X
causes	B-X
lymphoproliferative	B-X
disorders	B-X
in	B-X
cattle	B-X
,	B-X
and	B-X
infection	B-X
of	B-X
leucocytes	B-X
induces	B-X
a	B-X
transformed	B-X
phenotype	B-X
similar	B-X
to	B-X
tumour	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
parasite	B-X
induces	B-X
this	B-X
phenotype	B-X
are	B-X
not	B-X
understood	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
infected	B-X
B	B-X
lymphocytes	B-X
display	B-X
constitutive	B-X
phosphoinositide	B-X
3	B-X
-	B-X
kinase	B-X
(	B-X
PI3	B-X
-	B-X
K	B-X
)	B-X
activity	B-X
,	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
proliferation	B-X
,	B-X
but	B-X
not	B-X
survival	B-X

Lymphokine	B-protein
dependence	O
of	O
STAT3	O
activation	O
produced	O
by	O
surface	O
immunoglobulin	O
cross-linking	O
and	O
by	O
phorbol	O
ester	O
plus	O
calcium	O
ionophore	O
treatment	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Stimulation	O
of	O
B	B-cell_type
cells	I-cell_type
by	O
surface	B-protein
immunoglobulin	I-protein
(	O
sIg	B-protein
)	O
triggering	O
,	O
or	O
through	O
the	O
mitogenic	O
combination	O
of	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
,	O
is	O
accompanied	O
by	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
B	B-X
cells	B-X
by	B-X
surface	B-X
immunoglobulin	B-X
(	B-X
sIg	B-X
)	B-X
triggering	B-X
,	B-X
or	B-X
through	B-X
the	B-X
mitogenic	B-X
combination	B-X
of	B-X
phorbol	B-X
ester	B-X
and	B-X
calcium	B-X
ionophore	B-X
,	B-X
is	B-X
accompanied	B-X
by	B-X
activation	B-X
of	B-X
STAT	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Antigen	B-X
recognition	B-X
via	B-X
the	B-X
surface	B-X
immunoglobulin	B-X
(	B-X
sIg	B-X
)	B-X
receptor	B-X
leads	B-X
to	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
clonal	B-X
expansion	B-X
,	B-X
priming	B-X
the	B-X
cell	B-X
to	B-X
secrete	B-X
specific	B-X
antibody	B-X
<EOS>	B-X
Activation	B-X
of	B-X
human	B-X
B	B-X
cells	B-X
in	B-X
vitro	B-X
either	B-X
by	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
surface	B-X
immunoglobulins	B-X
(	B-X
sIg	B-X
)	B-X
or	B-X
by	B-X
triggering	B-X
CD40	B-X
antigen	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
interleukin	B-X
-	B-X
10	B-X
(	B-X
IL	B-X
-	B-X
10	B-X
)	B-X
and	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
,	B-X
may	B-X
result	B-X
in	B-X
high	B-X
levels	B-X
of	B-X
immunoglobulin	B-X
secretion	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
enter	B-X
S	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
combination	B-X
of	B-X
phorbol	B-X
ester	B-X
plus	B-X
calcium	B-X
ionophore	B-X
also	B-X
stimulated	B-X
nuclear	B-X
TRE	B-X
-	B-X
binding	B-X
activity	B-X
within	B-X
2	B-X
h	B-X
,	B-X
with	B-X
maximal	B-X
expression	B-X
at	B-X
4	B-X
h	B-X
;	B-X
however	B-X
,	B-X
phorbol	B-X
ester	B-X
and	B-X
calcium	B-X
ionophore	B-X
were	B-X
not	B-X
as	B-X
effective	B-X
in	B-X
stimulating	B-X
binding	B-X
activity	B-X
when	B-X
examined	B-X
separately	B-X

The	O
mechanism	O
responsible	O
for	O
the	O
delayed	O
nuclear	O
accumulation	O
of	O
phosphorylated	B-protein
STAT3	I-protein
was	O
examined	O
in	O
detail	O
,	O
focusing	O
on	O
the	O
role	O
of	O
B	B-protein
cell-derived	I-protein
lymphokines	I-protein
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
responsible	B-X
for	B-X
the	B-X
delayed	B-X
nuclear	B-X
accumulation	B-X
of	B-X
phosphorylated	B-X
STAT3	B-X
was	B-X
examined	B-X
in	B-X
detail	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
role	B-X
of	B-X
B	B-X
cell	B-X
-	B-X
derived	B-X
lymphokines	B-X
<EOS>	B-X
This	B-X
work	B-X
indicates	B-X
that	B-X
a	B-X
lymphokine	B-X
pathway	B-X
is	B-X
responsible	B-X
for	B-X
STAT3	B-X
activation	B-X
that	B-X
occurs	B-X
late	B-X
after	B-X
B	B-X
cell	B-X
stimulation	B-X
,	B-X
and	B-X
points	B-X
out	B-X
differences	B-X
in	B-X
B	B-X
cell	B-X
activation	B-X
that	B-X
result	B-X
from	B-X
stimulation	B-X
through	B-X
the	B-X
antigen	B-X
receptor	B-X
and	B-X
through	B-X
pharmacological	B-X
mimicry	B-X
of	B-X
signaling	B-X
mediators	B-X
<EOS>	B-X
In	B-X
keeping	B-X
with	B-X
these	B-X
results	B-X
,	B-X
soluble	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
were	B-X
found	B-X
in	B-X
supernatant	B-X
fluid	B-X
obtained	B-X
from	B-X
stimulated	B-X
B	B-X
cells	B-X
<EOS>	B-X
sIg	B-X
-	B-X
induced	B-X
STAT3	B-X
activation	B-X
was	B-X
completely	B-X
inhibited	B-X
by	B-X
combining	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
-	B-X
specific	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
or	B-X
by	B-X
adding	B-X
individual	B-X
neutralizing	B-X
antibodies	B-X
to	B-X
B	B-X
cells	B-X
obtained	B-X
from	B-X
lymphokine	B-X
-	B-X
deficient	B-X
animals	B-X

sIg	B-protein
-induced	O
activation	O
of	O
STAT3	B-protein
was	O
partially	O
inhibited	O
in	O
B	B-cell_type
cells	I-cell_type
obtained	O
from	O
IL-6-	O
or	O
IL-10-deficient	O
mice	O
,	O
and	O
was	O
partially	O
blocked	O
by	O
neutralizing	B-protein
antibodies	I-protein
directed	O
against	O
either	O
of	O
these	O
lymphokines	B-protein
.	O
<EOS>	B-X
sIg	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
STAT3	B-X
was	B-X
partially	B-X
inhibited	B-X
in	B-X
B	B-X
cells	B-X
obtained	B-X
from	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
	B-X
or	B-X
IL	B-X
-	B-X
10	B-X
-	B-X
deficient	B-X
mice	B-X
,	B-X
and	B-X
was	B-X
partially	B-X
blocked	B-X
by	B-X
neutralizing	B-X
antibodies	B-X
directed	B-X
against	B-X
either	B-X
of	B-X
these	B-X
lymphokines	B-X
<EOS>	B-X
sIg	B-X
-	B-X
induced	B-X
STAT3	B-X
activation	B-X
was	B-X
completely	B-X
inhibited	B-X
by	B-X
combining	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
-	B-X
specific	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
or	B-X
by	B-X
adding	B-X
individual	B-X
neutralizing	B-X
antibodies	B-X
to	B-X
B	B-X
cells	B-X
obtained	B-X
from	B-X
lymphokine	B-X
-	B-X
deficient	B-X
animals	B-X
<EOS>	B-X
Lymphokine	B-X
dependence	B-X
of	B-X
STAT3	B-X
activation	B-X
produced	B-X
by	B-X
surface	B-X
immunoglobulin	B-X
cross	B-X
-	B-X
linking	B-X
and	B-X
by	B-X
phorbol	B-X
ester	B-X
plus	B-X
calcium	B-X
ionophore	B-X
treatment	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
The	B-X
mechanism	B-X
responsible	B-X
for	B-X
the	B-X
delayed	B-X
nuclear	B-X
accumulation	B-X
of	B-X
phosphorylated	B-X
STAT3	B-X
was	B-X
examined	B-X
in	B-X
detail	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
role	B-X
of	B-X
B	B-X
cell	B-X
-	B-X
derived	B-X
lymphokines	B-X

sIg	B-protein
-induced	O
STAT3	O
activation	O
was	O
completely	O
inhibited	O
by	O
combining	O
IL-6-	B-protein
and	I-protein
IL-10-specific	I-protein
neutralizing	I-protein
antibodies	I-protein
,	O
or	O
by	O
adding	O
individual	O
neutralizing	B-protein
antibodies	I-protein
to	O
B	B-cell_type
cells	I-cell_type
obtained	O
from	O
lymphokine-deficient	O
animals	O
.	O
<EOS>	B-X
sIg	B-X
-	B-X
induced	B-X
STAT3	B-X
activation	B-X
was	B-X
completely	B-X
inhibited	B-X
by	B-X
combining	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
-	B-X
specific	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
or	B-X
by	B-X
adding	B-X
individual	B-X
neutralizing	B-X
antibodies	B-X
to	B-X
B	B-X
cells	B-X
obtained	B-X
from	B-X
lymphokine	B-X
-	B-X
deficient	B-X
animals	B-X
<EOS>	B-X
sIg	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
STAT3	B-X
was	B-X
partially	B-X
inhibited	B-X
in	B-X
B	B-X
cells	B-X
obtained	B-X
from	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
	B-X
or	B-X
IL	B-X
-	B-X
10	B-X
-	B-X
deficient	B-X
mice	B-X
,	B-X
and	B-X
was	B-X
partially	B-X
blocked	B-X
by	B-X
neutralizing	B-X
antibodies	B-X
directed	B-X
against	B-X
either	B-X
of	B-X
these	B-X
lymphokines	B-X
<EOS>	B-X
In	B-X
keeping	B-X
with	B-X
these	B-X
results	B-X
,	B-X
soluble	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
were	B-X
found	B-X
in	B-X
supernatant	B-X
fluid	B-X
obtained	B-X
from	B-X
stimulated	B-X
B	B-X
cells	B-X
<EOS>	B-X
Lymphokine	B-X
dependence	B-X
of	B-X
STAT3	B-X
activation	B-X
produced	B-X
by	B-X
surface	B-X
immunoglobulin	B-X
cross	B-X
-	B-X
linking	B-X
and	B-X
by	B-X
phorbol	B-X
ester	B-X
plus	B-X
calcium	B-X
ionophore	B-X
treatment	B-X
in	B-X
B	B-X
cells	B-X
.	B-X

In	O
contrast	O
,	O
IL-10	B-protein
alone	O
appeared	O
to	O
account	O
for	O
STAT3	O
activation	O
resulting	O
from	O
B	O
cell	O
stimulation	O
with	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
.	O

In	O
keeping	O
with	O
these	O
results	O
,	O
soluble	O
IL-6	B-protein
and	O
IL-10	B-protein
were	O
found	O
in	O
supernatant	O
fluid	O
obtained	O
from	O
stimulated	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
In	B-X
keeping	B-X
with	B-X
these	B-X
results	B-X
,	B-X
soluble	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
were	B-X
found	B-X
in	B-X
supernatant	B-X
fluid	B-X
obtained	B-X
from	B-X
stimulated	B-X
B	B-X
cells	B-X
<EOS>	B-X
sIg	B-X
-	B-X
induced	B-X
STAT3	B-X
activation	B-X
was	B-X
completely	B-X
inhibited	B-X
by	B-X
combining	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
-	B-X
specific	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
or	B-X
by	B-X
adding	B-X
individual	B-X
neutralizing	B-X
antibodies	B-X
to	B-X
B	B-X
cells	B-X
obtained	B-X
from	B-X
lymphokine	B-X
-	B-X
deficient	B-X
animals	B-X
<EOS>	B-X
sIg	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
STAT3	B-X
was	B-X
partially	B-X
inhibited	B-X
in	B-X
B	B-X
cells	B-X
obtained	B-X
from	B-X
IL	B-X
-	B-X
6	B-X
-	B-X
	B-X
or	B-X
IL	B-X
-	B-X
10	B-X
-	B-X
deficient	B-X
mice	B-X
,	B-X
and	B-X
was	B-X
partially	B-X
blocked	B-X
by	B-X
neutralizing	B-X
antibodies	B-X
directed	B-X
against	B-X
either	B-X
of	B-X
these	B-X
lymphokines	B-X
<EOS>	B-X
Lymphokine	B-X
dependence	B-X
of	B-X
STAT3	B-X
activation	B-X
produced	B-X
by	B-X
surface	B-X
immunoglobulin	B-X
cross	B-X
-	B-X
linking	B-X
and	B-X
by	B-X
phorbol	B-X
ester	B-X
plus	B-X
calcium	B-X
ionophore	B-X
treatment	B-X
in	B-X
B	B-X
cells	B-X
.	B-X

This	O
work	O
indicates	O
that	O
a	O
lymphokine	O
pathway	O
is	O
responsible	O
for	O
STAT3	O
activation	O
that	O
occurs	O
late	O
after	O
B	O
cell	O
stimulation	O
,	O
and	O
points	O
out	O
differences	O
in	O
B	O
cell	O
activation	O
that	O
result	O
from	O
stimulation	O
through	O
the	O
antigen	B-protein
receptor	I-protein
and	O
through	O
pharmacological	O
mimicry	O
of	O
signaling	B-protein
mediators	I-protein
.	O

Transcription	B-protein
factor	I-protein
AP-4	I-protein
is	O
a	O
ligand	B-protein
for	O
immunoglobulin-kappa	B-DNA
promoter	I-DNA
E-box	I-DNA
elements	I-DNA
.	O
<EOS>	B-X
Transcription	B-X
factor	B-X
AP	B-X
-	B-X
4	B-X
is	B-X
a	B-X
ligand	B-X
for	B-X
immunoglobulin	B-X
-	B-X
kappa	B-X
promoter	B-X
E	B-X
-	B-X
box	B-X
elements	B-X
.	B-X
<EOS>	B-X
3	B-X
has	B-X
been	B-X
recently	B-X
sequenced	B-X
and	B-X
the	B-X
interval	B-X
contains	B-X
a	B-X
transcription	B-X
factor	B-X
,	B-X
AP	B-X
-	B-X
4	B-X
,	B-X
that	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
ligand	B-X
for	B-X
immunoglobulin	B-X
-	B-X
kappa	B-X
promoter	B-X
E	B-X
-	B-X
box	B-X
elements	B-X
,	B-X
(	B-X
1	B-X
)	B-X
suggesting	B-X
that	B-X
AP	B-X
-	B-X
4	B-X
may	B-X
be	B-X
related	B-X
to	B-X
immunodeficiency	B-X
diseases	B-X
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
and	B-X
the	B-X
conservation	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
CAGCTG	B-X
-	B-X
3	B-X
'	B-X
motif	B-X
among	B-X
human	B-X
and	B-X
murine	B-X
kappa	B-X
promoters	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
AP	B-X
-	B-X
4	B-X
is	B-X
the	B-X
major	B-X
ligand	B-X
for	B-X
Ig	B-X
-	B-X
kappa	B-X
promoter	B-X
E	B-X
-	B-X
boxes	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
AP	B-X
-	B-X
4	B-X
,	B-X
unlike	B-X
E47	B-X
,	B-X
did	B-X
not	B-X
act	B-X
as	B-X
a	B-X
transactivator	B-X
,	B-X
which	B-X
is	B-X
in	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
on	B-X
intact	B-X
kappa	B-X
promoters	B-X
,	B-X
showing	B-X
that	B-X
transcription	B-X
is	B-X
absent	B-X
when	B-X
the	B-X
octamer	B-X
element	B-X
has	B-X
been	B-X
mutated	B-X

Immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
-kappa	I-DNA
promoters	I-DNA
from	O
humans	O
and	O
mice	O
share	O
conserved	B-DNA
sequences	I-DNA
.	O
<EOS>	B-X
Immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
	B-X
-	B-X
kappa	B-X
promoters	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
share	B-X
conserved	B-X
sequences	B-X
<EOS>	B-X
This	B-X
article	B-X
discusses	B-X
recent	B-X
discoveries	B-X
from	B-X
the	B-X
author	B-X
's	B-X
laboratory	B-X
that	B-X
address	B-X
this	B-X
long	B-X
-	B-X
standing	B-X
issue	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
transcriptional	B-X
promoters	B-X
are	B-X
critical	B-X
cis	B-X
-	B-X
acting	B-X
regulatory	B-X
elements	B-X
for	B-X
targeting	B-X
efficient	B-X
recombination	B-X
of	B-X
chromosomal	B-X
gene	B-X
segments	B-X
<EOS>	B-X
The	B-X
octamer	B-X
element	B-X
is	B-X
common	B-X
to	B-X
all	B-X
Ig	B-X
promoters	B-X
and	B-X
pivotal	B-X
for	B-X
their	B-X
function	B-X

The	O
octamer	B-DNA
element	I-DNA
is	O
common	O
to	O
all	O
Ig	B-DNA
promoters	I-DNA
and	O
pivotal	O
for	O
their	O
function	O
.	O
<EOS>	B-X
The	B-X
octamer	B-X
element	B-X
is	B-X
common	B-X
to	B-X
all	B-X
Ig	B-X
promoters	B-X
and	B-X
pivotal	B-X
for	B-X
their	B-X
function	B-X
<EOS>	B-X
However	B-X
,	B-X
other	B-X
conserved	B-X
sequence	B-X
motifs	B-X
,	B-X
that	B-X
differ	B-X
between	B-X
Ig	B-X
variable	B-X
gene	B-X
families	B-X
,	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
promoter	B-X
function	B-X
<EOS>	B-X
These	B-X
conserved	B-X
motifs	B-X
do	B-X
not	B-X
stimulate	B-X
transcription	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
octamer	B-X
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
and	B-X
the	B-X
conservation	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
CAGCTG	B-X
-	B-X
3	B-X
'	B-X
motif	B-X
among	B-X
human	B-X
and	B-X
murine	B-X
kappa	B-X
promoters	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
AP	B-X
-	B-X
4	B-X
is	B-X
the	B-X
major	B-X
ligand	B-X
for	B-X
Ig	B-X
-	B-X
kappa	B-X
promoter	B-X
E	B-X
-	B-X
boxes	B-X

However	O
,	O
other	O
conserved	B-DNA
sequence	I-DNA
motifs	I-DNA
,	O
that	O
differ	O
between	O
Ig	B-DNA
variable	I-DNA
gene	I-DNA
families	I-DNA
,	O
are	O
required	O
for	O
normal	O
promoter	O
function	O
.	O
<EOS>	B-X
However	B-X
,	B-X
other	B-X
conserved	B-X
sequence	B-X
motifs	B-X
,	B-X
that	B-X
differ	B-X
between	B-X
Ig	B-X
variable	B-X
gene	B-X
families	B-X
,	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
promoter	B-X
function	B-X
<EOS>	B-X
The	B-X
octamer	B-X
element	B-X
is	B-X
common	B-X
to	B-X
all	B-X
Ig	B-X
promoters	B-X
and	B-X
pivotal	B-X
for	B-X
their	B-X
function	B-X
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
and	B-X
the	B-X
conservation	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
CAGCTG	B-X
-	B-X
3	B-X
'	B-X
motif	B-X
among	B-X
human	B-X
and	B-X
murine	B-X
kappa	B-X
promoters	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
AP	B-X
-	B-X
4	B-X
is	B-X
the	B-X
major	B-X
ligand	B-X
for	B-X
Ig	B-X
-	B-X
kappa	B-X
promoter	B-X
E	B-X
-	B-X
boxes	B-X
<EOS>	B-X
These	B-X
conserved	B-X
motifs	B-X
do	B-X
not	B-X
stimulate	B-X
transcription	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
octamer	B-X

These	O
conserved	O
motifs	O
do	O
not	O
stimulate	O
transcription	O
in	O
the	O
absence	O
of	O
an	O
octamer	B-DNA
.	O
<EOS>	B-X
We	B-X
also	B-X
analyzed	B-X
these	B-X
substitutions	B-X
in	B-X
the	B-X
context	B-X
of	B-X
structure	B-X
<EOS>	B-X
This	B-X
highly	B-X
conserved	B-X
TCS	B-X
is	B-X
a	B-X
promising	B-X
target	B-X
for	B-X
the	B-X
construction	B-X
of	B-X
antibiotic	B-X
high	B-X
-	B-X
yield	B-X
strains	B-X
<EOS>	B-X
0	B-X
%	B-X
)	B-X
have	B-X
conserved	B-X
polymerase	B-X
active	B-X
-	B-X
site	B-X
motifs	B-X
,	B-X
while	B-X
HD	B-X
-	B-X
nuclease	B-X
domains	B-X
are	B-X
less	B-X
well	B-X
conserved	B-X
(	B-X
36	B-X
<EOS>	B-X
We	B-X
will	B-X
perform	B-X
a	B-X
genome	B-X
-	B-X
wide	B-X
analysis	B-X
of	B-X
the	B-X
LEA	B-X
gene	B-X
family	B-X
and	B-X
their	B-X
transcriptional	B-X
responses	B-X
to	B-X
dehydration	B-X
stress	B-X
in	B-X
recalcitrant	B-X
P	B-X

One	O
example	O
is	O
an	O
E-box	B-DNA
of	O
the	O
E47/E12	B-DNA
type	I-DNA
(	I-DNA
5'-CAGCTG-3	I-DNA
'	I-DNA
)	I-DNA
,	O
which	O
is	O
found	O
in	O
all	O
promoters	O
of	O
the	O
human	B-DNA
and	I-DNA
murine	I-DNA
Ig-kappa	I-DNA
gene	I-DNA
subgroups/families	I-DNA
,	O
with	O
the	O
exception	O
of	O
subgroups	O
II	O
and	O
VI	O
and	O
their	O
related	O
murine	B-DNA
families	I-DNA
.	O
<EOS>	B-X
One	B-X
example	B-X
is	B-X
an	B-X
E	B-X
-	B-X
box	B-X
of	B-X
the	B-X
E47	B-X
/	B-X
E12	B-X
type	B-X
(	B-X
5'	B-X
-	B-X
CAGCTG	B-X
-	B-X
3	B-X
'	B-X
)	B-X
,	B-X
which	B-X
is	B-X
found	B-X
in	B-X
all	B-X
promoters	B-X
of	B-X
the	B-X
human	B-X
and	B-X
murine	B-X
Ig	B-X
-	B-X
kappa	B-X
gene	B-X
subgroups	B-X
/	B-X
families	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
subgroups	B-X
II	B-X
and	B-X
VI	B-X
and	B-X
their	B-X
related	B-X
murine	B-X
families	B-X
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
and	B-X
the	B-X
conservation	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
CAGCTG	B-X
-	B-X
3	B-X
'	B-X
motif	B-X
among	B-X
human	B-X
and	B-X
murine	B-X
kappa	B-X
promoters	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
AP	B-X
-	B-X
4	B-X
is	B-X
the	B-X
major	B-X
ligand	B-X
for	B-X
Ig	B-X
-	B-X
kappa	B-X
promoter	B-X
E	B-X
-	B-X
boxes	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
AP	B-X
-	B-X
4	B-X
,	B-X
unlike	B-X
E47	B-X
,	B-X
did	B-X
not	B-X
act	B-X
as	B-X
a	B-X
transactivator	B-X
,	B-X
which	B-X
is	B-X
in	B-X
agreement	B-X
with	B-X
previous	B-X
studies	B-X
on	B-X
intact	B-X
kappa	B-X
promoters	B-X
,	B-X
showing	B-X
that	B-X
transcription	B-X
is	B-X
absent	B-X
when	B-X
the	B-X
octamer	B-X
element	B-X
has	B-X
been	B-X
mutated	B-X
<EOS>	B-X
However	B-X
,	B-X
other	B-X
conserved	B-X
sequence	B-X
motifs	B-X
,	B-X
that	B-X
differ	B-X
between	B-X
Ig	B-X
variable	B-X
gene	B-X
families	B-X
,	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
promoter	B-X
function	B-X

In	O
the	O
present	O
study	O
we	O
show	O
that	O
the	O
ubiquitously	O
expressed	O
transcription	B-protein
factor	I-protein
AP-4	I-protein
,	O
and	O
not	O
E47	B-protein
,	O
interacts	O
specifically	O
with	O
the	O
kappa	B-DNA
promoter	I-DNA
E-boxes	I-DNA
when	O
tested	O
in	O
electrophoretic	O
mobility-shift	O
assays	O
using	O
nuclear	O
extracts	O
derived	O
from	O
human	B-cell_line
and	I-cell_line
murine	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
Our	B-X
studies	B-X
also	B-X
show	B-X
that	B-X
transient	B-X
transfection	B-X
of	B-X
an	B-X
expression	B-X
vector	B-X
containing	B-X
AP4	B-X
coding	B-X
sequence	B-X
downregulates	B-X
the	B-X
expression	B-X
of	B-X
reporter	B-X
constructs	B-X
containing	B-X
human	B-X
angiotensinogen	B-X
gene	B-X
promoter	B-X
<EOS>	B-X
The	B-X
human	B-X
angiotensinogen	B-X
gene	B-X
has	B-X
a	B-X
C	B-X
/	B-X
A	B-X
polymorphism	B-X
located	B-X
at	B-X
	B-X
-	B-X
20	B-X
,	B-X
and	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
estrogen	B-X
receptor	B-X
-	B-X
alpha	B-X
binds	B-X
to	B-X
this	B-X
sequence	B-X
when	B-X
nucleoside	B-X
A	B-X
is	B-X
present	B-X
at	B-X
this	B-X
site	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
co	B-X
-	B-X
transfection	B-X
of	B-X
an	B-X
expression	B-X
vector	B-X
containing	B-X
AP4	B-X
coding	B-X
sequence	B-X
reduces	B-X
estrogen	B-X
-	B-X
induced	B-X
promoter	B-X
activity	B-X
of	B-X
reporter	B-X
constructs	B-X
containing	B-X
human	B-X
angiotensinogen	B-X
gene	B-X
promoter	B-X
(	B-X
with	B-X
nucleoside	B-X
A	B-X
at	B-X
	B-X
-	B-X
20	B-X
)	B-X
attached	B-X
to	B-X
the	B-X
CAT	B-X
gene	B-X
<EOS>	B-X
These	B-X
studies	B-X
partly	B-X
explain	B-X
the	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
tissue	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
the	B-X
human	B-X
angiotensinogen	B-X
gene	B-X

Furthermore	O
,	O
AP-4	B-protein
,	O
unlike	O
E47	B-protein
,	O
did	O
not	O
act	O
as	O
a	O
transactivator	B-protein
,	O
which	O
is	O
in	O
agreement	O
with	O
previous	O
studies	O
on	O
intact	O
kappa	B-DNA
promoters	I-DNA
,	O
showing	O
that	O
transcription	O
is	O
absent	O
when	O
the	O
octamer	B-DNA
element	I-DNA
has	O
been	O
mutated	O
.	O

Based	O
on	O
these	O
data	O
,	O
and	O
the	O
conservation	O
of	O
the	O
5'-CAGCTG-3	B-DNA
'	I-DNA
motif	I-DNA
among	O
human	B-DNA
and	I-DNA
murine	I-DNA
kappa	I-DNA
promoters	I-DNA
,	O
we	O
propose	O
that	O
AP-4	B-protein
is	O
the	O
major	B-protein
ligand	I-protein
for	O
Ig-kappa	B-DNA
promoter	I-DNA
E-boxes	I-DNA
.	O
<EOS>	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
and	B-X
the	B-X
conservation	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
CAGCTG	B-X
-	B-X
3	B-X
'	B-X
motif	B-X
among	B-X
human	B-X
and	B-X
murine	B-X
kappa	B-X
promoters	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
AP	B-X
-	B-X
4	B-X
is	B-X
the	B-X
major	B-X
ligand	B-X
for	B-X
Ig	B-X
-	B-X
kappa	B-X
promoter	B-X
E	B-X
-	B-X
boxes	B-X
<EOS>	B-X
However	B-X
,	B-X
other	B-X
conserved	B-X
sequence	B-X
motifs	B-X
,	B-X
that	B-X
differ	B-X
between	B-X
Ig	B-X
variable	B-X
gene	B-X
families	B-X
,	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
promoter	B-X
function	B-X
<EOS>	B-X
One	B-X
example	B-X
is	B-X
an	B-X
E	B-X
-	B-X
box	B-X
of	B-X
the	B-X
E47	B-X
/	B-X
E12	B-X
type	B-X
(	B-X
5'	B-X
-	B-X
CAGCTG	B-X
-	B-X
3	B-X
'	B-X
)	B-X
,	B-X
which	B-X
is	B-X
found	B-X
in	B-X
all	B-X
promoters	B-X
of	B-X
the	B-X
human	B-X
and	B-X
murine	B-X
Ig	B-X
-	B-X
kappa	B-X
gene	B-X
subgroups	B-X
/	B-X
families	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
subgroups	B-X
II	B-X
and	B-X
VI	B-X
and	B-X
their	B-X
related	B-X
murine	B-X
families	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
transcription	B-X
factor	B-X
AP	B-X
-	B-X
4	B-X
,	B-X
and	B-X
not	B-X
E47	B-X
,	B-X
interacts	B-X
specifically	B-X
with	B-X
the	B-X
kappa	B-X
promoter	B-X
E	B-X
-	B-X
boxes	B-X
when	B-X
tested	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
-	B-X
shift	B-X
assays	B-X
using	B-X
nuclear	B-X
extracts	B-X
derived	B-X
from	B-X
human	B-X
and	B-X
murine	B-X
B	B-X
-	B-X
cell	B-X
lines	B-X

A	O
16-mer	O
peptide	O
(	O
RQIKIWFQNRRMKWKK	O
)	O
from	O
antennapedia	O
preferentially	O
targets	O
the	O
Class	O
I	O
pathway	O
.	O

Translocation	O
of	O
antigenic	O
peptides	O
into	O
the	O
cytosol	O
of	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
facilitates	O
proteosomal	O
processing	O
and	O
loading	O
into	O
Class	B-protein
I	I-protein
molecules	I-protein
for	O
MHC	O
presentation	O
on	O
the	O
cell	O
surface	O
.	O

The	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
Drosophila	B-protein
transcription	I-protein
factor	I-protein
(	O
Antennapedia	B-protein
)	O
,	O
a	O
60	B-protein
amino	I-protein
acid	I-protein
protein	I-protein
,	O
is	O
rapidly	O
taken	O
up	O
by	O
cells	O
and	O
has	O
been	O
fused	O
to	O
selected	O
antigens	B-protein
to	O
enhance	O
their	O
immunogenicity	O
.	O
<EOS>	B-X
The	B-X
DNA	B-X
binding	B-X
domain	B-X
of	B-X
the	B-X
Drosophila	B-X
transcription	B-X
factor	B-X
(	B-X
Antennapedia	B-X
)	B-X
,	B-X
a	B-X
60	B-X
amino	B-X
acid	B-X
protein	B-X
,	B-X
is	B-X
rapidly	B-X
taken	B-X
up	B-X
by	B-X
cells	B-X
and	B-X
has	B-X
been	B-X
fused	B-X
to	B-X
selected	B-X
antigens	B-X
to	B-X
enhance	B-X
their	B-X
immunogenicity	B-X
<EOS>	B-X
We	B-X
now	B-X
demonstrate	B-X
that	B-X
a	B-X
16	B-X
amino	B-X
acid	B-X
peptide	B-X
from	B-X
antennapedia	B-X
can	B-X
facilitate	B-X
the	B-X
cytoplasmic	B-X
uptake	B-X
of	B-X
CTL	B-X
epitope	B-X
9	B-X
-	B-X
mer	B-X
peptides	B-X
<EOS>	B-X
The	B-X
production	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
other	B-X
CTL	B-X
peptide	B-X
epitopes	B-X
may	B-X
be	B-X
useful	B-X
for	B-X
priming	B-X
CTLs	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
hybrid	B-X
peptide	B-X
to	B-X
be	B-X
processed	B-X
and	B-X
presented	B-X
by	B-X
APCs	B-X
was	B-X
similar	B-X
,	B-X
whether	B-X
the	B-X
SIINFEKL	B-X
sequence	B-X
was	B-X
appended	B-X
at	B-X
the	B-X
C	B-X
-	B-X
terminus	B-X
or	B-X
N	B-X
-	B-X
terminus	B-X
of	B-X
the	B-X
Antennapedia	B-X
peptide	B-X

We	O
now	O
demonstrate	O
that	O
a	O
16	O
amino	O
acid	O
peptide	O
from	O
antennapedia	O
can	O
facilitate	O
the	O
cytoplasmic	O
uptake	O
of	O
CTL	O
epitope	O
9-mer	O
peptides	O
.	O
<EOS>	B-X
We	B-X
now	B-X
demonstrate	B-X
that	B-X
a	B-X
16	B-X
amino	B-X
acid	B-X
peptide	B-X
from	B-X
antennapedia	B-X
can	B-X
facilitate	B-X
the	B-X
cytoplasmic	B-X
uptake	B-X
of	B-X
CTL	B-X
epitope	B-X
9	B-X
-	B-X
mer	B-X
peptides	B-X
<EOS>	B-X
A	B-X
16	B-X
-	B-X
mer	B-X
peptide	B-X
(	B-X
RQIKIWFQNRRMKWKK	B-X
)	B-X
from	B-X
antennapedia	B-X
preferentially	B-X
targets	B-X
the	B-X
Class	B-X
I	B-X
pathway	B-X
.	B-X
<EOS>	B-X
Synthetic	B-X
peptides	B-X
were	B-X
made	B-X
containing	B-X
the	B-X
16	B-X
-	B-X
mer	B-X
antennapedia	B-X
peptide	B-X
linked	B-X
in	B-X
tandem	B-X
to	B-X
the	B-X
ovalbumin	B-X
SIINFEKL	B-X
CTL	B-X
peptide	B-X
<EOS>	B-X
The	B-X
DNA	B-X
binding	B-X
domain	B-X
of	B-X
the	B-X
Drosophila	B-X
transcription	B-X
factor	B-X
(	B-X
Antennapedia	B-X
)	B-X
,	B-X
a	B-X
60	B-X
amino	B-X
acid	B-X
protein	B-X
,	B-X
is	B-X
rapidly	B-X
taken	B-X
up	B-X
by	B-X
cells	B-X
and	B-X
has	B-X
been	B-X
fused	B-X
to	B-X
selected	B-X
antigens	B-X
to	B-X
enhance	B-X
their	B-X
immunogenicity	B-X

Synthetic	O
peptides	O
were	O
made	O
containing	O
the	O
16-mer	O
antennapedia	O
peptide	O
linked	O
in	O
tandem	O
to	O
the	O
ovalbumin	O
SIINFEKL	O
CTL	O
peptide	O
.	O

The	O
peptide	O
complex	O
was	O
shown	O
to	O
rapidly	O
internalise	O
into	O
APCs	B-cell_type
by	O
confocal	O
microscopy	O
.	O
<EOS>	B-X
The	B-X
peptide	B-X
complex	B-X
was	B-X
shown	B-X
to	B-X
rapidly	B-X
internalise	B-X
into	B-X
APCs	B-X
by	B-X
confocal	B-X
microscopy	B-X
<EOS>	B-X
Synthetic	B-X
peptides	B-X
were	B-X
made	B-X
containing	B-X
the	B-X
16	B-X
-	B-X
mer	B-X
antennapedia	B-X
peptide	B-X
linked	B-X
in	B-X
tandem	B-X
to	B-X
the	B-X
ovalbumin	B-X
SIINFEKL	B-X
CTL	B-X
peptide	B-X
<EOS>	B-X
This	B-X
peptide	B-X
induced	B-X
CTL	B-X
in	B-X
C57BL	B-X
/	B-X
6	B-X
mice	B-X
and	B-X
protected	B-X
them	B-X
against	B-X
growth	B-X
of	B-X
an	B-X
ovalbumin	B-X
expressing	B-X
tumour	B-X
cell	B-X
line	B-X
(	B-X
E	B-X
<EOS>	B-X
The	B-X
production	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
other	B-X
CTL	B-X
peptide	B-X
epitopes	B-X
may	B-X
be	B-X
useful	B-X
for	B-X
priming	B-X
CTLs	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X

This	O
peptide	O
induced	O
CTL	B-cell_type
in	O
C57BL/6	O
mice	O
and	O
protected	O
them	O
against	O
growth	O
of	O
an	O
ovalbumin	B-cell_line
expressing	I-cell_line
tumour	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
E.G7-OVA	B-cell_line
)	O
.	O
<EOS>	B-X
This	B-X
peptide	B-X
induced	B-X
CTL	B-X
in	B-X
C57BL	B-X
/	B-X
6	B-X
mice	B-X
and	B-X
protected	B-X
them	B-X
against	B-X
growth	B-X
of	B-X
an	B-X
ovalbumin	B-X
expressing	B-X
tumour	B-X
cell	B-X
line	B-X
(	B-X
E	B-X
<EOS>	B-X
The	B-X
peptide	B-X
complex	B-X
was	B-X
shown	B-X
to	B-X
rapidly	B-X
internalise	B-X
into	B-X
APCs	B-X
by	B-X
confocal	B-X
microscopy	B-X
<EOS>	B-X
Translocation	B-X
of	B-X
antigenic	B-X
peptides	B-X
into	B-X
the	B-X
cytosol	B-X
of	B-X
antigen	B-X
presenting	B-X
cells	B-X
facilitates	B-X
proteosomal	B-X
processing	B-X
and	B-X
loading	B-X
into	B-X
Class	B-X
I	B-X
molecules	B-X
for	B-X
MHC	B-X
presentation	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
hybrid	B-X
peptide	B-X
to	B-X
be	B-X
processed	B-X
and	B-X
presented	B-X
by	B-X
APCs	B-X
was	B-X
similar	B-X
,	B-X
whether	B-X
the	B-X
SIINFEKL	B-X
sequence	B-X
was	B-X
appended	B-X
at	B-X
the	B-X
C	B-X
-	B-X
terminus	B-X
or	B-X
N	B-X
-	B-X
terminus	B-X
of	B-X
the	B-X
Antennapedia	B-X
peptide	B-X

The	O
ability	O
of	O
the	O
hybrid	O
peptide	O
to	O
be	O
processed	O
and	O
presented	O
by	O
APCs	B-cell_type
was	O
similar	O
,	O
whether	O
the	O
SIINFEKL	O
sequence	O
was	O
appended	O
at	O
the	O
C-terminus	B-protein
or	O
N-terminus	B-protein
of	O
the	O
Antennapedia	O
peptide	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
hybrid	B-X
peptide	B-X
to	B-X
be	B-X
processed	B-X
and	B-X
presented	B-X
by	B-X
APCs	B-X
was	B-X
similar	B-X
,	B-X
whether	B-X
the	B-X
SIINFEKL	B-X
sequence	B-X
was	B-X
appended	B-X
at	B-X
the	B-X
C	B-X
-	B-X
terminus	B-X
or	B-X
N	B-X
-	B-X
terminus	B-X
of	B-X
the	B-X
Antennapedia	B-X
peptide	B-X
<EOS>	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
peptide	B-X
is	B-X
a	B-X
straight	B-X
helix	B-X
positioned	B-X
with	B-X
its	B-X
C	B-X
-	B-X
terminus	B-X
deep	B-X
inside	B-X
the	B-X
micelle	B-X
and	B-X
its	B-X
N	B-X
-	B-X
terminus	B-X
near	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
micelle	B-X
<EOS>	B-X
The	B-X
degree	B-X
of	B-X
hydrophobic	B-X
moment	B-X
and	B-X
helical	B-X
wheel	B-X
plots	B-X
for	B-X
these	B-X
peptides	B-X
correlated	B-X
directly	B-X
with	B-X
their	B-X
ability	B-X
to	B-X
transduce	B-X
the	B-X
p53	B-X
peptide	B-X
<EOS>	B-X
Correlation	B-X
between	B-X
hydrophobic	B-X
properties	B-X
and	B-X
efficiency	B-X
of	B-X
carrier	B-X
-	B-X
mediated	B-X
membrane	B-X
transduction	B-X
and	B-X
apoptosis	B-X
of	B-X
a	B-X
p53	B-X
C	B-X
-	B-X
terminal	B-X
peptide	B-X
.	B-X

The	O
production	O
of	O
synthetic	O
peptides	O
containing	O
other	O
CTL	O
peptide	O
epitopes	O
may	O
be	O
useful	O
for	O
priming	O
CTLs	B-cell_type
in	O
vitro	O
and	O
in	O
vivo	O
<EOS>	B-X
The	B-X
production	B-X
of	B-X
synthetic	B-X
peptides	B-X
containing	B-X
other	B-X
CTL	B-X
peptide	B-X
epitopes	B-X
may	B-X
be	B-X
useful	B-X
for	B-X
priming	B-X
CTLs	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Translocation	B-X
of	B-X
antigenic	B-X
peptides	B-X
into	B-X
the	B-X
cytosol	B-X
of	B-X
antigen	B-X
presenting	B-X
cells	B-X
facilitates	B-X
proteosomal	B-X
processing	B-X
and	B-X
loading	B-X
into	B-X
Class	B-X
I	B-X
molecules	B-X
for	B-X
MHC	B-X
presentation	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
hybrid	B-X
peptide	B-X
to	B-X
be	B-X
processed	B-X
and	B-X
presented	B-X
by	B-X
APCs	B-X
was	B-X
similar	B-X
,	B-X
whether	B-X
the	B-X
SIINFEKL	B-X
sequence	B-X
was	B-X
appended	B-X
at	B-X
the	B-X
C	B-X
-	B-X
terminus	B-X
or	B-X
N	B-X
-	B-X
terminus	B-X
of	B-X
the	B-X
Antennapedia	B-X
peptide	B-X
<EOS>	B-X
The	B-X
DNA	B-X
binding	B-X
domain	B-X
of	B-X
the	B-X
Drosophila	B-X
transcription	B-X
factor	B-X
(	B-X
Antennapedia	B-X
)	B-X
,	B-X
a	B-X
60	B-X
amino	B-X
acid	B-X
protein	B-X
,	B-X
is	B-X
rapidly	B-X
taken	B-X
up	B-X
by	B-X
cells	B-X
and	B-X
has	B-X
been	B-X
fused	B-X
to	B-X
selected	B-X
antigens	B-X
to	B-X
enhance	B-X
their	B-X
immunogenicity	B-X

Bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
promote	O
TH2	O
polarization	O
and	O
inhibit	O
virus-specific	O
CTL	O
generation	O
.	O
<EOS>	B-X
Bone	B-X
marrow	B-X
cells	B-X
promote	B-X
TH2	B-X
polarization	B-X
and	B-X
inhibit	B-X
virus	B-X
-	B-X
specific	B-X
CTL	B-X
generation	B-X
.	B-X
<EOS>	B-X
This	B-X
laboratory	B-X
recently	B-X
reported	B-X
that	B-X
human	B-X
bone	B-X
marrow	B-X
cells	B-X
(	B-X
BMC	B-X
)	B-X
inhibit	B-X
the	B-X
generation	B-X
of	B-X
virus	B-X
-	B-X
specific	B-X
CTL	B-X
in	B-X
culture	B-X
<EOS>	B-X
It	B-X
was	B-X
then	B-X
observed	B-X
that	B-X
CD3+	B-X
cells	B-X
obtained	B-X
after	B-X
7	B-X
days	B-X
of	B-X
culture	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
autologous	B-X
BMC	B-X
could	B-X
be	B-X
used	B-X
as	B-X
inhibitors	B-X
of	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
<EOS>	B-X
The	B-X
culture	B-X
supernatants	B-X
contained	B-X
increased	B-X
levels	B-X
of	B-X
prostaglandin	B-X
E	B-X
(	B-X
2	B-X
)	B-X
(	B-X
PGE	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
shown	B-X
to	B-X
favor	B-X
TH2	B-X
cell	B-X
development	B-X
)	B-X
and	B-X
also	B-X
inhibited	B-X
EBV	B-X
-	B-X
CTL	B-X
effector	B-X
cell	B-X
development	B-X

This	O
laboratory	O
recently	O
reported	O
that	O
human	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
(	O
BMC	B-cell_type
)	O
inhibit	O
the	O
generation	O
of	O
virus-specific	B-cell_type
CTL	I-cell_type
in	O
culture	O
.	O
<EOS>	B-X
This	B-X
laboratory	B-X
recently	B-X
reported	B-X
that	B-X
human	B-X
bone	B-X
marrow	B-X
cells	B-X
(	B-X
BMC	B-X
)	B-X
inhibit	B-X
the	B-X
generation	B-X
of	B-X
virus	B-X
-	B-X
specific	B-X
CTL	B-X
in	B-X
culture	B-X
<EOS>	B-X
Bone	B-X
marrow	B-X
cells	B-X
promote	B-X
TH2	B-X
polarization	B-X
and	B-X
inhibit	B-X
virus	B-X
-	B-X
specific	B-X
CTL	B-X
generation	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
the	B-X
BMC	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
soluble	B-X
factors	B-X
(	B-X
cytokines	B-X
)	B-X
and	B-X
that	B-X
cell	B-X
-	B-X
cell	B-X
contact	B-X
in	B-X
this	B-X
autologous	B-X
system	B-X
is	B-X
not	B-X
required	B-X
,	B-X
so	B-X
that	B-X
BMC	B-X
(	B-X
at	B-X
least	B-X
partially	B-X
,	B-X
via	B-X
cytokine	B-X
production	B-X
)	B-X
promote	B-X
TH2	B-X
polarization	B-X
in	B-X
culture	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
TH2	B-X
cells	B-X
induced	B-X
by	B-X
culturing	B-X
with	B-X
autologous	B-X
BMC	B-X
directly	B-X
inhibit	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
,	B-X
and	B-X
TH2	B-X
associated	B-X
PKA	B-X
,	B-X
CCR3	B-X
,	B-X
and	B-X
STAT	B-X
-	B-X
6	B-X
phosphorylation	B-X
are	B-X
enhanced	B-X
by	B-X
BMC	B-X

The	O
culture	O
supernatants	O
contained	O
increased	O
levels	O
of	O
prostaglandin	B-protein
E	I-protein
(	I-protein
2	I-protein
)	I-protein
(	I-protein
PGE	I-protein
(	I-protein
2	I-protein
)	I-protein
)	I-protein
(	O
shown	O
to	O
favor	O
TH2	O
cell	O
development	O
)	O
and	O
also	O
inhibited	O
EBV-CTL	O
effector	O
cell	O
development	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
PBL	B-cell_type
from	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
IgG	B-protein
antibody	I-protein
positive	O
kidney	O
transplant	O
recipients	O
(	O
R	O
)	O
and	O
their	O
living-related	O
donors	O
(	O
LRD	O
)	O
one	O
year	O
after	O
renal	O
transplantation	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
obtained	B-X
PBL	B-X
from	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
IgG	B-X
antibody	B-X
positive	B-X
kidney	B-X
transplant	B-X
recipients	B-X
(	B-X
R	B-X
)	B-X
and	B-X
their	B-X
living	B-X
-	B-X
related	B-X
donors	B-X
(	B-X
LRD	B-X
)	B-X
one	B-X
year	B-X
after	B-X
renal	B-X
transplantation	B-X
<EOS>	B-X
Inhibition	B-X
was	B-X
even	B-X
observed	B-X
by	B-X
preparing	B-X
EBV	B-X
-	B-X
CTL	B-X
generating	B-X
cultures	B-X
in	B-X
trans	B-X
-	B-X
wells	B-X
that	B-X
separated	B-X
the	B-X
autologous	B-X
BMC	B-X
from	B-X
the	B-X
PBL	B-X
+	B-X
EBV	B-X
-	B-X
B	B-X
<EOS>	B-X
It	B-X
was	B-X
then	B-X
observed	B-X
that	B-X
CD3+	B-X
cells	B-X
obtained	B-X
after	B-X
7	B-X
days	B-X
of	B-X
culture	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
autologous	B-X
BMC	B-X
could	B-X
be	B-X
used	B-X
as	B-X
inhibitors	B-X
of	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
mediated	B-X
signal	B-X
transduction	B-X
and	B-X
activation	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
-	B-X
6	B-X
)	B-X
phosphorylation	B-X
was	B-X
slightly	B-X
increased	B-X

EBV-specific	B-cell_type
CTL	I-cell_type
were	O
then	O
generated	O
in	O
vitro	O
by	O
stimulating	O
PBL	B-cell_type
with	O
autologous	O
EBV-transformed	B-cell_type
B	I-cell_type
cells	I-cell_type
(	O
EBV-B	B-cell_type
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
autologous	B-cell_type
BMC	I-cell_type
.	O
<EOS>	B-X
The	B-X
MD	B-X
-	B-X
DCs	B-X
were	B-X
stimulated	B-X
for	B-X
24	B-X
h	B-X
with	B-X
the	B-X
related	B-X
allergen	B-X
,	B-X
Der	B-X
p	B-X
1	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
PS	B-X
-	B-X
G	B-X
<EOS>	B-X
A	B-X
significant	B-X
reduction	B-X
in	B-X
GAG	B-X
content	B-X
per	B-X
pellet	B-X
was	B-X
also	B-X
observed	B-X
with	B-X
increasing	B-X
donor	B-X
age	B-X
in	B-X
male	B-X
BMC	B-X
<EOS>	B-X
Platelet	B-X
released	B-X
growth	B-X
factors	B-X
boost	B-X
expansion	B-X
of	B-X
bone	B-X
marrow	B-X
derived	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD133	B-X
(	B-X
+	B-X
)	B-X
endothelial	B-X
progenitor	B-X
cells	B-X
for	B-X
autologous	B-X
grafting	B-X
.	B-X
<EOS>	B-X
Ageing	B-X
is	B-X
regarded	B-X
among	B-X
the	B-X
most	B-X
detrimental	B-X
risk	B-X
factor	B-X
for	B-X
vascular	B-X
endothelium	B-X
and	B-X
predisposes	B-X
the	B-X
subject	B-X
to	B-X
atheroscleorosis	B-X
and	B-X
inflammatory	B-X
states	B-X
even	B-X
in	B-X
absence	B-X
of	B-X
traditional	B-X
comorbid	B-X
conditions	B-X

The	O
addition	O
of	O
BMC	B-cell_type
to	O
the	O
EBV-CTL	B-cell_type
generation	I-cell_type
cultures	I-cell_type
increased	O
the	O
intracellular	O
expression	O
in	O
CD3+	B-cell_type
cells	I-cell_type
of	O
IL-4	B-protein
,	I-protein
-5	I-protein
,	I-protein
-6	I-protein
,	I-protein
-10	I-protein
,	I-protein
and	I-protein
-13	I-protein
.	O

These	O
CD3+	B-cell_type
cells	I-cell_type
also	O
expressed	O
increased	O
levels	O
of	O
the	O
TH2	B-protein
associated	I-protein
receptor	I-protein
CCR3	I-protein
.	O
<EOS>	B-X
These	B-X
CD3+	B-X
cells	B-X
also	B-X
expressed	B-X
increased	B-X
levels	B-X
of	B-X
the	B-X
TH2	B-X
associated	B-X
receptor	B-X
CCR3	B-X
<EOS>	B-X
The	B-X
inflammation	B-X
is	B-X
typically	B-X
granulomatous	B-X
with	B-X
associated	B-X
vasculitis	B-X
<EOS>	B-X
The	B-X
culture	B-X
supernatants	B-X
contained	B-X
increased	B-X
levels	B-X
of	B-X
prostaglandin	B-X
E	B-X
(	B-X
2	B-X
)	B-X
(	B-X
PGE	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
shown	B-X
to	B-X
favor	B-X
TH2	B-X
cell	B-X
development	B-X
)	B-X
and	B-X
also	B-X
inhibited	B-X
EBV	B-X
-	B-X
CTL	B-X
effector	B-X
cell	B-X
development	B-X
<EOS>	B-X
There	B-X
was	B-X
increased	B-X
expression	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
no	B-X
detectable	B-X
IFN	B-X
-	B-X
gamma	B-X

Inhibition	O
was	O
even	O
observed	O
by	O
preparing	O
EBV-CTL	B-cell_type
generating	I-cell_type
cultures	I-cell_type
in	O
trans-wells	O
that	O
separated	O
the	O
autologous	B-cell_type
BMC	I-cell_type
from	O
the	O
PBL	B-cell_type
+	O
EBV-B	B-cell_type
.	O
<EOS>	B-X
Inhibition	B-X
was	B-X
even	B-X
observed	B-X
by	B-X
preparing	B-X
EBV	B-X
-	B-X
CTL	B-X
generating	B-X
cultures	B-X
in	B-X
trans	B-X
-	B-X
wells	B-X
that	B-X
separated	B-X
the	B-X
autologous	B-X
BMC	B-X
from	B-X
the	B-X
PBL	B-X
+	B-X
EBV	B-X
-	B-X
B	B-X
<EOS>	B-X
It	B-X
was	B-X
then	B-X
observed	B-X
that	B-X
CD3+	B-X
cells	B-X
obtained	B-X
after	B-X
7	B-X
days	B-X
of	B-X
culture	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
autologous	B-X
BMC	B-X
could	B-X
be	B-X
used	B-X
as	B-X
inhibitors	B-X
of	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
<EOS>	B-X
The	B-X
addition	B-X
of	B-X
BMC	B-X
to	B-X
the	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
cultures	B-X
increased	B-X
the	B-X
intracellular	B-X
expression	B-X
in	B-X
CD3+	B-X
cells	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
	B-X
-	B-X
5	B-X
,	B-X
	B-X
-	B-X
6	B-X
,	B-X
	B-X
-	B-X
10	B-X
,	B-X
and	B-X
	B-X
-	B-X
13	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
the	B-X
BMC	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
soluble	B-X
factors	B-X
(	B-X
cytokines	B-X
)	B-X
and	B-X
that	B-X
cell	B-X
-	B-X
cell	B-X
contact	B-X
in	B-X
this	B-X
autologous	B-X
system	B-X
is	B-X
not	B-X
required	B-X
,	B-X
so	B-X
that	B-X
BMC	B-X
(	B-X
at	B-X
least	B-X
partially	B-X
,	B-X
via	B-X
cytokine	B-X
production	B-X
)	B-X
promote	B-X
TH2	B-X
polarization	B-X
in	B-X
culture	B-X

It	O
was	O
then	O
observed	O
that	O
CD3+	B-cell_type
cells	I-cell_type
obtained	O
after	O
7	O
days	O
of	O
culture	O
in	O
the	O
presence	O
of	O
autologous	B-cell_type
BMC	I-cell_type
could	O
be	O
used	O
as	O
inhibitors	O
of	O
EBV-CTL	O
generation	O
.	O
<EOS>	B-X
It	B-X
was	B-X
then	B-X
observed	B-X
that	B-X
CD3+	B-X
cells	B-X
obtained	B-X
after	B-X
7	B-X
days	B-X
of	B-X
culture	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
autologous	B-X
BMC	B-X
could	B-X
be	B-X
used	B-X
as	B-X
inhibitors	B-X
of	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
<EOS>	B-X
It	B-X
was	B-X
also	B-X
observed	B-X
that	B-X
CD3	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
obtained	B-X
after	B-X
7	B-X
days	B-X
of	B-X
culture	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
autologous	B-X
BMC	B-X
could	B-X
be	B-X
used	B-X
as	B-X
inhibitors	B-X
of	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
<EOS>	B-X
The	B-X
addition	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
to	B-X
these	B-X
latter	B-X
cultures	B-X
augmented	B-X
,	B-X
but	B-X
could	B-X
not	B-X
fully	B-X
restore	B-X
,	B-X
the	B-X
response	B-X
<EOS>	B-X
Inhibition	B-X
was	B-X
even	B-X
observed	B-X
by	B-X
preparing	B-X
EBV	B-X
-	B-X
CTL	B-X
generating	B-X
cultures	B-X
in	B-X
trans	B-X
-	B-X
wells	B-X
that	B-X
separated	B-X
the	B-X
autologous	B-X
BMC	B-X
from	B-X
the	B-X
PBL	B-X
+	B-X
EBV	B-X
-	B-X
B	B-X

Protein	B-protein
Kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
,	O
a	O
cAMP	B-protein
kinase	I-protein
that	O
is	O
involved	O
in	O
the	O
upregulation	O
of	O
TH2	B-protein
cytokine	I-protein
activity	O
,	O
was	O
increased	O
in	O
EBV-CTL	B-cell_type
cultures	I-cell_type
by	O
the	O
presence	O
of	O
BMC	B-cell_type
.	O
<EOS>	B-X
Protein	B-X
Kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
,	B-X
a	B-X
cAMP	B-X
kinase	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
TH2	B-X
cytokine	B-X
activity	B-X
,	B-X
was	B-X
increased	B-X
in	B-X
EBV	B-X
-	B-X
CTL	B-X
cultures	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
BMC	B-X
<EOS>	B-X
These	B-X
results	B-X
show	B-X
that	B-X
the	B-X
BMC	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
soluble	B-X
factors	B-X
(	B-X
cytokines	B-X
)	B-X
and	B-X
that	B-X
cell	B-X
-	B-X
cell	B-X
contact	B-X
in	B-X
this	B-X
autologous	B-X
system	B-X
is	B-X
not	B-X
required	B-X
,	B-X
so	B-X
that	B-X
BMC	B-X
(	B-X
at	B-X
least	B-X
partially	B-X
,	B-X
via	B-X
cytokine	B-X
production	B-X
)	B-X
promote	B-X
TH2	B-X
polarization	B-X
in	B-X
culture	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
TH2	B-X
cells	B-X
induced	B-X
by	B-X
culturing	B-X
with	B-X
autologous	B-X
BMC	B-X
directly	B-X
inhibit	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
,	B-X
and	B-X
TH2	B-X
associated	B-X
PKA	B-X
,	B-X
CCR3	B-X
,	B-X
and	B-X
STAT	B-X
-	B-X
6	B-X
phosphorylation	B-X
are	B-X
enhanced	B-X
by	B-X
BMC	B-X
<EOS>	B-X
These	B-X
CD3+	B-X
cells	B-X
also	B-X
expressed	B-X
increased	B-X
levels	B-X
of	B-X
the	B-X
TH2	B-X
associated	B-X
receptor	B-X
CCR3	B-X

Additionally	O
,	O
IL-4-mediated	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
(	O
STAT-6	B-protein
)	O
phosphorylation	O
was	O
slightly	O
increased	O
.	O
<EOS>	B-X
Additionally	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
mediated	B-X
signal	B-X
transduction	B-X
and	B-X
activation	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
-	B-X
6	B-X
)	B-X
phosphorylation	B-X
was	B-X
slightly	B-X
increased	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
TH2	B-X
cells	B-X
induced	B-X
by	B-X
culturing	B-X
with	B-X
autologous	B-X
BMC	B-X
directly	B-X
inhibit	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
,	B-X
and	B-X
TH2	B-X
associated	B-X
PKA	B-X
,	B-X
CCR3	B-X
,	B-X
and	B-X
STAT	B-X
-	B-X
6	B-X
phosphorylation	B-X
are	B-X
enhanced	B-X
by	B-X
BMC	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
obtained	B-X
PBL	B-X
from	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
IgG	B-X
antibody	B-X
positive	B-X
kidney	B-X
transplant	B-X
recipients	B-X
(	B-X
R	B-X
)	B-X
and	B-X
their	B-X
living	B-X
-	B-X
related	B-X
donors	B-X
(	B-X
LRD	B-X
)	B-X
one	B-X
year	B-X
after	B-X
renal	B-X
transplantation	B-X
<EOS>	B-X
EBV	B-X
-	B-X
specific	B-X
CTL	B-X
were	B-X
then	B-X
generated	B-X
in	B-X
vitro	B-X
by	B-X
stimulating	B-X
PBL	B-X
with	B-X
autologous	B-X
EBV	B-X
-	B-X
transformed	B-X
B	B-X
cells	B-X
(	B-X
EBV	B-X
-	B-X
B	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
autologous	B-X
BMC	B-X

These	O
results	O
show	O
that	O
the	O
BMC	B-cell_type
inhibition	O
is	O
mediated	O
by	O
soluble	B-protein
factors	I-protein
(	O
cytokines	B-protein
)	O
and	O
that	O
cell-cell	O
contact	O
in	O
this	O
autologous	O
system	O
is	O
not	O
required	O
,	O
so	O
that	O
BMC	B-cell_type
(	O
at	O
least	O
partially	O
,	O
via	O
cytokine	O
production	O
)	O
promote	O
TH2	O
polarization	O
in	O
culture	O
.	O

Moreover	O
,	O
TH2	B-cell_type
cells	I-cell_type
induced	O
by	O
culturing	O
with	O
autologous	B-cell_type
BMC	I-cell_type
directly	O
inhibit	O
EBV-CTL	O
generation	O
,	O
and	O
TH2	B-protein
associated	O
PKA	B-protein
,	O
CCR3	B-protein
,	O
and	O
STAT-6	B-protein
phosphorylation	O
are	O
enhanced	O
by	O
BMC	B-cell_type
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
TH2	B-X
cells	B-X
induced	B-X
by	B-X
culturing	B-X
with	B-X
autologous	B-X
BMC	B-X
directly	B-X
inhibit	B-X
EBV	B-X
-	B-X
CTL	B-X
generation	B-X
,	B-X
and	B-X
TH2	B-X
associated	B-X
PKA	B-X
,	B-X
CCR3	B-X
,	B-X
and	B-X
STAT	B-X
-	B-X
6	B-X
phosphorylation	B-X
are	B-X
enhanced	B-X
by	B-X
BMC	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
mediated	B-X
signal	B-X
transduction	B-X
and	B-X
activation	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
-	B-X
6	B-X
)	B-X
phosphorylation	B-X
was	B-X
slightly	B-X
increased	B-X
<EOS>	B-X
Protein	B-X
Kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
,	B-X
a	B-X
cAMP	B-X
kinase	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
TH2	B-X
cytokine	B-X
activity	B-X
,	B-X
was	B-X
increased	B-X
in	B-X
EBV	B-X
-	B-X
CTL	B-X
cultures	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
BMC	B-X
<EOS>	B-X
These	B-X
CD3+	B-X
cells	B-X
also	B-X
expressed	B-X
increased	B-X
levels	B-X
of	B-X
the	B-X
TH2	B-X
associated	B-X
receptor	B-X
CCR3	B-X

Reduction	O
in	O
DNA	O
binding	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
Pax-5a	B-protein
in	O
B	B-cell_type
lymphocytes	I-cell_type
of	O
aged	O
mice	O
.	O

Aging	O
has	O
been	O
associated	O
with	O
intrinsic	O
changes	O
of	O
the	O
humoral	O
immune	O
response	O
,	O
which	O
may	O
lead	O
to	O
an	O
increased	O
occurrence	O
of	O
autoimmune	O
disorders	O
and	O
pathogenic	O
susceptibility	O
.	O

The	O
transcription	B-protein
factor	I-protein
Pax-5	B-protein
is	O
a	O
key	O
regulator	O
of	O
B	O
cell	O
development	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
Pax	B-X
-	B-X
5	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
B	B-X
cell	B-X
development	B-X
<EOS>	B-X
Pax	B-X
-	B-X
5	B-X
is	B-X
the	B-X
key	B-X
regulator	B-X
in	B-X
B	B-X
cell	B-X
development	B-X
<EOS>	B-X
Pax	B-X
-	B-X
5	B-X
is	B-X
a	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
restricted	B-X
transcription	B-X
factor	B-X
with	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
early	B-X
and	B-X
late	B-X
B	B-X
cell	B-X
development	B-X
<EOS>	B-X
The	B-X
Pax	B-X
-	B-X
5	B-X
oncogene	B-X
encodes	B-X
a	B-X
potent	B-X
transcription	B-X
factor	B-X
that	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
B	B-X
-	B-X
cell	B-X
development	B-X
and	B-X
cancerous	B-X
processes	B-X

Pax-5a/B	B-protein
cell-specific	I-protein
activator	I-protein
protein	I-protein
and	O
an	O
alternatively	B-protein
spliced	I-protein
isoform	I-protein
,	I-protein
Pax-5d	I-protein
,	O
may	O
have	O
opposing	O
functions	O
in	O
transcriptional	O
regulation	O
due	O
to	O
the	O
lack	O
of	O
a	O
transactivation	B-protein
domain	I-protein
in	O
Pax-5d	B-protein
.	O

To	O
study	O
B	B-cell_type
cell	I-cell_type
-specific	O
changes	O
that	O
occur	O
during	O
the	O
aging	O
process	O
,	O
we	O
investigated	O
expression	O
patterns	O
of	O
Pax-5a	B-protein
and	I-protein
5d	I-protein
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
of	O
young	O
and	O
aged	O
mice	O
.	O

RNase	O
protection	O
assays	O
showed	O
a	O
similar	O
transcriptional	O
pattern	O
for	O
both	O
age	O
groups	O
that	O
indicates	O
that	O
aging	O
has	O
no	O
affect	O
on	O
transcription	O
initiation	O
or	O
alternative	O
splicing	O
for	O
either	O
isoform	B-protein
.	O
<EOS>	B-X
SpliceTools	B-X
,	B-X
a	B-X
suite	B-X
of	B-X
downstream	B-X
RNA	B-X
splicing	B-X
analysis	B-X
tools	B-X
to	B-X
investigate	B-X
mechanisms	B-X
and	B-X
impact	B-X
of	B-X
alternative	B-X
splicing	B-X
.	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
Doublesex	B-X
(	B-X
Dsx	B-X
)	B-X
	B-X
-	B-X
like	B-X
mRNA	B-X
isoforms	B-X
in	B-X
the	B-X
brine	B-X
shrimp	B-X
Artemia	B-X
franciscana	B-X
(	B-X
Kellogg	B-X
1906	B-X
)	B-X
,	B-X
which	B-X
are	B-X
generated	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
alternative	B-X
promoters	B-X
,	B-X
alternative	B-X
splicing	B-X
and	B-X
alternative	B-X
polyadenylation	B-X
<EOS>	B-X
A	B-X
benchmark	B-X
against	B-X
two	B-X
other	B-X
popular	B-X
transcriptome	B-X
-	B-X
based	B-X
tools	B-X
shows	B-X
VIsoQLR	B-X
accurate	B-X
performance	B-X
on	B-X
both	B-X
detection	B-X
and	B-X
quantification	B-X
of	B-X
isoforms	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
a	B-X
considerable	B-X
amount	B-X
of	B-X
GluN2D	B-X
protein	B-X
existed	B-X
in	B-X
adult	B-X
brains	B-X
,	B-X
although	B-X
its	B-X
transcription	B-X
level	B-X
declines	B-X
after	B-X
early	B-X
postnatal	B-X
stages	B-X

In	O
contrast	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
Pax-5a	B-protein
but	O
not	O
Pax-5d	B-protein
protein	O
was	O
observed	O
in	O
aged	B-cell_type
B	I-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
while	O
Western	O
blot	O
analyses	O
showed	O
that	O
similar	O
levels	O
of	O
Pax-5a	B-protein
and	I-protein
5d	I-protein
proteins	O
were	O
present	O
in	O
both	O
age	O
groups	O
.	O

The	O
observed	O
decrease	O
in	O
Pax-5a	B-protein
binding	O
activity	O
correlated	O
with	O
changes	O
in	O
expression	O
of	O
two	O
Pax-5	B-DNA
target	I-DNA
genes	I-DNA
in	O
aged	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
observed	B-X
decrease	B-X
in	B-X
Pax	B-X
-	B-X
5a	B-X
binding	B-X
activity	B-X
correlated	B-X
with	B-X
changes	B-X
in	B-X
expression	B-X
of	B-X
two	B-X
Pax	B-X
-	B-X
5	B-X
target	B-X
genes	B-X
in	B-X
aged	B-X
B	B-X
cells	B-X
<EOS>	B-X
Reduction	B-X
in	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
Pax	B-X
-	B-X
5a	B-X
in	B-X
B	B-X
lymphocytes	B-X
of	B-X
aged	B-X
mice	B-X
.	B-X
<EOS>	B-X
To	B-X
study	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
changes	B-X
that	B-X
occur	B-X
during	B-X
the	B-X
aging	B-X
process	B-X
,	B-X
we	B-X
investigated	B-X
expression	B-X
patterns	B-X
of	B-X
Pax	B-X
-	B-X
5a	B-X
and	B-X
5d	B-X
in	B-X
mature	B-X
B	B-X
cells	B-X
of	B-X
young	B-X
and	B-X
aged	B-X
mice	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
Ig	B-X
J	B-X
chain	B-X
and	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
Ig	B-X
mu	B-X
,	B-X
which	B-X
are	B-X
both	B-X
known	B-X
to	B-X
be	B-X
suppressed	B-X
by	B-X
Pax	B-X
-	B-X
5a	B-X
in	B-X
mature	B-X
B	B-X
cells	B-X
,	B-X
were	B-X
increased	B-X
in	B-X
B	B-X
cells	B-X
of	B-X
aged	B-X
mice	B-X

Expression	O
of	O
the	O
Ig	B-protein
J	I-protein
chain	I-protein
and	O
the	O
secreted	O
form	O
of	O
Ig	B-protein
mu	I-protein
,	O
which	O
are	O
both	O
known	O
to	O
be	O
suppressed	O
by	O
Pax-5a	B-protein
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
were	O
increased	O
in	O
B	B-cell_type
cells	I-cell_type
of	O
aged	O
mice	O
.	O

Together	O
,	O
our	O
studies	O
suggest	O
that	O
changes	O
associated	O
with	O
the	O
aging	O
phenotype	O
cause	O
posttranslational	O
modification	O
(	O
s	O
)	O
of	O
Pax-5a	B-protein
but	O
not	O
Pax-5d	B-protein
,	O
which	O
may	O
lead	O
to	O
an	O
abnormal	O
B	O
cell	O
phenotype	O
in	O
aged	O
mice	O
,	O
associated	O
with	O
elevated	O
levels	O
of	O
J	B-protein
chain	I-protein
,	O
and	O
secretion	O
of	O
IgM	B-protein
<EOS>	B-X
Together	B-X
,	B-X
our	B-X
studies	B-X
suggest	B-X
that	B-X
changes	B-X
associated	B-X
with	B-X
the	B-X
aging	B-X
phenotype	B-X
cause	B-X
posttranslational	B-X
modification	B-X
(	B-X
s	B-X
)	B-X
of	B-X
Pax	B-X
-	B-X
5a	B-X
but	B-X
not	B-X
Pax	B-X
-	B-X
5d	B-X
,	B-X
which	B-X
may	B-X
lead	B-X
to	B-X
an	B-X
abnormal	B-X
B	B-X
cell	B-X
phenotype	B-X
in	B-X
aged	B-X
mice	B-X
,	B-X
associated	B-X
with	B-X
elevated	B-X
levels	B-X
of	B-X
J	B-X
chain	B-X
,	B-X
and	B-X
secretion	B-X
of	B-X
IgM	B-X
<EOS>	B-X
Aging	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
intrinsic	B-X
changes	B-X
of	B-X
the	B-X
humoral	B-X
immune	B-X
response	B-X
,	B-X
which	B-X
may	B-X
lead	B-X
to	B-X
an	B-X
increased	B-X
occurrence	B-X
of	B-X
autoimmune	B-X
disorders	B-X
and	B-X
pathogenic	B-X
susceptibility	B-X
<EOS>	B-X
To	B-X
study	B-X
B	B-X
cell	B-X
-	B-X
specific	B-X
changes	B-X
that	B-X
occur	B-X
during	B-X
the	B-X
aging	B-X
process	B-X
,	B-X
we	B-X
investigated	B-X
expression	B-X
patterns	B-X
of	B-X
Pax	B-X
-	B-X
5a	B-X
and	B-X
5d	B-X
in	B-X
mature	B-X
B	B-X
cells	B-X
of	B-X
young	B-X
and	B-X
aged	B-X
mice	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
Ig	B-X
J	B-X
chain	B-X
and	B-X
the	B-X
secreted	B-X
form	B-X
of	B-X
Ig	B-X
mu	B-X
,	B-X
which	B-X
are	B-X
both	B-X
known	B-X
to	B-X
be	B-X
suppressed	B-X
by	B-X
Pax	B-X
-	B-X
5a	B-X
in	B-X
mature	B-X
B	B-X
cells	B-X
,	B-X
were	B-X
increased	B-X
in	B-X
B	B-X
cells	B-X
of	B-X
aged	B-X
mice	B-X

NF-kappa	B-protein
B/Rel	I-protein
participation	O
in	O
the	O
lymphokine-dependent	O
proliferation	O
of	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
/	B-X
Rel	B-X
participation	B-X
in	B-X
the	B-X
lymphokine	B-X
-	B-X
dependent	B-X
proliferation	B-X
of	B-X
T	B-X
lymphoid	B-X
cells	B-X
.	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
family	B-X
represents	B-X
one	B-X
signal	B-X
transduction	B-X
pathway	B-X
induced	B-X
during	B-X
such	B-X
activation	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
/	B-X
IkappaBalpha	B-X
system	B-X
can	B-X
regulate	B-X
cytokine	B-X
receptor	B-X
capacitation	B-X
through	B-X
effects	B-X
on	B-X
the	B-X
induction	B-X
of	B-X
downstream	B-X
signaling	B-X
by	B-X
the	B-X
Stat	B-X
transcription	B-X
factor	B-X
family	B-X
<EOS>	B-X
However	B-X
,	B-X
transgenic	B-X
cells	B-X
exhibited	B-X
a	B-X
dramatic	B-X
defect	B-X
in	B-X
Stat5A	B-X
activation	B-X
treatment	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
and	B-X
a	B-X
similar	B-X
defect	B-X
was	B-X
observed	B-X
for	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
induced	B-X
Stat5	B-X

Proliferative	O
responses	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
to	O
IL-2	B-protein
and	O
IL-4	B-protein
depend	O
on	O
activation	O
of	O
the	O
cells	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
activation	O
enhances	O
cellular	O
competence	O
to	O
respond	O
to	O
cytokines	B-protein
is	O
not	O
fully	O
understood	O
.	O

The	O
NF-kappaB/Rel	B-protein
family	I-protein
represents	O
one	O
signal	O
transduction	O
pathway	O
induced	O
during	O
such	O
activation	O
.	O
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
family	B-X
represents	B-X
one	B-X
signal	B-X
transduction	B-X
pathway	B-X
induced	B-X
during	B-X
such	B-X
activation	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
/	B-X
IkappaBalpha	B-X
system	B-X
can	B-X
regulate	B-X
cytokine	B-X
receptor	B-X
capacitation	B-X
through	B-X
effects	B-X
on	B-X
the	B-X
induction	B-X
of	B-X
downstream	B-X
signaling	B-X
by	B-X
the	B-X
Stat	B-X
transcription	B-X
factor	B-X
family	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
inducible	B-X
transcription	B-X
factor	B-X
that	B-X
controls	B-X
genetic	B-X
networks	B-X
important	B-X
for	B-X
pathogen	B-X
-	B-X
	B-X
or	B-X
cytokine	B-X
-	B-X
induced	B-X
inflammation	B-X
,	B-X
immune	B-X
response	B-X
,	B-X
and	B-X
cellular	B-X
survival	B-X
<EOS>	B-X
The	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assay	B-X
has	B-X
recently	B-X
been	B-X
exploited	B-X
as	B-X
a	B-X
powerful	B-X
and	B-X
versatile	B-X
technique	B-X
for	B-X
probing	B-X
protein	B-X
-	B-X
DNA	B-X
interactions	B-X
within	B-X
the	B-X
chromatin	B-X
environment	B-X

We	O
show	O
in	O
this	O
study	O
that	O
inhibition	O
of	O
NF-kappaB	B-protein
through	O
the	O
expression	O
of	O
an	O
IkappaBalpha	B-protein
(	O
inhibitory	B-protein
protein	I-protein
that	O
dissociates	O
from	O
NF-kappaB	B-protein
)	O
mutant	O
refractory	O
to	O
signal-induced	O
degradation	O
(	O
IkappaBalpha	B-protein
(	I-protein
DeltaN	I-protein
)	I-protein
)	O
interfered	O
with	O
the	O
acquisition	O
of	O
competence	O
to	O
proliferate	O
in	O
response	O
to	O
IL-4	B-protein
as	O
well	O
as	O
IL-2	B-protein
.	O
<EOS>	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
that	B-X
inhibition	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
through	B-X
the	B-X
expression	B-X
of	B-X
an	B-X
IkappaBalpha	B-X
(	B-X
inhibitory	B-X
protein	B-X
that	B-X
dissociates	B-X
from	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
mutant	B-X
refractory	B-X
to	B-X
signal	B-X
-	B-X
induced	B-X
degradation	B-X
(	B-X
IkappaBalpha	B-X
(	B-X
DeltaN	B-X
)	B-X
)	B-X
interfered	B-X
with	B-X
the	B-X
acquisition	B-X
of	B-X
competence	B-X
to	B-X
proliferate	B-X
in	B-X
response	B-X
to	B-X
IL	B-X
-	B-X
4	B-X
as	B-X
well	B-X
as	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
T	B-X
lymphoid	B-X
cells	B-X
with	B-X
inhibition	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
showed	B-X
normal	B-X
insulin	B-X
receptor	B-X
substrate	B-X
-	B-X
2	B-X
phosphorylation	B-X
and	B-X
only	B-X
a	B-X
modest	B-X
decrease	B-X
in	B-X
Stat6	B-X
activation	B-X
and	B-X
insulin	B-X
receptor	B-X
substrate	B-X
-	B-X
1	B-X
phosphorylation	B-X
after	B-X
IL	B-X
-	B-X
4	B-X
stimulation	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
/	B-X
IkappaBalpha	B-X
system	B-X
can	B-X
regulate	B-X
cytokine	B-X
receptor	B-X
capacitation	B-X
through	B-X
effects	B-X
on	B-X
the	B-X
induction	B-X
of	B-X
downstream	B-X
signaling	B-X
by	B-X
the	B-X
Stat	B-X
transcription	B-X
factor	B-X
family	B-X
<EOS>	B-X
Proliferative	B-X
responses	B-X
of	B-X
lymphoid	B-X
cells	B-X
to	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
depend	B-X
on	B-X
activation	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
by	B-X
which	B-X
activation	B-X
enhances	B-X
cellular	B-X
competence	B-X
to	B-X
respond	B-X
to	B-X
cytokines	B-X
is	B-X
not	B-X
fully	B-X
understood	B-X

Thymocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
from	O
IkappaBalpha	B-protein
(	I-protein
DeltaN	I-protein
)	I-protein
transgenic	O
mice	O
expressed	O
normal	O
levels	O
of	O
IL-2R	B-protein
subunits	I-protein
.	O

However	O
,	O
transgenic	B-cell_type
cells	I-cell_type
exhibited	O
a	O
dramatic	O
defect	O
in	O
Stat5A	O
activation	O
treatment	O
with	O
IL-2	B-protein
,	O
and	O
a	O
similar	O
defect	O
was	O
observed	O
for	O
IL-4	B-protein
-induced	O
Stat5	B-protein
.	O

In	O
contrast	O
,	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
with	O
inhibition	O
of	O
NF-kappaB	B-protein
showed	O
normal	O
insulin	O
receptor	O
substrate-2	O
phosphorylation	O
and	O
only	O
a	O
modest	O
decrease	O
in	O
Stat6	O
activation	O
and	O
insulin	O
receptor	O
substrate-1	O
phosphorylation	O
after	O
IL-4	O
stimulation	O
.	O

These	O
results	O
indicate	O
that	O
the	O
NF-kappaB/Rel/IkappaBalpha	O
system	O
can	O
regulate	O
cytokine	B-protein
receptor	I-protein
capacitation	O
through	O
effects	O
on	O
the	O
induction	O
of	O
downstream	O
signaling	O
by	O
the	O
Stat	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
/	B-X
IkappaBalpha	B-X
system	B-X
can	B-X
regulate	B-X
cytokine	B-X
receptor	B-X
capacitation	B-X
through	B-X
effects	B-X
on	B-X
the	B-X
induction	B-X
of	B-X
downstream	B-X
signaling	B-X
by	B-X
the	B-X
Stat	B-X
transcription	B-X
factor	B-X
family	B-X
<EOS>	B-X
We	B-X
show	B-X
in	B-X
this	B-X
study	B-X
that	B-X
inhibition	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
through	B-X
the	B-X
expression	B-X
of	B-X
an	B-X
IkappaBalpha	B-X
(	B-X
inhibitory	B-X
protein	B-X
that	B-X
dissociates	B-X
from	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
mutant	B-X
refractory	B-X
to	B-X
signal	B-X
-	B-X
induced	B-X
degradation	B-X
(	B-X
IkappaBalpha	B-X
(	B-X
DeltaN	B-X
)	B-X
)	B-X
interfered	B-X
with	B-X
the	B-X
acquisition	B-X
of	B-X
competence	B-X
to	B-X
proliferate	B-X
in	B-X
response	B-X
to	B-X
IL	B-X
-	B-X
4	B-X
as	B-X
well	B-X
as	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
kappaB	B-X
/	B-X
Rel	B-X
family	B-X
represents	B-X
one	B-X
signal	B-X
transduction	B-X
pathway	B-X
induced	B-X
during	B-X
such	B-X
activation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
T	B-X
lymphoid	B-X
cells	B-X
with	B-X
inhibition	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
showed	B-X
normal	B-X
insulin	B-X
receptor	B-X
substrate	B-X
-	B-X
2	B-X
phosphorylation	B-X
and	B-X
only	B-X
a	B-X
modest	B-X
decrease	B-X
in	B-X
Stat6	B-X
activation	B-X
and	B-X
insulin	B-X
receptor	B-X
substrate	B-X
-	B-X
1	B-X
phosphorylation	B-X
after	B-X
IL	B-X
-	B-X
4	B-X
stimulation	B-X

BMS-189453	O
,	O
a	O
novel	O
retinoid	O
receptor	O
antagonist	O
,	O
is	O
a	O
potent	O
testicular	O
toxin	O
.	O
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
,	B-X
a	B-X
novel	B-X
retinoid	B-X
receptor	B-X
antagonist	B-X
,	B-X
is	B-X
a	B-X
potent	B-X
testicular	B-X
toxin	B-X
.	B-X
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
is	B-X
a	B-X
synthetic	B-X
retinoid	B-X
that	B-X
acts	B-X
as	B-X
an	B-X
antagonist	B-X
at	B-X
retinoic	B-X
acid	B-X
receptors	B-X
alpha	B-X
,	B-X
beta	B-X
,	B-X
and	B-X
gamma	B-X
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
was	B-X
then	B-X
administered	B-X
at	B-X
doses	B-X
of	B-X
2	B-X
,	B-X
10	B-X
,	B-X
or	B-X
50	B-X
mg	B-X
/	B-X
kg	B-X
to	B-X
male	B-X
rats	B-X
for	B-X
1	B-X
,	B-X
3	B-X
,	B-X
or	B-X
7	B-X
consecutive	B-X
days	B-X
<EOS>	B-X
When	B-X
BMS	B-X
-	B-X
189453	B-X
was	B-X
administered	B-X
to	B-X
male	B-X
rats	B-X
at	B-X
daily	B-X
doses	B-X
ranging	B-X
from	B-X
12	B-X

BMS-189453	O
is	O
a	O
synthetic	O
retinoid	O
that	O
acts	O
as	O
an	O
antagonist	O
at	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
alpha	I-protein
,	I-protein
beta	I-protein
,	I-protein
and	I-protein
gamma	I-protein
.	O
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
is	B-X
a	B-X
synthetic	B-X
retinoid	B-X
that	B-X
acts	B-X
as	B-X
an	B-X
antagonist	B-X
at	B-X
retinoic	B-X
acid	B-X
receptors	B-X
alpha	B-X
,	B-X
beta	B-X
,	B-X
and	B-X
gamma	B-X
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
,	B-X
a	B-X
novel	B-X
retinoid	B-X
receptor	B-X
antagonist	B-X
,	B-X
is	B-X
a	B-X
potent	B-X
testicular	B-X
toxin	B-X
.	B-X
<EOS>	B-X
When	B-X
BMS	B-X
-	B-X
189453	B-X
was	B-X
administered	B-X
to	B-X
male	B-X
rats	B-X
at	B-X
daily	B-X
doses	B-X
ranging	B-X
from	B-X
12	B-X
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
was	B-X
then	B-X
administered	B-X
at	B-X
doses	B-X
of	B-X
2	B-X
,	B-X
10	B-X
,	B-X
or	B-X
50	B-X
mg	B-X
/	B-X
kg	B-X
to	B-X
male	B-X
rats	B-X
for	B-X
1	B-X
,	B-X
3	B-X
,	B-X
or	B-X
7	B-X
consecutive	B-X
days	B-X

In	O
Sprague	O
Dawley	O
rats	O
at	O
daily	O
oral	O
doses	O
of	O
15	O
,	O
60	O
,	O
or	O
240	O
mg/kg	O
for	O
1	O
month	O
,	O
BMS-189453	O
produced	O
increases	O
in	O
leukocyte	B-cell_type
counts	O
,	O
alkaline	B-protein
phosphatase	I-protein
and	O
alanine	B-protein
aminotransferase	I-protein
levels	O
,	O
and	O
marked	O
testicular	O
degeneration	O
and	O
atrophy	O
at	O
all	O
doses	O
.	O
<EOS>	B-X
In	B-X
Sprague	B-X
Dawley	B-X
rats	B-X
at	B-X
daily	B-X
oral	B-X
doses	B-X
of	B-X
15	B-X
,	B-X
60	B-X
,	B-X
or	B-X
240	B-X
mg	B-X
/	B-X
kg	B-X
for	B-X
1	B-X
month	B-X
,	B-X
BMS	B-X
-	B-X
189453	B-X
produced	B-X
increases	B-X
in	B-X
leukocyte	B-X
counts	B-X
,	B-X
alkaline	B-X
phosphatase	B-X
and	B-X
alanine	B-X
aminotransferase	B-X
levels	B-X
,	B-X
and	B-X
marked	B-X
testicular	B-X
degeneration	B-X
and	B-X
atrophy	B-X
at	B-X
all	B-X
doses	B-X
<EOS>	B-X
In	B-X
rabbits	B-X
administered	B-X
BMS	B-X
-	B-X
189453	B-X
at	B-X
oral	B-X
doses	B-X
of	B-X
2	B-X
,	B-X
10	B-X
,	B-X
or	B-X
50	B-X
mg	B-X
/	B-X
kg	B-X
for	B-X
1	B-X
week	B-X
,	B-X
testicular	B-X
degeneration	B-X
and	B-X
atrophy	B-X
were	B-X
evident	B-X
in	B-X
the	B-X
high	B-X
-	B-X
dose	B-X
group	B-X
at	B-X
1	B-X
month	B-X
following	B-X
treatment	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
describes	B-X
a	B-X
model	B-X
of	B-X
maxillary	B-X
osteonecrosis	B-X
in	B-X
Sprague	B-X
-	B-X
Dawley	B-X
rats	B-X
,	B-X
applying	B-X
bisphosphonates	B-X
and	B-X
examines	B-X
the	B-X
changes	B-X
occurring	B-X
after	B-X
tooth	B-X
extraction	B-X
<EOS>	B-X
One	B-X
male	B-X
and	B-X
female	B-X
from	B-X
each	B-X
litter	B-X
were	B-X
selected	B-X
(	B-X
F1	B-X
generation	B-X
)	B-X
and	B-X
retained	B-X
for	B-X
assessments	B-X
,	B-X
including	B-X
growth	B-X
,	B-X
neurobehavior	B-X
,	B-X
fertility	B-X
,	B-X
and	B-X
their	B-X
ability	B-X
to	B-X
produce	B-X
an	B-X
F2	B-X
generation	B-X

Significant	O
overt	O
signs	O
of	O
toxicity	O
and	O
deaths	O
occurred	O
at	O
240	O
mg/kg	O
,	O
whereas	O
body-weight	O
and	O
food-consumption	O
decreases	O
occurred	O
at	O
60	O
and	O
240	O
mg/kg	O
.	O
<EOS>	B-X
Significant	B-X
overt	B-X
signs	B-X
of	B-X
toxicity	B-X
and	B-X
deaths	B-X
occurred	B-X
at	B-X
240	B-X
mg	B-X
/	B-X
kg	B-X
,	B-X
whereas	B-X
body	B-X
-	B-X
weight	B-X
and	B-X
food	B-X
-	B-X
consumption	B-X
decreases	B-X
occurred	B-X
at	B-X
60	B-X
and	B-X
240	B-X
mg	B-X
/	B-X
kg	B-X
<EOS>	B-X
Dose	B-X
-	B-X
	B-X
and	B-X
duration	B-X
-	B-X
dependent	B-X
testicular	B-X
toxicity	B-X
that	B-X
occurred	B-X
after	B-X
a	B-X
1	B-X
-	B-X
month	B-X
observation	B-X
period	B-X
did	B-X
not	B-X
recover	B-X
,	B-X
and	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
was	B-X
more	B-X
severe	B-X
4	B-X
months	B-X
after	B-X
the	B-X
last	B-X
dose	B-X
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
is	B-X
a	B-X
synthetic	B-X
retinoid	B-X
that	B-X
acts	B-X
as	B-X
an	B-X
antagonist	B-X
at	B-X
retinoic	B-X
acid	B-X
receptors	B-X
alpha	B-X
,	B-X
beta	B-X
,	B-X
and	B-X
gamma	B-X
<EOS>	B-X
In	B-X
Sprague	B-X
Dawley	B-X
rats	B-X
at	B-X
daily	B-X
oral	B-X
doses	B-X
of	B-X
15	B-X
,	B-X
60	B-X
,	B-X
or	B-X
240	B-X
mg	B-X
/	B-X
kg	B-X
for	B-X
1	B-X
month	B-X
,	B-X
BMS	B-X
-	B-X
189453	B-X
produced	B-X
increases	B-X
in	B-X
leukocyte	B-X
counts	B-X
,	B-X
alkaline	B-X
phosphatase	B-X
and	B-X
alanine	B-X
aminotransferase	B-X
levels	B-X
,	B-X
and	B-X
marked	B-X
testicular	B-X
degeneration	B-X
and	B-X
atrophy	B-X
at	B-X
all	B-X
doses	B-X

When	O
BMS-189453	O
was	O
administered	O
to	O
male	O
rats	O
at	O
daily	O
doses	O
ranging	O
from	O
12.5	O
to	O
100	O
mg/kg	O
for	O
1	O
week	O
,	O
only	O
minimal	O
testicular	O
changes	O
occurred	O
at	O
all	O
doses	O
,	O
shortly	O
after	O
the	O
dosing	O
period	O
.	O
<EOS>	B-X
5	B-X
to	B-X
100	B-X
mg	B-X
/	B-X
kg	B-X
for	B-X
1	B-X
week	B-X
,	B-X
only	B-X
minimal	B-X
testicular	B-X
changes	B-X
occurred	B-X
at	B-X
all	B-X
doses	B-X
,	B-X
shortly	B-X
after	B-X
the	B-X
dosing	B-X
period	B-X
<EOS>	B-X
When	B-X
BMS	B-X
-	B-X
189453	B-X
was	B-X
administered	B-X
to	B-X
male	B-X
rats	B-X
at	B-X
daily	B-X
doses	B-X
ranging	B-X
from	B-X
12	B-X
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
was	B-X
then	B-X
administered	B-X
at	B-X
doses	B-X
of	B-X
2	B-X
,	B-X
10	B-X
,	B-X
or	B-X
50	B-X
mg	B-X
/	B-X
kg	B-X
to	B-X
male	B-X
rats	B-X
for	B-X
1	B-X
,	B-X
3	B-X
,	B-X
or	B-X
7	B-X
consecutive	B-X
days	B-X
<EOS>	B-X
In	B-X
rabbits	B-X
administered	B-X
BMS	B-X
-	B-X
189453	B-X
at	B-X
oral	B-X
doses	B-X
of	B-X
2	B-X
,	B-X
10	B-X
,	B-X
or	B-X
50	B-X
mg	B-X
/	B-X
kg	B-X
for	B-X
1	B-X
week	B-X
,	B-X
testicular	B-X
degeneration	B-X
and	B-X
atrophy	B-X
were	B-X
evident	B-X
in	B-X
the	B-X
high	B-X
-	B-X
dose	B-X
group	B-X
at	B-X
1	B-X
month	B-X
following	B-X
treatment	B-X

However	O
,	O
after	O
a	O
1-month	O
drug-free	O
observation	O
period	O
,	O
marked	O
testicular	O
atrophy	O
was	O
evident	O
at	O
all	O
doses	O
.	O
<EOS>	B-X
However	B-X
,	B-X
after	B-X
a	B-X
1	B-X
-	B-X
month	B-X
drug	B-X
-	B-X
free	B-X
observation	B-X
period	B-X
,	B-X
marked	B-X
testicular	B-X
atrophy	B-X
was	B-X
evident	B-X
at	B-X
all	B-X
doses	B-X
<EOS>	B-X
Dose	B-X
-	B-X
	B-X
and	B-X
duration	B-X
-	B-X
dependent	B-X
testicular	B-X
toxicity	B-X
that	B-X
occurred	B-X
after	B-X
a	B-X
1	B-X
-	B-X
month	B-X
observation	B-X
period	B-X
did	B-X
not	B-X
recover	B-X
,	B-X
and	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
was	B-X
more	B-X
severe	B-X
4	B-X
months	B-X
after	B-X
the	B-X
last	B-X
dose	B-X
<EOS>	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
retinoid	B-X
antagonists	B-X
can	B-X
selectively	B-X
produce	B-X
progressive	B-X
and	B-X
prolonged	B-X
testicular	B-X
toxicity	B-X
after	B-X
single	B-X
or	B-X
repeated	B-X
oral	B-X
doses	B-X
that	B-X
are	B-X
otherwise	B-X
well	B-X
tolerated	B-X
<EOS>	B-X
In	B-X
rabbits	B-X
administered	B-X
BMS	B-X
-	B-X
189453	B-X
at	B-X
oral	B-X
doses	B-X
of	B-X
2	B-X
,	B-X
10	B-X
,	B-X
or	B-X
50	B-X
mg	B-X
/	B-X
kg	B-X
for	B-X
1	B-X
week	B-X
,	B-X
testicular	B-X
degeneration	B-X
and	B-X
atrophy	B-X
were	B-X
evident	B-X
in	B-X
the	B-X
high	B-X
-	B-X
dose	B-X
group	B-X
at	B-X
1	B-X
month	B-X
following	B-X
treatment	B-X

BMS-189453	O
was	O
then	O
administered	O
at	O
doses	O
of	O
2	O
,	O
10	O
,	O
or	O
50	O
mg/kg	O
to	O
male	O
rats	O
for	O
1	O
,	O
3	O
,	O
or	O
7	O
consecutive	O
days	O
.	O
<EOS>	B-X
LCM	B-X
was	B-X
injected	B-X
intraperitoneally	B-X
at	B-X
a	B-X
dose	B-X
of	B-X
90	B-X
mg	B-X
/	B-X
kg	B-X
/	B-X
day	B-X
for	B-X
7	B-X
consecutive	B-X
days	B-X
<EOS>	B-X
A	B-X
45	B-X
-	B-X
year	B-X
-	B-X
old	B-X
male	B-X
was	B-X
hospitalized	B-X
for	B-X
cough	B-X
,	B-X
chest	B-X
tightness	B-X
and	B-X
fatigue	B-X
for	B-X
3	B-X
consecutive	B-X
days	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
established	B-X
rat	B-X
and	B-X
mouse	B-X
models	B-X
of	B-X
morphine	B-X
tolerance	B-X
by	B-X
intrathecal	B-X
injection	B-X
of	B-X
morphine	B-X
for	B-X
7	B-X
consecutive	B-X
days	B-X
<EOS>	B-X
Starting	B-X
on	B-X
day	B-X
7	B-X
after	B-X
injury	B-X
,	B-X
CXCR7	B-X
-	B-X
neutralizing	B-X
antibody	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
lateral	B-X
ventricle	B-X
using	B-X
a	B-X
micro	B-X
drug	B-X
delivery	B-X
system	B-X
for	B-X
6	B-X
consecutive	B-X
days	B-X

Dose-	O
and	O
duration-dependent	O
testicular	O
toxicity	O
that	O
occurred	O
after	O
a	O
1-month	O
observation	O
period	O
did	O
not	O
recover	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
was	O
more	O
severe	O
4	O
months	O
after	O
the	O
last	O
dose	O
.	O

In	O
rabbits	O
administered	O
BMS-189453	O
at	O
oral	O
doses	O
of	O
2	O
,	O
10	O
,	O
or	O
50	O
mg/kg	O
for	O
1	O
week	O
,	O
testicular	O
degeneration	O
and	O
atrophy	O
were	O
evident	O
in	O
the	O
high-dose	O
group	O
at	O
1	O
month	O
following	O
treatment	O
.	O
<EOS>	B-X
In	B-X
rabbits	B-X
administered	B-X
BMS	B-X
-	B-X
189453	B-X
at	B-X
oral	B-X
doses	B-X
of	B-X
2	B-X
,	B-X
10	B-X
,	B-X
or	B-X
50	B-X
mg	B-X
/	B-X
kg	B-X
for	B-X
1	B-X
week	B-X
,	B-X
testicular	B-X
degeneration	B-X
and	B-X
atrophy	B-X
were	B-X
evident	B-X
in	B-X
the	B-X
high	B-X
-	B-X
dose	B-X
group	B-X
at	B-X
1	B-X
month	B-X
following	B-X
treatment	B-X
<EOS>	B-X
BMS	B-X
-	B-X
189453	B-X
was	B-X
then	B-X
administered	B-X
at	B-X
doses	B-X
of	B-X
2	B-X
,	B-X
10	B-X
,	B-X
or	B-X
50	B-X
mg	B-X
/	B-X
kg	B-X
to	B-X
male	B-X
rats	B-X
for	B-X
1	B-X
,	B-X
3	B-X
,	B-X
or	B-X
7	B-X
consecutive	B-X
days	B-X
<EOS>	B-X
In	B-X
Sprague	B-X
Dawley	B-X
rats	B-X
at	B-X
daily	B-X
oral	B-X
doses	B-X
of	B-X
15	B-X
,	B-X
60	B-X
,	B-X
or	B-X
240	B-X
mg	B-X
/	B-X
kg	B-X
for	B-X
1	B-X
month	B-X
,	B-X
BMS	B-X
-	B-X
189453	B-X
produced	B-X
increases	B-X
in	B-X
leukocyte	B-X
counts	B-X
,	B-X
alkaline	B-X
phosphatase	B-X
and	B-X
alanine	B-X
aminotransferase	B-X
levels	B-X
,	B-X
and	B-X
marked	B-X
testicular	B-X
degeneration	B-X
and	B-X
atrophy	B-X
at	B-X
all	B-X
doses	B-X
<EOS>	B-X
However	B-X
,	B-X
after	B-X
a	B-X
1	B-X
-	B-X
month	B-X
drug	B-X
-	B-X
free	B-X
observation	B-X
period	B-X
,	B-X
marked	B-X
testicular	B-X
atrophy	B-X
was	B-X
evident	B-X
at	B-X
all	B-X
doses	B-X

These	O
studies	O
indicate	O
that	O
retinoid	O
antagonists	O
can	O
selectively	O
produce	O
progressive	O
and	O
prolonged	O
testicular	O
toxicity	O
after	O
single	O
or	O
repeated	O
oral	O
doses	O
that	O
are	O
otherwise	O
well	O
tolerated	O
.	O
<EOS>	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
retinoid	B-X
antagonists	B-X
can	B-X
selectively	B-X
produce	B-X
progressive	B-X
and	B-X
prolonged	B-X
testicular	B-X
toxicity	B-X
after	B-X
single	B-X
or	B-X
repeated	B-X
oral	B-X
doses	B-X
that	B-X
are	B-X
otherwise	B-X
well	B-X
tolerated	B-X
<EOS>	B-X
Evidence	B-X
supporting	B-X
its	B-X
use	B-X
is	B-X
mostly	B-X
dated	B-X
,	B-X
but	B-X
more	B-X
recent	B-X
findings	B-X
support	B-X
short	B-X
-	B-X
term	B-X
use	B-X
for	B-X
pain	B-X
control	B-X
as	B-X
well	B-X
as	B-X
enabling	B-X
non	B-X
-	B-X
pharmacological	B-X
interventions	B-X
that	B-X
achieve	B-X
long	B-X
term	B-X
benefit	B-X
but	B-X
would	B-X
otherwise	B-X
not	B-X
be	B-X
tolerated	B-X
<EOS>	B-X
Cyclobenzaprine	B-X
carries	B-X
a	B-X
more	B-X
significant	B-X
adverse	B-X
events	B-X
profile	B-X
,	B-X
including	B-X
CNS	B-X
sedation	B-X
;	B-X
it	B-X
was	B-X
found	B-X
to	B-X
be	B-X
effective	B-X
,	B-X
possible	B-X
as	B-X
effective	B-X
as	B-X
diazepam	B-X
,	B-X
however	B-X
,	B-X
it	B-X
is	B-X
not	B-X
currently	B-X
FDA	B-X
approved	B-X
for	B-X
CP	B-X
-	B-X
related	B-X
spasticity	B-X
and	B-X
further	B-X
evidence	B-X
is	B-X
required	B-X
to	B-X
support	B-X
its	B-X
use	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
pain	B-X
is	B-X
crucial	B-X
,	B-X
and	B-X
focuses	B-X
mostly	B-X
on	B-X
treatment	B-X
of	B-X
spasticity	B-X
through	B-X
non	B-X
-	B-X
interventional	B-X
techniques	B-X
,	B-X
surgery	B-X
and	B-X
medical	B-X
treatment	B-X

Sequential	O
involvement	O
of	O
NFAT	B-protein
and	O
Egr	B-protein
transcription	B-protein
factors	I-protein
in	O
FasL	O
regulation	O
.	O
<EOS>	B-X
Sequential	B-X
involvement	B-X
of	B-X
NFAT	B-X
and	B-X
Egr	B-X
transcription	B-X
factors	B-X
in	B-X
FasL	B-X
regulation	B-X
.	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
Egr2	B-X
and	B-X
Egr3	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
FasL	B-X
expression	B-X
<EOS>	B-X
Here	B-X
we	B-X
find	B-X
that	B-X
Egr2	B-X
and	B-X
Egr3	B-X
are	B-X
NFAT	B-X
target	B-X
genes	B-X
<EOS>	B-X
The	B-X
critical	B-X
function	B-X
of	B-X
NFAT	B-X
proteins	B-X
in	B-X
maintaining	B-X
lymphoid	B-X
homeostasis	B-X
was	B-X
revealed	B-X
in	B-X
mice	B-X
lacking	B-X
both	B-X
NFATp	B-X
and	B-X
NFAT4	B-X
(	B-X
DKO	B-X
)	B-X

The	O
critical	O
function	O
of	O
NFAT	B-protein
proteins	I-protein
in	O
maintaining	O
lymphoid	O
homeostasis	O
was	O
revealed	O
in	O
mice	O
lacking	O
both	O
NFATp	B-protein
and	O
NFAT4	B-protein
(	O
DKO	O
)	O
.	O
<EOS>	B-X
The	B-X
critical	B-X
function	B-X
of	B-X
NFAT	B-X
proteins	B-X
in	B-X
maintaining	B-X
lymphoid	B-X
homeostasis	B-X
was	B-X
revealed	B-X
in	B-X
mice	B-X
lacking	B-X
both	B-X
NFATp	B-X
and	B-X
NFAT4	B-X
(	B-X
DKO	B-X
)	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
Egr2	B-X
and	B-X
Egr3	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
FasL	B-X
expression	B-X
<EOS>	B-X
Sequential	B-X
involvement	B-X
of	B-X
NFAT	B-X
and	B-X
Egr	B-X
transcription	B-X
factors	B-X
in	B-X
FasL	B-X
regulation	B-X
.	B-X
<EOS>	B-X
Activation	B-X
of	B-X
FasL	B-X
occurs	B-X
via	B-X
the	B-X
NFAT	B-X
-	B-X
dependent	B-X
induction	B-X
of	B-X
Egr3	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
exogenously	B-X
provided	B-X
NFATp	B-X
to	B-X
restore	B-X
Egr	B-X
-	B-X
dependent	B-X
FasL	B-X
promoter	B-X
activity	B-X
in	B-X
DKO	B-X
lymph	B-X
node	B-X
cells	B-X

DKO	O
mice	O
exhibit	O
increased	O
lymphoproliferation	O
,	O
decreased	O
activation-induced	O
cell	O
death	O
,	O
and	O
impaired	O
induction	O
of	O
FasL	B-protein
.	O
<EOS>	B-X
DKO	B-X
mice	B-X
exhibit	B-X
increased	B-X
lymphoproliferation	B-X
,	B-X
decreased	B-X
activation	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
and	B-X
impaired	B-X
induction	B-X
of	B-X
FasL	B-X
<EOS>	B-X
Further	B-X
,	B-X
Egr3	B-X
expression	B-X
is	B-X
enriched	B-X
in	B-X
Th1	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
known	B-X
preferential	B-X
expression	B-X
of	B-X
FasL	B-X
in	B-X
the	B-X
Th1	B-X
versus	B-X
Th2	B-X
subset	B-X
<EOS>	B-X
Sequential	B-X
involvement	B-X
of	B-X
NFAT	B-X
and	B-X
Egr	B-X
transcription	B-X
factors	B-X
in	B-X
FasL	B-X
regulation	B-X
.	B-X
<EOS>	B-X
Activation	B-X
of	B-X
FasL	B-X
occurs	B-X
via	B-X
the	B-X
NFAT	B-X
-	B-X
dependent	B-X
induction	B-X
of	B-X
Egr3	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
exogenously	B-X
provided	B-X
NFATp	B-X
to	B-X
restore	B-X
Egr	B-X
-	B-X
dependent	B-X
FasL	B-X
promoter	B-X
activity	B-X
in	B-X
DKO	B-X
lymph	B-X
node	B-X
cells	B-X

The	O
transcription	B-protein
factors	I-protein
Egr2	B-protein
and	O
Egr3	B-protein
are	O
potent	O
activators	O
of	O
FasL	O
expression	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
Egr2	B-X
and	B-X
Egr3	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
FasL	B-X
expression	B-X
<EOS>	B-X
Here	B-X
we	B-X
find	B-X
that	B-X
Egr2	B-X
and	B-X
Egr3	B-X
are	B-X
NFAT	B-X
target	B-X
genes	B-X
<EOS>	B-X
Sequential	B-X
involvement	B-X
of	B-X
NFAT	B-X
and	B-X
Egr	B-X
transcription	B-X
factors	B-X
in	B-X
FasL	B-X
regulation	B-X
.	B-X
<EOS>	B-X
Indeed	B-X
,	B-X
transient	B-X
expression	B-X
of	B-X
GILZ	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
blocked	B-X
induction	B-X
of	B-X
a	B-X
reporter	B-X
construct	B-X
driven	B-X
by	B-X
the	B-X
FasL	B-X
promoter	B-X

Here	O
we	O
find	O
that	O
Egr2	B-DNA
and	O
Egr3	B-DNA
are	O
NFAT	B-DNA
target	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
Here	B-X
we	B-X
find	B-X
that	B-X
Egr2	B-X
and	B-X
Egr3	B-X
are	B-X
NFAT	B-X
target	B-X
genes	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
Egr2	B-X
and	B-X
Egr3	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
FasL	B-X
expression	B-X
<EOS>	B-X
Sequential	B-X
involvement	B-X
of	B-X
NFAT	B-X
and	B-X
Egr	B-X
transcription	B-X
factors	B-X
in	B-X
FasL	B-X
regulation	B-X
.	B-X
<EOS>	B-X
DKO	B-X
mice	B-X
exhibit	B-X
increased	B-X
lymphoproliferation	B-X
,	B-X
decreased	B-X
activation	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
and	B-X
impaired	B-X
induction	B-X
of	B-X
FasL	B-X

Activation	O
of	O
FasL	B-protein
occurs	O
via	O
the	O
NFAT	B-protein
-dependent	O
induction	O
of	O
Egr3	B-DNA
,	O
as	O
demonstrated	O
by	O
the	O
ability	O
of	O
exogenously	O
provided	O
NFATp	B-protein
to	O
restore	O
Egr	B-protein
-dependent	O
FasL	O
promoter	O
activity	O
in	O
DKO	B-cell_type
lymph	I-cell_type
node	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Activation	B-X
of	B-X
FasL	B-X
occurs	B-X
via	B-X
the	B-X
NFAT	B-X
-	B-X
dependent	B-X
induction	B-X
of	B-X
Egr3	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
exogenously	B-X
provided	B-X
NFATp	B-X
to	B-X
restore	B-X
Egr	B-X
-	B-X
dependent	B-X
FasL	B-X
promoter	B-X
activity	B-X
in	B-X
DKO	B-X
lymph	B-X
node	B-X
cells	B-X
<EOS>	B-X
The	B-X
critical	B-X
function	B-X
of	B-X
NFAT	B-X
proteins	B-X
in	B-X
maintaining	B-X
lymphoid	B-X
homeostasis	B-X
was	B-X
revealed	B-X
in	B-X
mice	B-X
lacking	B-X
both	B-X
NFATp	B-X
and	B-X
NFAT4	B-X
(	B-X
DKO	B-X
)	B-X
<EOS>	B-X
DKO	B-X
mice	B-X
exhibit	B-X
increased	B-X
lymphoproliferation	B-X
,	B-X
decreased	B-X
activation	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
and	B-X
impaired	B-X
induction	B-X
of	B-X
FasL	B-X
<EOS>	B-X
Further	B-X
,	B-X
Egr3	B-X
expression	B-X
is	B-X
enriched	B-X
in	B-X
Th1	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
known	B-X
preferential	B-X
expression	B-X
of	B-X
FasL	B-X
in	B-X
the	B-X
Th1	B-X
versus	B-X
Th2	B-X
subset	B-X

Further	O
,	O
Egr3	B-DNA
expression	O
is	O
enriched	O
in	O
Th1	B-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
molecular	O
basis	O
for	O
the	O
known	O
preferential	O
expression	O
of	O
FasL	B-protein
in	O
the	O
Th1	O
versus	O
Th2	O
subset	O
.	O
<EOS>	B-X
Further	B-X
,	B-X
Egr3	B-X
expression	B-X
is	B-X
enriched	B-X
in	B-X
Th1	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
known	B-X
preferential	B-X
expression	B-X
of	B-X
FasL	B-X
in	B-X
the	B-X
Th1	B-X
versus	B-X
Th2	B-X
subset	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
Egr2	B-X
and	B-X
Egr3	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
FasL	B-X
expression	B-X
<EOS>	B-X
DKO	B-X
mice	B-X
exhibit	B-X
increased	B-X
lymphoproliferation	B-X
,	B-X
decreased	B-X
activation	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
and	B-X
impaired	B-X
induction	B-X
of	B-X
FasL	B-X
<EOS>	B-X
Activation	B-X
of	B-X
FasL	B-X
occurs	B-X
via	B-X
the	B-X
NFAT	B-X
-	B-X
dependent	B-X
induction	B-X
of	B-X
Egr3	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
exogenously	B-X
provided	B-X
NFATp	B-X
to	B-X
restore	B-X
Egr	B-X
-	B-X
dependent	B-X
FasL	B-X
promoter	B-X
activity	B-X
in	B-X
DKO	B-X
lymph	B-X
node	B-X
cells	B-X

Mechanisms	O
and	O
clinical	O
relevance	O
of	O
nongenomic	O
glucocorticoid	O
actions	O
.	O
<EOS>	B-X
Mechanisms	B-X
and	B-X
clinical	B-X
relevance	B-X
of	B-X
nongenomic	B-X
glucocorticoid	B-X
actions	B-X
.	B-X
<EOS>	B-X
Genomic	B-X
effects	B-X
are	B-X
the	B-X
most	B-X
important	B-X
while	B-X
the	B-X
clinical	B-X
relevance	B-X
of	B-X
nongenomic	B-X
actions	B-X
is	B-X
still	B-X
a	B-X
matter	B-X
of	B-X
debate	B-X
<EOS>	B-X
Glucocorticoids	B-X
act	B-X
via	B-X
genomic	B-X
and	B-X
non	B-X
-	B-X
genomic	B-X
actions	B-X
<EOS>	B-X
The	B-X
vascular	B-X
wall	B-X
is	B-X
a	B-X
site	B-X
where	B-X
non	B-X
-	B-X
genomic	B-X
steroid	B-X
hormones	B-X
actions	B-X
are	B-X
particularly	B-X
prominent	B-X

Glucocorticoids	O
have	O
profound	O
anti-inflammatory	O
and	O
immunosuppressive	O
actions	O
when	O
used	O
therapeutically	O
.	O
<EOS>	B-X
Glucocorticoids	B-X
have	B-X
profound	B-X
anti	B-X
-	B-X
inflammatory	B-X
and	B-X
immunosuppressive	B-X
actions	B-X
when	B-X
used	B-X
therapeutically	B-X
<EOS>	B-X
Glucocorticoids	B-X
(	B-X
GC	B-X
)	B-X
are	B-X
potent	B-X
anti	B-X
-	B-X
inflammatory	B-X
and	B-X
immunosuppressive	B-X
agents	B-X
that	B-X
act	B-X
on	B-X
many	B-X
cells	B-X
of	B-X
the	B-X
body	B-X
,	B-X
including	B-X
monocytes	B-X
<EOS>	B-X
Glucocorticoids	B-X
represent	B-X
the	B-X
most	B-X
powerful	B-X
endogenous	B-X
anti	B-X
-	B-X
inflammatory	B-X
and	B-X
immunosuppressive	B-X
effectors	B-X
,	B-X
interfering	B-X
with	B-X
virtually	B-X
every	B-X
step	B-X
of	B-X
immunoinflammatory	B-X
responses	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
beta	B-X
in	B-X
acute	B-X
and	B-X
chronic	B-X
inflammatory	B-X
conditions	B-X
:	B-X
clinical	B-X
implications	B-X
.	B-X

The	O
therapeutic	O
dose	O
is	O
quite	O
variable	O
and	O
depends	O
on	O
the	O
disease	O
,	O
but	O
ranges	O
from	O
very	O
low	O
to	O
extremely	O
high	O
.	O
<EOS>	B-X
The	B-X
therapeutic	B-X
dose	B-X
is	B-X
quite	B-X
variable	B-X
and	B-X
depends	B-X
on	B-X
the	B-X
disease	B-X
,	B-X
but	B-X
ranges	B-X
from	B-X
very	B-X
low	B-X
to	B-X
extremely	B-X
high	B-X
<EOS>	B-X
The	B-X
wide	B-X
variability	B-X
in	B-X
PTH	B-X
values	B-X
depending	B-X
on	B-X
the	B-X
assays	B-X
used	B-X
has	B-X
led	B-X
us	B-X
to	B-X
expand	B-X
the	B-X
recommended	B-X
PTH	B-X
range	B-X
in	B-X
stage	B-X
3	B-X
and	B-X
4	B-X
CKD	B-X
<EOS>	B-X
The	B-X
rationale	B-X
for	B-X
the	B-X
use	B-X
of	B-X
various	B-X
dosage	B-X
regimens	B-X
for	B-X
specific	B-X
clinical	B-X
indications	B-X
is	B-X
the	B-X
existence	B-X
of	B-X
three	B-X
distinct	B-X
,	B-X
therapeutically	B-X
relevant	B-X
effects	B-X
:	B-X
genomic	B-X
,	B-X
specific	B-X
nongenomic	B-X
and	B-X
unspecific	B-X
nongenomic	B-X
<EOS>	B-X
Considering	B-X
the	B-X
main	B-X
genetic	B-X
and	B-X
environmental	B-X
factors	B-X
we	B-X
can	B-X
predict	B-X
the	B-X
dose	B-X
of	B-X
oral	B-X
anticoagulants	B-X
required	B-X
in	B-X
about	B-X
two	B-X
-	B-X
thirds	B-X
of	B-X
cases	B-X

The	O
rationale	O
for	O
the	O
use	O
of	O
various	O
dosage	O
regimens	O
for	O
specific	O
clinical	O
indications	O
is	O
the	O
existence	O
of	O
three	O
distinct	O
,	O
therapeutically	O
relevant	O
effects	O
:	O
genomic	O
,	O
specific	O
nongenomic	O
and	O
unspecific	O
nongenomic	O
.	O
<EOS>	B-X
The	B-X
rationale	B-X
for	B-X
the	B-X
use	B-X
of	B-X
various	B-X
dosage	B-X
regimens	B-X
for	B-X
specific	B-X
clinical	B-X
indications	B-X
is	B-X
the	B-X
existence	B-X
of	B-X
three	B-X
distinct	B-X
,	B-X
therapeutically	B-X
relevant	B-X
effects	B-X
:	B-X
genomic	B-X
,	B-X
specific	B-X
nongenomic	B-X
and	B-X
unspecific	B-X
nongenomic	B-X
<EOS>	B-X
The	B-X
therapeutic	B-X
dose	B-X
is	B-X
quite	B-X
variable	B-X
and	B-X
depends	B-X
on	B-X
the	B-X
disease	B-X
,	B-X
but	B-X
ranges	B-X
from	B-X
very	B-X
low	B-X
to	B-X
extremely	B-X
high	B-X
<EOS>	B-X
It	B-X
is	B-X
proposed	B-X
that	B-X
the	B-X
additional	B-X
therapeutic	B-X
benefit	B-X
of	B-X
higher	B-X
doses	B-X
is	B-X
obtained	B-X
via	B-X
these	B-X
nongenomic	B-X
effects	B-X
<EOS>	B-X
Thus	B-X
,	B-X
glucocorticoids	B-X
could	B-X
diminish	B-X
or	B-X
prevent	B-X
the	B-X
acute	B-X
immune	B-X
response	B-X
by	B-X
interfering	B-X
with	B-X
processes	B-X
such	B-X
as	B-X
the	B-X
rise	B-X
in	B-X
intracellular	B-X
Ca2+	B-X
concentration	B-X

Genomic	O
effects	O
are	O
mediated	O
by	O
cytosolic	B-protein
receptors	I-protein
that	O
alter	O
expression	O
of	O
specific	O
genes	O
.	O
<EOS>	B-X
Genomic	B-X
effects	B-X
are	B-X
mediated	B-X
by	B-X
cytosolic	B-X
receptors	B-X
that	B-X
alter	B-X
expression	B-X
of	B-X
specific	B-X
genes	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
redundant	B-X
H1	B-X
-	B-X
mediated	B-X
silencing	B-X
of	B-X
heterochromatin	B-X
is	B-X
important	B-X
to	B-X
maintain	B-X
cell	B-X
homeostasis	B-X
and	B-X
to	B-X
avoid	B-X
an	B-X
unspecific	B-X
IFN	B-X
response	B-X
<EOS>	B-X
Knock	B-X
-	B-X
down	B-X
(	B-X
KD	B-X
)	B-X
of	B-X
each	B-X
H1	B-X
variant	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
results	B-X
in	B-X
altered	B-X
gene	B-X
expression	B-X
and	B-X
proliferation	B-X
differently	B-X
in	B-X
a	B-X
variant	B-X
specific	B-X
manner	B-X
with	B-X
H1	B-X
<EOS>	B-X
Numb	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
contraction	B-X
of	B-X
skeletal	B-X
muscle	B-X
.	B-X

Specific	O
nongenomic	O
effects	O
occur	O
within	O
a	O
few	O
minutes	O
and	O
are	O
mediated	O
by	O
steroid-selective	B-protein
membrane	I-protein
receptors	I-protein
.	O
<EOS>	B-X
Specific	B-X
nongenomic	B-X
effects	B-X
occur	B-X
within	B-X
a	B-X
few	B-X
minutes	B-X
and	B-X
are	B-X
mediated	B-X
by	B-X
steroid	B-X
-	B-X
selective	B-X
membrane	B-X
receptors	B-X
<EOS>	B-X
Unspecific	B-X
nongenomic	B-X
effects	B-X
occur	B-X
within	B-X
seconds	B-X
,	B-X
but	B-X
only	B-X
at	B-X
high	B-X
glucocorticoid	B-X
dosages	B-X
,	B-X
and	B-X
seem	B-X
to	B-X
result	B-X
from	B-X
direct	B-X
interactions	B-X
with	B-X
biological	B-X
membranes	B-X
<EOS>	B-X
For	B-X
unspecific	B-X
nongenomic	B-X
effects	B-X
,	B-X
methylprednisolone	B-X
and	B-X
other	B-X
glucocorticoids	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
cation	B-X
cycling	B-X
across	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
but	B-X
to	B-X
have	B-X
little	B-X
effect	B-X
on	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
Genomic	B-X
effects	B-X
are	B-X
mediated	B-X
by	B-X
cytosolic	B-X
receptors	B-X
that	B-X
alter	B-X
expression	B-X
of	B-X
specific	B-X
genes	B-X

Unspecific	O
nongenomic	O
effects	O
occur	O
within	O
seconds	O
,	O
but	O
only	O
at	O
high	O
glucocorticoid	O
dosages	O
,	O
and	O
seem	O
to	O
result	O
from	O
direct	O
interactions	O
with	O
biological	O
membranes	O
.	O
<EOS>	B-X
Unspecific	B-X
nongenomic	B-X
effects	B-X
occur	B-X
within	B-X
seconds	B-X
,	B-X
but	B-X
only	B-X
at	B-X
high	B-X
glucocorticoid	B-X
dosages	B-X
,	B-X
and	B-X
seem	B-X
to	B-X
result	B-X
from	B-X
direct	B-X
interactions	B-X
with	B-X
biological	B-X
membranes	B-X
<EOS>	B-X
Specific	B-X
nongenomic	B-X
effects	B-X
occur	B-X
within	B-X
a	B-X
few	B-X
minutes	B-X
and	B-X
are	B-X
mediated	B-X
by	B-X
steroid	B-X
-	B-X
selective	B-X
membrane	B-X
receptors	B-X
<EOS>	B-X
For	B-X
unspecific	B-X
nongenomic	B-X
effects	B-X
,	B-X
methylprednisolone	B-X
and	B-X
other	B-X
glucocorticoids	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
cation	B-X
cycling	B-X
across	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
but	B-X
to	B-X
have	B-X
little	B-X
effect	B-X
on	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
Genomic	B-X
effects	B-X
are	B-X
mediated	B-X
by	B-X
cytosolic	B-X
receptors	B-X
that	B-X
alter	B-X
expression	B-X
of	B-X
specific	B-X
genes	B-X

For	O
unspecific	O
nongenomic	O
effects	O
,	O
methylprednisolone	O
and	O
other	O
glucocorticoids	O
have	O
been	O
shown	O
to	O
inhibit	O
cation	O
cycling	O
across	O
the	O
plasma	O
membrane	O
,	O
but	O
to	O
have	O
little	O
effect	O
on	O
protein	O
synthesis	O
.	O
<EOS>	B-X
For	B-X
unspecific	B-X
nongenomic	B-X
effects	B-X
,	B-X
methylprednisolone	B-X
and	B-X
other	B-X
glucocorticoids	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
cation	B-X
cycling	B-X
across	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
but	B-X
to	B-X
have	B-X
little	B-X
effect	B-X
on	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
Unspecific	B-X
nongenomic	B-X
effects	B-X
occur	B-X
within	B-X
seconds	B-X
,	B-X
but	B-X
only	B-X
at	B-X
high	B-X
glucocorticoid	B-X
dosages	B-X
,	B-X
and	B-X
seem	B-X
to	B-X
result	B-X
from	B-X
direct	B-X
interactions	B-X
with	B-X
biological	B-X
membranes	B-X
<EOS>	B-X
Specific	B-X
nongenomic	B-X
effects	B-X
occur	B-X
within	B-X
a	B-X
few	B-X
minutes	B-X
and	B-X
are	B-X
mediated	B-X
by	B-X
steroid	B-X
-	B-X
selective	B-X
membrane	B-X
receptors	B-X
<EOS>	B-X
It	B-X
is	B-X
proposed	B-X
that	B-X
the	B-X
additional	B-X
therapeutic	B-X
benefit	B-X
of	B-X
higher	B-X
doses	B-X
is	B-X
obtained	B-X
via	B-X
these	B-X
nongenomic	B-X
effects	B-X

Thus	O
,	O
glucocorticoids	O
could	O
diminish	O
or	O
prevent	O
the	O
acute	O
immune	O
response	O
by	O
interfering	O
with	O
processes	O
such	O
as	O
the	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
.	O
<EOS>	B-X
The	B-X
complex	B-X
mechanism	B-X
by	B-X
which	B-X
stress	B-X
can	B-X
affect	B-X
sensory	B-X
processes	B-X
such	B-X
as	B-X
hearing	B-X
is	B-X
still	B-X
poorly	B-X
understood	B-X
<EOS>	B-X
Glucocorticoids	B-X
modulate	B-X
the	B-X
feto	B-X
-	B-X
maternal	B-X
interface	B-X
during	B-X
the	B-X
induction	B-X
of	B-X
parturition	B-X
<EOS>	B-X
After	B-X
glucocorticoid	B-X
and	B-X
immunosuppression	B-X
therapy	B-X
,	B-X
the	B-X
patient	B-X
's	B-X
immune	B-X
indexes	B-X
and	B-X
proteinuria	B-X
gradually	B-X
returned	B-X
to	B-X
normal	B-X
and	B-X
abdominal	B-X
pain	B-X
did	B-X
not	B-X
recur	B-X
during	B-X
the	B-X
follow	B-X
up	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
knockdown	B-X
diminishes	B-X
the	B-X
antioxidant	B-X
protection	B-X
of	B-X
murine	B-X
B16	B-X
-	B-X
F10	B-X
(	B-X
highly	B-X
metastatic	B-X
)	B-X
melanoma	B-X
cells	B-X
,	B-X
thus	B-X
leading	B-X
to	B-X
a	B-X
drastic	B-X
decrease	B-X
in	B-X
their	B-X
survival	B-X
during	B-X
interaction	B-X
with	B-X
the	B-X
vascular	B-X
endothelium	B-X

It	O
is	O
proposed	O
that	O
the	O
additional	O
therapeutic	O
benefit	O
of	O
higher	O
doses	O
is	O
obtained	O
via	O
these	O
nongenomic	O
effects	O
.	O
<EOS>	B-X
It	B-X
is	B-X
proposed	B-X
that	B-X
the	B-X
additional	B-X
therapeutic	B-X
benefit	B-X
of	B-X
higher	B-X
doses	B-X
is	B-X
obtained	B-X
via	B-X
these	B-X
nongenomic	B-X
effects	B-X
<EOS>	B-X
For	B-X
unspecific	B-X
nongenomic	B-X
effects	B-X
,	B-X
methylprednisolone	B-X
and	B-X
other	B-X
glucocorticoids	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
cation	B-X
cycling	B-X
across	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
but	B-X
to	B-X
have	B-X
little	B-X
effect	B-X
on	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
The	B-X
rationale	B-X
for	B-X
the	B-X
use	B-X
of	B-X
various	B-X
dosage	B-X
regimens	B-X
for	B-X
specific	B-X
clinical	B-X
indications	B-X
is	B-X
the	B-X
existence	B-X
of	B-X
three	B-X
distinct	B-X
,	B-X
therapeutically	B-X
relevant	B-X
effects	B-X
:	B-X
genomic	B-X
,	B-X
specific	B-X
nongenomic	B-X
and	B-X
unspecific	B-X
nongenomic	B-X
<EOS>	B-X
Genomic	B-X
effects	B-X
are	B-X
mediated	B-X
by	B-X
cytosolic	B-X
receptors	B-X
that	B-X
alter	B-X
expression	B-X
of	B-X
specific	B-X
genes	B-X

High	O
glucose-induced	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
expression	O
through	O
an	O
osmotic	O
effect	O
in	O
rat	B-cell_type
mesangial	I-cell_type
cells	I-cell_type
is	O
PKC-NF-kappa	O
B-dependent	O
.	O
<EOS>	B-X
High	B-X
glucose	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
(	B-X
ICAM	B-X
-	B-X
1	B-X
)	B-X
expression	B-X
through	B-X
an	B-X
osmotic	B-X
effect	B-X
in	B-X
rat	B-X
mesangial	B-X
cells	B-X
is	B-X
PKC	B-X
-	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
.	B-X
<EOS>	B-X
We	B-X
also	B-X
measured	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
semiquantitative	B-X
RT	B-X
-	B-X
PCR	B-X
in	B-X
mesangial	B-X
cells	B-X
and	B-X
the	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X
<EOS>	B-X
Neither	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
protein	B-X
nor	B-X
mRNA	B-X
expression	B-X
was	B-X
,	B-X
however	B-X
,	B-X
affected	B-X
by	B-X
high	B-X
glucose	B-X
and	B-X
high	B-X
mannitol	B-X
<EOS>	B-X
High	B-X
glucose	B-X
itself	B-X
can	B-X
also	B-X
promote	B-X
mesangial	B-X
cell	B-X
proliferation	B-X
through	B-X
the	B-X
PKC	B-X
-	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
pathways	B-X

AIMS/HYPOTHESIS	O
:	O
Infiltration	O
of	O
mononuclear	B-cell_type
cells	I-cell_type
and	O
glomerular	O
enlargement	O
accompanied	O
by	O
glomerular	B-cell_type
cell	I-cell_type
proliferation	O
are	O
very	O
early	O
characteristics	O
of	O
the	O
pathophysiology	O
of	O
diabetes	O
.	O
<EOS>	B-X
Infiltration	B-X
of	B-X
mononuclear	B-X
cells	B-X
and	B-X
glomerular	B-X
enlargement	B-X
accompanied	B-X
by	B-X
glomerular	B-X
cell	B-X
proliferation	B-X
are	B-X
very	B-X
early	B-X
characteristics	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
diabetes	B-X
<EOS>	B-X
High	B-X
glucose	B-X
itself	B-X
can	B-X
also	B-X
promote	B-X
mesangial	B-X
cell	B-X
proliferation	B-X
through	B-X
the	B-X
PKC	B-X
-	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
pathways	B-X
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
mesangial	B-X
cells	B-X
with	B-X
rat	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
monoclonal	B-X
antibody	B-X
,	B-X
calphostin	B-X
C	B-X
,	B-X
staurosporine	B-X
,	B-X
or	B-X
N	B-X
-	B-X
tosyl	B-X
-	B-X
L	B-X
-	B-X
phenylalanine	B-X
chloromethyl	B-X
ketone	B-X
significantly	B-X
inhibited	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
p	B-X
<	B-X
<	B-X
0	B-X
<EOS>	B-X
We	B-X
also	B-X
measured	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
semiquantitative	B-X
RT	B-X
-	B-X
PCR	B-X
in	B-X
mesangial	B-X
cells	B-X
and	B-X
the	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X

To	O
clarify	O
the	O
mechanism	O
of	O
early	O
diabetic	O
nephropathy	O
,	O
we	O
measured	O
[	O
3H	O
]	O
-thymidine	O
incorporation	O
and	O
cell	O
numbers	O
to	O
show	O
the	O
influence	O
of	O
a	O
high	O
ambient	O
glucose	O
concentration	O
and	O
the	O
osmotic	O
effect	O
on	O
rat	B-cell_type
mesangial	I-cell_type
cell	I-cell_type
proliferation	O
.	O
<EOS>	B-X
To	B-X
clarify	B-X
the	B-X
mechanism	B-X
of	B-X
early	B-X
diabetic	B-X
nephropathy	B-X
,	B-X
we	B-X
measured	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
thymidine	B-X
incorporation	B-X
and	B-X
cell	B-X
numbers	B-X
to	B-X
show	B-X
the	B-X
influence	B-X
of	B-X
a	B-X
high	B-X
ambient	B-X
glucose	B-X
concentration	B-X
and	B-X
the	B-X
osmotic	B-X
effect	B-X
on	B-X
rat	B-X
mesangial	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
high	B-X
D	B-X
-	B-X
glucose	B-X
(	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
thymidine	B-X
incorporation	B-X
and	B-X
cell	B-X
numbers	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h	B-X
and	B-X
normalized	B-X
at	B-X
72	B-X
h	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
Notably	B-X
,	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitors	B-X
calphostin	B-X
C	B-X
and	B-X
staurosporine	B-X
reduced	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
and	B-X
high	B-X
glucose	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
Results	B-X
showed	B-X
that	B-X
high	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
high	B-X
concentrations	B-X
of	B-X
osmotic	B-X
agents	B-X
remarkably	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X
(	B-X
p	B-X
<	B-X
0	B-X

We	O
also	O
measured	O
the	O
effect	O
of	O
high	O
glucose	O
on	O
the	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
by	O
flow	O
cytometry	O
and	O
semiquantitative	O
RT-PCR	O
in	O
mesangial	B-cell_type
cells	I-cell_type
and	O
the	O
adhesion	O
of	O
leukocytes	B-cell_type
to	O
mesangial	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
We	B-X
also	B-X
measured	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
semiquantitative	B-X
RT	B-X
-	B-X
PCR	B-X
in	B-X
mesangial	B-X
cells	B-X
and	B-X
the	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X
<EOS>	B-X
Results	B-X
showed	B-X
that	B-X
high	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
high	B-X
concentrations	B-X
of	B-X
osmotic	B-X
agents	B-X
remarkably	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
High	B-X
glucose	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
(	B-X
ICAM	B-X
-	B-X
1	B-X
)	B-X
expression	B-X
through	B-X
an	B-X
osmotic	B-X
effect	B-X
in	B-X
rat	B-X
mesangial	B-X
cells	B-X
is	B-X
PKC	B-X
-	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
glucose	B-X
can	B-X
upregulate	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
protein	B-X
and	B-X
mRNA	B-X
expression	B-X
but	B-X
not	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
mesangial	B-X
cells	B-X
and	B-X
promote	B-X
leukocyte	B-X
adhesion	B-X
through	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
through	B-X
osmotic	B-X
effect	B-X
,	B-X
possibly	B-X
depending	B-X
on	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
PKC	B-X
-	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
pathway	B-X

METHODS/RESULTS	O
:	O
Cells	O
exposed	O
to	O
high	O
D-glucose	O
(	O
30	O
mmol/l	O
)	O
caused	O
an	O
increase	O
in	O
[	O
3H	O
]	O
-thymidine	O
incorporation	O
and	O
cell	O
numbers	O
at	O
24	O
and	O
48	O
h	O
and	O
normalized	O
at	O
72	O
h	O
(	O
p	O
<	O
0.05	O
)	O
,	O
whereas	O
these	O
changes	O
were	O
not	O
found	O
in	O
high	O
mannitol	O
(	O
30	O
mmol/l	O
)	O
,	O
IL-1	B-protein
beta	I-protein
,	O
or	O
TNF	B-protein
alpha	I-protein
-stimulated	O
mesangial	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
BML	B-X
-	B-X
111	B-X
attenuates	B-X
high	B-X
glucose	B-X
-	B-X
induced	B-X
inflammation	B-X
,	B-X
oxidative	B-X
stress	B-X
and	B-X
reduces	B-X
extracellular	B-X
matrix	B-X
accumulation	B-X
via	B-X
targeting	B-X
Nrf2	B-X
in	B-X
rat	B-X
glomerular	B-X
mesangial	B-X
cells	B-X
.	B-X
<EOS>	B-X
It	B-X
exerted	B-X
an	B-X
inhibitory	B-X
effect	B-X
on	B-X
the	B-X
formation	B-X
of	B-X
Gd	B-X
-	B-X
IgA1	B-X
-	B-X
containing	B-X
immune	B-X
complexes	B-X
in	B-X
PBMCs	B-X
and	B-X
the	B-X
proliferation	B-X
and	B-X
inflammation	B-X
activation	B-X
in	B-X
mesangial	B-X
cells	B-X
<EOS>	B-X
Cyclooxygenase	B-X
-	B-X
2	B-X
(	B-X
COX	B-X
-	B-X
2	B-X
)	B-X
and	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
also	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
septic	B-X
AKI	B-X
and	B-X
both	B-X
of	B-X
them	B-X
are	B-X
induced	B-X
upon	B-X
LPS	B-X
-	B-X
stimulation	B-X
in	B-X
mesangial	B-X
cells	B-X
<EOS>	B-X
Objective	B-X
Injured	B-X
tubular	B-X
reabsorption	B-X
is	B-X
highlighted	B-X
as	B-X
one	B-X
of	B-X
the	B-X
causes	B-X
of	B-X
increased	B-X
albuminuria	B-X
in	B-X
the	B-X
early	B-X
stage	B-X
of	B-X
diabetic	B-X
nephropathy	B-X
;	B-X
however	B-X
,	B-X
the	B-X
underlying	B-X
mechanism	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X

Cells	O
exposed	O
to	O
high-glucose	O
(	O
15	O
,	O
30	O
,	O
or	O
60	O
mmol/l	O
)	O
or	O
osmotic	O
agents	O
(	O
L-glucose	O
,	O
raffinose	O
and	O
mannitol	O
)	O
showed	O
that	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
expression	O
began	O
to	O
increase	O
after	O
24	O
h	O
,	O
reached	O
its	O
maximum	O
at	O
24	O
and	O
48	O
h	O
and	O
gradually	O
decreased	O
afterwards	O
.	O
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
high	B-X
-	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
,	B-X
or	B-X
60	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
osmotic	B-X
agents	B-X
(	B-X
L	B-X
-	B-X
glucose	B-X
,	B-X
raffinose	B-X
and	B-X
mannitol	B-X
)	B-X
showed	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
expression	B-X
began	B-X
to	B-X
increase	B-X
after	B-X
24	B-X
h	B-X
,	B-X
reached	B-X
its	B-X
maximum	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h	B-X
and	B-X
gradually	B-X
decreased	B-X
afterwards	B-X
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
high	B-X
D	B-X
-	B-X
glucose	B-X
(	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
thymidine	B-X
incorporation	B-X
and	B-X
cell	B-X
numbers	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h	B-X
and	B-X
normalized	B-X
at	B-X
72	B-X
h	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
Results	B-X
showed	B-X
that	B-X
high	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
high	B-X
concentrations	B-X
of	B-X
osmotic	B-X
agents	B-X
remarkably	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
Notably	B-X
,	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitors	B-X
calphostin	B-X
C	B-X
and	B-X
staurosporine	B-X
reduced	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
and	B-X
high	B-X
glucose	B-X
-	B-X
induced	B-X
proliferation	B-X

The	O
stimulatory	O
effects	O
of	O
high	O
glucose	O
and	O
high	O
mannitol	O
on	O
mRNA	O
expression	O
were	O
observed	O
as	O
early	O
as	O
6	O
h	O
and	O
reached	O
its	O
maximum	O
at	O
12	O
h	O
.	O

Up-regulation	O
of	O
ICAM-1	B-protein
protein	O
and	O
mRNA	O
was	O
also	O
found	O
in	O
IL-1-beta	B-protein
and	O
TNF-alpha	B-protein
-stimulated	O
mesangial	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Up	B-X
-	B-X
regulation	B-X
of	B-X
ICAM	B-X
-	B-X
1	B-X
protein	B-X
and	B-X
mRNA	B-X
was	B-X
also	B-X
found	B-X
in	B-X
IL	B-X
-	B-X
1	B-X
-	B-X
beta	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
stimulated	B-X
mesangial	B-X
cells	B-X
<EOS>	B-X
05	B-X
)	B-X
,	B-X
whereas	B-X
these	B-X
changes	B-X
were	B-X
not	B-X
found	B-X
in	B-X
high	B-X
mannitol	B-X
(	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
,	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
or	B-X
TNF	B-X
alpha	B-X
-	B-X
stimulated	B-X
mesangial	B-X
cells	B-X
<EOS>	B-X
Research	B-X
on	B-X
the	B-X
mechanism	B-X
of	B-X
endothelin	B-X
inflammatory	B-X
effects	B-X
on	B-X
human	B-X
mesangial	B-X
cells	B-X
.	B-X
<EOS>	B-X
PHD3	B-X
expression	B-X
induced	B-X
by	B-X
cytokines	B-X
is	B-X
NF	B-X
-	B-X
κB	B-X
dependent	B-X
in	B-X
mesangial	B-X
cells	B-X

Neither	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
protein	O
nor	O
mRNA	O
expression	O
was	O
,	O
however	O
,	O
affected	O
by	O
high	O
glucose	O
and	O
high	O
mannitol	O
.	O
<EOS>	B-X
Neither	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
protein	B-X
nor	B-X
mRNA	B-X
expression	B-X
was	B-X
,	B-X
however	B-X
,	B-X
affected	B-X
by	B-X
high	B-X
glucose	B-X
and	B-X
high	B-X
mannitol	B-X
<EOS>	B-X
However	B-X
,	B-X
neither	B-X
VCAM	B-X
-	B-X
1	B-X
nor	B-X
E	B-X
-	B-X
selection	B-X
expression	B-X
were	B-X
affected	B-X
by	B-X
HG	B-X
conditions	B-X
<EOS>	B-X
Expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecules	B-X
1	B-X
(	B-X
ICAM	B-X
-	B-X
1	B-X
)	B-X
via	B-X
an	B-X
osmotic	B-X
effect	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
exposed	B-X
to	B-X
high	B-X
glucose	B-X
medium	B-X
.	B-X
<EOS>	B-X
The	B-X
stimulatory	B-X
effects	B-X
of	B-X
high	B-X
glucose	B-X
and	B-X
high	B-X
mannitol	B-X
on	B-X
mRNA	B-X
expression	B-X
were	B-X
observed	B-X
as	B-X
early	B-X
as	B-X
6	B-X
h	B-X
and	B-X
reached	B-X
its	B-X
maximum	B-X
at	B-X
12	B-X
h	B-X

Notably	O
,	O
the	O
protein	O
kinase	O
C	O
inhibitors	O
calphostin	O
C	O
and	O
staurosporine	O
reduced	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
intercellular	B-RNA
adhesion	I-RNA
molecule-1	I-RNA
mRNA	O
expression	O
and	O
high	O
glucose-induced	O
proliferation	O
.	O
<EOS>	B-X
Notably	B-X
,	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitors	B-X
calphostin	B-X
C	B-X
and	B-X
staurosporine	B-X
reduced	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
and	B-X
high	B-X
glucose	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
inhibitor	B-X
N	B-X
-	B-X
tosyl	B-X
-	B-X
L	B-X
-	B-X
phenylalanine	B-X
chloromethyl	B-X
ketone	B-X
reduced	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
and	B-X
high	B-X
glucose	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
high	B-X
-	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
,	B-X
or	B-X
60	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
osmotic	B-X
agents	B-X
(	B-X
L	B-X
-	B-X
glucose	B-X
,	B-X
raffinose	B-X
and	B-X
mannitol	B-X
)	B-X
showed	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
expression	B-X
began	B-X
to	B-X
increase	B-X
after	B-X
24	B-X
h	B-X
,	B-X
reached	B-X
its	B-X
maximum	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h	B-X
and	B-X
gradually	B-X
decreased	B-X
afterwards	B-X
<EOS>	B-X
The	B-X
stimulatory	B-X
effects	B-X
of	B-X
high	B-X
glucose	B-X
and	B-X
high	B-X
mannitol	B-X
on	B-X
mRNA	B-X
expression	B-X
were	B-X
observed	B-X
as	B-X
early	B-X
as	B-X
6	B-X
h	B-X
and	B-X
reached	B-X
its	B-X
maximum	B-X
at	B-X
12	B-X
h	B-X

Furthermore	O
,	O
the	O
NF-kappa	O
B	O
inhibitor	O
N-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
reduced	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
intercellular	B-RNA
adhesion	I-RNA
molecule-1	I-RNA
mRNA	O
expression	O
and	O
high	O
glucose-induced	O
proliferation	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
inhibitor	B-X
N	B-X
-	B-X
tosyl	B-X
-	B-X
L	B-X
-	B-X
phenylalanine	B-X
chloromethyl	B-X
ketone	B-X
reduced	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
and	B-X
high	B-X
glucose	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
Notably	B-X
,	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
inhibitors	B-X
calphostin	B-X
C	B-X
and	B-X
staurosporine	B-X
reduced	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
and	B-X
high	B-X
glucose	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
The	B-X
stimulatory	B-X
effects	B-X
of	B-X
high	B-X
glucose	B-X
and	B-X
high	B-X
mannitol	B-X
on	B-X
mRNA	B-X
expression	B-X
were	B-X
observed	B-X
as	B-X
early	B-X
as	B-X
6	B-X
h	B-X
and	B-X
reached	B-X
its	B-X
maximum	B-X
at	B-X
12	B-X
h	B-X
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
high	B-X
-	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
,	B-X
or	B-X
60	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
osmotic	B-X
agents	B-X
(	B-X
L	B-X
-	B-X
glucose	B-X
,	B-X
raffinose	B-X
and	B-X
mannitol	B-X
)	B-X
showed	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
expression	B-X
began	B-X
to	B-X
increase	B-X
after	B-X
24	B-X
h	B-X
,	B-X
reached	B-X
its	B-X
maximum	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h	B-X
and	B-X
gradually	B-X
decreased	B-X
afterwards	B-X

Results	O
showed	O
that	O
high	O
glucose	O
(	O
15	O
,	O
30	O
mmol/l	O
)	O
or	O
high	O
concentrations	O
of	O
osmotic	O
agents	O
remarkably	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	B-cell_type
to	O
mesangial	B-cell_type
cells	I-cell_type
(	O
p	O
<	O
0.01	O
)	O
compared	O
with	O
control	B-cell_type
cells	I-cell_type
(	O
5	O
mmol/l	O
D-glucose	O
)	O
.	O
<EOS>	B-X
Results	B-X
showed	B-X
that	B-X
high	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
high	B-X
concentrations	B-X
of	B-X
osmotic	B-X
agents	B-X
remarkably	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
high	B-X
D	B-X
-	B-X
glucose	B-X
(	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
thymidine	B-X
incorporation	B-X
and	B-X
cell	B-X
numbers	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h	B-X
and	B-X
normalized	B-X
at	B-X
72	B-X
h	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
high	B-X
-	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
,	B-X
or	B-X
60	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
osmotic	B-X
agents	B-X
(	B-X
L	B-X
-	B-X
glucose	B-X
,	B-X
raffinose	B-X
and	B-X
mannitol	B-X
)	B-X
showed	B-X
that	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
expression	B-X
began	B-X
to	B-X
increase	B-X
after	B-X
24	B-X
h	B-X
,	B-X
reached	B-X
its	B-X
maximum	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h	B-X
and	B-X
gradually	B-X
decreased	B-X
afterwards	B-X
<EOS>	B-X
And	B-X
it	B-X
was	B-X
in	B-X
a	B-X
concentration	B-X
-	B-X
	B-X
and	B-X
time	B-X
-	B-X
dependent	B-X
manner	B-X
as	B-X
compared	B-X
with	B-X
control	B-X
group	B-X
(	B-X
up	B-X
-	B-X
regulated	B-X
0	B-X

Functional	O
blocking	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
on	O
mesangial	B-cell_type
cells	I-cell_type
with	O
rat	B-protein
intercellular	I-protein
adhesion	I-protein
molecule-1	I-protein
monoclonal	I-protein
antibody	I-protein
,	O
calphostin	O
C	O
,	O
staurosporine	O
,	O
or	O
N-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
significantly	O
inhibited	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
increase	O
in	O
leukocyte	O
adhesion	O
(	O
p	O
<	O
<	O
0.05	O
)	O
.	O
<EOS>	B-X
Functional	B-X
blocking	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
on	B-X
mesangial	B-X
cells	B-X
with	B-X
rat	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
monoclonal	B-X
antibody	B-X
,	B-X
calphostin	B-X
C	B-X
,	B-X
staurosporine	B-X
,	B-X
or	B-X
N	B-X
-	B-X
tosyl	B-X
-	B-X
L	B-X
-	B-X
phenylalanine	B-X
chloromethyl	B-X
ketone	B-X
significantly	B-X
inhibited	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
leukocyte	B-X
adhesion	B-X
(	B-X
p	B-X
<	B-X
<	B-X
0	B-X
<EOS>	B-X
We	B-X
also	B-X
measured	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
semiquantitative	B-X
RT	B-X
-	B-X
PCR	B-X
in	B-X
mesangial	B-X
cells	B-X
and	B-X
the	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
high	B-X
glucose	B-X
can	B-X
upregulate	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
protein	B-X
and	B-X
mRNA	B-X
expression	B-X
but	B-X
not	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
expression	B-X
in	B-X
mesangial	B-X
cells	B-X
and	B-X
promote	B-X
leukocyte	B-X
adhesion	B-X
through	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
through	B-X
osmotic	B-X
effect	B-X
,	B-X
possibly	B-X
depending	B-X
on	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
PKC	B-X
-	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
pathway	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
inhibitor	B-X
N	B-X
-	B-X
tosyl	B-X
-	B-X
L	B-X
-	B-X
phenylalanine	B-X
chloromethyl	B-X
ketone	B-X
reduced	B-X
high	B-X
glucose	B-X
-	B-X
	B-X
or	B-X
high	B-X
mannitol	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
mRNA	B-X
expression	B-X
and	B-X
high	B-X
glucose	B-X
-	B-X
induced	B-X
proliferation	B-X

CONCLUSION/INTERPRETATION	O
:	O
These	O
results	O
suggest	O
that	O
high	O
glucose	O
can	O
upregulate	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
protein	O
and	O
mRNA	O
expression	O
but	O
not	O
vascular	O
adhesion	O
molecule-1	O
expression	O
in	O
mesangial	B-cell_type
cells	I-cell_type
and	O
promote	O
leukocyte	O
adhesion	O
through	O
up-regulation	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
through	O
osmotic	O
effect	O
,	O
possibly	O
depending	O
on	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
PKC	B-protein
-	O
NF-kappa	B-protein
B	I-protein
)	O
pathway	O
.	O

High	O
glucose	O
itself	O
can	O
also	O
promote	O
mesangial	O
cell	O
proliferation	O
through	O
the	O
PKC-NF-kappa	O
B	O
pathways	O
.	O
<EOS>	B-X
High	B-X
glucose	B-X
itself	B-X
can	B-X
also	B-X
promote	B-X
mesangial	B-X
cell	B-X
proliferation	B-X
through	B-X
the	B-X
PKC	B-X
-	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
pathways	B-X
<EOS>	B-X
High	B-X
glucose	B-X
-	B-X
induced	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
(	B-X
ICAM	B-X
-	B-X
1	B-X
)	B-X
expression	B-X
through	B-X
an	B-X
osmotic	B-X
effect	B-X
in	B-X
rat	B-X
mesangial	B-X
cells	B-X
is	B-X
PKC	B-X
-	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
.	B-X
<EOS>	B-X
Infiltration	B-X
of	B-X
mononuclear	B-X
cells	B-X
and	B-X
glomerular	B-X
enlargement	B-X
accompanied	B-X
by	B-X
glomerular	B-X
cell	B-X
proliferation	B-X
are	B-X
very	B-X
early	B-X
characteristics	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
diabetes	B-X
<EOS>	B-X
Cells	B-X
exposed	B-X
to	B-X
high	B-X
D	B-X
-	B-X
glucose	B-X
(	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
thymidine	B-X
incorporation	B-X
and	B-X
cell	B-X
numbers	B-X
at	B-X
24	B-X
and	B-X
48	B-X
h	B-X
and	B-X
normalized	B-X
at	B-X
72	B-X
h	B-X
(	B-X
p	B-X
<	B-X
0	B-X

We	O
conclude	O
that	O
hyperglycaemia	O
in	O
itself	O
seems	O
to	O
be	O
an	O
important	O
factor	O
in	O
the	O
development	O
of	O
early	O
diabetic	O
nephropathy	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
hyperglycaemia	B-X
in	B-X
itself	B-X
seems	B-X
to	B-X
be	B-X
an	B-X
important	B-X
factor	B-X
in	B-X
the	B-X
development	B-X
of	B-X
early	B-X
diabetic	B-X
nephropathy	B-X
<EOS>	B-X
Results	B-X
showed	B-X
that	B-X
high	B-X
glucose	B-X
(	B-X
15	B-X
,	B-X
30	B-X
mmol	B-X
/	B-X
l	B-X
)	B-X
or	B-X
high	B-X
concentrations	B-X
of	B-X
osmotic	B-X
agents	B-X
remarkably	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
To	B-X
clarify	B-X
the	B-X
mechanism	B-X
of	B-X
early	B-X
diabetic	B-X
nephropathy	B-X
,	B-X
we	B-X
measured	B-X
[	B-X
3H	B-X
]	B-X
	B-X
-	B-X
thymidine	B-X
incorporation	B-X
and	B-X
cell	B-X
numbers	B-X
to	B-X
show	B-X
the	B-X
influence	B-X
of	B-X
a	B-X
high	B-X
ambient	B-X
glucose	B-X
concentration	B-X
and	B-X
the	B-X
osmotic	B-X
effect	B-X
on	B-X
rat	B-X
mesangial	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
We	B-X
also	B-X
measured	B-X
the	B-X
effect	B-X
of	B-X
high	B-X
glucose	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
semiquantitative	B-X
RT	B-X
-	B-X
PCR	B-X
in	B-X
mesangial	B-X
cells	B-X
and	B-X
the	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
mesangial	B-X
cells	B-X

Combined	O
corticosteroid/	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
therapy	O
in	O
the	O
treatment	O
of	O
severe	O
congenital	O
neutropenia	O
unresponsive	O
to	O
G-CSF	B-protein
:	O
Activated	O
glucocorticoid	B-protein
receptors	I-protein
synergize	O
with	O
G-CSF	B-protein
signals	O
.	O
<EOS>	B-X
Combined	B-X
corticosteroid	B-X
/	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
G	B-X
-	B-X
CSF	B-X
)	B-X
therapy	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
severe	B-X
congenital	B-X
neutropenia	B-X
unresponsive	B-X
to	B-X
G	B-X
-	B-X
CSF	B-X
:	B-X
Activated	B-X
glucocorticoid	B-X
receptors	B-X
synergize	B-X
with	B-X
G	B-X
-	B-X
CSF	B-X
signals	B-X
.	B-X
<EOS>	B-X
More	B-X
than	B-X
90	B-X
%	B-X
of	B-X
patients	B-X
with	B-X
severe	B-X
congenital	B-X
neutropenia	B-X
(	B-X
SCN	B-X
)	B-X
respond	B-X
to	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
G	B-X
-	B-X
CSF	B-X
)	B-X
therapy	B-X
<EOS>	B-X
These	B-X
data	B-X
provide	B-X
insight	B-X
into	B-X
SCN	B-X
unresponsive	B-X
to	B-X
standard	B-X
G	B-X
-	B-X
CSF	B-X
treatment	B-X
and	B-X
to	B-X
the	B-X
potential	B-X
corrective	B-X
action	B-X
of	B-X
combined	B-X
treatment	B-X
with	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
corticosteroids	B-X
through	B-X
synergistic	B-X
activation	B-X
of	B-X
STAT5	B-X
<EOS>	B-X
The	B-X
in	B-X
vitro	B-X
effect	B-X
of	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
corticosteroids	B-X
on	B-X
granulopoiesis	B-X
was	B-X
evaluated	B-X
in	B-X
clonogenic	B-X
assays	B-X
of	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
,	B-X
by	B-X
proliferation	B-X
studies	B-X
of	B-X
the	B-X
murine	B-X
myeloid	B-X
cell	B-X
line	B-X
32D	B-X
expressing	B-X
the	B-X
patient	B-X
's	B-X
mutated	B-X
G	B-X
-	B-X
CSFR	B-X
,	B-X
and	B-X
by	B-X
measuring	B-X
STAT5	B-X
activation	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
stimulated	B-X
cells	B-X

More	O
than	O
90	O
%	O
of	O
patients	O
with	O
severe	O
congenital	O
neutropenia	O
(	O
SCN	O
)	O
respond	O
to	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
therapy	O
.	O
<EOS>	B-X
More	B-X
than	B-X
90	B-X
%	B-X
of	B-X
patients	B-X
with	B-X
severe	B-X
congenital	B-X
neutropenia	B-X
(	B-X
SCN	B-X
)	B-X
respond	B-X
to	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
G	B-X
-	B-X
CSF	B-X
)	B-X
therapy	B-X
<EOS>	B-X
Combined	B-X
corticosteroid	B-X
/	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
G	B-X
-	B-X
CSF	B-X
)	B-X
therapy	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
severe	B-X
congenital	B-X
neutropenia	B-X
unresponsive	B-X
to	B-X
G	B-X
-	B-X
CSF	B-X
:	B-X
Activated	B-X
glucocorticoid	B-X
receptors	B-X
synergize	B-X
with	B-X
G	B-X
-	B-X
CSF	B-X
signals	B-X
.	B-X
<EOS>	B-X
Normal	B-X
stroma	B-X
,	B-X
however	B-X
,	B-X
failed	B-X
to	B-X
induce	B-X
granulopoiesis	B-X
from	B-X
patient	B-X
's	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
<EOS>	B-X
To	B-X
address	B-X
this	B-X
issue	B-X
,	B-X
we	B-X
studied	B-X
a	B-X
child	B-X
with	B-X
SCN	B-X
who	B-X
was	B-X
totally	B-X
unresponsive	B-X
to	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
had	B-X
a	B-X
novel	B-X
point	B-X
mutation	B-X
in	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
the	B-X
G	B-X
-	B-X
CSF	B-X
receptor	B-X
(	B-X
GCSF	B-X
-	B-X
R	B-X
)	B-X

The	O
basis	O
for	O
the	O
refractory	O
state	O
in	O
the	O
remaining	O
patients	O
is	O
unknown	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
studied	O
a	O
child	O
with	O
SCN	O
who	O
was	O
totally	O
unresponsive	O
to	O
G-CSF	B-protein
and	O
had	O
a	O
novel	O
point	O
mutation	O
in	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
G-CSF	B-protein
receptor	I-protein
(	O
GCSF-R	B-protein
)	O
.	O
<EOS>	B-X
To	B-X
address	B-X
this	B-X
issue	B-X
,	B-X
we	B-X
studied	B-X
a	B-X
child	B-X
with	B-X
SCN	B-X
who	B-X
was	B-X
totally	B-X
unresponsive	B-X
to	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
had	B-X
a	B-X
novel	B-X
point	B-X
mutation	B-X
in	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
the	B-X
G	B-X
-	B-X
CSF	B-X
receptor	B-X
(	B-X
GCSF	B-X
-	B-X
R	B-X
)	B-X
<EOS>	B-X
When	B-X
small	B-X
daily	B-X
doses	B-X
of	B-X
oral	B-X
prednisone	B-X
were	B-X
then	B-X
administered	B-X
to	B-X
the	B-X
patient	B-X
with	B-X
conventional	B-X
doses	B-X
of	B-X
subcutaneous	B-X
G	B-X
-	B-X
CSF	B-X
,	B-X
the	B-X
patient	B-X
responded	B-X
with	B-X
increased	B-X
neutrophil	B-X
numbers	B-X
and	B-X
with	B-X
a	B-X
complete	B-X
reversal	B-X
of	B-X
the	B-X
infectious	B-X
problems	B-X
<EOS>	B-X
More	B-X
than	B-X
90	B-X
%	B-X
of	B-X
patients	B-X
with	B-X
severe	B-X
congenital	B-X
neutropenia	B-X
(	B-X
SCN	B-X
)	B-X
respond	B-X
to	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
G	B-X
-	B-X
CSF	B-X
)	B-X
therapy	B-X
<EOS>	B-X
Proliferation	B-X
of	B-X
32D	B-X
cells	B-X
expressing	B-X
the	B-X
mutated	B-X
receptor	B-X
and	B-X
STAT5	B-X
activation	B-X
were	B-X
improved	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
dexamethasone	B-X

Marrow	O
stromal	O
support	O
of	O
granulopoiesis	O
was	O
evaluated	O
by	O
plating	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
on	O
preformed	O
stromal	O
layers	O
.	O
<EOS>	B-X
Marrow	B-X
stromal	B-X
support	B-X
of	B-X
granulopoiesis	B-X
was	B-X
evaluated	B-X
by	B-X
plating	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
on	B-X
preformed	B-X
stromal	B-X
layers	B-X
<EOS>	B-X
Patient	B-X
's	B-X
stroma	B-X
supported	B-X
granulopoiesis	B-X
derived	B-X
from	B-X
control	B-X
marrow	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
in	B-X
a	B-X
normal	B-X
manner	B-X
<EOS>	B-X
Normal	B-X
stroma	B-X
,	B-X
however	B-X
,	B-X
failed	B-X
to	B-X
induce	B-X
granulopoiesis	B-X
from	B-X
patient	B-X
's	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
<EOS>	B-X
The	B-X
in	B-X
vitro	B-X
effect	B-X
of	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
corticosteroids	B-X
on	B-X
granulopoiesis	B-X
was	B-X
evaluated	B-X
in	B-X
clonogenic	B-X
assays	B-X
of	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
,	B-X
by	B-X
proliferation	B-X
studies	B-X
of	B-X
the	B-X
murine	B-X
myeloid	B-X
cell	B-X
line	B-X
32D	B-X
expressing	B-X
the	B-X
patient	B-X
's	B-X
mutated	B-X
G	B-X
-	B-X
CSFR	B-X
,	B-X
and	B-X
by	B-X
measuring	B-X
STAT5	B-X
activation	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
stimulated	B-X
cells	B-X

Nonadherent	B-cell_type
cells	I-cell_type
were	O
harvested	O
and	O
assayed	O
in	O
clonogenic	O
assays	O
for	O
granulocytic	O
colony	O
production	O
.	O
<EOS>	B-X
Nonadherent	B-X
cells	B-X
were	B-X
harvested	B-X
and	B-X
assayed	B-X
in	B-X
clonogenic	B-X
assays	B-X
for	B-X
granulocytic	B-X
colony	B-X
production	B-X
<EOS>	B-X
Nonadherent	B-X
cells	B-X
harvested	B-X
weekly	B-X
from	B-X
myeloid	B-X
or	B-X
lymphoid	B-X
long	B-X
-	B-X
term	B-X
cultures	B-X
were	B-X
assayed	B-X
for	B-X
CFU	B-X
-	B-X
O	B-X
-	B-X
derived	B-X
colony	B-X
formation	B-X
in	B-X
agar	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
murine	B-X
osteoclast	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
<EOS>	B-X
SD	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
plated	B-X
directly	B-X
in	B-X
standard	B-X
clonogenic	B-X
assays	B-X
showed	B-X
markedly	B-X
impaired	B-X
colony	B-X
production	B-X
potential	B-X
,	B-X
underscoring	B-X
an	B-X
intrinsically	B-X
aberrant	B-X
progenitor	B-X
population	B-X
<EOS>	B-X
Nonadherent	B-X
cells	B-X
harvested	B-X
weekly	B-X
from	B-X
N	B-X
/	B-X
SD	B-X
LTCs	B-X
were	B-X
strikingly	B-X
reduced	B-X
compared	B-X
with	B-X
N	B-X
/	B-X
N	B-X
LTCs	B-X
;	B-X
numbers	B-X
of	B-X
granulocyte	B-X
-	B-X
monocyte	B-X
colony	B-X
-	B-X
forming	B-X
units	B-X
(	B-X
CFU	B-X
-	B-X
GM	B-X
)	B-X
derived	B-X
from	B-X
N	B-X
/	B-X
SD	B-X
nonadherent	B-X
cells	B-X
were	B-X
also	B-X
lower	B-X

The	O
in	O
vitro	O
effect	O
of	O
G-CSF	B-protein
and	O
corticosteroids	O
on	O
granulopoiesis	O
was	O
evaluated	O
in	O
clonogenic	O
assays	O
of	O
marrow	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
by	O
proliferation	O
studies	O
of	O
the	O
murine	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
line	I-cell_line
32D	I-cell_line
expressing	O
the	O
patient	O
's	O
mutated	B-protein
G-CSFR	I-protein
,	O
and	O
by	O
measuring	O
STAT5	O
activation	O
in	O
nuclear	O
extracts	O
from	O
stimulated	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
in	B-X
vitro	B-X
effect	B-X
of	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
corticosteroids	B-X
on	B-X
granulopoiesis	B-X
was	B-X
evaluated	B-X
in	B-X
clonogenic	B-X
assays	B-X
of	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
,	B-X
by	B-X
proliferation	B-X
studies	B-X
of	B-X
the	B-X
murine	B-X
myeloid	B-X
cell	B-X
line	B-X
32D	B-X
expressing	B-X
the	B-X
patient	B-X
's	B-X
mutated	B-X
G	B-X
-	B-X
CSFR	B-X
,	B-X
and	B-X
by	B-X
measuring	B-X
STAT5	B-X
activation	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
stimulated	B-X
cells	B-X
<EOS>	B-X
Combined	B-X
corticosteroid	B-X
/	B-X
granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
G	B-X
-	B-X
CSF	B-X
)	B-X
therapy	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
severe	B-X
congenital	B-X
neutropenia	B-X
unresponsive	B-X
to	B-X
G	B-X
-	B-X
CSF	B-X
:	B-X
Activated	B-X
glucocorticoid	B-X
receptors	B-X
synergize	B-X
with	B-X
G	B-X
-	B-X
CSF	B-X
signals	B-X
.	B-X
<EOS>	B-X
Clonogenic	B-X
assays	B-X
of	B-X
the	B-X
patient	B-X
's	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
incorporating	B-X
either	B-X
G	B-X
-	B-X
CSF	B-X
or	B-X
hydrocortisone	B-X
produced	B-X
little	B-X
neutrophil	B-X
growth	B-X
<EOS>	B-X
These	B-X
data	B-X
provide	B-X
insight	B-X
into	B-X
SCN	B-X
unresponsive	B-X
to	B-X
standard	B-X
G	B-X
-	B-X
CSF	B-X
treatment	B-X
and	B-X
to	B-X
the	B-X
potential	B-X
corrective	B-X
action	B-X
of	B-X
combined	B-X
treatment	B-X
with	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
corticosteroids	B-X
through	B-X
synergistic	B-X
activation	B-X
of	B-X
STAT5	B-X

Patient	O
's	O
stroma	O
supported	O
granulopoiesis	O
derived	O
from	O
control	O
marrow	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
in	O
a	O
normal	O
manner	O
.	O

Normal	O
stroma	O
,	O
however	O
,	O
failed	O
to	O
induce	O
granulopoiesis	O
from	O
patient	O
's	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

Clonogenic	O
assays	O
of	O
the	O
patient	O
's	O
marrow	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
incorporating	O
either	O
G-CSF	B-protein
or	O
hydrocortisone	O
produced	O
little	O
neutrophil	O
growth	O
.	O
<EOS>	B-X
Clonogenic	B-X
assays	B-X
of	B-X
the	B-X
patient	B-X
's	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
incorporating	B-X
either	B-X
G	B-X
-	B-X
CSF	B-X
or	B-X
hydrocortisone	B-X
produced	B-X
little	B-X
neutrophil	B-X
growth	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
inclusion	B-X
of	B-X
both	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
hydrocortisone	B-X
in	B-X
the	B-X
cytokine	B-X
``	B-X
cocktail	B-X
''	B-X
markedly	B-X
increased	B-X
the	B-X
neutrophil	B-X
numbers	B-X
<EOS>	B-X
The	B-X
in	B-X
vitro	B-X
effect	B-X
of	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
corticosteroids	B-X
on	B-X
granulopoiesis	B-X
was	B-X
evaluated	B-X
in	B-X
clonogenic	B-X
assays	B-X
of	B-X
marrow	B-X
mononuclear	B-X
cells	B-X
,	B-X
by	B-X
proliferation	B-X
studies	B-X
of	B-X
the	B-X
murine	B-X
myeloid	B-X
cell	B-X
line	B-X
32D	B-X
expressing	B-X
the	B-X
patient	B-X
's	B-X
mutated	B-X
G	B-X
-	B-X
CSFR	B-X
,	B-X
and	B-X
by	B-X
measuring	B-X
STAT5	B-X
activation	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
stimulated	B-X
cells	B-X
<EOS>	B-X
When	B-X
small	B-X
daily	B-X
doses	B-X
of	B-X
oral	B-X
prednisone	B-X
were	B-X
then	B-X
administered	B-X
to	B-X
the	B-X
patient	B-X
with	B-X
conventional	B-X
doses	B-X
of	B-X
subcutaneous	B-X
G	B-X
-	B-X
CSF	B-X
,	B-X
the	B-X
patient	B-X
responded	B-X
with	B-X
increased	B-X
neutrophil	B-X
numbers	B-X
and	B-X
with	B-X
a	B-X
complete	B-X
reversal	B-X
of	B-X
the	B-X
infectious	B-X
problems	B-X

In	O
contrast	O
,	O
inclusion	O
of	O
both	O
G-CSF	B-protein
and	O
hydrocortisone	O
in	O
the	O
cytokine	B-protein
``	I-protein
cocktail	I-protein
''	I-protein
markedly	O
increased	O
the	O
neutrophil	O
numbers	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
inclusion	B-X
of	B-X
both	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
hydrocortisone	B-X
in	B-X
the	B-X
cytokine	B-X
``	B-X
cocktail	B-X
''	B-X
markedly	B-X
increased	B-X
the	B-X
neutrophil	B-X
numbers	B-X
<EOS>	B-X
These	B-X
data	B-X
provide	B-X
insight	B-X
into	B-X
SCN	B-X
unresponsive	B-X
to	B-X
standard	B-X
G	B-X
-	B-X
CSF	B-X
treatment	B-X
and	B-X
to	B-X
the	B-X
potential	B-X
corrective	B-X
action	B-X
of	B-X
combined	B-X
treatment	B-X
with	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
corticosteroids	B-X
through	B-X
synergistic	B-X
activation	B-X
of	B-X
STAT5	B-X
<EOS>	B-X
When	B-X
small	B-X
daily	B-X
doses	B-X
of	B-X
oral	B-X
prednisone	B-X
were	B-X
then	B-X
administered	B-X
to	B-X
the	B-X
patient	B-X
with	B-X
conventional	B-X
doses	B-X
of	B-X
subcutaneous	B-X
G	B-X
-	B-X
CSF	B-X
,	B-X
the	B-X
patient	B-X
responded	B-X
with	B-X
increased	B-X
neutrophil	B-X
numbers	B-X
and	B-X
with	B-X
a	B-X
complete	B-X
reversal	B-X
of	B-X
the	B-X
infectious	B-X
problems	B-X
<EOS>	B-X
The	B-X
basis	B-X
for	B-X
the	B-X
refractory	B-X
state	B-X
in	B-X
the	B-X
remaining	B-X
patients	B-X
is	B-X
unknown	B-X

Proliferation	O
of	O
32D	B-cell_line
cells	I-cell_line
expressing	O
the	O
mutated	B-protein
receptor	I-protein
and	O
STAT5	O
activation	O
were	O
improved	O
by	O
a	O
combination	O
of	O
G-CSF	B-protein
and	O
dexamethasone	O
.	O
<EOS>	B-X
Proliferation	B-X
of	B-X
32D	B-X
cells	B-X
expressing	B-X
the	B-X
mutated	B-X
receptor	B-X
and	B-X
STAT5	B-X
activation	B-X
were	B-X
improved	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
dexamethasone	B-X
<EOS>	B-X
These	B-X
data	B-X
provide	B-X
insight	B-X
into	B-X
SCN	B-X
unresponsive	B-X
to	B-X
standard	B-X
G	B-X
-	B-X
CSF	B-X
treatment	B-X
and	B-X
to	B-X
the	B-X
potential	B-X
corrective	B-X
action	B-X
of	B-X
combined	B-X
treatment	B-X
with	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
corticosteroids	B-X
through	B-X
synergistic	B-X
activation	B-X
of	B-X
STAT5	B-X
<EOS>	B-X
Nonadherent	B-X
cells	B-X
were	B-X
harvested	B-X
and	B-X
assayed	B-X
in	B-X
clonogenic	B-X
assays	B-X
for	B-X
granulocytic	B-X
colony	B-X
production	B-X
<EOS>	B-X
To	B-X
address	B-X
this	B-X
issue	B-X
,	B-X
we	B-X
studied	B-X
a	B-X
child	B-X
with	B-X
SCN	B-X
who	B-X
was	B-X
totally	B-X
unresponsive	B-X
to	B-X
G	B-X
-	B-X
CSF	B-X
and	B-X
had	B-X
a	B-X
novel	B-X
point	B-X
mutation	B-X
in	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
the	B-X
G	B-X
-	B-X
CSF	B-X
receptor	B-X
(	B-X
GCSF	B-X
-	B-X
R	B-X
)	B-X

When	O
small	O
daily	O
doses	O
of	O
oral	O
prednisone	O
were	O
then	O
administered	O
to	O
the	O
patient	O
with	O
conventional	O
doses	O
of	O
subcutaneous	B-protein
G-CSF	I-protein
,	O
the	O
patient	O
responded	O
with	O
increased	O
neutrophil	O
numbers	O
and	O
with	O
a	O
complete	O
reversal	O
of	O
the	O
infectious	O
problems	O
.	O

These	O
data	O
provide	O
insight	O
into	O
SCN	O
unresponsive	O
to	O
standard	O
G-CSF	B-protein
treatment	O
and	O
to	O
the	O
potential	O
corrective	O
action	O
of	O
combined	O
treatment	O
with	O
G-CSF	B-protein
and	O
corticosteroids	O
through	O
synergistic	O
activation	O
of	O
STAT5	B-protein
.	O

Human	B-cell_type
renal	I-cell_type
mesangial	I-cell_type
cells	I-cell_type
are	O
a	O
target	O
for	O
the	O
anti-inflammatory	O
action	O
of	O
9-cis	O
retinoic	O
acid	O
.	O
<EOS>	B-X
Human	B-X
renal	B-X
mesangial	B-X
cells	B-X
are	B-X
a	B-X
target	B-X
for	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
mesangial	B-X
cells	B-X
might	B-X
be	B-X
a	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
glomerulopathies	B-X
with	B-X
9	B-X
-	B-X
cRA	B-X
<EOS>	B-X
Mesangial	B-X
cells	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
the	B-X
inflammatory	B-X
response	B-X
to	B-X
glomerular	B-X
injury	B-X
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
in	B-X
cultured	B-X
human	B-X
mesangial	B-X
cells	B-X
(	B-X
CHMC	B-X
)	B-X
several	B-X
effects	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
(	B-X
9	B-X
-	B-X
cRA	B-X
)	B-X
,	B-X
an	B-X
activator	B-X
of	B-X
both	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
and	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X

Mesangial	B-cell_type
cells	I-cell_type
play	O
an	O
active	O
role	O
in	O
the	O
inflammatory	O
response	O
to	O
glomerular	O
injury	O
.	O
<EOS>	B-X
Mesangial	B-X
cells	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
the	B-X
inflammatory	B-X
response	B-X
to	B-X
glomerular	B-X
injury	B-X
<EOS>	B-X
Mesangial	B-X
cell	B-X
proliferation	B-X
is	B-X
a	B-X
common	B-X
cellular	B-X
response	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
different	B-X
types	B-X
of	B-X
glomerular	B-X
injury	B-X
<EOS>	B-X
Platelets	B-X
are	B-X
thought	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
initiation	B-X
and	B-X
the	B-X
progression	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
glomerulonephritides	B-X
<EOS>	B-X
Human	B-X
renal	B-X
mesangial	B-X
cells	B-X
are	B-X
a	B-X
target	B-X
for	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
.	B-X

We	O
have	O
studied	O
in	O
cultured	B-cell_line
human	I-cell_line
mesangial	I-cell_line
cells	I-cell_line
(	O
CHMC	B-cell_line
)	O
several	O
effects	O
of	O
9-cis	O
retinoic	O
acid	O
(	O
9-cRA	O
)	O
,	O
an	O
activator	O
of	O
both	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
in	B-X
cultured	B-X
human	B-X
mesangial	B-X
cells	B-X
(	B-X
CHMC	B-X
)	B-X
several	B-X
effects	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
(	B-X
9	B-X
-	B-X
cRA	B-X
)	B-X
,	B-X
an	B-X
activator	B-X
of	B-X
both	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
and	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
<EOS>	B-X
Human	B-X
renal	B-X
mesangial	B-X
cells	B-X
are	B-X
a	B-X
target	B-X
for	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
mesangial	B-X
cells	B-X
might	B-X
be	B-X
a	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
glomerulopathies	B-X
with	B-X
9	B-X
-	B-X
cRA	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
retinoid	B-X
also	B-X
inhibited	B-X
in	B-X
FCS	B-X
-	B-X
stimulated	B-X
cells	B-X
the	B-X
protein	B-X
expression	B-X
of	B-X
two	B-X
mesangial	B-X
adhesion	B-X
molecules	B-X
,	B-X
fibronectin	B-X
and	B-X
osteopontin	B-X
,	B-X
but	B-X
it	B-X
did	B-X
not	B-X
modify	B-X
the	B-X
protein	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X

9-cRA	O
inhibited	O
foetal	O
calf	O
serum-induced	O
CHMC	B-cell_line
proliferation	O
.	O
<EOS>	B-X
9	B-X
-	B-X
cRA	B-X
inhibited	B-X
foetal	B-X
calf	B-X
serum	B-X
-	B-X
induced	B-X
CHMC	B-X
proliferation	B-X
<EOS>	B-X
9	B-X
-	B-X
cRA	B-X
was	B-X
toxic	B-X
only	B-X
at	B-X
50	B-X
microM	B-X
(	B-X
a	B-X
concentration	B-X
50	B-X
	B-X
-	B-X
	B-X
5000	B-X
times	B-X
higher	B-X
than	B-X
required	B-X
for	B-X
the	B-X
effects	B-X
above	B-X
)	B-X
<EOS>	B-X
Human	B-X
renal	B-X
mesangial	B-X
cells	B-X
are	B-X
a	B-X
target	B-X
for	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
.	B-X
<EOS>	B-X
All	B-X
major	B-X
RARs	B-X
and	B-X
RXRs	B-X
isotypes	B-X
were	B-X
expressed	B-X
in	B-X
CHMC	B-X
regardless	B-X
of	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
9	B-X
-	B-X
cRA	B-X

It	O
also	O
prevented	O
CHMC	B-cell_line
death	O
induced	O
by	O
the	O
inflammatory	O
mediator	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
.	O

This	O
preventive	O
effect	O
was	O
not	O
due	O
to	O
any	O
increase	O
in	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
catabolism	O
and	O
it	O
persisted	O
even	O
when	O
both	O
catalase	O
and	O
glutathione	O
synthesis	O
were	O
inhibited	O
.	O

Finally	O
,	O
9-cRA	O
diminished	O
monocyte	O
adhesion	O
to	O
FCS-stimulated	B-cell_line
CHMC	I-cell_line
.	O
<EOS>	B-X
Finally	B-X
,	B-X
9	B-X
-	B-X
cRA	B-X
diminished	B-X
monocyte	B-X
adhesion	B-X
to	B-X
FCS	B-X
-	B-X
stimulated	B-X
CHMC	B-X
<EOS>	B-X
Mesangial	B-X
cells	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
the	B-X
inflammatory	B-X
response	B-X
to	B-X
glomerular	B-X
injury	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
mesangial	B-X
cells	B-X
might	B-X
be	B-X
a	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
glomerulopathies	B-X
with	B-X
9	B-X
-	B-X
cRA	B-X
<EOS>	B-X
Human	B-X
renal	B-X
mesangial	B-X
cells	B-X
are	B-X
a	B-X
target	B-X
for	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
.	B-X

Interestingly	O
,	O
the	O
retinoid	O
also	O
inhibited	O
in	O
FCS-stimulated	B-cell_type
cells	I-cell_type
the	O
protein	O
expression	O
of	O
two	O
mesangial	B-protein
adhesion	I-protein
molecules	I-protein
,	O
fibronectin	B-protein
and	O
osteopontin	B-protein
,	O
but	O
it	O
did	O
not	O
modify	O
the	O
protein	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O

All	O
major	O
RARs	B-protein
and	I-protein
RXRs	I-protein
isotypes	I-protein
were	O
expressed	O
in	O
CHMC	B-cell_line
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
9-cRA	O
.	O
<EOS>	B-X
Bovine	B-X
slaughterhouse	B-X
cumulus	B-X
-	B-X
oocyte	B-X
complexes	B-X
(	B-X
COC	B-X
)	B-X
were	B-X
matured	B-X
in	B-X
vitro	B-X
in	B-X
the	B-X
absence	B-X
or	B-X
presence	B-X
of	B-X
5	B-X
nM	B-X
9	B-X
-	B-X
cisRA	B-X
<EOS>	B-X
7	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
was	B-X
cultured	B-X
with	B-X
ox	B-X
-	B-X
LDL	B-X
for	B-X
48	B-X
h	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
presence	B-X
of	B-X
RXR	B-X
activator	B-X
9	B-X
-	B-X
cisRA	B-X
or	B-X
SR11237	B-X
<EOS>	B-X
RXR	B-X
strongly	B-X
bound	B-X
to	B-X
importinbeta	B-X
and	B-X
was	B-X
predominantly	B-X
nuclear	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ligand	B-X
<EOS>	B-X
Apoptosis	B-X
and	B-X
gene	B-X
expression	B-X
were	B-X
analyzed	B-X
in	B-X
d	B-X
-	B-X
8	B-X
blastocysts	B-X

Transcripts	O
to	O
RAR-alpha	B-RNA
,	O
RAR-beta	B-RNA
and	O
RXR-alpha	B-RNA
increased	O
after	O
incubation	O
with	O
9-cRA	O
whereas	O
RXR-gamma	B-RNA
was	O
inhibited	O
,	O
suggesting	O
a	O
major	O
role	O
for	O
RARs	B-protein
and	O
RXRs	B-protein
in	O
9-cRA-anti-inflammatory	O
effects	O
.	O

9-cRA	O
was	O
toxic	O
only	O
at	O
50	O
microM	O
(	O
a	O
concentration	O
50	O
-	O
5000	O
times	O
higher	O
than	O
required	O
for	O
the	O
effects	O
above	O
)	O
.	O
<EOS>	B-X
9	B-X
-	B-X
cRA	B-X
was	B-X
toxic	B-X
only	B-X
at	B-X
50	B-X
microM	B-X
(	B-X
a	B-X
concentration	B-X
50	B-X
	B-X
-	B-X
	B-X
5000	B-X
times	B-X
higher	B-X
than	B-X
required	B-X
for	B-X
the	B-X
effects	B-X
above	B-X
)	B-X
<EOS>	B-X
Cell	B-X
death	B-X
occurred	B-X
by	B-X
apoptosis	B-X
,	B-X
whose	B-X
onset	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
pronounced	B-X
increase	B-X
in	B-X
catalase	B-X
activity	B-X
and	B-X
reduced	B-X
glutathione	B-X
content	B-X
,	B-X
being	B-X
more	B-X
effectively	B-X
induced	B-X
by	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
<EOS>	B-X
Modulation	B-X
of	B-X
the	B-X
oxidant	B-X
/	B-X
antioxidant	B-X
balance	B-X
failed	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
<EOS>	B-X
9	B-X
-	B-X
cRA	B-X
inhibited	B-X
foetal	B-X
calf	B-X
serum	B-X
-	B-X
induced	B-X
CHMC	B-X
proliferation	B-X

Cell	O
death	O
occurred	O
by	O
apoptosis	O
,	O
whose	O
onset	O
was	O
associated	O
with	O
a	O
pronounced	O
increase	O
in	O
catalase	O
activity	O
and	O
reduced	O
glutathione	O
content	O
,	O
being	O
more	O
effectively	O
induced	O
by	O
all-trans	O
retinoic	O
acid	O
.	O
<EOS>	B-X
Cell	B-X
death	B-X
occurred	B-X
by	B-X
apoptosis	B-X
,	B-X
whose	B-X
onset	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
pronounced	B-X
increase	B-X
in	B-X
catalase	B-X
activity	B-X
and	B-X
reduced	B-X
glutathione	B-X
content	B-X
,	B-X
being	B-X
more	B-X
effectively	B-X
induced	B-X
by	B-X
all	B-X
-	B-X
trans	B-X
retinoic	B-X
acid	B-X
<EOS>	B-X
Human	B-X
renal	B-X
mesangial	B-X
cells	B-X
are	B-X
a	B-X
target	B-X
for	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
.	B-X
<EOS>	B-X
This	B-X
preventive	B-X
effect	B-X
was	B-X
not	B-X
due	B-X
to	B-X
any	B-X
increase	B-X
in	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
catabolism	B-X
and	B-X
it	B-X
persisted	B-X
even	B-X
when	B-X
both	B-X
catalase	B-X
and	B-X
glutathione	B-X
synthesis	B-X
were	B-X
inhibited	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
retinoid	B-X
also	B-X
inhibited	B-X
in	B-X
FCS	B-X
-	B-X
stimulated	B-X
cells	B-X
the	B-X
protein	B-X
expression	B-X
of	B-X
two	B-X
mesangial	B-X
adhesion	B-X
molecules	B-X
,	B-X
fibronectin	B-X
and	B-X
osteopontin	B-X
,	B-X
but	B-X
it	B-X
did	B-X
not	B-X
modify	B-X
the	B-X
protein	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X

Modulation	O
of	O
the	O
oxidant/antioxidant	O
balance	O
failed	O
to	O
inhibit	O
apoptosis	O
.	O
<EOS>	B-X
Modulation	B-X
of	B-X
the	B-X
oxidant	B-X
/	B-X
antioxidant	B-X
balance	B-X
failed	B-X
to	B-X
inhibit	B-X
apoptosis	B-X
<EOS>	B-X
9	B-X
-	B-X
cRA	B-X
was	B-X
toxic	B-X
only	B-X
at	B-X
50	B-X
microM	B-X
(	B-X
a	B-X
concentration	B-X
50	B-X
	B-X
-	B-X
	B-X
5000	B-X
times	B-X
higher	B-X
than	B-X
required	B-X
for	B-X
the	B-X
effects	B-X
above	B-X
)	B-X
<EOS>	B-X
This	B-X
preventive	B-X
effect	B-X
was	B-X
not	B-X
due	B-X
to	B-X
any	B-X
increase	B-X
in	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
catabolism	B-X
and	B-X
it	B-X
persisted	B-X
even	B-X
when	B-X
both	B-X
catalase	B-X
and	B-X
glutathione	B-X
synthesis	B-X
were	B-X
inhibited	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
mesangial	B-X
cells	B-X
might	B-X
be	B-X
a	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
glomerulopathies	B-X
with	B-X
9	B-X
-	B-X
cRA	B-X

We	O
conclude	O
that	O
mesangial	B-cell_type
cells	I-cell_type
might	O
be	O
a	O
target	O
for	O
the	O
treatment	O
of	O
inflammatory	O
glomerulopathies	O
with	O
9-cRA	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
mesangial	B-X
cells	B-X
might	B-X
be	B-X
a	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
glomerulopathies	B-X
with	B-X
9	B-X
-	B-X
cRA	B-X
<EOS>	B-X
Human	B-X
renal	B-X
mesangial	B-X
cells	B-X
are	B-X
a	B-X
target	B-X
for	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
of	B-X
9	B-X
-	B-X
cis	B-X
retinoic	B-X
acid	B-X
.	B-X
<EOS>	B-X
Mesangial	B-X
cells	B-X
play	B-X
an	B-X
active	B-X
role	B-X
in	B-X
the	B-X
inflammatory	B-X
response	B-X
to	B-X
glomerular	B-X
injury	B-X
<EOS>	B-X
It	B-X
also	B-X
prevented	B-X
CHMC	B-X
death	B-X
induced	B-X
by	B-X
the	B-X
inflammatory	B-X
mediator	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X

Expression	O
of	O
mammalian	B-DNA
defensin	I-DNA
genes	I-DNA
.	O
<EOS>	B-X
Expression	B-X
and	B-X
function	B-X
of	B-X
resolvin	B-X
RvD1	B-X
<EOS>	B-X
Antimicrobial	B-X
peptide	B-X
human	B-X
β	B-X
-	B-X
defensin	B-X
-	B-X
2	B-X
improves	B-X
<EOS>	B-X
For	B-X
the	B-X
present	B-X
report	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
temporal	B-X
expression	B-X
profiles	B-X
of	B-X
the	B-X
12	B-X
mammalian	B-X
annexin	B-X
genes	B-X
(	B-X
<EOS>	B-X
Down	B-X
regulation	B-X
of	B-X
defensin	B-X
genes	B-X
during	B-X
SARS	B-X
-	B-X
CoV	B-X
-	B-X
2	B-X
infection	B-X
.	B-X

Antimicrobial	O
peptides	O
are	O
a	O
prevalent	O
mechanism	O
of	O
host	O
defense	O
found	O
throughout	O
nature	O
.	O
<EOS>	B-X
Antimicrobial	B-X
peptides	B-X
are	B-X
a	B-X
prevalent	B-X
mechanism	B-X
of	B-X
host	B-X
defense	B-X
found	B-X
throughout	B-X
nature	B-X
<EOS>	B-X
The	B-X
defensin	B-X
peptides	B-X
are	B-X
especially	B-X
abundant	B-X
in	B-X
neutrophils	B-X
;	B-X
however	B-X
,	B-X
gene	B-X
expression	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
promyelocyte	B-X
stage	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
recognition	B-X
of	B-X
bacteria	B-X
coupled	B-X
with	B-X
a	B-X
nascent	B-X
inflammatory	B-X
response	B-X
can	B-X
bolster	B-X
this	B-X
defense	B-X
by	B-X
a	B-X
coordinated	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
the	B-X
peptides	B-X
<EOS>	B-X
In	B-X
mammals	B-X
,	B-X
defensins	B-X
are	B-X
among	B-X
the	B-X
most	B-X
abundant	B-X
of	B-X
these	B-X
broad	B-X
-	B-X
spectrum	B-X
antibiotics	B-X
,	B-X
and	B-X
are	B-X
expressed	B-X
in	B-X
epithelial	B-X
and	B-X
hematopoietic	B-X
cells	B-X

In	O
mammals	O
,	O
defensins	B-protein
are	O
among	O
the	O
most	O
abundant	O
of	O
these	O
broad-spectrum	O
antibiotics	O
,	O
and	O
are	O
expressed	O
in	O
epithelial	B-cell_type
and	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
In	B-X
mammals	B-X
,	B-X
defensins	B-X
are	B-X
among	B-X
the	B-X
most	B-X
abundant	B-X
of	B-X
these	B-X
broad	B-X
-	B-X
spectrum	B-X
antibiotics	B-X
,	B-X
and	B-X
are	B-X
expressed	B-X
in	B-X
epithelial	B-X
and	B-X
hematopoietic	B-X
cells	B-X
<EOS>	B-X
The	B-X
defensin	B-X
peptides	B-X
are	B-X
especially	B-X
abundant	B-X
in	B-X
neutrophils	B-X
;	B-X
however	B-X
,	B-X
gene	B-X
expression	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
promyelocyte	B-X
stage	B-X
<EOS>	B-X
In	B-X
epithelial	B-X
cells	B-X
,	B-X
defensin	B-X
genes	B-X
are	B-X
found	B-X
as	B-X
both	B-X
constitutively	B-X
expressed	B-X
and	B-X
inducible	B-X
<EOS>	B-X
Together	B-X
,	B-X
the	B-X
data	B-X
suggest	B-X
a	B-X
broad	B-X
-	B-X
based	B-X
innate	B-X
host	B-X
defense	B-X
whereby	B-X
potent	B-X
antimicrobial	B-X
peptides	B-X
are	B-X
present	B-X
to	B-X
prevent	B-X
initial	B-X
colonization	B-X
by	B-X
pathogenic	B-X
microorganisms	B-X

The	O
defensin	O
peptides	O
are	O
especially	O
abundant	O
in	O
neutrophils	B-cell_type
;	O
however	O
,	O
gene	O
expression	O
is	O
limited	O
to	O
the	O
promyelocyte	O
stage	O
.	O

In	O
epithelial	B-cell_type
cells	I-cell_type
,	O
defensin	B-DNA
genes	I-DNA
are	O
found	O
as	O
both	O
constitutively	O
expressed	O
and	O
inducible	O
.	O
<EOS>	B-X
In	B-X
epithelial	B-X
cells	B-X
,	B-X
defensin	B-X
genes	B-X
are	B-X
found	B-X
as	B-X
both	B-X
constitutively	B-X
expressed	B-X
and	B-X
inducible	B-X
<EOS>	B-X
They	B-X
are	B-X
expressed	B-X
by	B-X
oral	B-X
tissues	B-X
as	B-X
constitutive	B-X
and	B-X
inducible	B-X
genes	B-X
<EOS>	B-X
The	B-X
multiple	B-X
properties	B-X
of	B-X
defensins	B-X
contribute	B-X
to	B-X
human	B-X
innate	B-X
immunity	B-X
against	B-X
bacteria	B-X
,	B-X
bacterial	B-X
toxins	B-X
,	B-X
and	B-X
viruses	B-X
<EOS>	B-X
Infection	B-X
with	B-X
the	B-X
wild	B-X
type	B-X
SE	B-X
strain	B-X
temporarily	B-X
repressed	B-X
certain	B-X
highly	B-X
expressed	B-X
AvBDs	B-X
and	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
minimally	B-X
expressed	B-X
AvBDs	B-X

Induction	O
has	O
been	O
observed	O
in	O
vitro	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
as	O
well	O
as	O
inflammatory	O
mediators	O
.	O
<EOS>	B-X
Induction	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
vitro	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
as	B-X
well	B-X
as	B-X
inflammatory	B-X
mediators	B-X
<EOS>	B-X
In	B-X
vivo	B-X
,	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
several	B-X
defensin	B-X
genes	B-X
occurs	B-X
in	B-X
both	B-X
infectious	B-X
and	B-X
inflammatory	B-X
states	B-X
<EOS>	B-X
Preincubation	B-X
of	B-X
nonadherent	B-X
monocytes	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
caused	B-X
a	B-X
23	B-X
-	B-X
	B-X
to	B-X
30	B-X
-	B-X
fold	B-X
increase	B-X
of	B-X
specific	B-X
binding	B-X
sites	B-X
for	B-X
VT	B-X
-	B-X
1	B-X
as	B-X
shown	B-X
by	B-X
Scatchard	B-X
plot	B-X
analysis	B-X
<EOS>	B-X
Gene	B-X
regulation	B-X
occurs	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
common	B-X
to	B-X
other	B-X
innate	B-X
immune	B-X
responses	B-X
,	B-X
utilizing	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
interleukin	B-X
-	B-X
6	B-X

In	O
vivo	O
,	O
up-regulation	O
of	O
several	O
defensin	B-DNA
genes	I-DNA
occurs	O
in	O
both	O
infectious	O
and	O
inflammatory	O
states	O
.	O
<EOS>	B-X
In	B-X
vivo	B-X
,	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
several	B-X
defensin	B-X
genes	B-X
occurs	B-X
in	B-X
both	B-X
infectious	B-X
and	B-X
inflammatory	B-X
states	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
recognition	B-X
of	B-X
bacteria	B-X
coupled	B-X
with	B-X
a	B-X
nascent	B-X
inflammatory	B-X
response	B-X
can	B-X
bolster	B-X
this	B-X
defense	B-X
by	B-X
a	B-X
coordinated	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
the	B-X
peptides	B-X
<EOS>	B-X
In	B-X
epithelial	B-X
cells	B-X
,	B-X
defensin	B-X
genes	B-X
are	B-X
found	B-X
as	B-X
both	B-X
constitutively	B-X
expressed	B-X
and	B-X
inducible	B-X
<EOS>	B-X
Induction	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
vitro	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
as	B-X
well	B-X
as	B-X
inflammatory	B-X
mediators	B-X

Gene	O
regulation	O
occurs	O
via	O
signal	O
transduction	O
pathways	O
common	O
to	O
other	O
innate	O
immune	O
responses	O
,	O
utilizing	O
transcription	B-protein
factors	I-protein
such	O
as	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
and	O
NF	B-protein
interleukin-6	I-protein
.	O
<EOS>	B-X
Gene	B-X
regulation	B-X
occurs	B-X
via	B-X
signal	B-X
transduction	B-X
pathways	B-X
common	B-X
to	B-X
other	B-X
innate	B-X
immune	B-X
responses	B-X
,	B-X
utilizing	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
interleukin	B-X
-	B-X
6	B-X
<EOS>	B-X
Induction	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
vitro	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
as	B-X
well	B-X
as	B-X
inflammatory	B-X
mediators	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
recognition	B-X
of	B-X
bacteria	B-X
coupled	B-X
with	B-X
a	B-X
nascent	B-X
inflammatory	B-X
response	B-X
can	B-X
bolster	B-X
this	B-X
defense	B-X
by	B-X
a	B-X
coordinated	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
the	B-X
peptides	B-X
<EOS>	B-X
In	B-X
vivo	B-X
,	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
several	B-X
defensin	B-X
genes	B-X
occurs	B-X
in	B-X
both	B-X
infectious	B-X
and	B-X
inflammatory	B-X
states	B-X

Together	O
,	O
the	O
data	O
suggest	O
a	O
broad-based	O
innate	O
host	O
defense	O
whereby	O
potent	O
antimicrobial	O
peptides	O
are	O
present	O
to	O
prevent	O
initial	O
colonization	O
by	O
pathogenic	O
microorganisms	O
.	O
<EOS>	B-X
Together	B-X
,	B-X
the	B-X
data	B-X
suggest	B-X
a	B-X
broad	B-X
-	B-X
based	B-X
innate	B-X
host	B-X
defense	B-X
whereby	B-X
potent	B-X
antimicrobial	B-X
peptides	B-X
are	B-X
present	B-X
to	B-X
prevent	B-X
initial	B-X
colonization	B-X
by	B-X
pathogenic	B-X
microorganisms	B-X
<EOS>	B-X
In	B-X
mammals	B-X
,	B-X
defensins	B-X
are	B-X
among	B-X
the	B-X
most	B-X
abundant	B-X
of	B-X
these	B-X
broad	B-X
-	B-X
spectrum	B-X
antibiotics	B-X
,	B-X
and	B-X
are	B-X
expressed	B-X
in	B-X
epithelial	B-X
and	B-X
hematopoietic	B-X
cells	B-X
<EOS>	B-X
The	B-X
defensin	B-X
peptides	B-X
are	B-X
especially	B-X
abundant	B-X
in	B-X
neutrophils	B-X
;	B-X
however	B-X
,	B-X
gene	B-X
expression	B-X
is	B-X
limited	B-X
to	B-X
the	B-X
promyelocyte	B-X
stage	B-X
<EOS>	B-X
Induction	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
vitro	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
as	B-X
well	B-X
as	B-X
inflammatory	B-X
mediators	B-X

In	O
addition	O
,	O
the	O
recognition	O
of	O
bacteria	O
coupled	O
with	O
a	O
nascent	O
inflammatory	O
response	O
can	O
bolster	O
this	O
defense	O
by	O
a	O
coordinated	O
up-regulation	O
of	O
the	O
peptides	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
recognition	B-X
of	B-X
bacteria	B-X
coupled	B-X
with	B-X
a	B-X
nascent	B-X
inflammatory	B-X
response	B-X
can	B-X
bolster	B-X
this	B-X
defense	B-X
by	B-X
a	B-X
coordinated	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
the	B-X
peptides	B-X
<EOS>	B-X
In	B-X
vivo	B-X
,	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
several	B-X
defensin	B-X
genes	B-X
occurs	B-X
in	B-X
both	B-X
infectious	B-X
and	B-X
inflammatory	B-X
states	B-X
<EOS>	B-X
Antimicrobial	B-X
peptides	B-X
are	B-X
a	B-X
prevalent	B-X
mechanism	B-X
of	B-X
host	B-X
defense	B-X
found	B-X
throughout	B-X
nature	B-X
<EOS>	B-X
Induction	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
vitro	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
as	B-X
well	B-X
as	B-X
inflammatory	B-X
mediators	B-X

Multiple	O
signals	O
required	O
for	O
cyclic	B-protein
AMP-responsive	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
binding	O
protein	O
interaction	O
induced	O
by	O
CD3/CD28	O
costimulation	O
.	O
<EOS>	B-X
Multiple	B-X
signals	B-X
required	B-X
for	B-X
cyclic	B-X
AMP	B-X
-	B-X
responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
binding	B-X
protein	B-X
interaction	B-X
induced	B-X
by	B-X
CD3	B-X
/	B-X
CD28	B-X
costimulation	B-X
.	B-X
<EOS>	B-X
The	B-X
optimal	B-X
activation	B-X
of	B-X
cAMP	B-X
-	B-X
responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
the	B-X
full	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
,	B-X
requires	B-X
the	B-X
stimulation	B-X
of	B-X
both	B-X
CD3	B-X
and	B-X
CD28	B-X
<EOS>	B-X
Extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
,	B-X
CaMKIV	B-X
,	B-X
and	B-X
p38	B-X
MAPK	B-X
were	B-X
also	B-X
the	B-X
kinases	B-X
involved	B-X
in	B-X
CREB	B-X
Ser	B-X
(	B-X
133	B-X
)	B-X
phosphorylation	B-X
induced	B-X
by	B-X
CD3	B-X
/	B-X
CD28	B-X
<EOS>	B-X
Using	B-X
a	B-X
reporter	B-X
system	B-X
to	B-X
detect	B-X
interaction	B-X
of	B-X
CREB	B-X
and	B-X
CREB	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CBP	B-X
)	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
found	B-X
that	B-X
CREB	B-X
binds	B-X
to	B-X
CBP	B-X
only	B-X
by	B-X
engagement	B-X
of	B-X
both	B-X
CD3	B-X
and	B-X
CD28	B-X

The	O
optimal	O
activation	O
of	O
cAMP-responsive	B-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
similar	O
to	O
the	O
full	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
requires	O
the	O
stimulation	O
of	O
both	O
CD3	B-protein
and	O
CD28	B-protein
.	O

Using	O
a	O
reporter	O
system	O
to	O
detect	O
interaction	O
of	O
CREB	B-protein
and	O
CREB-binding	B-protein
protein	I-protein
(	O
CBP	B-protein
)	O
,	O
in	O
this	O
study	O
we	O
found	O
that	O
CREB	B-protein
binds	O
to	O
CBP	B-protein
only	O
by	O
engagement	O
of	O
both	O
CD3	B-protein
and	O
CD28	B-protein
.	O
<EOS>	B-X
Using	B-X
a	B-X
reporter	B-X
system	B-X
to	B-X
detect	B-X
interaction	B-X
of	B-X
CREB	B-X
and	B-X
CREB	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
CBP	B-X
)	B-X
,	B-X
in	B-X
this	B-X
study	B-X
we	B-X
found	B-X
that	B-X
CREB	B-X
binds	B-X
to	B-X
CBP	B-X
only	B-X
by	B-X
engagement	B-X
of	B-X
both	B-X
CD3	B-X
and	B-X
CD28	B-X
<EOS>	B-X
The	B-X
optimal	B-X
activation	B-X
of	B-X
cAMP	B-X
-	B-X
responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
the	B-X
full	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
,	B-X
requires	B-X
the	B-X
stimulation	B-X
of	B-X
both	B-X
CD3	B-X
and	B-X
CD28	B-X
<EOS>	B-X
These	B-X
results	B-X
support	B-X
the	B-X
model	B-X
of	B-X
a	B-X
minimum	B-X
activation	B-X
threshold	B-X
for	B-X
CREB	B-X
-	B-X
CBP	B-X
interaction	B-X
that	B-X
can	B-X
be	B-X
reached	B-X
only	B-X
when	B-X
both	B-X
CD3	B-X
and	B-X
CD28	B-X
are	B-X
stimulated	B-X
<EOS>	B-X
Multiple	B-X
signals	B-X
required	B-X
for	B-X
cyclic	B-X
AMP	B-X
-	B-X
responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
binding	B-X
protein	B-X
interaction	B-X
induced	B-X
by	B-X
CD3	B-X
/	B-X
CD28	B-X
costimulation	B-X
.	B-X

CD3/CD28	B-protein
-promoted	O
CREB	B-protein
-	O
CBP	B-protein
interaction	O
was	O
dependent	O
on	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
and	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
CaMK	I-protein
)	I-protein
IV	I-protein
in	O
addition	O
to	O
the	O
previously	O
identified	O
extracellular	O
signal-regulated	O
kinase	O
pathway	O
.	O

Extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
,	I-protein
CaMKIV	I-protein
,	O
and	O
p38	B-protein
MAPK	I-protein
were	O
also	O
the	O
kinases	O
involved	O
in	O
CREB	B-protein
Ser	O
(	O
133	O
)	O
phosphorylation	O
induced	O
by	O
CD3/CD28	B-protein
.	O
<EOS>	B-X
Extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
,	B-X
CaMKIV	B-X
,	B-X
and	B-X
p38	B-X
MAPK	B-X
were	B-X
also	B-X
the	B-X
kinases	B-X
involved	B-X
in	B-X
CREB	B-X
Ser	B-X
(	B-X
133	B-X
)	B-X
phosphorylation	B-X
induced	B-X
by	B-X
CD3	B-X
/	B-X
CD28	B-X
<EOS>	B-X
Multiple	B-X
signals	B-X
required	B-X
for	B-X
cyclic	B-X
AMP	B-X
-	B-X
responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
binding	B-X
protein	B-X
interaction	B-X
induced	B-X
by	B-X
CD3	B-X
/	B-X
CD28	B-X
costimulation	B-X
.	B-X
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
coordinated	B-X
activation	B-X
of	B-X
different	B-X
kinases	B-X
leads	B-X
to	B-X
full	B-X
activation	B-X
of	B-X
CREB	B-X
<EOS>	B-X
Notably	B-X
,	B-X
CD28	B-X
ligation	B-X
activated	B-X
p38	B-X
MAPK	B-X
and	B-X
CaMKIV	B-X
,	B-X
the	B-X
kinases	B-X
stimulated	B-X
by	B-X
CD3	B-X
engagement	B-X
,	B-X
suggesting	B-X
that	B-X
CD28	B-X
acts	B-X
by	B-X
increasing	B-X
the	B-X
activation	B-X
extent	B-X
of	B-X
p38	B-X
MAPK	B-X
and	B-X
CaMKIV	B-X

A	O
reconstitution	O
experiment	O
illustrated	O
that	O
optimum	O
CREB	B-protein
-	O
CBP	B-protein
interaction	O
and	O
CREB	B-protein
trans-activation	O
were	O
attained	O
when	O
these	O
three	O
kinase	O
pathways	O
were	O
simultaneously	O
activated	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Our	O
results	O
demonstrate	O
that	O
coordinated	O
activation	O
of	O
different	O
kinases	B-protein
leads	O
to	O
full	O
activation	O
of	O
CREB	B-protein
.	O
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
coordinated	B-X
activation	B-X
of	B-X
different	B-X
kinases	B-X
leads	B-X
to	B-X
full	B-X
activation	B-X
of	B-X
CREB	B-X
<EOS>	B-X
A	B-X
reconstitution	B-X
experiment	B-X
illustrated	B-X
that	B-X
optimum	B-X
CREB	B-X
-	B-X
CBP	B-X
interaction	B-X
and	B-X
CREB	B-X
trans	B-X
-	B-X
activation	B-X
were	B-X
attained	B-X
when	B-X
these	B-X
three	B-X
kinase	B-X
pathways	B-X
were	B-X
simultaneously	B-X
activated	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
support	B-X
the	B-X
model	B-X
of	B-X
a	B-X
minimum	B-X
activation	B-X
threshold	B-X
for	B-X
CREB	B-X
-	B-X
CBP	B-X
interaction	B-X
that	B-X
can	B-X
be	B-X
reached	B-X
only	B-X
when	B-X
both	B-X
CD3	B-X
and	B-X
CD28	B-X
are	B-X
stimulated	B-X
<EOS>	B-X
Extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
,	B-X
CaMKIV	B-X
,	B-X
and	B-X
p38	B-X
MAPK	B-X
were	B-X
also	B-X
the	B-X
kinases	B-X
involved	B-X
in	B-X
CREB	B-X
Ser	B-X
(	B-X
133	B-X
)	B-X
phosphorylation	B-X
induced	B-X
by	B-X
CD3	B-X
/	B-X
CD28	B-X

Notably	O
,	O
CD28	O
ligation	O
activated	O
p38	B-protein
MAPK	I-protein
and	O
CaMKIV	B-protein
,	O
the	O
kinases	B-protein
stimulated	O
by	O
CD3	O
engagement	O
,	O
suggesting	O
that	O
CD28	B-protein
acts	O
by	O
increasing	O
the	O
activation	O
extent	O
of	O
p38	B-protein
MAPK	I-protein
and	O
CaMKIV	B-protein
.	O
<EOS>	B-X
Notably	B-X
,	B-X
CD28	B-X
ligation	B-X
activated	B-X
p38	B-X
MAPK	B-X
and	B-X
CaMKIV	B-X
,	B-X
the	B-X
kinases	B-X
stimulated	B-X
by	B-X
CD3	B-X
engagement	B-X
,	B-X
suggesting	B-X
that	B-X
CD28	B-X
acts	B-X
by	B-X
increasing	B-X
the	B-X
activation	B-X
extent	B-X
of	B-X
p38	B-X
MAPK	B-X
and	B-X
CaMKIV	B-X
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
coordinated	B-X
activation	B-X
of	B-X
different	B-X
kinases	B-X
leads	B-X
to	B-X
full	B-X
activation	B-X
of	B-X
CREB	B-X
<EOS>	B-X
The	B-X
optimal	B-X
activation	B-X
of	B-X
cAMP	B-X
-	B-X
responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
the	B-X
full	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
,	B-X
requires	B-X
the	B-X
stimulation	B-X
of	B-X
both	B-X
CD3	B-X
and	B-X
CD28	B-X
<EOS>	B-X
CD3	B-X
/	B-X
CD28	B-X
-	B-X
promoted	B-X
CREB	B-X
-	B-X
CBP	B-X
interaction	B-X
was	B-X
dependent	B-X
on	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
and	B-X
calcium	B-X
/	B-X
calmodulin	B-X
-	B-X
dependent	B-X
protein	B-X
kinase	B-X
(	B-X
CaMK	B-X
)	B-X
IV	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
previously	B-X
identified	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
pathway	B-X

These	O
results	O
support	O
the	O
model	O
of	O
a	O
minimum	O
activation	O
threshold	O
for	O
CREB	B-protein
-	O
CBP	B-protein
interaction	O
that	O
can	O
be	O
reached	O
only	O
when	O
both	O
CD3	B-protein
and	O
CD28	B-protein
are	O
stimulated	O
.	O
<EOS>	B-X
These	B-X
results	B-X
support	B-X
the	B-X
model	B-X
of	B-X
a	B-X
minimum	B-X
activation	B-X
threshold	B-X
for	B-X
CREB	B-X
-	B-X
CBP	B-X
interaction	B-X
that	B-X
can	B-X
be	B-X
reached	B-X
only	B-X
when	B-X
both	B-X
CD3	B-X
and	B-X
CD28	B-X
are	B-X
stimulated	B-X
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
coordinated	B-X
activation	B-X
of	B-X
different	B-X
kinases	B-X
leads	B-X
to	B-X
full	B-X
activation	B-X
of	B-X
CREB	B-X
<EOS>	B-X
A	B-X
reconstitution	B-X
experiment	B-X
illustrated	B-X
that	B-X
optimum	B-X
CREB	B-X
-	B-X
CBP	B-X
interaction	B-X
and	B-X
CREB	B-X
trans	B-X
-	B-X
activation	B-X
were	B-X
attained	B-X
when	B-X
these	B-X
three	B-X
kinase	B-X
pathways	B-X
were	B-X
simultaneously	B-X
activated	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
Multiple	B-X
signals	B-X
required	B-X
for	B-X
cyclic	B-X
AMP	B-X
-	B-X
responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
binding	B-X
protein	B-X
interaction	B-X
induced	B-X
by	B-X
CD3	B-X
/	B-X
CD28	B-X
costimulation	B-X
.	B-X

The	O
murine	B-DNA
IL-2	I-DNA
promoter	I-DNA
contains	O
distal	B-DNA
regulatory	I-DNA
elements	I-DNA
responsive	O
to	O
the	O
Ah	B-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
evolutionarily	O
conserved	O
bHLH-PAS	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

Signaling	O
through	O
the	O
TCR	B-protein
and	O
costimulatory	O
signals	O
primarily	O
control	O
transcription	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Signaling	B-X
through	B-X
the	B-X
TCR	B-X
and	B-X
costimulatory	B-X
signals	B-X
primarily	B-X
control	B-X
transcription	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
naive	B-X
T	B-X
cells	B-X
<EOS>	B-X
However	B-X
,	B-X
in	B-X
spleen	B-X
cells	B-X
in	B-X
vitro	B-X
costimulation	B-X
via	B-X
the	B-X
TCR	B-X
is	B-X
necessary	B-X
for	B-X
optimal	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
induction	B-X
<EOS>	B-X
The	B-X
murine	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
contains	B-X
distal	B-X
regulatory	B-X
elements	B-X
responsive	B-X
to	B-X
the	B-X
Ah	B-X
receptor	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
bHLH	B-X
-	B-X
PAS	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
these	B-X
DNA	B-X
motifs	B-X
,	B-X
the	B-X
so	B-X
-	B-X
called	B-X
dioxin	B-X
response	B-X
elements	B-X
,	B-X
after	B-X
binding	B-X
to	B-X
the	B-X
liganded	B-X
AHR	B-X
are	B-X
sufficient	B-X
to	B-X
transactivate	B-X
luciferase	B-X
expression	B-X
in	B-X
a	B-X
reporter	B-X
gene	B-X
system	B-X

The	O
minimal	B-DNA
promoter	I-DNA
necessary	O
for	O
this	O
expression	O
lies	O
proximal	O
,	O
between	O
-300	O
and	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O
<EOS>	B-X
The	B-X
minimal	B-X
promoter	B-X
necessary	B-X
for	B-X
this	B-X
expression	B-X
lies	B-X
proximal	B-X
,	B-X
between	B-X
	B-X
-	B-X
300	B-X
and	B-X
the	B-X
transcription	B-X
start	B-X
site	B-X
<EOS>	B-X
The	B-X
murine	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
contains	B-X
distal	B-X
regulatory	B-X
elements	B-X
responsive	B-X
to	B-X
the	B-X
Ah	B-X
receptor	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
bHLH	B-X
-	B-X
PAS	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
region	B-X
contains	B-X
novel	B-X
distal	B-X
regulatory	B-X
elements	B-X
that	B-X
can	B-X
be	B-X
addressed	B-X
by	B-X
the	B-X
AHR	B-X
to	B-X
induce	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
proximal	B-X
promoter	B-X
in	B-X
this	B-X
<EOS>	B-X
The	B-X
AHR	B-X
mediates	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
induction	B-X
as	B-X
shown	B-X
with	B-X
AHR	B-X
-	B-X
deficient	B-X
mice	B-X

We	O
had	O
previously	O
shown	O
that	O
activation	O
of	O
the	O
arylhydrocarbon	B-protein
receptor	I-protein
(	O
AHR	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
bHLH-PAS	B-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
,	O
leads	O
to	O
increased	O
mRNA	O
expression	O
of	O
IL-2	B-RNA
in	O
murine	B-cell_type
fetal	I-cell_type
thymocytes	I-cell_type
.	O

The	O
AHR	B-protein
is	O
abundant	O
in	O
the	O
thymus	O
and	O
may	O
play	O
a	O
role	O
for	O
the	O
development	O
of	O
the	O
immune	O
system	O
.	O
<EOS>	B-X
The	B-X
AHR	B-X
is	B-X
abundant	B-X
in	B-X
the	B-X
thymus	B-X
and	B-X
may	B-X
play	B-X
a	B-X
role	B-X
for	B-X
the	B-X
development	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
<EOS>	B-X
The	B-X
AHR	B-X
mediates	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
induction	B-X
as	B-X
shown	B-X
with	B-X
AHR	B-X
-	B-X
deficient	B-X
mice	B-X
<EOS>	B-X
The	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
can	B-X
be	B-X
induced	B-X
by	B-X
the	B-X
AHR	B-X
also	B-X
in	B-X
thymocytes	B-X
in	B-X
vivo	B-X
after	B-X
injection	B-X
of	B-X
2,3,7	B-X
,	B-X
8	B-X
-	B-X
tetrachlorodibenzo	B-X
-	B-X
p	B-X
-	B-X
dioxin	B-X
,	B-X
a	B-X
potent	B-X
ligand	B-X
of	B-X
the	B-X
AHR	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
region	B-X
contains	B-X
novel	B-X
distal	B-X
regulatory	B-X
elements	B-X
that	B-X
can	B-X
be	B-X
addressed	B-X
by	B-X
the	B-X
AHR	B-X
to	B-X
induce	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
proximal	B-X
promoter	B-X
in	B-X
this	B-X

Moreover	O
,	O
its	O
overactivation	O
by	O
chemicals	O
such	O
as	O
dioxins	O
leads	O
to	O
immunosuppression	O
and	O
thymic	O
involution	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
its	B-X
overactivation	B-X
by	B-X
chemicals	B-X
such	B-X
as	B-X
dioxins	B-X
leads	B-X
to	B-X
immunosuppression	B-X
and	B-X
thymic	B-X
involution	B-X
<EOS>	B-X
We	B-X
had	B-X
previously	B-X
shown	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
arylhydrocarbon	B-X
receptor	B-X
(	B-X
AHR	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
bHLH	B-X
-	B-X
PAS	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
leads	B-X
to	B-X
increased	B-X
mRNA	B-X
expression	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
in	B-X
murine	B-X
fetal	B-X
thymocytes	B-X
<EOS>	B-X
However	B-X
,	B-X
in	B-X
spleen	B-X
cells	B-X
in	B-X
vitro	B-X
costimulation	B-X
via	B-X
the	B-X
TCR	B-X
is	B-X
necessary	B-X
for	B-X
optimal	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
induction	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
these	B-X
DNA	B-X
motifs	B-X
,	B-X
the	B-X
so	B-X
-	B-X
called	B-X
dioxin	B-X
response	B-X
elements	B-X
,	B-X
after	B-X
binding	B-X
to	B-X
the	B-X
liganded	B-X
AHR	B-X
are	B-X
sufficient	B-X
to	B-X
transactivate	B-X
luciferase	B-X
expression	B-X
in	B-X
a	B-X
reporter	B-X
gene	B-X
system	B-X

Binding	O
motifs	O
for	O
the	O
liganded	B-protein
AHR	I-protein
can	O
be	O
identified	O
in	O
the	O
distal	B-DNA
region	I-DNA
-1300	I-DNA
to	I-DNA
-800	I-DNA
of	O
the	O
mouse	B-DNA
IL-2	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Binding	B-X
motifs	B-X
for	B-X
the	B-X
liganded	B-X
AHR	B-X
can	B-X
be	B-X
identified	B-X
in	B-X
the	B-X
distal	B-X
region	B-X
	B-X
-	B-X
1300	B-X
to	B-X
	B-X
-	B-X
800	B-X
of	B-X
the	B-X
mouse	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
region	B-X
contains	B-X
novel	B-X
distal	B-X
regulatory	B-X
elements	B-X
that	B-X
can	B-X
be	B-X
addressed	B-X
by	B-X
the	B-X
AHR	B-X
to	B-X
induce	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
proximal	B-X
promoter	B-X
in	B-X
this	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
these	B-X
DNA	B-X
motifs	B-X
,	B-X
the	B-X
so	B-X
-	B-X
called	B-X
dioxin	B-X
response	B-X
elements	B-X
,	B-X
after	B-X
binding	B-X
to	B-X
the	B-X
liganded	B-X
AHR	B-X
are	B-X
sufficient	B-X
to	B-X
transactivate	B-X
luciferase	B-X
expression	B-X
in	B-X
a	B-X
reporter	B-X
gene	B-X
system	B-X
<EOS>	B-X
The	B-X
murine	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
contains	B-X
distal	B-X
regulatory	B-X
elements	B-X
responsive	B-X
to	B-X
the	B-X
Ah	B-X
receptor	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
bHLH	B-X
-	B-X
PAS	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X

We	O
show	O
here	O
that	O
these	O
DNA	B-DNA
motifs	I-DNA
,	O
the	O
so-called	O
dioxin	B-DNA
response	I-DNA
elements	I-DNA
,	O
after	O
binding	O
to	O
the	O
liganded	B-protein
AHR	I-protein
are	O
sufficient	O
to	O
transactivate	O
luciferase	O
expression	O
in	O
a	O
reporter	O
gene	O
system	O
.	O

The	O
IL-2	B-DNA
gene	I-DNA
can	O
be	O
induced	O
by	O
the	O
AHR	B-protein
also	O
in	O
thymocytes	B-cell_type
in	O
vivo	O
after	O
injection	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
,	O
a	O
potent	O
ligand	O
of	O
the	O
AHR	B-protein
.	O
<EOS>	B-X
The	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
can	B-X
be	B-X
induced	B-X
by	B-X
the	B-X
AHR	B-X
also	B-X
in	B-X
thymocytes	B-X
in	B-X
vivo	B-X
after	B-X
injection	B-X
of	B-X
2,3,7	B-X
,	B-X
8	B-X
-	B-X
tetrachlorodibenzo	B-X
-	B-X
p	B-X
-	B-X
dioxin	B-X
,	B-X
a	B-X
potent	B-X
ligand	B-X
of	B-X
the	B-X
AHR	B-X
<EOS>	B-X
The	B-X
AHR	B-X
is	B-X
abundant	B-X
in	B-X
the	B-X
thymus	B-X
and	B-X
may	B-X
play	B-X
a	B-X
role	B-X
for	B-X
the	B-X
development	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
these	B-X
DNA	B-X
motifs	B-X
,	B-X
the	B-X
so	B-X
-	B-X
called	B-X
dioxin	B-X
response	B-X
elements	B-X
,	B-X
after	B-X
binding	B-X
to	B-X
the	B-X
liganded	B-X
AHR	B-X
are	B-X
sufficient	B-X
to	B-X
transactivate	B-X
luciferase	B-X
expression	B-X
in	B-X
a	B-X
reporter	B-X
gene	B-X
system	B-X
<EOS>	B-X
However	B-X
,	B-X
in	B-X
spleen	B-X
cells	B-X
in	B-X
vitro	B-X
costimulation	B-X
via	B-X
the	B-X
TCR	B-X
is	B-X
necessary	B-X
for	B-X
optimal	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
induction	B-X

The	O
AHR	B-protein
mediates	O
the	O
IL-2	O
induction	O
as	O
shown	O
with	O
AHR	B-protein
-deficient	O
mice	O
.	O
<EOS>	B-X
The	B-X
AHR	B-X
mediates	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
induction	B-X
as	B-X
shown	B-X
with	B-X
AHR	B-X
-	B-X
deficient	B-X
mice	B-X
<EOS>	B-X
The	B-X
AHR	B-X
is	B-X
abundant	B-X
in	B-X
the	B-X
thymus	B-X
and	B-X
may	B-X
play	B-X
a	B-X
role	B-X
for	B-X
the	B-X
development	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
<EOS>	B-X
The	B-X
combination	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
18	B-X
was	B-X
ineffective	B-X
in	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
deficient	B-X
and	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
)	B-X
4	B-X
-	B-X
deficient	B-X
mice	B-X
<EOS>	B-X
IL	B-X
-	B-X
18	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
IFN	B-X
-	B-X
gamma	B-X
production	B-X
,	B-X
which	B-X
is	B-X
enhanced	B-X
when	B-X
combined	B-X
with	B-X
IL	B-X
-	B-X
2	B-X

However	O
,	O
in	O
spleen	B-cell_type
cells	I-cell_type
in	O
vitro	O
costimulation	O
via	O
the	O
TCR	B-protein
is	O
necessary	O
for	O
optimal	O
IL-2	B-DNA
gene	I-DNA
induction	O
.	O
<EOS>	B-X
However	B-X
,	B-X
in	B-X
spleen	B-X
cells	B-X
in	B-X
vitro	B-X
costimulation	B-X
via	B-X
the	B-X
TCR	B-X
is	B-X
necessary	B-X
for	B-X
optimal	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
induction	B-X
<EOS>	B-X
Signaling	B-X
through	B-X
the	B-X
TCR	B-X
and	B-X
costimulatory	B-X
signals	B-X
primarily	B-X
control	B-X
transcription	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
in	B-X
naive	B-X
T	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
region	B-X
contains	B-X
novel	B-X
distal	B-X
regulatory	B-X
elements	B-X
that	B-X
can	B-X
be	B-X
addressed	B-X
by	B-X
the	B-X
AHR	B-X
to	B-X
induce	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
proximal	B-X
promoter	B-X
in	B-X
this	B-X
<EOS>	B-X
The	B-X
murine	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
contains	B-X
distal	B-X
regulatory	B-X
elements	B-X
responsive	B-X
to	B-X
the	B-X
Ah	B-X
receptor	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
bHLH	B-X
-	B-X
PAS	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X

Thus	O
,	O
the	O
IL-2	B-DNA
promoter	I-DNA
region	I-DNA
contains	O
novel	O
distal	B-DNA
regulatory	I-DNA
elements	I-DNA
that	O
can	O
be	O
addressed	O
by	O
the	O
AHR	B-protein
to	O
induce	O
IL-2	B-DNA
and	O
can	O
cooperate	O
with	O
the	O
proximal	B-DNA
promoter	I-DNA
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
region	B-X
contains	B-X
novel	B-X
distal	B-X
regulatory	B-X
elements	B-X
that	B-X
can	B-X
be	B-X
addressed	B-X
by	B-X
the	B-X
AHR	B-X
to	B-X
induce	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
can	B-X
cooperate	B-X
with	B-X
the	B-X
proximal	B-X
promoter	B-X
in	B-X
this	B-X
<EOS>	B-X
The	B-X
murine	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
contains	B-X
distal	B-X
regulatory	B-X
elements	B-X
responsive	B-X
to	B-X
the	B-X
Ah	B-X
receptor	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
evolutionarily	B-X
conserved	B-X
bHLH	B-X
-	B-X
PAS	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
<EOS>	B-X
The	B-X
minimal	B-X
promoter	B-X
necessary	B-X
for	B-X
this	B-X
expression	B-X
lies	B-X
proximal	B-X
,	B-X
between	B-X
	B-X
-	B-X
300	B-X
and	B-X
the	B-X
transcription	B-X
start	B-X
site	B-X
<EOS>	B-X
Binding	B-X
motifs	B-X
for	B-X
the	B-X
liganded	B-X
AHR	B-X
can	B-X
be	B-X
identified	B-X
in	B-X
the	B-X
distal	B-X
region	B-X
	B-X
-	B-X
1300	B-X
to	B-X
	B-X
-	B-X
800	B-X
of	B-X
the	B-X
mouse	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X

Visualization	O
of	O
Syk-antigen	B-protein
receptor	I-protein
interactions	O
using	O
green	B-protein
fluorescent	I-protein
protein	I-protein
:	O
differential	O
roles	O
for	O
Syk	B-protein
and	O
Lyn	B-protein
in	O
the	O
regulation	O
of	O
receptor	O
capping	O
and	O
internalization	O
.	O
<EOS>	B-X
Visualization	B-X
of	B-X
Syk	B-X
-	B-X
antigen	B-X
receptor	B-X
interactions	B-X
using	B-X
green	B-X
fluorescent	B-X
protein	B-X
:	B-X
differential	B-X
roles	B-X
for	B-X
Syk	B-X
and	B-X
Lyn	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
receptor	B-X
capping	B-X
and	B-X
internalization	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
Lyn	B-X
appears	B-X
to	B-X
function	B-X
to	B-X
negatively	B-X
regulate	B-X
aspects	B-X
of	B-X
BCR	B-X
-	B-X
dependent	B-X
signaling	B-X
by	B-X
stimulating	B-X
receptor	B-X
internalization	B-X
and	B-X
down	B-X
-	B-X
regulation	B-X
<EOS>	B-X
The	B-X
Syk	B-X
-	B-X
receptor	B-X
complexes	B-X
aggregate	B-X
into	B-X
membrane	B-X
patches	B-X
that	B-X
redistribute	B-X
to	B-X
form	B-X
a	B-X
cap	B-X
at	B-X
one	B-X
pole	B-X
of	B-X
the	B-X
cell	B-X
<EOS>	B-X
The	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
Ag	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
is	B-X
coupled	B-X
to	B-X
the	B-X
stimulation	B-X
of	B-X
multiple	B-X
intracellular	B-X
signal	B-X
transduction	B-X
cascades	B-X
via	B-X
receptor	B-X
-	B-X
associated	B-X
,	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
of	B-X
both	B-X
the	B-X
Src	B-X
and	B-X
Syk	B-X
families	B-X

The	O
cross-linking	O
of	O
the	O
B	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
is	O
coupled	O
to	O
the	O
stimulation	O
of	O
multiple	O
intracellular	O
signal	O
transduction	O
cascades	O
via	O
receptor-associated	O
,	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
of	O
both	O
the	O
Src	B-protein
and	I-protein
Syk	I-protein
families	I-protein
.	O

To	O
monitor	O
changes	O
in	O
the	O
subcellular	O
distribution	O
of	O
Syk	B-protein
in	O
B	B-cell_type
cells	I-cell_type
responding	O
to	O
BCR	B-protein
cross-linking	O
,	O
we	O
expressed	O
in	O
Syk	B-protein
-deficient	O
DT40	B-cell_line
B	I-cell_line
cells	I-cell_line
a	O
fusion	B-protein
protein	I-protein
consisting	O
of	O
Syk	B-protein
coupled	O
to	O
green	B-protein
fluorescent	I-protein
protein	I-protein
.	O

Treatment	O
of	O
these	O
cells	O
with	O
anti-IgM	B-protein
Abs	I-protein
leads	O
to	O
the	O
recruitment	O
of	O
the	O
kinase	B-protein
from	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
to	O
the	O
site	O
of	O
the	O
cross-linked	B-protein
receptor	I-protein
at	O
the	O
plasma	O
membrane	O
.	O

The	O
Syk-receptor	B-protein
complexes	I-protein
aggregate	O
into	O
membrane	O
patches	O
that	O
redistribute	O
to	O
form	O
a	O
cap	O
at	O
one	O
pole	O
of	O
the	O
cell	O
.	O

Syk	B-protein
is	O
not	O
demonstrably	O
associated	O
with	O
the	O
internalized	B-protein
receptor	I-protein
.	O
<EOS>	B-X
Syk	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
in	B-X
some	B-X
solid	B-X
tumors	B-X
<EOS>	B-X
FcεRI	B-X
,	B-X
IgE	B-X
,	B-X
Ags	B-X
,	B-X
and	B-X
surface	B-X
receptors	B-X
were	B-X
not	B-X
internalized	B-X
during	B-X
desensitization	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
the	B-X
response	B-X
to	B-X
the	B-X
fungal	B-X
pathogen	B-X
,	B-X
<EOS>	B-X
The	B-X
rapid	B-X
inhibition	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
activation	B-X
markers	B-X
by	B-X
belimumab	B-X
was	B-X
associated	B-X
with	B-X
disease	B-X
control	B-X
in	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
patients	B-X
.	B-X

Catalytically	O
active	O
Syk	B-protein
promotes	O
and	O
stabilizes	O
the	O
formation	O
of	O
tightly	B-protein
capped	I-protein
BCR	I-protein
complexes	I-protein
at	O
the	O
plasma	O
membrane	O
.	O
<EOS>	B-X
Catalytically	B-X
active	B-X
Syk	B-X
promotes	B-X
and	B-X
stabilizes	B-X
the	B-X
formation	B-X
of	B-X
tightly	B-X
capped	B-X
BCR	B-X
complexes	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
IgM	B-X
Abs	B-X
leads	B-X
to	B-X
the	B-X
recruitment	B-X
of	B-X
the	B-X
kinase	B-X
from	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
compartments	B-X
to	B-X
the	B-X
site	B-X
of	B-X
the	B-X
cross	B-X
-	B-X
linked	B-X
receptor	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
<EOS>	B-X
Visualization	B-X
of	B-X
Syk	B-X
-	B-X
antigen	B-X
receptor	B-X
interactions	B-X
using	B-X
green	B-X
fluorescent	B-X
protein	B-X
:	B-X
differential	B-X
roles	B-X
for	B-X
Syk	B-X
and	B-X
Lyn	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
receptor	B-X
capping	B-X
and	B-X
internalization	B-X
.	B-X
<EOS>	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
Lyn	B-X
,	B-X
receptor	B-X
-	B-X
Syk	B-X
complexes	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
are	B-X
long	B-X
lived	B-X
,	B-X
and	B-X
the	B-X
receptor	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
AT	B-X
transcription	B-X
factor	B-X
is	B-X
enhanced	B-X

Lyn	B-protein
is	O
not	O
required	O
for	O
the	O
recruitment	O
of	O
Syk	B-protein
to	O
the	O
cross-linked	B-protein
receptor	I-protein
,	O
but	O
is	O
required	O
for	O
the	O
internalization	O
of	O
the	O
clustered	O
BCR	B-protein
complexes	I-protein
.	O
<EOS>	B-X
Further	B-X
research	B-X
is	B-X
required	B-X
to	B-X
assess	B-X
the	B-X
impact	B-X
of	B-X
the	B-X
intervention	B-X
outside	B-X
a	B-X
pandemic	B-X
<EOS>	B-X
Although	B-X
its	B-X
in	B-X
vivo	B-X
application	B-X
has	B-X
led	B-X
to	B-X
the	B-X
safe	B-X
reintroduction	B-X
of	B-X
drugs	B-X
and	B-X
foods	B-X
in	B-X
IgE	B-X
-	B-X
sensitized	B-X
patients	B-X
at	B-X
risk	B-X
for	B-X
anaphylaxis	B-X
,	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
inhibitory	B-X
process	B-X
have	B-X
remained	B-X
elusive	B-X
<EOS>	B-X
Thus	B-X
,	B-X
exploring	B-X
novel	B-X
mechanisms	B-X
for	B-X
doing	B-X
so	B-X
represents	B-X
an	B-X
urgent	B-X
need	B-X
for	B-X
the	B-X
prevention	B-X
and	B-X
treatment	B-X
of	B-X
AIS	B-X
<EOS>	B-X
The	B-X
patients	B-X
were	B-X
divided	B-X
into	B-X
surgical	B-X
and	B-X
non	B-X
-	B-X
surgical	B-X
groups	B-X
,	B-X
and	B-X
the	B-X
differences	B-X
in	B-X
outcomes	B-X
were	B-X
compared	B-X

In	O
the	O
absence	O
of	O
Lyn	B-protein
,	O
receptor-Syk	B-protein
complexes	I-protein
at	O
the	O
plasma	O
membrane	O
are	O
long	O
lived	O
,	O
and	O
the	O
receptor-mediated	O
activation	O
of	O
the	O
NF-AT	B-protein
transcription	I-protein
factor	I-protein
is	O
enhanced	O
.	O
<EOS>	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
Lyn	B-X
,	B-X
receptor	B-X
-	B-X
Syk	B-X
complexes	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
are	B-X
long	B-X
lived	B-X
,	B-X
and	B-X
the	B-X
receptor	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
AT	B-X
transcription	B-X
factor	B-X
is	B-X
enhanced	B-X
<EOS>	B-X
The	B-X
Syk	B-X
-	B-X
receptor	B-X
complexes	B-X
aggregate	B-X
into	B-X
membrane	B-X
patches	B-X
that	B-X
redistribute	B-X
to	B-X
form	B-X
a	B-X
cap	B-X
at	B-X
one	B-X
pole	B-X
of	B-X
the	B-X
cell	B-X
<EOS>	B-X
The	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
Ag	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
is	B-X
coupled	B-X
to	B-X
the	B-X
stimulation	B-X
of	B-X
multiple	B-X
intracellular	B-X
signal	B-X
transduction	B-X
cascades	B-X
via	B-X
receptor	B-X
-	B-X
associated	B-X
,	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
of	B-X
both	B-X
the	B-X
Src	B-X
and	B-X
Syk	B-X
families	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
anti	B-X
-	B-X
IgM	B-X
Abs	B-X
leads	B-X
to	B-X
the	B-X
recruitment	B-X
of	B-X
the	B-X
kinase	B-X
from	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
compartments	B-X
to	B-X
the	B-X
site	B-X
of	B-X
the	B-X
cross	B-X
-	B-X
linked	B-X
receptor	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X

Thus	O
,	O
Lyn	B-protein
appears	O
to	O
function	O
to	O
negatively	O
regulate	O
aspects	O
of	O
BCR	B-protein
-dependent	O
signaling	O
by	O
stimulating	O
receptor	O
internalization	O
and	O
down-regulation	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
Lyn	B-X
appears	B-X
to	B-X
function	B-X
to	B-X
negatively	B-X
regulate	B-X
aspects	B-X
of	B-X
BCR	B-X
-	B-X
dependent	B-X
signaling	B-X
by	B-X
stimulating	B-X
receptor	B-X
internalization	B-X
and	B-X
down	B-X
-	B-X
regulation	B-X
<EOS>	B-X
Visualization	B-X
of	B-X
Syk	B-X
-	B-X
antigen	B-X
receptor	B-X
interactions	B-X
using	B-X
green	B-X
fluorescent	B-X
protein	B-X
:	B-X
differential	B-X
roles	B-X
for	B-X
Syk	B-X
and	B-X
Lyn	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
receptor	B-X
capping	B-X
and	B-X
internalization	B-X
.	B-X
<EOS>	B-X
Syk	B-X
is	B-X
not	B-X
demonstrably	B-X
associated	B-X
with	B-X
the	B-X
internalized	B-X
receptor	B-X
<EOS>	B-X
The	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
Ag	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
is	B-X
coupled	B-X
to	B-X
the	B-X
stimulation	B-X
of	B-X
multiple	B-X
intracellular	B-X
signal	B-X
transduction	B-X
cascades	B-X
via	B-X
receptor	B-X
-	B-X
associated	B-X
,	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
of	B-X
both	B-X
the	B-X
Src	B-X
and	B-X
Syk	B-X
families	B-X

Renal	O
interstitial	O
fibrosis	O
is	O
reduced	O
in	O
angiotensin	B-protein
II	I-protein
type	I-protein
1a	I-protein
receptor	I-protein
-deficient	O
mice	O
.	O
<EOS>	B-X
Renal	B-X
interstitial	B-X
fibrosis	B-X
is	B-X
reduced	B-X
in	B-X
angiotensin	B-X
II	B-X
type	B-X
1a	B-X
receptor	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
PPARγ	B-X
activation	B-X
in	B-X
the	B-X
renal	B-X
protective	B-X
actions	B-X
of	B-X
telmisartan	B-X
using	B-X
Ang	B-X
II	B-X
type	B-X
1	B-X
receptor	B-X
-	B-X
deficient	B-X
mice	B-X
<EOS>	B-X
Telmisartan	B-X
exerts	B-X
renoprotective	B-X
actions	B-X
via	B-X
peroxisome	B-X
proliferator	B-X
-	B-X
activated	B-X
receptor	B-X
-	B-X
γ	B-X
/	B-X
hepatocyte	B-X
growth	B-X
factor	B-X
pathway	B-X
independent	B-X
of	B-X
angiotensin	B-X
II	B-X
type	B-X
1	B-X
receptor	B-X
blockade	B-X
.	B-X
<EOS>	B-X
The	B-X
results	B-X
provide	B-X
direct	B-X
evidence	B-X
that	B-X
angiotensin	B-X
II	B-X
acting	B-X
via	B-X
the	B-X
AT1a	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
tubulointerstitial	B-X
fibrosis	B-X
in	B-X
UUO	B-X

Unilateral	O
ureteral	O
obstruction	O
(	O
UUO	O
)	O
results	O
in	O
tubulointerstitial	O
fibrosis	O
of	O
the	O
affected	O
kidney	O
by	O
stimulating	O
the	O
renin-angiotensin	O
system	O
.	O
<EOS>	B-X
Unilateral	B-X
ureteral	B-X
obstruction	B-X
(	B-X
UUO	B-X
)	B-X
results	B-X
in	B-X
tubulointerstitial	B-X
fibrosis	B-X
of	B-X
the	B-X
affected	B-X
kidney	B-X
by	B-X
stimulating	B-X
the	B-X
renin	B-X
-	B-X
angiotensin	B-X
system	B-X
<EOS>	B-X
UUO	B-X
in	B-X
wild	B-X
mice	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
expansion	B-X
of	B-X
relative	B-X
volume	B-X
of	B-X
the	B-X
tubulointerstitium	B-X
,	B-X
together	B-X
with	B-X
increased	B-X
deposition	B-X
of	B-X
collagen	B-X
types	B-X
III	B-X
and	B-X
IV	B-X
and	B-X
number	B-X
of	B-X
infiltrated	B-X
monocytes	B-X
/	B-X
macrophages	B-X
in	B-X
the	B-X
interstitium	B-X
,	B-X
relative	B-X
to	B-X
sham	B-X
-	B-X
operated	B-X
mice	B-X
<EOS>	B-X
Renal	B-X
interstitial	B-X
fibrosis	B-X
is	B-X
reduced	B-X
in	B-X
angiotensin	B-X
II	B-X
type	B-X
1a	B-X
receptor	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X
<EOS>	B-X
Also	B-X
determined	B-X
were	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
by	B-X
Northern	B-X
blot	B-X
analysis	B-X

This	O
study	O
established	O
a	O
UUO	O
model	O
in	O
angiotensin	B-protein
type	I-protein
1a	I-protein
receptor	I-protein
(	O
AT1a	B-protein
)	O
deficient	O
(	O
mutant	O
)	O
mice	O
to	O
elucidate	O
the	O
role	O
of	O
angiotensin	B-protein
II	I-protein
through	O
AT1a	B-protein
on	O
the	O
fibrosis	O
of	O
the	O
obstructed	O
kidney	O
(	O
OBK	O
)	O
.	O
<EOS>	B-X
This	B-X
study	B-X
established	B-X
a	B-X
UUO	B-X
model	B-X
in	B-X
angiotensin	B-X
type	B-X
1a	B-X
receptor	B-X
(	B-X
AT1a	B-X
)	B-X
deficient	B-X
(	B-X
mutant	B-X
)	B-X
mice	B-X
to	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
angiotensin	B-X
II	B-X
through	B-X
AT1a	B-X
on	B-X
the	B-X
fibrosis	B-X
of	B-X
the	B-X
obstructed	B-X
kidney	B-X
(	B-X
OBK	B-X
)	B-X
<EOS>	B-X
The	B-X
results	B-X
provide	B-X
direct	B-X
evidence	B-X
that	B-X
angiotensin	B-X
II	B-X
acting	B-X
via	B-X
the	B-X
AT1a	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
tubulointerstitial	B-X
fibrosis	B-X
in	B-X
UUO	B-X
<EOS>	B-X
The	B-X
mRNA	B-X
level	B-X
of	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
wild	B-X
mice	B-X
with	B-X
UUO	B-X
compared	B-X
with	B-X
sham	B-X
-	B-X
operated	B-X
mice	B-X
<EOS>	B-X
Renal	B-X
interstitial	B-X
fibrosis	B-X
is	B-X
reduced	B-X
in	B-X
angiotensin	B-X
II	B-X
type	B-X
1a	B-X
receptor	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X

The	O
relative	O
volume	O
of	O
the	O
tubulointerstitium	O
was	O
measured	O
by	O
an	O
image	O
analyzer	O
;	O
deposition	O
of	O
collagen	B-protein
types	I-protein
III	I-protein
and	I-protein
IV	I-protein
and	O
monocyte	B-cell_type
/	O
macrophage	B-cell_type
infiltration	O
were	O
histologically	O
examined	O
using	O
specific	B-protein
antibodies	I-protein
.	O
<EOS>	B-X
The	B-X
relative	B-X
volume	B-X
of	B-X
the	B-X
tubulointerstitium	B-X
was	B-X
measured	B-X
by	B-X
an	B-X
image	B-X
analyzer	B-X
;	B-X
deposition	B-X
of	B-X
collagen	B-X
types	B-X
III	B-X
and	B-X
IV	B-X
and	B-X
monocyte	B-X
/	B-X
macrophage	B-X
infiltration	B-X
were	B-X
histologically	B-X
examined	B-X
using	B-X
specific	B-X
antibodies	B-X
<EOS>	B-X
UUO	B-X
in	B-X
wild	B-X
mice	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
expansion	B-X
of	B-X
relative	B-X
volume	B-X
of	B-X
the	B-X
tubulointerstitium	B-X
,	B-X
together	B-X
with	B-X
increased	B-X
deposition	B-X
of	B-X
collagen	B-X
types	B-X
III	B-X
and	B-X
IV	B-X
and	B-X
number	B-X
of	B-X
infiltrated	B-X
monocytes	B-X
/	B-X
macrophages	B-X
in	B-X
the	B-X
interstitium	B-X
,	B-X
relative	B-X
to	B-X
sham	B-X
-	B-X
operated	B-X
mice	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
mRNA	B-X
level	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
mutant	B-X
mice	B-X
was	B-X
significantly	B-X
less	B-X
than	B-X
in	B-X
wild	B-X
mice	B-X
<EOS>	B-X
The	B-X
results	B-X
provide	B-X
direct	B-X
evidence	B-X
that	B-X
angiotensin	B-X
II	B-X
acting	B-X
via	B-X
the	B-X
AT1a	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
tubulointerstitial	B-X
fibrosis	B-X
in	B-X
UUO	B-X

Also	O
determined	O
were	O
the	O
mRNA	O
levels	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
by	O
Northern	O
blot	O
analysis	O
.	O
<EOS>	B-X
Activin	B-X
E	B-X
is	B-X
a	B-X
newly	B-X
identified	B-X
member	B-X
of	B-X
the	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
superfamily	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
mRNA	B-X
level	B-X
of	B-X
betaglycan	B-X
was	B-X
highest	B-X
after	B-X
the	B-X
LH	B-X
surge	B-X
that	B-X
induced	B-X
ovulation	B-X
<EOS>	B-X
Activin	B-X
A	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
transforming	B-X
growth	B-X
factor	B-X
beta	B-X
(	B-X
TGF	B-X
-	B-X
beta	B-X
)	B-X
superfamily	B-X
,	B-X
is	B-X
often	B-X
overexpressed	B-X
in	B-X
solid	B-X
carcinomas	B-X
<EOS>	B-X
Propylthiouracil	B-X
caused	B-X
a	B-X
concentration	B-X
-	B-X
dependent	B-X
decrease	B-X
in	B-X
collagen	B-X
I	B-X
and	B-X
III	B-X
steady	B-X
-	B-X
state	B-X
protein	B-X
and	B-X
mRNA	B-X
levels	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
immuno	B-X
-	B-X
cytochemistry	B-X
,	B-X
Western	B-X
,	B-X
and	B-X
/	B-X
or	B-X
Northern	B-X
blot	B-X
analyses	B-X

Nuclear	B-protein
factor-kappaB	I-protein
activity	O
was	O
assessed	O
by	O
gel	O
shift	O
assay	O
.	O
<EOS>	B-X
Cell	B-X
viability	B-X
was	B-X
assessed	B-X
by	B-X
the	B-X
MTS	B-X
assay	B-X
<EOS>	B-X
The	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
was	B-X
assessed	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
NF	B-X
-	B-X
κB	B-X
activation	B-X
was	B-X
assessed	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
was	B-X
assessed	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X

UUO	O
in	O
wild	O
mice	O
resulted	O
in	O
a	O
marked	O
expansion	O
of	O
relative	O
volume	O
of	O
the	O
tubulointerstitium	O
,	O
together	O
with	O
increased	O
deposition	O
of	O
collagen	B-protein
types	I-protein
III	I-protein
and	I-protein
IV	I-protein
and	O
number	O
of	O
infiltrated	O
monocytes	B-cell_type
/	O
macrophages	B-cell_type
in	O
the	O
interstitium	O
,	O
relative	O
to	O
sham-operated	O
mice	O
.	O

In	O
comparison	O
,	O
these	O
changes	O
were	O
significantly	O
lower	O
in	O
mutant	O
mice	O
with	O
UUO	O
.	O
<EOS>	B-X
In	B-X
comparison	B-X
,	B-X
these	B-X
changes	B-X
were	B-X
significantly	B-X
lower	B-X
in	B-X
mutant	B-X
mice	B-X
with	B-X
UUO	B-X
<EOS>	B-X
The	B-X
mRNA	B-X
level	B-X
of	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
wild	B-X
mice	B-X
with	B-X
UUO	B-X
compared	B-X
with	B-X
sham	B-X
-	B-X
operated	B-X
mice	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
mRNA	B-X
level	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
mutant	B-X
mice	B-X
was	B-X
significantly	B-X
less	B-X
than	B-X
in	B-X
wild	B-X
mice	B-X
<EOS>	B-X
The	B-X
results	B-X
provide	B-X
direct	B-X
evidence	B-X
that	B-X
angiotensin	B-X
II	B-X
acting	B-X
via	B-X
the	B-X
AT1a	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
tubulointerstitial	B-X
fibrosis	B-X
in	B-X
UUO	B-X

The	O
mRNA	O
level	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
was	O
significantly	O
higher	O
in	O
the	O
OBK	O
of	O
wild	O
mice	O
with	O
UUO	O
compared	O
with	O
sham-operated	O
mice	O
.	O
<EOS>	B-X
The	B-X
mRNA	B-X
level	B-X
of	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
wild	B-X
mice	B-X
with	B-X
UUO	B-X
compared	B-X
with	B-X
sham	B-X
-	B-X
operated	B-X
mice	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
mRNA	B-X
level	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
mutant	B-X
mice	B-X
was	B-X
significantly	B-X
less	B-X
than	B-X
in	B-X
wild	B-X
mice	B-X
<EOS>	B-X
In	B-X
comparison	B-X
,	B-X
these	B-X
changes	B-X
were	B-X
significantly	B-X
lower	B-X
in	B-X
mutant	B-X
mice	B-X
with	B-X
UUO	B-X
<EOS>	B-X
UUO	B-X
in	B-X
wild	B-X
mice	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
expansion	B-X
of	B-X
relative	B-X
volume	B-X
of	B-X
the	B-X
tubulointerstitium	B-X
,	B-X
together	B-X
with	B-X
increased	B-X
deposition	B-X
of	B-X
collagen	B-X
types	B-X
III	B-X
and	B-X
IV	B-X
and	B-X
number	B-X
of	B-X
infiltrated	B-X
monocytes	B-X
/	B-X
macrophages	B-X
in	B-X
the	B-X
interstitium	B-X
,	B-X
relative	B-X
to	B-X
sham	B-X
-	B-X
operated	B-X
mice	B-X

In	O
contrast	O
,	O
the	O
increase	O
in	O
mRNA	O
level	O
in	O
the	O
OBK	O
of	O
mutant	O
mice	O
was	O
significantly	O
less	O
than	O
in	O
wild	O
mice	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
increase	B-X
in	B-X
mRNA	B-X
level	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
mutant	B-X
mice	B-X
was	B-X
significantly	B-X
less	B-X
than	B-X
in	B-X
wild	B-X
mice	B-X
<EOS>	B-X
The	B-X
mRNA	B-X
level	B-X
of	B-X
transforming	B-X
growth	B-X
factor	B-X
-	B-X
beta	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
wild	B-X
mice	B-X
with	B-X
UUO	B-X
compared	B-X
with	B-X
sham	B-X
-	B-X
operated	B-X
mice	B-X
<EOS>	B-X
In	B-X
comparison	B-X
,	B-X
these	B-X
changes	B-X
were	B-X
significantly	B-X
lower	B-X
in	B-X
mutant	B-X
mice	B-X
with	B-X
UUO	B-X
<EOS>	B-X
Renal	B-X
interstitial	B-X
fibrosis	B-X
is	B-X
reduced	B-X
in	B-X
angiotensin	B-X
II	B-X
type	B-X
1a	B-X
receptor	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X

Finally	O
,	O
UUO	O
resulted	O
in	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
in	O
wild	O
mice	O
but	O
was	O
inhibited	O
in	O
the	O
OBK	O
of	O
mutant	O
mice	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
UUO	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
in	B-X
wild	B-X
mice	B-X
but	B-X
was	B-X
inhibited	B-X
in	B-X
the	B-X
OBK	B-X
of	B-X
mutant	B-X
mice	B-X
<EOS>	B-X
Nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activity	B-X
was	B-X
assessed	B-X
by	B-X
gel	B-X
shift	B-X
assay	B-X
<EOS>	B-X
Renal	B-X
interstitial	B-X
fibrosis	B-X
is	B-X
reduced	B-X
in	B-X
angiotensin	B-X
II	B-X
type	B-X
1a	B-X
receptor	B-X
-	B-X
deficient	B-X
mice	B-X
.	B-X
<EOS>	B-X
This	B-X
study	B-X
established	B-X
a	B-X
UUO	B-X
model	B-X
in	B-X
angiotensin	B-X
type	B-X
1a	B-X
receptor	B-X
(	B-X
AT1a	B-X
)	B-X
deficient	B-X
(	B-X
mutant	B-X
)	B-X
mice	B-X
to	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
angiotensin	B-X
II	B-X
through	B-X
AT1a	B-X
on	B-X
the	B-X
fibrosis	B-X
of	B-X
the	B-X
obstructed	B-X
kidney	B-X
(	B-X
OBK	B-X
)	B-X

The	O
results	O
provide	O
direct	O
evidence	O
that	O
angiotensin	B-protein
II	I-protein
acting	O
via	O
the	O
AT1a	B-protein
plays	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
tubulointerstitial	O
fibrosis	O
in	O
UUO	O
.	O

HLA-DQ	B-protein
tetramers	I-protein
identify	O
epitope-specific	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
peripheral	O
blood	O
of	O
herpes	O
simplex	O
virus	O
type	O
2-infected	O
individuals	O
:	O
direct	O
detection	O
of	O
immunodominant	B-cell_type
antigen-responsive	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
HLA	B-X
-	B-X
DQ	B-X
tetramers	B-X
identify	B-X
epitope	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
:	B-X
direct	B-X
detection	B-X
of	B-X
immunodominant	B-X
antigen	B-X
-	B-X
responsive	B-X
cells	B-X
.	B-X
<EOS>	B-X
VP16	B-X
Ag	B-X
-	B-X
specific	B-X
DQ	B-X
-	B-X
restricted	B-X
T	B-X
cells	B-X
were	B-X
identified	B-X
and	B-X
expanded	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
HSV	B-X
-	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
,	B-X
representing	B-X
two	B-X
predominant	B-X
epitope	B-X
specificities	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
utilized	B-X
this	B-X
technology	B-X
to	B-X
identify	B-X
HLA	B-X
DQ	B-X
-	B-X
restricted	B-X
Ag	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
human	B-X
subjects	B-X
and	B-X
to	B-X
identify	B-X
immunodominant	B-X
epitopes	B-X
associated	B-X
with	B-X
viral	B-X
infection	B-X
<EOS>	B-X
MHC	B-X
tetramers	B-X
,	B-X
which	B-X
constitute	B-X
a	B-X
labeled	B-X
MHC	B-X
-	B-X
peptide	B-X
ligand	B-X
suitable	B-X
for	B-X
binding	B-X
to	B-X
the	B-X
Ag	B-X
-	B-X
specific	B-X
receptor	B-X
on	B-X
T	B-X
cells	B-X
,	B-X
provide	B-X
a	B-X
novel	B-X
approach	B-X
for	B-X
the	B-X
detection	B-X
and	B-X
characterization	B-X
of	B-X
such	B-X
rare	B-X
cells	B-X

Ag-specific	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
are	O
present	O
in	O
peripheral	O
blood	O
in	O
low	O
frequency	O
,	O
where	O
they	O
undergo	O
recruitment	O
and	O
expansion	O
during	O
immune	O
responses	O
and	O
in	O
the	O
pathogenesis	O
of	O
numerous	O
autoimmune	O
diseases	O
.	O
<EOS>	B-X
Ag	B-X
-	B-X
specific	B-X
CD4+	B-X
T	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
peripheral	B-X
blood	B-X
in	B-X
low	B-X
frequency	B-X
,	B-X
where	B-X
they	B-X
undergo	B-X
recruitment	B-X
and	B-X
expansion	B-X
during	B-X
immune	B-X
responses	B-X
and	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
numerous	B-X
autoimmune	B-X
diseases	B-X
<EOS>	B-X
VP16	B-X
Ag	B-X
-	B-X
specific	B-X
DQ	B-X
-	B-X
restricted	B-X
T	B-X
cells	B-X
were	B-X
identified	B-X
and	B-X
expanded	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
HSV	B-X
-	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
,	B-X
representing	B-X
two	B-X
predominant	B-X
epitope	B-X
specificities	B-X
<EOS>	B-X
Peptides	B-X
representing	B-X
potential	B-X
epitope	B-X
regions	B-X
of	B-X
the	B-X
VP16	B-X
protein	B-X
from	B-X
HSV	B-X
-	B-X
2	B-X
were	B-X
loaded	B-X
onto	B-X
recombinant	B-X
DQ0602	B-X
molecules	B-X
to	B-X
generate	B-X
a	B-X
panel	B-X
of	B-X
Ag	B-X
-	B-X
specific	B-X
DQ0602	B-X
tetramers	B-X
<EOS>	B-X
HLA	B-X
-	B-X
DQ	B-X
tetramers	B-X
identify	B-X
epitope	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
:	B-X
direct	B-X
detection	B-X
of	B-X
immunodominant	B-X
antigen	B-X
-	B-X
responsive	B-X
cells	B-X
.	B-X

MHC	B-protein
tetramers	I-protein
,	O
which	O
constitute	O
a	O
labeled	B-protein
MHC-peptide	I-protein
ligand	I-protein
suitable	O
for	O
binding	O
to	O
the	O
Ag-specific	B-protein
receptor	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
provide	O
a	O
novel	O
approach	O
for	O
the	O
detection	O
and	O
characterization	O
of	O
such	O
rare	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
this	O
technology	O
to	O
identify	O
HLA	B-protein
DQ	I-protein
-restricted	O
Ag-specific	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
the	O
peripheral	O
blood	O
of	O
human	O
subjects	O
and	O
to	O
identify	O
immunodominant	O
epitopes	O
associated	O
with	O
viral	O
infection	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
utilized	B-X
this	B-X
technology	B-X
to	B-X
identify	B-X
HLA	B-X
DQ	B-X
-	B-X
restricted	B-X
Ag	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
human	B-X
subjects	B-X
and	B-X
to	B-X
identify	B-X
immunodominant	B-X
epitopes	B-X
associated	B-X
with	B-X
viral	B-X
infection	B-X
<EOS>	B-X
VP16	B-X
Ag	B-X
-	B-X
specific	B-X
DQ	B-X
-	B-X
restricted	B-X
T	B-X
cells	B-X
were	B-X
identified	B-X
and	B-X
expanded	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
HSV	B-X
-	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
,	B-X
representing	B-X
two	B-X
predominant	B-X
epitope	B-X
specificities	B-X
<EOS>	B-X
HLA	B-X
-	B-X
DQ	B-X
tetramers	B-X
identify	B-X
epitope	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
:	B-X
direct	B-X
detection	B-X
of	B-X
immunodominant	B-X
antigen	B-X
-	B-X
responsive	B-X
cells	B-X
.	B-X
<EOS>	B-X
Although	B-X
the	B-X
VP16	B-X
369	B-X
-	B-X
380	B-X
peptide	B-X
has	B-X
a	B-X
lower	B-X
binding	B-X
affinity	B-X
for	B-X
DQ0602	B-X
molecules	B-X
than	B-X
the	B-X
VP16	B-X
33	B-X
-	B-X
52	B-X
peptide	B-X
,	B-X
T	B-X
cells	B-X
that	B-X
recognized	B-X
the	B-X
VP16	B-X
369	B-X
-	B-X
380	B-X
peptide	B-X
occurred	B-X
at	B-X
a	B-X
much	B-X
higher	B-X
frequency	B-X
than	B-X
those	B-X
that	B-X
were	B-X
specific	B-X
for	B-X
the	B-X
VP16	B-X
33	B-X
-	B-X
52	B-X
peptide	B-X

Peptides	O
representing	O
potential	O
epitope	B-protein
regions	I-protein
of	O
the	O
VP16	B-protein
protein	I-protein
from	O
HSV-2	O
were	O
loaded	O
onto	O
recombinant	B-protein
DQ0602	I-protein
molecules	I-protein
to	O
generate	O
a	O
panel	O
of	O
Ag-specific	B-protein
DQ0602	I-protein
tetramers	I-protein
.	O
<EOS>	B-X
Peptides	B-X
representing	B-X
potential	B-X
epitope	B-X
regions	B-X
of	B-X
the	B-X
VP16	B-X
protein	B-X
from	B-X
HSV	B-X
-	B-X
2	B-X
were	B-X
loaded	B-X
onto	B-X
recombinant	B-X
DQ0602	B-X
molecules	B-X
to	B-X
generate	B-X
a	B-X
panel	B-X
of	B-X
Ag	B-X
-	B-X
specific	B-X
DQ0602	B-X
tetramers	B-X
<EOS>	B-X
Although	B-X
the	B-X
VP16	B-X
369	B-X
-	B-X
380	B-X
peptide	B-X
has	B-X
a	B-X
lower	B-X
binding	B-X
affinity	B-X
for	B-X
DQ0602	B-X
molecules	B-X
than	B-X
the	B-X
VP16	B-X
33	B-X
-	B-X
52	B-X
peptide	B-X
,	B-X
T	B-X
cells	B-X
that	B-X
recognized	B-X
the	B-X
VP16	B-X
369	B-X
-	B-X
380	B-X
peptide	B-X
occurred	B-X
at	B-X
a	B-X
much	B-X
higher	B-X
frequency	B-X
than	B-X
those	B-X
that	B-X
were	B-X
specific	B-X
for	B-X
the	B-X
VP16	B-X
33	B-X
-	B-X
52	B-X
peptide	B-X
<EOS>	B-X
Ag	B-X
-	B-X
specific	B-X
CD4+	B-X
T	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
peripheral	B-X
blood	B-X
in	B-X
low	B-X
frequency	B-X
,	B-X
where	B-X
they	B-X
undergo	B-X
recruitment	B-X
and	B-X
expansion	B-X
during	B-X
immune	B-X
responses	B-X
and	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
numerous	B-X
autoimmune	B-X
diseases	B-X
<EOS>	B-X
HLA	B-X
-	B-X
DQ	B-X
tetramers	B-X
identify	B-X
epitope	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
:	B-X
direct	B-X
detection	B-X
of	B-X
immunodominant	B-X
antigen	B-X
-	B-X
responsive	B-X
cells	B-X
.	B-X

VP16	B-protein
Ag	I-protein
-specific	O
DQ-restricted	B-cell_type
T	I-cell_type
cells	I-cell_type
were	O
identified	O
and	O
expanded	O
from	O
the	O
peripheral	O
blood	O
of	O
HSV-2-infected	O
individuals	O
,	O
representing	O
two	O
predominant	O
epitope	O
specificities	O
.	O
<EOS>	B-X
VP16	B-X
Ag	B-X
-	B-X
specific	B-X
DQ	B-X
-	B-X
restricted	B-X
T	B-X
cells	B-X
were	B-X
identified	B-X
and	B-X
expanded	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
HSV	B-X
-	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
,	B-X
representing	B-X
two	B-X
predominant	B-X
epitope	B-X
specificities	B-X
<EOS>	B-X
HLA	B-X
-	B-X
DQ	B-X
tetramers	B-X
identify	B-X
epitope	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
-	B-X
infected	B-X
individuals	B-X
:	B-X
direct	B-X
detection	B-X
of	B-X
immunodominant	B-X
antigen	B-X
-	B-X
responsive	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
utilized	B-X
this	B-X
technology	B-X
to	B-X
identify	B-X
HLA	B-X
DQ	B-X
-	B-X
restricted	B-X
Ag	B-X
-	B-X
specific	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
human	B-X
subjects	B-X
and	B-X
to	B-X
identify	B-X
immunodominant	B-X
epitopes	B-X
associated	B-X
with	B-X
viral	B-X
infection	B-X
<EOS>	B-X
Ag	B-X
-	B-X
specific	B-X
CD4+	B-X
T	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
peripheral	B-X
blood	B-X
in	B-X
low	B-X
frequency	B-X
,	B-X
where	B-X
they	B-X
undergo	B-X
recruitment	B-X
and	B-X
expansion	B-X
during	B-X
immune	B-X
responses	B-X
and	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
numerous	B-X
autoimmune	B-X
diseases	B-X

Although	O
the	O
VP16	O
369-380	O
peptide	O
has	O
a	O
lower	O
binding	O
affinity	O
for	O
DQ0602	B-protein
molecules	I-protein
than	O
the	O
VP16	O
33-52	O
peptide	O
,	O
T	B-cell_type
cells	I-cell_type
that	O
recognized	O
the	O
VP16	O
369-380	O
peptide	O
occurred	O
at	O
a	O
much	O
higher	O
frequency	O
than	O
those	O
that	O
were	O
specific	O
for	O
the	O
VP16	O
33-52	O
peptide	O
.	O

Down-regulation	O
of	O
BOB.1/OBF.1	B-protein
and	O
Oct2	B-protein
in	O
classical	O
Hodgkin	O
disease	O
but	O
not	O
in	O
lymphocyte	O
predominant	O
Hodgkin	O
disease	O
correlates	O
with	O
immunoglobulin	O
transcription	O
.	O
<EOS>	B-X
1	B-X
deficiency	B-X
as	B-X
a	B-X
recurrent	B-X
defect	B-X
in	B-X
HRS	B-X
cells	B-X
that	B-X
might	B-X
contribute	B-X
to	B-X
their	B-X
impairment	B-X
of	B-X
immunoglobulin	B-X
transcription	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
transcription	B-X
typically	B-X
correlated	B-X
with	B-X
hypermethylation	B-X
<EOS>	B-X
Epigenetic	B-X
silencing	B-X
of	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
gene	B-X
in	B-X
classical	B-X
Hodgkin	B-X
lymphoma	B-X
-	B-X
derived	B-X
cell	B-X
lines	B-X
contributes	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
immunoglobulin	B-X
expression	B-X
.	B-X
<EOS>	B-X
1	B-X
and	B-X
Oct2	B-X
in	B-X
cultured	B-X
HRS	B-X
cells	B-X
restored	B-X
the	B-X
activity	B-X
of	B-X
cotransduced	B-X
immunoglobulin	B-X
enhancer	B-X
constructs	B-X

In	O
contrast	O
to	O
the	O
tumor	B-cell_type
cells	I-cell_type
(	O
L	B-cell_type
&	I-cell_type
H	I-cell_type
cells	I-cell_type
)	O
of	O
lymphocyte	O
predominant	O
Hodgkin	O
disease	O
(	O
LPHD	O
)	O
,	O
Hodgkin	B-cell_type
and	I-cell_type
Reed-Sternberg	I-cell_type
(	I-cell_type
HRS	I-cell_type
)	I-cell_type
cells	I-cell_type
of	O
classical	O
Hodgkin	O
disease	O
(	O
cHD	O
)	O
are	O
unable	O
to	O
transcribe	O
immunoglobulin	B-protein
,	O
despite	O
the	O
presence	O
of	O
rearranged	B-DNA
immunoglobulin	I-DNA
genes	I-DNA
.	O

Although	O
initial	O
studies	O
have	O
suggested	O
crippling	O
immunoglobulin	O
gene	O
mutations	O
to	O
be	O
the	O
cause	O
of	O
absent	O
immunoglobulin	O
expression	O
in	O
cHD	O
,	O
recent	O
work	O
of	O
our	O
group	O
has	O
demonstrated	O
an	O
impaired	O
activation	O
of	O
the	O
immunoglobulin	B-DNA
promoter	I-DNA
as	O
a	O
superior	O
mechanism	O
.	O
<EOS>	B-X
Although	B-X
initial	B-X
studies	B-X
have	B-X
suggested	B-X
crippling	B-X
immunoglobulin	B-X
gene	B-X
mutations	B-X
to	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
absent	B-X
immunoglobulin	B-X
expression	B-X
in	B-X
cHD	B-X
,	B-X
recent	B-X
work	B-X
of	B-X
our	B-X
group	B-X
has	B-X
demonstrated	B-X
an	B-X
impaired	B-X
activation	B-X
of	B-X
the	B-X
immunoglobulin	B-X
promoter	B-X
as	B-X
a	B-X
superior	B-X
mechanism	B-X
<EOS>	B-X
1	B-X
,	B-X
we	B-X
analyzed	B-X
35	B-X
cases	B-X
of	B-X
LPHD	B-X
,	B-X
32	B-X
cases	B-X
of	B-X
cHD	B-X
,	B-X
and	B-X
2	B-X
Hodgkin	B-X
disease	B-X
cell	B-X
lines	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
and	B-X
also	B-X
in	B-X
parallel	B-X
for	B-X
immunoglobulin	B-X
expression	B-X
<EOS>	B-X
Our	B-X
findings	B-X
dismiss	B-X
the	B-X
concept	B-X
that	B-X
the	B-X
different	B-X
immunoglobulin	B-X
expression	B-X
in	B-X
cHD	B-X
and	B-X
LPHD	B-X
is	B-X
due	B-X
to	B-X
disrupting	B-X
mutations	B-X
of	B-X
immunoglobulin	B-X
V	B-X
genes	B-X
in	B-X
cHD	B-X
but	B-X
is	B-X
most	B-X
likely	B-X
due	B-X
to	B-X
a	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
Oct2	B-X
and	B-X
/	B-X
or	B-X
BOB	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
BOB.1	B-X
/	B-X
OBF.1	B-X
and	B-X
Oct2	B-X
in	B-X
classical	B-X
Hodgkin	B-X
disease	B-X
but	B-X
not	B-X
in	B-X
lymphocyte	B-X
predominant	B-X
Hodgkin	B-X
disease	B-X
correlates	B-X
with	B-X
immunoglobulin	B-X
transcription	B-X
.	B-X

As	O
immunoglobulin	O
transcription	O
is	O
mainly	O
regulated	O
by	O
the	O
B-cell	B-protein
transcription	I-protein
factors	I-protein
Oct2	B-protein
and	O
BOB.1/OBF.1	B-protein
,	O
we	O
analyzed	O
35	O
cases	O
of	O
LPHD	O
,	O
32	O
cases	O
of	O
cHD	O
,	O
and	O
2	O
Hodgkin	B-cell_line
disease	I-cell_line
cell	I-cell_line
lines	I-cell_line
for	O
the	O
expression	O
of	O
these	O
transcription	B-protein
factors	I-protein
and	O
also	O
in	O
parallel	O
for	O
immunoglobulin	O
expression	O
.	O
<EOS>	B-X
1	B-X
,	B-X
we	B-X
analyzed	B-X
35	B-X
cases	B-X
of	B-X
LPHD	B-X
,	B-X
32	B-X
cases	B-X
of	B-X
cHD	B-X
,	B-X
and	B-X
2	B-X
Hodgkin	B-X
disease	B-X
cell	B-X
lines	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
and	B-X
also	B-X
in	B-X
parallel	B-X
for	B-X
immunoglobulin	B-X
expression	B-X
<EOS>	B-X
As	B-X
immunoglobulin	B-X
transcription	B-X
is	B-X
mainly	B-X
regulated	B-X
by	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
transcription	B-X
factors	B-X
Oct2	B-X
and	B-X
BOB	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
BOB.1	B-X
/	B-X
OBF.1	B-X
and	B-X
Oct2	B-X
in	B-X
classical	B-X
Hodgkin	B-X
disease	B-X
but	B-X
not	B-X
in	B-X
lymphocyte	B-X
predominant	B-X
Hodgkin	B-X
disease	B-X
correlates	B-X
with	B-X
immunoglobulin	B-X
transcription	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
tumor	B-X
cells	B-X
(	B-X
L	B-X
&	B-X
H	B-X
cells	B-X
)	B-X
of	B-X
lymphocyte	B-X
predominant	B-X
Hodgkin	B-X
disease	B-X
(	B-X
LPHD	B-X
)	B-X
,	B-X
Hodgkin	B-X
and	B-X
Reed	B-X
-	B-X
Sternberg	B-X
(	B-X
HRS	B-X
)	B-X
cells	B-X
of	B-X
classical	B-X
Hodgkin	B-X
disease	B-X
(	B-X
cHD	B-X
)	B-X
are	B-X
unable	B-X
to	B-X
transcribe	B-X
immunoglobulin	B-X
,	B-X
despite	B-X
the	B-X
presence	B-X
of	B-X
rearranged	B-X
immunoglobulin	B-X
genes	B-X

Our	O
results	O
demonstrate	O
an	O
absence	O
of	O
Oct2	B-protein
and/or	O
BOB.1/OBF.1	B-protein
in	O
cHD	O
and	O
a	O
striking	O
overexpression	O
of	O
Oct2	B-protein
in	O
LPHD	O
.	O
<EOS>	B-X
1	B-X
in	B-X
cHD	B-X
and	B-X
a	B-X
striking	B-X
overexpression	B-X
of	B-X
Oct2	B-X
in	B-X
LPHD	B-X
<EOS>	B-X
Our	B-X
results	B-X
demonstrate	B-X
an	B-X
absence	B-X
of	B-X
Oct2	B-X
and	B-X
/	B-X
or	B-X
BOB	B-X
<EOS>	B-X
The	B-X
results	B-X
demonstrate	B-X
the	B-X
importance	B-X
of	B-X
plasma	B-X
membrane	B-X
transport	B-X
of	B-X
antiviral	B-X
drugs	B-X
to	B-X
elicit	B-X
cytotoxicity	B-X
in	B-X
the	B-X
hPT	B-X
cell	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
degree	B-X
of	B-X
Tax	B-X
transactivation	B-X
can	B-X
be	B-X
influenced	B-X
by	B-X
the	B-X
elemental	B-X
composition	B-X
of	B-X
the	B-X
target	B-X
promoter	B-X

Immunoglobulin	O
expression	O
was	O
lacking	O
in	O
cHD	O
but	O
present	O
in	O
LPHD	O
.	O
<EOS>	B-X
Immunoglobulin	B-X
expression	B-X
was	B-X
lacking	B-X
in	B-X
cHD	B-X
but	B-X
present	B-X
in	B-X
LPHD	B-X
<EOS>	B-X
As	B-X
immunoglobulin	B-X
transcription	B-X
is	B-X
mainly	B-X
regulated	B-X
by	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
transcription	B-X
factors	B-X
Oct2	B-X
and	B-X
BOB	B-X
<EOS>	B-X
The	B-X
impairment	B-X
of	B-X
immunoglobulin	B-X
transcription	B-X
with	B-X
a	B-X
down	B-X
-	B-X
regulated	B-X
synthesis	B-X
of	B-X
Oct2	B-X
and	B-X
BOB	B-X
<EOS>	B-X
1	B-X
in	B-X
cHD	B-X
and	B-X
a	B-X
striking	B-X
overexpression	B-X
of	B-X
Oct2	B-X
in	B-X
LPHD	B-X

Furthermore	O
,	O
the	O
reintroduction	O
of	O
BOB.1/OBF.1	B-protein
and	O
Oct2	B-protein
into	O
cultured	O
HRS	B-cell_type
cells	I-cell_type
restored	O
the	O
activity	O
of	O
cotransduced	O
immunoglobulin	B-DNA
promoter	I-DNA
constructs	I-DNA
.	O
<EOS>	B-X
1	B-X
and	B-X
Oct2	B-X
into	B-X
cultured	B-X
HRS	B-X
cells	B-X
restored	B-X
the	B-X
activity	B-X
of	B-X
cotransduced	B-X
immunoglobulin	B-X
promoter	B-X
constructs	B-X
<EOS>	B-X
Down	B-X
-	B-X
regulation	B-X
of	B-X
BOB.1	B-X
/	B-X
OBF.1	B-X
and	B-X
Oct2	B-X
in	B-X
classical	B-X
Hodgkin	B-X
disease	B-X
but	B-X
not	B-X
in	B-X
lymphocyte	B-X
predominant	B-X
Hodgkin	B-X
disease	B-X
correlates	B-X
with	B-X
immunoglobulin	B-X
transcription	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
tumor	B-X
cells	B-X
(	B-X
L	B-X
&	B-X
H	B-X
cells	B-X
)	B-X
of	B-X
lymphocyte	B-X
predominant	B-X
Hodgkin	B-X
disease	B-X
(	B-X
LPHD	B-X
)	B-X
,	B-X
Hodgkin	B-X
and	B-X
Reed	B-X
-	B-X
Sternberg	B-X
(	B-X
HRS	B-X
)	B-X
cells	B-X
of	B-X
classical	B-X
Hodgkin	B-X
disease	B-X
(	B-X
cHD	B-X
)	B-X
are	B-X
unable	B-X
to	B-X
transcribe	B-X
immunoglobulin	B-X
,	B-X
despite	B-X
the	B-X
presence	B-X
of	B-X
rearranged	B-X
immunoglobulin	B-X
genes	B-X
<EOS>	B-X
Although	B-X
initial	B-X
studies	B-X
have	B-X
suggested	B-X
crippling	B-X
immunoglobulin	B-X
gene	B-X
mutations	B-X
to	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
absent	B-X
immunoglobulin	B-X
expression	B-X
in	B-X
cHD	B-X
,	B-X
recent	B-X
work	B-X
of	B-X
our	B-X
group	B-X
has	B-X
demonstrated	B-X
an	B-X
impaired	B-X
activation	B-X
of	B-X
the	B-X
immunoglobulin	B-X
promoter	B-X
as	B-X
a	B-X
superior	B-X
mechanism	B-X

Our	O
findings	O
dismiss	O
the	O
concept	O
that	O
the	O
different	O
immunoglobulin	O
expression	O
in	O
cHD	O
and	O
LPHD	O
is	O
due	O
to	O
disrupting	O
mutations	O
of	O
immunoglobulin	B-DNA
V	I-DNA
genes	I-DNA
in	O
cHD	O
but	O
is	O
most	O
likely	O
due	O
to	O
a	O
down-regulation	O
of	O
Oct2	B-protein
and/or	O
BOB.1/OBF.1	B-protein
.	O
<EOS>	B-X
This	B-X
supports	B-X
the	B-X
concept	B-X
that	B-X
the	B-X
down	B-X
-	B-X
regulation	B-X
of	B-X
Ig	B-X
in	B-X
cHL	B-X
does	B-X
not	B-X
reflect	B-X
a	B-X
physiological	B-X
situation	B-X
,	B-X
but	B-X
a	B-X
defect	B-X
probably	B-X
closely	B-X
linked	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
cHL	B-X
<EOS>	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
demonstrated	B-X
that	B-X
in	B-X
cultured	B-X
and	B-X
in	B-X
situ	B-X
tumour	B-X
cells	B-X
of	B-X
classical	B-X
Hodgkin	B-X
lymphoma	B-X
(	B-X
cHL	B-X
)	B-X
,	B-X
the	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
promoter	B-X
is	B-X
inactive	B-X
and	B-X
its	B-X
transcription	B-X
factors	B-X
Oct2	B-X
and	B-X
/	B-X
or	B-X
BOB	B-X
<EOS>	B-X
Epigenetic	B-X
silencing	B-X
of	B-X
the	B-X
immunoglobulin	B-X
heavy	B-X
-	B-X
chain	B-X
gene	B-X
in	B-X
classical	B-X
Hodgkin	B-X
lymphoma	B-X
-	B-X
derived	B-X
cell	B-X
lines	B-X
contributes	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
immunoglobulin	B-X
expression	B-X
.	B-X
<EOS>	B-X
Using	B-X
the	B-X
cDNA	B-X
representational	B-X
difference	B-X
analysis	B-X
method	B-X
we	B-X
could	B-X
identify	B-X
myosin	B-X
light	B-X
chain	B-X
1	B-X
atrial	B-X
(	B-X
MLC1A	B-X
)	B-X
isoform	B-X
as	B-X
a	B-X
gene	B-X
regulated	B-X
by	B-X
BOB	B-X

This	O
study	O
further	O
revealed	O
Oct2	B-protein
as	O
a	O
new	O
and	O
valuable	O
marker	O
for	O
the	O
identification	O
of	O
L	B-cell_type
&	I-cell_type
H	I-cell_type
cells	I-cell_type
and	O
their	O
distinction	O
from	O
HRS	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
This	B-X
study	B-X
further	B-X
revealed	B-X
Oct2	B-X
as	B-X
a	B-X
new	B-X
and	B-X
valuable	B-X
marker	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
L	B-X
&	B-X
H	B-X
cells	B-X
and	B-X
their	B-X
distinction	B-X
from	B-X
HRS	B-X
cells	B-X
<EOS>	B-X
1	B-X
is	B-X
the	B-X
first	B-X
established	B-X
general	B-X
recurrent	B-X
defect	B-X
found	B-X
in	B-X
HRS	B-X
cells	B-X
<EOS>	B-X
1	B-X
and	B-X
Oct2	B-X
into	B-X
cultured	B-X
HRS	B-X
cells	B-X
restored	B-X
the	B-X
activity	B-X
of	B-X
cotransduced	B-X
immunoglobulin	B-X
promoter	B-X
constructs	B-X
<EOS>	B-X
1	B-X
,	B-X
we	B-X
analyzed	B-X
35	B-X
cases	B-X
of	B-X
LPHD	B-X
,	B-X
32	B-X
cases	B-X
of	B-X
cHD	B-X
,	B-X
and	B-X
2	B-X
Hodgkin	B-X
disease	B-X
cell	B-X
lines	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
and	B-X
also	B-X
in	B-X
parallel	B-X
for	B-X
immunoglobulin	B-X
expression	B-X

The	O
impairment	O
of	O
immunoglobulin	O
transcription	O
with	O
a	O
down-regulated	O
synthesis	O
of	O
Oct2	B-protein
and	O
BOB.1/OBF.1	B-protein
is	O
the	O
first	O
established	O
general	O
recurrent	O
defect	O
found	O
in	O
HRS	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
impairment	B-X
of	B-X
immunoglobulin	B-X
transcription	B-X
with	B-X
a	B-X
down	B-X
-	B-X
regulated	B-X
synthesis	B-X
of	B-X
Oct2	B-X
and	B-X
BOB	B-X
<EOS>	B-X
1	B-X
is	B-X
the	B-X
first	B-X
established	B-X
general	B-X
recurrent	B-X
defect	B-X
found	B-X
in	B-X
HRS	B-X
cells	B-X
<EOS>	B-X
As	B-X
immunoglobulin	B-X
transcription	B-X
is	B-X
mainly	B-X
regulated	B-X
by	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
transcription	B-X
factors	B-X
Oct2	B-X
and	B-X
BOB	B-X
<EOS>	B-X
Although	B-X
initial	B-X
studies	B-X
have	B-X
suggested	B-X
crippling	B-X
immunoglobulin	B-X
gene	B-X
mutations	B-X
to	B-X
be	B-X
the	B-X
cause	B-X
of	B-X
absent	B-X
immunoglobulin	B-X
expression	B-X
in	B-X
cHD	B-X
,	B-X
recent	B-X
work	B-X
of	B-X
our	B-X
group	B-X
has	B-X
demonstrated	B-X
an	B-X
impaired	B-X
activation	B-X
of	B-X
the	B-X
immunoglobulin	B-X
promoter	B-X
as	B-X
a	B-X
superior	B-X
mechanism	B-X

Constitutive	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
a	O
characteristic	O
feature	O
of	O
mycosis	O
fungoides	O
:	O
implications	O
for	O
apoptosis	O
resistance	O
and	O
pathogenesis	O
.	O
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
mycosis	B-X
fungoides	B-X
:	B-X
implications	B-X
for	B-X
apoptosis	B-X
resistance	B-X
and	B-X
pathogenesis	B-X
.	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
in	B-X
cases	B-X
of	B-X
mycosis	B-X
fungoides	B-X
(	B-X
MF	B-X
)	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
chemical	B-X
inhibitors	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
on	B-X
apoptosis	B-X
in	B-X
cutaneous	B-X
T	B-X
cell	B-X
lymphoma	B-X
(	B-X
CTCL	B-X
)	B-X
cell	B-X
lines	B-X
<EOS>	B-X
In	B-X
CTCL	B-X
cell	B-X
lines	B-X
,	B-X
the	B-X
significant	B-X
decrease	B-X
in	B-X
nuclear	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
expression	B-X
and	B-X
the	B-X
marked	B-X
increase	B-X
in	B-X
spontaneous	B-X
apoptosis	B-X
caused	B-X
by	B-X
chemical	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
inhibition	B-X
suggest	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
the	B-X
pathogenesis	B-X
and	B-X
tumor	B-X
cell	B-X
maintenance	B-X
of	B-X
CTCLs	B-X
<EOS>	B-X
Nuclear	B-X
expression	B-X
of	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
before	B-X
and	B-X
after	B-X
treatment	B-X
with	B-X
the	B-X
various	B-X
inhibitory	B-X
compounds	B-X
was	B-X
measured	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
in	B-X
each	B-X
CTCL	B-X
cell	B-X
line	B-X

The	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
is	O
an	O
important	O
regulator	O
of	O
genes	O
expressed	O
during	O
inflammatory	O
responses	O
,	O
immunoglobulin	O
(	O
Ig	O
)	O
class	O
switching	O
,	O
cellular	O
differentiation	O
,	O
and	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
genes	B-X
expressed	B-X
during	B-X
inflammatory	B-X
responses	B-X
,	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
class	B-X
switching	B-X
,	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
the	B-X
active	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
is	B-X
commonly	B-X
expressed	B-X
in	B-X
neoplastic	B-X
T	B-X
lymphocytes	B-X
in	B-X
patients	B-X
with	B-X
MF	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
mycosis	B-X
fungoides	B-X
:	B-X
implications	B-X
for	B-X
apoptosis	B-X
resistance	B-X
and	B-X
pathogenesis	B-X
.	B-X
<EOS>	B-X
Nuclear	B-X
expression	B-X
of	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
before	B-X
and	B-X
after	B-X
treatment	B-X
with	B-X
the	B-X
various	B-X
inhibitory	B-X
compounds	B-X
was	B-X
measured	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
in	B-X
each	B-X
CTCL	B-X
cell	B-X
line	B-X

Recently	O
,	O
members	O
of	O
the	O
NF-kappaB	B-protein
family	I-protein
,	O
including	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
,	O
have	O
been	O
implicated	O
in	O
promoting	O
survival	O
of	O
various	O
hematopoeitic	O
neoplasms	O
,	O
including	O
T	O
cell	O
malignancies	O
such	O
as	O
adult	O
T	O
cell	O
leukemia-lymphoma	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
members	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
family	B-X
,	B-X
including	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
,	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
promoting	B-X
survival	B-X
of	B-X
various	B-X
hematopoeitic	B-X
neoplasms	B-X
,	B-X
including	B-X
T	B-X
cell	B-X
malignancies	B-X
such	B-X
as	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
-	B-X
lymphoma	B-X
<EOS>	B-X
Nuclear	B-X
expression	B-X
of	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
before	B-X
and	B-X
after	B-X
treatment	B-X
with	B-X
the	B-X
various	B-X
inhibitory	B-X
compounds	B-X
was	B-X
measured	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
in	B-X
each	B-X
CTCL	B-X
cell	B-X
line	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
mycosis	B-X
fungoides	B-X
:	B-X
implications	B-X
for	B-X
apoptosis	B-X
resistance	B-X
and	B-X
pathogenesis	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
the	B-X
active	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
is	B-X
commonly	B-X
expressed	B-X
in	B-X
neoplastic	B-X
T	B-X
lymphocytes	B-X
in	B-X
patients	B-X
with	B-X
MF	B-X

We	O
investigated	O
the	O
expression	O
of	O
active	B-protein
NF-kappa	I-protein
B	I-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
in	O
cases	O
of	O
mycosis	O
fungoides	O
(	O
MF	O
)	O
and	O
the	O
effect	O
of	O
chemical	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
on	O
apoptosis	O
in	O
cutaneous	B-cell_line
T	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
(	I-cell_line
CTCL	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
in	B-X
cases	B-X
of	B-X
mycosis	B-X
fungoides	B-X
(	B-X
MF	B-X
)	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
chemical	B-X
inhibitors	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
on	B-X
apoptosis	B-X
in	B-X
cutaneous	B-X
T	B-X
cell	B-X
lymphoma	B-X
(	B-X
CTCL	B-X
)	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
mycosis	B-X
fungoides	B-X
:	B-X
implications	B-X
for	B-X
apoptosis	B-X
resistance	B-X
and	B-X
pathogenesis	B-X
.	B-X
<EOS>	B-X
Nuclear	B-X
expression	B-X
of	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
before	B-X
and	B-X
after	B-X
treatment	B-X
with	B-X
the	B-X
various	B-X
inhibitory	B-X
compounds	B-X
was	B-X
measured	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
in	B-X
each	B-X
CTCL	B-X
cell	B-X
line	B-X
<EOS>	B-X
In	B-X
CTCL	B-X
cell	B-X
lines	B-X
,	B-X
the	B-X
significant	B-X
decrease	B-X
in	B-X
nuclear	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
expression	B-X
and	B-X
the	B-X
marked	B-X
increase	B-X
in	B-X
spontaneous	B-X
apoptosis	B-X
caused	B-X
by	B-X
chemical	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
inhibition	B-X
suggest	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
the	B-X
pathogenesis	B-X
and	B-X
tumor	B-X
cell	B-X
maintenance	B-X
of	B-X
CTCLs	B-X

Paraffin-embedded	O
tissues	O
from	O
23	O
cutaneous	O
lesions	O
and	O
a	O
single	O
lymph	O
node	O
biopsy	O
from	O
patients	O
diagnosed	O
with	O
MF	O
were	O
evaluated	O
for	O
p65	O
(	O
Rel	O
A	O
)	O
expression	O
by	O
using	O
a	O
monoclonal	B-protein
mouse	I-protein
antibody	I-protein
that	O
detects	O
the	O
activated	O
form	O
of	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
.	O

Apoptosis	O
after	O
treatment	O
with	O
the	O
NF-kappa	O
B	O
inhibitors	O
gliotoxin	O
,	O
MG132	O
,	O
BAY	O
11-7082	O
,	O
and	O
BAY	O
11-7085	O
was	O
quantitatively	O
measured	O
in	O
the	O
CTCL	B-cell_line
cell	I-cell_line
lines	I-cell_line
HuT-78	I-cell_line
and	I-cell_line
HH	I-cell_line
by	O
propidium	O
iodide	O
(	O
PI	O
)	O
/cell	O
cycle	O
analysis	O
for	O
detection	O
of	O
a	O
hypodiploid	O
(	O
sub-G	O
(	O
0	O
)	O
)	O
population	O
and	O
by	O
determination	O
of	O
increased	O
Annexin	O
V/7-amino-actinomycin	O
D	O
(	O
7-AAD	O
)	O
expression	O
.	O

Nuclear	O
extracts	O
from	O
CTCL	B-cell_type
cells	I-cell_type
before	O
and	O
after	O
chemical	O
inhibition	O
were	O
analyzed	O
for	O
NF-kappa	O
B	O
nuclear	O
DNA-binding	O
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
quantitative	O
densitometry	O
.	O
<EOS>	B-X
Nuclear	B-X
extracts	B-X
from	B-X
CTCL	B-X
cells	B-X
before	B-X
and	B-X
after	B-X
chemical	B-X
inhibition	B-X
were	B-X
analyzed	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
nuclear	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
with	B-X
quantitative	B-X
densitometry	B-X
<EOS>	B-X
Nuclear	B-X
expression	B-X
of	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
before	B-X
and	B-X
after	B-X
treatment	B-X
with	B-X
the	B-X
various	B-X
inhibitory	B-X
compounds	B-X
was	B-X
measured	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
in	B-X
each	B-X
CTCL	B-X
cell	B-X
line	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
the	B-X
active	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
is	B-X
commonly	B-X
expressed	B-X
in	B-X
neoplastic	B-X
T	B-X
lymphocytes	B-X
in	B-X
patients	B-X
with	B-X
MF	B-X
<EOS>	B-X
Compared	B-X
with	B-X
untreated	B-X
control	B-X
cells	B-X
,	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
apoptosis	B-X
,	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
,	B-X
and	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
nuclear	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
expression	B-X
were	B-X
seen	B-X
in	B-X
cells	B-X
from	B-X
both	B-X
CTCL	B-X
cell	B-X
lines	B-X
after	B-X
chemical	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
inhibition	B-X

Nuclear	O
expression	O
of	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
before	O
and	O
after	O
treatment	O
with	O
the	O
various	O
inhibitory	O
compounds	O
was	O
measured	O
by	O
immunofluorescence	O
staining	O
in	O
each	O
CTCL	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O
<EOS>	B-X
Nuclear	B-X
expression	B-X
of	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
before	B-X
and	B-X
after	B-X
treatment	B-X
with	B-X
the	B-X
various	B-X
inhibitory	B-X
compounds	B-X
was	B-X
measured	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
in	B-X
each	B-X
CTCL	B-X
cell	B-X
line	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
in	B-X
cases	B-X
of	B-X
mycosis	B-X
fungoides	B-X
(	B-X
MF	B-X
)	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
chemical	B-X
inhibitors	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
on	B-X
apoptosis	B-X
in	B-X
cutaneous	B-X
T	B-X
cell	B-X
lymphoma	B-X
(	B-X
CTCL	B-X
)	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Nuclear	B-X
extracts	B-X
from	B-X
CTCL	B-X
cells	B-X
before	B-X
and	B-X
after	B-X
chemical	B-X
inhibition	B-X
were	B-X
analyzed	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
nuclear	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
with	B-X
quantitative	B-X
densitometry	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
mycosis	B-X
fungoides	B-X
:	B-X
implications	B-X
for	B-X
apoptosis	B-X
resistance	B-X
and	B-X
pathogenesis	B-X
.	B-X

Neoplastic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
from	O
22	O
of	O
24	O
cases	O
of	O
MF	O
showed	O
strong	O
nuclear	O
and	O
cytoplasmic	O
expression	O
of	O
active	B-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
.	O
<EOS>	B-X
Neoplastic	B-X
T	B-X
lymphocytes	B-X
from	B-X
22	B-X
of	B-X
24	B-X
cases	B-X
of	B-X
MF	B-X
showed	B-X
strong	B-X
nuclear	B-X
and	B-X
cytoplasmic	B-X
expression	B-X
of	B-X
active	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
in	B-X
cases	B-X
of	B-X
mycosis	B-X
fungoides	B-X
(	B-X
MF	B-X
)	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
chemical	B-X
inhibitors	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
on	B-X
apoptosis	B-X
in	B-X
cutaneous	B-X
T	B-X
cell	B-X
lymphoma	B-X
(	B-X
CTCL	B-X
)	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Paraffin	B-X
-	B-X
embedded	B-X
tissues	B-X
from	B-X
23	B-X
cutaneous	B-X
lesions	B-X
and	B-X
a	B-X
single	B-X
lymph	B-X
node	B-X
biopsy	B-X
from	B-X
patients	B-X
diagnosed	B-X
with	B-X
MF	B-X
were	B-X
evaluated	B-X
for	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
expression	B-X
by	B-X
using	B-X
a	B-X
monoclonal	B-X
mouse	B-X
antibody	B-X
that	B-X
detects	B-X
the	B-X
activated	B-X
form	B-X
of	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
<EOS>	B-X
Nuclear	B-X
extracts	B-X
from	B-X
CTCL	B-X
cells	B-X
before	B-X
and	B-X
after	B-X
chemical	B-X
inhibition	B-X
were	B-X
analyzed	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
nuclear	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
with	B-X
quantitative	B-X
densitometry	B-X

Compared	O
with	O
untreated	O
control	B-cell_type
cells	I-cell_type
,	O
a	O
marked	O
increase	O
in	O
apoptosis	O
,	O
a	O
significant	O
decrease	O
in	O
NF-kappa	O
B	O
DNA-binding	O
activity	O
,	O
and	O
a	O
marked	O
decrease	O
in	O
nuclear	O
p65	O
(	O
Rel	O
A	O
)	O
expression	O
were	O
seen	O
in	O
cells	O
from	O
both	O
CTCL	B-cell_line
cell	I-cell_line
lines	I-cell_line
after	O
chemical	O
NF-kappa	O
B	O
inhibition	O
.	O

These	O
data	O
show	O
that	O
the	O
active	O
form	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
is	O
commonly	O
expressed	O
in	O
neoplastic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
patients	O
with	O
MF	O
.	O
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
the	B-X
active	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
is	B-X
commonly	B-X
expressed	B-X
in	B-X
neoplastic	B-X
T	B-X
lymphocytes	B-X
in	B-X
patients	B-X
with	B-X
MF	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
in	B-X
cases	B-X
of	B-X
mycosis	B-X
fungoides	B-X
(	B-X
MF	B-X
)	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
chemical	B-X
inhibitors	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
on	B-X
apoptosis	B-X
in	B-X
cutaneous	B-X
T	B-X
cell	B-X
lymphoma	B-X
(	B-X
CTCL	B-X
)	B-X
cell	B-X
lines	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
genes	B-X
expressed	B-X
during	B-X
inflammatory	B-X
responses	B-X
,	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
class	B-X
switching	B-X
,	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
Nuclear	B-X
extracts	B-X
from	B-X
CTCL	B-X
cells	B-X
before	B-X
and	B-X
after	B-X
chemical	B-X
inhibition	B-X
were	B-X
analyzed	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
nuclear	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
with	B-X
quantitative	B-X
densitometry	B-X

In	O
CTCL	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
significant	O
decrease	O
in	O
nuclear	O
NF-kappa	O
B	O
expression	O
and	O
the	O
marked	O
increase	O
in	O
spontaneous	O
apoptosis	O
caused	O
by	O
chemical	O
NF-kappa	O
B	O
inhibition	O
suggest	O
a	O
critical	O
role	O
for	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
pathogenesis	O
and	O
tumor	O
cell	O
maintenance	O
of	O
CTCLs	O
.	O
<EOS>	B-X
In	B-X
CTCL	B-X
cell	B-X
lines	B-X
,	B-X
the	B-X
significant	B-X
decrease	B-X
in	B-X
nuclear	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
expression	B-X
and	B-X
the	B-X
marked	B-X
increase	B-X
in	B-X
spontaneous	B-X
apoptosis	B-X
caused	B-X
by	B-X
chemical	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
inhibition	B-X
suggest	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
the	B-X
pathogenesis	B-X
and	B-X
tumor	B-X
cell	B-X
maintenance	B-X
of	B-X
CTCLs	B-X
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
in	B-X
cases	B-X
of	B-X
mycosis	B-X
fungoides	B-X
(	B-X
MF	B-X
)	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
chemical	B-X
inhibitors	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
on	B-X
apoptosis	B-X
in	B-X
cutaneous	B-X
T	B-X
cell	B-X
lymphoma	B-X
(	B-X
CTCL	B-X
)	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
mycosis	B-X
fungoides	B-X
:	B-X
implications	B-X
for	B-X
apoptosis	B-X
resistance	B-X
and	B-X
pathogenesis	B-X
.	B-X
<EOS>	B-X
Nuclear	B-X
expression	B-X
of	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
before	B-X
and	B-X
after	B-X
treatment	B-X
with	B-X
the	B-X
various	B-X
inhibitory	B-X
compounds	B-X
was	B-X
measured	B-X
by	B-X
immunofluorescence	B-X
staining	B-X
in	B-X
each	B-X
CTCL	B-X
cell	B-X
line	B-X

HUM	O
PATHOL	O
31	O
:	O
1482-1490	O
.	O
<EOS>	B-X
HUM	B-X
PATHOL	B-X
31:1482	B-X
-	B-X
1490	B-X
<EOS>	B-X
Neoplastic	B-X
T	B-X
lymphocytes	B-X
from	B-X
22	B-X
of	B-X
24	B-X
cases	B-X
of	B-X
MF	B-X
showed	B-X
strong	B-X
nuclear	B-X
and	B-X
cytoplasmic	B-X
expression	B-X
of	B-X
active	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
<EOS>	B-X
Constitutive	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
a	B-X
characteristic	B-X
feature	B-X
of	B-X
mycosis	B-X
fungoides	B-X
:	B-X
implications	B-X
for	B-X
apoptosis	B-X
resistance	B-X
and	B-X
pathogenesis	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
the	B-X
active	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
is	B-X
commonly	B-X
expressed	B-X
in	B-X
neoplastic	B-X
T	B-X
lymphocytes	B-X
in	B-X
patients	B-X
with	B-X
MF	B-X

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
tax	B-protein
protein	I-protein
activates	O
transcription	O
through	O
AP-1	B-DNA
site	I-DNA
by	O
inducing	O
DNA	O
binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B-protein
protein	I-protein
induces	O
the	O
expression	O
of	O
various	O
family	O
members	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
,	O
such	O
as	O
c-Jun	B-protein
,	O
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	O
Fra-1	B-protein
,	O
at	O
the	O
level	O
of	O
RNA	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
examined	O
the	O
activity	O
of	O
Tax	B-protein
in	O
transcription	O
through	O
AP-1-binding	B-DNA
sites	I-DNA
(	O
AP-1	B-DNA
site	I-DNA
)	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Transient	O
transfection	O
studies	O
showed	O
that	O
Tax	B-protein
activated	O
the	O
expression	O
of	O
a	O
luciferase	B-DNA
gene	I-DNA
regulated	O
by	O
two	O
copies	O
of	O
an	O
AP-1	B-DNA
site	I-DNA
in	O
the	O
human	B-cell_line
Jurkat	I-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
showed	B-X
that	B-X
Tax	B-X
activated	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
gene	B-X
regulated	B-X
by	B-X
two	B-X
copies	B-X
of	B-X
an	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
the	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
Unlike	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
Tax	B-X
,	B-X
Tax703	B-X
and	B-X
TaxM22	B-X
only	B-X
weakly	B-X
activated	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
mRNA	B-X
by	B-X
Tax	B-X
may	B-X
not	B-X
be	B-X
sufficient	B-X
for	B-X
a	B-X
complete	B-X
activation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
Tax	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
Tax	B-X
induced	B-X
strong	B-X
binding	B-X
activity	B-X
to	B-X
an	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
CTLL	B-X
-	B-X
2	B-X
,	B-X
whereas	B-X
Tax703	B-X
did	B-X
not	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
binding	B-X
activity	B-X
to	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
transcriptional	B-X
activation	B-X
by	B-X
Tax	B-X

Tax	B-protein
activates	O
the	O
expression	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
through	O
two	O
different	O
enhancers	O
:	O
a	O
cAMP-responsive	B-DNA
(	I-DNA
CRE	I-DNA
)	I-DNA
-like	I-DNA
element	I-DNA
and	O
a	O
kappaB	B-DNA
element	I-DNA
.	O

Two	O
Tax	B-protein
mutants	I-protein
differentially	O
activated	O
expression	O
of	O
these	O
two	O
elements	O
.	O
<EOS>	B-X
Two	B-X
Tax	B-X
mutants	B-X
differentially	B-X
activated	B-X
expression	B-X
of	B-X
these	B-X
two	B-X
elements	B-X
<EOS>	B-X
Tax703	B-X
preferentially	B-X
activated	B-X
the	B-X
kappaB	B-X
element	B-X
but	B-X
not	B-X
the	B-X
CRE	B-X
-	B-X
like	B-X
one	B-X
,	B-X
whereas	B-X
TaxM22	B-X
showed	B-X
the	B-X
reverse	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
showed	B-X
that	B-X
Tax	B-X
activated	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
gene	B-X
regulated	B-X
by	B-X
two	B-X
copies	B-X
of	B-X
an	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
the	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
Unlike	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
Tax	B-X
,	B-X
Tax703	B-X
and	B-X
TaxM22	B-X
only	B-X
weakly	B-X
activated	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
line	B-X

Tax703	B-protein
preferentially	O
activated	O
the	O
kappaB	B-DNA
element	I-DNA
but	O
not	O
the	O
CRE-like	O
one	O
,	O
whereas	O
TaxM22	B-protein
showed	O
the	O
reverse	O
.	O

In	O
addition	O
,	O
Tax703	B-protein
and	O
Tax	B-protein
,	O
but	O
not	O
TaxM22	B-protein
,	O
converted	O
cell	O
growth	O
of	O
a	O
mouse	B-cell_line
T-cell	I-cell_line
line	I-cell_line
from	O
being	O
interleukin	O
(	O
IL	O
)	O
-2-dependent	O
to	O
being	O
IL-2-independent	O
.	O

Unlike	O
the	O
wild-type	B-protein
Tax	I-protein
,	O
Tax703	B-protein
and	O
TaxM22	B-protein
only	O
weakly	O
activated	O
the	O
AP-1	B-DNA
site	I-DNA
in	O
the	O
T-cell	B-cell_line
line	I-cell_line
.	O
<EOS>	B-X
Unlike	B-X
the	B-X
wild	B-X
-	B-X
type	B-X
Tax	B-X
,	B-X
Tax703	B-X
and	B-X
TaxM22	B-X
only	B-X
weakly	B-X
activated	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
showed	B-X
that	B-X
Tax	B-X
activated	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
gene	B-X
regulated	B-X
by	B-X
two	B-X
copies	B-X
of	B-X
an	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
the	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
Two	B-X
Tax	B-X
mutants	B-X
differentially	B-X
activated	B-X
expression	B-X
of	B-X
these	B-X
two	B-X
elements	B-X
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
activity	B-X
of	B-X
Tax	B-X
in	B-X
transcription	B-X
through	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
binding	B-X
sites	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
)	B-X
in	B-X
T	B-X
cells	B-X

Thus	O
,	O
Tax	B-protein
seems	O
to	O
activate	O
the	O
AP-1	B-DNA
site	I-DNA
via	O
mechanisms	O
distinct	O
from	O
those	O
of	O
kappaB	B-DNA
or	I-DNA
CRE-like	I-DNA
elements	I-DNA
,	O
and	O
the	O
activation	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
is	O
dispensable	O
for	O
IL-2-independent	O
growth	O
of	O
CTLL-2	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
Tax	B-X
seems	B-X
to	B-X
activate	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
via	B-X
mechanisms	B-X
distinct	B-X
from	B-X
those	B-X
of	B-X
kappaB	B-X
or	B-X
CRE	B-X
-	B-X
like	B-X
elements	B-X
,	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
is	B-X
dispensable	B-X
for	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
independent	B-X
growth	B-X
of	B-X
CTLL	B-X
-	B-X
2	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
mRNA	B-X
by	B-X
Tax	B-X
may	B-X
not	B-X
be	B-X
sufficient	B-X
for	B-X
a	B-X
complete	B-X
activation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
Tax	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
Tax	B-X
induced	B-X
strong	B-X
binding	B-X
activity	B-X
to	B-X
an	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
CTLL	B-X
-	B-X
2	B-X
,	B-X
whereas	B-X
Tax703	B-X
did	B-X
not	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
binding	B-X
activity	B-X
to	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
transcriptional	B-X
activation	B-X
by	B-X
Tax	B-X
<EOS>	B-X
Tax703	B-X
preferentially	B-X
activated	B-X
the	B-X
kappaB	B-X
element	B-X
but	B-X
not	B-X
the	B-X
CRE	B-X
-	B-X
like	B-X
one	B-X
,	B-X
whereas	B-X
TaxM22	B-X
showed	B-X
the	B-X
reverse	B-X

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
Tax	B-protein
induced	O
strong	O
binding	O
activity	O
to	O
an	O
AP-1	B-DNA
site	I-DNA
in	O
CTLL-2	O
,	O
whereas	O
Tax703	B-protein
did	O
not	O
,	O
indicating	O
that	O
the	O
induction	O
of	O
binding	O
activity	O
to	O
the	O
AP-1	B-DNA
site	I-DNA
is	O
essential	O
for	O
the	O
transcriptional	O
activation	O
by	O
Tax	B-protein
.	O

The	O
binding	B-protein
complex	I-protein
induced	O
by	O
Tax	B-protein
in	O
CTLL-2	O
contained	O
JunD	B-protein
and	O
Fra-2	B-protein
.	O
<EOS>	B-X
The	B-X
binding	B-X
complex	B-X
induced	B-X
by	B-X
Tax	B-X
in	B-X
CTLL	B-X
-	B-X
2	B-X
contained	B-X
JunD	B-X
and	B-X
Fra	B-X
-	B-X
2	B-X
<EOS>	B-X
Activation	B-X
of	B-X
transcription	B-X
through	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
Jurkat	B-X
cells	B-X
by	B-X
JunD	B-X
and	B-X
/	B-X
or	B-X
Fra	B-X
-	B-X
2	B-X
was	B-X
weak	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
mRNA	B-X
by	B-X
Tax	B-X
may	B-X
not	B-X
be	B-X
sufficient	B-X
for	B-X
a	B-X
complete	B-X
activation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
Tax	B-X
<EOS>	B-X
Human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
tax	B-X
protein	B-X
activates	B-X
transcription	B-X
through	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
inducing	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
T	B-X
cells	B-X
.	B-X

Other	O
AP-1	B-protein
proteins	I-protein
were	O
undetectable	O
.	O
<EOS>	B-X
Other	B-X
AP	B-X
-	B-X
1	B-X
proteins	B-X
were	B-X
undetectable	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
did	B-X
not	B-X
increase	B-X
until	B-X
60	B-X
min	B-X
reperfusion	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
with	B-X
reporter	B-X
constructs	B-X
containing	B-X
1	B-X
<EOS>	B-X
0	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
5	B-X
pmol	B-X
/	B-X
10	B-X
(	B-X
6	B-X
)	B-X
cells	B-X
and	B-X
that	B-X
of	B-X
L	B-X
-	B-X
citrulline	B-X
(	B-X
L	B-X
-	B-X
Cit	B-X
)	B-X
from	B-X
undetectable	B-X
levels	B-X
to	B-X
47	B-X

Activation	O
of	O
transcription	O
through	O
the	O
AP-1	B-DNA
site	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
by	O
JunD	B-protein
and/or	O
Fra-2	B-protein
was	O
weak	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
transcription	B-X
through	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
Jurkat	B-X
cells	B-X
by	B-X
JunD	B-X
and	B-X
/	B-X
or	B-X
Fra	B-X
-	B-X
2	B-X
was	B-X
weak	B-X
<EOS>	B-X
FK506	B-X
suppressed	B-X
the	B-X
transcriptions	B-X
through	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
or	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
sites	B-X
induced	B-X
by	B-X
PMA	B-X
plus	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
	B-X
-	B-X
mobilizing	B-X
agents	B-X
,	B-X
but	B-X
not	B-X
those	B-X
induced	B-X
by	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
	B-X
-	B-X
independent	B-X
stimuli	B-X
<EOS>	B-X
The	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
transcription	B-X
factors	B-X
are	B-X
important	B-X
regulators	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
<EOS>	B-X
Human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
tax	B-X
protein	B-X
activates	B-X
transcription	B-X
through	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
inducing	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
T	B-X
cells	B-X
.	B-X

c-Jun	B-protein
,	O
JunB	B-protein
,	O
and	O
c-Fos	B-protein
activation	O
was	O
greater	O
,	O
although	O
the	O
level	O
was	O
still	O
less	O
than	O
that	O
with	O
Tax	B-protein
.	O
<EOS>	B-X
c	B-X
-	B-X
Jun	B-X
,	B-X
JunB	B-X
,	B-X
and	B-X
c	B-X
-	B-X
Fos	B-X
activation	B-X
was	B-X
greater	B-X
,	B-X
although	B-X
the	B-X
level	B-X
was	B-X
still	B-X
less	B-X
than	B-X
that	B-X
with	B-X
Tax	B-X
<EOS>	B-X
Human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
tax	B-X
protein	B-X
activates	B-X
transcription	B-X
through	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
inducing	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
showed	B-X
that	B-X
Tax	B-X
activated	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
gene	B-X
regulated	B-X
by	B-X
two	B-X
copies	B-X
of	B-X
an	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
in	B-X
the	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
Tax703	B-X
and	B-X
Tax	B-X
,	B-X
but	B-X
not	B-X
TaxM22	B-X
,	B-X
converted	B-X
cell	B-X
growth	B-X
of	B-X
a	B-X
mouse	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
from	B-X
being	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
to	B-X
being	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
independent	B-X

Thus	O
,	O
the	O
induction	O
of	O
AP-1	B-RNA
mRNA	I-RNA
by	O
Tax	B-protein
may	O
not	O
be	O
sufficient	O
for	O
a	O
complete	O
activation	O
of	O
AP-1	B-DNA
site	I-DNA
by	O
Tax	B-protein
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
MMP	B-X
-	B-X
7	B-X
by	B-X
Tax	B-X
is	B-X
regulated	B-X
by	B-X
JunD	B-X
and	B-X
that	B-X
MMP	B-X
-	B-X
7	B-X
could	B-X
facilitate	B-X
visceral	B-X
invasion	B-X
in	B-X
ATL	B-X
<EOS>	B-X
The	B-X
MMP	B-X
-	B-X
7	B-X
promoter	B-X
activity	B-X
was	B-X
increased	B-X
by	B-X
Tax	B-X
and	B-X
reduced	B-X
by	B-X
deletion	B-X
of	B-X
the	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
binding	B-X
site	B-X
<EOS>	B-X
Degradation	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
by	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMPs	B-X
)	B-X
is	B-X
a	B-X
crucial	B-X
process	B-X
in	B-X
invasion	B-X
of	B-X
tumors	B-X
and	B-X
metastasis	B-X
<EOS>	B-X
Changes	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
several	B-X
cellular	B-X
genes	B-X
were	B-X
assessed	B-X
by	B-X
reverse	B-X
transcription	B-X
-	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
enzyme	B-X
-	B-X
linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
flow	B-X
cytometry	B-X

Our	O
results	O
suggest	O
that	O
Tax	B-protein
activates	O
the	O
transcription	O
of	O
cellular	B-DNA
genes	I-DNA
with	O
AP-1	B-DNA
sites	I-DNA
by	O
inducing	O
the	O
DNA-binding	O
activity	O
of	O
AP-1	B-protein
proteins	I-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
a	O
mechanism	O
distinct	O
from	O
those	O
of	O
CRE-like	B-DNA
and	I-DNA
kappaB	I-DNA
elements	I-DNA
.	O

Strict	O
control	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
genetic	O
switch	O
:	O
Tet	O
for	O
Tat	O
.	O
<EOS>	B-X
Strict	B-X
control	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
replication	B-X
by	B-X
a	B-X
genetic	B-X
switch	B-X
:	B-X
Tet	B-X
for	B-X
Tat	B-X
.	B-X
<EOS>	B-X
Live	B-X
-	B-X
attenuated	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
variants	B-X
have	B-X
shown	B-X
great	B-X
promise	B-X
as	B-X
AIDS	B-X
vaccines	B-X
,	B-X
but	B-X
continued	B-X
replication	B-X
can	B-X
lead	B-X
to	B-X
the	B-X
selection	B-X
of	B-X
faster	B-X
-	B-X
replicating	B-X
variants	B-X
that	B-X
are	B-X
pathogenic	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
such	B-X
viruses	B-X
may	B-X
represent	B-X
improved	B-X
vaccine	B-X
candidates	B-X
because	B-X
their	B-X
replication	B-X
can	B-X
be	B-X
turned	B-X
on	B-X
and	B-X
off	B-X
at	B-X
will	B-X
<EOS>	B-X
This	B-X
was	B-X
achieved	B-X
by	B-X
replacement	B-X
of	B-X
the	B-X
viral	B-X
TAR	B-X
-	B-X
Tat	B-X
system	B-X
for	B-X
transcriptional	B-X
activation	B-X
by	B-X
the	B-X
Escherichia	B-X
coli	B-X
-	B-X
derived	B-X
Tet	B-X
system	B-X
for	B-X
inducible	B-X
gene	B-X
expression	B-X

Live-attenuated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
variants	O
have	O
shown	O
great	O
promise	O
as	O
AIDS	O
vaccines	O
,	O
but	O
continued	O
replication	O
can	O
lead	O
to	O
the	O
selection	O
of	O
faster-replicating	O
variants	O
that	O
are	O
pathogenic	O
.	O

We	O
therefore	O
designed	O
HIV-1	B-DNA
genomes	I-DNA
that	O
replicate	O
exclusively	O
upon	O
addition	O
of	O
the	O
nontoxic	O
effector	O
doxycycline	O
(	O
dox	O
)	O
.	O
<EOS>	B-X
We	B-X
therefore	B-X
designed	B-X
HIV	B-X
-	B-X
1	B-X
genomes	B-X
that	B-X
replicate	B-X
exclusively	B-X
upon	B-X
addition	B-X
of	B-X
the	B-X
nontoxic	B-X
effector	B-X
doxycycline	B-X
(	B-X
dox	B-X
)	B-X
<EOS>	B-X
These	B-X
designer	B-X
``	B-X
HIV	B-X
-	B-X
rtTA	B-X
''	B-X
viruses	B-X
replicate	B-X
in	B-X
a	B-X
strictly	B-X
dox	B-X
-	B-X
dependent	B-X
manner	B-X
both	B-X
in	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
and	B-X
in	B-X
primary	B-X
blood	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
rate	B-X
of	B-X
replication	B-X
can	B-X
be	B-X
fine	B-X
-	B-X
tuned	B-X
by	B-X
simple	B-X
variation	B-X
of	B-X
the	B-X
dox	B-X
concentration	B-X
<EOS>	B-X
Live	B-X
-	B-X
attenuated	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
variants	B-X
have	B-X
shown	B-X
great	B-X
promise	B-X
as	B-X
AIDS	B-X
vaccines	B-X
,	B-X
but	B-X
continued	B-X
replication	B-X
can	B-X
lead	B-X
to	B-X
the	B-X
selection	B-X
of	B-X
faster	B-X
-	B-X
replicating	B-X
variants	B-X
that	B-X
are	B-X
pathogenic	B-X
<EOS>	B-X
This	B-X
was	B-X
achieved	B-X
by	B-X
replacement	B-X
of	B-X
the	B-X
viral	B-X
TAR	B-X
-	B-X
Tat	B-X
system	B-X
for	B-X
transcriptional	B-X
activation	B-X
by	B-X
the	B-X
Escherichia	B-X
coli	B-X
-	B-X
derived	B-X
Tet	B-X
system	B-X
for	B-X
inducible	B-X
gene	B-X
expression	B-X

This	O
was	O
achieved	O
by	O
replacement	O
of	O
the	O
viral	O
TAR-Tat	O
system	O
for	O
transcriptional	O
activation	O
by	O
the	O
Escherichia	O
coli-derived	O
Tet	O
system	O
for	O
inducible	O
gene	O
expression	O
.	O
<EOS>	B-X
This	B-X
was	B-X
achieved	B-X
by	B-X
replacement	B-X
of	B-X
the	B-X
viral	B-X
TAR	B-X
-	B-X
Tat	B-X
system	B-X
for	B-X
transcriptional	B-X
activation	B-X
by	B-X
the	B-X
Escherichia	B-X
coli	B-X
-	B-X
derived	B-X
Tet	B-X
system	B-X
for	B-X
inducible	B-X
gene	B-X
expression	B-X
<EOS>	B-X
In	B-X
this	B-X
virus	B-X
,	B-X
additional	B-X
deletions	B-X
and	B-X
/	B-X
or	B-X
inactivating	B-X
mutations	B-X
were	B-X
introduced	B-X
in	B-X
the	B-X
genes	B-X
for	B-X
accessory	B-X
proteins	B-X
<EOS>	B-X
These	B-X
proteins	B-X
are	B-X
essential	B-X
for	B-X
virus	B-X
replication	B-X
in	B-X
untransformed	B-X
cells	B-X
,	B-X
but	B-X
dispensable	B-X
in	B-X
leukemic	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
optimised	B-X
Tet	B-X
system	B-X
may	B-X
be	B-X
of	B-X
particular	B-X
use	B-X
in	B-X
other	B-X
applications	B-X
such	B-X
as	B-X
inducible	B-X
expression	B-X
of	B-X
gene	B-X
therapy	B-X
vectors	B-X
in	B-X
the	B-X
brain	B-X

These	O
designer	O
``	O
HIV-rtTA	O
''	O
viruses	O
replicate	O
in	O
a	O
strictly	O
dox-dependent	O
manner	O
both	O
in	O
a	O
T-cell	B-cell_line
line	I-cell_line
and	O
in	O
primary	B-cell_type
blood	I-cell_type
cells	I-cell_type
,	O
and	O
the	O
rate	O
of	O
replication	O
can	O
be	O
fine-tuned	O
by	O
simple	O
variation	O
of	O
the	O
dox	O
concentration	O
.	O

These	O
HIV-rtTA	O
viruses	O
provide	O
a	O
tool	O
to	O
perform	O
genetics	O
,	O
e.g.	O
,	O
selection	O
and	O
optimization	O
experiments	O
,	O
with	O
the	O
E.	O
coli-derived	O
Tet	O
reagents	O
in	O
a	O
eukaryotic	O
background	O
.	O

Furthermore	O
,	O
such	O
viruses	O
may	O
represent	O
improved	O
vaccine	O
candidates	O
because	O
their	O
replication	O
can	O
be	O
turned	O
on	O
and	O
off	O
at	O
will	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
such	B-X
viruses	B-X
may	B-X
represent	B-X
improved	B-X
vaccine	B-X
candidates	B-X
because	B-X
their	B-X
replication	B-X
can	B-X
be	B-X
turned	B-X
on	B-X
and	B-X
off	B-X
at	B-X
will	B-X
<EOS>	B-X
These	B-X
designer	B-X
``	B-X
HIV	B-X
-	B-X
rtTA	B-X
''	B-X
viruses	B-X
replicate	B-X
in	B-X
a	B-X
strictly	B-X
dox	B-X
-	B-X
dependent	B-X
manner	B-X
both	B-X
in	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
and	B-X
in	B-X
primary	B-X
blood	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
rate	B-X
of	B-X
replication	B-X
can	B-X
be	B-X
fine	B-X
-	B-X
tuned	B-X
by	B-X
simple	B-X
variation	B-X
of	B-X
the	B-X
dox	B-X
concentration	B-X
<EOS>	B-X
Strict	B-X
control	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
replication	B-X
by	B-X
a	B-X
genetic	B-X
switch	B-X
:	B-X
Tet	B-X
for	B-X
Tat	B-X
.	B-X
<EOS>	B-X
Live	B-X
-	B-X
attenuated	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
variants	B-X
have	B-X
shown	B-X
great	B-X
promise	B-X
as	B-X
AIDS	B-X
vaccines	B-X
,	B-X
but	B-X
continued	B-X
replication	B-X
can	B-X
lead	B-X
to	B-X
the	B-X
selection	B-X
of	B-X
faster	B-X
-	B-X
replicating	B-X
variants	B-X
that	B-X
are	B-X
pathogenic	B-X

Synovial	O
fluid	O
induced	O
nuclear	B-protein
factor-kappaB	I-protein
DNA	O
binding	O
in	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
effects	O
of	O
synovial	O
fluids	O
(	O
SF	O
)	O
on	O
DNA	O
binding	O
activity	O
of	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
in	O
the	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
monocytic/macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
as	O
a	O
model	O
for	O
the	O
interaction	O
between	O
SF	O
and	O
synovial	B-cell_type
tissue	I-cell_type
macrophages	I-cell_type
in	O
arthritis	O
.	O

METHODS	O
:	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
were	O
incubated	O
with	O
SF	O
from	O
the	O
knee	O
joints	O
of	O
human	O
subjects	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
undifferentiated	O
seronegative	O
oligoarthritis	O
,	O
and	O
osteoarthritis	O
(	O
OA	O
)	O
.	O
<EOS>	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
SF	B-X
from	B-X
the	B-X
knee	B-X
joints	B-X
of	B-X
human	B-X
subjects	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
,	B-X
undifferentiated	B-X
seronegative	B-X
oligoarthritis	B-X
,	B-X
and	B-X
osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
<EOS>	B-X
Induction	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
by	B-X
the	B-X
p65	B-X
(	B-X
RelA	B-X
)	B-X
	B-X
/	B-X
p50	B-X
heterodimer	B-X
was	B-X
observed	B-X
in	B-X
response	B-X
to	B-X
incubation	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
SF	B-X
(	B-X
20	B-X
%	B-X
in	B-X
culture	B-X
medium	B-X
)	B-X
from	B-X
5	B-X
of	B-X
8	B-X
subjects	B-X
with	B-X
RA	B-X
,	B-X
4	B-X
of	B-X
5	B-X
with	B-X
OA	B-X
,	B-X
and	B-X
none	B-X
of	B-X
3	B-X
with	B-X
undifferentiated	B-X
seronegative	B-X
oligoarthritis	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
effects	B-X
of	B-X
synovial	B-X
fluids	B-X
(	B-X
SF	B-X
)	B-X
on	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
in	B-X
the	B-X
Mono	B-X
Mac	B-X
6	B-X
monocytic	B-X
/	B-X
macrophage	B-X
cell	B-X
line	B-X
as	B-X
a	B-X
model	B-X
for	B-X
the	B-X
interaction	B-X
between	B-X
SF	B-X
and	B-X
synovial	B-X
tissue	B-X
macrophages	B-X
in	B-X
arthritis	B-X
<EOS>	B-X
Biological	B-X
activity	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
in	B-X
SF	B-X
from	B-X
RA	B-X
and	B-X
OA	B-X
subjects	B-X
is	B-X
capable	B-X
of	B-X
inducing	B-X
p65	B-X
/	B-X
p50	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
macrophages	B-X

Nuclear	O
extracts	O
prepared	O
from	O
the	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
and	O
RA	O
synovial	O
tissue	O
were	O
analyzed	O
by	O
electrophoretic	O
mobility	O
shift	O
analysis	O
(	O
EMSA	O
)	O
for	O
NF-kappaB	B-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
.	O
<EOS>	B-X
Nuclear	B-X
extracts	B-X
prepared	B-X
from	B-X
the	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
and	B-X
RA	B-X
synovial	B-X
tissue	B-X
were	B-X
analyzed	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
analysis	B-X
(	B-X
EMSA	B-X
)	B-X
for	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
proteins	B-X
<EOS>	B-X
A	B-X
property	B-X
of	B-X
SF	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
and	B-X
other	B-X
cytokines	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
novel	B-X
slowly	B-X
migrating	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
binding	B-X
complex	B-X
<EOS>	B-X
Biological	B-X
activity	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
in	B-X
SF	B-X
from	B-X
RA	B-X
and	B-X
OA	B-X
subjects	B-X
is	B-X
capable	B-X
of	B-X
inducing	B-X
p65	B-X
/	B-X
p50	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
macrophages	B-X
<EOS>	B-X
Induction	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
by	B-X
the	B-X
p65	B-X
(	B-X
RelA	B-X
)	B-X
	B-X
/	B-X
p50	B-X
heterodimer	B-X
was	B-X
observed	B-X
in	B-X
response	B-X
to	B-X
incubation	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
SF	B-X
(	B-X
20	B-X
%	B-X
in	B-X
culture	B-X
medium	B-X
)	B-X
from	B-X
5	B-X
of	B-X
8	B-X
subjects	B-X
with	B-X
RA	B-X
,	B-X
4	B-X
of	B-X
5	B-X
with	B-X
OA	B-X
,	B-X
and	B-X
none	B-X
of	B-X
3	B-X
with	B-X
undifferentiated	B-X
seronegative	B-X
oligoarthritis	B-X

RESULTS	O
:	O
Induction	O
of	O
NF-kappaB	B-protein
DNA	O
binding	O
by	O
the	O
p65	B-protein
(	I-protein
RelA	I-protein
)	I-protein
/p50	I-protein
heterodimer	I-protein
was	O
observed	O
in	O
response	O
to	O
incubation	O
of	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
with	O
SF	O
(	O
20	O
%	O
in	O
culture	O
medium	O
)	O
from	O
5	O
of	O
8	O
subjects	O
with	O
RA	O
,	O
4	O
of	O
5	O
with	O
OA	O
,	O
and	O
none	O
of	O
3	O
with	O
undifferentiated	O
seronegative	O
oligoarthritis	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
by	B-X
the	B-X
p65	B-X
(	B-X
RelA	B-X
)	B-X
	B-X
/	B-X
p50	B-X
heterodimer	B-X
was	B-X
observed	B-X
in	B-X
response	B-X
to	B-X
incubation	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
SF	B-X
(	B-X
20	B-X
%	B-X
in	B-X
culture	B-X
medium	B-X
)	B-X
from	B-X
5	B-X
of	B-X
8	B-X
subjects	B-X
with	B-X
RA	B-X
,	B-X
4	B-X
of	B-X
5	B-X
with	B-X
OA	B-X
,	B-X
and	B-X
none	B-X
of	B-X
3	B-X
with	B-X
undifferentiated	B-X
seronegative	B-X
oligoarthritis	B-X
<EOS>	B-X
Unexpectedly	B-X
,	B-X
a	B-X
slowly	B-X
migrating	B-X
SF	B-X
inducible	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
binding	B-X
complex	B-X
was	B-X
observed	B-X
in	B-X
EMSA	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
after	B-X
incubation	B-X
with	B-X
SF	B-X
from	B-X
5	B-X
of	B-X
8	B-X
RA	B-X
and	B-X
2	B-X
of	B-X
5	B-X
OA	B-X
subjects	B-X
<EOS>	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
SF	B-X
from	B-X
the	B-X
knee	B-X
joints	B-X
of	B-X
human	B-X
subjects	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
,	B-X
undifferentiated	B-X
seronegative	B-X
oligoarthritis	B-X
,	B-X
and	B-X
osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
<EOS>	B-X
Soluble	B-X
mediators	B-X
in	B-X
SF	B-X
of	B-X
subjects	B-X
with	B-X
RA	B-X
and	B-X
OA	B-X
can	B-X
therefore	B-X
modulate	B-X
binding	B-X
of	B-X
nuclear	B-X
proteins	B-X
to	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
site	B-X
in	B-X
macrophages	B-X
and	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
arthritis	B-X

Incubation	O
of	O
SF	O
with	O
neutralizing	B-protein
antibodies	I-protein
against	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	I-protein
TNF-alpha	I-protein
)	I-protein
,	O
but	O
not	O
antibodies	B-protein
against	O
interleukin	B-protein
6	I-protein
(	I-protein
IL-6	I-protein
)	I-protein
,	O
significantly	O
reduced	O
the	O
induction	O
of	O
p65/p50	O
binding	O
activity	O
in	O
SF	O
from	O
subjects	O
with	O
RA	O
and	O
OA	O
.	O

Unexpectedly	O
,	O
a	O
slowly	O
migrating	O
SF	O
inducible	O
NF-kappaB	B-protein
-binding	O
complex	O
was	O
observed	O
in	O
EMSA	O
of	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
after	O
incubation	O
with	O
SF	O
from	O
5	O
of	O
8	O
RA	O
and	O
2	O
of	O
5	O
OA	O
subjects	O
.	O
<EOS>	B-X
Unexpectedly	B-X
,	B-X
a	B-X
slowly	B-X
migrating	B-X
SF	B-X
inducible	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
binding	B-X
complex	B-X
was	B-X
observed	B-X
in	B-X
EMSA	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
after	B-X
incubation	B-X
with	B-X
SF	B-X
from	B-X
5	B-X
of	B-X
8	B-X
RA	B-X
and	B-X
2	B-X
of	B-X
5	B-X
OA	B-X
subjects	B-X
<EOS>	B-X
Induction	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
by	B-X
the	B-X
p65	B-X
(	B-X
RelA	B-X
)	B-X
	B-X
/	B-X
p50	B-X
heterodimer	B-X
was	B-X
observed	B-X
in	B-X
response	B-X
to	B-X
incubation	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
SF	B-X
(	B-X
20	B-X
%	B-X
in	B-X
culture	B-X
medium	B-X
)	B-X
from	B-X
5	B-X
of	B-X
8	B-X
subjects	B-X
with	B-X
RA	B-X
,	B-X
4	B-X
of	B-X
5	B-X
with	B-X
OA	B-X
,	B-X
and	B-X
none	B-X
of	B-X
3	B-X
with	B-X
undifferentiated	B-X
seronegative	B-X
oligoarthritis	B-X
<EOS>	B-X
A	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
binding	B-X
complex	B-X
with	B-X
similar	B-X
slow	B-X
mobility	B-X
was	B-X
observed	B-X
in	B-X
nuclear	B-X
extracts	B-X
prepared	B-X
from	B-X
fresh	B-X
human	B-X
RA	B-X
synovial	B-X
tissue	B-X
<EOS>	B-X
Incubation	B-X
of	B-X
SF	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
against	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
but	B-X
not	B-X
antibodies	B-X
against	B-X
interleukin	B-X
6	B-X
(	B-X
IL	B-X
-	B-X
6	B-X
)	B-X
,	B-X
significantly	B-X
reduced	B-X
the	B-X
induction	B-X
of	B-X
p65	B-X
/	B-X
p50	B-X
binding	B-X
activity	B-X
in	B-X
SF	B-X
from	B-X
subjects	B-X
with	B-X
RA	B-X
and	B-X
OA	B-X

The	O
induction	O
of	O
this	O
complex	O
by	O
SF	O
was	O
not	O
affected	O
by	O
neutralization	O
of	O
TNF-alpha	B-protein
or	O
IL-6	B-protein
in	O
SF	O
,	O
and	O
the	O
complex	O
was	O
not	O
inducible	O
by	O
TNF-alpha	B-protein
,	O
IL-1beta	O
,	O
TNF-alpha	B-protein
/	O
IL-1beta	B-protein
,	O
IL-6	B-protein
,	O
platelet	B-protein
derived	I-protein
growth	I-protein
factor	I-protein
,	O
lipopolysaccharide	O
,	O
or	O
tetradecanoyl	O
phorbol	O
acetate	O
.	O
<EOS>	B-X
The	B-X
Toll	B-X
-	B-X
like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
	B-X
/	B-X
myeloid	B-X
differentiation	B-X
protein	B-X
-	B-X
2	B-X
(	B-X
MD	B-X
-	B-X
2	B-X
)	B-X
complex	B-X
is	B-X
considered	B-X
the	B-X
major	B-X
receptor	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
to	B-X
recognize	B-X
lipopolysaccharides	B-X
(	B-X
LPSs	B-X
)	B-X
<EOS>	B-X
The	B-X
19	B-X
evidence	B-X
-	B-X
based	B-X
statements	B-X
are	B-X
supported	B-X
by	B-X
information	B-X
on	B-X
the	B-X
quality	B-X
of	B-X
the	B-X
evidence	B-X
,	B-X
agreement	B-X
rate	B-X
among	B-X
panel	B-X
members	B-X
,	B-X
and	B-X
panel	B-X
comments	B-X
mainly	B-X
based	B-X
on	B-X
evidence	B-X
from	B-X
real	B-X
world	B-X
studies	B-X
<EOS>	B-X
This	B-X
could	B-X
be	B-X
shown	B-X
by	B-X
reporter	B-X
gene	B-X
assays	B-X
,	B-X
DNA	B-X
-	B-X
binding	B-X
measurements	B-X
,	B-X
and	B-X
immune	B-X
-	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
furthermore	B-X
by	B-X
a	B-X
whole	B-X
set	B-X
of	B-X
computational	B-X
methods	B-X
using	B-X
a	B-X
variety	B-X
of	B-X
datasets	B-X
<EOS>	B-X
Formalin	B-X
injection	B-X
into	B-X
rat	B-X
hind	B-X
paws	B-X
(	B-X
7	B-X
days	B-X
)	B-X
and	B-X
the	B-X
application	B-X
of	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoyl	B-X
phorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
TPA	B-X
)	B-X
on	B-X
mouse	B-X
ears	B-X
(	B-X
9	B-X
days	B-X
)	B-X
were	B-X
used	B-X
to	B-X
simulate	B-X
chronic	B-X
inflammation	B-X

The	O
slowly	O
migrating	B-protein
complex	I-protein
could	O
not	O
be	O
supershifted	O
with	O
antibodies	B-protein
against	O
NF-kappaB	B-protein
,	O
Jun	B-protein
,	O
or	O
the	O
transcriptional	O
coactivators	O
p300	B-protein
or	O
CBP	B-protein
.	O
<EOS>	B-X
Eleven	B-X
of	B-X
these	B-X
14	B-X
MMP	B-X
gene	B-X
promoters	B-X
contained	B-X
a	B-X
Runx2	B-X
(	B-X
runt	B-X
-	B-X
related	B-X
transcription	B-X
factor	B-X
2	B-X
)	B-X
binding	B-X
site	B-X
<EOS>	B-X
The	B-X
association	B-X
with	B-X
nighttime	B-X
BP	B-X
was	B-X
linearly	B-X
positive	B-X
for	B-X
brachial	B-X
BPs	B-X
,	B-X
and	B-X
only	B-X
increasing	B-X
for	B-X
Q5	B-X
for	B-X
cBP	B-X
<EOS>	B-X
Studies	B-X
on	B-X
the	B-X
role	B-X
of	B-X
transcription	B-X
factor	B-X
MYB	B-X
in	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
have	B-X
identified	B-X
MYB	B-X
as	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
a	B-X
transcriptional	B-X
program	B-X
for	B-X
self	B-X
-	B-X
renewal	B-X
of	B-X
AML	B-X
cells	B-X
<EOS>	B-X
Follow	B-X
-	B-X
up	B-X
transcriptional	B-X
analysis	B-X
suggested	B-X
that	B-X
L	B-X
-	B-X
Moses	B-X
provided	B-X
neuroprotection	B-X
by	B-X
partly	B-X
reversing	B-X
the	B-X
transcriptional	B-X
changes	B-X
caused	B-X
by	B-X
Tunicamycin	B-X

A	O
NF-kappaB-binding	B-protein
complex	I-protein
with	O
similar	O
slow	O
mobility	O
was	O
observed	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
fresh	O
human	O
RA	O
synovial	O
tissue	O
.	O
<EOS>	B-X
A	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
binding	B-X
complex	B-X
with	B-X
similar	B-X
slow	B-X
mobility	B-X
was	B-X
observed	B-X
in	B-X
nuclear	B-X
extracts	B-X
prepared	B-X
from	B-X
fresh	B-X
human	B-X
RA	B-X
synovial	B-X
tissue	B-X
<EOS>	B-X
Induction	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
by	B-X
the	B-X
p65	B-X
(	B-X
RelA	B-X
)	B-X
	B-X
/	B-X
p50	B-X
heterodimer	B-X
was	B-X
observed	B-X
in	B-X
response	B-X
to	B-X
incubation	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
SF	B-X
(	B-X
20	B-X
%	B-X
in	B-X
culture	B-X
medium	B-X
)	B-X
from	B-X
5	B-X
of	B-X
8	B-X
subjects	B-X
with	B-X
RA	B-X
,	B-X
4	B-X
of	B-X
5	B-X
with	B-X
OA	B-X
,	B-X
and	B-X
none	B-X
of	B-X
3	B-X
with	B-X
undifferentiated	B-X
seronegative	B-X
oligoarthritis	B-X
<EOS>	B-X
Unexpectedly	B-X
,	B-X
a	B-X
slowly	B-X
migrating	B-X
SF	B-X
inducible	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
binding	B-X
complex	B-X
was	B-X
observed	B-X
in	B-X
EMSA	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
after	B-X
incubation	B-X
with	B-X
SF	B-X
from	B-X
5	B-X
of	B-X
8	B-X
RA	B-X
and	B-X
2	B-X
of	B-X
5	B-X
OA	B-X
subjects	B-X
<EOS>	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
SF	B-X
from	B-X
the	B-X
knee	B-X
joints	B-X
of	B-X
human	B-X
subjects	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
,	B-X
undifferentiated	B-X
seronegative	B-X
oligoarthritis	B-X
,	B-X
and	B-X
osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X

CONCLUSION	O
:	O
Biological	O
activity	O
of	O
TNF-alpha	B-protein
in	O
SF	O
from	O
RA	O
and	O
OA	O
subjects	O
is	O
capable	O
of	O
inducing	O
p65/p50	B-protein
NF-kappaB	I-protein
DNA	O
binding	O
activity	O
in	O
macrophages	B-cell_type
.	O
<EOS>	B-X
Biological	B-X
activity	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
in	B-X
SF	B-X
from	B-X
RA	B-X
and	B-X
OA	B-X
subjects	B-X
is	B-X
capable	B-X
of	B-X
inducing	B-X
p65	B-X
/	B-X
p50	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
macrophages	B-X
<EOS>	B-X
Synovial	B-X
fluid	B-X
induced	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
in	B-X
a	B-X
monocytic	B-X
cell	B-X
line	B-X
.	B-X
<EOS>	B-X
Incubation	B-X
of	B-X
SF	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
against	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
but	B-X
not	B-X
antibodies	B-X
against	B-X
interleukin	B-X
6	B-X
(	B-X
IL	B-X
-	B-X
6	B-X
)	B-X
,	B-X
significantly	B-X
reduced	B-X
the	B-X
induction	B-X
of	B-X
p65	B-X
/	B-X
p50	B-X
binding	B-X
activity	B-X
in	B-X
SF	B-X
from	B-X
subjects	B-X
with	B-X
RA	B-X
and	B-X
OA	B-X
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
this	B-X
complex	B-X
by	B-X
SF	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
neutralization	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
or	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
SF	B-X
,	B-X
and	B-X
the	B-X
complex	B-X
was	B-X
not	B-X
inducible	B-X
by	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
TNF	B-X
-	B-X
alpha	B-X
/	B-X
IL	B-X
-	B-X
1beta	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
platelet	B-X
derived	B-X
growth	B-X
factor	B-X
,	B-X
lipopolysaccharide	B-X
,	B-X
or	B-X
tetradecanoyl	B-X
phorbol	B-X
acetate	B-X

A	O
property	O
of	O
SF	O
that	O
is	O
independent	O
of	O
TNF-alpha	B-protein
and	O
other	O
cytokines	B-protein
is	O
responsible	O
for	O
the	O
induction	O
of	O
a	O
novel	O
slowly	O
migrating	O
NF-kappaB-binding	B-protein
complex	I-protein
.	O
<EOS>	B-X
A	B-X
property	B-X
of	B-X
SF	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
and	B-X
other	B-X
cytokines	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
novel	B-X
slowly	B-X
migrating	B-X
NF	B-X
-	B-X
kappaB	B-X
-	B-X
binding	B-X
complex	B-X
<EOS>	B-X
Incubation	B-X
of	B-X
SF	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
against	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
but	B-X
not	B-X
antibodies	B-X
against	B-X
interleukin	B-X
6	B-X
(	B-X
IL	B-X
-	B-X
6	B-X
)	B-X
,	B-X
significantly	B-X
reduced	B-X
the	B-X
induction	B-X
of	B-X
p65	B-X
/	B-X
p50	B-X
binding	B-X
activity	B-X
in	B-X
SF	B-X
from	B-X
subjects	B-X
with	B-X
RA	B-X
and	B-X
OA	B-X
<EOS>	B-X
Nuclear	B-X
extracts	B-X
prepared	B-X
from	B-X
the	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
and	B-X
RA	B-X
synovial	B-X
tissue	B-X
were	B-X
analyzed	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
analysis	B-X
(	B-X
EMSA	B-X
)	B-X
for	B-X
NF	B-X
-	B-X
kappaB	B-X
DNA	B-X
binding	B-X
proteins	B-X
<EOS>	B-X
Soluble	B-X
mediators	B-X
in	B-X
SF	B-X
of	B-X
subjects	B-X
with	B-X
RA	B-X
and	B-X
OA	B-X
can	B-X
therefore	B-X
modulate	B-X
binding	B-X
of	B-X
nuclear	B-X
proteins	B-X
to	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
site	B-X
in	B-X
macrophages	B-X
and	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
arthritis	B-X

Soluble	O
mediators	O
in	O
SF	O
of	O
subjects	O
with	O
RA	O
and	O
OA	O
can	O
therefore	O
modulate	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
to	O
the	O
NF-kappaB	B-protein
binding	I-protein
site	I-protein
in	O
macrophages	B-cell_type
and	O
may	O
play	O
a	O
role	O
in	O
inflammatory	O
gene	O
expression	O
in	O
arthritis	O
.	O

Peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
agonists	O
and	O
15-deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
(	O
12	O
,	O
14	O
)	O
-PGJ	O
(	O
2	O
)	O
induce	O
apoptosis	O
in	O
normal	O
and	O
malignant	O
B-lineage	B-cell_type
cells	I-cell_type
.	O

The	O
research	O
described	O
herein	O
evaluates	O
the	O
expression	O
and	O
functional	O
significance	O
of	O
peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
(	I-protein
PPAR-gamma	I-protein
)	I-protein
on	O
B-lineage	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
research	B-X
described	B-X
herein	B-X
evaluates	B-X
the	B-X
expression	B-X
and	B-X
functional	B-X
significance	B-X
of	B-X
peroxisome	B-X
proliferator	B-X
activator	B-X
receptor	B-X
-	B-X
gamma	B-X
(	B-X
PPAR	B-X
-	B-X
gamma	B-X
)	B-X
on	B-X
B	B-X
-	B-X
lineage	B-X
cells	B-X
<EOS>	B-X
This	B-X
is	B-X
the	B-X
first	B-X
study	B-X
evaluating	B-X
PPAR	B-X
-	B-X
gamma	B-X
expression	B-X
and	B-X
its	B-X
significance	B-X
on	B-X
B	B-X
lymphocytes	B-X
<EOS>	B-X
Peroxisome	B-X
proliferator	B-X
activator	B-X
receptor	B-X
-	B-X
gamma	B-X
agonists	B-X
and	B-X
15	B-X
-	B-X
deoxy	B-X
-	B-X
Delta	B-X
(	B-X
12,14	B-X
)	B-X
(	B-X
12,14	B-X
)	B-X
	B-X
-	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
induce	B-X
apoptosis	B-X
in	B-X
normal	B-X
and	B-X
malignant	B-X
B	B-X
-	B-X
lineage	B-X
cells	B-X
.	B-X
<EOS>	B-X
,	B-X
70Z	B-X
/	B-X
3	B-X
,	B-X
CH31	B-X
,	B-X
WEHI	B-X
-	B-X
231	B-X
,	B-X
CH12	B-X
,	B-X
and	B-X
J558	B-X
)	B-X
express	B-X
PPAR	B-X
-	B-X
gamma	B-X
mRNA	B-X
and	B-X
,	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
the	B-X
67	B-X
-	B-X
kDa	B-X
PPAR	B-X
-	B-X
gamma	B-X
protein	B-X

Normal	B-cell_type
mouse	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
a	O
variety	O
of	O
B	B-cell_type
lymphoma	I-cell_type
cells	I-cell_type
reflective	O
of	O
stages	O
of	O
B	O
cell	O
differentiation	O
(	O
e.g.	O
,	O
70Z/3	O
,	O
CH31	O
,	O
WEHI-231	O
,	O
CH12	O
,	O
and	O
J558	O
)	O
express	O
PPAR-gamma	B-RNA
mRNA	I-RNA
and	O
,	O
by	O
Western	O
blot	O
analysis	O
,	O
the	O
67-kDa	B-protein
PPAR-gamma	I-protein
protein	I-protein
.	O

15-Deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
-PGJ	O
(	O
2	O
)	O
(	O
15d-PGJ	O
(	O
2	O
)	O
)	O
,	O
a	O
PPAR-gamma	O
agonist	O
,	O
has	O
a	O
dose-dependent	O
antiproliferative	O
and	O
cytotoxic	O
effect	O
on	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
B	I-cell_type
cells	I-cell_type
as	O
shown	O
by	O
[	O
(	O
3	O
)	O
H	O
]	O
thymidine	O
and	O
3-	O
[	O
4	O
,	O
5-dimethylthiazol-2-yl	O
]	O
-2	O
,	O
5-diphenyltetrazolium	O
bromide	O
assays	O
.	O

Only	O
PPAR-gamma	O
agonists	O
(	O
thiazolidinediones	O
)	O
,	O
and	O
not	O
PPAR-alpha	O
agonists	O
,	O
mimicked	O
the	O
effect	O
of	O
15d-PGJ	O
(	O
2	O
)	O
on	O
B-lineage	B-cell_type
cells	I-cell_type
,	O
indicating	O
that	O
the	O
mechanism	O
by	O
which	O
15d-PGJ	O
(	O
2	O
)	O
negatively	O
affects	O
B-lineage	B-cell_type
cells	I-cell_type
involves	O
in	O
part	O
PPAR-gamma	B-protein
.	O

The	O
mechanism	O
by	O
which	O
PPAR-gamma	O
agonists	O
induce	O
cytotoxicity	O
is	O
via	O
apoptosis	O
,	O
as	O
shown	O
by	O
annexin	O
V	O
staining	O
and	O
as	O
confirmed	O
by	O
DNA	O
fragmentation	O
detected	O
using	O
the	O
TUNEL	O
assay	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
PPAR	B-X
-	B-X
gamma	B-X
agonists	B-X
induce	B-X
cytotoxicity	B-X
is	B-X
via	B-X
apoptosis	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
annexin	B-X
V	B-X
staining	B-X
and	B-X
as	B-X
confirmed	B-X
by	B-X
DNA	B-X
fragmentation	B-X
detected	B-X
using	B-X
the	B-X
TUNEL	B-X
assay	B-X
<EOS>	B-X
The	B-X
mechanism	B-X
whereby	B-X
PPAR	B-X
-	B-X
gamma	B-X
agonists	B-X
induce	B-X
cytotoxicity	B-X
is	B-X
via	B-X
apoptosis	B-X
as	B-X
shown	B-X
by	B-X
Annexin	B-X
V	B-X
staining	B-X
and	B-X
as	B-X
confirmed	B-X
by	B-X
DNA	B-X
fragmentation	B-X
detected	B-X
using	B-X
the	B-X
TUNEL	B-X
assay	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
80	B-X
-	B-X
kDa	B-X
PPAR	B-X
-	B-X
gamma	B-X
on	B-X
human	B-X
B	B-X
lymphocytes	B-X
and	B-X
B	B-X
lymphomas	B-X
was	B-X
confirmed	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
15	B-X
-	B-X
Deoxy	B-X
-	B-X
Delta	B-X
(	B-X
12,14	B-X
)	B-X
	B-X
-	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
(	B-X
15d	B-X
-	B-X
PGJ	B-X
(	B-X
2	B-X
)	B-X
)	B-X
,	B-X
a	B-X
PPAR	B-X
-	B-X
gamma	B-X
agonist	B-X
,	B-X
has	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
antiproliferative	B-X
and	B-X
cytotoxic	B-X
effect	B-X
on	B-X
normal	B-X
and	B-X
malignant	B-X
B	B-X
cells	B-X
as	B-X
shown	B-X
by	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
thymidine	B-X
and	B-X
3	B-X
-	B-X
	B-X
[	B-X
4,5	B-X
-	B-X
dimethylthiazol	B-X
-	B-X
2	B-X
-	B-X
yl	B-X
]	B-X
	B-X
-	B-X
2	B-X
,	B-X
5	B-X
-	B-X
diphenyltetrazolium	B-X
bromide	B-X
assays	B-X

Interestingly	O
,	O
addition	O
of	O
PGF	O
(	O
2alpha	O
)	O
,	O
which	O
was	O
not	O
known	O
to	O
affect	O
lymphocytes	B-cell_type
,	O
dramatically	O
attenuated	O
the	O
deleterious	O
effects	O
of	O
PPAR-gamma	O
agonists	O
on	O
B	B-cell_type
lymphomas	I-cell_type
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
addition	B-X
of	B-X
PGF	B-X
(	B-X
2alpha	B-X
)	B-X
,	B-X
which	B-X
was	B-X
not	B-X
known	B-X
to	B-X
affect	B-X
lymphocytes	B-X
,	B-X
dramatically	B-X
attenuated	B-X
the	B-X
deleterious	B-X
effects	B-X
of	B-X
PPAR	B-X
-	B-X
gamma	B-X
agonists	B-X
on	B-X
B	B-X
lymphomas	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
inhibition	B-X
of	B-X
CES	B-X
by	B-X
bis	B-X
(	B-X
p	B-X
-	B-X
nitrophenyl	B-X
)	B-X
phosphate	B-X
(	B-X
BNPP	B-X
)	B-X
and	B-X
CES2	B-X
by	B-X
loperamide	B-X
enhanced	B-X
the	B-X
cytotoxicity	B-X
of	B-X
BisGMA	B-X
and	B-X
DBA	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
concomitant	B-X
treatment	B-X
with	B-X
PGE2	B-X
or	B-X
PGF	B-X
(	B-X
2alpha	B-X
)	B-X
in	B-X
addition	B-X
to	B-X
indomethacin	B-X
markedly	B-X
reversed	B-X
the	B-X
suppressive	B-X
effect	B-X
of	B-X
indomethacin	B-X
<EOS>	B-X
7	B-X
pM	B-X
for	B-X
24	B-X
h	B-X
)	B-X
stimulated	B-X
the	B-X
production	B-X
of	B-X
PG	B-X
in	B-X
Balb	B-X
/	B-X
c	B-X
3T3	B-X
cells	B-X
(	B-X
the	B-X
concentration	B-X
reached	B-X
3	B-X
-	B-X
4	B-X
microM	B-X
)	B-X
,	B-X
and	B-X
treatment	B-X
with	B-X
PGE2	B-X
or	B-X
PGF	B-X
(	B-X
2alpha	B-X
)	B-X
itself	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
transformed	B-X
foci	B-X
of	B-X
Balb	B-X
/	B-X
c	B-X
3T3	B-X
cells	B-X
after	B-X
initiation	B-X
by	B-X
MCA	B-X

Surprisingly	O
,	O
15d-PGJ	O
(	O
2	O
)	O
induced	O
a	O
massive	O
increase	O
in	O
nuclear	O
mitogen-activated	O
protein	O
kinase	O
activation	O
,	O
and	O
pretreatment	O
with	O
PGF	O
(	O
2alpha	O
)	O
blunted	O
the	O
mitogen-activated	O
protein	O
kinase	O
activation	O
.	O

This	O
is	O
the	O
first	O
study	O
evaluating	O
PPAR-gamma	O
expression	O
and	O
its	O
significance	O
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

PPAR-gamma	O
agonists	O
may	O
serve	O
as	O
a	O
counterbalance	O
to	O
the	O
stimulating	O
effects	O
of	O
other	O
PGs	O
,	O
namely	O
PGE	O
(	O
2	O
)	O
,	O
which	O
promotes	O
B	O
cell	O
differentiation	O
.	O

Finally	O
,	O
the	O
use	O
of	O
PGs	O
,	O
such	O
as	O
15d-PGJ	O
(	O
2	O
)	O
,	O
and	O
synthetic	O
PPAR-gamma	O
agonists	O
to	O
induce	O
apoptosis	O
in	O
B-lineage	B-cell_type
cells	I-cell_type
may	O
lead	O
to	O
the	O
development	O
of	O
novel	O
therapies	O
for	O
fatal	B-cell_type
B	I-cell_type
lymphomas	I-cell_type

Inhibition	O
of	O
STAT3	O
signaling	O
leads	O
to	O
apoptosis	O
of	O
leukemic	B-cell_type
large	I-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
and	O
decreased	O
Mcl-1	O
expression	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
STAT3	B-X
signaling	B-X
leads	B-X
to	B-X
apoptosis	B-X
of	B-X
leukemic	B-X
large	B-X
granular	B-X
lymphocytes	B-X
and	B-X
decreased	B-X
Mcl	B-X
-	B-X
1	B-X
expression	B-X
.	B-X
<EOS>	B-X
AG	B-X
-	B-X
490	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
leukemic	B-X
LGL	B-X
was	B-X
independent	B-X
of	B-X
Bcl	B-X
-	B-X
xL	B-X
or	B-X
Bcl	B-X
-	B-X
2	B-X
expression	B-X
<EOS>	B-X
Activated	B-X
STAT3	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
an	B-X
SIE	B-X
-	B-X
related	B-X
element	B-X
in	B-X
the	B-X
murine	B-X
mcl	B-X
-	B-X
1	B-X
promoter	B-X
<EOS>	B-X
Using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
v	B-X
-	B-X
src	B-X
overexpression	B-X
in	B-X
NIH3T3	B-X
induced	B-X
STAT3	B-X
-	B-X
dependent	B-X
transcriptional	B-X
activity	B-X
from	B-X
the	B-X
mcl	B-X
-	B-X
1	B-X
promoter	B-X
and	B-X
increased	B-X
endogenous	B-X
Mcl	B-X
-	B-X
1	B-X
protein	B-X
levels	B-X

Large	O
granular	O
lymphocyte	O
(	O
LGL	O
)	O
leukemia	O
is	O
characterized	O
by	O
the	O
expansion	O
of	O
antigen-activated	B-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Large	B-X
granular	B-X
lymphocyte	B-X
(	B-X
LGL	B-X
)	B-X
leukemia	B-X
is	B-X
characterized	B-X
by	B-X
the	B-X
expansion	B-X
of	B-X
antigen	B-X
-	B-X
activated	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
Large	B-X
granular	B-X
lymphocyte	B-X
(	B-X
LGL	B-X
)	B-X
leukemia	B-X
is	B-X
a	B-X
chronic	B-X
disease	B-X
characterized	B-X
by	B-X
a	B-X
proliferation	B-X
of	B-X
antigen	B-X
-	B-X
activated	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
STAT3	B-X
activation	B-X
contributed	B-X
to	B-X
accumulation	B-X
of	B-X
the	B-X
leukemic	B-X
LGL	B-X
clones	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
LGL	B-X
from	B-X
19	B-X
patients	B-X
displayed	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
STAT3	B-X

These	O
leukemic	B-cell_type
cells	I-cell_type
are	O
resistant	O
to	O
Fas-mediated	O
apoptosis	O
despite	O
expressing	O
high	O
levels	O
of	O
Fas	B-protein
.	O
<EOS>	B-X
These	B-X
leukemic	B-X
cells	B-X
are	B-X
resistant	B-X
to	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
despite	B-X
expressing	B-X
high	B-X
levels	B-X
of	B-X
Fas	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
leukemic	B-X
LGL	B-X
with	B-X
the	B-X
JAK	B-X
-	B-X
selective	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
AG	B-X
-	B-X
490	B-X
induced	B-X
apoptosis	B-X
with	B-X
a	B-X
corresponding	B-X
decrease	B-X
in	B-X
STAT	B-X
-	B-X
DNA	B-X
binding	B-X
activity	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
investigation	B-X
should	B-X
focus	B-X
on	B-X
novel	B-X
strategies	B-X
targeting	B-X
STAT3	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
LGL	B-X
leukemia	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
LGL	B-X
from	B-X
19	B-X
patients	B-X
displayed	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
STAT3	B-X

We	O
found	O
that	O
leukemic	B-cell_type
LGL	I-cell_type
from	O
19	O
patients	O
displayed	O
high	O
levels	O
of	O
activated	B-protein
STAT3	I-protein
.	O

Treatment	O
of	O
leukemic	B-cell_type
LGL	I-cell_type
with	O
the	O
JAK-selective	O
tyrosine	O
kinase	O
inhibitor	O
AG-490	O
induced	O
apoptosis	O
with	O
a	O
corresponding	O
decrease	O
in	O
STAT	B-protein
-DNA	O
binding	O
activity	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
leukemic	B-X
LGL	B-X
with	B-X
the	B-X
JAK	B-X
-	B-X
selective	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
AG	B-X
-	B-X
490	B-X
induced	B-X
apoptosis	B-X
with	B-X
a	B-X
corresponding	B-X
decrease	B-X
in	B-X
STAT	B-X
-	B-X
DNA	B-X
binding	B-X
activity	B-X
<EOS>	B-X
These	B-X
leukemic	B-X
cells	B-X
are	B-X
resistant	B-X
to	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
despite	B-X
expressing	B-X
high	B-X
levels	B-X
of	B-X
Fas	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
LGL	B-X
from	B-X
19	B-X
patients	B-X
displayed	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
STAT3	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
STAT3	B-X
signaling	B-X
leads	B-X
to	B-X
apoptosis	B-X
of	B-X
leukemic	B-X
large	B-X
granular	B-X
lymphocytes	B-X
and	B-X
decreased	B-X
Mcl	B-X
-	B-X
1	B-X
expression	B-X
.	B-X

Moreover	O
,	O
using	O
an	O
antisense	O
oligonucleotide	O
approach	O
to	O
diminish	O
STAT3	O
expression	O
,	O
we	O
found	O
that	O
Fas	O
sensitivity	O
was	O
restored	O
in	O
leukemic	B-cell_type
LGL	I-cell_type
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
using	B-X
an	B-X
antisense	B-X
oligonucleotide	B-X
approach	B-X
to	B-X
diminish	B-X
STAT3	B-X
expression	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Fas	B-X
sensitivity	B-X
was	B-X
restored	B-X
in	B-X
leukemic	B-X
LGL	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
STAT3	B-X
activation	B-X
contributed	B-X
to	B-X
accumulation	B-X
of	B-X
the	B-X
leukemic	B-X
LGL	B-X
clones	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
investigation	B-X
should	B-X
focus	B-X
on	B-X
novel	B-X
strategies	B-X
targeting	B-X
STAT3	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
LGL	B-X
leukemia	B-X
<EOS>	B-X
Large	B-X
granular	B-X
lymphocyte	B-X
(	B-X
LGL	B-X
)	B-X
leukemia	B-X
is	B-X
characterized	B-X
by	B-X
the	B-X
expansion	B-X
of	B-X
antigen	B-X
-	B-X
activated	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X

AG-490-induced	O
apoptosis	O
in	O
leukemic	B-cell_type
LGL	I-cell_type
was	O
independent	O
of	O
Bcl-xL	O
or	O
Bcl-2	O
expression	O
.	O
<EOS>	B-X
Hyperoxia	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
alveolar	B-X
epithelial	B-X
type	B-X
II	B-X
cells	B-X
(	B-X
AECIIs	B-X
)	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
bronchopulmonary	B-X
dysplasia	B-X
(	B-X
BPD	B-X
)	B-X
<EOS>	B-X
Although	B-X
sensitivity	B-X
to	B-X
venetoclax	B-X
was	B-X
reflected	B-X
by	B-X
BCL	B-X
-	B-X
2	B-X
levels	B-X
,	B-X
not	B-X
all	B-X
cell	B-X
lines	B-X
responded	B-X
consistently	B-X
despite	B-X
their	B-X
high	B-X
BCL	B-X
-	B-X
2	B-X
expression	B-X
<EOS>	B-X
Lead	B-X
-	B-X
induced	B-X
cardiomyocytes	B-X
apoptosis	B-X
by	B-X
inhibiting	B-X
gap	B-X
junction	B-X
intercellular	B-X
communication	B-X
via	B-X
modulating	B-X
the	B-X
PKCα	B-X
/	B-X
Cx43	B-X
signaling	B-X
pathway	B-X
.	B-X
<EOS>	B-X
Apoptotic	B-X
markers	B-X
,	B-X
including	B-X
Bax	B-X
/	B-X
Bcl	B-X
-	B-X
2	B-X
(	B-X
P	B-X
<	B-X
0	B-X

However	O
,	O
we	O
found	O
that	O
the	O
Bcl-2-family	B-protein
protein	I-protein
Mcl-1	I-protein
was	O
significantly	O
reduced	O
by	O
AG-490	O
treatment	O
.	O
<EOS>	B-X
However	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
Bcl	B-X
-	B-X
2	B-X
-	B-X
family	B-X
protein	B-X
Mcl	B-X
-	B-X
1	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
AG	B-X
-	B-X
490	B-X
treatment	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
LGL	B-X
from	B-X
19	B-X
patients	B-X
displayed	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
STAT3	B-X
<EOS>	B-X
PEL	B-X
cells	B-X
relay	B-X
on	B-X
the	B-X
constitutive	B-X
activation	B-X
of	B-X
STAT3	B-X
for	B-X
their	B-X
survival	B-X
,	B-X
thus	B-X
its	B-X
inhibition	B-X
by	B-X
AG490	B-X
leads	B-X
to	B-X
apoptotic	B-X
cell	B-X
death	B-X
<EOS>	B-X
AG490	B-X
as	B-X
well	B-X
as	B-X
HSF1	B-X
siRNA	B-X
reduced	B-X
the	B-X
expression	B-X
of	B-X
Mcl	B-X
-	B-X
1	B-X
,	B-X
a	B-X
Bcl	B-X
-	B-X
2	B-X
family	B-X
member	B-X
that	B-X
negatively	B-X
regulates	B-X
apoptosis	B-X
and	B-X
autophagy	B-X

Activated	B-protein
STAT3	I-protein
was	O
shown	O
to	O
bind	O
an	O
SIE-related	B-DNA
element	I-DNA
in	O
the	O
murine	B-DNA
mcl-1	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Activated	B-X
STAT3	B-X
was	B-X
shown	B-X
to	B-X
bind	B-X
an	B-X
SIE	B-X
-	B-X
related	B-X
element	B-X
in	B-X
the	B-X
murine	B-X
mcl	B-X
-	B-X
1	B-X
promoter	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
STAT3	B-X
signaling	B-X
leads	B-X
to	B-X
apoptosis	B-X
of	B-X
leukemic	B-X
large	B-X
granular	B-X
lymphocytes	B-X
and	B-X
decreased	B-X
Mcl	B-X
-	B-X
1	B-X
expression	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
investigation	B-X
should	B-X
focus	B-X
on	B-X
novel	B-X
strategies	B-X
targeting	B-X
STAT3	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
LGL	B-X
leukemia	B-X
<EOS>	B-X
Using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
v	B-X
-	B-X
src	B-X
overexpression	B-X
in	B-X
NIH3T3	B-X
induced	B-X
STAT3	B-X
-	B-X
dependent	B-X
transcriptional	B-X
activity	B-X
from	B-X
the	B-X
mcl	B-X
-	B-X
1	B-X
promoter	B-X
and	B-X
increased	B-X
endogenous	B-X
Mcl	B-X
-	B-X
1	B-X
protein	B-X
levels	B-X

Using	O
a	O
luciferase	O
reporter	O
assay	O
,	O
we	O
demonstrated	O
that	O
v-src	O
overexpression	O
in	O
NIH3T3	O
induced	O
STAT3	B-protein
-dependent	O
transcriptional	O
activity	O
from	O
the	O
mcl-1	B-DNA
promoter	I-DNA
and	O
increased	O
endogenous	O
Mcl-1	O
protein	O
levels	O
.	O
<EOS>	B-X
Using	B-X
a	B-X
luciferase	B-X
reporter	B-X
assay	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
v	B-X
-	B-X
src	B-X
overexpression	B-X
in	B-X
NIH3T3	B-X
induced	B-X
STAT3	B-X
-	B-X
dependent	B-X
transcriptional	B-X
activity	B-X
from	B-X
the	B-X
mcl	B-X
-	B-X
1	B-X
promoter	B-X
and	B-X
increased	B-X
endogenous	B-X
Mcl	B-X
-	B-X
1	B-X
protein	B-X
levels	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
STAT3	B-X
signaling	B-X
leads	B-X
to	B-X
apoptosis	B-X
of	B-X
leukemic	B-X
large	B-X
granular	B-X
lymphocytes	B-X
and	B-X
decreased	B-X
Mcl	B-X
-	B-X
1	B-X
expression	B-X
.	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
investigation	B-X
should	B-X
focus	B-X
on	B-X
novel	B-X
strategies	B-X
targeting	B-X
STAT3	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
LGL	B-X
leukemia	B-X
<EOS>	B-X
Large	B-X
granular	B-X
lymphocyte	B-X
(	B-X
LGL	B-X
)	B-X
leukemia	B-X
is	B-X
characterized	B-X
by	B-X
the	B-X
expansion	B-X
of	B-X
antigen	B-X
-	B-X
activated	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X

We	O
conclude	O
that	O
STAT3	B-protein
activation	O
contributed	O
to	O
accumulation	O
of	O
the	O
leukemic	B-cell_type
LGL	I-cell_type
clones	I-cell_type
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
STAT3	B-X
activation	B-X
contributed	B-X
to	B-X
accumulation	B-X
of	B-X
the	B-X
leukemic	B-X
LGL	B-X
clones	B-X
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
investigation	B-X
should	B-X
focus	B-X
on	B-X
novel	B-X
strategies	B-X
targeting	B-X
STAT3	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
LGL	B-X
leukemia	B-X
<EOS>	B-X
Large	B-X
granular	B-X
lymphocyte	B-X
(	B-X
LGL	B-X
)	B-X
leukemia	B-X
is	B-X
characterized	B-X
by	B-X
the	B-X
expansion	B-X
of	B-X
antigen	B-X
-	B-X
activated	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
leukemic	B-X
LGL	B-X
with	B-X
the	B-X
JAK	B-X
-	B-X
selective	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
AG	B-X
-	B-X
490	B-X
induced	B-X
apoptosis	B-X
with	B-X
a	B-X
corresponding	B-X
decrease	B-X
in	B-X
STAT	B-X
-	B-X
DNA	B-X
binding	B-X
activity	B-X

These	O
findings	O
suggest	O
that	O
investigation	O
should	O
focus	O
on	O
novel	O
strategies	O
targeting	O
STAT3	B-protein
in	O
the	O
treatment	O
of	O
LGL	O
leukemia	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
investigation	B-X
should	B-X
focus	B-X
on	B-X
novel	B-X
strategies	B-X
targeting	B-X
STAT3	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
LGL	B-X
leukemia	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
STAT3	B-X
activation	B-X
contributed	B-X
to	B-X
accumulation	B-X
of	B-X
the	B-X
leukemic	B-X
LGL	B-X
clones	B-X
<EOS>	B-X
These	B-X
leukemic	B-X
cells	B-X
are	B-X
resistant	B-X
to	B-X
Fas	B-X
-	B-X
mediated	B-X
apoptosis	B-X
despite	B-X
expressing	B-X
high	B-X
levels	B-X
of	B-X
Fas	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
LGL	B-X
from	B-X
19	B-X
patients	B-X
displayed	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
STAT3	B-X

Decreased	O
immediate	O
inflammatory	B-DNA
gene	I-DNA
induction	O
in	O
activating	B-protein
transcription	I-protein
factor-2	I-protein
mutant	O
mice	O
.	O
<EOS>	B-X
Decreased	B-X
immediate	B-X
inflammatory	B-X
gene	B-X
induction	B-X
in	B-X
activating	B-X
transcription	B-X
factor	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
.	B-X
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
is	B-X
essential	B-X
for	B-X
maximal	B-X
immediate	B-X
induction	B-X
of	B-X
adhesion	B-X
molecules	B-X
and	B-X
cytokine	B-X
genes	B-X
,	B-X
but	B-X
at	B-X
later	B-X
time	B-X
points	B-X
may	B-X
even	B-X
protect	B-X
against	B-X
overactive	B-X
immune	B-X
responses	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
lymphocytes	B-X
by	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
also	B-X
showed	B-X
less	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
1	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
tissues	B-X
<EOS>	B-X
To	B-X
better	B-X
define	B-X
the	B-X
role	B-X
of	B-X
ATF	B-X
-	B-X
2	B-X
in	B-X
inflammation	B-X
,	B-X
adult	B-X
mice	B-X
expressing	B-X
small	B-X
amounts	B-X
of	B-X
a	B-X
mutant	B-X
ATF	B-X
-	B-X
2	B-X
protein	B-X
were	B-X
challenged	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
or	B-X
virus	B-X

Transcription	B-protein
factor	I-protein
activating	I-protein
transcription	I-protein
factor	I-protein
(	I-protein
ATF	I-protein
)	I-protein
-2	I-protein
is	O
activated	O
by	O
inflammatory	O
signals	O
transduced	O
by	O
the	O
JNK	O
and	O
p38	O
MAP	O
kinase	O
pathways	O
.	O
<EOS>	B-X
Transcription	B-X
factor	B-X
activating	B-X
transcription	B-X
factor	B-X
(	B-X
ATF	B-X
)	B-X
	B-X
-	B-X
2	B-X
is	B-X
activated	B-X
by	B-X
inflammatory	B-X
signals	B-X
transduced	B-X
by	B-X
the	B-X
JNK	B-X
and	B-X
p38	B-X
MAP	B-X
kinase	B-X
pathways	B-X
<EOS>	B-X
However	B-X
,	B-X
similar	B-X
to	B-X
what	B-X
was	B-X
observed	B-X
after	B-X
p38	B-X
kinase	B-X
inhibition	B-X
in	B-X
normal	B-X
mice	B-X
,	B-X
relative	B-X
ATF	B-X
-	B-X
2	B-X
deficiency	B-X
did	B-X
not	B-X
prevent	B-X
the	B-X
development	B-X
of	B-X
a	B-X
mononuclear	B-X
cell	B-X
infiltrate	B-X
in	B-X
the	B-X
week	B-X
following	B-X
an	B-X
inflammatory	B-X
stimulus	B-X
<EOS>	B-X
Decreased	B-X
immediate	B-X
inflammatory	B-X
gene	B-X
induction	B-X
in	B-X
activating	B-X
transcription	B-X
factor	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
.	B-X
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
is	B-X
essential	B-X
for	B-X
maximal	B-X
immediate	B-X
induction	B-X
of	B-X
adhesion	B-X
molecules	B-X
and	B-X
cytokine	B-X
genes	B-X
,	B-X
but	B-X
at	B-X
later	B-X
time	B-X
points	B-X
may	B-X
even	B-X
protect	B-X
against	B-X
overactive	B-X
immune	B-X
responses	B-X

To	O
better	O
define	O
the	O
role	O
of	O
ATF-2	B-protein
in	O
inflammation	O
,	O
adult	O
mice	O
expressing	O
small	O
amounts	O
of	O
a	O
mutant	B-protein
ATF-2	I-protein
protein	I-protein
were	O
challenged	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
anti-CD3	B-protein
antibody	I-protein
or	O
virus	O
.	O
<EOS>	B-X
Older	B-X
age	B-X
,	B-X
risk	B-X
of	B-X
sarcopenia	B-X
and	B-X
arterial	B-X
hypertension	B-X
were	B-X
associated	B-X
with	B-X
falls	B-X
during	B-X
the	B-X
pre	B-X
-	B-X
pandemic	B-X
period	B-X
<EOS>	B-X
Precise	B-X
programming	B-X
of	B-X
multigene	B-X
expression	B-X
stoichiometry	B-X
in	B-X
mammalian	B-X
cells	B-X
by	B-X
a	B-X
modular	B-X
and	B-X
programmable	B-X
transcriptional	B-X
system	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
immunize	B-X
mice	B-X
with	B-X
prefusion	B-X
-	B-X
stabilized	B-X
NiV	B-X
F	B-X
and	B-X
isolate	B-X
ten	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
neutralize	B-X
pseudotyped	B-X
virus	B-X
<EOS>	B-X
These	B-X
experiments	B-X
proved	B-X
that	B-X
the	B-X
microfluidic	B-X
device	B-X
specifically	B-X
designed	B-X
for	B-X
phage	B-X
-	B-X
selection	B-X
is	B-X
rapid	B-X
,	B-X
sensitive	B-X
and	B-X
effective	B-X

Within	O
3	O
h	O
of	O
challenge	O
by	O
LPS	O
,	O
ATF-2	O
mutant	O
mice	O
had	O
decreased	O
induction	O
of	O
the	O
adhesion	B-protein
molecules	I-protein
E-selectin	B-protein
,	O
P-selectin	B-protein
and	O
VCAM-1	B-protein
as	O
well	O
as	O
the	O
cytokines	B-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
IL-1beta	B-protein
and	O
IL-6	B-protein
compared	O
with	O
control	O
mice	O
.	O
<EOS>	B-X
Within	B-X
3	B-X
h	B-X
of	B-X
challenge	B-X
by	B-X
LPS	B-X
,	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
had	B-X
decreased	B-X
induction	B-X
of	B-X
the	B-X
adhesion	B-X
molecules	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
P	B-X
-	B-X
selectin	B-X
and	B-X
VCAM	B-X
-	B-X
1	B-X
as	B-X
well	B-X
as	B-X
the	B-X
cytokines	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
compared	B-X
with	B-X
control	B-X
mice	B-X
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
is	B-X
essential	B-X
for	B-X
maximal	B-X
immediate	B-X
induction	B-X
of	B-X
adhesion	B-X
molecules	B-X
and	B-X
cytokine	B-X
genes	B-X
,	B-X
but	B-X
at	B-X
later	B-X
time	B-X
points	B-X
may	B-X
even	B-X
protect	B-X
against	B-X
overactive	B-X
immune	B-X
responses	B-X
<EOS>	B-X
To	B-X
better	B-X
define	B-X
the	B-X
role	B-X
of	B-X
ATF	B-X
-	B-X
2	B-X
in	B-X
inflammation	B-X
,	B-X
adult	B-X
mice	B-X
expressing	B-X
small	B-X
amounts	B-X
of	B-X
a	B-X
mutant	B-X
ATF	B-X
-	B-X
2	B-X
protein	B-X
were	B-X
challenged	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
or	B-X
virus	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
lymphocytes	B-X
by	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
also	B-X
showed	B-X
less	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
1	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
tissues	B-X

Stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
by	O
anti-CD3	B-protein
antibody	I-protein
also	O
showed	O
less	O
induction	O
of	O
IL-1	B-protein
and	O
IL-6	B-protein
in	O
ATF-2	O
mutant	O
tissues	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
lymphocytes	B-X
by	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
also	B-X
showed	B-X
less	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
1	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
tissues	B-X
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
thymocytes	B-X
treated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
in	B-X
vitro	B-X
demonstrated	B-X
reduced	B-X
induction	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
,	B-X
JunB	B-X
,	B-X
JunD	B-X
and	B-X
Fra	B-X
-	B-X
2	B-X
<EOS>	B-X
Decreased	B-X
immediate	B-X
inflammatory	B-X
gene	B-X
induction	B-X
in	B-X
activating	B-X
transcription	B-X
factor	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
.	B-X
<EOS>	B-X
Within	B-X
3	B-X
h	B-X
of	B-X
challenge	B-X
by	B-X
LPS	B-X
,	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
had	B-X
decreased	B-X
induction	B-X
of	B-X
the	B-X
adhesion	B-X
molecules	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
P	B-X
-	B-X
selectin	B-X
and	B-X
VCAM	B-X
-	B-X
1	B-X
as	B-X
well	B-X
as	B-X
the	B-X
cytokines	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
compared	B-X
with	B-X
control	B-X
mice	B-X

ATF-2	B-cell_type
mutant	I-cell_type
thymocytes	I-cell_type
treated	O
with	O
anti-CD3	B-protein
antibody	I-protein
in	O
vitro	O
demonstrated	O
reduced	O
induction	O
of	O
c-Jun	B-protein
,	O
JunB	B-protein
,	O
JunD	B-protein
and	O
Fra-2	B-protein
.	O
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
thymocytes	B-X
treated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
in	B-X
vitro	B-X
demonstrated	B-X
reduced	B-X
induction	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
,	B-X
JunB	B-X
,	B-X
JunD	B-X
and	B-X
Fra	B-X
-	B-X
2	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
lymphocytes	B-X
by	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
also	B-X
showed	B-X
less	B-X
induction	B-X
of	B-X
IL	B-X
-	B-X
1	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
in	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
tissues	B-X
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
proved	B-X
more	B-X
susceptible	B-X
to	B-X
death	B-X
than	B-X
control	B-X
mice	B-X
from	B-X
LPS	B-X
plus	B-X
D	B-X
-	B-X
galactosamine	B-X
injection	B-X
or	B-X
Coxsackievirus	B-X
B3	B-X
infection	B-X
and	B-X
had	B-X
a	B-X
higher	B-X
incidence	B-X
of	B-X
mononuclear	B-X
pulmonary	B-X
infiltrates	B-X
after	B-X
exposure	B-X
to	B-X
Herpes	B-X
simplex	B-X
virus	B-X
-	B-X
1	B-X
<EOS>	B-X
Decreased	B-X
immediate	B-X
inflammatory	B-X
gene	B-X
induction	B-X
in	B-X
activating	B-X
transcription	B-X
factor	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
.	B-X

However	O
,	O
similar	O
to	O
what	O
was	O
observed	O
after	O
p38	O
kinase	O
inhibition	O
in	O
normal	O
mice	O
,	O
relative	O
ATF-2	O
deficiency	O
did	O
not	O
prevent	O
the	O
development	O
of	O
a	O
mononuclear	B-cell_type
cell	I-cell_type
infiltrate	O
in	O
the	O
week	O
following	O
an	O
inflammatory	O
stimulus	O
.	O

ATF-2	O
mutant	O
mice	O
proved	O
more	O
susceptible	O
to	O
death	O
than	O
control	O
mice	O
from	O
LPS	O
plus	O
D-galactosamine	O
injection	O
or	O
Coxsackievirus	O
B3	O
infection	O
and	O
had	O
a	O
higher	O
incidence	O
of	O
mononuclear	O
pulmonary	O
infiltrates	O
after	O
exposure	O
to	O
Herpes	O
simplex	O
virus-1	O
.	O
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
proved	B-X
more	B-X
susceptible	B-X
to	B-X
death	B-X
than	B-X
control	B-X
mice	B-X
from	B-X
LPS	B-X
plus	B-X
D	B-X
-	B-X
galactosamine	B-X
injection	B-X
or	B-X
Coxsackievirus	B-X
B3	B-X
infection	B-X
and	B-X
had	B-X
a	B-X
higher	B-X
incidence	B-X
of	B-X
mononuclear	B-X
pulmonary	B-X
infiltrates	B-X
after	B-X
exposure	B-X
to	B-X
Herpes	B-X
simplex	B-X
virus	B-X
-	B-X
1	B-X
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
is	B-X
essential	B-X
for	B-X
maximal	B-X
immediate	B-X
induction	B-X
of	B-X
adhesion	B-X
molecules	B-X
and	B-X
cytokine	B-X
genes	B-X
,	B-X
but	B-X
at	B-X
later	B-X
time	B-X
points	B-X
may	B-X
even	B-X
protect	B-X
against	B-X
overactive	B-X
immune	B-X
responses	B-X
<EOS>	B-X
However	B-X
,	B-X
similar	B-X
to	B-X
what	B-X
was	B-X
observed	B-X
after	B-X
p38	B-X
kinase	B-X
inhibition	B-X
in	B-X
normal	B-X
mice	B-X
,	B-X
relative	B-X
ATF	B-X
-	B-X
2	B-X
deficiency	B-X
did	B-X
not	B-X
prevent	B-X
the	B-X
development	B-X
of	B-X
a	B-X
mononuclear	B-X
cell	B-X
infiltrate	B-X
in	B-X
the	B-X
week	B-X
following	B-X
an	B-X
inflammatory	B-X
stimulus	B-X
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
thymocytes	B-X
treated	B-X
with	B-X
anti	B-X
-	B-X
CD3	B-X
antibody	B-X
in	B-X
vitro	B-X
demonstrated	B-X
reduced	B-X
induction	B-X
of	B-X
c	B-X
-	B-X
Jun	B-X
,	B-X
JunB	B-X
,	B-X
JunD	B-X
and	B-X
Fra	B-X
-	B-X
2	B-X

ATF-2	B-protein
is	O
essential	O
for	O
maximal	O
immediate	O
induction	O
of	O
adhesion	B-protein
molecules	I-protein
and	O
cytokine	B-DNA
genes	I-DNA
,	O
but	O
at	O
later	O
time	O
points	O
may	O
even	O
protect	O
against	O
overactive	O
immune	O
responses	O
.	O
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
is	B-X
essential	B-X
for	B-X
maximal	B-X
immediate	B-X
induction	B-X
of	B-X
adhesion	B-X
molecules	B-X
and	B-X
cytokine	B-X
genes	B-X
,	B-X
but	B-X
at	B-X
later	B-X
time	B-X
points	B-X
may	B-X
even	B-X
protect	B-X
against	B-X
overactive	B-X
immune	B-X
responses	B-X
<EOS>	B-X
Within	B-X
3	B-X
h	B-X
of	B-X
challenge	B-X
by	B-X
LPS	B-X
,	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
had	B-X
decreased	B-X
induction	B-X
of	B-X
the	B-X
adhesion	B-X
molecules	B-X
E	B-X
-	B-X
selectin	B-X
,	B-X
P	B-X
-	B-X
selectin	B-X
and	B-X
VCAM	B-X
-	B-X
1	B-X
as	B-X
well	B-X
as	B-X
the	B-X
cytokines	B-X
tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
,	B-X
IL	B-X
-	B-X
1beta	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
compared	B-X
with	B-X
control	B-X
mice	B-X
<EOS>	B-X
Decreased	B-X
immediate	B-X
inflammatory	B-X
gene	B-X
induction	B-X
in	B-X
activating	B-X
transcription	B-X
factor	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
.	B-X
<EOS>	B-X
ATF	B-X
-	B-X
2	B-X
mutant	B-X
mice	B-X
proved	B-X
more	B-X
susceptible	B-X
to	B-X
death	B-X
than	B-X
control	B-X
mice	B-X
from	B-X
LPS	B-X
plus	B-X
D	B-X
-	B-X
galactosamine	B-X
injection	B-X
or	B-X
Coxsackievirus	B-X
B3	B-X
infection	B-X
and	B-X
had	B-X
a	B-X
higher	B-X
incidence	B-X
of	B-X
mononuclear	B-X
pulmonary	B-X
infiltrates	B-X
after	B-X
exposure	B-X
to	B-X
Herpes	B-X
simplex	B-X
virus	B-X
-	B-X
1	B-X

LIGHT	B-protein
,	O
a	O
TNF-like	B-protein
molecule	I-protein
,	O
costimulates	O
T	O
cell	O
proliferation	O
and	O
is	O
required	O
for	O
dendritic	B-cell_type
cell	I-cell_type
-mediated	O
allogeneic	O
T	O
cell	O
response	O
.	O

LIGHT	B-protein
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
TNF	B-protein
superfamily	I-protein
and	O
its	O
receptors	O
,	O
herpesvirus	B-protein
entry	I-protein
mediator	I-protein
and	O
lymphotoxin	B-protein
beta	I-protein
receptor	I-protein
,	O
are	O
found	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
stromal	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
LIGHT	B-protein
is	O
selectively	O
expressed	O
on	O
immature	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
DCs	B-cell_type
)	O
generated	O
from	O
human	B-cell_type
PBMCs	I-cell_type
.	O

In	O
contrast	O
,	O
LIGHT	B-protein
is	O
not	O
detectable	O
in	O
DCs	B-cell_type
either	O
freshly	O
isolated	O
from	O
PBMCs	B-cell_type
or	O
rendered	O
mature	O
in	O
vitro	O
by	O
LPS	O
treatment	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
LIGHT	B-X
is	B-X
not	B-X
detectable	B-X
in	B-X
DCs	B-X
either	B-X
freshly	B-X
isolated	B-X
from	B-X
PBMCs	B-X
or	B-X
rendered	B-X
mature	B-X
in	B-X
vitro	B-X
by	B-X
LPS	B-X
treatment	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
no	B-X
significant	B-X
decrease	B-X
in	B-X
response	B-X
to	B-X
the	B-X
mature	B-X
B	B-X
-	B-X
cell	B-X
activator	B-X
,	B-X
PPD	B-X
,	B-X
occurred	B-X
until	B-X
day	B-X
2	B-X
<EOS>	B-X
Their	B-X
activation	B-X
is	B-X
transient	B-X
and	B-X
occurs	B-X
earlier	B-X
and	B-X
more	B-X
briefly	B-X
than	B-X
in	B-X
cells	B-X
matured	B-X
with	B-X
LPS	B-X
alone	B-X
<EOS>	B-X
Peritoneal	B-X
macrophages	B-X
from	B-X
BALB	B-X
/	B-X
c	B-X
mice	B-X
after	B-X
treatment	B-X
for	B-X
24	B-X
h	B-X
in	B-X
vitro	B-X
with	B-X
cisplatin	B-X
,	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
mitomycin	B-X
-	B-X
C	B-X
were	B-X
rendered	B-X
significantly	B-X
cytotoxic	B-X
against	B-X
L	B-X
-	B-X
929	B-X
tumor	B-X
target	B-X
cells	B-X

Blockade	O
of	O
LIGHT	B-protein
by	O
its	O
soluble	B-protein
receptors	I-protein
,	O
lymphotoxin	B-protein
beta	I-protein
receptor-Ig	I-protein
or	O
HVEM-Ig	B-protein
,	O
inhibits	O
the	O
induction	O
of	O
DC	B-cell_type
-mediated	O
primary	O
allogeneic	O
T	O
cell	O
response	O
.	O
<EOS>	B-X
Blockade	B-X
of	B-X
LIGHT	B-X
by	B-X
its	B-X
soluble	B-X
receptors	B-X
,	B-X
lymphotoxin	B-X
beta	B-X
receptor	B-X
-	B-X
Ig	B-X
or	B-X
HVEM	B-X
-	B-X
Ig	B-X
,	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
DC	B-X
-	B-X
mediated	B-X
primary	B-X
allogeneic	B-X
T	B-X
cell	B-X
response	B-X
<EOS>	B-X
LIGHT	B-X
,	B-X
a	B-X
TNF	B-X
-	B-X
like	B-X
molecule	B-X
,	B-X
costimulates	B-X
T	B-X
cell	B-X
proliferation	B-X
and	B-X
is	B-X
required	B-X
for	B-X
dendritic	B-X
cell	B-X
-	B-X
mediated	B-X
allogeneic	B-X
T	B-X
cell	B-X
response	B-X
.	B-X
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
blockade	B-X
of	B-X
LIGHT	B-X
,	B-X
a	B-X
T	B-X
cell	B-X
costimulatory	B-X
molecule	B-X
belonging	B-X
to	B-X
the	B-X
TNF	B-X
superfamily	B-X
,	B-X
by	B-X
soluble	B-X
lymphotoxin	B-X
beta	B-X
receptor	B-X
-	B-X
Ig	B-X
(	B-X
LTbetaR	B-X
-	B-X
Ig	B-X
)	B-X
inhibits	B-X
the	B-X
cytotoxic	B-X
T	B-X
lymphocyte	B-X
(	B-X
CTL	B-X
)	B-X
response	B-X
to	B-X
host	B-X
antigenic	B-X
disparities	B-X
and	B-X
ameliorates	B-X
lethal	B-X
graft	B-X
-	B-X
versus	B-X
-	B-X
host	B-X
disease	B-X
(	B-X
GVHD	B-X
)	B-X
in	B-X
a	B-X
B6	B-X
to	B-X
BDF1	B-X
mouse	B-X
model	B-X
<EOS>	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
LIGHT	B-X
is	B-X
a	B-X
costimulatory	B-X
molecule	B-X
involved	B-X
in	B-X
DC	B-X
-	B-X
mediated	B-X
cellular	B-X
immune	B-X
responses	B-X

Furthermore	O
,	O
engagement	O
of	O
LIGHT	B-protein
costimulates	O
human	O
T	O
cell	O
proliferation	O
,	O
amplifies	O
the	O
NF-kappaB	O
signaling	O
pathway	O
,	O
and	O
preferentially	O
induces	O
the	O
production	O
of	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-4	B-protein
,	O
in	O
the	O
presence	O
of	O
an	O
antigenic	O
signal	O
.	O

Our	O
results	O
suggest	O
that	O
LIGHT	B-protein
is	O
a	O
costimulatory	B-protein
molecule	I-protein
involved	O
in	O
DC	B-cell_type
-mediated	O
cellular	O
immune	O
responses	O
.	O

Suppression	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
a	O
dominant-negative	B-protein
Ets-1	I-protein
mutant	I-protein
.	O
<EOS>	B-X
Suppression	B-X
of	B-X
HIV	B-X
type	B-X
1	B-X
replication	B-X
by	B-X
a	B-X
dominant	B-X
-	B-X
negative	B-X
Ets	B-X
-	B-X
1	B-X
mutant	B-X
.	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
biological	B-X
relevance	B-X
of	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
mutant	B-X
of	B-X
Ets	B-X
-	B-X
1	B-X
(	B-X
dnEts	B-X
-	B-X
1	B-X
)	B-X
on	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
distal	B-X
enhancer	B-X
region	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
potent	B-X
dominant	B-X
negative	B-X
effect	B-X
of	B-X
a	B-X
mutant	B-X
Ets	B-X
-	B-X
1	B-X
lacking	B-X
trans	B-X
-	B-X
activation	B-X
domains	B-X
on	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
LTR	B-X
<EOS>	B-X
Activity	B-X
of	B-X
the	B-X
distal	B-X
region	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
,	B-X
which	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
,	B-X
is	B-X
integral	B-X
for	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X

Activity	O
of	O
the	O
distal	B-DNA
region	I-DNA
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
which	O
contains	O
binding	B-DNA
sites	I-DNA
for	O
the	O
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
,	O
is	O
integral	O
for	O
HIV-1	O
replication	O
.	O
<EOS>	B-X
Activity	B-X
of	B-X
the	B-X
distal	B-X
region	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
,	B-X
which	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
,	B-X
is	B-X
integral	B-X
for	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
<EOS>	B-X
This	B-X
finding	B-X
indicates	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
transcriptionaly	B-X
active	B-X
USF	B-X
-	B-X
1	B-X
/	B-X
Ets	B-X
-	B-X
1	B-X
complex	B-X
is	B-X
important	B-X
in	B-X
the	B-X
productive	B-X
infection	B-X
of	B-X
cells	B-X
by	B-X
HIV	B-X
-	B-X
1	B-X
,	B-X
and	B-X
suggests	B-X
that	B-X
inhibition	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
USF	B-X
-	B-X
1	B-X
and	B-X
Ets	B-X
-	B-X
1	B-X
with	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
may	B-X
provide	B-X
a	B-X
new	B-X
target	B-X
for	B-X
anti	B-X
-	B-X
HIV	B-X
-	B-X
1	B-X
gene	B-X
therapy	B-X
<EOS>	B-X
The	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
distal	B-X
enhancer	B-X
region	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
potent	B-X
dominant	B-X
negative	B-X
effect	B-X
of	B-X
a	B-X
mutant	B-X
Ets	B-X
-	B-X
1	B-X
lacking	B-X
trans	B-X
-	B-X
activation	B-X
domains	B-X
on	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
LTR	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
biological	B-X
relevance	B-X
of	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
mutant	B-X
of	B-X
Ets	B-X
-	B-X
1	B-X
(	B-X
dnEts	B-X
-	B-X
1	B-X
)	B-X
on	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X

The	O
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
play	O
a	O
critical	O
role	O
in	O
the	O
activity	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
distal	I-DNA
enhancer	I-DNA
region	I-DNA
,	O
as	O
indicated	O
by	O
the	O
potent	O
dominant	O
negative	O
effect	O
of	O
a	O
mutant	B-DNA
Ets-1	I-DNA
lacking	I-DNA
trans-activation	I-DNA
domains	I-DNA
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
LTR	B-DNA
.	O
<EOS>	B-X
The	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
distal	B-X
enhancer	B-X
region	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
potent	B-X
dominant	B-X
negative	B-X
effect	B-X
of	B-X
a	B-X
mutant	B-X
Ets	B-X
-	B-X
1	B-X
lacking	B-X
trans	B-X
-	B-X
activation	B-X
domains	B-X
on	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
LTR	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
biological	B-X
relevance	B-X
of	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
mutant	B-X
of	B-X
Ets	B-X
-	B-X
1	B-X
(	B-X
dnEts	B-X
-	B-X
1	B-X
)	B-X
on	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
<EOS>	B-X
Activity	B-X
of	B-X
the	B-X
distal	B-X
region	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
,	B-X
which	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
,	B-X
is	B-X
integral	B-X
for	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
<EOS>	B-X
This	B-X
finding	B-X
indicates	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
transcriptionaly	B-X
active	B-X
USF	B-X
-	B-X
1	B-X
/	B-X
Ets	B-X
-	B-X
1	B-X
complex	B-X
is	B-X
important	B-X
in	B-X
the	B-X
productive	B-X
infection	B-X
of	B-X
cells	B-X
by	B-X
HIV	B-X
-	B-X
1	B-X
,	B-X
and	B-X
suggests	B-X
that	B-X
inhibition	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
USF	B-X
-	B-X
1	B-X
and	B-X
Ets	B-X
-	B-X
1	B-X
with	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
may	B-X
provide	B-X
a	B-X
new	B-X
target	B-X
for	B-X
anti	B-X
-	B-X
HIV	B-X
-	B-X
1	B-X
gene	B-X
therapy	B-X

To	O
determine	O
the	O
biological	O
relevance	O
of	O
the	O
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
in	O
HIV-1	O
replication	O
,	O
we	O
examined	O
the	O
effect	O
of	O
expression	O
of	O
the	O
dominant-negative	O
mutant	O
of	O
Ets-1	B-DNA
(	O
dnEts-1	B-DNA
)	O
on	O
HIV-1	O
infection	O
of	O
T	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
biological	B-X
relevance	B-X
of	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
mutant	B-X
of	B-X
Ets	B-X
-	B-X
1	B-X
(	B-X
dnEts	B-X
-	B-X
1	B-X
)	B-X
on	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
<EOS>	B-X
We	B-X
demonstrated	B-X
that	B-X
expression	B-X
of	B-X
dnEts	B-X
markedly	B-X
suppressed	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
a	B-X
T	B-X
cell	B-X
line	B-X
<EOS>	B-X
The	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
distal	B-X
enhancer	B-X
region	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
potent	B-X
dominant	B-X
negative	B-X
effect	B-X
of	B-X
a	B-X
mutant	B-X
Ets	B-X
-	B-X
1	B-X
lacking	B-X
trans	B-X
-	B-X
activation	B-X
domains	B-X
on	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
LTR	B-X
<EOS>	B-X
This	B-X
finding	B-X
indicates	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
transcriptionaly	B-X
active	B-X
USF	B-X
-	B-X
1	B-X
/	B-X
Ets	B-X
-	B-X
1	B-X
complex	B-X
is	B-X
important	B-X
in	B-X
the	B-X
productive	B-X
infection	B-X
of	B-X
cells	B-X
by	B-X
HIV	B-X
-	B-X
1	B-X
,	B-X
and	B-X
suggests	B-X
that	B-X
inhibition	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
USF	B-X
-	B-X
1	B-X
and	B-X
Ets	B-X
-	B-X
1	B-X
with	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
may	B-X
provide	B-X
a	B-X
new	B-X
target	B-X
for	B-X
anti	B-X
-	B-X
HIV	B-X
-	B-X
1	B-X
gene	B-X
therapy	B-X

We	O
demonstrated	O
that	O
expression	O
of	O
dnEts	B-DNA
markedly	O
suppressed	O
HIV-1	O
infection	O
of	O
a	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
finding	O
indicates	O
that	O
formation	O
of	O
a	O
transcriptionaly	B-protein
active	I-protein
USF-1/Ets-1	I-protein
complex	I-protein
is	O
important	O
in	O
the	O
productive	O
infection	O
of	O
cells	O
by	O
HIV-1	O
,	O
and	O
suggests	O
that	O
inhibition	O
of	O
the	O
interaction	O
between	O
USF-1	B-protein
and	O
Ets-1	B-protein
with	O
the	O
HIV-1	B-DNA
LTR	I-DNA
may	O
provide	O
a	O
new	O
target	O
for	O
anti-HIV-1	O
gene	O
therapy	O
.	O
<EOS>	B-X
This	B-X
finding	B-X
indicates	B-X
that	B-X
formation	B-X
of	B-X
a	B-X
transcriptionaly	B-X
active	B-X
USF	B-X
-	B-X
1	B-X
/	B-X
Ets	B-X
-	B-X
1	B-X
complex	B-X
is	B-X
important	B-X
in	B-X
the	B-X
productive	B-X
infection	B-X
of	B-X
cells	B-X
by	B-X
HIV	B-X
-	B-X
1	B-X
,	B-X
and	B-X
suggests	B-X
that	B-X
inhibition	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
USF	B-X
-	B-X
1	B-X
and	B-X
Ets	B-X
-	B-X
1	B-X
with	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
may	B-X
provide	B-X
a	B-X
new	B-X
target	B-X
for	B-X
anti	B-X
-	B-X
HIV	B-X
-	B-X
1	B-X
gene	B-X
therapy	B-X
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
biological	B-X
relevance	B-X
of	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
dominant	B-X
-	B-X
negative	B-X
mutant	B-X
of	B-X
Ets	B-X
-	B-X
1	B-X
(	B-X
dnEts	B-X
-	B-X
1	B-X
)	B-X
on	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
<EOS>	B-X
Activity	B-X
of	B-X
the	B-X
distal	B-X
region	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
,	B-X
which	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
,	B-X
is	B-X
integral	B-X
for	B-X
HIV	B-X
-	B-X
1	B-X
replication	B-X
<EOS>	B-X
The	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
USF	B-X
-	B-X
1	B-X
proteins	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
distal	B-X
enhancer	B-X
region	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
potent	B-X
dominant	B-X
negative	B-X
effect	B-X
of	B-X
a	B-X
mutant	B-X
Ets	B-X
-	B-X
1	B-X
lacking	B-X
trans	B-X
-	B-X
activation	B-X
domains	B-X
on	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
LTR	B-X

Human	B-cell_type
eosinophils	I-cell_type
constitutively	O
express	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
p	I-protein
and	I-protein
c	I-protein
.	O

BACKGROUND	O
:	O
Eosinophils	B-cell_type
are	O
now	O
known	O
to	O
produce	O
a	O
variety	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
although	O
the	O
molecular	O
factors	O
that	O
regulate	O
their	O
production	O
are	O
poorly	O
understood	O
.	O
<EOS>	B-X
Eosinophils	B-X
are	B-X
now	B-X
known	B-X
to	B-X
produce	B-X
a	B-X
variety	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
although	B-X
the	B-X
molecular	B-X
factors	B-X
that	B-X
regulate	B-X
their	B-X
production	B-X
are	B-X
poorly	B-X
understood	B-X
<EOS>	B-X
Human	B-X
eosinophils	B-X
constitutively	B-X
express	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
p	B-X
and	B-X
c	B-X
.	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
almost	B-X
all	B-X
of	B-X
the	B-X
cytokines	B-X
produced	B-X
by	B-X
eosinophils	B-X
,	B-X
including	B-X
the	B-X
proallergic	B-X
cytokine	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
is	B-X
now	B-X
known	B-X
to	B-X
be	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
by	B-X
members	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
A	B-X
brief	B-X
incubation	B-X
with	B-X
the	B-X
T	B-X
(	B-X
H	B-X
)	B-X
2	B-X
cytokines	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
5	B-X
was	B-X
sufficient	B-X
to	B-X
induce	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NFATc	B-X

The	O
expression	O
of	O
almost	O
all	O
of	O
the	O
cytokines	B-protein
produced	O
by	O
eosinophils	B-cell_type
,	O
including	O
the	O
proallergic	B-protein
cytokine	I-protein
IL-4	I-protein
,	O
is	O
now	O
known	O
to	O
be	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
members	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
family	O
of	O
transcription	O
factors	O
.	O
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
almost	B-X
all	B-X
of	B-X
the	B-X
cytokines	B-X
produced	B-X
by	B-X
eosinophils	B-X
,	B-X
including	B-X
the	B-X
proallergic	B-X
cytokine	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
is	B-X
now	B-X
known	B-X
to	B-X
be	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
by	B-X
members	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Eosinophils	B-X
are	B-X
now	B-X
known	B-X
to	B-X
produce	B-X
a	B-X
variety	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
although	B-X
the	B-X
molecular	B-X
factors	B-X
that	B-X
regulate	B-X
their	B-X
production	B-X
are	B-X
poorly	B-X
understood	B-X
<EOS>	B-X
NFATp	B-X
and	B-X
NFATc	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
other	B-X
genes	B-X
in	B-X
eosinophils	B-X
but	B-X
appear	B-X
to	B-X
be	B-X
regulated	B-X
by	B-X
a	B-X
novel	B-X
signal	B-X
transduction	B-X
mechanism	B-X
in	B-X
these	B-X
cells	B-X
<EOS>	B-X
Human	B-X
eosinophils	B-X
constitutively	B-X
express	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
p	B-X
and	B-X
c	B-X
.	B-X

OBJECTIVE	O
:	O
We	O
sought	O
to	O
characterize	O
the	O
expression	O
of	O
different	O
NFAT	B-protein
proteins	I-protein
in	O
resting	B-cell_type
and	I-cell_type
activated	I-cell_type
eosinophils	I-cell_type
.	O
<EOS>	B-X
We	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
expression	B-X
of	B-X
different	B-X
NFAT	B-X
proteins	B-X
in	B-X
resting	B-X
and	B-X
activated	B-X
eosinophils	B-X
<EOS>	B-X
Human	B-X
eosinophils	B-X
constitutively	B-X
express	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
p	B-X
and	B-X
c	B-X
.	B-X
<EOS>	B-X
NFATp	B-X
and	B-X
NFATc	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
other	B-X
genes	B-X
in	B-X
eosinophils	B-X
but	B-X
appear	B-X
to	B-X
be	B-X
regulated	B-X
by	B-X
a	B-X
novel	B-X
signal	B-X
transduction	B-X
mechanism	B-X
in	B-X
these	B-X
cells	B-X
<EOS>	B-X
NFAT	B-X
expression	B-X
was	B-X
determined	B-X
by	B-X
using	B-X
immunoprecipitation	B-X
and	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
DNA	B-X
-	B-X
binding	B-X
assays	B-X
,	B-X
and	B-X
RT	B-X
-	B-X
PCR	B-X
analysis	B-X
of	B-X
eosinophil	B-X
mRNA	B-X

METHODS	O
:	O
Nuclear	O
and	O
whole	O
cell	O
extracts	O
were	O
obtained	O
from	O
both	O
peripheral	B-cell_type
blood	I-cell_type
eosinophils	I-cell_type
and	O
those	O
obtained	O
from	O
bronchoalveolar	O
lavage	O
fluid	O
of	O
asthmatic	O
subjects	O
after	O
endobronchial	O
allergen	O
challenge	O
.	O
<EOS>	B-X
Nuclear	B-X
and	B-X
whole	B-X
cell	B-X
extracts	B-X
were	B-X
obtained	B-X
from	B-X
both	B-X
peripheral	B-X
blood	B-X
eosinophils	B-X
and	B-X
those	B-X
obtained	B-X
from	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
of	B-X
asthmatic	B-X
subjects	B-X
after	B-X
endobronchial	B-X
allergen	B-X
challenge	B-X
<EOS>	B-X
Both	B-X
peripheral	B-X
blood	B-X
and	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
eosinophils	B-X
expressed	B-X
NFATp	B-X
and	B-X
NFATc	B-X
protein	B-X
<EOS>	B-X
NFATp	B-X
and	B-X
NFATc	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
other	B-X
genes	B-X
in	B-X
eosinophils	B-X
but	B-X
appear	B-X
to	B-X
be	B-X
regulated	B-X
by	B-X
a	B-X
novel	B-X
signal	B-X
transduction	B-X
mechanism	B-X
in	B-X
these	B-X
cells	B-X
<EOS>	B-X
Eosinophil	B-X
nuclear	B-X
extracts	B-X
contain	B-X
multiple	B-X
factors	B-X
that	B-X
can	B-X
specifically	B-X
recognize	B-X
the	B-X
IL	B-X
-	B-X
4	B-X
promoter	B-X
P1	B-X
NFAT	B-X
site	B-X
in	B-X
DNA	B-X
-	B-X
binding	B-X
assays	B-X
,	B-X
including	B-X
NFATp	B-X

NFAT	B-protein
expression	O
was	O
determined	O
by	O
using	O
immunoprecipitation	O
and	O
Western	O
blot	O
analysis	O
,	O
DNA-binding	O
assays	O
,	O
and	O
RT-PCR	O
analysis	O
of	O
eosinophil	B-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
NFAT	B-X
expression	B-X
was	B-X
determined	B-X
by	B-X
using	B-X
immunoprecipitation	B-X
and	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
DNA	B-X
-	B-X
binding	B-X
assays	B-X
,	B-X
and	B-X
RT	B-X
-	B-X
PCR	B-X
analysis	B-X
of	B-X
eosinophil	B-X
mRNA	B-X
<EOS>	B-X
We	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
expression	B-X
of	B-X
different	B-X
NFAT	B-X
proteins	B-X
in	B-X
resting	B-X
and	B-X
activated	B-X
eosinophils	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
almost	B-X
all	B-X
of	B-X
the	B-X
cytokines	B-X
produced	B-X
by	B-X
eosinophils	B-X
,	B-X
including	B-X
the	B-X
proallergic	B-X
cytokine	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
is	B-X
now	B-X
known	B-X
to	B-X
be	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
by	B-X
members	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
Nuclear	B-X
and	B-X
whole	B-X
cell	B-X
extracts	B-X
were	B-X
obtained	B-X
from	B-X
both	B-X
peripheral	B-X
blood	B-X
eosinophils	B-X
and	B-X
those	B-X
obtained	B-X
from	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
of	B-X
asthmatic	B-X
subjects	B-X
after	B-X
endobronchial	B-X
allergen	B-X
challenge	B-X

RESULTS	O
:	O
Both	O
peripheral	B-cell_type
blood	I-cell_type
and	I-cell_type
bronchoalveolar	I-cell_type
lavage	I-cell_type
fluid	I-cell_type
eosinophils	I-cell_type
expressed	O
NFATp	B-protein
and	I-protein
NFATc	I-protein
protein	I-protein
.	O
<EOS>	B-X
Both	B-X
peripheral	B-X
blood	B-X
and	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
eosinophils	B-X
expressed	B-X
NFATp	B-X
and	B-X
NFATc	B-X
protein	B-X
<EOS>	B-X
Nuclear	B-X
and	B-X
whole	B-X
cell	B-X
extracts	B-X
were	B-X
obtained	B-X
from	B-X
both	B-X
peripheral	B-X
blood	B-X
eosinophils	B-X
and	B-X
those	B-X
obtained	B-X
from	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
of	B-X
asthmatic	B-X
subjects	B-X
after	B-X
endobronchial	B-X
allergen	B-X
challenge	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
eosinophils	B-X
were	B-X
found	B-X
to	B-X
constitutively	B-X
express	B-X
NFATc	B-X
mRNA	B-X
<EOS>	B-X
NFATp	B-X
and	B-X
NFATc	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
other	B-X
genes	B-X
in	B-X
eosinophils	B-X
but	B-X
appear	B-X
to	B-X
be	B-X
regulated	B-X
by	B-X
a	B-X
novel	B-X
signal	B-X
transduction	B-X
mechanism	B-X
in	B-X
these	B-X
cells	B-X

Unlike	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
which	O
express	O
multiple	O
NFATc	O
isoforms	O
,	O
eosinophils	B-cell_type
preferentially	O
express	O
the	O
approximately	O
85-kd	O
isoform	O
.	O
<EOS>	B-X
Unlike	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
multiple	B-X
NFATc	B-X
isoforms	B-X
,	B-X
eosinophils	B-X
preferentially	B-X
express	B-X
the	B-X
approximately	B-X
85	B-X
-	B-X
kd	B-X
isoform	B-X
<EOS>	B-X
NFATp	B-X
and	B-X
NFATc	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
other	B-X
genes	B-X
in	B-X
eosinophils	B-X
but	B-X
appear	B-X
to	B-X
be	B-X
regulated	B-X
by	B-X
a	B-X
novel	B-X
signal	B-X
transduction	B-X
mechanism	B-X
in	B-X
these	B-X
cells	B-X
<EOS>	B-X
We	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
expression	B-X
of	B-X
different	B-X
NFAT	B-X
proteins	B-X
in	B-X
resting	B-X
and	B-X
activated	B-X
eosinophils	B-X
<EOS>	B-X
Both	B-X
peripheral	B-X
blood	B-X
and	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
eosinophils	B-X
expressed	B-X
NFATp	B-X
and	B-X
NFATc	B-X
protein	B-X

In	O
addition	O
,	O
eosinophils	B-cell_type
were	O
found	O
to	O
constitutively	O
express	O
NFATc	B-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
eosinophils	B-X
were	B-X
found	B-X
to	B-X
constitutively	B-X
express	B-X
NFATc	B-X
mRNA	B-X
<EOS>	B-X
Both	B-X
peripheral	B-X
blood	B-X
and	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
eosinophils	B-X
expressed	B-X
NFATp	B-X
and	B-X
NFATc	B-X
protein	B-X
<EOS>	B-X
Unlike	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
multiple	B-X
NFATc	B-X
isoforms	B-X
,	B-X
eosinophils	B-X
preferentially	B-X
express	B-X
the	B-X
approximately	B-X
85	B-X
-	B-X
kd	B-X
isoform	B-X
<EOS>	B-X
Human	B-X
eosinophils	B-X
constitutively	B-X
express	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
p	B-X
and	B-X
c	B-X
.	B-X

A	O
brief	O
incubation	O
with	O
the	O
T	B-protein
(	I-protein
H	I-protein
)	I-protein
2	I-protein
cytokines	I-protein
IL-4	B-protein
and	O
IL-5	B-protein
was	O
sufficient	O
to	O
induce	O
the	O
nuclear	O
translocation	O
of	O
NFATc	B-protein
.	O

Eosinophil	O
nuclear	O
extracts	O
contain	O
multiple	O
factors	O
that	O
can	O
specifically	O
recognize	O
the	O
IL-4	B-DNA
promoter	I-DNA
P1	I-DNA
NFAT	I-DNA
site	I-DNA
in	O
DNA-binding	O
assays	O
,	O
including	O
NFATp	B-protein
.	O
<EOS>	B-X
Eosinophil	B-X
nuclear	B-X
extracts	B-X
contain	B-X
multiple	B-X
factors	B-X
that	B-X
can	B-X
specifically	B-X
recognize	B-X
the	B-X
IL	B-X
-	B-X
4	B-X
promoter	B-X
P1	B-X
NFAT	B-X
site	B-X
in	B-X
DNA	B-X
-	B-X
binding	B-X
assays	B-X
,	B-X
including	B-X
NFATp	B-X
<EOS>	B-X
Nuclear	B-X
and	B-X
whole	B-X
cell	B-X
extracts	B-X
were	B-X
obtained	B-X
from	B-X
both	B-X
peripheral	B-X
blood	B-X
eosinophils	B-X
and	B-X
those	B-X
obtained	B-X
from	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
of	B-X
asthmatic	B-X
subjects	B-X
after	B-X
endobronchial	B-X
allergen	B-X
challenge	B-X
<EOS>	B-X
We	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
expression	B-X
of	B-X
different	B-X
NFAT	B-X
proteins	B-X
in	B-X
resting	B-X
and	B-X
activated	B-X
eosinophils	B-X
<EOS>	B-X
Human	B-X
eosinophils	B-X
constitutively	B-X
express	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
p	B-X
and	B-X
c	B-X
.	B-X

CONCLUSION	O
:	O
NFATp	B-protein
and	O
NFATc	B-protein
can	O
regulate	O
the	O
expression	O
of	O
cytokines	B-protein
and	O
other	O
genes	O
in	O
eosinophils	B-cell_type
but	O
appear	O
to	O
be	O
regulated	O
by	O
a	O
novel	O
signal	O
transduction	O
mechanism	O
in	O
these	O
cells	O
.	O
<EOS>	B-X
NFATp	B-X
and	B-X
NFATc	B-X
can	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
other	B-X
genes	B-X
in	B-X
eosinophils	B-X
but	B-X
appear	B-X
to	B-X
be	B-X
regulated	B-X
by	B-X
a	B-X
novel	B-X
signal	B-X
transduction	B-X
mechanism	B-X
in	B-X
these	B-X
cells	B-X
<EOS>	B-X
We	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
expression	B-X
of	B-X
different	B-X
NFAT	B-X
proteins	B-X
in	B-X
resting	B-X
and	B-X
activated	B-X
eosinophils	B-X
<EOS>	B-X
A	B-X
brief	B-X
incubation	B-X
with	B-X
the	B-X
T	B-X
(	B-X
H	B-X
)	B-X
2	B-X
cytokines	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
5	B-X
was	B-X
sufficient	B-X
to	B-X
induce	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NFATc	B-X
<EOS>	B-X
Unlike	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
multiple	B-X
NFATc	B-X
isoforms	B-X
,	B-X
eosinophils	B-X
preferentially	B-X
express	B-X
the	B-X
approximately	B-X
85	B-X
-	B-X
kd	B-X
isoform	B-X

BLyS	B-protein
BINDS	O
TO	O
B	B-cell_type
CELLS	I-cell_type
WITH	O
HIGH	O
AFFINITY	O
AND	O
INDUCES	O
ACTIVATION	O
OF	O
THE	O
TRANSCRIPTION	B-protein
FACTORS	I-protein
NF-kappaB	B-protein
AND	O
ELF-1	B-protein
.	O

B	B-protein
lymphocyte	I-protein
stimulator	I-protein
(	O
BLyS	B-protein
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
TNF	B-protein
family	I-protein
of	I-protein
proteins	I-protein
expressed	O
by	O
myeloid	B-cell_type
cells	I-cell_type
as	O
membrane-bound	O
and	O
soluble	O
forms	O
.	O
<EOS>	B-X
B	B-X
lymphocyte	B-X
stimulator	B-X
(	B-X
BLyS	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
TNF	B-X
family	B-X
of	B-X
proteins	B-X
expressed	B-X
by	B-X
myeloid	B-X
cells	B-X
as	B-X
membrane	B-X
-	B-X
bound	B-X
and	B-X
soluble	B-X
forms	B-X
<EOS>	B-X
BLyS	B-X
binding	B-X
to	B-X
B	B-X
cells	B-X
is	B-X
specific	B-X
as	B-X
other	B-X
TNF	B-X
family	B-X
members	B-X
tested	B-X
did	B-X
not	B-X
compete	B-X
for	B-X
(	B-X
125	B-X
)	B-X
I	B-X
-	B-X
BLyS	B-X
binding	B-X
<EOS>	B-X
In	B-X
addition	B-X
we	B-X
report	B-X
that	B-X
BLyS	B-X
binding	B-X
to	B-X
B	B-X
cells	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
the	B-X
Ets	B-X
family	B-X
transcription	B-X
factor	B-X
,	B-X
ELF	B-X
-	B-X
1	B-X
,	B-X
and	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
mRNA	B-X
for	B-X
Polo	B-X
-	B-X
like	B-X
kinase	B-X
(	B-X
PLK	B-X
)	B-X
<EOS>	B-X
Similar	B-X
to	B-X
other	B-X
TNF	B-X
family	B-X
members	B-X
,	B-X
BLyS	B-X
is	B-X
present	B-X
in	B-X
solution	B-X
as	B-X
a	B-X
homotrimer	B-X
as	B-X
determined	B-X
by	B-X
gel	B-X
filtration	B-X
chromatography	B-X
and	B-X
light	B-X
scattering	B-X
analysis	B-X

BLyS	B-protein
was	O
shown	O
to	O
act	O
specifically	O
on	O
B	B-cell_type
cells	I-cell_type
,	O
inducing	O
proliferation	O
and	O
immunoglobulin	O
production	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
characterize	O
binding	O
of	O
radiolabeled	B-protein
BLyS	I-protein
to	O
its	O
cognate	B-protein
receptor	I-protein
on	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
examine	O
intracellular	O
events	O
initiated	O
by	O
BLyS	B-protein
binding	O
.	O

Similar	O
to	O
other	O
TNF	B-protein
family	I-protein
members	I-protein
,	O
BLyS	B-protein
is	O
present	O
in	O
solution	O
as	O
a	O
homotrimer	B-protein
as	O
determined	O
by	O
gel	O
filtration	O
chromatography	O
and	O
light	O
scattering	O
analysis	O
.	O
<EOS>	B-X
Similar	B-X
to	B-X
other	B-X
TNF	B-X
family	B-X
members	B-X
,	B-X
BLyS	B-X
is	B-X
present	B-X
in	B-X
solution	B-X
as	B-X
a	B-X
homotrimer	B-X
as	B-X
determined	B-X
by	B-X
gel	B-X
filtration	B-X
chromatography	B-X
and	B-X
light	B-X
scattering	B-X
analysis	B-X
<EOS>	B-X
BLyS	B-X
was	B-X
shown	B-X
to	B-X
act	B-X
specifically	B-X
on	B-X
B	B-X
cells	B-X
,	B-X
inducing	B-X
proliferation	B-X
and	B-X
immunoglobulin	B-X
production	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
<EOS>	B-X
B	B-X
lymphocyte	B-X
stimulator	B-X
(	B-X
BLyS	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
the	B-X
TNF	B-X
family	B-X
of	B-X
proteins	B-X
expressed	B-X
by	B-X
myeloid	B-X
cells	B-X
as	B-X
membrane	B-X
-	B-X
bound	B-X
and	B-X
soluble	B-X
forms	B-X
<EOS>	B-X
Scatchard	B-X
analysis	B-X
of	B-X
the	B-X
binding	B-X
data	B-X
revealed	B-X
a	B-X
single	B-X
class	B-X
of	B-X
high	B-X
-	B-X
affinity	B-X
binding	B-X
on	B-X
human	B-X
B	B-X
cells	B-X
with	B-X
approximately	B-X
2600	B-X
binding	B-X
sites	B-X
per	B-X
cell	B-X
and	B-X
an	B-X
apparent	B-X
dissociation	B-X
constant	B-X
(	B-X
K	B-X
(	B-X
D	B-X
)	B-X
)	B-X
of	B-X
about	B-X
0	B-X

BLyS	B-protein
binding	O
to	O
B	B-cell_type
cells	I-cell_type
is	O
specific	O
as	O
other	O
TNF	B-protein
family	I-protein
members	I-protein
tested	O
did	O
not	O
compete	O
for	O
(	O
125	O
)	O
I-	O
BLyS	B-protein
binding	O
.	O

Analysis	O
of	O
equilibrium	O
binding	O
of	O
(	B-protein
125	I-protein
)	I-protein
I-labeled	I-protein
BLyS	I-protein
to	O
purified	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	I-cell_type
demonstrated	O
saturable	O
binding	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
equilibrium	B-X
binding	B-X
of	B-X
(	B-X
125	B-X
)	B-X
I	B-X
-	B-X
labeled	B-X
BLyS	B-X
to	B-X
purified	B-X
human	B-X
tonsillar	B-X
B	B-X
cells	B-X
demonstrated	B-X
saturable	B-X
binding	B-X
<EOS>	B-X
The	B-X
present	B-X
study	B-X
was	B-X
undertaken	B-X
to	B-X
characterize	B-X
binding	B-X
of	B-X
radiolabeled	B-X
BLyS	B-X
to	B-X
its	B-X
cognate	B-X
receptor	B-X
on	B-X
human	B-X
B	B-X
lymphocytes	B-X
and	B-X
examine	B-X
intracellular	B-X
events	B-X
initiated	B-X
by	B-X
BLyS	B-X
binding	B-X
<EOS>	B-X
Scatchard	B-X
analysis	B-X
of	B-X
the	B-X
binding	B-X
data	B-X
revealed	B-X
a	B-X
single	B-X
class	B-X
of	B-X
high	B-X
-	B-X
affinity	B-X
binding	B-X
on	B-X
human	B-X
B	B-X
cells	B-X
with	B-X
approximately	B-X
2600	B-X
binding	B-X
sites	B-X
per	B-X
cell	B-X
and	B-X
an	B-X
apparent	B-X
dissociation	B-X
constant	B-X
(	B-X
K	B-X
(	B-X
D	B-X
)	B-X
)	B-X
of	B-X
about	B-X
0	B-X
<EOS>	B-X
In	B-X
addition	B-X
we	B-X
report	B-X
that	B-X
BLyS	B-X
binding	B-X
to	B-X
B	B-X
cells	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
the	B-X
Ets	B-X
family	B-X
transcription	B-X
factor	B-X
,	B-X
ELF	B-X
-	B-X
1	B-X
,	B-X
and	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
mRNA	B-X
for	B-X
Polo	B-X
-	B-X
like	B-X
kinase	B-X
(	B-X
PLK	B-X
)	B-X

Scatchard	O
analysis	O
of	O
the	O
binding	O
data	O
revealed	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
on	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
approximately	O
2600	O
binding	O
sites	O
per	O
cell	O
and	O
an	O
apparent	O
dissociation	O
constant	O
(	O
K	O
(	O
D	O
)	O
)	O
of	O
about	O
0.1	O
nM	O
.	O

In	O
addition	O
we	O
report	O
that	O
BLyS	B-protein
binding	O
to	O
B	B-cell_type
cells	I-cell_type
results	O
in	O
the	O
activation	O
of	O
NF-kappaB	B-protein
and	O
the	O
Ets	B-protein
family	I-protein
transcription	I-protein
factor	I-protein
,	O
ELF-1	B-protein
,	O
and	O
in	O
the	O
induction	O
of	O
mRNA	O
for	O
Polo-like	B-protein
kinase	I-protein
(	O
PLK	B-protein
)	O
.	O

Design	O
and	O
use	O
of	O
an	O
inducibly	O
activated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	B-protein
to	O
study	O
immune	O
modulation	O
.	O
<EOS>	B-X
Design	B-X
and	B-X
use	B-X
of	B-X
an	B-X
inducibly	B-X
activated	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
Nef	B-X
to	B-X
study	B-X
immune	B-X
modulation	B-X
.	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
Nef	B-X
-	B-X
ER	B-X
inducibly	B-X
associates	B-X
with	B-X
the	B-X
62	B-X
-	B-X
kDa	B-X
Ser	B-X
/	B-X
Thr	B-X
kinase	B-X
and	B-X
is	B-X
localized	B-X
to	B-X
specific	B-X
membrane	B-X
microdomains	B-X
(	B-X
lipid	B-X
rafts	B-X
)	B-X
only	B-X
after	B-X
activation	B-X
<EOS>	B-X
The	B-X
differential	B-X
timing	B-X
of	B-X
CD4	B-X
and	B-X
HLA	B-X
-	B-X
A2	B-X
downmodulation	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
HIV	B-X
pathogenesis	B-X
and	B-X
immune	B-X
evasion	B-X
<EOS>	B-X
The	B-X
Nef	B-X
-	B-X
ER	B-X
is	B-X
kept	B-X
in	B-X
an	B-X
inactive	B-X
state	B-X
due	B-X
to	B-X
steric	B-X
hindrance	B-X
,	B-X
and	B-X
addition	B-X
of	B-X
the	B-X
membrane	B-X
-	B-X
permeable	B-X
drug	B-X
4	B-X
-	B-X
hydroxytamoxifen	B-X
(	B-X
4	B-X
-	B-X
HT	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
ER	B-X
domain	B-X
,	B-X
leads	B-X
to	B-X
inducible	B-X
activation	B-X
of	B-X
Nef	B-X
-	B-X
ER	B-X
within	B-X
cells	B-X

The	O
Nef	B-protein
protein	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
infectivity	O
of	O
virus	O
particles	O
,	O
downmodulate	O
cell	B-protein
surface	I-protein
proteins	I-protein
,	O
and	O
associate	O
with	O
many	O
intracellular	B-protein
proteins	I-protein
that	O
are	O
thought	O
to	O
facilitate	O
HIV	O
infection	O
.	O
<EOS>	B-X
The	B-X
Nef	B-X
protein	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
enhance	B-X
the	B-X
infectivity	B-X
of	B-X
virus	B-X
particles	B-X
,	B-X
downmodulate	B-X
cell	B-X
surface	B-X
proteins	B-X
,	B-X
and	B-X
associate	B-X
with	B-X
many	B-X
intracellular	B-X
proteins	B-X
that	B-X
are	B-X
thought	B-X
to	B-X
facilitate	B-X
HIV	B-X
infection	B-X
<EOS>	B-X
The	B-X
Nef	B-X
-	B-X
ER	B-X
is	B-X
kept	B-X
in	B-X
an	B-X
inactive	B-X
state	B-X
due	B-X
to	B-X
steric	B-X
hindrance	B-X
,	B-X
and	B-X
addition	B-X
of	B-X
the	B-X
membrane	B-X
-	B-X
permeable	B-X
drug	B-X
4	B-X
-	B-X
hydroxytamoxifen	B-X
(	B-X
4	B-X
-	B-X
HT	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
ER	B-X
domain	B-X
,	B-X
leads	B-X
to	B-X
inducible	B-X
activation	B-X
of	B-X
Nef	B-X
-	B-X
ER	B-X
within	B-X
cells	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
Nef	B-X
-	B-X
ER	B-X
inducibly	B-X
associates	B-X
with	B-X
the	B-X
62	B-X
-	B-X
kDa	B-X
Ser	B-X
/	B-X
Thr	B-X
kinase	B-X
and	B-X
is	B-X
localized	B-X
to	B-X
specific	B-X
membrane	B-X
microdomains	B-X
(	B-X
lipid	B-X
rafts	B-X
)	B-X
only	B-X
after	B-X
activation	B-X
<EOS>	B-X
Using	B-X
this	B-X
inducible	B-X
Nef	B-X
,	B-X
we	B-X
also	B-X
compared	B-X
the	B-X
specific	B-X
requirements	B-X
for	B-X
CD4	B-X
and	B-X
HLA	B-X
-	B-X
A2	B-X
downmodulation	B-X
in	B-X
a	B-X
SupT1	B-X
T	B-X
-	B-X
cell	B-X
line	B-X

One	O
of	O
the	O
challenges	O
in	O
defining	O
the	O
molecular	O
events	O
regulated	O
by	O
Nef	B-protein
has	O
been	O
obtaining	O
good	O
expression	O
of	O
Nef	B-protein
protein	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

This	O
has	O
been	O
attributed	O
to	O
effects	O
of	O
Nef	B-protein
on	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O
<EOS>	B-X
This	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
Using	B-X
this	B-X
inducible	B-X
Nef	B-X
,	B-X
we	B-X
also	B-X
compared	B-X
the	B-X
specific	B-X
requirements	B-X
for	B-X
CD4	B-X
and	B-X
HLA	B-X
-	B-X
A2	B-X
downmodulation	B-X
in	B-X
a	B-X
SupT1	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
We	B-X
have	B-X
designed	B-X
a	B-X
Nef	B-X
protein	B-X
that	B-X
is	B-X
readily	B-X
expressed	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
lines	B-X
and	B-X
whose	B-X
function	B-X
is	B-X
inducibly	B-X
activated	B-X
<EOS>	B-X
It	B-X
is	B-X
composed	B-X
of	B-X
a	B-X
fusion	B-X
between	B-X
full	B-X
-	B-X
length	B-X
Nef	B-X
and	B-X
the	B-X
estrogen	B-X
receptor	B-X
hormone	B-X
-	B-X
binding	B-X
domain	B-X
(	B-X
Nef	B-X
-	B-X
ER	B-X
)	B-X

We	O
have	O
designed	O
a	O
Nef	B-protein
protein	I-protein
that	O
is	O
readily	O
expressed	O
in	O
T-cell	B-cell_line
lines	I-cell_line
and	O
whose	O
function	O
is	O
inducibly	O
activated	O
.	O
<EOS>	B-X
We	B-X
have	B-X
designed	B-X
a	B-X
Nef	B-X
protein	B-X
that	B-X
is	B-X
readily	B-X
expressed	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
lines	B-X
and	B-X
whose	B-X
function	B-X
is	B-X
inducibly	B-X
activated	B-X
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
Nef	B-X
-	B-X
ER	B-X
inducibly	B-X
associates	B-X
with	B-X
the	B-X
62	B-X
-	B-X
kDa	B-X
Ser	B-X
/	B-X
Thr	B-X
kinase	B-X
and	B-X
is	B-X
localized	B-X
to	B-X
specific	B-X
membrane	B-X
microdomains	B-X
(	B-X
lipid	B-X
rafts	B-X
)	B-X
only	B-X
after	B-X
activation	B-X
<EOS>	B-X
This	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
The	B-X
Nef	B-X
-	B-X
ER	B-X
is	B-X
kept	B-X
in	B-X
an	B-X
inactive	B-X
state	B-X
due	B-X
to	B-X
steric	B-X
hindrance	B-X
,	B-X
and	B-X
addition	B-X
of	B-X
the	B-X
membrane	B-X
-	B-X
permeable	B-X
drug	B-X
4	B-X
-	B-X
hydroxytamoxifen	B-X
(	B-X
4	B-X
-	B-X
HT	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
ER	B-X
domain	B-X
,	B-X
leads	B-X
to	B-X
inducible	B-X
activation	B-X
of	B-X
Nef	B-X
-	B-X
ER	B-X
within	B-X
cells	B-X

It	O
is	O
composed	O
of	O
a	O
fusion	O
between	O
full-length	B-protein
Nef	I-protein
and	O
the	O
estrogen	B-protein
receptor	I-protein
hormone-binding	I-protein
domain	I-protein
(	O
Nef-ER	B-protein
)	O
.	O
<EOS>	B-X
It	B-X
is	B-X
composed	B-X
of	B-X
a	B-X
fusion	B-X
between	B-X
full	B-X
-	B-X
length	B-X
Nef	B-X
and	B-X
the	B-X
estrogen	B-X
receptor	B-X
hormone	B-X
-	B-X
binding	B-X
domain	B-X
(	B-X
Nef	B-X
-	B-X
ER	B-X
)	B-X
<EOS>	B-X
This	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
The	B-X
Nef	B-X
-	B-X
ER	B-X
is	B-X
kept	B-X
in	B-X
an	B-X
inactive	B-X
state	B-X
due	B-X
to	B-X
steric	B-X
hindrance	B-X
,	B-X
and	B-X
addition	B-X
of	B-X
the	B-X
membrane	B-X
-	B-X
permeable	B-X
drug	B-X
4	B-X
-	B-X
hydroxytamoxifen	B-X
(	B-X
4	B-X
-	B-X
HT	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
ER	B-X
domain	B-X
,	B-X
leads	B-X
to	B-X
inducible	B-X
activation	B-X
of	B-X
Nef	B-X
-	B-X
ER	B-X
within	B-X
cells	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
challenges	B-X
in	B-X
defining	B-X
the	B-X
molecular	B-X
events	B-X
regulated	B-X
by	B-X
Nef	B-X
has	B-X
been	B-X
obtaining	B-X
good	B-X
expression	B-X
of	B-X
Nef	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X

The	O
Nef-ER	B-protein
is	O
kept	O
in	O
an	O
inactive	O
state	O
due	O
to	O
steric	O
hindrance	O
,	O
and	O
addition	O
of	O
the	O
membrane-permeable	O
drug	O
4-hydroxytamoxifen	O
(	O
4-HT	O
)	O
,	O
which	O
binds	O
to	O
the	O
ER	B-protein
domain	I-protein
,	O
leads	O
to	O
inducible	O
activation	O
of	O
Nef-ER	B-protein
within	O
cells	O
.	O

We	O
demonstrate	O
that	O
Nef-ER	B-protein
inducibly	O
associates	O
with	O
the	O
62-kDa	B-protein
Ser/Thr	I-protein
kinase	I-protein
and	O
is	O
localized	O
to	O
specific	O
membrane	O
microdomains	O
(	O
lipid	O
rafts	O
)	O
only	O
after	O
activation	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
Nef	B-X
-	B-X
ER	B-X
inducibly	B-X
associates	B-X
with	B-X
the	B-X
62	B-X
-	B-X
kDa	B-X
Ser	B-X
/	B-X
Thr	B-X
kinase	B-X
and	B-X
is	B-X
localized	B-X
to	B-X
specific	B-X
membrane	B-X
microdomains	B-X
(	B-X
lipid	B-X
rafts	B-X
)	B-X
only	B-X
after	B-X
activation	B-X
<EOS>	B-X
Design	B-X
and	B-X
use	B-X
of	B-X
an	B-X
inducibly	B-X
activated	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
Nef	B-X
to	B-X
study	B-X
immune	B-X
modulation	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
designed	B-X
a	B-X
Nef	B-X
protein	B-X
that	B-X
is	B-X
readily	B-X
expressed	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
lines	B-X
and	B-X
whose	B-X
function	B-X
is	B-X
inducibly	B-X
activated	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
challenges	B-X
in	B-X
defining	B-X
the	B-X
molecular	B-X
events	B-X
regulated	B-X
by	B-X
Nef	B-X
has	B-X
been	B-X
obtaining	B-X
good	B-X
expression	B-X
of	B-X
Nef	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X

Using	O
this	O
inducible	O
Nef	B-protein
,	O
we	O
also	O
compared	O
the	O
specific	O
requirements	O
for	O
CD4	B-protein
and	O
HLA-A2	B-protein
downmodulation	O
in	O
a	O
SupT1	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

Half-maximal	O
downmodulation	O
of	O
cell	B-protein
surface	I-protein
CD4	I-protein
required	O
very	O
little	O
active	O
Nef-ER	B-protein
and	O
occurred	O
as	O
early	O
as	O
4	O
h	O
after	O
addition	O
of	O
4-HT	O
.	O

In	O
contrast	O
,	O
50	O
%	O
downmodulation	O
of	O
HLA-A2	B-protein
by	O
Nef	B-protein
required	O
16	O
to	O
24	O
h	O
and	O
about	O
50-	O
to	O
100-fold-greater	O
concentrations	O
of	O
4-HT	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
50	B-X
%	B-X
downmodulation	B-X
of	B-X
HLA	B-X
-	B-X
A2	B-X
by	B-X
Nef	B-X
required	B-X
16	B-X
to	B-X
24	B-X
h	B-X
and	B-X
about	B-X
50	B-X
-	B-X
	B-X
to	B-X
100	B-X
-	B-X
fold	B-X
-	B-X
greater	B-X
concentrations	B-X
of	B-X
4	B-X
-	B-X
HT	B-X
<EOS>	B-X
Half	B-X
-	B-X
maximal	B-X
downmodulation	B-X
of	B-X
cell	B-X
surface	B-X
CD4	B-X
required	B-X
very	B-X
little	B-X
active	B-X
Nef	B-X
-	B-X
ER	B-X
and	B-X
occurred	B-X
as	B-X
early	B-X
as	B-X
4	B-X
h	B-X
after	B-X
addition	B-X
of	B-X
4	B-X
-	B-X
HT	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
HLA	B-X
-	B-X
A2	B-X
downmodulation	B-X
may	B-X
require	B-X
certain	B-X
threshold	B-X
levels	B-X
of	B-X
active	B-X
Nef	B-X
<EOS>	B-X
The	B-X
Nef	B-X
-	B-X
ER	B-X
is	B-X
kept	B-X
in	B-X
an	B-X
inactive	B-X
state	B-X
due	B-X
to	B-X
steric	B-X
hindrance	B-X
,	B-X
and	B-X
addition	B-X
of	B-X
the	B-X
membrane	B-X
-	B-X
permeable	B-X
drug	B-X
4	B-X
-	B-X
hydroxytamoxifen	B-X
(	B-X
4	B-X
-	B-X
HT	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
ER	B-X
domain	B-X
,	B-X
leads	B-X
to	B-X
inducible	B-X
activation	B-X
of	B-X
Nef	B-X
-	B-X
ER	B-X
within	B-X
cells	B-X

These	O
data	O
suggest	O
that	O
HLA-A2	B-protein
downmodulation	O
may	O
require	O
certain	O
threshold	O
levels	O
of	O
active	O
Nef	B-protein
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
HLA	B-X
-	B-X
A2	B-X
downmodulation	B-X
may	B-X
require	B-X
certain	B-X
threshold	B-X
levels	B-X
of	B-X
active	B-X
Nef	B-X
<EOS>	B-X
The	B-X
differential	B-X
timing	B-X
of	B-X
CD4	B-X
and	B-X
HLA	B-X
-	B-X
A2	B-X
downmodulation	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
HIV	B-X
pathogenesis	B-X
and	B-X
immune	B-X
evasion	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
challenges	B-X
in	B-X
defining	B-X
the	B-X
molecular	B-X
events	B-X
regulated	B-X
by	B-X
Nef	B-X
has	B-X
been	B-X
obtaining	B-X
good	B-X
expression	B-X
of	B-X
Nef	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
This	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X

The	O
differential	O
timing	O
of	O
CD4	B-protein
and	O
HLA-A2	B-protein
downmodulation	O
may	O
have	O
implications	O
for	O
HIV	O
pathogenesis	O
and	O
immune	O
evasion	O
.	O
<EOS>	B-X
The	B-X
differential	B-X
timing	B-X
of	B-X
CD4	B-X
and	B-X
HLA	B-X
-	B-X
A2	B-X
downmodulation	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
HIV	B-X
pathogenesis	B-X
and	B-X
immune	B-X
evasion	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
HLA	B-X
-	B-X
A2	B-X
downmodulation	B-X
may	B-X
require	B-X
certain	B-X
threshold	B-X
levels	B-X
of	B-X
active	B-X
Nef	B-X
<EOS>	B-X
Design	B-X
and	B-X
use	B-X
of	B-X
an	B-X
inducibly	B-X
activated	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
Nef	B-X
to	B-X
study	B-X
immune	B-X
modulation	B-X
.	B-X
<EOS>	B-X
This	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X

Regulation	O
of	O
chemokine	O
mRNA	O
expression	O
in	O
a	O
rat	O
model	O
of	O
vanadium-induced	O
pulmonary	O
inflammation	O
.	O

Environmental	O
and	O
occupational	O
exposure	O
to	O
vanadium	O
dusts	O
results	O
in	O
toxic	O
effects	O
mainly	O
confined	O
to	O
the	O
respiratory	O
system	O
.	O

Using	O
a	O
rat	O
model	O
of	O
acute	O
lung	O
inflammation	O
induced	O
by	O
intratracheal	O
instillation	O
of	O
sodium	O
metavanadate	O
(	O
NaVO3	O
)	O
at	O
the	O
dose	O
of	O
200	O
microg	O
V/kg	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
the	O
cytologic	O
characterization	O
of	O
pulmonary	O
inflammation	O
and	O
the	O
expression	O
of	O
chemokine	B-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
Using	B-X
a	B-X
rat	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
inflammation	B-X
induced	B-X
by	B-X
intratracheal	B-X
instillation	B-X
of	B-X
sodium	B-X
metavanadate	B-X
(	B-X
NaVO3	B-X
)	B-X
at	B-X
the	B-X
dose	B-X
of	B-X
200	B-X
microg	B-X
V	B-X
/	B-X
kg	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
cytologic	B-X
characterization	B-X
of	B-X
pulmonary	B-X
inflammation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
chemokine	B-X
mRNA	B-X
<EOS>	B-X
Using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
increased	B-X
nuclear	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
not	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
which	B-X
correlated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X
<EOS>	B-X
By	B-X
Northern	B-X
analysis	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
(	B-X
MIP	B-X
)	B-X
	B-X
-	B-X
2	B-X
mRNA	B-X
in	B-X
BAL	B-X
cells	B-X
increased	B-X
markedly	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
and	B-X
reduced	B-X
a	B-X
little	B-X
bit	B-X
at	B-X
4	B-X
h	B-X
,	B-X
whereas	B-X
MIP	B-X
-	B-X
1alpha	B-X
mRNA	B-X
in	B-X
BAL	B-X
cells	B-X
was	B-X
expressed	B-X
relatively	B-X
high	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
although	B-X
a	B-X
basal	B-X
expression	B-X
was	B-X
detected	B-X
in	B-X
control	B-X
group	B-X
,	B-X
and	B-X
returned	B-X
rapidly	B-X
nearly	B-X
to	B-X
control	B-X
level	B-X
at	B-X
4	B-X
h	B-X
<EOS>	B-X
01	B-X
)	B-X
into	B-X
the	B-X
lung	B-X
was	B-X
noted	B-X
4	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
whereas	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AMs	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
cells	B-X
appeared	B-X
to	B-X
decrease	B-X
significantly	B-X

Significant	O
polymorphonuclear	B-cell_type
leukocyte	I-cell_type
(	O
PMN	B-cell_type
)	O
influx	O
(	O
P	O
<	O
0.01	O
)	O
into	O
the	O
lung	O
was	O
noted	O
4	O
h	O
after	O
NaVO3	O
instillation	O
,	O
whereas	O
alveolar	B-cell_type
macrophages	I-cell_type
(	O
AMs	B-cell_type
)	O
in	O
bronchoalveolar	B-cell_type
lavage	I-cell_type
(	I-cell_type
BAL	I-cell_type
)	I-cell_type
cells	I-cell_type
appeared	O
to	O
decrease	O
significantly	O
.	O
<EOS>	B-X
01	B-X
)	B-X
into	B-X
the	B-X
lung	B-X
was	B-X
noted	B-X
4	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
whereas	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AMs	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
cells	B-X
appeared	B-X
to	B-X
decrease	B-X
significantly	B-X
<EOS>	B-X
By	B-X
Northern	B-X
analysis	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
(	B-X
MIP	B-X
)	B-X
	B-X
-	B-X
2	B-X
mRNA	B-X
in	B-X
BAL	B-X
cells	B-X
increased	B-X
markedly	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
and	B-X
reduced	B-X
a	B-X
little	B-X
bit	B-X
at	B-X
4	B-X
h	B-X
,	B-X
whereas	B-X
MIP	B-X
-	B-X
1alpha	B-X
mRNA	B-X
in	B-X
BAL	B-X
cells	B-X
was	B-X
expressed	B-X
relatively	B-X
high	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
although	B-X
a	B-X
basal	B-X
expression	B-X
was	B-X
detected	B-X
in	B-X
control	B-X
group	B-X
,	B-X
and	B-X
returned	B-X
rapidly	B-X
nearly	B-X
to	B-X
control	B-X
level	B-X
at	B-X
4	B-X
h	B-X
<EOS>	B-X
The	B-X
facts	B-X
that	B-X
PMN	B-X
influx	B-X
was	B-X
preceded	B-X
by	B-X
increased	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X
expression	B-X
,	B-X
suggesting	B-X
that	B-X
MIP	B-X
-	B-X
2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
NaVO3	B-X
-	B-X
induced	B-X
pulmonary	B-X
inflammation	B-X
,	B-X
whereas	B-X
increased	B-X
MIP	B-X
-	B-X
1alpha	B-X
mRNA	B-X
expression	B-X
was	B-X
followed	B-X
by	B-X
decreased	B-X
AMs	B-X
in	B-X
BAL	B-X
cells	B-X
,	B-X
suggesting	B-X
AMs	B-X
might	B-X
be	B-X
activated	B-X
by	B-X
MIP	B-X
-	B-X
1alpha	B-X
,	B-X
adherent	B-X
to	B-X
the	B-X
lining	B-X
surface	B-X
of	B-X
the	B-X
airways	B-X
and	B-X
then	B-X
resistant	B-X
to	B-X
be	B-X
washed	B-X
out	B-X
<EOS>	B-X
Significant	B-X
polymorphonuclear	B-X
leukocyte	B-X
(	B-X
PMN	B-X
)	B-X
influx	B-X
(	B-X
P	B-X
<	B-X
0	B-X

In	O
contrast	O
,	O
neither	O
PMNs	B-cell_type
nor	O
AMs	B-cell_type
changed	O
substantially	O
1	O
h	O
after	O
NaVO3	O
instillation	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
PMNs	B-X
nor	B-X
AMs	B-X
changed	B-X
substantially	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
<EOS>	B-X
Using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
increased	B-X
nuclear	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
not	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
which	B-X
correlated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
studies	B-X
suggest	B-X
that	B-X
MIP	B-X
-	B-X
2	B-X
is	B-X
an	B-X
important	B-X
mediator	B-X
of	B-X
NaVO3	B-X
-	B-X
induced	B-X
pulmonary	B-X
inflammation	B-X
in	B-X
the	B-X
rat	B-X
model	B-X
<EOS>	B-X
The	B-X
promotor	B-X
region	B-X
contains	B-X
consensus	B-X
binding	B-X
sites	B-X
for	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
and	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X

By	O
Northern	O
analysis	O
,	O
macrophage	B-RNA
inflammatory	I-RNA
protein	I-RNA
(	I-RNA
MIP	I-RNA
)	I-RNA
-2	I-RNA
mRNA	I-RNA
in	O
BAL	B-cell_type
cells	I-cell_type
increased	O
markedly	O
1	O
h	O
after	O
NaVO3	O
instillation	O
and	O
reduced	O
a	O
little	O
bit	O
at	O
4	O
h	O
,	O
whereas	O
MIP-1alpha	B-RNA
mRNA	I-RNA
in	O
BAL	B-cell_type
cells	I-cell_type
was	O
expressed	O
relatively	O
high	O
1	O
h	O
after	O
NaVO3	O
instillation	O
,	O
although	O
a	O
basal	O
expression	O
was	O
detected	O
in	O
control	O
group	O
,	O
and	O
returned	O
rapidly	O
nearly	O
to	O
control	O
level	O
at	O
4	O
h	O
.	O
<EOS>	B-X
By	B-X
Northern	B-X
analysis	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
(	B-X
MIP	B-X
)	B-X
	B-X
-	B-X
2	B-X
mRNA	B-X
in	B-X
BAL	B-X
cells	B-X
increased	B-X
markedly	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
and	B-X
reduced	B-X
a	B-X
little	B-X
bit	B-X
at	B-X
4	B-X
h	B-X
,	B-X
whereas	B-X
MIP	B-X
-	B-X
1alpha	B-X
mRNA	B-X
in	B-X
BAL	B-X
cells	B-X
was	B-X
expressed	B-X
relatively	B-X
high	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
although	B-X
a	B-X
basal	B-X
expression	B-X
was	B-X
detected	B-X
in	B-X
control	B-X
group	B-X
,	B-X
and	B-X
returned	B-X
rapidly	B-X
nearly	B-X
to	B-X
control	B-X
level	B-X
at	B-X
4	B-X
h	B-X
<EOS>	B-X
Using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
increased	B-X
nuclear	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
not	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
which	B-X
correlated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X
<EOS>	B-X
Using	B-X
a	B-X
rat	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
inflammation	B-X
induced	B-X
by	B-X
intratracheal	B-X
instillation	B-X
of	B-X
sodium	B-X
metavanadate	B-X
(	B-X
NaVO3	B-X
)	B-X
at	B-X
the	B-X
dose	B-X
of	B-X
200	B-X
microg	B-X
V	B-X
/	B-X
kg	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
cytologic	B-X
characterization	B-X
of	B-X
pulmonary	B-X
inflammation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
chemokine	B-X
mRNA	B-X
<EOS>	B-X
01	B-X
)	B-X
into	B-X
the	B-X
lung	B-X
was	B-X
noted	B-X
4	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
whereas	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AMs	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
cells	B-X
appeared	B-X
to	B-X
decrease	B-X
significantly	B-X

Since	O
MIP-2	B-protein
is	O
a	O
potent	O
PMN	B-cell_type
chemoattractant	O
and	O
MIP-1alpha	B-protein
is	O
a	O
potent	O
macrophage/monocyte	O
chemoattractant	O
has	O
been	O
well	O
known	O
.	O
<EOS>	B-X
Since	B-X
MIP	B-X
-	B-X
2	B-X
is	B-X
a	B-X
potent	B-X
PMN	B-X
chemoattractant	B-X
and	B-X
MIP	B-X
-	B-X
1alpha	B-X
is	B-X
a	B-X
potent	B-X
macrophage	B-X
/	B-X
monocyte	B-X
chemoattractant	B-X
has	B-X
been	B-X
well	B-X
known	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
elevated	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X
levels	B-X
are	B-X
accompanied	B-X
by	B-X
increased	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
activity	B-X
in	B-X
BAL	B-X
cells	B-X
,	B-X
suggesting	B-X
possible	B-X
MIP	B-X
-	B-X
2	B-X
transcriptional	B-X
regulation	B-X
through	B-X
NF	B-X
-	B-X
kappaB	B-X
<EOS>	B-X
01	B-X
)	B-X
into	B-X
the	B-X
lung	B-X
was	B-X
noted	B-X
4	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
whereas	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AMs	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
cells	B-X
appeared	B-X
to	B-X
decrease	B-X
significantly	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
PMNs	B-X
nor	B-X
AMs	B-X
changed	B-X
substantially	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X

The	O
facts	O
that	O
PMN	B-cell_type
influx	O
was	O
preceded	O
by	O
increased	O
MIP-2	O
mRNA	O
expression	O
,	O
suggesting	O
that	O
MIP-2	B-protein
is	O
involved	O
in	O
the	O
development	O
of	O
NaVO3-induced	O
pulmonary	O
inflammation	O
,	O
whereas	O
increased	O
MIP-1alpha	B-RNA
mRNA	I-RNA
expression	O
was	O
followed	O
by	O
decreased	O
AMs	B-cell_type
in	O
BAL	B-cell_type
cells	I-cell_type
,	O
suggesting	O
AMs	B-cell_type
might	O
be	O
activated	O
by	O
MIP-1alpha	B-protein
,	O
adherent	O
to	O
the	O
lining	O
surface	O
of	O
the	O
airways	O
and	O
then	O
resistant	O
to	O
be	O
washed	O
out	O
.	O

To	O
delineate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
,	O
we	O
recently	O
cloned	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
MIP-2	B-DNA
gene	I-DNA
.	O
<EOS>	B-X
To	B-X
delineate	B-X
the	B-X
mechanisms	B-X
of	B-X
transcriptional	B-X
activation	B-X
,	B-X
we	B-X
recently	B-X
cloned	B-X
the	B-X
5'	B-X
-	B-X
flanking	B-X
region	B-X
of	B-X
the	B-X
MIP	B-X
-	B-X
2	B-X
gene	B-X
<EOS>	B-X
The	B-X
promotor	B-X
region	B-X
contains	B-X
consensus	B-X
binding	B-X
sites	B-X
for	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
and	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
elevated	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X
levels	B-X
are	B-X
accompanied	B-X
by	B-X
increased	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
activity	B-X
in	B-X
BAL	B-X
cells	B-X
,	B-X
suggesting	B-X
possible	B-X
MIP	B-X
-	B-X
2	B-X
transcriptional	B-X
regulation	B-X
through	B-X
NF	B-X
-	B-X
kappaB	B-X
<EOS>	B-X
Using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
increased	B-X
nuclear	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
not	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
which	B-X
correlated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X

The	O
promotor	B-DNA
region	I-DNA
contains	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
and	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O
<EOS>	B-X
The	B-X
promotor	B-X
region	B-X
contains	B-X
consensus	B-X
binding	B-X
sites	B-X
for	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
and	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
The	B-X
promoter	B-X
contains	B-X
consensus	B-X
binding	B-X
sites	B-X
for	B-X
many	B-X
transcription	B-X
factors	B-X
including	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
and	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
Consensus	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
transcription	B-X
factors	B-X
Sp1	B-X
,	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
AP	B-X
-	B-X
2	B-X
,	B-X
GAF	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
and	B-X
NF	B-X
-	B-X
AT	B-X
were	B-X
found	B-X
<EOS>	B-X
No	B-X
significant	B-X
increase	B-X
in	B-X
other	B-X
transcription	B-X
factors	B-X
over	B-X
the	B-X
control	B-X
,	B-X
untreated	B-X
cells	B-X
was	B-X
observed	B-X

Using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
increased	O
nuclear	O
NF-kappaB	B-protein
,	O
not	O
AP-1	B-protein
,	O
binding	O
activity	O
was	O
detected	O
1	O
h	O
after	O
NaVO3	O
instillation	O
,	O
which	O
correlated	O
with	O
the	O
induction	O
of	O
MIP-2	B-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
With	B-X
the	B-X
use	B-X
of	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
,	B-X
an	B-X
oligonucleotide	B-X
(	B-X
	B-X
-	B-X
388	B-X
/	B-X
	B-X
-	B-X
353	B-X
)	B-X
showed	B-X
specific	B-X
protein	B-X
-	B-X
DNA	B-X
binding	B-X
that	B-X
was	B-X
blockshifted	B-X
with	B-X
an	B-X
anti	B-X
-	B-X
NFATc1	B-X
antibody	B-X
and	B-X
washed	B-X
out	B-X
with	B-X
excess	B-X
amounts	B-X
of	B-X
the	B-X
cold	B-X
consensus	B-X
sequence	B-X
<EOS>	B-X
The	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
was	B-X
used	B-X
to	B-X
validate	B-X
the	B-X
ability	B-X
of	B-X
miRNAs	B-X
to	B-X
bind	B-X
to	B-X
NF	B-X
-	B-X
κB	B-X
and	B-X
NFAT	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
detect	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
<EOS>	B-X
The	B-X
suppression	B-X
of	B-X
antioxidant	B-X
capacity	B-X
might	B-X
be	B-X
due	B-X
to	B-X
the	B-X
decrease	B-X
of	B-X
nuclear	B-X
Nrf2	B-X
protein	B-X
translocation	B-X
,	B-X
Nrf2	B-X
binding	B-X
to	B-X
antioxidant	B-X
response	B-X
element	B-X
(	B-X
ARE	B-X
)	B-X
sequences	B-X
,	B-X
and	B-X
subsequently	B-X
,	B-X
antioxidant	B-X
genes	B-X
transcription	B-X
as	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
luciferase	B-X
assay	B-X
showed	B-X

p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
and	O
p50	B-protein
protein	I-protein
appears	O
to	O
be	O
involved	O
in	O
MIP-2	O
NF-kappaB	B-protein
binding	O
.	O
<EOS>	B-X
p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
and	B-X
p50	B-X
protein	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
MIP	B-X
-	B-X
2	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
<EOS>	B-X
The	B-X
promotor	B-X
region	B-X
contains	B-X
consensus	B-X
binding	B-X
sites	B-X
for	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
and	B-X
activator	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
)	B-X
<EOS>	B-X
01	B-X
)	B-X
into	B-X
the	B-X
lung	B-X
was	B-X
noted	B-X
4	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
whereas	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AMs	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
cells	B-X
appeared	B-X
to	B-X
decrease	B-X
significantly	B-X
<EOS>	B-X
Environmental	B-X
and	B-X
occupational	B-X
exposure	B-X
to	B-X
vanadium	B-X
dusts	B-X
results	B-X
in	B-X
toxic	B-X
effects	B-X
mainly	B-X
confined	B-X
to	B-X
the	B-X
respiratory	B-X
system	B-X

Taken	O
together	O
,	O
our	O
studies	O
suggest	O
that	O
MIP-2	B-protein
is	O
an	O
important	O
mediator	O
of	O
NaVO3-induced	O
pulmonary	O
inflammation	O
in	O
the	O
rat	O
model	O
.	O
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
studies	B-X
suggest	B-X
that	B-X
MIP	B-X
-	B-X
2	B-X
is	B-X
an	B-X
important	B-X
mediator	B-X
of	B-X
NaVO3	B-X
-	B-X
induced	B-X
pulmonary	B-X
inflammation	B-X
in	B-X
the	B-X
rat	B-X
model	B-X
<EOS>	B-X
Regulation	B-X
of	B-X
chemokine	B-X
mRNA	B-X
expression	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
of	B-X
vanadium	B-X
-	B-X
induced	B-X
pulmonary	B-X
inflammation	B-X
.	B-X
<EOS>	B-X
Using	B-X
a	B-X
rat	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
inflammation	B-X
induced	B-X
by	B-X
intratracheal	B-X
instillation	B-X
of	B-X
sodium	B-X
metavanadate	B-X
(	B-X
NaVO3	B-X
)	B-X
at	B-X
the	B-X
dose	B-X
of	B-X
200	B-X
microg	B-X
V	B-X
/	B-X
kg	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
cytologic	B-X
characterization	B-X
of	B-X
pulmonary	B-X
inflammation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
chemokine	B-X
mRNA	B-X
<EOS>	B-X
Using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
increased	B-X
nuclear	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
not	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
which	B-X
correlated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X

In	O
addition	O
,	O
elevated	O
MIP-2	B-RNA
mRNA	I-RNA
levels	O
are	O
accompanied	O
by	O
increased	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
BAL	B-cell_type
cells	I-cell_type
,	O
suggesting	O
possible	O
MIP-2	B-protein
transcriptional	O
regulation	O
through	O
NF-kappaB	B-protein
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
elevated	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X
levels	B-X
are	B-X
accompanied	B-X
by	B-X
increased	B-X
NF	B-X
-	B-X
kappaB	B-X
binding	B-X
activity	B-X
in	B-X
BAL	B-X
cells	B-X
,	B-X
suggesting	B-X
possible	B-X
MIP	B-X
-	B-X
2	B-X
transcriptional	B-X
regulation	B-X
through	B-X
NF	B-X
-	B-X
kappaB	B-X
<EOS>	B-X
The	B-X
facts	B-X
that	B-X
PMN	B-X
influx	B-X
was	B-X
preceded	B-X
by	B-X
increased	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X
expression	B-X
,	B-X
suggesting	B-X
that	B-X
MIP	B-X
-	B-X
2	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
NaVO3	B-X
-	B-X
induced	B-X
pulmonary	B-X
inflammation	B-X
,	B-X
whereas	B-X
increased	B-X
MIP	B-X
-	B-X
1alpha	B-X
mRNA	B-X
expression	B-X
was	B-X
followed	B-X
by	B-X
decreased	B-X
AMs	B-X
in	B-X
BAL	B-X
cells	B-X
,	B-X
suggesting	B-X
AMs	B-X
might	B-X
be	B-X
activated	B-X
by	B-X
MIP	B-X
-	B-X
1alpha	B-X
,	B-X
adherent	B-X
to	B-X
the	B-X
lining	B-X
surface	B-X
of	B-X
the	B-X
airways	B-X
and	B-X
then	B-X
resistant	B-X
to	B-X
be	B-X
washed	B-X
out	B-X
<EOS>	B-X
To	B-X
delineate	B-X
the	B-X
mechanisms	B-X
of	B-X
transcriptional	B-X
activation	B-X
,	B-X
we	B-X
recently	B-X
cloned	B-X
the	B-X
5'	B-X
-	B-X
flanking	B-X
region	B-X
of	B-X
the	B-X
MIP	B-X
-	B-X
2	B-X
gene	B-X
<EOS>	B-X
Using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
increased	B-X
nuclear	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
not	B-X
AP	B-X
-	B-X
1	B-X
,	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
1	B-X
h	B-X
after	B-X
NaVO3	B-X
instillation	B-X
,	B-X
which	B-X
correlated	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
MIP	B-X
-	B-X
2	B-X
mRNA	B-X

Activation	O
of	O
signal	O
transduction	O
and	O
apoptosis	O
in	O
healthy	B-cell_type
lymphomonocytes	I-cell_type
exposed	O
to	O
bystander	O
HIV-1-infected	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
in	B-X
healthy	B-X
lymphomonocytes	B-X
exposed	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
.	B-X
<EOS>	B-X
All	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
uninfected	B-X
PBMC	B-X
can	B-X
undergo	B-X
activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
after	B-X
exposure	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
subsequent	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IFNs	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
analysed	B-X
the	B-X
induction	B-X
of	B-X
factors	B-X
involved	B-X
in	B-X
cytokine	B-X
signal	B-X
transduction	B-X
,	B-X
such	B-X
as	B-X
STAT	B-X
1	B-X
proteins	B-X
and	B-X
IRF	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
in	B-X
normal	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
exposed	B-X
to	B-X
HIV	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
<EOS>	B-X
Persistent	B-X
activation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
one	B-X
of	B-X
the	B-X
hallmarks	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X

Persistent	O
activation	O
of	O
the	O
immune	O
system	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
HIV-1	O
infection	O
.	O
<EOS>	B-X
Persistent	B-X
activation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
one	B-X
of	B-X
the	B-X
hallmarks	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
<EOS>	B-X
One	B-X
pathological	B-X
hallmark	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
is	B-X
chronic	B-X
activation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
driven	B-X
,	B-X
in	B-X
part	B-X
,	B-X
by	B-X
increased	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
<EOS>	B-X
The	B-X
immunosuppressive	B-X
role	B-X
of	B-X
IL	B-X
-	B-X
32	B-X
in	B-X
lymphatic	B-X
tissue	B-X
during	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
.	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
Tim	B-X
-	B-X
3	B-X
expression	B-X
on	B-X
the	B-X
cytotoxic	B-X
capabilities	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
context	B-X
of	B-X
HIV	B-X
infection	B-X

In	O
this	O
study	O
we	O
analysed	O
the	O
induction	O
of	O
factors	O
involved	O
in	O
cytokine	O
signal	O
transduction	O
,	O
such	O
as	O
STAT	B-protein
1	I-protein
proteins	I-protein
and	O
IRF-1	B-RNA
mRNA	I-RNA
,	O
in	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
exposed	O
to	O
HIV-infected	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
analysed	B-X
the	B-X
induction	B-X
of	B-X
factors	B-X
involved	B-X
in	B-X
cytokine	B-X
signal	B-X
transduction	B-X
,	B-X
such	B-X
as	B-X
STAT	B-X
1	B-X
proteins	B-X
and	B-X
IRF	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
in	B-X
normal	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
exposed	B-X
to	B-X
HIV	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
<EOS>	B-X
Activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
in	B-X
healthy	B-X
lymphomonocytes	B-X
exposed	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
.	B-X
<EOS>	B-X
All	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
uninfected	B-X
PBMC	B-X
can	B-X
undergo	B-X
activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
after	B-X
exposure	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
subsequent	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IFNs	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Apoptosis	B-X
induction	B-X
could	B-X
be	B-X
abrogated	B-X
mainly	B-X
by	B-X
antibodies	B-X
against	B-X
tumour	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
by	B-X
antibodies	B-X
against	B-X
IFN	B-X
-	B-X
gamma	B-X

Western	O
blot	O
analyses	O
and	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
results	O
indicate	O
that	O
both	O
cells	O
infected	O
with	O
a	O
X4	O
strain	O
and	O
cells	O
infected	O
with	O
a	O
R5	O
strain	O
are	O
able	O
to	O
increase	O
intracellular	O
levels	O
of	O
STAT	B-protein
1alpha	I-protein
and	I-protein
beta	I-protein
proteins	O
as	O
well	O
as	O
IRF-1	B-RNA
mRNA	I-RNA
.	O
<EOS>	B-X
Western	B-X
blot	B-X
analyses	B-X
and	B-X
reverse	B-X
transcriptase	B-X
-	B-X
polymerase	B-X
chain	B-X
reaction	B-X
results	B-X
indicate	B-X
that	B-X
both	B-X
cells	B-X
infected	B-X
with	B-X
a	B-X
X4	B-X
strain	B-X
and	B-X
cells	B-X
infected	B-X
with	B-X
a	B-X
R5	B-X
strain	B-X
are	B-X
able	B-X
to	B-X
increase	B-X
intracellular	B-X
levels	B-X
of	B-X
STAT	B-X
1alpha	B-X
and	B-X
beta	B-X
proteins	B-X
as	B-X
well	B-X
as	B-X
IRF	B-X
-	B-X
1	B-X
mRNA	B-X
<EOS>	B-X
Apoptosis	B-X
induction	B-X
could	B-X
be	B-X
abrogated	B-X
mainly	B-X
by	B-X
antibodies	B-X
against	B-X
tumour	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
by	B-X
antibodies	B-X
against	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
All	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
uninfected	B-X
PBMC	B-X
can	B-X
undergo	B-X
activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
after	B-X
exposure	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
subsequent	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IFNs	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
in	B-X
healthy	B-X
lymphomonocytes	B-X
exposed	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
.	B-X

This	O
effect	O
was	O
prevented	O
by	O
neutralizing	O
antibodies	O
against	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
.	O
<EOS>	B-X
This	B-X
effect	B-X
was	B-X
prevented	B-X
by	B-X
neutralizing	B-X
antibodies	B-X
against	B-X
interferon	B-X
-	B-X
alpha	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
<EOS>	B-X
Conversely	B-X
,	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
pigs	B-X
within	B-X
the	B-X
group	B-X
developed	B-X
neutralizing	B-X
antibodies	B-X
as	B-X
early	B-X
as	B-X
at	B-X
day	B-X
two	B-X
post	B-X
-	B-X
challenge	B-X
,	B-X
correlating	B-X
with	B-X
sterile	B-X
protection	B-X
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
transfer	B-X
to	B-X
T	B-X
lymphocytes	B-X
is	B-X
inhibited	B-X
by	B-X
broadly	B-X
neutralizing	B-X
antibody	B-X
VRC01	B-X
with	B-X
efficiency	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
cell	B-X
-	B-X
free	B-X
infection	B-X
of	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
all	B-X
pigs	B-X
co	B-X
-	B-X
immunized	B-X
with	B-X
B4	B-X
and	B-X
poly	B-X
(	B-X
I	B-X
:	B-X
C	B-X
)	B-X
elicited	B-X
FMDV	B-X
-	B-X
specific	B-X
neutralizing	B-X
antibodies	B-X
,	B-X
total	B-X
IgG	B-X
antibodies	B-X
,	B-X
type	B-X
I	B-X
interferon	B-X
(	B-X
IFN	B-X
-	B-X
α	B-X
/	B-X
β	B-X
)	B-X
and	B-X
cytokines	B-X
IFN	B-X
-	B-X
γ	B-X

HIV-1-infected	B-cell_type
cells	I-cell_type
dose-dependently	O
induced	O
apoptotic	O
commitment	O
in	O
normal	B-cell_type
PBMC	I-cell_type
,	O
as	O
revealed	O
by	O
DNA	O
fragmentation	O
analysis	O
,	O
but	O
this	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
of	O
caspase-3	O
activity	O
,	O
even	O
if	O
a	O
slight	O
up-regulation	O
of	O
IL-1beta-converting	B-RNA
enzyme	I-RNA
mRNA	I-RNA
was	O
detected	O
.	O
<EOS>	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
dose	B-X
-	B-X
dependently	B-X
induced	B-X
apoptotic	B-X
commitment	B-X
in	B-X
normal	B-X
PBMC	B-X
,	B-X
as	B-X
revealed	B-X
by	B-X
DNA	B-X
fragmentation	B-X
analysis	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
caspase	B-X
-	B-X
3	B-X
activity	B-X
,	B-X
even	B-X
if	B-X
a	B-X
slight	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
IL	B-X
-	B-X
1beta	B-X
-	B-X
converting	B-X
enzyme	B-X
mRNA	B-X
was	B-X
detected	B-X
<EOS>	B-X
All	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
uninfected	B-X
PBMC	B-X
can	B-X
undergo	B-X
activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
after	B-X
exposure	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
subsequent	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IFNs	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Apoptosis	B-X
induction	B-X
could	B-X
be	B-X
abrogated	B-X
mainly	B-X
by	B-X
antibodies	B-X
against	B-X
tumour	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
by	B-X
antibodies	B-X
against	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
analysed	B-X
the	B-X
induction	B-X
of	B-X
factors	B-X
involved	B-X
in	B-X
cytokine	B-X
signal	B-X
transduction	B-X
,	B-X
such	B-X
as	B-X
STAT	B-X
1	B-X
proteins	B-X
and	B-X
IRF	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
in	B-X
normal	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
exposed	B-X
to	B-X
HIV	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X

Apoptosis	O
induction	O
could	O
be	O
abrogated	O
mainly	O
by	O
antibodies	B-protein
against	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
by	O
antibodies	B-protein
against	O
IFN-gamma	B-protein
.	O
<EOS>	B-X
Apoptosis	B-X
induction	B-X
could	B-X
be	B-X
abrogated	B-X
mainly	B-X
by	B-X
antibodies	B-X
against	B-X
tumour	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
by	B-X
antibodies	B-X
against	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
All	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
uninfected	B-X
PBMC	B-X
can	B-X
undergo	B-X
activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
after	B-X
exposure	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
infected	B-X
cells	B-X
,	B-X
subsequent	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IFNs	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
<EOS>	B-X
This	B-X
effect	B-X
was	B-X
prevented	B-X
by	B-X
neutralizing	B-X
antibodies	B-X
against	B-X
interferon	B-X
-	B-X
alpha	B-X
(	B-X
IFN	B-X
-	B-X
alpha	B-X
)	B-X
<EOS>	B-X
Activation	B-X
of	B-X
signal	B-X
transduction	B-X
and	B-X
apoptosis	B-X
in	B-X
healthy	B-X
lymphomonocytes	B-X
exposed	B-X
to	B-X
bystander	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
.	B-X

All	O
these	O
findings	O
suggest	O
that	O
uninfected	B-cell_type
PBMC	I-cell_type
can	O
undergo	O
activation	O
of	O
signal	O
transduction	O
and	O
apoptosis	O
after	O
exposure	O
to	O
bystander	O
HIV-infected	B-cell_type
cells	I-cell_type
,	O
subsequent	O
to	O
the	O
induction	O
of	O
cytokines	B-protein
such	O
as	O
IFNs	B-protein
and	O
TNF-alpha	B-protein
.	O

The	O
physical	O
association	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
theta	I-protein
with	O
a	O
lipid	O
raft-associated	O
inhibitor	O
of	O
kappa	B-protein
B	I-protein
factor	I-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
complex	I-protein
plays	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	O
B	O
cascade	O
by	O
TCR	B-protein
and	O
CD28	B-protein
.	O

We	O
investigated	O
the	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
theta	I-protein
(	O
PKCtheta	B-protein
)	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	B-protein
cascade	O
in	O
primary	B-cell_type
human	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
theta	B-X
(	B-X
PKCtheta	B-X
)	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappaB	B-X
cascade	B-X
in	B-X
primary	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
<EOS>	B-X
The	B-X
physical	B-X
association	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
theta	B-X
with	B-X
a	B-X
lipid	B-X
raft	B-X
-	B-X
associated	B-X
inhibitor	B-X
of	B-X
kappa	B-X
B	B-X
factor	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
cascade	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
.	B-X
<EOS>	B-X
Constitutively	B-X
active	B-X
but	B-X
not	B-X
kinase	B-X
-	B-X
inactive	B-X
PKCtheta	B-X
activated	B-X
IKKbeta	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
<EOS>	B-X
Among	B-X
six	B-X
or	B-X
so	B-X
PKC	B-X
isoforms	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
only	B-X
PKCtheta	B-X
participates	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
supramolecular	B-X
activation	B-X
clusters	B-X
at	B-X
the	B-X
contact	B-X
site	B-X
of	B-X
the	B-X
TCR	B-X
with	B-X
Ag	B-X

Among	O
six	O
or	O
so	O
PKC	B-protein
isoforms	I-protein
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
only	O
PKCtheta	B-protein
participates	O
in	O
the	O
assembly	O
of	O
the	O
supramolecular	O
activation	O
clusters	O
at	O
the	O
contact	O
site	O
of	O
the	O
TCR	B-protein
with	O
Ag	B-protein
.	O
<EOS>	B-X
GmERF1	B-X
knockout	B-X
or	B-X
RNA	B-X
interference	B-X
resulted	B-X
in	B-X
significant	B-X
increases	B-X
in	B-X
root	B-X
and	B-X
P	B-X
uptake	B-X
efficiency	B-X
traits	B-X
,	B-X
while	B-X
the	B-X
overexpression	B-X
of	B-X
GmERF1	B-X
produced	B-X
an	B-X
LP	B-X
-	B-X
sensitive	B-X
phenotype	B-X
and	B-X
affected	B-X
the	B-X
expression	B-X
of	B-X
six	B-X
LP	B-X
stress	B-X
-	B-X
related	B-X
genes	B-X
<EOS>	B-X
Full	B-X
functional	B-X
status	B-X
recovery	B-X
which	B-X
is	B-X
a	B-X
multidimensional	B-X
concept	B-X
,	B-X
that	B-X
includes	B-X
personal	B-X
care	B-X
,	B-X
infant	B-X
and	B-X
family	B-X
care	B-X
,	B-X
social	B-X
and	B-X
occupational	B-X
activities	B-X
and	B-X
adjusting	B-X
to	B-X
the	B-X
role	B-X
of	B-X
motherhood	B-X
may	B-X
require	B-X
several	B-X
months	B-X
to	B-X
achieve	B-X
<EOS>	B-X
Interplay	B-X
between	B-X
biochemical	B-X
processes	B-X
and	B-X
network	B-X
properties	B-X
generates	B-X
neuronal	B-X
up	B-X
and	B-X
down	B-X
states	B-X
at	B-X
the	B-X
tripartite	B-X
synapse	B-X
.	B-X
<EOS>	B-X
Demonstrating	B-X
the	B-X
potential	B-X
for	B-X
improved	B-X
short	B-X
-	B-X
read	B-X
analysis	B-X
,	B-X
the	B-X
number	B-X
of	B-X
proper	B-X
read	B-X
pairs	B-X
recruited	B-X
to	B-X
the	B-X
MHC	B-X
was	B-X
found	B-X
to	B-X
be	B-X
increased	B-X
by	B-X
0	B-X

Signaling	O
via	O
both	O
the	O
TCR	B-protein
and	O
CD28	B-protein
is	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
multisubunit	B-protein
IkappaB	I-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
complex	I-protein
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
;	O
this	O
activation	O
could	O
be	O
inhibited	O
by	O
a	O
Ca	O
(	O
2+	O
)	O
-independent	O
PKC	O
isoform	O
inhibitor	O
,	O
rottlerin	O
.	O

Moreover	O
,	O
endogenous	O
PKCtheta	B-protein
physically	O
associates	O
with	O
activated	O
IKK	B-protein
complexes	I-protein
in	O
CD3/CD28-costimulated	B-cell_type
primary	I-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
endogenous	B-X
PKCtheta	B-X
physically	B-X
associates	B-X
with	B-X
activated	B-X
IKK	B-X
complexes	B-X
in	B-X
CD3	B-X
/	B-X
CD28	B-X
-	B-X
costimulated	B-X
primary	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
<EOS>	B-X
Confocal	B-X
microscopy	B-X
further	B-X
demonstrated	B-X
that	B-X
exogenously	B-X
expressed	B-X
PKCtheta	B-X
and	B-X
IKKss	B-X
colocalize	B-X
in	B-X
the	B-X
membrane	B-X
of	B-X
CD3	B-X
/	B-X
CD28	B-X
-	B-X
costimulated	B-X
Jurkat	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
physical	B-X
association	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
theta	B-X
with	B-X
a	B-X
lipid	B-X
raft	B-X
-	B-X
associated	B-X
inhibitor	B-X
of	B-X
kappa	B-X
B	B-X
factor	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
cascade	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
.	B-X
<EOS>	B-X
Constitutively	B-X
active	B-X
but	B-X
not	B-X
kinase	B-X
-	B-X
inactive	B-X
PKCtheta	B-X
activated	B-X
IKKbeta	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X

The	O
same	O
set	O
of	O
stimuli	O
also	O
induced	O
relocation	O
of	O
endogenous	O
PKCtheta	B-protein
and	O
IKKs	B-protein
to	O
a	O
GM1	O
ganglioside-enriched	O
,	O
detergent-insoluble	O
membrane	O
compartment	O
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
same	B-X
set	B-X
of	B-X
stimuli	B-X
also	B-X
induced	B-X
relocation	B-X
of	B-X
endogenous	B-X
PKCtheta	B-X
and	B-X
IKKs	B-X
to	B-X
a	B-X
GM1	B-X
ganglioside	B-X
-	B-X
enriched	B-X
,	B-X
detergent	B-X
-	B-X
insoluble	B-X
membrane	B-X
compartment	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X
<EOS>	B-X
Confocal	B-X
microscopy	B-X
further	B-X
demonstrated	B-X
that	B-X
exogenously	B-X
expressed	B-X
PKCtheta	B-X
and	B-X
IKKss	B-X
colocalize	B-X
in	B-X
the	B-X
membrane	B-X
of	B-X
CD3	B-X
/	B-X
CD28	B-X
-	B-X
costimulated	B-X
Jurkat	B-X
T	B-X
cells	B-X
<EOS>	B-X
Expression	B-X
of	B-X
dominant	B-X
-	B-X
active	B-X
PKCtheta	B-X
also	B-X
had	B-X
stimulatory	B-X
effects	B-X
on	B-X
the	B-X
CD28	B-X
response	B-X
element	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
endogenous	B-X
PKCtheta	B-X
physically	B-X
associates	B-X
with	B-X
activated	B-X
IKK	B-X
complexes	B-X
in	B-X
CD3	B-X
/	B-X
CD28	B-X
-	B-X
costimulated	B-X
primary	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X

IKKs	B-protein
recruited	O
to	O
these	O
lipid	O
rafts	O
were	O
capable	O
of	O
phosphorylating	O
a	O
recombinant	O
IkappaBalpha	O
sustrate	O
.	O
<EOS>	B-X
IKKs	B-X
recruited	B-X
to	B-X
these	B-X
lipid	B-X
rafts	B-X
were	B-X
capable	B-X
of	B-X
phosphorylating	B-X
a	B-X
recombinant	B-X
IkappaBalpha	B-X
sustrate	B-X
<EOS>	B-X
The	B-X
physical	B-X
association	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
theta	B-X
with	B-X
a	B-X
lipid	B-X
raft	B-X
-	B-X
associated	B-X
inhibitor	B-X
of	B-X
kappa	B-X
B	B-X
factor	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
cascade	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
.	B-X
<EOS>	B-X
Among	B-X
six	B-X
or	B-X
so	B-X
PKC	B-X
isoforms	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
only	B-X
PKCtheta	B-X
participates	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
supramolecular	B-X
activation	B-X
clusters	B-X
at	B-X
the	B-X
contact	B-X
site	B-X
of	B-X
the	B-X
TCR	B-X
with	B-X
Ag	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
show	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
PKCtheta	B-X
by	B-X
the	B-X
TCR	B-X
and	B-X
CD28	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
assembly	B-X
and	B-X
activation	B-X
of	B-X
IKK	B-X
complexes	B-X
in	B-X
the	B-X
T	B-X
cell	B-X
membrane	B-X

Confocal	O
microscopy	O
further	O
demonstrated	O
that	O
exogenously	O
expressed	O
PKCtheta	B-protein
and	O
IKKss	B-protein
colocalize	O
in	O
the	O
membrane	O
of	O
CD3/CD28-costimulated	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Constitutively	O
active	O
but	O
not	O
kinase-inactive	B-protein
PKCtheta	I-protein
activated	O
IKKbeta	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Constitutively	B-X
active	B-X
Lyn	B-X
kinase	B-X
causes	B-X
a	B-X
cutaneous	B-X
small	B-X
vessel	B-X
vasculitis	B-X
and	B-X
liver	B-X
fibrosis	B-X
syndrome	B-X
.	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
constitutively	B-X
active	B-X
Rab10	B-X
arrests	B-X
the	B-X
receptor	B-X
within	B-X
Rab5	B-X
-	B-X
positive	B-X
early	B-X
endosomes	B-X
and	B-X
significantly	B-X
hinders	B-X
the	B-X
resensitization	B-X
of	B-X
M4	B-X
-	B-X
mediated	B-X
Ca	B-X
<EOS>	B-X
This	B-X
report	B-X
identified	B-X
actin	B-X
-	B-X
related	B-X
protein	B-X
2	B-X
/	B-X
3	B-X
complex	B-X
inhibitor	B-X
(	B-X
ARPIN	B-X
)	B-X
as	B-X
a	B-X
target	B-X
of	B-X
ADAR1	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
<EOS>	B-X
To	B-X
cause	B-X
rice	B-X
blast	B-X
disease	B-X
,	B-X
the	B-X
filamentous	B-X
fungus	B-X

Expression	O
of	O
dominant-active	B-protein
PKCtheta	I-protein
also	O
had	O
stimulatory	O
effects	O
on	O
the	O
CD28	B-DNA
response	I-DNA
element	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Expression	B-X
of	B-X
dominant	B-X
-	B-X
active	B-X
PKCtheta	B-X
also	B-X
had	B-X
stimulatory	B-X
effects	B-X
on	B-X
the	B-X
CD28	B-X
response	B-X
element	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
show	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
PKCtheta	B-X
by	B-X
the	B-X
TCR	B-X
and	B-X
CD28	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
assembly	B-X
and	B-X
activation	B-X
of	B-X
IKK	B-X
complexes	B-X
in	B-X
the	B-X
T	B-X
cell	B-X
membrane	B-X
<EOS>	B-X
The	B-X
physical	B-X
association	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
theta	B-X
with	B-X
a	B-X
lipid	B-X
raft	B-X
-	B-X
associated	B-X
inhibitor	B-X
of	B-X
kappa	B-X
B	B-X
factor	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
cascade	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
.	B-X
<EOS>	B-X
The	B-X
same	B-X
set	B-X
of	B-X
stimuli	B-X
also	B-X
induced	B-X
relocation	B-X
of	B-X
endogenous	B-X
PKCtheta	B-X
and	B-X
IKKs	B-X
to	B-X
a	B-X
GM1	B-X
ganglioside	B-X
-	B-X
enriched	B-X
,	B-X
detergent	B-X
-	B-X
insoluble	B-X
membrane	B-X
compartment	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
activation	O
of	O
PKCtheta	B-protein
by	O
the	O
TCR	B-protein
and	O
CD28	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
assembly	O
and	O
activation	O
of	O
IKK	B-protein
complexes	I-protein
in	O
the	O
T	O
cell	O
membrane	O

T-cell	B-cell_type
-mediated	O
regulation	O
of	O
osteoclastogenesis	O
by	O
signalling	O
cross-talk	O
between	O
RANKL	B-protein
and	O
IFN-gamma	B-protein
.	O
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
mediated	B-X
regulation	B-X
of	B-X
osteoclastogenesis	B-X
by	B-X
signalling	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
RANKL	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
summarize	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
bone	B-X
metabolism	B-X
by	B-X
signalling	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
RANKL	B-X
and	B-X
IFNs	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
T	B-X
cell	B-X
-	B-X
mediated	B-X
regulation	B-X
of	B-X
osteoclastogenesis	B-X
by	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
T	B-X
-	B-X
cell	B-X
production	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
gamma	B-X
strongly	B-X
suppresses	B-X
osteoclastogenesis	B-X
by	B-X
interfering	B-X
with	B-X
the	B-X
RANKL	B-X
-	B-X
RANK	B-X
signalling	B-X
pathway	B-X
<EOS>	B-X
This	B-X
inhibition	B-X
of	B-X
osteoclastogenesis	B-X
is	B-X
rescued	B-X
by	B-X
overexpressing	B-X
TRAF6	B-X
in	B-X
precursor	B-X
cells	B-X
,	B-X
which	B-X
indicates	B-X
that	B-X
TRAF6	B-X
is	B-X
the	B-X
target	B-X
critical	B-X
for	B-X
the	B-X
IFN	B-X
-	B-X
gamma	B-X
action	B-X

Bone	O
resorption	O
is	O
regulated	O
by	O
the	O
immune	O
system	O
,	O
where	O
T-cell	B-cell_type
expression	O
of	O
RANKL	B-protein
(	O
receptor	B-protein
activator	I-protein
of	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
ligand	I-protein
)	O
,	O
a	O
member	O
of	O
the	O
tumour-necrosis	B-protein
factor	I-protein
family	I-protein
that	O
is	O
essential	O
for	O
osteoclastogenesis	O
,	O
may	O
contribute	O
to	O
pathological	O
conditions	O
,	O
such	O
as	O
autoimmune	O
arthritis	O
.	O
<EOS>	B-X
Bone	B-X
resorption	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
where	B-X
T	B-X
-	B-X
cell	B-X
expression	B-X
of	B-X
RANKL	B-X
(	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
ligand	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumour	B-X
-	B-X
necrosis	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
osteoclastogenesis	B-X
,	B-X
may	B-X
contribute	B-X
to	B-X
pathological	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
autoimmune	B-X
arthritis	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
T	B-X
-	B-X
cell	B-X
production	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
gamma	B-X
strongly	B-X
suppresses	B-X
osteoclastogenesis	B-X
by	B-X
interfering	B-X
with	B-X
the	B-X
RANKL	B-X
-	B-X
RANK	B-X
signalling	B-X
pathway	B-X
<EOS>	B-X
Our	B-X
study	B-X
shows	B-X
that	B-X
there	B-X
is	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
the	B-X
tumour	B-X
necrosis	B-X
factor	B-X
and	B-X
IFN	B-X
families	B-X
of	B-X
cytokines	B-X
,	B-X
through	B-X
which	B-X
IFN	B-X
-	B-X
gamma	B-X
provides	B-X
a	B-X
negative	B-X
link	B-X
between	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
and	B-X
bone	B-X
resorption	B-X
<EOS>	B-X
This	B-X
inhibition	B-X
of	B-X
osteoclastogenesis	B-X
is	B-X
rescued	B-X
by	B-X
overexpressing	B-X
TRAF6	B-X
in	B-X
precursor	B-X
cells	B-X
,	B-X
which	B-X
indicates	B-X
that	B-X
TRAF6	B-X
is	B-X
the	B-X
target	B-X
critical	B-X
for	B-X
the	B-X
IFN	B-X
-	B-X
gamma	B-X
action	B-X

However	O
,	O
whether	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
maintain	O
bone	O
homeostasis	O
by	O
counterbalancing	O
the	O
action	O
of	O
RANKL	B-protein
remains	O
unknown	O
.	O
<EOS>	B-X
However	B-X
,	B-X
whether	B-X
activated	B-X
T	B-X
cells	B-X
maintain	B-X
bone	B-X
homeostasis	B-X
by	B-X
counterbalancing	B-X
the	B-X
action	B-X
of	B-X
RANKL	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
T	B-X
-	B-X
cell	B-X
production	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
gamma	B-X
strongly	B-X
suppresses	B-X
osteoclastogenesis	B-X
by	B-X
interfering	B-X
with	B-X
the	B-X
RANKL	B-X
-	B-X
RANK	B-X
signalling	B-X
pathway	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
mediated	B-X
regulation	B-X
of	B-X
osteoclastogenesis	B-X
by	B-X
signalling	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
RANKL	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
accelerated	B-X
degradation	B-X
of	B-X
TRAF6	B-X
requires	B-X
both	B-X
its	B-X
ubiquitination	B-X
,	B-X
which	B-X
is	B-X
initiated	B-X
by	B-X
RANKL	B-X
,	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
ubiquitin	B-X
-	B-X
proteasome	B-X
system	B-X

Here	O
we	O
show	O
that	O
T-cell	B-cell_type
production	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
strongly	O
suppresses	O
osteoclastogenesis	O
by	O
interfering	O
with	O
the	O
RANKL	B-protein
-RANK	O
signalling	O
pathway	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
T	B-X
-	B-X
cell	B-X
production	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
gamma	B-X
strongly	B-X
suppresses	B-X
osteoclastogenesis	B-X
by	B-X
interfering	B-X
with	B-X
the	B-X
RANKL	B-X
-	B-X
RANK	B-X
signalling	B-X
pathway	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
mediated	B-X
regulation	B-X
of	B-X
osteoclastogenesis	B-X
by	B-X
signalling	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
RANKL	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
whether	B-X
activated	B-X
T	B-X
cells	B-X
maintain	B-X
bone	B-X
homeostasis	B-X
by	B-X
counterbalancing	B-X
the	B-X
action	B-X
of	B-X
RANKL	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
Bone	B-X
resorption	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
where	B-X
T	B-X
-	B-X
cell	B-X
expression	B-X
of	B-X
RANKL	B-X
(	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
ligand	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumour	B-X
-	B-X
necrosis	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
osteoclastogenesis	B-X
,	B-X
may	B-X
contribute	B-X
to	B-X
pathological	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
autoimmune	B-X
arthritis	B-X

IFN-gamma	B-protein
induces	O
rapid	O
degradation	O
of	O
the	O
RANK	B-protein
adapter	I-protein
protein	I-protein
,	O
TRAF6	B-protein
(	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
6	I-protein
)	O
,	O
which	O
results	O
in	O
strong	O
inhibition	O
of	O
the	O
RANKL	B-protein
-induced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
and	O
JNK	B-protein
.	O
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
induces	B-X
rapid	B-X
degradation	B-X
of	B-X
the	B-X
RANK	B-X
adapter	B-X
protein	B-X
,	B-X
TRAF6	B-X
(	B-X
tumour	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
6	B-X
)	B-X
,	B-X
which	B-X
results	B-X
in	B-X
strong	B-X
inhibition	B-X
of	B-X
the	B-X
RANKL	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
JNK	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
accelerated	B-X
degradation	B-X
of	B-X
TRAF6	B-X
requires	B-X
both	B-X
its	B-X
ubiquitination	B-X
,	B-X
which	B-X
is	B-X
initiated	B-X
by	B-X
RANKL	B-X
,	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
ubiquitin	B-X
-	B-X
proteasome	B-X
system	B-X
<EOS>	B-X
Our	B-X
study	B-X
shows	B-X
that	B-X
there	B-X
is	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
the	B-X
tumour	B-X
necrosis	B-X
factor	B-X
and	B-X
IFN	B-X
families	B-X
of	B-X
cytokines	B-X
,	B-X
through	B-X
which	B-X
IFN	B-X
-	B-X
gamma	B-X
provides	B-X
a	B-X
negative	B-X
link	B-X
between	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
and	B-X
bone	B-X
resorption	B-X
<EOS>	B-X
This	B-X
inhibition	B-X
of	B-X
osteoclastogenesis	B-X
is	B-X
rescued	B-X
by	B-X
overexpressing	B-X
TRAF6	B-X
in	B-X
precursor	B-X
cells	B-X
,	B-X
which	B-X
indicates	B-X
that	B-X
TRAF6	B-X
is	B-X
the	B-X
target	B-X
critical	B-X
for	B-X
the	B-X
IFN	B-X
-	B-X
gamma	B-X
action	B-X

This	O
inhibition	O
of	O
osteoclastogenesis	O
is	O
rescued	O
by	O
overexpressing	O
TRAF6	B-protein
in	O
precursor	B-cell_type
cells	I-cell_type
,	O
which	O
indicates	O
that	O
TRAF6	B-protein
is	O
the	O
target	O
critical	O
for	O
the	O
IFN-gamma	B-protein
action	O
.	O
<EOS>	B-X
This	B-X
inhibition	B-X
of	B-X
osteoclastogenesis	B-X
is	B-X
rescued	B-X
by	B-X
overexpressing	B-X
TRAF6	B-X
in	B-X
precursor	B-X
cells	B-X
,	B-X
which	B-X
indicates	B-X
that	B-X
TRAF6	B-X
is	B-X
the	B-X
target	B-X
critical	B-X
for	B-X
the	B-X
IFN	B-X
-	B-X
gamma	B-X
action	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
mediated	B-X
regulation	B-X
of	B-X
osteoclastogenesis	B-X
by	B-X
signalling	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
RANKL	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
.	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
induces	B-X
rapid	B-X
degradation	B-X
of	B-X
the	B-X
RANK	B-X
adapter	B-X
protein	B-X
,	B-X
TRAF6	B-X
(	B-X
tumour	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
6	B-X
)	B-X
,	B-X
which	B-X
results	B-X
in	B-X
strong	B-X
inhibition	B-X
of	B-X
the	B-X
RANKL	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
JNK	B-X
<EOS>	B-X
Bone	B-X
resorption	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
where	B-X
T	B-X
-	B-X
cell	B-X
expression	B-X
of	B-X
RANKL	B-X
(	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
ligand	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumour	B-X
-	B-X
necrosis	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
osteoclastogenesis	B-X
,	B-X
may	B-X
contribute	B-X
to	B-X
pathological	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
autoimmune	B-X
arthritis	B-X

Furthermore	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
accelerated	O
degradation	O
of	O
TRAF6	B-protein
requires	O
both	O
its	O
ubiquitination	O
,	O
which	O
is	O
initiated	O
by	O
RANKL	B-protein
,	O
and	O
IFN-gamma	B-protein
-induced	O
activation	O
of	O
the	O
ubiquitin-proteasome	O
system	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
accelerated	B-X
degradation	B-X
of	B-X
TRAF6	B-X
requires	B-X
both	B-X
its	B-X
ubiquitination	B-X
,	B-X
which	B-X
is	B-X
initiated	B-X
by	B-X
RANKL	B-X
,	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
ubiquitin	B-X
-	B-X
proteasome	B-X
system	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
induces	B-X
rapid	B-X
degradation	B-X
of	B-X
the	B-X
RANK	B-X
adapter	B-X
protein	B-X
,	B-X
TRAF6	B-X
(	B-X
tumour	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
6	B-X
)	B-X
,	B-X
which	B-X
results	B-X
in	B-X
strong	B-X
inhibition	B-X
of	B-X
the	B-X
RANKL	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
JNK	B-X
<EOS>	B-X
However	B-X
,	B-X
whether	B-X
activated	B-X
T	B-X
cells	B-X
maintain	B-X
bone	B-X
homeostasis	B-X
by	B-X
counterbalancing	B-X
the	B-X
action	B-X
of	B-X
RANKL	B-X
remains	B-X
unknown	B-X
<EOS>	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
mediated	B-X
regulation	B-X
of	B-X
osteoclastogenesis	B-X
by	B-X
signalling	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
RANKL	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
.	B-X

Our	O
study	O
shows	O
that	O
there	O
is	O
cross-talk	O
between	O
the	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
and	O
IFN	B-protein
families	I-protein
of	O
cytokines	B-protein
,	O
through	O
which	O
IFN-gamma	B-protein
provides	O
a	O
negative	O
link	O
between	O
T-cell	B-cell_type
activation	O
and	O
bone	O
resorption	O
.	O
<EOS>	B-X
Our	B-X
study	B-X
shows	B-X
that	B-X
there	B-X
is	B-X
cross	B-X
-	B-X
talk	B-X
between	B-X
the	B-X
tumour	B-X
necrosis	B-X
factor	B-X
and	B-X
IFN	B-X
families	B-X
of	B-X
cytokines	B-X
,	B-X
through	B-X
which	B-X
IFN	B-X
-	B-X
gamma	B-X
provides	B-X
a	B-X
negative	B-X
link	B-X
between	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
and	B-X
bone	B-X
resorption	B-X
<EOS>	B-X
IFN	B-X
-	B-X
gamma	B-X
induces	B-X
rapid	B-X
degradation	B-X
of	B-X
the	B-X
RANK	B-X
adapter	B-X
protein	B-X
,	B-X
TRAF6	B-X
(	B-X
tumour	B-X
necrosis	B-X
factor	B-X
receptor	B-X
-	B-X
associated	B-X
factor	B-X
6	B-X
)	B-X
,	B-X
which	B-X
results	B-X
in	B-X
strong	B-X
inhibition	B-X
of	B-X
the	B-X
RANKL	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
JNK	B-X
<EOS>	B-X
Bone	B-X
resorption	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
where	B-X
T	B-X
-	B-X
cell	B-X
expression	B-X
of	B-X
RANKL	B-X
(	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
	B-X
-	B-X
kappaB	B-X
ligand	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumour	B-X
-	B-X
necrosis	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
osteoclastogenesis	B-X
,	B-X
may	B-X
contribute	B-X
to	B-X
pathological	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
autoimmune	B-X
arthritis	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
T	B-X
-	B-X
cell	B-X
production	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
	B-X
-	B-X
gamma	B-X
strongly	B-X
suppresses	B-X
osteoclastogenesis	B-X
by	B-X
interfering	B-X
with	B-X
the	B-X
RANKL	B-X
-	B-X
RANK	B-X
signalling	B-X
pathway	B-X

Our	O
results	O
may	O
offer	O
a	O
therapeutic	O
approach	O
to	O
treat	O
the	O
inflammation-induced	O
tissue	O
breakdown	O
.	O

Stromal-derived	B-protein
factor	I-protein
1	I-protein
and	O
thrombopoietin	B-protein
regulate	O
distinct	O
aspects	O
of	O
human	O
megakaryopoiesis	O
.	O
<EOS>	B-X
Stromal	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
and	B-X
thrombopoietin	B-X
regulate	B-X
distinct	B-X
aspects	B-X
of	B-X
human	B-X
megakaryopoiesis	B-X
.	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
the	B-X
chemokine	B-X
binding	B-X
stromal	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
(	B-X
SDF	B-X
-	B-X
1	B-X
)	B-X
in	B-X
normal	B-X
human	B-X
megakaryopoiesis	B-X
at	B-X
the	B-X
cellular	B-X
and	B-X
molecular	B-X
levels	B-X
and	B-X
its	B-X
comparison	B-X
with	B-X
that	B-X
of	B-X
thrombopoietin	B-X
(	B-X
TPO	B-X
)	B-X
have	B-X
not	B-X
been	B-X
determined	B-X
<EOS>	B-X
Accordingly	B-X
,	B-X
PI	B-X
-	B-X
3K	B-X
is	B-X
involved	B-X
in	B-X
TPO	B-X
-	B-X
mediated	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
,	B-X
TPO	B-X
-	B-X
	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
regulated	B-X
adhesion	B-X
to	B-X
fibrinogen	B-X
and	B-X
vitronectin	B-X
,	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
migration	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
SDF	B-X
-	B-X
1	B-X
,	B-X
unlike	B-X
TPO	B-X
,	B-X
does	B-X
not	B-X
stimulate	B-X
alpha	B-X
(	B-X
IIb	B-X
)	B-X
beta	B-X
(	B-X
3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
cell	B-X
proliferation	B-X
or	B-X
differentiation	B-X
or	B-X
have	B-X
an	B-X
antiapoptotic	B-X
effect	B-X

The	O
role	O
of	O
the	O
chemokine	B-protein
binding	O
stromal-derived	B-protein
factor	I-protein
1	I-protein
(	O
SDF-1	B-protein
)	O
in	O
normal	O
human	O
megakaryopoiesis	O
at	O
the	O
cellular	O
and	O
molecular	O
levels	O
and	O
its	O
comparison	O
with	O
that	O
of	O
thrombopoietin	B-protein
(	O
TPO	B-protein
)	O
have	O
not	O
been	O
determined	O
.	O

In	O
this	O
study	O
it	O
was	O
found	O
that	O
SDF-1	B-protein
,	O
unlike	O
TPO	B-protein
,	O
does	O
not	O
stimulate	O
alpha	O
(	O
IIb	O
)	O
beta	O
(	O
3	O
)	O
(	O
+	O
)	O
cell	O
proliferation	O
or	O
differentiation	O
or	O
have	O
an	O
antiapoptotic	O
effect	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
it	B-X
was	B-X
proposed	B-X
that	B-X
improved	B-X
cognitive	B-X
processing	B-X
in	B-X
video	B-X
game	B-X
players	B-X
may	B-X
be	B-X
related	B-X
to	B-X
differential	B-X
alpha	B-X
activity	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
superrosid	B-X
species	B-X
Rhodiola	B-X
rosea	B-X
,	B-X
Boehmeria	B-X
nivea	B-X
,	B-X
and	B-X
Cucumis	B-X
sativus	B-X
for	B-X
their	B-X
root	B-X
epidermal	B-X
cell	B-X
patterns	B-X
<EOS>	B-X
Blastocystis	B-X
ST3	B-X
showed	B-X
high	B-X
genetic	B-X
diversity	B-X
in	B-X
wild	B-X
rhesus	B-X
macaques	B-X
and	B-X
significant	B-X
genetic	B-X
differentiation	B-X
between	B-X
the	B-X
HAG	B-X
and	B-X
LAG	B-X
<EOS>	B-X
A	B-X
fixed	B-X
sample	B-X
set	B-X
was	B-X
tested	B-X
three	B-X
times	B-X
by	B-X
the	B-X
same	B-X
operator	B-X
to	B-X
evaluate	B-X
the	B-X
repeatability	B-X
,	B-X
and	B-X
once	B-X
by	B-X
five	B-X
different	B-X
operators	B-X
to	B-X
assess	B-X
the	B-X
reproducibility	B-X

However	O
,	O
it	O
does	O
induce	O
chemotaxis	O
,	O
trans-Matrigel	O
migration	O
,	O
and	O
secretion	O
of	O
matrix	O
metalloproteinase	B-protein
9	I-protein
(	O
MMP-9	B-protein
)	O
and	O
vascular	B-protein
endothelial	I-protein
growth	I-protein
factor	I-protein
(	O
VEGF	B-protein
)	O
by	O
these	O
cells	O
,	O
and	O
both	O
SDF-1	B-protein
and	O
TPO	B-protein
increase	O
the	O
adhesion	O
of	O
alpha	B-cell_type
(	I-cell_type
IIb	I-cell_type
)	I-cell_type
beta	I-cell_type
(	I-cell_type
3	I-cell_type
)	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
to	O
fibrinogen	B-protein
and	O
vitronectin	B-protein
.	O

Investigating	O
the	O
intracellular	O
signaling	O
pathways	O
induced	O
by	O
SDF-1	B-protein
and	O
TPO	B-protein
revealed	O
some	O
overlapping	O
patterns	O
of	O
protein	O
phosphorylation/activation	O
(	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
[	I-protein
MAPK	I-protein
]	I-protein
p42/44	I-protein
,	O
MAPK	B-protein
p38	I-protein
,	O
and	O
AKT	B-protein
[	I-protein
protein	I-protein
kinase	I-protein
B	I-protein
]	I-protein
)	O
and	O
some	O
that	O
were	O
distinct	O
for	O
TPO	B-protein
(	O
eg	O
,	O
JAK-STAT	B-protein
)	O
and	O
for	O
SDF-1	B-protein
(	O
eg	O
,	O
NF-kappa	B-protein
B	I-protein
)	O
.	O
<EOS>	B-X
Investigating	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
induced	B-X
by	B-X
SDF	B-X
-	B-X
1	B-X
and	B-X
TPO	B-X
revealed	B-X
some	B-X
overlapping	B-X
patterns	B-X
of	B-X
protein	B-X
phosphorylation	B-X
/	B-X
activation	B-X
(	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
[	B-X
MAPK	B-X
]	B-X
p42	B-X
/	B-X
44	B-X
,	B-X
MAPK	B-X
p38	B-X
,	B-X
and	B-X
AKT	B-X
[	B-X
protein	B-X
kinase	B-X
B	B-X
]	B-X
)	B-X
and	B-X
some	B-X
that	B-X
were	B-X
distinct	B-X
for	B-X
TPO	B-X
(	B-X
eg	B-X
,	B-X
JAK	B-X
-	B-X
STAT	B-X
)	B-X
and	B-X
for	B-X
SDF	B-X
-	B-X
1	B-X
(	B-X
eg	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
<EOS>	B-X
Hence	B-X
,	B-X
it	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
TPO	B-X
is	B-X
more	B-X
related	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
JAK	B-X
-	B-X
STAT	B-X
pathway	B-X
(	B-X
unique	B-X
to	B-X
TPO	B-X
)	B-X
,	B-X
and	B-X
the	B-X
PI	B-X
-	B-X
3K	B-X
-	B-X
AKT	B-X
axis	B-X
is	B-X
differentially	B-X
involved	B-X
in	B-X
TPO	B-X
-	B-X
	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
signaling	B-X
<EOS>	B-X
This	B-X
study	B-X
expands	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
SDF	B-X
-	B-X
1	B-X
and	B-X
TPO	B-X
in	B-X
normal	B-X
human	B-X
megakaryopoiesis	B-X
and	B-X
indicates	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
observed	B-X
differences	B-X
in	B-X
cellular	B-X
responses	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
does	B-X
induce	B-X
chemotaxis	B-X
,	B-X
trans	B-X
-	B-X
Matrigel	B-X
migration	B-X
,	B-X
and	B-X
secretion	B-X
of	B-X
matrix	B-X
metalloproteinase	B-X
9	B-X
(	B-X
MMP	B-X
-	B-X
9	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
by	B-X
these	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
SDF	B-X
-	B-X
1	B-X
and	B-X
TPO	B-X
increase	B-X
the	B-X
adhesion	B-X
of	B-X
alpha	B-X
(	B-X
IIb	B-X
)	B-X
beta	B-X
(	B-X
3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
to	B-X
fibrinogen	B-X
and	B-X
vitronectin	B-X

It	O
was	O
also	O
found	O
that	O
though	O
inhibition	O
of	O
phosphatidyl-inositol	B-protein
3-kinase	I-protein
(	O
PI-3K	B-protein
)	O
by	O
LY294002	O
in	O
alpha	B-cell_type
(	I-cell_type
IIb	I-cell_type
)	I-cell_type
beta	I-cell_type
(	I-cell_type
3	I-cell_type
)	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
induced	O
apoptosis	O
and	O
inhibited	O
chemotaxis	O
adhesion	O
and	O
the	O
secretion	O
of	O
MMP-9	B-protein
and	O
VEGF	B-protein
,	O
the	O
inhibition	O
of	O
MAPK	B-protein
p42/44	I-protein
(	O
by	O
the	O
MEK	O
inhibitor	O
U0126	O
)	O
had	O
no	O
effect	O
on	O
the	O
survival	O
,	O
proliferation	O
,	O
and	O
migration	O
of	O
these	O
cells	O
.	O

Hence	O
,	O
it	O
is	O
suggested	O
that	O
the	O
proliferative	O
effect	O
of	O
TPO	B-protein
is	O
more	O
related	O
to	O
activation	O
of	O
the	O
JAK-STAT	O
pathway	O
(	O
unique	O
to	O
TPO	B-protein
)	O
,	O
and	O
the	O
PI-3K-AKT	O
axis	O
is	O
differentially	O
involved	O
in	O
TPO-	O
and	O
SDF-1-dependent	O
signaling	O
.	O
<EOS>	B-X
Hence	B-X
,	B-X
it	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
TPO	B-X
is	B-X
more	B-X
related	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
JAK	B-X
-	B-X
STAT	B-X
pathway	B-X
(	B-X
unique	B-X
to	B-X
TPO	B-X
)	B-X
,	B-X
and	B-X
the	B-X
PI	B-X
-	B-X
3K	B-X
-	B-X
AKT	B-X
axis	B-X
is	B-X
differentially	B-X
involved	B-X
in	B-X
TPO	B-X
-	B-X
	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
signaling	B-X
<EOS>	B-X
Accordingly	B-X
,	B-X
PI	B-X
-	B-X
3K	B-X
is	B-X
involved	B-X
in	B-X
TPO	B-X
-	B-X
mediated	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
,	B-X
TPO	B-X
-	B-X
	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
regulated	B-X
adhesion	B-X
to	B-X
fibrinogen	B-X
and	B-X
vitronectin	B-X
,	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
migration	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
it	B-X
was	B-X
found	B-X
that	B-X
SDF	B-X
-	B-X
1	B-X
,	B-X
unlike	B-X
TPO	B-X
,	B-X
does	B-X
not	B-X
stimulate	B-X
alpha	B-X
(	B-X
IIb	B-X
)	B-X
beta	B-X
(	B-X
3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
cell	B-X
proliferation	B-X
or	B-X
differentiation	B-X
or	B-X
have	B-X
an	B-X
antiapoptotic	B-X
effect	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
does	B-X
induce	B-X
chemotaxis	B-X
,	B-X
trans	B-X
-	B-X
Matrigel	B-X
migration	B-X
,	B-X
and	B-X
secretion	B-X
of	B-X
matrix	B-X
metalloproteinase	B-X
9	B-X
(	B-X
MMP	B-X
-	B-X
9	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
by	B-X
these	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
SDF	B-X
-	B-X
1	B-X
and	B-X
TPO	B-X
increase	B-X
the	B-X
adhesion	B-X
of	B-X
alpha	B-X
(	B-X
IIb	B-X
)	B-X
beta	B-X
(	B-X
3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
to	B-X
fibrinogen	B-X
and	B-X
vitronectin	B-X

Accordingly	O
,	O
PI-3K	B-protein
is	O
involved	O
in	O
TPO	B-protein
-mediated	O
inhibition	O
of	O
apoptosis	O
,	O
TPO-	O
and	O
SDF-1-regulated	O
adhesion	O
to	O
fibrinogen	B-protein
and	O
vitronectin	B-protein
,	O
and	O
SDF-1	B-protein
-mediated	O
migration	O
.	O
<EOS>	B-X
Accordingly	B-X
,	B-X
PI	B-X
-	B-X
3K	B-X
is	B-X
involved	B-X
in	B-X
TPO	B-X
-	B-X
mediated	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
,	B-X
TPO	B-X
-	B-X
	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
regulated	B-X
adhesion	B-X
to	B-X
fibrinogen	B-X
and	B-X
vitronectin	B-X
,	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
migration	B-X
<EOS>	B-X
Hence	B-X
,	B-X
it	B-X
is	B-X
suggested	B-X
that	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
TPO	B-X
is	B-X
more	B-X
related	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
JAK	B-X
-	B-X
STAT	B-X
pathway	B-X
(	B-X
unique	B-X
to	B-X
TPO	B-X
)	B-X
,	B-X
and	B-X
the	B-X
PI	B-X
-	B-X
3K	B-X
-	B-X
AKT	B-X
axis	B-X
is	B-X
differentially	B-X
involved	B-X
in	B-X
TPO	B-X
-	B-X
	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
dependent	B-X
signaling	B-X
<EOS>	B-X
Stromal	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
and	B-X
thrombopoietin	B-X
regulate	B-X
distinct	B-X
aspects	B-X
of	B-X
human	B-X
megakaryopoiesis	B-X
.	B-X
<EOS>	B-X
It	B-X
was	B-X
also	B-X
found	B-X
that	B-X
though	B-X
inhibition	B-X
of	B-X
phosphatidyl	B-X
-	B-X
inositol	B-X
3	B-X
-	B-X
kinase	B-X
(	B-X
PI	B-X
-	B-X
3K	B-X
)	B-X
by	B-X
LY294002	B-X
in	B-X
alpha	B-X
(	B-X
IIb	B-X
)	B-X
beta	B-X
(	B-X
3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
induced	B-X
apoptosis	B-X
and	B-X
inhibited	B-X
chemotaxis	B-X
adhesion	B-X
and	B-X
the	B-X
secretion	B-X
of	B-X
MMP	B-X
-	B-X
9	B-X
and	B-X
VEGF	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
MAPK	B-X
p42	B-X
/	B-X
44	B-X
(	B-X
by	B-X
the	B-X
MEK	B-X
inhibitor	B-X
U0126	B-X
)	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
migration	B-X
of	B-X
these	B-X
cells	B-X

This	O
study	O
expands	O
the	O
understanding	O
of	O
the	O
role	O
of	O
SDF-1	B-protein
and	O
TPO	B-protein
in	O
normal	O
human	O
megakaryopoiesis	O
and	O
indicates	O
the	O
molecular	O
basis	O
of	O
the	O
observed	O
differences	O
in	O
cellular	O
responses	O
.	O
<EOS>	B-X
This	B-X
study	B-X
expands	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
SDF	B-X
-	B-X
1	B-X
and	B-X
TPO	B-X
in	B-X
normal	B-X
human	B-X
megakaryopoiesis	B-X
and	B-X
indicates	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
observed	B-X
differences	B-X
in	B-X
cellular	B-X
responses	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
the	B-X
chemokine	B-X
binding	B-X
stromal	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
(	B-X
SDF	B-X
-	B-X
1	B-X
)	B-X
in	B-X
normal	B-X
human	B-X
megakaryopoiesis	B-X
at	B-X
the	B-X
cellular	B-X
and	B-X
molecular	B-X
levels	B-X
and	B-X
its	B-X
comparison	B-X
with	B-X
that	B-X
of	B-X
thrombopoietin	B-X
(	B-X
TPO	B-X
)	B-X
have	B-X
not	B-X
been	B-X
determined	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
does	B-X
induce	B-X
chemotaxis	B-X
,	B-X
trans	B-X
-	B-X
Matrigel	B-X
migration	B-X
,	B-X
and	B-X
secretion	B-X
of	B-X
matrix	B-X
metalloproteinase	B-X
9	B-X
(	B-X
MMP	B-X
-	B-X
9	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
by	B-X
these	B-X
cells	B-X
,	B-X
and	B-X
both	B-X
SDF	B-X
-	B-X
1	B-X
and	B-X
TPO	B-X
increase	B-X
the	B-X
adhesion	B-X
of	B-X
alpha	B-X
(	B-X
IIb	B-X
)	B-X
beta	B-X
(	B-X
3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
to	B-X
fibrinogen	B-X
and	B-X
vitronectin	B-X
<EOS>	B-X
Stromal	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
and	B-X
thrombopoietin	B-X
regulate	B-X
distinct	B-X
aspects	B-X
of	B-X
human	B-X
megakaryopoiesis	B-X
.	B-X

(	O
Blood.	O
2000	O
;	O
96	O
:	O
4142-4151	O
)	O
<EOS>	B-X
2000	B-X
;	B-X
96:4142	B-X
-	B-X
4151	B-X
)	B-X
<EOS>	B-X
(	B-X
Blood	B-X
<EOS>	B-X
Stromal	B-X
-	B-X
derived	B-X
factor	B-X
1	B-X
and	B-X
thrombopoietin	B-X
regulate	B-X
distinct	B-X
aspects	B-X
of	B-X
human	B-X
megakaryopoiesis	B-X
.	B-X
<EOS>	B-X
Accordingly	B-X
,	B-X
PI	B-X
-	B-X
3K	B-X
is	B-X
involved	B-X
in	B-X
TPO	B-X
-	B-X
mediated	B-X
inhibition	B-X
of	B-X
apoptosis	B-X
,	B-X
TPO	B-X
-	B-X
	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
regulated	B-X
adhesion	B-X
to	B-X
fibrinogen	B-X
and	B-X
vitronectin	B-X
,	B-X
and	B-X
SDF	B-X
-	B-X
1	B-X
-	B-X
mediated	B-X
migration	B-X

Adhesion	O
of	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
T	I-cell_type
cells	I-cell_type
induces	O
in	O
human	B-cell_type
thymic	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
(	O
TEC	B-cell_type
)	O
activation	O
of	O
IL-6	B-protein
gene	I-protein
trascription	I-protein
factors	I-protein
(	O
NF-kappaB	B-protein
and	O
NF-IL6	B-protein
)	O
and	O
IL-6	O
gene	O
expression	O
:	O
role	O
of	O
alpha3beta1	B-protein
and	I-protein
alpha6beta4	I-protein
integrins	I-protein
.	O
<EOS>	B-X
Adhesion	B-X
of	B-X
immature	B-X
and	B-X
mature	B-X
T	B-X
cells	B-X
induces	B-X
in	B-X
human	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
activation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
trascription	B-X
factors	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
)	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
:	B-X
role	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
integrins	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
thymocyte	B-X
adhesion	B-X
was	B-X
followed	B-X
by	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
gene	B-X
transcription	B-X
factors	B-X
and	B-X
enhanced	B-X
IL	B-X
-	B-X
6	B-X
production	B-X
<EOS>	B-X
Among	B-X
them	B-X
,	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
are	B-X
known	B-X
to	B-X
exert	B-X
dominant	B-X
roles	B-X
in	B-X
their	B-X
survival	B-X
and	B-X
functional	B-X
shaping	B-X
<EOS>	B-X
We	B-X
demonstrated	B-X
that	B-X
thymocytes	B-X
adhere	B-X
to	B-X
TEC	B-X
involving	B-X
beta1	B-X
and	B-X
beta4	B-X
integrins	B-X
and	B-X
induce	B-X
the	B-X
clustering	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
heterodimers	B-X
at	B-X
the	B-X
TEC	B-X
surface	B-X

T	B-cell_type
cell	I-cell_type
precursors	I-cell_type
homed	O
to	O
thymus	O
develop	O
in	O
close	O
contact	O
with	O
stromal	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
T	B-X
cell	B-X
precursors	B-X
homed	B-X
to	B-X
thymus	B-X
develop	B-X
in	B-X
close	B-X
contact	B-X
with	B-X
stromal	B-X
cells	B-X
<EOS>	B-X
Signaling	B-X
events	B-X
triggered	B-X
in	B-X
thymocytes	B-X
by	B-X
adhesion	B-X
to	B-X
epithelial	B-X
cells	B-X
have	B-X
been	B-X
extensively	B-X
investigated	B-X
,	B-X
whereas	B-X
little	B-X
is	B-X
known	B-X
on	B-X
the	B-X
opposite	B-X
phenomenon	B-X
<EOS>	B-X
Key	B-X
molecules	B-X
mediating	B-X
TEC	B-X
/	B-X
thymocytes	B-X
interactions	B-X
include	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
secreted	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
types	B-X
and	B-X
adhesion	B-X
receptors	B-X
mediating	B-X
cell	B-X
contact	B-X
<EOS>	B-X
In	B-X
addition	B-X
thymocyte	B-X
adhesion	B-X
was	B-X
followed	B-X
by	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
gene	B-X
transcription	B-X
factors	B-X
and	B-X
enhanced	B-X
IL	B-X
-	B-X
6	B-X
production	B-X

Among	O
them	O
,	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
(	O
TEC	B-cell_type
)	O
are	O
known	O
to	O
exert	O
dominant	O
roles	O
in	O
their	O
survival	O
and	O
functional	O
shaping	O
.	O
<EOS>	B-X
Among	B-X
them	B-X
,	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
are	B-X
known	B-X
to	B-X
exert	B-X
dominant	B-X
roles	B-X
in	B-X
their	B-X
survival	B-X
and	B-X
functional	B-X
shaping	B-X
<EOS>	B-X
Adhesion	B-X
of	B-X
immature	B-X
and	B-X
mature	B-X
T	B-X
cells	B-X
induces	B-X
in	B-X
human	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
activation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
trascription	B-X
factors	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
)	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
:	B-X
role	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
integrins	B-X
.	B-X
<EOS>	B-X
Signaling	B-X
events	B-X
triggered	B-X
in	B-X
thymocytes	B-X
by	B-X
adhesion	B-X
to	B-X
epithelial	B-X
cells	B-X
have	B-X
been	B-X
extensively	B-X
investigated	B-X
,	B-X
whereas	B-X
little	B-X
is	B-X
known	B-X
on	B-X
the	B-X
opposite	B-X
phenomenon	B-X
<EOS>	B-X
Key	B-X
molecules	B-X
mediating	B-X
TEC	B-X
/	B-X
thymocytes	B-X
interactions	B-X
include	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
secreted	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
types	B-X
and	B-X
adhesion	B-X
receptors	B-X
mediating	B-X
cell	B-X
contact	B-X

Key	O
molecules	O
mediating	O
TEC	B-cell_type
/	O
thymocytes	B-cell_type
interactions	O
include	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
secreted	O
by	O
the	O
two	O
cell	O
types	O
and	O
adhesion	B-protein
receptors	I-protein
mediating	O
cell	O
contact	O
.	O
<EOS>	B-X
Key	B-X
molecules	B-X
mediating	B-X
TEC	B-X
/	B-X
thymocytes	B-X
interactions	B-X
include	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
secreted	B-X
by	B-X
the	B-X
two	B-X
cell	B-X
types	B-X
and	B-X
adhesion	B-X
receptors	B-X
mediating	B-X
cell	B-X
contact	B-X
<EOS>	B-X
Among	B-X
them	B-X
,	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
are	B-X
known	B-X
to	B-X
exert	B-X
dominant	B-X
roles	B-X
in	B-X
their	B-X
survival	B-X
and	B-X
functional	B-X
shaping	B-X
<EOS>	B-X
In	B-X
addition	B-X
thymocyte	B-X
adhesion	B-X
was	B-X
followed	B-X
by	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
gene	B-X
transcription	B-X
factors	B-X
and	B-X
enhanced	B-X
IL	B-X
-	B-X
6	B-X
production	B-X
<EOS>	B-X
We	B-X
demonstrated	B-X
that	B-X
thymocytes	B-X
adhere	B-X
to	B-X
TEC	B-X
involving	B-X
beta1	B-X
and	B-X
beta4	B-X
integrins	B-X
and	B-X
induce	B-X
the	B-X
clustering	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
heterodimers	B-X
at	B-X
the	B-X
TEC	B-X
surface	B-X

Signaling	O
events	O
triggered	O
in	O
thymocytes	B-cell_type
by	O
adhesion	O
to	O
epithelial	B-cell_type
cells	I-cell_type
have	O
been	O
extensively	O
investigated	O
,	O
whereas	O
little	O
is	O
known	O
on	O
the	O
opposite	O
phenomenon	O
.	O
<EOS>	B-X
Signaling	B-X
events	B-X
triggered	B-X
in	B-X
thymocytes	B-X
by	B-X
adhesion	B-X
to	B-X
epithelial	B-X
cells	B-X
have	B-X
been	B-X
extensively	B-X
investigated	B-X
,	B-X
whereas	B-X
little	B-X
is	B-X
known	B-X
on	B-X
the	B-X
opposite	B-X
phenomenon	B-X
<EOS>	B-X
Among	B-X
them	B-X
,	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
are	B-X
known	B-X
to	B-X
exert	B-X
dominant	B-X
roles	B-X
in	B-X
their	B-X
survival	B-X
and	B-X
functional	B-X
shaping	B-X
<EOS>	B-X
We	B-X
have	B-X
extended	B-X
our	B-X
previous	B-X
work	B-X
investigating	B-X
in	B-X
the	B-X
same	B-X
experimental	B-X
setting	B-X
the	B-X
inducing	B-X
activity	B-X
of	B-X
non	B-X
stimulated	B-X
or	B-X
activated	B-X
policlonal	B-X
or	B-X
clonal	B-X
mature	B-X
T	B-X
cells	B-X
as	B-X
representative	B-X
of	B-X
the	B-X
more	B-X
mature	B-X
thymocyte	B-X
subset	B-X
<EOS>	B-X
Adhesion	B-X
of	B-X
immature	B-X
and	B-X
mature	B-X
T	B-X
cells	B-X
induces	B-X
in	B-X
human	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
activation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
trascription	B-X
factors	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
)	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
:	B-X
role	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
integrins	B-X
.	B-X

We	O
have	O
previously	O
investigated	O
this	O
issue	O
in	O
a	O
co-culture	O
system	O
composed	O
of	O
TEC	B-cell_type
cultures	I-cell_type
derived	O
from	O
human	O
normal	O
thymus	O
and	O
heterologous	B-cell_type
thymocytes	I-cell_type
.	O

We	O
demonstrated	O
that	O
thymocytes	B-cell_type
adhere	O
to	O
TEC	B-cell_type
involving	O
beta1	B-protein
and	I-protein
beta4	I-protein
integrins	I-protein
and	O
induce	O
the	O
clustering	O
of	O
alpha3beta1	B-protein
and	I-protein
alpha6beta4	I-protein
heterodimers	I-protein
at	O
the	O
TEC	O
surface	O
.	O
<EOS>	B-X
We	B-X
demonstrated	B-X
that	B-X
thymocytes	B-X
adhere	B-X
to	B-X
TEC	B-X
involving	B-X
beta1	B-X
and	B-X
beta4	B-X
integrins	B-X
and	B-X
induce	B-X
the	B-X
clustering	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
heterodimers	B-X
at	B-X
the	B-X
TEC	B-X
surface	B-X
<EOS>	B-X
The	B-X
two	B-X
latter	B-X
phenomena	B-X
were	B-X
reproduced	B-X
by	B-X
the	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
alpha3	B-X
,	B-X
alpha6	B-X
,	B-X
beta1	B-X
and	B-X
beta4	B-X
integrins	B-X
,	B-X
thus	B-X
implying	B-X
that	B-X
the	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
heterodimers	B-X
can	B-X
signal	B-X
during	B-X
thymocyte	B-X
adhesion	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
adhesion	B-X
of	B-X
unstimulated	B-X
T	B-X
cell	B-X
i	B-X
)	B-X
involved	B-X
beta1	B-X
,	B-X
but	B-X
not	B-X
beta4	B-X
integrin	B-X
functions	B-X
at	B-X
the	B-X
surface	B-X
ii	B-X
)	B-X
induced	B-X
the	B-X
clustering	B-X
of	B-X
alpha3beta1	B-X
,	B-X
but	B-X
not	B-X
alpha2beta1	B-X
heterodimers	B-X
at	B-X
the	B-X
TEC	B-X
surface	B-X
and	B-X
iii	B-X
)	B-X
up	B-X
-	B-X
regulated	B-X
the	B-X
nuclear	B-X
binding	B-X
activity	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
and	B-X
the	B-X
IL	B-X
-	B-X
6	B-X
secretion	B-X
<EOS>	B-X
In	B-X
addition	B-X
thymocyte	B-X
adhesion	B-X
was	B-X
followed	B-X
by	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
gene	B-X
transcription	B-X
factors	B-X
and	B-X
enhanced	B-X
IL	B-X
-	B-X
6	B-X
production	B-X

In	O
addition	O
thymocyte	O
adhesion	O
was	O
followed	O
by	O
activation	O
of	O
NF-kappaB	B-protein
and	O
NF-IL6	B-protein
gene	B-protein
transcription	I-protein
factors	I-protein
and	O
enhanced	O
IL-6	O
production	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
thymocyte	B-X
adhesion	B-X
was	B-X
followed	B-X
by	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
gene	B-X
transcription	B-X
factors	B-X
and	B-X
enhanced	B-X
IL	B-X
-	B-X
6	B-X
production	B-X
<EOS>	B-X
Adhesion	B-X
of	B-X
immature	B-X
and	B-X
mature	B-X
T	B-X
cells	B-X
induces	B-X
in	B-X
human	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
activation	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
trascription	B-X
factors	B-X
(	B-X
NF	B-X
-	B-X
kappaB	B-X
and	B-X
NF	B-X
-	B-X
IL6	B-X
)	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
gene	B-X
expression	B-X
:	B-X
role	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
integrins	B-X
.	B-X
<EOS>	B-X
We	B-X
demonstrated	B-X
that	B-X
thymocytes	B-X
adhere	B-X
to	B-X
TEC	B-X
involving	B-X
beta1	B-X
and	B-X
beta4	B-X
integrins	B-X
and	B-X
induce	B-X
the	B-X
clustering	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
heterodimers	B-X
at	B-X
the	B-X
TEC	B-X
surface	B-X
<EOS>	B-X
Among	B-X
them	B-X
,	B-X
thymic	B-X
epithelial	B-X
cells	B-X
(	B-X
TEC	B-X
)	B-X
are	B-X
known	B-X
to	B-X
exert	B-X
dominant	B-X
roles	B-X
in	B-X
their	B-X
survival	B-X
and	B-X
functional	B-X
shaping	B-X

The	O
two	O
latter	O
phenomena	O
were	O
reproduced	O
by	O
the	O
cross-linking	O
of	O
the	O
alpha3	B-protein
,	O
alpha6	B-protein
,	O
beta1	B-protein
and	I-protein
beta4	I-protein
integrins	I-protein
,	O
thus	O
implying	O
that	O
the	O
alpha3beta1	B-protein
and	I-protein
alpha6beta4	I-protein
heterodimers	I-protein
can	O
signal	O
during	O
thymocyte	O
adhesion	O
.	O
<EOS>	B-X
The	B-X
two	B-X
latter	B-X
phenomena	B-X
were	B-X
reproduced	B-X
by	B-X
the	B-X
cross	B-X
-	B-X
linking	B-X
of	B-X
the	B-X
alpha3	B-X
,	B-X
alpha6	B-X
,	B-X
beta1	B-X
and	B-X
beta4	B-X
integrins	B-X
,	B-X
thus	B-X
implying	B-X
that	B-X
the	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
heterodimers	B-X
can	B-X
signal	B-X
during	B-X
thymocyte	B-X
adhesion	B-X
<EOS>	B-X
We	B-X
demonstrated	B-X
that	B-X
thymocytes	B-X
adhere	B-X
to	B-X
TEC	B-X
involving	B-X
beta1	B-X
and	B-X
beta4	B-X
integrins	B-X
and	B-X
induce	B-X
the	B-X
clustering	B-X
of	B-X
alpha3beta1	B-X
and	B-X
alpha6beta4	B-X
heterodimers	B-X
at	B-X
the	B-X
TEC	B-X
surface	B-X
<EOS>	B-X
We	B-X
found	B-X
that	B-X
adhesion	B-X
of	B-X
unstimulated	B-X
T	B-X
cell	B-X
i	B-X
)	B-X
involved	B-X
beta1	B-X
,	B-X
but	B-X
not	B-X
beta4	B-X
integrin	B-X
functions	B-X
at	B-X
the	B-X
surface	B-X
ii	B-X
)	B-X
induced	B-X
the	B-X
clustering	B-X
of	B-X
alpha3beta1	B-X
,	B-X
but	B-X
not	B-X
alpha2beta1	B-X
heterodimers	B-X
at	B-X
the	B-X
TEC	B-X
surface	B-X
and	B-X
iii	B-X
)	B-X
up	B-X
-	B-X
regulated	B-X
the	B-X
nuclear	B-X
binding	B-X
activity	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
transcription	B-X
factor	B-X
and	B-X
the	B-X
IL	B-X
-	B-X
6	B-X
secretion	B-X
<EOS>	B-X
Signaling	B-X
events	B-X
triggered	B-X
in	B-X
thymocytes	B-X
by	B-X
adhesion	B-X
to	B-X
epithelial	B-X
cells	B-X
have	B-X
been	B-X
extensively	B-X
investigated	B-X
,	B-X
whereas	B-X
little	B-X
is	B-X
known	B-X
on	B-X
the	B-X
opposite	B-X
phenomenon	B-X

We	O
have	O
extended	O
our	O
previous	O
work	O
investigating	O
in	O
the	O
same	O
experimental	O
setting	O
the	O
inducing	O
activity	O
of	O
non	O
stimulated	O
or	O
activated	O
policlonal	B-cell_type
or	I-cell_type
clonal	I-cell_type
mature	I-cell_type
T	I-cell_type
cells	I-cell_type
as	O
representative	O
of	O
the	O
more	O
mature	B-cell_type
thymocyte	I-cell_type
subset	I-cell_type
.	O
<EOS>	B-X
We	B-X
have	B-X
extended	B-X
our	B-X
previous	B-X
work	B-X
investigating	B-X
in	B-X
the	B-X
same	B-X
experimental	B-X
setting	B-X
the	B-X
inducing	B-X
activity	B-X
of	B-X
non	B-X
stimulated	B-X
or	B-X
activated	B-X
policlonal	B-X
or	B-X
clonal	B-X
mature	B-X
T	B-X
cells	B-X
as	B-X
representative	B-X
of	B-X
the	B-X
more	B-X
mature	B-X
thymocyte	B-X
subset	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
investigated	B-X
this	B-X
issue	B-X
in	B-X
a	B-X
co	B-X
-	B-X
culture	B-X
system	B-X
composed	B-X
of	B-X
TEC	B-X
cultures	B-X
derived	B-X
from	B-X
human	B-X
normal	B-X
thymus	B-X
and	B-X
heterologous	B-X
thymocytes	B-X
<EOS>	B-X
There	B-X
were	B-X
no	B-X
significant	B-X
changes	B-X
in	B-X
the	B-X
interferon	B-X
-	B-X
gamma	B-X
/	B-X
interleukin	B-X
-	B-X
4	B-X
ratio	B-X
in	B-X
peripheral	B-X
blood	B-X
CD8+	B-X
T	B-X
cells	B-X
at	B-X
the	B-X
three	B-X
times	B-X
of	B-X
the	B-X
study	B-X
<EOS>	B-X
They	B-X
are	B-X
binding	B-X
these	B-X
muscle	B-X
with	B-X
the	B-X
enterous	B-X
nervous	B-X
system	B-X
and	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
motility	B-X
of	B-X
the	B-X
GI	B-X
tract	B-X

We	O
found	O
that	O
adhesion	O
of	O
unstimulated	B-cell_type
T	I-cell_type
cell	I-cell_type
i	O
)	O
involved	O
beta1	O
,	O
but	O
not	O
beta4	O
integrin	O
functions	O
at	O
the	O
surface	O
ii	O
)	O
induced	O
the	O
clustering	O
of	O
alpha3beta1	B-protein
,	O
but	O
not	O
alpha2beta1	B-protein
heterodimers	I-protein
at	O
the	O
TEC	O
surface	O
and	O
iii	O
)	O
up-regulated	O
the	O
nuclear	O
binding	O
activity	O
of	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
and	O
the	O
IL-6	O
secretion	O
.	O
<EOS>	B-X
The	B-X
rapid	B-X
and	B-X
reversible	B-X
upregulation	B-X
of	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
integrin	B-X
receptors	B-X
on	B-X
T	B-X
lymphocytes	B-X
is	B-X
a	B-X
vital	B-X
step	B-X
in	B-X
the	B-X
adhesive	B-X
interactions	B-X
that	B-X
occur	B-X
during	B-X
successful	B-X
T	B-X
cell	B-X
recognition	B-X
of	B-X
foreign	B-X
antigen	B-X
and	B-X
transendothelial	B-X
migration	B-X
<EOS>	B-X
Despite	B-X
the	B-X
widespread	B-X
use	B-X
of	B-X
corticosteroids	B-X
in	B-X
asthma	B-X
therapy	B-X
,	B-X
little	B-X
is	B-X
known	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
corticosteroids	B-X
on	B-X
cell	B-X
surface	B-X
markers	B-X
involved	B-X
in	B-X
T	B-X
lymphocyte	B-X
activation	B-X
and	B-X
adhesion	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
used	B-X
DNA	B-X
-	B-X
mediated	B-X
gene	B-X
transfer	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
phosphatidylinositol	B-X
3	B-X
-	B-X
kinase	B-X
(	B-X
PI	B-X
3	B-X
-	B-X
K	B-X
)	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
beta	B-X
1	B-X
integrin	B-X
functional	B-X
activity	B-X
mediated	B-X
by	B-X
the	B-X
CD2	B-X
antigen	B-X
<EOS>	B-X
1	B-X
cells	B-X
with	B-X
stimulated	B-X
fixed	B-X
T	B-X
cells	B-X
or	B-X
isolated	B-X
T	B-X
-	B-X
cell	B-X
membranes	B-X
potently	B-X
enhanced	B-X
HIV	B-X
replication	B-X
in	B-X
a	B-X
TNF	B-X
-	B-X
dependent	B-X
manner	B-X
,	B-X
while	B-X
in	B-X
contrast	B-X
,	B-X
unstimulated	B-X
fixed	B-X
T	B-X
cells	B-X
or	B-X
T	B-X
-	B-X
cell	B-X
membranes	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
HIV	B-X
replication	B-X

We	O
propose	O
that	O
alpha3beta1	B-protein
and	I-protein
alpha6beta4	I-protein
heterodimers	I-protein
are	O
induced	O
to	O
cluster	O
at	O
the	O
TEC	O
surface	O
recognizing	O
yet	O
unknown	O
cellular	B-protein
ligands	I-protein
differentially	O
expressed	O
during	O
T	O
cell	O
development	O
.	O

Identification	O
and	O
characterization	O
of	O
SKAT-2	B-DNA
,	O
a	O
novel	O
Th2-specific	B-DNA
zinc	I-DNA
finger	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
SKAT	B-X
-	B-X
2	B-X
,	B-X
a	B-X
novel	B-X
Th2	B-X
-	B-X
specific	B-X
zinc	B-X
finger	B-X
gene	B-X
.	B-X
<EOS>	B-X
This	B-X
result	B-X
was	B-X
confirmed	B-X
using	B-X
clones	B-X
of	B-X
EL4	B-X
cells	B-X
stably	B-X
expressing	B-X
an	B-X
inducible	B-X
form	B-X
of	B-X
SKAT	B-X
-	B-X
2	B-X
,	B-X
thus	B-X
SKAT	B-X
-	B-X
2	B-X
is	B-X
a	B-X
novel	B-X
Th2	B-X
-	B-X
specific	B-X
gene	B-X
that	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
selective	B-X
regulation	B-X
of	B-X
cytokine	B-X
genes	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
Kruppel	B-X
-	B-X
type	B-X
zinc	B-X
finger	B-X
(	B-X
ZF	B-X
)	B-X
gene	B-X
,	B-X
SKAT	B-X
-	B-X
2	B-X
,	B-X
which	B-X
is	B-X
selectively	B-X
expressed	B-X
by	B-X
murine	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
By	B-X
in	B-X
situ	B-X
hybridization	B-X
,	B-X
SKAT	B-X
-	B-X
2	B-X
expression	B-X
was	B-X
found	B-X
to	B-X
peak	B-X
in	B-X
antigen	B-X
-	B-X
stimulated	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
after	B-X
2	B-X
-	B-X
3	B-X
days	B-X
of	B-X
culture	B-X
under	B-X
Th2	B-X
but	B-X
not	B-X
Th1	B-X
biasing	B-X
conditions	B-X

We	O
have	O
identified	O
a	O
novel	O
Kruppel-type	B-DNA
zinc	I-DNA
finger	I-DNA
(	I-DNA
ZF	I-DNA
)	I-DNA
gene	I-DNA
,	O
SKAT-2	B-DNA
,	O
which	O
is	O
selectively	O
expressed	O
by	O
murine	B-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
novel	B-X
Kruppel	B-X
-	B-X
type	B-X
zinc	B-X
finger	B-X
(	B-X
ZF	B-X
)	B-X
gene	B-X
,	B-X
SKAT	B-X
-	B-X
2	B-X
,	B-X
which	B-X
is	B-X
selectively	B-X
expressed	B-X
by	B-X
murine	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
This	B-X
result	B-X
was	B-X
confirmed	B-X
using	B-X
clones	B-X
of	B-X
EL4	B-X
cells	B-X
stably	B-X
expressing	B-X
an	B-X
inducible	B-X
form	B-X
of	B-X
SKAT	B-X
-	B-X
2	B-X
,	B-X
thus	B-X
SKAT	B-X
-	B-X
2	B-X
is	B-X
a	B-X
novel	B-X
Th2	B-X
-	B-X
specific	B-X
gene	B-X
that	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
selective	B-X
regulation	B-X
of	B-X
cytokine	B-X
genes	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
SKAT	B-X
-	B-X
2	B-X
,	B-X
a	B-X
novel	B-X
Th2	B-X
-	B-X
specific	B-X
zinc	B-X
finger	B-X
gene	B-X
.	B-X
<EOS>	B-X
This	B-X
pattern	B-X
of	B-X
expression	B-X
closely	B-X
mirrored	B-X
that	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
the	B-X
same	B-X
cells	B-X

The	O
protein	O
encoded	O
by	O
this	O
gene	O
has	O
14	O
C2H2-type	O
ZF	O
tandemly	O
arrayed	O
at	O
its	O
C	B-DNA
terminus	I-DNA
and	O
N-terminal	B-DNA
SCAN	B-DNA
box	I-DNA
and	O
KRAB	B-DNA
domains	I-DNA
.	O
<EOS>	B-X
The	B-X
protein	B-X
encoded	B-X
by	B-X
this	B-X
gene	B-X
has	B-X
14	B-X
C2H2	B-X
-	B-X
type	B-X
ZF	B-X
tandemly	B-X
arrayed	B-X
at	B-X
its	B-X
C	B-X
terminus	B-X
and	B-X
N	B-X
-	B-X
terminal	B-X
SCAN	B-X
box	B-X
and	B-X
KRAB	B-X
domains	B-X
<EOS>	B-X
SKAT	B-X
-	B-X
2	B-X
is	B-X
tissue	B-X
restricted	B-X
in	B-X
expression	B-X
at	B-X
the	B-X
RNA	B-X
level	B-X
,	B-X
detectable	B-X
only	B-X
in	B-X
brain	B-X
and	B-X
at	B-X
low	B-X
levels	B-X
in	B-X
kidney	B-X
and	B-X
spleen	B-X
and	B-X
few	B-X
hematopoietic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
This	B-X
pattern	B-X
of	B-X
expression	B-X
closely	B-X
mirrored	B-X
that	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
<EOS>	B-X
This	B-X
result	B-X
was	B-X
confirmed	B-X
using	B-X
clones	B-X
of	B-X
EL4	B-X
cells	B-X
stably	B-X
expressing	B-X
an	B-X
inducible	B-X
form	B-X
of	B-X
SKAT	B-X
-	B-X
2	B-X
,	B-X
thus	B-X
SKAT	B-X
-	B-X
2	B-X
is	B-X
a	B-X
novel	B-X
Th2	B-X
-	B-X
specific	B-X
gene	B-X
that	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
selective	B-X
regulation	B-X
of	B-X
cytokine	B-X
genes	B-X
in	B-X
T	B-X
cells	B-X

SKAT-2	B-DNA
is	O
tissue	O
restricted	O
in	O
expression	O
at	O
the	O
RNA	O
level	O
,	O
detectable	O
only	O
in	O
brain	O
and	O
at	O
low	O
levels	O
in	O
kidney	O
and	O
spleen	O
and	O
few	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
SKAT	B-X
-	B-X
2	B-X
is	B-X
tissue	B-X
restricted	B-X
in	B-X
expression	B-X
at	B-X
the	B-X
RNA	B-X
level	B-X
,	B-X
detectable	B-X
only	B-X
in	B-X
brain	B-X
and	B-X
at	B-X
low	B-X
levels	B-X
in	B-X
kidney	B-X
and	B-X
spleen	B-X
and	B-X
few	B-X
hematopoietic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
This	B-X
pattern	B-X
of	B-X
expression	B-X
closely	B-X
mirrored	B-X
that	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
<EOS>	B-X
This	B-X
result	B-X
was	B-X
confirmed	B-X
using	B-X
clones	B-X
of	B-X
EL4	B-X
cells	B-X
stably	B-X
expressing	B-X
an	B-X
inducible	B-X
form	B-X
of	B-X
SKAT	B-X
-	B-X
2	B-X
,	B-X
thus	B-X
SKAT	B-X
-	B-X
2	B-X
is	B-X
a	B-X
novel	B-X
Th2	B-X
-	B-X
specific	B-X
gene	B-X
that	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
selective	B-X
regulation	B-X
of	B-X
cytokine	B-X
genes	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
The	B-X
protein	B-X
encoded	B-X
by	B-X
this	B-X
gene	B-X
has	B-X
14	B-X
C2H2	B-X
-	B-X
type	B-X
ZF	B-X
tandemly	B-X
arrayed	B-X
at	B-X
its	B-X
C	B-X
terminus	B-X
and	B-X
N	B-X
-	B-X
terminal	B-X
SCAN	B-X
box	B-X
and	B-X
KRAB	B-X
domains	B-X

By	O
in	O
situ	O
hybridization	O
,	O
SKAT-2	B-DNA
expression	O
was	O
found	O
to	O
peak	O
in	O
antigen-stimulated	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
after	O
2-3	O
days	O
of	O
culture	O
under	O
Th2	O
but	O
not	O
Th1	O
biasing	O
conditions	O
.	O

This	O
pattern	O
of	O
expression	O
closely	O
mirrored	O
that	O
of	O
GATA-3	B-protein
in	O
the	O
same	O
cells	O
.	O
<EOS>	B-X
This	B-X
pattern	B-X
of	B-X
expression	B-X
closely	B-X
mirrored	B-X
that	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
<EOS>	B-X
SKAT	B-X
-	B-X
2	B-X
is	B-X
tissue	B-X
restricted	B-X
in	B-X
expression	B-X
at	B-X
the	B-X
RNA	B-X
level	B-X
,	B-X
detectable	B-X
only	B-X
in	B-X
brain	B-X
and	B-X
at	B-X
low	B-X
levels	B-X
in	B-X
kidney	B-X
and	B-X
spleen	B-X
and	B-X
few	B-X
hematopoietic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
By	B-X
in	B-X
situ	B-X
hybridization	B-X
,	B-X
SKAT	B-X
-	B-X
2	B-X
expression	B-X
was	B-X
found	B-X
to	B-X
peak	B-X
in	B-X
antigen	B-X
-	B-X
stimulated	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
after	B-X
2	B-X
-	B-X
3	B-X
days	B-X
of	B-X
culture	B-X
under	B-X
Th2	B-X
but	B-X
not	B-X
Th1	B-X
biasing	B-X
conditions	B-X
<EOS>	B-X
The	B-X
protein	B-X
encoded	B-X
by	B-X
this	B-X
gene	B-X
has	B-X
14	B-X
C2H2	B-X
-	B-X
type	B-X
ZF	B-X
tandemly	B-X
arrayed	B-X
at	B-X
its	B-X
C	B-X
terminus	B-X
and	B-X
N	B-X
-	B-X
terminal	B-X
SCAN	B-X
box	B-X
and	B-X
KRAB	B-X
domains	B-X

In	O
transient	O
transfection	O
experiments	O
in	O
phorbol	O
12-myristate	O
13-acetate/ionomycin-stimulated	O
EL4	B-cell_line
cells	I-cell_line
,	O
SKAT-2	B-DNA
was	O
found	O
to	O
up-regulate	O
the	O
activity	O
of	O
the	O
IL-4	B-DNA
but	I-DNA
not	I-DNA
the	I-DNA
IL-5	I-DNA
promoter	I-DNA
,	O
contrasting	O
with	O
the	O
ability	O
of	O
GATA-3	B-protein
to	O
activate	O
both	O
promoters	B-DNA
.	O

This	O
result	O
was	O
confirmed	O
using	O
clones	O
of	O
EL4	B-cell_line
cells	I-cell_line
stably	O
expressing	O
an	O
inducible	O
form	O
of	O
SKAT-2	B-DNA
,	O
thus	O
SKAT-2	B-DNA
is	O
a	O
novel	O
Th2-specific	B-DNA
gene	I-DNA
that	O
may	O
play	O
a	O
role	O
in	O
selective	O
regulation	O
of	O
cytokine	B-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

hsp70	B-protein
interacting	I-protein
protein	I-protein
Hip	I-protein
does	O
not	O
affect	O
glucocorticoid	B-protein
receptor	I-protein
folding	O
by	O
the	O
hsp90-based	O
chaperone	O
machinery	O
except	O
to	O
oppose	O
the	O
effect	O
of	O
BAG-1	B-protein
.	O
<EOS>	B-X
The	B-X
Hsp70	B-X
-	B-X
interacting	B-X
protein	B-X
,	B-X
Hip	B-X
,	B-X
cooperates	B-X
with	B-X
the	B-X
chaperone	B-X
Hsp70	B-X
in	B-X
protein	B-X
folding	B-X
and	B-X
prevention	B-X
of	B-X
aggregation	B-X
<EOS>	B-X
Impact	B-X
of	B-X
aging	B-X
on	B-X
heat	B-X
shock	B-X
protein	B-X
expression	B-X
in	B-X
the	B-X
substantia	B-X
nigra	B-X
and	B-X
striatum	B-X
of	B-X
the	B-X
female	B-X
rat	B-X
.	B-X
<EOS>	B-X
Proteostasis	B-X
of	B-X
the	B-X
polyQ	B-X
AR	B-X
is	B-X
controlled	B-X
by	B-X
the	B-X
heat	B-X
shock	B-X
protein	B-X
90	B-X
(	B-X
Hsp90	B-X
)	B-X
	B-X
-	B-X
	B-X
and	B-X
Hsp70	B-X
-	B-X
based	B-X
chaperone	B-X
machinery	B-X
,	B-X
but	B-X
mechanisms	B-X
regulating	B-X
the	B-X
protein	B-X
's	B-X
turnover	B-X
are	B-X
incompletely	B-X
understood	B-X
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
CIP73	B-X
and	B-X
HIP	B-X
occurred	B-X
in	B-X
both	B-X
the	B-X
nuclei	B-X
and	B-X
cytoplasm	B-X
in	B-X
Nicotiana	B-X
benthamiana	B-X
leaf	B-X
cells	B-X

Reticulocyte	O
lysate	O
contains	O
a	O
chaperone	O
system	O
that	O
assembles	O
glucocorticoid	B-protein
receptor	I-protein
(	I-protein
GR	I-protein
)	I-protein
.hsp90	I-protein
heterocomplexes	I-protein
.	O
<EOS>	B-X
Reticulocyte	B-X
lysate	B-X
contains	B-X
a	B-X
chaperone	B-X
system	B-X
that	B-X
assembles	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
<EOS>	B-X
Rabbit	B-X
reticulocyte	B-X
lysate	B-X
contains	B-X
a	B-X
multiprotein	B-X
system	B-X
that	B-X
assembles	B-X
steroid	B-X
receptors	B-X
into	B-X
a	B-X
heterocomplex	B-X
with	B-X
hsp90	B-X
<EOS>	B-X
Rabbit	B-X
reticulocyte	B-X
lysate	B-X
contains	B-X
a	B-X
multiprotein	B-X
chaperone	B-X
system	B-X
that	B-X
assembles	B-X
steroid	B-X
receptors	B-X
into	B-X
a	B-X
complex	B-X
with	B-X
hsp90	B-X
<EOS>	B-X
Ability	B-X
of	B-X
various	B-X
members	B-X
of	B-X
the	B-X
hsp70	B-X
family	B-X
of	B-X
chaperones	B-X
to	B-X
promote	B-X
assembly	B-X
of	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
into	B-X
a	B-X
functional	B-X
heterocomplex	B-X
with	B-X
hsp90	B-X
.	B-X

Using	O
purified	B-protein
proteins	I-protein
,	O
we	O
have	O
prepared	O
a	O
five-protein	O
heterocomplex	O
assembly	O
system	O
consisting	O
of	O
two	O
proteins	O
essential	O
for	O
heterocomplex	O
assembly-	O
hsp90	B-protein
and	O
hsp70	B-protein
-and	O
three	O
proteins	O
that	O
act	O
as	O
co-chaperones	O
to	O
enhance	O
assembly-	O
Hop	B-protein
,	O
hsp40	B-protein
,	O
p23	B-protein
[	O
Morishima	O
,	O
Y.	O
,	O
Kanelakis	O
,	O
K.	O
C.	O
,	O
Silverstein	O
,	O
A.	O
M.	O
,	O
Dittmar	O
,	O
K.	O
D.	O
,	O
Estrada	O
,	O
L.	O
,	O
and	O
Pratt	O
,	O
W.	O
B.	O
(	O
2000	O
)	O
J.	O
Biol.	O
Chem.	O
275	O
,	O
6894-6900	O
]	O
.	O

The	O
hsp70	B-protein
co-chaperone	I-protein
Hip	I-protein
has	O
been	O
recovered	O
in	O
receptor.hsp90	B-protein
heterocomplexes	I-protein
at	O
an	O
intermediate	O
stage	O
of	O
assembly	O
in	O
reticulocyte	O
lysate	O
,	O
and	O
Hip	B-protein
is	O
also	O
thought	O
to	O
be	O
an	O
intrinsic	O
component	O
of	O
the	O
assembly	O
machinery	O
.	O
<EOS>	B-X
hsp90	B-X
heterocomplexes	B-X
at	B-X
an	B-X
intermediate	B-X
stage	B-X
of	B-X
assembly	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
,	B-X
and	B-X
Hip	B-X
is	B-X
also	B-X
thought	B-X
to	B-X
be	B-X
an	B-X
intrinsic	B-X
component	B-X
of	B-X
the	B-X
assembly	B-X
machinery	B-X
<EOS>	B-X
Using	B-X
purified	B-X
proteins	B-X
,	B-X
we	B-X
have	B-X
prepared	B-X
a	B-X
five	B-X
-	B-X
protein	B-X
heterocomplex	B-X
assembly	B-X
system	B-X
consisting	B-X
of	B-X
two	B-X
proteins	B-X
essential	B-X
for	B-X
heterocomplex	B-X
assembly	B-X
-	B-X
hsp90	B-X
and	B-X
hsp70	B-X
-	B-X
and	B-X
three	B-X
proteins	B-X
that	B-X
act	B-X
as	B-X
co	B-X
-	B-X
chaperones	B-X
to	B-X
enhance	B-X
assembly	B-X
-	B-X
Hop	B-X
,	B-X
hsp40	B-X
,	B-X
p23	B-X
[	B-X
Morishima	B-X
,	B-X
Y	B-X
<EOS>	B-X
hsp90	B-X
heterocomplex	B-X
assembly	B-X
or	B-X
the	B-X
activation	B-X
of	B-X
steroid	B-X
binding	B-X
activity	B-X
that	B-X
occurs	B-X
with	B-X
assembly	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
Hip	B-X
is	B-X
not	B-X
a	B-X
component	B-X
of	B-X
the	B-X
assembly	B-X
machinery	B-X
but	B-X
that	B-X
it	B-X
could	B-X
play	B-X
a	B-X
regulatory	B-X
role	B-X
in	B-X
opposition	B-X
to	B-X
BAG	B-X
-	B-X
1	B-X

Here	O
we	O
show	O
that	O
immunodepletion	O
of	O
Hip	B-protein
from	O
reticulocyte	O
lysate	O
or	O
addition	O
of	O
high	O
levels	O
of	O
Hip	B-protein
to	O
the	O
purified	O
five-protein	O
system	O
does	O
not	O
affect	O
GR.hsp90	O
heterocomplex	O
assembly	O
or	O
the	O
activation	O
of	O
steroid	O
binding	O
activity	O
that	O
occurs	O
with	O
assembly	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
loss	B-X
of	B-X
the	B-X
PcG	B-X
genes	B-X
Sce	B-X
,	B-X
Scm	B-X
,	B-X
or	B-X
Pc	B-X
specifically	B-X
affects	B-X
one	B-X
of	B-X
the	B-X
three	B-X
binary	B-X
fate	B-X
choices	B-X
that	B-X
R7	B-X
precursors	B-X
must	B-X
make	B-X
:	B-X
mutant	B-X
R7s	B-X
derepress	B-X
Sens	B-X
and	B-X
adopt	B-X
R8	B-X
fate	B-X
characteristics	B-X
<EOS>	B-X
These	B-X
changes	B-X
were	B-X
specific	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
three	B-X
pre	B-X
-	B-X
mixed	B-X
proteins	B-X
and	B-X
were	B-X
not	B-X
observed	B-X
for	B-X
a	B-X
binary	B-X
mixture	B-X
of	B-X
P450	B-X
and	B-X
Adx	B-X
,	B-X
or	B-X
sequential	B-X
binding	B-X
of	B-X
the	B-X
three	B-X
proteins	B-X
<EOS>	B-X
Other	B-X
reports	B-X
have	B-X
proposed	B-X
a	B-X
phytosterol	B-X
/	B-X
phytostanol	B-X
action	B-X
on	B-X
cholesterol	B-X
esterification	B-X
and	B-X
lipoprotein	B-X
assembly	B-X
,	B-X
cholesterol	B-X
synthesis	B-X
and	B-X
apolipoprotein	B-X
(	B-X
apo	B-X
)	B-X
B100	B-X
-	B-X
containing	B-X
lipoprotein	B-X
removal	B-X
<EOS>	B-X
Concomitant	B-X
changes	B-X
in	B-X
the	B-X
dissipation	B-X
revealed	B-X
specific	B-X
protein	B-X
-	B-X
protein	B-X
interaction	B-X
occurs	B-X
upon	B-X
reaching	B-X
a	B-X
critical	B-X
concentration	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
membrane	B-X
layer	B-X

Despite	O
the	O
fact	O
that	O
Hip	B-protein
does	O
not	O
affect	O
assembly	O
,	O
it	O
is	O
recovered	O
in	O
GR.hsp90	B-protein
heterocomplexes	I-protein
assembled	O
by	O
both	O
systems	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
fact	B-X
that	B-X
the	B-X
left	B-X
hip	B-X
is	B-X
most	B-X
frequently	B-X
affected	B-X
,	B-X
literature	B-X
and	B-X
clinical	B-X
experience	B-X
suggest	B-X
a	B-X
poorer	B-X
outcome	B-X
for	B-X
right	B-X
-	B-X
sided	B-X
hip	B-X
dislocation	B-X
in	B-X
DDH	B-X
<EOS>	B-X
Despite	B-X
the	B-X
fact	B-X
that	B-X
CKD	B-X
is	B-X
becoming	B-X
more	B-X
prevalent	B-X
,	B-X
public	B-X
knowledge	B-X
of	B-X
the	B-X
disease	B-X
remains	B-X
low	B-X
<EOS>	B-X
Despite	B-X
the	B-X
fact	B-X
that	B-X
there	B-X
was	B-X
no	B-X
significant	B-X
intergroup	B-X
difference	B-X
in	B-X
BMD	B-X
measurement	B-X
rate	B-X
,	B-X
the	B-X
period	B-X
2	B-X
group	B-X
had	B-X
a	B-X
higher	B-X
prescription	B-X
rate	B-X
for	B-X
anti	B-X
-	B-X
osteoporosis	B-X
drugs	B-X
within	B-X
3	B-X
months	B-X
of	B-X
HFS	B-X
<EOS>	B-X
Despite	B-X
the	B-X
fact	B-X
that	B-X
during	B-X
the	B-X
GBI	B-X
the	B-X
participants	B-X
of	B-X
the	B-X
experiment	B-X
performed	B-X
regular	B-X
physical	B-X
training	B-X
,	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
performance	B-X
indicators	B-X
values	B-X
was	B-X
detected	B-X
,	B-X
especially	B-X
pronounced	B-X
after	B-X
100	B-X
days	B-X
of	B-X
GBI	B-X

In	O
the	O
five-protein	O
system	O
,	O
Hip	B-protein
prevents	O
inhibition	O
of	O
assembly	O
by	O
the	O
hsp70	B-protein
co-chaperone	I-protein
BAG-1	I-protein
,	O
and	O
cotransfection	O
of	O
Hip	B-protein
with	O
BAG-1	B-protein
opposes	O
BAG-1	B-protein
reduction	O
of	O
steroid	O
binding	O
activity	O
in	O
COS	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
In	B-X
the	B-X
five	B-X
-	B-X
protein	B-X
system	B-X
,	B-X
Hip	B-X
prevents	B-X
inhibition	B-X
of	B-X
assembly	B-X
by	B-X
the	B-X
hsp70	B-X
co	B-X
-	B-X
chaperone	B-X
BAG	B-X
-	B-X
1	B-X
,	B-X
and	B-X
cotransfection	B-X
of	B-X
Hip	B-X
with	B-X
BAG	B-X
-	B-X
1	B-X
opposes	B-X
BAG	B-X
-	B-X
1	B-X
reduction	B-X
of	B-X
steroid	B-X
binding	B-X
activity	B-X
in	B-X
COS	B-X
cells	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
Hip	B-X
is	B-X
not	B-X
a	B-X
component	B-X
of	B-X
the	B-X
assembly	B-X
machinery	B-X
but	B-X
that	B-X
it	B-X
could	B-X
play	B-X
a	B-X
regulatory	B-X
role	B-X
in	B-X
opposition	B-X
to	B-X
BAG	B-X
-	B-X
1	B-X
<EOS>	B-X
Using	B-X
purified	B-X
proteins	B-X
,	B-X
we	B-X
have	B-X
prepared	B-X
a	B-X
five	B-X
-	B-X
protein	B-X
heterocomplex	B-X
assembly	B-X
system	B-X
consisting	B-X
of	B-X
two	B-X
proteins	B-X
essential	B-X
for	B-X
heterocomplex	B-X
assembly	B-X
-	B-X
hsp90	B-X
and	B-X
hsp70	B-X
-	B-X
and	B-X
three	B-X
proteins	B-X
that	B-X
act	B-X
as	B-X
co	B-X
-	B-X
chaperones	B-X
to	B-X
enhance	B-X
assembly	B-X
-	B-X
Hop	B-X
,	B-X
hsp40	B-X
,	B-X
p23	B-X
[	B-X
Morishima	B-X
,	B-X
Y	B-X
<EOS>	B-X
hsp90	B-X
heterocomplexes	B-X
at	B-X
an	B-X
intermediate	B-X
stage	B-X
of	B-X
assembly	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
,	B-X
and	B-X
Hip	B-X
is	B-X
also	B-X
thought	B-X
to	B-X
be	B-X
an	B-X
intrinsic	B-X
component	B-X
of	B-X
the	B-X
assembly	B-X
machinery	B-X

We	O
conclude	O
that	O
Hip	B-protein
is	O
not	O
a	O
component	O
of	O
the	O
assembly	O
machinery	O
but	O
that	O
it	O
could	O
play	O
a	O
regulatory	O
role	O
in	O
opposition	O
to	O
BAG-1	B-protein
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
age	B-X
and	B-X
the	B-X
initial	B-X
motor	B-X
impairment	B-X
of	B-X
the	B-X
affected	B-X
lower	B-X
limb	B-X
can	B-X
inform	B-X
the	B-X
state	B-X
of	B-X
balance	B-X
function	B-X
at	B-X
3	B-X
and	B-X
6	B-X
months	B-X
after	B-X
stroke	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
CoC	B-X
bearings	B-X
may	B-X
not	B-X
be	B-X
completely	B-X
inert	B-X
and	B-X
can	B-X
result	B-X
in	B-X
ALTRs	B-X
and	B-X
nerve	B-X
compression	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
activation	B-X
of	B-X
each	B-X
longitudinal	B-X
section	B-X
of	B-X
the	B-X
RF	B-X
is	B-X
possible	B-X
depending	B-X
on	B-X
the	B-X
hip	B-X
joint	B-X
angle	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
lower	B-X
complication	B-X
rate	B-X
observed	B-X
in	B-X
the	B-X
arthrotomy	B-X
group	B-X
outweighs	B-X
by	B-X
far	B-X
scar	B-X
cosmesis	B-X
and	B-X
post	B-X
-	B-X
operative	B-X
pain	B-X
advantages	B-X
in	B-X
the	B-X
aspiration	B-X
-	B-X
lavage	B-X
group	B-X

Cutting	O
edge	O
:	O
STAT6-deficient	O
mice	O
have	O
enhanced	O
tumor	O
immunity	O
to	O
primary	O
and	O
metastatic	O
mammary	O
carcinoma	O
.	O
<EOS>	B-X
Cutting	B-X
edge	B-X
:	B-X
STAT6	B-X
-	B-X
deficient	B-X
mice	B-X
have	B-X
enhanced	B-X
tumor	B-X
immunity	B-X
to	B-X
primary	B-X
and	B-X
metastatic	B-X
mammary	B-X
carcinoma	B-X
.	B-X
<EOS>	B-X
BALB	B-X
/	B-X
c	B-X
and	B-X
knockout	B-X
mice	B-X
were	B-X
challenged	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
with	B-X
the	B-X
highly	B-X
malignant	B-X
and	B-X
spontaneously	B-X
metastatic	B-X
BALB	B-X
/	B-X
c	B-X
-	B-X
derived	B-X
4T1	B-X
mammary	B-X
carcinoma	B-X
<EOS>	B-X
Tumor	B-X
immunologists	B-X
have	B-X
hypothesized	B-X
that	B-X
Th1	B-X
cells	B-X
are	B-X
critical	B-X
in	B-X
tumor	B-X
immunity	B-X
because	B-X
they	B-X
facilitate	B-X
differentiation	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
potent	B-X
anti	B-X
-	B-X
tumor	B-X
effectors	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
deletion	B-X
of	B-X
the	B-X
STAT6	B-X
gene	B-X
facilitates	B-X
development	B-X
of	B-X
potent	B-X
anti	B-X
-	B-X
tumor	B-X
immunity	B-X
via	B-X
a	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
	B-X
-	B-X
independent	B-X
pathway	B-X

STAT4	B-protein
and	O
STAT6	B-protein
are	O
essential	O
for	O
the	O
development	O
of	O
CD4	O
(	O
+	O
)	O
Th1	O
and	O
Th2	O
development	O
,	O
respectively	O
.	O
<EOS>	B-X
STAT4	B-X
and	B-X
STAT6	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
development	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Th1	B-X
and	B-X
Th2	B-X
development	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
(	B-X
STATs	B-X
)	B-X
,	B-X
in	B-X
particular	B-X
STAT4	B-X
and	B-X
STAT6	B-X
,	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
development	B-X
of	B-X
Th1	B-X
and	B-X
Th2	B-X
cells	B-X
,	B-X
respectively	B-X
<EOS>	B-X
STAT4	B-X
/	B-X
6	B-X
-	B-X
dependent	B-X
differential	B-X
regulation	B-X
of	B-X
chemokine	B-X
receptors	B-X
.	B-X
<EOS>	B-X
The	B-X
major	B-X
cell	B-X
fate	B-X
decision	B-X
of	B-X
the	B-X
CD4+	B-X
helper	B-X
T	B-X
cells	B-X
is	B-X
the	B-X
development	B-X
of	B-X
Th1	B-X
and	B-X
Th2	B-X
phenotype	B-X
,	B-X
the	B-X
balance	B-X
of	B-X
which	B-X
determines	B-X
the	B-X
outcome	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
autoimmune	B-X
responses	B-X

Tumor	O
immunologists	O
have	O
hypothesized	O
that	O
Th1	B-cell_type
cells	I-cell_type
are	O
critical	O
in	O
tumor	O
immunity	O
because	O
they	O
facilitate	O
differentiation	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
which	O
are	O
potent	O
anti-tumor	B-cell_type
effectors	I-cell_type
.	O
<EOS>	B-X
Tumor	B-X
immunologists	B-X
have	B-X
hypothesized	B-X
that	B-X
Th1	B-X
cells	B-X
are	B-X
critical	B-X
in	B-X
tumor	B-X
immunity	B-X
because	B-X
they	B-X
facilitate	B-X
differentiation	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
potent	B-X
anti	B-X
-	B-X
tumor	B-X
effectors	B-X
<EOS>	B-X
Surprisingly	B-X
,	B-X
Th1	B-X
or	B-X
Th2	B-X
cells	B-X
are	B-X
not	B-X
involved	B-X
,	B-X
because	B-X
CD4	B-X
depletion	B-X
does	B-X
not	B-X
diminish	B-X
the	B-X
anti	B-X
-	B-X
tumor	B-X
effect	B-X
<EOS>	B-X
Cutting	B-X
edge	B-X
:	B-X
STAT6	B-X
-	B-X
deficient	B-X
mice	B-X
have	B-X
enhanced	B-X
tumor	B-X
immunity	B-X
to	B-X
primary	B-X
and	B-X
metastatic	B-X
mammary	B-X
carcinoma	B-X
.	B-X
<EOS>	B-X
STAT4	B-X
and	B-X
STAT6	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
development	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Th1	B-X
and	B-X
Th2	B-X
development	B-X
,	B-X
respectively	B-X

We	O
have	O
used	O
STAT4	O
(	O
-/-	O
)	O
and	O
STAT6	O
(	O
-/-	O
)	O
mice	O
to	O
test	O
this	O
hypothesis	O
.	O

BALB/c	O
and	O
knockout	O
mice	O
were	O
challenged	O
in	O
the	O
mammary	O
gland	O
with	O
the	O
highly	O
malignant	O
and	O
spontaneously	O
metastatic	O
BALB/c-derived	O
4T1	O
mammary	O
carcinoma	O
.	O
<EOS>	B-X
BALB	B-X
/	B-X
c	B-X
and	B-X
knockout	B-X
mice	B-X
were	B-X
challenged	B-X
in	B-X
the	B-X
mammary	B-X
gland	B-X
with	B-X
the	B-X
highly	B-X
malignant	B-X
and	B-X
spontaneously	B-X
metastatic	B-X
BALB	B-X
/	B-X
c	B-X
-	B-X
derived	B-X
4T1	B-X
mammary	B-X
carcinoma	B-X
<EOS>	B-X
Cutting	B-X
edge	B-X
:	B-X
STAT6	B-X
-	B-X
deficient	B-X
mice	B-X
have	B-X
enhanced	B-X
tumor	B-X
immunity	B-X
to	B-X
primary	B-X
and	B-X
metastatic	B-X
mammary	B-X
carcinoma	B-X
.	B-X
<EOS>	B-X
STAT4	B-X
and	B-X
STAT6	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
development	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Th1	B-X
and	B-X
Th2	B-X
development	B-X
,	B-X
respectively	B-X
<EOS>	B-X
Primary	B-X
tumor	B-X
growth	B-X
and	B-X
metastatic	B-X
disease	B-X
are	B-X
reduced	B-X
in	B-X
STAT6	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X
relative	B-X
to	B-X
BALB	B-X
/	B-X
c	B-X
and	B-X
STAT4	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
mice	B-X

Primary	O
tumor	O
growth	O
and	O
metastatic	O
disease	O
are	O
reduced	O
in	O
STAT6	O
(	O
-/-	O
)	O
mice	O
relative	O
to	O
BALB/c	O
and	O
STAT4	O
(	O
-/-	O
)	O
mice	O
.	O

Ab	O
depletions	O
demonstrate	O
that	O
the	O
effect	O
is	O
mediated	O
by	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
immunized	O
STAT6	O
(	O
-/-	O
)	O
mice	O
have	O
higher	O
levels	O
of	O
4T1-specific	B-cell_type
CTL	I-cell_type
than	O
BALB/c	O
or	O
STAT4	O
(	O
-/-	O
)	O
mice	O
.	O

Surprisingly	O
,	O
Th1	B-cell_type
or	I-cell_type
Th2	I-cell_type
cells	I-cell_type
are	O
not	O
involved	O
,	O
because	O
CD4	O
depletion	O
does	O
not	O
diminish	O
the	O
anti-tumor	O
effect	O
.	O
<EOS>	B-X
Alveolar	B-X
macrophages	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
host	B-X
defense	B-X
against	B-X
Pneumocystis	B-X
,	B-X
and	B-X
several	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
M2	B-X
polarized	B-X
macrophages	B-X
have	B-X
anti	B-X
-	B-X
Pneumocystis	B-X
effector	B-X
activity	B-X
<EOS>	B-X
JWDCP	B-X
is	B-X
likely	B-X
to	B-X
reduce	B-X
the	B-X
protein	B-X
concentration	B-X
by	B-X
regulating	B-X
the	B-X
imbalance	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
enhancing	B-X
antioxidant	B-X
capacity	B-X
,	B-X
thus	B-X
achieving	B-X
therapeutic	B-X
effects	B-X
<EOS>	B-X
Egg	B-X
deposition	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
typical	B-X
Th2	B-X
immune	B-X
response	B-X
in	B-X
the	B-X
liver	B-X
after	B-X
unisexual	B-X
reinfection	B-X
,	B-X
accompanied	B-X
by	B-X
increased	B-X
recruitment	B-X
of	B-X
CD4+	B-X
T	B-X
cells	B-X
<EOS>	B-X
As	B-X
in	B-X
other	B-X
persistent	B-X
infections	B-X
,	B-X
low	B-X
-	B-X
level	B-X
Plasmodium	B-X
chabaudi	B-X
infection	B-X
protects	B-X
the	B-X
host	B-X
from	B-X
reinfection	B-X
at	B-X
2	B-X
months	B-X
postinfection	B-X
,	B-X
a	B-X
phenomenon	B-X
termed	B-X
premunition	B-X

Therefore	O
,	O
deletion	O
of	O
the	O
STAT6	B-DNA
gene	I-DNA
facilitates	O
development	O
of	O
potent	O
anti-tumor	O
immunity	O
via	O
a	O
CD4	O
(	O
+	O
)	O
-independent	O
pathway	O
.	O

Activation	O
of	O
oncogenic	B-protein
transcription	I-protein
factor	I-protein
AP-1	I-protein
in	O
T	B-cell_type
cells	I-cell_type
infected	O
with	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O

Human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B-protein
protein	I-protein
transforms	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
.	O

We	O
previously	O
showed	O
that	O
Tax	B-protein
induces	O
the	O
expression	O
of	O
various	O
family	O
members	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
such	O
as	O
c-Jun	B-protein
,	O
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	O
Fra-1	B-protein
at	O
the	O
mRNA	O
level	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
ability	O
of	O
Tax	B-protein
to	O
activate	O
transcription	O
through	O
the	O
AP-1-binding	B-DNA
site	I-DNA
(	O
AP-1	B-DNA
site	I-DNA
)	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
Tax	B-X
to	B-X
activate	B-X
transcription	B-X
through	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
binding	B-X
site	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
)	B-X
<EOS>	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
Tax	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
various	B-X
family	B-X
members	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP	B-X
-	B-X
1	B-X
such	B-X
as	B-X
c	B-X
-	B-X
Jun	B-X
,	B-X
JunD	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
,	B-X
and	B-X
Fra	B-X
-	B-X
1	B-X
at	B-X
the	B-X
mRNA	B-X
level	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
Fresh	B-X
peripheral	B-X
blood	B-X
leukemia	B-X
cells	B-X
of	B-X
all	B-X
surveyed	B-X
ATL	B-X
patients	B-X
displayed	B-X
constitutive	B-X
AP	B-X
-	B-X
1	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
,	B-X
whereas	B-X
no	B-X
normal	B-X
individuals	B-X
did	B-X
<EOS>	B-X
A	B-X
transient	B-X
transfection	B-X
study	B-X
showed	B-X
that	B-X
Tax	B-X
can	B-X
activate	B-X
transcription	B-X
through	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
binding	B-X
site	B-X
in	B-X
a	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
,	B-X
whereas	B-X
any	B-X
combination	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
proteins	B-X
did	B-X
so	B-X
much	B-X
less	B-X
than	B-X
Tax	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
Tax	B-X
may	B-X
require	B-X
a	B-X
mechanism	B-X
other	B-X
than	B-X
the	B-X
induction	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
mRNA	B-X

A	O
transient	O
transfection	O
study	O
showed	O
that	O
Tax	B-protein
can	O
activate	O
transcription	O
through	O
the	O
AP-1-binding	B-DNA
site	I-DNA
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
whereas	O
any	O
combination	O
of	O
AP-1	B-protein
proteins	I-protein
did	O
so	O
much	O
less	O
than	O
Tax	B-protein
,	O
indicating	O
that	O
the	O
activation	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
by	O
Tax	B-protein
may	O
require	O
a	O
mechanism	O
other	O
than	O
the	O
induction	O
of	O
AP-1	B-RNA
mRNA	I-RNA
.	O

Fresh	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
of	O
all	O
surveyed	O
ATL	O
patients	O
displayed	O
constitutive	O
AP-1	O
DNA-binding	O
activity	O
,	O
whereas	O
no	O
normal	O
individuals	O
did	O
.	O
<EOS>	B-X
Fresh	B-X
peripheral	B-X
blood	B-X
leukemia	B-X
cells	B-X
of	B-X
all	B-X
surveyed	B-X
ATL	B-X
patients	B-X
displayed	B-X
constitutive	B-X
AP	B-X
-	B-X
1	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
,	B-X
whereas	B-X
no	B-X
normal	B-X
individuals	B-X
did	B-X
<EOS>	B-X
Human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
Tax	B-X
protein	B-X
transforms	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
in	B-X
vitro	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
Tax	B-X
to	B-X
activate	B-X
transcription	B-X
through	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
binding	B-X
site	B-X
(	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
)	B-X
<EOS>	B-X
A	B-X
transient	B-X
transfection	B-X
study	B-X
showed	B-X
that	B-X
Tax	B-X
can	B-X
activate	B-X
transcription	B-X
through	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
binding	B-X
site	B-X
in	B-X
a	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
,	B-X
whereas	B-X
any	B-X
combination	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
proteins	B-X
did	B-X
so	B-X
much	B-X
less	B-X
than	B-X
Tax	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
Tax	B-X
may	B-X
require	B-X
a	B-X
mechanism	B-X
other	B-X
than	B-X
the	B-X
induction	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
mRNA	B-X

However	O
,	O
the	O
HTLV-1	B-DNA
genes	I-DNA
,	O
including	O
tax	B-DNA
,	O
are	O
not	O
significantly	O
expressed	O
in	O
fresh	O
leukemia	B-cell_type
cells	I-cell_type
from	O
ATL	O
patients	O
.	O
<EOS>	B-X
However	B-X
,	B-X
tumor	B-X
-	B-X
associated	B-X
macrophage	B-X
/	B-X
M2	B-X
macrophages	B-X
significantly	B-X
correlated	B-X
with	B-X
worse	B-X
overall	B-X
survival	B-X
(	B-X
OS	B-X
)	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
viral	B-X
proteins	B-X
coordinate	B-X
these	B-X
perturbations	B-X
remains	B-X
unclear	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
through	B-X
which	B-X
the	B-X
two	B-X
viral	B-X
proteins	B-X
,	B-X
particularly	B-X
HBZ	B-X
,	B-X
induce	B-X
and	B-X
/	B-X
or	B-X
sustain	B-X
the	B-X
oncogenic	B-X
process	B-X
are	B-X
still	B-X
largely	B-X
elusive	B-X
<EOS>	B-X
Transgenic	B-X
mice	B-X
with	B-X
HTLV	B-X
-	B-X
1	B-X
genes	B-X
showed	B-X
sialadenitis	B-X
resembling	B-X
SS	B-X
,	B-X
but	B-X
their	B-X
phenotypic	B-X
symptoms	B-X
differed	B-X
based	B-X
on	B-X
the	B-X
adopted	B-X
region	B-X
of	B-X
HTLV	B-X
-	B-X
1	B-X
genes	B-X

Our	O
present	O
results	O
suggest	O
that	O
activation	O
of	O
AP-1	B-protein
occurs	O
through	O
Tax-dependent	O
and	O
-independent	O
mechanisms	O
in	O
HTLV-1-infected	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
may	O
play	O
some	O
roles	O
in	O
dysregulated	O
phenotypes	O
of	O
HTLV-1-infected	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Our	B-X
present	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
occurs	B-X
through	B-X
Tax	B-X
-	B-X
dependent	B-X
and	B-X
	B-X
-	B-X
independent	B-X
mechanisms	B-X
in	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
may	B-X
play	B-X
some	B-X
roles	B-X
in	B-X
dysregulated	B-X
phenotypes	B-X
of	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
<EOS>	B-X
A	B-X
transient	B-X
transfection	B-X
study	B-X
showed	B-X
that	B-X
Tax	B-X
can	B-X
activate	B-X
transcription	B-X
through	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
binding	B-X
site	B-X
in	B-X
a	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
,	B-X
whereas	B-X
any	B-X
combination	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
proteins	B-X
did	B-X
so	B-X
much	B-X
less	B-X
than	B-X
Tax	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
by	B-X
Tax	B-X
may	B-X
require	B-X
a	B-X
mechanism	B-X
other	B-X
than	B-X
the	B-X
induction	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
mRNA	B-X
<EOS>	B-X
Activation	B-X
of	B-X
oncogenic	B-X
transcription	B-X
factor	B-X
AP	B-X
-	B-X
1	B-X
in	B-X
T	B-X
cells	B-X
infected	B-X
with	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
.	B-X
<EOS>	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
Tax	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
various	B-X
family	B-X
members	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP	B-X
-	B-X
1	B-X
such	B-X
as	B-X
c	B-X
-	B-X
Jun	B-X
,	B-X
JunD	B-X
,	B-X
c	B-X
-	B-X
Fos	B-X
,	B-X
and	B-X
Fra	B-X
-	B-X
1	B-X
at	B-X
the	B-X
mRNA	B-X
level	B-X
in	B-X
T	B-X
cells	B-X

2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-pentachlorobiphenyl	O
induces	O
apoptosis	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
2,2',4,6,6'	B-X
-	B-X
pentachlorobiphenyl	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
PCBs	B-X
on	B-X
immune	B-X
system	B-X
by	B-X
assessing	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
monocytic	B-X
U937	B-X
cells	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
data	B-X
indicate	B-X
that	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
through	B-X
a	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
arylhydrocarbon	B-X
receptor	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
3,3',4,4',5	B-X
-	B-X
PeCB	B-X
,	B-X
a	B-X
congener	B-X
of	B-X
coplanar	B-X
structure	B-X
,	B-X
as	B-X
well	B-X
as	B-X
2,3,7,8	B-X
-	B-X
TCDD	B-X
did	B-X
not	B-X
induce	B-X
apoptosis	B-X
in	B-X
these	B-X
human	B-X
monocytic	B-X
cells	B-X
,	B-X
although	B-X
they	B-X
potently	B-X
induced	B-X
CYP	B-X
1A1	B-X
in	B-X
human	B-X
hepatoma	B-X
Hep	B-X
G2	B-X
cells	B-X

Polychlorinatedbiphenyls	O
(	O
PCBs	O
)	O
are	O
a	O
group	O
of	O
persistent	O
and	O
widely	O
dispersed	O
environmental	O
pollutants	O
,	O
some	O
of	O
which	O
may	O
be	O
immunotoxic	O
.	O
<EOS>	B-X
Polychlorinatedbiphenyls	B-X
(	B-X
PCBs	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
persistent	B-X
and	B-X
widely	B-X
dispersed	B-X
environmental	B-X
pollutants	B-X
,	B-X
some	B-X
of	B-X
which	B-X
may	B-X
be	B-X
immunotoxic	B-X
<EOS>	B-X
Among	B-X
the	B-X
various	B-X
congeners	B-X
tested	B-X
,	B-X
2,2',4,6	B-X
,	B-X
6'	B-X
-	B-X
pentachlorobiphenyl	B-X
(	B-X
PeCB	B-X
)	B-X
,	B-X
a	B-X
highly	B-X
ortho	B-X
-	B-X
substituted	B-X
congener	B-X
,	B-X
specifically	B-X
induced	B-X
DNA	B-X
fragmentation	B-X
,	B-X
a	B-X
hallmark	B-X
of	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
other	B-X
examined	B-X
di	B-X
-	B-X
	B-X
,	B-X
tri	B-X
-	B-X
	B-X
,	B-X
tetra	B-X
-	B-X
	B-X
,	B-X
and	B-X
pentachlorobiphenyls	B-X
did	B-X
not	B-X
<EOS>	B-X
This	B-X
suggests	B-X
a	B-X
possibly	B-X
separate	B-X
mechanism	B-X
by	B-X
which	B-X
PCBs	B-X
cause	B-X
immunosuppression	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
3,3',4,4',5	B-X
-	B-X
PeCB	B-X
,	B-X
a	B-X
congener	B-X
of	B-X
coplanar	B-X
structure	B-X
,	B-X
as	B-X
well	B-X
as	B-X
2,3,7,8	B-X
-	B-X
TCDD	B-X
did	B-X
not	B-X
induce	B-X
apoptosis	B-X
in	B-X
these	B-X
human	B-X
monocytic	B-X
cells	B-X
,	B-X
although	B-X
they	B-X
potently	B-X
induced	B-X
CYP	B-X
1A1	B-X
in	B-X
human	B-X
hepatoma	B-X
Hep	B-X
G2	B-X
cells	B-X

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
PCBs	O
on	O
immune	O
system	O
by	O
assessing	O
apoptotic	O
cell	O
death	O
in	O
human	B-cell_line
monocytic	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
PCBs	B-X
on	B-X
immune	B-X
system	B-X
by	B-X
assessing	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
monocytic	B-X
U937	B-X
cells	B-X
<EOS>	B-X
2,2',4,6,6'	B-X
-	B-X
pentachlorobiphenyl	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
3,3',4,4',5	B-X
-	B-X
PeCB	B-X
,	B-X
a	B-X
congener	B-X
of	B-X
coplanar	B-X
structure	B-X
,	B-X
as	B-X
well	B-X
as	B-X
2,3,7,8	B-X
-	B-X
TCDD	B-X
did	B-X
not	B-X
induce	B-X
apoptosis	B-X
in	B-X
these	B-X
human	B-X
monocytic	B-X
cells	B-X
,	B-X
although	B-X
they	B-X
potently	B-X
induced	B-X
CYP	B-X
1A1	B-X
in	B-X
human	B-X
hepatoma	B-X
Hep	B-X
G2	B-X
cells	B-X
<EOS>	B-X
Among	B-X
the	B-X
various	B-X
congeners	B-X
tested	B-X
,	B-X
2,2',4,6	B-X
,	B-X
6'	B-X
-	B-X
pentachlorobiphenyl	B-X
(	B-X
PeCB	B-X
)	B-X
,	B-X
a	B-X
highly	B-X
ortho	B-X
-	B-X
substituted	B-X
congener	B-X
,	B-X
specifically	B-X
induced	B-X
DNA	B-X
fragmentation	B-X
,	B-X
a	B-X
hallmark	B-X
of	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
other	B-X
examined	B-X
di	B-X
-	B-X
	B-X
,	B-X
tri	B-X
-	B-X
	B-X
,	B-X
tetra	B-X
-	B-X
	B-X
,	B-X
and	B-X
pentachlorobiphenyls	B-X
did	B-X
not	B-X

Among	O
the	O
various	O
congeners	O
tested	O
,	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-pentachlorobiphenyl	O
(	O
PeCB	O
)	O
,	O
a	O
highly	O
ortho-substituted	O
congener	O
,	O
specifically	O
induced	O
DNA	O
fragmentation	O
,	O
a	O
hallmark	O
of	O
apoptosis	O
,	O
while	O
the	O
other	O
examined	O
di-	O
,	O
tri-	O
,	O
tetra-	O
,	O
and	O
pentachlorobiphenyls	O
did	O
not	O
.	O
<EOS>	B-X
Among	B-X
the	B-X
various	B-X
congeners	B-X
tested	B-X
,	B-X
2,2',4,6	B-X
,	B-X
6'	B-X
-	B-X
pentachlorobiphenyl	B-X
(	B-X
PeCB	B-X
)	B-X
,	B-X
a	B-X
highly	B-X
ortho	B-X
-	B-X
substituted	B-X
congener	B-X
,	B-X
specifically	B-X
induced	B-X
DNA	B-X
fragmentation	B-X
,	B-X
a	B-X
hallmark	B-X
of	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
other	B-X
examined	B-X
di	B-X
-	B-X
	B-X
,	B-X
tri	B-X
-	B-X
	B-X
,	B-X
tetra	B-X
-	B-X
	B-X
,	B-X
and	B-X
pentachlorobiphenyls	B-X
did	B-X
not	B-X
<EOS>	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
caused	B-X
a	B-X
decrease	B-X
in	B-X
cell	B-X
viability	B-X
and	B-X
induced	B-X
cellular	B-X
morphologic	B-X
features	B-X
characteristic	B-X
of	B-X
apoptosis	B-X
such	B-X
as	B-X
chromatin	B-X
aggregation	B-X
and	B-X
apoptotic	B-X
bodies	B-X
<EOS>	B-X
To	B-X
further	B-X
study	B-X
the	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
various	B-X
features	B-X
of	B-X
apoptosis	B-X
were	B-X
examined	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
data	B-X
indicate	B-X
that	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
through	B-X
a	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
arylhydrocarbon	B-X
receptor	B-X

To	O
further	O
study	O
the	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-PeCB-induced	O
cell	O
death	O
,	O
various	O
features	O
of	O
apoptosis	O
were	O
examined	O
.	O

2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-PeCB	O
caused	O
a	O
decrease	O
in	O
cell	O
viability	O
and	O
induced	O
cellular	O
morphologic	O
features	O
characteristic	O
of	O
apoptosis	O
such	O
as	O
chromatin	O
aggregation	O
and	O
apoptotic	O
bodies	O
.	O
<EOS>	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
caused	B-X
a	B-X
decrease	B-X
in	B-X
cell	B-X
viability	B-X
and	B-X
induced	B-X
cellular	B-X
morphologic	B-X
features	B-X
characteristic	B-X
of	B-X
apoptosis	B-X
such	B-X
as	B-X
chromatin	B-X
aggregation	B-X
and	B-X
apoptotic	B-X
bodies	B-X
<EOS>	B-X
2,2',4,6,6'	B-X
-	B-X
pentachlorobiphenyl	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
<EOS>	B-X
To	B-X
further	B-X
study	B-X
the	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
various	B-X
features	B-X
of	B-X
apoptosis	B-X
were	B-X
examined	B-X
<EOS>	B-X
Among	B-X
the	B-X
various	B-X
congeners	B-X
tested	B-X
,	B-X
2,2',4,6	B-X
,	B-X
6'	B-X
-	B-X
pentachlorobiphenyl	B-X
(	B-X
PeCB	B-X
)	B-X
,	B-X
a	B-X
highly	B-X
ortho	B-X
-	B-X
substituted	B-X
congener	B-X
,	B-X
specifically	B-X
induced	B-X
DNA	B-X
fragmentation	B-X
,	B-X
a	B-X
hallmark	B-X
of	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
other	B-X
examined	B-X
di	B-X
-	B-X
	B-X
,	B-X
tri	B-X
-	B-X
	B-X
,	B-X
tetra	B-X
-	B-X
	B-X
,	B-X
and	B-X
pentachlorobiphenyls	B-X
did	B-X
not	B-X

In	O
addition	O
,	O
caspase-3	B-protein
,	O
an	O
executioner	O
of	O
apoptosis	O
,	O
was	O
activated	O
and	O
its	O
substrate	O
,	O
poly	B-protein
(	I-protein
ADP-ribose	I-protein
)	I-protein
polymerase	I-protein
(	O
PARP	B-protein
)	O
,	O
was	O
cleaved	O
during	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-PeCB-induced	O
apoptosis	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
,	B-X
an	B-X
executioner	B-X
of	B-X
apoptosis	B-X
,	B-X
was	B-X
activated	B-X
and	B-X
its	B-X
substrate	B-X
,	B-X
poly	B-X
(	B-X
ADP	B-X
-	B-X
ribose	B-X
)	B-X
polymerase	B-X
(	B-X
PARP	B-X
)	B-X
,	B-X
was	B-X
cleaved	B-X
during	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
-	B-X
induced	B-X
apoptosis	B-X
<EOS>	B-X
Among	B-X
the	B-X
various	B-X
congeners	B-X
tested	B-X
,	B-X
2,2',4,6	B-X
,	B-X
6'	B-X
-	B-X
pentachlorobiphenyl	B-X
(	B-X
PeCB	B-X
)	B-X
,	B-X
a	B-X
highly	B-X
ortho	B-X
-	B-X
substituted	B-X
congener	B-X
,	B-X
specifically	B-X
induced	B-X
DNA	B-X
fragmentation	B-X
,	B-X
a	B-X
hallmark	B-X
of	B-X
apoptosis	B-X
,	B-X
while	B-X
the	B-X
other	B-X
examined	B-X
di	B-X
-	B-X
	B-X
,	B-X
tri	B-X
-	B-X
	B-X
,	B-X
tetra	B-X
-	B-X
	B-X
,	B-X
and	B-X
pentachlorobiphenyls	B-X
did	B-X
not	B-X
<EOS>	B-X
Polychlorinatedbiphenyls	B-X
(	B-X
PCBs	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
persistent	B-X
and	B-X
widely	B-X
dispersed	B-X
environmental	B-X
pollutants	B-X
,	B-X
some	B-X
of	B-X
which	B-X
may	B-X
be	B-X
immunotoxic	B-X
<EOS>	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
caused	B-X
a	B-X
decrease	B-X
in	B-X
cell	B-X
viability	B-X
and	B-X
induced	B-X
cellular	B-X
morphologic	B-X
features	B-X
characteristic	B-X
of	B-X
apoptosis	B-X
such	B-X
as	B-X
chromatin	B-X
aggregation	B-X
and	B-X
apoptotic	B-X
bodies	B-X

In	O
contrast	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
,	O
5-PeCB	O
,	O
a	O
congener	O
of	O
coplanar	O
structure	O
,	O
as	O
well	O
as	O
2	O
,	O
3	O
,	O
7	O
,	O
8-TCDD	O
did	O
not	O
induce	O
apoptosis	O
in	O
these	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
,	O
although	O
they	O
potently	O
induced	O
CYP	B-protein
1A1	I-protein
in	O
human	B-cell_line
hepatoma	I-cell_line
Hep	I-cell_line
G2	I-cell_line
cells	I-cell_line
.	O

Taken	O
together	O
,	O
the	O
data	O
indicate	O
that	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-PeCB	O
induces	O
apoptosis	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
through	O
a	O
mechanism	O
that	O
is	O
independent	O
of	O
the	O
arylhydrocarbon	B-protein
receptor	I-protein
.	O
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
data	B-X
indicate	B-X
that	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
through	B-X
a	B-X
mechanism	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
arylhydrocarbon	B-X
receptor	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
3,3',4,4',5	B-X
-	B-X
PeCB	B-X
,	B-X
a	B-X
congener	B-X
of	B-X
coplanar	B-X
structure	B-X
,	B-X
as	B-X
well	B-X
as	B-X
2,3,7,8	B-X
-	B-X
TCDD	B-X
did	B-X
not	B-X
induce	B-X
apoptosis	B-X
in	B-X
these	B-X
human	B-X
monocytic	B-X
cells	B-X
,	B-X
although	B-X
they	B-X
potently	B-X
induced	B-X
CYP	B-X
1A1	B-X
in	B-X
human	B-X
hepatoma	B-X
Hep	B-X
G2	B-X
cells	B-X
<EOS>	B-X
To	B-X
further	B-X
study	B-X
the	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
various	B-X
features	B-X
of	B-X
apoptosis	B-X
were	B-X
examined	B-X
<EOS>	B-X
2,2',4,6,6'	B-X
-	B-X
pentachlorobiphenyl	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X

This	O
suggests	O
a	O
possibly	O
separate	O
mechanism	O
by	O
which	O
PCBs	O
cause	O
immunosuppression	O
.	O
<EOS>	B-X
This	B-X
suggests	B-X
a	B-X
possibly	B-X
separate	B-X
mechanism	B-X
by	B-X
which	B-X
PCBs	B-X
cause	B-X
immunosuppression	B-X
<EOS>	B-X
Polychlorinatedbiphenyls	B-X
(	B-X
PCBs	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
persistent	B-X
and	B-X
widely	B-X
dispersed	B-X
environmental	B-X
pollutants	B-X
,	B-X
some	B-X
of	B-X
which	B-X
may	B-X
be	B-X
immunotoxic	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
PCBs	B-X
on	B-X
immune	B-X
system	B-X
by	B-X
assessing	B-X
apoptotic	B-X
cell	B-X
death	B-X
in	B-X
human	B-X
monocytic	B-X
U937	B-X
cells	B-X
<EOS>	B-X
To	B-X
further	B-X
study	B-X
the	B-X
2,2',4,6,6'	B-X
-	B-X
PeCB	B-X
-	B-X
induced	B-X
cell	B-X
death	B-X
,	B-X
various	B-X
features	B-X
of	B-X
apoptosis	B-X
were	B-X
examined	B-X

Effects	O
of	O
deregulated	O
Raf	O
activation	O
on	O
integrin	B-protein
,	O
cytokine-receptor	O
expression	O
and	O
the	O
induction	O
of	O
apoptosis	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Effects	B-X
of	B-X
deregulated	B-X
Raf	B-X
activation	B-X
on	B-X
integrin	B-X
,	B-X
cytokine	B-X
-	B-X
receptor	B-X
expression	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
deregulated	B-X
Raf	B-X
activation	B-X
on	B-X
the	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
were	B-X
investigated	B-X
<EOS>	B-X
Thus	B-X
deregulated	B-X
Raf	B-X
expression	B-X
can	B-X
alter	B-X
cytokine	B-X
dependency	B-X
,	B-X
integrin	B-X
expression	B-X
and	B-X
the	B-X
stage	B-X
of	B-X
differentiation	B-X
<EOS>	B-X
Expression	B-X
of	B-X
activated	B-X
Raf	B-X
oncoproteins	B-X
also	B-X
abrogated	B-X
cytokine	B-X
dependency	B-X
and	B-X
prevented	B-X
apoptosis	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X

The	O
effects	O
of	O
deregulated	O
Raf	O
activation	O
on	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
were	O
investigated	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
deregulated	B-X
Raf	B-X
activation	B-X
on	B-X
the	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
hematopoietic	B-X
cells	B-X
were	B-X
investigated	B-X
<EOS>	B-X
Effects	B-X
of	B-X
deregulated	B-X
Raf	B-X
activation	B-X
on	B-X
integrin	B-X
,	B-X
cytokine	B-X
-	B-X
receptor	B-X
expression	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
Raf	B-X
activation	B-X
counterbalanced	B-X
the	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
caused	B-X
by	B-X
RA	B-X
but	B-X
not	B-X
PMA	B-X
<EOS>	B-X
These	B-X
Raf	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
will	B-X
be	B-X
useful	B-X
in	B-X
elucidating	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
MAP	B-X
kinase	B-X
cascade	B-X
on	B-X
hematopoietic	B-X
cell	B-X
differentiation	B-X
and	B-X
malignant	B-X
transformation	B-X

The	O
cytokine-dependent	B-cell_line
murine	I-cell_line
myeloid	I-cell_line
FDC-P1	I-cell_line
and	O
human	B-cell_line
erythroleukemic	I-cell_line
TF-1	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
transformed	O
to	O
grow	O
in	O
response	O
to	O
deregulated	O
Raf	O
expression	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
-	B-X
dependent	B-X
murine	B-X
myeloid	B-X
FDC	B-X
-	B-X
P1	B-X
and	B-X
human	B-X
erythroleukemic	B-X
TF	B-X
-	B-X
1	B-X
cell	B-X
lines	B-X
were	B-X
transformed	B-X
to	B-X
grow	B-X
in	B-X
response	B-X
to	B-X
deregulated	B-X
Raf	B-X
expression	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
exogenous	B-X
cytokines	B-X
<EOS>	B-X
Thus	B-X
deregulated	B-X
Raf	B-X
expression	B-X
can	B-X
alter	B-X
cytokine	B-X
dependency	B-X
,	B-X
integrin	B-X
expression	B-X
and	B-X
the	B-X
stage	B-X
of	B-X
differentiation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
these	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
IL	B-X
-	B-X
3	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
Effects	B-X
of	B-X
deregulated	B-X
Raf	B-X
activation	B-X
on	B-X
integrin	B-X
,	B-X
cytokine	B-X
-	B-X
receptor	B-X
expression	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X

The	O
conditionally	O
active	O
Raf	B-protein
proteins	I-protein
were	O
regulated	O
by	O
beta-estradiol	O
as	O
cDNAs	B-DNA
containing	O
the	O
Raf	B-protein
catalytic	I-protein
,	O
but	O
lacking	O
negative-regulatory	B-protein
domains	I-protein
,	O
were	O
ligated	O
to	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
deltaRaf	B-protein
:	I-protein
ER	I-protein
)	O
.	O

Continuous	O
deltaRaf	B-protein
expression	O
prevented	O
apoptosis	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
and	O
altered	O
the	O
morphology	O
of	O
the	O
FD/deltaRaf	B-cell_type
:	I-cell_type
ER	I-cell_type
cells	I-cell_type
as	O
they	O
grew	O
in	O
large	O
aggregated	O
masses	O
(	O
>	O
100	O
cells	O
)	O
whereas	O
the	O
parental	B-cell_line
cytokine-dependent	I-cell_line
FDC-P1	I-cell_line
cells	I-cell_line
grew	O
in	O
smaller	O
grape-like	O
clusters	O
(	O
<	O
10	O
cells	O
)	O
.	O
<EOS>	B-X
Continuous	B-X
deltaRaf	B-X
expression	B-X
prevented	B-X
apoptosis	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
exogenous	B-X
cytokines	B-X
and	B-X
altered	B-X
the	B-X
morphology	B-X
of	B-X
the	B-X
FD	B-X
/	B-X
deltaRaf	B-X
:	B-X
ER	B-X
cells	B-X
as	B-X
they	B-X
grew	B-X
in	B-X
large	B-X
aggregated	B-X
masses	B-X
(	B-X
>	B-X
100	B-X
cells	B-X
)	B-X
whereas	B-X
the	B-X
parental	B-X
cytokine	B-X
-	B-X
dependent	B-X
FDC	B-X
-	B-X
P1	B-X
cells	B-X
grew	B-X
in	B-X
smaller	B-X
grape	B-X
-	B-X
like	B-X
clusters	B-X
(	B-X
<	B-X
10	B-X
cells	B-X
)	B-X
<EOS>	B-X
These	B-X
Raf	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
will	B-X
be	B-X
useful	B-X
in	B-X
elucidating	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
MAP	B-X
kinase	B-X
cascade	B-X
on	B-X
hematopoietic	B-X
cell	B-X
differentiation	B-X
and	B-X
malignant	B-X
transformation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
when	B-X
the	B-X
Raf	B-X
-	B-X
responsive	B-X
cells	B-X
were	B-X
induced	B-X
to	B-X
differentiate	B-X
with	B-X
PMA	B-X
and	B-X
GM	B-X
-	B-X
CSF	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
deltaRaf	B-X
:	B-X
ER	B-X
activation	B-X
,	B-X
increased	B-X
levels	B-X
of	B-X
the	B-X
CD11b	B-X
and	B-X
CD18	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
FD	B-X
/	B-X
deltaRaf	B-X
-	B-X
1	B-X
:	B-X
ER	B-X
cells	B-X
growing	B-X
in	B-X
response	B-X
to	B-X
Raf	B-X
activation	B-X
displayed	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
Mac	B-X
-	B-X
2	B-X
and	B-X
Mac	B-X
-	B-X
3	B-X
molecules	B-X
on	B-X
their	B-X
cell	B-X
surface	B-X

FD/deltaRaf-1	B-cell_line
:	I-cell_line
ER	I-cell_line
cells	I-cell_line
growing	O
in	O
response	O
to	O
Raf	O
activation	O
displayed	O
decreased	O
levels	O
of	O
the	O
Mac-2	B-protein
and	I-protein
Mac-3	I-protein
molecules	I-protein
on	O
their	O
cell	B-cell_type
surface	I-cell_type
.	O
<EOS>	B-X
FD	B-X
/	B-X
deltaRaf	B-X
-	B-X
1	B-X
:	B-X
ER	B-X
cells	B-X
growing	B-X
in	B-X
response	B-X
to	B-X
Raf	B-X
activation	B-X
displayed	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
Mac	B-X
-	B-X
2	B-X
and	B-X
Mac	B-X
-	B-X
3	B-X
molecules	B-X
on	B-X
their	B-X
cell	B-X
surface	B-X
<EOS>	B-X
In	B-X
contrast	B-X
when	B-X
the	B-X
Raf	B-X
-	B-X
responsive	B-X
cells	B-X
were	B-X
induced	B-X
to	B-X
differentiate	B-X
with	B-X
PMA	B-X
and	B-X
GM	B-X
-	B-X
CSF	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
deltaRaf	B-X
:	B-X
ER	B-X
activation	B-X
,	B-X
increased	B-X
levels	B-X
of	B-X
the	B-X
CD11b	B-X
and	B-X
CD18	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
these	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
IL	B-X
-	B-X
3	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
differentiation	B-X
status	B-X
of	B-X
these	B-X
Raf	B-X
-	B-X
responsive	B-X
cells	B-X
was	B-X
more	B-X
immature	B-X
upon	B-X
Raf	B-X
activation	B-X
as	B-X
culture	B-X
with	B-X
the	B-X
differentiation	B-X
-	B-X
inducing	B-X
agent	B-X
phorbol	B-X
12	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
beta	B-X
-	B-X
estradiol	B-X
resulted	B-X
in	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
CD11b	B-X
and	B-X
CD18	B-X
integrin	B-X
molecules	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X

In	O
contrast	O
,	O
when	O
these	O
cells	O
were	O
cultured	O
in	O
IL-3	B-protein
,	O
higher	O
levels	O
of	O
these	O
adhesion	B-protein
molecules	I-protein
were	O
detected	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
these	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
IL	B-X
-	B-X
3	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
In	B-X
contrast	B-X
when	B-X
the	B-X
Raf	B-X
-	B-X
responsive	B-X
cells	B-X
were	B-X
induced	B-X
to	B-X
differentiate	B-X
with	B-X
PMA	B-X
and	B-X
GM	B-X
-	B-X
CSF	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
deltaRaf	B-X
:	B-X
ER	B-X
activation	B-X
,	B-X
increased	B-X
levels	B-X
of	B-X
the	B-X
CD11b	B-X
and	B-X
CD18	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
FD	B-X
/	B-X
deltaRaf	B-X
-	B-X
1	B-X
:	B-X
ER	B-X
cells	B-X
growing	B-X
in	B-X
response	B-X
to	B-X
Raf	B-X
activation	B-X
displayed	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
Mac	B-X
-	B-X
2	B-X
and	B-X
Mac	B-X
-	B-X
3	B-X
molecules	B-X
on	B-X
their	B-X
cell	B-X
surface	B-X
<EOS>	B-X
The	B-X
cytokine	B-X
-	B-X
dependent	B-X
murine	B-X
myeloid	B-X
FDC	B-X
-	B-X
P1	B-X
and	B-X
human	B-X
erythroleukemic	B-X
TF	B-X
-	B-X
1	B-X
cell	B-X
lines	B-X
were	B-X
transformed	B-X
to	B-X
grow	B-X
in	B-X
response	B-X
to	B-X
deregulated	B-X
Raf	B-X
expression	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
exogenous	B-X
cytokines	B-X

Expression	O
of	O
activated	O
Raf	B-protein
oncoproteins	I-protein
also	O
abrogated	O
cytokine	O
dependency	O
and	O
prevented	O
apoptosis	O
of	O
TF-1	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Expression	B-X
of	B-X
activated	B-X
Raf	B-X
oncoproteins	B-X
also	B-X
abrogated	B-X
cytokine	B-X
dependency	B-X
and	B-X
prevented	B-X
apoptosis	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
Differential	B-X
abilities	B-X
of	B-X
activated	B-X
Raf	B-X
oncoproteins	B-X
to	B-X
abrogate	B-X
cytokine	B-X
dependency	B-X
,	B-X
prevent	B-X
apoptosis	B-X
and	B-X
induce	B-X
autocrine	B-X
growth	B-X
factor	B-X
synthesis	B-X
in	B-X
human	B-X
hematopoietic	B-X
cells	B-X
.	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
activated	B-X
PI3K	B-X
or	B-X
Akt	B-X
does	B-X
not	B-X
abrogate	B-X
the	B-X
cytokine	B-X
dependence	B-X
of	B-X
these	B-X
hematopoietic	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
does	B-X
have	B-X
positive	B-X
effects	B-X
on	B-X
cell	B-X
survival	B-X
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
these	B-X
observations	B-X
indicate	B-X
that	B-X
the	B-X
aberrant	B-X
expression	B-X
of	B-X
certain	B-X
activated	B-X
deltaRaf	B-X
:	B-X
ER	B-X
oncoproteins	B-X
can	B-X
alter	B-X
the	B-X
cytokine	B-X
dependency	B-X
of	B-X
human	B-X
hematopoietic	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X

Moreover	O
,	O
the	O
differentiation	O
status	O
of	O
these	O
Raf-responsive	B-cell_type
cells	I-cell_type
was	O
more	O
immature	O
upon	O
Raf	O
activation	O
as	O
culture	O
with	O
the	O
differentiation-inducing	O
agent	O
phorbol	O
12	O
myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
beta-estradiol	O
resulted	O
in	O
decreased	O
levels	O
of	O
the	O
CD11b	B-protein
and	I-protein
CD18	I-protein
integrin	I-protein
molecules	I-protein
on	O
the	O
cell	B-cell_type
surface	I-cell_type
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
differentiation	B-X
status	B-X
of	B-X
these	B-X
Raf	B-X
-	B-X
responsive	B-X
cells	B-X
was	B-X
more	B-X
immature	B-X
upon	B-X
Raf	B-X
activation	B-X
as	B-X
culture	B-X
with	B-X
the	B-X
differentiation	B-X
-	B-X
inducing	B-X
agent	B-X
phorbol	B-X
12	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
beta	B-X
-	B-X
estradiol	B-X
resulted	B-X
in	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
CD11b	B-X
and	B-X
CD18	B-X
integrin	B-X
molecules	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
<EOS>	B-X
In	B-X
contrast	B-X
when	B-X
the	B-X
Raf	B-X
-	B-X
responsive	B-X
cells	B-X
were	B-X
induced	B-X
to	B-X
differentiate	B-X
with	B-X
PMA	B-X
and	B-X
GM	B-X
-	B-X
CSF	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
deltaRaf	B-X
:	B-X
ER	B-X
activation	B-X
,	B-X
increased	B-X
levels	B-X
of	B-X
the	B-X
CD11b	B-X
and	B-X
CD18	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
FD	B-X
/	B-X
deltaRaf	B-X
-	B-X
1	B-X
:	B-X
ER	B-X
cells	B-X
growing	B-X
in	B-X
response	B-X
to	B-X
Raf	B-X
activation	B-X
displayed	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
Mac	B-X
-	B-X
2	B-X
and	B-X
Mac	B-X
-	B-X
3	B-X
molecules	B-X
on	B-X
their	B-X
cell	B-X
surface	B-X
<EOS>	B-X
These	B-X
Raf	B-X
-	B-X
responsive	B-X
cell	B-X
lines	B-X
will	B-X
be	B-X
useful	B-X
in	B-X
elucidating	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
MAP	B-X
kinase	B-X
cascade	B-X
on	B-X
hematopoietic	B-X
cell	B-X
differentiation	B-X
and	B-X
malignant	B-X
transformation	B-X

In	O
contrast	O
when	O
the	O
Raf-responsive	B-cell_type
cells	I-cell_type
were	O
induced	O
to	O
differentiate	O
with	O
PMA	O
and	O
GM-CSF	B-protein
,	O
in	O
the	O
absence	O
of	O
deltaRaf	B-protein
:	I-protein
ER	I-protein
activation	O
,	O
increased	O
levels	O
of	O
the	O
CD11b	B-protein
and	I-protein
CD18	I-protein
molecules	I-protein
were	O
detected	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
when	B-X
the	B-X
Raf	B-X
-	B-X
responsive	B-X
cells	B-X
were	B-X
induced	B-X
to	B-X
differentiate	B-X
with	B-X
PMA	B-X
and	B-X
GM	B-X
-	B-X
CSF	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
deltaRaf	B-X
:	B-X
ER	B-X
activation	B-X
,	B-X
increased	B-X
levels	B-X
of	B-X
the	B-X
CD11b	B-X
and	B-X
CD18	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
these	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
IL	B-X
-	B-X
3	B-X
,	B-X
higher	B-X
levels	B-X
of	B-X
these	B-X
adhesion	B-X
molecules	B-X
were	B-X
detected	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
differentiation	B-X
status	B-X
of	B-X
these	B-X
Raf	B-X
-	B-X
responsive	B-X
cells	B-X
was	B-X
more	B-X
immature	B-X
upon	B-X
Raf	B-X
activation	B-X
as	B-X
culture	B-X
with	B-X
the	B-X
differentiation	B-X
-	B-X
inducing	B-X
agent	B-X
phorbol	B-X
12	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
beta	B-X
-	B-X
estradiol	B-X
resulted	B-X
in	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
CD11b	B-X
and	B-X
CD18	B-X
integrin	B-X
molecules	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
<EOS>	B-X
FD	B-X
/	B-X
deltaRaf	B-X
-	B-X
1	B-X
:	B-X
ER	B-X
cells	B-X
growing	B-X
in	B-X
response	B-X
to	B-X
Raf	B-X
activation	B-X
displayed	B-X
decreased	B-X
levels	B-X
of	B-X
the	B-X
Mac	B-X
-	B-X
2	B-X
and	B-X
Mac	B-X
-	B-X
3	B-X
molecules	B-X
on	B-X
their	B-X
cell	B-X
surface	B-X

Retinoic	O
acid	O
(	O
RA	O
)	O
inhibited	O
3H-thymidine	O
incorporation	O
in	O
response	O
to	O
GM-CSF	B-protein
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
inhibited	B-X
3H	B-X
-	B-X
thymidine	B-X
incorporation	B-X
in	B-X
response	B-X
to	B-X
GM	B-X
-	B-X
CSF	B-X
<EOS>	B-X
Effects	B-X
of	B-X
deregulated	B-X
Raf	B-X
activation	B-X
on	B-X
integrin	B-X
,	B-X
cytokine	B-X
-	B-X
receptor	B-X
expression	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Expression	B-X
of	B-X
activated	B-X
Raf	B-X
oncoproteins	B-X
also	B-X
abrogated	B-X
cytokine	B-X
dependency	B-X
and	B-X
prevented	B-X
apoptosis	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
Raf	B-X
activation	B-X
counterbalanced	B-X
the	B-X
inhibition	B-X
of	B-X
DNA	B-X
synthesis	B-X
caused	B-X
by	B-X
RA	B-X
but	B-X
not	B-X
PMA	B-X

Interestingly	O
,	O
Raf	O
activation	O
counterbalanced	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
caused	O
by	O
RA	O
but	O
not	O
PMA	O
.	O

Thus	O
deregulated	O
Raf	O
expression	O
can	O
alter	O
cytokine	O
dependency	O
,	O
integrin	O
expression	O
and	O
the	O
stage	O
of	O
differentiation	O
.	O
<EOS>	B-X
Thus	B-X
deregulated	B-X
Raf	B-X
expression	B-X
can	B-X
alter	B-X
cytokine	B-X
dependency	B-X
,	B-X
integrin	B-X
expression	B-X
and	B-X
the	B-X
stage	B-X
of	B-X
differentiation	B-X
<EOS>	B-X
Effects	B-X
of	B-X
deregulated	B-X
Raf	B-X
activation	B-X
on	B-X
integrin	B-X
,	B-X
cytokine	B-X
-	B-X
receptor	B-X
expression	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Expression	B-X
of	B-X
activated	B-X
Raf	B-X
oncoproteins	B-X
also	B-X
abrogated	B-X
cytokine	B-X
dependency	B-X
and	B-X
prevented	B-X
apoptosis	B-X
of	B-X
TF	B-X
-	B-X
1	B-X
cells	B-X
<EOS>	B-X
The	B-X
cytokine	B-X
-	B-X
dependent	B-X
murine	B-X
myeloid	B-X
FDC	B-X
-	B-X
P1	B-X
and	B-X
human	B-X
erythroleukemic	B-X
TF	B-X
-	B-X
1	B-X
cell	B-X
lines	B-X
were	B-X
transformed	B-X
to	B-X
grow	B-X
in	B-X
response	B-X
to	B-X
deregulated	B-X
Raf	B-X
expression	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
exogenous	B-X
cytokines	B-X

These	O
Raf-responsive	B-cell_line
cell	I-cell_line
lines	I-cell_line
will	O
be	O
useful	O
in	O
elucidating	O
the	O
roles	O
of	O
the	O
MAP	O
kinase	O
cascade	O
on	O
hematopoietic	B-cell_type
cell	I-cell_type
differentiation	O
and	O
malignant	O
transformation	O

Cyclic	O
AMP	O
activates	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	O
Th2	B-cell_type
cells	I-cell_type
:	O
phosphorylation	O
of	O
GATA-3	B-protein
and	O
stimulation	O
of	O
Th2	B-cell_type
cytokine	O
gene	O
expression	O
.	O
<EOS>	B-X
Cyclic	B-X
AMP	B-X
activates	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
:	B-X
phosphorylation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
and	B-X
stimulation	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
Th2	B-X
-	B-X
specific	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
activation	B-X
together	B-X
provide	B-X
a	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
differential	B-X
effects	B-X
of	B-X
cAMP	B-X
in	B-X
the	B-X
two	B-X
T	B-X
helper	B-X
cell	B-X
subsets	B-X
<EOS>	B-X
Instead	B-X
,	B-X
cAMP	B-X
stimulates	B-X
activation	B-X
of	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
Our	B-X
data	B-X
also	B-X
show	B-X
that	B-X
cAMP	B-X
causes	B-X
increased	B-X
phosphorylation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
3	B-X
,	B-X
which	B-X
we	B-X
have	B-X
shown	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
of	B-X
airway	B-X
inflammation	B-X
in	B-X
mice	B-X

cAMP	O
is	O
an	O
important	O
second	O
messenger	O
with	O
immunomodulatory	O
properties	O
.	O
<EOS>	B-X
cAMP	B-X
is	B-X
an	B-X
important	B-X
second	B-X
messenger	B-X
with	B-X
immunomodulatory	B-X
properties	B-X
<EOS>	B-X
cAMP	B-X
,	B-X
an	B-X
intracellular	B-X
second	B-X
messenger	B-X
,	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulation	B-X
of	B-X
cytokine	B-X
biosynthesis	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
i	B-X
<EOS>	B-X
Induction	B-X
of	B-X
intracellular	B-X
cAMP	B-X
by	B-X
a	B-X
synthetic	B-X
retroviral	B-X
envelope	B-X
peptide	B-X
:	B-X
a	B-X
possible	B-X
mechanism	B-X
of	B-X
immunopathogenesis	B-X
in	B-X
retroviral	B-X
infections	B-X
.	B-X
<EOS>	B-X
Cyclic	B-X
AMP	B-X
activates	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
:	B-X
phosphorylation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
and	B-X
stimulation	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X

Elevation	O
of	O
intracellular	O
cAMP	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
induced	O
by	O
agents	O
such	O
as	O
IL-1alpha	B-protein
or	O
PGs	B-protein
,	O
inhibits	O
T	O
cell	O
activation	O
.	O
<EOS>	B-X
Elevation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
was	B-X
essential	B-X
because	B-X
PGE2	B-X
could	B-X
be	B-X
substituted	B-X
with	B-X
the	B-X
adenylyl	B-X
cyclase	B-X
agonist	B-X
forskolin	B-X
,	B-X
and	B-X
CCR8	B-X
expression	B-X
was	B-X
sensitive	B-X
to	B-X
protein	B-X
kinase	B-X
A	B-X
inhibition	B-X
<EOS>	B-X
Evasion	B-X
of	B-X
immunosurveillance	B-X
by	B-X
genomic	B-X
alterations	B-X
of	B-X
PPARγ	B-X
/	B-X
RXRα	B-X
in	B-X
bladder	B-X
cancer	B-X
.	B-X
<EOS>	B-X
The	B-X
importance	B-X
of	B-X
tissue	B-X
environments	B-X
in	B-X
maintaining	B-X
cellular	B-X
immune	B-X
surveillance	B-X
networks	B-X
within	B-X
distinct	B-X
healthy	B-X
tissues	B-X
provides	B-X
a	B-X
paradigm	B-X
shift	B-X
in	B-X
adaptive	B-X
immunity	B-X
<EOS>	B-X
The	B-X
capacity	B-X
of	B-X
DCs	B-X
to	B-X
activate	B-X
T	B-X
cells	B-X
depends	B-X
on	B-X
their	B-X
maturation	B-X
state	B-X
as	B-X
well	B-X
as	B-X
their	B-X
ability	B-X
to	B-X
migrate	B-X
to	B-X
the	B-X
T	B-X
cell	B-X
areas	B-X
of	B-X
draining	B-X
lymph	B-X
nodes	B-X

In	O
effector	O
T	B-cell_type
cells	I-cell_type
,	O
an	O
increase	O
in	O
the	O
level	O
of	O
intracellular	O
cAMP	O
inhibits	O
cytokine	B-protein
production	O
in	O
Th1	B-cell_type
cells	I-cell_type
but	O
stimulates	O
cytokine	B-protein
production	O
in	O
Th2	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
In	B-X
effector	B-X
T	B-X
cells	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
intracellular	B-X
cAMP	B-X
inhibits	B-X
cytokine	B-X
production	B-X
in	B-X
Th1	B-X
cells	B-X
but	B-X
stimulates	B-X
cytokine	B-X
production	B-X
in	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
This	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
Th2	B-X
-	B-X
selective	B-X
event	B-X
because	B-X
cAMP	B-X
barely	B-X
increased	B-X
p38	B-X
phosphorylation	B-X
in	B-X
Th1	B-X
cells	B-X
<EOS>	B-X
Instead	B-X
,	B-X
cAMP	B-X
stimulates	B-X
activation	B-X
of	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
Elevation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
induced	B-X
by	B-X
agents	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
1alpha	B-X
or	B-X
PGs	B-X
,	B-X
inhibits	B-X
T	B-X
cell	B-X
activation	B-X

Here	O
we	O
report	O
that	O
cAMP-induced	O
effects	O
in	O
Th2	B-cell_type
cells	I-cell_type
occur	O
independently	O
of	O
the	O
protein	B-protein
kinase	I-protein
A	I-protein
pathway	O
,	O
which	O
is	O
the	O
major	O
mediator	O
of	O
cAMP-induced	O
signaling	O
events	O
in	O
most	O
cell	O
types	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
cAMP	B-X
-	B-X
induced	B-X
effects	B-X
in	B-X
Th2	B-X
cells	B-X
occur	B-X
independently	B-X
of	B-X
the	B-X
protein	B-X
kinase	B-X
A	B-X
pathway	B-X
,	B-X
which	B-X
is	B-X
the	B-X
major	B-X
mediator	B-X
of	B-X
cAMP	B-X
-	B-X
induced	B-X
signaling	B-X
events	B-X
in	B-X
most	B-X
cell	B-X
types	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
in	B-X
Th2	B-X
cells	B-X
,	B-X
cAMP	B-X
promotes	B-X
the	B-X
production	B-X
of	B-X
both	B-X
IL	B-X
-	B-X
5	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
,	B-X
which	B-X
play	B-X
distinct	B-X
but	B-X
critical	B-X
roles	B-X
in	B-X
asthma	B-X
pathogenesis	B-X
<EOS>	B-X
Cyclic	B-X
AMP	B-X
activates	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
:	B-X
phosphorylation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
and	B-X
stimulation	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Elevation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
induced	B-X
by	B-X
agents	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
1alpha	B-X
or	B-X
PGs	B-X
,	B-X
inhibits	B-X
T	B-X
cell	B-X
activation	B-X

Instead	O
,	O
cAMP	O
stimulates	O
activation	O
of	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	O
Th2	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Instead	B-X
,	B-X
cAMP	B-X
stimulates	B-X
activation	B-X
of	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
Cyclic	B-X
AMP	B-X
activates	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
:	B-X
phosphorylation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
and	B-X
stimulation	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
in	B-X
Th2	B-X
cells	B-X
,	B-X
cAMP	B-X
promotes	B-X
the	B-X
production	B-X
of	B-X
both	B-X
IL	B-X
-	B-X
5	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
,	B-X
which	B-X
play	B-X
distinct	B-X
but	B-X
critical	B-X
roles	B-X
in	B-X
asthma	B-X
pathogenesis	B-X
<EOS>	B-X
In	B-X
effector	B-X
T	B-X
cells	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
intracellular	B-X
cAMP	B-X
inhibits	B-X
cytokine	B-X
production	B-X
in	B-X
Th1	B-X
cells	B-X
but	B-X
stimulates	B-X
cytokine	B-X
production	B-X
in	B-X
Th2	B-X
cells	B-X

This	O
appears	O
to	O
be	O
a	O
Th2	B-cell_type
-selective	O
event	O
because	O
cAMP	O
barely	O
increased	O
p38	B-protein
phosphorylation	O
in	O
Th1	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
This	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
Th2	B-X
-	B-X
selective	B-X
event	B-X
because	B-X
cAMP	B-X
barely	B-X
increased	B-X
p38	B-X
phosphorylation	B-X
in	B-X
Th1	B-X
cells	B-X
<EOS>	B-X
In	B-X
effector	B-X
T	B-X
cells	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
intracellular	B-X
cAMP	B-X
inhibits	B-X
cytokine	B-X
production	B-X
in	B-X
Th1	B-X
cells	B-X
but	B-X
stimulates	B-X
cytokine	B-X
production	B-X
in	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
Instead	B-X
,	B-X
cAMP	B-X
stimulates	B-X
activation	B-X
of	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
Th2	B-X
-	B-X
specific	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
activation	B-X
together	B-X
provide	B-X
a	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
differential	B-X
effects	B-X
of	B-X
cAMP	B-X
in	B-X
the	B-X
two	B-X
T	B-X
helper	B-X
cell	B-X
subsets	B-X

We	O
show	O
that	O
in	O
Th2	B-cell_type
cells	I-cell_type
,	O
cAMP	O
promotes	O
the	O
production	O
of	O
both	O
IL-5	B-protein
and	O
IL-13	B-protein
,	O
which	O
play	O
distinct	O
but	O
critical	O
roles	O
in	O
asthma	O
pathogenesis	O
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
in	B-X
Th2	B-X
cells	B-X
,	B-X
cAMP	B-X
promotes	B-X
the	B-X
production	B-X
of	B-X
both	B-X
IL	B-X
-	B-X
5	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
,	B-X
which	B-X
play	B-X
distinct	B-X
but	B-X
critical	B-X
roles	B-X
in	B-X
asthma	B-X
pathogenesis	B-X
<EOS>	B-X
Elevation	B-X
of	B-X
intracellular	B-X
cAMP	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
induced	B-X
by	B-X
agents	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
1alpha	B-X
or	B-X
PGs	B-X
,	B-X
inhibits	B-X
T	B-X
cell	B-X
activation	B-X
<EOS>	B-X
Our	B-X
data	B-X
also	B-X
show	B-X
that	B-X
cAMP	B-X
causes	B-X
increased	B-X
phosphorylation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
3	B-X
,	B-X
which	B-X
we	B-X
have	B-X
shown	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
of	B-X
airway	B-X
inflammation	B-X
in	B-X
mice	B-X
<EOS>	B-X
Instead	B-X
,	B-X
cAMP	B-X
stimulates	B-X
activation	B-X
of	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X

Our	O
data	O
also	O
show	O
that	O
cAMP	O
causes	O
increased	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
,	O
which	O
we	O
have	O
shown	O
is	O
a	O
critical	O
regulator	O
of	O
Th2	B-cell_type
cytokine	O
gene	O
expression	O
and	O
,	O
in	O
turn	O
,	O
of	O
airway	O
inflammation	O
in	O
mice	O
.	O
<EOS>	B-X
Our	B-X
data	B-X
also	B-X
show	B-X
that	B-X
cAMP	B-X
causes	B-X
increased	B-X
phosphorylation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
GATA	B-X
-	B-X
3	B-X
,	B-X
which	B-X
we	B-X
have	B-X
shown	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
of	B-X
airway	B-X
inflammation	B-X
in	B-X
mice	B-X
<EOS>	B-X
Cyclic	B-X
AMP	B-X
activates	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
:	B-X
phosphorylation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
and	B-X
stimulation	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
in	B-X
Th2	B-X
cells	B-X
,	B-X
cAMP	B-X
promotes	B-X
the	B-X
production	B-X
of	B-X
both	B-X
IL	B-X
-	B-X
5	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
,	B-X
which	B-X
play	B-X
distinct	B-X
but	B-X
critical	B-X
roles	B-X
in	B-X
asthma	B-X
pathogenesis	B-X
<EOS>	B-X
In	B-X
effector	B-X
T	B-X
cells	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
intracellular	B-X
cAMP	B-X
inhibits	B-X
cytokine	B-X
production	B-X
in	B-X
Th1	B-X
cells	B-X
but	B-X
stimulates	B-X
cytokine	B-X
production	B-X
in	B-X
Th2	B-X
cells	B-X

Thus	O
,	O
Th2	B-cell_type
-specific	O
GATA-3	B-protein
expression	O
and	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
activation	O
together	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
differential	O
effects	O
of	O
cAMP	O
in	O
the	O
two	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
subsets	I-cell_type
.	O
<EOS>	B-X
Thus	B-X
,	B-X
Th2	B-X
-	B-X
specific	B-X
GATA	B-X
-	B-X
3	B-X
expression	B-X
and	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
activation	B-X
together	B-X
provide	B-X
a	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
differential	B-X
effects	B-X
of	B-X
cAMP	B-X
in	B-X
the	B-X
two	B-X
T	B-X
helper	B-X
cell	B-X
subsets	B-X
<EOS>	B-X
Cyclic	B-X
AMP	B-X
activates	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
:	B-X
phosphorylation	B-X
of	B-X
GATA	B-X
-	B-X
3	B-X
and	B-X
stimulation	B-X
of	B-X
Th2	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
<EOS>	B-X
Instead	B-X
,	B-X
cAMP	B-X
stimulates	B-X
activation	B-X
of	B-X
p38	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
in	B-X
Th2	B-X
cells	B-X
<EOS>	B-X
This	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
Th2	B-X
-	B-X
selective	B-X
event	B-X
because	B-X
cAMP	B-X
barely	B-X
increased	B-X
p38	B-X
phosphorylation	B-X
in	B-X
Th1	B-X
cells	B-X

Characterization	O
of	O
IL-4	B-protein
and	O
IL-13	B-protein
signals	O
dependent	O
on	O
the	O
human	B-protein
IL-13	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
1	I-protein
:	O
redundancy	O
of	O
requirement	O
of	O
tyrosine	O
residue	O
for	O
STAT3	O
activation	O
.	O
<EOS>	B-X
Characterization	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
signals	B-X
dependent	B-X
on	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
13	B-X
receptor	B-X
alpha	B-X
chain	B-X
1	B-X
:	B-X
redundancy	B-X
of	B-X
requirement	B-X
of	B-X
tyrosine	B-X
residue	B-X
for	B-X
STAT3	B-X
activation	B-X
.	B-X
<EOS>	B-X
Replacement	B-X
of	B-X
the	B-X
two	B-X
tyrosine	B-X
residues	B-X
completely	B-X
abolished	B-X
STAT3	B-X
activation	B-X
,	B-X
although	B-X
replacing	B-X
either	B-X
tyrosine	B-X
residue	B-X
alone	B-X
retained	B-X
it	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
STAT3	B-X
activation	B-X
is	B-X
involved	B-X
with	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
signals	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
along	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
STAT6	B-X
,	B-X
and	B-X
that	B-X
there	B-X
is	B-X
a	B-X
unique	B-X
sequence	B-X
in	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
to	B-X
activate	B-X
STAT3	B-X
<EOS>	B-X
Expression	B-X
of	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
evoked	B-X
STAT3	B-X
activation	B-X
by	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
,	B-X
and	B-X
in	B-X
stimulated	B-X
human	B-X
B	B-X
cells	B-X
,	B-X
on	B-X
which	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
was	B-X
highly	B-X
expressed	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
induced	B-X
STAT3	B-X
activation	B-X

IL-4	B-protein
and	O
IL-13	B-protein
are	O
pleiotropic	B-protein
cytokines	I-protein
whose	O
biological	O
activities	O
overlap	O
with	O
each	O
other	O
.	O
<EOS>	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
are	B-X
pleiotropic	B-X
cytokines	B-X
whose	B-X
biological	B-X
activities	B-X
overlap	B-X
with	B-X
each	B-X
other	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
for	B-X
some	B-X
of	B-X
these	B-X
cytokines	B-X
,	B-X
a	B-X
linkage	B-X
was	B-X
also	B-X
established	B-X
between	B-X
asthma	B-X
and	B-X
their	B-X
receptor	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
inhibition	B-X
of	B-X
IL	B-X
-	B-X
13	B-X
,	B-X
another	B-X
TH2	B-X
cytokine	B-X
whose	B-X
signal	B-X
transduction	B-X
pathway	B-X
overlaps	B-X
with	B-X
that	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
completely	B-X
blocks	B-X
airway	B-X
hyperreactivity	B-X
in	B-X
mouse	B-X
asthma	B-X
models	B-X
<EOS>	B-X
New	B-X
insights	B-X
into	B-X
the	B-X
role	B-X
of	B-X
cytokines	B-X
in	B-X
asthma	B-X
.	B-X

IL-13	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
1	I-protein
(	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
)	O
is	O
necessary	O
for	O
binding	O
to	O
IL-13	B-protein
,	O
and	O
the	O
heterodimer	O
composed	O
of	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
and	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
transduces	O
IL-13	B-protein
and	O
IL-4	B-protein
signals	O
;	O
however	O
,	O
the	O
functional	O
mapping	O
of	O
the	O
intracellular	B-protein
domain	I-protein
of	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
is	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
wild	O
and	O
mutated	O
types	O
of	O
human	B-protein
IL-13R	I-protein
alpha	I-protein
1	I-protein
,	O
and	O
analyzed	O
IL-4	B-protein
and	O
IL-13	B-protein
signals	O
using	O
an	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
-transfected	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Expression	O
of	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
evoked	O
STAT3	B-protein
activation	O
by	O
IL-4	B-protein
and	O
IL-13	B-protein
,	O
and	O
in	O
stimulated	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
on	O
which	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
was	O
highly	O
expressed	O
,	O
IL-4	B-protein
and	O
IL-13	B-protein
induced	O
STAT3	B-protein
activation	O
.	O

Replacement	O
of	O
the	O
two	O
tyrosine	O
residues	O
completely	O
abolished	O
STAT3	B-protein
activation	O
,	O
although	O
replacing	O
either	O
tyrosine	O
residue	O
alone	O
retained	O
it	O
.	O
<EOS>	B-X
Replacement	B-X
of	B-X
the	B-X
two	B-X
tyrosine	B-X
residues	B-X
completely	B-X
abolished	B-X
STAT3	B-X
activation	B-X
,	B-X
although	B-X
replacing	B-X
either	B-X
tyrosine	B-X
residue	B-X
alone	B-X
retained	B-X
it	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
signals	B-X
dependent	B-X
on	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
13	B-X
receptor	B-X
alpha	B-X
chain	B-X
1	B-X
:	B-X
redundancy	B-X
of	B-X
requirement	B-X
of	B-X
tyrosine	B-X
residue	B-X
for	B-X
STAT3	B-X
activation	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
STAT3	B-X
activation	B-X
is	B-X
involved	B-X
with	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
signals	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
along	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
STAT6	B-X
,	B-X
and	B-X
that	B-X
there	B-X
is	B-X
a	B-X
unique	B-X
sequence	B-X
in	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
to	B-X
activate	B-X
STAT3	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
Box1	B-X
region	B-X
and	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
tail	B-X
of	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
were	B-X
critical	B-X
for	B-X
binding	B-X
to	B-X
Tyk2	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
Jak1	B-X
,	B-X
Tyk2	B-X
,	B-X
the	B-X
insulin	B-X
receptor	B-X
substrate	B-X
-	B-X
1	B-X
and	B-X
STAT6	B-X
respectively	B-X

Furthermore	O
,	O
we	O
found	O
that	O
the	O
Box1	B-protein
region	I-protein
and	O
the	O
C-terminal	B-protein
tail	I-protein
of	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
were	O
critical	O
for	O
binding	O
to	O
Tyk2	B-protein
,	O
and	O
activation	O
of	O
Jak1	B-protein
,	O
Tyk2	B-protein
,	O
the	O
insulin	B-protein
receptor	I-protein
substrate-1	I-protein
and	O
STAT6	B-protein
respectively	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
Box1	B-X
region	B-X
and	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
tail	B-X
of	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
were	B-X
critical	B-X
for	B-X
binding	B-X
to	B-X
Tyk2	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
Jak1	B-X
,	B-X
Tyk2	B-X
,	B-X
the	B-X
insulin	B-X
receptor	B-X
substrate	B-X
-	B-X
1	B-X
and	B-X
STAT6	B-X
respectively	B-X
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
constructed	B-X
wild	B-X
and	B-X
mutated	B-X
types	B-X
of	B-X
human	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
,	B-X
and	B-X
analyzed	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
signals	B-X
using	B-X
an	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
-	B-X
transfected	B-X
human	B-X
B	B-X
cell	B-X
line	B-X
<EOS>	B-X
IL	B-X
-	B-X
13	B-X
receptor	B-X
alpha	B-X
chain	B-X
1	B-X
(	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
)	B-X
is	B-X
necessary	B-X
for	B-X
binding	B-X
to	B-X
IL	B-X
-	B-X
13	B-X
,	B-X
and	B-X
the	B-X
heterodimer	B-X
composed	B-X
of	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
and	B-X
IL	B-X
-	B-X
4R	B-X
alpha	B-X
chain	B-X
transduces	B-X
IL	B-X
-	B-X
13	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
signals	B-X
;	B-X
however	B-X
,	B-X
the	B-X
functional	B-X
mapping	B-X
of	B-X
the	B-X
intracellular	B-X
domain	B-X
of	B-X
IL	B-X
-	B-X
13R	B-X
alpha	B-X
1	B-X
is	B-X
not	B-X
fully	B-X
understood	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IL	B-X
-	B-X
13	B-X
signals	B-X
dependent	B-X
on	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
13	B-X
receptor	B-X
alpha	B-X
chain	B-X
1	B-X
:	B-X
redundancy	B-X
of	B-X
requirement	B-X
of	B-X
tyrosine	B-X
residue	B-X
for	B-X
STAT3	B-X
activation	B-X
.	B-X

These	O
results	O
suggest	O
that	O
STAT3	B-protein
activation	O
is	O
involved	O
with	O
IL-4	B-protein
and	O
IL-13	B-protein
signals	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
along	O
with	O
the	O
activation	O
of	O
STAT6	B-protein
,	O
and	O
that	O
there	O
is	O
a	O
unique	O
sequence	O
in	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
to	O
activate	O
STAT3	B-protein
.	O

Functional	O
uncoupling	O
of	O
the	O
Janus	O
kinase	O
3-Stat5	O
pathway	O
in	O
malignant	O
growth	O
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1-transformed	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transforms	O
cytokine	B-protein
-dependent	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
causes	O
adult	O
T	O
cell	O
leukemia	O
.	O
<EOS>	B-X
Human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
transforms	B-X
cytokine	B-X
-	B-X
dependent	B-X
T	B-X
lymphocytes	B-X
and	B-X
causes	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
<EOS>	B-X
Human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
is	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
<EOS>	B-X
Human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV	B-X
-	B-X
I	B-X
)	B-X
is	B-X
the	B-X
causative	B-X
agent	B-X
of	B-X
adult	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
<EOS>	B-X
Human	B-X
T	B-X
-	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
leukemia	B-X
/	B-X
lymphoma	B-X
and	B-X
neurologic	B-X
disorders	B-X

Janus	B-protein
tyrosine	I-protein
kinase	I-protein
(	I-protein
Jak	I-protein
)	I-protein
3	I-protein
and	O
transcription	B-protein
factors	I-protein
Stat5a	B-protein
and	O
Stat5b	B-protein
are	O
essential	O
for	O
the	O
proliferation	O
of	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
are	O
constitutively	O
hyperactivated	O
in	O
both	O
HTLV-1-transformed	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
lymphocytes	B-cell_type
isolated	O
from	O
HTLV-1-infected	O
patients	O
;	O
therefore	O
,	O
a	O
critical	O
role	O
for	O
the	O
Jak3-Stat5	O
pathway	O
in	O
the	O
progression	O
of	O
this	O
disease	O
has	O
been	O
postulated	O
.	O

We	O
recently	O
reported	O
that	O
tyrphostin	O
AG-490	O
selectively	O
blocked	O
IL-2	O
activation	O
of	O
Jak3/Stat5	B-protein
and	O
growth	O
of	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
tyrphostin	B-X
AG	B-X
-	B-X
490	B-X
selectively	B-X
blocked	B-X
IL	B-X
-	B-X
2	B-X
activation	B-X
of	B-X
Jak3	B-X
/	B-X
Stat5	B-X
and	B-X
growth	B-X
of	B-X
murine	B-X
T	B-X
cell	B-X
lines	B-X
<EOS>	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
disruption	B-X
of	B-X
Jak3	B-X
/	B-X
Stat5a	B-X
/	B-X
b	B-X
signaling	B-X
with	B-X
AG	B-X
-	B-X
490	B-X
(	B-X
50	B-X
microM	B-X
)	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
lymphocytes	B-X
,	B-X
but	B-X
paradoxically	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
proliferation	B-X
of	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
transformed	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
HuT	B-X
-	B-X
102	B-X
and	B-X
MT	B-X
-	B-X
2	B-X
<EOS>	B-X
Structural	B-X
homologues	B-X
of	B-X
AG	B-X
-	B-X
490	B-X
also	B-X
inhibited	B-X
the	B-X
proliferation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X
<EOS>	B-X
Human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV	B-X
-	B-X
1	B-X
)	B-X
transforms	B-X
cytokine	B-X
-	B-X
dependent	B-X
T	B-X
lymphocytes	B-X
and	B-X
causes	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X

Here	O
we	O
demonstrate	O
that	O
disruption	O
of	O
Jak3/Stat5a/b	O
signaling	O
with	O
AG-490	O
(	O
50	O
&	O
mgr	O
;	O
M	O
)	O
blocked	O
the	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
but	O
paradoxically	O
failed	O
to	O
inhibit	O
the	O
proliferation	O
of	O
HTLV-1-transformed	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HuT-102	B-cell_line
and	O
MT-2	B-cell_line
.	O

Structural	O
homologues	O
of	O
AG-490	O
also	O
inhibited	O
the	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
HTLV-1-infected	B-cell_type
cells	I-cell_type
.	O

Disruption	O
of	O
constitutive	O
Jak3/Stat5	O
activation	O
by	O
AG-490	O
was	O
demonstrated	O
by	O
inhibition	O
of	O
1	O
)	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
,	O
Stat5a	B-protein
(	O
Tyr	O
(	O
694	O
)	O
)	O
,	O
and	O
Stat5b	B-protein
(	O
Tyr	O
(	O
699	O
)	O
)	O
;	O
2	O
)	O
serine	O
phosphorylation	O
of	O
Stat5a	B-protein
(	O
Ser	O
(	O
726	O
)	O
)	O
as	O
determined	O
by	O
a	O
novel	O
phosphospecific	B-protein
Ab	I-protein
;	O
and	O
3	O
)	O
Stat5a/b	O
DNA	O
binding	O
to	O
the	O
Stat5-responsive	B-DNA
beta-casein	I-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
AG-490	O
had	O
no	O
effect	O
on	O
DNA	O
binding	O
by	O
p50/p65	B-protein
components	I-protein
of	O
NF-kappaB	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
the	O
HTLV-1-encoded	B-protein
phosphoprotein	I-protein
,	I-protein
Tax	I-protein
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
AG	B-X
-	B-X
490	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
DNA	B-X
binding	B-X
by	B-X
p50	B-X
/	B-X
p65	B-X
components	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
activated	B-X
by	B-X
the	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
encoded	B-X
phosphoprotein	B-X
,	B-X
Tax	B-X
<EOS>	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
disruption	B-X
of	B-X
Jak3	B-X
/	B-X
Stat5a	B-X
/	B-X
b	B-X
signaling	B-X
with	B-X
AG	B-X
-	B-X
490	B-X
(	B-X
50	B-X
microM	B-X
)	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
lymphocytes	B-X
,	B-X
but	B-X
paradoxically	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
proliferation	B-X
of	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
transformed	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
HuT	B-X
-	B-X
102	B-X
and	B-X
MT	B-X
-	B-X
2	B-X
<EOS>	B-X
Disruption	B-X
of	B-X
constitutive	B-X
Jak3	B-X
/	B-X
Stat5	B-X
activation	B-X
by	B-X
AG	B-X
-	B-X
490	B-X
was	B-X
demonstrated	B-X
by	B-X
inhibition	B-X
of	B-X
1	B-X
)	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
Jak3	B-X
,	B-X
Stat5a	B-X
(	B-X
Tyr	B-X
(	B-X
694	B-X
)	B-X
)	B-X
,	B-X
and	B-X
Stat5b	B-X
(	B-X
Tyr	B-X
(	B-X
699	B-X
)	B-X
)	B-X
;	B-X
2	B-X
)	B-X
serine	B-X
phosphorylation	B-X
of	B-X
Stat5a	B-X
(	B-X
Ser	B-X
(	B-X
726	B-X
)	B-X
)	B-X
as	B-X
determined	B-X
by	B-X
a	B-X
novel	B-X
phosphospecific	B-X
Ab	B-X
;	B-X
and	B-X
3	B-X
)	B-X
Stat5a	B-X
/	B-X
b	B-X
DNA	B-X
binding	B-X
to	B-X
the	B-X
Stat5	B-X
-	B-X
responsive	B-X
beta	B-X
-	B-X
casein	B-X
promoter	B-X
<EOS>	B-X
Structural	B-X
homologues	B-X
of	B-X
AG	B-X
-	B-X
490	B-X
also	B-X
inhibited	B-X
the	B-X
proliferation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
cells	B-X

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
Jak3-Stat5	O
pathway	O
in	O
HTLV-1-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
has	O
become	O
functionally	O
redundant	O
for	O
proliferation	O
.	O
<EOS>	B-X
Collectively	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
Jak3	B-X
-	B-X
Stat5	B-X
pathway	B-X
in	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
transformed	B-X
T	B-X
cells	B-X
has	B-X
become	B-X
functionally	B-X
redundant	B-X
for	B-X
proliferation	B-X
<EOS>	B-X
Functional	B-X
uncoupling	B-X
of	B-X
the	B-X
Janus	B-X
kinase	B-X
3	B-X
-	B-X
Stat5	B-X
pathway	B-X
in	B-X
malignant	B-X
growth	B-X
of	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
-	B-X
transformed	B-X
human	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
Janus	B-X
tyrosine	B-X
kinase	B-X
(	B-X
Jak	B-X
)	B-X
3	B-X
and	B-X
transcription	B-X
factors	B-X
Stat5a	B-X
and	B-X
Stat5b	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
proliferation	B-X
of	B-X
normal	B-X
T	B-X
cells	B-X
and	B-X
are	B-X
constitutively	B-X
hyperactivated	B-X
in	B-X
both	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
transformed	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
and	B-X
lymphocytes	B-X
isolated	B-X
from	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
patients	B-X
;	B-X
therefore	B-X
,	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
the	B-X
Jak3	B-X
-	B-X
Stat5	B-X
pathway	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
this	B-X
disease	B-X
has	B-X
been	B-X
postulated	B-X
<EOS>	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
disruption	B-X
of	B-X
Jak3	B-X
/	B-X
Stat5a	B-X
/	B-X
b	B-X
signaling	B-X
with	B-X
AG	B-X
-	B-X
490	B-X
(	B-X
50	B-X
microM	B-X
)	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
lymphocytes	B-X
,	B-X
but	B-X
paradoxically	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
proliferation	B-X
of	B-X
HTLV	B-X
-	B-X
1	B-X
-	B-X
transformed	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
HuT	B-X
-	B-X
102	B-X
and	B-X
MT	B-X
-	B-X
2	B-X

Reversal	O
of	O
this	O
functional	O
uncoupling	O
may	O
be	O
required	O
before	O
Jak3/Stat5	O
inhibitors	O
will	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
this	O
malignancy	O
.	O

The	O
Epstein-Barr	B-DNA
virus	I-DNA
promoter	I-DNA
initiating	O
B-cell	O
transformation	O
is	O
activated	O
by	O
RFX	B-protein
proteins	I-protein
and	O
the	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
BSAP/Pax5	I-protein
.	O
<EOS>	B-X
The	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
promoter	B-X
initiating	B-X
B	B-X
-	B-X
cell	B-X
transformation	B-X
is	B-X
activated	B-X
by	B-X
RFX	B-X
proteins	B-X
and	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activator	B-X
protein	B-X
BSAP	B-X
/	B-X
Pax5	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
site	B-X
C	B-X
binds	B-X
members	B-X
of	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
RFX	B-X
family	B-X
of	B-X
proteins	B-X
,	B-X
notably	B-X
RFX1	B-X
,	B-X
RFX3	B-X
,	B-X
and	B-X
the	B-X
associated	B-X
factor	B-X
MIBP1	B-X
,	B-X
whereas	B-X
sites	B-X
B	B-X
and	B-X
D	B-X
both	B-X
bind	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activator	B-X
protein	B-X
BSAP	B-X
/	B-X
Pax5	B-X
<EOS>	B-X
The	B-X
present	B-X
work	B-X
focuses	B-X
on	B-X
a	B-X
region	B-X
of	B-X
Wp	B-X
which	B-X
in	B-X
reporter	B-X
assays	B-X
confers	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activity	B-X
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
	B-X
-	B-X
induced	B-X
B	B-X
-	B-X
cell	B-X
growth	B-X
transformation	B-X
,	B-X
a	B-X
central	B-X
feature	B-X
of	B-X
the	B-X
virus	B-X
'	B-X
strategy	B-X
for	B-X
colonizing	B-X
the	B-X
human	B-X
B	B-X
-	B-X
cell	B-X
system	B-X
,	B-X
requires	B-X
full	B-X
virus	B-X
latent	B-X
gene	B-X
expression	B-X
and	B-X
is	B-X
initiated	B-X
by	B-X
transcription	B-X
from	B-X
the	B-X
viral	B-X
promoter	B-X
Wp	B-X

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-induced	O
B-cell	B-cell_type
growth	O
transformation	O
,	O
a	O
central	O
feature	O
of	O
the	O
virus	O
'	O
strategy	O
for	O
colonizing	O
the	O
human	O
B-cell	O
system	O
,	O
requires	O
full	O
virus	O
latent	O
gene	O
expression	O
and	O
is	O
initiated	O
by	O
transcription	O
from	O
the	O
viral	B-DNA
promoter	I-DNA
Wp	I-DNA
.	O
<EOS>	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
	B-X
-	B-X
induced	B-X
B	B-X
-	B-X
cell	B-X
growth	B-X
transformation	B-X
,	B-X
a	B-X
central	B-X
feature	B-X
of	B-X
the	B-X
virus	B-X
'	B-X
strategy	B-X
for	B-X
colonizing	B-X
the	B-X
human	B-X
B	B-X
-	B-X
cell	B-X
system	B-X
,	B-X
requires	B-X
full	B-X
virus	B-X
latent	B-X
gene	B-X
expression	B-X
and	B-X
is	B-X
initiated	B-X
by	B-X
transcription	B-X
from	B-X
the	B-X
viral	B-X
promoter	B-X
Wp	B-X
<EOS>	B-X
The	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
promoter	B-X
initiating	B-X
B	B-X
-	B-X
cell	B-X
transformation	B-X
is	B-X
activated	B-X
by	B-X
RFX	B-X
proteins	B-X
and	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activator	B-X
protein	B-X
BSAP	B-X
/	B-X
Pax5	B-X
.	B-X
<EOS>	B-X
Bandshift	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
region	B-X
contains	B-X
three	B-X
factor	B-X
binding	B-X
sites	B-X
,	B-X
termed	B-X
sites	B-X
B	B-X
,	B-X
C	B-X
,	B-X
and	B-X
D	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
a	B-X
previously	B-X
characterized	B-X
CREB	B-X
site	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
when	B-X
EBV	B-X
accesses	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
this	B-X
growth	B-X
-	B-X
transforming	B-X
program	B-X
is	B-X
not	B-X
activated	B-X

Interestingly	O
,	O
when	O
EBV	O
accesses	O
other	O
cell	O
types	O
,	O
this	O
growth-transforming	O
program	O
is	O
not	O
activated	O
.	O

The	O
present	O
work	O
focuses	O
on	O
a	O
region	O
of	O
Wp	B-DNA
which	O
in	O
reporter	O
assays	O
confers	O
B-cell	B-cell_type
-specific	O
activity	O
.	O
<EOS>	B-X
The	B-X
present	B-X
work	B-X
focuses	B-X
on	B-X
a	B-X
region	B-X
of	B-X
Wp	B-X
which	B-X
in	B-X
reporter	B-X
assays	B-X
confers	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activity	B-X
<EOS>	B-X
The	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
promoter	B-X
initiating	B-X
B	B-X
-	B-X
cell	B-X
transformation	B-X
is	B-X
activated	B-X
by	B-X
RFX	B-X
proteins	B-X
and	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activator	B-X
protein	B-X
BSAP	B-X
/	B-X
Pax5	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
site	B-X
C	B-X
binds	B-X
members	B-X
of	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
RFX	B-X
family	B-X
of	B-X
proteins	B-X
,	B-X
notably	B-X
RFX1	B-X
,	B-X
RFX3	B-X
,	B-X
and	B-X
the	B-X
associated	B-X
factor	B-X
MIBP1	B-X
,	B-X
whereas	B-X
sites	B-X
B	B-X
and	B-X
D	B-X
both	B-X
bind	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activator	B-X
protein	B-X
BSAP	B-X
/	B-X
Pax5	B-X
<EOS>	B-X
Bandshift	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
region	B-X
contains	B-X
three	B-X
factor	B-X
binding	B-X
sites	B-X
,	B-X
termed	B-X
sites	B-X
B	B-X
,	B-X
C	B-X
,	B-X
and	B-X
D	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
a	B-X
previously	B-X
characterized	B-X
CREB	B-X
site	B-X

Bandshift	O
studies	O
indicate	O
that	O
this	O
region	O
contains	O
three	O
factor	O
binding	O
sites	O
,	O
termed	O
sites	B-DNA
B	I-DNA
,	I-DNA
C	I-DNA
,	I-DNA
and	I-DNA
D	I-DNA
,	O
in	O
addition	O
to	O
a	O
previously	O
characterized	O
CREB	B-DNA
site	I-DNA
.	O

Here	O
we	O
show	O
that	O
site	B-DNA
C	I-DNA
binds	O
members	O
of	O
the	O
ubiquitously	O
expressed	O
RFX	B-protein
family	I-protein
of	I-protein
proteins	I-protein
,	O
notably	O
RFX1	B-protein
,	O
RFX3	B-protein
,	O
and	O
the	O
associated	O
factor	O
MIBP1	B-protein
,	O
whereas	O
sites	B-DNA
B	I-DNA
and	I-DNA
D	I-DNA
both	O
bind	O
the	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
BSAP/Pax5	I-protein
.	O

In	O
reporter	O
assays	O
with	O
mutant	B-DNA
Wp	I-DNA
constructs	I-DNA
,	O
the	O
loss	O
of	O
factor	O
binding	O
to	O
any	O
one	O
of	O
these	O
sites	O
severely	O
impaired	O
promoter	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
wild-type	B-DNA
promoter	I-DNA
could	O
be	O
activated	O
in	O
non-B	B-cell_type
cells	I-cell_type
by	O
ectopic	O
BSAP	O
expression	O
.	O

We	O
suggest	O
that	O
Wp	B-DNA
regulation	O
by	O
BSAP	B-protein
helps	O
to	O
ensure	O
the	O
B-cell	B-cell_type
specificity	O
of	O
EBV	O
's	O
growth-transforming	O
function	O
.	O
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
Wp	B-X
regulation	B-X
by	B-X
BSAP	B-X
helps	B-X
to	B-X
ensure	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
specificity	B-X
of	B-X
EBV	B-X
's	B-X
growth	B-X
-	B-X
transforming	B-X
function	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
when	B-X
EBV	B-X
accesses	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
this	B-X
growth	B-X
-	B-X
transforming	B-X
program	B-X
is	B-X
not	B-X
activated	B-X
<EOS>	B-X
The	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
promoter	B-X
initiating	B-X
B	B-X
-	B-X
cell	B-X
transformation	B-X
is	B-X
activated	B-X
by	B-X
RFX	B-X
proteins	B-X
and	B-X
the	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
activator	B-X
protein	B-X
BSAP	B-X
/	B-X
Pax5	B-X
.	B-X
<EOS>	B-X
Bandshift	B-X
studies	B-X
indicate	B-X
that	B-X
this	B-X
region	B-X
contains	B-X
three	B-X
factor	B-X
binding	B-X
sites	B-X
,	B-X
termed	B-X
sites	B-X
B	B-X
,	B-X
C	B-X
,	B-X
and	B-X
D	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
a	B-X
previously	B-X
characterized	B-X
CREB	B-X
site	B-X

Activation	O
of	O
the	O
Lck	B-protein
tyrosine	I-protein
protein	I-protein
kinase	I-protein
by	O
the	O
Herpesvirus	O
saimiri	O
tip	B-protein
protein	I-protein
involves	O
two	O
binding	O
interactions	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
Lck	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
by	B-X
the	B-X
Herpesvirus	B-X
saimiri	B-X
tip	B-X
protein	B-X
involves	B-X
two	B-X
binding	B-X
interactions	B-X
.	B-X
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
lck	B-X
tyrosine	B-X
-	B-X
protein	B-X
kinase	B-X
by	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
tip	B-X
protein	B-X
of	B-X
herpesvirus	B-X
saimiri	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
regulatory	B-X
tyrosine	B-X
phosphorylation	B-X
.	B-X
<EOS>	B-X
Two	B-X
sequences	B-X
in	B-X
the	B-X
Tip	B-X
protein	B-X
were	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
binding	B-X
to	B-X
Lck	B-X
<EOS>	B-X
Growth	B-X
transformation	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
by	B-X
herpesvirus	B-X
saimiri	B-X
requires	B-X
multiple	B-X
Tip	B-X
-	B-X
Lck	B-X
interaction	B-X
motifs	B-X
.	B-X

The	O
Tip	B-protein
protein	I-protein
of	O
Herpesvirus	O
saimiri	O
strain	O
484C	O
binds	O
to	O
and	O
activates	O
the	O
Lck	B-protein
tyrosine	I-protein
protein	I-protein
kinase	I-protein
.	O
<EOS>	B-X
The	B-X
Tip	B-X
protein	B-X
of	B-X
Herpesvirus	B-X
saimiri	B-X
strain	B-X
484C	B-X
binds	B-X
to	B-X
and	B-X
activates	B-X
the	B-X
Lck	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
<EOS>	B-X
A	B-X
proline	B-X
-	B-X
rich	B-X
region	B-X
,	B-X
residues	B-X
132	B-X
-	B-X
141	B-X
,	B-X
binds	B-X
to	B-X
the	B-X
SH3	B-X
domain	B-X
of	B-X
the	B-X
Lck	B-X
protein	B-X
<EOS>	B-X
Mutated	B-X
Tip	B-X
containing	B-X
only	B-X
one	B-X
functional	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
can	B-X
bind	B-X
stably	B-X
to	B-X
Lck	B-X
,	B-X
although	B-X
not	B-X
as	B-X
strongly	B-X
as	B-X
wild	B-X
-	B-X
type	B-X
Tip	B-X
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
Lck	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
by	B-X
the	B-X
Herpesvirus	B-X
saimiri	B-X
tip	B-X
protein	B-X
involves	B-X
two	B-X
binding	B-X
interactions	B-X
.	B-X

Two	O
sequences	O
in	O
the	O
Tip	B-protein
protein	I-protein
were	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
binding	O
to	O
Lck	B-protein
.	O
<EOS>	B-X
Two	B-X
sequences	B-X
in	B-X
the	B-X
Tip	B-X
protein	B-X
were	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
binding	B-X
to	B-X
Lck	B-X
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
Lck	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
by	B-X
the	B-X
Herpesvirus	B-X
saimiri	B-X
tip	B-X
protein	B-X
involves	B-X
two	B-X
binding	B-X
interactions	B-X
.	B-X
<EOS>	B-X
The	B-X
transient	B-X
expression	B-X
of	B-X
Tip	B-X
in	B-X
T	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
stimulate	B-X
both	B-X
Stat3	B-X
-	B-X
dependent	B-X
and	B-X
NF	B-X
-	B-X
AT	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
other	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
,	B-X
residues	B-X
104	B-X
-	B-X
113	B-X
,	B-X
binds	B-X
to	B-X
the	B-X
carboxyl	B-X
-	B-X
terminal	B-X
half	B-X
of	B-X
Lck	B-X
and	B-X
that	B-X
this	B-X
binding	B-X
does	B-X
not	B-X
require	B-X
the	B-X
Lck	B-X
SH3	B-X
domain	B-X

A	O
proline-rich	B-protein
region	I-protein
,	O
residues	O
132-141	O
,	O
binds	O
to	O
the	O
SH3	B-protein
domain	I-protein
of	O
the	O
Lck	B-protein
protein	I-protein
.	O

We	O
show	O
here	O
that	O
the	O
other	O
Lck-binding	B-protein
domain	I-protein
,	O
residues	O
104-113	O
,	O
binds	O
to	O
the	O
carboxyl-terminal	B-protein
half	I-protein
of	O
Lck	B-protein
and	O
that	O
this	O
binding	O
does	O
not	O
require	O
the	O
Lck	B-protein
SH3	I-protein
domain	I-protein
.	O

Mutated	O
Tip	B-protein
containing	O
only	O
one	O
functional	O
Lck-binding	B-protein
domain	I-protein
can	O
bind	O
stably	O
to	O
Lck	B-protein
,	O
although	O
not	O
as	O
strongly	O
as	O
wild-type	B-protein
Tip	I-protein
.	O

Interaction	O
of	O
Tip	B-protein
with	O
Lck	B-protein
through	O
either	O
Lck-binding	B-protein
domain	I-protein
increases	O
the	O
activity	O
of	O
Lck	B-protein
in	O
vivo	O
.	O
<EOS>	B-X
Interaction	B-X
of	B-X
Tip	B-X
with	B-X
Lck	B-X
through	B-X
either	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
Lck	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Mutant	B-X
forms	B-X
of	B-X
Tip	B-X
lacking	B-X
one	B-X
or	B-X
the	B-X
other	B-X
of	B-X
the	B-X
two	B-X
Lck	B-X
-	B-X
binding	B-X
domains	B-X
retained	B-X
the	B-X
ability	B-X
to	B-X
stimulate	B-X
Stat3	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
Tip	B-X
lacking	B-X
the	B-X
proline	B-X
-	B-X
rich	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
exhibited	B-X
almost	B-X
wild	B-X
-	B-X
type	B-X
activity	B-X
in	B-X
this	B-X
assay	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
ablation	B-X
of	B-X
either	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
abolished	B-X
the	B-X
ability	B-X
of	B-X
Tip	B-X
to	B-X
stimulate	B-X
NF	B-X
-	B-X
AT	B-X
-	B-X
dependent	B-X
transcription	B-X

Simultaneous	O
binding	O
of	O
both	O
domains	O
is	O
required	O
for	O
maximal	O
activation	O
of	O
Lck	B-protein
.	O
<EOS>	B-X
Simultaneous	B-X
binding	B-X
of	B-X
both	B-X
domains	B-X
is	B-X
required	B-X
for	B-X
maximal	B-X
activation	B-X
of	B-X
Lck	B-X
<EOS>	B-X
Tip	B-X
lacking	B-X
the	B-X
proline	B-X
-	B-X
rich	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
exhibited	B-X
almost	B-X
wild	B-X
-	B-X
type	B-X
activity	B-X
in	B-X
this	B-X
assay	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
Tip	B-X
with	B-X
Lck	B-X
through	B-X
either	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
Lck	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Mutant	B-X
forms	B-X
of	B-X
Tip	B-X
lacking	B-X
one	B-X
or	B-X
the	B-X
other	B-X
of	B-X
the	B-X
two	B-X
Lck	B-X
-	B-X
binding	B-X
domains	B-X
retained	B-X
the	B-X
ability	B-X
to	B-X
stimulate	B-X
Stat3	B-X
-	B-X
dependent	B-X
transcription	B-X

The	O
transient	O
expression	O
of	O
Tip	B-protein
in	O
T	B-cell_type
cells	I-cell_type
was	O
found	O
to	O
stimulate	O
both	O
Stat3	B-protein
-dependent	O
and	O
NF-AT	B-protein
-dependent	O
transcription	O
.	O

Mutant	O
forms	O
of	O
Tip	B-protein
lacking	O
one	O
or	O
the	O
other	O
of	O
the	O
two	O
Lck-binding	B-protein
domains	I-protein
retained	O
the	O
ability	O
to	O
stimulate	O
Stat3	B-protein
-dependent	O
transcription	O
.	O
<EOS>	B-X
Mutant	B-X
forms	B-X
of	B-X
Tip	B-X
lacking	B-X
one	B-X
or	B-X
the	B-X
other	B-X
of	B-X
the	B-X
two	B-X
Lck	B-X
-	B-X
binding	B-X
domains	B-X
retained	B-X
the	B-X
ability	B-X
to	B-X
stimulate	B-X
Stat3	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
ablation	B-X
of	B-X
either	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
abolished	B-X
the	B-X
ability	B-X
of	B-X
Tip	B-X
to	B-X
stimulate	B-X
NF	B-X
-	B-X
AT	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
Tip	B-X
with	B-X
Lck	B-X
through	B-X
either	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
Lck	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Tip	B-X
lacking	B-X
the	B-X
proline	B-X
-	B-X
rich	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
exhibited	B-X
almost	B-X
wild	B-X
-	B-X
type	B-X
activity	B-X
in	B-X
this	B-X
assay	B-X

Tip	B-protein
lacking	O
the	O
proline-rich	O
Lck-binding	B-protein
domain	I-protein
exhibited	O
almost	O
wild-type	O
activity	O
in	O
this	O
assay	O
.	O
<EOS>	B-X
Tip	B-X
lacking	B-X
the	B-X
proline	B-X
-	B-X
rich	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
exhibited	B-X
almost	B-X
wild	B-X
-	B-X
type	B-X
activity	B-X
in	B-X
this	B-X
assay	B-X
<EOS>	B-X
Mutant	B-X
forms	B-X
of	B-X
Tip	B-X
lacking	B-X
one	B-X
or	B-X
the	B-X
other	B-X
of	B-X
the	B-X
two	B-X
Lck	B-X
-	B-X
binding	B-X
domains	B-X
retained	B-X
the	B-X
ability	B-X
to	B-X
stimulate	B-X
Stat3	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
Tip	B-X
with	B-X
Lck	B-X
through	B-X
either	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
Lck	B-X
in	B-X
vivo	B-X
<EOS>	B-X
Mutated	B-X
Tip	B-X
containing	B-X
only	B-X
one	B-X
functional	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
can	B-X
bind	B-X
stably	B-X
to	B-X
Lck	B-X
,	B-X
although	B-X
not	B-X
as	B-X
strongly	B-X
as	B-X
wild	B-X
-	B-X
type	B-X
Tip	B-X

In	O
contrast	O
,	O
ablation	O
of	O
either	O
Lck-binding	B-protein
domain	I-protein
abolished	O
the	O
ability	O
of	O
Tip	B-protein
to	O
stimulate	O
NF-AT	B-protein
-dependent	O
transcription	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
ablation	B-X
of	B-X
either	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
abolished	B-X
the	B-X
ability	B-X
of	B-X
Tip	B-X
to	B-X
stimulate	B-X
NF	B-X
-	B-X
AT	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
Mutant	B-X
forms	B-X
of	B-X
Tip	B-X
lacking	B-X
one	B-X
or	B-X
the	B-X
other	B-X
of	B-X
the	B-X
two	B-X
Lck	B-X
-	B-X
binding	B-X
domains	B-X
retained	B-X
the	B-X
ability	B-X
to	B-X
stimulate	B-X
Stat3	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
The	B-X
transient	B-X
expression	B-X
of	B-X
Tip	B-X
in	B-X
T	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
stimulate	B-X
both	B-X
Stat3	B-X
-	B-X
dependent	B-X
and	B-X
NF	B-X
-	B-X
AT	B-X
-	B-X
dependent	B-X
transcription	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
Tip	B-X
with	B-X
Lck	B-X
through	B-X
either	B-X
Lck	B-X
-	B-X
binding	B-X
domain	B-X
increases	B-X
the	B-X
activity	B-X
of	B-X
Lck	B-X
in	B-X
vivo	B-X

Full	O
biological	O
activity	O
of	O
Tip	B-protein
,	O
therefore	O
,	O
appears	O
to	O
require	O
both	O
Lck-binding	B-protein
domains	I-protein
.	O
<EOS>	B-X
Full	B-X
biological	B-X
activity	B-X
of	B-X
Tip	B-X
,	B-X
therefore	B-X
,	B-X
appears	B-X
to	B-X
require	B-X
both	B-X
Lck	B-X
-	B-X
binding	B-X
domains	B-X
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
Lck	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
by	B-X
the	B-X
Herpesvirus	B-X
saimiri	B-X
tip	B-X
protein	B-X
involves	B-X
two	B-X
binding	B-X
interactions	B-X
.	B-X
<EOS>	B-X
Two	B-X
sequences	B-X
in	B-X
the	B-X
Tip	B-X
protein	B-X
were	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
binding	B-X
to	B-X
Lck	B-X
<EOS>	B-X
Mutant	B-X
forms	B-X
of	B-X
Tip	B-X
lacking	B-X
one	B-X
or	B-X
the	B-X
other	B-X
of	B-X
the	B-X
two	B-X
Lck	B-X
-	B-X
binding	B-X
domains	B-X
retained	B-X
the	B-X
ability	B-X
to	B-X
stimulate	B-X
Stat3	B-X
-	B-X
dependent	B-X
transcription	B-X

Accumulation	O
of	O
RXR	B-protein
alpha	I-protein
during	O
activation	O
of	O
cycling	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
:	O
modulation	O
of	O
RXRE	O
transactivation	O
function	O
by	O
mitogen-activated	O
protein	O
kinase	O
pathways	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
resting	O
human	B-cell_type
immature	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
(	I-cell_type
PBT	I-cell_type
)	I-cell_type
lymphocytes	I-cell_type
is	O
associated	O
with	O
the	O
loss	O
of	O
retinoid	B-protein
X	I-protein
receptor	I-protein
alpha	I-protein
(	O
RXRalpha	B-protein
)	O
expression	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
,	O
unlike	O
resting	O
cells	O
,	O
activation	O
of	O
cycling	B-cell_type
human	I-cell_type
mature	I-cell_type
PBT	I-cell_type
lymphocytes	I-cell_type
,	O
and	O
T	B-cell_line
lymphocyte	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
accompanied	O
by	O
the	O
accumulation	O
of	O
RXRalpha	B-protein
mRNA	O
and	O
protein	O
.	O

Interestingly	O
,	O
cyclosporin	O
A	O
further	O
augmented	O
RXRalpha	B-protein
expression	O
,	O
indicating	O
the	O
involvement	O
of	O
calcineurin	O
pathways	O
in	O
the	O
process	O
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
cyclosporin	B-X
A	B-X
further	B-X
augmented	B-X
RXRalpha	B-X
expression	B-X
,	B-X
indicating	B-X
the	B-X
involvement	B-X
of	B-X
calcineurin	B-X
pathways	B-X
in	B-X
the	B-X
process	B-X
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
constitutively	B-X
active	B-X
MAP	B-X
/	B-X
ERK	B-X
kinase	B-X
kinase	B-X
1	B-X
(	B-X
MEKK1	B-X
)	B-X
inhibited	B-X
RXRE	B-X
-	B-X
dependent	B-X
transcription	B-X
,	B-X
whereas	B-X
dominant	B-X
negative	B-X
MEKK1	B-X
increased	B-X
the	B-X
transcription	B-X
,	B-X
indicating	B-X
the	B-X
involvement	B-X
of	B-X
JNK	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
process	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
a	B-X
dual	B-X
regulatory	B-X
control	B-X
of	B-X
RXRalpha	B-X
expression	B-X
during	B-X
the	B-X
activation	B-X
of	B-X
resting	B-X
and	B-X
cycling	B-X
T	B-X
lymphocytes	B-X
and	B-X
indicate	B-X
a	B-X
dynamic	B-X
balance	B-X
between	B-X
JNK	B-X
and	B-X
ERK	B-X
pathways	B-X
in	B-X
modulating	B-X
RXRE	B-X
-	B-X
mediated	B-X
transactivation	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
have	B-X
demonstrated	B-X
that	B-X
,	B-X
unlike	B-X
resting	B-X
cells	B-X
,	B-X
activation	B-X
of	B-X
cycling	B-X
human	B-X
mature	B-X
PBT	B-X
lymphocytes	B-X
,	B-X
and	B-X
T	B-X
lymphocyte	B-X
leukemia	B-X
cell	B-X
lines	B-X
is	B-X
accompanied	B-X
by	B-X
the	B-X
accumulation	B-X
of	B-X
RXRalpha	B-X
mRNA	B-X
and	B-X
protein	B-X

9-cis	O
retinoic	O
acid	O
inhibited	O
the	O
accumulation	O
,	O
suggesting	O
that	O
retinoids	O
can	O
regulate	O
the	O
synthesis	O
of	O
their	O
own	O
receptors	O
during	O
T	O
cell	O
activation	O
.	O

Transfection	O
analysis	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
using	O
RXRE-dependent	O
reporter	O
assays	O
,	O
showed	O
that	O
RXRalpha	B-protein
accumulated	O
during	O
T	O
cell	O
activation	O
was	O
transcriptionally	O
inactive	O
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
such	O
inhibition	O
,	O
the	O
role	O
of	O
two	O
mitogen-activated	O
protein	O
kinase	O
pathways	O
,	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
and	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
,	O
in	O
modulating	O
RXRE-dependent	O
transcription	O
,	O
was	O
explored	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
such	B-X
inhibition	B-X
,	B-X
the	B-X
role	B-X
of	B-X
two	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
pathways	B-X
,	B-X
c	B-X
-	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
and	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
,	B-X
in	B-X
modulating	B-X
RXRE	B-X
-	B-X
dependent	B-X
transcription	B-X
,	B-X
was	B-X
explored	B-X
<EOS>	B-X
When	B-X
both	B-X
were	B-X
activated	B-X
simultaneously	B-X
,	B-X
JNK	B-X
pathway	B-X
was	B-X
dominant	B-X
over	B-X
ERK	B-X
pathway	B-X
and	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
RXRE	B-X
-	B-X
mediated	B-X
transcription	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
a	B-X
dual	B-X
regulatory	B-X
control	B-X
of	B-X
RXRalpha	B-X
expression	B-X
during	B-X
the	B-X
activation	B-X
of	B-X
resting	B-X
and	B-X
cycling	B-X
T	B-X
lymphocytes	B-X
and	B-X
indicate	B-X
a	B-X
dynamic	B-X
balance	B-X
between	B-X
JNK	B-X
and	B-X
ERK	B-X
pathways	B-X
in	B-X
modulating	B-X
RXRE	B-X
-	B-X
mediated	B-X
transactivation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
constitutively	B-X
active	B-X
MEK1	B-X
,	B-X
which	B-X
activates	B-X
ERK	B-X
pathway	B-X
,	B-X
enhanced	B-X
RXRE	B-X
-	B-X
dependent	B-X
activation	B-X

The	O
expression	O
of	O
constitutively	O
active	O
MAP/ERK	B-protein
kinase	I-protein
kinase	I-protein
1	I-protein
(	O
MEKK1	B-protein
)	O
inhibited	O
RXRE-dependent	O
transcription	O
,	O
whereas	O
dominant	B-protein
negative	I-protein
MEKK1	I-protein
increased	O
the	O
transcription	O
,	O
indicating	O
the	O
involvement	O
of	O
JNK	B-protein
signaling	O
pathways	O
in	O
the	O
process	O
.	O
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
constitutively	B-X
active	B-X
MAP	B-X
/	B-X
ERK	B-X
kinase	B-X
kinase	B-X
1	B-X
(	B-X
MEKK1	B-X
)	B-X
inhibited	B-X
RXRE	B-X
-	B-X
dependent	B-X
transcription	B-X
,	B-X
whereas	B-X
dominant	B-X
negative	B-X
MEKK1	B-X
increased	B-X
the	B-X
transcription	B-X
,	B-X
indicating	B-X
the	B-X
involvement	B-X
of	B-X
JNK	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
process	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
cyclosporin	B-X
A	B-X
further	B-X
augmented	B-X
RXRalpha	B-X
expression	B-X
,	B-X
indicating	B-X
the	B-X
involvement	B-X
of	B-X
calcineurin	B-X
pathways	B-X
in	B-X
the	B-X
process	B-X
<EOS>	B-X
Transfection	B-X
analysis	B-X
in	B-X
Jurkat	B-X
cells	B-X
,	B-X
using	B-X
RXRE	B-X
-	B-X
dependent	B-X
reporter	B-X
assays	B-X
,	B-X
showed	B-X
that	B-X
RXRalpha	B-X
accumulated	B-X
during	B-X
T	B-X
cell	B-X
activation	B-X
was	B-X
transcriptionally	B-X
inactive	B-X
<EOS>	B-X
When	B-X
both	B-X
were	B-X
activated	B-X
simultaneously	B-X
,	B-X
JNK	B-X
pathway	B-X
was	B-X
dominant	B-X
over	B-X
ERK	B-X
pathway	B-X
and	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
RXRE	B-X
-	B-X
mediated	B-X
transcription	B-X

In	O
contrast	O
,	O
expression	O
of	O
constitutively	B-protein
active	I-protein
MEK1	I-protein
,	O
which	O
activates	O
ERK	B-protein
pathway	O
,	O
enhanced	O
RXRE-dependent	O
activation	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
constitutively	B-X
active	B-X
MEK1	B-X
,	B-X
which	B-X
activates	B-X
ERK	B-X
pathway	B-X
,	B-X
enhanced	B-X
RXRE	B-X
-	B-X
dependent	B-X
activation	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
a	B-X
dual	B-X
regulatory	B-X
control	B-X
of	B-X
RXRalpha	B-X
expression	B-X
during	B-X
the	B-X
activation	B-X
of	B-X
resting	B-X
and	B-X
cycling	B-X
T	B-X
lymphocytes	B-X
and	B-X
indicate	B-X
a	B-X
dynamic	B-X
balance	B-X
between	B-X
JNK	B-X
and	B-X
ERK	B-X
pathways	B-X
in	B-X
modulating	B-X
RXRE	B-X
-	B-X
mediated	B-X
transactivation	B-X
<EOS>	B-X
When	B-X
both	B-X
were	B-X
activated	B-X
simultaneously	B-X
,	B-X
JNK	B-X
pathway	B-X
was	B-X
dominant	B-X
over	B-X
ERK	B-X
pathway	B-X
and	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
RXRE	B-X
-	B-X
mediated	B-X
transcription	B-X
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
such	B-X
inhibition	B-X
,	B-X
the	B-X
role	B-X
of	B-X
two	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
pathways	B-X
,	B-X
c	B-X
-	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
and	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
,	B-X
in	B-X
modulating	B-X
RXRE	B-X
-	B-X
dependent	B-X
transcription	B-X
,	B-X
was	B-X
explored	B-X

When	O
both	O
were	O
activated	O
simultaneously	O
,	O
JNK	B-protein
pathway	O
was	O
dominant	O
over	O
ERK	B-protein
pathway	O
and	O
resulted	O
in	O
inhibition	O
of	O
RXRE-mediated	O
transcription	O
.	O
<EOS>	B-X
When	B-X
both	B-X
were	B-X
activated	B-X
simultaneously	B-X
,	B-X
JNK	B-X
pathway	B-X
was	B-X
dominant	B-X
over	B-X
ERK	B-X
pathway	B-X
and	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
RXRE	B-X
-	B-X
mediated	B-X
transcription	B-X
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
mechanism	B-X
of	B-X
such	B-X
inhibition	B-X
,	B-X
the	B-X
role	B-X
of	B-X
two	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
pathways	B-X
,	B-X
c	B-X
-	B-X
Jun	B-X
N	B-X
-	B-X
terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
and	B-X
extracellular	B-X
signal	B-X
-	B-X
regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
,	B-X
in	B-X
modulating	B-X
RXRE	B-X
-	B-X
dependent	B-X
transcription	B-X
,	B-X
was	B-X
explored	B-X
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
a	B-X
dual	B-X
regulatory	B-X
control	B-X
of	B-X
RXRalpha	B-X
expression	B-X
during	B-X
the	B-X
activation	B-X
of	B-X
resting	B-X
and	B-X
cycling	B-X
T	B-X
lymphocytes	B-X
and	B-X
indicate	B-X
a	B-X
dynamic	B-X
balance	B-X
between	B-X
JNK	B-X
and	B-X
ERK	B-X
pathways	B-X
in	B-X
modulating	B-X
RXRE	B-X
-	B-X
mediated	B-X
transactivation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
constitutively	B-X
active	B-X
MEK1	B-X
,	B-X
which	B-X
activates	B-X
ERK	B-X
pathway	B-X
,	B-X
enhanced	B-X
RXRE	B-X
-	B-X
dependent	B-X
activation	B-X

These	O
data	O
demonstrate	O
a	O
dual	O
regulatory	O
control	O
of	O
RXRalpha	B-protein
expression	O
during	O
the	O
activation	O
of	O
resting	B-cell_type
and	I-cell_type
cycling	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
indicate	O
a	O
dynamic	O
balance	O
between	O
JNK	O
and	O
ERK	O
pathways	O
in	O
modulating	O
RXRE-mediated	O
transactivation	O
.	O
<EOS>	B-X
These	B-X
data	B-X
demonstrate	B-X
a	B-X
dual	B-X
regulatory	B-X
control	B-X
of	B-X
RXRalpha	B-X
expression	B-X
during	B-X
the	B-X
activation	B-X
of	B-X
resting	B-X
and	B-X
cycling	B-X
T	B-X
lymphocytes	B-X
and	B-X
indicate	B-X
a	B-X
dynamic	B-X
balance	B-X
between	B-X
JNK	B-X
and	B-X
ERK	B-X
pathways	B-X
in	B-X
modulating	B-X
RXRE	B-X
-	B-X
mediated	B-X
transactivation	B-X
<EOS>	B-X
Accumulation	B-X
of	B-X
RXR	B-X
alpha	B-X
during	B-X
activation	B-X
of	B-X
cycling	B-X
human	B-X
T	B-X
lymphocytes	B-X
:	B-X
modulation	B-X
of	B-X
RXRE	B-X
transactivation	B-X
function	B-X
by	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
pathways	B-X
.	B-X
<EOS>	B-X
When	B-X
both	B-X
were	B-X
activated	B-X
simultaneously	B-X
,	B-X
JNK	B-X
pathway	B-X
was	B-X
dominant	B-X
over	B-X
ERK	B-X
pathway	B-X
and	B-X
resulted	B-X
in	B-X
inhibition	B-X
of	B-X
RXRE	B-X
-	B-X
mediated	B-X
transcription	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
have	B-X
demonstrated	B-X
that	B-X
,	B-X
unlike	B-X
resting	B-X
cells	B-X
,	B-X
activation	B-X
of	B-X
cycling	B-X
human	B-X
mature	B-X
PBT	B-X
lymphocytes	B-X
,	B-X
and	B-X
T	B-X
lymphocyte	B-X
leukemia	B-X
cell	B-X
lines	B-X
is	B-X
accompanied	B-X
by	B-X
the	B-X
accumulation	B-X
of	B-X
RXRalpha	B-X
mRNA	B-X
and	B-X
protein	B-X

The	O
proteasome	B-protein
regulates	O
receptor-mediated	O
endocytosis	O
of	O
interleukin-2	B-protein
.	O
<EOS>	B-X
The	B-X
proteasome	B-X
regulates	B-X
receptor	B-X
-	B-X
mediated	B-X
endocytosis	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
.	B-X
<EOS>	B-X
Proteasome	B-X
inhibitors	B-X
impaired	B-X
internalization	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
Based	B-X
on	B-X
time	B-X
-	B-X
course	B-X
studies	B-X
,	B-X
proteasome	B-X
activity	B-X
is	B-X
primarily	B-X
required	B-X
after	B-X
initial	B-X
endocytosis	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
for	B-X
ligand	B-X
-	B-X
dependent	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
	B-X
-	B-X
interleukin	B-X
-	B-X
2	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
complex	B-X

Recent	O
studies	O
have	O
increasingly	O
implicated	O
the	O
proteasome	B-protein
in	O
the	O
regulation	O
of	O
cell	B-protein
surface	I-protein
receptors	I-protein
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
increasingly	B-X
implicated	B-X
the	B-X
proteasome	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
surface	B-X
receptors	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
for	B-X
ligand	B-X
-	B-X
dependent	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
	B-X
-	B-X
interleukin	B-X
-	B-X
2	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
complex	B-X
<EOS>	B-X
IL	B-X
-	B-X
2R	B-X
and	B-X
prevented	B-X
the	B-X
lysosomal	B-X
degradation	B-X
of	B-X
this	B-X
cytokine	B-X
<EOS>	B-X
The	B-X
proteasome	B-X
regulates	B-X
receptor	B-X
-	B-X
mediated	B-X
endocytosis	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
proteasome	B-protein
for	O
ligand-dependent	O
endocytosis	O
and	O
degradation	O
of	O
the	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
-interleukin-2	I-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
complex	I-protein
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
for	B-X
ligand	B-X
-	B-X
dependent	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
	B-X
-	B-X
interleukin	B-X
-	B-X
2	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
complex	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
increasingly	B-X
implicated	B-X
the	B-X
proteasome	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
surface	B-X
receptors	B-X
<EOS>	B-X
The	B-X
proteasome	B-X
regulates	B-X
receptor	B-X
-	B-X
mediated	B-X
endocytosis	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
.	B-X
<EOS>	B-X
IL	B-X
-	B-X
2R	B-X
and	B-X
prevented	B-X
the	B-X
lysosomal	B-X
degradation	B-X
of	B-X
this	B-X
cytokine	B-X

Proteasome	O
inhibitors	O
impaired	O
internalization	O
of	O
IL-2.IL-2R	B-protein
and	O
prevented	O
the	O
lysosomal	O
degradation	O
of	O
this	O
cytokine	B-protein
.	O
<EOS>	B-X
IL	B-X
-	B-X
2R	B-X
and	B-X
prevented	B-X
the	B-X
lysosomal	B-X
degradation	B-X
of	B-X
this	B-X
cytokine	B-X
<EOS>	B-X
Proteasome	B-X
inhibitors	B-X
impaired	B-X
internalization	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
a	B-X
functional	B-X
proteasome	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
endocytosis	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2R	B-X
/	B-X
ligand	B-X
complex	B-X
and	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
subsequent	B-X
lysosomal	B-X
degradation	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
possibly	B-X
by	B-X
regulating	B-X
trafficking	B-X
to	B-X
the	B-X
lysosome	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
for	B-X
ligand	B-X
-	B-X
dependent	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
	B-X
-	B-X
interleukin	B-X
-	B-X
2	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
complex	B-X

Based	O
on	O
time-course	O
studies	O
,	O
proteasome	B-protein
activity	O
is	O
primarily	O
required	O
after	O
initial	O
endocytosis	O
of	O
the	O
IL-2.IL-2R	B-protein
.	O
<EOS>	B-X
Based	B-X
on	B-X
time	B-X
-	B-X
course	B-X
studies	B-X
,	B-X
proteasome	B-X
activity	B-X
is	B-X
primarily	B-X
required	B-X
after	B-X
initial	B-X
endocytosis	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
The	B-X
proteasome	B-X
regulates	B-X
receptor	B-X
-	B-X
mediated	B-X
endocytosis	B-X
of	B-X
interleukin	B-X
-	B-X
2	B-X
.	B-X
<EOS>	B-X
Proteasome	B-X
inhibitors	B-X
impaired	B-X
internalization	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
for	B-X
ligand	B-X
-	B-X
dependent	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
	B-X
-	B-X
interleukin	B-X
-	B-X
2	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
complex	B-X

Proteasome	O
function	O
was	O
also	O
necessary	O
for	O
the	O
lysosomal	O
degradation	O
of	O
IL-2	B-protein
internalized	O
by	O
IL-2R	B-protein
that	O
were	O
comprised	O
of	O
cytoplasmic	B-protein
tailless	I-protein
beta-	B-protein
or	I-protein
gamma	I-protein
c-subunits	I-protein
,	O
suggesting	O
that	O
the	O
target	O
protein	O
for	O
the	O
proteasome	B-protein
is	O
independent	O
of	O
either	O
the	O
cytoplasmic	B-protein
tail	I-protein
of	O
the	O
IL-2R	B-protein
beta-	B-protein
or	I-protein
gamma	I-protein
c-subunits	I-protein
and	O
their	O
associated	O
signaling	O
components	O
.	O
<EOS>	B-X
Proteasome	B-X
function	B-X
was	B-X
also	B-X
necessary	B-X
for	B-X
the	B-X
lysosomal	B-X
degradation	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
internalized	B-X
by	B-X
IL	B-X
-	B-X
2R	B-X
that	B-X
were	B-X
comprised	B-X
of	B-X
cytoplasmic	B-X
tailless	B-X
beta	B-X
-	B-X
	B-X
or	B-X
gamma	B-X
c	B-X
-	B-X
subunits	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
target	B-X
protein	B-X
for	B-X
the	B-X
proteasome	B-X
is	B-X
independent	B-X
of	B-X
either	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2R	B-X
beta	B-X
-	B-X
	B-X
or	B-X
gamma	B-X
c	B-X
-	B-X
subunits	B-X
and	B-X
their	B-X
associated	B-X
signaling	B-X
components	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
a	B-X
functional	B-X
proteasome	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
endocytosis	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2R	B-X
/	B-X
ligand	B-X
complex	B-X
and	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
subsequent	B-X
lysosomal	B-X
degradation	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
possibly	B-X
by	B-X
regulating	B-X
trafficking	B-X
to	B-X
the	B-X
lysosome	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
proteasome	B-X
for	B-X
ligand	B-X
-	B-X
dependent	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
interleukin	B-X
-	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
	B-X
-	B-X
interleukin	B-X
-	B-X
2	B-X
receptor	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
complex	B-X
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
increasingly	B-X
implicated	B-X
the	B-X
proteasome	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
surface	B-X
receptors	B-X

Therefore	O
,	O
a	O
functional	O
proteasome	B-protein
is	O
required	O
for	O
optimal	O
endocytosis	O
of	O
the	O
IL-2R/ligand	B-protein
complex	I-protein
and	O
is	O
essential	O
for	O
the	O
subsequent	O
lysosomal	O
degradation	O
of	O
IL-2	B-protein
,	O
possibly	O
by	O
regulating	O
trafficking	O
to	O
the	O
lysosome	O
.	O

Functional	O
characterization	O
of	O
the	O
two	O
alternative	O
promoters	O
of	O
human	B-DNA
p45	I-DNA
NF-E2	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
Functional	B-X
characterization	B-X
of	B-X
the	B-X
two	B-X
alternative	B-X
promoters	B-X
of	B-X
human	B-X
p45	B-X
NF	B-X
-	B-X
E2	B-X
gene	B-X
.	B-X
<EOS>	B-X
For	B-X
functional	B-X
characterization	B-X
of	B-X
both	B-X
promoters	B-X
,	B-X
plasmids	B-X
in	B-X
which	B-X
reporter	B-X
genes	B-X
were	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
series	B-X
of	B-X
truncated	B-X
or	B-X
mutated	B-X
promoter	B-X
fragments	B-X
were	B-X
transfected	B-X
to	B-X
human	B-X
hematopoietic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
We	B-X
have	B-X
isolated	B-X
and	B-X
characterized	B-X
the	B-X
mouse	B-X
p45	B-X
NF	B-X
-	B-X
E2	B-X
gene	B-X
;	B-X
we	B-X
show	B-X
here	B-X
that	B-X
,	B-X
similar	B-X
to	B-X
the	B-X
human	B-X
gene	B-X
,	B-X
the	B-X
mouse	B-X
gene	B-X
has	B-X
two	B-X
alternative	B-X
promoters	B-X
,	B-X
which	B-X
are	B-X
differentially	B-X
active	B-X
during	B-X
development	B-X
and	B-X
in	B-X
different	B-X
hematopoietic	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
GATA	B-X
proteins	B-X
,	B-X
which	B-X
govern	B-X
the	B-X
differentiation	B-X
of	B-X
erythroid	B-X
lineage	B-X
cells	B-X
,	B-X
are	B-X
required	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
of	B-X
the	B-X
p45	B-X
gene	B-X

OBJECTIVE	O
:	O
The	O
transcription	B-protein
factor	I-protein
NF-E2	I-protein
,	O
a	O
heterodimeric	B-protein
protein	I-protein
complex	I-protein
composed	O
of	O
p45	B-protein
and	O
small	O
Maf	B-protein
family	I-protein
proteins	I-protein
,	O
is	O
considered	O
crucial	O
for	O
the	O
proper	O
differentiation	O
of	O
erythrocytes	B-cell_type
and	O
megakaryocytes	B-cell_type
in	O
vivo	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
E2	B-X
,	B-X
a	B-X
heterodimeric	B-X
protein	B-X
complex	B-X
composed	B-X
of	B-X
p45	B-X
and	B-X
small	B-X
Maf	B-X
family	B-X
proteins	B-X
,	B-X
is	B-X
considered	B-X
crucial	B-X
for	B-X
the	B-X
proper	B-X
differentiation	B-X
of	B-X
erythrocytes	B-X
and	B-X
megakaryocytes	B-X
in	B-X
vivo	B-X
<EOS>	B-X
When	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
isolated	B-X
from	B-X
human	B-X
cord	B-X
blood	B-X
were	B-X
induced	B-X
to	B-X
unilineage	B-X
erythroid	B-X
or	B-X
megakaryocytic	B-X
differentiation	B-X
in	B-X
liquid	B-X
suspension	B-X
culture	B-X
,	B-X
both	B-X
transcripts	B-X
,	B-X
although	B-X
barely	B-X
detected	B-X
at	B-X
day	B-X
0	B-X
,	B-X
were	B-X
induced	B-X
in	B-X
both	B-X
erythroid	B-X
and	B-X
megakaryocytic	B-X
cultures	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
results	B-X
of	B-X
studies	B-X
aimed	B-X
at	B-X
understanding	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
controlling	B-X
p45	B-X
gene	B-X
expression	B-X
in	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
GATA	B-X
proteins	B-X
,	B-X
which	B-X
govern	B-X
the	B-X
differentiation	B-X
of	B-X
erythroid	B-X
lineage	B-X
cells	B-X
,	B-X
are	B-X
required	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
of	B-X
the	B-X
p45	B-X
gene	B-X

We	O
report	O
the	O
results	O
of	O
studies	O
aimed	O
at	O
understanding	O
the	O
regulatory	O
mechanisms	O
controlling	O
p45	B-DNA
gene	I-DNA
expression	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
results	B-X
of	B-X
studies	B-X
aimed	B-X
at	B-X
understanding	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
controlling	B-X
p45	B-X
gene	B-X
expression	B-X
in	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
We	B-X
investigated	B-X
lineage	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
both	B-X
isomers	B-X
in	B-X
human	B-X
erythroid	B-X
and	B-X
megakaryocytic	B-X
cells	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
or	B-X
Northern	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
E2	B-X
,	B-X
a	B-X
heterodimeric	B-X
protein	B-X
complex	B-X
composed	B-X
of	B-X
p45	B-X
and	B-X
small	B-X
Maf	B-X
family	B-X
proteins	B-X
,	B-X
is	B-X
considered	B-X
crucial	B-X
for	B-X
the	B-X
proper	B-X
differentiation	B-X
of	B-X
erythrocytes	B-X
and	B-X
megakaryocytes	B-X
in	B-X
vivo	B-X
<EOS>	B-X
For	B-X
functional	B-X
characterization	B-X
of	B-X
both	B-X
promoters	B-X
,	B-X
plasmids	B-X
in	B-X
which	B-X
reporter	B-X
genes	B-X
were	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
series	B-X
of	B-X
truncated	B-X
or	B-X
mutated	B-X
promoter	B-X
fragments	B-X
were	B-X
transfected	B-X
to	B-X
human	B-X
hematopoietic	B-X
cell	B-X
lines	B-X

MATERIALS	O
AND	O
METHODS	O
:	O
Human	B-RNA
p45	I-RNA
mRNAs	I-RNA
have	O
two	O
alternative	O
isoforms	O
,	O
aNF-E2	B-RNA
and	O
fNF-E2	B-RNA
,	O
and	O
these	O
isoforms	O
are	O
transcribed	O
from	O
the	O
alternative	B-DNA
promoters	I-DNA
.	O
<EOS>	B-X
Human	B-X
p45	B-X
mRNAs	B-X
have	B-X
two	B-X
alternative	B-X
isoforms	B-X
,	B-X
aNF	B-X
-	B-X
E2	B-X
and	B-X
fNF	B-X
-	B-X
E2	B-X
,	B-X
and	B-X
these	B-X
isoforms	B-X
are	B-X
transcribed	B-X
from	B-X
the	B-X
alternative	B-X
promoters	B-X
<EOS>	B-X
Functional	B-X
characterization	B-X
of	B-X
the	B-X
two	B-X
alternative	B-X
promoters	B-X
of	B-X
human	B-X
p45	B-X
NF	B-X
-	B-X
E2	B-X
gene	B-X
.	B-X
<EOS>	B-X
When	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
isolated	B-X
from	B-X
human	B-X
cord	B-X
blood	B-X
were	B-X
induced	B-X
to	B-X
unilineage	B-X
erythroid	B-X
or	B-X
megakaryocytic	B-X
differentiation	B-X
in	B-X
liquid	B-X
suspension	B-X
culture	B-X
,	B-X
both	B-X
transcripts	B-X
,	B-X
although	B-X
barely	B-X
detected	B-X
at	B-X
day	B-X
0	B-X
,	B-X
were	B-X
induced	B-X
in	B-X
both	B-X
erythroid	B-X
and	B-X
megakaryocytic	B-X
cultures	B-X
<EOS>	B-X
For	B-X
functional	B-X
characterization	B-X
of	B-X
both	B-X
promoters	B-X
,	B-X
plasmids	B-X
in	B-X
which	B-X
reporter	B-X
genes	B-X
were	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
series	B-X
of	B-X
truncated	B-X
or	B-X
mutated	B-X
promoter	B-X
fragments	B-X
were	B-X
transfected	B-X
to	B-X
human	B-X
hematopoietic	B-X
cell	B-X
lines	B-X

We	O
investigated	O
lineage-specific	O
expression	O
of	O
both	O
isomers	O
in	O
human	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
cells	I-cell_type
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
or	O
Northern	O
blot	O
analysis	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
exosomes	B-X
extracted	B-X
from	B-X
splenic	B-X
ischemic	B-X
preconditioning	B-X
(	B-X
sIPC	B-X
)	B-X
models	B-X
on	B-X
renal	B-X
ischemia	B-X
-	B-X
reperfusion	B-X
injury	B-X
(	B-X
IRI	B-X
)	B-X
<EOS>	B-X
Conversely	B-X
,	B-X
overexpression	B-X
of	B-X
mt	B-X
-	B-X
Ty	B-X
5'tiRNAs	B-X
in	B-X
C2C12	B-X
cells	B-X
led	B-X
to	B-X
a	B-X
reversal	B-X
of	B-X
these	B-X
transcriptional	B-X
trends	B-X
<EOS>	B-X
RelB	B-X
represses	B-X
miR	B-X
-	B-X
193a	B-X
-	B-X
5p	B-X
expression	B-X
to	B-X
promote	B-X
the	B-X
phenotypic	B-X
transformation	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
in	B-X
aortic	B-X
aneurysm	B-X
.	B-X
<EOS>	B-X
WB	B-X
results	B-X
showed	B-X
that	B-X
Bax	B-X
expression	B-X
was	B-X
increased	B-X
and	B-X
Bcl	B-X
-	B-X
2	B-X
expression	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
H	B-X
/	B-X
R	B-X
group	B-X

For	O
functional	O
characterization	O
of	O
both	O
promoters	O
,	O
plasmids	O
in	O
which	O
reporter	B-DNA
genes	I-DNA
were	O
placed	O
under	O
the	O
control	O
of	O
a	O
series	O
of	O
truncated	O
or	O
mutated	O
promoter	B-DNA
fragments	I-DNA
were	O
transfected	O
to	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O
<EOS>	B-X
For	B-X
functional	B-X
characterization	B-X
of	B-X
both	B-X
promoters	B-X
,	B-X
plasmids	B-X
in	B-X
which	B-X
reporter	B-X
genes	B-X
were	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
series	B-X
of	B-X
truncated	B-X
or	B-X
mutated	B-X
promoter	B-X
fragments	B-X
were	B-X
transfected	B-X
to	B-X
human	B-X
hematopoietic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
sequence	B-X
located	B-X
between	B-X
	B-X
-	B-X
170	B-X
and	B-X
	B-X
-	B-X
73	B-X
that	B-X
exhibited	B-X
a	B-X
repressor	B-X
activity	B-X
based	B-X
on	B-X
an	B-X
analysis	B-X
of	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
5'	B-X
-	B-X
deleted	B-X
GPIIb	B-X
promoter	B-X
fragments	B-X
transfected	B-X
in	B-X
the	B-X
nonhematopoietic	B-X
HeLa	B-X
cells	B-X
<EOS>	B-X
Functional	B-X
conservation	B-X
of	B-X
platelet	B-X
glycoprotein	B-X
V	B-X
promoter	B-X
between	B-X
mouse	B-X
and	B-X
human	B-X
megakaryocytes	B-X
.	B-X
<EOS>	B-X
Functional	B-X
characterization	B-X
of	B-X
the	B-X
two	B-X
alternative	B-X
promoters	B-X
of	B-X
human	B-X
p45	B-X
NF	B-X
-	B-X
E2	B-X
gene	B-X
.	B-X

RESULTS	O
:	O
When	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
isolated	O
from	O
human	O
cord	O
blood	O
were	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
in	O
liquid	O
suspension	O
culture	O
,	O
both	O
transcripts	O
,	O
although	O
barely	O
detected	O
at	O
day	O
0	O
,	O
were	O
induced	O
in	O
both	O
erythroid	O
and	O
megakaryocytic	O
cultures	O
.	O
<EOS>	B-X
When	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
isolated	B-X
from	B-X
human	B-X
cord	B-X
blood	B-X
were	B-X
induced	B-X
to	B-X
unilineage	B-X
erythroid	B-X
or	B-X
megakaryocytic	B-X
differentiation	B-X
in	B-X
liquid	B-X
suspension	B-X
culture	B-X
,	B-X
both	B-X
transcripts	B-X
,	B-X
although	B-X
barely	B-X
detected	B-X
at	B-X
day	B-X
0	B-X
,	B-X
were	B-X
induced	B-X
in	B-X
both	B-X
erythroid	B-X
and	B-X
megakaryocytic	B-X
cultures	B-X
<EOS>	B-X
CD34+	B-X
cells	B-X
isolated	B-X
from	B-X
human	B-X
cord	B-X
blood	B-X
were	B-X
induced	B-X
to	B-X
unilineage	B-X
megakaryocytic	B-X
or	B-X
erythroid	B-X
differentiation	B-X
in	B-X
liquid	B-X
suspension	B-X
culture	B-X
in	B-X
the	B-X
presense	B-X
of	B-X
thrombopoietin	B-X
or	B-X
erythropoietin	B-X
,	B-X
respectively	B-X
<EOS>	B-X
The	B-X
dynamic	B-X
changes	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
different	B-X
transcription	B-X
factors	B-X
that	B-X
occur	B-X
during	B-X
primary	B-X
megakaryocytic	B-X
differentiation	B-X
suggest	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
these	B-X
factors	B-X
may	B-X
influence	B-X
the	B-X
progression	B-X
to	B-X
specific	B-X
hematopoietic	B-X
pathways	B-X
<EOS>	B-X
Expression	B-X
of	B-X
transcription	B-X
factors	B-X
during	B-X
megakaryocytic	B-X
differentiation	B-X
of	B-X
CD34+	B-X
cells	B-X
from	B-X
human	B-X
cord	B-X
blood	B-X
induced	B-X
by	B-X
thrombopoietin	B-X
.	B-X

fNF-E2	B-RNA
mRNA	I-RNA
was	O
found	O
to	O
be	O
more	O
abundant	O
in	O
erythroid	B-cell_type
cells	I-cell_type
than	O
megakaryocytic	B-cell_type
cells	I-cell_type
at	O
day	O
7	O
of	O
culture	O
.	O
<EOS>	B-X
fNF	B-X
-	B-X
E2	B-X
mRNA	B-X
was	B-X
found	B-X
to	B-X
be	B-X
more	B-X
abundant	B-X
in	B-X
erythroid	B-X
cells	B-X
than	B-X
megakaryocytic	B-X
cells	B-X
at	B-X
day	B-X
7	B-X
of	B-X
culture	B-X
<EOS>	B-X
Functional	B-X
analysis	B-X
of	B-X
fNF	B-X
-	B-X
E2	B-X
promoter	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
is	B-X
active	B-X
only	B-X
in	B-X
erythroid	B-X
-	B-X
megakaryocytic	B-X
cells	B-X
and	B-X
that	B-X
the	B-X
double	B-X
GATA	B-X
site	B-X
in	B-X
the	B-X
proximal	B-X
region	B-X
is	B-X
necessary	B-X
for	B-X
its	B-X
efficient	B-X
activity	B-X
<EOS>	B-X
We	B-X
investigated	B-X
lineage	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
both	B-X
isomers	B-X
in	B-X
human	B-X
erythroid	B-X
and	B-X
megakaryocytic	B-X
cells	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
or	B-X
Northern	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
GATA	B-X
proteins	B-X
,	B-X
which	B-X
govern	B-X
the	B-X
differentiation	B-X
of	B-X
erythroid	B-X
lineage	B-X
cells	B-X
,	B-X
are	B-X
required	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
of	B-X
the	B-X
p45	B-X
gene	B-X

Although	O
both	O
isomers	O
were	O
expressed	O
in	O
human	B-cell_line
erythroid-megakaryocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
megakaryocytic	O
maturation	O
with	O
loss	O
of	O
erythroid	O
phenotype	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
resulted	O
in	O
exclusive	O
downregulation	O
of	O
fNF-E2	B-RNA
,	O
suggesting	O
that	O
fNF-E2	B-DNA
promoter	I-DNA
is	O
more	O
erythroid	O
specific	O
.	O
<EOS>	B-X
Although	B-X
both	B-X
isomers	B-X
were	B-X
expressed	B-X
in	B-X
human	B-X
erythroid	B-X
-	B-X
megakaryocytic	B-X
cell	B-X
lines	B-X
,	B-X
megakaryocytic	B-X
maturation	B-X
with	B-X
loss	B-X
of	B-X
erythroid	B-X
phenotype	B-X
induced	B-X
by	B-X
phorbol	B-X
12	B-X
-	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
resulted	B-X
in	B-X
exclusive	B-X
downregulation	B-X
of	B-X
fNF	B-X
-	B-X
E2	B-X
,	B-X
suggesting	B-X
that	B-X
fNF	B-X
-	B-X
E2	B-X
promoter	B-X
is	B-X
more	B-X
erythroid	B-X
specific	B-X
<EOS>	B-X
Functional	B-X
analysis	B-X
of	B-X
fNF	B-X
-	B-X
E2	B-X
promoter	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
is	B-X
active	B-X
only	B-X
in	B-X
erythroid	B-X
-	B-X
megakaryocytic	B-X
cells	B-X
and	B-X
that	B-X
the	B-X
double	B-X
GATA	B-X
site	B-X
in	B-X
the	B-X
proximal	B-X
region	B-X
is	B-X
necessary	B-X
for	B-X
its	B-X
efficient	B-X
activity	B-X
<EOS>	B-X
We	B-X
investigated	B-X
lineage	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
both	B-X
isomers	B-X
in	B-X
human	B-X
erythroid	B-X
and	B-X
megakaryocytic	B-X
cells	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
or	B-X
Northern	B-X
blot	B-X
analysis	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
GATA	B-X
proteins	B-X
,	B-X
which	B-X
govern	B-X
the	B-X
differentiation	B-X
of	B-X
erythroid	B-X
lineage	B-X
cells	B-X
,	B-X
are	B-X
required	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
of	B-X
the	B-X
p45	B-X
gene	B-X

Functional	O
analysis	O
of	O
fNF-E2	B-DNA
promoter	I-DNA
showed	O
that	O
the	O
promoter	O
is	O
active	O
only	O
in	O
erythroid-megakaryocytic	B-cell_type
cells	I-cell_type
and	O
that	O
the	O
double	B-DNA
GATA	I-DNA
sit	I-DNA
e	O
in	O
the	O
proximal	O
region	O
is	O
necessary	O
for	O
its	O
efficient	O
activity	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
GATA	B-protein
proteins	I-protein
,	O
which	O
govern	O
the	O
differentiation	O
of	O
erythroid	B-cell_type
lineage	I-cell_type
cells	I-cell_type
,	O
are	O
required	O
for	O
full	O
promoter	O
activity	O
of	O
the	O
p45	B-DNA
gene	I-DNA
.	O
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
GATA	B-X
proteins	B-X
,	B-X
which	B-X
govern	B-X
the	B-X
differentiation	B-X
of	B-X
erythroid	B-X
lineage	B-X
cells	B-X
,	B-X
are	B-X
required	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
of	B-X
the	B-X
p45	B-X
gene	B-X
<EOS>	B-X
For	B-X
functional	B-X
characterization	B-X
of	B-X
both	B-X
promoters	B-X
,	B-X
plasmids	B-X
in	B-X
which	B-X
reporter	B-X
genes	B-X
were	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
series	B-X
of	B-X
truncated	B-X
or	B-X
mutated	B-X
promoter	B-X
fragments	B-X
were	B-X
transfected	B-X
to	B-X
human	B-X
hematopoietic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
fNF	B-X
-	B-X
E2	B-X
mRNA	B-X
was	B-X
found	B-X
to	B-X
be	B-X
more	B-X
abundant	B-X
in	B-X
erythroid	B-X
cells	B-X
than	B-X
megakaryocytic	B-X
cells	B-X
at	B-X
day	B-X
7	B-X
of	B-X
culture	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
results	B-X
of	B-X
studies	B-X
aimed	B-X
at	B-X
understanding	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
controlling	B-X
p45	B-X
gene	B-X
expression	B-X
in	B-X
erythroid	B-X
cells	B-X

Transcriptional	O
activation	O
of	O
heme	B-DNA
oxygenase-1	I-DNA
and	O
its	O
functional	O
significance	O
in	O
acetaminophen-induced	O
hepatitis	O
and	O
hepatocellular	O
injury	O
in	O
the	O
rat	O
.	O
<EOS>	B-X
Transcriptional	B-X
activation	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
its	B-X
functional	B-X
significance	B-X
in	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatitis	B-X
and	B-X
hepatocellular	B-X
injury	B-X
in	B-X
the	B-X
rat	B-X
.	B-X
<EOS>	B-X
However	B-X
,	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
has	B-X
no	B-X
permissive	B-X
effect	B-X
on	B-X
sinusoidal	B-X
perfusion	B-X
and	B-X
does	B-X
not	B-X
affect	B-X
liver	B-X
injury	B-X
in	B-X
this	B-X
model	B-X
<EOS>	B-X
Gene	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
-	B-X
	B-X
and	B-X
Western	B-X
analysis	B-X
as	B-X
well	B-X
as	B-X
immunohistochemistry	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
cell	B-X
-	B-X
type	B-X
specific	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
liver	B-X
injury	B-X
and	B-X
microcirculatory	B-X
disturbances	B-X
in	B-X
a	B-X
model	B-X
of	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatitis	B-X

BACKGROUND/AIM	O
:	O
Glutathione	O
depletion	O
contributes	O
to	O
acetaminophen	O
hepatotoxicity	O
and	O
is	O
known	O
to	O
induce	O
the	O
oxidative	O
stress	O
reactant	O
heme	B-protein
oxygenase-1	I-protein
.	O
<EOS>	B-X
Glutathione	B-X
depletion	B-X
contributes	B-X
to	B-X
acetaminophen	B-X
hepatotoxicity	B-X
and	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
the	B-X
oxidative	B-X
stress	B-X
reactant	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
<EOS>	B-X
The	B-X
inflammatory	B-X
response	B-X
associated	B-X
with	B-X
acetaminophen	B-X
hepatotoxicity	B-X
is	B-X
modulated	B-X
by	B-X
the	B-X
parallel	B-X
induction	B-X
of	B-X
the	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
gene	B-X
<EOS>	B-X
Blockade	B-X
of	B-X
heme	B-X
oxygenase	B-X
activity	B-X
with	B-X
tin	B-X
-	B-X
protoporphyrin	B-X
-	B-X
IX	B-X
abrogated	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatic	B-X
neutrophil	B-X
accumulation	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
sinusoidal	B-X
perfusion	B-X
and	B-X
liver	B-X
injury	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
cell	B-X
-	B-X
type	B-X
specific	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
liver	B-X
injury	B-X
and	B-X
microcirculatory	B-X
disturbances	B-X
in	B-X
a	B-X
model	B-X
of	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatitis	B-X

The	O
metabolites	O
of	O
the	O
heme	O
oxygenase	O
pathway	O
,	O
biliverdin	O
,	O
carbon	O
monoxide	O
,	O
and	O
iron	O
may	O
modulate	O
acetaminophen	O
toxicity	O
.	O
<EOS>	B-X
The	B-X
metabolites	B-X
of	B-X
the	B-X
heme	B-X
oxygenase	B-X
pathway	B-X
,	B-X
biliverdin	B-X
,	B-X
carbon	B-X
monoxide	B-X
,	B-X
and	B-X
iron	B-X
may	B-X
modulate	B-X
acetaminophen	B-X
toxicity	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
cell	B-X
-	B-X
type	B-X
specific	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
liver	B-X
injury	B-X
and	B-X
microcirculatory	B-X
disturbances	B-X
in	B-X
a	B-X
model	B-X
of	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatitis	B-X
<EOS>	B-X
These	B-X
data	B-X
argue	B-X
against	B-X
a	B-X
central	B-X
role	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
neutrophil	B-X
infiltration	B-X
as	B-X
perpetuating	B-X
factors	B-X
of	B-X
liver	B-X
injury	B-X
in	B-X
acetaminophen	B-X
toxicity	B-X
<EOS>	B-X
Gene	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
-	B-X
	B-X
and	B-X
Western	B-X
analysis	B-X
as	B-X
well	B-X
as	B-X
immunohistochemistry	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
cell-type	O
specific	O
expression	O
of	O
heme	B-DNA
oxygenase-1	I-DNA
and	O
its	O
impact	O
on	O
liver	O
injury	O
and	O
microcirculatory	O
disturbances	O
in	O
a	O
model	O
of	O
acetaminophen-induced	O
hepatitis	O
.	O

METHODS	O
:	O
Gene	O
expression	O
of	O
heme	B-DNA
oxygenase-1	I-DNA
was	O
studied	O
by	O
Northern-	O
and	O
Western	O
analysis	O
as	O
well	O
as	O
immunohistochemistry	O
.	O
<EOS>	B-X
Gene	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
-	B-X
	B-X
and	B-X
Western	B-X
analysis	B-X
as	B-X
well	B-X
as	B-X
immunohistochemistry	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
cell	B-X
-	B-X
type	B-X
specific	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
its	B-X
impact	B-X
on	B-X
liver	B-X
injury	B-X
and	B-X
microcirculatory	B-X
disturbances	B-X
in	B-X
a	B-X
model	B-X
of	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatitis	B-X
<EOS>	B-X
Transcriptional	B-X
activation	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
its	B-X
functional	B-X
significance	B-X
in	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatitis	B-X
and	B-X
hepatocellular	B-X
injury	B-X
in	B-X
the	B-X
rat	B-X
.	B-X
<EOS>	B-X
The	B-X
time	B-X
course	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
	B-X
-	B-X
2	B-X
,	B-X
cytokine	B-X
-	B-X
induced	B-X
neutrophil	B-X
chemoattractant	B-X
-	B-X
1	B-X
,	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
analysis	B-X

The	O
time	O
course	O
of	O
heme	B-protein
oxygenase-1	I-protein
and	I-protein
-2	I-protein
,	O
cytokine-induced	B-protein
neutrophil	I-protein
chemoattractant-1	I-protein
,	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
was	O
studied	O
by	O
Northern	O
analysis	O
.	O
<EOS>	B-X
The	B-X
time	B-X
course	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
	B-X
-	B-X
2	B-X
,	B-X
cytokine	B-X
-	B-X
induced	B-X
neutrophil	B-X
chemoattractant	B-X
-	B-X
1	B-X
,	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
analysis	B-X
<EOS>	B-X
Acetaminophen	B-X
caused	B-X
a	B-X
moderate	B-X
sinusoidal	B-X
perfusion	B-X
failure	B-X
(	B-X
	B-X
-	B-X
15	B-X
%	B-X
)	B-X
and	B-X
infiltration	B-X
of	B-X
neutrophils	B-X
along	B-X
with	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
cytokine	B-X
-	B-X
induced	B-X
neutrophil	B-X
chemoattractant	B-X
-	B-X
1	B-X
mRNAs	B-X
<EOS>	B-X
The	B-X
metabolites	B-X
of	B-X
the	B-X
heme	B-X
oxygenase	B-X
pathway	B-X
,	B-X
biliverdin	B-X
,	B-X
carbon	B-X
monoxide	B-X
,	B-X
and	B-X
iron	B-X
may	B-X
modulate	B-X
acetaminophen	B-X
toxicity	B-X
<EOS>	B-X
Gene	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
-	B-X
	B-X
and	B-X
Western	B-X
analysis	B-X
as	B-X
well	B-X
as	B-X
immunohistochemistry	B-X

DNA-binding	O
activity	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
was	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
<EOS>	B-X
The	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
was	B-X
assessed	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
was	B-X
assessed	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
The	B-X
molecular	B-X
mechanism	B-X
research	B-X
was	B-X
performed	B-X
by	B-X
RT	B-X
-	B-X
PCR	B-X
,	B-X
Western	B-X
blot	B-X
,	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
<EOS>	B-X
The	B-X
NF	B-X
-	B-X
κB	B-X
(	B-X
p65	B-X
)	B-X
nuclear	B-X
localization	B-X
was	B-X
detected	B-X
by	B-X
immunofluorescence	B-X
assay	B-X
,	B-X
and	B-X
NF	B-X
-	B-X
κB	B-X
/	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X

Sinusoidal	O
perfusion	O
and	O
leukocyte-endothelial	O
interactions	O
were	O
assessed	O
by	O
intravital	O
microscopy	O
.	O
<EOS>	B-X
Sinusoidal	B-X
perfusion	B-X
and	B-X
leukocyte	B-X
-	B-X
endothelial	B-X
interactions	B-X
were	B-X
assessed	B-X
by	B-X
intravital	B-X
microscopy	B-X
<EOS>	B-X
Leukocyte	B-X
accumulation	B-X
and	B-X
leukocyte	B-X
-	B-X
endothelial	B-X
interaction	B-X
were	B-X
directly	B-X
measured	B-X
using	B-X
fluorescence	B-X
intravital	B-X
microscopy	B-X
<EOS>	B-X
Six	B-X
hours	B-X
after	B-X
LPS	B-X
exposure	B-X
the	B-X
hepatic	B-X
microcirculation	B-X
and	B-X
leukocyte	B-X
-	B-X
endothelial	B-X
cell	B-X
interaction	B-X
were	B-X
analyzed	B-X
by	B-X
intravital	B-X
fluorescence	B-X
microscopy	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
leukocyte	B-X
-	B-X
endothelial	B-X
cell	B-X
interactions	B-X
were	B-X
assessed	B-X
by	B-X
IVM	B-X

RESULTS	O
:	O
Acetaminophen	O
caused	O
a	O
moderate	O
sinusoidal	O
perfusion	O
failure	O
(	O
-15	O
%	O
)	O
and	O
infiltration	O
of	O
neutrophils	B-cell_type
along	O
with	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
cytokine-induced	B-protein
neutrophil	I-protein
chemoattractant-1	I-protein
mRNAs	O
.	O
<EOS>	B-X
Acetaminophen	B-X
caused	B-X
a	B-X
moderate	B-X
sinusoidal	B-X
perfusion	B-X
failure	B-X
(	B-X
	B-X
-	B-X
15	B-X
%	B-X
)	B-X
and	B-X
infiltration	B-X
of	B-X
neutrophils	B-X
along	B-X
with	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
cytokine	B-X
-	B-X
induced	B-X
neutrophil	B-X
chemoattractant	B-X
-	B-X
1	B-X
mRNAs	B-X
<EOS>	B-X
The	B-X
time	B-X
course	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
	B-X
-	B-X
2	B-X
,	B-X
cytokine	B-X
-	B-X
induced	B-X
neutrophil	B-X
chemoattractant	B-X
-	B-X
1	B-X
,	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
analysis	B-X
<EOS>	B-X
These	B-X
data	B-X
argue	B-X
against	B-X
a	B-X
central	B-X
role	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
neutrophil	B-X
infiltration	B-X
as	B-X
perpetuating	B-X
factors	B-X
of	B-X
liver	B-X
injury	B-X
in	B-X
acetaminophen	B-X
toxicity	B-X
<EOS>	B-X
Blockade	B-X
of	B-X
heme	B-X
oxygenase	B-X
activity	B-X
with	B-X
tin	B-X
-	B-X
protoporphyrin	B-X
-	B-X
IX	B-X
abrogated	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatic	B-X
neutrophil	B-X
accumulation	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
sinusoidal	B-X
perfusion	B-X
and	B-X
liver	B-X
injury	B-X

Induction	O
of	O
heme	B-protein
oxygenase-1	I-protein
mRNA	O
and	O
protein	O
(	O
approximately	O
30-fold	O
)	O
in	O
hepatocytes	B-cell_type
and	O
non-parenchymal	B-cell_type
cells	I-cell_type
paralleled	O
the	O
inflammatory	O
response	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
mRNA	B-X
and	B-X
protein	B-X
(	B-X
approximately	B-X
30	B-X
-	B-X
fold	B-X
)	B-X
in	B-X
hepatocytes	B-X
and	B-X
non	B-X
-	B-X
parenchymal	B-X
cells	B-X
paralleled	B-X
the	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
Gene	B-X
expression	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
-	B-X
	B-X
and	B-X
Western	B-X
analysis	B-X
as	B-X
well	B-X
as	B-X
immunohistochemistry	B-X
<EOS>	B-X
Blockade	B-X
of	B-X
heme	B-X
oxygenase	B-X
activity	B-X
with	B-X
tin	B-X
-	B-X
protoporphyrin	B-X
-	B-X
IX	B-X
abrogated	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatic	B-X
neutrophil	B-X
accumulation	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
sinusoidal	B-X
perfusion	B-X
and	B-X
liver	B-X
injury	B-X
<EOS>	B-X
However	B-X
,	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
has	B-X
no	B-X
permissive	B-X
effect	B-X
on	B-X
sinusoidal	B-X
perfusion	B-X
and	B-X
does	B-X
not	B-X
affect	B-X
liver	B-X
injury	B-X
in	B-X
this	B-X
model	B-X

Blockade	O
of	O
heme	O
oxygenase	O
activity	O
with	O
tin-protoporphyrin-IX	O
abrogated	O
acetaminophen-induced	O
hepatic	B-cell_type
neutrophil	I-cell_type
accumulation	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
,	O
but	O
failed	O
to	O
affect	O
sinusoidal	O
perfusion	O
and	O
liver	O
injury	O
.	O
<EOS>	B-X
Blockade	B-X
of	B-X
heme	B-X
oxygenase	B-X
activity	B-X
with	B-X
tin	B-X
-	B-X
protoporphyrin	B-X
-	B-X
IX	B-X
abrogated	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatic	B-X
neutrophil	B-X
accumulation	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
sinusoidal	B-X
perfusion	B-X
and	B-X
liver	B-X
injury	B-X
<EOS>	B-X
The	B-X
time	B-X
course	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
	B-X
-	B-X
2	B-X
,	B-X
cytokine	B-X
-	B-X
induced	B-X
neutrophil	B-X
chemoattractant	B-X
-	B-X
1	B-X
,	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
was	B-X
studied	B-X
by	B-X
Northern	B-X
analysis	B-X
<EOS>	B-X
Induction	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
mRNA	B-X
and	B-X
protein	B-X
(	B-X
approximately	B-X
30	B-X
-	B-X
fold	B-X
)	B-X
in	B-X
hepatocytes	B-X
and	B-X
non	B-X
-	B-X
parenchymal	B-X
cells	B-X
paralleled	B-X
the	B-X
inflammatory	B-X
response	B-X
<EOS>	B-X
Transcriptional	B-X
activation	B-X
of	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
and	B-X
its	B-X
functional	B-X
significance	B-X
in	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatitis	B-X
and	B-X
hepatocellular	B-X
injury	B-X
in	B-X
the	B-X
rat	B-X
.	B-X

CONCLUSIONS	O
:	O
The	O
inflammatory	O
response	O
associated	O
with	O
acetaminophen	O
hepatotoxicity	O
is	O
modulated	O
by	O
the	O
parallel	O
induction	O
of	O
the	O
heme	B-DNA
oxygenase-1	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
The	B-X
inflammatory	B-X
response	B-X
associated	B-X
with	B-X
acetaminophen	B-X
hepatotoxicity	B-X
is	B-X
modulated	B-X
by	B-X
the	B-X
parallel	B-X
induction	B-X
of	B-X
the	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
gene	B-X
<EOS>	B-X
Glutathione	B-X
depletion	B-X
contributes	B-X
to	B-X
acetaminophen	B-X
hepatotoxicity	B-X
and	B-X
is	B-X
known	B-X
to	B-X
induce	B-X
the	B-X
oxidative	B-X
stress	B-X
reactant	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
<EOS>	B-X
Blockade	B-X
of	B-X
heme	B-X
oxygenase	B-X
activity	B-X
with	B-X
tin	B-X
-	B-X
protoporphyrin	B-X
-	B-X
IX	B-X
abrogated	B-X
acetaminophen	B-X
-	B-X
induced	B-X
hepatic	B-X
neutrophil	B-X
accumulation	B-X
and	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
sinusoidal	B-X
perfusion	B-X
and	B-X
liver	B-X
injury	B-X
<EOS>	B-X
Acetaminophen	B-X
caused	B-X
a	B-X
moderate	B-X
sinusoidal	B-X
perfusion	B-X
failure	B-X
(	B-X
	B-X
-	B-X
15	B-X
%	B-X
)	B-X
and	B-X
infiltration	B-X
of	B-X
neutrophils	B-X
along	B-X
with	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
and	B-X
cytokine	B-X
-	B-X
induced	B-X
neutrophil	B-X
chemoattractant	B-X
-	B-X
1	B-X
mRNAs	B-X

However	O
,	O
heme	B-DNA
oxygenase-1	I-DNA
has	O
no	O
permissive	O
effect	O
on	O
sinusoidal	O
perfusion	O
and	O
does	O
not	O
affect	O
liver	O
injury	O
in	O
this	O
model	O
.	O

These	O
data	O
argue	O
against	O
a	O
central	O
role	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
and	O
neutrophil	O
infiltration	O
as	O
perpetuating	O
factors	O
of	O
liver	O
injury	O
in	O
acetaminophen	O
toxicity	O
.	O
<EOS>	B-X
These	B-X
data	B-X
argue	B-X
against	B-X
a	B-X
central	B-X
role	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
neutrophil	B-X
infiltration	B-X
as	B-X
perpetuating	B-X
factors	B-X
of	B-X
liver	B-X
injury	B-X
in	B-X
acetaminophen	B-X
toxicity	B-X
<EOS>	B-X
The	B-X
metabolites	B-X
of	B-X
the	B-X
heme	B-X
oxygenase	B-X
pathway	B-X
,	B-X
biliverdin	B-X
,	B-X
carbon	B-X
monoxide	B-X
,	B-X
and	B-X
iron	B-X
may	B-X
modulate	B-X
acetaminophen	B-X
toxicity	B-X
<EOS>	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappaB	B-X
was	B-X
determined	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
<EOS>	B-X
However	B-X
,	B-X
heme	B-X
oxygenase	B-X
-	B-X
1	B-X
has	B-X
no	B-X
permissive	B-X
effect	B-X
on	B-X
sinusoidal	B-X
perfusion	B-X
and	B-X
does	B-X
not	B-X
affect	B-X
liver	B-X
injury	B-X
in	B-X
this	B-X
model	B-X

Tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
proliferation	O
requires	O
synthesis	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
proliferation	B-X
requires	B-X
synthesis	B-X
of	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
.	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
can	B-X
induce	B-X
proliferation	B-X
as	B-X
well	B-X
as	B-X
apoptosis	B-X
in	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
	B-X
-	B-X
derived	B-X
cells	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
required	B-X
for	B-X
development	B-X
of	B-X
human	B-X
DC	B-X
,	B-X
was	B-X
found	B-X
to	B-X
enhance	B-X
the	B-X
maturation	B-X
of	B-X
mouse	B-X
DC	B-X
in	B-X
the	B-X
last	B-X
two	B-X
days	B-X
of	B-X
culture	B-X
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
recently	B-X
that	B-X
these	B-X
seemingly	B-X
contradictory	B-X
effects	B-X
are	B-X
based	B-X
on	B-X
the	B-X
divergent	B-X
capacities	B-X
of	B-X
the	B-X
cells	B-X
to	B-X
produce	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
upon	B-X
stimulation	B-X
with	B-X
TNF	B-X

OBJECTIVE	O
:	O
Tumor	B-protein
necrosis	I-protein
factor-	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
induces	O
a	O
variety	O
of	O
cellular	O
responses	O
,	O
some	O
of	O
them	O
being	O
at	O
least	O
seemingly	O
contradictory	O
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
induces	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
responses	B-X
,	B-X
some	B-X
of	B-X
them	B-X
being	B-X
at	B-X
least	B-X
seemingly	B-X
contradictory	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
proliferation	B-X
requires	B-X
synthesis	B-X
of	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
.	B-X
<EOS>	B-X
Nevertheless	B-X
,	B-X
inhibitors	B-X
of	B-X
these	B-X
pathways	B-X
clearly	B-X
reduced	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
cell	B-X
growth	B-X
,	B-X
indicating	B-X
that	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
proliferative	B-X
cells	B-X
produced	B-X
a	B-X
growth	B-X
factor	B-X
that	B-X
induced	B-X
proliferation	B-X
upon	B-X
stimulation	B-X
of	B-X
the	B-X
above	B-X
pathways	B-X
<EOS>	B-X
Anti	B-X
-	B-X
GM	B-X
-	B-X
CSF	B-X
antibodies	B-X
inhibited	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
growth	B-X
,	B-X
suggesting	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
autocrine	B-X
loop	B-X
for	B-X
cell	B-X
proliferation	B-X
mediated	B-X
by	B-X
GM	B-X
-	B-X
CSF	B-X

Thus	O
,	O
we	O
set	O
out	O
to	O
find	O
differences	O
in	O
the	O
modes	O
of	O
proliferative	O
and	O
apoptotic	O
responses	O
to	O
TNF-	B-protein
alpha	I-protein
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
screened	O
a	O
panel	O
of	O
acute	B-cell_line
myeloid	I-cell_line
leukemia-derived	I-cell_line
cell	I-cell_line
lines	I-cell_line
for	O
TNF-	B-protein
alpha	I-protein
-responsiveness	O
.	O
<EOS>	B-X
We	B-X
screened	B-X
a	B-X
panel	B-X
of	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
-	B-X
derived	B-X
cell	B-X
lines	B-X
for	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
responsiveness	B-X
<EOS>	B-X
Supporting	B-X
this	B-X
notion	B-X
,	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
upregulation	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
mRNA	B-X
levels	B-X
and	B-X
protein	B-X
secretion	B-X
in	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
proliferative	B-X
,	B-X
but	B-X
not	B-X
in	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
apoptotic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
These	B-X
data	B-X
identify	B-X
GM	B-X
-	B-X
CSF	B-X
synthesis	B-X
as	B-X
an	B-X
early	B-X
and	B-X
essential	B-X
step	B-X
in	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
this	B-X
context	B-X
,	B-X
we	B-X
discuss	B-X
arguments	B-X
pointing	B-X
at	B-X
NF	B-X
-	B-X
kappaB	B-X
as	B-X
regulator	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
synthesis	B-X
and	B-X
thus	B-X
indirectly	B-X
as	B-X
regulator	B-X
for	B-X
the	B-X
escape	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
apoptosis	B-X

In	O
two	O
lines	O
(	O
OCI-AML-1	B-cell_line
,	O
OCI-AML-11	B-cell_line
)	O
,	O
TNF-	B-protein
alpha	I-protein
acted	O
as	O
an	O
apoptotic	O
agent	O
;	O
in	O
others	O
(	O
HU-3	B-cell_line
,	O
M-07e	B-cell_line
,	O
TF-1	B-cell_line
)	O
,	O
it	O
had	O
the	O
opposite	O
effect	O
,	O
preventing	O
apoptosis	O
and	O
inducing	O
proliferation	O
.	O
<EOS>	B-X
In	B-X
two	B-X
lines	B-X
(	B-X
OCI	B-X
-	B-X
AML	B-X
-	B-X
1	B-X
,	B-X
OCI	B-X
-	B-X
AML	B-X
-	B-X
11	B-X
)	B-X
,	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
acted	B-X
as	B-X
an	B-X
apoptotic	B-X
agent	B-X
;	B-X
in	B-X
others	B-X
(	B-X
HU	B-X
-	B-X
3	B-X
,	B-X
M	B-X
-	B-X
07e	B-X
,	B-X
TF	B-X
-	B-X
1	B-X
)	B-X
,	B-X
it	B-X
had	B-X
the	B-X
opposite	B-X
effect	B-X
,	B-X
preventing	B-X
apoptosis	B-X
and	B-X
inducing	B-X
proliferation	B-X
<EOS>	B-X
These	B-X
data	B-X
identify	B-X
GM	B-X
-	B-X
CSF	B-X
synthesis	B-X
as	B-X
an	B-X
early	B-X
and	B-X
essential	B-X
step	B-X
in	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
All	B-X
cell	B-X
lines	B-X
tested	B-X
expressed	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
receptors	B-X
I	B-X
and	B-X
II	B-X
and	B-X
responded	B-X
to	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
by	B-X
upregulation	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
induces	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
responses	B-X
,	B-X
some	B-X
of	B-X
them	B-X
being	B-X
at	B-X
least	B-X
seemingly	B-X
contradictory	B-X

Direct	O
and	O
indirect	O
signaling	O
mechanisms	O
,	O
including	O
NF-kappaB	B-protein
activation	O
and	O
cytokine	O
synthesis	O
,	O
were	O
analyzed	O
.	O
<EOS>	B-X
Direct	B-X
and	B-X
indirect	B-X
signaling	B-X
mechanisms	B-X
,	B-X
including	B-X
NF	B-X
-	B-X
kappaB	B-X
activation	B-X
and	B-X
cytokine	B-X
synthesis	B-X
,	B-X
were	B-X
analyzed	B-X
<EOS>	B-X
In	B-X
this	B-X
context	B-X
,	B-X
we	B-X
discuss	B-X
arguments	B-X
pointing	B-X
at	B-X
NF	B-X
-	B-X
kappaB	B-X
as	B-X
regulator	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
synthesis	B-X
and	B-X
thus	B-X
indirectly	B-X
as	B-X
regulator	B-X
for	B-X
the	B-X
escape	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
apoptosis	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
,	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
did	B-X
not	B-X
activate	B-X
the	B-X
MAP	B-X
kinase	B-X
and	B-X
p70S6	B-X
kinase	B-X
pathways	B-X
<EOS>	B-X
All	B-X
cell	B-X
lines	B-X
tested	B-X
expressed	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
receptors	B-X
I	B-X
and	B-X
II	B-X
and	B-X
responded	B-X
to	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
by	B-X
upregulation	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X

RESULTS	O
:	O
All	O
cell	O
lines	O
tested	O
expressed	O
TNF-	B-protein
alpha	I-protein
receptors	I-protein
I	I-protein
and	I-protein
II	I-protein
and	O
responded	O
to	O
TNF-	B-protein
alpha	I-protein
by	O
upregulation	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O

In	O
contrast	O
to	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
TNF-	B-protein
alpha	I-protein
did	O
not	O
activate	O
the	O
MAP	B-protein
kinase	I-protein
and	O
p70S6	O
kinase	O
pathways	O
.	O
<EOS>	B-X
Specifically	B-X
,	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
γ	B-X
)	B-X
,	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
,	B-X
interleukin	B-X
1α	B-X
(	B-X
IL	B-X
-	B-X
1α	B-X
)	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
α	B-X
(	B-X
TNFα	B-X
)	B-X
were	B-X
elevated	B-X
in	B-X
both	B-X
males	B-X
and	B-X
females	B-X
<EOS>	B-X
Granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
numerous	B-X
chronic	B-X
inflammatory	B-X
diseases	B-X
,	B-X
including	B-X
multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
<EOS>	B-X
The	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
(	B-X
or	B-X
CSF	B-X
-	B-X
2	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
myeloid	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
,	B-X
and	B-X
,	B-X
possibly	B-X
,	B-X
a	B-X
major	B-X
mediator	B-X
of	B-X
inflammation	B-X
in	B-X
body	B-X
tissues	B-X
<EOS>	B-X
Granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
-	B-X
stimulated	B-X
human	B-X
macrophages	B-X
demonstrate	B-X
enhanced	B-X
functions	B-X
contributing	B-X
to	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
.	B-X

Nevertheless	O
,	O
inhibitors	O
of	O
these	O
pathways	O
clearly	O
reduced	O
the	O
TNF-alpha	B-protein
-induced	O
cell	O
growth	O
,	O
indicating	O
that	O
TNF-	B-cell_type
alpha-proliferative	I-cell_type
cells	I-cell_type
produced	O
a	O
growth	O
factor	O
that	O
induced	O
proliferation	O
upon	O
stimulation	O
of	O
the	O
above	O
pathways	O
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
inhibitors	B-X
of	B-X
these	B-X
pathways	B-X
clearly	B-X
reduced	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
cell	B-X
growth	B-X
,	B-X
indicating	B-X
that	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
proliferative	B-X
cells	B-X
produced	B-X
a	B-X
growth	B-X
factor	B-X
that	B-X
induced	B-X
proliferation	B-X
upon	B-X
stimulation	B-X
of	B-X
the	B-X
above	B-X
pathways	B-X
<EOS>	B-X
Anti	B-X
-	B-X
GM	B-X
-	B-X
CSF	B-X
antibodies	B-X
inhibited	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
growth	B-X
,	B-X
suggesting	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
autocrine	B-X
loop	B-X
for	B-X
cell	B-X
proliferation	B-X
mediated	B-X
by	B-X
GM	B-X
-	B-X
CSF	B-X
<EOS>	B-X
Supporting	B-X
this	B-X
notion	B-X
,	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
upregulation	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
mRNA	B-X
levels	B-X
and	B-X
protein	B-X
secretion	B-X
in	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
proliferative	B-X
,	B-X
but	B-X
not	B-X
in	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
apoptotic	B-X
cell	B-X
lines	B-X
<EOS>	B-X
All	B-X
cell	B-X
lines	B-X
tested	B-X
expressed	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
receptors	B-X
I	B-X
and	B-X
II	B-X
and	B-X
responded	B-X
to	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
by	B-X
upregulation	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X

Anti-GM-CSF	B-protein
antibodies	I-protein
inhibited	O
the	O
TNF-alpha	B-protein
-induced	O
growth	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
autocrine	O
loop	O
for	O
cell	O
proliferation	O
mediated	O
by	O
GM-CSF	B-protein
.	O
<EOS>	B-X
Anti	B-X
-	B-X
GM	B-X
-	B-X
CSF	B-X
antibodies	B-X
inhibited	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
growth	B-X
,	B-X
suggesting	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
autocrine	B-X
loop	B-X
for	B-X
cell	B-X
proliferation	B-X
mediated	B-X
by	B-X
GM	B-X
-	B-X
CSF	B-X
<EOS>	B-X
Nevertheless	B-X
,	B-X
inhibitors	B-X
of	B-X
these	B-X
pathways	B-X
clearly	B-X
reduced	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
cell	B-X
growth	B-X
,	B-X
indicating	B-X
that	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
proliferative	B-X
cells	B-X
produced	B-X
a	B-X
growth	B-X
factor	B-X
that	B-X
induced	B-X
proliferation	B-X
upon	B-X
stimulation	B-X
of	B-X
the	B-X
above	B-X
pathways	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
proliferation	B-X
requires	B-X
synthesis	B-X
of	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
.	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
-	B-X
	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
induces	B-X
a	B-X
variety	B-X
of	B-X
cellular	B-X
responses	B-X
,	B-X
some	B-X
of	B-X
them	B-X
being	B-X
at	B-X
least	B-X
seemingly	B-X
contradictory	B-X

Supporting	O
this	O
notion	O
,	O
TNF-alpha	B-protein
-induced	O
upregulation	O
of	O
GM-CSF	B-RNA
mRNA	I-RNA
levels	O
and	O
protein	O
secretion	O
in	O
the	O
TNF-alpha	B-protein
-proliferative	O
,	O
but	O
not	O
in	O
the	O
TNF-alpha-apoptotic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

CONCLUSION	O
:	O
These	O
data	O
identify	O
GM-CSF	B-protein
synthesis	O
as	O
an	O
early	O
and	O
essential	O
step	O
in	O
TNF-	O
alpha-induced	O
proliferation	O
.	O
<EOS>	B-X
These	B-X
data	B-X
identify	B-X
GM	B-X
-	B-X
CSF	B-X
synthesis	B-X
as	B-X
an	B-X
early	B-X
and	B-X
essential	B-X
step	B-X
in	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
In	B-X
this	B-X
context	B-X
,	B-X
we	B-X
discuss	B-X
arguments	B-X
pointing	B-X
at	B-X
NF	B-X
-	B-X
kappaB	B-X
as	B-X
regulator	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
synthesis	B-X
and	B-X
thus	B-X
indirectly	B-X
as	B-X
regulator	B-X
for	B-X
the	B-X
escape	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
apoptosis	B-X
<EOS>	B-X
We	B-X
screened	B-X
a	B-X
panel	B-X
of	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
-	B-X
derived	B-X
cell	B-X
lines	B-X
for	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
responsiveness	B-X
<EOS>	B-X
Supporting	B-X
this	B-X
notion	B-X
,	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
upregulation	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
mRNA	B-X
levels	B-X
and	B-X
protein	B-X
secretion	B-X
in	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
proliferative	B-X
,	B-X
but	B-X
not	B-X
in	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
apoptotic	B-X
cell	B-X
lines	B-X

We	O
show	O
for	O
the	O
first	O
time	O
that	O
TNF-alpha-treated	B-cell_line
cell	I-cell_line
lines	I-cell_line
producing	O
no	O
or	O
only	O
minimal	O
amounts	O
of	O
GM-CSF	B-protein
demonstrate	O
an	O
apoptotic	O
phenotype	O
,	O
while	O
cell	O
lines	O
with	O
high	O
GM-CSF	B-protein
expression	O
rates	O
can	O
escape	O
from	O
growth	O
arrest	O
or	O
even	O
apoptosis	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
use	B-X
in	B-X
vivo	B-X
mouse	B-X
models	B-X
of	B-X
syngeneic	B-X
pancreatic	B-X
cancer	B-X
that	B-X
generate	B-X
endogenous	B-X
T	B-X
cell	B-X
responses	B-X
ranging	B-X
from	B-X
moderate	B-X
to	B-X
poor	B-X
<EOS>	B-X
Myeloproliferative	B-X
neoplasms	B-X
(	B-X
MPNs	B-X
)	B-X
are	B-X
hematologic	B-X
malignancies	B-X
characterized	B-X
by	B-X
gene	B-X
mutations	B-X
that	B-X
promote	B-X
myeloproliferation	B-X
and	B-X
resistance	B-X
to	B-X
apoptosis	B-X
via	B-X
constitutively	B-X
active	B-X
signaling	B-X
pathways	B-X
,	B-X
with	B-X
Janus	B-X
kinase	B-X
2	B-X
-	B-X
signal	B-X
transducers	B-X
and	B-X
the	B-X
activators	B-X
of	B-X
transcription	B-X
(	B-X
JAK	B-X
-	B-X
STAT	B-X
)	B-X
axis	B-X
as	B-X
a	B-X
core	B-X
part	B-X
<EOS>	B-X
Almost	B-X
half	B-X
of	B-X
these	B-X
patients	B-X
had	B-X
been	B-X
previously	B-X
diagnosed	B-X
with	B-X
more	B-X
common	B-X
rheumatologic	B-X
entities	B-X
(	B-X
such	B-X
as	B-X
Behcet	B-X
's	B-X
Disease	B-X
;	B-X
BD	B-X
)	B-X
prior	B-X
to	B-X
the	B-X
discovery	B-X
of	B-X
their	B-X
pathogenic	B-X
RELA	B-X
variants	B-X
<EOS>	B-X
One	B-X
part	B-X
from	B-X
tumor	B-X
tissues	B-X
was	B-X
prepared	B-X
for	B-X
assessment	B-X
of	B-X
multidrug	B-X
resistance	B-X
protein	B-X
-	B-X
1	B-X
(	B-X
MDR	B-X
-	B-X
1	B-X
)	B-X
,	B-X
caspase	B-X
-	B-X
3	B-X
,	B-X
reduced	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
and	B-X
malondialdehyde	B-X
(	B-X
MDA	B-X
)	B-X
,	B-X
while	B-X
the	B-X
other	B-X
part	B-X
was	B-X
processed	B-X
for	B-X
histopathological	B-X
examination	B-X
and	B-X
immunohistochemical	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
Ki	B-X
-	B-X
67	B-X

In	O
this	O
context	O
,	O
we	O
discuss	O
arguments	O
pointing	O
at	O
NF-kappaB	B-protein
as	O
regulator	O
of	O
GM-CSF	B-protein
synthesis	O
and	O
thus	O
indirectly	O
as	O
regulator	O
for	O
the	O
escape	O
of	O
TNF-alpha	B-protein
-induced	O
apoptosis	O
<EOS>	B-X
In	B-X
this	B-X
context	B-X
,	B-X
we	B-X
discuss	B-X
arguments	B-X
pointing	B-X
at	B-X
NF	B-X
-	B-X
kappaB	B-X
as	B-X
regulator	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
synthesis	B-X
and	B-X
thus	B-X
indirectly	B-X
as	B-X
regulator	B-X
for	B-X
the	B-X
escape	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
induced	B-X
apoptosis	B-X
<EOS>	B-X
These	B-X
data	B-X
identify	B-X
GM	B-X
-	B-X
CSF	B-X
synthesis	B-X
as	B-X
an	B-X
early	B-X
and	B-X
essential	B-X
step	B-X
in	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
-	B-X
induced	B-X
proliferation	B-X
<EOS>	B-X
We	B-X
show	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
TNF	B-X
-	B-X
alpha	B-X
-	B-X
treated	B-X
cell	B-X
lines	B-X
producing	B-X
no	B-X
or	B-X
only	B-X
minimal	B-X
amounts	B-X
of	B-X
GM	B-X
-	B-X
CSF	B-X
demonstrate	B-X
an	B-X
apoptotic	B-X
phenotype	B-X
,	B-X
while	B-X
cell	B-X
lines	B-X
with	B-X
high	B-X
GM	B-X
-	B-X
CSF	B-X
expression	B-X
rates	B-X
can	B-X
escape	B-X
from	B-X
growth	B-X
arrest	B-X
or	B-X
even	B-X
apoptosis	B-X
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
,	B-X
TNF	B-X
-	B-X
	B-X
alpha	B-X
did	B-X
not	B-X
activate	B-X
the	B-X
MAP	B-X
kinase	B-X
and	B-X
p70S6	B-X
kinase	B-X
pathways	B-X

Glucocorticoid	B-protein
receptor	I-protein
content	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
:	O
evidence	O
for	O
heterogeneity	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
content	B-X
of	B-X
T	B-X
lymphocytes	B-X
:	B-X
evidence	B-X
for	B-X
heterogeneity	B-X
.	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
were	B-X
measured	B-X
in	B-X
T	B-X
lymphocytes	B-X
that	B-X
were	B-X
isolated	B-X
from	B-X
peripheral	B-X
blood	B-X
by	B-X
either	B-X
nylon	B-X
wool	B-X
filtration	B-X
or	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
<EOS>	B-X
2	B-X
fmol	B-X
of	B-X
dexamethasone	B-X
per	B-X
million	B-X
cells	B-X
(	B-X
equivalent	B-X
to	B-X
4000	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
200	B-X
receptors	B-X
per	B-X
cell	B-X
)	B-X
,	B-X
whereas	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
bind	B-X
12	B-X
<EOS>	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
following	B-X
by	B-X
nylon	B-X
wool	B-X
filtration	B-X
bind	B-X
less	B-X
dexamethasone	B-X
than	B-X
do	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
alone	B-X

Glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
either	O
nylon	O
wool	O
filtration	O
or	O
E-rosette	O
sedimentation	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
were	B-X
measured	B-X
in	B-X
T	B-X
lymphocytes	B-X
that	B-X
were	B-X
isolated	B-X
from	B-X
peripheral	B-X
blood	B-X
by	B-X
either	B-X
nylon	B-X
wool	B-X
filtration	B-X
or	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
<EOS>	B-X
Peripheral	B-X
T	B-X
lymphocytes	B-X
were	B-X
isolated	B-X
from	B-X
normal	B-X
adult	B-X
peripheral	B-X
blood	B-X
by	B-X
E	B-X
rosette	B-X
sedimentation	B-X
<EOS>	B-X
The	B-X
T	B-X
cells	B-X
were	B-X
separated	B-X
from	B-X
the	B-X
null	B-X
cells	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
content	B-X
of	B-X
T	B-X
lymphocytes	B-X
:	B-X
evidence	B-X
for	B-X
heterogeneity	B-X
.	B-X

T	B-cell_type
cells	I-cell_type
isolated	O
by	O
nylon	O
wool	O
filtration	O
specifically	O
bind	O
6.7	O
+/-	O
0.2	O
fmol	O
of	O
dexamethasone	O
per	O
million	O
cells	O
(	O
equivalent	O
to	O
4000	O
+/-	O
200	O
receptors	O
per	O
cell	O
)	O
,	O
whereas	O
T	B-cell_type
cells	I-cell_type
isolated	O
by	O
E-rosette	O
sedimentation	O
bind	O
12.0	O
+/-	O
0.7	O
fmol	O
of	O
dexamethasone	O
per	O
million	O
cells	O
(	O
equivalent	O
to	O
7200	O
+/-	O
400	O
receptors	O
per	O
cell	O
)	O
.	O
<EOS>	B-X
2	B-X
fmol	B-X
of	B-X
dexamethasone	B-X
per	B-X
million	B-X
cells	B-X
(	B-X
equivalent	B-X
to	B-X
4000	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
200	B-X
receptors	B-X
per	B-X
cell	B-X
)	B-X
,	B-X
whereas	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
bind	B-X
12	B-X
<EOS>	B-X
T	B-X
cells	B-X
that	B-X
are	B-X
isolated	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
nylon	B-X
wool	B-X
filtration	B-X
followed	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
bind	B-X
the	B-X
same	B-X
amount	B-X
of	B-X
dexamethasone	B-X
as	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
nylon	B-X
wool	B-X
filtration	B-X
alone	B-X
<EOS>	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
following	B-X
by	B-X
nylon	B-X
wool	B-X
filtration	B-X
bind	B-X
less	B-X
dexamethasone	B-X
than	B-X
do	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
alone	B-X
<EOS>	B-X
Isolation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
enriches	B-X
for	B-X
T	B-X
cells	B-X
that	B-X
have	B-X
a	B-X
greater	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
,	B-X
and	B-X
isolation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
nylon	B-X
wool	B-X
filtration	B-X
enriches	B-X
for	B-X
T	B-X
cells	B-X
that	B-X
have	B-X
a	B-X
lesser	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X

This	O
difference	O
in	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
by	O
the	O
two	O
T	O
cell	O
preparations	O
was	O
significant	O
(	O
p	O
less	O
than	O
.001	O
)	O
and	O
was	O
present	O
immediately	O
after	O
cell	O
isolation	O
.	O
<EOS>	B-X
This	B-X
difference	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
by	B-X
the	B-X
two	B-X
T	B-X
cell	B-X
preparations	B-X
was	B-X
significant	B-X
(	B-X
p	B-X
less	B-X
than	B-X
<EOS>	B-X
The	B-X
binding	B-X
affinities	B-X
of	B-X
the	B-X
different	B-X
T	B-X
cell	B-X
preparations	B-X
for	B-X
dexamethasone	B-X
were	B-X
similar	B-X
<EOS>	B-X
7	B-X
fmol	B-X
of	B-X
dexamethasone	B-X
per	B-X
million	B-X
cells	B-X
(	B-X
equivalent	B-X
to	B-X
7200	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
400	B-X
receptors	B-X
per	B-X
cell	B-X
)	B-X
<EOS>	B-X
001	B-X
)	B-X
and	B-X
was	B-X
present	B-X
immediately	B-X
after	B-X
cell	B-X
isolation	B-X

The	O
binding	O
affinities	O
of	O
the	O
different	O
T	B-cell_line
cell	I-cell_line
preparations	I-cell_line
for	O
dexamethasone	O
were	O
similar	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
affinities	B-X
of	B-X
the	B-X
different	B-X
T	B-X
cell	B-X
preparations	B-X
for	B-X
dexamethasone	B-X
were	B-X
similar	B-X
<EOS>	B-X
This	B-X
difference	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
dexamethasone	B-X
bound	B-X
by	B-X
the	B-X
two	B-X
T	B-X
cell	B-X
preparations	B-X
was	B-X
significant	B-X
(	B-X
p	B-X
less	B-X
than	B-X
<EOS>	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
following	B-X
by	B-X
nylon	B-X
wool	B-X
filtration	B-X
bind	B-X
less	B-X
dexamethasone	B-X
than	B-X
do	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
alone	B-X
<EOS>	B-X
T	B-X
cells	B-X
that	B-X
are	B-X
isolated	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
nylon	B-X
wool	B-X
filtration	B-X
followed	B-X
by	B-X
E	B-X
-	B-X
rosette	B-X
sedimentation	B-X
bind	B-X
the	B-X
same	B-X
amount	B-X
of	B-X
dexamethasone	B-X
as	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
nylon	B-X
wool	B-X
filtration	B-X
alone	B-X

T	O
cells	O
that	O
are	O
isolated	O
by	O
a	O
combination	O
of	O
nylon	O
wool	O
filtration	O
followed	O
by	O
E-rosette	O
sedimentation	O
bind	O
the	O
same	O
amount	O
of	O
dexamethasone	O
as	O
T	B-cell_type
cells	I-cell_type
isolated	O
by	O
nylon	O
wool	O
filtration	O
alone	O
.	O

T	B-cell_type
cells	I-cell_type
isolated	O
by	O
a	O
combination	O
of	O
E-rosette	O
sedimentation	O
following	O
by	O
nylon	O
wool	O
filtration	O
bind	O
less	O
dexamethasone	O
than	O
do	O
T	B-cell_type
cells	I-cell_type
isolated	O
by	O
E-rosette	O
sedimentation	O
alone	O
.	O

These	O
findings	O
suggest	O
that	O
T	B-cell_type
cells	I-cell_type
are	O
heterogeneous	O
with	O
respect	O
to	O
their	O
quantity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Isolation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
E-rosette	O
sedimentation	O
enriches	O
for	O
T	B-cell_type
cells	I-cell_type
that	O
have	O
a	O
greater	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
,	O
and	O
isolation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
nylon	O
wool	O
filtration	O
enriches	O
for	O
T	B-cell_type
cells	I-cell_type
that	O
have	O
a	O
lesser	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Glucocorticoid	B-protein
receptors	I-protein
and	O
glucocorticoid	O
sensitivity	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
RCAN1	B-X
is	B-X
an	B-X
important	B-X
mediator	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
apoptosis	B-X
in	B-X
human	B-X
leukemic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Inherited	B-X
genetic	B-X
variants	B-X
associated	B-X
with	B-X
glucocorticoid	B-X
sensitivity	B-X
in	B-X
leukaemia	B-X
cells	B-X
.	B-X
<EOS>	B-X
Protein	B-X
kinase	B-X
A	B-X
,	B-X
not	B-X
Epac	B-X
,	B-X
suppresses	B-X
hedgehog	B-X
activity	B-X
and	B-X
regulates	B-X
glucocorticoid	B-X
sensitivity	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cells	B-X
.	B-X
<EOS>	B-X
c	B-X
-	B-X
Myb	B-X
interacts	B-X
with	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
regulates	B-X
its	B-X
level	B-X
in	B-X
pre	B-X
-	B-X
B	B-X
-	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cells	B-X
.	B-X

We	O
have	O
established	O
optimal	O
conditions	O
for	O
the	O
measurement	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
human	B-cell_type
white	I-cell_type
cells	I-cell_type
using	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	O
as	O
the	O
ligand	O
,	O
and	O
the	O
subsequent	O
determination	O
of	O
the	O
GR	B-protein
content	O
in	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
and	O
in	O
leukemic	B-cell_type
cells	I-cell_type
of	O
patients	O
with	O
various	O
forms	O
of	O
acute	O
and	O
chronic	O
leukemia	O
.	O

A	O
number	O
of	O
leukemia	B-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
continuous	O
culture	O
were	O
also	O
subjected	O
to	O
the	O
GR	B-protein
assay	O
,	O
and	O
the	O
results	O
were	O
correlated	O
with	O
the	O
sensitivity	O
of	O
these	O
cell	B-cell_line
lines	I-cell_line
to	O
glucocorticoid	O
steroids	O
in	O
vitro	O
.	O

The	O
GR	B-protein
content	O
of	O
normal	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
amounted	O
to	O
4	O
,	O
850	O
+/-	O
1	O
,	O
340	O
(	O
mean	O
+/-	O
SD	O
)	O
receptors/cell	O
.	O
<EOS>	B-X
The	B-X
GR	B-X
content	B-X
of	B-X
normal	B-X
human	B-X
lymphocytes	B-X
amounted	B-X
to	B-X
4,850	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
1,340	B-X
(	B-X
mean	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
SD	B-X
)	B-X
receptors	B-X
/	B-X
cell	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
GR	B-X
is	B-X
probably	B-X
a	B-X
universal	B-X
feature	B-X
of	B-X
the	B-X
leukemic	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
from	B-X
a	B-X
clinical	B-X
standpoint	B-X
,	B-X
probably	B-X
does	B-X
not	B-X
alone	B-X
imply	B-X
steroid	B-X
responsiveness	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
apparent	B-X
correlation	B-X
between	B-X
the	B-X
GR	B-X
concentration	B-X
and	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cells	B-X
in	B-X
vitro	B-X
to	B-X
glucocorticoids	B-X
as	B-X
judged	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
studies	B-X
<EOS>	B-X
Steroidal	B-X
compounds	B-X
with	B-X
a	B-X
known	B-X
glucocorticoid	B-X
potency	B-X
effectively	B-X
competed	B-X
for	B-X
the	B-X
binding	B-X
,	B-X
whereas	B-X
steroids	B-X
devoid	B-X
of	B-X
glucocorticoid	B-X
activity	B-X
(	B-X
e	B-X

The	O
mean	O
equilibrium	O
dissociation	O
constant	O
(	O
KD	O
)	O
of	O
the	O
interaction	O
of	O
[	O
3H	O
]	O
dexamethasone	O
with	O
the	O
GR	B-protein
was	O
1.2	O
x	O
10	O
(	O
-8	O
)	O
M	O
.	O
<EOS>	B-X
The	B-X
mean	B-X
equilibrium	B-X
dissociation	B-X
constant	B-X
(	B-X
KD	B-X
)	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
with	B-X
the	B-X
GR	B-X
was	B-X
1	B-X
<EOS>	B-X
A	B-X
number	B-X
of	B-X
leukemia	B-X
cell	B-X
lines	B-X
in	B-X
continuous	B-X
culture	B-X
were	B-X
also	B-X
subjected	B-X
to	B-X
the	B-X
GR	B-X
assay	B-X
,	B-X
and	B-X
the	B-X
results	B-X
were	B-X
correlated	B-X
with	B-X
the	B-X
sensitivity	B-X
of	B-X
these	B-X
cell	B-X
lines	B-X
to	B-X
glucocorticoid	B-X
steroids	B-X
in	B-X
vitro	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
apparent	B-X
correlation	B-X
between	B-X
the	B-X
GR	B-X
concentration	B-X
and	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cells	B-X
in	B-X
vitro	B-X
to	B-X
glucocorticoids	B-X
as	B-X
judged	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
studies	B-X
<EOS>	B-X
GR	B-X
was	B-X
identified	B-X
in	B-X
all	B-X
the	B-X
12	B-X
malignant	B-X
continuous	B-X
white	B-X
cell	B-X
lines	B-X
studied	B-X

Steroidal	O
compounds	O
with	O
a	O
known	O
glucocorticoid	O
potency	O
effectively	O
competed	O
for	O
the	O
binding	O
,	O
whereas	O
steroids	O
devoid	O
of	O
glucocorticoid	O
activity	O
(	O
e.g.	O
estradiol-17	O
beta	O
and	O
testosterone	O
)	O
were	O
ineffective	O
.	O
<EOS>	B-X
Steroidal	B-X
compounds	B-X
with	B-X
a	B-X
known	B-X
glucocorticoid	B-X
potency	B-X
effectively	B-X
competed	B-X
for	B-X
the	B-X
binding	B-X
,	B-X
whereas	B-X
steroids	B-X
devoid	B-X
of	B-X
glucocorticoid	B-X
activity	B-X
(	B-X
e	B-X
<EOS>	B-X
We	B-X
have	B-X
established	B-X
optimal	B-X
conditions	B-X
for	B-X
the	B-X
measurement	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
GR	B-X
)	B-X
in	B-X
human	B-X
white	B-X
cells	B-X
using	B-X
a	B-X
whole	B-X
-	B-X
cell	B-X
binding	B-X
assay	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
as	B-X
the	B-X
ligand	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
determination	B-X
of	B-X
the	B-X
GR	B-X
content	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
patients	B-X
with	B-X
various	B-X
forms	B-X
of	B-X
acute	B-X
and	B-X
chronic	B-X
leukemia	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
apparent	B-X
correlation	B-X
between	B-X
the	B-X
GR	B-X
concentration	B-X
and	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cells	B-X
in	B-X
vitro	B-X
to	B-X
glucocorticoids	B-X
as	B-X
judged	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
studies	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
GR	B-X
is	B-X
probably	B-X
a	B-X
universal	B-X
feature	B-X
of	B-X
the	B-X
leukemic	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
from	B-X
a	B-X
clinical	B-X
standpoint	B-X
,	B-X
probably	B-X
does	B-X
not	B-X
alone	B-X
imply	B-X
steroid	B-X
responsiveness	B-X

The	O
GR	B-protein
content	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
obtained	O
from	O
eight	O
patients	O
suffering	O
from	O
acute	O
leukemia	O
and	O
four	O
patients	O
with	O
a	O
blast	O
crisis	O
of	O
chronic	O
myelocytic	O
leukemia	O
was	O
found	O
to	O
be	O
highly	O
variable	O
(	O
3	O
,	O
230-29	O
,	O
900	O
receptors/cell	O
)	O
,	O
while	O
the	O
lymphocytes	B-cell_type
of	O
six	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
contained	O
a	O
rather	O
stable	O
GR	B-protein
content	O
(	O
2	O
,	O
930-5	O
,	O
120	O
receptors/cell	O
)	O
,	O
which	O
was	O
comparable	O
with	O
that	O
of	O
normal	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
The	B-X
GR	B-X
content	B-X
of	B-X
the	B-X
blast	B-X
cells	B-X
obtained	B-X
from	B-X
eight	B-X
patients	B-X
suffering	B-X
from	B-X
acute	B-X
leukemia	B-X
and	B-X
four	B-X
patients	B-X
with	B-X
a	B-X
blast	B-X
crisis	B-X
of	B-X
chronic	B-X
myelocytic	B-X
leukemia	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highly	B-X
variable	B-X
(	B-X
3,230	B-X
-	B-X
29,900	B-X
receptors	B-X
/	B-X
cell	B-X
)	B-X
,	B-X
while	B-X
the	B-X
lymphocytes	B-X
of	B-X
six	B-X
patients	B-X
with	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
contained	B-X
a	B-X
rather	B-X
stable	B-X
GR	B-X
content	B-X
(	B-X
2,930	B-X
-	B-X
5,120	B-X
receptors	B-X
/	B-X
cell	B-X
)	B-X
,	B-X
which	B-X
was	B-X
comparable	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
lymphocytes	B-X
<EOS>	B-X
A	B-X
number	B-X
of	B-X
leukemia	B-X
cell	B-X
lines	B-X
in	B-X
continuous	B-X
culture	B-X
were	B-X
also	B-X
subjected	B-X
to	B-X
the	B-X
GR	B-X
assay	B-X
,	B-X
and	B-X
the	B-X
results	B-X
were	B-X
correlated	B-X
with	B-X
the	B-X
sensitivity	B-X
of	B-X
these	B-X
cell	B-X
lines	B-X
to	B-X
glucocorticoid	B-X
steroids	B-X
in	B-X
vitro	B-X
<EOS>	B-X
We	B-X
have	B-X
established	B-X
optimal	B-X
conditions	B-X
for	B-X
the	B-X
measurement	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
GR	B-X
)	B-X
in	B-X
human	B-X
white	B-X
cells	B-X
using	B-X
a	B-X
whole	B-X
-	B-X
cell	B-X
binding	B-X
assay	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
as	B-X
the	B-X
ligand	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
determination	B-X
of	B-X
the	B-X
GR	B-X
content	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
patients	B-X
with	B-X
various	B-X
forms	B-X
of	B-X
acute	B-X
and	B-X
chronic	B-X
leukemia	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
GR	B-X
is	B-X
probably	B-X
a	B-X
universal	B-X
feature	B-X
of	B-X
the	B-X
leukemic	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
from	B-X
a	B-X
clinical	B-X
standpoint	B-X
,	B-X
probably	B-X
does	B-X
not	B-X
alone	B-X
imply	B-X
steroid	B-X
responsiveness	B-X

GR	B-protein
was	O
identified	O
in	O
all	O
the	O
12	O
malignant	B-cell_line
continuous	I-cell_line
white	I-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
.	O
<EOS>	B-X
GR	B-X
was	B-X
identified	B-X
in	B-X
all	B-X
the	B-X
12	B-X
malignant	B-X
continuous	B-X
white	B-X
cell	B-X
lines	B-X
studied	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
apparent	B-X
correlation	B-X
between	B-X
the	B-X
GR	B-X
concentration	B-X
and	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cells	B-X
in	B-X
vitro	B-X
to	B-X
glucocorticoids	B-X
as	B-X
judged	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
studies	B-X
<EOS>	B-X
estradiol	B-X
-	B-X
17	B-X
beta	B-X
and	B-X
testosterone	B-X
)	B-X
were	B-X
ineffective	B-X
<EOS>	B-X
The	B-X
mean	B-X
equilibrium	B-X
dissociation	B-X
constant	B-X
(	B-X
KD	B-X
)	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
with	B-X
the	B-X
GR	B-X
was	B-X
1	B-X

Large	O
cells	O
contained	O
more	O
GR	B-protein
than	O
the	O
smaller	O
ones	O
.	O

There	O
was	O
no	O
apparent	O
correlation	O
between	O
the	O
GR	B-protein
concentration	O
and	O
the	O
sensitivity	O
of	O
the	O
cells	O
in	O
vitro	O
to	O
glucocorticoids	O
as	O
judged	O
by	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
studies	O
.	O
<EOS>	B-X
There	B-X
was	B-X
no	B-X
apparent	B-X
correlation	B-X
between	B-X
the	B-X
GR	B-X
concentration	B-X
and	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cells	B-X
in	B-X
vitro	B-X
to	B-X
glucocorticoids	B-X
as	B-X
judged	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
studies	B-X
<EOS>	B-X
The	B-X
mean	B-X
equilibrium	B-X
dissociation	B-X
constant	B-X
(	B-X
KD	B-X
)	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
with	B-X
the	B-X
GR	B-X
was	B-X
1	B-X
<EOS>	B-X
Distribution	B-X
of	B-X
the	B-X
surface	B-X
markers	B-X
in	B-X
the	B-X
leukemic	B-X
cell	B-X
lines	B-X
did	B-X
not	B-X
relate	B-X
to	B-X
the	B-X
GR	B-X
concentration	B-X
<EOS>	B-X
GR	B-X
was	B-X
identified	B-X
in	B-X
all	B-X
the	B-X
12	B-X
malignant	B-X
continuous	B-X
white	B-X
cell	B-X
lines	B-X
studied	B-X

Distribution	O
of	O
the	O
surface	O
markers	O
in	O
the	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
did	O
not	O
relate	O
to	O
the	O
GR	B-protein
concentration	O
.	O
<EOS>	B-X
Distribution	B-X
of	B-X
the	B-X
surface	B-X
markers	B-X
in	B-X
the	B-X
leukemic	B-X
cell	B-X
lines	B-X
did	B-X
not	B-X
relate	B-X
to	B-X
the	B-X
GR	B-X
concentration	B-X
<EOS>	B-X
Leukemic	B-X
distribution	B-X
of	B-X
a	B-X
human	B-X
acute	B-X
lymphocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
(	B-X
Ichikawa	B-X
strain	B-X
)	B-X
in	B-X
nude	B-X
mice	B-X
conditioned	B-X
with	B-X
whole	B-X
-	B-X
body	B-X
irradiation	B-X
.	B-X
<EOS>	B-X
The	B-X
pattern	B-X
of	B-X
uPAR	B-X
expression	B-X
on	B-X
leukemic	B-X
cell	B-X
lines	B-X
was	B-X
also	B-X
studied	B-X
on	B-X
bone	B-X
marrow	B-X
blast	B-X
cells	B-X
from	B-X
leukemic	B-X
patients	B-X
<EOS>	B-X
PMA	B-X
stimulation	B-X
induced	B-X
surface	B-X
expression	B-X
of	B-X
uPAR	B-X
in	B-X
lymphocytes	B-X
but	B-X
did	B-X
not	B-X
induce	B-X
expression	B-X
of	B-X
LRP	B-X
by	B-X
these	B-X
cells	B-X

We	O
conclude	O
that	O
the	O
presence	O
of	O
GR	B-protein
is	O
probably	O
a	O
universal	O
feature	O
of	O
the	O
leukemic	B-cell_type
cells	I-cell_type
,	O
and	O
,	O
from	O
a	O
clinical	O
standpoint	O
,	O
probably	O
does	O
not	O
alone	O
imply	O
steroid	O
responsiveness	O
.	O

Evidence	O
for	O
a	O
steroid	B-protein
receptor	I-protein
in	O
rheumatoid	B-cell_type
synovial	I-cell_type
tissue	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Evidence	B-X
for	B-X
a	B-X
steroid	B-X
receptor	B-X
in	B-X
rheumatoid	B-X
synovial	B-X
tissue	B-X
cells	B-X
.	B-X
<EOS>	B-X
Evidence	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
androgen	B-X
receptors	B-X
in	B-X
the	B-X
synovial	B-X
tissue	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
patients	B-X
and	B-X
healthy	B-X
controls	B-X
.	B-X
<EOS>	B-X
Endocrine	B-X
end	B-X
-	B-X
points	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
<EOS>	B-X
A	B-X
role	B-X
for	B-X
sex	B-X
steroids	B-X
in	B-X
autoimmune	B-X
diseases	B-X
:	B-X
a	B-X
working	B-X
hypothesis	B-X
and	B-X
supporting	B-X
data	B-X
.	B-X

One	O
mechanism	O
by	O
which	O
glucocorticoids	O
could	O
exert	O
their	O
anti-inflammatory	O
action	O
is	O
via	O
rapidly	O
saturable	O
,	O
stereo-specific	B-protein
cytoplasmic	I-protein
protein	I-protein
receptors	I-protein
.	O
<EOS>	B-X
One	B-X
mechanism	B-X
by	B-X
which	B-X
glucocorticoids	B-X
could	B-X
exert	B-X
their	B-X
anti	B-X
-	B-X
inflammatory	B-X
action	B-X
is	B-X
via	B-X
rapidly	B-X
saturable	B-X
,	B-X
stereo	B-X
-	B-X
specific	B-X
cytoplasmic	B-X
protein	B-X
receptors	B-X
<EOS>	B-X
These	B-X
,	B-X
together	B-X
with	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
fluid	B-X
aspirated	B-X
from	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
were	B-X
identified	B-X
by	B-X
electron	B-X
microscopy	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
proportion	B-X
of	B-X
steroid	B-X
bound	B-X
to	B-X
whole	B-X
cells	B-X
showed	B-X
evidence	B-X
for	B-X
specific	B-X
,	B-X
rapidly	B-X
saturable	B-X
,	B-X
receptors	B-X
in	B-X
the	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
tissue	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
found	B-X
in	B-X
synovial	B-X
fluid	B-X
cells	B-X
<EOS>	B-X
We	B-X
concluded	B-X
from	B-X
this	B-X
,	B-X
that	B-X
one	B-X
or	B-X
more	B-X
of	B-X
the	B-X
cell	B-X
types	B-X
present	B-X
in	B-X
synovial	B-X
tissue	B-X
contain	B-X
a	B-X
specific	B-X
steroid	B-X
receptor	B-X
,	B-X
but	B-X
that	B-X
this	B-X
is	B-X
lacking	B-X
in	B-X
synovial	B-X
fluid	B-X
polymorphonuclear	B-X
leucocytes	B-X

This	O
report	O
is	O
of	O
an	O
investigation	O
into	O
such	O
a	O
possibility	O
in	O
synovial	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Molecular	B-X
investigation	B-X
ruled	B-X
out	B-X
synovial	B-X
sarcoma	B-X
<EOS>	B-X
Further	B-X
clinical	B-X
investigations	B-X
are	B-X
clearly	B-X
warranted	B-X
<EOS>	B-X
Persistent	B-X
parvovirus	B-X
B19	B-X
infection	B-X
in	B-X
non	B-X
-	B-X
erythroid	B-X
tissues	B-X
:	B-X
possible	B-X
role	B-X
in	B-X
the	B-X
inflammatory	B-X
and	B-X
disease	B-X
process	B-X
.	B-X
<EOS>	B-X
Chondrocyte	B-X
proliferation	B-X
,	B-X
evaluated	B-X
by	B-X
measuring	B-X
total	B-X
DNA	B-X
content	B-X
,	B-X
was	B-X
prolongated	B-X
by	B-X
periosteal	B-X
and	B-X
synovial	B-X
explants	B-X

Synovium	O
,	O
obtained	O
from	O
knee	O
joints	O
of	O
rheumatoid	O
patients	O
undergoing	O
surgery	O
,	O
was	O
incubated	O
with	O
clostridiopeptidase	B-protein
A	I-protein
and	O
trypsin-EDTA	B-protein
to	O
obtain	O
cell	O
suspensions	O
.	O
<EOS>	B-X
Synovium	B-X
,	B-X
obtained	B-X
from	B-X
knee	B-X
joints	B-X
of	B-X
rheumatoid	B-X
patients	B-X
undergoing	B-X
surgery	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
clostridiopeptidase	B-X
A	B-X
and	B-X
trypsin	B-X
-	B-X
EDTA	B-X
to	B-X
obtain	B-X
cell	B-X
suspensions	B-X
<EOS>	B-X
This	B-X
report	B-X
is	B-X
of	B-X
an	B-X
investigation	B-X
into	B-X
such	B-X
a	B-X
possibility	B-X
in	B-X
synovial	B-X
cells	B-X
<EOS>	B-X
However	B-X
,	B-X
in	B-X
synovial	B-X
fluid	B-X
cell	B-X
type	B-X
polymorphonuclear	B-X
leucocytes	B-X
were	B-X
the	B-X
predominant	B-X
cell	B-X
type	B-X
<EOS>	B-X
Evidence	B-X
for	B-X
a	B-X
steroid	B-X
receptor	B-X
in	B-X
rheumatoid	B-X
synovial	B-X
tissue	B-X
cells	B-X
.	B-X

These	O
,	O
together	O
with	O
cells	O
obtained	O
from	O
synovial	O
fluid	O
aspirated	O
from	O
patients	O
with	O
rheumatoid	O
arthritis	O
,	O
were	O
identified	O
by	O
electron	O
microscopy	O
.	O
<EOS>	B-X
These	B-X
,	B-X
together	B-X
with	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
fluid	B-X
aspirated	B-X
from	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
were	B-X
identified	B-X
by	B-X
electron	B-X
microscopy	B-X
<EOS>	B-X
Electron	B-X
micrographs	B-X
showed	B-X
that	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
tissue	B-X
consisted	B-X
of	B-X
synovial	B-X
fibroblast	B-X
	B-X
-	B-X
	B-X
and	B-X
macrophage	B-X
-	B-X
types	B-X
,	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
and	B-X
macrophages	B-X
<EOS>	B-X
However	B-X
,	B-X
in	B-X
synovial	B-X
fluid	B-X
cell	B-X
type	B-X
polymorphonuclear	B-X
leucocytes	B-X
were	B-X
the	B-X
predominant	B-X
cell	B-X
type	B-X
<EOS>	B-X
We	B-X
concluded	B-X
from	B-X
this	B-X
,	B-X
that	B-X
one	B-X
or	B-X
more	B-X
of	B-X
the	B-X
cell	B-X
types	B-X
present	B-X
in	B-X
synovial	B-X
tissue	B-X
contain	B-X
a	B-X
specific	B-X
steroid	B-X
receptor	B-X
,	B-X
but	B-X
that	B-X
this	B-X
is	B-X
lacking	B-X
in	B-X
synovial	B-X
fluid	B-X
polymorphonuclear	B-X
leucocytes	B-X

Duplicate	O
samples	O
of	O
these	O
cell	O
suspensions	O
were	O
incubated	O
with	O
increasing	O
concentrations	O
of	O
H3Dexamethasone	O
(	O
1	O
x	O
10	O
(	O
-10	O
)	O
M-1	O
x	O
10	O
(	O
-9	O
)	O
M	O
)	O
for	O
30	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O
<EOS>	B-X
Duplicate	B-X
samples	B-X
of	B-X
these	B-X
cell	B-X
suspensions	B-X
were	B-X
incubated	B-X
with	B-X
increasing	B-X
concentrations	B-X
of	B-X
H3Dexamethasone	B-X
(	B-X
1	B-X
x	B-X
10	B-X
(	B-X
	B-X
-	B-X
10	B-X
)	B-X
M	B-X
-	B-X
1	B-X
x	B-X
10	B-X
(	B-X
	B-X
-	B-X
9	B-X
)	B-X
M	B-X
)	B-X
for	B-X
30	B-X
minutes	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
proportion	B-X
of	B-X
steroid	B-X
bound	B-X
to	B-X
whole	B-X
cells	B-X
showed	B-X
evidence	B-X
for	B-X
specific	B-X
,	B-X
rapidly	B-X
saturable	B-X
,	B-X
receptors	B-X
in	B-X
the	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
tissue	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
found	B-X
in	B-X
synovial	B-X
fluid	B-X
cells	B-X
<EOS>	B-X
These	B-X
,	B-X
together	B-X
with	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
fluid	B-X
aspirated	B-X
from	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
were	B-X
identified	B-X
by	B-X
electron	B-X
microscopy	B-X
<EOS>	B-X
Synovium	B-X
,	B-X
obtained	B-X
from	B-X
knee	B-X
joints	B-X
of	B-X
rheumatoid	B-X
patients	B-X
undergoing	B-X
surgery	B-X
,	B-X
was	B-X
incubated	B-X
with	B-X
clostridiopeptidase	B-X
A	B-X
and	B-X
trypsin	B-X
-	B-X
EDTA	B-X
to	B-X
obtain	B-X
cell	B-X
suspensions	B-X

Analysis	O
of	O
the	O
proportion	O
of	O
steroid	O
bound	O
to	O
whole	B-cell_type
cells	I-cell_type
showed	O
evidence	O
for	O
specific	O
,	O
rapidly	O
saturable	O
,	O
receptors	O
in	O
the	O
cells	O
obtained	O
from	O
synovial	O
tissue	O
,	O
but	O
this	O
was	O
not	O
found	O
in	O
synovial	B-cell_type
fluid	I-cell_type
cells	I-cell_type
.	O

Electron	O
micrographs	O
showed	O
that	O
cells	O
obtained	O
from	O
synovial	O
tissue	O
consisted	O
of	O
synovial	B-cell_type
fibroblast	I-cell_type
-	O
and	O
macrophage-types	B-cell_type
,	O
lymphocytes	B-cell_type
,	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
.	O
<EOS>	B-X
Electron	B-X
micrographs	B-X
showed	B-X
that	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
tissue	B-X
consisted	B-X
of	B-X
synovial	B-X
fibroblast	B-X
	B-X
-	B-X
	B-X
and	B-X
macrophage	B-X
-	B-X
types	B-X
,	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
and	B-X
macrophages	B-X
<EOS>	B-X
These	B-X
,	B-X
together	B-X
with	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
fluid	B-X
aspirated	B-X
from	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
were	B-X
identified	B-X
by	B-X
electron	B-X
microscopy	B-X
<EOS>	B-X
We	B-X
concluded	B-X
from	B-X
this	B-X
,	B-X
that	B-X
one	B-X
or	B-X
more	B-X
of	B-X
the	B-X
cell	B-X
types	B-X
present	B-X
in	B-X
synovial	B-X
tissue	B-X
contain	B-X
a	B-X
specific	B-X
steroid	B-X
receptor	B-X
,	B-X
but	B-X
that	B-X
this	B-X
is	B-X
lacking	B-X
in	B-X
synovial	B-X
fluid	B-X
polymorphonuclear	B-X
leucocytes	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
the	B-X
proportion	B-X
of	B-X
steroid	B-X
bound	B-X
to	B-X
whole	B-X
cells	B-X
showed	B-X
evidence	B-X
for	B-X
specific	B-X
,	B-X
rapidly	B-X
saturable	B-X
,	B-X
receptors	B-X
in	B-X
the	B-X
cells	B-X
obtained	B-X
from	B-X
synovial	B-X
tissue	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
found	B-X
in	B-X
synovial	B-X
fluid	B-X
cells	B-X

Polymorphonuclear	B-cell_type
leucocytes	I-cell_type
appeared	O
to	O
be	O
absent	O
.	O
<EOS>	B-X
Chronic	B-X
inflammatory	B-X
cells	B-X
were	B-X
abundant	B-X
,	B-X
but	B-X
polymorphonuclear	B-X
leukocytes	B-X
were	B-X
notably	B-X
absent	B-X
<EOS>	B-X
By	B-X
24	B-X
hr	B-X
,	B-X
abundant	B-X
polymorphonuclear	B-X
leucocytes	B-X
and	B-X
macrophages	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
interstitial	B-X
space	B-X
as	B-X
well	B-X
as	B-X
inside	B-X
necrotic	B-X
fibers	B-X
<EOS>	B-X
Septic	B-X
complications	B-X
were	B-X
absent	B-X
<EOS>	B-X
Also	B-X
,	B-X
some	B-X
inflammatory	B-X
cells	B-X
(	B-X
mainly	B-X
polymorphonuclear	B-X
leukocytes	B-X
,	B-X
PMNs	B-X
)	B-X
present	B-X
in	B-X
the	B-X
corneal	B-X
stroma	B-X
are	B-X
enzymatically	B-X
active	B-X

However	O
,	O
in	O
synovial	B-cell_type
fluid	I-cell_type
cell	I-cell_type
type	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
were	O
the	O
predominant	O
cell	O
type	O
.	O
<EOS>	B-X
As	B-X
the	B-X
disease	B-X
worsens	B-X
and	B-X
the	B-X
cell	B-X
count	B-X
increases	B-X
,	B-X
the	B-X
polymorphonuclear	B-X
leucocyte	B-X
becomes	B-X
the	B-X
predominant	B-X
cell	B-X
type	B-X
<EOS>	B-X
Polymorphonuclear	B-X
(	B-X
PMN	B-X
)	B-X
leucocytes	B-X
were	B-X
the	B-X
predominant	B-X
cell	B-X
type	B-X
<EOS>	B-X
Monocytes	B-X
/	B-X
macrophages	B-X
were	B-X
the	B-X
predominant	B-X
cell	B-X
type	B-X
<EOS>	B-X
The	B-X
synovial	B-X
fluid	B-X
possessed	B-X
strong	B-X
chemotactic	B-X
activity	B-X
to	B-X
polymorphonuclear	B-X
leukocytes	B-X
but	B-X
rather	B-X
suppressed	B-X
one	B-X
to	B-X
monocytes	B-X

We	O
concluded	O
from	O
this	O
,	O
that	O
one	O
or	O
more	O
of	O
the	O
cell	O
types	O
present	O
in	O
synovial	O
tissue	O
contain	O
a	O
specific	B-protein
steroid	I-protein
receptor	I-protein
,	O
but	O
that	O
this	O
is	O
lacking	O
in	O
synovial	B-cell_type
fluid	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
.	O
<EOS>	B-X
We	B-X
concluded	B-X
that	B-X
the	B-X
BMI	B-X
of	B-X
PCOS	B-X
patients	B-X
had	B-X
a	B-X
negative	B-X
one	B-X
-	B-X
line	B-X
linear	B-X
correlation	B-X
with	B-X
CLBR	B-X
over	B-X
multiple	B-X
complete	B-X
cycles	B-X
<EOS>	B-X
We	B-X
concluded	B-X
that	B-X
hemin	B-X
administration	B-X
can	B-X
antagonize	B-X
the	B-X
cell	B-X
stress	B-X
induced	B-X
by	B-X
estrogen	B-X
and	B-X
progesterone	B-X
and	B-X
protect	B-X
against	B-X
the	B-X
development	B-X
of	B-X
mammary	B-X
gland	B-X
hyperplasia	B-X
via	B-X
modulation	B-X
of	B-X
Nrf2	B-X
/	B-X
HO	B-X
-	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
κB	B-X
pathways	B-X
<EOS>	B-X
We	B-X
concluded	B-X
that	B-X
in	B-X
research	B-X
on	B-X
the	B-X
mineral	B-X
status	B-X
of	B-X
the	B-X
population	B-X
,	B-X
apart	B-X
from	B-X
the	B-X
availability	B-X
of	B-X
trace	B-X
elements	B-X
in	B-X
the	B-X
environment	B-X
,	B-X
the	B-X
health	B-X
condition	B-X
of	B-X
the	B-X
studied	B-X
individuals	B-X
should	B-X
also	B-X
be	B-X
considered	B-X
<EOS>	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
many	B-X
aspects	B-X
of	B-X
the	B-X
living	B-X
actualize	B-X
codified	B-X
relations	B-X
which	B-X
incorporate	B-X
both	B-X
heteronomous	B-X
and	B-X
autonomous	B-X
traits	B-X

Glucorticoid	B-protein
receptors	I-protein
were	O
studied	O
in	O
various	O
populations	O
of	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
leukemic	B-cell_type
lymphoblasts	I-cell_type
.	O
<EOS>	B-X
Glucorticoid	B-X
receptors	B-X
were	B-X
studied	B-X
in	B-X
various	B-X
populations	B-X
of	B-X
normal	B-X
human	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
and	B-X
leukemic	B-X
lymphoblasts	B-X
<EOS>	B-X
Presence	B-X
of	B-X
receptor	B-X
is	B-X
correlated	B-X
with	B-X
in	B-X
vitro	B-X
sensitivitiy	B-X
to	B-X
glucocorticoids	B-X
and	B-X
in	B-X
vivo	B-X
response	B-X
to	B-X
therapy	B-X
<EOS>	B-X
Clinical	B-X
implications	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
Quantitative	B-X
determination	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
may	B-X
be	B-X
of	B-X
value	B-X
both	B-X
as	B-X
an	B-X
independent	B-X
prognostic	B-X
variable	B-X
and	B-X
in	B-X
suggesting	B-X
which	B-X
patients	B-X
should	B-X
receive	B-X
glucocorticoid	B-X
therapy	B-X

Normal	B-cell_type
lymphocytes	I-cell_type
contain	O
low	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
approximately	O
2	O
,	O
500	O
sites/cell	O
)	O
which	O
are	O
identical	O
in	O
T-	O
and	O
non-T-fractions	O
.	O

Phytohemagglutinin	B-protein
treatment	O
increases	O
levels	O
about	O
3-fold	O
.	O
<EOS>	B-X
Phytohemagglutinin	B-X
treatment	B-X
increases	B-X
levels	B-X
about	B-X
3	B-X
-	B-X
fold	B-X
<EOS>	B-X
Phytohemagglutinin	B-X
-	B-X
induced	B-X
IL2	B-X
mRNA	B-X
in	B-X
whole	B-X
blood	B-X
can	B-X
predict	B-X
bortezomib	B-X
-	B-X
induced	B-X
peripheral	B-X
neuropathy	B-X
for	B-X
multiple	B-X
myeloma	B-X
patients	B-X
.	B-X
<EOS>	B-X
Blood	B-X
lymphocyte	B-X
responses	B-X
were	B-X
similarly	B-X
increased	B-X
after	B-X
5	B-X
weeks	B-X
of	B-X
isolation	B-X
<EOS>	B-X
The	B-X
increased	B-X
response	B-X
found	B-X
with	B-X
the	B-X
combination	B-X
treatment	B-X
was	B-X
of	B-X
the	B-X
same	B-X
magnitude	B-X
as	B-X
that	B-X
found	B-X
with	B-X
each	B-X
stressor	B-X
alone	B-X

Leukemic	B-cell_type
lymphoblasts	I-cell_type
contain	O
larger	O
numbers	O
of	O
receptor	O
sites	O
.	O
<EOS>	B-X
Leukemic	B-X
lymphoblasts	B-X
contain	B-X
larger	B-X
numbers	B-X
of	B-X
receptor	B-X
sites	B-X
<EOS>	B-X
Normal	B-X
lymphocytes	B-X
contain	B-X
low	B-X
levels	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
approximately	B-X
2,500	B-X
sites	B-X
/	B-X
cell	B-X
)	B-X
which	B-X
are	B-X
identical	B-X
in	B-X
T	B-X
-	B-X
	B-X
and	B-X
non	B-X
-	B-X
T	B-X
-	B-X
fractions	B-X
<EOS>	B-X
Also	B-X
,	B-X
the	B-X
mean	B-X
influx	B-X
for	B-X
myeloblasts	B-X
was	B-X
fourfold	B-X
greater	B-X
than	B-X
the	B-X
mean	B-X
for	B-X
lymphoblasts	B-X
<EOS>	B-X
AraC	B-X
transport	B-X
varied	B-X
>	B-X
10	B-X
-	B-X
fold	B-X
between	B-X
leukemic	B-X
blasts	B-X
and	B-X
normal	B-X
leukocytes	B-X
,	B-X
but	B-X
transport	B-X
capacity	B-X
related	B-X
directly	B-X
to	B-X
the	B-X
number	B-X
of	B-X
nucleoside	B-X
transport	B-X
sites	B-X
on	B-X
the	B-X
cell	B-X

Presence	O
of	O
receptor	O
is	O
correlated	O
with	O
in	O
vitro	O
sensitivitiy	O
to	O
glucocorticoids	O
and	O
in	O
vivo	O
response	O
to	O
therapy	O
.	O
<EOS>	B-X
Presence	B-X
of	B-X
receptor	B-X
is	B-X
correlated	B-X
with	B-X
in	B-X
vitro	B-X
sensitivitiy	B-X
to	B-X
glucocorticoids	B-X
and	B-X
in	B-X
vivo	B-X
response	B-X
to	B-X
therapy	B-X
<EOS>	B-X
Quantity	B-X
of	B-X
receptor	B-X
is	B-X
also	B-X
correlated	B-X
with	B-X
complete	B-X
remission	B-X
duration	B-X
independently	B-X
of	B-X
leukemic	B-X
cell	B-X
type	B-X
(	B-X
T	B-X
or	B-X
null	B-X
)	B-X
,	B-X
initial	B-X
WBC	B-X
,	B-X
or	B-X
age	B-X
of	B-X
patient	B-X
<EOS>	B-X
Clinical	B-X
implications	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
Glucorticoid	B-X
receptors	B-X
were	B-X
studied	B-X
in	B-X
various	B-X
populations	B-X
of	B-X
normal	B-X
human	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
and	B-X
leukemic	B-X
lymphoblasts	B-X

Quantity	O
of	O
receptor	O
is	O
also	O
correlated	O
with	O
complete	O
remission	O
duration	O
independently	O
of	O
leukemic	B-cell_type
cell	I-cell_type
type	I-cell_type
(	O
T	O
or	O
null	O
)	O
,	O
initial	O
WBC	B-cell_type
,	O
or	O
age	O
of	O
patient	O
.	O
<EOS>	B-X
In	B-X
the	B-X
multivariate	B-X
analysis	B-X
,	B-X
age	B-X
behaved	B-X
as	B-X
an	B-X
independent	B-X
risk	B-X
variable	B-X
only	B-X
for	B-X
overall	B-X
survival	B-X
,	B-X
with	B-X
a	B-X
HR	B-X
of	B-X
2	B-X
<EOS>	B-X
Five	B-X
years	B-X
of	B-X
follow	B-X
-	B-X
up	B-X
shows	B-X
that	B-X
complete	B-X
remission	B-X
on	B-X
minimal	B-X
therapy	B-X
was	B-X
achieved	B-X
more	B-X
in	B-X
patients	B-X
who	B-X
received	B-X
Rituximab	B-X
<EOS>	B-X
Our	B-X
study	B-X
,	B-X
therefore	B-X
,	B-X
identifies	B-X
a	B-X
gap	B-X
in	B-X
implementation	B-X
of	B-X
guidelines	B-X
for	B-X
HIS	B-X
use	B-X
,	B-X
particularly	B-X
among	B-X
the	B-X
medically	B-X
treated	B-X
ACS	B-X
patients	B-X
<EOS>	B-X
We	B-X
present	B-X
two	B-X
cases	B-X
of	B-X
Wilms	B-X
tumour	B-X
developing	B-X
tumour	B-X
lysis	B-X
syndrome	B-X
in	B-X
the	B-X
first	B-X
week	B-X
of	B-X
initiation	B-X
of	B-X
chemotherapy	B-X

Quantitative	O
determination	O
of	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
acute	O
lymphoblastic	O
leukemia	O
may	O
be	O
of	O
value	O
both	O
as	O
an	O
independent	O
prognostic	O
variable	O
and	O
in	O
suggesting	O
which	O
patients	O
should	O
receive	O
glucocorticoid	O
therapy	O
.	O

Functional	O
and	O
physical	O
interaction	O
of	O
protein-tyrosine	B-protein
kinases	I-protein
Fyn	I-protein
and	I-protein
Csk	I-protein
in	O
the	O
T-cell	O
signaling	O
system	O
.	O
<EOS>	B-X
Functional	B-X
and	B-X
physical	B-X
interaction	B-X
of	B-X
protein	B-X
-	B-X
tyrosine	B-X
kinases	B-X
Fyn	B-X
and	B-X
Csk	B-X
in	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
signaling	B-X
system	B-X
.	B-X
<EOS>	B-X
The	B-X
Src	B-X
-	B-X
like	B-X
protein	B-X
-	B-X
tyrosine	B-X
kinase	B-X
Fyn	B-X
is	B-X
associated	B-X
with	B-X
T	B-X
-	B-X
cell	B-X
antigen	B-X
receptor	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
normal	B-X
and	B-X
active	B-X
Fyn	B-X
stimulated	B-X
transcription	B-X
from	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
promoter	B-X
when	B-X
transfected	B-X
cells	B-X
were	B-X
stimulated	B-X
by	B-X
concanavalin	B-X
A	B-X
plus	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoylphorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
<EOS>	B-X
Csk	B-X
,	B-X
which	B-X
phosphorylates	B-X
tyrosine	B-X
residues	B-X
in	B-X
the	B-X
negative	B-X
regulatory	B-X
sites	B-X
of	B-X
Src	B-X
family	B-X
kinases	B-X
,	B-X
down	B-X
-	B-X
regulated	B-X
Fyn	B-X
-	B-X
	B-X
and	B-X
Lck	B-X
-	B-X
mediated	B-X
stimulation	B-X
of	B-X
the	B-X
serum	B-X
response	B-X
element	B-X
and	B-X
Fyn	B-X
-	B-X
mediated	B-X
enhancement	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X

The	O
Src-like	B-protein
protein-tyrosine	I-protein
kinase	I-protein
Fyn	B-protein
is	O
associated	O
with	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
.	O
<EOS>	B-X
The	B-X
Src	B-X
-	B-X
like	B-X
protein	B-X
-	B-X
tyrosine	B-X
kinase	B-X
Fyn	B-X
is	B-X
associated	B-X
with	B-X
T	B-X
-	B-X
cell	B-X
antigen	B-X
receptor	B-X
<EOS>	B-X
The	B-X
Src	B-X
-	B-X
like	B-X
protein	B-X
-	B-X
tyrosine	B-X
kinases	B-X
Fyn	B-X
and	B-X
Lyn	B-X
are	B-X
expressed	B-X
in	B-X
lymphocytes	B-X
<EOS>	B-X
The	B-X
Src	B-X
-	B-X
like	B-X
protein	B-X
-	B-X
tyrosine	B-X
kinase	B-X
Lyn	B-X
is	B-X
expressed	B-X
preferentially	B-X
in	B-X
B	B-X
cells	B-X
and	B-X
is	B-X
an	B-X
intracytoplasmic	B-X
constituent	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
complex	B-X
<EOS>	B-X
Co	B-X
-	B-X
immunoprecipitation	B-X
experiments	B-X
showed	B-X
that	B-X
Fyn	B-X
was	B-X
physically	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
-	B-X
CD3	B-X
complex	B-X

Transient	O
expression	O
of	O
actively	O
mutated	O
Fyn	B-protein
,	O
having	O
Phe-528	O
instead	O
of	O
Tyr-528	O
or	O
Thr-338	O
instead	O
of	O
Ile-338	O
,	O
in	O
Jurkat	B-cell_type
T-cells	I-cell_type
stimulated	B-DNA
the	I-DNA
serum	I-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
,	O
12-O-tetradecanoyl-phorbol-13-acetate	B-DNA
response	I-DNA
element	I-DNA
,	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
,	O
and	O
c-fos	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Transient	B-X
expression	B-X
of	B-X
actively	B-X
mutated	B-X
Fyn	B-X
,	B-X
having	B-X
Phe	B-X
-	B-X
528	B-X
instead	B-X
of	B-X
Tyr	B-X
-	B-X
528	B-X
or	B-X
Thr	B-X
-	B-X
338	B-X
instead	B-X
of	B-X
Ile	B-X
-	B-X
338	B-X
,	B-X
in	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
stimulated	B-X
the	B-X
serum	B-X
response	B-X
element	B-X
(	B-X
SRE	B-X
)	B-X
,	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoyl	B-X
-	B-X
phorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
response	B-X
element	B-X
,	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
,	B-X
and	B-X
c	B-X
-	B-X
fos	B-X
promoter	B-X
<EOS>	B-X
Transient	B-X
expression	B-X
of	B-X
actively	B-X
mutated	B-X
Fyn	B-X
,	B-X
having	B-X
Phe	B-X
-	B-X
528	B-X
instead	B-X
of	B-X
Tyr	B-X
-	B-X
528	B-X
,	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
stimulated	B-X
the	B-X
fos	B-X
promoter	B-X
and	B-X
serum	B-X
response	B-X
element	B-X
(	B-X
SRE	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Fyn	B-X
kinase	B-X
stimulates	B-X
c	B-X
-	B-X
fos	B-X
expression	B-X
through	B-X
SRE	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
normal	B-X
and	B-X
active	B-X
Fyn	B-X
stimulated	B-X
transcription	B-X
from	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
promoter	B-X
when	B-X
transfected	B-X
cells	B-X
were	B-X
stimulated	B-X
by	B-X
concanavalin	B-X
A	B-X
plus	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoylphorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
<EOS>	B-X
However	B-X
,	B-X
it	B-X
could	B-X
stimulate	B-X
transcription	B-X
from	B-X
this	B-X
promoter	B-X
when	B-X
transfected	B-X
cells	B-X
were	B-X
stimulated	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
Concanavalin	B-X
A	B-X
(	B-X
ConA	B-X
)	B-X
and	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoylphorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
(	B-X
TPA	B-X
)	B-X

The	O
stimulation	O
of	O
SRE	B-DNA
was	O
particularly	O
prominent	O
not	O
only	O
with	O
active	O
Fyn	B-protein
but	O
also	O
with	O
normal	B-protein
(	I-protein
wild-type	I-protein
)	I-protein
Fyn	I-protein
.	O

SRE	B-DNA
was	O
also	O
stimulated	O
by	O
both	O
normal	B-protein
and	I-protein
active	I-protein
Lck	I-protein
.	O
<EOS>	B-X
SRE	B-X
was	B-X
also	B-X
stimulated	B-X
by	B-X
both	B-X
normal	B-X
and	B-X
active	B-X
Lck	B-X
<EOS>	B-X
Under	B-X
the	B-X
same	B-X
conditions	B-X
,	B-X
Lck	B-X
did	B-X
not	B-X
stimulate	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
unless	B-X
it	B-X
was	B-X
activated	B-X
by	B-X
mutation	B-X
<EOS>	B-X
The	B-X
stimulation	B-X
of	B-X
SRE	B-X
was	B-X
particularly	B-X
prominent	B-X
not	B-X
only	B-X
with	B-X
active	B-X
Fyn	B-X
but	B-X
also	B-X
with	B-X
normal	B-X
(	B-X
wild	B-X
-	B-X
type	B-X
)	B-X
Fyn	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
accumulating	B-X
evidence	B-X
shows	B-X
that	B-X
Fyn	B-X
and	B-X
Lck	B-X
are	B-X
involved	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X

Furthermore	O
,	O
normal	B-protein
and	I-protein
active	I-protein
Fyn	I-protein
stimulated	O
transcription	O
from	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
when	O
transfected	O
cells	O
were	O
stimulated	O
by	O
concanavalin	B-protein
A	I-protein
plus	O
12-O-tetradecanoylphorbol-13-acetate	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
normal	B-X
and	B-X
active	B-X
Fyn	B-X
stimulated	B-X
transcription	B-X
from	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
gene	B-X
promoter	B-X
when	B-X
transfected	B-X
cells	B-X
were	B-X
stimulated	B-X
by	B-X
concanavalin	B-X
A	B-X
plus	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoylphorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
<EOS>	B-X
Transient	B-X
expression	B-X
of	B-X
actively	B-X
mutated	B-X
Fyn	B-X
,	B-X
having	B-X
Phe	B-X
-	B-X
528	B-X
instead	B-X
of	B-X
Tyr	B-X
-	B-X
528	B-X
or	B-X
Thr	B-X
-	B-X
338	B-X
instead	B-X
of	B-X
Ile	B-X
-	B-X
338	B-X
,	B-X
in	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
stimulated	B-X
the	B-X
serum	B-X
response	B-X
element	B-X
(	B-X
SRE	B-X
)	B-X
,	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoyl	B-X
-	B-X
phorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
response	B-X
element	B-X
,	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
,	B-X
and	B-X
c	B-X
-	B-X
fos	B-X
promoter	B-X
<EOS>	B-X
Under	B-X
the	B-X
same	B-X
conditions	B-X
,	B-X
Lck	B-X
did	B-X
not	B-X
stimulate	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
unless	B-X
it	B-X
was	B-X
activated	B-X
by	B-X
mutation	B-X
<EOS>	B-X
Functional	B-X
and	B-X
physical	B-X
interaction	B-X
of	B-X
protein	B-X
-	B-X
tyrosine	B-X
kinases	B-X
Fyn	B-X
and	B-X
Csk	B-X
in	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
signaling	B-X
system	B-X
.	B-X

Under	O
the	O
same	O
conditions	O
,	O
Lck	B-protein
did	O
not	O
stimulate	O
IL-2	B-DNA
promoter	I-DNA
unless	O
it	O
was	O
activated	O
by	O
mutation	O
.	O
<EOS>	B-X
Under	B-X
the	B-X
same	B-X
conditions	B-X
,	B-X
normal	B-X
Lck	B-X
and	B-X
Lyn	B-X
could	B-X
not	B-X
stimulate	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
Under	B-X
these	B-X
conditions	B-X
CD2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
p56lck	B-X
and	B-X
p59fyn	B-X
as	B-X
well	B-X
as	B-X
two	B-X
low	B-X
molecular	B-X
weight	B-X
phosphoproteins	B-X
<EOS>	B-X
Under	B-X
detergent	B-X
-	B-X
free	B-X
conditions	B-X
,	B-X
we	B-X
isolated	B-X
a	B-X
GPI	B-X
-	B-X
enriched	B-X
plasma	B-X
membrane	B-X
fraction	B-X
,	B-X
also	B-X
containing	B-X
transmembrane	B-X
proteins	B-X
,	B-X
selectively	B-X
associated	B-X
with	B-X
sphingolipid	B-X
microdomains	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
same	B-X
zeta	B-X
and	B-X
epsilon	B-X
chains	B-X
which	B-X
are	B-X
components	B-X
of	B-X
a	B-X
functional	B-X
TcR	B-X
complex	B-X
appear	B-X
to	B-X
also	B-X
couple	B-X
to	B-X
the	B-X
CD2	B-X
molecular	B-X
complex	B-X

Interestingly	O
,	O
a	O
mutant	B-protein
Fyn	I-protein
,	O
which	O
has	O
deletions	O
within	O
the	O
SH2	B-protein
region	I-protein
and	O
so	O
is	O
able	O
to	O
transform	O
chicken	B-cell_type
embryo	I-cell_type
fibroblasts	I-cell_type
,	O
did	O
not	O
stimulate	O
either	O
the	O
c-fos	B-DNA
or	I-DNA
IL-2	I-DNA
promoter	I-DNA
,	O
suggesting	O
the	O
importance	O
of	O
this	O
region	O
in	O
T-cell	B-cell_type
signaling	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
point	B-X
to	B-X
the	B-X
function	B-X
of	B-X
TSAd	B-X
as	B-X
a	B-X
novel	B-X
transcription	B-X
-	B-X
regulatory	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
illustrate	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
TSAd	B-X
SH2	B-X
domain	B-X
in	B-X
this	B-X
role	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
SLAP	B-X
-	B-X
130	B-X
/	B-X
SLP	B-X
-	B-X
76	B-X
association	B-X
is	B-X
important	B-X
for	B-X
the	B-X
negative	B-X
regulatory	B-X
role	B-X
that	B-X
SLAP	B-X
-	B-X
130	B-X
appears	B-X
to	B-X
play	B-X
in	B-X
T	B-X
cell	B-X
signaling	B-X
<EOS>	B-X
This	B-X
response	B-X
was	B-X
partially	B-X
inhibited	B-X
by	B-X
cyclosporin	B-X
A	B-X
and	B-X
staurosporine	B-X
,	B-X
suggesting	B-X
the	B-X
participation	B-X
of	B-X
both	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
the	B-X
protein	B-X
kinase	B-X
C	B-X
pathways	B-X
in	B-X
CD43	B-X
signaling	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
induction	B-X
of	B-X
c	B-X
-	B-X
myb	B-X
transcription	B-X
is	B-X
an	B-X
important	B-X
downstream	B-X
event	B-X
for	B-X
PKB	B-X
-	B-X
mediated	B-X
protection	B-X
of	B-X
T	B-X
cells	B-X
from	B-X
programmed	B-X
cell	B-X
death	B-X

Csk	B-protein
,	O
which	O
phosphorylates	O
tyrosine	O
residues	O
in	O
the	O
negative	O
regulatory	O
sites	O
of	O
Src	B-protein
family	I-protein
kinases	I-protein
,	O
down-regulated	O
Fyn-	O
and	O
Lck-mediated	O
stimulation	O
of	O
the	O
serum	B-DNA
response	I-DNA
element	I-DNA
and	O
Fyn-mediated	O
enhancement	O
of	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O
<EOS>	B-X
Csk	B-X
,	B-X
which	B-X
phosphorylates	B-X
tyrosine	B-X
residues	B-X
in	B-X
the	B-X
negative	B-X
regulatory	B-X
sites	B-X
of	B-X
Src	B-X
family	B-X
kinases	B-X
,	B-X
down	B-X
-	B-X
regulated	B-X
Fyn	B-X
-	B-X
	B-X
and	B-X
Lck	B-X
-	B-X
mediated	B-X
stimulation	B-X
of	B-X
the	B-X
serum	B-X
response	B-X
element	B-X
and	B-X
Fyn	B-X
-	B-X
mediated	B-X
enhancement	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Fyn	B-X
and	B-X
Lck	B-X
,	B-X
whose	B-X
activities	B-X
are	B-X
regulated	B-X
by	B-X
Csk	B-X
,	B-X
are	B-X
involved	B-X
in	B-X
different	B-X
phases	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
<EOS>	B-X
Transient	B-X
expression	B-X
of	B-X
actively	B-X
mutated	B-X
Fyn	B-X
,	B-X
having	B-X
Phe	B-X
-	B-X
528	B-X
instead	B-X
of	B-X
Tyr	B-X
-	B-X
528	B-X
or	B-X
Thr	B-X
-	B-X
338	B-X
instead	B-X
of	B-X
Ile	B-X
-	B-X
338	B-X
,	B-X
in	B-X
Jurkat	B-X
T	B-X
-	B-X
cells	B-X
stimulated	B-X
the	B-X
serum	B-X
response	B-X
element	B-X
(	B-X
SRE	B-X
)	B-X
,	B-X
12	B-X
-	B-X
O	B-X
-	B-X
tetradecanoyl	B-X
-	B-X
phorbol	B-X
-	B-X
13	B-X
-	B-X
acetate	B-X
response	B-X
element	B-X
,	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
,	B-X
and	B-X
c	B-X
-	B-X
fos	B-X
promoter	B-X
<EOS>	B-X
Functional	B-X
and	B-X
physical	B-X
interaction	B-X
of	B-X
protein	B-X
-	B-X
tyrosine	B-X
kinases	B-X
Fyn	B-X
and	B-X
Csk	B-X
in	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
signaling	B-X
system	B-X
.	B-X

These	O
data	O
suggest	O
that	O
Fyn	B-protein
and	O
Lck	B-protein
,	O
whose	O
activities	O
are	O
regulated	O
by	O
Csk	B-protein
,	O
are	O
involved	O
in	O
different	O
phases	O
of	O
T-cell	B-cell_type
activation	O
.	O
<EOS>	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Fyn	B-X
and	B-X
Lck	B-X
,	B-X
whose	B-X
activities	B-X
are	B-X
regulated	B-X
by	B-X
Csk	B-X
,	B-X
are	B-X
involved	B-X
in	B-X
different	B-X
phases	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
<EOS>	B-X
Under	B-X
the	B-X
same	B-X
conditions	B-X
,	B-X
Lck	B-X
did	B-X
not	B-X
stimulate	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
unless	B-X
it	B-X
was	B-X
activated	B-X
by	B-X
mutation	B-X
<EOS>	B-X
Csk	B-X
,	B-X
which	B-X
phosphorylates	B-X
tyrosine	B-X
residues	B-X
in	B-X
the	B-X
negative	B-X
regulatory	B-X
sites	B-X
of	B-X
Src	B-X
family	B-X
kinases	B-X
,	B-X
down	B-X
-	B-X
regulated	B-X
Fyn	B-X
-	B-X
	B-X
and	B-X
Lck	B-X
-	B-X
mediated	B-X
stimulation	B-X
of	B-X
the	B-X
serum	B-X
response	B-X
element	B-X
and	B-X
Fyn	B-X
-	B-X
mediated	B-X
enhancement	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
activity	B-X
<EOS>	B-X
The	B-X
Src	B-X
-	B-X
like	B-X
protein	B-X
-	B-X
tyrosine	B-X
kinase	B-X
Fyn	B-X
is	B-X
associated	B-X
with	B-X
T	B-X
-	B-X
cell	B-X
antigen	B-X
receptor	B-X

A	O
novel	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
containing	O
p65	B-protein
homodimers	I-protein
:	O
implications	O
for	O
transcriptional	O
control	O
at	O
the	O
level	O
of	O
subunit	O
dimerization	O
.	O
<EOS>	B-X
A	B-X
novel	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complex	B-X
containing	B-X
p65	B-X
homodimers	B-X
:	B-X
implications	B-X
for	B-X
transcriptional	B-X
control	B-X
at	B-X
the	B-X
level	B-X
of	B-X
subunit	B-X
dimerization	B-X
.	B-X
<EOS>	B-X
As	B-X
with	B-X
the	B-X
prototypical	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p50	B-X
-	B-X
p65	B-X
heterodimer	B-X
,	B-X
this	B-X
novel	B-X
p65	B-X
homodimeric	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
functionally	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
but	B-X
rapidly	B-X
appears	B-X
in	B-X
the	B-X
nuclear	B-X
compartment	B-X
following	B-X
cellular	B-X
stimulation	B-X
<EOS>	B-X
While	B-X
authentic	B-X
p50	B-X
homodimers	B-X
(	B-X
previously	B-X
termed	B-X
KBF1	B-X
)	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
nontransfected	B-X
cells	B-X
,	B-X
experimental	B-X
evidence	B-X
supporting	B-X
the	B-X
existence	B-X
of	B-X
p65	B-X
homodimers	B-X
in	B-X
vivo	B-X
was	B-X
lacking	B-X
<EOS>	B-X
The	B-X
predominant	B-X
inducible	B-X
form	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcription	B-X
factor	B-X
is	B-X
a	B-X
heteromeric	B-X
complex	B-X
containing	B-X
two	B-X
Rel	B-X
-	B-X
related	B-X
DNA	B-X
-	B-X
binding	B-X
subunits	B-X
,	B-X
termed	B-X
p65	B-X
and	B-X
p50	B-X

The	O
predominant	O
inducible	O
form	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
is	O
a	O
heteromeric	B-protein
complex	I-protein
containing	O
two	O
Rel-related	B-protein
DNA-binding	I-protein
subunits	I-protein
,	O
termed	B-protein
p65	I-protein
and	O
p50	B-protein
.	O
<EOS>	B-X
The	B-X
predominant	B-X
inducible	B-X
form	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcription	B-X
factor	B-X
is	B-X
a	B-X
heteromeric	B-X
complex	B-X
containing	B-X
two	B-X
Rel	B-X
-	B-X
related	B-X
DNA	B-X
-	B-X
binding	B-X
subunits	B-X
,	B-X
termed	B-X
p65	B-X
and	B-X
p50	B-X
<EOS>	B-X
A	B-X
novel	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complex	B-X
containing	B-X
p65	B-X
homodimers	B-X
:	B-X
implications	B-X
for	B-X
transcriptional	B-X
control	B-X
at	B-X
the	B-X
level	B-X
of	B-X
subunit	B-X
dimerization	B-X
.	B-X
<EOS>	B-X
These	B-X
later	B-X
findings	B-X
indicate	B-X
that	B-X
neither	B-X
homo	B-X
-	B-X
	B-X
nor	B-X
heterodimer	B-X
formation	B-X
is	B-X
an	B-X
absolute	B-X
prerequisite	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
recognition	B-X
of	B-X
p65	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
at	B-X
these	B-X
two	B-X
sites	B-X
do	B-X
not	B-X
affect	B-X
heterodimerization	B-X
of	B-X
p65	B-X
with	B-X
p50	B-X
or	B-X
its	B-X
functional	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X

Prior	O
transfection	O
studies	O
have	O
shown	O
that	O
when	O
these	O
p65	B-protein
and	I-protein
p50	I-protein
subunits	I-protein
are	O
expressed	O
independently	O
as	O
stable	B-protein
homodimers	I-protein
,	O
p65	B-protein
stimulates	O
kappa	O
B-directed	O
transcription	O
,	O
whereas	O
p50	B-protein
functions	O
as	O
a	O
kappa	O
B-specific	O
repressor	O
.	O
<EOS>	B-X
Prior	B-X
transfection	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
when	B-X
these	B-X
p65	B-X
and	B-X
p50	B-X
subunits	B-X
are	B-X
expressed	B-X
independently	B-X
as	B-X
stable	B-X
homodimers	B-X
,	B-X
p65	B-X
stimulates	B-X
kappa	B-X
B	B-X
-	B-X
directed	B-X
transcription	B-X
,	B-X
whereas	B-X
p50	B-X
functions	B-X
as	B-X
a	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
repressor	B-X
<EOS>	B-X
Taken	B-X
together	B-X
with	B-X
prior	B-X
in	B-X
vivo	B-X
transcription	B-X
studies	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
biological	B-X
activities	B-X
of	B-X
p65	B-X
and	B-X
p50	B-X
homodimers	B-X
are	B-X
independently	B-X
regulated	B-X
,	B-X
thereby	B-X
providing	B-X
an	B-X
integrated	B-X
and	B-X
flexible	B-X
control	B-X
mechanism	B-X
for	B-X
the	B-X
rapid	B-X
activation	B-X
and	B-X
repression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
/	B-X
Rel	B-X
-	B-X
directed	B-X
gene	B-X
expression	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
at	B-X
these	B-X
two	B-X
sites	B-X
do	B-X
not	B-X
affect	B-X
heterodimerization	B-X
of	B-X
p65	B-X
with	B-X
p50	B-X
or	B-X
its	B-X
functional	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
<EOS>	B-X
These	B-X
later	B-X
findings	B-X
indicate	B-X
that	B-X
neither	B-X
homo	B-X
-	B-X
	B-X
nor	B-X
heterodimer	B-X
formation	B-X
is	B-X
an	B-X
absolute	B-X
prerequisite	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
recognition	B-X
of	B-X
p65	B-X

While	O
authentic	O
p50	B-protein
homodimers	I-protein
(	O
previously	O
termed	O
KBF1	B-protein
)	O
have	O
been	O
detected	O
in	O
nuclear	O
extracts	O
from	O
nontransfected	O
cells	O
,	O
experimental	O
evidence	O
supporting	O
the	O
existence	O
of	O
p65	B-protein
homodimers	I-protein
in	O
vivo	O
was	O
lacking	O
.	O
<EOS>	B-X
While	B-X
authentic	B-X
p50	B-X
homodimers	B-X
(	B-X
previously	B-X
termed	B-X
KBF1	B-X
)	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
nontransfected	B-X
cells	B-X
,	B-X
experimental	B-X
evidence	B-X
supporting	B-X
the	B-X
existence	B-X
of	B-X
p65	B-X
homodimers	B-X
in	B-X
vivo	B-X
was	B-X
lacking	B-X
<EOS>	B-X
We	B-X
now	B-X
provide	B-X
direct	B-X
biochemical	B-X
evidence	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
endogenous	B-X
pool	B-X
of	B-X
inducible	B-X
p65	B-X
homodimers	B-X
in	B-X
intact	B-X
human	B-X
T	B-X
cells	B-X
<EOS>	B-X
A	B-X
novel	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complex	B-X
containing	B-X
p65	B-X
homodimers	B-X
:	B-X
implications	B-X
for	B-X
transcriptional	B-X
control	B-X
at	B-X
the	B-X
level	B-X
of	B-X
subunit	B-X
dimerization	B-X
.	B-X
<EOS>	B-X
Site	B-X
-	B-X
directed	B-X
mutagenesis	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
homodimerization	B-X
function	B-X
of	B-X
p65	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
presence	B-X
of	B-X
cysteine	B-X
216	B-X
and	B-X
a	B-X
conserved	B-X
recognition	B-X
motif	B-X
for	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
RRPS	B-X
;	B-X
amino	B-X
acids	B-X
273	B-X
to	B-X
276	B-X
)	B-X
,	B-X
both	B-X
of	B-X
which	B-X
reside	B-X
within	B-X
a	B-X
91	B-X
-	B-X
amino	B-X
-	B-X
acid	B-X
segment	B-X
of	B-X
the	B-X
Rel	B-X
homology	B-X
domain	B-X
that	B-X
mediates	B-X
self	B-X
-	B-X
association	B-X

We	O
now	O
provide	O
direct	O
biochemical	O
evidence	O
for	O
the	O
presence	O
of	O
an	O
endogenous	O
pool	O
of	O
inducible	O
p65	B-protein
homodimers	I-protein
in	O
intact	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

As	O
with	O
the	O
prototypical	O
NF-kappa	B-protein
B	I-protein
p50-p65	I-protein
heterodimer	I-protein
,	O
this	O
novel	O
p65	B-protein
homodimeric	I-protein
form	I-protein
of	O
NF-kappa	B-protein
B	I-protein
is	O
functionally	O
sequestered	O
in	O
the	O
cytoplasm	O
but	O
rapidly	O
appears	O
in	O
the	O
nuclear	O
compartment	O
following	O
cellular	O
stimulation	O
.	O
<EOS>	B-X
As	B-X
with	B-X
the	B-X
prototypical	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p50	B-X
-	B-X
p65	B-X
heterodimer	B-X
,	B-X
this	B-X
novel	B-X
p65	B-X
homodimeric	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
functionally	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
but	B-X
rapidly	B-X
appears	B-X
in	B-X
the	B-X
nuclear	B-X
compartment	B-X
following	B-X
cellular	B-X
stimulation	B-X
<EOS>	B-X
A	B-X
novel	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complex	B-X
containing	B-X
p65	B-X
homodimers	B-X
:	B-X
implications	B-X
for	B-X
transcriptional	B-X
control	B-X
at	B-X
the	B-X
level	B-X
of	B-X
subunit	B-X
dimerization	B-X
.	B-X
<EOS>	B-X
These	B-X
later	B-X
findings	B-X
indicate	B-X
that	B-X
neither	B-X
homo	B-X
-	B-X
	B-X
nor	B-X
heterodimer	B-X
formation	B-X
is	B-X
an	B-X
absolute	B-X
prerequisite	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
recognition	B-X
of	B-X
p65	B-X
<EOS>	B-X
Taken	B-X
together	B-X
with	B-X
prior	B-X
in	B-X
vivo	B-X
transcription	B-X
studies	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
biological	B-X
activities	B-X
of	B-X
p65	B-X
and	B-X
p50	B-X
homodimers	B-X
are	B-X
independently	B-X
regulated	B-X
,	B-X
thereby	B-X
providing	B-X
an	B-X
integrated	B-X
and	B-X
flexible	B-X
control	B-X
mechanism	B-X
for	B-X
the	B-X
rapid	B-X
activation	B-X
and	B-X
repression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
/	B-X
Rel	B-X
-	B-X
directed	B-X
gene	B-X
expression	B-X

Site-directed	O
mutagenesis	O
studies	O
indicate	O
that	O
the	O
homodimerization	O
function	O
of	O
p65	B-protein
is	O
dependent	O
upon	O
the	O
presence	O
of	O
cysteine	O
216	O
and	O
a	O
conserved	O
recognition	O
motif	O
for	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
RRPS	B-protein
;	O
amino	O
acids	O
273	O
to	O
276	O
)	O
,	O
both	O
of	O
which	O
reside	O
within	O
a	O
91-amino-acid	O
segment	O
of	O
the	O
Rel	B-protein
homology	I-protein
domain	I-protein
that	O
mediates	O
self-association	O
.	O

In	O
contrast	O
,	O
mutations	O
at	O
these	O
two	O
sites	O
do	O
not	O
affect	O
heterodimerization	O
of	O
p65	B-protein
with	O
p50	B-protein
or	O
its	O
functional	O
interaction	O
with	O
I	O
kappa	O
B	O
alpha	O
.	O
<EOS>	B-X
TP53	B-X
mutation	B-X
and	B-X
the	B-X
copy	B-X
number	B-X
alteration	B-X
similarities	B-X
were	B-X
observed	B-X
only	B-X
in	B-X
nonkeratinizing	B-X
SCC	B-X
samples	B-X
<EOS>	B-X
It	B-X
broadens	B-X
the	B-X
target	B-X
sites	B-X
for	B-X
diseases	B-X
associated	B-X
with	B-X
various	B-X
mutations	B-X
or	B-X
splice	B-X
variants	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
nonmalignant	B-X
epithelium	B-X
showed	B-X
almost	B-X
no	B-X
somatic	B-X
mutations	B-X
in	B-X
case	B-X
2	B-X
<EOS>	B-X
In	B-X
both	B-X
cases	B-X
,	B-X
several	B-X
exonization	B-X
events	B-X
,	B-X
such	B-X
as	B-X
pseudoexon	B-X
inclusions	B-X
and	B-X
partial	B-X
intronic	B-X
retention	B-X
,	B-X
were	B-X
observed	B-X
due	B-X
to	B-X
the	B-X
creation	B-X
or	B-X
activation	B-X
of	B-X
new	B-X
/	B-X
cryptic	B-X
non	B-X
-	B-X
canonical	B-X
splicing	B-X
sites	B-X
,	B-X
including	B-X
a	B-X
shared	B-X
intronic	B-X
donor	B-X
site	B-X

These	O
later	O
findings	O
indicate	O
that	O
neither	O
homo-	O
nor	O
heterodimer	O
formation	O
is	O
an	O
absolute	O
prerequisite	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
recognition	O
of	O
p65	B-protein
.	O
<EOS>	B-X
These	B-X
later	B-X
findings	B-X
indicate	B-X
that	B-X
neither	B-X
homo	B-X
-	B-X
	B-X
nor	B-X
heterodimer	B-X
formation	B-X
is	B-X
an	B-X
absolute	B-X
prerequisite	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
recognition	B-X
of	B-X
p65	B-X
<EOS>	B-X
As	B-X
with	B-X
the	B-X
prototypical	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p50	B-X
-	B-X
p65	B-X
heterodimer	B-X
,	B-X
this	B-X
novel	B-X
p65	B-X
homodimeric	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
functionally	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
but	B-X
rapidly	B-X
appears	B-X
in	B-X
the	B-X
nuclear	B-X
compartment	B-X
following	B-X
cellular	B-X
stimulation	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
at	B-X
these	B-X
two	B-X
sites	B-X
do	B-X
not	B-X
affect	B-X
heterodimerization	B-X
of	B-X
p65	B-X
with	B-X
p50	B-X
or	B-X
its	B-X
functional	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
<EOS>	B-X
The	B-X
predominant	B-X
inducible	B-X
form	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
transcription	B-X
factor	B-X
is	B-X
a	B-X
heteromeric	B-X
complex	B-X
containing	B-X
two	B-X
Rel	B-X
-	B-X
related	B-X
DNA	B-X
-	B-X
binding	B-X
subunits	B-X
,	B-X
termed	B-X
p65	B-X
and	B-X
p50	B-X

Taken	O
together	O
with	O
prior	O
in	O
vivo	O
transcription	O
studies	O
,	O
these	O
results	O
suggest	O
that	O
the	O
biological	O
activities	O
of	O
p65	B-protein
and	I-protein
p50	I-protein
homodimers	I-protein
are	O
independently	O
regulated	O
,	O
thereby	O
providing	O
an	O
integrated	O
and	O
flexible	O
control	O
mechanism	O
for	O
the	O
rapid	O
activation	O
and	O
repression	O
of	O
NF-kappa	B-protein
B	I-protein
/	O
Rel	B-protein
-directed	O
gene	O
expression	O
.	O
<EOS>	B-X
Taken	B-X
together	B-X
with	B-X
prior	B-X
in	B-X
vivo	B-X
transcription	B-X
studies	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
biological	B-X
activities	B-X
of	B-X
p65	B-X
and	B-X
p50	B-X
homodimers	B-X
are	B-X
independently	B-X
regulated	B-X
,	B-X
thereby	B-X
providing	B-X
an	B-X
integrated	B-X
and	B-X
flexible	B-X
control	B-X
mechanism	B-X
for	B-X
the	B-X
rapid	B-X
activation	B-X
and	B-X
repression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
/	B-X
Rel	B-X
-	B-X
directed	B-X
gene	B-X
expression	B-X
<EOS>	B-X
Prior	B-X
transfection	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
when	B-X
these	B-X
p65	B-X
and	B-X
p50	B-X
subunits	B-X
are	B-X
expressed	B-X
independently	B-X
as	B-X
stable	B-X
homodimers	B-X
,	B-X
p65	B-X
stimulates	B-X
kappa	B-X
B	B-X
-	B-X
directed	B-X
transcription	B-X
,	B-X
whereas	B-X
p50	B-X
functions	B-X
as	B-X
a	B-X
kappa	B-X
B	B-X
-	B-X
specific	B-X
repressor	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
at	B-X
these	B-X
two	B-X
sites	B-X
do	B-X
not	B-X
affect	B-X
heterodimerization	B-X
of	B-X
p65	B-X
with	B-X
p50	B-X
or	B-X
its	B-X
functional	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
<EOS>	B-X
As	B-X
with	B-X
the	B-X
prototypical	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
p50	B-X
-	B-X
p65	B-X
heterodimer	B-X
,	B-X
this	B-X
novel	B-X
p65	B-X
homodimeric	B-X
form	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
functionally	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
but	B-X
rapidly	B-X
appears	B-X
in	B-X
the	B-X
nuclear	B-X
compartment	B-X
following	B-X
cellular	B-X
stimulation	B-X

Carrier	O
determination	O
for	O
X-linked	O
agammaglobulinemia	O
using	O
X	O
inactivation	O
analysis	O
of	O
purified	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Carrier	B-X
determination	B-X
for	B-X
X	B-X
-	B-X
linked	B-X
agammaglobulinemia	B-X
using	B-X
X	B-X
inactivation	B-X
analysis	B-X
of	B-X
purified	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
Improved	B-X
HUMARA	B-X
for	B-X
the	B-X
Detection	B-X
of	B-X
X	B-X
-	B-X
Linked	B-X
Agammaglobulinemia	B-X
Carriers	B-X
.	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
development	B-X
of	B-X
a	B-X
relatively	B-X
quick	B-X
and	B-X
simple	B-X
method	B-X
for	B-X
the	B-X
assessment	B-X
of	B-X
X	B-X
inactivation	B-X
status	B-X
for	B-X
carrier	B-X
determination	B-X
in	B-X
families	B-X
affected	B-X
by	B-X
X	B-X
-	B-X
linked	B-X
agammaglobulinemia	B-X
(	B-X
XLA	B-X
)	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
results	B-X
we	B-X
have	B-X
obtained	B-X
using	B-X
this	B-X
assay	B-X
to	B-X
investigate	B-X
females	B-X
known	B-X
to	B-X
be	B-X
carriers	B-X
of	B-X
various	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
disorders	B-X

We	O
report	O
the	O
development	O
of	O
a	O
relatively	O
quick	O
and	O
simple	O
method	O
for	O
the	O
assessment	O
of	O
X	O
inactivation	O
status	O
for	O
carrier	O
determination	O
in	O
families	O
affected	O
by	O
X-linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
development	B-X
of	B-X
a	B-X
relatively	B-X
quick	B-X
and	B-X
simple	B-X
method	B-X
for	B-X
the	B-X
assessment	B-X
of	B-X
X	B-X
inactivation	B-X
status	B-X
for	B-X
carrier	B-X
determination	B-X
in	B-X
families	B-X
affected	B-X
by	B-X
X	B-X
-	B-X
linked	B-X
agammaglobulinemia	B-X
(	B-X
XLA	B-X
)	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
results	B-X
we	B-X
have	B-X
obtained	B-X
using	B-X
this	B-X
assay	B-X
to	B-X
investigate	B-X
females	B-X
known	B-X
to	B-X
be	B-X
carriers	B-X
of	B-X
various	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
disorders	B-X
<EOS>	B-X
This	B-X
method	B-X
utilises	B-X
an	B-X
immunomagnetic	B-X
separation	B-X
technique	B-X
for	B-X
B	B-X
cell	B-X
purification	B-X
and	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
based	B-X
assay	B-X
for	B-X
the	B-X
determination	B-X
of	B-X
methylation	B-X
status	B-X
at	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
gene	B-X
locus	B-X
to	B-X
assess	B-X
whether	B-X
X	B-X
inactivation	B-X
is	B-X
random	B-X
or	B-X
non	B-X
-	B-X
random	B-X
at	B-X
this	B-X
locus	B-X
<EOS>	B-X
Carrier	B-X
determination	B-X
for	B-X
X	B-X
-	B-X
linked	B-X
agammaglobulinemia	B-X
using	B-X
X	B-X
inactivation	B-X
analysis	B-X
of	B-X
purified	B-X
B	B-X
cells	B-X
.	B-X

This	O
method	O
utilises	O
an	O
immunomagnetic	O
separation	O
technique	O
for	O
B	B-cell_type
cell	I-cell_type
purification	O
and	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
based	O
assay	O
for	O
the	O
determination	O
of	O
methylation	O
status	O
at	O
the	O
androgen	B-DNA
receptor	I-DNA
(	I-DNA
AR	I-DNA
)	I-DNA
gene	I-DNA
locus	I-DNA
to	O
assess	O
whether	O
X	O
inactivation	O
is	O
random	O
or	O
non-random	O
at	O
this	O
locus	O
.	O
<EOS>	B-X
In	B-X
this	B-X
note	B-X
we	B-X
show	B-X
that	B-X
this	B-X
is	B-X
not	B-X
necessarily	B-X
the	B-X
case	B-X
since	B-X
the	B-X
average	B-X
effect	B-X
of	B-X
an	B-X
allele	B-X
on	B-X
fitness	B-X
may	B-X
be	B-X
different	B-X
from	B-X
its	B-X
marginal	B-X
additive	B-X
fitness	B-X
even	B-X
in	B-X
a	B-X
one	B-X
-	B-X
locus	B-X
setting	B-X
in	B-X
non	B-X
-	B-X
random	B-X
-	B-X
mating	B-X
populations	B-X
<EOS>	B-X
This	B-X
study	B-X
provides	B-X
assets	B-X
for	B-X
quinoa	B-X
breeding	B-X
because	B-X
superior	B-X
haplotypes	B-X
can	B-X
be	B-X
assembled	B-X
in	B-X
a	B-X
predictive	B-X
breeding	B-X
approach	B-X
to	B-X
produce	B-X
well	B-X
-	B-X
adapted	B-X
early	B-X
flowering	B-X
lines	B-X
under	B-X
long	B-X
-	B-X
day	B-X
photoperiods	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
carriage	B-X
of	B-X
rs10895068	B-X
minor	B-X
allele	B-X
in	B-X
breast	B-X
cancer	B-X
women	B-X
were	B-X
also	B-X
associated	B-X
with	B-X
age	B-X
at	B-X
first	B-X
pregnancy	B-X
,	B-X
hormone	B-X
receptor	B-X
(	B-X
RH	B-X
)	B-X
status	B-X
,	B-X
and	B-X
previous	B-X
use	B-X
of	B-X
oral	B-X
contraceptives	B-X
<EOS>	B-X
This	B-X
can	B-X
help	B-X
understand	B-X
processes	B-X
contributing	B-X
to	B-X
the	B-X
diversification	B-X
and	B-X
evolution	B-X
of	B-X
this	B-X
pathogenic	B-X
bacteria	B-X
,	B-X
thereby	B-X
facilitating	B-X
development	B-X
of	B-X
effective	B-X
control	B-X
measures	B-X

We	O
report	O
the	O
results	O
we	O
have	O
obtained	O
using	O
this	O
assay	O
to	O
investigate	O
females	O
known	O
to	O
be	O
carriers	O
of	O
various	O
X-linked	O
immunodeficiency	O
disorders	O
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
results	B-X
we	B-X
have	B-X
obtained	B-X
using	B-X
this	B-X
assay	B-X
to	B-X
investigate	B-X
females	B-X
known	B-X
to	B-X
be	B-X
carriers	B-X
of	B-X
various	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
disorders	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
development	B-X
of	B-X
a	B-X
relatively	B-X
quick	B-X
and	B-X
simple	B-X
method	B-X
for	B-X
the	B-X
assessment	B-X
of	B-X
X	B-X
inactivation	B-X
status	B-X
for	B-X
carrier	B-X
determination	B-X
in	B-X
families	B-X
affected	B-X
by	B-X
X	B-X
-	B-X
linked	B-X
agammaglobulinemia	B-X
(	B-X
XLA	B-X
)	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
investigated	B-X
four	B-X
females	B-X
from	B-X
different	B-X
families	B-X
affected	B-X
by	B-X
XLA	B-X
,	B-X
two	B-X
of	B-X
whom	B-X
were	B-X
of	B-X
unknown	B-X
carrier	B-X
status	B-X
,	B-X
and	B-X
we	B-X
discuss	B-X
the	B-X
results	B-X
obtained	B-X
with	B-X
this	B-X
and	B-X
other	B-X
X	B-X
-	B-X
inactivation	B-X
assays	B-X
<EOS>	B-X
Carrier	B-X
determination	B-X
for	B-X
X	B-X
-	B-X
linked	B-X
agammaglobulinemia	B-X
using	B-X
X	B-X
inactivation	B-X
analysis	B-X
of	B-X
purified	B-X
B	B-X
cells	B-X
.	B-X

In	O
addition	O
,	O
we	O
investigated	O
four	O
females	O
from	O
different	O
families	O
affected	O
by	O
XLA	O
,	O
two	O
of	O
whom	O
were	O
of	O
unknown	O
carrier	O
status	O
,	O
and	O
we	O
discuss	O
the	O
results	O
obtained	O
with	O
this	O
and	O
other	O
X-inactivation	O
assays	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
investigated	B-X
four	B-X
females	B-X
from	B-X
different	B-X
families	B-X
affected	B-X
by	B-X
XLA	B-X
,	B-X
two	B-X
of	B-X
whom	B-X
were	B-X
of	B-X
unknown	B-X
carrier	B-X
status	B-X
,	B-X
and	B-X
we	B-X
discuss	B-X
the	B-X
results	B-X
obtained	B-X
with	B-X
this	B-X
and	B-X
other	B-X
X	B-X
-	B-X
inactivation	B-X
assays	B-X
<EOS>	B-X
This	B-X
method	B-X
utilises	B-X
an	B-X
immunomagnetic	B-X
separation	B-X
technique	B-X
for	B-X
B	B-X
cell	B-X
purification	B-X
and	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
based	B-X
assay	B-X
for	B-X
the	B-X
determination	B-X
of	B-X
methylation	B-X
status	B-X
at	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
gene	B-X
locus	B-X
to	B-X
assess	B-X
whether	B-X
X	B-X
inactivation	B-X
is	B-X
random	B-X
or	B-X
non	B-X
-	B-X
random	B-X
at	B-X
this	B-X
locus	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
results	B-X
we	B-X
have	B-X
obtained	B-X
using	B-X
this	B-X
assay	B-X
to	B-X
investigate	B-X
females	B-X
known	B-X
to	B-X
be	B-X
carriers	B-X
of	B-X
various	B-X
X	B-X
-	B-X
linked	B-X
immunodeficiency	B-X
disorders	B-X
<EOS>	B-X
We	B-X
report	B-X
the	B-X
development	B-X
of	B-X
a	B-X
relatively	B-X
quick	B-X
and	B-X
simple	B-X
method	B-X
for	B-X
the	B-X
assessment	B-X
of	B-X
X	B-X
inactivation	B-X
status	B-X
for	B-X
carrier	B-X
determination	B-X
in	B-X
families	B-X
affected	B-X
by	B-X
X	B-X
-	B-X
linked	B-X
agammaglobulinemia	B-X
(	B-X
XLA	B-X
)	B-X

A	O
similar	O
assay	O
has	O
recently	O
been	O
described	O
by	O
Allen	O
et	O
al.	O
(	O
1992	O
)	O
and	O
applied	O
to	O
members	O
of	O
one	O
family	O
affected	O
by	O
XLA	O
.	O

Effects	O
of	O
IL-4	B-protein
and	O
Fc	B-protein
gamma	I-protein
receptor	I-protein
II	I-protein
engagement	O
on	O
Egr-1	B-protein
expression	O
during	O
stimulation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
by	O
membrane	O
immunoglobulin	O
crosslinking	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
Fc	B-X
gamma	B-X
receptor	B-X
II	B-X
engagement	B-X
on	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
stimulation	B-X
of	B-X
B	B-X
lymphocytes	B-X
by	B-X
membrane	B-X
immunoglobulin	B-X
crosslinking	B-X
.	B-X
<EOS>	B-X
While	B-X
mitogenic	B-X
doses	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
induce	B-X
large	B-X
and	B-X
rapid	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
results	B-X
in	B-X
smaller	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
comparable	B-X
to	B-X
that	B-X
seen	B-X
with	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
overcomes	B-X
Fc	B-X
receptor	B-X
-	B-X
mediated	B-X
inhibition	B-X
of	B-X
B	B-X
cell	B-X
proliferation	B-X
without	B-X
affecting	B-X
inhibition	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
induction	B-X
,	B-X
as	B-X
demonstrated	B-X
earlier	B-X
for	B-X
c	B-X
-	B-X
myc	B-X
mRNA	B-X
in	B-X
this	B-X
system	B-X
<EOS>	B-X
We	B-X
compared	B-X
the	B-X
expression	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
during	B-X
B	B-X
cell	B-X
stimulation	B-X
with	B-X
Fab	B-X
'	B-X
2	B-X
and	B-X
IgG	B-X
anti	B-X
-	B-X
immunoglobulin	B-X
(	B-X
anti	B-X
-	B-X
Ig	B-X
)	B-X
,	B-X
since	B-X
it	B-X
is	B-X
known	B-X
that	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
is	B-X
mitogenic	B-X
while	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
is	B-X
not	B-X
,	B-X
owing	B-X
to	B-X
a	B-X
dominant	B-X
inhibitory	B-X
effect	B-X
of	B-X
crosslinking	B-X
the	B-X
B	B-X
cell	B-X
Fc	B-X
gamma	B-X
RII	B-X
to	B-X
membrane	B-X
Ig	B-X

Egr-1	B-DNA
is	O
an	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
that	O
is	O
rapidly	O
upregulated	O
in	O
response	O
to	O
mitogenic	O
signals	O
induced	O
by	O
antigen	O
receptor	O
crosslinking	O
on	O
murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Egr	B-X
-	B-X
1	B-X
is	B-X
an	B-X
immediate	B-X
early	B-X
gene	B-X
that	B-X
is	B-X
rapidly	B-X
upregulated	B-X
in	B-X
response	B-X
to	B-X
mitogenic	B-X
signals	B-X
induced	B-X
by	B-X
antigen	B-X
receptor	B-X
crosslinking	B-X
on	B-X
murine	B-X
B	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
compared	B-X
the	B-X
expression	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
during	B-X
B	B-X
cell	B-X
stimulation	B-X
with	B-X
Fab	B-X
'	B-X
2	B-X
and	B-X
IgG	B-X
anti	B-X
-	B-X
immunoglobulin	B-X
(	B-X
anti	B-X
-	B-X
Ig	B-X
)	B-X
,	B-X
since	B-X
it	B-X
is	B-X
known	B-X
that	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
is	B-X
mitogenic	B-X
while	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
is	B-X
not	B-X
,	B-X
owing	B-X
to	B-X
a	B-X
dominant	B-X
inhibitory	B-X
effect	B-X
of	B-X
crosslinking	B-X
the	B-X
B	B-X
cell	B-X
Fc	B-X
gamma	B-X
RII	B-X
to	B-X
membrane	B-X
Ig	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
B	B-X
cell	B-X
proliferation	B-X
breaks	B-X
down	B-X
when	B-X
IL	B-X
-	B-X
4	B-X
is	B-X
added	B-X
as	B-X
a	B-X
co	B-X
-	B-X
mitogen	B-X
to	B-X
induce	B-X
B	B-X
cell	B-X
proliferation	B-X
with	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
or	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
While	B-X
mitogenic	B-X
doses	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
induce	B-X
large	B-X
and	B-X
rapid	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
results	B-X
in	B-X
smaller	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
comparable	B-X
to	B-X
that	B-X
seen	B-X
with	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X

It	O
has	O
been	O
shown	O
that	O
levels	O
of	O
Egr-1	B-DNA
expression	O
are	O
closely	O
correlated	O
with	O
B	B-cell_type
cell	I-cell_type
proliferation	O
in	O
several	O
models	O
of	O
B	O
cell	O
activation	O
and	O
tolerance	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
levels	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
are	B-X
closely	B-X
correlated	B-X
with	B-X
B	B-X
cell	B-X
proliferation	B-X
in	B-X
several	B-X
models	B-X
of	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
tolerance	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
B	B-X
cell	B-X
proliferation	B-X
breaks	B-X
down	B-X
when	B-X
IL	B-X
-	B-X
4	B-X
is	B-X
added	B-X
as	B-X
a	B-X
co	B-X
-	B-X
mitogen	B-X
to	B-X
induce	B-X
B	B-X
cell	B-X
proliferation	B-X
with	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
or	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
While	B-X
mitogenic	B-X
doses	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
induce	B-X
large	B-X
and	B-X
rapid	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
results	B-X
in	B-X
smaller	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
comparable	B-X
to	B-X
that	B-X
seen	B-X
with	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
We	B-X
compared	B-X
the	B-X
expression	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
during	B-X
B	B-X
cell	B-X
stimulation	B-X
with	B-X
Fab	B-X
'	B-X
2	B-X
and	B-X
IgG	B-X
anti	B-X
-	B-X
immunoglobulin	B-X
(	B-X
anti	B-X
-	B-X
Ig	B-X
)	B-X
,	B-X
since	B-X
it	B-X
is	B-X
known	B-X
that	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
is	B-X
mitogenic	B-X
while	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
is	B-X
not	B-X
,	B-X
owing	B-X
to	B-X
a	B-X
dominant	B-X
inhibitory	B-X
effect	B-X
of	B-X
crosslinking	B-X
the	B-X
B	B-X
cell	B-X
Fc	B-X
gamma	B-X
RII	B-X
to	B-X
membrane	B-X
Ig	B-X

We	O
compared	O
the	O
expression	O
of	O
Egr-1	B-DNA
during	O
B	O
cell	O
stimulation	O
with	O
Fab'2	B-protein
and	O
IgG	B-protein
anti-immunoglobulin	I-protein
(	O
anti-Ig	B-protein
)	O
,	O
since	O
it	O
is	O
known	O
that	O
Fab'2	B-protein
anti-Ig	I-protein
is	O
mitogenic	O
while	O
IgG	B-protein
anti-Ig	I-protein
is	O
not	O
,	O
owing	O
to	O
a	O
dominant	O
inhibitory	O
effect	O
of	O
crosslinking	O
the	O
B	B-protein
cell	I-protein
Fc	I-protein
gamma	I-protein
RII	I-protein
to	O
membrane	B-protein
Ig	I-protein
.	O

While	O
mitogenic	O
doses	O
of	O
Fab'2	B-protein
anti-Ig	I-protein
induce	O
large	O
and	O
rapid	O
increases	O
in	O
Egr-1	O
expression	O
,	O
IgG	B-protein
anti-Ig	I-protein
results	O
in	O
smaller	O
increases	O
in	O
Egr-1	B-RNA
mRNA	I-RNA
,	O
comparable	O
to	O
that	O
seen	O
with	O
submitogenic	O
concentrations	O
of	O
Fab'2	B-protein
anti-Ig	I-protein
.	O
<EOS>	B-X
While	B-X
mitogenic	B-X
doses	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
induce	B-X
large	B-X
and	B-X
rapid	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
results	B-X
in	B-X
smaller	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
comparable	B-X
to	B-X
that	B-X
seen	B-X
with	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
B	B-X
cell	B-X
proliferation	B-X
breaks	B-X
down	B-X
when	B-X
IL	B-X
-	B-X
4	B-X
is	B-X
added	B-X
as	B-X
a	B-X
co	B-X
-	B-X
mitogen	B-X
to	B-X
induce	B-X
B	B-X
cell	B-X
proliferation	B-X
with	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
or	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
Effects	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
Fc	B-X
gamma	B-X
receptor	B-X
II	B-X
engagement	B-X
on	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
stimulation	B-X
of	B-X
B	B-X
lymphocytes	B-X
by	B-X
membrane	B-X
immunoglobulin	B-X
crosslinking	B-X
.	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
levels	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
are	B-X
closely	B-X
correlated	B-X
with	B-X
B	B-X
cell	B-X
proliferation	B-X
in	B-X
several	B-X
models	B-X
of	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
tolerance	B-X

However	O
,	O
the	O
correlation	O
between	O
Egr-1	O
expression	O
and	O
B	O
cell	O
proliferation	O
breaks	O
down	O
when	O
IL-4	B-protein
is	O
added	O
as	O
a	O
co-mitogen	O
to	O
induce	O
B	O
cell	O
proliferation	O
with	O
IgG	B-protein
anti-Ig	I-protein
or	O
submitogenic	O
concentrations	O
of	O
Fab'2	B-protein
anti-Ig	I-protein
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
B	B-X
cell	B-X
proliferation	B-X
breaks	B-X
down	B-X
when	B-X
IL	B-X
-	B-X
4	B-X
is	B-X
added	B-X
as	B-X
a	B-X
co	B-X
-	B-X
mitogen	B-X
to	B-X
induce	B-X
B	B-X
cell	B-X
proliferation	B-X
with	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
or	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
While	B-X
mitogenic	B-X
doses	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
induce	B-X
large	B-X
and	B-X
rapid	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
results	B-X
in	B-X
smaller	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
comparable	B-X
to	B-X
that	B-X
seen	B-X
with	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
levels	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
are	B-X
closely	B-X
correlated	B-X
with	B-X
B	B-X
cell	B-X
proliferation	B-X
in	B-X
several	B-X
models	B-X
of	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
tolerance	B-X
<EOS>	B-X
We	B-X
compared	B-X
the	B-X
expression	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
during	B-X
B	B-X
cell	B-X
stimulation	B-X
with	B-X
Fab	B-X
'	B-X
2	B-X
and	B-X
IgG	B-X
anti	B-X
-	B-X
immunoglobulin	B-X
(	B-X
anti	B-X
-	B-X
Ig	B-X
)	B-X
,	B-X
since	B-X
it	B-X
is	B-X
known	B-X
that	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
is	B-X
mitogenic	B-X
while	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
is	B-X
not	B-X
,	B-X
owing	B-X
to	B-X
a	B-X
dominant	B-X
inhibitory	B-X
effect	B-X
of	B-X
crosslinking	B-X
the	B-X
B	B-X
cell	B-X
Fc	B-X
gamma	B-X
RII	B-X
to	B-X
membrane	B-X
Ig	B-X

No	O
corresponding	O
increases	O
in	O
Egr-1	B-RNA
mRNA	I-RNA
levels	O
are	O
observed	O
when	O
IL-4	B-protein
is	O
added	O
.	O
<EOS>	B-X
No	B-X
corresponding	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
levels	B-X
are	B-X
observed	B-X
when	B-X
IL	B-X
-	B-X
4	B-X
is	B-X
added	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
overcomes	B-X
Fc	B-X
receptor	B-X
-	B-X
mediated	B-X
inhibition	B-X
of	B-X
B	B-X
cell	B-X
proliferation	B-X
without	B-X
affecting	B-X
inhibition	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
induction	B-X
,	B-X
as	B-X
demonstrated	B-X
earlier	B-X
for	B-X
c	B-X
-	B-X
myc	B-X
mRNA	B-X
in	B-X
this	B-X
system	B-X
<EOS>	B-X
While	B-X
mitogenic	B-X
doses	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
induce	B-X
large	B-X
and	B-X
rapid	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
,	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
results	B-X
in	B-X
smaller	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
,	B-X
comparable	B-X
to	B-X
that	B-X
seen	B-X
with	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
levels	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
are	B-X
closely	B-X
correlated	B-X
with	B-X
B	B-X
cell	B-X
proliferation	B-X
in	B-X
several	B-X
models	B-X
of	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
tolerance	B-X

Therefore	O
,	O
IL-4	B-protein
overcomes	O
Fc	O
receptor-mediated	O
inhibition	O
of	O
B	B-cell_type
cell	I-cell_type
proliferation	O
without	O
affecting	O
inhibition	O
of	O
Egr-1	B-RNA
mRNA	I-RNA
induction	O
,	O
as	O
demonstrated	O
earlier	O
for	O
c-myc	B-RNA
mRNA	I-RNA
in	O
this	O
system	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
overcomes	B-X
Fc	B-X
receptor	B-X
-	B-X
mediated	B-X
inhibition	B-X
of	B-X
B	B-X
cell	B-X
proliferation	B-X
without	B-X
affecting	B-X
inhibition	B-X
of	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
induction	B-X
,	B-X
as	B-X
demonstrated	B-X
earlier	B-X
for	B-X
c	B-X
-	B-X
myc	B-X
mRNA	B-X
in	B-X
this	B-X
system	B-X
<EOS>	B-X
Effects	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
Fc	B-X
gamma	B-X
receptor	B-X
II	B-X
engagement	B-X
on	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
during	B-X
stimulation	B-X
of	B-X
B	B-X
lymphocytes	B-X
by	B-X
membrane	B-X
immunoglobulin	B-X
crosslinking	B-X
.	B-X
<EOS>	B-X
No	B-X
corresponding	B-X
increases	B-X
in	B-X
Egr	B-X
-	B-X
1	B-X
mRNA	B-X
levels	B-X
are	B-X
observed	B-X
when	B-X
IL	B-X
-	B-X
4	B-X
is	B-X
added	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
Egr	B-X
-	B-X
1	B-X
expression	B-X
and	B-X
B	B-X
cell	B-X
proliferation	B-X
breaks	B-X
down	B-X
when	B-X
IL	B-X
-	B-X
4	B-X
is	B-X
added	B-X
as	B-X
a	B-X
co	B-X
-	B-X
mitogen	B-X
to	B-X
induce	B-X
B	B-X
cell	B-X
proliferation	B-X
with	B-X
IgG	B-X
anti	B-X
-	B-X
Ig	B-X
or	B-X
submitogenic	B-X
concentrations	B-X
of	B-X
Fab	B-X
'	B-X
2	B-X
anti	B-X
-	B-X
Ig	B-X

Identification	O
of	O
a	O
novel	O
cyclosporin-sensitive	B-DNA
element	I-DNA
in	O
the	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
gene	I-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
cyclosporin	B-X
-	B-X
sensitive	B-X
element	B-X
in	B-X
the	B-X
human	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
gene	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Induction	B-X
of	B-X
the	B-X
inducible	B-X
nuclear	B-X
complexes	B-X
is	B-X
rapid	B-X
,	B-X
independent	B-X
of	B-X
protein	B-X
synthesis	B-X
,	B-X
and	B-X
blocked	B-X
by	B-X
CsA	B-X
,	B-X
and	B-X
thus	B-X
,	B-X
exactly	B-X
parallels	B-X
the	B-X
induction	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
by	B-X
TCR	B-X
ligands	B-X
or	B-X
by	B-X
calcium	B-X
ionophore	B-X
<EOS>	B-X
Our	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
kappa	B-X
3	B-X
binding	B-X
factor	B-X
resembles	B-X
the	B-X
preexisting	B-X
component	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
In	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
,	B-X
an	B-X
oligonucleotide	B-X
containing	B-X
kappa	B-X
3	B-X
forms	B-X
two	B-X
DNA	B-X
protein	B-X
complexes	B-X
with	B-X
proteins	B-X
that	B-X
are	B-X
present	B-X
in	B-X
extracts	B-X
from	B-X
unstimulated	B-X
T	B-X
cells	B-X

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
a	O
cytokine	B-protein
with	O
pleiotropic	O
biological	O
effects	O
,	O
is	O
produced	O
by	O
a	O
variety	O
of	O
cell	O
types	O
in	O
response	O
to	O
induction	O
by	O
diverse	O
stimuli	O
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF	B-X
-	B-X
alpha	B-X
)	B-X
,	B-X
a	B-X
cytokine	B-X
with	B-X
pleiotropic	B-X
biological	B-X
effects	B-X
,	B-X
is	B-X
produced	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
in	B-X
response	B-X
to	B-X
induction	B-X
by	B-X
diverse	B-X
stimuli	B-X
<EOS>	B-X
Our	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
kappa	B-X
3	B-X
binding	B-X
factor	B-X
resembles	B-X
the	B-X
preexisting	B-X
component	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
human	B-X
TNF	B-X
-	B-X
alpha	B-X
promoter	B-X
element	B-X
,	B-X
kappa	B-X
3	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
calcium	B-X
-	B-X
mediated	B-X
inducibility	B-X
and	B-X
CsA	B-X
sensitivity	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
These	B-X
complexes	B-X
appear	B-X
in	B-X
nuclear	B-X
extracts	B-X
only	B-X
after	B-X
T	B-X
cell	B-X
stimulation	B-X

In	O
this	O
paper	O
,	O
TNF-alpha	B-RNA
mRNA	I-RNA
is	O
shown	O
to	O
be	O
highly	O
induced	O
in	O
a	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
clone	I-cell_line
by	O
stimulation	O
with	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
ligands	O
or	O
by	O
calcium	O
ionophores	O
alone	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
using	B-X
the	B-X
calcium	B-X
ionophore	B-X
ionomycin	B-X
and	B-X
/	B-X
or	B-X
PMA	B-X
on	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
gene	B-X
expression	B-X
program	B-X
associated	B-X
with	B-X
activation	B-X
of	B-X
TCR	B-X
signaling	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
specific	B-X
chromatin	B-X
landscapes	B-X
<EOS>	B-X
This	B-X
is	B-X
also	B-X
the	B-X
first	B-X
study	B-X
to	B-X
provide	B-X
characterization	B-X
of	B-X
Mg2+	B-X
transport	B-X
in	B-X
the	B-X
gut	B-X
of	B-X
C	B-X
<EOS>	B-X
Many	B-X
of	B-X
these	B-X
elements	B-X
contain	B-X
composite	B-X
NFAT	B-X
/	B-X
AP	B-X
-	B-X
1	B-X
sites	B-X
,	B-X
which	B-X
typically	B-X
support	B-X
cooperative	B-X
binding	B-X
,	B-X
thus	B-X
further	B-X
reinforcing	B-X
the	B-X
need	B-X
for	B-X
cooperation	B-X
between	B-X
calcium	B-X
and	B-X
kinase	B-X
signaling	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
genes	B-X
in	B-X
T	B-X
cells	B-X
<EOS>	B-X
These	B-X
findings	B-X
demonstrate	B-X
that	B-X
Hla	B-X
is	B-X
able	B-X
to	B-X
enhance	B-X
the	B-X
degranulation	B-X
of	B-X
mast	B-X
cells	B-X
induced	B-X
by	B-X
FcεRI	B-X
cross	B-X
-	B-X
linking	B-X
and	B-X
ionomycin	B-X
,	B-X
although	B-X
it	B-X
alone	B-X
does	B-X
not	B-X
induce	B-X
the	B-X
degranulation	B-X
,	B-X
and	B-X
the	B-X
pore	B-X
-	B-X
formation	B-X
of	B-X
Hla	B-X
followed	B-X
by	B-X
potassium	B-X
efflux	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
augmentation	B-X

Induction	O
is	O
rapid	O
,	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
is	O
completely	O
blocked	O
by	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
tried	B-X
to	B-X
examine	B-X
the	B-X
anti	B-X
-	B-X
metastasis	B-X
and	B-X
apoptosis	B-X
/	B-X
autophagy	B-X
actions	B-X
of	B-X
Coenzyme	B-X
Q	B-X
<EOS>	B-X
Functionalized	B-X
calcium	B-X
phosphate	B-X
nanoparticles	B-X
to	B-X
direct	B-X
osteoprotegerin	B-X
to	B-X
bone	B-X
lesion	B-X
sites	B-X
in	B-X
a	B-X
medaka	B-X
(	B-X
<EOS>	B-X
Activation	B-X
of	B-X
β	B-X
-	B-X
catenin	B-X
in	B-X
mesenchymal	B-X
progenitors	B-X
leads	B-X
to	B-X
muscle	B-X
mass	B-X
loss	B-X
.	B-X
<EOS>	B-X
Oxytocin	B-X
is	B-X
a	B-X
peptide	B-X
neurophysin	B-X
hormone	B-X
made	B-X
up	B-X
of	B-X
nine	B-X
amino	B-X
acids	B-X
and	B-X
is	B-X
used	B-X
in	B-X
induction	B-X
of	B-X
one	B-X
in	B-X
four	B-X
births	B-X
worldwide	B-X
(	B-X
more	B-X
than	B-X
13	B-X
percent	B-X
in	B-X
the	B-X
United	B-X
States	B-X
)	B-X

We	O
have	O
identified	O
a	O
human	B-DNA
TNF-alpha	I-DNA
promoter	I-DNA
element	I-DNA
,	O
kappa	B-DNA
3	I-DNA
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
calcium-mediated	O
inducibility	O
and	O
CsA	O
sensitivity	O
of	O
the	O
gene	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
an	O
oligonucleotide	O
containing	O
kappa	B-DNA
3	I-DNA
forms	O
two	O
DNA	O
protein	O
complexes	O
with	O
proteins	O
that	O
are	O
present	O
in	O
extracts	O
from	O
unstimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
In	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
,	B-X
an	B-X
oligonucleotide	B-X
containing	B-X
kappa	B-X
3	B-X
forms	B-X
two	B-X
DNA	B-X
protein	B-X
complexes	B-X
with	B-X
proteins	B-X
that	B-X
are	B-X
present	B-X
in	B-X
extracts	B-X
from	B-X
unstimulated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Our	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
kappa	B-X
3	B-X
binding	B-X
factor	B-X
resembles	B-X
the	B-X
preexisting	B-X
component	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
gene	B-X
is	B-X
an	B-X
immediate	B-X
early	B-X
gene	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
provides	B-X
a	B-X
new	B-X
model	B-X
system	B-X
in	B-X
which	B-X
to	B-X
study	B-X
CsA	B-X
-	B-X
sensitive	B-X
gene	B-X
induction	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Induction	B-X
is	B-X
rapid	B-X
,	B-X
does	B-X
not	B-X
require	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
,	B-X
and	B-X
is	B-X
completely	B-X
blocked	B-X
by	B-X
the	B-X
immunosuppressant	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X

These	O
complexes	O
appear	O
in	O
nuclear	O
extracts	O
only	O
after	O
T	O
cell	O
stimulation	O
.	O

Induction	O
of	O
the	O
inducible	O
nuclear	B-protein
complexes	I-protein
is	O
rapid	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
and	O
blocked	O
by	O
CsA	O
,	O
and	O
thus	O
,	O
exactly	O
parallels	O
the	O
induction	O
of	O
TNF-alpha	B-RNA
mRNA	I-RNA
by	O
TCR	O
ligands	O
or	O
by	O
calcium	O
ionophore	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
calcium	B-X
pattern	B-X
induced	B-X
by	B-X
the	B-X
male	B-X
patient	B-X
's	B-X
sperm	B-X
was	B-X
investigated	B-X
by	B-X
mouse	B-X
oocyte	B-X
calcium	B-X
analysis	B-X
<EOS>	B-X
Of	B-X
the	B-X
42	B-X
couples	B-X
included	B-X
,	B-X
17	B-X
underwent	B-X
an	B-X
ICSI	B-X
-	B-X
AOA	B-X
cycle	B-X
consisting	B-X
of	B-X
CaCl2	B-X
injection	B-X
and	B-X
double	B-X
ionomycin	B-X
exposure	B-X
<EOS>	B-X
Multi	B-X
-	B-X
colour	B-X
panels	B-X
of	B-X
fluorescent	B-X
antibodies	B-X
and	B-X
dyes	B-X
were	B-X
used	B-X
to	B-X
identify	B-X
the	B-X
features	B-X
of	B-X
subpopulations	B-X
by	B-X
imaging	B-X
flow	B-X
cytometry	B-X
<EOS>	B-X
Platelet	B-X
cultures	B-X
were	B-X
fractionated	B-X
into	B-X
conditioned	B-X
medium	B-X
(	B-X
CM	B-X
)	B-X
and	B-X
pellet	B-X
,	B-X
which	B-X
were	B-X
then	B-X
overlaid	B-X
on	B-X
eosinophils	B-X
to	B-X
examine	B-X
EET	B-X
formation	B-X

Our	O
studies	O
indicate	O
that	O
the	O
kappa	B-protein
3	I-protein
binding	I-protein
factor	I-protein
resembles	O
the	O
preexisting	O
component	O
of	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Our	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
kappa	B-X
3	B-X
binding	B-X
factor	B-X
resembles	B-X
the	B-X
preexisting	B-X
component	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
gene	B-X
is	B-X
an	B-X
immediate	B-X
early	B-X
gene	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
provides	B-X
a	B-X
new	B-X
model	B-X
system	B-X
in	B-X
which	B-X
to	B-X
study	B-X
CsA	B-X
-	B-X
sensitive	B-X
gene	B-X
induction	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
In	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
,	B-X
an	B-X
oligonucleotide	B-X
containing	B-X
kappa	B-X
3	B-X
forms	B-X
two	B-X
DNA	B-X
protein	B-X
complexes	B-X
with	B-X
proteins	B-X
that	B-X
are	B-X
present	B-X
in	B-X
extracts	B-X
from	B-X
unstimulated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
novel	B-X
cyclosporin	B-X
-	B-X
sensitive	B-X
element	B-X
in	B-X
the	B-X
human	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
gene	B-X
promoter	B-X
.	B-X

Thus	O
,	O
the	O
TNF-alpha	B-DNA
gene	I-DNA
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
and	O
provides	O
a	O
new	O
model	O
system	O
in	O
which	O
to	O
study	O
CsA-sensitive	B-DNA
gene	I-DNA
induction	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
TNF	B-X
-	B-X
alpha	B-X
gene	B-X
is	B-X
an	B-X
immediate	B-X
early	B-X
gene	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
provides	B-X
a	B-X
new	B-X
model	B-X
system	B-X
in	B-X
which	B-X
to	B-X
study	B-X
CsA	B-X
-	B-X
sensitive	B-X
gene	B-X
induction	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
Our	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
kappa	B-X
3	B-X
binding	B-X
factor	B-X
resembles	B-X
the	B-X
preexisting	B-X
component	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
<EOS>	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
is	B-X
shown	B-X
to	B-X
be	B-X
highly	B-X
induced	B-X
in	B-X
a	B-X
murine	B-X
T	B-X
cell	B-X
clone	B-X
by	B-X
stimulation	B-X
with	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligands	B-X
or	B-X
by	B-X
calcium	B-X
ionophores	B-X
alone	B-X
<EOS>	B-X
Induction	B-X
of	B-X
the	B-X
inducible	B-X
nuclear	B-X
complexes	B-X
is	B-X
rapid	B-X
,	B-X
independent	B-X
of	B-X
protein	B-X
synthesis	B-X
,	B-X
and	B-X
blocked	B-X
by	B-X
CsA	B-X
,	B-X
and	B-X
thus	B-X
,	B-X
exactly	B-X
parallels	B-X
the	B-X
induction	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
by	B-X
TCR	B-X
ligands	B-X
or	B-X
by	B-X
calcium	B-X
ionophore	B-X

Differences	O
in	O
expression	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
human	B-cell_line
promyelocytic	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
during	O
differentiation	O
towards	O
macrophages	B-cell_type
versus	O
granulocytes	B-cell_type
.	O
<EOS>	B-X
Differences	B-X
in	B-X
expression	B-X
of	B-X
transcription	B-X
factor	B-X
AP	B-X
-	B-X
1	B-X
in	B-X
human	B-X
promyelocytic	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
during	B-X
differentiation	B-X
towards	B-X
macrophages	B-X
versus	B-X
granulocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
differential	B-X
expression	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
activity	B-X
may	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
towards	B-X
monocytic	B-X
or	B-X
granulocytic	B-X
lineages	B-X
<EOS>	B-X
Nevertheless	B-X
,	B-X
gel	B-X
retardation	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
activity	B-X
detected	B-X
in	B-X
untreated	B-X
cells	B-X
was	B-X
drastically	B-X
reduced	B-X
during	B-X
the	B-X
commitment	B-X
stage	B-X
of	B-X
DMSO	B-X
-	B-X
induced	B-X
HL	B-X
-	B-X
60	B-X
differentiation	B-X
towards	B-X
granulocytes	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
formation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
HL	B-X
-	B-X
60	B-X
differentiation	B-X
towards	B-X
granulocytes	B-X
,	B-X
whereas	B-X
induction	B-X
of	B-X
monocytic	B-X
differentiation	B-X
is	B-X
correlated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
AP	B-X
-	B-X
1	B-X
activity	B-X

Commitment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
to	O
macrophage	O
or	O
granulocytic	O
differentiation	O
was	O
achieved	O
by	O
incubation	O
with	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
for	O
30-60	O
min	O
or	O
with	O
dimethyl	O
sulphoxide	O
(	O
DMSO	O
)	O
for	O
24	O
h	O
respectively	O
.	O
<EOS>	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
in	B-X
the	B-X
logarithmic	B-X
growth	B-X
phase	B-X
were	B-X
treated	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
and	B-X
2	B-X
<EOS>	B-X
The	B-X
cytotoxic	B-X
assessment	B-X
of	B-X
all	B-X
three	B-X
essential	B-X
oils	B-X
revealed	B-X
that	B-X
they	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
MDBK	B-X
cells	B-X
compared	B-X
to	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
used	B-X
as	B-X
the	B-X
control	B-X
substance	B-X
<EOS>	B-X
INS	B-X
-	B-X
1	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
RPMI	B-X
-	B-X
1640	B-X
medium	B-X
containing	B-X
10	B-X
%	B-X
fetal	B-X
bovine	B-X
serum	B-X
and	B-X
treated	B-X
with	B-X
15	B-X
,	B-X
30	B-X
,	B-X
60	B-X
and	B-X
120	B-X
μmol	B-X
/	B-X
L	B-X
of	B-X
DBP	B-X
and	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
vehicle	B-X
,	B-X
<	B-X
0	B-X
<EOS>	B-X
HepG2	B-X
cells	B-X
pretreated	B-X
with	B-X
100	B-X
μmol	B-X
/	B-X
L	B-X
olanzapine	B-X
were	B-X
transfected	B-X
with	B-X
siRNA	B-X
and	B-X
scrambled	B-X
siRNA	B-X
(	B-X
negative	B-X
control	B-X
)	B-X
,	B-X
respectively	B-X

The	O
commitment	O
stage	O
towards	O
PMA-induced	O
macrophage	O
differentiation	O
was	O
associated	O
with	O
increases	O
in	O
jun	O
B	O
and	O
c-fos	O
mRNA	O
levels	O
,	O
as	O
well	O
as	O
with	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Nevertheless	O
,	O
gel	O
retardation	O
analysis	O
indicated	O
that	O
the	O
AP-1	B-protein
activity	O
detected	O
in	O
untreated	O
cells	O
was	O
drastically	O
reduced	O
during	O
the	O
commitment	O
stage	O
of	O
DMSO-induced	O
HL-60	O
differentiation	O
towards	O
granulocytes	B-cell_type
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
gel	B-X
retardation	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
activity	B-X
detected	B-X
in	B-X
untreated	B-X
cells	B-X
was	B-X
drastically	B-X
reduced	B-X
during	B-X
the	B-X
commitment	B-X
stage	B-X
of	B-X
DMSO	B-X
-	B-X
induced	B-X
HL	B-X
-	B-X
60	B-X
differentiation	B-X
towards	B-X
granulocytes	B-X
<EOS>	B-X
The	B-X
differential	B-X
expression	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
activity	B-X
may	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
towards	B-X
monocytic	B-X
or	B-X
granulocytic	B-X
lineages	B-X
<EOS>	B-X
Differences	B-X
in	B-X
expression	B-X
of	B-X
transcription	B-X
factor	B-X
AP	B-X
-	B-X
1	B-X
in	B-X
human	B-X
promyelocytic	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
during	B-X
differentiation	B-X
towards	B-X
macrophages	B-X
versus	B-X
granulocytes	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
addition	B-X
of	B-X
sodium	B-X
butyrate	B-X
or	B-X
1	B-X
alpha,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
to	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
c	B-X
-	B-X
fos	B-X
,	B-X
c	B-X
-	B-X
jun	B-X
,	B-X
jun	B-X
B	B-X
and	B-X
jun	B-X
D	B-X
proto	B-X
-	B-X
oncogenes	B-X

When	O
HL-60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
sodium	O
butyrate	O
,	O
which	O
induced	O
monocytic	O
differentiation	O
,	O
a	O
remarkable	O
increase	O
in	O
AP-1	O
binding	O
activity	O
was	O
detected	O
.	O
<EOS>	B-X
When	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
sodium	B-X
butyrate	B-X
,	B-X
which	B-X
induced	B-X
monocytic	B-X
differentiation	B-X
,	B-X
a	B-X
remarkable	B-X
increase	B-X
in	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
retinoic	B-X
acid	B-X
,	B-X
a	B-X
granulocytic	B-X
differentiation	B-X
inducer	B-X
,	B-X
no	B-X
enhanced	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
activity	B-X
was	B-X
observed	B-X
,	B-X
and	B-X
only	B-X
a	B-X
weak	B-X
increase	B-X
in	B-X
jun	B-X
D	B-X
mRNA	B-X
level	B-X
was	B-X
detected	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
with	B-X
1	B-X
alpha,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
,	B-X
another	B-X
monocytic	B-X
differentiation	B-X
agent	B-X
,	B-X
induced	B-X
a	B-X
weak	B-X
,	B-X
but	B-X
appreciable	B-X
,	B-X
increase	B-X
in	B-X
AP	B-X
-	B-X
1	B-X
activity	B-X
<EOS>	B-X
The	B-X
commitment	B-X
stage	B-X
towards	B-X
PMA	B-X
-	B-X
induced	B-X
macrophage	B-X
differentiation	B-X
was	B-X
associated	B-X
with	B-X
increases	B-X
in	B-X
jun	B-X
B	B-X
and	B-X
c	B-X
-	B-X
fos	B-X
mRNA	B-X
levels	B-X
,	B-X
as	B-X
well	B-X
as	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
transcription	B-X
factor	B-X
AP	B-X
-	B-X
1	B-X

Treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
,	O
another	O
monocytic	O
differentiation	O
agent	O
,	O
induced	O
a	O
weak	O
,	O
but	O
appreciable	O
,	O
increase	O
in	O
AP-1	B-protein
activity	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
with	B-X
1	B-X
alpha,25	B-X
-	B-X
dihydroxyvitamin	B-X
D3	B-X
,	B-X
another	B-X
monocytic	B-X
differentiation	B-X
agent	B-X
,	B-X
induced	B-X
a	B-X
weak	B-X
,	B-X
but	B-X
appreciable	B-X
,	B-X
increase	B-X
in	B-X
AP	B-X
-	B-X
1	B-X
activity	B-X
<EOS>	B-X
When	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
sodium	B-X
butyrate	B-X
,	B-X
which	B-X
induced	B-X
monocytic	B-X
differentiation	B-X
,	B-X
a	B-X
remarkable	B-X
increase	B-X
in	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
activity	B-X
was	B-X
detected	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
HL	B-X
-	B-X
60	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
retinoic	B-X
acid	B-X
,	B-X
a	B-X
granulocytic	B-X
differentiation	B-X
inducer	B-X
,	B-X
no	B-X
enhanced	B-X
AP	B-X
-	B-X
1	B-X
binding	B-X
activity	B-X
was	B-X
observed	B-X
,	B-X
and	B-X
only	B-X
a	B-X
weak	B-X
increase	B-X
in	B-X
jun	B-X
D	B-X
mRNA	B-X
level	B-X
was	B-X
detected	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
formation	B-X
of	B-X
AP	B-X
-	B-X
1	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
HL	B-X
-	B-X
60	B-X
differentiation	B-X
towards	B-X
granulocytes	B-X
,	B-X
whereas	B-X
induction	B-X
of	B-X
monocytic	B-X
differentiation	B-X
is	B-X
correlated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
AP	B-X
-	B-X
1	B-X
activity	B-X

Furthermore	O
,	O
addition	O
of	O
sodium	O
butyrate	O
or	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
to	O
HL-60	B-cell_line
cells	I-cell_line
induced	O
the	O
expression	O
of	O
c-fos	B-DNA
,	I-DNA
c-jun	I-DNA
,	I-DNA
jun	I-DNA
B	I-DNA
and	I-DNA
jun	I-DNA
D	I-DNA
proto-oncogenes	I-DNA
.	O
<EOS>	B-X
TSA	B-X
increased	B-X
histone	B-X
H3	B-X
acetylation	B-X
levels	B-X
and	B-X
affected	B-X
the	B-X
expression	B-X
of	B-X
CDK	B-X
,	B-X
CYCD3	B-X
-	B-X
1	B-X
,	B-X
and	B-X
WUS	B-X
in	B-X
tobacco	B-X
protoplasts	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
intestinal	B-X
permeability	B-X
,	B-X
intestinal	B-X
flora	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
short	B-X
-	B-X
chain	B-X
fatty	B-X
acids	B-X
(	B-X
SCFA	B-X
)	B-X
were	B-X
also	B-X
assessed	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
serum	B-X
follicle	B-X
-	B-X
stimulating	B-X
hormone	B-X
and	B-X
luteinizing	B-X
hormone	B-X
were	B-X
increased	B-X
in	B-X
the	B-X
4	B-X
%	B-X
FSM	B-X
and	B-X
FMM	B-X
groups	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
arabinose	B-X
in	B-X
PGPs	B-X
was	B-X
preferentially	B-X
utilized	B-X
by	B-X
the	B-X
gut	B-X
microbiota	B-X
followed	B-X
by	B-X
galactose	B-X
and	B-X
xylose	B-X

In	O
contrast	O
,	O
when	O
HL-60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
retinoic	O
acid	O
,	O
a	O
granulocytic	O
differentiation	O
inducer	O
,	O
no	O
enhanced	O
AP-1	O
binding	O
activity	O
was	O
observed	O
,	O
and	O
only	O
a	O
weak	O
increase	O
in	O
jun	B-RNA
D	I-RNA
mRNA	I-RNA
level	O
was	O
detected	O
.	O

These	O
data	O
indicate	O
that	O
formation	O
of	O
AP-1	B-protein
is	O
not	O
required	O
for	O
the	O
induction	O
of	O
HL-60	B-cell_line
differentiation	O
towards	O
granulocytes	B-cell_type
,	O
whereas	O
induction	O
of	O
monocytic	O
differentiation	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
AP-1	B-protein
activity	O
.	O
<EOS>	B-X
Evidence	B-X
indicates	B-X
that	B-X
RBPMS	B-X
controls	B-X
the	B-X
activity	B-X
of	B-X
transcription	B-X
factors	B-X
associated	B-X
with	B-X
cell	B-X
growth	B-X
and	B-X
proliferation	B-X
,	B-X
including	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Smads	B-X
<EOS>	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
CpEA	B-X
(	B-X
compared	B-X
with	B-X
CpEE	B-X
)	B-X
and	B-X
hesperetin	B-X
(	B-X
compared	B-X
with	B-X
hesperidin	B-X
)	B-X
exhibited	B-X
greater	B-X
anti	B-X
-	B-X
inflammatory	B-X
properties	B-X
upon	B-X
Spike	B-X
S1	B-X
induction	B-X
through	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
IL	B-X
-	B-X
1β	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
18	B-X
cytokine	B-X
releases	B-X
in	B-X
A549	B-X
cells	B-X
culture	B-X
supernatant	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
At	B-X
the	B-X
molecular	B-X
level	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
ROS	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
reduction	B-X
in	B-X
antioxidant	B-X
enzymes	B-X
expression	B-X
while	B-X
inhibiting	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2	B-X
-	B-X
related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
activity	B-X
<EOS>	B-X
While	B-X
the	B-X
function	B-X
of	B-X
PACER	B-X
is	B-X
not	B-X
entirely	B-X
understood	B-X
,	B-X
PACER	B-X
is	B-X
known	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
inflammation	B-X
-	B-X
associated	B-X
conditions	B-X

The	O
differential	O
expression	O
of	O
AP-1	B-protein
activity	O
may	O
be	O
critical	O
in	O
the	O
differentiation	O
of	O
HL-60	B-cell_line
cells	I-cell_line
towards	O
monocytic	B-cell_type
or	I-cell_type
granulocytic	I-cell_type
lineages	I-cell_type
<EOS>	B-X
HSC	B-X
differentiation	B-X
was	B-X
also	B-X
independent	B-X
from	B-X
the	B-X
ablation	B-X
of	B-X
various	B-X
cellular	B-X
compartments	B-X
-	B-X
bleeding	B-X
,	B-X
the	B-X
antibody	B-X
-	B-X
mediated	B-X
ablation	B-X
of	B-X
granulocytes	B-X
or	B-X
B	B-X
lymphocytes	B-X
,	B-X
and	B-X
genetic	B-X
lymphocyte	B-X
deficiency	B-X
<EOS>	B-X
These	B-X
findings	B-X
afford	B-X
evidence	B-X
how	B-X
an	B-X
ANKRD26	B-X
overexpression	B-X
or	B-X
the	B-X
absence	B-X
of	B-X
its	B-X
silencing	B-X
during	B-X
differentiation	B-X
is	B-X
responsible	B-X
of	B-X
myeloid	B-X
blood	B-X
cell	B-X
abnormalities	B-X
in	B-X
TCH2	B-X
patients	B-X
<EOS>	B-X
Granulocyte	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
G	B-X
-	B-X
CSF	B-X
)	B-X
regulates	B-X
the	B-X
survival	B-X
,	B-X
proliferation	B-X
and	B-X
differentiation	B-X
of	B-X
all	B-X
cells	B-X
in	B-X
the	B-X
neutrophil	B-X
lineage	B-X
,	B-X
and	B-X
is	B-X
consequently	B-X
used	B-X
for	B-X
neutropenic	B-X
conditions	B-X
<EOS>	B-X
The	B-X
pathology	B-X
of	B-X
sepsis	B-X
is	B-X
tightly	B-X
associated	B-X
with	B-X
dysregulation	B-X
of	B-X
innate	B-X
immune	B-X
responses	B-X

Glucocorticoid	B-protein
receptors	I-protein
and	O
sensitivity	O
in	O
leukemias	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
ß	B-X
(	B-X
GRß	B-X
)	B-X
and	B-X
total	B-X
ERK	B-X
(	B-X
t	B-X
-	B-X
ERK	B-X
)	B-X
had	B-X
no	B-X
significant	B-X
changes	B-X
<EOS>	B-X
Glucocorticoid	B-X
(	B-X
GC	B-X
)	B-X
shows	B-X
antileukaemic	B-X
activity	B-X
via	B-X
binding	B-X
to	B-X
the	B-X
GC	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
<EOS>	B-X
Ibrutinib	B-X
reprograms	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
cells	B-X
.	B-X
<EOS>	B-X
Inherited	B-X
genetic	B-X
variants	B-X
associated	B-X
with	B-X
glucocorticoid	B-X
sensitivity	B-X
in	B-X
leukaemia	B-X
cells	B-X
.	B-X

In	O
an	O
attempt	O
to	O
investigate	O
the	O
utility	O
of	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
to	O
predict	O
clinical	O
responsiveness	O
in	O
human	O
leukemias	O
we	O
have	O
studied	O
glucocorticoid	B-protein
receptors	I-protein
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
from	O
46	O
patients	O
and	O
in	O
the	O
lymphocytes	B-cell_type
from	O
18	O
normal	O
donors	O
.	O

In	O
the	O
normal	B-cell_type
lymphocytes	I-cell_type
there	O
were	O
3	O
,	O
875	O
(	O
Median	O
)	O
specific	O
binding	O
sites	O
per	O
cell	O
.	O
<EOS>	B-X
In	B-X
the	B-X
normal	B-X
lymphocytes	B-X
there	B-X
were	B-X
3,875	B-X
(	B-X
Median	B-X
)	B-X
specific	B-X
binding	B-X
sites	B-X
per	B-X
cell	B-X
<EOS>	B-X
Their	B-X
lymphocytes	B-X
had	B-X
lower	B-X
number	B-X
of	B-X
receptors	B-X
(	B-X
Median	B-X
=	B-X
2,000	B-X
)	B-X
than	B-X
the	B-X
other	B-X
cases	B-X
which	B-X
were	B-X
newly	B-X
diagnosed	B-X
(	B-X
Median	B-X
=	B-X
4,500	B-X
)	B-X
<EOS>	B-X
Four	B-X
patients	B-X
had	B-X
ALL	B-X
/	B-X
AUL	B-X
,	B-X
three	B-X
patients	B-X
had	B-X
blast	B-X
crisis	B-X
as	B-X
terminal	B-X
phase	B-X
of	B-X
CML	B-X
,	B-X
and	B-X
seven	B-X
had	B-X
leukemic	B-X
Non	B-X
-	B-X
Hodgkin	B-X
lymphomas	B-X
(	B-X
Median	B-X
=	B-X
3,500	B-X
sites	B-X
/	B-X
cell	B-X
)	B-X
<EOS>	B-X
The	B-X
blasts	B-X
from	B-X
17	B-X
patients	B-X
with	B-X
ANLL	B-X
had	B-X
on	B-X
average	B-X
higher	B-X
levels	B-X
of	B-X
binding	B-X
sites	B-X
per	B-X
cell	B-X
(	B-X
Median	B-X
=	B-X
7,250	B-X
,	B-X
range	B-X
:	B-X
0	B-X
to	B-X
15,295	B-X
)	B-X
than	B-X
the	B-X
other	B-X
leukemias	B-X

The	O
blasts	B-cell_type
from	O
17	O
patients	O
with	O
ANLL	O
had	O
on	O
average	O
higher	O
levels	O
of	O
binding	B-protein
sites	I-protein
per	O
cell	O
(	O
Median	O
=	O
7	O
,	O
250	O
,	O
range	O
:	O
0	O
to	O
15	O
,	O
295	O
)	O
than	O
the	O
other	O
leukemias	O
.	O

Of	O
the	O
15	O
patients	O
with	O
CLL	O
,	O
six	O
had	O
received	O
glucocorticoid	O
treatment	O
for	O
3	O
to	O
5	O
years	O
.	O
<EOS>	B-X
Of	B-X
the	B-X
15	B-X
patients	B-X
with	B-X
CLL	B-X
,	B-X
six	B-X
had	B-X
received	B-X
glucocorticoid	B-X
treatment	B-X
for	B-X
3	B-X
to	B-X
5	B-X
years	B-X
<EOS>	B-X
The	B-X
blasts	B-X
from	B-X
17	B-X
patients	B-X
with	B-X
ANLL	B-X
had	B-X
on	B-X
average	B-X
higher	B-X
levels	B-X
of	B-X
binding	B-X
sites	B-X
per	B-X
cell	B-X
(	B-X
Median	B-X
=	B-X
7,250	B-X
,	B-X
range	B-X
:	B-X
0	B-X
to	B-X
15,295	B-X
)	B-X
than	B-X
the	B-X
other	B-X
leukemias	B-X
<EOS>	B-X
There	B-X
was	B-X
no	B-X
marked	B-X
correlation	B-X
between	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
<EOS>	B-X
In	B-X
24	B-X
patients	B-X
we	B-X
have	B-X
also	B-X
studied	B-X
the	B-X
in	B-X
vitro	B-X
sensitivity	B-X
of	B-X
the	B-X
leukemic	B-X
cells	B-X
to	B-X
dexamethasone	B-X

Their	O
lymphocytes	B-cell_type
had	O
lower	O
number	O
of	O
receptors	O
(	O
Median	O
=	O
2	O
,	O
000	O
)	O
than	O
the	O
other	O
cases	O
which	O
were	O
newly	O
diagnosed	O
(	O
Median	O
=	O
4	O
,	O
500	O
)	O
.	O

Four	O
patients	O
had	O
ALL/AUL	O
,	O
three	O
patients	O
had	O
blast	O
crisis	O
as	O
terminal	O
phase	O
of	O
CML	O
,	O
and	O
seven	O
had	O
leukemic	O
Non-Hodgkin	O
lymphomas	O
(	O
Median	O
=	O
3	O
,	O
500	O
sites/cell	O
)	O
.	O
<EOS>	B-X
Four	B-X
patients	B-X
had	B-X
ALL	B-X
/	B-X
AUL	B-X
,	B-X
three	B-X
patients	B-X
had	B-X
blast	B-X
crisis	B-X
as	B-X
terminal	B-X
phase	B-X
of	B-X
CML	B-X
,	B-X
and	B-X
seven	B-X
had	B-X
leukemic	B-X
Non	B-X
-	B-X
Hodgkin	B-X
lymphomas	B-X
(	B-X
Median	B-X
=	B-X
3,500	B-X
sites	B-X
/	B-X
cell	B-X
)	B-X
<EOS>	B-X
Their	B-X
lymphocytes	B-X
had	B-X
lower	B-X
number	B-X
of	B-X
receptors	B-X
(	B-X
Median	B-X
=	B-X
2,000	B-X
)	B-X
than	B-X
the	B-X
other	B-X
cases	B-X
which	B-X
were	B-X
newly	B-X
diagnosed	B-X
(	B-X
Median	B-X
=	B-X
4,500	B-X
)	B-X
<EOS>	B-X
An	B-X
attempt	B-X
to	B-X
correlate	B-X
receptor	B-X
levels	B-X
with	B-X
clinical	B-X
responsiveness	B-X
demonstrated	B-X
that	B-X
glucocorticoid	B-X
receptor	B-X
determination	B-X
might	B-X
be	B-X
of	B-X
value	B-X
in	B-X
patients	B-X
with	B-X
lymphoid	B-X
malignancies	B-X
but	B-X
probably	B-X
not	B-X
in	B-X
patients	B-X
with	B-X
other	B-X
leukemias	B-X
<EOS>	B-X
In	B-X
24	B-X
patients	B-X
we	B-X
have	B-X
also	B-X
studied	B-X
the	B-X
in	B-X
vitro	B-X
sensitivity	B-X
of	B-X
the	B-X
leukemic	B-X
cells	B-X
to	B-X
dexamethasone	B-X

In	O
24	O
patients	O
we	O
have	O
also	O
studied	O
the	O
in	O
vitro	O
sensitivity	O
of	O
the	O
leukemic	B-cell_type
cells	I-cell_type
to	O
dexamethasone	O
.	O
<EOS>	B-X
In	B-X
24	B-X
patients	B-X
we	B-X
have	B-X
also	B-X
studied	B-X
the	B-X
in	B-X
vitro	B-X
sensitivity	B-X
of	B-X
the	B-X
leukemic	B-X
cells	B-X
to	B-X
dexamethasone	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
sensitivity	B-X
in	B-X
leukemias	B-X
.	B-X
<EOS>	B-X
Of	B-X
the	B-X
15	B-X
patients	B-X
with	B-X
CLL	B-X
,	B-X
six	B-X
had	B-X
received	B-X
glucocorticoid	B-X
treatment	B-X
for	B-X
3	B-X
to	B-X
5	B-X
years	B-X
<EOS>	B-X
The	B-X
blasts	B-X
from	B-X
17	B-X
patients	B-X
with	B-X
ANLL	B-X
had	B-X
on	B-X
average	B-X
higher	B-X
levels	B-X
of	B-X
binding	B-X
sites	B-X
per	B-X
cell	B-X
(	B-X
Median	B-X
=	B-X
7,250	B-X
,	B-X
range	B-X
:	B-X
0	B-X
to	B-X
15,295	B-X
)	B-X
than	B-X
the	B-X
other	B-X
leukemias	B-X

There	O
was	O
no	O
marked	O
correlation	O
between	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
and	O
in	O
vitro	O
sensitivity	O
.	O
<EOS>	B-X
There	B-X
was	B-X
no	B-X
marked	B-X
correlation	B-X
between	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
<EOS>	B-X
Attempts	B-X
made	B-X
to	B-X
establish	B-X
a	B-X
correlation	B-X
between	B-X
the	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
leucocytes	B-X
of	B-X
leukemic	B-X
patients	B-X
and	B-X
any	B-X
parameter	B-X
of	B-X
steroid	B-X
sensitivity	B-X
in	B-X
vitro	B-X
have	B-X
been	B-X
unsuccessful	B-X
in	B-X
most	B-X
of	B-X
the	B-X
cases	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
sensitivity	B-X
in	B-X
leukemias	B-X
.	B-X
<EOS>	B-X
[	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
leukemia	B-X
(	B-X
author	B-X
's	B-X
transl	B-X
)	B-X
]	B-X
.	B-X

An	O
attempt	O
to	O
correlate	O
receptor	O
levels	O
with	O
clinical	O
responsiveness	O
demonstrated	O
that	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
might	O
be	O
of	O
value	O
in	O
patients	O
with	O
lymphoid	O
malignancies	O
but	O
probably	O
not	O
in	O
patients	O
with	O
other	O
leukemias	O
.	O

'Activation-labile	B-protein
'	I-protein
glucocorticoid-receptor	I-protein
complexes	I-protein
of	O
a	O
steroid-resistant	O
variant	O
of	O
CEM-C7	B-cell_line
human	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
'Activation	B-X
-	B-X
labile	B-X
'	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complexes	B-X
of	B-X
a	B-X
steroid	B-X
-	B-X
resistant	B-X
variant	B-X
of	B-X
CEM	B-X
-	B-X
C7	B-X
human	B-X
lymphoid	B-X
cells	B-X
.	B-X
<EOS>	B-X
For	B-X
cytoplasmic	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complexes	B-X
to	B-X
enter	B-X
and	B-X
accumulate	B-X
in	B-X
the	B-X
nucleus	B-X
a	B-X
temperature	B-X
-	B-X
dependent	B-X
event	B-X
,	B-X
'activation	B-X
'	B-X
is	B-X
required	B-X
<EOS>	B-X
Activation	B-X
can	B-X
be	B-X
achieved	B-X
in	B-X
vitro	B-X
by	B-X
increased	B-X
ionic	B-X
strength	B-X
,	B-X
dilution	B-X
or	B-X
gel	B-X
filtration	B-X
and	B-X
is	B-X
manifested	B-X
by	B-X
an	B-X
increased	B-X
affinity	B-X
of	B-X
steroid	B-X
-	B-X
receptor	B-X
complex	B-X
for	B-X
DNA	B-X
and	B-X
an	B-X
altered	B-X
elution	B-X
profile	B-X
from	B-X
ion	B-X
-	B-X
exchange	B-X
resins	B-X
<EOS>	B-X
This	B-X
defines	B-X
a	B-X
new	B-X
defect	B-X
in	B-X
receptor	B-X
action	B-X
,	B-X
activation	B-X
lability	B-X
(	B-X
r+act1	B-X
)	B-X
,	B-X
which	B-X
is	B-X
unlike	B-X
either	B-X
the	B-X
r	B-X
-	B-X
	B-X
,	B-X
r+nt	B-X
-	B-X
	B-X
,	B-X
or	B-X
r+nti	B-X
phenotypes	B-X
previously	B-X
described	B-X
for	B-X
mouse	B-X
lymphoid	B-X
variants	B-X

For	O
cytoplasmic	B-protein
glucocorticoid-receptor	I-protein
complexes	I-protein
to	O
enter	O
and	O
accumulate	O
in	O
the	O
nucleus	O
a	O
temperature-dependent	O
event	O
,	O
'activation	O
'	O
is	O
required	O
.	O
<EOS>	B-X
For	B-X
cytoplasmic	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complexes	B-X
to	B-X
enter	B-X
and	B-X
accumulate	B-X
in	B-X
the	B-X
nucleus	B-X
a	B-X
temperature	B-X
-	B-X
dependent	B-X
event	B-X
,	B-X
'activation	B-X
'	B-X
is	B-X
required	B-X
<EOS>	B-X
'Activation	B-X
-	B-X
labile	B-X
'	B-X
glucocorticoid	B-X
-	B-X
receptor	B-X
complexes	B-X
of	B-X
a	B-X
steroid	B-X
-	B-X
resistant	B-X
variant	B-X
of	B-X
CEM	B-X
-	B-X
C7	B-X
human	B-X
lymphoid	B-X
cells	B-X
.	B-X
<EOS>	B-X
We	B-X
report	B-X
here	B-X
that	B-X
DEAE	B-X
-	B-X
cellulose	B-X
chromatography	B-X
of	B-X
steroid	B-X
-	B-X
receptor	B-X
complexes	B-X
from	B-X
CEM	B-X
-	B-X
C7	B-X
,	B-X
a	B-X
cloned	B-X
human	B-X
leukaemic	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
sensitive	B-X
to	B-X
the	B-X
cytolytic	B-X
action	B-X
of	B-X
glucocorticoids	B-X
,	B-X
and	B-X
its	B-X
steroid	B-X
-	B-X
resistant	B-X
subclone	B-X
4R4	B-X
demonstrated	B-X
that	B-X
steroid	B-X
receptors	B-X
of	B-X
clone	B-X
4R4	B-X
can	B-X
not	B-X
form	B-X
stable	B-X
activated	B-X
complexes	B-X
<EOS>	B-X
Activation	B-X
can	B-X
be	B-X
achieved	B-X
in	B-X
vitro	B-X
by	B-X
increased	B-X
ionic	B-X
strength	B-X
,	B-X
dilution	B-X
or	B-X
gel	B-X
filtration	B-X
and	B-X
is	B-X
manifested	B-X
by	B-X
an	B-X
increased	B-X
affinity	B-X
of	B-X
steroid	B-X
-	B-X
receptor	B-X
complex	B-X
for	B-X
DNA	B-X
and	B-X
an	B-X
altered	B-X
elution	B-X
profile	B-X
from	B-X
ion	B-X
-	B-X
exchange	B-X
resins	B-X

Activation	O
can	O
be	O
achieved	O
in	O
vitro	O
by	O
increased	O
ionic	O
strength	O
,	O
dilution	O
or	O
gel	O
filtration	O
and	O
is	O
manifested	O
by	O
an	O
increased	O
affinity	O
of	O
steroid-receptor	B-protein
complex	I-protein
for	O
DNA	B-DNA
and	O
an	O
altered	O
elution	O
profile	O
from	O
ion-exchange	O
resins	O
.	O
<EOS>	B-X
Activation	B-X
can	B-X
be	B-X
achieved	B-X
in	B-X
vitro	B-X
by	B-X
increased	B-X
ionic	B-X
strength	B-X
,	B-X
dilution	B-X
or	B-X
gel	B-X
filtration	B-X
and	B-X
is	B-X
manifested	B-X
by	B-X
an	B-X
increased	B-X
affinity	B-X
of	B-X
steroid	B-X
-	B-X
receptor	B-X
complex	B-X
for	B-X
DNA	B-X
and	B-X
an	B-X
altered	B-X
elution	B-X
profile	B-X
from	B-X
ion	B-X
-	B-X
exchange	B-X
resins	B-X
<EOS>	B-X
Release	B-X
of	B-X
ectoine	B-X
from	B-X
the	B-X
cells	B-X
was	B-X
carried	B-X
out	B-X
within	B-X
5	B-X
min	B-X
and	B-X
its	B-X
rates	B-X
were	B-X
increased	B-X
by	B-X
the	B-X
dilution	B-X
in	B-X
the	B-X
downshock	B-X
treatment	B-X
<EOS>	B-X
It	B-X
is	B-X
unlikely	B-X
that	B-X
such	B-X
activation	B-X
reflects	B-X
effects	B-X
of	B-X
the	B-X
increased	B-X
cAMP	B-X
liberated	B-X
at	B-X
the	B-X
time	B-X
of	B-X
homogenization	B-X
<EOS>	B-X
Within	B-X
1	B-X
to	B-X
3	B-X
min	B-X
of	B-X
incubation	B-X
of	B-X
thyroid	B-X
slices	B-X
with	B-X
TSH	B-X
,	B-X
protein	B-X
kinase	B-X
activity	B-X
and	B-X
the	B-X
activity	B-X
ratio	B-X
were	B-X
increased	B-X
significantly	B-X

Munck	O
and	O
Foley	O
have	O
shown	O
that	O
activated	B-protein
complexes	I-protein
isolated	O
from	O
thymocytes	O
elute	O
from	O
DEAE-cellulose	O
in	O
a	O
manner	O
identical	O
to	O
complexes	O
activated	O
in	O
vitro	O
.	O

We	O
report	O
here	O
that	O
DEAE-cellulose	O
chromatography	O
of	O
steroid-receptor	B-protein
complexes	I-protein
from	O
CEM-C7	B-cell_line
,	O
a	O
cloned	B-cell_line
human	I-cell_line
leukaemic	I-cell_line
T-cell	I-cell_line
line	I-cell_line
sensitive	O
to	O
the	O
cytolytic	O
action	O
of	O
glucocorticoids	O
,	O
and	O
its	O
steroid-resistant	B-cell_line
subclone	I-cell_line
4R4	I-cell_line
demonstrated	O
that	O
steroid	B-protein
receptors	I-protein
of	O
clone	B-cell_line
4R4	I-cell_line
can	O
not	O
form	O
stable	O
activated	O
complexes	O
.	O

This	O
defines	O
a	O
new	O
defect	O
in	O
receptor	O
action	O
,	O
activation	O
lability	O
(	O
r+act1	O
)	O
,	O
which	O
is	O
unlike	O
either	O
the	O
r-	B-cell_line
,	I-cell_line
r+nt-	I-cell_line
,	I-cell_line
or	I-cell_line
r+nti	I-cell_line
phenotypes	I-cell_line
previously	O
described	O
for	O
mouse	B-cell_line
lymphoid	I-cell_line
variants	I-cell_line
.	O
<EOS>	B-X
This	B-X
defines	B-X
a	B-X
new	B-X
defect	B-X
in	B-X
receptor	B-X
action	B-X
,	B-X
activation	B-X
lability	B-X
(	B-X
r+act1	B-X
)	B-X
,	B-X
which	B-X
is	B-X
unlike	B-X
either	B-X
the	B-X
r	B-X
-	B-X
	B-X
,	B-X
r+nt	B-X
-	B-X
	B-X
,	B-X
or	B-X
r+nti	B-X
phenotypes	B-X
previously	B-X
described	B-X
for	B-X
mouse	B-X
lymphoid	B-X
variants	B-X
<EOS>	B-X
These	B-X
results	B-X
,	B-X
identifying	B-X
trafficking	B-X
areas	B-X
and	B-X
subsets	B-X
in	B-X
constitutive	B-X
lymphoid	B-X
and	B-X
inflammatory	B-X
tissues	B-X
,	B-X
obtained	B-X
using	B-X
this	B-X
genetic	B-X
marker	B-X
,	B-X
extend	B-X
those	B-X
obtained	B-X
previously	B-X
using	B-X
fluorescein	B-X
isothiocyanate	B-X
(	B-X
FITC	B-X
)	B-X
	B-X
-	B-X
labelled	B-X
donor	B-X
cells	B-X
<EOS>	B-X
To	B-X
capture	B-X
this	B-X
phenotypic	B-X
diversity	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
38	B-X
-	B-X
antibody	B-X
panel	B-X
for	B-X
mass	B-X
cytometry	B-X
and	B-X
used	B-X
dimensionality	B-X
reduction	B-X
with	B-X
machine	B-X
learning	B-X
-	B-X
aided	B-X
cluster	B-X
analysis	B-X
to	B-X
build	B-X
a	B-X
composite	B-X
of	B-X
murine	B-X
(	B-X
mouse	B-X
)	B-X
myeloid	B-X
cells	B-X
in	B-X
the	B-X
steady	B-X
state	B-X
across	B-X
lymphoid	B-X
and	B-X
nonlymphoid	B-X
tissues	B-X
<EOS>	B-X
Using	B-X
mice	B-X
that	B-X
can	B-X
not	B-X
sense	B-X
granulocyte	B-X
macrophage	B-X
-	B-X
colony	B-X
stimulating	B-X
factor	B-X
GM	B-X
-	B-X
CSF	B-X
(	B-X
Csf2rb	B-X
(	B-X
	B-X
-	B-X
	B-X
/	B-X
	B-X
-	B-X
	B-X
)	B-X
)	B-X
,	B-X
which	B-X
have	B-X
discrete	B-X
alterations	B-X
in	B-X
myeloid	B-X
development	B-X
,	B-X
we	B-X
confirmed	B-X
differences	B-X
in	B-X
barrier	B-X
tissue	B-X
dendritic	B-X
cells	B-X
,	B-X
lung	B-X
macrophages	B-X
and	B-X
eosinophils	B-X

Granulocytes	B-cell_type
in	O
the	O
endometrium	O
of	O
post-partum	O
women	O
.	O
<EOS>	B-X
Granulocytes	B-X
in	B-X
the	B-X
endometrium	B-X
of	B-X
post	B-X
-	B-X
partum	B-X
women	B-X
.	B-X
<EOS>	B-X
3	B-X
%	B-X
of	B-X
cases	B-X
in	B-X
the	B-X
first	B-X
group	B-X
,	B-X
whereas	B-X
none	B-X
was	B-X
noted	B-X
in	B-X
the	B-X
control	B-X
group	B-X
<EOS>	B-X
Although	B-X
samples	B-X
at	B-X
all	B-X
the	B-X
stages	B-X
contained	B-X
significant	B-X
numbers	B-X
of	B-X
the	B-X
granulocytes	B-X
(	B-X
i	B-X
<EOS>	B-X
Thirteen	B-X
excision	B-X
specimens	B-X
obtained	B-X
from	B-X
non	B-X
pregnant	B-X
patients	B-X
served	B-X
as	B-X
controls	B-X

Endometrial	O
samples	O
of	O
women	O
at	O
various	O
stages	O
of	O
gonadal	O
activity	O
after	O
parturition	O
were	O
examined	O
for	O
the	O
presence	O
and	O
numbers	O
of	O
endometrial	B-cell_type
granulocytes	I-cell_type
.	O
<EOS>	B-X
Endometrial	B-X
samples	B-X
of	B-X
women	B-X
at	B-X
various	B-X
stages	B-X
of	B-X
gonadal	B-X
activity	B-X
after	B-X
parturition	B-X
were	B-X
examined	B-X
for	B-X
the	B-X
presence	B-X
and	B-X
numbers	B-X
of	B-X
endometrial	B-X
granulocytes	B-X
<EOS>	B-X
Although	B-X
samples	B-X
at	B-X
all	B-X
the	B-X
stages	B-X
contained	B-X
significant	B-X
numbers	B-X
of	B-X
the	B-X
granulocytes	B-X
(	B-X
i	B-X
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
this	B-X
correlates	B-X
with	B-X
the	B-X
suggestion	B-X
that	B-X
the	B-X
granulocytes	B-X
constitute	B-X
a	B-X
receptor	B-X
system	B-X
for	B-X
oestrogens	B-X
<EOS>	B-X
Granulocytes	B-X
in	B-X
the	B-X
endometrium	B-X
of	B-X
post	B-X
-	B-X
partum	B-X
women	B-X
.	B-X

Although	O
samples	O
at	O
all	O
the	O
stages	O
contained	O
significant	O
numbers	O
of	O
the	O
granulocytes	B-cell_type
(	O
i.e.	O
greater	O
than	O
7/high-power	O
field	O
)	O
,	O
the	O
100	O
%	O
values	O
for	O
late-proliferative	O
and	O
adaptation	O
hyperplasia	O
were	O
significantly	O
higher	O
than	O
the	O
values	O
for	O
the	O
resting	O
(	O
81.8	O
%	O
)	O
,	O
early	O
(	O
82.4	O
%	O
)	O
and	O
mid-	O
(	O
87.9	O
%	O
)	O
proliferative	O
and	O
secretory	O
(	O
83.3	O
%	O
)	O
phases	O
.	O

We	O
suggest	O
that	O
this	O
correlates	O
with	O
the	O
suggestion	O
that	O
the	O
granulocytes	B-cell_type
constitute	O
a	O
receptor	O
system	O
for	O
oestrogens	O
.	O
<EOS>	B-X
We	B-X
suggest	B-X
that	B-X
this	B-X
correlates	B-X
with	B-X
the	B-X
suggestion	B-X
that	B-X
the	B-X
granulocytes	B-X
constitute	B-X
a	B-X
receptor	B-X
system	B-X
for	B-X
oestrogens	B-X
<EOS>	B-X
Although	B-X
samples	B-X
at	B-X
all	B-X
the	B-X
stages	B-X
contained	B-X
significant	B-X
numbers	B-X
of	B-X
the	B-X
granulocytes	B-X
(	B-X
i	B-X
<EOS>	B-X
greater	B-X
than	B-X
7	B-X
/	B-X
high	B-X
-	B-X
power	B-X
field	B-X
)	B-X
,	B-X
the	B-X
100	B-X
%	B-X
values	B-X
for	B-X
late	B-X
-	B-X
proliferative	B-X
and	B-X
adaptation	B-X
hyperplasia	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
the	B-X
values	B-X
for	B-X
the	B-X
resting	B-X
(	B-X
81	B-X
<EOS>	B-X
Granulocytes	B-X
in	B-X
the	B-X
endometrium	B-X
of	B-X
post	B-X
-	B-X
partum	B-X
women	B-X
.	B-X

Interaction	O
of	O
glucocorticoids	O
with	O
macrophages	B-cell_type
.	O
<EOS>	B-X
Hypoxia	B-X
can	B-X
maintain	B-X
inflammation	B-X
by	B-X
attracting	B-X
inflammatory	B-X
cells	B-X
such	B-X
as	B-X
macrophages	B-X
(	B-X
MQ	B-X
)	B-X
<EOS>	B-X
The	B-X
first	B-X
phase	B-X
of	B-X
glucocorticoid	B-X
-	B-X
induced	B-X
osteoporosis	B-X
is	B-X
increased	B-X
bone	B-X
resorption	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
immune	B-X
cells	B-X
in	B-X
pulmonary	B-X
hypertension	B-X
:	B-X
Focusing	B-X
on	B-X
macrophages	B-X
.	B-X
<EOS>	B-X
Dose	B-X
-	B-X
Dependent	B-X
Glucocorticoid	B-X
Regulation	B-X
of	B-X
Transcription	B-X
Factors	B-X
in	B-X
Vocal	B-X
Fold	B-X
Fibroblasts	B-X
and	B-X
Macrophages	B-X
.	B-X

Identification	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
.	O
<EOS>	B-X
Interaction	B-X
of	B-X
glucocorticoids	B-X
with	B-X
macrophages	B-X
.	B-X
Identification	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
monocytes	B-X
and	B-X
macrophages	B-X
.	B-X
<EOS>	B-X
Identification	B-X
of	B-X
the	B-X
hemoglobin	B-X
scavenger	B-X
receptor	B-X
/	B-X
CD163	B-X
as	B-X
a	B-X
natural	B-X
soluble	B-X
protein	B-X
in	B-X
plasma	B-X
.	B-X
<EOS>	B-X
The	B-X
RM3	B-X
/	B-X
1	B-X
Ag	B-X
is	B-X
a	B-X
membrane	B-X
glycoprotein	B-X
restricted	B-X
to	B-X
human	B-X
monocytes	B-X
and	B-X
macrophages	B-X
that	B-X
evolve	B-X
in	B-X
the	B-X
late	B-X
phase	B-X
of	B-X
inflammation	B-X
<EOS>	B-X
Identification	B-X
of	B-X
the	B-X
integral	B-X
membrane	B-X
protein	B-X
RM3	B-X
/	B-X
1	B-X
on	B-X
human	B-X
monocytes	B-X
as	B-X
a	B-X
glucocorticoid	B-X
-	B-X
inducible	B-X
member	B-X
of	B-X
the	B-X
scavenger	B-X
receptor	B-X
cysteine	B-X
-	B-X
rich	B-X
family	B-X
(	B-X
CD163	B-X
)	B-X
.	B-X

Glucocorticoid	O
binding	O
was	O
measured	O
in	O
resident	O
and	O
thioglycollate-elicited	B-cell_type
mouse	I-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
,	O
rabbit	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
,	O
and	O
human	B-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
Glucocorticoid	B-X
binding	B-X
was	B-X
measured	B-X
in	B-X
resident	B-X
and	B-X
thioglycollate	B-X
-	B-X
elicited	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
,	B-X
rabbit	B-X
alveolar	B-X
macrophages	B-X
,	B-X
and	B-X
human	B-X
monocytes	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
corticosteroids	B-X
interact	B-X
with	B-X
macrophages	B-X
at	B-X
physiological	B-X
concentrations	B-X
<EOS>	B-X
The	B-X
binding	B-X
to	B-X
the	B-X
saturable	B-X
sites	B-X
was	B-X
specific	B-X
for	B-X
steroids	B-X
with	B-X
glucocorticoid	B-X
or	B-X
antiglucocorticoid	B-X
activity	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
glucocorticoids	B-X
with	B-X
macrophages	B-X
.	B-X
Identification	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
monocytes	B-X
and	B-X
macrophages	B-X
.	B-X

Two	O
assays	O
of	O
binding	O
were	O
used	O
--	O
an	O
assay	O
with	O
intact	B-cell_type
cells	I-cell_type
in	O
suspension	O
or	O
monolayers	O
,	O
and	O
an	O
assay	O
of	O
cytosol	O
and	O
nuclear	O
forms	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O
<EOS>	B-X
The	B-X
binding	B-X
site	B-X
also	B-X
possessed	B-X
the	B-X
drug	B-X
specificity	B-X
typical	B-X
of	B-X
an	B-X
M2	B-X
muscarinic	B-X
receptor	B-X
<EOS>	B-X
Thus	B-X
,	B-X
this	B-X
binding	B-X
site	B-X
exhibits	B-X
the	B-X
characteristics	B-X
expected	B-X
for	B-X
a	B-X
functional	B-X
systemin	B-X
receptor	B-X
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
using	B-X
cultured	B-X
adult	B-X
rat	B-X
dorsal	B-X
root	B-X
ganglion	B-X
neurons	B-X
either	B-X
in	B-X
suspension	B-X
or	B-X
attached	B-X
to	B-X
the	B-X
tissue	B-X
culture	B-X
plates	B-X
,	B-X
we	B-X
developed	B-X
an	B-X
assay	B-X
to	B-X
measure	B-X
specific	B-X
[	B-X
3H	B-X
]	B-X
RTX	B-X
binding	B-X
by	B-X
the	B-X
intact	B-X
cells	B-X
<EOS>	B-X
We	B-X
compare	B-X
selections	B-X
on	B-X
cultured	B-X
cell	B-X
monolayers	B-X
with	B-X
selections	B-X
on	B-X
cell	B-X
suspensions	B-X
immobilised	B-X
on	B-X
columns	B-X
,	B-X
to	B-X
determine	B-X
which	B-X
selection	B-X
approach	B-X
is	B-X
most	B-X
suitable	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
novel	B-X
tumour	B-X
endothelial	B-X
cell	B-X
markers	B-X

The	O
mononuclear	B-cell_type
phagocytes	I-cell_type
contained	O
approximately	O
equal	O
to	O
4	O
--	O
10	O
X	O
10	O
(	O
3	O
)	O
high	B-protein
affinity	I-protein
receptor	I-protein
sites	I-protein
per	O
cell	O
,	O
with	O
dissociation	O
constants	O
of	O
approximately	O
equal	O
to	O
2	O
--	O
8	O
nM	O
dexamethasone	O
.	O
<EOS>	B-X
The	B-X
mononuclear	B-X
phagocytes	B-X
contained	B-X
approximately	B-X
equal	B-X
to	B-X
4	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
10	B-X
X	B-X
10	B-X
(	B-X
3	B-X
)	B-X
high	B-X
affinity	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
with	B-X
dissociation	B-X
constants	B-X
of	B-X
approximately	B-X
equal	B-X
to	B-X
2	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
8	B-X
nM	B-X
dexamethasone	B-X
<EOS>	B-X
The	B-X
binding	B-X
to	B-X
the	B-X
saturable	B-X
sites	B-X
was	B-X
specific	B-X
for	B-X
steroids	B-X
with	B-X
glucocorticoid	B-X
or	B-X
antiglucocorticoid	B-X
activity	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
corticosteroids	B-X
interact	B-X
with	B-X
macrophages	B-X
at	B-X
physiological	B-X
concentrations	B-X
<EOS>	B-X
Binding	B-X
of	B-X
dexamethasone	B-X
to	B-X
cytosol	B-X
and	B-X
nuclear	B-X
forms	B-X
of	B-X
the	B-X
receptor	B-X
complex	B-X
and	B-X
temperature	B-X
-	B-X
sensitive	B-X
translocation	B-X
of	B-X
cytosol	B-X
forms	B-X
to	B-X
nuclear	B-X
forms	B-X
were	B-X
shown	B-X

The	O
binding	O
to	O
the	O
saturable	B-protein
sites	I-protein
was	O
specific	O
for	O
steroids	O
with	O
glucocorticoid	O
or	O
antiglucocorticoid	O
activity	O
.	O
<EOS>	B-X
In	B-X
the	B-X
MDA	B-X
-	B-X
kb2	B-X
reporter	B-X
cell	B-X
line	B-X
,	B-X
compounds	B-X
possessed	B-X
anti	B-X
-	B-X
androgen	B-X
-	B-X
	B-X
,	B-X
glucocorticoid	B-X
-	B-X
	B-X
,	B-X
and	B-X
anti	B-X
-	B-X
glucocorticoid	B-X
-	B-X
like	B-X
activities	B-X
(	B-X
except	B-X
AVB	B-X
)	B-X
<EOS>	B-X
Potential	B-X
endocrine	B-X
-	B-X
disrupting	B-X
effects	B-X
of	B-X
metals	B-X
via	B-X
interference	B-X
with	B-X
glucocorticoid	B-X
and	B-X
mineralocorticoid	B-X
receptors	B-X
.	B-X
<EOS>	B-X
Their	B-X
binary	B-X
and	B-X
ternary	B-X
mixtures	B-X
at	B-X
EC50	B-X
or	B-X
IC50	B-X
concentrations	B-X
have	B-X
also	B-X
been	B-X
examined	B-X
for	B-X
anti	B-X
-	B-X
androgen	B-X
-	B-X
	B-X
,	B-X
glucocorticoid	B-X
-	B-X
	B-X
,	B-X
and	B-X
thyroid	B-X
hormone	B-X
-	B-X
like	B-X
activities	B-X
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
meta	B-X
-	B-X
analysis	B-X
was	B-X
to	B-X
investigate	B-X
whether	B-X
baseline	B-X
cortisol	B-X
levels	B-X
influence	B-X
the	B-X
efficacy	B-X
of	B-X
antiglucocorticoid	B-X
drugs	B-X
in	B-X
patients	B-X
with	B-X
mood	B-X
disorders	B-X

Cortisol	O
,	O
corticosterone	O
,	O
and	O
progesterone	O
competed	O
with	O
dexamethasone	O
for	O
binding	O
,	O
whereas	O
estradiol	O
,	O
dihydrotestosterone	O
,	O
and	O
11-epicortisol	O
competed	O
very	O
little	O
.	O
<EOS>	B-X
Cortisol	B-X
,	B-X
corticosterone	B-X
,	B-X
and	B-X
progesterone	B-X
competed	B-X
with	B-X
dexamethasone	B-X
for	B-X
binding	B-X
,	B-X
whereas	B-X
estradiol	B-X
,	B-X
dihydrotestosterone	B-X
,	B-X
and	B-X
11	B-X
-	B-X
epicortisol	B-X
competed	B-X
very	B-X
little	B-X
<EOS>	B-X
The	B-X
binding	B-X
to	B-X
the	B-X
saturable	B-X
sites	B-X
was	B-X
specific	B-X
for	B-X
steroids	B-X
with	B-X
glucocorticoid	B-X
or	B-X
antiglucocorticoid	B-X
activity	B-X
<EOS>	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
the	B-X
predominant	B-X
form	B-X
of	B-X
the	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
was	B-X
nuclear	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
corticosteroids	B-X
interact	B-X
with	B-X
macrophages	B-X
at	B-X
physiological	B-X
concentrations	B-X

Binding	O
of	O
dexamethasone	O
to	O
cytosol	O
and	O
nuclear	O
forms	O
of	O
the	O
receptor	B-protein
complex	I-protein
and	O
temperature-sensitive	O
translocation	O
of	O
cytosol	O
forms	O
to	O
nuclear	O
forms	O
were	O
shown	O
.	O
<EOS>	B-X
Binding	B-X
of	B-X
dexamethasone	B-X
to	B-X
cytosol	B-X
and	B-X
nuclear	B-X
forms	B-X
of	B-X
the	B-X
receptor	B-X
complex	B-X
and	B-X
temperature	B-X
-	B-X
sensitive	B-X
translocation	B-X
of	B-X
cytosol	B-X
forms	B-X
to	B-X
nuclear	B-X
forms	B-X
were	B-X
shown	B-X
<EOS>	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
the	B-X
predominant	B-X
form	B-X
of	B-X
the	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
was	B-X
nuclear	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
corticosteroids	B-X
interact	B-X
with	B-X
macrophages	B-X
at	B-X
physiological	B-X
concentrations	B-X
<EOS>	B-X
The	B-X
binding	B-X
to	B-X
the	B-X
saturable	B-X
sites	B-X
was	B-X
specific	B-X
for	B-X
steroids	B-X
with	B-X
glucocorticoid	B-X
or	B-X
antiglucocorticoid	B-X
activity	B-X

At	O
37	O
degrees	O
C	O
the	O
predominant	O
form	O
of	O
the	O
hormone-receptor	B-protein
complex	I-protein
was	O
nuclear	O
.	O
<EOS>	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
the	B-X
predominant	B-X
form	B-X
of	B-X
the	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
was	B-X
nuclear	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
glucocorticoids	B-X
with	B-X
macrophages	B-X
.	B-X
Identification	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
monocytes	B-X
and	B-X
macrophages	B-X
.	B-X
<EOS>	B-X
Binding	B-X
of	B-X
dexamethasone	B-X
to	B-X
cytosol	B-X
and	B-X
nuclear	B-X
forms	B-X
of	B-X
the	B-X
receptor	B-X
complex	B-X
and	B-X
temperature	B-X
-	B-X
sensitive	B-X
translocation	B-X
of	B-X
cytosol	B-X
forms	B-X
to	B-X
nuclear	B-X
forms	B-X
were	B-X
shown	B-X
<EOS>	B-X
Glucocorticoid	B-X
binding	B-X
was	B-X
measured	B-X
in	B-X
resident	B-X
and	B-X
thioglycollate	B-X
-	B-X
elicited	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
,	B-X
rabbit	B-X
alveolar	B-X
macrophages	B-X
,	B-X
and	B-X
human	B-X
monocytes	B-X

These	O
results	O
demonstrate	O
that	O
corticosteroids	O
interact	O
with	O
macrophages	B-cell_type
at	O
physiological	O
concentrations	O
.	O
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
corticosteroids	B-X
interact	B-X
with	B-X
macrophages	B-X
at	B-X
physiological	B-X
concentrations	B-X
<EOS>	B-X
Glucocorticoid	B-X
binding	B-X
was	B-X
measured	B-X
in	B-X
resident	B-X
and	B-X
thioglycollate	B-X
-	B-X
elicited	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
,	B-X
rabbit	B-X
alveolar	B-X
macrophages	B-X
,	B-X
and	B-X
human	B-X
monocytes	B-X
<EOS>	B-X
The	B-X
binding	B-X
to	B-X
the	B-X
saturable	B-X
sites	B-X
was	B-X
specific	B-X
for	B-X
steroids	B-X
with	B-X
glucocorticoid	B-X
or	B-X
antiglucocorticoid	B-X
activity	B-X
<EOS>	B-X
Cortisol	B-X
,	B-X
corticosterone	B-X
,	B-X
and	B-X
progesterone	B-X
competed	B-X
with	B-X
dexamethasone	B-X
for	B-X
binding	B-X
,	B-X
whereas	B-X
estradiol	B-X
,	B-X
dihydrotestosterone	B-X
,	B-X
and	B-X
11	B-X
-	B-X
epicortisol	B-X
competed	B-X
very	B-X
little	B-X

Nitric	O
oxide	O
signaling	O
:	O
a	O
possible	O
role	O
for	O
G	B-protein
proteins	I-protein
.	O

We	O
have	O
previously	O
reported	O
various	O
inductive	O
effects	O
of	O
nitric	O
oxide	O
on	O
human	B-cell_type
PBMC	I-cell_type
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
various	B-X
inductive	B-X
effects	B-X
of	B-X
nitric	B-X
oxide	B-X
on	B-X
human	B-X
PBMC	B-X
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
novel	B-X
and	B-X
potentially	B-X
important	B-X
mechanism	B-X
of	B-X
nitric	B-X
oxide	B-X
signaling	B-X
-	B-X
through	B-X
direct	B-X
activation	B-X
of	B-X
guanine	B-X
nucleotide	B-X
-	B-X
binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
<EOS>	B-X
Because	B-X
G	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
many	B-X
diverse	B-X
signaling	B-X
systems	B-X
,	B-X
activation	B-X
by	B-X
an	B-X
endogenous	B-X
and	B-X
inducible	B-X
oxidant	B-X
may	B-X
represent	B-X
a	B-X
novel	B-X
signaling	B-X
pathway	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
nitric	B-X
oxide	B-X
greatly	B-X
reduced	B-X
the	B-X
pertussis	B-X
toxin	B-X
-	B-X
mediated	B-X
ADP	B-X
-	B-X
ribosylation	B-X
of	B-X
45	B-X
-	B-X
	B-X
and	B-X
41	B-X
-	B-X
kDa	B-X
proteins	B-X
in	B-X
membranes	B-X
of	B-X
these	B-X
cells	B-X

We	O
describe	O
a	O
novel	O
and	O
potentially	O
important	O
mechanism	O
of	O
nitric	O
oxide	O
signaling-through	O
direct	O
activation	O
of	O
guanine	B-protein
nucleotide-binding	I-protein
proteins	I-protein
(	O
G	B-protein
proteins	I-protein
)	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
novel	B-X
and	B-X
potentially	B-X
important	B-X
mechanism	B-X
of	B-X
nitric	B-X
oxide	B-X
signaling	B-X
-	B-X
through	B-X
direct	B-X
activation	B-X
of	B-X
guanine	B-X
nucleotide	B-X
-	B-X
binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
various	B-X
inductive	B-X
effects	B-X
of	B-X
nitric	B-X
oxide	B-X
on	B-X
human	B-X
PBMC	B-X
<EOS>	B-X
Nitric	B-X
oxide	B-X
signaling	B-X
:	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
G	B-X
proteins	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
treatment	B-X
of	B-X
whole	B-X
cells	B-X
with	B-X
nitric	B-X
oxide	B-X
yielded	B-X
membranes	B-X
with	B-X
enhanced	B-X
GTPase	B-X
activity	B-X

We	O
have	O
found	O
that	O
nitric	O
oxide	O
treatment	O
of	O
membranes	O
isolated	O
from	O
fresh	B-cell_type
human	I-cell_type
PBMC	I-cell_type
enhances	O
the	O
ability	O
of	O
these	O
membranes	O
to	O
hydrolyze	O
[	O
gamma-32P	O
]	O
GTP	O
and	O
bind	O
[	O
gamma-35S	O
]	O
GTP	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
nitric	B-X
oxide	B-X
treatment	B-X
of	B-X
membranes	B-X
isolated	B-X
from	B-X
fresh	B-X
human	B-X
PBMC	B-X
enhances	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
membranes	B-X
to	B-X
hydrolyze	B-X
[	B-X
gamma	B-X
-	B-X
32P	B-X
]	B-X
GTP	B-X
and	B-X
bind	B-X
[	B-X
gamma	B-X
-	B-X
35S	B-X
]	B-X
GTP	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
treatment	B-X
of	B-X
whole	B-X
cells	B-X
with	B-X
nitric	B-X
oxide	B-X
yielded	B-X
membranes	B-X
with	B-X
enhanced	B-X
GTPase	B-X
activity	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
nitric	B-X
oxide	B-X
greatly	B-X
reduced	B-X
the	B-X
pertussis	B-X
toxin	B-X
-	B-X
mediated	B-X
ADP	B-X
-	B-X
ribosylation	B-X
of	B-X
45	B-X
-	B-X
	B-X
and	B-X
41	B-X
-	B-X
kDa	B-X
proteins	B-X
in	B-X
membranes	B-X
of	B-X
these	B-X
cells	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
pure	B-X
,	B-X
recombinant	B-X
Gs	B-X
alpha	B-X
,	B-X
Gi	B-X
alpha	B-X
1	B-X
,	B-X
and	B-X
p21ras	B-X
was	B-X
greatly	B-X
enhanced	B-X
by	B-X
nitric	B-X
oxide	B-X

In	O
addition	O
,	O
treatment	O
of	O
whole	O
cells	O
with	O
nitric	O
oxide	O
yielded	O
membranes	O
with	O
enhanced	O
GTPase	O
activity	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
treatment	B-X
of	B-X
whole	B-X
cells	B-X
with	B-X
nitric	B-X
oxide	B-X
yielded	B-X
membranes	B-X
with	B-X
enhanced	B-X
GTPase	B-X
activity	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
nitric	B-X
oxide	B-X
treatment	B-X
of	B-X
membranes	B-X
isolated	B-X
from	B-X
fresh	B-X
human	B-X
PBMC	B-X
enhances	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
membranes	B-X
to	B-X
hydrolyze	B-X
[	B-X
gamma	B-X
-	B-X
32P	B-X
]	B-X
GTP	B-X
and	B-X
bind	B-X
[	B-X
gamma	B-X
-	B-X
35S	B-X
]	B-X
GTP	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
nitric	B-X
oxide	B-X
greatly	B-X
reduced	B-X
the	B-X
pertussis	B-X
toxin	B-X
-	B-X
mediated	B-X
ADP	B-X
-	B-X
ribosylation	B-X
of	B-X
45	B-X
-	B-X
	B-X
and	B-X
41	B-X
-	B-X
kDa	B-X
proteins	B-X
in	B-X
membranes	B-X
of	B-X
these	B-X
cells	B-X
<EOS>	B-X
In	B-X
support	B-X
of	B-X
the	B-X
existence	B-X
of	B-X
this	B-X
pathway	B-X
in	B-X
whole	B-X
cells	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
G	B-X
protein	B-X
inhibitor	B-X
,	B-X
GDP	B-X
-	B-X
beta	B-X
-	B-X
S	B-X
,	B-X
blocked	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
translocation	B-X
induced	B-X
by	B-X
nitric	B-X
oxide	B-X
or	B-X
LPS	B-X
in	B-X
permeabilized	B-X
cells	B-X

Furthermore	O
,	O
the	O
GTPase	O
activity	O
of	O
pure	O
,	O
recombinant	O
Gs	B-protein
alpha	I-protein
,	O
Gi	B-protein
alpha	I-protein
1	I-protein
,	O
and	O
p21ras	B-protein
was	O
greatly	O
enhanced	O
by	O
nitric	O
oxide	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
pure	B-X
,	B-X
recombinant	B-X
Gs	B-X
alpha	B-X
,	B-X
Gi	B-X
alpha	B-X
1	B-X
,	B-X
and	B-X
p21ras	B-X
was	B-X
greatly	B-X
enhanced	B-X
by	B-X
nitric	B-X
oxide	B-X
<EOS>	B-X
In	B-X
support	B-X
of	B-X
the	B-X
existence	B-X
of	B-X
this	B-X
pathway	B-X
in	B-X
whole	B-X
cells	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
G	B-X
protein	B-X
inhibitor	B-X
,	B-X
GDP	B-X
-	B-X
beta	B-X
-	B-X
S	B-X
,	B-X
blocked	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
translocation	B-X
induced	B-X
by	B-X
nitric	B-X
oxide	B-X
or	B-X
LPS	B-X
in	B-X
permeabilized	B-X
cells	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
treatment	B-X
of	B-X
whole	B-X
cells	B-X
with	B-X
nitric	B-X
oxide	B-X
yielded	B-X
membranes	B-X
with	B-X
enhanced	B-X
GTPase	B-X
activity	B-X
<EOS>	B-X
Because	B-X
G	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
many	B-X
diverse	B-X
signaling	B-X
systems	B-X
,	B-X
activation	B-X
by	B-X
an	B-X
endogenous	B-X
and	B-X
inducible	B-X
oxidant	B-X
may	B-X
represent	B-X
a	B-X
novel	B-X
signaling	B-X
pathway	B-X

In	O
support	O
of	O
the	O
existence	O
of	O
this	O
pathway	O
in	O
whole	O
cells	O
,	O
we	O
found	O
that	O
the	O
G	O
protein	O
inhibitor	O
,	O
GDP-beta-S	O
,	O
blocked	O
NF-kappa	B-protein
B	I-protein
translocation	O
induced	O
by	O
nitric	O
oxide	O
or	O
LPS	O
in	O
permeabilized	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
A	B-X
higher	B-X
proportion	B-X
of	B-X
phospholipids	B-X
with	B-X
neutral	B-X
charge	B-X
such	B-X
as	B-X
phosphatidylethanolamine	B-X
or	B-X
phosphatidylcholine	B-X
reduces	B-X
the	B-X
LPPO	B-X
permeabilizing	B-X
potential	B-X
<EOS>	B-X
LPPO	B-X
activity	B-X
is	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
value	B-X
of	B-X
the	B-X
target	B-X
membrane	B-X
potential	B-X
,	B-X
and	B-X
thus	B-X
they	B-X
are	B-X
also	B-X
active	B-X
against	B-X
persister	B-X
cells	B-X
<EOS>	B-X
The	B-X
percentage	B-X
of	B-X
R	B-X
-	B-X
PE	B-X
positive	B-X
B	B-X
cells	B-X
varied	B-X
,	B-X
according	B-X
to	B-X
the	B-X
used	B-X
antibodies	B-X
or	B-X
the	B-X
fixation	B-X
/	B-X
permeabilization	B-X
kit	B-X
<EOS>	B-X
Role	B-X
of	B-X
lipopolysaccharide	B-X
in	B-X
antimicrobial	B-X
and	B-X
cell	B-X
penetrating	B-X
peptide	B-X
membrane	B-X
interactions	B-X
probed	B-X
by	B-X
deuterium	B-X
NMR	B-X
of	B-X
whole	B-X
cells	B-X
.	B-X

In	O
addition	O
,	O
nitric	O
oxide	O
greatly	O
reduced	O
the	O
pertussis	O
toxin-mediated	O
ADP-ribosylation	O
of	O
45-	B-protein
and	I-protein
41-kDa	I-protein
proteins	I-protein
in	O
membranes	O
of	O
these	O
cells	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
nitric	B-X
oxide	B-X
greatly	B-X
reduced	B-X
the	B-X
pertussis	B-X
toxin	B-X
-	B-X
mediated	B-X
ADP	B-X
-	B-X
ribosylation	B-X
of	B-X
45	B-X
-	B-X
	B-X
and	B-X
41	B-X
-	B-X
kDa	B-X
proteins	B-X
in	B-X
membranes	B-X
of	B-X
these	B-X
cells	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
treatment	B-X
of	B-X
whole	B-X
cells	B-X
with	B-X
nitric	B-X
oxide	B-X
yielded	B-X
membranes	B-X
with	B-X
enhanced	B-X
GTPase	B-X
activity	B-X
<EOS>	B-X
In	B-X
support	B-X
of	B-X
the	B-X
existence	B-X
of	B-X
this	B-X
pathway	B-X
in	B-X
whole	B-X
cells	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
G	B-X
protein	B-X
inhibitor	B-X
,	B-X
GDP	B-X
-	B-X
beta	B-X
-	B-X
S	B-X
,	B-X
blocked	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
translocation	B-X
induced	B-X
by	B-X
nitric	B-X
oxide	B-X
or	B-X
LPS	B-X
in	B-X
permeabilized	B-X
cells	B-X
<EOS>	B-X
Nitric	B-X
oxide	B-X
signaling	B-X
:	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
G	B-X
proteins	B-X
.	B-X

Because	O
G	B-protein
proteins	I-protein
play	O
a	O
central	O
role	O
in	O
many	O
diverse	O
signaling	O
systems	O
,	O
activation	O
by	O
an	O
endogenous	O
and	O
inducible	O
oxidant	O
may	O
represent	O
a	O
novel	O
signaling	O
pathway	O
.	O
<EOS>	B-X
Because	B-X
G	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
many	B-X
diverse	B-X
signaling	B-X
systems	B-X
,	B-X
activation	B-X
by	B-X
an	B-X
endogenous	B-X
and	B-X
inducible	B-X
oxidant	B-X
may	B-X
represent	B-X
a	B-X
novel	B-X
signaling	B-X
pathway	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
various	B-X
inductive	B-X
effects	B-X
of	B-X
nitric	B-X
oxide	B-X
on	B-X
human	B-X
PBMC	B-X
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
novel	B-X
and	B-X
potentially	B-X
important	B-X
mechanism	B-X
of	B-X
nitric	B-X
oxide	B-X
signaling	B-X
-	B-X
through	B-X
direct	B-X
activation	B-X
of	B-X
guanine	B-X
nucleotide	B-X
-	B-X
binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
treatment	B-X
of	B-X
whole	B-X
cells	B-X
with	B-X
nitric	B-X
oxide	B-X
yielded	B-X
membranes	B-X
with	B-X
enhanced	B-X
GTPase	B-X
activity	B-X

The	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
promoter	I-DNA
cis-acting	I-DNA
element	I-DNA
CLE0	B-DNA
mediates	O
induction	O
signals	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
is	O
recognized	O
by	O
factors	O
related	O
to	O
AP1	B-protein
and	O
NFAT	B-protein
.	O

Expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
in	O
T	O
cells	O
is	O
activated	O
by	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
phorbol	O
myristate	O
acetate	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
which	O
mimic	O
antigen	O
stimulation	O
through	O
the	O
T-cell	B-protein
receptor	I-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
fragment	O
containing	O
bp	B-DNA
-95	I-DNA
to	I-DNA
+27	I-DNA
of	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
can	O
confer	O
inducibility	O
to	O
reporter	B-DNA
genes	I-DNA
in	O
the	O
human	B-cell_line
Jurkat	I-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
a	B-X
fragment	B-X
containing	B-X
bp	B-X
	B-X
-	B-X
95	B-X
to	B-X
+27	B-X
of	B-X
the	B-X
mouse	B-X
GM	B-X
-	B-X
CSF	B-X
promoter	B-X
can	B-X
confer	B-X
inducibility	B-X
to	B-X
reporter	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
We	B-X
observed	B-X
induction	B-X
with	B-X
templates	B-X
containing	B-X
intact	B-X
CLE0	B-X
but	B-X
not	B-X
with	B-X
templates	B-X
with	B-X
deleted	B-X
or	B-X
mutated	B-X
CLE0	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
gene	B-X
in	B-X
T	B-X
cells	B-X
is	B-X
activated	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
phorbol	B-X
ester	B-X
(	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
)	B-X
and	B-X
calcium	B-X
ionophore	B-X
(	B-X
A23187	B-X
)	B-X
,	B-X
which	B-X
mimic	B-X
antigen	B-X
stimulation	B-X
through	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
CLE0	B-X
-	B-X
like	B-X
elements	B-X
in	B-X
the	B-X
promoters	B-X
of	B-X
interleukin	B-X
-	B-X
3	B-X
(	B-X
IL	B-X
-	B-X
3	B-X
)	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
IL	B-X
-	B-X
5	B-X
,	B-X
GM	B-X
-	B-X
CSF	B-X
,	B-X
and	B-X
NFAT	B-X
sites	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
suggests	B-X
that	B-X
the	B-X
factors	B-X
we	B-X
detected	B-X
,	B-X
or	B-X
related	B-X
factors	B-X
that	B-X
recognize	B-X
these	B-X
sites	B-X
,	B-X
may	B-X
account	B-X
for	B-X
the	B-X
coordinate	B-X
induction	B-X
of	B-X
these	B-X
genes	B-X
during	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X

Here	O
we	O
use	O
an	O
in	O
vitro	O
transcription	O
system	O
to	O
demonstrate	O
that	O
a	O
cis-acting	B-DNA
element	I-DNA
(	O
positions	B-DNA
-54	I-DNA
to	I-DNA
-40	I-DNA
)	O
,	O
referred	O
to	O
as	O
CLE0	B-DNA
,	O
is	O
a	O
target	O
for	O
the	O
induction	O
signals	O
.	O

We	O
observed	O
induction	O
with	O
templates	O
containing	O
intact	O
CLE0	B-DNA
but	O
not	O
with	O
templates	O
with	O
deleted	B-DNA
or	I-DNA
mutated	I-DNA
CLE0	I-DNA
.	O
<EOS>	B-X
We	B-X
observed	B-X
induction	B-X
with	B-X
templates	B-X
containing	B-X
intact	B-X
CLE0	B-X
but	B-X
not	B-X
with	B-X
templates	B-X
with	B-X
deleted	B-X
or	B-X
mutated	B-X
CLE0	B-X
<EOS>	B-X
We	B-X
also	B-X
observed	B-X
that	B-X
two	B-X
distinct	B-X
signals	B-X
were	B-X
required	B-X
for	B-X
the	B-X
stimulation	B-X
through	B-X
CLE0	B-X
,	B-X
since	B-X
only	B-X
extracts	B-X
from	B-X
cells	B-X
treated	B-X
with	B-X
both	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
and	B-X
A23187	B-X
supported	B-X
optimal	B-X
induction	B-X
<EOS>	B-X
The	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
promoter	B-X
cis	B-X
-	B-X
acting	B-X
element	B-X
CLE0	B-X
mediates	B-X
induction	B-X
signals	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
is	B-X
recognized	B-X
by	B-X
factors	B-X
related	B-X
to	B-X
AP1	B-X
and	B-X
NFAT	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
a	B-X
fragment	B-X
containing	B-X
bp	B-X
	B-X
-	B-X
95	B-X
to	B-X
+27	B-X
of	B-X
the	B-X
mouse	B-X
GM	B-X
-	B-X
CSF	B-X
promoter	B-X
can	B-X
confer	B-X
inducibility	B-X
to	B-X
reporter	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cell	B-X
line	B-X

We	O
also	O
observed	O
that	O
two	O
distinct	O
signals	O
were	O
required	O
for	O
the	O
stimulation	O
through	O
CLE0	B-DNA
,	O
since	O
only	O
extracts	O
from	O
cells	O
treated	O
with	O
both	O
phorbol	O
myristate	O
acetate	O
and	O
A23187	O
supported	O
optimal	O
induction	O
.	O
<EOS>	B-X
We	B-X
also	B-X
observed	B-X
that	B-X
two	B-X
distinct	B-X
signals	B-X
were	B-X
required	B-X
for	B-X
the	B-X
stimulation	B-X
through	B-X
CLE0	B-X
,	B-X
since	B-X
only	B-X
extracts	B-X
from	B-X
cells	B-X
treated	B-X
with	B-X
both	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
and	B-X
A23187	B-X
supported	B-X
optimal	B-X
induction	B-X
<EOS>	B-X
We	B-X
observed	B-X
induction	B-X
with	B-X
templates	B-X
containing	B-X
intact	B-X
CLE0	B-X
but	B-X
not	B-X
with	B-X
templates	B-X
with	B-X
deleted	B-X
or	B-X
mutated	B-X
CLE0	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
(	B-X
GM	B-X
-	B-X
CSF	B-X
)	B-X
gene	B-X
in	B-X
T	B-X
cells	B-X
is	B-X
activated	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
phorbol	B-X
ester	B-X
(	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
)	B-X
and	B-X
calcium	B-X
ionophore	B-X
(	B-X
A23187	B-X
)	B-X
,	B-X
which	B-X
mimic	B-X
antigen	B-X
stimulation	B-X
through	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
<EOS>	B-X
The	B-X
characteristics	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
are	B-X
consistent	B-X
with	B-X
their	B-X
involvement	B-X
in	B-X
GM	B-X
-	B-X
CSF	B-X
induction	B-X

Stimulation	O
probably	O
was	O
mediated	O
by	O
CLE0-binding	B-protein
proteins	I-protein
because	O
depletion	O
of	O
these	O
proteins	O
specifically	O
reduced	O
GM-CSF	B-protein
transcription	O
.	O
<EOS>	B-X
Stimulation	B-X
probably	B-X
was	B-X
mediated	B-X
by	B-X
CLE0	B-X
-	B-X
binding	B-X
proteins	B-X
because	B-X
depletion	B-X
of	B-X
these	B-X
proteins	B-X
specifically	B-X
reduced	B-X
GM	B-X
-	B-X
CSF	B-X
transcription	B-X
<EOS>	B-X
The	B-X
characteristics	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
are	B-X
consistent	B-X
with	B-X
their	B-X
involvement	B-X
in	B-X
GM	B-X
-	B-X
CSF	B-X
induction	B-X
<EOS>	B-X
We	B-X
observed	B-X
induction	B-X
with	B-X
templates	B-X
containing	B-X
intact	B-X
CLE0	B-X
but	B-X
not	B-X
with	B-X
templates	B-X
with	B-X
deleted	B-X
or	B-X
mutated	B-X
CLE0	B-X
<EOS>	B-X
The	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
promoter	B-X
cis	B-X
-	B-X
acting	B-X
element	B-X
CLE0	B-X
mediates	B-X
induction	B-X
signals	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
is	B-X
recognized	B-X
by	B-X
factors	B-X
related	B-X
to	B-X
AP1	B-X
and	B-X
NFAT	B-X
.	B-X

One	O
of	O
the	O
binding	B-protein
factors	I-protein
possessed	O
biochemical	O
and	O
immunological	O
features	O
identical	O
to	O
those	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP1	I-protein
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
binding	B-X
factors	B-X
possessed	B-X
biochemical	B-X
and	B-X
immunological	B-X
features	B-X
identical	B-X
to	B-X
those	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP1	B-X
<EOS>	B-X
Another	B-X
factor	B-X
resembled	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
factor	B-X
NFAT	B-X
<EOS>	B-X
Here	B-X
we	B-X
use	B-X
an	B-X
in	B-X
vitro	B-X
transcription	B-X
system	B-X
to	B-X
demonstrate	B-X
that	B-X
a	B-X
cis	B-X
-	B-X
acting	B-X
element	B-X
(	B-X
positions	B-X
	B-X
-	B-X
54	B-X
to	B-X
	B-X
-	B-X
40	B-X
)	B-X
,	B-X
referred	B-X
to	B-X
as	B-X
CLE0	B-X
,	B-X
is	B-X
a	B-X
target	B-X
for	B-X
the	B-X
induction	B-X
signals	B-X
<EOS>	B-X
The	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
promoter	B-X
cis	B-X
-	B-X
acting	B-X
element	B-X
CLE0	B-X
mediates	B-X
induction	B-X
signals	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
is	B-X
recognized	B-X
by	B-X
factors	B-X
related	B-X
to	B-X
AP1	B-X
and	B-X
NFAT	B-X
.	B-X

Another	O
factor	O
resembled	O
the	O
T-cell-specific	B-protein
factor	I-protein
NFAT	I-protein
.	O
<EOS>	B-X
Another	B-X
factor	B-X
resembled	B-X
the	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
factor	B-X
NFAT	B-X
<EOS>	B-X
Three	B-X
of	B-X
these	B-X
AP1	B-X
elements	B-X
lie	B-X
within	B-X
sequences	B-X
that	B-X
also	B-X
associate	B-X
with	B-X
factors	B-X
resembling	B-X
the	B-X
CsA	B-X
-	B-X
sensitive	B-X
,	B-X
T	B-X
cell	B-X
-	B-X
specific	B-X
transcription	B-X
factor	B-X
NFAT	B-X
<EOS>	B-X
We	B-X
show	B-X
that	B-X
it	B-X
is	B-X
bound	B-X
by	B-X
the	B-X
ets	B-X
-	B-X
related	B-X
factor	B-X
,	B-X
Elf1	B-X
<EOS>	B-X
One	B-X
of	B-X
the	B-X
binding	B-X
factors	B-X
possessed	B-X
biochemical	B-X
and	B-X
immunological	B-X
features	B-X
identical	B-X
to	B-X
those	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP1	B-X

The	O
characteristics	O
of	O
these	O
two	O
factors	O
are	O
consistent	O
with	O
their	O
involvement	O
in	O
GM-CSF	O
induction	O
.	O
<EOS>	B-X
The	B-X
characteristics	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
are	B-X
consistent	B-X
with	B-X
their	B-X
involvement	B-X
in	B-X
GM	B-X
-	B-X
CSF	B-X
induction	B-X
<EOS>	B-X
The	B-X
granulocyte	B-X
-	B-X
macrophage	B-X
colony	B-X
-	B-X
stimulating	B-X
factor	B-X
promoter	B-X
cis	B-X
-	B-X
acting	B-X
element	B-X
CLE0	B-X
mediates	B-X
induction	B-X
signals	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
is	B-X
recognized	B-X
by	B-X
factors	B-X
related	B-X
to	B-X
AP1	B-X
and	B-X
NFAT	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
use	B-X
an	B-X
in	B-X
vitro	B-X
transcription	B-X
system	B-X
to	B-X
demonstrate	B-X
that	B-X
a	B-X
cis	B-X
-	B-X
acting	B-X
element	B-X
(	B-X
positions	B-X
	B-X
-	B-X
54	B-X
to	B-X
	B-X
-	B-X
40	B-X
)	B-X
,	B-X
referred	B-X
to	B-X
as	B-X
CLE0	B-X
,	B-X
is	B-X
a	B-X
target	B-X
for	B-X
the	B-X
induction	B-X
signals	B-X
<EOS>	B-X
We	B-X
also	B-X
observed	B-X
that	B-X
two	B-X
distinct	B-X
signals	B-X
were	B-X
required	B-X
for	B-X
the	B-X
stimulation	B-X
through	B-X
CLE0	B-X
,	B-X
since	B-X
only	B-X
extracts	B-X
from	B-X
cells	B-X
treated	B-X
with	B-X
both	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
and	B-X
A23187	B-X
supported	B-X
optimal	B-X
induction	B-X

The	O
presence	O
of	O
CLE0-like	B-DNA
elements	I-DNA
in	O
the	O
promoters	B-DNA
of	O
interleukin-3	B-DNA
(	I-DNA
IL-3	I-DNA
)	I-DNA
,	I-DNA
IL-4	I-DNA
,	I-DNA
IL-5	I-DNA
,	I-DNA
GM-CSF	I-DNA
,	I-DNA
and	I-DNA
NFAT	I-DNA
sites	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
suggests	O
that	O
the	O
factors	O
we	O
detected	O
,	O
or	O
related	O
factors	O
that	O
recognize	O
these	O
sites	O
,	O
may	O
account	O
for	O
the	O
coordinate	O
induction	O
of	O
these	O
genes	O
during	O
T-cell	B-cell_type
activation	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
CLE0	B-X
-	B-X
like	B-X
elements	B-X
in	B-X
the	B-X
promoters	B-X
of	B-X
interleukin	B-X
-	B-X
3	B-X
(	B-X
IL	B-X
-	B-X
3	B-X
)	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
IL	B-X
-	B-X
5	B-X
,	B-X
GM	B-X
-	B-X
CSF	B-X
,	B-X
and	B-X
NFAT	B-X
sites	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
promoter	B-X
suggests	B-X
that	B-X
the	B-X
factors	B-X
we	B-X
detected	B-X
,	B-X
or	B-X
related	B-X
factors	B-X
that	B-X
recognize	B-X
these	B-X
sites	B-X
,	B-X
may	B-X
account	B-X
for	B-X
the	B-X
coordinate	B-X
induction	B-X
of	B-X
these	B-X
genes	B-X
during	B-X
T	B-X
-	B-X
cell	B-X
activation	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
a	B-X
fragment	B-X
containing	B-X
bp	B-X
	B-X
-	B-X
95	B-X
to	B-X
+27	B-X
of	B-X
the	B-X
mouse	B-X
GM	B-X
-	B-X
CSF	B-X
promoter	B-X
can	B-X
confer	B-X
inducibility	B-X
to	B-X
reporter	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
Jurkat	B-X
T	B-X
-	B-X
cell	B-X
line	B-X
<EOS>	B-X
Here	B-X
we	B-X
use	B-X
an	B-X
in	B-X
vitro	B-X
transcription	B-X
system	B-X
to	B-X
demonstrate	B-X
that	B-X
a	B-X
cis	B-X
-	B-X
acting	B-X
element	B-X
(	B-X
positions	B-X
	B-X
-	B-X
54	B-X
to	B-X
	B-X
-	B-X
40	B-X
)	B-X
,	B-X
referred	B-X
to	B-X
as	B-X
CLE0	B-X
,	B-X
is	B-X
a	B-X
target	B-X
for	B-X
the	B-X
induction	B-X
signals	B-X
<EOS>	B-X
We	B-X
also	B-X
observed	B-X
that	B-X
two	B-X
distinct	B-X
signals	B-X
were	B-X
required	B-X
for	B-X
the	B-X
stimulation	B-X
through	B-X
CLE0	B-X
,	B-X
since	B-X
only	B-X
extracts	B-X
from	B-X
cells	B-X
treated	B-X
with	B-X
both	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
and	B-X
A23187	B-X
supported	B-X
optimal	B-X
induction	B-X

Identification	O
and	O
characterization	O
of	O
an	O
Alu-containing	B-DNA
,	I-DNA
T-cell-specific	I-DNA
enhancer	I-DNA
located	O
in	O
the	O
last	O
intron	B-DNA
of	O
the	O
human	B-DNA
CD8	I-DNA
alpha	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
an	B-X
Alu	B-X
-	B-X
containing	B-X
,	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
.	B-X
<EOS>	B-X
By	B-X
using	B-X
a	B-X
reporter	B-X
-	B-X
based	B-X
expression	B-X
approach	B-X
,	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
was	B-X
identified	B-X
by	B-X
its	B-X
close	B-X
association	B-X
with	B-X
a	B-X
prominent	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
restricted	B-X
hypersensitive	B-X
sites	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
CD8	B-X
alpha	B-X
gene	B-X
<EOS>	B-X
Comparison	B-X
of	B-X
the	B-X
CD8	B-X
alpha	B-X
enhancer	B-X
with	B-X
other	B-X
recently	B-X
identified	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
regulatory	B-X
elements	B-X
suggests	B-X
that	B-X
a	B-X
common	B-X
set	B-X
of	B-X
transcription	B-X
factors	B-X
regulates	B-X
several	B-X
T	B-X
-	B-X
cell	B-X
genes	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
multiple	B-X
T	B-X
-	B-X
cell	B-X
nuclear	B-X
proteins	B-X
with	B-X
a	B-X
transcriptional	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
gene	B-X

Expression	O
of	O
the	O
human	B-DNA
CD8	I-DNA
alpha	I-DNA
gene	I-DNA
is	O
restricted	O
to	O
cells	O
of	O
the	O
lymphoid	B-cell_type
lineage	I-cell_type
and	O
developmentally	O
regulated	O
during	O
thymopoiesis	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
restricted	B-X
to	B-X
cells	B-X
of	B-X
the	B-X
lymphoid	B-X
lineage	B-X
and	B-X
developmentally	B-X
regulated	B-X
during	B-X
thymopoiesis	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
multiple	B-X
T	B-X
-	B-X
cell	B-X
nuclear	B-X
proteins	B-X
with	B-X
a	B-X
transcriptional	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Comparison	B-X
of	B-X
the	B-X
CD8	B-X
alpha	B-X
enhancer	B-X
with	B-X
other	B-X
recently	B-X
identified	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
regulatory	B-X
elements	B-X
suggests	B-X
that	B-X
a	B-X
common	B-X
set	B-X
of	B-X
transcription	B-X
factors	B-X
regulates	B-X
several	B-X
T	B-X
-	B-X
cell	B-X
genes	B-X
<EOS>	B-X
Deletion	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
minimal	B-X
enhancer	B-X
is	B-X
adjacent	B-X
to	B-X
a	B-X
negative	B-X
regulatory	B-X
element	B-X

As	O
an	O
initial	O
step	O
towards	O
understanding	O
the	O
molecular	O
basis	O
for	O
tissue-specific	O
expression	O
of	O
this	O
gene	O
,	O
we	O
surveyed	O
the	O
surrounding	O
chromatin	O
structure	O
for	O
potential	O
cis-acting	B-DNA
regulatory	I-DNA
regions	I-DNA
by	O
DNase	B-protein
I	I-protein
hypersensitivity	O
mapping	O
and	O
found	O
four	O
hypersensitive	O
sites	O
,	O
three	O
of	O
which	O
were	O
T	O
cell	O
restricted	O
.	O

By	O
using	O
a	O
reporter-based	O
expression	O
approach	O
,	O
a	O
T-cell-specific	B-DNA
enhancer	I-DNA
was	O
identified	O
by	O
its	O
close	O
association	O
with	O
a	O
prominent	O
T-cell-restricted	B-DNA
hypersensitive	I-DNA
sites	I-DNA
in	O
the	O
last	O
intron	O
of	O
the	O
CD8	B-DNA
alpha	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
By	B-X
using	B-X
a	B-X
reporter	B-X
-	B-X
based	B-X
expression	B-X
approach	B-X
,	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
was	B-X
identified	B-X
by	B-X
its	B-X
close	B-X
association	B-X
with	B-X
a	B-X
prominent	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
restricted	B-X
hypersensitive	B-X
sites	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
CD8	B-X
alpha	B-X
gene	B-X
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
an	B-X
Alu	B-X
-	B-X
containing	B-X
,	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
.	B-X
<EOS>	B-X
As	B-X
an	B-X
initial	B-X
step	B-X
towards	B-X
understanding	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
tissue	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
,	B-X
we	B-X
surveyed	B-X
the	B-X
surrounding	B-X
chromatin	B-X
structure	B-X
for	B-X
potential	B-X
cis	B-X
-	B-X
acting	B-X
regulatory	B-X
regions	B-X
by	B-X
DNase	B-X
I	B-X
hypersensitivity	B-X
mapping	B-X
and	B-X
found	B-X
four	B-X
hypersensitive	B-X
sites	B-X
,	B-X
three	B-X
of	B-X
which	B-X
were	B-X
T	B-X
cell	B-X
restricted	B-X
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
multiple	B-X
T	B-X
-	B-X
cell	B-X
nuclear	B-X
proteins	B-X
with	B-X
a	B-X
transcriptional	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
gene	B-X

Deletion	O
studies	O
demonstrated	O
that	O
the	O
minimal	O
enhancer	O
is	O
adjacent	O
to	O
a	O
negative	O
regulatory	O
element	O
.	O
<EOS>	B-X
Deletion	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
minimal	B-X
enhancer	B-X
is	B-X
adjacent	B-X
to	B-X
a	B-X
negative	B-X
regulatory	B-X
element	B-X
<EOS>	B-X
The	B-X
functional	B-X
importance	B-X
of	B-X
the	B-X
other	B-X
binding	B-X
sites	B-X
only	B-X
became	B-X
apparent	B-X
when	B-X
combinations	B-X
of	B-X
mutations	B-X
were	B-X
analyzed	B-X
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
an	B-X
Alu	B-X
-	B-X
containing	B-X
,	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
.	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
restricted	B-X
to	B-X
cells	B-X
of	B-X
the	B-X
lymphoid	B-X
lineage	B-X
and	B-X
developmentally	B-X
regulated	B-X
during	B-X
thymopoiesis	B-X

DNA	O
sequence	O
analysis	O
of	O
the	O
minimal	B-DNA
enhancer	I-DNA
revealed	O
a	O
striking	O
cluster	O
of	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
Ets-1	B-protein
,	I-protein
TCF-1	I-protein
,	I-protein
CRE	I-protein
,	I-protein
GATA-3	I-protein
,	I-protein
LyF-1	I-protein
,	I-protein
and	I-protein
bHLH	I-protein
proteins	I-protein
which	O
were	O
verified	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
<EOS>	B-X
DNA	B-X
sequence	B-X
analysis	B-X
of	B-X
the	B-X
minimal	B-X
enhancer	B-X
revealed	B-X
a	B-X
striking	B-X
cluster	B-X
of	B-X
consensus	B-X
binding	B-X
sites	B-X
for	B-X
Ets	B-X
-	B-X
1	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
,	B-X
CRE	B-X
,	B-X
GATA	B-X
-	B-X
3	B-X
,	B-X
LyF	B-X
-	B-X
1	B-X
,	B-X
and	B-X
bHLH	B-X
proteins	B-X
which	B-X
were	B-X
verified	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
<EOS>	B-X
The	B-X
functional	B-X
importance	B-X
of	B-X
the	B-X
other	B-X
binding	B-X
sites	B-X
only	B-X
became	B-X
apparent	B-X
when	B-X
combinations	B-X
of	B-X
mutations	B-X
were	B-X
analyzed	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
enhancer	B-X
was	B-X
composed	B-X
of	B-X
an	B-X
Alu	B-X
repeat	B-X
which	B-X
contained	B-X
the	B-X
GATA	B-X
-	B-X
3	B-X
,	B-X
bHLH	B-X
,	B-X
and	B-X
LyF	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
restricted	B-X
to	B-X
cells	B-X
of	B-X
the	B-X
lymphoid	B-X
lineage	B-X
and	B-X
developmentally	B-X
regulated	B-X
during	B-X
thymopoiesis	B-X

In	O
addition	O
,	O
the	O
5	B-DNA
'	I-DNA
end	I-DNA
of	O
the	O
enhancer	B-DNA
was	O
composed	O
of	O
an	O
Alu	O
repeat	O
which	O
contained	O
the	O
GATA-3	B-DNA
,	I-DNA
bHLH	I-DNA
,	I-DNA
and	I-DNA
LyF-1	I-DNA
binding	I-DNA
sites	I-DNA
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
enhancer	B-X
was	B-X
composed	B-X
of	B-X
an	B-X
Alu	B-X
repeat	B-X
which	B-X
contained	B-X
the	B-X
GATA	B-X
-	B-X
3	B-X
,	B-X
bHLH	B-X
,	B-X
and	B-X
LyF	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
<EOS>	B-X
DNA	B-X
sequence	B-X
analysis	B-X
of	B-X
the	B-X
minimal	B-X
enhancer	B-X
revealed	B-X
a	B-X
striking	B-X
cluster	B-X
of	B-X
consensus	B-X
binding	B-X
sites	B-X
for	B-X
Ets	B-X
-	B-X
1	B-X
,	B-X
TCF	B-X
-	B-X
1	B-X
,	B-X
CRE	B-X
,	B-X
GATA	B-X
-	B-X
3	B-X
,	B-X
LyF	B-X
-	B-X
1	B-X
,	B-X
and	B-X
bHLH	B-X
proteins	B-X
which	B-X
were	B-X
verified	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
<EOS>	B-X
By	B-X
using	B-X
a	B-X
reporter	B-X
-	B-X
based	B-X
expression	B-X
approach	B-X
,	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
was	B-X
identified	B-X
by	B-X
its	B-X
close	B-X
association	B-X
with	B-X
a	B-X
prominent	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
restricted	B-X
hypersensitive	B-X
sites	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
CD8	B-X
alpha	B-X
gene	B-X
<EOS>	B-X
The	B-X
functional	B-X
importance	B-X
of	B-X
the	B-X
other	B-X
binding	B-X
sites	B-X
only	B-X
became	B-X
apparent	B-X
when	B-X
combinations	B-X
of	B-X
mutations	B-X
were	B-X
analyzed	B-X

Site-directed	O
mutation	O
of	O
the	O
Ets-1	B-DNA
and	I-DNA
GATA-3	I-DNA
sites	I-DNA
dramatically	O
reduced	O
enhancer	O
activity	O
.	O
<EOS>	B-X
Site	B-X
-	B-X
directed	B-X
mutation	B-X
of	B-X
the	B-X
Ets	B-X
-	B-X
1	B-X
and	B-X
GATA	B-X
-	B-X
3	B-X
sites	B-X
dramatically	B-X
reduced	B-X
enhancer	B-X
activity	B-X
<EOS>	B-X
The	B-X
functional	B-X
importance	B-X
of	B-X
the	B-X
other	B-X
binding	B-X
sites	B-X
only	B-X
became	B-X
apparent	B-X
when	B-X
combinations	B-X
of	B-X
mutations	B-X
were	B-X
analyzed	B-X
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
an	B-X
Alu	B-X
-	B-X
containing	B-X
,	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
.	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
restricted	B-X
to	B-X
cells	B-X
of	B-X
the	B-X
lymphoid	B-X
lineage	B-X
and	B-X
developmentally	B-X
regulated	B-X
during	B-X
thymopoiesis	B-X

The	O
functional	O
importance	O
of	O
the	O
other	O
binding	O
sites	O
only	O
became	O
apparent	O
when	O
combinations	O
of	O
mutations	O
were	O
analyzed	O
.	O
<EOS>	B-X
The	B-X
functional	B-X
importance	B-X
of	B-X
the	B-X
other	B-X
binding	B-X
sites	B-X
only	B-X
became	B-X
apparent	B-X
when	B-X
combinations	B-X
of	B-X
mutations	B-X
were	B-X
analyzed	B-X
<EOS>	B-X
Deletion	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
minimal	B-X
enhancer	B-X
is	B-X
adjacent	B-X
to	B-X
a	B-X
negative	B-X
regulatory	B-X
element	B-X
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
an	B-X
Alu	B-X
-	B-X
containing	B-X
,	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
.	B-X
<EOS>	B-X
Comparison	B-X
of	B-X
the	B-X
CD8	B-X
alpha	B-X
enhancer	B-X
with	B-X
other	B-X
recently	B-X
identified	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
regulatory	B-X
elements	B-X
suggests	B-X
that	B-X
a	B-X
common	B-X
set	B-X
of	B-X
transcription	B-X
factors	B-X
regulates	B-X
several	B-X
T	B-X
-	B-X
cell	B-X
genes	B-X

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
human	B-DNA
CD8	I-DNA
alpha	I-DNA
gene	I-DNA
is	O
regulated	O
by	O
the	O
interaction	O
of	O
multiple	O
T-cell	B-protein
nuclear	I-protein
proteins	I-protein
with	O
a	O
transcriptional	O
enhancer	O
located	O
in	O
the	O
last	O
intron	B-DNA
of	O
the	O
gene	O
.	O
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
multiple	B-X
T	B-X
-	B-X
cell	B-X
nuclear	B-X
proteins	B-X
with	B-X
a	B-X
transcriptional	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
gene	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
restricted	B-X
to	B-X
cells	B-X
of	B-X
the	B-X
lymphoid	B-X
lineage	B-X
and	B-X
developmentally	B-X
regulated	B-X
during	B-X
thymopoiesis	B-X
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
an	B-X
Alu	B-X
-	B-X
containing	B-X
,	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
.	B-X
<EOS>	B-X
By	B-X
using	B-X
a	B-X
reporter	B-X
-	B-X
based	B-X
expression	B-X
approach	B-X
,	B-X
a	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
was	B-X
identified	B-X
by	B-X
its	B-X
close	B-X
association	B-X
with	B-X
a	B-X
prominent	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
restricted	B-X
hypersensitive	B-X
sites	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
CD8	B-X
alpha	B-X
gene	B-X

Comparison	O
of	O
the	O
CD8	B-DNA
alpha	I-DNA
enhancer	I-DNA
with	O
other	O
recently	O
identified	O
T-cell-specific	B-DNA
regulatory	I-DNA
elements	I-DNA
suggests	O
that	O
a	O
common	O
set	O
of	O
transcription	B-protein
factors	I-protein
regulates	O
several	O
T-cell	B-DNA
genes	I-DNA
.	O
<EOS>	B-X
Comparison	B-X
of	B-X
the	B-X
CD8	B-X
alpha	B-X
enhancer	B-X
with	B-X
other	B-X
recently	B-X
identified	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
regulatory	B-X
elements	B-X
suggests	B-X
that	B-X
a	B-X
common	B-X
set	B-X
of	B-X
transcription	B-X
factors	B-X
regulates	B-X
several	B-X
T	B-X
-	B-X
cell	B-X
genes	B-X
<EOS>	B-X
Identification	B-X
and	B-X
characterization	B-X
of	B-X
an	B-X
Alu	B-X
-	B-X
containing	B-X
,	B-X
T	B-X
-	B-X
cell	B-X
-	B-X
specific	B-X
enhancer	B-X
located	B-X
in	B-X
the	B-X
last	B-X
intron	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
.	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
human	B-X
CD8	B-X
alpha	B-X
gene	B-X
is	B-X
restricted	B-X
to	B-X
cells	B-X
of	B-X
the	B-X
lymphoid	B-X
lineage	B-X
and	B-X
developmentally	B-X
regulated	B-X
during	B-X
thymopoiesis	B-X
<EOS>	B-X
The	B-X
functional	B-X
importance	B-X
of	B-X
the	B-X
other	B-X
binding	B-X
sites	B-X
only	B-X
became	B-X
apparent	B-X
when	B-X
combinations	B-X
of	B-X
mutations	B-X
were	B-X
analyzed	B-X

Molecular	O
regulation	O
of	O
the	O
human	B-DNA
IL-3	I-DNA
gene	I-DNA
:	O
inducible	O
T	O
cell-restricted	O
expression	O
requires	O
intact	O
AP-1	B-DNA
and	I-DNA
Elf-1	I-DNA
nuclear	I-DNA
protein	I-DNA
binding	I-DNA
sites	I-DNA
.	O
<EOS>	B-X
Molecular	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
3	B-X
gene	B-X
:	B-X
inducible	B-X
T	B-X
cell	B-X
-	B-X
restricted	B-X
expression	B-X
requires	B-X
intact	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
nuclear	B-X
protein	B-X
binding	B-X
sites	B-X
.	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
expression	B-X
of	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
3	B-X
gene	B-X
requires	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
;	B-X
however	B-X
,	B-X
unlike	B-X
other	B-X
previously	B-X
characterized	B-X
cytokine	B-X
genes	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
factors	B-X
can	B-X
bind	B-X
independently	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
3	B-X
gene	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
in	B-X
MLA	B-X
-	B-X
144	B-X
T	B-X
cells	B-X
revealed	B-X
that	B-X
constructs	B-X
containing	B-X
mutations	B-X
in	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
almost	B-X
completely	B-X
abolished	B-X
CAT	B-X
activity	B-X
while	B-X
mutation	B-X
of	B-X
the	B-X
Elf	B-X
-	B-X
1	B-X
site	B-X
or	B-X
the	B-X
NF	B-X
-	B-X
IL	B-X
-	B-X
3	B-X
site	B-X
,	B-X
a	B-X
previously	B-X
described	B-X
nuclear	B-X
protein	B-X
binding	B-X
site	B-X
(	B-X
bp	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
extracts	B-X
prepared	B-X
from	B-X
purified	B-X
human	B-X
T	B-X
cells	B-X
contained	B-X
proteins	B-X
that	B-X
bound	B-X
to	B-X
synthetic	B-X
oligonucleotides	B-X
corresponding	B-X
to	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X

Interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
is	O
a	O
hematopoietic	B-protein
stem-cell	I-protein
growth	I-protein
and	I-protein
differentiation	I-protein
factor	I-protein
that	O
is	O
expressed	O
solely	O
in	O
activated	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Interleukin	B-X
3	B-X
(	B-X
IL	B-X
-	B-X
3	B-X
)	B-X
is	B-X
a	B-X
hematopoietic	B-X
stem	B-X
-	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
factor	B-X
that	B-X
is	B-X
expressed	B-X
solely	B-X
in	B-X
activated	B-X
T	B-X
and	B-X
NK	B-X
cells	B-X
<EOS>	B-X
In	B-X
vitro	B-X
-	B-X
transcribed	B-X
and	B-X
	B-X
-	B-X
translated	B-X
Elf	B-X
-	B-X
1	B-X
protein	B-X
bound	B-X
specifically	B-X
to	B-X
the	B-X
Elf	B-X
-	B-X
1	B-X
site	B-X
,	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
antisera	B-X
competed	B-X
and	B-X
super	B-X
shifted	B-X
nuclear	B-X
protein	B-X
complexes	B-X
present	B-X
in	B-X
MLA	B-X
-	B-X
144	B-X
nuclear	B-X
extracts	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
in	B-X
MLA	B-X
-	B-X
144	B-X
T	B-X
cells	B-X
revealed	B-X
that	B-X
constructs	B-X
containing	B-X
mutations	B-X
in	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
almost	B-X
completely	B-X
abolished	B-X
CAT	B-X
activity	B-X
while	B-X
mutation	B-X
of	B-X
the	B-X
Elf	B-X
-	B-X
1	B-X
site	B-X
or	B-X
the	B-X
NF	B-X
-	B-X
IL	B-X
-	B-X
3	B-X
site	B-X
,	B-X
a	B-X
previously	B-X
described	B-X
nuclear	B-X
protein	B-X
binding	B-X
site	B-X
(	B-X
bp	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
extracts	B-X
prepared	B-X
from	B-X
purified	B-X
human	B-X
T	B-X
cells	B-X
contained	B-X
proteins	B-X
that	B-X
bound	B-X
to	B-X
synthetic	B-X
oligonucleotides	B-X
corresponding	B-X
to	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X

Studies	O
to	O
date	O
have	O
identified	O
elements	O
5	O
'	O
to	O
the	O
IL-3	B-DNA
coding	I-DNA
sequences	I-DNA
that	O
regulate	O
its	O
transcription	O
,	O
but	O
the	O
sequences	O
that	O
confer	O
T	O
cell-specific	O
expression	O
remain	O
to	O
be	O
clearly	O
defined	O
.	O

We	O
have	O
now	O
identified	O
DNA	B-DNA
sequences	I-DNA
that	O
are	O
required	O
for	O
T	O
cell-restricted	O
IL-3	B-DNA
gene	I-DNA
transcription	O
.	O

A	O
series	O
of	O
transient	O
transfections	O
performed	O
with	O
human	B-DNA
IL-3-chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
plasmids	I-DNA
in	O
T	B-cell_type
and	I-cell_type
non-T	I-cell_type
cells	I-cell_type
revealed	O
that	O
a	O
plasmid	B-DNA
containing	O
319	O
bp	O
of	O
5	B-DNA
'	I-DNA
flanking	I-DNA
sequences	I-DNA
was	O
active	O
exclusively	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Deletion	O
analysis	O
revealed	O
that	O
T	B-cell_type
cell	I-cell_type
specificity	O
was	O
conferred	O
by	O
a	O
49-bp	B-DNA
fragment	I-DNA
(	O
bp	B-DNA
-319	I-DNA
to	I-DNA
-270	I-DNA
)	O
that	O
included	O
a	O
potential	B-DNA
binding	I-DNA
site	I-DNA
for	O
AP-1	B-protein
transcription	I-protein
factors	I-protein
6	O
bp	O
upstream	O
of	O
a	O
binding	B-DNA
site	I-DNA
for	I-DNA
Elf-1	I-DNA
,	O
a	O
member	O
of	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

DNaseI	B-protein
footprint	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
analyses	O
performed	O
with	O
MLA-144	B-cell_line
T	I-cell_line
cell	I-cell_line
nuclear	O
extracts	O
demonstrated	O
that	O
this	O
49-bp	B-DNA
region	I-DNA
contains	O
a	O
nuclear	B-DNA
protein	I-DNA
binding	I-DNA
region	I-DNA
that	O
includes	O
consensus	B-DNA
AP-1	I-DNA
and	I-DNA
Elf-1	I-DNA
binding	I-DNA
sites	I-DNA
.	O
<EOS>	B-X
DNaseI	B-X
footprint	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
analyses	B-X
performed	B-X
with	B-X
MLA	B-X
-	B-X
144	B-X
T	B-X
cell	B-X
nuclear	B-X
extracts	B-X
demonstrated	B-X
that	B-X
this	B-X
49	B-X
-	B-X
bp	B-X
region	B-X
contains	B-X
a	B-X
nuclear	B-X
protein	B-X
binding	B-X
region	B-X
that	B-X
includes	B-X
consensus	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
extracts	B-X
prepared	B-X
from	B-X
purified	B-X
human	B-X
T	B-X
cells	B-X
contained	B-X
proteins	B-X
that	B-X
bound	B-X
to	B-X
synthetic	B-X
oligonucleotides	B-X
corresponding	B-X
to	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Molecular	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
3	B-X
gene	B-X
:	B-X
inducible	B-X
T	B-X
cell	B-X
-	B-X
restricted	B-X
expression	B-X
requires	B-X
intact	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
nuclear	B-X
protein	B-X
binding	B-X
sites	B-X
.	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
addition	B-X
of	B-X
anti	B-X
-	B-X
Jun	B-X
family	B-X
antiserum	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
reactions	B-X
completely	B-X
blocked	B-X
formation	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
related	B-X
complexes	B-X

In	O
addition	O
,	O
extracts	O
prepared	O
from	O
purified	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
contained	O
proteins	O
that	O
bound	O
to	O
synthetic	O
oligonucleotides	O
corresponding	O
to	O
the	O
AP-1	B-DNA
and	I-DNA
Elf-1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

In	O
vitro-transcribed	O
and	O
-translated	O
Elf-1	B-protein
protein	I-protein
bound	O
specifically	O
to	O
the	O
Elf-1	B-DNA
site	I-DNA
,	O
and	O
Elf-1	O
antisera	O
competed	O
and	O
super	O
shifted	O
nuclear	O
protein	O
complexes	O
present	O
in	O
MLA-144	B-cell_line
nuclear	O
extracts	O
.	O

Moreover	O
,	O
addition	O
of	O
anti-Jun	O
family	O
antiserum	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
reactions	O
completely	O
blocked	O
formation	O
of	O
the	O
AP-1-related	B-protein
complexes	I-protein
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
addition	B-X
of	B-X
anti	B-X
-	B-X
Jun	B-X
family	B-X
antiserum	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
reactions	B-X
completely	B-X
blocked	B-X
formation	B-X
of	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
-	B-X
related	B-X
complexes	B-X
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
in	B-X
MLA	B-X
-	B-X
144	B-X
T	B-X
cells	B-X
revealed	B-X
that	B-X
constructs	B-X
containing	B-X
mutations	B-X
in	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
almost	B-X
completely	B-X
abolished	B-X
CAT	B-X
activity	B-X
while	B-X
mutation	B-X
of	B-X
the	B-X
Elf	B-X
-	B-X
1	B-X
site	B-X
or	B-X
the	B-X
NF	B-X
-	B-X
IL	B-X
-	B-X
3	B-X
site	B-X
,	B-X
a	B-X
previously	B-X
described	B-X
nuclear	B-X
protein	B-X
binding	B-X
site	B-X
(	B-X
bp	B-X
<EOS>	B-X
DNaseI	B-X
footprint	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
analyses	B-X
performed	B-X
with	B-X
MLA	B-X
-	B-X
144	B-X
T	B-X
cell	B-X
nuclear	B-X
extracts	B-X
demonstrated	B-X
that	B-X
this	B-X
49	B-X
-	B-X
bp	B-X
region	B-X
contains	B-X
a	B-X
nuclear	B-X
protein	B-X
binding	B-X
region	B-X
that	B-X
includes	B-X
consensus	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
<EOS>	B-X
We	B-X
have	B-X
now	B-X
identified	B-X
DNA	B-X
sequences	B-X
that	B-X
are	B-X
required	B-X
for	B-X
T	B-X
cell	B-X
-	B-X
restricted	B-X
IL	B-X
-	B-X
3	B-X
gene	B-X
transcription	B-X

Transient	O
transfection	O
studies	O
in	O
MLA-144	B-cell_line
T	I-cell_line
cells	I-cell_line
revealed	O
that	O
constructs	O
containing	O
mutations	O
in	O
the	O
AP-1	B-DNA
site	I-DNA
almost	O
completely	O
abolished	O
CAT	O
activity	O
while	O
mutation	O
of	O
the	O
Elf-1	B-DNA
site	I-DNA
or	O
the	O
NF-IL-3	B-DNA
site	I-DNA
,	O
a	O
previously	O
described	O
nuclear	B-DNA
protein	I-DNA
binding	I-DNA
site	I-DNA
(	O
bp.	B-DNA
-155	I-DNA
to	I-DNA
-148	I-DNA
)	O
in	O
the	O
IL-3	B-DNA
promoter	I-DNA
,	O
reduced	O
CAT	O
activity	O
to	O
<	O
25	O
%	O
of	O
the	O
activity	O
given	O
by	O
wild-type	O
constructs	O
.	O
<EOS>	B-X
Transient	B-X
transfection	B-X
studies	B-X
in	B-X
MLA	B-X
-	B-X
144	B-X
T	B-X
cells	B-X
revealed	B-X
that	B-X
constructs	B-X
containing	B-X
mutations	B-X
in	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
site	B-X
almost	B-X
completely	B-X
abolished	B-X
CAT	B-X
activity	B-X
while	B-X
mutation	B-X
of	B-X
the	B-X
Elf	B-X
-	B-X
1	B-X
site	B-X
or	B-X
the	B-X
NF	B-X
-	B-X
IL	B-X
-	B-X
3	B-X
site	B-X
,	B-X
a	B-X
previously	B-X
described	B-X
nuclear	B-X
protein	B-X
binding	B-X
site	B-X
(	B-X
bp	B-X
<EOS>	B-X
	B-X
-	B-X
155	B-X
to	B-X
	B-X
-	B-X
148	B-X
)	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
3	B-X
promoter	B-X
,	B-X
reduced	B-X
CAT	B-X
activity	B-X
to	B-X
<	B-X
25	B-X
%	B-X
of	B-X
the	B-X
activity	B-X
given	B-X
by	B-X
wild	B-X
-	B-X
type	B-X
constructs	B-X
<EOS>	B-X
Deletion	B-X
analysis	B-X
revealed	B-X
that	B-X
T	B-X
cell	B-X
specificity	B-X
was	B-X
conferred	B-X
by	B-X
a	B-X
49	B-X
-	B-X
bp	B-X
fragment	B-X
(	B-X
bp	B-X
	B-X
-	B-X
319	B-X
to	B-X
	B-X
-	B-X
270	B-X
)	B-X
that	B-X
included	B-X
a	B-X
potential	B-X
binding	B-X
site	B-X
for	B-X
AP	B-X
-	B-X
1	B-X
transcription	B-X
factors	B-X
6	B-X
bp	B-X
upstream	B-X
of	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
Elf	B-X
-	B-X
1	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Ets	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
<EOS>	B-X
DNaseI	B-X
footprint	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
analyses	B-X
performed	B-X
with	B-X
MLA	B-X
-	B-X
144	B-X
T	B-X
cell	B-X
nuclear	B-X
extracts	B-X
demonstrated	B-X
that	B-X
this	B-X
49	B-X
-	B-X
bp	B-X
region	B-X
contains	B-X
a	B-X
nuclear	B-X
protein	B-X
binding	B-X
region	B-X
that	B-X
includes	B-X
consensus	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X

We	O
conclude	O
that	O
expression	O
of	O
the	O
human	B-DNA
IL-3	I-DNA
gene	I-DNA
requires	O
the	O
AP-1	B-DNA
and	I-DNA
Elf-1	I-DNA
binding	I-DNA
sites	I-DNA
;	O
however	O
,	O
unlike	O
other	O
previously	O
characterized	O
cytokine	B-DNA
genes	I-DNA
such	O
as	O
IL-2	B-protein
,	O
the	O
AP-1	B-protein
and	I-protein
Elf-1	I-protein
factors	I-protein
can	O
bind	O
independently	O
in	O
the	O
IL-3	B-DNA
gene	I-DNA
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
expression	B-X
of	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
3	B-X
gene	B-X
requires	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
;	B-X
however	B-X
,	B-X
unlike	B-X
other	B-X
previously	B-X
characterized	B-X
cytokine	B-X
genes	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
factors	B-X
can	B-X
bind	B-X
independently	B-X
in	B-X
the	B-X
IL	B-X
-	B-X
3	B-X
gene	B-X
<EOS>	B-X
Molecular	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
IL	B-X
-	B-X
3	B-X
gene	B-X
:	B-X
inducible	B-X
T	B-X
cell	B-X
-	B-X
restricted	B-X
expression	B-X
requires	B-X
intact	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
nuclear	B-X
protein	B-X
binding	B-X
sites	B-X
.	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
extracts	B-X
prepared	B-X
from	B-X
purified	B-X
human	B-X
T	B-X
cells	B-X
contained	B-X
proteins	B-X
that	B-X
bound	B-X
to	B-X
synthetic	B-X
oligonucleotides	B-X
corresponding	B-X
to	B-X
the	B-X
AP	B-X
-	B-X
1	B-X
and	B-X
Elf	B-X
-	B-X
1	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Studies	B-X
to	B-X
date	B-X
have	B-X
identified	B-X
elements	B-X
5	B-X
'	B-X
to	B-X
the	B-X
IL	B-X
-	B-X
3	B-X
coding	B-X
sequences	B-X
that	B-X
regulate	B-X
its	B-X
transcription	B-X
,	B-X
but	B-X
the	B-X
sequences	B-X
that	B-X
confer	B-X
T	B-X
cell	B-X
-	B-X
specific	B-X
expression	B-X
remain	B-X
to	B-X
be	B-X
clearly	B-X
defined	B-X

Combination	O
IL-2	B-protein
and	O
IL-4	B-protein
reduces	O
glucocorticoid	O
receptor-binding	O
affinity	O
and	O
T	B-cell_type
cell	I-cell_type
response	O
to	O
glucocorticoids	O
.	O

The	O
mechanisms	O
contributing	O
to	O
persistent	O
T	B-cell_type
cell	I-cell_type
activation	O
and	O
poor	O
response	O
to	O
glucocorticoids	O
in	O
chronic	O
inflammatory	O
illnesses	O
such	O
as	O
steroid	O
resistant	O
(	O
SR	O
)	O
asthma	O
are	O
poorly	O
defined	O
.	O
<EOS>	B-X
The	B-X
mechanisms	B-X
contributing	B-X
to	B-X
persistent	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
poor	B-X
response	B-X
to	B-X
glucocorticoids	B-X
in	B-X
chronic	B-X
inflammatory	B-X
illnesses	B-X
such	B-X
as	B-X
steroid	B-X
resistant	B-X
(	B-X
SR	B-X
)	B-X
asthma	B-X
are	B-X
poorly	B-X
defined	B-X
<EOS>	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
with	B-X
persistent	B-X
inflammation	B-X
certain	B-X
cytokines	B-X
may	B-X
contribute	B-X
to	B-X
an	B-X
impaired	B-X
response	B-X
to	B-X
glucocorticoids	B-X
<EOS>	B-X
Combination	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
reduces	B-X
glucocorticoid	B-X
receptor	B-X
-	B-X
binding	B-X
affinity	B-X
and	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
glucocorticoids	B-X
.	B-X
<EOS>	B-X
The	B-X
altered	B-X
PBMC	B-X
GR	B-X
binding	B-X
from	B-X
patients	B-X
with	B-X
SR	B-X
asthma	B-X
reversed	B-X
to	B-X
normal	B-X
when	B-X
incubated	B-X
with	B-X
medium	B-X
alone	B-X
,	B-X
but	B-X
was	B-X
sustained	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X

We	O
examined	O
the	O
possibility	O
that	O
certain	O
cytokines	O
,	O
specifically	O
IL-2	B-protein
and	O
IL-4	B-protein
,	O
could	O
affect	O
T	O
cell	O
response	O
to	O
glucocorticoids	O
.	O
<EOS>	B-X
We	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
certain	B-X
cytokines	B-X
,	B-X
specifically	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
could	B-X
affect	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
glucocorticoids	B-X
<EOS>	B-X
Combination	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
reduces	B-X
glucocorticoid	B-X
receptor	B-X
-	B-X
binding	B-X
affinity	B-X
and	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
glucocorticoids	B-X
.	B-X
<EOS>	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
with	B-X
persistent	B-X
inflammation	B-X
certain	B-X
cytokines	B-X
may	B-X
contribute	B-X
to	B-X
an	B-X
impaired	B-X
response	B-X
to	B-X
glucocorticoids	B-X
<EOS>	B-X
More	B-X
importantly	B-X
,	B-X
the	B-X
alteration	B-X
in	B-X
PBMC	B-X
GR	B-X
-	B-X
binding	B-X
affinity	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
functional	B-X
change	B-X
in	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
methylprednisolone	B-X
MPN	B-X
,	B-X
i	B-X

A	O
[	O
3H	O
]	O
dexamethasone	O
radioligand-binding	O
assay	O
was	O
used	O
to	O
measure	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
and	O
dissociation	O
constant	O
(	O
Kd	O
)	O
in	O
PBMC	B-cell_type
from	O
normal	O
donors	O
and	O
patients	O
with	O
SR	O
asthma	O
,	O
cultured	O
in	O
the	O
absence	O
and	O
presence	O
of	O
these	O
cytokines	B-protein
.	O
<EOS>	B-X
A	B-X
[	B-X
3H	B-X
]	B-X
dexamethasone	B-X
radioligand	B-X
-	B-X
binding	B-X
assay	B-X
was	B-X
used	B-X
to	B-X
measure	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
(	B-X
GR	B-X
)	B-X
and	B-X
dissociation	B-X
constant	B-X
(	B-X
Kd	B-X
)	B-X
in	B-X
PBMC	B-X
from	B-X
normal	B-X
donors	B-X
and	B-X
patients	B-X
with	B-X
SR	B-X
asthma	B-X
,	B-X
cultured	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
presence	B-X
of	B-X
these	B-X
cytokines	B-X
<EOS>	B-X
Combination	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
reduces	B-X
glucocorticoid	B-X
receptor	B-X
-	B-X
binding	B-X
affinity	B-X
and	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
glucocorticoids	B-X
.	B-X
<EOS>	B-X
The	B-X
mechanisms	B-X
contributing	B-X
to	B-X
persistent	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
poor	B-X
response	B-X
to	B-X
glucocorticoids	B-X
in	B-X
chronic	B-X
inflammatory	B-X
illnesses	B-X
such	B-X
as	B-X
steroid	B-X
resistant	B-X
(	B-X
SR	B-X
)	B-X
asthma	B-X
are	B-X
poorly	B-X
defined	B-X
<EOS>	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
with	B-X
persistent	B-X
inflammation	B-X
certain	B-X
cytokines	B-X
may	B-X
contribute	B-X
to	B-X
an	B-X
impaired	B-X
response	B-X
to	B-X
glucocorticoids	B-X

PBMC	O
from	O
normal	O
donors	O
incubated	O
for	O
48	O
h	O
in	O
the	O
presence	O
of	O
combination	O
IL-2	B-protein
+	O
IL-4	B-protein
had	O
nuclear	O
GR	O
with	O
significantly	O
reduced	O
binding	O
affinity	O
(	O
GR	O
Kd	O
=	O
36.1	O
+/-	O
1.63	O
nM	O
,	O
mean	O
+/-	O
SEM	O
;	O
p	O
=	O
0.0001	O
)	O
as	O
compared	O
with	O
PBMC	B-cell_type
incubated	O
with	O
medium	O
alone	O
(	O
GR	O
Kd	O
=	O
6.74	O
+/-	O
0.46	O
nM	O
)	O
.	O

The	O
cytosolic	O
GR	O
Kd	O
remained	O
unchanged	O
.	O
<EOS>	B-X
The	B-X
cytosolic	B-X
GR	B-X
Kd	B-X
remained	B-X
unchanged	B-X
<EOS>	B-X
Bmax	B-X
of	B-X
MR	B-X
was	B-X
also	B-X
significantly	B-X
increased	B-X
after	B-X
3	B-X
days	B-X
,	B-X
whereas	B-X
its	B-X
Kd	B-X
remained	B-X
unchanged	B-X
for	B-X
the	B-X
entire	B-X
duration	B-X
of	B-X
the	B-X
the	B-X
study	B-X
<EOS>	B-X
Bmax	B-X
and	B-X
Kd	B-X
for	B-X
GR	B-X
showed	B-X
a	B-X
significant	B-X
increase	B-X
after	B-X
3	B-X
days	B-X
and	B-X
1	B-X
week	B-X
<EOS>	B-X
These	B-X
effects	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
on	B-X
PBMC	B-X
GR	B-X
affinity	B-X
and	B-X
response	B-X
to	B-X
MPN	B-X
were	B-X
blocked	B-X
by	B-X
co	B-X
-	B-X
incubation	B-X
with	B-X
IFN	B-X
-	B-X
gamma	B-X

However	O
,	O
when	O
PBMC	B-cell_type
were	O
incubated	O
with	O
IL-2	B-protein
alone	O
or	O
IL-4	B-protein
alone	O
,	O
no	O
change	O
in	O
GR-binding	O
affinity	O
was	O
observed	O
.	O
<EOS>	B-X
When	B-X
PBMC	B-X
from	B-X
SS	B-X
,	B-X
SD	B-X
and	B-X
SR	B-X
was	B-X
incubated	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
or	B-X
IL	B-X
-	B-X
4	B-X
alone	B-X
,	B-X
no	B-X
changes	B-X
in	B-X
GR	B-X
and	B-X
HSP90	B-X
mRNA	B-X
expression	B-X
were	B-X
observed	B-X
<EOS>	B-X
However	B-X
,	B-X
cells	B-X
incubated	B-X
with	B-X
the	B-X
anti	B-X
-	B-X
CD3	B-X
mAb	B-X
displayed	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
nuclear	B-X
activity	B-X
in	B-X
7	B-X
of	B-X
the	B-X
11	B-X
cases	B-X
<EOS>	B-X
1	B-X
-	B-X
100	B-X
U	B-X
/	B-X
ml	B-X
were	B-X
incubated	B-X
for	B-X
48	B-X
h	B-X
with	B-X
PBMC	B-X
alone	B-X
or	B-X
with	B-X
PBMC	B-X
and	B-X
various	B-X
mitogens	B-X
<EOS>	B-X
Incubation	B-X
of	B-X
PBMC	B-X
with	B-X
NK	B-X
-	B-X
stimulatory	B-X
cytokines	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
IL	B-X
-	B-X
12	B-X
,	B-X
or	B-X
IL	B-X
-	B-X
15	B-X
)	B-X
led	B-X
to	B-X
significant	B-X
increases	B-X
in	B-X
cytotoxic	B-X
activity	B-X
regardless	B-X
of	B-X
IES	B-X
/	B-X
NK	B-X
(	B-X
50	B-X
)	B-X
scores	B-X

Furthermore	O
,	O
when	O
T	B-cell_type
cells	I-cell_type
and	O
non-T	B-cell_type
cells	I-cell_type
were	O
individually	O
stimulated	O
with	O
combination	O
IL-2	O
+	O
IL-4	O
,	O
a	O
significant	O
reduction	O
in	O
GR-binding	O
affinity	O
was	O
observed	O
only	O
in	O
the	O
T	B-cell_type
cell	I-cell_type
population	I-cell_type
(	O
p	O
=	O
0.0001	O
)	O
.	O

The	O
IL-2	O
+	O
IL-4-induced	O
alteration	O
in	O
PBMC	O
GR	O
Kd	O
was	O
associated	O
with	O
an	O
increase	O
in	O
GR	O
number	O
(	O
8348	O
+/-	O
964	O
vs	O
1710	O
+/-	O
228	O
sites/cell	O
;	O
p	O
=	O
0.0003	O
)	O
.	O
<EOS>	B-X
The	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
induced	B-X
alteration	B-X
in	B-X
PBMC	B-X
GR	B-X
Kd	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
GR	B-X
number	B-X
(	B-X
8348	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
964	B-X
vs	B-X
1710	B-X
+	B-X
/	B-X
	B-X
-	B-X
	B-X
228	B-X
sites	B-X
/	B-X
cell	B-X
;	B-X
p	B-X
=	B-X
0	B-X
<EOS>	B-X
More	B-X
importantly	B-X
,	B-X
the	B-X
alteration	B-X
in	B-X
PBMC	B-X
GR	B-X
-	B-X
binding	B-X
affinity	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
functional	B-X
change	B-X
in	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
methylprednisolone	B-X
MPN	B-X
,	B-X
i	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
when	B-X
T	B-X
cells	B-X
and	B-X
non	B-X
-	B-X
T	B-X
cells	B-X
were	B-X
individually	B-X
stimulated	B-X
with	B-X
combination	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
,	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
GR	B-X
-	B-X
binding	B-X
affinity	B-X
was	B-X
observed	B-X
only	B-X
in	B-X
the	B-X
T	B-X
cell	B-X
population	B-X
(	B-X
p	B-X
=	B-X
0	B-X
<EOS>	B-X
These	B-X
effects	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
on	B-X
PBMC	B-X
GR	B-X
affinity	B-X
and	B-X
response	B-X
to	B-X
MPN	B-X
were	B-X
blocked	B-X
by	B-X
co	B-X
-	B-X
incubation	B-X
with	B-X
IFN	B-X
-	B-X
gamma	B-X

More	O
importantly	O
,	O
the	O
alteration	O
in	O
PBMC	O
GR-binding	O
affinity	O
with	O
IL-2	B-protein
+	O
IL-4	B-protein
was	O
associated	O
with	O
a	O
functional	O
change	O
in	O
T	O
cell	O
response	O
to	O
methylprednisolone	O
MPN	O
,	O
i.e.	O
,	O
a	O
reduced	O
inhibitory	O
effect	O
of	O
MPN	O
on	O
PMA/ionomycin-induced	O
T	B-cell_type
cell	I-cell_type
proliferation	O
.	O

These	O
effects	O
of	O
IL-2	B-protein
+	O
IL-4	B-protein
on	O
PBMC	B-cell_type
GR	B-protein
affinity	O
and	O
response	O
to	O
MPN	O
were	O
blocked	O
by	O
co-incubation	O
with	O
IFN-gamma	B-protein
.	O
<EOS>	B-X
These	B-X
effects	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
on	B-X
PBMC	B-X
GR	B-X
affinity	B-X
and	B-X
response	B-X
to	B-X
MPN	B-X
were	B-X
blocked	B-X
by	B-X
co	B-X
-	B-X
incubation	B-X
with	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
were	B-X
blocked	B-X
by	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
The	B-X
altered	B-X
PBMC	B-X
GR	B-X
binding	B-X
from	B-X
patients	B-X
with	B-X
SR	B-X
asthma	B-X
reversed	B-X
to	B-X
normal	B-X
when	B-X
incubated	B-X
with	B-X
medium	B-X
alone	B-X
,	B-X
but	B-X
was	B-X
sustained	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
The	B-X
mechanisms	B-X
contributing	B-X
to	B-X
persistent	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
poor	B-X
response	B-X
to	B-X
glucocorticoids	B-X
in	B-X
chronic	B-X
inflammatory	B-X
illnesses	B-X
such	B-X
as	B-X
steroid	B-X
resistant	B-X
(	B-X
SR	B-X
)	B-X
asthma	B-X
are	B-X
poorly	B-X
defined	B-X

Freshly	O
isolated	O
PBMC	B-cell_type
from	O
four	O
patients	O
with	O
SR	O
asthma	O
had	O
a	O
significantly	O
reduced	O
GR-binding	O
affinity	O
(	O
Kd	O
=	O
40.0	O
+/-	O
2.68	O
nM	O
;	O
p	O
=	O
0.0001	O
)	O
when	O
compared	O
with	O
seven	O
normal	O
subjects	O
(	O
7.15	O
+/-	O
0.41	O
nM	O
)	O
.	O
<EOS>	B-X
Freshly	B-X
isolated	B-X
PBMC	B-X
from	B-X
four	B-X
patients	B-X
with	B-X
SR	B-X
asthma	B-X
had	B-X
a	B-X
significantly	B-X
reduced	B-X
GR	B-X
-	B-X
binding	B-X
affinity	B-X
(	B-X
Kd	B-X
=	B-X
40	B-X
<EOS>	B-X
The	B-X
altered	B-X
PBMC	B-X
GR	B-X
binding	B-X
from	B-X
patients	B-X
with	B-X
SR	B-X
asthma	B-X
reversed	B-X
to	B-X
normal	B-X
when	B-X
incubated	B-X
with	B-X
medium	B-X
alone	B-X
,	B-X
but	B-X
was	B-X
sustained	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
More	B-X
importantly	B-X
,	B-X
the	B-X
alteration	B-X
in	B-X
PBMC	B-X
GR	B-X
-	B-X
binding	B-X
affinity	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
functional	B-X
change	B-X
in	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
methylprednisolone	B-X
MPN	B-X
,	B-X
i	B-X
<EOS>	B-X
Combination	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
reduces	B-X
glucocorticoid	B-X
receptor	B-X
-	B-X
binding	B-X
affinity	B-X
and	B-X
T	B-X
cell	B-X
response	B-X
to	B-X
glucocorticoids	B-X
.	B-X

The	O
altered	O
PBMC	O
GR	O
binding	O
from	O
patients	O
with	O
SR	O
asthma	O
reversed	O
to	O
normal	O
when	O
incubated	O
with	O
medium	O
alone	O
,	O
but	O
was	O
sustained	O
with	O
IL-2	B-protein
+	O
IL-4	B-protein
.	O
<EOS>	B-X
The	B-X
altered	B-X
PBMC	B-X
GR	B-X
binding	B-X
from	B-X
patients	B-X
with	B-X
SR	B-X
asthma	B-X
reversed	B-X
to	B-X
normal	B-X
when	B-X
incubated	B-X
with	B-X
medium	B-X
alone	B-X
,	B-X
but	B-X
was	B-X
sustained	B-X
with	B-X
IL	B-X
-	B-X
2	B-X
+	B-X
IL	B-X
-	B-X
4	B-X
<EOS>	B-X
Freshly	B-X
isolated	B-X
PBMC	B-X
from	B-X
four	B-X
patients	B-X
with	B-X
SR	B-X
asthma	B-X
had	B-X
a	B-X
significantly	B-X
reduced	B-X
GR	B-X
-	B-X
binding	B-X
affinity	B-X
(	B-X
Kd	B-X
=	B-X
40	B-X
<EOS>	B-X
0001	B-X
)	B-X
as	B-X
compared	B-X
with	B-X
PBMC	B-X
incubated	B-X
with	B-X
medium	B-X
alone	B-X
(	B-X
GR	B-X
Kd	B-X
=	B-X
6	B-X
<EOS>	B-X
The	B-X
mechanisms	B-X
contributing	B-X
to	B-X
persistent	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
poor	B-X
response	B-X
to	B-X
glucocorticoids	B-X
in	B-X
chronic	B-X
inflammatory	B-X
illnesses	B-X
such	B-X
as	B-X
steroid	B-X
resistant	B-X
(	B-X
SR	B-X
)	B-X
asthma	B-X
are	B-X
poorly	B-X
defined	B-X

These	O
observations	O
suggest	O
that	O
with	O
persistent	O
inflammation	O
certain	O
cytokines	B-protein
may	O
contribute	O
to	O
an	O
impaired	O
response	O
to	O
glucocorticoids	O
.	O

Furthermore	O
,	O
the	O
effects	O
of	O
IL-2	B-protein
and	O
IL-4	B-protein
were	O
blocked	O
by	O
IFN-gamma	B-protein
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
serum	B-X
(	B-X
NAS	B-X
)	B-X
on	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
	B-X
or	B-X
IFN	B-X
-	B-X
gamma	B-X
-	B-X
induced	B-X
spleen	B-X
NK	B-X
cell	B-X
activity	B-X
was	B-X
determined	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
IL	B-X
-	B-X
21	B-X
fails	B-X
to	B-X
induce	B-X
IFN	B-X
-	B-X
gamma	B-X
or	B-X
IL	B-X
-	B-X
4	B-X
production	B-X
and	B-X
can	B-X
partially	B-X
block	B-X
IL	B-X
-	B-X
12	B-X
induction	B-X
of	B-X
IFN	B-X
-	B-X
gamma	B-X
production	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
proportions	B-X
of	B-X
Th17	B-X
cells	B-X
were	B-X
decreased	B-X
and	B-X
that	B-X
of	B-X
Treg	B-X
cells	B-X
were	B-X
upregulated	B-X
by	B-X
PD	B-X
-	B-X
L1	B-X
-	B-X
EVs	B-X
treatment	B-X
<EOS>	B-X
Intracellular	B-X
IFN	B-X
-	B-X
gamma	B-X
and	B-X
IL	B-X
-	B-X
4	B-X
were	B-X
studied	B-X
by	B-X
FACS	B-X
analysis	B-X

Characterization	O
of	O
the	O
human	B-DNA
CD4	I-DNA
gene	I-DNA
promoter	I-DNA
:	O
transcription	O
from	O
the	O
CD4	B-DNA
gene	I-DNA
core	I-DNA
promoter	I-DNA
is	O
tissue-specific	O
and	O
is	O
activated	O
by	O
Ets	B-protein
proteins	I-protein
.	O
<EOS>	B-X
Characterization	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
promoter	B-X
:	B-X
transcription	B-X
from	B-X
the	B-X
CD4	B-X
gene	B-X
core	B-X
promoter	B-X
is	B-X
tissue	B-X
-	B-X
specific	B-X
and	B-X
is	B-X
activated	B-X
by	B-X
Ets	B-X
proteins	B-X
.	B-X
<EOS>	B-X
Our	B-X
investigation	B-X
of	B-X
the	B-X
human	B-X
TCR	B-X
beta	B-X
gene	B-X
uncovers	B-X
a	B-X
surprisingly	B-X
complex	B-X
and	B-X
tissue	B-X
-	B-X
specific	B-X
structure	B-X
at	B-X
the	B-X
TCR	B-X
Vbeta	B-X
8	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
CD4	B-X
core	B-X
promoter	B-X
also	B-X
displayed	B-X
a	B-X
tissue	B-X
-	B-X
specific	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
promoter	B-X
correlated	B-X
with	B-X
CD4	B-X
expression	B-X
in	B-X
various	B-X
cell	B-X
types	B-X

We	O
analyzed	O
the	O
5	B-DNA
'	I-DNA
transcription	I-DNA
control	I-DNA
sequences	I-DNA
of	O
the	O
human	B-DNA
CD4	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
We	B-X
then	B-X
analyzed	B-X
the	B-X
5	B-X
'	B-X
transcription	B-X
control	B-X
sequences	B-X
of	B-X
LAG	B-X
-	B-X
3	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
transcriptome	B-X
of	B-X
detailed	B-X
CD4	B-X
<EOS>	B-X
AIE	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
mutations	B-X
in	B-X
FOXP3	B-X
-	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
controls	B-X
regulatory	B-X
T	B-X
-	B-X
cell	B-X
development	B-X
and	B-X
function	B-X
<EOS>	B-X
To	B-X
characterize	B-X
perforin	B-X
gene	B-X
expression	B-X
and	B-X
its	B-X
transcriptional	B-X
control	B-X
mechanisms	B-X
in	B-X
vivo	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
cell	B-X
surface	B-X
tag	B-X
,	B-X
i	B-X

We	O
located	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
and	O
showed	O
that	O
the	O
CD4	B-DNA
core	I-DNA
promoter	I-DNA
(	O
positions	B-DNA
-40	I-DNA
to	I-DNA
+16	I-DNA
)	O
lacks	O
a	O
classical	O
``	O
TATA	O
''	O
or	O
initiator	B-DNA
positioning	I-DNA
consensus	I-DNA
sequence	I-DNA
but	O
directs	O
precise	O
and	O
efficient	O
transcription	O
when	O
coupled	O
to	O
the	O
ubiquitously	O
active	O
simian	B-DNA
virus	I-DNA
40	I-DNA
enhancer	I-DNA
.	O
<EOS>	B-X
We	B-X
located	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
and	B-X
showed	B-X
that	B-X
the	B-X
CD4	B-X
core	B-X
promoter	B-X
(	B-X
positions	B-X
	B-X
-	B-X
40	B-X
to	B-X
+16	B-X
)	B-X
lacks	B-X
a	B-X
classical	B-X
``	B-X
TATA	B-X
''	B-X
or	B-X
initiator	B-X
positioning	B-X
consensus	B-X
sequence	B-X
but	B-X
directs	B-X
precise	B-X
and	B-X
efficient	B-X
transcription	B-X
when	B-X
coupled	B-X
to	B-X
the	B-X
ubiquitously	B-X
active	B-X
simian	B-X
virus	B-X
40	B-X
enhancer	B-X
<EOS>	B-X
Electrophoretic	B-X
-	B-X
mobility	B-X
-	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
core	B-X
promoter	B-X
ETS	B-X
motif	B-X
binds	B-X
an	B-X
Ets	B-X
-	B-X
related	B-X
protein	B-X
specifically	B-X
expressed	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
CD4+	B-X
cells	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
promoter	B-X
:	B-X
transcription	B-X
from	B-X
the	B-X
CD4	B-X
gene	B-X
core	B-X
promoter	B-X
is	B-X
tissue	B-X
-	B-X
specific	B-X
and	B-X
is	B-X
activated	B-X
by	B-X
Ets	B-X
proteins	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
Ets	B-X
transcription	B-X
factors	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
controlling	B-X
CD4	B-X
gene	B-X
expression	B-X
,	B-X
by	B-X
binding	B-X
to	B-X
both	B-X
a	B-X
classical	B-X
remote	B-X
site	B-X
and	B-X
an	B-X
unusual	B-X
proximal	B-X
activator	B-X
sequence	B-X

The	O
transcriptional	O
activity	O
of	O
the	O
CD4	B-DNA
gene	I-DNA
promoter	I-DNA
correlated	O
with	O
CD4	O
expression	O
in	O
various	O
cell	O
types	O
.	O
<EOS>	B-X
Enhanced	B-X
Transcriptional	B-X
Strength	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
Subtype	B-X
C	B-X
Minimizes	B-X
Gene	B-X
Expression	B-X
Noise	B-X
and	B-X
Confers	B-X
Stability	B-X
to	B-X
the	B-X
Viral	B-X
Latent	B-X
State	B-X
.	B-X
<EOS>	B-X
ZEB1	B-X
transcription	B-X
factor	B-X
promotes	B-X
immune	B-X
escape	B-X
in	B-X
melanoma	B-X
.	B-X
<EOS>	B-X
1	B-X
binds	B-X
to	B-X
the	B-X
Ccr7	B-X
promoter	B-X
-	B-X
proximal	B-X
region	B-X
in	B-X
spleen	B-X
naïve	B-X
CD4	B-X
<EOS>	B-X
Transcription	B-X
of	B-X
KIR3DL2	B-X
may	B-X
be	B-X
triggered	B-X
by	B-X
HTLV	B-X
-	B-X
1	B-X
infection	B-X
and	B-X
correlates	B-X
with	B-X
hypomethylation	B-X
of	B-X
the	B-X
promoter	B-X

Interestingly	O
,	O
the	O
CD4	B-DNA
core	I-DNA
promoter	I-DNA
also	O
displayed	O
a	O
tissue-specific	O
transcriptional	O
activity	O
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
CD4	B-X
core	B-X
promoter	B-X
also	B-X
displayed	B-X
a	B-X
tissue	B-X
-	B-X
specific	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
Characterization	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
promoter	B-X
:	B-X
transcription	B-X
from	B-X
the	B-X
CD4	B-X
gene	B-X
core	B-X
promoter	B-X
is	B-X
tissue	B-X
-	B-X
specific	B-X
and	B-X
is	B-X
activated	B-X
by	B-X
Ets	B-X
proteins	B-X
.	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
promoter	B-X
correlated	B-X
with	B-X
CD4	B-X
expression	B-X
in	B-X
various	B-X
cell	B-X
types	B-X
<EOS>	B-X
Electrophoretic	B-X
-	B-X
mobility	B-X
-	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
core	B-X
promoter	B-X
ETS	B-X
motif	B-X
binds	B-X
an	B-X
Ets	B-X
-	B-X
related	B-X
protein	B-X
specifically	B-X
expressed	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
CD4+	B-X
cells	B-X

Within	O
this	O
fragment	O
,	O
three	O
nucleic	O
acid	O
sequences	O
are	O
completely	O
conserved	O
in	O
the	O
murine	B-DNA
CD4	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
Within	B-X
this	B-X
fragment	B-X
,	B-X
three	B-X
nucleic	B-X
acid	B-X
sequences	B-X
are	B-X
completely	B-X
conserved	B-X
in	B-X
the	B-X
murine	B-X
CD4	B-X
gene	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
5	B-X
'	B-X
transcription	B-X
control	B-X
sequences	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
<EOS>	B-X
One	B-X
of	B-X
these	B-X
sequences	B-X
contains	B-X
a	B-X
perfect	B-X
ETS	B-X
consensus	B-X
sequence	B-X
<EOS>	B-X
Another	B-X
ETS	B-X
consensus	B-X
sequence	B-X
is	B-X
located	B-X
1060	B-X
nt	B-X
upstream	B-X

One	O
of	O
these	O
sequences	O
contains	O
a	O
perfect	B-DNA
ETS	I-DNA
consensus	I-DNA
sequence	I-DNA
.	O
<EOS>	B-X
One	B-X
of	B-X
these	B-X
sequences	B-X
contains	B-X
a	B-X
perfect	B-X
ETS	B-X
consensus	B-X
sequence	B-X
<EOS>	B-X
Within	B-X
this	B-X
fragment	B-X
,	B-X
three	B-X
nucleic	B-X
acid	B-X
sequences	B-X
are	B-X
completely	B-X
conserved	B-X
in	B-X
the	B-X
murine	B-X
CD4	B-X
gene	B-X
<EOS>	B-X
Another	B-X
ETS	B-X
consensus	B-X
sequence	B-X
is	B-X
located	B-X
1060	B-X
nt	B-X
upstream	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
promoter	B-X
correlated	B-X
with	B-X
CD4	B-X
expression	B-X
in	B-X
various	B-X
cell	B-X
types	B-X

Another	O
ETS	B-DNA
consensus	I-DNA
sequence	I-DNA
is	O
located	O
1060	O
nt	O
upstream	O
.	O
<EOS>	B-X
Another	B-X
ETS	B-X
consensus	B-X
sequence	B-X
is	B-X
located	B-X
1060	B-X
nt	B-X
upstream	B-X
<EOS>	B-X
Within	B-X
this	B-X
fragment	B-X
,	B-X
three	B-X
nucleic	B-X
acid	B-X
sequences	B-X
are	B-X
completely	B-X
conserved	B-X
in	B-X
the	B-X
murine	B-X
CD4	B-X
gene	B-X
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
5	B-X
'	B-X
transcription	B-X
control	B-X
sequences	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
<EOS>	B-X
One	B-X
of	B-X
these	B-X
sequences	B-X
contains	B-X
a	B-X
perfect	B-X
ETS	B-X
consensus	B-X
sequence	B-X

Electrophoretic-mobility-shift	O
assays	O
showed	O
that	O
the	O
core	O
promoter	O
ETS	O
motif	O
binds	O
an	O
Ets-related	B-protein
protein	I-protein
specifically	O
expressed	O
at	O
high	O
levels	O
in	O
CD4+	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Electrophoretic	B-X
-	B-X
mobility	B-X
-	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
core	B-X
promoter	B-X
ETS	B-X
motif	B-X
binds	B-X
an	B-X
Ets	B-X
-	B-X
related	B-X
protein	B-X
specifically	B-X
expressed	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
CD4+	B-X
cells	B-X
<EOS>	B-X
The	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
promoter	B-X
correlated	B-X
with	B-X
CD4	B-X
expression	B-X
in	B-X
various	B-X
cell	B-X
types	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
CD4	B-X
core	B-X
promoter	B-X
also	B-X
displayed	B-X
a	B-X
tissue	B-X
-	B-X
specific	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
We	B-X
located	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
and	B-X
showed	B-X
that	B-X
the	B-X
CD4	B-X
core	B-X
promoter	B-X
(	B-X
positions	B-X
	B-X
-	B-X
40	B-X
to	B-X
+16	B-X
)	B-X
lacks	B-X
a	B-X
classical	B-X
``	B-X
TATA	B-X
''	B-X
or	B-X
initiator	B-X
positioning	B-X
consensus	B-X
sequence	B-X
but	B-X
directs	B-X
precise	B-X
and	B-X
efficient	B-X
transcription	B-X
when	B-X
coupled	B-X
to	B-X
the	B-X
ubiquitously	B-X
active	B-X
simian	B-X
virus	B-X
40	B-X
enhancer	B-X

Moreover	O
,	O
in	O
CD4-	B-cell_type
cells	I-cell_type
,	O
overexpression	O
of	O
Ets-1	B-protein
or	O
Ets-2	B-protein
efficiently	O
and	O
specifically	O
activated	O
transcription	O
from	O
the	O
CD4	B-DNA
promoter	I-DNA
and	O
core	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
in	B-X
CD4	B-X
-	B-X
	B-X
cells	B-X
,	B-X
overexpression	B-X
of	B-X
Ets	B-X
-	B-X
1	B-X
or	B-X
Ets	B-X
-	B-X
2	B-X
efficiently	B-X
and	B-X
specifically	B-X
activated	B-X
transcription	B-X
from	B-X
the	B-X
CD4	B-X
promoter	B-X
and	B-X
core	B-X
promoter	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
the	B-X
CD4	B-X
core	B-X
promoter	B-X
also	B-X
displayed	B-X
a	B-X
tissue	B-X
-	B-X
specific	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
miRNA	B-X
-	B-X
451a	B-X
knockdown	B-X
enhanced	B-X
Th2	B-X
cell	B-X
polarization	B-X
	B-X
-	B-X
	B-X
cells	B-X
positive	B-X
for	B-X
both	B-X
GATA3	B-X
(	B-X
GATA	B-X
binding	B-X
protein	B-X
3	B-X
,	B-X
a	B-X
Th2	B-X
-	B-X
transcription	B-X
factor	B-X
)	B-X
and	B-X
CD4	B-X
increased	B-X
,	B-X
and	B-X
the	B-X
generation	B-X
of	B-X
Th2	B-X
cell	B-X
cytokines	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
5	B-X
and	B-X
IL13	B-X
,	B-X
increased	B-X
<EOS>	B-X
Moreover	B-X
,	B-X
enforced	B-X
expression	B-X
of	B-X
ETS1	B-X
partially	B-X
restored	B-X
miRNA	B-X
-	B-X
451a	B-X
-	B-X
induced	B-X
inhibition	B-X
of	B-X
IL5	B-X
and	B-X
IL13	B-X
,	B-X
and	B-X
increased	B-X
the	B-X
GATA3+CD4+	B-X
cell	B-X
population	B-X

These	O
data	O
indicate	O
that	O
Ets	B-protein
transcription	I-protein
factors	I-protein
play	O
a	O
central	O
role	O
in	O
controlling	O
CD4	O
gene	O
expression	O
,	O
by	O
binding	O
to	O
both	O
a	O
classical	B-DNA
remote	I-DNA
site	I-DNA
and	O
an	O
unusual	O
proximal	B-DNA
activator	I-DNA
sequence	I-DNA

Glucocorticoid	O
receptor	O
activation	O
and	O
inactivation	O
in	O
c	O
ultured	B-cell_line
human	I-cell_line
lymphocytes	I-cell_line
.	O

Although	O
glucocorticoids	O
are	O
not	O
cytolytic	O
for	O
and	O
do	O
not	O
inhibit	O
the	O
growth	O
of	O
the	O
IM-9	B-cell_line
line	I-cell_line
of	O
cultured	B-cell_line
human	I-cell_line
lymphoblasts	I-cell_line
,	O
these	O
cells	O
have	O
a	O
high	O
steroid-binding	O
capacity	O
.	O
<EOS>	B-X
Oral	B-X
glucocorticoids	B-X
were	B-X
more	B-X
frequently	B-X
used	B-X
whereas	B-X
methotrexate	B-X
was	B-X
less	B-X
likely	B-X
to	B-X
be	B-X
used	B-X
in	B-X
RA	B-X
-	B-X
ILD	B-X
patients	B-X
<EOS>	B-X
Glucocorticoids	B-X
are	B-X
used	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
autoimmune	B-X
disorders	B-X
;	B-X
however	B-X
,	B-X
they	B-X
can	B-X
elicit	B-X
several	B-X
side	B-X
effects	B-X
such	B-X
as	B-X
osteoporosis	B-X
<EOS>	B-X
Glucocorticoids	B-X
are	B-X
the	B-X
first	B-X
-	B-X
line	B-X
therapeutic	B-X
medication	B-X
for	B-X
IgG4	B-X
-	B-X
RD	B-X
and	B-X
can	B-X
significantly	B-X
improve	B-X
renal	B-X
function	B-X
<EOS>	B-X
Although	B-X
only	B-X
a	B-X
small	B-X
subset	B-X
of	B-X
children	B-X
and	B-X
adolescents	B-X
falls	B-X
in	B-X
this	B-X
category	B-X
,	B-X
the	B-X
management	B-X
of	B-X
affected	B-X
patients	B-X
represents	B-X
a	B-X
major	B-X
concern	B-X
for	B-X
pediatricians	B-X

We	O
have	O
used	O
IM-9	B-cell_type
cells	I-cell_type
in	O
order	O
to	O
examine	O
whether	O
unoccupied	B-protein
glucocorticoid	I-protein
receptors	I-protein
are	O
inactivated	O
and	O
activated	O
in	O
intact	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
We	B-X
have	B-X
used	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X
in	B-X
order	B-X
to	B-X
examine	B-X
whether	B-X
unoccupied	B-X
glucocorticoid	B-X
receptors	B-X
are	B-X
inactivated	B-X
and	B-X
activated	B-X
in	B-X
intact	B-X
cells	B-X
<EOS>	B-X
The	B-X
experiments	B-X
with	B-X
intact	B-X
human	B-X
lymphoblasts	B-X
suggest	B-X
that	B-X
assays	B-X
of	B-X
specific	B-X
glucocorticoid	B-X
-	B-X
binding	B-X
capacity	B-X
do	B-X
not	B-X
necessarily	B-X
reflect	B-X
the	B-X
cellular	B-X
content	B-X
of	B-X
receptor	B-X
protein	B-X
<EOS>	B-X
Cytosol	B-X
prepared	B-X
from	B-X
inactivated	B-X
cells	B-X
can	B-X
not	B-X
be	B-X
activated	B-X
by	B-X
addition	B-X
of	B-X
ATP	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
activation	B-X
and	B-X
inactivation	B-X
in	B-X
cultured	B-X
human	B-X
lymphocytes	B-X
.	B-X

when	O
IM-9	B-cell_type
cells	I-cell_type
are	O
incubated	O
in	O
glucose-free	O
medium	O
in	O
a	O
nitrogen	O
atmosphere	O
,	O
both	O
their	O
ability	O
to	O
bind	O
triamcinolone	O
acetonide	O
and	O
their	O
ATP	O
levels	O
decline	O
and	O
,	O
when	O
glucose	O
and	O
oxygen	O
are	O
reintroduced	O
,	O
ATP	O
levels	O
and	O
receptor	O
activity	O
return	O
.	O

The	O
specific	O
glucocorticoid-binding	O
activity	O
of	O
cytosol	O
prepared	O
from	O
cells	O
exposed	O
to	O
various	O
degrees	O
of	O
energy	O
limitation	O
is	O
directly	O
correlated	O
with	O
the	O
ATP	O
content	O
.	O
<EOS>	B-X
The	B-X
specific	B-X
glucocorticoid	B-X
-	B-X
binding	B-X
activity	B-X
of	B-X
cytosol	B-X
prepared	B-X
from	B-X
cells	B-X
exposed	B-X
to	B-X
various	B-X
degrees	B-X
of	B-X
energy	B-X
limitation	B-X
is	B-X
directly	B-X
correlated	B-X
with	B-X
the	B-X
ATP	B-X
content	B-X
<EOS>	B-X
The	B-X
inactivation	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
that	B-X
occurs	B-X
when	B-X
cytosol	B-X
from	B-X
normal	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X
is	B-X
incubated	B-X
at	B-X
25	B-X
degrees	B-X
C	B-X
is	B-X
inhibited	B-X
by	B-X
molybdate	B-X
,	B-X
vanadate	B-X
,	B-X
fluoride	B-X
,	B-X
ATP	B-X
,	B-X
and	B-X
several	B-X
other	B-X
nucleotides	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
activation	B-X
and	B-X
inactivation	B-X
in	B-X
cultured	B-X
human	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Cytosol	B-X
prepared	B-X
from	B-X
inactivated	B-X
cells	B-X
can	B-X
not	B-X
be	B-X
activated	B-X
by	B-X
addition	B-X
of	B-X
ATP	B-X

Receptor	O
activation	O
in	O
intact	B-cell_type
cells	I-cell_type
is	O
rapid	O
and	O
independent	O
of	O
protein	O
synthesis	O
.	O
<EOS>	B-X
Receptor	B-X
activation	B-X
in	B-X
intact	B-X
cells	B-X
is	B-X
rapid	B-X
and	B-X
independent	B-X
of	B-X
protein	B-X
synthesis	B-X
<EOS>	B-X
The	B-X
uPA	B-X
-	B-X
induced	B-X
increase	B-X
in	B-X
intracellular	B-X
Ca2+	B-X
was	B-X
independent	B-X
of	B-X
uPA	B-X
proteolytic	B-X
activity	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
genistein	B-X
effect	B-X
on	B-X
eNOS	B-X
was	B-X
also	B-X
independent	B-X
of	B-X
tyrosine	B-X
kinase	B-X
inhibition	B-X
<EOS>	B-X
The	B-X
enzyme	B-X
induction	B-X
is	B-X
dependent	B-X
upon	B-X
an	B-X
intact	B-X
mobility	B-X
of	B-X
ligand	B-X
-	B-X
receptor	B-X
complex	B-X
,	B-X
requires	B-X
a	B-X
functioning	B-X
energy	B-X
metabolism	B-X
,	B-X
but	B-X
is	B-X
independent	B-X
of	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X

Cytosol	O
prepared	O
from	O
inactivated	O
cells	O
can	O
not	O
be	O
activated	O
by	O
addition	O
of	O
ATP	O
.	O
<EOS>	B-X
Cytosolic	B-X
Delivery	B-X
of	B-X
Liposomal	B-X
Vaccines	B-X
by	B-X
Means	B-X
of	B-X
the	B-X
Concomitant	B-X
Photosensitization	B-X
of	B-X
Phagosomes	B-X
.	B-X
<EOS>	B-X
Microsomal	B-X
aromatase	B-X
prepared	B-X
from	B-X
JEG	B-X
-	B-X
3	B-X
cells	B-X
was	B-X
rapidly	B-X
inactivated	B-X
and	B-X
subsequently	B-X
degraded	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
cytosolic	B-X
fraction	B-X
with	B-X
calcium	B-X
,	B-X
magnesium	B-X
,	B-X
and	B-X
ATP	B-X
<EOS>	B-X
The	B-X
post	B-X
-	B-X
translational	B-X
regulation	B-X
of	B-X
aromatase	B-X
has	B-X
not	B-X
been	B-X
well	B-X
characterized	B-X
as	B-X
compared	B-X
with	B-X
transcriptional	B-X
regulation	B-X
<EOS>	B-X
Construction	B-X
of	B-X
Ag	B-X
-	B-X
decorated	B-X
ZnO	B-X
with	B-X
oxygen	B-X
vacancies	B-X
for	B-X
enhanced	B-X
antibacterial	B-X
activity	B-X
via	B-X
increased	B-X
H	B-X

The	O
inactivation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
that	O
occurs	O
when	O
cytosol	O
from	O
normal	O
IM-9	B-cell_line
cells	I-cell_line
is	O
incubated	O
at	O
25	O
degrees	O
C	O
is	O
inhibited	O
by	O
molybdate	O
,	O
vanadate	O
,	O
fluoride	O
,	O
ATP	O
,	O
and	O
several	O
other	O
nucleotides	O
.	O
<EOS>	B-X
The	B-X
inactivation	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
that	B-X
occurs	B-X
when	B-X
cytosol	B-X
from	B-X
normal	B-X
IM	B-X
-	B-X
9	B-X
cells	B-X
is	B-X
incubated	B-X
at	B-X
25	B-X
degrees	B-X
C	B-X
is	B-X
inhibited	B-X
by	B-X
molybdate	B-X
,	B-X
vanadate	B-X
,	B-X
fluoride	B-X
,	B-X
ATP	B-X
,	B-X
and	B-X
several	B-X
other	B-X
nucleotides	B-X
<EOS>	B-X
The	B-X
specific	B-X
glucocorticoid	B-X
-	B-X
binding	B-X
activity	B-X
of	B-X
cytosol	B-X
prepared	B-X
from	B-X
cells	B-X
exposed	B-X
to	B-X
various	B-X
degrees	B-X
of	B-X
energy	B-X
limitation	B-X
is	B-X
directly	B-X
correlated	B-X
with	B-X
the	B-X
ATP	B-X
content	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
activation	B-X
and	B-X
inactivation	B-X
in	B-X
cultured	B-X
human	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Although	B-X
glucocorticoids	B-X
are	B-X
not	B-X
cytolytic	B-X
for	B-X
and	B-X
do	B-X
not	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
the	B-X
IM	B-X
-	B-X
9	B-X
line	B-X
of	B-X
cultured	B-X
human	B-X
lymphoblasts	B-X
,	B-X
these	B-X
cells	B-X
have	B-X
a	B-X
high	B-X
steroid	B-X
-	B-X
binding	B-X
capacity	B-X

The	O
experiments	O
with	O
intact	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
suggest	O
that	O
assays	O
of	O
specific	O
glucocorticoid-binding	O
capacity	O
do	O
not	O
necessarily	O
reflect	O
the	O
cellular	O
content	O
of	O
receptor	B-protein
protein	I-protein
.	O

Glucocorticoids	O
and	O
lymphocytes	B-cell_type
.	O
<EOS>	B-X
Glucocorticoid	B-X
therapy	B-X
rapidly	B-X
improved	B-X
his	B-X
symptoms	B-X
<EOS>	B-X
9	B-X
%	B-X
,	B-X
glucocorticoids	B-X
:	B-X
19	B-X
<EOS>	B-X
Glucocorticoids	B-X
are	B-X
the	B-X
mainstay	B-X
of	B-X
treatment	B-X
for	B-X
most	B-X
symptomatic	B-X
hypophysitis	B-X
<EOS>	B-X
The	B-X
skin	B-X
,	B-X
oral	B-X
cavity	B-X
and	B-X
lungs	B-X
are	B-X
commonly	B-X
affected	B-X
organs	B-X

II	O
.	O
<EOS>	B-X
15	B-X
,	B-X
0	B-X
<EOS>	B-X
9	B-X
(	B-X
IQR	B-X
25	B-X
-	B-X
30	B-X
<EOS>	B-X
72	B-X
±	B-X
0	B-X
<EOS>	B-X
63	B-X
±	B-X
0	B-X

Cell	O
cycle-dependent	O
changes	O
in	O
glucocorticoid	B-protein
receptor	I-protein
content	O
.	O
<EOS>	B-X
Glucocorticoids	B-X
and	B-X
lymphocytes	B-X
.	B-X
II	B-X
.	B-X
Cell	B-X
cycle	B-X
-	B-X
dependent	B-X
changes	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
.	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
may	B-X
explain	B-X
the	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
mitogen	B-X
-	B-X
stimulated	B-X
lymphocytes	B-X
<EOS>	B-X
These	B-X
observations	B-X
together	B-X
with	B-X
those	B-X
from	B-X
other	B-X
studies	B-X
indicate	B-X
that	B-X
formation	B-X
of	B-X
new	B-X
glucocorticoid	B-X
receptors	B-X
near	B-X
the	B-X
S	B-X
phase	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
in	B-X
proliferating	B-X
cells	B-X
<EOS>	B-X
By	B-X
morphologic	B-X
criteria	B-X
and	B-X
thymidine	B-X
incorporation	B-X
,	B-X
the	B-X
fractions	B-X
were	B-X
separated	B-X
into	B-X
populations	B-X
of	B-X
G0	B-X
and	B-X
G1	B-X
phase	B-X
and	B-X
S	B-X
and	B-X
post	B-X
-	B-X
S	B-X
phase	B-X
cells	B-X

To	O
study	O
variations	O
in	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
during	O
the	O
cell	O
cycle	O
,	O
we	O
have	O
separated	O
mitogen-stimulated	B-cell_line
human	I-cell_line
peripheral	I-cell_line
lymphocytes	I-cell_line
and	O
rat	B-cell_type
lymph	I-cell_type
node	I-cell_type
cells	I-cell_type
by	O
unit	O
gravity	O
sedimentation	O
and	O
measured	O
glucocorticoid	O
binding	O
in	O
the	O
resultant	O
fractions	O
.	O
<EOS>	B-X
To	B-X
study	B-X
variations	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
we	B-X
have	B-X
separated	B-X
mitogen	B-X
-	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
and	B-X
rat	B-X
lymph	B-X
node	B-X
cells	B-X
by	B-X
unit	B-X
gravity	B-X
sedimentation	B-X
and	B-X
measured	B-X
glucocorticoid	B-X
binding	B-X
in	B-X
the	B-X
resultant	B-X
fractions	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
may	B-X
explain	B-X
the	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
mitogen	B-X
-	B-X
stimulated	B-X
lymphocytes	B-X
<EOS>	B-X
A	B-X
2	B-X
-	B-X
	B-X
to	B-X
3	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
for	B-X
cells	B-X
in	B-X
the	B-X
S	B-X
and	B-X
post	B-X
-	B-X
S	B-X
phase	B-X
over	B-X
those	B-X
in	B-X
G0	B-X
and	B-X
G1	B-X
,	B-X
was	B-X
observed	B-X
with	B-X
both	B-X
nonstimulated	B-X
rat	B-X
lymph	B-X
node	B-X
cell	B-X
suspensions	B-X
and	B-X
concanavalin	B-X
A	B-X
-	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
<EOS>	B-X
These	B-X
observations	B-X
together	B-X
with	B-X
those	B-X
from	B-X
other	B-X
studies	B-X
indicate	B-X
that	B-X
formation	B-X
of	B-X
new	B-X
glucocorticoid	B-X
receptors	B-X
near	B-X
the	B-X
S	B-X
phase	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
in	B-X
proliferating	B-X
cells	B-X

By	O
morphologic	O
criteria	O
and	O
thymidine	O
incorporation	O
,	O
the	O
fractions	O
were	O
separated	O
into	O
populations	O
of	O
G0	B-cell_type
and	I-cell_type
G1	I-cell_type
phase	I-cell_type
and	I-cell_type
S	I-cell_type
and	I-cell_type
post-S	I-cell_type
phase	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
By	B-X
morphologic	B-X
criteria	B-X
and	B-X
thymidine	B-X
incorporation	B-X
,	B-X
the	B-X
fractions	B-X
were	B-X
separated	B-X
into	B-X
populations	B-X
of	B-X
G0	B-X
and	B-X
G1	B-X
phase	B-X
and	B-X
S	B-X
and	B-X
post	B-X
-	B-X
S	B-X
phase	B-X
cells	B-X
<EOS>	B-X
These	B-X
observations	B-X
together	B-X
with	B-X
those	B-X
from	B-X
other	B-X
studies	B-X
indicate	B-X
that	B-X
formation	B-X
of	B-X
new	B-X
glucocorticoid	B-X
receptors	B-X
near	B-X
the	B-X
S	B-X
phase	B-X
may	B-X
be	B-X
a	B-X
general	B-X
phenomenon	B-X
in	B-X
proliferating	B-X
cells	B-X
<EOS>	B-X
A	B-X
2	B-X
-	B-X
	B-X
to	B-X
3	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
for	B-X
cells	B-X
in	B-X
the	B-X
S	B-X
and	B-X
post	B-X
-	B-X
S	B-X
phase	B-X
over	B-X
those	B-X
in	B-X
G0	B-X
and	B-X
G1	B-X
,	B-X
was	B-X
observed	B-X
with	B-X
both	B-X
nonstimulated	B-X
rat	B-X
lymph	B-X
node	B-X
cell	B-X
suspensions	B-X
and	B-X
concanavalin	B-X
A	B-X
-	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
<EOS>	B-X
To	B-X
study	B-X
variations	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
we	B-X
have	B-X
separated	B-X
mitogen	B-X
-	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
and	B-X
rat	B-X
lymph	B-X
node	B-X
cells	B-X
by	B-X
unit	B-X
gravity	B-X
sedimentation	B-X
and	B-X
measured	B-X
glucocorticoid	B-X
binding	B-X
in	B-X
the	B-X
resultant	B-X
fractions	B-X

A	O
2-	O
to	O
3-fold	O
increase	O
in	O
glucocorticoid	O
receptor	O
sites	O
per	O
cell	O
,	O
for	O
cells	O
in	O
the	O
S	O
and	O
post-S	O
phase	O
over	O
those	O
in	O
G0	O
and	O
G1	O
,	O
was	O
observed	O
with	O
both	O
nonstimulated	B-cell_type
rat	I-cell_type
lymph	I-cell_type
node	I-cell_type
cell	I-cell_type
suspensions	I-cell_type
and	O
concanavalin	B-cell_line
A-stimulated	I-cell_line
human	I-cell_line
peripheral	I-cell_line
lymphocytes	I-cell_line
.	O

These	O
observations	O
together	O
with	O
those	O
from	O
other	O
studies	O
indicate	O
that	O
formation	O
of	O
new	O
glucocorticoid	B-protein
receptors	I-protein
near	O
the	O
S	O
phase	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
proliferating	B-cell_type
cells	I-cell_type
.	O

We	O
propose	O
that	O
this	O
increase	O
in	O
glucocorticoid	B-protein
receptors	I-protein
during	O
the	O
cell	O
cycle	O
may	O
explain	O
the	O
increase	O
in	O
glucocorticoid	B-protein
receptors	I-protein
in	O
mitogen-stimulated	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
may	B-X
explain	B-X
the	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
mitogen	B-X
-	B-X
stimulated	B-X
lymphocytes	B-X
<EOS>	B-X
A	B-X
2	B-X
-	B-X
	B-X
to	B-X
3	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
for	B-X
cells	B-X
in	B-X
the	B-X
S	B-X
and	B-X
post	B-X
-	B-X
S	B-X
phase	B-X
over	B-X
those	B-X
in	B-X
G0	B-X
and	B-X
G1	B-X
,	B-X
was	B-X
observed	B-X
with	B-X
both	B-X
nonstimulated	B-X
rat	B-X
lymph	B-X
node	B-X
cell	B-X
suspensions	B-X
and	B-X
concanavalin	B-X
A	B-X
-	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
<EOS>	B-X
Glucocorticoids	B-X
and	B-X
lymphocytes	B-X
.	B-X
II	B-X
.	B-X
Cell	B-X
cycle	B-X
-	B-X
dependent	B-X
changes	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
.	B-X
<EOS>	B-X
To	B-X
study	B-X
variations	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
during	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
we	B-X
have	B-X
separated	B-X
mitogen	B-X
-	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
and	B-X
rat	B-X
lymph	B-X
node	B-X
cells	B-X
by	B-X
unit	B-X
gravity	B-X
sedimentation	B-X
and	B-X
measured	B-X
glucocorticoid	B-X
binding	B-X
in	B-X
the	B-X
resultant	B-X
fractions	B-X

The	O
leukocyte	B-cell_type
migration	O
inhibition	O
response	O
to	O
certain	O
breast	B-protein
cancer-related	I-protein
antigens	I-protein
(	O
MCF-7	B-protein
and	O
MuMTV	B-protein
)	O
:	O
their	O
potential	O
as	O
discriminants	O
.	O
<EOS>	B-X
The	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
response	B-X
to	B-X
certain	B-X
breast	B-X
cancer	B-X
-	B-X
related	B-X
antigens	B-X
(	B-X
MCF	B-X
-	B-X
7	B-X
and	B-X
MuMTV	B-X
)	B-X
:	B-X
their	B-X
potential	B-X
as	B-X
discriminants	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
the	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
(	B-X
LMI	B-X
)	B-X
response	B-X
to	B-X
assay	B-X
the	B-X
response	B-X
to	B-X
several	B-X
potential	B-X
breast	B-X
cancer	B-X
-	B-X
related	B-X
antigens	B-X
,	B-X
including	B-X
MuMTV	B-X
,	B-X
MPMV	B-X
,	B-X
and	B-X
a	B-X
breast	B-X
cancer	B-X
cultured	B-X
cell	B-X
line	B-X
,	B-X
MCF	B-X
-	B-X
7	B-X
,	B-X
in	B-X
96	B-X
breast	B-X
cancer	B-X
patients	B-X
,	B-X
in	B-X
32	B-X
women	B-X
with	B-X
benign	B-X
breast	B-X
disease	B-X
,	B-X
and	B-X
in	B-X
67	B-X
normal	B-X
women	B-X
<EOS>	B-X
The	B-X
above	B-X
reactions	B-X
suggest	B-X
that	B-X
a	B-X
large	B-X
proportion	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
exhibit	B-X
presensitization	B-X
to	B-X
antigenfs	B-X
found	B-X
in	B-X
MuMTV	B-X
and	B-X
MCF	B-X
-	B-X
7	B-X
,	B-X
which	B-X
may	B-X
be	B-X
cross	B-X
-	B-X
reactive	B-X
with	B-X
antigens	B-X
in	B-X
the	B-X
primary	B-X
cancer	B-X
<EOS>	B-X
The	B-X
potential	B-X
for	B-X
this	B-X
assay	B-X
to	B-X
distinguish	B-X
``	B-X
normal	B-X
''	B-X
from	B-X
``	B-X
breast	B-X
cancer	B-X
''	B-X
was	B-X
analyzed	B-X
using	B-X
a	B-X
migration	B-X
index	B-X
derived	B-X
from	B-X
discriminant	B-X
analysis	B-X

Certain	O
oncogenic	O
viruses	O
have	O
been	O
implicated	O
in	O
human	O
breast	O
cancer	O
,	O
including	O
the	O
murine	O
mammary	O
tumor	O
virus	O
(	O
MuMTV	O
)	O
and	O
the	O
Mason-Pfizer	O
monkey	O
virus	O
(	O
MPMV	O
)	O
.	O
<EOS>	B-X
Certain	B-X
oncogenic	B-X
viruses	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
human	B-X
breast	B-X
cancer	B-X
,	B-X
including	B-X
the	B-X
murine	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MuMTV	B-X
)	B-X
and	B-X
the	B-X
Mason	B-X
-	B-X
Pfizer	B-X
monkey	B-X
virus	B-X
(	B-X
MPMV	B-X
)	B-X
<EOS>	B-X
The	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
response	B-X
to	B-X
certain	B-X
breast	B-X
cancer	B-X
-	B-X
related	B-X
antigens	B-X
(	B-X
MCF	B-X
-	B-X
7	B-X
and	B-X
MuMTV	B-X
)	B-X
:	B-X
their	B-X
potential	B-X
as	B-X
discriminants	B-X
.	B-X
<EOS>	B-X
Breast	B-X
cancer	B-X
patients	B-X
showed	B-X
significant	B-X
responses	B-X
to	B-X
MuMTV	B-X
(	B-X
49	B-X
%	B-X
and	B-X
to	B-X
MCF	B-X
-	B-X
7	B-X
(	B-X
50	B-X
%	B-X
)	B-X
,	B-X
but	B-X
not	B-X
to	B-X
MPMV	B-X
(	B-X
29	B-X
%	B-X
)	B-X
<EOS>	B-X
In	B-X
a	B-X
paired	B-X
-	B-X
antigen	B-X
study	B-X
using	B-X
MuMTV	B-X
and	B-X
MCF	B-X
-	B-X
7	B-X
,	B-X
75	B-X
%	B-X
of	B-X
the	B-X
breast	B-X
cancer	B-X
patients	B-X
responded	B-X
,	B-X
versus	B-X
18	B-X
%	B-X
of	B-X
the	B-X
normal	B-X
women	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X

We	O
have	O
used	O
the	O
leukocyte	O
migration	O
inhibition	O
(	O
LMI	O
)	O
response	O
to	O
assay	O
the	O
response	O
to	O
several	O
potential	O
breast	O
cancer-related	O
antigens	O
,	O
including	O
MuMTV	B-protein
,	O
MPMV	B-protein
,	O
and	O
a	O
breast	B-cell_line
cancer	I-cell_line
cultured	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
MCF-7	B-cell_line
,	O
in	O
96	O
breast	O
cancer	O
patients	O
,	O
in	O
32	O
women	O
with	O
benign	O
breast	O
disease	O
,	O
and	O
in	O
67	O
normal	O
women	O
.	O

The	O
lowest	O
tenth	O
percentile	O
of	O
control	O
(	O
LMI	O
)	O
responses	O
was	O
used	O
as	O
the	O
cutoff	O
point	O
to	O
designate	O
responders	O
.	O
<EOS>	B-X
The	B-X
lowest	B-X
tenth	B-X
percentile	B-X
of	B-X
control	B-X
(	B-X
LMI	B-X
)	B-X
responses	B-X
was	B-X
used	B-X
as	B-X
the	B-X
cutoff	B-X
point	B-X
to	B-X
designate	B-X
responders	B-X
<EOS>	B-X
The	B-X
potential	B-X
for	B-X
this	B-X
assay	B-X
to	B-X
distinguish	B-X
``	B-X
normal	B-X
''	B-X
from	B-X
``	B-X
breast	B-X
cancer	B-X
''	B-X
was	B-X
analyzed	B-X
using	B-X
a	B-X
migration	B-X
index	B-X
derived	B-X
from	B-X
discriminant	B-X
analysis	B-X
<EOS>	B-X
The	B-X
overall	B-X
responses	B-X
to	B-X
MuMTV	B-X
and	B-X
MCF	B-X
-	B-X
7	B-X
were	B-X
analyzed	B-X
with	B-X
reference	B-X
to	B-X
certain	B-X
prognostic	B-X
factors	B-X
,	B-X
but	B-X
showed	B-X
no	B-X
relation	B-X
to	B-X
age	B-X
,	B-X
menstrual	B-X
status	B-X
,	B-X
estrogen	B-X
receptor	B-X
status	B-X
,	B-X
or	B-X
stage	B-X
of	B-X
disease	B-X
<EOS>	B-X
The	B-X
above	B-X
reactions	B-X
suggest	B-X
that	B-X
a	B-X
large	B-X
proportion	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
exhibit	B-X
presensitization	B-X
to	B-X
antigenfs	B-X
found	B-X
in	B-X
MuMTV	B-X
and	B-X
MCF	B-X
-	B-X
7	B-X
,	B-X
which	B-X
may	B-X
be	B-X
cross	B-X
-	B-X
reactive	B-X
with	B-X
antigens	B-X
in	B-X
the	B-X
primary	B-X
cancer	B-X

Breast	O
cancer	O
patients	O
showed	O
significant	O
responses	O
to	O
MuMTV	B-protein
(	O
49	O
%	O
and	O
to	O
MCF-7	O
(	O
50	O
%	O
)	O
,	O
but	O
not	O
to	O
MPMV	B-protein
(	O
29	O
%	O
)	O
.	O

In	O
a	O
paired-antigen	O
study	O
using	O
MuMTV	B-protein
and	O
MCF-7	B-protein
,	O
75	O
%	O
of	O
the	O
breast	O
cancer	O
patients	O
responded	O
,	O
versus	O
18	O
%	O
of	O
the	O
normal	O
women	O
(	O
P	O
less	O
than	O
0.0050	O
)	O
.	O

The	O
potential	O
for	O
this	O
assay	O
to	O
distinguish	O
``	O
normal	O
''	O
from	O
``	O
breast	O
cancer	O
''	O
was	O
analyzed	O
using	O
a	O
migration	O
index	O
derived	O
from	O
discriminant	O
analysis	O
.	O
<EOS>	B-X
The	B-X
potential	B-X
for	B-X
this	B-X
assay	B-X
to	B-X
distinguish	B-X
``	B-X
normal	B-X
''	B-X
from	B-X
``	B-X
breast	B-X
cancer	B-X
''	B-X
was	B-X
analyzed	B-X
using	B-X
a	B-X
migration	B-X
index	B-X
derived	B-X
from	B-X
discriminant	B-X
analysis	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
assay	B-X
to	B-X
discriminate	B-X
``	B-X
normal	B-X
''	B-X
from	B-X
``	B-X
cancer	B-X
''	B-X
was	B-X
significant	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
The	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
response	B-X
to	B-X
certain	B-X
breast	B-X
cancer	B-X
-	B-X
related	B-X
antigens	B-X
(	B-X
MCF	B-X
-	B-X
7	B-X
and	B-X
MuMTV	B-X
)	B-X
:	B-X
their	B-X
potential	B-X
as	B-X
discriminants	B-X
.	B-X
<EOS>	B-X
The	B-X
lowest	B-X
tenth	B-X
percentile	B-X
of	B-X
control	B-X
(	B-X
LMI	B-X
)	B-X
responses	B-X
was	B-X
used	B-X
as	B-X
the	B-X
cutoff	B-X
point	B-X
to	B-X
designate	B-X
responders	B-X

The	O
ability	O
of	O
the	O
assay	O
to	O
discriminate	O
``	O
normal	O
''	O
from	O
``	O
cancer	O
''	O
was	O
significant	O
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
showed	O
a	O
sensitivity	O
of	O
detecting	O
``	O
cancer	O
''	O
of	O
75	O
%	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
assay	B-X
to	B-X
discriminate	B-X
``	B-X
normal	B-X
''	B-X
from	B-X
``	B-X
cancer	B-X
''	B-X
was	B-X
significant	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
The	B-X
potential	B-X
for	B-X
this	B-X
assay	B-X
to	B-X
distinguish	B-X
``	B-X
normal	B-X
''	B-X
from	B-X
``	B-X
breast	B-X
cancer	B-X
''	B-X
was	B-X
analyzed	B-X
using	B-X
a	B-X
migration	B-X
index	B-X
derived	B-X
from	B-X
discriminant	B-X
analysis	B-X
<EOS>	B-X
001	B-X
)	B-X
and	B-X
showed	B-X
a	B-X
sensitivity	B-X
of	B-X
detecting	B-X
``	B-X
cancer	B-X
''	B-X
of	B-X
75	B-X
%	B-X
<EOS>	B-X
The	B-X
above	B-X
reactions	B-X
suggest	B-X
that	B-X
a	B-X
large	B-X
proportion	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
exhibit	B-X
presensitization	B-X
to	B-X
antigenfs	B-X
found	B-X
in	B-X
MuMTV	B-X
and	B-X
MCF	B-X
-	B-X
7	B-X
,	B-X
which	B-X
may	B-X
be	B-X
cross	B-X
-	B-X
reactive	B-X
with	B-X
antigens	B-X
in	B-X
the	B-X
primary	B-X
cancer	B-X

The	O
overall	O
responses	O
to	O
MuMTV	B-protein
and	O
MCF-7	B-protein
were	O
analyzed	O
with	O
reference	O
to	O
certain	O
prognostic	O
factors	O
,	O
but	O
showed	O
no	O
relation	O
to	O
age	O
,	O
menstrual	O
status	O
,	O
estrogen	O
receptor	O
status	O
,	O
or	O
stage	O
of	O
disease	O
.	O
<EOS>	B-X
The	B-X
inverse	B-X
relationship	B-X
between	B-X
TBSs	B-X
and	B-X
AGP	B-X
may	B-X
reflect	B-X
decreased	B-X
stores	B-X
after	B-X
infection	B-X
or	B-X
an	B-X
effect	B-X
of	B-X
inflammation	B-X
on	B-X
isotope	B-X
partitioning	B-X
<EOS>	B-X
Our	B-X
questionnaire	B-X
responses	B-X
emphasized	B-X
the	B-X
heterogeneity	B-X
in	B-X
imaging	B-X
practice	B-X
as	B-X
performed	B-X
at	B-X
numerous	B-X
academic	B-X
cancer	B-X
centers	B-X
across	B-X
the	B-X
United	B-X
States	B-X
and	B-X
underscore	B-X
the	B-X
need	B-X
for	B-X
further	B-X
reconciliation	B-X
and	B-X
establishment	B-X
of	B-X
best	B-X
imaging	B-X
practice	B-X
guidelines	B-X
for	B-X
optimized	B-X
patient	B-X
care	B-X
in	B-X
anal	B-X
cancer	B-X
<EOS>	B-X
Findings	B-X
indicate	B-X
that	B-X
IR	B-X
may	B-X
not	B-X
be	B-X
related	B-X
to	B-X
tau	B-X
in	B-X
generally	B-X
healthy	B-X
middle	B-X
-	B-X
aged	B-X
and	B-X
older	B-X
adults	B-X
who	B-X
are	B-X
in	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
the	B-X
AD	B-X
clinicopathologic	B-X
continuum	B-X
but	B-X
suggest	B-X
the	B-X
need	B-X
for	B-X
additional	B-X
research	B-X
to	B-X
investigate	B-X
whether	B-X
a	B-X
synergistic	B-X
relationship	B-X
between	B-X
type	B-X
2	B-X
diabetes	B-X
and	B-X
amyloid	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
tau	B-X
levels	B-X
<EOS>	B-X
Thus	B-X
,	B-X
accurate	B-X
and	B-X
less	B-X
invasive	B-X
screening	B-X
tests	B-X
that	B-X
detect	B-X
EC	B-X
in	B-X
women	B-X
with	B-X
early	B-X
stages	B-X
of	B-X
the	B-X
disease	B-X
are	B-X
needed	B-X

The	O
above	O
reactions	O
suggest	O
that	O
a	O
large	O
proportion	O
of	O
breast	O
cancer	O
patients	O
exhibit	O
presensitization	O
to	O
antigenfs	O
found	O
in	O
MuMTV	B-protein
and	O
MCF-7	B-protein
,	O
which	O
may	O
be	O
cross-reactive	O
with	O
antigens	O
in	O
the	O
primary	O
cancer	O
.	O
<EOS>	B-X
The	B-X
above	B-X
reactions	B-X
suggest	B-X
that	B-X
a	B-X
large	B-X
proportion	B-X
of	B-X
breast	B-X
cancer	B-X
patients	B-X
exhibit	B-X
presensitization	B-X
to	B-X
antigenfs	B-X
found	B-X
in	B-X
MuMTV	B-X
and	B-X
MCF	B-X
-	B-X
7	B-X
,	B-X
which	B-X
may	B-X
be	B-X
cross	B-X
-	B-X
reactive	B-X
with	B-X
antigens	B-X
in	B-X
the	B-X
primary	B-X
cancer	B-X
<EOS>	B-X
The	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
response	B-X
to	B-X
certain	B-X
breast	B-X
cancer	B-X
-	B-X
related	B-X
antigens	B-X
(	B-X
MCF	B-X
-	B-X
7	B-X
and	B-X
MuMTV	B-X
)	B-X
:	B-X
their	B-X
potential	B-X
as	B-X
discriminants	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
used	B-X
the	B-X
leukocyte	B-X
migration	B-X
inhibition	B-X
(	B-X
LMI	B-X
)	B-X
response	B-X
to	B-X
assay	B-X
the	B-X
response	B-X
to	B-X
several	B-X
potential	B-X
breast	B-X
cancer	B-X
-	B-X
related	B-X
antigens	B-X
,	B-X
including	B-X
MuMTV	B-X
,	B-X
MPMV	B-X
,	B-X
and	B-X
a	B-X
breast	B-X
cancer	B-X
cultured	B-X
cell	B-X
line	B-X
,	B-X
MCF	B-X
-	B-X
7	B-X
,	B-X
in	B-X
96	B-X
breast	B-X
cancer	B-X
patients	B-X
,	B-X
in	B-X
32	B-X
women	B-X
with	B-X
benign	B-X
breast	B-X
disease	B-X
,	B-X
and	B-X
in	B-X
67	B-X
normal	B-X
women	B-X
<EOS>	B-X
In	B-X
a	B-X
paired	B-X
-	B-X
antigen	B-X
study	B-X
using	B-X
MuMTV	B-X
and	B-X
MCF	B-X
-	B-X
7	B-X
,	B-X
75	B-X
%	B-X
of	B-X
the	B-X
breast	B-X
cancer	B-X
patients	B-X
responded	B-X
,	B-X
versus	B-X
18	B-X
%	B-X
of	B-X
the	B-X
normal	B-X
women	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X

These	O
responses	O
appear	O
to	O
be	O
independent	O
of	O
major	O
prognostic	O
variables	O
.	O
<EOS>	B-X
These	B-X
responses	B-X
appear	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
major	B-X
prognostic	B-X
variables	B-X
<EOS>	B-X
03	B-X
)	B-X
,	B-X
independent	B-X
from	B-X
other	B-X
major	B-X
prognosticators	B-X
(	B-X
p	B-X
=	B-X
0	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
these	B-X
prognostic	B-X
factors	B-X
was	B-X
independent	B-X
of	B-X
symptom	B-X
severity	B-X
and	B-X
global	B-X
functioning	B-X
<EOS>	B-X
Based	B-X
on	B-X
pooled	B-X
analysis	B-X
,	B-X
CKD	B-X
appeared	B-X
correlated	B-X
with	B-X
HPR	B-X
and	B-X
this	B-X
association	B-X
had	B-X
prognostic	B-X
significance	B-X

Further	O
refinement	O
of	O
this	O
assay	O
may	O
yield	O
one	O
which	O
is	O
more	O
highly	O
discriminating	O
for	O
breast	O
cancer	O
.	O
<EOS>	B-X
Further	B-X
refinement	B-X
of	B-X
this	B-X
assay	B-X
may	B-X
yield	B-X
one	B-X
which	B-X
is	B-X
more	B-X
highly	B-X
discriminating	B-X
for	B-X
breast	B-X
cancer	B-X
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
assay	B-X
to	B-X
discriminate	B-X
``	B-X
normal	B-X
''	B-X
from	B-X
``	B-X
cancer	B-X
''	B-X
was	B-X
significant	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X
<EOS>	B-X
The	B-X
potential	B-X
for	B-X
this	B-X
assay	B-X
to	B-X
distinguish	B-X
``	B-X
normal	B-X
''	B-X
from	B-X
``	B-X
breast	B-X
cancer	B-X
''	B-X
was	B-X
analyzed	B-X
using	B-X
a	B-X
migration	B-X
index	B-X
derived	B-X
from	B-X
discriminant	B-X
analysis	B-X
<EOS>	B-X
Certain	B-X
oncogenic	B-X
viruses	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
human	B-X
breast	B-X
cancer	B-X
,	B-X
including	B-X
the	B-X
murine	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MuMTV	B-X
)	B-X
and	B-X
the	B-X
Mason	B-X
-	B-X
Pfizer	B-X
monkey	B-X
virus	B-X
(	B-X
MPMV	B-X
)	B-X

Chronic	O
lymphatic	O
leukaemia	O
:	O
cellular	O
effects	O
of	O
glucocorticoids	O
in	O
vitro	O
.	O
<EOS>	B-X
Chronic	B-X
lymphocytic	B-X
leukaemia	B-X
(	B-X
CLL	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
haematological	B-X
malignancy	B-X
in	B-X
the	B-X
U	B-X
<EOS>	B-X
Chronic	B-X
lymphoid	B-X
leukemia	B-X
cells	B-X
are	B-X
highly	B-X
sensitive	B-X
to	B-X
the	B-X
combination	B-X
of	B-X
prednisolone	B-X
and	B-X
daunorubicin	B-X
,	B-X
but	B-X
much	B-X
less	B-X
to	B-X
doxorubicin	B-X
or	B-X
epirubicin	B-X
.	B-X
<EOS>	B-X
The	B-X
putative	B-X
benefits	B-X
of	B-X
its	B-X
combination	B-X
with	B-X
glucocorticoids	B-X
were	B-X
evaluated	B-X
here	B-X
<EOS>	B-X
Chronic	B-X
lymphocytic	B-X
leukaemia	B-X
(	B-X
CLL	B-X
)	B-X
is	B-X
a	B-X
lymphoproliferative	B-X
disease	B-X
characterised	B-X
by	B-X
accumulation	B-X
of	B-X
monoclonal	B-X
CD19+CD5+CD23+	B-X
lymphocytes	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
and	B-X
bone	B-X
marrow	B-X

Glucocorticoid	B-protein
receptor	I-protein
levels	O
and	O
steroid	O
induced	O
inhibition	O
of	O
nucleic	O
acid	O
precursors	O
have	O
been	O
examined	O
in	O
lymphocytes	B-cell_type
from	O
27	O
patients	O
at	O
different	O
stages	O
of	O
chronic	O
lymphatic	O
leukaemia	O
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptor	B-X
levels	B-X
and	B-X
steroid	B-X
induced	B-X
inhibition	B-X
of	B-X
nucleic	B-X
acid	B-X
precursors	B-X
have	B-X
been	B-X
examined	B-X
in	B-X
lymphocytes	B-X
from	B-X
27	B-X
patients	B-X
at	B-X
different	B-X
stages	B-X
of	B-X
chronic	B-X
lymphatic	B-X
leukaemia	B-X
<EOS>	B-X
No	B-X
correlation	B-X
can	B-X
be	B-X
found	B-X
between	B-X
the	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
the	B-X
stage	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
02	B-X
)	B-X
was	B-X
found	B-X
between	B-X
stage	B-X
O	B-X
and	B-X
stage	B-X
III	B-X
/	B-X
IV	B-X
patients	B-X
,	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
effect	B-X
of	B-X
dexamethasone	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
uridine	B-X
incorporation	B-X
<EOS>	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
a	B-X
significant	B-X
difference	B-X
(	B-X
P	B-X
less	B-X
than	B-X
0	B-X

No	O
correlation	O
can	O
be	O
found	O
between	O
the	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
the	O
stage	O
of	O
the	O
disease	O
.	O
<EOS>	B-X
No	B-X
correlation	B-X
can	B-X
be	B-X
found	B-X
between	B-X
the	B-X
level	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
the	B-X
stage	B-X
of	B-X
the	B-X
disease	B-X
<EOS>	B-X
An	B-X
inverse	B-X
relationship	B-X
was	B-X
observed	B-X
between	B-X
cortisol	B-X
levels	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
<EOS>	B-X
Changes	B-X
in	B-X
the	B-X
pulmonary	B-X
glucocorticoid	B-X
receptor	B-X
content	B-X
in	B-X
the	B-X
course	B-X
of	B-X
interstitial	B-X
disease	B-X
.	B-X
<EOS>	B-X
A	B-X
positive	B-X
correlation	B-X
was	B-X
noticed	B-X
between	B-X
plasma	B-X
IL	B-X
-	B-X
8	B-X
,	B-X
the	B-X
percentage	B-X
of	B-X
milk	B-X
neutrophils	B-X
and	B-X
expression	B-X
of	B-X
chemokine	B-X
receptors	B-X
(	B-X
CXCR1	B-X
and	B-X
CXCR2	B-X
)	B-X

On	O
the	O
other	O
hand	O
,	O
a	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0.02	O
)	O
was	O
found	O
between	O
stage	O
O	O
and	O
stage	O
III/IV	O
patients	O
,	O
in	O
terms	O
of	O
the	O
in	O
vitro	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
uridine	O
incorporation	O
.	O

Pyrrolidine	O
dithiocarbamate	O
inhibits	O
NF-kappa	B-protein
B	I-protein
mobilization	O
and	O
TNF	O
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
Pyrrolidine	B-X
dithiocarbamate	B-X
inhibits	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
mobilization	B-X
and	B-X
TNF	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
dithiocarbamates	B-X
can	B-X
profoundly	B-X
affect	B-X
cytokine	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
involved	B-X
in	B-X
LPS	B-X
-	B-X
induced	B-X
TNF	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytes	B-X
<EOS>	B-X
PDTC	B-X
did	B-X
not	B-X
shift	B-X
this	B-X
response	B-X
to	B-X
LPS	B-X
to	B-X
a	B-X
later	B-X
time	B-X
,	B-X
but	B-X
suppressed	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
mobilization	B-X
,	B-X
TNF	B-X
transcripts	B-X
,	B-X
and	B-X
TNF	B-X
protein	B-X
over	B-X
the	B-X
entire	B-X
8	B-X
-	B-X
h	B-X
observation	B-X
period	B-X
<EOS>	B-X
Kinetic	B-X
analyses	B-X
show	B-X
that	B-X
after	B-X
LPS	B-X
stimulation	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
will	B-X
peak	B-X
at	B-X
1	B-X
h	B-X
,	B-X
TNF	B-X
transcript	B-X
prevalence	B-X
at	B-X
2	B-X
h	B-X
,	B-X
and	B-X
TNF	B-X
protein	B-X
at	B-X
4	B-X
h	B-X

The	O
human	B-DNA
TNF	I-DNA
promoter	I-DNA
contains	O
four	O
potential	O
nuclear	B-DNA
factor-kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
-binding	I-DNA
sites	I-DNA
,	O
with	O
the	O
strongest	O
binding	O
seen	O
for	O
the	O
-605	O
motif	O
.	O
<EOS>	B-X
The	B-X
human	B-X
TNF	B-X
promoter	B-X
contains	B-X
four	B-X
potential	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
	B-X
-	B-X
binding	B-X
sites	B-X
,	B-X
with	B-X
the	B-X
strongest	B-X
binding	B-X
seen	B-X
for	B-X
the	B-X
	B-X
-	B-X
605	B-X
motif	B-X
<EOS>	B-X
Pyrrolidine	B-X
dithiocarbamate	B-X
inhibits	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
mobilization	B-X
and	B-X
TNF	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Kinetic	B-X
analyses	B-X
show	B-X
that	B-X
after	B-X
LPS	B-X
stimulation	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
will	B-X
peak	B-X
at	B-X
1	B-X
h	B-X
,	B-X
TNF	B-X
transcript	B-X
prevalence	B-X
at	B-X
2	B-X
h	B-X
,	B-X
and	B-X
TNF	B-X
protein	B-X
at	B-X
4	B-X
h	B-X
<EOS>	B-X
Nuclear	B-X
extracts	B-X
from	B-X
unstimulated	B-X
cells	B-X
of	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
Mono	B-X
Mac	B-X
6	B-X
,	B-X
contain	B-X
one	B-X
specific	B-X
binding	B-X
protein	B-X
(	B-X
complex	B-X
II	B-X
)	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
constitutive	B-X
p50	B-X
homodimer	B-X

Nuclear	O
extracts	O
from	O
unstimulated	B-cell_line
cells	I-cell_line
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
,	O
contain	O
one	O
specific	B-protein
binding	I-protein
protein	I-protein
(	O
complex	B-protein
II	I-protein
)	O
,	O
consistent	O
with	O
a	O
constitutive	B-protein
p50	I-protein
homodimer	I-protein
.	O
<EOS>	B-X
Nuclear	B-X
extracts	B-X
from	B-X
unstimulated	B-X
cells	B-X
of	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
Mono	B-X
Mac	B-X
6	B-X
,	B-X
contain	B-X
one	B-X
specific	B-X
binding	B-X
protein	B-X
(	B-X
complex	B-X
II	B-X
)	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
constitutive	B-X
p50	B-X
homodimer	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
LPS	B-X
will	B-X
increase	B-X
complex	B-X
II	B-X
and	B-X
will	B-X
strongly	B-X
induce	B-X
a	B-X
second	B-X
specific	B-X
complex	B-X
(	B-X
complex	B-X
I	B-X
)	B-X
,	B-X
which	B-X
represents	B-X
the	B-X
p50	B-X
/	B-X
65	B-X
heterodimer	B-X
<EOS>	B-X
The	B-X
human	B-X
TNF	B-X
promoter	B-X
contains	B-X
four	B-X
potential	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
	B-X
-	B-X
binding	B-X
sites	B-X
,	B-X
with	B-X
the	B-X
strongest	B-X
binding	B-X
seen	B-X
for	B-X
the	B-X
	B-X
-	B-X
605	B-X
motif	B-X
<EOS>	B-X
Binding	B-X
activity	B-X
of	B-X
other	B-X
nuclear	B-X
factors	B-X
that	B-X
recognize	B-X
the	B-X
SP	B-X
-	B-X
1	B-X
and	B-X
c	B-X
/	B-X
EBP	B-X
motifs	B-X
of	B-X
the	B-X
human	B-X
TNF	B-X
promoter	B-X
is	B-X
not	B-X
affected	B-X
by	B-X
such	B-X
treatment	B-X

Stimulation	O
of	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
with	O
LPS	O
will	O
increase	O
complex	B-protein
II	I-protein
and	O
will	O
strongly	O
induce	O
a	O
second	O
specific	O
complex	O
(	O
complex	B-protein
I	I-protein
)	O
,	O
which	O
represents	O
the	O
p50/65	B-protein
heterodimer	I-protein
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
LPS	B-X
will	B-X
increase	B-X
complex	B-X
II	B-X
and	B-X
will	B-X
strongly	B-X
induce	B-X
a	B-X
second	B-X
specific	B-X
complex	B-X
(	B-X
complex	B-X
I	B-X
)	B-X
,	B-X
which	B-X
represents	B-X
the	B-X
p50	B-X
/	B-X
65	B-X
heterodimer	B-X
<EOS>	B-X
Treatment	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
pyrrolidine	B-X
-	B-X
dithiocarbamate	B-X
(	B-X
PDTC	B-X
)	B-X
at	B-X
300	B-X
microM	B-X
will	B-X
block	B-X
the	B-X
LPS	B-X
-	B-X
induced	B-X
complex	B-X
I	B-X
almost	B-X
completely	B-X
and	B-X
will	B-X
reduce	B-X
complex	B-X
II	B-X
to	B-X
the	B-X
constitutive	B-X
level	B-X
<EOS>	B-X
Nuclear	B-X
extracts	B-X
from	B-X
unstimulated	B-X
cells	B-X
of	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
Mono	B-X
Mac	B-X
6	B-X
,	B-X
contain	B-X
one	B-X
specific	B-X
binding	B-X
protein	B-X
(	B-X
complex	B-X
II	B-X
)	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
constitutive	B-X
p50	B-X
homodimer	B-X
<EOS>	B-X
Northern	B-X
blot	B-X
analysis	B-X
demonstrates	B-X
that	B-X
PDTC	B-X
treatment	B-X
will	B-X
strongly	B-X
reduce	B-X
LPS	B-X
-	B-X
induced	B-X
TNF	B-X
transcripts	B-X

Treatment	O
of	O
Mono	B-cell_type
Mac	I-cell_type
6	I-cell_type
cells	I-cell_type
with	O
pyrrolidine-dithiocarbamate	O
(	O
PDTC	O
)	O
at	O
300	O
microM	O
will	O
block	O
the	O
LPS-induced	B-protein
complex	I-protein
I	I-protein
almost	O
completely	O
and	O
will	O
reduce	O
complex	B-protein
II	I-protein
to	O
the	O
constitutive	O
level	O
.	O

Binding	O
activity	O
of	O
other	O
nuclear	B-protein
factors	I-protein
that	O
recognize	O
the	O
SP-1	O
and	O
c/EBP	O
motifs	O
of	O
the	O
human	B-DNA
TNF	I-DNA
promoter	I-DNA
is	O
not	O
affected	O
by	O
such	O
treatment	O
.	O

Northern	O
blot	O
analysis	O
demonstrates	O
that	O
PDTC	O
treatment	O
will	O
strongly	O
reduce	O
LPS-induced	B-protein
TNF	I-protein
transcripts	I-protein
.	O
<EOS>	B-X
Northern	B-X
blot	B-X
analysis	B-X
demonstrates	B-X
that	B-X
PDTC	B-X
treatment	B-X
will	B-X
strongly	B-X
reduce	B-X
LPS	B-X
-	B-X
induced	B-X
TNF	B-X
transcripts	B-X
<EOS>	B-X
Kinetic	B-X
analyses	B-X
show	B-X
that	B-X
after	B-X
LPS	B-X
stimulation	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
will	B-X
peak	B-X
at	B-X
1	B-X
h	B-X
,	B-X
TNF	B-X
transcript	B-X
prevalence	B-X
at	B-X
2	B-X
h	B-X
,	B-X
and	B-X
TNF	B-X
protein	B-X
at	B-X
4	B-X
h	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
with	B-X
LPS	B-X
will	B-X
increase	B-X
complex	B-X
II	B-X
and	B-X
will	B-X
strongly	B-X
induce	B-X
a	B-X
second	B-X
specific	B-X
complex	B-X
(	B-X
complex	B-X
I	B-X
)	B-X
,	B-X
which	B-X
represents	B-X
the	B-X
p50	B-X
/	B-X
65	B-X
heterodimer	B-X
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
dithiocarbamates	B-X
can	B-X
profoundly	B-X
affect	B-X
cytokine	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
involved	B-X
in	B-X
LPS	B-X
-	B-X
induced	B-X
TNF	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytes	B-X

Secreted	O
TNF	B-protein
protein	I-protein
as	O
detected	O
in	O
the	O
Wehi	O
164S/ActD	O
bioassay	O
and	O
in	O
a	O
sandwich	O
immunoassay	O
was	O
similarly	O
reduced	O
by	O
PDTC	O
.	O

Kinetic	O
analyses	O
show	O
that	O
after	O
LPS	O
stimulation	O
,	O
NF-kappa	B-protein
B	I-protein
will	O
peak	O
at	O
1	O
h	O
,	O
TNF	O
transcript	O
prevalence	O
at	O
2	O
h	O
,	O
and	O
TNF	B-protein
protein	I-protein
at	O
4	O
h	O
.	O

PDTC	O
did	O
not	O
shift	O
this	O
response	O
to	O
LPS	O
to	O
a	O
later	O
time	O
,	O
but	O
suppressed	O
NF-kappa	O
B	O
mobilization	O
,	O
TNF	B-protein
transcripts	I-protein
,	O
and	O
TNF	B-protein
protein	I-protein
over	O
the	O
entire	O
8-h	O
observation	O
period	O
.	O
<EOS>	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
report	B-X
the	B-X
effectiveness	B-X
and	B-X
tolerability	B-X
of	B-X
lenvatinib	B-X
in	B-X
our	B-X
series	B-X
of	B-X
PDTC	B-X
patients	B-X
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
our	B-X
study	B-X
is	B-X
the	B-X
comprehensive	B-X
identification	B-X
of	B-X
molecular	B-X
circuitry	B-X
involved	B-X
in	B-X
low	B-X
shear	B-X
stress	B-X
-	B-X
induced	B-X
inflammation	B-X
in	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
through	B-X
protein	B-X
profiling	B-X
and	B-X
cell	B-X
function	B-X
experiment	B-X
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
aspirin	B-X
triggers	B-X
ferroptosis	B-X
by	B-X
restricting	B-X
NF	B-X
-	B-X
κB	B-X
-	B-X
activated	B-X
SLC7A11	B-X
transcription	B-X
to	B-X
suppress	B-X
the	B-X
growth	B-X
of	B-X
HCC	B-X
<EOS>	B-X
We	B-X
aim	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
overexposure	B-X
to	B-X
blue	B-X
light	B-X
on	B-X
the	B-X
rat	B-X
ocular	B-X
surface	B-X
and	B-X
explore	B-X
the	B-X
potential	B-X
mechanisms	B-X

Analysis	O
of	O
freshly	O
isolated	O
,	O
LPS-stimulated	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
showed	O
a	O
similar	O
blockade	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
freshly	B-X
isolated	B-X
,	B-X
LPS	B-X
-	B-X
stimulated	B-X
blood	B-X
monocytes	B-X
showed	B-X
a	B-X
similar	B-X
blockade	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
Kinetic	B-X
analyses	B-X
show	B-X
that	B-X
after	B-X
LPS	B-X
stimulation	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
will	B-X
peak	B-X
at	B-X
1	B-X
h	B-X
,	B-X
TNF	B-X
transcript	B-X
prevalence	B-X
at	B-X
2	B-X
h	B-X
,	B-X
and	B-X
TNF	B-X
protein	B-X
at	B-X
4	B-X
h	B-X
<EOS>	B-X
Binding	B-X
activity	B-X
of	B-X
other	B-X
nuclear	B-X
factors	B-X
that	B-X
recognize	B-X
the	B-X
SP	B-X
-	B-X
1	B-X
and	B-X
c	B-X
/	B-X
EBP	B-X
motifs	B-X
of	B-X
the	B-X
human	B-X
TNF	B-X
promoter	B-X
is	B-X
not	B-X
affected	B-X
by	B-X
such	B-X
treatment	B-X
<EOS>	B-X
PDTC	B-X
did	B-X
not	B-X
shift	B-X
this	B-X
response	B-X
to	B-X
LPS	B-X
to	B-X
a	B-X
later	B-X
time	B-X
,	B-X
but	B-X
suppressed	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
mobilization	B-X
,	B-X
TNF	B-X
transcripts	B-X
,	B-X
and	B-X
TNF	B-X
protein	B-X
over	B-X
the	B-X
entire	B-X
8	B-X
-	B-X
h	B-X
observation	B-X
period	B-X

Furthermore	O
,	O
in	O
these	O
primary	O
cells	O
,	O
induction	O
of	O
TNF	B-protein
transcripts	I-protein
,	O
as	O
determined	O
by	O
Northern	O
blot	O
analysis	O
and	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
was	O
prevented	O
by	O
PDTC	O
as	O
was	O
TNF	B-protein
protein	I-protein
production	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
in	B-X
these	B-X
primary	B-X
cells	B-X
,	B-X
induction	B-X
of	B-X
TNF	B-X
transcripts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
Northern	B-X
blot	B-X
analysis	B-X
and	B-X
by	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
was	B-X
prevented	B-X
by	B-X
PDTC	B-X
as	B-X
was	B-X
TNF	B-X
protein	B-X
production	B-X
<EOS>	B-X
Kinetic	B-X
analyses	B-X
show	B-X
that	B-X
after	B-X
LPS	B-X
stimulation	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
will	B-X
peak	B-X
at	B-X
1	B-X
h	B-X
,	B-X
TNF	B-X
transcript	B-X
prevalence	B-X
at	B-X
2	B-X
h	B-X
,	B-X
and	B-X
TNF	B-X
protein	B-X
at	B-X
4	B-X
h	B-X
<EOS>	B-X
Secreted	B-X
TNF	B-X
protein	B-X
as	B-X
detected	B-X
in	B-X
the	B-X
Wehi	B-X
164S	B-X
/	B-X
ActD	B-X
bioassay	B-X
and	B-X
in	B-X
a	B-X
sandwich	B-X
immunoassay	B-X
was	B-X
similarly	B-X
reduced	B-X
by	B-X
PDTC	B-X
<EOS>	B-X
Binding	B-X
activity	B-X
of	B-X
other	B-X
nuclear	B-X
factors	B-X
that	B-X
recognize	B-X
the	B-X
SP	B-X
-	B-X
1	B-X
and	B-X
c	B-X
/	B-X
EBP	B-X
motifs	B-X
of	B-X
the	B-X
human	B-X
TNF	B-X
promoter	B-X
is	B-X
not	B-X
affected	B-X
by	B-X
such	B-X
treatment	B-X

These	O
data	O
show	O
that	O
dithiocarbamates	O
can	O
profoundly	O
affect	O
cytokine	O
expression	O
and	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
is	O
involved	O
in	O
LPS-induced	O
TNF	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
These	B-X
data	B-X
show	B-X
that	B-X
dithiocarbamates	B-X
can	B-X
profoundly	B-X
affect	B-X
cytokine	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
involved	B-X
in	B-X
LPS	B-X
-	B-X
induced	B-X
TNF	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytes	B-X
<EOS>	B-X
Pyrrolidine	B-X
dithiocarbamate	B-X
inhibits	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
mobilization	B-X
and	B-X
TNF	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Northern	B-X
blot	B-X
analysis	B-X
demonstrates	B-X
that	B-X
PDTC	B-X
treatment	B-X
will	B-X
strongly	B-X
reduce	B-X
LPS	B-X
-	B-X
induced	B-X
TNF	B-X
transcripts	B-X
<EOS>	B-X
Kinetic	B-X
analyses	B-X
show	B-X
that	B-X
after	B-X
LPS	B-X
stimulation	B-X
,	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
will	B-X
peak	B-X
at	B-X
1	B-X
h	B-X
,	B-X
TNF	B-X
transcript	B-X
prevalence	B-X
at	B-X
2	B-X
h	B-X
,	B-X
and	B-X
TNF	B-X
protein	B-X
at	B-X
4	B-X
h	B-X

Comparing	O
regions	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
which	O
function	O
as	O
transcriptional	B-DNA
activating	I-DNA
sequences	I-DNA
in	O
Saccharomyces	O
cerevisiae	O
and	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
ZEBRA	B-protein
protein	I-protein
activates	O
expression	O
of	O
Epstein-Barr	O
virus	O
early-lytic-cycle	B-DNA
genes	I-DNA
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Here	O
it	O
is	O
shown	O
that	O
ZEBRA	B-protein
also	O
behaves	O
as	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
activator	I-protein
in	O
Saccharomyces	O
cerevisiae	O
.	O
<EOS>	B-X
Here	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
ZEBRA	B-X
also	B-X
behaves	B-X
as	B-X
a	B-X
sequence	B-X
-	B-X
specific	B-X
transcriptional	B-X
activator	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
<EOS>	B-X
Comparing	B-X
regions	B-X
of	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
ZEBRA	B-X
protein	B-X
which	B-X
function	B-X
as	B-X
transcriptional	B-X
activating	B-X
sequences	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
and	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
Regions	B-X
of	B-X
ZEBRA	B-X
which	B-X
affected	B-X
activation	B-X
in	B-X
S	B-X
<EOS>	B-X
Deletional	B-X
mutagenesis	B-X
defined	B-X
three	B-X
regions	B-X
of	B-X
ZEBRA	B-X
that	B-X
participate	B-X
in	B-X
activation	B-X
in	B-X
S	B-X

Deletional	O
mutagenesis	O
defined	O
three	O
regions	O
of	O
ZEBRA	B-protein
that	O
participate	O
in	O
activation	O
in	O
S.	O
cerevisiae	O
.	O

These	O
regions	O
are	O
designated	O
YI	B-protein
(	O
amino	B-protein
acids	I-protein
[	I-protein
aa	I-protein
]	I-protein
1	I-protein
to	I-protein
25	I-protein
)	O
,	O
YII	B-protein
(	O
aa	B-protein
51	I-protein
to	I-protein
102	I-protein
)	O
,	O
and	O
YIII	B-protein
(	O
aa	B-protein
228	I-protein
to	I-protein
245	I-protein
)	O
.	O

Two	O
of	O
the	O
three	O
regions	O
of	O
the	O
native	O
ZEBRA	B-protein
protein	I-protein
act	O
together	O
to	O
mediate	O
activation	O
when	O
assayed	O
on	O
ZEBRA	B-protein
binding	I-protein
sites	I-protein
.	O
<EOS>	B-X
Two	B-X
of	B-X
the	B-X
three	B-X
regions	B-X
of	B-X
the	B-X
native	B-X
ZEBRA	B-X
protein	B-X
act	B-X
together	B-X
to	B-X
mediate	B-X
activation	B-X
when	B-X
assayed	B-X
on	B-X
ZEBRA	B-X
binding	B-X
sites	B-X
<EOS>	B-X
Comparing	B-X
regions	B-X
of	B-X
the	B-X
Epstein	B-X
-	B-X
Barr	B-X
virus	B-X
ZEBRA	B-X
protein	B-X
which	B-X
function	B-X
as	B-X
transcriptional	B-X
activating	B-X
sequences	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
and	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
<EOS>	B-X
The	B-X
amino	B-X
-	B-X
terminal	B-X
region	B-X
of	B-X
ZEBRA	B-X
(	B-X
aa	B-X
1	B-X
to	B-X
98	B-X
)	B-X
was	B-X
required	B-X
for	B-X
activation	B-X
both	B-X
in	B-X
S	B-X
<EOS>	B-X
Regions	B-X
of	B-X
ZEBRA	B-X
which	B-X
affected	B-X
activation	B-X
in	B-X
S	B-X

However	O
,	O
when	O
fused	O
to	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
GAL	B-protein
4	O
and	O
assayed	O
on	O
GAL4	B-protein
binding	I-protein
sites	I-protein
,	O
regions	B-protein
YII	I-protein
and	I-protein
YIII	I-protein
were	O
each	O
sufficient	O
to	O
confer	O
activation	O
in	O
S.	O
cerevisiae	O
.	O

Regions	O
of	O
ZEBRA	B-protein
which	O
affected	O
activation	O
in	O
S.	O
cerevisiae	O
were	O
also	O
required	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
amino-terminal	B-protein
region	I-protein
of	O
ZEBRA	B-protein
(	O
aa	B-protein
1	I-protein
to	I-protein
98	I-protein
)	O
was	O
required	O
for	O
activation	O
both	O
in	O
S.	O
cerevisiae	O
and	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
;	O
deletion	O
of	O
the	O
carboxy-terminal	B-protein
18	I-protein
aa	I-protein
also	O
significantly	O
reduced	O
activation	O
in	O
both	O
cell	O
types	O
.	O

Thus	O
,	O
the	O
behavior	O
of	O
ZEBRA	B-protein
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
S.	O
cerevisiae	O
suggests	O
that	O
the	O
protein	O
contains	O
universal	B-protein
activation	I-protein
motifs	I-protein
that	O
interact	O
with	O
conserved	O
components	O
of	O
the	O
transcription	O
machinery	O
.	O

However	O
,	O
certain	O
deletion	B-protein
mutants	I-protein
of	O
ZEBRA	B-protein
containing	O
mutations	O
in	O
the	O
N-terminal	B-protein
region	I-protein
exhibited	O
discordant	O
behaviors	O
in	O
S.	O
cerevisiae	O
and	O
in	O
B	O
cells	O
.	O

For	O
example	O
,	O
deletion	O
of	O
ZEBRA	B-protein
aa	I-protein
26	I-protein
to	I-protein
51	I-protein
impaired	O
activation	O
to	O
a	O
great	O
extent	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
had	O
little	O
or	O
no	O
effect	O
in	O
S.	O
cerevisiae	O
.	O

The	O
discordant	O
mutants	O
may	O
reflect	O
interactions	O
with	O
a	O
variable	B-protein
domain	I-protein
of	O
a	O
conserved	O
component	O
or	O
unique	O
interactions	O
with	O
specialized	O
components	O
of	O
the	O
basal	O
transcription	O
apparatus	O
in	O
different	O
cells	O
.	O
<EOS>	B-X
The	B-X
discordant	B-X
mutants	B-X
may	B-X
reflect	B-X
interactions	B-X
with	B-X
a	B-X
variable	B-X
domain	B-X
of	B-X
a	B-X
conserved	B-X
component	B-X
or	B-X
unique	B-X
interactions	B-X
with	B-X
specialized	B-X
components	B-X
of	B-X
the	B-X
basal	B-X
transcription	B-X
apparatus	B-X
in	B-X
different	B-X
cells	B-X
<EOS>	B-X
cerevisiae	B-X
suggests	B-X
that	B-X
the	B-X
protein	B-X
contains	B-X
universal	B-X
activation	B-X
motifs	B-X
that	B-X
interact	B-X
with	B-X
conserved	B-X
components	B-X
of	B-X
the	B-X
transcription	B-X
machinery	B-X
<EOS>	B-X
Two	B-X
of	B-X
the	B-X
three	B-X
regions	B-X
of	B-X
the	B-X
native	B-X
ZEBRA	B-X
protein	B-X
act	B-X
together	B-X
to	B-X
mediate	B-X
activation	B-X
when	B-X
assayed	B-X
on	B-X
ZEBRA	B-X
binding	B-X
sites	B-X
<EOS>	B-X
For	B-X
example	B-X
,	B-X
deletion	B-X
of	B-X
ZEBRA	B-X
aa	B-X
26	B-X
to	B-X
51	B-X
impaired	B-X
activation	B-X
to	B-X
a	B-X
great	B-X
extent	B-X
in	B-X
B	B-X
cells	B-X
but	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
in	B-X
S	B-X

Functional	O
interaction	O
of	O
the	O
v-Rel	B-protein
and	I-protein
c-Rel	I-protein
oncoproteins	I-protein
with	O
the	O
TATA-binding	B-protein
protein	I-protein
and	O
association	O
with	O
transcription	B-protein
factor	I-protein
IIB	I-protein
.	O
<EOS>	B-X
Functional	B-X
interaction	B-X
of	B-X
the	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
oncoproteins	B-X
with	B-X
the	B-X
TATA	B-X
-	B-X
binding	B-X
protein	B-X
and	B-X
association	B-X
with	B-X
transcription	B-X
factor	B-X
IIB	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
oncoproteins	B-X
to	B-X
interact	B-X
with	B-X
components	B-X
of	B-X
the	B-X
basal	B-X
transcription	B-X
machinery	B-X
<EOS>	B-X
Combined	B-X
with	B-X
the	B-X
observation	B-X
that	B-X
the	B-X
mouse	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
human	B-X
RelA	B-X
proteins	B-X
also	B-X
interact	B-X
with	B-X
TBP	B-X
and	B-X
TFIIB	B-X
in	B-X
vitro	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
association	B-X
with	B-X
basal	B-X
transcription	B-X
factors	B-X
is	B-X
important	B-X
for	B-X
the	B-X
transcriptional	B-X
activities	B-X
of	B-X
Rel	B-X
family	B-X
proteins	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
both	B-X
the	B-X
acidic	B-X
transcription	B-X
activation	B-X
domain	B-X
mapping	B-X
to	B-X
the	B-X
unique	B-X
C	B-X
terminus	B-X
of	B-X
chicken	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
the	B-X
F9	B-X
cell	B-X
-	B-X
specific	B-X
activation	B-X
region	B-X
common	B-X
to	B-X
both	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
interact	B-X
with	B-X
the	B-X
TATA	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
TBP	B-X
)	B-X
and	B-X
transcription	B-X
factor	B-X
IIB	B-X
(	B-X
TFIIB	B-X
)	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X

Rel	B-protein
family	I-protein
proteins	I-protein
regulate	O
the	O
expression	O
of	O
genes	O
linked	O
to	O
kappa	O
B-binding	O
motifs	O
.	O
<EOS>	B-X
Rel	B-X
family	B-X
proteins	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
linked	B-X
to	B-X
kappa	B-X
B	B-X
-	B-X
binding	B-X
motifs	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
c	B-X
-	B-X
rel	B-X
protein	B-X
can	B-X
activate	B-X
expression	B-X
of	B-X
genes	B-X
linked	B-X
to	B-X
kappa	B-X
B	B-X
motifs	B-X
when	B-X
low	B-X
levels	B-X
of	B-X
endogenous	B-X
kappa	B-X
B	B-X
-	B-X
binding	B-X
activity	B-X
are	B-X
present	B-X
<EOS>	B-X
Our	B-X
studies	B-X
originally	B-X
demonstrated	B-X
that	B-X
the	B-X
v	B-X
-	B-X
rel	B-X
oncoprotein	B-X
repressed	B-X
gene	B-X
expression	B-X
in	B-X
chicken	B-X
lymphoid	B-X
cells	B-X
,	B-X
while	B-X
it	B-X
activated	B-X
transcription	B-X
in	B-X
rodent	B-X
fibroblasts	B-X
<EOS>	B-X
We	B-X
also	B-X
demonstrate	B-X
that	B-X
TPB	B-X
interaction	B-X
with	B-X
Rel	B-X
activation	B-X
regions	B-X
leads	B-X
to	B-X
synergistic	B-X
activation	B-X
of	B-X
transcription	B-X
of	B-X
a	B-X
kappa	B-X
B	B-X
-	B-X
linked	B-X
reporter	B-X
gene	B-X

Little	O
is	O
known	O
,	O
however	O
,	O
of	O
the	O
mechanism	O
by	O
which	O
they	O
enhance	O
transcription	O
.	O
<EOS>	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
molecular	B-X
mechanism	B-X
that	B-X
underpin	B-X
endothelial	B-X
cell	B-X
regeneration	B-X
in	B-X
ARDS	B-X
<EOS>	B-X
Still	B-X
,	B-X
little	B-X
has	B-X
been	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
of	B-X
their	B-X
metabolism	B-X
in	B-X
plants	B-X
<EOS>	B-X
Lost	B-X
CBSs	B-X
are	B-X
enriched	B-X
at	B-X
enhancers	B-X
and	B-X
promoters	B-X
and	B-X
associate	B-X
with	B-X
active	B-X
chromatin	B-X
marks	B-X
and	B-X
higher	B-X
transcriptional	B-X
activity	B-X
<EOS>	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
of	B-X
macrophage	B-X
activation	B-X
beyond	B-X
signals	B-X
from	B-X
cytokines	B-X
and	B-X
chemokines	B-X

We	O
have	O
investigated	O
the	O
ability	O
of	O
the	O
v-Rel	B-protein
and	I-protein
c-Rel	I-protein
oncoproteins	I-protein
to	O
interact	O
with	O
components	O
of	O
the	O
basal	O
transcription	O
machinery	O
.	O
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
oncoproteins	B-X
to	B-X
interact	B-X
with	B-X
components	B-X
of	B-X
the	B-X
basal	B-X
transcription	B-X
machinery	B-X
<EOS>	B-X
Functional	B-X
interaction	B-X
of	B-X
the	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
oncoproteins	B-X
with	B-X
the	B-X
TATA	B-X
-	B-X
binding	B-X
protein	B-X
and	B-X
association	B-X
with	B-X
transcription	B-X
factor	B-X
IIB	B-X
.	B-X
<EOS>	B-X
Combined	B-X
with	B-X
the	B-X
observation	B-X
that	B-X
the	B-X
mouse	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
human	B-X
RelA	B-X
proteins	B-X
also	B-X
interact	B-X
with	B-X
TBP	B-X
and	B-X
TFIIB	B-X
in	B-X
vitro	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
association	B-X
with	B-X
basal	B-X
transcription	B-X
factors	B-X
is	B-X
important	B-X
for	B-X
the	B-X
transcriptional	B-X
activities	B-X
of	B-X
Rel	B-X
family	B-X
proteins	B-X
<EOS>	B-X
Little	B-X
is	B-X
known	B-X
,	B-X
however	B-X
,	B-X
of	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
they	B-X
enhance	B-X
transcription	B-X

Here	O
we	O
report	O
that	O
both	O
the	O
acidic	O
transcription	O
activation	O
domain	O
mapping	O
to	O
the	O
unique	O
C	B-protein
terminus	I-protein
of	O
chicken	B-protein
c-Rel	I-protein
and	O
the	O
F9	B-protein
cell-specific	I-protein
activation	I-protein
region	I-protein
common	O
to	O
both	O
v-Rel	B-protein
and	O
c-Rel	B-protein
interact	O
with	O
the	O
TATA-binding	B-protein
protein	I-protein
(	O
TBP	B-protein
)	O
and	O
transcription	B-protein
factor	I-protein
IIB	I-protein
(	O
TFIIB	B-protein
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
also	O
demonstrate	O
that	O
TPB	B-protein
interaction	O
with	O
Rel	B-protein
activation	I-protein
regions	I-protein
leads	O
to	O
synergistic	O
activation	O
of	O
transcription	O
of	O
a	O
kappa	B-DNA
B-linked	I-DNA
reporter	I-DNA
gene	I-DNA
.	O
<EOS>	B-X
We	B-X
also	B-X
demonstrate	B-X
that	B-X
TPB	B-X
interaction	B-X
with	B-X
Rel	B-X
activation	B-X
regions	B-X
leads	B-X
to	B-X
synergistic	B-X
activation	B-X
of	B-X
transcription	B-X
of	B-X
a	B-X
kappa	B-X
B	B-X
-	B-X
linked	B-X
reporter	B-X
gene	B-X
<EOS>	B-X
Combined	B-X
with	B-X
the	B-X
observation	B-X
that	B-X
the	B-X
mouse	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
human	B-X
RelA	B-X
proteins	B-X
also	B-X
interact	B-X
with	B-X
TBP	B-X
and	B-X
TFIIB	B-X
in	B-X
vitro	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
association	B-X
with	B-X
basal	B-X
transcription	B-X
factors	B-X
is	B-X
important	B-X
for	B-X
the	B-X
transcriptional	B-X
activities	B-X
of	B-X
Rel	B-X
family	B-X
proteins	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
oncoproteins	B-X
to	B-X
interact	B-X
with	B-X
components	B-X
of	B-X
the	B-X
basal	B-X
transcription	B-X
machinery	B-X
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
both	B-X
the	B-X
acidic	B-X
transcription	B-X
activation	B-X
domain	B-X
mapping	B-X
to	B-X
the	B-X
unique	B-X
C	B-X
terminus	B-X
of	B-X
chicken	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
the	B-X
F9	B-X
cell	B-X
-	B-X
specific	B-X
activation	B-X
region	B-X
common	B-X
to	B-X
both	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
interact	B-X
with	B-X
the	B-X
TATA	B-X
-	B-X
binding	B-X
protein	B-X
(	B-X
TBP	B-X
)	B-X
and	B-X
transcription	B-X
factor	B-X
IIB	B-X
(	B-X
TFIIB	B-X
)	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X

Combined	O
with	O
the	O
observation	O
that	O
the	O
mouse	B-protein
c-Rel	I-protein
and	I-protein
human	I-protein
RelA	I-protein
proteins	I-protein
also	O
interact	O
with	O
TBP	B-protein
and	O
TFIIB	B-protein
in	O
vitro	O
,	O
these	O
results	O
suggest	O
that	O
association	O
with	O
basal	B-protein
transcription	I-protein
factors	I-protein
is	O
important	O
for	O
the	O
transcriptional	O
activities	O
of	O
Rel	B-protein
family	I-protein
proteins	I-protein
.	O
<EOS>	B-X
Combined	B-X
with	B-X
the	B-X
observation	B-X
that	B-X
the	B-X
mouse	B-X
c	B-X
-	B-X
Rel	B-X
and	B-X
human	B-X
RelA	B-X
proteins	B-X
also	B-X
interact	B-X
with	B-X
TBP	B-X
and	B-X
TFIIB	B-X
in	B-X
vitro	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
association	B-X
with	B-X
basal	B-X
transcription	B-X
factors	B-X
is	B-X
important	B-X
for	B-X
the	B-X
transcriptional	B-X
activities	B-X
of	B-X
Rel	B-X
family	B-X
proteins	B-X
<EOS>	B-X
Functional	B-X
interaction	B-X
of	B-X
the	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
oncoproteins	B-X
with	B-X
the	B-X
TATA	B-X
-	B-X
binding	B-X
protein	B-X
and	B-X
association	B-X
with	B-X
transcription	B-X
factor	B-X
IIB	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
v	B-X
-	B-X
Rel	B-X
and	B-X
c	B-X
-	B-X
Rel	B-X
oncoproteins	B-X
to	B-X
interact	B-X
with	B-X
components	B-X
of	B-X
the	B-X
basal	B-X
transcription	B-X
machinery	B-X
<EOS>	B-X
We	B-X
also	B-X
demonstrate	B-X
that	B-X
TPB	B-X
interaction	B-X
with	B-X
Rel	B-X
activation	B-X
regions	B-X
leads	B-X
to	B-X
synergistic	B-X
activation	B-X
of	B-X
transcription	B-X
of	B-X
a	B-X
kappa	B-X
B	B-X
-	B-X
linked	B-X
reporter	B-X
gene	B-X

p21ras	B-protein
and	O
calcineurin	O
synergize	O
to	O
regulate	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
p21ras	B-X
and	B-X
calcineurin	B-X
synergize	B-X
to	B-X
regulate	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
Multiple	B-X
p21ras	B-X
effector	B-X
pathways	B-X
regulate	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
<EOS>	B-X
Thus	B-X
,	B-X
p21ras	B-X
regulation	B-X
of	B-X
NFAT	B-X
in	B-X
T	B-X
cells	B-X
requires	B-X
the	B-X
activity	B-X
of	B-X
multiple	B-X
effector	B-X
pathways	B-X
including	B-X
those	B-X
regulated	B-X
by	B-X
MAPKK	B-X
-	B-X
1	B-X
/	B-X
ERK	B-X
-	B-X
2	B-X
and	B-X
Rac	B-X
-	B-X
1	B-X
<EOS>	B-X
One	B-X
p21ras	B-X
effector	B-X
pathway	B-X
involves	B-X
the	B-X
MAP	B-X
kinase	B-X
ERK	B-X
-	B-X
2	B-X
,	B-X
and	B-X
we	B-X
have	B-X
examined	B-X
its	B-X
role	B-X
in	B-X
NFAT	B-X
regulation	B-X

In	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
triggering	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
induces	O
several	O
signaling	O
cascades	O
which	O
ultimately	O
synergize	O
to	O
induce	O
the	O
activity	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	B-cell_type
cells	I-cell_type
(	O
NFAT	B-cell_line
)	O
,	O
a	O
DNA	B-protein
binding	I-protein
complex	I-protein
critical	O
to	O
the	O
inducibility	O
and	O
T	O
cell	O
specificity	O
of	O
the	O
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
interleukin	B-protein
2	I-protein
.	O

One	O
immediate	O
consequence	O
of	O
T	O
cell	O
activation	O
via	O
the	O
TCR	B-protein
is	O
an	O
increase	O
in	O
cytosolic	O
calcium	O
.	O
<EOS>	B-X
One	B-X
immediate	B-X
consequence	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
via	B-X
the	B-X
TCR	B-X
is	B-X
an	B-X
increase	B-X
in	B-X
cytosolic	B-X
calcium	B-X
<EOS>	B-X
The	B-X
experiments	B-X
presented	B-X
here	B-X
show	B-X
that	B-X
expression	B-X
by	B-X
transfection	B-X
of	B-X
mutationally	B-X
activated	B-X
calcineurin	B-X
or	B-X
activated	B-X
p21ras	B-X
alone	B-X
is	B-X
insufficient	B-X
for	B-X
NFAT	B-X
transactivation	B-X
<EOS>	B-X
A	B-X
second	B-X
important	B-X
molecule	B-X
in	B-X
TCR	B-X
signal	B-X
transduction	B-X
is	B-X
the	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
protein	B-X
,	B-X
p21ras	B-X
,	B-X
which	B-X
is	B-X
coupled	B-X
to	B-X
the	B-X
TCR	B-X
by	B-X
a	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
dependent	B-X
mechanism	B-X
<EOS>	B-X
However	B-X
,	B-X
coexpression	B-X
of	B-X
the	B-X
activated	B-X
calcineurin	B-X
with	B-X
activated	B-X
p21ras	B-X
could	B-X
mimic	B-X
TCR	B-X
signals	B-X
in	B-X
NFAT	B-X
induction	B-X

Calcium	O
signals	O
are	O
important	O
for	O
NFAT	B-cell_line
induction	O
,	O
and	O
recent	O
studies	O
have	O
identified	O
calcineurin	B-protein
,	O
a	O
calcium-calmodulin	B-protein
dependent	I-protein
serine-threonine	I-protein
phosphatase	I-protein
,	O
as	O
a	O
prominent	O
component	O
of	O
the	O
calcium	O
signaling	O
pathway	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

A	O
second	O
important	O
molecule	O
in	O
TCR	O
signal	O
transduction	O
is	O
the	O
guanine	B-protein
nucleotide	I-protein
binding	I-protein
protein	I-protein
,	O
p21ras	B-protein
,	O
which	O
is	O
coupled	O
to	O
the	O
TCR	B-protein
by	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
dependent	O
mechanism	O
.	O

The	O
experiments	O
presented	O
here	O
show	O
that	O
expression	O
by	O
transfection	O
of	O
mutationally	O
activated	O
calcineurin	B-protein
or	O
activated	O
p21ras	B-protein
alone	O
is	O
insufficient	O
for	O
NFAT	B-cell_type
transactivation	O
.	O
<EOS>	B-X
The	B-X
experiments	B-X
presented	B-X
here	B-X
show	B-X
that	B-X
expression	B-X
by	B-X
transfection	B-X
of	B-X
mutationally	B-X
activated	B-X
calcineurin	B-X
or	B-X
activated	B-X
p21ras	B-X
alone	B-X
is	B-X
insufficient	B-X
for	B-X
NFAT	B-X
transactivation	B-X
<EOS>	B-X
However	B-X
,	B-X
coexpression	B-X
of	B-X
the	B-X
activated	B-X
calcineurin	B-X
with	B-X
activated	B-X
p21ras	B-X
could	B-X
mimic	B-X
TCR	B-X
signals	B-X
in	B-X
NFAT	B-X
induction	B-X
<EOS>	B-X
These	B-X
data	B-X
identify	B-X
calcineurin	B-X
and	B-X
p21ras	B-X
as	B-X
cooperative	B-X
partners	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
<EOS>	B-X
One	B-X
immediate	B-X
consequence	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
via	B-X
the	B-X
TCR	B-X
is	B-X
an	B-X
increase	B-X
in	B-X
cytosolic	B-X
calcium	B-X

However	O
,	O
coexpression	O
of	O
the	O
activated	O
calcineurin	O
with	O
activated	O
p21ras	O
could	O
mimic	O
TCR	O
signals	O
in	O
NFAT	B-cell_type
induction	O
.	O
<EOS>	B-X
However	B-X
,	B-X
coexpression	B-X
of	B-X
the	B-X
activated	B-X
calcineurin	B-X
with	B-X
activated	B-X
p21ras	B-X
could	B-X
mimic	B-X
TCR	B-X
signals	B-X
in	B-X
NFAT	B-X
induction	B-X
<EOS>	B-X
The	B-X
experiments	B-X
presented	B-X
here	B-X
show	B-X
that	B-X
expression	B-X
by	B-X
transfection	B-X
of	B-X
mutationally	B-X
activated	B-X
calcineurin	B-X
or	B-X
activated	B-X
p21ras	B-X
alone	B-X
is	B-X
insufficient	B-X
for	B-X
NFAT	B-X
transactivation	B-X
<EOS>	B-X
These	B-X
data	B-X
identify	B-X
calcineurin	B-X
and	B-X
p21ras	B-X
as	B-X
cooperative	B-X
partners	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
<EOS>	B-X
A	B-X
second	B-X
important	B-X
molecule	B-X
in	B-X
TCR	B-X
signal	B-X
transduction	B-X
is	B-X
the	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
protein	B-X
,	B-X
p21ras	B-X
,	B-X
which	B-X
is	B-X
coupled	B-X
to	B-X
the	B-X
TCR	B-X
by	B-X
a	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
dependent	B-X
mechanism	B-X

These	O
data	O
identify	O
calcineurin	B-protein
and	O
p21ras	B-protein
as	O
cooperative	O
partners	O
in	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O

Expression	O
of	O
the	O
chicken	B-protein
GATA	I-protein
factor	I-protein
family	I-protein
during	O
early	O
erythroid	O
development	O
and	O
differentiation	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
chicken	B-X
GATA	B-X
factor	B-X
family	B-X
during	B-X
early	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
The	B-X
developmental	B-X
switch	B-X
in	B-X
embryonic	B-X
rho	B-X
-	B-X
globin	B-X
expression	B-X
is	B-X
correlated	B-X
with	B-X
erythroid	B-X
lineage	B-X
-	B-X
specific	B-X
differences	B-X
in	B-X
transcription	B-X
factor	B-X
levels	B-X
.	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
,	B-X
as	B-X
in	B-X
chickens	B-X
,	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
GATA	B-X
factor	B-X
family	B-X
are	B-X
expressed	B-X
in	B-X
human	B-X
and	B-X
murine	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
The	B-X
timing	B-X
and	B-X
pattern	B-X
of	B-X
expression	B-X
of	B-X
these	B-X
different	B-X
mRNAs	B-X
during	B-X
avian	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
suggests	B-X
that	B-X
temporally	B-X
regulated	B-X
changes	B-X
in	B-X
GATA	B-X
factor	B-X
expression	B-X
are	B-X
required	B-X
for	B-X
vertebrate	B-X
hematopoiesis	B-X

The	O
DNA	O
motif	O
WGATAR	O
has	O
been	O
identified	O
within	O
transcriptional	B-DNA
regulatory	I-DNA
domains	I-DNA
of	O
globin	B-DNA
and	O
other	O
erythroid-specific	B-DNA
genes	I-DNA
and	O
the	O
activator	B-protein
proteins	I-protein
that	O
bind	O
to	O
this	O
regulatory	B-DNA
element	I-DNA
,	O
the	O
GATA	B-protein
factors	I-protein
,	O
belong	O
to	O
a	O
multi-gene	B-protein
family	I-protein
that	O
is	O
expressed	O
in	O
chicken	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
The	B-X
DNA	B-X
motif	B-X
WGATAR	B-X
has	B-X
been	B-X
identified	B-X
within	B-X
transcriptional	B-X
regulatory	B-X
domains	B-X
of	B-X
globin	B-X
and	B-X
other	B-X
erythroid	B-X
-	B-X
specific	B-X
genes	B-X
and	B-X
the	B-X
activator	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
this	B-X
regulatory	B-X
element	B-X
,	B-X
the	B-X
GATA	B-X
factors	B-X
,	B-X
belong	B-X
to	B-X
a	B-X
multi	B-X
-	B-X
gene	B-X
family	B-X
that	B-X
is	B-X
expressed	B-X
in	B-X
chicken	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
The	B-X
timing	B-X
and	B-X
pattern	B-X
of	B-X
expression	B-X
of	B-X
these	B-X
different	B-X
mRNAs	B-X
during	B-X
avian	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
suggests	B-X
that	B-X
temporally	B-X
regulated	B-X
changes	B-X
in	B-X
GATA	B-X
factor	B-X
expression	B-X
are	B-X
required	B-X
for	B-X
vertebrate	B-X
hematopoiesis	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
,	B-X
as	B-X
in	B-X
chickens	B-X
,	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
GATA	B-X
factor	B-X
family	B-X
are	B-X
expressed	B-X
in	B-X
human	B-X
and	B-X
murine	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
In	B-X
the	B-X
primitive	B-X
erythroid	B-X
lineage	B-X
,	B-X
transcription	B-X
of	B-X
the	B-X
embryonic	B-X
epsilon	B-X
-	B-X
globin	B-X
gene	B-X
parallels	B-X
GATA	B-X
-	B-X
1	B-X
expression	B-X
while	B-X
the	B-X
switch	B-X
to	B-X
beta	B-X
-	B-X
globin	B-X
transcription	B-X
in	B-X
definitive	B-X
erythroid	B-X
cells	B-X
is	B-X
directly	B-X
preceded	B-X
by	B-X
a	B-X
pronounced	B-X
increase	B-X
in	B-X
GATA	B-X
-	B-X
3	B-X
accumulation	B-X

Here	O
we	O
show	O
that	O
,	O
as	O
in	O
chickens	O
,	O
multiple	O
members	O
of	O
the	O
GATA	B-protein
factor	I-protein
family	I-protein
are	O
expressed	O
in	O
human	B-cell_type
and	I-cell_type
murine	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
,	B-X
as	B-X
in	B-X
chickens	B-X
,	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
GATA	B-X
factor	B-X
family	B-X
are	B-X
expressed	B-X
in	B-X
human	B-X
and	B-X
murine	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
chicken	B-X
GATA	B-X
factor	B-X
family	B-X
during	B-X
early	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
During	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
chicken	B-X
embryogenesis	B-X
(	B-X
well	B-X
before	B-X
blood	B-X
island	B-X
formation	B-X
)	B-X
,	B-X
each	B-X
of	B-X
the	B-X
GATA	B-X
family	B-X
members	B-X
is	B-X
transcribed	B-X
with	B-X
a	B-X
unique	B-X
temporal	B-X
and	B-X
spatial	B-X
pattern	B-X
<EOS>	B-X
The	B-X
DNA	B-X
motif	B-X
WGATAR	B-X
has	B-X
been	B-X
identified	B-X
within	B-X
transcriptional	B-X
regulatory	B-X
domains	B-X
of	B-X
globin	B-X
and	B-X
other	B-X
erythroid	B-X
-	B-X
specific	B-X
genes	B-X
and	B-X
the	B-X
activator	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
this	B-X
regulatory	B-X
element	B-X
,	B-X
the	B-X
GATA	B-X
factors	B-X
,	B-X
belong	B-X
to	B-X
a	B-X
multi	B-X
-	B-X
gene	B-X
family	B-X
that	B-X
is	B-X
expressed	B-X
in	B-X
chicken	B-X
erythroid	B-X
cells	B-X

During	O
the	O
early	O
stages	O
of	O
chicken	O
embryogenesis	O
(	O
well	O
before	O
blood	O
island	O
formation	O
)	O
,	O
each	O
of	O
the	O
GATA	B-protein
family	I-protein
members	I-protein
is	O
transcribed	O
with	O
a	O
unique	O
temporal	O
and	O
spatial	O
pattern	O
.	O
<EOS>	B-X
During	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
chicken	B-X
embryogenesis	B-X
(	B-X
well	B-X
before	B-X
blood	B-X
island	B-X
formation	B-X
)	B-X
,	B-X
each	B-X
of	B-X
the	B-X
GATA	B-X
family	B-X
members	B-X
is	B-X
transcribed	B-X
with	B-X
a	B-X
unique	B-X
temporal	B-X
and	B-X
spatial	B-X
pattern	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
,	B-X
as	B-X
in	B-X
chickens	B-X
,	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
GATA	B-X
factor	B-X
family	B-X
are	B-X
expressed	B-X
in	B-X
human	B-X
and	B-X
murine	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
The	B-X
timing	B-X
and	B-X
pattern	B-X
of	B-X
expression	B-X
of	B-X
these	B-X
different	B-X
mRNAs	B-X
during	B-X
avian	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
suggests	B-X
that	B-X
temporally	B-X
regulated	B-X
changes	B-X
in	B-X
GATA	B-X
factor	B-X
expression	B-X
are	B-X
required	B-X
for	B-X
vertebrate	B-X
hematopoiesis	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
chicken	B-X
GATA	B-X
factor	B-X
family	B-X
during	B-X
early	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
.	B-X

In	O
the	O
primitive	B-cell_type
erythroid	I-cell_type
lineage	I-cell_type
,	O
transcription	O
of	O
the	O
embryonic	B-DNA
epsilon-globin	I-DNA
gene	I-DNA
parallels	O
GATA-1	O
expression	O
while	O
the	O
switch	O
to	O
beta-globin	O
transcription	O
in	O
definitive	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
is	O
directly	O
preceded	O
by	O
a	O
pronounced	O
increase	O
in	O
GATA-3	B-protein
accumulation	O
.	O
<EOS>	B-X
In	B-X
the	B-X
primitive	B-X
erythroid	B-X
lineage	B-X
,	B-X
transcription	B-X
of	B-X
the	B-X
embryonic	B-X
epsilon	B-X
-	B-X
globin	B-X
gene	B-X
parallels	B-X
GATA	B-X
-	B-X
1	B-X
expression	B-X
while	B-X
the	B-X
switch	B-X
to	B-X
beta	B-X
-	B-X
globin	B-X
transcription	B-X
in	B-X
definitive	B-X
erythroid	B-X
cells	B-X
is	B-X
directly	B-X
preceded	B-X
by	B-X
a	B-X
pronounced	B-X
increase	B-X
in	B-X
GATA	B-X
-	B-X
3	B-X
accumulation	B-X
<EOS>	B-X
During	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
chicken	B-X
embryogenesis	B-X
(	B-X
well	B-X
before	B-X
blood	B-X
island	B-X
formation	B-X
)	B-X
,	B-X
each	B-X
of	B-X
the	B-X
GATA	B-X
family	B-X
members	B-X
is	B-X
transcribed	B-X
with	B-X
a	B-X
unique	B-X
temporal	B-X
and	B-X
spatial	B-X
pattern	B-X
<EOS>	B-X
The	B-X
DNA	B-X
motif	B-X
WGATAR	B-X
has	B-X
been	B-X
identified	B-X
within	B-X
transcriptional	B-X
regulatory	B-X
domains	B-X
of	B-X
globin	B-X
and	B-X
other	B-X
erythroid	B-X
-	B-X
specific	B-X
genes	B-X
and	B-X
the	B-X
activator	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
this	B-X
regulatory	B-X
element	B-X
,	B-X
the	B-X
GATA	B-X
factors	B-X
,	B-X
belong	B-X
to	B-X
a	B-X
multi	B-X
-	B-X
gene	B-X
family	B-X
that	B-X
is	B-X
expressed	B-X
in	B-X
chicken	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
chicken	B-X
GATA	B-X
factor	B-X
family	B-X
during	B-X
early	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
.	B-X

The	O
timing	O
and	O
pattern	O
of	O
expression	O
of	O
these	O
different	O
mRNAs	B-RNA
during	O
avian	O
erythroid	O
development	O
and	O
differentiation	O
suggests	O
that	O
temporally	O
regulated	O
changes	O
in	O
GATA	B-protein
factor	I-protein
expression	O
are	O
required	O
for	O
vertebrate	O
hematopoiesis	O
.	O
<EOS>	B-X
The	B-X
timing	B-X
and	B-X
pattern	B-X
of	B-X
expression	B-X
of	B-X
these	B-X
different	B-X
mRNAs	B-X
during	B-X
avian	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
suggests	B-X
that	B-X
temporally	B-X
regulated	B-X
changes	B-X
in	B-X
GATA	B-X
factor	B-X
expression	B-X
are	B-X
required	B-X
for	B-X
vertebrate	B-X
hematopoiesis	B-X
<EOS>	B-X
The	B-X
DNA	B-X
motif	B-X
WGATAR	B-X
has	B-X
been	B-X
identified	B-X
within	B-X
transcriptional	B-X
regulatory	B-X
domains	B-X
of	B-X
globin	B-X
and	B-X
other	B-X
erythroid	B-X
-	B-X
specific	B-X
genes	B-X
and	B-X
the	B-X
activator	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
this	B-X
regulatory	B-X
element	B-X
,	B-X
the	B-X
GATA	B-X
factors	B-X
,	B-X
belong	B-X
to	B-X
a	B-X
multi	B-X
-	B-X
gene	B-X
family	B-X
that	B-X
is	B-X
expressed	B-X
in	B-X
chicken	B-X
erythroid	B-X
cells	B-X
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
chicken	B-X
GATA	B-X
factor	B-X
family	B-X
during	B-X
early	B-X
erythroid	B-X
development	B-X
and	B-X
differentiation	B-X
.	B-X
<EOS>	B-X
During	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
chicken	B-X
embryogenesis	B-X
(	B-X
well	B-X
before	B-X
blood	B-X
island	B-X
formation	B-X
)	B-X
,	B-X
each	B-X
of	B-X
the	B-X
GATA	B-X
family	B-X
members	B-X
is	B-X
transcribed	B-X
with	B-X
a	B-X
unique	B-X
temporal	B-X
and	B-X
spatial	B-X
pattern	B-X

Molecular	O
regulation	O
of	O
human	B-protein
interleukin	I-protein
2	I-protein
and	O
T-cell	B-cell_type
function	O
by	O
interleukin	B-protein
4	I-protein
.	O
<EOS>	B-X
Modulation	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
signaling	B-X
transduction	B-X
by	B-X
lovastatin	B-X
.	B-X
<EOS>	B-X
Differential	B-X
regulation	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
4	B-X
,	B-X
IL	B-X
-	B-X
5	B-X
,	B-X
and	B-X
IL	B-X
-	B-X
10	B-X
during	B-X
measles	B-X
in	B-X
Zambian	B-X
children	B-X
.	B-X
<EOS>	B-X
Pimecrolimus	B-X
inhibits	B-X
up	B-X
-	B-X
regulation	B-X
of	B-X
OX40	B-X
and	B-X
synthesis	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
upon	B-X
secondary	B-X
T	B-X
cell	B-X
activation	B-X
by	B-X
allogeneic	B-X
dendritic	B-X
cells	B-X
.	B-X
<EOS>	B-X
ICOS	B-X
-	B-X
ligand	B-X
,	B-X
expressed	B-X
on	B-X
human	B-X
endothelial	B-X
cells	B-X
,	B-X
costimulates	B-X
Th1	B-X
and	B-X
Th2	B-X
cytokine	B-X
secretion	B-X
by	B-X
memory	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X

Distinct	O
functional	O
T-cell	B-cell_type
subsets	I-cell_type
,	O
differing	O
in	O
the	O
patterns	O
of	O
lymphokines	B-protein
produced	O
,	O
regulate	O
cell-mediated	O
and	O
humoral	O
immune	O
responses	O
.	O
<EOS>	B-X
Distinct	B-X
functional	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
,	B-X
differing	B-X
in	B-X
the	B-X
patterns	B-X
of	B-X
lymphokines	B-X
produced	B-X
,	B-X
regulate	B-X
cell	B-X
-	B-X
mediated	B-X
and	B-X
humoral	B-X
immune	B-X
responses	B-X
<EOS>	B-X
Molecular	B-X
regulation	B-X
of	B-X
human	B-X
interleukin	B-X
2	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
function	B-X
by	B-X
interleukin	B-X
4	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
IL	B-X
-	B-X
4	B-X
may	B-X
regulate	B-X
development	B-X
and	B-X
function	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
involved	B-X
in	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
in	B-X
part	B-X
by	B-X
inhibiting	B-X
factors	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
the	B-X
IL2	B-X
gene	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
a	B-X
DNA	B-X
oligomer	B-X
containing	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
binding	B-X
site	B-X
indicated	B-X
that	B-X
IL	B-X
-	B-X
4	B-X
inhibited	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
complex	B-X
and	B-X
that	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
DNA	B-X
binding	B-X
factor	B-X
is	B-X
distinct	B-X
from	B-X
AP	B-X
-	B-X
1	B-X

The	O
two	O
major	O
types	O
and	O
their	O
principal	O
products	O
,	O
interleukin	B-protein
4	I-protein
and	O
interferon	B-protein
gamma	I-protein
(	O
IL-4	B-protein
and	O
IFN-gamma	B-protein
)	O
,	O
are	O
reciprocally	O
negatively	O
interactive	O
.	O
<EOS>	B-X
The	B-X
two	B-X
major	B-X
types	B-X
and	B-X
their	B-X
principal	B-X
products	B-X
,	B-X
interleukin	B-X
4	B-X
and	B-X
interferon	B-X
gamma	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
,	B-X
are	B-X
reciprocally	B-X
negatively	B-X
interactive	B-X
<EOS>	B-X
Molecular	B-X
regulation	B-X
of	B-X
human	B-X
interleukin	B-X
2	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
function	B-X
by	B-X
interleukin	B-X
4	B-X
.	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
a	B-X
DNA	B-X
oligomer	B-X
containing	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
binding	B-X
site	B-X
indicated	B-X
that	B-X
IL	B-X
-	B-X
4	B-X
inhibited	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
complex	B-X
and	B-X
that	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
DNA	B-X
binding	B-X
factor	B-X
is	B-X
distinct	B-X
from	B-X
AP	B-X
-	B-X
1	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
IL	B-X
-	B-X
4	B-X
may	B-X
regulate	B-X
development	B-X
and	B-X
function	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
involved	B-X
in	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
in	B-X
part	B-X
by	B-X
inhibiting	B-X
factors	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
the	B-X
IL2	B-X
gene	B-X

To	O
analyze	O
the	O
molecular	O
mechanism	O
of	O
IL-4-mediated	O
suppression	O
of	O
cell-mediated	O
immunity	O
we	O
studied	O
its	O
effects	O
on	O
expression	O
of	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
IFN-gamma	B-protein
.	O
<EOS>	B-X
To	B-X
analyze	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
mediated	B-X
suppression	B-X
of	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
we	B-X
studied	B-X
its	B-X
effects	B-X
on	B-X
expression	B-X
of	B-X
interleukin	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
Molecular	B-X
regulation	B-X
of	B-X
human	B-X
interleukin	B-X
2	B-X
and	B-X
T	B-X
-	B-X
cell	B-X
function	B-X
by	B-X
interleukin	B-X
4	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
IL	B-X
-	B-X
4	B-X
may	B-X
regulate	B-X
development	B-X
and	B-X
function	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
involved	B-X
in	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
in	B-X
part	B-X
by	B-X
inhibiting	B-X
factors	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
the	B-X
IL2	B-X
gene	B-X
<EOS>	B-X
IL	B-X
-	B-X
4	B-X
pretreatment	B-X
of	B-X
Jurkat	B-X
cells	B-X
prior	B-X
to	B-X
stimulation	B-X
resulted	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
transcription	B-X
of	B-X
the	B-X
IL2	B-X
gene	B-X

IL-4	B-protein
pretreatment	O
of	O
Jurkat	B-cell_type
cells	I-cell_type
prior	O
to	O
stimulation	O
resulted	O
in	O
a	O
decrease	O
in	O
transcription	O
of	O
the	O
IL2	B-DNA
gene	I-DNA
.	O

IL-4	B-protein
suppressed	O
IL-2	O
and	O
IFN-gamma	O
mRNA	O
levels	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
addition	O
of	O
anti-CD28	B-protein
antibodies	I-protein
relieved	O
this	O
suppression	O
.	O

Using	O
enhancer-reporter	B-DNA
constructs	I-DNA
,	O
IL-4	B-protein
specifically	O
down-regulated	O
the	O
NFIL-2B	B-DNA
element	I-DNA
.	O
<EOS>	B-X
Using	B-X
enhancer	B-X
-	B-X
reporter	B-X
constructs	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
specifically	B-X
down	B-X
-	B-X
regulated	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
element	B-X
<EOS>	B-X
Distinct	B-X
functional	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
,	B-X
differing	B-X
in	B-X
the	B-X
patterns	B-X
of	B-X
lymphokines	B-X
produced	B-X
,	B-X
regulate	B-X
cell	B-X
-	B-X
mediated	B-X
and	B-X
humoral	B-X
immune	B-X
responses	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
a	B-X
DNA	B-X
oligomer	B-X
containing	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
binding	B-X
site	B-X
indicated	B-X
that	B-X
IL	B-X
-	B-X
4	B-X
inhibited	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
complex	B-X
and	B-X
that	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
DNA	B-X
binding	B-X
factor	B-X
is	B-X
distinct	B-X
from	B-X
AP	B-X
-	B-X
1	B-X
<EOS>	B-X
The	B-X
two	B-X
major	B-X
types	B-X
and	B-X
their	B-X
principal	B-X
products	B-X
,	B-X
interleukin	B-X
4	B-X
and	B-X
interferon	B-X
gamma	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
,	B-X
are	B-X
reciprocally	B-X
negatively	B-X
interactive	B-X

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
a	O
DNA	O
oligomer	O
containing	O
the	O
NFIL-2B	B-DNA
binding	I-DNA
site	I-DNA
indicated	O
that	O
IL-4	B-protein
inhibited	O
the	O
NFIL-2B	B-protein
complex	I-protein
and	O
that	O
the	O
NFIL-2B	B-protein
DNA	I-protein
binding	I-protein
factor	I-protein
is	O
distinct	O
from	O
AP-	B-protein
1	O
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
using	B-X
a	B-X
DNA	B-X
oligomer	B-X
containing	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
binding	B-X
site	B-X
indicated	B-X
that	B-X
IL	B-X
-	B-X
4	B-X
inhibited	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
complex	B-X
and	B-X
that	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
DNA	B-X
binding	B-X
factor	B-X
is	B-X
distinct	B-X
from	B-X
AP	B-X
-	B-X
1	B-X
<EOS>	B-X
The	B-X
two	B-X
major	B-X
types	B-X
and	B-X
their	B-X
principal	B-X
products	B-X
,	B-X
interleukin	B-X
4	B-X
and	B-X
interferon	B-X
gamma	B-X
(	B-X
IL	B-X
-	B-X
4	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
)	B-X
,	B-X
are	B-X
reciprocally	B-X
negatively	B-X
interactive	B-X
<EOS>	B-X
Distinct	B-X
functional	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
,	B-X
differing	B-X
in	B-X
the	B-X
patterns	B-X
of	B-X
lymphokines	B-X
produced	B-X
,	B-X
regulate	B-X
cell	B-X
-	B-X
mediated	B-X
and	B-X
humoral	B-X
immune	B-X
responses	B-X
<EOS>	B-X
Using	B-X
enhancer	B-X
-	B-X
reporter	B-X
constructs	B-X
,	B-X
IL	B-X
-	B-X
4	B-X
specifically	B-X
down	B-X
-	B-X
regulated	B-X
the	B-X
NFIL	B-X
-	B-X
2B	B-X
element	B-X

These	O
results	O
suggest	O
that	O
IL-4	B-protein
may	O
regulate	O
development	O
and	O
function	O
of	O
T-cell	B-cell_type
subsets	I-cell_type
involved	O
in	O
cell-mediated	O
immunity	O
in	O
part	O
by	O
inhibiting	B-protein
factors	I-protein
required	O
for	O
transcription	O
of	O
the	O
IL2	B-DNA
gene	I-DNA
<EOS>	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
IL	B-X
-	B-X
4	B-X
may	B-X
regulate	B-X
development	B-X
and	B-X
function	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
subsets	B-X
involved	B-X
in	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
in	B-X
part	B-X
by	B-X
inhibiting	B-X
factors	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
the	B-X
IL2	B-X
gene	B-X
<EOS>	B-X
IL	B-X
-	B-X
4	B-X
pretreatment	B-X
of	B-X
Jurkat	B-X
cells	B-X
prior	B-X
to	B-X
stimulation	B-X
resulted	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
transcription	B-X
of	B-X
the	B-X
IL2	B-X
gene	B-X
<EOS>	B-X
To	B-X
analyze	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
IL	B-X
-	B-X
4	B-X
-	B-X
mediated	B-X
suppression	B-X
of	B-X
cell	B-X
-	B-X
mediated	B-X
immunity	B-X
we	B-X
studied	B-X
its	B-X
effects	B-X
on	B-X
expression	B-X
of	B-X
interleukin	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
<EOS>	B-X
IL	B-X
-	B-X
4	B-X
suppressed	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IFN	B-X
-	B-X
gamma	B-X
mRNA	B-X
levels	B-X
in	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
addition	B-X
of	B-X
anti	B-X
-	B-X
CD28	B-X
antibodies	B-X
relieved	B-X
this	B-X
suppression	B-X

Immunochemical	O
differences	O
between	O
glucocorticoid	B-protein
receptors	I-protein
from	O
corticoid-sensitive	B-cell_type
and	I-cell_type
-resistant	I-cell_type
malignant	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Immunochemical	B-X
differences	B-X
between	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
corticoid	B-X
-	B-X
sensitive	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
malignant	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Mouse	B-X
thymus	B-X
was	B-X
used	B-X
as	B-X
a	B-X
source	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
from	B-X
normal	B-X
CS	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
have	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
antibodies	B-X
against	B-X
purified	B-X
rat	B-X
liver	B-X
glucocorticoid	B-X
receptors	B-X
to	B-X
study	B-X
the	B-X
immunochemical	B-X
properties	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
murine	B-X
and	B-X
human	B-X
malignant	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
then	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
affinity	B-X
gel	B-X
to	B-X
recognize	B-X
cytosolic	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
-	B-X
receptor	B-X
complexes	B-X
from	B-X
the	B-X
corticoid	B-X
-	B-X
sensitive	B-X
(	B-X
CS	B-X
)	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
strains	B-X
of	B-X
mouse	B-X
lymphoma	B-X
P1798	B-X
,	B-X
from	B-X
CS	B-X
lymphocytes	B-X
of	B-X
patients	B-X
with	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
,	B-X
and	B-X
from	B-X
a	B-X
CS	B-X
clone	B-X
of	B-X
human	B-X
leukemic	B-X
lymphoblasts	B-X
in	B-X
tissue	B-X
culture	B-X
(	B-X
CH6	B-X
)	B-X

We	O
have	O
explored	O
the	O
possibility	O
of	O
using	O
antibodies	B-protein
against	O
purified	O
rat	O
liver	O
glucocorticoid	B-protein
receptors	I-protein
to	O
study	O
the	O
immunochemical	O
properties	O
of	O
glucocorticoid	B-protein
receptors	I-protein
from	O
murine	B-cell_type
and	I-cell_type
human	I-cell_type
malignant	I-cell_type
lymphocytes	I-cell_type
.	O

For	O
this	O
purpose	O
,	O
purified	B-protein
immune	I-protein
immunoglobulin	I-protein
G	I-protein
was	O
covalently	O
linked	O
to	O
Sepharose	B-protein
CL-4B	I-protein
.	O
<EOS>	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
purified	B-X
immune	B-X
immunoglobulin	B-X
G	B-X
was	B-X
covalently	B-X
linked	B-X
to	B-X
Sepharose	B-X
CL	B-X
-	B-X
4B	B-X
<EOS>	B-X
We	B-X
have	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
antibodies	B-X
against	B-X
purified	B-X
rat	B-X
liver	B-X
glucocorticoid	B-X
receptors	B-X
to	B-X
study	B-X
the	B-X
immunochemical	B-X
properties	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
murine	B-X
and	B-X
human	B-X
malignant	B-X
lymphocytes	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
under	B-X
appropriate	B-X
experimental	B-X
conditions	B-X
,	B-X
it	B-X
was	B-X
possible	B-X
to	B-X
demonstrate	B-X
cross	B-X
-	B-X
reactivity	B-X
between	B-X
the	B-X
antiserum	B-X
against	B-X
rat	B-X
liver	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
the	B-X
58	B-X
-	B-X
	B-X
to	B-X
62	B-X
-	B-X
A	B-X
(	B-X
Stokes	B-X
radius	B-X
)	B-X
glucocorticoid	B-X
receptor	B-X
from	B-X
species	B-X
as	B-X
diverse	B-X
as	B-X
mouse	B-X
and	B-X
humans	B-X
<EOS>	B-X
Immunochemical	B-X
differences	B-X
between	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
corticoid	B-X
-	B-X
sensitive	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
malignant	B-X
lymphocytes	B-X
.	B-X

We	O
then	O
examined	O
the	O
ability	O
of	O
the	O
affinity	O
gel	O
to	O
recognize	O
cytosolic	B-protein
[	I-protein
3H	I-protein
]	I-protein
triamcinolone	I-protein
acetonide-receptor	I-protein
complexes	I-protein
from	O
the	O
corticoid-sensitive	B-cell_line
(	I-cell_line
CS	I-cell_line
)	I-cell_line
and	I-cell_line
-resistant	I-cell_line
strains	I-cell_line
of	I-cell_line
mouse	I-cell_line
lymphoma	I-cell_line
P1798	I-cell_line
,	O
from	O
CS	B-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
,	O
and	O
from	O
a	O
CS	B-cell_line
clone	I-cell_line
of	O
human	B-cell_type
leukemic	I-cell_type
lymphoblasts	I-cell_type
in	O
tissue	O
culture	O
(	O
CH6	B-cell_line
)	O
.	O

Mouse	O
thymus	O
was	O
used	O
as	O
a	O
source	O
of	O
glucocorticoid	B-protein
receptor	I-protein
from	O
normal	B-cell_type
CS	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Mouse	B-X
thymus	B-X
was	B-X
used	B-X
as	B-X
a	B-X
source	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
from	B-X
normal	B-X
CS	B-X
lymphocytes	B-X
<EOS>	B-X
Immunochemical	B-X
differences	B-X
between	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
corticoid	B-X
-	B-X
sensitive	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
malignant	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
antibodies	B-X
against	B-X
purified	B-X
rat	B-X
liver	B-X
glucocorticoid	B-X
receptors	B-X
to	B-X
study	B-X
the	B-X
immunochemical	B-X
properties	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
murine	B-X
and	B-X
human	B-X
malignant	B-X
lymphocytes	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
under	B-X
appropriate	B-X
experimental	B-X
conditions	B-X
,	B-X
it	B-X
was	B-X
possible	B-X
to	B-X
demonstrate	B-X
cross	B-X
-	B-X
reactivity	B-X
between	B-X
the	B-X
antiserum	B-X
against	B-X
rat	B-X
liver	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
the	B-X
58	B-X
-	B-X
	B-X
to	B-X
62	B-X
-	B-X
A	B-X
(	B-X
Stokes	B-X
radius	B-X
)	B-X
glucocorticoid	B-X
receptor	B-X
from	B-X
species	B-X
as	B-X
diverse	B-X
as	B-X
mouse	B-X
and	B-X
humans	B-X

Whereas	O
the	O
immunoaffinity	O
column	O
retained	O
70	O
to	O
84	O
%	O
of	O
the	O
58-	O
to	O
62-A	O
(	O
Stokes	O
radius	O
)	O
[	B-protein
3H	I-protein
]	I-protein
triamcinolone	I-protein
acetonide-receptor	I-protein
complexes	I-protein
characteristic	O
of	O
the	O
CS	B-cell_line
mouse	I-cell_line
and	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
,	O
it	O
failed	O
to	O
recognize	O
the	O
27-	O
to	O
28-A	O
(	O
Stokes	O
radius	O
)	O
glucocorticoid	B-protein
receptor	I-protein
present	O
in	O
corticoid-resistant	O
mouse	B-cell_line
lymphoma	I-cell_line
P1798	I-cell_line
cells	I-cell_line
.	O

Therefore	O
,	O
under	O
appropriate	O
experimental	O
conditions	O
,	O
it	O
was	O
possible	O
to	O
demonstrate	O
cross-reactivity	O
between	O
the	O
antiserum	O
against	O
rat	B-protein
liver	I-protein
glucocorticoid	I-protein
receptor	I-protein
and	O
the	O
58-	O
to	O
62-A	O
(	O
Stokes	O
radius	O
)	O
glucocorticoid	B-protein
receptor	I-protein
from	O
species	O
as	O
diverse	O
as	O
mouse	O
and	O
humans	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
under	B-X
appropriate	B-X
experimental	B-X
conditions	B-X
,	B-X
it	B-X
was	B-X
possible	B-X
to	B-X
demonstrate	B-X
cross	B-X
-	B-X
reactivity	B-X
between	B-X
the	B-X
antiserum	B-X
against	B-X
rat	B-X
liver	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
the	B-X
58	B-X
-	B-X
	B-X
to	B-X
62	B-X
-	B-X
A	B-X
(	B-X
Stokes	B-X
radius	B-X
)	B-X
glucocorticoid	B-X
receptor	B-X
from	B-X
species	B-X
as	B-X
diverse	B-X
as	B-X
mouse	B-X
and	B-X
humans	B-X
<EOS>	B-X
We	B-X
have	B-X
explored	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
antibodies	B-X
against	B-X
purified	B-X
rat	B-X
liver	B-X
glucocorticoid	B-X
receptors	B-X
to	B-X
study	B-X
the	B-X
immunochemical	B-X
properties	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
murine	B-X
and	B-X
human	B-X
malignant	B-X
lymphocytes	B-X
<EOS>	B-X
Whereas	B-X
the	B-X
immunoaffinity	B-X
column	B-X
retained	B-X
70	B-X
to	B-X
84	B-X
%	B-X
of	B-X
the	B-X
58	B-X
-	B-X
	B-X
to	B-X
62	B-X
-	B-X
A	B-X
(	B-X
Stokes	B-X
radius	B-X
)	B-X
[	B-X
3H	B-X
]	B-X
triamcinolone	B-X
acetonide	B-X
-	B-X
receptor	B-X
complexes	B-X
characteristic	B-X
of	B-X
the	B-X
CS	B-X
mouse	B-X
and	B-X
human	B-X
lymphocytes	B-X
,	B-X
it	B-X
failed	B-X
to	B-X
recognize	B-X
the	B-X
27	B-X
-	B-X
	B-X
to	B-X
28	B-X
-	B-X
A	B-X
(	B-X
Stokes	B-X
radius	B-X
)	B-X
glucocorticoid	B-X
receptor	B-X
present	B-X
in	B-X
corticoid	B-X
-	B-X
resistant	B-X
mouse	B-X
lymphoma	B-X
P1798	B-X
cells	B-X
<EOS>	B-X
Immunochemical	B-X
differences	B-X
between	B-X
glucocorticoid	B-X
receptors	B-X
from	B-X
corticoid	B-X
-	B-X
sensitive	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
malignant	B-X
lymphocytes	B-X
.	B-X

Heterogeneity	O
of	O
the	O
in	O
vitro	O
responses	O
to	O
glucocorticoids	O
in	O
acute	O
leukemia	O
.	O
<EOS>	B-X
Heterogeneity	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
responses	B-X
to	B-X
glucocorticoids	B-X
in	B-X
acute	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
dexamethasone	B-X
and	B-X
tetradecanoyl	B-X
phorbol	B-X
acetate	B-X
on	B-X
plasminogen	B-X
activator	B-X
release	B-X
by	B-X
human	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
cells	B-X
.	B-X
<EOS>	B-X
Leukemia	B-X
-	B-X
initiating	B-X
/	B-X
repopulating	B-X
cells	B-X
(	B-X
LICs	B-X
)	B-X
,	B-X
also	B-X
named	B-X
leukemic	B-X
stem	B-X
cells	B-X
,	B-X
are	B-X
responsible	B-X
for	B-X
propagating	B-X
human	B-X
acute	B-X
leukemia	B-X
<EOS>	B-X
We	B-X
tested	B-X
these	B-X
populations	B-X
in	B-X
both	B-X
in	B-X
vitro	B-X
culture	B-X
assays	B-X
and	B-X
in	B-X
vivo	B-X
for	B-X
growth	B-X
and	B-X
leukemia	B-X
development	B-X
in	B-X
immune	B-X
-	B-X
deficient	B-X
mice	B-X

In	O
leukocyte	B-cell_type
population	I-cell_type
freshly	O
isolated	O
from	O
the	O
blood	O
of	O
26	O
patients	O
with	O
acute	O
leukemia	O
,	O
we	O
have	O
measured	O
several	O
parameters	O
including	O
glucocorticoid	B-protein
receptors	I-protein
,	O
nucleoside	O
incorporation	O
,	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
,	O
and	O
steroid-induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
in	O
some	O
cases	O
,	O
the	O
short-term	O
response	O
to	O
steroid	O
therapy	O
was	O
determined	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
the	B-X
short	B-X
-	B-X
term	B-X
response	B-X
to	B-X
steroid	B-X
therapy	B-X
was	B-X
determined	B-X
<EOS>	B-X
Limited	B-X
data	B-X
suggest	B-X
that	B-X
short	B-X
-	B-X
term	B-X
risk	B-X
of	B-X
cancer	B-X
is	B-X
low	B-X
<EOS>	B-X
Disease	B-X
activity	B-X
in	B-X
some	B-X
patients	B-X
with	B-X
BP	B-X
,	B-X
but	B-X
not	B-X
in	B-X
all	B-X
,	B-X
was	B-X
poorly	B-X
correlated	B-X
with	B-X
ELISA	B-X
values	B-X
in	B-X
short	B-X
-	B-X
term	B-X
follow	B-X
-	B-X
up	B-X
<EOS>	B-X
Heterogeneity	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
responses	B-X
to	B-X
glucocorticoids	B-X
in	B-X
acute	B-X
leukemia	B-X
.	B-X

Although	O
,	O
in	O
all	O
the	O
patients	O
studied	O
,	O
leukocytes	B-cell_type
were	O
found	O
to	O
contain	O
glucocorticoid	B-protein
receptors	I-protein
,	O
we	O
failed	O
to	O
demonstrate	O
any	O
correlation	O
between	O
the	O
level	O
of	O
binding	O
sites	O
and	O
the	O
in	O
vitro	O
or	O
in	O
vivo	O
response	O
to	O
glucocorticoids	O
.	O
<EOS>	B-X
We	B-X
then	B-X
evaluated	B-X
the	B-X
expression	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
the	B-X
ENS	B-X
and	B-X
their	B-X
functional	B-X
impact	B-X
upon	B-X
RASt	B-X
-	B-X
induced	B-X
changes	B-X
in	B-X
ENS	B-X
phenotype	B-X
and	B-X
motor	B-X
response	B-X
<EOS>	B-X
A	B-X
panel	B-X
of	B-X
triple	B-X
negative	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
were	B-X
treated	B-X
with	B-X
the	B-X
glucocorticoid	B-X
,	B-X
cortisol	B-X
which	B-X
resulted	B-X
in	B-X
epigenetic	B-X
alteration	B-X
characterised	B-X
by	B-X
loss	B-X
of	B-X
methylation	B-X
on	B-X
promoter	B-X
regions	B-X
of	B-X
tumour	B-X
suppressor	B-X
genes	B-X
including	B-X
ESR1	B-X
,	B-X
and	B-X
loss	B-X
of	B-X
methylation	B-X
on	B-X
LINE	B-X
-	B-X
1	B-X
repetitive	B-X
element	B-X
used	B-X
as	B-X
a	B-X
surrogate	B-X
marker	B-X
for	B-X
global	B-X
methylation	B-X
<EOS>	B-X
The	B-X
iPS	B-X
-	B-X
microglia	B-X
predominantly	B-X
expressed	B-X
glucocorticoid	B-X
receptors	B-X
over	B-X
mineralocorticoid	B-X
receptors	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
the	B-X
GR	B-X
-	B-X
α	B-X
splice	B-X
variant	B-X
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
this	B-X
work	B-X
was	B-X
to	B-X
elucidate	B-X
at	B-X
least	B-X
some	B-X
aspects	B-X
of	B-X
the	B-X
molecular	B-X
differences	B-X
between	B-X
matched	B-X
pairs	B-X
of	B-X
GC	B-X
-	B-X
sensitive	B-X
and	B-X
	B-X
-	B-X
resistant	B-X
cell	B-X
lines	B-X

This	O
absence	O
of	O
correlation	O
could	O
be	O
in	O
part	O
explained	O
by	O
the	O
marked	O
heterogeneity	O
of	O
the	O
steroid	O
response	O
demonstrated	O
in	O
leukocyte	O
subpopulations	O
.	O
<EOS>	B-X
This	B-X
absence	B-X
of	B-X
correlation	B-X
could	B-X
be	B-X
in	B-X
part	B-X
explained	B-X
by	B-X
the	B-X
marked	B-X
heterogeneity	B-X
of	B-X
the	B-X
steroid	B-X
response	B-X
demonstrated	B-X
in	B-X
leukocyte	B-X
subpopulations	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
the	B-X
short	B-X
-	B-X
term	B-X
response	B-X
to	B-X
steroid	B-X
therapy	B-X
was	B-X
determined	B-X
<EOS>	B-X
Although	B-X
,	B-X
in	B-X
all	B-X
the	B-X
patients	B-X
studied	B-X
,	B-X
leukocytes	B-X
were	B-X
found	B-X
to	B-X
contain	B-X
glucocorticoid	B-X
receptors	B-X
,	B-X
we	B-X
failed	B-X
to	B-X
demonstrate	B-X
any	B-X
correlation	B-X
between	B-X
the	B-X
level	B-X
of	B-X
binding	B-X
sites	B-X
and	B-X
the	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
response	B-X
to	B-X
glucocorticoids	B-X
<EOS>	B-X
In	B-X
leukocyte	B-X
population	B-X
freshly	B-X
isolated	B-X
from	B-X
the	B-X
blood	B-X
of	B-X
26	B-X
patients	B-X
with	B-X
acute	B-X
leukemia	B-X
,	B-X
we	B-X
have	B-X
measured	B-X
several	B-X
parameters	B-X
including	B-X
glucocorticoid	B-X
receptors	B-X
,	B-X
nucleoside	B-X
incorporation	B-X
,	B-X
percentage	B-X
of	B-X
cells	B-X
in	B-X
S	B-X
phase	B-X
,	B-X
and	B-X
steroid	B-X
-	B-X
induced	B-X
cell	B-X
lysis	B-X

It	O
appears	O
,	O
however	O
,	O
that	O
the	O
degree	O
of	O
steroid	O
action	O
in	O
vitro	O
as	O
well	O
as	O
the	O
extent	O
of	O
spontaneous	O
and	O
dexamethasone-induced	O
cell	O
death	O
may	O
be	O
related	O
to	O
the	O
number	O
of	O
cells	O
in	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
cytosol	O
and	O
nuclear	O
extract	O
of	O
human	B-cell_type
leukocytes	I-cell_type
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
cytosol	B-X
and	B-X
nuclear	B-X
extract	B-X
of	B-X
human	B-X
leukocytes	B-X
.	B-X
<EOS>	B-X
Soluble	B-X
receptor	B-X
	B-X
-	B-X
	B-X
-	B-X
	B-X
3H	B-X
-	B-X
steroid	B-X
complex	B-X
(	B-X
cytosol	B-X
or	B-X
nuclear	B-X
extract	B-X
)	B-X
is	B-X
adsorbed	B-X
quantitatively	B-X
within	B-X
the	B-X
crevasses	B-X
of	B-X
porous	B-X
glass	B-X
beads	B-X
<EOS>	B-X
A	B-X
controlled	B-X
pore	B-X
glass	B-X
bead	B-X
assay	B-X
for	B-X
the	B-X
measurement	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
.	B-X
<EOS>	B-X
An	B-X
assay	B-X
for	B-X
the	B-X
quantitation	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
lymphoid	B-X
tissue	B-X
has	B-X
been	B-X
developed	B-X
using	B-X
controlled	B-X
pore	B-X
glass	B-X
(	B-X
CPG	B-X
)	B-X
beads	B-X

Cortisol	O
binding	O
by	O
cytosol	O
and	O
0.4	O
M	O
KCl	O
extract	O
of	O
the	O
nuclear	O
fraction	O
of	O
human	B-cell_type
leukocytes	I-cell_type
were	O
studied	O
by	O
gel	O
chromatography	O
and	O
ion	O
exchange	O
filtration	O
on	O
DEAE	O
cellulose	O
.	O
<EOS>	B-X
4	B-X
M	B-X
KCl	B-X
extract	B-X
of	B-X
the	B-X
nuclear	B-X
fraction	B-X
of	B-X
human	B-X
leukocytes	B-X
were	B-X
studied	B-X
by	B-X
gel	B-X
chromatography	B-X
and	B-X
ion	B-X
exchange	B-X
filtration	B-X
on	B-X
DEAE	B-X
cellulose	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
cytosol	B-X
and	B-X
nuclear	B-X
extract	B-X
of	B-X
human	B-X
leukocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
cytoplasmic	B-X
cortisol	B-X
binding	B-X
protein	B-X
has	B-X
a	B-X
molecular	B-X
weight	B-X
95	B-X
000	B-X
and	B-X
the	B-X
soluble	B-X
nuclear	B-X
binding	B-X
protein	B-X
50	B-X
000	B-X
<EOS>	B-X
The	B-X
association	B-X
constant	B-X
characterising	B-X
the	B-X
binding	B-X
of	B-X
cortisol	B-X
to	B-X
cytosol	B-X
was	B-X
KA	B-X
=	B-X
3	B-X

The	O
cytoplasmic	B-protein
cortisol	I-protein
binding	I-protein
protein	I-protein
has	O
a	O
molecular	O
weight	O
95	O
000	O
and	O
the	O
soluble	B-protein
nuclear	I-protein
binding	I-protein
protein	I-protein
50	O
000	O
.	O

The	O
absence	O
of	O
the	O
uptake	O
of	O
radioactive	O
cortisol	O
by	O
isolated	O
nuclei	O
and	O
the	O
apparent	O
requirement	O
of	O
the	O
cytosol	O
for	O
glucocorticoid	O
specific	O
binding	O
in	O
nuclear	O
receptor	O
sites	O
was	O
observed	O
.	O
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
the	B-X
uptake	B-X
of	B-X
radioactive	B-X
cortisol	B-X
by	B-X
isolated	B-X
nuclei	B-X
and	B-X
the	B-X
apparent	B-X
requirement	B-X
of	B-X
the	B-X
cytosol	B-X
for	B-X
glucocorticoid	B-X
specific	B-X
binding	B-X
in	B-X
nuclear	B-X
receptor	B-X
sites	B-X
was	B-X
observed	B-X
<EOS>	B-X
The	B-X
cytoplasmic	B-X
cortisol	B-X
binding	B-X
protein	B-X
has	B-X
a	B-X
molecular	B-X
weight	B-X
95	B-X
000	B-X
and	B-X
the	B-X
soluble	B-X
nuclear	B-X
binding	B-X
protein	B-X
50	B-X
000	B-X
<EOS>	B-X
The	B-X
association	B-X
constant	B-X
characterising	B-X
the	B-X
binding	B-X
of	B-X
cortisol	B-X
to	B-X
cytosol	B-X
was	B-X
KA	B-X
=	B-X
3	B-X
<EOS>	B-X
4	B-X
M	B-X
KCl	B-X
extract	B-X
of	B-X
the	B-X
nuclear	B-X
fraction	B-X
of	B-X
human	B-X
leukocytes	B-X
were	B-X
studied	B-X
by	B-X
gel	B-X
chromatography	B-X
and	B-X
ion	B-X
exchange	B-X
filtration	B-X
on	B-X
DEAE	B-X
cellulose	B-X

The	O
association	O
constant	O
characterising	O
the	O
binding	O
of	O
cortisol	O
to	O
cytosol	O
was	O
KA	O
=	O
3.5	O
.	O
10	O
(	O
9	O
)	O
l/mol	O
.	O
<EOS>	B-X
The	B-X
association	B-X
constant	B-X
characterising	B-X
the	B-X
binding	B-X
of	B-X
cortisol	B-X
to	B-X
cytosol	B-X
was	B-X
KA	B-X
=	B-X
3	B-X
<EOS>	B-X
The	B-X
absence	B-X
of	B-X
the	B-X
uptake	B-X
of	B-X
radioactive	B-X
cortisol	B-X
by	B-X
isolated	B-X
nuclei	B-X
and	B-X
the	B-X
apparent	B-X
requirement	B-X
of	B-X
the	B-X
cytosol	B-X
for	B-X
glucocorticoid	B-X
specific	B-X
binding	B-X
in	B-X
nuclear	B-X
receptor	B-X
sites	B-X
was	B-X
observed	B-X
<EOS>	B-X
Cortisol	B-X
binding	B-X
by	B-X
cytosol	B-X
and	B-X
0	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
in	B-X
cytosol	B-X
and	B-X
nuclear	B-X
extract	B-X
of	B-X
human	B-X
leukocytes	B-X
.	B-X

Corticosteroid-induced	O
lymphopenia	O
,	O
immunosuppression	O
,	O
and	O
body	O
defense	O
.	O
<EOS>	B-X
Corticosteroid	B-X
-	B-X
induced	B-X
lymphopenia	B-X
,	B-X
immunosuppression	B-X
,	B-X
and	B-X
body	B-X
defense	B-X
.	B-X
<EOS>	B-X
The	B-X
classic	B-X
rat	B-X
model	B-X
with	B-X
corticosteroid	B-X
-	B-X
induced	B-X
reactivation	B-X
of	B-X
a	B-X
latent	B-X
infection	B-X
has	B-X
been	B-X
most	B-X
widely	B-X
used	B-X
<EOS>	B-X
Experimental	B-X
corticosteroid	B-X
induction	B-X
of	B-X
Pneumocystis	B-X
carinii	B-X
pneumonia	B-X
in	B-X
piglets	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
they	B-X
developed	B-X
``	B-X
moon	B-X
face	B-X
''	B-X
and	B-X
``	B-X
pot	B-X
belly	B-X
''	B-X
,	B-X
snoring	B-X
sounds	B-X
while	B-X
eating	B-X
,	B-X
and	B-X
pronounced	B-X
respiratory	B-X
distress	B-X
during	B-X
handling	B-X

The	O
apparent	O
paradox	O
of	O
heightened	O
adrenal	O
corticosteroid	O
levels	O
associated	O
with	O
reduction	O
in	O
the	O
competence	O
of	O
the	O
body	O
's	O
defensive	O
apparatus	O
to	O
cope	O
with	O
exposure	O
to	O
new	O
microbial	B-protein
antigens	I-protein
is	O
considered	O
.	O

The	O
question	O
is	O
asked	O
how	O
this	O
lowered	O
defensive	O
capability	O
,	O
which	O
occurs	O
in	O
the	O
face	O
of	O
a	O
threat	O
to	O
body	O
integrity	O
,	O
is	O
consistent	O
with	O
Cannon	O
's	O
principals	O
of	O
the	O
``	O
wisdom	O
of	O
the	O
body.	O
''	O

The	O
suggestion	O
is	O
offered	O
that	O
the	O
immunologic	O
response	O
to	O
self-antigens	B-protein
exposed	O
by	O
disease	O
or	O
trauma	O
may	O
be	O
suppressed	O
by	O
corticosteroid	O
to	O
offset	O
the	O
likelihood	O
of	O
autoimmune	O
attack	O
.	O
<EOS>	B-X
``	B-X
The	B-X
suggestion	B-X
is	B-X
offered	B-X
that	B-X
the	B-X
immunologic	B-X
response	B-X
to	B-X
self	B-X
-	B-X
antigens	B-X
exposed	B-X
by	B-X
disease	B-X
or	B-X
trauma	B-X
may	B-X
be	B-X
suppressed	B-X
by	B-X
corticosteroid	B-X
to	B-X
offset	B-X
the	B-X
likelihood	B-X
of	B-X
autoimmune	B-X
attack	B-X
<EOS>	B-X
Clinical	B-X
evidence	B-X
suggests	B-X
that	B-X
chronic	B-X
or	B-X
repeated	B-X
exposure	B-X
to	B-X
self	B-X
antigen	B-X
within	B-X
tissues	B-X
leads	B-X
to	B-X
an	B-X
attenuation	B-X
of	B-X
pathological	B-X
autoimmune	B-X
responses	B-X
,	B-X
possibly	B-X
as	B-X
a	B-X
means	B-X
to	B-X
mitigate	B-X
inflammatory	B-X
damage	B-X
and	B-X
preserve	B-X
function	B-X
<EOS>	B-X
In	B-X
the	B-X
practice	B-X
of	B-X
antigen	B-X
-	B-X
specific	B-X
immunotherapy	B-X
,	B-X
allergens	B-X
or	B-X
self	B-X
antigens	B-X
are	B-X
repeatedly	B-X
injected	B-X
in	B-X
the	B-X
skin	B-X
,	B-X
with	B-X
a	B-X
diminution	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
occurring	B-X
after	B-X
each	B-X
successive	B-X
exposure	B-X
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
upon	B-X
expression	B-X
of	B-X
self	B-X
antigen	B-X
in	B-X
a	B-X
peripheral	B-X
tissue	B-X
,	B-X
thymus	B-X
-	B-X
derived	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
T	B-X
(	B-X
reg	B-X
)	B-X
cells	B-X
)	B-X
become	B-X
activated	B-X
,	B-X
proliferate	B-X
and	B-X
differentiate	B-X
into	B-X
more	B-X
potent	B-X
suppressors	B-X
,	B-X
which	B-X
mediate	B-X
resolution	B-X
of	B-X
organ	B-X
-	B-X
specific	B-X
autoimmunity	B-X
in	B-X
mice	B-X

Protein	B-protein
tyrosine	I-protein
kinase	I-protein
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
cytokines	B-protein
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O
<EOS>	B-X
Protein	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
lipopolysaccharide	B-X
induction	B-X
of	B-X
cytokines	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Protein	B-X
-	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
lipopolysaccharide	B-X
induction	B-X
of	B-X
interleukin	B-X
1beta	B-X
and	B-X
NFkappaB	B-X
activation	B-X
,	B-X
but	B-X
not	B-X
NFkappaB	B-X
nuclear	B-X
translocation	B-X
.	B-X
<EOS>	B-X
Tyrosine	B-X
kinases	B-X
are	B-X
not	B-X
required	B-X
for	B-X
lipopolysaccharide	B-X
-	B-X
mediated	B-X
nuclear	B-X
translocation	B-X
of	B-X
NFkappaB	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
,	B-X
in	B-X
the	B-X
human	B-X
pro	B-X
-	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
THP	B-X
-	B-X
1	B-X
,	B-X
the	B-X
lipopolysaccharide	B-X
-	B-X
induced	B-X
expression	B-X
of	B-X
interleukin	B-X
1beta	B-X
is	B-X
dependent	B-X
on	B-X
tyrosine	B-X
kinase	B-X
activation	B-X

Bacterial	O
LPS	O
induce	O
production	O
of	O
cytokines	B-protein
such	O
as	O
IL-1	B-protein
,	O
IL-6	B-protein
,	O
and	O
TNF	B-protein
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
,	O
and	O
this	O
represents	O
a	O
central	O
component	O
in	O
the	O
pathogenesis	O
of	O
septic	O
shock	O
syndrome	O
.	O
<EOS>	B-X
Bacterial	B-X
LPS	B-X
induce	B-X
production	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
1	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
TNF	B-X
in	B-X
mononuclear	B-X
phagocytes	B-X
,	B-X
and	B-X
this	B-X
represents	B-X
a	B-X
central	B-X
component	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
septic	B-X
shock	B-X
syndrome	B-X
<EOS>	B-X
It	B-X
is	B-X
shown	B-X
that	B-X
LPS	B-X
induced	B-X
a	B-X
12	B-X
-	B-X
	B-X
to	B-X
16	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
levels	B-X
,	B-X
and	B-X
this	B-X
was	B-X
completely	B-X
or	B-X
more	B-X
than	B-X
80	B-X
%	B-X
blocked	B-X
by	B-X
the	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
specific	B-X
inhibitors	B-X
herbimycin	B-X
A	B-X
and	B-X
genistein	B-X
at	B-X
the	B-X
concentrations	B-X
of	B-X
1	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
was	B-X
also	B-X
reduced	B-X
by	B-X
H89	B-X
,	B-X
whereas	B-X
staurosporine	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
this	B-X
response	B-X
<EOS>	B-X
Protein	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
lipopolysaccharide	B-X
induction	B-X
of	B-X
cytokines	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X

However	O
,	O
the	O
mechanisms	O
by	O
which	O
LPS	O
activates	O
these	O
cells	O
to	O
express	O
cytokines	B-protein
are	O
not	O
completely	O
characterized	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
maintain	B-X
choriodecidual	B-X
immune	B-X
homeostasis	B-X
or	B-X
compromise	B-X
immune	B-X
barrier	B-X
functions	B-X
remain	B-X
unclear	B-X
<EOS>	B-X
Infection	B-X
and	B-X
infiltration	B-X
of	B-X
activated	B-X
immune	B-X
cells	B-X
toward	B-X
the	B-X
chorion	B-X
are	B-X
often	B-X
associated	B-X
with	B-X
preterm	B-X
birth	B-X
<EOS>	B-X
PTE	B-X
treatment	B-X
also	B-X
significantly	B-X
reduced	B-X
LPS	B-X
-	B-X
activated	B-X
increase	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
	B-X
-	B-X
α	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
	B-X
-	B-X
6	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
tumor	B-X
-	B-X
bearing	B-X
mice	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
detailed	B-X
underlying	B-X
anti	B-X
-	B-X
inflammatory	B-X
mechanism	B-X
of	B-X
EAC	B-X
is	B-X
still	B-X
unclear	B-X

The	O
present	O
study	O
addressed	O
the	O
role	O
of	O
different	O
protein	B-protein
kinases	I-protein
in	O
the	O
LPS	O
induction	O
of	O
cytokines	B-protein
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
addressed	B-X
the	B-X
role	B-X
of	B-X
different	B-X
protein	B-X
kinases	B-X
in	B-X
the	B-X
LPS	B-X
induction	B-X
of	B-X
cytokines	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
PI3K	B-X
inhibition	B-X
increased	B-X
the	B-X
production	B-X
of	B-X
IL	B-X
-	B-X
1beta	B-X
protein	B-X
in	B-X
both	B-X
CE	B-X
(	B-X
sHUT	B-X
)	B-X
	B-X
-	B-X
	B-X
and	B-X
LPS	B-X
-	B-X
activated	B-X
monocytes	B-X
,	B-X
the	B-X
enhancement	B-X
being	B-X
drastically	B-X
higher	B-X
in	B-X
the	B-X
former	B-X
<EOS>	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
activation	B-X
of	B-X
PI3Ks	B-X
is	B-X
a	B-X
prerequisite	B-X
of	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
sIL	B-X
-	B-X
1Ra	B-X
gene	B-X
in	B-X
human	B-X
monocytes	B-X
activated	B-X
by	B-X
IFN	B-X
-	B-X
beta	B-X
<EOS>	B-X
The	B-X
predicted	B-X
three	B-X
-	B-X
dimensional	B-X
structure	B-X
of	B-X
AjIKKα	B-X
is	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
human	B-X
IKKα	B-X

It	O
is	O
shown	O
that	O
LPS	O
induced	O
a	O
12-	O
to	O
16-fold	O
increase	O
in	O
IL-1	O
beta	O
,	O
IL-6	O
,	O
and	O
TNF-alpha	O
mRNA	O
levels	O
,	O
and	O
this	O
was	O
completely	O
or	O
more	O
than	O
80	O
%	O
blocked	O
by	O
the	O
protein	O
tyrosine	O
kinase	O
specific	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
at	O
the	O
concentrations	O
of	O
1.7	O
and	O
37	O
microM	O
,	O
respectively	O
.	O
<EOS>	B-X
It	B-X
is	B-X
shown	B-X
that	B-X
LPS	B-X
induced	B-X
a	B-X
12	B-X
-	B-X
	B-X
to	B-X
16	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
levels	B-X
,	B-X
and	B-X
this	B-X
was	B-X
completely	B-X
or	B-X
more	B-X
than	B-X
80	B-X
%	B-X
blocked	B-X
by	B-X
the	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
specific	B-X
inhibitors	B-X
herbimycin	B-X
A	B-X
and	B-X
genistein	B-X
at	B-X
the	B-X
concentrations	B-X
of	B-X
1	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
cytokine	B-X
mRNA	B-X
levels	B-X
,	B-X
LPS	B-X
-	B-X
induced	B-X
IL	B-X
-	B-X
6	B-X
protein	B-X
synthesis	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
bioactivity	B-X
were	B-X
also	B-X
reduced	B-X
to	B-X
baseline	B-X
levels	B-X
by	B-X
the	B-X
PTK	B-X
inhibitors	B-X
herbimycin	B-X
A	B-X
and	B-X
genistein	B-X
<EOS>	B-X
Bacterial	B-X
LPS	B-X
induce	B-X
production	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
1	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
TNF	B-X
in	B-X
mononuclear	B-X
phagocytes	B-X
,	B-X
and	B-X
this	B-X
represents	B-X
a	B-X
central	B-X
component	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
septic	B-X
shock	B-X
syndrome	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
LPS	B-X
did	B-X
not	B-X
increase	B-X
leukemia	B-X
inhibitory	B-X
factor	B-X
mRNA	B-X
,	B-X
which	B-X
was	B-X
constitutively	B-X
expressed	B-X
and	B-X
not	B-X
significantly	B-X
reduced	B-X
by	B-X
these	B-X
inhibitors	B-X

Protein	B-protein
kinase	I-protein
C	I-protein
inhibition	O
by	O
staurosporine	O
reduced	O
LPS	O
induction	O
of	O
TNF-alpha	B-protein
,	O
whereas	O
it	O
had	O
no	O
effects	O
on	O
IL-6	B-protein
and	O
IL-1	O
beta	O
.	O
<EOS>	B-X
Protein	B-X
kinase	B-X
C	B-X
inhibition	B-X
by	B-X
staurosporine	B-X
reduced	B-X
LPS	B-X
induction	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
whereas	B-X
it	B-X
had	B-X
no	B-X
effects	B-X
on	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
and	B-X
protein	B-X
kinase	B-X
A	B-X
appear	B-X
to	B-X
have	B-X
selective	B-X
effects	B-X
in	B-X
the	B-X
LPS	B-X
induction	B-X
of	B-X
cytokines	B-X
,	B-X
whereas	B-X
PTK	B-X
is	B-X
required	B-X
for	B-X
LPS	B-X
induction	B-X
of	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
cytokines	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
monocytes	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
was	B-X
also	B-X
reduced	B-X
by	B-X
H89	B-X
,	B-X
whereas	B-X
staurosporine	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
this	B-X
response	B-X
<EOS>	B-X
Protein	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
lipopolysaccharide	B-X
induction	B-X
of	B-X
cytokines	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X

Inhibition	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
by	O
H89	O
reduced	O
IL-6	B-RNA
mRNA	I-RNA
levels	O
but	O
did	O
not	O
detectably	O
change	O
IL-1	O
beta	O
or	O
TNF-alpha	O
mRNA	O
levels	O
.	O
<EOS>	B-X
Whole	B-X
milk	B-X
digested	B-X
samples	B-X
induced	B-X
higher	B-X
mRNA	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
p65	B-X
and	B-X
IL	B-X
-	B-X
1β	B-X
than	B-X
fat	B-X
-	B-X
free	B-X
milk	B-X
(	B-X
p	B-X
<	B-X
0	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
SWFC	B-X
improved	B-X
mucosal	B-X
C3	B-X
,	B-X
T	B-X
-	B-X
AOC	B-X
,	B-X
SOD	B-X
activities	B-X
,	B-X
and	B-X
decreased	B-X
lipid	B-X
peroxidation	B-X
product	B-X
MDA	B-X
level	B-X
,	B-X
which	B-X
were	B-X
notably	B-X
better	B-X
than	B-X
those	B-X
in	B-X
the	B-X
control	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0	B-X
<EOS>	B-X
Additionally	B-X
,	B-X
abdominal	B-X
irradiation	B-X
markedly	B-X
increased	B-X
in	B-X
colonic	B-X
inflammation	B-X
levels	B-X
(	B-X
3	B-X
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
HRECs	B-X
was	B-X
not	B-X
significantly	B-X
affected	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
20	B-X
μM	B-X
or	B-X
less	B-X
of	B-X
GA	B-X
,	B-X
and	B-X
15	B-X
μM	B-X
of	B-X
GA	B-X
could	B-X
restore	B-X
the	B-X
diminished	B-X
activity	B-X
of	B-X
HRECs	B-X
induced	B-X
by	B-X
high	B-X
glucose	B-X

In	O
contrast	O
,	O
LPS	O
did	O
not	O
increase	O
leukemia	B-RNA
inhibitory	I-RNA
factor	I-RNA
mRNA	I-RNA
,	O
which	O
was	O
constitutively	O
expressed	O
and	O
not	O
significantly	O
reduced	O
by	O
these	O
inhibitors	O
.	O
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
lutein	B-X
can	B-X
improve	B-X
chronic	B-X
alcoholic	B-X
liver	B-X
injury	B-X
and	B-X
intestinal	B-X
barrier	B-X
dysfunction	B-X
in	B-X
rats	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
cCSE	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
curdlan	B-X
-	B-X
	B-X
or	B-X
IFN	B-X
-	B-X
γ	B-X
-	B-X
stimulated	B-X
BMDCs	B-X
,	B-X
and	B-X
curdlan	B-X
-	B-X
stimulated	B-X
BMDCs	B-X
suppressed	B-X
IL	B-X
-	B-X
17	B-X
production	B-X
from	B-X
T	B-X
cells	B-X
and	B-X
enhanced	B-X
IFN	B-X
-	B-X
γ	B-X
production	B-X
<EOS>	B-X
The	B-X
contents	B-X
of	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
IL	B-X
-	B-X
17	B-X
,	B-X
IL	B-X
-	B-X
1β	B-X
,	B-X
and	B-X
TNF	B-X
-	B-X
α	B-X
in	B-X
the	B-X
intestinal	B-X
tissues	B-X
of	B-X
mice	B-X
were	B-X
significantly	B-X
reduced	B-X
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
cCSE	B-X
suppressed	B-X
the	B-X
induction	B-X
of	B-X
CD86	B-X
induced	B-X
by	B-X
stimulation	B-X
with	B-X
curdlan	B-X
and	B-X
interferon	B-X
-	B-X
gamma	B-X
(	B-X
IFN	B-X
-	B-X
γ	B-X
)	B-X

In	O
addition	O
to	O
cytokine	B-RNA
mRNA	I-RNA
levels	O
,	O
LPS-induced	O
IL-6	O
protein	O
synthesis	O
and	O
IL-6	O
bioactivity	O
were	O
also	O
reduced	O
to	O
baseline	O
levels	O
by	O
the	O
PTK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
cytokine	B-X
mRNA	B-X
levels	B-X
,	B-X
LPS	B-X
-	B-X
induced	B-X
IL	B-X
-	B-X
6	B-X
protein	B-X
synthesis	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
bioactivity	B-X
were	B-X
also	B-X
reduced	B-X
to	B-X
baseline	B-X
levels	B-X
by	B-X
the	B-X
PTK	B-X
inhibitors	B-X
herbimycin	B-X
A	B-X
and	B-X
genistein	B-X
<EOS>	B-X
It	B-X
is	B-X
shown	B-X
that	B-X
LPS	B-X
induced	B-X
a	B-X
12	B-X
-	B-X
	B-X
to	B-X
16	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
,	B-X
IL	B-X
-	B-X
6	B-X
,	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
levels	B-X
,	B-X
and	B-X
this	B-X
was	B-X
completely	B-X
or	B-X
more	B-X
than	B-X
80	B-X
%	B-X
blocked	B-X
by	B-X
the	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
specific	B-X
inhibitors	B-X
herbimycin	B-X
A	B-X
and	B-X
genistein	B-X
at	B-X
the	B-X
concentrations	B-X
of	B-X
1	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
by	B-X
H89	B-X
reduced	B-X
IL	B-X
-	B-X
6	B-X
mRNA	B-X
levels	B-X
but	B-X
did	B-X
not	B-X
detectably	B-X
change	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
or	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
levels	B-X
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
and	B-X
protein	B-X
kinase	B-X
A	B-X
appear	B-X
to	B-X
have	B-X
selective	B-X
effects	B-X
in	B-X
the	B-X
LPS	B-X
induction	B-X
of	B-X
cytokines	B-X
,	B-X
whereas	B-X
PTK	B-X
is	B-X
required	B-X
for	B-X
LPS	B-X
induction	B-X
of	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
cytokines	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
monocytes	B-X

Both	O
PTK	O
inhibitors	O
also	O
reduced	O
the	O
LPS	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
which	O
is	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
expression	O
of	O
cytokine	B-RNA
genes	I-RNA
such	O
as	O
IL-6	B-DNA
and	O
TNF-alpha	B-DNA
.	O
<EOS>	B-X
Both	B-X
PTK	B-X
inhibitors	B-X
also	B-X
reduced	B-X
the	B-X
LPS	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
involved	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
cytokine	B-X
genes	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X
<EOS>	B-X
Protein	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
lipopolysaccharide	B-X
induction	B-X
of	B-X
cytokines	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Protein	B-X
kinase	B-X
C	B-X
inhibition	B-X
by	B-X
staurosporine	B-X
reduced	B-X
LPS	B-X
induction	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
whereas	B-X
it	B-X
had	B-X
no	B-X
effects	B-X
on	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
was	B-X
also	B-X
reduced	B-X
by	B-X
H89	B-X
,	B-X
whereas	B-X
staurosporine	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
this	B-X
response	B-X

The	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
also	O
reduced	O
by	O
H89	O
,	O
whereas	O
staurosporine	O
had	O
no	O
effect	O
on	O
this	O
response	O
.	O
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
was	B-X
also	B-X
reduced	B-X
by	B-X
H89	B-X
,	B-X
whereas	B-X
staurosporine	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
this	B-X
response	B-X
<EOS>	B-X
Protein	B-X
kinase	B-X
C	B-X
inhibition	B-X
by	B-X
staurosporine	B-X
reduced	B-X
LPS	B-X
induction	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
whereas	B-X
it	B-X
had	B-X
no	B-X
effects	B-X
on	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
by	B-X
H89	B-X
reduced	B-X
IL	B-X
-	B-X
6	B-X
mRNA	B-X
levels	B-X
but	B-X
did	B-X
not	B-X
detectably	B-X
change	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
or	B-X
TNF	B-X
-	B-X
alpha	B-X
mRNA	B-X
levels	B-X
<EOS>	B-X
Both	B-X
PTK	B-X
inhibitors	B-X
also	B-X
reduced	B-X
the	B-X
LPS	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
-	B-X
kappa	B-X
B	B-X
(	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
involved	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
cytokine	B-X
genes	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
TNF	B-X
-	B-X
alpha	B-X

In	O
summary	O
,	O
these	O
findings	O
suggest	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
protein	B-protein
kinase	I-protein
A	I-protein
appear	O
to	O
have	O
selective	O
effects	O
in	O
the	O
LPS	O
induction	O
of	O
cytokines	B-protein
,	O
whereas	O
PTK	B-protein
is	O
required	O
for	O
LPS	O
induction	O
of	O
a	O
broad	O
spectrum	O
of	O
cytokines	B-protein
and	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
monocytes	B-cell_type
.	O
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
and	B-X
protein	B-X
kinase	B-X
A	B-X
appear	B-X
to	B-X
have	B-X
selective	B-X
effects	B-X
in	B-X
the	B-X
LPS	B-X
induction	B-X
of	B-X
cytokines	B-X
,	B-X
whereas	B-X
PTK	B-X
is	B-X
required	B-X
for	B-X
LPS	B-X
induction	B-X
of	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
cytokines	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
in	B-X
monocytes	B-X
<EOS>	B-X
Protein	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
lipopolysaccharide	B-X
induction	B-X
of	B-X
cytokines	B-X
in	B-X
human	B-X
blood	B-X
monocytes	B-X
.	B-X
<EOS>	B-X
Protein	B-X
kinase	B-X
C	B-X
inhibition	B-X
by	B-X
staurosporine	B-X
reduced	B-X
LPS	B-X
induction	B-X
of	B-X
TNF	B-X
-	B-X
alpha	B-X
,	B-X
whereas	B-X
it	B-X
had	B-X
no	B-X
effects	B-X
on	B-X
IL	B-X
-	B-X
6	B-X
and	B-X
IL	B-X
-	B-X
1	B-X
beta	B-X
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
cytokine	B-X
mRNA	B-X
levels	B-X
,	B-X
LPS	B-X
-	B-X
induced	B-X
IL	B-X
-	B-X
6	B-X
protein	B-X
synthesis	B-X
and	B-X
IL	B-X
-	B-X
6	B-X
bioactivity	B-X
were	B-X
also	B-X
reduced	B-X
to	B-X
baseline	B-X
levels	B-X
by	B-X
the	B-X
PTK	B-X
inhibitors	B-X
herbimycin	B-X
A	B-X
and	B-X
genistein	B-X

In	O
vivo	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
<EOS>	B-X
The	B-X
control	B-X
group	B-X
was	B-X
given	B-X
normal	B-X
saline	B-X
(	B-X
i	B-X
<EOS>	B-X
Elevated	B-X
expression	B-X
of	B-X
RhoGTPases	B-X
was	B-X
a	B-X
consequence	B-X
of	B-X
activation	B-X
of	B-X
the	B-X
NF	B-X
-	B-X
κB	B-X
pathway	B-X
<EOS>	B-X
STOP	B-X
control	B-X
virus	B-X
impaired	B-X
LTβR	B-X
-	B-X
mediated	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
p52	B-X
upon	B-X
fibroblast	B-X
infection	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
targets	B-X
of	B-X
anisomycin	B-X
and	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
have	B-X
not	B-X
been	B-X
explained	B-X
in	B-X
macrophages	B-X

The	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
is	O
stored	O
in	O
the	O
cytoplasm	O
in	O
complexes	O
with	O
the	O
inhibitor	B-protein
protein	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
stored	B-X
in	B-X
the	B-X
cytoplasm	B-X
in	B-X
complexes	B-X
with	B-X
the	B-X
inhibitor	B-X
protein	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
<EOS>	B-X
In	B-X
vivo	B-X
control	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
by	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
<EOS>	B-X
Quite	B-X
unexpectedly	B-X
,	B-X
we	B-X
also	B-X
found	B-X
that	B-X
in	B-X
unstimulated	B-X
cells	B-X
there	B-X
is	B-X
a	B-X
constant	B-X
ongoing	B-X
process	B-X
of	B-X
degradation	B-X
and	B-X
replacement	B-X
of	B-X
complexed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
turnover	B-X
results	B-X
in	B-X
the	B-X
low	B-X
level	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
presumably	B-X
necessary	B-X
even	B-X
in	B-X
the	B-X
unstimulated	B-X
cell	B-X
,	B-X
and	B-X
that	B-X
the	B-X
high	B-X
rate	B-X
of	B-X
synthesis	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
provides	B-X
the	B-X
ability	B-X
to	B-X
turn	B-X
off	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activity	B-X
rapidly	B-X
as	B-X
soon	B-X
as	B-X
the	B-X
activating	B-X
signal	B-X
ceases	B-X

It	O
has	O
been	O
shown	O
in	O
vitro	O
that	O
dissociation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
these	O
complexes	O
results	O
in	O
active	B-protein
NF-kappa	I-protein
B	I-protein
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
vitro	B-X
that	B-X
dissociation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
from	B-X
these	B-X
complexes	B-X
results	B-X
in	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
postulated	B-X
that	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
leads	B-X
to	B-X
its	B-X
dissociation	B-X
from	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
and	B-X
free	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
targeted	B-X
for	B-X
rapid	B-X
degradation	B-X
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
-	B-X
induced	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
a	B-X
signal	B-X
for	B-X
its	B-X
degradation	B-X
but	B-X
not	B-X
dissociation	B-X
from	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
.	B-X
<EOS>	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
Tax	B-X
binds	B-X
to	B-X
the	B-X
ankyrin	B-X
motifs	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
-	B-X
gamma	B-X
,	B-X
and	B-X
dissociates	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
-	B-X
gamma	B-X
/	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
complexes	B-X
,	B-X
resulting	B-X
in	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
proteins	B-X

In	O
this	O
report	O
we	O
show	O
that	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
activation	O
of	O
B	B-cell_type
or	I-cell_type
pre-B	I-cell_type
cells	I-cell_type
results	O
in	O
loss	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
in	O
vivo	O
.	O
<EOS>	B-X
In	B-X
this	B-X
research	B-X
,	B-X
we	B-X
established	B-X
a	B-X
mouse	B-X
sepsis	B-X
model	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
investigated	B-X
the	B-X
protective	B-X
effects	B-X
of	B-X
LIE	B-X
on	B-X
sepsis	B-X
spleen	B-X
injury	B-X
in	B-X
terms	B-X
of	B-X
inflammatory	B-X
response	B-X
,	B-X
oxidative	B-X
stress	B-X
,	B-X
and	B-X
apoptosis	B-X
<EOS>	B-X
Fexofenadine	B-X
protects	B-X
against	B-X
lipopolysaccharide	B-X
-	B-X
induced	B-X
acute	B-X
lung	B-X
injury	B-X
by	B-X
targeting	B-X
cytosolic	B-X
phospholipase	B-X
A2	B-X
.	B-X
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
and	B-X
effects	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
	B-X
-	B-X
pretreated	B-X
bone	B-X
marrow	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
(	B-X
BMSCs	B-X
)	B-X
	B-X
-	B-X
derived	B-X
exosomes	B-X
(	B-X
L	B-X
-	B-X
Exo	B-X
)	B-X
on	B-X
macrophage	B-X
STING	B-X
signaling	B-X
in	B-X
septic	B-X
liver	B-X
injury	B-X
<EOS>	B-X
Human	B-X
THP	B-X
-	B-X
1	B-X
cells	B-X
stimulated	B-X
with	B-X
either	B-X
lipopolysaccharide	B-X
or	B-X
TNF	B-X
-	B-X
α	B-X
showed	B-X
increased	B-X
expression	B-X
of	B-X
inflammatory	B-X
genes	B-X
,	B-X
although	B-X
this	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
SB	B-X
,	B-X
confirming	B-X
the	B-X
anti	B-X
-	B-X
inflammatory	B-X
effects	B-X
of	B-X
SB	B-X

Many	O
liberated	O
NF-kappa	B-protein
B	I-protein
dimers	I-protein
reached	O
the	O
nucleus	O
,	O
where	O
increased	O
c-rel	B-protein
,	O
p65	O
and	O
p50	O
were	O
detected	O
by	O
immunoblotting	O
and	O
by	O
DNA	O
binding	O
assays	O
.	O
<EOS>	B-X
Many	B-X
liberated	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
dimers	B-X
reached	B-X
the	B-X
nucleus	B-X
,	B-X
where	B-X
increased	B-X
c	B-X
-	B-X
rel	B-X
,	B-X
p65	B-X
and	B-X
p50	B-X
were	B-X
detected	B-X
by	B-X
immunoblotting	B-X
and	B-X
by	B-X
DNA	B-X
binding	B-X
assays	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
turnover	B-X
results	B-X
in	B-X
the	B-X
low	B-X
level	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
presumably	B-X
necessary	B-X
even	B-X
in	B-X
the	B-X
unstimulated	B-X
cell	B-X
,	B-X
and	B-X
that	B-X
the	B-X
high	B-X
rate	B-X
of	B-X
synthesis	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
provides	B-X
the	B-X
ability	B-X
to	B-X
turn	B-X
off	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activity	B-X
rapidly	B-X
as	B-X
soon	B-X
as	B-X
the	B-X
activating	B-X
signal	B-X
ceases	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
stored	B-X
in	B-X
the	B-X
cytoplasm	B-X
in	B-X
complexes	B-X
with	B-X
the	B-X
inhibitor	B-X
protein	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
vitro	B-X
that	B-X
dissociation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
from	B-X
these	B-X
complexes	B-X
results	B-X
in	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X

Some	O
liberated	B-protein
dimers	I-protein
were	O
retained	O
in	O
the	O
cytoplasm	O
,	O
however	O
,	O
through	O
binding	O
to	O
newly	O
synthesized	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
a	O
finding	O
which	O
strongly	O
suggests	O
(	O
i	O
)	O
that	O
the	O
LPS-induced	O
signal	O
causes	O
dissociation	O
of	O
complexes	O
rather	O
than	O
preventing	O
their	O
association	O
and	O
(	O
ii	O
)	O
that	O
dissociation	O
results	O
from	O
modification	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
not	O
of	O
c-rel	B-protein
or	O
p65	B-protein
.	O
<EOS>	B-X
Our	B-X
findings	B-X
demonstrate	B-X
that	B-X
HDAC9	B-X
suppression	B-X
ameliorates	B-X
LPS	B-X
-	B-X
induced	B-X
cardiac	B-X
dysfunction	B-X
by	B-X
inhibiting	B-X
the	B-X
NF	B-X
-	B-X
κB	B-X
signaling	B-X
pathway	B-X
and	B-X
presents	B-X
a	B-X
promising	B-X
therapeutic	B-X
agent	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
LPS	B-X
-	B-X
stimulated	B-X
myocardial	B-X
injury	B-X
<EOS>	B-X
Ginsenoside	B-X
Re	B-X
could	B-X
improve	B-X
cardiac	B-X
function	B-X
,	B-X
inhibit	B-X
collagen	B-X
deposition	B-X
and	B-X
CFs	B-X
migration	B-X
,	B-X
promote	B-X
the	B-X
transcription	B-X
of	B-X
miR	B-X
-	B-X
489	B-X
,	B-X
and	B-X
reduce	B-X
the	B-X
expression	B-X
of	B-X
myd88	B-X
and	B-X
the	B-X
phosphorylation	B-X
of	B-X
NF	B-X
-	B-X
κB	B-X
p65	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
Western	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
CUR	B-X
inhibited	B-X
the	B-X
increase	B-X
in	B-X
AMP	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
AMPK	B-X
)	B-X
phosphorylation	B-X
,	B-X
glycolysis	B-X
,	B-X
and	B-X
triacylglycerol	B-X
synthesis	B-X
and	B-X
the	B-X
reduction	B-X
in	B-X
oxidative	B-X
phosphorylation	B-X
induced	B-X
by	B-X
PRV	B-X
infection	B-X
<EOS>	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
experiments	B-X
proved	B-X
that	B-X
combined	B-X
thermoradiotherapy	B-X
of	B-X
DRBCM	B-X
-	B-X
BNFs	B-X
exhibited	B-X
significantly	B-X
enhanced	B-X
tumor	B-X
inhibition	B-X
efficacy	B-X
than	B-X
monotherapy	B-X
with	B-X
good	B-X
biocompatibility	B-X
and	B-X
low	B-X
toxicity	B-X
due	B-X
to	B-X
its	B-X
biodegradability	B-X

No	O
effect	O
of	O
LPS	O
treatment	O
was	O
detected	O
on	O
p105	B-protein
or	O
p100	B-protein
,	O
which	O
also	O
retain	O
rel	B-protein
family	I-protein
members	I-protein
in	O
the	O
cytoplasm	O
.	O
<EOS>	B-X
No	B-X
effect	B-X
of	B-X
LPS	B-X
treatment	B-X
was	B-X
detected	B-X
on	B-X
p105	B-X
or	B-X
p100	B-X
,	B-X
which	B-X
also	B-X
retain	B-X
rel	B-X
family	B-X
members	B-X
in	B-X
the	B-X
cytoplasm	B-X
<EOS>	B-X
p105	B-X
and	B-X
p100	B-X
are	B-X
known	B-X
to	B-X
function	B-X
additionally	B-X
as	B-X
IkappaBs	B-X
(	B-X
inhibitors	B-X
of	B-X
NF	B-X
-	B-X
kappaB	B-X
)	B-X
,	B-X
which	B-X
retain	B-X
associated	B-X
NF	B-X
-	B-X
kappaB	B-X
subunits	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
unstimulated	B-X
cells	B-X
<EOS>	B-X
In	B-X
contrast	B-X
with	B-X
p100	B-X
,	B-X
p105	B-X
is	B-X
constitutively	B-X
processed	B-X
to	B-X
p50	B-X
<EOS>	B-X
One	B-X
class	B-X
of	B-X
target	B-X
sites	B-X
for	B-X
Tax	B-X
are	B-X
the	B-X
kappa	B-X
B	B-X
sequences	B-X
which	B-X
are	B-X
bound	B-X
by	B-X
members	B-X
of	B-X
the	B-X
rel	B-X
/	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
family	B-X

Quite	O
unexpectedly	O
,	O
we	O
also	O
found	O
that	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
there	O
is	O
a	O
constant	O
ongoing	O
process	O
of	O
degradation	O
and	O
replacement	O
of	O
complexed	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
<EOS>	B-X
Quite	B-X
unexpectedly	B-X
,	B-X
we	B-X
also	B-X
found	B-X
that	B-X
in	B-X
unstimulated	B-X
cells	B-X
there	B-X
is	B-X
a	B-X
constant	B-X
ongoing	B-X
process	B-X
of	B-X
degradation	B-X
and	B-X
replacement	B-X
of	B-X
complexed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
is	B-X
stored	B-X
in	B-X
the	B-X
cytoplasm	B-X
in	B-X
complexes	B-X
with	B-X
the	B-X
inhibitor	B-X
protein	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
turnover	B-X
results	B-X
in	B-X
the	B-X
low	B-X
level	B-X
of	B-X
active	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
presumably	B-X
necessary	B-X
even	B-X
in	B-X
the	B-X
unstimulated	B-X
cell	B-X
,	B-X
and	B-X
that	B-X
the	B-X
high	B-X
rate	B-X
of	B-X
synthesis	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
provides	B-X
the	B-X
ability	B-X
to	B-X
turn	B-X
off	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activity	B-X
rapidly	B-X
as	B-X
soon	B-X
as	B-X
the	B-X
activating	B-X
signal	B-X
ceases	B-X
<EOS>	B-X
No	B-X
effect	B-X
of	B-X
LPS	B-X
treatment	B-X
was	B-X
detected	B-X
on	B-X
p105	B-X
or	B-X
p100	B-X
,	B-X
which	B-X
also	B-X
retain	B-X
rel	B-X
family	B-X
members	B-X
in	B-X
the	B-X
cytoplasm	B-X

We	O
propose	O
that	O
this	O
turnover	O
results	O
in	O
the	O
low	O
level	O
of	O
active	B-protein
NF-kappa	I-protein
B	I-protein
presumably	O
necessary	O
even	O
in	O
the	O
unstimulated	O
cell	O
,	O
and	O
that	O
the	O
high	O
rate	O
of	O
synthesis	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
provides	O
the	O
ability	O
to	O
turn	O
off	O
NF-kappa	B-protein
B	I-protein
activity	O
rapidly	O
as	O
soon	O
as	O
the	O
activating	O
signal	O
ceases	O
.	O

Identification	O
of	O
a	O
killer	B-DNA
cell-specific	I-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
mouse	B-DNA
perforin	I-DNA
gene	I-DNA
:	O
an	O
Ets-binding	O
site-homologous	O
motif	O
that	O
interacts	O
with	O
Ets-related	B-protein
proteins	I-protein
.	O
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
killer	B-X
cell	B-X
-	B-X
specific	B-X
regulatory	B-X
element	B-X
of	B-X
the	B-X
mouse	B-X
perforin	B-X
gene	B-X
:	B-X
an	B-X
Ets	B-X
-	B-X
binding	B-X
site	B-X
-	B-X
homologous	B-X
motif	B-X
that	B-X
interacts	B-X
with	B-X
Ets	B-X
-	B-X
related	B-X
proteins	B-X
.	B-X
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
,	B-X
we	B-X
have	B-X
characterized	B-X
the	B-X
regulatory	B-X
functions	B-X
and	B-X
the	B-X
DNA	B-X
-	B-X
protein	B-X
interactions	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
perforin	B-X
gene	B-X
(	B-X
Pfp	B-X
)	B-X
<EOS>	B-X
Within	B-X
this	B-X
segment	B-X
,	B-X
a	B-X
9	B-X
-	B-X
mer	B-X
motif	B-X
(	B-X
5'	B-X
-	B-X
ACAGGAAGT	B-X
-	B-X
3	B-X
'	B-X
,	B-X
residues	B-X
	B-X
-	B-X
505	B-X
to	B-X
	B-X
-	B-X
497	B-X
;	B-X
designated	B-X
NF	B-X
-	B-X
P	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
homologous	B-X
to	B-X
the	B-X
Ets	B-X
proto	B-X
-	B-X
oncoprotein	B-X
-	B-X
binding	B-X
site	B-X
,	B-X
was	B-X
found	B-X
to	B-X
interact	B-X
with	B-X
two	B-X
proteins	B-X
,	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X
<EOS>	B-X
Results	B-X
obtained	B-X
from	B-X
the	B-X
binding	B-X
competition	B-X
assay	B-X
,	B-X
nevertheless	B-X
,	B-X
suggest	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X
are	B-X
related	B-X
to	B-X
but	B-X
distinct	B-X
from	B-X
Ets	B-X
proteins	B-X
,	B-X
e	B-X

The	O
gene	O
encoding	O
the	O
cytolytic	B-protein
protein	I-protein
perforin	B-protein
is	O
selectively	O
expressed	O
by	O
activated	B-cell_type
killer	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
The	B-X
gene	B-X
encoding	B-X
the	B-X
cytolytic	B-X
protein	B-X
perforin	B-X
is	B-X
selectively	B-X
expressed	B-X
by	B-X
activated	B-X
killer	B-X
lymphocytes	B-X
<EOS>	B-X
NF	B-X
-	B-X
P2	B-X
appears	B-X
to	B-X
be	B-X
induced	B-X
by	B-X
reagents	B-X
known	B-X
to	B-X
up	B-X
-	B-X
regulate	B-X
the	B-X
perforin	B-X
message	B-X
level	B-X
and	B-X
is	B-X
present	B-X
exclusively	B-X
in	B-X
killer	B-X
cells	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
32	B-X
-	B-X
mer	B-X
sequence	B-X
(	B-X
residues	B-X
	B-X
-	B-X
491	B-X
to	B-X
	B-X
-	B-X
522	B-X
)	B-X
which	B-X
appeared	B-X
to	B-X
be	B-X
capable	B-X
of	B-X
enhancing	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
killer	B-X
cell	B-X
-	B-X
specific	B-X
manner	B-X
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
,	B-X
we	B-X
have	B-X
characterized	B-X
the	B-X
regulatory	B-X
functions	B-X
and	B-X
the	B-X
DNA	B-X
-	B-X
protein	B-X
interactions	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
perforin	B-X
gene	B-X
(	B-X
Pfp	B-X
)	B-X

To	O
understand	O
the	O
mechanisms	O
underlying	O
the	O
cell-type-specific	O
expression	O
of	O
this	O
gene	O
,	O
we	O
have	O
characterized	O
the	O
regulatory	O
functions	O
and	O
the	O
DNA-protein	O
interactions	O
of	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
mouse	B-DNA
perforin	I-DNA
gene	I-DNA
(	O
Pfp	B-DNA
)	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
,	B-X
we	B-X
have	B-X
characterized	B-X
the	B-X
regulatory	B-X
functions	B-X
and	B-X
the	B-X
DNA	B-X
-	B-X
protein	B-X
interactions	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
perforin	B-X
gene	B-X
(	B-X
Pfp	B-X
)	B-X
<EOS>	B-X
Identification	B-X
of	B-X
a	B-X
killer	B-X
cell	B-X
-	B-X
specific	B-X
regulatory	B-X
element	B-X
of	B-X
the	B-X
mouse	B-X
perforin	B-X
gene	B-X
:	B-X
an	B-X
Ets	B-X
-	B-X
binding	B-X
site	B-X
-	B-X
homologous	B-X
motif	B-X
that	B-X
interacts	B-X
with	B-X
Ets	B-X
-	B-X
related	B-X
proteins	B-X
.	B-X
<EOS>	B-X
In	B-X
view	B-X
of	B-X
the	B-X
homology	B-X
between	B-X
the	B-X
NF	B-X
-	B-X
P	B-X
motif	B-X
and	B-X
other	B-X
Ets	B-X
proto	B-X
-	B-X
oncoprotein	B-X
-	B-X
binding	B-X
sites	B-X
,	B-X
it	B-X
is	B-X
postulated	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X
belong	B-X
to	B-X
the	B-X
Ets	B-X
protein	B-X
family	B-X
<EOS>	B-X
The	B-X
region	B-X
between	B-X
residues	B-X
	B-X
-	B-X
411	B-X
and	B-X
	B-X
-	B-X
566	B-X
was	B-X
chosen	B-X
for	B-X
further	B-X
characterization	B-X
,	B-X
since	B-X
it	B-X
contains	B-X
an	B-X
enhancer	B-X
-	B-X
like	B-X
activity	B-X

A	O
region	O
extending	O
from	O
residues	B-DNA
+62	I-DNA
through	I-DNA
-141	I-DNA
,	O
which	O
possesses	O
the	O
essential	O
promoter	O
activity	O
,	O
and	O
regions	O
further	O
upstream	O
,	O
which	O
are	O
able	O
to	O
either	O
enhance	O
or	O
suppress	O
gene	O
expression	O
,	O
were	O
identified	O
.	O
<EOS>	B-X
Transcriptional	B-X
profiling	B-X
studies	B-X
have	B-X
identified	B-X
several	B-X
protective	B-X
genes	B-X
upregulated	B-X
in	B-X
tubular	B-X
epithelial	B-X
cells	B-X
during	B-X
acute	B-X
kidney	B-X
injury	B-X
(	B-X
AKI	B-X
)	B-X
<EOS>	B-X
The	B-X
gene	B-X
cargo	B-X
is	B-X
released	B-X
in	B-X
response	B-X
to	B-X
the	B-X
reductive	B-X
cellular	B-X
environment	B-X
that	B-X
is	B-X
upregulated	B-X
in	B-X
cancer	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
enhanced	B-X
gene	B-X
delivery	B-X
and	B-X
protein	B-X
expression	B-X
efficiency	B-X
<EOS>	B-X
SLTNCR	B-X
can	B-X
alleviate	B-X
symptoms	B-X
of	B-X
IS	B-X
and	B-X
the	B-X
potential	B-X
mechanism	B-X
of	B-X
its	B-X
effect	B-X
is	B-X
to	B-X
protect	B-X
brain	B-X
tissue	B-X
by	B-X
suppressing	B-X
inflammation	B-X
<EOS>	B-X
Our	B-X
study	B-X
presents	B-X
the	B-X
detailed	B-X
molecular	B-X
expression	B-X
profile	B-X
during	B-X
axonal	B-X
regeneration	B-X
of	B-X
dorsal	B-X
root	B-X
ganglion	B-X
neurons	B-X
after	B-X
peripheral	B-X
nerve	B-X
injury	B-X

The	O
region	O
between	O
residues	B-DNA
-411	I-DNA
and	I-DNA
-566	I-DNA
was	O
chosen	O
for	O
further	O
characterization	O
,	O
since	O
it	O
contains	O
an	O
enhancer-like	O
activity	O
.	O
<EOS>	B-X
The	B-X
region	B-X
between	B-X
residues	B-X
	B-X
-	B-X
411	B-X
and	B-X
	B-X
-	B-X
566	B-X
was	B-X
chosen	B-X
for	B-X
further	B-X
characterization	B-X
,	B-X
since	B-X
it	B-X
contains	B-X
an	B-X
enhancer	B-X
-	B-X
like	B-X
activity	B-X
<EOS>	B-X
A	B-X
region	B-X
extending	B-X
from	B-X
residues	B-X
+62	B-X
through	B-X
	B-X
-	B-X
141	B-X
,	B-X
which	B-X
possesses	B-X
the	B-X
essential	B-X
promoter	B-X
activity	B-X
,	B-X
and	B-X
regions	B-X
further	B-X
upstream	B-X
,	B-X
which	B-X
are	B-X
able	B-X
to	B-X
either	B-X
enhance	B-X
or	B-X
suppress	B-X
gene	B-X
expression	B-X
,	B-X
were	B-X
identified	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
32	B-X
-	B-X
mer	B-X
sequence	B-X
(	B-X
residues	B-X
	B-X
-	B-X
491	B-X
to	B-X
	B-X
-	B-X
522	B-X
)	B-X
which	B-X
appeared	B-X
to	B-X
be	B-X
capable	B-X
of	B-X
enhancing	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
killer	B-X
cell	B-X
-	B-X
specific	B-X
manner	B-X
<EOS>	B-X
Within	B-X
this	B-X
segment	B-X
,	B-X
a	B-X
9	B-X
-	B-X
mer	B-X
motif	B-X
(	B-X
5'	B-X
-	B-X
ACAGGAAGT	B-X
-	B-X
3	B-X
'	B-X
,	B-X
residues	B-X
	B-X
-	B-X
505	B-X
to	B-X
	B-X
-	B-X
497	B-X
;	B-X
designated	B-X
NF	B-X
-	B-X
P	B-X
motif	B-X
)	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
homologous	B-X
to	B-X
the	B-X
Ets	B-X
proto	B-X
-	B-X
oncoprotein	B-X
-	B-X
binding	B-X
site	B-X
,	B-X
was	B-X
found	B-X
to	B-X
interact	B-X
with	B-X
two	B-X
proteins	B-X
,	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X

We	O
have	O
identified	O
a	O
32-mer	O
sequence	O
(	O
residues	B-DNA
-491	I-DNA
to	I-DNA
-522	I-DNA
)	O
which	O
appeared	O
to	O
be	O
capable	O
of	O
enhancing	O
gene	O
expression	O
in	O
a	O
killer	O
cell-specific	O
manner	O
.	O

Within	O
this	O
segment	O
,	O
a	O
9-mer	O
motif	O
(	O
5'-ACAGGAAGT-3	O
'	O
,	O
residues	B-DNA
-505	I-DNA
to	I-DNA
-497	I-DNA
;	O
designated	O
NF-P	O
motif	O
)	O
,	O
which	O
is	O
highly	O
homologous	O
to	O
the	O
Ets	B-DNA
proto-oncoprotein-binding	I-DNA
site	I-DNA
,	O
was	O
found	O
to	O
interact	O
with	O
two	O
proteins	O
,	O
NF-P1	B-protein
and	O
NF-P2	B-protein
.	O

NF-P2	B-protein
appears	O
to	O
be	O
induced	O
by	O
reagents	O
known	O
to	O
up-regulate	O
the	O
perforin	O
message	O
level	O
and	O
is	O
present	O
exclusively	O
in	O
killer	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
NF	B-X
-	B-X
P2	B-X
appears	B-X
to	B-X
be	B-X
induced	B-X
by	B-X
reagents	B-X
known	B-X
to	B-X
up	B-X
-	B-X
regulate	B-X
the	B-X
perforin	B-X
message	B-X
level	B-X
and	B-X
is	B-X
present	B-X
exclusively	B-X
in	B-X
killer	B-X
cells	B-X
<EOS>	B-X
The	B-X
gene	B-X
encoding	B-X
the	B-X
cytolytic	B-X
protein	B-X
perforin	B-X
is	B-X
selectively	B-X
expressed	B-X
by	B-X
activated	B-X
killer	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
32	B-X
-	B-X
mer	B-X
sequence	B-X
(	B-X
residues	B-X
	B-X
-	B-X
491	B-X
to	B-X
	B-X
-	B-X
522	B-X
)	B-X
which	B-X
appeared	B-X
to	B-X
be	B-X
capable	B-X
of	B-X
enhancing	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
killer	B-X
cell	B-X
-	B-X
specific	B-X
manner	B-X
<EOS>	B-X
,	B-X
Ets	B-X
-	B-X
1	B-X
,	B-X
Ets	B-X
-	B-X
2	B-X
,	B-X
and	B-X
NF	B-X
-	B-X
AT	B-X
/	B-X
Elf	B-X
-	B-X
1	B-X
,	B-X
known	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X

Electrophoretic	O
mobility	O
shift	O
assay	O
and	O
UV	O
cross-linking	O
experiments	O
revealed	O
that	O
NF-P1	B-protein
and	O
NF-P2	B-protein
may	O
possess	O
common	O
DNA-binding	B-protein
subunits	I-protein
.	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
and	B-X
UV	B-X
cross	B-X
-	B-X
linking	B-X
experiments	B-X
revealed	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X
may	B-X
possess	B-X
common	B-X
DNA	B-X
-	B-X
binding	B-X
subunits	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
larger	B-X
native	B-X
molecular	B-X
mass	B-X
of	B-X
NF	B-X
-	B-X
P1	B-X
suggests	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
contains	B-X
an	B-X
additional	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
subunit	B-X
(	B-X
s	B-X
)	B-X
<EOS>	B-X
In	B-X
view	B-X
of	B-X
the	B-X
homology	B-X
between	B-X
the	B-X
NF	B-X
-	B-X
P	B-X
motif	B-X
and	B-X
other	B-X
Ets	B-X
proto	B-X
-	B-X
oncoprotein	B-X
-	B-X
binding	B-X
sites	B-X
,	B-X
it	B-X
is	B-X
postulated	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X
belong	B-X
to	B-X
the	B-X
Ets	B-X
protein	B-X
family	B-X
<EOS>	B-X
Results	B-X
obtained	B-X
from	B-X
the	B-X
binding	B-X
competition	B-X
assay	B-X
,	B-X
nevertheless	B-X
,	B-X
suggest	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X
are	B-X
related	B-X
to	B-X
but	B-X
distinct	B-X
from	B-X
Ets	B-X
proteins	B-X
,	B-X
e	B-X

However	O
,	O
the	O
larger	O
native	O
molecular	O
mass	O
of	O
NF-P1	B-protein
suggests	O
that	O
NF-P1	B-protein
contains	O
an	O
additional	O
non-DNA-binding	B-protein
subunit	I-protein
(	O
s	O
)	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
larger	B-X
native	B-X
molecular	B-X
mass	B-X
of	B-X
NF	B-X
-	B-X
P1	B-X
suggests	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
contains	B-X
an	B-X
additional	B-X
non	B-X
-	B-X
DNA	B-X
-	B-X
binding	B-X
subunit	B-X
(	B-X
s	B-X
)	B-X
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
and	B-X
UV	B-X
cross	B-X
-	B-X
linking	B-X
experiments	B-X
revealed	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X
may	B-X
possess	B-X
common	B-X
DNA	B-X
-	B-X
binding	B-X
subunits	B-X
<EOS>	B-X
Results	B-X
obtained	B-X
from	B-X
the	B-X
binding	B-X
competition	B-X
assay	B-X
,	B-X
nevertheless	B-X
,	B-X
suggest	B-X
that	B-X
NF	B-X
-	B-X
P1	B-X
and	B-X
NF	B-X
-	B-X
P2	B-X
are	B-X
related	B-X
to	B-X
but	B-X
distinct	B-X
from	B-X
Ets	B-X
proteins	B-X
,	B-X
e	B-X
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
cell	B-X
-	B-X
type	B-X
-	B-X
specific	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
,	B-X
we	B-X
have	B-X
characterized	B-X
the	B-X
regulatory	B-X
functions	B-X
and	B-X
the	B-X
DNA	B-X
-	B-X
protein	B-X
interactions	B-X
of	B-X
the	B-X
5'	B-X
-	B-X
flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
perforin	B-X
gene	B-X
(	B-X
Pfp	B-X
)	B-X

In	O
view	O
of	O
the	O
homology	O
between	O
the	O
NF-P	B-protein
motif	I-protein
and	O
other	O
Ets	B-protein
proto-oncoprotein-binding	I-protein
sites	I-protein
,	O
it	O
is	O
postulated	O
that	O
NF-P1	B-protein
and	O
NF-P2	B-protein
belong	O
to	O
the	O
Ets	B-protein
protein	I-protein
family	I-protein
.	O

Results	O
obtained	O
from	O
the	O
binding	O
competition	O
assay	O
,	O
nevertheless	O
,	O
suggest	O
that	O
NF-P1	B-protein
and	O
NF-P2	B-protein
are	O
related	O
to	O
but	O
distinct	O
from	O
Ets	B-protein
proteins	I-protein
,	O
e.g.	O
,	O
Ets-1	B-protein
,	O
Ets-2	B-protein
,	O
and	O
NF-AT/Elf-1	B-protein
,	O
known	O
to	O
be	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
role	O
of	O
NF-kappa	B-DNA
B1	I-DNA
(	I-DNA
p50/p105	I-DNA
)	I-DNA
gene	I-DNA
expression	O
in	O
activation	O
of	O
human	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
via	O
CD2	B-protein
and	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
(	B-X
p50	B-X
/	B-X
p105	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
activation	B-X
of	B-X
human	B-X
blood	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
.	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
T	B-X
-	B-X
lymphocytes	B-X
,	B-X
we	B-X
previously	B-X
analyzed	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
related	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
CD2+CD28	B-X
costimulation	B-X
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
both	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
genes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
multiple	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
Partial	B-X
inhibition	B-X
of	B-X
p50	B-X
and	B-X
p105	B-X
expression	B-X
by	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
antisense	B-X
oligonucleotides	B-X
significantly	B-X
reduced	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
and	B-X
CD25	B-X
/	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X

Stimulation	O
of	O
primary	B-cell_type
human	I-cell_type
T-lymphocytes	I-cell_type
via	O
CD2	B-protein
and	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
induces	O
a	O
long-lasting	O
proliferation	O
(	O
>	O
3	O
weeks	O
)	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
proliferation	B-X
(	B-X
>	B-X
3	B-X
weeks	B-X
)	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
T	B-X
-	B-X
cells	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
and	B-X
maintains	B-X
proliferation	B-X
for	B-X
more	B-X
than	B-X
3	B-X
weeks	B-X
<EOS>	B-X
Activation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
-	B-X
lymphocytes	B-X
through	B-X
CD2	B-X
plus	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
long	B-X
-	B-X
term	B-X
nuclear	B-X
expression	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
.	B-X
<EOS>	B-X
Partial	B-X
inhibition	B-X
of	B-X
p50	B-X
and	B-X
p105	B-X
expression	B-X
by	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
antisense	B-X
oligonucleotides	B-X
significantly	B-X
reduced	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
and	B-X
CD25	B-X
/	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X

This	O
potent	O
activation	O
does	O
not	O
require	O
accessory	O
cells	O
,	O
such	O
as	O
monocytes	B-cell_type
,	O
but	O
depends	O
on	O
persistent	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
secretion	O
and	O
receptivity	O
,	O
which	O
is	O
associated	O
with	O
high	O
and	O
prolonged	O
expression	O
of	O
the	O
inducible	O
CD25/IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
chain	I-DNA
gene	I-DNA
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
participates	O
in	O
the	O
regulation	O
of	O
both	O
IL-2	B-DNA
and	I-DNA
IL-2R	I-DNA
alpha	I-DNA
genes	I-DNA
,	O
as	O
well	O
as	O
multiple	B-DNA
cellular	I-DNA
genes	I-DNA
involved	O
in	O
T-cell	O
proliferation	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
both	B-X
IL	B-X
-	B-X
2	B-X
and	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
genes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
multiple	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
(	B-X
p50	B-X
/	B-X
p105	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
activation	B-X
of	B-X
human	B-X
blood	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
.	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
proliferation	B-X
(	B-X
>	B-X
3	B-X
weeks	B-X
)	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
T	B-X
-	B-X
lymphocytes	B-X
,	B-X
we	B-X
previously	B-X
analyzed	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
related	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
CD2+CD28	B-X
costimulation	B-X

To	O
evaluate	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
,	O
we	O
previously	O
analyzed	O
the	O
activation	O
of	O
NF-kappa	B-protein
B-related	I-protein
complexes	I-protein
in	O
response	O
to	O
CD2+CD28	O
costimulation	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
T	B-X
-	B-X
lymphocytes	B-X
,	B-X
we	B-X
previously	B-X
analyzed	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
related	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
CD2+CD28	B-X
costimulation	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
(	B-X
p50	B-X
/	B-X
p105	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
activation	B-X
of	B-X
human	B-X
blood	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
.	B-X
<EOS>	B-X
As	B-X
the	B-X
role	B-X
of	B-X
p50	B-X
remains	B-X
unclear	B-X
,	B-X
we	B-X
focused	B-X
our	B-X
present	B-X
study	B-X
on	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
(	B-X
p50	B-X
/	B-X
p105	B-X
)	B-X
gene	B-X
regulation	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
proliferation	B-X
(	B-X
>	B-X
3	B-X
weeks	B-X
)	B-X

We	O
demonstrated	O
a	O
long-term	O
induction	O
of	O
p50/p65	B-protein
heterodimer	I-protein
,	O
a	O
putative	B-protein
p65/c-Rel	I-protein
heterodimer	I-protein
,	O
and	O
a	O
constitutive	O
nuclear	O
expression	O
of	O
KBF1/p50	B-protein
homodimers	I-protein
.	I-protein

As	O
the	O
role	O
of	O
p50	B-protein
remains	O
unclear	O
,	O
we	O
focused	O
our	O
present	O
study	O
on	O
NF-kappa	B-protein
B1	I-protein
(	O
p50/p105	B-protein
)	O
gene	O
regulation	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Western	O
and	O
Northern	O
blot	O
analyses	O
,	O
we	O
studied	O
NF-kappa	B-DNA
B1	I-DNA
gene	I-DNA
expression	O
during	O
T-cell	O
stimulation	O
via	O
CD2+CD28	B-protein
.	O
<EOS>	B-X
Using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
and	B-X
Western	B-X
and	B-X
Northern	B-X
blot	B-X
analyses	B-X
,	B-X
we	B-X
studied	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
gene	B-X
expression	B-X
during	B-X
T	B-X
-	B-X
cell	B-X
stimulation	B-X
via	B-X
CD2+CD28	B-X
<EOS>	B-X
As	B-X
the	B-X
role	B-X
of	B-X
p50	B-X
remains	B-X
unclear	B-X
,	B-X
we	B-X
focused	B-X
our	B-X
present	B-X
study	B-X
on	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
(	B-X
p50	B-X
/	B-X
p105	B-X
)	B-X
gene	B-X
regulation	B-X
<EOS>	B-X
This	B-X
potent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
accessory	B-X
cells	B-X
,	B-X
such	B-X
as	B-X
monocytes	B-X
,	B-X
but	B-X
depends	B-X
on	B-X
persistent	B-X
interleukin	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
secretion	B-X
and	B-X
receptivity	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
high	B-X
and	B-X
prolonged	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
CD25	B-X
/	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
alpha	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
)	B-X
chain	B-X
gene	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
proliferation	B-X
(	B-X
>	B-X
3	B-X
weeks	B-X
)	B-X

We	O
observed	O
a	O
transient	O
4-	O
to	O
5-fold	O
increase	O
of	O
NF-kappa	O
B1	O
gene	O
expression	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
,	O
lasting	O
for	O
at	O
least	O
24	O
h	O
.	O
<EOS>	B-X
We	B-X
observed	B-X
a	B-X
transient	B-X
4	B-X
-	B-X
	B-X
to	B-X
5	B-X
-	B-X
fold	B-X
increase	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
gene	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
,	B-X
lasting	B-X
for	B-X
at	B-X
least	B-X
24	B-X
h	B-X
<EOS>	B-X
Partial	B-X
inhibition	B-X
of	B-X
p50	B-X
and	B-X
p105	B-X
expression	B-X
by	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
antisense	B-X
oligonucleotides	B-X
significantly	B-X
reduced	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
and	B-X
CD25	B-X
/	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
T	B-X
-	B-X
lymphocytes	B-X
,	B-X
we	B-X
previously	B-X
analyzed	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
related	B-X
complexes	B-X
in	B-X
response	B-X
to	B-X
CD2+CD28	B-X
costimulation	B-X
<EOS>	B-X
This	B-X
potent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
accessory	B-X
cells	B-X
,	B-X
such	B-X
as	B-X
monocytes	B-X
,	B-X
but	B-X
depends	B-X
on	B-X
persistent	B-X
interleukin	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
secretion	B-X
and	B-X
receptivity	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
high	B-X
and	B-X
prolonged	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
CD25	B-X
/	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
alpha	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
)	B-X
chain	B-X
gene	B-X

p50	O
DNA-binding	O
activity	O
apparently	O
stays	O
highly	O
controlled	O
when	O
p105	O
expression	O
is	O
enhanced	O
by	O
a	O
physiological	O
stimulus	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T-cells	I-cell_type
.	O
<EOS>	B-X
p50	B-X
DNA	B-X
-	B-X
binding	B-X
activity	B-X
apparently	B-X
stays	B-X
highly	B-X
controlled	B-X
when	B-X
p105	B-X
expression	B-X
is	B-X
enhanced	B-X
by	B-X
a	B-X
physiological	B-X
stimulus	B-X
of	B-X
peripheral	B-X
blood	B-X
T	B-X
-	B-X
cells	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
proliferation	B-X
(	B-X
>	B-X
3	B-X
weeks	B-X
)	B-X
<EOS>	B-X
We	B-X
observed	B-X
a	B-X
transient	B-X
4	B-X
-	B-X
	B-X
to	B-X
5	B-X
-	B-X
fold	B-X
increase	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
gene	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
,	B-X
lasting	B-X
for	B-X
at	B-X
least	B-X
24	B-X
h	B-X
<EOS>	B-X
This	B-X
potent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
accessory	B-X
cells	B-X
,	B-X
such	B-X
as	B-X
monocytes	B-X
,	B-X
but	B-X
depends	B-X
on	B-X
persistent	B-X
interleukin	B-X
2	B-X
(	B-X
IL	B-X
-	B-X
2	B-X
)	B-X
secretion	B-X
and	B-X
receptivity	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
high	B-X
and	B-X
prolonged	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
CD25	B-X
/	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
alpha	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
)	B-X
chain	B-X
gene	B-X

Partial	O
inhibition	O
of	O
p50	O
and	O
p105	O
expression	O
by	O
NF-kappa	B-protein
B1	I-protein
antisense	O
oligonucleotides	O
significantly	O
reduced	O
T-cell	O
proliferation	O
and	O
CD25/IL-2R	B-protein
alpha	I-protein
cell	O
surface	O
expression	O
.	O
<EOS>	B-X
Partial	B-X
inhibition	B-X
of	B-X
p50	B-X
and	B-X
p105	B-X
expression	B-X
by	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
antisense	B-X
oligonucleotides	B-X
significantly	B-X
reduced	B-X
T	B-X
-	B-X
cell	B-X
proliferation	B-X
and	B-X
CD25	B-X
/	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X
<EOS>	B-X
The	B-X
role	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
(	B-X
p50	B-X
/	B-X
p105	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
activation	B-X
of	B-X
human	B-X
blood	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
.	B-X
<EOS>	B-X
We	B-X
observed	B-X
a	B-X
transient	B-X
4	B-X
-	B-X
	B-X
to	B-X
5	B-X
-	B-X
fold	B-X
increase	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B1	B-X
gene	B-X
expression	B-X
at	B-X
both	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
,	B-X
lasting	B-X
for	B-X
at	B-X
least	B-X
24	B-X
h	B-X
<EOS>	B-X
Stimulation	B-X
of	B-X
primary	B-X
human	B-X
T	B-X
-	B-X
lymphocytes	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
a	B-X
long	B-X
-	B-X
lasting	B-X
proliferation	B-X
(	B-X
>	B-X
3	B-X
weeks	B-X
)	B-X

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
<EOS>	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
<EOS>	B-X
95	B-X
,	B-X
p	B-X
<	B-X
or	B-X
=	B-X
0	B-X
<EOS>	B-X
7	B-X
%	B-X
,	B-X
n	B-X
=	B-X
65	B-X
)	B-X
<EOS>	B-X
26	B-X
,	B-X
p	B-X
<	B-X
or	B-X
=	B-X
0	B-X

Vitamin	B-protein
D	I-protein
receptor	I-protein
quantitation	O
in	O
human	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
health	O
and	O
disease	O
.	O
<EOS>	B-X
Vitamin	B-X
D	B-X
receptor	B-X
quantitation	B-X
in	B-X
human	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X
<EOS>	B-X
Vitamin	B-X
D	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
concentration	B-X
was	B-X
quantitated	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
absorptive	B-X
hypercalciuria	B-X
(	B-X
AH	B-X
)	B-X
and	B-X
patients	B-X
with	B-X
high	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
due	B-X
to	B-X
acquired	B-X
or	B-X
transient	B-X
disease	B-X
states	B-X
and	B-X
the	B-X
results	B-X
compared	B-X
to	B-X
those	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
VDR	B-X
concentration	B-X
in	B-X
resting	B-X
cells	B-X
was	B-X
not	B-X
different	B-X
between	B-X
the	B-X
three	B-X
groups	B-X
and	B-X
represented	B-X
constitutive	B-X
receptor	B-X
expression	B-X
of	B-X
monocytes	B-X
<EOS>	B-X
Following	B-X
activation	B-X
with	B-X
phytohemagglutinin	B-X
,	B-X
patients	B-X
with	B-X
hypercalcitriolemia	B-X
demonstrated	B-X
significantly	B-X
greater	B-X
VDR	B-X
concentrations	B-X

Vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	O
)	O
concentration	O
was	O
quantitated	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
from	O
patients	O
with	O
absorptive	O
hypercalciuria	O
(	O
AH	O
)	O
and	O
patients	O
with	O
high	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
due	O
to	O
acquired	O
or	O
transient	O
disease	O
states	O
and	O
the	O
results	O
compared	O
to	O
those	O
in	O
normal	O
subjects	O
.	O
<EOS>	B-X
This	B-X
technique	B-X
may	B-X
improve	B-X
non	B-X
-	B-X
contrast	B-X
myocardial	B-X
tissue	B-X
characterization	B-X
in	B-X
patients	B-X
with	B-X
heart	B-X
disease	B-X
in	B-X
a	B-X
scan	B-X
time	B-X
appropriate	B-X
for	B-X
patients	B-X
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
cerebral	B-X
dynamic	B-X
response	B-X
to	B-X
induced	B-X
desaturation	B-X
in	B-X
SCD	B-X
patients	B-X
with	B-X
and	B-X
without	B-X
SCI	B-X
,	B-X
chronic	B-X
anemia	B-X
,	B-X
and	B-X
healthy	B-X
subjects	B-X
<EOS>	B-X
However	B-X
,	B-X
the	B-X
cone	B-X
-	B-X
mediated	B-X
PLR	B-X
was	B-X
larger	B-X
for	B-X
the	B-X
short	B-X
-	B-X
wavelength	B-X
stimulus	B-X
compared	B-X
to	B-X
the	B-X
photopically	B-X
matched	B-X
long	B-X
-	B-X
wavelength	B-X
stimulus	B-X
at	B-X
high	B-X
luminances	B-X
,	B-X
a	B-X
pattern	B-X
that	B-X
was	B-X
not	B-X
observed	B-X
for	B-X
control	B-X
subjects	B-X
<EOS>	B-X
Despite	B-X
concerns	B-X
regarding	B-X
hypoperfusion	B-X
in	B-X
patients	B-X
with	B-X
large	B-X
-	B-X
artery	B-X
occlusive	B-X
disease	B-X
,	B-X
strict	B-X
blood	B-X
pressure	B-X
(	B-X
BP	B-X
)	B-X
control	B-X
has	B-X
become	B-X
adopted	B-X
as	B-X
a	B-X
safe	B-X
strategy	B-X
for	B-X
risk	B-X
reduction	B-X
of	B-X
stroke	B-X

VDR	O
concentration	O
in	O
resting	B-cell_type
cells	I-cell_type
was	O
not	O
different	O
between	O
the	O
three	O
groups	O
and	O
represented	O
constitutive	O
receptor	O
expression	O
of	O
monocytes	B-cell_type
.	O
<EOS>	B-X
The	B-X
concentration	B-X
of	B-X
the	B-X
VDR	B-X
mRNA	B-X
,	B-X
corrected	B-X
for	B-X
the	B-X
number	B-X
of	B-X
monocytes	B-X
,	B-X
was	B-X
similar	B-X
among	B-X
the	B-X
three	B-X
genotype	B-X
groups	B-X
,	B-X
as	B-X
were	B-X
the	B-X
other	B-X
variables	B-X
examined	B-X
:	B-X
serum	B-X
calcitriol	B-X
,	B-X
serum	B-X
osteocalcin	B-X
,	B-X
and	B-X
vertebral	B-X
and	B-X
hip	B-X
bone	B-X
density	B-X
<EOS>	B-X
These	B-X
observations	B-X
were	B-X
confirmed	B-X
by	B-X
intracellular	B-X
staining	B-X
of	B-X
the	B-X
different	B-X
isotypes	B-X
in	B-X
B	B-X
cells	B-X
after	B-X
anti	B-X
-	B-X
CD40+IL	B-X
-	B-X
4	B-X
stimulation	B-X
,	B-X
which	B-X
showed	B-X
a	B-X
strong	B-X
reduction	B-X
of	B-X
IgE	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VD	B-X
<EOS>	B-X
But	B-X
the	B-X
nuclei	B-X
immunostaining	B-X
patterns	B-X
before	B-X
and	B-X
after	B-X
mitosis	B-X
were	B-X
different	B-X
in	B-X
proliferative	B-X
chondrocytes	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
immunoreactive	B-X
VDR	B-X
receptors	B-X
in	B-X
nucleoli	B-X
of	B-X
chondrocytes	B-X
,	B-X
particularly	B-X
the	B-X
fibrillar	B-X
component	B-X
,	B-X
suggests	B-X
that	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
regulation	B-X
of	B-X
ribosomal	B-X
genes	B-X

Following	O
activation	O
with	O
phytohemagglutinin	B-protein
,	O
patients	B-cell_type
with	O
hypercalcitriolemia	O
demonstrated	O
significantly	O
greater	O
VDR	O
concentrations	O
.	O
<EOS>	B-X
Following	B-X
activation	B-X
with	B-X
phytohemagglutinin	B-X
,	B-X
patients	B-X
with	B-X
hypercalcitriolemia	B-X
demonstrated	B-X
significantly	B-X
greater	B-X
VDR	B-X
concentrations	B-X
<EOS>	B-X
Vitamin	B-X
D	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
concentration	B-X
was	B-X
quantitated	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
absorptive	B-X
hypercalciuria	B-X
(	B-X
AH	B-X
)	B-X
and	B-X
patients	B-X
with	B-X
high	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
due	B-X
to	B-X
acquired	B-X
or	B-X
transient	B-X
disease	B-X
states	B-X
and	B-X
the	B-X
results	B-X
compared	B-X
to	B-X
those	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
Vitamin	B-X
D	B-X
receptor	B-X
quantitation	B-X
in	B-X
human	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
studies	B-X
in	B-X
patients	B-X
with	B-X
absorptive	B-X
hypercalciuria	B-X
disclosed	B-X
it	B-X
to	B-X
be	B-X
a	B-X
heterogeneous	B-X
disorder	B-X
,	B-X
characterized	B-X
by	B-X
both	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
and	B-X
D	B-X
-	B-X
independent	B-X
forms	B-X
of	B-X
receptor	B-X
up	B-X
-	B-X
regulation	B-X

Patients	O
with	O
AH	O
demonstrated	O
a	O
normal	O
value	O
for	O
the	O
group	O
,	O
but	O
6	O
patients	O
had	O
significantly	O
greater	O
concentrations	O
of	O
VDR	B-protein
despite	O
normal	O
plasma	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
four	O
of	O
the	O
patients	O
.	O

Proliferation	O
,	O
as	O
assessed	O
from	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
inversely	O
correlated	O
with	O
serum	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
was	O
significant	O
(	O
R	O
=	O
-0.299	O
,	O
p	O
=	O
0.048	O
)	O
.	O
<EOS>	B-X
Proliferation	B-X
,	B-X
as	B-X
assessed	B-X
from	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
was	B-X
inversely	B-X
correlated	B-X
with	B-X
serum	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
and	B-X
was	B-X
significant	B-X
(	B-X
R	B-X
=	B-X
	B-X
-	B-X
0	B-X
<EOS>	B-X
Vitamin	B-X
D	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
concentration	B-X
was	B-X
quantitated	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
absorptive	B-X
hypercalciuria	B-X
(	B-X
AH	B-X
)	B-X
and	B-X
patients	B-X
with	B-X
high	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
due	B-X
to	B-X
acquired	B-X
or	B-X
transient	B-X
disease	B-X
states	B-X
and	B-X
the	B-X
results	B-X
compared	B-X
to	B-X
those	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
Following	B-X
activation	B-X
with	B-X
phytohemagglutinin	B-X
,	B-X
patients	B-X
with	B-X
hypercalcitriolemia	B-X
demonstrated	B-X
significantly	B-X
greater	B-X
VDR	B-X
concentrations	B-X
<EOS>	B-X
Patients	B-X
with	B-X
AH	B-X
demonstrated	B-X
a	B-X
normal	B-X
value	B-X
for	B-X
the	B-X
group	B-X
,	B-X
but	B-X
6	B-X
patients	B-X
had	B-X
significantly	B-X
greater	B-X
concentrations	B-X
of	B-X
VDR	B-X
despite	B-X
normal	B-X
plasma	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
in	B-X
four	B-X
of	B-X
the	B-X
patients	B-X

Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
PBMC	B-cell_type
provide	O
a	O
useful	O
system	O
for	O
studying	O
VDR	B-protein
status	O
in	O
transient	O
or	O
acquired	O
states	O
of	O
hypercalcitriolemia	O
.	O
<EOS>	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
PBMC	B-X
provide	B-X
a	B-X
useful	B-X
system	B-X
for	B-X
studying	B-X
VDR	B-X
status	B-X
in	B-X
transient	B-X
or	B-X
acquired	B-X
states	B-X
of	B-X
hypercalcitriolemia	B-X
<EOS>	B-X
Vitamin	B-X
D	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
concentration	B-X
was	B-X
quantitated	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
absorptive	B-X
hypercalciuria	B-X
(	B-X
AH	B-X
)	B-X
and	B-X
patients	B-X
with	B-X
high	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
due	B-X
to	B-X
acquired	B-X
or	B-X
transient	B-X
disease	B-X
states	B-X
and	B-X
the	B-X
results	B-X
compared	B-X
to	B-X
those	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
studies	B-X
in	B-X
patients	B-X
with	B-X
absorptive	B-X
hypercalciuria	B-X
disclosed	B-X
it	B-X
to	B-X
be	B-X
a	B-X
heterogeneous	B-X
disorder	B-X
,	B-X
characterized	B-X
by	B-X
both	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
and	B-X
D	B-X
-	B-X
independent	B-X
forms	B-X
of	B-X
receptor	B-X
up	B-X
-	B-X
regulation	B-X
<EOS>	B-X
Vitamin	B-X
D	B-X
receptor	B-X
quantitation	B-X
in	B-X
human	B-X
blood	B-X
mononuclear	B-X
cells	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X

Furthermore	O
,	O
the	O
studies	O
in	O
patients	O
with	O
absorptive	O
hypercalciuria	O
disclosed	O
it	O
to	O
be	O
a	O
heterogeneous	O
disorder	O
,	O
characterized	O
by	O
both	O
vitamin	O
D-dependent	O
and	O
D-independent	O
forms	O
of	O
receptor	O
up-regulation	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
studies	B-X
in	B-X
patients	B-X
with	B-X
absorptive	B-X
hypercalciuria	B-X
disclosed	B-X
it	B-X
to	B-X
be	B-X
a	B-X
heterogeneous	B-X
disorder	B-X
,	B-X
characterized	B-X
by	B-X
both	B-X
vitamin	B-X
D	B-X
-	B-X
dependent	B-X
and	B-X
D	B-X
-	B-X
independent	B-X
forms	B-X
of	B-X
receptor	B-X
up	B-X
-	B-X
regulation	B-X
<EOS>	B-X
Following	B-X
activation	B-X
with	B-X
phytohemagglutinin	B-X
,	B-X
patients	B-X
with	B-X
hypercalcitriolemia	B-X
demonstrated	B-X
significantly	B-X
greater	B-X
VDR	B-X
concentrations	B-X
<EOS>	B-X
Vitamin	B-X
D	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
concentration	B-X
was	B-X
quantitated	B-X
in	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
absorptive	B-X
hypercalciuria	B-X
(	B-X
AH	B-X
)	B-X
and	B-X
patients	B-X
with	B-X
high	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
due	B-X
to	B-X
acquired	B-X
or	B-X
transient	B-X
disease	B-X
states	B-X
and	B-X
the	B-X
results	B-X
compared	B-X
to	B-X
those	B-X
in	B-X
normal	B-X
subjects	B-X
<EOS>	B-X
VDR	B-X
concentration	B-X
in	B-X
resting	B-X
cells	B-X
was	B-X
not	B-X
different	B-X
between	B-X
the	B-X
three	B-X
groups	B-X
and	B-X
represented	B-X
constitutive	B-X
receptor	B-X
expression	B-X
of	B-X
monocytes	B-X

Reactive	O
oxygen	O
intermediates	O
activate	O
NF-kappa	B-protein
B	I-protein
in	O
a	O
tyrosine	O
kinase-dependent	O
mechanism	O
and	O
in	O
combination	O
with	O
vanadate	O
activate	O
the	O
p56lck	B-protein
and	I-protein
p59fyn	I-protein
tyrosine	I-protein
kinases	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
have	O
previously	O
observed	O
that	O
ionizing	O
radiation	O
induces	O
tyrosine	O
phosphorylation	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
by	O
stimulation	O
of	O
unidentified	O
tyrosine	B-protein
kinases	I-protein
and	O
this	O
phosphorylation	O
is	O
substantially	O
augmented	O
by	O
vanadate	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
observed	B-X
that	B-X
ionizing	B-X
radiation	B-X
induces	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
human	B-X
B	B-X
-	B-X
lymphocyte	B-X
precursors	B-X
by	B-X
stimulation	B-X
of	B-X
unidentified	B-X
tyrosine	B-X
kinases	B-X
and	B-X
this	B-X
phosphorylation	B-X
is	B-X
substantially	B-X
augmented	B-X
by	B-X
vanadate	B-X
<EOS>	B-X
The	B-X
synergistic	B-X
induction	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
by	B-X
H2O2	B-X
plus	B-X
vanadate	B-X
included	B-X
physiologically	B-X
relevant	B-X
proteins	B-X
such	B-X
as	B-X
PLC	B-X
gamma	B-X
1	B-X
<EOS>	B-X
H2O2	B-X
was	B-X
found	B-X
to	B-X
stimulate	B-X
Ins	B-X
-	B-X
1,4,5	B-X
-	B-X
P3	B-X
production	B-X
in	B-X
a	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
manner	B-X
and	B-X
to	B-X
induce	B-X
calcium	B-X
signals	B-X
that	B-X
were	B-X
greatly	B-X
augmented	B-X
by	B-X
vanadate	B-X
<EOS>	B-X
The	B-X
combined	B-X
inhibition	B-X
of	B-X
phosphatases	B-X
and	B-X
activation	B-X
of	B-X
kinases	B-X
provides	B-X
a	B-X
potent	B-X
mechanism	B-X
for	B-X
the	B-X
synergistic	B-X
effects	B-X
of	B-X
H2O2	B-X
plus	B-X
vanadate	B-X

Ionizing	O
radiation	O
generates	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
.	O
<EOS>	B-X
Ionizing	B-X
radiation	B-X
generates	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
(	B-X
ROI	B-X
)	B-X
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
this	B-X
tissue	B-X
injury	B-X
is	B-X
related	B-X
to	B-X
the	B-X
generation	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
(	B-X
ROI	B-X
)	B-X
which	B-X
chemically	B-X
alter	B-X
biological	B-X
molecules	B-X
and	B-X
cell	B-X
physiology	B-X
<EOS>	B-X
An	B-X
Immunohistochemical	B-X
Study	B-X
on	B-X
the	B-X
Role	B-X
of	B-X
Oxidative	B-X
and	B-X
Nitrosative	B-X
Stress	B-X
in	B-X
Irradiated	B-X
Skin	B-X
.	B-X
<EOS>	B-X
This	B-X
indicated	B-X
that	B-X
PDT	B-X
-	B-X
induced	B-X
SAPK	B-X
and	B-X
p38	B-X
HOG1	B-X
activation	B-X
may	B-X
be	B-X
partially	B-X
mediated	B-X
by	B-X
ROI	B-X

Because	O
H2O2	O
is	O
a	O
potent	O
ROI	O
generator	O
that	O
readily	O
crosses	O
the	O
plasma	O
membrane	O
,	O
we	O
used	O
H2O2	O
to	O
examine	O
the	O
effects	O
of	O
ROI	O
on	O
signal	O
transduction	O
.	O
<EOS>	B-X
Because	B-X
H2O2	B-X
is	B-X
a	B-X
potent	B-X
ROI	B-X
generator	B-X
that	B-X
readily	B-X
crosses	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
we	B-X
used	B-X
H2O2	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
ROI	B-X
on	B-X
signal	B-X
transduction	B-X
<EOS>	B-X
The	B-X
combined	B-X
inhibition	B-X
of	B-X
phosphatases	B-X
and	B-X
activation	B-X
of	B-X
kinases	B-X
provides	B-X
a	B-X
potent	B-X
mechanism	B-X
for	B-X
the	B-X
synergistic	B-X
effects	B-X
of	B-X
H2O2	B-X
plus	B-X
vanadate	B-X
<EOS>	B-X
Reactive	B-X
oxygen	B-X
intermediates	B-X
activate	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
a	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
mechanism	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
vanadate	B-X
activate	B-X
the	B-X
p56lck	B-X
and	B-X
p59fyn	B-X
tyrosine	B-X
kinases	B-X
in	B-X
human	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
now	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
herbimycin	B-X
A	B-X
and	B-X
the	B-X
free	B-X
radical	B-X
scavenger	B-X
N	B-X
-	B-X
acetyl	B-X
-	B-X
cysteine	B-X
inhibit	B-X
both	B-X
radiation	B-X
-	B-X
induced	B-X
and	B-X
H2O2	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
indicating	B-X
that	B-X
activation	B-X
triggered	B-X
by	B-X
ROI	B-X
is	B-X
dependent	B-X
on	B-X
tyrosine	B-X
kinase	B-X
activity	B-X

We	O
now	O
provide	O
evidence	O
that	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
A	O
and	O
the	O
free	O
radical	O
scavenger	O
N-acetyl-cysteine	O
inhibit	O
both	O
radiation-induced	O
and	O
H2O2-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
indicating	O
that	O
activation	O
triggered	O
by	O
ROI	O
is	O
dependent	O
on	O
tyrosine	O
kinase	O
activity	O
.	O
<EOS>	B-X
We	B-X
now	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
herbimycin	B-X
A	B-X
and	B-X
the	B-X
free	B-X
radical	B-X
scavenger	B-X
N	B-X
-	B-X
acetyl	B-X
-	B-X
cysteine	B-X
inhibit	B-X
both	B-X
radiation	B-X
-	B-X
induced	B-X
and	B-X
H2O2	B-X
-	B-X
induced	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
,	B-X
indicating	B-X
that	B-X
activation	B-X
triggered	B-X
by	B-X
ROI	B-X
is	B-X
dependent	B-X
on	B-X
tyrosine	B-X
kinase	B-X
activity	B-X
<EOS>	B-X
Although	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
H2O2	B-X
alone	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
src	B-X
family	B-X
kinases	B-X
,	B-X
treatment	B-X
with	B-X
H2O2	B-X
plus	B-X
vanadate	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
p56lck	B-X
and	B-X
p59fyn	B-X
tyrosine	B-X
kinases	B-X
<EOS>	B-X
Reactive	B-X
oxygen	B-X
intermediates	B-X
activate	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
a	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
mechanism	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
vanadate	B-X
activate	B-X
the	B-X
p56lck	B-X
and	B-X
p59fyn	B-X
tyrosine	B-X
kinases	B-X
in	B-X
human	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
observed	B-X
that	B-X
ionizing	B-X
radiation	B-X
induces	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
human	B-X
B	B-X
-	B-X
lymphocyte	B-X
precursors	B-X
by	B-X
stimulation	B-X
of	B-X
unidentified	B-X
tyrosine	B-X
kinases	B-X
and	B-X
this	B-X
phosphorylation	B-X
is	B-X
substantially	B-X
augmented	B-X
by	B-X
vanadate	B-X

H2O2	O
was	O
found	O
to	O
stimulate	O
Ins-1	B-protein
,	I-protein
4	I-protein
,	I-protein
5-P3	I-protein
production	O
in	O
a	O
tyrosine	O
kinase-dependent	O
manner	O
and	O
to	O
induce	O
calcium	O
signals	O
that	O
were	O
greatly	O
augmented	O
by	O
vanadate	O
.	O

The	O
synergistic	O
induction	O
of	O
tyrosine	O
phosphorylation	O
by	O
H2O2	O
plus	O
vanadate	O
included	O
physiologically	O
relevant	O
proteins	O
such	O
as	O
PLC	B-protein
gamma	I-protein
1	I-protein
.	O
<EOS>	B-X
The	B-X
synergistic	B-X
induction	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
by	B-X
H2O2	B-X
plus	B-X
vanadate	B-X
included	B-X
physiologically	B-X
relevant	B-X
proteins	B-X
such	B-X
as	B-X
PLC	B-X
gamma	B-X
1	B-X
<EOS>	B-X
Induction	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
by	B-X
ROI	B-X
may	B-X
thus	B-X
lead	B-X
to	B-X
many	B-X
of	B-X
the	B-X
pleiotropic	B-X
effects	B-X
of	B-X
ROI	B-X
in	B-X
lymphoid	B-X
cells	B-X
,	B-X
including	B-X
downstream	B-X
activation	B-X
of	B-X
PLC	B-X
gamma	B-X
1	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
observed	B-X
that	B-X
ionizing	B-X
radiation	B-X
induces	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
human	B-X
B	B-X
-	B-X
lymphocyte	B-X
precursors	B-X
by	B-X
stimulation	B-X
of	B-X
unidentified	B-X
tyrosine	B-X
kinases	B-X
and	B-X
this	B-X
phosphorylation	B-X
is	B-X
substantially	B-X
augmented	B-X
by	B-X
vanadate	B-X
<EOS>	B-X
Reactive	B-X
oxygen	B-X
intermediates	B-X
activate	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
in	B-X
a	B-X
tyrosine	B-X
kinase	B-X
-	B-X
dependent	B-X
mechanism	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
vanadate	B-X
activate	B-X
the	B-X
p56lck	B-X
and	B-X
p59fyn	B-X
tyrosine	B-X
kinases	B-X
in	B-X
human	B-X
lymphocytes	B-X
.	B-X

Although	O
treatment	O
of	O
cells	O
with	O
H2O2	O
alone	O
did	O
not	O
affect	O
the	O
activity	O
of	O
src	B-protein
family	I-protein
kinases	I-protein
,	O
treatment	O
with	O
H2O2	O
plus	O
vanadate	O
led	O
to	O
activation	O
of	O
the	O
p56lck	B-protein
and	I-protein
p59fyn	I-protein
tyrosine	I-protein
kinases	I-protein
.	O
<EOS>	B-X
At	B-X
the	B-X
4	B-X
-	B-X
leaf	B-X
stage	B-X
,	B-X
they	B-X
were	B-X
applied	B-X
with	B-X
the	B-X
treatments	B-X
of	B-X
cadmium	B-X
nitrate	B-X
at	B-X
three	B-X
levels	B-X
(	B-X
0	B-X
,	B-X
50	B-X
,	B-X
and	B-X
100	B-X
mg	B-X
/	B-X
L	B-X
)	B-X
,	B-X
EDTA	B-X
and	B-X
MA	B-X
at	B-X
two	B-X
levels	B-X
(	B-X
0	B-X
<EOS>	B-X
Oxidative	B-X
stress	B-X
is	B-X
one	B-X
of	B-X
the	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
several	B-X
neurodegenerative	B-X
diseases	B-X
<EOS>	B-X
Although	B-X
these	B-X
combination	B-X
therapy	B-X
strategies	B-X
are	B-X
more	B-X
effective	B-X
in	B-X
cancer	B-X
therapy	B-X
,	B-X
the	B-X
toxicity	B-X
side	B-X
effects	B-X
to	B-X
the	B-X
liver	B-X
and	B-X
cause	B-X
metabolic	B-X
acidosis	B-X
still	B-X
exist	B-X
<EOS>	B-X
Interestingly	B-X
,	B-X
10	B-X
μg	B-X
/	B-X
mL	B-X
MMC	B-X
alone	B-X
caused	B-X
similar	B-X
tail	B-X
intensity	B-X
and	B-X
tail	B-X
moment	B-X
values	B-X
with	B-X
RSV	B-X
alone	B-X

The	O
combined	O
inhibition	O
of	O
phosphatases	B-protein
and	O
activation	O
of	O
kinases	B-protein
provides	O
a	O
potent	O
mechanism	O
for	O
the	O
synergistic	O
effects	O
of	O
H2O2	O
plus	O
vanadate	O
.	O
<EOS>	B-X
The	B-X
combined	B-X
inhibition	B-X
of	B-X
phosphatases	B-X
and	B-X
activation	B-X
of	B-X
kinases	B-X
provides	B-X
a	B-X
potent	B-X
mechanism	B-X
for	B-X
the	B-X
synergistic	B-X
effects	B-X
of	B-X
H2O2	B-X
plus	B-X
vanadate	B-X
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
observed	B-X
that	B-X
ionizing	B-X
radiation	B-X
induces	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
human	B-X
B	B-X
-	B-X
lymphocyte	B-X
precursors	B-X
by	B-X
stimulation	B-X
of	B-X
unidentified	B-X
tyrosine	B-X
kinases	B-X
and	B-X
this	B-X
phosphorylation	B-X
is	B-X
substantially	B-X
augmented	B-X
by	B-X
vanadate	B-X
<EOS>	B-X
Because	B-X
H2O2	B-X
is	B-X
a	B-X
potent	B-X
ROI	B-X
generator	B-X
that	B-X
readily	B-X
crosses	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
we	B-X
used	B-X
H2O2	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
ROI	B-X
on	B-X
signal	B-X
transduction	B-X
<EOS>	B-X
Although	B-X
treatment	B-X
of	B-X
cells	B-X
with	B-X
H2O2	B-X
alone	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
src	B-X
family	B-X
kinases	B-X
,	B-X
treatment	B-X
with	B-X
H2O2	B-X
plus	B-X
vanadate	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
p56lck	B-X
and	B-X
p59fyn	B-X
tyrosine	B-X
kinases	B-X

Induction	O
of	O
tyrosine	O
phosphorylation	O
by	O
ROI	O
may	O
thus	O
lead	O
to	O
many	O
of	O
the	O
pleiotropic	O
effects	O
of	O
ROI	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
including	O
downstream	O
activation	O
of	O
PLC	B-protein
gamma	I-protein
1	I-protein
and	O
NF-kappa	B-protein
B	I-protein

Influence	O
of	O
sex	B-protein
hormone	I-protein
binding	I-protein
globulin	I-protein
and	O
serum	B-protein
albumin	I-protein
on	O
the	O
conversion	O
of	O
androstenedione	O
to	O
testosterone	O
by	O
human	B-cell_type
erythrocytes	I-cell_type
.	O
<EOS>	B-X
Influence	B-X
of	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
and	B-X
serum	B-X
albumin	B-X
on	B-X
the	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
by	B-X
human	B-X
erythrocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
influence	B-X
of	B-X
human	B-X
serum	B-X
albumin	B-X
and	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
(	B-X
SHBG	B-X
)	B-X
on	B-X
the	B-X
enzymic	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
in	B-X
human	B-X
erythrocytes	B-X
was	B-X
investigated	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Total	B-X
plasma	B-X
and	B-X
albumin	B-X
delayed	B-X
the	B-X
conversion	B-X
rate	B-X
of	B-X
androstenedione	B-X
,	B-X
while	B-X
SHBG	B-X
increased	B-X
it	B-X
markedly	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
both	B-X
proteins	B-X
was	B-X
found	B-X
to	B-X
be	B-X
related	B-X
to	B-X
their	B-X
concentration	B-X

The	O
influence	O
of	O
human	B-protein
serum	I-protein
albumin	I-protein
and	O
sex	B-protein
hormone	I-protein
binding	I-protein
globulin	I-protein
(	O
SHBG	B-protein
)	O
on	O
the	O
enzymic	O
conversion	O
of	O
androstenedione	O
to	O
testosterone	O
in	O
human	B-cell_type
erythrocytes	I-cell_type
was	O
investigated	O
in	O
vitro	O
.	O
<EOS>	B-X
The	B-X
influence	B-X
of	B-X
human	B-X
serum	B-X
albumin	B-X
and	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
(	B-X
SHBG	B-X
)	B-X
on	B-X
the	B-X
enzymic	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
in	B-X
human	B-X
erythrocytes	B-X
was	B-X
investigated	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Influence	B-X
of	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
and	B-X
serum	B-X
albumin	B-X
on	B-X
the	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
by	B-X
human	B-X
erythrocytes	B-X
.	B-X
<EOS>	B-X
Total	B-X
plasma	B-X
and	B-X
albumin	B-X
delayed	B-X
the	B-X
conversion	B-X
rate	B-X
of	B-X
androstenedione	B-X
,	B-X
while	B-X
SHBG	B-X
increased	B-X
it	B-X
markedly	B-X
<EOS>	B-X
It	B-X
appears	B-X
that	B-X
the	B-X
binding	B-X
sites	B-X
of	B-X
albumin	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
retarding	B-X
androstenedione	B-X
uptake	B-X
by	B-X
the	B-X
erythrocytes	B-X
and	B-X
that	B-X
the	B-X
high	B-X
binding	B-X
affinity	B-X
of	B-X
SHBG	B-X
for	B-X
testosterone	B-X
facilitates	B-X
the	B-X
diffusion	B-X
of	B-X
this	B-X
steroid	B-X
out	B-X
of	B-X
the	B-X
cell	B-X
and	B-X
thus	B-X
,	B-X
displaces	B-X
the	B-X
chemical	B-X
equilibrium	B-X
within	B-X
the	B-X
cell	B-X

Total	O
plasma	O
and	O
albumin	B-protein
delayed	O
the	O
conversion	O
rate	O
of	O
androstenedione	O
,	O
while	O
SHBG	B-protein
increased	O
it	O
markedly	O
.	O
<EOS>	B-X
Total	B-X
plasma	B-X
and	B-X
albumin	B-X
delayed	B-X
the	B-X
conversion	B-X
rate	B-X
of	B-X
androstenedione	B-X
,	B-X
while	B-X
SHBG	B-X
increased	B-X
it	B-X
markedly	B-X
<EOS>	B-X
Influence	B-X
of	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
and	B-X
serum	B-X
albumin	B-X
on	B-X
the	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
by	B-X
human	B-X
erythrocytes	B-X
.	B-X
<EOS>	B-X
The	B-X
influence	B-X
of	B-X
human	B-X
serum	B-X
albumin	B-X
and	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
(	B-X
SHBG	B-X
)	B-X
on	B-X
the	B-X
enzymic	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
in	B-X
human	B-X
erythrocytes	B-X
was	B-X
investigated	B-X
in	B-X
vitro	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
both	B-X
proteins	B-X
was	B-X
found	B-X
to	B-X
be	B-X
related	B-X
to	B-X
their	B-X
concentration	B-X

The	O
effect	O
of	O
SHBG	B-protein
was	O
largely	O
abolished	O
by	O
heating	O
to	O
60	O
degrees	O
C	O
for	O
1	O
h	O
and	O
by	O
saturating	O
its	O
binding	O
sites	O
by	O
DHT	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
SHBG	B-X
was	B-X
largely	B-X
abolished	B-X
by	B-X
heating	B-X
to	B-X
60	B-X
degrees	B-X
C	B-X
for	B-X
1	B-X
h	B-X
and	B-X
by	B-X
saturating	B-X
its	B-X
binding	B-X
sites	B-X
by	B-X
DHT	B-X
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
both	B-X
proteins	B-X
was	B-X
found	B-X
to	B-X
be	B-X
related	B-X
to	B-X
their	B-X
concentration	B-X
<EOS>	B-X
The	B-X
influence	B-X
of	B-X
human	B-X
serum	B-X
albumin	B-X
and	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
(	B-X
SHBG	B-X
)	B-X
on	B-X
the	B-X
enzymic	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
in	B-X
human	B-X
erythrocytes	B-X
was	B-X
investigated	B-X
in	B-X
vitro	B-X
<EOS>	B-X
It	B-X
appears	B-X
that	B-X
the	B-X
binding	B-X
sites	B-X
of	B-X
albumin	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
retarding	B-X
androstenedione	B-X
uptake	B-X
by	B-X
the	B-X
erythrocytes	B-X
and	B-X
that	B-X
the	B-X
high	B-X
binding	B-X
affinity	B-X
of	B-X
SHBG	B-X
for	B-X
testosterone	B-X
facilitates	B-X
the	B-X
diffusion	B-X
of	B-X
this	B-X
steroid	B-X
out	B-X
of	B-X
the	B-X
cell	B-X
and	B-X
thus	B-X
,	B-X
displaces	B-X
the	B-X
chemical	B-X
equilibrium	B-X
within	B-X
the	B-X
cell	B-X

The	O
effect	O
of	O
both	O
proteins	O
was	O
found	O
to	O
be	O
related	O
to	O
their	O
concentration	O
.	O
<EOS>	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
these	B-X
proteins	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
in	B-X
the	B-X
HSR	B-X
group	B-X
after	B-X
CQ	B-X
+	B-X
DEX	B-X
administration	B-X
<EOS>	B-X
No	B-X
significant	B-X
toxicity	B-X
of	B-X
kaempferol	B-X
was	B-X
found	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
normal	B-X
cell	B-X
lines	B-X
at	B-X
non	B-X
-	B-X
cytotoxic	B-X
concentrations	B-X
<EOS>	B-X
The	B-X
remaining	B-X
peptides	B-X
with	B-X
carboxy	B-X
-	B-X
terminal	B-X
D	B-X
-	B-X
amino	B-X
acids	B-X
are	B-X
then	B-X
more	B-X
easily	B-X
concentrated	B-X
and	B-X
identified	B-X
<EOS>	B-X
Higher	B-X
levels	B-X
of	B-X
C	B-X
-	B-X
reactive	B-X
protein	B-X
(	B-X
CRP	B-X
)	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
steers	B-X
from	B-X
both	B-X
groups	B-X
that	B-X
consumed	B-X
pepper	B-X
(	B-X
P	B-X
<	B-X
0	B-X

It	O
appears	O
that	O
the	O
binding	O
sites	O
of	O
albumin	B-protein
provide	O
a	O
mechanism	O
for	O
retarding	O
androstenedione	O
uptake	O
by	O
the	O
erythrocytes	B-cell_type
and	O
that	O
the	O
high	O
binding	O
affinity	O
of	O
SHBG	B-protein
for	O
testosterone	O
facilitates	O
the	O
diffusion	O
of	O
this	O
steroid	O
out	O
of	O
the	O
cell	O
and	O
thus	O
,	O
displaces	O
the	O
chemical	O
equilibrium	O
within	O
the	O
cell	O
.	O
<EOS>	B-X
It	B-X
appears	B-X
that	B-X
the	B-X
binding	B-X
sites	B-X
of	B-X
albumin	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
retarding	B-X
androstenedione	B-X
uptake	B-X
by	B-X
the	B-X
erythrocytes	B-X
and	B-X
that	B-X
the	B-X
high	B-X
binding	B-X
affinity	B-X
of	B-X
SHBG	B-X
for	B-X
testosterone	B-X
facilitates	B-X
the	B-X
diffusion	B-X
of	B-X
this	B-X
steroid	B-X
out	B-X
of	B-X
the	B-X
cell	B-X
and	B-X
thus	B-X
,	B-X
displaces	B-X
the	B-X
chemical	B-X
equilibrium	B-X
within	B-X
the	B-X
cell	B-X
<EOS>	B-X
The	B-X
influence	B-X
of	B-X
human	B-X
serum	B-X
albumin	B-X
and	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
(	B-X
SHBG	B-X
)	B-X
on	B-X
the	B-X
enzymic	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
in	B-X
human	B-X
erythrocytes	B-X
was	B-X
investigated	B-X
in	B-X
vitro	B-X
<EOS>	B-X
Influence	B-X
of	B-X
sex	B-X
hormone	B-X
binding	B-X
globulin	B-X
and	B-X
serum	B-X
albumin	B-X
on	B-X
the	B-X
conversion	B-X
of	B-X
androstenedione	B-X
to	B-X
testosterone	B-X
by	B-X
human	B-X
erythrocytes	B-X
.	B-X
<EOS>	B-X
Total	B-X
plasma	B-X
and	B-X
albumin	B-X
delayed	B-X
the	B-X
conversion	B-X
rate	B-X
of	B-X
androstenedione	B-X
,	B-X
while	B-X
SHBG	B-X
increased	B-X
it	B-X
markedly	B-X

I	O
.	O

Increased	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
antigen-stimulated	B-cell_line
lymphocytes	I-cell_line
.	O
<EOS>	B-X
Glucocorticoids	B-X
and	B-X
lymphocytes	B-X
.	B-X
I	B-X
.	B-X
Increased	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
in	B-X
antigen	B-X
-	B-X
stimulated	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Recently	B-X
a	B-X
2	B-X
-	B-X
	B-X
to	B-X
3	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
has	B-X
been	B-X
noted	B-X
after	B-X
in	B-X
vitro	B-X
mitogen	B-X
stimulation	B-X
<EOS>	B-X
Clinically	B-X
,	B-X
GCs	B-X
are	B-X
used	B-X
for	B-X
allergies	B-X
,	B-X
autoimmunity	B-X
,	B-X
and	B-X
chronic	B-X
inflammation	B-X
,	B-X
because	B-X
they	B-X
have	B-X
strong	B-X
anti	B-X
-	B-X
inflammatory	B-X
effects	B-X
and	B-X
induce	B-X
the	B-X
apoptosis	B-X
of	B-X
lymphocytes	B-X
<EOS>	B-X
GC	B-X
secretion	B-X
is	B-X
induced	B-X
by	B-X
circadian	B-X
rhythm	B-X
and	B-X
stress	B-X
,	B-X
and	B-X
plasma	B-X
GC	B-X
levels	B-X
are	B-X
high	B-X
at	B-X
the	B-X
active	B-X
phase	B-X
of	B-X
animals	B-X
and	B-X
under	B-X
stress	B-X
condition	B-X

Recently	O
a	O
2-	O
to	O
3-fold	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
has	O
been	O
noted	O
after	O
in	O
vitro	O
mitogen	O
stimulation	O
.	O
<EOS>	B-X
Recently	B-X
a	B-X
2	B-X
-	B-X
	B-X
to	B-X
3	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
has	B-X
been	B-X
noted	B-X
after	B-X
in	B-X
vitro	B-X
mitogen	B-X
stimulation	B-X
<EOS>	B-X
After	B-X
unilateral	B-X
immunization	B-X
of	B-X
adrenalectomized	B-X
male	B-X
rats	B-X
,	B-X
a	B-X
50	B-X
%	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
determined	B-X
by	B-X
binding	B-X
of	B-X
dexamethasone	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
cell	B-X
suspensions	B-X
of	B-X
homolateral	B-X
lymph	B-X
nodes	B-X
over	B-X
those	B-X
from	B-X
the	B-X
contralateral	B-X
nonimmunized	B-X
side	B-X
of	B-X
the	B-X
same	B-X
animal	B-X
<EOS>	B-X
Glucocorticoids	B-X
and	B-X
lymphocytes	B-X
.	B-X
I	B-X
.	B-X
Increased	B-X
glucocorticoid	B-X
receptor	B-X
levels	B-X
in	B-X
antigen	B-X
-	B-X
stimulated	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Despite	B-X
a	B-X
50	B-X
%	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
the	B-X
cells	B-X
from	B-X
the	B-X
homolateral	B-X
and	B-X
controlateral	B-X
lymph	B-X
nodes	B-X
were	B-X
equally	B-X
sensitive	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
dexamethasone	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
measurements	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
radiolabeled	B-X
precursors	B-X
of	B-X
protein	B-X
,	B-X
RNA	B-X
,	B-X
and	B-X
DNA	B-X
,	B-X
or	B-X
measurements	B-X
of	B-X
in	B-X
vitro	B-X
cell	B-X
survival	B-X

Here	O
,	O
we	O
extend	O
these	O
observations	O
to	O
in	O
vivo	O
immunization	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
define	B-X
target	B-X
organ	B-X
expression	B-X
and	B-X
biomarker	B-X
characteristics	B-X
of	B-X
CCL21	B-X
<EOS>	B-X
Antitumor	B-X
impact	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
mouse	B-X
models	B-X
of	B-X
ovarian	B-X
and	B-X
pancreatic	B-X
cancer	B-X
<EOS>	B-X
CAR	B-X
-	B-X
T	B-X
cells	B-X
effectively	B-X
killed	B-X
macrophages	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
without	B-X
toxicity	B-X
<EOS>	B-X
In	B-X
patients	B-X
with	B-X
diverse	B-X
malignancies	B-X
,	B-X
we	B-X
observed	B-X
NeoAg	B-X
clonal	B-X
conservation	B-X
and	B-X
spontaneous	B-X
immunogenicity	B-X
to	B-X
the	B-X
neoepitope	B-X

After	O
unilateral	O
immunization	O
of	O
adrenalectomized	O
male	O
rats	O
,	O
a	O
50	O
%	O
increase	O
in	O
glucocorticoid	O
receptor	O
sites	O
per	O
cell	O
,	O
determined	O
by	O
binding	O
of	O
dexamethasone	O
,	O
was	O
observed	O
in	O
cell	O
suspensions	O
of	O
homolateral	O
lymph	O
nodes	O
over	O
those	O
from	O
the	O
contralateral	O
nonimmunized	O
side	O
of	O
the	O
same	O
animal	O
.	O
<EOS>	B-X
After	B-X
unilateral	B-X
immunization	B-X
of	B-X
adrenalectomized	B-X
male	B-X
rats	B-X
,	B-X
a	B-X
50	B-X
%	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
determined	B-X
by	B-X
binding	B-X
of	B-X
dexamethasone	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
cell	B-X
suspensions	B-X
of	B-X
homolateral	B-X
lymph	B-X
nodes	B-X
over	B-X
those	B-X
from	B-X
the	B-X
contralateral	B-X
nonimmunized	B-X
side	B-X
of	B-X
the	B-X
same	B-X
animal	B-X
<EOS>	B-X
Recently	B-X
a	B-X
2	B-X
-	B-X
	B-X
to	B-X
3	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
has	B-X
been	B-X
noted	B-X
after	B-X
in	B-X
vitro	B-X
mitogen	B-X
stimulation	B-X
<EOS>	B-X
Despite	B-X
a	B-X
50	B-X
%	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
the	B-X
cells	B-X
from	B-X
the	B-X
homolateral	B-X
and	B-X
controlateral	B-X
lymph	B-X
nodes	B-X
were	B-X
equally	B-X
sensitive	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
dexamethasone	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
measurements	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
radiolabeled	B-X
precursors	B-X
of	B-X
protein	B-X
,	B-X
RNA	B-X
,	B-X
and	B-X
DNA	B-X
,	B-X
or	B-X
measurements	B-X
of	B-X
in	B-X
vitro	B-X
cell	B-X
survival	B-X
<EOS>	B-X
The	B-X
association	B-X
constant	B-X
for	B-X
dexamethasone	B-X
was	B-X
similar	B-X
in	B-X
both	B-X
groups	B-X
,	B-X
as	B-X
was	B-X
the	B-X
stereospecificity	B-X
for	B-X
various	B-X
steroids	B-X
,	B-X
the	B-X
time	B-X
course	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
association	B-X
,	B-X
and	B-X
cytoplasmic	B-X
-	B-X
to	B-X
-	B-X
nuclear	B-X
translocation	B-X

The	O
association	O
constant	O
for	O
dexamethasone	O
was	O
similar	O
in	O
both	O
groups	O
,	O
as	O
was	O
the	O
stereospecificity	O
for	O
various	O
steroids	O
,	O
the	O
time	O
course	O
of	O
cytoplasmic	O
and	O
nuclear	O
association	O
,	O
and	O
cytoplasmic-to-nuclear	O
translocation	O
.	O
<EOS>	B-X
The	B-X
association	B-X
constant	B-X
for	B-X
dexamethasone	B-X
was	B-X
similar	B-X
in	B-X
both	B-X
groups	B-X
,	B-X
as	B-X
was	B-X
the	B-X
stereospecificity	B-X
for	B-X
various	B-X
steroids	B-X
,	B-X
the	B-X
time	B-X
course	B-X
of	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
association	B-X
,	B-X
and	B-X
cytoplasmic	B-X
-	B-X
to	B-X
-	B-X
nuclear	B-X
translocation	B-X
<EOS>	B-X
Despite	B-X
a	B-X
50	B-X
%	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
the	B-X
cells	B-X
from	B-X
the	B-X
homolateral	B-X
and	B-X
controlateral	B-X
lymph	B-X
nodes	B-X
were	B-X
equally	B-X
sensitive	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
dexamethasone	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
measurements	B-X
of	B-X
the	B-X
incorporation	B-X
of	B-X
radiolabeled	B-X
precursors	B-X
of	B-X
protein	B-X
,	B-X
RNA	B-X
,	B-X
and	B-X
DNA	B-X
,	B-X
or	B-X
measurements	B-X
of	B-X
in	B-X
vitro	B-X
cell	B-X
survival	B-X
<EOS>	B-X
Recently	B-X
a	B-X
2	B-X
-	B-X
	B-X
to	B-X
3	B-X
-	B-X
fold	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
has	B-X
been	B-X
noted	B-X
after	B-X
in	B-X
vitro	B-X
mitogen	B-X
stimulation	B-X
<EOS>	B-X
After	B-X
unilateral	B-X
immunization	B-X
of	B-X
adrenalectomized	B-X
male	B-X
rats	B-X
,	B-X
a	B-X
50	B-X
%	B-X
increase	B-X
in	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
,	B-X
determined	B-X
by	B-X
binding	B-X
of	B-X
dexamethasone	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
cell	B-X
suspensions	B-X
of	B-X
homolateral	B-X
lymph	B-X
nodes	B-X
over	B-X
those	B-X
from	B-X
the	B-X
contralateral	B-X
nonimmunized	B-X
side	B-X
of	B-X
the	B-X
same	B-X
animal	B-X

Despite	O
a	O
50	O
%	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	O
receptor	O
sites	O
per	O
cell	O
,	O
the	O
cells	O
from	O
the	O
homolateral	O
and	O
controlateral	O
lymph	O
nodes	O
were	O
equally	O
sensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
dexamethasone	O
,	O
as	O
determined	O
by	O
measurements	O
of	O
the	O
incorporation	O
of	O
radiolabeled	O
precursors	O
of	O
protein	O
,	O
RNA	O
,	O
and	O
DNA	O
,	O
or	O
measurements	O
of	O
in	O
vitro	O
cell	O
survival	O
.	O
<EOS>	B-X
Telomere	B-X
length	B-X
(	B-X
TL	B-X
)	B-X
,	B-X
which	B-X
is	B-X
maintained	B-X
by	B-X
hTERT	B-X
(	B-X
component	B-X
of	B-X
telomerase	B-X
)	B-X
and	B-X
/	B-X
or	B-X
TRF1	B-X
/	B-X
TRF2	B-X
(	B-X
core	B-X
components	B-X
of	B-X
shelterin	B-X
)	B-X
via	B-X
different	B-X
mechanisms	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
chromosomal	B-X
stability	B-X
and	B-X
cell	B-X
survival	B-X
<EOS>	B-X
The	B-X
Rt	B-X
-	B-X
Ga	B-X
complex	B-X
-	B-X
mediated	B-X
anti	B-X
-	B-X
virulence	B-X
and	B-X
antimicrobial	B-X
photodynamic	B-X
effects	B-X
were	B-X
superior	B-X
to	B-X
the	B-X
one	B-X
caused	B-X
by	B-X
rutin	B-X
alone	B-X
making	B-X
the	B-X
Rt	B-X
-	B-X
Ga	B-X
complex	B-X
a	B-X
more	B-X
promising	B-X
photosensitizer	B-X
than	B-X
the	B-X
parent	B-X
material	B-X
<EOS>	B-X
Radiotherapy	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
treatments	B-X
for	B-X
lung	B-X
cancer	B-X
,	B-X
and	B-X
about	B-X
40	B-X
%	B-X
	B-X
-	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
after	B-X
radiotherapy	B-X
will	B-X
appear	B-X
uncontrolled	B-X
or	B-X
recurrence	B-X
in	B-X
the	B-X
case	B-X
of	B-X
local	B-X
tumors	B-X
<EOS>	B-X
The	B-X
survival	B-X
and	B-X
growth	B-X
of	B-X
cells	B-X
were	B-X
measured	B-X
by	B-X
thiazole	B-X
blue	B-X
(	B-X
MTT	B-X
)	B-X
colorimetry	B-X
,	B-X
and	B-X
the	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
invasion	B-X
of	B-X
cells	B-X
were	B-X
detected	B-X
by	B-X
5	B-X
-	B-X
ethynyl	B-X
-	B-X
2'	B-X
-	B-X
deoxyuridine	B-X
(	B-X
EdU	B-X
)	B-X
test	B-X
and	B-X
Transwell	B-X
assay	B-X

Glucocorticoid	O
receptors	O
and	O
actions	O
in	O
rat	B-cell_type
thymocytes	I-cell_type
and	O
immunologically	O
stimulated	O
human	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
actions	B-X
in	B-X
rat	B-X
thymocytes	B-X
and	B-X
immunologically	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
After	B-X
reviewing	B-X
briefly	B-X
our	B-X
earlier	B-X
studies	B-X
on	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
mechanisms	B-X
in	B-X
thymus	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
outlined	B-X
results	B-X
from	B-X
the	B-X
following	B-X
two	B-X
areas	B-X
of	B-X
current	B-X
interest	B-X
in	B-X
our	B-X
laboratories	B-X
:	B-X
the	B-X
``	B-X
life	B-X
-	B-X
cycle	B-X
''	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
complexes	B-X
in	B-X
thymus	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
sensitivity	B-X
in	B-X
immunologically	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
<EOS>	B-X
Several	B-X
of	B-X
our	B-X
results	B-X
on	B-X
energetics	B-X
and	B-X
kinetics	B-X
of	B-X
hormone	B-X
binding	B-X
to	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
rat	B-X
thymus	B-X
cells	B-X
seem	B-X
to	B-X
require	B-X
extension	B-X
of	B-X
the	B-X
simplest	B-X
model	B-X
of	B-X
hormone	B-X
-	B-X
receptor	B-X
transformations	B-X
in	B-X
intact	B-X
cells	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
mitogen	B-X
or	B-X
immunologic	B-X
stimulation	B-X
of	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
in	B-X
culture	B-X
leads	B-X
within	B-X
24	B-X
h	B-X
or	B-X
so	B-X
to	B-X
a	B-X
striking	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X

After	O
reviewing	O
briefly	O
our	O
earlier	O
studies	O
on	O
glucocorticoid	O
receptors	O
and	O
mechanisms	O
in	O
thymus	B-cell_type
cells	I-cell_type
,	O
we	O
have	O
outlined	O
results	O
from	O
the	O
following	O
two	O
areas	O
of	O
current	O
interest	O
in	O
our	O
laboratories	O
:	O
the	O
``	O
life-cycle	O
''	O
of	O
glucocorticoid	O
receptors	O
and	O
complexes	O
in	O
thymus	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
levels	O
of	O
glucocorticoid	O
receptors	O
and	O
sensitivity	O
in	O
immunologically	B-cell_type
stimulated	I-cell_type
human	I-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
After	B-X
reviewing	B-X
briefly	B-X
our	B-X
earlier	B-X
studies	B-X
on	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
mechanisms	B-X
in	B-X
thymus	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
outlined	B-X
results	B-X
from	B-X
the	B-X
following	B-X
two	B-X
areas	B-X
of	B-X
current	B-X
interest	B-X
in	B-X
our	B-X
laboratories	B-X
:	B-X
the	B-X
``	B-X
life	B-X
-	B-X
cycle	B-X
''	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
complexes	B-X
in	B-X
thymus	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
sensitivity	B-X
in	B-X
immunologically	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
<EOS>	B-X
Several	B-X
of	B-X
our	B-X
results	B-X
on	B-X
energetics	B-X
and	B-X
kinetics	B-X
of	B-X
hormone	B-X
binding	B-X
to	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
rat	B-X
thymus	B-X
cells	B-X
seem	B-X
to	B-X
require	B-X
extension	B-X
of	B-X
the	B-X
simplest	B-X
model	B-X
of	B-X
hormone	B-X
-	B-X
receptor	B-X
transformations	B-X
in	B-X
intact	B-X
cells	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
mitogen	B-X
or	B-X
immunologic	B-X
stimulation	B-X
of	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
in	B-X
culture	B-X
leads	B-X
within	B-X
24	B-X
h	B-X
or	B-X
so	B-X
to	B-X
a	B-X
striking	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X
<EOS>	B-X
Glucocorticoid	B-X
receptors	B-X
and	B-X
actions	B-X
in	B-X
rat	B-X
thymocytes	B-X
and	B-X
immunologically	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
.	B-X

Several	O
of	O
our	O
results	O
on	O
energetics	O
and	O
kinetics	O
of	O
hormone	O
binding	O
to	O
glucocorticoid	B-protein
receptors	I-protein
in	O
rat	B-cell_type
thymus	I-cell_type
cells	I-cell_type
seem	O
to	O
require	O
extension	O
of	O
the	O
simplest	O
model	O
of	O
hormone-receptor	O
transformations	O
in	O
intact	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Several	B-X
of	B-X
our	B-X
results	B-X
on	B-X
energetics	B-X
and	B-X
kinetics	B-X
of	B-X
hormone	B-X
binding	B-X
to	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
rat	B-X
thymus	B-X
cells	B-X
seem	B-X
to	B-X
require	B-X
extension	B-X
of	B-X
the	B-X
simplest	B-X
model	B-X
of	B-X
hormone	B-X
-	B-X
receptor	B-X
transformations	B-X
in	B-X
intact	B-X
cells	B-X
<EOS>	B-X
Contrary	B-X
to	B-X
the	B-X
widely	B-X
held	B-X
view	B-X
that	B-X
mitogen	B-X
-	B-X
stimulated	B-X
cells	B-X
become	B-X
insensitive	B-X
to	B-X
glucocorticoids	B-X
,	B-X
our	B-X
experiments	B-X
show	B-X
that	B-X
with	B-X
respect	B-X
to	B-X
inhibition	B-X
of	B-X
thymidine	B-X
and	B-X
uridine	B-X
incorporation	B-X
and	B-X
glucose	B-X
uptake	B-X
,	B-X
the	B-X
cells	B-X
are	B-X
highly	B-X
sensitive	B-X
to	B-X
dexamethasone	B-X
at	B-X
24	B-X
,	B-X
48	B-X
,	B-X
and	B-X
72	B-X
h	B-X
after	B-X
stimulation	B-X
with	B-X
concanavalin	B-X
A	B-X
<EOS>	B-X
After	B-X
reviewing	B-X
briefly	B-X
our	B-X
earlier	B-X
studies	B-X
on	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
mechanisms	B-X
in	B-X
thymus	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
outlined	B-X
results	B-X
from	B-X
the	B-X
following	B-X
two	B-X
areas	B-X
of	B-X
current	B-X
interest	B-X
in	B-X
our	B-X
laboratories	B-X
:	B-X
the	B-X
``	B-X
life	B-X
-	B-X
cycle	B-X
''	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
complexes	B-X
in	B-X
thymus	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
glucocorticoid	B-X
receptors	B-X
and	B-X
sensitivity	B-X
in	B-X
immunologically	B-X
stimulated	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
believe	B-X
this	B-X
increase	B-X
may	B-X
be	B-X
due	B-X
to	B-X
partial	B-X
synchronization	B-X
of	B-X
the	B-X
cell	B-X
population	B-X
in	B-X
a	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
in	B-X
which	B-X
receptor	B-X
content	B-X
is	B-X
high	B-X

ATP-depletion	O
experiments	O
suggest	O
the	O
existence	O
of	O
a	O
nonbinding	O
form	O
of	O
the	O
receptor	O
;	O
``	O
chase	O
''	O
experiments	O
suggest	O
reaction	O
of	O
hormone	O
directly	O
with	O
nuclear-bound	O
receptor	O
;	O
experiments	O
on	O
depletion	O
and	O
replenishment	O
of	O
cytoplasmic	B-protein
receptor	I-protein
using	O
cortisol	O
and	O
dexamethasone	O
suggest	O
the	O
existence	O
of	O
at	O
least	O
two	O
subpopulations	O
of	O
nuclear-bound	B-protein
hormone-receptor	I-protein
complex	I-protein
.	O
<EOS>	B-X
ATP	B-X
-	B-X
depletion	B-X
experiments	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
nonbinding	B-X
form	B-X
of	B-X
the	B-X
receptor	B-X
;	B-X
``	B-X
chase	B-X
''	B-X
experiments	B-X
suggest	B-X
reaction	B-X
of	B-X
hormone	B-X
directly	B-X
with	B-X
nuclear	B-X
-	B-X
bound	B-X
receptor	B-X
;	B-X
experiments	B-X
on	B-X
depletion	B-X
and	B-X
replenishment	B-X
of	B-X
cytoplasmic	B-X
receptor	B-X
using	B-X
cortisol	B-X
and	B-X
dexamethasone	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
at	B-X
least	B-X
two	B-X
subpopulations	B-X
of	B-X
nuclear	B-X
-	B-X
bound	B-X
hormone	B-X
-	B-X
receptor	B-X
complex	B-X
<EOS>	B-X
Several	B-X
of	B-X
our	B-X
results	B-X
on	B-X
energetics	B-X
and	B-X
kinetics	B-X
of	B-X
hormone	B-X
binding	B-X
to	B-X
glucocorticoid	B-X
receptors	B-X
in	B-X
rat	B-X
thymus	B-X
cells	B-X
seem	B-X
to	B-X
require	B-X
extension	B-X
of	B-X
the	B-X
simplest	B-X
model	B-X
of	B-X
hormone	B-X
-	B-X
receptor	B-X
transformations	B-X
in	B-X
intact	B-X
cells	B-X
<EOS>	B-X
Contrary	B-X
to	B-X
the	B-X
widely	B-X
held	B-X
view	B-X
that	B-X
mitogen	B-X
-	B-X
stimulated	B-X
cells	B-X
become	B-X
insensitive	B-X
to	B-X
glucocorticoids	B-X
,	B-X
our	B-X
experiments	B-X
show	B-X
that	B-X
with	B-X
respect	B-X
to	B-X
inhibition	B-X
of	B-X
thymidine	B-X
and	B-X
uridine	B-X
incorporation	B-X
and	B-X
glucose	B-X
uptake	B-X
,	B-X
the	B-X
cells	B-X
are	B-X
highly	B-X
sensitive	B-X
to	B-X
dexamethasone	B-X
at	B-X
24	B-X
,	B-X
48	B-X
,	B-X
and	B-X
72	B-X
h	B-X
after	B-X
stimulation	B-X
with	B-X
concanavalin	B-X
A	B-X
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
mitogen	B-X
or	B-X
immunologic	B-X
stimulation	B-X
of	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
in	B-X
culture	B-X
leads	B-X
within	B-X
24	B-X
h	B-X
or	B-X
so	B-X
to	B-X
a	B-X
striking	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
glucocorticoid	B-X
receptor	B-X
sites	B-X
per	B-X
cell	B-X

We	O
have	O
found	O
that	O
mitogen	O
or	O
immunologic	O
stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
in	O
culture	O
leads	O
within	O
24	O
h	O
or	O
so	O
to	O
a	O
striking	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	O
per	O
cell	O
.	O
<EOS>	B-X
The	B-X
concentration	B-X
of	B-X
glucose	B-X
in	B-X
circulation	B-X
is	B-X
proportional	B-X
to	B-X
the	B-X
secretion	B-X
of	B-X
insulin	B-X
by	B-X
these	B-X
cells	B-X
<EOS>	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
mitogen	B-X
-	B-X
activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
Fus3	B-X
is	B-X
required	B-X
for	B-X
chemotropism	B-X
towards	B-X
nutrients	B-X
,	B-X
while	B-X
the	B-X
G	B-X
protein	B-X
-	B-X
coupled	B-X
receptor	B-X
(	B-X
GPCR	B-X
)	B-X
Ste2	B-X
and	B-X
the	B-X
MAPK	B-X
Slt2	B-X
control	B-X
chemosensing	B-X
of	B-X
plant	B-X
-	B-X
derived	B-X
signals	B-X
and	B-X
α	B-X
-	B-X
pheromone	B-X
<EOS>	B-X
We	B-X
demonstrated	B-X
the	B-X
robust	B-X
photoactivation	B-X
of	B-X
MEK1	B-X
/	B-X
2	B-X
inhibition	B-X
and	B-X
antimelanoma	B-X
activity	B-X
in	B-X
cultured	B-X
human	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
a	B-X
xenograft	B-X
zebrafish	B-X
model	B-X
<EOS>	B-X
Typical	B-X
lesions	B-X
consist	B-X
of	B-X
erythematous	B-X
papules	B-X
and	B-X
pustules	B-X
without	B-X
comedones	B-X
,	B-X
accompanying	B-X
with	B-X
burning	B-X
,	B-X
pruritus	B-X
,	B-X
or	B-X
xerosis	B-X

We	O
believe	O
this	O
increase	O
may	O
be	O
due	O
to	O
partial	O
synchronization	O
of	O
the	O
cell	O
population	O
in	O
a	O
phase	O
of	O
the	O
cell	O
cycle	O
in	O
which	O
receptor	O
content	O
is	O
high	O
.	O

Contrary	O
to	O
the	O
widely	O
held	O
view	O
that	O
mitogen-stimulated	B-cell_type
cells	I-cell_type
become	O
insensitive	O
to	O
glucocorticoids	O
,	O
our	O
experiments	O
show	O
that	O
with	O
respect	O
to	O
inhibition	O
of	O
thymidine	O
and	O
uridine	O
incorporation	O
and	O
glucose	O
uptake	O
,	O
the	O
cells	O
are	O
highly	O
sensitive	O
to	O
dexamethasone	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
after	O
stimulation	O
with	O
concanavalin	B-protein
A	I-protein
.	O

Nuclear	O
glucocorticoid	O
binding	O
in	O
chronic	B-cell_type
lymphatic	I-cell_type
leukemia	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Nuclear	B-X
glucocorticoid	B-X
binding	B-X
in	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Drug	B-X
resistance	B-X
mechanisms	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
PPARα	B-X
and	B-X
fatty	B-X
acid	B-X
oxidation	B-X
mediate	B-X
glucocorticoid	B-X
resistance	B-X
in	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
.	B-X
<EOS>	B-X
DNA	B-X
-	B-X
Dependent	B-X
protein	B-X
kinase	B-X
activity	B-X
correlates	B-X
with	B-X
clinical	B-X
and	B-X
in	B-X
vitro	B-X
sensitivity	B-X
of	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
lymphocytes	B-X
to	B-X
nitrogen	B-X
mustards	B-X
.	B-X

A	O
reliable	O
procedure	O
is	O
described	O
for	O
isolating	O
3H-triamcinolone	B-protein
acetonide	I-protein
(	I-protein
3H-TA	I-protein
)	I-protein
receptor	I-protein
complexes	I-protein
from	O
purified	O
chronic	O
lymphatic	B-cell_type
leukemia	I-cell_type
(	I-cell_type
CLL	I-cell_type
)	I-cell_type
lymphocyte	I-cell_type
nuclei	O
,	O
based	O
on	O
the	O
use	O
of	O
carbobenzoxy-L-phenylalanine	O
(	O
CBZ-L-phe	O
)	O
to	O
prevent	O
breakdown	O
of	O
hormone-receptor	B-protein
complexes	I-protein
during	O
extraction	O
of	O
nuclei	O
with	O
0.6M	O
KCl	O
.	O
<EOS>	B-X
A	B-X
reliable	B-X
procedure	B-X
is	B-X
described	B-X
for	B-X
isolating	B-X
3H	B-X
-	B-X
triamcinolone	B-X
acetonide	B-X
(	B-X
3H	B-X
-	B-X
TA	B-X
)	B-X
receptor	B-X
complexes	B-X
from	B-X
purified	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
lymphocyte	B-X
nuclei	B-X
,	B-X
based	B-X
on	B-X
the	B-X
use	B-X
of	B-X
carbobenzoxy	B-X
-	B-X
L	B-X
-	B-X
phenylalanine	B-X
(	B-X
CBZ	B-X
-	B-X
L	B-X
-	B-X
phe	B-X
)	B-X
to	B-X
prevent	B-X
breakdown	B-X
of	B-X
hormone	B-X
-	B-X
receptor	B-X
complexes	B-X
during	B-X
extraction	B-X
of	B-X
nuclei	B-X
with	B-X
0	B-X
<EOS>	B-X
No	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
levels	B-X
of	B-X
nuclear	B-X
-	B-X
associated	B-X
3H	B-X
-	B-X
TA	B-X
and	B-X
peripheral	B-X
white	B-X
blood	B-X
cell	B-X
count	B-X
or	B-X
rosetting	B-X
ability	B-X
of	B-X
circulating	B-X
lymphocytes	B-X
<EOS>	B-X
Using	B-X
this	B-X
method	B-X
,	B-X
specific	B-X
nuclear	B-X
glucocorticoid	B-X
binding	B-X
was	B-X
demonstrated	B-X
in	B-X
14	B-X
/	B-X
14	B-X
patients	B-X
with	B-X
untreated	B-X
CLL	B-X
<EOS>	B-X
Nuclear	B-X
glucocorticoid	B-X
binding	B-X
in	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
lymphocytes	B-X
.	B-X

Using	O
this	O
method	O
,	O
specific	O
nuclear	O
glucocorticoid	O
binding	O
was	O
demonstrated	O
in	O
14/14	O
patients	O
with	O
untreated	O
CLL	O
.	O
<EOS>	B-X
Using	B-X
this	B-X
method	B-X
,	B-X
specific	B-X
nuclear	B-X
glucocorticoid	B-X
binding	B-X
was	B-X
demonstrated	B-X
in	B-X
14	B-X
/	B-X
14	B-X
patients	B-X
with	B-X
untreated	B-X
CLL	B-X
<EOS>	B-X
Nuclear	B-X
glucocorticoid	B-X
binding	B-X
in	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
No	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
levels	B-X
of	B-X
nuclear	B-X
-	B-X
associated	B-X
3H	B-X
-	B-X
TA	B-X
and	B-X
peripheral	B-X
white	B-X
blood	B-X
cell	B-X
count	B-X
or	B-X
rosetting	B-X
ability	B-X
of	B-X
circulating	B-X
lymphocytes	B-X
<EOS>	B-X
A	B-X
reliable	B-X
procedure	B-X
is	B-X
described	B-X
for	B-X
isolating	B-X
3H	B-X
-	B-X
triamcinolone	B-X
acetonide	B-X
(	B-X
3H	B-X
-	B-X
TA	B-X
)	B-X
receptor	B-X
complexes	B-X
from	B-X
purified	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
lymphocyte	B-X
nuclei	B-X
,	B-X
based	B-X
on	B-X
the	B-X
use	B-X
of	B-X
carbobenzoxy	B-X
-	B-X
L	B-X
-	B-X
phenylalanine	B-X
(	B-X
CBZ	B-X
-	B-X
L	B-X
-	B-X
phe	B-X
)	B-X
to	B-X
prevent	B-X
breakdown	B-X
of	B-X
hormone	B-X
-	B-X
receptor	B-X
complexes	B-X
during	B-X
extraction	B-X
of	B-X
nuclei	B-X
with	B-X
0	B-X

No	O
correlation	O
was	O
found	O
between	O
levels	O
of	O
nuclear-associated	O
3H-TA	O
and	O
peripheral	O
white	O
blood	O
cell	O
count	O
or	O
rosetting	O
ability	O
of	O
circulating	B-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
No	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
levels	B-X
of	B-X
nuclear	B-X
-	B-X
associated	B-X
3H	B-X
-	B-X
TA	B-X
and	B-X
peripheral	B-X
white	B-X
blood	B-X
cell	B-X
count	B-X
or	B-X
rosetting	B-X
ability	B-X
of	B-X
circulating	B-X
lymphocytes	B-X
<EOS>	B-X
Mechanisms	B-X
of	B-X
cell	B-X
-	B-X
mediated	B-X
myocytotoxicity	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
patients	B-X
with	B-X
inflammatory	B-X
myopathies	B-X
.	B-X
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
the	B-X
inhibitory	B-X
substance	B-X
in	B-X
serum	B-X
correlated	B-X
with	B-X
depressed	B-X
levels	B-X
of	B-X
circulating	B-X
mean	B-X
percentage	B-X
E	B-X
-	B-X
rosetting	B-X
lymphocytes	B-X
<EOS>	B-X
We	B-X
determined	B-X
whether	B-X
lymphocytes	B-X
circulating	B-X
in	B-X
patient	B-X
peripheral	B-X
blood	B-X
contain	B-X
automyocytotoxic	B-X
precursors	B-X

Multiple	O
closely-linked	O
NFAT/octamer	B-DNA
and	O
HMG	B-DNA
I	I-DNA
(	I-DNA
Y	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
are	O
part	O
of	O
the	O
interleukin-4	O
promoter	O
.	O
<EOS>	B-X
Multiple	B-X
closely	B-X
-	B-X
linked	B-X
NFAT	B-X
/	B-X
octamer	B-X
and	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X
binding	B-X
sites	B-X
are	B-X
part	B-X
of	B-X
the	B-X
interleukin	B-X
-	B-X
4	B-X
promoter	B-X
.	B-X
<EOS>	B-X
Three	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
NFAT	B-X
-	B-X
1	B-X
sites	B-X
are	B-X
closely	B-X
linked	B-X
to	B-X
weak	B-X
binding	B-X
sites	B-X
of	B-X
Octamer	B-X
factors	B-X
<EOS>	B-X
Several	B-X
purine	B-X
boxes	B-X
and	B-X
an	B-X
AT	B-X
-	B-X
rich	B-X
protein	B-X
-	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
are	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
high	B-X
mobility	B-X
group	B-X
protein	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X
<EOS>	B-X
Whereas	B-X
the	B-X
binding	B-X
of	B-X
NFAT	B-X
-	B-X
1	B-X
and	B-X
Octamer	B-X
factors	B-X
enhance	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X
suppresses	B-X
its	B-X
activity	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
suppression	B-X
of	B-X
Il	B-X
-	B-X
4	B-X
transcription	B-X
in	B-X
resting	B-X
T	B-X
lymphocytes	B-X

We	O
show	O
here	O
that	O
the	O
immediate	B-DNA
upstream	I-DNA
region	I-DNA
(	O
from	O
position	O
-12	O
to	O
-270	O
)	O
of	O
the	O
murine	B-DNA
interleukin	I-DNA
4	I-DNA
(	I-DNA
Il-4	I-DNA
)	I-DNA
gene	I-DNA
harbors	O
a	O
strong	O
cell-type	O
specific	O
transcriptional	B-DNA
enhancer	I-DNA
.	O

In	O
T	B-cell_type
lymphoma	I-cell_type
cells	I-cell_type
,	O
the	O
activity	O
of	O
the	O
Il-4	B-DNA
promoter/enhancer	I-DNA
is	O
stimulated	O
by	O
phorbol	O
esters	O
,	O
Ca++	O
ionophores	O
and	O
agonists	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
and	O
inhibited	O
by	O
low	O
doses	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O

The	O
Il-4	B-DNA
promoter/enhancer	I-DNA
is	O
transcriptionally	O
inactive	O
in	O
B	B-cell_type
lymphoma	I-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_type
cells	I-cell_type
.	O

DNase	O
I	O
footprint	O
protection	O
experiments	O
revealed	O
six	O
sites	O
of	O
the	O
Il-4	B-DNA
promoter/enhancer	I-DNA
to	O
be	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
DNase	B-X
I	B-X
footprint	B-X
protection	B-X
experiments	B-X
revealed	B-X
six	B-X
sites	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
/	B-X
enhancer	B-X
to	B-X
be	B-X
bound	B-X
by	B-X
nuclear	B-X
proteins	B-X
from	B-X
lymphoid	B-X
and	B-X
myeloid	B-X
cells	B-X
<EOS>	B-X
Several	B-X
purine	B-X
boxes	B-X
and	B-X
an	B-X
AT	B-X
-	B-X
rich	B-X
protein	B-X
-	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
are	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
high	B-X
mobility	B-X
group	B-X
protein	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X
<EOS>	B-X
The	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
/	B-X
enhancer	B-X
is	B-X
transcriptionally	B-X
inactive	B-X
in	B-X
B	B-X
lymphoma	B-X
cells	B-X
and	B-X
HeLa	B-X
cells	B-X
<EOS>	B-X
Whereas	B-X
the	B-X
binding	B-X
of	B-X
NFAT	B-X
-	B-X
1	B-X
and	B-X
Octamer	B-X
factors	B-X
enhance	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X
suppresses	B-X
its	B-X
activity	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
suppression	B-X
of	B-X
Il	B-X
-	B-X
4	B-X
transcription	B-X
in	B-X
resting	B-X
T	B-X
lymphocytes	B-X

Among	O
them	O
are	O
four	O
purine	O
boxes	O
which	O
have	O
been	O
described	O
to	O
be	O
important	O
sequence	O
motifs	O
of	O
the	O
Il-2	B-DNA
promoter	I-DNA
.	O
<EOS>	B-X
Among	B-X
them	B-X
are	B-X
four	B-X
purine	B-X
boxes	B-X
which	B-X
have	B-X
been	B-X
described	B-X
to	B-X
be	B-X
important	B-X
sequence	B-X
motifs	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
Three	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
NFAT	B-X
-	B-X
1	B-X
sites	B-X
are	B-X
closely	B-X
linked	B-X
to	B-X
weak	B-X
binding	B-X
sites	B-X
of	B-X
Octamer	B-X
factors	B-X
<EOS>	B-X
DNase	B-X
I	B-X
footprint	B-X
protection	B-X
experiments	B-X
revealed	B-X
six	B-X
sites	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
/	B-X
enhancer	B-X
to	B-X
be	B-X
bound	B-X
by	B-X
nuclear	B-X
proteins	B-X
from	B-X
lymphoid	B-X
and	B-X
myeloid	B-X
cells	B-X
<EOS>	B-X
Several	B-X
purine	B-X
boxes	B-X
and	B-X
an	B-X
AT	B-X
-	B-X
rich	B-X
protein	B-X
-	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
are	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
high	B-X
mobility	B-X
group	B-X
protein	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X

They	O
contain	O
the	O
motif	O
GGAAA	O
and	O
are	O
recognized	O
by	O
the	O
inducible	B-protein
and	I-protein
cyclosporin	I-protein
A-sensitive	I-protein
transcription	I-protein
factor	I-protein
NFAT-1	I-protein
.	O
<EOS>	B-X
They	B-X
contain	B-X
the	B-X
motif	B-X
GGAAA	B-X
and	B-X
are	B-X
recognized	B-X
by	B-X
the	B-X
inducible	B-X
and	B-X
cyclosporin	B-X
A	B-X
-	B-X
sensitive	B-X
transcription	B-X
factor	B-X
NFAT	B-X
-	B-X
1	B-X
<EOS>	B-X
Three	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
NFAT	B-X
-	B-X
1	B-X
sites	B-X
are	B-X
closely	B-X
linked	B-X
to	B-X
weak	B-X
binding	B-X
sites	B-X
of	B-X
Octamer	B-X
factors	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
immediate	B-X
upstream	B-X
region	B-X
(	B-X
from	B-X
position	B-X
	B-X
-	B-X
12	B-X
to	B-X
	B-X
-	B-X
270	B-X
)	B-X
of	B-X
the	B-X
murine	B-X
interleukin	B-X
4	B-X
(	B-X
Il	B-X
-	B-X
4	B-X
)	B-X
gene	B-X
harbors	B-X
a	B-X
strong	B-X
cell	B-X
-	B-X
type	B-X
specific	B-X
transcriptional	B-X
enhancer	B-X
<EOS>	B-X
Whereas	B-X
the	B-X
binding	B-X
of	B-X
NFAT	B-X
-	B-X
1	B-X
and	B-X
Octamer	B-X
factors	B-X
enhance	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X
suppresses	B-X
its	B-X
activity	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
suppression	B-X
of	B-X
Il	B-X
-	B-X
4	B-X
transcription	B-X
in	B-X
resting	B-X
T	B-X
lymphocytes	B-X

Three	O
of	O
the	O
Il-4	B-DNA
NFAT-1	I-DNA
sites	I-DNA
are	O
closely	O
linked	O
to	O
weak	O
binding	O
sites	O
of	O
Octamer	B-protein
factors	I-protein
.	O
<EOS>	B-X
Three	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
NFAT	B-X
-	B-X
1	B-X
sites	B-X
are	B-X
closely	B-X
linked	B-X
to	B-X
weak	B-X
binding	B-X
sites	B-X
of	B-X
Octamer	B-X
factors	B-X
<EOS>	B-X
They	B-X
contain	B-X
the	B-X
motif	B-X
GGAAA	B-X
and	B-X
are	B-X
recognized	B-X
by	B-X
the	B-X
inducible	B-X
and	B-X
cyclosporin	B-X
A	B-X
-	B-X
sensitive	B-X
transcription	B-X
factor	B-X
NFAT	B-X
-	B-X
1	B-X
<EOS>	B-X
Among	B-X
them	B-X
are	B-X
four	B-X
purine	B-X
boxes	B-X
which	B-X
have	B-X
been	B-X
described	B-X
to	B-X
be	B-X
important	B-X
sequence	B-X
motifs	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
2	B-X
promoter	B-X
<EOS>	B-X
In	B-X
T	B-X
lymphoma	B-X
cells	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
/	B-X
enhancer	B-X
is	B-X
stimulated	B-X
by	B-X
phorbol	B-X
esters	B-X
,	B-X
Ca++	B-X
ionophores	B-X
and	B-X
agonists	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
and	B-X
inhibited	B-X
by	B-X
low	B-X
doses	B-X
of	B-X
the	B-X
immunosuppressant	B-X
cyclosporin	B-X
A	B-X

Several	O
purine	O
boxes	O
and	O
an	O
AT-rich	B-DNA
protein-binding	I-DNA
site	I-DNA
of	O
the	O
Il-4	O
promoter	O
are	O
also	O
recognized	O
by	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
HMG	B-protein
I	I-protein
(	I-protein
Y	I-protein
)	O
.	O

Whereas	O
the	O
binding	O
of	O
NFAT-1	B-protein
and	O
Octamer	B-protein
factors	I-protein
enhance	O
the	O
activity	O
of	O
the	O
Il-4	B-DNA
promoter	I-DNA
,	O
the	O
binding	O
of	O
HMG	O
I	O
(	O
Y	O
)	O
suppresses	O
its	O
activity	O
and	O
,	O
therefore	O
,	O
appears	O
to	O
be	O
involved	O
in	O
the	O
suppression	O
of	O
Il-4	B-protein
transcription	O
in	O
resting	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O
<EOS>	B-X
Whereas	B-X
the	B-X
binding	B-X
of	B-X
NFAT	B-X
-	B-X
1	B-X
and	B-X
Octamer	B-X
factors	B-X
enhance	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X
suppresses	B-X
its	B-X
activity	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
suppression	B-X
of	B-X
Il	B-X
-	B-X
4	B-X
transcription	B-X
in	B-X
resting	B-X
T	B-X
lymphocytes	B-X
<EOS>	B-X
In	B-X
T	B-X
lymphoma	B-X
cells	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
/	B-X
enhancer	B-X
is	B-X
stimulated	B-X
by	B-X
phorbol	B-X
esters	B-X
,	B-X
Ca++	B-X
ionophores	B-X
and	B-X
agonists	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
and	B-X
inhibited	B-X
by	B-X
low	B-X
doses	B-X
of	B-X
the	B-X
immunosuppressant	B-X
cyclosporin	B-X
A	B-X
<EOS>	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
immediate	B-X
upstream	B-X
region	B-X
(	B-X
from	B-X
position	B-X
	B-X
-	B-X
12	B-X
to	B-X
	B-X
-	B-X
270	B-X
)	B-X
of	B-X
the	B-X
murine	B-X
interleukin	B-X
4	B-X
(	B-X
Il	B-X
-	B-X
4	B-X
)	B-X
gene	B-X
harbors	B-X
a	B-X
strong	B-X
cell	B-X
-	B-X
type	B-X
specific	B-X
transcriptional	B-X
enhancer	B-X
<EOS>	B-X
Several	B-X
purine	B-X
boxes	B-X
and	B-X
an	B-X
AT	B-X
-	B-X
rich	B-X
protein	B-X
-	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
Il	B-X
-	B-X
4	B-X
promoter	B-X
are	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
high	B-X
mobility	B-X
group	B-X
protein	B-X
HMG	B-X
I	B-X
(	B-X
Y	B-X
)	B-X

Reversibility	O
of	O
the	O
differentiated	O
state	O
in	O
somatic	B-cell_type
cells	I-cell_type
.	O

Analysis	O
of	O
de	O
novo	O
gene	O
activation	O
in	O
multinucleated	B-cell_type
heterokaryons	I-cell_type
has	O
shown	O
that	O
the	O
differentiated	O
state	O
,	O
although	O
stable	O
,	O
is	O
not	O
irreversible	O
,	O
and	O
can	O
be	O
reprogrammed	O
in	O
the	O
presence	O
of	O
appropriate	O
combinations	O
of	O
trans-acting	B-protein
regulatory	I-protein
molecules	I-protein
.	O

These	O
properties	O
have	O
been	O
exploited	O
to	O
design	O
strategies	O
for	O
identifying	O
novel	O
regulators	O
of	O
cellular	O
differentiation	O
.	O
<EOS>	B-X
These	B-X
properties	B-X
have	B-X
been	B-X
exploited	B-X
to	B-X
design	B-X
strategies	B-X
for	B-X
identifying	B-X
novel	B-X
regulators	B-X
of	B-X
cellular	B-X
differentiation	B-X
<EOS>	B-X
Reversibility	B-X
of	B-X
the	B-X
differentiated	B-X
state	B-X
in	B-X
somatic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Analysis	B-X
of	B-X
de	B-X
novo	B-X
gene	B-X
activation	B-X
in	B-X
multinucleated	B-X
heterokaryons	B-X
has	B-X
shown	B-X
that	B-X
the	B-X
differentiated	B-X
state	B-X
,	B-X
although	B-X
stable	B-X
,	B-X
is	B-X
not	B-X
irreversible	B-X
,	B-X
and	B-X
can	B-X
be	B-X
reprogrammed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
appropriate	B-X
combinations	B-X
of	B-X
trans	B-X
-	B-X
acting	B-X
regulatory	B-X
molecules	B-X

Phosphatidylcholine	O
hydrolysis	O
activates	O
NF-kappa	B-protein
B	I-protein
and	O
increases	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
have	O
tested	O
whether	O
breakdown	O
of	O
phosphatidylcholine	O
(	O
PC	O
)	O
initiated	O
by	O
exogenous	O
addition	O
of	O
a	O
PC-specific	B-protein
phospholipase	I-protein
C	I-protein
(	O
PC-PLC	B-protein
)	O
from	O
Bacillus	O
cereus	O
or	O
by	O
endogenous	O
overexpression	O
of	O
PC-PLC	B-protein
induces	O
functional	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
increases	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
enhancer	I-DNA
activity	O
.	O
<EOS>	B-X
We	B-X
have	B-X
tested	B-X
whether	B-X
breakdown	B-X
of	B-X
phosphatidylcholine	B-X
(	B-X
PC	B-X
)	B-X
initiated	B-X
by	B-X
exogenous	B-X
addition	B-X
of	B-X
a	B-X
PC	B-X
-	B-X
specific	B-X
phospholipase	B-X
C	B-X
(	B-X
PC	B-X
-	B-X
PLC	B-X
)	B-X
from	B-X
Bacillus	B-X
cereus	B-X
or	B-X
by	B-X
endogenous	B-X
overexpression	B-X
of	B-X
PC	B-X
-	B-X
PLC	B-X
induces	B-X
functional	B-X
activation	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
increases	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
enhancer	B-X
activity	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
cellular	B-X
transduction	B-X
pathway	B-X
,	B-X
dependent	B-X
on	B-X
specific	B-X
PC	B-X
breakdown	B-X
,	B-X
is	B-X
functional	B-X
in	B-X
T	B-X
lymphocytes	B-X
and	B-X
monocytes	B-X
and	B-X
may	B-X
be	B-X
used	B-X
by	B-X
various	B-X
transmembrane	B-X
receptors	B-X
to	B-X
activate	B-X
HIV	B-X
transcription	B-X
through	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
induction	B-X
of	B-X
the	B-X
HIV	B-X
enhancer	B-X
<EOS>	B-X
Phosphatidylcholine	B-X
hydrolysis	B-X
activates	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
increases	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
replication	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
In	B-X
human	B-X
monocytic	B-X
and	B-X
lymphoblastoid	B-X
T	B-X
-	B-X
cell	B-X
lines	B-X
,	B-X
induction	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
by	B-X
PC	B-X
-	B-X
PLC	B-X
resulted	B-X
in	B-X
clear	B-X
induction	B-X
of	B-X
luciferase	B-X
expression	B-X
vectors	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
synthetic	B-X
kappa	B-X
B	B-X
enhancers	B-X
or	B-X
wild	B-X
type	B-X
,	B-X
but	B-X
not	B-X
kappa	B-X
B	B-X
-	B-X
mutated	B-X
,	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat	B-X
constructs	B-X

PC-PLC-activated	O
hydrolysis	O
of	O
PC	O
was	O
found	O
to	O
induce	O
bona	O
fide	O
p50/p65	B-protein
NF-kappa	I-protein
B	I-protein
binding	O
activity	O
in	O
three	O
different	O
cell	B-cell_line
lines	I-cell_line
of	O
human	O
or	O
murine	O
origin	O
.	O
<EOS>	B-X
AAV	B-X
-	B-X
Net1	B-X
facilitates	B-X
the	B-X
trans	B-X
-	B-X
differentiation	B-X
of	B-X
supporting	B-X
cells	B-X
into	B-X
hair	B-X
cells	B-X
in	B-X
the	B-X
murine	B-X
cochlea	B-X
.	B-X
<EOS>	B-X
Mesenchymal	B-X
stem	B-X
cells	B-X
(	B-X
MSCs	B-X
)	B-X
are	B-X
known	B-X
to	B-X
have	B-X
different	B-X
differentiation	B-X
potential	B-X
depending	B-X
on	B-X
the	B-X
tissue	B-X
of	B-X
origin	B-X
<EOS>	B-X
We	B-X
also	B-X
evaluated	B-X
in	B-X
vivo	B-X
bone	B-X
regeneration	B-X
ability	B-X
of	B-X
these	B-X
cells	B-X
using	B-X
a	B-X
mouse	B-X
femoral	B-X
fracture	B-X
model	B-X
<EOS>	B-X
Immunopanning	B-X
refers	B-X
to	B-X
a	B-X
method	B-X
of	B-X
removing	B-X
cell	B-X
types	B-X
by	B-X
adhering	B-X
antibodies	B-X
to	B-X
cell	B-X
culture	B-X
dishes	B-X

No	O
significant	O
changes	O
in	O
the	O
turnover	O
of	O
other	O
cellular	O
phospholipids	O
were	O
detected	O
in	O
PC-PLC-treated	B-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
No	B-X
significant	B-X
changes	B-X
in	B-X
the	B-X
turnover	B-X
of	B-X
other	B-X
cellular	B-X
phospholipids	B-X
were	B-X
detected	B-X
in	B-X
PC	B-X
-	B-X
PLC	B-X
-	B-X
treated	B-X
cells	B-X
<EOS>	B-X
However	B-X
,	B-X
addition	B-X
of	B-X
a	B-X
phosphatidylinositol	B-X
-	B-X
specific	B-X
PLC	B-X
from	B-X
B	B-X
<EOS>	B-X
Phosphatidylcholine	B-X
hydrolysis	B-X
activates	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
and	B-X
increases	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
replication	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
<EOS>	B-X
Induction	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
by	B-X
PC	B-X
-	B-X
PLC	B-X
did	B-X
not	B-X
depend	B-X
on	B-X
de	B-X
novo	B-X
synthesis	B-X
of	B-X
proteins	B-X
or	B-X
autocrine	B-X
secretion	B-X
of	B-X
either	B-X
tumor	B-X
necrosis	B-X
factor	B-X
or	B-X
interleukin	B-X
1	B-X

Induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
PC-PLC	B-protein
did	O
not	O
depend	O
on	O
de	O
novo	O
synthesis	O
of	O
proteins	O
or	O
autocrine	O
secretion	O
of	O
either	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
interleukin	B-protein
1	I-protein
.	O
<EOS>	B-X
Increased	B-X
hepatic	B-X
interleukin	B-X
-	B-X
1	B-X
,	B-X
arachidonic	B-X
acid	B-X
,	B-X
and	B-X
reactive	B-X
oxygen	B-X
species	B-X
mediate	B-X
the	B-X
protective	B-X
potential	B-X
of	B-X
peptides	B-X
shared	B-X
by	B-X
gut	B-X
cysteine	B-X
peptidases	B-X
against	B-X
Schistosoma	B-X
mansoni	B-X
infection	B-X
in	B-X
mice	B-X
.	B-X
<EOS>	B-X
The	B-X
nanoparticles	B-X
can	B-X
be	B-X
loaded	B-X
with	B-X
molecules	B-X
of	B-X
interest	B-X
such	B-X
as	B-X
drugs	B-X
,	B-X
proteins	B-X
and	B-X
peptides	B-X
,	B-X
and	B-X
are	B-X
a	B-X
promising	B-X
new	B-X
addition	B-X
to	B-X
the	B-X
drug	B-X
delivery	B-X
platforms	B-X
currently	B-X
in	B-X
use	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
data	B-X
highlighted	B-X
differences	B-X
in	B-X
the	B-X
VAT	B-X
and	B-X
SAT	B-X
lipidomes	B-X
,	B-X
inflammatory	B-X
profiles	B-X
and	B-X
lipolytic	B-X
function	B-X
,	B-X
which	B-X
suggest	B-X
a	B-X
distinct	B-X
metabolism	B-X
of	B-X
these	B-X
two	B-X
white	B-X
adipose	B-X
tissue	B-X
depots	B-X
after	B-X
the	B-X
empagliflozin	B-X
treatment	B-X
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
inflammasomes	B-X
is	B-X
regulated	B-X
at	B-X
both	B-X
transcription	B-X
and	B-X
posttranscription	B-X
levels	B-X
,	B-X
which	B-X
is	B-X
crucial	B-X
in	B-X
protecting	B-X
the	B-X
host	B-X
from	B-X
infections	B-X
and	B-X
sterile	B-X
insults	B-X

In	O
human	B-cell_line
monocytic	I-cell_line
and	I-cell_line
lymphoblastoid	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
,	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
PC-PLC	B-protein
resulted	O
in	O
clear	O
induction	O
of	O
luciferase	B-protein
expression	O
vectors	O
placed	O
under	O
the	O
control	O
of	O
synthetic	B-DNA
kappa	I-DNA
B	I-DNA
enhancers	I-DNA
or	O
wild	O
type	O
,	O
but	O
not	O
kappa	O
B-mutated	O
,	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
constructs	I-DNA
.	O
<EOS>	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
patients	B-X
have	B-X
reduced	B-X
cerebral	B-X
gray	B-X
matter	B-X
and	B-X
altered	B-X
white	B-X
matter	B-X
ultrastructure	B-X
(	B-X
detected	B-X
by	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
)	B-X
compared	B-X
to	B-X
age	B-X
-	B-X
matched	B-X
controls	B-X
<EOS>	B-X
Consistent	B-X
with	B-X
these	B-X
results	B-X
,	B-X
the	B-X
signature	B-X
expression	B-X
and	B-X
release	B-X
in	B-X
the	B-X
conditioned	B-X
medium	B-X
of	B-X
glioma	B-X
cells	B-X
was	B-X
lower	B-X
in	B-X
IDH	B-X
-	B-X
wild	B-X
type	B-X
cells	B-X
compared	B-X
to	B-X
the	B-X
mutated	B-X
counterpart	B-X
<EOS>	B-X
Targeted	B-X
genetic	B-X
screening	B-X
might	B-X
be	B-X
too	B-X
restricted	B-X
to	B-X
identify	B-X
a	B-X
genetic	B-X
cause	B-X
underlying	B-X
the	B-X
phenotype	B-X
of	B-X
poor	B-X
embryo	B-X
development	B-X
for	B-X
all	B-X
patients	B-X
<EOS>	B-X
Ongoing	B-X
and	B-X
longitudinal	B-X
evaluation	B-X
of	B-X
SARS	B-X
-	B-X
CoV	B-X
-	B-X
2	B-X
humoral	B-X
and	B-X
cellular	B-X
responses	B-X
is	B-X
valuable	B-X
and	B-X
necessary	B-X
to	B-X
allow	B-X
frequent	B-X
re	B-X
-	B-X
evaluation	B-X
of	B-X
these	B-X
patient	B-X
populations	B-X

HIV	O
replication	O
was	O
increased	O
by	O
PC-PLC	B-protein
in	O
chronically	O
infected	O
monocytes	B-cell_type
and	O
T	O
lymphocytes	B-cell_type
.	O

NF-kappa	O
B	O
activation	O
promoted	O
by	O
addition	O
of	O
exogenous	B-protein
PC-PLC	I-protein
correlated	O
with	O
an	O
intense	O
production	O
of	O
diacylglycerol	O
.	O
<EOS>	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
activation	B-X
promoted	B-X
by	B-X
addition	B-X
of	B-X
exogenous	B-X
PC	B-X
-	B-X
PLC	B-X
correlated	B-X
with	B-X
an	B-X
intense	B-X
production	B-X
of	B-X
diacylglycerol	B-X
<EOS>	B-X
Induction	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
by	B-X
PC	B-X
-	B-X
PLC	B-X
did	B-X
not	B-X
depend	B-X
on	B-X
de	B-X
novo	B-X
synthesis	B-X
of	B-X
proteins	B-X
or	B-X
autocrine	B-X
secretion	B-X
of	B-X
either	B-X
tumor	B-X
necrosis	B-X
factor	B-X
or	B-X
interleukin	B-X
1	B-X
<EOS>	B-X
However	B-X
,	B-X
addition	B-X
of	B-X
a	B-X
phosphatidylinositol	B-X
-	B-X
specific	B-X
PLC	B-X
from	B-X
B	B-X
<EOS>	B-X
HIV	B-X
replication	B-X
was	B-X
increased	B-X
by	B-X
PC	B-X
-	B-X
PLC	B-X
in	B-X
chronically	B-X
infected	B-X
monocytes	B-X
and	B-X
T	B-X
lymphocytes	B-X

However	O
,	O
addition	O
of	O
a	O
phosphatidylinositol-specific	B-protein
PLC	I-protein
from	O
B.cereus	O
also	O
induced	O
diacylglycerol	O
but	O
did	O
not	O
activate	O
kappa	B-protein
B	I-protein
enhancer-directed	I-protein
vectors	I-protein
.	O

PC-PLC-induced	O
NF-kappa	O
B	O
activation	O
could	O
not	O
be	O
blocked	O
by	O
a	O
specific	O
inhibitor	O
of	O
phorbol	B-protein
ester-inducible	I-protein
protein	I-protein
kinases	I-protein
C	I-protein
.	O

These	O
results	O
indicate	O
that	O
a	O
cellular	O
transduction	O
pathway	O
,	O
dependent	O
on	O
specific	O
PC	O
breakdown	O
,	O
is	O
functional	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
and	O
may	O
be	O
used	O
by	O
various	O
transmembrane	O
receptors	O
to	O
activate	O
HIV	O
transcription	O
through	O
NF-kappa	O
B-dependent	O
induction	O
of	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O

Novel	O
mechanism	O
for	O
inhibition	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
inhibit	O
signal	O
transduction	O
through	O
IL-2	B-protein
receptor	I-protein
.	O
<EOS>	B-X
Glucocorticoids	B-X
(	B-X
GCs	B-X
)	B-X
are	B-X
potent	B-X
anti	B-X
-	B-X
inflammatory	B-X
agents	B-X
that	B-X
block	B-X
cytokine	B-X
production	B-X
<EOS>	B-X
Western	B-X
blotting	B-X
analysis	B-X
was	B-X
used	B-X
to	B-X
detect	B-X
the	B-X
effects	B-X
of	B-X
nilotinib	B-X
on	B-X
the	B-X
signal	B-X
transduction	B-X
cascade	B-X
of	B-X
T	B-X
-	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
in	B-X
Tregs	B-X
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
inhibition	B-X
involved	B-X
suppression	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
and	B-X
Jak3	B-X
expression	B-X
<EOS>	B-X
Dasatinib	B-X
inhibits	B-X
the	B-X
proliferation	B-X
and	B-X
function	B-X
of	B-X
CD4+CD25+	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X

Interaction	O
of	O
IL-2	B-protein
with	O
its	O
high	B-protein
affinity	I-protein
membrane	I-protein
receptor	I-protein
complex	I-protein
(	O
IL-2R	B-protein
)	O
present	O
on	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
induces	O
cell	O
proliferation	O
and	O
mediates	O
effector	O
functions	O
.	O
<EOS>	B-X
Interaction	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
with	B-X
its	B-X
high	B-X
affinity	B-X
membrane	B-X
receptor	B-X
complex	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
present	B-X
on	B-X
activated	B-X
T	B-X
lymphocytes	B-X
induces	B-X
cell	B-X
proliferation	B-X
and	B-X
mediates	B-X
effector	B-X
functions	B-X
<EOS>	B-X
Inhibition	B-X
of	B-X
T	B-X
cell	B-X
proliferation	B-X
by	B-X
Dex	B-X
was	B-X
associated	B-X
with	B-X
decreased	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
several	B-X
intracellular	B-X
proteins	B-X
and	B-X
decreased	B-X
phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
gene	B-X
product	B-X
Rb	B-X
,	B-X
a	B-X
protein	B-X
essential	B-X
for	B-X
controlling	B-X
the	B-X
progression	B-X
of	B-X
cells	B-X
through	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
Glucocorticoids	B-X
inhibit	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
by	B-X
inhibiting	B-X
TCR	B-X
-	B-X
mediated	B-X
signal	B-X
transduction	B-X
<EOS>	B-X
We	B-X
asked	B-X
whether	B-X
they	B-X
also	B-X
inhibit	B-X
the	B-X
action	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
by	B-X
inhibiting	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2R	B-X

Glucocorticoids	O
inhibit	O
IL-2	B-protein
production	O
by	O
inhibiting	O
TCR-mediated	O
signal	O
transduction	O
.	O
<EOS>	B-X
Glucocorticoids	B-X
inhibit	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
by	B-X
inhibiting	B-X
TCR	B-X
-	B-X
mediated	B-X
signal	B-X
transduction	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
glucocorticoids	B-X
inhibit	B-X
preactivated	B-X
T	B-X
cells	B-X
by	B-X
down	B-X
-	B-X
regulating	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2R	B-X
<EOS>	B-X
We	B-X
asked	B-X
whether	B-X
they	B-X
also	B-X
inhibit	B-X
the	B-X
action	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
by	B-X
inhibiting	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2R	B-X
<EOS>	B-X
Novel	B-X
mechanism	B-X
for	B-X
inhibition	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
Glucocorticoids	B-X
inhibit	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
.	B-X

We	O
asked	O
whether	O
they	O
also	O
inhibit	O
the	O
action	O
of	O
IL-2	B-protein
by	O
inhibiting	O
signal	O
transduction	O
through	O
IL-2R	B-protein
.	O
<EOS>	B-X
We	B-X
asked	B-X
whether	B-X
they	B-X
also	B-X
inhibit	B-X
the	B-X
action	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
by	B-X
inhibiting	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2R	B-X
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
glucocorticoids	B-X
inhibit	B-X
preactivated	B-X
T	B-X
cells	B-X
by	B-X
down	B-X
-	B-X
regulating	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2R	B-X
<EOS>	B-X
Novel	B-X
mechanism	B-X
for	B-X
inhibition	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
Glucocorticoids	B-X
inhibit	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
.	B-X
<EOS>	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
CT	B-X
-	B-X
B	B-X
did	B-X
not	B-X
inhibit	B-X
IP3	B-X
generation	B-X
or	B-X
action	B-X

Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
stimulated	O
with	O
PMA	O
for	O
48	O
h	O
(	O
PMA	B-cell_line
blasts	I-cell_line
)	O
,	O
were	O
incubated	O
with	O
IL-2	B-protein
in	O
the	O
presence	O
of	O
incremental	O
dosages	O
of	O
dexamethasone	O
(	O
Dex	O
;	O
10	O
(	O
-5	O
)	O
-10	O
(	O
-9	O
)	O
M	O
)	O
.	O

Dex	O
inhibited	O
the	O
IL-2-dependent	O
proliferation	O
of	O
PMA	B-cell_line
blasts	I-cell_line
in	O
a	O
dose-dependent	O
fashion	O
(	O
IC50	O
,	O
5	O
x	O
10	O
(	O
-8	O
)	O
M	O
)	O
.	O

Cell	O
surface	O
expression	O
of	O
IL-2R	B-protein
alpha-	I-protein
and	I-protein
beta-chains	I-protein
as	O
determined	O
by	O
immunofluorescence	O
analysis	O
was	O
not	O
affected	O
by	O
Dex	O
.	O
<EOS>	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL2	B-X
)	B-X
receptor	B-X
chains	B-X
was	B-X
investigated	B-X
by	B-X
immunofluorescence	B-X
and	B-X
mRNA	B-X
analysis	B-X
in	B-X
typical	B-X
and	B-X
variant	B-X
hairy	B-X
cell	B-X
leukemia	B-X
(	B-X
HCL	B-X
)	B-X
cases	B-X
<EOS>	B-X
While	B-X
typical	B-X
hairy	B-X
cells	B-X
express	B-X
both	B-X
the	B-X
alpha	B-X
and	B-X
the	B-X
beta	B-X
chains	B-X
,	B-X
variant	B-X
HCL	B-X
express	B-X
the	B-X
IL2	B-X
receptor	B-X
beta	B-X
chain	B-X
on	B-X
the	B-X
surface	B-X
membrane	B-X
but	B-X
not	B-X
the	B-X
alpha	B-X
chain	B-X
<EOS>	B-X
The	B-X
results	B-X
of	B-X
this	B-X
study	B-X
suggest	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
of	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
appears	B-X
to	B-X
be	B-X
upregulated	B-X
or	B-X
downregulated	B-X
during	B-X
the	B-X
process	B-X
of	B-X
B	B-X
-	B-X
cell	B-X
-	B-X
lineage	B-X
activation	B-X
and	B-X
differentiation	B-X
<EOS>	B-X
IL	B-X
-	B-X
2	B-X
transfection	B-X
did	B-X
not	B-X
produce	B-X
significant	B-X
modifications	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
surface	B-X
molecules	B-X
such	B-X
as	B-X
IL	B-X
-	B-X
2R	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
-	B-X
1	B-X
(	B-X
ICAM	B-X
-	B-X
1	B-X
)	B-X
,	B-X
CD44	B-X
,	B-X
HLA	B-X
class	B-X
I	B-X
and	B-X
II	B-X
or	B-X
in	B-X
IL	B-X
-	B-X
2R	B-X
beta	B-X
or	B-X
gamma	B-X
mRNA	B-X

In	O
addition	O
,	O
Scatchard	O
plot	O
analysis	O
of	O
125I-labeled	B-protein
IL-2	I-protein
showed	O
that	O
Dex	O
did	O
not	O
affect	O
the	O
binding	O
of	O
IL-2	B-protein
,	O
thus	O
suggesting	O
that	O
inhibition	O
is	O
due	O
to	O
a	O
postreceptor	O
effect	O
.	O

Inhibition	O
of	O
T	O
cell	O
proliferation	O
by	O
Dex	O
was	O
associated	O
with	O
decreased	O
IL-2-dependent	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	B-protein
proteins	I-protein
and	O
decreased	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
Rb	I-protein
,	O
a	O
protein	O
essential	O
for	O
controlling	O
the	O
progression	O
of	O
cells	O
through	O
the	O
cell	O
cycle	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
T	B-X
cell	B-X
proliferation	B-X
by	B-X
Dex	B-X
was	B-X
associated	B-X
with	B-X
decreased	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
several	B-X
intracellular	B-X
proteins	B-X
and	B-X
decreased	B-X
phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
gene	B-X
product	B-X
Rb	B-X
,	B-X
a	B-X
protein	B-X
essential	B-X
for	B-X
controlling	B-X
the	B-X
progression	B-X
of	B-X
cells	B-X
through	B-X
the	B-X
cell	B-X
cycle	B-X
<EOS>	B-X
Interaction	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
with	B-X
its	B-X
high	B-X
affinity	B-X
membrane	B-X
receptor	B-X
complex	B-X
(	B-X
IL	B-X
-	B-X
2R	B-X
)	B-X
present	B-X
on	B-X
activated	B-X
T	B-X
lymphocytes	B-X
induces	B-X
cell	B-X
proliferation	B-X
and	B-X
mediates	B-X
effector	B-X
functions	B-X
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
Scatchard	B-X
plot	B-X
analysis	B-X
of	B-X
125I	B-X
-	B-X
labeled	B-X
IL	B-X
-	B-X
2	B-X
showed	B-X
that	B-X
Dex	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
binding	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
,	B-X
thus	B-X
suggesting	B-X
that	B-X
inhibition	B-X
is	B-X
due	B-X
to	B-X
a	B-X
postreceptor	B-X
effect	B-X
<EOS>	B-X
Dex	B-X
inhibited	B-X
the	B-X
IL	B-X
-	B-X
2	B-X
-	B-X
dependent	B-X
proliferation	B-X
of	B-X
PMA	B-X
blasts	B-X
in	B-X
a	B-X
dose	B-X
-	B-X
dependent	B-X
fashion	B-X
(	B-X
IC50	B-X
,	B-X
5	B-X
x	B-X
10	B-X
(	B-X
	B-X
-	B-X
8	B-X
)	B-X
M	B-X
)	B-X

IL-2-dependent	O
IL-2R	O
alpha	O
expression	O
in	O
PMA	B-cell_line
blasts	I-cell_line
and	O
NF-kB	B-protein
induction	O
in	O
resting	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
were	O
also	O
inhibited	O
by	O
Dex	O
.	O

These	O
results	O
demonstrate	O
that	O
glucocorticoids	O
inhibit	O
preactivated	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
down-regulating	O
signal	O
transduction	O
through	O
IL-2R	B-protein
.	O
<EOS>	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
glucocorticoids	B-X
inhibit	B-X
preactivated	B-X
T	B-X
cells	B-X
by	B-X
down	B-X
-	B-X
regulating	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2R	B-X
<EOS>	B-X
We	B-X
asked	B-X
whether	B-X
they	B-X
also	B-X
inhibit	B-X
the	B-X
action	B-X
of	B-X
IL	B-X
-	B-X
2	B-X
by	B-X
inhibiting	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2R	B-X
<EOS>	B-X
Glucocorticoids	B-X
inhibit	B-X
IL	B-X
-	B-X
2	B-X
production	B-X
by	B-X
inhibiting	B-X
TCR	B-X
-	B-X
mediated	B-X
signal	B-X
transduction	B-X
<EOS>	B-X
Novel	B-X
mechanism	B-X
for	B-X
inhibition	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
by	B-X
glucocorticoids	B-X
.	B-X
Glucocorticoids	B-X
inhibit	B-X
signal	B-X
transduction	B-X
through	B-X
IL	B-X
-	B-X
2	B-X
receptor	B-X
.	B-X

Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
stimulates	O
distinct	O
NF-kappa	O
B/rel	O
DNA	O
binding	O
activities	O
in	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O
<EOS>	B-X
Chronic	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
infection	B-X
stimulates	B-X
distinct	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
/	B-X
rel	B-X
DNA	B-X
binding	B-X
activities	B-X
in	B-X
myelomonoblastic	B-X
cells	B-X
.	B-X
<EOS>	B-X
The	B-X
relationship	B-X
between	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
infection	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
examined	B-X
in	B-X
a	B-X
myeloid	B-X
cell	B-X
model	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
derived	B-X
from	B-X
the	B-X
PLB	B-X
-	B-X
985	B-X
cell	B-X
line	B-X
<EOS>	B-X
Chronic	B-X
infection	B-X
of	B-X
PLB	B-X
-	B-X
985	B-X
cells	B-X
led	B-X
to	B-X
increased	B-X
monocyte	B-X
-	B-X
specific	B-X
surface	B-X
marker	B-X
expression	B-X
,	B-X
increased	B-X
c	B-X
-	B-X
fms	B-X
gene	B-X
transcription	B-X
,	B-X
and	B-X
morphological	B-X
alterations	B-X
consistent	B-X
with	B-X
differentiation	B-X
along	B-X
the	B-X
monocytic	B-X
pathway	B-X
<EOS>	B-X
Transient	B-X
cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
RelA	B-X
and	B-X
NFKB1	B-X
expression	B-X
maximally	B-X
stimulated	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
reporter	B-X
genes	B-X
;	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
binding	B-X
activity	B-X
were	B-X
also	B-X
reflected	B-X
in	B-X
higher	B-X
constitutive	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
regulated	B-X
gene	B-X
expression	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
myeloid	B-X
cells	B-X

The	O
relationship	O
between	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
the	O
induction	O
of	O
NF-kappa	O
B	O
binding	O
activity	O
was	O
examined	O
in	O
a	O
myeloid	B-cell_line
cell	I-cell_line
model	I-cell_line
of	O
HIV-1	O
infection	O
derived	O
from	O
the	O
PLB-985	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Chronic	O
infection	O
of	O
PLB-985	B-cell_line
cells	I-cell_line
led	O
to	O
increased	O
monocyte-specific	O
surface	O
marker	O
expression	O
,	O
increased	O
c-fms	O
gene	O
transcription	O
,	O
and	O
morphological	O
alterations	O
consistent	O
with	O
differentiation	O
along	O
the	O
monocytic	O
pathway	O
.	O
<EOS>	B-X
Chronic	B-X
infection	B-X
of	B-X
PLB	B-X
-	B-X
985	B-X
cells	B-X
led	B-X
to	B-X
increased	B-X
monocyte	B-X
-	B-X
specific	B-X
surface	B-X
marker	B-X
expression	B-X
,	B-X
increased	B-X
c	B-X
-	B-X
fms	B-X
gene	B-X
transcription	B-X
,	B-X
and	B-X
morphological	B-X
alterations	B-X
consistent	B-X
with	B-X
differentiation	B-X
along	B-X
the	B-X
monocytic	B-X
pathway	B-X
<EOS>	B-X
Chronic	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
infection	B-X
stimulates	B-X
distinct	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
/	B-X
rel	B-X
DNA	B-X
binding	B-X
activities	B-X
in	B-X
myelomonoblastic	B-X
cells	B-X
.	B-X
<EOS>	B-X
DNA	B-X
binding	B-X
of	B-X
the	B-X
90	B-X
-	B-X
	B-X
to	B-X
100	B-X
-	B-X
kDa	B-X
proteins	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
recombinant	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
/	B-X
MAD	B-X
-	B-X
3	B-X
and	B-X
was	B-X
resistant	B-X
to	B-X
tryptic	B-X
digestion	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
may	B-X
not	B-X
be	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
related	B-X
<EOS>	B-X
Transient	B-X
cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
RelA	B-X
and	B-X
NFKB1	B-X
expression	B-X
maximally	B-X
stimulated	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
reporter	B-X
genes	B-X
;	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
binding	B-X
activity	B-X
were	B-X
also	B-X
reflected	B-X
in	B-X
higher	B-X
constitutive	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
regulated	B-X
gene	B-X
expression	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
myeloid	B-X
cells	B-X

PLB-IIIB	B-cell_line
cells	I-cell_line
displayed	O
a	O
constitutive	O
NF-kappa	O
B-like	O
binding	O
activity	O
that	O
was	O
distinct	O
from	O
that	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	O
phorbol	O
12-myristate	O
13-acetate	O
treatment	O
of	O
the	O
parental	B-cell_line
PLB-985	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O
<EOS>	B-X
PLB	B-X
-	B-X
IIIB	B-X
cells	B-X
displayed	B-X
a	B-X
constitutive	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
binding	B-X
activity	B-X
that	B-X
was	B-X
distinct	B-X
from	B-X
that	B-X
induced	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
or	B-X
phorbol	B-X
12	B-X
-	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
treatment	B-X
of	B-X
the	B-X
parental	B-X
PLB	B-X
-	B-X
985	B-X
cell	B-X
line	B-X
<EOS>	B-X
The	B-X
70	B-X
-	B-X
kDa	B-X
protein	B-X
corresponds	B-X
to	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
subunit	B-X
,	B-X
which	B-X
is	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
an	B-X
acute	B-X
paramyxovirus	B-X
infection	B-X
or	B-X
a	B-X
chronic	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
<EOS>	B-X
The	B-X
virally	B-X
induced	B-X
90	B-X
-	B-X
	B-X
to	B-X
100	B-X
-	B-X
kDa	B-X
proteins	B-X
have	B-X
a	B-X
distinct	B-X
binding	B-X
specificity	B-X
for	B-X
the	B-X
PRDII	B-X
domain	B-X
and	B-X
an	B-X
AT	B-X
-	B-X
rich	B-X
sequence	B-X
but	B-X
do	B-X
not	B-X
cross	B-X
-	B-X
react	B-X
with	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
subunit	B-X
-	B-X
specific	B-X
antisera	B-X
directed	B-X
against	B-X
NFKB1	B-X
(	B-X
p105	B-X
or	B-X
p50	B-X
)	B-X
,	B-X
NFKB2	B-X
(	B-X
p100	B-X
or	B-X
p52	B-X
)	B-X
,	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
,	B-X
or	B-X
c	B-X
-	B-X
rel	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
characterize	B-X
the	B-X
nature	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
demonstrate	B-X
that	B-X
binding	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
also	B-X
induced	B-X
following	B-X
Sendai	B-X
paramyxovirus	B-X
infection	B-X

This	O
unique	O
DNA	O
binding	O
activity	O
consisted	O
of	O
proteins	O
of	O
70	B-protein
,	I-protein
90	I-protein
,	I-protein
and	I-protein
100	I-protein
kDa	I-protein
with	O
a	O
high	O
degree	O
of	O
binding	O
specificity	O
for	O
the	O
NF-kappa	B-protein
B	I-protein
site	I-protein
within	O
the	O
PRDII	B-protein
domain	I-protein
of	O
beta	B-protein
interferon	I-protein
.	O
<EOS>	B-X
This	B-X
unique	B-X
DNA	B-X
binding	B-X
activity	B-X
consisted	B-X
of	B-X
proteins	B-X
of	B-X
70	B-X
,	B-X
90	B-X
,	B-X
and	B-X
100	B-X
kDa	B-X
with	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
binding	B-X
specificity	B-X
for	B-X
the	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
site	B-X
within	B-X
the	B-X
PRDII	B-X
domain	B-X
of	B-X
beta	B-X
interferon	B-X
<EOS>	B-X
Chronic	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
infection	B-X
stimulates	B-X
distinct	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
/	B-X
rel	B-X
DNA	B-X
binding	B-X
activities	B-X
in	B-X
myelomonoblastic	B-X
cells	B-X
.	B-X
<EOS>	B-X
Transient	B-X
cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
RelA	B-X
and	B-X
NFKB1	B-X
expression	B-X
maximally	B-X
stimulated	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
reporter	B-X
genes	B-X
;	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
binding	B-X
activity	B-X
were	B-X
also	B-X
reflected	B-X
in	B-X
higher	B-X
constitutive	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
regulated	B-X
gene	B-X
expression	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
myeloid	B-X
cells	B-X
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
characterize	B-X
the	B-X
nature	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
demonstrate	B-X
that	B-X
binding	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
also	B-X
induced	B-X
following	B-X
Sendai	B-X
paramyxovirus	B-X
infection	B-X

In	O
this	O
report	O
,	O
we	O
characterize	O
the	O
nature	O
of	O
these	O
proteins	O
and	O
demonstrate	O
that	O
binding	O
of	O
these	O
proteins	O
is	O
also	O
induced	O
following	O
Sendai	O
paramyxovirus	O
infection	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
characterize	B-X
the	B-X
nature	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
demonstrate	B-X
that	B-X
binding	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
also	B-X
induced	B-X
following	B-X
Sendai	B-X
paramyxovirus	B-X
infection	B-X
<EOS>	B-X
The	B-X
relationship	B-X
between	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
infection	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
examined	B-X
in	B-X
a	B-X
myeloid	B-X
cell	B-X
model	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
derived	B-X
from	B-X
the	B-X
PLB	B-X
-	B-X
985	B-X
cell	B-X
line	B-X
<EOS>	B-X
Virus	B-X
infection	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
alter	B-X
the	B-X
amount	B-X
of	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
or	B-X
NFKB1	B-X
(	B-X
p50	B-X
)	B-X
but	B-X
rather	B-X
affects	B-X
the	B-X
capacity	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
sequester	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
,	B-X
therefore	B-X
leading	B-X
to	B-X
constitutive	B-X
levels	B-X
of	B-X
RelA	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
to	B-X
increased	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
gene	B-X
activity	B-X
<EOS>	B-X
PLB	B-X
-	B-X
IIIB	B-X
cells	B-X
displayed	B-X
a	B-X
constitutive	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
binding	B-X
activity	B-X
that	B-X
was	B-X
distinct	B-X
from	B-X
that	B-X
induced	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
or	B-X
phorbol	B-X
12	B-X
-	B-X
myristate	B-X
13	B-X
-	B-X
acetate	B-X
treatment	B-X
of	B-X
the	B-X
parental	B-X
PLB	B-X
-	B-X
985	B-X
cell	B-X
line	B-X

The	O
70-kDa	B-protein
protein	I-protein
corresponds	O
to	O
the	O
NF-kappa	B-protein
B	I-protein
RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
subunit	I-protein
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
an	O
acute	O
paramyxovirus	O
infection	O
or	O
a	O
chronic	O
HIV-1	O
infection	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
impact	B-X
of	B-X
Tfh	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
function	B-X
on	B-X
T	B-X
helper	B-X
cell	B-X
recovery	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
or	B-X
chronic	B-X
HIV	B-X
infection	B-X
<EOS>	B-X
Previously	B-X
,	B-X
insertions	B-X
/	B-X
deletions	B-X
were	B-X
rarely	B-X
reported	B-X
for	B-X
antiviral	B-X
antibodies	B-X
except	B-X
for	B-X
those	B-X
induced	B-X
by	B-X
HIV	B-X
-	B-X
1	B-X
chronic	B-X
infections	B-X
<EOS>	B-X
A	B-X
broad	B-X
spectrum	B-X
of	B-X
kidney	B-X
disorders	B-X
can	B-X
be	B-X
observed	B-X
in	B-X
PWH	B-X
,	B-X
some	B-X
of	B-X
which	B-X
are	B-X
directly	B-X
related	B-X
to	B-X
intrarenal	B-X
HIV	B-X
infection	B-X
and	B-X
gene	B-X
expression	B-X
<EOS>	B-X
The	B-X
literature	B-X
supports	B-X
key	B-X
roles	B-X
for	B-X
this	B-X
signaling	B-X
mechanism	B-X
in	B-X
cell	B-X
-	B-X
to	B-X
-	B-X
cell	B-X
communication	B-X
and	B-X
in	B-X
activating	B-X
transcriptional	B-X
changes	B-X
that	B-X
impact	B-X
the	B-X
inflammatory	B-X
state	B-X
leading	B-X
to	B-X
disease	B-X
progression	B-X

Virus	O
infection	O
does	O
not	O
appear	O
to	O
alter	O
the	O
amount	O
of	O
RelA	B-protein
(	O
p65	B-protein
)	O
or	O
NFKB1	B-protein
(	O
p50	B-protein
)	O
but	O
rather	O
affects	O
the	O
capacity	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
sequester	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
,	O
therefore	O
leading	O
to	O
constitutive	O
levels	O
of	O
RelA	O
DNA	O
binding	O
activity	O
and	O
to	O
increased	O
levels	O
of	O
NF-kappa	O
B-dependent	O
gene	O
activity	O
.	O
<EOS>	B-X
Virus	B-X
infection	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
alter	B-X
the	B-X
amount	B-X
of	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
or	B-X
NFKB1	B-X
(	B-X
p50	B-X
)	B-X
but	B-X
rather	B-X
affects	B-X
the	B-X
capacity	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
sequester	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
,	B-X
therefore	B-X
leading	B-X
to	B-X
constitutive	B-X
levels	B-X
of	B-X
RelA	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
to	B-X
increased	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
gene	B-X
activity	B-X
<EOS>	B-X
DNA	B-X
binding	B-X
of	B-X
the	B-X
90	B-X
-	B-X
	B-X
to	B-X
100	B-X
-	B-X
kDa	B-X
proteins	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
recombinant	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
/	B-X
MAD	B-X
-	B-X
3	B-X
and	B-X
was	B-X
resistant	B-X
to	B-X
tryptic	B-X
digestion	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
may	B-X
not	B-X
be	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
related	B-X
<EOS>	B-X
The	B-X
relationship	B-X
between	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
infection	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
examined	B-X
in	B-X
a	B-X
myeloid	B-X
cell	B-X
model	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
derived	B-X
from	B-X
the	B-X
PLB	B-X
-	B-X
985	B-X
cell	B-X
line	B-X
<EOS>	B-X
Transient	B-X
cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
RelA	B-X
and	B-X
NFKB1	B-X
expression	B-X
maximally	B-X
stimulated	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
reporter	B-X
genes	B-X
;	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
binding	B-X
activity	B-X
were	B-X
also	B-X
reflected	B-X
in	B-X
higher	B-X
constitutive	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
regulated	B-X
gene	B-X
expression	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
myeloid	B-X
cells	B-X

The	O
virally	O
induced	O
90-	B-protein
to	I-protein
100-kDa	I-protein
proteins	I-protein
have	O
a	O
distinct	O
binding	O
specificity	O
for	O
the	O
PRDII	B-DNA
domain	I-DNA
and	O
an	O
AT-rich	B-DNA
sequence	I-DNA
but	O
do	O
not	O
cross-react	O
with	O
NF-kappa	O
B	O
subunit-specific	O
antisera	O
directed	O
against	O
NFKB1	B-protein
(	O
p105	B-protein
or	O
p50	B-protein
)	O
,	O
NFKB2	B-protein
(	O
p100	B-protein
or	O
p52	B-protein
)	O
,	O
RelA	B-protein
(	O
p65	B-protein
)	O
,	O
or	O
c-rel	B-protein
.	O
<EOS>	B-X
Mutations	B-X
at	B-X
the	B-X
EXO	B-X
domain	B-X
and	B-X
other	B-X
missense	B-X
mutations	B-X
on	B-X
POLE	B-X
with	B-X
unknown	B-X
significance	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
cancers	B-X
<EOS>	B-X
We	B-X
observed	B-X
that	B-X
human	B-X
forebrain	B-X
NPCs	B-X
did	B-X
not	B-X
respond	B-X
to	B-X
acute	B-X
IL	B-X
-	B-X
6	B-X
exposure	B-X
in	B-X
monoculture	B-X
at	B-X
both	B-X
protein	B-X
and	B-X
transcript	B-X
levels	B-X
due	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
IL6R	B-X
expression	B-X
and	B-X
soluble	B-X
(	B-X
s	B-X
)	B-X
IL6Ra	B-X
secretion	B-X
<EOS>	B-X
The	B-X
observed	B-X
penetrance	B-X
of	B-X
deletions	B-X
encompassing	B-X
different	B-X
SROs	B-X
and	B-X
that	B-X
predicted	B-X
when	B-X
considering	B-X
each	B-X
single	B-X
SRO	B-X
as	B-X
acting	B-X
independently	B-X
,	B-X
may	B-X
reflect	B-X
a	B-X
more	B-X
complex	B-X
model	B-X
than	B-X
the	B-X
additive	B-X
one	B-X
<EOS>	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
provided	B-X
important	B-X
insights	B-X
and	B-X
invaluable	B-X
resources	B-X
for	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
characteristics	B-X
of	B-X
the	B-X
musk	B-X
gland	B-X
,	B-X
which	B-X
will	B-X
lay	B-X
a	B-X
foundation	B-X
for	B-X
the	B-X
study	B-X
of	B-X
musk	B-X
secretion	B-X
mechanism	B-X
in	B-X
the	B-X
future	B-X

DNA	O
binding	O
of	O
the	O
90-	B-protein
to	I-protein
100-kDa	I-protein
proteins	I-protein
was	O
not	O
inhibited	O
by	O
recombinant	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha/MAD-3	I-protein
and	O
was	O
resistant	O
to	O
tryptic	O
digestion	O
,	O
suggesting	O
that	O
these	O
proteins	O
may	O
not	O
be	O
NF-kappa	B-protein
B	I-protein
related	I-protein
.	O
<EOS>	B-X
A	B-X
synthetic	B-X
DNA	B-X
encoding	B-X
a	B-X
modified	B-X
human	B-X
urokinase	B-X
resistant	B-X
to	B-X
inhibition	B-X
by	B-X
serum	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
.	B-X
<EOS>	B-X
Relationship	B-X
of	B-X
the	B-X
90	B-X
-	B-X
kDa	B-X
murine	B-X
heat	B-X
shock	B-X
protein	B-X
to	B-X
the	B-X
untransformed	B-X
and	B-X
transformed	B-X
states	B-X
of	B-X
the	B-X
L	B-X
cell	B-X
glucocorticoid	B-X
receptor	B-X
.	B-X
<EOS>	B-X
The	B-X
reactivity	B-X
of	B-X
the	B-X
mAbs	B-X
against	B-X
DT40	B-X
cells	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
excess	B-X
chicken	B-X
serum	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
cell	B-X
death	B-X
induced	B-X
by	B-X
D18	B-X
and	B-X
D19	B-X
was	B-X
not	B-X
caused	B-X
by	B-X
inhibition	B-X
of	B-X
the	B-X
binding	B-X
of	B-X
transferrin	B-X
(	B-X
Tf	B-X
)	B-X
to	B-X
chicken	B-X
TfR	B-X
<EOS>	B-X
The	B-X
N	B-X
-	B-X
terminal	B-X
one	B-X
showed	B-X
characteristics	B-X
of	B-X
leader	B-X
peptide	B-X
for	B-X
secretion	B-X
and	B-X
the	B-X
C	B-X
-	B-X
terminal	B-X
one	B-X
contained	B-X
a	B-X
possible	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
anchoring	B-X
site	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
APN	B-X
encoded	B-X
by	B-X
the	B-X
cDNA	B-X
is	B-X
not	B-X
only	B-X
a	B-X
zinc	B-X
-	B-X
binding	B-X
enzyme	B-X
,	B-X
but	B-X
also	B-X
a	B-X
GPI	B-X
-	B-X
anchored	B-X
protein	B-X

Transient	O
cotransfection	O
experiments	O
demonstrated	O
that	O
RelA	O
and	O
NFKB1	O
expression	O
maximally	O
stimulated	O
HIV-1	B-DNA
LTR-	I-DNA
and	I-DNA
NF-kappa	I-DNA
B-dependent	I-DNA
reporter	I-DNA
genes	I-DNA
;	O
differences	O
in	O
NF-kappa	O
B-like	O
binding	O
activity	O
were	O
also	O
reflected	O
in	O
higher	O
constitutive	O
levels	O
of	O
NF-kappa	O
B-regulated	O
gene	O
expression	O
in	O
HIV-1-infected	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
.	O
<EOS>	B-X
Transient	B-X
cotransfection	B-X
experiments	B-X
demonstrated	B-X
that	B-X
RelA	B-X
and	B-X
NFKB1	B-X
expression	B-X
maximally	B-X
stimulated	B-X
HIV	B-X
-	B-X
1	B-X
LTR	B-X
-	B-X
	B-X
and	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
reporter	B-X
genes	B-X
;	B-X
differences	B-X
in	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
like	B-X
binding	B-X
activity	B-X
were	B-X
also	B-X
reflected	B-X
in	B-X
higher	B-X
constitutive	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
regulated	B-X
gene	B-X
expression	B-X
in	B-X
HIV	B-X
-	B-X
1	B-X
-	B-X
infected	B-X
myeloid	B-X
cells	B-X
<EOS>	B-X
The	B-X
relationship	B-X
between	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV	B-X
-	B-X
1	B-X
)	B-X
infection	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
examined	B-X
in	B-X
a	B-X
myeloid	B-X
cell	B-X
model	B-X
of	B-X
HIV	B-X
-	B-X
1	B-X
infection	B-X
derived	B-X
from	B-X
the	B-X
PLB	B-X
-	B-X
985	B-X
cell	B-X
line	B-X
<EOS>	B-X
Virus	B-X
infection	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
alter	B-X
the	B-X
amount	B-X
of	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
or	B-X
NFKB1	B-X
(	B-X
p50	B-X
)	B-X
but	B-X
rather	B-X
affects	B-X
the	B-X
capacity	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
sequester	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
,	B-X
therefore	B-X
leading	B-X
to	B-X
constitutive	B-X
levels	B-X
of	B-X
RelA	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
to	B-X
increased	B-X
levels	B-X
of	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
-	B-X
dependent	B-X
gene	B-X
activity	B-X
<EOS>	B-X
Chronic	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
infection	B-X
stimulates	B-X
distinct	B-X
NF	B-X
-	B-X
kappa	B-X
B	B-X
/	B-X
rel	B-X
DNA	B-X
binding	B-X
activities	B-X
in	B-X
myelomonoblastic	B-X
cells	B-X
.	B-X

Presence	O
of	O
estrogen-binding	O
sites	O
on	O
macrophage-like	B-cell_type
synoviocytes	I-cell_type
and	O
CD8+	B-cell_line
,	I-cell_line
CD29+	I-cell_line
,	I-cell_line
CD45RO+	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
in	O
normal	O
and	O
rheumatoid	O
synovium	O
.	O
<EOS>	B-X
Presence	B-X
of	B-X
estrogen	B-X
-	B-X
binding	B-X
sites	B-X
on	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
and	B-X
CD8+	B-X
,	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
T	B-X
lymphocytes	B-X
in	B-X
normal	B-X
and	B-X
rheumatoid	B-X
synovium	B-X
.	B-X
<EOS>	B-X
Immunostaining	B-X
showed	B-X
the	B-X
estrogen	B-X
receptor	B-X
-	B-X
positive	B-X
cells	B-X
to	B-X
be	B-X
the	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
and	B-X
the	B-X
CD8+	B-X
,	B-X
CD29+	B-X
T	B-X
cells	B-X
both	B-X
in	B-X
RA	B-X
and	B-X
in	B-X
control	B-X
synovial	B-X
tissues	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
presence	B-X
of	B-X
estrogen	B-X
-	B-X
binding	B-X
sites	B-X
(	B-X
EBS	B-X
)	B-X
in	B-X
the	B-X
synovial	B-X
tissues	B-X
of	B-X
male	B-X
and	B-X
female	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
in	B-X
age	B-X
-	B-X
	B-X
and	B-X
sex	B-X
-	B-X
matched	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
Double	B-X
immunostaining	B-X
with	B-X
the	B-X
anti	B-X
-	B-X
ER	B-X
MAb	B-X
and	B-X
with	B-X
specific	B-X
MAb	B-X
to	B-X
detect	B-X
different	B-X
macrophage	B-X
antigens	B-X
(	B-X
Ber	B-X
-	B-X
MAC3	B-X
,	B-X
MAC387	B-X
,	B-X
CD68	B-X
)	B-X
and	B-X
CD8+	B-X
T	B-X
cell	B-X
subsets	B-X
(	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
and	B-X
CD29	B-X
-	B-X
	B-X
,	B-X
CD45RO	B-X
-	B-X
	B-X
)	B-X
was	B-X
performed	B-X

OBJECTIVE	O
.	O
<EOS>	B-X
39	B-X
,	B-X
CI	B-X
:	B-X
1	B-X
<EOS>	B-X
35	B-X
,	B-X
CI	B-X
:	B-X
1	B-X
<EOS>	B-X
01	B-X
,	B-X
CI	B-X
:	B-X
1	B-X
<EOS>	B-X
6	B-X
%	B-X
in	B-X
January	B-X
and	B-X
6	B-X

To	O
study	O
the	O
presence	O
of	O
estrogen-binding	O
sites	O
(	O
EBS	O
)	O
in	O
the	O
synovial	O
tissues	O
of	O
male	O
and	O
female	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
in	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
.	O

METHODS	O
.	O
<EOS>	B-X
27	B-X
mmHg	B-X
(	B-X
SD	B-X
±	B-X
15	B-X
<EOS>	B-X
18	B-X
mmHg	B-X
(	B-X
SD	B-X
±	B-X
12	B-X
<EOS>	B-X
98	B-X
;	B-X
2	B-X
<EOS>	B-X
85	B-X
;	B-X
0	B-X

Both	O
type	O
1	O
(	O
high	O
affinity	O
,	O
low	O
binding	O
capacity	O
)	O
and	O
type	O
2	O
(	O
reduced	O
affinity	O
,	O
higher	O
binding	O
capacity	O
)	O
EBS	O
were	O
investigated	O
in	O
both	O
soluble	O
and	O
nuclear	O
fractions	O
of	O
homogenized	O
synovial	O
tissue	O
samples	O
by	O
a	O
dextran-coated	O
charcoal	O
method	O
.	O
<EOS>	B-X
Both	B-X
type	B-X
1	B-X
(	B-X
high	B-X
affinity	B-X
,	B-X
low	B-X
binding	B-X
capacity	B-X
)	B-X
and	B-X
type	B-X
2	B-X
(	B-X
reduced	B-X
affinity	B-X
,	B-X
higher	B-X
binding	B-X
capacity	B-X
)	B-X
EBS	B-X
were	B-X
investigated	B-X
in	B-X
both	B-X
soluble	B-X
and	B-X
nuclear	B-X
fractions	B-X
of	B-X
homogenized	B-X
synovial	B-X
tissue	B-X
samples	B-X
by	B-X
a	B-X
dextran	B-X
-	B-X
coated	B-X
charcoal	B-X
method	B-X
<EOS>	B-X
Higher	B-X
affinity	B-X
EBS	B-X
were	B-X
found	B-X
mostly	B-X
in	B-X
nuclear	B-X
cell	B-X
fractions	B-X
of	B-X
either	B-X
RA	B-X
or	B-X
control	B-X
synovial	B-X
tissues	B-X
(	B-X
28	B-X
of	B-X
the	B-X
33	B-X
)	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
presence	B-X
of	B-X
estrogen	B-X
-	B-X
binding	B-X
sites	B-X
(	B-X
EBS	B-X
)	B-X
in	B-X
the	B-X
synovial	B-X
tissues	B-X
of	B-X
male	B-X
and	B-X
female	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
in	B-X
age	B-X
-	B-X
	B-X
and	B-X
sex	B-X
-	B-X
matched	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
Higher	B-X
nuclear	B-X
content	B-X
of	B-X
EBS	B-X
was	B-X
consistent	B-X
with	B-X
more	B-X
intense	B-X
nuclear	B-X
staining	B-X
of	B-X
synoviocytes	B-X
and	B-X
T	B-X
cells	B-X

To	O
determine	O
what	O
type	O
of	O
synovial	B-cell_type
cell	I-cell_type
was	O
positive	O
for	O
EBS	O
,	O
cryosections	O
of	O
synovial	O
tissues	O
were	O
immunostained	O
with	O
a	O
specific	O
monoclonal	B-protein
anti-estrogen	I-protein
receptor	I-protein
antibody	I-protein
(	O
anti-ER	B-protein
MAb	I-protein
)	O
using	O
both	O
immunofluorescence	O
and	O
immunoperoxidase	O
techniques	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
what	B-X
type	B-X
of	B-X
synovial	B-X
cell	B-X
was	B-X
positive	B-X
for	B-X
EBS	B-X
,	B-X
cryosections	B-X
of	B-X
synovial	B-X
tissues	B-X
were	B-X
immunostained	B-X
with	B-X
a	B-X
specific	B-X
monoclonal	B-X
anti	B-X
-	B-X
estrogen	B-X
receptor	B-X
antibody	B-X
(	B-X
anti	B-X
-	B-X
ER	B-X
MAb	B-X
)	B-X
using	B-X
both	B-X
immunofluorescence	B-X
and	B-X
immunoperoxidase	B-X
techniques	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
presence	B-X
of	B-X
estrogen	B-X
-	B-X
binding	B-X
sites	B-X
(	B-X
EBS	B-X
)	B-X
in	B-X
the	B-X
synovial	B-X
tissues	B-X
of	B-X
male	B-X
and	B-X
female	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
in	B-X
age	B-X
-	B-X
	B-X
and	B-X
sex	B-X
-	B-X
matched	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
Immunostaining	B-X
showed	B-X
the	B-X
estrogen	B-X
receptor	B-X
-	B-X
positive	B-X
cells	B-X
to	B-X
be	B-X
the	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
and	B-X
the	B-X
CD8+	B-X
,	B-X
CD29+	B-X
T	B-X
cells	B-X
both	B-X
in	B-X
RA	B-X
and	B-X
in	B-X
control	B-X
synovial	B-X
tissues	B-X
<EOS>	B-X
Higher	B-X
nuclear	B-X
content	B-X
of	B-X
EBS	B-X
was	B-X
consistent	B-X
with	B-X
more	B-X
intense	B-X
nuclear	B-X
staining	B-X
of	B-X
synoviocytes	B-X
and	B-X
T	B-X
cells	B-X

Double	O
immunostaining	O
with	O
the	O
anti-ER	B-protein
MAb	I-protein
and	O
with	O
specific	B-protein
MAb	I-protein
to	O
detect	O
different	O
macrophage	B-protein
antigens	I-protein
(	O
Ber-MAC3	B-protein
,	O
MAC387	B-protein
,	O
CD68	B-protein
)	O
and	O
CD8+	B-cell_line
T	I-cell_line
cell	I-cell_line
subsets	I-cell_line
(	O
CD29+	B-cell_line
,	O
CD45RO+	B-cell_line
and	O
CD29-	B-cell_line
,	O
CD45RO-	B-cell_line
)	O
was	O
performed	O
.	O
<EOS>	B-X
Double	B-X
immunostaining	B-X
with	B-X
the	B-X
anti	B-X
-	B-X
ER	B-X
MAb	B-X
and	B-X
with	B-X
specific	B-X
MAb	B-X
to	B-X
detect	B-X
different	B-X
macrophage	B-X
antigens	B-X
(	B-X
Ber	B-X
-	B-X
MAC3	B-X
,	B-X
MAC387	B-X
,	B-X
CD68	B-X
)	B-X
and	B-X
CD8+	B-X
T	B-X
cell	B-X
subsets	B-X
(	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
and	B-X
CD29	B-X
-	B-X
	B-X
,	B-X
CD45RO	B-X
-	B-X
	B-X
)	B-X
was	B-X
performed	B-X
<EOS>	B-X
Immunostaining	B-X
showed	B-X
the	B-X
estrogen	B-X
receptor	B-X
-	B-X
positive	B-X
cells	B-X
to	B-X
be	B-X
the	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
and	B-X
the	B-X
CD8+	B-X
,	B-X
CD29+	B-X
T	B-X
cells	B-X
both	B-X
in	B-X
RA	B-X
and	B-X
in	B-X
control	B-X
synovial	B-X
tissues	B-X
<EOS>	B-X
Presence	B-X
of	B-X
estrogen	B-X
-	B-X
binding	B-X
sites	B-X
on	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
and	B-X
CD8+	B-X
,	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
T	B-X
lymphocytes	B-X
in	B-X
normal	B-X
and	B-X
rheumatoid	B-X
synovium	B-X
.	B-X
<EOS>	B-X
It	B-X
is	B-X
conceivable	B-X
that	B-X
the	B-X
immunomodulatory	B-X
activity	B-X
exerted	B-X
by	B-X
estrogens	B-X
is	B-X
at	B-X
least	B-X
partly	B-X
mediated	B-X
through	B-X
their	B-X
interaction	B-X
with	B-X
EBS	B-X
that	B-X
are	B-X
present	B-X
on	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
,	B-X
functioning	B-X
as	B-X
antigen	B-X
-	B-X
processing	B-X
and	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
,	B-X
and	B-X
on	B-X
antigen	B-X
-	B-X
experienced	B-X
(	B-X
memory	B-X
)	B-X
CD8+	B-X
T	B-X
lymphocytes	B-X
(	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
)	B-X

RESULTS	O
.	O
<EOS>	B-X
niveus	B-X
,	B-X
S	B-X
<EOS>	B-X
R	B-X
<EOS>	B-X
39	B-X
,	B-X
CI	B-X
:	B-X
1	B-X
<EOS>	B-X
35	B-X
,	B-X
CI	B-X
:	B-X
1	B-X

Higher	O
affinity	O
EBS	O
were	O
found	O
mostly	O
in	O
nuclear	O
cell	O
fractions	O
of	O
either	O
RA	O
or	O
control	O
synovial	O
tissues	O
(	O
28	O
of	O
the	O
33	O
)	O
.	O
<EOS>	B-X
Higher	B-X
affinity	B-X
EBS	B-X
were	B-X
found	B-X
mostly	B-X
in	B-X
nuclear	B-X
cell	B-X
fractions	B-X
of	B-X
either	B-X
RA	B-X
or	B-X
control	B-X
synovial	B-X
tissues	B-X
(	B-X
28	B-X
of	B-X
the	B-X
33	B-X
)	B-X
<EOS>	B-X
These	B-X
EBS	B-X
were	B-X
present	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
in	B-X
soluble	B-X
cell	B-X
fractions	B-X
(	B-X
11	B-X
of	B-X
the	B-X
33	B-X
)	B-X
<EOS>	B-X
Similarly	B-X
,	B-X
the	B-X
serum	B-X
levels	B-X
of	B-X
BAP	B-X
and	B-X
CHON	B-X
compared	B-X
with	B-X
control	B-X
values	B-X
were	B-X
higher	B-X
(	B-X
27	B-X
<EOS>	B-X
Intra	B-X
-	B-X
articular	B-X
injection	B-X
of	B-X
hyaluronic	B-X
acid	B-X
following	B-X
arthroscopic	B-X
partial	B-X
meniscectomy	B-X
of	B-X
the	B-X
knee	B-X
.	B-X

These	O
EBS	O
were	O
present	O
to	O
a	O
lesser	O
extent	O
in	O
soluble	O
cell	O
fractions	O
(	O
11	O
of	O
the	O
33	O
)	O
.	O
<EOS>	B-X
These	B-X
EBS	B-X
were	B-X
present	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
in	B-X
soluble	B-X
cell	B-X
fractions	B-X
(	B-X
11	B-X
of	B-X
the	B-X
33	B-X
)	B-X
<EOS>	B-X
Higher	B-X
affinity	B-X
EBS	B-X
were	B-X
found	B-X
mostly	B-X
in	B-X
nuclear	B-X
cell	B-X
fractions	B-X
of	B-X
either	B-X
RA	B-X
or	B-X
control	B-X
synovial	B-X
tissues	B-X
(	B-X
28	B-X
of	B-X
the	B-X
33	B-X
)	B-X
<EOS>	B-X
Higher	B-X
nuclear	B-X
content	B-X
of	B-X
EBS	B-X
was	B-X
consistent	B-X
with	B-X
more	B-X
intense	B-X
nuclear	B-X
staining	B-X
of	B-X
synoviocytes	B-X
and	B-X
T	B-X
cells	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
presence	B-X
of	B-X
estrogen	B-X
-	B-X
binding	B-X
sites	B-X
(	B-X
EBS	B-X
)	B-X
in	B-X
the	B-X
synovial	B-X
tissues	B-X
of	B-X
male	B-X
and	B-X
female	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
in	B-X
age	B-X
-	B-X
	B-X
and	B-X
sex	B-X
-	B-X
matched	B-X
healthy	B-X
controls	B-X

Immunostaining	O
showed	O
the	O
estrogen	B-cell_type
receptor-positive	I-cell_type
cells	I-cell_type
to	O
be	O
the	O
macrophage-like	B-cell_type
synoviocytes	I-cell_type
and	O
the	O
CD8+	B-cell_line
,	O
CD29+	B-cell_line
T	I-cell_line
cells	I-cell_line
both	O
in	O
RA	O
and	O
in	O
control	O
synovial	O
tissues	O
.	O
<EOS>	B-X
Immunostaining	B-X
showed	B-X
the	B-X
estrogen	B-X
receptor	B-X
-	B-X
positive	B-X
cells	B-X
to	B-X
be	B-X
the	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
and	B-X
the	B-X
CD8+	B-X
,	B-X
CD29+	B-X
T	B-X
cells	B-X
both	B-X
in	B-X
RA	B-X
and	B-X
in	B-X
control	B-X
synovial	B-X
tissues	B-X
<EOS>	B-X
Presence	B-X
of	B-X
estrogen	B-X
-	B-X
binding	B-X
sites	B-X
on	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
and	B-X
CD8+	B-X
,	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
T	B-X
lymphocytes	B-X
in	B-X
normal	B-X
and	B-X
rheumatoid	B-X
synovium	B-X
.	B-X
<EOS>	B-X
Double	B-X
immunostaining	B-X
with	B-X
the	B-X
anti	B-X
-	B-X
ER	B-X
MAb	B-X
and	B-X
with	B-X
specific	B-X
MAb	B-X
to	B-X
detect	B-X
different	B-X
macrophage	B-X
antigens	B-X
(	B-X
Ber	B-X
-	B-X
MAC3	B-X
,	B-X
MAC387	B-X
,	B-X
CD68	B-X
)	B-X
and	B-X
CD8+	B-X
T	B-X
cell	B-X
subsets	B-X
(	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
and	B-X
CD29	B-X
-	B-X
	B-X
,	B-X
CD45RO	B-X
-	B-X
	B-X
)	B-X
was	B-X
performed	B-X
<EOS>	B-X
It	B-X
is	B-X
conceivable	B-X
that	B-X
the	B-X
immunomodulatory	B-X
activity	B-X
exerted	B-X
by	B-X
estrogens	B-X
is	B-X
at	B-X
least	B-X
partly	B-X
mediated	B-X
through	B-X
their	B-X
interaction	B-X
with	B-X
EBS	B-X
that	B-X
are	B-X
present	B-X
on	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
,	B-X
functioning	B-X
as	B-X
antigen	B-X
-	B-X
processing	B-X
and	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
,	B-X
and	B-X
on	B-X
antigen	B-X
-	B-X
experienced	B-X
(	B-X
memory	B-X
)	B-X
CD8+	B-X
T	B-X
lymphocytes	B-X
(	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
)	B-X

Higher	O
nuclear	O
content	O
of	O
EBS	O
was	O
consistent	O
with	O
more	O
intense	O
nuclear	O
staining	O
of	O
synoviocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

CONCLUSION	O
.	O
<EOS>	B-X
6	B-X
years	B-X
(	B-X
IQR	B-X
3	B-X
<EOS>	B-X
1	B-X
%	B-X
and	B-X
TIA	B-X
/	B-X
stroke	B-X
in	B-X
2	B-X
<EOS>	B-X
98	B-X
;	B-X
2	B-X
<EOS>	B-X
97	B-X
mg	B-X
/	B-X
kg	B-X
,	B-X
2	B-X

It	O
is	O
conceivable	O
that	O
the	O
immunomodulatory	O
activity	O
exerted	O
by	O
estrogens	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
their	O
interaction	O
with	O
EBS	O
that	O
are	O
present	O
on	O
macrophage-like	B-cell_type
synoviocytes	I-cell_type
,	O
functioning	O
as	O
antigen-processing	B-cell_type
and	I-cell_type
antigen-presenting	I-cell_type
cells	I-cell_type
,	O
and	O
on	O
antigen-experienced	B-cell_line
(	I-cell_line
memory	I-cell_line
)	I-cell_line
CD8+	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
(	O
CD29+	B-cell_line
,	O
CD45RO+	B-cell_line
<EOS>	B-X
It	B-X
is	B-X
conceivable	B-X
that	B-X
the	B-X
immunomodulatory	B-X
activity	B-X
exerted	B-X
by	B-X
estrogens	B-X
is	B-X
at	B-X
least	B-X
partly	B-X
mediated	B-X
through	B-X
their	B-X
interaction	B-X
with	B-X
EBS	B-X
that	B-X
are	B-X
present	B-X
on	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
,	B-X
functioning	B-X
as	B-X
antigen	B-X
-	B-X
processing	B-X
and	B-X
antigen	B-X
-	B-X
presenting	B-X
cells	B-X
,	B-X
and	B-X
on	B-X
antigen	B-X
-	B-X
experienced	B-X
(	B-X
memory	B-X
)	B-X
CD8+	B-X
T	B-X
lymphocytes	B-X
(	B-X
CD29+	B-X
,	B-X
CD45RO+	B-X
)	B-X
<EOS>	B-X
Immunostaining	B-X
showed	B-X
the	B-X
estrogen	B-X
receptor	B-X
-	B-X
positive	B-X
cells	B-X
to	B-X
be	B-X
the	B-X
macrophage	B-X
-	B-X
like	B-X
synoviocytes	B-X
and	B-X
the	B-X
CD8+	B-X
,	B-X
CD29+	B-X
T	B-X
cells	B-X
both	B-X
in	B-X
RA	B-X
and	B-X
in	B-X
control	B-X
synovial	B-X
tissues	B-X
<EOS>	B-X
To	B-X
study	B-X
the	B-X
presence	B-X
of	B-X
estrogen	B-X
-	B-X
binding	B-X
sites	B-X
(	B-X
EBS	B-X
)	B-X
in	B-X
the	B-X
synovial	B-X
tissues	B-X
of	B-X
male	B-X
and	B-X
female	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
in	B-X
age	B-X
-	B-X
	B-X
and	B-X
sex	B-X
-	B-X
matched	B-X
healthy	B-X
controls	B-X
<EOS>	B-X
To	B-X
determine	B-X
what	B-X
type	B-X
of	B-X
synovial	B-X
cell	B-X
was	B-X
positive	B-X
for	B-X
EBS	B-X
,	B-X
cryosections	B-X
of	B-X
synovial	B-X
tissues	B-X
were	B-X
immunostained	B-X
with	B-X
a	B-X
specific	B-X
monoclonal	B-X
anti	B-X
-	B-X
estrogen	B-X
receptor	B-X
antibody	B-X
(	B-X
anti	B-X
-	B-X
ER	B-X
MAb	B-X
)	B-X
using	B-X
both	B-X
immunofluorescence	B-X
and	B-X
immunoperoxidase	B-X
techniques	B-X

